entity,fact,text
resazurin,"Resazurin is used as a fluorogenic indicator in the coupled enzymatic assay for formate determination, with its fluorescence intensity decreasing upon reaction with formate dehydrogenase.","Entity: resazurin. SMILES: O=c1ccc2[n+]([O-])c3ccc(O)cc3oc-2c1. Resazurin is used as a fluorogenic indicator in the coupled enzymatic assay for formate determination, with its fluorescence intensity decreasing upon reaction with formate dehydrogenase."
formate,"Formate can be quantitatively determined in a coupled enzymatic assay using formate dehydrogenase, resazurin, and diaphorase, with optimal conditions involving 1 mM formate and 0.006 units of formate dehydrogenase per ml reaction mixture.","Entity: formate. SMILES: O=C[O-]. Formate can be quantitatively determined in a coupled enzymatic assay using formate dehydrogenase, resazurin, and diaphorase, with optimal conditions involving 1 mM formate and 0.006 units of formate dehydrogenase per ml reaction mixture."
NAD,"NAD is used as a cofactor in the enzymatic assay for formate determination, with optimal conditions involving 1.0 mM NAD.","Entity: NAD. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NAD is used as a cofactor in the enzymatic assay for formate determination, with optimal conditions involving 1.0 mM NAD."
formic acid,"Formic acid is involved in the toxicity of methanol in humans and lower animals, but its role is not fully understood due to the lack of a sensitive and specific assay for its measurement in vivo.","Entity: formic acid. SMILES: O=CO. Formic acid is involved in the toxicity of methanol in humans and lower animals, but its role is not fully understood due to the lack of a sensitive and specific assay for its measurement in vivo."
methanol,"Methanol toxicity in humans and lower animals is associated with the oxidation of methanol, a process that involves formic acid as a metabolite.","Entity: methanol. SMILES: CO. Methanol toxicity in humans and lower animals is associated with the oxidation of methanol, a process that involves formic acid as a metabolite."
formaldehyde,"The disposition of formaldehyde in animals has been studied, contributing to our understanding of its metabolic pathways.","Entity: formaldehyde. SMILES: C=O. The disposition of formaldehyde in animals has been studied, contributing to our understanding of its metabolic pathways."
formate,"Increased blood levels of formate are associated with metabolic acidosis in pigtail monkeys, as indicated by a decrease in arterial pH and pCO2.","Entity: formate. SMILES: O=C[O-]. Increased blood levels of formate are associated with metabolic acidosis in pigtail monkeys, as indicated by a decrease in arterial pH and pCO2."
sodium oxalate,Sodium oxalate is used as a component (5 mM concentration) in nutrient agar slopes to support the maintenance and growth of P. oxalaticus cultures.,Entity: sodium oxalate. SMILES: O=C([O-])C(=O)[O-].[Na+].[Na+]. Sodium oxalate is used as a component (5 mM concentration) in nutrient agar slopes to support the maintenance and growth of P. oxalaticus cultures.
resazurin,"Resazurin is used as a chromogenic substrate in diaphorase and coupled enzyme assays, with optimal concentrations for the diaphorase reaction being 20 mM.","Entity: resazurin. SMILES: O=c1ccc2[n+]([O-])c3ccc(O)cc3oc-2c1. Resazurin is used as a chromogenic substrate in diaphorase and coupled enzyme assays, with optimal concentrations for the diaphorase reaction being 20 mM."
formate,"Formate is a substrate for diaphorase, with the K, for formate measured by the coupled fluorometric assay being about 0.15 mM, which closely approximates the value at pH 7.4 using the spectrophotometric method.","Entity: formate. SMILES: O=C[O-]. Formate is a substrate for diaphorase, with the K, for formate measured by the coupled fluorometric assay being about 0.15 mM, which closely approximates the value at pH 7.4 using the spectrophotometric method."
phosphate,Phosphate buffer at 100 mM is used as the incubation medium for both diaphorase and coupled enzyme assays.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate buffer at 100 mM is used as the incubation medium for both diaphorase and coupled enzyme assays.
sodium hydroxide,"Sodium hydroxide, in combination with zinc sulfate, is more effective than perchloric acid for protein precipitation from blood.","Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide, in combination with zinc sulfate, is more effective than perchloric acid for protein precipitation from blood."
zinc sulfate,"Zinc sulfate, when combined with sodium hydroxide, is more effective than perchloric acid for protein precipitation from blood and removes inhibitory substances and interfering pigments retained after perchloric acid treatment.","Entity: zinc sulfate. SMILES: O=S(=O)([O-])[O-].[Zn+2]. Zinc sulfate, when combined with sodium hydroxide, is more effective than perchloric acid for protein precipitation from blood and removes inhibitory substances and interfering pigments retained after perchloric acid treatment."
perchloric acid,Perchloric acid is unsatisfactory as a protein precipitant.,Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid is unsatisfactory as a protein precipitant.
sodium hydroxide,Sodium hydroxide is used in a protein precipitation method with zinc sulfate for the recovery of formate from blood samples.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used in a protein precipitation method with zinc sulfate for the recovery of formate from blood samples.
zinc sulfate,Zinc sulfate is used in a protein precipitation method with sodium hydroxide for the recovery of formate from blood samples.,Entity: zinc sulfate. SMILES: O=S(=O)([O-])[O-].[Zn+2]. Zinc sulfate is used in a protein precipitation method with sodium hydroxide for the recovery of formate from blood samples.
formate,"Formate can be quantitatively determined in blood samples using a protein precipitation method with zinc sulfate and sodium hydroxide, achieving an average recovery of about 95%.","Entity: formate. SMILES: O=C[O-].[Na+]. Formate can be quantitatively determined in blood samples using a protein precipitation method with zinc sulfate and sodium hydroxide, achieving an average recovery of about 95%."
formate,The limit of sensitivity for formate determination in this method is about 0.5 pg/ml of reaction mixture.,Entity: formate. SMILES: O=C[O-].[Na+]. The limit of sensitivity for formate determination in this method is about 0.5 pg/ml of reaction mixture.
trichloroacetic acid,Trichloroacetic acid is inhibitory to the coupled reaction for formate determination and acts competitively with formate.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is inhibitory to the coupled reaction for formate determination and acts competitively with formate.
methanol,Methanol poisoning in monkeys can be monitored by measuring blood formic acid levels using a formate dehydrogenase-based enzymatic assay.,Entity: methanol. SMILES: CO. Methanol poisoning in monkeys can be monitored by measuring blood formic acid levels using a formate dehydrogenase-based enzymatic assay.
resazurin,"Resazurin is a nonfluorescent substance that is reduced by diaphorase in a coupled reaction to form resorufin, a fluorescent dye.","Entity: resazurin. SMILES: O=c1ccc2[n+]([O-])c3ccc(O)cc3oc-2c1. Resazurin is a nonfluorescent substance that is reduced by diaphorase in a coupled reaction to form resorufin, a fluorescent dye."
resorufin,Resorufin is a fluorescent dye produced from the reduction of resazurin by diaphorase in a coupled enzymatic assay.,Entity: resorufin. SMILES: O=c1ccc2nc3ccc(O)cc3oc-2c1. Resorufin is a fluorescent dye produced from the reduction of resazurin by diaphorase in a coupled enzymatic assay.
formic acid,"Formic acid can be specifically and sensitively determined using a coupled reaction of formate dehydrogenase with diaphorase-catalyzed resazurin reduction, with the assay adaptable for measurement in body fluids.","Entity: formic acid. SMILES: O=CO. Formic acid can be specifically and sensitively determined using a coupled reaction of formate dehydrogenase with diaphorase-catalyzed resazurin reduction, with the assay adaptable for measurement in body fluids."
dithiothreitol,"Dithiothreitol at 0.1 mM helps stabilize crude enzyme preparations, maintaining about 100% enzymatic activity at -80°C for at least 6 months.","Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol at 0.1 mM helps stabilize crude enzyme preparations, maintaining about 100% enzymatic activity at -80°C for at least 6 months."
disodium EDTA,"Disodium EDTA at 1.0 mM helps stabilize crude enzyme preparations, maintaining about 100% enzymatic activity at -80°C for at least 6 months.","Entity: disodium EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.[Na+]. Disodium EDTA at 1.0 mM helps stabilize crude enzyme preparations, maintaining about 100% enzymatic activity at -80°C for at least 6 months."
resazurin,"Resazurin is a substrate that is reduced by the enzyme in a diaphorase-catalyzed reaction to form resorufin, which can be measured spectrophotometrically.","Entity: resazurin. SMILES: O=c1ccc2[n+]([O-])c3ccc(O)cc3oc-2c1. Resazurin is a substrate that is reduced by the enzyme in a diaphorase-catalyzed reaction to form resorufin, which can be measured spectrophotometrically."
resorufin,Resorufin is the product of resazurin reduction by the enzyme in a diaphorase-catalyzed reaction and can be measured spectrophotometrically.,Entity: resorufin. SMILES: O=c1ccc2nc3ccc(O)cc3oc-2c1. Resorufin is the product of resazurin reduction by the enzyme in a diaphorase-catalyzed reaction and can be measured spectrophotometrically.
formate,"Formate can be quantitatively measured in body fluids using a coupled enzymatic assay with crude P. oxalaticus enzyme extract, providing about ten times increased sensitivity compared to spectrophotometric methods and requiring less enzyme.","Entity: formate. SMILES: O=C[O-]. Formate can be quantitatively measured in body fluids using a coupled enzymatic assay with crude P. oxalaticus enzyme extract, providing about ten times increased sensitivity compared to spectrophotometric methods and requiring less enzyme."
formate,"Formate can be measured using a coupled fluorometric method in the presence of formate dehydrogenase (FDH), providing a sensitive and fast assay without extensive enzyme purification or tissue preparation.","Entity: formate. SMILES: O=C[O-]. Formate can be measured using a coupled fluorometric method in the presence of formate dehydrogenase (FDH), providing a sensitive and fast assay without extensive enzyme purification or tissue preparation."
oxalate,Oxalate does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.,Entity: oxalate. SMILES: O=C([O-])C(=O)[O-]. Oxalate does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.
acetate,Acetate does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.,Entity: acetate. SMILES: CC(=O)[O-]. Acetate does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.
methanol,Methanol does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.,Entity: methanol. SMILES: CO. Methanol does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.
malate,Malate does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.,Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.
formaldehyde,Formaldehyde does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.,Entity: formaldehyde. SMILES: C=O. Formaldehyde does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.
ethanol,Ethanol does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.,Entity: ethanol. SMILES: CCO. Ethanol does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.
pyruvate,Pyruvate does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate does not react with or inhibit the activity of formate dehydrogenase (FDH) in crude preparations.
formate,Formate can be measured in blood with a sensitivity that allows detection at concentrations as low as 1.0 mg%.,Entity: formate. SMILES: O=CO. Formate can be measured in blood with a sensitivity that allows detection at concentrations as low as 1.0 mg%.
formate,"Formate can serve as a product of the metabolism of certain drugs or chemicals, including demethylated compounds and certain one-carbon halogenated compounds.","Entity: formate. SMILES: O=CO. Formate can serve as a product of the metabolism of certain drugs or chemicals, including demethylated compounds and certain one-carbon halogenated compounds."
methanol,"Methanol poisoning can lead to increased blood formate levels, contributing to metabolic acidosis in primates and humans.","Entity: methanol. SMILES: CO. Methanol poisoning can lead to increased blood formate levels, contributing to metabolic acidosis in primates and humans."
formate,Formate can be quantified in body fluids using analytical methods that rely on its reduction to formaldehyde.,Entity: formate. SMILES: O=C[O-]. Formate can be quantified in body fluids using analytical methods that rely on its reduction to formaldehyde.
formaldehyde,Formaldehyde is used as an analytical endpoint in assays for quantifying formate in body fluids.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as an analytical endpoint in assays for quantifying formate in body fluids.
dithiothreitol,Dithiothreitol is used as a reducing agent to stabilize enzyme preparations during storage at -80°C.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used as a reducing agent to stabilize enzyme preparations during storage at -80°C.
disodium EDTA,Disodium EDTA is used as a chelating agent to stabilize enzyme preparations during storage at -80°C.,Entity: disodium EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.[Na+]. Disodium EDTA is used as a chelating agent to stabilize enzyme preparations during storage at -80°C.
phosphate,Phosphate buffer at 100 mM and pH 6.0 is used as the reaction medium in formate analysis assays.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate buffer at 100 mM and pH 6.0 is used as the reaction medium in formate analysis assays.
resazurin,Resazurin is used as a redox indicator in formate analysis assays at a concentration of 20 mM.,Entity: resazurin. SMILES: O=c1ccc2[n+]([O-])c3ccc(O)cc3oc-2c1. Resazurin is used as a redox indicator in formate analysis assays at a concentration of 20 mM.
NAD,NAD is used as a substrate in formate analysis assays at a concentration of 1 mM.,Entity: NAD. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NAD is used as a substrate in formate analysis assays at a concentration of 1 mM.
resorufin,"Resorufin is a fluorescent product generated from the reduction of resazurin by bacterial formate dehydrogenase in the presence of diaphorase, used as a detection substrate in formate assays.","Entity: resorufin. SMILES: O=c1ccc2nc3ccc(O)cc3oc-2c1. Resorufin is a fluorescent product generated from the reduction of resazurin by bacterial formate dehydrogenase in the presence of diaphorase, used as a detection substrate in formate assays."
methanol,Methanol can be analyzed in small volumes of body fluids using a sensitive and specific assay that also measures formate concentrations.,Entity: methanol. SMILES: CO. Methanol can be analyzed in small volumes of body fluids using a sensitive and specific assay that also measures formate concentrations.
formic acid,Formic acid can be accurately quantified in body fluids using an enzymatic assay based on its reaction with bacterial formate dehydrogenase and diaphorase-catalyzed resazurin reduction.,Entity: formic acid. SMILES: O=CO. Formic acid can be accurately quantified in body fluids using an enzymatic assay based on its reaction with bacterial formate dehydrogenase and diaphorase-catalyzed resazurin reduction.
resazurin,Resazurin is a nonfluorescent dye that is reduced by bacterial formate dehydrogenase coupled to diaphorase to produce the fluorescent product resorufin in an enzymatic assay for formate measurement.,Entity: resazurin. SMILES: O=c1ccc2[n+]([O-])c3ccc(O)cc3oc-2c1. Resazurin is a nonfluorescent dye that is reduced by bacterial formate dehydrogenase coupled to diaphorase to produce the fluorescent product resorufin in an enzymatic assay for formate measurement.
formate,Formate at 0.1 mM does not inhibit the enzymatic activity of formate dehydrogenase (FDH) in the resorufin formation assay.,Entity: formate. SMILES: O=C[O-]. Formate at 0.1 mM does not inhibit the enzymatic activity of formate dehydrogenase (FDH) in the resorufin formation assay.
pyruvate,Pyruvate at 0.1 mM produces about a 10% inhibition of the reaction catalyzed by formate dehydrogenase (FDH) in the resorufin formation assay.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate at 0.1 mM produces about a 10% inhibition of the reaction catalyzed by formate dehydrogenase (FDH) in the resorufin formation assay.
oxalate,Oxalate at 0.1 mM produces about a 10% inhibition of the reaction catalyzed by formate dehydrogenase (FDH) in the resorufin formation assay.,Entity: oxalate. SMILES: O=C([O-])C(=O)[O-]. Oxalate at 0.1 mM produces about a 10% inhibition of the reaction catalyzed by formate dehydrogenase (FDH) in the resorufin formation assay.
malate,Malate at 0.1 mM produces about a 10% inhibition of the reaction catalyzed by formate dehydrogenase (FDH) in the resorufin formation assay.,Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate at 0.1 mM produces about a 10% inhibition of the reaction catalyzed by formate dehydrogenase (FDH) in the resorufin formation assay.
methanol,Methanol blood levels can be determined in arterial blood samples using a modified Baker et al. method.,Entity: methanol. SMILES: CO. Methanol blood levels can be determined in arterial blood samples using a modified Baker et al. method.
formate,Formate can be analyzed in blood samples using a specific analytical method.,Entity: formate. SMILES: O=C[O-]. Formate can be analyzed in blood samples using a specific analytical method.
water,Water (H2O) is used as a diluent in the preparation of blood samples for formate and methanol analysis.,Entity: water. SMILES: O. Water (H2O) is used as a diluent in the preparation of blood samples for formate and methanol analysis.
carbon dioxide,Carbon dioxide (pCO2) is measured in arterial blood samples using a blood gas analyzer.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide (pCO2) is measured in arterial blood samples using a blood gas analyzer.
oxygen,Oxygen (pOz) is measured in arterial blood samples using a blood gas analyzer.,Entity: oxygen. SMILES: [O]. Oxygen (pOz) is measured in arterial blood samples using a blood gas analyzer.
sodium hydroxide,Sodium hydroxide (0.4 N NaOH) is used to adjust pH during the preparation of blood samples for formate and methanol analysis.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide (0.4 N NaOH) is used to adjust pH during the preparation of blood samples for formate and methanol analysis.
zinc sulfate heptahydrate,Zinc sulfate heptahydrate (7.5% ZnSO4·7H2O) is used as a reagent in the preparation of blood samples for formate analysis.,Entity: zinc sulfate heptahydrate. SMILES: O.O.O.O.O.O.O.O=S(=O)([O-])[O-].[Zn+2]. Zinc sulfate heptahydrate (7.5% ZnSO4·7H2O) is used as a reagent in the preparation of blood samples for formate analysis.
phenanthrene quinone,"Phenanthrene quinone is sensitive but not very specific, as it can also stain peptides containing phenylalanine and sometimes tyrosine, though the fluorescence is typically bluer than for arginine.","Entity: phenanthrene quinone. SMILES: O=C1C=Cc2c(ccc3ccccc23)C1=O. Phenanthrene quinone is sensitive but not very specific, as it can also stain peptides containing phenylalanine and sometimes tyrosine, though the fluorescence is typically bluer than for arginine."
ninhydrin,"Ninhydrin is used as a staining reagent to detect peptides, with plain ninhydrin staining for general peptide detection and cadmium-ninhydrin for specific amino acid identification.","Entity: ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is used as a staining reagent to detect peptides, with plain ninhydrin staining for general peptide detection and cadmium-ninhydrin for specific amino acid identification."
butanol,Butanol is a component of the butanolacetic acid-water-pyridine (BAWP) solvent system used for chromatographic peptide separation.,Entity: butanol. SMILES: CCCCO. Butanol is a component of the butanolacetic acid-water-pyridine (BAWP) solvent system used for chromatographic peptide separation.
acetone,Acetone is used as a solvent for drying peptide fractions and as a medium for staining with ninhydrin and hydrochloric acid in peptide analysis.,Entity: acetone. SMILES: CC(C)=O. Acetone is used as a solvent for drying peptide fractions and as a medium for staining with ninhydrin and hydrochloric acid in peptide analysis.
nitric acid,Nitric acid is used in combination with 1-nitroso-2-naphthol to detect tyrosine residues in peptide analysis.,Entity: nitric acid. SMILES: O=[N+]([O-])O. Nitric acid is used in combination with 1-nitroso-2-naphthol to detect tyrosine residues in peptide analysis.
1-nitroso-2-naphthol,"1-nitroso-2-naphthol is used as a reagent to detect tyrosine residues in peptide analysis, followed by staining with nitric acid.","Entity: 1-nitroso-2-naphthol. SMILES: O=Nc1c(O)ccc2ccccc12. 1-nitroso-2-naphthol is used as a reagent to detect tyrosine residues in peptide analysis, followed by staining with nitric acid."
pyridine,Pyridine is used as a component of the butanolacetic acid-water-pyridine (BAWP) solvent system for chromatographic peptide separation.,Entity: pyridine. SMILES: c1ccncc1. Pyridine is used as a component of the butanolacetic acid-water-pyridine (BAWP) solvent system for chromatographic peptide separation.
hydrochloric acid,Hydrochloric acid (1% v/v in acetone) is used to bleach peptide chromatograms after staining.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (1% v/v in acetone) is used to bleach peptide chromatograms after staining.
ammonium bicarbonate,Ammonium bicarbonate is used as a buffer (0.1 M) for peptide fraction collection in chromatographic peptide analysis.,Entity: ammonium bicarbonate. SMILES: O=C([O-])O.[NH4+]. Ammonium bicarbonate is used as a buffer (0.1 M) for peptide fraction collection in chromatographic peptide analysis.
water,Water is a component of the butanolacetic acid-water-pyridine (BAWP) solvent system used for chromatographic peptide separation.,Entity: water. SMILES: O. Water is a component of the butanolacetic acid-water-pyridine (BAWP) solvent system used for chromatographic peptide separation.
phenanthrene quinone,"Phenanthrene quinone is used as a fluorescent reagent to stain peptides containing arginine, revealing them as green fluorescent spots under ultraviolet illumination.","Entity: phenanthrene quinone. SMILES: O=C1C=Cc2c(ccc3ccccc23)C1=O. Phenanthrene quinone is used as a fluorescent reagent to stain peptides containing arginine, revealing them as green fluorescent spots under ultraviolet illumination."
L-glutamate,L-glutamate is used as a growth supplement at 5 mM concentration for the auxotrophic mutant am2 of the wild-type glutamate dehydrogenase-producing fungus.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)O)C(=O)[O-].[Na+]. L-glutamate is used as a growth supplement at 5 mM concentration for the auxotrophic mutant am2 of the wild-type glutamate dehydrogenase-producing fungus.
ammonium bicarbonate,Ammonium bicarbonate at 0.05 M concentration is used to swell gel-filtration columns and as the buffer for applying and eluting peptides during gel-filtration fractionation.,Entity: ammonium bicarbonate. SMILES: O=C([O-])O.[NH4+]. Ammonium bicarbonate at 0.05 M concentration is used to swell gel-filtration columns and as the buffer for applying and eluting peptides during gel-filtration fractionation.
thiodiglycol,Thiodiglycol at 0.01% (v/v) is sometimes added to peptide mixtures during gel-filtration to aid in peptide identification.,Entity: thiodiglycol. SMILES: OCCSCCO. Thiodiglycol at 0.01% (v/v) is sometimes added to peptide mixtures during gel-filtration to aid in peptide identification.
tryptophan,Tryptophan-containing peptides can be identified by measuring their absorbance at 280 nm (E280) during gel-filtration.,Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan-containing peptides can be identified by measuring their absorbance at 280 nm (E280) during gel-filtration.
tyrosine,Tyrosine-containing peptides can be identified by measuring their absorbance at 280 nm (E280) during gel-filtration.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine-containing peptides can be identified by measuring their absorbance at 280 nm (E280) during gel-filtration.
thiodiglycol,Thiodiglycol is used as a 0.1% (v/v) additive in 0.1 M ammonium bicarbonate solution for peptide storage at -200°C.,Entity: thiodiglycol. SMILES: OCCSCCO. Thiodiglycol is used as a 0.1% (v/v) additive in 0.1 M ammonium bicarbonate solution for peptide storage at -200°C.
ammonium bicarbonate,"Ammonium bicarbonate at 0.1 M concentration is used as a solvent for redissolving pooled, dried peptide fractions prior to storage at -200°C.","Entity: ammonium bicarbonate. SMILES: O=C([O-])O.[NH4+]. Ammonium bicarbonate at 0.1 M concentration is used as a solvent for redissolving pooled, dried peptide fractions prior to storage at -200°C."
N-acetyl-serine,N-acetyl-serine is identified as the blocked N-terminus of peptide TI after analysis and sequencing.,Entity: N-acetyl-serine. SMILES: CC(=O)N[C@@H](CO)C(=O)O. N-acetyl-serine is identified as the blocked N-terminus of peptide TI after analysis and sequencing.
butyl acetate,Butyl acetate is used to remove residual pyridine from peptides prior to tryptophan quantification by absorption spectra in peptide analysis.,Entity: butyl acetate. SMILES: CCCCOC(C)=O. Butyl acetate is used to remove residual pyridine from peptides prior to tryptophan quantification by absorption spectra in peptide analysis.
tryptophan,"Tryptophan can be determined in peptides by measuring the absorption spectra of peptides before hydrolysis, following pyridine removal.","Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan can be determined in peptides by measuring the absorption spectra of peptides before hydrolysis, following pyridine removal."
hydrochloric acid,"Hydrochloric acid (6M-HCl) is used to hydrolyze samples for amino acid analysis, often supplemented with phenol to prevent tyrosine loss.","Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (6M-HCl) is used to hydrolyze samples for amino acid analysis, often supplemented with phenol to prevent tyrosine loss."
pyridine,"Pyridine is a reagent used in peptide analysis that can interfere with tryptophan quantification, and is removed by treatment with butyl acetate.","Entity: pyridine. SMILES: c1ccncc1. Pyridine is a reagent used in peptide analysis that can interfere with tryptophan quantification, and is removed by treatment with butyl acetate."
methionine,"Methionine can be lost during acid hydrolysis in peptide analysis, although some residual methionine may remain for qualitative detection.","Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine can be lost during acid hydrolysis in peptide analysis, although some residual methionine may remain for qualitative detection."
phenol,Phenol is added at 3 mg/ml to 6M-HCl during sample hydrolysis to prevent losses of tyrosine.,Entity: phenol. SMILES: Oc1ccccc1. Phenol is added at 3 mg/ml to 6M-HCl during sample hydrolysis to prevent losses of tyrosine.
tyrosine,"Tyrosine is susceptible to loss during acid hydrolysis, and phenol supplementation in 6M-HCl helps to prevent this loss in peptide analysis.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine is susceptible to loss during acid hydrolysis, and phenol supplementation in 6M-HCl helps to prevent this loss in peptide analysis."
glutamine,Glutamine can block N-terminal sequence determination by forming a pyrrolidone ring during peptide degradation.,Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine can block N-terminal sequence determination by forming a pyrrolidone ring during peptide degradation.
glutamate,Glutamate is revealed at the N-terminus after glutamine-mediated blockage is removed by the methanolysis procedure of Kawasaki & Itano (1972).,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate is revealed at the N-terminus after glutamine-mediated blockage is removed by the methanolysis procedure of Kawasaki & Itano (1972).
pyridine,Pyridine is used as a component of the buffer system (1.25 M-pyridine-acetic acid at pH 6.5) in paper electrophoresis for peptide fractionation.,Entity: pyridine. SMILES: c1ccncc1. Pyridine is used as a component of the buffer system (1.25 M-pyridine-acetic acid at pH 6.5) in paper electrophoresis for peptide fractionation.
formic acid,Formic acid is used in combination with acetic acid and water to create a buffer at pH 2.1 for paper electrophoresis of peptides.,Entity: formic acid. SMILES: O=CO. Formic acid is used in combination with acetic acid and water to create a buffer at pH 2.1 for paper electrophoresis of peptides.
acetic acid,Acetic acid is used as a component of buffer systems (with formic acid or pyridine) for paper electrophoresis of peptides.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component of buffer systems (with formic acid or pyridine) for paper electrophoresis of peptides.
ammonium bicarbonate,Ammonium bicarbonate at 0.1 M concentration is used as an elution buffer for peptides after electrophoresis.,Entity: ammonium bicarbonate. SMILES: O=C([O-])O.[NH4+]. Ammonium bicarbonate at 0.1 M concentration is used as an elution buffer for peptides after electrophoresis.
ammonia,Ammonia is used at 0.1 M concentration as an elution buffer for peptides after electrophoresis.,Entity: ammonia. SMILES: N. Ammonia is used at 0.1 M concentration as an elution buffer for peptides after electrophoresis.
ninhydrin,Ninhydrin is used to stain peptides on reference strips for visualization after electrophoresis.,Entity: ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is used to stain peptides on reference strips for visualization after electrophoresis.
vinylidene polymer,Vinylidene polymer is used as a thin plastic sheet (Saran) to cover the bottom of electrophoresis plates and to create a reservoir for Vaseline in protein gel preparation.,Entity: vinylidene polymer. SMILES: C=C(Cl)Cl.C=CCl. Vinylidene polymer is used as a thin plastic sheet (Saran) to cover the bottom of electrophoresis plates and to create a reservoir for Vaseline in protein gel preparation.
elastin,Elastin particles can be used as a substrate in agar gel electrophoretograms to detect elastase activity by producing undigested zones in the electrophoretogram.,Entity: elastin. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(C)=O)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NC)C(C)C. Elastin particles can be used as a substrate in agar gel electrophoretograms to detect elastase activity by producing undigested zones in the electrophoretogram.
hemoglobin,"Hemoglobin can serve as a substrate overlay in agar gel electrophoretograms to detect elastase activity, with undigested hemoglobin zones indicating the presence of elastase inhibitors.","Entity: hemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. Hemoglobin can serve as a substrate overlay in agar gel electrophoretograms to detect elastase activity, with undigested hemoglobin zones indicating the presence of elastase inhibitors."
sodium hydroxide,Sodium hydroxide is used at 0.1 M concentration in the cathode buffer for discontinuous acid starch gel electrophoresis of human serum.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used at 0.1 M concentration in the cathode buffer for discontinuous acid starch gel electrophoresis of human serum.
sodium phosphate,Sodium phosphate is used at 0.088 M concentration in the anode buffer for discontinuous acid starch gel electrophoresis of human serum.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used at 0.088 M concentration in the anode buffer for discontinuous acid starch gel electrophoresis of human serum.
citric acid,Citric acid is used as a buffer component at 0.006 M in the gel buffer and 0.056 M in the anode buffer for discontinuous acid starch gel electrophoresis of human serum.,Entity: citric acid. SMILES: O=C(O)CC(O)(CC(=O)O)C(=O)O. Citric acid is used as a buffer component at 0.006 M in the gel buffer and 0.056 M in the anode buffer for discontinuous acid starch gel electrophoresis of human serum.
boric acid,Boric acid is used at 0.65 M concentration in the cathode buffer for discontinuous acid starch gel electrophoresis of human serum.,Entity: boric acid. SMILES: OB(O)O. Boric acid is used at 0.65 M concentration in the cathode buffer for discontinuous acid starch gel electrophoresis of human serum.
magnesium,"Magnesium inhibits the acrosome reaction in guinea pig spermatozoa in vitro, with complete suppression at 10 mM magnesium and a concentration-dependent effect observed between 1 mM and 10 mM.","Entity: magnesium. SMILES: [Mg]. Magnesium inhibits the acrosome reaction in guinea pig spermatozoa in vitro, with complete suppression at 10 mM magnesium and a concentration-dependent effect observed between 1 mM and 10 mM."
magnesium,"The inhibitory effect of magnesium on the acrosome reaction in guinea pig spermatozoa is competitive with respect to calcium, as shown by the ability of 3 or 5 mM calcium to overcome the inhibition at 1 mM magnesium.","Entity: magnesium. SMILES: [Mg]. The inhibitory effect of magnesium on the acrosome reaction in guinea pig spermatozoa is competitive with respect to calcium, as shown by the ability of 3 or 5 mM calcium to overcome the inhibition at 1 mM magnesium."
calcium,"Calcium can overcome the inhibitory effect of magnesium on the acrosome reaction in guinea pig spermatozoa in vitro, with 3 or 5 mM calcium sufficient to restore acrosome reaction activity in the presence of 1 mM magnesium.","Entity: calcium. SMILES: [Ca]. Calcium can overcome the inhibitory effect of magnesium on the acrosome reaction in guinea pig spermatozoa in vitro, with 3 or 5 mM calcium sufficient to restore acrosome reaction activity in the presence of 1 mM magnesium."
"N,N'-Methylene-bis-acrylamide","N,N'-Methylene-bis-acrylamide is used as a cross-linking agent at 5% concentration in Cyanogum-41 gel matrices for polyacrylamide gel electrophoresis.","Entity: N,N'-Methylene-bis-acrylamide. SMILES: C=CC(=O)NCNC(=O)C=C. N,N'-Methylene-bis-acrylamide is used as a cross-linking agent at 5% concentration in Cyanogum-41 gel matrices for polyacrylamide gel electrophoresis."
methoxyflurane,Methoxyflurane is used as an anesthetic agent for gilts during uterine flushing and protein analysis procedures.,Entity: methoxyflurane. SMILES: COC(F)(F)C(Cl)Cl. Methoxyflurane is used as an anesthetic agent for gilts during uterine flushing and protein analysis procedures.
trichloroacetic acid,Trichloroacetic acid is used at 12.5% concentration to fix polyacrylamide gels prior to staining with Coomassie blue.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used at 12.5% concentration to fix polyacrylamide gels prior to staining with Coomassie blue.
progesterone,"Progesterone treatment of gilts induces secretion of both acidic and basic uterine specific proteins, which are characteristic of mature gilt uterine secretions.","Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone treatment of gilts induces secretion of both acidic and basic uterine specific proteins, which are characteristic of mature gilt uterine secretions."
progesterone,The ability of progesterone to induce secretion of uterine specific proteins in gilts is most effective when administered from about 122 to 166 days of age.,Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. The ability of progesterone to induce secretion of uterine specific proteins in gilts is most effective when administered from about 122 to 166 days of age.
estradiol,"Estradiol alone does not induce secretion of uterine specific proteins in gilts, but when combined with progesterone, it promotes the secretion of both acidic and basic uterine specific proteins.","Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Estradiol alone does not induce secretion of uterine specific proteins in gilts, but when combined with progesterone, it promotes the secretion of both acidic and basic uterine specific proteins."
potassium,"Potassium concentration in the caput and corpus epididymidis of the hamster is higher than in the proximal and distal cauda, and is lower in the cauda compared to the caput and corpus.","Entity: potassium. SMILES: [K]. Potassium concentration in the caput and corpus epididymidis of the hamster is higher than in the proximal and distal cauda, and is lower in the cauda compared to the caput and corpus."
potassium,"Potassium concentration in the caput epididymidis of the hamster is 22–62 mEq/1, showing considerable fluctuation in secretion and/or absorption.","Entity: potassium. SMILES: [K]. Potassium concentration in the caput epididymidis of the hamster is 22–62 mEq/1, showing considerable fluctuation in secretion and/or absorption."
potassium,"Potassium concentration in the cauda epididymidis of the hamster is lower than in the caput or corpus, and is similar to previously reported values in other species.","Entity: potassium. SMILES: [K]. Potassium concentration in the cauda epididymidis of the hamster is lower than in the caput or corpus, and is similar to previously reported values in other species."
potassium,"Potassium concentration in the rete testis and caput epididymidis of the hamster increases from 15 mEq/1 to 39.3 mEq/1, indicating net absorption between these regions.","Entity: potassium. SMILES: [K]. Potassium concentration in the rete testis and caput epididymidis of the hamster increases from 15 mEq/1 to 39.3 mEq/1, indicating net absorption between these regions."
potassium,"The K/Na4 ratio in the cauda epididymidis of the hamster approaches its highest value, coinciding with the plateauing of potassium and sodium levels and the onset of sperm fertility.","Entity: potassium. SMILES: [K]. The K/Na4 ratio in the cauda epididymidis of the hamster approaches its highest value, coinciding with the plateauing of potassium and sodium levels and the onset of sperm fertility."
sodium,"Sodium concentration in the caput and corpus epididymidis of the hamster is 28.4 ± 0.6 mEq/1 and 31.1 ± 2.0 mEq/1, respectively, higher than in the proximal cauda (13.6 ± 1.2 mEq/1), distal cauda (6.1 ± 0.5 mEq/1), and epididymal vas (6.7 ± 0.6 mEq/1).","Entity: sodium. SMILES: [Na]. Sodium concentration in the caput and corpus epididymidis of the hamster is 28.4 ± 0.6 mEq/1 and 31.1 ± 2.0 mEq/1, respectively, higher than in the proximal cauda (13.6 ± 1.2 mEq/1), distal cauda (6.1 ± 0.5 mEq/1), and epididymal vas (6.7 ± 0.6 mEq/1)."
sodium,"Sodium is secreted between the caput and corpus epididymidis of the hamster, and then reabsorbed between the corpus and cauda.","Entity: sodium. SMILES: [Na]. Sodium is secreted between the caput and corpus epididymidis of the hamster, and then reabsorbed between the corpus and cauda."
sodium,"The sodium concentration in the cauda epididymidis of the hamster is much lower than in the caput or corpus, and is similar to previously reported values in other species.","Entity: sodium. SMILES: [Na]. The sodium concentration in the cauda epididymidis of the hamster is much lower than in the caput or corpus, and is similar to previously reported values in other species."
sodium,"Sodium concentration in the rete testis and caput epididymidis of the hamster decreases from 28.4 mEq/1 to 28.4 mEq/1, indicating net absorption between these regions.","Entity: sodium. SMILES: [Na]. Sodium concentration in the rete testis and caput epididymidis of the hamster decreases from 28.4 mEq/1 to 28.4 mEq/1, indicating net absorption between these regions."
Ammonium phosphate,Ammonium phosphate is used as a diluent in the preparation of tubular fluid samples for ion concentration measurements in the hamster epididymis.,Entity: Ammonium phosphate. SMILES: O=P([O-])([O-])[O-].[NH4+].[NH4+].[NH4+]. Ammonium phosphate is used as a diluent in the preparation of tubular fluid samples for ion concentration measurements in the hamster epididymis.
Cesium nitrate,Cesium nitrate is used as a diluent in the preparation of tubular fluid samples for ion concentration measurements in the hamster epididymis.,Entity: Cesium nitrate. SMILES: O=[N+]([O-])[O-].[Cs+]. Cesium nitrate is used as a diluent in the preparation of tubular fluid samples for ion concentration measurements in the hamster epididymis.
Sodium,Plasma sodium concentrations in the hamster epididymis can be measured using a flame photometer.,Entity: Sodium. SMILES: [Na]. Plasma sodium concentrations in the hamster epididymis can be measured using a flame photometer.
Potassium,"Intratubular potassium concentrations in the hamster epididymis caput are higher (39.3 ± 0.8 mEq/1) than in the proximal cauda (20.8 ± 1.1 mEq/1), distal cauda (23.9 ± 1.0 mEq/1), and epididymal vas (22.2 ± 0.9 mEq/1), with no statistically significant difference between the corpus (4.8 ± 0.9 mEq/1) and proximal cauda/epididymal vas.","Entity: Potassium. SMILES: [K]. Intratubular potassium concentrations in the hamster epididymis caput are higher (39.3 ± 0.8 mEq/1) than in the proximal cauda (20.8 ± 1.1 mEq/1), distal cauda (23.9 ± 1.0 mEq/1), and epididymal vas (22.2 ± 0.9 mEq/1), with no statistically significant difference between the corpus (4.8 ± 0.9 mEq/1) and proximal cauda/epididymal vas."
potassium,"The potassium concentration in the caput of the epididymis is 39.3 ± 4.8 mEq/l, which is significantly higher than in the proximal cauda (20.8 ± 1.1 mEq/l), distal cauda (23.9 ± 1.0 mEq/l), and epididymal vas (22.2 ± 0.9 mEq/l).","Entity: potassium. SMILES: [K]. The potassium concentration in the caput of the epididymis is 39.3 ± 4.8 mEq/l, which is significantly higher than in the proximal cauda (20.8 ± 1.1 mEq/l), distal cauda (23.9 ± 1.0 mEq/l), and epididymal vas (22.2 ± 0.9 mEq/l)."
potassium,Forty-five percent of the potassium present in the caput of the epididymis is absorbed between the caput and the proximal cauda.,Entity: potassium. SMILES: [K]. Forty-five percent of the potassium present in the caput of the epididymis is absorbed between the caput and the proximal cauda.
sodium,"The concentration of sodium in the caput of the epididymis is 28.4 ± 0.6 mEq/l, and in the corpus is 31.1 mEq/l.","Entity: sodium. SMILES: [Na]. The concentration of sodium in the caput of the epididymis is 28.4 ± 0.6 mEq/l, and in the corpus is 31.1 mEq/l."
5-ethyl-5-(1-methylpropyl)-2-thiobarbiturate,5-ethyl-5-(1-methylpropyl)-2-thiobarbiturate (Inactin) is used as an anesthetic agent at a dose of 200 mg/kg body weight in male golden hamsters.,Entity: 5-ethyl-5-(1-methylpropyl)-2-thiobarbiturate. SMILES: CCC(C)C1(CC)C(=O)NC(=S)NC1=O. 5-ethyl-5-(1-methylpropyl)-2-thiobarbiturate (Inactin) is used as an anesthetic agent at a dose of 200 mg/kg body weight in male golden hamsters.
uridine,Uridine is used as a nucleolar label in embryos to assess cell division and embryonic development by measuring the proportion of blastomeres containing labeled nucleoli.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine is used as a nucleolar label in embryos to assess cell division and embryonic development by measuring the proportion of blastomeres containing labeled nucleoli.
Uridine,"Uridine is incorporated into embryonic cells during normal development, with incorporation primarily into heterogeneous nuclear RNA (hnRNA), 4S RNA, and to a lesser extent, precursor ribosomal RNA.","Entity: Uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine is incorporated into embryonic cells during normal development, with incorporation primarily into heterogeneous nuclear RNA (hnRNA), 4S RNA, and to a lesser extent, precursor ribosomal RNA."
oxygen,"Both 5% CO2 in air and 90% nitrogen, 5% CO2, and 5% oxygen are suitable gassing conditions for maintaining fertility in mouse sperm-egg fertilization media.","Entity: oxygen. SMILES: [O]. Both 5% CO2 in air and 90% nitrogen, 5% CO2, and 5% oxygen are suitable gassing conditions for maintaining fertility in mouse sperm-egg fertilization media."
nitrogen,"Nitrogen at 90% concentration, combined with 5% CO2 and 5% oxygen, is suitable for maintaining fertility in mouse sperm-egg fertilization media.","Entity: nitrogen. SMILES: [N]. Nitrogen at 90% concentration, combined with 5% CO2 and 5% oxygen, is suitable for maintaining fertility in mouse sperm-egg fertilization media."
carbon dioxide,"Carbon dioxide at 5% concentration, whether in air or in combination with nitrogen and oxygen, supports fertility in mouse sperm-egg fertilization media.","Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide at 5% concentration, whether in air or in combination with nitrogen and oxygen, supports fertility in mouse sperm-egg fertilization media."
sodium lactate,"Sodium lactate is an important component of the fertilization medium, as its addition consistently increases the proportion of mouse eggs fertilized in vitro.","Entity: sodium lactate. SMILES: CC(O)C(=O)[O-].[Na+]. Sodium lactate is an important component of the fertilization medium, as its addition consistently increases the proportion of mouse eggs fertilized in vitro."
sodium chloride,Lowering sodium chloride to 94.6 mM after the addition of sodium lactate does not improve fertilization rates in mouse eggs in vitro.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Lowering sodium chloride to 94.6 mM after the addition of sodium lactate does not improve fertilization rates in mouse eggs in vitro.
sodium pyruvate,Sodium pyruvate at 0.5 mM is included in modified Tyrode's C medium to support in vitro fertilization of mouse eggs.,Entity: sodium pyruvate. SMILES: CC(=O)C(=O)[O-].[Na+]. Sodium pyruvate at 0.5 mM is included in modified Tyrode's C medium to support in vitro fertilization of mouse eggs.
calcium lactate,"Calcium lactate is used as a source of calcium in modified Krebs-Ringer bicarbonate solutions for in vitro fertilization of mouse eggs, providing 1.71 mM CaC12 in the solution.","Entity: calcium lactate. SMILES: CC(O)C(=O)[O-].CC(O)C(=O)[O-].[Ca+2]. Calcium lactate is used as a source of calcium in modified Krebs-Ringer bicarbonate solutions for in vitro fertilization of mouse eggs, providing 1.71 mM CaC12 in the solution."
calcium chloride,"Calcium chloride is used as a source of calcium in modified Krebs-Ringer bicarbonate solutions for in vitro fertilization of mouse eggs, providing 1.71 mM CaC12 in the solution.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride is used as a source of calcium in modified Krebs-Ringer bicarbonate solutions for in vitro fertilization of mouse eggs, providing 1.71 mM CaC12 in the solution."
calcium chloride,"In modified Tyrode's solution, the concentration of calcium chloride is 1.80 mM, which is higher than in the modified Krebs-Ringer bicarbonate solutions.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. In modified Tyrode's solution, the concentration of calcium chloride is 1.80 mM, which is higher than in the modified Krebs-Ringer bicarbonate solutions."
sodium pyruvate,Sodium pyruvate is used as a component (1.0 mM) in modified Krebs-Ringer bicarbonate solution for in vitro fertilization experiments.,Entity: sodium pyruvate. SMILES: CC(=O)C(=O)[O-].[Na+]. Sodium pyruvate is used as a component (1.0 mM) in modified Krebs-Ringer bicarbonate solution for in vitro fertilization experiments.
glucose,Glucose is included at 5.56 mM concentration in the modified Krebs-Ringer bicarbonate solution used for in vitro fertilization.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is included at 5.56 mM concentration in the modified Krebs-Ringer bicarbonate solution used for in vitro fertilization.
sodium chloride,"Sodium chloride concentration in the fertilization medium is varied between 119.37 mM and 94.6 mM, with lower concentrations (94.6 mM) not increasing fertilization rates in C57BL/6 mouse spermatozoa.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride concentration in the fertilization medium is varied between 119.37 mM and 94.6 mM, with lower concentrations (94.6 mM) not increasing fertilization rates in C57BL/6 mouse spermatozoa."
carbon dioxide,Carbon dioxide is used at 5% concentration in air to maintain incubation at 37°C during in vitro fertilization experiments.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is used at 5% concentration in air to maintain incubation at 37°C during in vitro fertilization experiments.
sodium lactate,"Sodium lactate at 21.58 mM is used as an additive in the fertilization medium, either alone or in combination with lower sodium chloride, for in vitro fertilization studies.","Entity: sodium lactate. SMILES: CC(O)C(=O)[O-].[Na+]. Sodium lactate at 21.58 mM is used as an additive in the fertilization medium, either alone or in combination with lower sodium chloride, for in vitro fertilization studies."
estradiol,"Estradiol (E2) induces differentiation and growth of the oviductal epithelium in cats after ovariectomy, as evidenced by increased ciliated cell numbers and reduced cell height in the fimbriae and ampulla.","Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2O. Estradiol (E2) induces differentiation and growth of the oviductal epithelium in cats after ovariectomy, as evidenced by increased ciliated cell numbers and reduced cell height in the fimbriae and ampulla."
progesterone,"Progesterone (P) antagonizes the effects of estradiol (E2) in the cat oviduct, leading to delayed atrophy and dedifferentiation of the epithelium, with maximal antagonism observed several days after E2 administration.","Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone (P) antagonizes the effects of estradiol (E2) in the cat oviduct, leading to delayed atrophy and dedifferentiation of the epithelium, with maximal antagonism observed several days after E2 administration."
propranolol,Propranolol is administered in large oral doses as part of medical management for patients in the coronary care unit.,Entity: propranolol. SMILES: CC(C)NCC(O)COc1cccc2ccccc12. Propranolol is administered in large oral doses as part of medical management for patients in the coronary care unit.
isosorbide dinitrate,Isosorbide dinitrate is administered sublingually at 5 mg every 3 hours as part of medical management in the coronary care unit.,Entity: isosorbide dinitrate. SMILES: O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]. Isosorbide dinitrate is administered sublingually at 5 mg every 3 hours as part of medical management in the coronary care unit.
nitroglycerin,Nitroglycerin is administered sublingually and as a topical ointment (2%) at 1 to 2 inches every 4 hours as part of medical management in the coronary care unit.,Entity: nitroglycerin. SMILES: O=[N+]([O-])C(O)C(O)CO. Nitroglycerin is administered sublingually and as a topical ointment (2%) at 1 to 2 inches every 4 hours as part of medical management in the coronary care unit.
potassium,"Perfusiate potassium levels in the coronary bypass oxygenator were monitored, and additional potassium was added to the oxygenator if the perfusate level decreased to less than 4.0 mEq/liter during cardiopulmonary bypass.","Entity: potassium. SMILES: [K]. Perfusiate potassium levels in the coronary bypass oxygenator were monitored, and additional potassium was added to the oxygenator if the perfusate level decreased to less than 4.0 mEq/liter during cardiopulmonary bypass."
nitroglycerin,"Nitroglycerin is used to relieve angina pain, but in patients with unstable angina pectoris, pain not completely relieved by nitroglycerin is a diagnostic criterion.","Entity: nitroglycerin. SMILES: O=[N+]([O-])C(O)C(O)CO. Nitroglycerin is used to relieve angina pain, but in patients with unstable angina pectoris, pain not completely relieved by nitroglycerin is a diagnostic criterion."
aluminium,The uptake of aluminium by rat liver nuclei and DNA is specific and can be blocked by prior treatment with stable aluminium.,Entity: aluminium. SMILES: [Al]. The uptake of aluminium by rat liver nuclei and DNA is specific and can be blocked by prior treatment with stable aluminium.
aluminium,"Aluminium may enter liver cells via a specific mechanism and react with DNA inside the hepatocyte nucleus, potentially contributing to the development of aluminium-induced experimental porphyria in rats.","Entity: aluminium. SMILES: [Al]. Aluminium may enter liver cells via a specific mechanism and react with DNA inside the hepatocyte nucleus, potentially contributing to the development of aluminium-induced experimental porphyria in rats."
aluminium,"Aluminium undergoes specific uptake in the rat liver, accumulating in liver cell nuclei and DNA.","Entity: aluminium. SMILES: [Al]. Aluminium undergoes specific uptake in the rat liver, accumulating in liver cell nuclei and DNA."
TRH,"In patients with thyrotoxicosis, plasma PRL response to TRH is impaired, but not absent, as some patients show a normal PRL increment after TRH treatment.","Entity: TRH. In patients with thyrotoxicosis, plasma PRL response to TRH is impaired, but not absent, as some patients show a normal PRL increment after TRH treatment."
PRL,"Plasma PRL levels in patients with thyrotoxicosis can be suppressed by L-dopa and released by metaclopramide, even when thyroid hormone levels are elevated.","Entity: PRL. Plasma PRL levels in patients with thyrotoxicosis can be suppressed by L-dopa and released by metaclopramide, even when thyroid hormone levels are elevated."
18-hydroxycorticosterone,18-hydroxycorticosterone synthesis from triated corticosterone in sheep adrenal homogenate is approximately 98% inhibited by 2 x 10^-4 M SKF 12185.,Entity: 18-hydroxycorticosterone. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(CO)[C@@H](C(=O)CO)CC[C@@H]12. 18-hydroxycorticosterone synthesis from triated corticosterone in sheep adrenal homogenate is approximately 98% inhibited by 2 x 10^-4 M SKF 12185.
calcium,"In growing rats fed a low-phosphorous diet adequate in vitamin-D3, mucosal calcium concentration increases in parallel with duodenal calcium-binding protein and fractional calcium absorption.","Entity: calcium. SMILES: [Ca]. In growing rats fed a low-phosphorous diet adequate in vitamin-D3, mucosal calcium concentration increases in parallel with duodenal calcium-binding protein and fractional calcium absorption."
calcium-binding protein,"In growing rats fed a low-phosphorous diet adequate in vitamin-D3, the mucosal concentration of calcium-binding protein increases in parallel with mucosal calcium concentration, fractional calcium absorption, and duodenal calcium transport capacity.","Entity: calcium-binding protein. In growing rats fed a low-phosphorous diet adequate in vitamin-D3, the mucosal concentration of calcium-binding protein increases in parallel with mucosal calcium concentration, fractional calcium absorption, and duodenal calcium transport capacity."
methylene blue,"Methylene blue accelerates the photoinactivation of T2L by 30-fold when the phage transitions from the fast to the slow form, which may be due to increased reaction rates at higher temperatures favored by the slow form.","Entity: methylene blue. SMILES: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.[Cl-]. Methylene blue accelerates the photoinactivation of T2L by 30-fold when the phage transitions from the fast to the slow form, which may be due to increased reaction rates at higher temperatures favored by the slow form."
methylene blue,Methylene blue is structurally similar to proflavin and is used to measure bacteriophage capsid permeability via photoinactivation.,Entity: methylene blue. SMILES: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.[Cl-]. Methylene blue is structurally similar to proflavin and is used to measure bacteriophage capsid permeability via photoinactivation.
hydroxymethyl cytosine,"Hydroxymethyl cytosine is a DNA base that can be present in phage DNA, replacing cytosine and being further modified by glucosylation.","Entity: hydroxymethyl cytosine. SMILES: O=c1nc(NCO)cc[nH]1. Hydroxymethyl cytosine is a DNA base that can be present in phage DNA, replacing cytosine and being further modified by glucosylation."
glycerol,Glycerol is present at 2.4% in Fraser's medium for phage growth.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is present at 2.4% in Fraser's medium for phage growth.
sodium dihydrogen phosphate,Sodium dihydrogen phosphate is used in a 10x phosphate buffer (Solution B) at 0.074 M and 0.033 M concentrations for phage purification.,Entity: sodium dihydrogen phosphate. SMILES: O=P([O-])(O)O.[Na+]. Sodium dihydrogen phosphate is used in a 10x phosphate buffer (Solution B) at 0.074 M and 0.033 M concentrations for phage purification.
potassium dihydrogen phosphate,Potassium dihydrogen phosphate is included in a 10x phosphate buffer (Solution B) at 0.033 M concentration for phage purification.,Entity: potassium dihydrogen phosphate. SMILES: O=P([O-])(O)O.[K+]. Potassium dihydrogen phosphate is included in a 10x phosphate buffer (Solution B) at 0.033 M concentration for phage purification.
chloroform,Chloroform is used to lyse E. coli cells during phage purification.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used to lyse E. coli cells during phage purification.
ammonium chloride,Ammonium chloride is used as a component of Fraser's medium at a concentration of 0.019 M for phage growth.,Entity: ammonium chloride. SMILES: [Cl-].[NH4+]. Ammonium chloride is used as a component of Fraser's medium at a concentration of 0.019 M for phage growth.
magnesium sulfate,Magnesium sulfate is included in Fraser's medium at a concentration of 0.0025 M for phage growth.,Entity: magnesium sulfate. SMILES: O=S(=O)([O-])[O-].[Mg+2]. Magnesium sulfate is included in Fraser's medium at a concentration of 0.0025 M for phage growth.
calcium chloride,Calcium chloride is used in Fraser's medium at a concentration of 0.0003 M for phage growth.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride is used in Fraser's medium at a concentration of 0.0003 M for phage growth.
hydrogen bromide,"Hydrogen bromide is used to obtain XXIII, a polypentapeptide precursor, from its parent compound.","Entity: hydrogen bromide. SMILES: Br. Hydrogen bromide is used to obtain XXIII, a polypentapeptide precursor, from its parent compound."
water,"Water enables the formation of coacervates, which are necessary for the synthesis of cross-linked polypentapeptide H-(Val-Pro-Gly-#-Gly),-Val-OMe in a filamentous state.","Entity: water. SMILES: O. Water enables the formation of coacervates, which are necessary for the synthesis of cross-linked polypentapeptide H-(Val-Pro-Gly-#-Gly),-Val-OMe in a filamentous state."
water,"Water provides sufficient protonation of one nitrogen atom in carbodiimide, which is necessary for the initial reaction with the gamma-carboxylate anion of glutamic acid residues during cross-linking.","Entity: water. SMILES: O. Water provides sufficient protonation of one nitrogen atom in carbodiimide, which is necessary for the initial reaction with the gamma-carboxylate anion of glutamic acid residues during cross-linking."
ninhydrin,Ninhydrin is used as a reagent in the amino-acid analysis method to detect amino acids after hydrolysis of peptides.,Entity: ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is used as a reagent in the amino-acid analysis method to detect amino acids after hydrolysis of peptides.
hydrochloric acid,Hydrochloric acid (6 N) is used to hydrolyze synthetic intermediates and cross-linked polypentapeptides for amino-acid analysis.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (6 N) is used to hydrolyze synthetic intermediates and cross-linked polypentapeptides for amino-acid analysis.
Boc-Val-Gly-OMe,Boc-Val-Gly-OMe is used as a starting material for the synthesis of active monomers in peptide synthesis.,Entity: Boc-Val-Gly-OMe. SMILES: COC(=O)CNC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C. Boc-Val-Gly-OMe is used as a starting material for the synthesis of active monomers in peptide synthesis.
F3AcOH,F3AcOH is a moderately acidic medium used for selective cleavage of Boc groups during peptide synthesis.,Entity: F3AcOH. SMILES: O=C(O)C(F)(F)F. F3AcOH is a moderately acidic medium used for selective cleavage of Boc groups during peptide synthesis.
triethylamine,Triethylamine is used in excess to facilitate polymerization of active monomers in peptide synthesis.,Entity: triethylamine. SMILES: CCN(CC)CC. Triethylamine is used in excess to facilitate polymerization of active monomers in peptide synthesis.
Boc-Val-Pro-Gly-Val-Gly-ONp,Boc-Val-Pro-Gly-Val-Gly-ONp is a synthetic polypeptide monomer that can be selectively deprotected using mild acidolysis in F3AcOH at -50°C to remove the t-Z group and C-terminal activated esters.,Entity: Boc-Val-Pro-Gly-Val-Gly-ONp. SMILES: CC(C)[C@H](NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)C(=O)NCC(=O)Oc1ccc([N+](=O)[O-])cc1. Boc-Val-Pro-Gly-Val-Gly-ONp is a synthetic polypeptide monomer that can be selectively deprotected using mild acidolysis in F3AcOH at -50°C to remove the t-Z group and C-terminal activated esters.
dimethyl sulfoxide,Anhydrous dimethyl sulfoxide is used as a solvent for the polymerization of active monomers to obtain polypentapeptides.,Entity: dimethyl sulfoxide. SMILES: CS(C)=O. Anhydrous dimethyl sulfoxide is used as a solvent for the polymerization of active monomers to obtain polypentapeptides.
ninhydrin,Ninhydrin is used as a spray reagent to detect molecules with free amino groups on thin-layer chromatography plates.,Entity: ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is used as a spray reagent to detect molecules with free amino groups on thin-layer chromatography plates.
hydrobromic acid,Hydrobromic acid (48%) is used in combination with ninhydrin as a spray reagent for detecting molecules with Z or Boc protecting groups on thin-layer chromatography plates.,Entity: hydrobromic acid. SMILES: Br. Hydrobromic acid (48%) is used in combination with ninhydrin as a spray reagent for detecting molecules with Z or Boc protecting groups on thin-layer chromatography plates.
n-butanol,"n-Butanol is used as a component in the solvent system n-butanol/acetic acid/pyridine/water (15:3:10:12, v/v) for thin-layer chromatography.","Entity: n-butanol. SMILES: CCCCO. n-Butanol is used as a component in the solvent system n-butanol/acetic acid/pyridine/water (15:3:10:12, v/v) for thin-layer chromatography."
pyridine,"Pyridine is used as a component in the solvent system n-butanol/acetic acid/pyridine/water (15:3:10:12, v/v) for thin-layer chromatography.","Entity: pyridine. SMILES: c1ccncc1. Pyridine is used as a component in the solvent system n-butanol/acetic acid/pyridine/water (15:3:10:12, v/v) for thin-layer chromatography."
methanol,"Methanol is used as a solvent in thin-layer chromatography, including in the solvent system chloroform/methanol (5:1, v/v).","Entity: methanol. SMILES: CO. Methanol is used as a solvent in thin-layer chromatography, including in the solvent system chloroform/methanol (5:1, v/v)."
water,"Water is used as a component in the solvent system n-butanol/acetic acid/pyridine/water (15:3:10:12, v/v) for thin-layer chromatography.","Entity: water. SMILES: O. Water is used as a component in the solvent system n-butanol/acetic acid/pyridine/water (15:3:10:12, v/v) for thin-layer chromatography."
acetic acid,"Acetic acid is used as a component in solvent systems for thin-layer chromatography, such as chloroform/methanol/acetic acid (95:5:1, v/v) and n-butanol/acetic acid/pyridine/water (15:3:10:12, v/v).","Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component in solvent systems for thin-layer chromatography, such as chloroform/methanol/acetic acid (95:5:1, v/v) and n-butanol/acetic acid/pyridine/water (15:3:10:12, v/v)."
chloroform,"Chloroform is used as a solvent in thin-layer chromatography, including in the solvent system chloroform/methanol (5:1, v/v).","Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a solvent in thin-layer chromatography, including in the solvent system chloroform/methanol (5:1, v/v)."
tetramethyl silane,Tetramethyl silane is used as an internal reference standard in organic solvents for proton and carbon-13 magnetic resonance spectroscopy.,Entity: tetramethyl silane. SMILES: C[Si](C)(C)C. Tetramethyl silane is used as an internal reference standard in organic solvents for proton and carbon-13 magnetic resonance spectroscopy.
ethylene glycol,Ethylene glycol is used to calibrate sample temperature in proton magnetic resonance spectroscopy.,Entity: ethylene glycol. SMILES: OCCO. Ethylene glycol is used to calibrate sample temperature in proton magnetic resonance spectroscopy.
methanol,Methanol is used to calibrate sample temperature in proton magnetic resonance spectroscopy.,Entity: methanol. SMILES: CO. Methanol is used to calibrate sample temperature in proton magnetic resonance spectroscopy.
sodium dodecyl sulfate,"Sodium dodecyl sulfate at 0.1% (w/v) induces a negative thermal perturbation in the spinae polypeptide backbone, moderating the native α-helix structure and causing a negative shoulder in the CD spectrum from 220 to 215 nm (181 = -13,970).","Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate at 0.1% (w/v) induces a negative thermal perturbation in the spinae polypeptide backbone, moderating the native α-helix structure and causing a negative shoulder in the CD spectrum from 220 to 215 nm (181 = -13,970)."
sodium dodecyl sulfate,Sodium dodecyl sulfate induces a conversion of the spinin polypeptide chain backbone from predominant antiparallel δ-sheet to a moderate α-helix during heating at 90°C for 5 minutes.,Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate induces a conversion of the spinin polypeptide chain backbone from predominant antiparallel δ-sheet to a moderate α-helix during heating at 90°C for 5 minutes.
sodium dodecyl sulfate,Sodium dodecyl sulfate is used at 0.1% (w/v) concentration to denature proteins in phosphate buffer at 90°C for 5 minutes.,Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate is used at 0.1% (w/v) concentration to denature proteins in phosphate buffer at 90°C for 5 minutes.
sodium dodecyl sulfate,"Sodium dodecyl sulfate is used as a denaturing agent in proteins, causing an increase in the magnitude of the 1650–1653 cm⁻¹ band and a decrease in the 1625–1628 cm⁻¹ band in the amide I region of infrared spectra.","Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate is used as a denaturing agent in proteins, causing an increase in the magnitude of the 1650–1653 cm⁻¹ band and a decrease in the 1625–1628 cm⁻¹ band in the amide I region of infrared spectra."
silver chloride,Silver chloride is used as a 2-mm thick disc material for casting films in infrared spectrophotometry.,Entity: silver chloride. SMILES: Cl[Ag]. Silver chloride is used as a 2-mm thick disc material for casting films in infrared spectrophotometry.
nitrogen,Nitrogen is used to purge the spectrophotometer to maintain a dry atmosphere during infrared spectral recording.,Entity: nitrogen. SMILES: [N]. Nitrogen is used to purge the spectrophotometer to maintain a dry atmosphere during infrared spectral recording.
water,Double-distilled water is used as a solvent for dialysis of spina solutions in infrared spectrophotometry.,Entity: water. SMILES: O. Double-distilled water is used as a solvent for dialysis of spina solutions in infrared spectrophotometry.
sodium dodecyl sulfate,Sodium dodecyl sulfate is used at 0.1% concentration as a component of the dialysis buffer for spina solutions in infrared spectrophotometry.,Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate is used at 0.1% concentration as a component of the dialysis buffer for spina solutions in infrared spectrophotometry.
sodium dodecyl sulfate,"Sodium dodecyl sulfate (Na-DodS04) is used to dissociate spinae by heating in the presence or absence of the detergent, enabling analysis of changes in secondary structural modes.","Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate (Na-DodS04) is used to dissociate spinae by heating in the presence or absence of the detergent, enabling analysis of changes in secondary structural modes."
ethylene glycol,The heat of fusion for the collagen-ethylene glycol mixture is reported as 24 cal/g based on conventional melting theory.,Entity: ethylene glycol. SMILES: OCCO. The heat of fusion for the collagen-ethylene glycol mixture is reported as 24 cal/g based on conventional melting theory.
water,The enthalpy change associated with the phase transition in the collagen-water system is reported as 7.2 k-cal/mol using a thermodynamic approach.,Entity: water. SMILES: O. The enthalpy change associated with the phase transition in the collagen-water system is reported as 7.2 k-cal/mol using a thermodynamic approach.
urea,Urea decreases the transition temperature (tt) and the enthalpy change (AH) of the studied system as its concentration increases.,Entity: urea. SMILES: NC(N)=O. Urea decreases the transition temperature (tt) and the enthalpy change (AH) of the studied system as its concentration increases.
sodium iodide,The presence of sodium iodide in solution decreases the transition temperature (tt) and the enthalpy change (AH) of the studied system.,Entity: sodium iodide. SMILES: [I-].[Na+]. The presence of sodium iodide in solution decreases the transition temperature (tt) and the enthalpy change (AH) of the studied system.
sodium chloride,The presence of sodium chloride in solution decreases the transition temperature (tt) and the enthalpy change (AH) of the studied system.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. The presence of sodium chloride in solution decreases the transition temperature (tt) and the enthalpy change (AH) of the studied system.
sodium fluoride,"The presence of sodium fluoride in solution increases the transition temperature (tt) and the enthalpy change (AH) of the studied system, with tt increasing more steeply for fluoride than for chloride above 0.1 M concentration.","Entity: sodium fluoride. SMILES: [F-].[Na+]. The presence of sodium fluoride in solution increases the transition temperature (tt) and the enthalpy change (AH) of the studied system, with tt increasing more steeply for fluoride than for chloride above 0.1 M concentration."
sodium fluoride,Saturation of the effect of sodium fluoride on transition temperature (tt) is reached at about 1 M concentration.,Entity: sodium fluoride. SMILES: [F-].[Na+]. Saturation of the effect of sodium fluoride on transition temperature (tt) is reached at about 1 M concentration.
sodium bromide,The presence of sodium bromide in solution decreases the transition temperature (tt) and the enthalpy change (AH) of the studied system.,Entity: sodium bromide. SMILES: [Br-].[Na+]. The presence of sodium bromide in solution decreases the transition temperature (tt) and the enthalpy change (AH) of the studied system.
formaldehyde,The presence of formaldehyde in solution decreases the transition temperature (tt) and the enthalpy change (AH) of the studied system.,Entity: formaldehyde. SMILES: C=O. The presence of formaldehyde in solution decreases the transition temperature (tt) and the enthalpy change (AH) of the studied system.
sodium bromide,"Sodium bromide forms cross-linking bonds in the presence of formaldehyde and fluoride ions, with a lower entropy change than water alone.","Entity: sodium bromide. SMILES: [Br-].[Na+]. Sodium bromide forms cross-linking bonds in the presence of formaldehyde and fluoride ions, with a lower entropy change than water alone."
sodium chloride,"Sodium chloride forms cross-linking bonds in the presence of formaldehyde and fluoride ions, leading to lower entropy changes compared to water alone.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride forms cross-linking bonds in the presence of formaldehyde and fluoride ions, leading to lower entropy changes compared to water alone."
sodium iodide,"Sodium iodide forms cross-linking bonds in the presence of formaldehyde and fluoride ions, resulting in lower entropy changes than water alone.","Entity: sodium iodide. SMILES: [I-].[Na+]. Sodium iodide forms cross-linking bonds in the presence of formaldehyde and fluoride ions, resulting in lower entropy changes than water alone."
sodium chloride,The molar effectiveness coefficient for sodium chloride in DTA analysis of solid tendon samples follows the order NaCl < MgCl2 < CaCl2.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. The molar effectiveness coefficient for sodium chloride in DTA analysis of solid tendon samples follows the order NaCl < MgCl2 < CaCl2.
sodium fluoride,"Sodium fluoride forms cross-linking bonds in the presence of formaldehyde and water, with a lower entropy change than water alone.","Entity: sodium fluoride. SMILES: [F-].[Na+]. Sodium fluoride forms cross-linking bonds in the presence of formaldehyde and water, with a lower entropy change than water alone."
sodium chloride,"At high concentrations, sodium chloride exhibits a positive molar effectiveness coefficient in DTA analysis, potentially due to differences between solid and reconstituted samples.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. At high concentrations, sodium chloride exhibits a positive molar effectiveness coefficient in DTA analysis, potentially due to differences between solid and reconstituted samples."
magnesium chloride,"Magnesium chloride forms cross-linking bonds in the presence of formaldehyde and fluoride ions, resulting in lower entropy changes than water alone.","Entity: magnesium chloride. SMILES: [Cl-].[Cl-].[Mg+2]. Magnesium chloride forms cross-linking bonds in the presence of formaldehyde and fluoride ions, resulting in lower entropy changes than water alone."
magnesium chloride,The molar effectiveness coefficient for magnesium chloride in DTA analysis of solid tendon samples is higher than that of sodium chloride and calcium chloride.,Entity: magnesium chloride. SMILES: [Cl-].[Cl-].[Mg+2]. The molar effectiveness coefficient for magnesium chloride in DTA analysis of solid tendon samples is higher than that of sodium chloride and calcium chloride.
calcium chloride,"Calcium chloride forms cross-linking bonds in the presence of formaldehyde and fluoride ions, leading to lower entropy changes than water alone.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride forms cross-linking bonds in the presence of formaldehyde and fluoride ions, leading to lower entropy changes than water alone."
calcium chloride,The molar effectiveness coefficient for calcium chloride in DTA analysis of solid tendon samples is lower than that of sodium chloride and magnesium chloride.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. The molar effectiveness coefficient for calcium chloride in DTA analysis of solid tendon samples is lower than that of sodium chloride and magnesium chloride.
water,"Water forms cross-linking bonds in the presence of formaldehyde and fluoride ions, but the presence of diluent can disrupt these hydrogen bonds and reduce the number of available sites for cross-linking.","Entity: water. SMILES: O. Water forms cross-linking bonds in the presence of formaldehyde and fluoride ions, but the presence of diluent can disrupt these hydrogen bonds and reduce the number of available sites for cross-linking."
urea,"Urea forms cross-linking bonds in the presence of formaldehyde and fluoride ions, resulting in lower entropy changes than water alone.","Entity: urea. SMILES: NC(N)=O. Urea forms cross-linking bonds in the presence of formaldehyde and fluoride ions, resulting in lower entropy changes than water alone."
formaldehyde,"For formaldehyde (HCHO), the entropy change increases as a function of the molar concentration of diluents above 0.5 M.","Entity: formaldehyde. SMILES: C=O. For formaldehyde (HCHO), the entropy change increases as a function of the molar concentration of diluents above 0.5 M."
sodium iodide,"For sodium iodide (NaI), the entropy change decreases as the molar concentration of diluents increases.","Entity: sodium iodide. SMILES: [I-].[Na+]. For sodium iodide (NaI), the entropy change decreases as the molar concentration of diluents increases."
sodium bromide,"For sodium bromide (NaBr), the entropy change decreases as the molar concentration of diluents increases.","Entity: sodium bromide. SMILES: [Br-].[Na+]. For sodium bromide (NaBr), the entropy change decreases as the molar concentration of diluents increases."
sodium fluoride,"For sodium fluoride (NaF), the entropy change increases as a function of the molar concentration of diluents.","Entity: sodium fluoride. SMILES: [F-].[Na+]. For sodium fluoride (NaF), the entropy change increases as a function of the molar concentration of diluents."
sodium chloride,"For sodium chloride (NaCl), the entropy change increases as a function of the molar concentration of diluents above 0.5 M.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. For sodium chloride (NaCl), the entropy change increases as a function of the molar concentration of diluents above 0.5 M."
water,"Water can participate in hydrogen bonding interactions with protein residues, including NH–···O and CH–···O hydrogen bonds, which may be stabilized by the presence of certain ions.","Entity: water. SMILES: O. Water can participate in hydrogen bonding interactions with protein residues, including NH–···O and CH–···O hydrogen bonds, which may be stabilized by the presence of certain ions."
sodium chloride,"In the presence of sodium chloride, the association number (A−S) increases as the concentration of sodium chloride increases in studies of NaF, HCHO, and NaCl.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. In the presence of sodium chloride, the association number (A−S) increases as the concentration of sodium chloride increases in studies of NaF, HCHO, and NaCl."
formaldehyde,"Formaldehyde (HCHO) can form hydrogen bonds with protein residues, and its effect on the association number (A−S) increases with higher concentration.","Entity: formaldehyde. SMILES: C=O. Formaldehyde (HCHO) can form hydrogen bonds with protein residues, and its effect on the association number (A−S) increases with higher concentration."
sodium fluoride,"In the presence of sodium fluoride, the association number (A−S) increases as the concentration of sodium fluoride increases in studies of NaF, HCHO, and NaCl.","Entity: sodium fluoride. SMILES: [F-].[Na+]. In the presence of sodium fluoride, the association number (A−S) increases as the concentration of sodium fluoride increases in studies of NaF, HCHO, and NaCl."
bromide ion,"Bromide ion causes a linear depression in transition temperature of collagen, consistent with previously published reports.","Entity: bromide ion. SMILES: [Br-]. Bromide ion causes a linear depression in transition temperature of collagen, consistent with previously published reports."
sodium fluoride,"Sodium fluoride causes a linear depression in transition temperature of collagen, consistent with previously published reports.","Entity: sodium fluoride. SMILES: [F-].[Na+]. Sodium fluoride causes a linear depression in transition temperature of collagen, consistent with previously published reports."
calcium chloride,"Calcium chloride acts as a destabilizing agent of collagen at low concentrations, with its destabilizing effect following the order NaCl < MgCl2 < CaCl2.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride acts as a destabilizing agent of collagen at low concentrations, with its destabilizing effect following the order NaCl < MgCl2 < CaCl2."
magnesium chloride,"Magnesium chloride destabilizes collagen at low concentrations, with its effect following the order NaCl < MgCl2 < CaCl2.","Entity: magnesium chloride. SMILES: [Cl-].[Cl-].[Mg+2]. Magnesium chloride destabilizes collagen at low concentrations, with its effect following the order NaCl < MgCl2 < CaCl2."
urea,"Urea causes a linear decrease in transition temperature of collagen with a molar effectiveness of -4.2, indicating destabilization.","Entity: urea. SMILES: NC(N)=O. Urea causes a linear decrease in transition temperature of collagen with a molar effectiveness of -4.2, indicating destabilization."
iodide ion,"Iodide ion causes a linear depression in transition temperature of collagen, consistent with previously published reports.","Entity: iodide ion. SMILES: [I-]. Iodide ion causes a linear depression in transition temperature of collagen, consistent with previously published reports."
formaldehyde,"Formaldehyde is an effective stabilizer of collagen, causing an elevation in transition temperature, with its stabilizing effect becoming saturable above 0.5 M concentration.","Entity: formaldehyde. SMILES: C=O. Formaldehyde is an effective stabilizer of collagen, causing an elevation in transition temperature, with its stabilizing effect becoming saturable above 0.5 M concentration."
water,Pure water is used as a reference in studies of transition temperature and molar effectiveness of solutes in collagen.,Entity: water. SMILES: O. Pure water is used as a reference in studies of transition temperature and molar effectiveness of solutes in collagen.
sodium chloride,"Sodium chloride destabilizes collagen at low concentrations, with its destabilizing effect being less than that of magnesium chloride and calcium chloride.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride destabilizes collagen at low concentrations, with its destabilizing effect being less than that of magnesium chloride and calcium chloride."
bromine,"The effect of bromine on enthalpy change (AH) is less than that of iodine, but the general trend is similar to that of the tt parameter.","Entity: bromine. SMILES: [Br]. The effect of bromine on enthalpy change (AH) is less than that of iodine, but the general trend is similar to that of the tt parameter."
formaldehyde,Formaldehyde causes an initial increase in enthalpy change (AH) and this effect is also observed in the tt parameter.,Entity: formaldehyde. SMILES: C=O. Formaldehyde causes an initial increase in enthalpy change (AH) and this effect is also observed in the tt parameter.
iodine,"Iodine has a greater effect on enthalpy change (AH) than bromine, though the overall trend is similar to that of the tt parameter.","Entity: iodine. SMILES: [I]. Iodine has a greater effect on enthalpy change (AH) than bromine, though the overall trend is similar to that of the tt parameter."
urea,"Urea exhibits a linearly decreasing behavior of enthalpy change (AH) as a function of concentration, similar to the observed trend in the tt parameter.","Entity: urea. SMILES: NC(N)=O. Urea exhibits a linearly decreasing behavior of enthalpy change (AH) as a function of concentration, similar to the observed trend in the tt parameter."
sodium fluoride,"Sodium fluoride causes saturation in enthalpy change (AH), similar to the saturation observed in the tt parameter.","Entity: sodium fluoride. SMILES: [F-].[Na+]. Sodium fluoride causes saturation in enthalpy change (AH), similar to the saturation observed in the tt parameter."
magnesium chloride,"Magnesium chloride exhibits a linearly decreasing behavior of enthalpy change (AH) as a function of concentration, similar to the observed trend in the tt parameter.","Entity: magnesium chloride. SMILES: [Cl-].[Cl-].[Mg+2]. Magnesium chloride exhibits a linearly decreasing behavior of enthalpy change (AH) as a function of concentration, similar to the observed trend in the tt parameter."
calcium chloride,"Calcium chloride exhibits a linearly decreasing behavior of enthalpy change (AH) as a function of concentration, similar to the observed trend in the tt parameter.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride exhibits a linearly decreasing behavior of enthalpy change (AH) as a function of concentration, similar to the observed trend in the tt parameter."
sodium chloride,Sodium chloride causes saturation in enthalpy change (AH) and shows a less clear saturation in the tt parameter.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride causes saturation in enthalpy change (AH) and shows a less clear saturation in the tt parameter.
water,"In a collagen model, water can form hydrogen bonds with available binding sites, and when water is plentiful, these sites are used to satisfy equations describing water-protein interactions.","Entity: water. SMILES: O. In a collagen model, water can form hydrogen bonds with available binding sites, and when water is plentiful, these sites are used to satisfy equations describing water-protein interactions."
hydroxyproline,The pyrrolydine ring of hydroxyproline contains an OH group that can potentially participate in hydrogen bonding with water molecules.,Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. The pyrrolydine ring of hydroxyproline contains an OH group that can potentially participate in hydrogen bonding with water molecules.
sodium chloride,"Addition of 0.1 M sodium chloride to D2O solution stabilizes the backbone geometry of polynucleotide random coil chains, making it resemble the geometry of unperturbed polynucleotide chains at the same temperature.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. Addition of 0.1 M sodium chloride to D2O solution stabilizes the backbone geometry of polynucleotide random coil chains, making it resemble the geometry of unperturbed polynucleotide chains at the same temperature."
deuterium oxide,Deuterium oxide (D2O) is used as a solvent to study the conformational stability and backbone geometry of polynucleotide random coils in solution.,Entity: deuterium oxide. SMILES: [2H]O[2H]. Deuterium oxide (D2O) is used as a solvent to study the conformational stability and backbone geometry of polynucleotide random coils in solution.
hydrochloric acid,Hydrochloric acid is used to adjust the pH of aqueous solution to the range of 0.8 to 3.0 by titration.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to adjust the pH of aqueous solution to the range of 0.8 to 3.0 by titration.
potassium chloride,Potassium chloride is used to adjust salt molarity in aqueous solution to the range of 0.01 M to 0.20 M by constant-chloride titration.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is used to adjust salt molarity in aqueous solution to the range of 0.01 M to 0.20 M by constant-chloride titration.
guanidine hydrochloride,Guanidine hydrochloride is used as a denaturing agent to study the thermal denaturation of proteins such as lysozyme.,Entity: guanidine hydrochloride. SMILES: Cl.N=C(N)N. Guanidine hydrochloride is used as a denaturing agent to study the thermal denaturation of proteins such as lysozyme.
lysozyme,"Lysozyme in its native state has an average charge (ZN) of approximately +19, as determined by titration data.","Entity: lysozyme. SMILES: CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(C)C)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C. Lysozyme in its native state has an average charge (ZN) of approximately +19, as determined by titration data."
urea,"Urea is a chemical agent used to induce protein unfolding, with the extent of unfolding measurable by intrinsic viscosity.","Entity: urea. SMILES: NC(N)=O. Urea is a chemical agent used to induce protein unfolding, with the extent of unfolding measurable by intrinsic viscosity."
guanidine hydrochloride,"Guanidine hydrochloride is a chemical agent that induces protein unfolding, and its addition to globular proteins can produce additional unfolding transitions beyond those caused by thermal denaturation.","Entity: guanidine hydrochloride. SMILES: Cl.N=C(N)N. Guanidine hydrochloride is a chemical agent that induces protein unfolding, and its addition to globular proteins can produce additional unfolding transitions beyond those caused by thermal denaturation."
KC1,"In protein solutions at 0.2 M KCl concentration, partial protein aggregation is observed upon cooling from 50°C or 60°C after several minutes, as indicated by increased scattered intensity, decreased average diffusion coefficient, and a sharp increase in the variance of diffusion coefficients.","Entity: KC1. SMILES: [Cl-].[K+]. In protein solutions at 0.2 M KCl concentration, partial protein aggregation is observed upon cooling from 50°C or 60°C after several minutes, as indicated by increased scattered intensity, decreased average diffusion coefficient, and a sharp increase in the variance of diffusion coefficients."
guanidine hydrochloride,"Guanidine hydrochloride induces protein denaturation, causing a 45% radius increase (swelling) in lysozyme at 6 M concentration compared to 18% swelling upon temperature-induced denaturation.","Entity: guanidine hydrochloride. SMILES: Cl.N=C(N)N. Guanidine hydrochloride induces protein denaturation, causing a 45% radius increase (swelling) in lysozyme at 6 M concentration compared to 18% swelling upon temperature-induced denaturation."
N-methyl acetamide,A general valence force field has been developed and refined for N-methyl acetamide and some of its deuterated derivatives.,Entity: N-methyl acetamide. SMILES: CNC(C)=O. A general valence force field has been developed and refined for N-methyl acetamide and some of its deuterated derivatives.
dichloroacetic acid,"Dichloroacetic acid induces the formation of an alpha-helical conformation in (Ala-Gly) peptides, as evidenced by increased intensity in the 375-371 cm-' band and enhanced absorption at 527-523 cm-'.","Entity: dichloroacetic acid. SMILES: O=C(O)C(Cl)Cl. Dichloroacetic acid induces the formation of an alpha-helical conformation in (Ala-Gly) peptides, as evidenced by increased intensity in the 375-371 cm-' band and enhanced absorption at 527-523 cm-'."
(Ala-Gly),"(Ala-Gly) peptides adopt an alpha-helical conformation upon treatment with dichloroacetic acid, as shown by a large increase in the 375-371 cm-' band intensity and enhanced absorption at 527-523 cm-'.","Entity: (Ala-Gly). SMILES: C[C@H](N)C(=O)O.NCC(=O)O. (Ala-Gly) peptides adopt an alpha-helical conformation upon treatment with dichloroacetic acid, as shown by a large increase in the 375-371 cm-' band intensity and enhanced absorption at 527-523 cm-'."
N-Methyl acetamide,"N-Methyl acetamide is the simplest molecule with a peptide backbone and has been studied using X-ray diffraction, IR, and Raman spectroscopy to provide information about its structure.","Entity: N-Methyl acetamide. SMILES: CNC(C)=O. N-Methyl acetamide is the simplest molecule with a peptide backbone and has been studied using X-ray diffraction, IR, and Raman spectroscopy to provide information about its structure."
polyethylene,"In crystalline polyethylene, hydrogen bonds (H–··H) between chains are important for determining low-frequency modes due to close contacts of approximately -2.5 Å.","Entity: polyethylene. SMILES: C(C[*:2])[*:1]. In crystalline polyethylene, hydrogen bonds (H–··H) between chains are important for determining low-frequency modes due to close contacts of approximately -2.5 Å."
NAM,"In the context of the described conformational analysis, the NAM residue can form interresidue hydrogen bonds with NAG residues, but local interactions within NAM can destabilize conformations involving these hydrogen bonds.","Entity: NAM. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. In the context of the described conformational analysis, the NAM residue can form interresidue hydrogen bonds with NAG residues, but local interactions within NAM can destabilize conformations involving these hydrogen bonds."
NAG,"NAG residues can participate in interresidue hydrogen bonds with NAM residues, and the presence or absence of such hydrogen bonds depends on the specific conformation adopted by the residues.","Entity: NAG. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. NAG residues can participate in interresidue hydrogen bonds with NAM residues, and the presence or absence of such hydrogen bonds depends on the specific conformation adopted by the residues."
lactic acid,"The lactic acid side chain can adopt different conformations, and placing it in certain conformations (e.g., dihedral angle 5·7°) can disrupt local hydrogen bonding and destabilize the overall conformation by about 6 kcal/mol.","Entity: lactic acid. SMILES: CC(O)C(=O)O. The lactic acid side chain can adopt different conformations, and placing it in certain conformations (e.g., dihedral angle 5·7°) can disrupt local hydrogen bonding and destabilize the overall conformation by about 6 kcal/mol."
NAM,"NAM residues contain a lactic acid side chain, which prevents the formation of a hydrogen bond between the 082H162 (donor) and 010H162 (acceptor) groups due to the absence of a hydrogen on the 02 carbon of NAM.","Entity: NAM. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. NAM residues contain a lactic acid side chain, which prevents the formation of a hydrogen bond between the 082H162 (donor) and 010H162 (acceptor) groups due to the absence of a hydrogen on the 02 carbon of NAM."
NAG,"NAG residues can participate in hydrogen bonding interactions, such as the 082H162→010H162 hydrogen bond, which is not possible in NAM-containing copolymers due to the absence of a hydrogen on the 02 carbon of NAM.","Entity: NAG. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. NAG residues can participate in hydrogen bonding interactions, such as the 082H162→010H162 hydrogen bond, which is not possible in NAM-containing copolymers due to the absence of a hydrogen on the 02 carbon of NAM."
lactic acid,"In oligosaccharides, the dihedral angle (2') of the lactic acid side chain influences the conformational stability and preferred orientation, with angles between -120° and 150° being more likely for oligosaccharides containing NAM in positions other than the first.","Entity: lactic acid. SMILES: CC(O)C(=O)O. In oligosaccharides, the dihedral angle (2') of the lactic acid side chain influences the conformational stability and preferred orientation, with angles between -120° and 150° being more likely for oligosaccharides containing NAM in positions other than the first."
NAG,NAG (N-acetylglucosamine) residues in oligosaccharides can participate in intraresidue and nearest neighbor interactions that stabilize specific conformations.,Entity: NAG. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. NAG (N-acetylglucosamine) residues in oligosaccharides can participate in intraresidue and nearest neighbor interactions that stabilize specific conformations.
NAM,NAM (N-acetylmuramic acid) residues in oligosaccharides can participate in intraresidue and nearest neighbor interactions that stabilize specific conformations.,Entity: NAM. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. NAM (N-acetylmuramic acid) residues in oligosaccharides can participate in intraresidue and nearest neighbor interactions that stabilize specific conformations.
lactic acid,"In the NAG-NAM complex, the lactic acid side chain adopts a conformation with dihedral angle 22 = -60°, which is associated with lower stability.","Entity: lactic acid. SMILES: CC(O)C(=O)O. In the NAG-NAM complex, the lactic acid side chain adopts a conformation with dihedral angle 22 = -60°, which is associated with lower stability."
N-acetylglucosamine,"N-acetylglucosamine is a component of the NAG-NAM (N-acetylglucosamine-N-acetylmuramic acid) complex, where its N-acetyl group can form a hydrogen bond with the -CH'OH group of N-acetylmuramic acid.","Entity: N-acetylglucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. N-acetylglucosamine is a component of the NAG-NAM (N-acetylglucosamine-N-acetylmuramic acid) complex, where its N-acetyl group can form a hydrogen bond with the -CH'OH group of N-acetylmuramic acid."
N-acetylmuramic acid,"N-acetylmuramic acid is a component of the NAG-NAM (N-acetylglucosamine-N-acetylmuramic acid) complex, where its -CH'OH group can participate in hydrogen bonding with the N-acetyl group of N-acetylglucosamine.","Entity: N-acetylmuramic acid. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. N-acetylmuramic acid is a component of the NAG-NAM (N-acetylglucosamine-N-acetylmuramic acid) complex, where its -CH'OH group can participate in hydrogen bonding with the N-acetyl group of N-acetylglucosamine."
N-acetylneuraminic acid,"The conformational energy surface of N-acetylneuraminic acid (NAM) can be explored by examining the low-energy positions of its lactic side chain relative to the N-acetyl and H16Og-groups, and refining these positions by minimization.","Entity: N-acetylneuraminic acid. SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(O)(C(=O)O)C[C@@H]1O. The conformational energy surface of N-acetylneuraminic acid (NAM) can be explored by examining the low-energy positions of its lactic side chain relative to the N-acetyl and H16Og-groups, and refining these positions by minimization."
N-acetylmuramic acid,"N-acetylmuramic acid (NAM) is a residue in the NAM-NAG di-NAG mimic, and its atoms do not interact closely with the lactic acid side chain of the adjacent N-acetylglucosamine (NAG) residue.","Entity: N-acetylmuramic acid. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. N-acetylmuramic acid (NAM) is a residue in the NAM-NAG di-NAG mimic, and its atoms do not interact closely with the lactic acid side chain of the adjacent N-acetylglucosamine (NAG) residue."
lactic acid,"In the NAM-NAG di-NAG mimic, the lactic acid side chain does not make close contacts with the atoms of the adjoining N-acetylglucosamine (NAG) residue.","Entity: lactic acid. SMILES: CC(O)C(=O)O. In the NAM-NAG di-NAG mimic, the lactic acid side chain does not make close contacts with the atoms of the adjoining N-acetylglucosamine (NAG) residue."
N-acetylglucosamine,"N-acetylglucosamine (NAG) is a residue in the NAM-NAG di-NAG mimic, and its atoms do not interact closely with the lactic acid side chain of the adjacent residue.","Entity: N-acetylglucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. N-acetylglucosamine (NAG) is a residue in the NAM-NAG di-NAG mimic, and its atoms do not interact closely with the lactic acid side chain of the adjacent residue."
NAM,"NAM (N-acetylmuramic acid) has a stable dihedral angle of 115° for its side chain (dihedral angle a2), which corresponds to a conformation that minimizes nonbonded contacts with neighboring residues.","Entity: NAM. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. NAM (N-acetylmuramic acid) has a stable dihedral angle of 115° for its side chain (dihedral angle a2), which corresponds to a conformation that minimizes nonbonded contacts with neighboring residues."
NAM,"When the dihedral angle a2 of NAM is changed to -140°, it relieves nonbonded contacts between the -CH3 group of the NAM side chain and the Cg, Cs, 010, and C1 atoms of the preceding NAG residue.","Entity: NAM. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. When the dihedral angle a2 of NAM is changed to -140°, it relieves nonbonded contacts between the -CH3 group of the NAM side chain and the Cg, Cs, 010, and C1 atoms of the preceding NAG residue."
NAM,"The dihedral angle a2 of NAM can be adjusted from 115° to -136° when the side chain dihedral angle is set to -120° and the glycosidic bond angle is 60°, indicating conformational flexibility in NAM.","Entity: NAM. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. The dihedral angle a2 of NAM can be adjusted from 115° to -136° when the side chain dihedral angle is set to -120° and the glycosidic bond angle is 60°, indicating conformational flexibility in NAM."
NAG,"NAG (N-acetylglucosamine) residues can form nonbonded contacts with the -CH3 group of the NAM side chain when the dihedral angles are not optimized, which can contribute to structural strain.","Entity: NAG. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. NAG (N-acetylglucosamine) residues can form nonbonded contacts with the -CH3 group of the NAM side chain when the dihedral angles are not optimized, which can contribute to structural strain."
N-acetylmuramic acid,"The N-acetyl group of N-acetylmuramic acid prevents the lactic acid side chain from rotating toward the neighboring NAG residue, contributing to the conformational stability of NAM-NAG complexes.","Entity: N-acetylmuramic acid. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. The N-acetyl group of N-acetylmuramic acid prevents the lactic acid side chain from rotating toward the neighboring NAG residue, contributing to the conformational stability of NAM-NAG complexes."
N-acetylglucosamine,"In energy minimization studies, N-acetylglucosamine (di-NAG) adopts local minima for its side chain dihedral angles between -120° and +60°, and for the -CH2OH group between -60° and +120°.","Entity: N-acetylglucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. In energy minimization studies, N-acetylglucosamine (di-NAG) adopts local minima for its side chain dihedral angles between -120° and +60°, and for the -CH2OH group between -60° and +120°."
lactic acid,"In energy minimization of NAM-lactic acid complexes, the dihedral angle 2' for the lactic acid side chain is set to either 115° or -60° as starting values.","Entity: lactic acid. SMILES: CC(O)C(=O)O. In energy minimization of NAM-lactic acid complexes, the dihedral angle 2' for the lactic acid side chain is set to either 115° or -60° as starting values."
lactic acid,A strong hydrogen bond can form between the C=O of the lactic acid side chain and the 09H16 group in certain NAM-lactic acid conformers.,Entity: lactic acid. SMILES: CC(O)C(=O)O. A strong hydrogen bond can form between the C=O of the lactic acid side chain and the 09H16 group in certain NAM-lactic acid conformers.
N-acetylmuramic acid,"In energy minimization studies, N-acetylmuramic acid (NAM) adopts local minima for its side chain dihedral angles between -120° and +60°, and for the -CH2OH group between -60° and +120°.","Entity: N-acetylmuramic acid. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. In energy minimization studies, N-acetylmuramic acid (NAM) adopts local minima for its side chain dihedral angles between -120° and +60°, and for the -CH2OH group between -60° and +120°."
lactic acid,"Lactic acid can form stable hydrogen bonds with the C=O of residue 1 in NAM, and its side chain adopts low-energy conformations with dihedral angles 7 and 8 of approximately 120° and -120°, respectively, when dihedral angle 2 is 120°.","Entity: lactic acid. SMILES: CC(O)C(=O)O. Lactic acid can form stable hydrogen bonds with the C=O of residue 1 in NAM, and its side chain adopts low-energy conformations with dihedral angles 7 and 8 of approximately 120° and -120°, respectively, when dihedral angle 2 is 120°."
lactic acid,"When dihedral angle 2 is -60°, lactic acid side chain conformations with dihedral angles 7 and 8 of approximately 120° and -120°, respectively, are possible, and these conformations are energetically favored over the -60° conformer.","Entity: lactic acid. SMILES: CC(O)C(=O)O. When dihedral angle 2 is -60°, lactic acid side chain conformations with dihedral angles 7 and 8 of approximately 120° and -120°, respectively, are possible, and these conformations are energetically favored over the -60° conformer."
N-acetylmuramic acid,"In oligosaccharide nomenclature, the C152 atom refers to the methyl group of the N-acetyl group in the first residue of the reducing end of di-NAG.","Entity: N-acetylmuramic acid. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. In oligosaccharide nomenclature, the C152 atom refers to the methyl group of the N-acetyl group in the first residue of the reducing end of di-NAG."
N-acetylglucosamine,"In oligosaccharide nomenclature, the C152 atom refers to the methyl group of the N-acetyl group in the first residue of the reducing end of di-NAG.","Entity: N-acetylglucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. In oligosaccharide nomenclature, the C152 atom refers to the methyl group of the N-acetyl group in the first residue of the reducing end of di-NAG."
lactic acid,"In oligosaccharide nomenclature, the side-chain atoms of the lactic acid residue in NAM are labeled with superscripts to distinguish them from atoms in other residues.","Entity: lactic acid. SMILES: CC(O)C(=O)O. In oligosaccharide nomenclature, the side-chain atoms of the lactic acid residue in NAM are labeled with superscripts to distinguish them from atoms in other residues."
6-NAM,"The conformation of 6-NAM can be optimized by minimizing its energy using X-ray dihedral angles as a starting point, resulting in a specific conformer.","Entity: 6-NAM. SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(O)(C(=O)O)C[C@@H]1O. The conformation of 6-NAM can be optimized by minimizing its energy using X-ray dihedral angles as a starting point, resulting in a specific conformer."
N-acetylglucosamine,"N-acetylglucosamine (NAG) has been analyzed for its local conformational energy minima, which have been used to predict the low-energy conformers of NAM and all energetically favored conformations of di-, tri-, and higher oligosaccharides containing NAM and NAG.","Entity: N-acetylglucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. N-acetylglucosamine (NAG) has been analyzed for its local conformational energy minima, which have been used to predict the low-energy conformers of NAM and all energetically favored conformations of di-, tri-, and higher oligosaccharides containing NAM and NAG."
N-acetylmuramic acid,N-acetylmuramic acid (NAM) conformers have been predicted based on the local conformational energy minima of NAG and NAM-containing oligosaccharides.,Entity: N-acetylmuramic acid. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. N-acetylmuramic acid (NAM) conformers have been predicted based on the local conformational energy minima of NAG and NAM-containing oligosaccharides.
glucose,A simple method for searching the entire conformational space has been applied to derivatives of glucose to identify its low-energy conformers.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. A simple method for searching the entire conformational space has been applied to derivatives of glucose to identify its low-energy conformers.
N-acetylmuramic acid,"N-acetylmuramic acid exists in two anomeric forms, the n-anomer and the 6-anomer, with the lowest energy conformations of the n-anomer being similar to those determined by X-ray analysis.","Entity: N-acetylmuramic acid. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. N-acetylmuramic acid exists in two anomeric forms, the n-anomer and the 6-anomer, with the lowest energy conformations of the n-anomer being similar to those determined by X-ray analysis."
N-acetylglucosamine,N-acetylglucosamine has a conformational preference for its N-acetyl group that closely matches the conformation determined by X-ray analysis.,Entity: N-acetylglucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. N-acetylglucosamine has a conformational preference for its N-acetyl group that closely matches the conformation determined by X-ray analysis.
N-acetylglucosamine,The bond lengths and bond angles for the amide group of N-acetylglucosamine are the same as those used by Momany et al.,Entity: N-acetylglucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. The bond lengths and bond angles for the amide group of N-acetylglucosamine are the same as those used by Momany et al.
N-acetylmuramic acid,The bond lengths and bond angles for the amide group of N-acetylmuramic acid are the same as those used by Momany et al.,Entity: N-acetylmuramic acid. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. The bond lengths and bond angles for the amide group of N-acetylmuramic acid are the same as those used by Momany et al.
D-lactic acid,The bond lengths and bond angles for the D-lactic acid group in both alpha- and beta-N-acetylmuramic acid are derived from the crystallographic structure of alpha-N-acetylmuramic acid.,Entity: D-lactic acid. SMILES: C[C@@H](O)C(=O)O. The bond lengths and bond angles for the D-lactic acid group in both alpha- and beta-N-acetylmuramic acid are derived from the crystallographic structure of alpha-N-acetylmuramic acid.
N-acetylmuramic acid,"N-acetylmuramic acid is a derivative of D-glucosamine, with a hexopyranosyl ring in the C1 conformation and a nitrogen atom attached to the carbon adjacent to the glycosidic carbon atom of the ring.","Entity: N-acetylmuramic acid. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. N-acetylmuramic acid is a derivative of D-glucosamine, with a hexopyranosyl ring in the C1 conformation and a nitrogen atom attached to the carbon adjacent to the glycosidic carbon atom of the ring."
N-acetylglucosamine,"N-acetylglucosamine is a derivative of D-glucosamine, featuring a hexopyranosyl ring in the C1 conformation with a nitrogen atom attached to the carbon adjacent to the glycosidic carbon atom of the ring.","Entity: N-acetylglucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. N-acetylglucosamine is a derivative of D-glucosamine, featuring a hexopyranosyl ring in the C1 conformation with a nitrogen atom attached to the carbon adjacent to the glycosidic carbon atom of the ring."
N-acetylmuramic acid,"In the described conformational analysis, a conformer of N-acetylmuramic acid was found with a dihedral angle of approximately 70° for dihedral angle 1 and close to 120° for dihedral angle 2, stabilized by a hydrogen bond between the NH of the N-acetyl group and the C=O of the lactic acid side chain, and this structure closely matches the X-ray crystallography structure.","Entity: N-acetylmuramic acid. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)O. In the described conformational analysis, a conformer of N-acetylmuramic acid was found with a dihedral angle of approximately 70° for dihedral angle 1 and close to 120° for dihedral angle 2, stabilized by a hydrogen bond between the NH of the N-acetyl group and the C=O of the lactic acid side chain, and this structure closely matches the X-ray crystallography structure."
N-acetylmuramic acid amide,"A conformer of N-acetylmuramic acid amide was identified with a dihedral angle of approximately 70° for dihedral angle 1 and close to 120° for dihedral angle 2, stabilized by a hydrogen bond between the NH of the N-acetyl group and the C=O of the lactic acid side chain, and this structure closely matches the X-ray crystallography structure.","Entity: N-acetylmuramic acid amide. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(N)=O. A conformer of N-acetylmuramic acid amide was identified with a dihedral angle of approximately 70° for dihedral angle 1 and close to 120° for dihedral angle 2, stabilized by a hydrogen bond between the NH of the N-acetyl group and the C=O of the lactic acid side chain, and this structure closely matches the X-ray crystallography structure."
N-acetyl-(S)-thiazolidine-4-carboxamide,"N-acetyl-(S)-thiazolidine-4-carboxamide forms hydrogen-bonded networks in the solid state, with hydrogen-bond lengths of N2H···O1 = 2.887 Å and N2H···O0 = 3.046 Å, and both carbonyl groups participate in hydrogen bonding.","Entity: N-acetyl-(S)-thiazolidine-4-carboxamide. SMILES: CC(=O)NC(=O)[C@H]1CSCN1. N-acetyl-(S)-thiazolidine-4-carboxamide forms hydrogen-bonded networks in the solid state, with hydrogen-bond lengths of N2H···O1 = 2.887 Å and N2H···O0 = 3.046 Å, and both carbonyl groups participate in hydrogen bonding."
N-acetyl-L-prolinamide,"N-acetyl-L-prolinamide forms hydrogen-bonded networks in the solid state, with hydrogen-bond lengths of N2H···O1 = 2.896 Å and N2H···O0 = 3.071 Å, and both carbonyl groups participate in hydrogen bonding.","Entity: N-acetyl-L-prolinamide. SMILES: CC(=O)NC(=O)[C@@H]1CCCN1. N-acetyl-L-prolinamide forms hydrogen-bonded networks in the solid state, with hydrogen-bond lengths of N2H···O1 = 2.896 Å and N2H···O0 = 3.071 Å, and both carbonyl groups participate in hydrogen bonding."
N-acetyl-L-prolinamide,The crystal structure of N-acetyl-L-prolinamide has been determined and reported in the literature.,Entity: N-acetyl-L-prolinamide. SMILES: CC(=O)NC(=O)[C@@H]1CCCN1. The crystal structure of N-acetyl-L-prolinamide has been determined and reported in the literature.
N-acetyl-L-prolinamide,N-acetyl-L-prolinamide forms isomorphous crystal structures with N'-acetyl-(S)-thiazolidine-4-carboxamide.,Entity: N-acetyl-L-prolinamide. SMILES: CC(=O)NC(=O)[C@@H]1CCCN1. N-acetyl-L-prolinamide forms isomorphous crystal structures with N'-acetyl-(S)-thiazolidine-4-carboxamide.
N-acetyl-(S)-thiazolidine-4-carboxamide,N-acetyl-(S)-thiazolidine-4-carboxamide forms isomorphous crystal structures with N-acetyl-L-prolinamide.,Entity: N-acetyl-(S)-thiazolidine-4-carboxamide. SMILES: CC(=O)NC(=O)[C@H]1CSCN1. N-acetyl-(S)-thiazolidine-4-carboxamide forms isomorphous crystal structures with N-acetyl-L-prolinamide.
N-acetyl-L-prolinamide,"N-acetyl-L-prolinamide has two carboxamide hydrogens, which can favor intermolecular hydrogen bonding in molecular arrangements.","Entity: N-acetyl-L-prolinamide. SMILES: CC(=O)NC(=O)[C@@H]1CCCN1. N-acetyl-L-prolinamide has two carboxamide hydrogens, which can favor intermolecular hydrogen bonding in molecular arrangements."
N-AcetyI-(S)-Thiazolidine-4-Carboxamide,N-AcetyI-(S)-Thiazolidine-4-Carboxamide crystallizes in the orthorhombic crystal system with space group P212121 and is isomorphous with its N-acetyl-(S)-thiazolidine-4-carboxamide form.,Entity: N-AcetyI-(S)-Thiazolidine-4-Carboxamide. SMILES: CC(=O)NC(=O)[C@H]1CSCN1. N-AcetyI-(S)-Thiazolidine-4-Carboxamide crystallizes in the orthorhombic crystal system with space group P212121 and is isomorphous with its N-acetyl-(S)-thiazolidine-4-carboxamide form.
N-acetyl-L-prolinamide,"N-acetyl-L-prolinamide crystallizes in two different unit cell dimensions, one obtained at room temperature (23°C) and the other at approximately -150°C.","Entity: N-acetyl-L-prolinamide. SMILES: CC(=O)NC(=O)[C@@H]1CCCN1. N-acetyl-L-prolinamide crystallizes in two different unit cell dimensions, one obtained at room temperature (23°C) and the other at approximately -150°C."
N-acetyl-(S)-thiazolidine-4-carboxamide,"N-acetyl-(S)-thiazolidine-4-carboxamide has a crystal structure that was solved by the Patterson method, with the sulfur atom located and subsequent difference Fourier transformation yielding the positions of all atoms except hydrogens.","Entity: N-acetyl-(S)-thiazolidine-4-carboxamide. SMILES: CC(=O)NC(=O)[C@H]1CSCN1. N-acetyl-(S)-thiazolidine-4-carboxamide has a crystal structure that was solved by the Patterson method, with the sulfur atom located and subsequent difference Fourier transformation yielding the positions of all atoms except hydrogens."
N-acetyl-(S)-thiazolidine-4-carboxamide,"The structure of N-acetyl-(S)-thiazolidine-4-carboxamide was refined using full matrix least squares procedures, resulting in an R value of 0.14 for 789 measured reflections and an R value of 0.059 after anisotropic refinement for heavy atoms and isotropic temperature factors for hydrogen atoms.","Entity: N-acetyl-(S)-thiazolidine-4-carboxamide. SMILES: CC(=O)NC(=O)[C@H]1CSCN1. The structure of N-acetyl-(S)-thiazolidine-4-carboxamide was refined using full matrix least squares procedures, resulting in an R value of 0.14 for 789 measured reflections and an R value of 0.059 after anisotropic refinement for heavy atoms and isotropic temperature factors for hydrogen atoms."
N-acetyl prolinamide,"N-acetyl prolinamide can adopt a seven-membered ring conformation in dilute nonpolar solvents as shown by IR, ORD, and CD measurements.","Entity: N-acetyl prolinamide. SMILES: CC(=O)NC(=O)[C@@H]1CCCN1. N-acetyl prolinamide can adopt a seven-membered ring conformation in dilute nonpolar solvents as shown by IR, ORD, and CD measurements."
Me2SO,Me2SO is a solvent in which NMR studies have shown that thyroliberin (L-PY-roglutamyl-L-histidyl-L-prolinamide) adopts an extended conformation with short-range interaction between the prolyl carboxamide and the unprotonated histidine side-chain residue.,Entity: Me2SO. SMILES: CS(C)=O. Me2SO is a solvent in which NMR studies have shown that thyroliberin (L-PY-roglutamyl-L-histidyl-L-prolinamide) adopts an extended conformation with short-range interaction between the prolyl carboxamide and the unprotonated histidine side-chain residue.
N-acetyl proline methylamide,"N-acetyl proline methylamide can adopt a seven-membered ring conformation in dilute nonpolar solvents as shown by IR, ORD, and CD measurements.","Entity: N-acetyl proline methylamide. SMILES: CNC(=O)[C@@H]1CCCN1C(C)=O. N-acetyl proline methylamide can adopt a seven-membered ring conformation in dilute nonpolar solvents as shown by IR, ORD, and CD measurements."
cyclo(Pro-Pro),"In cyclo(Pro-Pro), the central pyrrolidine ring adopts a twist conformation, with Cδ and Cβ atoms positioned on opposite sides of the plane formed by the remaining three atoms.","Entity: cyclo(Pro-Pro). SMILES: O=C1C2CCCN2C(=O)C2CCCN12. In cyclo(Pro-Pro), the central pyrrolidine ring adopts a twist conformation, with Cδ and Cβ atoms positioned on opposite sides of the plane formed by the remaining three atoms."
acetyl-L-proline N-methylamide,"The crystal structure of acetyl-L-proline N-methylamide exhibits a molecular conformation with ε = -77° and π/ π = -16°, which is close to the right-handed α-helix region.","Entity: acetyl-L-proline N-methylamide. SMILES: CNC(=O)[C@@H]1CCCN1C(C)=O. The crystal structure of acetyl-L-proline N-methylamide exhibits a molecular conformation with ε = -77° and π/ π = -16°, which is close to the right-handed α-helix region."
acetyl-L-proline N-methylamide,"In the crystal structure of acetyl-L-proline N-methylamide, molecules are intermolecularly hydrogen bonded to form chains.","Entity: acetyl-L-proline N-methylamide. SMILES: CNC(=O)[C@@H]1CCCN1C(C)=O. In the crystal structure of acetyl-L-proline N-methylamide, molecules are intermolecularly hydrogen bonded to form chains."
N-acetyl-(S)-thiazolidine-4-carboxamide,"In the solid state, the tertiary amide of N-acetyl-(S)-thiazolidine-4-carboxamide adopts a trans configuration, with the carbonyl oxygen atom ̑ 1 to the CA carbon atom.","Entity: N-acetyl-(S)-thiazolidine-4-carboxamide. SMILES: CC(=O)NC(=O)[C@H]1CSCN1. In the solid state, the tertiary amide of N-acetyl-(S)-thiazolidine-4-carboxamide adopts a trans configuration, with the carbonyl oxygen atom ̑ 1 to the CA carbon atom."
N-acetyl-(S)-thiazolidine-4-carboxamide,The dihedral angle between the tertiary amide plane and the five-membered ring plane in N-acetyl-(S)-thiazolidine-4-carboxamide is -171°.,Entity: N-acetyl-(S)-thiazolidine-4-carboxamide. SMILES: CC(=O)NC(=O)[C@H]1CSCN1. The dihedral angle between the tertiary amide plane and the five-membered ring plane in N-acetyl-(S)-thiazolidine-4-carboxamide is -171°.
acetyl thiazolidine amine,"In the solid state, the primary amide (N-H) group of acetyl thiazolidine amine is over the ring plane, with a dihedral angle of -9° between the primary amide plane and the mean ring plane.","Entity: acetyl thiazolidine amine. SMILES: CC(=O)C1(N)NCCS1. In the solid state, the primary amide (N-H) group of acetyl thiazolidine amine is over the ring plane, with a dihedral angle of -9° between the primary amide plane and the mean ring plane."
acetyl proline,"In the solid state, the primary amide (N-H) group of acetyl proline is over the ring plane, with a dihedral angle of -14° between the primary amide plane and the mean ring plane.","Entity: acetyl proline. SMILES: CC(=O)N1CCC[C@H]1C(=O)O. In the solid state, the primary amide (N-H) group of acetyl proline is over the ring plane, with a dihedral angle of -14° between the primary amide plane and the mean ring plane."
N-acetyl-L-prolinamide,"In the solid state, the tertiary amide of N-acetyl-L-prolinamide adopts a trans configuration, with the carbonyl oxygen atom ̑ 1 to the CA carbon atom.","Entity: N-acetyl-L-prolinamide. SMILES: CC(=O)NC(=O)[C@@H]1CCCN1. In the solid state, the tertiary amide of N-acetyl-L-prolinamide adopts a trans configuration, with the carbonyl oxygen atom ̑ 1 to the CA carbon atom."
N-acetyl-L-prolinamide,The dihedral angle between the tertiary amide plane and the five-membered ring plane in N-acetyl-L-prolinamide is -176°.,Entity: N-acetyl-L-prolinamide. SMILES: CC(=O)NC(=O)[C@@H]1CCCN1. The dihedral angle between the tertiary amide plane and the five-membered ring plane in N-acetyl-L-prolinamide is -176°.
leucyl-prolylglycine,"In the crystal structure of leucyl-prolylglycine, the carbon atom (Cr) of the proline ring deviates from the plane formed by the other four ring atoms by 0.26–0.60 Å.","Entity: leucyl-prolylglycine. SMILES: CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O. In the crystal structure of leucyl-prolylglycine, the carbon atom (Cr) of the proline ring deviates from the plane formed by the other four ring atoms by 0.26–0.60 Å."
p-bromocarbobenzoxyglycyl-prolyl-leucyl-glycine,"In p-bromocarbobenzoxyglycyl-prolyl-leucyl-glycine, the carbon atom (C'i) of the proline ring puckers on the opposite side of the succeeding peptide bond.","Entity: p-bromocarbobenzoxyglycyl-prolyl-leucyl-glycine. SMILES: CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)OCc1ccc(Br)cc1)C(=O)NCC(=O)O. In p-bromocarbobenzoxyglycyl-prolyl-leucyl-glycine, the carbon atom (C'i) of the proline ring puckers on the opposite side of the succeeding peptide bond."
N-tosyl-prolyl-hydroxyproline,"In N-tosyl-prolyl-hydroxyproline, the carbon atom (Cy) of the proline ring puckers on the same side of the succeeding peptide bond.","Entity: N-tosyl-prolyl-hydroxyproline. SMILES: Cc1ccc(S(=O)(=O)N2CCC[C@H]2C(=O)N2C[C@H](O)C[C@H]2C(=O)O)cc1. In N-tosyl-prolyl-hydroxyproline, the carbon atom (Cy) of the proline ring puckers on the same side of the succeeding peptide bond."
N-acetyl-proline-N-methylamide,"In N-acetyl-proline-N-methylamide, the carbon atom (Cy) of the proline ring puckers on the same side of the succeeding peptide bond.","Entity: N-acetyl-proline-N-methylamide. SMILES: CNC(=O)[C@@H]1CCCN1C(C)=O. In N-acetyl-proline-N-methylamide, the carbon atom (Cy) of the proline ring puckers on the same side of the succeeding peptide bond."
N-acetyl-L-prolinamide,"N-acetyl-L-prolinamide exhibits differences in bond lengths and geometries between room-temperature and low-temperature X-ray diffraction data, attributed to molecular vibration and thermal factors.","Entity: N-acetyl-L-prolinamide. SMILES: CC(=O)NC(=O)[C@@H]1CCCN1. N-acetyl-L-prolinamide exhibits differences in bond lengths and geometries between room-temperature and low-temperature X-ray diffraction data, attributed to molecular vibration and thermal factors."
N-acetyl-thiazolidine-4-carboxamide,"The structure of N-acetyl-thiazolidine-4-carboxamide was determined using room-temperature X-ray diffraction data, which results in larger thermal factors and greater standard deviations in atomic parameters compared to low-temperature data.","Entity: N-acetyl-thiazolidine-4-carboxamide. SMILES: CC(=O)NC(=O)C1CSCN1. The structure of N-acetyl-thiazolidine-4-carboxamide was determined using room-temperature X-ray diffraction data, which results in larger thermal factors and greater standard deviations in atomic parameters compared to low-temperature data."
N-acetyl-(S)-thiazolidine-4-carboxamide,"N-acetyl-(S)-thiazolidine-4-carboxamide has a molecular geometry that closely resembles that of N-acetyl-L-proline-N'-methylamide and can be described in the solid state by three planes: the primary amide grouping, the tertiary amide grouping, and the pyrrolidine or thiazolidine ring system.","Entity: N-acetyl-(S)-thiazolidine-4-carboxamide. SMILES: CC(=O)NC(=O)[C@H]1CSCN1. N-acetyl-(S)-thiazolidine-4-carboxamide has a molecular geometry that closely resembles that of N-acetyl-L-proline-N'-methylamide and can be described in the solid state by three planes: the primary amide grouping, the tertiary amide grouping, and the pyrrolidine or thiazolidine ring system."
N-acetyl-L-prolinamide,"N-acetyl-L-prolinamide has a molecular geometry very similar to N-acetyl-(S)-thiazolidine-4-carboxamide and can be described in the solid state by three planes: the primary amide grouping, the tertiary amide grouping, and the pyrrolidine or thiazolidine ring system.","Entity: N-acetyl-L-prolinamide. SMILES: CC(=O)NC(=O)[C@@H]1CCCN1. N-acetyl-L-prolinamide has a molecular geometry very similar to N-acetyl-(S)-thiazolidine-4-carboxamide and can be described in the solid state by three planes: the primary amide grouping, the tertiary amide grouping, and the pyrrolidine or thiazolidine ring system."
isobutane,Isobutane is used as a reagent gas in gas-liquid chromatography for the analysis of polyunsaturated fatty acids.,Entity: isobutane. SMILES: CC(C)C. Isobutane is used as a reagent gas in gas-liquid chromatography for the analysis of polyunsaturated fatty acids.
trimethylsilyl ether,Trimethylsilyl ether derivatization is useful for locating double bonds in unsaturated fatty acids during chemical ionization mass spectrometry.,Entity: trimethylsilyl ether. SMILES: C[Si](C)(C)O[Si](C)(C)C. Trimethylsilyl ether derivatization is useful for locating double bonds in unsaturated fatty acids during chemical ionization mass spectrometry.
salinomycin,"Salinomycin free acid exhibits prominent peaks in the mass spectrum at m/e 773 [M+Na]+, 751, 185, 143, and 113, corresponding to its A and E rings.","Entity: salinomycin. SMILES: CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C. Salinomycin free acid exhibits prominent peaks in the mass spectrum at m/e 773 [M+Na]+, 751, 185, 143, and 113, corresponding to its A and E rings."
narasin,"Narasin contains an extra methyl group on the A ring, a feature attributed to biogenetic reasons and confirmed by mass spectrometry analysis of its p-iodophenacyl ester.","Entity: narasin. SMILES: CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C. Narasin contains an extra methyl group on the A ring, a feature attributed to biogenetic reasons and confirmed by mass spectrometry analysis of its p-iodophenacyl ester."
narasin,"The molecular ion of the sodium salt of A28086B, a compound isolated from fermentation that yields narasin, has a composition of C43H69O11Na, indicating two fewer hydrogen atoms than in sodium narasin.","Entity: narasin. SMILES: CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C. The molecular ion of the sodium salt of A28086B, a compound isolated from fermentation that yields narasin, has a composition of C43H69O11Na, indicating two fewer hydrogen atoms than in sodium narasin."
A28086B,"A28086B, a fermentation-derived compound that yields narasin, has an accurate mass composition of C43H69O11Na, which is two hydrogen atoms less than the sodium salt of narasin.","Entity: A28086B. SMILES: CCC(C(=O)O)C1OC(C(C)C(O)C(C)C(=O)C(CC)C2OC3(C=CC(=O)C4(CCC(C)(C5CCC(O)(CC)C(C)O5)O4)O3)C(C)CC2C)C(C)CC1C. A28086B, a fermentation-derived compound that yields narasin, has an accurate mass composition of C43H69O11Na, which is two hydrogen atoms less than the sodium salt of narasin."
narasin,"Narasin has a molecular structure with one more methyl (CH3) group than salinomycin, as indicated by mass spectral data.","Entity: narasin. SMILES: CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C. Narasin has a molecular structure with one more methyl (CH3) group than salinomycin, as indicated by mass spectral data."
narasin,"Narasin and salinomycin have similar molecular skeletons and exhibit overlapping proton NMR, CD, and IR spectra, supporting their structural similarity.","Entity: narasin. SMILES: CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C. Narasin and salinomycin have similar molecular skeletons and exhibit overlapping proton NMR, CD, and IR spectra, supporting their structural similarity."
salinomycin,Salinomycin is a compound with a defined fragmentation pattern that can be used to rationalize the structure of related molecules such as narasin.,Entity: salinomycin. SMILES: CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C. Salinomycin is a compound with a defined fragmentation pattern that can be used to rationalize the structure of related molecules such as narasin.
salinomycin,"Salinomycin free acid can scavenge sodium ions from an ion source that has been previously exposed to sodium salts, including those of other ionophores.","Entity: salinomycin. SMILES: CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C. Salinomycin free acid can scavenge sodium ions from an ion source that has been previously exposed to sodium salts, including those of other ionophores."
narasin,"Narasin free acid can scavenge sodium ions from an ion source that has been previously exposed to sodium salts, including those of other ionophores.","Entity: narasin. SMILES: CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C. Narasin free acid can scavenge sodium ions from an ion source that has been previously exposed to sodium salts, including those of other ionophores."
narasin,"Narasin is a compound with a methyl group located to the left of fission 'a' in its fragmentation scheme, as indicated by mass spectrometry analysis.","Entity: narasin. SMILES: CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C. Narasin is a compound with a methyl group located to the left of fission 'a' in its fragmentation scheme, as indicated by mass spectrometry analysis."
salinomycin,"Salinomycin can be fragmented to yield two possible structures at m/e 530 and 508, which are partially shifted to m/e 544 and 522 in the spectrum of narasin.","Entity: salinomycin. SMILES: CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C. Salinomycin can be fragmented to yield two possible structures at m/e 530 and 508, which are partially shifted to m/e 544 and 522 in the spectrum of narasin."
narasin,Narasin is an ionophore whose structural complexity necessitates X-ray crystallography for detailed elucidation.,Entity: narasin. SMILES: CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C. Narasin is an ionophore whose structural complexity necessitates X-ray crystallography for detailed elucidation.
salinomycin,Salinomycin is an ionophore with structural complexity that requires X-ray crystallography for detailed structural analysis.,Entity: salinomycin. SMILES: CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C. Salinomycin is an ionophore with structural complexity that requires X-ray crystallography for detailed structural analysis.
narasin,Narasin is a compound whose structure can be proposed based on ionic fragmentation patterns analyzed by electron impact and field desorption mass spectrometry.,Entity: narasin. SMILES: CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C. Narasin is a compound whose structure can be proposed based on ionic fragmentation patterns analyzed by electron impact and field desorption mass spectrometry.
A28086B,A28086B is an ionophore structurally related to narasin and can be characterized by its ionic fragmentation pattern as determined by mass spectrometry.,Entity: A28086B. SMILES: CCC(C(=O)O)C1OC(C(C)C(O)C(C)C(=O)C(CC)C2OC3(C=CC(=O)C4(CCC(C)(C5CCC(O)(CC)C(C)O5)O4)O3)C(C)CC2C)C(C)CC1C. A28086B is an ionophore structurally related to narasin and can be characterized by its ionic fragmentation pattern as determined by mass spectrometry.
salinomycin,The structure of salinomycin has been determined by X-ray diffraction.,Entity: salinomycin. SMILES: CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C. The structure of salinomycin has been determined by X-ray diffraction.
A28086B,"A28086B contains a -CH=CH-CO-chromophore, as indicated by an ultraviolet absorption at 220 nm with an extinction coefficient of 10,480.","Entity: A28086B. SMILES: CCC(C(=O)O)C1OC(C(C)C(O)C(C)C(=O)C(CC)C2OC3(C=CC(=O)C4(CCC(C)(C5CCC(O)(CC)C(C)O5)O4)O3)C(C)CC2C)C(C)CC1C. A28086B contains a -CH=CH-CO-chromophore, as indicated by an ultraviolet absorption at 220 nm with an extinction coefficient of 10,480."
narasin,Narasin contains a secondary alcohol group on the C ring of its carbon skeleton.,Entity: narasin. SMILES: CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C. Narasin contains a secondary alcohol group on the C ring of its carbon skeleton.
A28086B,A28086B differs from narasin by having a keto group in place of the secondary alcohol group on the C ring of the carbon skeleton.,Entity: A28086B. SMILES: CCC(C(=O)O)C1OC(C(C)C(O)C(C)C(=O)C(CC)C2OC3(C=CC(=O)C4(CCC(C)(C5CCC(O)(CC)C(C)O5)O4)O3)C(C)CC2C)C(C)CC1C. A28086B differs from narasin by having a keto group in place of the secondary alcohol group on the C ring of the carbon skeleton.
progesterone,Some benign ovarian tumours (cysts) can contain abnormally large amounts of progesterone.,Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Some benign ovarian tumours (cysts) can contain abnormally large amounts of progesterone.
progesterone,Progesterone levels in ovarian tissue can be directly quantified by quantitative high resolution mass fragmentography without the need for extraction or purification.,Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone levels in ovarian tissue can be directly quantified by quantitative high resolution mass fragmentography without the need for extraction or purification.
sodium sulfate,Sodium sulfate anhydrous is used as an inert solid carrier for preparing calibration mixtures of steroids in quantitative mass spectrometry analysis.,Entity: sodium sulfate. SMILES: O=S(=O)([O-])[O-].[Na+].[Na+]. Sodium sulfate anhydrous is used as an inert solid carrier for preparing calibration mixtures of steroids in quantitative mass spectrometry analysis.
progesterone,Progesterone is a steroid hormone whose molecular ion can be detected by high resolution mass spectrometry and used for quantitative measurement in dried tissue samples.,Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone is a steroid hormone whose molecular ion can be detected by high resolution mass spectrometry and used for quantitative measurement in dried tissue samples.
ellipticine,Ellipticine (NSC 71795) is an antitumor agent whose major metabolites in rats are two hydroxylated conjugates secreted in bile.,Entity: ellipticine. SMILES: Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12. Ellipticine (NSC 71795) is an antitumor agent whose major metabolites in rats are two hydroxylated conjugates secreted in bile.
ellipticine,The major metabolic pathway of elipticine prior to conjugation and excretion in rat bile involves aromatic hydroxylation without an arene oxide/NIH shift mechanism.,Entity: ellipticine. SMILES: Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12. The major metabolic pathway of elipticine prior to conjugation and excretion in rat bile involves aromatic hydroxylation without an arene oxide/NIH shift mechanism.
oxygen,Oxygenases catalyze the oxidation of organic compounds by incorporating one (monooxygenases) or two (dioxygenases) oxygen atoms into the substrate.,Entity: oxygen. SMILES: [O]. Oxygenases catalyze the oxidation of organic compounds by incorporating one (monooxygenases) or two (dioxygenases) oxygen atoms into the substrate.
3-hydroxycarbazole,3-hydroxycarbazole is the major urinary metabolite in rats and rabbits and is conjugated with glucuronic acid.,Entity: 3-hydroxycarbazole. SMILES: Oc1ccc2[nH]c3ccccc3c2c1. 3-hydroxycarbazole is the major urinary metabolite in rats and rabbits and is conjugated with glucuronic acid.
ellipticine,"Ellipticine is a compound with a carbon-carbon skeleton and considerable unsaturation, as indicated by its fragmentation pattern in mass spectrometry.","Entity: ellipticine. SMILES: Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12. Ellipticine is a compound with a carbon-carbon skeleton and considerable unsaturation, as indicated by its fragmentation pattern in mass spectrometry."
9-hydroxyellipticine,"9-hydroxyellipticine is a polar conjugate of ellipticine, as shown by its lower polarity compared to metabolite B in chromatographic analyses.","Entity: 9-hydroxyellipticine. SMILES: Cc1c2ccncc2c(C)c2c1[nH]c1ccc(O)cc12. 9-hydroxyellipticine is a polar conjugate of ellipticine, as shown by its lower polarity compared to metabolite B in chromatographic analyses."
9-hydroxyellipticine,"The methanolyzed product of 9-hydroxyellipticine has identical low resolution mass spectra, h.p.1.c., and t.1.c. properties to 9-hydroxyellipticine.","Entity: 9-hydroxyellipticine. SMILES: Cc1c2ccncc2c(C)c2c1[nH]c1ccc(O)cc12. The methanolyzed product of 9-hydroxyellipticine has identical low resolution mass spectra, h.p.1.c., and t.1.c. properties to 9-hydroxyellipticine."
HCl,HCl is used as a catalyst (3.0% HCl in methanol at 65°C) for the methanolyzation of 9-hydroxyellipticine.,Entity: HCl. SMILES: Cl. HCl is used as a catalyst (3.0% HCl in methanol at 65°C) for the methanolyzation of 9-hydroxyellipticine.
methanol,Methanol is used as a solvent (3.0% HCl + methanol at 65°C) for the methanolyzation of 9-hydroxyellipticine.,Entity: methanol. SMILES: CO. Methanol is used as a solvent (3.0% HCl + methanol at 65°C) for the methanolyzation of 9-hydroxyellipticine.
5-hydroxytryptophan,"5-hydroxytryptophan is formed by the action of tryptophan hydroxylase on 5-tryptophan, with 85% retention of tritium via an NIH shift mechanism involving migration of the tritium label.","Entity: 5-hydroxytryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccc(O)c(C(F)(F)F)c12)C(=O)O. 5-hydroxytryptophan is formed by the action of tryptophan hydroxylase on 5-tryptophan, with 85% retention of tritium via an NIH shift mechanism involving migration of the tritium label."
ellipticine,"Ellipticine exhibits oncolytic activity associated with inhibition of RNA, DNA, and protein synthesis.","Entity: ellipticine. SMILES: Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12. Ellipticine exhibits oncolytic activity associated with inhibition of RNA, DNA, and protein synthesis."
ellipticine,Ellipticine and its analogs are capable of strongly binding to nucleic acid polymers by intercalation.,Entity: ellipticine. SMILES: Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12. Ellipticine and its analogs are capable of strongly binding to nucleic acid polymers by intercalation.
ellipticine,Hepatic monooxygenase systems catalyze the formation of phenol-type analogs of ellipticine through arene oxide intermediates.,Entity: ellipticine. SMILES: Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12. Hepatic monooxygenase systems catalyze the formation of phenol-type analogs of ellipticine through arene oxide intermediates.
sodium dihydrogen phosphate,"Sodium dihydrogen phosphate is used as a buffer at 1 mM and 10 mM concentrations, adjusted to pH 7.5, for protein purification and dialysis procedures.","Entity: sodium dihydrogen phosphate. SMILES: O=P([O-])(O)O.[Na+]. Sodium dihydrogen phosphate is used as a buffer at 1 mM and 10 mM concentrations, adjusted to pH 7.5, for protein purification and dialysis procedures."
sodium dodecyl sulfate,"Sodium dodecyl sulfate is used as a detergent to dissolve lyophilized clot protein preparations, typically at a concentration of 1% in the presence of 0.1 M f3 mercaptoethanol.","Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate is used as a detergent to dissolve lyophilized clot protein preparations, typically at a concentration of 1% in the presence of 0.1 M f3 mercaptoethanol."
2-mercaptoethanol,"f3 mercaptoethanol is used as a reducing agent to facilitate the dissolution of clot protein preparations, often at a concentration of 0.1 M.","Entity: 2-mercaptoethanol. SMILES: OCCS. f3 mercaptoethanol is used as a reducing agent to facilitate the dissolution of clot protein preparations, often at a concentration of 0.1 M."
SDS,SDS is used as a detergent in SDS-containing gels for protein separation and molecular weight calibration.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used as a detergent in SDS-containing gels for protein separation and molecular weight calibration.
chloral hydrate,Chloral hydrate is used to treat whole lysate at 6 M concentration and pH 3 to facilitate the isolation of clot protein from other cellular components.,Entity: chloral hydrate. SMILES: OC(O)C(Cl)(Cl)Cl. Chloral hydrate is used to treat whole lysate at 6 M concentration and pH 3 to facilitate the isolation of clot protein from other cellular components.
urea,"Urea at 8 M concentration, alone or with 0.1 M 8-mercaptoethanol, can dissolve only a small proportion of a clot.","Entity: urea. SMILES: NC(N)=O. Urea at 8 M concentration, alone or with 0.1 M 8-mercaptoethanol, can dissolve only a small proportion of a clot."
Triton X-100,"Triton X-100 cannot dissolve a clot under any tested conditions, including with or without 8-mercaptoethanol or warming.","Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 cannot dissolve a clot under any tested conditions, including with or without 8-mercaptoethanol or warming."
SDS,"SDS at 1% concentration can solubilize a whole clot, but not when used alone.","Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS at 1% concentration can solubilize a whole clot, but not when used alone."
SDS,"SDS can irreversibly bind to γ-clot protein, altering the protein's solubility properties and causing precipitation in 1% SDS solution.","Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS can irreversibly bind to γ-clot protein, altering the protein's solubility properties and causing precipitation in 1% SDS solution."
urea,"Urea at concentrations of 3 M or greater prevents γ-clot protein from precipitating during dialysis against water or salts, maintaining it in a completely dissolved state.","Entity: urea. SMILES: NC(N)=O. Urea at concentrations of 3 M or greater prevents γ-clot protein from precipitating during dialysis against water or salts, maintaining it in a completely dissolved state."
NaH2PO4,NaH2PO4 is used as a buffer at 10 mM concentration and pH 7.5 in chromatographic elution and as a component of the mobile phase for Sephadex G-200 column chromatography.,Entity: NaH2PO4. SMILES: O=P([O-])(O)O.[Na+]. NaH2PO4 is used as a buffer at 10 mM concentration and pH 7.5 in chromatographic elution and as a component of the mobile phase for Sephadex G-200 column chromatography.
SDS,SDS is used at 1% concentration as a component of the mobile phase for Sephadex G-200 column chromatography.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used at 1% concentration as a component of the mobile phase for Sephadex G-200 column chromatography.
dithiothreitol,"Dithiothreitol, also known as 2-mercaptoethanol, is required along with SDS to dissolve the clot protein, indicating its role in regenerating sulfhydryl groups and facilitating protein solubilization.","Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol, also known as 2-mercaptoethanol, is required along with SDS to dissolve the clot protein, indicating its role in regenerating sulfhydryl groups and facilitating protein solubilization."
SDS,"SDS at 1% concentration, when combined with 2-mercaptoethanol, is required to dissolve the clot protein, suggesting that SDS disrupts hydrophobic bonding and facilitates protein solubilization by regenerating sulfhydryl groups.","Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS at 1% concentration, when combined with 2-mercaptoethanol, is required to dissolve the clot protein, suggesting that SDS disrupts hydrophobic bonding and facilitates protein solubilization by regenerating sulfhydryl groups."
urea,"Urea at 8 M concentration alone cannot completely dissolve the clot protein, indicating that urea alone is insufficient to disrupt the protein's structure.","Entity: urea. SMILES: NC(N)=O. Urea at 8 M concentration alone cannot completely dissolve the clot protein, indicating that urea alone is insufficient to disrupt the protein's structure."
Triton X-100,"Triton X-100 at 1% concentration, when combined with 8 M urea and 2-mercaptoethanol, does not completely dissolve the clot protein, indicating its limited ability to disrupt the protein's structure.","Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 at 1% concentration, when combined with 8 M urea and 2-mercaptoethanol, does not completely dissolve the clot protein, indicating its limited ability to disrupt the protein's structure."
1/2 cysteine,Both clot protein and purified {3 clot protein are characterized by high content of 1/2 cysteine.,Entity: 1/2 cysteine. SMILES: N[C@@H](CS)C(=O)O. Both clot protein and purified {3 clot protein are characterized by high content of 1/2 cysteine.
SDS,SDS is used in both SDS gel electrophoresis and in the purification process for clot protein and {3 clot protein.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used in both SDS gel electrophoresis and in the purification process for clot protein and {3 clot protein.
phenylalanine,Both clot protein and purified {3 clot protein are characterized by high content of phenylalanine.,Entity: phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. Both clot protein and purified {3 clot protein are characterized by high content of phenylalanine.
methionine,Both clot protein and purified {3 clot protein are characterized by the absence of methionine.,Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Both clot protein and purified {3 clot protein are characterized by the absence of methionine.
urea,Dialysis against 3 M urea is used to purify clot protein and {3 clot protein prior to further use.,Entity: urea. SMILES: NC(N)=O. Dialysis against 3 M urea is used to purify clot protein and {3 clot protein prior to further use.
iodide,Iodide is a trace element that is included in total parenteral nutrition solutions for its physiologic importance.,Entity: iodide. SMILES: [I-]. Iodide is a trace element that is included in total parenteral nutrition solutions for its physiologic importance.
Etiocholanolone,Etiocholanolone is a naturally occurring nonandrogenic testosterone metabolite that enables cells not in active cell cycle to respond to colony-stimulating factor or erythropoietin.,Entity: Etiocholanolone. SMILES: C[C@]12CC[C@@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. Etiocholanolone is a naturally occurring nonandrogenic testosterone metabolite that enables cells not in active cell cycle to respond to colony-stimulating factor or erythropoietin.
Fluoxymesterone,"Fluoxymesterone is a synthetic androgen that enhances in vitro granulocytic and erythroid colony formation by mouse marrow cells by increasing the responsiveness of target cells to tropic stimuli, particularly in cells undergoing active DNA synthesis.","Entity: Fluoxymesterone. SMILES: C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C. Fluoxymesterone is a synthetic androgen that enhances in vitro granulocytic and erythroid colony formation by mouse marrow cells by increasing the responsiveness of target cells to tropic stimuli, particularly in cells undergoing active DNA synthesis."
steroids,"Both androgenic and nonandrogenic steroids can enhance in vitro granulocytic and erythroid colony formation by mouse marrow cells, with different steroids affecting different target cells or cells in different states of the cell cycle.","Entity: steroids. SMILES: CC(=O)N(C)[C@H](C)[C@@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](N(C)C)CC[C@@]4(C)[C@@H]3CC[C@]21C. Both androgenic and nonandrogenic steroids can enhance in vitro granulocytic and erythroid colony formation by mouse marrow cells, with different steroids affecting different target cells or cells in different states of the cell cycle."
erythropoietin,"Erythropoietin stimulates erythroid colony formation in mouse marrow cells, and etiocholanolone enables cells not in active cell cycle to respond to erythropoietin.","Entity: erythropoietin. Erythropoietin stimulates erythroid colony formation in mouse marrow cells, and etiocholanolone enables cells not in active cell cycle to respond to erythropoietin."
colony-stimulating factor,"Colony-stimulating factor can stimulate erythroid and granulocytic colony formation in mouse marrow cells, and etiocholanolone enables cells not in active cell cycle to respond to colony-stimulating factor.","Entity: colony-stimulating factor. Colony-stimulating factor can stimulate erythroid and granulocytic colony formation in mouse marrow cells, and etiocholanolone enables cells not in active cell cycle to respond to colony-stimulating factor."
"2,3-dihydroxybenzoic acid","2,3-dihydroxybenzoic acid promotes the mobilization of ferritin iron and its release from Chang cells when transferrin saturation is 100% in the culture medium.","Entity: 2,3-dihydroxybenzoic acid. SMILES: O=C(O)c1cccc(O)c1O. 2,3-dihydroxybenzoic acid promotes the mobilization of ferritin iron and its release from Chang cells when transferrin saturation is 100% in the culture medium."
rhodotorulic acid,Rhodotorulic acid promotes the mobilization of ferritin iron and its release from Chang cells when transferrin saturation is 100% in the culture medium.,Entity: rhodotorulic acid. SMILES: CC(=O)N(O)CCC[C@@H]1NC(=O)[C@H](CCCN(O)C(C)=O)NC1=O. Rhodotorulic acid promotes the mobilization of ferritin iron and its release from Chang cells when transferrin saturation is 100% in the culture medium.
tropolone,"Tropolone promotes the mobilization of ferritin iron and its release from Chang cells when transferrin saturation is 100% in the culture medium, and at a molar ratio of 1:500 in vitro, it transfers most of the labeled iron to the chelator due to its exceptionally high binding constant.","Entity: tropolone. SMILES: O=c1cccccc1O. Tropolone promotes the mobilization of ferritin iron and its release from Chang cells when transferrin saturation is 100% in the culture medium, and at a molar ratio of 1:500 in vitro, it transfers most of the labeled iron to the chelator due to its exceptionally high binding constant."
cholylhydroxamic acid,Cholylhydroxamic acid promotes the mobilization of ferritin iron and its release from Chang cells when transferrin saturation is 100% in the culture medium.,Entity: cholylhydroxamic acid. SMILES: C[C@H](CCC(=O)NO)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Cholylhydroxamic acid promotes the mobilization of ferritin iron and its release from Chang cells when transferrin saturation is 100% in the culture medium.
etiocholanolone,"Etiocholanolone acts as a pyrogen that elicits an increase in the transit rate of granulocytes, specifically band and segmented neutrophils, from bone marrow to blood.","Entity: etiocholanolone. SMILES: C[C@]12CC[C@@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. Etiocholanolone acts as a pyrogen that elicits an increase in the transit rate of granulocytes, specifically band and segmented neutrophils, from bone marrow to blood."
endotoxin,Bacterial endotoxin acts as a humoral factor that enhances the egress rate of mature neutrophils from bone marrow into the blood.,Entity: endotoxin. SMILES: CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)O[C@@H]1[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H](OC[C@H]2O[C@H](OP(=O)(O)O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]2O)O[C@H](CO[C@]2(C(=O)O)C[C@@H](O[C@]3(C(=O)O)C[C@@H](O[C@]4(C(=O)O)C[C@@H](OP(=O)(O)OCCN)[C@H](O)[C@@H]([C@@H](O)CO)O4)[C@H](O)[C@@H]([C@@H](O)CO)O3)[C@H](OC3O[C@H]([C@@H](O)CO)[C@@H](OP(=O)(O)OP(=O)(O)OCCN)[C@H](OC4O[C@H]([C@@H](O)COC5O[C@H]([C@@H](O)CO)[C@@H](OP(=O)(O)O)[C@H](O)[C@@H]5O)[C@@H](O)[C@H](OC5O[C@H](CO[C@H]6O[C@H](CO)[C@H](O)[C@H](O)[C@H]6O)[C@@H](O)[C@H](O[C@H]6O[C@H](CO)[C@H](O)[C@H](O)[C@H]6OC6O[C@H](CO)[C@@H](O)[C@H](O[C@@H]7O[C@H](CO[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8NC(C)=O)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@H](O)[C@H](O[C@H]9O[C@H](CO[C@H]%10O[C@H](CO)[C@H](O)[C@H](O)[C@H]%10O)[C@H](O)[C@H](O)[C@H]9O)[C@H]8NC(C)=O)[C@H]7NC(C)=O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6NC(C)=O)[C@H]5O)[C@@H]4O)[C@@H]3O)[C@@H]([C@@H](O)CO)O2)[C@H]1OP(=O)(O)O. Bacterial endotoxin acts as a humoral factor that enhances the egress rate of mature neutrophils from bone marrow into the blood.
etiocholanolone,Etiocholanolone functions as a humoral factor that promotes the release of mature neutrophils from bone marrow into the blood.,Entity: etiocholanolone. SMILES: C[C@]12CC[C@@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. Etiocholanolone functions as a humoral factor that promotes the release of mature neutrophils from bone marrow into the blood.
iso-1,"Iso-1 cytochrome c from baker's yeast is a methylated form of iso-cytochrome c that shows no appreciable difference in stability towards acid, thermal, or guanidinium hydrochloride denaturations compared to other baker's yeast cytochromes.","Entity: iso-1. Iso-1 cytochrome c from baker's yeast is a methylated form of iso-cytochrome c that shows no appreciable difference in stability towards acid, thermal, or guanidinium hydrochloride denaturations compared to other baker's yeast cytochromes."
gold sodium thiomalate,Gold sodium thiomalate is used in chrysotherapy for the treatment of rheumatoid arthritis.,Entity: gold sodium thiomalate. SMILES: O=C([O-])CC(S)C(=O)[O-].O=C([O-])CC(S)C(=O)[O-].[Au+3].[Na+]. Gold sodium thiomalate is used in chrysotherapy for the treatment of rheumatoid arthritis.
gold sodium thiomalate,"Gold sodium thiomalate can induce aplastic anemia, a potentially fatal hematologic side effect, in patients with rheumatoid arthritis.","Entity: gold sodium thiomalate. SMILES: O=C([O-])CC(S)C(=O)[O-].O=C([O-])CC(S)C(=O)[O-].[Au+3].[Na+]. Gold sodium thiomalate can induce aplastic anemia, a potentially fatal hematologic side effect, in patients with rheumatoid arthritis."
ZnSO4,ZnSO4 is used as a protein precipitating agent in the preparation of plasma and muscle samples for analytical procedures.,Entity: ZnSO4. SMILES: O=S(=O)([O-])[O-].[Zn+2]. ZnSO4 is used as a protein precipitating agent in the preparation of plasma and muscle samples for analytical procedures.
NaOH,NaOH is used as a diluent in the preparation of plasma samples for subsequent protein analysis.,Entity: NaOH. SMILES: [Na+].[OH-]. NaOH is used as a diluent in the preparation of plasma samples for subsequent protein analysis.
chloride ion,Chloride ion is passively distributed across the plasma membrane of frog skeletal muscle under in vitro conditions at external K concentrations higher than physiological levels.,Entity: chloride ion. SMILES: [Cl-]. Chloride ion is passively distributed across the plasma membrane of frog skeletal muscle under in vitro conditions at external K concentrations higher than physiological levels.
Chloride,Chloride content in heart and semitendinosus muscle tissue samples can be determined by weighing the dried tissue after removal of moisture in a vacuum drying oven at 95°C.,Entity: Chloride. SMILES: [Cl-]. Chloride content in heart and semitendinosus muscle tissue samples can be determined by weighing the dried tissue after removal of moisture in a vacuum drying oven at 95°C.
chloride,"In vivo, intracellular chloride concentrations in semitendinosus and ventricular muscles of Bufo and Rana frogs are 1.4 ± 0.3 pmol/cell water and 2.3 ± 0.8 pmol/cell water, respectively, within 1 hour after injection of 36Cl.","Entity: chloride. SMILES: [Cl-]. In vivo, intracellular chloride concentrations in semitendinosus and ventricular muscles of Bufo and Rana frogs are 1.4 ± 0.3 pmol/cell water and 2.3 ± 0.8 pmol/cell water, respectively, within 1 hour after injection of 36Cl."
chloride ion,Chloride ion is actively transported into frog ventricular myocardial cells.,Entity: chloride ion. SMILES: [Cl-]. Chloride ion is actively transported into frog ventricular myocardial cells.
chloride ion,The maximal cellular chloride activity in frog ventricular myocardial cells is consistent with a permeability ratio of approximately 4.8 ± 2.4 mmol/kg cell water under in vivo conditions.,Entity: chloride ion. SMILES: [Cl-]. The maximal cellular chloride activity in frog ventricular myocardial cells is consistent with a permeability ratio of approximately 4.8 ± 2.4 mmol/kg cell water under in vivo conditions.
chloride ion,"The corrected estimate for chloride ion concentration in frog ventricle is -2.6 mM, accounting for possible interference from intracellular bicarbonate ion.","Entity: chloride ion. SMILES: [Cl-]. The corrected estimate for chloride ion concentration in frog ventricle is -2.6 mM, accounting for possible interference from intracellular bicarbonate ion."
acetic acid,Acetic acid (50%) is used to adjust the pH of treated muscle tissue samples to below 1.2 prior to chlorine content determination by electrometric titration.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid (50%) is used to adjust the pH of treated muscle tissue samples to below 1.2 prior to chlorine content determination by electrometric titration.
sodium hydroxide,Sodium hydroxide is used as a reagent for digesting dried tissue samples to prepare them for chlorine content determination in muscle tissue.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used as a reagent for digesting dried tissue samples to prepare them for chlorine content determination in muscle tissue.
zinc sulfate,Zinc sulfate is used to precipitate protein from the alkaline digestion of muscle tissue samples prior to chlorine content analysis.,Entity: zinc sulfate. SMILES: O=S(=O)([O-])[O-].[Zn+2]. Zinc sulfate is used to precipitate protein from the alkaline digestion of muscle tissue samples prior to chlorine content analysis.
nitric acid,Nitric acid is used in a 0.1 N concentration to extract chlorine from wet or minced dried muscle tissue samples.,Entity: nitric acid. SMILES: O=[N+]([O-])O. Nitric acid is used in a 0.1 N concentration to extract chlorine from wet or minced dried muscle tissue samples.
chloride,"Chloride content in ventricular muscle of toads is significantly higher than in skeletal muscle, with values of 113–114 pmoll/g dry weight in ventricle and 72–73 pmoll/g dry weight in semitendinosus muscle.","Entity: chloride. SMILES: [Cl-]. Chloride content in ventricular muscle of toads is significantly higher than in skeletal muscle, with values of 113–114 pmoll/g dry weight in ventricle and 72–73 pmoll/g dry weight in semitendinosus muscle."
chloride,"Chloride content in muscle can be determined by combining titrimetry and 36C1 radioassay, with specific activity being constant and equal to that in plasma within 1.5–3 hours after intraperitoneal injection of 36C1 in toad and frog skeletal muscle, and 20–185 minutes in frog heart.","Entity: chloride. SMILES: [Cl-]. Chloride content in muscle can be determined by combining titrimetry and 36C1 radioassay, with specific activity being constant and equal to that in plasma within 1.5–3 hours after intraperitoneal injection of 36C1 in toad and frog skeletal muscle, and 20–185 minutes in frog heart."
chloride,"In frog semitendinosus muscle, the sarcoplasmic reticulum contains approximately 3.5% of the total cell volume as terminal cisterns and 5.3% as longitudinal portions.","Entity: chloride. SMILES: [Cl-]. In frog semitendinosus muscle, the sarcoplasmic reticulum contains approximately 3.5% of the total cell volume as terminal cisterns and 5.3% as longitudinal portions."
chloride,"Chloride in the sarcoplasmic reticulum of frog semitendinosus is assumed to be distributed uniformly throughout the SR water, with a concentration equal to the plasma chloride concentration (83.77 pmol/g plasma water).","Entity: chloride. SMILES: [Cl-]. Chloride in the sarcoplasmic reticulum of frog semitendinosus is assumed to be distributed uniformly throughout the SR water, with a concentration equal to the plasma chloride concentration (83.77 pmol/g plasma water)."
chloride ion,"The intracellular chloride ion activity in frog ventricular myocardial cells is 17.6 ± 8 mM, which is much higher than predicted for passive chloride ion distribution under conditions of constant conductance or constant permeability.","Entity: chloride ion. SMILES: [Cl-]. The intracellular chloride ion activity in frog ventricular myocardial cells is 17.6 ± 8 mM, which is much higher than predicted for passive chloride ion distribution under conditions of constant conductance or constant permeability."
calcium chloride,Calcium chloride is included in Krebs solution at a concentration of 2.5 mM for organ bath experiments on the sphincter of Oddi.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride is included in Krebs solution at a concentration of 2.5 mM for organ bath experiments on the sphincter of Oddi.
oxygen,Oxygen is used as part of a 95% oxygen/5% carbon dioxide gas mixture to maintain tissue perfusion in organ bath preparations.,Entity: oxygen. SMILES: [O]. Oxygen is used as part of a 95% oxygen/5% carbon dioxide gas mixture to maintain tissue perfusion in organ bath preparations.
magnesium sulfate,Magnesium sulfate is present in Krebs solution at a concentration of 1.15 mM for in vitro studies of the sphincter of Oddi.,Entity: magnesium sulfate. SMILES: O=S(=O)([O-])[O-].[Mg+2]. Magnesium sulfate is present in Krebs solution at a concentration of 1.15 mM for in vitro studies of the sphincter of Oddi.
glucose,Glucose is included in Krebs solution at a concentration of 5.5 mM for maintaining metabolic activity in organ bath experiments on the sphincter of Oddi.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is included in Krebs solution at a concentration of 5.5 mM for maintaining metabolic activity in organ bath experiments on the sphincter of Oddi.
sodium bicarbonate,Sodium bicarbonate is used in Krebs solution at a concentration of 24.9 mM to regulate pH in organ bath preparations for sphincter of Oddi studies.,Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Sodium bicarbonate is used in Krebs solution at a concentration of 24.9 mM to regulate pH in organ bath preparations for sphincter of Oddi studies.
sodium chloride,Sodium chloride is a component of Krebs solution at a concentration of 118.0 mM for in vitro studies of the sphincter of Oddi.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is a component of Krebs solution at a concentration of 118.0 mM for in vitro studies of the sphincter of Oddi.
carbon dioxide,Carbon dioxide is used in a 5% concentration within a 95% oxygen/5% carbon dioxide gas mixture to maintain tissue perfusion in organ bath experiments.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is used in a 5% concentration within a 95% oxygen/5% carbon dioxide gas mixture to maintain tissue perfusion in organ bath experiments.
potassium dihydrogen phosphate,Potassium dihydrogen phosphate is included in Krebs solution at a concentration of 1.15 mM for organ bath experiments on the sphincter of Oddi.,Entity: potassium dihydrogen phosphate. SMILES: O=P([O-])(O)O.[K+]. Potassium dihydrogen phosphate is included in Krebs solution at a concentration of 1.15 mM for organ bath experiments on the sphincter of Oddi.
potassium chloride,Potassium chloride is used as a component of Krebs solution at a concentration of 4.6 mM in organ bath preparations for studying sphincter of Oddi function.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is used as a component of Krebs solution at a concentration of 4.6 mM in organ bath preparations for studying sphincter of Oddi function.
tetrodotoxin,Tetrodotoxin at concentrations of 0.1–0.5 µg/ml prevents electrical stimulation-induced inhibition of the cat isolated sphincter of Oddi contractile activity.,Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at concentrations of 0.1–0.5 µg/ml prevents electrical stimulation-induced inhibition of the cat isolated sphincter of Oddi contractile activity.
cholecystokinin,Cholecystokinin inhibits the activity and tone of the sphincter of Oddi without involving nerves.,Entity: cholecystokinin. SMILES: CCC(C)C(NC(=O)C(CCCNC(=N)N)NC(=O)C(Cc1c[nH]cn1)NC(=O)C(CO)NC(=O)C1CCCN1C(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(CO)NC(=O)C1CCCN1C(=O)C(C)NC(=O)C(N)CCCCN)C(C)CC)C(C)C)C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)NC(CCSC)C(=O)NCC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(Cc1ccccc1)C(N)=O)c1ccc(OS(=O)(=O)O)cc1. Cholecystokinin inhibits the activity and tone of the sphincter of Oddi without involving nerves.
acetylcholine,Exogenous acetylcholine contracts the sphincter of Oddi in most species.,Entity: acetylcholine. SMILES: CC(=O)OCC[N+](C)(C)C. Exogenous acetylcholine contracts the sphincter of Oddi in most species.
tetrodotoxin,"Tetrodotoxin at 0.5 µg/ml fully inhibits the response to 0.2 ms electrical pulses in the isolated sphincter 5 minutes after bath application, and this inhibition is reversible upon washout.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at 0.5 µg/ml fully inhibits the response to 0.2 ms electrical pulses in the isolated sphincter 5 minutes after bath application, and this inhibition is reversible upon washout."
tetrodotoxin,"Tetrodotoxin can produce a stimulant effect on the isolated sphincter in some preparations, but this effect shows tachyphylaxis.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin can produce a stimulant effect on the isolated sphincter in some preparations, but this effect shows tachyphylaxis."
adenosine triphosphate,"Adenosine triphosphate (ATP) can relax the sphincter of Oddi, but alone it does not fully mimic the neural response, requiring the presence of dipyridamole for potentiation.","Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine triphosphate (ATP) can relax the sphincter of Oddi, but alone it does not fully mimic the neural response, requiring the presence of dipyridamole for potentiation."
adenosine diphosphate,"Adenosine diphosphate (ADP) can induce relaxation of the sphincter of Oddi, indicating involvement of purinergic nerves in sphincter regulation.","Entity: adenosine diphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine diphosphate (ADP) can induce relaxation of the sphincter of Oddi, indicating involvement of purinergic nerves in sphincter regulation."
dipyridamole,"Dipyridamole diminishes the concentration of ATP required to produce inhibitory effects on the sphincter of Oddi, likely by blocking adenosine uptake.","Entity: dipyridamole. SMILES: OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1. Dipyridamole diminishes the concentration of ATP required to produce inhibitory effects on the sphincter of Oddi, likely by blocking adenosine uptake."
cholecystokinin,"The octa-peptide of cholecystokinin produces sphincter relaxation of the Oddi, indicating a role for cholecystokinin in modulating sphincter function.","Entity: cholecystokinin. SMILES: CCC(C)C(NC(=O)C(CCCNC(=N)N)NC(=O)C(Cc1c[nH]cn1)NC(=O)C(CO)NC(=O)C1CCCN1C(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(CO)NC(=O)C1CCCN1C(=O)C(C)NC(=O)C(N)CCCCN)C(C)CC)C(C)C)C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)NC(CCSC)C(=O)NCC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(Cc1ccccc1)C(N)=O)c1ccc(OS(=O)(=O)O)cc1. The octa-peptide of cholecystokinin produces sphincter relaxation of the Oddi, indicating a role for cholecystokinin in modulating sphincter function."
adenosine-5'-diphosphate,Adenosine-5'-diphosphate at concentrations of 4–30 µg/ml inhibits spontaneous activity of the sphincter in vitro.,Entity: adenosine-5'-diphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine-5'-diphosphate at concentrations of 4–30 µg/ml inhibits spontaneous activity of the sphincter in vitro.
dipyridamole,Dipyridamole at 1 µg/ml produces a pronounced relaxation in the presence of low concentrations of ATP (approximately 10 µg/ml) in the tested system.,Entity: dipyridamole. SMILES: OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1. Dipyridamole at 1 µg/ml produces a pronounced relaxation in the presence of low concentrations of ATP (approximately 10 µg/ml) in the tested system.
adenosine-5'-triphosphate,Adenosine-5'-triphosphate at concentrations of 2–30 µg/ml inhibits spontaneous activity of the sphincter in vitro.,Entity: adenosine-5'-triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine-5'-triphosphate at concentrations of 2–30 µg/ml inhibits spontaneous activity of the sphincter in vitro.
adenosine-5'-triphosphate,Adenosine-5'-triphosphate at concentrations above 100 µg/ml produces a relaxation response in the tested system that is as pronounced as that induced by electrical stimulation.,Entity: adenosine-5'-triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine-5'-triphosphate at concentrations above 100 µg/ml produces a relaxation response in the tested system that is as pronounced as that induced by electrical stimulation.
tetrodotoxin,"Tetrodotoxin (TTX) inhibits conduction in non-adrenergic, possibly purinergic, inhibitory nerves, which may explain its effect on the isolated sphincter of Oddi.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin (TTX) inhibits conduction in non-adrenergic, possibly purinergic, inhibitory nerves, which may explain its effect on the isolated sphincter of Oddi."
cholecystokinin,The C-terminal octapeptide of cholecystokinin (C8-CCK) inhibits the spontaneous contractile activity of the cat isolated sphincter of Oddi and induces relaxation.,Entity: cholecystokinin. The C-terminal octapeptide of cholecystokinin (C8-CCK) inhibits the spontaneous contractile activity of the cat isolated sphincter of Oddi and induces relaxation.
bretylium,Bretylium is an adrenergic neurone blocker that induces changes in the intra-neuronal distribution of noradrenaline in the spleen and heart following administration in cats and rats.,Entity: bretylium. SMILES: CC[N+](C)(C)Cc1ccccc1Br. Bretylium is an adrenergic neurone blocker that induces changes in the intra-neuronal distribution of noradrenaline in the spleen and heart following administration in cats and rats.
cocaine,"Cocaine is an inhibitor of the neuronal membrane transport mechanism and can reverse adrenergic neuronal blockade, but does so more gradually than amphetamine and is less effective at preventing blockade than reversing it.","Entity: cocaine. SMILES: COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C. Cocaine is an inhibitor of the neuronal membrane transport mechanism and can reverse adrenergic neuronal blockade, but does so more gradually than amphetamine and is less effective at preventing blockade than reversing it."
amphetamine,"Amphetamine reverses adrenergic neuronal blockade more rapidly and completely than cocaine, and may do so by displacing adrenergic neuronal blockers from intraneuronal binding sites, allowing noradrenaline to refill and restore nerve function.","Entity: amphetamine. SMILES: CC(N)Cc1ccccc1. Amphetamine reverses adrenergic neuronal blockade more rapidly and completely than cocaine, and may do so by displacing adrenergic neuronal blockers from intraneuronal binding sites, allowing noradrenaline to refill and restore nerve function."
amphetamine,"Amphetamine can displace bound ['4C]-guanethidine and [3H1-bretylium] accumulated in rat atria, indicating its ability to displace intraneuronal drug binding sites.","Entity: amphetamine. SMILES: CC(N)Cc1ccccc1. Amphetamine can displace bound ['4C]-guanethidine and [3H1-bretylium] accumulated in rat atria, indicating its ability to displace intraneuronal drug binding sites."
noradrenaline,"Noradrenaline is released from storage vesicles in response to depolarization of the neuronal membrane by nerve impulses, playing a key role in adrenergic transmission.","Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline is released from storage vesicles in response to depolarization of the neuronal membrane by nerve impulses, playing a key role in adrenergic transmission."
noradrenaline,"Tissue levels of noradrenaline can be quantified by measuring total radioactivity in perchloric acid extracts after homogenization and centrifugation, with recovery corrected to 53.4%.","Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Tissue levels of noradrenaline can be quantified by measuring total radioactivity in perchloric acid extracts after homogenization and centrifugation, with recovery corrected to 53.4%."
bethanidine,Bethanidine is a compound that is released from adrenergic nerve endings in response to nerve stimulation.,Entity: bethanidine. SMILES: CN=C(NC)NCc1ccccc1. Bethanidine is a compound that is released from adrenergic nerve endings in response to nerve stimulation.
guanethidine,Guanethidine is a compound that is released from adrenergic nerve endings in response to nerve stimulation.,Entity: guanethidine. SMILES: NC(N)=NCCN1CCCCCCC1. Guanethidine is a compound that is released from adrenergic nerve endings in response to nerve stimulation.
barbiturate,Barbiturate withdrawal can induce seizures in some resistant strains of mice and rats.,Entity: barbiturate. SMILES: O=C1CC([O-])=NC(=O)N1. Barbiturate withdrawal can induce seizures in some resistant strains of mice and rats.
glucagon,"In the context of the syndrome of hypothalamic obesity and advanced hyperinsulinemia, there are reports of decreased serum glucagon concentration associated with reduced size of salivary glands.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. In the context of the syndrome of hypothalamic obesity and advanced hyperinsulinemia, there are reports of decreased serum glucagon concentration associated with reduced size of salivary glands."
ascorbic acid,Ascorbic acid is included at 2.2 µmol in the incubation mixture for neurotransmitter uptake assays in brain homogenates.,Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid is included at 2.2 µmol in the incubation mixture for neurotransmitter uptake assays in brain homogenates.
tyramine,Tyramine is used as a substrate at 1 mM concentration in the dopamine-p-hydroxylase activity assay in brain and heart homogenates.,Entity: tyramine. SMILES: NCCc1ccc(O)cc1. Tyramine is used as a substrate at 1 mM concentration in the dopamine-p-hydroxylase activity assay in brain and heart homogenates.
dopamine,Dopamine is used as a substrate at 0.2 nmol in the dopamine-p-hydroxylase activity assay in brain homogenates.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine is used as a substrate at 0.2 nmol in the dopamine-p-hydroxylase activity assay in brain homogenates.
CuS04,"CuS04 is used as a cofactor in the dopamine-p-hydroxylase activity assay, with the optimal concentration determined for each tissue and brain region.","Entity: CuS04. SMILES: O=S(=O)([O-])[O-].[Cu+2]. CuS04 is used as a cofactor in the dopamine-p-hydroxylase activity assay, with the optimal concentration determined for each tissue and brain region."
ethylenediaminetetra-acetic acid disodium salt,Ethylenediaminetetra-acetic acid disodium salt (EDTA) is used as a component in the incubation mixture for measuring neurotransmitter uptake in brain homogenates at a concentration of 0.26 µmol per assay.,Entity: ethylenediaminetetra-acetic acid disodium salt. SMILES: O=C([O-])CN(CCN(CC(=O)O)CC(=O)O)CC(=O)[O-].[Na+].[Na+]. Ethylenediaminetetra-acetic acid disodium salt (EDTA) is used as a component in the incubation mixture for measuring neurotransmitter uptake in brain homogenates at a concentration of 0.26 µmol per assay.
glucose,Glucose is included at 11 µmol in the incubation mixture for assessing neurotransmitter uptake in brain homogenates.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is included at 11 µmol in the incubation mixture for assessing neurotransmitter uptake in brain homogenates.
pargyline,Pargyline is used at 0.48 µmol in the incubation mixture to inhibit monoamine oxidase during neurotransmitter uptake assays in brain homogenates.,Entity: pargyline. SMILES: C#CCN(C)Cc1ccccc1. Pargyline is used at 0.48 µmol in the incubation mixture to inhibit monoamine oxidase during neurotransmitter uptake assays in brain homogenates.
NaCl,Cold 0.9% w/v NaCl solution is used for washing brain homogenate pellets in the preparation of samples for radioactivity measurement.,Entity: NaCl. SMILES: [Cl-].[Na+]. Cold 0.9% w/v NaCl solution is used for washing brain homogenate pellets in the preparation of samples for radioactivity measurement.
sucrose,Sucrose is used at 0.25 M concentration as the homogenizing medium for brain tissue samples in neurotransmitter uptake assays.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used at 0.25 M concentration as the homogenizing medium for brain tissue samples in neurotransmitter uptake assays.
5-HT,5-HT ([14C]-5-HT) is used as a substrate at 0.2 nmol in the incubation mixture to measure its uptake in brain homogenates.,Entity: 5-HT. SMILES: NCCc1c[nH]c2ccc(O)cc12. 5-HT ([14C]-5-HT) is used as a substrate at 0.2 nmol in the incubation mixture to measure its uptake in brain homogenates.
copper(II) sulfate,"In rat frontal cerebral cortex, DBH activity using 0.1 mM CuSO4 is 128 ± 4 nmol octopamine g⁻¹ h⁻¹.","Entity: copper(II) sulfate. SMILES: O=S(=O)([O-])[O-].[Cu+2]. In rat frontal cerebral cortex, DBH activity using 0.1 mM CuSO4 is 128 ± 4 nmol octopamine g⁻¹ h⁻¹."
copper(II) sulfate,"In rat hypothalamus, DBH activity using 0.1 mM CuSO4 is 340 ± 15 nmol octopamine g⁻¹ h⁻¹.","Entity: copper(II) sulfate. SMILES: O=S(=O)([O-])[O-].[Cu+2]. In rat hypothalamus, DBH activity using 0.1 mM CuSO4 is 340 ± 15 nmol octopamine g⁻¹ h⁻¹."
octopamine,"Octopamine levels in rat atrium (cocaine-sensitive part) are measured by [3H]-NA uptake assays, with values of 0.181 ± 0.010 nmol/g in 10 minutes.","Entity: octopamine. SMILES: NCC(O)c1ccc(O)cc1. Octopamine levels in rat atrium (cocaine-sensitive part) are measured by [3H]-NA uptake assays, with values of 0.181 ± 0.010 nmol/g in 10 minutes."
N-2-chloroethyl-N-methyl-2-bromobenzylamine hydrochloride,N-2-chloroethyl-N-methyl-2-bromobenzylamine hydrochloride (DSP 4) is an alkylating compound that exhibits very sustained inhibition of noradrenaline uptake in mouse brain slices and in vitro.,Entity: N-2-chloroethyl-N-methyl-2-bromobenzylamine hydrochloride. SMILES: CN(CCCl)Cc1ccccc1Br.Cl. N-2-chloroethyl-N-methyl-2-bromobenzylamine hydrochloride (DSP 4) is an alkylating compound that exhibits very sustained inhibition of noradrenaline uptake in mouse brain slices and in vitro.
N-2-chloroethyl-N-methyl-2-bromobenzylamine hydrochloride,N-2-chloroethyl-N-methyl-2-bromobenzylamine hydrochloride (DSP 4) specifically inhibits noradrenaline uptake without affecting dopamine or 5-hydroxytryptamine uptake.,Entity: N-2-chloroethyl-N-methyl-2-bromobenzylamine hydrochloride. SMILES: CN(CCCl)Cc1ccccc1Br.Cl. N-2-chloroethyl-N-methyl-2-bromobenzylamine hydrochloride (DSP 4) specifically inhibits noradrenaline uptake without affecting dopamine or 5-hydroxytryptamine uptake.
sodium,"In the isolated caudal epididymis, a component of fluid reabsorption is dependent on the presence of sodium ions in the luminal fluid, as shown by a reduction in reabsorption rate when sodium is replaced by a sodium-free solution.","Entity: sodium. SMILES: [Na]. In the isolated caudal epididymis, a component of fluid reabsorption is dependent on the presence of sodium ions in the luminal fluid, as shown by a reduction in reabsorption rate when sodium is replaced by a sodium-free solution."
amiloride,Amiloride (0.1 mM) completely blocks the component of fluid reabsorption in the isolated caudal epididymis that is dependent on sodium ions in the luminal fluid.,Entity: amiloride. SMILES: NC(N)=NC(=O)c1nc(Cl)c(N)nc1N. Amiloride (0.1 mM) completely blocks the component of fluid reabsorption in the isolated caudal epididymis that is dependent on sodium ions in the luminal fluid.
potassium,"The concentration of potassium decreases along the length of the epididymis, with the lowest concentrations found in the caudal epididymis.","Entity: potassium. SMILES: [K]. The concentration of potassium decreases along the length of the epididymis, with the lowest concentrations found in the caudal epididymis."
testosterone,Treatment with a testosterone implant can reverse the effect of low sodium and chloride concentrations in the caudal epididymal fluid in rabbits.,Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Treatment with a testosterone implant can reverse the effect of low sodium and chloride concentrations in the caudal epididymal fluid in rabbits.
chloride,"The caudal epididymal fluid in rabbits contains very low concentrations of chloride, which increase after castration.","Entity: chloride. SMILES: [Cl-]. The caudal epididymal fluid in rabbits contains very low concentrations of chloride, which increase after castration."
sodium,"The concentration of sodium decreases along the length of the epididymis, with the lowest concentrations found in the caudal epididymis.","Entity: sodium. SMILES: [Na]. The concentration of sodium decreases along the length of the epididymis, with the lowest concentrations found in the caudal epididymis."
sodium,"In the caudal region of the rat epididymis, the transluminal potential is 25 mV with the inside negative with respect to the outside, which may be caused by active transport of sodium from the lumen into the peritubular fluid.","Entity: sodium. SMILES: [Na]. In the caudal region of the rat epididymis, the transluminal potential is 25 mV with the inside negative with respect to the outside, which may be caused by active transport of sodium from the lumen into the peritubular fluid."
"2, 4 dinitrophenol","2, 4 dinitrophenol inhibits the rate of fluid reabsorption in the isolated caudal epididymis, indicating that the reabsorption process is energy-dependent.","Entity: 2, 4 dinitrophenol. SMILES: O=[N+]([O-])c1ccc(O)c([N+](=O)[O-])c1. 2, 4 dinitrophenol inhibits the rate of fluid reabsorption in the isolated caudal epididymis, indicating that the reabsorption process is energy-dependent."
sodium,"A complete removal of intraluminal sodium in the isolated caudal epididymis results in a 48.7% reduction in fluid reabsorption, indicating that sodium reabsorption is partially dependent on intraluminal sodium concentration.","Entity: sodium. SMILES: [Na]. A complete removal of intraluminal sodium in the isolated caudal epididymis results in a 48.7% reduction in fluid reabsorption, indicating that sodium reabsorption is partially dependent on intraluminal sodium concentration."
amiloride,"Amiloride decreases Na+-dependent fluid reabsorption in the isolated caudal epididymis, with an IC50 of 1.6 ELM for inhibiting fluid reabsorption, which is comparable to its ability to inhibit passive Na+ transport in the distal tubule of the kidney.","Entity: amiloride. SMILES: NC(N)=NC(=O)c1nc(Cl)c(N)nc1N. Amiloride decreases Na+-dependent fluid reabsorption in the isolated caudal epididymis, with an IC50 of 1.6 ELM for inhibiting fluid reabsorption, which is comparable to its ability to inhibit passive Na+ transport in the distal tubule of the kidney."
digoxin,"Digoxin exhibits very fast initial myocardial uptake in dogs, particularly in those without long-term digitalization.","Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin exhibits very fast initial myocardial uptake in dogs, particularly in those without long-term digitalization."
digoxin,Digoxin plasma concentrations can be measured with a sensitivity of 0.25 nmol/l and a precision of 0.06 nmol/l using radioimmunoassay.,Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin plasma concentrations can be measured with a sensitivity of 0.25 nmol/l and a precision of 0.06 nmol/l using radioimmunoassay.
digoxin,Digoxin tissue concentrations can be measured with a sensitivity of 10 nmol/kg tissue and a precision of 5 nmol/kg tissue using radioimmunoassay.,Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin tissue concentrations can be measured with a sensitivity of 10 nmol/kg tissue and a precision of 5 nmol/kg tissue using radioimmunoassay.
potassium,Plasma potassium concentrations can be determined by flame-photometry.,Entity: potassium. SMILES: [K]. Plasma potassium concentrations can be determined by flame-photometry.
potassium,Tissue potassium concentrations can be measured in mmol/kg fat-free solids using a validated method.,Entity: potassium. SMILES: [K]. Tissue potassium concentrations can be measured in mmol/kg fat-free solids using a validated method.
sodium,Plasma sodium concentrations can be determined by flame-photometry.,Entity: sodium. SMILES: [Na]. Plasma sodium concentrations can be determined by flame-photometry.
potassium,"Myocardial potassium concentration decreases rapidly after digoxin administration, being significantly lower than initial content at 30 minutes post-administration.","Entity: potassium. SMILES: [K]. Myocardial potassium concentration decreases rapidly after digoxin administration, being significantly lower than initial content at 30 minutes post-administration."
potassium,Plasma potassium concentrations show only minor changes after digoxin administration.,Entity: potassium. SMILES: [K]. Plasma potassium concentrations show only minor changes after digoxin administration.
sodium,Plasma sodium concentrations show only minor changes after digoxin administration.,Entity: sodium. SMILES: [Na]. Plasma sodium concentrations show only minor changes after digoxin administration.
digoxin,Digoxin administration leads to a rapid decrease in myocardial potassium concentration within 30 minutes.,Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin administration leads to a rapid decrease in myocardial potassium concentration within 30 minutes.
digoxin,Digoxin exhibits very fast myocardial uptake in dogs with intact circulation.,Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin exhibits very fast myocardial uptake in dogs with intact circulation.
digoxin,The positive inotropic effect of digoxin is secondary to changes in intracellular sodium and potassium concentrations induced by digoxin.,Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. The positive inotropic effect of digoxin is secondary to changes in intracellular sodium and potassium concentrations induced by digoxin.
sodium,"Digoxin induces changes in intracellular sodium concentrations, which contribute to its positive inotropic effect.","Entity: sodium. SMILES: [Na]. Digoxin induces changes in intracellular sodium concentrations, which contribute to its positive inotropic effect."
potassium,"Digoxin induces changes in intracellular potassium concentrations, which contribute to its positive inotropic effect.","Entity: potassium. SMILES: [K]. Digoxin induces changes in intracellular potassium concentrations, which contribute to its positive inotropic effect."
digoxin,"Digoxin produces a positive inotropic effect in the myocardium without inhibiting the Na-K membrane ATPase, as demonstrated in both in vitro and in vivo studies.","Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin produces a positive inotropic effect in the myocardium without inhibiting the Na-K membrane ATPase, as demonstrated in both in vitro and in vivo studies."
calcium,"Ionized calcium is liberated and rebound during the contractile cycle of myocardial cells, and its interaction with a myocardial receptor site may be correlated with the positive inotropic effect of digitalis.","Entity: calcium. SMILES: [Ca]. Ionized calcium is liberated and rebound during the contractile cycle of myocardial cells, and its interaction with a myocardial receptor site may be correlated with the positive inotropic effect of digitalis."
digoxin,"Following intravenous administration in long-term digitalized dogs, digoxin myocardial uptake increases from 60 to 306 nmol/kg tissue at 10 min, with a peak concentration of 250 nmol/kg tissue at 30 min and then a secondary increase.","Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Following intravenous administration in long-term digitalized dogs, digoxin myocardial uptake increases from 60 to 306 nmol/kg tissue at 10 min, with a peak concentration of 250 nmol/kg tissue at 30 min and then a secondary increase."
digoxin,"At 10 min after digoxin administration in long-term digitalized dogs, both subepicardial and subendocardial digoxin concentrations are significantly lower than those of the mesocardial layer, indicating altered myocardial blood flow distribution.","Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. At 10 min after digoxin administration in long-term digitalized dogs, both subepicardial and subendocardial digoxin concentrations are significantly lower than those of the mesocardial layer, indicating altered myocardial blood flow distribution."
digoxin,"Digoxin increases dp/dtmax to 135% of control levels during the first 10 min after intravenous administration in long-term digitalized dogs, with no further change during the study.","Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin increases dp/dtmax to 135% of control levels during the first 10 min after intravenous administration in long-term digitalized dogs, with no further change during the study."
digoxin,"Digoxin binds to at least two different myocardial receptor sites, which can be estimated by measuring changes in myocardial potassium content or the development of positive inotropic effects.","Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin binds to at least two different myocardial receptor sites, which can be estimated by measuring changes in myocardial potassium content or the development of positive inotropic effects."
digoxin,Digoxin does not alter the affinity of its binding to the Na-K ATPase receptor.,Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin does not alter the affinity of its binding to the Na-K ATPase receptor.
digoxin,"Digoxin inhibits the Na-K ATPase, leading to a decrease in myocardial potassium content, with effects becoming apparent within about 15 minutes after intravenous administration in non-digitalized dogs.","Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin inhibits the Na-K ATPase, leading to a decrease in myocardial potassium content, with effects becoming apparent within about 15 minutes after intravenous administration in non-digitalized dogs."
digoxin,Digoxin is used to induce a positive inotropic effect and can cause myocardial loss of potassium when administered intravenously.,Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin is used to induce a positive inotropic effect and can cause myocardial loss of potassium when administered intravenously.
tubocurarine,Tubocurarine is used as an anaesthetic and muscle relaxant agent in veterinary procedures.,Entity: tubocurarine. SMILES: COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C. Tubocurarine is used as an anaesthetic and muscle relaxant agent in veterinary procedures.
nitrous oxide,Nitrous oxide is used in combination with oxygen as part of a respiratory gas mixture (N20/02) to maintain anaesthesia and facilitate recovery in veterinary medicine.,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used in combination with oxygen as part of a respiratory gas mixture (N20/02) to maintain anaesthesia and facilitate recovery in veterinary medicine.
noradrenaline,Noradrenaline brain concentrations are not significantly affected by amantadine hydrochloride administration in rats.,Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline brain concentrations are not significantly affected by amantadine hydrochloride administration in rats.
catecholamine,Catecholamine metabolism in the rat brain is not significantly altered by amantadine hydrochloride administration.,Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Catecholamine metabolism in the rat brain is not significantly altered by amantadine hydrochloride administration.
amantadine hydrochloride,Amantadine hydrochloride does not significantly affect brain concentrations of dopamine or noradrenaline even when administered daily for 9 days in rats.,Entity: amantadine hydrochloride. SMILES: Cl.NC12CC3CC(CC(C3)C1)C2. Amantadine hydrochloride does not significantly affect brain concentrations of dopamine or noradrenaline even when administered daily for 9 days in rats.
amantadine hydrochloride,Amantadine hydrochloride does not alter the rate of decline of noradrenaline and dopamine concentrations after alpha-methyl-p-tyrosine administration in rats.,Entity: amantadine hydrochloride. SMILES: Cl.NC12CC3CC(CC(C3)C1)C2. Amantadine hydrochloride does not alter the rate of decline of noradrenaline and dopamine concentrations after alpha-methyl-p-tyrosine administration in rats.
amantadine hydrochloride,"At high concentrations, amantadine hydrochloride inhibits dopamine uptake into rat brain synaptosomes but causes little dopamine release from these cells in vitro.","Entity: amantadine hydrochloride. SMILES: Cl.NC12CC3CC(CC(C3)C1)C2. At high concentrations, amantadine hydrochloride inhibits dopamine uptake into rat brain synaptosomes but causes little dopamine release from these cells in vitro."
amantadine hydrochloride,The anti-Parkinsonian effect of amantadine hydrochloride is not related to its action on dopaminergic mechanisms.,Entity: amantadine hydrochloride. SMILES: Cl.NC12CC3CC(CC(C3)C1)C2. The anti-Parkinsonian effect of amantadine hydrochloride is not related to its action on dopaminergic mechanisms.
dopamine,Dopamine brain concentrations are not significantly affected by amantadine hydrochloride administration in rats.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine brain concentrations are not significantly affected by amantadine hydrochloride administration in rats.
sodium bicarbonate,Sodium bicarbonate is used to adjust the pH of 0.32M sucrose to 7.0 for brain homogenate preparation.,Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Sodium bicarbonate is used to adjust the pH of 0.32M sucrose to 7.0 for brain homogenate preparation.
sucrose,Sucrose at 0.32 M concentration is used as the buffer for homogenizing brain tissue samples.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose at 0.32 M concentration is used as the buffer for homogenizing brain tissue samples.
dopamine,Dopamine is used as a radiolabeled substrate to measure dopamine uptake into brain homogenates by synaptosomes.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine is used as a radiolabeled substrate to measure dopamine uptake into brain homogenates by synaptosomes.
sodium hydroxide,Sodium hydroxide at 0.5 M concentration is used to disperse collected pellets in the dopamine uptake assay protocol.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide at 0.5 M concentration is used to disperse collected pellets in the dopamine uptake assay protocol.
water,Distilled water is used to shake the dried membrane filter in the dopamine uptake assay prior to liquid scintillation counting.,Entity: water. SMILES: O. Distilled water is used to shake the dried membrane filter in the dopamine uptake assay prior to liquid scintillation counting.
benapryzine,Benapryzine inhibits dopamine uptake more effectively than amantadine in vitro.,Entity: benapryzine. SMILES: CCCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1. Benapryzine inhibits dopamine uptake more effectively than amantadine in vitro.
rimantadine,"Rimantadine, an amantadine analogue, inhibits dopamine uptake more effectively than amantadine in vitro.","Entity: rimantadine. SMILES: CC(N)C12CC3CC(CC(C3)C1)C2. Rimantadine, an amantadine analogue, inhibits dopamine uptake more effectively than amantadine in vitro."
haloperidol,Haloperidol inhibits dopamine uptake more effectively than amantadine in vitro.,Entity: haloperidol. SMILES: O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1. Haloperidol inhibits dopamine uptake more effectively than amantadine in vitro.
5-hydroxytryptamine,"Amantadine is no more effective than other drugs in blocking 5-hydroxytryptamine uptake, indicating a limited role for this mechanism in its pharmacological effects.","Entity: 5-hydroxytryptamine. SMILES: NCCc1c[nH]c2ccc(O)cc12. Amantadine is no more effective than other drugs in blocking 5-hydroxytryptamine uptake, indicating a limited role for this mechanism in its pharmacological effects."
amantadine,"Amantadine acts as a non-competitive inhibitor of dopamine uptake in vitro, as indicated by a downward displacement of Vmax in linear plots of uptake versus initial concentration.","Entity: amantadine. SMILES: NC12CC3CC(CC(C3)C1)C2. Amantadine acts as a non-competitive inhibitor of dopamine uptake in vitro, as indicated by a downward displacement of Vmax in linear plots of uptake versus initial concentration."
amantadine,"Amantadine is less effective than other drugs such as amphetamine, benapryzine, and rimantadine in inhibiting dopamine uptake in vitro.","Entity: amantadine. SMILES: NC12CC3CC(CC(C3)C1)C2. Amantadine is less effective than other drugs such as amphetamine, benapryzine, and rimantadine in inhibiting dopamine uptake in vitro."
amantadine,"Amantadine shows similar effectiveness in blocking dopamine uptake as in blocking noradrenaline or 5-hydroxytryptamine uptake, suggesting its mechanism is unlikely to underlie the anti-Parkinsonian action of amantadine.","Entity: amantadine. SMILES: NC12CC3CC(CC(C3)C1)C2. Amantadine shows similar effectiveness in blocking dopamine uptake as in blocking noradrenaline or 5-hydroxytryptamine uptake, suggesting its mechanism is unlikely to underlie the anti-Parkinsonian action of amantadine."
amphetamine,"Amphetamine acts as a competitive inhibitor of dopamine uptake in vitro, as indicated by a rightward displacement of apparent Km in linear plots of uptake versus initial concentration.","Entity: amphetamine. SMILES: CC(N)Cc1ccccc1. Amphetamine acts as a competitive inhibitor of dopamine uptake in vitro, as indicated by a rightward displacement of apparent Km in linear plots of uptake versus initial concentration."
amphetamine,"Amphetamine is a powerful inhibitor of noradrenaline uptake in vitro, with minimal effect on noradrenaline release.","Entity: amphetamine. SMILES: CC(N)Cc1ccccc1. Amphetamine is a powerful inhibitor of noradrenaline uptake in vitro, with minimal effect on noradrenaline release."
calcium,Increased availability of calcium at active sodium (NA) releasing sites in the axon leads to decreased inhibition of NA release by prostaglandin E2.,Entity: calcium. SMILES: [Ca]. Increased availability of calcium at active sodium (NA) releasing sites in the axon leads to decreased inhibition of NA release by prostaglandin E2.
tetracaine,Tetracaine can counteract the inhibitory action of prostaglandin E2 on nerve impulse-mediated neurotransmitter release by increasing norepinephrine release per nerve impulse.,Entity: tetracaine. SMILES: CCCCNc1ccc(C(=O)OCCN(C)C)cc1. Tetracaine can counteract the inhibitory action of prostaglandin E2 on nerve impulse-mediated neurotransmitter release by increasing norepinephrine release per nerve impulse.
rubidium,Rubidium can counteract the inhibitory action of prostaglandin E2 on nerve impulse-mediated neurotransmitter release by increasing norepinephrine release per nerve impulse.,Entity: rubidium. SMILES: [Rb]. Rubidium can counteract the inhibitory action of prostaglandin E2 on nerve impulse-mediated neurotransmitter release by increasing norepinephrine release per nerve impulse.
propranolol,"Propranolol increases norepinephrine release per nerve impulse, and this effect persists even after blockade of norepinephrine uptake mechanisms.","Entity: propranolol. SMILES: CC(C)NCC(O)COc1cccc2ccccc12. Propranolol increases norepinephrine release per nerve impulse, and this effect persists even after blockade of norepinephrine uptake mechanisms."
tetraethylammonium,"Tetraethylammonium enhances the evoked overflow of [3H]-(-)-NA and increases NA release per nerve impulse in the guinea-pig vas deferens, with this effect persisting after blockade of NA uptake mechanisms.","Entity: tetraethylammonium. SMILES: CC[N+](CC)(CC)CC. Tetraethylammonium enhances the evoked overflow of [3H]-(-)-NA and increases NA release per nerve impulse in the guinea-pig vas deferens, with this effect persisting after blockade of NA uptake mechanisms."
rubidium,"Rubidium enhances the evoked overflow of [3H]-(-)-NA and increases NA release per nerve impulse in the guinea-pig vas deferens, with this effect remaining after blockade of NA uptake mechanisms.","Entity: rubidium. SMILES: [Rb]. Rubidium enhances the evoked overflow of [3H]-(-)-NA and increases NA release per nerve impulse in the guinea-pig vas deferens, with this effect remaining after blockade of NA uptake mechanisms."
tetraethylammonium,"Tetraethylammonium (TEA) enhances nerve action potential duration and increases evoked norepinephrine (NA) release, likely by prolonging the action potential through increased calcium influx.","Entity: tetraethylammonium. SMILES: CC[N+](CC)(CC)CC. Tetraethylammonium (TEA) enhances nerve action potential duration and increases evoked norepinephrine (NA) release, likely by prolonging the action potential through increased calcium influx."
tetraethylammonium,"Tetraethylammonium (TEA) at concentrations of 1 mM and 10 mM causes maximal enhancement of evoked NA release, suggesting complete inactivation of potassium channels in nerve axons.","Entity: tetraethylammonium. SMILES: CC[N+](CC)(CC)CC. Tetraethylammonium (TEA) at concentrations of 1 mM and 10 mM causes maximal enhancement of evoked NA release, suggesting complete inactivation of potassium channels in nerve axons."
rubidium,"Rubidium ions prolong the nerve action potential and enhance evoked NA release, likely by increasing calcium influx into the axon.","Entity: rubidium. SMILES: [Rb]. Rubidium ions prolong the nerve action potential and enhance evoked NA release, likely by increasing calcium influx into the axon."
potassium,The outward movement of potassium during the nerve action potential is proposed to modulate calcium entry into the axon and thereby control norepinephrine release.,Entity: potassium. SMILES: [K]. The outward movement of potassium during the nerve action potential is proposed to modulate calcium entry into the axon and thereby control norepinephrine release.
calcium,Increased calcium entry into the axon during the nerve action potential is implicated in the mechanisms of enhanced transmitter release and action potential prolongation.,Entity: calcium. SMILES: [Ca]. Increased calcium entry into the axon during the nerve action potential is implicated in the mechanisms of enhanced transmitter release and action potential prolongation.
rubidium,"Rubidium at 6 mM significantly increases the overflow of [3H]-(-)-noradrenaline induced by transmural nerve stimulation (5 Hz, 1 ms, 450 pulses) in guinea-pig vasa deferentia, without affecting spontaneous efflux.","Entity: rubidium. SMILES: [Rb]. Rubidium at 6 mM significantly increases the overflow of [3H]-(-)-noradrenaline induced by transmural nerve stimulation (5 Hz, 1 ms, 450 pulses) in guinea-pig vasa deferentia, without affecting spontaneous efflux."
tetraethylammonium,"Tetraethylammonium at 2 mM significantly increases the overflow of [3H]-(-)-noradrenaline induced by transmural nerve stimulation (5 Hz, 1 ms, 450 pulses) in guinea-pig vasa deferentia, without affecting spontaneous efflux.","Entity: tetraethylammonium. SMILES: CC[N+](CC)(CC)CC. Tetraethylammonium at 2 mM significantly increases the overflow of [3H]-(-)-noradrenaline induced by transmural nerve stimulation (5 Hz, 1 ms, 450 pulses) in guinea-pig vasa deferentia, without affecting spontaneous efflux."
prostaglandin B2,"Prostaglandin B2 inhibits the overflow of [3H]-(-)-noradrenaline induced by transmural nerve stimulation (5 Hz, 1 ms, 450 pulses) in guinea-pig vasa deferentia, and its inhibitory effect can be modulated by TEA and rubidium.","Entity: prostaglandin B2. SMILES: CCCCC[C@H](O)/C=C/C1=C(C/C=C\CCCC(=O)O)C(=O)CC1. Prostaglandin B2 inhibits the overflow of [3H]-(-)-noradrenaline induced by transmural nerve stimulation (5 Hz, 1 ms, 450 pulses) in guinea-pig vasa deferentia, and its inhibitory effect can be modulated by TEA and rubidium."
desipramine,"Desipramine at 0.5 µM, when given prior to transmural nerve stimulation, does not affect the TEA- and rubidium-induced enhancement of [3H]-(-)-noradrenaline release in guinea-pig vasa deferentia.","Entity: desipramine. SMILES: CNCCCN1c2ccccc2CCc2ccccc21. Desipramine at 0.5 µM, when given prior to transmural nerve stimulation, does not affect the TEA- and rubidium-induced enhancement of [3H]-(-)-noradrenaline release in guinea-pig vasa deferentia."
normetanephrine,"Normetanephrine at 1 µM, when administered prior to transmural nerve stimulation, does not affect the TEA- and rubidium-induced enhancement of [3H]-(-)-noradrenaline release in guinea-pig vasa deferentia.","Entity: normetanephrine. SMILES: COc1cc(C(O)CN)ccc1O. Normetanephrine at 1 µM, when administered prior to transmural nerve stimulation, does not affect the TEA- and rubidium-induced enhancement of [3H]-(-)-noradrenaline release in guinea-pig vasa deferentia."
glucose,"Glucose at 5.5 mM is a component of the Tyrode solution used to superfuse guinea-pig vasa deferentia, supporting nerve stimulation-induced [3H]-(-)-noradrenaline release.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose at 5.5 mM is a component of the Tyrode solution used to superfuse guinea-pig vasa deferentia, supporting nerve stimulation-induced [3H]-(-)-noradrenaline release."
ascorbic acid,Ascorbic acid at 0.1 mM is included in the Tyrode solution for superfusion of guinea-pig vasa deferentia during nerve stimulation experiments.,Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid at 0.1 mM is included in the Tyrode solution for superfusion of guinea-pig vasa deferentia during nerve stimulation experiments.
tetraethylammonium,"Tetraethylammonium increases calcium influx during the nerve action potential, thereby reducing the inhibitory effect of prostaglandin E2 on noradrenaline release in the guinea-pig vas deferens.","Entity: tetraethylammonium. SMILES: CC[N+](CC)(CC)CC. Tetraethylammonium increases calcium influx during the nerve action potential, thereby reducing the inhibitory effect of prostaglandin E2 on noradrenaline release in the guinea-pig vas deferens."
rubidium,"Rubidium increases calcium influx during the nerve action potential, which significantly reduces the inhibitory effect of prostaglandin E2 on noradrenaline release in the guinea-pig vas deferens.","Entity: rubidium. SMILES: [Rb]. Rubidium increases calcium influx during the nerve action potential, which significantly reduces the inhibitory effect of prostaglandin E2 on noradrenaline release in the guinea-pig vas deferens."
calcium,"Calcium influx is necessary for the extrusion of noradrenaline (NA) into the synaptic junction, and prostaglandin E inhibits adrenergic neurotransmission by reducing this influx.","Entity: calcium. SMILES: [Ca]. Calcium influx is necessary for the extrusion of noradrenaline (NA) into the synaptic junction, and prostaglandin E inhibits adrenergic neurotransmission by reducing this influx."
calcium,Prostaglandin E inhibits the uptake of calcium into membranes and facilitates its efflux from membranes.,Entity: calcium. SMILES: [Ca]. Prostaglandin E inhibits the uptake of calcium into membranes and facilitates its efflux from membranes.
tyramine,Tyramine-induced noradrenaline (NA) release is a calcium-independent process.,Entity: tyramine. SMILES: NCCc1ccc(O)cc1. Tyramine-induced noradrenaline (NA) release is a calcium-independent process.
tetraethylammonium,Tetraethylammonium (2 mM) increases the inhibitory action of prostaglandin E2 on noradrenaline release by reducing residual calcium at the active releasing sites in the axon.,Entity: tetraethylammonium. SMILES: CC[N+](CC)(CC)CC. Tetraethylammonium (2 mM) increases the inhibitory action of prostaglandin E2 on noradrenaline release by reducing residual calcium at the active releasing sites in the axon.
rubidium,Rubidium (6 mM) increases the inhibitory action of prostaglandin E2 on noradrenaline release by reducing residual calcium at the active releasing sites in the axon.,Entity: rubidium. SMILES: [Rb]. Rubidium (6 mM) increases the inhibitory action of prostaglandin E2 on noradrenaline release by reducing residual calcium at the active releasing sites in the axon.
prostaglandins,Prostaglandins inhibit the release of noradrenaline by restricting calcium availability during the nerve action potential.,Entity: prostaglandins. SMILES: CCCCCC(/C=C/C1C=CC(=O)C1C/C=C/CCCC(=O)OC)OC(C)=O. Prostaglandins inhibit the release of noradrenaline by restricting calcium availability during the nerve action potential.
calcium,Calcium influx during the nerve action potential is required for the inhibitory effect of prostaglandins on noradrenaline release.,Entity: calcium. SMILES: [Ca]. Calcium influx during the nerve action potential is required for the inhibitory effect of prostaglandins on noradrenaline release.
rubidium,"Rubidium (6 mM) increases the release of [3H]-(-)-noradrenaline per nerve impulse in guinea-pig vasa deferentia by counteracting the inhibitory effect of prostaglandin E2, likely by promoting calcium influx.","Entity: rubidium. SMILES: [Rb]. Rubidium (6 mM) increases the release of [3H]-(-)-noradrenaline per nerve impulse in guinea-pig vasa deferentia by counteracting the inhibitory effect of prostaglandin E2, likely by promoting calcium influx."
tetraethylammonium,"Tetraethylammonium (2 mM) increases the release of [3H]-(-)-noradrenaline per nerve impulse in guinea-pig vasa deferentia by counteracting the inhibitory effect of prostaglandin E2, likely by promoting calcium influx.","Entity: tetraethylammonium. SMILES: CC[N+](CC)(CC)CC. Tetraethylammonium (2 mM) increases the release of [3H]-(-)-noradrenaline per nerve impulse in guinea-pig vasa deferentia by counteracting the inhibitory effect of prostaglandin E2, likely by promoting calcium influx."
atropine,"Atropine acts as an antagonist at receptors mediating the inotropic actions of carbachol on guinea-pig atrial cells, with a log K value of 9.10 (dose-response ratio 127 at 10^-7 M) and 9.13 (dose-response ratio 135 at 10^-7 M) in Tyrode solution at 30°C.","Entity: atropine. SMILES: CN1[C@@H]2CC[C@H]1CC(OC(=O)C(CO)c1ccccc1)C2. Atropine acts as an antagonist at receptors mediating the inotropic actions of carbachol on guinea-pig atrial cells, with a log K value of 9.10 (dose-response ratio 127 at 10^-7 M) and 9.13 (dose-response ratio 135 at 10^-7 M) in Tyrode solution at 30°C."
dexetimide,"Dexetimide is an enantiomer with measured affinity for the inotropic carbachol receptor, and its stereospecificity has been demonstrated.","Entity: dexetimide. SMILES: O=C1CC[C@@](c2ccccc2)(C2CCN(Cc3ccccc3)CC2)C(=O)N1. Dexetimide is an enantiomer with measured affinity for the inotropic carbachol receptor, and its stereospecificity has been demonstrated."
levetimide,"Levetimide is an enantiomer with measured affinity for the inotropic carbachol receptor, and its stereospecificity has been demonstrated.","Entity: levetimide. SMILES: O=C1CC[C@](c2ccccc2)(C2CCN(Cc3ccccc3)CC2)C(=O)N1. Levetimide is an enantiomer with measured affinity for the inotropic carbachol receptor, and its stereospecificity has been demonstrated."
carbachol,Carbachol acts on different receptors to affect the rate of beating and the force of contraction in guinea-pig atrial cells.,Entity: carbachol. SMILES: C[N+](C)(C)CCOC(N)=O.[Cl-]. Carbachol acts on different receptors to affect the rate of beating and the force of contraction in guinea-pig atrial cells.
hyoscine,"The value of A1 for hyoscine, calculated from mean dose-ratios, weighted mean dose-ratios, and the difference between mean values of log K, is 0.584.","Entity: hyoscine. SMILES: CN1[C@@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12. The value of A1 for hyoscine, calculated from mean dose-ratios, weighted mean dose-ratios, and the difference between mean values of log K, is 0.584."
phenylacetoxyethyl-N-methylpiperidinium iodide,Phenylacetoxyethyl-N-methylpiperidinium iodide exhibits a change in total free energy of adsorption (AG) of -0.4 kcal/mol when the temperature is lowered from 370°C to 270°C.,Entity: phenylacetoxyethyl-N-methylpiperidinium iodide. SMILES: C[N+]1(CCOC(=O)Cc2ccccc2)CCCCC1.[I-]. Phenylacetoxyethyl-N-methylpiperidinium iodide exhibits a change in total free energy of adsorption (AG) of -0.4 kcal/mol when the temperature is lowered from 370°C to 270°C.
lachesine,Lachesine binds to muscarine-sensitive receptors in guinea-pig ileum with an affinity increased 1.3-fold by lowering the temperature from 37.50°C to 30.50°C.,Entity: lachesine. SMILES: CC[N+](C)(C)CCOC(=O)C(O)(c1ccccc1)c1ccccc1. Lachesine binds to muscarine-sensitive receptors in guinea-pig ileum with an affinity increased 1.3-fold by lowering the temperature from 37.50°C to 30.50°C.
lachesine,Lachesine has an enthalpy of adsorption (AH) of approximately -7 kcal/mol (-29 kJ/mol) and a free energy of adsorption (AG) of -12.6 kcal/mol (-53 kJ/mol) for binding to muscarine-sensitive receptors.,Entity: lachesine. SMILES: CC[N+](C)(C)CCOC(=O)C(O)(c1ccccc1)c1ccccc1. Lachesine has an enthalpy of adsorption (AH) of approximately -7 kcal/mol (-29 kJ/mol) and a free energy of adsorption (AG) of -12.6 kcal/mol (-53 kJ/mol) for binding to muscarine-sensitive receptors.
lachesine,Lachesine exhibits a change in total free energy of adsorption (AG) of +5.6 kcal/mol when the temperature is lowered from 37.50°C to 30.50°C.,Entity: lachesine. SMILES: CC[N+](C)(C)CCOC(=O)C(O)(c1ccccc1)c1ccccc1. Lachesine exhibits a change in total free energy of adsorption (AG) of +5.6 kcal/mol when the temperature is lowered from 37.50°C to 30.50°C.
phenylacetoxyethyl-N-methylpiperidinium iodide,Phenylacetoxyethyl-N-methylpiperidinium iodide has a log K increased by 0.18 when the temperature is lowered from 370°C to 270°C.,Entity: phenylacetoxyethyl-N-methylpiperidinium iodide. SMILES: C[N+]1(CCOC(=O)Cc2ccccc2)CCCCC1.[I-]. Phenylacetoxyethyl-N-methylpiperidinium iodide has a log K increased by 0.18 when the temperature is lowered from 370°C to 270°C.
phenylacetoxyethyl-N-methylpiperidinium iodide,Phenylacetoxyethyl-N-methylpiperidinium iodide has an enthalpy of adsorption (AH) of approximately -7.8 kcal/mol (-33 kJ/mol) and a free energy of adsorption (AG) of -7.4 kcal/mol (-31 kJ/mol) for binding to muscarine-sensitive receptors.,Entity: phenylacetoxyethyl-N-methylpiperidinium iodide. SMILES: C[N+]1(CCOC(=O)Cc2ccccc2)CCCCC1.[I-]. Phenylacetoxyethyl-N-methylpiperidinium iodide has an enthalpy of adsorption (AH) of approximately -7.8 kcal/mol (-33 kJ/mol) and a free energy of adsorption (AG) of -7.4 kcal/mol (-31 kJ/mol) for binding to muscarine-sensitive receptors.
scopine,Scopines have higher specificity for muscarinesensitive acetylcholine receptors in the ileum than their tropine analogues.,Entity: scopine. SMILES: CN1[C@@H]2CC(O)C[C@H]1[C@@H]1O[C@@H]12. Scopines have higher specificity for muscarinesensitive acetylcholine receptors in the ileum than their tropine analogues.
4-hydroxy-N-methylpiperidine,Replacement of choline by 4-hydroxy-N-methylpiperidine in muscarinesensitive acetylcholine receptor analogues greatly increases specificity for ileal receptors.,Entity: 4-hydroxy-N-methylpiperidine. SMILES: CN1CCC(O)CC1. Replacement of choline by 4-hydroxy-N-methylpiperidine in muscarinesensitive acetylcholine receptor analogues greatly increases specificity for ileal receptors.
tropine,Tropine analogues have lower specificity for muscarinesensitive acetylcholine receptors in the ileum compared to scopines and 4-hydroxy-N-methylpiperidine analogues.,Entity: tropine. SMILES: CN1[C@@H]2CC[C@H]1CC(O)C2. Tropine analogues have lower specificity for muscarinesensitive acetylcholine receptors in the ileum compared to scopines and 4-hydroxy-N-methylpiperidine analogues.
atropine,Atropine is a quaternary salt that exhibits relatively high affinity for muscarinesensitive acetylcholine receptors in the ileum compared to other quaternary salts studied.,Entity: atropine. SMILES: CN1[C@@H]2CC[C@H]1CC(OC(=O)C(CO)c1ccccc1)C2. Atropine is a quaternary salt that exhibits relatively high affinity for muscarinesensitive acetylcholine receptors in the ileum compared to other quaternary salts studied.
3-hydroxyquinuclidine,The replacement of choline by 3-hydroxyquinuclidine in muscarinesensitive acetylcholine receptor analogues reduces specificity for ileal receptors.,Entity: 3-hydroxyquinuclidine. SMILES: OC1CN2CCC1CC2. The replacement of choline by 3-hydroxyquinuclidine in muscarinesensitive acetylcholine receptor analogues reduces specificity for ileal receptors.
diphenylethoxyethyltrimethylammonium bromide,"The mean estimate of log K for diphenylethoxyethyltrimethylammonium bromide is 6.421, based on independent experiments.","Entity: diphenylethoxyethyltrimethylammonium bromide. SMILES: C[N+](C)(C)CCOCC(c1ccccc1)c1ccccc1.[Br-]. The mean estimate of log K for diphenylethoxyethyltrimethylammonium bromide is 6.421, based on independent experiments."
pargyline,Pargyline is used as an additive in blood collection tubes to facilitate the determination of norepinephrine concentration.,Entity: pargyline. SMILES: C#CCN(C)Cc1ccccc1. Pargyline is used as an additive in blood collection tubes to facilitate the determination of norepinephrine concentration.
ethylenediaminetetraacetic acid,Ethylenediaminetetraacetic acid (EDTA) is used at 5 mM concentration in muscle homogenates to stabilize enzymes during glycogen synthase activity assays.,Entity: ethylenediaminetetraacetic acid. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. Ethylenediaminetetraacetic acid (EDTA) is used at 5 mM concentration in muscle homogenates to stabilize enzymes during glycogen synthase activity assays.
reduced glutathione,Reduced glutathione is included in blood collection tubes to aid in the preparation of plasma samples for norepinephrine analysis.,Entity: reduced glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Reduced glutathione is included in blood collection tubes to aid in the preparation of plasma samples for norepinephrine analysis.
glucose 6-phosphate,Glucose 6-phosphate is used at 6.7 mM concentration as a substrate in the assay for glycogen synthase activity in muscle homogenates.,Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose 6-phosphate is used at 6.7 mM concentration as a substrate in the assay for glycogen synthase activity in muscle homogenates.
glucose 6-phosphate,"Glucose 6-phosphate is required at high concentrations to activate the phosphorylated form of glycogen synthase (glycogen synthase D), which is the primary form of the enzyme active in glycogen synthesis.","Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose 6-phosphate is required at high concentrations to activate the phosphorylated form of glycogen synthase (glycogen synthase D), which is the primary form of the enzyme active in glycogen synthesis."
glucose 6-phosphate,"In muscle cells, high concentrations of glucose 6-phosphate are present along with other phosphate species and contribute to severe inhibition of glycogen synthase activity in the presence of glycogen synthase I at 20% activity.","Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. In muscle cells, high concentrations of glucose 6-phosphate are present along with other phosphate species and contribute to severe inhibition of glycogen synthase activity in the presence of glycogen synthase I at 20% activity."
phosphate,"In muscle cells, high concentrations of phosphate (2 mol per enzyme subunit) inhibit glycogen synthase activity, resulting in very low actual glycogen synthase activity.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. In muscle cells, high concentrations of phosphate (2 mol per enzyme subunit) inhibit glycogen synthase activity, resulting in very low actual glycogen synthase activity."
norepinephrine,"Plasma norepinephrine concentrations are elevated in the postexercise period, which is associated with increased glycogen synthesis despite low insulin.","Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Plasma norepinephrine concentrations are elevated in the postexercise period, which is associated with increased glycogen synthesis despite low insulin."
glucagon,"Plasma glucagon concentrations are elevated in the postexercise period, which is associated with increased glycogen synthesis despite low insulin.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Plasma glucagon concentrations are elevated in the postexercise period, which is associated with increased glycogen synthesis despite low insulin."
glucagon,"Glucagon concentrations are elevated in the postexercise period, which is associated with increased glycogen synthesis despite low plasma insulin.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon concentrations are elevated in the postexercise period, which is associated with increased glycogen synthesis despite low plasma insulin."
norepinephrine,"Norepinephrine concentrations are elevated in the postexercise period, which is associated with increased glycogen synthesis despite low plasma insulin.","Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Norepinephrine concentrations are elevated in the postexercise period, which is associated with increased glycogen synthesis despite low plasma insulin."
norepinephrine,"Elevated plasma norepinephrine levels inhibit glycogen synthesis and promote glycogenolysis, contributing to a hormonal environment that opposes glycogen synthesis.","Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Elevated plasma norepinephrine levels inhibit glycogen synthesis and promote glycogenolysis, contributing to a hormonal environment that opposes glycogen synthesis."
glucagon,"Elevated plasma glucagon concentrations inhibit glycogen synthesis and promote glycogenolysis, creating a hormonal milieu unfavorable for glycogen synthesis.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Elevated plasma glucagon concentrations inhibit glycogen synthesis and promote glycogenolysis, creating a hormonal milieu unfavorable for glycogen synthesis."
glucagon,"Plasma glucagon concentrations are elevated in the postexercise period, contributing to a hormonal milieu that is generally conducive to glycogenolysis but does not prevent rapid glycogen synthesis in muscle.","Entity: glucagon. Plasma glucagon concentrations are elevated in the postexercise period, contributing to a hormonal milieu that is generally conducive to glycogenolysis but does not prevent rapid glycogen synthesis in muscle."
potassium,"Urinary potassium excretion in monkeys varies by 24-hour mean, with a mean rate of 74 µeq/h in animals fed early in the light period and 129 µeq/h in those fed late in the light period, correlating with differences in food intake.","Entity: potassium. SMILES: [K]. Urinary potassium excretion in monkeys varies by 24-hour mean, with a mean rate of 74 µeq/h in animals fed early in the light period and 129 µeq/h in those fed late in the light period, correlating with differences in food intake."
potassium,Potassium concentration in urine can be measured by flame photometry.,Entity: potassium. SMILES: [K]. Potassium concentration in urine can be measured by flame photometry.
potassium,"Urinary potassium excretion in squirrel monkeys is modulated by feeding (EF) cycles, which provide temporal information that entrains circadian rhythms.","Entity: potassium. SMILES: [K]. Urinary potassium excretion in squirrel monkeys is modulated by feeding (EF) cycles, which provide temporal information that entrains circadian rhythms."
potassium,"In group 1 monkeys, the urinary rhythm for potassium was observed at 7.1 ± 4.7 h, indicating a period of increased urinary excretion at this time.","Entity: potassium. SMILES: [K]. In group 1 monkeys, the urinary rhythm for potassium was observed at 7.1 ± 4.7 h, indicating a period of increased urinary excretion at this time."
procaine,"After intra-articular injection of procaine hydrochloride in horses, blood levels of procaine rise and then decline rapidly, with no detectable plasma levels remaining after treatment.","Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1.Cl. After intra-articular injection of procaine hydrochloride in horses, blood levels of procaine rise and then decline rapidly, with no detectable plasma levels remaining after treatment."
procaine penicillin,"After intramuscular injection of procaine penicillin in horses, blood levels of procaine reach a peak relatively slowly and decline very slowly, with an apparent plasma half-life of about 10 hours.","Entity: procaine penicillin. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O.CCN(CC)CCOC(=O)c1ccc(N)cc1.O. After intramuscular injection of procaine penicillin in horses, blood levels of procaine reach a peak relatively slowly and decline very slowly, with an apparent plasma half-life of about 10 hours."
procaine,"Procaine can be quantified in plasma using Brodie's colorimetric method, which involves extraction at pH 8 and detection with ethylene diamine.","Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1. Procaine can be quantified in plasma using Brodie's colorimetric method, which involves extraction at pH 8 and detection with ethylene diamine."
arsenite,Arsenite is used to stop the reaction in Brodie's colorimetric method for procaine quantification in plasma.,Entity: arsenite. SMILES: [O-][As]([O-])[O-]. Arsenite is used to stop the reaction in Brodie's colorimetric method for procaine quantification in plasma.
para-amino-benzoic acid,Para-amino-benzoic acid is not extracted under alkaline conditions (pH 8) during Brodie's colorimetric method for procaine detection.,Entity: para-amino-benzoic acid. SMILES: Nc1ccc(C(=O)O)cc1. Para-amino-benzoic acid is not extracted under alkaline conditions (pH 8) during Brodie's colorimetric method for procaine detection.
procaine,"After subcutaneous injection of procaine HCl (3.3 mg/kg) in horses, plasma levels peak at about 400 ng/ml and decline with a half-life of about 75 minutes, fitting a modified Model I with a first-order absorption rate constant (K = 0.048 min-1) from the subcutaneous site.","Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1. After subcutaneous injection of procaine HCl (3.3 mg/kg) in horses, plasma levels peak at about 400 ng/ml and decline with a half-life of about 75 minutes, fitting a modified Model I with a first-order absorption rate constant (K = 0.048 min-1) from the subcutaneous site."
procaine,"After intramuscular injection of procaine penicillin (33,000 I.U./kg) in horses, plasma levels reach a peak at about 270 ng/ml and decline with a half-life of about 9 hours, fitting a Model II with a first-order absorption rate constant for procaine of 0.0024 min-1.","Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1. After intramuscular injection of procaine penicillin (33,000 I.U./kg) in horses, plasma levels reach a peak at about 270 ng/ml and decline with a half-life of about 9 hours, fitting a Model II with a first-order absorption rate constant for procaine of 0.0024 min-1."
procaine,"After intramuscular injection of procaine HCl (10 mg/kg) in horses, plasma levels peak rapidly at about 600 ng/ml but decline slowly with a half-life of about 2 hours, making pharmacokinetic modeling difficult.","Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1. After intramuscular injection of procaine HCl (10 mg/kg) in horses, plasma levels peak rapidly at about 600 ng/ml but decline slowly with a half-life of about 2 hours, making pharmacokinetic modeling difficult."
procaine,"After intra-articular administration of procaine (0.33 mg/kg) in horses, plasma levels reach a peak at about 17 ng/ml and decline with a half-life of about 2 hours.","Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1. After intra-articular administration of procaine (0.33 mg/kg) in horses, plasma levels reach a peak at about 17 ng/ml and decline with a half-life of about 2 hours."
procaine penicillin,"After intramuscular injection of procaine penicillin (33,000 I.U./kg) in horses, plasma levels reach a peak at about 270 ng/ml and decline with a half-life of about 9 hours.","Entity: procaine penicillin. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O.CCN(CC)CCOC(=O)c1ccc(N)cc1.O. After intramuscular injection of procaine penicillin (33,000 I.U./kg) in horses, plasma levels reach a peak at about 270 ng/ml and decline with a half-life of about 9 hours."
procaine,"Procaine is a drug with both local anaesthetic and central stimulant actions, and its presence in the blood or urine of racing horses is forbidden.","Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1. Procaine is a drug with both local anaesthetic and central stimulant actions, and its presence in the blood or urine of racing horses is forbidden."
procaine,"After rapid intravenous injection of procaine HCl (2.5 mg/kg) in thoroughbred mares, plasma levels fall rapidly (t1/2 alpha = 5 min) and then more slowly (t1/2 beta = 50.2 min), fitting a two-compartment open model (Model I) with an apparent Vdbeta of about 3,500 litres.","Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1. After rapid intravenous injection of procaine HCl (2.5 mg/kg) in thoroughbred mares, plasma levels fall rapidly (t1/2 alpha = 5 min) and then more slowly (t1/2 beta = 50.2 min), fitting a two-compartment open model (Model I) with an apparent Vdbeta of about 3,500 litres."
procaine,"Due to approximately 45% binding to equine plasma protein, the true Vdbeta for procaine in horses is about 6,500 litres.","Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1. Due to approximately 45% binding to equine plasma protein, the true Vdbeta for procaine in horses is about 6,500 litres."
fluoride,"Fluoride, when combined with oxalate and cooling, produces essentially complete inhibition of equine plasma esterases.","Entity: fluoride. SMILES: [F-]. Fluoride, when combined with oxalate and cooling, produces essentially complete inhibition of equine plasma esterases."
oxalate,"Oxalate, when combined with fluoride and cooling, produces essentially complete inhibition of equine plasma esterases.","Entity: oxalate. SMILES: O=C([O-])C(=O)[O-]. Oxalate, when combined with fluoride and cooling, produces essentially complete inhibition of equine plasma esterases."
procaine,Procaine levels in equine plasma can be preserved by adding 1 mM eserine to Vacutainer tubes during blood collection.,Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1. Procaine levels in equine plasma can be preserved by adding 1 mM eserine to Vacutainer tubes during blood collection.
procaine,Procaine is hydrolyzed by equine plasma esterases with an apparent half-life of about 9 minutes at 37°C when 2 µg/ml of procaine is added to freshly drawn equine blood in vitro.,Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1. Procaine is hydrolyzed by equine plasma esterases with an apparent half-life of about 9 minutes at 37°C when 2 µg/ml of procaine is added to freshly drawn equine blood in vitro.
procaine,Procaine undergoes hydrolysis in equine blood at a rate that is about one-tenth as fast as in human blood.,Entity: procaine. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1. Procaine undergoes hydrolysis in equine blood at a rate that is about one-tenth as fast as in human blood.
sodium fluoride,"Sodium fluoride inhibits equine plasma esterase activity, as shown in in vitro experiments.","Entity: sodium fluoride. SMILES: [F-].[Na+]. Sodium fluoride inhibits equine plasma esterase activity, as shown in in vitro experiments."
oxalate,"Oxalate inhibits equine plasma esterase activity, as demonstrated in in vitro experiments.","Entity: oxalate. SMILES: O=C([O-])C(=O)[O-]. Oxalate inhibits equine plasma esterase activity, as demonstrated in in vitro experiments."
procaine,"Procaine is relatively rapidly hydrolyzed in equine plasma, and this hydrolysis is blocked by eserine or cooling plus oxalate and fluoride.","Entity: procaine. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O.CCN(CC)CCOC(=O)c1ccc(N)cc1.O. Procaine is relatively rapidly hydrolyzed in equine plasma, and this hydrolysis is blocked by eserine or cooling plus oxalate and fluoride."
procaine,"Procaine has a metabolic or d3 phase half-life in horses of about 50 minutes, which is attributed to wide distribution and tissue binding.","Entity: procaine. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O.CCN(CC)CCOC(=O)c1ccc(N)cc1.O. Procaine has a metabolic or d3 phase half-life in horses of about 50 minutes, which is attributed to wide distribution and tissue binding."
procaine,"When administered to horses, procaine has a bloodstream half-life of about 2.0 hours or less, regardless of the route of administration.","Entity: procaine. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O.CCN(CC)CCOC(=O)c1ccc(N)cc1.O. When administered to horses, procaine has a bloodstream half-life of about 2.0 hours or less, regardless of the route of administration."
procaine,"When administered to horses as procaine penicillin, the half-life of procaine is about 10 hours.","Entity: procaine. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O.CCN(CC)CCOC(=O)c1ccc(N)cc1.O. When administered to horses as procaine penicillin, the half-life of procaine is about 10 hours."
procaine,Procaine is detectable in the urine of horses for some time after it has disappeared from their bloodstream.,Entity: procaine. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O.CCN(CC)CCOC(=O)c1ccc(N)cc1.O. Procaine is detectable in the urine of horses for some time after it has disappeared from their bloodstream.
procaine hydrochloride,"Procaine hydrochloride is administered intravenously and exhibits pharmacokinetic parameters including a clearance of 0.1262 min⁻¹, a volume of distribution (Vc) of 1.19 Litres/kg, and a half-life (t1/2) of 5.49 minutes after intravenous administration in horses.","Entity: procaine hydrochloride. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1.Cl. Procaine hydrochloride is administered intravenously and exhibits pharmacokinetic parameters including a clearance of 0.1262 min⁻¹, a volume of distribution (Vc) of 1.19 Litres/kg, and a half-life (t1/2) of 5.49 minutes after intravenous administration in horses."
potassium dichromate,"Potassium dichromate is used for oxidative fragmentation of drugs to form derivatizable groups, enabling subsequent direct derivatization for gas-liquid chromatographic analysis.","Entity: potassium dichromate. SMILES: O=[Cr](=O)([O-])O[Cr](=O)(=O)[O-].[K+].[K+]. Potassium dichromate is used for oxidative fragmentation of drugs to form derivatizable groups, enabling subsequent direct derivatization for gas-liquid chromatographic analysis."
lithium aluminum hydride,"Lithium aluminum hydride is used for reductive fragmentation of drugs to form alcohols, which can subsequently be converted to ester derivatives for gas-liquid chromatographic analysis.","Entity: lithium aluminum hydride. SMILES: [AlH4-].[Li+]. Lithium aluminum hydride is used for reductive fragmentation of drugs to form alcohols, which can subsequently be converted to ester derivatives for gas-liquid chromatographic analysis."
heptafluorobutyric,Heptafluorobutyric anhydride is used as a derivatizing agent to form strongly electron-capturing amides and esters for gas-liquid chromatographic detection of drugs.,Entity: heptafluorobutyric. SMILES: O=C(O)C(F)(F)C(F)(F)C(F)(F)F. Heptafluorobutyric anhydride is used as a derivatizing agent to form strongly electron-capturing amides and esters for gas-liquid chromatographic detection of drugs.
trichloroethanol,"Trichloroethanol is a neutral compound formed from chloral hydrate metabolism and is present in saliva and plasma at concentrations similar to those of chloral hydrate, persisting up to 24 hours after administration.","Entity: trichloroethanol. SMILES: OCC(Cl)(Cl)Cl. Trichloroethanol is a neutral compound formed from chloral hydrate metabolism and is present in saliva and plasma at concentrations similar to those of chloral hydrate, persisting up to 24 hours after administration."
chloral hydrate,Chloral hydrate is rapidly metabolized in the body to trichloroethanol.,Entity: chloral hydrate. SMILES: OC(O)C(Cl)(Cl)Cl. Chloral hydrate is rapidly metabolized in the body to trichloroethanol.
sodium salicylate,"Sodium salicylate is rapidly excreted in horses, with only a small percentage being metabolized mainly to glucuronides, which are likely to have low fat solubility and may not pass into saliva.","Entity: sodium salicylate. SMILES: O=C([O-])c1ccccc1O.[Na+]. Sodium salicylate is rapidly excreted in horses, with only a small percentage being metabolized mainly to glucuronides, which are likely to have low fat solubility and may not pass into saliva."
malate,"Malate is in rapid equilibrium with oxalacetate, citrate, and aspartate during the initial stage of gluconeogenesis.","Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate is in rapid equilibrium with oxalacetate, citrate, and aspartate during the initial stage of gluconeogenesis."
citrate,"Citrate is in rapid equilibrium with oxalacetate, malate, and aspartate during the initial stage of gluconeogenesis.","Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Citrate is in rapid equilibrium with oxalacetate, malate, and aspartate during the initial stage of gluconeogenesis."
aspartate,"Aspartate is in rapid equilibrium with oxalacetate, malate, and citrate during the initial stage of gluconeogenesis.","Entity: aspartate. SMILES: N[C@@H](CC(=O)[O-])C(=O)[O-]. Aspartate is in rapid equilibrium with oxalacetate, malate, and citrate during the initial stage of gluconeogenesis."
glucose,The incorporation of 14C from bicarbonate into blood glucose is suppressed during glucose loading.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. The incorporation of 14C from bicarbonate into blood glucose is suppressed during glucose loading.
bicarbonate,The incorporation of 14C from bicarbonate into blood glucose is suppressed during glucose loading.,Entity: bicarbonate. SMILES: O=C([O-])O. The incorporation of 14C from bicarbonate into blood glucose is suppressed during glucose loading.
epinephrine,"Epinephrine may retard peripheral glucose utilization, potentially affecting blood glucose homeostasis.","Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. Epinephrine may retard peripheral glucose utilization, potentially affecting blood glucose homeostasis."
pyruvate,"Pyruvate is carboxylated in the initial stage of gluconeogenesis to yield oxalacetate, which is in rapid equilibrium with malate, citrate, and aspartate.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is carboxylated in the initial stage of gluconeogenesis to yield oxalacetate, which is in rapid equilibrium with malate, citrate, and aspartate."
oxalacetate,"Oxalacetate is produced by the carboxylation of pyruvate in the initial stage of gluconeogenesis and is in rapid equilibrium with malate, citrate, and aspartate.","Entity: oxalacetate. SMILES: O=C([O-])CC(=O)C(=O)[O-]. Oxalacetate is produced by the carboxylation of pyruvate in the initial stage of gluconeogenesis and is in rapid equilibrium with malate, citrate, and aspartate."
fructose,Increasing the dose of fructose to 600 mg results in a slight but significant decline in blood glucose 14C content in vivo.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Increasing the dose of fructose to 600 mg results in a slight but significant decline in blood glucose 14C content in vivo.
glucose,Glucose possesses unique properties for stimulating glycogenesis via the gluconeogenic pathway at the expense of glucose production.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose possesses unique properties for stimulating glycogenesis via the gluconeogenic pathway at the expense of glucose production.
xylose,"Injection of xylose at 500 mg/100 g body weight does not reduce the 14C content of blood glucose in vivo, with blood glucose 14C content remaining at 561 ± 34 cpm/0.1 ml blood 40 min after administration.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Injection of xylose at 500 mg/100 g body weight does not reduce the 14C content of blood glucose in vivo, with blood glucose 14C content remaining at 561 ± 34 cpm/0.1 ml blood 40 min after administration."
3-O-methylglucose,"Injection of 3-O-methylglucose at 500 mg/100 g body weight does not reduce the 14C content of blood glucose in vivo, with blood glucose 14C content remaining at 505 ± 33 cpm/0.1 ml blood 40 min after administration.","Entity: 3-O-methylglucose. SMILES: CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](O)C=O. Injection of 3-O-methylglucose at 500 mg/100 g body weight does not reduce the 14C content of blood glucose in vivo, with blood glucose 14C content remaining at 505 ± 33 cpm/0.1 ml blood 40 min after administration."
2-deoxyglucose,Injection of a large amount of 2-deoxyglucose does not suppress the incorporation of 14C into blood glucose and is ineffective in inducing glycogenesis in vivo.,Entity: 2-deoxyglucose. SMILES: O=CC[C@@H](O)[C@H](O)[C@H](O)CO. Injection of a large amount of 2-deoxyglucose does not suppress the incorporation of 14C into blood glucose and is ineffective in inducing glycogenesis in vivo.
glucose,Glucose incorporation of T-bicarbonate leads to increased glycogen formation and inhibition of glucose production.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose incorporation of T-bicarbonate leads to increased glycogen formation and inhibition of glucose production.
2-deoxyglucose,"2-deoxyglucose, a hexose structurally related to glucose, does not inhibit T-bicarbonate incorporation or glucose production.","Entity: 2-deoxyglucose. SMILES: O=CC[C@@H](O)[C@H](O)[C@H](O)CO. 2-deoxyglucose, a hexose structurally related to glucose, does not inhibit T-bicarbonate incorporation or glucose production."
3-O-methylglucose,"3-O-methylglucose, a hexose structurally related to glucose, does not inhibit T-bicarbonate incorporation or glucose production.","Entity: 3-O-methylglucose. SMILES: CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](O)C=O. 3-O-methylglucose, a hexose structurally related to glucose, does not inhibit T-bicarbonate incorporation or glucose production."
fructose,Fructose at a dose equivalent to glucose does not suppress 14C incorporation from bicarbonate into blood glucose.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose at a dose equivalent to glucose does not suppress 14C incorporation from bicarbonate into blood glucose.
fructose,Increasing fructose dose to 7 times that of glucose causes significant hyperglycemia and slight inhibition of [14C]glucose formation.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Increasing fructose dose to 7 times that of glucose causes significant hyperglycemia and slight inhibition of [14C]glucose formation.
glucose,Glucose injection inactivates phosphorylase and activates glycogen synthetase in rats.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose injection inactivates phosphorylase and activates glycogen synthetase in rats.
fructose,Fructose injection inactivates phosphorylase and activates glycogen synthetase in rats.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose injection inactivates phosphorylase and activates glycogen synthetase in rats.
xylose,Xylose does not affect phosphorylase or glycogen synthetase activities in rats.,Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose does not affect phosphorylase or glycogen synthetase activities in rats.
maltose,Maltose does not affect phosphorylase or glycogen synthetase activities in rats.,Entity: maltose. SMILES: OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O. Maltose does not affect phosphorylase or glycogen synthetase activities in rats.
fructose,"Fructose stimulates glycogenesis and increases glycogen synthesis, which is associated with increased glycogen synthetase I and decreased phosphorylase a activity.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose stimulates glycogenesis and increases glycogen synthesis, which is associated with increased glycogen synthetase I and decreased phosphorylase a activity."
fructose,Fructose is converted to glycogen and also stimulates glycogen formation via gluconeogenesis involving carbon dioxide fixation.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose is converted to glycogen and also stimulates glycogen formation via gluconeogenesis involving carbon dioxide fixation.
glucose,"Glucose induces glycogenesis, which is associated with increased glycogen synthetase I and decreased phosphorylase a activity.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose induces glycogenesis, which is associated with increased glycogen synthetase I and decreased phosphorylase a activity."
glucose,"Glucose is metabolized in liver cells, leading to the accumulation of intermediates such as Glu-6-P, Fru-6-P, and Glu-l-P after a glucose load.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is metabolized in liver cells, leading to the accumulation of intermediates such as Glu-6-P, Fru-6-P, and Glu-l-P after a glucose load."
Fru-6-P,Fru-6-P accumulates in liver cells after a glucose load due to its role as an intermediate in glucose metabolism.,Entity: Fru-6-P. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fru-6-P accumulates in liver cells after a glucose load due to its role as an intermediate in glucose metabolism.
Glu-6-P,Glu-6-P accumulates in liver cells after a glucose load as an intermediate in the initial stages of glucose metabolism.,Entity: Glu-6-P. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glu-6-P accumulates in liver cells after a glucose load as an intermediate in the initial stages of glucose metabolism.
fructose,Fructose at a dose of 600 mg/100 g body weight elevates blood glucose concentration in fasted rats.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose at a dose of 600 mg/100 g body weight elevates blood glucose concentration in fasted rats.
glucose,"Glucose administration, whether intravenous or oral, significantly suppresses the incorporation of glucose in vivo.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose administration, whether intravenous or oral, significantly suppresses the incorporation of glucose in vivo."
Glu-6-P,"Glu-6-P accumulation is indicative of activation of glucokinase, which redirects blood glucose toward glycogen synthesis rather than gluconeogenesis.","Entity: Glu-6-P. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glu-6-P accumulation is indicative of activation of glucokinase, which redirects blood glucose toward glycogen synthesis rather than gluconeogenesis."
glucose,"Glucose loading activates glycogen synthetase and inactivates phosphorylase in the liver, leading to increased glycogen synthesis.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose loading activates glycogen synthetase and inactivates phosphorylase in the liver, leading to increased glycogen synthesis."
glucose,Blood glucose levels are not affected by intravenous fructose administration at a dose of 100 mg/100 g body weight.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Blood glucose levels are not affected by intravenous fructose administration at a dose of 100 mg/100 g body weight.
fructose,"Injection of fructose at a dose of 100 mg/100 g body weight increases tissue-level liver glycogen and [14C]glycogen in the liver, without affecting blood glucose levels.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Injection of fructose at a dose of 100 mg/100 g body weight increases tissue-level liver glycogen and [14C]glycogen in the liver, without affecting blood glucose levels."
fructose,No 14C is incorporated into fructose during its metabolic processing in the liver.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. No 14C is incorporated into fructose during its metabolic processing in the liver.
glucagon,Glucagon is a hormone that suppresses glucose production in the liver and its secretion can be suppressed by a glucose load.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon is a hormone that suppresses glucose production in the liver and its secretion can be suppressed by a glucose load.
glucose,"Glucose is the final product of gluconeogenesis that is normally diverted to glycogen in the liver, but this process is impaired in adrenalectomized rats.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is the final product of gluconeogenesis that is normally diverted to glycogen in the liver, but this process is impaired in adrenalectomized rats."
epinephrine,"Epinephrine can reduce glucose production in adrenalectomized rats, likely by promoting rapid glycogenesis.","Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. Epinephrine can reduce glucose production in adrenalectomized rats, likely by promoting rapid glycogenesis."
glucose,Glucose can inhibit gluconeogenesis by acting as an allosteric inhibitor of glucose-6-phosphatase in the liver.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose can inhibit gluconeogenesis by acting as an allosteric inhibitor of glucose-6-phosphatase in the liver.
glucose-6-phosphate,"Accumulation of glucose-6-phosphate is associated with reduced 14C flow to glucose, indicating a crossover between glucose-6-phosphate and glucose in gluconeogenesis.","Entity: glucose-6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Accumulation of glucose-6-phosphate is associated with reduced 14C flow to glucose, indicating a crossover between glucose-6-phosphate and glucose in gluconeogenesis."
oxygen,Oxygen can be used in combination with carbon dioxide to create ventilatory mixtures for experimental studies.,Entity: oxygen. SMILES: [O]. Oxygen can be used in combination with carbon dioxide to create ventilatory mixtures for experimental studies.
acetazolamide,Acetazolamide is a carbonic anhydrase inhibitor that can be administered as a single bolus at 50 mg/kg into the contralateral jugular vein.,Entity: acetazolamide. SMILES: CC(=O)Nc1nnc(S(N)(=O)=O)s1. Acetazolamide is a carbonic anhydrase inhibitor that can be administered as a single bolus at 50 mg/kg into the contralateral jugular vein.
methazolamide,Methazolamide is a carbonic anhydrase inhibitor that can be administered as a single bolus at 25 mg/kg into the contralateral jugular vein.,Entity: methazolamide. SMILES: CC(=O)N=c1sc(S(N)(=O)=O)nn1C. Methazolamide is a carbonic anhydrase inhibitor that can be administered as a single bolus at 25 mg/kg into the contralateral jugular vein.
carbon dioxide,Carbon dioxide can be used to create a ventilatory mixture containing 10% CO2 and 90% O2 for experimental purposes.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide can be used to create a ventilatory mixture containing 10% CO2 and 90% O2 for experimental purposes.
potassium acetate,Potassium acetate is used as an electrolyte solution (4 M concentration) for filling glass microelectrodes in electrophysiological recordings.,Entity: potassium acetate. SMILES: CC(=O)[O-].[K+]. Potassium acetate is used as an electrolyte solution (4 M concentration) for filling glass microelectrodes in electrophysiological recordings.
"2,4-dinitrophenol","2,4-dinitrophenol is an inhibitor used to study the metabolic dependence of the endocochlear potential.","Entity: 2,4-dinitrophenol. SMILES: O=[N+]([O-])c1ccc(O)c([N+](=O)[O-])c1. 2,4-dinitrophenol is an inhibitor used to study the metabolic dependence of the endocochlear potential."
oxygen,"During hypercapnia with 10% CO2 and 90% O2, cochlear oxygen tension increases from 23.01 to 101.7 mmHg.","Entity: oxygen. SMILES: [O]. During hypercapnia with 10% CO2 and 90% O2, cochlear oxygen tension increases from 23.01 to 101.7 mmHg."
tetrodotoxin,Tetrodotoxin is an inhibitor that has been used to study the metabolic dependence of the endocochlear potential.,Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin is an inhibitor that has been used to study the metabolic dependence of the endocochlear potential.
ouabain,Ouabain is an inhibitor used to investigate the metabolic dependence of the endocochlear potential.,Entity: ouabain. SMILES: C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O. Ouabain is an inhibitor used to investigate the metabolic dependence of the endocochlear potential.
methazolamide,Methazolamide is an inhibitor of carbonic anhydrase used at a dose of 25 mg/kg administered intravenously to investigate its effect in guinea pigs.,Entity: methazolamide. SMILES: CC(=O)N=c1sc(S(N)(=O)=O)nn1C. Methazolamide is an inhibitor of carbonic anhydrase used at a dose of 25 mg/kg administered intravenously to investigate its effect in guinea pigs.
oxygen,Oxygen is used as a carrier gas (90%) in hypercapnia experiments to generate high carbon dioxide levels in guinea pigs.,Entity: oxygen. SMILES: [O]. Oxygen is used as a carrier gas (90%) in hypercapnia experiments to generate high carbon dioxide levels in guinea pigs.
carbon dioxide,Carbon dioxide is used at 10% concentration in a gas mixture to generate hypercapnia in guinea pigs.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is used at 10% concentration in a gas mixture to generate hypercapnia in guinea pigs.
acetazolamide,Acetazolamide is an inhibitor of carbonic anhydrase used at a dose of 50 mg/kg administered intravenously to investigate its effect in guinea pigs.,Entity: acetazolamide. SMILES: CC(=O)Nc1nnc(S(N)(=O)=O)s1. Acetazolamide is an inhibitor of carbonic anhydrase used at a dose of 50 mg/kg administered intravenously to investigate its effect in guinea pigs.
glucagon,Glucagon is effective in relaxing the colon during bowel examination and promotes patient comfort.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon is effective in relaxing the colon during bowel examination and promotes patient comfort.
glucagon,Pre-treatment with glucagon does not increase the incidence or severity of electrocardiographic abnormalities in elderly patients undergoing bowel examination.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Pre-treatment with glucagon does not increase the incidence or severity of electrocardiographic abnormalities in elderly patients undergoing bowel examination.
catecholamine,"Catecholamine release is stimulated by factors such as dehydration, fear, and discomfort during barium enema, leading to increased heart rate and frequency of ectopic heartbeats.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Catecholamine release is stimulated by factors such as dehydration, fear, and discomfort during barium enema, leading to increased heart rate and frequency of ectopic heartbeats."
glucagon,Pre-treatment with glucagon in patients undergoing intravenous administration did not reduce the incidence of electrocardiographic abnormalities such as ST segment changes.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Pre-treatment with glucagon in patients undergoing intravenous administration did not reduce the incidence of electrocardiographic abnormalities such as ST segment changes.
pertechnetate,Pertechnetate is concentrated in human saliva and salivary glands.,Entity: pertechnetate. SMILES: O=[Tc](=O)(=O)[O-]. Pertechnetate is concentrated in human saliva and salivary glands.
Iodide,"In humans, iodide clearance in the parotid gland increases proportionally to the rate of salivary secretion when the gland is stimulated.","Entity: Iodide. SMILES: [I-]. In humans, iodide clearance in the parotid gland increases proportionally to the rate of salivary secretion when the gland is stimulated."
Technetium pertechnetate,"Technetium pertechnetate is used as a radiotracer in salivary gland imaging, with uptake values measured as a percentage of injected dose at 3, 8, and 13 minutes post-injection in parotid and submandibular glands.","Entity: Technetium pertechnetate. SMILES: O=[Tc](=O)(=O)[O-].O=[Tc](=O)(=O)[O-].O=[Tc](=O)(=O)[O-].O=[Tc](=O)(=O)[O-].[Tc+4]. Technetium pertechnetate is used as a radiotracer in salivary gland imaging, with uptake values measured as a percentage of injected dose at 3, 8, and 13 minutes post-injection in parotid and submandibular glands."
Pertechnetate,"Pertechnetate concentration in human parotid and submandibular salivary glands varies depending on salivary stimulation, with higher levels observed at the initial scan time and plateauing by 8 minutes in stimulated subjects.","Entity: Pertechnetate. SMILES: O=[Tc](=O)(=O)[O-]. Pertechnetate concentration in human parotid and submandibular salivary glands varies depending on salivary stimulation, with higher levels observed at the initial scan time and plateauing by 8 minutes in stimulated subjects."
Atropine,"Atropine administration can delay, but not erase, 'mouth' activity in salivary gland imaging studies, indicating its effect on salivary flow rather than isotope adsorption.","Entity: Atropine. SMILES: CN1[C@@H]2CC[C@H]1CC(OC(=O)C(CO)c1ccccc1)C2. Atropine administration can delay, but not erase, 'mouth' activity in salivary gland imaging studies, indicating its effect on salivary flow rather than isotope adsorption."
pertechnetate,"Pertechnetate is handled similarly by the thyroid and salivary glands, with both organs showing equal uptake in humans.","Entity: pertechnetate. SMILES: O=[Tc](=O)(=O)[O-]. Pertechnetate is handled similarly by the thyroid and salivary glands, with both organs showing equal uptake in humans."
DMC,DMC does not affect basal or ADH-mediated Na+ transport when added to the mucosal medium.,Entity: DMC. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12. DMC does not affect basal or ADH-mediated Na+ transport when added to the mucosal medium.
MNC,MNC does not affect basal or ADH-mediated Na+ transport when added to the mucosal medium.,Entity: MNC. SMILES: CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]3(O)C(=O)C1=C2O. MNC does not affect basal or ADH-mediated Na+ transport when added to the mucosal medium.
amiloride,Amiloride is used to measure epithelial sodium channel (ENa) activity by determining ENa in the presence of the drug.,Entity: amiloride. SMILES: NC(N)=NC(=O)c1nc(Cl)c(N)nc1N. Amiloride is used to measure epithelial sodium channel (ENa) activity by determining ENa in the presence of the drug.
sodium,Increased mucosal permeability to sodium is thought to be a mechanism of action for aquaporin-2 (ADH).,Entity: sodium. SMILES: [Na]. Increased mucosal permeability to sodium is thought to be a mechanism of action for aquaporin-2 (ADH).
DMC,DMC inhibits basal Na+ transport but does not affect ADH-mediated Na+ transport in the context of a matched time control hemibladder during a 1-hour incubation period.,Entity: DMC. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12. DMC inhibits basal Na+ transport but does not affect ADH-mediated Na+ transport in the context of a matched time control hemibladder during a 1-hour incubation period.
MNC,MNC inhibits ADH-mediated Na+ transport but does not significantly affect basal Na+ transport during a 1-hour incubation period in a matched time control hemibladder.,Entity: MNC. SMILES: CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]3(O)C(=O)C1=C2O. MNC inhibits ADH-mediated Na+ transport but does not significantly affect basal Na+ transport during a 1-hour incubation period in a matched time control hemibladder.
OTC,OTC does not significantly affect either basal Na+ transport or ADH-mediated Na+ transport during a 1-hour incubation period in a matched time control hemibladder.,Entity: OTC. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12. OTC does not significantly affect either basal Na+ transport or ADH-mediated Na+ transport during a 1-hour incubation period in a matched time control hemibladder.
oxytetracycline,Oxytetracycline inhibits basal Na+ transport in toad urinary bladders during a 1-hour incubation period when measured as short-circuit current in Ussing chambers.,Entity: oxytetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12. Oxytetracycline inhibits basal Na+ transport in toad urinary bladders during a 1-hour incubation period when measured as short-circuit current in Ussing chambers.
oxytetracycline,Oxytetracycline does not inhibit ADH-stimulated Na+ transport in toad urinary bladders during a 1-hour incubation period.,Entity: oxytetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12. Oxytetracycline does not inhibit ADH-stimulated Na+ transport in toad urinary bladders during a 1-hour incubation period.
tetracycline,"Tetracyclines, including oxytetracycline, inhibit basal Na+ transport in toad urinary bladders during a 1-hour incubation period.","Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracyclines, including oxytetracycline, inhibit basal Na+ transport in toad urinary bladders during a 1-hour incubation period."
OTC,OTC (oxytetracycline) is included in the TBR solution at a final concentration of 0.5 mg/ml in experimental quarter-bladders for studies of sodium channel inhibition.,Entity: OTC. SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O. OTC (oxytetracycline) is included in the TBR solution at a final concentration of 0.5 mg/ml in experimental quarter-bladders for studies of sodium channel inhibition.
tetracycline,Tetracycline is included in the TBR solution at a final concentration of 0.5 mg/ml in experimental quarter-bladders for studies of sodium channel inhibition.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline is included in the TBR solution at a final concentration of 0.5 mg/ml in experimental quarter-bladders for studies of sodium channel inhibition.
DMSO,DMSO (dimethyl sulfoxide) is used as a control carrier in TBR solution at a final concentration of 0.5 mg/ml in experimental quarter-bladders.,Entity: DMSO. SMILES: CS(C)=O. DMSO (dimethyl sulfoxide) is used as a control carrier in TBR solution at a final concentration of 0.5 mg/ml in experimental quarter-bladders.
amiloride,"Amiloride is used to manipulate sodium channels in kidney tissue, as indicated by its effect on basolateral K+ in quarter-bladders.","Entity: amiloride. SMILES: NC(N)=NC(=O)c1nc(Cl)c(N)nc1N. Amiloride is used to manipulate sodium channels in kidney tissue, as indicated by its effect on basolateral K+ in quarter-bladders."
amiloride,Amiloride is stored as a 10 mM stock solution in water at 3–5 °C.,Entity: amiloride. SMILES: NC(N)=NC(=O)c1nc(Cl)c(N)nc1N. Amiloride is stored as a 10 mM stock solution in water at 3–5 °C.
MNC,"MNC inhibits ADH-mediated water flow and ADH-mediated Na+ transport in the toad urinary bladder, but is not an inhibitor of ADH-mediated Na+ transport.","Entity: MNC. SMILES: COc1nc2ccccc2s1. MNC inhibits ADH-mediated water flow and ADH-mediated Na+ transport in the toad urinary bladder, but is not an inhibitor of ADH-mediated Na+ transport."
MNC,MNC is strongly protein bound but its effect on ADH-mediated Na+ transport does not correlate with its protein binding.,Entity: MNC. SMILES: COc1nc2ccccc2s1. MNC is strongly protein bound but its effect on ADH-mediated Na+ transport does not correlate with its protein binding.
OTC,"OTC affects ADH-mediated water flow and ADH-mediated Na+ transport in the toad urinary bladder, but its effects do not correlate with binding to human serum proteins or soluble toad bladder epithelial cell proteins.","Entity: OTC. SMILES: C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O. OTC affects ADH-mediated water flow and ADH-mediated Na+ transport in the toad urinary bladder, but its effects do not correlate with binding to human serum proteins or soluble toad bladder epithelial cell proteins."
DMC,"DMC inhibits ADH-mediated water flow and is strongly protein bound, but does not inhibit ADH-mediated Na+ transport in the toad urinary bladder.","Entity: DMC. SMILES: CC(=O)Nc1nnc(S(N)(=O)=O)s1. DMC inhibits ADH-mediated water flow and is strongly protein bound, but does not inhibit ADH-mediated Na+ transport in the toad urinary bladder."
DMC,DMC causes natriuresis in patients with pathologic edema-forming states but not in normal subjects on a normal Na+ intake or in patients with the syndrome of inappropriate ADH secretion.,Entity: DMC. SMILES: CC(=O)Nc1nnc(S(N)(=O)=O)s1. DMC causes natriuresis in patients with pathologic edema-forming states but not in normal subjects on a normal Na+ intake or in patients with the syndrome of inappropriate ADH secretion.
DMC,"DMC is excreted in the bile, and use of conventional doses in patients with impaired liver function may result in very high (toxic) concentrations of this drug.","Entity: DMC. SMILES: CC(=O)Nc1nnc(S(N)(=O)=O)s1. DMC is excreted in the bile, and use of conventional doses in patients with impaired liver function may result in very high (toxic) concentrations of this drug."
Aldosterone,Aldosterone plays an important role in controlling renal Na+ excretion in edema-forming states.,Entity: Aldosterone. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12. Aldosterone plays an important role in controlling renal Na+ excretion in edema-forming states.
sodium,"In the presence of MNC ADH, net ADH-stimulated sodium transport across small intestinal epithelium is measured by single-cell capacitance calorimetry, yielding a flux of 1.84 ± 0.13 peq/h per 2.3 cm2 for stimulated and 1.73 ± 0.10 µeq/h per 2.3 cm2 for isotopic labeling.","Entity: sodium. SMILES: [Na]. In the presence of MNC ADH, net ADH-stimulated sodium transport across small intestinal epithelium is measured by single-cell capacitance calorimetry, yielding a flux of 1.84 ± 0.13 peq/h per 2.3 cm2 for stimulated and 1.73 ± 0.10 µeq/h per 2.3 cm2 for isotopic labeling."
tetracycline,"Tetracycline inhibits basal Na+ transport in the bladder, and this inhibition is not a nonspecific toxic effect as treated bladders still respond to subsequent addition of ADH.","Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline inhibits basal Na+ transport in the bladder, and this inhibition is not a nonspecific toxic effect as treated bladders still respond to subsequent addition of ADH."
OTC,OTC at 0.5 mg/ml does not significantly affect basal Na+ transport in the toad urinary bladder in vitro within a 1-hour incubation period.,Entity: OTC. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12. OTC at 0.5 mg/ml does not significantly affect basal Na+ transport in the toad urinary bladder in vitro within a 1-hour incubation period.
DMC,DMC at 0.5 mg/ml significantly inhibits basal Na+ transport in the toad urinary bladder in vitro within a 1-hour incubation period.,Entity: DMC. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12. DMC at 0.5 mg/ml significantly inhibits basal Na+ transport in the toad urinary bladder in vitro within a 1-hour incubation period.
MNC,MNC at 0.5 mg/ml does not significantly affect basal Na+ transport in the toad urinary bladder in vitro within a 1-hour incubation period.,Entity: MNC. SMILES: CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]3(O)C(=O)C1=C2O. MNC at 0.5 mg/ml does not significantly affect basal Na+ transport in the toad urinary bladder in vitro within a 1-hour incubation period.
Na+,"The apparent lack of effect of MNC on ENa may be due to a decrease in Na+ entry into the cell, leading to reduced amounts of Na+ available for transport by the Na+ pump.","Entity: Na+. SMILES: [Na]. The apparent lack of effect of MNC on ENa may be due to a decrease in Na+ entry into the cell, leading to reduced amounts of Na+ available for transport by the Na+ pump."
Na+,"In the presence of DMC or MNC, net Na+ flux across the basolateral side of small collecting cavern (SCC) can be accurately measured, with values of 1.65 ± 0.25 peq/h per 2.3 cm2 (DMC) and 0.71 ± 0.12 and 0.66 ± 0.11 peq/h per 2.3 cm2 (MNC) during 24Na+ flux studies.","Entity: Na+. SMILES: [Na]. In the presence of DMC or MNC, net Na+ flux across the basolateral side of small collecting cavern (SCC) can be accurately measured, with values of 1.65 ± 0.25 peq/h per 2.3 cm2 (DMC) and 0.71 ± 0.12 and 0.66 ± 0.11 peq/h per 2.3 cm2 (MNC) during 24Na+ flux studies."
minocycline,"Minocycline is a tetracycline antibiotic that inhibits ADH-induced osmotic water flow in toad urinary bladders, a model of the mammalian distal nephron.","Entity: minocycline. SMILES: CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]3(O)C(=O)C1=C2O. Minocycline is a tetracycline antibiotic that inhibits ADH-induced osmotic water flow in toad urinary bladders, a model of the mammalian distal nephron."
oxytetracycline,Oxytetracycline is a tetracycline antibiotic that does not inhibit ADH-induced osmotic water flow in toad urinary bladders.,Entity: oxytetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12. Oxytetracycline is a tetracycline antibiotic that does not inhibit ADH-induced osmotic water flow in toad urinary bladders.
amiloride,Amiloride is used in the amiloride method to assess sodium pump potential (ENa) and active conductance (K+) in the mammalian distal nephron by measuring changes in bladder electrical conductance.,Entity: amiloride. SMILES: NC(N)=NC(=O)c1nc(Cl)c(N)nc1N. Amiloride is used in the amiloride method to assess sodium pump potential (ENa) and active conductance (K+) in the mammalian distal nephron by measuring changes in bladder electrical conductance.
DMC,DMC (desmopressin) is known to cause nephrogenic diabetes insipidus in human subjects.,Entity: DMC. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. DMC (desmopressin) is known to cause nephrogenic diabetes insipidus in human subjects.
DMC,DMC has been shown to cause natriuresis in patients with cirrhosis or congestive heart failure.,Entity: DMC. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. DMC has been shown to cause natriuresis in patients with cirrhosis or congestive heart failure.
DMC,"DMC is a tetracycline antibiotic that inhibits ADH-induced osmotic water flow in toad urinary bladders, a model of the mammalian distal nephron.","Entity: DMC. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. DMC is a tetracycline antibiotic that inhibits ADH-induced osmotic water flow in toad urinary bladders, a model of the mammalian distal nephron."
MNC,MNC inhibits ADH-mediated osmotic water flow in the toad urinary bladder.,Entity: MNC. SMILES: CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]3(O)C(=O)C1=C2O. MNC inhibits ADH-mediated osmotic water flow in the toad urinary bladder.
OTC,OTC does not inhibit ADH-mediated osmotic water flow in the toad urinary bladder.,Entity: OTC. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12. OTC does not inhibit ADH-mediated osmotic water flow in the toad urinary bladder.
Talc,Talc is not immunogenic in guinea-pig models and does not cross-react in skin tests with starch glove powder.,Entity: Talc. SMILES: O=[Si]([O-])O.O=[Si]([O-])O.O=[Si]([O-])[O-].O=[Si]([O-])[O-].[Mg+2].[Mg+2].[Mg+2]. Talc is not immunogenic in guinea-pig models and does not cross-react in skin tests with starch glove powder.
dextran 70,"Dextran 70 is administered variably during surgical operations, with amounts ranging from 1 to 5 litres per patient, depending on the severity of the operation.","Entity: dextran 70. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran 70 is administered variably during surgical operations, with amounts ranging from 1 to 5 litres per patient, depending on the severity of the operation."
azathioprine,Azathioprine is used as an immunosuppressive agent in transplant patients at a dose of 2 mg/kg body weight.,Entity: azathioprine. SMILES: Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12. Azathioprine is used as an immunosuppressive agent in transplant patients at a dose of 2 mg/kg body weight.
prednisolone,Prednisolone is administered as part of immunosuppressive treatment in transplant patients.,Entity: prednisolone. SMILES: C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO. Prednisolone is administered as part of immunosuppressive treatment in transplant patients.
actinomycin C,Actinomycin C is used as an immunosuppressive agent in some transplant patients during the first six months after transplantation.,Entity: actinomycin C. SMILES: CCC(C)C1NC(=O)C(NC(=O)c2c3nc4c(C(=O)NC5C(=O)NC(C(C)C)C(=O)N6CCCC6C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC5C)ccc(C)c4oc-3c(C)c(=O)c2N)C(C)OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C1=O. Actinomycin C is used as an immunosuppressive agent in some transplant patients during the first six months after transplantation.
lithium,"The neonatal kidney is capable of excreting lithium against a concentration gradient, with mean urinary lithium concentration being 0.57 mmol/l, which is almost 10 times higher than mean serum levels.","Entity: lithium. SMILES: [Li]. The neonatal kidney is capable of excreting lithium against a concentration gradient, with mean urinary lithium concentration being 0.57 mmol/l, which is almost 10 times higher than mean serum levels."
lithium,Breast-milk lithium levels are about half those of maternal serum levels and increase with higher maternal oral lithium dose.,Entity: lithium. SMILES: [Li]. Breast-milk lithium levels are about half those of maternal serum levels and increase with higher maternal oral lithium dose.
lithium,"Despite rising concentrations in breast milk, a baby's serum lithium levels remain much lower than those experienced during pregnancy.","Entity: lithium. SMILES: [Li]. Despite rising concentrations in breast milk, a baby's serum lithium levels remain much lower than those experienced during pregnancy."
lithium,Breast-feeding is discouraged and may be stopped at 10 weeks due to lithium's known inhibition of cyclic 3'5' adenosine monophosphate and the theoretical risk to the developing brain.,Entity: lithium. SMILES: [Li]. Breast-feeding is discouraged and may be stopped at 10 weeks due to lithium's known inhibition of cyclic 3'5' adenosine monophosphate and the theoretical risk to the developing brain.
lithium,"Lithium crosses the placenta freely, resulting in similar serum levels for mother and baby at delivery.","Entity: lithium. SMILES: [Li]. Lithium crosses the placenta freely, resulting in similar serum levels for mother and baby at delivery."
melibiose,Melibiose is fermented to produce acid after five days in the described bacterial fermentation test.,Entity: melibiose. SMILES: OC[C@H]1O[C@H](OC[C@H]2O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1O. Melibiose is fermented to produce acid after five days in the described bacterial fermentation test.
trehalose,Trehalose is fermented to produce acid after five days in the described bacterial fermentation test.,Entity: trehalose. SMILES: OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O. Trehalose is fermented to produce acid after five days in the described bacterial fermentation test.
salicin,Salicin is fermented to produce acid after five days in the described bacterial fermentation test.,Entity: salicin. SMILES: OCc1ccccc1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. Salicin is fermented to produce acid after five days in the described bacterial fermentation test.
sorbitol,Sorbitol does not acidify after five days in the described bacterial fermentation test.,Entity: sorbitol. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CO. Sorbitol does not acidify after five days in the described bacterial fermentation test.
mannitol,Mannitol does not acidify after five days in the described bacterial fermentation test.,Entity: mannitol. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannitol does not acidify after five days in the described bacterial fermentation test.
arabinose,Arabinose does not acidify after five days in the described bacterial fermentation test.,Entity: arabinose. SMILES: O=C[C@@H](O)[C@H](O)[C@H](O)CO. Arabinose does not acidify after five days in the described bacterial fermentation test.
melezitose,Melezitose does not acidify after five days in the described bacterial fermentation test.,Entity: melezitose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H]1O. Melezitose does not acidify after five days in the described bacterial fermentation test.
sucrose,Sucrose is fermented to produce acid after five days in the described bacterial fermentation test.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is fermented to produce acid after five days in the described bacterial fermentation test.
lactose,Lactose is fermented to produce acid after five days in the described bacterial fermentation test.,Entity: lactose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O. Lactose is fermented to produce acid after five days in the described bacterial fermentation test.
raffinose,Raffinose is fermented to produce acid after five days in the described bacterial fermentation test.,Entity: raffinose. SMILES: OC[C@H]1O[C@H](OC[C@H]2O[C@H](O[C@]3(CO)O[C@H](CO)[C@@H](O)[C@@H]3O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1O. Raffinose is fermented to produce acid after five days in the described bacterial fermentation test.
Lithium,"Lithium can be transferred from mother to infant via breast milk, with the infant's serum lithium levels closely tracking the mother's during the initial period of breast-feeding.","Entity: Lithium. SMILES: [Li]. Lithium can be transferred from mother to infant via breast milk, with the infant's serum lithium levels closely tracking the mother's during the initial period of breast-feeding."
Dextran,"Dextran did not help the primary condition of patients with acute renal failure, as described in the case histories.","Entity: Dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran did not help the primary condition of patients with acute renal failure, as described in the case histories."
dextran,"Dextrans with molecular weights below 60,000 can easily filter through the glomerulus and may accumulate in proximal tubular cells, causing a swollen, vacuolated appearance associated with osmotic nephropathy.","Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextrans with molecular weights below 60,000 can easily filter through the glomerulus and may accumulate in proximal tubular cells, causing a swollen, vacuolated appearance associated with osmotic nephropathy."
dextran,The high viscosity of concentrated dextran is likely responsible for renal dysfunction by causing tubular plugging.,Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. The high viscosity of concentrated dextran is likely responsible for renal dysfunction by causing tubular plugging.
saralasin,"Saralasin is an agonist of the angiotensin II receptor, and its effects on blood pressure can be interpreted differently depending on the patient's baseline sodium and water balance.","Entity: saralasin. SMILES: CNCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C)C(C)C. Saralasin is an agonist of the angiotensin II receptor, and its effects on blood pressure can be interpreted differently depending on the patient's baseline sodium and water balance."
saralasin,Saralasin restores recumbent blood pressure to normal in most patients with angiotensin-dependent hypertension after volume depletion.,Entity: saralasin. SMILES: CNCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C)C(C)C. Saralasin restores recumbent blood pressure to normal in most patients with angiotensin-dependent hypertension after volume depletion.
angiotensin II,Angiotensin II contributes to high blood pressure in patients with angiotensin-dependent hypertension.,Entity: angiotensin II. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O. Angiotensin II contributes to high blood pressure in patients with angiotensin-dependent hypertension.
sodium,Sodium contributes to high blood pressure in patients with angiotensin-dependent hypertension.,Entity: sodium. SMILES: [Na]. Sodium contributes to high blood pressure in patients with angiotensin-dependent hypertension.
saralasin,Saralasin is a competitive inhibitor of angiotensin II.,Entity: saralasin. SMILES: CNCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C)C(C)C. Saralasin is a competitive inhibitor of angiotensin II.
saralasin,"Saralasin infusion can cause hypotension, especially in untreated patients with malignant hypertension or on dialysis, and in patients with cirrhosis.","Entity: saralasin. SMILES: CNCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C)C(C)C. Saralasin infusion can cause hypotension, especially in untreated patients with malignant hypertension or on dialysis, and in patients with cirrhosis."
saralasin,"Hypotension during saralasin infusion can be controlled by using an incremental infusion starting at low rates (e.g., 0.05–0.25 Fcg/kg/min) and increasing the rate progressively.","Entity: saralasin. SMILES: CNCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C)C(C)C. Hypotension during saralasin infusion can be controlled by using an incremental infusion starting at low rates (e.g., 0.05–0.25 Fcg/kg/min) and increasing the rate progressively."
angiotensin II,Angiotensin II blockade with saralasin can lead to hypotension in situations where patients are volume depleted or have low-renin hypertension.,Entity: angiotensin II. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O. Angiotensin II blockade with saralasin can lead to hypotension in situations where patients are volume depleted or have low-renin hypertension.
L-tyrosine,L-tyrosine is a substrate for both monophenolase and diphenolase activities of mushroom tyrosinase isoenzymes.,Entity: L-tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. L-tyrosine is a substrate for both monophenolase and diphenolase activities of mushroom tyrosinase isoenzymes.
p-cresol,p-cresol serves as a substrate for both monophenolase and diphenolase activities of mushroom tyrosinase isoenzymes.,Entity: p-cresol. SMILES: Cc1ccc(O)cc1. p-cresol serves as a substrate for both monophenolase and diphenolase activities of mushroom tyrosinase isoenzymes.
tyramine,Tyramine is a substrate for both monophenolase and diphenolase activities of mushroom tyrosinase isoenzymes.,Entity: tyramine. SMILES: NCCc1ccc(O)cc1. Tyramine is a substrate for both monophenolase and diphenolase activities of mushroom tyrosinase isoenzymes.
Ampholine,"Ampholine is used as a buffer mixture to separate isoenzymes in electrophoretic assays, providing clear separation of major activity bands but impairing resolution of minor components.","Entity: Ampholine. SMILES: [Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb]. Ampholine is used as a buffer mixture to separate isoenzymes in electrophoretic assays, providing clear separation of major activity bands but impairing resolution of minor components."
methanol,Methanol is used as a solvent for preparing a 1% phenolic substrate solution in the paper print technique for isoenzyme detection.,Entity: methanol. SMILES: CO. Methanol is used as a solvent for preparing a 1% phenolic substrate solution in the paper print technique for isoenzyme detection.
potassium phosphate,Potassium phosphate buffer at 0.1 M and pH 7.0 is used to impregnate filter paper to counteract carrier ampholyte buffering capacity and maintain optimal pH during enzymatic reactions in the paper print method.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate buffer at 0.1 M and pH 7.0 is used to impregnate filter paper to counteract carrier ampholyte buffering capacity and maintain optimal pH during enzymatic reactions in the paper print method.
Ampholine,Ampholine is used as a pH-range gel suspending medium for protein separation techniques such as SDS-PAGE and is effective in the pH range 3–10.,Entity: Ampholine. SMILES: [Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb]. Ampholine is used as a pH-range gel suspending medium for protein separation techniques such as SDS-PAGE and is effective in the pH range 3–10.
pyrocatechol,Pyrocatechol can be used as a substrate to visualize diphenolase activity of mushroom tyrosinase isoenzymes in protein separation assays.,Entity: pyrocatechol. SMILES: Oc1ccccc1O. Pyrocatechol can be used as a substrate to visualize diphenolase activity of mushroom tyrosinase isoenzymes in protein separation assays.
L-proline,"L-proline, in combination with pyrocatechol, serves as a substrate for detecting diphenolase activity of mushroom tyrosinase isoenzymes during protein electrophoresis.","Entity: L-proline. SMILES: O=C(O)[C@@H]1CCCN1. L-proline, in combination with pyrocatechol, serves as a substrate for detecting diphenolase activity of mushroom tyrosinase isoenzymes during protein electrophoresis."
chlorogenic acid,Chlorogenic acid produces metachromatic zones when used as a substrate in the print technique for isoenzyme detection by gel electrophoresis.,Entity: chlorogenic acid. SMILES: O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O. Chlorogenic acid produces metachromatic zones when used as a substrate in the print technique for isoenzyme detection by gel electrophoresis.
m-phenylenediamine,"m-phenylenediamine, when used as a coupling agent in the print technique, results in high background staining and is unsuitable for isoenzyme analysis.","Entity: m-phenylenediamine. SMILES: Nc1cccc(N)c1. m-phenylenediamine, when used as a coupling agent in the print technique, results in high background staining and is unsuitable for isoenzyme analysis."
proline,"Proline reacts with quinone, the oxidized product of catechol, to form a red compound used to indicate the presence of polyphenol oxidase isoenzymes in gel electrophoresis.","Entity: proline. SMILES: O=C(O)[C@@H]1CCCN1. Proline reacts with quinone, the oxidized product of catechol, to form a red compound used to indicate the presence of polyphenol oxidase isoenzymes in gel electrophoresis."
quinone,"Quinone, the oxidized product of catechol, reacts with proline to form a red compound used for isoenzyme detection in gel electrophoresis.","Entity: quinone. SMILES: O=C1C=CC(=O)C=C1. Quinone, the oxidized product of catechol, reacts with proline to form a red compound used for isoenzyme detection in gel electrophoresis."
catechol,"Catechol serves as a substrate in the print technique for isoenzyme detection, producing yellowish orange to orange zones with a clear background and being sensitive to low enzyme activity.","Entity: catechol. SMILES: Oc1ccccc1O. Catechol serves as a substrate in the print technique for isoenzyme detection, producing yellowish orange to orange zones with a clear background and being sensitive to low enzyme activity."
catechol,Catechol alone can produce metachromatic zones in the print technique for isoenzyme analysis.,Entity: catechol. SMILES: Oc1ccccc1O. Catechol alone can produce metachromatic zones in the print technique for isoenzyme analysis.
p-cresol,p-cresol produces metachromatic zones in the print technique for isoenzyme detection by gel electrophoresis.,Entity: p-cresol. SMILES: Cc1ccc(O)cc1. p-cresol produces metachromatic zones in the print technique for isoenzyme detection by gel electrophoresis.
tyramine,"Tyramine, a monophenol, is better than other monophenols in the print technique for isoenzyme detection, producing stable colored zones.","Entity: tyramine. SMILES: NCCc1ccc(O)cc1. Tyramine, a monophenol, is better than other monophenols in the print technique for isoenzyme detection, producing stable colored zones."
oxygen,"In the paper print technique for polyphenoloxidase assays, oxygen does not become rate-limiting for the reaction as it is supplied from the air and not from the substrate or liquid phase.","Entity: oxygen. SMILES: [O]. In the paper print technique for polyphenoloxidase assays, oxygen does not become rate-limiting for the reaction as it is supplied from the air and not from the substrate or liquid phase."
Ampholine,Ampholine is used as a carrier ampholyte in pH ranges 4–6 and 3–10 for thin-layer isoelectric focusing of proteins.,Entity: Ampholine. SMILES: [Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb]. Ampholine is used as a carrier ampholyte in pH ranges 4–6 and 3–10 for thin-layer isoelectric focusing of proteins.
dextrose,Dextrose is used as an intravenous solution at a concentration of 500 mg/ml for fluid administration in neonatal care.,Entity: dextrose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Dextrose is used as an intravenous solution at a concentration of 500 mg/ml for fluid administration in neonatal care.
sodium,Plasma sodium concentration can rise from 140 mmol/l to 161 mmol/l in a low birth weight infant with hypernatraemic dehydration during the first three days of life.,Entity: sodium. SMILES: [Na]. Plasma sodium concentration can rise from 140 mmol/l to 161 mmol/l in a low birth weight infant with hypernatraemic dehydration during the first three days of life.
sodium,"In preterm infants nursed under radiant heaters, plasma sodium levels can exceed 145 mmol/l and, in some cases, rise to over 160 mmol/l during the first 96 hours of life.","Entity: sodium. SMILES: [Na]. In preterm infants nursed under radiant heaters, plasma sodium levels can exceed 145 mmol/l and, in some cases, rise to over 160 mmol/l during the first 96 hours of life."
glucose 6-phosphate,"Glucose 6-phosphate dehydrogenase produces an activity of 0.00425 Å min/2.2 x 10^7 cells in sonicated extracts, with activity relative to a sonication control of 100.","Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose 6-phosphate dehydrogenase produces an activity of 0.00425 Å min/2.2 x 10^7 cells in sonicated extracts, with activity relative to a sonication control of 100."
6-phosphogluconate,"6-phosphogluconate dehydrogenase produces an activity of 0.00138 Å min/2.2 x 10^7 cells in sonicated extracts, with activity relative to a sonication control of 100.","Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 6-phosphogluconate dehydrogenase produces an activity of 0.00138 Å min/2.2 x 10^7 cells in sonicated extracts, with activity relative to a sonication control of 100."
sodium isocitrate,"In isocitric dehydrogenase assays, 2 pmol of sodium isocitrate are used as substrate in 1-ml reaction mixtures containing 0.3 pmol NADP, 0.5 pmol MnCl2, and 0.4 ml Tris-HCl buffer at pH 7.5.","Entity: sodium isocitrate. SMILES: O=C([O-])CC(C(=O)[O-])C(O)C(=O)[O-].[Na+].[Na+].[Na+]. In isocitric dehydrogenase assays, 2 pmol of sodium isocitrate are used as substrate in 1-ml reaction mixtures containing 0.3 pmol NADP, 0.5 pmol MnCl2, and 0.4 ml Tris-HCl buffer at pH 7.5."
NADP,"In isocitric dehydrogenase assays, 0.3 pmol NADP is used as cofactor in 1-ml reaction mixtures with 2 pmol sodium isocitrate, 0.5 pmol MnCl2, and 0.4 ml Tris-HCl buffer at pH 7.5.","Entity: NADP. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. In isocitric dehydrogenase assays, 0.3 pmol NADP is used as cofactor in 1-ml reaction mixtures with 2 pmol sodium isocitrate, 0.5 pmol MnCl2, and 0.4 ml Tris-HCl buffer at pH 7.5."
MnCl2,"In isocitric dehydrogenase assays, 0.5 pmol MnCl2 is included in 1-ml reaction mixtures with 2 pmol sodium isocitrate and 0.3 pmol NADP, buffered at pH 7.5.","Entity: MnCl2. SMILES: [Cl-].[Cl-].[Mn+2]. In isocitric dehydrogenase assays, 0.5 pmol MnCl2 is included in 1-ml reaction mixtures with 2 pmol sodium isocitrate and 0.3 pmol NADP, buffered at pH 7.5."
toluene,Shaking cultures with 0.02 ml toluene and 2 ml culture for 10 sets yields the highest enzymatic activity in the described assays.,Entity: toluene. SMILES: Cc1ccccc1. Shaking cultures with 0.02 ml toluene and 2 ml culture for 10 sets yields the highest enzymatic activity in the described assays.
glucose,Beta-galactosidase activity is measured in cells grown in glucose medium.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Beta-galactosidase activity is measured in cells grown in glucose medium.
glycerol,Beta-galactosidase activity is measured in cells grown in glycerol medium.,Entity: glycerol. SMILES: OCC(O)CO. Beta-galactosidase activity is measured in cells grown in glycerol medium.
6-phosphogluconate,"6-phosphogluconate is used as substrate in assays for 6-phosphogluconate dehydrogenase, replacing glucose 6-phosphate.","Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 6-phosphogluconate is used as substrate in assays for 6-phosphogluconate dehydrogenase, replacing glucose 6-phosphate."
CaCl2,CaCl2 is used as a component in E. coli growth media at concentrations of 5 x 10^-5 M for α-galactosidase studies and 9 x 10^-5 M for other enzyme studies.,Entity: CaCl2. SMILES: [Ca+2].[Cl-].[Cl-]. CaCl2 is used as a component in E. coli growth media at concentrations of 5 x 10^-5 M for α-galactosidase studies and 9 x 10^-5 M for other enzyme studies.
NH4NO3,NH4NO3 is included in E. coli growth media at a concentration of 2.0 g/L for α-galactosidase studies and 9 x 10^-5 M for other enzyme studies.,Entity: NH4NO3. SMILES: O=[N+]([O-])[O-].[NH4+]. NH4NO3 is included in E. coli growth media at a concentration of 2.0 g/L for α-galactosidase studies and 9 x 10^-5 M for other enzyme studies.
HCl,HCl is used to adjust the pH of E. coli growth media to 7.2 for α-galactosidase studies and to 7.5 for other enzyme studies.,Entity: HCl. SMILES: Cl. HCl is used to adjust the pH of E. coli growth media to 7.2 for α-galactosidase studies and to 7.5 for other enzyme studies.
FeSO4,FeSO4·7H2O is a component of E. coli growth media at concentrations of 2 x 10^-6 M for α-galactosidase studies and 1.8 x 10^-6 M for other enzyme studies.,Entity: FeSO4. SMILES: O=S(=O)([O-])[O-].[Fe+2]. FeSO4·7H2O is a component of E. coli growth media at concentrations of 2 x 10^-6 M for α-galactosidase studies and 1.8 x 10^-6 M for other enzyme studies.
toluene,"Toluene is used to extract total and soluble enzyme activities from E. coli cell lysates by disrupting cell membranes, with varying volumes (0.02 ml, 0.04 ml, 0.2 ml, 0.1 ml, 0.5 ml) added to 2 ml of log phase culture and shaken for 30 minutes at 37°C.","Entity: toluene. SMILES: Cc1ccccc1. Toluene is used to extract total and soluble enzyme activities from E. coli cell lysates by disrupting cell membranes, with varying volumes (0.02 ml, 0.04 ml, 0.2 ml, 0.1 ml, 0.5 ml) added to 2 ml of log phase culture and shaken for 30 minutes at 37°C."
NaOH,NaOH (2.5 N) is used to develop colorimetric product formation for measuring enzyme activity in assays involving p-nitrophenylphosphate.,Entity: NaOH. SMILES: [Na+].[OH-]. NaOH (2.5 N) is used to develop colorimetric product formation for measuring enzyme activity in assays involving p-nitrophenylphosphate.
puromycin,"Puromycin is included in enzyme activity assays to serve as a substrate for alkaline phosphatase, with assays performed in the absence and presence of phage ghost.","Entity: puromycin. SMILES: COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@H](n3cnc4c(N(C)C)ncnc43)O[C@@H]2CO)cc1. Puromycin is included in enzyme activity assays to serve as a substrate for alkaline phosphatase, with assays performed in the absence and presence of phage ghost."
p-nitrophenylphosphate,"p-nitrophenylphosphate is used as a substrate in enzyme activity assays, where its hydrolysis is measured by colorimetric detection after incubation with enzyme and subsequent addition of NaOH.","Entity: p-nitrophenylphosphate. SMILES: O=[N+]([O-])c1ccc(OP(=O)([O-])[O-])cc1. p-nitrophenylphosphate is used as a substrate in enzyme activity assays, where its hydrolysis is measured by colorimetric detection after incubation with enzyme and subsequent addition of NaOH."
NADPH,"In crude E. coli extracts, approximately 87% of NADPH formation is due to glucose 6-phosphate dehydrogenase and 13% is due to 6-phosphogluconate dehydrogenase under the described assay conditions.","Entity: NADPH. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. In crude E. coli extracts, approximately 87% of NADPH formation is due to glucose 6-phosphate dehydrogenase and 13% is due to 6-phosphogluconate dehydrogenase under the described assay conditions."
testosterone,Testosterone concentrations in serum and urine can be measured with high specificity (100%) using a radioimmunoassay antiserum.,Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone concentrations in serum and urine can be measured with high specificity (100%) using a radioimmunoassay antiserum.
"5α-androstane-3β,17β-diol","The antiserum used for testosterone measurement cross-reacts with 5α-androstane-3β,17β-diol at a level of 300 or less.","Entity: 5α-androstane-3β,17β-diol. SMILES: C[C@]12CC[C@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. The antiserum used for testosterone measurement cross-reacts with 5α-androstane-3β,17β-diol at a level of 300 or less."
oestriol,Oestriol shows less than 0.40% cross-reacting with oestradiol in a radioimmunoassay assay using an oestradiol-specific antiserum.,Entity: oestriol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O. Oestriol shows less than 0.40% cross-reacting with oestradiol in a radioimmunoassay assay using an oestradiol-specific antiserum.
oestradiol,Oestradiol is measured in serum and urine by radioimmunoassay using a highly specific oestradiol-antiserum raised in rabbits against oestradiol-6-carboxymethyloxime-bovine serum albumin.,Entity: oestradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Oestradiol is measured in serum and urine by radioimmunoassay using a highly specific oestradiol-antiserum raised in rabbits against oestradiol-6-carboxymethyloxime-bovine serum albumin.
oestradiol,"Oestradiol in the assay shows less than 0.40% cross-reacting with oestrone, oestriol, and ethinyloestradiol.","Entity: oestradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Oestradiol in the assay shows less than 0.40% cross-reacting with oestrone, oestriol, and ethinyloestradiol."
ethyl acetate,Ethyl acetate is used as a component (in a 3:2 ratio with cyclohexane) of the solvent system for thin-layer chromatography to separate oestrogens.,Entity: ethyl acetate. SMILES: CCOC(C)=O. Ethyl acetate is used as a component (in a 3:2 ratio with cyclohexane) of the solvent system for thin-layer chromatography to separate oestrogens.
cyclohexane,Cyclohexane is used as a component (in a 3:2 ratio with ethyl acetate) of the solvent system for thin-layer chromatography to separate oestrogens.,Entity: cyclohexane. SMILES: C1CCCCC1. Cyclohexane is used as a component (in a 3:2 ratio with ethyl acetate) of the solvent system for thin-layer chromatography to separate oestrogens.
benzene,Benzene is used as a component (in a 1:1 ratio with diethyl ether) of the solvent system for thin-layer chromatography to separate urinary oestradiol.,Entity: benzene. SMILES: c1ccccc1. Benzene is used as a component (in a 1:1 ratio with diethyl ether) of the solvent system for thin-layer chromatography to separate urinary oestradiol.
diethyl ether,Diethyl ether is used as a component (in a 1:1 ratio with benzene) of the solvent system for thin-layer chromatography to separate urinary oestradiol.,Entity: diethyl ether. SMILES: CCOCC. Diethyl ether is used as a component (in a 1:1 ratio with benzene) of the solvent system for thin-layer chromatography to separate urinary oestradiol.
calcium,"In patients with hypercalcaemic sarcoidosis and normal renal function, calcium balance is typically negative, and becomes more negative under corticosteroid treatment.","Entity: calcium. SMILES: [Ca]. In patients with hypercalcaemic sarcoidosis and normal renal function, calcium balance is typically negative, and becomes more negative under corticosteroid treatment."
calcium,"In patients with sarcoidosis, the mean percentage of oral calcium absorption is higher (61.5%) than in controls (49.0%).","Entity: calcium. SMILES: [Ca]. In patients with sarcoidosis, the mean percentage of oral calcium absorption is higher (61.5%) than in controls (49.0%)."
calcium,"Urinary calcium output is proportional to intestinal absorption of calcium, with a correlation coefficient of r = 0.70.","Entity: calcium. SMILES: [Ca]. Urinary calcium output is proportional to intestinal absorption of calcium, with a correlation coefficient of r = 0.70."
calcium,"Calcium uptake by bone can be measured using a turnover-difference method with a single compartment model and an intravenous injection of 47Ca, with results reported in plasma units (volume-corrected for body weight) and expressed as mmol calcium/kg body weight (2 mEq/kg).","Entity: calcium. SMILES: [Ca]. Calcium uptake by bone can be measured using a turnover-difference method with a single compartment model and an intravenous injection of 47Ca, with results reported in plasma units (volume-corrected for body weight) and expressed as mmol calcium/kg body weight (2 mEq/kg)."
calcium,"In sarcoidosis, low faecal calcium content is a commonly observed finding, leading to the belief that hyperabsorption is a major cause of hypercalcaemia and hypercalcuria.","Entity: calcium. SMILES: [Ca]. In sarcoidosis, low faecal calcium content is a commonly observed finding, leading to the belief that hyperabsorption is a major cause of hypercalcaemia and hypercalcuria."
calcium,"Corticosteroids exert a discriminative effect on calcium metabolism in sarcoidosis patients, leading to an immediate rise in faecal calcium output and a delayed fall in urine calcium.","Entity: calcium. SMILES: [Ca]. Corticosteroids exert a discriminative effect on calcium metabolism in sarcoidosis patients, leading to an immediate rise in faecal calcium output and a delayed fall in urine calcium."
corticosteroids,"Corticosteroids have a discriminative effect on calcium metabolism in sarcoidosis patients, causing an immediate increase in faecal calcium output and a delayed decrease in urine calcium.","Entity: corticosteroids. SMILES: CC(=O)N(C)[C@H](C)[C@@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](N(C)C)CC[C@@]4(C)[C@@H]3CC[C@]21C. Corticosteroids have a discriminative effect on calcium metabolism in sarcoidosis patients, causing an immediate increase in faecal calcium output and a delayed decrease in urine calcium."
cholecalciferol,"No evidence was found of excessive formation of the biologically active metabolites 25-hydroxycholecalciferol or 1,25-dihydroxycholecalciferol in patients with sarcoidosis.","Entity: cholecalciferol. SMILES: C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12. No evidence was found of excessive formation of the biologically active metabolites 25-hydroxycholecalciferol or 1,25-dihydroxycholecalciferol in patients with sarcoidosis."
calcium,"In patients with sarcoidosis, hypercalcaemia is associated with abnormalities in calcium metabolism, including altered gut and bone calcium handling.","Entity: calcium. SMILES: [Ca]. In patients with sarcoidosis, hypercalcaemia is associated with abnormalities in calcium metabolism, including altered gut and bone calcium handling."
calcium,"In patients with severe sarcoidosis, hypercalcaemia can occur even when calcium intake is very low, indicating that skeletal resorption becomes a substantial source of calcium in such cases.","Entity: calcium. SMILES: [Ca]. In patients with severe sarcoidosis, hypercalcaemia can occur even when calcium intake is very low, indicating that skeletal resorption becomes a substantial source of calcium in such cases."
calcium,"In patients with elevated urinary calcium output, mean serum calcium levels were found to be in the upper half of the normal range.","Entity: calcium. SMILES: [Ca]. In patients with elevated urinary calcium output, mean serum calcium levels were found to be in the upper half of the normal range."
calcium,"In healthy adults, the normal range for calcium absorption, as measured by a double isotope method, is 32–650% of the administered dose, with a mean of 490% (SD 11–8%).","Entity: calcium. SMILES: [Ca]. In healthy adults, the normal range for calcium absorption, as measured by a double isotope method, is 32–650% of the administered dose, with a mean of 490% (SD 11–8%)."
calcium,Hyperabsorption of calcium by the gut is a common feature in both normocalcaemic and hypercalcaemic sarcoidosis.,Entity: calcium. SMILES: [Ca]. Hyperabsorption of calcium by the gut is a common feature in both normocalcaemic and hypercalcaemic sarcoidosis.
calcium,"Increased bone turnover is observed in sarcoid patients, as indicated by calcium kinetic studies and correlation with serum alkaline phosphatase concentration.","Entity: calcium. SMILES: [Ca]. Increased bone turnover is observed in sarcoid patients, as indicated by calcium kinetic studies and correlation with serum alkaline phosphatase concentration."
calcium,Hypercalcuria in sarcoidosis correlates with both intestinal calcium absorption (r = 0.70) and bone turnover (r = 0.65).,Entity: calcium. SMILES: [Ca]. Hypercalcuria in sarcoidosis correlates with both intestinal calcium absorption (r = 0.70) and bone turnover (r = 0.65).
alkaline phosphatase,Serum alkaline phosphatase concentration correlates with increased bone turnover in sarcoid patients.,Entity: alkaline phosphatase. SMILES: CC(N)C(=O)N1CCCC1C(=O)NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)O. Serum alkaline phosphatase concentration correlates with increased bone turnover in sarcoid patients.
calcium,Calcium metabolism is abnormal in some sarcoid patients even when serum calcium concentrations are normal.,Entity: calcium. SMILES: [Ca]. Calcium metabolism is abnormal in some sarcoid patients even when serum calcium concentrations are normal.
hydroxyproline,"Hydroxyproline excretion increases in patients with short-lived sarcoidosis, indicating a phase of increased bone resorption, but becomes normal in cases of longstanding sarcoidosis.","Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Hydroxyproline excretion increases in patients with short-lived sarcoidosis, indicating a phase of increased bone resorption, but becomes normal in cases of longstanding sarcoidosis."
calcium,"Endogenous faecal calcium, representing the unreabsorbed fraction of digestive juice calcium, can be estimated by measuring the amount of intravenously injected 47Ca excreted in faeces over six to nine days.","Entity: calcium. SMILES: [Ca]. Endogenous faecal calcium, representing the unreabsorbed fraction of digestive juice calcium, can be estimated by measuring the amount of intravenously injected 47Ca excreted in faeces over six to nine days."
calcium,"In normal subjects, the range of endogenous faecal calcium excretion is 3.4–5.45 mmol/day, as determined from intra-venous 47Ca excretion studies.","Entity: calcium. SMILES: [Ca]. In normal subjects, the range of endogenous faecal calcium excretion is 3.4–5.45 mmol/day, as determined from intra-venous 47Ca excretion studies."
Calcium,"Bone turnover is increased in six out of ten kinetic studies using 47Ca in sarcoidosis patients, indicating altered calcium metabolism.","Entity: Calcium. SMILES: [Ca]. Bone turnover is increased in six out of ten kinetic studies using 47Ca in sarcoidosis patients, indicating altered calcium metabolism."
Calcium,"In sarcoidosis, abnormalities in calcium metabolism are common but rarely lead to sustained hypercalcaemia.","Entity: Calcium. SMILES: [Ca]. In sarcoidosis, abnormalities in calcium metabolism are common but rarely lead to sustained hypercalcaemia."
Calcium,"In untreated sarcoidosis patients, calcium absorption can be assessed using a double isotope test, and hyperabsorption of 45Ca occurs in a significant proportion of individuals.","Entity: Calcium. SMILES: [Ca]. In untreated sarcoidosis patients, calcium absorption can be assessed using a double isotope test, and hyperabsorption of 45Ca occurs in a significant proportion of individuals."
N-acetylneuraminic acid,"N-acetylneuraminic acid concentration can be qualitatively determined in intestinal tissue lyophilizates, as indicated by a blue-violet color reaction.","Entity: N-acetylneuraminic acid. SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(O)(C(=O)O)C[C@@H]1O. N-acetylneuraminic acid concentration can be qualitatively determined in intestinal tissue lyophilizates, as indicated by a blue-violet color reaction."
Brulidine,"Brulidine is an antimicrobial agent to which Ps cepacia can grow in the presence of undiluted Brulidine, indicating high intrinsic resistance.","Entity: Brulidine. SMILES: N=C(N)c1ccc(OCCCOc2ccc(C(=N)N)cc2Br)c(Br)c1.O=S(=O)(O)CCO. Brulidine is an antimicrobial agent to which Ps cepacia can grow in the presence of undiluted Brulidine, indicating high intrinsic resistance."
promethazine hydrochloride,"Promethazine hydrochloride is commonly used as a premedication agent in adult patients undergoing surgical procedures, typically administered at a dose of 12–5 mg intramuscularly one hour before surgery.","Entity: promethazine hydrochloride. SMILES: CC(CN1c2ccccc2Sc2ccccc21)N(C)C.Cl. Promethazine hydrochloride is commonly used as a premedication agent in adult patients undergoing surgical procedures, typically administered at a dose of 12–5 mg intramuscularly one hour before surgery."
halothane,Halothane is an inhaled anesthetic agent that can be used in combination with nitrous oxide to achieve general anesthesia in surgical settings.,Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane is an inhaled anesthetic agent that can be used in combination with nitrous oxide to achieve general anesthesia in surgical settings.
nitrous oxide,"Nitrous oxide is used as an anesthetic adjunct, often in combination with halothane, to facilitate general anesthesia during surgical procedures.","Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used as an anesthetic adjunct, often in combination with halothane, to facilitate general anesthesia during surgical procedures."
meperidine,Meperidine is an opioid analgesic that is frequently administered as a premedication agent at a dose of 50 mg intramuscularly before surgery.,Entity: meperidine. SMILES: CCOC(=O)C1(c2ccccc2)CCN(C)CC1. Meperidine is an opioid analgesic that is frequently administered as a premedication agent at a dose of 50 mg intramuscularly before surgery.
Hematoxylin,Hematoxylin is used as a histological stain for examining brain tissue sections.,Entity: Hematoxylin. SMILES: Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2. Hematoxylin is used as a histological stain for examining brain tissue sections.
Serotonin,Serotonin (5HT) is a biogenic amine that can be extracted from brain tissue and quantified using specific fluorimetric assays.,Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin (5HT) is a biogenic amine that can be extracted from brain tissue and quantified using specific fluorimetric assays.
Eosin,Eosin is used as a histological stain for examining brain tissue sections.,Entity: Eosin. SMILES: O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+]. Eosin is used as a histological stain for examining brain tissue sections.
Dopamine,Dopamine is a biogenic amine that can be extracted from brain tissue and quantified using specific fluorimetric assays.,Entity: Dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine is a biogenic amine that can be extracted from brain tissue and quantified using specific fluorimetric assays.
Norepinephrine,Norepinephrine is a biogenic amine that can be extracted from brain tissue and quantified using fluorimetric methods.,Entity: Norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Norepinephrine is a biogenic amine that can be extracted from brain tissue and quantified using fluorimetric methods.
Butanol,"Butanol, in the form of cold acidified butanol, is used as a solvent for extracting biogenic amines from brain tissue.","Entity: Butanol. SMILES: CCCCO. Butanol, in the form of cold acidified butanol, is used as a solvent for extracting biogenic amines from brain tissue."
Isopentane,Isopentane is used as a freezing agent to rapidly dissect and preserve brain-stem tissue for subsequent histological analysis.,Entity: Isopentane. SMILES: CCC(C)C. Isopentane is used as a freezing agent to rapidly dissect and preserve brain-stem tissue for subsequent histological analysis.
Bicuculline,Bicuculline is a plant alkaloid that blocks the inhibitory action of gamma-aminobutyric acid (GABA) at post-synaptic sites.,Entity: Bicuculline. SMILES: CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3. Bicuculline is a plant alkaloid that blocks the inhibitory action of gamma-aminobutyric acid (GABA) at post-synaptic sites.
Bicuculline,"Intravenous injection of Bicuculline in lightly anaesthetized rats induces electro-corticographic seizures that can last for more than two hours in paralysed, artificially ventilated animals.","Entity: Bicuculline. SMILES: CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3. Intravenous injection of Bicuculline in lightly anaesthetized rats induces electro-corticographic seizures that can last for more than two hours in paralysed, artificially ventilated animals."
γ-amino butyric acid,Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter whose action at post-synaptic sites can be blocked by Bicuculline.,Entity: γ-amino butyric acid. SMILES: NCCCC(=O)O. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter whose action at post-synaptic sites can be blocked by Bicuculline.
bicuculline,"Bicuculline is administered intravenously at 1–2 mg/kg in rats to induce an increase in arterial pressure and venous outflow, as evidenced by cerebral blood flow changes.","Entity: bicuculline. SMILES: CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3. Bicuculline is administered intravenously at 1–2 mg/kg in rats to induce an increase in arterial pressure and venous outflow, as evidenced by cerebral blood flow changes."
phentolamine,Phentolamine is used in combination with bicuculline to stabilize blood pressure during cerebral blood flow measurement in rats.,Entity: phentolamine. SMILES: Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1. Phentolamine is used in combination with bicuculline to stabilize blood pressure during cerebral blood flow measurement in rats.
nitrous oxide,Nitrous oxide is used as part of the inspired gas mixture (with oxygen) to maintain normocapnic conditions in rats during cerebral blood flow studies.,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used as part of the inspired gas mixture (with oxygen) to maintain normocapnic conditions in rats during cerebral blood flow studies.
Xe,133Xe is used in a desaturation technique to measure cerebral blood flow (CBF) in rats.,Entity: Xe. SMILES: [Xe]. 133Xe is used in a desaturation technique to measure cerebral blood flow (CBF) in rats.
bicuculline,"Bicuculline is an intravenous drug that can cause transient hypotension followed by hypertension in rats, with mean arterial pressure fluctuations not exceeding 15 torr during 133Xe desaturation for CBF measurement.","Entity: bicuculline. SMILES: CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3. Bicuculline is an intravenous drug that can cause transient hypotension followed by hypertension in rats, with mean arterial pressure fluctuations not exceeding 15 torr during 133Xe desaturation for CBF measurement."
phentolamine mesylate,Phentolamine mesylate is an intravenous medication that can reduce arterial pressure to 60–80 torr when administered approximately 1 minute before bicuculline in rats.,Entity: phentolamine mesylate. SMILES: CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1. Phentolamine mesylate is an intravenous medication that can reduce arterial pressure to 60–80 torr when administered approximately 1 minute before bicuculline in rats.
xenon,The partition coefficient for xenon between blood and brain (A) is 0.82.,Entity: xenon. SMILES: [Xe]. The partition coefficient for xenon between blood and brain (A) is 0.82.
bicuculline,Bicuculline induces prolonged seizures in rats that are paralysed and mechanically ventilated with nitrous oxide and oxygen.,Entity: bicuculline. SMILES: CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3. Bicuculline induces prolonged seizures in rats that are paralysed and mechanically ventilated with nitrous oxide and oxygen.
nitrous oxide,Nitrous oxide is used as part of the ventilatory gas mixture in mechanically ventilated rats during bicuculline-induced seizures.,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used as part of the ventilatory gas mixture in mechanically ventilated rats during bicuculline-induced seizures.
xenon,Xenon is used to measure cerebral blood flow (CBF) and CMR O in rats during the course of bicuculline-induced seizures.,Entity: xenon. SMILES: [Xe]. Xenon is used to measure cerebral blood flow (CBF) and CMR O in rats during the course of bicuculline-induced seizures.
oxygen,Oxygen is administered as part of the ventilatory gas mixture in mechanically ventilated rats during bicuculline-induced seizures.,Entity: oxygen. SMILES: [O]. Oxygen is administered as part of the ventilatory gas mixture in mechanically ventilated rats during bicuculline-induced seizures.
lactate,"During generalized seizures, the accumulation of lactate increases due to the maximal rate of glycolysis being more than three times its basal level.","Entity: lactate. SMILES: CC(O)C(=O)[O-]. During generalized seizures, the accumulation of lactate increases due to the maximal rate of glycolysis being more than three times its basal level."
oxygen,"Cerebral glucose utilization during seizure activity increases twofold after one hour, matching the stoichiometric increase in oxygen consumption.","Entity: oxygen. SMILES: [O]. Cerebral glucose utilization during seizure activity increases twofold after one hour, matching the stoichiometric increase in oxygen consumption."
glucose,Cerebral glucose utilization increases fourfold during the first two minutes of bicuculline-induced seizure activity.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Cerebral glucose utilization increases fourfold during the first two minutes of bicuculline-induced seizure activity.
glucose,Cerebral glucose utilization increases twofold compared to control after one hour of seizure activity.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Cerebral glucose utilization increases twofold compared to control after one hour of seizure activity.
bicuculline,"Bicuculline induces seizure activity in rats, as measured by increased cerebral metabolic rate of oxygen (CMR O).","Entity: bicuculline. SMILES: CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3. Bicuculline induces seizure activity in rats, as measured by increased cerebral metabolic rate of oxygen (CMR O)."
bicuculline,Bicuculline is administered intravenously and is used in studies investigating the relationship between EEG seizure activity and systemic haemodynamic changes.,Entity: bicuculline. SMILES: CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3. Bicuculline is administered intravenously and is used in studies investigating the relationship between EEG seizure activity and systemic haemodynamic changes.
phentolamine,"Phentolamine at 1 mg/kg, given intravenously directly after bicuculline, prevents the occurrence of systemic changes during EEG seizure activity, indicating its role in modulating haemodynamic responses.","Entity: phentolamine. SMILES: Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1. Phentolamine at 1 mg/kg, given intravenously directly after bicuculline, prevents the occurrence of systemic changes during EEG seizure activity, indicating its role in modulating haemodynamic responses."
CO2,Changes in arterial CO2 tension are associated with systemic alterations observed during EEG seizure activity.,Entity: CO2. SMILES: O=C=O. Changes in arterial CO2 tension are associated with systemic alterations observed during EEG seizure activity.
lactic acid,A marked increase in blood lactic acid leads to a metabolic acidosis that is relatively constant despite low or normal CO2 tension during EEG seizure activity.,Entity: lactic acid. SMILES: CC(O)C(=O)O. A marked increase in blood lactic acid leads to a metabolic acidosis that is relatively constant despite low or normal CO2 tension during EEG seizure activity.
bicuculline,Bicuculline is used to induce sustained epileptic seizures in rats at a dose of 1–2 mg/kg intravenously.,Entity: bicuculline. SMILES: CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3. Bicuculline is used to induce sustained epileptic seizures in rats at a dose of 1–2 mg/kg intravenously.
oxygen,Oxygen is administered during the procedure to maintain normal arterial oxygenation in rats undergoing seizure induction.,Entity: oxygen. SMILES: [O]. Oxygen is administered during the procedure to maintain normal arterial oxygenation in rats undergoing seizure induction.
nitrous oxide,Nitrous oxide is used in combination with oxygen as the carrier gas for artificial ventilation in rats during seizure studies.,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used in combination with oxygen as the carrier gas for artificial ventilation in rats during seizure studies.
glucose,Blood glucose concentration is maintained at normal or high levels throughout the seizure induction procedure in rats.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Blood glucose concentration is maintained at normal or high levels throughout the seizure induction procedure in rats.
xenon,133Xe is used to measure cerebral blood flow by desaturation in rats.,Entity: xenon. SMILES: [Xe]. 133Xe is used to measure cerebral blood flow by desaturation in rats.
bicuculline,"Bicuculline is administered at a dose of 1–2 mg/kg intravenously to produce a transient increase in cerebral blood flow in rats, as measured by 133Xe desaturation techniques.","Entity: bicuculline. SMILES: CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3. Bicuculline is administered at a dose of 1–2 mg/kg intravenously to produce a transient increase in cerebral blood flow in rats, as measured by 133Xe desaturation techniques."
nitrous oxide,Nitrous oxide is used as a carrier gas (70%) in combination with oxygen (30%) for rat ventilation during cerebral blood flow studies.,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used as a carrier gas (70%) in combination with oxygen (30%) for rat ventilation during cerebral blood flow studies.
xenon,"133Xe is used as a tracer to measure cerebral blood flow in rats, with activity recorded as a percentage of the initial saturation value.","Entity: xenon. SMILES: [Xe]. 133Xe is used as a tracer to measure cerebral blood flow in rats, with activity recorded as a percentage of the initial saturation value."
carbon dioxide,"PaCO2 is monitored in rats during cerebral blood flow studies, with values such as 37.6 torr in control conditions and 38 torr in bicuculline-treated animals.","Entity: carbon dioxide. SMILES: O=C=O. PaCO2 is monitored in rats during cerebral blood flow studies, with values such as 37.6 torr in control conditions and 38 torr in bicuculline-treated animals."
tubocurarine chloride,Tubocurarine chloride is used to prevent the peripheral motor component of seizure activity in animal experiments.,Entity: tubocurarine chloride. SMILES: COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.Cl.[Cl-]. Tubocurarine chloride is used to prevent the peripheral motor component of seizure activity in animal experiments.
oxygen,"Oxygen is used as part of the mechanical ventilation mixture (70% nitrous oxide, 30% oxygen) to maintain arterial oxygen tension greater than 100 torr in anesthetized rats.","Entity: oxygen. SMILES: [O]. Oxygen is used as part of the mechanical ventilation mixture (70% nitrous oxide, 30% oxygen) to maintain arterial oxygen tension greater than 100 torr in anesthetized rats."
halothane,Halothane is an anesthetic agent used to anesthetize rats at a concentration of 3% for surgical procedures.,Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane is an anesthetic agent used to anesthetize rats at a concentration of 3% for surgical procedures.
nitrous oxide,"Nitrous oxide is used as part of the mechanical ventilation mixture (70% nitrous oxide, 30% oxygen) to maintain arterial carbon dioxide tension of 35–40 torr in anesthetized rats.","Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used as part of the mechanical ventilation mixture (70% nitrous oxide, 30% oxygen) to maintain arterial carbon dioxide tension of 35–40 torr in anesthetized rats."
bicuculline,"Bicuculline is administered to animals prior to recording EEG, with baseline blood pressure and blood gas measurements taken 10–20 minutes afterward.","Entity: bicuculline. SMILES: CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3. Bicuculline is administered to animals prior to recording EEG, with baseline blood pressure and blood gas measurements taken 10–20 minutes afterward."
carbon dioxide,Arterial carbon dioxide tension (Paco2) is maintained at 35–40 torr during mechanical ventilation in anesthetized rats.,Entity: carbon dioxide. SMILES: O=C=O. Arterial carbon dioxide tension (Paco2) is maintained at 35–40 torr during mechanical ventilation in anesthetized rats.
bicuculline,Bicuculline is an intravenous drug (1–2 mg/kg) used to induce seizure activity in rats for experimental studies of cerebral perfusion and metabolism.,Entity: bicuculline. SMILES: CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3. Bicuculline is an intravenous drug (1–2 mg/kg) used to induce seizure activity in rats for experimental studies of cerebral perfusion and metabolism.
phentolamine,"Phentolamine (1 mg/kg, i.v.) is administered to rats 1 min after bicuculline to study its effects on cerebral perfusion and metabolism.","Entity: phentolamine. SMILES: Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1. Phentolamine (1 mg/kg, i.v.) is administered to rats 1 min after bicuculline to study its effects on cerebral perfusion and metabolism."
nitrous oxide,Nitrous oxide is used as a component of the ventilator gas mixture (70%) in combination with oxygen (30%) for mechanical ventilation in rats during experimental studies.,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used as a component of the ventilator gas mixture (70%) in combination with oxygen (30%) for mechanical ventilation in rats during experimental studies.
xenon,Xenon is used in the form of 133 Xe for cerebral blood flow determination by desaturation in rat studies.,Entity: xenon. SMILES: [Xe]. Xenon is used in the form of 133 Xe for cerebral blood flow determination by desaturation in rat studies.
adenosine,"A 10⁻¹ mol/min infusion of adenosine produces a 15% increase in CBF, which is weaker than the 40% increase caused by a 10⁻¹ mol/min infusion.","Entity: adenosine. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O. A 10⁻¹ mol/min infusion of adenosine produces a 15% increase in CBF, which is weaker than the 40% increase caused by a 10⁻¹ mol/min infusion."
lactic acid,Tissue content of lactic acid increases rapidly during seizures.,Entity: lactic acid. SMILES: CC(O)C(=O)O. Tissue content of lactic acid increases rapidly during seizures.
ADP,"During the initial 10 seconds of seizure discharge, there are increases in ADP and AMP concentration in brain tissue.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. During the initial 10 seconds of seizure discharge, there are increases in ADP and AMP concentration in brain tissue."
AMP,"During the initial 10 seconds of seizure discharge, there are increases in AMP concentration in brain tissue.","Entity: AMP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. During the initial 10 seconds of seizure discharge, there are increases in AMP concentration in brain tissue."
ATP,"During the initial 10 seconds of seizure discharge, there are decreases in ATP concentration in brain tissue.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. During the initial 10 seconds of seizure discharge, there are decreases in ATP concentration in brain tissue."
creatine phosphate,"Hydrolysis of creatine phosphate in brain tissue is marked, with concentrations falling from 4–6 to 2–5 µmol/g after 10 seconds during seizure activity.","Entity: creatine phosphate. SMILES: CN(CC(=O)O)C(=N)N.O=P(O)(O)O. Hydrolysis of creatine phosphate in brain tissue is marked, with concentrations falling from 4–6 to 2–5 µmol/g after 10 seconds during seizure activity."
CO2,"Tissue PCO2 decreases during seizures, and changes in total CO2 content support the conclusion that there is no net decrease in tissue pH during the initial phase of seizure activity.","Entity: CO2. SMILES: O=C=O. Tissue PCO2 decreases during seizures, and changes in total CO2 content support the conclusion that there is no net decrease in tissue pH during the initial phase of seizure activity."
adenosine,Adenosine exerts a vasodilator action that may contribute to metabolic control of cerebral vascular resistance (CVR).,Entity: adenosine. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O. Adenosine exerts a vasodilator action that may contribute to metabolic control of cerebral vascular resistance (CVR).
creatine phosphate,"During the first few seconds of electroshock-induced seizures in mice, the rate of breakdown of creatine phosphate is increased threefold or more compared to normal metabolic rates.","Entity: creatine phosphate. SMILES: CN(CC(=O)O)C(=N)N.O=P(O)(O)O. During the first few seconds of electroshock-induced seizures in mice, the rate of breakdown of creatine phosphate is increased threefold or more compared to normal metabolic rates."
oxygen,"Elevated oxygen tension in cerebral venous blood is observed during epileptic seizures, indicating increased cerebral blood flow and oxygen consumption.","Entity: oxygen. SMILES: [O]. Elevated oxygen tension in cerebral venous blood is observed during epileptic seizures, indicating increased cerebral blood flow and oxygen consumption."
flurothyl,"Flurothyl is used to induce seizures in mice, which allows measurement of substrate utilization rates such as creatine phosphate breakdown and ATP conversion during seizures.","Entity: flurothyl. SMILES: FC(F)(F)COCC(F)(F)F. Flurothyl is used to induce seizures in mice, which allows measurement of substrate utilization rates such as creatine phosphate breakdown and ATP conversion during seizures."
glucose,"Glucose is metabolized at an increased rate during the first few seconds of epileptic seizures in mice, as indicated by elevated substrate utilization.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is metabolized at an increased rate during the first few seconds of epileptic seizures in mice, as indicated by elevated substrate utilization."
lactate,The conversion of glucose to lactate in the brain is increased threefold or more during the first few seconds of electroshock-induced seizures in mice.,Entity: lactate. SMILES: CC(O)C(=O)[O-]. The conversion of glucose to lactate in the brain is increased threefold or more during the first few seconds of electroshock-induced seizures in mice.
adenosine triphosphate,The rate of breakdown of adenosine triphosphate is increased threefold or more during the first few seconds of electroshock-induced seizures in mice.,Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. The rate of breakdown of adenosine triphosphate is increased threefold or more during the first few seconds of electroshock-induced seizures in mice.
Potassium ferricyanide,Potassium ferricyanide is used in a modified method to determine total oxygen content in arterial and venous blood samples.,Entity: Potassium ferricyanide. SMILES: N#C[Fe-3](C#N)(C#N)(C#N)(C#N)C#N.[K+].[K+].[K+]. Potassium ferricyanide is used in a modified method to determine total oxygen content in arterial and venous blood samples.
Sodium hydroxide,Sodium hydroxide is used to adjust the pH of Bicuculline methochloride solution to 5–6 for analysis.,Entity: Sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to adjust the pH of Bicuculline methochloride solution to 5–6 for analysis.
Bicuculline methochloride,Bicuculline methochloride is a chemical compound that can be dissolved in 0.1 N hydrochloric acid and its pH adjusted to 5–6 for experimental use.,Entity: Bicuculline methochloride. SMILES: C[N+]1(C)CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3.[Cl-]. Bicuculline methochloride is a chemical compound that can be dissolved in 0.1 N hydrochloric acid and its pH adjusted to 5–6 for experimental use.
Hydrochloric acid,Hydrochloric acid is used to dissolve Bicuculline methochloride for experimental preparation.,Entity: Hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to dissolve Bicuculline methochloride for experimental preparation.
glucose,"During sustained, generalized seizure activity, cerebral glucose consumption increases twofold to threefold compared to normal levels, reflecting the elevated energy requirements of brain tissue.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. During sustained, generalized seizure activity, cerebral glucose consumption increases twofold to threefold compared to normal levels, reflecting the elevated energy requirements of brain tissue."
oxygen,"During sustained, generalized seizure activity, cerebral oxygen consumption increases twofold to threefold compared to normal levels, supporting the need for maintained arterial oxygen content to meet tissue energy demands.","Entity: oxygen. SMILES: [O]. During sustained, generalized seizure activity, cerebral oxygen consumption increases twofold to threefold compared to normal levels, supporting the need for maintained arterial oxygen content to meet tissue energy demands."
Xe,Xe is used in the l33 Xe desaturation technique for simultaneous determination of cerebral blood flow (CBF) and CMRo in brain studies.,Entity: Xe. SMILES: [Xe]. Xe is used in the l33 Xe desaturation technique for simultaneous determination of cerebral blood flow (CBF) and CMRo in brain studies.
oxygen,Total oxygen content in venous blood can be determined by sampling via a branch cannula during experimental procedures.,Entity: oxygen. SMILES: [O]. Total oxygen content in venous blood can be determined by sampling via a branch cannula during experimental procedures.
Oxygen,Oxygen content in blood can be measured in small blood samples (25 µL) using a micromethod to determine the cerebral arteriovenous difference (CMR 0] ) and cerebral blood flow (CBF) in studies of brain tissue.,Entity: Oxygen. SMILES: [O]. Oxygen content in blood can be measured in small blood samples (25 µL) using a micromethod to determine the cerebral arteriovenous difference (CMR 0] ) and cerebral blood flow (CBF) in studies of brain tissue.
ethambutol,Ethambutol prevents the emergence of further drug resistance during chemotherapy in patients with initial resistance to both isoniazid and streptomycin.,Entity: ethambutol. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO. Ethambutol prevents the emergence of further drug resistance during chemotherapy in patients with initial resistance to both isoniazid and streptomycin.
rifampin,"Rifampin is used as part of a chemotherapy regimen with streptomycin and isoniazid, administered daily for 6 months or in combination with pyrazinamide for shorter durations, in the treatment of tuberculosis.","Entity: rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Rifampin is used as part of a chemotherapy regimen with streptomycin and isoniazid, administered daily for 6 months or in combination with pyrazinamide for shorter durations, in the treatment of tuberculosis."
isoniazid,"Isoniazid is administered daily as part of a chemotherapy regimen with streptomycin and rifampin, or in combination with pyrazinamide, for the treatment of tuberculosis.","Entity: isoniazid. SMILES: NNC(=O)c1ccncc1. Isoniazid is administered daily as part of a chemotherapy regimen with streptomycin and rifampin, or in combination with pyrazinamide, for the treatment of tuberculosis."
pyrazinamide,"Pyrazinamide is used in combination with streptomycin and isoniazid, or as part of a regimen administered daily for 6 months or with a 9-month regimen including both daily and intermittent dosing, in the treatment of tuberculosis.","Entity: pyrazinamide. SMILES: NC(=O)c1cnccn1. Pyrazinamide is used in combination with streptomycin and isoniazid, or as part of a regimen administered daily for 6 months or with a 9-month regimen including both daily and intermittent dosing, in the treatment of tuberculosis."
streptomycin,"Streptomycin is used as part of a chemotherapy regimen with isoniazid and rifampin, or in combination with pyrazinamide, administered daily or on specific schedules, for the treatment of tuberculosis.","Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used as part of a chemotherapy regimen with isoniazid and rifampin, or in combination with pyrazinamide, administered daily or on specific schedules, for the treatment of tuberculosis."
ethambutol,Ethambutol susceptibility in sputum cultures is tested to define isoniazid and rifampin monotherapy resistance in tuberculosis treatment.,Entity: ethambutol. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO. Ethambutol susceptibility in sputum cultures is tested to define isoniazid and rifampin monotherapy resistance in tuberculosis treatment.
rifampin,Rifampin susceptibility in sputum cultures is tested to define isoniazid monotherapy resistance in tuberculosis treatment.,Entity: rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Rifampin susceptibility in sputum cultures is tested to define isoniazid monotherapy resistance in tuberculosis treatment.
streptomycin,Streptomycin susceptibility in sputum cultures is tested to define rifampin monotherapy resistance in tuberculosis treatment.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin susceptibility in sputum cultures is tested to define rifampin monotherapy resistance in tuberculosis treatment.
isoniazid,Isoniazid monotherapy resistance in tuberculosis treatment is defined by ethambutol and rifampin susceptibility testing in sputum cultures.,Entity: isoniazid. SMILES: NNC(=O)c1ccncc1. Isoniazid monotherapy resistance in tuberculosis treatment is defined by ethambutol and rifampin susceptibility testing in sputum cultures.
ethambutol,"All 10 patients with resistance to both isoniazid and streptomycin, who received the ethambutol regimen, had a favorable bacteriologic status at the end of chemotherapy.","Entity: ethambutol. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO. All 10 patients with resistance to both isoniazid and streptomycin, who received the ethambutol regimen, had a favorable bacteriologic status at the end of chemotherapy."
rifampin,Chemotherapy regimens with 4 months of rifampin were more effective than those with 2 months in treating patients with strains resistant to 2 drugs.,Entity: rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Chemotherapy regimens with 4 months of rifampin were more effective than those with 2 months in treating patients with strains resistant to 2 drugs.
streptomycin,Patients with strains resistant to streptomycin before treatment had a higher risk of relapse during the 6 months after the end of chemotherapy compared to those with isoniazid-only resistance.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Patients with strains resistant to streptomycin before treatment had a higher risk of relapse during the 6 months after the end of chemotherapy compared to those with isoniazid-only resistance.
isoniazid,"Patients with strains resistant to isoniazid before treatment generally had a favorable bacteriologic status at the end of chemotherapy, especially when treated with the ethambutol regimen.","Entity: isoniazid. SMILES: NNC(=O)c1ccncc1. Patients with strains resistant to isoniazid before treatment generally had a favorable bacteriologic status at the end of chemotherapy, especially when treated with the ethambutol regimen."
Pyrazinamide,"Pyrazinamide is a bactericidal drug used in tuberculosis treatment regimens, but in Hong Kong studies, it was replaced by ethambutol in some regimens to reduce toxicity.","Entity: Pyrazinamide. SMILES: NC(=O)c1cnccn1. Pyrazinamide is a bactericidal drug used in tuberculosis treatment regimens, but in Hong Kong studies, it was replaced by ethambutol in some regimens to reduce toxicity."
Isoniazid,Isoniazid is an anti-tuberculosis drug used in combination regimens for both daily and intermittent chemotherapy in Hong Kong.,Entity: Isoniazid. SMILES: NNC(=O)c1ccncc1. Isoniazid is an anti-tuberculosis drug used in combination regimens for both daily and intermittent chemotherapy in Hong Kong.
Streptomycin,"Streptomycin is an anti-tuberculosis drug used in combination regimens, and its use in Hong Kong was associated with higher relapse rates compared to East Africa, particularly in regimens with pyrazinamide.","Entity: Streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is an anti-tuberculosis drug used in combination regimens, and its use in Hong Kong was associated with higher relapse rates compared to East Africa, particularly in regimens with pyrazinamide."
Ethambutol,Ethambutol is a relatively nontoxic bacteriostatic drug studied as an alternative to pyrazinamide in tuberculosis chemotherapy regimens in Hong Kong.,Entity: Ethambutol. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO. Ethambutol is a relatively nontoxic bacteriostatic drug studied as an alternative to pyrazinamide in tuberculosis chemotherapy regimens in Hong Kong.
Rifampin,"Rifampin is a relatively nontoxic but bacteriostatic drug used in tuberculosis chemotherapy regimens, either as an intensive phase or in combination with other agents.","Entity: Rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Rifampin is a relatively nontoxic but bacteriostatic drug used in tuberculosis chemotherapy regimens, either as an intensive phase or in combination with other agents."
Rifampin,"In Hong Kong, rifampin was administered at a maximum of 60 doses during an initial 2-month intensive phase or as part of an intermittent intensive phase for 4 months in tuberculosis treatment regimens.","Entity: Rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. In Hong Kong, rifampin was administered at a maximum of 60 doses during an initial 2-month intensive phase or as part of an intermittent intensive phase for 4 months in tuberculosis treatment regimens."
Rifampin,Rifampin has not been encountered to cause initial resistance in the Hong Kong/BMRC tuberculosis studies.,Entity: Rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Rifampin has not been encountered to cause initial resistance in the Hong Kong/BMRC tuberculosis studies.
streptomycin,Patients treated with the SHRE/S 2 H 2 E 2 regimen can develop sputum cultures at 6 months that are resistant to streptomycin but remain fully drug-susceptible thereafter.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Patients treated with the SHRE/S 2 H 2 E 2 regimen can develop sputum cultures at 6 months that are resistant to streptomycin but remain fully drug-susceptible thereafter.
rifampin,Patients treated with the SHRE/S 2 H 2 E 2 regimen can develop sputum cultures at 6 months that are resistant to streptomycin but remain fully drug-susceptible thereafter.,Entity: rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Patients treated with the SHRE/S 2 H 2 E 2 regimen can develop sputum cultures at 6 months that are resistant to streptomycin but remain fully drug-susceptible thereafter.
isoniazid,Patients treated with the SHRE/S 2 H 2 E 2 regimen can develop sputum cultures at 6 months that are resistant to streptomycin but remain fully drug-susceptible thereafter.,Entity: isoniazid. SMILES: NNC(=O)c1ccncc1. Patients treated with the SHRE/S 2 H 2 E 2 regimen can develop sputum cultures at 6 months that are resistant to streptomycin but remain fully drug-susceptible thereafter.
streptomycin,"Bacterial resistance to streptomycin is defined as the ability to grow 20 or more colonies in cultures treated with 8 mg/L streptomycin, or to grow in cultures treated with 16 mg/L or more streptomycin.","Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Bacterial resistance to streptomycin is defined as the ability to grow 20 or more colonies in cultures treated with 8 mg/L streptomycin, or to grow in cultures treated with 16 mg/L or more streptomycin."
isoniazid,Bacterial resistance to isoniazid is defined as the ability to grow in cultures treated with 0.2 mg/L isoniazid or more in at least one culture.,Entity: isoniazid. SMILES: NNC(=O)c1ccncc1. Bacterial resistance to isoniazid is defined as the ability to grow in cultures treated with 0.2 mg/L isoniazid or more in at least one culture.
rifampin,Bacterial resistance to rifampin is defined as the ability to grow in cultures treated with 32 mg/L rifampin or more in at least one culture.,Entity: rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Bacterial resistance to rifampin is defined as the ability to grow in cultures treated with 32 mg/L rifampin or more in at least one culture.
ethambutol,Bacterial resistance to ethambutol is defined as the ability to grow in cultures treated with 4.0 mg/L ethambutol or more in at least one culture.,Entity: ethambutol. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO. Bacterial resistance to ethambutol is defined as the ability to grow in cultures treated with 4.0 mg/L ethambutol or more in at least one culture.
isoniazid,Isoniazid is considered an important drug in short-course chemotherapy for its bactericidal and sterilizing actions.,Entity: isoniazid. SMILES: NNC(=O)c1ccncc1. Isoniazid is considered an important drug in short-course chemotherapy for its bactericidal and sterilizing actions.
streptomycin,Streptomycin has a small role in short-course chemotherapy compared to other agents.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin has a small role in short-course chemotherapy compared to other agents.
ethambutol,Ethambutol is considered important for bactericidal and sterilizing actions in short-course chemotherapy.,Entity: ethambutol. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO. Ethambutol is considered important for bactericidal and sterilizing actions in short-course chemotherapy.
pyrazinamide,"Pyrazinamide has a special sterilizing role in short-course chemotherapy, contributing to the elimination of slowly or irregularly metabolizing bacilli.","Entity: pyrazinamide. SMILES: NC(=O)c1cnccn1. Pyrazinamide has a special sterilizing role in short-course chemotherapy, contributing to the elimination of slowly or irregularly metabolizing bacilli."
pyrazinamide,Pyrazinamide is considered important for bactericidal and sterilizing actions in short-course chemotherapy.,Entity: pyrazinamide. SMILES: NC(=O)c1cnccn1. Pyrazinamide is considered important for bactericidal and sterilizing actions in short-course chemotherapy.
rifampin,"Rifampin has a special sterilizing role in short-course chemotherapy, aiding in the elimination of slowly or irregularly metabolizing bacilli.","Entity: rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Rifampin has a special sterilizing role in short-course chemotherapy, aiding in the elimination of slowly or irregularly metabolizing bacilli."
rifampin,"Rifampin is administered in combination with streptomycin and isoniazid for the treatment of tuberculosis, either daily or twice weekly, as part of various drug regimens.","Entity: rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Rifampin is administered in combination with streptomycin and isoniazid for the treatment of tuberculosis, either daily or twice weekly, as part of various drug regimens."
ethambutol,"Ethambutol is used as an alternative to pyrazinamide in tuberculosis treatment regimens, replacing pyrazinamide in both daily and twice-weekly dosing schedules.","Entity: ethambutol. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO. Ethambutol is used as an alternative to pyrazinamide in tuberculosis treatment regimens, replacing pyrazinamide in both daily and twice-weekly dosing schedules."
streptomycin,"Streptomycin is used in combination with isoniazid and rifampin for tuberculosis treatment, administered daily or twice weekly depending on the regimen.","Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used in combination with isoniazid and rifampin for tuberculosis treatment, administered daily or twice weekly depending on the regimen."
pyrazinamide,"Pyrazinamide is included in tuberculosis treatment regimens, either as part of daily dosing or as twice-weekly administration in combination with streptomycin and isoniazid.","Entity: pyrazinamide. SMILES: NC(=O)c1cnccn1. Pyrazinamide is included in tuberculosis treatment regimens, either as part of daily dosing or as twice-weekly administration in combination with streptomycin and isoniazid."
isoniazid,"Isoniazid is used in combination with streptomycin and rifampin as part of tuberculosis treatment regimens, either daily or twice weekly, depending on the protocol.","Entity: isoniazid. SMILES: NNC(=O)c1ccncc1. Isoniazid is used in combination with streptomycin and rifampin as part of tuberculosis treatment regimens, either daily or twice weekly, depending on the protocol."
isoniazid,Isoniazid is an antimicrobial agent used in the treatment of tuberculosis and is effective in patients with fully susceptible organisms and in those initially resistant to isoniazid or streptomycin.,Entity: isoniazid. SMILES: NNC(=O)c1ccncc1. Isoniazid is an antimicrobial agent used in the treatment of tuberculosis and is effective in patients with fully susceptible organisms and in those initially resistant to isoniazid or streptomycin.
streptomycin,Streptomycin is an antimicrobial agent used in the treatment of tuberculosis and is effective in patients with fully susceptible organisms and in those initially resistant to isoniazid or streptomycin.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is an antimicrobial agent used in the treatment of tuberculosis and is effective in patients with fully susceptible organisms and in those initially resistant to isoniazid or streptomycin.
Ethambutol,"Ethambutol is used as an alternative to pyrazinamide in tuberculosis chemotherapy regimens, such as in the SHRE/S2H2E2 regimen.","Entity: Ethambutol. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO. Ethambutol is used as an alternative to pyrazinamide in tuberculosis chemotherapy regimens, such as in the SHRE/S2H2E2 regimen."
Isoniazid,"Isoniazid is used in combination with streptomycin and rifampin as part of various tuberculosis chemotherapy regimens, including daily and twice-weekly dosing schedules.","Entity: Isoniazid. SMILES: NNC(=O)c1ccncc1. Isoniazid is used in combination with streptomycin and rifampin as part of various tuberculosis chemotherapy regimens, including daily and twice-weekly dosing schedules."
Streptomycin,Streptomycin is administered daily or twice per week in combination with isoniazid and rifampin as part of tuberculosis chemotherapy regimens.,Entity: Streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is administered daily or twice per week in combination with isoniazid and rifampin as part of tuberculosis chemotherapy regimens.
Rifampin,Rifampin is used in combination with streptomycin and isoniazid in daily or twice-weekly dosing schedules for tuberculosis chemotherapy.,Entity: Rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Rifampin is used in combination with streptomycin and isoniazid in daily or twice-weekly dosing schedules for tuberculosis chemotherapy.
Pyrazinamide,"Pyrazinamide is included in tuberculosis chemotherapy regimens, either as a daily or twice-weekly component, and can be substituted by ethambutol in certain regimens.","Entity: Pyrazinamide. SMILES: NC(=O)c1cnccn1. Pyrazinamide is included in tuberculosis chemotherapy regimens, either as a daily or twice-weekly component, and can be substituted by ethambutol in certain regimens."
streptomycin,"Streptomycin is used as part of short-course antituberculosis regimens, either given daily for 6 months or in combination with isoniazid and rifampin.","Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used as part of short-course antituberculosis regimens, either given daily for 6 months or in combination with isoniazid and rifampin."
ethambutol,"Ethambutol can be used as an alternative to pyrazinamide in antituberculosis regimens, but in a regimen where ethambutol replaced pyrazinamide, 19% of patients relapsed after 6 months and 8% after 8 months of treatment.","Entity: ethambutol. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO. Ethambutol can be used as an alternative to pyrazinamide in antituberculosis regimens, but in a regimen where ethambutol replaced pyrazinamide, 19% of patients relapsed after 6 months and 8% after 8 months of treatment."
isoniazid,"In patients with drug-susceptible Mycobacterium tuberculosis strains, relapse is associated with strains that remain fully susceptible to isoniazid.","Entity: isoniazid. SMILES: NNC(=O)c1ccncc1. In patients with drug-susceptible Mycobacterium tuberculosis strains, relapse is associated with strains that remain fully susceptible to isoniazid."
rifampin,"In patients with drug-susceptible Mycobacterium tuberculosis strains, relapse is associated with strains that remain fully susceptible to rifampin.","Entity: rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. In patients with drug-susceptible Mycobacterium tuberculosis strains, relapse is associated with strains that remain fully susceptible to rifampin."
streptomycin,"In patients with drug-susceptible Mycobacterium tuberculosis strains, relapse is associated with strains that remain fully susceptible to streptomycin.","Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. In patients with drug-susceptible Mycobacterium tuberculosis strains, relapse is associated with strains that remain fully susceptible to streptomycin."
ethambutol,Ethambutol is administered at a dosage of 25 mg per kg of body weight per day and 45 mg per kg of body weight twice per week.,Entity: ethambutol. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO. Ethambutol is administered at a dosage of 25 mg per kg of body weight per day and 45 mg per kg of body weight twice per week.
streptomycin,Streptomycin is administered at a dosage of 0.75 g per day and 1.0 g three times and twice per week.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is administered at a dosage of 0.75 g per day and 1.0 g three times and twice per week.
isoniazid,Isoniazid is administered at a dosage of 300 mg per day and 15 mg per kg of body weight three times and twice per week.,Entity: isoniazid. SMILES: NNC(=O)c1ccncc1. Isoniazid is administered at a dosage of 300 mg per day and 15 mg per kg of body weight three times and twice per week.
rifampin,"Rifampin is administered at a dosage of 450 mg per day, with 600 mg for patients weighing 50 kg or more, and in doses of 3 times and twice per week.","Entity: rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Rifampin is administered at a dosage of 450 mg per day, with 600 mg for patients weighing 50 kg or more, and in doses of 3 times and twice per week."
pyrazinamide,"Pyrazinamide is administered at a dosage of 1.5 g per day, with additional regimens of 2.0 g three times per week, 3.0 g twice per week, and higher doses (2.0, 2.5, and 3.5 g, respectively) for patients weighing 50 kg or more.","Entity: pyrazinamide. SMILES: NC(=O)c1cnccn1. Pyrazinamide is administered at a dosage of 1.5 g per day, with additional regimens of 2.0 g three times per week, 3.0 g twice per week, and higher doses (2.0, 2.5, and 3.5 g, respectively) for patients weighing 50 kg or more."
BrdU,BrdU treatment in rats delays myelination in the cerebellum but does so at a rate proportional to cerebellar size.,Entity: BrdU. SMILES: O=c1ccn([C@@]2(Br)C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. BrdU treatment in rats delays myelination in the cerebellum but does so at a rate proportional to cerebellar size.
N-ethylmaleimide,"N-ethylmaleimide inhibits the DNA polymerase activity in mouse sperm nuclei, but does not lower the activity when used at low concentrations.","Entity: N-ethylmaleimide. SMILES: CCN1C(=O)C=CC1=O. N-ethylmaleimide inhibits the DNA polymerase activity in mouse sperm nuclei, but does not lower the activity when used at low concentrations."
methanol,Methanol pretreatment of mouse sperm nuclei enhances the activity of nuclear DNA polymerase during incubation in the reaction medium.,Entity: methanol. SMILES: CO. Methanol pretreatment of mouse sperm nuclei enhances the activity of nuclear DNA polymerase during incubation in the reaction medium.
netropsin,Netropsin at concentrations of 5–50 µg/ml lowers the DNA polymerization activity of the nuclear DNA polymerase in mouse sperm nuclei.,Entity: netropsin. SMILES: Cn1cc(NC(=O)c2cc(NC(=O)CN=C(N)N)cn2C)cc1C(=O)NCCC(=N)N. Netropsin at concentrations of 5–50 µg/ml lowers the DNA polymerization activity of the nuclear DNA polymerase in mouse sperm nuclei.
p-hydroxymercuribenzoate,p-hydroxymercuribenzoate does not inhibit the DNA polymerase activity in mouse sperm nuclei.,Entity: p-hydroxymercuribenzoate. SMILES: O.O=C([O-])c1ccc([Hg])cc1. p-hydroxymercuribenzoate does not inhibit the DNA polymerase activity in mouse sperm nuclei.
urea,"Urea slightly stimulates the DNA polymerase activity in mouse sperm nuclei, and this stimulation is reversed by treatment with N-ethylmaleimide.","Entity: urea. SMILES: NC(N)=O. Urea slightly stimulates the DNA polymerase activity in mouse sperm nuclei, and this stimulation is reversed by treatment with N-ethylmaleimide."
Triton X-100,"Triton X-100 only partially solubilizes the radioactive acid-precipitable product of DNA polymerization in mouse sperm nuclei, indicating it is not preferentially associated with nuclear membranes.","Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 only partially solubilizes the radioactive acid-precipitable product of DNA polymerization in mouse sperm nuclei, indicating it is not preferentially associated with nuclear membranes."
spermidine,Spermidine at concentrations of 0.5–2.5 mM lowers the DNA polymerization activity of the nuclear DNA polymerase in mouse sperm nuclei.,Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine at concentrations of 0.5–2.5 mM lowers the DNA polymerization activity of the nuclear DNA polymerase in mouse sperm nuclei.
iproniazid,Iproniazid is used as a monoamine oxidase inhibitor to prevent degradation of monoamines in cerebrospinal fluid assays.,Entity: iproniazid. SMILES: CC(C)NNC(=O)c1ccncc1. Iproniazid is used as a monoamine oxidase inhibitor to prevent degradation of monoamines in cerebrospinal fluid assays.
hydrochloric acid,Hydrochloric acid is used to adjust the pH of cerebrospinal fluid samples to 6 N prior to 5-hydroxyindole quantification.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to adjust the pH of cerebrospinal fluid samples to 6 N prior to 5-hydroxyindole quantification.
cysteine,Cysteine is added to cerebrospinal fluid specimens to protect them during the orthophthalaldehyde condensation assay for 5-hydroxyindoles.,Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. Cysteine is added to cerebrospinal fluid specimens to protect them during the orthophthalaldehyde condensation assay for 5-hydroxyindoles.
5-hydroxyindole,"Total 5-hydroxyindoles in cerebrospinal fluid can be quantified by a modified orthophthalaldehyde condensation method, with fluorescence detection at 360 nm (excitation)/485 nm (emission).","Entity: 5-hydroxyindole. SMILES: Oc1ccc2[nH]ccc2c1. Total 5-hydroxyindoles in cerebrospinal fluid can be quantified by a modified orthophthalaldehyde condensation method, with fluorescence detection at 360 nm (excitation)/485 nm (emission)."
ferricyanide,Ferricyanide is used to oxidize cerebrospinal fluid blanks during the orthophthalaldehyde condensation assay for 5-hydroxyindoles.,Entity: ferricyanide. SMILES: N#C[Fe-3](C#N)(C#N)(C#N)(C#N)C#N. Ferricyanide is used to oxidize cerebrospinal fluid blanks during the orthophthalaldehyde condensation assay for 5-hydroxyindoles.
perchloric acid,Perchloric acid is used to deproteinize cerebrospinal fluid samples prior to 5-hydroxyindole quantification.,Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid is used to deproteinize cerebrospinal fluid samples prior to 5-hydroxyindole quantification.
chromic oxide,"Chromic oxide (Cr2O3) is used as a marker in digestibility studies, where it is supplemented at 5 g/kg in quail diets and its passage through the digestive tract can be monitored by X-ray fluorescence spectrophotometry.","Entity: chromic oxide. SMILES: [Cr+3].[Cr+3].[O-2].[O-2].[O-2]. Chromic oxide (Cr2O3) is used as a marker in digestibility studies, where it is supplemented at 5 g/kg in quail diets and its passage through the digestive tract can be monitored by X-ray fluorescence spectrophotometry."
chromium(III) oxide,"Chromium(III) oxide is used as a marker in digestibility studies in Japanese quail, with maximum excretion occurring 2 to 3 hours after introduction of marked food and ceasing 4 to 5 hours after removal.","Entity: chromium(III) oxide. SMILES: [Cr+3].[Cr+3].[O-2].[O-2].[O-2]. Chromium(III) oxide is used as a marker in digestibility studies in Japanese quail, with maximum excretion occurring 2 to 3 hours after introduction of marked food and ceasing 4 to 5 hours after removal."
chromium(III) oxide,"In Japanese quail, chromium(III) oxide concentrations are generally higher in droppings when birds are fed a low-fibre diet, likely due to increased digestion of the diet.","Entity: chromium(III) oxide. SMILES: [Cr+3].[Cr+3].[O-2].[O-2].[O-2]. In Japanese quail, chromium(III) oxide concentrations are generally higher in droppings when birds are fed a low-fibre diet, likely due to increased digestion of the diet."
phosphorus,"Dietary vitamin A supplementation can influence the phosphorus content in bone ash, as evidenced by a quadratic effect in experiment 4.","Entity: phosphorus. SMILES: [P]. Dietary vitamin A supplementation can influence the phosphorus content in bone ash, as evidenced by a quadratic effect in experiment 4."
calcium,"Dietary vitamin A supplementation can affect the calcium to phosphorus (Ca/P) ratio in bone ash, which is used as an indicator of bone mineralization.","Entity: calcium. SMILES: [Ca]. Dietary vitamin A supplementation can affect the calcium to phosphorus (Ca/P) ratio in bone ash, which is used as an indicator of bone mineralization."
Phosphorus,Dietary vitamin A produces a linear log-dose effect on plasma phosphorus concentration.,Entity: Phosphorus. SMILES: [P]. Dietary vitamin A produces a linear log-dose effect on plasma phosphorus concentration.
Phosphorus,A 4xNRC vitamin A concentration results in a significant decrease in plasma phosphorus at each week of the experiment.,Entity: Phosphorus. SMILES: [P]. A 4xNRC vitamin A concentration results in a significant decrease in plasma phosphorus at each week of the experiment.
Calcium,Dietary vitamin A and ascorbic acid have no effect on plasma calcium concentrations.,Entity: Calcium. SMILES: [Ca]. Dietary vitamin A and ascorbic acid have no effect on plasma calcium concentrations.
Magnesium,Magnesium content of the femur increases significantly during each week of the P. DORR AND S. L. BAIXOUN experiment.,Entity: Magnesium. SMILES: [Mg]. Magnesium content of the femur increases significantly during each week of the P. DORR AND S. L. BAIXOUN experiment.
Magnesium,Increased vitamin A results in linear decreases in percentage magnesium.,Entity: Magnesium. SMILES: [Mg]. Increased vitamin A results in linear decreases in percentage magnesium.
Magnesium,Dietary vitamin A and ascorbic acid have no effect on plasma magnesium concentrations.,Entity: Magnesium. SMILES: [Mg]. Dietary vitamin A and ascorbic acid have no effect on plasma magnesium concentrations.
Phosphorus,Bone phosphorus concentration increases significantly during each week of the P. DORR AND S. L. BAIXOUN experiment.,Entity: Phosphorus. SMILES: [P]. Bone phosphorus concentration increases significantly during each week of the P. DORR AND S. L. BAIXOUN experiment.
phosphorus,"Plasma phosphorus concentrations in poultry are not significantly affected by dietary vitamin A, ascorbic acid, or sex at 8, 12, or 18 weeks of age.","Entity: phosphorus. SMILES: [P]. Plasma phosphorus concentrations in poultry are not significantly affected by dietary vitamin A, ascorbic acid, or sex at 8, 12, or 18 weeks of age."
magnesium,"Plasma magnesium concentrations in poultry are not significantly affected by dietary vitamin A, ascorbic acid, or sex at 8, 12, or 18 weeks of age.","Entity: magnesium. SMILES: [Mg]. Plasma magnesium concentrations in poultry are not significantly affected by dietary vitamin A, ascorbic acid, or sex at 8, 12, or 18 weeks of age."
ascorbic acid,Dietary supplementation with 3000 mg ascorbic acid per kg diet reduces absolute and relative femur weights in male poultry at 12 weeks.,Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Dietary supplementation with 3000 mg ascorbic acid per kg diet reduces absolute and relative femur weights in male poultry at 12 weeks.
ascorbic acid,"Dietary ascorbic acid increases plasma ascorbic acid concentrations in poultry, with levels increasing over time.","Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Dietary ascorbic acid increases plasma ascorbic acid concentrations in poultry, with levels increasing over time."
calcium,"Plasma calcium concentrations in poultry are not significantly affected by dietary vitamin A, ascorbic acid, or sex at 8, 12, or 18 weeks of age.","Entity: calcium. SMILES: [Ca]. Plasma calcium concentrations in poultry are not significantly affected by dietary vitamin A, ascorbic acid, or sex at 8, 12, or 18 weeks of age."
ascorbic acid,"At dietary levels up to 3000 mg/kg, added ascorbic acid does not affect growth or femur mineralisation in poults.","Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. At dietary levels up to 3000 mg/kg, added ascorbic acid does not affect growth or femur mineralisation in poults."
calcium,"Plasma calcium is not affected by dietary vitamin A supplementation at 1000, 4000, or 16,000 IU/kg in poults.","Entity: calcium. SMILES: [Ca]. Plasma calcium is not affected by dietary vitamin A supplementation at 1000, 4000, or 16,000 IU/kg in poults."
magnesium,"Plasma magnesium is not affected by dietary vitamin A supplementation at 1000, 4000, or 16,000 IU/kg in poults.","Entity: magnesium. SMILES: [Mg]. Plasma magnesium is not affected by dietary vitamin A supplementation at 1000, 4000, or 16,000 IU/kg in poults."
Ascorbic acid,"Ascorbic acid supplementation in birds does not affect the ash, calcium, phosphorus, or magnesium content of fat-free dry femur.","Entity: Ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid supplementation in birds does not affect the ash, calcium, phosphorus, or magnesium content of fat-free dry femur."
Calcium,Plasma calcium levels in birds are not influenced by dietary ascorbic acid supplementation.,Entity: Calcium. SMILES: [Ca]. Plasma calcium levels in birds are not influenced by dietary ascorbic acid supplementation.
Phosphorus,Plasma inorganic phosphorus levels in birds are not affected by dietary ascorbic acid supplementation.,Entity: Phosphorus. SMILES: [P]. Plasma inorganic phosphorus levels in birds are not affected by dietary ascorbic acid supplementation.
Magnesium,Plasma magnesium levels in birds are not altered by dietary ascorbic acid supplementation.,Entity: Magnesium. SMILES: [Mg]. Plasma magnesium levels in birds are not altered by dietary ascorbic acid supplementation.
phosphorus,Plasma inorganic phosphorus concentrations are decreased by dietary vitamin A at a level four times the NRC (National Research Council) recommended level in turkeys.,Entity: phosphorus. SMILES: [P]. Plasma inorganic phosphorus concentrations are decreased by dietary vitamin A at a level four times the NRC (National Research Council) recommended level in turkeys.
magnesium,Plasma magnesium concentrations are not influenced by dietary vitamin A concentrations in turkeys.,Entity: magnesium. SMILES: [Mg]. Plasma magnesium concentrations are not influenced by dietary vitamin A concentrations in turkeys.
calcium,Plasma calcium concentrations are not influenced by dietary vitamin A concentrations in turkeys.,Entity: calcium. SMILES: [Ca]. Plasma calcium concentrations are not influenced by dietary vitamin A concentrations in turkeys.
Ascorbic acid,Ascorbic acid does not affect the ash content of femurs in the experimental conditions described.,Entity: Ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid does not affect the ash content of femurs in the experimental conditions described.
Calcium,"Calcium content in bone (femurs) increases significantly from week 1 to week 2, but no further significant increases are observed during the experiment.","Entity: Calcium. SMILES: [Ca]. Calcium content in bone (femurs) increases significantly from week 1 to week 2, but no further significant increases are observed during the experiment."
Ascorbic acid,Exogenous ascorbic acid causes the release of calcium from bone.,Entity: Ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Exogenous ascorbic acid causes the release of calcium from bone.
Ascorbic acid,Ascorbic acid is involved in the formation of the collagen matrix in bone.,Entity: Ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid is involved in the formation of the collagen matrix in bone.
Magnesium,Increasing dietary vitamin A reduces magnesium concentration in femurs.,Entity: Magnesium. SMILES: [Mg]. Increasing dietary vitamin A reduces magnesium concentration in femurs.
Ascorbic acid,"Increasing dietary ascorbic acid tends to reduce bone ash, but this effect is not statistically significant.","Entity: Ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Increasing dietary ascorbic acid tends to reduce bone ash, but this effect is not statistically significant."
Phosphorus,Increasing dietary vitamin A does not significantly affect bone phosphorus content.,Entity: Phosphorus. SMILES: [P]. Increasing dietary vitamin A does not significantly affect bone phosphorus content.
Calcium,Increasing dietary vitamin A causes a significant linear decrease in the percentage of calcium in bone ash.,Entity: Calcium. SMILES: [Ca]. Increasing dietary vitamin A causes a significant linear decrease in the percentage of calcium in bone ash.
magnesium,Dietary ascorbic acid increases plasma magnesium at the NRC vitamin A concentration but decreases it at 4 x NRC vitamin A concentration.,Entity: magnesium. SMILES: [Mg]. Dietary ascorbic acid increases plasma magnesium at the NRC vitamin A concentration but decreases it at 4 x NRC vitamin A concentration.
phosphorus,"Plasma inorganic phosphorus concentration is not significantly affected by dietary treatments, with overall mean values of 5 µ 73 mg/100 ml.","Entity: phosphorus. SMILES: [P]. Plasma inorganic phosphorus concentration is not significantly affected by dietary treatments, with overall mean values of 5 µ 73 mg/100 ml."
calcium,"Plasma calcium concentration is not significantly affected by dietary treatments, with overall mean values of 10 µ 97 mg/100 ml.","Entity: calcium. SMILES: [Ca]. Plasma calcium concentration is not significantly affected by dietary treatments, with overall mean values of 10 µ 97 mg/100 ml."
ascorbic acid,"Dietary ascorbic acid interacts with vitamin A to influence plasma magnesium concentration, with increased ascorbic acid at 4 x NRC vitamin A concentration significantly reducing plasma magnesium.","Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Dietary ascorbic acid interacts with vitamin A to influence plasma magnesium concentration, with increased ascorbic acid at 4 x NRC vitamin A concentration significantly reducing plasma magnesium."
magnesium,"Plasma magnesium concentration is not significantly affected by dietary treatments, with overall mean values of 10 µ 97 mg/100 ml.","Entity: magnesium. SMILES: [Mg]. Plasma magnesium concentration is not significantly affected by dietary treatments, with overall mean values of 10 µ 97 mg/100 ml."
Phosphorus,"Plasma phosphorus concentrations in the foot (mg/100 ml) were measured in chickens at weeks 1, 2, 3, and 4, corresponding to dietary vitamin A levels of 1000, 4000, and 16,000 IU/kg.","Entity: Phosphorus. SMILES: [P]. Plasma phosphorus concentrations in the foot (mg/100 ml) were measured in chickens at weeks 1, 2, 3, and 4, corresponding to dietary vitamin A levels of 1000, 4000, and 16,000 IU/kg."
Iron,"Iron is supplied in trace mineral mixes for animal diets at levels of 55 mg/kg in starter diets, 28 mg/kg in grower diets, and 55 mg/kg in finisher diets.","Entity: Iron. SMILES: [Fe]. Iron is supplied in trace mineral mixes for animal diets at levels of 55 mg/kg in starter diets, 28 mg/kg in grower diets, and 55 mg/kg in finisher diets."
Methionine,Methionine is included in vitamin mixes for animal diets as an equivalent of 1000 mg per kg diet.,Entity: Methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine is included in vitamin mixes for animal diets as an equivalent of 1000 mg per kg diet.
Ethoxyquin,Ethoxyquin is included in vitamin mixes for animal diets at a level of 175 mg per kg diet.,Entity: Ethoxyquin. SMILES: CCOc1ccc2c(c1)C(C)=CC(C)(C)N2. Ethoxyquin is included in vitamin mixes for animal diets at a level of 175 mg per kg diet.
Ascorbic acid,Ascorbic acid is added to experimental diets to meet vitamin requirements.,Entity: Ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid is added to experimental diets to meet vitamin requirements.
Manganese,"Manganese is supplied in trace mineral mixes for animal diets at levels of 136 mg/kg in starter diets, 77 mg/kg in grower diets, and 136 mg/kg in finisher diets.","Entity: Manganese. SMILES: [Mn]. Manganese is supplied in trace mineral mixes for animal diets at levels of 136 mg/kg in starter diets, 77 mg/kg in grower diets, and 136 mg/kg in finisher diets."
Biotin,Biotin is included in vitamin mixes for animal diets at a level of 1 mg per kg diet.,Entity: Biotin. SMILES: O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biotin is included in vitamin mixes for animal diets at a level of 1 mg per kg diet.
Riboflavin,Riboflavin is included in vitamin mixes for animal diets at a level of 9 mg per kg diet.,Entity: Riboflavin. SMILES: Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C. Riboflavin is included in vitamin mixes for animal diets at a level of 9 mg per kg diet.
Vitamin K,Vitamin K is included in vitamin mixes for animal diets at a level of 3–5 mg per kg diet.,Entity: Vitamin K. SMILES: CC1=C(C/C=C(\C)CCCC(C)CCCC(C)CCCC(C)C)C(=O)c2ccccc2C1=O. Vitamin K is included in vitamin mixes for animal diets at a level of 3–5 mg per kg diet.
Pyridoxine,Pyridoxine is included in vitamin mixes for animal diets at a level of 5 mg per kg diet.,Entity: Pyridoxine. SMILES: Cc1ncc(CO)c(CO)c1O. Pyridoxine is included in vitamin mixes for animal diets at a level of 5 mg per kg diet.
Folic acid,Folic acid is included in vitamin mixes for animal diets at a level of 2–35 mg per kg diet.,Entity: Folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid is included in vitamin mixes for animal diets at a level of 2–35 mg per kg diet.
Copper,"Copper is supplied in trace mineral mixes for animal diets at the following levels: 9 mg/kg in starter diets, 44 mg/kg in grower diets, and 4 mg/kg in finisher diets.","Entity: Copper. SMILES: [Cu]. Copper is supplied in trace mineral mixes for animal diets at the following levels: 9 mg/kg in starter diets, 44 mg/kg in grower diets, and 4 mg/kg in finisher diets."
Calcium pantothenate,Calcium pantothenate is included in vitamin mixes for animal diets at a level of 40 mg per kg diet.,Entity: Calcium pantothenate. SMILES: CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)[O-].CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)[O-].[Ca+2]. Calcium pantothenate is included in vitamin mixes for animal diets at a level of 40 mg per kg diet.
Thiamin,Thiamin is included in vitamin mixes for animal diets at a level of 5 mg per kg diet.,Entity: Thiamin. SMILES: Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.[Cl-]. Thiamin is included in vitamin mixes for animal diets at a level of 5 mg per kg diet.
Iodine,"Iodine is supplied in trace mineral mixes for animal diets at levels of 2 mg/kg in starter diets, 1–3 mg/kg in grower diets, and 2 mg/kg in finisher diets.","Entity: Iodine. SMILES: [I]. Iodine is supplied in trace mineral mixes for animal diets at levels of 2 mg/kg in starter diets, 1–3 mg/kg in grower diets, and 2 mg/kg in finisher diets."
Sodium chloride,"Sodium chloride is a component of trace mineral mixes for animal diets at levels of 4400 mg/kg in starter diets, 4500 mg/kg in grower diets, and 4500 mg/kg in finisher diets.","Entity: Sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is a component of trace mineral mixes for animal diets at levels of 4400 mg/kg in starter diets, 4500 mg/kg in grower diets, and 4500 mg/kg in finisher diets."
Vitamin D3,Vitamin D3 is included in vitamin mixes for animal diets at a level of 2250 IU per kg diet.,Entity: Vitamin D3. SMILES: C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12. Vitamin D3 is included in vitamin mixes for animal diets at a level of 2250 IU per kg diet.
Zinc,"Zinc is supplied in trace mineral mixes for animal diets at levels of 75 mg/kg in starter diets, 38 mg/kg in grower diets, and 75 mg/kg in finisher diets.","Entity: Zinc. SMILES: [Zn]. Zinc is supplied in trace mineral mixes for animal diets at levels of 75 mg/kg in starter diets, 38 mg/kg in grower diets, and 75 mg/kg in finisher diets."
Cobalt,"Cobalt is supplied in trace mineral mixes for animal diets at levels of 0–55 mg/kg in starter diets, 0–23 mg/kg in grower diets, and 0–55 mg/kg in finisher diets.","Entity: Cobalt. SMILES: [Co]. Cobalt is supplied in trace mineral mixes for animal diets at levels of 0–55 mg/kg in starter diets, 0–23 mg/kg in grower diets, and 0–55 mg/kg in finisher diets."
Vitamin B12,Vitamin B12 is included in vitamin mixes for animal diets at a level of 10 µg per kg diet.,Entity: Vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 is included in vitamin mixes for animal diets at a level of 10 µg per kg diet.
Niacin,Niacin is included in vitamin mixes for animal diets at a level of 175 mg per kg diet.,Entity: Niacin. SMILES: O=C(O)c1cccnc1. Niacin is included in vitamin mixes for animal diets at a level of 175 mg per kg diet.
sodium,Dietary sodium deficiency does not cause behavioral changes such as foot pecking in birds.,Entity: sodium. SMILES: [Na]. Dietary sodium deficiency does not cause behavioral changes such as foot pecking in birds.
sodium,"Dietary sodium content influences food consumption in animals, with consumption decreasing as sodium content decreases and becoming relatively constant at 0–2, 0–3, 0–4, 0–5, 0–6, and 0–9 g sodium per kg diet over a 4–5 week period.","Entity: sodium. SMILES: [Na]. Dietary sodium content influences food consumption in animals, with consumption decreasing as sodium content decreases and becoming relatively constant at 0–2, 0–3, 0–4, 0–5, 0–6, and 0–9 g sodium per kg diet over a 4–5 week period."
sodium,"Dietary sodium content in poultry affects egg production, with optimal levels for inducing a pause in egg-laying being 0–4 g/kg.","Entity: sodium. SMILES: [Na]. Dietary sodium content in poultry affects egg production, with optimal levels for inducing a pause in egg-laying being 0–4 g/kg."
sodium,"Insufficient dietary sodium leads to only partial reduction in egg production and no ill effects on birds, while excessive sodium can cause reproductive regression and mortality.","Entity: sodium. SMILES: [Na]. Insufficient dietary sodium leads to only partial reduction in egg production and no ill effects on birds, while excessive sodium can cause reproductive regression and mortality."
sodium,"A diet with very low sodium content (0–2 g/kg) causes virtual cessation of egg production, reproductive organ regression, progressive weight loss, and increased mortality in poultry.","Entity: sodium. SMILES: [Na]. A diet with very low sodium content (0–2 g/kg) causes virtual cessation of egg production, reproductive organ regression, progressive weight loss, and increased mortality in poultry."
sodium,"Dietary sodium content affects plasma sodium concentrations in birds, with low-sodium diets resulting in significantly lower plasma sodium levels compared to control diets.","Entity: sodium. SMILES: [Na]. Dietary sodium content affects plasma sodium concentrations in birds, with low-sodium diets resulting in significantly lower plasma sodium levels compared to control diets."
calcium,"Dietary sodium content affects plasma calcium concentrations in birds, with low-sodium diets resulting in significantly lower plasma calcium levels compared to control diets.","Entity: calcium. SMILES: [Ca]. Dietary sodium content affects plasma calcium concentrations in birds, with low-sodium diets resulting in significantly lower plasma calcium levels compared to control diets."
sodium,"Dietary sodium deficiency in hens is associated with a decrease in the number and/or size of yellow-white yolky follicles in the ovary, with the incidence of atresia in these follicles increasing to about 30% in hens fed 0–6 g sodium/kg diet.","Entity: sodium. SMILES: [Na]. Dietary sodium deficiency in hens is associated with a decrease in the number and/or size of yellow-white yolky follicles in the ovary, with the incidence of atresia in these follicles increasing to about 30% in hens fed 0–6 g sodium/kg diet."
sodium,"Sodium deficiency in hens is associated with progressive decreases in oviducal and comb weights, and with loss of large yellow yolky follicles.","Entity: sodium. SMILES: [Na]. Sodium deficiency in hens is associated with progressive decreases in oviducal and comb weights, and with loss of large yellow yolky follicles."
sodium,"Dietary sodium content has a marked effect on plasma calcium concentration in birds, with proportional decreases in plasma calcium exceeding decreases in food intake.","Entity: sodium. SMILES: [Na]. Dietary sodium content has a marked effect on plasma calcium concentration in birds, with proportional decreases in plasma calcium exceeding decreases in food intake."
calcium,"Plasma calcium concentration in birds is markedly affected by dietary sodium content, with proportional decreases in plasma calcium greater than those in food intake.","Entity: calcium. SMILES: [Ca]. Plasma calcium concentration in birds is markedly affected by dietary sodium content, with proportional decreases in plasma calcium greater than those in food intake."
sodium,"Birds with completely regressed reproductive organs, even after receiving 0–2 g sodium/kg diet, can increase egg production when dietary sodium is increased.","Entity: sodium. SMILES: [Na]. Birds with completely regressed reproductive organs, even after receiving 0–2 g sodium/kg diet, can increase egg production when dietary sodium is increased."
sodium,"Dietary sodium content in laying hens affects egg production and food consumption, with low sodium levels (0–2 g/kg) depressing these parameters and high sodium levels (0–9 g/kg) supporting normal production.","Entity: sodium. SMILES: [Na]. Dietary sodium content in laying hens affects egg production and food consumption, with low sodium levels (0–2 g/kg) depressing these parameters and high sodium levels (0–9 g/kg) supporting normal production."
sodium,"A dietary sodium intake of 0–4 g/kg induces a pause in egg laying in laying hens, while 0–3 g/kg to 0–6 g/kg causes temporary weight loss followed by recovery.","Entity: sodium. SMILES: [Na]. A dietary sodium intake of 0–4 g/kg induces a pause in egg laying in laying hens, while 0–3 g/kg to 0–6 g/kg causes temporary weight loss followed by recovery."
sodium,"In laying hens, the optimal range of dietary sodium for inducing a pause in egg laying is 0–4 g/kg.","Entity: sodium. SMILES: [Na]. In laying hens, the optimal range of dietary sodium for inducing a pause in egg laying is 0–4 g/kg."
chloride,Chloride is present in sodium chloride and is provided to laying hens as part of their dietary sodium chloride supplementation.,Entity: chloride. SMILES: [Cl-]. Chloride is present in sodium chloride and is provided to laying hens as part of their dietary sodium chloride supplementation.
sodium,"The primary requirement of laying hens is sodium rather than chloride, with dietary sodium requirements ranging from 0.76 to 1.0 g/kg for optimal egg production, hatchability, and body weight maintenance.","Entity: sodium. SMILES: [Na]. The primary requirement of laying hens is sodium rather than chloride, with dietary sodium requirements ranging from 0.76 to 1.0 g/kg for optimal egg production, hatchability, and body weight maintenance."
sodium chloride,"Sodium chloride is supplemented in the diet of laying hens to meet the hens' requirement for sodium, with levels below 0.76 g/kg limiting egg production.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is supplemented in the diet of laying hens to meet the hens' requirement for sodium, with levels below 0.76 g/kg limiting egg production."
sodium,"In hens, dietary sodium content between 0.3 and 0.4 g/kg leads to reproductive organ conditions similar to those observed in point-of-lay pullets, while sodium content of 0.2 g/kg or less causes complete regression of reproductive organs.","Entity: sodium. SMILES: [Na]. In hens, dietary sodium content between 0.3 and 0.4 g/kg leads to reproductive organ conditions similar to those observed in point-of-lay pullets, while sodium content of 0.2 g/kg or less causes complete regression of reproductive organs."
sodium,"Dietary sodium content affects body weight in birds, with sodium levels of 0–2 g/kg leading to continued weight loss during the first 3 weeks of feeding, while levels of 0–6 g/kg allow for weight regain and 0–4 g/kg support continued weight loss.","Entity: sodium. SMILES: [Na]. Dietary sodium content affects body weight in birds, with sodium levels of 0–2 g/kg leading to continued weight loss during the first 3 weeks of feeding, while levels of 0–6 g/kg allow for weight regain and 0–4 g/kg support continued weight loss."
sodium,"Dietary sodium content in hens can range from 0–6 g/kg to 0–3 g/kg without causing lasting adverse effects, with food consumption and egg production decreasing rapidly at the lower end of this range and stabilizing at rates proportional to sodium content.","Entity: sodium. SMILES: [Na]. Dietary sodium content in hens can range from 0–6 g/kg to 0–3 g/kg without causing lasting adverse effects, with food consumption and egg production decreasing rapidly at the lower end of this range and stabilizing at rates proportional to sodium content."
biotin,Dietary biotin content in unsupplemented diets for birds is similar to that reported by Whitehead (1974) and is lower than the requirement estimated by Payne et al. (1974) for broilers.,Entity: biotin. SMILES: O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Dietary biotin content in unsupplemented diets for birds is similar to that reported by Whitehead (1974) and is lower than the requirement estimated by Payne et al. (1974) for broilers.
"fructose-1,6-biphosphate","Fructose-1,6-biphosphate serves as a substrate in enzymatic assays measuring D-Fructose-1,6-biphosphate 1-phosphohydrolase (hexosediphosphatase) activity.","Entity: fructose-1,6-biphosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose-1,6-biphosphate serves as a substrate in enzymatic assays measuring D-Fructose-1,6-biphosphate 1-phosphohydrolase (hexosediphosphatase) activity."
NADP,"NADP is used as a cofactor in enzymatic assays to monitor the reduction of NADP during the activity measurement of D-Fructose-1,6-biphosphate 1-phosphohydrolase.","Entity: NADP. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)(O)OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP is used as a cofactor in enzymatic assays to monitor the reduction of NADP during the activity measurement of D-Fructose-1,6-biphosphate 1-phosphohydrolase."
6-phosphogluconate,"6-phosphogluconate is produced from fructose-6-phosphate by the action of glucose-6-phosphate dehydrogenase, with sufficient enzyme to catalyze the conversion of 10 µmol fructose-6-phosphate to 6-phosphogluconate in 1 minute.","Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 6-phosphogluconate is produced from fructose-6-phosphate by the action of glucose-6-phosphate dehydrogenase, with sufficient enzyme to catalyze the conversion of 10 µmol fructose-6-phosphate to 6-phosphogluconate in 1 minute."
Pregnenolone,Pregnenolone does not affect ovulation in hens.,Entity: Pregnenolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Pregnenolone does not affect ovulation in hens.
potassium dichromate,Potassium dichromate is used to maintain 98% relative humidity in an electrically shielded aluminum climate chamber.,Entity: potassium dichromate. SMILES: O=[Cr](=O)([O-])O[Cr](=O)(=O)[O-].[K+].[K+]. Potassium dichromate is used to maintain 98% relative humidity in an electrically shielded aluminum climate chamber.
"24,25 dihydroxyvitamin D3","Intravenous administration of 24,25 dihydroxyvitamin D3 at a dose of 650 pmoles induces a slight, but significant, increase in serum calcium in a calcium-deficient diet group.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. Intravenous administration of 24,25 dihydroxyvitamin D3 at a dose of 650 pmoles induces a slight, but significant, increase in serum calcium in a calcium-deficient diet group."
"24,25 diOIID3","24,25 diOIID3 is a synthetic metabolite of vitamin D that has been studied for its biological activity at high doses (25 µg) in vitamin D-deficient rats using 45Ca kinetics procedures.","Entity: 24,25 diOIID3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 diOIID3 is a synthetic metabolite of vitamin D that has been studied for its biological activity at high doses (25 µg) in vitamin D-deficient rats using 45Ca kinetics procedures."
tritium,Tritium is a radioactive isotope commonly measured using liquid scintillation counting techniques.,Entity: tritium. SMILES: [3H][3H]. Tritium is a radioactive isotope commonly measured using liquid scintillation counting techniques.
POPOP,POPOP is used as a quenching agent in liquid scintillation counting solutions for radioactive samples.,Entity: POPOP. SMILES: c1ccc(-c2cnc(-c3ccc(-c4ncc(-c5ccccc5)o4)cc3)o2)cc1. POPOP is used as a quenching agent in liquid scintillation counting solutions for radioactive samples.
toluene,Toluene is used as a solvent in liquid scintillation counting solutions for samples containing tritium.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a solvent in liquid scintillation counting solutions for samples containing tritium.
"24,25 dihydroxyvitamin D3","24,25 dihydroxyvitamin D3, produced by biological synthesis, is used as a chronic treatment in studies investigating its effects on intestinal calcium transport, plasma calcium, and bone ash calcium in vitamin D-deficient rats.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxyvitamin D3, produced by biological synthesis, is used as a chronic treatment in studies investigating its effects on intestinal calcium transport, plasma calcium, and bone ash calcium in vitamin D-deficient rats."
"24,25 dihydroxyvitamin D3","24,25 dihydroxyvitamin D3 stimulates intestinal calcium absorption in nephrectomized rats.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxyvitamin D3 stimulates intestinal calcium absorption in nephrectomized rats."
"24,25 dihydroxyvitamin D3","24,25 dihydroxyvitamin D3 is a metabolite that can be synthesized from 3 fl-hydroxy-27-nor-5-cholesten-25-one and is obtained as a mixture of diastereoisomers in approximately equal proportions.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxyvitamin D3 is a metabolite that can be synthesized from 3 fl-hydroxy-27-nor-5-cholesten-25-one and is obtained as a mixture of diastereoisomers in approximately equal proportions."
"24,25 dihydroxyvitamin D3","In rats fed a normal diet, biosynthetic 24,25 dihydroxyvitamin D3 induces a higher blood calcium level compared to chemically derived 24,25 dihydroxyvitamin D3.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. In rats fed a normal diet, biosynthetic 24,25 dihydroxyvitamin D3 induces a higher blood calcium level compared to chemically derived 24,25 dihydroxyvitamin D3."
calcium,"Serum calcium levels are reduced rapidly and remain decreased for 48 hours after administration of 650 pmoles of 24,25 dihydroxyvitamin D3 in phosphorus-deficient individuals.","Entity: calcium. SMILES: [Ca]. Serum calcium levels are reduced rapidly and remain decreased for 48 hours after administration of 650 pmoles of 24,25 dihydroxyvitamin D3 in phosphorus-deficient individuals."
"24,25 dihydroxyvitamin D3","Administration of 650 pmoles 24,25 dihydroxyvitamin D3 causes a rapid and sustained decrease in serum calcium for 48 hours in phosphorus-deficient individuals.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. Administration of 650 pmoles 24,25 dihydroxyvitamin D3 causes a rapid and sustained decrease in serum calcium for 48 hours in phosphorus-deficient individuals."
"24,25 dihydroxyvitamin D3","24,25 dihydroxyvitamin D3 was administered orally at 650 pmol or intravenously at 325 pmol to phosphate-depleted, vitamin D-depleted rats in the context of bone calcification assays.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxyvitamin D3 was administered orally at 650 pmol or intravenously at 325 pmol to phosphate-depleted, vitamin D-depleted rats in the context of bone calcification assays."
"24,25 dihydroxyvitamin D3","24,25 dihydroxyvitamin D3 can be administered to rats via intrajugular injection at a dose of 650 pmoles in 0.05 ml ethanol to induce bone calcium mobilization.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxyvitamin D3 can be administered to rats via intrajugular injection at a dose of 650 pmoles in 0.05 ml ethanol to induce bone calcium mobilization."
"24,25 dihydroxycholecalciferol","24,25 dihydroxycholecalciferol is a polar derivative of vitamin D3 of renal origin that appears in plasma under normal or hypercalcemic conditions.","Entity: 24,25 dihydroxycholecalciferol. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxycholecalciferol is a polar derivative of vitamin D3 of renal origin that appears in plasma under normal or hypercalcemic conditions."
"24,25 dihydroxycholecalciferol","The stimulation of intestinal calcium transport by 24,25 dihydroxycholecalciferol in intact rats depends on its renal conversion to a more polar metabolite, possibly 1,24,25 triOHD3.","Entity: 24,25 dihydroxycholecalciferol. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. The stimulation of intestinal calcium transport by 24,25 dihydroxycholecalciferol in intact rats depends on its renal conversion to a more polar metabolite, possibly 1,24,25 triOHD3."
"24,25 dihydroxyvitamin D3","24,25 dihydroxyvitamin D3 requires further metabolism in the kidney, most likely to 1,24,25 trihydroxyvitamin D3, before it can stimulate intestinal calcium transport activity.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxyvitamin D3 requires further metabolism in the kidney, most likely to 1,24,25 trihydroxyvitamin D3, before it can stimulate intestinal calcium transport activity."
"24,25 diOHD3","24,25 diOHD3, when administered intravenously in rats fed a normal calcium diet, slightly increases intestinal calcium absorption 24 hours post-injection.","Entity: 24,25 diOHD3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 diOHD3, when administered intravenously in rats fed a normal calcium diet, slightly increases intestinal calcium absorption 24 hours post-injection."
"24,25 diOHD3","24,25 diOHD3, when administered intravenously in rats fed a low calcium diet, considerably increases intestinal calcium absorption after 48 hours.","Entity: 24,25 diOHD3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 diOHD3, when administered intravenously in rats fed a low calcium diet, considerably increases intestinal calcium absorption after 48 hours."
"24,25 dihydroxyvitamin D3","24,25 dihydroxyvitamin D3 can be obtained by in vitro biological synthesis in cockerels fed a standard diet supplemented with vitamin D3.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxyvitamin D3 can be obtained by in vitro biological synthesis in cockerels fed a standard diet supplemented with vitamin D3."
calcium,"In synthetic vitamin D-free diets for rats, the calcium content is 0.47%.","Entity: calcium. SMILES: [Ca]. In synthetic vitamin D-free diets for rats, the calcium content is 0.47%."
phosphorus,"In synthetic vitamin D-free diets for rats, the phosphorus content is 0.30%.","Entity: phosphorus. SMILES: [P]. In synthetic vitamin D-free diets for rats, the phosphorus content is 0.30%."
"24,25 dihydroxyvitamin D3","24,25 dihydroxyvitamin D3 increases calcium content in bone ash and exhibits antirachitic activity after intravenous administration in phosphorus and vitamin D-deprived rats.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxyvitamin D3 increases calcium content in bone ash and exhibits antirachitic activity after intravenous administration in phosphorus and vitamin D-deprived rats."
"24,25 dihydroxyvitamin D3","24,25 dihydroxyvitamin D3 improves mineralization and stimulates osteoblastic activity in rachitic rats, as indicated by histologic evaluation.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxyvitamin D3 improves mineralization and stimulates osteoblastic activity in rachitic rats, as indicated by histologic evaluation."
"24,25 dihydroxyvitamin D3","24,25 dihydroxyvitamin D3 may accelerate the disappearance of plasma calcium and improve calcium uptake by osteoid in vitamin D- and phosphate-deficient rats.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxyvitamin D3 may accelerate the disappearance of plasma calcium and improve calcium uptake by osteoid in vitamin D- and phosphate-deficient rats."
"24,25 dihydroxyvitamin D3","24,25 dihydroxyvitamin D3 inhibits PTH secretion, which may contribute to reduced serum calcium levels.","Entity: 24,25 dihydroxyvitamin D3. SMILES: C=C1CC[C@@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]1CC[C@H]2[C@@H](C)CC[C@H](O)C(C)(C)O. 24,25 dihydroxyvitamin D3 inhibits PTH secretion, which may contribute to reduced serum calcium levels."
calcium,"Serum calcium levels decrease in vitamin D- and phosphate-deficient rats following intravenous administration of 24,25 dihydroxyvitamin D3, prior to significant metabolic conversion.","Entity: calcium. SMILES: [Ca]. Serum calcium levels decrease in vitamin D- and phosphate-deficient rats following intravenous administration of 24,25 dihydroxyvitamin D3, prior to significant metabolic conversion."
calcium,"24,25 dihydroxyvitamin D3 increases calcium content in bone ash without causing dramatic changes in serum calcium.","Entity: calcium. SMILES: [Ca]. 24,25 dihydroxyvitamin D3 increases calcium content in bone ash without causing dramatic changes in serum calcium."
calcium,"Serum calcium levels increase in animals injected intraperitoneally with 24,25 dihydroxyvitamin D3 for 5 days.","Entity: calcium. SMILES: [Ca]. Serum calcium levels increase in animals injected intraperitoneally with 24,25 dihydroxyvitamin D3 for 5 days."
calcium,"Serum calcium can be increased by both 24,25 and 25,26 diOHD3 in vitamin D-deficient rats, with a more significant increase observed with 24,25 diOHD3 when serum calcium is initially low.","Entity: calcium. SMILES: [Ca]. Serum calcium can be increased by both 24,25 and 25,26 diOHD3 in vitamin D-deficient rats, with a more significant increase observed with 24,25 diOHD3 when serum calcium is initially low."
calcium,"Serum calcium can be decreased by both 24,25 and 25,26 diOHD3 in rats when serum calcium is normal before administration, with a greater decrease observed with 24,25 diOHD3.","Entity: calcium. SMILES: [Ca]. Serum calcium can be decreased by both 24,25 and 25,26 diOHD3 in rats when serum calcium is normal before administration, with a greater decrease observed with 24,25 diOHD3."
calcium,"Intraperitoneal administration of 24,25 and 25,26 diOHD3 for 5 days leads to a significant increase in serum and bone calcium in rats.","Entity: calcium. SMILES: [Ca]. Intraperitoneal administration of 24,25 and 25,26 diOHD3 for 5 days leads to a significant increase in serum and bone calcium in rats."
"1,25-dihydroxyvitamin D3","1,25-dihydroxyvitamin D3, when administered intravenously at 325 pmol daily for 5 days, produces an increment in bone ash calcium and a decrease in bone ash phosphorus in vitamin D-deficient rats, similar to 24,25-dihydroxyvitamin D3.","Entity: 1,25-dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. 1,25-dihydroxyvitamin D3, when administered intravenously at 325 pmol daily for 5 days, produces an increment in bone ash calcium and a decrease in bone ash phosphorus in vitamin D-deficient rats, similar to 24,25-dihydroxyvitamin D3."
"24,25-dihydroxyvitamin D3","24,25-dihydroxyvitamin D3, administered intravenously at 325 pmol daily for 5 days, increases bone ash calcium and decreases bone ash phosphorus in vitamin D-deficient rats to the same extent as 5 UI (325 pmol) Bone Ash Calcium and Phosphorus.","Entity: 24,25-dihydroxyvitamin D3. SMILES: C=C1CCC(O)C/C1=C/C=C1\CCCC2(C)C1CCC2C(C)CCC(O)C(C)(C)O. 24,25-dihydroxyvitamin D3, administered intravenously at 325 pmol daily for 5 days, increases bone ash calcium and decreases bone ash phosphorus in vitamin D-deficient rats to the same extent as 5 UI (325 pmol) Bone Ash Calcium and Phosphorus."
"24,25-dihydroxyvitamin D3","Synthetic 24,25-dihydroxyvitamin D3 increases bone ash calcium to a lesser degree than 1,25-dihydroxyvitamin D3, but raises calcium/phosphorus ratios significantly in vitamin D-deficient rats.","Entity: 24,25-dihydroxyvitamin D3. SMILES: C=C1CCC(O)C/C1=C/C=C1\CCCC2(C)C1CCC2C(C)CCC(O)C(C)(C)O. Synthetic 24,25-dihydroxyvitamin D3 increases bone ash calcium to a lesser degree than 1,25-dihydroxyvitamin D3, but raises calcium/phosphorus ratios significantly in vitamin D-deficient rats."
tin,Uptake of several percent of tin into areas adjacent to amalgam fillings has been demonstrated.,Entity: tin. SMILES: [Sn]. Uptake of several percent of tin into areas adjacent to amalgam fillings has been demonstrated.
zinc,Uptake of several percent of zinc into areas adjacent to amalgam fillings has been demonstrated.,Entity: zinc. SMILES: [Zn]. Uptake of several percent of zinc into areas adjacent to amalgam fillings has been demonstrated.
fluoride,Fluoride released from silicate fillings is suggested to contribute to the lower demineralization and reduced frequency of outer lesions in secondary carious lesions associated with silicate fillings compared to those adjacent to silver amalgam fillings.,Entity: fluoride. SMILES: [F-]. Fluoride released from silicate fillings is suggested to contribute to the lower demineralization and reduced frequency of outer lesions in secondary carious lesions associated with silicate fillings compared to those adjacent to silver amalgam fillings.
silicon,"Silicon in cavity walls appears as irregular accumulations of variable size, with these areas containing little calcium and phosphorus.","Entity: silicon. SMILES: [Si]. Silicon in cavity walls appears as irregular accumulations of variable size, with these areas containing little calcium and phosphorus."
phosphorus,Phosphorus is present in low amounts in Si-rich areas of cavity walls.,Entity: phosphorus. SMILES: [P]. Phosphorus is present in low amounts in Si-rich areas of cavity walls.
calcium,Calcium is present in low amounts in Si-rich areas of cavity walls.,Entity: calcium. SMILES: [Ca]. Calcium is present in low amounts in Si-rich areas of cavity walls.
zinc,Zinc profiles in cavity walls show a peak at the level of 1–2% that always coincides with a similar configuration of the silicon profile.,Entity: zinc. SMILES: [Zn]. Zinc profiles in cavity walls show a peak at the level of 1–2% that always coincides with a similar configuration of the silicon profile.
Sulfur,Sulfur can be analyzed by electron microprobe using its characteristic Ke emission.,Entity: Sulfur. SMILES: [S]. Sulfur can be analyzed by electron microprobe using its characteristic Ke emission.
Zinc,Zinc can be analyzed by electron microprobe using its characteristic Ke emission.,Entity: Zinc. SMILES: [Zn]. Zinc can be analyzed by electron microprobe using its characteristic Ke emission.
Magnesium,Magnesium can be analyzed by electron microprobe using its characteristic Ke emission.,Entity: Magnesium. SMILES: [Mg]. Magnesium can be analyzed by electron microprobe using its characteristic Ke emission.
Fluorine,"Fluorine can be analyzed by electron microprobe using its characteristic Ke emission, with pulse height discrimination used to eliminate interference from phosphorus.","Entity: Fluorine. SMILES: [F]. Fluorine can be analyzed by electron microprobe using its characteristic Ke emission, with pulse height discrimination used to eliminate interference from phosphorus."
Phosphorus,"Phosphorus can be analyzed by electron microprobe using its characteristic Ke emission, with pulse height discrimination used to eliminate interference from fluorine.","Entity: Phosphorus. SMILES: [P]. Phosphorus can be analyzed by electron microprobe using its characteristic Ke emission, with pulse height discrimination used to eliminate interference from fluorine."
Silicon,Silicon can be analyzed by electron microprobe using its characteristic Ke emission.,Entity: Silicon. SMILES: [Si]. Silicon can be analyzed by electron microprobe using its characteristic Ke emission.
Calcium,Calcium can be analyzed by electron microprobe using its characteristic Ke emission.,Entity: Calcium. SMILES: [Ca]. Calcium can be analyzed by electron microprobe using its characteristic Ke emission.
Aluminum,Aluminum can be analyzed by electron microprobe using its characteristic Ke emission.,Entity: Aluminum. SMILES: [Al]. Aluminum can be analyzed by electron microprobe using its characteristic Ke emission.
calcium,Calcium concentrations vary in incipient carious lesions around silicate fillings compared to unaltered tissues.,Entity: calcium. SMILES: [Ca]. Calcium concentrations vary in incipient carious lesions around silicate fillings compared to unaltered tissues.
phosphorus,Phosphorus concentrations differ in incipient carious lesions adjacent to silicate fillings compared to unaltered tissues.,Entity: phosphorus. SMILES: [P]. Phosphorus concentrations differ in incipient carious lesions adjacent to silicate fillings compared to unaltered tissues.
silicate,"Silicate fillings can release elements into the surrounding dental tissues, which are incorporated into incipient carious lesions.","Entity: silicate. SMILES: [O-][Si]([O-])([O-])[O-]. Silicate fillings can release elements into the surrounding dental tissues, which are incorporated into incipient carious lesions."
Aluminum,"Aluminum released from silicate fillings is regularly found in enamel and dentine and most often occurs in a 20–40 µm-wide zone near the cavity, with maximum concentrations of 2–3% near the cavity.","Entity: Aluminum. SMILES: [Al]. Aluminum released from silicate fillings is regularly found in enamel and dentine and most often occurs in a 20–40 µm-wide zone near the cavity, with maximum concentrations of 2–3% near the cavity."
Aluminum,Aluminum may enhance the cariostatic effect of fluoride by forming complexes with fluoride.,Entity: Aluminum. SMILES: [Al]. Aluminum may enhance the cariostatic effect of fluoride by forming complexes with fluoride.
silicate,"Silicate fillings can release elements such as fluorine, aluminum, and sulfur into adjacent enamel and dentine, which can modify the progression of carious lesions.","Entity: silicate. SMILES: [O-][Si]([O-])([O-])[O-]. Silicate fillings can release elements such as fluorine, aluminum, and sulfur into adjacent enamel and dentine, which can modify the progression of carious lesions."
zinc,Increased concentrations of zinc are correlated with increased radiopacity of dentine adjacent to incipient caries with amalgam fillings.,Entity: zinc. SMILES: [Zn]. Increased concentrations of zinc are correlated with increased radiopacity of dentine adjacent to incipient caries with amalgam fillings.
tin,Increased concentrations of tin are correlated with increased radiopacity of dentine adjacent to incipient caries with amalgam fillings.,Entity: tin. SMILES: [Sn]. Increased concentrations of tin are correlated with increased radiopacity of dentine adjacent to incipient caries with amalgam fillings.
calcium phosphate,Accumulation of calcium phosphates is associated with increased radiopacity of dentine adjacent to silicate fillings.,Entity: calcium phosphate. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]. Accumulation of calcium phosphates is associated with increased radiopacity of dentine adjacent to silicate fillings.
fluoride,High fluoride content in the hypermineralized zone of dental cavities may promote deposition of calcium phosphates in the cavity wall.,Entity: fluoride. SMILES: [F-]. High fluoride content in the hypermineralized zone of dental cavities may promote deposition of calcium phosphates in the cavity wall.
calcium,Elevated calcium levels in hypermineralized zones of dental cavities differ from those observed in cavities with amalgam fillings.,Entity: calcium. SMILES: [Ca]. Elevated calcium levels in hypermineralized zones of dental cavities differ from those observed in cavities with amalgam fillings.
phosphorus,Elevated phosphorus levels in hypermineralized zones of dental cavities differ from those observed in cavities with amalgam fillings.,Entity: phosphorus. SMILES: [P]. Elevated phosphorus levels in hypermineralized zones of dental cavities differ from those observed in cavities with amalgam fillings.
silicate,"Silicate filling material causes superficial demineralization of cavity walls, with greater effect on dentine than on enamel.","Entity: silicate. SMILES: [O-][Si]([O-])([O-])[O-]. Silicate filling material causes superficial demineralization of cavity walls, with greater effect on dentine than on enamel."
zinc,Zinc can slightly penetrate the dentine wall when in contact with silicate filling material.,Entity: zinc. SMILES: [Zn]. Zinc can slightly penetrate the dentine wall when in contact with silicate filling material.
phosphorus,Phosphorus can be released from silicate materials and may be available for incorporation into the partly demineralized cavity wall.,Entity: phosphorus. SMILES: [P]. Phosphorus can be released from silicate materials and may be available for incorporation into the partly demineralized cavity wall.
zinc,Zinc can be released from silicate materials and may be available for incorporation into the partly demineralized cavity wall.,Entity: zinc. SMILES: [Zn]. Zinc can be released from silicate materials and may be available for incorporation into the partly demineralized cavity wall.
aluminum,Aluminum can be released from silicate materials and may be available for incorporation into the partly demineralized cavity wall.,Entity: aluminum. SMILES: [Al]. Aluminum can be released from silicate materials and may be available for incorporation into the partly demineralized cavity wall.
fluoride,Fluoride can be released from silicate materials and may be available for incorporation into the partly demineralized cavity wall.,Entity: fluoride. SMILES: [F-]. Fluoride can be released from silicate materials and may be available for incorporation into the partly demineralized cavity wall.
calcium,Calcium can be released from silicate materials and may be available for incorporation into the partly demineralized cavity wall.,Entity: calcium. SMILES: [Ca]. Calcium can be released from silicate materials and may be available for incorporation into the partly demineralized cavity wall.
fluorapatite,"Fluorapatite is a calcium fluoride mineral that can form in dental tissue, but only a fraction of the total fluorine present is bound as fluorapatite.","Entity: fluorapatite. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[F-]. Fluorapatite is a calcium fluoride mineral that can form in dental tissue, but only a fraction of the total fluorine present is bound as fluorapatite."
calcium fluoride,Calcium fluoride (CaF2) is more soluble than fluorapatite and can form when high concentrations of fluoride ions react with calcium.,Entity: calcium fluoride. SMILES: [Ca+2].[F-].[F-]. Calcium fluoride (CaF2) is more soluble than fluorapatite and can form when high concentrations of fluoride ions react with calcium.
aluminum fluoride,Aluminum fluoride complexes can form in the presence of fluoride at acid pH.,Entity: aluminum fluoride. SMILES: [Al+3].[F-].[F-].[F-]. Aluminum fluoride complexes can form in the presence of fluoride at acid pH.
aluminum,Aluminum is present in considerable amounts in dental tissue and can form complexes with fluoride and phosphate.,Entity: aluminum. SMILES: [Al]. Aluminum is present in considerable amounts in dental tissue and can form complexes with fluoride and phosphate.
magnesium,"In dentin wall lesions, magnesium concentrations are most frequently lower than in the underlying tissue, but increased magnesium content is observed in some instances.","Entity: magnesium. SMILES: [Mg]. In dentin wall lesions, magnesium concentrations are most frequently lower than in the underlying tissue, but increased magnesium content is observed in some instances."
calcium,"In dentin wall lesions, linear scans across the radiopaque zone show increased concentrations of calcium.","Entity: calcium. SMILES: [Ca]. In dentin wall lesions, linear scans across the radiopaque zone show increased concentrations of calcium."
phosphorus,"In dentin wall lesions, linear scans across the radiopaque zone show increased concentrations of phosphorus.","Entity: phosphorus. SMILES: [P]. In dentin wall lesions, linear scans across the radiopaque zone show increased concentrations of phosphorus."
aluminum,"Aluminum is present in enamel and dentine near cavity walls, typically forming an Al-rich zone 20–40 µm wide that can extend up to 140 µm into dentine and enamel in some cases.","Entity: aluminum. SMILES: [Al]. Aluminum is present in enamel and dentine near cavity walls, typically forming an Al-rich zone 20–40 µm wide that can extend up to 140 µm into dentine and enamel in some cases."
zinc,"Zinc is found in both enamel and dentine near cavity walls, with concentrations of 2–4% in dentine close to the cavity and can show a high content in a narrow zone close to the cavity or a gradual decrease from the cavity wall, penetrating up to 400 µm into dentin in some specimens.","Entity: zinc. SMILES: [Zn]. Zinc is found in both enamel and dentine near cavity walls, with concentrations of 2–4% in dentine close to the cavity and can show a high content in a narrow zone close to the cavity or a gradual decrease from the cavity wall, penetrating up to 400 µm into dentin in some specimens."
fluoride,Fluoride uptake in cavity walls of silicate-filled teeth is generally assumed to reduce the frequency of secondary caries.,Entity: fluoride. SMILES: [F-]. Fluoride uptake in cavity walls of silicate-filled teeth is generally assumed to reduce the frequency of secondary caries.
hydroxyproline,Hydroxyproline levels in rat femora decrease significantly 8 days after bone operation and remain decreased relative to control levels at 15 days.,Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Hydroxyproline levels in rat femora decrease significantly 8 days after bone operation and remain decreased relative to control levels at 15 days.
phosphate,Phosphate levels in rat femora decrease less significantly than hydroxyproline 8 days after bone operation and remain decreased relative to control levels at 15 days.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate levels in rat femora decrease less significantly than hydroxyproline 8 days after bone operation and remain decreased relative to control levels at 15 days.
potassium,Potassium levels in rat femora do not decrease relative to control levels at 15 days after bone operation.,Entity: potassium. SMILES: [K]. Potassium levels in rat femora do not decrease relative to control levels at 15 days after bone operation.
bicarbonate,"Bicarbonate feeding increases bone calcium content in animals, likely by altering the net charge of bone matrix proteins.","Entity: bicarbonate. SMILES: O=C([O-])O. Bicarbonate feeding increases bone calcium content in animals, likely by altering the net charge of bone matrix proteins."
hydrochloric acid,Hydrochloric acid is used as a solvent to dissolve bone tissue for the measurement of calcium and radioactivity content.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used as a solvent to dissolve bone tissue for the measurement of calcium and radioactivity content.
calcium,Calcium content in bone tissue can be measured by dissolving the bone in hydrochloric acid and using an instrumental assay.,Entity: calcium. SMILES: [Ca]. Calcium content in bone tissue can be measured by dissolving the bone in hydrochloric acid and using an instrumental assay.
hydroxyproline,"Reduction in hydroxyproline content in bone is associated with early signs of bone lesion, such as decreased bone volume and periosteal resorption in experimentally immobilized rat models.","Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Reduction in hydroxyproline content in bone is associated with early signs of bone lesion, such as decreased bone volume and periosteal resorption in experimentally immobilized rat models."
bicarbonate,Bicarbonate treatment reduces citrate content in bone mineral.,Entity: bicarbonate. SMILES: O=C([O-])O. Bicarbonate treatment reduces citrate content in bone mineral.
calcium,Bicarbonate treatment significantly reduces rates of calcium exchange in bone in nonparalyzed animals.,Entity: calcium. SMILES: [Ca]. Bicarbonate treatment significantly reduces rates of calcium exchange in bone in nonparalyzed animals.
calcium,Bicarbonate treatment increases bone calcium content in nonparalyzed animals.,Entity: calcium. SMILES: [Ca]. Bicarbonate treatment increases bone calcium content in nonparalyzed animals.
phosphate,Bicarbonate treatment does not significantly increase phosphate content in bone.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Bicarbonate treatment does not significantly increase phosphate content in bone.
carbonate,Bicarbonate treatment does not significantly increase carbonate content in bone.,Entity: carbonate. SMILES: O=C([O-])[O-]. Bicarbonate treatment does not significantly increase carbonate content in bone.
citrate,Bicarbonate treatment reduces citrate content in bone.,Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Bicarbonate treatment reduces citrate content in bone.
hydroxyproline,"Hydroxyproline content in the humeri of operated animals is significantly increased at 15 days after operation, coinciding with increased bone formation.","Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Hydroxyproline content in the humeri of operated animals is significantly increased at 15 days after operation, coinciding with increased bone formation."
bicarbonate,Bicarbonate administration increases calcium accretion in normal bone but accentuates bone resorption in immobilized bones.,Entity: bicarbonate. SMILES: O=C([O-])O. Bicarbonate administration increases calcium accretion in normal bone but accentuates bone resorption in immobilized bones.
bicarbonate,Bicarbonate has been suggested to aid in the prevention and treatment of disuse osteoporosis based on studies in rats and human volunteers.,Entity: bicarbonate. SMILES: O=C([O-])O. Bicarbonate has been suggested to aid in the prevention and treatment of disuse osteoporosis based on studies in rats and human volunteers.
calcium,Calcium accretion in normal bone is increased by bicarbonate feeding.,Entity: calcium. SMILES: [Ca]. Calcium accretion in normal bone is increased by bicarbonate feeding.
carbon dioxide,"Alkaline administration, such as bicarbonate, is associated with higher blood pCO2 values in immobilized conditions.","Entity: carbon dioxide. SMILES: O=C=O. Alkaline administration, such as bicarbonate, is associated with higher blood pCO2 values in immobilized conditions."
carbonate,Carbonate content in bone powder can be measured using the Van Slyke and Folch method.,Entity: carbonate. SMILES: O=C([O-])[O-]. Carbonate content in bone powder can be measured using the Van Slyke and Folch method.
citrate,Citrate content in bone solutions can be measured using the Natelson et al. method.,Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Citrate content in bone solutions can be measured using the Natelson et al. method.
phosphorus,Phosphorus content in bone solutions can be measured using the Allen method.,Entity: phosphorus. SMILES: [P]. Phosphorus content in bone solutions can be measured using the Allen method.
hydroxyproline,Hydroxyproline content in bone solutions can be measured using the Neuman and Logan method.,Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Hydroxyproline content in bone solutions can be measured using the Neuman and Logan method.
hydrochloric acid,Hydrochloric acid (HCl) at 50% concentration is used to dissolve bones for elemental analysis.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (HCl) at 50% concentration is used to dissolve bones for elemental analysis.
hydroxyproline,Hydroxyproline content in bone tissue decreases by 15% compared to controls 8 days after operation in a rat model.,Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Hydroxyproline content in bone tissue decreases by 15% compared to controls 8 days after operation in a rat model.
phosphate,Phosphate content in bone tissue decreases by 8% compared to controls 8 days after operation in a rat model.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate content in bone tissue decreases by 8% compared to controls 8 days after operation in a rat model.
calcium,Calcium content in bone tissue shows a nonsignificant decrease and the rate constants for slow and fast exchangeable calcium compartments do not significantly differ from controls in a rat model.,Entity: calcium. SMILES: [Ca]. Calcium content in bone tissue shows a nonsignificant decrease and the rate constants for slow and fast exchangeable calcium compartments do not significantly differ from controls in a rat model.
potassium,Potassium content in bone tissue remains unchanged in a rat model following denervation.,Entity: potassium. SMILES: [K]. Potassium content in bone tissue remains unchanged in a rat model following denervation.
calcium,"Calcium metabolism parameters, including the size of fast and slow exchangeable Ca pools and the rate of Ca accretion per gram of skeletal calcium, decrease together with bone mass in immobilized skeletal portions.","Entity: calcium. SMILES: [Ca]. Calcium metabolism parameters, including the size of fast and slow exchangeable Ca pools and the rate of Ca accretion per gram of skeletal calcium, decrease together with bone mass in immobilized skeletal portions."
calcium,"In animals fed an alkaline diet, the rate of calcium exchange in bone is increased compared to those fed a standard diet.","Entity: calcium. SMILES: [Ca]. In animals fed an alkaline diet, the rate of calcium exchange in bone is increased compared to those fed a standard diet."
potassium,Bone resorption in immobilized limbs is not affected by the decrease in all bone components except potassium.,Entity: potassium. SMILES: [K]. Bone resorption in immobilized limbs is not affected by the decrease in all bone components except potassium.
copper sulfate,Copper sulfate is used as a disinfectant for washing the abdomen of animals to prevent infection in experimental procedures.,Entity: copper sulfate. SMILES: O=S(=O)([O-])[O-].[Cu+2]. Copper sulfate is used as a disinfectant for washing the abdomen of animals to prevent infection in experimental procedures.
carbonate,Carbonate content in bone is significantly decreased 15 days after hind limb immobilization in rats.,Entity: carbonate. SMILES: O=C([O-])[O-]. Carbonate content in bone is significantly decreased 15 days after hind limb immobilization in rats.
phosphate,Phosphate content in bone is significantly reduced 8 days after hind limb immobilization in rats.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate content in bone is significantly reduced 8 days after hind limb immobilization in rats.
magnesium,Magnesium content in bone is significantly decreased at 15 days after hind limb immobilization in rats.,Entity: magnesium. SMILES: [Mg]. Magnesium content in bone is significantly decreased at 15 days after hind limb immobilization in rats.
sodium,Sodium content in bone is significantly decreased at 15 days after hind limb immobilization in rats.,Entity: sodium. SMILES: [Na]. Sodium content in bone is significantly decreased at 15 days after hind limb immobilization in rats.
calcium,Calcium content in bone is significantly decreased at 15 days after hind limb immobilization in rats.,Entity: calcium. SMILES: [Ca]. Calcium content in bone is significantly decreased at 15 days after hind limb immobilization in rats.
bicarbonate,"Feeding bicarbonate-enriched diet to rats increases rates of calcium accretion and bone calcium content, but does not increase phosphate or carbonate contents.","Entity: bicarbonate. SMILES: O=C([O-])O. Feeding bicarbonate-enriched diet to rats increases rates of calcium accretion and bone calcium content, but does not increase phosphate or carbonate contents."
parathyroid hormone,"Feeding bicarbonate-enriched diet to operated rats increases the rate of bone resorption, which is attributed to higher parathyroid hormone secretion.","Entity: parathyroid hormone. Feeding bicarbonate-enriched diet to operated rats increases the rate of bone resorption, which is attributed to higher parathyroid hormone secretion."
parathyroid hormone,"1,25-dihydroxycholecalciferol increases bone resorption independently of parathyroid hormone.","Entity: parathyroid hormone. 1,25-dihydroxycholecalciferol increases bone resorption independently of parathyroid hormone."
calcium,Vitamin D and its polar metabolites regulate calcium transport in the small intestine.,Entity: calcium. SMILES: [Ca]. Vitamin D and its polar metabolites regulate calcium transport in the small intestine.
calcium chloride,Calcium chloride was included at a concentration of 0.00025 M in the mucosal medium for in vitro duodenal calcium transport studies.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride was included at a concentration of 0.00025 M in the mucosal medium for in vitro duodenal calcium transport studies.
sodium chloride,Sodium chloride was used at a concentration of 0.119 M in the mucosal medium for in vitro duodenal calcium transport assays.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride was used at a concentration of 0.119 M in the mucosal medium for in vitro duodenal calcium transport assays.
fructose,Fructose was used at a concentration of 0.01 M in the mucosal medium for in vitro measurement of duodenal calcium transport.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose was used at a concentration of 0.01 M in the mucosal medium for in vitro measurement of duodenal calcium transport.
calcium,"Calcium transport ratios, measured as the serosal/mucosM concentration ratio of 45Ca in everted gut sacs, are increased in vitamin D-deficient animals (mean ~1.6 • 0.3) and decreased in vitamin D-replete animals (mean ~4.8 • 0.5), indicating altered intestinal calcium absorption.","Entity: calcium. SMILES: [Ca]. Calcium transport ratios, measured as the serosal/mucosM concentration ratio of 45Ca in everted gut sacs, are increased in vitamin D-deficient animals (mean ~1.6 • 0.3) and decreased in vitamin D-replete animals (mean ~4.8 • 0.5), indicating altered intestinal calcium absorption."
Calcium,"Vitamin D administration increases intramicrovillus calcium content, which may be related to changes in microvilli structure and function.","Entity: Calcium. SMILES: [Ca]. Vitamin D administration increases intramicrovillus calcium content, which may be related to changes in microvilli structure and function."
calcium phosphate,"Calcium phosphate can exist in both amorphous and crystalline forms, with the amorphous form serving as a regulatory phase in the metabolic relationship between bone and plasma.","Entity: calcium phosphate. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]. Calcium phosphate can exist in both amorphous and crystalline forms, with the amorphous form serving as a regulatory phase in the metabolic relationship between bone and plasma."
phosphate,"Addition of phosphate to human serum causes removal of all ~2HS-glycoprotein from the serum, while increasing the amount of albumin bound.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Addition of phosphate to human serum causes removal of all ~2HS-glycoprotein from the serum, while increasing the amount of albumin bound."
calcium,"Addition of calcium to human serum causes removal of all ~2HS-glycoprotein from the serum, while increasing the amount of albumin bound.","Entity: calcium. SMILES: [Ca]. Addition of calcium to human serum causes removal of all ~2HS-glycoprotein from the serum, while increasing the amount of albumin bound."
CaC12,CaC12 is used as a calcium phosphate source in in vitro binding assays with plasma proteins.,Entity: CaC12. SMILES: [Ca+2].[Cl-].[Cl-]. CaC12 is used as a calcium phosphate source in in vitro binding assays with plasma proteins.
EDTA,EDTA is used as a chelating agent to solubilize precipitates containing proteins from binding assays.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used as a chelating agent to solubilize precipitates containing proteins from binding assays.
NaC1,NaC1 is used as a washing solution to remove unbound proteins from precipitates in in vitro binding assays.,Entity: NaC1. SMILES: [Cl-].[Na+]. NaC1 is used as a washing solution to remove unbound proteins from precipitates in in vitro binding assays.
calcium phosphate,Precipitation of calcium phosphate at a low precipitate: serum ratio is used as the first stage in a laboratory method for preparing high-molecular-weight glycoprotein (approximately HS-glycoprotein).,Entity: calcium phosphate. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]. Precipitation of calcium phosphate at a low precipitate: serum ratio is used as the first stage in a laboratory method for preparing high-molecular-weight glycoprotein (approximately HS-glycoprotein).
EDTA,"EDTA is used to extract proteins from precipitates, yielding extracts containing albumin and approximately HS-glycoprotein as predominant components.","Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used to extract proteins from precipitates, yielding extracts containing albumin and approximately HS-glycoprotein as predominant components."
calcium phosphate,Calcium phosphate is generated within serum and can bind to plasma proteins such as alpha2HS-glycoprotein and albumin.,Entity: calcium phosphate. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]. Calcium phosphate is generated within serum and can bind to plasma proteins such as alpha2HS-glycoprotein and albumin.
calcium phosphate,"Calcium phosphate in bone can differentially bind to plasma proteins, contributing to the enrichment of certain proteins such as the β-glycoprotein over other plasma proteins in bone.","Entity: calcium phosphate. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]. Calcium phosphate in bone can differentially bind to plasma proteins, contributing to the enrichment of certain proteins such as the β-glycoprotein over other plasma proteins in bone."
alpha2HS-glycoprotein,"In serum samples, alpha2HS-glycoprotein binds to calcium phosphates and is preferentially removed from the samples compared to albumin, with concentration ratios relative to albumin varying from 370 at high serum:precipitate ratios to 25 at low ratios.","Entity: alpha2HS-glycoprotein. In serum samples, alpha2HS-glycoprotein binds to calcium phosphates and is preferentially removed from the samples compared to albumin, with concentration ratios relative to albumin varying from 370 at high serum:precipitate ratios to 25 at low ratios."
alpha2HS-glycoprotein,"alpha2HS-glycoprotein is concentrated in mineralized tissues such as bone and dentine compared to other plasma proteins, with enrichment factors ranging from 30 to 100.","Entity: alpha2HS-glycoprotein. alpha2HS-glycoprotein is concentrated in mineralized tissues such as bone and dentine compared to other plasma proteins, with enrichment factors ranging from 30 to 100."
alpha2HS-glycoprotein,"Plasma alpha2HS-glycoprotein concentrations are substantially lower in patients with Paget's disease of bone compared to normal values, with a significant negative correlation between alpha2HS-glycoprotein concentration and plasma alkaline phosphatase activity.","Entity: alpha2HS-glycoprotein. Plasma alpha2HS-glycoprotein concentrations are substantially lower in patients with Paget's disease of bone compared to normal values, with a significant negative correlation between alpha2HS-glycoprotein concentration and plasma alkaline phosphatase activity."
alpha2HS-glycoprotein,alpha2HS-glycoprotein is a plasma glycoprotein present at high concentrations in human cortical bone and permanent dentine.,Entity: alpha2HS-glycoprotein. alpha2HS-glycoprotein is a plasma glycoprotein present at high concentrations in human cortical bone and permanent dentine.
glucosylgalactosyl-hydroxylysine,"Glucosylgalactosyl-hydroxylysine is a glycosylated form of hydroxylysine found in collagen, with its proportion in skin collagen being twice as high as in bone collagen.","Entity: glucosylgalactosyl-hydroxylysine. SMILES: NC[C@H](O)CC[C@@H](C(=O)O)N(C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. Glucosylgalactosyl-hydroxylysine is a glycosylated form of hydroxylysine found in collagen, with its proportion in skin collagen being twice as high as in bone collagen."
galactosyl-hydroxylysine,"Galactosyl-hydroxylysine is a glycosylated form of hydroxylysine present in collagen, being seven times more abundant than glucosylgalactosyl-hydroxylysine in bone collagen.","Entity: galactosyl-hydroxylysine. SMILES: NC[C@H](O)CC[C@H](NC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C(=O)O. Galactosyl-hydroxylysine is a glycosylated form of hydroxylysine present in collagen, being seven times more abundant than glucosylgalactosyl-hydroxylysine in bone collagen."
hydroxylysine,Hydroxylysine deficiency in the skin is associated with Ehlers-Danlos type VI syndrome.,Entity: hydroxylysine. SMILES: NC[C@H](O)CC[C@H](N)C(=O)O. Hydroxylysine deficiency in the skin is associated with Ehlers-Danlos type VI syndrome.
glc-gal-hyl,Some urinary glc-gal-hyl is derived from bone collagen metabolism.,Entity: glc-gal-hyl. SMILES: NC[C@H](O)CC[C@@H](C(=O)O)N(C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. Some urinary glc-gal-hyl is derived from bone collagen metabolism.
Galactosylglycerol,A single injection of calcitonin decreases the excretion of the monosaccharidic form of galactosylglycerol (gal-hyl) in the urine after a few hours.,Entity: Galactosylglycerol. SMILES: OCC(O)C(O)C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O. A single injection of calcitonin decreases the excretion of the monosaccharidic form of galactosylglycerol (gal-hyl) in the urine after a few hours.
hydroxylysine,"Urinary excretion of hydroxylysine is practically normal in Ehlers-Danlos syndrome type VI, which is caused by a deficiency in hydroxylysine affecting mainly skin collagen.","Entity: hydroxylysine. SMILES: NC[C@H](O)CC[C@H](N)C(=O)O. Urinary excretion of hydroxylysine is practically normal in Ehlers-Danlos syndrome type VI, which is caused by a deficiency in hydroxylysine affecting mainly skin collagen."
gal-hyl,Gal-hyl is predominantly excreted in bone diseases and its great amounts in Paget's disease originate from bone collagen.,Entity: gal-hyl. SMILES: NC[C@H](O)CC[C@H](NC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C(=O)O. Gal-hyl is predominantly excreted in bone diseases and its great amounts in Paget's disease originate from bone collagen.
glc-gal-hyl,Glc-gal-hyl is found in urine of normal subjects and its excretion is increased in conditions involving collagen.,Entity: glc-gal-hyl. SMILES: NC[C@H](O)CC[C@@H](C(=O)O)N(C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. Glc-gal-hyl is found in urine of normal subjects and its excretion is increased in conditions involving collagen.
glc-gal-hyl,Glucosyl-galactosyl-hydroxylysine is not abundant in bone collagen but may originate from calcified tissue.,Entity: glc-gal-hyl. SMILES: NC[C@H](O)CC[C@@H](C(=O)O)N(C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. Glucosyl-galactosyl-hydroxylysine is not abundant in bone collagen but may originate from calcified tissue.
gal-hyl,Galactosyl-hydroxylysine is a urinary metabolite whose excretion is increased in Paget's disease of bone and primary hyperparathyroidism.,Entity: gal-hyl. SMILES: NC[C@H](O)CC[C@H](NC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C(=O)O. Galactosyl-hydroxylysine is a urinary metabolite whose excretion is increased in Paget's disease of bone and primary hyperparathyroidism.
glc-gal-hyl,Glucosyl-galactosyl-hydroxylysine is a urinary metabolite whose excretion is increased in Paget's disease of bone and primary hyperparathyroidism.,Entity: glc-gal-hyl. SMILES: NC[C@H](O)CC[C@@H](C(=O)O)N(C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. Glucosyl-galactosyl-hydroxylysine is a urinary metabolite whose excretion is increased in Paget's disease of bone and primary hyperparathyroidism.
galactosylhydroxyproline,"Galactosylhydroxyproline is a component of bone collagen, with approximately 1/7 the molar ratio of glucosylgalactosylhydroxyproline in the molecule.","Entity: galactosylhydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O. Galactosylhydroxyproline is a component of bone collagen, with approximately 1/7 the molar ratio of glucosylgalactosylhydroxyproline in the molecule."
glucosylgalactosylhydroxyproline,"Glucosylgalactosylhydroxyproline is a component of bone collagen, present in a 7-fold higher molar ratio than galactosylhydroxyproline.","Entity: glucosylgalactosylhydroxyproline. SMILES: O=C(O)[C@]1(C2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C[C@@H](O)CN1C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O. Glucosylgalactosylhydroxyproline is a component of bone collagen, present in a 7-fold higher molar ratio than galactosylhydroxyproline."
gal-hyl,"Urinary excretion of gal-hyl is correlated with plasma alkaline phosphatase levels in both Paget's disease (r = -0.59, p ~0.05) and hyperparathyroidism (r = 0.63, p ~0.01).","Entity: gal-hyl. SMILES: NC[C@H](O)CC[C@H](NC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)C(=O)O. Urinary excretion of gal-hyl is correlated with plasma alkaline phosphatase levels in both Paget's disease (r = -0.59, p ~0.05) and hyperparathyroidism (r = 0.63, p ~0.01)."
hydroxylysine,"Total glycosylated hydroxylysine is correlated with plasma alkaline phosphatase in hyperparathyroidism (r = 0.64, p ~0.01), but not in Paget's disease.","Entity: hydroxylysine. SMILES: NC[C@H](O)CC[C@H](N)C(=O)O. Total glycosylated hydroxylysine is correlated with plasma alkaline phosphatase in hyperparathyroidism (r = 0.64, p ~0.01), but not in Paget's disease."
calcium,"Increased bone formation, as indicated by a high calcium-accretion rate, is observed during the development of tissue osteoporosis, particularly following immobilization.","Entity: calcium. SMILES: [Ca]. Increased bone formation, as indicated by a high calcium-accretion rate, is observed during the development of tissue osteoporosis, particularly following immobilization."
calcium,"Lowered calcium accretion rates in bone are observed in individuals with hypothyroidism and hypoparathyroidism, reflecting reduced bone turnover.","Entity: calcium. SMILES: [Ca]. Lowered calcium accretion rates in bone are observed in individuals with hypothyroidism and hypoparathyroidism, reflecting reduced bone turnover."
calcium,"Calcium uptake by bone can be used to measure total bone formation, but must account for bone resorption and long-term exchange to avoid inaccurate results.","Entity: calcium. SMILES: [Ca]. Calcium uptake by bone can be used to measure total bone formation, but must account for bone resorption and long-term exchange to avoid inaccurate results."
calcium,"In rats, the rate of 45Ca accretion in bone increases in response to immobilization, with this increase being proportional in both thyroparathyroidectomized and intact animals.","Entity: calcium. SMILES: [Ca]. In rats, the rate of 45Ca accretion in bone increases in response to immobilization, with this increase being proportional in both thyroparathyroidectomized and intact animals."
OsO4,OsO4 (osmium tetroxide) is used as a post-fixative in tissue embedding for microscopy.,Entity: OsO4. SMILES: O=[Os](=O)(=O)=O. OsO4 (osmium tetroxide) is used as a post-fixative in tissue embedding for microscopy.
uranyl acetate,Uranyl acetate is used as a staining agent in microscopy.,Entity: uranyl acetate. SMILES: CC(=O)[O-].CC(=O)[O-].O=[U+2]=O. Uranyl acetate is used as a staining agent in microscopy.
lead citrate,Lead citrate is used as a staining agent in microscopy.,Entity: lead citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Pb+2].[Pb+2].[Pb+2]. Lead citrate is used as a staining agent in microscopy.
colchicine,Colchicine is an alkaloid that causes the disappearance of mierotubules and the cessation of movements of membrane-bound cell inclusions.,Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine is an alkaloid that causes the disappearance of mierotubules and the cessation of movements of membrane-bound cell inclusions.
vinblastine,Vinblastine is an alkaloid that causes the disappearance of mierotubules and the cessation of movements of membrane-bound cell inclusions.,Entity: vinblastine. SMILES: CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1. Vinblastine is an alkaloid that causes the disappearance of mierotubules and the cessation of movements of membrane-bound cell inclusions.
glutaraldehyde,Glutaraldehyde is used as a 3% fixative for tissue preparation in microscopy.,Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a 3% fixative for tissue preparation in microscopy.
oxytetracycline,"Oxytetracycline is administered intraperitoneally at 6 mg/kg body weight to rats, a dose that does not disrupt developing rat enamel but provides sufficient ultraviolet fluorescent labeling of dentine.","Entity: oxytetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12. Oxytetracycline is administered intraperitoneally at 6 mg/kg body weight to rats, a dose that does not disrupt developing rat enamel but provides sufficient ultraviolet fluorescent labeling of dentine."
oxytetracycline,"Oxy~etracycline injections do not produce microscopically detectable changes in enamel mineralization in rats, as determined by fluorescent labeling and comparison to control animals.","Entity: oxytetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12. Oxy~etracycline injections do not produce microscopically detectable changes in enamel mineralization in rats, as determined by fluorescent labeling and comparison to control animals."
tetracycline,"Tetracycline exposure of short duration is unlikely to significantly aggravate disturbances in amelogenesis, as any effects should manifest as distinct bands in the normal mineralization pattern of dentine.","Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline exposure of short duration is unlikely to significantly aggravate disturbances in amelogenesis, as any effects should manifest as distinct bands in the normal mineralization pattern of dentine."
fluoride,Fluoride supplementation during tetracycline administration decreases the damaging effect of tetracycline and oxytetracycline on developing enamel.,Entity: fluoride. SMILES: [F-]. Fluoride supplementation during tetracycline administration decreases the damaging effect of tetracycline and oxytetracycline on developing enamel.
oxytetracycline,"Oxytetracycline exposure of short duration is unlikely to significantly aggravate disturbances in amelogenesis, as any effects should manifest as distinct bands in the normal mineralization pattern of dentine.","Entity: oxytetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12. Oxytetracycline exposure of short duration is unlikely to significantly aggravate disturbances in amelogenesis, as any effects should manifest as distinct bands in the normal mineralization pattern of dentine."
oxytetracycline,"Oxytetracycline is used to label dentine in vivo, with the intensity of the fluorescent band indicating the forming dentine layer at the time of injection.","Entity: oxytetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12. Oxytetracycline is used to label dentine in vivo, with the intensity of the fluorescent band indicating the forming dentine layer at the time of injection."
phosphate,"Phosphate supplementation stimulates cortical bone formation in long bones by 11% to 372% in mature mongrel dogs, on average doubling bone formation rates.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation stimulates cortical bone formation in long bones by 11% to 372% in mature mongrel dogs, on average doubling bone formation rates."
methyl methacrylate,Methyl methacrylate is used as an embedding medium for preparing biological tissue sections for histological and radiographic analysis.,Entity: methyl methacrylate. SMILES: C=C(C)C(=O)OC. Methyl methacrylate is used as an embedding medium for preparing biological tissue sections for histological and radiographic analysis.
tetracycline,Tetracycline is used as a bone formation marker in studies to assess bone formation in animal models.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline is used as a bone formation marker in studies to assess bone formation in animal models.
phosphate,"Phosphate supplementation has been suggested to stimulate bone formation, although studies in this area are often indirect and confounded by other factors.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation has been suggested to stimulate bone formation, although studies in this area are often indirect and confounded by other factors."
calcium,Calcium kinetic methods are used to measure bone formation rates in animal studies.,Entity: calcium. SMILES: [Ca]. Calcium kinetic methods are used to measure bone formation rates in animal studies.
phosphate,Phosphate supplementation can lead to metastatic calcification in patients with hypercalcemia.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation can lead to metastatic calcification in patients with hypercalcemia.
phosphate,Phosphate supplementation is used to treat conditions associated with metastatic calcification.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation is used to treat conditions associated with metastatic calcification.
phosphate,Phosphate supplementation has been used to prevent renal stone formation in patients with idiopathic hypercalciuria.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation has been used to prevent renal stone formation in patients with idiopathic hypercalciuria.
phosphate,"Phosphate supplementation in dogs produces a peak serum phosphate rise that is virtually identical in magnitude to that produced by a control diet, though occurring at a slightly shorter interval.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation in dogs produces a peak serum phosphate rise that is virtually identical in magnitude to that produced by a control diet, though occurring at a slightly shorter interval."
calcium,"During the experimental period, serum calcium levels in dogs tended to decrease, but these changes were not statistically significant and did not result in serum calcium values dropping below the normal range.","Entity: calcium. SMILES: [Ca]. During the experimental period, serum calcium levels in dogs tended to decrease, but these changes were not statistically significant and did not result in serum calcium values dropping below the normal range."
phosphate,"Phosphate supplementation may inhibit osteoblast function, thereby reducing bone resorption and potentially increasing parathyroid hormone production.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation may inhibit osteoblast function, thereby reducing bone resorption and potentially increasing parathyroid hormone production."
calcium,"Phosphate supplementation can increase osteoblastic activity, leading to increased calcium consumption and a tendency toward hypocalcemia.","Entity: calcium. SMILES: [Ca]. Phosphate supplementation can increase osteoblastic activity, leading to increased calcium consumption and a tendency toward hypocalcemia."
phosphate,"Phosphate supplementation can increase osteoblastic activity, which may result in increased calcium consumption and hypocalcemia.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation can increase osteoblastic activity, which may result in increased calcium consumption and hypocalcemia."
tetracycline,Tetracycline is used to label bone in histological sections for quantitative assessment of bone formation and porosity.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline is used to label bone in histological sections for quantitative assessment of bone formation and porosity.
phosphorus,The Ca/P ratio is more important than the absolute amount of phosphorus in producing nephrocalcinosis in rats.,Entity: phosphorus. SMILES: [P]. The Ca/P ratio is more important than the absolute amount of phosphorus in producing nephrocalcinosis in rats.
calcium,Differences in the total amount of calcium or phosphorus absorbed can influence the effect of phosphate supplementation on skeletal mass.,Entity: calcium. SMILES: [Ca]. Differences in the total amount of calcium or phosphorus absorbed can influence the effect of phosphate supplementation on skeletal mass.
phosphate,Addition of phosphate increases bone formation and skeletal mass in individuals with phosphate diabetes.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Addition of phosphate increases bone formation and skeletal mass in individuals with phosphate diabetes.
phosphate,Infusion of added phosphate blocks the rise in serum calcium and increased urinary calcium loss induced by parathyroid hormone in thyroparathroidectomized rats.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Infusion of added phosphate blocks the rise in serum calcium and increased urinary calcium loss induced by parathyroid hormone in thyroparathroidectomized rats.
phosphate,Addition of phosphate stimulates new bone formation rather than increasing soft tissue calcium content or blocking bone resorption induced by parathyroid hormone.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Addition of phosphate stimulates new bone formation rather than increasing soft tissue calcium content or blocking bone resorption induced by parathyroid hormone.
calcium,Increased urinary calcium loss is a customary response to additional parathyroid hormone in thyroparathroidectomized rats.,Entity: calcium. SMILES: [Ca]. Increased urinary calcium loss is a customary response to additional parathyroid hormone in thyroparathroidectomized rats.
thyroxin,Thyroxin is used in combination with parathyroid hormone in thyroparathroidectomized rats to maintain stable calcium levels.,Entity: thyroxin. SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O. Thyroxin is used in combination with parathyroid hormone in thyroparathroidectomized rats to maintain stable calcium levels.
tetracycline,"Tetracycline is administered in three different forms with differing fluorescent spectra during intravital imaging studies in dogs: demethylchlortetracycline (450 mg for 4 weeks), methacycline (300 mg for 4 weeks), and doxycycline (300 mg for 4 weeks).","Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline is administered in three different forms with differing fluorescent spectra during intravital imaging studies in dogs: demethylchlortetracycline (450 mg for 4 weeks), methacycline (300 mg for 4 weeks), and doxycycline (300 mg for 4 weeks)."
potassium phosphate,"Potassium phosphate is used as a phosphorus supplement in dogs, administered orally at a total daily dose of 1169 mg phosphorus in three divided doses every 8 hours.","Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate is used as a phosphorus supplement in dogs, administered orally at a total daily dose of 1169 mg phosphorus in three divided doses every 8 hours."
phosphate,"Phosphate supplementation in intact mature dogs stimulates new bone formation by increasing osteoblastic activity, with effects observed at plasma phosphate levels no higher than those associated with the absorptive peak after non-supplemented diets.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation in intact mature dogs stimulates new bone formation by increasing osteoblastic activity, with effects observed at plasma phosphate levels no higher than those associated with the absorptive peak after non-supplemented diets."
potassium phosphate,Potassium phosphate can be administered orally in divided doses at 108 mg P/kg per day for 12 weeks to stimulate bone formation in adult dogs.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate can be administered orally in divided doses at 108 mg P/kg per day for 12 weeks to stimulate bone formation in adult dogs.
phosphate,"Phosphate supplementation in adult dogs doubles the rate of bone formation within cortical bone, increasing it from an average of 2.7% to 5.3% per year.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation in adult dogs doubles the rate of bone formation within cortical bone, increasing it from an average of 2.7% to 5.3% per year."
phosphate,Phosphate supplementation in adult dogs increases whole skeletal mineral accretion by 45% above an average control value of 0.154 g/day.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation in adult dogs increases whole skeletal mineral accretion by 45% above an average control value of 0.154 g/day.
phosphate,"In adult dogs, normal plasma phosphate levels are suboptimal for new bone formation, as supplementation is required to stimulate bone formation.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. In adult dogs, normal plasma phosphate levels are suboptimal for new bone formation, as supplementation is required to stimulate bone formation."
phosphate,Short-term phosphate supplementation in adult dogs produces microscopic calcification of the renal parenchyma without causing biochemical evidence of renal functional impairment.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Short-term phosphate supplementation in adult dogs produces microscopic calcification of the renal parenchyma without causing biochemical evidence of renal functional impairment.
calcium,Whole skeletal mineral accretion in adult dogs can be measured kinetically using 47Ca administration to assess bone formation rates.,Entity: calcium. SMILES: [Ca]. Whole skeletal mineral accretion in adult dogs can be measured kinetically using 47Ca administration to assess bone formation rates.
calcium,Serum calcium levels decrease as a result of phosphate supplementation.,Entity: calcium. SMILES: [Ca]. Serum calcium levels decrease as a result of phosphate supplementation.
calcium,Urinary calcium levels decrease following phosphate supplementation.,Entity: calcium. SMILES: [Ca]. Urinary calcium levels decrease following phosphate supplementation.
phosphate,Phosphate supplementation increases parathyroid hormone secretion.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation increases parathyroid hormone secretion.
phosphate,Phosphate supplementation initially decreases both serum calcium and urinary calcium levels.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate supplementation initially decreases both serum calcium and urinary calcium levels.
phosphorus,"In adult beagle dogs fed a chemically defined diet with 0.4% Jones-Foster salt mixture, the dietary phosphorus intake is approximately 0.6% of the salt mixture, which is considered normal for adults.","Entity: phosphorus. SMILES: [P]. In adult beagle dogs fed a chemically defined diet with 0.4% Jones-Foster salt mixture, the dietary phosphorus intake is approximately 0.6% of the salt mixture, which is considered normal for adults."
calcium,"In adult beagle dogs fed a chemically defined diet with 0.4% Jones-Foster salt mixture, the dietary calcium intake is approximately 0.6% of the salt mixture, which is considered normal for adults.","Entity: calcium. SMILES: [Ca]. In adult beagle dogs fed a chemically defined diet with 0.4% Jones-Foster salt mixture, the dietary calcium intake is approximately 0.6% of the salt mixture, which is considered normal for adults."
calcium,"Calcium deficiency decreases animal weight gain, bone ash, femur cortical thickness, and maximal load, and reduces breaking strength and modulus and limit of elasticity in bones.","Entity: calcium. SMILES: [Ca]. Calcium deficiency decreases animal weight gain, bone ash, femur cortical thickness, and maximal load, and reduces breaking strength and modulus and limit of elasticity in bones."
phosphorus,"Phosphorus deficiency decreases animal weight gain, bone ash, femur cortical thickness, and maximal load, and reduces breaking strength and modulus and limit of elasticity in bones.","Entity: phosphorus. SMILES: [P]. Phosphorus deficiency decreases animal weight gain, bone ash, femur cortical thickness, and maximal load, and reduces breaking strength and modulus and limit of elasticity in bones."
fluorine,"Fluorine at high levels tends to decrease bone ash, cortical thickness, and mechanical strength parameters in bones, but its effect is smaller when bone ash is decreased by calcium and/or phosphorus deficiency.","Entity: fluorine. SMILES: [F]. Fluorine at high levels tends to decrease bone ash, cortical thickness, and mechanical strength parameters in bones, but its effect is smaller when bone ash is decreased by calcium and/or phosphorus deficiency."
phosphorus,Supplementation with 50 ppm fluoride in phosphorus-deficient diets improves weight gain in rats.,Entity: phosphorus. SMILES: [P]. Supplementation with 50 ppm fluoride in phosphorus-deficient diets improves weight gain in rats.
fluoride,High dietary fluoride levels (150 ppm) inhibit weight gain in rats more when dietary phosphorus is normal than when phosphorus is low.,Entity: fluoride. SMILES: [F-]. High dietary fluoride levels (150 ppm) inhibit weight gain in rats more when dietary phosphorus is normal than when phosphorus is low.
calcium,Dietary deficiency of calcium in rats leads to decreased weight gain and reduced femur ash concentration compared to normal calcium intake.,Entity: calcium. SMILES: [Ca]. Dietary deficiency of calcium in rats leads to decreased weight gain and reduced femur ash concentration compared to normal calcium intake.
phosphorus,Dietary deficiency of phosphorus in rats leads to decreased weight gain and reduced femur ash concentration compared to normal phosphorus intake.,Entity: phosphorus. SMILES: [P]. Dietary deficiency of phosphorus in rats leads to decreased weight gain and reduced femur ash concentration compared to normal phosphorus intake.
fluoride,High levels of fluoride in drinking water inhibit weight gain in weanling rats.,Entity: fluoride. SMILES: [F-]. High levels of fluoride in drinking water inhibit weight gain in weanling rats.
fluoride,"At low concentrations, fluoride supplementation in drinking water does not affect bone ash, femoral cortical bone thickness, or mechanical strength parameters such as maximal load, ultimate stress to breaking, and limit of elasticity in weanling rats.","Entity: fluoride. SMILES: [F-]. At low concentrations, fluoride supplementation in drinking water does not affect bone ash, femoral cortical bone thickness, or mechanical strength parameters such as maximal load, ultimate stress to breaking, and limit of elasticity in weanling rats."
fluoride,"At higher concentrations, fluoride in drinking water tends to decrease bone ash, femoral cortical bone thickness, and mechanical strength parameters in weanling rats, except in rats deficient in both calcium and phosphorus.","Entity: fluoride. SMILES: [F-]. At higher concentrations, fluoride in drinking water tends to decrease bone ash, femoral cortical bone thickness, and mechanical strength parameters in weanling rats, except in rats deficient in both calcium and phosphorus."
fluoride,"The effect of fluoride on bone parameters is modified by dietary calcium and phosphorus, being weaker in rats deficient in these nutrients.","Entity: fluoride. SMILES: [F-]. The effect of fluoride on bone parameters is modified by dietary calcium and phosphorus, being weaker in rats deficient in these nutrients."
calcium,Lack of dietary calcium decreases bone strength more than fluoride content in drinking water or bone mineral in weanling rats.,Entity: calcium. SMILES: [Ca]. Lack of dietary calcium decreases bone strength more than fluoride content in drinking water or bone mineral in weanling rats.
fluorine,"Fluorine can affect body weight gain, bone composition, and mechanical properties, with the extent of these effects depending on dietary sufficiency of calcium and phosphorus.","Entity: fluorine. SMILES: [F]. Fluorine can affect body weight gain, bone composition, and mechanical properties, with the extent of these effects depending on dietary sufficiency of calcium and phosphorus."
phosphorus,Phosphorus is a dietary nutrient whose sufficiency interacts with fluorine and calcium to influence bone strength and composition.,Entity: phosphorus. SMILES: [P]. Phosphorus is a dietary nutrient whose sufficiency interacts with fluorine and calcium to influence bone strength and composition.
calcium,Calcium is a dietary nutrient whose sufficiency interacts with fluorine and phosphorus to affect bone strength and composition.,Entity: calcium. SMILES: [Ca]. Calcium is a dietary nutrient whose sufficiency interacts with fluorine and phosphorus to affect bone strength and composition.
calcium,"Dietary calcium affects parameters such as body weight gain, bone ash, femur cross-sectional area, and maximal load in experimental animals.","Entity: calcium. SMILES: [Ca]. Dietary calcium affects parameters such as body weight gain, bone ash, femur cross-sectional area, and maximal load in experimental animals."
phosphorus,"Dietary phosphorus affects body weight gain, bone ash, femur cross-sectional area, and maximal load in experimental animals.","Entity: phosphorus. SMILES: [P]. Dietary phosphorus affects body weight gain, bone ash, femur cross-sectional area, and maximal load in experimental animals."
fluoride,"Fluoride influences parameters such as body weight gain, bone ash, femur cross-sectional area, and maximal load in experimental animals, but does not affect the limit of elasticity.","Entity: fluoride. SMILES: [F-]. Fluoride influences parameters such as body weight gain, bone ash, femur cross-sectional area, and maximal load in experimental animals, but does not affect the limit of elasticity."
phosphorus,"Phosphorus is a dietary mineral whose content, when combined with normal calcium intake, has a strong effect on bone strength in rats.","Entity: phosphorus. SMILES: [P]. Phosphorus is a dietary mineral whose content, when combined with normal calcium intake, has a strong effect on bone strength in rats."
fluoride,"Increasing fluoride concentration in bone ash, when dietary calcium and phosphorus are normal, leads to a gradual decrease in bone cortical thickness, maximal load, breaking strength, and modulus of elasticity in rats.","Entity: fluoride. SMILES: [F-]. Increasing fluoride concentration in bone ash, when dietary calcium and phosphorus are normal, leads to a gradual decrease in bone cortical thickness, maximal load, breaking strength, and modulus of elasticity in rats."
calcium,"Calcium is a dietary mineral whose content, when combined with normal phosphorus intake, has a strong effect on bone strength in rats.","Entity: calcium. SMILES: [Ca]. Calcium is a dietary mineral whose content, when combined with normal phosphorus intake, has a strong effect on bone strength in rats."
phosphorus,"Dietary phosphorus deficiency reduces bone cross-sectional area and mechanical parameters more than calcium deficiency, especially when calcium is also deficient.","Entity: phosphorus. SMILES: [P]. Dietary phosphorus deficiency reduces bone cross-sectional area and mechanical parameters more than calcium deficiency, especially when calcium is also deficient."
calcium,"Dietary calcium deficiency increases bone fluoride deposition but has a greater effect on reducing bone mechanical parameters (cross-sectional area, maximal load, breaking strength, and modulus of elasticity) compared to phosphorus deficiency.","Entity: calcium. SMILES: [Ca]. Dietary calcium deficiency increases bone fluoride deposition but has a greater effect on reducing bone mechanical parameters (cross-sectional area, maximal load, breaking strength, and modulus of elasticity) compared to phosphorus deficiency."
fluoride,"Increasing dietary fluoride concentration in drinking water tends to reduce bone mechanical parameters such as cross-sectional area, maximal load, breaking strength, and modulus of elasticity in rats.","Entity: fluoride. SMILES: [F-]. Increasing dietary fluoride concentration in drinking water tends to reduce bone mechanical parameters such as cross-sectional area, maximal load, breaking strength, and modulus of elasticity in rats."
fluoride,Fluoride is considered essential for optimal growth in animals and has long been appreciated to have beneficial effects on human bone and teeth.,Entity: fluoride. SMILES: [F-]. Fluoride is considered essential for optimal growth in animals and has long been appreciated to have beneficial effects on human bone and teeth.
fluoride,"Increased skeletal density following fluoride ingestion is presumed to result from new bone formation and/or incorporation of fluoride into bone hydroxyapatite, which increases bone stability and resistance to mineral dissolution and bone loss.","Entity: fluoride. SMILES: [F-]. Increased skeletal density following fluoride ingestion is presumed to result from new bone formation and/or incorporation of fluoride into bone hydroxyapatite, which increases bone stability and resistance to mineral dissolution and bone loss."
fluoride,Fluoride has been suggested as a potential agent for the prevention and treatment of primary osteoporosis in humans.,Entity: fluoride. SMILES: [F-]. Fluoride has been suggested as a potential agent for the prevention and treatment of primary osteoporosis in humans.
calcium,"Treatment with fluoride may not always result in a positive calcium balance in humans, and under certain conditions, fluoride can exert deleterious effects on the skeleton.","Entity: calcium. SMILES: [Ca]. Treatment with fluoride may not always result in a positive calcium balance in humans, and under certain conditions, fluoride can exert deleterious effects on the skeleton."
fluoride,"Fluoride increases bone flexibility, lowers bone strength, and increases the amount of energy absorbed before bone fracture.","Entity: fluoride. SMILES: [F-]. Fluoride increases bone flexibility, lowers bone strength, and increases the amount of energy absorbed before bone fracture."
fluoride,"Fluoride increases bone diameter, indicating stimulation of bone formation.","Entity: fluoride. SMILES: [F-]. Fluoride increases bone diameter, indicating stimulation of bone formation."
fluoride,High fluoride content in bone offers little protection against decreased breaking strength in osteoporotic femora.,Entity: fluoride. SMILES: [F-]. High fluoride content in bone offers little protection against decreased breaking strength in osteoporotic femora.
calcium,"Inadequate dietary calcium intake leads to increased intestinal absorption of fluorine, resulting in higher fluorine deposition in bones.","Entity: calcium. SMILES: [Ca]. Inadequate dietary calcium intake leads to increased intestinal absorption of fluorine, resulting in higher fluorine deposition in bones."
fluorine,"Increased intestinal absorption of fluorine, often associated with low dietary calcium, results in higher fluorine deposition in bones and can cause fluorine intoxication as evidenced by exostoses and fluorine retention in bone.","Entity: fluorine. SMILES: [F]. Increased intestinal absorption of fluorine, often associated with low dietary calcium, results in higher fluorine deposition in bones and can cause fluorine intoxication as evidenced by exostoses and fluorine retention in bone."
phosphorus,Phosphorus is a dietary mineral whose content can be manipulated to affect bone ash content and mechanical properties in rats.,Entity: phosphorus. SMILES: [P]. Phosphorus is a dietary mineral whose content can be manipulated to affect bone ash content and mechanical properties in rats.
fluoride,"Fluoride can be administered to rats via drinking water at concentrations of 0, 50, 75, or 150 ppm as NaF to study its effects on bone ash content and mechanical properties.","Entity: fluoride. SMILES: [F-]. Fluoride can be administered to rats via drinking water at concentrations of 0, 50, 75, or 150 ppm as NaF to study its effects on bone ash content and mechanical properties."
calcium,Calcium is a dietary mineral whose content can be varied to influence bone ash content and mechanical properties in rats.,Entity: calcium. SMILES: [Ca]. Calcium is a dietary mineral whose content can be varied to influence bone ash content and mechanical properties in rats.
fluoride,"In rats, dietary fluoride supplementation at 75 ppm decreases ash concentration and mechanical strength, while 150 ppm has no effect on these parameters.","Entity: fluoride. SMILES: [F-]. In rats, dietary fluoride supplementation at 75 ppm decreases ash concentration and mechanical strength, while 150 ppm has no effect on these parameters."
fluoride,"In pigs, maternal dietary fluoride supplementation at 0 or 450 ppm is associated with high humerus density at birth, whereas supplementation at 30 or 150 ppm is associated with low humerus density.","Entity: fluoride. SMILES: [F-]. In pigs, maternal dietary fluoride supplementation at 0 or 450 ppm is associated with high humerus density at birth, whereas supplementation at 30 or 150 ppm is associated with low humerus density."
guanidinium hydrochloride,"Guanidinium hydrochloride at 4 M concentration is used to extract most proteoglycans from cartilage, leaving resistant proteoglycans in the tissue.","Entity: guanidinium hydrochloride. SMILES: Cl.NC(N)=[NH2+]. Guanidinium hydrochloride at 4 M concentration is used to extract most proteoglycans from cartilage, leaving resistant proteoglycans in the tissue."
keratan sulfate,"In calcified cartilage, the proportion of keratan sulfate increases relative to the 6-isomer and other mucopolysaccharides.","Entity: keratan sulfate. SMILES: CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)O[C@H](COS(=O)(=O)O)[C@@H]2O)O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@H](COS(=O)(=O)O)[C@H](O)[C@H](O[C@@H]3O[C@H](COS(=O)(=O)O)C[C@H](O)[C@H]3NC(C)=O)[C@H]2O)[C@@H]1O. In calcified cartilage, the proportion of keratan sulfate increases relative to the 6-isomer and other mucopolysaccharides."
35S-sulfate,"35S-sulfate is used in autoradiographic studies to detect changes in the concentration of sulfated glycosaminoglycans (GAGs) in growing epiphyseal plates, with decreased concentrations observed in regions where calcification is occurring.","Entity: 35S-sulfate. SMILES: O=S(=O)([O-])[O-]. 35S-sulfate is used in autoradiographic studies to detect changes in the concentration of sulfated glycosaminoglycans (GAGs) in growing epiphyseal plates, with decreased concentrations observed in regions where calcification is occurring."
toluidine blue,Calcified cartilage proteoglycans stain more intensely with toluidine blue compared to non-calcified cartilage proteoglycans.,Entity: toluidine blue. SMILES: Cc1ccc(Nc2ccc(O)c3c2C(=O)c2c(O)ccc(Nc4ccc(C)cc4S(=O)(=O)[O-])c2C3=O)c(S(=O)(=O)[O-])c1.[Na+].[Na+]. Calcified cartilage proteoglycans stain more intensely with toluidine blue compared to non-calcified cartilage proteoglycans.
CaCl2,CaCl2 is used in calcifying solutions to maintain the histologic appearance of extracted bone tissue.,Entity: CaCl2. SMILES: [Ca+2].[Cl-].[Cl-]. CaCl2 is used in calcifying solutions to maintain the histologic appearance of extracted bone tissue.
AgNO3,"AgNO3 is used as a histological stain to detect mineralization in bone tissue, but previously mineralized regions of bone extracted at low pH or with EDTA fail to stain with AgNO3.","Entity: AgNO3. SMILES: O=[N+]([O-])[O-].[Ag+]. AgNO3 is used as a histological stain to detect mineralization in bone tissue, but previously mineralized regions of bone extracted at low pH or with EDTA fail to stain with AgNO3."
MgCl2,MgCl2 is used in calcifying solutions to maintain the histologic appearance of extracted bone tissue.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used in calcifying solutions to maintain the histologic appearance of extracted bone tissue.
GuHC1,GuHC1 is used in calcifying solutions to maintain the histologic appearance of extracted bone tissue.,Entity: GuHC1. SMILES: Cl.NC(N)=[NH2+]. GuHC1 is used in calcifying solutions to maintain the histologic appearance of extracted bone tissue.
EDTA,EDTA is used in extraction solutions to destroy the calcifiability of previously mineralized bone tissue.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used in extraction solutions to destroy the calcifiability of previously mineralized bone tissue.
acetic acid,"Acetic acid is used as a component of the buffer solution (0.05 M acetic acid-sodium acetate, pH 4.0) for extracting uronic acid from rat bones.","Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component of the buffer solution (0.05 M acetic acid-sodium acetate, pH 4.0) for extracting uronic acid from rat bones."
guanidinium hydrochloride,"Guanidinium hydrochloride (4 M, Grade I) is used as an extracting agent in the preparation of uronic acid from rat bones.","Entity: guanidinium hydrochloride. SMILES: Cl.NC(N)=[NH2+]. Guanidinium hydrochloride (4 M, Grade I) is used as an extracting agent in the preparation of uronic acid from rat bones."
ethanol,"Ethanol is used as a component of histological staining solutions, such as 30% ethanol for staining with toluidine blue.","Entity: ethanol. SMILES: CCO. Ethanol is used as a component of histological staining solutions, such as 30% ethanol for staining with toluidine blue."
water,Deionized water is used for rinsing bone slices during histological processing.,Entity: water. SMILES: O. Deionized water is used for rinsing bone slices during histological processing.
xylene,Xylene is used as a clearing agent in the preparation of histological sections.,Entity: xylene. SMILES: Cc1ccccc1C. Xylene is used as a clearing agent in the preparation of histological sections.
toluidine blue,Toluidine blue is a histological stain used at 0.1% concentration in 30% ethanol for staining bone tissue sections.,Entity: toluidine blue. SMILES: Cc1ccc(Nc2ccc(O)c3c2C(=O)c2c(O)ccc(Nc4ccc(C)cc4S(=O)(=O)[O-])c2C3=O)c(S(=O)(=O)[O-])c1.[Na+].[Na+]. Toluidine blue is a histological stain used at 0.1% concentration in 30% ethanol for staining bone tissue sections.
phosphate,Plasma phosphate concentrations decrease following parathyroid hormone (PTH) injection due to PTH's effect on renal tubular resorption of phosphate.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Plasma phosphate concentrations decrease following parathyroid hormone (PTH) injection due to PTH's effect on renal tubular resorption of phosphate.
calcium,Plasma calcium levels increase more rapidly in rats when parathyroid hormone (PTH) is administered after a dietary source of calcium is available (fed state) compared to when calcium intake is temporarily depleted (fasted state).,Entity: calcium. SMILES: [Ca]. Plasma calcium levels increase more rapidly in rats when parathyroid hormone (PTH) is administered after a dietary source of calcium is available (fed state) compared to when calcium intake is temporarily depleted (fasted state).
calcium lactate,"Calcium lactate is used as a dietary supplement in rats, administered in drinking water for 3 days post-thyroparathyroidectomy.","Entity: calcium lactate. SMILES: CC(O)C(=O)[O-].CC(O)C(=O)[O-].[Ca+2]. Calcium lactate is used as a dietary supplement in rats, administered in drinking water for 3 days post-thyroparathyroidectomy."
thyroxine,Thyroxine is administered to rats at a dose of 0.05 g/g body weight twice weekly.,Entity: thyroxine. SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O. Thyroxine is administered to rats at a dose of 0.05 g/g body weight twice weekly.
calcium,Calcium entering bone fluid from the extracellular fluid (ECF) is diluted by exchange and mixing with calcium already within bone fluid and by contact with bone surfaces before being returned to the ECF.,Entity: calcium. SMILES: [Ca]. Calcium entering bone fluid from the extracellular fluid (ECF) is diluted by exchange and mixing with calcium already within bone fluid and by contact with bone surfaces before being returned to the ECF.
phosphate,"Phosphate is resorbable from bone matrix by osteoclasts, but changes in 45Ca specific activity do not correspond to changes in 32P specific activity, indicating that osteoclasts do not resorb both calcium and phosphate from bone matrix.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate is resorbable from bone matrix by osteoclasts, but changes in 45Ca specific activity do not correspond to changes in 32P specific activity, indicating that osteoclasts do not resorb both calcium and phosphate from bone matrix."
calcium,"Calcium is actively transported across bone surfaces, with the active transport system concentrated in lining cells and utilizing calcium from bone fluid bathing their basal borders.","Entity: calcium. SMILES: [Ca]. Calcium is actively transported across bone surfaces, with the active transport system concentrated in lining cells and utilizing calcium from bone fluid bathing their basal borders."
calcium,"Plasma calcium levels in rats increase following parathyroid hormone (PTH) injection, with a more rapid and pronounced rise in fed rats compared to fasted rats.","Entity: calcium. SMILES: [Ca]. Plasma calcium levels in rats increase following parathyroid hormone (PTH) injection, with a more rapid and pronounced rise in fed rats compared to fasted rats."
calcium,"Plasma calcium levels increase in rats following parathyroid hormone (PTH) treatment, even when the isotope has been administered only a few hours prior.","Entity: calcium. SMILES: [Ca]. Plasma calcium levels increase in rats following parathyroid hormone (PTH) treatment, even when the isotope has been administered only a few hours prior."
calcium,"Calcium is transported out of bone fluid into the extracellular fluid (ECF) via bone cell units, and this process is stimulated by parathyroid hormone (PTH), which increases the rate of calcium transport outward from bone fluid.","Entity: calcium. SMILES: [Ca]. Calcium is transported out of bone fluid into the extracellular fluid (ECF) via bone cell units, and this process is stimulated by parathyroid hormone (PTH), which increases the rate of calcium transport outward from bone fluid."
calcium,"Plasma calcium concentrations increase when parathyroid hormone (PTH) is administered to fed, but not fasted, young adult male thyroparathyroidectomized rats.","Entity: calcium. SMILES: [Ca]. Plasma calcium concentrations increase when parathyroid hormone (PTH) is administered to fed, but not fasted, young adult male thyroparathyroidectomized rats."
calcium,"Plasma calcium levels are controlled by the interplay of bone remodelling (mediated by PTH and osteoclastic bone resorption) and other physiological processes, with PTH exerting effects on both bone remodelling and calcium homeostasis.","Entity: calcium. SMILES: [Ca]. Plasma calcium levels are controlled by the interplay of bone remodelling (mediated by PTH and osteoclastic bone resorption) and other physiological processes, with PTH exerting effects on both bone remodelling and calcium homeostasis."
calcium,Calcium is initially sourced from bone fluid and its return to the extracellular fluid (ECF) is increased by P T I t during non-steady state conditions when plasma calcium is rising.,Entity: calcium. SMILES: [Ca]. Calcium is initially sourced from bone fluid and its return to the extracellular fluid (ECF) is increased by P T I t during non-steady state conditions when plasma calcium is rising.
calcium,"Plasma calcium values rise when a source of calcium is available at the surface of bone, such as during PTH injection.","Entity: calcium. SMILES: [Ca]. Plasma calcium values rise when a source of calcium is available at the surface of bone, such as during PTH injection."
calcium,Plasma samples can be analyzed for total calcium using a modified method from Borle and Briggs (1968).,Entity: calcium. SMILES: [Ca]. Plasma samples can be analyzed for total calcium using a modified method from Borle and Briggs (1968).
phosphate,Plasma samples can be analyzed for inorganic phosphate using a method described by Chen et al. (1965).,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Plasma samples can be analyzed for inorganic phosphate using a method described by Chen et al. (1965).
calcium,Plasma calcium levels increase slowly following administration of parathyroid hormone (PTH) in rats.,Entity: calcium. SMILES: [Ca]. Plasma calcium levels increase slowly following administration of parathyroid hormone (PTH) in rats.
calcium,"In rats, plasma calcium levels are increased by parathyroid hormone (PTH) injection, with the increase being more pronounced in previously fed rats compared to fasted rats.","Entity: calcium. SMILES: [Ca]. In rats, plasma calcium levels are increased by parathyroid hormone (PTH) injection, with the increase being more pronounced in previously fed rats compared to fasted rats."
calcium,"Plasma calcium concentrations are controlled in part by osteoclast activity, as evidenced by the use of radioactive calcium isotopes as tracers.","Entity: calcium. SMILES: [Ca]. Plasma calcium concentrations are controlled in part by osteoclast activity, as evidenced by the use of radioactive calcium isotopes as tracers."
parathyroid hormone,Parathyroid hormone increases plasma calcium concentrations in rats by promoting calcium transport through the osteocyte-lining cell (osteoblast) bone cell complex from the bone fluid compartment to the extracellular fluid compartment.,Entity: parathyroid hormone. Parathyroid hormone increases plasma calcium concentrations in rats by promoting calcium transport through the osteocyte-lining cell (osteoblast) bone cell complex from the bone fluid compartment to the extracellular fluid compartment.
Cobalt(II) chloride,Cobalt(II) chloride induces severe necrosis in mouse subcutaneous tissues but does not produce calcification.,Entity: Cobalt(II) chloride. SMILES: Cl[Co]Cl. Cobalt(II) chloride induces severe necrosis in mouse subcutaneous tissues but does not produce calcification.
Zinc dodecyl sulfate,"Zinc dodecyl sulfate at a dose of 10 mg in 0.2 ml solution causes necrosis of full-thickness skin, swelling and fragmentation of panniculus carnosus muscle fibres, loss of nuclear definition, and accumulation of phosphate in damaged muscle fibres in mice.","Entity: Zinc dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].CCCCCCCCCCCCOS(=O)(=O)[O-].[Zn+2]. Zinc dodecyl sulfate at a dose of 10 mg in 0.2 ml solution causes necrosis of full-thickness skin, swelling and fragmentation of panniculus carnosus muscle fibres, loss of nuclear definition, and accumulation of phosphate in damaged muscle fibres in mice."
Copper(II) sulfate,Copper(II) sulfate treatment fails to produce calcification in mouse subcutaneous tissues.,Entity: Copper(II) sulfate. SMILES: O=S(=O)([O-])[O-].[Cu+2]. Copper(II) sulfate treatment fails to produce calcification in mouse subcutaneous tissues.
zinc chloride,"Subcutaneous injection of zinc chloride at doses of 1 mg, 5 mg, and 10 mg in 0.2 ml solution produces a similar area of necrosis with early repair, with increasing lesion severity and fibre disruption in the panniculus carnosus muscle as the dose increases.","Entity: zinc chloride. SMILES: [Cl-].[Cl-].[Zn+2]. Subcutaneous injection of zinc chloride at doses of 1 mg, 5 mg, and 10 mg in 0.2 ml solution produces a similar area of necrosis with early repair, with increasing lesion severity and fibre disruption in the panniculus carnosus muscle as the dose increases."
copper(II) sulfate,"Injection of copper(II) sulfate solution in animals results in areas of acute inflammation, necrosis, granulation tissue formation, and repair, but does not induce calcification as detected by histochemical techniques.","Entity: copper(II) sulfate. SMILES: O=S(=O)([O-])[O-].[Cu+2]. Injection of copper(II) sulfate solution in animals results in areas of acute inflammation, necrosis, granulation tissue formation, and repair, but does not induce calcification as detected by histochemical techniques."
Potassium Permanganate,"Potassium Permanganate at doses of 100 µg, 200 tzg, 500 µzg, and 1 mg induces areas of necrosis with acute inflammatory responses and early repair in tissue.","Entity: Potassium Permanganate. SMILES: O=[Mn](=O)(=O)[O-].[K+]. Potassium Permanganate at doses of 100 µg, 200 tzg, 500 µzg, and 1 mg induces areas of necrosis with acute inflammatory responses and early repair in tissue."
Potassium Permanganate,"Potassium Permanganate administered at 5 mg in subcutaneous tissues causes severe damage to muscle fibers of the panniculus carnosus muscle, resulting in swollen, fragmented, and structureless fibers with faint uniform basophilia on H&E staining.","Entity: Potassium Permanganate. SMILES: O=[Mn](=O)(=O)[O-].[K+]. Potassium Permanganate administered at 5 mg in subcutaneous tissues causes severe damage to muscle fibers of the panniculus carnosus muscle, resulting in swollen, fragmented, and structureless fibers with faint uniform basophilia on H&E staining."
lead,The calcification reaction induced by lead salt injection is dependent on the presence of lead and is not affected by the anion associated with lead.,Entity: lead. SMILES: [Pb]. The calcification reaction induced by lead salt injection is dependent on the presence of lead and is not affected by the anion associated with lead.
lead,"Lead salts can induce a calcification reaction in the dorsal fascia of mice, requiring only a small quantity of lead salt to elicit the reaction.","Entity: lead. SMILES: [Pb]. Lead salts can induce a calcification reaction in the dorsal fascia of mice, requiring only a small quantity of lead salt to elicit the reaction."
potassium permanganate,"Injection of potassium permanganate at 10 mg/0.2 ml into mouse tissue results in accumulation of Ca++ ions and presence of phosphorus pentoxide in the damaged panniculus carnosus, along with severe necrosis and inflammation.","Entity: potassium permanganate. SMILES: O=[Mn](=O)(=O)[O-].[K+]. Injection of potassium permanganate at 10 mg/0.2 ml into mouse tissue results in accumulation of Ca++ ions and presence of phosphorus pentoxide in the damaged panniculus carnosus, along with severe necrosis and inflammation."
phosphorus pentoxide,Phosphorus pentoxide can be demonstrated histochemically in damaged fibers of the panniculus carnosus following injection of potassium permanganate or lead salts in mice.,Entity: phosphorus pentoxide. SMILES: O=P(=O)OP(=O)=O. Phosphorus pentoxide can be demonstrated histochemically in damaged fibers of the panniculus carnosus following injection of potassium permanganate or lead salts in mice.
zinc dodecyl sulfate,"Injection of zinc dodecyl sulfate at 5 mg/0.2 ml into mouse tissue results in the presence of phosphorus pentoxide in the damaged fibers of the panniculus carnosus, with no calcification in surrounding connective tissue fibers but extensive necrosis.","Entity: zinc dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].CCCCCCCCCCCCOS(=O)(=O)[O-].[Zn+2]. Injection of zinc dodecyl sulfate at 5 mg/0.2 ml into mouse tissue results in the presence of phosphorus pentoxide in the damaged fibers of the panniculus carnosus, with no calcification in surrounding connective tissue fibers but extensive necrosis."
lead acetate,"Lead acetate is used as an inducing agent to produce simple calcergy, a localized calcification reaction at the site of subcutaneous injection in rats.","Entity: lead acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Pb+2]. Lead acetate is used as an inducing agent to produce simple calcergy, a localized calcification reaction at the site of subcutaneous injection in rats."
lead,"Lead salts, when applied subcutaneously at 100 µg/0.2 ml, cause 1 cm diameter areas of calcification in the skin within 6 days, involving the collagenous fibres of the dorsal fascia.","Entity: lead. SMILES: [Pb]. Lead salts, when applied subcutaneously at 100 µg/0.2 ml, cause 1 cm diameter areas of calcification in the skin within 6 days, involving the collagenous fibres of the dorsal fascia."
potassium permanganate,"Treatment with potassium permanganate at doses of 5 mg and 10 mg/0.2 ml solution causes severe damage, marked swelling, fragmentation, and loss of structural detail in the fibers of the panniculus carnosus.","Entity: potassium permanganate. SMILES: O=[Mn](=O)(=O)[O-].[K+]. Treatment with potassium permanganate at doses of 5 mg and 10 mg/0.2 ml solution causes severe damage, marked swelling, fragmentation, and loss of structural detail in the fibers of the panniculus carnosus."
zinc chloride,"In tissues treated with zinc chloride, there is no accumulation of calcium ions compared to preparations treated with potassium permanganate.","Entity: zinc chloride. SMILES: [Cl-].[Cl-].[Zn+2]. In tissues treated with zinc chloride, there is no accumulation of calcium ions compared to preparations treated with potassium permanganate."
zinc chloride,"Zinc chloride, when injected subcutaneously at 500 tzg, induces full thickness necrosis, granulation tissue formation, and squamous epithelium ingrowth at the lesion margin, but does not induce calcification in treated tissues at 6 days.","Entity: zinc chloride. SMILES: [Cl-].[Cl-].[Zn+2]. Zinc chloride, when injected subcutaneously at 500 tzg, induces full thickness necrosis, granulation tissue formation, and squamous epithelium ingrowth at the lesion margin, but does not induce calcification in treated tissues at 6 days."
calcium,Calcium is present in dense precipitates within spherules in tissue sections fixed with a pyroantimoniate-containing osmium fixative.,Entity: calcium. SMILES: [Ca]. Calcium is present in dense precipitates within spherules in tissue sections fixed with a pyroantimoniate-containing osmium fixative.
calcium,Mitochondria adjacent to spherules and the outer plasma membrane are positive for calcium in tissue sections fixed with a pyroantimoniate-containing osmium fixative.,Entity: calcium. SMILES: [Ca]. Mitochondria adjacent to spherules and the outer plasma membrane are positive for calcium in tissue sections fixed with a pyroantimoniate-containing osmium fixative.
sodium,X-ray analysis indicates that spherules in tissue sections fixed with a pyroantimoniate-containing osmium fixative have a high sodium content.,Entity: sodium. SMILES: [Na]. X-ray analysis indicates that spherules in tissue sections fixed with a pyroantimoniate-containing osmium fixative have a high sodium content.
iron,Minute spherules containing both iron and calcium have been observed in atherosclerotic plaques of pigeons.,Entity: iron. SMILES: [Fe]. Minute spherules containing both iron and calcium have been observed in atherosclerotic plaques of pigeons.
calcium,Calcium deposits in atherosclerotic plaques can appear as pleomorphic or laminated electron-dense spherules among elastin fibers in human arterial aorta.,Entity: calcium. SMILES: [Ca]. Calcium deposits in atherosclerotic plaques can appear as pleomorphic or laminated electron-dense spherules among elastin fibers in human arterial aorta.
calcium,"Isolated aortic spherules contain large amounts of calcium but no magnesium or phosphorus, as determined by energy dispersive X-ray analysis.","Entity: calcium. SMILES: [Ca]. Isolated aortic spherules contain large amounts of calcium but no magnesium or phosphorus, as determined by energy dispersive X-ray analysis."
sodium hypochlorite,Sodium hypochlorite is used to isolate individual spherules and groups of spherules from the aorta for microscopic examination.,Entity: sodium hypochlorite. SMILES: [Na+].[O-]Cl. Sodium hypochlorite is used to isolate individual spherules and groups of spherules from the aorta for microscopic examination.
magnesium,"Aortic spherules isolated by sodium hypochlorite treatment do not contain magnesium, according to energy dispersive X-ray analysis.","Entity: magnesium. SMILES: [Mg]. Aortic spherules isolated by sodium hypochlorite treatment do not contain magnesium, according to energy dispersive X-ray analysis."
phosphorus,"Aortic spherules isolated by sodium hypochlorite treatment do not contain phosphorus, according to energy dispersive X-ray analysis.","Entity: phosphorus. SMILES: [P]. Aortic spherules isolated by sodium hypochlorite treatment do not contain phosphorus, according to energy dispersive X-ray analysis."
calcium,"Calcium deposits are found associated with blood vessels in various mollusks, including slugs and snails, and can form concretions within or along arterial walls.","Entity: calcium. SMILES: [Ca]. Calcium deposits are found associated with blood vessels in various mollusks, including slugs and snails, and can form concretions within or along arterial walls."
calcium,Leydig cells in mollusks are characterized by their close association with blood vessels and may contain vacuoles or granules that give strong histochemical reactions for calcium.,Entity: calcium. SMILES: [Ca]. Leydig cells in mollusks are characterized by their close association with blood vessels and may contain vacuoles or granules that give strong histochemical reactions for calcium.
calcium chloride,"Calcium chloride is used as a source of calcium in biological experiments, as demonstrated by its injection into snails and subsequent deposition along cell membranes.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride is used as a source of calcium in biological experiments, as demonstrated by its injection into snails and subsequent deposition along cell membranes."
sodium,Sodium is present in high content within calcium-rich granules detected by X-ray microprobe analysis in snail tissues.,Entity: sodium. SMILES: [Na]. Sodium is present in high content within calcium-rich granules detected by X-ray microprobe analysis in snail tissues.
calcium carbonate,Calcium carbonate is a carbonate salt of calcium that can form spherules and recrystallize during processing for transmission electron microscopy.,Entity: calcium carbonate. SMILES: O=C([O-])[O-].[Ca+2]. Calcium carbonate is a carbonate salt of calcium that can form spherules and recrystallize during processing for transmission electron microscopy.
calcium,"Calcium deposits are present in the walls of the anterior aorta and major arteries of the land pulmonate snail Anguispira alternata, accumulating inside spherule cells.","Entity: calcium. SMILES: [Ca]. Calcium deposits are present in the walls of the anterior aorta and major arteries of the land pulmonate snail Anguispira alternata, accumulating inside spherule cells."
calcium carbonate,"The calcium in the arterial walls of Anguispira alternata occurs as amorphous calcium carbonate, forming intracellular spherules with alternating layers of organic and inorganic material.","Entity: calcium carbonate. SMILES: O=C([O-])[O-].[Ca+2]. The calcium in the arterial walls of Anguispira alternata occurs as amorphous calcium carbonate, forming intracellular spherules with alternating layers of organic and inorganic material."
calcium,"Calcium is present in the arterial layers of paraffin-embedded tissue, including the extracellular vascular coat, circular muscle layer, longitudinal muscle layer, spherule cell layer, and Leydig cell layer.","Entity: calcium. SMILES: [Ca]. Calcium is present in the arterial layers of paraffin-embedded tissue, including the extracellular vascular coat, circular muscle layer, longitudinal muscle layer, spherule cell layer, and Leydig cell layer."
hematoxylin,Hematoxylin is used as a histological stain that binds heavily to arteries in paraffin-embedded tissue.,Entity: hematoxylin. SMILES: Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2. Hematoxylin is used as a histological stain that binds heavily to arteries in paraffin-embedded tissue.
alizarin red S,Alizarin red S is a dye that produces a positive reaction for calcium in histological staining of arterial tissue.,Entity: alizarin red S. SMILES: O=C1c2ccccc2C(=O)c2c1cc(S(=O)(=O)[O-])c(O)c2O.[Na+]. Alizarin red S is a dye that produces a positive reaction for calcium in histological staining of arterial tissue.
calcium,Spherule cells of arteries are capable of sequestering excess blood calcium.,Entity: calcium. SMILES: [Ca]. Spherule cells of arteries are capable of sequestering excess blood calcium.
bicarbonate,Spherule cells of arteries may be involved in the release of bicarbonate to the blood under certain conditions such as sudden hypocalcemia or drastic pH change.,Entity: bicarbonate. SMILES: O=C([O-])O. Spherule cells of arteries may be involved in the release of bicarbonate to the blood under certain conditions such as sudden hypocalcemia or drastic pH change.
guanidinium chloride,Guanidinium chloride residues are washed in water and then digested with papain during the preparation of glycosaminoglycans (GAGs) for analysis.,Entity: guanidinium chloride. SMILES: NC(N)=[NH2+].[Cl-]. Guanidinium chloride residues are washed in water and then digested with papain during the preparation of glycosaminoglycans (GAGs) for analysis.
cetylpyridinium chloride,Cetylpyridinium chloride is used at 1% concentration to precipitate glycosaminoglycans (GAGs) from solution.,Entity: cetylpyridinium chloride. SMILES: CCCCCCCCCCCCCCCC[n+]1ccccc1.[Cl-]. Cetylpyridinium chloride is used at 1% concentration to precipitate glycosaminoglycans (GAGs) from solution.
cetylpyridinium chloride,Cetylpyridinium chloride is used at 2.5% concentration in 90% ethanol to precipitate sodium salt forms of glycosaminoglycans (GAGs).,Entity: cetylpyridinium chloride. SMILES: CCCCCCCCCCCCCCCC[n+]1ccccc1.[Cl-]. Cetylpyridinium chloride is used at 2.5% concentration in 90% ethanol to precipitate sodium salt forms of glycosaminoglycans (GAGs).
n-propanol,n-propanol (60%) containing 0.4% cetylpyridinium chloride is used to dissolve precipitated glycosaminoglycans (GAGs) for further processing.,Entity: n-propanol. SMILES: CCCO. n-propanol (60%) containing 0.4% cetylpyridinium chloride is used to dissolve precipitated glycosaminoglycans (GAGs) for further processing.
sodium acetate,Sodium acetate (2.5%) is included in 90% ethanol to facilitate precipitation of glycosaminoglycan sodium salts.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate (2.5%) is included in 90% ethanol to facilitate precipitation of glycosaminoglycan sodium salts.
ethanol,99.5% ethanol is used to wash precipitated glycosaminoglycan sodium salts prior to analysis.,Entity: ethanol. SMILES: CCO. 99.5% ethanol is used to wash precipitated glycosaminoglycan sodium salts prior to analysis.
sodium chloride,Sodium chloride (0.05 M) is used to dissolve glycosaminoglycan sodium salts to a final hexosamine concentration of 0.5 mg/ml for subsequent assays.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride (0.05 M) is used to dissolve glycosaminoglycan sodium salts to a final hexosamine concentration of 0.5 mg/ml for subsequent assays.
thiobarbituric acid,The thiobarbituric acid reaction is used to estimate the ratio of chondroitin sulfate 4 and 6 in glycosaminoglycan preparations.,Entity: thiobarbituric acid. SMILES: O=C1CC(=O)NC(=S)N1. The thiobarbituric acid reaction is used to estimate the ratio of chondroitin sulfate 4 and 6 in glycosaminoglycan preparations.
methanol,"Methanol, in combination with n-propanol, is used as a solvent to recover the majority (72–80%) of total hexosamines from papain-digested extraction residues of tissue-derived GAGs by CPC-ellulose chromatography.","Entity: methanol. SMILES: CO. Methanol, in combination with n-propanol, is used as a solvent to recover the majority (72–80%) of total hexosamines from papain-digested extraction residues of tissue-derived GAGs by CPC-ellulose chromatography."
n-propanol,"n-propanol, when used with methanol, is effective in extracting 72–80% of total hexosamines from papain-digested extraction residues of tissue-derived GAGs by CPC-ellulose chromatography.","Entity: n-propanol. SMILES: CCCO. n-propanol, when used with methanol, is effective in extracting 72–80% of total hexosamines from papain-digested extraction residues of tissue-derived GAGs by CPC-ellulose chromatography."
MgCl2,MgCl2 is used as an acid fraction in CPC-ellulose chromatography to recover 17–20% of total hexosamines from papain-digested extraction residues of tissue-derived GAGs.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used as an acid fraction in CPC-ellulose chromatography to recover 17–20% of total hexosamines from papain-digested extraction residues of tissue-derived GAGs.
chondroitin,"In all three tissue fractions analyzed, 80% of the polysaccharides are composed of chondroitin sulfate (CS-4), with smaller amounts of CS-6.","Entity: chondroitin. SMILES: CC(=O)N[C@H]1[C@@H](OC2OC(C(=O)O)=C[C@@H](O)[C@H]2O)[C@@H](O)[C@@H](CO)O[C@H]1O. In all three tissue fractions analyzed, 80% of the polysaccharides are composed of chondroitin sulfate (CS-4), with smaller amounts of CS-6."
sodium chloride,Sodium chloride at 0.3 M concentration is used to elute traces of material from Sepharose subfractions after amino acid composition analysis by chromatography.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride at 0.3 M concentration is used to elute traces of material from Sepharose subfractions after amino acid composition analysis by chromatography.
hydrochloric acid,Hydrochloric acid at 0.06 M and 6 M concentrations is used to elute hexosamines and other material from Sepharose subfractions in amino acid composition studies.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid at 0.06 M and 6 M concentrations is used to elute hexosamines and other material from Sepharose subfractions in amino acid composition studies.
guanidinium chloride,"Guanidinium chloride is used as an extraction reagent for proteins from tissue samples, typically in acetate buffer at pH 5.8 containing 0.2 mM EDTA.","Entity: guanidinium chloride. SMILES: NC(N)=[NH2+].[Cl-]. Guanidinium chloride is used as an extraction reagent for proteins from tissue samples, typically in acetate buffer at pH 5.8 containing 0.2 mM EDTA."
urea,Urea is used as a dialysis buffer (7 M urea in 0.05 M Tris buffer) for protein purification following extraction and chromatography steps.,Entity: urea. SMILES: NC(N)=O. Urea is used as a dialysis buffer (7 M urea in 0.05 M Tris buffer) for protein purification following extraction and chromatography steps.
Ninhydrin,Ninhydrin is used in the ninhydrin method for determining amino nitrogen content in samples.,Entity: Ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is used in the ninhydrin method for determining amino nitrogen content in samples.
calcium,The impulse response function H(t) for bone and other slowly metabolising pools of calcium can be calculated from calcium kinetic data following intravenous injection of a calcium tracer.,Entity: calcium. SMILES: [Ca]. The impulse response function H(t) for bone and other slowly metabolising pools of calcium can be calculated from calcium kinetic data following intravenous injection of a calcium tracer.
calcium,Both calcium and strontium tracers leave the skeleton via resorption (bone destruction) and diminution (ionic substitution) processes.,Entity: calcium. SMILES: [Ca]. Both calcium and strontium tracers leave the skeleton via resorption (bone destruction) and diminution (ionic substitution) processes.
strontium,"Strontium can be used as a tracer to measure the initial entry rates of strontium into the skeleton, providing an alternative to calcium tracers when calcium tracers are impractical.","Entity: strontium. SMILES: [Sr]. Strontium can be used as a tracer to measure the initial entry rates of strontium into the skeleton, providing an alternative to calcium tracers when calcium tracers are impractical."
strontium,"Both calcium and strontium tracers leave the skeleton via two processes: resorption, involving bone destruction, and diminution through ionic substitution.","Entity: strontium. SMILES: [Sr]. Both calcium and strontium tracers leave the skeleton via two processes: resorption, involving bone destruction, and diminution through ionic substitution."
calcium,Calcium tracers are not suitable for practical measurement of initial entry rates into the skeleton due to limitations in their use.,Entity: calcium. SMILES: [Ca]. Calcium tracers are not suitable for practical measurement of initial entry rates into the skeleton due to limitations in their use.
calcium,"The uptake and early release of calcium by bone, as measured by bone-seeking tracers, are indistinguishable from those of strontium when using retention functions HB(t).","Entity: calcium. SMILES: [Ca]. The uptake and early release of calcium by bone, as measured by bone-seeking tracers, are indistinguishable from those of strontium when using retention functions HB(t)."
strontium,"The uptake and early release of strontium by bone, as measured by bone-seeking tracers, are indistinguishable from those of calcium when using retention functions HB(t).","Entity: strontium. SMILES: [Sr]. The uptake and early release of strontium by bone, as measured by bone-seeking tracers, are indistinguishable from those of calcium when using retention functions HB(t)."
calcium,The initial value of the endogenous faecal rate of calcium clearance is determined by measuring the urinary excretion rate of calcium and combining it with the endogenous faecal rate.,Entity: calcium. SMILES: [Ca]. The initial value of the endogenous faecal rate of calcium clearance is determined by measuring the urinary excretion rate of calcium and combining it with the endogenous faecal rate.
calcium,"Measurement errors in specific activity assays for calcium, particularly when urinary calcium excretion is low, lead to increased errors in calculating the accretion rate of calcium and related kinetic parameters.","Entity: calcium. SMILES: [Ca]. Measurement errors in specific activity assays for calcium, particularly when urinary calcium excretion is low, lead to increased errors in calculating the accretion rate of calcium and related kinetic parameters."
calcium,"The coefficient of variation for specific activity measurement of calcium varies with urinary calcium excretion, averaging 25% for excretion <1.5 mmol/day, 10% for 1.5–4.0 mmol/day, and 5% for >4.0 mmol/day.","Entity: calcium. SMILES: [Ca]. The coefficient of variation for specific activity measurement of calcium varies with urinary calcium excretion, averaging 25% for excretion <1.5 mmol/day, 10% for 1.5–4.0 mmol/day, and 5% for >4.0 mmol/day."
strontium,"85Sr is an adequate tracer for bone calcium in most in vivo studies, as the differences in bone flux between 47Ca and 85Sr can be fully accounted for by measurement errors.","Entity: strontium. SMILES: [Sr]. 85Sr is an adequate tracer for bone calcium in most in vivo studies, as the differences in bone flux between 47Ca and 85Sr can be fully accounted for by measurement errors."
calcium,"47Ca is used as a bone-seeking tracer, and its impulse response function can be compared to that of 85Sr in vivo to estimate the contribution of measurement errors to differences in bone flux.","Entity: calcium. SMILES: [Ca]. 47Ca is used as a bone-seeking tracer, and its impulse response function can be compared to that of 85Sr in vivo to estimate the contribution of measurement errors to differences in bone flux."
strontium,Strontium is preferentially excreted by the kidney and absorbed less avidly from the gut compared to calcium in the body.,Entity: strontium. SMILES: [Sr]. Strontium is preferentially excreted by the kidney and absorbed less avidly from the gut compared to calcium in the body.
strontium,"Strontium and calcium are resorbed at similar rates in vivo, and their rates of accretion within measurable limits are also identical.","Entity: strontium. SMILES: [Sr]. Strontium and calcium are resorbed at similar rates in vivo, and their rates of accretion within measurable limits are also identical."
strontium,"The rate of removal of strontium from bone by processes other than resorption, such as solid state diffusion, is similar to that of calcium under the specified conditions.","Entity: strontium. SMILES: [Sr]. The rate of removal of strontium from bone by processes other than resorption, such as solid state diffusion, is similar to that of calcium under the specified conditions."
calcium,"Calcium and strontium are resorbed at similar rates in vivo, and their rates of accretion within measurable limits are also identical.","Entity: calcium. SMILES: [Ca]. Calcium and strontium are resorbed at similar rates in vivo, and their rates of accretion within measurable limits are also identical."
calcium,"The rate of removal of calcium from bone by processes other than resorption, such as solid state diffusion, is similar to that of strontium under the specified conditions.","Entity: calcium. SMILES: [Ca]. The rate of removal of calcium from bone by processes other than resorption, such as solid state diffusion, is similar to that of strontium under the specified conditions."
calcium,"In both normal and osteoporotic subjects, half of calcium accretion occurs in cancellous bone, assuming a normal surface to volume ratio four times higher for cancellous bone than compact bone in normals and nine times higher in osteoporosis.","Entity: calcium. SMILES: [Ca]. In both normal and osteoporotic subjects, half of calcium accretion occurs in cancellous bone, assuming a normal surface to volume ratio four times higher for cancellous bone than compact bone in normals and nine times higher in osteoporosis."
strontium,"The renal discrimination factor between calcium and strontium turnover fraction is used to correct for variations in bone mass composition, such as the difference between 20% cancellous bone in normals and 10% in osteoporotic patients.","Entity: strontium. SMILES: [Sr]. The renal discrimination factor between calcium and strontium turnover fraction is used to correct for variations in bone mass composition, such as the difference between 20% cancellous bone in normals and 10% in osteoporotic patients."
calcium,"In bone tissue, the uptake of trace calcium into the skeleton follows a function HB(t) with dimensions MT⁻¹, where HB(t) represents the mass of trace calcium taken up per unit time and approaches a constant value over time, reflecting the accretion rate of calcium in bone.","Entity: calcium. SMILES: [Ca]. In bone tissue, the uptake of trace calcium into the skeleton follows a function HB(t) with dimensions MT⁻¹, where HB(t) represents the mass of trace calcium taken up per unit time and approaches a constant value over time, reflecting the accretion rate of calcium in bone."
calcium,"Calcium is exchanged between bone surfaces and the extracellular fluid, with apposition and resorption processes affecting bone volume.","Entity: calcium. SMILES: [Ca]. Calcium is exchanged between bone surfaces and the extracellular fluid, with apposition and resorption processes affecting bone volume."
calcium,Apparent differences in rates of calcium uptake by bone in vivo are more likely due to model simplifications than to real differences in tracer uptake.,Entity: calcium. SMILES: [Ca]. Apparent differences in rates of calcium uptake by bone in vivo are more likely due to model simplifications than to real differences in tracer uptake.
strontium,"Strontium and calcium have the same coefficient of diffusion in hydroxyapatite, indicating similar incorporation and residence times within bone.","Entity: strontium. SMILES: [Sr]. Strontium and calcium have the same coefficient of diffusion in hydroxyapatite, indicating similar incorporation and residence times within bone."
strontium,"Once incorporated into bone, strontium has the same mean residence time as calcium, making it an adequate tracer for bone calcium in certain contexts.","Entity: strontium. SMILES: [Sr]. Once incorporated into bone, strontium has the same mean residence time as calcium, making it an adequate tracer for bone calcium in certain contexts."
calcium,Accurate quantification of calcium entry (accretion) rates into fixed bone is important for resolving controversies in the interpretation of human skeletal kinetics.,Entity: calcium. SMILES: [Ca]. Accurate quantification of calcium entry (accretion) rates into fixed bone is important for resolving controversies in the interpretation of human skeletal kinetics.
calcium,"Calcium excretion from the body can be monitored using whole body counting, with the calculation of total body calcium content (θCa(t)) possible for 35 days due to its short half-life of 4.7 days.","Entity: calcium. SMILES: [Ca]. Calcium excretion from the body can be monitored using whole body counting, with the calculation of total body calcium content (θCa(t)) possible for 35 days due to its short half-life of 4.7 days."
strontium,"Strontium retention in the body (βSr) can be measured for much longer periods, up to a year, using whole body counting with a whole body radiation dose of approximately 65 days, owing to its long half-life of 65 days.","Entity: strontium. SMILES: [Sr]. Strontium retention in the body (βSr) can be measured for much longer periods, up to a year, using whole body counting with a whole body radiation dose of approximately 65 days, owing to its long half-life of 65 days."
strontium,"The whole body retention of strontium-90 (ssSr) can be described by a power function, and the exponent 'b' in this function has a coefficient of variation of less than 10% as estimated by regression analysis.","Entity: strontium. SMILES: [Sr]. The whole body retention of strontium-90 (ssSr) can be described by a power function, and the exponent 'b' in this function has a coefficient of variation of less than 10% as estimated by regression analysis."
calcium,Whole body calcium can be estimated from femur densitometry with a coefficient of variation of less than 11%.,Entity: calcium. SMILES: [Ca]. Whole body calcium can be estimated from femur densitometry with a coefficient of variation of less than 11%.
tetracycline,"Tetracycline is used as a labelling technique to measure bone turnover rates in animal studies, such as in dogs and humans.","Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline is used as a labelling technique to measure bone turnover rates in animal studies, such as in dogs and humans."
calcium,Calcium isotopes can be used to systematically study bone turnover rates in skeletal analysis.,Entity: calcium. SMILES: [Ca]. Calcium isotopes can be used to systematically study bone turnover rates in skeletal analysis.
strontium,Strontium isotopes are utilized in bone turnover rate measurements as part of systematic error analysis in skeletal studies.,Entity: strontium. SMILES: [Sr]. Strontium isotopes are utilized in bone turnover rate measurements as part of systematic error analysis in skeletal studies.
calcium,Calcium balance studies involve measuring calcium accretion rates and whole body retention in patients.,Entity: calcium. SMILES: [Ca]. Calcium balance studies involve measuring calcium accretion rates and whole body retention in patients.
strontium,"Strontium is administered intravenously as a tracer in whole body retention studies, with typical doses ranging from 2–5 µCi for 47Ca and ssSr.","Entity: strontium. SMILES: [Sr]. Strontium is administered intravenously as a tracer in whole body retention studies, with typical doses ranging from 2–5 µCi for 47Ca and ssSr."
calcium,"Calcium accretion to bone occurs through two processes: apposition, which involves the laying down of new bone, and augmentation, which is the result of slow exchange of non-surface bone calcium with plasma calcium pools via solid-state diffusion.","Entity: calcium. SMILES: [Ca]. Calcium accretion to bone occurs through two processes: apposition, which involves the laying down of new bone, and augmentation, which is the result of slow exchange of non-surface bone calcium with plasma calcium pools via solid-state diffusion."
calcium,"Total skeletal calcium is used as an input in calculations of bone resorption and apposition rates, and its measurement error is substantially diminished when raised to the power of fl/(l--fl) in the calculation.","Entity: calcium. SMILES: [Ca]. Total skeletal calcium is used as an input in calculations of bone resorption and apposition rates, and its measurement error is substantially diminished when raised to the power of fl/(l--fl) in the calculation."
hydroxyproline,"Urinary hydroxyproline excretion is a measurement used to detect bone resorption, but it may not detect small increases in bone resorption rates.","Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Urinary hydroxyproline excretion is a measurement used to detect bone resorption, but it may not detect small increases in bone resorption rates."
calcium,"Calcium turnover rate in bone can be estimated using deconvolution techniques, which provide an augmentation or diminution rate that is parametric and may distinguish from fluxes into and out of exchangeable pools.","Entity: calcium. SMILES: [Ca]. Calcium turnover rate in bone can be estimated using deconvolution techniques, which provide an augmentation or diminution rate that is parametric and may distinguish from fluxes into and out of exchangeable pools."
radium,"Radium is used as a tracer in bone studies and has a higher avidity for certain sites in hydroxyapatite, leading to higher estimates of accretion and diminution rates compared to calcium and strontium.","Entity: radium. SMILES: [Ra]. Radium is used as a tracer in bone studies and has a higher avidity for certain sites in hydroxyapatite, leading to higher estimates of accretion and diminution rates compared to calcium and strontium."
barium,"Barium is used as a tracer in bone studies and has a higher avidity for certain sites in hydroxyapatite, leading to higher estimates of accretion and diminution rates compared to calcium and strontium.","Entity: barium. SMILES: [Ba]. Barium is used as a tracer in bone studies and has a higher avidity for certain sites in hydroxyapatite, leading to higher estimates of accretion and diminution rates compared to calcium and strontium."
strontium,"Strontium acts as a tracer in bone studies, and its diffusion coefficient in hydroxyapatite is likely higher than that of barium and radium.","Entity: strontium. SMILES: [Sr]. Strontium acts as a tracer in bone studies, and its diffusion coefficient in hydroxyapatite is likely higher than that of barium and radium."
calcium,"Calcium is used as a tracer in bone studies, and its diffusion coefficient in hydroxyapatite is likely higher than that of barium and radium.","Entity: calcium. SMILES: [Ca]. Calcium is used as a tracer in bone studies, and its diffusion coefficient in hydroxyapatite is likely higher than that of barium and radium."
calcium,"In bone, calcium exists in both exchangeable and fixed pools, with the efflux from exchangeable pools described by an early, steeply-falling power function and the more slowly declining efflux from fixed pools having an exponent (fl) similar to the measured value of b.","Entity: calcium. SMILES: [Ca]. In bone, calcium exists in both exchangeable and fixed pools, with the efflux from exchangeable pools described by an early, steeply-falling power function and the more slowly declining efflux from fixed pools having an exponent (fl) similar to the measured value of b."
calcium,"Calcium accretion rate to the skeleton can be measured using impulse analysis, a method that requires fewer a priori assumptions than previous approaches.","Entity: calcium. SMILES: [Ca]. Calcium accretion rate to the skeleton can be measured using impulse analysis, a method that requires fewer a priori assumptions than previous approaches."
calcium,"Calcium in bone is distributed in exchangeable pools located at bone surfaces such as endosteum, periosteum, trabecular surfaces, and the surfaces of Volkmann and Haversian canals, which are in immediate proximity to blood supply.","Entity: calcium. SMILES: [Ca]. Calcium in bone is distributed in exchangeable pools located at bone surfaces such as endosteum, periosteum, trabecular surfaces, and the surfaces of Volkmann and Haversian canals, which are in immediate proximity to blood supply."
calcium,The accretion (addition) rate of calcium to bone occurs primarily through volume-increasing processes such as apposition at bone-forming surfaces by osteoblasts.,Entity: calcium. SMILES: [Ca]. The accretion (addition) rate of calcium to bone occurs primarily through volume-increasing processes such as apposition at bone-forming surfaces by osteoblasts.
calcium,"A portion of calcium uptake in bone occurs via augmentation, involving solid-state diffusion of calcium ions within bone.","Entity: calcium. SMILES: [Ca]. A portion of calcium uptake in bone occurs via augmentation, involving solid-state diffusion of calcium ions within bone."
calcium,High doses of estrogens have been shown to inhibit PTH-induced release of calcium from bones in fetal rats and newborn mice in organ culture.,Entity: calcium. SMILES: [Ca]. High doses of estrogens have been shown to inhibit PTH-induced release of calcium from bones in fetal rats and newborn mice in organ culture.
ethinyl estradiol,Ethinyl estradiol is active at much lower doses than other estrogens and acts via a mechanism similar to that of calcitonin.,Entity: ethinyl estradiol. SMILES: C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C. Ethinyl estradiol is active at much lower doses than other estrogens and acts via a mechanism similar to that of calcitonin.
phosphorus,"In egg-laying birds, estrogens stimulate the formation of medullary bone, which stores calcium and phosphorus necessary for shell mineralization.","Entity: phosphorus. SMILES: [P]. In egg-laying birds, estrogens stimulate the formation of medullary bone, which stores calcium and phosphorus necessary for shell mineralization."
calcium,"In egg-laying birds, estrogens stimulate the formation of medullary bone, which stores calcium and phosphorus necessary for shell mineralization.","Entity: calcium. SMILES: [Ca]. In egg-laying birds, estrogens stimulate the formation of medullary bone, which stores calcium and phosphorus necessary for shell mineralization."
calcium,Calcium released from bones into culture medium can be quantified as counts per minute per 0.1 ml of medium or as a percentage of bone-45Ca released.,Entity: calcium. SMILES: [Ca]. Calcium released from bones into culture medium can be quantified as counts per minute per 0.1 ml of medium or as a percentage of bone-45Ca released.
hydrochloric acid,Hydrochloric acid is used to dissolve ashed bone samples for radioactivity determination in bone experiments.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to dissolve ashed bone samples for radioactivity determination in bone experiments.
calcium,Calcium can be labeled with 45Ca and administered intravenously to pregnant rats at a dose of 1.0 µCi per gram body weight on the 17th day of gestation for experimental studies.,Entity: calcium. SMILES: [Ca]. Calcium can be labeled with 45Ca and administered intravenously to pregnant rats at a dose of 1.0 µCi per gram body weight on the 17th day of gestation for experimental studies.
fluorapatite,Fluorapatite has a shorter c-axis unit cell parameter compared to hydroxyapatite (+0.009 Å) and a longer a-axis unit cell parameter than hydroxyapatite (-0.048 Å).,Entity: fluorapatite. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[F-]. Fluorapatite has a shorter c-axis unit cell parameter compared to hydroxyapatite (+0.009 Å) and a longer a-axis unit cell parameter than hydroxyapatite (-0.048 Å).
fluorapatite,"Fluorapatite is a calcium phosphate mineral that can undergo isomorphous substitution, such as the replacement of hydroxyl ions with fluoride ions.","Entity: fluorapatite. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[F-]. Fluorapatite is a calcium phosphate mineral that can undergo isomorphous substitution, such as the replacement of hydroxyl ions with fluoride ions."
EDTA,"EDTA is used as a decalcification agent in Visking tubing at 5% wt/vol, pH 7.4, for 3 days at 4°C to remove calcium from biological materials.","Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used as a decalcification agent in Visking tubing at 5% wt/vol, pH 7.4, for 3 days at 4°C to remove calcium from biological materials."
CaC12,CaC12 is used as a 2 M solution to solubilize organic material from Visking sac at 4°C for 2 days during protein purification.,Entity: CaC12. SMILES: [Ca+2].[Cl-].[Cl-]. CaC12 is used as a 2 M solution to solubilize organic material from Visking sac at 4°C for 2 days during protein purification.
ethanol,Ethanol at 80% vol/vol is used to precipitate protein digestion products and to recover the final product by ether drying in protein purification protocols.,Entity: ethanol. SMILES: CCO. Ethanol at 80% vol/vol is used to precipitate protein digestion products and to recover the final product by ether drying in protein purification protocols.
hexuronic acid,Hexuronic acid constitutes 5% of the final product extracted from dental calculus and is present as a major component in the alcian blue positive bands observed in cellulose acetate electrophoresis.,Entity: hexuronic acid. SMILES: O=C(O)C1OC(O)C(O)C(O)C1O. Hexuronic acid constitutes 5% of the final product extracted from dental calculus and is present as a major component in the alcian blue positive bands observed in cellulose acetate electrophoresis.
calcium chloride,The inclusion of a 2 M calcium chloride extraction step increases the yield of organic material extracted from powdered dental calculus from 8% to 16% by weight.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. The inclusion of a 2 M calcium chloride extraction step increases the yield of organic material extracted from powdered dental calculus from 8% to 16% by weight.
calcium acetate,Calcium acetate at 0.2 M and pH 7.2 is used as a buffer for cellulose acetate electrophoresis of anionic polysaccharides.,Entity: calcium acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Ca+2]. Calcium acetate at 0.2 M and pH 7.2 is used as a buffer for cellulose acetate electrophoresis of anionic polysaccharides.
acetic acid,Acetic acid at 1% (vol/vol) is used for washing to remove residual stain after staining with alcian blue in cellulose acetate electrophoresis.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid at 1% (vol/vol) is used for washing to remove residual stain after staining with alcian blue in cellulose acetate electrophoresis.
sodium acetate,Sodium acetate at 0.1 M and pH 4.0 is used as a buffer in hyaluronidase digestion assays to assess the susceptibility of polysaccharides to hyaluronidase digestion.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate at 0.1 M and pH 4.0 is used as a buffer in hyaluronidase digestion assays to assess the susceptibility of polysaccharides to hyaluronidase digestion.
alcian blue,Alcian blue at 0.5% (wt/vol) is used to stain separated components in cellulose acetate electrophoresis.,Entity: alcian blue. SMILES: CN(C)C(SCc1ccc2c(c1)C1=NC2=NC2=NC(=NC3[N-]C(N=c4[n-]c(c5ccc(CSC(N(C)C)=[N+](C)C)cc45)=N1)c1ccc(CSC(N(C)C)=[N+](C)C)cc13)c1cc(CSC(N(C)C)=[N+](C)C)ccc12)=[N+](C)C.[Cl-].[Cl-].[Cl-].[Cl-].[Cu+2]. Alcian blue at 0.5% (wt/vol) is used to stain separated components in cellulose acetate electrophoresis.
cetylpyridinium chloride,Cetylpyridinium chloride is used in CPC-cellulose columns for separating anionic polysaccharides by differential solubility.,Entity: cetylpyridinium chloride. SMILES: CCCCCCCCCCCCCCCC[n+]1ccccc1.[Cl-]. Cetylpyridinium chloride is used in CPC-cellulose columns for separating anionic polysaccharides by differential solubility.
hexuronic acid,Hexuronic acid can be quantitatively determined using the carbazole-tetraborate method.,Entity: hexuronic acid. SMILES: O=C(O)C1OC(O)C(O)C(O)C1O. Hexuronic acid can be quantitatively determined using the carbazole-tetraborate method.
dimethyl adipimidate,Dimethyl adipimidate is used as a cross-linking agent to study the monomer-dimer equilibrium and to induce protein complexes in the alpha-subunit of human hemoglobin.,Entity: dimethyl adipimidate. SMILES: COC(=N)CCCCC(=N)OC. Dimethyl adipimidate is used as a cross-linking agent to study the monomer-dimer equilibrium and to induce protein complexes in the alpha-subunit of human hemoglobin.
haptoglobin,Haptoglobin forms a stable complex with the dimer fraction of cross-linked human hemoglobin alpha-subunit.,Entity: haptoglobin. Haptoglobin forms a stable complex with the dimer fraction of cross-linked human hemoglobin alpha-subunit.
haptoglobin,"Haptoglobin binds two human hemoglobin alpha-subunits per molecule, as shown by gel filtration in an alpha-subunit-containing medium.","Entity: haptoglobin. Haptoglobin binds two human hemoglobin alpha-subunits per molecule, as shown by gel filtration in an alpha-subunit-containing medium."
methanol,"Methanol is used as a cold solvent to extract carotenoids from biological material, as demonstrated in the extraction of 16.3 ppm dry weight of carotenoids from Arthrobcscber cultures.","Entity: methanol. SMILES: CO. Methanol is used as a cold solvent to extract carotenoids from biological material, as demonstrated in the extraction of 16.3 ppm dry weight of carotenoids from Arthrobcscber cultures."
Echinenone,"Echinenone contains a keto group whose electronic absorption spectrum in visible light contributes approximately 690 nm (main band), consistent with a 6-keto assignment.","Entity: Echinenone. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)CCC2(C)C)C(C)(C)CCC1. Echinenone contains a keto group whose electronic absorption spectrum in visible light contributes approximately 690 nm (main band), consistent with a 6-keto assignment."
Lycopene,The 144–69 ions in the mass spectra of water- and hydride-reduced carotenoids are consistent with a lycopene-type end group.,Entity: Lycopene. SMILES: CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C. The 144–69 ions in the mass spectra of water- and hydride-reduced carotenoids are consistent with a lycopene-type end group.
lipid A,"Lipid A, a component of Gram-negative bacterial endotoxins, cannot be detected in the components extracted from Gram-positive bacteria or Gram-negative bacteria that induce type II interferon.","Entity: lipid A. SMILES: CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)O[C@@H]1[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H](OC[C@H]2O[C@H](OP(=O)(O)O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]2O)O[C@H](CO)[C@H]1OP(=O)(O)O. Lipid A, a component of Gram-negative bacterial endotoxins, cannot be detected in the components extracted from Gram-positive bacteria or Gram-negative bacteria that induce type II interferon."
Methylmalonyl-CoA,"Methylmalonyl-CoA competitively inhibits human liver fatty acid synthetase with respect to malonyl-CoA, with a Ki of 8.4 µM.","Entity: Methylmalonyl-CoA. SMILES: CC(C(=O)O)C(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Methylmalonyl-CoA competitively inhibits human liver fatty acid synthetase with respect to malonyl-CoA, with a Ki of 8.4 µM."
propionyl-CoA,Propionyl-CoA serves as a better primer for fatty acid synthesis than acetyl-CoA in the presence of [14C]malonyl-CoA and NADPH.,Entity: propionyl-CoA. SMILES: CCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Propionyl-CoA serves as a better primer for fatty acid synthesis than acetyl-CoA in the presence of [14C]malonyl-CoA and NADPH.
cetyltrimethylammonium bromide,Cetyltrimethylammonium bromide (CTAB) is a detergent used to perturb protein structure and induce difference spectra for tryptophan and tyrosine residues.,Entity: cetyltrimethylammonium bromide. SMILES: CCCCCCCCCCCCCCCC[N+](C)(C)C.[Br-]. Cetyltrimethylammonium bromide (CTAB) is a detergent used to perturb protein structure and induce difference spectra for tryptophan and tyrosine residues.
cetyltrimethylammonium bromide,"At low concentrations, cetyltrimethylammonium bromide (CTAB) induces difference spectra with delta epsilonM values of 1300 at 292 nm for Ac-Trp-OEt and 400 at 287 nm for Ac-Tyr-OEt.","Entity: cetyltrimethylammonium bromide. SMILES: CCCCCCCCCCCCCCCC[N+](C)(C)C.[Br-]. At low concentrations, cetyltrimethylammonium bromide (CTAB) induces difference spectra with delta epsilonM values of 1300 at 292 nm for Ac-Trp-OEt and 400 at 287 nm for Ac-Tyr-OEt."
cetyltrimethylammonium bromide,"Cetyltrimethylammonium bromide (CTAB) causes a 60% loss in ellipticity at the tested concentration for tropomyosin, indicating high sensitivity to the detergent.","Entity: cetyltrimethylammonium bromide. SMILES: CCCCCCCCCCCCCCCC[N+](C)(C)C.[Br-]. Cetyltrimethylammonium bromide (CTAB) causes a 60% loss in ellipticity at the tested concentration for tropomyosin, indicating high sensitivity to the detergent."
tyrosine,"In tropomyosin and troponin C, all tyrosine residues are accessible to cetyltrimethylammonium bromide (CTAB) as shown by difference spectroscopy.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. In tropomyosin and troponin C, all tyrosine residues are accessible to cetyltrimethylammonium bromide (CTAB) as shown by difference spectroscopy."
tyrosine,"In troponin I, both tyrosine residues are fully exposed to cetyltrimethylammonium bromide (CTAB), as indicated by difference spectroscopy.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. In troponin I, both tyrosine residues are fully exposed to cetyltrimethylammonium bromide (CTAB), as indicated by difference spectroscopy."
NaF,"NaF causes a sevenfold increase in adenylate cyclase activity in liver preparations, but the degree of stimulation is reduced in cholera toxin-activated enzyme compared to control.","Entity: NaF. SMILES: [F-].[Na+]. NaF causes a sevenfold increase in adenylate cyclase activity in liver preparations, but the degree of stimulation is reduced in cholera toxin-activated enzyme compared to control."
epinephrine,"Epinephrine stimulates adenylate cyclase activity in liver preparations, but only in the presence of 10 mM GTP and is not enhanced by cholera toxin.","Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. Epinephrine stimulates adenylate cyclase activity in liver preparations, but only in the presence of 10 mM GTP and is not enhanced by cholera toxin."
glucagon,"Glucagon stimulates adenylate cyclase activity in liver preparations, but the degree of stimulation is reduced in cholera toxin-activated enzyme compared to control.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon stimulates adenylate cyclase activity in liver preparations, but the degree of stimulation is reduced in cholera toxin-activated enzyme compared to control."
glucagon,"Glucagon stimulates adenylate cyclase activity in liver plasma membranes, causing a sevenfold increase in activity in both normal and cholera-toxin-treated animal preparations.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon stimulates adenylate cyclase activity in liver plasma membranes, causing a sevenfold increase in activity in both normal and cholera-toxin-treated animal preparations."
sodium fluoride,"Sodium fluoride stimulates adenylate cyclase activity in liver plasma membranes, causing a sevenfold increase in activity in both normal and cholera-toxin-treated animal preparations.","Entity: sodium fluoride. SMILES: [F-].[Na+]. Sodium fluoride stimulates adenylate cyclase activity in liver plasma membranes, causing a sevenfold increase in activity in both normal and cholera-toxin-treated animal preparations."
epinephrine,Epinephrine does not stimulate adenylate cyclase activity in liver plasma membranes.,Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. Epinephrine does not stimulate adenylate cyclase activity in liver plasma membranes.
GTP,GTP increases basal adenylate cyclase activity twofold and toxin-activated adenylate cyclase activity by the same fold in several tissues.,Entity: GTP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. GTP increases basal adenylate cyclase activity twofold and toxin-activated adenylate cyclase activity by the same fold in several tissues.
GTP,"In the presence of GTP, glucagon becomes the most potent activator of both control and toxin-treated adenylate cyclase enzymes.","Entity: GTP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. In the presence of GTP, glucagon becomes the most potent activator of both control and toxin-treated adenylate cyclase enzymes."
glucagon,"Glucagon is a potent activator of adenylate cyclase, becoming the most potent activator in the presence of GTP.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon is a potent activator of adenylate cyclase, becoming the most potent activator in the presence of GTP."
epinephrine,Epinephrine stimulates adenylate cyclase activity significantly in the presence of GTP.,Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. Epinephrine stimulates adenylate cyclase activity significantly in the presence of GTP.
NaF,NaF activates adenylate cyclase by increasing its V (enzyme activity).,Entity: NaF. SMILES: [F-].[Na+]. NaF activates adenylate cyclase by increasing its V (enzyme activity).
ATP,"The mean apparent Km for ATP-Mg in adenylate cyclase assays is 0.63 ± 0.02 mM, with no deviation from linearity of either basal or stimulated activity over the concentrations of ATP used.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. The mean apparent Km for ATP-Mg in adenylate cyclase assays is 0.63 ± 0.02 mM, with no deviation from linearity of either basal or stimulated activity over the concentrations of ATP used."
NaF,"NaF inhibits cholera-toxin-activated adenylate cyclase activity, and this inhibition is not due to the formation of Mg2+ ion complexes.","Entity: NaF. SMILES: [F-].[Na+]. NaF inhibits cholera-toxin-activated adenylate cyclase activity, and this inhibition is not due to the formation of Mg2+ ion complexes."
glucagon,"Glucagon inhibits cholera-toxin-activated adenylate cyclase activity, and this inhibition is not due to the formation of Mg2+ ion complexes.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon inhibits cholera-toxin-activated adenylate cyclase activity, and this inhibition is not due to the formation of Mg2+ ion complexes."
ATP,"ATP binds to adenylate cyclase in the presence of Mg2+, forming a complex whose affinity is not altered by cholera toxin.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP binds to adenylate cyclase in the presence of Mg2+, forming a complex whose affinity is not altered by cholera toxin."
GTP,"GTP stimulates adenylate cyclase activity, which remains constant even at high Mg2+ concentrations (up to 50 mM).","Entity: GTP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. GTP stimulates adenylate cyclase activity, which remains constant even at high Mg2+ concentrations (up to 50 mM)."
ATP,The concentration of ATP-Mg is 0.5 mM in the described adenylate cyclase activity assays.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. The concentration of ATP-Mg is 0.5 mM in the described adenylate cyclase activity assays.
NaF,"NaF at 1 mM stimulates adenylate cyclase activity, which is maximal at 2.5–5 mM Mg2+ and inhibited at concentrations above 10 mM Mg2+.","Entity: NaF. SMILES: [F-].[Na+]. NaF at 1 mM stimulates adenylate cyclase activity, which is maximal at 2.5–5 mM Mg2+ and inhibited at concentrations above 10 mM Mg2+."
glucagon,"Glucagon at 1 µM stimulates adenylate cyclase activity, which is maximal at 2.5–5 mM Mg2+ and inhibited at concentrations above 10 mM Mg2+.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon at 1 µM stimulates adenylate cyclase activity, which is maximal at 2.5–5 mM Mg2+ and inhibited at concentrations above 10 mM Mg2+."
GTP,"GTP at 10⁻⁵ M stimulates adenylate cyclase activity, which is maximal at 5–10 mM Mg2+ and remains constant as Mg2+ is raised to 50 mM.","Entity: GTP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. GTP at 10⁻⁵ M stimulates adenylate cyclase activity, which is maximal at 5–10 mM Mg2+ and remains constant as Mg2+ is raised to 50 mM."
NaF,NaF inhibits ATPase activity and does not affect the adenylate cyclase activity in the presence or absence of an ATP regeneration system.,Entity: NaF. SMILES: [F-].[Na+]. NaF inhibits ATPase activity and does not affect the adenylate cyclase activity in the presence or absence of an ATP regeneration system.
glucagon,"Glucagon stimulates liver plasma membrane adenylate cyclase activity, but in the absence of an ATP regeneration system, the activity becomes linear only for 2 minutes at 37°C when low ATP concentrations are used as substrate.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon stimulates liver plasma membrane adenylate cyclase activity, but in the absence of an ATP regeneration system, the activity becomes linear only for 2 minutes at 37°C when low ATP concentrations are used as substrate."
ATP,"Low ATP concentrations as substrate for liver plasma membrane adenylate cyclase show only 1 minute of linear activity in the absence of an ATP regeneration system, but at least 4 minutes of linear activity in its presence.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Low ATP concentrations as substrate for liver plasma membrane adenylate cyclase show only 1 minute of linear activity in the absence of an ATP regeneration system, but at least 4 minutes of linear activity in its presence."
ATP,"ATP is used as a substrate at 1 mM concentration in the adenylate cyclase enzyme assay, with a regeneration system involving phosphoenolpyruvate and pyruvate kinase.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP is used as a substrate at 1 mM concentration in the adenylate cyclase enzyme assay, with a regeneration system involving phosphoenolpyruvate and pyruvate kinase."
dithiothreitol,Dithiothreitol is included at 1 mM concentration in the adenylate cyclase enzyme assay reaction mixture to maintain reducing conditions.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is included at 1 mM concentration in the adenylate cyclase enzyme assay reaction mixture to maintain reducing conditions.
phosphoenolpyruvate,Phosphoenolpyruvate is used at 5.4 mM concentration as part of the ATP regeneration system in the adenylate cyclase enzyme assay.,Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate is used at 5.4 mM concentration as part of the ATP regeneration system in the adenylate cyclase enzyme assay.
GTP,"GTP increases both basal and hormone-stimulated adenylate cyclase activity in liver plasma membranes, with a twofold increase in both activities.","Entity: GTP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. GTP increases both basal and hormone-stimulated adenylate cyclase activity in liver plasma membranes, with a twofold increase in both activities."
GTP,"The effect of GTP on adenylate cyclase is distinct from that of guanylyl imidodiphosphate, as GTP and guanylyl imidodiphosphate have different effects on the enzyme.","Entity: GTP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. The effect of GTP on adenylate cyclase is distinct from that of guanylyl imidodiphosphate, as GTP and guanylyl imidodiphosphate have different effects on the enzyme."
GTP,"GTP acts as an amplifier of adenylate cyclase activity, increasing all activities except those stimulated by NaF.","Entity: GTP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. GTP acts as an amplifier of adenylate cyclase activity, increasing all activities except those stimulated by NaF."
NaF,"NaF increases basal adenylate cyclase activity to a much higher level than cholera toxin alone, and this stimulation is unaffected by cholera toxin.","Entity: NaF. SMILES: [F-].[Na+]. NaF increases basal adenylate cyclase activity to a much higher level than cholera toxin alone, and this stimulation is unaffected by cholera toxin."
glucagon,"Glucagon increases basal adenylate cyclase activity to a much higher level than cholera toxin alone, and this stimulation is unaffected by cholera toxin.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon increases basal adenylate cyclase activity to a much higher level than cholera toxin alone, and this stimulation is unaffected by cholera toxin."
guanylyl imidodiphosphate,Guanylyl imidodiphosphate competes with cholera toxin for activation of liver adenylate cyclase.,Entity: guanylyl imidodiphosphate. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)NP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. Guanylyl imidodiphosphate competes with cholera toxin for activation of liver adenylate cyclase.
glucagon,"Glucagon is a potent activator of mouse liver adenylate cyclase, maintaining its activity as the most potent activator even when the enzyme is stimulated by cholera toxin.","Entity: glucagon. Glucagon is a potent activator of mouse liver adenylate cyclase, maintaining its activity as the most potent activator even when the enzyme is stimulated by cholera toxin."
mercaptoethanol,"Mercaptoethanol is used as a stabilizing agent in enzymatic assays, such as for measuring PNMT activity, at a concentration of 1 x 10^-1 M.","Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol is used as a stabilizing agent in enzymatic assays, such as for measuring PNMT activity, at a concentration of 1 x 10^-1 M."
octopamine,Octopamine is produced from p-tyramine by the enzyme DPH in a coupled enzymatic assay.,Entity: octopamine. SMILES: NCC(O)c1ccc(O)cc1. Octopamine is produced from p-tyramine by the enzyme DPH in a coupled enzymatic assay.
S-adenosylmethionine,S-adenosylmethionine (SAM) serves as a methyl donor in the enzymatic conversion of octopamine to N-methyl-4-hydroxyphenylethanolamine (synephrine) in the presence of PNMT.,Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine (SAM) serves as a methyl donor in the enzymatic conversion of octopamine to N-methyl-4-hydroxyphenylethanolamine (synephrine) in the presence of PNMT.
N-methyl-4-hydroxyphenylethanolamine,N-methyl-4-hydroxyphenylethanolamine (synephrine) is the end product of the enzymatic reaction in which octopamine is converted to it using S-adenosylmethionine and PNMT.,Entity: N-methyl-4-hydroxyphenylethanolamine. SMILES: CNCC(O)c1ccc(O)cc1. N-methyl-4-hydroxyphenylethanolamine (synephrine) is the end product of the enzymatic reaction in which octopamine is converted to it using S-adenosylmethionine and PNMT.
N-ethylmaleimide,N-ethylmaleimide is included at a concentration of 6 M in the assay mixture for the enzymatic reaction.,Entity: N-ethylmaleimide. SMILES: CCN1C(=O)C=CC1=O. N-ethylmaleimide is included at a concentration of 6 M in the assay mixture for the enzymatic reaction.
mercaptoethanol,Mercaptoethanol at a concentration of 0.1 M is used to terminate the enzymatic reaction in the assay.,Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol at a concentration of 0.1 M is used to terminate the enzymatic reaction in the assay.
sodium fumarate,Sodium fumarate is used at a concentration of 0.5 M as a component of the reaction mixture in the enzyme assay.,Entity: sodium fumarate. SMILES: O=C([O-])/C=C/C(=O)[O-].[Na+].[Na+]. Sodium fumarate is used at a concentration of 0.5 M as a component of the reaction mixture in the enzyme assay.
ascorbic acid,Ascorbic acid is used as a substrate at a concentration of 0.05 M in a p-hydroxylation enzyme assay.,Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid is used as a substrate at a concentration of 0.05 M in a p-hydroxylation enzyme assay.
Octopamine,Octopamine is present and heterogeneously distributed in regions of the rat brain.,Entity: Octopamine. SMILES: NCC(O)c1ccc(O)cc1. Octopamine is present and heterogeneously distributed in regions of the rat brain.
N-ethylmaleimide,The presence of N-ethylmaleimide allows a linear response in BPH activity assays at hornogenate dilutions ranging from 18-fold to 100-fold and Cu2+ concentrations of 40 and 800 pM.,Entity: N-ethylmaleimide. SMILES: CCN1C(=O)C=CC1=O. The presence of N-ethylmaleimide allows a linear response in BPH activity assays at hornogenate dilutions ranging from 18-fold to 100-fold and Cu2+ concentrations of 40 and 800 pM.
N-ethylmaleimide,"N-ethylmaleimide is an inhibitor of the enzyme PNMT, and its inhibitory effect can be neutralized by mercaptoethanol at a concentration of 3 x 10^-6 M.","Entity: N-ethylmaleimide. SMILES: CCN1C(=O)C=CC1=O. N-ethylmaleimide is an inhibitor of the enzyme PNMT, and its inhibitory effect can be neutralized by mercaptoethanol at a concentration of 3 x 10^-6 M."
mercaptoethanol,Mercaptoethanol at a concentration of 3 x 10^-6 M can neutralize the inhibitory effects of N-ethylmaleimide on PNMT activity.,Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol at a concentration of 3 x 10^-6 M can neutralize the inhibitory effects of N-ethylmaleimide on PNMT activity.
sucrose,Sucrose is used as a 20% solution in the sample buffer for preparative polyacrylamide gel electrophoresis.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used as a 20% solution in the sample buffer for preparative polyacrylamide gel electrophoresis.
glycine,Glycine is used as a component of the electrode buffer at pH 8.9 in a hybrid PAGE system for studying microheterogeneity.,Entity: glycine. SMILES: NCC(=O)O. Glycine is used as a component of the electrode buffer at pH 8.9 in a hybrid PAGE system for studying microheterogeneity.
haptoglobin,"Porcine haptoglobin is microheterogeneous, consisting of more than 14 components that can be partially resolved by gel filtration.","Entity: haptoglobin. Porcine haptoglobin is microheterogeneous, consisting of more than 14 components that can be partially resolved by gel filtration."
vasotocin,Vasotocin does not produce parallel dose response curves with crude stalk median eminence extract in a specific AVP antibody radioimmunoassay assay.,Entity: vasotocin. SMILES: CCC(C)C1NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC1=O. Vasotocin does not produce parallel dose response curves with crude stalk median eminence extract in a specific AVP antibody radioimmunoassay assay.
pressinoic acid,Pressinoic acid does not produce parallel dose response curves with crude stalk median eminence extract in a specific AVP antibody radioimmunoassay assay.,Entity: pressinoic acid. SMILES: NC(=O)CC[C@@H]1NC(=O)C(Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)O)NC(=O)[C@H](CC(N)=O)NC1=O. Pressinoic acid does not produce parallel dose response curves with crude stalk median eminence extract in a specific AVP antibody radioimmunoassay assay.
oxytocin,Oxytocin does not produce parallel dose response curves with crude stalk median eminence extract in a specific AVP antibody radioimmunoassay assay.,Entity: oxytocin. SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O. Oxytocin does not produce parallel dose response curves with crude stalk median eminence extract in a specific AVP antibody radioimmunoassay assay.
mercury,"In adult female and juvenile ranch mink, dietary intake of 0.44 ppm total mercury over 145 days resulted in tissue mercury concentrations below levels associated with toxicity, with no clinical or pathological evidence of intoxication.","Entity: mercury. SMILES: [Hg]. In adult female and juvenile ranch mink, dietary intake of 0.44 ppm total mercury over 145 days resulted in tissue mercury concentrations below levels associated with toxicity, with no clinical or pathological evidence of intoxication."
mercury,Mercury toxicity in adult female mink is associated with clinical intoxication when dietary mercury content is between 1.8 and 15.0 ppm.,Entity: mercury. SMILES: [Hg]. Mercury toxicity in adult female mink is associated with clinical intoxication when dietary mercury content is between 1.8 and 15.0 ppm.
methyl mercury chloride,"Methyl mercury chloride is used as a dietary source of mercury in mink studies, with toxicity in mink directly related to the mercury content of the diet.","Entity: methyl mercury chloride. SMILES: C[Hg]Cl. Methyl mercury chloride is used as a dietary source of mercury in mink studies, with toxicity in mink directly related to the mercury content of the diet."
glucagon,Glucagon secretion is stimulated by acute trauma and is associated with increased hyperglycemia and inhibition of insulin secretion.,Entity: glucagon. Glucagon secretion is stimulated by acute trauma and is associated with increased hyperglycemia and inhibition of insulin secretion.
Aflatoxin B1,Aflatoxin B1 was detected at a level of 50 ppb in a sample of alfalfa brome hay.,Entity: Aflatoxin B1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2. Aflatoxin B1 was detected at a level of 50 ppb in a sample of alfalfa brome hay.
Ochratoxin A,Ochratoxin A was detected in six samples of wheat at levels between 30 and 6000 ppb and in one sample of hay at a level of 30 ppb.,Entity: Ochratoxin A. SMILES: C[C@@H]1Cc2c(Cl)cc(C(=O)N[C@@H](Cc3ccccc3)C(=O)O)c(O)c2C(=O)O1. Ochratoxin A was detected in six samples of wheat at levels between 30 and 6000 ppb and in one sample of hay at a level of 30 ppb.
mercury,"Mean mercury levels in Canadian animal liver and kidney samples (winter 1973-1974) were 0.001 ppm in pork liver, 0.007 ppm in bovine liver, 0.008 ppm in bovine kidney, 0.001 ppm in pork kidney, and 0.003 ppm in poultry liver, all below the Canadian administrative tolerance of 0.5 ppm.","Entity: mercury. SMILES: [Hg]. Mean mercury levels in Canadian animal liver and kidney samples (winter 1973-1974) were 0.001 ppm in pork liver, 0.007 ppm in bovine liver, 0.008 ppm in bovine kidney, 0.001 ppm in pork kidney, and 0.003 ppm in poultry liver, all below the Canadian administrative tolerance of 0.5 ppm."
glucagon,"Glucagon significantly increases net hepatic production of acetoacetate in alloxanized sheep, raising it from -0.54 ± 0.08 to 0.46 ± 0.07 g/hr after two hours of intraportal infusion at 90 µg/hr.","Entity: glucagon. Glucagon significantly increases net hepatic production of acetoacetate in alloxanized sheep, raising it from -0.54 ± 0.08 to 0.46 ± 0.07 g/hr after two hours of intraportal infusion at 90 µg/hr."
glucagon,"Glucagon increases lipolysis in alloxanized sheep, but this effect is readily suppressed by hyperinsulinemia.","Entity: glucagon. Glucagon increases lipolysis in alloxanized sheep, but this effect is readily suppressed by hyperinsulinemia."
Mg,The optimal concentration of Mg for the enzymatic reaction is 2.5 mM.,Entity: Mg. SMILES: [Mg]. The optimal concentration of Mg for the enzymatic reaction is 2.5 mM.
K,The optimal concentration of K is 75 mM for the enzymatic reaction.,Entity: K. SMILES: [K]. The optimal concentration of K is 75 mM for the enzymatic reaction.
spermine,"Spermine enhances enzymatic activity in the rye embryo and wheat germ systems, as observed in biochemical assays.","Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine enhances enzymatic activity in the rye embryo and wheat germ systems, as observed in biochemical assays."
KC1,KC1 is used as a component of buffer A at a concentration of 120 mM for protein extraction from embryos.,Entity: KC1. SMILES: [Cl-].[K+]. KC1 is used as a component of buffer A at a concentration of 120 mM for protein extraction from embryos.
mercaptoethanol,Mercaptoethanol is included in buffer A at a concentration of 6 mM to maintain a reduced environment during protein extraction from embryos.,Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol is included in buffer A at a concentration of 6 mM to maintain a reduced environment during protein extraction from embryos.
magnesium acetate,Magnesium acetate is used in buffer A at a concentration of 2 mM as a component for protein extraction from embryos.,Entity: magnesium acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Mg+2]. Magnesium acetate is used in buffer A at a concentration of 2 mM as a component for protein extraction from embryos.
cyclohexane,Cyclohexane is used as a component of a 1:2 (v/v) mixture with carbon tetrachloride for separating rye embryos from endosperm fragments.,Entity: cyclohexane. SMILES: C1CCCCC1. Cyclohexane is used as a component of a 1:2 (v/v) mixture with carbon tetrachloride for separating rye embryos from endosperm fragments.
carbon tetrachloride,Carbon tetrachloride is used as a component of a 1:2 (v/v) mixture with cyclohexane for separating rye embryos from endosperm fragments.,Entity: carbon tetrachloride. SMILES: ClC(Cl)(Cl)Cl. Carbon tetrachloride is used as a component of a 1:2 (v/v) mixture with cyclohexane for separating rye embryos from endosperm fragments.
spermine,"Spermine at concentrations between 60 and 80 pM enhances the incorporation activity by increasing the reaction rate, rather than prolonging incorporation time.","Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine at concentrations between 60 and 80 pM enhances the incorporation activity by increasing the reaction rate, rather than prolonging incorporation time."
creatine phosphate,Creatine phosphate is used at 8 mM concentration with 50 µg/ml creatine kinase in amino acid incorporation assays to provide phosphate for energy transfer.,Entity: creatine phosphate. SMILES: CN(CC(=O)O)C(=N)N.O=P(O)(O)O. Creatine phosphate is used at 8 mM concentration with 50 µg/ml creatine kinase in amino acid incorporation assays to provide phosphate for energy transfer.
trichloroacetic acid,"Trichloroacetic acid is used to precipitate proteins and other insoluble material from RNA in amino acid incorporation assays, allowing for the determination of hot radioactivity.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to precipitate proteins and other insoluble material from RNA in amino acid incorporation assays, allowing for the determination of hot radioactivity."
leucine,"Leucine is incorporated into RNA in amino acid incorporation assays, with [4C]leucine at 0.1 pCi (50.6 Ci/mol) or [3H]leucine at 2 pCi (208 Ci/mol) used to label the product.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine is incorporated into RNA in amino acid incorporation assays, with [4C]leucine at 0.1 pCi (50.6 Ci/mol) or [3H]leucine at 2 pCi (208 Ci/mol) used to label the product."
magnesium acetate,Magnesium acetate is included at 2.5 mM concentration in amino acid incorporation reactions to serve as a cofactor for RNA-dependent RNA polymerase.,Entity: magnesium acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Mg+2]. Magnesium acetate is included at 2.5 mM concentration in amino acid incorporation reactions to serve as a cofactor for RNA-dependent RNA polymerase.
dithiothreitol,Dithiothreitol is used at 2 mM concentration in amino acid incorporation assays to maintain reducing conditions and protect RNA from degradation.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used at 2 mM concentration in amino acid incorporation assays to maintain reducing conditions and protect RNA from degradation.
creatine phosphate,Creatine phosphate is included at 8 mM concentration in the presence of 1 mM ATP and 2.5 mM Mg2+ for 65 mM K+ to reduce endogenous enzymatic activity in rye embryo extracts.,Entity: creatine phosphate. SMILES: CN(CC(=O)O)C(=N)N.O=P(O)(O)O. Creatine phosphate is included at 8 mM concentration in the presence of 1 mM ATP and 2.5 mM Mg2+ for 65 mM K+ to reduce endogenous enzymatic activity in rye embryo extracts.
adenosine triphosphate,Adenosine triphosphate (ATP) is included at 1 mM concentration in the presence of 2.5 mM Mg2+ and 65 mM K+ for 65 mM K+ to reduce endogenous enzymatic activity in rye embryo extracts.,Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine triphosphate (ATP) is included at 1 mM concentration in the presence of 2.5 mM Mg2+ and 65 mM K+ for 65 mM K+ to reduce endogenous enzymatic activity in rye embryo extracts.
2-mercaptoethanol,2-mercaptoethanol is used at 4 mM concentration in buffer B for homogenizing rye embryo extracts to enhance their enzymatic activity.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is used at 4 mM concentration in buffer B for homogenizing rye embryo extracts to enhance their enzymatic activity.
potassium chloride,Potassium chloride is included at 87.5 mM concentration in buffer B for homogenizing rye embryo extracts to increase their enzymatic activity.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is included at 87.5 mM concentration in buffer B for homogenizing rye embryo extracts to increase their enzymatic activity.
magnesium acetate,Magnesium acetate is used at 3.25 mM concentration in buffer B for homogenizing rye embryo extracts to boost their enzymatic activity.,Entity: magnesium acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Mg+2]. Magnesium acetate is used at 3.25 mM concentration in buffer B for homogenizing rye embryo extracts to boost their enzymatic activity.
sucrose,"Sucrose can be hydrolyzed by liposomal invertase, which is released from the liposome and acts within lysosomes to relieve their load.","Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose can be hydrolyzed by liposomal invertase, which is released from the liposome and acts within lysosomes to relieve their load."
catecholamine,Treatment with liposomes made of bovine brain phospholipid has been reported to increase catecholamine metabolism in the brain of mice.,Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Treatment with liposomes made of bovine brain phospholipid has been reported to increase catecholamine metabolism in the brain of mice.
glucose,Treatment with liposomes made of bovine brain phospholipid has been reported to modify glucose distribution in mice.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Treatment with liposomes made of bovine brain phospholipid has been reported to modify glucose distribution in mice.
lecithin,"Egg lecithin is routinely administered intravenously in gram quantities as Intralipid¹, and liposomes made of this lipid may be considered safe for clinical use.","Entity: lecithin. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C. Egg lecithin is routinely administered intravenously in gram quantities as Intralipid¹, and liposomes made of this lipid may be considered safe for clinical use."
cholesterol,Cholesterol is a component of egg lecithin-based liposomes used for enzyme delivery in lysosomal storage disease treatment.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is a component of egg lecithin-based liposomes used for enzyme delivery in lysosomal storage disease treatment.
Triton X-100,Triton X-100 is a detergent used to dissolve liposomes after they have been reisolated from human plasma and washed to eliminate contaminating proteins.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a detergent used to dissolve liposomes after they have been reisolated from human plasma and washed to eliminate contaminating proteins.
cis-dichlorobiscyclopentylamine platinum,Uptake of cis-dichlorobiscyclopentylamine platinum entrapped in egg lecithin liposomes by ADJ/PCGA subcutaneous tumor in mice is greater than with the free drug and greater than with dipalmitoyl lecithin liposomes.,Entity: cis-dichlorobiscyclopentylamine platinum. SMILES: Cl[C@@H]1CCC[C@@]1(Cl)NC1CCCC1.[Pt]. Uptake of cis-dichlorobiscyclopentylamine platinum entrapped in egg lecithin liposomes by ADJ/PCGA subcutaneous tumor in mice is greater than with the free drug and greater than with dipalmitoyl lecithin liposomes.
Bleomycin,In vivo uptake of lllIn-labeled bleomycin by tumors in mice is considerable and can be increased up to about 7.0 percent of the dose per g tumor tissue by reducing the average size of the liposomes.,Entity: Bleomycin. SMILES: Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1. In vivo uptake of lllIn-labeled bleomycin by tumors in mice is considerable and can be increased up to about 7.0 percent of the dose per g tumor tissue by reducing the average size of the liposomes.
saponin,"When mixed with diphtheria toxoid-containing liposomes and injected into animals, saponin enhances the antibody response to the antigen compared to liposome-entrapped antigen alone.","Entity: saponin. SMILES: CC1(C)C2CC[C@]3(C)[C@H](CCC45OCC6(CC[C@@](C)(C=O)C[C@@H]64)[C@H](O)C[C@]53C)[C@@]2(C)CC[C@@H]1O[C@@H]1OC[C@H](O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. When mixed with diphtheria toxoid-containing liposomes and injected into animals, saponin enhances the antibody response to the antigen compared to liposome-entrapped antigen alone."
Mg-ATP,Mg-ATP (Mg-ATPase) activity in red blood cells can be modulated by liposomal phospholipids that are transferred to plasma lipoproteins and subsequently incorporated into red blood cells.,Entity: Mg-ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)([O-])OP(=O)([O-])O)[C@@H](O)[C@H]1O.[Mg+2]. Mg-ATP (Mg-ATPase) activity in red blood cells can be modulated by liposomal phospholipids that are transferred to plasma lipoproteins and subsequently incorporated into red blood cells.
cholesterol,"Cholesterol can exchange between liposomes and cell plasma membranes in vivo, potentially due to reversible adsorption that does not affect liposome integrity.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol can exchange between liposomes and cell plasma membranes in vivo, potentially due to reversible adsorption that does not affect liposome integrity."
cholesterol,"Liposomes can exchange cholesterol with low- and high-density lipoprotein fractions after intravenous injection in rats, with exchange into tissue possibly occurring via these lipoproteins.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Liposomes can exchange cholesterol with low- and high-density lipoprotein fractions after intravenous injection in rats, with exchange into tissue possibly occurring via these lipoproteins."
1-beta-D-arabinofuranosylcytosine,"Liposome-entrapped 1-beta-D-arabinofuranosylcytosine has demonstrated increased antitumor effects in L1210 tumor-bearing mice, regardless of liposome charge (negatively or positively charged).","Entity: 1-beta-D-arabinofuranosylcytosine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1. Liposome-entrapped 1-beta-D-arabinofuranosylcytosine has demonstrated increased antitumor effects in L1210 tumor-bearing mice, regardless of liposome charge (negatively or positively charged)."
8-azaguanine,Liposome-entrapped 8-azaguanine showed no increased antitumor effect compared to free drug against L1210 cells in mice.,Entity: 8-azaguanine. SMILES: Nc1nc2nn[nH]c2c(=O)[nH]1. Liposome-entrapped 8-azaguanine showed no increased antitumor effect compared to free drug against L1210 cells in mice.
stearylamine,Stearylamine is included in the lipid mixture forming the positively charged liposomes for methotrexate encapsulation.,Entity: stearylamine. SMILES: CCCCCCCCCCCCCCCCCCN. Stearylamine is included in the lipid mixture forming the positively charged liposomes for methotrexate encapsulation.
methotrexate,"Methotrexate can be encapsulated in positively charged, sonicated liposomes composed of egg phosphatidylcholine, cholesterol, and stearylamine for intravenous administration.","Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Methotrexate can be encapsulated in positively charged, sonicated liposomes composed of egg phosphatidylcholine, cholesterol, and stearylamine for intravenous administration."
Triton X-100,Triton X-100 at 0.2% (v/v) is used to pretreat blood samples to liberate free methotrexate for enzymatic assay.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 at 0.2% (v/v) is used to pretreat blood samples to liberate free methotrexate for enzymatic assay.
cholesterol,Cholesterol is a component of the liposomal formulation used to encapsulate methotrexate for intravenous delivery.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is a component of the liposomal formulation used to encapsulate methotrexate for intravenous delivery.
cholesterol,"Cholesterol is used as a component of the liposomes, with 14C-labeled cholesterol included to track its distribution and clearance in plasma after intravenous injection.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is used as a component of the liposomes, with 14C-labeled cholesterol included to track its distribution and clearance in plasma after intravenous injection."
methotrexate,"Methotrexate (MTX) entrapped in sonicated, positively charged liposomes shows up to 10^3-fold higher levels of intact drug in plasma four hours after intravenous injection compared to free MTX, due to much slower clearance and reduced metabolic breakdown.","Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Methotrexate (MTX) entrapped in sonicated, positively charged liposomes shows up to 10^3-fold higher levels of intact drug in plasma four hours after intravenous injection compared to free MTX, due to much slower clearance and reduced metabolic breakdown."
methotrexate,"Liposome-entrapped methotrexate (MTX) in plasma is almost entirely protected from metabolic breakdown, resulting in much slower clearance and higher intact drug levels compared to free MTX.","Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Liposome-entrapped methotrexate (MTX) in plasma is almost entirely protected from metabolic breakdown, resulting in much slower clearance and higher intact drug levels compared to free MTX."
Triton X-100,Triton X-100 is used to lyse liposomes in plasma samples to determine the amount of intact methotrexate (MTX) present.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used to lyse liposomes in plasma samples to determine the amount of intact methotrexate (MTX) present.
L-histidine,L-histidine is used as a buffer component at a concentration of 20 mM in intravenous injection solutions for pharmacokinetic studies.,Entity: L-histidine. SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O. L-histidine is used as a buffer component at a concentration of 20 mM in intravenous injection solutions for pharmacokinetic studies.
sodium chloride,Sodium chloride is used as a buffer component at a concentration of 120 mM in intravenous injection solutions for pharmacokinetic studies.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used as a buffer component at a concentration of 120 mM in intravenous injection solutions for pharmacokinetic studies.
potassium chloride,Potassium chloride is included in buffer solutions at a concentration of 4 mM for intravenous administration in pharmacokinetic experiments.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is included in buffer solutions at a concentration of 4 mM for intravenous administration in pharmacokinetic experiments.
methotrexate,Methotrexate is administered intravenously at a dose of 5.0 mg/kg in combination with 100 pCi of [3H]methotrexate in cynomolgus monkeys for pharmacokinetic analysis.,Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Methotrexate is administered intravenously at a dose of 5.0 mg/kg in combination with 100 pCi of [3H]methotrexate in cynomolgus monkeys for pharmacokinetic analysis.
Oxygen,"Oxygen has a direct effect on cerebral vessels, influencing cerebral blood flow.","Entity: Oxygen. SMILES: [O]. Oxygen has a direct effect on cerebral vessels, influencing cerebral blood flow."
CO2,"Changes in pCO2 (partial pressure of CO2) in the middle cerebral artery can induce constriction or dilatation, with marked responses observed only when there is a large change from normal pCO2 levels.","Entity: CO2. SMILES: O=C=O. Changes in pCO2 (partial pressure of CO2) in the middle cerebral artery can induce constriction or dilatation, with marked responses observed only when there is a large change from normal pCO2 levels."
O2,"O2 (oxygen) exposure in the middle cerebral artery can induce constriction, particularly when pCO2 is lowered further from normal.","Entity: O2. SMILES: [O]. O2 (oxygen) exposure in the middle cerebral artery can induce constriction, particularly when pCO2 is lowered further from normal."
pCh,pCh (intracerebrovascular carbon dioxide) affects cerebrovascular resistance primarily through an indirect effect via changes in acid-base balance within the brain.,Entity: pCh. SMILES: CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C.Cl. pCh (intracerebrovascular carbon dioxide) affects cerebrovascular resistance primarily through an indirect effect via changes in acid-base balance within the brain.
pCCh,pCCh (intracerebrovascular bicarbonate) affects cerebrovascular resistance mainly by altering acid-base balance in the brain.,Entity: pCCh. SMILES: C[N+](C)(C)CCOC(N)=O.[Cl-]. pCCh (intracerebrovascular bicarbonate) affects cerebrovascular resistance mainly by altering acid-base balance in the brain.
oxygen,"Low oxygen partial pressure (pO2) in solution induces a sudden, large constriction in the middle cerebral arteries, lasting 2 to 17 minutes, followed by recovery to baseline tension even when pO2 remains low.","Entity: oxygen. SMILES: [O]. Low oxygen partial pressure (pO2) in solution induces a sudden, large constriction in the middle cerebral arteries, lasting 2 to 17 minutes, followed by recovery to baseline tension even when pO2 remains low."
oxygen,"Hypoxia (low oxygen) sensitizes middle cerebral arteries, so repeated episodes of hypoxia cause progressively larger contractions in the arteries.","Entity: oxygen. SMILES: [O]. Hypoxia (low oxygen) sensitizes middle cerebral arteries, so repeated episodes of hypoxia cause progressively larger contractions in the arteries."
Oxygen,Inhaling 100% oxygen at normal atmospheric pressure causes a decrease in cerebral blood flow of up to 15% in middle cerebral artery preparations.,Entity: Oxygen. SMILES: [O]. Inhaling 100% oxygen at normal atmospheric pressure causes a decrease in cerebral blood flow of up to 15% in middle cerebral artery preparations.
oxygen,"Oxygen is available in compressed air as gas mixtures with 0%, 7%, 15%, 21%, and 95% O2 in 5% CO2 for regulating partial pressure (pO2) in solution.","Entity: oxygen. SMILES: [O]. Oxygen is available in compressed air as gas mixtures with 0%, 7%, 15%, 21%, and 95% O2 in 5% CO2 for regulating partial pressure (pO2) in solution."
carbon dioxide,"Carbon dioxide is available in compressed air as gas mixtures with 2%, 4%, 5%, 6%, 8%, and 13% CO2 in 21% O2, and also as a 2% CO2/0% O2 mixture for controlling partial pressure (pCO2) in solution.","Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is available in compressed air as gas mixtures with 2%, 4%, 5%, 6%, 8%, and 13% CO2 in 21% O2, and also as a 2% CO2/0% O2 mixture for controlling partial pressure (pCO2) in solution."
O2,"Changes in O2 (oxygen) levels can affect cerebral blood flow, particularly in the context of chronic hypoxia.","Entity: O2. SMILES: [O]. Changes in O2 (oxygen) levels can affect cerebral blood flow, particularly in the context of chronic hypoxia."
ATP,Chronic hypoxia can lead to increased ATP production in cerebral tissue via anaerobic pathways as an adaptation to low oxygen.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Chronic hypoxia can lead to increased ATP production in cerebral tissue via anaerobic pathways as an adaptation to low oxygen.
Oxygen,"Oxygen is required to allow normal constriction in response to low pCO2, suggesting its role in energy production for vascular contractile processes.","Entity: Oxygen. SMILES: [O]. Oxygen is required to allow normal constriction in response to low pCO2, suggesting its role in energy production for vascular contractile processes."
Carbon dioxide,"Low pCO2 (2% CO2) produces constriction in arteries, and this constriction is abolished or inhibited by hypoxia, indicating a role for CO2 in vascular reactivity.","Entity: Carbon dioxide. SMILES: O=C=O. Low pCO2 (2% CO2) produces constriction in arteries, and this constriction is abolished or inhibited by hypoxia, indicating a role for CO2 in vascular reactivity."
urea,Serum urea levels were within normal limits in all 50 patients with suspected Friedreich's ataxia.,Entity: urea. SMILES: NC(N)=O. Serum urea levels were within normal limits in all 50 patients with suspected Friedreich's ataxia.
uric acid,"Serum uric acid was elevated in only one patient with suspected Friedreich's ataxia, at a value of 9.7 mg%.","Entity: uric acid. SMILES: O=c1[nH]c(=O)c2[nH]c(=O)[nH]c2[nH]1. Serum uric acid was elevated in only one patient with suspected Friedreich's ataxia, at a value of 9.7 mg%."
vitamin B12,Serum vitamin B12 levels were within normal limits in all 50 patients with suspected Friedreich's ataxia.,Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Serum vitamin B12 levels were within normal limits in all 50 patients with suspected Friedreich's ataxia.
creatinine,"Serum creatinine was elevated in 5 out of 50 patients with suspected Friedreich's ataxia, with values ranging from 1.3 to 3.3 mg/dL.","Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Serum creatinine was elevated in 5 out of 50 patients with suspected Friedreich's ataxia, with values ranging from 1.3 to 3.3 mg/dL."
bilirubin,"The mean normal value for total serum bilirubin is 0.4 ± 0.2 mg% with an upper limit of normal of 0.8 mg per 100 ml (95% confidence limit = 0.75 mg per 100 ml), and in this study, the 95% confidence limit for the control group was 0.98 mg per 100 ml (1.0 mg%).","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. The mean normal value for total serum bilirubin is 0.4 ± 0.2 mg% with an upper limit of normal of 0.8 mg per 100 ml (95% confidence limit = 0.75 mg per 100 ml), and in this study, the 95% confidence limit for the control group was 0.98 mg per 100 ml (1.0 mg%)."
alkaline phosphatase,"Mean values for alkaline phosphatase, a test of liver function, are higher in ataxic patients compared to controls.","Entity: alkaline phosphatase. SMILES: CC(N)C(=O)N1CCCC1C(=O)NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)O. Mean values for alkaline phosphatase, a test of liver function, are higher in ataxic patients compared to controls."
bilirubin,"Bilirubin is an endogenous compound whose unconjugated form can reach levels over 12–15 mg/100 ml in rats, leading to signs resembling kernicterus with ataxia.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin is an endogenous compound whose unconjugated form can reach levels over 12–15 mg/100 ml in rats, leading to signs resembling kernicterus with ataxia."
bilirubin,"Bilirubin can interfere with sodium and urea transport in the renal medulla, contributing to polyuria and dehydration in rats with hyperbilirubinemia.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin can interfere with sodium and urea transport in the renal medulla, contributing to polyuria and dehydration in rats with hyperbilirubinemia."
urea,"Urea transport in the renal medulla can be disrupted by bilirubin, leading to polyuria and dehydration in rats with hyperbilirubinemia.","Entity: urea. SMILES: NC(N)=O. Urea transport in the renal medulla can be disrupted by bilirubin, leading to polyuria and dehydration in rats with hyperbilirubinemia."
sodium,"Sodium transport in the renal medulla can be affected by bilirubin, contributing to polyuria and dehydration in rats with hyperbilirubinemia.","Entity: sodium. SMILES: [Na]. Sodium transport in the renal medulla can be affected by bilirubin, contributing to polyuria and dehydration in rats with hyperbilirubinemia."
Taurine,Taurine administration leads to a significant increase in biliary excretion of both total cholesterol and congo red during perfusion.,Entity: Taurine. SMILES: NCCS(=O)(=O)O. Taurine administration leads to a significant increase in biliary excretion of both total cholesterol and congo red during perfusion.
2-aminoethanesulfonic acid,2-aminoethanesulfonic acid (taurine) is taken up into the brain and is metabolically inert in the kidney.,Entity: 2-aminoethanesulfonic acid. SMILES: NCCS(=O)(=O)O. 2-aminoethanesulfonic acid (taurine) is taken up into the brain and is metabolically inert in the kidney.
3-aminoisobutyric acid,"3-aminoisobutyric acid is handled by a α3-amino preferring tubular reabsorption system in mammalian kidney, along with α3-alanine and taurine.","Entity: 3-aminoisobutyric acid. SMILES: CC(CN)C(=O)O. 3-aminoisobutyric acid is handled by a α3-amino preferring tubular reabsorption system in mammalian kidney, along with α3-alanine and taurine."
2-aminoethanesulfonic acid,"2-aminoethanesulfonic acid, also known as taurine, is an ubiquitous amino acid found in large amounts in muscle, brain, heart, and posterior spinal cord.","Entity: 2-aminoethanesulfonic acid. SMILES: NCCS(=O)(=O)O. 2-aminoethanesulfonic acid, also known as taurine, is an ubiquitous amino acid found in large amounts in muscle, brain, heart, and posterior spinal cord."
2-aminoethanesulfonic acid,"2-aminoethanesulfonic acid (taurine) is present at high concentrations in urine and is influenced by drugs, hormones, or dietary input.","Entity: 2-aminoethanesulfonic acid. SMILES: NCCS(=O)(=O)O. 2-aminoethanesulfonic acid (taurine) is present at high concentrations in urine and is influenced by drugs, hormones, or dietary input."
taurine,"Taurine is subject to a tubular reabsorption defect in the kidney, resulting in abnormally high urinary excretion despite normal plasma values.","Entity: taurine. SMILES: NCCS(=O)(=O)O. Taurine is subject to a tubular reabsorption defect in the kidney, resulting in abnormally high urinary excretion despite normal plasma values."
3-alanine,"3-alanine is involved in a tubular reabsorption defect, leading to increased urinary excretion and competition with taurine for renal reabsorption.","Entity: 3-alanine. SMILES: NCCC(=O)O. 3-alanine is involved in a tubular reabsorption defect, leading to increased urinary excretion and competition with taurine for renal reabsorption."
BAIB,"BAIB is subject to a tubular reabsorption defect, resulting in increased urinary excretion and competition with taurine for renal reabsorption.","Entity: BAIB. SMILES: CC(CN)C(=O)O. BAIB is subject to a tubular reabsorption defect, resulting in increased urinary excretion and competition with taurine for renal reabsorption."
aspartic acid,Plasma concentrations of aspartic acid are significantly decreased in patients with Friedreich's ataxia compared to normal adults.,Entity: aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. Plasma concentrations of aspartic acid are significantly decreased in patients with Friedreich's ataxia compared to normal adults.
glutamic acid,Plasma concentrations of glutamic acid are significantly decreased in patients with Friedreich's ataxia compared to normal adults.,Entity: glutamic acid. SMILES: N[C@@H](CCC(=O)O)C(=O)O. Plasma concentrations of glutamic acid are significantly decreased in patients with Friedreich's ataxia compared to normal adults.
histidine,Plasma concentrations of histidine are significantly decreased in patients with Friedreich's ataxia compared to normal adults.,Entity: histidine. SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O. Plasma concentrations of histidine are significantly decreased in patients with Friedreich's ataxia compared to normal adults.
alanine,Plasma concentrations of alanine are slightly elevated in patients with Friedreich's ataxia compared to normal adults.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Plasma concentrations of alanine are slightly elevated in patients with Friedreich's ataxia compared to normal adults.
phenylalanine,Plasma concentrations of phenylalanine are significantly decreased in patients with Friedreich's ataxia compared to normal adults.,Entity: phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. Plasma concentrations of phenylalanine are significantly decreased in patients with Friedreich's ataxia compared to normal adults.
α-amino-N-butyric acid,Plasma concentrations of α-amino-N-butyric acid are significantly decreased in patients with Friedreich's ataxia compared to normal adults.,Entity: α-amino-N-butyric acid. SMILES: CCC(N)C(=O)O. Plasma concentrations of α-amino-N-butyric acid are significantly decreased in patients with Friedreich's ataxia compared to normal adults.
asparagine,Plasma concentrations of asparagine are significantly decreased in patients with Friedreich's ataxia compared to normal adults.,Entity: asparagine. SMILES: NC(=O)C[C@H](N)C(=O)O. Plasma concentrations of asparagine are significantly decreased in patients with Friedreich's ataxia compared to normal adults.
glycine,Plasma concentrations of glycine are significantly decreased in patients with Friedreich's ataxia compared to normal adults.,Entity: glycine. SMILES: NCC(=O)O. Plasma concentrations of glycine are significantly decreased in patients with Friedreich's ataxia compared to normal adults.
ornithine,Plasma concentrations of ornithine are significantly decreased in patients with Friedreich's ataxia compared to normal adults.,Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Plasma concentrations of ornithine are significantly decreased in patients with Friedreich's ataxia compared to normal adults.
norleucine,Norleucine is used as an internal standard in serum amino acid analysis protocols.,Entity: norleucine. SMILES: CCCC[C@H](N)C(=O)O. Norleucine is used as an internal standard in serum amino acid analysis protocols.
L-aspartate,"L-aspartate is widely distributed throughout the brain, as indicated by the localization of its oxidase.","Entity: L-aspartate. SMILES: N[C@@H](CC(=O)O)C(=O)O. L-aspartate is widely distributed throughout the brain, as indicated by the localization of its oxidase."
L-aspartate,L-aspartate is involved in metabolic functions such as the citric acid cycle.,Entity: L-aspartate. SMILES: N[C@@H](CC(=O)O)C(=O)O. L-aspartate is involved in metabolic functions such as the citric acid cycle.
L-aspartate,L-aspartate can undergo β-decarboxylation into L-alanine.,Entity: L-aspartate. SMILES: N[C@@H](CC(=O)O)C(=O)O. L-aspartate can undergo β-decarboxylation into L-alanine.
L-aspartate,L-aspartate is possibly an excitatory synaptic transmitter in the mammalian central nervous system.,Entity: L-aspartate. SMILES: N[C@@H](CC(=O)O)C(=O)O. L-aspartate is possibly an excitatory synaptic transmitter in the mammalian central nervous system.
norleucine,Norleucine is used as an internal standard at a concentration of 0.1 M in cerebrospinal fluid assays.,Entity: norleucine. SMILES: CCCC[C@H](N)C(=O)O. Norleucine is used as an internal standard at a concentration of 0.1 M in cerebrospinal fluid assays.
pyruvate,"Pyruvate is a key intermediate in cellular respiration, and its oxidation involves a complex series of enzymatic reactions.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is a key intermediate in cellular respiration, and its oxidation involves a complex series of enzymatic reactions."
pyruvate,Impairment of pyruvate oxidation can occur due to defects in specific enzymes within the pyruvate oxidation pathway.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Impairment of pyruvate oxidation can occur due to defects in specific enzymes within the pyruvate oxidation pathway.
pyruvate,"Abnormal pyruvate responses to glucose have been reported in polyneuropathies, motor neuron disease, and certain myopathies.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Abnormal pyruvate responses to glucose have been reported in polyneuropathies, motor neuron disease, and certain myopathies."
pyruvate,Elevated fasting pyruvate and lactate levels are commonly observed in individuals with specific defects in pyruvate oxidation enzymes.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Elevated fasting pyruvate and lactate levels are commonly observed in individuals with specific defects in pyruvate oxidation enzymes.
thiamine,"Thiamine deficiency can impair the first step of pyruvate oxidation, catalyzed by Ei-pyruvate decarboxylase.","Entity: thiamine. SMILES: Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1. Thiamine deficiency can impair the first step of pyruvate oxidation, catalyzed by Ei-pyruvate decarboxylase."
mercury,"Elemental or organic mercury poisoning can impair the first step of pyruvate oxidation, catalyzed by Ei-pyruvate decarboxylase.","Entity: mercury. SMILES: [Hg]. Elemental or organic mercury poisoning can impair the first step of pyruvate oxidation, catalyzed by Ei-pyruvate decarboxylase."
alanine,"Elevated levels of alanine in blood and urine can be found in individuals with specific defects in pyruvate oxidation enzymes, as alanine is the transamination product of pyruvate.","Entity: alanine. SMILES: C[C@H](N)C(=O)O. Elevated levels of alanine in blood and urine can be found in individuals with specific defects in pyruvate oxidation enzymes, as alanine is the transamination product of pyruvate."
lactate,Elevated lactate levels are commonly observed in individuals with specific defects in pyruvate oxidation enzymes.,Entity: lactate. SMILES: CC(O)C(=O)[O-]. Elevated lactate levels are commonly observed in individuals with specific defects in pyruvate oxidation enzymes.
phytanic acid,"Phytanic acid storage is a manifestation of Refsum's disease, an inborn error of metabolism that can cause familial ataxia.","Entity: phytanic acid. SMILES: CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)O. Phytanic acid storage is a manifestation of Refsum's disease, an inborn error of metabolism that can cause familial ataxia."
2-oxo-glutarate,"2-oxo-glutarate dehydrogenase shares a regenerating component (LAD; lipoamide dehydrogenase, E3) with pyruvate dehydrogenase, indicating a common enzymatic basis for their function.","Entity: 2-oxo-glutarate. SMILES: O=C([O-])CCC(=O)C(=O)[O-]. 2-oxo-glutarate dehydrogenase shares a regenerating component (LAD; lipoamide dehydrogenase, E3) with pyruvate dehydrogenase, indicating a common enzymatic basis for their function."
pyruvate,"Pyruvate oxidation is dependent on the regenerating component (LAD; lipoamide dehydrogenase, E3) of the pyruvate dehydrogenase complex, and deficiency in this component can cause impaired pyruvate oxidation to manifest only under metabolic stress such as glucose load.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate oxidation is dependent on the regenerating component (LAD; lipoamide dehydrogenase, E3) of the pyruvate dehydrogenase complex, and deficiency in this component can cause impaired pyruvate oxidation to manifest only under metabolic stress such as glucose load."
glucose,"A glucose load induces metabolic stress that can unmask deficiencies in the regenerating component (LAD; lipoamide dehydrogenase, E3) of the pyruvate dehydrogenase complex, leading to impaired pyruvate oxidation.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. A glucose load induces metabolic stress that can unmask deficiencies in the regenerating component (LAD; lipoamide dehydrogenase, E3) of the pyruvate dehydrogenase complex, leading to impaired pyruvate oxidation."
2-oxoglutarate,"In patients with Friedreich's ataxia, the 2-oxoglutarate dehydrogenase complex shows a 50–12% reduction in activity compared to normal, as measured in disrupted cultured fibroblasts.","Entity: 2-oxoglutarate. SMILES: O=C([O-])CCC(=O)C(=O)[O-]. In patients with Friedreich's ataxia, the 2-oxoglutarate dehydrogenase complex shows a 50–12% reduction in activity compared to normal, as measured in disrupted cultured fibroblasts."
pyruvate,"Pyruvate oxidation in muscle is reduced in patients with Friedreich's ataxia, with low values found in 4 of 7 cases and in 8 of 19 neuropathies studied, though 3 of 7 Friedreich's patients were normal.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate oxidation in muscle is reduced in patients with Friedreich's ataxia, with low values found in 4 of 7 cases and in 8 of 19 neuropathies studied, though 3 of 7 Friedreich's patients were normal."
pyruvate,Blood pyruvate response to glucose load is abnormal in only 2 of 3 Friedreich's ataxia patients with low muscle pyruvate oxidation rates.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Blood pyruvate response to glucose load is abnormal in only 2 of 3 Friedreich's ataxia patients with low muscle pyruvate oxidation rates.
pyruvate,Abnormal pyruvate values after a glucose challenge are observed in Friedreich's ataxia due to slow pyruvate oxidation.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Abnormal pyruvate values after a glucose challenge are observed in Friedreich's ataxia due to slow pyruvate oxidation.
acetoacetate,A block in the pyruvate dehydrogenase pathway can lead to overuse of the direct pyruvate to acetoacetate pathway to keep the Krebs Cycle active.,Entity: acetoacetate. SMILES: CC(=O)CC(=O)[O-]. A block in the pyruvate dehydrogenase pathway can lead to overuse of the direct pyruvate to acetoacetate pathway to keep the Krebs Cycle active.
taurine,Impairment of pyruvate flow can affect the metabolism of taurine in Friedreich's ataxia.,Entity: taurine. SMILES: NCCS(=O)(=O)O. Impairment of pyruvate flow can affect the metabolism of taurine in Friedreich's ataxia.
bilirubin,Impairment of pyruvate flow can affect the metabolism of bilirubin in Friedreich's ataxia.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Impairment of pyruvate flow can affect the metabolism of bilirubin in Friedreich's ataxia.
acetyl co-enzyme A,Decreased availability of acetyl co-enzyme A (acetyl CoA) in Friedreich's ataxia can be reflected in a cholinergic deficit.,Entity: acetyl co-enzyme A. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Decreased availability of acetyl co-enzyme A (acetyl CoA) in Friedreich's ataxia can be reflected in a cholinergic deficit.
alanine,Overflow of alanine into the urine is observed in Friedreich's ataxia due to impaired pyruvate oxidation.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Overflow of alanine into the urine is observed in Friedreich's ataxia due to impaired pyruvate oxidation.
aspartic acid,"Aspartic acid is present in low concentrations in the plasma of Friedreich's ataxia patients, potentially due to altered pyruvate dehydrogenase pathway activity.","Entity: aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. Aspartic acid is present in low concentrations in the plasma of Friedreich's ataxia patients, potentially due to altered pyruvate dehydrogenase pathway activity."
asparagine,"Asparagine is present in low concentrations in the plasma of Friedreich's ataxia patients, potentially due to altered pyruvate dehydrogenase pathway activity.","Entity: asparagine. SMILES: NC(=O)C[C@H](N)C(=O)O. Asparagine is present in low concentrations in the plasma of Friedreich's ataxia patients, potentially due to altered pyruvate dehydrogenase pathway activity."
lactate,Lactate levels are expected to be high in Friedreich's ataxia due to slow pyruvate oxidation.,Entity: lactate. SMILES: CC(O)C(=O)[O-]. Lactate levels are expected to be high in Friedreich's ataxia due to slow pyruvate oxidation.
taurine,"Serum taurine levels are low in Friedreich's ataxia, while urinary taurine levels are normal or high with abnormally high renal clearances, suggesting a possible tubular reabsorption defect.","Entity: taurine. SMILES: NCCS(=O)(=O)O. Serum taurine levels are low in Friedreich's ataxia, while urinary taurine levels are normal or high with abnormally high renal clearances, suggesting a possible tubular reabsorption defect."
phytanic acid,No abnormality in phytanic acid levels is found in Friedreich's ataxia.,Entity: phytanic acid. SMILES: CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)O. No abnormality in phytanic acid levels is found in Friedreich's ataxia.
alanine,"Serum and mainly urinary alanine levels are elevated in Friedreich's ataxia, possibly due to amino acid overflow.","Entity: alanine. SMILES: NCCC(=O)O. Serum and mainly urinary alanine levels are elevated in Friedreich's ataxia, possibly due to amino acid overflow."
3-aminoisobutyric acid,High urinary excretion of 3-aminoisobutyric acid (BAIB) is observed in Friedreich's ataxia.,Entity: 3-aminoisobutyric acid. SMILES: CC(CN)C(=O)O. High urinary excretion of 3-aminoisobutyric acid (BAIB) is observed in Friedreich's ataxia.
aspartic acid,Abnormally low levels of aspartic acid are found in the spinal cord of patients with Friedreich's ataxia.,Entity: aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. Abnormally low levels of aspartic acid are found in the spinal cord of patients with Friedreich's ataxia.
isoleucine,Serum leucine/isoleucine value is lowered in the spinal cord of patients with Friedreich's ataxia.,Entity: isoleucine. SMILES: CC[C@H](C)[C@H](N)C(=O)O. Serum leucine/isoleucine value is lowered in the spinal cord of patients with Friedreich's ataxia.
aspartic acid,Low CSF aspartic acid levels are observed in Friedreich's ataxia.,Entity: aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. Low CSF aspartic acid levels are observed in Friedreich's ataxia.
bilirubin,"Frequent occurrence of elevated unconjugated bilirubinemia in Friedreich's ataxia, with increases after fasting and essentially normal liver function tests.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Frequent occurrence of elevated unconjugated bilirubinemia in Friedreich's ataxia, with increases after fasting and essentially normal liver function tests."
aspartic acid,"Normal serum, but considerably increased levels of urinary aspartic acid are present in Friedreich's ataxia.","Entity: aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. Normal serum, but considerably increased levels of urinary aspartic acid are present in Friedreich's ataxia."
NAD,A binding defect of NAD on the lipoamide dehydrogenase molecule may contribute to impaired pyruvate dehydrogenase function in Friedreich's ataxia.,Entity: NAD. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. A binding defect of NAD on the lipoamide dehydrogenase molecule may contribute to impaired pyruvate dehydrogenase function in Friedreich's ataxia.
pyridoxal phosphate,A binding defect of FAD or NAD on the lipoamide dehydrogenase molecule may be mediated by pyridoxal phosphate.,Entity: pyridoxal phosphate. SMILES: Cc1ncc(COP(=O)(O)O)c(C=O)c1O. A binding defect of FAD or NAD on the lipoamide dehydrogenase molecule may be mediated by pyridoxal phosphate.
pyruvate,"Friedreich's ataxia patients show a clearly abnormal response of pyruvate to glucose load, indicating slow pyruvate oxidation.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Friedreich's ataxia patients show a clearly abnormal response of pyruvate to glucose load, indicating slow pyruvate oxidation."
pyruvate,Serum values of most enzymes of the glycolytic pathway are normal except as indicated above for pyruvate dehydrogenase in vivo.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Serum values of most enzymes of the glycolytic pathway are normal except as indicated above for pyruvate dehydrogenase in vivo.
glucose,"Serum glucose is used to assess pyruvate oxidation in Friedreich's ataxia, with abnormal responses indicating impaired pyruvate oxidation.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Serum glucose is used to assess pyruvate oxidation in Friedreich's ataxia, with abnormal responses indicating impaired pyruvate oxidation."
lactate,"Lactate levels show a parallel response with pyruvate in Friedreich's ataxia, reflecting impaired pyruvate oxidation.","Entity: lactate. SMILES: CC(O)C(=O)[O-]. Lactate levels show a parallel response with pyruvate in Friedreich's ataxia, reflecting impaired pyruvate oxidation."
bilirubin,"Bilirubin levels may be abnormal in some individuals with Gilbert's disease, but this abnormality is not considered to be primarily responsible for other abnormalities in pyruvate oxidation and glucose metabolism.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin levels may be abnormal in some individuals with Gilbert's disease, but this abnormality is not considered to be primarily responsible for other abnormalities in pyruvate oxidation and glucose metabolism."
ornithine,"Patients with Gilbert's disease may have a high output of ornithine, although the significance of this finding is not clear.","Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Patients with Gilbert's disease may have a high output of ornithine, although the significance of this finding is not clear."
pyruvate,"Abnormalities in pyruvate oxidation are associated with Gilbert's disease, but bilirubin defects are not considered the primary cause.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Abnormalities in pyruvate oxidation are associated with Gilbert's disease, but bilirubin defects are not considered the primary cause."
glucose,"Abnormalities in glucose metabolism are associated with Gilbert's disease, but bilirubin defects are not considered the primary cause.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Abnormalities in glucose metabolism are associated with Gilbert's disease, but bilirubin defects are not considered the primary cause."
Bromodeoxyuridine,Bromodeoxyuridine (BU) is used in selection systems to induce DNA synthesis arrest and select for cells with mutations that confer resistance to DNA synthesis inhibition.,Entity: Bromodeoxyuridine. SMILES: O=c1ccn([C@@]2(Br)C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. Bromodeoxyuridine (BU) is used in selection systems to induce DNA synthesis arrest and select for cells with mutations that confer resistance to DNA synthesis inhibition.
Bromodeoxyuridine,"Bromodeoxyuridine (BU) is used in a selection system to increase the frequency of transversion (ts) mutants in bacterial populations, with BU-treated populations showing more than 10-fold higher frequencies of ts mutants compared to untreated populations.","Entity: Bromodeoxyuridine. SMILES: O=c1ccn([C@@]2(Br)C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. Bromodeoxyuridine (BU) is used in a selection system to increase the frequency of transversion (ts) mutants in bacterial populations, with BU-treated populations showing more than 10-fold higher frequencies of ts mutants compared to untreated populations."
n-methyl-n'-nitro-n-nitrosoguanidine,n-methyl-n'-nitro-n-nitrosoguanidine is a chemical mutagen used at a concentration of 75 pg/ml for 45 minutes in mutagenesis experiments.,Entity: n-methyl-n'-nitro-n-nitrosoguanidine. SMILES: CN(N=O)C(=N)N[N+](=O)[O-]. n-methyl-n'-nitro-n-nitrosoguanidine is a chemical mutagen used at a concentration of 75 pg/ml for 45 minutes in mutagenesis experiments.
bile acid,Bile acids can obstruct the biliary tract in newborn rabbits when administered intravenously to the mother.,Entity: bile acid. SMILES: CC(CCC(=O)O)C1CCC2C3C(C[C@H](O)C12C)C1(C)CC[C@@H](O)C[C@H]1C[C@H]3O. Bile acids can obstruct the biliary tract in newborn rabbits when administered intravenously to the mother.
lithocholic acid,Lithocholic acid is a bile acid that can induce obstruction within the biliary tract of newborn rabbits when administered intravenously to the mother.,Entity: lithocholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Lithocholic acid is a bile acid that can induce obstruction within the biliary tract of newborn rabbits when administered intravenously to the mother.
Benzoyl peroxide,"Benzoyl peroxide is a powerful organic oxidizing agent used topically to treat cutaneous ulcers, including deep, complex ulcers resistant to other therapies.","Entity: Benzoyl peroxide. SMILES: O=C(OOC(=O)c1ccccc1)c1ccccc1. Benzoyl peroxide is a powerful organic oxidizing agent used topically to treat cutaneous ulcers, including deep, complex ulcers resistant to other therapies."
Benzoyl peroxide,Benzoyl peroxide accelerates healing in cutaneous ulcers by promoting rapid development of healthy granulation tissue and epithelial ingrowth.,Entity: Benzoyl peroxide. SMILES: O=C(OOC(=O)c1ccccc1)c1ccccc1. Benzoyl peroxide accelerates healing in cutaneous ulcers by promoting rapid development of healthy granulation tissue and epithelial ingrowth.
Benzoyl peroxide,"The slow, sustained release of oxygen by benzoyl peroxide is thought to be responsible for its therapeutic effect in cutaneous ulcer healing.","Entity: Benzoyl peroxide. SMILES: O=C(OOC(=O)c1ccccc1)c1ccccc1. The slow, sustained release of oxygen by benzoyl peroxide is thought to be responsible for its therapeutic effect in cutaneous ulcer healing."
Benzoyl peroxide,Topical benzoyl peroxide treatment of cutaneous ulcers is associated with contact irritant dermatitis in 3% and contact allergic dermatitis in 2% of patients.,Entity: Benzoyl peroxide. SMILES: O=C(OOC(=O)c1ccccc1)c1ccccc1. Topical benzoyl peroxide treatment of cutaneous ulcers is associated with contact irritant dermatitis in 3% and contact allergic dermatitis in 2% of patients.
epinephrine,"Epinephrine at 5 pM induces a second wave of platelet aggregation in 35% of normal controls and 85% of leukemic patients, and this response is not altered by co-administration of CA.","Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. Epinephrine at 5 pM induces a second wave of platelet aggregation in 35% of normal controls and 85% of leukemic patients, and this response is not altered by co-administration of CA."
adenosine diphosphate,"Adenosine diphosphate at 2.5 pM induces a second wave of platelet aggregation in 35% of normal controls and 20% of leukemic patients, and this response is not altered by co-administration of CA.","Entity: adenosine diphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine diphosphate at 2.5 pM induces a second wave of platelet aggregation in 35% of normal controls and 20% of leukemic patients, and this response is not altered by co-administration of CA."
alkaline phosphatase,Alkaline phosphatase is measured as a laboratory test at 6-month intervals in postoperative patients to monitor health status.,Entity: alkaline phosphatase. SMILES: CC(N)C(=O)N1CCCC1C(=O)NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)O. Alkaline phosphatase is measured as a laboratory test at 6-month intervals in postoperative patients to monitor health status.
agar,"Agar is a solid nutrient medium that, when used to immediately dilute propolys alcohol extracts, eliminates the extract's inhibitory effect on microbial growth and allows for accurate antimicrobial activity estimation.","Entity: agar. SMILES: CO[C@H]1[C@@H](O)[C@@H](CO)OC(OC2C3CO[C@H]2[C@H](O)C(C)O3)[C@@H]1O. Agar is a solid nutrient medium that, when used to immediately dilute propolys alcohol extracts, eliminates the extract's inhibitory effect on microbial growth and allows for accurate antimicrobial activity estimation."
ammonium acetate,Ammonium acetate at 0.01 M (pH 6.5) is used as the buffer for preparing the standard inhibition curve in the Hansen zirconyl phosphate gel (Z-gel) radioimmunoassay (KIA) assay for CEA activity.,Entity: ammonium acetate. SMILES: CC(=O)[O-].[NH4+]. Ammonium acetate at 0.01 M (pH 6.5) is used as the buffer for preparing the standard inhibition curve in the Hansen zirconyl phosphate gel (Z-gel) radioimmunoassay (KIA) assay for CEA activity.
cobalt,"Cobalt is used as an adjunct to vincristine, actinomycin D, and cyclophosphamide in the treatment of endodermal sinus tumors in the pineal region.","Entity: cobalt. SMILES: [Co]. Cobalt is used as an adjunct to vincristine, actinomycin D, and cyclophosphamide in the treatment of endodermal sinus tumors in the pineal region."
vincristine,"Vincristine is administered as part of a combination chemotherapy regimen with actinomycin D, cyclophosphamide, and cobalt for the treatment of endodermal sinus tumors in the pineal region.","Entity: vincristine. SMILES: CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1. Vincristine is administered as part of a combination chemotherapy regimen with actinomycin D, cyclophosphamide, and cobalt for the treatment of endodermal sinus tumors in the pineal region."
Hydroxyproline,"The excretion ratio of hydroxyproline to creatinine in urine can be accurately measured using a half-hour fasting sample, with day-to-day variation of approximately 0.2 ± 0.2.","Entity: Hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. The excretion ratio of hydroxyproline to creatinine in urine can be accurately measured using a half-hour fasting sample, with day-to-day variation of approximately 0.2 ± 0.2."
Hydroxyproline,"Dietary intake of gelatin (up to 15 gm/day for two days) has minimal effect on the urinary excretion ratio of hydroxyproline to creatinine, whereas the 24-hour urinary test is significantly affected by gelatin intake as little as 5 gm/day.","Entity: Hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Dietary intake of gelatin (up to 15 gm/day for two days) has minimal effect on the urinary excretion ratio of hydroxyproline to creatinine, whereas the 24-hour urinary test is significantly affected by gelatin intake as little as 5 gm/day."
Creatinine,"The excretion ratio of hydroxyproline to creatinine in urine can be accurately measured using a half-hour fasting sample, with day-to-day variation of approximately 0.2 ± 0.2.","Entity: Creatinine. SMILES: CN1CC(=O)N=C1N. The excretion ratio of hydroxyproline to creatinine in urine can be accurately measured using a half-hour fasting sample, with day-to-day variation of approximately 0.2 ± 0.2."
hydroxyproline,"Hydroxyproline excretion in a 30-minute period closely correlates with 24-hour hydroxyproline excretion in patients, with a correlation coefficient of 0.93 (p < 0.001).","Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Hydroxyproline excretion in a 30-minute period closely correlates with 24-hour hydroxyproline excretion in patients, with a correlation coefficient of 0.93 (p < 0.001)."
creatinine,"Creatinine is used as a reference compound in the estimation of hydroxyproline excretion, with close correlation observed between hydroxyproline/creatinine and hydroxyproline/creatine excretion over 24 hours.","Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine is used as a reference compound in the estimation of hydroxyproline excretion, with close correlation observed between hydroxyproline/creatinine and hydroxyproline/creatine excretion over 24 hours."
steroids,The glucocorticoid receptors in rat liver from tumor-bearing rats have slightly higher affinities than those in normal rat liver for all the steroids tested.,Entity: steroids. SMILES: CC(=O)N(C)[C@H](C)[C@@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](N(C)C)CC[C@@]4(C)[C@@H]3CC[C@]21C. The glucocorticoid receptors in rat liver from tumor-bearing rats have slightly higher affinities than those in normal rat liver for all the steroids tested.
rhodium(II) acetate,The rate of inactivation of enzymes by rhodium(II) acetate parallels its toxicity and antitumor activity.,Entity: rhodium(II) acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Rh+2]. The rate of inactivation of enzymes by rhodium(II) acetate parallels its toxicity and antitumor activity.
propionate,Rhodium(II) propionate is more effective at irreversibly inhibiting sulfhydryl-dependent enzymes than rhodium(II) acetate.,Entity: propionate. SMILES: CCC(=O)[O-]. Rhodium(II) propionate is more effective at irreversibly inhibiting sulfhydryl-dependent enzymes than rhodium(II) acetate.
rhodium(II) acetate,Proton nuclear magnetic resonance shows that rhodium(II) acetate breaks down its carboxylate cage upon reaction with cysteine.,Entity: rhodium(II) acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Rh+2]. Proton nuclear magnetic resonance shows that rhodium(II) acetate breaks down its carboxylate cage upon reaction with cysteine.
rhodium(II) propionate,Rhodium(II) propionate irreversibly inhibits enzymes with essential sulfhydryl groups in or near their active site.,Entity: rhodium(II) propionate. SMILES: CCC(=O)[O-].CCC(=O)[O-].[Rh+2]. Rhodium(II) propionate irreversibly inhibits enzymes with essential sulfhydryl groups in or near their active site.
rhodium(II) propionate,The rate of inactivation of enzymes by rhodium(II) propionate closely parallels its toxicity and antitumor activity.,Entity: rhodium(II) propionate. SMILES: CCC(=O)[O-].CCC(=O)[O-].[Rh+2]. The rate of inactivation of enzymes by rhodium(II) propionate closely parallels its toxicity and antitumor activity.
rhodium(II) propionate,Rhodium(II) propionate is more effective at irreversibly inhibiting sulfhydryl-dependent enzymes than rhodium(II) acetate.,Entity: rhodium(II) propionate. SMILES: CCC(=O)[O-].CCC(=O)[O-].[Rh+2]. Rhodium(II) propionate is more effective at irreversibly inhibiting sulfhydryl-dependent enzymes than rhodium(II) acetate.
methoxyacetate,Rhodium(II) methoxyacetate irreversibly inhibits enzymes that have essential sulfhydryl groups in or near their active site.,Entity: methoxyacetate. SMILES: COCC(=O)[O-]. Rhodium(II) methoxyacetate irreversibly inhibits enzymes that have essential sulfhydryl groups in or near their active site.
methoxyacetate,The rate of inactivation of enzymes by rhodium(II) methoxyacetate parallels its toxicity and antitumor activity.,Entity: methoxyacetate. SMILES: COCC(=O)[O-]. The rate of inactivation of enzymes by rhodium(II) methoxyacetate parallels its toxicity and antitumor activity.
methoxyacetate,Rhodium(II) methoxyacetate is less effective at irreversibly inhibiting sulfhydryl-dependent enzymes than rhodium(II) acetate or propionate.,Entity: methoxyacetate. SMILES: COCC(=O)[O-]. Rhodium(II) methoxyacetate is less effective at irreversibly inhibiting sulfhydryl-dependent enzymes than rhodium(II) acetate or propionate.
sulfhydryl,Enzymes with essential sulfhydryl groups in or near their active site are irreversibly inhibited by rhodium(II) carboxylates.,Entity: sulfhydryl. SMILES: [SH]. Enzymes with essential sulfhydryl groups in or near their active site are irreversibly inhibited by rhodium(II) carboxylates.
rhodium(II) acetate,Rhodium(II) acetate irreversibly inhibits enzymes that have essential sulfhydryl groups in or near their active site.,Entity: rhodium(II) acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Rh+2]. Rhodium(II) acetate irreversibly inhibits enzymes that have essential sulfhydryl groups in or near their active site.
cysteine,"Cysteine reacts with rhodium(II) acetate, causing breakdown of the carboxylate cage as detected by proton nuclear magnetic resonance.","Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. Cysteine reacts with rhodium(II) acetate, causing breakdown of the carboxylate cage as detected by proton nuclear magnetic resonance."
aminopyrine,Aminopyrine is used as a model substrate to quantitate drug-metabolizing activity in liver microsomes and lung homogenates.,Entity: aminopyrine. SMILES: Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C. Aminopyrine is used as a model substrate to quantitate drug-metabolizing activity in liver microsomes and lung homogenates.
benzo(a)pyrene,Benzo(a)pyrene is used as a model substrate to assess drug-metabolizing activity in liver microsomes and lung homogenates.,Entity: benzo(a)pyrene. SMILES: c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34. Benzo(a)pyrene is used as a model substrate to assess drug-metabolizing activity in liver microsomes and lung homogenates.
p-nitroanisole,p-nitroanisole serves as a model substrate for measuring drug-metabolizing activity in liver microsomes and lung homogenates.,Entity: p-nitroanisole. SMILES: COc1ccc([N+](=O)[O-])cc1. p-nitroanisole serves as a model substrate for measuring drug-metabolizing activity in liver microsomes and lung homogenates.
benzo(a)pyrene,"Benzo(a)pyrene undergoes oxidative metabolism in liver microsomes, producing intermediates whose visible spectra resemble those of several benzo(a)pyrene phenols.","Entity: benzo(a)pyrene. SMILES: c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34. Benzo(a)pyrene undergoes oxidative metabolism in liver microsomes, producing intermediates whose visible spectra resemble those of several benzo(a)pyrene phenols."
phenol,"Phenols are formed as intermediates during the oxidative metabolism of benzo(a)pyrene by liver microsomes, with the rate of formation enhanced by the epoxide hydrase inhibitor 1,1,1-trichloropropene-2,3-oxide.","Entity: phenol. SMILES: Oc1ccccc1. Phenols are formed as intermediates during the oxidative metabolism of benzo(a)pyrene by liver microsomes, with the rate of formation enhanced by the epoxide hydrase inhibitor 1,1,1-trichloropropene-2,3-oxide."
3-hydroxybenzo(a)pyrene,3-hydroxybenzo(a)pyrene is used as a standard for comparison of benzo(a)pyrene phenol formation rates in liver microsomal assays.,Entity: 3-hydroxybenzo(a)pyrene. SMILES: Oc1ccc2ccc3c4ccccc4cc4ccc1c2c43. 3-hydroxybenzo(a)pyrene is used as a standard for comparison of benzo(a)pyrene phenol formation rates in liver microsomal assays.
3-methylcholanthrene,Liver microsomes from 3-methylcholanthrene-treated rats show a greater rate of formation of benzo(a)pyrene phenols compared to control animals.,Entity: 3-methylcholanthrene. SMILES: Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3. Liver microsomes from 3-methylcholanthrene-treated rats show a greater rate of formation of benzo(a)pyrene phenols compared to control animals.
phenobarbital,Liver microsomes from phenobarbital-pretreated rats catalyze the formation of benzo(a)pyrene phenols at an intermediate rate compared to 3-methylcholanthrene- and control-treated microsomes.,Entity: phenobarbital. SMILES: CCC1(c2ccccc2)C(=O)NC(=O)NC1=O. Liver microsomes from phenobarbital-pretreated rats catalyze the formation of benzo(a)pyrene phenols at an intermediate rate compared to 3-methylcholanthrene- and control-treated microsomes.
9-hydroxybenzo(a)-pyrene,"In mouse and hamster embryo secondary cultures, there is a marked increase in the formation of 9-hydroxybenzo(a)-pyrene during benzo(a)pyrene metabolism.","Entity: 9-hydroxybenzo(a)-pyrene. SMILES: Oc1ccc2cc3ccc4cccc5ccc(c2c1)c3c45. In mouse and hamster embryo secondary cultures, there is a marked increase in the formation of 9-hydroxybenzo(a)-pyrene during benzo(a)pyrene metabolism."
benzo(a)pyrene,"Benzo(a)pyrene is metabolized by rodent liver microsomes and embryo cells in a species- and tissue-dependent manner, with regional differences in metabolite patterns due to region-specific monooxygenase attack.","Entity: benzo(a)pyrene. SMILES: c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34. Benzo(a)pyrene is metabolized by rodent liver microsomes and embryo cells in a species- and tissue-dependent manner, with regional differences in metabolite patterns due to region-specific monooxygenase attack."
benzo(a)pyrene,"Activation and detoxification of benzo(a)pyrene can vary by species and tissue, influencing susceptibility and resistance to malignant transformation.","Entity: benzo(a)pyrene. SMILES: c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34. Activation and detoxification of benzo(a)pyrene can vary by species and tissue, influencing susceptibility and resistance to malignant transformation."
L-fucose,"L-fucose can be used to label glycopeptides on the surface of human neuroblastoma tumor cells, allowing their removal and subsequent chromatographic analysis.","Entity: L-fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. L-fucose can be used to label glycopeptides on the surface of human neuroblastoma tumor cells, allowing their removal and subsequent chromatographic analysis."
uridine,"Uridine exhibits five diagnostic Raman bands at approximately 591, 1017, 1230, 1293, and 1397 cm-1, which are sensitive to protonation and can be used to qualitatively and quantitatively assess the proportion of uridine species in solution.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine exhibits five diagnostic Raman bands at approximately 591, 1017, 1230, 1293, and 1397 cm-1, which are sensitive to protonation and can be used to qualitatively and quantitatively assess the proportion of uridine species in solution."
uridine,"The most intense and variable Raman band of uridine, at 1230 cm-1, reflects the neutral form and its intensity change upon deprotonation yields a pK value of 9.2.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. The most intense and variable Raman band of uridine, at 1230 cm-1, reflects the neutral form and its intensity change upon deprotonation yields a pK value of 9.2."
uridine,"The intensity of the 786 cm-1 and 868 cm-1 Raman bands of uridine is invariant, with the 786 cm-1 band shifting to 783 cm-1 on protonation and the 868 cm-1 band remaining frequency invariant.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. The intensity of the 786 cm-1 and 868 cm-1 Raman bands of uridine is invariant, with the 786 cm-1 band shifting to 783 cm-1 on protonation and the 868 cm-1 band remaining frequency invariant."
cytidine,"Cytidine has a characteristic Raman band at 1254 cm-1, which is analogous to the 1230 cm-1 band of uridine and serves as a qualitative and quantitative indicator of uridine species in solution.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine has a characteristic Raman band at 1254 cm-1, which is analogous to the 1230 cm-1 band of uridine and serves as a qualitative and quantitative indicator of uridine species in solution."
cytidine,"Cytidine exhibits a characteristic band at 1254 cm-1 in acid, which shows the greatest intensity change as a function of pH, and its deprotonation causes a significant decrease in band intensity with splitting into multiple bands within the 1180–1330 cm-1 region.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine exhibits a characteristic band at 1254 cm-1 in acid, which shows the greatest intensity change as a function of pH, and its deprotonation causes a significant decrease in band intensity with splitting into multiple bands within the 1180–1330 cm-1 region."
cytidine,"The protonation state of cytidine can be quantitatively and qualitatively monitored by the intensity variation of the 1180–1330 cm-1 band, yielding a pK value of 4.0.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. The protonation state of cytidine can be quantitatively and qualitatively monitored by the intensity variation of the 1180–1330 cm-1 band, yielding a pK value of 4.0."
cytidine,"Experimental analysis of cytidine species in solution generally yields pK values of 4.1 ± 0.2, as determined by percent species plots from spectral intensities.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Experimental analysis of cytidine species in solution generally yields pK values of 4.1 ± 0.2, as determined by percent species plots from spectral intensities."
cytidine,"Cytidine exhibits intensity invariant vibrational bands at approximately 786 cm⁻¹ and 864 cm⁻¹ over a wide pH range, with the 786 cm⁻¹ band assigned to ring breathing and the 864 cm⁻¹ band to (CN) and (CC) stretching mode coupling.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine exhibits intensity invariant vibrational bands at approximately 786 cm⁻¹ and 864 cm⁻¹ over a wide pH range, with the 786 cm⁻¹ band assigned to ring breathing and the 864 cm⁻¹ band to (CN) and (CC) stretching mode coupling."
cytidine,"The diagnostic bands of cytidine in poly(C) spectra qualitatively follow the pH behavior of cytidine, with changes in band intensities at 1190–1310 cm⁻¹, 1465, 600, and 1527 cm⁻¹ regions corresponding to cytidine's pH sensitivity.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. The diagnostic bands of cytidine in poly(C) spectra qualitatively follow the pH behavior of cytidine, with changes in band intensities at 1190–1310 cm⁻¹, 1465, 600, and 1527 cm⁻¹ regions corresponding to cytidine's pH sensitivity."
cytidine,"Cytidine is a nucleoside with a reported pK value of 4.1, indicating it is protonated at the N-3 position under physiological conditions.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine is a nucleoside with a reported pK value of 4.1, indicating it is protonated at the N-3 position under physiological conditions."
uridine,"Uridine is a nucleoside with a reported pK value of 9.2, indicating it is predominantly in the deprotonated form under physiological conditions.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine is a nucleoside with a reported pK value of 9.2, indicating it is predominantly in the deprotonated form under physiological conditions."
NaClO4,NaClO4 is used as an internal standard at a concentration of 50 mM in cytidine studies.,Entity: NaClO4. SMILES: [Na+].[O-][Cl+3]([O-])([O-])[O-]. NaClO4 is used as an internal standard at a concentration of 50 mM in cytidine studies.
NaPF6,"NaPF6 is used as an internal standard in uridine studies, with the 743 cm⁻¹ band intensity normalized to that of the 932 cm⁻¹ band in CIO: over pH 0.5–12.5, showing less than 3% intensity variation and thus being suitable as an internal standard.","Entity: NaPF6. SMILES: F[P-](F)(F)(F)(F)F.[Na+]. NaPF6 is used as an internal standard in uridine studies, with the 743 cm⁻¹ band intensity normalized to that of the 932 cm⁻¹ band in CIO: over pH 0.5–12.5, showing less than 3% intensity variation and thus being suitable as an internal standard."
cytidine,"Cytidine exhibits multiple proton dissociation (tautomeric) forms, as indicated by the presence of several Raman peaks corresponding to different pK values (e.g., pK 4.20, 4.23, 3.88, 4.00) in the pH range of 1.1 to 6.9 under conditions of 50–100 mM ionic strength and 25°C.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine exhibits multiple proton dissociation (tautomeric) forms, as indicated by the presence of several Raman peaks corresponding to different pK values (e.g., pK 4.20, 4.23, 3.88, 4.00) in the pH range of 1.1 to 6.9 under conditions of 50–100 mM ionic strength and 25°C."
cytidine,"At neutral pH, cytidine exists as a single-stranded, partially ordered structure, and its spectral features at pH 6.8 are similar to those of poly(C).","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. At neutral pH, cytidine exists as a single-stranded, partially ordered structure, and its spectral features at pH 6.8 are similar to those of poly(C)."
uracil,"Normal coordinate analyses of uracil reveal complex normal modes, particularly in the 1000–1600 cm⁻¹ region, involving coupling of ring vibrations with the -NH2 scissoring mode or in-plane N(3)-H deformation.","Entity: uracil. SMILES: O=c1cc[nH]c(=O)[nH]1. Normal coordinate analyses of uracil reveal complex normal modes, particularly in the 1000–1600 cm⁻¹ region, involving coupling of ring vibrations with the -NH2 scissoring mode or in-plane N(3)-H deformation."
cytosine,"Normal coordinate analyses of cytosine show complex normal modes, especially in the 1000–1600 cm⁻¹ region, with significant coupling between ring vibrations and the -NH2 scissoring mode or in-plane N(3)-H deformation.","Entity: cytosine. SMILES: Nc1cc[nH]c(=O)n1. Normal coordinate analyses of cytosine show complex normal modes, especially in the 1000–1600 cm⁻¹ region, with significant coupling between ring vibrations and the -NH2 scissoring mode or in-plane N(3)-H deformation."
diethyl phosphate,"The diethyl phosphate anion has been used as a model for the phosphodiester linkage in the DNA backbone, with its normal coordinate analysis allowing diagnosis of DNA conformation (A-form or B-form) based on specific vibrational shifts.","Entity: diethyl phosphate. SMILES: CCOP(=O)([O-])OCC. The diethyl phosphate anion has been used as a model for the phosphodiester linkage in the DNA backbone, with its normal coordinate analysis allowing diagnosis of DNA conformation (A-form or B-form) based on specific vibrational shifts."
uridine,Uridine forms pH-sensitive Raman bands whose intensities and vibrational frequencies can be monitored to determine its concentration and species distribution in aqueous solution.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine forms pH-sensitive Raman bands whose intensities and vibrational frequencies can be monitored to determine its concentration and species distribution in aqueous solution.
cytidine,Cytidine forms pH-sensitive Raman bands that can be used to monitor its concentration and species distribution in aqueous solution.,Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine forms pH-sensitive Raman bands that can be used to monitor its concentration and species distribution in aqueous solution.
cytidine,"Acidification affects the structural and conformational characteristics of polycytidylic acid in solution, as evidenced by changes in cytidine's pH profile.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Acidification affects the structural and conformational characteristics of polycytidylic acid in solution, as evidenced by changes in cytidine's pH profile."
uridine,Uridine is a nucleoside whose vibrational bands are diagnostic of its concentration in solution and are indicative of the pK value of its conjugate acid.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine is a nucleoside whose vibrational bands are diagnostic of its concentration in solution and are indicative of the pK value of its conjugate acid.
NaPF6,NaPF6 is used as an internal intensity standard in the preparation of nucleotide solutions for pH studies.,Entity: NaPF6. SMILES: F[P-](F)(F)(F)(F)F.[Na+]. NaPF6 is used as an internal intensity standard in the preparation of nucleotide solutions for pH studies.
NaClO4,NaClO4 is used as an internal intensity standard in the preparation of nucleotide solutions for pH studies.,Entity: NaClO4. SMILES: [Na+].[O-][Cl+3]([O-])([O-])[O-]. NaClO4 is used as an internal intensity standard in the preparation of nucleotide solutions for pH studies.
HCl,HCl is used to adjust the pH of nucleotide solutions in studies of cytidine and uridine.,Entity: HCl. SMILES: Cl. HCl is used to adjust the pH of nucleotide solutions in studies of cytidine and uridine.
NaOH,NaOH is used to adjust the pH of nucleotide solutions in studies of cytidine and uridine.,Entity: NaOH. SMILES: [Na+].[OH-]. NaOH is used to adjust the pH of nucleotide solutions in studies of cytidine and uridine.
cytidine,Cytidine is a nucleoside whose vibrational bands are diagnostic of its concentration in solution and are indicative of the pK value of its conjugate acid.,Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine is a nucleoside whose vibrational bands are diagnostic of its concentration in solution and are indicative of the pK value of its conjugate acid.
[125I]iododeoxyuridine,In vivo uptake and reutilization of [125I]iododeoxyuridine into intestinal and tumor DNA are almost completely suppressed when thymidine blood plasma levels are maintained at 40–8 × 10⁻⁶ M in adult mice.,Entity: [125I]iododeoxyuridine. SMILES: O=c1ccn([C@@]2([125I])C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. In vivo uptake and reutilization of [125I]iododeoxyuridine into intestinal and tumor DNA are almost completely suppressed when thymidine blood plasma levels are maintained at 40–8 × 10⁻⁶ M in adult mice.
iododeoxyuridine,"Reutilization of iododeoxyuridine in large, rapidly growing ascites tumors is over 30% in vivo, even in the absence of thymidine pellet implants.","Entity: iododeoxyuridine. SMILES: O=c1ccn([C@@]2(I)C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. Reutilization of iododeoxyuridine in large, rapidly growing ascites tumors is over 30% in vivo, even in the absence of thymidine pellet implants."
thymidine,Implantation of a long-acting thymidine pellet in adult mice maintains blood plasma thymidine concentrations at 40–8 × 10⁻⁶ M for up to 48 hours.,Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Implantation of a long-acting thymidine pellet in adult mice maintains blood plasma thymidine concentrations at 40–8 × 10⁻⁶ M for up to 48 hours.
thymidine,A thymidine pool in vivo is at least 10 times larger than the 4-nmole pool of extracellular thymidine.,Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. A thymidine pool in vivo is at least 10 times larger than the 4-nmole pool of extracellular thymidine.
cyproterone acetate,Cyproterone acetate is an antiandrogen that inhibits both protein and DNA synthesis in human breast cancer cells and blocks androgen-mediated stimulation.,Entity: cyproterone acetate. SMILES: CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C. Cyproterone acetate is an antiandrogen that inhibits both protein and DNA synthesis in human breast cancer cells and blocks androgen-mediated stimulation.
5alpha-androstanediol,5alpha-androstanediol is a more polar metabolite formed from [3H]-5alpha-dihydrotestosterone upon incubation at 37°C.,Entity: 5alpha-androstanediol. SMILES: C[C@]12CCC(O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. 5alpha-androstanediol is a more polar metabolite formed from [3H]-5alpha-dihydrotestosterone upon incubation at 37°C.
3'-methyl-4-dimethylaminoazobenzene,Sublethal doses of 3'-methyl-4-dimethylaminoazobenzene in rats significantly reduce the apparent concentration of nuclear binding sites and the Kd of glucocorticoid-nuclear acceptor site interactions in rat liver.,Entity: 3'-methyl-4-dimethylaminoazobenzene. SMILES: Cc1cccc(N=Nc2ccc(N(C)C)cc2)c1. Sublethal doses of 3'-methyl-4-dimethylaminoazobenzene in rats significantly reduce the apparent concentration of nuclear binding sites and the Kd of glucocorticoid-nuclear acceptor site interactions in rat liver.
aflatoxin B2,"Aflatoxin B2, a weakly toxic aflatoxin B1 cognate, does not affect the kinetics or binding capacity of glucocorticoid-nuclear acceptor site interaction in rat liver.","Entity: aflatoxin B2. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1CCO[C@@H]1O2. Aflatoxin B2, a weakly toxic aflatoxin B1 cognate, does not affect the kinetics or binding capacity of glucocorticoid-nuclear acceptor site interaction in rat liver."
4-dimethylaminoazobenzene,Sublethal doses of 4-dimethylaminoazobenzene in rats significantly reduce the apparent concentration of nuclear binding sites and the Kd of glucocorticoid-nuclear acceptor site interactions in rat liver.,Entity: 4-dimethylaminoazobenzene. SMILES: CN(C)c1ccc(N=Nc2ccccc2)cc1. Sublethal doses of 4-dimethylaminoazobenzene in rats significantly reduce the apparent concentration of nuclear binding sites and the Kd of glucocorticoid-nuclear acceptor site interactions in rat liver.
thioacetamide,Sublethal doses of thioacetamide in rats significantly reduce the apparent concentration of nuclear binding sites and the Kd of glucocorticoid-nuclear acceptor site interactions in rat liver.,Entity: thioacetamide. SMILES: CC(N)=S. Sublethal doses of thioacetamide in rats significantly reduce the apparent concentration of nuclear binding sites and the Kd of glucocorticoid-nuclear acceptor site interactions in rat liver.
3-methylcholanthrene,Sublethal doses of 3-methylcholanthrene in rats significantly reduce the apparent concentration of nuclear binding sites and the Kd of glucocorticoid-nuclear acceptor site interactions in rat liver.,Entity: 3-methylcholanthrene. SMILES: Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3. Sublethal doses of 3-methylcholanthrene in rats significantly reduce the apparent concentration of nuclear binding sites and the Kd of glucocorticoid-nuclear acceptor site interactions in rat liver.
aflatoxin B1,Sublethal doses of aflatoxin B1 in rats significantly reduce the apparent concentration of nuclear binding sites and the Kd of glucocorticoid-nuclear acceptor site interactions in rat liver.,Entity: aflatoxin B1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2. Sublethal doses of aflatoxin B1 in rats significantly reduce the apparent concentration of nuclear binding sites and the Kd of glucocorticoid-nuclear acceptor site interactions in rat liver.
aflatoxin B1,"Aflatoxin B1, despite being a hepatotoxin, does not affect the kinetics or binding capacity of glucocorticoid-nuclear acceptor site interaction in rat liver.","Entity: aflatoxin B1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2. Aflatoxin B1, despite being a hepatotoxin, does not affect the kinetics or binding capacity of glucocorticoid-nuclear acceptor site interaction in rat liver."
acetaminophen,"Acetaminophen, a hepatotoxic but noncarcinogenic analgesic, does not affect the kinetics or binding capacity of glucocorticoid-nuclear acceptor site interaction in rat liver.","Entity: acetaminophen. SMILES: CC(=O)Nc1ccc(O)cc1. Acetaminophen, a hepatotoxic but noncarcinogenic analgesic, does not affect the kinetics or binding capacity of glucocorticoid-nuclear acceptor site interaction in rat liver."
testosterone,"Testosterone treatment (4 mg/rat, 3 times/week for 6 weeks) enhances the hepatic metabolism of aflatoxin B1 in castrated immature male and female rats.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone treatment (4 mg/rat, 3 times/week for 6 weeks) enhances the hepatic metabolism of aflatoxin B1 in castrated immature male and female rats."
aflatoxin B1,"Aflatoxin B1 undergoes hepatic microsome-catalyzed metabolism in rats to form aflatoxin M1 and aflatoxin Q1, as well as DNA-alkylating metabolites.","Entity: aflatoxin B1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2. Aflatoxin B1 undergoes hepatic microsome-catalyzed metabolism in rats to form aflatoxin M1 and aflatoxin Q1, as well as DNA-alkylating metabolites."
aflatoxin B1,"Hepatic microsomes from male rats metabolize aflatoxin B1 to aflatoxin M1, aflatoxin Q1, and DNA-alkylating metabolites 2- to 5-fold more efficiently than those from female rats.","Entity: aflatoxin B1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2. Hepatic microsomes from male rats metabolize aflatoxin B1 to aflatoxin M1, aflatoxin Q1, and DNA-alkylating metabolites 2- to 5-fold more efficiently than those from female rats."
aflatoxin B1,Castration reduces the hepatic metabolism of aflatoxin B1 by male rats by about 50% compared to intact males.,Entity: aflatoxin B1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2. Castration reduces the hepatic metabolism of aflatoxin B1 by male rats by about 50% compared to intact males.
aflatoxin B1,Ovariectomy in female rats does not significantly affect hepatic microsome-mediated metabolism of aflatoxin B1.,Entity: aflatoxin B1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2. Ovariectomy in female rats does not significantly affect hepatic microsome-mediated metabolism of aflatoxin B1.
aflatoxin B1,"Kidney microsomes have 1% to 4% of the metabolic activation activity of liver microsomes for aflatoxin B1, and this activity is generally lower in male rats than in female rats of Sprague-Dawley, Wistar, and Long-Evans strains.","Entity: aflatoxin B1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2. Kidney microsomes have 1% to 4% of the metabolic activation activity of liver microsomes for aflatoxin B1, and this activity is generally lower in male rats than in female rats of Sprague-Dawley, Wistar, and Long-Evans strains."
aflatoxin B1,More aflatoxin B1 becomes bound to hepatic DNA in vivo in male rats and in a female rat treated with testosterone compared to control female rats.,Entity: aflatoxin B1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2. More aflatoxin B1 becomes bound to hepatic DNA in vivo in male rats and in a female rat treated with testosterone compared to control female rats.
aflatoxin B1,Sex differences in hepatic metabolism of aflatoxin B1 may underlie sex differences in the toxicity and carcinogenicity of aflatoxin B1 observed in rats.,Entity: aflatoxin B1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2. Sex differences in hepatic metabolism of aflatoxin B1 may underlie sex differences in the toxicity and carcinogenicity of aflatoxin B1 observed in rats.
aflatoxin M1,Aflatoxin M1 is a metabolite formed from aflatoxin B1 by hepatic microsome-catalyzed metabolism in rats.,Entity: aflatoxin M1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@]1(O)C=CO[C@@H]1O2. Aflatoxin M1 is a metabolite formed from aflatoxin B1 by hepatic microsome-catalyzed metabolism in rats.
6-amino penicillanic acid,6-amino penicillanic acid is used at a concentration of 150 µg/ml in nutrient agar to induce β-lactamase expression in P. aeruginosa colonies during selection of noninducible mutants.,Entity: 6-amino penicillanic acid. SMILES: CC1(C)S[C@@H]2C(N)C(=O)N2[C@H]1C(=O)O. 6-amino penicillanic acid is used at a concentration of 150 µg/ml in nutrient agar to induce β-lactamase expression in P. aeruginosa colonies during selection of noninducible mutants.
N-methyl-N'-nitro-N-nitrosoguanidine,N-methyl-N'-nitro-N-nitrosoguanidine is used at a final concentration of 100 µg/ml in citrate buffer to treat P. aeruginosa cultures during the selection of type Id/8-lactamase noninducible mutants.,Entity: N-methyl-N'-nitro-N-nitrosoguanidine. SMILES: CN(N=O)C(=N)N[N+](=O)[O-]. N-methyl-N'-nitro-N-nitrosoguanidine is used at a final concentration of 100 µg/ml in citrate buffer to treat P. aeruginosa cultures during the selection of type Id/8-lactamase noninducible mutants.
carbenicillin,"Carbenicillin is an inhibitor of peptidoglycan transpeptidase activity, and resistance to carbenicillin in Pseudomonas aeruginosa mutants is associated with significantly increased resistance to other beta-lactam antibiotics such as ampicillin and cephaloridine.","Entity: carbenicillin. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)O)c3ccccc3)C(=O)N2[C@H]1C(=O)O. Carbenicillin is an inhibitor of peptidoglycan transpeptidase activity, and resistance to carbenicillin in Pseudomonas aeruginosa mutants is associated with significantly increased resistance to other beta-lactam antibiotics such as ampicillin and cephaloridine."
ampicillin,"Ampicillin inhibits peptidoglycan transpeptidase activity, and resistance to ampicillin in Pseudomonas aeruginosa mutants is linked to increased resistance to other beta-lactam antibiotics.","Entity: ampicillin. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O. Ampicillin inhibits peptidoglycan transpeptidase activity, and resistance to ampicillin in Pseudomonas aeruginosa mutants is linked to increased resistance to other beta-lactam antibiotics."
kanamycin,"Kanamycin is an aminoglycoside antibiotic, and resistance to kanamycin in Pseudomonas aeruginosa mutants is not affected by increased resistance to beta-lactam antibiotics.","Entity: kanamycin. SMILES: NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](O)[C@@H](O)[C@@H]1O. Kanamycin is an aminoglycoside antibiotic, and resistance to kanamycin in Pseudomonas aeruginosa mutants is not affected by increased resistance to beta-lactam antibiotics."
streptomycin,"Streptomycin is an aminoglycoside antibiotic, and resistance to streptomycin in Pseudomonas aeruginosa mutants is not affected by increased resistance to beta-lactam antibiotics.","Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is an aminoglycoside antibiotic, and resistance to streptomycin in Pseudomonas aeruginosa mutants is not affected by increased resistance to beta-lactam antibiotics."
ethylenediaminetetraacetic acid,Ethylenediaminetetraacetic acid is used at a final concentration of 250 µg/ml to lyse cells in nucleic acid extraction protocols.,Entity: ethylenediaminetetraacetic acid. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. Ethylenediaminetetraacetic acid is used at a final concentration of 250 µg/ml to lyse cells in nucleic acid extraction protocols.
dithiothreitol,Dithiothreitol is included at 0.2 mM in Tris-hydrochloride buffer (pH 7.9) to reduce viscosity and aid in protein purification during nucleic acid extraction.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is included at 0.2 mM in Tris-hydrochloride buffer (pH 7.9) to reduce viscosity and aid in protein purification during nucleic acid extraction.
glycine,"Glycine is used at a concentration of 1,000 mM in biochemical reaction mixtures.","Entity: glycine. SMILES: NCC(=O)O. Glycine is used at a concentration of 1,000 mM in biochemical reaction mixtures."
water,Distilled water is used as a solvent in biochemical reaction mixtures.,Entity: water. SMILES: O. Distilled water is used as a solvent in biochemical reaction mixtures.
dithiothreitol,Dithiothreitol is used as a reducing agent in biochemical reaction mixtures at a concentration of 1.4 mM.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used as a reducing agent in biochemical reaction mixtures at a concentration of 1.4 mM.
ampicillin,Ampicillin inhibits the transpeptidase activity of Pseudomonas aeruginosa 18sH.,Entity: ampicillin. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O. Ampicillin inhibits the transpeptidase activity of Pseudomonas aeruginosa 18sH.
carbenicillin,Carbenicillin inhibits the transpeptidase activity of Pseudomonas aeruginosa 18sH.,Entity: carbenicillin. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)O)c3ccccc3)C(=O)N2[C@H]1C(=O)O. Carbenicillin inhibits the transpeptidase activity of Pseudomonas aeruginosa 18sH.
cephaloridine,Cephaloridine inhibits the transpeptidase activity of Pseudomonas aeruginosa 18sH.,Entity: cephaloridine. SMILES: O=C(Cc1cccs1)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12. Cephaloridine inhibits the transpeptidase activity of Pseudomonas aeruginosa 18sH.
streptomycin,"High-level resistance to streptomycin in Pseudomonas aeruginosa can result from mutations at the transpeptidase target, leading to increased resistance to inhibition by β-lactam antibiotics.","Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. High-level resistance to streptomycin in Pseudomonas aeruginosa can result from mutations at the transpeptidase target, leading to increased resistance to inhibition by β-lactam antibiotics."
nalidixic acid,"Resistance to nalidixic acid in Pseudomonas aeruginosa is linked to mutations at the transpeptidase target, which enhances resistance to inhibition by β-lactam antibiotics.","Entity: nalidixic acid. SMILES: CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21. Resistance to nalidixic acid in Pseudomonas aeruginosa is linked to mutations at the transpeptidase target, which enhances resistance to inhibition by β-lactam antibiotics."
carbenicillin,"Carbenicillin resistance in Pseudomonas aeruginosa is associated with a modified membrane-bound transpeptidase target, resulting in increased resistance to inhibition by β-lactam antibiotics.","Entity: carbenicillin. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)O)c3ccccc3)C(=O)N2[C@H]1C(=O)O. Carbenicillin resistance in Pseudomonas aeruginosa is associated with a modified membrane-bound transpeptidase target, resulting in increased resistance to inhibition by β-lactam antibiotics."
cephalosporin,"Resistance to cephalosporin in Pseudomonas aeruginosa is associated with a modified membrane-bound transpeptidase target, conferring increased resistance to inhibition by β-lactam antibiotics.","Entity: cephalosporin. SMILES: C=C1CS[C@H]([C@H](NC(=O)CCCC[C@@H](N)C(=O)O)C(=O)O)N=C1C(=O)O. Resistance to cephalosporin in Pseudomonas aeruginosa is associated with a modified membrane-bound transpeptidase target, conferring increased resistance to inhibition by β-lactam antibiotics."
methotrexate,"Methotrexate is used in combination chemotherapy for L1210 leukemia, and resistance to methotrexate develops more slowly when administered in combination with other agents compared to single-drug schedules.","Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Methotrexate is used in combination chemotherapy for L1210 leukemia, and resistance to methotrexate develops more slowly when administered in combination with other agents compared to single-drug schedules."
6-mercaptopurine,"6-mercaptopurine is used in combination chemotherapy for L1210 leukemia, and resistance to 6-mercaptopurine develops more slowly when administered in combination with other agents compared to single-drug schedules.","Entity: 6-mercaptopurine. SMILES: Sc1ncnc2nc[nH]c12. 6-mercaptopurine is used in combination chemotherapy for L1210 leukemia, and resistance to 6-mercaptopurine develops more slowly when administered in combination with other agents compared to single-drug schedules."
6-mercaptopurine,Resistance to 6-mercaptopurine in L1210 leukemia is completed after four generations in offset combination schedules and after 28 generations in simultaneous combination schedules.,Entity: 6-mercaptopurine. SMILES: Sc1ncnc2nc[nH]c12. Resistance to 6-mercaptopurine in L1210 leukemia is completed after four generations in offset combination schedules and after 28 generations in simultaneous combination schedules.
raffinose,"The infrared spectra of raffinose and related oligosaccharides can be analyzed in the region 1,000–40 cm⁻¹, which is suitable for determining the configuration of the glycosidic linkage.","Entity: raffinose. SMILES: OC[C@H]1O[C@H](OC[C@H]2O[C@H](O[C@]3(CO)O[C@H](CO)[C@@H](O)[C@@H]3O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1O. The infrared spectra of raffinose and related oligosaccharides can be analyzed in the region 1,000–40 cm⁻¹, which is suitable for determining the configuration of the glycosidic linkage."
2-acetamido-2-deoxy-D-mannose,"In D,O equilibrium, the pyranose ring of 2-acetamido-2-deoxy-D-mannose preferentially adopts the 4c1(D) conformation.","Entity: 2-acetamido-2-deoxy-D-mannose. SMILES: CC(=O)N[C@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO. In D,O equilibrium, the pyranose ring of 2-acetamido-2-deoxy-D-mannose preferentially adopts the 4c1(D) conformation."
2-acetamido-2-deoxy-D-galactose,"In D,O equilibrium, the pyranose ring of 2-acetamido-2-deoxy-D-galactose preferentially adopts the 4c1(D) conformation.","Entity: 2-acetamido-2-deoxy-D-galactose. SMILES: CC(=O)N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@H](O)CO. In D,O equilibrium, the pyranose ring of 2-acetamido-2-deoxy-D-galactose preferentially adopts the 4c1(D) conformation."
2-acetamido-2-deoxy-D-glucose,"In D,O equilibrium, the pyranose ring of 2-acetamido-2-deoxy-D-glucose preferentially adopts the 4c1(D) conformation.","Entity: 2-acetamido-2-deoxy-D-glucose. SMILES: CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO. In D,O equilibrium, the pyranose ring of 2-acetamido-2-deoxy-D-glucose preferentially adopts the 4c1(D) conformation."
muramic acid,Muramic acid forms part of the glycan backbone of peptidoglycan in almost all bacteria.,Entity: muramic acid. SMILES: C[C@@H](O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1N)C(=O)O. Muramic acid forms part of the glycan backbone of peptidoglycan in almost all bacteria.
D-mannose,"In equilibrium mixtures in solution, the percentage of D-mannose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom.","Entity: D-mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In equilibrium mixtures in solution, the percentage of D-mannose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom."
2-acetamido-2-deoxy-D-mannose,"In equilibrium mixtures in solution, the percentage of 2-acetamido-2-deoxy-D-mannose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom.","Entity: 2-acetamido-2-deoxy-D-mannose. SMILES: CC(=O)N[C@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO. In equilibrium mixtures in solution, the percentage of 2-acetamido-2-deoxy-D-mannose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom."
2-acetamido-2-deoxy-D-galactose,"In equilibrium mixtures in solution, the percentage of 2-acetamido-2-deoxy-D-galactose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom.","Entity: 2-acetamido-2-deoxy-D-galactose. SMILES: CC(=O)N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@H](O)CO. In equilibrium mixtures in solution, the percentage of 2-acetamido-2-deoxy-D-galactose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom."
2-acetamido-2-deoxy-D-glucose,"In equilibrium mixtures in solution, the percentage of 2-acetamido-2-deoxy-D-glucose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom.","Entity: 2-acetamido-2-deoxy-D-glucose. SMILES: CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO. In equilibrium mixtures in solution, the percentage of 2-acetamido-2-deoxy-D-glucose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom."
D-galactose,"In equilibrium mixtures in solution, the percentage of D-galactose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom.","Entity: D-galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. In equilibrium mixtures in solution, the percentage of D-galactose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom."
D-glucose,"In equilibrium mixtures in solution, the percentage of D-glucose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom.","Entity: D-glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In equilibrium mixtures in solution, the percentage of D-glucose anomers is small, with an anomeric effect of about 0.55 kcal/mol, and this effect does not depend significantly on the nature or configuration of the group at the C-2 atom."
sialic acid,Sialic acid can be quantitatively removed from a hexasaccharide by hydrolysis with 0.05 M H2SO4 for 1 hour at 80°C.,Entity: sialic acid. SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(O)(C(=O)O)C[C@@H]1O. Sialic acid can be quantitatively removed from a hexasaccharide by hydrolysis with 0.05 M H2SO4 for 1 hour at 80°C.
mannitol,Mannitol is used as a standard monosaccharide for quantitative analysis by gas chromatography-mass spectrometry (g.1.c.) after direct trimethylsilylation.,Entity: mannitol. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannitol is used as a standard monosaccharide for quantitative analysis by gas chromatography-mass spectrometry (g.1.c.) after direct trimethylsilylation.
HCl,"Hydrochloric acid (HCl) is used to hydrolyze polysaccharides for 4 hours at 100°C in the determination of neutral hexoses, acetylhexosamines, 6-deoxyhexoses, and sialic acid.","Entity: HCl. SMILES: Cl. Hydrochloric acid (HCl) is used to hydrolyze polysaccharides for 4 hours at 100°C in the determination of neutral hexoses, acetylhexosamines, 6-deoxyhexoses, and sialic acid."
lactose,Lactose serves as a structural residue at the reducing end of certain urinary oligosaccharides isolated from pregnant women.,Entity: lactose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O. Lactose serves as a structural residue at the reducing end of certain urinary oligosaccharides isolated from pregnant women.
D-galactose,D-galactose can serve as a substrate for glycosyltransferases that add monosaccharides to form urinary oligosaccharides.,Entity: D-galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. D-galactose can serve as a substrate for glycosyltransferases that add monosaccharides to form urinary oligosaccharides.
L-fucose,"Oligosaccharides containing L-fucose, such as lacto-N-tetraose, are found in urinary oligosaccharides from pregnant women.","Entity: L-fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Oligosaccharides containing L-fucose, such as lacto-N-tetraose, are found in urinary oligosaccharides from pregnant women."
D-glucose,D-glucose can be a substrate for glycosyltransferases involved in the biosynthesis of urinary oligosaccharides.,Entity: D-glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. D-glucose can be a substrate for glycosyltransferases involved in the biosynthesis of urinary oligosaccharides.
neuraminyllactose,Neuraminyllactose is an oligosaccharide found in human milk but is not related to pregnancy.,Entity: neuraminyllactose. SMILES: N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)(C2(O)O[C@H](CO)[C@@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)C[C@@H]1O. Neuraminyllactose is an oligosaccharide found in human milk but is not related to pregnancy.
2-acetamido-2-deoxy-3-O-D-galactopyranosyl-D-glucose,"2-acetamido-2-deoxy-3-O-D-galactopyranosyl-D-glucose can be slowly hydrolyzed by jack-bean α-D-galactosidase to liberate D-galactose, indicating that the external 8-D-galactopyranosyl group is α–(1+3)-linked to an N-acetyl-D-glucosamine residue.","Entity: 2-acetamido-2-deoxy-3-O-D-galactopyranosyl-D-glucose. SMILES: CC(=O)N[C@@H](C=O)[C@@H](OC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CO. 2-acetamido-2-deoxy-3-O-D-galactopyranosyl-D-glucose can be slowly hydrolyzed by jack-bean α-D-galactosidase to liberate D-galactose, indicating that the external 8-D-galactopyranosyl group is α–(1+3)-linked to an N-acetyl-D-glucosamine residue."
lactose,"Lactose is produced by the enzymatic hydrolysis of a hexasaccharide containing a terminal D-galactose residue, with partial removal of D-galactose (0.39 mol/mol of saccharide) and N-acetyl-D-glucosamine (0.35 mol/mol of saccharide).","Entity: lactose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O. Lactose is produced by the enzymatic hydrolysis of a hexasaccharide containing a terminal D-galactose residue, with partial removal of D-galactose (0.39 mol/mol of saccharide) and N-acetyl-D-glucosamine (0.35 mol/mol of saccharide)."
D-galactose,"D-galactose is present at the nonreducing end of a tetrasaccharide in the hexasaccharide, and its terminal position is confirmed by the slow release by jack-bean α-D-galactosidase (0.09 residue) and efficient release by beef-liver α-D-galactosidase (0.39 residue).","Entity: D-galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. D-galactose is present at the nonreducing end of a tetrasaccharide in the hexasaccharide, and its terminal position is confirmed by the slow release by jack-bean α-D-galactosidase (0.09 residue) and efficient release by beef-liver α-D-galactosidase (0.39 residue)."
N-acetyl-D-glucosamine,"N-acetyl-D-glucosamine is present at the reducing end of a hexasaccharide, with partial removal of 0.35 mol/mol of saccharide during enzymatic hydrolysis.","Entity: N-acetyl-D-glucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. N-acetyl-D-glucosamine is present at the reducing end of a hexasaccharide, with partial removal of 0.35 mol/mol of saccharide during enzymatic hydrolysis."
N-acetyl-D-glucosamine,"N-acetyl-D-glucosamine is a component of the hexasaccharide obtained from human urine, present in the proportion of 1 out of six monosaccharide residues.","Entity: N-acetyl-D-glucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. N-acetyl-D-glucosamine is a component of the hexasaccharide obtained from human urine, present in the proportion of 1 out of six monosaccharide residues."
N-acetylneuraminic acid,"N-acetylneuraminic acid is a component of the hexasaccharide from human urine, present in the proportion of 2 out of six monosaccharide residues.","Entity: N-acetylneuraminic acid. SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(O)(C(=O)O)C[C@@H]1O. N-acetylneuraminic acid is a component of the hexasaccharide from human urine, present in the proportion of 2 out of six monosaccharide residues."
D-galactose,"D-galactose is a component of the hexasaccharide derived from human urine, present in the proportion of 2 out of six monosaccharide residues.","Entity: D-galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. D-galactose is a component of the hexasaccharide derived from human urine, present in the proportion of 2 out of six monosaccharide residues."
D-glucose,"D-glucose is present in the hexasaccharide from human urine, but is converted to D-glucitol upon potassium borohydride reduction, with 0.07 residue remaining.","Entity: D-glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. D-glucose is present in the hexasaccharide from human urine, but is converted to D-glucitol upon potassium borohydride reduction, with 0.07 residue remaining."
aniline oxalate,The aniline oxalate reagent is used to detect the presence of reducing sugars in the hexasaccharide from human urine.,Entity: aniline oxalate. SMILES: Nc1ccccc1.O=C(O)C(=O)O. The aniline oxalate reagent is used to detect the presence of reducing sugars in the hexasaccharide from human urine.
D-glucitol,D-glucitol is present in a residue of 1.05 after potassium borohydride reduction of a hexasaccharide derived from human urine.,Entity: D-glucitol. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CO. D-glucitol is present in a residue of 1.05 after potassium borohydride reduction of a hexasaccharide derived from human urine.
potassium borohydride,"Potassium borohydride is used as a reducing agent to convert a hexasaccharide into its constituent monosaccharides, resulting in the detection of D-glucitol and the absence of D-glucose.","Entity: potassium borohydride. SMILES: [BH4-].[K+]. Potassium borohydride is used as a reducing agent to convert a hexasaccharide into its constituent monosaccharides, resulting in the detection of D-glucitol and the absence of D-glucose."
L-fucose,Oligosaccharides containing L-fucose are present in human urine and are specifically related to pregnancy.,Entity: L-fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Oligosaccharides containing L-fucose are present in human urine and are specifically related to pregnancy.
aniline oxalate,Aniline oxalate is used as a staining reagent to reveal basic and neutral fractions in paper electrophoresis.,Entity: aniline oxalate. SMILES: Nc1ccccc1.O=C(O)C(=O)O. Aniline oxalate is used as a staining reagent to reveal basic and neutral fractions in paper electrophoresis.
D-mannose,D-mannose is used as a standard monosaccharide in paper electrophoresis and as a reference for the neutral fraction.,Entity: D-mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. D-mannose is used as a standard monosaccharide in paper electrophoresis and as a reference for the neutral fraction.
boric acid,Boric acid can be removed from reaction mixtures by conversion to its methyl borate salt.,Entity: boric acid. SMILES: OB(O)O. Boric acid can be removed from reaction mixtures by conversion to its methyl borate salt.
D-glucosamine hydrochloride,D-glucosamine hydrochloride is used as a standard monosaccharide in paper electrophoresis and as a reference for the basic fraction.,Entity: D-glucosamine hydrochloride. SMILES: Cl.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. D-glucosamine hydrochloride is used as a standard monosaccharide in paper electrophoresis and as a reference for the basic fraction.
acetic acid,Acetic acid is used to destroy excess potassium borohydride in chemical reduction reactions.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used to destroy excess potassium borohydride in chemical reduction reactions.
potassium borohydride,Potassium borohydride is used as a reducing agent for hexasaccharides in water at room temperature for 15 hours.,Entity: potassium borohydride. SMILES: [BH4-].[K+]. Potassium borohydride is used as a reducing agent for hexasaccharides in water at room temperature for 15 hours.
methyl borate,Methyl borate is formed by the conversion of boric acid and can be removed from reaction mixtures by evaporation.,Entity: methyl borate. SMILES: COB([O-])[O-]. Methyl borate is formed by the conversion of boric acid and can be removed from reaction mixtures by evaporation.
methanol,Methanol is used as a component (in a 9:1 v/v mixture with chloroform) for thin-layer chromatography (TLC) analysis of methylated saccharides.,Entity: methanol. SMILES: CO. Methanol is used as a component (in a 9:1 v/v mixture with chloroform) for thin-layer chromatography (TLC) analysis of methylated saccharides.
chloroform,Chloroform is used as a component (in a 9:1 v/v mixture with methanol) for thin-layer chromatography (TLC) analysis of methylated saccharides.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a component (in a 9:1 v/v mixture with methanol) for thin-layer chromatography (TLC) analysis of methylated saccharides.
hydrochloric acid,Hydrochloric acid (4 M) is used for hydrolysis of methyl ethers from saccharides at 100°C for 4 hours.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (4 M) is used for hydrolysis of methyl ethers from saccharides at 100°C for 4 hours.
ninhydrin,Ninhydrin is used as a staining reagent to visualize basic and neutral fractions in paper electrophoresis.,Entity: ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is used as a staining reagent to visualize basic and neutral fractions in paper electrophoresis.
acetic acid,"Acetic acid is used as a component in solvent systems for analytical paper chromatography and electrophoresis, such as in the 1:3:36 formic acid-acetic acid-water system at pH 1.9 and the 25:1:1974 pyridine-acetic acid-water system at pH 6.4.","Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component in solvent systems for analytical paper chromatography and electrophoresis, such as in the 1:3:36 formic acid-acetic acid-water system at pH 1.9 and the 25:1:1974 pyridine-acetic acid-water system at pH 6.4."
pyridine,"Pyridine is used as a component in solvent systems for analytical paper chromatography, such as in the 1:3:36 formic acid-acetic acid-water system at pH 1.9 and the 25:1:1974 pyridine-acetic acid-water system at pH 6.4.","Entity: pyridine. SMILES: c1ccncc1. Pyridine is used as a component in solvent systems for analytical paper chromatography, such as in the 1:3:36 formic acid-acetic acid-water system at pH 1.9 and the 25:1:1974 pyridine-acetic acid-water system at pH 6.4."
formic acid,Formic acid is used as a component in the 1:3:36 formic acid-acetic acid-water system for high-voltage paper electrophoresis at pH 1.9.,Entity: formic acid. SMILES: O=CO. Formic acid is used as a component in the 1:3:36 formic acid-acetic acid-water system for high-voltage paper electrophoresis at pH 1.9.
ethyl acetate,"Ethyl acetate is used as a component in solvent systems for analytical paper chromatography, such as in the 2:1:2 ethyl acetate-pyridine-water system.","Entity: ethyl acetate. SMILES: CCOC(C)=O. Ethyl acetate is used as a component in solvent systems for analytical paper chromatography, such as in the 2:1:2 ethyl acetate-pyridine-water system."
lactose,"Lactose can be detected by analytical paper chromatography using solvent systems (A) 5:5:1:3 pyridine-ethyl acetate-acetic acid-water, (B) 13:6 propanol-water, or (C) 2:1:2 ethyl acetate-pyridine-water, producing peaks at approximately 2.98 and 3.35.","Entity: lactose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O. Lactose can be detected by analytical paper chromatography using solvent systems (A) 5:5:1:3 pyridine-ethyl acetate-acetic acid-water, (B) 13:6 propanol-water, or (C) 2:1:2 ethyl acetate-pyridine-water, producing peaks at approximately 2.98 and 3.35."
hydrochloric acid,"Hydrochloric acid is used to hydrolyze amino acids from protein samples, typically for 7 hours at 100°C.","Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to hydrolyze amino acids from protein samples, typically for 7 hours at 100°C."
propanol,"Propanol is used as a component of solvent systems for analytical paper chromatography, such as in the 13:6 propanol-water system.","Entity: propanol. SMILES: CCCO. Propanol is used as a component of solvent systems for analytical paper chromatography, such as in the 13:6 propanol-water system."
water,"Water is used as a component in various solvent systems for analytical paper chromatography and electrophoresis, including in the 1:3:36 formic acid-acetic acid-water system at pH 1.9 and the 25:1:1974 pyridine-acetic acid-water system at pH 6.4.","Entity: water. SMILES: O. Water is used as a component in various solvent systems for analytical paper chromatography and electrophoresis, including in the 1:3:36 formic acid-acetic acid-water system at pH 1.9 and the 25:1:1974 pyridine-acetic acid-water system at pH 6.4."
lacto-N-tetraose,"Lacto-N-tetraose is a hexasaccharide containing D-glucose, N-acetyl-D-glucosamine, and two sialic acid residues, with one sialic acid linked alpha-(2→3) to the terminal nonreducing residue of D-galactose and the other linked alpha-(2→6) to the N-acetyl-D-glucosamine residue.","Entity: lacto-N-tetraose. SMILES: CC(=O)N[C@H]1[C@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]3[C@H](O)[C@@H](O)C(O)O[C@@H]3CO)[C@@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O. Lacto-N-tetraose is a hexasaccharide containing D-glucose, N-acetyl-D-glucosamine, and two sialic acid residues, with one sialic acid linked alpha-(2→3) to the terminal nonreducing residue of D-galactose and the other linked alpha-(2→6) to the N-acetyl-D-glucosamine residue."
lacto-N-tetraose,"Lacto-N-tetraose with a sialic acid modification is found in the urine of pregnant women but not in nonpregnant, normal women, and is present in human milk.","Entity: lacto-N-tetraose. SMILES: CC(=O)N[C@H]1[C@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]3[C@H](O)[C@@H](O)C(O)O[C@@H]3CO)[C@@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O. Lacto-N-tetraose with a sialic acid modification is found in the urine of pregnant women but not in nonpregnant, normal women, and is present in human milk."
D-glucose,D-glucose is a component of the hexasaccharide lacto-N-tetraose found in the urine of pregnant women.,Entity: D-glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. D-glucose is a component of the hexasaccharide lacto-N-tetraose found in the urine of pregnant women.
oxygen,Oxygen serves as the terminal electron acceptor for the highest glucose and gluconate transport rate in Pseudomonas aeruginosa.,Entity: oxygen. SMILES: [O]. Oxygen serves as the terminal electron acceptor for the highest glucose and gluconate transport rate in Pseudomonas aeruginosa.
Nitrite,"Nitrite acts as a terminal electron acceptor in Pseudomonas aeruginosa denitrification, supporting poor growth when concentrations are less than 15 mM due to toxicity.","Entity: Nitrite. SMILES: O=N[O-]. Nitrite acts as a terminal electron acceptor in Pseudomonas aeruginosa denitrification, supporting poor growth when concentrations are less than 15 mM due to toxicity."
Nitrite,Nitrite accumulates in the medium during early exponential phase when nitrate is the terminal electron acceptor and decreases to extinction before midexponential phase in Pseudomonas aeruginosa.,Entity: Nitrite. SMILES: O=N[O-]. Nitrite accumulates in the medium during early exponential phase when nitrate is the terminal electron acceptor and decreases to extinction before midexponential phase in Pseudomonas aeruginosa.
Nitrite,Nitrite supports maximal rates of glucose and gluconate transport in Pseudomonas aeruginosa under anaerobic conditions at a concentration of 1 mM.,Entity: Nitrite. SMILES: O=N[O-]. Nitrite supports maximal rates of glucose and gluconate transport in Pseudomonas aeruginosa under anaerobic conditions at a concentration of 1 mM.
glucose,The maximal rate of glucose transport in Pseudomonas aeruginosa is supported by 1 mM nitrate or nitrite as the terminal electron acceptor under anaerobic conditions.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. The maximal rate of glucose transport in Pseudomonas aeruginosa is supported by 1 mM nitrate or nitrite as the terminal electron acceptor under anaerobic conditions.
gluconate,The maximal rate of gluconate transport in Pseudomonas aeruginosa is supported by 1 mM nitrate or nitrite as the terminal electron acceptor under anaerobic conditions.,Entity: gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. The maximal rate of gluconate transport in Pseudomonas aeruginosa is supported by 1 mM nitrate or nitrite as the terminal electron acceptor under anaerobic conditions.
3H-TdR,"3H-TdR is used as a radiolabel to continuously infuse hepatocytes, enabling labeling of up to 93–95% of parenchymal cells in young rats at 61 and 67 hours.","Entity: 3H-TdR. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. 3H-TdR is used as a radiolabel to continuously infuse hepatocytes, enabling labeling of up to 93–95% of parenchymal cells in young rats at 61 and 67 hours."
allyl formate,"Allyl formate is used to selectively destroy periportal liver cells, allowing induction of the replicative cycle in cells near the hepatic vein in the liver.","Entity: allyl formate. SMILES: C=CCOC=O. Allyl formate is used to selectively destroy periportal liver cells, allowing induction of the replicative cycle in cells near the hepatic vein in the liver."
achromycin,Achromycin is used as an antibiotic in snail cerebral ganglion complex culture media at a concentration of 3 mg/100 ml Ringer solution.,Entity: achromycin. SMILES: CN(C)C1C(=O)C(C(N)=O)=C(O)C2(O)C(=O)C3=C(O)c4c(O)cccc4C(C)(O)C3CC12. Achromycin is used as an antibiotic in snail cerebral ganglion complex culture media at a concentration of 3 mg/100 ml Ringer solution.
streptomycin,Streptomycin is used as an antibiotic in snail cerebral ganglion complex culture media at a concentration of 50 mg/100 ml Ringer solution.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used as an antibiotic in snail cerebral ganglion complex culture media at a concentration of 50 mg/100 ml Ringer solution.
achromycin,Achromycin is used as an antibiotic supplement in snail pleural ganglia (PPC) culture media to prevent bacterial contamination.,Entity: achromycin. SMILES: CN(C)C1C(=O)C(C(N)=O)=C(O)C2(O)C(=O)C3=C(O)c4c(O)cccc4C(C)(O)C3CC12. Achromycin is used as an antibiotic supplement in snail pleural ganglia (PPC) culture media to prevent bacterial contamination.
streptomycin,Streptomycin is included as an antibiotic in snail pleural ganglia (PPC) culture media to inhibit bacterial growth.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is included as an antibiotic in snail pleural ganglia (PPC) culture media to inhibit bacterial growth.
sodium chloride,Sodium chloride is used to adjust the osmolality of culture media for snail pleural ganglia (PPC) to 160 mOsm/kg H2O (medium 160) and 190 mOsm/kg H2O (medium 190).,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used to adjust the osmolality of culture media for snail pleural ganglia (PPC) to 160 mOsm/kg H2O (medium 160) and 190 mOsm/kg H2O (medium 190).
acetylthiocholine iodide,Acetylthiocholine iodide is used as a substrate for cholinesterase histochemical assays in tissue sections.,Entity: acetylthiocholine iodide. SMILES: CC(=O)SCC[N+](C)(C)C.[I-]. Acetylthiocholine iodide is used as a substrate for cholinesterase histochemical assays in tissue sections.
butyrylthiocholine iodide,Butyrylthiocholine iodide is used as a substrate for cholinesterase histochemical assays in tissue sections.,Entity: butyrylthiocholine iodide. SMILES: CCCC(=O)SCC[N+](C)(C)C.[I-]. Butyrylthiocholine iodide is used as a substrate for cholinesterase histochemical assays in tissue sections.
2-methylbutane,2-methylbutane is used as a cooling medium for rapid freezing of biological tissue specimens prior to histological processing.,Entity: 2-methylbutane. SMILES: CCC(C)C. 2-methylbutane is used as a cooling medium for rapid freezing of biological tissue specimens prior to histological processing.
acetylcholinesterase,Subepithelial striated muscle cells in the proximal urethra of the male guinea-pig contain a rich acetylcholinesterase content.,Entity: acetylcholinesterase. Subepithelial striated muscle cells in the proximal urethra of the male guinea-pig contain a rich acetylcholinesterase content.
Glutaraldehyde,"Glutaraldehyde is used as a fixative in tissue preparation, and its hypotonicity can cause distension of extracisternal tubules in muscle cells.","Entity: Glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a fixative in tissue preparation, and its hypotonicity can cause distension of extracisternal tubules in muscle cells."
Alcian blue,"Alcian blue is a dye that has been applied to muscle tissue to stain structures such as the sarcoplasmic reticulum and extracisternal tubules, but it does not enter the lumina of extracisternal tubules.","Entity: Alcian blue. SMILES: CN(C)C(SCc1ccc2c(c1)C1=NC2=NC2=NC(=NC3[N-]C(N=c4[n-]c(c5ccc(CSC(N(C)C)=[N+](C)C)cc45)=N1)c1ccc(CSC(N(C)C)=[N+](C)C)cc13)c1cc(CSC(N(C)C)=[N+](C)C)ccc12)=[N+](C)C.[Cl-].[Cl-].[Cl-].[Cl-].[Cu+2]. Alcian blue is a dye that has been applied to muscle tissue to stain structures such as the sarcoplasmic reticulum and extracisternal tubules, but it does not enter the lumina of extracisternal tubules."
Ruthenium red,"Ruthenium red is a dye that has been applied to muscle tissue to stain structures such as the sarcoplasmic reticulum and extracisternal tubules, but it does not enter the lumina of extracisternal tubules.","Entity: Ruthenium red. SMILES: N.N.N.N.N.N.N.N.N.N.N.N.N.N.[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[O-2].[O-2].[Ru+3].[Ru+3].[Ru+4]. Ruthenium red is a dye that has been applied to muscle tissue to stain structures such as the sarcoplasmic reticulum and extracisternal tubules, but it does not enter the lumina of extracisternal tubules."
osmium tetroxide,"Osmium tetroxide, when used in buffered form, enhances the visibility of myofilaments and cross-bridges in sarcomeres but disrupts the organization of cellular and intracellular membranes.","Entity: osmium tetroxide. SMILES: O=[Os](=O)(=O)=O. Osmium tetroxide, when used in buffered form, enhances the visibility of myofilaments and cross-bridges in sarcomeres but disrupts the organization of cellular and intracellular membranes."
silicon,"Silicon (Si) is rapidly sequestered in the kidney and excreted in the urine, with administered silicon accounting for only about 0.056% of total 31Si(OH)4 in mitochondrial granules.","Entity: silicon. SMILES: [Si]. Silicon (Si) is rapidly sequestered in the kidney and excreted in the urine, with administered silicon accounting for only about 0.056% of total 31Si(OH)4 in mitochondrial granules."
Germanium,"Germanium-68 (68Ge) can be incorporated into mitochondrial granules via 6SGe(OH)4, resulting in a 3- to 7-fold increase in specific activity during isolation from tissue to granular fraction.","Entity: Germanium. SMILES: [Ge]. Germanium-68 (68Ge) can be incorporated into mitochondrial granules via 6SGe(OH)4, resulting in a 3- to 7-fold increase in specific activity during isolation from tissue to granular fraction."
Silicon,"Silicon is used to administer 6SGe(OH)4 for labeling mitochondrial granules, and its content in these granules shows turnover, with more than half of 6SGe/lag Si retained at 10 h post-injection but decreasing to only 1/7 of the original content by 42 h.","Entity: Silicon. SMILES: [Si]. Silicon is used to administer 6SGe(OH)4 for labeling mitochondrial granules, and its content in these granules shows turnover, with more than half of 6SGe/lag Si retained at 10 h post-injection but decreasing to only 1/7 of the original content by 42 h."
Si(OH)4,"Si(OH)4 is used as a 31Si labeling agent in rat liver mitochondrial granule studies, with 64.5 g of liver yielding 1 g of labeled granules.","Entity: Si(OH)4. SMILES: O[Si](O)(O)O. Si(OH)4 is used as a 31Si labeling agent in rat liver mitochondrial granule studies, with 64.5 g of liver yielding 1 g of labeled granules."
SDS,"SDS is used to treat isolated rat liver mitochondrial granule pellets, with a 10-minute incubation at 2° SDS.","Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used to treat isolated rat liver mitochondrial granule pellets, with a 10-minute incubation at 2° SDS."
Triton X-100,Triton X-100 is used to solubilize rat liver mitochondria for preparation of mitochondrial granule fractions.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used to solubilize rat liver mitochondria for preparation of mitochondrial granule fractions.
uranyl acetate,Uranyl acetate is used as a surface-staining agent for visualizing granule aggregates in rat liver mitochondrial granule fractions.,Entity: uranyl acetate. SMILES: CC(=O)[O-].CC(=O)[O-].O=[U+2]=O. Uranyl acetate is used as a surface-staining agent for visualizing granule aggregates in rat liver mitochondrial granule fractions.
phosphorus,Phosphorus is present in higher amounts than silicon in small single granules and has a lower Si/P ratio in granule aggregates compared to small granules.,Entity: phosphorus. SMILES: [P]. Phosphorus is present in higher amounts than silicon in small single granules and has a lower Si/P ratio in granule aggregates compared to small granules.
magnesium,Magnesium is present in minor amounts in both small granule aggregates and small single granules.,Entity: magnesium. SMILES: [Mg]. Magnesium is present in minor amounts in both small granule aggregates and small single granules.
carbon,Carbon is present in minor amounts in both small granule aggregates and small single granules.,Entity: carbon. SMILES: [C]. Carbon is present in minor amounts in both small granule aggregates and small single granules.
sulfur,Sulfur is present in minor amounts in both small granule aggregates and small single granules.,Entity: sulfur. SMILES: [S]. Sulfur is present in minor amounts in both small granule aggregates and small single granules.
silicon,"Silicon is the predominant element in small 5 to 10 nm granule aggregates, with a higher Si/P ratio in aggregates compared to small granules.","Entity: silicon. SMILES: [Si]. Silicon is the predominant element in small 5 to 10 nm granule aggregates, with a higher Si/P ratio in aggregates compared to small granules."
silicon,Silicon is present in vacuum pump oil and its absence is recommended to prevent specimen contamination in electron microscopy.,Entity: silicon. SMILES: [Si]. Silicon is present in vacuum pump oil and its absence is recommended to prevent specimen contamination in electron microscopy.
nitrogen,Nitrogen is used in liquid nitrogen cold traps to maintain low temperatures during electron microscopy sample preparation.,Entity: nitrogen. SMILES: [N]. Nitrogen is used in liquid nitrogen cold traps to maintain low temperatures during electron microscopy sample preparation.
uranyl acetate,Uranyl acetate is used as a surface stain in electron microscopy to enhance contrast in thin sections.,Entity: uranyl acetate. SMILES: CC(=O)[O-].CC(=O)[O-].O=[U+2]=O. Uranyl acetate is used as a surface stain in electron microscopy to enhance contrast in thin sections.
silicic acid,"Silicic acid is taken up by in situ mitochondria in diatoms and rats, but cannot be completely extracted by distilled water wash, indicating it may be bound to membranes or polymerized into insoluble aggregates.","Entity: silicic acid. SMILES: O[Si](O)(O)O. Silicic acid is taken up by in situ mitochondria in diatoms and rats, but cannot be completely extracted by distilled water wash, indicating it may be bound to membranes or polymerized into insoluble aggregates."
Triton X-100,Triton X-100 is a detergent used to solubilize mitochondrial membranes for the isolation of granule fractions.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a detergent used to solubilize mitochondrial membranes for the isolation of granule fractions.
sodium dodecyl sulfate,Sodium dodecyl sulfate is a detergent used to solubilize mitochondrial membranes for the isolation of granule fractions.,Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate is a detergent used to solubilize mitochondrial membranes for the isolation of granule fractions.
Sodium hydroxide,Sodium hydroxide is used to adjust the pH to 8.0 in the preparation of carrier-free 68Ge(OH)4 from 68GeCI4.,Entity: Sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to adjust the pH to 8.0 in the preparation of carrier-free 68Ge(OH)4 from 68GeCI4.
Diphosphorus pentasodium phosphate,Diphosphorus pentasodium phosphate (Na2HPO4) is administered at a dose of 0.1 gmole/kg rat in injection solutions containing 31Si(OH)4 or 68Ge(OH)4.,Entity: Diphosphorus pentasodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[P+3].[P+3]. Diphosphorus pentasodium phosphate (Na2HPO4) is administered at a dose of 0.1 gmole/kg rat in injection solutions containing 31Si(OH)4 or 68Ge(OH)4.
Germanium(IV) chloride,Germanium(IV) chloride (68GeCI4) is used as a precursor for the preparation of carrier-free 68Ge(OH)4 with a specific activity of 6.7 Ci/mg and a half-life of 282 days.,Entity: Germanium(IV) chloride. SMILES: Cl[Ge](Cl)(Cl)Cl. Germanium(IV) chloride (68GeCI4) is used as a precursor for the preparation of carrier-free 68Ge(OH)4 with a specific activity of 6.7 Ci/mg and a half-life of 282 days.
Silicon dioxide,Silicon dioxide (SiO2) serves as the target material for neutron activation to produce carrier-free 31Si(OH)4 with a specific activity of 0.1 mCi/mg and a half-life of 152 days.,Entity: Silicon dioxide. SMILES: O=[Si]=O. Silicon dioxide (SiO2) serves as the target material for neutron activation to produce carrier-free 31Si(OH)4 with a specific activity of 0.1 mCi/mg and a half-life of 152 days.
Germanium(IV) hydroxide,Germanium(IV) hydroxide (68Ge(OH)4) is prepared by adjusting the pH of 68GeCI4 with NaOH and is used as a radiolabel in animal studies.,Entity: Germanium(IV) hydroxide. SMILES: O[Ge](O)(O)O. Germanium(IV) hydroxide (68Ge(OH)4) is prepared by adjusting the pH of 68GeCI4 with NaOH and is used as a radiolabel in animal studies.
Silicic acid,"Silicic acid (Si(OH)4) is used as a radiolabel in animal studies, administered at a dose of 1 gmole/kg rat in combination with 68Ge(OH)4 and Na2HPO4.","Entity: Silicic acid. SMILES: O[Si](O)(O)O. Silicic acid (Si(OH)4) is used as a radiolabel in animal studies, administered at a dose of 1 gmole/kg rat in combination with 68Ge(OH)4 and Na2HPO4."
Triton X-100,"Triton X-100 is a non-ionic detergent used for washing and solubilizing cellular membranes, such as liver mitochondria, in biochemical fractionation protocols.","Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent used for washing and solubilizing cellular membranes, such as liver mitochondria, in biochemical fractionation protocols."
silicon,"Silicon can be quantitatively and qualitatively determined in thin sections of biological specimens using X-ray microanalysis, with detection limits as low as 10⁻⁲1 g/10⁻⁲1 for elemental standards.","Entity: silicon. SMILES: [Si]. Silicon can be quantitatively and qualitatively determined in thin sections of biological specimens using X-ray microanalysis, with detection limits as low as 10⁻⁲1 g/10⁻⁲1 for elemental standards."
silicon,"Silicon is present in granule aggregates (25–75 nm) and small (5–10 nm) electron opaque granules in rat liver mitochondria, as confirmed by electron probe X-ray microanalysis and chemical analysis.","Entity: silicon. SMILES: [Si]. Silicon is present in granule aggregates (25–75 nm) and small (5–10 nm) electron opaque granules in rat liver mitochondria, as confirmed by electron probe X-ray microanalysis and chemical analysis."
silicon,"Silicon is detected in both isolated granule aggregates and small granules in rat liver, spleen, and kidney mitochondria, and its presence in granules is confirmed by in vivo radiolabeling with 31Si and 68Ge.","Entity: silicon. SMILES: [Si]. Silicon is detected in both isolated granule aggregates and small granules in rat liver, spleen, and kidney mitochondria, and its presence in granules is confirmed by in vivo radiolabeling with 31Si and 68Ge."
phosphate,Phosphate is an element with well-established biological importance.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate is an element with well-established biological importance.
silicate,Silicate can be exchanged for phosphate in bacterial ion uptake studies.,Entity: silicate. SMILES: [O-][Si]([O-])([O-])[O-]. Silicate can be exchanged for phosphate in bacterial ion uptake studies.
tetraethyl orthosilicate,"The concentration of tetraethyl orthosilicate in embedded specimens can be accurately determined using a linear relationship between count rate and concentration, as confirmed by chemical analysis.","Entity: tetraethyl orthosilicate. SMILES: CCO[Si](OCC)(OCC)OCC. The concentration of tetraethyl orthosilicate in embedded specimens can be accurately determined using a linear relationship between count rate and concentration, as confirmed by chemical analysis."
Phosphorus,"Phosphorus content in isolated mitochondrial granules from rat liver, spleen, and kidney increases with each treatment, indicating that phosphorus is not lost during the solubilization process.","Entity: Phosphorus. SMILES: [P]. Phosphorus content in isolated mitochondrial granules from rat liver, spleen, and kidney increases with each treatment, indicating that phosphorus is not lost during the solubilization process."
Silicon,"Silicon is present in isolated mitochondrial granules from rat liver, spleen, and kidney, with the highest concentration per gram wet weight found in spleen and the lowest in liver.","Entity: Silicon. SMILES: [Si]. Silicon is present in isolated mitochondrial granules from rat liver, spleen, and kidney, with the highest concentration per gram wet weight found in spleen and the lowest in liver."
Silicon,"The Si/P ratio in isolated mitochondrial granules decreases with each treatment, indicating progressive solubilization of silicon during the preparation process.","Entity: Silicon. SMILES: [Si]. The Si/P ratio in isolated mitochondrial granules decreases with each treatment, indicating progressive solubilization of silicon during the preparation process."
tetraethyl orthosilicate,"Tetraethyl orthosilicate can be incorporated at concentrations of 1%, 5%, or 10% into Spurr's epoxy resin for embedding samples, with 100% tetraethyl orthosilicate preventing polymerization of the resin.","Entity: tetraethyl orthosilicate. SMILES: CCO[Si](OCC)(OCC)OCC. Tetraethyl orthosilicate can be incorporated at concentrations of 1%, 5%, or 10% into Spurr's epoxy resin for embedding samples, with 100% tetraethyl orthosilicate preventing polymerization of the resin."
[14C]glucose,"A temperature increase from 35 to 44.5 °C drastically reduces the rate of [14C]glucose uptake in nonfecal coliforms, indicating increased temperature sensitivity for glucose uptake in these bacteria.","Entity: [14C]glucose. SMILES: O=[14CH][C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. A temperature increase from 35 to 44.5 °C drastically reduces the rate of [14C]glucose uptake in nonfecal coliforms, indicating increased temperature sensitivity for glucose uptake in these bacteria."
lactose,"Lactose metabolism in coliforms involves both aerobic and fermentative pathways, with cell membrane function being a principal factor for temperature sensitivity at 44.5 °C.","Entity: lactose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O. Lactose metabolism in coliforms involves both aerobic and fermentative pathways, with cell membrane function being a principal factor for temperature sensitivity at 44.5 °C."
thiosemicarbazide,"Thiosemicarbazide is used as a reagent in cytochemical detection methods for glycogen thin sections, where sections are incubated in thiosemicarbazide for 30 to 120 minutes.","Entity: thiosemicarbazide. SMILES: NNC(N)=S. Thiosemicarbazide is used as a reagent in cytochemical detection methods for glycogen thin sections, where sections are incubated in thiosemicarbazide for 30 to 120 minutes."
lead citrate,"Lead citrate is used as a staining agent for electron microscopy, applied briefly to cytochemical sections for observation.","Entity: lead citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Pb+2].[Pb+2].[Pb+2]. Lead citrate is used as a staining agent for electron microscopy, applied briefly to cytochemical sections for observation."
cresyl violet,Cresyl violet is a staining agent used in semithin sections to make capillary cross-sections in muscle tissue easily discernible.,Entity: cresyl violet. SMILES: Cc1cc2nc3c(cc(N)c4ccccc43)oc-2cc1=[N+](C)C.[Cl-]. Cresyl violet is a staining agent used in semithin sections to make capillary cross-sections in muscle tissue easily discernible.
glycerolphosphate,"Subsarcolemmal mitochondria are rich in glycerolphosphate dehydrogenase, in contrast to interfibrillar mitochondria.","Entity: glycerolphosphate. SMILES: O=P12OC(O)(CO)C(O)(O1)O2. Subsarcolemmal mitochondria are rich in glycerolphosphate dehydrogenase, in contrast to interfibrillar mitochondria."
triiodothyronine,Treatment of rats with triiodothyronine increases the volume density of subsarcolemmal mitochondria by 1.8 and interfibrillar mitochondria by 1.7 in the soleus muscle.,Entity: triiodothyronine. SMILES: N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O. Treatment of rats with triiodothyronine increases the volume density of subsarcolemmal mitochondria by 1.8 and interfibrillar mitochondria by 1.7 in the soleus muscle.
oxygen,The amount of interfibrillar mitochondria in muscle is correlated with the muscle's capacity for endurance exercise and with the maximum oxygen intake of an individual.,Entity: oxygen. SMILES: [O]. The amount of interfibrillar mitochondria in muscle is correlated with the muscle's capacity for endurance exercise and with the maximum oxygen intake of an individual.
oxygen,The partial pressure of oxygen at the fiber surface depends on the capillary density.,Entity: oxygen. SMILES: [O]. The partial pressure of oxygen at the fiber surface depends on the capillary density.
sodium cacodylate,Sodium cacodylate is used as a buffer at 0.1 M concentration and pH 7.4 in histological staining protocols involving cresyl violet.,Entity: sodium cacodylate. SMILES: C[As](C)(=O)[O-].[Na+]. Sodium cacodylate is used as a buffer at 0.1 M concentration and pH 7.4 in histological staining protocols involving cresyl violet.
cresyl violet,"Cresyl violet is used as a histological stain to colour mitochondria, with optimal staining achieved when applied to slides in 0.1 M sodium cacodylate buffer at pH 7.4 and incubated at 80–95°C for 2–5 minutes until the solution is nearly dried.","Entity: cresyl violet. SMILES: Cc1cc2nc3c(cc(N)c4ccccc43)oc-2cc1=[N+](C)C.[Cl-]. Cresyl violet is used as a histological stain to colour mitochondria, with optimal staining achieved when applied to slides in 0.1 M sodium cacodylate buffer at pH 7.4 and incubated at 80–95°C for 2–5 minutes until the solution is nearly dried."
prolactin,Prolactin is one of the most important hormones involved in the control of vernal premigratory fattening in White-crowned Sparrows.,Entity: prolactin. Prolactin is one of the most important hormones involved in the control of vernal premigratory fattening in White-crowned Sparrows.
ecdysone,"Ecdysone is an endocrine molecule involved in embryonic diapause and morphogenesis in Aulocara elliotti, with its release from ventral head glands triggered by juvenile hormone analogue treatment.","Entity: ecdysone. SMILES: C[C@H]([C@H](O)CCC(C)(C)O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C. Ecdysone is an endocrine molecule involved in embryonic diapause and morphogenesis in Aulocara elliotti, with its release from ventral head glands triggered by juvenile hormone analogue treatment."
Sudan black B,"Sudan black B stains gray or black globules in both embryonic pericardial cells and subesophageal body cells, indicating the presence of lipids or lipoproteins.","Entity: Sudan black B. SMILES: CC1(C)Nc2cccc3c(N=Nc4ccc(N=Nc5ccccc5)c5ccccc45)ccc(c23)N1. Sudan black B stains gray or black globules in both embryonic pericardial cells and subesophageal body cells, indicating the presence of lipids or lipoproteins."
methanol,Methanol is used as a solvent for immersing eggs in a 10% juvenile hormone analogue solution and for brief immersion (2 minutes) in redistilled methanol during experimental procedures.,Entity: methanol. SMILES: CO. Methanol is used as a solvent for immersing eggs in a 10% juvenile hormone analogue solution and for brief immersion (2 minutes) in redistilled methanol during experimental procedures.
sodium hypochlorite,Sodium hypochlorite solution (53%) is used for rinsing eggs prior to further processing in experimental studies.,Entity: sodium hypochlorite. SMILES: [Na+].[O-]Cl. Sodium hypochlorite solution (53%) is used for rinsing eggs prior to further processing in experimental studies.
ethanol,"Ethanol at 70% concentration is used as a storage solvent for fixed, diapause-state eggs during experimental preparation.","Entity: ethanol. SMILES: CCO. Ethanol at 70% concentration is used as a storage solvent for fixed, diapause-state eggs during experimental preparation."
ecdysone,Ecdysone is a hormone whose alpha form is synthesized by the prothoracic gland and converted to the active beta ecdysone form by pericardial and somatic epidermal branch (SEB) cells in insects.,Entity: ecdysone. SMILES: C[C@H]([C@H](O)CCC(C)(C)O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C. Ecdysone is a hormone whose alpha form is synthesized by the prothoracic gland and converted to the active beta ecdysone form by pericardial and somatic epidermal branch (SEB) cells in insects.
osmium,Osmium is used as a component of a paraformaldehyde-osmium mixture for fixation of corpora lutea in histological and electron microscopy procedures.,Entity: osmium. SMILES: [Os]. Osmium is used as a component of a paraformaldehyde-osmium mixture for fixation of corpora lutea in histological and electron microscopy procedures.
uranyl acetate,Uranyl acetate is used as a staining agent for en bloc staining of fixed corpora lutea in electron microscopy.,Entity: uranyl acetate. SMILES: CC(=O)[O-].CC(=O)[O-].O=[U+2]=O. Uranyl acetate is used as a staining agent for en bloc staining of fixed corpora lutea in electron microscopy.
streptomycin,Streptomycin is used at 100 µg per ml as an antibiotic supplement in cell culture.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used at 100 µg per ml as an antibiotic supplement in cell culture.
NaOH,NaOH is used to adjust the pH of Dulbecco's Modified Eagle's Medium to 7.5 in cell culture.,Entity: NaOH. SMILES: [Na+].[OH-]. NaOH is used to adjust the pH of Dulbecco's Modified Eagle's Medium to 7.5 in cell culture.
NaHCO3,NaHCO3 is included at 10% (v/v) concentration in Dulbecco's Modified Eagle's Medium for maintaining pH in cell culture.,Entity: NaHCO3. SMILES: O=C([O-])O.[Na+]. NaHCO3 is included at 10% (v/v) concentration in Dulbecco's Modified Eagle's Medium for maintaining pH in cell culture.
Versene,Versene is used at 0.02% (v/v) to dissociate cell monolayers for aggregation assays.,Entity: Versene. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. Versene is used at 0.02% (v/v) to dissociate cell monolayers for aggregation assays.
thionin,Thionin is used as a histological stain at 0.1% concentration to facilitate recognition of cellular organization in tissue sections.,Entity: thionin. SMILES: c1ccccsccc1. Thionin is used as a histological stain at 0.1% concentration to facilitate recognition of cellular organization in tissue sections.
CO2,CO2 is used to gasify Ringer solution in cell culture preparations.,Entity: CO2. SMILES: O=C=O. CO2 is used to gasify Ringer solution in cell culture preparations.
streptomycin,Streptomycin is used as an antibiotic supplement in cell culture media at a concentration of 100 U/ml.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used as an antibiotic supplement in cell culture media at a concentration of 100 U/ml.
glucose,Glucose is included in cell culture media at a concentration of 2 mg/ml.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is included in cell culture media at a concentration of 2 mg/ml.
oxygen,Oxygen is used in combination with CO2 to gasify Ringer solution for cell culture.,Entity: oxygen. SMILES: [O]. Oxygen is used in combination with CO2 to gasify Ringer solution for cell culture.
sodium,"High sodium medium promotes the formation of more abundant and widely distributed Golgi bodies, more frequent secretory granule release, and a higher percentage of cytoplasmic volume occupied by secretory granules in cultured eel hemi-pituitary prolactin cells compared to low sodium medium.","Entity: sodium. SMILES: [Na]. High sodium medium promotes the formation of more abundant and widely distributed Golgi bodies, more frequent secretory granule release, and a higher percentage of cytoplasmic volume occupied by secretory granules in cultured eel hemi-pituitary prolactin cells compared to low sodium medium."
prolactin,"Prolactin release from eel hemi-pituitaries is differentially affected by high and low sodium media in vitro, with low sodium media promoting higher prolactin release.","Entity: prolactin. Prolactin release from eel hemi-pituitaries is differentially affected by high and low sodium media in vitro, with low sodium media promoting higher prolactin release."
growth hormone,"Growth hormone release from eel hemi-pituitaries is differentially affected by high and low sodium media in vitro, with high sodium media promoting higher growth hormone release.","Entity: growth hormone. Growth hormone release from eel hemi-pituitaries is differentially affected by high and low sodium media in vitro, with high sodium media promoting higher growth hormone release."
fructose,Fructose is produced from blood glucose via glycogen as an intermediary step in the conversion process.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose is produced from blood glucose via glycogen as an intermediary step in the conversion process.
glucose,Glucose is converted to seminal fructose through glycogen as an intermediary step in the metabolic pathway.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is converted to seminal fructose through glycogen as an intermediary step in the metabolic pathway.
mercuric sulfide,"Colloidal mercuric sulfide can be injected into the rete testis, reabsorbed by epithelial cells, and transported below the basal membrane.","Entity: mercuric sulfide. SMILES: S=[Hg]. Colloidal mercuric sulfide can be injected into the rete testis, reabsorbed by epithelial cells, and transported below the basal membrane."
citrate,"Citrate is used as a chelating agent in the form of Fe59-citrate, which can be injected into the rete testis and reabsorbed by epithelial cells.","Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Citrate is used as a chelating agent in the form of Fe59-citrate, which can be injected into the rete testis and reabsorbed by epithelial cells."
toluidine blue,Toluidine blue is a staining dye used for semi-thin sections in light microscopy.,Entity: toluidine blue. SMILES: Cc1ccc(Nc2ccc(O)c3c2C(=O)c2c(O)ccc(Nc4ccc(C)cc4S(=O)(=O)[O-])c2C3=O)c(S(=O)(=O)[O-])c1.[Na+].[Na+]. Toluidine blue is a staining dye used for semi-thin sections in light microscopy.
uranyl acetate,Uranyl acetate is used as a contrasting agent for thin sections in electron microscopy.,Entity: uranyl acetate. SMILES: CC(=O)[O-].CC(=O)[O-].O=[U+2]=O. Uranyl acetate is used as a contrasting agent for thin sections in electron microscopy.
lead citrate,Lead citrate is used as a contrasting agent for thin sections in electron microscopy.,Entity: lead citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Pb+2].[Pb+2].[Pb+2]. Lead citrate is used as a contrasting agent for thin sections in electron microscopy.
glucose,Glucose is absorbed in vitro in the intratesticular portion of the duct system of experimental animals.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is absorbed in vitro in the intratesticular portion of the duct system of experimental animals.
sodium,Sodium is absorbed in vitro in the intratesticular portion of the duct system of experimental animals.,Entity: sodium. SMILES: [Na]. Sodium is absorbed in vitro in the intratesticular portion of the duct system of experimental animals.
water,Water is absorbed in vitro in the intratesticular portion of the duct system of experimental animals.,Entity: water. SMILES: O. Water is absorbed in vitro in the intratesticular portion of the duct system of experimental animals.
acetylcholine,Acetylcholine is released at afferent synapses by preganglionic cholinergic terminals that are acetylcholinesterase-positive.,Entity: acetylcholine. SMILES: CC(=O)OCC[N+](C)(C)C. Acetylcholine is released at afferent synapses by preganglionic cholinergic terminals that are acetylcholinesterase-positive.
dopamine,"Granule-containing cells store dopamine, and activity at afferent synapses can lead to the release of this catecholamine from the cell.","Entity: dopamine. SMILES: Nc1cccc(O)c1O. Granule-containing cells store dopamine, and activity at afferent synapses can lead to the release of this catecholamine from the cell."
5-hydroxydopamine,"5-hydroxydopamine is administered intraperitoneally at 100 mg/kg to postnatal animals or incubated in Krebs-Henseleit solution at 1 mg/ml, pH 7.4, for 30 minutes at 37°C to treat tissue prior to electron microscopy.","Entity: 5-hydroxydopamine. SMILES: NCCc1cc(O)c(O)c(O)c1. 5-hydroxydopamine is administered intraperitoneally at 100 mg/kg to postnatal animals or incubated in Krebs-Henseleit solution at 1 mg/ml, pH 7.4, for 30 minutes at 37°C to treat tissue prior to electron microscopy."
oxygen,Oxygen is used to saturate the incubation solution (95% O2–5% CO2) during the 5-hydroxydopamine-induced tissue treatment prior to electron microscopy.,Entity: oxygen. SMILES: [O]. Oxygen is used to saturate the incubation solution (95% O2–5% CO2) during the 5-hydroxydopamine-induced tissue treatment prior to electron microscopy.
carbon dioxide,Carbon dioxide is used in combination with oxygen to achieve a 95% O2–5% CO2 atmosphere during the incubation of tissue with 5-hydroxydopamine prior to electron microscopy.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is used in combination with oxygen to achieve a 95% O2–5% CO2 atmosphere during the incubation of tissue with 5-hydroxydopamine prior to electron microscopy.
HC-3,"HC-3 exerts its effects at low dose levels, as assessed by its specificity of action.","Entity: HC-3. SMILES: C[N+](C)(C)CCCCCC[N+](C)(C)C.[Br-].[Br-]. HC-3 exerts its effects at low dose levels, as assessed by its specificity of action."
HC-3,"In mouse diaphragm neuromuscular junctions, HC-3 produces effects almost exclusively at the presynaptic site at a concentration of 4 x 10^6 M.","Entity: HC-3. SMILES: C[N+](C)(C)CCCCCC[N+](C)(C)C.[Br-].[Br-]. In mouse diaphragm neuromuscular junctions, HC-3 produces effects almost exclusively at the presynaptic site at a concentration of 4 x 10^6 M."
HC-3,"An intraperitoneal dose of 2 x 5 mg/kg HC-3 is estimated to achieve an overall concentration of approximately 10^-8 M in the body, assuming instant and even distribution.","Entity: HC-3. SMILES: C[N+](C)(C)CCCCCC[N+](C)(C)C.[Br-].[Br-]. An intraperitoneal dose of 2 x 5 mg/kg HC-3 is estimated to achieve an overall concentration of approximately 10^-8 M in the body, assuming instant and even distribution."
HC-3,"The presence of a blood-brain barrier limits the maximum concentration of HC-3 that reaches photoreceptors, presumably to well below 10^-5 M.","Entity: HC-3. SMILES: C[N+](C)(C)CCCCCC[N+](C)(C)C.[Br-].[Br-]. The presence of a blood-brain barrier limits the maximum concentration of HC-3 that reaches photoreceptors, presumably to well below 10^-5 M."
Iodoacetate,Iodoacetate is a metabolic inhibitor that is considerably more effective at inhibiting rods than cones in the eye.,Entity: Iodoacetate. SMILES: O=C([O-])CI. Iodoacetate is a metabolic inhibitor that is considerably more effective at inhibiting rods than cones in the eye.
HC-3,"HC-3 has been reported to damage mitochondria in cholinergic nerve cells, possibly by mobilizing choline from mitochondrial membranes.","Entity: HC-3. SMILES: C[N+]1(C)CCOC(O)(c2ccc(-c3ccc(C4(O)C[N+](C)(C)CCO4)cc3)cc2)C1.[Br-].[Br-]. HC-3 has been reported to damage mitochondria in cholinergic nerve cells, possibly by mobilizing choline from mitochondrial membranes."
choline,HC-3 acts as a competitive inhibitor for the uptake of choline at the surface membrane of nerve cells.,Entity: choline. SMILES: C[N+](C)(C)CCO. HC-3 acts as a competitive inhibitor for the uptake of choline at the surface membrane of nerve cells.
acetyl coenzyme A,Acetyl coenzyme A provides the acetyl group for the acetylation of choline and is a mitochondrial product.,Entity: acetyl coenzyme A. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Acetyl coenzyme A provides the acetyl group for the acetylation of choline and is a mitochondrial product.
phosphorylcholine,The synthesis of phosphorylcholine in rat brain is stimulated by HC-3.,Entity: phosphorylcholine. SMILES: C[N+](C)(C#P=O)CCO. The synthesis of phosphorylcholine in rat brain is stimulated by HC-3.
acetylcholine,The synthesis of acetylcholine in nerve cells may be reduced by HC-3 due to disruption of mitochondrial acetyl coenzyme A availability.,Entity: acetylcholine. SMILES: CC(=O)OCC[N+](C)(C)C. The synthesis of acetylcholine in nerve cells may be reduced by HC-3 due to disruption of mitochondrial acetyl coenzyme A availability.
HC-3,"HC-3 blocks the acetylation of choline by preventing substrate access to choline acetylase, acting as a competitive inhibitor at the surface membrane of nerve cells.","Entity: HC-3. SMILES: C[N+]1(C)CCOC(O)(c2ccc(-c3ccc(C4(O)C[N+](C)(C)CCO4)cc3)cc2)C1.[Br-].[Br-]. HC-3 blocks the acetylation of choline by preventing substrate access to choline acetylase, acting as a competitive inhibitor at the surface membrane of nerve cells."
HC-3,"HC-3 inhibits the synthesis of phosphorylcholine and stimulates the synthesis of phosphoditylcholine in rat brain, affecting choline metabolism.","Entity: HC-3. SMILES: C[N+]1(C)CCOC(O)(c2ccc(-c3ccc(C4(O)C[N+](C)(C)CCO4)cc3)cc2)C1.[Br-].[Br-]. HC-3 inhibits the synthesis of phosphorylcholine and stimulates the synthesis of phosphoditylcholine in rat brain, affecting choline metabolism."
HC-3,"HC-3 is bound to mitochondria upon entering cells and may interfere with mitochondrial metabolic processes, potentially disrupting mitochondrial oxidative systems and reducing acetyl coenzyme A availability.","Entity: HC-3. SMILES: C[N+]1(C)CCOC(O)(c2ccc(-c3ccc(C4(O)C[N+](C)(C)CCO4)cc3)cc2)C1.[Br-].[Br-]. HC-3 is bound to mitochondria upon entering cells and may interfere with mitochondrial metabolic processes, potentially disrupting mitochondrial oxidative systems and reducing acetyl coenzyme A availability."
acetylcholine,"Acetylcholine is synthesized by photoreceptor cells in turtle retina, as demonstrated by isolated photoreceptor cell studies.","Entity: acetylcholine. SMILES: CC(=O)OCC[N+](C)(C)C. Acetylcholine is synthesized by photoreceptor cells in turtle retina, as demonstrated by isolated photoreceptor cell studies."
gamma-amino butyric acid,"Photoreceptor cells from turtle retina do not synthesize gamma-amino butyric acid, but acetylcholine and dopamine are produced.","Entity: gamma-amino butyric acid. SMILES: NCCCC(=O)O. Photoreceptor cells from turtle retina do not synthesize gamma-amino butyric acid, but acetylcholine and dopamine are produced."
dopamine,"Photoreceptor cells from turtle retina do not synthesize dopamine, but acetylcholine is produced.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Photoreceptor cells from turtle retina do not synthesize dopamine, but acetylcholine is produced."
acetylcholine,"Acetylcholine is suggested as a possible neurotransmitter for photoreceptors in the vertebrate retina, as it can be synthesized by turtle photoreceptors.","Entity: acetylcholine. SMILES: CC(=O)OCC[N+](C)(C)C. Acetylcholine is suggested as a possible neurotransmitter for photoreceptors in the vertebrate retina, as it can be synthesized by turtle photoreceptors."
L-aspartate,L-aspartate is considered a putative neurotransmitter released by rod and cone photoreceptors in the vertebrate retina based on neurophysiological evidence.,Entity: L-aspartate. SMILES: N[C@@H](CC(=O)[O-])C(=O)[O-]. L-aspartate is considered a putative neurotransmitter released by rod and cone photoreceptors in the vertebrate retina based on neurophysiological evidence.
L-glutamate,L-glutamate is suggested as a putative neurotransmitter released by rod and cone photoreceptors in the vertebrate retina according to neurophysiological evidence.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate is suggested as a putative neurotransmitter released by rod and cone photoreceptors in the vertebrate retina according to neurophysiological evidence.
taurine,Taurine is proposed as a possible neurotransmitter for photoreceptors in the vertebrate retina.,Entity: taurine. SMILES: NCCS(=O)(=O)O. Taurine is proposed as a possible neurotransmitter for photoreceptors in the vertebrate retina.
hemicholinium-3,Hemicholinium-3 is a drug that prevents synthesis of acetylcholine in neurons.,Entity: hemicholinium-3. SMILES: C[N+]1(C)CCOC(O)(c2ccc(-c3ccc(C4(O)C[N+](C)(C)CCO4)cc3)cc2)C1.[Br-].[Br-]. Hemicholinium-3 is a drug that prevents synthesis of acetylcholine in neurons.
hemicholinium-3,Intraperitoneal injection of hemicholinium-3 at doses as low as 2 × 5 mg/kg produces marked ultrastructural changes and damage in rod but not in cone photoreceptors.,Entity: hemicholinium-3. SMILES: C[N+]1(C)CCOC(O)(c2ccc(-c3ccc(C4(O)C[N+](C)(C)CCO4)cc3)cc2)C1.[Br-].[Br-]. Intraperitoneal injection of hemicholinium-3 at doses as low as 2 × 5 mg/kg produces marked ultrastructural changes and damage in rod but not in cone photoreceptors.
glutaraldehyde,"Glutaraldehyde is used as a fixative for retinal tissue, applied at a concentration of 2% in ice-cold conditions for up to 1 hour.","Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a fixative for retinal tissue, applied at a concentration of 2% in ice-cold conditions for up to 1 hour."
osmium tetroxide,"Osmium tetroxide is used as a post-fixative in retinal tissue fixation, applied at a concentration of 1 mM in 0°C for 2 hours.","Entity: osmium tetroxide. SMILES: O=[Os](=O)(=O)=O. Osmium tetroxide is used as a post-fixative in retinal tissue fixation, applied at a concentration of 1 mM in 0°C for 2 hours."
sucrose,Sucrose is used to make solutions isosmotic with Xenopus blood during retinal fixation procedures.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used to make solutions isosmotic with Xenopus blood during retinal fixation procedures.
sodium perchlorate,Sodium perchlorate is used at a concentration of 30 mM in combination with 100 mM sodium hexafluorophosphate to maintain intensity invariance of the 743 cm-1 band in PF~.,Entity: sodium perchlorate. SMILES: [Na+].[O-][Cl+3]([O-])([O-])[O-]. Sodium perchlorate is used at a concentration of 30 mM in combination with 100 mM sodium hexafluorophosphate to maintain intensity invariance of the 743 cm-1 band in PF~.
sodium hexafluorophosphate,Sodium hexafluorophosphate is used at a concentration of 100 mM in combination with 30 mM sodium perchlorate to confirm intensity invariance of the 743 cm-1 band in PF~.,Entity: sodium hexafluorophosphate. SMILES: F[P-](F)(F)(F)(F)F.[Na+]. Sodium hexafluorophosphate is used at a concentration of 100 mM in combination with 30 mM sodium perchlorate to confirm intensity invariance of the 743 cm-1 band in PF~.
malonic acid,Malonic acid is used at a concentration of 100 mM in 1.5% polyadenylic acid solutions.,Entity: malonic acid. SMILES: O=C(O)CC(=O)O. Malonic acid is used at a concentration of 100 mM in 1.5% polyadenylic acid solutions.
hydrochloric acid,Hydrochloric acid is used to adjust the final pH of solutions containing polyadenylic acid.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to adjust the final pH of solutions containing polyadenylic acid.
sodium hydroxide,Sodium hydroxide is used to adjust the final pH of solutions containing polyadenylic acid.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to adjust the final pH of solutions containing polyadenylic acid.
5'-AMP,5'-AMP is used at a concentration of 25 mM in 25 mM NaC104 to obtain experimental spectra.,Entity: 5'-AMP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. 5'-AMP is used at a concentration of 25 mM in 25 mM NaC104 to obtain experimental spectra.
5'-GMP,5'-GMP is used at a concentration of 50 mM in 100 mM NaPF6 to obtain experimental spectra.,Entity: 5'-GMP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. 5'-GMP is used at a concentration of 50 mM in 100 mM NaPF6 to obtain experimental spectra.
5'-GMP,"In acidic conditions below approximately pH 5.0, 5'-GMP solutions become very viscous, with the most pronounced viscosity between pH 5 and 3 and reduced viscosity at lower pH (around 2).","Entity: 5'-GMP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. In acidic conditions below approximately pH 5.0, 5'-GMP solutions become very viscous, with the most pronounced viscosity between pH 5 and 3 and reduced viscosity at lower pH (around 2)."
NaOH,NaOH is used to adjust the pH of nucleotide solution to the desired value for experimental preparation.,Entity: NaOH. SMILES: [Na+].[OH-]. NaOH is used to adjust the pH of nucleotide solution to the desired value for experimental preparation.
NaClO4,NaClO4 serves as an internal intensity standard in the preparation of 5'-nucleotide solutions.,Entity: NaClO4. SMILES: [Na+].[O-][Cl+3]([O-])([O-])[O-]. NaClO4 serves as an internal intensity standard in the preparation of 5'-nucleotide solutions.
HCl,HCl is used to adjust the pH of nucleotide solution to the desired value for experimental preparation.,Entity: HCl. SMILES: Cl. HCl is used to adjust the pH of nucleotide solution to the desired value for experimental preparation.
NaPF6,NaPF6 is used as an internal intensity standard in the preparation of 5'-nucleotide solutions.,Entity: NaPF6. SMILES: F[P-](F)(F)(F)(F)F.[Na+]. NaPF6 is used as an internal intensity standard in the preparation of 5'-nucleotide solutions.
Alcian Blue,"The Alcian Blue method was used to stain cells in histological sections, but gave negative results for neurosecretory material in the described tissue.","Entity: Alcian Blue. SMILES: CN(C)C(SCc1ccc2c(c1)C1=NC2=NC2=NC(=NC3[N-]C(N=c4[n-]c(c5ccc(CSC(N(C)C)=[N+](C)C)cc45)=N1)c1ccc(CSC(N(C)C)=[N+](C)C)cc13)c1cc(CSC(N(C)C)=[N+](C)C)ccc12)=[N+](C)C.[Cl-].[Cl-].[Cl-].[Cl-].[Cu+2]. The Alcian Blue method was used to stain cells in histological sections, but gave negative results for neurosecretory material in the described tissue."
Alcian Blue,Alcian Blue is a histological stain that selectively and faintly stains medium-sized neurons in the preoptic nucleus of Gymnophiona diencephalon.,Entity: Alcian Blue. SMILES: CN(C)C(SCc1ccc2c(c1)C1=NC2=NC2=NC(=NC3[N-]C(N=c4[n-]c(c5ccc(CSC(N(C)C)=[N+](C)C)cc45)=N1)c1ccc(CSC(N(C)C)=[N+](C)C)cc13)c1cc(CSC(N(C)C)=[N+](C)C)ccc12)=[N+](C)C.[Cl-].[Cl-].[Cl-].[Cl-].[Cu+2]. Alcian Blue is a histological stain that selectively and faintly stains medium-sized neurons in the preoptic nucleus of Gymnophiona diencephalon.
Alcian Blue,Alcian Blue is a histological stain used to detect acidic polysaccharides in tissue sections.,Entity: Alcian Blue. SMILES: CN(C)C(SCc1ccc2c(c1)C1=NC2=NC2=NC(=NC3[N-]C(N=c4[n-]c(c5ccc(CSC(N(C)C)=[N+](C)C)cc45)=N1)c1ccc(CSC(N(C)C)=[N+](C)C)cc13)c1cc(CSC(N(C)C)=[N+](C)C)ccc12)=[N+](C)C.[Cl-].[Cl-].[Cl-].[Cl-].[Cu+2]. Alcian Blue is a histological stain used to detect acidic polysaccharides in tissue sections.
Phloxine,"Phloxine is a component of Gomori's Chrome haematoxylin-Phloxine stain, used for histological visualization of tissue structures.","Entity: Phloxine. SMILES: O=C1OC2(c3cc(Br)c([O-])c(Br)c3Oc3c2cc(Br)c([O-])c3Br)c2c(Cl)ccc(Cl)c21.[K+].[K+]. Phloxine is a component of Gomori's Chrome haematoxylin-Phloxine stain, used for histological visualization of tissue structures."
formaldehyde,Formaldehyde is used as a cold buffer in histological fixation of brain tissue for enzyme histochemical methods.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a cold buffer in histological fixation of brain tissue for enzyme histochemical methods.
Alcian Blue,"Alcian Blue is used as a histological stain to identify cells in the preoptic nucleus and hypothalamo-hypophyseal tract, with Alcian Blue positive material found only in medium-sized cells and Herring bodies stained with Alcian Blue appearing smaller than those stained with Chromehaematoxyline or Aldehyde Fuchsine.","Entity: Alcian Blue. SMILES: CN(C)C(SCc1ccc2c(c1)C1=NC2=NC2=NC(=NC3[N-]C(N=c4[n-]c(c5ccc(CSC(N(C)C)=[N+](C)C)cc45)=N1)c1ccc(CSC(N(C)C)=[N+](C)C)cc13)c1cc(CSC(N(C)C)=[N+](C)C)ccc12)=[N+](C)C.[Cl-].[Cl-].[Cl-].[Cl-].[Cu+2]. Alcian Blue is used as a histological stain to identify cells in the preoptic nucleus and hypothalamo-hypophyseal tract, with Alcian Blue positive material found only in medium-sized cells and Herring bodies stained with Alcian Blue appearing smaller than those stained with Chromehaematoxyline or Aldehyde Fuchsine."
calcium carbonate,"Calcium carbonate in the vicinity of statoconic crystals can be removed by local modification of the surrounding fluid, facilitating the removal of crystals that are not required in those statocyst regions.","Entity: calcium carbonate. SMILES: O=C([O-])[O-].[Ca+2]. Calcium carbonate in the vicinity of statoconic crystals can be removed by local modification of the surrounding fluid, facilitating the removal of crystals that are not required in those statocyst regions."
tetracycline,Tetracycline labeling techniques can be used to detect slow but continuous exchange of material at the periphery of mammalian statoconia.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline labeling techniques can be used to detect slow but continuous exchange of material at the periphery of mammalian statoconia.
hydrochloric acid,"Hydrochloric acid can be used to etch off the smooth surface of the statolith, revealing the needle-like crystal structure beneath it.","Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid can be used to etch off the smooth surface of the statolith, revealing the needle-like crystal structure beneath it."
galactose,Galactose is present in secretory proteins of rat pancreatic juice.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose is present in secretory proteins of rat pancreatic juice.
mannose,Mannose is present in secretory proteins of rat pancreatic juice.,Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose is present in secretory proteins of rat pancreatic juice.
fucose,Fucose is present in secretory proteins of rat pancreatic juice.,Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose is present in secretory proteins of rat pancreatic juice.
fucose,Fucose is incorporated mainly into smooth (Golgi-associated) endoplasmic reticulum membranes during protein synthesis in rat pancreas.,Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose is incorporated mainly into smooth (Golgi-associated) endoplasmic reticulum membranes during protein synthesis in rat pancreas.
leucine,"Leucine is incorporated into secretory proteins, but a greater proportion of leucine incorporation occurs in membrane proteins.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine is incorporated into secretory proteins, but a greater proportion of leucine incorporation occurs in membrane proteins."
fucose,"Fucose can be incorporated into both secretory and membrane proteins, with some fucosylated proteins remaining in the cell.","Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose can be incorporated into both secretory and membrane proteins, with some fucosylated proteins remaining in the cell."
fucose,"Fucose is used as a tracer in the synthesis rate measurement of both regular and fucosylated secretory proteins in pancreatic lobules, with L-(1-3H) fucose incorporated at 2.5 gCi/ml for 10–60 minute incubation periods.","Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose is used as a tracer in the synthesis rate measurement of both regular and fucosylated secretory proteins in pancreatic lobules, with L-(1-3H) fucose incorporated at 2.5 gCi/ml for 10–60 minute incubation periods."
perchloric acid,"Perchloric acid is used to precipitate 1 ml of pancreatic protein homogenate for DNA determination, applied at a final concentration of 0.5 N.","Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid is used to precipitate 1 ml of pancreatic protein homogenate for DNA determination, applied at a final concentration of 0.5 N."
leucine,"Leucine is used as a tracer in the synthesis rate measurement of secretory proteins in pancreatic lobules, with L-(U-14C) leucine incorporated at 0.01 µCi/ml for 10–60 minute incubation periods.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine is used as a tracer in the synthesis rate measurement of secretory proteins in pancreatic lobules, with L-(U-14C) leucine incorporated at 0.01 µCi/ml for 10–60 minute incubation periods."
trichloroacetic acid,"Trichloroacetic acid is used in a mixture with phosphotungstic acid to precipitate 2 ml of pancreatic protein homogenate for scintillation counting, at a final concentration of 8% TCA.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used in a mixture with phosphotungstic acid to precipitate 2 ml of pancreatic protein homogenate for scintillation counting, at a final concentration of 8% TCA."
carbamylcholine,Carbamylcholine at 5 x 10^-6 M acts as a secretagogue to stimulate the secretion of proteins from pancreatic lobules in vitro.,Entity: carbamylcholine. SMILES: C[N+](C)(C)CCOC(N)=O. Carbamylcholine at 5 x 10^-6 M acts as a secretagogue to stimulate the secretion of proteins from pancreatic lobules in vitro.
fucose,"Fucose can be incorporated into secretory proteins, and its release from pancreatic lobules in vitro is used as a marker for protein secretion.","Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose can be incorporated into secretory proteins, and its release from pancreatic lobules in vitro is used as a marker for protein secretion."
fucose,"Fucose undergoes unspecific absorption to unidentified pancreatic proteins in vitro, resulting in high labeling in isolated pancreatic lobules during incubation at 37°C.","Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose undergoes unspecific absorption to unidentified pancreatic proteins in vitro, resulting in high labeling in isolated pancreatic lobules during incubation at 37°C."
fucose,"Fucose is used as a tracer in pancreatic secretory protein studies, incorporated at 2 gCi/ml into KRH-medium for pulse-labeling pancreatic lobules.","Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose is used as a tracer in pancreatic secretory protein studies, incorporated at 2 gCi/ml into KRH-medium for pulse-labeling pancreatic lobules."
leucine,"Leucine is used as a tracer in pancreatic secretory protein studies, incorporated at 2 gCi/ml into KRH-medium for pulse-labeling pancreatic lobules.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine is used as a tracer in pancreatic secretory protein studies, incorporated at 2 gCi/ml into KRH-medium for pulse-labeling pancreatic lobules."
carbamylcholine,Carbamylcholine is used as an in vitro secretagogue to stimulate pancreatic secretory protein release from isolated lobules at a concentration of 5 x 10^-6 M.,Entity: carbamylcholine. SMILES: C[N+](C)(C)CCOC(N)=O. Carbamylcholine is used as an in vitro secretagogue to stimulate pancreatic secretory protein release from isolated lobules at a concentration of 5 x 10^-6 M.
TCA,"TCA is used for protein precipitation from pancreatic secretory protein media, with a final concentration of 8→ TCA/0.8→ PTA.","Entity: TCA. SMILES: O=C(O)C(Cl)(Cl)Cl. TCA is used for protein precipitation from pancreatic secretory protein media, with a final concentration of 8→ TCA/0.8→ PTA."
PTA,"PTA is used in combination with TCA for protein precipitation from pancreatic secretory protein media, with a final concentration of 0.8→ PTA.","Entity: PTA. SMILES: [O-][Cl+3]([O-])([O-])O. PTA is used in combination with TCA for protein precipitation from pancreatic secretory protein media, with a final concentration of 0.8→ PTA."
fucose,Fucose is a sugar present in the hydrolyzed protein mixture of chromatographically purified secretory enzymes from the rat exocrine pancreas.,Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose is a sugar present in the hydrolyzed protein mixture of chromatographically purified secretory enzymes from the rat exocrine pancreas.
fucose,"Fucose is the least metabolized of the sugars mannose, galactose, and fucose in pancreatic secretory enzymes.","Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose is the least metabolized of the sugars mannose, galactose, and fucose in pancreatic secretory enzymes."
fucose,Tritiated fucose can be progressively incorporated into the smooth microsomal fraction (representing Golgi elements and plasma membranes) but not substantially into the rough microsomal fraction (representing RER elements) in rat exocrine pancreas.,Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Tritiated fucose can be progressively incorporated into the smooth microsomal fraction (representing Golgi elements and plasma membranes) but not substantially into the rough microsomal fraction (representing RER elements) in rat exocrine pancreas.
fucose,Fucose can be used as a label for secretory glycoproteins synthesized in the Golgi complex in pancreatic enzyme studies.,Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose can be used as a label for secretory glycoproteins synthesized in the Golgi complex in pancreatic enzyme studies.
mannose,Mannose is present in the hydrolyzed protein mixture of chromatographically purified secretory enzymes from the rat exocrine pancreas.,Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose is present in the hydrolyzed protein mixture of chromatographically purified secretory enzymes from the rat exocrine pancreas.
galactose,Galactose is present in the hydrolyzed protein mixture of chromatographically purified secretory enzymes from the rat exocrine pancreas.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose is present in the hydrolyzed protein mixture of chromatographically purified secretory enzymes from the rat exocrine pancreas.
leucine,Leucine can be used as a label for 'regular' proteins synthesized in the rough endoplasmic reticulum (RER) in pancreatic enzyme studies.,Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine can be used as a label for 'regular' proteins synthesized in the rough endoplasmic reticulum (RER) in pancreatic enzyme studies.
fucose,"Fucose is incorporated into pancreatic secretory proteins at a linear rate in isolated rat pancreatic lobules, and this incorporation is potentiated by in vivo stimulation with caerulein.","Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose is incorporated into pancreatic secretory proteins at a linear rate in isolated rat pancreatic lobules, and this incorporation is potentiated by in vivo stimulation with caerulein."
leucine,"Leucine is incorporated into pancreatic secretory proteins at a linear rate in isolated rat pancreatic lobules, and this incorporation is potentiated by in vivo stimulation with caerulein.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine is incorporated into pancreatic secretory proteins at a linear rate in isolated rat pancreatic lobules, and this incorporation is potentiated by in vivo stimulation with caerulein."
fucose,Fucose is mainly incorporated into glycoproteins in the Golgi complex during protein synthesis.,Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose is mainly incorporated into glycoproteins in the Golgi complex during protein synthesis.
leucine,"Leucine is used as a label for proteins, and in vitro, the release of leucine-labeled proteins from pancreatic secretory granules is linear over 30 minutes, totaling two percent of total protein content.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine is used as a label for proteins, and in vitro, the release of leucine-labeled proteins from pancreatic secretory granules is linear over 30 minutes, totaling two percent of total protein content."
sodium acetate,Sodium acetate is used as a buffer at 0.1 M concentration and pH 4.5 in enzymatic assays involving glucosaminidase and β-glucuronidase.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate is used as a buffer at 0.1 M concentration and pH 4.5 in enzymatic assays involving glucosaminidase and β-glucuronidase.
sodium citrate,Sodium citrate is used as a buffer at 0.1 M concentration and pH 4.5 in enzymatic assays involving glucosaminidase and β-glucuronidase.,Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used as a buffer at 0.1 M concentration and pH 4.5 in enzymatic assays involving glucosaminidase and β-glucuronidase.
2-methoxyethanol,2-methoxyethanol is used as a solvent to dissolve naphthol AS-BI glucosaminide for enzymatic assays.,Entity: 2-methoxyethanol. SMILES: COCCO. 2-methoxyethanol is used as a solvent to dissolve naphthol AS-BI glucosaminide for enzymatic assays.
magnesium chloride,Magnesium chloride was present in the injection solution at a concentration of 5.386 g/l (0.25 ml in 1 litre of sterile saline) for thermal stress experiments in mussels.,Entity: magnesium chloride. SMILES: [Cl-].[Cl-].[Mg+2]. Magnesium chloride was present in the injection solution at a concentration of 5.386 g/l (0.25 ml in 1 litre of sterile saline) for thermal stress experiments in mussels.
hydrocortisone hemisuccinate,Hydrocortisone hemisuccinate was administered at a dose of 0.1 mg/ml in sterile saline to mussels during thermal stress experiments.,Entity: hydrocortisone hemisuccinate. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O. Hydrocortisone hemisuccinate was administered at a dose of 0.1 mg/ml in sterile saline to mussels during thermal stress experiments.
hydrocortisone hemisuccinate,Hydrocortisone hemisuccinate is a synthetic glucocorticoid used to study its effects under thermal stress in mussels.,Entity: hydrocortisone hemisuccinate. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O. Hydrocortisone hemisuccinate is a synthetic glucocorticoid used to study its effects under thermal stress in mussels.
hydrochloric acid,Hydrochloric acid was included in the injection solution at a concentration of 1 M (42.5 ml in 1 litre of sterile saline) for thermal stress experiments in mussels.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid was included in the injection solution at a concentration of 1 M (42.5 ml in 1 litre of sterile saline) for thermal stress experiments in mussels.
sodium chloride,Sodium chloride was used in the injection solution at a concentration of 33.7 g/l (0.25 ml in 1 litre of sterile saline) for thermal stress experiments in mussels.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride was used in the injection solution at a concentration of 33.7 g/l (0.25 ml in 1 litre of sterile saline) for thermal stress experiments in mussels.
disodium phosphate,Disodium phosphate was included in the injection solution at a concentration of 0.193 g/l (0.1 mg/ml in 1 litre of sterile saline) for thermal stress experiments in mussels.,Entity: disodium phosphate. SMILES: O=P([O-])([O-])O.[Na+].[Na+]. Disodium phosphate was included in the injection solution at a concentration of 0.193 g/l (0.1 mg/ml in 1 litre of sterile saline) for thermal stress experiments in mussels.
potassium chloride,Potassium chloride was present in the injection solution at a concentration of 0.938 g/l (0.25 ml in 1 litre of sterile saline) for thermal stress experiments in mussels.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride was present in the injection solution at a concentration of 0.938 g/l (0.25 ml in 1 litre of sterile saline) for thermal stress experiments in mussels.
calcium carbonate,Calcium carbonate was included in the injection solution at a concentration of 2.83 g/l (0.25 ml in 1 litre of sterile saline) for thermal stress experiments in mussels.,Entity: calcium carbonate. SMILES: O=C([O-])[O-].[Ca+2]. Calcium carbonate was included in the injection solution at a concentration of 2.83 g/l (0.25 ml in 1 litre of sterile saline) for thermal stress experiments in mussels.
colchicine,Colchicine is administered intraperitoneally at a dose of 5 µg per g body weight in mice to induce mitotic activity in skin wound sites.,Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine is administered intraperitoneally at a dose of 5 µg per g body weight in mice to induce mitotic activity in skin wound sites.
eosin,"Eosin is used as a histological stain to visualize tissue sections, including those from skin wound sites in mice.","Entity: eosin. SMILES: O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+]. Eosin is used as a histological stain to visualize tissue sections, including those from skin wound sites in mice."
hematoxylin,"Hematoxylin is used as a histological stain to visualize tissue sections, including those from skin wound sites in mice.","Entity: hematoxylin. SMILES: Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2. Hematoxylin is used as a histological stain to visualize tissue sections, including those from skin wound sites in mice."
formaldehyde,"Formaldehyde is used to induce fluorescence in tissue samples, such as neuronal or SIF cell cytoplasm, by incubation for 1 to 3 hours in formaldehyde vapor at 80°C.","Entity: formaldehyde. SMILES: C=O. Formaldehyde is used to induce fluorescence in tissue samples, such as neuronal or SIF cell cytoplasm, by incubation for 1 to 3 hours in formaldehyde vapor at 80°C."
glutaraldehyde,Glutaraldehyde reacts with noradrenaline to form an insoluble product that can produce a coloured reaction product when combined with potassium dichromate.,Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde reacts with noradrenaline to form an insoluble product that can produce a coloured reaction product when combined with potassium dichromate.
potassium dichromate,Potassium dichromate reacts with glutaraldehyde-noradrenaline complexes to produce a yellow 'chromaffin-like' reaction product in sympathetic ganglion cells.,Entity: potassium dichromate. SMILES: O=[Cr](=O)([O-])O[Cr](=O)(=O)[O-].[K+].[K+]. Potassium dichromate reacts with glutaraldehyde-noradrenaline complexes to produce a yellow 'chromaffin-like' reaction product in sympathetic ganglion cells.
Hydrocortisone,"Hydrocortisone at 10 µg/ml increases fluorescence intensity of SIF cells in cultured neuronal perikarya compared to untreated controls, but does not significantly increase SIF cell brightness or induce SIF cell hyperplasia after three days of treatment.","Entity: Hydrocortisone. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO. Hydrocortisone at 10 µg/ml increases fluorescence intensity of SIF cells in cultured neuronal perikarya compared to untreated controls, but does not significantly increase SIF cell brightness or induce SIF cell hyperplasia after three days of treatment."
noradrenaline,Noradrenaline at 2 x 10^-5 M increases SIF cell fluorescence approximately 3-fold after 1 hour incubation in ganglia-derived SIF cells.,Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline at 2 x 10^-5 M increases SIF cell fluorescence approximately 3-fold after 1 hour incubation in ganglia-derived SIF cells.
dopamine,Dopamine at 2 x 10^-5 M increases SIF cell fluorescence approximately 3-fold after 1 hour incubation in ganglia-derived SIF cells.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine at 2 x 10^-5 M increases SIF cell fluorescence approximately 3-fold after 1 hour incubation in ganglia-derived SIF cells.
adrenaline,Adrenaline at 2 x 10^-5 M increases SIF cell fluorescence approximately 2-fold after 1 hour incubation in ganglia-derived SIF cells.,Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenaline at 2 x 10^-5 M increases SIF cell fluorescence approximately 2-fold after 1 hour incubation in ganglia-derived SIF cells.
noradrenaline,"Noradrenaline at concentrations of 2 × 10⁻⁶ M and 2 × 10⁻⁵ M significantly increases fluorescence levels in chick embryo sympathetic ganglion neurons after 1 hour incubation in vitro, indicating an increase in catecholamine content.","Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline at concentrations of 2 × 10⁻⁶ M and 2 × 10⁻⁵ M significantly increases fluorescence levels in chick embryo sympathetic ganglion neurons after 1 hour incubation in vitro, indicating an increase in catecholamine content."
noradrenaline,"Noradrenaline is taken up by small intensely fluorescent (SIF) cells in chick embryo sympathetic ganglia, as evidenced by increased fluorescence upon incubation with noradrenaline at 2 × 10⁻⁵ M.","Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline is taken up by small intensely fluorescent (SIF) cells in chick embryo sympathetic ganglia, as evidenced by increased fluorescence upon incubation with noradrenaline at 2 × 10⁻⁵ M."
catecholamine,"Catecholamines are biogenic monoamines present in chick embryo sympathetic ganglion neurons and SIF cells, as demonstrated by formaldehyde-induced fluorescence techniques.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Catecholamines are biogenic monoamines present in chick embryo sympathetic ganglion neurons and SIF cells, as demonstrated by formaldehyde-induced fluorescence techniques."
adrenaline,"Adrenaline at 2 × 10⁻⁵ M induces a fluorescent response in SIF cells of chick embryo sympathetic ganglia, indicating uptake and metabolism of adrenaline.","Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenaline at 2 × 10⁻⁵ M induces a fluorescent response in SIF cells of chick embryo sympathetic ganglia, indicating uptake and metabolism of adrenaline."
hydrocortisone acetate,"Hydrocortisone acetate at 10 µg/ml increases the fluorescence of SIF cells in chick embryo sympathetic ganglia after three days of culture, compared to control.","Entity: hydrocortisone acetate. SMILES: CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C. Hydrocortisone acetate at 10 µg/ml increases the fluorescence of SIF cells in chick embryo sympathetic ganglia after three days of culture, compared to control."
dopamine,"Dopamine is taken up by SIF cells in chick embryo sympathetic ganglia, as shown by increased fluorescence upon incubation with dopamine.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine is taken up by SIF cells in chick embryo sympathetic ganglia, as shown by increased fluorescence upon incubation with dopamine."
styrol methacrylate,Styrol methacrylate is used as an embedding medium for infiltrating biological tissue samples prior to freeze-drying and ultrathin sectioning.,Entity: styrol methacrylate. SMILES: C=C(C)C(=O)O.C=Cc1ccccc1. Styrol methacrylate is used as an embedding medium for infiltrating biological tissue samples prior to freeze-drying and ultrathin sectioning.
calcium,Calcium can be quantitatively measured in mineralized collagen fibrils and extracollagenous regions of bone tissue using X-ray absorption techniques.,Entity: calcium. SMILES: [Ca]. Calcium can be quantitatively measured in mineralized collagen fibrils and extracollagenous regions of bone tissue using X-ray absorption techniques.
phosphorus,Phosphorus content in mineralized collagen fibrils and extracollagenous regions of bone tissue can be quantified using X-ray absorption methods.,Entity: phosphorus. SMILES: [P]. Phosphorus content in mineralized collagen fibrils and extracollagenous regions of bone tissue can be quantified using X-ray absorption methods.
aluminium,Aluminium can be used as a coating material for X-ray microscope holders to reduce X-ray stray radiation.,Entity: aluminium. SMILES: [Al]. Aluminium can be used as a coating material for X-ray microscope holders to reduce X-ray stray radiation.
carbon,Carbon can serve as a coating for X-ray microscope holders to minimize X-ray stray radiation.,Entity: carbon. SMILES: [C]. Carbon can serve as a coating for X-ray microscope holders to minimize X-ray stray radiation.
water,Water contact with ultrathin sections during sectioning should be minimized to prevent artifacts in electron microscopy.,Entity: water. SMILES: O. Water contact with ultrathin sections during sectioning should be minimized to prevent artifacts in electron microscopy.
calcium,"In the mineralized region of turkey tibia tendon, calcium is present as round microcompartments surrounded by a mineral sheath, with the central region consisting mainly of plate-like crystallites and the peripheral region containing closely packed needles.","Entity: calcium. SMILES: [Ca]. In the mineralized region of turkey tibia tendon, calcium is present as round microcompartments surrounded by a mineral sheath, with the central region consisting mainly of plate-like crystallites and the peripheral region containing closely packed needles."
phosphorus,"In the mineralized region of turkey tibia tendon, phosphorus is associated with the round microcompartments and the mineral sheath, and the central region contains plate-like crystallites.","Entity: phosphorus. SMILES: [P]. In the mineralized region of turkey tibia tendon, phosphorus is associated with the round microcompartments and the mineral sheath, and the central region contains plate-like crystallites."
isosorbide dinitrate,"Isosorbide dinitrate is often administered with sedation and/or atropine, making it difficult to determine its independent role in preventing or causing esophageal spasm.","Entity: isosorbide dinitrate. SMILES: O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]. Isosorbide dinitrate is often administered with sedation and/or atropine, making it difficult to determine its independent role in preventing or causing esophageal spasm."
nitroglycerin,"Nitroglycerin is frequently used with sedation and/or atropine, complicating the assessment of its independent effect on esophageal spasm.","Entity: nitroglycerin. SMILES: O=[N+]([O-])C(O)C(O)CO. Nitroglycerin is frequently used with sedation and/or atropine, complicating the assessment of its independent effect on esophageal spasm."
atropine,Atropine is commonly used as a premedication to decrease the likelihood of esophageal spasm during diagnostic procedures.,Entity: atropine. SMILES: CN1[C@@H]2CC[C@H]1CC(OC(=O)C(CO)c1ccccc1)C2. Atropine is commonly used as a premedication to decrease the likelihood of esophageal spasm during diagnostic procedures.
nitroglycerin,Nitroglycerin is used to challenge narrowed coronary artery segments after obtaining a complete set of multiple view coronary angiograms.,Entity: nitroglycerin. SMILES: O=[N+]([O-])C(O)C(O)CO. Nitroglycerin is used to challenge narrowed coronary artery segments after obtaining a complete set of multiple view coronary angiograms.
atropine,Atropine is administered sparingly and only when bradycardia occurs during cardiac catheterization.,Entity: atropine. SMILES: CN1[C@@H]2CC[C@H]1CC(OC(=O)C(CO)c1ccccc1)C2. Atropine is administered sparingly and only when bradycardia occurs during cardiac catheterization.
nitroglycerin,Nitroglycerin was excluded from all medications at least 48 hours prior to hemodynamic studies in patients with angina pectoris.,Entity: nitroglycerin. SMILES: O=[N+]([O-])C(O)C(O)CO. Nitroglycerin was excluded from all medications at least 48 hours prior to hemodynamic studies in patients with angina pectoris.
nifedipine,"Nifedipine, when administered intravenously, reduces left ventricular end-diastolic pressure and Vmax during exercise in patients with angina pectoris.","Entity: nifedipine. SMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]. Nifedipine, when administered intravenously, reduces left ventricular end-diastolic pressure and Vmax during exercise in patients with angina pectoris."
nifedipine,Nifedipine decreases myocardial oxygen requirements primarily by reducing left ventricular volume.,Entity: nifedipine. SMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]. Nifedipine decreases myocardial oxygen requirements primarily by reducing left ventricular volume.
nitroglycerin,Nitroglycerin is suggested to reduce myocardial oxygen needs by reducing left ventricular volume.,Entity: nitroglycerin. SMILES: O=[N+]([O-])C(O)C(O)CO. Nitroglycerin is suggested to reduce myocardial oxygen needs by reducing left ventricular volume.
propranolol,"Propranolol suppresses positive chronotropic and inotropic responses, which are major determinants of myocardial oxygen consumption.","Entity: propranolol. SMILES: CC(C)NCC(O)COc1cccc2ccccc12. Propranolol suppresses positive chronotropic and inotropic responses, which are major determinants of myocardial oxygen consumption."
nitroglycerin,Nitroglycerin administration leads to a significant fall in left ventricular end-diastolic pressure.,Entity: nitroglycerin. SMILES: O=[N+]([O-])C(O)C(O)CO. Nitroglycerin administration leads to a significant fall in left ventricular end-diastolic pressure.
diazepam,"Diazepam reduces aortic systolic and left ventricular end-diastolic pressure, indicating a direct peripheral action on arteries and/or veins, even in the presence of autonomic blockade.","Entity: diazepam. SMILES: CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21. Diazepam reduces aortic systolic and left ventricular end-diastolic pressure, indicating a direct peripheral action on arteries and/or veins, even in the presence of autonomic blockade."
nitroglycerin,"Nitroglycerin is suggested to cause venous dilatation, as indicated by a reduction in left ventricular end-diastolic pressure.","Entity: nitroglycerin. SMILES: O=[N+]([O-])C(O)C(O)CO. Nitroglycerin is suggested to cause venous dilatation, as indicated by a reduction in left ventricular end-diastolic pressure."
diazepam,"Diazepam increases myocardial blood flow, as measured by the 133 Xenon clearance method, especially after autonomic nervous blockade.","Entity: diazepam. SMILES: CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21. Diazepam increases myocardial blood flow, as measured by the 133 Xenon clearance method, especially after autonomic nervous blockade."
diazepam,Diazepam at intravenous doses higher than 1 mg/kg or intracoronary doses higher than 0.1 mg/kg can induce coronary hemodynamic changes.,Entity: diazepam. SMILES: CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21. Diazepam at intravenous doses higher than 1 mg/kg or intracoronary doses higher than 0.1 mg/kg can induce coronary hemodynamic changes.
diazepam,"Diazepam improves myocardial metabolism of lactate, likely due to its beneficial effects on systemic hemodynamics.","Entity: diazepam. SMILES: CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21. Diazepam improves myocardial metabolism of lactate, likely due to its beneficial effects on systemic hemodynamics."
propranolol,Propranolol is administered at a dose of 5 mg over 5 minutes intravenously to monitor its effects on heart rate and left ventricular pressures.,Entity: propranolol. SMILES: CC(C)NCC(O)COc1cccc2ccccc12. Propranolol is administered at a dose of 5 mg over 5 minutes intravenously to monitor its effects on heart rate and left ventricular pressures.
diazepam,Diazepam is administered at a dose of 0.1 mg/kg intravenously over 1 minute to assess its effects in a clinical setting.,Entity: diazepam. SMILES: CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21. Diazepam is administered at a dose of 0.1 mg/kg intravenously over 1 minute to assess its effects in a clinical setting.
atropine sulfate,Atropine sulfate is administered as a 0.8 mg intravenous bolus to evaluate its effects in a clinical protocol.,Entity: atropine sulfate. SMILES: CN1[C@@H]2CC[C@H]1CC(OC(=O)C(CO)c1ccccc1)C2.CN1[C@@H]2CC[C@H]1CC(OC(=O)C(CO)c1ccccc1)C2.O=S(=O)(O)O. Atropine sulfate is administered as a 0.8 mg intravenous bolus to evaluate its effects in a clinical protocol.
phosphorylcholine,The experimentally determined solubility of the free acid form of phosphorylcholine is available in the referenced table.,Entity: phosphorylcholine. SMILES: C[N+](C)(C#P=O)CCO. The experimentally determined solubility of the free acid form of phosphorylcholine is available in the referenced table.
phosphorylcholine,The aqueous solubility of the free acid form of phosphorylcholine is below the polar group concentrations calculated for bilayers of the corresponding phospholipids.,Entity: phosphorylcholine. SMILES: C[N+](C)(C#P=O)CCO. The aqueous solubility of the free acid form of phosphorylcholine is below the polar group concentrations calculated for bilayers of the corresponding phospholipids.
sulfuric acid,Sulfuric acid is used to prepare the free acid form of phosphorylcholine from its Ca salt by stoichiometric addition to aqueous solutions.,Entity: sulfuric acid. SMILES: O=S(=O)(O)O. Sulfuric acid is used to prepare the free acid form of phosphorylcholine from its Ca salt by stoichiometric addition to aqueous solutions.
sodium sulfate,Sodium sulfate is used to prepare the Na salt form of phosphorylcholine from its Ca salt by stoichiometric addition to aqueous solutions followed by precipitation with propanol-2.,Entity: sodium sulfate. SMILES: O=S(=O)([O-])[O-].[Na+].[Na+]. Sodium sulfate is used to prepare the Na salt form of phosphorylcholine from its Ca salt by stoichiometric addition to aqueous solutions followed by precipitation with propanol-2.
ammonia,Ammonia is used as a component of the solvent system (in a 5:3 v/v mixture with isobutyric acid) for paper chromatography analysis.,Entity: ammonia. SMILES: N. Ammonia is used as a component of the solvent system (in a 5:3 v/v mixture with isobutyric acid) for paper chromatography analysis.
isobutyric acid,Isobutyric acid is used as a component of the solvent system (in a 5:3 v/v mixture with 1 M ammonia) for paper chromatography analysis.,Entity: isobutyric acid. SMILES: CC(C)C(=O)O. Isobutyric acid is used as a component of the solvent system (in a 5:3 v/v mixture with 1 M ammonia) for paper chromatography analysis.
ninhydrin,Ninhydrin is used as a detection reagent for paper chromatography analysis.,Entity: ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is used as a detection reagent for paper chromatography analysis.
phosphoric acid,The free acid form of phosphoric acid has very low solubility and is a primitive model compound for the polar group of phosphatidic acid.,Entity: phosphoric acid. SMILES: O=P(O)(O)O. The free acid form of phosphoric acid has very low solubility and is a primitive model compound for the polar group of phosphatidic acid.
sodium hydroxide,Sodium hydroxide is used to prepare the Na salt form of phosphorylethanolamine from its free acid form by stoichiometric addition to aqueous solutions.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to prepare the Na salt form of phosphorylethanolamine from its free acid form by stoichiometric addition to aqueous solutions.
calcium chloride,"Calcium chloride is used to prepare the Ca salt form of D,L-phospho-serine from its free acid form by stoichiometric addition to aqueous solutions.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride is used to prepare the Ca salt form of D,L-phospho-serine from its free acid form by stoichiometric addition to aqueous solutions."
phosphatidylserine,"The free acid form of phosphatidylserine fails to form fluid bilayers in excess water, whereas the Na salt readily does.","Entity: phosphatidylserine. SMILES: CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCCCCCCCCCCCCCCCC. The free acid form of phosphatidylserine fails to form fluid bilayers in excess water, whereas the Na salt readily does."
phosphorylcholine,"The free acid form of phosphorylcholine does not form fluid bilayers in excess water, whereas the Na salt readily does.","Entity: phosphorylcholine. SMILES: C[N+](C)(C#P=O)CCO. The free acid form of phosphorylcholine does not form fluid bilayers in excess water, whereas the Na salt readily does."
sodium glycinate,Sodium glycinate is used as a buffer at pH 9.5 in enzyme assays measuring arginase activity.,Entity: sodium glycinate. SMILES: NCC(=O)[O-].[Na+]. Sodium glycinate is used as a buffer at pH 9.5 in enzyme assays measuring arginase activity.
ornithine,Ornithine production is used as a quantitative measure of arginase activity in enzymatic assays.,Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine production is used as a quantitative measure of arginase activity in enzymatic assays.
urea,"Aphanocapsa 6308 does not grow on urea as a sole carbon source, but possesses a very active urease and arginase, indicating metabolic activity toward arginine.","Entity: urea. SMILES: NC(N)=O. Aphanocapsa 6308 does not grow on urea as a sole carbon source, but possesses a very active urease and arginase, indicating metabolic activity toward arginine."
arginine,"Arginine is the only organic, nitrogenous compound among those tested that supports growth in Aphanocapsa 6308 under CO2-free conditions.","Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine is the only organic, nitrogenous compound among those tested that supports growth in Aphanocapsa 6308 under CO2-free conditions."
arginine,"Aphanocapsa 6308 can metabolize arginine via both the arginine dihydrolase pathway (producing ornithine, CO2, NH4+, and ATP) and the arginase pathway.","Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Aphanocapsa 6308 can metabolize arginine via both the arginine dihydrolase pathway (producing ornithine, CO2, NH4+, and ATP) and the arginase pathway."
ornithine,"In Aphanocapsa 6308, ornithine is excreted at higher concentrations than citrulline, indicating its production via the arginine dihydrolase pathway.","Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. In Aphanocapsa 6308, ornithine is excreted at higher concentrations than citrulline, indicating its production via the arginine dihydrolase pathway."
carbon dioxide,The arginine dihydrolase pathway in Aphanocapsa 6308 produces carbon dioxide as a catabolic product.,Entity: carbon dioxide. SMILES: O=C=O. The arginine dihydrolase pathway in Aphanocapsa 6308 produces carbon dioxide as a catabolic product.
nitrogen,"The arginine dihydrolase pathway in Aphanocapsa 6308 provides both nitrogen and carbon dioxide as catabolic products, while the arginase pathway provides only nitrogen.","Entity: nitrogen. SMILES: [N]. The arginine dihydrolase pathway in Aphanocapsa 6308 provides both nitrogen and carbon dioxide as catabolic products, while the arginase pathway provides only nitrogen."
L-arginine,"L-arginine is a component of cell culture medium that supports exponential growth of cells, as measured by increases in dry weight.","Entity: L-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. L-arginine is a component of cell culture medium that supports exponential growth of cells, as measured by increases in dry weight."
L-aspartic acid,Supplementation with L-aspartic acid enhances cell growth in culture.,Entity: L-aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. Supplementation with L-aspartic acid enhances cell growth in culture.
ornithine,"Ornithine, an arginine analogue, does not support cell growth in culture.","Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine, an arginine analogue, does not support cell growth in culture."
citrulline,"Citrulline, an arginine analogue, does not support cell growth in culture.","Entity: citrulline. SMILES: NC(=O)NCCC[C@H](N)C(=O)O. Citrulline, an arginine analogue, does not support cell growth in culture."
urea,Increased urea concentrations are toxic to cells in culture.,Entity: urea. SMILES: NC(N)=O. Increased urea concentrations are toxic to cells in culture.
L-arginine,"L-arginine serves as a substrate for arginase activity assays, with 40 pmoles used in Tris buffer pH 8.3, 0.01 M at 35°C.","Entity: L-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. L-arginine serves as a substrate for arginase activity assays, with 40 pmoles used in Tris buffer pH 8.3, 0.01 M at 35°C."
putrescine,"Putrescine is a product formed in assays measuring arginase activity, and its appearance can be quantified in enzymatic assays.","Entity: putrescine. SMILES: NCCCCN. Putrescine is a product formed in assays measuring arginase activity, and its appearance can be quantified in enzymatic assays."
agmatine,Agmatine is a product of arginase-catalyzed reactions and can be quantified in enzymatic assays using the Goldschmidt and Lockhart method.,Entity: agmatine. SMILES: N=C(N)NCCCCN.O=S(=O)(O)O. Agmatine is a product of arginase-catalyzed reactions and can be quantified in enzymatic assays using the Goldschmidt and Lockhart method.
ornithine,Ornithine is produced from L-arginine by arginase in Aphanocapsa 6308.,Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine is produced from L-arginine by arginase in Aphanocapsa 6308.
putrescine,Putrescine is not produced as a product of cultures of Aphanocapsa 6308 under the experimental conditions used.,Entity: putrescine. SMILES: NCCCCN. Putrescine is not produced as a product of cultures of Aphanocapsa 6308 under the experimental conditions used.
urea,Urea is produced from L-arginine by arginase in Aphanocapsa 6308.,Entity: urea. SMILES: NC(N)=O. Urea is produced from L-arginine by arginase in Aphanocapsa 6308.
urea,Urea is metabolized to carbon dioxide and ammonia by an active urease in Aphanocapsa 6308.,Entity: urea. SMILES: NC(N)=O. Urea is metabolized to carbon dioxide and ammonia by an active urease in Aphanocapsa 6308.
carbamyl phosphate,Carbamyl phosphate is formed from citrulline by ornithine carbamyl transferase in Aphanocapsa 6308.,Entity: carbamyl phosphate. SMILES: NC(=O)OP(=O)([O-])[O-]. Carbamyl phosphate is formed from citrulline by ornithine carbamyl transferase in Aphanocapsa 6308.
L-arginine,"L-arginine is converted by Aphanocapsa 6308 to citrulline, ornithine, carbon dioxide, and ammonia via the arginine dihydrolase pathway.","Entity: L-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. L-arginine is converted by Aphanocapsa 6308 to citrulline, ornithine, carbon dioxide, and ammonia via the arginine dihydrolase pathway."
carbamyl phosphate,"Carbamyl phosphate is further metabolized to carbon dioxide, ammonia, and ATP via carbamyl phosphokinase in Aphanocapsa 6308.","Entity: carbamyl phosphate. SMILES: NC(=O)OP(=O)([O-])[O-]. Carbamyl phosphate is further metabolized to carbon dioxide, ammonia, and ATP via carbamyl phosphokinase in Aphanocapsa 6308."
L-arginine,"L-arginine is also converted by Aphanocapsa 6308 to ornithine and urea via the arginase pathway, with carbon dioxide and ammonia as by-products.","Entity: L-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. L-arginine is also converted by Aphanocapsa 6308 to ornithine and urea via the arginase pathway, with carbon dioxide and ammonia as by-products."
ammonia,Ammonia is produced as a by-product from L-arginine metabolism by Aphanocapsa 6308 via the arginine dihydrolase and arginase pathways.,Entity: ammonia. SMILES: N. Ammonia is produced as a by-product from L-arginine metabolism by Aphanocapsa 6308 via the arginine dihydrolase and arginase pathways.
citrulline,Citrulline is produced from L-arginine by Aphanocapsa 6308 via the arginine dihydrolase pathway.,Entity: citrulline. SMILES: NC(=O)NCCC[C@H](N)C(=O)O. Citrulline is produced from L-arginine by Aphanocapsa 6308 via the arginine dihydrolase pathway.
ammonia,Ammonia is produced from urea by an active urease in Aphanocapsa 6308.,Entity: ammonia. SMILES: N. Ammonia is produced from urea by an active urease in Aphanocapsa 6308.
citrulline,Citrulline is metabolized to ornithine and carbamyl phosphate by ornithine carbamyl transferase in Aphanocapsa 6308.,Entity: citrulline. SMILES: NC(=O)NCCC[C@H](N)C(=O)O. Citrulline is metabolized to ornithine and carbamyl phosphate by ornithine carbamyl transferase in Aphanocapsa 6308.
carbon dioxide,Carbon dioxide is produced as a by-product from L-arginine metabolism by Aphanocapsa 6308 via the arginine dihydrolase and arginase pathways.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is produced as a by-product from L-arginine metabolism by Aphanocapsa 6308 via the arginine dihydrolase and arginase pathways.
ornithine,Ornithine is produced from L-arginine by Aphanocapsa 6308 via the arginine dihydrolase pathway.,Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine is produced from L-arginine by Aphanocapsa 6308 via the arginine dihydrolase pathway.
carbon dioxide,Carbon dioxide is produced from carbamyl phosphate by carbamyl phosphokinase in Aphanocapsa 6308.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is produced from carbamyl phosphate by carbamyl phosphokinase in Aphanocapsa 6308.
ornithine,Ornithine is formed from citrulline by ornithine carbamyl transferase in Aphanocapsa 6308.,Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine is formed from citrulline by ornithine carbamyl transferase in Aphanocapsa 6308.
agmatine,Agmatine is not produced as a product of cultures of Aphanocapsa 6308 under the experimental conditions used.,Entity: agmatine. SMILES: N=C(N)NCCCCN. Agmatine is not produced as a product of cultures of Aphanocapsa 6308 under the experimental conditions used.
arginine,"Arginine alone is unable to sustain growth in the presence of photosynthetic inhibitors such as DCMU or CCCP, even when supplemented with electron donors like ascorbate, succinate, or glycolate.","Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine alone is unable to sustain growth in the presence of photosynthetic inhibitors such as DCMU or CCCP, even when supplemented with electron donors like ascorbate, succinate, or glycolate."
cyanophycin,Cyanophycin granules cannot be used as a carbon source for growth in the absence of CO2.,Entity: cyanophycin. SMILES: NC(N)=NCCC[C@H](NC(=O)CC(N)C(=O)O)C(=O)O. Cyanophycin granules cannot be used as a carbon source for growth in the absence of CO2.
arginine,Arginine can serve as a source of energy in the form of ATP for cells.,Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine can serve as a source of energy in the form of ATP for cells.
L-arginine,"L-arginine serves as a substrate in the arginine catabolic pathway, leading to the production of metabolic intermediates detectable in Aphanocapsa 6308 culture supernatants.","Entity: L-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. L-arginine serves as a substrate in the arginine catabolic pathway, leading to the production of metabolic intermediates detectable in Aphanocapsa 6308 culture supernatants."
L-arginine,"In Aphanocapsa 6308, the concentration of L-arginine in culture media is higher than that of ornithine and citrulline, as indicated by the intensity of the ninhydrin reaction in thin layer chromatography.","Entity: L-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. In Aphanocapsa 6308, the concentration of L-arginine in culture media is higher than that of ornithine and citrulline, as indicated by the intensity of the ninhydrin reaction in thin layer chromatography."
L-arginine,"L-arginine is metabolized by Aphanocapsa 6308 to produce carbon dioxide, with an in vitro evolution rate of 1.87 x 10^-5 mol CO2/min per mg protein.","Entity: L-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. L-arginine is metabolized by Aphanocapsa 6308 to produce carbon dioxide, with an in vitro evolution rate of 1.87 x 10^-5 mol CO2/min per mg protein."
NADP,"NADP serves as the electron acceptor in the glucose-6-phosphate dehydrogenase reaction, with its reduction measured by absorbance at 340 nm.","Entity: NADP. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)(O)OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP serves as the electron acceptor in the glucose-6-phosphate dehydrogenase reaction, with its reduction measured by absorbance at 340 nm."
glucose-6-phosphate,Glucose-6-phosphate is formed by the phosphorylation of glucose catalyzed by yeast hexokinase in a coupled enzyme assay.,Entity: glucose-6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose-6-phosphate is formed by the phosphorylation of glucose catalyzed by yeast hexokinase in a coupled enzyme assay.
carbamyl phosphate,Carbamyl phosphate (dilithium salt) serves as the substrate for carbamyl phosphokinase in a coupled enzyme assay.,Entity: carbamyl phosphate. SMILES: NC(=O)OP(=O)([O-])[O-]. Carbamyl phosphate (dilithium salt) serves as the substrate for carbamyl phosphokinase in a coupled enzyme assay.
L-citrulline,L-citrulline is used as the substrate for ornithine carbamyl transferase in a coupled enzyme assay.,Entity: L-citrulline. SMILES: NC(=O)NCCC[C@H](N)C(=O)O. L-citrulline is used as the substrate for ornithine carbamyl transferase in a coupled enzyme assay.
glucose,Glucose is phosphorylated by yeast hexokinase to form glucose-6-phosphate in a coupled enzyme assay.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is phosphorylated by yeast hexokinase to form glucose-6-phosphate in a coupled enzyme assay.
L-arginine,L-arginine is used as the substrate for L-arginine deiminase in a coupled enzyme assay in the presence of phosphate.,Entity: L-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. L-arginine is used as the substrate for L-arginine deiminase in a coupled enzyme assay in the presence of phosphate.
carbamyl phosphate,"The carbamyl phosphate-ATP reaction is potentially inhibited by CCCP, which also inhibits phosphorylation.","Entity: carbamyl phosphate. SMILES: NC(=O)OP(=O)([O-])[O-]. The carbamyl phosphate-ATP reaction is potentially inhibited by CCCP, which also inhibits phosphorylation."
succinate,"Succinate, when provided as an extracellular reductant in the presence of arginine, does not enhance the growth of Aphanocapsa6308.","Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate, when provided as an extracellular reductant in the presence of arginine, does not enhance the growth of Aphanocapsa6308."
ascorbate,"Ascorbate, when provided as an extracellular reductant in the presence of arginine, does not enhance the growth of Aphanocapsa6308.","Entity: ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O. Ascorbate, when provided as an extracellular reductant in the presence of arginine, does not enhance the growth of Aphanocapsa6308."
CCCP,"CCCP is a potent inhibitor of many types of phosphorylation, likely affecting both photosynthesis and the carbamyl phosphate-ATP reaction.","Entity: CCCP. SMILES: N#CC(C#N)=NNc1cccc(Cl)c1. CCCP is a potent inhibitor of many types of phosphorylation, likely affecting both photosynthesis and the carbamyl phosphate-ATP reaction."
NADP,"NADP is required for growth of Aphanocapsa6308, and its depletion due to DCMU inhibition is critical for cell growth.","Entity: NADP. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)(O)OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP is required for growth of Aphanocapsa6308, and its depletion due to DCMU inhibition is critical for cell growth."
arginine,"Arginine supplies a large, though not major, portion of the energy required for growth of Aphanocapsa6308.","Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine supplies a large, though not major, portion of the energy required for growth of Aphanocapsa6308."
urea,"Urea cannot support the growth of Aphanocapsa 6308, indicating it is not a viable carbon source for this organism.","Entity: urea. SMILES: NC(N)=O. Urea cannot support the growth of Aphanocapsa 6308, indicating it is not a viable carbon source for this organism."
ammonia,Ammonia is produced from arginine by the arginine dihydrolase pathway and serves as a source of nitrogen for Aphanocapsa 6308.,Entity: ammonia. SMILES: N. Ammonia is produced from arginine by the arginine dihydrolase pathway and serves as a source of nitrogen for Aphanocapsa 6308.
arginine,"Arginine serves as a source of both nitrogen (as ammonia) and carbon dioxide (CO2) for Aphanocapsa 6308, with the arginine dihydrolase pathway providing CO2 and the urease pathway providing nitrogen.","Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine serves as a source of both nitrogen (as ammonia) and carbon dioxide (CO2) for Aphanocapsa 6308, with the arginine dihydrolase pathway providing CO2 and the urease pathway providing nitrogen."
arginine,"In Aphanocapsa 6308, the incorporation of arginine label (either universally or in the guanido carbon) is 2.47 × 10⁻² mmol/mg dry weight.","Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. In Aphanocapsa 6308, the incorporation of arginine label (either universally or in the guanido carbon) is 2.47 × 10⁻² mmol/mg dry weight."
carbon dioxide,"Carbon dioxide is produced as an end product by both the arginase and arginine dihydrolase pathways, but only the arginine dihydrolase pathway provides a metabolic source of CO2 for Aphanocapsa 6308.","Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is produced as an end product by both the arginase and arginine dihydrolase pathways, but only the arginine dihydrolase pathway provides a metabolic source of CO2 for Aphanocapsa 6308."
ornithine,"Ornithine is a metabolic product of arginine and serves as a carbon backbone for other amino acids, being primarily localized in the insoluble protein fraction of the cell.","Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine is a metabolic product of arginine and serves as a carbon backbone for other amino acids, being primarily localized in the insoluble protein fraction of the cell."
ornithine,Ornithine can be synthesized from citrulline via conversion.,Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine can be synthesized from citrulline via conversion.
citrulline,Citrulline is a metabolic product of arginine and can be converted to ornithine.,Entity: citrulline. SMILES: NC(=O)NCCC[C@H](N)C(=O)O. Citrulline is a metabolic product of arginine and can be converted to ornithine.
arginine,Arginine is metabolized to produce citrulline and ornithine as useful metabolic products.,Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine is metabolized to produce citrulline and ornithine as useful metabolic products.
carbon dioxide,The guanido group can serve as a source of carbon dioxide for cells.,Entity: carbon dioxide. SMILES: O=C=O. The guanido group can serve as a source of carbon dioxide for cells.
ornithine,Ornithine is a product of the arginine dihydrolase pathway and the arginase pathway of arginine metabolism.,Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine is a product of the arginine dihydrolase pathway and the arginase pathway of arginine metabolism.
adenosine triphosphate,"Adenosine triphosphate is a product of the arginine dihydrolase pathway in which arginine is converted to carbon dioxide, ammonia, and ornithine.","Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine triphosphate is a product of the arginine dihydrolase pathway in which arginine is converted to carbon dioxide, ammonia, and ornithine."
carbon dioxide,"Carbon dioxide is a final product of the arginine dihydrolase pathway in which arginine is converted to CO2, NH3, ATP, and ornithine.","Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is a final product of the arginine dihydrolase pathway in which arginine is converted to CO2, NH3, ATP, and ornithine."
ammonia,"Ammonia is a product of the arginine dihydrolase pathway in which arginine is converted to CO2, NH3, ATP, and ornithine.","Entity: ammonia. SMILES: N. Ammonia is a product of the arginine dihydrolase pathway in which arginine is converted to CO2, NH3, ATP, and ornithine."
urea,Urea is produced from arginine by the arginase pathway.,Entity: urea. SMILES: NC(N)=O. Urea is produced from arginine by the arginase pathway.
putrescine,Putrescine is produced from arginine by the decarboxylase pathway.,Entity: putrescine. SMILES: NCCCCN. Putrescine is produced from arginine by the decarboxylase pathway.
arginine,"Arginine can be converted to carbon dioxide, ammonia, ATP, and ornithine via the arginine dihydrolase pathway in nonfermenting Mycoplasma and several anaerobes.","Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine can be converted to carbon dioxide, ammonia, ATP, and ornithine via the arginine dihydrolase pathway in nonfermenting Mycoplasma and several anaerobes."
arginine,Arginine can be metabolized by a decarboxylase pathway to produce putrescine.,Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine can be metabolized by a decarboxylase pathway to produce putrescine.
arginine,Arginine can be metabolized by an arginase pathway to produce urea and ornithine.,Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine can be metabolized by an arginase pathway to produce urea and ornithine.
arginine,"Arginine serves as an organic source of carbon for Aphanocapsa 6308, enabling it to grow in a CO2-free atmosphere.","Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine serves as an organic source of carbon for Aphanocapsa 6308, enabling it to grow in a CO2-free atmosphere."
CO2,"CO2 is the major cellular source of carbon in most organisms, and its absence inhibits the growth of photoheterotrophic organisms unless an organic substrate is provided.","Entity: CO2. SMILES: O=C=O. CO2 is the major cellular source of carbon in most organisms, and its absence inhibits the growth of photoheterotrophic organisms unless an organic substrate is provided."
urea,"Urea is hydrolyzed by urease enzymes, with its hydrolysis quantified as moles of urea hydrolyzed per hour per mg protein using the Nessler technique to measure ammonia production.","Entity: urea. SMILES: NC(N)=O. Urea is hydrolyzed by urease enzymes, with its hydrolysis quantified as moles of urea hydrolyzed per hour per mg protein using the Nessler technique to measure ammonia production."
ammonia,"Ammonia production is used as a measure of urease activity, with quantification performed using the Nessler technique.","Entity: ammonia. SMILES: N. Ammonia production is used as a measure of urease activity, with quantification performed using the Nessler technique."
succinate,Succinate is used as a supplement in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.,Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate is used as a supplement in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.
L-aspartic acid,L-aspartic acid is included in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.,Entity: L-aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. L-aspartic acid is included in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.
L-ornithine,L-ornithine is used at a concentration in the 5–50 mM range as a supplement in the culture medium for Aphanoeapsa 6308.,Entity: L-ornithine. SMILES: NCCC[C@H](N)C(=O)O. L-ornithine is used at a concentration in the 5–50 mM range as a supplement in the culture medium for Aphanoeapsa 6308.
glycolate,Glycolate is included in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.,Entity: glycolate. SMILES: O=C([O-])CO. Glycolate is included in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.
L-citrulline,L-citrulline is used as a supplement in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.,Entity: L-citrulline. SMILES: NC(=O)NCCC[C@H](N)C(=O)O. L-citrulline is used as a supplement in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.
carbonylcyanide m-chlorophenyl hydrazone,Carbonylcyanide m-chlorophenyl hydrazone (CCCP) is used at a concentration of 10⁻⁴ M as a growth-inhibiting agent in Aphanoeapsa 6308 culture experiments.,Entity: carbonylcyanide m-chlorophenyl hydrazone. SMILES: N#CC(C#N)=NNc1cccc(Cl)c1. Carbonylcyanide m-chlorophenyl hydrazone (CCCP) is used at a concentration of 10⁻⁴ M as a growth-inhibiting agent in Aphanoeapsa 6308 culture experiments.
L-arginine,L-arginine is included in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.,Entity: L-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. L-arginine is included in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.
L-ascorbate,L-ascorbate is used as a supplement in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.,Entity: L-ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O. L-ascorbate is used as a supplement in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.
"3-(3,4-dichlorophenyl)-1,1-dimethylurea","3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU) is used at a concentration of 10⁻⁵ M as a growth-inhibiting agent in Aphanoeapsa 6308 culture experiments.","Entity: 3-(3,4-dichlorophenyl)-1,1-dimethylurea. SMILES: CN(C)C(=O)Nc1ccc(Cl)c(Cl)c1. 3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU) is used at a concentration of 10⁻⁵ M as a growth-inhibiting agent in Aphanoeapsa 6308 culture experiments."
urea,Urea is included in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.,Entity: urea. SMILES: NC(N)=O. Urea is included in the culture medium for Aphanoeapsa 6308 at a concentration in the 5–50 mM range.
citrulline,"Citrulline is expelled into the growth media when cells are grown in arginine, suggesting that citrulline is excreted more rapidly than it can be fully utilized.","Entity: citrulline. SMILES: NC(=O)NCCC[C@H](N)C(=O)O. Citrulline is expelled into the growth media when cells are grown in arginine, suggesting that citrulline is excreted more rapidly than it can be fully utilized."
arginine,"Arginine serves as a substrate for ornithine carbamyl transferase and arginine deiminase, with the latter producing citrulline in excess of the conversion ability of ornithine carbamyl transferase.","Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine serves as a substrate for ornithine carbamyl transferase and arginine deiminase, with the latter producing citrulline in excess of the conversion ability of ornithine carbamyl transferase."
arginine,Arginine synthesis in cyanobacteria is feedback inhibited at the level of N-acetyl glutamate kinase.,Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine synthesis in cyanobacteria is feedback inhibited at the level of N-acetyl glutamate kinase.
citrulline,"Citrulline serves as an intermediate in arginine catabolism, but is not produced by any other known pathway except for arginine-grown cells.","Entity: citrulline. SMILES: NC(=O)NCCC[C@H](N)C(=O)O. Citrulline serves as an intermediate in arginine catabolism, but is not produced by any other known pathway except for arginine-grown cells."
citrulline,"In cells grown in citrulline, ornithine is produced from citrulline via conversion, but citrulline alone cannot provide the necessary stimulus for growth in the absence of carbon dioxide.","Entity: citrulline. SMILES: NC(=O)NCCC[C@H](N)C(=O)O. In cells grown in citrulline, ornithine is produced from citrulline via conversion, but citrulline alone cannot provide the necessary stimulus for growth in the absence of carbon dioxide."
arginine,Arginine is not resynthesized from citrulline or ornithine in detectable levels in cells grown in citrulline and ornithine.,Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine is not resynthesized from citrulline or ornithine in detectable levels in cells grown in citrulline and ornithine.
ornithine,"Ornithine is produced from citrulline in cells grown in citrulline, but ornithine alone cannot support cell growth in the absence of carbon dioxide.","Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine is produced from citrulline in cells grown in citrulline, but ornithine alone cannot support cell growth in the absence of carbon dioxide."
carbon dioxide,"Carbon dioxide is required to provide the necessary stimulus for cell growth in the absence of arginine, citrulline, or ornithine.","Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is required to provide the necessary stimulus for cell growth in the absence of arginine, citrulline, or ornithine."
thymine,Thymine is used to fully label Escherichia coli cells for use as a radioactive standard in metabolic labeling experiments.,Entity: thymine. SMILES: Cc1c[nH]c(=O)[nH]c1=O. Thymine is used to fully label Escherichia coli cells for use as a radioactive standard in metabolic labeling experiments.
rifampin,Rifampin is used at a concentration of 100 µg per sample in bacterial labeling experiments involving Escherichia coli.,Entity: rifampin. SMILES: CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C. Rifampin is used at a concentration of 100 µg per sample in bacterial labeling experiments involving Escherichia coli.
OsO4,OsO4 (osmium tetroxyd) is used as a reagent for fixation of Escherichia coli cells in the presence of uracil and thymine during metabolic labeling experiments.,Entity: OsO4. SMILES: O=[Os](=O)(=O)=O. OsO4 (osmium tetroxyd) is used as a reagent for fixation of Escherichia coli cells in the presence of uracil and thymine during metabolic labeling experiments.
TCA,TCA (trichloroacetic acid) is used to precipitate acid-insoluble radioactivity from bacterial cultures in metabolic labeling assays.,Entity: TCA. SMILES: O=C(O)C(Cl)(Cl)Cl. TCA (trichloroacetic acid) is used to precipitate acid-insoluble radioactivity from bacterial cultures in metabolic labeling assays.
uracil,Uracil is used as a metabolic label in bacterial cultures at a concentration of 0.6 µg/ml (0.6 g/ml) and is supplemented with non-radioactive uracil during fixation steps in metabolic labeling protocols.,Entity: uracil. SMILES: O=c1cc[nH]c(=O)[nH]1. Uracil is used as a metabolic label in bacterial cultures at a concentration of 0.6 µg/ml (0.6 g/ml) and is supplemented with non-radioactive uracil during fixation steps in metabolic labeling protocols.
osmium tetroxide,"Osmium tetroxide fixation of bacteria can cause RNA degradation, whereas glutaraldehyde fixation does not.","Entity: osmium tetroxide. SMILES: O=[Os](=O)(=O)=O. Osmium tetroxide fixation of bacteria can cause RNA degradation, whereas glutaraldehyde fixation does not."
glutaraldehyde,"Glutaraldehyde fixation of bacteria does not retain large amounts of RNA precursors, unlike osmium tetroxide fixation.","Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde fixation of bacteria does not retain large amounts of RNA precursors, unlike osmium tetroxide fixation."
osmium tetroxide,Osmium tetroxide fixation of bacteria retains a much higher amount of RNA precursors than glutaraldehyde fixation.,Entity: osmium tetroxide. SMILES: O=[Os](=O)(=O)=O. Osmium tetroxide fixation of bacteria retains a much higher amount of RNA precursors than glutaraldehyde fixation.
glutaraldehyde,"Glutaraldehyde is a fixative used in microscopy, but osmium tetroxide is preferred for autoradiography of sporulating bacteria because it provides better visualization of cellular membranes.","Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is a fixative used in microscopy, but osmium tetroxide is preferred for autoradiography of sporulating bacteria because it provides better visualization of cellular membranes."
osmium tetroxide,Osmium tetroxide is a fixative that does not trap RNA precursors inside cells and is suitable for autoradiography of sporulating bacteria due to its membrane-staining properties.,Entity: osmium tetroxide. SMILES: O=[Os](=O)(=O)=O. Osmium tetroxide is a fixative that does not trap RNA precursors inside cells and is suitable for autoradiography of sporulating bacteria due to its membrane-staining properties.
glutaraldehyde,"Glutaraldehyde is used as a fixative in bacterial sample preparation, but its use can result in the formation of small cellular aggregates that are difficult to dissociate and may lead to irregular results in radioactivity assays.","Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a fixative in bacterial sample preparation, but its use can result in the formation of small cellular aggregates that are difficult to dissociate and may lead to irregular results in radioactivity assays."
osmium tetroxide,"Osmium tetroxide is used as a fixative in bacterial sample preparation, with concentrations ranging from 0.1% to 1% applied under various conditions.","Entity: osmium tetroxide. SMILES: O=[Os](=O)(=O)=O. Osmium tetroxide is used as a fixative in bacterial sample preparation, with concentrations ranging from 0.1% to 1% applied under various conditions."
TCA,TCA (Trichloroacetic acid) is used at 5% concentration for sample preparation in bacterial radioactivity assays.,Entity: TCA. SMILES: O=C(O)C(Cl)(Cl)Cl. TCA (Trichloroacetic acid) is used at 5% concentration for sample preparation in bacterial radioactivity assays.
OsO4,"OsO4 (osmium tetroxide) is used as a precursor for electron microscopy sample preparation, typically applied at a concentration of 0.2% for fixation of bacteria.","Entity: OsO4. SMILES: O=[Os](=O)(=O)=O. OsO4 (osmium tetroxide) is used as a precursor for electron microscopy sample preparation, typically applied at a concentration of 0.2% for fixation of bacteria."
agar,"Agar is used as a solidifying medium for electron microscopy sample preparation, providing a cushion for spinning down bacterial suspensions during the process.","Entity: agar. SMILES: CO[C@H]1[C@@H](O)[C@@H](CO)OC(OC2C3CO[C@H]2[C@H](O)C(C)O3)[C@@H]1O. Agar is used as a solidifying medium for electron microscopy sample preparation, providing a cushion for spinning down bacterial suspensions during the process."
glutaraldehyde,Glutaraldehyde is used as a fixative in biological sample preparation.,Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a fixative in biological sample preparation.
osmium tetroxide,"Osmium tetroxide is used as a fixative in biological sample preparation, and samples fixed with osmium tetroxide show radioactivity levels similar to those treated with TCA.","Entity: osmium tetroxide. SMILES: O=[Os](=O)(=O)=O. Osmium tetroxide is used as a fixative in biological sample preparation, and samples fixed with osmium tetroxide show radioactivity levels similar to those treated with TCA."
TCA,"TCA (Trichloroacetic acid) is used as a fixative in biological sample preparation, and samples fixed with TCA show radioactivity levels similar to those fixed with osmium tetroxide regardless of fixation duration.","Entity: TCA. SMILES: O=C(O)C(Cl)(Cl)Cl. TCA (Trichloroacetic acid) is used as a fixative in biological sample preparation, and samples fixed with TCA show radioactivity levels similar to those fixed with osmium tetroxide regardless of fixation duration."
ethanol,Ethanol is used as a cold 70% solution for washing cell pellets during DNA extraction.,Entity: ethanol. SMILES: CCO. Ethanol is used as a cold 70% solution for washing cell pellets during DNA extraction.
sodium chloride,Sodium chloride is included at 0.015 M concentration in dilute saline citrate solution for resuspending DNA precipitates.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is included at 0.015 M concentration in dilute saline citrate solution for resuspending DNA precipitates.
formic acid,Formic acid at 98% concentration is used to acid hydrolyze DNA precipitates at 175°C for 30 minutes.,Entity: formic acid. SMILES: O=CO. Formic acid at 98% concentration is used to acid hydrolyze DNA precipitates at 175°C for 30 minutes.
sodium citrate,Sodium citrate is used at 0.0015 M concentration in dilute saline citrate solution for resuspending DNA precipitates.,Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used at 0.0015 M concentration in dilute saline citrate solution for resuspending DNA precipitates.
hydrochloric acid,Hydrochloric acid at 6 N concentration is used to neutralize basic mixtures during DNA extraction.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid at 6 N concentration is used to neutralize basic mixtures during DNA extraction.
sodium hydroxide,Sodium hydroxide is used to hydrolyze RNA in cell pellets by incubation at 37°C for 24 hours.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to hydrolyze RNA in cell pellets by incubation at 37°C for 24 hours.
perchloric acid,Perchloric acid is used for washing cell pellets and for precipitating DNA in the extraction protocol.,Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid is used for washing cell pellets and for precipitating DNA in the extraction protocol.
sodium tetraborate,Sodium tetraborate is used to saturate water in the solvent system for chromatographic analysis of pyrimidine dimers.,Entity: sodium tetraborate. SMILES: [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-]. Sodium tetraborate is used to saturate water in the solvent system for chromatographic analysis of pyrimidine dimers.
isobutyric acid,Isobutyric acid is used as a component of the solvent system at 37.5% volume in chromatographic analysis of pyrimidine dimers.,Entity: isobutyric acid. SMILES: CC(C)C(=O)O. Isobutyric acid is used as a component of the solvent system at 37.5% volume in chromatographic analysis of pyrimidine dimers.
n-butanol,n-Butanol is used as a component of the solvent system at 100% volume in chromatographic analysis of pyrimidine dimers.,Entity: n-butanol. SMILES: CCCCO. n-Butanol is used as a component of the solvent system at 100% volume in chromatographic analysis of pyrimidine dimers.
toluene,Toluene is used as the solvent for 0.5% PPO and 0.3% POPOP in scintillation fluid for detection in chromatographic analysis.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as the solvent for 0.5% PPO and 0.3% POPOP in scintillation fluid for detection in chromatographic analysis.
ammonia,Ammonia is used as a 25% aqueous solution as a component of the solvent system in chromatographic analysis of pyrimidine dimers.,Entity: ammonia. SMILES: N. Ammonia is used as a 25% aqueous solution as a component of the solvent system in chromatographic analysis of pyrimidine dimers.
POPOP,POPOP is used as a fluorescent component at 0.3% concentration in scintillation fluid for detection in chromatographic analysis.,Entity: POPOP. SMILES: c1ccc(-c2cnc(-c3ccc(-c4ncc(-c5ccccc5)o4)cc3)o2)cc1. POPOP is used as a fluorescent component at 0.3% concentration in scintillation fluid for detection in chromatographic analysis.
water,"Water is used as a component of the solvent system in chromatographic analysis, saturated with sodium tetraborate, and is present at 25% volume in the mixture.","Entity: water. SMILES: O. Water is used as a component of the solvent system in chromatographic analysis, saturated with sodium tetraborate, and is present at 25% volume in the mixture."
alantolactone,Alantolactone at a concentration of 2 pg per culture of 10^6 lymphocytes reduces lymphocyte stimulation by approximately 50% in the presence of PWM.,Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone at a concentration of 2 pg per culture of 10^6 lymphocytes reduces lymphocyte stimulation by approximately 50% in the presence of PWM.
alantolactone,Alantolactone at concentrations higher than 2 pg per culture rapidly decreases lymphocyte stimulation in the presence of PWM.,Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone at concentrations higher than 2 pg per culture rapidly decreases lymphocyte stimulation in the presence of PWM.
alantolactone,"Alantolactone at concentrations of 0.25–1.0 pg per culture does not stimulate lymphocytes on its own, but increases stimulation when PWM is used as a stimulant.","Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone at concentrations of 0.25–1.0 pg per culture does not stimulate lymphocytes on its own, but increases stimulation when PWM is used as a stimulant."
alantolactone,"Alantolactone is toxic to PHA-stimulated lymphocytes, causing a 50% decrease in stimulation at a concentration of 2 pg per culture.","Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone is toxic to PHA-stimulated lymphocytes, causing a 50% decrease in stimulation at a concentration of 2 pg per culture."
alantolactone,"Alantolactone at concentrations of 20 ?t (not specified as pg) in combination with PWM increases stimulation in lymphocyte cultures, likely due to a mixed lymphocyte reaction.","Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone at concentrations of 20 ?t (not specified as pg) in combination with PWM increases stimulation in lymphocyte cultures, likely due to a mixed lymphocyte reaction."
DHA,"DHA at concentrations of 1 pg in combination with PWM increases stimulation in lymphocyte cultures, possibly through a mixed lymphocyte reaction.","Entity: DHA. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)O. DHA at concentrations of 1 pg in combination with PWM increases stimulation in lymphocyte cultures, possibly through a mixed lymphocyte reaction."
alantolactone,Alantolactone at concentrations lower than 1 pg/culture alone does not significantly stimulate lymphocyte cultures.,Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone at concentrations lower than 1 pg/culture alone does not significantly stimulate lymphocyte cultures.
alantolactone,Alantolactone is toxic to lymphocyte cultures.,Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone is toxic to lymphocyte cultures.
alantolactone,Alantolactone can be reduced by sodium borohydride treatment.,Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone can be reduced by sodium borohydride treatment.
dihydroalantolactone,Dihydroalantolactone is toxic to lymphocyte cultures.,Entity: dihydroalantolactone. SMILES: C[C@@H]1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Dihydroalantolactone is toxic to lymphocyte cultures.
alantolactone,Alantolactone is used to measure its toxic effect on lymphocyte stimulation in vitro by assessing its ability to decrease lymphocyte response to PWM.,Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone is used to measure its toxic effect on lymphocyte stimulation in vitro by assessing its ability to decrease lymphocyte response to PWM.
alantolactone,Alantolactone is a sesquiterpene lactone (eudesmanolide) produced by Inula helenium that acts as a strong allergen capable of producing positive patch-tests and eliciting sensitization in sensitive patients.,Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone is a sesquiterpene lactone (eudesmanolide) produced by Inula helenium that acts as a strong allergen capable of producing positive patch-tests and eliciting sensitization in sensitive patients.
ilicic acid,Ilicic acid is a sesquiterpene lactone that lacks a chemically reactive system with an a-methylene group conjugated to a carbonyl within a y-lactone and therefore fails to produce positive patch-tests in patients sensitive to sesquiterpene lactones.,Entity: ilicic acid. SMILES: C=C(C(=O)O)[C@@H]1CC[C@@]2(C)CCC[C@@](C)(O)[C@@H]2C1. Ilicic acid is a sesquiterpene lactone that lacks a chemically reactive system with an a-methylene group conjugated to a carbonyl within a y-lactone and therefore fails to produce positive patch-tests in patients sensitive to sesquiterpene lactones.
Alantolactone,Alantolactone is a hapten that can react with nucleophilic molecules such as free amino acids and proteins.,Entity: Alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone is a hapten that can react with nucleophilic molecules such as free amino acids and proteins.
Alantolactone,"Alantolactone can react with free amino acids including lysine, cysteine, and histidine.","Entity: Alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone can react with free amino acids including lysine, cysteine, and histidine."
Alantolactone,Alantolactone can react with proteins such as RNAase A and purified protein fractions from epidermal-dermal tissues.,Entity: Alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone can react with proteins such as RNAase A and purified protein fractions from epidermal-dermal tissues.
Histidine,Histidine is a free amino acid that can react with the hapten alantolactone.,Entity: Histidine. SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O. Histidine is a free amino acid that can react with the hapten alantolactone.
Cysteine,Cysteine is a free amino acid that can react with the hapten alantolactone.,Entity: Cysteine. SMILES: N[C@@H](CS)C(=O)O. Cysteine is a free amino acid that can react with the hapten alantolactone.
Lysine,Lysine is a free amino acid that can react with the hapten alantolactone.,Entity: Lysine. SMILES: NCCCC[C@H](N)C(=O)O. Lysine is a free amino acid that can react with the hapten alantolactone.
alantolactone,"Alantolactone is a sesquiterpene lactone whose cytotoxicity is mainly due to its lipophilic nature, enabling it to penetrate lymphocyte membranes and interfere with cellular metabolic activity.","Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone is a sesquiterpene lactone whose cytotoxicity is mainly due to its lipophilic nature, enabling it to penetrate lymphocyte membranes and interfere with cellular metabolic activity."
alantolactone,"The cytotoxic effect of alantolactone is abolished when its hydrophobic character is altered by reaction with cysteine or lysine, indicating that its lipophilicity is important for its activity.","Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. The cytotoxic effect of alantolactone is abolished when its hydrophobic character is altered by reaction with cysteine or lysine, indicating that its lipophilicity is important for its activity."
DHA,"The cytotoxic effect of DHA is likely due to its lipophilic nature, allowing it to penetrate lymphocyte membranes and interfere with cellular metabolic activity.","Entity: DHA. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)O. The cytotoxic effect of DHA is likely due to its lipophilic nature, allowing it to penetrate lymphocyte membranes and interfere with cellular metabolic activity."
cysteine,"Reaction of alantolactone with cysteine increases its hydrophilicity, abolishing its cytotoxic effect.","Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. Reaction of alantolactone with cysteine increases its hydrophilicity, abolishing its cytotoxic effect."
lysine,"Reaction of alantolactone with lysine increases its hydrophilicity, abolishing its cytotoxic effect.","Entity: lysine. SMILES: NCCCC[C@H](N)C(=O)O. Reaction of alantolactone with lysine increases its hydrophilicity, abolishing its cytotoxic effect."
alantolactone,"Alantolactone induces cell death in lymphocytes in culture after 5 days, with toxicity observed in the concentration range of 1–10 pg.","Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone induces cell death in lymphocytes in culture after 5 days, with toxicity observed in the concentration range of 1–10 pg."
DHA,"DHA induces cell death in lymphocytes in culture after 5 days, with toxicity in the concentration range of 1–10 pg.","Entity: DHA. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)O. DHA induces cell death in lymphocytes in culture after 5 days, with toxicity in the concentration range of 1–10 pg."
DHA,DHA is less toxic to lymphocytes in culture than alantolactone at a concentration of 20 pg.,Entity: DHA. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)O. DHA is less toxic to lymphocytes in culture than alantolactone at a concentration of 20 pg.
alantolactone,"Alantolactone is a sesquiterpene lactone that is toxic to lymphocytes, as shown by decreased stimulation and reduced cell viability in vitro.","Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone is a sesquiterpene lactone that is toxic to lymphocytes, as shown by decreased stimulation and reduced cell viability in vitro."
alantolactone,"At concentrations of 2 pg/culture, alantolactone causes a 50% decrease in lymphocyte stimulation by PWM, and at 5 pg/culture, stimulation becomes complete.","Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. At concentrations of 2 pg/culture, alantolactone causes a 50% decrease in lymphocyte stimulation by PWM, and at 5 pg/culture, stimulation becomes complete."
Alantolactone,Alantolactone is an allergenic sesquiterpene lactone that is toxic to leukocytes in in vitro cultures.,Entity: Alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone is an allergenic sesquiterpene lactone that is toxic to leukocytes in in vitro cultures.
Alantolactone,A concentration of 1 µg/ml alantolactone in culture decreases pokeweed mitogen-stimulated leukocyte stimulation by 50%.,Entity: Alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. A concentration of 1 µg/ml alantolactone in culture decreases pokeweed mitogen-stimulated leukocyte stimulation by 50%.
Alantolactone,Alantolactone toxicity to leukocytes is not due to the presence of the alpha-methylene group conjugated to the carbonyl function of the gamma-lactone system.,Entity: Alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone toxicity to leukocytes is not due to the presence of the alpha-methylene group conjugated to the carbonyl function of the gamma-lactone system.
alantolactone,"Alantolactone is soluble in ethanol, as ethanol is used as a solvent for it in stimulation assays.","Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone is soluble in ethanol, as ethanol is used as a solvent for it in stimulation assays."
ethanol,"Ethanol can slightly decrease lymphocyte stimulation by PWM when used at 20 µL volume, but does not impair stimulation at 5–10 µL volumes.","Entity: ethanol. SMILES: CCO. Ethanol can slightly decrease lymphocyte stimulation by PWM when used at 20 µL volume, but does not impair stimulation at 5–10 µL volumes."
alantolactone,"Alantolactone has a toxic effect on leukocytes in vitro, as observed in lymphocyte cultures from patients with clinically established sensitivity to alantolactone.","Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone has a toxic effect on leukocytes in vitro, as observed in lymphocyte cultures from patients with clinically established sensitivity to alantolactone."
alantolactone,Alantolactone is dissolved in absolute ethanol at 1% (w/v) concentration for use in cell culture experiments.,Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone is dissolved in absolute ethanol at 1% (w/v) concentration for use in cell culture experiments.
methanol,Methanol is used as a final wash solution (2 ml) to remove residual reagents from cell pellets during lymphocyte culture preparation.,Entity: methanol. SMILES: CO. Methanol is used as a final wash solution (2 ml) to remove residual reagents from cell pellets during lymphocyte culture preparation.
thymidine,Tritiated thymidine (2 pCi/culture bottle) is added 12 hours prior to cell harvesting in lymphocyte culture experiments.,Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Tritiated thymidine (2 pCi/culture bottle) is added 12 hours prior to cell harvesting in lymphocyte culture experiments.
DHA,DHA is dissolved in absolute ethanol at 1% (w/v) concentration for use in cell culture experiments.,Entity: DHA. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)O. DHA is dissolved in absolute ethanol at 1% (w/v) concentration for use in cell culture experiments.
citric acid,Citric acid is used as a component (0.1 M) in crystal violet solution for cell dilution and counting in hematology procedures.,Entity: citric acid. SMILES: O=C(O)CC(O)(CC(=O)O)C(=O)O. Citric acid is used as a component (0.1 M) in crystal violet solution for cell dilution and counting in hematology procedures.
CO2,CO2 is used at a 5% concentration in the incubator atmosphere for maintaining cell cultures at 37°C.,Entity: CO2. SMILES: O=C=O. CO2 is used at a 5% concentration in the incubator atmosphere for maintaining cell cultures at 37°C.
TCA,TCA (5%) is used to precipitate proteins from cell pellets during the preparation of lymphocyte cultures for analysis.,Entity: TCA. SMILES: O=C(O)C(Cl)(Cl)Cl. TCA (5%) is used to precipitate proteins from cell pellets during the preparation of lymphocyte cultures for analysis.
alantolactone,"Alantolactone is a terpene whose effects on lymphocyte stimulation can be studied by assessing its interaction with mitogens such as PWM, rather than solely measuring cell viability by dye exclusion.","Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone is a terpene whose effects on lymphocyte stimulation can be studied by assessing its interaction with mitogens such as PWM, rather than solely measuring cell viability by dye exclusion."
DHA,DHA is capable of reducing or abolishing the allergenic response of alantolactone as measured by patch-testing.,Entity: DHA. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)O. DHA is capable of reducing or abolishing the allergenic response of alantolactone as measured by patch-testing.
alantolactone,Reduction of the exocyclic double bond of alantolactone abolishes its allergenic response as measured by patch-testing.,Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Reduction of the exocyclic double bond of alantolactone abolishes its allergenic response as measured by patch-testing.
alantolactone,Alantolactone can suppress the mitogenic properties of PWM (phytohemagglutinin) in lymphocyte stimulation assays.,Entity: alantolactone. SMILES: C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12. Alantolactone can suppress the mitogenic properties of PWM (phytohemagglutinin) in lymphocyte stimulation assays.
sucrose,Sucrose is used as a component of the lysis buffer (0.25 M) for preparing chromatin from frozen duck erythrocytes.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used as a component of the lysis buffer (0.25 M) for preparing chromatin from frozen duck erythrocytes.
Triton X-100,"Triton X-100 is included at 0.5% in the lysis buffer and as a washing buffer (0.5% in Tris-HCl, pH 7.9) during chromatin extraction from nuclei.","Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is included at 0.5% in the lysis buffer and as a washing buffer (0.5% in Tris-HCl, pH 7.9) during chromatin extraction from nuclei."
MgCl2,MgCl2 is present at 1 mM in the lysis buffer for chromatin extraction from duck erythrocyte nuclei.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is present at 1 mM in the lysis buffer for chromatin extraction from duck erythrocyte nuclei.
NaCl,NaCl is used at 0.25 M in the washing buffer for nuclei during chromatin preparation.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used at 0.25 M in the washing buffer for nuclei during chromatin preparation.
N-AcO-AAF,"N-AcO-AAF is a carcinogen that can be released from chromatin during digestion with staphylococcal nuclease, with its release kinetics differing from those of the released nucleotides.","Entity: N-AcO-AAF. SMILES: CC(=O)OCC(=O)Nc1cccc2c1Cc1ccccc1-2. N-AcO-AAF is a carcinogen that can be released from chromatin during digestion with staphylococcal nuclease, with its release kinetics differing from those of the released nucleotides."
guanine,Approximately 80% of a certain carcinogen binds to the cytosine (C~) position of guanine in DNA.,Entity: guanine. SMILES: Nc1nc2nc[nH]c2c(=O)[nH]1. Approximately 80% of a certain carcinogen binds to the cytosine (C~) position of guanine in DNA.
glycerol,Glycerol is used as a buffer component at 5% concentration in enzymatic digestion assays involving chromatin and single-strand nucleases.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is used as a buffer component at 5% concentration in enzymatic digestion assays involving chromatin and single-strand nucleases.
sodium chloride,Sodium chloride is included at 0.05 M concentration in buffer for enzymatic digestion of chromatin with single-strand nucleases.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is included at 0.05 M concentration in buffer for enzymatic digestion of chromatin with single-strand nucleases.
sodium acetate,Sodium acetate is used as a buffer at 0.03 M concentration and pH 4.6 in enzymatic digestion experiments with chromatin and single-strand nucleases.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate is used as a buffer at 0.03 M concentration and pH 4.6 in enzymatic digestion experiments with chromatin and single-strand nucleases.
zinc sulfate,Zinc sulfate is present at 0.2 mM or 1 mM concentration in the buffer for chromatin digestion assays with single-strand nucleases.,Entity: zinc sulfate. SMILES: O=S(=O)([O-])[O-].[Zn+2]. Zinc sulfate is present at 0.2 mM or 1 mM concentration in the buffer for chromatin digestion assays with single-strand nucleases.
N-Ac-O-AAF,"N-Ac-O-AAF is a carcinogen that induces chemical and physical alterations in the DNA double helix, both in vivo and in vitro.","Entity: N-Ac-O-AAF. SMILES: CC(=O)OCC(=O)Nc1cccc2c1Cc1ccccc1-2. N-Ac-O-AAF is a carcinogen that induces chemical and physical alterations in the DNA double helix, both in vivo and in vitro."
N-Ac-O-AAF,"In native chromatin, only 15% to 20% of DNA is accessible to N-Ac-O-AAF.","Entity: N-Ac-O-AAF. SMILES: CC(=O)OCC(=O)Nc1cccc2c1Cc1ccccc1-2. In native chromatin, only 15% to 20% of DNA is accessible to N-Ac-O-AAF."
N-AcO-AAF,"N-AcO-AAF is a chemical modifier that can be used to modify DNA and chromatin, with 5% of bases in DNA and about 0.5% of bases in chromatin being modified under standard digestion conditions.","Entity: N-AcO-AAF. SMILES: CC(=O)OCC(=O)Nc1cccc2c1Cc1ccccc1-2. N-AcO-AAF is a chemical modifier that can be used to modify DNA and chromatin, with 5% of bases in DNA and about 0.5% of bases in chromatin being modified under standard digestion conditions."
phenol,Phenol is used for proteinase K-mediated deproteinization of chromatin prior to DNA extraction.,Entity: phenol. SMILES: Oc1ccccc1. Phenol is used for proteinase K-mediated deproteinization of chromatin prior to DNA extraction.
sodium chloride,Sodium chloride is included at 0.05 M concentration in the storage buffer for nuclease S from Aspergillus oryzae.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is included at 0.05 M concentration in the storage buffer for nuclease S from Aspergillus oryzae.
ethanol,95% ethanol is used to precipitate DNA from solution during the preparation of DNA fragments for electrophoresis.,Entity: ethanol. SMILES: CCO. 95% ethanol is used to precipitate DNA from solution during the preparation of DNA fragments for electrophoresis.
sodium acetate,Sodium acetate is used as a buffer at 0.03 M concentration and pH 4.6 for storing nuclease S from Aspergillus oryzae.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate is used as a buffer at 0.03 M concentration and pH 4.6 for storing nuclease S from Aspergillus oryzae.
zinc sulfate,Zinc sulfate is included at 1 mM concentration in the storage buffer for nuclease S from Aspergillus oryzae.,Entity: zinc sulfate. SMILES: O=S(=O)([O-])[O-].[Zn+2]. Zinc sulfate is included at 1 mM concentration in the storage buffer for nuclease S from Aspergillus oryzae.
acrylamide,Acrylamide is used to form 6% gels for electrophoresis of DNA fragments.,Entity: acrylamide. SMILES: C=CC(N)=O. Acrylamide is used to form 6% gels for electrophoresis of DNA fragments.
glycerol,Glycerol is used as a component (50% concentration) in the storage buffer for nuclease S from Aspergillus oryzae to maintain enzyme stability.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is used as a component (50% concentration) in the storage buffer for nuclease S from Aspergillus oryzae to maintain enzyme stability.
N-Ac-O-AAF,"N-Ac-O-AAF is a carcinogen that modifies DNA, with DNA accessible to staphylococcal nuclease containing twice as many modified bases as DNA tightly bound to histones and protected from nuclease attack.","Entity: N-Ac-O-AAF. SMILES: CC(=O)OCC(=O)Nc1cccc2c1Cc1ccccc1-2. N-Ac-O-AAF is a carcinogen that modifies DNA, with DNA accessible to staphylococcal nuclease containing twice as many modified bases as DNA tightly bound to histones and protected from nuclease attack."
N-AcO-AAF,"N-AcO-AAF is a chemical carcinogen used for chromatin modification, applied at concentrations of 0.015 to 0.1 N-AcO-AAF per nucleotide in chromatin and 0.002 to 0.02 N-AcO-AAF per nucleotide in pure DNA to achieve 0.16 to 1.1% and 0.16 to 1.2% modification of DNA bases, respectively.","Entity: N-AcO-AAF. SMILES: CC(=O)OCC(=O)Nc1cccc2c1Cc1ccccc1-2. N-AcO-AAF is a chemical carcinogen used for chromatin modification, applied at concentrations of 0.015 to 0.1 N-AcO-AAF per nucleotide in chromatin and 0.002 to 0.02 N-AcO-AAF per nucleotide in pure DNA to achieve 0.16 to 1.1% and 0.16 to 1.2% modification of DNA bases, respectively."
Na EDTA,Na EDTA is used to stop enzymatic reactions by chelating divalent cations such as Ca2+.,Entity: Na EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.[Na]. Na EDTA is used to stop enzymatic reactions by chelating divalent cations such as Ca2+.
perchloric acid,Perchloric acid is used to precipitate insoluble material from solution.,Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid is used to precipitate insoluble material from solution.
CaCl2,CaCl2 is used as a component of the reaction solvent to provide calcium ions for enzymatic digestion.,Entity: CaCl2. SMILES: [Ca+2].[Cl-].[Cl-]. CaCl2 is used as a component of the reaction solvent to provide calcium ions for enzymatic digestion.
N-AcO-AAF,"N-AcO-AAF can react with DNA by forming a 3(guanine N2-yl)2-AAF moiety through reaction with the 2 amino group of guanine, especially in chromatin where DNA is tightly bound by proteins.","Entity: N-AcO-AAF. SMILES: CC(=O)ONc1ccc2c(c1)Cc1ccccc1-2. N-AcO-AAF can react with DNA by forming a 3(guanine N2-yl)2-AAF moiety through reaction with the 2 amino group of guanine, especially in chromatin where DNA is tightly bound by proteins."
N-AcO-AAF,"N-AcO-AAF is a carcinogen that modifies chromatin, and when chromatin is digested with staphylococcal nuclease, up to 42% of the DNA is degraded to acid-soluble oligonucleotides under the same conditions for both native and modified chromatin.","Entity: N-AcO-AAF. SMILES: CC(=O)OCC(=O)Nc1cccc2c1Cc1ccccc1-2. N-AcO-AAF is a carcinogen that modifies chromatin, and when chromatin is digested with staphylococcal nuclease, up to 42% of the DNA is degraded to acid-soluble oligonucleotides under the same conditions for both native and modified chromatin."
N-AcO-AAF,N-AcO-AAF is a carcinogen that reacts with DNA or chromatin under buffered conditions at 37°C for 3 hours in ethanol/water mixtures.,Entity: N-AcO-AAF. SMILES: CC(=O)ONc1ccc2c(c1)Cc1ccccc1-2. N-AcO-AAF is a carcinogen that reacts with DNA or chromatin under buffered conditions at 37°C for 3 hours in ethanol/water mixtures.
ethylic ether,Ethylic ether is used to extract excess fluorene derivative from DNA or chromatin mixtures after reaction with [9-14C]N-AcO-AAF.,Entity: ethylic ether. SMILES: CCOCC. Ethylic ether is used to extract excess fluorene derivative from DNA or chromatin mixtures after reaction with [9-14C]N-AcO-AAF.
sodium citrate,Sodium citrate is used as a buffer at 0.1 mM concentration and pH 7 in DNA and chromatin reactions involving [9-14C]N-AcO-AAF.,Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used as a buffer at 0.1 mM concentration and pH 7 in DNA and chromatin reactions involving [9-14C]N-AcO-AAF.
ethanol,"Ethanol is used as a solvent to dissolve [9-14C]N-AcO-AAF, comprising 10% of the volume of the DNA or chromatin solution in biochemical assays.","Entity: ethanol. SMILES: CCO. Ethanol is used as a solvent to dissolve [9-14C]N-AcO-AAF, comprising 10% of the volume of the DNA or chromatin solution in biochemical assays."
cadmium,"Cadmium can redistribute in liver supernatant when co-administered with copper, coinciding with impaired sequestration by metallothionein.","Entity: cadmium. SMILES: [Cd]. Cadmium can redistribute in liver supernatant when co-administered with copper, coinciding with impaired sequestration by metallothionein."
copper,"Copper can induce aggregation of metallothionein, which may impair cadmium sequestration in vitro.","Entity: copper. SMILES: [Cu]. Copper can induce aggregation of metallothionein, which may impair cadmium sequestration in vitro."
zinc,Zinc concentration in samples can be determined using atomic absorption spectroscopy.,Entity: zinc. SMILES: [Zn]. Zinc concentration in samples can be determined using atomic absorption spectroscopy.
copper,Copper concentration in samples can be determined using atomic absorption spectroscopy.,Entity: copper. SMILES: [Cu]. Copper concentration in samples can be determined using atomic absorption spectroscopy.
cadmium,Cadmium concentration in samples can be determined using atomic absorption spectroscopy.,Entity: cadmium. SMILES: [Cd]. Cadmium concentration in samples can be determined using atomic absorption spectroscopy.
water,Distilled deionized water is used to equilibrate and desalt protein fractions in chromatographic procedures.,Entity: water. SMILES: O. Distilled deionized water is used to equilibrate and desalt protein fractions in chromatographic procedures.
cadmium,Cadmium in rats is primarily distributed to fractions consistent with metallothionein or cadmium-binding protein (Cd-BP) after Cd treatment.,Entity: cadmium. SMILES: [Cd]. Cadmium in rats is primarily distributed to fractions consistent with metallothionein or cadmium-binding protein (Cd-BP) after Cd treatment.
cadmium,"Concomitant dosing of cadmium and copper in rats results in cadmium eluting in liver supernatant fractions of higher molecular weight, indicating altered distribution.","Entity: cadmium. SMILES: [Cd]. Concomitant dosing of cadmium and copper in rats results in cadmium eluting in liver supernatant fractions of higher molecular weight, indicating altered distribution."
copper,"Copper can induce a shift in cadmium distribution in rat liver to higher molecular weight fractions, as observed after concomitant Cd-Cu dosing.","Entity: copper. SMILES: [Cu]. Copper can induce a shift in cadmium distribution in rat liver to higher molecular weight fractions, as observed after concomitant Cd-Cu dosing."
copper,"A protein fraction enriched in copper, referred to as Cu t, is present in rats treated with copper alone and is of protein nature.","Entity: copper. SMILES: [Cu]. A protein fraction enriched in copper, referred to as Cu t, is present in rats treated with copper alone and is of protein nature."
zinc,Zinc is a significant constituent of metallothioneins isolated from rat liver.,Entity: zinc. SMILES: [Zn]. Zinc is a significant constituent of metallothioneins isolated from rat liver.
zinc,Zinc is the principal metal constituent in naturally occurring metallothionein isolated from human liver.,Entity: zinc. SMILES: [Zn]. Zinc is the principal metal constituent in naturally occurring metallothionein isolated from human liver.
cysteine,"The cadmium-binding protein sub-fractions Cd-BP~ and Cd-BP2 contain 30.7% and 27.0% cysteine, respectively, as determined by DEAE Sephadex Ao25 chromatography.","Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. The cadmium-binding protein sub-fractions Cd-BP~ and Cd-BP2 contain 30.7% and 27.0% cysteine, respectively, as determined by DEAE Sephadex Ao25 chromatography."
cadmium,"Cadmium administration induces the synthesis of low molecular weight cadmium-binding proteins, or metallothioneins, in the liver.","Entity: cadmium. SMILES: [Cd]. Cadmium administration induces the synthesis of low molecular weight cadmium-binding proteins, or metallothioneins, in the liver."
copper,Copper is a major constituent of metallothionein isolated from cadmium-treated rats.,Entity: copper. SMILES: [Cu]. Copper is a major constituent of metallothionein isolated from cadmium-treated rats.
zinc,Zinc supplementation in pigs leads to the incorporation of zinc into metallothionein.,Entity: zinc. SMILES: [Zn]. Zinc supplementation in pigs leads to the incorporation of zinc into metallothionein.
streptomycin,Streptomycin inhibits chloroplastic phenylalanyl-tRNA synthetase in E. gracilis by 80% during the logarithmically growing phase of the culture.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin inhibits chloroplastic phenylalanyl-tRNA synthetase in E. gracilis by 80% during the logarithmically growing phase of the culture.
tetracycline,Tetracycline inhibits chloroplastic phenylalanyl-tRNA synthetase in E. gracilis by 100% during the logarithmically growing phase of the culture.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline inhibits chloroplastic phenylalanyl-tRNA synthetase in E. gracilis by 100% during the logarithmically growing phase of the culture.
streptomycin,Streptomycin at a concentration of 78% decreases the activity of chloroplastic phenylalanyl-tRNA synthetase in E. gracilis cultures during the logarithmic growth phase.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin at a concentration of 78% decreases the activity of chloroplastic phenylalanyl-tRNA synthetase in E. gracilis cultures during the logarithmic growth phase.
tetracycline,Tetracycline at a concentration of 100% decreases the activity of chloroplastic phenylalanyl-tRNA synthetase in E. gracilis cultures during the logarithmic growth phase.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline at a concentration of 100% decreases the activity of chloroplastic phenylalanyl-tRNA synthetase in E. gracilis cultures during the logarithmic growth phase.
streptomycin,The concentration of streptomycin required for bleaching Euglena gracilis varies by as much as 100-fold depending on the carbon source provided for growth.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. The concentration of streptomycin required for bleaching Euglena gracilis varies by as much as 100-fold depending on the carbon source provided for growth.
cycloheximide,"Cycloheximide is an inhibitor of eucaryotic protein synthesis that effectively inhibits the chloroplast enzyme in greening, dividing E. gracilis cells.","Entity: cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Cycloheximide is an inhibitor of eucaryotic protein synthesis that effectively inhibits the chloroplast enzyme in greening, dividing E. gracilis cells."
streptomycin,"Streptomycin is an antibiotic that is ineffective as an inhibitor of the chloroplast enzyme in non-dividing, greening E. gracilis cells.","Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is an antibiotic that is ineffective as an inhibitor of the chloroplast enzyme in non-dividing, greening E. gracilis cells."
chloramphenicol,Chloramphenicol is an inhibitor of procaryotic protein synthesis that reduces the activity of the chloroplast enzyme in E. gracilis cultures.,Entity: chloramphenicol. SMILES: O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl. Chloramphenicol is an inhibitor of procaryotic protein synthesis that reduces the activity of the chloroplast enzyme in E. gracilis cultures.
KCl,"KCl solution in compartment A of a perfused papillary muscle preparation does not alter the resting membrane potential of cells in compartment B, indicating absence of leakage under these experimental conditions.","Entity: KCl. SMILES: [Cl-].[K+]. KCl solution in compartment A of a perfused papillary muscle preparation does not alter the resting membrane potential of cells in compartment B, indicating absence of leakage under these experimental conditions."
sodium,"The rapid sodium-carrying system may not be completely inactivated within the membrane potential range of -50 to -40 mV, which could contribute to the generation of re-entrant dips (RAD) under these conditions.","Entity: sodium. SMILES: [Na]. The rapid sodium-carrying system may not be completely inactivated within the membrane potential range of -50 to -40 mV, which could contribute to the generation of re-entrant dips (RAD) under these conditions."
Manganese(II) chloride,"Manganese(II) chloride at 6 mM concentration inhibits rhythmic automatic depolarizations (RAD) in depolarized ventricular muscle fibers when applied for 20 minutes, as membrane potentials between -70 and +18 mV do not elicit RAD.","Entity: Manganese(II) chloride. SMILES: [Cl-].[Cl-].[Mn+2]. Manganese(II) chloride at 6 mM concentration inhibits rhythmic automatic depolarizations (RAD) in depolarized ventricular muscle fibers when applied for 20 minutes, as membrane potentials between -70 and +18 mV do not elicit RAD."
potassium,Increasing extracellular potassium concentration ([K+o]) depolarizes the resting membrane potential of ventricular muscle fibers by 18 mV.,Entity: potassium. SMILES: [K]. Increasing extracellular potassium concentration ([K+o]) depolarizes the resting membrane potential of ventricular muscle fibers by 18 mV.
calcium,"Calcium ions influence the automaticity of papillary muscles from guinea pigs, cats, and dog trabeculae after depolarizations to membrane potentials less negative than -60 mV.","Entity: calcium. SMILES: [Ca]. Calcium ions influence the automaticity of papillary muscles from guinea pigs, cats, and dog trabeculae after depolarizations to membrane potentials less negative than -60 mV."
barium,Exposure to barium salts induces automaticity of ventricular myocardial fibers by depolarizing membrane potentials to levels where rapid inward sodium current is partly or completely inactivated.,Entity: barium. SMILES: [Ba]. Exposure to barium salts induces automaticity of ventricular myocardial fibers by depolarizing membrane potentials to levels where rapid inward sodium current is partly or completely inactivated.
sodium,"Rapid inward sodium current is inactivated at membrane potentials less negative than -60 mV, which is associated with the automaticity of ventricular myocardium.","Entity: sodium. SMILES: [Na]. Rapid inward sodium current is inactivated at membrane potentials less negative than -60 mV, which is associated with the automaticity of ventricular myocardium."
isoproterenol,"Isoproterenol increases the rate of ventricular depolarizations and induces rhythmic automatic depolarizations in isolated ventricular fibers after administration of 10 µg/ml, with effects lasting up to 20 minutes.","Entity: isoproterenol. SMILES: CC(C)NCC(O)c1ccc(O)c(O)c1. Isoproterenol increases the rate of ventricular depolarizations and induces rhythmic automatic depolarizations in isolated ventricular fibers after administration of 10 µg/ml, with effects lasting up to 20 minutes."
potassium,Low extracellular potassium concentration increases the driving force for repolarization in cardiac fibers by increasing the difference between membrane potential and potassium equilibrium potential.,Entity: potassium. SMILES: [K]. Low extracellular potassium concentration increases the driving force for repolarization in cardiac fibers by increasing the difference between membrane potential and potassium equilibrium potential.
potassium chloride,"In dog and cat papillary muscles superfused with Tyrode's solution containing 13.5 mmol/liter potassium chloride, the duration of the action potential increases with increasing strength of depolarizing stimuli.","Entity: potassium chloride. SMILES: [Cl-].[K+]. In dog and cat papillary muscles superfused with Tyrode's solution containing 13.5 mmol/liter potassium chloride, the duration of the action potential increases with increasing strength of depolarizing stimuli."
isoproterenol,"Isoproterenol-induced rhythmic automatic depolarizations (RAD) in ventricular fibers are transient, as they disappear 20 minutes after returning the fibers to control solution without isoproterenol.","Entity: isoproterenol. SMILES: CC(C)NCC(O)c1ccc(O)c(O)c1. Isoproterenol-induced rhythmic automatic depolarizations (RAD) in ventricular fibers are transient, as they disappear 20 minutes after returning the fibers to control solution without isoproterenol."
potassium,Raising extracellular potassium concentration to 40.4 mM completely abolishes isoproterenol-induced rhythmic automatic depolarizations (RAD) in ventricular fibers.,Entity: potassium. SMILES: [K]. Raising extracellular potassium concentration to 40.4 mM completely abolishes isoproterenol-induced rhythmic automatic depolarizations (RAD) in ventricular fibers.
isoproterenol,Isoproterenol induces rhythmic automatic depolarizations (RAD) in ventricular fibers at membrane potentials between -60 and +30 mV when administered at 10 µg/ml for 20 minutes.,Entity: isoproterenol. SMILES: CC(C)NCC(O)c1ccc(O)c(O)c1. Isoproterenol induces rhythmic automatic depolarizations (RAD) in ventricular fibers at membrane potentials between -60 and +30 mV when administered at 10 µg/ml for 20 minutes.
potassium,High extracellular potassium concentration (increased [K + ] o) produces opposite effects on spontaneous electrical activity in ventricular myocardium compared to depolarization.,Entity: potassium. SMILES: [K]. High extracellular potassium concentration (increased [K + ] o) produces opposite effects on spontaneous electrical activity in ventricular myocardium compared to depolarization.
potassium,An increase in extracellular potassium concentration to 15.4 mM can totally abolish rhythmic automatic depolarizations (RAD) in ventricular fibers.,Entity: potassium. SMILES: [K]. An increase in extracellular potassium concentration to 15.4 mM can totally abolish rhythmic automatic depolarizations (RAD) in ventricular fibers.
isoproterenol,Isoproterenol increases the incidence of rhythmic automatic depolarizations (RAD) in ventricular fibers at membrane potentials between -60 and +30 mV when administered at 10 µg/ml for 20 minutes.,Entity: isoproterenol. SMILES: CC(C)NCC(O)c1ccc(O)c(O)c1. Isoproterenol increases the incidence of rhythmic automatic depolarizations (RAD) in ventricular fibers at membrane potentials between -60 and +30 mV when administered at 10 µg/ml for 20 minutes.
isoproterenol,"Isoproterenol-induced increase in rhythmic automatic depolarizations (RAD) in ventricular fibers is transient, as RAD disappear 20 minutes after return to control solution without isoproterenol.","Entity: isoproterenol. SMILES: CC(C)NCC(O)c1ccc(O)c(O)c1. Isoproterenol-induced increase in rhythmic automatic depolarizations (RAD) in ventricular fibers is transient, as RAD disappear 20 minutes after return to control solution without isoproterenol."
potassium,Increasing extracellular potassium concentration to 15.4 mM in ventricular fibers slows the rate of rhythmic automatic depolarizations (RAD) induced by depolarization to membrane potentials between -60 and +30 mV.,Entity: potassium. SMILES: [K]. Increasing extracellular potassium concentration to 15.4 mM in ventricular fibers slows the rate of rhythmic automatic depolarizations (RAD) induced by depolarization to membrane potentials between -60 and +30 mV.
Manganese(II) chloride,Application of 6 mM manganese(II) chloride depolarizations to ventricular muscle fibers for 20 minutes does not elicit rhythmic automatic depolarizations (RAD) under control conditions.,Entity: Manganese(II) chloride. SMILES: [Cl-].[Cl-].[Mn+2]. Application of 6 mM manganese(II) chloride depolarizations to ventricular muscle fibers for 20 minutes does not elicit rhythmic automatic depolarizations (RAD) under control conditions.
Potassium,"Increasing extracellular potassium concentration ([K+]o) suppresses rhythmic automatic depolarizations (RAD) in ventricular muscle fibers, with suppression observed at [K+]o = 40.4 mM and 15.4 mM, and at resting membrane potentials of -48 mV and -62 mV, respectively.","Entity: Potassium. SMILES: [K]. Increasing extracellular potassium concentration ([K+]o) suppresses rhythmic automatic depolarizations (RAD) in ventricular muscle fibers, with suppression observed at [K+]o = 40.4 mM and 15.4 mM, and at resting membrane potentials of -48 mV and -62 mV, respectively."
sodium,Sodium intake in dogs was maintained at 40 mEq/day during chronic angiotensin II administration studies.,Entity: sodium. SMILES: [Na]. Sodium intake in dogs was maintained at 40 mEq/day during chronic angiotensin II administration studies.
angiotensin II,Angiotensin II was administered to dogs at a constant rate of 5.0 ng/kg per minute for 2–3 weeks during chronic administration studies.,Entity: angiotensin II. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O. Angiotensin II was administered to dogs at a constant rate of 5.0 ng/kg per minute for 2–3 weeks during chronic administration studies.
angiotensin II,"Angiotensin II, when administered intravenously at 4–6 ng/kg per min in dogs, causes an increase in arterial pressure that is evident within the first 15 minutes of infusion.","Entity: angiotensin II. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O. Angiotensin II, when administered intravenously at 4–6 ng/kg per min in dogs, causes an increase in arterial pressure that is evident within the first 15 minutes of infusion."
sodium,Maintaining sodium intake at 120 mEq/day in dogs does not significantly affect the arterial pressure response to continuous intravenous angiotensin II infusion.,Entity: sodium. SMILES: [Na]. Maintaining sodium intake at 120 mEq/day in dogs does not significantly affect the arterial pressure response to continuous intravenous angiotensin II infusion.
Angiotensin II amide,Angiotensin II amide can be administered intravenously at a concentration of 2.5 µg/ml in 0.9% saline to dogs at infusion rates between 0.01 and 1.0 ml/min.,Entity: Angiotensin II amide. SMILES: CC(C)C(NC(=O)C(CCCN=C(N)N)NC(=O)C(N)CC(N)=O)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(C(=O)NC(Cc1cnc[nH]1)C(=O)N1CCCC1C(=O)NC(Cc1ccccc1)C(=O)O)C(C)C. Angiotensin II amide can be administered intravenously at a concentration of 2.5 µg/ml in 0.9% saline to dogs at infusion rates between 0.01 and 1.0 ml/min.
sodium,"In intact dogs, administration of angiotensin with an additional 80 mEq of sodium per day leads to a net retention of water, as indicated by a 45 ml/kg per day increase in water intake exceeding the 28.5 ml/kg per day required to maintain isotonicity.","Entity: sodium. SMILES: [Na]. In intact dogs, administration of angiotensin with an additional 80 mEq of sodium per day leads to a net retention of water, as indicated by a 45 ml/kg per day increase in water intake exceeding the 28.5 ml/kg per day required to maintain isotonicity."
sodium,Sodium excretion by the kidney can be depressed by small doses of angiotensin II.,Entity: sodium. SMILES: [Na]. Sodium excretion by the kidney can be depressed by small doses of angiotensin II.
water,Water excretion by the kidney can be depressed by small doses of angiotensin II.,Entity: water. SMILES: O. Water excretion by the kidney can be depressed by small doses of angiotensin II.
aldosterone,Aldosterone levels return to near normal by the 24th hour of angiotensin II infusion.,Entity: aldosterone. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12. Aldosterone levels return to near normal by the 24th hour of angiotensin II infusion.
angiotensin II,"Angiotensin II can depress sodium and water excretion by the kidney, even at small doses.","Entity: angiotensin II. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O. Angiotensin II can depress sodium and water excretion by the kidney, even at small doses."
sodium,Dogs were maintained on a sodium intake of 120 mEq/day during the experimental protocol.,Entity: sodium. SMILES: [Na]. Dogs were maintained on a sodium intake of 120 mEq/day during the experimental protocol.
angiotensin II,Angiotensin II was administered at a continuous infusion rate of 5.0 ng/kg per min in both intact and denervated dogs.,Entity: angiotensin II. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O. Angiotensin II was administered at a continuous infusion rate of 5.0 ng/kg per min in both intact and denervated dogs.
sodium,A sodium intake of 40 mEq/day was maintained in dogs during angiotensin II infusion experiments.,Entity: sodium. SMILES: [Na]. A sodium intake of 40 mEq/day was maintained in dogs during angiotensin II infusion experiments.
angiotensin II,"Angiotensin II administered at 4–6 ng/kg/min intravenously causes changes in arterial pressure in dogs, with the magnitude and timing of the response influenced by sodium intake.","Entity: angiotensin II. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O. Angiotensin II administered at 4–6 ng/kg/min intravenously causes changes in arterial pressure in dogs, with the magnitude and timing of the response influenced by sodium intake."
trimethaphan,"Trimethaphan is used to assess neurogenic vascular tone by inducing a decrease in blood pressure, indicating reduced sympathetic nervous system activity.","Entity: trimethaphan. SMILES: O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1. Trimethaphan is used to assess neurogenic vascular tone by inducing a decrease in blood pressure, indicating reduced sympathetic nervous system activity."
angiotensin II,"Angiotensin II, when administered intravenously at 4–6 ng/kg per min in dogs, causes a sustained increase in arterial pressure, with intact dogs showing 50% above control values for 2 hours and returning to control by the 14th hour, while denervated dogs show a 15% increase above control values for 2 hours and return to control by the 4th hour.","Entity: angiotensin II. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O. Angiotensin II, when administered intravenously at 4–6 ng/kg per min in dogs, causes a sustained increase in arterial pressure, with intact dogs showing 50% above control values for 2 hours and returning to control by the 14th hour, while denervated dogs show a 15% increase above control values for 2 hours and return to control by the 4th hour."
sodium,Maintaining sodium intake at 120 mEq/day in dogs does not affect the arterial pressure response to continuous intravenous angiotensin II infusion.,Entity: sodium. SMILES: [Na]. Maintaining sodium intake at 120 mEq/day in dogs does not affect the arterial pressure response to continuous intravenous angiotensin II infusion.
Evans blue dye,Evans blue dye is used as a spectrophotometric indicator for measuring plasma volume in animal studies.,Entity: Evans blue dye. SMILES: Cc1cc(-c2ccc(N/N=C3/C=Cc4c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c4C3=O)c(C)c2)ccc1N/N=C1/C=Cc2c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c2C1=O.[Na+].[Na+].[Na+].[Na+]. Evans blue dye is used as a spectrophotometric indicator for measuring plasma volume in animal studies.
indocyanine green,Indocyanine green dye is used in dye dilution techniques to determine cardiac output in animal experiments.,Entity: indocyanine green. SMILES: CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+]. Indocyanine green dye is used in dye dilution techniques to determine cardiac output in animal experiments.
renin,"Plasma renin activity in dogs is undetectable after 24 hours of angiotensin II infusion, indicating that renin is not involved in the sustained hypertensive response to chronic low-dose angiotensin II.","Entity: renin. Plasma renin activity in dogs is undetectable after 24 hours of angiotensin II infusion, indicating that renin is not involved in the sustained hypertensive response to chronic low-dose angiotensin II."
sodium,"Sodium intake modulates the relationship between angiotensin II infusion and plasma aldosterone concentration, with higher sodium intake (120 mEq/day) leading to a transient increase in plasma aldosterone during the first day of A II infusion in dogs.","Entity: sodium. SMILES: [Na]. Sodium intake modulates the relationship between angiotensin II infusion and plasma aldosterone concentration, with higher sodium intake (120 mEq/day) leading to a transient increase in plasma aldosterone during the first day of A II infusion in dogs."
sodium,"Increasing sodium intake from 40 to 120 mEq/day during angiotensin II infusion results in higher levels of hypertension in dogs, reaching 125% compared to 140% of control values.","Entity: sodium. SMILES: [Na]. Increasing sodium intake from 40 to 120 mEq/day during angiotensin II infusion results in higher levels of hypertension in dogs, reaching 125% compared to 140% of control values."
ruthenium red,"Ruthenium red is used to stain the endothelial luminal membrane, and its staining pattern can be altered within 10 minutes after rapid hemodynamic induction of arterial intimal fibromuscular lesions in a dog renal artery model.","Entity: ruthenium red. SMILES: N.N.N.N.N.N.N.N.N.N.N.N.N.N.[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[O-2].[O-2].[Ru+3].[Ru+3].[Ru+4]. Ruthenium red is used to stain the endothelial luminal membrane, and its staining pattern can be altered within 10 minutes after rapid hemodynamic induction of arterial intimal fibromuscular lesions in a dog renal artery model."
hydroxyproline,Hydroxyproline is used as a biochemical marker for collagen.,Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Hydroxyproline is used as a biochemical marker for collagen.
"2,5-diphenyloxazole","2,5-diphenyloxazole is used as a scintillation counting reagent in liquid scintillation spectrometry.","Entity: 2,5-diphenyloxazole. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. 2,5-diphenyloxazole is used as a scintillation counting reagent in liquid scintillation spectrometry."
hydrochloric acid,Hydrochloric acid (6 N) is used to hydrolyze samples for hydroxyproline determination.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (6 N) is used to hydrolyze samples for hydroxyproline determination.
Triton X-100,"Triton X-100 is used as a solvent component in liquid scintillation spectrometry, mixed with toluene in a 1:2 ratio.","Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used as a solvent component in liquid scintillation spectrometry, mixed with toluene in a 1:2 ratio."
toluene,"Toluene is used as a solvent component in liquid scintillation spectrometry, mixed with Triton X-100 in a 1:2 ratio.","Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a solvent component in liquid scintillation spectrometry, mixed with Triton X-100 in a 1:2 ratio."
sulfate,"Sulfate is incorporated into glycosaminoglycans (GAGs), and variations in sulfate uptake reflect changes in the level of GAG metabolism.","Entity: sulfate. SMILES: O=S(=O)([O-])[O-]. Sulfate is incorporated into glycosaminoglycans (GAGs), and variations in sulfate uptake reflect changes in the level of GAG metabolism."
chondroitin 4-sulfate,Cyclic mechanical stretching of arterial smooth muscle cells for 2 days causes no significant increase in chondroitin 4-sulfate synthesis compared to stationary cells.,Entity: chondroitin 4-sulfate. SMILES: CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H](OS(=O)(=O)O)O[C@H]1O. Cyclic mechanical stretching of arterial smooth muscle cells for 2 days causes no significant increase in chondroitin 4-sulfate synthesis compared to stationary cells.
dermatan sulfate,Cyclic mechanical stretching of arterial smooth muscle cells for 2 days causes no significant increase in dermatan sulfate synthesis compared to stationary cells.,Entity: dermatan sulfate. SMILES: CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O)[C@H](O)[C@H]2O)[C@@H](OS(=O)(=O)[O-])[C@@H](CO)O[C@H]1O. Cyclic mechanical stretching of arterial smooth muscle cells for 2 days causes no significant increase in dermatan sulfate synthesis compared to stationary cells.
acetate,"Cyclic mechanical stretching of arterial smooth muscle cells for 2 days stimulates a 3-fold increase in 3H-acetate incorporation into hyaluronate and chondroitin 6-sulfate, compared to stationary cells.","Entity: acetate. SMILES: CC(=O)[O-]. Cyclic mechanical stretching of arterial smooth muscle cells for 2 days stimulates a 3-fold increase in 3H-acetate incorporation into hyaluronate and chondroitin 6-sulfate, compared to stationary cells."
Sulfate,"Sulfate (SO4) can be used as an index of glycosaminoglycan (GAG) metabolism, with a constant molar ratio of SO4 to 3H observed in GAG isolated from eight different tissues in three dogs (2.5 ± 0.2, 2.2 ± 0.2, and 2.8 ± 0.6).","Entity: Sulfate. SMILES: O=S(=O)([O-])[O-]. Sulfate (SO4) can be used as an index of glycosaminoglycan (GAG) metabolism, with a constant molar ratio of SO4 to 3H observed in GAG isolated from eight different tissues in three dogs (2.5 ± 0.2, 2.2 ± 0.2, and 2.8 ± 0.6)."
Acetate,Acetate (H-acetate) serves as a precursor for the carbohydrate moiety of glycosaminoglycans (GAGs).,Entity: Acetate. SMILES: CC(=O)[O-]. Acetate (H-acetate) serves as a precursor for the carbohydrate moiety of glycosaminoglycans (GAGs).
cysteine,Cysteine is used as a reducing agent at 0.005 M concentration in acetate buffer during papain-mediated enzymatic digestion of tissue for carbohydrate preparation.,Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. Cysteine is used as a reducing agent at 0.005 M concentration in acetate buffer during papain-mediated enzymatic digestion of tissue for carbohydrate preparation.
disodium edetate,Disodium edetate is used at 0.005 M concentration in acetate buffer as a chelating agent during papain-mediated enzymatic digestion of tissue for carbohydrate preparation.,Entity: disodium edetate. SMILES: O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)O)CC(=O)O.[Na+].[Na+]. Disodium edetate is used at 0.005 M concentration in acetate buffer as a chelating agent during papain-mediated enzymatic digestion of tissue for carbohydrate preparation.
trichloroacetic acid,Trichloroacetic acid (TCA) is used at 10% concentration for washing and precipitating glycoconjugates during tissue carbohydrate isolation procedures.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid (TCA) is used at 10% concentration for washing and precipitating glycoconjugates during tissue carbohydrate isolation procedures.
potassium acetate,Potassium acetate is used at 5% concentration in cold absolute ethanol to precipitate glycoconjugates during carbohydrate isolation from enzymatic digests.,Entity: potassium acetate. SMILES: CC(=O)[O-].[K+]. Potassium acetate is used at 5% concentration in cold absolute ethanol to precipitate glycoconjugates during carbohydrate isolation from enzymatic digests.
ethanol,Absolute ethanol is used at 5% concentration with potassium acetate to precipitate glycoconjugates during carbohydrate isolation from enzymatic digests.,Entity: ethanol. SMILES: CCO. Absolute ethanol is used at 5% concentration with potassium acetate to precipitate glycoconjugates during carbohydrate isolation from enzymatic digests.
water,Cold water is used to dissolve precipitated glycoconjugates after enzymatic digestion and reprecipitation steps in carbohydrate isolation protocols.,Entity: water. SMILES: O. Cold water is used to dissolve precipitated glycoconjugates after enzymatic digestion and reprecipitation steps in carbohydrate isolation protocols.
procaine penicillin G,Procaine penicillin G is administered intramuscularly at a dose of 6 x 10^5 U to animals for 5 days post-surgery as part of postoperative antibiotic therapy.,Entity: procaine penicillin G. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O. Procaine penicillin G is administered intramuscularly at a dose of 6 x 10^5 U to animals for 5 days post-surgery as part of postoperative antibiotic therapy.
dihydrostreptomycin,Dihydrostreptomycin is administered intramuscularly at a dose of 0.5 g to animals for 5 days post-surgery as part of postoperative antibiotic therapy.,Entity: dihydrostreptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O. Dihydrostreptomycin is administered intramuscularly at a dose of 0.5 g to animals for 5 days post-surgery as part of postoperative antibiotic therapy.
catecholamine,Catecholamine release may be involved in the initial transient component of the force-frequency relationship following changes in muscle length.,Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Catecholamine release may be involved in the initial transient component of the force-frequency relationship following changes in muscle length.
propranolol,"Propranolol reduces the magnitude and duration of the initial transient in the force-frequency relationship after changes in muscle length, indicating its effect on catecholamine-mediated responses.","Entity: propranolol. SMILES: CC(C)NCC(O)COc1cccc2ccccc12. Propranolol reduces the magnitude and duration of the initial transient in the force-frequency relationship after changes in muscle length, indicating its effect on catecholamine-mediated responses."
sodium pentobarbital,"Sodium pentobarbital is used as an anesthetic agent in animal studies, administered at a dose of 25 mg/kg intravenously.","Entity: sodium pentobarbital. SMILES: CCCC(C)C1(CC)C(=O)NC(=O)NC1=O. Sodium pentobarbital is used as an anesthetic agent in animal studies, administered at a dose of 25 mg/kg intravenously."
oxygen,Oxygen is used as part of a 95% O2/5% CO2 gas mixture to aerate Krebs-Henseleit solution during in vitro myocardial tissue bath experiments at 38°C.,Entity: oxygen. SMILES: [O]. Oxygen is used as part of a 95% O2/5% CO2 gas mixture to aerate Krebs-Henseleit solution during in vitro myocardial tissue bath experiments at 38°C.
carbon dioxide,Carbon dioxide is included at 5% in a 95% O2/5% CO2 gas mixture for aeration of Krebs-Henseleit solution in in vitro myocardial tissue bath experiments at 38°C.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is included at 5% in a 95% O2/5% CO2 gas mixture for aeration of Krebs-Henseleit solution in in vitro myocardial tissue bath experiments at 38°C.
calcium chloride,Intrarenal calcium chloride infusion in dogs increases peripheral plasma calcium by 1.7–2.9 mEq/liter and renal venous plasma calcium by 2.3–4.6 mEq/liter.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Intrarenal calcium chloride infusion in dogs increases peripheral plasma calcium by 1.7–2.9 mEq/liter and renal venous plasma calcium by 2.3–4.6 mEq/liter.
calcium chloride,Calcium chloride infusion elevates peripheral plasma chloride concentration from 113.3 ± 1.9 mEq/liter to 115.3 ± 2.1 mEq/liter in dogs.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride infusion elevates peripheral plasma chloride concentration from 113.3 ± 1.9 mEq/liter to 115.3 ± 2.1 mEq/liter in dogs.
calcium chloride,Calcium chloride infusion raises renal venous chloride concentration from 115.2 ± 1.4 mEq/liter to an average of 117.8 ± 1.4 mEq/liter in dogs.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride infusion raises renal venous chloride concentration from 115.2 ± 1.4 mEq/liter to an average of 117.8 ± 1.4 mEq/liter in dogs.
calcium gluconate,"Pre-infusion of calcium gluconate in dogs results in elevated control plasma calcium values of 4.9 and 5.2 mEq/liter for peripheral and renal venous plasma, respectively.","Entity: calcium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Pre-infusion of calcium gluconate in dogs results in elevated control plasma calcium values of 4.9 and 5.2 mEq/liter for peripheral and renal venous plasma, respectively."
calcium,"Calcium loading increases renal sodium excretion, which may contribute to decreased renin secretion via a macula densa mechanism.","Entity: calcium. SMILES: [Ca]. Calcium loading increases renal sodium excretion, which may contribute to decreased renin secretion via a macula densa mechanism."
calcium,Intrarenal calcium infusion in dogs increases renal sodium excretion and increases renin secretion.,Entity: calcium. SMILES: [Ca]. Intrarenal calcium infusion in dogs increases renal sodium excretion and increases renin secretion.
calcium chloride,Calcium chloride infusion does not alter renal sodium excretion in dogs.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride infusion does not alter renal sodium excretion in dogs.
calcium gluconate,Calcium gluconate infusion does not alter renal sodium excretion in dogs.,Entity: calcium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Calcium gluconate infusion does not alter renal sodium excretion in dogs.
sodium,Increased sodium load at the macula densa is considered a possible mechanism by which calcium decreases renin secretion.,Entity: sodium. SMILES: [Na]. Increased sodium load at the macula densa is considered a possible mechanism by which calcium decreases renin secretion.
calcium gluconate,Intrarenal calcium gluconate infusion increases renal calcium excretion and urinary potassium excretion in dogs with intact kidneys.,Entity: calcium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Intrarenal calcium gluconate infusion increases renal calcium excretion and urinary potassium excretion in dogs with intact kidneys.
calcium gluconate,Intrarenal calcium gluconate infusion does not significantly affect urinary sodium or chloride excretion in dogs with intact kidneys.,Entity: calcium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Intrarenal calcium gluconate infusion does not significantly affect urinary sodium or chloride excretion in dogs with intact kidneys.
calcium gluconate,Intrarenal calcium gluconate infusion does not alter mean arterial blood pressure in dogs with intact kidneys.,Entity: calcium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Intrarenal calcium gluconate infusion does not alter mean arterial blood pressure in dogs with intact kidneys.
potassium,Renal potassium excretion increases from 25 to 43 µEq/min following intrarenal calcium gluconate infusion in dogs with intact kidneys.,Entity: potassium. SMILES: [K]. Renal potassium excretion increases from 25 to 43 µEq/min following intrarenal calcium gluconate infusion in dogs with intact kidneys.
calcium chloride,"Intrarenal calcium chloride infusion at 0.14 ± 0.018 mg Ca2+/kg per min in dogs with nonfiltering kidneys reduces renal blood flow by 30 minutes, with recovery toward control levels observed at 60 and 75 minutes after cessation of infusion.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Intrarenal calcium chloride infusion at 0.14 ± 0.018 mg Ca2+/kg per min in dogs with nonfiltering kidneys reduces renal blood flow by 30 minutes, with recovery toward control levels observed at 60 and 75 minutes after cessation of infusion."
calcium chloride,"Calcium chloride infusion in dogs with nonfiltering kidneys causes a 50% reduction in renin secretion during the last 30 minutes of infusion, with sustained suppression of renin secretion during recovery.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride infusion in dogs with nonfiltering kidneys causes a 50% reduction in renin secretion during the last 30 minutes of infusion, with sustained suppression of renin secretion during recovery."
chloride,Urinary chloride excretion increases from 8.4 ± 3.0 µEq/min to 18.3 ± 6.8 µEq/min during intrarenal calcium chloride infusion in dogs with intact kidneys.,Entity: chloride. SMILES: [Cl-]. Urinary chloride excretion increases from 8.4 ± 3.0 µEq/min to 18.3 ± 6.8 µEq/min during intrarenal calcium chloride infusion in dogs with intact kidneys.
potassium,Potassium excretion increases from 29.4 ± 6.3 µEq/min to 40.7 ± 7.6 µEq/min during the first 15 minutes of intrarenal calcium chloride infusion in dogs with intact kidneys.,Entity: potassium. SMILES: [K]. Potassium excretion increases from 29.4 ± 6.3 µEq/min to 40.7 ± 7.6 µEq/min during the first 15 minutes of intrarenal calcium chloride infusion in dogs with intact kidneys.
sodium,Intrarenal infusion of calcium chloride does not alter the rate of renal excretion of sodium in dogs with intact kidneys.,Entity: sodium. SMILES: [Na]. Intrarenal infusion of calcium chloride does not alter the rate of renal excretion of sodium in dogs with intact kidneys.
creatinine,Creatinine clearance is not significantly altered by intrarenal infusion of calcium chloride in dogs with intact kidneys.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine clearance is not significantly altered by intrarenal infusion of calcium chloride in dogs with intact kidneys.
calcium chloride,"Intrarenal infusion of calcium chloride in dogs with intact kidneys produces a transient slight kaliuresis during the first 15 minutes, with potassium excretion increasing from 29.4 ± 6.3 µEq/min to 40.7 ± 7.6 µEq/min.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Intrarenal infusion of calcium chloride in dogs with intact kidneys produces a transient slight kaliuresis during the first 15 minutes, with potassium excretion increasing from 29.4 ± 6.3 µEq/min to 40.7 ± 7.6 µEq/min."
calcium chloride,"Calcium chloride infusion in dogs with intact kidneys increases urinary calcium excretion and urinary chloride excretion, with chloride excretion rising from 8.4 ± 3.0 µEq/min to 18.3 ± 6.8 µEq/min during the infusion.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride infusion in dogs with intact kidneys increases urinary calcium excretion and urinary chloride excretion, with chloride excretion rising from 8.4 ± 3.0 µEq/min to 18.3 ± 6.8 µEq/min during the infusion."
calcium chloride,Calcium chloride infusion in dogs with intact kidneys causes a slight decrease in mean arterial pressure from 140 ± 3 mm Hg to 132 ± 5 mm Hg after the end of infusion.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride infusion in dogs with intact kidneys causes a slight decrease in mean arterial pressure from 140 ± 3 mm Hg to 132 ± 5 mm Hg after the end of infusion.
calcium chloride,Calcium chloride infusion in dogs with intact kidneys decreases hematocrit from 53.1 ± 1.7% to 51.5 ± 1.4%.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride infusion in dogs with intact kidneys decreases hematocrit from 53.1 ± 1.7% to 51.5 ± 1.4%.
meralluride,Meralluride (Mercuhydrin) is administered intramuscularly to augment the rate of renin secretion in dogs.,Entity: meralluride. SMILES: COC(C[Hg+])CNC(=O)NC(=O)CCC(=O)[O-].Cn1c(=O)c2[nH]cnc2n(C)c1=O.[Na+].[OH-]. Meralluride (Mercuhydrin) is administered intramuscularly to augment the rate of renin secretion in dogs.
sodium,"Sodium depletion in dogs, with a net loss of 138 ± 12 mEq over three days, is used to enhance renin secretion in experimental studies.","Entity: sodium. SMILES: [Na]. Sodium depletion in dogs, with a net loss of 138 ± 12 mEq over three days, is used to enhance renin secretion in experimental studies."
calcium chloride,Intravenous calcium chloride infusion increases plasma calcium concentrations in both peripheral and renal venous plasma in dogs.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Intravenous calcium chloride infusion increases plasma calcium concentrations in both peripheral and renal venous plasma in dogs.
calcium chloride,Calcium chloride infusion does not significantly elevate peripheral or renal venous plasma chloride concentrations in dogs.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride infusion does not significantly elevate peripheral or renal venous plasma chloride concentrations in dogs.
calcium chloride,Calcium chloride infusion does not affect sodium concentrations in peripheral or renal venous plasma in dogs.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride infusion does not affect sodium concentrations in peripheral or renal venous plasma in dogs.
aldosterone,High plasma levels of aldosterone are known to occur in sodium-depleted dogs and mediate enhanced distal tubular sodium reabsorption.,Entity: aldosterone. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12. High plasma levels of aldosterone are known to occur in sodium-depleted dogs and mediate enhanced distal tubular sodium reabsorption.
calcium,Calcium inhibits sodium reabsorption from the thick ascending limb of Henle's loop.,Entity: calcium. SMILES: [Ca]. Calcium inhibits sodium reabsorption from the thick ascending limb of Henle's loop.
sodium,Increased sodium load at the macula densa can be associated with decreased renin release.,Entity: sodium. SMILES: [Na]. Increased sodium load at the macula densa can be associated with decreased renin release.
calcium chloride,"Intrarenal infusion of calcium chloride at 0.25 mg Ca2+/kg per minute in dogs with intact kidney causes a slight reduction in renal blood flow at 30 and 45 minutes, with suppression persisting during recovery periods at 60 and 75 minutes.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Intrarenal infusion of calcium chloride at 0.25 mg Ca2+/kg per minute in dogs with intact kidney causes a slight reduction in renal blood flow at 30 and 45 minutes, with suppression persisting during recovery periods at 60 and 75 minutes."
potassium,"Intrarenal potassium infusion increases potassium excretion and decreases renin secretion in dogs, with the effect dependent on an intact renal tubular system.","Entity: potassium. SMILES: [K]. Intrarenal potassium infusion increases potassium excretion and decreases renin secretion in dogs, with the effect dependent on an intact renal tubular system."
calcium,"Calcium infusion produces a slight increase in potassium excretion in dogs with an intact kidney, but this response is not dependent on a functioning renal tubular system.","Entity: calcium. SMILES: [Ca]. Calcium infusion produces a slight increase in potassium excretion in dogs with an intact kidney, but this response is not dependent on a functioning renal tubular system."
chloride,Chloride ions can affect the macula densa receptor in the early distal renal tubule.,Entity: chloride. SMILES: [Cl-]. Chloride ions can affect the macula densa receptor in the early distal renal tubule.
chloride,"Chloride is actively transported in the thick ascending limb of the loop of Henle, rather than sodium.","Entity: chloride. SMILES: [Cl-]. Chloride is actively transported in the thick ascending limb of the loop of Henle, rather than sodium."
calcium,Calcium influences the chloride load and its effects at the macula densa in the kidney.,Entity: calcium. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Calcium influences the chloride load and its effects at the macula densa in the kidney.
Calcium chloride,"Calcium chloride is used as an intrarenal infusion agent to increase renal venous calcium concentration in dogs with nonfiltering kidneys, with the dose adjusted based on the degree of suppression of renal blood flow compared to dogs with intact kidneys.","Entity: Calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride is used as an intrarenal infusion agent to increase renal venous calcium concentration in dogs with nonfiltering kidneys, with the dose adjusted based on the degree of suppression of renal blood flow compared to dogs with intact kidneys."
Lissamine green,Lissamine green dye is injected into the aorta above the kidney to verify the absence of glomerular filtration by assessing whether the dye appears in the renal tubules.,Entity: Lissamine green. SMILES: CCN(Cc1cccc(S(=O)(=O)[O-])c1)c1ccc(C(=C2C=CC(=[N+](CC)Cc3cccc(S(=O)(=O)[O-])c3)C=C2)c2ccccc2Cl)cc1. Lissamine green dye is injected into the aorta above the kidney to verify the absence of glomerular filtration by assessing whether the dye appears in the renal tubules.
calcium gluconate,Intrarenal infusion of calcium gluconate at 0.3 mg/kg per minute decreases renal venous plasma renin activity in normal dogs during mannitol diuresis.,Entity: calcium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Intrarenal infusion of calcium gluconate at 0.3 mg/kg per minute decreases renal venous plasma renin activity in normal dogs during mannitol diuresis.
calcium chloride,Intrarenal infusion of calcium chloride at 0.3 mg/kg per minute decreases renal venous plasma renin activity in normal dogs during mannitol diuresis.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Intrarenal infusion of calcium chloride at 0.3 mg/kg per minute decreases renal venous plasma renin activity in normal dogs during mannitol diuresis.
calcium chloride,Intrarenal infusion of calcium chloride at 14 mg Ca++/min increases renin secretion in dogs.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Intrarenal infusion of calcium chloride at 14 mg Ca++/min increases renin secretion in dogs.
calcium gluconate,Plasma calcium concentration remains elevated slightly during the 60 and 75 minute recovery periods after cessation of calcium gluconate infusion in dogs.,Entity: calcium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Plasma calcium concentration remains elevated slightly during the 60 and 75 minute recovery periods after cessation of calcium gluconate infusion in dogs.
calcium chloride,"Prior infusion of calcium chloride in five dogs elevates peripheral and renal venous calcium concentrations to 5.3 and 5.4 mEq/L, respectively, which is used as a control in group III.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Prior infusion of calcium chloride in five dogs elevates peripheral and renal venous calcium concentrations to 5.3 and 5.4 mEq/L, respectively, which is used as a control in group III."
calcium chloride,"In group IV, control values for peripheral and renal venous calcium concentration were 4.5 and 4.6 mEq/L, respectively, measured before calcium gluconate infusion.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. In group IV, control values for peripheral and renal venous calcium concentration were 4.5 and 4.6 mEq/L, respectively, measured before calcium gluconate infusion."
calcium,Intrarenal calcium gluconate infusion increases both peripheral plasma and renal venous calcium concentrations in dogs with intact kidneys.,Entity: calcium. SMILES: [Ca]. Intrarenal calcium gluconate infusion increases both peripheral plasma and renal venous calcium concentrations in dogs with intact kidneys.
sodium,Intrarenal calcium gluconate infusion does not alter peripheral or renal venous plasma sodium concentrations in dogs with intact kidneys.,Entity: sodium. SMILES: [Na]. Intrarenal calcium gluconate infusion does not alter peripheral or renal venous plasma sodium concentrations in dogs with intact kidneys.
potassium,Intrarenal calcium gluconate infusion does not alter peripheral or renal venous plasma potassium concentrations in dogs with intact kidneys.,Entity: potassium. SMILES: [K]. Intrarenal calcium gluconate infusion does not alter peripheral or renal venous plasma potassium concentrations in dogs with intact kidneys.
chloride,Intrarenal calcium gluconate infusion does not alter peripheral or renal venous plasma chloride concentrations in dogs with intact kidneys.,Entity: chloride. SMILES: [Cl-]. Intrarenal calcium gluconate infusion does not alter peripheral or renal venous plasma chloride concentrations in dogs with intact kidneys.
calcium gluconate,Intrarenal infusion of calcium gluconate at 0.25 mg Ca/kg per min progressively reduces renal blood flow in dogs with intact kidneys.,Entity: calcium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Intrarenal infusion of calcium gluconate at 0.25 mg Ca/kg per min progressively reduces renal blood flow in dogs with intact kidneys.
calcium gluconate,Calcium gluconate infusion markedly decreases renin secretion throughout the experimental period in dogs with intact kidneys.,Entity: calcium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Calcium gluconate infusion markedly decreases renin secretion throughout the experimental period in dogs with intact kidneys.
calcium gluconate,Intrarenal calcium gluconate infusion increases peripheral plasma calcium concentration by 1.7–2.9 mEq/L and renal venous calcium concentration by 2.9–6.3 mEq/L above control levels in dogs.,Entity: calcium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Intrarenal calcium gluconate infusion increases peripheral plasma calcium concentration by 1.7–2.9 mEq/L and renal venous calcium concentration by 2.9–6.3 mEq/L above control levels in dogs.
prostaglandins,"During plasma renin activity bioassays, molecules such as prostaglandins are dialyzed out of plasma samples unless they are bound to higher molecular weight proteins.","Entity: prostaglandins. SMILES: CCCCCC(/C=C/C1C=CC(=O)C1C/C=C/CCCC(=O)OC)OC(C)=O. During plasma renin activity bioassays, molecules such as prostaglandins are dialyzed out of plasma samples unless they are bound to higher molecular weight proteins."
calcium,Intrarenal calcium infusion can be administered to dogs at a dose of 0.25 mg/kg per minute for 45 minutes using calcium chloride or calcium gluconate in saline at a rate of 0.59 ml/min.,Entity: calcium. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. Intrarenal calcium infusion can be administered to dogs at a dose of 0.25 mg/kg per minute for 45 minutes using calcium chloride or calcium gluconate in saline at a rate of 0.59 ml/min.
sodium,Urinary sodium excretion can be measured in dogs using flame photometry following collection of urine samples via a ureteral catheter.,Entity: sodium. SMILES: [Na]. Urinary sodium excretion can be measured in dogs using flame photometry following collection of urine samples via a ureteral catheter.
potassium,Urinary potassium excretion can be measured in dogs using flame photometry following collection of urine samples via a ureteral catheter.,Entity: potassium. SMILES: [K]. Urinary potassium excretion can be measured in dogs using flame photometry following collection of urine samples via a ureteral catheter.
creatinine,Plasma creatinine levels can be measured in dogs at the midpoint of each 15-minute renal clearance period during experimental protocols.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Plasma creatinine levels can be measured in dogs at the midpoint of each 15-minute renal clearance period during experimental protocols.
creatinine,Urinary creatinine is used as a marker for renal function and is measured in dogs following collection of urine samples via a ureteral catheter.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Urinary creatinine is used as a marker for renal function and is measured in dogs following collection of urine samples via a ureteral catheter.
chloride,Urinary chloride excretion can be measured in dogs using a chloridometer following collection of urine samples via a ureteral catheter.,Entity: chloride. SMILES: [Cl-]. Urinary chloride excretion can be measured in dogs using a chloridometer following collection of urine samples via a ureteral catheter.
calcium chloride,"Intrarenal administration of calcium chloride affects renin secretion in dogs, with effects similar in both filtering and nonfiltering kidneys, indicating that a direct action of calcium at the macula densa is not important for renin secretion control.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Intrarenal administration of calcium chloride affects renin secretion in dogs, with effects similar in both filtering and nonfiltering kidneys, indicating that a direct action of calcium at the macula densa is not important for renin secretion control."
potassium,Intrarenal potassium infusion does not reduce renin secretion in dogs with nonfiltering kidneys.,Entity: potassium. SMILES: [K]. Intrarenal potassium infusion does not reduce renin secretion in dogs with nonfiltering kidneys.
renin,"Intrarenal calcium infusion directly inhibits renin secretion in dogs, acting through mechanisms independent of renal vascular or macula densa sodium or chloride load, and likely involves direct action on juxtaglomerular cells.","Entity: renin. Intrarenal calcium infusion directly inhibits renin secretion in dogs, acting through mechanisms independent of renal vascular or macula densa sodium or chloride load, and likely involves direct action on juxtaglomerular cells."
tetrodotoxin,Tetrodotoxin at a concentration of 0.6 (IM) completely prevents the biphasic relaxation response to transmural nerve stimulation of the facial vein intramural nerves.,Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at a concentration of 0.6 (IM) completely prevents the biphasic relaxation response to transmural nerve stimulation of the facial vein intramural nerves.
propranolol,"Propranolol at a concentration of 10²8 M, a α-adrenergic blocking agent, reverses the relaxation response to transmural nerve stimulation of the facial vein intramural nerves and induces a contractile response instead.","Entity: propranolol. SMILES: CC(C)NCC(O)COc1cccc2ccccc12. Propranolol at a concentration of 10²8 M, a α-adrenergic blocking agent, reverses the relaxation response to transmural nerve stimulation of the facial vein intramural nerves and induces a contractile response instead."
pyrophosphate,"99mTc(Sc)-labeled pyrophosphate uptake is markedly increased in irreversibly damaged myocardium and to a lesser degree in reversibly injured myocardium, independent of blood flow.","Entity: pyrophosphate. SMILES: O=P([O-])([O-])OP(=O)([O-])[O-]. 99mTc(Sc)-labeled pyrophosphate uptake is markedly increased in irreversibly damaged myocardium and to a lesser degree in reversibly injured myocardium, independent of blood flow."
pyrophosphate,Necrotic hearts accumulate even more 99mTc(Sc)-labeled pyrophosphate than reversibly injured hearts after 24 hours of recovery from myocardial injury.,Entity: pyrophosphate. SMILES: O=P([O-])([O-])OP(=O)([O-])[O-]. Necrotic hearts accumulate even more 99mTc(Sc)-labeled pyrophosphate than reversibly injured hearts after 24 hours of recovery from myocardial injury.
pyrophosphate,"Uptake of 99mTc(Sc)-labeled pyrophosphate is not reduced in hearts cultured in calcium-free medium, indicating it is not dependent on calcium uptake.","Entity: pyrophosphate. SMILES: O=P([O-])([O-])OP(=O)([O-])[O-]. Uptake of 99mTc(Sc)-labeled pyrophosphate is not reduced in hearts cultured in calcium-free medium, indicating it is not dependent on calcium uptake."
glucoheptonate,"99mTc(Sc)-labeled glucoheptonate uptake is markedly increased in irreversibly damaged myocardium and to a lesser degree in reversibly injured myocardium, independent of blood flow.","Entity: glucoheptonate. SMILES: O=C([O-])C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Na+]. 99mTc(Sc)-labeled glucoheptonate uptake is markedly increased in irreversibly damaged myocardium and to a lesser degree in reversibly injured myocardium, independent of blood flow."
glucoheptonate,Necrotic hearts accumulate more 99mTc(Sc)-labeled glucoheptonate than reversibly injured hearts after 24 hours of recovery from myocardial injury.,Entity: glucoheptonate. SMILES: O=C([O-])C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Na+]. Necrotic hearts accumulate more 99mTc(Sc)-labeled glucoheptonate than reversibly injured hearts after 24 hours of recovery from myocardial injury.
isopentane,"Isopentane is used as a rapid freezing agent, chilled with liquid nitrogen, for preserving biological tissue specimens prior to histological analysis.","Entity: isopentane. SMILES: CCC(C)C. Isopentane is used as a rapid freezing agent, chilled with liquid nitrogen, for preserving biological tissue specimens prior to histological analysis."
formaldehyde,"Formaldehyde is used as a fixative for preserving biological tissue specimens, such as facial veins from rabbits, in histological and fluorescence histochemical studies.","Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a fixative for preserving biological tissue specimens, such as facial veins from rabbits, in histological and fluorescence histochemical studies."
glyoxylic acid,Glyoxylic acid is used in a 2% solution at pH 7.5–8.5 for 3–5 minutes at 0°C to detect and visualize vascular structures by fluorescence in histological procedures.,Entity: glyoxylic acid. SMILES: O=CC(=O)O. Glyoxylic acid is used in a 2% solution at pH 7.5–8.5 for 3–5 minutes at 0°C to detect and visualize vascular structures by fluorescence in histological procedures.
normetanephrine,Normetanephrine is formed in the presence of catechol O-methyltransferase (COMT) from μ-norepinephrine and μ-S-adenosylmethionine.,Entity: normetanephrine. SMILES: COc1cc(C(O)CN)ccc1O. Normetanephrine is formed in the presence of catechol O-methyltransferase (COMT) from μ-norepinephrine and μ-S-adenosylmethionine.
isoamyl alcohol,Isoamyl alcohol is used as a component of the toluene-isoamyl alcohol mixture (3:2) for extraction of indole-containing compounds such as 14 C-indolylacetic acid and 14 C-normetanephrine.,Entity: isoamyl alcohol. SMILES: CC(C)CCO. Isoamyl alcohol is used as a component of the toluene-isoamyl alcohol mixture (3:2) for extraction of indole-containing compounds such as 14 C-indolylacetic acid and 14 C-normetanephrine.
norepinephrine,Norepinephrine serves as a substrate for catechol O-methyltransferase (COMT) in the formation of normetanephrine.,Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Norepinephrine serves as a substrate for catechol O-methyltransferase (COMT) in the formation of normetanephrine.
tryptamine,Tryptamine is converted to indolylacetic acid by monoamine oxidase (MAO) in enzymatic assays.,Entity: tryptamine. SMILES: NCCc1c[nH]c2ccccc12. Tryptamine is converted to indolylacetic acid by monoamine oxidase (MAO) in enzymatic assays.
indolylacetic acid,Indolylacetic acid is produced from tryptamine by the action of monoamine oxidase (MAO) in enzymatic assays.,Entity: indolylacetic acid. SMILES: O=C(O)Cc1cc2ccccc2[nH]1. Indolylacetic acid is produced from tryptamine by the action of monoamine oxidase (MAO) in enzymatic assays.
S-adenosylmethionine,S-adenosylmethionine is a substrate for catechol O-methyltransferase (COMT) in the formation of normetanephrine.,Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine is a substrate for catechol O-methyltransferase (COMT) in the formation of normetanephrine.
toluene,Toluene is used as a component of the toluene-isoamyl alcohol mixture (3:2) for extraction of indole-containing compounds from enzymatic assays.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a component of the toluene-isoamyl alcohol mixture (3:2) for extraction of indole-containing compounds from enzymatic assays.
ethylenediaminetetraacetic acid,Ethylenediaminetetraacetic acid (EDTA) is used as an inhibitor of angiotensinase and converting enzyme activity in renin assays at a final concentration of 3.5 x 10^-3 M.,Entity: ethylenediaminetetraacetic acid. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. Ethylenediaminetetraacetic acid (EDTA) is used as an inhibitor of angiotensinase and converting enzyme activity in renin assays at a final concentration of 3.5 x 10^-3 M.
angiotensin I,"Angiotensin I is used as a standard substrate for quantifying renin activity in enzyme assays, with 400 ng/mg protein expressed as angiotensin I.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I is used as a standard substrate for quantifying renin activity in enzyme assays, with 400 ng/mg protein expressed as angiotensin I."
arachidonic acid,Arachidonic acid (C20:4) at concentrations of 10^-7 to 10^-6 M does not affect the angiotensin formation rate in vitro in a renin-renin substrate mixture.,Entity: arachidonic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. Arachidonic acid (C20:4) at concentrations of 10^-7 to 10^-6 M does not affect the angiotensin formation rate in vitro in a renin-renin substrate mixture.
calcium chloride,Calcium chloride is included in the Krebs-Henseleit buffer at a concentration of 0.11 M (3 parts per 100 ml) for kidney slice incubation.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride is included in the Krebs-Henseleit buffer at a concentration of 0.11 M (3 parts per 100 ml) for kidney slice incubation.
potassium dihydrogen phosphate,Potassium dihydrogen phosphate is present in the Krebs-Henseleit buffer at a concentration of 0.154 M (1 part per 100 ml) for kidney slice incubation.,Entity: potassium dihydrogen phosphate. SMILES: O=P([O-])(O)O.[K+]. Potassium dihydrogen phosphate is present in the Krebs-Henseleit buffer at a concentration of 0.154 M (1 part per 100 ml) for kidney slice incubation.
glucose,Glucose is added to the Krebs-Henseleit buffer at a concentration of 200 mg/100 ml for kidney slice incubation.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is added to the Krebs-Henseleit buffer at a concentration of 200 mg/100 ml for kidney slice incubation.
magnesium sulfate,Magnesium sulfate is included in the Krebs-Henseleit buffer at a concentration of 0.154 M (1 part per 100 ml) for kidney slice incubation.,Entity: magnesium sulfate. SMILES: O=S(=O)([O-])[O-].[Mg+2]. Magnesium sulfate is included in the Krebs-Henseleit buffer at a concentration of 0.154 M (1 part per 100 ml) for kidney slice incubation.
sodium chloride,Sodium chloride is present in the Krebs-Henseleit buffer at a concentration of 0.154 M (100 parts per 100 ml) for kidney slice incubation.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is present in the Krebs-Henseleit buffer at a concentration of 0.154 M (100 parts per 100 ml) for kidney slice incubation.
potassium chloride,Potassium chloride is included in the Krebs-Henseleit buffer at a concentration of 0.154 M (4 parts per 100 ml) for kidney slice incubation.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is included in the Krebs-Henseleit buffer at a concentration of 0.154 M (4 parts per 100 ml) for kidney slice incubation.
sodium bicarbonate,Sodium bicarbonate is used as a buffering agent in ice-cold buffer for decapsulation and initial incubation of kidney slices.,Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Sodium bicarbonate is used as a buffering agent in ice-cold buffer for decapsulation and initial incubation of kidney slices.
pentobarbital,Pentobarbital is used as an anesthetic agent at a dose of 40 mg/kg intravenously to quickly remove the left kidney under anesthesia in rabbit tissue preparation.,Entity: pentobarbital. SMILES: CCCC(C)C1(CC)C(=O)NC(=O)NC1=O. Pentobarbital is used as an anesthetic agent at a dose of 40 mg/kg intravenously to quickly remove the left kidney under anesthesia in rabbit tissue preparation.
EPA I,"EPA I increases renin release from the kidney in a dose-dependent manner, with a maximum increase of about 60% at 0.7–2.8 × 10^6 M and a decrease in response at higher concentrations approaching control values at 2.24 × 10^-5 M.","Entity: EPA I. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC(=O)O. EPA I increases renin release from the kidney in a dose-dependent manner, with a maximum increase of about 60% at 0.7–2.8 × 10^6 M and a decrease in response at higher concentrations approaching control values at 2.24 × 10^-5 M."
EPA I,"Pretreatment with indomethacin reduces the renin release response to EPA I, as shown by a decrease from 62% to 12% increase at 2.8 × 10^6 M after indomethacin pretreatment.","Entity: EPA I. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC(=O)O. Pretreatment with indomethacin reduces the renin release response to EPA I, as shown by a decrease from 62% to 12% increase at 2.8 × 10^6 M after indomethacin pretreatment."
indomethacin,"Indomethacin pretreatment decreases the renin release response to EPA I, indicating that EPA I effects on renin release are mediated by prostaglandins.","Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin pretreatment decreases the renin release response to EPA I, indicating that EPA I effects on renin release are mediated by prostaglandins."
EPA I,EPA I stimulates renin release by approximately 60% at maximally effective concentrations.,Entity: EPA I. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC(=O)O. EPA I stimulates renin release by approximately 60% at maximally effective concentrations.
EPA I,EPA I is five times more potent than EPA II in stimulating renin release at the concentrations used.,Entity: EPA I. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC(=O)O. EPA I is five times more potent than EPA II in stimulating renin release at the concentrations used.
PGG 2,PGG 2 stimulates renin release by approximately 60% at maximally effective concentrations.,Entity: PGG 2. SMILES: CCCCC[C@@H](/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H]2C[C@H]1OO2)OO. PGG 2 stimulates renin release by approximately 60% at maximally effective concentrations.
PGG 2,"PGG 2 is rapidly degraded under the experimental conditions, resulting in very short-lasting stimulation of renin release.","Entity: PGG 2. SMILES: CCCCC[C@@H](/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H]2C[C@H]1OO2)OO. PGG 2 is rapidly degraded under the experimental conditions, resulting in very short-lasting stimulation of renin release."
indomethacin,Indomethacin is used as a pretreatment to inhibit renin release in experimental studies.,Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin is used as a pretreatment to inhibit renin release in experimental studies.
C20:4,C20:4 stimulates renin release to a maximum of 350% compared to control.,Entity: C20:4. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. C20:4 stimulates renin release to a maximum of 350% compared to control.
Prostaglandin G2,"Prostaglandin G2 increases renin release in a manner similar to other endoperoxides, but requires relatively high concentrations due to rapid cleavage in aqueous solutions to PGE, PGD2, or PGF to.","Entity: Prostaglandin G2. SMILES: CCCCC[C@@H](/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H]2C[C@H]1OO2)OO. Prostaglandin G2 increases renin release in a manner similar to other endoperoxides, but requires relatively high concentrations due to rapid cleavage in aqueous solutions to PGE, PGD2, or PGF to."
indomethacin,"Indomethacin, a prostaglandin synthesis inhibitor, significantly decreases both basal and C20:4- or EPA I-stimulated renin release from rabbit renal cortex slices in vitro at 10⁻⁴ M.","Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin, a prostaglandin synthesis inhibitor, significantly decreases both basal and C20:4- or EPA I-stimulated renin release from rabbit renal cortex slices in vitro at 10⁻⁴ M."
prostaglandins,"Prostaglandins directly stimulate renin secretion from rabbit renal cortex slices in vitro, with the effect dependent on the specific endoperoxide species and concentration.","Entity: prostaglandins. SMILES: CCCCCC(/C=C/C1C=CC(=O)C1C/C=C/CCCC(=O)OC)OC(C)=O. Prostaglandins directly stimulate renin secretion from rabbit renal cortex slices in vitro, with the effect dependent on the specific endoperoxide species and concentration."
arachidonic acid,"Arachidonic acid (C20:4), a prostaglandin precursor, stimulates renin release from rabbit renal cortex slices in vitro in a concentration-dependent manner between 0.6 and 4.5 × 10⁻⁶ M.","Entity: arachidonic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. Arachidonic acid (C20:4), a prostaglandin precursor, stimulates renin release from rabbit renal cortex slices in vitro in a concentration-dependent manner between 0.6 and 4.5 × 10⁻⁶ M."
"5,8,11,14-eicosatetraynoic acid","5,8,11,14-eicosatetraynoic acid (ETA), a prostaglandin synthesis inhibitor, significantly decreases both basal and C20:4- or EPA I-stimulated renin release from rabbit renal cortex slices in vitro at 10⁻⁴ M.","Entity: 5,8,11,14-eicosatetraynoic acid. SMILES: CCCCCC#CCC#CCC#CCC#CCCCC(=O)O. 5,8,11,14-eicosatetraynoic acid (ETA), a prostaglandin synthesis inhibitor, significantly decreases both basal and C20:4- or EPA I-stimulated renin release from rabbit renal cortex slices in vitro at 10⁻⁴ M."
thromboxane B2,"In rabbit kidney slices, the formation of PGE t and PGF^ exceeds that of thromboxane B2.","Entity: thromboxane B2. SMILES: CCCCC[C@H](O)/C=C/[C@H]1OC(O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O. In rabbit kidney slices, the formation of PGE t and PGF^ exceeds that of thromboxane B2."
indomethacin,"Indomethacin partially antagonizes the effect of EPA I on renin release, suggesting a role for prostaglandin biosynthesis in mediating this effect.","Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin partially antagonizes the effect of EPA I on renin release, suggesting a role for prostaglandin biosynthesis in mediating this effect."
C20:4,C20:4 increases renin release in rabbit kidney slices mainly through the formation of endoperoxides rather than thromboxanes.,Entity: C20:4. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. C20:4 increases renin release in rabbit kidney slices mainly through the formation of endoperoxides rather than thromboxanes.
catecholamine,The rate of firing of ventricular cells is strongly dependent on catecholamine stimulation.,Entity: catecholamine. SMILES: Nc1cccc(O)c1O. The rate of firing of ventricular cells is strongly dependent on catecholamine stimulation.
dextrose,Dextrose is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 5.5 mM.,Entity: dextrose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Dextrose is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 5.5 mM.
Mg2+,Mg2+ (magnesium) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 0.5 mM.,Entity: Mg2+. SMILES: [Mg]. Mg2+ (magnesium) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 0.5 mM.
pentobarbital,Pentobarbital is used as an anesthetic agent in dogs at a dose of 30 mg/kg for cardiac dissection preparations.,Entity: pentobarbital. SMILES: CCCC(C)C1(CC)C(=O)NC(=O)NC1=O. Pentobarbital is used as an anesthetic agent in dogs at a dose of 30 mg/kg for cardiac dissection preparations.
HCO3-,HCO3- (bicarbonate) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 24.0 mM.,Entity: HCO3-. SMILES: O=C([O-])O. HCO3- (bicarbonate) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 24.0 mM.
HPO4,HPO4 (phosphate) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 1.8 mM.,Entity: HPO4. SMILES: O=P([O-])([O-])[O-]. HPO4 (phosphate) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 1.8 mM.
Na+,Na+ (sodium) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 151.1 mM.,Entity: Na+. SMILES: [Na]. Na+ (sodium) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 151.1 mM.
Cl-,Cl- (chloride) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 131.3 mM.,Entity: Cl-. SMILES: [Cl-]. Cl- (chloride) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 131.3 mM.
Ca2+,Ca2+ (calcium) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 1.4 mM.,Entity: Ca2+. SMILES: [Ca]. Ca2+ (calcium) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 1.4 mM.
K+,K+ (potassium) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 4.0 mM.,Entity: K+. SMILES: [K]. K+ (potassium) is included in the superfusion solution for isolated canine ventricular preparations at a concentration of 4.0 mM.
urea,The reference range for urea was adjusted from 141 to 142 mg/dl in the calibration of the analyzed serum assays.,Entity: urea. SMILES: NC(N)=O. The reference range for urea was adjusted from 141 to 142 mg/dl in the calibration of the analyzed serum assays.
phosphate,The reference range for phosphate was adjusted from 5.5 to 5.8 mg/dl in the calibration of the analyzed serum assays.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. The reference range for phosphate was adjusted from 5.5 to 5.8 mg/dl in the calibration of the analyzed serum assays.
bilirubin,The reference range for bilirubin was adjusted from 2.3 to 2.15 mg/dl in the calibration of the analyzed serum assays.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. The reference range for bilirubin was adjusted from 2.3 to 2.15 mg/dl in the calibration of the analyzed serum assays.
chloride,The reference range for chloride was adjusted from 106 to 105 mmol/l in the calibration of the analyzed serum assays.,Entity: chloride. SMILES: [Cl-]. The reference range for chloride was adjusted from 106 to 105 mmol/l in the calibration of the analyzed serum assays.
calcium,"In the calibration process, the reference range for calcium was adjusted from 9.6 to 10.0 mg/dl in the analyzed serum assays.","Entity: calcium. SMILES: [Ca]. In the calibration process, the reference range for calcium was adjusted from 9.6 to 10.0 mg/dl in the analyzed serum assays."
bilirubin,"Assayed control sera values for bilirubin are frequently inconsistent, indicating potential issues with the quality or reliability of some bilirubin-containing control sera products.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Assayed control sera values for bilirubin are frequently inconsistent, indicating potential issues with the quality or reliability of some bilirubin-containing control sera products."
calcium,"Assayed control sera values for calcium are often inconsistent, suggesting that some calcium-containing control sera products may require improvement.","Entity: calcium. SMILES: [Ca]. Assayed control sera values for calcium are often inconsistent, suggesting that some calcium-containing control sera products may require improvement."
phosphate,"Assayed control sera values for phosphate are frequently inconsistent, indicating potential problems with the quality or reliability of some phosphate-containing control sera products.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Assayed control sera values for phosphate are frequently inconsistent, indicating potential problems with the quality or reliability of some phosphate-containing control sera products."
bilirubin,The allocated values for bilirubin in the Technicon SMA Reference Serum have been identified as potentially inaccurate based on quality control and external reference data.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. The allocated values for bilirubin in the Technicon SMA Reference Serum have been identified as potentially inaccurate based on quality control and external reference data.
chloride,"The allocated values for chloride in the Technicon SMA Reference Serum have been subject to uncertainty and possible error, as supported by multiple quality control and reference laboratory analyses.","Entity: chloride. SMILES: [Cl-]. The allocated values for chloride in the Technicon SMA Reference Serum have been subject to uncertainty and possible error, as supported by multiple quality control and reference laboratory analyses."
calcium,"The allocated values for calcium in the Technicon SMA Reference Serum have been subject to uncertainty and potential error, as indicated by comparisons with other laboratories and national quality control schemes.","Entity: calcium. SMILES: [Ca]. The allocated values for calcium in the Technicon SMA Reference Serum have been subject to uncertainty and potential error, as indicated by comparisons with other laboratories and national quality control schemes."
urea,"The allocated values for urea in the Technicon SMA Reference Serum have been associated with possible errors, as demonstrated by multiple sources of comparison and quality control data.","Entity: urea. SMILES: NC(N)=O. The allocated values for urea in the Technicon SMA Reference Serum have been associated with possible errors, as demonstrated by multiple sources of comparison and quality control data."
phosphate,The allocated values for phosphate in the Technicon SMA Reference Serum have been questioned due to discrepancies observed in quality control and interlaboratory comparisons.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. The allocated values for phosphate in the Technicon SMA Reference Serum have been questioned due to discrepancies observed in quality control and interlaboratory comparisons.
Lithium,"Lithium is used as a prior treatment for patients with primary affective disorders, including unipolar and bipolar depression.","Entity: Lithium. SMILES: [Li]. Lithium is used as a prior treatment for patients with primary affective disorders, including unipolar and bipolar depression."
prolactin,Plasma prolactin levels can be increased by intravenous administration of LH-RH (150 µg) in some patients with primary affective disorders.,Entity: prolactin. Plasma prolactin levels can be increased by intravenous administration of LH-RH (150 µg) in some patients with primary affective disorders.
growth hormone,"Plasma growth hormone levels can be increased by intravenous administration of TRH (500 µg) or LH-RH (150 µg) in patients with primary affective disorders, although this response is abnormal compared to controls.","Entity: growth hormone. Plasma growth hormone levels can be increased by intravenous administration of TRH (500 µg) or LH-RH (150 µg) in patients with primary affective disorders, although this response is abnormal compared to controls."
haptoglobin,Haptoglobin combines stoichiometrically with hemoglobin to form a complex that exhibits peroxidase-like activity proportional to the quantity of haptoglobin present.,Entity: haptoglobin. Haptoglobin combines stoichiometrically with hemoglobin to form a complex that exhibits peroxidase-like activity proportional to the quantity of haptoglobin present.
calcium bicarbonate,"Calcium bicarbonate is the major individual calcium complex in serum, with a mean concentration of 0.14 mmol/liter in healthy individuals.","Entity: calcium bicarbonate. SMILES: O=C([O-])O.O=C([O-])O.[Ca+2]. Calcium bicarbonate is the major individual calcium complex in serum, with a mean concentration of 0.14 mmol/liter in healthy individuals."
phosphate,"Phosphate forms a major calcium complex in serum, present in healthy individuals.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate forms a major calcium complex in serum, present in healthy individuals."
citrate,"Citrate forms a major calcium complex in serum, present in healthy individuals.","Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Citrate forms a major calcium complex in serum, present in healthy individuals."
calcium,"In healthy individuals, the mean distribution of calcium in serum is 1.00 mmol as protein-bound calcium, 0.31 mmol as complexes with citrate, phosphate, lactate, and sulfate, and 1.07 mmol as ionic calcium, as determined by gel filtration.","Entity: calcium. SMILES: [Ca]. In healthy individuals, the mean distribution of calcium in serum is 1.00 mmol as protein-bound calcium, 0.31 mmol as complexes with citrate, phosphate, lactate, and sulfate, and 1.07 mmol as ionic calcium, as determined by gel filtration."
calcium bicarbonate,Calcium bicarbonate forms a distinct peak in serum after gel filtration using polyacrylamide beads (Biogel P-2) under physiological conditions.,Entity: calcium bicarbonate. SMILES: O=C([O-])O.O=C([O-])O.[Ca+2]. Calcium bicarbonate forms a distinct peak in serum after gel filtration using polyacrylamide beads (Biogel P-2) under physiological conditions.
2-([tris(hydroxymethyl)methyl]amino)ethanesulfonic acid,2-([tris(hydroxymethyl)methyl]amino)ethanesulfonic acid is used at 10 mmol/L (pH 7.40 at 37°C) as an eluent component to provide physiological conditions for calcium complex equilibria in gel filtration assays.,Entity: 2-([tris(hydroxymethyl)methyl]amino)ethanesulfonic acid. SMILES: O=S(=O)(O)CCNC(CO)(CO)CO. 2-([tris(hydroxymethyl)methyl]amino)ethanesulfonic acid is used at 10 mmol/L (pH 7.40 at 37°C) as an eluent component to provide physiological conditions for calcium complex equilibria in gel filtration assays.
magnesium,Magnesium is included at 0.50 mmol/L in the eluent for gel filtration of serum to maintain physiological conditions for calcium complex equilibria.,Entity: magnesium. SMILES: [Mg]. Magnesium is included at 0.50 mmol/L in the eluent for gel filtration of serum to maintain physiological conditions for calcium complex equilibria.
sodium,Sodium is present at 140 mmol/L in the eluent for gel filtration of serum to provide physiological conditions for calcium complex equilibria.,Entity: sodium. SMILES: [Na]. Sodium is present at 140 mmol/L in the eluent for gel filtration of serum to provide physiological conditions for calcium complex equilibria.
phosphate,Phosphate forms calcium complexes in serum that contribute to the second peak in gel filtration under physiological conditions.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate forms calcium complexes in serum that contribute to the second peak in gel filtration under physiological conditions.
calcium phosphate,Association constants for calcium phosphate in serum are consistent with previously reported values.,Entity: calcium phosphate. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]. Association constants for calcium phosphate in serum are consistent with previously reported values.
calcium citrate,Association constants for calcium citrate in serum are consistent with previously reported values.,Entity: calcium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2]. Association constants for calcium citrate in serum are consistent with previously reported values.
calcium sulfate,Association constants for calcium sulfate in serum are consistent with previously reported values.,Entity: calcium sulfate. SMILES: O=S(=O)([O-])[O-].[Ca+2]. Association constants for calcium sulfate in serum are consistent with previously reported values.
calcium bicarbonate,Association constants for calcium bicarbonate in serum are consistent with previously reported values.,Entity: calcium bicarbonate. SMILES: O=C([O-])O.O=C([O-])O.[Ca+2]. Association constants for calcium bicarbonate in serum are consistent with previously reported values.
calcium lactate,Association constants for calcium lactate in serum are consistent with previously reported values.,Entity: calcium lactate. SMILES: CC(O)C(=O)[O-].CC(O)C(=O)[O-].[Ca+2]. Association constants for calcium lactate in serum are consistent with previously reported values.
magnesium,"Magnesium concentration in serum is maintained at physiological levels during column chromatography, influencing calcium equilibria.","Entity: magnesium. SMILES: [Mg]. Magnesium concentration in serum is maintained at physiological levels during column chromatography, influencing calcium equilibria."
calcium bicarbonate,"Calcium bicarbonate is the major complexed calcium form in serum, accounting for a large proportion of total complexed calcium.","Entity: calcium bicarbonate. SMILES: O=C([O-])O.O=C([O-])O.[Ca+2]. Calcium bicarbonate is the major complexed calcium form in serum, accounting for a large proportion of total complexed calcium."
calcium citrate,Calcium citrate is a major complexed calcium form in serum.,Entity: calcium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2]. Calcium citrate is a major complexed calcium form in serum.
calcium phosphate,Calcium phosphate is a major complexed calcium form in serum.,Entity: calcium phosphate. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]. Calcium phosphate is a major complexed calcium form in serum.
calcium lactate,Calcium lactate is a minor complexed calcium form in serum.,Entity: calcium lactate. SMILES: CC(O)C(=O)[O-].CC(O)C(=O)[O-].[Ca+2]. Calcium lactate is a minor complexed calcium form in serum.
calcium sulfate,"Calcium sulfate is a minor complexed calcium form in serum, present at concentrations less than 10 mol/liter.","Entity: calcium sulfate. SMILES: O=S(=O)([O-])[O-].[Ca+2]. Calcium sulfate is a minor complexed calcium form in serum, present at concentrations less than 10 mol/liter."
calcium,"In serum, the eluant composition is designed to control the equilibria between different calcium species during gel filtration.","Entity: calcium. SMILES: [Ca]. In serum, the eluant composition is designed to control the equilibria between different calcium species during gel filtration."
magnesium,Magnesium concentration is one of the parameters controlled in the eluant to maintain calcium equilibria in serum during gel filtration.,Entity: magnesium. SMILES: [Mg]. Magnesium concentration is one of the parameters controlled in the eluant to maintain calcium equilibria in serum during gel filtration.
calcium citrate,"Calcium citrate forms a complex with an apparent association constant (K') of 1280 ± 230 ± 3.11 (mol/liter)⁻¹ in aqueous solution at ionic strength 0.15, pH 7.40, and 37°C, as determined by gel filtration on Biogel P-2.","Entity: calcium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2]. Calcium citrate forms a complex with an apparent association constant (K') of 1280 ± 230 ± 3.11 (mol/liter)⁻¹ in aqueous solution at ionic strength 0.15, pH 7.40, and 37°C, as determined by gel filtration on Biogel P-2."
calcium bicarbonate,"Calcium bicarbonate forms a complex with an apparent association constant (K') of 1.87 ± 0.49 ± 0.73 (mol/liter)⁻¹ in aqueous solution at ionic strength 0.15, pH 7.40, and 37°C, as determined by gel filtration on Biogel P-2.","Entity: calcium bicarbonate. SMILES: O=C([O-])O.O=C([O-])O.[Ca+2]. Calcium bicarbonate forms a complex with an apparent association constant (K') of 1.87 ± 0.49 ± 0.73 (mol/liter)⁻¹ in aqueous solution at ionic strength 0.15, pH 7.40, and 37°C, as determined by gel filtration on Biogel P-2."
calcium sulfate,"Calcium sulfate forms a complex with an apparent association constant (K') of 29.3 ± 0.9 ± 1.47 (mol/liter)⁻¹ in aqueous solution at ionic strength 0.15, pH 7.40, and 37°C, as determined by gel filtration on Biogel P-2.","Entity: calcium sulfate. SMILES: O=S(=O)([O-])[O-].[Ca+2]. Calcium sulfate forms a complex with an apparent association constant (K') of 29.3 ± 0.9 ± 1.47 (mol/liter)⁻¹ in aqueous solution at ionic strength 0.15, pH 7.40, and 37°C, as determined by gel filtration on Biogel P-2."
calcium lactate,"Calcium lactate forms a complex with an apparent association constant (K') of 14.5 ± 1.7 ± 1.16 (mol/liter)⁻¹ in aqueous solution at ionic strength 0.15, pH 7.40, and 37°C, as determined by gel filtration on Biogel P-2.","Entity: calcium lactate. SMILES: CC(O)C(=O)[O-].CC(O)C(=O)[O-].[Ca+2]. Calcium lactate forms a complex with an apparent association constant (K') of 14.5 ± 1.7 ± 1.16 (mol/liter)⁻¹ in aqueous solution at ionic strength 0.15, pH 7.40, and 37°C, as determined by gel filtration on Biogel P-2."
calcium phosphate,"Calcium phosphate forms a complex with an apparent association constant (K') of 45.8 ± 17.2 ± 1.66 (mol/liter)⁻¹ in aqueous solution at ionic strength 0.15, pH 7.40, and 37°C, as determined by gel filtration on Biogel P-2.","Entity: calcium phosphate. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]. Calcium phosphate forms a complex with an apparent association constant (K') of 45.8 ± 17.2 ± 1.66 (mol/liter)⁻¹ in aqueous solution at ionic strength 0.15, pH 7.40, and 37°C, as determined by gel filtration on Biogel P-2."
calcium,"In serum, approximately 45% of total calcium is bound to nondiffusing protein material, while the protein-free ultrafiltrate contains primarily ionic calcium and about 10% diffusibly bound calcium.","Entity: calcium. SMILES: [Ca]. In serum, approximately 45% of total calcium is bound to nondiffusing protein material, while the protein-free ultrafiltrate contains primarily ionic calcium and about 10% diffusibly bound calcium."
calcium,"The amount of bound calcium in serum remains constant when the concentration of ionic calcium and other calcium-binding conditions such as pH, temperature, ionic strength, and magnesium ion concentration are maintained during gel filtration.","Entity: calcium. SMILES: [Ca]. The amount of bound calcium in serum remains constant when the concentration of ionic calcium and other calcium-binding conditions such as pH, temperature, ionic strength, and magnesium ion concentration are maintained during gel filtration."
magnesium,"Magnesium ion concentration affects the binding of calcium in serum, and maintaining constant magnesium ion concentration during gel filtration helps preserve the amount of bound calcium.","Entity: magnesium. SMILES: [Mg]. Magnesium ion concentration affects the binding of calcium in serum, and maintaining constant magnesium ion concentration during gel filtration helps preserve the amount of bound calcium."
calcium lactate,"Calcium lactate is present at minor concentrations in blood, with its accumulation being observed after blood collection.","Entity: calcium lactate. SMILES: CC(O)C(=O)[O-].CC(O)C(=O)[O-].[Ca+2]. Calcium lactate is present at minor concentrations in blood, with its accumulation being observed after blood collection."
calcium sulfate,"Calcium sulfate is present at concentrations less than 10 tmol/liter in blood, which is below the limits of detectability for gel filtration techniques.","Entity: calcium sulfate. SMILES: O=S(=O)([O-])[O-].[Ca+2]. Calcium sulfate is present at concentrations less than 10 tmol/liter in blood, which is below the limits of detectability for gel filtration techniques."
ammonia,"The mean venous plasma ammonia concentration in 27 apparently healthy adults is 16 µmol/liter, with a range of 0–39 µmol/liter.","Entity: ammonia. SMILES: N. The mean venous plasma ammonia concentration in 27 apparently healthy adults is 16 µmol/liter, with a range of 0–39 µmol/liter."
sodium hydroxide,Sodium hydroxide (NaOH) is used at 0.1 mol/liter concentration to wash resin during preparation.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide (NaOH) is used at 0.1 mol/liter concentration to wash resin during preparation.
ammonia,Ammonia content in the saline over the resin is monitored and the saline is changed as required during resin storage.,Entity: ammonia. SMILES: N. Ammonia content in the saline over the resin is monitored and the saline is changed as required during resin storage.
hydrochloric acid,"Hydrochloric acid (HCl) is used to wash resin in a preparation protocol, with one bed volume of concentrated HCl applied after washing with tap water and before de-ionized water.","Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (HCl) is used to wash resin in a preparation protocol, with one bed volume of concentrated HCl applied after washing with tap water and before de-ionized water."
sodium chloride,"Sodium chloride (NaCl) is used at 2 mol/liter concentration to wash resin during preparation, and subsequently at 4 mol/liter to suspend and store the resin.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride (NaCl) is used at 2 mol/liter concentration to wash resin during preparation, and subsequently at 4 mol/liter to suspend and store the resin."
disodium ethylenediaminetetraacetate,Disodium ethylenediaminetetraacetate is used at 50 mmol/liter concentration and pH 7-8 to wash resin in the preparation process.,Entity: disodium ethylenediaminetetraacetate. SMILES: O=C([O-])CN(CCN(CC(=O)O)CC(=O)O)CC(=O)[O-].[Na+].[Na+]. Disodium ethylenediaminetetraacetate is used at 50 mmol/liter concentration and pH 7-8 to wash resin in the preparation process.
ammonia,Plasma ammonia values in canine blood remain stable in trichloroacetic acid filtrates stored at -10 °C for up to 24 days.,Entity: ammonia. SMILES: N. Plasma ammonia values in canine blood remain stable in trichloroacetic acid filtrates stored at -10 °C for up to 24 days.
ammonia,Plasma samples can be stored at -70 °C or below for up to 40 hours with only subtle changes in the lower ranges of plasma ammonia values.,Entity: ammonia. SMILES: N. Plasma samples can be stored at -70 °C or below for up to 40 hours with only subtle changes in the lower ranges of plasma ammonia values.
ammonia,"Clinically significant hyperammonemia usually occurs when plasma ammonia values exceed the highest value obtained in a frozen sample, allowing for plasma storage up to 48 hours.","Entity: ammonia. SMILES: N. Clinically significant hyperammonemia usually occurs when plasma ammonia values exceed the highest value obtained in a frozen sample, allowing for plasma storage up to 48 hours."
glutamine,"Glutamine undergoes slow decomposition during storage of plasma at -20 °C, which may contribute to increased plasma ammonia levels over time.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine undergoes slow decomposition during storage of plasma at -20 °C, which may contribute to increased plasma ammonia levels over time."
trichloroacetic acid,Trichloroacetic acid is used to stabilize ammonia in canine blood plasma for storage at -10 °C.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to stabilize ammonia in canine blood plasma for storage at -10 °C.
ammonia,"Plasma ammonia can be measured using various methods, including cation-exchange resins, glutamate dehydrogenase-based assays, and ammonia-selective electrodes, with each requiring at least 1.0 ml of plasma.","Entity: ammonia. SMILES: N. Plasma ammonia can be measured using various methods, including cation-exchange resins, glutamate dehydrogenase-based assays, and ammonia-selective electrodes, with each requiring at least 1.0 ml of plasma."
ammonia,"Hyperammonemic syndromes, such as urea cycle enzyme deficiencies, ketotic hyperglycinemias, ornithinemia, hyperlysinemia, and hyperammonemia complicating total parenteral nutrition, are often detected in the newborn period.","Entity: ammonia. SMILES: N. Hyperammonemic syndromes, such as urea cycle enzyme deficiencies, ketotic hyperglycinemias, ornithinemia, hyperlysinemia, and hyperammonemia complicating total parenteral nutrition, are often detected in the newborn period."
urea,Deficiencies of urea cycle enzymes can cause hyperammonemic syndromes detectable in the newborn period.,Entity: urea. SMILES: NC(N)=O. Deficiencies of urea cycle enzymes can cause hyperammonemic syndromes detectable in the newborn period.
ammonia,"Ammonia is eluted from a column using four 200 ml portions of 4 mol/liter saline solution, with each portion allowed to run through completely before the next is applied.","Entity: ammonia. SMILES: N. Ammonia is eluted from a column using four 200 ml portions of 4 mol/liter saline solution, with each portion allowed to run through completely before the next is applied."
phenol,"Phenol reagent is added to the eluate of a protein assay to develop color, followed by the addition of hypochlorite solution and incubation at 37°C in the dark for 30 minutes.","Entity: phenol. SMILES: Oc1ccccc1. Phenol reagent is added to the eluate of a protein assay to develop color, followed by the addition of hypochlorite solution and incubation at 37°C in the dark for 30 minutes."
sodium chloride,Sodium chloride is used as a 4 mol/liter saline solution for washing columns and as a slurry medium for resin in protein assay protocols.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used as a 4 mol/liter saline solution for washing columns and as a slurry medium for resin in protein assay protocols.
hypochlorite,"Hypochlorite solution is used in the color development step of a protein assay, where 60 ml is added to the eluate after phenol reagent, and the mixture is incubated at 37°C in the dark for 30 minutes.","Entity: hypochlorite. SMILES: [O-]Cl. Hypochlorite solution is used in the color development step of a protein assay, where 60 ml is added to the eluate after phenol reagent, and the mixture is incubated at 37°C in the dark for 30 minutes."
ammonia,"Capillary blood ammonia values in newborns are generally higher than venous plasma ammonia values, likely reflecting increased ammonia flux in muscle tissue or differences in tissue uptake.","Entity: ammonia. SMILES: N. Capillary blood ammonia values in newborns are generally higher than venous plasma ammonia values, likely reflecting increased ammonia flux in muscle tissue or differences in tissue uptake."
ammonia,Clinically significant hyperammonemia in infants is typically defined as ammonia levels in the range of 350–1400 zmol/liter.,Entity: ammonia. SMILES: N. Clinically significant hyperammonemia in infants is typically defined as ammonia levels in the range of 350–1400 zmol/liter.
urea,"Defects in the urea cycle can cause a more pronounced arterial-venous difference in ammonia levels, indicating impaired ammonia removal.","Entity: urea. SMILES: NC(N)=O. Defects in the urea cycle can cause a more pronounced arterial-venous difference in ammonia levels, indicating impaired ammonia removal."
ammonia,Plasma ammonia values in children with ornithine transcarbamylase deficiency under dietary management typically range from 36 to 90 tmol/liter.,Entity: ammonia. SMILES: N. Plasma ammonia values in children with ornithine transcarbamylase deficiency under dietary management typically range from 36 to 90 tmol/liter.
ammonia,"Elevated plasma ammonia levels, such as 322 imol/liter, can cause agitated delirium in patients receiving total parenteral nutrition.","Entity: ammonia. SMILES: N. Elevated plasma ammonia levels, such as 322 imol/liter, can cause agitated delirium in patients receiving total parenteral nutrition."
ammonia,"Mean plasma venous ammonia concentration in adults is 16 µmol/liter (range 0–39 µmol/liter), while in newborns it is 60 µmol/liter (range 34–102 µmol/liter).","Entity: ammonia. SMILES: N. Mean plasma venous ammonia concentration in adults is 16 µmol/liter (range 0–39 µmol/liter), while in newborns it is 60 µmol/liter (range 34–102 µmol/liter)."
ammonia,Plasma ammonia values measured by the batch procedure with cation-exchange resin columns are likely to reflect physiological plasma ammonia levels due to reduced interference from plasma proteins.,Entity: ammonia. SMILES: N. Plasma ammonia values measured by the batch procedure with cation-exchange resin columns are likely to reflect physiological plasma ammonia levels due to reduced interference from plasma proteins.
heparin,"Heparin is used as an anticoagulant in blood collection tubes, and blood samples anticoagulated with heparin yield URO-S assay activities that are 10–15% lower than those from unclotted samples.","Entity: heparin. SMILES: CC(=O)N[C@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](CS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@@H](O[C@H]4[C@H](O)[C@@H](OS(=O)(=O)O)C(O)O[C@H]4C(=O)O)O[C@@H]3O)O[C@@H]2C(=O)O)O[C@H](COS(=O)(=O)O)[C@@H](O)[C@@H]1O. Heparin is used as an anticoagulant in blood collection tubes, and blood samples anticoagulated with heparin yield URO-S assay activities that are 10–15% lower than those from unclotted samples."
porphobilinogen,"Porphobilinogen is used as a reagent in a colorimetric assay for blood spot analysis, where it reacts with blood-derived heme in the presence of a trichloroacetic acid stop solution.","Entity: porphobilinogen. SMILES: NCc1[nH]cc(CCC(=O)O)c1CC(=O)O. Porphobilinogen is used as a reagent in a colorimetric assay for blood spot analysis, where it reacts with blood-derived heme in the presence of a trichloroacetic acid stop solution."
trichloroacetic acid,"Trichloroacetic acid is used to stop the reaction in a colorimetric assay involving porphobilinogen and blood, enabling detection of heme in dried blood spots.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to stop the reaction in a colorimetric assay involving porphobilinogen and blood, enabling detection of heme in dried blood spots."
trichloroacetic acid,Trichloroacetic acid is used to treat samples in the quantitative URO-S assay for fluorescence measurement.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to treat samples in the quantitative URO-S assay for fluorescence measurement.
coproporphyrin I,Coproporphyrin I is used as a standard in the quantitative URO-S assay to prepare standard curves for fluorescence measurement.,Entity: coproporphyrin I. SMILES: CC1=C(CCC(=O)O)c2cc3nc(cc4[nH]c(cc5[nH]c(cc1n2)c(CCC(=O)O)c5C)c(CCC(=O)O)c4C)C(CCC(=O)O)=C3C. Coproporphyrin I is used as a standard in the quantitative URO-S assay to prepare standard curves for fluorescence measurement.
hemoglobin,"Hemoglobin concentration in blood can be measured from dried blood spots, providing direct evidence of anemia.","Entity: hemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. Hemoglobin concentration in blood can be measured from dried blood spots, providing direct evidence of anemia."
hemoglobin,Hemoglobin concentrations as low as 89 g per liter in nonporphyric blood can be distinguished from those in porphyric subjects in a URO-S spot test.,Entity: hemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. Hemoglobin concentrations as low as 89 g per liter in nonporphyric blood can be distinguished from those in porphyric subjects in a URO-S spot test.
Trichloroacetic acid,"Trichloroacetic acid is used in the enzyme assay for uroporphyrinogen I synthase activity, where it is added to the porphobilinogen-incubated filter paper disc supernatant after incubation.","Entity: Trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used in the enzyme assay for uroporphyrinogen I synthase activity, where it is added to the porphobilinogen-incubated filter paper disc supernatant after incubation."
porphyrin,"Porphyrin fluorescence is used as a visual indicator of uroporphyrinogen I synthase activity in dried blood filter paper discs, with normal and porphyric samples being readily differentiated by color and intensity.","Entity: porphyrin. SMILES: C1=Cc2cc3ccc(cc4nc(cc5ccc(cc1n2)[nH]5)C=C4)[nH]3. Porphyrin fluorescence is used as a visual indicator of uroporphyrinogen I synthase activity in dried blood filter paper discs, with normal and porphyric samples being readily differentiated by color and intensity."
porphobilinogen,"Porphobilinogen is used as a substrate in the enzyme assay for uroporphyrinogen I synthase activity, applied at a concentration of 0.11 mmol/liter in tris(hydroxymethyl)aminomethane HCl buffer, pH 8.2, in the dark at 37°C for 3.5 hours.","Entity: porphobilinogen. SMILES: NCc1[nH]cc(CCC(=O)O)c1CC(=O)O. Porphobilinogen is used as a substrate in the enzyme assay for uroporphyrinogen I synthase activity, applied at a concentration of 0.11 mmol/liter in tris(hydroxymethyl)aminomethane HCl buffer, pH 8.2, in the dark at 37°C for 3.5 hours."
porphobilinogen,Porphobilinogen serves as a substrate in assays to measure URO-S activity by generating fluorescence in erythrocytes through hemolysis.,Entity: porphobilinogen. SMILES: NCc1[nH]cc(CCC(=O)O)c1CC(=O)O. Porphobilinogen serves as a substrate in assays to measure URO-S activity by generating fluorescence in erythrocytes through hemolysis.
porphyrin,Porphyrin is produced from porphobilinogen in erythrocyte hemolysates and its fluorescence is measured to assess URO-S activity in clinical assays.,Entity: porphyrin. SMILES: C1=Cc2cc3ccc(cc4nc(cc5ccc(cc1n2)[nH]5)C=C4)[nH]3. Porphyrin is produced from porphobilinogen in erythrocyte hemolysates and its fluorescence is measured to assess URO-S activity in clinical assays.
triglyceride,High plasma triglyceride concentrations interfere with in vitro determination of amylase activity.,Entity: triglyceride. SMILES: O=COCC(COC=O)OC=O. High plasma triglyceride concentrations interfere with in vitro determination of amylase activity.
sodium chloride,Sodium chloride is used as a component of the reagent blank solution (70 g/liter) in the Dyamyl-L amylase assay.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used as a component of the reagent blank solution (70 g/liter) in the Dyamyl-L amylase assay.
zinc chloride,Zinc chloride is used as a precipitant in the Dyamyl-L amylase assay to precipitate unhydrolyzed starch substrate and sample proteins.,Entity: zinc chloride. SMILES: [Cl-].[Cl-].[Zn+2]. Zinc chloride is used as a precipitant in the Dyamyl-L amylase assay to precipitate unhydrolyzed starch substrate and sample proteins.
water,Water is used as a component (82% by volume) of the solvent mixture in the Dyamyl-L amylase assay.,Entity: water. SMILES: O. Water is used as a component (82% by volume) of the solvent mixture in the Dyamyl-L amylase assay.
2-ethoxyethanol,2-ethoxyethanol is used as a component (18% by volume) of the solvent mixture in the Dyamyl-L amylase assay.,Entity: 2-ethoxyethanol. SMILES: CCOCCO. 2-ethoxyethanol is used as a component (18% by volume) of the solvent mixture in the Dyamyl-L amylase assay.
benzoate,Benzoate is used at a concentration of 0.1 mol per liter in the Dyamyl-L amylase assay to help precipitate unhydrolyzed starch substrate and sample proteins.,Entity: benzoate. SMILES: O=C([O-])c1ccccc1. Benzoate is used at a concentration of 0.1 mol per liter in the Dyamyl-L amylase assay to help precipitate unhydrolyzed starch substrate and sample proteins.
iodine,"Iodine can interact with starch, but its interaction can be blocked by proteins even at low concentrations, possibly due to preferential binding of iodine by protein.","Entity: iodine. SMILES: [I]. Iodine can interact with starch, but its interaction can be blocked by proteins even at low concentrations, possibly due to preferential binding of iodine by protein."
amylopectin,Unhydrolyzed dyed amylopectin can be precipitated out of solution by alcoholic precipitant in serum samples.,Entity: amylopectin. SMILES: OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](OC[C@H]3O[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]4CO)[C@H](O)[C@@H](O)[C@@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O. Unhydrolyzed dyed amylopectin can be precipitated out of solution by alcoholic precipitant in serum samples.
[1-14C]glucose,[1-14C]glucose is used as a substrate to measure glucose metabolism in erythrocytes by detecting the amount of CO2 produced.,Entity: [1-14C]glucose. SMILES: O=[14CH][C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. [1-14C]glucose is used as a substrate to measure glucose metabolism in erythrocytes by detecting the amount of CO2 produced.
ethanolamine,Ethanolamine is used as a trapping agent for CO2 evolved during erythrocyte metabolism assays.,Entity: ethanolamine. SMILES: NCCO. Ethanolamine is used as a trapping agent for CO2 evolved during erythrocyte metabolism assays.
glucose,"In normal adults, erythrocytes metabolize glucose at a rate of 37.8 µmol/liter per minute.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In normal adults, erythrocytes metabolize glucose at a rate of 37.8 µmol/liter per minute."
tris (hydroxymethyl)-aminomethane,"In chloroplast thylakoids, tris (hydroxymethyl)-aminomethane acts as a buffer that, when combined with orthophosphate, delays acidification of the inner aqueous phase by 1500 ms in somewhat swollen chloroplasts.","Entity: tris (hydroxymethyl)-aminomethane. SMILES: NC(CO)(CO)CO. In chloroplast thylakoids, tris (hydroxymethyl)-aminomethane acts as a buffer that, when combined with orthophosphate, delays acidification of the inner aqueous phase by 1500 ms in somewhat swollen chloroplasts."
imidazole,Imidazole delays the development of post-illumination ATP formation and increases the maximum amount of ATP formed in thylakoid membranes.,Entity: imidazole. SMILES: c1c[nH]cn1. Imidazole delays the development of post-illumination ATP formation and increases the maximum amount of ATP formed in thylakoid membranes.
pyridine,Pyridine delays the development of post-illumination ATP formation and increases the maximum amount of ATP formed in thylakoid membranes.,Entity: pyridine. SMILES: c1ccncc1. Pyridine delays the development of post-illumination ATP formation and increases the maximum amount of ATP formed in thylakoid membranes.
valinomycin,"Valinomycin, when present in the thylakoid membrane, delays the initiation of photophosphorylation by 65 ms even in the presence of saturating amounts of bicarbonate and orthophosphate.","Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin, when present in the thylakoid membrane, delays the initiation of photophosphorylation by 65 ms even in the presence of saturating amounts of bicarbonate and orthophosphate."
orthophosphate,"Orthophosphate, when present in chloroplast thylakoids, acts as a buffer that, when combined with tris (hydroxymethyl)-aminomethane, delays acidification of the inner aqueous phase by 1500 ms in somewhat swollen chloroplasts.","Entity: orthophosphate. SMILES: O=P([O-])([O-])[O-]. Orthophosphate, when present in chloroplast thylakoids, acts as a buffer that, when combined with tris (hydroxymethyl)-aminomethane, delays acidification of the inner aqueous phase by 1500 ms in somewhat swollen chloroplasts."
bicarbonate,A concentration of bicarbonate that would delay acidification of the bulk of the inner aqueous phase for at least 350 ms has no effect on the time of initiation of photophosphorylation in thylakoids.,Entity: bicarbonate. SMILES: O=C([O-])O. A concentration of bicarbonate that would delay acidification of the bulk of the inner aqueous phase for at least 350 ms has no effect on the time of initiation of photophosphorylation in thylakoids.
potassium ferricyanide,Potassium ferricyanide is used at 100 µM concentration in chloroplast-based phosphorylation assays and is reduced photochemically to generate ferrocyanide.,Entity: potassium ferricyanide. SMILES: N#C[Fe-3](C#N)(C#N)(C#N)(C#N)C#N.[K+].[K+].[K+]. Potassium ferricyanide is used at 100 µM concentration in chloroplast-based phosphorylation assays and is reduced photochemically to generate ferrocyanide.
Na2H32PO4,Na2H32PO4 is used as a phosphate buffer component at 5 mM concentration in chloroplast-based phosphorylation assays.,Entity: Na2H32PO4. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Na2H32PO4 is used as a phosphate buffer component at 5 mM concentration in chloroplast-based phosphorylation assays.
formate,Formate is used at 100 mM concentration and pH 3.0 in the developing solution for quantifying ferrocyanide in chloroplast assays.,Entity: formate. SMILES: O=C[O-]. Formate is used at 100 mM concentration and pH 3.0 in the developing solution for quantifying ferrocyanide in chloroplast assays.
sucrose,Sucrose is used as a buffer component at 0.1 M concentration in chloroplast-based phosphorylation assays.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used as a buffer component at 0.1 M concentration in chloroplast-based phosphorylation assays.
MgCI2,MgCl2 is included at 2 mM concentration in chloroplast-based phosphorylation assays.,Entity: MgCI2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is included at 2 mM concentration in chloroplast-based phosphorylation assays.
"3-(3,4-Dichlorophenyl)-1,1-dimethylurea","3-(3,4-Dichlorophenyl)-1,1-dimethylurea is used as a reagent to detect ferrocyanide formation in chloroplast-based assays, with 0.1 ml of 10 mM solution injected into each sample.","Entity: 3-(3,4-Dichlorophenyl)-1,1-dimethylurea. SMILES: CN(C)C(=O)Nc1ccc(Cl)c(Cl)c1. 3-(3,4-Dichlorophenyl)-1,1-dimethylurea is used as a reagent to detect ferrocyanide formation in chloroplast-based assays, with 0.1 ml of 10 mM solution injected into each sample."
ferric nitrate,Ferric nitrate is included at 0.56 mM concentration in the developing solution for quantifying ferrocyanide formation in chloroplast assays.,Entity: ferric nitrate. SMILES: O=[N+]([O-])[O-].O=[N+]([O-])[O-].O=[N+]([O-])[O-].[Fe+3]. Ferric nitrate is included at 0.56 mM concentration in the developing solution for quantifying ferrocyanide formation in chloroplast assays.
valinomycin,Valinomycin is used at 0.2 µM concentration in chloroplast-based phosphorylation assays to influence membrane buffering.,Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin is used at 0.2 µM concentration in chloroplast-based phosphorylation assays to influence membrane buffering.
chlorophyll,Chlorophyll is present at 60 µg per 2 ml reaction mixture in chloroplast-based phosphorylation assays.,Entity: chlorophyll. SMILES: C=CC1=C(C)C2=NC1=CC1=NC(=Cc3[n-]c4c(c3C)=C([O-])C(C(=O)OC)C=4C3=NC(=C2)C(C)C3CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C(CC)=C1C.[Mg+2]. Chlorophyll is present at 60 µg per 2 ml reaction mixture in chloroplast-based phosphorylation assays.
KCI,KCl is used at 20 mM concentration in chloroplast-based phosphorylation assays to modulate membrane buffering.,Entity: KCI. SMILES: [Cl-].[K+]. KCl is used at 20 mM concentration in chloroplast-based phosphorylation assays to modulate membrane buffering.
ADP,ADP is included at 2 mM concentration in chloroplast-based phosphorylation assays.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP is included at 2 mM concentration in chloroplast-based phosphorylation assays.
N-(2-hydroxyethyl)ethylenediamine triacetic acid,N-(2-hydroxyethyl)ethylenediamine triacetic acid is used at 0.4 mM concentration in the developing solution for quantifying ferrocyanide in chloroplast assays.,Entity: N-(2-hydroxyethyl)ethylenediamine triacetic acid. SMILES: CC(=O)O.CC(=O)O.CC(=O)O.NCCNCCO. N-(2-hydroxyethyl)ethylenediamine triacetic acid is used at 0.4 mM concentration in the developing solution for quantifying ferrocyanide in chloroplast assays.
Valinomycin,Valinomycin is used in combination with K+ to study the effect of internal buffers on the lag in the initiation of phosphorylation in chloroplasts.,Entity: Valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin is used in combination with K+ to study the effect of internal buffers on the lag in the initiation of phosphorylation in chloroplasts.
Tris(hydroxymethyl) aminomethane,"Tris(hydroxymethyl) aminomethane acts as an uncoupler in chloroplasts, extending the lag in the initiation of phosphorylation and lowering both the efficiency and rate of steady-state phosphorylation.","Entity: Tris(hydroxymethyl) aminomethane. SMILES: NC(CO)(CO)CO. Tris(hydroxymethyl) aminomethane acts as an uncoupler in chloroplasts, extending the lag in the initiation of phosphorylation and lowering both the efficiency and rate of steady-state phosphorylation."
Tris(hydroxymethyl) aminomethane,"Tris(hydroxymethyl) aminomethane causes chloroplasts to swell in the dark, increasing the amount of Tris and phosphate inside the thylakoid.","Entity: Tris(hydroxymethyl) aminomethane. SMILES: NC(CO)(CO)CO. Tris(hydroxymethyl) aminomethane causes chloroplasts to swell in the dark, increasing the amount of Tris and phosphate inside the thylakoid."
Methylamine,"Methylamine, a basic amine that uncouples but does not buffer, extends the lag in the initiation of phosphorylation in chloroplasts in the presence of valinomycin and K+.","Entity: Methylamine. SMILES: CN. Methylamine, a basic amine that uncouples but does not buffer, extends the lag in the initiation of phosphorylation in chloroplasts in the presence of valinomycin and K+."
Carbonylcyanide phenylhydrazone,"Trace amounts of carbonylcyanide phenylhydrazone, an uncoupler, extend the lag in the initiation of phosphorylation in chloroplasts for very long periods.","Entity: Carbonylcyanide phenylhydrazone. SMILES: N#CC(C#N)=NNc1ccccc1. Trace amounts of carbonylcyanide phenylhydrazone, an uncoupler, extend the lag in the initiation of phosphorylation in chloroplasts for very long periods."
bicarbonate,Bicarbonate ions do not uncouple the electron transport chain.,Entity: bicarbonate. SMILES: O=C([O-])O. Bicarbonate ions do not uncouple the electron transport chain.
valinomycin,"In the presence of valinomycin and KCl, bicarbonate ions do not affect the delay in the initiation of phosphorylation in the thylakoid, with acidification delay remaining approximately 350 ms.","Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. In the presence of valinomycin and KCl, bicarbonate ions do not affect the delay in the initiation of phosphorylation in the thylakoid, with acidification delay remaining approximately 350 ms."
imidazole,The presence of imidazole delays acidification of the thylakoid inside by about 68 ms during electron transport.,Entity: imidazole. SMILES: c1c[nH]cn1. The presence of imidazole delays acidification of the thylakoid inside by about 68 ms during electron transport.
KCI,"In the presence of valinomycin and KCl, bicarbonate ions do not affect the delay in the initiation of phosphorylation in the thylakoid, with acidification delay remaining approximately 350 ms.","Entity: KCI. SMILES: [Cl-].[K+]. In the presence of valinomycin and KCl, bicarbonate ions do not affect the delay in the initiation of phosphorylation in the thylakoid, with acidification delay remaining approximately 350 ms."
chlorophyll,"The internal volume of the thylakoid lumen is approximately 21 ×l/mg chlorophyll, and an additional 38 nmol of hydrogen ions per mg chlorophyll are required to neutralize amine that enters the thylakoid in the dark.","Entity: chlorophyll. SMILES: C=CC1=C(C)C2=NC1=CC1=NC(=Cc3[n-]c4c(c3C)=C([O-])C(C(=O)OC)C=4C3=NC(=C2)C(C)C3CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C(CC)=C1C.[Mg+2]. The internal volume of the thylakoid lumen is approximately 21 ×l/mg chlorophyll, and an additional 38 nmol of hydrogen ions per mg chlorophyll are required to neutralize amine that enters the thylakoid in the dark."
imidazole,Imidazole acts as a weak uncoupler and inhibits steady-state photophosphorylation.,Entity: imidazole. SMILES: c1c[nH]cn1. Imidazole acts as a weak uncoupler and inhibits steady-state photophosphorylation.
imidazole,Imidazole buffers most effectively against changes in hydrogen ion concentration around pH 7.0.,Entity: imidazole. SMILES: c1c[nH]cn1. Imidazole buffers most effectively against changes in hydrogen ion concentration around pH 7.0.
KCl,KCl is used in combination with valinomycin to facilitate proton leak in studies of photophosphorylation.,Entity: KCl. SMILES: [Cl-].[K+]. KCl is used in combination with valinomycin to facilitate proton leak in studies of photophosphorylation.
valinomycin,Valinomycin is used with KCl to promote proton leak in experiments investigating photophosphorylation.,Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin is used with KCl to promote proton leak in experiments investigating photophosphorylation.
cresol red,Cresol red is a pH-indicating dye used to measure pH changes in thylakoid membranes.,Entity: cresol red. SMILES: Cc1cc(C2(c3ccc(O)c(C)c3)OS(=O)(=O)c3ccccc32)ccc1O. Cresol red is a pH-indicating dye used to measure pH changes in thylakoid membranes.
chlorophyll,"Chlorophyll concentration is used as a reference in thylakoid phosphorylation assays, with a value of mg chlorophyll-· specified in the experimental setup.","Entity: chlorophyll. SMILES: C=CC1=C(C)C2=NC1=CC1=NC(=Cc3[n-]c4c(c3C)=C([O-])C(C(=O)OC)C=4C3=NC(=C2)C(C)C3CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C(CC)=C1C.[Mg+2]. Chlorophyll concentration is used as a reference in thylakoid phosphorylation assays, with a value of mg chlorophyll-· specified in the experimental setup."
orthophosphate,Orthophosphate is used as a component of the internal buffer at 5 mM concentration in thylakoid phosphorylation assays.,Entity: orthophosphate. SMILES: O=P([O-])([O-])[O-]. Orthophosphate is used as a component of the internal buffer at 5 mM concentration in thylakoid phosphorylation assays.
pyridine,"Pyridine, when used as a permeant buffer during the light phase of chloroplast illumination, increases the ultimate ATP formation capacity even though it slows the development of phosphorylation capacity during preillumination.","Entity: pyridine. SMILES: c1ccncc1. Pyridine, when used as a permeant buffer during the light phase of chloroplast illumination, increases the ultimate ATP formation capacity even though it slows the development of phosphorylation capacity during preillumination."
imidazole,"Imidazole, when used as a permeant buffer during chloroplast illumination, slows the development of phosphorylation capacity during preillumination but increases the ultimate ATP formation capacity if illumination is sufficiently prolonged.","Entity: imidazole. SMILES: c1c[nH]cn1. Imidazole, when used as a permeant buffer during chloroplast illumination, slows the development of phosphorylation capacity during preillumination but increases the ultimate ATP formation capacity if illumination is sufficiently prolonged."
ATP,"ATP formation in chloroplasts can be stimulated by the addition of permeant buffers such as imidazole and pyridine, especially when illumination is prolonged.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP formation in chloroplasts can be stimulated by the addition of permeant buffers such as imidazole and pyridine, especially when illumination is prolonged."
ADP,Chloroplasts illuminated in the absence of ADP and phosphate develop the ability to produce ATP when transferred in the dark to a medium containing ADP and phosphate.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Chloroplasts illuminated in the absence of ADP and phosphate develop the ability to produce ATP when transferred in the dark to a medium containing ADP and phosphate.
phosphate,Chloroplasts illuminated in the absence of ADP and phosphate develop the ability to produce ATP when transferred in the dark to a medium containing ADP and phosphate.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Chloroplasts illuminated in the absence of ADP and phosphate develop the ability to produce ATP when transferred in the dark to a medium containing ADP and phosphate.
ATP,"In thylakoid phosphorylation, an H+ : ATP ratio of 2 is argued to be the case, indicating that two protons are used for each ATP molecule formed.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. In thylakoid phosphorylation, an H+ : ATP ratio of 2 is argued to be the case, indicating that two protons are used for each ATP molecule formed."
phosphate,Phosphate is used directly for phosphorylation in thylakoid vesicles in the presence of ADP and protons.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate is used directly for phosphorylation in thylakoid vesicles in the presence of ADP and protons.
ADP,ADP is required together with phosphate and protons for phosphorylation in thylakoid vesicles.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP is required together with phosphate and protons for phosphorylation in thylakoid vesicles.
sucrose,Sucrose was used at a concentration of 10% in the lower aqueous phase during chloroplast suspension assays.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose was used at a concentration of 10% in the lower aqueous phase during chloroplast suspension assays.
Triton X-100,Triton X-100 was included at approximately 1% in the lower aqueous phase of chloroplast suspension assays.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 was included at approximately 1% in the lower aqueous phase of chloroplast suspension assays.
sodium lauryl sulfate,Sodium lauryl sulfate was used at a concentration of 5 mM as a bleaching agent for 18–24 hours at 45°C in chloroplast suspension assays.,Entity: sodium lauryl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium lauryl sulfate was used at a concentration of 5 mM as a bleaching agent for 18–24 hours at 45°C in chloroplast suspension assays.
chlorophyll,"Approximately 10 s of chlorophyll molecules are required to drive phosphorylation in the photosynthetic electron transport system, as observed with gramicidin D uncoupling experiments.","Entity: chlorophyll. SMILES: C=CC1=C(C)C2=NC1=CC1=NC(=Cc3[n-]c4c(c3C)=C([O-])C(C(=O)OC)C=4C3=NC(=C2)C(C)C3CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C(CC)=C1C.[Mg+2]. Approximately 10 s of chlorophyll molecules are required to drive phosphorylation in the photosynthetic electron transport system, as observed with gramicidin D uncoupling experiments."
gramicidin D,"Gramicidin D acts as an ionophore that can uncouple phosphorylation in the photosynthetic electron transport system, with one molecule of gramicidin D being able to uncouple the phosphorylation driven by about 10 s chlorophyll molecules.","Entity: gramicidin D. SMILES: CC(C)C[C@@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCO)C(C)C)C(C)C)C(C)C. Gramicidin D acts as an ionophore that can uncouple phosphorylation in the photosynthetic electron transport system, with one molecule of gramicidin D being able to uncouple the phosphorylation driven by about 10 s chlorophyll molecules."
potassium chloride,Potassium chloride (KCl) is included at 15 mM concentration in phosphorylation reaction mixtures to study its effect on ATP formation.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride (KCl) is included at 15 mM concentration in phosphorylation reaction mixtures to study its effect on ATP formation.
adenosine diphosphate,Adenosine diphosphate (ADP) is used as a substrate in phosphorylation experiments in chloroplasts under controlled conditions.,Entity: adenosine diphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine diphosphate (ADP) is used as a substrate in phosphorylation experiments in chloroplasts under controlled conditions.
chlorophyll,Chlorophyll is present in chloroplasts at a concentration of 80 µg per 2 ml reaction mixture in phosphorylation assays.,Entity: chlorophyll. SMILES: C=CC1=C(C)C2=NC1=CC1=NC(=Cc3[n-]c4c(c3C)=C([O-])C(C(=O)OC)C=4C3=NC(=C2)C(C)C3CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C(CC)=C1C.[Mg+2]. Chlorophyll is present in chloroplasts at a concentration of 80 µg per 2 ml reaction mixture in phosphorylation assays.
sodium phosphate,Sodium phosphate (Na2H32PO4) is included at 0.75 mM concentration in phosphorylation reaction mixtures to provide internal phosphate buffering.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate (Na2H32PO4) is included at 0.75 mM concentration in phosphorylation reaction mixtures to provide internal phosphate buffering.
magnesium chloride,Magnesium chloride (MgCl2) is used at 2 mM concentration in phosphorylation reaction mixtures to facilitate electron transport.,Entity: magnesium chloride. SMILES: [Cl-].[Cl-].[Mg+2]. Magnesium chloride (MgCl2) is used at 2 mM concentration in phosphorylation reaction mixtures to facilitate electron transport.
valinomycin,Valinomycin is used at 2 µM concentration in phosphorylation experiments to aid in the transport of phosphate across thylakoid membranes.,Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin is used at 2 µM concentration in phosphorylation experiments to aid in the transport of phosphate across thylakoid membranes.
phosphate,Phosphate is present both inside and outside the thylakoid membrane in chloroplasts and is required for all phosphorylation experiments.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate is present both inside and outside the thylakoid membrane in chloroplasts and is required for all phosphorylation experiments.
bicarbonate,"Bicarbonate uptake by chloroplasts in the dark is highly variable and the computed internal concentration of bicarbonate inside chloroplasts is very close to, but slightly lower than, the concentration in the suspending medium.","Entity: bicarbonate. SMILES: O=C([O-])O. Bicarbonate uptake by chloroplasts in the dark is highly variable and the computed internal concentration of bicarbonate inside chloroplasts is very close to, but slightly lower than, the concentration in the suspending medium."
glucose,Plasma glucose decreases by 36 mg/liter per hour in blood from adults and 60 mg/liter per hour in blood from newborns when whole blood is kept at room temperature without preservative.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Plasma glucose decreases by 36 mg/liter per hour in blood from adults and 60 mg/liter per hour in blood from newborns when whole blood is kept at room temperature without preservative.
glucose,"Cooling blood samples on ice slows the rate of plasma glucose decrease to 3.9 mg/liter per hour in adults and 11 mg/liter per hour in newborns, effectively stabilizing plasma glucose for 4 hours.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Cooling blood samples on ice slows the rate of plasma glucose decrease to 3.9 mg/liter per hour in adults and 11 mg/liter per hour in newborns, effectively stabilizing plasma glucose for 4 hours."
calcium,Plasma calcium values are unaffected by cooling whole blood samples at room temperature or on ice.,Entity: calcium. SMILES: [Ca]. Plasma calcium values are unaffected by cooling whole blood samples at room temperature or on ice.
sodium,Plasma sodium values are unaffected by cooling whole blood samples at room temperature or on ice.,Entity: sodium. SMILES: [Na]. Plasma sodium values are unaffected by cooling whole blood samples at room temperature or on ice.
urea,Plasma urea values are unaffected by cooling whole blood samples at room temperature or on ice.,Entity: urea. SMILES: NC(N)=O. Plasma urea values are unaffected by cooling whole blood samples at room temperature or on ice.
chloride,Plasma chloride values are unaffected by cooling whole blood samples at room temperature or on ice.,Entity: chloride. SMILES: [Cl-]. Plasma chloride values are unaffected by cooling whole blood samples at room temperature or on ice.
L(+) -lactate,"L(+) -lactate is selectively oxidized by lactate dehydrogenase (EC 1.1.1.27) in the presence of NAD+ to form NADH, which can be spectrophotometrically measured.","Entity: L(+) -lactate. SMILES: C[C@H](O)C(=O)[O-]. L(+) -lactate is selectively oxidized by lactate dehydrogenase (EC 1.1.1.27) in the presence of NAD+ to form NADH, which can be spectrophotometrically measured."
lithium lactate,Aqueous lithium lactate standards are used to generate calibration curves for the spectrophotometric determination of L(+) -lactate concentrations in serum.,Entity: lithium lactate. SMILES: CC(O)C(=O)[O-].[Li+]. Aqueous lithium lactate standards are used to generate calibration curves for the spectrophotometric determination of L(+) -lactate concentrations in serum.
α-amanitin,Each of the three transcription waves required for herpes simplex virus replication is catalyzed by amanitin-sensitive RNA polymerase(s).,Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. Each of the three transcription waves required for herpes simplex virus replication is catalyzed by amanitin-sensitive RNA polymerase(s).
α-amanitin,α-amanitin is used to establish that a specific decrease in RNA polymerase B activity leads to impaired RNA synthesis in frog virus 3-infected cells.,Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. α-amanitin is used to establish that a specific decrease in RNA polymerase B activity leads to impaired RNA synthesis in frog virus 3-infected cells.
α-amanitin,"α-amanitin inhibits influenzavirus replication and transcription by acting as an inhibitor of cellular RNA polymerase B, a requirement for viral RNA synthesis.","Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. α-amanitin inhibits influenzavirus replication and transcription by acting as an inhibitor of cellular RNA polymerase B, a requirement for viral RNA synthesis."
α-amanitin,"In influenzavirus-infected wildtype CHO cells, α-amanitin impairs early transcription and blocks the switch to complementary RNA synthesis, indicating a role in regulating viral gene expression.","Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. In influenzavirus-infected wildtype CHO cells, α-amanitin impairs early transcription and blocks the switch to complementary RNA synthesis, indicating a role in regulating viral gene expression."
α-amanitin,"In mengovirus-infected cells, RNA polymerase B (sensitive to 10 μg/ml α-amanitin) shows decreased activity more rapidly than the α-amanitin-insensitive RNA polymerase, indicating that α-amanitin primarily inhibits RNA polymerase B activity.","Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. In mengovirus-infected cells, RNA polymerase B (sensitive to 10 μg/ml α-amanitin) shows decreased activity more rapidly than the α-amanitin-insensitive RNA polymerase, indicating that α-amanitin primarily inhibits RNA polymerase B activity."
amanitin,Amanitin is used as a tool to determine the number of RNA polymerase B molecules in virus-infected cells by direct titration with labeled amanitin.,Entity: amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)S(=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N2. Amanitin is used as a tool to determine the number of RNA polymerase B molecules in virus-infected cells by direct titration with labeled amanitin.
amanitins,Amanitins are used in virus research to enable the determination of the genetic source of viral RNA polymerase and to elucidate the mechanism of virus-induced shut-off of host RNA synthesis.,Entity: amanitins. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitins are used in virus research to enable the determination of the genetic source of viral RNA polymerase and to elucidate the mechanism of virus-induced shut-off of host RNA synthesis.
α-amanitin,c¢-amanitin inhibits the synthesis of Rous sarcoma virus I~NA in isolated nuclei by reducing it to less than 5% of control levels at a concentration of 0.01 αg/ml.,Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. c¢-amanitin inhibits the synthesis of Rous sarcoma virus I~NA in isolated nuclei by reducing it to less than 5% of control levels at a concentration of 0.01 αg/ml.
α-amanitin,c¢-amanitin inhibits the synthesis of avian myeloblastosis virus RNA in isolated nuclei.,Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. c¢-amanitin inhibits the synthesis of avian myeloblastosis virus RNA in isolated nuclei.
α-amanitin,"The cytoplasmic I~NA polymerase activity in cells infected by vaccinia virus is insensitive to α-amanitin, indicating it is not inhibited by this toxin.","Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. The cytoplasmic I~NA polymerase activity in cells infected by vaccinia virus is insensitive to α-amanitin, indicating it is not inhibited by this toxin."
O-methyl-y-amanitin,O-methyl-y-amanitin binds tightly to RNA polymerase B with a dissociation constant (Kd) ranging from 10^-10 to 10^-9 M at 4°C.,Entity: O-methyl-y-amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. O-methyl-y-amanitin binds tightly to RNA polymerase B with a dissociation constant (Kd) ranging from 10^-10 to 10^-9 M at 4°C.
amanitin,"Amanitin is a toxin that inhibits viral transcription by targeting RNA polymerase B, an enzyme that is generally considered amanitin-sensitive in most organisms.","Entity: amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin is a toxin that inhibits viral transcription by targeting RNA polymerase B, an enzyme that is generally considered amanitin-sensitive in most organisms."
amanitin,"Amanitin is a toxin with a free carboxylic group that, when used to pretreat cells with DEAE-dextran and glucose, causes approximately 70% inhibition of total RNA synthesis in HEp-2 and BHK cells within 2 hours.","Entity: amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin is a toxin with a free carboxylic group that, when used to pretreat cells with DEAE-dextran and glucose, causes approximately 70% inhibition of total RNA synthesis in HEp-2 and BHK cells within 2 hours."
α-amanitin,α-amanitin is used to inhibit RNA polymerase activity in both isolated nuclei and solubilized enzyme systems during studies of virus-induced inhibition of host cell RNA synthesis.,Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. α-amanitin is used to inhibit RNA polymerase activity in both isolated nuclei and solubilized enzyme systems during studies of virus-induced inhibition of host cell RNA synthesis.
α-amanitin,"Amanitin inhibits DNA transcription in isolated nuclei, with an effective concentration of approximately 0.9 αg/ml for simian virus 40.","Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. Amanitin inhibits DNA transcription in isolated nuclei, with an effective concentration of approximately 0.9 αg/ml for simian virus 40."
amanitin,"Amanitin inhibits RNA synthesis in cultured cells only several hours after addition to the culture medium, in contrast to hepatocytes and kidney cells where inhibition starts more rapidly after toxin exposure.","Entity: amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. Amanitin inhibits RNA synthesis in cultured cells only several hours after addition to the culture medium, in contrast to hepatocytes and kidney cells where inhibition starts more rapidly after toxin exposure."
amanitin,Amanitin inhibits RNA polymerase B in nuclei isolated from both cultured cells and hepatocytes.,Entity: amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. Amanitin inhibits RNA polymerase B in nuclei isolated from both cultured cells and hepatocytes.
amanitin,"The toxicity of amanitin for highly pinocytosing cells such as mouse peritoneal macrophages increases several times when the toxin is conjugated to albumin, forcing entry via pinocytosis.","Entity: amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. The toxicity of amanitin for highly pinocytosing cells such as mouse peritoneal macrophages increases several times when the toxin is conjugated to albumin, forcing entry via pinocytosis."
α-amanitin,"In chick embryo fibroblasts, α-amanitin at 3 µg/ml causes nearly 50% inhibition of total RNA synthesis in 20 hours, while at 50 µg/ml it achieves the same inhibition in 6 hours.","Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. In chick embryo fibroblasts, α-amanitin at 3 µg/ml causes nearly 50% inhibition of total RNA synthesis in 20 hours, while at 50 µg/ml it achieves the same inhibition in 6 hours."
amanitin,Amanitin is used as a radioactive label to quantify the number of gNA polymerase B molecules in frog virus 3-infected cells by binding assays.,Entity: amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin is used as a radioactive label to quantify the number of gNA polymerase B molecules in frog virus 3-infected cells by binding assays.
amphotericin B,Amphotericin B is a potyene antifungal agent that creates holes in plasma membranes.,Entity: amphotericin B. SMILES: C[C@@H]1[C@H](O)[C@@H](C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@H]1C)C[C@H](O)[C@H]2C(=O)O. Amphotericin B is a potyene antifungal agent that creates holes in plasma membranes.
amphotericin B,Amphotericin B at a concentration of 2 µg/ml inhibits total RNA synthesis by 70% in HEp-2 cells after 6 hours.,Entity: amphotericin B. SMILES: C[C@@H]1[C@H](O)[C@@H](C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@H]1C)C[C@H](O)[C@H]2C(=O)O. Amphotericin B at a concentration of 2 µg/ml inhibits total RNA synthesis by 70% in HEp-2 cells after 6 hours.
amanullin,Amanullin is a chemically modified amanitin that inhibits solubilized tRNA polymerase B and reduces in vitro synthesized I~NA synthesis more rapidly than amanitin in cultured cells.,Entity: amanullin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)CC)C(=O)N2. Amanullin is a chemically modified amanitin that inhibits solubilized tRNA polymerase B and reduces in vitro synthesized I~NA synthesis more rapidly than amanitin in cultured cells.
amanitin,Amanitin is a naturally occurring compound that inhibits solubilized tRNA polymerase B and reduces in vitro synthesized I~NA synthesis.,Entity: amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin is a naturally occurring compound that inhibits solubilized tRNA polymerase B and reduces in vitro synthesized I~NA synthesis.
amanitin,Amanitin is a toxin that is used mainly in cell-free systems due to its slow penetration into in vitro cultured cells.,Entity: amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin is a toxin that is used mainly in cell-free systems due to its slow penetration into in vitro cultured cells.
amanitin,The penetration of amanitin into cultured cells can be accelerated by using derivatives of the toxin or by pretreatment with DEAE-dextran.,Entity: amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. The penetration of amanitin into cultured cells can be accelerated by using derivatives of the toxin or by pretreatment with DEAE-dextran.
amanitin,"Amanitin is a toxin that inhibits host RNA polymerase but does not affect viral RNA polymerase, allowing its selective toxicity in cells with amanitin-resistant RNA polymerase.","Entity: amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin is a toxin that inhibits host RNA polymerase but does not affect viral RNA polymerase, allowing its selective toxicity in cells with amanitin-resistant RNA polymerase."
amanitin,"Amanitin is a toxin that inhibits viral transcription, with the general assumption that this inhibition is mediated by host RNA polymerase B.","Entity: amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin is a toxin that inhibits viral transcription, with the general assumption that this inhibition is mediated by host RNA polymerase B."
α-amanitin,"Amanitin is a toxin that inhibits eukaryotic RNA polymerases, with class A (RNA polymerase I) enzymes not being inhibited, class B (RNA polymerase II) enzymes being inhibited at concentrations of 10⁻⁹ to 10⁻⁸ α-amanitin, and class C (RNA polymerase III) enzymes being inhibited at concentrations of 10⁻⁵ to 10⁻⁴ M.","Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. Amanitin is a toxin that inhibits eukaryotic RNA polymerases, with class A (RNA polymerase I) enzymes not being inhibited, class B (RNA polymerase II) enzymes being inhibited at concentrations of 10⁻⁹ to 10⁻⁸ α-amanitin, and class C (RNA polymerase III) enzymes being inhibited at concentrations of 10⁻⁵ to 10⁻⁴ M."
e-amanitin,"e-amanitin inhibits influenzavirus replication, but not influenzavirus in vitro transcription mediated by the virion-associated gag-dependent RNA polymerase.","Entity: e-amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. e-amanitin inhibits influenzavirus replication, but not influenzavirus in vitro transcription mediated by the virion-associated gag-dependent RNA polymerase."
amanitin,Amanitin inhibits RNA polymerase C activity in isolated nuclei at concentrations ranging from 10 to 200 µg/ml.,Entity: amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin inhibits RNA polymerase C activity in isolated nuclei at concentrations ranging from 10 to 200 µg/ml.
α-amanitin,A transcription complex from adenovirus-infected cell nuclei contains adenovirus DNA and an RNA polymerase activity sensitive to 0.1 µg/µl α-amanitin.,Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. A transcription complex from adenovirus-infected cell nuclei contains adenovirus DNA and an RNA polymerase activity sensitive to 0.1 µg/µl α-amanitin.
α-amanitin,Virus-associated 5.5 S RNA synthesized in isolated nuclei by a polymerase resistant to 0.4 µg/µl α-amanitin but inhibited by 200 µg/µl α-amanitin is classified as t~NA polymerase C.,Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. Virus-associated 5.5 S RNA synthesized in isolated nuclei by a polymerase resistant to 0.4 µg/µl α-amanitin but inhibited by 200 µg/µl α-amanitin is classified as t~NA polymerase C.
ammonium sulfate,Ammonium sulfate stimulates the sensitivity of host RNA polymerase B to α-amanitin during adenovirus RNA synthesis in isolated nuclei.,Entity: ammonium sulfate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Ammonium sulfate stimulates the sensitivity of host RNA polymerase B to α-amanitin during adenovirus RNA synthesis in isolated nuclei.
α-amanitin,"-α-amanitin inhibits adenovirus RNA synthesis, with inhibition curves for gNA synthesized by adenovirus-infected cell nuclei showing inflection points at about 0.02 µg/µl and 20 µg/µl, indicating involvement of both RNA polymerases B and C in viral transcription.","Entity: α-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. -α-amanitin inhibits adenovirus RNA synthesis, with inhibition curves for gNA synthesized by adenovirus-infected cell nuclei showing inflection points at about 0.02 µg/µl and 20 µg/µl, indicating involvement of both RNA polymerases B and C in viral transcription."
amanitin,"Amanitin inhibits the three herpesvirus DNA transcription waves responsible for the synthesis of c-, ~-, and T-polypeptides, indicating that it targets herpesvirus DNA-dependent RNA polymerase(s) required for viral genome transcription.","Entity: amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin inhibits the three herpesvirus DNA transcription waves responsible for the synthesis of c-, ~-, and T-polypeptides, indicating that it targets herpesvirus DNA-dependent RNA polymerase(s) required for viral genome transcription."
maltotriose,"The apparent dissociation constant (K) for maltotriose as a substrate of purified human pancreatic, salivary, and tumor-extracted amylases ranges from 48.0 to 67.0, with tumor-extracted amylase showing the lowest K value (0.58) and purified pancreatic amylase the highest (67.0), when measured in the concentration range of 1.0 to 100 g/l.","Entity: maltotriose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O[C@H]1O[C@H](CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO. The apparent dissociation constant (K) for maltotriose as a substrate of purified human pancreatic, salivary, and tumor-extracted amylases ranges from 48.0 to 67.0, with tumor-extracted amylase showing the lowest K value (0.58) and purified pancreatic amylase the highest (67.0), when measured in the concentration range of 1.0 to 100 g/l."
maltotriose,Purified human salivary and pancreatic amylases digest maltotriose very slowly and have a weak affinity for this substrate.,Entity: maltotriose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O[C@H]1O[C@H](CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO. Purified human salivary and pancreatic amylases digest maltotriose very slowly and have a weak affinity for this substrate.
maltose,"Maltose is an end product of amylase digestion of soluble starch by both pancreatic and salivary amylases, and of maltotriose by pancreatic and salivary amylases.","Entity: maltose. SMILES: OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O. Maltose is an end product of amylase digestion of soluble starch by both pancreatic and salivary amylases, and of maltotriose by pancreatic and salivary amylases."
maltotriose,"Maltotriose is completely digested by pancreatic and salivary amylases to glucose and maltose, but not by purified tumor-extracted amylase.","Entity: maltotriose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O[C@H]1O[C@H](CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO. Maltotriose is completely digested by pancreatic and salivary amylases to glucose and maltose, but not by purified tumor-extracted amylase."
calcium,Calcium is included at 2 mM concentration in the buffered substrate for amylase digestion assays.,Entity: calcium. SMILES: [Ca]. Calcium is included at 2 mM concentration in the buffered substrate for amylase digestion assays.
glucose,"Glucose is an end product of amylase digestion of soluble starch by both pancreatic and salivary amylases, and of maltotriose by pancreatic and salivary amylases.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is an end product of amylase digestion of soluble starch by both pancreatic and salivary amylases, and of maltotriose by pancreatic and salivary amylases."
chloride,Chloride ions are included at 50 mM concentration in the buffered substrate for amylase digestion assays.,Entity: chloride. SMILES: [Cl-]. Chloride ions are included at 50 mM concentration in the buffered substrate for amylase digestion assays.
maltotriose,Maltotriose has no affinity for amylase extracted from lung carcinoma and is not digested to maltose and glucose by this enzyme.,Entity: maltotriose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O[C@H]1O[C@H](CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO. Maltotriose has no affinity for amylase extracted from lung carcinoma and is not digested to maltose and glucose by this enzyme.
maltotriose,Maltotriose is a trisaccharide that can be digested by human pancreatic and salivary amylases to yield maltose and glucose.,Entity: maltotriose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O[C@H]1O[C@H](CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO. Maltotriose is a trisaccharide that can be digested by human pancreatic and salivary amylases to yield maltose and glucose.
maltotriose,"The dissociation constants of human pancreatic and salivary amylases for maltotriose digestion are 48.0 g/l and 67.0 g/l, respectively.","Entity: maltotriose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O[C@H]1O[C@H](CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO. The dissociation constants of human pancreatic and salivary amylases for maltotriose digestion are 48.0 g/l and 67.0 g/l, respectively."
creatinine,Creatinine does not inhibit parathyroid extract-induced bone resorption in the tested assay.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine does not inhibit parathyroid extract-induced bone resorption in the tested assay.
3-methylhistidine,"3-methylhistidine inhibits parathyroid extract-induced bone resorption, as measured by 45Ca release assays.","Entity: 3-methylhistidine. SMILES: Cn1cncc1C[C@H](N)C(=O)O. 3-methylhistidine inhibits parathyroid extract-induced bone resorption, as measured by 45Ca release assays."
hippuric acid,"Hippuric acid inhibits parathyroid extract-induced bone resorption, as shown by reduced 45Ca release in the assay.","Entity: hippuric acid. SMILES: O=C(O)CNC(=O)c1ccccc1. Hippuric acid inhibits parathyroid extract-induced bone resorption, as shown by reduced 45Ca release in the assay."
methylguanidine,"Methylguanidine inhibits parathyroid extract-induced bone resorption, as indicated by decreased 45Ca release in the assay.","Entity: methylguanidine. SMILES: CNC(=N)N. Methylguanidine inhibits parathyroid extract-induced bone resorption, as indicated by decreased 45Ca release in the assay."
phosphate,"Phosphate inhibits parathyroid extract-induced bone resorption, as evidenced by reduced 45Ca release in the assay.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate inhibits parathyroid extract-induced bone resorption, as evidenced by reduced 45Ca release in the assay."
p-hydroxybenzoic acid,"p-hydroxybenzoic acid inhibits parathyroid extract-induced bone resorption, as shown by decreased 45Ca release in the assay.","Entity: p-hydroxybenzoic acid. SMILES: O=C(O)c1ccc(O)cc1. p-hydroxybenzoic acid inhibits parathyroid extract-induced bone resorption, as shown by decreased 45Ca release in the assay."
3-methoxy-4-hydroxycinnamic acid,"3-methoxy-4-hydroxycinnamic acid inhibits parathyroid extract-induced bone resorption, as indicated by reduced 45Ca release in the assay.","Entity: 3-methoxy-4-hydroxycinnamic acid. SMILES: COc1cc(C=CC(=O)O)ccc1O. 3-methoxy-4-hydroxycinnamic acid inhibits parathyroid extract-induced bone resorption, as indicated by reduced 45Ca release in the assay."
p-hydroxybenzoic acid,p-hydroxybenzoic acid inhibits bone resorption induced by parathyroid extract at a concentration of 20 mg per 100 ml in vitro.,Entity: p-hydroxybenzoic acid. SMILES: O=C(O)c1ccc(O)cc1. p-hydroxybenzoic acid inhibits bone resorption induced by parathyroid extract at a concentration of 20 mg per 100 ml in vitro.
p-hydroxybenzoic acid,p-hydroxybenzoic acid is a phenolic acid known to act as an enzyme inhibitor in brain tissue using an in vitro system.,Entity: p-hydroxybenzoic acid. SMILES: O=C(O)c1ccc(O)cc1. p-hydroxybenzoic acid is a phenolic acid known to act as an enzyme inhibitor in brain tissue using an in vitro system.
3-methylhistidine,3-methylhistidine inhibits bone resorption induced by parathyroid extract in vitro.,Entity: 3-methylhistidine. SMILES: Cn1cncc1C[C@H](N)C(=O)O. 3-methylhistidine inhibits bone resorption induced by parathyroid extract in vitro.
3-methoxy-4-hydroxycinnamic acid,3-methoxy-4-hydroxycinnamic acid inhibits bone resorption induced by parathyroid extract at a concentration of 20 mg per 100 ml in vitro.,Entity: 3-methoxy-4-hydroxycinnamic acid. SMILES: COc1cc(C=CC(=O)O)ccc1O. 3-methoxy-4-hydroxycinnamic acid inhibits bone resorption induced by parathyroid extract at a concentration of 20 mg per 100 ml in vitro.
3-methoxy-4-hydroxycinnamic acid,3-methoxy-4-hydroxycinnamic acid is a phenolic acid known to act as an enzyme inhibitor in brain tissue using an in vitro system.,Entity: 3-methoxy-4-hydroxycinnamic acid. SMILES: COc1cc(C=CC(=O)O)ccc1O. 3-methoxy-4-hydroxycinnamic acid is a phenolic acid known to act as an enzyme inhibitor in brain tissue using an in vitro system.
hippuric acid,Hippuric acid inhibits bone resorption induced by parathyroid extract in vitro.,Entity: hippuric acid. SMILES: O=C(O)CNC(=O)c1ccccc1. Hippuric acid inhibits bone resorption induced by parathyroid extract in vitro.
methylguanidine,Methylguanidine inhibits bone resorption induced by parathyroid extract in vitro.,Entity: methylguanidine. SMILES: CNC(=N)N. Methylguanidine inhibits bone resorption induced by parathyroid extract in vitro.
HVA,"HVA can be detected and quantified in metabolite monitoring using OV-17 mass spectrometry, with its detection possible in combination with DOPAC-DHPPA or DOPAC-VMA.","Entity: HVA. SMILES: COc1cc(CC(=O)O)ccc1O. HVA can be detected and quantified in metabolite monitoring using OV-17 mass spectrometry, with its detection possible in combination with DOPAC-DHPPA or DOPAC-VMA."
DHPPA,"DHPPA can be detected and quantified in metabolite monitoring using OV-17 mass spectrometry, with its detection possible in combination with DOPAC-DHPPA or DOPAC-VMA.","Entity: DHPPA. SMILES: CC(C(=O)O)c1ccc(O)c(O)c1. DHPPA can be detected and quantified in metabolite monitoring using OV-17 mass spectrometry, with its detection possible in combination with DOPAC-DHPPA or DOPAC-VMA."
DOPAC,"DOPAC can be detected and quantified in metabolite monitoring using OV-17 mass spectrometry, with its detection possible in combination with DOPAC-DHPPA or DOPAC-VMA.","Entity: DOPAC. SMILES: O=C(O)Cc1ccc(O)c(O)c1. DOPAC can be detected and quantified in metabolite monitoring using OV-17 mass spectrometry, with its detection possible in combination with DOPAC-DHPPA or DOPAC-VMA."
VMA,"VMA can be detected and quantified in metabolite monitoring using OV-17 mass spectrometry, with its detection possible in combination with DOPAC-VMA or DOPAC-DHPPA.","Entity: VMA. SMILES: COc1cc(C(O)C(=O)O)ccc1O. VMA can be detected and quantified in metabolite monitoring using OV-17 mass spectrometry, with its detection possible in combination with DOPAC-VMA or DOPAC-DHPPA."
"3,4-dihydroxyphenylpropionic acid","3,4-dihydroxyphenylpropionic acid is used as an internal standard in urine sample preparation, added to urine at a concentration of 616 ng/ml.","Entity: 3,4-dihydroxyphenylpropionic acid. SMILES: CC(C(=O)O)c1ccc(O)c(O)c1. 3,4-dihydroxyphenylpropionic acid is used as an internal standard in urine sample preparation, added to urine at a concentration of 616 ng/ml."
ethyl acetate,"Ethyl acetate, in chromatographic grade, is used as an extraction solvent for isolating analytes from urine samples.","Entity: ethyl acetate. SMILES: CCOC(C)=O. Ethyl acetate, in chromatographic grade, is used as an extraction solvent for isolating analytes from urine samples."
DOPAC,"DOPAC (3,4-dihydroxyphenylacetic acid) can be quantitatively measured in urine samples using 3,4-dihydroxyphenylpropionic acid (DHPPA) as an internal standard.","Entity: DOPAC. SMILES: O=C(O)Cc1ccc(O)c(O)c1. DOPAC (3,4-dihydroxyphenylacetic acid) can be quantitatively measured in urine samples using 3,4-dihydroxyphenylpropionic acid (DHPPA) as an internal standard."
HVA,"HVA (homovanillic acid) can be quantitatively measured in urine samples using 3,4-dihydroxyphenylpropionic acid (DHPPA) as an internal standard.","Entity: HVA. SMILES: COc1cc(CC(=O)O)ccc1O. HVA (homovanillic acid) can be quantitatively measured in urine samples using 3,4-dihydroxyphenylpropionic acid (DHPPA) as an internal standard."
vanillylmandelic acid,Vanillylmandelic acid (VMA) can be simultaneously analyzed in urine samples using a single ion monitoring method.,Entity: vanillylmandelic acid. SMILES: COc1cc(C(O)C(=O)O)ccc1O. Vanillylmandelic acid (VMA) can be simultaneously analyzed in urine samples using a single ion monitoring method.
"3,4-dihydroxyphenylpropionic acid","3,4-dihydroxyphenylpropionic acid (DHPPA) is used as an internal standard for quantitative analysis of DOPAC and HVA in urine samples.","Entity: 3,4-dihydroxyphenylpropionic acid. SMILES: CC(C(=O)O)c1ccc(O)c(O)c1. 3,4-dihydroxyphenylpropionic acid (DHPPA) is used as an internal standard for quantitative analysis of DOPAC and HVA in urine samples."
DOPAC,"For monitoring DOPAC, the most convenient m/e values to use are 415 and 474, as they are more distinct from background peaks than m/e 252.","Entity: DOPAC. SMILES: O=C(O)Cc1ccc(O)c(O)c1. For monitoring DOPAC, the most convenient m/e values to use are 415 and 474, as they are more distinct from background peaks than m/e 252."
HVA,"For monitoring HVA, the most convenient m/e values to use are 342 and 283, as they are more distinct from background peaks than m/e 255.","Entity: HVA. SMILES: COc1cc(CC(=O)O)ccc1O. For monitoring HVA, the most convenient m/e values to use are 342 and 283, as they are more distinct from background peaks than m/e 255."
VMA,"For monitoring VMA, the most convenient m/e values to use are 417 and 504, as they are more distinct from background peaks than m/e 415 and 503.","Entity: VMA. SMILES: COc1cc(C(O)C(=O)O)ccc1O. For monitoring VMA, the most convenient m/e values to use are 417 and 504, as they are more distinct from background peaks than m/e 415 and 503."
Ethyl acetate,"Ethyl acetate is used as a solvent in the extraction procedure for urinary metabolites, and elimination of water dissolved in ethyl acetate during extraction is important for maintaining method reproducibility.","Entity: Ethyl acetate. SMILES: CCOC(C)=O. Ethyl acetate is used as a solvent in the extraction procedure for urinary metabolites, and elimination of water dissolved in ethyl acetate during extraction is important for maintaining method reproducibility."
Dihydroxyphenylacetic acid,Dihydroxyphenylacetic acid (DOPAC) is a urinary metabolite whose concentration falls within the physiological range and for which the method shows higher reproducibility (o = 6%) compared to Homovanillic acid (a = 8.6%) when analyzing urine samples.,Entity: Dihydroxyphenylacetic acid. SMILES: O=C(O)C(O)(O)c1ccccc1. Dihydroxyphenylacetic acid (DOPAC) is a urinary metabolite whose concentration falls within the physiological range and for which the method shows higher reproducibility (o = 6%) compared to Homovanillic acid (a = 8.6%) when analyzing urine samples.
aminoglutethimide,"During aminoglutethimide treatment, the adrenal gland may directly convert cholesterol to 17,20-dihydroxycholesterol as an intermediate in the pathway to DHA, rather than via pregnenolone.","Entity: aminoglutethimide. SMILES: CCC1(c2ccc(N)cc2)CCC(=O)NC1=O. During aminoglutethimide treatment, the adrenal gland may directly convert cholesterol to 17,20-dihydroxycholesterol as an intermediate in the pathway to DHA, rather than via pregnenolone."
prednisolone,Prednisolone is used in combination with aminoglutethimide to maintain adrenal suppression in patients with certain conditions.,Entity: prednisolone. SMILES: C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO. Prednisolone is used in combination with aminoglutethimide to maintain adrenal suppression in patients with certain conditions.
testosterone,"Urinary testosterone levels may rise during aminoglutethimide treatment, particularly when adrenal suppression is inadequate.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Urinary testosterone levels may rise during aminoglutethimide treatment, particularly when adrenal suppression is inadequate."
"20,22-dihydroxycholesterol","20,22-dihydroxycholesterol is an intermediate compound synthesized in the adrenal gland during aminoglutethimide blockade, and its urinary excretion may increase during the night when aminoglutethimide effects are withdrawn.","Entity: 20,22-dihydroxycholesterol. SMILES: CC(C)CCC(O)[C@](C)(O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C. 20,22-dihydroxycholesterol is an intermediate compound synthesized in the adrenal gland during aminoglutethimide blockade, and its urinary excretion may increase during the night when aminoglutethimide effects are withdrawn."
cholesterol,"Cholesterol serves as the precursor for dehydroepiandrosterone (DHA) synthesis in the adrenal gland, a pathway that can be directly converted to 17,20-dihydroxycholesterol during aminoglutethimide treatment.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol serves as the precursor for dehydroepiandrosterone (DHA) synthesis in the adrenal gland, a pathway that can be directly converted to 17,20-dihydroxycholesterol during aminoglutethimide treatment."
pregnenolone,Pregnenolone is an intermediate in the normal pathway from cholesterol to dehydroepiandrosterone (DHA) in the adrenal gland.,Entity: pregnenolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Pregnenolone is an intermediate in the normal pathway from cholesterol to dehydroepiandrosterone (DHA) in the adrenal gland.
"17,20-dihydroxycholesterol","17,20-dihydroxycholesterol is an intermediate formed directly from cholesterol by the adrenal gland during aminoglutethimide blockade, and its urinary excretion increases during the night when aminoglutethimide effects are withdrawn.","Entity: 17,20-dihydroxycholesterol. SMILES: CC(C)CCC[C@](C)(O)[C@@]1(O)CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C. 17,20-dihydroxycholesterol is an intermediate formed directly from cholesterol by the adrenal gland during aminoglutethimide blockade, and its urinary excretion increases during the night when aminoglutethimide effects are withdrawn."
aminoglutethimide,Aminoglutethimide blocks adrenal steroidogenesis by inhibiting the conversion of cholesterol to dehydroepiandrosterone (DHA) in the adrenal gland.,Entity: aminoglutethimide. SMILES: CCC1(c2ccc(N)cc2)CCC(=O)NC1=O. Aminoglutethimide blocks adrenal steroidogenesis by inhibiting the conversion of cholesterol to dehydroepiandrosterone (DHA) in the adrenal gland.
aminoglutethimide,Aminoglutethimide inhibits steroidogenesis less than prednisolone in patients with congenital adrenal hyperplasia due to C21-hydroxylase defect.,Entity: aminoglutethimide. SMILES: CCC1(c2ccc(N)cc2)CCC(=O)NC1=O. Aminoglutethimide inhibits steroidogenesis less than prednisolone in patients with congenital adrenal hyperplasia due to C21-hydroxylase defect.
aminoglutethimide,"Aminoglutethimide may inhibit 11 beta-hydroxylase activity, particularly for pregnenes.","Entity: aminoglutethimide. SMILES: CCC1(c2ccc(N)cc2)CCC(=O)NC1=O. Aminoglutethimide may inhibit 11 beta-hydroxylase activity, particularly for pregnenes."
aminoglutethimide,"Long-term aminoglutethimide therapy may promote a pathway from cholesterol via 17 alpha, 20 alpha-dihydroxycholesterol to dehydroepiandrosterone.","Entity: aminoglutethimide. SMILES: CCC1(c2ccc(N)cc2)CCC(=O)NC1=O. Long-term aminoglutethimide therapy may promote a pathway from cholesterol via 17 alpha, 20 alpha-dihydroxycholesterol to dehydroepiandrosterone."
aminoglutethimide,The metabolic breakdown of testosterone may be delayed by aminoglutethimide treatment.,Entity: aminoglutethimide. SMILES: CCC1(c2ccc(N)cc2)CCC(=O)NC1=O. The metabolic breakdown of testosterone may be delayed by aminoglutethimide treatment.
pregnanetriol,Urinary pregnanetriol levels can be normal in patients with congenital adrenal hyperplasia due to C21-hydroxylase defect despite low total 17-hydroxy-corticosteroids.,Entity: pregnanetriol. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4CCCC[C@@]43C)[C@@H]1CC[C@@H]2CC(O)(O)O. Urinary pregnanetriol levels can be normal in patients with congenital adrenal hyperplasia due to C21-hydroxylase defect despite low total 17-hydroxy-corticosteroids.
cholesterol,"Cholesterol serves as a precursor in the adrenal metabolic pathway, potentially leading to 17 alpha, 20 alpha-dihydroxycholesterol and dehydroepiandrosterone after long-term aminoglutethimide therapy.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol serves as a precursor in the adrenal metabolic pathway, potentially leading to 17 alpha, 20 alpha-dihydroxycholesterol and dehydroepiandrosterone after long-term aminoglutethimide therapy."
testosterone,"Urinary testosterone levels were present in excess amounts in all three cases, indicating inadequate adrenal suppression.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Urinary testosterone levels were present in excess amounts in all three cases, indicating inadequate adrenal suppression."
cholesterol,"Cholesterol can be metabolized via alternative pathways involving 20a-hydroxy-cholesterol, 17a,20a-dihydroxycholesterol, or other intermediates with subsequent side-chain cleavage to produce dehydrotestosterone (DHA).","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol can be metabolized via alternative pathways involving 20a-hydroxy-cholesterol, 17a,20a-dihydroxycholesterol, or other intermediates with subsequent side-chain cleavage to produce dehydrotestosterone (DHA)."
pregnanetriolone,Urinary pregnanetriolone values were abnormally high in two 9-year-old girls despite combined adrenocortical suppression and steroidogenic blockade.,Entity: pregnanetriolone. SMILES: C[C@H](O)[C@@]1(O)CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C. Urinary pregnanetriolone values were abnormally high in two 9-year-old girls despite combined adrenocortical suppression and steroidogenic blockade.
androsterone,"Urinary androsterone levels were increased in Case 2, a patient with inadequate adrenal suppression and steroidogenic blockade.","Entity: androsterone. SMILES: C[C@]12CC[C@@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. Urinary androsterone levels were increased in Case 2, a patient with inadequate adrenal suppression and steroidogenic blockade."
pregnenolone,"Pregnenolone can be metabolized via the progesterone pathway to produce pre~anetriol, potentially contributing to increased urinary pregnanetriol levels in cases with inadequate suppression.","Entity: pregnenolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Pregnenolone can be metabolized via the progesterone pathway to produce pre~anetriol, potentially contributing to increased urinary pregnanetriol levels in cases with inadequate suppression."
progesterone,"Progesterone is a downstream metabolite in the progesterone pathway originating from cholesterol, and its elaboration can contribute to increased urinary pregnanetriol levels.","Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone is a downstream metabolite in the progesterone pathway originating from cholesterol, and its elaboration can contribute to increased urinary pregnanetriol levels."
prednisolone,Prednisolone alone provides more effective adrenal suppression than AG in maintaining normal urinary steroid excretion in the described patient population.,Entity: prednisolone. SMILES: C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO. Prednisolone alone provides more effective adrenal suppression than AG in maintaining normal urinary steroid excretion in the described patient population.
pregnanetriol,"Urinary pregnanetriol values were low in three younger children and in Cases 3, 4, and 5, but abnormally high in two 9-year-old girls despite combined therapy.","Entity: pregnanetriol. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4CCCC[C@@]43C)[C@@H]1CC[C@@H]2CC(O)(O)O. Urinary pregnanetriol values were low in three younger children and in Cases 3, 4, and 5, but abnormally high in two 9-year-old girls despite combined therapy."
"17a,20a-dihydroxycholesterol","17a,20a-dihydroxycholesterol is a potential intermediate in alternative cholesterol metabolic pathways that can lead to the formation of dehydrotestosterone (DHA).","Entity: 17a,20a-dihydroxycholesterol. SMILES: CC(C)CCC[C@@](C)(O)[C@@]1(O)CCC2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)C3CC[C@@]21C. 17a,20a-dihydroxycholesterol is a potential intermediate in alternative cholesterol metabolic pathways that can lead to the formation of dehydrotestosterone (DHA)."
androstenedione,"Urinary androstenedione levels were increased in Case 2, a patient with inadequate adrenal suppression and steroidogenic blockade.","Entity: androstenedione. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. Urinary androstenedione levels were increased in Case 2, a patient with inadequate adrenal suppression and steroidogenic blockade."
androsterone,"In patients treated with AG for more than 3 years, urinary excretion of androsterone was increased in some cases and within the normal range in others, indicating altered metabolism of testosterone.","Entity: androsterone. SMILES: C[C@]12CC[C@@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. In patients treated with AG for more than 3 years, urinary excretion of androsterone was increased in some cases and within the normal range in others, indicating altered metabolism of testosterone."
DHA,"Urinary excretion of DHA was increased in patients treated with AG for more than 3 years, suggesting a metabolic effect of AG.","Entity: DHA. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)O. Urinary excretion of DHA was increased in patients treated with AG for more than 3 years, suggesting a metabolic effect of AG."
testosterone,"Urinary excretion of testosterone was increased in patients treated with AG for more than 3 years, indicating altered metabolism of testosterone.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Urinary excretion of testosterone was increased in patients treated with AG for more than 3 years, indicating altered metabolism of testosterone."
testosterone,"Testosterone exhibits high urinary values in certain patients, attributed to its formation from DHA, which is derived from 17,20-dihydroxycholesterol.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone exhibits high urinary values in certain patients, attributed to its formation from DHA, which is derived from 17,20-dihydroxycholesterol."
androstenedione,"Androstenedione is suggested to be formed immediately from DHA, which is derived from 17,20-dihydroxycholesterol.","Entity: androstenedione. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. Androstenedione is suggested to be formed immediately from DHA, which is derived from 17,20-dihydroxycholesterol."
aminoglutethimide,Aminoglutethimide inhibits adrenal 11/3-hydroxylase in addition to its action on the desmolase complex.,Entity: aminoglutethimide. SMILES: CCC1(c2ccc(N)cc2)CCC(=O)NC1=O. Aminoglutethimide inhibits adrenal 11/3-hydroxylase in addition to its action on the desmolase complex.
pregnanetriol,"Pregnanetriol is present at low levels in the urine of patients with high urinary values of active androgens, indicating it is not an intermediate C21-compound in this context.","Entity: pregnanetriol. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4CCCC[C@@]43C)[C@@H]1CC[C@@H]2CC(O)(O)O. Pregnanetriol is present at low levels in the urine of patients with high urinary values of active androgens, indicating it is not an intermediate C21-compound in this context."
DHA,"DHA, formed directly from 17,20-dihydroxycholesterol, is suggested to be the immediate precursor for androstenedione, testosterone, and their metabolites.","Entity: DHA. SMILES: CC(C)CCC[C@](C)(O)[C@@]1(O)CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C. DHA, formed directly from 17,20-dihydroxycholesterol, is suggested to be the immediate precursor for androstenedione, testosterone, and their metabolites."
pregnanetriol,"In most patients, the excretion of pregnanetriol is acceptably low, but in two older girls, it is unacceptably high, exceeding the upper normal limit of 0.89 pmol/24 h both by day and by night.","Entity: pregnanetriol. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4CCCC[C@@]43C)[C@@H]1CC[C@@H]2CC(O)(O)O. In most patients, the excretion of pregnanetriol is acceptably low, but in two older girls, it is unacceptably high, exceeding the upper normal limit of 0.89 pmol/24 h both by day and by night."
pregnanetriolone,"The excretion of pregnanetriolone is acceptably low for all patients, regardless of the time of day.","Entity: pregnanetriolone. SMILES: C[C@H](O)[C@@]1(O)CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C. The excretion of pregnanetriolone is acceptably low for all patients, regardless of the time of day."
pregnanediol,"The excretion of pregnanediol is acceptably low for all patients, regardless of the time of day.","Entity: pregnanediol. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4CCCC[C@@]43C)[C@@H]1CC[C@@H]2CC(O)O. The excretion of pregnanediol is acceptably low for all patients, regardless of the time of day."
"17,20-dihydroxycholesterol","17,20-dihydroxycholesterol may serve as an intermediate in a metabolic pathway leading to dehydroepiandrosterone in patients treated with androgens.","Entity: 17,20-dihydroxycholesterol. SMILES: CC(C)CCC[C@](C)(O)[C@@]1(O)CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C. 17,20-dihydroxycholesterol may serve as an intermediate in a metabolic pathway leading to dehydroepiandrosterone in patients treated with androgens."
ll@-hydroxyandrosterone,"ll@-hydroxyandrosterone can be separated by thin-layer chromatography using a benzene:ethyl acetate (40:60, v/v) solvent system and visualized with 0.1% Rhodamine 6-G in ethanol.","Entity: ll@-hydroxyandrosterone. SMILES: C[C@]12CC[C@@H](O)C[C@@H]1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)C(=O)CC[C@@H]12. ll@-hydroxyandrosterone can be separated by thin-layer chromatography using a benzene:ethyl acetate (40:60, v/v) solvent system and visualized with 0.1% Rhodamine 6-G in ethanol."
pregnanetriol,"Pregnanetriol can be separated by thin-layer chromatography using a benzene:ethyl acetate (40:60, v/v) solvent system and visualized with 0.1% Rhodamine 6-G in ethanol.","Entity: pregnanetriol. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4CCCC[C@@]43C)[C@@H]1CC[C@@H]2CC(O)(O)O. Pregnanetriol can be separated by thin-layer chromatography using a benzene:ethyl acetate (40:60, v/v) solvent system and visualized with 0.1% Rhodamine 6-G in ethanol."
testosterone,"Testosterone can be separated by thin-layer chromatography using a benzene:ethyl acetate (40:60, v/v) solvent system and visualized with 0.1% Rhodamine 6-G in ethanol.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone can be separated by thin-layer chromatography using a benzene:ethyl acetate (40:60, v/v) solvent system and visualized with 0.1% Rhodamine 6-G in ethanol."
cholesterol,"Cholesterol can be separated by thin-layer chromatography using a benzene:ethyl acetate (40:60, v/v) solvent system and visualized with 0.1% Rhodamine 6-G in ethanol.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol can be separated by thin-layer chromatography using a benzene:ethyl acetate (40:60, v/v) solvent system and visualized with 0.1% Rhodamine 6-G in ethanol."
trimethylsilyl,Trimethylsilyl ethers can be formed from compounds in Zone 3 prior to gas chromatography separation.,Entity: trimethylsilyl. SMILES: C[Si](C)C. Trimethylsilyl ethers can be formed from compounds in Zone 3 prior to gas chromatography separation.
"20,22-dihydroxycholesterol","Sulphate esters of 20,22-dihydroxycholesterol have been isolated from meconium and faeces of newborns.","Entity: 20,22-dihydroxycholesterol. SMILES: CC(C)CCC(O)[C@](C)(O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C. Sulphate esters of 20,22-dihydroxycholesterol have been isolated from meconium and faeces of newborns."
22-hydroxycholesterol,Sulphate esters of 22-hydroxycholesterol have been isolated from meconium and faeces of newborns.,Entity: 22-hydroxycholesterol. SMILES: CC(C)CCC(O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Sulphate esters of 22-hydroxycholesterol have been isolated from meconium and faeces of newborns.
23-hydroxycholesterol,Sulphate esters of 23-hydroxycholesterol have been isolated from meconium and faeces of newborns.,Entity: 23-hydroxycholesterol. SMILES: CC(C)CC(O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Sulphate esters of 23-hydroxycholesterol have been isolated from meconium and faeces of newborns.
24-hydroxycholesterol,Sulphate esters of 24-hydroxycholesterol have been isolated from meconium and faeces of newborns.,Entity: 24-hydroxycholesterol. SMILES: CC(C)C(O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Sulphate esters of 24-hydroxycholesterol have been isolated from meconium and faeces of newborns.
pregnenolone,Pregnenolone is not a required intermediate in the direct pathway from cholesterol to dehydroepiandrosterone (DHA) in the adrenal gland.,Entity: pregnenolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Pregnenolone is not a required intermediate in the direct pathway from cholesterol to dehydroepiandrosterone (DHA) in the adrenal gland.
AG,"The action of AG is to block 20,22-desmolase in the adrenal gland, leading to abnormal adrenal storage of cholesterol.","Entity: AG. SMILES: CCC1(c2ccc(N)cc2)CCC(=O)NC1=O. The action of AG is to block 20,22-desmolase in the adrenal gland, leading to abnormal adrenal storage of cholesterol."
cholesterol,"Cholesterol can be converted to 20a-hydroxycholesterol and further to 17a,20β-dihydroxycholesterol in human fetal adrenal slices.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol can be converted to 20a-hydroxycholesterol and further to 17a,20β-dihydroxycholesterol in human fetal adrenal slices."
cholesterol,"In congenital lipoid adrenal hyperplasia, deficiency of cholesterol 20a-hydroxylase leads to defective synthesis of 17a,20β-dihydroxycholesterol, blocking the pathway to dehydroepiandrosterone (DHA).","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. In congenital lipoid adrenal hyperplasia, deficiency of cholesterol 20a-hydroxylase leads to defective synthesis of 17a,20β-dihydroxycholesterol, blocking the pathway to dehydroepiandrosterone (DHA)."
"17a,20β-dihydroxycholesterol","17a,20β-dihydroxycholesterol is an intermediate in the biosynthetic pathway from cholesterol to dehydroepiandrosterone (DHA) in the adrenal gland.","Entity: 17a,20β-dihydroxycholesterol. SMILES: CC(C)CCC[C@](C)(O)[C@@]1(O)CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C. 17a,20β-dihydroxycholesterol is an intermediate in the biosynthetic pathway from cholesterol to dehydroepiandrosterone (DHA) in the adrenal gland."
methionine,"Methionine is involved in methionine metabolism, which can be disrupted in the inborn error of homocystinuria.","Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine is involved in methionine metabolism, which can be disrupted in the inborn error of homocystinuria."
homocysteine,Homocysteine is a product of methionine metabolism that can accumulate due to failure of remethylation in homocystinuria.,Entity: homocysteine. SMILES: N[C@@H](CCS)C(=O)O. Homocysteine is a product of methionine metabolism that can accumulate due to failure of remethylation in homocystinuria.
cystathionine,"Cystathionine is part of the methionine biosynthetic pathway, and defects in its synthesis can cause homocystinuria.","Entity: cystathionine. SMILES: N[C@@H](CCSC[C@H](N)C(=O)O)C(=O)O. Cystathionine is part of the methionine biosynthetic pathway, and defects in its synthesis can cause homocystinuria."
streptomycin,Streptomycin is used as an antibiotic supplement in cell culture medium at a concentration of 63 mg/l to prevent bacterial contamination.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used as an antibiotic supplement in cell culture medium at a concentration of 63 mg/l to prevent bacterial contamination.
pyridoxine hydrochloride,Pyridoxine hydrochloride is used as a vitamin supplement in cell culture medium at a concentration of 1 mg/l to support cell growth.,Entity: pyridoxine hydrochloride. SMILES: Cc1ncc(CO)c(CO)c1O.Cl. Pyridoxine hydrochloride is used as a vitamin supplement in cell culture medium at a concentration of 1 mg/l to support cell growth.
ascorbic acid,Ascorbic acid is used as a vitamin supplement in cell culture medium at a concentration of 33 mg/l to support cell growth.,Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid is used as a vitamin supplement in cell culture medium at a concentration of 33 mg/l to support cell growth.
pyridoxine,"Pyridoxine (vitamin B6) is required as a cofactor for cystathionine synthase activity in normal and homozygous fibroblasts, with optimal activity observed at 25 mg/l pyridoxine–HCl in culture medium.","Entity: pyridoxine. SMILES: Cc1ncc(CO)c(CO)c1O.Cl. Pyridoxine (vitamin B6) is required as a cofactor for cystathionine synthase activity in normal and homozygous fibroblasts, with optimal activity observed at 25 mg/l pyridoxine–HCl in culture medium."
pyridoxine,Cystathionine synthase activity in normal fibroblasts is maximal at 25 mg/l pyridoxine–HCl and minimal at 1 mg/l pyridoxine–HCl in culture medium.,Entity: pyridoxine. SMILES: Cc1ncc(CO)c(CO)c1O.Cl. Cystathionine synthase activity in normal fibroblasts is maximal at 25 mg/l pyridoxine–HCl and minimal at 1 mg/l pyridoxine–HCl in culture medium.
pyridoxine,High concentrations of pyridoxine–HCl (50 mg/l) cause a striking diminution in cystathionine synthase activity in both normal and homozygous fibroblasts.,Entity: pyridoxine. SMILES: Cc1ncc(CO)c(CO)c1O.Cl. High concentrations of pyridoxine–HCl (50 mg/l) cause a striking diminution in cystathionine synthase activity in both normal and homozygous fibroblasts.
pyridoxal phosphate,Pyridoxal phosphate has the capacity to protect cystathionine synthase in vitro.,Entity: pyridoxal phosphate. SMILES: Cc1ncc(COP(=O)(O)O)c(C=O)c1O. Pyridoxal phosphate has the capacity to protect cystathionine synthase in vitro.
urobilinogen,"Urobilinogen is a urinary analyte that can be semiquantitatively estimated using a reagent strip method (Ugentest) and quantitatively measured in urine with modifications involving extraction, reagent composition, and wavelength selection.","Entity: urobilinogen. SMILES: CCC1=C(C)C(Cc2[nH]c(Cc3[nH]c(CC4NC(=O)C(C)=C4CC)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Urobilinogen is a urinary analyte that can be semiquantitatively estimated using a reagent strip method (Ugentest) and quantitatively measured in urine with modifications involving extraction, reagent composition, and wavelength selection."
porphobilinogen,Porphobilinogen does not interfere with the Ehrlich method for colorimetric determination.,Entity: porphobilinogen. SMILES: NCc1[nH]cc(CCC(=O)O)c1CC(=O)O. Porphobilinogen does not interfere with the Ehrlich method for colorimetric determination.
5-HIAA,5-HIAA does not interfere with the Ehrlich method for colorimetric determination.,Entity: 5-HIAA. SMILES: O=C(O)Cc1cc2cc(O)ccc2[nH]1. 5-HIAA does not interfere with the Ehrlich method for colorimetric determination.
urobilinogen,Urobilinogen reacts with p-MDFB to form a colored product measurable by a single maximum at 505 nm between 400 nm and 600 nm in spectrophotometric assays.,Entity: urobilinogen. SMILES: CCC1=C(C)C(Cc2[nH]c(Cc3[nH]c(CC4NC(=O)C(C)=C4CC)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Urobilinogen reacts with p-MDFB to form a colored product measurable by a single maximum at 505 nm between 400 nm and 600 nm in spectrophotometric assays.
porphobilinogen,Porphobilinogen can interfere with the colorimetric reaction between urobilinogen and p-MDFB if not properly extracted from urine samples.,Entity: porphobilinogen. SMILES: NCc1[nH]cc(CCC(=O)O)c1CC(=O)O. Porphobilinogen can interfere with the colorimetric reaction between urobilinogen and p-MDFB if not properly extracted from urine samples.
bilirubin,Bilirubin can interfere with the colorimetric reaction between urobilinogen and p-MDFB if not removed by extraction.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin can interfere with the colorimetric reaction between urobilinogen and p-MDFB if not removed by extraction.
hydrochloric acid,"Hydrochloric acid can be used as an acidifying agent in the colorimetric reaction between urobilinogen and p-MDFB without affecting the duration, intensity, or absorption curve of the colored product.","Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid can be used as an acidifying agent in the colorimetric reaction between urobilinogen and p-MDFB without affecting the duration, intensity, or absorption curve of the colored product."
p-toluenesulfonic acid,p-toluenesulfonic acid is an expensive acidifying agent that is relatively less suitable for the colorimetric reaction between urobilinogen and p-MDFB.,Entity: p-toluenesulfonic acid. SMILES: Cc1ccc(S(=O)(=O)O)cc1. p-toluenesulfonic acid is an expensive acidifying agent that is relatively less suitable for the colorimetric reaction between urobilinogen and p-MDFB.
urobilin,"Urobilin is a reduced product that can be present in small amounts in urine and may produce color in the reference method for urobilinogen quantification, but not in procedures lacking extraction.","Entity: urobilin. SMILES: CCC1=C(C)[C@H](CC2=N/C(=C\c3[nH]c(C[C@@H]4NC(=O)C(C)=C4CC)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC1=O. Urobilin is a reduced product that can be present in small amounts in urine and may produce color in the reference method for urobilinogen quantification, but not in procedures lacking extraction."
p-aminosalicylic acid,p-aminosalicylic acid at 1 g/l does not interfere with the colorimetric reaction measured by the described method up to 250 pmol/l.,Entity: p-aminosalicylic acid. SMILES: Nc1ccc(C(=O)O)c(O)c1. p-aminosalicylic acid at 1 g/l does not interfere with the colorimetric reaction measured by the described method up to 250 pmol/l.
chlorpromazine,chlorpromazine at 1 g/l does not interfere with the colorimetric reaction measured by the described method up to 250 pmol/l.,Entity: chlorpromazine. SMILES: CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21. chlorpromazine at 1 g/l does not interfere with the colorimetric reaction measured by the described method up to 250 pmol/l.
sulfadiazine,sulfadiazine at 1 g/l does not interfere with the colorimetric reaction measured by the described method up to 250 pmol/l.,Entity: sulfadiazine. SMILES: Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1. sulfadiazine at 1 g/l does not interfere with the colorimetric reaction measured by the described method up to 250 pmol/l.
tetracycline,tetracycline at 1 g/l does not interfere with the colorimetric reaction measured by the described method up to 250 pmol/l.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. tetracycline at 1 g/l does not interfere with the colorimetric reaction measured by the described method up to 250 pmol/l.
sulfisoxazole,sulfisoxazole at 1 g/l does not interfere with the colorimetric reaction measured by the described method up to 250 pmol/l.,Entity: sulfisoxazole. SMILES: Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C. sulfisoxazole at 1 g/l does not interfere with the colorimetric reaction measured by the described method up to 250 pmol/l.
porphobilinogen,Urine samples containing porphobilinogen and no urobilinogen produce an intense red color that is not extractable by chloroform.,Entity: porphobilinogen. SMILES: NCc1[nH]cc(CCC(=O)O)c1CC(=O)O. Urine samples containing porphobilinogen and no urobilinogen produce an intense red color that is not extractable by chloroform.
methylenecyclopropylacetic acid,Methylenecyclopropylacetic acid is a toxic metabolite of hypoglycin A that can be detected in the urine of patients and treated rats exposed to hypoglycin A.,Entity: methylenecyclopropylacetic acid. SMILES: C=C(C(=O)O)C1CC1. Methylenecyclopropylacetic acid is a toxic metabolite of hypoglycin A that can be detected in the urine of patients and treated rats exposed to hypoglycin A.
hypoglycin A,Hypoglycin A is a toxic compound that can cause Jamaican vomiting sickness and is linked to the presence of its toxic metabolite methylenecyclopropylacetic acid and alipathic dicarboxylic acids in patient and animal urine.,Entity: hypoglycin A. SMILES: C=C1C[C@H]1C[C@H](N)C(=O)O. Hypoglycin A is a toxic compound that can cause Jamaican vomiting sickness and is linked to the presence of its toxic metabolite methylenecyclopropylacetic acid and alipathic dicarboxylic acids in patient and animal urine.
n-hexanoylglycine,n-hexanoylglycine is a compound that can be identified in human urine using gas chromatography-mass spectrometry (GC-MS) analysis.,Entity: n-hexanoylglycine. SMILES: CCCCCC(=O)NCC(=O)O. n-hexanoylglycine is a compound that can be identified in human urine using gas chromatography-mass spectrometry (GC-MS) analysis.
helium,Helium is used as a carrier gas in gas chromatography for the analysis of urinary organic acids.,Entity: helium. SMILES: [He]. Helium is used as a carrier gas in gas chromatography for the analysis of urinary organic acids.
n-hexanoylglycine,"n-hexanoylglycine is present in human urine, with urinary excretion levels of 106 µg/mg creatinine and 73 µg/mg creatinine in patients with phenylketonuria, accounting for 24–42% of n-hexanoic acids detected after Ba(OH)2 hydrolysis.","Entity: n-hexanoylglycine. SMILES: CCCCCC(=O)NCC(=O)O. n-hexanoylglycine is present in human urine, with urinary excretion levels of 106 µg/mg creatinine and 73 µg/mg creatinine in patients with phenylketonuria, accounting for 24–42% of n-hexanoic acids detected after Ba(OH)2 hydrolysis."
n-hexanoylglycine,A 5% neopentylglycol adipate column at 160°C is effective for separating n-hexanoylglycine from normal constituents in human urine by GC analysis.,Entity: n-hexanoylglycine. SMILES: CCCCCC(=O)NCC(=O)O. A 5% neopentylglycol adipate column at 160°C is effective for separating n-hexanoylglycine from normal constituents in human urine by GC analysis.
n-hexanoylglycine,n-hexanoylglycine is not detectable in the urine of normal humans by GC-MS analysis using an OV-1 column inlet.,Entity: n-hexanoylglycine. SMILES: CCCCCC(=O)NCC(=O)O. n-hexanoylglycine is not detectable in the urine of normal humans by GC-MS analysis using an OV-1 column inlet.
hexanoic acid,No detectable amount of hexanoic acid is present in the urine of five normal children after Ba(OH)3 hydrolysis.,Entity: hexanoic acid. SMILES: CCCCCC(=O)O. No detectable amount of hexanoic acid is present in the urine of five normal children after Ba(OH)3 hydrolysis.
angiotensin I,"Angiotensin I can be quantified using a standard curve with a specific radioactivity of 50,000 cpm/0.186 ng, resulting in a tracer with a specific radioactivity of 202 nCi/ng when labeled with 125I.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I can be quantified using a standard curve with a specific radioactivity of 50,000 cpm/0.186 ng, resulting in a tracer with a specific radioactivity of 202 nCi/ng when labeled with 125I."
arachidonic acid,Arachidonic acid has an interferent reactivity index over 200 times greater in the colorimetric protein binding reaction (CPBR) assay for T4 than in the radioimmunoassay (RIA) assay.,Entity: arachidonic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. Arachidonic acid has an interferent reactivity index over 200 times greater in the colorimetric protein binding reaction (CPBR) assay for T4 than in the radioimmunoassay (RIA) assay.
tripalmitin,Tripalmitin does not interfere in either the colorimetric protein binding reaction (CPBR) or radioimmunoassay (RIA) assays for T4.,Entity: tripalmitin. SMILES: CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC. Tripalmitin does not interfere in either the colorimetric protein binding reaction (CPBR) or radioimmunoassay (RIA) assays for T4.
triolein,"Triolein interferes slightly in the radioimmunoassay (RIA) assay for T4, but not in the colorimetric protein binding reaction (CPBR).","Entity: triolein. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC. Triolein interferes slightly in the radioimmunoassay (RIA) assay for T4, but not in the colorimetric protein binding reaction (CPBR)."
catecholamine,"Catecholamine injections can elevate nonesterified fatty acids in serum, which may falsely elevate T4 results in the total T4 carbonylpyridinium blue reaction (CPBR) assay.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Catecholamine injections can elevate nonesterified fatty acids in serum, which may falsely elevate T4 results in the total T4 carbonylpyridinium blue reaction (CPBR) assay."
nicotinic acid,"Nicotinic acid administration can cause a rebound effect that elevates nonesterified fatty acids in serum, potentially leading to falsely elevated T4 results in the total T4 CPBR assay.","Entity: nicotinic acid. SMILES: O=C(O)c1cccnc1. Nicotinic acid administration can cause a rebound effect that elevates nonesterified fatty acids in serum, potentially leading to falsely elevated T4 results in the total T4 CPBR assay."
Phenobarbital,Phenobarbital is an antiepileptic drug whose plasma concentrations can be quantitatively measured by high-speed liquid chromatography with sensitivity down to 1.0 µg per 0.5 ml of plasma.,Entity: Phenobarbital. SMILES: CCC1(c2ccccc2)C(=O)NC(=O)NC1=O. Phenobarbital is an antiepileptic drug whose plasma concentrations can be quantitatively measured by high-speed liquid chromatography with sensitivity down to 1.0 µg per 0.5 ml of plasma.
Diphenylhydantoin,Diphenylhydantoin is an antiepileptic drug whose plasma concentrations can be quantitatively measured by high-speed liquid chromatography with sensitivity down to 1.0 µg per 0.5 ml of plasma.,Entity: Diphenylhydantoin. SMILES: O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1. Diphenylhydantoin is an antiepileptic drug whose plasma concentrations can be quantitatively measured by high-speed liquid chromatography with sensitivity down to 1.0 µg per 0.5 ml of plasma.
Carbamazepine,Carbamazepine is an antiepileptic drug whose plasma concentrations can be quantitatively measured by high-speed liquid chromatography with sensitivity down to 1.0 µg per 0.5 ml of plasma.,Entity: Carbamazepine. SMILES: NC(=O)N1c2ccccc2C=Cc2ccccc21. Carbamazepine is an antiepileptic drug whose plasma concentrations can be quantitatively measured by high-speed liquid chromatography with sensitivity down to 1.0 µg per 0.5 ml of plasma.
methanol,Methanol is used as a reagent to reduce undissolved material buildup on chromatographic columns by being injected before and after sample injections.,Entity: methanol. SMILES: CO. Methanol is used as a reagent to reduce undissolved material buildup on chromatographic columns by being injected before and after sample injections.
sodium sulfate,Sodium sulfate is used as a dehydrating agent in organic extraction procedures.,Entity: sodium sulfate. SMILES: O=S(=O)([O-])[O-].[Na+].[Na+]. Sodium sulfate is used as a dehydrating agent in organic extraction procedures.
sodium hydroxide,Sodium hydroxide (NaOH) is used as an aqueous base in organic extraction and workup procedures.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide (NaOH) is used as an aqueous base in organic extraction and workup procedures.
sodium sulfate,Sodium sulfate is used as a dehydrating agent in organic extraction procedures.,Entity: sodium sulfate. SMILES: O=S(=O)([O-])[O-].[Na+].[Na+]. Sodium sulfate is used as a dehydrating agent in organic extraction procedures.
hydrochloric acid,Hydrochloric acid (6 N HCl) is used for acidification in aqueous layer extraction during sample preparation.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (6 N HCl) is used for acidification in aqueous layer extraction during sample preparation.
chloroform,Chloroform is used as an organic solvent for extraction in sample preparation protocols.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as an organic solvent for extraction in sample preparation protocols.
formiminoglutamate,Formiminoglutamate excretion in urine shows sex and age dependence in healthy individuals.,Entity: formiminoglutamate. SMILES: N=CN[C@@H](CCC(=O)[O-])C(=O)[O-]. Formiminoglutamate excretion in urine shows sex and age dependence in healthy individuals.
formiminoglutamate,"Short-term calorie restriction or fasting decreases urinary formiminoglutamate excretion, while acute alcohol intoxication or chronic alcohol administration increases it.","Entity: formiminoglutamate. SMILES: N=CN[C@@H](CCC(=O)[O-])C(=O)[O-]. Short-term calorie restriction or fasting decreases urinary formiminoglutamate excretion, while acute alcohol intoxication or chronic alcohol administration increases it."
diacetyl monoxime,Diacetyl monoxime is a reagent used for the colorimetric determination of urea in biological specimens.,Entity: diacetyl monoxime. SMILES: CC(=O)/C(C)=N/O.CC(=O)/C(C)=N/O.CC(=O)/C(C)=N/O. Diacetyl monoxime is a reagent used for the colorimetric determination of urea in biological specimens.
urea,Urea in plasma and urine can be quantified using the diacetyl monoxime method.,Entity: urea. SMILES: NC(N)=O. Urea in plasma and urine can be quantified using the diacetyl monoxime method.
creatinine,Creatinine in plasma and urine can be quantified using the Jaffe reaction.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine in plasma and urine can be quantified using the Jaffe reaction.
urate,Uratic acid (urate) in plasma and urine can be quantified using the phosphotungstate method.,Entity: urate. SMILES: O=c1[nH]c(=O)c2[nH]c(=O)[nH]c2[nH]1. Uratic acid (urate) in plasma and urine can be quantified using the phosphotungstate method.
dermatan sulfate,Dermatan sulfate is not present in circulating lymphocytes.,Entity: dermatan sulfate. SMILES: CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O)[C@H](O)[C@H]2O)[C@@H](OS(=O)(=O)[O-])[C@@H](CO)O[C@H]1O. Dermatan sulfate is not present in circulating lymphocytes.
galactosamine,All galactosamine is completely removed from circulating lymphocyte glycoconjugates by digestion with testicular hyaluronidase.,Entity: galactosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. All galactosamine is completely removed from circulating lymphocyte glycoconjugates by digestion with testicular hyaluronidase.
glucosamine,"A small amount of hyaluronidase-resistant glucosamine-containing glycoconjugates in circulating lymphocytes may represent heparan sulfate, which is a minor component of cellular glycoconjugates in leukocytes.","Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. A small amount of hyaluronidase-resistant glucosamine-containing glycoconjugates in circulating lymphocytes may represent heparan sulfate, which is a minor component of cellular glycoconjugates in leukocytes."
dermatan sulfate,"Dermatan sulfate is not present in circulating lymphocytes of either cystic fibrosis patients or controls, as detected by gas chromatographic analysis and cellulose acetate electrophoresis.","Entity: dermatan sulfate. SMILES: CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O)[C@H](O)[C@H]2O)[C@@H](OS(=O)(=O)[O-])[C@@H](CO)O[C@H]1O. Dermatan sulfate is not present in circulating lymphocytes of either cystic fibrosis patients or controls, as detected by gas chromatographic analysis and cellulose acetate electrophoresis."
dermatan sulfate,Dermatan sulfate is not detected in circulating lymphocytes from either cystic fibrosis patients or controls.,Entity: dermatan sulfate. SMILES: CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O)[C@H](O)[C@H]2O)[C@@H](OS(=O)(=O)[O-])[C@@H](CO)O[C@H]1O. Dermatan sulfate is not detected in circulating lymphocytes from either cystic fibrosis patients or controls.
galactosamine,"The total content of galactosamine in circulating lymphocytes from cystic fibrosis patients and controls is not different from controls, as measured by gas chromatography.","Entity: galactosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. The total content of galactosamine in circulating lymphocytes from cystic fibrosis patients and controls is not different from controls, as measured by gas chromatography."
glucosamine,"The total content of glucosamine in circulating lymphocytes from cystic fibrosis patients and controls is not different from controls, as measured by gas chromatography.","Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. The total content of glucosamine in circulating lymphocytes from cystic fibrosis patients and controls is not different from controls, as measured by gas chromatography."
ethanol,"Ethanol at 95% concentration, with 1% potassium acetate and 1% acetic acid, is used to precipitate glycosaminoglycans (GAGs) from tissue extracts.","Entity: ethanol. SMILES: CCO. Ethanol at 95% concentration, with 1% potassium acetate and 1% acetic acid, is used to precipitate glycosaminoglycans (GAGs) from tissue extracts."
trichloroacetic acid,Trichloroacetic acid is used to precipitate proteins from cell lysates at a concentration of 50%.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to precipitate proteins from cell lysates at a concentration of 50%.
galactosamine,Galactosamine is a component of total tissue glycosaminoglycans (GAGs) and can be analyzed as its acetylated derivative by gas chromatography.,Entity: galactosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. Galactosamine is a component of total tissue glycosaminoglycans (GAGs) and can be analyzed as its acetylated derivative by gas chromatography.
acetic acid,Acetic acid is used at 1% concentration in 95% ethanol to precipitate glycosaminoglycans (GAGs) from tissue extracts.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used at 1% concentration in 95% ethanol to precipitate glycosaminoglycans (GAGs) from tissue extracts.
glucosamine,Glucosamine is a component of total tissue glycosaminoglycans (GAGs) and can be analyzed as its acetylated derivative by gas chromatography.,Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine is a component of total tissue glycosaminoglycans (GAGs) and can be analyzed as its acetylated derivative by gas chromatography.
chloroform,Chloroform is used in combination with methanol (50:50 v/v) to delipidize cells for 24 hours.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used in combination with methanol (50:50 v/v) to delipidize cells for 24 hours.
potassium acetate,Potassium acetate is used at 1% concentration in 95% ethanol to aid in the precipitation of glycosaminoglycans (GAGs) from tissue extracts.,Entity: potassium acetate. SMILES: CC(=O)[O-].[K+]. Potassium acetate is used at 1% concentration in 95% ethanol to aid in the precipitation of glycosaminoglycans (GAGs) from tissue extracts.
methanol,Methanol is used in combination with chloroform (50:50 v/v) to delipidize cells for 24 hours.,Entity: methanol. SMILES: CO. Methanol is used in combination with chloroform (50:50 v/v) to delipidize cells for 24 hours.
dermatan sulfate,The proportion of dermatan sulfate in circulating lymphocytes is increased in patients with cystic fibrosis and their parents compared to controls.,Entity: dermatan sulfate. SMILES: CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O)[C@H](O)[C@H]2O)[C@@H](OS(=O)(=O)[O-])[C@@H](CO)O[C@H]1O. The proportion of dermatan sulfate in circulating lymphocytes is increased in patients with cystic fibrosis and their parents compared to controls.
angiotensin I,"Angiotensin I released from plasma into solution can be quantified using a protease release assay, with values of 2.6–5.0 ng angiotensin I/ml plasma/h depending on the assay system and enzyme used.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I released from plasma into solution can be quantified using a protease release assay, with values of 2.6–5.0 ng angiotensin I/ml plasma/h depending on the assay system and enzyme used."
DFP,DFP is a serine protease inhibitor that effectively inhibits the chymotrypsin-like proteolytic activity of lysozyme.,Entity: DFP. SMILES: CC(C)OP(=O)(F)OC(C)C. DFP is a serine protease inhibitor that effectively inhibits the chymotrypsin-like proteolytic activity of lysozyme.
DFP,"DFP is a toxic substance that can be used to inhibit proteolytic activity in radioimmunoassay buffers or by heating lysozyme, but should only be handled by qualified personnel under controlled conditions.","Entity: DFP. SMILES: O=P([O-])(F)F. DFP is a toxic substance that can be used to inhibit proteolytic activity in radioimmunoassay buffers or by heating lysozyme, but should only be handled by qualified personnel under controlled conditions."
angiotensin I,"Angiotensin I is a substrate for proteolytic enzymes, and its destruction during sample preparation can lead to increased displacement of the antibody in radioimmunoassay, indicating reduced binding of angiotensin I to its antibody.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I is a substrate for proteolytic enzymes, and its destruction during sample preparation can lead to increased displacement of the antibody in radioimmunoassay, indicating reduced binding of angiotensin I to its antibody."
angiotensin I,Angiotensin I can be degraded by proteolytic activity present in commonly used carrier proteins such as lysozyme and albumin.,Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I can be degraded by proteolytic activity present in commonly used carrier proteins such as lysozyme and albumin.
angiotensin I,"Angiotensin I is measured in plasma using radioimmunoassay, and its quantification can be affected by proteolytic activity present in human plasma.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I is measured in plasma using radioimmunoassay, and its quantification can be affected by proteolytic activity present in human plasma."
diisopropyl fluorophosphate,Diisopropyl fluorophosphate inhibits proteolytic activity in human plasma that can falsely elevate observed plasma renin activity during radioimmunoassay of angiotensin I.,Entity: diisopropyl fluorophosphate. SMILES: CC(C)OP(=O)(F)OC(C)C. Diisopropyl fluorophosphate inhibits proteolytic activity in human plasma that can falsely elevate observed plasma renin activity during radioimmunoassay of angiotensin I.
putrescine,"Putrescine levels in red blood cells can be used to estimate cell age, with 100% of top fractions (young cells) corresponding to a putrescine value of 20.030 nmol/10^6 cells and 90% of bottom fractions (old cells) corresponding to a putrescine value less than 0.025 nmol/10^6 cells.","Entity: putrescine. SMILES: NCCCCN. Putrescine levels in red blood cells can be used to estimate cell age, with 100% of top fractions (young cells) corresponding to a putrescine value of 20.030 nmol/10^6 cells and 90% of bottom fractions (old cells) corresponding to a putrescine value less than 0.025 nmol/10^6 cells."
spermine,"Spermine levels in red blood cells serve as an indicator of cell age, with 90% of top fractions (young cells) corresponding to a spermine value of 20.75 nmol/10^6 cells and 100% of bottom fractions (old cells) corresponding to a spermine value of 0.60 nmol/10^6 cells.","Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine levels in red blood cells serve as an indicator of cell age, with 90% of top fractions (young cells) corresponding to a spermine value of 20.75 nmol/10^6 cells and 100% of bottom fractions (old cells) corresponding to a spermine value of 0.60 nmol/10^6 cells."
spermidine,"Spermidine levels in red blood cells can distinguish between young and old cell populations, with 90% of top fractions (young cells) corresponding to a spermidine value of 1.40 nmol/10^6 cells and 90% of middle fractions corresponding to middle-aged cells.","Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine levels in red blood cells can distinguish between young and old cell populations, with 90% of top fractions (young cells) corresponding to a spermidine value of 1.40 nmol/10^6 cells and 90% of middle fractions corresponding to middle-aged cells."
spermine,Spermine concentrations per 10^9 cells are several orders of magnitude higher in leukocytes than in erythrocytes in human blood.,Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine concentrations per 10^9 cells are several orders of magnitude higher in leukocytes than in erythrocytes in human blood.
spermidine,Spermidine concentrations per 10^9 cells are several orders of magnitude higher in leukocytes than in erythrocytes in human blood.,Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine concentrations per 10^9 cells are several orders of magnitude higher in leukocytes than in erythrocytes in human blood.
putrescine,Putrescine concentrations per 10^9 cells are several orders of magnitude higher in leukocytes than in erythrocytes in human blood.,Entity: putrescine. SMILES: NCCCCN. Putrescine concentrations per 10^9 cells are several orders of magnitude higher in leukocytes than in erythrocytes in human blood.
spermidine,"Spermidine levels increase by 7.46-fold with age in blood, making it a sensitive indicator of red cell age.","Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine levels increase by 7.46-fold with age in blood, making it a sensitive indicator of red cell age."
spermine,"Spermine levels increase by 4.6-fold with age in blood, serving as a sensitive indicator of red cell age.","Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine levels increase by 4.6-fold with age in blood, serving as a sensitive indicator of red cell age."
putrescine,"Putrescine levels increase by 2.6-fold with age in blood, reflecting changes associated with red cell aging.","Entity: putrescine. SMILES: NCCCCN. Putrescine levels increase by 2.6-fold with age in blood, reflecting changes associated with red cell aging."
hemoglobin,Hemoglobin concentration in red blood cells increases with age due to decreased red cell size (MCV) but constant mean hemoglobin (MCH) as a result of membrane loss.,Entity: hemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. Hemoglobin concentration in red blood cells increases with age due to decreased red cell size (MCV) but constant mean hemoglobin (MCH) as a result of membrane loss.
putrescine,Putrescine concentrations in age-separated erythrocytes vary depending on the age fraction of the red blood cell population.,Entity: putrescine. SMILES: NCCCCN. Putrescine concentrations in age-separated erythrocytes vary depending on the age fraction of the red blood cell population.
spermidine,Spermidine concentrations in age-separated erythrocytes differ according to the age group of the red blood cells.,Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine concentrations in age-separated erythrocytes differ according to the age group of the red blood cells.
spermine,Spermine concentrations in age-separated erythrocytes are associated with the age of the red blood cells.,Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine concentrations in age-separated erythrocytes are associated with the age of the red blood cells.
spermidine,Spermidine is a naturally occurring polyamine found in virtually all living cells.,Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine is a naturally occurring polyamine found in virtually all living cells.
spermidine,"Spermidine levels are elevated in the blood and urine of cancer patients, in the blood of leukemics, and in the blood of cystic fibrosis and psoriasis patients.","Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine levels are elevated in the blood and urine of cancer patients, in the blood of leukemics, and in the blood of cystic fibrosis and psoriasis patients."
putrescine,Putrescine is a naturally occurring polyamine present in virtually all living cells.,Entity: putrescine. SMILES: NCCCCN. Putrescine is a naturally occurring polyamine present in virtually all living cells.
putrescine,"Putrescine levels are increased in the blood and urine of cancer patients, in the blood of leukemics, and in the blood of cystic fibrosis and psoriasis patients.","Entity: putrescine. SMILES: NCCCCN. Putrescine levels are increased in the blood and urine of cancer patients, in the blood of leukemics, and in the blood of cystic fibrosis and psoriasis patients."
spermine,Spermine is a naturally occurring polyamine found in virtually all living cells.,Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine is a naturally occurring polyamine found in virtually all living cells.
spermine,"Spermine levels are elevated in the blood and urine of cancer patients, in the blood of leukemics, and in the blood of cystic fibrosis and psoriasis patients.","Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine levels are elevated in the blood and urine of cancer patients, in the blood of leukemics, and in the blood of cystic fibrosis and psoriasis patients."
Hypaque,"Hypaque is used as a density gradient medium in cell separation protocols, with concentrations ranging from 33.9% (w/v) to 50% (w/v) depending on the desired density layer.","Entity: Hypaque. SMILES: CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.[Na+]. Hypaque is used as a density gradient medium in cell separation protocols, with concentrations ranging from 33.9% (w/v) to 50% (w/v) depending on the desired density layer."
NH4Cl,NH4Cl is used at 0.83% (w/v) in cold solution to lyse red blood cells during blood fractionation procedures.,Entity: NH4Cl. SMILES: [Cl-].[NH4+]. NH4Cl is used at 0.83% (w/v) in cold solution to lyse red blood cells during blood fractionation procedures.
spermidine,"Spermidine levels decrease with increasing red cell age, which is significant for understanding red cell aging and polyamine function in human cells.","Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine levels decrease with increasing red cell age, which is significant for understanding red cell aging and polyamine function in human cells."
putrescine,"Putrescine levels decrease with increasing red cell age, contributing to the understanding of red cell aging and polyamine function in human cells.","Entity: putrescine. SMILES: NCCCCN. Putrescine levels decrease with increasing red cell age, contributing to the understanding of red cell aging and polyamine function in human cells."
spermine,"Spermine levels decrease with increasing red cell age, which is important for studying red cell aging and the role of polyamines in human cells.","Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine levels decrease with increasing red cell age, which is important for studying red cell aging and the role of polyamines in human cells."
ammonium oxalate,Ammonium oxalate is used as a 1% (w/v) solution to dilute platelet suspensions for differential cell counts.,Entity: ammonium oxalate. SMILES: O=C([O-])C(=O)[O-].[NH4+].[NH4+]. Ammonium oxalate is used as a 1% (w/v) solution to dilute platelet suspensions for differential cell counts.
putrescine,"Putrescine is an acid-soluble, free polyamine whose cellular concentrations in blood can be measured using an internal standard recovery of 83%.","Entity: putrescine. SMILES: NCCCCN. Putrescine is an acid-soluble, free polyamine whose cellular concentrations in blood can be measured using an internal standard recovery of 83%."
spermidine,"Spermidine is an acid-soluble, free polyamine whose cellular concentrations in blood can be measured using an internal standard recovery of 81%.","Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine is an acid-soluble, free polyamine whose cellular concentrations in blood can be measured using an internal standard recovery of 81%."
spermine,"Spermine is an acid-soluble, free polyamine whose cellular concentrations in blood can be measured using an internal standard recovery of 86%.","Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine is an acid-soluble, free polyamine whose cellular concentrations in blood can be measured using an internal standard recovery of 86%."
putrescine,"In MNC samples, the maximal contribution of platelets to the total putrescine concentration is less than 13%.","Entity: putrescine. SMILES: NCCCCN. In MNC samples, the maximal contribution of platelets to the total putrescine concentration is less than 13%."
spermidine,"In MNC samples, the maximal contribution of platelets to the total spermidine concentration is less than 8%.","Entity: spermidine. SMILES: NCCCCNCCCN. In MNC samples, the maximal contribution of platelets to the total spermidine concentration is less than 8%."
spermine,"In MNC samples, the maximal contribution of platelets to the total spermine concentration is less than 1.4%.","Entity: spermine. SMILES: NCCCNCCCCNCCCN. In MNC samples, the maximal contribution of platelets to the total spermine concentration is less than 1.4%."
Trypan Blue,"Trypan Blue is used to assess cell viability by exclusion, with intact leukocyte preparations showing less than 2% cell uptake of the dye.","Entity: Trypan Blue. SMILES: Cc1cc(-c2ccc(N=Nc3c(S(=O)(=O)[O-])cc4cc(S(=O)(=O)[O-])cc(N)c4c3O)c(C)c2)ccc1N=Nc1c(S(=O)(=O)[O-])cc2cc(S(=O)(=O)[O-])cc(N)c2c1O.[Na+].[Na+].[Na+].[Na+]. Trypan Blue is used to assess cell viability by exclusion, with intact leukocyte preparations showing less than 2% cell uptake of the dye."
ammonium chloride,"Ammonium chloride is used in leukocyte preparation to remove red blood cells, with preparations yielding less than 1% red blood cells after lysis and removal.","Entity: ammonium chloride. SMILES: [Cl-].[NH4+]. Ammonium chloride is used in leukocyte preparation to remove red blood cells, with preparations yielding less than 1% red blood cells after lysis and removal."
putrescine,"In unseparated red blood cells, the concentration of putrescine decreases from the top to the bottom fraction, showing a 260% difference between the two extremes.","Entity: putrescine. SMILES: NCCCCN. In unseparated red blood cells, the concentration of putrescine decreases from the top to the bottom fraction, showing a 260% difference between the two extremes."
spermidine,"In unseparated red blood cells, the concentration of spermidine decreases from the top to the bottom fraction, showing a 746% difference between the two extremes.","Entity: spermidine. SMILES: NCCCCNCCCN. In unseparated red blood cells, the concentration of spermidine decreases from the top to the bottom fraction, showing a 746% difference between the two extremes."
spermine,"In unseparated red blood cells, the concentration of spermine decreases from the top to the bottom fraction, showing a 460% difference between the two extremes.","Entity: spermine. SMILES: NCCCNCCCCNCCCN. In unseparated red blood cells, the concentration of spermine decreases from the top to the bottom fraction, showing a 460% difference between the two extremes."
sodium citrate,Sodium citrate is used as a buffer component at pH 6.16 in polyamine analysis protocols.,Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used as a buffer component at pH 6.16 in polyamine analysis protocols.
sodium chloride,Sodium chloride is used as a buffer component in combination with sodium citrate at pH 4.68 for polyamine analysis.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used as a buffer component in combination with sodium citrate at pH 4.68 for polyamine analysis.
o-phthalaldehyde,o-phthalaldehyde is used as a reagent for fluorescence detection in polyamine analysis with a Durrum D-500 Amino Acid Analyzer.,Entity: o-phthalaldehyde. SMILES: O=Cc1ccccc1C=O. o-phthalaldehyde is used as a reagent for fluorescence detection in polyamine analysis with a Durrum D-500 Amino Acid Analyzer.
putrescine,The concentration of putrescine in erythrocytes markedly decreases with age.,Entity: putrescine. SMILES: NCCCCN. The concentration of putrescine in erythrocytes markedly decreases with age.
spermidine,The concentration of spermidine in erythrocytes markedly decreases with age.,Entity: spermidine. SMILES: NCCCCNCCCN. The concentration of spermidine in erythrocytes markedly decreases with age.
spermine,The concentration of spermine in erythrocytes markedly decreases with age.,Entity: spermine. SMILES: NCCCNCCCCNCCCN. The concentration of spermine in erythrocytes markedly decreases with age.
hemoglobin,There is no loss of hemoglobin (MCH) during the lifespan of erythrocytes.,Entity: hemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. There is no loss of hemoglobin (MCH) during the lifespan of erythrocytes.
spermidine,"In whole blood, the major proportion of spermidine is contributed by red blood cells (RBCs).","Entity: spermidine. SMILES: NCCCCNCCCN. In whole blood, the major proportion of spermidine is contributed by red blood cells (RBCs)."
putrescine,"In whole blood, the major proportion of putrescine is contributed by white blood cells (WBCs).","Entity: putrescine. SMILES: NCCCCN. In whole blood, the major proportion of putrescine is contributed by white blood cells (WBCs)."
spermine,"In whole blood, spermine is contributed equally by white blood cells (WBCs) and red blood cells (RBCs).","Entity: spermine. SMILES: NCCCNCCCCNCCCN. In whole blood, spermine is contributed equally by white blood cells (WBCs) and red blood cells (RBCs)."
putrescine,Putrescine is a polyamine present in platelets at concentrations roughly equivalent to those in red blood cells.,Entity: putrescine. SMILES: NCCCCN. Putrescine is a polyamine present in platelets at concentrations roughly equivalent to those in red blood cells.
serotonin,"Serotonin is a biogenic amine concentrated and stored by platelets and is released during platelet aggregation, with amounts in platelets being 100 times greater than those of putrescine.","Entity: serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin is a biogenic amine concentrated and stored by platelets and is released during platelet aggregation, with amounts in platelets being 100 times greater than those of putrescine."
spermidine,The mean content of spermidine in a single mononuclear cell is 265.9 × 10⁻⁹ nmol.,Entity: spermidine. SMILES: NCCCCNCCCN. The mean content of spermidine in a single mononuclear cell is 265.9 × 10⁻⁹ nmol.
spermidine,The mean content of spermidine in a single platelet is 0.119 × 10⁻⁹ nmol.,Entity: spermidine. SMILES: NCCCCNCCCN. The mean content of spermidine in a single platelet is 0.119 × 10⁻⁹ nmol.
nitrogen,Nitrogen is used as the carrier gas at a flow rate of 0.9 ml/min in gas chromatography with a 5-meter column and a column head pressure of 0.15 atm.,Entity: nitrogen. SMILES: [N]. Nitrogen is used as the carrier gas at a flow rate of 0.9 ml/min in gas chromatography with a 5-meter column and a column head pressure of 0.15 atm.
digitonin,"Digitonin is used to remove cholesterol from serum during experimental procedures, but excessive digitonin can cause gel formation and drug inclusion.","Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin is used to remove cholesterol from serum during experimental procedures, but excessive digitonin can cause gel formation and drug inclusion."
carbon tetrachloride,Carbon tetrachloride is used as a solvent in the preparation of SCOT-columns with a pokr (UV-225) stationary phase containing OV-225.,Entity: carbon tetrachloride. SMILES: ClC(Cl)(Cl)Cl. Carbon tetrachloride is used as a solvent in the preparation of SCOT-columns with a pokr (UV-225) stationary phase containing OV-225.
phenyl,Phenyl is a component (25%) of the OV-225 polar stationary phase used in the preparation of SCOT-columns for gas chromatography.,Entity: phenyl. SMILES: [c]1ccccc1. Phenyl is a component (25%) of the OV-225 polar stationary phase used in the preparation of SCOT-columns for gas chromatography.
digitonin,"Digitonin is used as a reagent for the removal of cholesterol from mixtures, with optimal recovery and repeatability achieved at approximately 50°C for 5 minutes.","Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin is used as a reagent for the removal of cholesterol from mixtures, with optimal recovery and repeatability achieved at approximately 50°C for 5 minutes."
cholesterol,"Cholesterol can be removed from mixtures using digitonin, with the efficiency of removal influenced by reaction temperature and time.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol can be removed from mixtures using digitonin, with the efficiency of removal influenced by reaction temperature and time."
hydrogen chloride,Gaseous hydrogen chloride can be used to etch glass walls to create a rough surface that promotes the adhesion of polar stationary phases in chromatography columns.,Entity: hydrogen chloride. SMILES: Cl. Gaseous hydrogen chloride can be used to etch glass walls to create a rough surface that promotes the adhesion of polar stationary phases in chromatography columns.
sodium tungstate,"Sodium tungstate is used as a precipitation reagent in the preparation of creatinine-containing supernatants from serum samples, applied at a concentration of 100 g/l (w/v) in water.","Entity: sodium tungstate. SMILES: O=[W](=O)([O-])[O-].[Na+].[Na+]. Sodium tungstate is used as a precipitation reagent in the preparation of creatinine-containing supernatants from serum samples, applied at a concentration of 100 g/l (w/v) in water."
sulfuric acid,Sulfuric acid (l/12 N) is used in combination with sodium tungstate to precipitate proteins from serum samples.,Entity: sulfuric acid. SMILES: O=S(=O)(O)O. Sulfuric acid (l/12 N) is used in combination with sodium tungstate to precipitate proteins from serum samples.
water,Water is used as a solvent for both sodium tungstate and for diluting creatinine standards in the preparation of serum supernatants.,Entity: water. SMILES: O. Water is used as a solvent for both sodium tungstate and for diluting creatinine standards in the preparation of serum supernatants.
creatinine,"Enzymatic methods have been developed for the determination of creatinine, but these are generally not used for routine clinical applications due to their complexity.","Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Enzymatic methods have been developed for the determination of creatinine, but these are generally not used for routine clinical applications due to their complexity."
creatinine,"Creatinine can be determined by a kinetic assay, which requires sophisticated automated equipment such as centrifugal analyzers.","Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine can be determined by a kinetic assay, which requires sophisticated automated equipment such as centrifugal analyzers."
o-nitrobenzaldehyde,o-nitrobenzaldehyde is used to convert creatinine to methylguanidine in a colorimetric assay for creatinine quantification.,Entity: o-nitrobenzaldehyde. SMILES: O=Cc1ccccc1[N+](=O)[O-]. o-nitrobenzaldehyde is used to convert creatinine to methylguanidine in a colorimetric assay for creatinine quantification.
methylguanidine,Methylguanidine is an intermediate formed from creatinine by reaction with o-nitrobenzaldehyde in the Sakaguchi reaction for creatinine quantification.,Entity: methylguanidine. SMILES: CNC(=N)N. Methylguanidine is an intermediate formed from creatinine by reaction with o-nitrobenzaldehyde in the Sakaguchi reaction for creatinine quantification.
creatinine,Creatinine can be selectively adsorbed from interfering agents using Lloyd's reagent prior to alkaline picrate assay.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine can be selectively adsorbed from interfering agents using Lloyd's reagent prior to alkaline picrate assay.
creatinine,Creatinine can be converted to methylguanidine with o-nitrobenzaldehyde and quantified by the Sakaguchi reaction.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine can be converted to methylguanidine with o-nitrobenzaldehyde and quantified by the Sakaguchi reaction.
creatinine,Creatinine can be specifically destroyed by NC bacteria in a biochemical assay.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine can be specifically destroyed by NC bacteria in a biochemical assay.
creatinine,Cation exchange chromatography can be used to isolate creatinine from samples.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Cation exchange chromatography can be used to isolate creatinine from samples.
creatine,"Serum creatine can be quantitatively determined using a method based on its reaction with 3,5-dinitrobenzoyl chloride in an organic medium.","Entity: creatine. SMILES: CN(CC(=O)O)C(=N)N. Serum creatine can be quantitatively determined using a method based on its reaction with 3,5-dinitrobenzoyl chloride in an organic medium."
"3,4-dihydroxyphenylalanine","3,4-dihydroxyphenylalanine (DOPA) interferes with both the proposed creatinine assay method and the SMA 12/60 alkaline picrate procedure.","Entity: 3,4-dihydroxyphenylalanine. SMILES: N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O. 3,4-dihydroxyphenylalanine (DOPA) interferes with both the proposed creatinine assay method and the SMA 12/60 alkaline picrate procedure."
resorcinol,Resorcinol interferes with the proposed creatinine assay method and the SMA 12/60 alkaline picrate procedure.,Entity: resorcinol. SMILES: Oc1cccc(O)c1. Resorcinol interferes with the proposed creatinine assay method and the SMA 12/60 alkaline picrate procedure.
creatinine,"Creatinine concentration in serum can be determined using a colorimetric method with DNBCl in the color reagent, achieving a linear standard curve for graphical or mathematical calculation.","Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine concentration in serum can be determined using a colorimetric method with DNBCl in the color reagent, achieving a linear standard curve for graphical or mathematical calculation."
TMAH,TMAH (organic base) used in methanol provides a much greater increase in color intensity and maintains color stability compared to inorganic bases in aqueous medium for creatinine measurement.,Entity: TMAH. SMILES: C[N+](C)(C)C.[OH-]. TMAH (organic base) used in methanol provides a much greater increase in color intensity and maintains color stability compared to inorganic bases in aqueous medium for creatinine measurement.
TMAH,"When TMAH is used in methanol for the creatinine colorimetric assay, the wavelength of absorption maxima shifts from 525 nm to 545 nm, resulting in a twofold increase in absorbance.","Entity: TMAH. SMILES: C[N+](C)(C)C.[OH-]. When TMAH is used in methanol for the creatinine colorimetric assay, the wavelength of absorption maxima shifts from 525 nm to 545 nm, resulting in a twofold increase in absorbance."
methanol,"Methanol serves as the solvent for TMAH in the creatinine colorimetric assay, enabling a shift in absorption maxima to 545 nm and a twofold increase in absorbance compared to aqueous conditions.","Entity: methanol. SMILES: CO. Methanol serves as the solvent for TMAH in the creatinine colorimetric assay, enabling a shift in absorption maxima to 545 nm and a twofold increase in absorbance compared to aqueous conditions."
creatinine,"The DNBCl method is more sensitive than the manual alkaline picrate procedure for creatinine measurement, especially when higher sample dilution is required for a given amount of creatinine.","Entity: creatinine. SMILES: CN1CC(=O)N=C1N. The DNBCl method is more sensitive than the manual alkaline picrate procedure for creatinine measurement, especially when higher sample dilution is required for a given amount of creatinine."
"3,5-dinitrobenzoyl chloride","3,5-dinitrobenzoyl chloride is a reactive derivative of DNBA that produces a stronger reaction with creatinine compared to DNBA.","Entity: 3,5-dinitrobenzoyl chloride. SMILES: O=C(Cl)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1. 3,5-dinitrobenzoyl chloride is a reactive derivative of DNBA that produces a stronger reaction with creatinine compared to DNBA."
glycerol,"Glycerol, when used as a solvent in the color reagent, increases color intensity but decreases the stability of the color for creatinine quantification compared to isopropanol.","Entity: glycerol. SMILES: OCC(O)CO. Glycerol, when used as a solvent in the color reagent, increases color intensity but decreases the stability of the color for creatinine quantification compared to isopropanol."
creatinine,"Creatinine concentration can be quantified using a colorimetric reagent system based on DNBCl and trisodium phosphate, with color intensity and stability influenced by solvent choice.","Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine concentration can be quantified using a colorimetric reagent system based on DNBCl and trisodium phosphate, with color intensity and stability influenced by solvent choice."
trisodium phosphate,Trisodium phosphate is used as a buffer component at 40 g/l (95 mM) concentration in the DNBCl-based color reagent for creatinine quantification.,Entity: trisodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Trisodium phosphate is used as a buffer component at 40 g/l (95 mM) concentration in the DNBCl-based color reagent for creatinine quantification.
sodium hydroxide,Sodium hydroxide is included at 2 N concentration in the DNBCl-based color reagent for creatinine quantification.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is included at 2 N concentration in the DNBCl-based color reagent for creatinine quantification.
ethylene glycol,"Ethylene glycol, when used as a solvent in the color reagent, increases color intensity but markedly decreases the stability of the color developed for creatinine quantification.","Entity: ethylene glycol. SMILES: OCCO. Ethylene glycol, when used as a solvent in the color reagent, increases color intensity but markedly decreases the stability of the color developed for creatinine quantification."
ethanol,"Ethanol, used as a solvent in the color reagent, increases color intensity but decreases the stability of the color for creatinine quantification compared to methanol.","Entity: ethanol. SMILES: CCO. Ethanol, used as a solvent in the color reagent, increases color intensity but decreases the stability of the color for creatinine quantification compared to methanol."
methanol,"Methanol, when used as a solvent in the color reagent, increases color intensity but decreases the stability of the color for creatinine quantification compared to ethylene glycol.","Entity: methanol. SMILES: CO. Methanol, when used as a solvent in the color reagent, increases color intensity but decreases the stability of the color for creatinine quantification compared to ethylene glycol."
isopropanol,"Isopropanol, used as a solvent in the color reagent, increases color intensity but decreases the stability of the color for creatinine quantification compared to glycerol.","Entity: isopropanol. SMILES: CC(C)O. Isopropanol, used as a solvent in the color reagent, increases color intensity but decreases the stability of the color for creatinine quantification compared to glycerol."
picrate,"Picrate is used in alkaline picrate methods for quantifying proteins, but these methods can be less sensitive and precise compared to alternative approaches such as the DNBCl method.","Entity: picrate. SMILES: O=[N+]([O-])c1cc([N+](=O)[O-])c([O-])c([N+](=O)[O-])c1. Picrate is used in alkaline picrate methods for quantifying proteins, but these methods can be less sensitive and precise compared to alternative approaches such as the DNBCl method."
hydantoin,"Hydantoin, a creatinine derivative, produces less interfering color in colorimetric assays using 3,5-dinitrobenzoic acid than in the Jaffe reaction.","Entity: hydantoin. SMILES: O=C1CNC(=O)N1. Hydantoin, a creatinine derivative, produces less interfering color in colorimetric assays using 3,5-dinitrobenzoic acid than in the Jaffe reaction."
creatinine,"Creatinine can be quantitatively measured in urine or serum using colorimetric methods based on 3,5-dinitrobenzoic acid in alkaline solution.","Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine can be quantitatively measured in urine or serum using colorimetric methods based on 3,5-dinitrobenzoic acid in alkaline solution."
"3,5-dinitrobenzoic acid","3,5-dinitrobenzoic acid (DNBA) is used in alkaline solution as a reagent for colorimetric detection of creatinine in urine or serum.","Entity: 3,5-dinitrobenzoic acid. SMILES: O=C(O)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1. 3,5-dinitrobenzoic acid (DNBA) is used in alkaline solution as a reagent for colorimetric detection of creatinine in urine or serum."
mercaptoethanol,"Mercaptoethanol is used as a reducing agent at a concentration of 1 mM in isotonic saline phosphate buffer (0.1 M, pH 7.2) for column chromatography applications.","Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol is used as a reducing agent at a concentration of 1 mM in isotonic saline phosphate buffer (0.1 M, pH 7.2) for column chromatography applications."
dithiothreitol,"Dithiothreitol is a reducing agent that, when added to a saline incubation mixture of BB-type CPK after 20 hours of incubation, intensifies the BB-type band in electrophoresis, indicating its ability to reduce the electrophoretic mobility of BB-type CPK.","Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is a reducing agent that, when added to a saline incubation mixture of BB-type CPK after 20 hours of incubation, intensifies the BB-type band in electrophoresis, indicating its ability to reduce the electrophoretic mobility of BB-type CPK."
phenazine methosulfate,Phenazine methosulfate is used at a concentration of 1.8 mg per 100 ml glycylglycine buffer as a staining reagent for electrophoresed proteins.,Entity: phenazine methosulfate. SMILES: COS(=O)(=O)[O-].C[n+]1c2ccccc2nc2ccccc21. Phenazine methosulfate is used at a concentration of 1.8 mg per 100 ml glycylglycine buffer as a staining reagent for electrophoresed proteins.
agarose,Agarose is used as a gel matrix for the electrophoretic separation of creatine kinase isozymes.,Entity: agarose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H]3OC[C@@H]2O[C@@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]4[C@H]5OC[C@@H]4O[C@@H](O)[C@H]5O)[C@@H]2O)[C@H]3O)[C@H](O)[C@@H](O)[C@H]1O. Agarose is used as a gel matrix for the electrophoretic separation of creatine kinase isozymes.
Tris,Tris is a component of the buffer system used in the electrophoresis of creatine kinase isozymes.,Entity: Tris. SMILES: NC(CO)(CO)CO. Tris is a component of the buffer system used in the electrophoresis of creatine kinase isozymes.
nitroblue tetrazolium,Nitroblue tetrazolium is used at a concentration of 37 mg per 100 ml glycylglycine buffer as a staining reagent in the detection of electrophoresed proteins.,Entity: nitroblue tetrazolium. SMILES: COc1cc(-c2ccc(-n3nc(-c4ccccc4)n[n+]3-c3ccc([N+](=O)[O-])cc3)c(OC)c2)ccc1-n1nc(-c2ccccc2)n[n+]1-c1ccc([N+](=O)[O-])cc1. Nitroblue tetrazolium is used at a concentration of 37 mg per 100 ml glycylglycine buffer as a staining reagent in the detection of electrophoresed proteins.
glycylglycine,"Glycylglycine buffer is used as the incubation and staining solution for electrophoresed proteins, including creatine kinase isozymes.","Entity: glycylglycine. SMILES: NCC(=O)NCC(=O)O. Glycylglycine buffer is used as the incubation and staining solution for electrophoresed proteins, including creatine kinase isozymes."
water,Distilled water is included at 20% concentration in the destaining solution for protein electrophoresis.,Entity: water. SMILES: O. Distilled water is included at 20% concentration in the destaining solution for protein electrophoresis.
acetic acid,Acetic acid is used at 5% concentration in the destaining solution for protein electrophoresis.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used at 5% concentration in the destaining solution for protein electrophoresis.
glycylglycine,"Glycylglycine is used at 50 mM concentration as a component of glycylglycine buffer (with 10 mM magnesium acetate, pH 7.2) in biochemical assays.","Entity: glycylglycine. SMILES: NCC(=O)NCC(=O)O. Glycylglycine is used at 50 mM concentration as a component of glycylglycine buffer (with 10 mM magnesium acetate, pH 7.2) in biochemical assays."
ethanol,Ethanol is used at 75% concentration as the solvent in the destaining solution for protein electrophoresis.,Entity: ethanol. SMILES: CCO. Ethanol is used at 75% concentration as the solvent in the destaining solution for protein electrophoresis.
barbital,Barbital is used as a component of Tris/barbital/sodium barbitol buffer (pH 8.8) for electrophoresis.,Entity: barbital. SMILES: CCC1(CC)C(=O)NC(=O)NC1=O. Barbital is used as a component of Tris/barbital/sodium barbitol buffer (pH 8.8) for electrophoresis.
magnesium acetate,Magnesium acetate is used as a component of glycylglycine buffer at 10 mM concentration for biochemical assays.,Entity: magnesium acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Mg+2]. Magnesium acetate is used as a component of glycylglycine buffer at 10 mM concentration for biochemical assays.
mercaptoethanol,"Mercaptoethanol at 15 mM is present in human plasma during incubation, and at 20 mM is added after 17 hours of incubation.","Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol at 15 mM is present in human plasma during incubation, and at 20 mM is added after 17 hours of incubation."
mercaptoethanol,Mercaptoethanol acts as a reducing agent that tends to reduce the rate of change in electrophoretic mobility of brain-type creatine phosphokinase (CPK) during incubation in human plasma.,Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol acts as a reducing agent that tends to reduce the rate of change in electrophoretic mobility of brain-type creatine phosphokinase (CPK) during incubation in human plasma.
mercaptoethanol,Mercaptoethanol is used as a reducing agent to assess the involvement of SH group oxidation in changes of electrophoretic mobility of BB-type creatine kinase.,Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol is used as a reducing agent to assess the involvement of SH group oxidation in changes of electrophoretic mobility of BB-type creatine kinase.
dithiothreitol,"Dithiothreitol (DTT) can fully reverse weak BB-type creatine kinase (CK) activity in rat and human brain homogenates incubated in saline without magnesium or phosphate, but only partially restore CK activity in homogenates incubated in saline containing magnesium and phosphate.","Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol (DTT) can fully reverse weak BB-type creatine kinase (CK) activity in rat and human brain homogenates incubated in saline without magnesium or phosphate, but only partially restore CK activity in homogenates incubated in saline containing magnesium and phosphate."
2-mercaptoethanol,2-mercaptoethanol reduces the rate of decrease in BB-CPK enzyme activity during incubation in human plasma.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol reduces the rate of decrease in BB-CPK enzyme activity during incubation in human plasma.
sodium azide,Sodium azide is used as a preservative in buffer solutions at a concentration of 3 mM for protein purification procedures.,Entity: sodium azide. SMILES: [N-]=[N+]=[N-].[Na+]. Sodium azide is used as a preservative in buffer solutions at a concentration of 3 mM for protein purification procedures.
sodium chloride,Sodium chloride is used at a concentration of 0.15 M in buffer solutions for protein purification and at 1 M in coupling buffer for protein immobilization.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at a concentration of 0.15 M in buffer solutions for protein purification and at 1 M in coupling buffer for protein immobilization.
ethanolamine,Ethanolamine is used at a concentration of 1 M in ethanolamine/HCl buffer (pH 8) for protein immobilization steps.,Entity: ethanolamine. SMILES: NCCO. Ethanolamine is used at a concentration of 1 M in ethanolamine/HCl buffer (pH 8) for protein immobilization steps.
sodium bicarbonate,Sodium bicarbonate is used at a concentration of 0.01 M (pH 7.5) in swelling buffer and at 0.1 M/Na2CO3 (pH 8.3) in coupling buffer for protein purification.,Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Sodium bicarbonate is used at a concentration of 0.01 M (pH 7.5) in swelling buffer and at 0.1 M/Na2CO3 (pH 8.3) in coupling buffer for protein purification.
hydrochloric acid,Hydrochloric acid is used at a concentration of 1 mM for washing Sepharose 4-B beads during protein immobilization.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used at a concentration of 1 mM for washing Sepharose 4-B beads during protein immobilization.
sodium acetate,Sodium acetate is used as a component of the coupling buffer at a concentration of 0.1 M NaAc/HAc and in acetate buffer at pH 4.0 for protein purification procedures.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate is used as a component of the coupling buffer at a concentration of 0.1 M NaAc/HAc and in acetate buffer at pH 4.0 for protein purification procedures.
sodium chloride,Sodium chloride is included at a concentration of 1 M in the coupling buffer and acetate buffer (pH 4.0) during protein purification protocols.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is included at a concentration of 1 M in the coupling buffer and acetate buffer (pH 4.0) during protein purification protocols.
hydrochloric acid,Hydrochloric acid is used in combination with sodium acetate to prepare the coupling buffer at pH 4.0 for protein purification applications.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used in combination with sodium acetate to prepare the coupling buffer at pH 4.0 for protein purification applications.
sodium chloride,Sodium chloride at a concentration of 1 M is used in combination with 0.01 M phosphate buffer (pH 7.4) and 3 mM sodium azide to achieve optimal binding of a tracer in the described assay.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride at a concentration of 1 M is used in combination with 0.01 M phosphate buffer (pH 7.4) and 3 mM sodium azide to achieve optimal binding of a tracer in the described assay.
sodium azide,Sodium azide at a concentration of 3 mM is included with 0.01 M phosphate buffer (pH 7.4) and 1 M sodium chloride to optimize tracer binding in the analyzed assay.,Entity: sodium azide. SMILES: [N-]=[N+]=[N-].[Na+]. Sodium azide at a concentration of 3 mM is included with 0.01 M phosphate buffer (pH 7.4) and 1 M sodium chloride to optimize tracer binding in the analyzed assay.
bile acid,Bile acid concentration in serum or bile can be roughly estimated using a modified radioimmunoassay for conjugated cholates.,Entity: bile acid. SMILES: CC(CCC(=O)O)C1CCC2C3C(C[C@H](O)C12C)C1(C)CC[C@@H](O)C[C@H]1C[C@H]3O. Bile acid concentration in serum or bile can be roughly estimated using a modified radioimmunoassay for conjugated cholates.
KH2PO4,KH2PO4 is used as a component of phosphate buffer at a concentration of 0.01 M in protein assay buffers.,Entity: KH2PO4. SMILES: O=P([O-])(O)O.[K+]. KH2PO4 is used as a component of phosphate buffer at a concentration of 0.01 M in protein assay buffers.
NaCl,NaCl is used at a concentration of 1 M in phosphate buffer for protein assay buffers.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used at a concentration of 1 M in phosphate buffer for protein assay buffers.
NaN3,NaN3 is used as a component of phosphate buffer at a concentration of 3 mM in protein assay buffers.,Entity: NaN3. SMILES: [N-]=[N+]=[N-].[Na+]. NaN3 is used as a component of phosphate buffer at a concentration of 3 mM in protein assay buffers.
K2HPO4,K2HPO4 is used as a component of phosphate buffer at a concentration of 0.01 M in protein assay buffers.,Entity: K2HPO4. SMILES: O=P([O-])([O-])O.[K+].[K+]. K2HPO4 is used as a component of phosphate buffer at a concentration of 0.01 M in protein assay buffers.
lysozyme,"Lysozyme diffusion assays can be quantified by measuring the diameter of the lysis zone formed around wells containing lysozyme, with the lysis zone diameter plotted against the logarithm of lysozyme concentration.","Entity: lysozyme. SMILES: CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(C)C)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C. Lysozyme diffusion assays can be quantified by measuring the diameter of the lysis zone formed around wells containing lysozyme, with the lysis zone diameter plotted against the logarithm of lysozyme concentration."
sulfate,"Sulfate ester groups are attached to the backbone of agarose in varying amounts, contributing to the chemical and physical properties of the hydrocolloid.","Entity: sulfate. SMILES: O=S(=O)([O-])[O-]. Sulfate ester groups are attached to the backbone of agarose in varying amounts, contributing to the chemical and physical properties of the hydrocolloid."
galactopyranose,"Agarose is composed of a backbone of agarbiose, which consists of repeating units of galactopyranose moieties.","Entity: galactopyranose. SMILES: OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O. Agarose is composed of a backbone of agarbiose, which consists of repeating units of galactopyranose moieties."
agarose,"The ionic parameters of agarose, specifically its sulfate content, significantly affect the diameter of the lysis zones in lysoplate assays, with lower sulfate content leading to larger lysis zones.","Entity: agarose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H]3OC[C@@H]2O[C@@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]4[C@H]5OC[C@@H]4O[C@@H](O)[C@H]5O)[C@@H]2O)[C@H]3O)[C@H](O)[C@@H](O)[C@H]1O. The ionic parameters of agarose, specifically its sulfate content, significantly affect the diameter of the lysis zones in lysoplate assays, with lower sulfate content leading to larger lysis zones."
lysine,"Lysine is a highly positively charged amino acid that contributes to the high cationic nature of human lysozyme, with a high proportion of lysine residues resulting in an isoelectric point of 11.1.","Entity: lysine. SMILES: NCCCC[C@H](N)C(=O)O. Lysine is a highly positively charged amino acid that contributes to the high cationic nature of human lysozyme, with a high proportion of lysine residues resulting in an isoelectric point of 11.1."
arginine,"Arginine is a highly positively charged amino acid that contributes to the high cationic nature of human lysozyme, with a high proportion of arginine residues resulting in an isoelectric point of 11.1.","Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine is a highly positively charged amino acid that contributes to the high cationic nature of human lysozyme, with a high proportion of arginine residues resulting in an isoelectric point of 11.1."
sulfate,"Sulfate anions are present in agarose preparations and influence the ionic composition of the gel, thereby affecting the diffusion of proteins such as lysozyme.","Entity: sulfate. SMILES: O=S(=O)([O-])[O-]. Sulfate anions are present in agarose preparations and influence the ionic composition of the gel, thereby affecting the diffusion of proteins such as lysozyme."
isobutane,Isobutane is used as a reagent in direct chemical ionization mass spectrometry for the determination of amino acids and other nitrogenous compounds in human urine.,Entity: isobutane. SMILES: CC(C)C. Isobutane is used as a reagent in direct chemical ionization mass spectrometry for the determination of amino acids and other nitrogenous compounds in human urine.
Vanillylmandelic acid,Vanillylmandelic acid (VMA) in urine can be quantitatively determined with a recovery of about 86% and a minimum detectable concentration of 2 mg/l using chromatographic methods.,Entity: Vanillylmandelic acid. SMILES: COc1cc(C(O)C(=O)O)ccc1O. Vanillylmandelic acid (VMA) in urine can be quantitatively determined with a recovery of about 86% and a minimum detectable concentration of 2 mg/l using chromatographic methods.
Vanillylmandelic acid,Vanillylmandelic acid (VMA) is stable under acidic conditions at -15°C during storage.,Entity: Vanillylmandelic acid. SMILES: COc1cc(C(O)C(=O)O)ccc1O. Vanillylmandelic acid (VMA) is stable under acidic conditions at -15°C during storage.
Homovanillic acid,Homovanillic acid (HVA) in urine can be quantitatively determined with a recovery of about 96% and a minimum detectable concentration of 2 mg/l using chromatographic methods.,Entity: Homovanillic acid. SMILES: COc1cc(CC(=O)O)ccc1O. Homovanillic acid (HVA) in urine can be quantitatively determined with a recovery of about 96% and a minimum detectable concentration of 2 mg/l using chromatographic methods.
Homovanillic acid,Homovanillic acid (HVA) is stable under acidic conditions at -15°C during storage.,Entity: Homovanillic acid. SMILES: COc1cc(CC(=O)O)ccc1O. Homovanillic acid (HVA) is stable under acidic conditions at -15°C during storage.
epinephrine,"Epinephrine is metabolized to vanillylmandelic acid, which is a major urinary catecholamine metabolite.","Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. Epinephrine is metabolized to vanillylmandelic acid, which is a major urinary catecholamine metabolite."
homovanillic acid,Homovanillic acid is a metabolite of dopamine and is one of the two most abundant catecholamine metabolites excreted in urine by patients with catecholamine-secreting tumors.,Entity: homovanillic acid. SMILES: COc1cc(CC(=O)O)ccc1O. Homovanillic acid is a metabolite of dopamine and is one of the two most abundant catecholamine metabolites excreted in urine by patients with catecholamine-secreting tumors.
vanillylmandelic acid,Vanillylmandelic acid is a metabolite of norepinephrine or epinephrine and is one of the two most abundant catecholamine metabolites excreted in urine by patients with catecholamine-secreting tumors.,Entity: vanillylmandelic acid. SMILES: COc1cc(C(O)C(=O)O)ccc1O. Vanillylmandelic acid is a metabolite of norepinephrine or epinephrine and is one of the two most abundant catecholamine metabolites excreted in urine by patients with catecholamine-secreting tumors.
dopamine,"Dopamine is metabolized to homovanillic acid, which is a major urinary catecholamine metabolite.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine is metabolized to homovanillic acid, which is a major urinary catecholamine metabolite."
norepinephrine,"Norepinephrine is metabolized to vanillylmandelic acid, which is a major urinary catecholamine metabolite.","Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Norepinephrine is metabolized to vanillylmandelic acid, which is a major urinary catecholamine metabolite."
HVA,The mean urinary excretion of HVA in normal subjects not consuming refreshments is 4.0 ± 1.0 mg/day (range 2.6–6.0 mg/day).,Entity: HVA. SMILES: COc1cc(CC(=O)O)ccc1O. The mean urinary excretion of HVA in normal subjects not consuming refreshments is 4.0 ± 1.0 mg/day (range 2.6–6.0 mg/day).
VMA,The mean urinary excretion of VMA in normal subjects not consuming refreshments is 2.0 ± 0.7 mg/day (range 0.6–3.2 mg/day).,Entity: VMA. SMILES: COc1cc(C(O)C(=O)O)ccc1O. The mean urinary excretion of VMA in normal subjects not consuming refreshments is 2.0 ± 0.7 mg/day (range 0.6–3.2 mg/day).
VMA,"In normal subjects, the mean urinary excretion of vanilmandelic acid (VMA) is 2.0 ± 0.7 mg/day.","Entity: VMA. SMILES: COc1cc(C(O)C(=O)O)ccc1O. In normal subjects, the mean urinary excretion of vanilmandelic acid (VMA) is 2.0 ± 0.7 mg/day."
HVA,"In normal subjects, the mean urinary excretion of homovanillic acid (HVA) is 4.0 ± 1.0 mg/day.","Entity: HVA. SMILES: COc1cc(CC(=O)O)ccc1O. In normal subjects, the mean urinary excretion of homovanillic acid (HVA) is 4.0 ± 1.0 mg/day."
5-Hydroxyindoleacetic acid,5-Hydroxyindoleacetic acid (5-HIAA) is an indole acid that is excreted in urine and can be eluted from a chromatographic column under the described conditions.,Entity: 5-Hydroxyindoleacetic acid. SMILES: O=C(O)Cc1cc2cc(O)ccc2[nH]1. 5-Hydroxyindoleacetic acid (5-HIAA) is an indole acid that is excreted in urine and can be eluted from a chromatographic column under the described conditions.
mandelic acid,Mandelic acid is an aromatic acid that is excreted in urine and can be eluted from a chromatographic column at 60 to 120 minutes under the described conditions.,Entity: mandelic acid. SMILES: O=C(O)C(O)c1ccccc1. Mandelic acid is an aromatic acid that is excreted in urine and can be eluted from a chromatographic column at 60 to 120 minutes under the described conditions.
4-hydroxy-3-methoxyphenylethanol,4-hydroxy-3-methoxyphenylethanol is a phenolic acid that is not eluted from the described chromatographic column under the present conditions.,Entity: 4-hydroxy-3-methoxyphenylethanol. SMILES: COc1cc(C(C)O)ccc1O. 4-hydroxy-3-methoxyphenylethanol is a phenolic acid that is not eluted from the described chromatographic column under the present conditions.
phenylpyruvic acid,Phenylpyruvic acid is an aromatic acid that is excreted in urine and can be eluted from a chromatographic column at 60 to 120 minutes under the described conditions.,Entity: phenylpyruvic acid. SMILES: O=C(O)C(=O)Cc1ccccc1. Phenylpyruvic acid is an aromatic acid that is excreted in urine and can be eluted from a chromatographic column at 60 to 120 minutes under the described conditions.
phenylacetic acid,Phenylacetic acid is an aromatic acid that is excreted in urine and can be eluted from a chromatographic column at 60 to 120 minutes under the described conditions.,Entity: phenylacetic acid. SMILES: O=C(O)Cc1ccccc1. Phenylacetic acid is an aromatic acid that is excreted in urine and can be eluted from a chromatographic column at 60 to 120 minutes under the described conditions.
VMA,VMA (3-methoxy-4-hydroxyphenyllactic acid) is a catecholamine-originated phenolic acid that is excreted in urine and can be separated from iso-HVA by chromatographic methods.,Entity: VMA. SMILES: COc1cc(C(O)C(=O)O)ccc1O. VMA (3-methoxy-4-hydroxyphenyllactic acid) is a catecholamine-originated phenolic acid that is excreted in urine and can be separated from iso-HVA by chromatographic methods.
phenyllactic acid,Phenyllactic acid is an aromatic acid that is excreted in urine and can be eluted from a chromatographic column at 60 to 120 minutes under the described conditions.,Entity: phenyllactic acid. SMILES: CC(O)(C(=O)O)c1ccccc1. Phenyllactic acid is an aromatic acid that is excreted in urine and can be eluted from a chromatographic column at 60 to 120 minutes under the described conditions.
Homovanillic acid,"Homovanillic acid (HVA) can form conjugates in urine that are detectable in patients with neuroblastoma and in normal subjects, though only at trace levels in the latter.","Entity: Homovanillic acid. SMILES: COc1cc(CC(=O)O)ccc1O. Homovanillic acid (HVA) can form conjugates in urine that are detectable in patients with neuroblastoma and in normal subjects, though only at trace levels in the latter."
Hydrochloric acid,"Addition of one tenth volume of 12 N hydrochloric acid to HVA conjugate solutions lowers the pH below 0.1, inducing partial hydrolysis of HVA conjugates.","Entity: Hydrochloric acid. SMILES: Cl. Addition of one tenth volume of 12 N hydrochloric acid to HVA conjugate solutions lowers the pH below 0.1, inducing partial hydrolysis of HVA conjugates."
VMA,VMA (3-methoxy-4-methylaminobutyric acid) excretion in the urine is normal in patients with neuroblastoma but may be elevated in patients with phaeochromocytoma.,Entity: VMA. SMILES: COc1cc(C(O)C(=O)O)ccc1O. VMA (3-methoxy-4-methylaminobutyric acid) excretion in the urine is normal in patients with neuroblastoma but may be elevated in patients with phaeochromocytoma.
HVA,HVA (3-methoxy-4-hydroxyphenyllactic acid) excretion in the urine is elevated in patients with neuroblastoma but not in patients with phaeochromocytoma.,Entity: HVA. SMILES: COc1cc(CC(=O)O)ccc1O. HVA (3-methoxy-4-hydroxyphenyllactic acid) excretion in the urine is elevated in patients with neuroblastoma but not in patients with phaeochromocytoma.
thyroxine,The mean physiological day-to-day variation in serum thyroxine concentration in healthy subjects is 7.5% as measured by coefficient of variation.,Entity: thyroxine. SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O. The mean physiological day-to-day variation in serum thyroxine concentration in healthy subjects is 7.5% as measured by coefficient of variation.
triglyceride,The mean physiological day-to-day variation in serum triglyceride concentration in healthy subjects is 25.0% as measured by coefficient of variation.,Entity: triglyceride. SMILES: O=COCC(COC=O)OC=O. The mean physiological day-to-day variation in serum triglyceride concentration in healthy subjects is 25.0% as measured by coefficient of variation.
methanol,Methanol should be routinely added to the scintillation cocktail when toluene-based scintillation fluid is used to prevent interference with sphingolipid binding assays.,Entity: methanol. SMILES: CO. Methanol should be routinely added to the scintillation cocktail when toluene-based scintillation fluid is used to prevent interference with sphingolipid binding assays.
toluene,"Toluene-based scintillation fluid can bind sphingolipids, leading to inaccurate enzyme activity measurements unless methanol is added to the cocktail.","Entity: toluene. SMILES: Cc1ccccc1. Toluene-based scintillation fluid can bind sphingolipids, leading to inaccurate enzyme activity measurements unless methanol is added to the cocktail."
galactocerebroside,"Galactocerebroside binds to the wall of glass scintillation vials, decreasing counting efficiency when used to label sphingolipids.","Entity: galactocerebroside. SMILES: CCCCCCCCCCCCC/C=C\C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O. Galactocerebroside binds to the wall of glass scintillation vials, decreasing counting efficiency when used to label sphingolipids."
methanol,"Methanol (6–10%, v/v) in scintillation fluid largely eliminates the binding of lipids such as galactocerebroside and sphingomyelin to glass vial walls, thereby improving counting efficiency.","Entity: methanol. SMILES: CO. Methanol (6–10%, v/v) in scintillation fluid largely eliminates the binding of lipids such as galactocerebroside and sphingomyelin to glass vial walls, thereby improving counting efficiency."
methanol,"Methanol is highly effective in stripping lipids from the walls of scintillation vials, and its incorporation into scintillation cocktails greatly reduces or eliminates lipid-induced background counts.","Entity: methanol. SMILES: CO. Methanol is highly effective in stripping lipids from the walls of scintillation vials, and its incorporation into scintillation cocktails greatly reduces or eliminates lipid-induced background counts."
POPOP,"POPOP is used as a component of scintillation cocktails, such as in a mixture with PPO and toluene for liquid scintillation counting.","Entity: POPOP. SMILES: c1ccc(-c2cnc(-c3ccc(-c4ncc(-c5ccccc5)o4)cc3)o2)cc1. POPOP is used as a component of scintillation cocktails, such as in a mixture with PPO and toluene for liquid scintillation counting."
PPO,"PPO is used as a component of scintillation cocktails, such as in a mixture with POPOP and toluene for liquid scintillation counting.","Entity: PPO. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. PPO is used as a component of scintillation cocktails, such as in a mixture with POPOP and toluene for liquid scintillation counting."
toluene,Toluene is used as a solvent for preparing scintillation cocktails containing PPO and POPOP for liquid scintillation counting.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a solvent for preparing scintillation cocktails containing PPO and POPOP for liquid scintillation counting.
methanol,Methanol at 10% (v/v) in toluene increases the counting efficiency of a scintillation cocktail from 63% to 48% when using PPO and POPOP.,Entity: methanol. SMILES: CO. Methanol at 10% (v/v) in toluene increases the counting efficiency of a scintillation cocktail from 63% to 48% when using PPO and POPOP.
trichloroacetic acid,Trichloroacetic acid (TCA) is used at 2.2 mol/l concentration to precipitate proteins from solution.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid (TCA) is used at 2.2 mol/l concentration to precipitate proteins from solution.
sodium hydroxide,Sodium hydroxide is used to adjust the pH of acetic acid to 6.5 during glycoprotein material preparation.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to adjust the pH of acetic acid to 6.5 during glycoprotein material preparation.
sodium chloride,Sodium chloride at 50 mmol/l is used as an elution buffer in Sephadex G-100 chromatography to resolve protein fractions.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride at 50 mmol/l is used as an elution buffer in Sephadex G-100 chromatography to resolve protein fractions.
ethanol,Ethanol at 2 mol/l is used as a solvent for suspending wheat gluten in the preparation of glycoprotein material.,Entity: ethanol. SMILES: CCO. Ethanol at 2 mol/l is used as a solvent for suspending wheat gluten in the preparation of glycoprotein material.
acetic acid,Acetic acid at 0.1 mol/l is used as a solvent for redissolving protein precipitates and as a buffer in glycoprotein material preparation.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid at 0.1 mol/l is used as a solvent for redissolving protein precipitates and as a buffer in glycoprotein material preparation.
methionine,"In glyc-gli protein, the proportion of methionine is greater than in other gluten-containing proteins.","Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. In glyc-gli protein, the proportion of methionine is greater than in other gluten-containing proteins."
glutamic acid,"In glyc-gli protein, the proportion of glutamic acid is much smaller than in gluten or cu-gliadin.","Entity: glutamic acid. SMILES: N[C@@H](CCC(=O)O)C(=O)O. In glyc-gli protein, the proportion of glutamic acid is much smaller than in gluten or cu-gliadin."
proline,"In glyc-gli protein, the proportion of proline is much greater than in gluten or cu-gliadin.","Entity: proline. SMILES: O=C(O)[C@@H]1CCCN1. In glyc-gli protein, the proportion of proline is much greater than in gluten or cu-gliadin."
phenylalanine,"In glyc-gli protein, the proportion of phenylalanine is small compared to other gluten-containing proteins.","Entity: phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. In glyc-gli protein, the proportion of phenylalanine is small compared to other gluten-containing proteins."
lysine,"In glyc-gli protein, the proportion of lysine is greater than in other gluten-containing proteins.","Entity: lysine. SMILES: NCCCC[C@H](N)C(=O)O. In glyc-gli protein, the proportion of lysine is greater than in other gluten-containing proteins."
alanine,"In glyc-gli protein, the proportion of alanine is greater than in other gluten-containing proteins.","Entity: alanine. SMILES: C[C@H](N)C(=O)O. In glyc-gli protein, the proportion of alanine is greater than in other gluten-containing proteins."
tyrosine,"In glyc-gli protein, the proportion of tyrosine is apparently absent.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. In glyc-gli protein, the proportion of tyrosine is apparently absent."
serine,"In glyc-gli protein, the proportion of serine is small compared to other gluten-containing proteins.","Entity: serine. SMILES: N[C@@H](CO)C(=O)O. In glyc-gli protein, the proportion of serine is small compared to other gluten-containing proteins."
threonine,"In glyc-gli protein, the proportion of threonine is small compared to other gluten-containing proteins.","Entity: threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. In glyc-gli protein, the proportion of threonine is small compared to other gluten-containing proteins."
glycine,"In glyc-gli protein, the proportion of glycine is greater than in other gluten-containing proteins.","Entity: glycine. SMILES: NCC(=O)O. In glyc-gli protein, the proportion of glycine is greater than in other gluten-containing proteins."
fucose,Fucose can be quantified in glyc-gli material using standard analytical methods such as paper chromatography.,Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose can be quantified in glyc-gli material using standard analytical methods such as paper chromatography.
hexose,Total hexoses in glyc-gli material can be measured using standard analytical methods.,Entity: hexose. SMILES: OCC1OC(O)C(O)C(O)C1O. Total hexoses in glyc-gli material can be measured using standard analytical methods.
concanavalin A,Concanavalin A can affect cell multiplication or directly kill cells by acting on the cell membrane.,Entity: concanavalin A. SMILES: CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1.Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O. Concanavalin A can affect cell multiplication or directly kill cells by acting on the cell membrane.
rhamnose,"Rhamnose can block binding of a carbohydrate-containing material from gluten to coeliac intestinal mucosa, suggesting it acts as a sugar haptene.","Entity: rhamnose. SMILES: C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O. Rhamnose can block binding of a carbohydrate-containing material from gluten to coeliac intestinal mucosa, suggesting it acts as a sugar haptene."
rhamnose,Rhamnose interferes with binding to a carbohydrate-containing macromolecule on the surface of intestinal cell membranes.,Entity: rhamnose. SMILES: C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O. Rhamnose interferes with binding to a carbohydrate-containing macromolecule on the surface of intestinal cell membranes.
galactosamine,Galactosamine interferes with binding to a carbohydrate-containing macromolecule on the surface of intestinal cell membranes.,Entity: galactosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. Galactosamine interferes with binding to a carbohydrate-containing macromolecule on the surface of intestinal cell membranes.
arabinose,Arabinose interferes with binding to a carbohydrate-containing macromolecule on the surface of intestinal cell membranes.,Entity: arabinose. SMILES: O=C[C@@H](O)[C@H](O)[C@H](O)CO. Arabinose interferes with binding to a carbohydrate-containing macromolecule on the surface of intestinal cell membranes.
rhamnose,Rhamnose reduces coeliac mucosa binding by 40.0% ± 3.5 in the tested assay.,Entity: rhamnose. SMILES: C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O. Rhamnose reduces coeliac mucosa binding by 40.0% ± 3.5 in the tested assay.
galactosamine,Galactosamine increases coeliac mucosa binding by 46.6% ± 10.2 and normal mucosa binding by 41.3% ± 10.1 in the tested assay.,Entity: galactosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. Galactosamine increases coeliac mucosa binding by 46.6% ± 10.2 and normal mucosa binding by 41.3% ± 10.1 in the tested assay.
arabinose,Arabinose reduces coeliac mucosa binding by 30.5% ± 6.2 and normal mucosa binding by 26.0% ± 3.2 in the tested assay.,Entity: arabinose. SMILES: O=C[C@@H](O)[C@H](O)[C@H](O)CO. Arabinose reduces coeliac mucosa binding by 30.5% ± 6.2 and normal mucosa binding by 26.0% ± 3.2 in the tested assay.
Prolactin,Prolactin concentrations in amniotic fluid are about 9-fold higher than those in plasma from the same women.,Entity: Prolactin. Prolactin concentrations in amniotic fluid are about 9-fold higher than those in plasma from the same women.
Prolactin,"Prolactin concentrations in amniotic fluid range from 36 ng/ml to 1800 ng/ml (mean ± S.D. = 408 ± 297 ng/ml) in women with normal pregnancies, with no significant difference in levels between normal and complicated pregnancies.","Entity: Prolactin. Prolactin concentrations in amniotic fluid range from 36 ng/ml to 1800 ng/ml (mean ± S.D. = 408 ± 297 ng/ml) in women with normal pregnancies, with no significant difference in levels between normal and complicated pregnancies."
glutathione disulfide,"Glutathione disulfide acts as an oxidizing agent that decreases the affinities of PK for PEP and FDP, and this effect can be partially or completely reversed by certain reducing agents.","Entity: glutathione disulfide. SMILES: N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O. Glutathione disulfide acts as an oxidizing agent that decreases the affinities of PK for PEP and FDP, and this effect can be partially or completely reversed by certain reducing agents."
mercaptoethanol,Mercaptoethanol restores the kinetics of a PK isozyme with increased PEP affinity (decreased half-saturation constant) and loss of cooperativity between PEP binding sites.,Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol restores the kinetics of a PK isozyme with increased PEP affinity (decreased half-saturation constant) and loss of cooperativity between PEP binding sites.
glutathione,Physiologic concentrations of glutathione are ineffective in altering the kinetics of normal or PK-deficient enzyme in hemolysates or purified preparations.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Physiologic concentrations of glutathione are ineffective in altering the kinetics of normal or PK-deficient enzyme in hemolysates or purified preparations.
PEP,"In erythrocyte glycolytic enzyme systems, the K0.5 for PEP is more than 10 times greater than normal and decreases to half its original value after FDP activation, but remains 10-fold greater than control systems with FDP.","Entity: PEP. SMILES: C=C(OP(=O)(O)O)C(=O)O. In erythrocyte glycolytic enzyme systems, the K0.5 for PEP is more than 10 times greater than normal and decreases to half its original value after FDP activation, but remains 10-fold greater than control systems with FDP."
PEP,"The mean Hill coefficient (nu) for PEP binding in erythrocyte glycolytic enzyme systems is 1.3, indicating slight positive cooperativity between PEP binding sites in the absence of FDP, which is lost after FDP activation (nu < 1).","Entity: PEP. SMILES: C=C(OP(=O)(O)O)C(=O)O. The mean Hill coefficient (nu) for PEP binding in erythrocyte glycolytic enzyme systems is 1.3, indicating slight positive cooperativity between PEP binding sites in the absence of FDP, which is lost after FDP activation (nu < 1)."
PEP,"PEP can serve as a variable substrate in kinetic studies of erythrocyte glycolytic enzymes, where its absence leads to first-order reaction kinetics over a broad concentration range.","Entity: PEP. SMILES: C=C(OP(=O)(O)O)C(=O)O. PEP can serve as a variable substrate in kinetic studies of erythrocyte glycolytic enzymes, where its absence leads to first-order reaction kinetics over a broad concentration range."
magnesium sulfate,Magnesium sulfate is used at 8 mM concentration in the assay system for measuring phosphokinase (PK) activities in erythrocyte lysates.,Entity: magnesium sulfate. SMILES: O=S(=O)([O-])[O-].[Mg+2]. Magnesium sulfate is used at 8 mM concentration in the assay system for measuring phosphokinase (PK) activities in erythrocyte lysates.
phosphoenolpyruvate,Phosphoenolpyruvate is included at final concentrations of 2.0 mM or 3.0 mM in the assay system for assessing phosphokinase (PK) activity in erythrocytes.,Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate is included at final concentrations of 2.0 mM or 3.0 mM in the assay system for assessing phosphokinase (PK) activity in erythrocytes.
triethanolamine hydrochloride,Triethanolamine hydrochloride buffer at 8.3 mM and pH 7.5 is used as the reaction medium in the assay for measuring phosphokinase (PK) activity in erythrocytes.,Entity: triethanolamine hydrochloride. SMILES: Cl.OCCN(CCO)CCO. Triethanolamine hydrochloride buffer at 8.3 mM and pH 7.5 is used as the reaction medium in the assay for measuring phosphokinase (PK) activity in erythrocytes.
glutathione,Glutathione concentration in fresh blood perchloric acid extracts can be measured using the Beutler et al. assay method.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione concentration in fresh blood perchloric acid extracts can be measured using the Beutler et al. assay method.
adenosine diphosphate,Adenosine diphosphate is used at a final concentration of 0.4 mM in the assay system to determine apparent Michaelis-Menten constants for phosphokinase (PK) activity in erythrocytes.,Entity: adenosine diphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine diphosphate is used at a final concentration of 0.4 mM in the assay system to determine apparent Michaelis-Menten constants for phosphokinase (PK) activity in erythrocytes.
potassium chloride,Potassium chloride is included at 75 mM concentration in the assay system for measuring phosphokinase (PK) activity in erythrocyte lysates.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is included at 75 mM concentration in the assay system for measuring phosphokinase (PK) activity in erythrocyte lysates.
PEP,"In a PK enzyme assay system using 0.4 mM ADP and 2.0 mM PEP, normal controls exhibited a mean pyruvate kinase activity of 2.7 U (SD = 0.5 U).","Entity: PEP. SMILES: C=C(OP(=O)(O)O)C(=O)O. In a PK enzyme assay system using 0.4 mM ADP and 2.0 mM PEP, normal controls exhibited a mean pyruvate kinase activity of 2.7 U (SD = 0.5 U)."
ADP,"In a PK enzyme assay system containing 0.4 mM ADP and 2.0 mM PEP, normal controls showed a mean pyruvate kinase activity of 2.7 U (SD = 0.5 U).","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. In a PK enzyme assay system containing 0.4 mM ADP and 2.0 mM PEP, normal controls showed a mean pyruvate kinase activity of 2.7 U (SD = 0.5 U)."
PEP,"For proband hemolysates, a substrate concentration of 5 to 10 mM PEP is required to achieve maximum pyruvate kinase (PK) activity in kinetic assays.","Entity: PEP. SMILES: C=C(OP(=O)(O)O)C(=O)O. For proband hemolysates, a substrate concentration of 5 to 10 mM PEP is required to achieve maximum pyruvate kinase (PK) activity in kinetic assays."
ADP,"The half-saturation constant (K0.5s) for PEP in erythrocyte pyruvate kinase assays is progressively dependent on ADP concentrations, indicating that ADP concentration modulates enzyme activity.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. The half-saturation constant (K0.5s) for PEP in erythrocyte pyruvate kinase assays is progressively dependent on ADP concentrations, indicating that ADP concentration modulates enzyme activity."
FDP,FDP reduces the K0.5 of PEP to 0.08 mM in normal control preparations.,Entity: FDP. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. FDP reduces the K0.5 of PEP to 0.08 mM in normal control preparations.
FDP,FDP doubles the observed enzymatic activities over the full range of ADP concentrations studied.,Entity: FDP. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. FDP doubles the observed enzymatic activities over the full range of ADP concentrations studied.
ADP,"ADP is a variable substrate in enzymatic assays, and its concentration influences the observed enzymatic activities.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP is a variable substrate in enzymatic assays, and its concentration influences the observed enzymatic activities."
FDP,FDP requires concentrations that are two orders of magnitude higher than controls to achieve half-maximal activation of the described isozyme.,Entity: FDP. SMILES: [F-]. FDP requires concentrations that are two orders of magnitude higher than controls to achieve half-maximal activation of the described isozyme.
PEP,"The described isozyme exhibits a lower affinity for PEP and reduced cooperative interaction between PEP binding sites, as indicated by Hill coefficients lower than normal.","Entity: PEP. SMILES: C=C(OP(=O)(O)O)C(=O)O. The described isozyme exhibits a lower affinity for PEP and reduced cooperative interaction between PEP binding sites, as indicated by Hill coefficients lower than normal."
phosphoglycerate,Elevated phosphoglycerates are a characteristic finding in patients with quantitative PK deficiency.,Entity: phosphoglycerate. SMILES: O=C([O-])C(CO)OP(=O)(O)O. Elevated phosphoglycerates are a characteristic finding in patients with quantitative PK deficiency.
PEP,Elevated PEP levels are commonly observed in patients with quantitative PK deficiency.,Entity: PEP. SMILES: C=C(OP(=O)(O)O)C(=O)O. Elevated PEP levels are commonly observed in patients with quantitative PK deficiency.
glutathione,Glutathione content is normal in patients with quantitative PK deficiency.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione content is normal in patients with quantitative PK deficiency.
FDP,"FDP (fluoride-dopamine phosphate) addition to the assay system maintains the initial level of plasminogen kinase (PK) activity in erythrocytes from propositus II-1 for more than 18 days, whereas in normal controls, PK activity decays over the same period.","Entity: FDP. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)CO. FDP (fluoride-dopamine phosphate) addition to the assay system maintains the initial level of plasminogen kinase (PK) activity in erythrocytes from propositus II-1 for more than 18 days, whereas in normal controls, PK activity decays over the same period."
ADP,ADP (adenosine diphosphate) is used as a substrate at 2.0 mM concentration in the plasminogen kinase activity assay system.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP (adenosine diphosphate) is used as a substrate at 2.0 mM concentration in the plasminogen kinase activity assay system.
PEP,PEP (phosphoryl ethyl phosphoryl) is used as a substrate at 3.0 mM concentration in the plasminogen kinase activity assay system.,Entity: PEP. SMILES: C=C(OP(=O)(O)O)C(=O)O. PEP (phosphoryl ethyl phosphoryl) is used as a substrate at 3.0 mM concentration in the plasminogen kinase activity assay system.
phosphoenolpyruvate,"The mutant erythrocyte pyruvate kinase isozyme exhibits a 5- to 10-fold increase in half-saturation constant for phosphoenolpyruvate compared to the normal enzyme, indicating markedly decreased affinity for the substrate.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. The mutant erythrocyte pyruvate kinase isozyme exhibits a 5- to 10-fold increase in half-saturation constant for phosphoenolpyruvate compared to the normal enzyme, indicating markedly decreased affinity for the substrate."
PEP,"The half-saturation constant (Koass) for PEP in propositus 11-2 cells is 2.4 mM in young, buoyant cells and decreases to 0.8–0.9 mM after FDP activation, with no difference between young and old cell populations.","Entity: PEP. SMILES: C=C(OP(=O)(O)O)C(=O)O. The half-saturation constant (Koass) for PEP in propositus 11-2 cells is 2.4 mM in young, buoyant cells and decreases to 0.8–0.9 mM after FDP activation, with no difference between young and old cell populations."
phosphoenolpyruvate,"Phosphoenolpyruvate is the substrate for erythrocyte pyruvate kinase (PK), and in PK-deficient states, the PK isozyme may exhibit markedly decreased affinity for this substrate.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate is the substrate for erythrocyte pyruvate kinase (PK), and in PK-deficient states, the PK isozyme may exhibit markedly decreased affinity for this substrate."
"fructose 1,6-diphosphate","Fructose 1,6-diphosphate acts as an activator of erythrocyte pyruvate kinase (PK), and in families with PK deficiency, the PK isozyme may have markedly decreased affinity for this activator.","Entity: fructose 1,6-diphosphate. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose 1,6-diphosphate acts as an activator of erythrocyte pyruvate kinase (PK), and in families with PK deficiency, the PK isozyme may have markedly decreased affinity for this activator."
oxygen,Oxygen is utilized as a measure of electron transfer during the oxidation of free cholesterol by cholesterol oxidase in an enzymatic assay.,Entity: oxygen. SMILES: [O]. Oxygen is utilized as a measure of electron transfer during the oxidation of free cholesterol by cholesterol oxidase in an enzymatic assay.
sterols,Sterols can be assayed in subcellular fractions of cells using a method that measures oxygen consumption during cholesterol oxidase-mediated oxidation.,Entity: sterols. SMILES: OC1CCC2C(CCC3C4CCCC4CCC23)C1. Sterols can be assayed in subcellular fractions of cells using a method that measures oxygen consumption during cholesterol oxidase-mediated oxidation.
NaN3,"NaN3 is used as a preservative at 0.05% concentration in 0.01 M Tris/HCl buffer, pH 7.3, for equilibration of Sephadex G-75 columns in gel chromatography.","Entity: NaN3. SMILES: [N-]=[N+]=[N-].[Na+]. NaN3 is used as a preservative at 0.05% concentration in 0.01 M Tris/HCl buffer, pH 7.3, for equilibration of Sephadex G-75 columns in gel chromatography."
sulfuric acid,Sulfuric acid (0.25 M) is used at 100°C for 18 hours in the hydrolysis of sugars released from α-microglobulin.,Entity: sulfuric acid. SMILES: O=S(=O)(O)O. Sulfuric acid (0.25 M) is used at 100°C for 18 hours in the hydrolysis of sugars released from α-microglobulin.
D-xylose,D-xylose is used as an internal standard in the hydrolysis of α-microglobulin for sugar analysis.,Entity: D-xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. D-xylose is used as an internal standard in the hydrolysis of α-microglobulin for sugar analysis.
formic acid,Formic acid (90%) is used as a reagent for hydrolyzing α-microglobulin in sugar analysis protocols.,Entity: formic acid. SMILES: O=CO. Formic acid (90%) is used as a reagent for hydrolyzing α-microglobulin in sugar analysis protocols.
phenylalanine,"Deuterated phenylalanine can be quantitatively recovered from human plasma using a method involving Edman reaction derivatization, high pressure liquid chromatography, and mass spectrometry.","Entity: phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. Deuterated phenylalanine can be quantitatively recovered from human plasma using a method involving Edman reaction derivatization, high pressure liquid chromatography, and mass spectrometry."
tyrosine,"Deuterated tyrosine can be quantitatively recovered from human plasma using a method involving Edman reaction derivatization, high pressure liquid chromatography, and mass spectrometry.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Deuterated tyrosine can be quantitatively recovered from human plasma using a method involving Edman reaction derivatization, high pressure liquid chromatography, and mass spectrometry."
Phenylthiohydantoine,Phenylthiohydantoine derivatives are formed from amino acids such as phenylalanine and tyrosine via the Edman reaction and are used for their separation and isolation in plasma.,Entity: Phenylthiohydantoine. SMILES: O=C1CN(c2ccccc2)C(=S)N1. Phenylthiohydantoine derivatives are formed from amino acids such as phenylalanine and tyrosine via the Edman reaction and are used for their separation and isolation in plasma.
acetone,Acetone is used as a solvent to precipitate proteins from plasma during blood sample preparation.,Entity: acetone. SMILES: CC(C)=O. Acetone is used as a solvent to precipitate proteins from plasma during blood sample preparation.
hydrochloric acid,Hydrochloric acid is used to adjust the pH to 0-1 during the extraction of PTH amino acids from reaction mixtures.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to adjust the pH to 0-1 during the extraction of PTH amino acids from reaction mixtures.
triethylammonium acetate,Triethylammonium acetate is used as a buffer in chemical reactions involving amino acid derivatization.,Entity: triethylammonium acetate. SMILES: CC(=O)[O-].CC[NH+](CC)CC. Triethylammonium acetate is used as a buffer in chemical reactions involving amino acid derivatization.
dichloromethane,Dichloromethane is used as an extraction solvent to isolate PTH amino acids from reaction mixtures.,Entity: dichloromethane. SMILES: ClCCl. Dichloromethane is used as an extraction solvent to isolate PTH amino acids from reaction mixtures.
benzene,Benzene is used as an organic phase in the extraction process for separating compounds from aqueous solutions.,Entity: benzene. SMILES: c1ccccc1. Benzene is used as an organic phase in the extraction process for separating compounds from aqueous solutions.
phenylthioisocyanate,Phenylthioisocyanate is used as a reagent in chemical reactions to derivatize amino acids for subsequent extraction and analysis.,Entity: phenylthioisocyanate. SMILES: O=C=NSc1ccccc1. Phenylthioisocyanate is used as a reagent in chemical reactions to derivatize amino acids for subsequent extraction and analysis.
acetic acid,Acetic acid is used as a component of 1 N hydrochloride in acetic acid to adjust the pH during chemical processing.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component of 1 N hydrochloride in acetic acid to adjust the pH during chemical processing.
phenylalanine,"In healthy individuals, total phenylalanine plasma concentrations after a phenylalanine load typically range from the observed peak values in the referenced study.","Entity: phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. In healthy individuals, total phenylalanine plasma concentrations after a phenylalanine load typically range from the observed peak values in the referenced study."
phenylalanine,Deuterated phenylalanine in plasma reaches a peak value of 3.19 mg/100 ml after one hour in healthy individuals.,Entity: phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. Deuterated phenylalanine in plasma reaches a peak value of 3.19 mg/100 ml after one hour in healthy individuals.
tyrosine,"In healthy individuals, total tyrosine plasma concentrations after a tyrosine load typically range from the observed peak values in the referenced study.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. In healthy individuals, total tyrosine plasma concentrations after a tyrosine load typically range from the observed peak values in the referenced study."
tyrosine,Deuterated tyrosine in plasma reaches a peak value of 0.60 mg/100 ml after one hour in healthy individuals.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Deuterated tyrosine in plasma reaches a peak value of 0.60 mg/100 ml after one hour in healthy individuals.
phenylalanine,The molecular ion peak of PTH-phenylalanine (m/e 282) is used for mass spectroscopic determination of its deuterium content.,Entity: phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. The molecular ion peak of PTH-phenylalanine (m/e 282) is used for mass spectroscopic determination of its deuterium content.
valine,Valine can be partially separated from phenylalanine in plasma samples using chromatography with increased hexane content in the elution solvent.,Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. Valine can be partially separated from phenylalanine in plasma samples using chromatography with increased hexane content in the elution solvent.
valine,"Valine has a lower evaporation temperature in the ion source compared to phenylalanine, which can reduce its interference in mass spectrometry analyses.","Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. Valine has a lower evaporation temperature in the ion source compared to phenylalanine, which can reduce its interference in mass spectrometry analyses."
tyrosine,The deuterium content of tyrosine in plasma can be determined by comparing the intensity of the molecular ion peak (M') to the M + 1 peak after correcting for the contribution of naturally occurring 13C and 'H.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. The deuterium content of tyrosine in plasma can be determined by comparing the intensity of the molecular ion peak (M') to the M + 1 peak after correcting for the contribution of naturally occurring 13C and 'H.
phenylalanine,The deuterium content of phenylalanine in plasma can be determined by comparing the intensity of the molecular ion peak (M') to the M + 1 peak after correcting for the contribution of naturally occurring 13C and 'H.,Entity: phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. The deuterium content of phenylalanine in plasma can be determined by comparing the intensity of the molecular ion peak (M') to the M + 1 peak after correcting for the contribution of naturally occurring 13C and 'H.
carbodiimide,"Carbodiimide is a reagent used for conjugating haptens to protein carriers, but it is not suitable for conjugating labile hormones such as secretin and pancreozymin due to denaturation of the hormone during the process.","Entity: carbodiimide. SMILES: N=C=N. Carbodiimide is a reagent used for conjugating haptens to protein carriers, but it is not suitable for conjugating labile hormones such as secretin and pancreozymin due to denaturation of the hormone during the process."
secretin,"Specific antibodies against secretin can be generated by coupling secretin peptide with N,N'-carbonyldiimidazole to bovine serum albumin, and the resulting antisera are useful for detecting secretin in human serum at concentrations of 5–250 pg with a dilution of 1:150,000.","Entity: secretin. Specific antibodies against secretin can be generated by coupling secretin peptide with N,N'-carbonyldiimidazole to bovine serum albumin, and the resulting antisera are useful for detecting secretin in human serum at concentrations of 5–250 pg with a dilution of 1:150,000."
CK-M,CK-M is a subunit of creatine kinase whose activity can be blocked by inhibiting antibodies in assays to measure CK-MB activity.,Entity: CK-M. CK-M is a subunit of creatine kinase whose activity can be blocked by inhibiting antibodies in assays to measure CK-MB activity.
carbamazepine,Carbamazepine can be quantitatively determined in human serum using gas-liquid chromatography after extraction and methylation with phenyltrimethylammonium hydroxide.,Entity: carbamazepine. SMILES: NC(=O)N1c2ccccc2C=Cc2ccccc21. Carbamazepine can be quantitatively determined in human serum using gas-liquid chromatography after extraction and methylation with phenyltrimethylammonium hydroxide.
phenobarbital,Phenobarbital can be quantitatively determined in human serum using gas-liquid chromatography after extraction and methylation with phenyltrimethylammonium hydroxide.,Entity: phenobarbital. SMILES: CCC1(c2ccccc2)C(=O)NC(=O)NC1=O. Phenobarbital can be quantitatively determined in human serum using gas-liquid chromatography after extraction and methylation with phenyltrimethylammonium hydroxide.
dimethylformamide,Dimethylformamide is used as a solvent for methylation of anticonvulsant drugs with phenyltrimethylammonium hydroxide prior to gas-liquid chromatographic analysis.,Entity: dimethylformamide. SMILES: CN(C)C=O. Dimethylformamide is used as a solvent for methylation of anticonvulsant drugs with phenyltrimethylammonium hydroxide prior to gas-liquid chromatographic analysis.
phenyltrimethylammonium hydroxide,Phenyltrimethylammonium hydroxide is used to methylate anticonvulsant drugs in dimethylformamide at 85°C for gas-liquid chromatographic analysis.,Entity: phenyltrimethylammonium hydroxide. SMILES: C[N+](C)(C)c1ccccc1.[OH-]. Phenyltrimethylammonium hydroxide is used to methylate anticonvulsant drugs in dimethylformamide at 85°C for gas-liquid chromatographic analysis.
nitrogen,"Nitrogen is used as a carrier gas in gas chromatography, applied at a flow rate of 60 ml/min in the described analytical setup.","Entity: nitrogen. SMILES: [N]. Nitrogen is used as a carrier gas in gas chromatography, applied at a flow rate of 60 ml/min in the described analytical setup."
hydrogen,"Hydrogen is used as a carrier gas in gas chromatography, applied at a flow rate of 40 ml/min in the described analytical setup.","Entity: hydrogen. SMILES: [HH]. Hydrogen is used as a carrier gas in gas chromatography, applied at a flow rate of 40 ml/min in the described analytical setup."
"N,N-Dimethylformamide","N,N-Dimethylformamide is a dipolar aprotic solvent that, when used in on-column methylation for anticonvulsant drug analysis, produces more free methyl groups from PTMAH than other solvents like dioxan and methanol, enabling shorter reaction times and milder conditions.","Entity: N,N-Dimethylformamide. SMILES: CN(C)C=O. N,N-Dimethylformamide is a dipolar aprotic solvent that, when used in on-column methylation for anticonvulsant drug analysis, produces more free methyl groups from PTMAH than other solvents like dioxan and methanol, enabling shorter reaction times and milder conditions."
"N,N-Dimethylformamide","Using N,N-Dimethylformamide as a reaction solvent in on-column methylation for anticonvulsant drugs allows for complete methylation and a coefficient of variation of 4.5%–6.2% on a day-to-day basis.","Entity: N,N-Dimethylformamide. SMILES: CN(C)C=O. Using N,N-Dimethylformamide as a reaction solvent in on-column methylation for anticonvulsant drugs allows for complete methylation and a coefficient of variation of 4.5%–6.2% on a day-to-day basis."
Dioxane,"Dioxane is used as a solvent in on-column methylation methods for anticonvulsant drugs, but produces fewer free methyl groups from PTMAH compared to N,N-Dimethylformamide.","Entity: Dioxane. SMILES: C1COCCO1. Dioxane is used as a solvent in on-column methylation methods for anticonvulsant drugs, but produces fewer free methyl groups from PTMAH compared to N,N-Dimethylformamide."
Methanol,"Methanol is used as a solvent in on-column methylation methods for anticonvulsant drugs, but produces fewer free methyl groups from PTMAH compared to N,N-Dimethylformamide.","Entity: Methanol. SMILES: CO. Methanol is used as a solvent in on-column methylation methods for anticonvulsant drugs, but produces fewer free methyl groups from PTMAH compared to N,N-Dimethylformamide."
Cholestane,Preincubating the reaction mixture at 85°C for 10 min ensures a constant peak height for cholestane in on-column methylation analysis.,Entity: Cholestane. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4CCCC[C@]4(C)[C@H]3CC[C@]12C. Preincubating the reaction mixture at 85°C for 10 min ensures a constant peak height for cholestane in on-column methylation analysis.
dimethylformamide,Dimethylformamide can be used as a solvent in place of dioxane for on-column methylation reactions to achieve satisfactory and reproducible results.,Entity: dimethylformamide. SMILES: CN(C)C=O. Dimethylformamide can be used as a solvent in place of dioxane for on-column methylation reactions to achieve satisfactory and reproducible results.
angiotensin I,"Angiotensin I can be measured in plasma samples using radioimmunoassay following incubation, allowing for the simultaneous determination of renin-angiotensin system parameters such as PRA, PRC, and PRS.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I can be measured in plasma samples using radioimmunoassay following incubation, allowing for the simultaneous determination of renin-angiotensin system parameters such as PRA, PRC, and PRS."
furosemide,"Furosemide administration in healthy subjects alters the kinetic pattern of angiotensin I generation during plasma incubation, indicating its effect on the renin-angiotensin system.","Entity: furosemide. SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl. Furosemide administration in healthy subjects alters the kinetic pattern of angiotensin I generation during plasma incubation, indicating its effect on the renin-angiotensin system."
angiotensin I,Angiotensin I generation from plasma during incubation is not linear with time and is influenced by furosemide administration in healthy subjects.,Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I generation from plasma during incubation is not linear with time and is influenced by furosemide administration in healthy subjects.
angiotensin I,Angiotensin I is a product of the renin angiotensin system and its plasma concentration can be measured to assess the activity of the renin angiotensin system.,Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I is a product of the renin angiotensin system and its plasma concentration can be measured to assess the activity of the renin angiotensin system.
angiotensin I,"Angiotensin I is generated from renin substrate via a first-order kinetic reaction, and its maximal plasma concentration can be used to determine the initial plasma renin substrate concentration in ng/ml.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I is generated from renin substrate via a first-order kinetic reaction, and its maximal plasma concentration can be used to determine the initial plasma renin substrate concentration in ng/ml."
Mn(NO3)2,Mn(NO3)2 has a boiling point of 130°C.,Entity: Mn(NO3)2. SMILES: O=[N+]([O-])[O-].O=[N+]([O-])[O-].[Mn+2]. Mn(NO3)2 has a boiling point of 130°C.
H2SO4,H2SO4 is used as a pretreatment reagent to prevent loss of manganese as Mn(NO3)2 during sample preparation.,Entity: H2SO4. SMILES: O=S(=O)(O)O. H2SO4 is used as a pretreatment reagent to prevent loss of manganese as Mn(NO3)2 during sample preparation.
HC104,HC104 is used as an acid in the mineralization process of blood samples for manganese recovery analysis.,Entity: HC104. SMILES: Cl. HC104 is used as an acid in the mineralization process of blood samples for manganese recovery analysis.
Manganese,Manganese can be quantified in blood samples at concentrations ranging from 10 to 50 pg/100 ml using a mineralization and spectrophotometric assay.,Entity: Manganese. SMILES: [Mn]. Manganese can be quantified in blood samples at concentrations ranging from 10 to 50 pg/100 ml using a mineralization and spectrophotometric assay.
cupferron,Cupferron forms a chelate with manganese that can be extracted for instrumental analysis.,Entity: cupferron. SMILES: [NH4+].[O-]/N=[N+](\[O-])c1ccccc1. Cupferron forms a chelate with manganese that can be extracted for instrumental analysis.
methylisobutylketone,Methylisobutylketone is used as an extraction solvent for manganese chelates in analytical procedures.,Entity: methylisobutylketone. SMILES: CC(=O)CC(C)C. Methylisobutylketone is used as an extraction solvent for manganese chelates in analytical procedures.
manganese,Manganese can be quantitatively determined in urine and blood using a chelation-extraction-flameless atomic absorption spectrophotometry method with cupferron and methylisobutylketone.,Entity: manganese. SMILES: [Mn]. Manganese can be quantitatively determined in urine and blood using a chelation-extraction-flameless atomic absorption spectrophotometry method with cupferron and methylisobutylketone.
MIBK,"MIBK (methyl isobutyl ketone) is used as an organic phase in liquid-liquid extraction protocols, such as in the separation of organic phases from aqueous solutions.","Entity: MIBK. SMILES: CC(=O)CC(C)C. MIBK (methyl isobutyl ketone) is used as an organic phase in liquid-liquid extraction protocols, such as in the separation of organic phases from aqueous solutions."
cupferron,"Cupferron is used as a reagent in the form of a 10% solution in imidazole-HCl buffer (0.1 M, pH 7.1) for analytical procedures.","Entity: cupferron. SMILES: [NH4+].[O-]/N=[N+](\[O-])c1ccccc1. Cupferron is used as a reagent in the form of a 10% solution in imidazole-HCl buffer (0.1 M, pH 7.1) for analytical procedures."
MIBK,MIBK is used as a solvent for diluting the organic phase in manganese concentration measurements in biological samples.,Entity: MIBK. SMILES: CC(=O)CC(C)C. MIBK is used as a solvent for diluting the organic phase in manganese concentration measurements in biological samples.
manganese,Manganese concentrations in biological materials can be measured using a linear response in the concentration range of 1–25 pg/l with a Perkin-Elmer instrument (5 mV scale).,Entity: manganese. SMILES: [Mn]. Manganese concentrations in biological materials can be measured using a linear response in the concentration range of 1–25 pg/l with a Perkin-Elmer instrument (5 mV scale).
manganese,"When manganese concentrations in biological material exceed 50 pg/l, the signal increment from internal standards becomes insufficient for precise measurement, making dilution of the sample preferable.","Entity: manganese. SMILES: [Mn]. When manganese concentrations in biological material exceed 50 pg/l, the signal increment from internal standards becomes insufficient for precise measurement, making dilution of the sample preferable."
manganese,Manganese in urine can be quantitatively determined by extraction using MIBK after chelation with cupferron.,Entity: manganese. SMILES: [Mn]. Manganese in urine can be quantitatively determined by extraction using MIBK after chelation with cupferron.
MnCl,MnCl is used as a manganese source to inject rats intraperitoneally at a dose of 10 mg/kg for experimental purposes.,Entity: MnCl. SMILES: [Cl-].[Cl-].[Mn+2]. MnCl is used as a manganese source to inject rats intraperitoneally at a dose of 10 mg/kg for experimental purposes.
cupferron,Cupferron forms a chelate with manganese that can be extracted from urine using MIBK.,Entity: cupferron. SMILES: [NH4+].[O-]/N=[N+](\[O-])c1ccccc1. Cupferron forms a chelate with manganese that can be extracted from urine using MIBK.
MIBK,MIBK is used as an extraction solvent for cupferron-manganese chelates from urine.,Entity: MIBK. SMILES: CC(=O)CC(C)C. MIBK is used as an extraction solvent for cupferron-manganese chelates from urine.
perchloric acid,Perchloric acid is used for deproteinization in biochemical assays.,Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid is used for deproteinization in biochemical assays.
chloride,"Chloride acts as an endogenous quenching agent in biochemical assays, with its quenching effect being stronger in the Hamfelt method due to a smaller dilution factor.","Entity: chloride. SMILES: [Cl-]. Chloride acts as an endogenous quenching agent in biochemical assays, with its quenching effect being stronger in the Hamfelt method due to a smaller dilution factor."
quinidine,Quinidine is a cinchona alkaloid that can be selectively extracted from serum using specific extraction methods.,Entity: quinidine. SMILES: C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12. Quinidine is a cinchona alkaloid that can be selectively extracted from serum using specific extraction methods.
hydroquinidine,"Hydroquinidine is a cinchona alkaloid that can be determined in serum using methods that extract all cinchona alkaloids, including hydroquinidine and its metabolites.","Entity: hydroquinidine. SMILES: CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12. Hydroquinidine is a cinchona alkaloid that can be determined in serum using methods that extract all cinchona alkaloids, including hydroquinidine and its metabolites."
quinidine,"Quinidine can be quantitatively determined in human serum by fluorometry using a method that specifically quenches the fluorescence of cinchona alkaloids by chloride ions, with good reproducibility, linearity, and 98% recovery.","Entity: quinidine. SMILES: C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12. Quinidine can be quantitatively determined in human serum by fluorometry using a method that specifically quenches the fluorescence of cinchona alkaloids by chloride ions, with good reproducibility, linearity, and 98% recovery."
triamterene,"Triamterene does not interfere with the fluorometric determination of quinidine in human serum, unlike other diuretics.","Entity: triamterene. SMILES: Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1. Triamterene does not interfere with the fluorometric determination of quinidine in human serum, unlike other diuretics."
chloride,"Chloride ions quench the fluorescence of cinchona alkaloids, enabling the specific detection of quinidine in human serum by fluorometry.","Entity: chloride. SMILES: [Cl-]. Chloride ions quench the fluorescence of cinchona alkaloids, enabling the specific detection of quinidine in human serum by fluorometry."
quinidine,"Unmetabolized quinidine can be extracted from alkalinized serum using benzene or toluene, with the extracted amount quantified by fluorescence intensity measurement in acid solution.","Entity: quinidine. SMILES: C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12. Unmetabolized quinidine can be extracted from alkalinized serum using benzene or toluene, with the extracted amount quantified by fluorescence intensity measurement in acid solution."
toluene,Toluene is used as an organic solvent for extracting unmetabolized quinidine from alkalinized serum in analytical methods.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as an organic solvent for extracting unmetabolized quinidine from alkalinized serum in analytical methods.
benzene,Benzene is used as an organic solvent for extracting unmetabolized quinidine from alkalinized serum in analytical methods.,Entity: benzene. SMILES: c1ccccc1. Benzene is used as an organic solvent for extracting unmetabolized quinidine from alkalinized serum in analytical methods.
sodium hydroxide,Sodium hydroxide (0.1 N) is used to wash the organic layer during the extraction of unmetabolized quinidine from serum.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide (0.1 N) is used to wash the organic layer during the extraction of unmetabolized quinidine from serum.
sulphuric acid,Sulphuric acid (0.1 N) is used to re-extract quinidine from the organic layer after washing with sodium hydroxide in the extraction process.,Entity: sulphuric acid. SMILES: O=S(=O)(O)O. Sulphuric acid (0.1 N) is used to re-extract quinidine from the organic layer after washing with sodium hydroxide in the extraction process.
hydroquinidine,Hydroquinidine has anti-arrhythmic activity in animal experiments of the same order as or greater than quinidine.,Entity: hydroquinidine. SMILES: CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12. Hydroquinidine has anti-arrhythmic activity in animal experiments of the same order as or greater than quinidine.
hydroquinidine,Hydroquinidine and its hydroxylated metabolites may have pharmacological activity.,Entity: hydroquinidine. SMILES: CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12. Hydroquinidine and its hydroxylated metabolites may have pharmacological activity.
quinidine,Quinidine is a drug whose commercial preparations typically contain about 10% hydroquinidine.,Entity: quinidine. SMILES: C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12. Quinidine is a drug whose commercial preparations typically contain about 10% hydroquinidine.
quinidine,Quinidine has anti-arrhythmic activity in animal experiments of the same order as or greater than hydroquinidine.,Entity: quinidine. SMILES: C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12. Quinidine has anti-arrhythmic activity in animal experiments of the same order as or greater than hydroquinidine.
hydroquinidine,Hydroquinidine is present at about 10% in commercial quinidine preparations.,Entity: hydroquinidine. SMILES: CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12. Hydroquinidine is present at about 10% in commercial quinidine preparations.
hydroquinidine,Hydroquinidine has the same photofluorometric properties as quinidine.,Entity: hydroquinidine. SMILES: CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12. Hydroquinidine has the same photofluorometric properties as quinidine.
"N,O-bis(trimethylsilyl)acetamide","N,O-bis(trimethylsilyl)acetamide does not form trimethylsilyl derivatives of sodium salts of many organic acids.","Entity: N,O-bis(trimethylsilyl)acetamide. SMILES: C/C(=N\[Si](C)(C)C)O[Si](C)(C)C. N,O-bis(trimethylsilyl)acetamide does not form trimethylsilyl derivatives of sodium salts of many organic acids."
hydroxylamine hydrochloride,"Hydroxylamine hydrochloride, when present, promotes the formation of trimethylsilyl derivatives of sodium salts of organic acids.","Entity: hydroxylamine hydrochloride. SMILES: Cl.NO. Hydroxylamine hydrochloride, when present, promotes the formation of trimethylsilyl derivatives of sodium salts of organic acids."
trimethylchlorosilane,"Trimethylchlorosilane, when present, promotes the formation of trimethylsilyl derivatives of sodium salts of organic acids.","Entity: trimethylchlorosilane. SMILES: C[Si](C)(C)Cl. Trimethylchlorosilane, when present, promotes the formation of trimethylsilyl derivatives of sodium salts of organic acids."
triglyceride,"In the AutoAnalyzer assay, 1.00 mol triglyceride corresponds to the same response as 3.09 mol human serum total phospholipid up to 13.00 mmol/l phospholipid.","Entity: triglyceride. SMILES: O=COCC(COC=O)OC=O. In the AutoAnalyzer assay, 1.00 mol triglyceride corresponds to the same response as 3.09 mol human serum total phospholipid up to 13.00 mmol/l phospholipid."
formaldehyde,Formaldehyde is produced by the oxidation of glycerophosphoryl bases derived from glycerophospholipids or triglycerides using periodate.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is produced by the oxidation of glycerophosphoryl bases derived from glycerophospholipids or triglycerides using periodate.
3-hydroxy-3-methylglutaric acid,3-hydroxy-3-methylglutaric acid can be quantitatively recovered from urine with an estimated recovery efficiency of 30% using the described extraction procedure.,Entity: 3-hydroxy-3-methylglutaric acid. SMILES: CC(O)(CC(=O)O)CC(=O)O. 3-hydroxy-3-methylglutaric acid can be quantitatively recovered from urine with an estimated recovery efficiency of 30% using the described extraction procedure.
succinic acid,Succinic acid can be quantitatively recovered from urine with an estimated recovery efficiency of 64% using the described extraction procedure.,Entity: succinic acid. SMILES: O=C(O)CCC(=O)O. Succinic acid can be quantitatively recovered from urine with an estimated recovery efficiency of 64% using the described extraction procedure.
3-methylglutaric acid,3-methylglutaric acid can be quantitatively recovered from urine with an estimated recovery efficiency of 71% using the described extraction procedure.,Entity: 3-methylglutaric acid. SMILES: CC(CC(=O)O)CC(=O)O. 3-methylglutaric acid can be quantitatively recovered from urine with an estimated recovery efficiency of 71% using the described extraction procedure.
3-methylglutaconic acid,3-methylglutaconic acid can be quantitatively recovered from urine with an estimated recovery efficiency of 75% using the described extraction procedure.,Entity: 3-methylglutaconic acid. SMILES: CC(=CC(=O)O)CC(=O)O. 3-methylglutaconic acid can be quantitatively recovered from urine with an estimated recovery efficiency of 75% using the described extraction procedure.
3-methylglutaconyl-CoA,3-methylglutaconyl-CoA can act as a substrate for the reverse dehydrogenation reaction that converts 3-methylcrotonyl-CoA to isovaleryl-CoA.,Entity: 3-methylglutaconyl-CoA. SMILES: CC(=CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)CC(=O)O. 3-methylglutaconyl-CoA can act as a substrate for the reverse dehydrogenation reaction that converts 3-methylcrotonyl-CoA to isovaleryl-CoA.
3-methylcrotonyl-CoA,3-methylcrotonyl-CoA is normally converted to isovaleryl-CoA via a dehydrogenation reaction.,Entity: 3-methylcrotonyl-CoA. SMILES: CC(C)=CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. 3-methylcrotonyl-CoA is normally converted to isovaleryl-CoA via a dehydrogenation reaction.
isovaleryl-CoA,Isovaleryl-CoA is produced from 3-methylcrotonyl-CoA through a dehydrogenation reaction.,Entity: isovaleryl-CoA. SMILES: CC(C)CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Isovaleryl-CoA is produced from 3-methylcrotonyl-CoA through a dehydrogenation reaction.
3-methylglutaric acid,3-methylglutaric acid is not typically found in the urine of patients with isovaleric acidemia or 3-methylcrotonylglycinuria.,Entity: 3-methylglutaric acid. SMILES: CC(CC(=O)O)CC(=O)O. 3-methylglutaric acid is not typically found in the urine of patients with isovaleric acidemia or 3-methylcrotonylglycinuria.
glycine,"In patients with 3-methylcrotonylglycinuria, 3-methylcrotonic acid is primarily excreted as a glycine conjugate.","Entity: glycine. SMILES: NCC(=O)O. In patients with 3-methylcrotonylglycinuria, 3-methylcrotonic acid is primarily excreted as a glycine conjugate."
3-hydroxyisovaleric acid,3-hydroxyisovaleric acid can be converted to 3-methylcrotonic acid by dehydration during gas chromatography of underivatized volatile fatty acid extracts on acidic GC columns.,Entity: 3-hydroxyisovaleric acid. SMILES: CC(C)(O)CC(=O)O. 3-hydroxyisovaleric acid can be converted to 3-methylcrotonic acid by dehydration during gas chromatography of underivatized volatile fatty acid extracts on acidic GC columns.
3-hydroxyisovaleric acid,"Dehydration of tertiary alcohols, such as 3-hydroxyisovaleric acid, is facile at low pH.","Entity: 3-hydroxyisovaleric acid. SMILES: CC(C)(O)CC(=O)O. Dehydration of tertiary alcohols, such as 3-hydroxyisovaleric acid, is facile at low pH."
3-methylcrotonic acid,3-methylcrotonic acid is a metabolite in the leucine degradative pathway and can be formed from 3-hydroxyisovaleric acid by dehydration during gas chromatography.,Entity: 3-methylcrotonic acid. SMILES: CC(C)=CC(=O)O. 3-methylcrotonic acid is a metabolite in the leucine degradative pathway and can be formed from 3-hydroxyisovaleric acid by dehydration during gas chromatography.
3-methylcrotonic acid,"In patients with 3-methylcrotonylglycinuria, 3-methylcrotonic acid accumulates but is primarily conjugated with glycine and little, if any, is excreted as the free acid.","Entity: 3-methylcrotonic acid. SMILES: CC(C)=CC(=O)O. In patients with 3-methylcrotonylglycinuria, 3-methylcrotonic acid accumulates but is primarily conjugated with glycine and little, if any, is excreted as the free acid."
3-methylcrotonylglycine,"3-methylcrotonylglycine is difficult to extract from urine with ethyl acetate, and has not been identified in the present patient's urine using published extraction, derivatization, and chromatography procedures.","Entity: 3-methylcrotonylglycine. SMILES: CC(C)=CC(=O)NCC(=O)O. 3-methylcrotonylglycine is difficult to extract from urine with ethyl acetate, and has not been identified in the present patient's urine using published extraction, derivatization, and chromatography procedures."
3-hydroxy-3-methylglutaric acid,"3-hydroxy-3-methylglutaric acid is a urinary organic acid excreted in increased amounts by patients with 3-hydroxy-3-methylglutaric aciduria, a defect in the leucine catabolic pathway.","Entity: 3-hydroxy-3-methylglutaric acid. SMILES: CC(O)(CC(=O)O)CC(=O)O. 3-hydroxy-3-methylglutaric acid is a urinary organic acid excreted in increased amounts by patients with 3-hydroxy-3-methylglutaric aciduria, a defect in the leucine catabolic pathway."
3-methylcrotonic acid,"3-methylcrotonic acid is a urinary organic acid excreted in copious quantities by patients with 3-hydroxy-3-methylglutaric aciduria, a disorder of the leucine catabolic pathway.","Entity: 3-methylcrotonic acid. SMILES: CC(C)=CC(=O)O. 3-methylcrotonic acid is a urinary organic acid excreted in copious quantities by patients with 3-hydroxy-3-methylglutaric aciduria, a disorder of the leucine catabolic pathway."
3-methylglutaconic acid,"3-methylglutaconic acid is a urinary organic acid excreted in increased amounts by patients with 3-hydroxy-3-methylglutaric aciduria, a defect in the leucine catabolic pathway.","Entity: 3-methylglutaconic acid. SMILES: CC(=CC(=O)O)CC(=O)O. 3-methylglutaconic acid is a urinary organic acid excreted in increased amounts by patients with 3-hydroxy-3-methylglutaric aciduria, a defect in the leucine catabolic pathway."
Succinic acid,Succinic acid is used as an internal standard at a concentration of 100 pg in urinary acid quantitation assays.,Entity: Succinic acid. SMILES: O=C(O)CCC(=O)O. Succinic acid is used as an internal standard at a concentration of 100 pg in urinary acid quantitation assays.
"N,O-bis(trimethylsilyl)trifluroacetamide","N,O-bis(trimethylsilyl)trifluroacetamide (BSTFA) is used as a derivatisation reagent for preparing urinary acid samples for GC analysis.","Entity: N,O-bis(trimethylsilyl)trifluroacetamide. SMILES: C[Si](C)(C)Cl.C[Si](C)(C)N=C(O[Si](C)(C)C)C(F)(F)F. N,O-bis(trimethylsilyl)trifluroacetamide (BSTFA) is used as a derivatisation reagent for preparing urinary acid samples for GC analysis."
Magnesium sulphate,Anhydrous magnesium sulphate is used to dry organic extracts during the preparation of urinary acid samples for GC analysis.,Entity: Magnesium sulphate. SMILES: O=S(=O)([O-])[O-].[Mg+2]. Anhydrous magnesium sulphate is used to dry organic extracts during the preparation of urinary acid samples for GC analysis.
3-methylglutaconic acid,"In urine, the ratio of the height of the first peak to the height of the second peak corresponding to 3-methylglutaconic acid is, on average, 3:2 after derivatisation and extraction.","Entity: 3-methylglutaconic acid. SMILES: CC(=CC(=O)O)CC(=O)O. In urine, the ratio of the height of the first peak to the height of the second peak corresponding to 3-methylglutaconic acid is, on average, 3:2 after derivatisation and extraction."
3-hydroxy-3-methylglutaric acid,3-hydroxy-3-methylglutaric acid was identified as a urinary metabolite based on GC-MS analysis of derivatised ethyl acetate urine extracts.,Entity: 3-hydroxy-3-methylglutaric acid. SMILES: CC(O)(CC(=O)O)CC(=O)O. 3-hydroxy-3-methylglutaric acid was identified as a urinary metabolite based on GC-MS analysis of derivatised ethyl acetate urine extracts.
3-hydroxyisovaleric acid,3-hydroxyisovaleric acid was identified as a urinary metabolite based on GC-MS analysis of derivatised ethyl acetate urine extracts.,Entity: 3-hydroxyisovaleric acid. SMILES: CC(C)(O)CC(=O)O. 3-hydroxyisovaleric acid was identified as a urinary metabolite based on GC-MS analysis of derivatised ethyl acetate urine extracts.
3-methylglutaric acid,3-methylglutaric acid was identified as a urinary metabolite based on GC-MS analysis of derivatised ethyl acetate urine extracts.,Entity: 3-methylglutaric acid. SMILES: CC(CC(=O)O)CC(=O)O. 3-methylglutaric acid was identified as a urinary metabolite based on GC-MS analysis of derivatised ethyl acetate urine extracts.
creatinine,Creatinine was measured in urine using the Jaffe reaction.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine was measured in urine using the Jaffe reaction.
dimethyldichlorosilane,Dimethyldichlorosilane is used as a stationary phase support (SO-100 mesh) in gas chromatography columns for the separation of volatile compounds.,Entity: dimethyldichlorosilane. SMILES: C[Si](C)(Cl)Cl. Dimethyldichlorosilane is used as a stationary phase support (SO-100 mesh) in gas chromatography columns for the separation of volatile compounds.
helium,Helium is used as the carrier gas at a flow rate of 25 ml/min in gas chromatography for the analysis of volatile metabolites.,Entity: helium. SMILES: [He]. Helium is used as the carrier gas at a flow rate of 25 ml/min in gas chromatography for the analysis of volatile metabolites.
3-methylglutaconyl-CoA,3-methylglutaconyl-CoA is the product of the biotin-dependent COZ fixation step that converts 3-methylcrotonyl-CoA.,Entity: 3-methylglutaconyl-CoA. SMILES: CC(=CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)CC(=O)O. 3-methylglutaconyl-CoA is the product of the biotin-dependent COZ fixation step that converts 3-methylcrotonyl-CoA.
isovaleryl-CoA,Isovaleryl-CoA can act as a substrate for the biotin-dependent COZ fixation step that converts 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA.,Entity: isovaleryl-CoA. SMILES: CC(C)CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Isovaleryl-CoA can act as a substrate for the biotin-dependent COZ fixation step that converts 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA.
3-methylcrotonyl-CoA,3-methylcrotonyl-CoA is normally converted to 3-methylglutaconyl-CoA by the biotin-dependent COZ fixation step.,Entity: 3-methylcrotonyl-CoA. SMILES: CC(C)=CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. 3-methylcrotonyl-CoA is normally converted to 3-methylglutaconyl-CoA by the biotin-dependent COZ fixation step.
sodium diatrizoate,Sodium diatrizoate (Hypaque) is used as a water-soluble contrast medium in valvography to visualize the cardiac portion of the Spitz Holter system shunt.,Entity: sodium diatrizoate. SMILES: CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.[Na+]. Sodium diatrizoate (Hypaque) is used as a water-soluble contrast medium in valvography to visualize the cardiac portion of the Spitz Holter system shunt.
valinomycin,"Valinomycin increases the K+ conductance of the membrane, leading to an increase in light-stimulated K+ efflux and a decrease in net Mg2+ influx.","Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin increases the K+ conductance of the membrane, leading to an increase in light-stimulated K+ efflux and a decrease in net Mg2+ influx."
nigericin,"Nigericin acts as an uncoupler in chloroplasts, stimulating electron transport rate and inhibiting light-induced pH change.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin acts as an uncoupler in chloroplasts, stimulating electron transport rate and inhibiting light-induced pH change."
nigericin,"In chloroplasts, nigericin increases net K+ influx in the light when the K/Mg concentration ratio is decreased, and restores K+ uptake in the light in the presence of Mg2+.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. In chloroplasts, nigericin increases net K+ influx in the light when the K/Mg concentration ratio is decreased, and restores K+ uptake in the light in the presence of Mg2+."
H+,H+ uptake in broken chloroplasts is associated with light-induced release of Mg2+ and is specifically reversed in the presence of A23187.,Entity: H+. SMILES: [1H+]. H+ uptake in broken chloroplasts is associated with light-induced release of Mg2+ and is specifically reversed in the presence of A23187.
nigericin,Nigericin affects light-induced K+ movement across the thylakoid membrane.,Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin affects light-induced K+ movement across the thylakoid membrane.
chlorophyll a,The fluorescence quenching of chlorophyll a in cation-free suspensions of intact chloroplasts is used to study the involvement of Mg2+ transport in electrogenic proton loading of thylakoids.,Entity: chlorophyll a. SMILES: C=Cc1c(C)c2cc3nc(c4c5[n-]c(cc6nc(cc1[n-]2)C(C)=C6CC)c(C)c5C(=O)[C@@H]4C(=O)OC)[C@@H](CCC(=O)OC/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@@H]3C.[Mg+2]. The fluorescence quenching of chlorophyll a in cation-free suspensions of intact chloroplasts is used to study the involvement of Mg2+ transport in electrogenic proton loading of thylakoids.
MgCl2,"In intact chloroplasts, Mg2+ concentrations range from 15 to 30 mM, and in broken chloroplasts suspended in 1 mM MgCl2, the magnitude of light-driven Mg2+ efflux is not increased above 1 mM regardless of K+ concentration.","Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. In intact chloroplasts, Mg2+ concentrations range from 15 to 30 mM, and in broken chloroplasts suspended in 1 mM MgCl2, the magnitude of light-driven Mg2+ efflux is not increased above 1 mM regardless of K+ concentration."
KCI,Broken chloroplasts suspended in 50 mM KCl and 1 mM MgCl2 provide a system more representative of intact chloroplasts for studying K+ and Mg2+ fluxes.,Entity: KCI. SMILES: [Cl-].[K+]. Broken chloroplasts suspended in 50 mM KCl and 1 mM MgCl2 provide a system more representative of intact chloroplasts for studying K+ and Mg2+ fluxes.
nigericin,"In intact chloroplasts, nigericin at low concentrations does not inhibit the fluorescence quenching of chlorophyll a, likely due to low stromal K+ concentrations (less than 0.3 mM in K+ free suspensions).","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. In intact chloroplasts, nigericin at low concentrations does not inhibit the fluorescence quenching of chlorophyll a, likely due to low stromal K+ concentrations (less than 0.3 mM in K+ free suspensions)."
chloride ion,Chloride ion (Cl-) is reported to be taken up across thylakoid membranes of chloroplasts during illumination.,Entity: chloride ion. SMILES: [Cl-]. Chloride ion (Cl-) is reported to be taken up across thylakoid membranes of chloroplasts during illumination.
choline chloride,Choline chloride is used to fill micro-electrodes for measuring electric potential changes across chloroplast (thylakoid) membranes.,Entity: choline chloride. SMILES: C[N+](C)(C)CCO.[Cl-]. Choline chloride is used to fill micro-electrodes for measuring electric potential changes across chloroplast (thylakoid) membranes.
potassium chloride,Potassium chloride is included at a concentration of 1 mM in the suspension medium for isolated Peperomia metallica chloroplasts.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is included at a concentration of 1 mM in the suspension medium for isolated Peperomia metallica chloroplasts.
sucrose,Sucrose is used at a concentration of 0.25 M in the suspension medium for isolated Peperomia metallica chloroplasts.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used at a concentration of 0.25 M in the suspension medium for isolated Peperomia metallica chloroplasts.
tricine,Tricine buffer at 0.01 M and pH 7.8 is used to maintain the pH of the suspension medium for isolated Peperomia metallica chloroplasts.,Entity: tricine. SMILES: O=C(O)CNC(CO)(CO)CO. Tricine buffer at 0.01 M and pH 7.8 is used to maintain the pH of the suspension medium for isolated Peperomia metallica chloroplasts.
valinomycin,"Valinomycin increases the Mg2+ influx across thylakoid membranes in the presence of A23187, indicating its role in enhancing cation permeability under conditions of active proton pumping.","Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin increases the Mg2+ influx across thylakoid membranes in the presence of A23187, indicating its role in enhancing cation permeability under conditions of active proton pumping."
nigericin,"Nigericin induces a light-dependent K+ influx across thylakoid membranes, with the magnitude of this influx increasing as the K/Mg concentration ratio increases.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin induces a light-dependent K+ influx across thylakoid membranes, with the magnitude of this influx increasing as the K/Mg concentration ratio increases."
hydrogen,Hydrogen ions are involved in the light-driven electrogenic influx that drives passive ion redistributions across thylakoid membranes in chloroplasts.,Entity: hydrogen. SMILES: [H]. Hydrogen ions are involved in the light-driven electrogenic influx that drives passive ion redistributions across thylakoid membranes in chloroplasts.
H+,"In intact chloroplasts, H+ acts as the main exchange ion for proton uptake in vivo.","Entity: H+. SMILES: [1H+]. In intact chloroplasts, H+ acts as the main exchange ion for proton uptake in vivo."
nigericin,"Nigericin facilitates a K+/H+ exchange in biological membranes, but is inactive in restoring light-induced fluorescence quenching in intact chloroplasts unless K+ is present in the suspending medium.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin facilitates a K+/H+ exchange in biological membranes, but is inactive in restoring light-induced fluorescence quenching in intact chloroplasts unless K+ is present in the suspending medium."
nigericin,Nigericin acts as an ionophore that affects the light-induced redistribution of monovalent and divalent cations across the thylakoid membrane.,Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin acts as an ionophore that affects the light-induced redistribution of monovalent and divalent cations across the thylakoid membrane.
nigericin,"Nigericin completely inhibits light-induced pH change and increases the rate of photosynthetic electron transport by a factor of about 3.5 in chloroplast suspension assays with 50 mM K·, 0.5 mM Mg2+, and 20 µM diquat as electron acceptor.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin completely inhibits light-induced pH change and increases the rate of photosynthetic electron transport by a factor of about 3.5 in chloroplast suspension assays with 50 mM K·, 0.5 mM Mg2+, and 20 µM diquat as electron acceptor."
nigericin,"Nigericin alone produces a complete inhibition of pH change and an increase in electron transport rate by a factor of about 8.7 under conditions of 50 mM K·, 0.5 mM Mg2+, and 20 µM diquat as electron acceptor.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin alone produces a complete inhibition of pH change and an increase in electron transport rate by a factor of about 8.7 under conditions of 50 mM K·, 0.5 mM Mg2+, and 20 µM diquat as electron acceptor."
H +,"In the absence of ionophores, the light-induced cation flux across the thylakoid membrane favors H + influx, especially when the K/Mg concentration ratio is low.","Entity: H +. SMILES: [1H+]. In the absence of ionophores, the light-induced cation flux across the thylakoid membrane favors H + influx, especially when the K/Mg concentration ratio is low."
nigericin,Nigericin promotes a backflow of H + from the thylakoids to the outer medium and facilitates the influx of K + and Mg 2+ across the thylakoid membrane.,Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin promotes a backflow of H + from the thylakoids to the outer medium and facilitates the influx of K + and Mg 2+ across the thylakoid membrane.
MgCl2,MgCl2 at 1 mM concentration in the presence of 50 mM KCl does not induce light-induced redistribution of magnesium ions in chloroplasts.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 at 1 mM concentration in the presence of 50 mM KCl does not induce light-induced redistribution of magnesium ions in chloroplasts.
valinomycin,Valinomycin at concentrations up to 1 mM has little effect on Mg2+ uptake in chloroplasts under conditions where Mg2+ is supplied by 1 mM MgCl2 and 50 mM KCl.,Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin at concentrations up to 1 mM has little effect on Mg2+ uptake in chloroplasts under conditions where Mg2+ is supplied by 1 mM MgCl2 and 50 mM KCl.
sorbitol,"Sorbitol is used as a component of the suspension medium for chloroplasts, at a concentration of 0.33 M.","Entity: sorbitol. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CO. Sorbitol is used as a component of the suspension medium for chloroplasts, at a concentration of 0.33 M."
MgCl2,MgCl2 is included in the chloroplast suspension medium at a final concentration of 2 mM.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is included in the chloroplast suspension medium at a final concentration of 2 mM.
NaOH,NaOH is used to adjust the pH of the HEPES buffer to 7.4 in the preparation of chloroplast suspensions.,Entity: NaOH. SMILES: [Na+].[OH-]. NaOH is used to adjust the pH of the HEPES buffer to 7.4 in the preparation of chloroplast suspensions.
KCl,KCl is added to chloroplast suspension media at final concentrations ranging from 0.5 to 50 mM to study its effects on chlorophyll content.,Entity: KCl. SMILES: [Cl-].[K+]. KCl is added to chloroplast suspension media at final concentrations ranging from 0.5 to 50 mM to study its effects on chlorophyll content.
nigericin,Nigericin is an ionophore that specifically induces light-dependent uptake of K+ in isolated chloroplasts.,Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin is an ionophore that specifically induces light-dependent uptake of K+ in isolated chloroplasts.
nigericin,"Nigericin inhibits light-induced changes in chloroplast membrane potential and the associated slow rise and decay in both light and dark, as well as the transient potential undershoot upon darkening.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin inhibits light-induced changes in chloroplast membrane potential and the associated slow rise and decay in both light and dark, as well as the transient potential undershoot upon darkening."
nigericin,Nigericin inhibits the formation of a K+ concentration gradient and its associated diffusion potential across the thylakoid membrane in isolated chloroplasts of Peperomia metalliea.,Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin inhibits the formation of a K+ concentration gradient and its associated diffusion potential across the thylakoid membrane in isolated chloroplasts of Peperomia metalliea.
oxygen,Oxygen uptake is used as a measure of photosynthetic electron transport in the presence of diquat and 0.2 mM azide.,Entity: oxygen. SMILES: [O]. Oxygen uptake is used as a measure of photosynthetic electron transport in the presence of diquat and 0.2 mM azide.
diquat,Diquat is used as a reagent to initiate photosynthetic electron transport in studies measuring O2 uptake.,Entity: diquat. SMILES: c1cc[n+]2c(c1)-c1cccc[n+]1CC2. Diquat is used as a reagent to initiate photosynthetic electron transport in studies measuring O2 uptake.
azide,Azide at 0.2 mM concentration is used together with diquat to facilitate photosynthetic electron transport in O2 uptake assays.,Entity: azide. SMILES: [N-]=[N+]=[N-]. Azide at 0.2 mM concentration is used together with diquat to facilitate photosynthetic electron transport in O2 uptake assays.
nigericin,"Nigericin enhances light-induced K+ uptake into chloroplasts, with the extent of uptake increasing approximately 2-fold for each 1 mM increase in Mg2+ concentration from 0.1 to 3 mM in the medium.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin enhances light-induced K+ uptake into chloroplasts, with the extent of uptake increasing approximately 2-fold for each 1 mM increase in Mg2+ concentration from 0.1 to 3 mM in the medium."
2-acetylaminofluorene,"2-acetylaminofluorene is metabolized in the body to form N-hydroxy-2-acetylaminofluorene, which is further conjugated with sulfate to produce N-0-sulfate-2-acetylaminofluorene, considered the major chemically reactive metabolite responsible for toxicity.","Entity: 2-acetylaminofluorene. SMILES: CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2. 2-acetylaminofluorene is metabolized in the body to form N-hydroxy-2-acetylaminofluorene, which is further conjugated with sulfate to produce N-0-sulfate-2-acetylaminofluorene, considered the major chemically reactive metabolite responsible for toxicity."
N-hydroxy-2-acetylaminofluorene,N-hydroxy-2-acetylaminofluorene is a chemically reactive metabolite formed from 2-acetylaminofluorene and serves as a precursor for further conjugation reactions leading to toxic metabolites.,Entity: N-hydroxy-2-acetylaminofluorene. SMILES: CC(=O)N(O)c1ccc2c(c1)Cc1ccccc1-2. N-hydroxy-2-acetylaminofluorene is a chemically reactive metabolite formed from 2-acetylaminofluorene and serves as a precursor for further conjugation reactions leading to toxic metabolites.
bromobenzene,"Bromobenzene is metabolized in the liver to its chemically reactive metabolite bromobenzene 3,4-epoxide primarily by a cytochrome P-450 enzyme system localized mainly in the endoplasmic reticulum.","Entity: bromobenzene. SMILES: Brc1ccccc1. Bromobenzene is metabolized in the liver to its chemically reactive metabolite bromobenzene 3,4-epoxide primarily by a cytochrome P-450 enzyme system localized mainly in the endoplasmic reticulum."
bromobenzene,"Nearly all administered bromobenzene is converted to bromobenzene 3,4-epoxide in animals.","Entity: bromobenzene. SMILES: Brc1ccccc1. Nearly all administered bromobenzene is converted to bromobenzene 3,4-epoxide in animals."
bromobenzene,"About 70% of bromobenzene 3,4-epoxide formed in rats at a nontoxic dose is converted to a glutathione conjugate by one or more glutathione transferases in the soluble fraction of liver.","Entity: bromobenzene. SMILES: Brc1ccccc1. About 70% of bromobenzene 3,4-epoxide formed in rats at a nontoxic dose is converted to a glutathione conjugate by one or more glutathione transferases in the soluble fraction of liver."
bromobenzene,"The urinary metabolites of bromobenzene include 4-bromophenol, glutathione conjugates, and other derivatives formed via metabolic conversion.","Entity: bromobenzene. SMILES: Brc1ccccc1. The urinary metabolites of bromobenzene include 4-bromophenol, glutathione conjugates, and other derivatives formed via metabolic conversion."
4-bromophenol,"4-bromophenol is formed nonenzymatically from bromobenzene 3,4-epoxide.","Entity: 4-bromophenol. SMILES: Oc1ccc(Br)cc1. 4-bromophenol is formed nonenzymatically from bromobenzene 3,4-epoxide."
"3,4-dihydro-3,4-dihydroxy-bromobenzene","3,4-dihydro-3,4-dihydroxy-bromobenzene is formed from bromobenzene 3,4-epoxide via an epoxide hydrolase-catalyzed reaction.","Entity: 3,4-dihydro-3,4-dihydroxy-bromobenzene. SMILES: OC1C=CC(Br)=CC1O. 3,4-dihydro-3,4-dihydroxy-bromobenzene is formed from bromobenzene 3,4-epoxide via an epoxide hydrolase-catalyzed reaction."
"3,4-dihydro-3-hydroxy-4-glutathionyl-bromobenzene","3,4-dihydro-3-hydroxy-4-glutathionyl-bromobenzene is formed from bromobenzene 3,4-epoxide and is a glutathione conjugate.","Entity: 3,4-dihydro-3-hydroxy-4-glutathionyl-bromobenzene. SMILES: O=C(O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](NC1C=CC(Br)=CC1O)C(=O)O. 3,4-dihydro-3-hydroxy-4-glutathionyl-bromobenzene is formed from bromobenzene 3,4-epoxide and is a glutathione conjugate."
glutathione,"Glutathione conjugates are formed from bromobenzene 3,4-epoxide by glutathione transferases in the liver and are subsequently hydrolyzed to their cysteinyl derivative, which can be acetylated to form mercapturic acid excreted in urine.","Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione conjugates are formed from bromobenzene 3,4-epoxide by glutathione transferases in the liver and are subsequently hydrolyzed to their cysteinyl derivative, which can be acetylated to form mercapturic acid excreted in urine."
MgATP,MgATP is an effective inhibitor of the Oplophorus muscle pyruvate kinase with a Kl value of 3.15 mM.,Entity: MgATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)([O-])OP(=O)([O-])O)[C@@H](O)[C@H]1O.[Mg+2]. MgATP is an effective inhibitor of the Oplophorus muscle pyruvate kinase with a Kl value of 3.15 mM.
arginine phosphate,Arginine phosphate is an effective inhibitor of the Oplophorus muscle pyruvate kinase with a Kl value of 3.5 mM.,Entity: arginine phosphate. SMILES: N=C(N)NCCC[C@H](N)C(=O)O.O=P(O)(O)O. Arginine phosphate is an effective inhibitor of the Oplophorus muscle pyruvate kinase with a Kl value of 3.5 mM.
KCI,"KCI is used as a substrate in enzyme assays to measure pyruvate kinase activity, with a standard concentration of 100 mM.","Entity: KCI. SMILES: [Cl-].[K+]. KCI is used as a substrate in enzyme assays to measure pyruvate kinase activity, with a standard concentration of 100 mM."
PEP,"PEP is used as a substrate in enzyme assays to measure pyruvate kinase activity, with a standard concentration of 5 mM.","Entity: PEP. SMILES: C=C(OP(=O)(O)O)C(=O)O. PEP is used as a substrate in enzyme assays to measure pyruvate kinase activity, with a standard concentration of 5 mM."
ADP,"ADP is used as a substrate in enzyme assays to measure pyruvate kinase activity, with a standard concentration of 5 mM.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP is used as a substrate in enzyme assays to measure pyruvate kinase activity, with a standard concentration of 5 mM."
ribose-5-phosphate,Ribose-5-phosphate inhibits the activity of FDPase in king crab and tanner crab muscle.,Entity: ribose-5-phosphate. SMILES: O=C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Ribose-5-phosphate inhibits the activity of FDPase in king crab and tanner crab muscle.
mannose-6-phosphate,Mannose-6-phosphate inhibits the activity of FDPase in king crab and tanner crab muscle.,Entity: mannose-6-phosphate. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Mannose-6-phosphate inhibits the activity of FDPase in king crab and tanner crab muscle.
arginine phosphate,Arginine phosphate levels are high in resting muscle and inhibit pyruvate kinase activity.,Entity: arginine phosphate. SMILES: N=C(N)NCCC[C@H](N)C(=O)O.O=P(O)(O)O. Arginine phosphate levels are high in resting muscle and inhibit pyruvate kinase activity.
malate,Increased malate levels inhibit pyruvate kinase activity.,Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Increased malate levels inhibit pyruvate kinase activity.
Mg2citrate,Mg2citrate at 10 mM significantly influences the activity of shrimp muscle pyruvate kinase.,Entity: Mg2citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2]. Mg2citrate at 10 mM significantly influences the activity of shrimp muscle pyruvate kinase.
Mg-malate,Mg-malate at 10 mM significantly influences the activity of shrimp muscle pyruvate kinase.,Entity: Mg-malate. SMILES: O=C([O-])CC(O)C(=O)[O-].[Mg+2]. Mg-malate at 10 mM significantly influences the activity of shrimp muscle pyruvate kinase.
CaCI2,CaCI2 at 5 mM significantly influences the activity of shrimp muscle pyruvate kinase.,Entity: CaCI2. SMILES: [Ca+2].[Cl-].[Cl-]. CaCI2 at 5 mM significantly influences the activity of shrimp muscle pyruvate kinase.
arginine phosphate,Arginine phosphate at 10 mM significantly influences the activity of shrimp muscle pyruvate kinase.,Entity: arginine phosphate. SMILES: N=C(N)NCCC[C@H](N)C(=O)O.O=P(O)(O)O. Arginine phosphate at 10 mM significantly influences the activity of shrimp muscle pyruvate kinase.
PEP,"The pyruvate kinase enzyme from Oplophorus gracilirostris has a high affinity for PEP, with a Km of 0.04 mM, which is within physiological levels.","Entity: PEP. SMILES: C=C(OP(=O)(O)O)C(=O)O. The pyruvate kinase enzyme from Oplophorus gracilirostris has a high affinity for PEP, with a Km of 0.04 mM, which is within physiological levels."
ADP,The pyruvate kinase enzyme from Oplophorus gracilirostris has a Km for ADP within physiological levels.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. The pyruvate kinase enzyme from Oplophorus gracilirostris has a Km for ADP within physiological levels.
phosphoenolpyruvate,"The shrimp pyruvate kinase enzyme exhibits high affinity for phosphoenolpyruvate with a Km value of 0.04 mM, which is not affected by variations in ADP concentration.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. The shrimp pyruvate kinase enzyme exhibits high affinity for phosphoenolpyruvate with a Km value of 0.04 mM, which is not affected by variations in ADP concentration."
"fructose 1,6 diphosphate","The affinity of the shrimp pyruvate kinase enzyme for either phosphoenolpyruvate or ADP is not affected by the addition of fructose 1,6 diphosphate at concentrations from 0.005 mM to 0.1 mM.","Entity: fructose 1,6 diphosphate. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. The affinity of the shrimp pyruvate kinase enzyme for either phosphoenolpyruvate or ADP is not affected by the addition of fructose 1,6 diphosphate at concentrations from 0.005 mM to 0.1 mM."
arginine phosphate,"Arginine phosphate serves as the storage phosphagen for crustacean muscle and its levels decrease during contraction, leading to deinhibition of pyruvate kinase.","Entity: arginine phosphate. SMILES: N=C(N)NCCC[C@H](N)C(=O)O.O=P(O)(O)O. Arginine phosphate serves as the storage phosphagen for crustacean muscle and its levels decrease during contraction, leading to deinhibition of pyruvate kinase."
arginine phosphate,"In resting crustacean muscle, arginine phosphate levels are near 30 mM.","Entity: arginine phosphate. SMILES: N=C(N)NCCC[C@H](N)C(=O)O.O=P(O)(O)O. In resting crustacean muscle, arginine phosphate levels are near 30 mM."
malate,Malate levels rise to near 1 mM in mammalian tissues under certain metabolic conditions.,Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate levels rise to near 1 mM in mammalian tissues under certain metabolic conditions.
malate,Malate is in equilibrium with oxaloacetate through the malate dehydrogenase reaction.,Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate is in equilibrium with oxaloacetate through the malate dehydrogenase reaction.
malate,"During periods of gluconeogenesis, cytosolic malate levels tend to rise.","Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. During periods of gluconeogenesis, cytosolic malate levels tend to rise."
malate,"Inhibition of pyruvate kinase activity can occur during periods of high Krebs cycle flux, potentially due to elevated malate levels.","Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Inhibition of pyruvate kinase activity can occur during periods of high Krebs cycle flux, potentially due to elevated malate levels."
oxaloacetate,Oxaloacetate is an intermediate of the pyruvate kinase bypass and is produced from malate via the malate dehydrogenase reaction.,Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. Oxaloacetate is an intermediate of the pyruvate kinase bypass and is produced from malate via the malate dehydrogenase reaction.
Mg-malate,"Mg-malate inhibits the pyruvate dehydrogenase (PFK-FDPase) reaction, and this inhibition is integrated with activity at the pyruvate kinase locus.","Entity: Mg-malate. SMILES: O=C([O-])CC(O)C(=O)[O-].[Mg+2]. Mg-malate inhibits the pyruvate dehydrogenase (PFK-FDPase) reaction, and this inhibition is integrated with activity at the pyruvate kinase locus."
arginine phosphate,"Arginine phosphate inhibits both the pyruvate dehydrogenase (PFK-FDPase) reaction and the pyruvate kinase reaction, thereby integrating activity at these two loci.","Entity: arginine phosphate. SMILES: N=C(N)NCCC[C@H](N)C(=O)O.O=P(O)(O)O. Arginine phosphate inhibits both the pyruvate dehydrogenase (PFK-FDPase) reaction and the pyruvate kinase reaction, thereby integrating activity at these two loci."
arginine phosphate,Arginine phosphate is a mixed competitive inhibitor of pyruvate kinase with respect to PEP (Ki = 4.2 mM) and ADP (Ki = 3.5 mM).,Entity: arginine phosphate. SMILES: N=C(N)NCCC[C@H](N)C(=O)O.O=P(O)(O)O. Arginine phosphate is a mixed competitive inhibitor of pyruvate kinase with respect to PEP (Ki = 4.2 mM) and ADP (Ki = 3.5 mM).
calcium,Calcium acts as a competitive inhibitor of Mg2+ in pyruvate kinase with a Ki of 0.3 mM.,Entity: calcium. SMILES: [Ca]. Calcium acts as a competitive inhibitor of Mg2+ in pyruvate kinase with a Ki of 0.3 mM.
FDP,FDP does not reverse the inhibition of pyruvate kinase by MgATP.,Entity: FDP. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. FDP does not reverse the inhibition of pyruvate kinase by MgATP.
Mg2citrate,Mg2citrate is a mixed competitive inhibitor of pyruvate kinase with respect to PEP (Ki = 6.06 mM) and ADP (Ki = 6.35 mM).,Entity: Mg2citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2]. Mg2citrate is a mixed competitive inhibitor of pyruvate kinase with respect to PEP (Ki = 6.06 mM) and ADP (Ki = 6.35 mM).
Mgmalate,Mgmalate is a mixed competitive inhibitor of pyruvate kinase with respect to PEP (Ki = 1.7 mM) and ADP (Ki = 3.78 mM).,Entity: Mgmalate. SMILES: O=C([O-])CC(O)C(=O)[O-].[Mg+2]. Mgmalate is a mixed competitive inhibitor of pyruvate kinase with respect to PEP (Ki = 1.7 mM) and ADP (Ki = 3.78 mM).
trifluoroacetic anhydride,Trifluoroacetic anhydride is used as a derivatization reagent for preparing 5-aminovaleric acid samples for gas chromatography (GC) and gas chromatography-mass spectrometry (GCMS) analysis.,Entity: trifluoroacetic anhydride. SMILES: O=C(OC(=O)C(F)(F)F)C(F)(F)F. Trifluoroacetic anhydride is used as a derivatization reagent for preparing 5-aminovaleric acid samples for gas chromatography (GC) and gas chromatography-mass spectrometry (GCMS) analysis.
bis-(trimethylsilyl)-trifluoroacetamide,Bis-(trimethylsilyl)-trifluoroacetamide (BTFSA) is used as a derivatization reagent to prepare 5-aminovaleric acid samples for gas chromatography (GC) and gas chromatography-mass spectrometry (GCMS) analysis.,Entity: bis-(trimethylsilyl)-trifluoroacetamide. SMILES: C[Si](C)(C)N(C(=O)C(F)(F)F)[Si](C)(C)C. Bis-(trimethylsilyl)-trifluoroacetamide (BTFSA) is used as a derivatization reagent to prepare 5-aminovaleric acid samples for gas chromatography (GC) and gas chromatography-mass spectrometry (GCMS) analysis.
diazomethane,Diazomethane is used to derivatize 5-aminovaleric acid samples by reaction with diethyl ether prior to gas chromatography (GC) and gas chromatography-mass spectrometry (GCMS) analysis.,Entity: diazomethane. SMILES: C=[N+]=[N-]. Diazomethane is used to derivatize 5-aminovaleric acid samples by reaction with diethyl ether prior to gas chromatography (GC) and gas chromatography-mass spectrometry (GCMS) analysis.
hydrochloric acid,Hydrochloric acid is used to acidify anal sac secretions prior to extraction and derivatization of 5-aminovaleric acid for GC and GCMS analysis.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to acidify anal sac secretions prior to extraction and derivatization of 5-aminovaleric acid for GC and GCMS analysis.
diethyl ether,Diethyl ether is used as an extraction solvent for isolating 5-aminovaleric acid from anal sac secretions and as a reaction medium for derivatization with diazomethane prior to GC and GCMS analysis.,Entity: diethyl ether. SMILES: CCOCC. Diethyl ether is used as an extraction solvent for isolating 5-aminovaleric acid from anal sac secretions and as a reaction medium for derivatization with diazomethane prior to GC and GCMS analysis.
5-aminovaleric acid,5-aminovaleric acid is a compound that can be derivatized and analyzed by gas chromatography (GC) and gas chromatography-mass spectrometry (GCMS) after extraction from anal sac secretions.,Entity: 5-aminovaleric acid. SMILES: NCCCCC(=O)O. 5-aminovaleric acid is a compound that can be derivatized and analyzed by gas chromatography (GC) and gas chromatography-mass spectrometry (GCMS) after extraction from anal sac secretions.
trifluoroacetic acid,Trifluoroacetic acid is used as a derivatization reagent for preparing 5-aminovaleric acid samples for gas chromatography (GC) and gas chromatography-mass spectrometry (GCMS) analysis.,Entity: trifluoroacetic acid. SMILES: O=C(O)C(F)(F)F. Trifluoroacetic acid is used as a derivatization reagent for preparing 5-aminovaleric acid samples for gas chromatography (GC) and gas chromatography-mass spectrometry (GCMS) analysis.
ammonia,"Ammonia in red fox anal sac secretion is likely of microbial origin and shows a strong positive correlation with 5-aminovaleric acid concentration, with a linear regression slope of 27.5 and an intercept of 15.8 mM ammonia for 5-aminovaleric acid in these samples.","Entity: ammonia. SMILES: N. Ammonia in red fox anal sac secretion is likely of microbial origin and shows a strong positive correlation with 5-aminovaleric acid concentration, with a linear regression slope of 27.5 and an intercept of 15.8 mM ammonia for 5-aminovaleric acid in these samples."
putrescine,Putrescine in red fox anal sac secretion is probably of microbial origin.,Entity: putrescine. SMILES: NCCCCN. Putrescine in red fox anal sac secretion is probably of microbial origin.
cadaverine,Cadaverine in red fox anal sac secretion is probably of microbial origin.,Entity: cadaverine. SMILES: NCCCCCN. Cadaverine in red fox anal sac secretion is probably of microbial origin.
5-aminovaleric acid,"5-aminovaleric acid in red fox anal sac secretion is present at concentrations that correlate strongly with total volatile fatty acid concentration, with a linear regression slope of 16.6 and an intercept of 9.5 mM VFA for 5-aminovaleric acid in these samples.","Entity: 5-aminovaleric acid. SMILES: NCCCCC(=O)O. 5-aminovaleric acid in red fox anal sac secretion is present at concentrations that correlate strongly with total volatile fatty acid concentration, with a linear regression slope of 16.6 and an intercept of 9.5 mM VFA for 5-aminovaleric acid in these samples."
5-aminovaleric acid,"5-aminovaleric acid in red fox anal sac secretion shares a largely microbial origin with volatile fatty acids, as their concentrations vary similarly with fermentation (sac residence) times.","Entity: 5-aminovaleric acid. SMILES: NCCCCC(=O)O. 5-aminovaleric acid in red fox anal sac secretion shares a largely microbial origin with volatile fatty acids, as their concentrations vary similarly with fermentation (sac residence) times."
5-aminovaleric acid,"Under certain conditions, 5-aminovaleric acid is microbially converted to n-valeric acid and ammonia.","Entity: 5-aminovaleric acid. SMILES: NCCCCC(=O)O. Under certain conditions, 5-aminovaleric acid is microbially converted to n-valeric acid and ammonia."
5-aminovaleric acid,"5-aminovaleric acid may inhibit the growth of certain microorganisms, such as Staphylococci, which could colonize the anal sac.","Entity: 5-aminovaleric acid. SMILES: NCCCCC(=O)O. 5-aminovaleric acid may inhibit the growth of certain microorganisms, such as Staphylococci, which could colonize the anal sac."
5-aminovaleric acid,"5-aminovaleric acid is present in the secretion and forms mono- and bis-trimethylsilyl derivatives detectable by mass spectrometry (m/e 285(M+), 270(40.0) for mono-, and m/e 375(M+,4.5), 212(34) for bis-trimethylsilyl derivatives).","Entity: 5-aminovaleric acid. SMILES: O=C(O)CCCCNC(=O)C(F)(F)F. 5-aminovaleric acid is present in the secretion and forms mono- and bis-trimethylsilyl derivatives detectable by mass spectrometry (m/e 285(M+), 270(40.0) for mono-, and m/e 375(M+,4.5), 212(34) for bis-trimethylsilyl derivatives)."
5-aminovaleric acid,"5-aminovaleric acid is a major component of red fox anal sac secretion, as indicated by a major peak in the free amino acid chromatogram with elution characteristics matching 5-aminovaleric acid and a 440 nm: 570 nm ninhydrin complex absorption ratio of 1:5.1.","Entity: 5-aminovaleric acid. SMILES: NCCCCC(=O)O. 5-aminovaleric acid is a major component of red fox anal sac secretion, as indicated by a major peak in the free amino acid chromatogram with elution characteristics matching 5-aminovaleric acid and a 440 nm: 570 nm ninhydrin complex absorption ratio of 1:5.1."
ornithine,"Ornithine is a basic amino acid that is generally absent in red fox anal sac secretion, with only a minor constituent present in the approximate position of ornithine on the chromatogram.","Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine is a basic amino acid that is generally absent in red fox anal sac secretion, with only a minor constituent present in the approximate position of ornithine on the chromatogram."
putrescine,"Putrescine (1,4-diaminobutane) is not eluted under the chromatographic conditions used for red fox anal sac secretion analysis.","Entity: putrescine. SMILES: NCCCCN. Putrescine (1,4-diaminobutane) is not eluted under the chromatographic conditions used for red fox anal sac secretion analysis."
ammonia,A large peak corresponding to ammonia is observed on the basic column in the chromatogram of red fox anal sac secretion.,Entity: ammonia. SMILES: N. A large peak corresponding to ammonia is observed on the basic column in the chromatogram of red fox anal sac secretion.
4-Aminobutyric acid,4-Aminobutyric acid (GABA) is absent in red fox anal sac secretion.,Entity: 4-Aminobutyric acid. SMILES: NCCCC(=O)O. 4-Aminobutyric acid (GABA) is absent in red fox anal sac secretion.
cadaverine,"Cadaverine (1,5-diaminopentane) is not eluted under the chromatographic conditions used for red fox anal sac secretion analysis.","Entity: cadaverine. SMILES: NCCCCCN. Cadaverine (1,5-diaminopentane) is not eluted under the chromatographic conditions used for red fox anal sac secretion analysis."
putrescine,"Putrescine (1,4-diaminobutane) is a diamine component of the aqueous odorous liquid in red fox anal sacs, likely of microbial origin.","Entity: putrescine. SMILES: NCCCCN. Putrescine (1,4-diaminobutane) is a diamine component of the aqueous odorous liquid in red fox anal sacs, likely of microbial origin."
ammonia,Ammonia of probable microbial origin is a major component of the aqueous odorous liquid in red fox anal sacs.,Entity: ammonia. SMILES: N. Ammonia of probable microbial origin is a major component of the aqueous odorous liquid in red fox anal sacs.
cadaverine,"Cadaverine (1,5-diaminopentane) is a diamine present in the aqueous odorous liquid of red fox anal sacs, likely produced by microbes.","Entity: cadaverine. SMILES: NCCCCCN. Cadaverine (1,5-diaminopentane) is a diamine present in the aqueous odorous liquid of red fox anal sacs, likely produced by microbes."
trimethylamine,Trimethylamine has been observed as a component of the aqueous odorous liquid in red fox anal sacs.,Entity: trimethylamine. SMILES: CN(C)C. Trimethylamine has been observed as a component of the aqueous odorous liquid in red fox anal sacs.
sodium citrate,"Sodium citrate is used as a buffer at concentrations of 0.35 M (pH 5.25) for eluting basic amino acids and at 0.2 M (pH 2.9, 3.25, 4.25) for eluting acidic and neutral amino acids in amino acid analysis.","Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used as a buffer at concentrations of 0.35 M (pH 5.25) for eluting basic amino acids and at 0.2 M (pH 2.9, 3.25, 4.25) for eluting acidic and neutral amino acids in amino acid analysis."
N-trifluoroacetyl-5-aminovaleric acid methyl ester,"N-trifluoroacetyl-5-aminovaleric acid methyl ester elutes at 9.2 minutes under gas chromatography-mass spectrometry conditions with a 225 cmx 3.2 mm ID glass column of 3° OV-17, 70 eV electron energy, injection temperature 200°C, source temperature 270°C, separator temperature 225°C, and helium flow rate of 30 ml/min.","Entity: N-trifluoroacetyl-5-aminovaleric acid methyl ester. SMILES: COC(=O)CCCCNC(=O)C(F)(F)F. N-trifluoroacetyl-5-aminovaleric acid methyl ester elutes at 9.2 minutes under gas chromatography-mass spectrometry conditions with a 225 cmx 3.2 mm ID glass column of 3° OV-17, 70 eV electron energy, injection temperature 200°C, source temperature 270°C, separator temperature 225°C, and helium flow rate of 30 ml/min."
helium,Helium is used as the carrier gas at a flow rate of 30 ml/min in gas chromatography-mass spectrometry analysis.,Entity: helium. SMILES: [He]. Helium is used as the carrier gas at a flow rate of 30 ml/min in gas chromatography-mass spectrometry analysis.
aspartic acid,"Aspartic acid is present in anal sac secretion but at lower relative concentrations compared to amino acids with hydrophobic side chains, as determined by ion-exchange chromatography.","Entity: aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. Aspartic acid is present in anal sac secretion but at lower relative concentrations compared to amino acids with hydrophobic side chains, as determined by ion-exchange chromatography."
glutamic acid,"Glutamic acid is present in anal sac secretion but at lower relative concentrations than amino acids with hydrophobic side chains, according to ion-exchange chromatography.","Entity: glutamic acid. SMILES: N[C@@H](CCC(=O)O)C(=O)O. Glutamic acid is present in anal sac secretion but at lower relative concentrations than amino acids with hydrophobic side chains, according to ion-exchange chromatography."
threonine,"Threonine is present in anal sac secretion but at lower relative concentrations than amino acids with hydrophobic side chains, as determined by ion-exchange chromatography.","Entity: threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. Threonine is present in anal sac secretion but at lower relative concentrations than amino acids with hydrophobic side chains, as determined by ion-exchange chromatography."
serine,"Serine is present in anal sac secretion but at lower relative concentrations than amino acids with hydrophobic side chains, as determined by ion-exchange chromatography.","Entity: serine. SMILES: N[C@@H](CO)C(=O)O. Serine is present in anal sac secretion but at lower relative concentrations than amino acids with hydrophobic side chains, as determined by ion-exchange chromatography."
5-aminovaleric acid,"5-aminovaleric acid concentrations differ between right and left anal sacs in animal secretions, as detected by ion-exchange column analysis.","Entity: 5-aminovaleric acid. SMILES: NCCCCC(=O)O. 5-aminovaleric acid concentrations differ between right and left anal sacs in animal secretions, as detected by ion-exchange column analysis."
proline,"Proline is present in anal sac secretion but at lower relative concentrations than amino acids with hydrophobic side chains, according to ion-exchange chromatography.","Entity: proline. SMILES: O=C(O)[C@@H]1CCCN1. Proline is present in anal sac secretion but at lower relative concentrations than amino acids with hydrophobic side chains, according to ion-exchange chromatography."
ammonia,"Ammonia concentrations vary between right and left anal sacs in animal secretions, as determined by ion-exchange column analysis.","Entity: ammonia. SMILES: N. Ammonia concentrations vary between right and left anal sacs in animal secretions, as determined by ion-exchange column analysis."
glycine,"Glycine is present in anal sac secretion but at lower relative concentrations than amino acids with hydrophobic side chains, as determined by ion-exchange chromatography.","Entity: glycine. SMILES: NCC(=O)O. Glycine is present in anal sac secretion but at lower relative concentrations than amino acids with hydrophobic side chains, as determined by ion-exchange chromatography."
valine,"Valine is a major amino acid component in anal sac secretion, characterized by its hydrophobic side chain and detected by ion-exchange chromatography.","Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. Valine is a major amino acid component in anal sac secretion, characterized by its hydrophobic side chain and detected by ion-exchange chromatography."
2-aminobutyric acid,"2-aminobutyric acid is a major amino acid component in anal sac secretion, characterized by its hydrophobic side chain and detected by ion-exchange chromatography.","Entity: 2-aminobutyric acid. SMILES: CCC(N)C(=O)O. 2-aminobutyric acid is a major amino acid component in anal sac secretion, characterized by its hydrophobic side chain and detected by ion-exchange chromatography."
leucine,"Leucine is a major amino acid component in anal sac secretion, with a hydrophobic side chain, and was identified by ion-exchange chromatography.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine is a major amino acid component in anal sac secretion, with a hydrophobic side chain, and was identified by ion-exchange chromatography."
alanine,"Alanine is a major amino acid component in anal sac secretion, possessing a hydrophobic side chain, and was detected by ion-exchange chromatography.","Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine is a major amino acid component in anal sac secretion, possessing a hydrophobic side chain, and was detected by ion-exchange chromatography."
isoleucine,"Iso-leucine is a major amino acid component in anal sac secretion, with a hydrophobic side chain, and was identified by ion-exchange chromatography.","Entity: isoleucine. SMILES: CC[C@H](C)[C@H](N)C(=O)O. Iso-leucine is a major amino acid component in anal sac secretion, with a hydrophobic side chain, and was identified by ion-exchange chromatography."
Proline,"Proline serves as a substrate for certain Clostridia, which ferment it to produce 5-Aminovaleric acid.","Entity: Proline. SMILES: O=C(O)[C@@H]1CCCN1. Proline serves as a substrate for certain Clostridia, which ferment it to produce 5-Aminovaleric acid."
Ornithine,"Ornithine is a substrate for certain Clostridia, which ferment it to produce 5-Aminovaleric acid.","Entity: Ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine is a substrate for certain Clostridia, which ferment it to produce 5-Aminovaleric acid."
5-Aminovaleric acid,5-Aminovaleric acid is formed by the fermenting action of certain Clostridia on proline and ornithine.,Entity: 5-Aminovaleric acid. SMILES: NCCCCC(=O)O. 5-Aminovaleric acid is formed by the fermenting action of certain Clostridia on proline and ornithine.
5-Aminovaleric acid,"5-Aminovaleric acid is produced by rumen bacteria, rumen ciliates, and may occur in human saliva possibly due to microbial activity.","Entity: 5-Aminovaleric acid. SMILES: NCCCCC(=O)O. 5-Aminovaleric acid is produced by rumen bacteria, rumen ciliates, and may occur in human saliva possibly due to microbial activity."
hydroxyproline,Hydroxyproline is an amino acid that contributes to the stabilization of the collagen molecule.,Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Hydroxyproline is an amino acid that contributes to the stabilization of the collagen molecule.
hydroxyproline,"Hydroxyproline content in starved myocommata collagen is 8.2 ± 0.17% (by weight of total amino acids), and in starved skin collagen is 8.1 ± 0.26% (by weight of total amino acids), as determined by the Leach method.","Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Hydroxyproline content in starved myocommata collagen is 8.2 ± 0.17% (by weight of total amino acids), and in starved skin collagen is 8.1 ± 0.26% (by weight of total amino acids), as determined by the Leach method."
proline,Proline is an amino acid that contributes to the stabilization of the collagen molecule.,Entity: proline. SMILES: O=C(O)[C@@H]1CCCN1. Proline is an amino acid that contributes to the stabilization of the collagen molecule.
sodium citrate,"Sodium citrate buffer (I = 0.089, pH 3.5) is used as a solvent to determine the intrinsic viscosity of undenatured acid-soluble collagen solutions at 7°C.","Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate buffer (I = 0.089, pH 3.5) is used as a solvent to determine the intrinsic viscosity of undenatured acid-soluble collagen solutions at 7°C."
hydroxyproline,Hydroxyproline content in collagen is used as an indicator of protein modification and can influence denaturation temperature.,Entity: hydroxyproline. SMILES: O=C(O)[C@@H]1C[C@@H](O)CN1. Hydroxyproline content in collagen is used as an indicator of protein modification and can influence denaturation temperature.
sodium citrate,Sodium citrate is used as a buffer to denature collagen solutions at 30°C for 2 hours prior to sedimentation analysis in analytical ultracentrifugation.,Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used as a buffer to denature collagen solutions at 30°C for 2 hours prior to sedimentation analysis in analytical ultracentrifugation.
NaCl,NaCl is used as a 1.0 M solution for dialysis and washing steps in the purification of paramyosin from muscle extracts.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used as a 1.0 M solution for dialysis and washing steps in the purification of paramyosin from muscle extracts.
NaH2PO4,NaH2PO4 is used as a 0.05 M solution for dialysis and washing steps during the purification of paramyosin from muscle extracts.,Entity: NaH2PO4. SMILES: O=P([O-])(O)O.[Na+]. NaH2PO4 is used as a 0.05 M solution for dialysis and washing steps during the purification of paramyosin from muscle extracts.
HCl,HCl is used at 0.02 N concentration for precipitating impurities and at pH 5.0 for dissolving paramyosin pellets during protein purification.,Entity: HCl. SMILES: Cl. HCl is used at 0.02 N concentration for precipitating impurities and at pH 5.0 for dissolving paramyosin pellets during protein purification.
Na2HPO4,Na2HPO4 is used as a 0.05 M solution for dialysis and washing steps in the purification of paramyosin from muscle extracts.,Entity: Na2HPO4. SMILES: O=P([O-])([O-])O.[Na+].[Na+]. Na2HPO4 is used as a 0.05 M solution for dialysis and washing steps in the purification of paramyosin from muscle extracts.
tyrosine,The quantum yield of tyrosyl residues in paramyosins can be compared using the quantum yield (Rtyr) of the amino acid tyrosine at pH 7.0 as a reference.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. The quantum yield of tyrosyl residues in paramyosins can be compared using the quantum yield (Rtyr) of the amino acid tyrosine at pH 7.0 as a reference.
guanidine-HCl,"Guanidine-HCl is used to denature paramyosin by disrupting its helical conformation, as measured by changes in fluorescence of tyrosyl residues.","Entity: guanidine-HCl. SMILES: Cl.N=C(N)N. Guanidine-HCl is used to denature paramyosin by disrupting its helical conformation, as measured by changes in fluorescence of tyrosyl residues."
dodecyl sulfate,"Dodecyl sulfate is used in gel electrophoresis to distinguish between different molecular sizes of paramyosin, such as the ~- and 3-paramyosin forms from M. mercenaria.","Entity: dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-]. Dodecyl sulfate is used in gel electrophoresis to distinguish between different molecular sizes of paramyosin, such as the ~- and 3-paramyosin forms from M. mercenaria."
EDTA,EDTA is used as a protease inhibitor during paramyosin extraction to prevent degradation of the protein.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used as a protease inhibitor during paramyosin extraction to prevent degradation of the protein.
EDTA,"EDTA is used for chelation of heavy metal ions in protein studies, with recommended concentrations ranging from 10⁻⁳ M to 10⁻⁳ M for effective inhibition of tissue proteases.","Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used for chelation of heavy metal ions in protein studies, with recommended concentrations ranging from 10⁻⁳ M to 10⁻⁳ M for effective inhibition of tissue proteases."
NaCl,NaCl is used as a salt to adjust the ionic strength of dialysis buffers for protein solubility studies.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used as a salt to adjust the ionic strength of dialysis buffers for protein solubility studies.
Na2HPO4,Na2HPO4 is used as a buffer component at 0.02 M concentration and pH 7.5 in dialysis buffers for protein solubility studies.,Entity: Na2HPO4. SMILES: O=P([O-])([O-])O.[Na+].[Na+]. Na2HPO4 is used as a buffer component at 0.02 M concentration and pH 7.5 in dialysis buffers for protein solubility studies.
acrylamide,Acrylamide is used as a monomer in the formation of 5~o and 0.135~o bisacrylamide gels for sodium dodecyl sulfate gel electrophoresis to determine molecular weights.,Entity: acrylamide. SMILES: C=CC(N)=O. Acrylamide is used as a monomer in the formation of 5~o and 0.135~o bisacrylamide gels for sodium dodecyl sulfate gel electrophoresis to determine molecular weights.
sodium dodecyl sulfate,"Sodium dodecyl sulfate is used in gel electrophoresis, specifically in sodium dodecyl sulfate gel electrophoresis, for the determination of protein molecular weights.","Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate is used in gel electrophoresis, specifically in sodium dodecyl sulfate gel electrophoresis, for the determination of protein molecular weights."
guanidine-HCl,"Guanidine-HCl is used to induce denaturation of paramyosin, as evidenced by the gradual loss of fluorescence over a wide range of guanidine-HCl concentration in gel electrophoresis assays.","Entity: guanidine-HCl. SMILES: Cl.N=C(N)N. Guanidine-HCl is used to induce denaturation of paramyosin, as evidenced by the gradual loss of fluorescence over a wide range of guanidine-HCl concentration in gel electrophoresis assays."
dodecyl sulfate,"Dodecyl sulfate gel electrophoresis is used to determine the molecular weights of paramyosin segments by separating polypeptide chains under neutral pH, with the assumption that each segment consists of two intertwined β-helical polypeptide chains.","Entity: dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-]. Dodecyl sulfate gel electrophoresis is used to determine the molecular weights of paramyosin segments by separating polypeptide chains under neutral pH, with the assumption that each segment consists of two intertwined β-helical polypeptide chains."
linolenic acid,Linolenic acid (C18:3) is present at a much higher content in the lima bean diet compared to cotton seeds.,Entity: linolenic acid. SMILES: CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O. Linolenic acid (C18:3) is present at a much higher content in the lima bean diet compared to cotton seeds.
stearic acid,Stearic acid (C18:0) is a fatty acid present in the lima bean diet.,Entity: stearic acid. SMILES: CCCCCCCCCCCCCCCCCC(=O)O. Stearic acid (C18:0) is a fatty acid present in the lima bean diet.
palmitic acid,Palmitic acid is a fatty acid present in the lima bean diet.,Entity: palmitic acid. SMILES: CCCCCCCCCCCCCCCC(=O)O. Palmitic acid is a fatty acid present in the lima bean diet.
palmitoleic acid,Palmitoleic acid (C16:l) is a fatty acid present in the lima bean diet.,Entity: palmitoleic acid. SMILES: CCCCCC/C=C\CCCCCCCC(=O)O. Palmitoleic acid (C16:l) is a fatty acid present in the lima bean diet.
linoleic acid,Linoleic acid (C18:2) is a major fatty acid constituent of the lima bean diet.,Entity: linoleic acid. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. Linoleic acid (C18:2) is a major fatty acid constituent of the lima bean diet.
C18:2,Addition of C18:2 to the diet is effective in initiating and maintaining diapause in the khapra beetle Trogoderma oranarium.,Entity: C18:2. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. Addition of C18:2 to the diet is effective in initiating and maintaining diapause in the khapra beetle Trogoderma oranarium.
C18:2,"In diapause larvae of Trogoderma oranarium, bound fatty acids show an increase of 5.7° C18:2 in the diet.","Entity: C18:2. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. In diapause larvae of Trogoderma oranarium, bound fatty acids show an increase of 5.7° C18:2 in the diet."
C16:0,"In diapause larvae of Trogoderma oranarium, bound fatty acids show a decrease of 8.4° C16:0 in the diet.","Entity: C16:0. SMILES: CCCCCCCCCCCCCCCC(=O)O. In diapause larvae of Trogoderma oranarium, bound fatty acids show a decrease of 8.4° C16:0 in the diet."
C18:0,"In diapause larvae of Trogoderma oranarium, free fatty acids show an increase of 5.77° C18:0 in the diet.","Entity: C18:0. SMILES: CCCCCCCCCCCCCCCCCC(=O)O. In diapause larvae of Trogoderma oranarium, free fatty acids show an increase of 5.77° C18:0 in the diet."
C18:1,"In diapause larvae of Trogoderma oranarium, free fatty acids show a decline of 5.67° C18:1 in the diet.","Entity: C18:1. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. In diapause larvae of Trogoderma oranarium, free fatty acids show a decline of 5.67° C18:1 in the diet."
stearic acid,Stearic acid (C18:0) is present at the lowest levels in both low-density (LD) and fractionated distillate (FD) fractions compared to the high-density (HND) fraction.,Entity: stearic acid. SMILES: CCCCCCCCCCCCCCCCCC(=O)O. Stearic acid (C18:0) is present at the lowest levels in both low-density (LD) and fractionated distillate (FD) fractions compared to the high-density (HND) fraction.
palmitic acid,Palmitic acid (C16:0) is present at the lowest levels in low-density (LD) and fractionated distillate (FD) fractions compared to the high-density (HND) fraction.,Entity: palmitic acid. SMILES: CCCCCCCCCCCCCCCC(=O)O. Palmitic acid (C16:0) is present at the lowest levels in low-density (LD) and fractionated distillate (FD) fractions compared to the high-density (HND) fraction.
oleic acid,Oleic acid (C18:1) is present at the highest level in low-density (LD) and the lowest level in fractionated distillate (FD) fractions.,Entity: oleic acid. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. Oleic acid (C18:1) is present at the highest level in low-density (LD) and the lowest level in fractionated distillate (FD) fractions.
linoleic acid,Linoleic acid (C18:2) is present at the highest level in the fractionated distillate (FD) fraction and at the lowest levels in low-density (LD) and high-density (HND) fractions.,Entity: linoleic acid. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. Linoleic acid (C18:2) is present at the highest level in the fractionated distillate (FD) fraction and at the lowest levels in low-density (LD) and high-density (HND) fractions.
palmitic acid,"Palmitic acid (C16:0) accumulates at higher levels in the sterol ester fraction of laboratory-reared nondiapause larvae compared to laboratory-reared diapause larvae, under conditions of higher temperature and longer photophase.","Entity: palmitic acid. SMILES: CCCCCCCCCCCCCCCC(=O)O. Palmitic acid (C16:0) accumulates at higher levels in the sterol ester fraction of laboratory-reared nondiapause larvae compared to laboratory-reared diapause larvae, under conditions of higher temperature and longer photophase."
linolenic acid,"In Heliothis zea, dietary levels of linolenic acid (C18:3) up to 59.8% can result in high levels of C18:3 in the insect's tissues, such as 31.8%.","Entity: linolenic acid. SMILES: CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O. In Heliothis zea, dietary levels of linolenic acid (C18:3) up to 59.8% can result in high levels of C18:3 in the insect's tissues, such as 31.8%."
stearic acid,"Stearic acid (C18:0) accumulates at higher levels in all lipid fractions except phospholipids in laboratory-reared nondiapause larvae compared to laboratory-reared diapause larvae, under conditions of higher temperature and longer photophase.","Entity: stearic acid. SMILES: CCCCCCCCCCCCCCCCCC(=O)O. Stearic acid (C18:0) accumulates at higher levels in all lipid fractions except phospholipids in laboratory-reared nondiapause larvae compared to laboratory-reared diapause larvae, under conditions of higher temperature and longer photophase."
C18:3,C18:3 is present at approximately 13.1% in a lima bean diet and at about 1.0% in cotton seeds.,Entity: C18:3. SMILES: CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O. C18:3 is present at approximately 13.1% in a lima bean diet and at about 1.0% in cotton seeds.
C16:0,Levels of C16:0 are usually higher in larvae than in the diet they are fed.,Entity: C16:0. SMILES: CCCCCCCCCCCCCCCC(=O)O. Levels of C16:0 are usually higher in larvae than in the diet they are fed.
C18:2,The ratio of C18:2 to C18:1 is 1:5 in cotton seeds but 1:1 in larvae.,Entity: C18:2. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. The ratio of C18:2 to C18:1 is 1:5 in cotton seeds but 1:1 in larvae.
C18:1,"C18:1 is present at the highest amount in larvae fed a diet high in C18:2, despite being the least abundant fatty acid in the diet.","Entity: C18:1. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. C18:1 is present at the highest amount in larvae fed a diet high in C18:2, despite being the least abundant fatty acid in the diet."
linoleic acid,Linoleic acid (C18:2) is a major fatty acid present in high content in cotton seeds.,Entity: linoleic acid. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. Linoleic acid (C18:2) is a major fatty acid present in high content in cotton seeds.
linolenic acid,Linolenic acid (C18:3) is a major fatty acid present in low content in cotton seeds.,Entity: linolenic acid. SMILES: CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O. Linolenic acid (C18:3) is a major fatty acid present in low content in cotton seeds.
palmitic acid,Palmitic acid (C16:0) is a major fatty acid found in cotton seeds.,Entity: palmitic acid. SMILES: CCCCCCCCCCCCCCCC(=O)O. Palmitic acid (C16:0) is a major fatty acid found in cotton seeds.
oleic acid,Oleic acid (C18:1) is a major fatty acid present in cotton seeds.,Entity: oleic acid. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. Oleic acid (C18:1) is a major fatty acid present in cotton seeds.
diethyleneglycol succinate,Diethyleneglycol succinate is used as a stationary phase component (15%) in gas chromatography columns for the separation of fatty acids.,Entity: diethyleneglycol succinate. SMILES: O=C(O)CCC(=O)O.OCCOCCO. Diethyleneglycol succinate is used as a stationary phase component (15%) in gas chromatography columns for the separation of fatty acids.
chloroform,Chloroform is used as a component of the chloroform:methanol (2:1) solvent mixture for lipid extraction.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a component of the chloroform:methanol (2:1) solvent mixture for lipid extraction.
acetic acid,"Acetic acid is used as a component of the hexane:diethyl ether:acetic acid (80:20:1, v/v) solvent system for thin-layer chromatography separation of lipid classes.","Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component of the hexane:diethyl ether:acetic acid (80:20:1, v/v) solvent system for thin-layer chromatography separation of lipid classes."
hexane,Hexane is used as a solvent for extracting methyl esters of fatty acids from lipid fractions and for redissolving purified methyl esters.,Entity: hexane. SMILES: CCCCCC. Hexane is used as a solvent for extracting methyl esters of fatty acids from lipid fractions and for redissolving purified methyl esters.
methanol,Methanol is used as a solvent for esterifying fatty acids with 5% sulfuric acid at 100°C for 2.5 hours.,Entity: methanol. SMILES: CO. Methanol is used as a solvent for esterifying fatty acids with 5% sulfuric acid at 100°C for 2.5 hours.
diethyl ether,"Diethyl ether is used as a component of the hexane:diethyl ether:acetic acid (80:20:1, v/v) solvent system for thin-layer chromatography separation of lipid classes.","Entity: diethyl ether. SMILES: CCOCC. Diethyl ether is used as a component of the hexane:diethyl ether:acetic acid (80:20:1, v/v) solvent system for thin-layer chromatography separation of lipid classes."
sulfuric acid,Sulfuric acid (5%) is used as a catalyst in methanol for esterifying fatty acids at 100°C for 2.5 hours.,Entity: sulfuric acid. SMILES: O=S(=O)(O)O. Sulfuric acid (5%) is used as a catalyst in methanol for esterifying fatty acids at 100°C for 2.5 hours.
palmitoleic acid,Palmitoleic acid (C16:0) content is lower than that of palmitic acid in Vespa orientalis larval fat body.,Entity: palmitoleic acid. SMILES: CCCCCC/C=C\CCCCCCCC(=O)O. Palmitoleic acid (C16:0) content is lower than that of palmitic acid in Vespa orientalis larval fat body.
oleic acid,"Oleic acid content in larval fat body varies by species: Vespa orientalis (49.4%), Dolichovespula media (43.8%), Vespa crabro (40.9%), Dolichovespula saxonica (40.5%), and Paravespula vulgaris (22.5%).","Entity: oleic acid. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. Oleic acid content in larval fat body varies by species: Vespa orientalis (49.4%), Dolichovespula media (43.8%), Vespa crabro (40.9%), Dolichovespula saxonica (40.5%), and Paravespula vulgaris (22.5%)."
oleic acid,"Oleic acid content in larval midgut varies by species: Vespa orientalis (33.6%), Paravespula vulgaris (22.3%), and Vespa crabro (10.0%).","Entity: oleic acid. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. Oleic acid content in larval midgut varies by species: Vespa orientalis (33.6%), Paravespula vulgaris (22.3%), and Vespa crabro (10.0%)."
palmitic acid,Palmitic acid (C16) content is higher than that of palmitoleic acid in Vespa orientalis larval fat body.,Entity: palmitic acid. SMILES: CCCCCCCCCCCCCCCC(=O)O. Palmitic acid (C16) content is higher than that of palmitoleic acid in Vespa orientalis larval fat body.
oleic acid,Oleic acid (C12-C~s) content in Vespa orientalis tissues increases gradually from June to October.,Entity: oleic acid. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. Oleic acid (C12-C~s) content in Vespa orientalis tissues increases gradually from June to October.
linoleic acid,Linoleic acid (Cls:3) content in Vespa orientalis tissues decreases from queen to male to worker within each species.,Entity: linoleic acid. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. Linoleic acid (Cls:3) content in Vespa orientalis tissues decreases from queen to male to worker within each species.
linoleic acid,The Cls:3 (linoleic acid) content in Vespa orientalis tissues is rather similar between the two species studied.,Entity: linoleic acid. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. The Cls:3 (linoleic acid) content in Vespa orientalis tissues is rather similar between the two species studied.
arachidonic acid,"Arachidonic acid (C~a:I) content in larval hemolymph, fat body, and midgut of Vespa orientalis decreases from June to October, except in the fat body where it remains stable in October.","Entity: arachidonic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. Arachidonic acid (C~a:I) content in larval hemolymph, fat body, and midgut of Vespa orientalis decreases from June to October, except in the fat body where it remains stable in October."
L-malate,L-malate is used as a substrate in mitochondrial assays measuring the oxidation of palmitoyl-L-carnitine.,Entity: L-malate. SMILES: O=C([O-])C[C@H](O)C(=O)[O-]. L-malate is used as a substrate in mitochondrial assays measuring the oxidation of palmitoyl-L-carnitine.
citrate,Citrate inhibits rat heart citrate synthase competitively with respect to oxaloacetate.,Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Citrate inhibits rat heart citrate synthase competitively with respect to oxaloacetate.
palmitoylcarnitine,Palmitoylcarnitine is oxidized in mitochondrial assays to study changes in mitochondrial metabolite content.,Entity: palmitoylcarnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoylcarnitine is oxidized in mitochondrial assays to study changes in mitochondrial metabolite content.
acetyl-CoA,"During controlled mitochondrial respiration, pronounced accumulation of acetyl-CoA occurs, which is related to the limitation in flux through citrate synthase.","Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. During controlled mitochondrial respiration, pronounced accumulation of acetyl-CoA occurs, which is related to the limitation in flux through citrate synthase."
oxaloacetate,Increased mitochondrial citrate content during controlled respiration may decrease the binding of oxaloacetate to citrate synthase.,Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. Increased mitochondrial citrate content during controlled respiration may decrease the binding of oxaloacetate to citrate synthase.
succinyl-CoA,The mitochondrial content of succinyl-CoA is measured during the oxidation of palmitoyl-L-carnitine plus L-malate in mitochondrial assays.,Entity: succinyl-CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(=O)O. The mitochondrial content of succinyl-CoA is measured during the oxidation of palmitoyl-L-carnitine plus L-malate in mitochondrial assays.
carnitine,"Carnitine causes a small reduction of mitochondrial NAD(P), consistent with its lower activity of carnitine palmitoyltransferase outside the mitochondrial inner membrane.","Entity: carnitine. SMILES: C[N+](C)(C)CC(O)CC(=O)[O-]. Carnitine causes a small reduction of mitochondrial NAD(P), consistent with its lower activity of carnitine palmitoyltransferase outside the mitochondrial inner membrane."
palmitoyl-CoA,"Palmitoyl-CoA is oxidized by mitochondria, as evidenced by its ability to reduce mitochondrial NAD(P) in the presence of antimycin.","Entity: palmitoyl-CoA. SMILES: CCCCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Palmitoyl-CoA is oxidized by mitochondria, as evidenced by its ability to reduce mitochondrial NAD(P) in the presence of antimycin."
palmitate,"Palmitate does not cause a reduction of mitochondrial NAD(P) unless carnitine is added, indicating that carnitine is required for its oxidation by mitochondria.","Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Palmitate does not cause a reduction of mitochondrial NAD(P) unless carnitine is added, indicating that carnitine is required for its oxidation by mitochondria."
palmitoyl-L-carnitine,"Palmitoyl-L-carnitine induces a much larger reduction of mitochondrial NAD(P) than carnitine, indicating higher activity of carnitine palmitoyltransferase (EC 2.3.1.23) within the mitochondrial inner membrane.","Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoyl-L-carnitine induces a much larger reduction of mitochondrial NAD(P) than carnitine, indicating higher activity of carnitine palmitoyltransferase (EC 2.3.1.23) within the mitochondrial inner membrane."
L-malate,L-malate is a dicarboxylate that can permeate mitochondria and causes a reduction of mitochondrial NAD(P) in the presence of antimycin.,Entity: L-malate. SMILES: O=C([O-])C[C@H](O)C(=O)[O-]. L-malate is a dicarboxylate that can permeate mitochondria and causes a reduction of mitochondrial NAD(P) in the presence of antimycin.
carbonyl cyanide p-trifluoromethoxyphenylhydrazone,"Carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) is used to permeabilize mitochondrial membranes, as shown by its effect on mitochondrial NAD(P) reduction in the presence of substrates.","Entity: carbonyl cyanide p-trifluoromethoxyphenylhydrazone. SMILES: N#CC(C#N)=NNc1ccc(OC(F)(F)F)cc1. Carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) is used to permeabilize mitochondrial membranes, as shown by its effect on mitochondrial NAD(P) reduction in the presence of substrates."
NADPH,"The assay for mitochondrial nicotinamide nucleotide reduction does not distinguish between NADH and NADPH, and the measured quantity is referred to as NAD(P)H.","Entity: NADPH. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. The assay for mitochondrial nicotinamide nucleotide reduction does not distinguish between NADH and NADPH, and the measured quantity is referred to as NAD(P)H."
Potassium chloride,Potassium chloride is used as a component of the basal mitochondrial incubation medium at a concentration of 0.12 M.,Entity: Potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is used as a component of the basal mitochondrial incubation medium at a concentration of 0.12 M.
NAD,"In insect flight muscle, NAD predominates over NADP, with NAD being the major form of nicotinamide nucleotide.","Entity: NAD. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. In insect flight muscle, NAD predominates over NADP, with NAD being the major form of nicotinamide nucleotide."
citrate,"In blowfly flight muscle, decreased oxaloacetate/citrate ratio leads to diminished binding of oxaloacetate to citrate synthase and lowered enzyme activity.","Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. In blowfly flight muscle, decreased oxaloacetate/citrate ratio leads to diminished binding of oxaloacetate to citrate synthase and lowered enzyme activity."
carnitine,"Mitochondria from Prodenia eridania do not oxidize carnitine esters, in contrast to mitochondria from other animal classes.","Entity: carnitine. SMILES: C[N+](C)(C)CC(O)CC(=O)[O-]. Mitochondria from Prodenia eridania do not oxidize carnitine esters, in contrast to mitochondria from other animal classes."
pyruvate,"In blowfly flight muscle, pyruvate oxidation is the sole source of acetyl-CoA.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. In blowfly flight muscle, pyruvate oxidation is the sole source of acetyl-CoA."
adenosine triphosphate,A high mitochondrial ATP/ADP ratio inhibits isocitrate dehydrogenase in the tricarboxylate cycle in blowfly flight muscle.,Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. A high mitochondrial ATP/ADP ratio inhibits isocitrate dehydrogenase in the tricarboxylate cycle in blowfly flight muscle.
adenosine diphosphate,A high mitochondrial ATP/ADP ratio inhibits isocitrate dehydrogenase in the tricarboxylate cycle in blowfly flight muscle.,Entity: adenosine diphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. A high mitochondrial ATP/ADP ratio inhibits isocitrate dehydrogenase in the tricarboxylate cycle in blowfly flight muscle.
acetyl-CoA,"In blowfly flight muscle, acetyl-CoA accumulates due to inhibition of pyruvate dehydrogenase following reduced oxaloacetate/citrate ratio.","Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. In blowfly flight muscle, acetyl-CoA accumulates due to inhibition of pyruvate dehydrogenase following reduced oxaloacetate/citrate ratio."
oxaloacetate,A decreased oxaloacetate/citrate ratio in blowfly flight muscle leads to diminished binding of oxaloacetate to citrate synthase and lowered enzyme activity.,Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. A decreased oxaloacetate/citrate ratio in blowfly flight muscle leads to diminished binding of oxaloacetate to citrate synthase and lowered enzyme activity.
palmitate,"Mitochondria from Prodenia eridania rapidly oxidize palmitate, but do not oxidize carnitine esters.","Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Mitochondria from Prodenia eridania rapidly oxidize palmitate, but do not oxidize carnitine esters."
CoASH,Information on mitochondrial CoA thioester (CoASH) content during lipid oxidation is not available for any insect.,Entity: CoASH. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. Information on mitochondrial CoA thioester (CoASH) content during lipid oxidation is not available for any insect.
pyruvate,"In the context of insect flight muscle mitochondria, pyruvate oxidation takes precedence over palmitoyl-L-carnitine oxidation under certain experimental conditions.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. In the context of insect flight muscle mitochondria, pyruvate oxidation takes precedence over palmitoyl-L-carnitine oxidation under certain experimental conditions."
palmitoyl-L-carnitine,"In insect flight muscle mitochondria, palmitoyl-L-carnitine oxidation is subordinate to pyruvate oxidation in the presence of a high ADP/ATP ratio.","Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. In insect flight muscle mitochondria, palmitoyl-L-carnitine oxidation is subordinate to pyruvate oxidation in the presence of a high ADP/ATP ratio."
ATP,A high ADP/ATP ratio in mitochondrial experiments can influence the relative preference for pyruvate oxidation versus palmitoyl-L-carnitine oxidation.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. A high ADP/ATP ratio in mitochondrial experiments can influence the relative preference for pyruvate oxidation versus palmitoyl-L-carnitine oxidation.
ADP,A high ADP/ATP ratio in mitochondrial experiments can override the normal regulation of pyruvate dehydrogenase and affect substrate oxidation preference.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. A high ADP/ATP ratio in mitochondrial experiments can override the normal regulation of pyruvate dehydrogenase and affect substrate oxidation preference.
glucose,"In isolated rat liver mitochondria and perfused rat heart, fatty acids inhibit glucose oxidation.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In isolated rat liver mitochondria and perfused rat heart, fatty acids inhibit glucose oxidation."
pyruvate,"Pyruvate is used as a substrate in mitochondrial respiration assays to measure CO2 release, with 0.6 mM pyruvate and 1% of the total pyruvate being labeled as [1-14C]pyruvate for quantification.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is used as a substrate in mitochondrial respiration assays to measure CO2 release, with 0.6 mM pyruvate and 1% of the total pyruvate being labeled as [1-14C]pyruvate for quantification."
O2,Oxygen is used to saturate the medium in mitochondrial respiration assays to maintain mitochondrial respiration in state 4.,Entity: O2. SMILES: [O]. Oxygen is used to saturate the medium in mitochondrial respiration assays to maintain mitochondrial respiration in state 4.
palmitoyl-L-carnitine,Palmitoyl-L-carnitine is included at 50 µM concentration in mitochondrial respiration assays to study its effect on mitochondrial function.,Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoyl-L-carnitine is included at 50 µM concentration in mitochondrial respiration assays to study its effect on mitochondrial function.
HC104,HC104 (62% w/w) is used to terminate mitochondrial reactions in respiration assays.,Entity: HC104. SMILES: Cl. HC104 (62% w/w) is used to terminate mitochondrial reactions in respiration assays.
malate,Malate is included at 0.13 mM concentration in the basal medium for mitochondrial respiration assays.,Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate is included at 0.13 mM concentration in the basal medium for mitochondrial respiration assays.
ADP,ADP is used at 0.2 M concentration to initiate mitochondrial respiration and is present in the initial injection mixture for assay measurement.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP is used at 0.2 M concentration to initiate mitochondrial respiration and is present in the initial injection mixture for assay measurement.
CO2,CO2 released during mitochondrial respiration is trapped in hyamine for quantification in metabolic assays.,Entity: CO2. SMILES: O=C=O. CO2 released during mitochondrial respiration is trapped in hyamine for quantification in metabolic assays.
oxygen,Oxygen consumption is used as a measure of mitochondrial respiration rates in biochemical assays.,Entity: oxygen. SMILES: [O]. Oxygen consumption is used as a measure of mitochondrial respiration rates in biochemical assays.
ADP,ADP is used to initiate mitochondrial respiration in assays measuring oxygen consumption rates.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP is used to initiate mitochondrial respiration in assays measuring oxygen consumption rates.
palmitoyl-L-carnitine,Mitochondria isolated from Manduca sexta flight muscle oxidize palmitoyl-L-carnitine in the presence of L-malate with high activity and significant respiratory control.,Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Mitochondria isolated from Manduca sexta flight muscle oxidize palmitoyl-L-carnitine in the presence of L-malate with high activity and significant respiratory control.
palmitate,Mitochondria from Manduca sexta flight muscle do not oxidize palmitate when the ratio of palmitate to bovine serum albumin is between 3.5:1 and 7:1.,Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Mitochondria from Manduca sexta flight muscle do not oxidize palmitate when the ratio of palmitate to bovine serum albumin is between 3.5:1 and 7:1.
pyruvate,Mitochondria isolated from Manduca sexta flight muscle oxidize pyruvate in the presence of L-malate with activity equal to that of palmitoyl-L-carnitine oxidation.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Mitochondria isolated from Manduca sexta flight muscle oxidize pyruvate in the presence of L-malate with activity equal to that of palmitoyl-L-carnitine oxidation.
L-malate,L-malate is required as a substrate for both palmitoyl-L-carnitine and pyruvate oxidation by mitochondria from Manduca sexta flight muscle.,Entity: L-malate. SMILES: O=C([O-])C[C@H](O)C(=O)[O-]. L-malate is required as a substrate for both palmitoyl-L-carnitine and pyruvate oxidation by mitochondria from Manduca sexta flight muscle.
ADP,"ADP stimulates oxidation in metabolic pathways, affecting the flux and steady-state concentrations of key intermediates.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP stimulates oxidation in metabolic pathways, affecting the flux and steady-state concentrations of key intermediates."
NAD(P),"NAD(P) can be reduced by electron transfer from endogenous flavoprotein-linked substrates in mitochondrial experiments, and its reduction can be prevented by the addition of oligomycin.","Entity: NAD(P). SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)(O)OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NAD(P) can be reduced by electron transfer from endogenous flavoprotein-linked substrates in mitochondrial experiments, and its reduction can be prevented by the addition of oligomycin."
CoASH,Some CoASH can leak out from the mitochondrial matrix to support palmitate activation in fatty acid oxidation.,Entity: CoASH. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. Some CoASH can leak out from the mitochondrial matrix to support palmitate activation in fatty acid oxidation.
palmitate,Palmitate activation in mammalian mitochondria requires substrate oxidation and can be supported by leaked mitochondrial matrix CoASH.,Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Palmitate activation in mammalian mitochondria requires substrate oxidation and can be supported by leaked mitochondrial matrix CoASH.
oxaloacetate,"The intramitochondrial concentration of oxaloacetate, and thus its availability to citrate synthase, is affected by the mitochondrial NADH/NAD+ ratio.","Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. The intramitochondrial concentration of oxaloacetate, and thus its availability to citrate synthase, is affected by the mitochondrial NADH/NAD+ ratio."
L-malate,L-malate can be used as a substrate in mitochondrial respiration assays to estimate the mitochondrial NADH/NAD+ ratio by fluorimetric measurement.,Entity: L-malate. SMILES: O=C([O-])C[C@H](O)C(=O)[O-]. L-malate can be used as a substrate in mitochondrial respiration assays to estimate the mitochondrial NADH/NAD+ ratio by fluorimetric measurement.
pyruvate,"Pyruvate, when combined with L-malate as substrates in mitochondrial respiration assays, leads to high oxidation of NAD(P) during controlled respiration.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate, when combined with L-malate as substrates in mitochondrial respiration assays, leads to high oxidation of NAD(P) during controlled respiration."
palmitoylcarnitine,"Palmitoylcarnitine, when combined with L-malate as substrates in mitochondrial respiration assays, leads to high oxidation of NAD(P) during controlled respiration.","Entity: palmitoylcarnitine. SMILES: CCCCCCCCCCCCCCCC(=O)C(O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoylcarnitine, when combined with L-malate as substrates in mitochondrial respiration assays, leads to high oxidation of NAD(P) during controlled respiration."
HClO4,"HClO4 is used to extract mitochondria, resulting in neutralized HClO4-extracts for the estimation of CoASH and CoA thioesters.","Entity: HClO4. SMILES: [O-][Cl+3]([O-])([O-])O. HClO4 is used to extract mitochondria, resulting in neutralized HClO4-extracts for the estimation of CoASH and CoA thioesters."
CoASH,CoASH and CoA thioesters in mitochondria can be quantified using a kinetic assay in neutralized HClO4-extracts.,Entity: CoASH. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. CoASH and CoA thioesters in mitochondria can be quantified using a kinetic assay in neutralized HClO4-extracts.
acetyl-CoA,Mitochondrial acetyl-CoA content is extremely high during resting respiration and decreases with activation by ADP.,Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Mitochondrial acetyl-CoA content is extremely high during resting respiration and decreases with activation by ADP.
acetyl-CoA,"The tricarboxylate cycle regulates acetyl-CoA flux, and its activity is stimulated more than pyruvate dehydrogenase during ADP-induced activation.","Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. The tricarboxylate cycle regulates acetyl-CoA flux, and its activity is stimulated more than pyruvate dehydrogenase during ADP-induced activation."
isocitrate,"Isocitrate content in mitochondria decreases upon ADP addition, indicating its role as a cycle intermediate whose concentration is affected by non-equilibrium regulation.","Entity: isocitrate. SMILES: O=C([O-])CC(C(=O)[O-])C(O)C(=O)[O-]. Isocitrate content in mitochondria decreases upon ADP addition, indicating its role as a cycle intermediate whose concentration is affected by non-equilibrium regulation."
citrate,"Mitochondrial citrate content decreases with ADP addition, reflecting changes in the tricarboxylate cycle and isocitrate dehydrogenase activation.","Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Mitochondrial citrate content decreases with ADP addition, reflecting changes in the tricarboxylate cycle and isocitrate dehydrogenase activation."
malate,"During the rest-to-flight transition in intact insects, thoracic malate levels rise, consistent with changes in mitochondrial metabolite ratios during flight.","Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. During the rest-to-flight transition in intact insects, thoracic malate levels rise, consistent with changes in mitochondrial metabolite ratios during flight."
oxaloacetate,"Increased mitochondrial oxaloacetate/citrate ratio is suggested to result from activation of isocitrate dehydrogenase, which in turn enhances citrate synthase activity.","Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. Increased mitochondrial oxaloacetate/citrate ratio is suggested to result from activation of isocitrate dehydrogenase, which in turn enhances citrate synthase activity."
pyruvate,"Pyruvate serves as a substrate in the tricarboxylate cycle, and its metabolism is associated with increased flux through the cycle.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate serves as a substrate in the tricarboxylate cycle, and its metabolism is associated with increased flux through the cycle."
palmitoyl-L-carnitine,Palmitoyl-L-carnitine is used as a substrate in mitochondrial respiration to study the regulation of the tricarboxylate cycle and CoA pool composition.,Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoyl-L-carnitine is used as a substrate in mitochondrial respiration to study the regulation of the tricarboxylate cycle and CoA pool composition.
pyruvate,Pyruvate serves as a substrate in mitochondrial respiration to assess the regulation of the tricarboxylate cycle and CoA pool composition.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate serves as a substrate in mitochondrial respiration to assess the regulation of the tricarboxylate cycle and CoA pool composition.
NAD+,The NADH/NAD+ ratio in mitochondrial extracts reflects the degree of electron transport chain activity and influences the regulation of the tricarboxylate cycle and CoA pool composition.,Entity: NAD+. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. The NADH/NAD+ ratio in mitochondrial extracts reflects the degree of electron transport chain activity and influences the regulation of the tricarboxylate cycle and CoA pool composition.
isocitrate,"Adenine nucleotide control at the dehydrogenase level, specifically at isocitrate dehydrogenase, is a key regulatory mechanism in insect flight muscle mitochondria.","Entity: isocitrate. SMILES: O=C([O-])CC(C(=O)[O-])C(O)C(=O)[O-]. Adenine nucleotide control at the dehydrogenase level, specifically at isocitrate dehydrogenase, is a key regulatory mechanism in insect flight muscle mitochondria."
CoASH,CoASH is a mitochondrial intermediate whose concentration can be measured to estimate flux through the tricarboxylate cycle.,Entity: CoASH. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. CoASH is a mitochondrial intermediate whose concentration can be measured to estimate flux through the tricarboxylate cycle.
CoASH,"In mammalian heart mitochondria, CoASH remains measurable during controlled state 4 oxidation of pyruvate or palmitoyl-L-carnitine, indicating continued flux through the tricarboxylate cycle.","Entity: CoASH. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. In mammalian heart mitochondria, CoASH remains measurable during controlled state 4 oxidation of pyruvate or palmitoyl-L-carnitine, indicating continued flux through the tricarboxylate cycle."
CoASH,"In Manduca sexta mitochondria, CoASH is essentially depleted during state 4 respiration due to high NADH/NAD+ ratio and dominant acetyl-CoA formation.","Entity: CoASH. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. In Manduca sexta mitochondria, CoASH is essentially depleted during state 4 respiration due to high NADH/NAD+ ratio and dominant acetyl-CoA formation."
acetyl-CoA,Acetyl-CoA is a mitochondrial intermediate whose concentration can be measured to estimate flux through the tricarboxylate cycle.,Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Acetyl-CoA is a mitochondrial intermediate whose concentration can be measured to estimate flux through the tricarboxylate cycle.
ADP,Activation of respiration by ADP in mitochondria leads to decreased mitochondrial content of both citrate and isocitrate when pyruvate and L-malate are used as substrates.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Activation of respiration by ADP in mitochondria leads to decreased mitochondrial content of both citrate and isocitrate when pyruvate and L-malate are used as substrates.
L-malate,"L-malate, when combined with pyruvate as substrates, causes a decrease in mitochondrial citrate and isocitrate content upon ADP activation in mitochondria.","Entity: L-malate. SMILES: O=C([O-])C[C@H](O)C(=O)[O-]. L-malate, when combined with pyruvate as substrates, causes a decrease in mitochondrial citrate and isocitrate content upon ADP activation in mitochondria."
pyruvate,"Pyruvate, when combined with L-malate as substrates, leads to decreased mitochondrial citrate and isocitrate content upon ADP activation in mitochondria.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate, when combined with L-malate as substrates, leads to decreased mitochondrial citrate and isocitrate content upon ADP activation in mitochondria."
isocitrate,Mitochondrial isocitrate content decreases upon ADP activation in the presence of pyruvate and L-malate as substrates.,Entity: isocitrate. SMILES: O=C([O-])CC(C(=O)[O-])C(O)C(=O)[O-]. Mitochondrial isocitrate content decreases upon ADP activation in the presence of pyruvate and L-malate as substrates.
palmitoylcarnitine,"Palmitoylcarnitine, when used as a substrate with L-malate, results in lower tricarboxylate concentrations and a rise in ADP phosphorylation completion in mitochondrial assays.","Entity: palmitoylcarnitine. SMILES: CCCCCCCCCCCCCCCC(=O)C(O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoylcarnitine, when used as a substrate with L-malate, results in lower tricarboxylate concentrations and a rise in ADP phosphorylation completion in mitochondrial assays."
citrate,Mitochondrial citrate content decreases upon ADP activation in the presence of pyruvate and L-malate as substrates.,Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Mitochondrial citrate content decreases upon ADP activation in the presence of pyruvate and L-malate as substrates.
palmitate,Palmitate oxidation by Manduca sexta flight muscle mitochondria is totally dependent on carnitine.,Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Palmitate oxidation by Manduca sexta flight muscle mitochondria is totally dependent on carnitine.
carnitine,Carnitine is required for the oxidation of palmitate by Manduca sexta flight muscle mitochondria.,Entity: carnitine. SMILES: C[N+](C)(C)CC(O)CC(=O)[O-]. Carnitine is required for the oxidation of palmitate by Manduca sexta flight muscle mitochondria.
L-malate,"L-malate, when used as a substrate with palmitoyl-L-carnitine, supports mitochondrial respiration and is involved in flux through the tricarboxylate cycle.","Entity: L-malate. SMILES: O=C([O-])C[C@H](O)C(=O)[O-]. L-malate, when used as a substrate with palmitoyl-L-carnitine, supports mitochondrial respiration and is involved in flux through the tricarboxylate cycle."
palmitoyl-CoA,"Palmitoyl-CoA content in mitochondrial suspensions is minimized by poor recovery, with only about 52% of added palmitoyl-CoA recovered in control experiments.","Entity: palmitoyl-CoA. SMILES: CCCCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Palmitoyl-CoA content in mitochondrial suspensions is minimized by poor recovery, with only about 52% of added palmitoyl-CoA recovered in control experiments."
CoASH,The total pool of CoASH and CoA thioester is 5 times higher in Manduca sexta flight muscle mitochondria compared to Phormia regina and Popillia japonica.,Entity: CoASH. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. The total pool of CoASH and CoA thioester is 5 times higher in Manduca sexta flight muscle mitochondria compared to Phormia regina and Popillia japonica.
palmitoyl-L-carnitine,"Palmitoyl-L-carnitine is a substrate for mitochondrial respiration, and its concentration of 50 pM is used to prolong sample collection during metabolic assays.","Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoyl-L-carnitine is a substrate for mitochondrial respiration, and its concentration of 50 pM is used to prolong sample collection during metabolic assays."
citrate,"Citrate is not oxidized in mitochondria, likely due to a permeability barrier that restricts its passage from the mitochondrial matrix to the intermembrane space.","Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Citrate is not oxidized in mitochondria, likely due to a permeability barrier that restricts its passage from the mitochondrial matrix to the intermembrane space."
potassium phosphate,"Potassium phosphate can accumulate slowly in mitochondria, and this accumulation may be required before maximum rates of oxidative phosphorylation are expressed.","Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate can accumulate slowly in mitochondria, and this accumulation may be required before maximum rates of oxidative phosphorylation are expressed."
2-oxoglutarate,"2-oxoglutarate is oxidized in mitochondria via the tricarboxylate cycle, but this oxidation is subject to respiratory control.","Entity: 2-oxoglutarate. SMILES: O=C([O-])CCC(=O)C(=O)[O-]. 2-oxoglutarate is oxidized in mitochondria via the tricarboxylate cycle, but this oxidation is subject to respiratory control."
succinate,Succinate is oxidized in mitochondria as part of the tricarboxylate cycle.,Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate is oxidized in mitochondria as part of the tricarboxylate cycle.
Pyruvate,"Pyruvate is oxidized at a rate 20% higher than glycerol-3-phosphate in the studied mitochondrial system, assuming complete and simultaneous oxidation on a molar basis.","Entity: Pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is oxidized at a rate 20% higher than glycerol-3-phosphate in the studied mitochondrial system, assuming complete and simultaneous oxidation on a molar basis."
Glycerol-3-phosphate,"Glycerol-3-phosphate is oxidized at a rate that is 20% lower than pyruvate in the mitochondrial system, assuming complete and simultaneous oxidation on a molar basis.","Entity: Glycerol-3-phosphate. SMILES: O=P(O)(O)OCC(O)CO. Glycerol-3-phosphate is oxidized at a rate that is 20% lower than pyruvate in the mitochondrial system, assuming complete and simultaneous oxidation on a molar basis."
Oxygen,Oxygen uptake is expected to be 20% higher when both pyruvate and glycerol-3-phosphate are oxidized completely and at the same rate on a molar basis.,Entity: Oxygen. SMILES: [O]. Oxygen uptake is expected to be 20% higher when both pyruvate and glycerol-3-phosphate are oxidized completely and at the same rate on a molar basis.
citrate,"Citrate is an intramitochondrial substrate whose content changes during the oxidation of pyruvate plus L-malate, with total citrate increasing from 11.80 to 17.01 µmol/mg protein in mitochondria over a 10-minute incubation in state 4 (control) and from 4.94 to 8.70 µmol/mg protein in state 3 (active) conditions.","Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Citrate is an intramitochondrial substrate whose content changes during the oxidation of pyruvate plus L-malate, with total citrate increasing from 11.80 to 17.01 µmol/mg protein in mitochondria over a 10-minute incubation in state 4 (control) and from 4.94 to 8.70 µmol/mg protein in state 3 (active) conditions."
isocitrate,"Isocitrate is an intramitochondrial substrate whose content changes during the oxidation of pyruvate plus L-malate, with total isocitrate increasing from 0.84 to 1.39 µmol/mg protein in mitochondria over a 10-minute incubation in state 4 (control) and from 0.55 to 0.77 µmol/mg protein in state 3 (active) conditions.","Entity: isocitrate. SMILES: O=C([O-])CC(C(=O)[O-])C(O)C(=O)[O-]. Isocitrate is an intramitochondrial substrate whose content changes during the oxidation of pyruvate plus L-malate, with total isocitrate increasing from 0.84 to 1.39 µmol/mg protein in mitochondria over a 10-minute incubation in state 4 (control) and from 0.55 to 0.77 µmol/mg protein in state 3 (active) conditions."
ADP,ADP is used as a mitochondrial substrate at 2.5 mM concentration in the oxidation of pyruvate plus L-malate assays.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP is used as a mitochondrial substrate at 2.5 mM concentration in the oxidation of pyruvate plus L-malate assays.
L-malate,"L-malate is used as a substrate in mitochondrial oxidation assays with pyruvate or palmitoyl-L-carnitine, measuring changes in intramitochondrial citrate and isocitrate content.","Entity: L-malate. SMILES: O=C([O-])C[C@H](O)C(=O)[O-]. L-malate is used as a substrate in mitochondrial oxidation assays with pyruvate or palmitoyl-L-carnitine, measuring changes in intramitochondrial citrate and isocitrate content."
palmitoyl-L-carnitine,"Palmitoyl-L-carnitine is used as a substrate in mitochondrial oxidation assays with L-malate, resulting in changes in intramitochondrial citrate and isocitrate content.","Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoyl-L-carnitine is used as a substrate in mitochondrial oxidation assays with L-malate, resulting in changes in intramitochondrial citrate and isocitrate content."
pyruvate,"Pyruvate is used as a substrate in mitochondrial oxidation assays with L-malate, measuring changes in intramitochondrial citrate and isocitrate content.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is used as a substrate in mitochondrial oxidation assays with L-malate, measuring changes in intramitochondrial citrate and isocitrate content."
palmitoyl-L-carnitine,"Palmitoyl-L-carnitine is oxidized by moth (Manduca sexta) mitochondria, and this oxidation is dependent on carnitine.","Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoyl-L-carnitine is oxidized by moth (Manduca sexta) mitochondria, and this oxidation is dependent on carnitine."
palmitoyl-L-carnitine,Palmitoyl-L-carnitine oxidation by moth mitochondria is inhibited by pyruvate oxidation.,Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoyl-L-carnitine oxidation by moth mitochondria is inhibited by pyruvate oxidation.
palmitate,Palmitate is not oxidized in a carnitine-independent manner by moth (Manduca sexta) mitochondria.,Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Palmitate is not oxidized in a carnitine-independent manner by moth (Manduca sexta) mitochondria.
pyruvate,Pyruvate oxidation by moth (Manduca sexta) mitochondria inhibits the oxidation of palmitoyl-L-carnitine.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate oxidation by moth (Manduca sexta) mitochondria inhibits the oxidation of palmitoyl-L-carnitine.
palmitoyl-L-carnitine,"Palmitoyl-L-carnitine inhibits pyruvate oxidation by approximately 27% in the presence of pyruvate and albumin, as measured by oxygen consumption rates.","Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoyl-L-carnitine inhibits pyruvate oxidation by approximately 27% in the presence of pyruvate and albumin, as measured by oxygen consumption rates."
palmitoyl-L-carnitine,"In the presence of pyruvate and palmitoyl-L-carnitine, the rate of oxygen consumption is 0.96 p.g.atoms O/min/mg protein, indicating a lower rate of pyruvate oxidation compared to pyruvate alone.","Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. In the presence of pyruvate and palmitoyl-L-carnitine, the rate of oxygen consumption is 0.96 p.g.atoms O/min/mg protein, indicating a lower rate of pyruvate oxidation compared to pyruvate alone."
pyruvate,Pyruvate oxidation in the presence of albumin and malate is associated with an oxygen consumption rate of 0.71 p.g.atoms O/min/mg protein.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate oxidation in the presence of albumin and malate is associated with an oxygen consumption rate of 0.71 p.g.atoms O/min/mg protein.
malate,Malate is required to initiate the tricarboxylate cycle in experiments measuring pyruvate and palmitoyl-L-carnitine oxidation.,Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate is required to initiate the tricarboxylate cycle in experiments measuring pyruvate and palmitoyl-L-carnitine oxidation.
pyruvate,"Pyruvate oxidation is limited by the tricarboxylate cycle, which catabolizes acetyl-CoA, in the controlled (low-flux) state.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate oxidation is limited by the tricarboxylate cycle, which catabolizes acetyl-CoA, in the controlled (low-flux) state."
palmitoyl-L-carnitine,"Palmitoyl-L-carnitine oxidation is limited by the tricarboxylate cycle, which catabolizes acetyl-CoA, in the controlled (low-flux) state.","Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoyl-L-carnitine oxidation is limited by the tricarboxylate cycle, which catabolizes acetyl-CoA, in the controlled (low-flux) state."
acetyl-CoA,"Acetyl-CoA is catabolized by the tricarboxylate cycle, which limits the oxidation of pyruvate and palmitoyl-L-carnitine in the controlled (low-flux) state.","Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Acetyl-CoA is catabolized by the tricarboxylate cycle, which limits the oxidation of pyruvate and palmitoyl-L-carnitine in the controlled (low-flux) state."
HCIO4,HCIO4 extracts can be prepared from single moths for the analysis of thoracic tissue content.,Entity: HCIO4. SMILES: [O-][Cl+3]([O-])([O-])O. HCIO4 extracts can be prepared from single moths for the analysis of thoracic tissue content.
NAD,Tissue NAD content in moths can be estimated using established extraction and analytical methods.,Entity: NAD. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. Tissue NAD content in moths can be estimated using established extraction and analytical methods.
malate,Tissue malate content in moths can be estimated using established extraction and analytical methods.,Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Tissue malate content in moths can be estimated using established extraction and analytical methods.
palmitoyl-L-carnitine,Palmitoyl-L-carnitine is used as a mitochondrial substrate at a concentration of 10 µM in mitochondrial respiration assays.,Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoyl-L-carnitine is used as a mitochondrial substrate at a concentration of 10 µM in mitochondrial respiration assays.
L-malate,L-malate is used as a mitochondrial substrate at a concentration of 0.13 mM in respiration assays.,Entity: L-malate. SMILES: O=C([O-])C[C@H](O)C(=O)[O-]. L-malate is used as a mitochondrial substrate at a concentration of 0.13 mM in respiration assays.
pyruvate,"Pyruvate is used as a respiratory substrate in mitochondrial respiration assays, but its addition can cause apparent oxidation artefacts due to fluorescence quenching.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is used as a respiratory substrate in mitochondrial respiration assays, but its addition can cause apparent oxidation artefacts due to fluorescence quenching."
oxaloacetate,A low NADH/NAD+ ratio during mitochondrial state 4 respiration indicates tight control at the dehydrogenase level and suggests that increased flux through citrate synthase during transition from state 4 to 3 is due to a rise in the total pool of malate plus oxaloacetate rather than decreased oxaloacetate availability.,Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. A low NADH/NAD+ ratio during mitochondrial state 4 respiration indicates tight control at the dehydrogenase level and suggests that increased flux through citrate synthase during transition from state 4 to 3 is due to a rise in the total pool of malate plus oxaloacetate rather than decreased oxaloacetate availability.
citrate,"A decrease in the concentration of citrate in mitochondria, along with an increase in the total pool of malate plus oxaloacetate, is implicated in the regulation of mitochondrial respiration during the transition from state 4 to 3.","Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. A decrease in the concentration of citrate in mitochondria, along with an increase in the total pool of malate plus oxaloacetate, is implicated in the regulation of mitochondrial respiration during the transition from state 4 to 3."
citrate,"Mitochondria in controlled skate are impermeable to citrate, as shown by the inability to prevent its passage across mitochondrial membranes.","Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Mitochondria in controlled skate are impermeable to citrate, as shown by the inability to prevent its passage across mitochondrial membranes."
ADP,Stimulation of mitochondrial respiration with ADP leads to a decrease in mitochondrial citrate and isocitrate content in controlled skate.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Stimulation of mitochondrial respiration with ADP leads to a decrease in mitochondrial citrate and isocitrate content in controlled skate.
isocitrate,Mitochondrial isocitrate content decreases when mitochondrial respiration is stimulated with ADP in controlled skate.,Entity: isocitrate. SMILES: O=C([O-])CC(C(=O)[O-])C(O)C(=O)[O-]. Mitochondrial isocitrate content decreases when mitochondrial respiration is stimulated with ADP in controlled skate.
palmitoylcarnitine,Control of the oxidation of palmitoylcarnitine in mitochondria can affect the concentration of downstream tricarboxylate cycle metabolites such as malate and oxaloacetate in controlled skate.,Entity: palmitoylcarnitine. SMILES: CCCCCCCCCCCCCCCC(=O)C(O)(CC(=O)[O-])C[N+](C)(C)C. Control of the oxidation of palmitoylcarnitine in mitochondria can affect the concentration of downstream tricarboxylate cycle metabolites such as malate and oxaloacetate in controlled skate.
malate,Malate is a metabolite of the tricarboxylate cycle whose concentration in whole thoraces increases during flight in controlled skate.,Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate is a metabolite of the tricarboxylate cycle whose concentration in whole thoraces increases during flight in controlled skate.
oxaloacetate,Changes in malate concentration in the tricarboxylate cycle are likely to reflect alterations in oxaloacetate concentration in controlled skate.,Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. Changes in malate concentration in the tricarboxylate cycle are likely to reflect alterations in oxaloacetate concentration in controlled skate.
NAD(P),"NAD(P) reduction is used as an indicator of mitochondrial permeability, as mitochondria are permeable to malate but impermeable to citrate.","Entity: NAD(P). SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. NAD(P) reduction is used as an indicator of mitochondrial permeability, as mitochondria are permeable to malate but impermeable to citrate."
ADP,"ADP is used to stimulate mitochondrial respiration in the assay, with phosphorylation of ADP by mitochondria occurring at the beginning of the experiment.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP is used to stimulate mitochondrial respiration in the assay, with phosphorylation of ADP by mitochondria occurring at the beginning of the experiment."
palmitoyl-L-carnitine,Palmitoyl-L-carnitine is used as a substrate in mitochondrial respiration assays at a concentration maintained between 5–15 µM during the experiment.,Entity: palmitoyl-L-carnitine. SMILES: CCCCCCCCCCCCCCCC(=O)[C@@](O)(CC(=O)[O-])C[N+](C)(C)C. Palmitoyl-L-carnitine is used as a substrate in mitochondrial respiration assays at a concentration maintained between 5–15 µM during the experiment.
L-malate,L-malate is included as a substrate in mitochondrial respiration assays at a concentration of 0.13 mM.,Entity: L-malate. SMILES: O=C([O-])C[C@H](O)C(=O)[O-]. L-malate is included as a substrate in mitochondrial respiration assays at a concentration of 0.13 mM.
digitonin,Digitonin is used as a precipitating agent for purifying ether fractions (free sterols) from column fractions in analytical procedures.,Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin is used as a precipitating agent for purifying ether fractions (free sterols) from column fractions in analytical procedures.
digitonin,"Digitonin is used as a precipitating agent for sterols, with two successive digitonin treatments reducing radioactivity to very low levels in A. vulgate sterols and only one treatment in the other two isopod species.","Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin is used as a precipitating agent for sterols, with two successive digitonin treatments reducing radioactivity to very low levels in A. vulgate sterols and only one treatment in the other two isopod species."
potassium hydroxide,"Potassium hydroxide is used to saponify total lipids, typically at a concentration of 10% in 95% ethanol for 1.5 hours.","Entity: potassium hydroxide. SMILES: [K+].[OH-]. Potassium hydroxide is used to saponify total lipids, typically at a concentration of 10% in 95% ethanol for 1.5 hours."
ethyl ether,Ethyl ether is used to remove unsaponifiable lipids from the aqueous phase and to extract saponifiable lipids from the aqueous fraction during lipid analysis.,Entity: ethyl ether. SMILES: CCOCC. Ethyl ether is used to remove unsaponifiable lipids from the aqueous phase and to extract saponifiable lipids from the aqueous fraction during lipid analysis.
sodium sulfate,Anhydrous sodium sulfate is used to dry lipid extracts prior to weighing and radioassaying.,Entity: sodium sulfate. SMILES: O=S(=O)([O-])[O-].[Na+].[Na+]. Anhydrous sodium sulfate is used to dry lipid extracts prior to weighing and radioassaying.
water,Water is used to deactivate Woelm neutral aluminum oxide columns in dual column chromatography for lipid fractionation.,Entity: water. SMILES: O. Water is used to deactivate Woelm neutral aluminum oxide columns in dual column chromatography for lipid fractionation.
methanol,Methanol is used as the elution solvent for the final column in dual column chromatography during lipid fractionation.,Entity: methanol. SMILES: CO. Methanol is used as the elution solvent for the final column in dual column chromatography during lipid fractionation.
n-hexane,n-Hexane is used as the elution solvent for the first column in dual column chromatography during lipid fractionation.,Entity: n-hexane. SMILES: CCCCCC. n-Hexane is used as the elution solvent for the first column in dual column chromatography during lipid fractionation.
benzene,Benzene is used as the elution solvent for the second column in dual column chromatography during lipid fractionation.,Entity: benzene. SMILES: c1ccccc1. Benzene is used as the elution solvent for the second column in dual column chromatography during lipid fractionation.
ethanol,Ethanol (95%) is used as a solvent for saponifying total lipids with potassium hydroxide.,Entity: ethanol. SMILES: CCO. Ethanol (95%) is used as a solvent for saponifying total lipids with potassium hydroxide.
cholesterol,"Cholesterol is a sterol compound that can be detected by gas chromatography (GLC) in certain species, such as in the analysis of Cirolana harfordi.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is a sterol compound that can be detected by gas chromatography (GLC) in certain species, such as in the analysis of Cirolana harfordi."
fl-sitosterol,"fl-sitosterol is a sterol compound present in all three species analyzed by GLC, with retention times similar to cholesterol.","Entity: fl-sitosterol. SMILES: CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C. fl-sitosterol is a sterol compound present in all three species analyzed by GLC, with retention times similar to cholesterol."
campesterol,"Campesterol is a sterol compound found in the species A. vulgate, as detected by GLC.","Entity: campesterol. SMILES: CC(C)[C@H](C)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Campesterol is a sterol compound found in the species A. vulgate, as detected by GLC."
7-Dehydrocholesterol,"7-Dehydrocholesterol is a sterol compound identified in certain species, such as in the analysis of Cirolana harfordi.","Entity: 7-Dehydrocholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. 7-Dehydrocholesterol is a sterol compound identified in certain species, such as in the analysis of Cirolana harfordi."
linoleic acid,"Linoleic acid is a prevalent fatty acid in three isopod species, with a reported abundance of 1–19% in their fatty acid methyl ester profiles.","Entity: linoleic acid. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. Linoleic acid is a prevalent fatty acid in three isopod species, with a reported abundance of 1–19% in their fatty acid methyl ester profiles."
oleic acid,"Oleic acid is a predominant fatty acid in three isopod species, present in a range of 30–40% in their fatty acid methyl ester analysis.","Entity: oleic acid. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. Oleic acid is a predominant fatty acid in three isopod species, present in a range of 30–40% in their fatty acid methyl ester analysis."
stearic acid,Stearic acid is found at 4–5% in the fatty acid methyl ester composition of three isopod species.,Entity: stearic acid. SMILES: CCCCCCCCCCCCCCCCCC(=O)O. Stearic acid is found at 4–5% in the fatty acid methyl ester composition of three isopod species.
palmitic acid,Palmitic acid constitutes 21–37% of the fatty acid methyl ester profile in three isopod species.,Entity: palmitic acid. SMILES: CCCCCCCCCCCCCCCC(=O)O. Palmitic acid constitutes 21–37% of the fatty acid methyl ester profile in three isopod species.
palmitoleic acid,Palmitoleic acid is present at 11–19% in the fatty acid methyl ester composition of three isopod species.,Entity: palmitoleic acid. SMILES: CCCCCC/C=C\CCCCCCCC(=O)O. Palmitoleic acid is present at 11–19% in the fatty acid methyl ester composition of three isopod species.
linolenic acid,Linolenic acid is present in major proportions in the fatty acid composition of the three isopods studied.,Entity: linolenic acid. SMILES: CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O. Linolenic acid is present in major proportions in the fatty acid composition of the three isopods studied.
stearic acid,Stearic acid is present in major proportions in the fatty acid composition of the three isopods studied.,Entity: stearic acid. SMILES: CCCCCCCCCCCCCCCCCC(=O)O. Stearic acid is present in major proportions in the fatty acid composition of the three isopods studied.
palmitic acid,Palmitic acid is present in major proportions in the fatty acid composition of the three isopods studied.,Entity: palmitic acid. SMILES: CCCCCCCCCCCCCCCC(=O)O. Palmitic acid is present in major proportions in the fatty acid composition of the three isopods studied.
fucosterol,"Fucosterol is a plant sterol found in brown algae such as Fucus sp., which can serve as a precursor for β-sitosterol metabolism in phytophagous insects and crustaceans.","Entity: fucosterol. SMILES: C/C=C(\CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C. Fucosterol is a plant sterol found in brown algae such as Fucus sp., which can serve as a precursor for β-sitosterol metabolism in phytophagous insects and crustaceans."
campesterol,Campesterol is a ubiquitous fungal sterol that has been detected in trace amounts in certain arthropods such as A. vulgare and L. occidentalis.,Entity: campesterol. SMILES: CC(C)[C@H](C)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Campesterol is a ubiquitous fungal sterol that has been detected in trace amounts in certain arthropods such as A. vulgare and L. occidentalis.
cholesterol,Cholesterol cannot be synthesized from acetate in isopods such as A. vulgare and L. occidentalis.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol cannot be synthesized from acetate in isopods such as A. vulgare and L. occidentalis.
desmosterol,Desmosterol is an intermediate in the metabolic pathway by which β-sitosterol is converted to cholesterol in phytophagous insects and certain crustaceans.,Entity: desmosterol. SMILES: CC(C)=CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Desmosterol is an intermediate in the metabolic pathway by which β-sitosterol is converted to cholesterol in phytophagous insects and certain crustaceans.
palmitoleic acid,Palmitoleic acid is present in major proportions in the fatty acid composition of the three isopods studied.,Entity: palmitoleic acid. SMILES: CCCCCC/C=C\CCCCCCCC(=O)O. Palmitoleic acid is present in major proportions in the fatty acid composition of the three isopods studied.
oleic acid,Oleic acid is present in major proportions in the fatty acid composition of the three isopods studied.,Entity: oleic acid. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. Oleic acid is present in major proportions in the fatty acid composition of the three isopods studied.
linoleic acid,Linoleic acid is present in major proportions in the fatty acid composition of the three isopods studied.,Entity: linoleic acid. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. Linoleic acid is present in major proportions in the fatty acid composition of the three isopods studied.
monoethanolamine,"Monoethanolamine is used as a trapping agent in combustion analysis, specifically in a 1:2 mixture with methyl cellosolve to capture carbon dioxide.","Entity: monoethanolamine. SMILES: NCCO. Monoethanolamine is used as a trapping agent in combustion analysis, specifically in a 1:2 mixture with methyl cellosolve to capture carbon dioxide."
carbon dioxide,Carbon dioxide is produced during combustion analysis and can be trapped and quantified using a monoethanolamine-methyl cellosolve (1:2) solution for radioassay.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is produced during combustion analysis and can be trapped and quantified using a monoethanolamine-methyl cellosolve (1:2) solution for radioassay.
linoleic acid,"Linoleic acid (C18:2) is a dietary fatty acid that can serve as a precursor for the biosynthesis of longer chain polyunsaturated fatty acids such as arachidonate (C20:4), eicosapentaenoate (C20:5), and docosahexaenoate (C22:6) in marine organisms.","Entity: linoleic acid. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. Linoleic acid (C18:2) is a dietary fatty acid that can serve as a precursor for the biosynthesis of longer chain polyunsaturated fatty acids such as arachidonate (C20:4), eicosapentaenoate (C20:5), and docosahexaenoate (C22:6) in marine organisms."
linolenic acid,"Linolenic acid (C18:3) is a dietary fatty acid that can be converted into longer chain polyunsaturated fatty acids including arachidonate (C20:4), eicosapentaenoate (C20:5), and docosahexaenoate (C22:6) in marine organisms.","Entity: linolenic acid. SMILES: CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O. Linolenic acid (C18:3) is a dietary fatty acid that can be converted into longer chain polyunsaturated fatty acids including arachidonate (C20:4), eicosapentaenoate (C20:5), and docosahexaenoate (C22:6) in marine organisms."
arachidonate,Arachidonate (C20:4) is a polyunsaturated fatty acid that is likely derived from dietary linoleic or linolenic acids in marine crustaceans.,Entity: arachidonate. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)[O-]. Arachidonate (C20:4) is a polyunsaturated fatty acid that is likely derived from dietary linoleic or linolenic acids in marine crustaceans.
eicosapentaenoate,Eicosapentaenoate (C20:5) is a polyunsaturated fatty acid that is probably synthesized from dietary linoleic or linolenic acids in marine organisms.,Entity: eicosapentaenoate. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC(=O)[O-]. Eicosapentaenoate (C20:5) is a polyunsaturated fatty acid that is probably synthesized from dietary linoleic or linolenic acids in marine organisms.
docosahexaenoate,Docosahexaenoate (C22:6) is a long chain polyunsaturated fatty acid found in C. harfordi and is likely derived from dietary linoleic or linolenic acids.,Entity: docosahexaenoate. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)[O-]. Docosahexaenoate (C22:6) is a long chain polyunsaturated fatty acid found in C. harfordi and is likely derived from dietary linoleic or linolenic acids.
POPOP,POPOP is used as a fluorescent quenching agent in both modified Bray's solution and standard fluor mixtures for liquid scintillation counting assays.,Entity: POPOP. SMILES: c1ccc(-c2cnc(-c3ccc(-c4ncc(-c5ccccc5)o4)cc3)o2)cc1. POPOP is used as a fluorescent quenching agent in both modified Bray's solution and standard fluor mixtures for liquid scintillation counting assays.
ethylene glycol monomethyl ether,Ethylene glycol monomethyl ether is a component of modified Bray's solution used in aqueous radioassay formulations.,Entity: ethylene glycol monomethyl ether. SMILES: COCCO. Ethylene glycol monomethyl ether is a component of modified Bray's solution used in aqueous radioassay formulations.
toluene,Toluene is used as a solvent in both modified Bray's solution and standard fluor mixtures for liquid scintillation counting assays.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a solvent in both modified Bray's solution and standard fluor mixtures for liquid scintillation counting assays.
PPO,PPO is used as a fluorescent quenching agent in both modified Bray's solution and standard fluor mixtures for liquid scintillation counting assays.,Entity: PPO. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. PPO is used as a fluorescent quenching agent in both modified Bray's solution and standard fluor mixtures for liquid scintillation counting assays.
sodium sulfate,Anhydrous sodium sulfate is used as a drying agent to remove residual water from organic extracts.,Entity: sodium sulfate. SMILES: O=S(=O)([O-])[O-].[Na+].[Na+]. Anhydrous sodium sulfate is used as a drying agent to remove residual water from organic extracts.
hydrochloric acid,Hydrochloric acid is used to acidify aqueous solutions to facilitate extraction of lipids into organic solvents.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to acidify aqueous solutions to facilitate extraction of lipids into organic solvents.
ethyl ether,Ethyl ether is an organic solvent commonly used to quantitatively extract lipids from aqueous solutions.,Entity: ethyl ether. SMILES: CCOCC. Ethyl ether is an organic solvent commonly used to quantitatively extract lipids from aqueous solutions.
diethylene glycol succinate,Diethylene glycol succinate is used as a liquid phase in gas liquid chromatography for the analysis of fatty acid methyl esters.,Entity: diethylene glycol succinate. SMILES: O=C(O)CCC(=O)O.OCCOCCO. Diethylene glycol succinate is used as a liquid phase in gas liquid chromatography for the analysis of fatty acid methyl esters.
methanol,Methanol is used as a solvent for esterifying free fatty acids with boron trifluoride during lipid analysis.,Entity: methanol. SMILES: CO. Methanol is used as a solvent for esterifying free fatty acids with boron trifluoride during lipid analysis.
nitrogen,Nitrogen serves as the carrier gas in gas liquid chromatography for the analysis of fatty acid methyl esters.,Entity: nitrogen. SMILES: [N]. Nitrogen serves as the carrier gas in gas liquid chromatography for the analysis of fatty acid methyl esters.
boron trifluoride,Boron trifluoride is used to esterify free fatty acids with methanol in the preparation of fatty acid methyl esters for gas liquid chromatography analysis.,Entity: boron trifluoride. SMILES: FB(F)F. Boron trifluoride is used to esterify free fatty acids with methanol in the preparation of fatty acid methyl esters for gas liquid chromatography analysis.
palmitate,"Palmitate is a 16 carbon fatty acid present in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues.","Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)O. Palmitate is a 16 carbon fatty acid present in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues."
linoleate,"Linoleate is a 16 or 18 carbon fatty acid present in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues.","Entity: linoleate. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. Linoleate is a 16 or 18 carbon fatty acid present in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues."
linolenate,"Linolenate is a 16 or 18 carbon fatty acid found in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues.","Entity: linolenate. SMILES: CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O. Linolenate is a 16 or 18 carbon fatty acid found in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues."
palmitoleate,"Palmitoleate is a 16 or 18 carbon fatty acid present in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues.","Entity: palmitoleate. SMILES: CCCCCC/C=C\CCCCCCCC(=O)O. Palmitoleate is a 16 or 18 carbon fatty acid present in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues."
oleate,"Oleate is a 16 or 18 carbon fatty acid present in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues.","Entity: oleate. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. Oleate is a 16 or 18 carbon fatty acid present in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues."
stearate,"Stearate is a 16 or 18 carbon fatty acid found in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues.","Entity: stearate. SMILES: CCCCCCCCCCCCCCCCCC(=O)O. Stearate is a 16 or 18 carbon fatty acid found in the triglyceride, diglyceride, and free fatty acid fractions of both parasite and host tissues."
silicic acid,Silicic acid is used as a stationary phase for column chromatography to separate lipid classes in insect larvae.,Entity: silicic acid. SMILES: O[Si](O)(O)O. Silicic acid is used as a stationary phase for column chromatography to separate lipid classes in insect larvae.
benzene,Benzene is used as a component of the eluting solvent system (benzene/hexane) and in various concentrations for eluting different lipid classes from insect larvae during chromatography.,Entity: benzene. SMILES: c1ccccc1. Benzene is used as a component of the eluting solvent system (benzene/hexane) and in various concentrations for eluting different lipid classes from insect larvae during chromatography.
chloroform,Chloroform is used as a component of the chloroform-methanol (1:2 v/v) solvent mixture for extracting total lipids from insect larvae.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a component of the chloroform-methanol (1:2 v/v) solvent mixture for extracting total lipids from insect larvae.
hexane,Hexane is used as a component of the eluting solvent system (benzene/hexane) for separating lipid classes by column chromatography on silicic acid.,Entity: hexane. SMILES: CCCCCC. Hexane is used as a component of the eluting solvent system (benzene/hexane) for separating lipid classes by column chromatography on silicic acid.
methanol,Methanol is used in combination with chloroform (1:2 v/v) as a solvent for extracting total lipids from insect larvae.,Entity: methanol. SMILES: CO. Methanol is used in combination with chloroform (1:2 v/v) as a solvent for extracting total lipids from insect larvae.
oxygen,"Oxygen is represented by the pO2 value, which is corrected for pH fluctuations and used in conjunction with sulfur dioxide measurements in phase 3 data processing.","Entity: oxygen. SMILES: [O]. Oxygen is represented by the pO2 value, which is corrected for pH fluctuations and used in conjunction with sulfur dioxide measurements in phase 3 data processing."
sulfur dioxide,"Sulfur dioxide (SO2) is measured and its corresponding pO2 value is determined using the Severinghaus formula, with corrections applied for pH and phase adjustments.","Entity: sulfur dioxide. SMILES: O=S=O. Sulfur dioxide (SO2) is measured and its corresponding pO2 value is determined using the Severinghaus formula, with corrections applied for pH and phase adjustments."
oxygen,Oxygen partial pressure (pO2) is measured and corrected in experimental data analysis to account for potential shifts in the pO2 axis.,Entity: oxygen. SMILES: [O]. Oxygen partial pressure (pO2) is measured and corrected in experimental data analysis to account for potential shifts in the pO2 axis.
sulfur dioxide,"Sulfur dioxide (SO2) concentration is expressed as a percentage (–% of SO2) on oxygen depletion curves, ranging from 95% to 0.5% and from 99% to 0.1% depending on the pH and pO2 region.","Entity: sulfur dioxide. SMILES: O=S=O. Sulfur dioxide (SO2) concentration is expressed as a percentage (–% of SO2) on oxygen depletion curves, ranging from 95% to 0.5% and from 99% to 0.1% depending on the pH and pO2 region."
sulfur dioxide,Sulfur dioxide is measured in blood using a photometric method with a light emitter diode at 670 nm during the oxygenation process in a Farhi tonometer assay.,Entity: sulfur dioxide. SMILES: O=S=O. Sulfur dioxide is measured in blood using a photometric method with a light emitter diode at 670 nm during the oxygenation process in a Farhi tonometer assay.
nitrogen,Nitrogen is used as a reducing mixture gas (5.6% CO2) to deoxygenate whole blood prior to oxygenation measurements in a Farhi tonometer assay.,Entity: nitrogen. SMILES: [N]. Nitrogen is used as a reducing mixture gas (5.6% CO2) to deoxygenate whole blood prior to oxygenation measurements in a Farhi tonometer assay.
oxygen,Oxygen is used in a 5.6% CO2 mixture to achieve a baseline pO2 of 0 in blood for the purpose of measuring oxygenation in a Farhi tonometer assay.,Entity: oxygen. SMILES: [O]. Oxygen is used in a 5.6% CO2 mixture to achieve a baseline pO2 of 0 in blood for the purpose of measuring oxygenation in a Farhi tonometer assay.
carbon dioxide,Carbon dioxide is used in a 5.6% mixture with oxygen to establish a baseline pO2 of 0 in blood for oxygenation measurements in a Farhi tonometer assay.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is used in a 5.6% mixture with oxygen to establish a baseline pO2 of 0 in blood for oxygenation measurements in a Farhi tonometer assay.
methanolic HCI,"Methanolic HCl is used to treat peptides containing pyrrolidone rings, facilitating the opening of the ring and rendering the peptide reactive to phenylisothiocyanate.","Entity: methanolic HCI. SMILES: CO. Methanolic HCl is used to treat peptides containing pyrrolidone rings, facilitating the opening of the ring and rendering the peptide reactive to phenylisothiocyanate."
phenylisothiocyanate,"Phenylisothiocyanate reacts with peptides that have been treated with methanolic HCl, enabling the identification of the N-terminal amino acid.","Entity: phenylisothiocyanate. SMILES: S=C=Nc1ccccc1. Phenylisothiocyanate reacts with peptides that have been treated with methanolic HCl, enabling the identification of the N-terminal amino acid."
oxygen,"Oxygen binds to high spin ferric cytochrome P-450 during its catalytic cycle, following one electron reduction.","Entity: oxygen. SMILES: [O]. Oxygen binds to high spin ferric cytochrome P-450 during its catalytic cycle, following one electron reduction."
pregnenolone,Pregnenolone metabolism can be prevented in mitochondrial assays by adding cyanoketone at a concentration of 3 pM.,Entity: pregnenolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Pregnenolone metabolism can be prevented in mitochondrial assays by adding cyanoketone at a concentration of 3 pM.
triethanolamine hydrochloride,Triethanolamine hydrochloride is included at a concentration of 10 mM in the mitochondrial suspension buffer for EPR assays.,Entity: triethanolamine hydrochloride. SMILES: Cl.OCCN(CCO)CCO. Triethanolamine hydrochloride is included at a concentration of 10 mM in the mitochondrial suspension buffer for EPR assays.
metyrapone,Metyrapone is used as an aqueous solution to study mitochondrial function in EPR assays.,Entity: metyrapone. SMILES: CC(C)(C(=O)c1cccnc1)c1cccnc1. Metyrapone is used as an aqueous solution to study mitochondrial function in EPR assays.
aminoglutethimide,Aminoglutethimide is used as an aqueous solution to investigate mitochondrial activity in EPR assays.,Entity: aminoglutethimide. SMILES: CCC1(c2ccc(N)cc2)CCC(=O)NC1=O. Aminoglutethimide is used as an aqueous solution to investigate mitochondrial activity in EPR assays.
MgCl2,MgCl2 is included at a concentration of 5 mM in the mitochondrial suspension buffer to maintain mitochondrial function in EPR assays.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is included at a concentration of 5 mM in the mitochondrial suspension buffer to maintain mitochondrial function in EPR assays.
ethanol,Ethanol is reported to affect the EPR spectra of cytochrome P-450 and is avoided in mitochondrial suspension buffers in EPR assays.,Entity: ethanol. SMILES: CCO. Ethanol is reported to affect the EPR spectra of cytochrome P-450 and is avoided in mitochondrial suspension buffers in EPR assays.
KCI,KCl is included at a concentration of 20 mM in the mitochondrial suspension buffer to support mitochondrial activity in EPR assays.,Entity: KCI. SMILES: [Cl-].[K+]. KCl is included at a concentration of 20 mM in the mitochondrial suspension buffer to support mitochondrial activity in EPR assays.
cyanoketone,"Cyanoketone is added at a concentration of 3 pM to mitochondrial suspensions to prevent metabolism of pregnenolone in EPR assays, without affecting EPR spectra at this concentration.","Entity: cyanoketone. SMILES: N#CC(=O)C#N. Cyanoketone is added at a concentration of 3 pM to mitochondrial suspensions to prevent metabolism of pregnenolone in EPR assays, without affecting EPR spectra at this concentration."
sucrose,Sucrose is used at a concentration of 0.25 M as a component of the mitochondrial suspension buffer in EPR assays.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used at a concentration of 0.25 M as a component of the mitochondrial suspension buffer in EPR assays.
acetone,"Acetone is used to add steroids to mitochondrial suspensions at a final concentration of 50 pM in EPR assays, preferred over ethanol due to its effect on EPR spectra.","Entity: acetone. SMILES: CC(C)=O. Acetone is used to add steroids to mitochondrial suspensions at a final concentration of 50 pM in EPR assays, preferred over ethanol due to its effect on EPR spectra."
sucrose,Sucrose at 0.25 M concentration is used as an ice-cold buffer for storing and homogenising rat adrenal tissue.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose at 0.25 M concentration is used as an ice-cold buffer for storing and homogenising rat adrenal tissue.
ethylenediamine tetracetic acid,Ethylenediamine tetracetic acid is included at approximately 100 µM in the homogenising medium for rat adrenal tissue preparation.,Entity: ethylenediamine tetracetic acid. SMILES: CC(=O)O.CC(=O)O.CC(=O)O.CC(=O)O.NCCN. Ethylenediamine tetracetic acid is included at approximately 100 µM in the homogenising medium for rat adrenal tissue preparation.
triethanolamine hydrochloride,Triethanolamine hydrochloride is used as a component of the homogenising medium (10 mM) for preparing rat adrenal tissue samples.,Entity: triethanolamine hydrochloride. SMILES: Cl.OCCN(CCO)CCO. Triethanolamine hydrochloride is used as a component of the homogenising medium (10 mM) for preparing rat adrenal tissue samples.
pregnenolone,Pregnenolone can induce shifts in the g values of low spin ferric cytochrome P-450 in rat adrenal fractions.,Entity: pregnenolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Pregnenolone can induce shifts in the g values of low spin ferric cytochrome P-450 in rat adrenal fractions.
cholesterol,"Addition of reducing equivalents can induce cholesterol side-chain cleavage, leading to pregnenolone formation.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Addition of reducing equivalents can induce cholesterol side-chain cleavage, leading to pregnenolone formation."
succinate,"Succinate, as a reducing equivalent, can induce shifts in the g values of low spin ferric cytochrome P-450 in rat adrenal fractions.","Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate, as a reducing equivalent, can induce shifts in the g values of low spin ferric cytochrome P-450 in rat adrenal fractions."
isocitrate,"Isocitrate, as a reducing equivalent, can induce shifts in the g values of low spin ferric cytochrome P-450 in rat adrenal fractions.","Entity: isocitrate. SMILES: O=C([O-])CC(C(=O)[O-])C(O)C(=O)[O-]. Isocitrate, as a reducing equivalent, can induce shifts in the g values of low spin ferric cytochrome P-450 in rat adrenal fractions."
cholesterol,"Cholesterol serves as a substrate for cytochrome P-450sc c, whose binding to cholesterol within mitochondria is increased by calcium phosphate.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol serves as a substrate for cytochrome P-450sc c, whose binding to cholesterol within mitochondria is increased by calcium phosphate."
calcium phosphate,Calcium phosphate at 5 mM increases the magnitude of the high spin ferric cytochrome P-450 EPR spectrum and has no effect on the low spin ferric cytochrome P-450 spectrum in decapsulated adrenal mitochondria.,Entity: calcium phosphate. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]. Calcium phosphate at 5 mM increases the magnitude of the high spin ferric cytochrome P-450 EPR spectrum and has no effect on the low spin ferric cytochrome P-450 spectrum in decapsulated adrenal mitochondria.
calcium phosphate,"Calcium phosphate stimulates cholesterol side chain cleavage in mitochondria, as indicated by the increase in the magnitude of the pregnenolone inverted type 1 difference spectrum.","Entity: calcium phosphate. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]. Calcium phosphate stimulates cholesterol side chain cleavage in mitochondria, as indicated by the increase in the magnitude of the pregnenolone inverted type 1 difference spectrum."
calcium phosphate,Calcium phosphate increases the amount of cytochrome P-450sc c bound to cholesterol within mitochondria.,Entity: calcium phosphate. SMILES: O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2]. Calcium phosphate increases the amount of cytochrome P-450sc c bound to cholesterol within mitochondria.
metyrapone,"Metyrapone induces a change in the low spin ferric cytochrome P-450 EPR spectrum and increases the magnitude of the high spin ferric cytochrome P-450 EPR spectrum in liver microsomes, similar to the effect of calcium phosphate.","Entity: metyrapone. SMILES: CC(C)(C(=O)c1cccnc1)c1cccnc1. Metyrapone induces a change in the low spin ferric cytochrome P-450 EPR spectrum and increases the magnitude of the high spin ferric cytochrome P-450 EPR spectrum in liver microsomes, similar to the effect of calcium phosphate."
aniline,"Aniline induces a change in the low spin ferric cytochrome P-450 EPR spectrum and increases the magnitude of the high spin ferric cytochrome P-450 EPR spectrum in liver microsomes, similar to the effect of calcium phosphate.","Entity: aniline. SMILES: Nc1ccccc1. Aniline induces a change in the low spin ferric cytochrome P-450 EPR spectrum and increases the magnitude of the high spin ferric cytochrome P-450 EPR spectrum in liver microsomes, similar to the effect of calcium phosphate."
pregnenolone,"The magnitude of the pregnenolone inverted type 1 difference spectrum increases in response to calcium phosphate in mitochondria, reflecting enhanced cholesterol side chain cleavage.","Entity: pregnenolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. The magnitude of the pregnenolone inverted type 1 difference spectrum increases in response to calcium phosphate in mitochondria, reflecting enhanced cholesterol side chain cleavage."
DL-isocitrate,"DL-isocitrate at 5 mM causes small shifts in the g1 and gα lines of the EPR spectrum of low spin ferric cytochrome P-450 in decapsulated adrenal mitochondria, without affecting the g2 or g = 7.8 signals.","Entity: DL-isocitrate. SMILES: O=C([O-])CC(C(=O)[O-])C(O)C(=O)[O-]. DL-isocitrate at 5 mM causes small shifts in the g1 and gα lines of the EPR spectrum of low spin ferric cytochrome P-450 in decapsulated adrenal mitochondria, without affecting the g2 or g = 7.8 signals."
pregnenolone,"Pregnenolone at 50 µM does not affect the magnitude of the EPR spectrum of low spin ferric cytochrome P-450 in decapsulated adrenal mitochondria, but causes loss of the g–8.1 signal without decreasing the g = 7.8 signal.","Entity: pregnenolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Pregnenolone at 50 µM does not affect the magnitude of the EPR spectrum of low spin ferric cytochrome P-450 in decapsulated adrenal mitochondria, but causes loss of the g–8.1 signal without decreasing the g = 7.8 signal."
succinate,"Succinate at 2.5 mM produces small shifts in the g1 and gα lines of the EPR spectrum of low spin ferric cytochrome P-450 in decapsulated adrenal mitochondria, similar to DL-isocitrate.","Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate at 2.5 mM produces small shifts in the g1 and gα lines of the EPR spectrum of low spin ferric cytochrome P-450 in decapsulated adrenal mitochondria, similar to DL-isocitrate."
cholesterol,"Cholesterol forms a complex with cytochrome P-450s¢ c, as identified by a high spin ferric EPR signal at g = 8.1 in rat adrenal mitochondria.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol forms a complex with cytochrome P-450s¢ c, as identified by a high spin ferric EPR signal at g = 8.1 in rat adrenal mitochondria."
18-hydroxycholesterol,"Addition of 200–hydroxycholesterol to bovine adrenal cortex mitochondria leads to a loss of the g = 8.1 EPR signal for high spin ferric cytochrome P-450 and an increase in the low spin form, due to increased concentration of the high spin form.","Entity: 18-hydroxycholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12CO. Addition of 200–hydroxycholesterol to bovine adrenal cortex mitochondria leads to a loss of the g = 8.1 EPR signal for high spin ferric cytochrome P-450 and an increase in the low spin form, due to increased concentration of the high spin form."
isocitrate,"Addition of isocitrate to rat adrenal mitochondria causes a loss of the EPR spectra of high spin cytochrome P-450, indicating conversion of endogenous cholesterol to pregnenolone.","Entity: isocitrate. SMILES: O=C([O-])CC(C(=O)[O-])C(O)C(=O)[O-]. Addition of isocitrate to rat adrenal mitochondria causes a loss of the EPR spectra of high spin cytochrome P-450, indicating conversion of endogenous cholesterol to pregnenolone."
pregnenolone,"Addition of pregnenolone to rat adrenal mitochondria specifically removes the component with the g = 8.08 EPR signal, presumably by converting it to low spin ferric cytochrome P-450.","Entity: pregnenolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Addition of pregnenolone to rat adrenal mitochondria specifically removes the component with the g = 8.08 EPR signal, presumably by converting it to low spin ferric cytochrome P-450."
cytochrome P-450,"The low spin ferric cytochrome P-450 with g = 2.424 in rat adrenal zona fasciculata mitochondria is attributed to cholesterol side chain cleavage cytochrome P-450, and the high spin ferric cytochrome P-450 with g = 8.08 is attributed to 11beta-hydroxylase cytochrome P-450.","Entity: cytochrome P-450. The low spin ferric cytochrome P-450 with g = 2.424 in rat adrenal zona fasciculata mitochondria is attributed to cholesterol side chain cleavage cytochrome P-450, and the high spin ferric cytochrome P-450 with g = 8.08 is attributed to 11beta-hydroxylase cytochrome P-450."
cytochrome P-450,"In rat adrenal zona fasciculata mitochondria, low spin ferric cytochrome P-450 is associated with EPR g values of 2.424, 2.248, and 1.917, while high spin ferric cytochrome P-450 is associated with g values of 8.08 and 7.80.","Entity: cytochrome P-450. In rat adrenal zona fasciculata mitochondria, low spin ferric cytochrome P-450 is associated with EPR g values of 2.424, 2.248, and 1.917, while high spin ferric cytochrome P-450 is associated with g values of 8.08 and 7.80."
cytochrome P-450,"In rat adrenal microsomal cytochrome P-450, low spin ferric g values are 2.417, 2.244, and 1.919, and high spin ferric gxy values are 7.90 and 3.85.","Entity: cytochrome P-450. In rat adrenal microsomal cytochrome P-450, low spin ferric g values are 2.417, 2.244, and 1.919, and high spin ferric gxy values are 7.90 and 3.85."
digitonin,"Digitonin is used to remove lysosomal enzymes from mitochondrial preparations, as in the LOWENSTEINS procedure for mitochondrial isolation.","Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin is used to remove lysosomal enzymes from mitochondrial preparations, as in the LOWENSTEINS procedure for mitochondrial isolation."
sucrose,"Sucrose is used to form gradients for density-based separation of mitochondria, allowing the identification of mitochondrial subpopulations based on their buoyant density.","Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used to form gradients for density-based separation of mitochondria, allowing the identification of mitochondrial subpopulations based on their buoyant density."
cytochrome b,Mitochondria of rat kidney red medulla contain more cytochrome b than the M1 mitochondrial population that predominates in the cortex.,Entity: cytochrome b. Mitochondria of rat kidney red medulla contain more cytochrome b than the M1 mitochondrial population that predominates in the cortex.
insulin,Insulin is directly catabolized in the renal interstitium due to the high permeability of peritubular capillaries to insulin.,Entity: insulin. Insulin is directly catabolized in the renal interstitium due to the high permeability of peritubular capillaries to insulin.
insulin,"Insulin undergoes uptake from the tubular fluid by renal tubules, a process that can be inhibited by diuretics acting primarily on the proximal tubules.","Entity: insulin. Insulin undergoes uptake from the tubular fluid by renal tubules, a process that can be inhibited by diuretics acting primarily on the proximal tubules."
ribulose bisphosphate,"Ribulose bisphosphate concentration in Chlorella pyrenoidosa is about 2 mM, which is sufficient to significantly increase the extent of activation of the ribulose bisphosphate-binding enzyme.","Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. Ribulose bisphosphate concentration in Chlorella pyrenoidosa is about 2 mM, which is sufficient to significantly increase the extent of activation of the ribulose bisphosphate-binding enzyme."
ribulose bisphosphate,Ribulose bisphosphate increases the final activation state (ne) of the ribulose bisphosphate-binding enzyme from R. rubrum without inhibiting the rate of activation or catalysis.,Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. Ribulose bisphosphate increases the final activation state (ne) of the ribulose bisphosphate-binding enzyme from R. rubrum without inhibiting the rate of activation or catalysis.
ribulose bisphosphate,"The catalytic site for ribulose bisphosphate on the active enzyme of R. rubrum cannot bind 6-phosphogluconate, indicating a functionally distinct site.","Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. The catalytic site for ribulose bisphosphate on the active enzyme of R. rubrum cannot bind 6-phosphogluconate, indicating a functionally distinct site."
NADPH,NADPH is suggested to act as an effector that binds with high affinity to an effector site on the higher-plant ribulose bisphosphate-binding enzyme and promotes activation.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is suggested to act as an effector that binds with high affinity to an effector site on the higher-plant ribulose bisphosphate-binding enzyme and promotes activation.
6-phosphogluconate,"6-phosphogluconate binds to an effector site on the higher-plant ribulose bisphosphate-binding enzyme and promotes activation, but at a concentration of 0.2 mM it has little effect on the rate of activation.","Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 6-phosphogluconate binds to an effector site on the higher-plant ribulose bisphosphate-binding enzyme and promotes activation, but at a concentration of 0.2 mM it has little effect on the rate of activation."
6-phosphogluconate,6-phosphogluconate competes with ribulose bisphosphate for the ribulose bisphosphate catalytic site on both inactive and active plant enzymes and decreases the rate of activation of inactive enzyme and catalysis by active enzyme.,Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 6-phosphogluconate competes with ribulose bisphosphate for the ribulose bisphosphate catalytic site on both inactive and active plant enzymes and decreases the rate of activation of inactive enzyme and catalysis by active enzyme.
6-phosphogluconate,"6-phosphogluconate decreases KCKMg, which may increase the extent of activation at physiological concentrations of CO2 and potentially enhance photosynthesis in vivo.","Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 6-phosphogluconate decreases KCKMg, which may increase the extent of activation at physiological concentrations of CO2 and potentially enhance photosynthesis in vivo."
6-phosphogluconate,"6-phosphogluconate acts as a substrate for ribulose bisphosphate carboxylase, and its concentration affects the enzyme's activation kinetics.","Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 6-phosphogluconate acts as a substrate for ribulose bisphosphate carboxylase, and its concentration affects the enzyme's activation kinetics."
ribulose bisphosphate,"Ribulose bisphosphate serves as a substrate for ribulose bisphosphate carboxylase, and its concentration influences the kinetics of enzyme activation.","Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. Ribulose bisphosphate serves as a substrate for ribulose bisphosphate carboxylase, and its concentration influences the kinetics of enzyme activation."
ribulose bisphosphate,Ribulose bisphosphate is used as a substrate to study its effect on the activation rate and equilibrium of enzyme activity assays at 30°C in Tris/HCl buffer (pH 8.2) with MgCl2 and NaH14CO3.,Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. Ribulose bisphosphate is used as a substrate to study its effect on the activation rate and equilibrium of enzyme activity assays at 30°C in Tris/HCl buffer (pH 8.2) with MgCl2 and NaH14CO3.
6-phosphogluconate,6-phosphogluconate is used as a substrate to investigate its impact on the activation rate and equilibrium of enzyme activity in Tris/HCl buffer (pH 8.2) with MgCl2 and NaH14CO3 at 30°C.,Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 6-phosphogluconate is used as a substrate to investigate its impact on the activation rate and equilibrium of enzyme activity in Tris/HCl buffer (pH 8.2) with MgCl2 and NaH14CO3 at 30°C.
3-Phosphoglyceric acid,3-Phosphoglyceric acid is used as a substrate to measure the effect of ribulose bisphosphate and 6-phosphogluconate on the activation process of an enzyme in a Tris/HCl buffer (pH 8.2) assay at 30°C.,Entity: 3-Phosphoglyceric acid. SMILES: O=C(O)C(O)COP(=O)(O)O. 3-Phosphoglyceric acid is used as a substrate to measure the effect of ribulose bisphosphate and 6-phosphogluconate on the activation process of an enzyme in a Tris/HCl buffer (pH 8.2) assay at 30°C.
6-phosphogluconate,"6-phosphogluconate increases the activation of inactive R. rubrum ribulose bisphosphate carboxylase in the presence of CO2 and Mg2+, but this stimulation decreases as CO2 concentration increases.","Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 6-phosphogluconate increases the activation of inactive R. rubrum ribulose bisphosphate carboxylase in the presence of CO2 and Mg2+, but this stimulation decreases as CO2 concentration increases."
6-phosphogluconate,The response of activation extent to CO2 for R. rubrum ribulose bisphosphate carboxylase is used to measure the product KCKMg.,Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. The response of activation extent to CO2 for R. rubrum ribulose bisphosphate carboxylase is used to measure the product KCKMg.
CO2,"CO2 concentration modulates the activation of R. rubrum ribulose bisphosphate carboxylase, with increased CO2 reducing the extent of activation stimulated by 6-phosphogluconate.","Entity: CO2. SMILES: O=C=O. CO2 concentration modulates the activation of R. rubrum ribulose bisphosphate carboxylase, with increased CO2 reducing the extent of activation stimulated by 6-phosphogluconate."
NaHCO3,NaHCO3 is used to provide bicarbonate (CO2) for measuring light-dependent CO2 fixation in R. rubrum whole-cell assays.,Entity: NaHCO3. SMILES: O=C([O-])O.[Na+]. NaHCO3 is used to provide bicarbonate (CO2) for measuring light-dependent CO2 fixation in R. rubrum whole-cell assays.
ribulose bisphosphate,The Km for ribulose bisphosphate was determined for the active enzyme in the context of CO2-dependent fixation assays.,Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. The Km for ribulose bisphosphate was determined for the active enzyme in the context of CO2-dependent fixation assays.
CO2,The Km for CO2 was determined for the active enzyme in the context of CO2-dependent fixation assays.,Entity: CO2. SMILES: O=C=O. The Km for CO2 was determined for the active enzyme in the context of CO2-dependent fixation assays.
CO2,"The enzyme assays for CO2 fixation were linear over a 30-second period at CO2 concentrations used, indicating no deactivation at low CO2.","Entity: CO2. SMILES: O=C=O. The enzyme assays for CO2 fixation were linear over a 30-second period at CO2 concentrations used, indicating no deactivation at low CO2."
HCl,HCl is used to stop enzymatic reactions in assay mixtures and to prepare 1 M-HCl in ethanol for sample collection and radioactivity counting.,Entity: HCl. SMILES: Cl. HCl is used to stop enzymatic reactions in assay mixtures and to prepare 1 M-HCl in ethanol for sample collection and radioactivity counting.
NaHCO3,"NaHCO3 is included in enzyme assay mixtures to activate inactive enzyme, with variable concentrations tested.","Entity: NaHCO3. SMILES: O=C([O-])O.[Na+]. NaHCO3 is included in enzyme assay mixtures to activate inactive enzyme, with variable concentrations tested."
ethanol,Ethanol is used to prepare 1 M-HCl for sample collection and radioactivity counting in enzyme assay protocols.,Entity: ethanol. SMILES: CCO. Ethanol is used to prepare 1 M-HCl for sample collection and radioactivity counting in enzyme assay protocols.
ribulose bisphosphate,Ribulose bisphosphate is used as an effector in enzyme assay mixtures at concentrations of 0.5–0.92 mM.,Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. Ribulose bisphosphate is used as an effector in enzyme assay mixtures at concentrations of 0.5–0.92 mM.
MgCl2,"MgCl2 is used as an activator in enzyme assay mixtures, with concentrations ranging from 0 to 20 mM depending on the experimental protocol.","Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used as an activator in enzyme assay mixtures, with concentrations ranging from 0 to 20 mM depending on the experimental protocol."
NaH14CO3,NaH14CO3 serves as a substrate in enzyme assay mixtures at a concentration of 0.7 mM (5 Ci/mol).,Entity: NaH14CO3. SMILES: O=[14C]([O-])O.[Na+]. NaH14CO3 serves as a substrate in enzyme assay mixtures at a concentration of 0.7 mM (5 Ci/mol).
(NH4)2SO4,(NH4)2SO4 is removed from enzyme preparations by Sephadex G-25 chromatography to prevent interference in enzyme assays.,Entity: (NH4)2SO4. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. (NH4)2SO4 is removed from enzyme preparations by Sephadex G-25 chromatography to prevent interference in enzyme assays.
ribulose bisphosphate,"Ribulose bisphosphate is a substrate involved in the activation of spinach ribulose bisphosphate carboxylase, with 0.73 mM ribulose bisphosphate used in the assay described by Lorimer et al. (1976).","Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. Ribulose bisphosphate is a substrate involved in the activation of spinach ribulose bisphosphate carboxylase, with 0.73 mM ribulose bisphosphate used in the assay described by Lorimer et al. (1976)."
ribulose bisphosphate,"In R. rubrum, ribulose bisphosphate has little effect on the rate of activation of the R. rubrum enzyme but strongly increases the extent of activation.","Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. In R. rubrum, ribulose bisphosphate has little effect on the rate of activation of the R. rubrum enzyme but strongly increases the extent of activation."
ribulose bisphosphate,"In higher plants, ribulose bisphosphate strongly inhibits the initial rate of activation of the plant enzyme.","Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. In higher plants, ribulose bisphosphate strongly inhibits the initial rate of activation of the plant enzyme."
MgCl2,MgCl2 is used at a concentration of 10 mM during activation and catalysis assays of ribulose bisphosphate carboxylase.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used at a concentration of 10 mM during activation and catalysis assays of ribulose bisphosphate carboxylase.
NaHCO3,NaHCO3 is used at a concentration of 20 mM as the buffer component in activation assays of ribulose bisphosphate carboxylase.,Entity: NaHCO3. SMILES: O=C([O-])O.[Na+]. NaHCO3 is used at a concentration of 20 mM as the buffer component in activation assays of ribulose bisphosphate carboxylase.
ribulose bisphosphate,Ribulose bisphosphate is used at a concentration of 0.5 mM as the substrate in assays measuring the specific activity of ribulose bisphosphate carboxylase.,Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. Ribulose bisphosphate is used at a concentration of 0.5 mM as the substrate in assays measuring the specific activity of ribulose bisphosphate carboxylase.
CO2,CO2 is used at a subsaturating concentration during activation and catalysis assays of ribulose bisphosphate carboxylase to analyze its activation process.,Entity: CO2. SMILES: O=C=O. CO2 is used at a subsaturating concentration during activation and catalysis assays of ribulose bisphosphate carboxylase to analyze its activation process.
ribulose bisphosphate,Ribulose bisphosphate can be consumed by the catalytic reaction with CO2 and Mg2+ in the presence of ribulose bisphosphate carboxylase/oxygenase.,Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. Ribulose bisphosphate can be consumed by the catalytic reaction with CO2 and Mg2+ in the presence of ribulose bisphosphate carboxylase/oxygenase.
ribulose bisphosphate,Ribulose bisphosphate increases the extent of activation of inactive ribulose bisphosphate carboxylase and does not inhibit its rate of activation.,Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. Ribulose bisphosphate increases the extent of activation of inactive ribulose bisphosphate carboxylase and does not inhibit its rate of activation.
6-phosphogluconate,6-phosphogluconate has little effect on the active ribulose bisphosphate carboxylase but increases the extent of activation of the inactive enzyme.,Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 6-phosphogluconate has little effect on the active ribulose bisphosphate carboxylase but increases the extent of activation of the inactive enzyme.
2-phosphoglycolic acid,"2-phosphoglycolic acid stimulates the extent of activation of ribulose bisphosphate carboxylase, potentially through its role as a reaction product.","Entity: 2-phosphoglycolic acid. SMILES: O=C(O)COP(=O)(O)O. 2-phosphoglycolic acid stimulates the extent of activation of ribulose bisphosphate carboxylase, potentially through its role as a reaction product."
CO2,CO2 activates ribulose bisphosphate carboxylase with an equilibrium constant of 600 µM and a second-order activation constant (k+1) of 0.25 × 10⁻⁳ min⁻¹ µM⁻¹.,Entity: CO2. SMILES: O=C=O. CO2 activates ribulose bisphosphate carboxylase with an equilibrium constant of 600 µM and a second-order activation constant (k+1) of 0.25 × 10⁻⁳ min⁻¹ µM⁻¹.
6-phosphogluconate,The presence of 6-phosphogluconate during the assay causes little inhibition of the reaction with inactive ribulose bisphosphate carboxylase from R. rubrum.,Entity: 6-phosphogluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. The presence of 6-phosphogluconate during the assay causes little inhibition of the reaction with inactive ribulose bisphosphate carboxylase from R. rubrum.
ribulose bisphosphate,Ribulose bisphosphate inhibits the activation rate of inactivated ribulose bisphosphate carboxylase from spinach and soya bean in an inversely related manner to its concentration.,Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. Ribulose bisphosphate inhibits the activation rate of inactivated ribulose bisphosphate carboxylase from spinach and soya bean in an inversely related manner to its concentration.
ribulose bisphosphate,"In inactive ribulose bisphosphate carboxylase from R. rubrum, the reaction rate during incubation is directly and hyperbolically related to ribulose bisphosphate concentration.","Entity: ribulose bisphosphate. SMILES: O=C(CO)[C@H](O)[C@H](O)CO.O=P(O)(O)O.O=P(O)(O)O. In inactive ribulose bisphosphate carboxylase from R. rubrum, the reaction rate during incubation is directly and hyperbolically related to ribulose bisphosphate concentration."
Glutaminase,"Kidney mitochondria contain more than one isoenzyme of glutaminase, and these isoenzymes have different sensitivities to phosphate.","Entity: Glutaminase. Kidney mitochondria contain more than one isoenzyme of glutaminase, and these isoenzymes have different sensitivities to phosphate."
Glutaminase,"Glutaminase is present in both mitochondrial and cytosolic fractions of rat kidney, with mitochondrial glutaminase being more sensitive to phosphate supplementation regardless of sonication or acidosis.","Entity: Glutaminase. Glutaminase is present in both mitochondrial and cytosolic fractions of rat kidney, with mitochondrial glutaminase being more sensitive to phosphate supplementation regardless of sonication or acidosis."
aspartate,Aspartate accumulates to high levels in the proximal convoluted and straight tubules of the kidney after administration as a glomerular filtrate load.,Entity: aspartate. SMILES: N[C@@H](CC(=O)[O-])C(=O)[O-]. Aspartate accumulates to high levels in the proximal convoluted and straight tubules of the kidney after administration as a glomerular filtrate load.
glutamate,Glutamate accumulates to high levels in the proximal convoluted and straight tubules of the kidney after administration as a glomerular filtrate load.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate accumulates to high levels in the proximal convoluted and straight tubules of the kidney after administration as a glomerular filtrate load.
Glutamine,Glutamine accumulates to a high degree in the proximal straight tubule of the kidney after administration as a glomerular filtrate load.,Entity: Glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine accumulates to a high degree in the proximal straight tubule of the kidney after administration as a glomerular filtrate load.
oxygen,The oxygen requirements for 14CO2 formation in rat kidney cortical tubular fragments cannot be calculated from the total CO2 formation when using endogenous substrates without single-carbon labelled substrates.,Entity: oxygen. SMILES: [O]. The oxygen requirements for 14CO2 formation in rat kidney cortical tubular fragments cannot be calculated from the total CO2 formation when using endogenous substrates without single-carbon labelled substrates.
glucose,"In rat kidney cortical tubular fragments, C-2 and C-3 atoms from exogenous single-carbon labelled substrates are incorporated into newly formed glucose to a higher extent than carboxyl groups.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In rat kidney cortical tubular fragments, C-2 and C-3 atoms from exogenous single-carbon labelled substrates are incorporated into newly formed glucose to a higher extent than carboxyl groups."
L-iso-leucine,L-iso-leucine shares a reabsorption mechanism with L-methionine and L-phenylalanine in the rat proximal tubule.,Entity: L-iso-leucine. SMILES: CC[C@H](C)[C@H](N)C(=O)O. L-iso-leucine shares a reabsorption mechanism with L-methionine and L-phenylalanine in the rat proximal tubule.
D-methionine,"D-methionine is reabsorbed in the rat proximal tubule via a saturable system with a Km of 23 mM, which has much lower affinity than L-methionine.","Entity: D-methionine. SMILES: CSCC[C@@H](N)C(=O)O. D-methionine is reabsorbed in the rat proximal tubule via a saturable system with a Km of 23 mM, which has much lower affinity than L-methionine."
L-lysine,L-lysine and L-arginine compete for specific receptors located at the luminal membrane of the rat proximal tubule.,Entity: L-lysine. SMILES: NCCCC[C@H](N)C(=O)O. L-lysine and L-arginine compete for specific receptors located at the luminal membrane of the rat proximal tubule.
L-arginine,L-arginine reabsorption in the rat proximal tubule is a saturable process with an optimal methylene group count of 3 to 4 in certain derivatives for inhibition.,Entity: L-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. L-arginine reabsorption in the rat proximal tubule is a saturable process with an optimal methylene group count of 3 to 4 in certain derivatives for inhibition.
L-arginine,"The reabsorption of L-arginine in the rat proximal tubule can be inhibited by cycloleucine and some L-arginine derivatives with the structure -OOC -- CH (N+H3) -- (CH2)x -- N+H (R1) -- R2, where x is 3 to 4 and R1 and R2 permit ionization of the vicinal nitrogen.","Entity: L-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. The reabsorption of L-arginine in the rat proximal tubule can be inhibited by cycloleucine and some L-arginine derivatives with the structure -OOC -- CH (N+H3) -- (CH2)x -- N+H (R1) -- R2, where x is 3 to 4 and R1 and R2 permit ionization of the vicinal nitrogen."
L-cysteine,L-cysteine does not inhibit the reabsorption of L-arginine in the rat proximal tubule.,Entity: L-cysteine. SMILES: N[C@@H](CS)C(=O)O. L-cysteine does not inhibit the reabsorption of L-arginine in the rat proximal tubule.
L-homoserine,L-homoserine does not inhibit the reabsorption of L-arginine in the rat proximal tubule.,Entity: L-homoserine. SMILES: N[C@@H](CCO)C(=O)O. L-homoserine does not inhibit the reabsorption of L-arginine in the rat proximal tubule.
L-phenylalanine,L-phenylalanine shares a reabsorption mechanism with L-methionine and L-iso-leucine in the rat proximal tubule.,Entity: L-phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. L-phenylalanine shares a reabsorption mechanism with L-methionine and L-iso-leucine in the rat proximal tubule.
ouabain,"Ouabain reduces L-alanine accumulation in rat renal proximal tubuli, indicating inhibition of the Na+ carrier involved in L-alanine transport.","Entity: ouabain. SMILES: C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O. Ouabain reduces L-alanine accumulation in rat renal proximal tubuli, indicating inhibition of the Na+ carrier involved in L-alanine transport."
p-hydroxymercuribenzoate,"p-hydroxymercuribenzoate completely abolishes L-alanine accumulation in rat renal proximal tubuli, indicating inhibition of the Na+ carrier responsible for L-alanine transport.","Entity: p-hydroxymercuribenzoate. SMILES: O.O=C([O-])c1ccc([Hg])cc1. p-hydroxymercuribenzoate completely abolishes L-alanine accumulation in rat renal proximal tubuli, indicating inhibition of the Na+ carrier responsible for L-alanine transport."
glucose,"Glucose is produced in rat renal proximal tubuli at 37°C during incubation, with production being reduced to less than half compared to 37°C when the temperature is lowered to 27°C.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is produced in rat renal proximal tubuli at 37°C during incubation, with production being reduced to less than half compared to 37°C when the temperature is lowered to 27°C."
L-alanine,"L-alanine accumulates in rat renal proximal tubuli at 37°C when the Na+ concentration gradient between extracellular and intracellular spaces is maintained, with accumulation being reduced by 2,4-dinitrophenol, antimycin A, ouabain, and p-hydroxymercuribenzoate, and completely abolished when the Na+ gradient is reversed.","Entity: L-alanine. SMILES: C[C@H](N)C(=O)O. L-alanine accumulates in rat renal proximal tubuli at 37°C when the Na+ concentration gradient between extracellular and intracellular spaces is maintained, with accumulation being reduced by 2,4-dinitrophenol, antimycin A, ouabain, and p-hydroxymercuribenzoate, and completely abolished when the Na+ gradient is reversed."
L-alanine,L-alanine accumulation in rat renal proximal tubuli is a direct function of the energy provided by the Na+ concentration gradient and is mediated by a carrier that can be inhibited by sulfhydryl group reagents such as p-hydroxymercuribenzoate.,Entity: L-alanine. SMILES: C[C@H](N)C(=O)O. L-alanine accumulation in rat renal proximal tubuli is a direct function of the energy provided by the Na+ concentration gradient and is mediated by a carrier that can be inhibited by sulfhydryl group reagents such as p-hydroxymercuribenzoate.
oxygen,Oxygen is an energy-yielding substrate whose uptake and consumption are studied in isolated rat kidney tubules at various low temperatures to assess its influence on metabolic performance during kidney preservation.,Entity: oxygen. SMILES: [O]. Oxygen is an energy-yielding substrate whose uptake and consumption are studied in isolated rat kidney tubules at various low temperatures to assess its influence on metabolic performance during kidney preservation.
sodium,"The ouabain-sensitive sodium pump, which accounts for 50% of sodium transport in the perfused kidney, has a Na+/O2 ratio of 34.5 or a Na+/ATP ratio of 5.8.","Entity: sodium. SMILES: [Na]. The ouabain-sensitive sodium pump, which accounts for 50% of sodium transport in the perfused kidney, has a Na+/O2 ratio of 34.5 or a Na+/ATP ratio of 5.8."
sodium,Na-K-ATP-ase activity accounts for 15% of renal oxygen uptake and 15% of renal sodium transport.,Entity: sodium. SMILES: [Na]. Na-K-ATP-ase activity accounts for 15% of renal oxygen uptake and 15% of renal sodium transport.
glutamine,"Glutamine is oxidized at a low rate in the kidney, which is consistent with limited sodium transport.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine is oxidized at a low rate in the kidney, which is consistent with limited sodium transport."
glucose,"The rate of glucose oxidation in the kidney closely matches the expected rate, indicating efficient glucose utilization.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. The rate of glucose oxidation in the kidney closely matches the expected rate, indicating efficient glucose utilization."
oxygen,"Renal oxygen uptake is primarily driven by sodium transport (30%) and Na-K-ATP-ase activity (15%), with the remainder used for other processes such as hydrogen ion secretion.","Entity: oxygen. SMILES: [O]. Renal oxygen uptake is primarily driven by sodium transport (30%) and Na-K-ATP-ase activity (15%), with the remainder used for other processes such as hydrogen ion secretion."
ouabain,"Ouabain does not prevent an increase in respiration caused by increased filtered potassium load, indicating it does not block potassium secretion.","Entity: ouabain. SMILES: C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O. Ouabain does not prevent an increase in respiration caused by increased filtered potassium load, indicating it does not block potassium secretion."
sodium,Sodium transport in the perfused kidney accounts for approximately 30% of total renal oxygen uptake.,Entity: sodium. SMILES: [Na]. Sodium transport in the perfused kidney accounts for approximately 30% of total renal oxygen uptake.
lead hydroxide phosphate,Lead hydroxide phosphate localizes as electron-dense granules in the cell walls and in vesicles associated with dictyosomes of oat coleoptile segments after lead treatment.,Entity: lead hydroxide phosphate. SMILES: O=P([O-])([O-])[O-].O[Pb+3]O. Lead hydroxide phosphate localizes as electron-dense granules in the cell walls and in vesicles associated with dictyosomes of oat coleoptile segments after lead treatment.
methanol,"Methanol is used in combination with chloroform for delipidization of lipoproteins and as an elution solvent for cholesteryl ester, triacylglycerol, unesterified cholesterol, and phospholipid fractions in lipid analysis.","Entity: methanol. SMILES: CO. Methanol is used in combination with chloroform for delipidization of lipoproteins and as an elution solvent for cholesteryl ester, triacylglycerol, unesterified cholesterol, and phospholipid fractions in lipid analysis."
sulfuric acid,Sulfuric acid is used as a spray reagent for detecting lipids on silica gel G plates in thin layer chromatography.,Entity: sulfuric acid. SMILES: O=S(=O)(O)O. Sulfuric acid is used as a spray reagent for detecting lipids on silica gel G plates in thin layer chromatography.
acetic acid,Acetic acid is used as a component of the solvent system for developing lipid fractions on silica gel G in thin layer chromatography.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component of the solvent system for developing lipid fractions on silica gel G in thin layer chromatography.
trioleoylglycerol,Trioleoylglycerol is used as a component in artificial lipid mixtures to validate the effectiveness of lipid fractionation and detection methods.,Entity: trioleoylglycerol. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)C(O)(CO)C(O)(C(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC. Trioleoylglycerol is used as a component in artificial lipid mixtures to validate the effectiveness of lipid fractionation and detection methods.
cholesteryl oleate,Cholesteryl oleate is used as a component in artificial lipid mixtures to validate the effectiveness of lipid fractionation and detection methods.,Entity: cholesteryl oleate. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. Cholesteryl oleate is used as a component in artificial lipid mixtures to validate the effectiveness of lipid fractionation and detection methods.
water,Water is used as a component of the solvent system for developing lipid fractions on silica gel G in thin layer chromatography.,Entity: water. SMILES: O. Water is used as a component of the solvent system for developing lipid fractions on silica gel G in thin layer chromatography.
cyclohexane,Cyclohexane is used as a solvent (1:1 with chloroform) for developing lipid fractions on silica gel G in thin layer chromatography.,Entity: cyclohexane. SMILES: C1CCCCC1. Cyclohexane is used as a solvent (1:1 with chloroform) for developing lipid fractions on silica gel G in thin layer chromatography.
cholesterol,Cholesterol can be separated from other lipids in lipoproteins using a chloroform/methanol delipidization and subsequent elution with ether and methanol on silica gel columns.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol can be separated from other lipids in lipoproteins using a chloroform/methanol delipidization and subsequent elution with ether and methanol on silica gel columns.
chloroform,Chloroform is used as a component of the delipidization solvent (with methanol) and as a solvent for developing lipid fractions on silica gel G in lipid analysis.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a component of the delipidization solvent (with methanol) and as a solvent for developing lipid fractions on silica gel G in lipid analysis.
sodium bromide,Sodium bromide is used to adjust the density of serum to 1.215 g/ml for lipoprotein isolation.,Entity: sodium bromide. SMILES: [Br-].[Na+]. Sodium bromide is used to adjust the density of serum to 1.215 g/ml for lipoprotein isolation.
agarose,"Agarose is a polysaccharide used as a gel matrix in electrophoresis, typically at a concentration of 0.7 g/100 ml in veronal buffer at pH 8.6.","Entity: agarose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H]3OC[C@@H]2O[C@@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]4[C@H]5OC[C@@H]4O[C@@H](O)[C@H]5O)[C@@H]2O)[C@H]3O)[C@H](O)[C@@H](O)[C@H]1O. Agarose is a polysaccharide used as a gel matrix in electrophoresis, typically at a concentration of 0.7 g/100 ml in veronal buffer at pH 8.6."
sodium diethylbarbiturate,Sodium diethylbarbiturate is used as a component of the veronal buffer system at 8.3 mM in electrophoresis at pH 8.6.,Entity: sodium diethylbarbiturate. SMILES: CCC1(CC)C(=O)NC(=O)NC1=O.[Na]. Sodium diethylbarbiturate is used as a component of the veronal buffer system at 8.3 mM in electrophoresis at pH 8.6.
diethylbarbituric acid,Diethylbarbituric acid is used as a component of the veronal buffer system at 41.6 mM in electrophoresis at pH 8.6.,Entity: diethylbarbituric acid. SMILES: CCC1(CC)C(=O)NC(=O)NC1=O. Diethylbarbituric acid is used as a component of the veronal buffer system at 41.6 mM in electrophoresis at pH 8.6.
EDTA,EDTA is used at 0.01% concentration in NaBr solutions during lipoprotein preparation to chelate divalent cations and prevent nonspecific protein binding.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used at 0.01% concentration in NaBr solutions during lipoprotein preparation to chelate divalent cations and prevent nonspecific protein binding.
NaBr,"NaBr is used as a density gradient medium in lipoprotein fractionation, with solutions prepared at densities ranging from 1.020 to 1.326 g/ml for separating VLDL, LDL, and HDL lipoproteins.","Entity: NaBr. SMILES: [Br-].[Na+]. NaBr is used as a density gradient medium in lipoprotein fractionation, with solutions prepared at densities ranging from 1.020 to 1.326 g/ml for separating VLDL, LDL, and HDL lipoproteins."
HCl,HCl is used as a strong acid (5.5 M concentration) to hydrolyze apoproteins for amino acid analysis.,Entity: HCl. SMILES: Cl. HCl is used as a strong acid (5.5 M concentration) to hydrolyze apoproteins for amino acid analysis.
bromophenol blue,Bromophenol Blue is used as a marker for the buffer front in polyacrylamide gel electrophoresis.,Entity: bromophenol blue. SMILES: O=S1(=O)OC(c2cc(Br)c(O)c(Br)c2)(c2cc(Br)c(O)c(Br)c2)c2ccccc21. Bromophenol Blue is used as a marker for the buffer front in polyacrylamide gel electrophoresis.
acrylamide,"Acrylamide is used to make polyacrylamide gels for electrophoresis, with concentrations of 3.75% (w/v) for the separating gel and 2.5% (w/v) for the spacer gel at pH 8.9 and 6.8, respectively.","Entity: acrylamide. SMILES: C=CC(N)=O. Acrylamide is used to make polyacrylamide gels for electrophoresis, with concentrations of 3.75% (w/v) for the separating gel and 2.5% (w/v) for the spacer gel at pH 8.9 and 6.8, respectively."
sodium bromide,Sodium bromide is removed from lipoprotein samples by dialysis against 0.9% sodium chloride prior to electrophoresis.,Entity: sodium bromide. SMILES: [Br-].[Na+]. Sodium bromide is removed from lipoprotein samples by dialysis against 0.9% sodium chloride prior to electrophoresis.
urea,Urea is used at 8 M concentration in separating gels for the electrophoresis of apoproteins.,Entity: urea. SMILES: NC(N)=O. Urea is used at 8 M concentration in separating gels for the electrophoresis of apoproteins.
sucrose,Sucrose is included in the sample buffer for lipoprotein electrophoresis to aid in the separation of components.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is included in the sample buffer for lipoprotein electrophoresis to aid in the separation of components.
amido black,Amido Black is used as a protein stain to detect proteins separated by electrophoresis.,Entity: amido black. SMILES: Nc1c(N=Nc2ccc([N+](=O)[O-])cc2)c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3ccccc3)c(O)c12.[Na+]. Amido Black is used as a protein stain to detect proteins separated by electrophoresis.
sodium chloride,Sodium chloride is used at 0.9% concentration for dialysis to remove sodium bromide from lipoprotein samples prior to electrophoresis.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at 0.9% concentration for dialysis to remove sodium bromide from lipoprotein samples prior to electrophoresis.
"C22:4,6 acids","C22:4,6 acids are used as standard mixtures for routine retention time checks in gas chromatography analysis of fatty acids.","Entity: C22:4,6 acids. SMILES: CCCCCCCCCCCC=CC=CC=CC=CC(=O)O. C22:4,6 acids are used as standard mixtures for routine retention time checks in gas chromatography analysis of fatty acids."
ethylene glycol succinate,Ethylene glycol succinate is used as a co-polymer in the stationary phase of gas chromatography columns to provide high and medium polarity phases for the separation of methyl esters of fatty acids.,Entity: ethylene glycol succinate. SMILES: O=C(O)CCC(=O)O.OCCO. Ethylene glycol succinate is used as a co-polymer in the stationary phase of gas chromatography columns to provide high and medium polarity phases for the separation of methyl esters of fatty acids.
C18:1 acid,C18:1 acid is used as a standard mixture for routine retention time checks in gas chromatography analysis of fatty acids.,Entity: C18:1 acid. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. C18:1 acid is used as a standard mixture for routine retention time checks in gas chromatography analysis of fatty acids.
colchicine,"Colchicine is an antimitotic drug that inhibits spindle microtubule assembly, leading to mitotic arrest in mammalian cells.","Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine is an antimitotic drug that inhibits spindle microtubule assembly, leading to mitotic arrest in mammalian cells."
sodium bisulfite,Sodium bisulfite is used in bisulphite treatment to facilitate the digestion and quantification of cytidine-containing products in pancreatic ribonuclease assays.,Entity: sodium bisulfite. SMILES: O=S([O-])O.[Na+]. Sodium bisulfite is used in bisulphite treatment to facilitate the digestion and quantification of cytidine-containing products in pancreatic ribonuclease assays.
NaHSO3,"NaHSO3 is a chemical modifying agent that can access and modify nucleotide bases projecting from the ribo or peptide nucleic acid backbone, such as in the loops I, II, III, and V of HeLa-cell 5.8S rRNA.","Entity: NaHSO3. SMILES: O=S([O-])O.[Na+]. NaHSO3 is a chemical modifying agent that can access and modify nucleotide bases projecting from the ribo or peptide nucleic acid backbone, such as in the loops I, II, III, and V of HeLa-cell 5.8S rRNA."
2'-O-methylguanosine,2'-O-methylguanosine is a modified guanosine base that can be present in cytidine-containing oligonucleotides and is detected as a product after sodium bisulfite treatment.,Entity: 2'-O-methylguanosine. SMILES: CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(=O)[nH]c(N)nc21. 2'-O-methylguanosine is a modified guanosine base that can be present in cytidine-containing oligonucleotides and is detected as a product after sodium bisulfite treatment.
uridine,Uridine is produced by deamination of cytidine upon reaction with sodium bisulfite (NaHSO3).,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine is produced by deamination of cytidine upon reaction with sodium bisulfite (NaHSO3).
2'-O-methyluridine,2'-O-methyluridine is a modified uridine base that can be present in cytidine-containing oligonucleotides and is detected as a product after sodium bisulfite treatment.,Entity: 2'-O-methyluridine. SMILES: CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O. 2'-O-methyluridine is a modified uridine base that can be present in cytidine-containing oligonucleotides and is detected as a product after sodium bisulfite treatment.
cytidine,Cytidine residues in oligonucleotides are differentially reactive and their reactivities can be estimated by comparing molar yields before and after sodium bisulfite treatment.,Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine residues in oligonucleotides are differentially reactive and their reactivities can be estimated by comparing molar yields before and after sodium bisulfite treatment.
sodium bisulfite,"Sodium bisulfite (NaHSO3) reacts with cytidine in oligonucleotides to cause deamination to uridine, resulting in lower yields of cytidine-containing products and increased yields of uridine-containing products.","Entity: sodium bisulfite. SMILES: O=S([O-])O.[Na+]. Sodium bisulfite (NaHSO3) reacts with cytidine in oligonucleotides to cause deamination to uridine, resulting in lower yields of cytidine-containing products and increased yields of uridine-containing products."
guanosine 3'-phosphate,Guanosine 3'-phosphate (Gp) is a modified guanine base present in oligonucleotides and can be incorporated into cytidine-containing oligonucleotides.,Entity: guanosine 3'-phosphate. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](CO)[C@@H](OP(=O)(O)O)[C@H]2O)c(=O)[nH]1. Guanosine 3'-phosphate (Gp) is a modified guanine base present in oligonucleotides and can be incorporated into cytidine-containing oligonucleotides.
urea,Urea is used at 7 M concentration in the first dimension of cellulose acetate electrophoresis at pH 3.5 to separate RNA fragments.,Entity: urea. SMILES: NC(N)=O. Urea is used at 7 M concentration in the first dimension of cellulose acetate electrophoresis at pH 3.5 to separate RNA fragments.
sodium sulfite,"Sodium sulfite (NaHSO3) at 3 M concentration reacts with RNA, resulting in the cleavage of cytidine-containing sequences and the generation of new sequences as observed in HeLa-cell 5.8 S rRNA digests.","Entity: sodium sulfite. SMILES: O=S([O-])[O-].[Na+].[Na+]. Sodium sulfite (NaHSO3) at 3 M concentration reacts with RNA, resulting in the cleavage of cytidine-containing sequences and the generation of new sequences as observed in HeLa-cell 5.8 S rRNA digests."
formic acid,Formic acid at 7% concentration is used in the second dimension of DEAE-paper electrophoresis at 1.2 kV for 16 hours to separate RNA fragments.,Entity: formic acid. SMILES: O=CO. Formic acid at 7% concentration is used in the second dimension of DEAE-paper electrophoresis at 1.2 kV for 16 hours to separate RNA fragments.
acetic acid,Acetic acid at 5% (v/v) concentration is used in the first dimension of cellulose acetate electrophoresis at pH 3.5 for 3 hours to separate RNA fragments.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid at 5% (v/v) concentration is used in the first dimension of cellulose acetate electrophoresis at pH 3.5 for 3 hours to separate RNA fragments.
sodium bisulfite,"Sodium bisulfite (NaHSO3) is used to chemically modify cytidine residues in RNA, such as 5.8S rRNA, under conditions of 3 M NaHSO3, pH 6, and 10 mM Mg2+ at 25°C.","Entity: sodium bisulfite. SMILES: O=S([O-])O.[Na+]. Sodium bisulfite (NaHSO3) is used to chemically modify cytidine residues in RNA, such as 5.8S rRNA, under conditions of 3 M NaHSO3, pH 6, and 10 mM Mg2+ at 25°C."
sodium sulfite,"Sodium sulfite treatment leads to the disappearance of about 50% of the total material in T1-ribonuclease products, largely due to the loss of the C-U-C-Gp component.","Entity: sodium sulfite. SMILES: O=S([O-])[O-].[Na+].[Na+]. Sodium sulfite treatment leads to the disappearance of about 50% of the total material in T1-ribonuclease products, largely due to the loss of the C-U-C-Gp component."
bisulphite,"Bisulphite reacts with pancreatic-ribo-nuclease product A-G-Cp, decreasing its yield by 60%.","Entity: bisulphite. SMILES: O=S([O-])O. Bisulphite reacts with pancreatic-ribo-nuclease product A-G-Cp, decreasing its yield by 60%."
formic acid,Formic acid is used as a 7% solution in DEAE-paper for electrophoretic separation of RNA digests.,Entity: formic acid. SMILES: O=CO. Formic acid is used as a 7% solution in DEAE-paper for electrophoretic separation of RNA digests.
NaHSO3,"NaHSO3 does not significantly react with residues C35 and C155 of the TI-ribonuclease product U-C-Gp (T 11), indicating these residues are essentially unreactive under the conditions tested.","Entity: NaHSO3. SMILES: O=S(=O)([O-])O.[Na+]. NaHSO3 does not significantly react with residues C35 and C155 of the TI-ribonuclease product U-C-Gp (T 11), indicating these residues are essentially unreactive under the conditions tested."
NaHSO3,"NaHSO3 reacts with 5.8S rRNA, decreasing the yield of the T1-ribonuclease product containing residues C4 and C6 by approximately 40%.","Entity: NaHSO3. SMILES: O=S([O-])O.[Na+]. NaHSO3 reacts with 5.8S rRNA, decreasing the yield of the T1-ribonuclease product containing residues C4 and C6 by approximately 40%."
NaHSO3,NaHSO3 is used to catalyze the hydrolysis of cytidine in 5.8S rRNA under alkaline conditions.,Entity: NaHSO3. SMILES: O=S([O-])O.[Na+]. NaHSO3 is used to catalyze the hydrolysis of cytidine in 5.8S rRNA under alkaline conditions.
cytidine,"Cytidine in 5.8S rRNA undergoes hydrolysis with NaHSO3, with approximately 50% of available cytidine residues reacting in 25 hours under the described conditions.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine in 5.8S rRNA undergoes hydrolysis with NaHSO3, with approximately 50% of available cytidine residues reacting in 25 hours under the described conditions."
uridine,"Uridine is produced from cytidine hydrolysis in 5.8S rRNA, and its formation can be quantified by comparing the distribution of 32p label between CMP and UMP.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine is produced from cytidine hydrolysis in 5.8S rRNA, and its formation can be quantified by comparing the distribution of 32p label between CMP and UMP."
cytidine,Cytidine residues in RNA can be converted into uridine via intermediate adduct formation and deamination upon reaction with sodium sulfite (NaHSO3).,Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine residues in RNA can be converted into uridine via intermediate adduct formation and deamination upon reaction with sodium sulfite (NaHSO3).
sodium sulfite,"Sodium sulfite (NaHSO3) reacts with exposed cytidine residues in RNA, converting them into uridine through intermediate adduct formation and deamination.","Entity: sodium sulfite. SMILES: O=S([O-])[O-].[Na+].[Na+]. Sodium sulfite (NaHSO3) reacts with exposed cytidine residues in RNA, converting them into uridine through intermediate adduct formation and deamination."
uridine,Uridine can be formed from cytidine in RNA by reaction with sodium sulfite (NaHSO3) via intermediate adduct formation and deamination.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine can be formed from cytidine in RNA by reaction with sodium sulfite (NaHSO3) via intermediate adduct formation and deamination.
cytidine,"Cytidine residues in HeLa-cell 5.8S rRNA can be deaminated to uridine upon reaction with sodium sulfite, with reactivity varying depending on their position within single-stranded loops, double-helical regions, and near the 3'-terminus.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine residues in HeLa-cell 5.8S rRNA can be deaminated to uridine upon reaction with sodium sulfite, with reactivity varying depending on their position within single-stranded loops, double-helical regions, and near the 3'-terminus."
cytidine,Cytidine residues in the loop closest to the 3'-terminus of HeLa-cell 5.8S rRNA are reactive towards bisulphite at 25°C.,Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine residues in the loop closest to the 3'-terminus of HeLa-cell 5.8S rRNA are reactive towards bisulphite at 25°C.
cytidine,"Cytidine residues within proposed double-helical regions of HeLa-cell 5.8S rRNA show little or no reactivity towards bisulphite at 25°C, while those at the ends of helical regions show some reactivity.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine residues within proposed double-helical regions of HeLa-cell 5.8S rRNA show little or no reactivity towards bisulphite at 25°C, while those at the ends of helical regions show some reactivity."
cytidine,Cytidine residues in loops that are thought to be 'looped out' by small helix imperfections in HeLa-cell 5.8S rRNA show some reactivity towards bisulphite at 25°C.,Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine residues in loops that are thought to be 'looped out' by small helix imperfections in HeLa-cell 5.8S rRNA show some reactivity towards bisulphite at 25°C.
sodium sulfite,"Sodium sulfite reacts with exposed cytidine residues in HeLa-cell 5.8S rRNA, converting them to uridine under conditions where deamination occurs.","Entity: sodium sulfite. SMILES: O=S([O-])[O-].[Na+].[Na+]. Sodium sulfite reacts with exposed cytidine residues in HeLa-cell 5.8S rRNA, converting them to uridine under conditions where deamination occurs."
bisulphite,"Bisulphite treatment of HeLa-cell 5.8S rRNA at 25°C selectively deaminates certain cytidine residues, allowing identification of reactive sites in the rRNA molecule.","Entity: bisulphite. SMILES: O=S([O-])O. Bisulphite treatment of HeLa-cell 5.8S rRNA at 25°C selectively deaminates certain cytidine residues, allowing identification of reactive sites in the rRNA molecule."
sodium bisulfite,"Sodium bisulfite (NaHSO3) reacts with cytidine residues in 5.8S rRNA, resulting in a decrease in the number of reactive cytidine residues over time, with approximately 30% of cytidine residues remaining unreactive after a defined period.","Entity: sodium bisulfite. SMILES: O=S([O-])O.[Na+]. Sodium bisulfite (NaHSO3) reacts with cytidine residues in 5.8S rRNA, resulting in a decrease in the number of reactive cytidine residues over time, with approximately 30% of cytidine residues remaining unreactive after a defined period."
cytidine,"Cytidine residues at the ends of helical regions in RNA can form C–G base pairs that are more reactive towards bisulphite than internally located cytidine residues, likely due to the equilibrium between open and closed states of these terminal base pairs.","Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine residues at the ends of helical regions in RNA can form C–G base pairs that are more reactive towards bisulphite than internally located cytidine residues, likely due to the equilibrium between open and closed states of these terminal base pairs."
sodium sulfite,"Sodium sulfite at 3 M concentration and pH 6 is used as a reagent to study the reactivity of cytidine residues in 5.8S rRNA, with a reaction period of 24 hours at 25°C.","Entity: sodium sulfite. SMILES: O=S([O-])[O-].[Na+].[Na+]. Sodium sulfite at 3 M concentration and pH 6 is used as a reagent to study the reactivity of cytidine residues in 5.8S rRNA, with a reaction period of 24 hours at 25°C."
iron(III) nitrilotriacetate,"iron(III) nitrilotriacetate is used to saturate proteins with iron(II) in amino acid analysis protocols, as judged by A470 absorbance.","Entity: iron(III) nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. iron(III) nitrilotriacetate is used to saturate proteins with iron(II) in amino acid analysis protocols, as judged by A470 absorbance."
sodium bicarbonate,"sodium bicarbonate is used as a component of the buffer system (0.01 M-NaHCO3, pH 5.5) in protein preparation for amino acid analysis.","Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. sodium bicarbonate is used as a component of the buffer system (0.01 M-NaHCO3, pH 5.5) in protein preparation for amino acid analysis."
sodium hydroxide,sodium hydroxide is used to adjust the pH of protein solutions to 7.45 during protein preparation.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. sodium hydroxide is used to adjust the pH of protein solutions to 7.45 during protein preparation.
Hepes,"Hepes is used as a buffering agent (0.1 M-Hepes, pH 5.5) in protein preparation for amino acid analysis.","Entity: Hepes. SMILES: O=S(=O)(O)CCN1CCN(CCO)CC1. Hepes is used as a buffering agent (0.1 M-Hepes, pH 5.5) in protein preparation for amino acid analysis."
N-acetylglucosamine,"N-acetylglucosamine is a component of carbohydrate fragments in glycopeptides, with each fragment containing 8 N-acetylglucosamine groups.","Entity: N-acetylglucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. N-acetylglucosamine is a component of carbohydrate fragments in glycopeptides, with each fragment containing 8 N-acetylglucosamine groups."
mannose,"Mannose is a component of carbohydrate fragments in glycopeptides, with each fragment containing 4 mannose residues.","Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose is a component of carbohydrate fragments in glycopeptides, with each fragment containing 4 mannose residues."
galactose,"Galactose is a component of carbohydrate fragments in glycopeptides, with each fragment containing 2 galactose residues.","Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose is a component of carbohydrate fragments in glycopeptides, with each fragment containing 2 galactose residues."
Coomassie Brilliant Blue R-250,Coomassie Brilliant Blue R-250 is a dye used to stain proteins in polyacrylamide-gel electrophoresis.,Entity: Coomassie Brilliant Blue R-250. SMILES: CCOc1ccc(Nc2ccc(C(=C3C=CC(=[N+](CC)Cc4cccc(S(=O)(=O)[O-])c4)C=C3)c3ccc(N(CC)Cc4cccc(S(=O)(=O)[O-])c4)cc3)cc2)cc1.[Na+]. Coomassie Brilliant Blue R-250 is a dye used to stain proteins in polyacrylamide-gel electrophoresis.
periodic acid,"Periodic acid is used as part of a stain for carbohydrates in polyacrylamide-gel electrophoresis, in combination with Schiff's-base staining.","Entity: periodic acid. SMILES: [O-][I+3]([O-])([O-])O. Periodic acid is used as part of a stain for carbohydrates in polyacrylamide-gel electrophoresis, in combination with Schiff's-base staining."
iron(III)-nitrilotriacetate,iron(III)-nitrilotriacetate is a non-physiological iron donor that preferentially binds to the C-terminal site of proteins at both pH 5.5 and pH 8.5.,Entity: iron(III)-nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. iron(III)-nitrilotriacetate is a non-physiological iron donor that preferentially binds to the C-terminal site of proteins at both pH 5.5 and pH 8.5.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used in sodium dodecyl sulphate/polyacrylamide gel electrophoresis to analyze protein molecular weight and integrity.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used in sodium dodecyl sulphate/polyacrylamide gel electrophoresis to analyze protein molecular weight and integrity.
2-mercaptoethanol,"2-mercaptoethanol is used in sodium dodecyl sulphate-polyacrylamide gel electrophoresis to reduce protein disulfide bridges, resulting in the appearance of multiple protein bands.","Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is used in sodium dodecyl sulphate-polyacrylamide gel electrophoresis to reduce protein disulfide bridges, resulting in the appearance of multiple protein bands."
formic acid,Formic acid is used as a 5% (v/v) solution for protein solubilization prior to enzymatic digestion.,Entity: formic acid. SMILES: O=CO. Formic acid is used as a 5% (v/v) solution for protein solubilization prior to enzymatic digestion.
ninhydrin,Ninhydrin is used as a staining reagent for peptides in electrophoretic protein digestion assays.,Entity: ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is used as a staining reagent for peptides in electrophoretic protein digestion assays.
cadmium acetate,Cadmium acetate is used as a staining reagent for peptides in electrophoretic protein digestion assays.,Entity: cadmium acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Cd+2]. Cadmium acetate is used as a staining reagent for peptides in electrophoretic protein digestion assays.
tyrosine,Tyrosine-containing peptides can be specifically detected using a tyrosine-specific stain in electrophoretic protein digestion assays.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine-containing peptides can be specifically detected using a tyrosine-specific stain in electrophoretic protein digestion assays.
tryptophan,Tryptophan-containing peptides can be specifically detected using a tryptophan-specific stain in electrophoretic protein digestion assays.,Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan-containing peptides can be specifically detected using a tryptophan-specific stain in electrophoretic protein digestion assays.
iron(III) citrate,"Iron(III) citrate-treated protein fragments partially saturate human serum transferrin antiserum in the Ouchterlony test, with precipitin lines that show partial identity to whole protein.","Entity: iron(III) citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Fe+3]. Iron(III) citrate-treated protein fragments partially saturate human serum transferrin antiserum in the Ouchterlony test, with precipitin lines that show partial identity to whole protein."
iron(II) ascorbate,"Iron(II) ascorbate-treated protein fragments partially saturate human serum transferrin antiserum in the Ouchterlony test, with precipitin lines that show partial identity to whole protein.","Entity: iron(II) ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Fe+2]. Iron(II) ascorbate-treated protein fragments partially saturate human serum transferrin antiserum in the Ouchterlony test, with precipitin lines that show partial identity to whole protein."
iron(III) chloride,"Iron(III) chloride-treated protein fragments partially saturate human serum transferrin antiserum in the Ouchterlony test, with precipitin lines that show partial identity to whole protein.","Entity: iron(III) chloride. SMILES: Cl[Fe](Cl)Cl. Iron(III) chloride-treated protein fragments partially saturate human serum transferrin antiserum in the Ouchterlony test, with precipitin lines that show partial identity to whole protein."
iron(III) nitrilotriacetate,"Iron(III) nitrilotriacetate forms protein fragments that do not have a single-chain structure, even when fully saturated, due to limited proteolytic cleavage.","Entity: iron(III) nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. Iron(III) nitrilotriacetate forms protein fragments that do not have a single-chain structure, even when fully saturated, due to limited proteolytic cleavage."
FeCl3,FeCl3 is a source of iron(III) ions that can be used to partially saturate transferrin for biochemical analysis.,Entity: FeCl3. SMILES: Cl[Fe](Cl)Cl. FeCl3 is a source of iron(III) ions that can be used to partially saturate transferrin for biochemical analysis.
iron(III) citrate,"Iron(III) citrate can be used to partially saturate transferrin, and the resulting iron(III) complexes are detectable by gel electrophoresis as components with similar mobility to FeCl3, iron(II) ascorbate, and (NH4)2SO4·FeSO4.","Entity: iron(III) citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Fe+3]. Iron(III) citrate can be used to partially saturate transferrin, and the resulting iron(III) complexes are detectable by gel electrophoresis as components with similar mobility to FeCl3, iron(II) ascorbate, and (NH4)2SO4·FeSO4."
iron(III)-nitrilotriacetate,Iron(III)-nitrilotriacetate is a chelating agent that can be used to partially saturate transferrin for biochemical studies.,Entity: iron(III)-nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. Iron(III)-nitrilotriacetate is a chelating agent that can be used to partially saturate transferrin for biochemical studies.
iron(II) ascorbate,"Iron(II) ascorbate is a form of iron(II) that can be detected by gel electrophoresis as a component with similar mobility to FeCl3, iron(III) citrate, and (NH4)2SO4·FeSO4 after digestion of partially iron-saturated transferrin with trypsin.","Entity: iron(II) ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Fe+2]. Iron(II) ascorbate is a form of iron(II) that can be detected by gel electrophoresis as a component with similar mobility to FeCl3, iron(III) citrate, and (NH4)2SO4·FeSO4 after digestion of partially iron-saturated transferrin with trypsin."
FeSO4,"FeSO4, when associated with (NH4)2SO4, can be detected by gel electrophoresis as a component with similar mobility to FeCl3, iron(II) ascorbate, and iron(III) citrate after digestion of partially iron-saturated transferrin with trypsin.","Entity: FeSO4. SMILES: O=S(=O)([O-])[O-].[Fe+2]. FeSO4, when associated with (NH4)2SO4, can be detected by gel electrophoresis as a component with similar mobility to FeCl3, iron(II) ascorbate, and iron(III) citrate after digestion of partially iron-saturated transferrin with trypsin."
ninhydrin,Ninhydrin is a staining reagent used in one-dimensional electrophoresis to visualize protein fragments by producing colored bands.,Entity: ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is a staining reagent used in one-dimensional electrophoresis to visualize protein fragments by producing colored bands.
tyrosine,Tyrosine can be specifically stained in protein electrophoresis to distinguish protein fragments based on their amino acid composition.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine can be specifically stained in protein electrophoresis to distinguish protein fragments based on their amino acid composition.
tryptophan,Tryptophan residues in proteins can be specifically stained in electrophoresis to help identify and characterize protein fragments.,Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan residues in proteins can be specifically stained in electrophoresis to help identify and characterize protein fragments.
iron(III) citrate,Iron(III) citrate is used as a partial saturant for protein digests to facilitate the resolution of protein components by gel filtration.,Entity: iron(III) citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Fe+3]. Iron(III) citrate is used as a partial saturant for protein digests to facilitate the resolution of protein components by gel filtration.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used in combination with polyacrylamide gel electrophoresis to determine the molecular weights of protein peaks separated by gel filtration.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used in combination with polyacrylamide gel electrophoresis to determine the molecular weights of protein peaks separated by gel filtration.
iron(III) nitrilotriacetate,"Partial saturation of protein digests with iron(III) nitrilotriacetate results in the formation of protein fragments with molecular weights of 43000 and 80000, as determined by gel filtration and SDS-PAGE.","Entity: iron(III) nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. Partial saturation of protein digests with iron(III) nitrilotriacetate results in the formation of protein fragments with molecular weights of 43000 and 80000, as determined by gel filtration and SDS-PAGE."
ammonium sulfate,Ammonium sulfate is used as a partial saturant for protein digests to facilitate the resolution of protein components by gel filtration.,Entity: ammonium sulfate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Ammonium sulfate is used as a partial saturant for protein digests to facilitate the resolution of protein components by gel filtration.
iron(III) chloride,Iron(III) chloride is used as a partial saturant for protein digests to aid in the separation of protein components by gel filtration.,Entity: iron(III) chloride. SMILES: Cl[Fe](Cl)Cl. Iron(III) chloride is used as a partial saturant for protein digests to aid in the separation of protein components by gel filtration.
iron(II) ascorbate,Iron(II) ascorbate is used as a partial saturant for protein digests to facilitate the resolution of protein components by gel filtration.,Entity: iron(II) ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Fe+2]. Iron(II) ascorbate is used as a partial saturant for protein digests to facilitate the resolution of protein components by gel filtration.
iron(II) sulfate,Iron(II) sulfate is used as a partial saturant for protein digests to aid in the separation of protein components by gel filtration.,Entity: iron(II) sulfate. SMILES: O=S(=O)([O-])[O-].[Fe+2]. Iron(II) sulfate is used as a partial saturant for protein digests to aid in the separation of protein components by gel filtration.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used at 5% (w/v) concentration in buffers for sodium dodecyl sulphate/polyacrylamide-gel electrophoresis sample preparation.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used at 5% (w/v) concentration in buffers for sodium dodecyl sulphate/polyacrylamide-gel electrophoresis sample preparation.
glycerol,Glycerol is included at 10% (v/v) concentration in buffers for sodium dodecyl sulphate/polyacrylamide-gel electrophoresis sample preparation.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is included at 10% (v/v) concentration in buffers for sodium dodecyl sulphate/polyacrylamide-gel electrophoresis sample preparation.
2-mercaptoethanol,"2-mercaptoethanol is used at 1% concentration in buffers for sodium dodecyl sulphate/polyacrylamide-gel electrophoresis sample preparation, but is omitted for unreduced samples.","Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is used at 1% concentration in buffers for sodium dodecyl sulphate/polyacrylamide-gel electrophoresis sample preparation, but is omitted for unreduced samples."
sodium phosphate,Sodium phosphate is used at 5 mM concentration and pH 7.0 in buffers for sodium dodecyl sulphate/polyacrylamide-gel electrophoresis sample preparation.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used at 5 mM concentration and pH 7.0 in buffers for sodium dodecyl sulphate/polyacrylamide-gel electrophoresis sample preparation.
sodium phosphate,Sodium phosphate is used as a buffer at 0.1 M concentration and pH 7.0 for dissolving protein in immunological antigen preparation.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used as a buffer at 0.1 M concentration and pH 7.0 for dissolving protein in immunological antigen preparation.
iron(III) chloride,"Iron(III) chloride is used as an iron donor in transferrin binding assays, but its uptake by transferrin is slow, necessitating longer incubation times for partial saturation.","Entity: iron(III) chloride. SMILES: Cl[Fe](Cl)Cl. Iron(III) chloride is used as an iron donor in transferrin binding assays, but its uptake by transferrin is slow, necessitating longer incubation times for partial saturation."
iron(II) ascorbate,"Iron(II) ascorbate is used as an iron donor in transferrin binding assays, and samples of protein partially saturated with iron(II) ascorbate can be prepared by adjusting the amount of donor based on its chelating properties.","Entity: iron(II) ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Fe+2]. Iron(II) ascorbate is used as an iron donor in transferrin binding assays, and samples of protein partially saturated with iron(II) ascorbate can be prepared by adjusting the amount of donor based on its chelating properties."
iron(III) nitrilotriacetate,"Iron(III) nitrilotriacetate is used as an iron donor in transferrin binding assays, and samples of protein partially saturated with iron(III) nitrilotriacetate can be prepared by adjusting the amount of donor based on its chelating properties.","Entity: iron(III) nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. Iron(III) nitrilotriacetate is used as an iron donor in transferrin binding assays, and samples of protein partially saturated with iron(III) nitrilotriacetate can be prepared by adjusting the amount of donor based on its chelating properties."
iron(II) sulfate,"Iron(II) sulfate is used as an iron donor in transferrin binding assays, and samples of protein partially saturated with iron(II) sulfate can be prepared by adjusting the amount of donor based on its chelating properties.","Entity: iron(II) sulfate. SMILES: O=S(=O)([O-])[O-].[Fe+2]. Iron(II) sulfate is used as an iron donor in transferrin binding assays, and samples of protein partially saturated with iron(II) sulfate can be prepared by adjusting the amount of donor based on its chelating properties."
ammonium sulfate,"Ammonium sulfate is used as an iron donor in transferrin binding assays, and samples of protein partially saturated with ammonium sulfate can be prepared by adjusting the amount of donor based on its chelating properties.","Entity: ammonium sulfate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Ammonium sulfate is used as an iron donor in transferrin binding assays, and samples of protein partially saturated with ammonium sulfate can be prepared by adjusting the amount of donor based on its chelating properties."
sodium bicarbonate,"Sodium bicarbonate is used as a buffer (0.1 M, pH 8.5) in the preparation of human serum transferrin samples for iron binding assays.","Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Sodium bicarbonate is used as a buffer (0.1 M, pH 8.5) in the preparation of human serum transferrin samples for iron binding assays."
iron(III) citrate,"Iron(III) citrate is used as an iron donor in transferrin binding assays, but its uptake by transferrin is slow, requiring longer incubation times for partial saturation.","Entity: iron(III) citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Fe+3]. Iron(III) citrate is used as an iron donor in transferrin binding assays, but its uptake by transferrin is slow, requiring longer incubation times for partial saturation."
iron(III)-nitrilotriacetate,"Addition of iron(III)-nitrilotriacetate to iron-free human serum transferrin at pH 8.5 enhances the migration of the two monoferric species, resulting in a slower-migrating band on electrophoresis.","Entity: iron(III)-nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. Addition of iron(III)-nitrilotriacetate to iron-free human serum transferrin at pH 8.5 enhances the migration of the two monoferric species, resulting in a slower-migrating band on electrophoresis."
iron(III) chloride,"When FeCl3 is used as an iron donor in transferrin binding studies, it preferentially forms a faster-moving intermediate band on electrophoresis at pH 8.4.","Entity: iron(III) chloride. SMILES: Cl[Fe](Cl)Cl. When FeCl3 is used as an iron donor in transferrin binding studies, it preferentially forms a faster-moving intermediate band on electrophoresis at pH 8.4."
ammonium sulfate,"Ammonium sulfate, when used as an iron donor in transferrin binding studies, leads to the formation of a faster-moving intermediate band on electrophoresis at pH 8.4.","Entity: ammonium sulfate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Ammonium sulfate, when used as an iron donor in transferrin binding studies, leads to the formation of a faster-moving intermediate band on electrophoresis at pH 8.4."
urea,Urea at 6 M concentration is used in polyacrylamide gels to separate the four species of iron-binding transferrin by electrophoresis at pH 8.4.,Entity: urea. SMILES: NC(N)=O. Urea at 6 M concentration is used in polyacrylamide gels to separate the four species of iron-binding transferrin by electrophoresis at pH 8.4.
iron(II) ascorbate,"Iron(II) ascorbate can be used as an iron donor to partially saturate proteins, leading to proteolytic digestion yielding fragments of molecular weight 36000 that lack carbohydrate.","Entity: iron(II) ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Fe+2]. Iron(II) ascorbate can be used as an iron donor to partially saturate proteins, leading to proteolytic digestion yielding fragments of molecular weight 36000 that lack carbohydrate."
iron(II) sulfate,"Iron(II) sulfate can serve as an iron donor for partial protein saturation, resulting in proteolytic digestion producing a 36000 molecular weight fragment lacking carbohydrate.","Entity: iron(II) sulfate. SMILES: O=S(=O)([O-])[O-].[Fe+2]. Iron(II) sulfate can serve as an iron donor for partial protein saturation, resulting in proteolytic digestion producing a 36000 molecular weight fragment lacking carbohydrate."
iron(III) citrate,"Iron(III) citrate is used as an iron donor to partially saturate proteins, and proteolytic digestion of these partially saturated proteins yields a 36000 molecular weight fragment devoid of carbohydrate.","Entity: iron(III) citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Fe+3]. Iron(III) citrate is used as an iron donor to partially saturate proteins, and proteolytic digestion of these partially saturated proteins yields a 36000 molecular weight fragment devoid of carbohydrate."
iron(III),"Iron(III) can partially saturate proteins, resulting in the appearance of two main species with molecular weights 80,000 and 43,000 Da in SDS/PAGE gels.","Entity: iron(III). SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. Iron(III) can partially saturate proteins, resulting in the appearance of two main species with molecular weights 80,000 and 43,000 Da in SDS/PAGE gels."
sodium dodecyl sulphate,Sodium dodecyl sulphate is used in SDS/PAGE gel electrophoresis to separate proteins based on molecular weight.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used in SDS/PAGE gel electrophoresis to separate proteins based on molecular weight.
nitrilotriacetate,Nitrilotriacetate is used as a chelating agent to bind iron(III) ions in protein samples for molecular weight analysis by SDS/PAGE.,Entity: nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-]. Nitrilotriacetate is used as a chelating agent to bind iron(III) ions in protein samples for molecular weight analysis by SDS/PAGE.
iron(II) ascorbate,iron(II) ascorbate is an iron chelate prepared by the method of Woodworth (1966).,Entity: iron(II) ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Fe+2]. iron(II) ascorbate is an iron chelate prepared by the method of Woodworth (1966).
iron(III) citrate,"iron(III) citrate is an iron chelate prepared with an iron/citrate molar ratio of 1:20, under which the predominant species in solution is thought to be iron(III) dicitrate.","Entity: iron(III) citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Fe+3].[Fe+3]. iron(III) citrate is an iron chelate prepared with an iron/citrate molar ratio of 1:20, under which the predominant species in solution is thought to be iron(III) dicitrate."
iron(III)-nitrilotriacetate,Addition of iron(III)-nitrilotriacetate to isolated human serum transferrin at pH 6.0 or 8.5 produces a monoferric transferrin species with iron in the C-terminal site.,Entity: iron(III)-nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. Addition of iron(III)-nitrilotriacetate to isolated human serum transferrin at pH 6.0 or 8.5 produces a monoferric transferrin species with iron in the C-terminal site.
sodium phosphate,Sodium phosphate is used as a buffer at 0.05 M concentration and pH 7.0 in polyacrylamide-gel electrophoresis.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used as a buffer at 0.05 M concentration and pH 7.0 in polyacrylamide-gel electrophoresis.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used at 0.1% (w/v) concentration as a detergent in polyacrylamide-gel electrophoresis.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used at 0.1% (w/v) concentration as a detergent in polyacrylamide-gel electrophoresis.
acrylamide,Acrylamide is used at 7.5% (w/v) concentration in the gel matrix for polyacrylamide-gel electrophoresis.,Entity: acrylamide. SMILES: C=CC(N)=O. Acrylamide is used at 7.5% (w/v) concentration in the gel matrix for polyacrylamide-gel electrophoresis.
iron(II) ascorbate,Iron(II) ascorbate is used to iron-saturate human serum transferrin samples for proteomic analysis.,Entity: iron(II) ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Fe+2]. Iron(II) ascorbate is used to iron-saturate human serum transferrin samples for proteomic analysis.
(NH4)2SO4,(NH4)2SO4 is used in combination with FeSO4 to iron-saturate human serum transferrin samples for proteomic analysis.,Entity: (NH4)2SO4. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. (NH4)2SO4 is used in combination with FeSO4 to iron-saturate human serum transferrin samples for proteomic analysis.
2-mercaptoethanol,2-mercaptoethanol is used as a reducing agent during SDS-PAGE gel electrophoresis.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is used as a reducing agent during SDS-PAGE gel electrophoresis.
FeCl3,FeCl3 is used to iron-saturate human serum transferrin samples for proteomic analysis.,Entity: FeCl3. SMILES: Cl[Fe](Cl)Cl. FeCl3 is used to iron-saturate human serum transferrin samples for proteomic analysis.
iron(III)-nitrilotriacetate,"Iron(III)-nitrilotriacetate is used to partially saturate human serum transferrin, resulting in a carbohydrate-containing iron-binding fragment of molecular weight 43000 upon trypsin digestion at pH 5.5 or 8.5.","Entity: iron(III)-nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. Iron(III)-nitrilotriacetate is used to partially saturate human serum transferrin, resulting in a carbohydrate-containing iron-binding fragment of molecular weight 43000 upon trypsin digestion at pH 5.5 or 8.5."
iron,"In human serum transferrin, iron is distributed in two possible monoferric forms, with the C-terminal region designated as site A and the N-terminal region as site B.","Entity: iron. SMILES: [Fe]. In human serum transferrin, iron is distributed in two possible monoferric forms, with the C-terminal region designated as site A and the N-terminal region as site B."
iron(III)-nitrilotriacetate,"iron(III)-nitrilotriacetate acts as an iron(III) donor that can reversibly bind to protein fragments, with higher-molecular-weight fragments (mol.wt. 43,000) taking up their original complement of iron and lower-molecular-weight fragments only taking up about 30% of the theoretical iron.","Entity: iron(III)-nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. iron(III)-nitrilotriacetate acts as an iron(III) donor that can reversibly bind to protein fragments, with higher-molecular-weight fragments (mol.wt. 43,000) taking up their original complement of iron and lower-molecular-weight fragments only taking up about 30% of the theoretical iron."
ammonium sulfate,"Ammonium sulfate, when added to human serum transferrin at pH 6.7, facilitates the separation of transferrin into three species corresponding to 0, 1, and 2 atoms of iron bound to the protein.","Entity: ammonium sulfate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Ammonium sulfate, when added to human serum transferrin at pH 6.7, facilitates the separation of transferrin into three species corresponding to 0, 1, and 2 atoms of iron bound to the protein."
iron(II) chloride,"Partial saturation of human serum transferrin with iron(II) chloride at pH 5.0, followed by raising the pH to 7.9, enables separation of two monoferric forms of transferrin by chromatography on DEAE-cellulose.","Entity: iron(II) chloride. SMILES: Cl[Fe]Cl. Partial saturation of human serum transferrin with iron(II) chloride at pH 5.0, followed by raising the pH to 7.9, enables separation of two monoferric forms of transferrin by chromatography on DEAE-cellulose."
urea,"Polyacrylamide-gel electrophoresis in the presence of 6 M-urea resolves iron-free human serum transferrin, the two monoferric forms of transferrin, and fully saturated transferrin.","Entity: urea. SMILES: NC(N)=O. Polyacrylamide-gel electrophoresis in the presence of 6 M-urea resolves iron-free human serum transferrin, the two monoferric forms of transferrin, and fully saturated transferrin."
(NH4)2SO4,Partial saturation of human serum transferrin with (NH4)2SO4·FeSO4 at pH 8.5 results in a trypsin-digested fragment lacking carbohydrate and having a molecular weight of 36000.,Entity: (NH4)2SO4. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Partial saturation of human serum transferrin with (NH4)2SO4·FeSO4 at pH 8.5 results in a trypsin-digested fragment lacking carbohydrate and having a molecular weight of 36000.
iron(III)-nitrilotriacetate,Saturating human serum transferrin to 30% with iron(III)-nitrilotriacetate at pH 5.5 or 8.5 produces a carbohydrate-containing fragment of molecular weight 43000 after proteolytic digestion.,Entity: iron(III)-nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. Saturating human serum transferrin to 30% with iron(III)-nitrilotriacetate at pH 5.5 or 8.5 produces a carbohydrate-containing fragment of molecular weight 43000 after proteolytic digestion.
iron(III) citrate,Partial saturation of human serum transferrin with iron(III) citrate at pH 8.5 results in a trypsin-digested fragment lacking carbohydrate and having a molecular weight of 36000.,Entity: iron(III) citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Fe+3]. Partial saturation of human serum transferrin with iron(III) citrate at pH 8.5 results in a trypsin-digested fragment lacking carbohydrate and having a molecular weight of 36000.
FeCI3,Partial saturation of human serum transferrin with FeCI3 at pH 8.5 produces a trypsin-digested fragment lacking carbohydrate and having a molecular weight of 36000.,Entity: FeCI3. SMILES: Cl[Fe](Cl)Cl. Partial saturation of human serum transferrin with FeCI3 at pH 8.5 produces a trypsin-digested fragment lacking carbohydrate and having a molecular weight of 36000.
iron(II) ascorbate,Partial saturation of human serum transferrin with iron(II) ascorbate at pH 8.5 yields a trypsin-digested fragment lacking carbohydrate and having a molecular weight of 36000.,Entity: iron(II) ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O.[Fe+2]. Partial saturation of human serum transferrin with iron(II) ascorbate at pH 8.5 yields a trypsin-digested fragment lacking carbohydrate and having a molecular weight of 36000.
iron(III)-nitrilotriacetate,"iron(III)-nitrilotriacetate is used as an iron chelate to partially saturate proteins, and its use at pH 5.5 or 8.5 produces similar gel-filtration patterns after removal of unbound iron and trypsin digestion.","Entity: iron(III)-nitrilotriacetate. SMILES: O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+3]. iron(III)-nitrilotriacetate is used as an iron chelate to partially saturate proteins, and its use at pH 5.5 or 8.5 produces similar gel-filtration patterns after removal of unbound iron and trypsin digestion."
ethanol,"Ethanol is used in hydration steps for chromosome preparation, with 95% ethanol for 3 minutes and 70% ethanol for 3 minutes, followed by glass distilled water for 2 minutes.","Entity: ethanol. SMILES: CCO. Ethanol is used in hydration steps for chromosome preparation, with 95% ethanol for 3 minutes and 70% ethanol for 3 minutes, followed by glass distilled water for 2 minutes."
quinacrine mustard,"Quinacrine mustard is a fluorescent dye used to induce differential fluorescence along chromosome length, enhancing fluorescence in AT-rich DNA and quenching it in GC-rich regions.","Entity: quinacrine mustard. SMILES: COc1ccc2nc3cc(Cl)ccc3c(NC(C)CCCN(CCCl)CCCl)c2c1. Quinacrine mustard is a fluorescent dye used to induce differential fluorescence along chromosome length, enhancing fluorescence in AT-rich DNA and quenching it in GC-rich regions."
quinacrine mustard,Quinacrine mustard is used at a 0.05% solution in glass distilled water to stain chromosomes for 5 minutes in cytogenetic banding procedures.,Entity: quinacrine mustard. SMILES: COc1ccc2nc3cc(Cl)ccc3c(NC(C)CCCN(CCCl)CCCl)c2c1. Quinacrine mustard is used at a 0.05% solution in glass distilled water to stain chromosomes for 5 minutes in cytogenetic banding procedures.
citric acid,Citric acid is used to adjust the pH of mounting medium (0.2M Na2HPO4) to 5.5 in chromosome mounting solutions.,Entity: citric acid. SMILES: O=C(O)CC(O)(CC(=O)O)C(=O)O. Citric acid is used to adjust the pH of mounting medium (0.2M Na2HPO4) to 5.5 in chromosome mounting solutions.
sodium phosphate,Sodium phosphate (0.2M Na2HPO4) is used as the mounting medium pH adjuster to 5.5 in chromosome preparation protocols.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate (0.2M Na2HPO4) is used as the mounting medium pH adjuster to 5.5 in chromosome preparation protocols.
methanol,Methanol is used as a component of Carnoy's fixative (3 parts methanol: 1 part acetic acid) for chromosome fixation.,Entity: methanol. SMILES: CO. Methanol is used as a component of Carnoy's fixative (3 parts methanol: 1 part acetic acid) for chromosome fixation.
acetic acid,Acetic acid is used as a component of Carnoy's fixative (3 parts methanol: 1 part acetic acid) for chromosome fixation.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component of Carnoy's fixative (3 parts methanol: 1 part acetic acid) for chromosome fixation.
isoetharine,Isoetharine is used to induce reversible airway disease in patients for diagnostic purposes.,Entity: isoetharine. SMILES: CCC(NC(C)C)C(O)c1ccc(O)c(O)c1. Isoetharine is used to induce reversible airway disease in patients for diagnostic purposes.
isoproterenol sulfate,Isoproterenol sulfate is administered via inhalation at 250 p.g by cartridge nebulizer to assess airway responsiveness in patients with suspected reversible airway disease.,Entity: isoproterenol sulfate. SMILES: CC(C)NCC(O)c1ccc(O)c(O)c1.CC(C)NCC(O)c1ccc(O)c(O)c1.O.O.O=S(=O)(O)O. Isoproterenol sulfate is administered via inhalation at 250 p.g by cartridge nebulizer to assess airway responsiveness in patients with suspected reversible airway disease.
terbutaline,Terbutaline is used as an inhalation therapy to induce a response in patients with reversible airway disease.,Entity: terbutaline. SMILES: CC(C)(C)NCC(O)c1cc(O)cc(O)c1. Terbutaline is used as an inhalation therapy to induce a response in patients with reversible airway disease.
endotoxin,"Endotoxin can potentiate β-adrenergic contraction in vitro, with the effect being magnified in patients with chronic bronchitis.","Entity: endotoxin. SMILES: CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)O[C@@H]1[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H](OC[C@H]2O[C@H](OP(=O)(O)O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]2O)O[C@H](CO[C@]2(C(=O)O)C[C@@H](O[C@]3(C(=O)O)C[C@@H](O[C@]4(C(=O)O)C[C@@H](OP(=O)(O)OCCN)[C@H](O)[C@@H]([C@@H](O)CO)O4)[C@H](O)[C@@H]([C@@H](O)CO)O3)[C@H](OC3O[C@H]([C@@H](O)CO)[C@@H](OP(=O)(O)OP(=O)(O)OCCN)[C@H](OC4O[C@H]([C@@H](O)COC5O[C@H]([C@@H](O)CO)[C@@H](OP(=O)(O)O)[C@H](O)[C@@H]5O)[C@@H](O)[C@H](OC5O[C@H](CO[C@H]6O[C@H](CO)[C@H](O)[C@H](O)[C@H]6O)[C@@H](O)[C@H](O[C@H]6O[C@H](CO)[C@H](O)[C@H](O)[C@H]6OC6O[C@H](CO)[C@@H](O)[C@H](O[C@@H]7O[C@H](CO[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8NC(C)=O)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@H](O)[C@H](O[C@H]9O[C@H](CO[C@H]%10O[C@H](CO)[C@H](O)[C@H](O)[C@H]%10O)[C@H](O)[C@H](O)[C@H]9O)[C@H]8NC(C)=O)[C@H]7NC(C)=O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6NC(C)=O)[C@H]5O)[C@@H]4O)[C@@H]3O)[C@@H]([C@@H](O)CO)O2)[C@H]1OP(=O)(O)O. Endotoxin can potentiate β-adrenergic contraction in vitro, with the effect being magnified in patients with chronic bronchitis."
isoproterenol,Isoproterenol is a weak β-adrenergic (pressor) agonist that can induce tachyphylaxis after prolonged in vitro exposure.,Entity: isoproterenol. SMILES: CC(C)NCC(O)c1ccc(O)c(O)c1. Isoproterenol is a weak β-adrenergic (pressor) agonist that can induce tachyphylaxis after prolonged in vitro exposure.
pyrophosphate,The bond linking beta-(1→3)-glucan to aglycone in Euglena gracilis is possibly a pyrophosphate linkage.,Entity: pyrophosphate. SMILES: O=P([O-])([O-])OP(=O)([O-])[O-]. The bond linking beta-(1→3)-glucan to aglycone in Euglena gracilis is possibly a pyrophosphate linkage.
deoxycholate,Deoxycholate is used as a component of extracts from Euglena gracilis to solubilize glucosyltransferase activity.,Entity: deoxycholate. SMILES: C[C@H](CCC(=O)[O-])[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Deoxycholate is used as a component of extracts from Euglena gracilis to solubilize glucosyltransferase activity.
glucose,Glucose is transferred from UDP-[14C]glucose to a protein-linked beta-(1→3)-glucan oligosaccharide in Euglena gracilis by glucosyltransferase activity.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is transferred from UDP-[14C]glucose to a protein-linked beta-(1→3)-glucan oligosaccharide in Euglena gracilis by glucosyltransferase activity.
sodium deoxycholate,Sodium deoxycholate is used to extract glucosyltransferase activity from Euglena gracilis.,Entity: sodium deoxycholate. SMILES: C[C@H](CCC(=O)[O-])[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C.[Na+]. Sodium deoxycholate is used to extract glucosyltransferase activity from Euglena gracilis.
trichloroacetic acid,Trichloroacetic acid is used to precipitate material containing beta-(1→3)-glucan oligosaccharides released from glucan-protein conjugates in Euglena gracilis.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to precipitate material containing beta-(1→3)-glucan oligosaccharides released from glucan-protein conjugates in Euglena gracilis.
laminaribiose,"Laminaribiose can be released from certain enzyme-synthesized materials after prolonged storage at 4°C, as detected by electrophoresis at pH 2.0.","Entity: laminaribiose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](CO)OC(O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O. Laminaribiose can be released from certain enzyme-synthesized materials after prolonged storage at 4°C, as detected by electrophoresis at pH 2.0."
trehalose,"Trehalose can be released from certain enzyme-synthesized materials after prolonged storage at 4°C, as detected by electrophoresis at pH 2.0.","Entity: trehalose. SMILES: O=P([O-])([O-])OC[C@H]1OC(OC2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O. Trehalose can be released from certain enzyme-synthesized materials after prolonged storage at 4°C, as detected by electrophoresis at pH 2.0."
pyrophosphate,"Pyrophosphate forms an extremely alkali-labile bond with aglycone-glucan linkages, making it sensitive to acid.","Entity: pyrophosphate. SMILES: O=P([O-])([O-])OP(=O)([O-])[O-]. Pyrophosphate forms an extremely alkali-labile bond with aglycone-glucan linkages, making it sensitive to acid."
serine,Glycosidic linkages to serine are not as resistant to alkali hydrolysis as the aglycone-glucan bond in paramylon.,Entity: serine. SMILES: N[C@@H](CO)C(=O)O. Glycosidic linkages to serine are not as resistant to alkali hydrolysis as the aglycone-glucan bond in paramylon.
threonine,Glycosidic linkages to threonine are not as resistant to alkali hydrolysis as the aglycone-glucan bond in paramylon.,Entity: threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. Glycosidic linkages to threonine are not as resistant to alkali hydrolysis as the aglycone-glucan bond in paramylon.
sodium hydroxide,Sodium hydroxide is used in mild alkaline hydrolysis at 0.07 M concentration and pH 12.5 to hydrolyze membrane extract material at room temperature for 5 minutes.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used in mild alkaline hydrolysis at 0.07 M concentration and pH 12.5 to hydrolyze membrane extract material at room temperature for 5 minutes.
butanol,Butanol is used as a solvent containing 6% trichloroacetic acid for terminating mild alkaline hydrolysis reactions by precipitating proteins.,Entity: butanol. SMILES: CCCCO. Butanol is used as a solvent containing 6% trichloroacetic acid for terminating mild alkaline hydrolysis reactions by precipitating proteins.
trichloroacetic acid,Trichloroacetic acid is used at 6% concentration in butanol to precipitate proteins after mild alkaline hydrolysis.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used at 6% concentration in butanol to precipitate proteins after mild alkaline hydrolysis.
hydrochloric acid,Hydrochloric acid is used at 0.1 M concentration to perform mild acid hydrolysis at 100°C for 10 minutes.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used at 0.1 M concentration to perform mild acid hydrolysis at 100°C for 10 minutes.
sodium phosphate,Sodium phosphate at 10 mM concentration and pH 7.4 is used as a buffer for dialysis in transglucosylase activity assays.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate at 10 mM concentration and pH 7.4 is used as a buffer for dialysis in transglucosylase activity assays.
KCI,KCl at 1.5 M concentration is included in the detergent suspension for homogenizing samples in transglucosylase activity assays.,Entity: KCI. SMILES: [Cl-].[K+]. KCl at 1.5 M concentration is included in the detergent suspension for homogenizing samples in transglucosylase activity assays.
EDTA,EDTA at 1 mM concentration is included in the dialysis buffer for transglucosylase activity assays.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA at 1 mM concentration is included in the dialysis buffer for transglucosylase activity assays.
sodium deoxycholate,Sodium deoxycholate at 0.8% concentration is used as a detergent in the homogenization buffer for transglucosylase activity assays.,Entity: sodium deoxycholate. SMILES: C[C@H](CCC(=O)[O-])[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C.[Na+]. Sodium deoxycholate at 0.8% concentration is used as a detergent in the homogenization buffer for transglucosylase activity assays.
MgCl2,MgCl2 at 1 mM concentration is included in the detergent suspension for homogenizing samples in transglucosylase activity assays.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 at 1 mM concentration is included in the detergent suspension for homogenizing samples in transglucosylase activity assays.
ethyl acetate,"Ethyl acetate is used as a component of the ethyl acetate/pyridine/water (8:2:1, by volume) solvent system for paper chromatography of monosaccharides.","Entity: ethyl acetate. SMILES: CCOC(C)=O. Ethyl acetate is used as a component of the ethyl acetate/pyridine/water (8:2:1, by volume) solvent system for paper chromatography of monosaccharides."
glucose,"Glucose can be separated from erythritol and glycerol by paper chromatography using an ethyl acetate/pyridine/water (8:2:1, by volume) solvent system.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose can be separated from erythritol and glycerol by paper chromatography using an ethyl acetate/pyridine/water (8:2:1, by volume) solvent system."
sodium hydroxide,Sodium hydroxide is used to make the sodium borohydride solution alkaline during the reduction step in polysaccharide hydrolysis.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to make the sodium borohydride solution alkaline during the reduction step in polysaccharide hydrolysis.
glycerol,"Glycerol can be separated from glucose by paper chromatography using an ethyl acetate/pyridine/water (8:2:1, by volume) solvent system.","Entity: glycerol. SMILES: OCC(O)CO. Glycerol can be separated from glucose by paper chromatography using an ethyl acetate/pyridine/water (8:2:1, by volume) solvent system."
water,"Water is used as a component of the ethyl acetate/pyridine/water (8:2:1, by volume) solvent system for paper chromatography of monosaccharides.","Entity: water. SMILES: O. Water is used as a component of the ethyl acetate/pyridine/water (8:2:1, by volume) solvent system for paper chromatography of monosaccharides."
erythritol,"Erythritol can be separated from glucose and glycerol by paper chromatography using an ethyl acetate/pyridine/water (8:2:1, by volume) solvent system.","Entity: erythritol. SMILES: OC[C@@H](O)[C@@H](O)CO. Erythritol can be separated from glucose and glycerol by paper chromatography using an ethyl acetate/pyridine/water (8:2:1, by volume) solvent system."
sodium metaperiodate,Sodium metaperiodate is used as an oxidizing agent to convert polysaccharides to their constituent monosaccharides in the presence of membrane extracts.,Entity: sodium metaperiodate. SMILES: [Na+].[O-][I+3]([O-])([O-])[O-]. Sodium metaperiodate is used as an oxidizing agent to convert polysaccharides to their constituent monosaccharides in the presence of membrane extracts.
sodium borohydride,Sodium borohydride is used as a reducing agent to convert the oxidized monosaccharides back to their original form during the hydrolysis of polysaccharide extracts.,Entity: sodium borohydride. SMILES: [BH4-].[Na+]. Sodium borohydride is used as a reducing agent to convert the oxidized monosaccharides back to their original form during the hydrolysis of polysaccharide extracts.
sulfuric acid,Sulfuric acid is used to hydrolyze the polysaccharide hydrolysate at 103 kPa and 120°C for 1 hour.,Entity: sulfuric acid. SMILES: O=S(=O)(O)O. Sulfuric acid is used to hydrolyze the polysaccharide hydrolysate at 103 kPa and 120°C for 1 hour.
pyridine,"Pyridine is used as a component of the ethyl acetate/pyridine/water (8:2:1, by volume) solvent system for paper chromatography of monosaccharides.","Entity: pyridine. SMILES: c1ccncc1. Pyridine is used as a component of the ethyl acetate/pyridine/water (8:2:1, by volume) solvent system for paper chromatography of monosaccharides."
laminaribiose,Laminaribiose is present in equal amounts with laminaritriose and glucose in the solubilized material after enzymatic treatment with LI Cytophaga glucosidase.,Entity: laminaribiose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](CO)OC(O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O. Laminaribiose is present in equal amounts with laminaritriose and glucose in the solubilized material after enzymatic treatment with LI Cytophaga glucosidase.
sodium borate,Sodium borate is used as a buffer for electrophoresis to analyze the composition of solubilized polysaccharides.,Entity: sodium borate. SMILES: [Na+].[Na+].[Na+].[O-]B([O-])[O-]. Sodium borate is used as a buffer for electrophoresis to analyze the composition of solubilized polysaccharides.
glucose,Glucose is present in equal amounts with laminaritriose and laminaribiose in the solubilized material after enzymatic treatment with LI Cytophaga glucosidase.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is present in equal amounts with laminaritriose and laminaribiose in the solubilized material after enzymatic treatment with LI Cytophaga glucosidase.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used to extract soluble radioactive components from incubation mixtures for subsequent polyacrylamide-gel electrophoresis analysis.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used to extract soluble radioactive components from incubation mixtures for subsequent polyacrylamide-gel electrophoresis analysis.
hydrochloric acid,Hydrochloric acid (0.1 M) is used to rehydrate dried gel discs prior to protein solubilization and analysis by diffusion methods.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (0.1 M) is used to rehydrate dried gel discs prior to protein solubilization and analysis by diffusion methods.
sodium hydroxide,Sodium hydroxide is used as a desiccant over which dried gel discs are stored to prevent rehydration during sample preparation.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used as a desiccant over which dried gel discs are stored to prevent rehydration during sample preparation.
water,Water is used to rehydrate gel discs and to facilitate diffusion of soluble material from gel slices during protein solubilization protocols.,Entity: water. SMILES: O. Water is used to rehydrate gel discs and to facilitate diffusion of soluble material from gel slices during protein solubilization protocols.
glucose,Glucose is produced quantitatively from solubilized material treated with LI Cyto-phaga glucosidase.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is produced quantitatively from solubilized material treated with LI Cyto-phaga glucosidase.
laminaribiose,Laminaribiose is generated quantitatively from solubilized material treated with LI Cyto-phaga glucosidase.,Entity: laminaribiose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](CO)OC(O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O. Laminaribiose is generated quantitatively from solubilized material treated with LI Cyto-phaga glucosidase.
sodium phosphate,Sodium phosphate buffer at pH 7.0 at room temperature (21°C) for 5 minutes does not release significant material from the radioactive glucan fraction.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate buffer at pH 7.0 at room temperature (21°C) for 5 minutes does not release significant material from the radioactive glucan fraction.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used at a final concentration of 2% in buffer for solubilizing membrane extract proteins prior to gel filtration.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used at a final concentration of 2% in buffer for solubilizing membrane extract proteins prior to gel filtration.
phosphate,Phosphate is used at a final concentration of 20 mM and pH 7.4 in the buffer for both solubilization and gel filtration of membrane proteins.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate is used at a final concentration of 20 mM and pH 7.4 in the buffer for both solubilization and gel filtration of membrane proteins.
glucose,Glucose can be labeled with a radioactive isotope such as 4C to facilitate its detection in biochemical assays.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose can be labeled with a radioactive isotope such as 4C to facilitate its detection in biochemical assays.
laminarin,Laminarin is a series of oligosaccharides composed of at least 25 glucose units as determined by periodate oxidation.,Entity: laminarin. SMILES: OC[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@@H](O)O[C@H](CO)[C@H]3O)O[C@H](CO)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O. Laminarin is a series of oligosaccharides composed of at least 25 glucose units as determined by periodate oxidation.
glucose,"Glucose is covalently linked to a radioactive glucan in the insoluble fraction, and this bond is labile under mild acid hydrolysis conditions.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is covalently linked to a radioactive glucan in the insoluble fraction, and this bond is labile under mild acid hydrolysis conditions."
Sodium dodecyl sulphate,"Sodium dodecyl sulphate binds to glycoprotein components with molecular weights of at least 180000, which can increase the molecular weight of the complex by up to 40%.","Entity: Sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate binds to glycoprotein components with molecular weights of at least 180000, which can increase the molecular weight of the complex by up to 40%."
cyanocobalamin,Cyanocobalamin (vitamin B12) is used as a supplement in Euglena gracilis culture media at a concentration of 10 µg per litre.,Entity: cyanocobalamin. SMILES: C/C1=C2/N=C(/C=C3\N/C(=C(/C)C4=N[C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)(O)O[C@H]1[C@@H](O)[C@@H]([n+]6c[nH]c7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(=N)[O-])[C@@](C)(CC(N)=O)[C@@H]3CCC(=N)[O-])C(C)(C)[C@@H]2CCC(=N)[O-].[C]#N.[Co+2]. Cyanocobalamin (vitamin B12) is used as a supplement in Euglena gracilis culture media at a concentration of 10 µg per litre.
glucose,Glucose is used as a carbon source in Euglena gracilis culture media at a concentration of 15 g per litre.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is used as a carbon source in Euglena gracilis culture media at a concentration of 15 g per litre.
sodium borate,Sodium borate is used as a buffer for electrophoresis analysis of carbohydrate hydrolysates.,Entity: sodium borate. SMILES: [Na+].[Na+].[Na+].[O-]B([O-])[O-]. Sodium borate is used as a buffer for electrophoresis analysis of carbohydrate hydrolysates.
HCO3,HCO3- (bicarbonate) is used as an anion-exchange resin to deionize carbohydrate hydrolysates during sample preparation.,Entity: HCO3. SMILES: O=C([O-])O. HCO3- (bicarbonate) is used as an anion-exchange resin to deionize carbohydrate hydrolysates during sample preparation.
laminaribiose,Laminaribiose is a high-molecular-weight carbohydrate that can be detected in hydrolysates by electrophoresis in sodium borate and paper chromatography.,Entity: laminaribiose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](CO)OC(O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O. Laminaribiose is a high-molecular-weight carbohydrate that can be detected in hydrolysates by electrophoresis in sodium borate and paper chromatography.
glucose,Glucose is a high-molecular-weight carbohydrate that can be detected in hydrolysates by electrophoresis in sodium borate and paper chromatography.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is a high-molecular-weight carbohydrate that can be detected in hydrolysates by electrophoresis in sodium borate and paper chromatography.
HCl,HCl is used to acidify high-molecular-weight materials for subsequent enzymatic hydrolysis in carbohydrate analysis.,Entity: HCl. SMILES: Cl. HCl is used to acidify high-molecular-weight materials for subsequent enzymatic hydrolysis in carbohydrate analysis.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used as a detergent in membrane protein solubilization and in sodium dodecyl sulphate/polyacrylamide gel electrophoresis to separate proteins based on molecular weight.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used as a detergent in membrane protein solubilization and in sodium dodecyl sulphate/polyacrylamide gel electrophoresis to separate proteins based on molecular weight.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used as an anionic detergent in biochemical electrophoresis to solubilize proteins and nucleic acids.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used as an anionic detergent in biochemical electrophoresis to solubilize proteins and nucleic acids.
glucose,"Glucose can be linked to aglycones via a bond to form oligosaccharides, such as dolichyl phosphate glucose, which can be separated by sodium dodecyl sulphate/polyacrylamide-gel electrophoresis.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose can be linked to aglycones via a bond to form oligosaccharides, such as dolichyl phosphate glucose, which can be separated by sodium dodecyl sulphate/polyacrylamide-gel electrophoresis."
acetic acid,Acetic acid is used as a component of the buffer system at 8% (v/v) concentration in sodium tetraborate buffer for electrophoretic separation of sugar phosphates.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component of the buffer system at 8% (v/v) concentration in sodium tetraborate buffer for electrophoretic separation of sugar phosphates.
formic acid,Formic acid is used at 2% (v/v) concentration in combination with acetic acid in a sodium tetraborate buffer for electrophoretic separation of sugar phosphates.,Entity: formic acid. SMILES: O=CO. Formic acid is used at 2% (v/v) concentration in combination with acetic acid in a sodium tetraborate buffer for electrophoretic separation of sugar phosphates.
sodium tetraborate,Sodium tetraborate is used as a buffer at 19 g/L and pH 9.4 for electrophoretic separation of UDP-['4C]glucose sugars and sugar phosphates.,Entity: sodium tetraborate. SMILES: [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-]. Sodium tetraborate is used as a buffer at 19 g/L and pH 9.4 for electrophoretic separation of UDP-['4C]glucose sugars and sugar phosphates.
sodium phosphate,"Sodium phosphate is used as a buffer at concentrations of 0.1 M and 0.2 M and pH 7.0, 7.2, 7.4, and 8.9 for enzymatic incubations at 25°C.","Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used as a buffer at concentrations of 0.1 M and 0.2 M and pH 7.0, 7.2, 7.4, and 8.9 for enzymatic incubations at 25°C."
acetic acid,Acetic acid is used in combination with sodium phosphate to form a buffer at pH 5.0 for enzymatic reactions at 37°C.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used in combination with sodium phosphate to form a buffer at pH 5.0 for enzymatic reactions at 37°C.
hydrochloric acid,Hydrochloric acid at 0.1 M concentration is used for mild acid hydrolysis at 100°C for 10 minutes to release labelled material from samples.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid at 0.1 M concentration is used for mild acid hydrolysis at 100°C for 10 minutes to release labelled material from samples.
toluene,Toluene is used as a solvent to prevent bacterial hydrolytic activity during enzymatic incubations.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a solvent to prevent bacterial hydrolytic activity during enzymatic incubations.
"2,5-diphenyloxazole","2,5-diphenyloxazole is used as a fluor at a concentration of 2.67 g/L in radioactivity counting experiments.","Entity: 2,5-diphenyloxazole. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. 2,5-diphenyloxazole is used as a fluor at a concentration of 2.67 g/L in radioactivity counting experiments."
"1,4-bis-(5-phenyloxazol-2-yl)benzene","1,4-bis-(5-phenyloxazol-2-yl)benzene is used as a fluor at a concentration of 33.3 mg/L in radioactivity counting experiments.","Entity: 1,4-bis-(5-phenyloxazol-2-yl)benzene. SMILES: c1ccc(-c2cnc(-c3ccc(-c4ncc(-c5ccccc5)o4)cc3)o2)cc1. 1,4-bis-(5-phenyloxazol-2-yl)benzene is used as a fluor at a concentration of 33.3 mg/L in radioactivity counting experiments."
hydrogen peroxide,Hydrogen peroxide is used to oxidize and destroy cross-linked gel in gel slice solubilization protocols.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide is used to oxidize and destroy cross-linked gel in gel slice solubilization protocols.
glucose,"Glucose can serve as a substrate for transglycosylase-catalyzed synthesis of paramylon, as evidenced by the incorporation of [14C]glucose into polysaccharide fractions.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose can serve as a substrate for transglycosylase-catalyzed synthesis of paramylon, as evidenced by the incorporation of [14C]glucose into polysaccharide fractions."
sodium dodecyl sulphate,"Sodium dodecyl sulphate can be present in hydrolysates of polysaccharide fractions, complicating the removal of interfering anions during analysis.","Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate can be present in hydrolysates of polysaccharide fractions, complicating the removal of interfering anions during analysis."
trichloroacetic acid,Trichloroacetic acid is used for precipitation of oligosaccharide phosphate from Millipore filters in polysaccharide analysis.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used for precipitation of oligosaccharide phosphate from Millipore filters in polysaccharide analysis.
trichloroacetic acid,Trichloroacetic acid is used to precipitate material containing glucan oligosaccharides released from a protein-glucan intermediate during paramylon synthesis in Euglena gracilis.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to precipitate material containing glucan oligosaccharides released from a protein-glucan intermediate during paramylon synthesis in Euglena gracilis.
pyrophosphate,A pyrophosphate linkage is proposed to link glucan to aglycone in the protein-glucan intermediate during paramylon synthesis in Euglena gracilis.,Entity: pyrophosphate. SMILES: O=P([O-])([O-])OP(=O)([O-])[O-]. A pyrophosphate linkage is proposed to link glucan to aglycone in the protein-glucan intermediate during paramylon synthesis in Euglena gracilis.
sodium deoxycholate,"Sodium deoxycholate extract from Euglena gracilis contains glucosyltransferase activity that transfers glucose from UDP-glucose to protein, forming a protein-glucan intermediate during paramylon synthesis.","Entity: sodium deoxycholate. SMILES: C[C@H](CCC(=O)[O-])[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C.[Na+]. Sodium deoxycholate extract from Euglena gracilis contains glucosyltransferase activity that transfers glucose from UDP-glucose to protein, forming a protein-glucan intermediate during paramylon synthesis."
sodium dodecyl sulphate,Sodium dodecyl sulphate is used in sodium dodecyl sulphate/polyacrylamide-gel electrophoresis to analyze the products of deoxycholate extract with UDP-glucose during paramylon synthesis.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used in sodium dodecyl sulphate/polyacrylamide-gel electrophoresis to analyze the products of deoxycholate extract with UDP-glucose during paramylon synthesis.
glucose,Glucose is transferred from UDP-glucose to protein by glucosyltransferase activity in a sodium deoxycholate extract from Euglena gracilis during the synthesis of paramylon.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is transferred from UDP-glucose to protein by glucosyltransferase activity in a sodium deoxycholate extract from Euglena gracilis during the synthesis of paramylon.
ammonium phosphate,Ammonium phosphate (NH4)2HPO4 is used as a washing buffer at 2.2% (w/v) and pH 7.9 in cell pellet preparation for enzymatic assays.,Entity: ammonium phosphate. SMILES: O=P([O-])([O-])[O-].[NH4+].[NH4+].[NH4+]. Ammonium phosphate (NH4)2HPO4 is used as a washing buffer at 2.2% (w/v) and pH 7.9 in cell pellet preparation for enzymatic assays.
laminaribiose,"Laminaribiose can be identified in hydrolysates of components A, B, and C by electrophoresis and paper chromatography.","Entity: laminaribiose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](CO)OC(O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O. Laminaribiose can be identified in hydrolysates of components A, B, and C by electrophoresis and paper chromatography."
sodium borate,Sodium borate is used as a buffer for electrophoresis analysis of hydrolysates.,Entity: sodium borate. SMILES: [Na+].[Na+].[Na+].[O-]B([O-])[O-]. Sodium borate is used as a buffer for electrophoresis analysis of hydrolysates.
glucose,Glucose is present in hydrolysates from fractions E and F and can be identified by electrophoresis and paper chromatography.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is present in hydrolysates from fractions E and F and can be identified by electrophoresis and paper chromatography.
miconazole,"Miconazole, an imidazole drug, is effective in preventing death and restricting lung fungal replication and extrapulmonary dissemination in experimental lethal coccidioidomycosis of mice when administered intramuscularly.","Entity: miconazole. SMILES: Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1. Miconazole, an imidazole drug, is effective in preventing death and restricting lung fungal replication and extrapulmonary dissemination in experimental lethal coccidioidomycosis of mice when administered intramuscularly."
imidazole,"Imidazole drugs, such as miconazole and econazole, can be effective in preventing and treating coccidioidomycosis when administered intramuscularly, but are less effective orally compared to intramuscularly.","Entity: imidazole. SMILES: c1c[nH]cn1. Imidazole drugs, such as miconazole and econazole, can be effective in preventing and treating coccidioidomycosis when administered intramuscularly, but are less effective orally compared to intramuscularly."
dioxolane imidazole,"Dioxolane imidazole, exemplified by R34000, is highly effective in preventing lethal coccidioidomycosis in mice when administered orally, with plasma or serum concentrations exceeding the minimum inhibitory concentration against virulent Coccidioides immitis.","Entity: dioxolane imidazole. SMILES: C1COCO1.c1c[nH]cn1. Dioxolane imidazole, exemplified by R34000, is highly effective in preventing lethal coccidioidomycosis in mice when administered orally, with plasma or serum concentrations exceeding the minimum inhibitory concentration against virulent Coccidioides immitis."
econazole,"Econazole, an imidazole drug, is effective in preventing death and restricting lung fungal replication and extrapulmonary dissemination in experimental lethal coccidioidomycosis of mice when administered intramuscularly.","Entity: econazole. SMILES: Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1. Econazole, an imidazole drug, is effective in preventing death and restricting lung fungal replication and extrapulmonary dissemination in experimental lethal coccidioidomycosis of mice when administered intramuscularly."
ampicillin,Ampicillin is administered orally at 1 gram every four hours for the treatment of respiratory infections.,Entity: ampicillin. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O. Ampicillin is administered orally at 1 gram every four hours for the treatment of respiratory infections.
codeine,Codeine is administered orally at 30 mg every four hours for the relief of headache.,Entity: codeine. SMILES: COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341. Codeine is administered orally at 30 mg every four hours for the relief of headache.
tetracycline,Tetracycline is used as an antibiotic for the treatment of infections.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline is used as an antibiotic for the treatment of infections.
oxygen,Exposure to high concentrations of oxygen is detrimental to health.,Entity: oxygen. SMILES: [O]. Exposure to high concentrations of oxygen is detrimental to health.
paraquat,"In animal experiments, dipyridyl aerosols have been associated with progressive deterioration over several days, mimicking the pattern of Loffier's pneumonia.","Entity: paraquat. SMILES: C[n+]1ccc(-c2cc[n+](C)cc2)cc1. In animal experiments, dipyridyl aerosols have been associated with progressive deterioration over several days, mimicking the pattern of Loffier's pneumonia."
potassium,Serum potassium levels were elevated at 6.8 mEq/L in the context of extensive anterolateral myocardial infarction.,Entity: potassium. SMILES: [K]. Serum potassium levels were elevated at 6.8 mEq/L in the context of extensive anterolateral myocardial infarction.
creatinine,Serum creatinine levels were elevated at 3.4 mg/percent in the context of extensive anterolateral myocardial infarction.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Serum creatinine levels were elevated at 3.4 mg/percent in the context of extensive anterolateral myocardial infarction.
PARI,"The Parental Attitude Research Instrument (PARI) is used to assess the main factorial dimensions of adoptive parents' attitudes, which were found to be unrelated to children's performance on the Children's Embedded Figures Test.","Entity: PARI. The Parental Attitude Research Instrument (PARI) is used to assess the main factorial dimensions of adoptive parents' attitudes, which were found to be unrelated to children's performance on the Children's Embedded Figures Test."
sodium chloride,Sodium chloride is used as a component in the standard hepatocyte incubation medium at a concentration of 6.7 g per 1000 ml.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used as a component in the standard hepatocyte incubation medium at a concentration of 6.7 g per 1000 ml.
potassium chloride,Potassium chloride is included in the hepatocyte incubation medium at a concentration of 0.4 g per 1000 ml.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is included in the hepatocyte incubation medium at a concentration of 0.4 g per 1000 ml.
disodium phosphate,Disodium phosphate is used in the hepatocyte incubation medium at a concentration of 0.06 g per 1000 ml.,Entity: disodium phosphate. SMILES: O=P([O-])([O-])O.[Na+].[Na+]. Disodium phosphate is used in the hepatocyte incubation medium at a concentration of 0.06 g per 1000 ml.
potassium dihydrogen phosphate,Potassium dihydrogen phosphate is present in the hepatocyte incubation medium at a concentration of 0.06 g per 1000 ml.,Entity: potassium dihydrogen phosphate. SMILES: O=P([O-])(O)O.[K+]. Potassium dihydrogen phosphate is present in the hepatocyte incubation medium at a concentration of 0.06 g per 1000 ml.
sodium hydroxide,Sodium hydroxide is used to adjust the pH of the hepatocyte incubation medium to 7.5.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to adjust the pH of the hepatocyte incubation medium to 7.5.
calcium chloride,Calcium chloride is included in the hepatocyte incubation medium at a concentration of 0.2 g per 1000 ml.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride is included in the hepatocyte incubation medium at a concentration of 0.2 g per 1000 ml.
magnesium sulfate,Magnesium sulfate is used in the hepatocyte incubation medium at a concentration of 0.06 g per 1000 ml.,Entity: magnesium sulfate. SMILES: O=S(=O)([O-])[O-].[Mg+2]. Magnesium sulfate is used in the hepatocyte incubation medium at a concentration of 0.06 g per 1000 ml.
cholesterol,Cholesterol esterification in hepatocytes is independent of serum concentration between 25% and 75% (w/v) and is linear with time over 24 hours at 37°C.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol esterification in hepatocytes is independent of serum concentration between 25% and 75% (w/v) and is linear with time over 24 hours at 37°C.
Colchicine,Colchicine inhibits the secretion of lecithin:cholesterol acyltransferase from isolated rat hepatocytes.,Entity: Colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine inhibits the secretion of lecithin:cholesterol acyltransferase from isolated rat hepatocytes.
cholesterol,Unesterified cholesterol is secreted concurrently with lecithin:cholesterol acyltransferase from isolated rat hepatocytes.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Unesterified cholesterol is secreted concurrently with lecithin:cholesterol acyltransferase from isolated rat hepatocytes.
lecithin,"Lecithin:cholesterol acyltransferase is secreted from isolated rat hepatocytes, with secretion stimulated by serum and optimal conditions including 5–10µg hepatocytes per ml, 5 h incubation, pH 7.3–7.4, and 25% serum in the medium.","Entity: lecithin. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C. Lecithin:cholesterol acyltransferase is secreted from isolated rat hepatocytes, with secretion stimulated by serum and optimal conditions including 5–10µg hepatocytes per ml, 5 h incubation, pH 7.3–7.4, and 25% serum in the medium."
lecithin,Lecithin stimulates the activity of lecithin:cholesterol acyltransferase in vitro.,Entity: lecithin. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C. Lecithin stimulates the activity of lecithin:cholesterol acyltransferase in vitro.
cholesterol,"Cholesterol is a substrate for lecithin:cholesterol acyltransferase, whose activity is stimulated by lecithin and other factors.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is a substrate for lecithin:cholesterol acyltransferase, whose activity is stimulated by lecithin and other factors."
cholesterol,Cholesterol is a chemical compound with a specific activity of 12.6 Ci/mmol.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is a chemical compound with a specific activity of 12.6 Ci/mmol.
cholesterol,Cholesterol secretion from rat liver is stimulated by increasing serum concentration in the medium.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol secretion from rat liver is stimulated by increasing serum concentration in the medium.
lecithin,"The secretion of 1ecithin:cholesterol acyltransferase, cholesterol, and triacylglycerol from rat liver shows a similar relationship to serum concentration in the medium, suggesting a possible association between acyltransferase and lipoproteins during secretion.","Entity: lecithin. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C. The secretion of 1ecithin:cholesterol acyltransferase, cholesterol, and triacylglycerol from rat liver shows a similar relationship to serum concentration in the medium, suggesting a possible association between acyltransferase and lipoproteins during secretion."
Lecithin:cholesterol acyltransferase,The secretion of lecithin:cholesterol acyltransferase from rat hepatocytes is inhibited by colchicine or cycloheximide in the incubation medium.,Entity: Lecithin:cholesterol acyltransferase. The secretion of lecithin:cholesterol acyltransferase from rat hepatocytes is inhibited by colchicine or cycloheximide in the incubation medium.
Lecithin:cholesterol acyltransferase,"Lecithin:cholesterol acyltransferase is secreted from isolated rat hepatocytes, with secretion stimulated by serum and optimal conditions including 5–10µ hepatocytes per ml, 5 h incubation, pH 7.3–7.4, and 25% serum in the medium.","Entity: Lecithin:cholesterol acyltransferase. Lecithin:cholesterol acyltransferase is secreted from isolated rat hepatocytes, with secretion stimulated by serum and optimal conditions including 5–10µ hepatocytes per ml, 5 h incubation, pH 7.3–7.4, and 25% serum in the medium."
chlorophyll-a,Chlorophyll-a can be purified and isolated from Porphyra yezoensis without the need for chromatographic procedures.,Entity: chlorophyll-a. SMILES: C=CC1=C(C)C2=NC1=CC1=NC(=Cc3[n-]c4c(c3C)=C([O-])[C@H](C(=O)OC)C=4C3=NC(=C2)[C@@H](C)[C@@H]3CCC(=O)OC/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(CC)=C1C.[Mg+2]. Chlorophyll-a can be purified and isolated from Porphyra yezoensis without the need for chromatographic procedures.
chlorophyll-a,"Chlorophyll-a preparations obtained from Porphyra yezoensis by the described method do not contain other photosynthetic pigments or their degradation products, as confirmed by thin-layer and high-performance liquid chromatography.","Entity: chlorophyll-a. SMILES: C=CC1=C(C)C2=NC1=CC1=NC(=Cc3[n-]c4c(c3C)=C([O-])[C@H](C(=O)OC)C=4C3=NC(=C2)[C@@H](C)[C@@H]3CCC(=O)OC/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(CC)=C1C.[Mg+2]. Chlorophyll-a preparations obtained from Porphyra yezoensis by the described method do not contain other photosynthetic pigments or their degradation products, as confirmed by thin-layer and high-performance liquid chromatography."
ammonium,"In the presence of high ammonium levels, alternative pathways for ammonium assimilation such as those involving glutamate dehydrogenase and alanine dehydrogenase are not important for primary ammonium assimilation.","Entity: ammonium. SMILES: [NH4+]. In the presence of high ammonium levels, alternative pathways for ammonium assimilation such as those involving glutamate dehydrogenase and alanine dehydrogenase are not important for primary ammonium assimilation."
glutamine,"Exogenous glutamine supplementation can support algal growth even in the presence of HYL, indicating that glutamine provides an alternative carbon source when primary ammonium assimilation is blocked.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Exogenous glutamine supplementation can support algal growth even in the presence of HYL, indicating that glutamine provides an alternative carbon source when primary ammonium assimilation is blocked."
ammonium,"Ammonium (NH4+) is involved in primary nitrogen assimilation in certain algal cultures, as its production is inhibited by HYL and its assimilation is not dependent on glutamate dehydrogenase or alanine dehydrogenase.","Entity: ammonium. SMILES: [NH4+]. Ammonium (NH4+) is involved in primary nitrogen assimilation in certain algal cultures, as its production is inhibited by HYL and its assimilation is not dependent on glutamate dehydrogenase or alanine dehydrogenase."
ammonium,"In Anabaena cylindrica, extracellular ammonium production occurs when Hyl is added, indicating that Hyl blocks the primary route of ammonium assimilation, leading to the release of intracellularly stored ammonium.","Entity: ammonium. SMILES: [NH4+]. In Anabaena cylindrica, extracellular ammonium production occurs when Hyl is added, indicating that Hyl blocks the primary route of ammonium assimilation, leading to the release of intracellularly stored ammonium."
glutamate,"In the absence of reactivation, the intracellular free glutamate pool decreases to 60% of its original level after 24 hours in the untreated control series.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. In the absence of reactivation, the intracellular free glutamate pool decreases to 60% of its original level after 24 hours in the untreated control series."
ammonium,The proportion of total nitrogen fixed by Anabaena cylindrica that is released as extracellular NH4+ increases from 37% at 25 PM HYL to 91% at 500 PM HYL.,Entity: ammonium. SMILES: [NH4+]. The proportion of total nitrogen fixed by Anabaena cylindrica that is released as extracellular NH4+ increases from 37% at 25 PM HYL to 91% at 500 PM HYL.
chlorophyll,Chlorophyll concentrations can be measured in axenic batch culture of cyanobacteria under continuous light at 3 m lux and 26°C.,Entity: chlorophyll. SMILES: C=CC1=C(C)C2=NC1=CC1=NC(=Cc3[n-]c4c(c3C)=C([O-])C(C(=O)OC)C=4C3=NC(=C2)C(C)C3CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C(CC)=C1C.[Mg+2]. Chlorophyll concentrations can be measured in axenic batch culture of cyanobacteria under continuous light at 3 m lux and 26°C.
ammonia,Ammonia can be assayed in biological studies using a method described by Solorzano.,Entity: ammonia. SMILES: N. Ammonia can be assayed in biological studies using a method described by Solorzano.
glutamine,Glutamine inhibits heterocyst production and nitrogenase activity.,Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine inhibits heterocyst production and nitrogenase activity.
glutamine,"Glutamine production can be inhibited by HYL, which prevents inhibition of nitrogenase activity and heterocyst development by glutamine.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine production can be inhibited by HYL, which prevents inhibition of nitrogenase activity and heterocyst development by glutamine."
glutamine,"Glutamine allows growth in the presence of HYL, resulting in decreased NH4 production.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine allows growth in the presence of HYL, resulting in decreased NH4 production."
sodium hydroxide,"Sodium hydroxide is used in a C-band staining procedure to identify constitutive heterochromatic segments in meiotic chromosomes, with a typical treatment duration of 20–30 seconds in 0.01 N concentration.","Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used in a C-band staining procedure to identify constitutive heterochromatic segments in meiotic chromosomes, with a typical treatment duration of 20–30 seconds in 0.01 N concentration."
thymidine,"Thymidine can be used as a radiolabeling agent in tissue preparations, incorporated as 3H-thymidine at a specific activity of 17.7 Ci/mM and a concentration of 0.5 Ci/ml for 5-minute incubation.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine can be used as a radiolabeling agent in tissue preparations, incorporated as 3H-thymidine at a specific activity of 17.7 Ci/mM and a concentration of 0.5 Ci/ml for 5-minute incubation."
thymidine,"Thymidine is used as a radiolabel in cell culture assays, with a specific activity of 4.6 Ci/mM (1 gCi/ml) for incorporation studies.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine is used as a radiolabel in cell culture assays, with a specific activity of 4.6 Ci/mM (1 gCi/ml) for incorporation studies."
colchicine,Colchicine is used at a concentration of 0.5 µg/ml to treat cells prior to fixation in cytogenetic experiments.,Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine is used at a concentration of 0.5 µg/ml to treat cells prior to fixation in cytogenetic experiments.
potassium chloride,Potassium chloride is used as a hypotonic solution in cell culture protocols.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is used as a hypotonic solution in cell culture protocols.
methanol,Methanol is used in a 3:1 mixture with acetic acid to fix cells in cytogenetic procedures.,Entity: methanol. SMILES: CO. Methanol is used in a 3:1 mixture with acetic acid to fix cells in cytogenetic procedures.
acetic acid,Acetic acid is used in a 3:1 mixture with methanol to fix cells in cytogenetic experiments.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used in a 3:1 mixture with methanol to fix cells in cytogenetic experiments.
colchicine,Colchicine is used at a concentration of 0.5 µg/ml to treat cells one hour before fixation in cell culture experiments.,Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine is used at a concentration of 0.5 µg/ml to treat cells one hour before fixation in cell culture experiments.
acetic acid,Acetic acid is used as a component of a methanol-acetic acid mixture (3:1) for cell fixation in primary fibroblast cultures.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component of a methanol-acetic acid mixture (3:1) for cell fixation in primary fibroblast cultures.
methanol,Methanol is used in combination with acetic acid (3:1) as a fixative for cells in primary fibroblast cultures.,Entity: methanol. SMILES: CO. Methanol is used in combination with acetic acid (3:1) as a fixative for cells in primary fibroblast cultures.
sodium citrate,Sodium citrate (1% solution) is used as a hypotonic solution for cell permeabilization during fixation procedures.,Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate (1% solution) is used as a hypotonic solution for cell permeabilization during fixation procedures.
thymidine,"3H-thymidine is used as a radiolabel in cell culture experiments, with a specific activity of 4.6 Ci/mM.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. 3H-thymidine is used as a radiolabel in cell culture experiments, with a specific activity of 4.6 Ci/mM."
ecdysone,The expression of Balbiani rings in C. thummi is apparently dependent on ecdysone titer in the haemolymph.,Entity: ecdysone. SMILES: C[C@H]([C@H](O)CCC(C)(C)O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C. The expression of Balbiani rings in C. thummi is apparently dependent on ecdysone titer in the haemolymph.
toluidine blue,Toluidine blue is used as a staining agent for cytological examination of in situ hybridization slides.,Entity: toluidine blue. SMILES: Cc1ccc(Nc2ccc(O)c3c2C(=O)c2c(O)ccc(Nc4ccc(C)cc4S(=O)(=O)[O-])c2C3=O)c(S(=O)(=O)[O-])c1.[Na+].[Na+]. Toluidine blue is used as a staining agent for cytological examination of in situ hybridization slides.
SDS,SDS is used in a pronase-SDS mixture to digest RNA from microisolated brain regions for in situ hybridization protocols.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used in a pronase-SDS mixture to digest RNA from microisolated brain regions for in situ hybridization protocols.
cytidine,Cytidine is incorporated at least twice as much as uridine into Balbiani Ring 2 RNA in Chironomus salivary gland chromosomes.,Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine is incorporated at least twice as much as uridine into Balbiani Ring 2 RNA in Chironomus salivary gland chromosomes.
uridine,Uridine is incorporated at least twice as much as cytidine into Balbiani Ring 2 RNA in Chironomus salivary gland chromosomes.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine is incorporated at least twice as much as cytidine into Balbiani Ring 2 RNA in Chironomus salivary gland chromosomes.
urea,Urea is used at a concentration of 4 M in agarose gels for RNA fractionation in molecular weight analysis.,Entity: urea. SMILES: NC(N)=O. Urea is used at a concentration of 4 M in agarose gels for RNA fractionation in molecular weight analysis.
methylene blue,Methylene blue is used as a staining agent for RNA gels.,Entity: methylene blue. SMILES: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.[Cl-]. Methylene blue is used as a staining agent for RNA gels.
formamide,"Formamide is used as a buffer component at 90% concentration, buffered with 0.01 M Tris, 1% SDS, and 10 mM EDTA to pH 7.4, for formamide treatment of RNA at 37°C for 15 minutes.","Entity: formamide. SMILES: NC=O. Formamide is used as a buffer component at 90% concentration, buffered with 0.01 M Tris, 1% SDS, and 10 mM EDTA to pH 7.4, for formamide treatment of RNA at 37°C for 15 minutes."
SDS,"SDS (sodium dodecyl sulfate) is used at 1% concentration in Tris-buffer (10 mM Tris, pH 7.4, 1% SDS, 5 mM EDTA) for heating RNA samples at 65°C for 2 minutes.","Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS (sodium dodecyl sulfate) is used at 1% concentration in Tris-buffer (10 mM Tris, pH 7.4, 1% SDS, 5 mM EDTA) for heating RNA samples at 65°C for 2 minutes."
NaCl,"NaCl is used at 0.2 M concentration in 8 M urea, 0.02 M Tris (pH 8.0), and 2 mM EDTA for urea treatment of RNA at 65°C for 2 minutes.","Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used at 0.2 M concentration in 8 M urea, 0.02 M Tris (pH 8.0), and 2 mM EDTA for urea treatment of RNA at 65°C for 2 minutes."
Tris,"Tris is used as a buffer at 10 mM concentration, pH 7.4, in both formamide and urea treatment protocols for RNA.","Entity: Tris. SMILES: NC(CO)(CO)CO. Tris is used as a buffer at 10 mM concentration, pH 7.4, in both formamide and urea treatment protocols for RNA."
toluene,Toluene is used as a solvent for suspending RNA slices after scintillation counting.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a solvent for suspending RNA slices after scintillation counting.
ethanol,Ethanol is used to precipitate urea before deionization by stirring in Dowex prior to use in RNA treatment protocols.,Entity: ethanol. SMILES: CCO. Ethanol is used to precipitate urea before deionization by stirring in Dowex prior to use in RNA treatment protocols.
sucrose,Sucrose is used as a RNase-free component in RNA sample preparation and as a buffer in electrophoresis.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used as a RNase-free component in RNA sample preparation and as a buffer in electrophoresis.
urea,"Urea is used at 8 M concentration, with 0.02 M Tris (pH 8.0), 0.2 M NaCl, and 2 mM EDTA, for RNA treatment at 65°C for 2 minutes.","Entity: urea. SMILES: NC(N)=O. Urea is used at 8 M concentration, with 0.02 M Tris (pH 8.0), 0.2 M NaCl, and 2 mM EDTA, for RNA treatment at 65°C for 2 minutes."
EDTA,EDTA is used at 5 mM concentration in Tris-SDS buffer for RNA heating and at 2 mM concentration in urea buffer for RNA treatment.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used at 5 mM concentration in Tris-SDS buffer for RNA heating and at 2 mM concentration in urea buffer for RNA treatment.
ecdysone,"Ecdysone is a hormone that affects the BR 1 protein in C. tentans salivary gland chromosomes, as indicated by its sensitivity in this system.","Entity: ecdysone. SMILES: C[C@H]([C@H](O)CCC(C)(C)O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C. Ecdysone is a hormone that affects the BR 1 protein in C. tentans salivary gland chromosomes, as indicated by its sensitivity in this system."
uridine,"Uridine can be used as a radioactive label in insect tissues, such as salivary glands, for cytological and biochemical studies.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine can be used as a radioactive label in insect tissues, such as salivary glands, for cytological and biochemical studies."
cytidine,"Cytidine can be used as a radioactive label in insect tissues, such as salivary glands, for cytological and biochemical studies.","Entity: cytidine. SMILES: N=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Cytidine can be used as a radioactive label in insect tissues, such as salivary glands, for cytological and biochemical studies."
formamide,"Formamide is a well-known agent capable of dissociating nucleic acids, including RNA.","Entity: formamide. SMILES: NC=O. Formamide is a well-known agent capable of dissociating nucleic acids, including RNA."
urea,"Urea is a well-known agent capable of dissociating nucleic acids, including RNA.","Entity: urea. SMILES: NC(N)=O. Urea is a well-known agent capable of dissociating nucleic acids, including RNA."
formamide,Formamide is used in stepwise elution of bound RNA from poly (U) sepharose to provide information about the length and homogeneity of poly (A) sequences in RNA preparations.,Entity: formamide. SMILES: NC=O. Formamide is used in stepwise elution of bound RNA from poly (U) sepharose to provide information about the length and homogeneity of poly (A) sequences in RNA preparations.
urea,Urea is used at 8 M concentration in buffer to suspend and heat BR1 RNA for 2 minutes at 65°C prior to separation on a 4 M urea-agarose gel.,Entity: urea. SMILES: NC(N)=O. Urea is used at 8 M concentration in buffer to suspend and heat BR1 RNA for 2 minutes at 65°C prior to separation on a 4 M urea-agarose gel.
NaCl,NaCl is used at 0.4 M concentration in buffer to suspend BR1 RNA labeled for 3 hours and to wash RNA after filtration through poly (U) sepharose.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used at 0.4 M concentration in buffer to suspend BR1 RNA labeled for 3 hours and to wash RNA after filtration through poly (U) sepharose.
sodium dodecyl sulfate,Sodium dodecyl sulfate is used in a 3 min pronase-SDS digestion at room temperature to release RNA from 120 BRs in salivary gland cells.,Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate is used in a 3 min pronase-SDS digestion at room temperature to release RNA from 120 BRs in salivary gland cells.
diethylpyrocarbonate,Diethylpyrocarbonate is used at 0.1% concentration to treat extraction buffer for 2 hours at 37°C to prevent RNA degradation during RNA extraction procedures.,Entity: diethylpyrocarbonate. SMILES: CCOC(=O)OC(=O)OCC. Diethylpyrocarbonate is used at 0.1% concentration to treat extraction buffer for 2 hours at 37°C to prevent RNA degradation during RNA extraction procedures.
acetic acid,Acetic acid is used in a 1:1 ethanol/acetic acid mixture for fixation of salivary glands during RNA extraction.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used in a 1:1 ethanol/acetic acid mixture for fixation of salivary glands during RNA extraction.
SDS,SDS is used as a detergent at 0.5% concentration in a pronase-SDS solution for RNA digestion from Balbiani rings.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used as a detergent at 0.5% concentration in a pronase-SDS solution for RNA digestion from Balbiani rings.
Tris,Tris is used as a buffer at 0.02 M concentration and pH 7.4 in the pronase-SDS solution for RNA digestion from Balbiani rings.,Entity: Tris. SMILES: NC(CO)(CO)CO. Tris is used as a buffer at 0.02 M concentration and pH 7.4 in the pronase-SDS solution for RNA digestion from Balbiani rings.
ethanol,Ethanol is used as a component of fixation solutions (70% ethanol) and as a component of the glycerin/ethanol (1:1) solution for isolating Balbiani rings.,Entity: ethanol. SMILES: CCO. Ethanol is used as a component of fixation solutions (70% ethanol) and as a component of the glycerin/ethanol (1:1) solution for isolating Balbiani rings.
glycerin,Glycerin is used in combination with ethanol (1:1) as a solution for isolating Balbiani rings from chromosomes.,Entity: glycerin. SMILES: OCC(O)CO. Glycerin is used in combination with ethanol (1:1) as a solution for isolating Balbiani rings from chromosomes.
formamide,"Formamide at 25–50% concentration is used to elute RNA that binds tightly to poly(U) sepharose columns, with approximately 40% of nucleoplasmic RNA and 20% of cytoplasmic RNA being eluted in this manner.","Entity: formamide. SMILES: NC=O. Formamide at 25–50% concentration is used to elute RNA that binds tightly to poly(U) sepharose columns, with approximately 40% of nucleoplasmic RNA and 20% of cytoplasmic RNA being eluted in this manner."
3H-adenosine,3H-adenosine is used as a radiolabeling agent for in vitro labeling of salivary gland RNA at a concentration of 22 Ci/mMol for 3 hours.,Entity: 3H-adenosine. SMILES: N=c1nc[nH]c2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O. 3H-adenosine is used as a radiolabeling agent for in vitro labeling of salivary gland RNA at a concentration of 22 Ci/mMol for 3 hours.
diethylpyrocarbonate,Diethylpyrocarbonate is used to treat binding buffer for RNA chromatography to prevent unwanted binding during the purification process.,Entity: diethylpyrocarbonate. SMILES: CCOC(=O)OC(=O)OCC. Diethylpyrocarbonate is used to treat binding buffer for RNA chromatography to prevent unwanted binding during the purification process.
trichloroacetic acid,Trichloroacetic acid is used at 5% concentration to precipitate RNA during the preparation of samples for radioactive counting.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used at 5% concentration to precipitate RNA during the preparation of samples for radioactive counting.
formamide,"Formamide is used at concentrations ranging from 10% to 90% in 0.01 M Tris buffer (pH 7.4, 10 mM EDTA) to elute RNA from poly(U) Sepharose columns.","Entity: formamide. SMILES: NC=O. Formamide is used at concentrations ranging from 10% to 90% in 0.01 M Tris buffer (pH 7.4, 10 mM EDTA) to elute RNA from poly(U) Sepharose columns."
toluene,Toluene is used as a scintillator solvent for counting precipitated RNA samples.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a scintillator solvent for counting precipitated RNA samples.
CsCl,"CsCl is used as a density gradient medium to determine the buoyant density of DNA, with buoyant densities of 1.693 g/cm³ in neutral CsCl gradients and 1.748 g/cm³ in alkaline CsCl gradients for DNA from Pseudococcus obscurus.","Entity: CsCl. SMILES: [Cl-].[Cs+]. CsCl is used as a density gradient medium to determine the buoyant density of DNA, with buoyant densities of 1.693 g/cm³ in neutral CsCl gradients and 1.748 g/cm³ in alkaline CsCl gradients for DNA from Pseudococcus obscurus."
potassium chloride,Potassium chloride is included in the homogenization buffer for DNA extraction from adult female mealy bugs at a concentration of 0.025 M.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is included in the homogenization buffer for DNA extraction from adult female mealy bugs at a concentration of 0.025 M.
sucrose,Sucrose is used at a concentration of 0.35 M in the homogenization buffer for DNA extraction from adult female mealy bugs.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used at a concentration of 0.35 M in the homogenization buffer for DNA extraction from adult female mealy bugs.
magnesium acetate,"Magnesium acetate is used as a component of the homogenization buffer for preparing DNA from adult female mealy bugs, at a concentration of 0.005 M.","Entity: magnesium acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Mg+2]. Magnesium acetate is used as a component of the homogenization buffer for preparing DNA from adult female mealy bugs, at a concentration of 0.005 M."
CsCl,CsCl is used as a density gradient medium in equilibrium centrifugation to determine the buoyant densities of DNA and protein samples.,Entity: CsCl. SMILES: [Cl-].[Cs+]. CsCl is used as a density gradient medium in equilibrium centrifugation to determine the buoyant densities of DNA and protein samples.
KOH,KOH is used to adjust the pH to about 12 in CsCl gradients for constructing alkaline density gradients in centrifugation experiments.,Entity: KOH. SMILES: [K+].[OH-]. KOH is used to adjust the pH to about 12 in CsCl gradients for constructing alkaline density gradients in centrifugation experiments.
tris(hydroxymethyl)amine,tris(hydroxymethyl)amine is used as a buffering agent at pH 7.2 in isotonic saline for terminating DNA strand labeling pulses in cell-based experiments.,Entity: tris(hydroxymethyl)amine. SMILES: OCN(CO)CO. tris(hydroxymethyl)amine is used as a buffering agent at pH 7.2 in isotonic saline for terminating DNA strand labeling pulses in cell-based experiments.
thymidine,thymidine is used as a radioactive label at a concentration of 5 x 10^-6 M (40 Ci/millimole) for 4–40 minutes to facilitate pulse labeling of DNA strands in cells.,Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. thymidine is used as a radioactive label at a concentration of 5 x 10^-6 M (40 Ci/millimole) for 4–40 minutes to facilitate pulse labeling of DNA strands in cells.
FdU,"FdU is used at concentrations of 10⁻⁶ M or 10⁻⁵ M in thymidine-free medium to inhibit the conversion of dUMP to dTMP, thereby starving cells of thymidylate.","Entity: FdU. SMILES: O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F. FdU is used at concentrations of 10⁻⁶ M or 10⁻⁵ M in thymidine-free medium to inhibit the conversion of dUMP to dTMP, thereby starving cells of thymidylate."
dUMP,"dUMP is converted to dTMP by thymidylate synthase, and this conversion can be inhibited by FdU in cell culture experiments.","Entity: dUMP. SMILES: O=c1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)O)O2)c(=O)[nH]1. dUMP is converted to dTMP by thymidylate synthase, and this conversion can be inhibited by FdU in cell culture experiments."
dTMP,dTMP is produced from dUMP by thymidylate synthase and its synthesis can be inhibited by FdU in cell culture.,Entity: dTMP. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)O)O2)c(=O)[nH]c1=O. dTMP is produced from dUMP by thymidylate synthase and its synthesis can be inhibited by FdU in cell culture.
thymidine,"Traces of thymidine in cell culture medium can be enzymatically converted to thymine by thymidine phosphorylase, which is then poorly utilized by hamster cells.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Traces of thymidine in cell culture medium can be enzymatically converted to thymine by thymidine phosphorylase, which is then poorly utilized by hamster cells."
thymine,Thymine is produced from thymidine by thymidine phosphorylase and is poorly utilized by Chinese hamster ovary (CHO) cells.,Entity: thymine. SMILES: Cc1c[nH]c(=O)[nH]c1=O. Thymine is produced from thymidine by thymidine phosphorylase and is poorly utilized by Chinese hamster ovary (CHO) cells.
fluorodeoxyuridine,Fluorodeoxyuridine is a drug that blocks DNA synthesis and can be used to synchronize cells at the beginning of S phase for autoradiographic studies of DNA replication initiation sites.,Entity: fluorodeoxyuridine. SMILES: O=c1ccn([C@@]2(F)C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. Fluorodeoxyuridine is a drug that blocks DNA synthesis and can be used to synchronize cells at the beginning of S phase for autoradiographic studies of DNA replication initiation sites.
propionic acid,"Propionic acid is used as a component of 1% lacto-propionic orcein, a staining solution for tissue preparation in insect studies.","Entity: propionic acid. SMILES: CCC(=O)O. Propionic acid is used as a component of 1% lacto-propionic orcein, a staining solution for tissue preparation in insect studies."
acetic acid,Acetic acid is used in combination with ethanol to fix tissues for 30 seconds during histological examination in insects.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used in combination with ethanol to fix tissues for 30 seconds during histological examination in insects.
ethanol,Ethanol is used as a solvent for tissue fixation and as a medium for preparing malpighian tubules for slide staining in insect studies.,Entity: ethanol. SMILES: CCO. Ethanol is used as a solvent for tissue fixation and as a medium for preparing malpighian tubules for slide staining in insect studies.
orcein,"Orcen, in the form of 1% Gurrs synthetic orcein (a mixture of lactic and propionic acids), is used as a staining solution for preserving and mounting insect tissues.","Entity: orcein. SMILES: CC1=c2c(oc3cc(O)c(Nc4c(C)cc(O)cc4O)c(C)c23)=CC(=O)C1=Nc1c(C)cc(O)cc1O. Orcen, in the form of 1% Gurrs synthetic orcein (a mixture of lactic and propionic acids), is used as a staining solution for preserving and mounting insect tissues."
lactic acid,"Lactic acid is used as a component of 1% lacto-propionic orcein, a staining solution for tissue preparation in insect studies.","Entity: lactic acid. SMILES: CC(O)C(=O)O. Lactic acid is used as a component of 1% lacto-propionic orcein, a staining solution for tissue preparation in insect studies."
sucrose,Sucrose is used at 20% concentration as a buffer component in the electrophoresis buffer for polyacrylamide-formamide gel electrophoresis.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used at 20% concentration as a buffer component in the electrophoresis buffer for polyacrylamide-formamide gel electrophoresis.
toluene,Toluene is used as a component of the toluene-tergitol scintillator for determining radioactivity in liquid scintillation counting.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a component of the toluene-tergitol scintillator for determining radioactivity in liquid scintillation counting.
formamide,Formamide is used as a buffer component at 98.5% concentration in polyacrylamide-formamide gel electrophoresis.,Entity: formamide. SMILES: NC=O. Formamide is used as a buffer component at 98.5% concentration in polyacrylamide-formamide gel electrophoresis.
"N,N'-methylenebisacrylamide","N,N'-methylenebisacrylamide is used at 1.05% (w/v) concentration as a crosslinker in polyacrylamide gels for electrophoresis.","Entity: N,N'-methylenebisacrylamide. SMILES: C=CC(=O)NCNC(=O)C=C. N,N'-methylenebisacrylamide is used at 1.05% (w/v) concentration as a crosslinker in polyacrylamide gels for electrophoresis."
EDTA,EDTA is used at 0.001 M concentration as a buffer component in the electrophoresis buffer for polyacrylamide-formamide gel electrophoresis.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used at 0.001 M concentration as a buffer component in the electrophoresis buffer for polyacrylamide-formamide gel electrophoresis.
acrylamide,Acrylamide is used at 5.95% (w/v) concentration as the main matrix component in polyacrylamide gels for electrophoresis.,Entity: acrylamide. SMILES: C=CC(N)=O. Acrylamide is used at 5.95% (w/v) concentration as the main matrix component in polyacrylamide gels for electrophoresis.
perchloric acid,Perchloric acid at 5% concentration is used to extract RNA from gel slices in polyacrylamide-formamide gel electrophoresis.,Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid at 5% concentration is used to extract RNA from gel slices in polyacrylamide-formamide gel electrophoresis.
NaOH,NaOH was used at a final concentration of 0.1 N in the neutralization of sucrose gradient fractions during DNA purification.,Entity: NaOH. SMILES: [Na+].[OH-]. NaOH was used at a final concentration of 0.1 N in the neutralization of sucrose gradient fractions during DNA purification.
NaCl,NaCl was included at a concentration of 0.9 M in the sucrose gradient buffer for DNA purification.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl was included at a concentration of 0.9 M in the sucrose gradient buffer for DNA purification.
HCl,HCl was used to neutralize sucrose gradient fractions during DNA purification.,Entity: HCl. SMILES: Cl. HCl was used to neutralize sucrose gradient fractions during DNA purification.
EDTA,EDTA was used at concentrations of 0.12 M in the initial reassociation mixture and 10^-3 M in the sucrose gradient buffers during DNA purification.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA was used at concentrations of 0.12 M in the initial reassociation mixture and 10^-3 M in the sucrose gradient buffers during DNA purification.
formamide,Formamide is used as a component of the hybridization buffer (50% v/v in 4 x SSC) for in situ hybridization of DNA to cellular preparations.,Entity: formamide. SMILES: NC=O. Formamide is used as a component of the hybridization buffer (50% v/v in 4 x SSC) for in situ hybridization of DNA to cellular preparations.
ethanol,"Ethanol is used in the form of 70% and 95% solutions for washing slides after in situ hybridization, with washes performed at room temperature.","Entity: ethanol. SMILES: CCO. Ethanol is used in the form of 70% and 95% solutions for washing slides after in situ hybridization, with washes performed at room temperature."
formamide,Formamide is used as a component of the hybridization buffer at 50% concentration in the filter reaction system for studying DNA-RNA hybridization.,Entity: formamide. SMILES: NC=O. Formamide is used as a component of the hybridization buffer at 50% concentration in the filter reaction system for studying DNA-RNA hybridization.
TCA,TCA (trichloroacetic acid) is used to precipitate DNA-RNA hybrids after reassociation in hybridization experiments.,Entity: TCA. SMILES: O=C(O)C(Cl)(Cl)Cl. TCA (trichloroacetic acid) is used to precipitate DNA-RNA hybrids after reassociation in hybridization experiments.
KI,KI (potassium iodide) is included at 0.1 M concentration in the hybridization buffer for the filter reaction involving membrane-bound DNA and RNA.,Entity: KI. SMILES: [I-].[K+]. KI (potassium iodide) is included at 0.1 M concentration in the hybridization buffer for the filter reaction involving membrane-bound DNA and RNA.
hydrochloric acid,Hydrochloric acid is used to adjust the pH of DNA solutions to approximately 8.5 after DNA denaturation in the preparation of DNA-filters.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to adjust the pH of DNA solutions to approximately 8.5 after DNA denaturation in the preparation of DNA-filters.
sodium chloride,Sodium chloride is used in combination with Tris-HCl buffer at 3.0 M concentration and 0.5 M KCl in the preparation of DNA-filters from unfractionated P. dunni DNA.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used in combination with Tris-HCl buffer at 3.0 M concentration and 0.5 M KCl in the preparation of DNA-filters from unfractionated P. dunni DNA.
potassium chloride,Potassium chloride is used at 0.5 M concentration in the preparation of DNA-filters from unfractionated P. dunni DNA.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is used at 0.5 M concentration in the preparation of DNA-filters from unfractionated P. dunni DNA.
sodium hydroxide,Sodium hydroxide is used to denature DNA in CsCl density gradient fractions during the preparation of DNA-filters.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to denature DNA in CsCl density gradient fractions during the preparation of DNA-filters.
Na2HPO4,"Na2HPO4 is used as a component of phosphate buffer (PB) at 1 M concentration, mixed with 1 M NaH2PO4 to achieve a pH of 6.8 for DNA manipulation procedures.","Entity: Na2HPO4. SMILES: O=P([O-])([O-])O.[Na+].[Na+]. Na2HPO4 is used as a component of phosphate buffer (PB) at 1 M concentration, mixed with 1 M NaH2PO4 to achieve a pH of 6.8 for DNA manipulation procedures."
NaH2PO4,"NaH2PO4 is used as a component of phosphate buffer (PB) at 1 M concentration, mixed with 1 M Na2HPO4 to achieve a pH of 6.8 for DNA manipulation procedures.","Entity: NaH2PO4. SMILES: O=P([O-])(O)O.[Na+]. NaH2PO4 is used as a component of phosphate buffer (PB) at 1 M concentration, mixed with 1 M Na2HPO4 to achieve a pH of 6.8 for DNA manipulation procedures."
NaCl,"NaCl is used as a component of the buffer system (0.1 M NaCl in 0.05 M Tris-HCl, pH 7.5) for washing and eluting RNA from DEAE-cellulose columns during iodination procedures.","Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used as a component of the buffer system (0.1 M NaCl in 0.05 M Tris-HCl, pH 7.5) for washing and eluting RNA from DEAE-cellulose columns during iodination procedures."
ammonium acetate,"Ammonium acetate is used as a component of the buffer system (ammonium acetate-NH4OH, pH 9.3) for iodinating 4S and 5S RNAs in vitro.","Entity: ammonium acetate. SMILES: CC(=O)[O-].[NH4+]. Ammonium acetate is used as a component of the buffer system (ammonium acetate-NH4OH, pH 9.3) for iodinating 4S and 5S RNAs in vitro."
NH4OH,NH4OH is used in combination with ammonium acetate (pH 9.3) as part of the buffer system for iodinating 4S and 5S RNAs in vitro.,Entity: NH4OH. SMILES: [NH4+].[OH-]. NH4OH is used in combination with ammonium acetate (pH 9.3) as part of the buffer system for iodinating 4S and 5S RNAs in vitro.
toluene,Toluene is used as the solvent in ordinary toluene-based scintillator systems for liquid scintillation counting of radioactively labeled DNA and RNA samples.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as the solvent in ordinary toluene-based scintillator systems for liquid scintillation counting of radioactively labeled DNA and RNA samples.
CsCl,CsCl is used as a density gradient medium for fractionating DNA by equilibrium density gradient centrifugation.,Entity: CsCl. SMILES: [Cl-].[Cs+]. CsCl is used as a density gradient medium for fractionating DNA by equilibrium density gradient centrifugation.
Cs2SO4,Cs2SO4 is used as a density gradient medium for fractionating DNA by equilibrium density gradient centrifugation.,Entity: Cs2SO4. SMILES: O=S(=O)([O-])[O-].[Cs+].[Cs+]. Cs2SO4 is used as a density gradient medium for fractionating DNA by equilibrium density gradient centrifugation.
AgNO3,AgNO3 is used in combination with DNA in a Cs2SO4 density gradient system to achieve an Ag+/DNA-P molar ratio of 0.30.,Entity: AgNO3. SMILES: O=[N+]([O-])[O-].[Ag+]. AgNO3 is used in combination with DNA in a Cs2SO4 density gradient system to achieve an Ag+/DNA-P molar ratio of 0.30.
borate,"Borate buffer (Na2B4O7, 0.01 M, pH 9.2) is used to dialyze DNA prior to Cs2SO4 density gradient centrifugation.","Entity: borate. SMILES: [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-]. Borate buffer (Na2B4O7, 0.01 M, pH 9.2) is used to dialyze DNA prior to Cs2SO4 density gradient centrifugation."
sodium formate,Sodium formate at 0.18 M was used as a buffer in the hybridization and reassociation reactions of DNA fragments from P. cinereus and P. dunni.,Entity: sodium formate. SMILES: O=C[O-].[Na+]. Sodium formate at 0.18 M was used as a buffer in the hybridization and reassociation reactions of DNA fragments from P. cinereus and P. dunni.
trichloroacetic acid,Trichloroacetic acid at 5% concentration was used to precipitate and remove unincorporated radioactivity from DNA hybridization reactions.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid at 5% concentration was used to precipitate and remove unincorporated radioactivity from DNA hybridization reactions.
phenol,Phenol extraction is a standard step in DNA purification protocols to remove proteins from DNA samples.,Entity: phenol. SMILES: Oc1ccccc1. Phenol extraction is a standard step in DNA purification protocols to remove proteins from DNA samples.
Netropsin,Netropsin is used in combination with CsCl to achieve density gradient purification of DNA.,Entity: Netropsin. SMILES: Cn1cc(NC(=O)c2cc(NC(=O)CN=C(N)N)cn2C)cc1C(=O)NCCC(=N)N. Netropsin is used in combination with CsCl to achieve density gradient purification of DNA.
secondary butanol,Secondary butanol is used to extract residual AmD (ammonium acetate) from DNA during purification procedures.,Entity: secondary butanol. SMILES: CCC(C)O. Secondary butanol is used to extract residual AmD (ammonium acetate) from DNA during purification procedures.
Netropsin,Netropsin binds to AT-rich regions of DNA and can be used to separate these regions to the lighter side of a gradient during purification procedures.,Entity: Netropsin. SMILES: Cn1cc(NC(=O)c2cc(NC(=O)CN=C(N)N)cn2C)cc1C(=O)NCCC(=N)N. Netropsin binds to AT-rich regions of DNA and can be used to separate these regions to the lighter side of a gradient during purification procedures.
sucrose,Sucrose is used as a component of formamide-sucrose gradients for the separation of 18S and 28S rRNAs.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used as a component of formamide-sucrose gradients for the separation of 18S and 28S rRNAs.
sodium iodide,Sodium iodide (125INa) is used to label 18S and 28S rRNAs for biochemical analysis.,Entity: sodium iodide. SMILES: [I-].[Na+]. Sodium iodide (125INa) is used to label 18S and 28S rRNAs for biochemical analysis.
phenol,Phenol is used in phenol-cresol extraction procedures for isolating unlabeled rRNA from tissues such as mouse liver.,Entity: phenol. SMILES: Oc1ccccc1. Phenol is used in phenol-cresol extraction procedures for isolating unlabeled rRNA from tissues such as mouse liver.
cresol,Cresol is used in combination with phenol in phenol-cresol extraction to purify unlabeled rRNA from tissues.,Entity: cresol. SMILES: Cc1ccccc1O. Cresol is used in combination with phenol in phenol-cresol extraction to purify unlabeled rRNA from tissues.
formamide,Formamide is used in formamide-sucrose gradients for the separation of 18S and 28S rRNAs.,Entity: formamide. SMILES: NC=O. Formamide is used in formamide-sucrose gradients for the separation of 18S and 28S rRNAs.
Cs2SO4,"Cs2SO4 is used in analytical and preparative gradient purification protocols for ribosomal DNA (rDNA) to achieve high-purity samples, as demonstrated by the successful separation of rDNA from contaminants using a Cs2SO4 gradient.","Entity: Cs2SO4. SMILES: O=S(=O)([O-])[O-].[Cs+].[Cs+]. Cs2SO4 is used in analytical and preparative gradient purification protocols for ribosomal DNA (rDNA) to achieve high-purity samples, as demonstrated by the successful separation of rDNA from contaminants using a Cs2SO4 gradient."
amido black,"Amido black is used as a staining reagent for visualizing proteins separated by electrophoresis, typically at a concentration of 1% in 7% acetic acid.","Entity: amido black. SMILES: Nc1c(N=Nc2ccc([N+](=O)[O-])cc2)c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3ccccc3)c(O)c12.[Na+]. Amido black is used as a staining reagent for visualizing proteins separated by electrophoresis, typically at a concentration of 1% in 7% acetic acid."
acetic acid,"Acetic acid is used as a buffer and as a component of staining solutions (e.g., 7% acetic acid) in electrophoretic protein analysis.","Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a buffer and as a component of staining solutions (e.g., 7% acetic acid) in electrophoretic protein analysis."
ecdysone,Ecdysone treatment of 4th intermolt larvae of Chironomus tentans affects the morphology of Balbiani ring 1 (B1) and increases its content of radioactively labeled RNA.,Entity: ecdysone. SMILES: C[C@H]([C@H](O)CCC(C)(C)O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C. Ecdysone treatment of 4th intermolt larvae of Chironomus tentans affects the morphology of Balbiani ring 1 (B1) and increases its content of radioactively labeled RNA.
galactose,Treatment with galactose reduces the size of Balbiani ring 2 (B2) in the larval salivary glands of Chironomus tentans.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Treatment with galactose reduces the size of Balbiani ring 2 (B2) in the larval salivary glands of Chironomus tentans.
dithiothreitol,Dithiothreitol is used as a reducing agent at 0.1 M concentration in the preparation of secretory proteins for electrophoresis.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used as a reducing agent at 0.1 M concentration in the preparation of secretory proteins for electrophoresis.
ethylene-diamine-tetraacetate,Ethylene-diamine-tetraacetate (EDTA) is used at 0.02 M concentration as a chelating agent in the reduction and alkylation of secretory proteins.,Entity: ethylene-diamine-tetraacetate. SMILES: O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-]. Ethylene-diamine-tetraacetate (EDTA) is used at 0.02 M concentration as a chelating agent in the reduction and alkylation of secretory proteins.
iodoacetamide,Iodoacetamide is used at 20% concentration for alkylation of proteins after reduction in the preparation of secretory proteins for electrophoresis.,Entity: iodoacetamide. SMILES: NC(=O)CI. Iodoacetamide is used at 20% concentration for alkylation of proteins after reduction in the preparation of secretory proteins for electrophoresis.
tris-(hydroxymethyl)-aminomethan,tris-(hydroxymethyl)-aminomethan is used as a buffer component at 0.04 M concentration and pH 8 in the reduction and alkylation of secretory proteins.,Entity: tris-(hydroxymethyl)-aminomethan. SMILES: NC(CO)(CO)CO. tris-(hydroxymethyl)-aminomethan is used as a buffer component at 0.04 M concentration and pH 8 in the reduction and alkylation of secretory proteins.
urea,Urea is used at 8 M concentration as a denaturing agent in the reduction and alkylation of secretory proteins.,Entity: urea. SMILES: NC(N)=O. Urea is used at 8 M concentration as a denaturing agent in the reduction and alkylation of secretory proteins.
lysine,"Lysine is the prevailing amino acid residue in secretory proteins, making it suitable as a tracer for studying protein synthesis in tissues such as salivary glands.","Entity: lysine. SMILES: NCCCC[C@H](N)C(=O)O. Lysine is the prevailing amino acid residue in secretory proteins, making it suitable as a tracer for studying protein synthesis in tissues such as salivary glands."
hydrogen peroxide,"Hydrogen peroxide is used as a solubilizing and destaining agent for proteins in gel slices, applied at 30% concentration in 100 gl water at 50°C for 6 hours.","Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide is used as a solubilizing and destaining agent for proteins in gel slices, applied at 30% concentration in 100 gl water at 50°C for 6 hours."
ecdysone,"Injection of ecdysone into intermolt larvae of Galleria tentans increases the relative amount of RNA in Balbiani ring B1, indicating an effect on Balbiani ring activity and secretory protein synthesis.","Entity: ecdysone. SMILES: C[C@H]([C@H](O)CCC(C)(C)O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C. Injection of ecdysone into intermolt larvae of Galleria tentans increases the relative amount of RNA in Balbiani ring B1, indicating an effect on Balbiani ring activity and secretory protein synthesis."
galactose,Feeding larvae of Galleria tentans or Galleria pallivittatus with galactose selectively increases the expansion of Balbiani ring B1 and decreases the expansion of Balbiani ring B2.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Feeding larvae of Galleria tentans or Galleria pallivittatus with galactose selectively increases the expansion of Balbiani ring B1 and decreases the expansion of Balbiani ring B2.
ecdysone,"Ecdysone is a hormone that can induce puffing changes in chromosomal regions, but there is no protein whose induction by ecdysone is closely related to ecdysone-dependent formation of a puff in the chromosomal region containing its primary structure.","Entity: ecdysone. SMILES: C[C@H]([C@H](O)CCC(C)(C)O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C. Ecdysone is a hormone that can induce puffing changes in chromosomal regions, but there is no protein whose induction by ecdysone is closely related to ecdysone-dependent formation of a puff in the chromosomal region containing its primary structure."
lysine,"Lysine can be incorporated into salivary gland tissue, as evidenced by the uptake and incorporation of 3H-lysine in animal experiments.","Entity: lysine. SMILES: NCCCC[C@H](N)C(=O)O. Lysine can be incorporated into salivary gland tissue, as evidenced by the uptake and incorporation of 3H-lysine in animal experiments."
methylen blue,"In electrophoretic analysis of salivary gland proteins, the band migrating to the same position as methylen blue is considered an artifact rather than a genuine secretory protein fraction due to its sensitivity to electrophoresis voltage and sample load.","Entity: methylen blue. SMILES: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.[Cl-]. In electrophoretic analysis of salivary gland proteins, the band migrating to the same position as methylen blue is considered an artifact rather than a genuine secretory protein fraction due to its sensitivity to electrophoresis voltage and sample load."
galactose,"Galactose injection does not induce Balbiani Ring enlargement in Drosophila prepupae, which may be due to resistance at this developmental stage.","Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose injection does not induce Balbiani Ring enlargement in Drosophila prepupae, which may be due to resistance at this developmental stage."
ecdysone,"Ecdysone induces Balbiani Ring enlargement in Drosophila, indicating its action is closer to the site of effect (the Balbiani ring) than galactose.","Entity: ecdysone. SMILES: C[C@H]([C@H](O)CCC(C)(C)O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C. Ecdysone induces Balbiani Ring enlargement in Drosophila, indicating its action is closer to the site of effect (the Balbiani ring) than galactose."
glycine ethyl ester,"Glycine ethyl ester, when used during isolation of salivary gland secretion, can result in the appearance of polypeptides in the range of 30,000 to 60,000 Daltons rather than the typical 100,000 to 1,000,000 Dalton size range for secretory proteins.","Entity: glycine ethyl ester. SMILES: CCOC(=O)CN. Glycine ethyl ester, when used during isolation of salivary gland secretion, can result in the appearance of polypeptides in the range of 30,000 to 60,000 Daltons rather than the typical 100,000 to 1,000,000 Dalton size range for secretory proteins."
EDTA,"EDTA, when used during isolation of salivary gland secretion, can induce the formation of polypeptides in the size range of 30,000 to 60,000 Daltons instead of the usual 100,000 to 1,000,000 Dalton range for secretory proteins.","Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA, when used during isolation of salivary gland secretion, can induce the formation of polypeptides in the size range of 30,000 to 60,000 Daltons instead of the usual 100,000 to 1,000,000 Dalton range for secretory proteins."
NaCl,NaCl is used as a 0.65% solution as a carrier for injecting substances into animal larvae.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used as a 0.65% solution as a carrier for injecting substances into animal larvae.
lysine,Lysine is administered at concentrations of 1 pC (3 or 20 C per mMol) or 0.1 gC (0.3 C per mMol) in a 0.65% NaCl solution for injection into animal larvae.,Entity: lysine. SMILES: NCCCC[C@H](N)C(=O)O. Lysine is administered at concentrations of 1 pC (3 or 20 C per mMol) or 0.1 gC (0.3 C per mMol) in a 0.65% NaCl solution for injection into animal larvae.
toluene,"Toluene is used as a solvent for 2,5-diphenyl oxazole in scintillation cocktails for radioactivity measurements.","Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a solvent for 2,5-diphenyl oxazole in scintillation cocktails for radioactivity measurements."
acetic acid,Acetic acid is used to quench luminescence in samples containing hydrogen peroxide during radioactivity counting.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used to quench luminescence in samples containing hydrogen peroxide during radioactivity counting.
"2,5-diphenyl oxazole","2,5-diphenyl oxazole serves as a scintillator in toluene solution for detecting radioactivity in scintillation counting.","Entity: 2,5-diphenyl oxazole. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. 2,5-diphenyl oxazole serves as a scintillator in toluene solution for detecting radioactivity in scintillation counting."
lysine,Lysine is used as a competitor at 0.2% L-lysine in 10% trichloroacetic acid solution during the preparation of total salivary gland protein precipitates for biochemical analysis.,Entity: lysine. SMILES: NCCCC[C@H](N)C(=O)O. Lysine is used as a competitor at 0.2% L-lysine in 10% trichloroacetic acid solution during the preparation of total salivary gland protein precipitates for biochemical analysis.
trichloroacetic acid,"Trichloroacetic acid is used to precipitate proteins from saliva, with 10% TCA solution and 0.2% L-lysine as a competitor.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to precipitate proteins from saliva, with 10% TCA solution and 0.2% L-lysine as a competitor."
sodium hydroxide,Sodium hydroxide (1 N) is used to dissolve the precipitated protein pellet after trichloroacetic acid precipitation in the preparation of total salivary gland protein extracts.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide (1 N) is used to dissolve the precipitated protein pellet after trichloroacetic acid precipitation in the preparation of total salivary gland protein extracts.
CsCl,"CsCl is used in isopycnic DNA fractionation to separate DNA into four density components: principal (1.698 g/ml), intermediate-density (1.702 g/ml), MS (1.707 g/ml), and HS (1.713 g/ml), based on absorbance at 265 nm.","Entity: CsCl. SMILES: [Cl-].[Cs+]. CsCl is used in isopycnic DNA fractionation to separate DNA into four density components: principal (1.698 g/ml), intermediate-density (1.702 g/ml), MS (1.707 g/ml), and HS (1.713 g/ml), based on absorbance at 265 nm."
formamide,"The absolute length of single-strand DNA decreases as the concentration of formamide increases, becoming significant above a formamide concentration of 30%.","Entity: formamide. SMILES: NC=O. The absolute length of single-strand DNA decreases as the concentration of formamide increases, becoming significant above a formamide concentration of 30%."
EDTA,EDTA is included at 0.01 M concentration in the dialyzed buffer for rRNA genes to maintain pH 8.5 during preparation for electron microscopy.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is included at 0.01 M concentration in the dialyzed buffer for rRNA genes to maintain pH 8.5 during preparation for electron microscopy.
formamide,Formamide is used at 5% concentration in the buffer for dialyzed rRNA genes to facilitate their visualization by electron microscopy.,Entity: formamide. SMILES: NC=O. Formamide is used at 5% concentration in the buffer for dialyzed rRNA genes to facilitate their visualization by electron microscopy.
Tris-HCI,Tris-HCI is used as a buffer component at 0.1 M concentration and pH 8.5 for dialyzed rRNA genes prior to electron microscopy.,Entity: Tris-HCI. SMILES: NC(CO)(CO)CO. Tris-HCI is used as a buffer component at 0.1 M concentration and pH 8.5 for dialyzed rRNA genes prior to electron microscopy.
formamide,"At a concentration of 92% (vol./vol.), formamide causes approximately 22% denaturation of rDNA molecules.","Entity: formamide. SMILES: NC=O. At a concentration of 92% (vol./vol.), formamide causes approximately 22% denaturation of rDNA molecules."
Na-phosphate,"Na-phosphate solution at temperatures ranging from 69–75 °C is used to differentially stain chromosomes in metaphase cells, revealing BrdU-substituted DNA regions as lighter or dotted areas.","Entity: Na-phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Na-phosphate solution at temperatures ranging from 69–75 °C is used to differentially stain chromosomes in metaphase cells, revealing BrdU-substituted DNA regions as lighter or dotted areas."
BrdU,"BrdU is incorporated into DNA during the late S phase, and its presence can be detected as lighter or dotted regions on chromosomes after treatment with Na-phosphate.","Entity: BrdU. SMILES: O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1Br. BrdU is incorporated into DNA during the late S phase, and its presence can be detected as lighter or dotted regions on chromosomes after treatment with Na-phosphate."
sodium dihydrogen phosphate,Sodium dihydrogen phosphate (NaH2PO4) can be dissolved in distilled water to form a 1.0 M solution.,Entity: sodium dihydrogen phosphate. SMILES: O=P([O-])(O)O.[Na+]. Sodium dihydrogen phosphate (NaH2PO4) can be dissolved in distilled water to form a 1.0 M solution.
sodium bicarbonate,Sodium bicarbonate (NaHCO3) can be added to a NaH2PO4 solution to create a supersaturated solution with a pH of about 9.0 and visible NaHCO3 precipitate.,Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Sodium bicarbonate (NaHCO3) can be added to a NaH2PO4 solution to create a supersaturated solution with a pH of about 9.0 and visible NaHCO3 precipitate.
Potassium chloride,Potassium chloride (KCl) at 0.075 M is used to hypothetically lyse cells for 10 minutes at 37°C during chromosome preparation.,Entity: Potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride (KCl) at 0.075 M is used to hypothetically lyse cells for 10 minutes at 37°C during chromosome preparation.
Methanol,Methanol is used in combination with glacial acetic acid (3:1) to fix chromosomes for preparation.,Entity: Methanol. SMILES: CO. Methanol is used in combination with glacial acetic acid (3:1) to fix chromosomes for preparation.
Acetic acid,"Acetic acid, in a 3:1 mixture with methanol, is used as a fixative for preparing chromosomes.","Entity: Acetic acid. SMILES: CC(=O)O. Acetic acid, in a 3:1 mixture with methanol, is used as a fixative for preparing chromosomes."
Bromodeoxyuridine,Bromodeoxyuridine (BrdU) is used to label late DNA replicating sites on chromosomes in mammalian cells by incorporation during the S phase.,Entity: Bromodeoxyuridine. SMILES: O=c1ccn([C@@]2(Br)C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. Bromodeoxyuridine (BrdU) is used to label late DNA replicating sites on chromosomes in mammalian cells by incorporation during the S phase.
ethanol,"Ethanol is used as a fixative for biological specimens, with 70% ethanol serving as a storage solution for fixed oocytes.","Entity: ethanol. SMILES: CCO. Ethanol is used as a fixative for biological specimens, with 70% ethanol serving as a storage solution for fixed oocytes."
hematoxylin,"Hematoxylin is a histological stain used to color tissue sections, such as oocyte slices, for microscopic examination.","Entity: hematoxylin. SMILES: Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2. Hematoxylin is a histological stain used to color tissue sections, such as oocyte slices, for microscopic examination."
urea,Urea is used at 8 M concentration in MUP buffer for washing DNA on HAP columns to remove contaminants.,Entity: urea. SMILES: NC(N)=O. Urea is used at 8 M concentration in MUP buffer for washing DNA on HAP columns to remove contaminants.
Triton X-100,Triton X-100 is used at 1% concentration in N buffer for tissue homogenization during DNA extraction.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used at 1% concentration in N buffer for tissue homogenization during DNA extraction.
sucrose,Sucrose is used at 0.35 M concentration in N buffer for preparing insect tissue homogenates for DNA extraction.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used at 0.35 M concentration in N buffer for preparing insect tissue homogenates for DNA extraction.
phenol,Phenol is used to extract DNA from lysed nuclei during the purification process.,Entity: phenol. SMILES: Oc1ccccc1. Phenol is used to extract DNA from lysed nuclei during the purification process.
EDTA,"EDTA is used at 0.05 M and 0.1 M concentrations in SEDTA and MUP buffers, respectively, for DNA purification and washing steps.","Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used at 0.05 M and 0.1 M concentrations in SEDTA and MUP buffers, respectively, for DNA purification and washing steps."
NaCl,"NaCl is used at 0.1 M and 1 M concentrations in SEDTA and MUP buffers, respectively, during DNA purification and washing procedures.","Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used at 0.1 M and 1 M concentrations in SEDTA and MUP buffers, respectively, during DNA purification and washing procedures."
Tris,Tris is used at 50 mM concentration and pH 7.8 in N buffer for tissue homogenization during DNA extraction.,Entity: Tris. SMILES: NC(CO)(CO)CO. Tris is used at 50 mM concentration and pH 7.8 in N buffer for tissue homogenization during DNA extraction.
chloroform,Chloroform is used in the phenol-chloroform-isoamyl alcohol (IAC) extraction method to precipitate proteins from DNA during purification.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used in the phenol-chloroform-isoamyl alcohol (IAC) extraction method to precipitate proteins from DNA during purification.
isoamyl alcohol,Isoamyl alcohol is used in the phenol-chloroform-isoamyl alcohol (IAC) extraction method to facilitate protein precipitation from DNA during purification.,Entity: isoamyl alcohol. SMILES: CC(C)CCO. Isoamyl alcohol is used in the phenol-chloroform-isoamyl alcohol (IAC) extraction method to facilitate protein precipitation from DNA during purification.
SDS,SDS is used at 1% concentration to lyse nuclei and as a detergent in the phenol-chloroform-isoamyl alcohol (IAC) extraction and MUP buffer for DNA purification.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used at 1% concentration to lyse nuclei and as a detergent in the phenol-chloroform-isoamyl alcohol (IAC) extraction and MUP buffer for DNA purification.
ethanol,Ethanol at 95% concentration is used to precipitate DNA during the purification process.,Entity: ethanol. SMILES: CCO. Ethanol at 95% concentration is used to precipitate DNA during the purification process.
KC1,KC1 is used at 25 mM concentration in N buffer for tissue homogenization during DNA extraction.,Entity: KC1. SMILES: [Cl-].[K+]. KC1 is used at 25 mM concentration in N buffer for tissue homogenization during DNA extraction.
ZnSO4,ZnSO4 is used as a cofactor at 0.1 mM concentration in S1 nuclease digestion of DNA fragments.,Entity: ZnSO4. SMILES: O=S(=O)([O-])[O-].[Zn+2]. ZnSO4 is used as a cofactor at 0.1 mM concentration in S1 nuclease digestion of DNA fragments.
NaCl,NaCl is used at 0.15 M concentration in S1 nuclease digestion of DNA fragments.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used at 0.15 M concentration in S1 nuclease digestion of DNA fragments.
Pipes,Pipes is used at 0.005 M concentration in S1 nuclease digestion of DNA fragments.,Entity: Pipes. SMILES: O=S(=O)(O)CCN1CCN(CCS(=O)(=O)O)CC1. Pipes is used at 0.005 M concentration in S1 nuclease digestion of DNA fragments.
Na acetate,Na acetate is used at 0.025 M concentration and pH 4.3 in S1 nuclease digestion of DNA fragments.,Entity: Na acetate. SMILES: CC(=O)[O-].[Na+]. Na acetate is used at 0.025 M concentration and pH 4.3 in S1 nuclease digestion of DNA fragments.
ZnSO4,ZnSO4 is used at a concentration of 0.1 mM in DNA sample preparation for S1 nuclease treatment.,Entity: ZnSO4. SMILES: O=S(=O)([O-])[O-].[Zn+2]. ZnSO4 is used at a concentration of 0.1 mM in DNA sample preparation for S1 nuclease treatment.
PIPES,PIPES is included at a concentration of 0.005 M in DNA sample preparation for S1 nuclease treatment.,Entity: PIPES. SMILES: O=S(=O)(O)CCN1CCN(CCS(=O)(=O)O)CC1. PIPES is included at a concentration of 0.005 M in DNA sample preparation for S1 nuclease treatment.
dithiothreitol,Dithiothreitol is used at a concentration of 0.005 M in DNA sample preparation for S1 nuclease treatment.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used at a concentration of 0.005 M in DNA sample preparation for S1 nuclease treatment.
sodium acetate,Sodium acetate is included at a concentration of 0.025 M in DNA sample preparation for S1 nuclease treatment.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate is included at a concentration of 0.025 M in DNA sample preparation for S1 nuclease treatment.
cesium chloride,Cesium chloride is used in gradient fractionation to isolate DNA families for preparative purposes.,Entity: cesium chloride. SMILES: [Cl-].[Cs+]. Cesium chloride is used in gradient fractionation to isolate DNA families for preparative purposes.
Cs2SO4,"Cs2SO4 is used in equilibrium gradient centrifugation to band high molecular weight human DNA, with an Ag+/DNA phosphate ratio of 0.2.","Entity: Cs2SO4. SMILES: O=S(=O)([O-])[O-].[Cs+].[Cs+]. Cs2SO4 is used in equilibrium gradient centrifugation to band high molecular weight human DNA, with an Ag+/DNA phosphate ratio of 0.2."
CsCl,CsCl is used in gradient centrifugation in analytical ultracentrifuges for further stringent renaturation and band separation of DNA families.,Entity: CsCl. SMILES: [Cl-].[Cs+]. CsCl is used in gradient centrifugation in analytical ultracentrifuges for further stringent renaturation and band separation of DNA families.
sodium chloride,Sodium chloride is used at 5 M concentration for dialysis to remove silver ions from DNA fractions.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at 5 M concentration for dialysis to remove silver ions from DNA fractions.
phosphate,Phosphate is used at 0.12 M concentration and pH 6.8 in buffer for dialysis of DNA fractions.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate is used at 0.12 M concentration and pH 6.8 in buffer for dialysis of DNA fractions.
cesium sulfate,Cesium sulfate is used to establish DNA gradients for fractionation at a 0.20 Ag+ : DNA phosphate ratio.,Entity: cesium sulfate. SMILES: O=S(=O)([O-])[O-].[Cs+].[Cs+]. Cesium sulfate is used to establish DNA gradients for fractionation at a 0.20 Ag+ : DNA phosphate ratio.
methanol,Methanol is used as a component of the fixative solution (in a 3:1 ratio with acetic acid) for preparing cells for cytogenetic analysis.,Entity: methanol. SMILES: CO. Methanol is used as a component of the fixative solution (in a 3:1 ratio with acetic acid) for preparing cells for cytogenetic analysis.
acetic acid,Acetic acid is used as a component of the fixative solution (in a 3:1 ratio with methanol) for preparing cells for cytogenetic analysis.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component of the fixative solution (in a 3:1 ratio with methanol) for preparing cells for cytogenetic analysis.
Cs2SO4,"Cs2SO4 is used in equilibrium density gradient centrifugation to separate DNA and satellite DNA based on buoyant density, with gradients at a Ag+ to DNA-phosphate ratio (Rr) of 0.25.","Entity: Cs2SO4. SMILES: O=S(=O)([O-])[O-].[Cs+].[Cs+]. Cs2SO4 is used in equilibrium density gradient centrifugation to separate DNA and satellite DNA based on buoyant density, with gradients at a Ag+ to DNA-phosphate ratio (Rr) of 0.25."
CsCl,"CsCl is used in neutral density gradient centrifugation to purify satellite I DNA from chicken, with buoyant density determined to be 1,695 g/cm³.","Entity: CsCl. SMILES: [Cl-].[Cs+]. CsCl is used in neutral density gradient centrifugation to purify satellite I DNA from chicken, with buoyant density determined to be 1,695 g/cm³."
hydrochloric acid,Hydrochloric acid (HCl) is used to treat chromosomes at 0.2 N concentration for 1 hour at room temperature in C-banding procedures to facilitate constitutive heterochromatin staining.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (HCl) is used to treat chromosomes at 0.2 N concentration for 1 hour at room temperature in C-banding procedures to facilitate constitutive heterochromatin staining.
barium hydroxide octahydrate,Barium hydroxide octahydrate is used at 5% aqueous solution for 4–10 minutes in C-banding procedures to assist in the staining of constitutive heterochromatin.,Entity: barium hydroxide octahydrate. SMILES: O.O.O.O.O.O.O.O.[Ba+2].[OH-].[OH-]. Barium hydroxide octahydrate is used at 5% aqueous solution for 4–10 minutes in C-banding procedures to assist in the staining of constitutive heterochromatin.
CsCl,"CsCl is used as a density gradient medium for centrifugation, enabling the separation of DNA species with different buoyant densities.","Entity: CsCl. SMILES: [Cl-].[Cs+]. CsCl is used as a density gradient medium for centrifugation, enabling the separation of DNA species with different buoyant densities."
Cs2SO4,"Cs2SO4 is used as a density gradient medium for centrifugation, facilitating the isolation of DNA satellites with distinct buoyant densities.","Entity: Cs2SO4. SMILES: O=S(=O)([O-])[O-].[Cs+].[Cs+]. Cs2SO4 is used as a density gradient medium for centrifugation, facilitating the isolation of DNA satellites with distinct buoyant densities."
phenol,"Phenol is used in the DNA isolation protocol, together with chloroform, to treat tissues during DNA extraction.","Entity: phenol. SMILES: Oc1ccccc1. Phenol is used in the DNA isolation protocol, together with chloroform, to treat tissues during DNA extraction."
Cs2SO4,Cs2SO4 is used in centrifugation steps for the purification of satellite DNA in the preparation of Elaphe radiata and Xenopeltis unicolor.,Entity: Cs2SO4. SMILES: O=S(=O)([O-])[O-].[Cs+].[Cs+]. Cs2SO4 is used in centrifugation steps for the purification of satellite DNA in the preparation of Elaphe radiata and Xenopeltis unicolor.
CsCl,CsCl is used in centrifugation steps for the purification of satellite DNA in the preparation of Elaphe radiata and Xenopeltis unicolor.,Entity: CsCl. SMILES: [Cl-].[Cs+]. CsCl is used in centrifugation steps for the purification of satellite DNA in the preparation of Elaphe radiata and Xenopeltis unicolor.
chloroform,"Chloroform is used as a reagent in the DNA isolation protocol, specifically in combination with phenol, for tissue processing.","Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a reagent in the DNA isolation protocol, specifically in combination with phenol, for tissue processing."
potassium chloride,Potassium chloride is used at a concentration of 0.075 M for 8 minutes during the preparation of chromosome preparations from cells.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is used at a concentration of 0.075 M for 8 minutes during the preparation of chromosome preparations from cells.
acetic acid,Acetic acid is used in a 1:3 ratio with ethanol to fix chromosome preparations.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used in a 1:3 ratio with ethanol to fix chromosome preparations.
ethanol,Ethanol is used in a 1:3 ratio with acetic acid to fix chromosome preparations.,Entity: ethanol. SMILES: CCO. Ethanol is used in a 1:3 ratio with acetic acid to fix chromosome preparations.
colchicine,Colchicine is used at a concentration of 0.015 µg/ml to treat cells for 4 hours during chromosome preparation.,Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine is used at a concentration of 0.015 µg/ml to treat cells for 4 hours during chromosome preparation.
trichloroacetic acid,"Trichloroacetic acid is used to precipitate RNA from solution, serving as a method for recovering released RNA in hybridization experiments.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to precipitate RNA from solution, serving as a method for recovering released RNA in hybridization experiments."
diethylpyrocarbonate,Diethylpyrocarbonate is used at 0.1% concentration in 1 x SSC buffer to remove nuclease activity from RNA filters during hybridization procedures.,Entity: diethylpyrocarbonate. SMILES: CCOC(=O)OC(=O)OCC. Diethylpyrocarbonate is used at 0.1% concentration in 1 x SSC buffer to remove nuclease activity from RNA filters during hybridization procedures.
naphthalene,"Naphthalene is a common denaturant used in rectified spirits for domestic, industrial, or medical purposes.","Entity: naphthalene. SMILES: c1ccc2ccccc2c1. Naphthalene is a common denaturant used in rectified spirits for domestic, industrial, or medical purposes."
methyl alcohol,Methyl alcohol is frequently used as a denaturant in rectified spirits.,Entity: methyl alcohol. SMILES: CO. Methyl alcohol is frequently used as a denaturant in rectified spirits.
pyridine,"Pyridine is used as a denaturant in rectified spirits for domestic, industrial, or medical applications.","Entity: pyridine. SMILES: c1ccncc1. Pyridine is used as a denaturant in rectified spirits for domestic, industrial, or medical applications."
benzene,Benzene is employed as a denaturant in rectified spirits.,Entity: benzene. SMILES: c1ccccc1. Benzene is employed as a denaturant in rectified spirits.
3'-deoxyadenosine,"3'-deoxyadenosine has an absorbance value (A5,5) of 6.5 in the adenosine deaminase assay using 265 nm as the wavelength.","Entity: 3'-deoxyadenosine. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C[C@H]1O. 3'-deoxyadenosine has an absorbance value (A5,5) of 6.5 in the adenosine deaminase assay using 265 nm as the wavelength."
2'-deoxyadenosine,"2'-deoxyadenosine has an absorbance value (A5,5) of 6.5 in the adenosine deaminase assay using 265 nm as the wavelength.","Entity: 2'-deoxyadenosine. SMILES: Nc1ncnc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1. 2'-deoxyadenosine has an absorbance value (A5,5) of 6.5 in the adenosine deaminase assay using 265 nm as the wavelength."
inosine,"Inosine is produced from adenosine by adenosine deaminase, with a millimolar absorbance change (As,,, = 6.5) measured at 265 nm in the assay.","Entity: inosine. SMILES: OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O. Inosine is produced from adenosine by adenosine deaminase, with a millimolar absorbance change (As,,, = 6.5) measured at 265 nm in the assay."
formycin B,"The deamination of formycin B is monitored at 310 nm in the adenosine deaminase assay, with an absorbance change (AF,,, = 5.0) assumed from spectral data.","Entity: formycin B. SMILES: O=c1[nH]cnc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)[nH]nc12. The deamination of formycin B is monitored at 310 nm in the adenosine deaminase assay, with an absorbance change (AF,,, = 5.0) assumed from spectral data."
MgCl2,MgCl2 is used at a concentration of 1 mM in the standard incubation mixture for the adenosine deaminase assay.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used at a concentration of 1 mM in the standard incubation mixture for the adenosine deaminase assay.
2'deoxycytidine,The antiviral efficacy of 2'deoxycytidine analogues is closely associated with the ability of the virus to induce its own kinase(s).,Entity: 2'deoxycytidine. SMILES: Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1. The antiviral efficacy of 2'deoxycytidine analogues is closely associated with the ability of the virus to induce its own kinase(s).
Formycin,Formycin is a pyrazolopyrimidine C-nucleoside antibiotic that is readily deaminated by human sperm flagellar (HSF) and porcine renal (PRK) cell extracts.,Entity: Formycin. SMILES: Nc1ncnc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)[nH]nc12. Formycin is a pyrazolopyrimidine C-nucleoside antibiotic that is readily deaminated by human sperm flagellar (HSF) and porcine renal (PRK) cell extracts.
Formycin,"Formycin functions as a substrate for adenosine deaminase from calf intestinal mucosa, blood parasites Schistosoma mansoni, and human erythrocytes.","Entity: Formycin. SMILES: Nc1ncnc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)[nH]nc12. Formycin functions as a substrate for adenosine deaminase from calf intestinal mucosa, blood parasites Schistosoma mansoni, and human erythrocytes."
6-methyluridine,6-methyluridine is a nucleoside that is presumed to be in the syn conformation about the glycosidic bond.,Entity: 6-methyluridine. SMILES: Cc1cc(=O)[nH]c(=O)n1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O. 6-methyluridine is a nucleoside that is presumed to be in the syn conformation about the glycosidic bond.
6-methyluridine,6-methyluridine serves as a good substrate for a bacterial enzyme.,Entity: 6-methyluridine. SMILES: Cc1cc(=O)[nH]c(=O)n1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O. 6-methyluridine serves as a good substrate for a bacterial enzyme.
deoxyuridine,The PRK enzyme from mammalian cells shows low activity against deoxyuridine compared to uracil nucleosides.,Entity: deoxyuridine. SMILES: O=c1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. The PRK enzyme from mammalian cells shows low activity against deoxyuridine compared to uracil nucleosides.
5-ribosyluracil,The PRK enzyme from mammalian cells is inactive against 5-ribosyluracil (pseudouridine).,Entity: 5-ribosyluracil. SMILES: O=c1[nH]cc(C2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. The PRK enzyme from mammalian cells is inactive against 5-ribosyluracil (pseudouridine).
2'-methyluridine,The PRK enzyme from mammalian cells exhibits activity with 2'-methyluridine comparable to its activity with deoxyuridine.,Entity: 2'-methyluridine. SMILES: C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O. The PRK enzyme from mammalian cells exhibits activity with 2'-methyluridine comparable to its activity with deoxyuridine.
3'-O-methyluridine,The PRK enzyme from mammalian cells is inactive against 3'-O-methyluridine.,Entity: 3'-O-methyluridine. SMILES: CO[C@H]1[C@@H](O)[C@H](n2ccc(=O)[nH]c2=O)O[C@@H]1CO. The PRK enzyme from mammalian cells is inactive against 3'-O-methyluridine.
5'-methyluridine,The PRK enzyme from mammalian cells is inactive against 5'-methyluridine.,Entity: 5'-methyluridine. SMILES: CC(O)[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](O)[C@@H]1O. The PRK enzyme from mammalian cells is inactive against 5'-methyluridine.
inosine,"Inosine serves as a substrate for purine nucleoside phosphorylase activity in PRK cells, with activity levels ranging from 1 to 20 Ulmg protein, which is approximately 25-fold higher than for uridine phosphorylase.","Entity: inosine. SMILES: OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O. Inosine serves as a substrate for purine nucleoside phosphorylase activity in PRK cells, with activity levels ranging from 1 to 20 Ulmg protein, which is approximately 25-fold higher than for uridine phosphorylase."
ara-C,ara-C is a substrate for cytidine deaminase.,Entity: ara-C. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1. ara-C is a substrate for cytidine deaminase.
ara-C,"ara-C exhibits pronounced antiviral activity in both PRK and HSF cells and, at low concentrations, inhibits PRK cell DNA synthesis.","Entity: ara-C. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1. ara-C exhibits pronounced antiviral activity in both PRK and HSF cells and, at low concentrations, inhibits PRK cell DNA synthesis."
dCMP,dCMP deaminase activity is present in peripheral human leukocytes and is not detected in HSF and PRK cell extracts under the described assay conditions.,Entity: dCMP. SMILES: Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1. dCMP deaminase activity is present in peripheral human leukocytes and is not detected in HSF and PRK cell extracts under the described assay conditions.
CdR,CdR is a substrate for cytidine deaminase.,Entity: CdR. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. CdR is a substrate for cytidine deaminase.
arsenate,"In PRK cell extracts, arsenate can substitute for phosphate in the incubation medium without altering pyrimidine ribonucleoside phosphorylase activity.","Entity: arsenate. SMILES: O=[As]([O-])([O-])[O-]. In PRK cell extracts, arsenate can substitute for phosphate in the incubation medium without altering pyrimidine ribonucleoside phosphorylase activity."
uridine,"Uridine serves as a substrate for pyrimidine ribonucleoside phosphorylase activity in PRK cell extracts, with a specific activity of 421 LJ/mg protein.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine serves as a substrate for pyrimidine ribonucleoside phosphorylase activity in PRK cell extracts, with a specific activity of 421 LJ/mg protein."
adenosine,"Adenosine is a nucleoside whose interaction with adenosine deaminase is determined by its functional groups, and these functional groups have been characterized using the commercial enzyme from calf intestinal mucosa.","Entity: adenosine. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O. Adenosine is a nucleoside whose interaction with adenosine deaminase is determined by its functional groups, and these functional groups have been characterized using the commercial enzyme from calf intestinal mucosa."
cytidine,Cytidine is a nucleoside that serves as a substrate for cytidine deaminase (also known as cytidine aminohydrolase).,Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine is a nucleoside that serves as a substrate for cytidine deaminase (also known as cytidine aminohydrolase).
uridine,"Uridine is recognized by uridine phosphorylase, which exhibits activity against deoxyuridine and S-fluorodeoxyuridine.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine is recognized by uridine phosphorylase, which exhibits activity against deoxyuridine and S-fluorodeoxyuridine."
thymidine,"Thymidine is not recognized by uridine phosphorylase, indicating that thymidine and uridine are processed by different molecular entities.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine is not recognized by uridine phosphorylase, indicating that thymidine and uridine are processed by different molecular entities."
deoxyuridine,"Deoxyuridine is a substrate for uridine phosphorylase, which shows activity against it.","Entity: deoxyuridine. SMILES: O=c1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. Deoxyuridine is a substrate for uridine phosphorylase, which shows activity against it."
5-fluorodeoxyuridine,5-fluorodeoxyuridine is recognized by uridine phosphorylase.,Entity: 5-fluorodeoxyuridine. SMILES: O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F. 5-fluorodeoxyuridine is recognized by uridine phosphorylase.
PGD2,PGD2 is produced from the spontaneous decomposition of endoperoxides in aqueous media and serves as a downstream product in the arachidonate metabolic pathway.,Entity: PGD2. SMILES: CCCCC[C@H](O)/C=C/[C@H]1C(=O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O. PGD2 is produced from the spontaneous decomposition of endoperoxides in aqueous media and serves as a downstream product in the arachidonate metabolic pathway.
indomethacin,"Indomethacin is an aspirin-like drug that inhibits cyclooxygenase, thereby abolishing the biosynthesis of all prostaglandins.","Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin is an aspirin-like drug that inhibits cyclooxygenase, thereby abolishing the biosynthesis of all prostaglandins."
eicosatetraynoic acid,Eicosatetraynoic acid inhibits both lipoxygenase and cyclooxygenase enzymes in the arachidonate metabolic pathway.,Entity: eicosatetraynoic acid. SMILES: CCCCCCCCCCCC#CC#CC#CC#CC(=O)O. Eicosatetraynoic acid inhibits both lipoxygenase and cyclooxygenase enzymes in the arachidonate metabolic pathway.
PGG2,PGG2 is a cyclic endoperoxide formed by the enzymatic oxygenation of arachidonic acid via cyclooxygenase in the prostaglandin biosynthetic pathway.,Entity: PGG2. SMILES: CCCCC[C@@H](/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H]2C[C@H]1OO2)OO. PGG2 is a cyclic endoperoxide formed by the enzymatic oxygenation of arachidonic acid via cyclooxygenase in the prostaglandin biosynthetic pathway.
arachidonic acid,"Arachidonic acid (5,8,11,14eicosatetranoic acid) is the most abundant precursor for prostaglandin formation, serving as a substrate for cyclooxygenase to produce PGG2 and PGH2.","Entity: arachidonic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. Arachidonic acid (5,8,11,14eicosatetranoic acid) is the most abundant precursor for prostaglandin formation, serving as a substrate for cyclooxygenase to produce PGG2 and PGH2."
PGH2,PGH2 is a cyclic endoperoxide prostaglandin formed by the oxygenation of arachidonic acid via cyclooxygenase.,Entity: PGH2. SMILES: CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H]2C[C@H]1OO2. PGH2 is a cyclic endoperoxide prostaglandin formed by the oxygenation of arachidonic acid via cyclooxygenase.
12-hydroxy-eicosatetraenoic acid,12-hydroxy-eicosatetraenoic acid (HETE) is a noncyclized product formed from arachidonic acid by the action of lipoxygenase in platelets.,Entity: 12-hydroxy-eicosatetraenoic acid. SMILES: CCCCCCCCC(O)CCC=CC=CC=CC=CC(=O)O. 12-hydroxy-eicosatetraenoic acid (HETE) is a noncyclized product formed from arachidonic acid by the action of lipoxygenase in platelets.
dihomo-y-linolenic acid,"Dihomo-y-linolenic acid (8,11,14eicosatrienoic acid) is a major precursor for prostaglandin formation, specifically forming PG of the 1 series.","Entity: dihomo-y-linolenic acid. SMILES: CCCCCC=CCC=CCC=CCCCCCCC(=O)O. Dihomo-y-linolenic acid (8,11,14eicosatrienoic acid) is a major precursor for prostaglandin formation, specifically forming PG of the 1 series."
oxygen,Decreased oxygen tension can stimulate the release of prostaglandins from organs such as kidney and heart.,Entity: oxygen. SMILES: [O]. Decreased oxygen tension can stimulate the release of prostaglandins from organs such as kidney and heart.
bradykinin,Bradykinin can stimulate the release of prostaglandins from organs such as kidney and heart.,Entity: bradykinin. SMILES: NC(N)=NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N)C(=O)O. Bradykinin can stimulate the release of prostaglandins from organs such as kidney and heart.
thromboxane A2,Thromboxane A2 is a potent labile vasoconstrictor and aggregatory substance predominantly synthesized by platelets.,Entity: thromboxane A2. SMILES: CCCCC[C@H](O)/C=C/[C@H]1O[C@H]2C[C@H](O2)[C@@H]1C/C=C\CCCC(=O)O. Thromboxane A2 is a potent labile vasoconstrictor and aggregatory substance predominantly synthesized by platelets.
12-hydroxy-heptadecatrienoic acid,12-hydroxy-heptadecatrienoic acid (HHT) is synthesized by platelets as part of the arachidonate metabolic pathway.,Entity: 12-hydroxy-heptadecatrienoic acid. SMILES: CCCCCC(O)CCCCC=CC=CC=CC(=O)O. 12-hydroxy-heptadecatrienoic acid (HHT) is synthesized by platelets as part of the arachidonate metabolic pathway.
arachidonate,"Arachidonate is the precursor for the biosynthesis of prostaglandins, thromboxane A2, HETE, 12-hydroxy-heptadecatrienoic acid (HHT), PGE2, and PGI2, among other metabolites.","Entity: arachidonate. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)[O-]. Arachidonate is the precursor for the biosynthesis of prostaglandins, thromboxane A2, HETE, 12-hydroxy-heptadecatrienoic acid (HHT), PGE2, and PGI2, among other metabolites."
arachidonic acid,"Arachidonic acid is a precursor for the biosynthesis of PGI~, which is synthesized from arachidonic acid but not from dihomo-y-linolenic acid.","Entity: arachidonic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. Arachidonic acid is a precursor for the biosynthesis of PGI~, which is synthesized from arachidonic acid but not from dihomo-y-linolenic acid."
prostaglandin H2,Prostaglandin H2 is not a precursor for the biosynthesis of PGI~.,Entity: prostaglandin H2. SMILES: CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H]2C[C@H]1OO2. Prostaglandin H2 is not a precursor for the biosynthesis of PGI~.
arachidonic acid,Arachidonic acid serves as a substrate for the enzymatic synthesis of thromboxane A2 by platelet microsomes.,Entity: arachidonic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. Arachidonic acid serves as a substrate for the enzymatic synthesis of thromboxane A2 by platelet microsomes.
PGH2,PGH2 (prostaglandin H2) serves as a substrate for the enzymatic synthesis of thromboxane A2 by platelet microsomes.,Entity: PGH2. SMILES: CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H]2C[C@H]1OO2. PGH2 (prostaglandin H2) serves as a substrate for the enzymatic synthesis of thromboxane A2 by platelet microsomes.
imidazole,Imidazole acts as a thromboxane synthetase antagonist and blocks the biosynthesis of thromboxane A2 in vitro.,Entity: imidazole. SMILES: c1c[nH]cn1. Imidazole acts as a thromboxane synthetase antagonist and blocks the biosynthesis of thromboxane A2 in vitro.
thromboxane A2,"Thromboxane A2 contracts isolated blood vessels, is enzymatically synthesized from arachidonic acid (but not dihomo-y-linolenic acid) or PGH2 (but not PGH1), has an aqueous decay time of 30 seconds, aggregates platelets, and spontaneously forms the stable metabolite thromboxane B2.","Entity: thromboxane A2. SMILES: CCCCC[C@H](O)/C=C/[C@H]1O[C@H]2C[C@H](O2)[C@@H]1C/C=C\CCCC(=O)O. Thromboxane A2 contracts isolated blood vessels, is enzymatically synthesized from arachidonic acid (but not dihomo-y-linolenic acid) or PGH2 (but not PGH1), has an aqueous decay time of 30 seconds, aggregates platelets, and spontaneously forms the stable metabolite thromboxane B2."
thromboxane A2,The biosynthesis of thromboxane A2 in vitro is blocked by thromboxane synthetase antagonists such as imidazole or U-51605.,Entity: thromboxane A2. SMILES: CCCCC[C@H](O)/C=C/[C@H]1O[C@H]2C[C@H](O2)[C@@H]1C/C=C\CCCC(=O)O. The biosynthesis of thromboxane A2 in vitro is blocked by thromboxane synthetase antagonists such as imidazole or U-51605.
thromboxane B2,"Thromboxane B2 is a stable metabolite of thromboxane A2 that can be identified by thin-layer chromatography, radioimmunoassay, or gas chromatography-mass spectrometry.","Entity: thromboxane B2. SMILES: CCCCC[C@H](O)/C=C/[C@H]1OC(O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O. Thromboxane B2 is a stable metabolite of thromboxane A2 that can be identified by thin-layer chromatography, radioimmunoassay, or gas chromatography-mass spectrometry."
Bromsulfalein,Increased Bromsulfalein retention in serum is used as a marker for liver function impairment and can serve as an early indicator of hypernephroidem Nierenkarzinom.,Entity: Bromsulfalein. SMILES: O=C1OC(c2ccc(O)c(S(=O)(=O)O)c2)(c2ccc(O)c(S(=O)(=O)O)c2)c2c(Br)c(Br)c(Br)c(Br)c21.[Na].[Na]. Increased Bromsulfalein retention in serum is used as a marker for liver function impairment and can serve as an early indicator of hypernephroidem Nierenkarzinom.
Oxygen,"Hyperbaric oxygenation can increase tissue oxygen uptake, but primarily benefits the first quarter of the supply area of a nutritive vessel, leaving poorly supplied tumor regions largely unaffected.","Entity: Oxygen. SMILES: [O]. Hyperbaric oxygenation can increase tissue oxygen uptake, but primarily benefits the first quarter of the supply area of a nutritive vessel, leaving poorly supplied tumor regions largely unaffected."
Oxygen,"Hyperbaric oxygenation does not provide a widespread or general improvement in oxygen supply to solid tumors, unlike hyperbaric oxygenation.","Entity: Oxygen. SMILES: [O]. Hyperbaric oxygenation does not provide a widespread or general improvement in oxygen supply to solid tumors, unlike hyperbaric oxygenation."
Sauerstoff,"Sauerstoff is present in the environment during aerobic glycolysis, a metabolic process that is a hallmark of malignant tumors.","Entity: Sauerstoff. SMILES: [O]. Sauerstoff is present in the environment during aerobic glycolysis, a metabolic process that is a hallmark of malignant tumors."
Glucose,"Glucose serves as the primary substrate for aerobic glycolysis, which is the main source of energy production in malignant tumors.","Entity: Glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose serves as the primary substrate for aerobic glycolysis, which is the main source of energy production in malignant tumors."
Glucose,"Increased glucose supply to tumor cells, due to improved vascularization and arterial concentration, leads to enhanced glucose uptake and glycolysis in cancer cells.","Entity: Glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Increased glucose supply to tumor cells, due to improved vascularization and arterial concentration, leads to enhanced glucose uptake and glycolysis in cancer cells."
Glucose,"The increased glucose uptake and glycolysis in tumor cells can initially inhibit oxygen uptake, contributing to the Crabtree effect.","Entity: Glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. The increased glucose uptake and glycolysis in tumor cells can initially inhibit oxygen uptake, contributing to the Crabtree effect."
Glucose,Elevated glucose uptake and glycolysis in tumor cells are associated with increased lactate production and tissue lactate acidosis.,Entity: Glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Elevated glucose uptake and glycolysis in tumor cells are associated with increased lactate production and tissue lactate acidosis.
Lactat,"Increased glycolysis in tumor cells leads to elevated lactate production, contributing to tissue lactate acidosis.","Entity: Lactat. SMILES: CC(O)C(=O)O. Increased glycolysis in tumor cells leads to elevated lactate production, contributing to tissue lactate acidosis."
Sauerstoff,"Enhanced glucose uptake in tumor cells can initially inhibit oxygen uptake, as described by the Crabtree effect.","Entity: Sauerstoff. SMILES: [O]. Enhanced glucose uptake in tumor cells can initially inhibit oxygen uptake, as described by the Crabtree effect."
Glucose,"Glucose is considered a limiting substrate for tumor growth in solid tumors, with tissue glucose concentrations decreasing to very low levels in older tumors due to high metabolic consumption.","Entity: Glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is considered a limiting substrate for tumor growth in solid tumors, with tissue glucose concentrations decreasing to very low levels in older tumors due to high metabolic consumption."
Glucose,"Glucose concentrations in the interstitium of various tumors are very low, measured at 6 mg/l with a mean blood glucose of 1.72 g/l.","Entity: Glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose concentrations in the interstitium of various tumors are very low, measured at 6 mg/l with a mean blood glucose of 1.72 g/l."
Sauerstoff,Sauerstoff is not the only limiting factor for tumor growth; glucose also plays a critical role as a substrate in the metabolic support of tumor expansion.,Entity: Sauerstoff. SMILES: [O]. Sauerstoff is not the only limiting factor for tumor growth; glucose also plays a critical role as a substrate in the metabolic support of tumor expansion.
Oxygen,"In most solid malignant tumors, well-vascularized cells near capillaries exhibit relatively high oxygen consumption rates above the global mean, resulting in a steep oxygen pressure gradient.","Entity: Oxygen. SMILES: [O]. In most solid malignant tumors, well-vascularized cells near capillaries exhibit relatively high oxygen consumption rates above the global mean, resulting in a steep oxygen pressure gradient."
Oxygen,"In solid tumors, cells further from capillaries experience low oxygen supply and a critical oxygen pressure drop, leading to limited oxygen uptake.","Entity: Oxygen. SMILES: [O]. In solid tumors, cells further from capillaries experience low oxygen supply and a critical oxygen pressure drop, leading to limited oxygen uptake."
Oxygen,"In oxygen-deprived or critically supplied zones of solid tumors, particularly at the veno-capillary interface, the local oxygen pressure gradient flattens due to low oxygen uptake.","Entity: Oxygen. SMILES: [O]. In oxygen-deprived or critically supplied zones of solid tumors, particularly at the veno-capillary interface, the local oxygen pressure gradient flattens due to low oxygen uptake."
Glucose,"In the absence of oxygen, glucose in solid tumors can be metabolized anaerobically, while oxygen can serve as the terminal electron acceptor for the oxidation of endogenous substrates such as fatty acids and/or amino acids when glucose is scarce.","Entity: Glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In the absence of oxygen, glucose in solid tumors can be metabolized anaerobically, while oxygen can serve as the terminal electron acceptor for the oxidation of endogenous substrates such as fatty acids and/or amino acids when glucose is scarce."
Sauerstoff,Sauerstoff is required for the aerobic metabolism of endogenous substrates such as fatty acids and amino acids in the absence of glucose in solid tumors.,Entity: Sauerstoff. SMILES: [O]. Sauerstoff is required for the aerobic metabolism of endogenous substrates such as fatty acids and amino acids in the absence of glucose in solid tumors.
Glucose,"Glucose is considered a limiting substrate of the metabolic exchange in cancer cells, and its insufficient supply leads to obligate cell lysis and tissue necrosis in solid tumors.","Entity: Glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is considered a limiting substrate of the metabolic exchange in cancer cells, and its insufficient supply leads to obligate cell lysis and tissue necrosis in solid tumors."
Oxygen,"Oxygen consumption in tumor tissue depends primarily on tissue oxygen transport conditions, especially vascularization, rather than just the metabolic activity of tumor cells.","Entity: Oxygen. SMILES: [O]. Oxygen consumption in tumor tissue depends primarily on tissue oxygen transport conditions, especially vascularization, rather than just the metabolic activity of tumor cells."
Oxygen,"Partial hypoxia and hypoxia are more consequences than causes of malignant growth, with reduced tissue oxygen supply leading to decreased oxygen uptake from the blood.","Entity: Oxygen. SMILES: [O]. Partial hypoxia and hypoxia are more consequences than causes of malignant growth, with reduced tissue oxygen supply leading to decreased oxygen uptake from the blood."
Oxygen,"Oxygen concentration in solid tumor tissue is typically lower than in the surrounding host organ and shows a reduced range of variation, indicating impaired vascularization and oxygen supply during tumor growth.","Entity: Oxygen. SMILES: [O]. Oxygen concentration in solid tumor tissue is typically lower than in the surrounding host organ and shows a reduced range of variation, indicating impaired vascularization and oxygen supply during tumor growth."
Oxygen,"Oxygen partial pressure in solid tumor tissue increases from 50% to 80% in the 0–5 mmHg range as tumor growth progresses, reflecting worsening oxygen deprivation.","Entity: Oxygen. SMILES: [O]. Oxygen partial pressure in solid tumor tissue increases from 50% to 80% in the 0–5 mmHg range as tumor growth progresses, reflecting worsening oxygen deprivation."
Oxygen,"The mean oxygen pressure in tumor tissue decreases exponentially with increasing tumor weight, indicating a critical oxygen pressure threshold below which cellular metabolism is impaired.","Entity: Oxygen. SMILES: [O]. The mean oxygen pressure in tumor tissue decreases exponentially with increasing tumor weight, indicating a critical oxygen pressure threshold below which cellular metabolism is impaired."
Sauerstoff,"The consumption of oxygen by cancer cells is not determined by the metabolic capacity of the cells, but by the limited supply of oxygen reaching the tumor tissue through diffusion and convection.","Entity: Sauerstoff. SMILES: [O]. The consumption of oxygen by cancer cells is not determined by the metabolic capacity of the cells, but by the limited supply of oxygen reaching the tumor tissue through diffusion and convection."
Zucker,"The consumption of sugar by cancer cells is not determined by the metabolic capacity of the cells, but rather by the limited supply of sugar delivered to the tumor tissue via diffusion and convection.","Entity: Zucker. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. The consumption of sugar by cancer cells is not determined by the metabolic capacity of the cells, but rather by the limited supply of sugar delivered to the tumor tissue via diffusion and convection."
putrescine,Putrescine oxidation by pig kidney diamine oxidase is linear with time under the described assay conditions.,Entity: putrescine. SMILES: NCCCCN. Putrescine oxidation by pig kidney diamine oxidase is linear with time under the described assay conditions.
diaminoguanidine,"Diaminoguanidine inhibits the oxidation of putrescine by pig kidney diamine oxidase, but is less active on a molar basis than MBAG in this assay.","Entity: diaminoguanidine. SMILES: N=C(NN)NN. Diaminoguanidine inhibits the oxidation of putrescine by pig kidney diamine oxidase, but is less active on a molar basis than MBAG in this assay."
Spermidine,"Spermidine is a higher polyamine that can be targeted by diamine oxidase, which may contribute to the observed effects of certain inhibitors.","Entity: Spermidine. SMILES: NCCCCNCCCN. Spermidine is a higher polyamine that can be targeted by diamine oxidase, which may contribute to the observed effects of certain inhibitors."
Aminoguanidine,"Aminoguanidine is an inhibitor of diamine oxidase with potency comparable to MGBG and MBAG, but inhibits S-adenosylmethionine decarboxylase only at concentrations greater than 1 mM.","Entity: Aminoguanidine. SMILES: N=C(N)NN. Aminoguanidine is an inhibitor of diamine oxidase with potency comparable to MGBG and MBAG, but inhibits S-adenosylmethionine decarboxylase only at concentrations greater than 1 mM."
S-adenosylmethionine,"S-adenosylmethionine is a substrate for S-adenosylmethionine decarboxylase, which can be inhibited by certain drugs such as MGBG and MBAG.","Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine is a substrate for S-adenosylmethionine decarboxylase, which can be inhibited by certain drugs such as MGBG and MBAG."
Spermine,"Spermine is a higher polyamine that can be targeted by diamine oxidase, which may contribute to the observed effects of certain inhibitors.","Entity: Spermine. SMILES: NCCCNCCCCNCCCN. Spermine is a higher polyamine that can be targeted by diamine oxidase, which may contribute to the observed effects of certain inhibitors."
Putrescine,"Putrescine is a substrate for diamine oxidase, and its degradation can be blocked by certain drugs, potentially leading to increased levels.","Entity: Putrescine. SMILES: NCCCCN. Putrescine is a substrate for diamine oxidase, and its degradation can be blocked by certain drugs, potentially leading to increased levels."
Histamine,"Histamine is a substrate for diamine oxidase, and its levels may be increased by inhibitors such as MGBG and MBAG.","Entity: Histamine. SMILES: NCCc1c[nH]cn1. Histamine is a substrate for diamine oxidase, and its levels may be increased by inhibitors such as MGBG and MBAG."
MGBG,MGBG is a potent inhibitor of mammalian diamine oxidase in vitro and inhibits putresine degradation in vivo for a considerable period.,Entity: MGBG. SMILES: CC(C=NNC(=N)N)=NNC(=N)N. MGBG is a potent inhibitor of mammalian diamine oxidase in vitro and inhibits putresine degradation in vivo for a considerable period.
MGBG,"MGBG is a potent inhibitor of mammalian S-adenosylmethionine decarboxylase, but its effects on this enzyme are short-lived due to stabilization against normal degradation.","Entity: MGBG. SMILES: CC(C=NNC(=N)N)=NNC(=N)N. MGBG is a potent inhibitor of mammalian S-adenosylmethionine decarboxylase, but its effects on this enzyme are short-lived due to stabilization against normal degradation."
MGBG,MGBG completely inhibits spermidine synthesis in rat liver and kidney for only 8 hours after a dose comparable to that used in the study.,Entity: MGBG. SMILES: CC(C=NNC(=N)N)=NNC(=N)N. MGBG completely inhibits spermidine synthesis in rat liver and kidney for only 8 hours after a dose comparable to that used in the study.
putrescine,Most exogenous putrescine oxidation in rats occurs via diamine oxidase activity in the gastrointestinal tract.,Entity: putrescine. SMILES: NCCCCN. Most exogenous putrescine oxidation in rats occurs via diamine oxidase activity in the gastrointestinal tract.
putrescine,"Putrescine is a substrate that can be oxidized by diamine oxidase, with one unit of enzyme activity defined as the oxidation of 1 pmole putrescine per hour at 37°C at saturating substrate concentrations.","Entity: putrescine. SMILES: NCCCCN. Putrescine is a substrate that can be oxidized by diamine oxidase, with one unit of enzyme activity defined as the oxidation of 1 pmole putrescine per hour at 37°C at saturating substrate concentrations."
sodium chloride,Sodium chloride (0.9% w/v) is used as a solution vehicle for both inhibitors and [14C]putrescine in in vivo rat experiments.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride (0.9% w/v) is used as a solution vehicle for both inhibitors and [14C]putrescine in in vivo rat experiments.
toluene,Toluene is used to extract oxidized putrescine from reaction mixtures in enzymatic assays.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used to extract oxidized putrescine from reaction mixtures in enzymatic assays.
carbon dioxide,Carbon dioxide is trapped in wash bottles containing 1 N sodium hydroxide during in vivo rat experiments to measure exhaled CO2.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is trapped in wash bottles containing 1 N sodium hydroxide during in vivo rat experiments to measure exhaled CO2.
sodium hydroxide,Sodium hydroxide (1 N) is used to neutralize exhaled carbon dioxide in rat chamber experiments.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide (1 N) is used to neutralize exhaled carbon dioxide in rat chamber experiments.
water,Water is used to dilute LSC-Cocktail Formula 947 prior to liquid scintillation counting in rat chamber experiments.,Entity: water. SMILES: O. Water is used to dilute LSC-Cocktail Formula 947 prior to liquid scintillation counting in rat chamber experiments.
Aminoguanidine,Aminoguanidine is a classical inhibitor of diamine oxidase.,Entity: Aminoguanidine. SMILES: N=C(N)NN. Aminoguanidine is a classical inhibitor of diamine oxidase.
MBAG,MBAG is a powerful inhibitor of diamine oxidase in vitro and in vivo.,Entity: MBAG. SMILES: CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.N=C(N)N. MBAG is a powerful inhibitor of diamine oxidase in vitro and in vivo.
MGBG,MGBG is a powerful inhibitor of diamine oxidase in vitro and in vivo.,Entity: MGBG. SMILES: CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OB(O)O. MGBG is a powerful inhibitor of diamine oxidase in vitro and in vivo.
Putrescine,Putrescine is used as a substrate for diamine oxidase assays and can be diluted with unlabeled putrescine to adjust specific activity.,Entity: Putrescine. SMILES: NCCCCN. Putrescine is used as a substrate for diamine oxidase assays and can be diluted with unlabeled putrescine to adjust specific activity.
S-adenosylmethionine,"S-adenosylmethionine is a substrate for S-adenosylmethionine decarboxylase, which can be potently inhibited by compounds such as MGBG and MBAG.","Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine is a substrate for S-adenosylmethionine decarboxylase, which can be potently inhibited by compounds such as MGBG and MBAG."
S-adenosylmethionine,S-adenosylmethionine is irreversibly inhibited by dinitrilo] -bis -(3aminoguanidine) (MBAG).,Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine is irreversibly inhibited by dinitrilo] -bis -(3aminoguanidine) (MBAG).
spermidine,"Spermidine levels are increased by MBAG and MGBG, likely due to reduced conversion to putrescine.","Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine levels are increased by MBAG and MGBG, likely due to reduced conversion to putrescine."
putrescine,"Cellular levels of putrescine are increased by MBAG and MGBG, possibly because these compounds inhibit spermidine formation.","Entity: putrescine. SMILES: NCCCCN. Cellular levels of putrescine are increased by MBAG and MGBG, possibly because these compounds inhibit spermidine formation."
putrescine,"Putrescine is produced from L-ornithine decarboxylation, a reaction inhibited by polyamines such as MGBG.","Entity: putrescine. SMILES: NCCCCN. Putrescine is produced from L-ornithine decarboxylation, a reaction inhibited by polyamines such as MGBG."
spermidine,"Spermidine is formed from decarboxylated S-adenosylmethionine, which provides propylamine groups for its synthesis.","Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine is formed from decarboxylated S-adenosylmethionine, which provides propylamine groups for its synthesis."
S-adenosylmethionine,S-adenosylmethionine undergoes decarboxylation to provide propylamine groups for the conversion of putrescine into spermidine.,Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine undergoes decarboxylation to provide propylamine groups for the conversion of putrescine into spermidine.
Dextran 40,Dextran 40 prophylaxis appears to be more effective in reducing the incidence of deep vein thrombosis as the age-related risk increases.,Entity: Dextran 40. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran 40 prophylaxis appears to be more effective in reducing the incidence of deep vein thrombosis as the age-related risk increases.
Dextran,Dextran prophylaxis reduces the incidence of bilateral deep vein thrombosis in patients with deep vein thrombosis.,Entity: Dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran prophylaxis reduces the incidence of bilateral deep vein thrombosis in patients with deep vein thrombosis.
dextran,"Dextran prophylaxis, specifically 4 x 500 ml dextran-40 infusions (Rheomacrodex), reduces the incidence of postoperative deep vein thrombosis in urological and general surgical patients, with 21.7% of patients in the dextran group developing deep vein thrombosis compared to 36% in the control group.","Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran prophylaxis, specifically 4 x 500 ml dextran-40 infusions (Rheomacrodex), reduces the incidence of postoperative deep vein thrombosis in urological and general surgical patients, with 21.7% of patients in the dextran group developing deep vein thrombosis compared to 36% in the control group."
Dextran 40,"Dextran 40 has a pronounced antithrombotic effect and can significantly prevent the occurrence of deep vein thrombosis after orthopedic hip surgery, both when administered as Dextran 40 infusions and in combination with Cumarin.","Entity: Dextran 40. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran 40 has a pronounced antithrombotic effect and can significantly prevent the occurrence of deep vein thrombosis after orthopedic hip surgery, both when administered as Dextran 40 infusions and in combination with Cumarin."
Dextran 40,Thrombi formed under Dextran 40 prophylaxis are relatively rapidly dissolved by the body's endogenous fibrinolysis.,Entity: Dextran 40. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Thrombi formed under Dextran 40 prophylaxis are relatively rapidly dissolved by the body's endogenous fibrinolysis.
Cumarin,"Cumarin, when applied postoperatively in combination with Dextran 40, significantly prevents the occurrence of deep vein thrombosis after total hip replacement surgery.","Entity: Cumarin. SMILES: O=c1ccc2ccccc2o1. Cumarin, when applied postoperatively in combination with Dextran 40, significantly prevents the occurrence of deep vein thrombosis after total hip replacement surgery."
Acetylsalicylsäure,Acetylsalicylsäure alone is ineffective in preventing deep vein thrombosis after orthopedic hip surgery.,Entity: Acetylsalicylsäure. SMILES: CC(=O)Oc1ccccc1C(=O)O. Acetylsalicylsäure alone is ineffective in preventing deep vein thrombosis after orthopedic hip surgery.
testosterone,"Testosterone was the only detectable product formed during the described incubation assay, and the product isolated was 96% pure based on recrystallization with authentic crystalline testosterone.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone was the only detectable product formed during the described incubation assay, and the product isolated was 96% pure based on recrystallization with authentic crystalline testosterone."
testosterone,Enzyme activity is quantified as pmol or nmol testosterone formed per minute per mg microsomal protein in the described assay.,Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Enzyme activity is quantified as pmol or nmol testosterone formed per minute per mg microsomal protein in the described assay.
androstenedione,"Androstenedione serves as the substrate for 17-ketosteroid reductase in enzyme assays, being reduced to testosterone in the presence of NADPH and KC1.","Entity: androstenedione. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. Androstenedione serves as the substrate for 17-ketosteroid reductase in enzyme assays, being reduced to testosterone in the presence of NADPH and KC1."
KC1,KC1 is included at 0.1 M concentration in the buffer for 17-ketosteroid reductase enzyme assays to maintain physiological salt conditions.,Entity: KC1. SMILES: [Cl-].[K+]. KC1 is included at 0.1 M concentration in the buffer for 17-ketosteroid reductase enzyme assays to maintain physiological salt conditions.
dime~ylsulfoxide,Dime~ylsulfoxide is used as a solvent for dissolving [7cu-3H]androstenedione prior to enzyme assay reactions.,Entity: dime~ylsulfoxide. SMILES: CS(C)=O. Dime~ylsulfoxide is used as a solvent for dissolving [7cu-3H]androstenedione prior to enzyme assay reactions.
NADPH,NADPH is used as a cofactor in enzyme assays to support the reduction of androstenedione to testosterone by 17-ketosteroid reductase.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is used as a cofactor in enzyme assays to support the reduction of androstenedione to testosterone by 17-ketosteroid reductase.
testosterone,Testosterone is the product formed by the reduction of androstenedione catalyzed by 17-ketosteroid reductase in enzyme assays.,Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone is the product formed by the reduction of androstenedione catalyzed by 17-ketosteroid reductase in enzyme assays.
"5a-Androstane-3,17-diol","5a-Androstane-3,17-diol inhibits the activity of 17-ketosteroid reductase in interstitial tissue but does not affect seminiferous tubular enzyme activity.","Entity: 5a-Androstane-3,17-diol. SMILES: C[C@]12CCC(O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(O)CC[C@@H]12. 5a-Androstane-3,17-diol inhibits the activity of 17-ketosteroid reductase in interstitial tissue but does not affect seminiferous tubular enzyme activity."
potassium phosphate,Potassium phosphate buffer at 0.05 M and pH 7.4 is used as the reaction buffer in the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity assay.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate buffer at 0.05 M and pH 7.4 is used as the reaction buffer in the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity assay.
chloroform,Chloroform is used as a component (99.5%) of the chloroform/methanol solvent system for thin layer chromatography (ITLC-SA) to separate progesterone in the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity assay.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a component (99.5%) of the chloroform/methanol solvent system for thin layer chromatography (ITLC-SA) to separate progesterone in the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity assay.
methanol,Methanol is used as a solvent for dissolving the chromatographic residue and for eluting progesterone from thin layer plates in the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity assay.,Entity: methanol. SMILES: CO. Methanol is used as a solvent for dissolving the chromatographic residue and for eluting progesterone from thin layer plates in the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity assay.
pregnenolone,Pregnenolone serves as a substrate in assays measuring 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity by its conversion to progesterone.,Entity: pregnenolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Pregnenolone serves as a substrate in assays measuring 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity by its conversion to progesterone.
progesterone,Progesterone is the product formed from pregnenolone by 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity in microsomal preparations.,Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone is the product formed from pregnenolone by 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity in microsomal preparations.
progesterone,The product progesterone in the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase assay can be quantitatively measured by adding 14C-progesterone and detecting the area under ultraviolet light after thin layer chromatography.,Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. The product progesterone in the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase assay can be quantitatively measured by adding 14C-progesterone and detecting the area under ultraviolet light after thin layer chromatography.
progesterone,The progesterone obtained from the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase assay was 99% pure as determined by recrystallization with authentic crystalline progesterone.,Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. The progesterone obtained from the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase assay was 99% pure as determined by recrystallization with authentic crystalline progesterone.
dimethylsulfoxide,Dimethylsulfoxide is used as a solvent for dissolving [3H]pregnenolone prior to the addition of buffer and microsomal preparation in the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity assay.,Entity: dimethylsulfoxide. SMILES: CS(C)=O. Dimethylsulfoxide is used as a solvent for dissolving [3H]pregnenolone prior to the addition of buffer and microsomal preparation in the 3·H-androstenedione A '-3P-hydroxysteroid dehydrogenase-isomerase activity assay.
testosterone,Testosterone increases 17-ketosteroid reductase activity to 251% of control in isolated interstitial tissue.,Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone increases 17-ketosteroid reductase activity to 251% of control in isolated interstitial tissue.
testosterone,"Testosterone inhibits the activity of the 17-ketosteroid reductase enzyme from rat interstitial tissue, with inhibition being most potent at low concentrations.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone inhibits the activity of the 17-ketosteroid reductase enzyme from rat interstitial tissue, with inhibition being most potent at low concentrations."
testosterone,Testosterone stimulates the 17-ketosteroid reductase activity of seminiferous tubules in rats.,Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone stimulates the 17-ketosteroid reductase activity of seminiferous tubules in rats.
estrone,"Estrone inhibits the activity of the 17-ketosteroid reductase enzyme from rat interstitial tissue, but less potently than testosterone and its metabolites.","Entity: estrone. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O. Estrone inhibits the activity of the 17-ketosteroid reductase enzyme from rat interstitial tissue, but less potently than testosterone and its metabolites."
"5α-androstane-3α,17β-diol","5α-androstane-3α,17β-diol is a potent inhibitor of the 17-ketosteroid reductase enzyme from rat interstitial tissue, with an apparent inhibition constant (Ki) of 2.2 PM.","Entity: 5α-androstane-3α,17β-diol. SMILES: C[C@]12CC[C@@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. 5α-androstane-3α,17β-diol is a potent inhibitor of the 17-ketosteroid reductase enzyme from rat interstitial tissue, with an apparent inhibition constant (Ki) of 2.2 PM."
5β-dihydrotestosterone,"5β-dihydrotestosterone inhibits the 17-ketosteroid reductase activity of seminiferous tubules in rats, but only at very high concentrations.","Entity: 5β-dihydrotestosterone. SMILES: C[C@]12CCC(=O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. 5β-dihydrotestosterone inhibits the 17-ketosteroid reductase activity of seminiferous tubules in rats, but only at very high concentrations."
estriol,"Estriol inhibits the activity of the 17-ketosteroid reductase enzyme from rat interstitial tissue, but less potently than testosterone and its metabolites.","Entity: estriol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O. Estriol inhibits the activity of the 17-ketosteroid reductase enzyme from rat interstitial tissue, but less potently than testosterone and its metabolites."
5α-androstane-3α-diol,5α-androstane-3α-diol is the most potent inhibitor among the steroids tested for inhibition of the 17-ketosteroid reductase enzyme from rat interstitial tissue.,Entity: 5α-androstane-3α-diol. SMILES: C[C@@]12CCC[C@H]1[C@@H]1CC[C@H]3CC(O)CC[C@]3(C)[C@H]1CC2. 5α-androstane-3α-diol is the most potent inhibitor among the steroids tested for inhibition of the 17-ketosteroid reductase enzyme from rat interstitial tissue.
"5alpha-androstane-3alpha, 17beta-diol","5alpha-androstane-3alpha, 17beta-diol acts as a competitive inhibitor of 17-ketosteroid reductase with an apparent Ki of 2.2 µM.","Entity: 5alpha-androstane-3alpha, 17beta-diol. SMILES: C[C@]12CC[C@@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. 5alpha-androstane-3alpha, 17beta-diol acts as a competitive inhibitor of 17-ketosteroid reductase with an apparent Ki of 2.2 µM."
"5alpha-androstane-3alpha, 17beta-diol","At low concentrations, 5alpha-androstane-3alpha, 17beta-diol stimulates the 17-ketosteroid reductase activity of seminiferous tubules in rat testes, but at high concentrations it has no effect.","Entity: 5alpha-androstane-3alpha, 17beta-diol. SMILES: C[C@]12CC[C@@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. At low concentrations, 5alpha-androstane-3alpha, 17beta-diol stimulates the 17-ketosteroid reductase activity of seminiferous tubules in rat testes, but at high concentrations it has no effect."
testosterone,Testosterone inhibits the activity of the 17-ketosteroid reductase enzyme from rat interstitial testicular tissue.,Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone inhibits the activity of the 17-ketosteroid reductase enzyme from rat interstitial testicular tissue.
testosterone,Testosterone stimulates the 17-ketosteroid reductase activity of seminiferous tubules in rat testes.,Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone stimulates the 17-ketosteroid reductase activity of seminiferous tubules in rat testes.
estrone,Estrone has minimal inhibitory effect on the 17-ketosteroid reductase enzyme from rat interstitial testicular tissue compared to other steroids tested.,Entity: estrone. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O. Estrone has minimal inhibitory effect on the 17-ketosteroid reductase enzyme from rat interstitial testicular tissue compared to other steroids tested.
estriol,Estrinol has minimal inhibitory effect on the 17-ketosteroid reductase enzyme from rat interstitial testicular tissue compared to other steroids tested.,Entity: estriol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O. Estrinol has minimal inhibitory effect on the 17-ketosteroid reductase enzyme from rat interstitial testicular tissue compared to other steroids tested.
androstenedione,Androstenedione is the substrate for the 17-ketosteroid reductase enzyme that catalyzes the final step in testosterone biosynthesis.,Entity: androstenedione. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. Androstenedione is the substrate for the 17-ketosteroid reductase enzyme that catalyzes the final step in testosterone biosynthesis.
"5alpha-androstane-3alpha, 17beta-diol","5alpha-androstane-3alpha, 17beta-diol is a potent inhibitor of the 17-ketosteroid reductase enzyme from rat interstitial testicular tissue, with an apparent Ki value of 2.2 µM.","Entity: 5alpha-androstane-3alpha, 17beta-diol. SMILES: C[C@]12CC[C@@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. 5alpha-androstane-3alpha, 17beta-diol is a potent inhibitor of the 17-ketosteroid reductase enzyme from rat interstitial testicular tissue, with an apparent Ki value of 2.2 µM."
"5β-androstane-3β,17β-diol","5β-androstane-3β,17β-diol is a potent inhibitor of interstitial tissue 17-ketosteroid reductase activity.","Entity: 5β-androstane-3β,17β-diol. SMILES: C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. 5β-androstane-3β,17β-diol is a potent inhibitor of interstitial tissue 17-ketosteroid reductase activity."
"5β-androstane-3β,17β-diol","At low concentrations, 5β-androstane-3β,17β-diol stimulates 17-ketosteroid reductase activity in seminiferous tubules, but at 0.1 mM it has no effect.","Entity: 5β-androstane-3β,17β-diol. SMILES: C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. At low concentrations, 5β-androstane-3β,17β-diol stimulates 17-ketosteroid reductase activity in seminiferous tubules, but at 0.1 mM it has no effect."
"5β-androstane-3β,17β-diol","The stimulatory effect of 5β-androstane-3β,17β-diol on 17-ketosteroid reductase activity in seminiferous tubules is specific for this steroid and is not observed with structurally similar androgens such as dihydrotestosterone or 5β-androstane-3/3,17fldiol.","Entity: 5β-androstane-3β,17β-diol. SMILES: C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. The stimulatory effect of 5β-androstane-3β,17β-diol on 17-ketosteroid reductase activity in seminiferous tubules is specific for this steroid and is not observed with structurally similar androgens such as dihydrotestosterone or 5β-androstane-3/3,17fldiol."
testosterone,"Testosterone stimulates 17-ketosteroid reductase activity in seminiferous tubules, with the effect being specific for testosterone and not observed with structurally similar androgens.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone stimulates 17-ketosteroid reductase activity in seminiferous tubules, with the effect being specific for testosterone and not observed with structurally similar androgens."
γ-amino butyraldehyde,γ-amino butyraldehyde is an intermediate formed during the oxidation of putrescine by diamine oxidase (DAO) and can cyclize into γ-pyrroline.,Entity: γ-amino butyraldehyde. SMILES: NCCCC=O. γ-amino butyraldehyde is an intermediate formed during the oxidation of putrescine by diamine oxidase (DAO) and can cyclize into γ-pyrroline.
putrescine,"Putrescine is oxidized by diamine oxidase (DAO) to form γ-amino butyraldehyde, which can cyclize into γ-pyrroline.","Entity: putrescine. SMILES: NCCCCN. Putrescine is oxidized by diamine oxidase (DAO) to form γ-amino butyraldehyde, which can cyclize into γ-pyrroline."
toluene,"Toluene is an organic solvent in which the aldimine and its polymers are soluble, facilitating their separation from insoluble compounds.","Entity: toluene. SMILES: Cc1ccccc1. Toluene is an organic solvent in which the aldimine and its polymers are soluble, facilitating their separation from insoluble compounds."
putrescine,"Unlike the aldimine and its polymers, putrescine is insoluble in organic solvents such as toluene.","Entity: putrescine. SMILES: NCCCCN. Unlike the aldimine and its polymers, putrescine is insoluble in organic solvents such as toluene."
o-aminobenzaldehyde,The aldimine and its polymers can interact with o-aminobenzaldehyde.,Entity: o-aminobenzaldehyde. SMILES: Nc1ccccc1C=O. The aldimine and its polymers can interact with o-aminobenzaldehyde.
perchloric acid,Perchloric acid (0.4 M) is used to terminate enzymatic reactions in biochemical assays.,Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid (0.4 M) is used to terminate enzymatic reactions in biochemical assays.
sodium bicarbonate,Saturated sodium bicarbonate solution is used to adjust the pH of reaction mixtures to approximately 9.9 during neutralization steps in biochemical protocols.,Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Saturated sodium bicarbonate solution is used to adjust the pH of reaction mixtures to approximately 9.9 during neutralization steps in biochemical protocols.
sodium hydroxide,"Sodium hydroxide (2 N, pH about 12) is used in combination with saturated sodium bicarbonate to adjust the pH to 9.9 in biochemical reaction mixtures.","Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide (2 N, pH about 12) is used in combination with saturated sodium bicarbonate to adjust the pH to 9.9 in biochemical reaction mixtures."
toluene,Toluene (0.35% PPO) is used as an organic solvent for extracting A'pyrroline and its polymers from aqueous reaction mixtures in biochemical assays.,Entity: toluene. SMILES: Cc1ccccc1. Toluene (0.35% PPO) is used as an organic solvent for extracting A'pyrroline and its polymers from aqueous reaction mixtures in biochemical assays.
"2,5-diphenyloxazole","2,5-diphenyloxazole (PPO) is used as a scintillant in toluene to enable radioactivity measurement in scintillation counting assays.","Entity: 2,5-diphenyloxazole. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. 2,5-diphenyloxazole (PPO) is used as a scintillant in toluene to enable radioactivity measurement in scintillation counting assays."
pyrazole,Pyrazole exhibits weak inhibitory effects on A'pyrroline formation in various tissue homogenates and stronger inhibitory action on purified pea seedling DAO.,Entity: pyrazole. SMILES: c1cn[nH]c1. Pyrazole exhibits weak inhibitory effects on A'pyrroline formation in various tissue homogenates and stronger inhibitory action on purified pea seedling DAO.
putrescine,Putrescine is the direct product of oxidative deamination and serves as a precursor for y-aminobutyraldehyde.,Entity: putrescine. SMILES: NCCCCN. Putrescine is the direct product of oxidative deamination and serves as a precursor for y-aminobutyraldehyde.
GABA,GABA can be produced by the oxidation of y-aminobutyraldehyde via the action of AldDH (aldehyde dehydrogenase).,Entity: GABA. SMILES: NCCCC(=O)O. GABA can be produced by the oxidation of y-aminobutyraldehyde via the action of AldDH (aldehyde dehydrogenase).
aminohydroxybutane,Aminohydroxybutane can be formed by the reduction of y-aminobutyraldehyde through the action of AldR or ADH (alcohol dehydrogenase).,Entity: aminohydroxybutane. SMILES: CCCC(N)O. Aminohydroxybutane can be formed by the reduction of y-aminobutyraldehyde through the action of AldR or ADH (alcohol dehydrogenase).
4-imidazolylacetaldehyde,"4-imidazolylacetaldehyde is unstable and can form an artefact, acetone dinitrophenylhydrazone, which is often mistaken for its product of reaction with histamine.","Entity: 4-imidazolylacetaldehyde. SMILES: O=CCc1c[nH]cn1. 4-imidazolylacetaldehyde is unstable and can form an artefact, acetone dinitrophenylhydrazone, which is often mistaken for its product of reaction with histamine."
acetone dinitrophenylhydrazone,Acetone dinitrophenylhydrazone is an artefact that can be mistaken for the product of histamine reaction with 4-imidazolylacetaldehyde.,Entity: acetone dinitrophenylhydrazone. SMILES: CC(C)=NNc1cccc([N+](=O)[O-])c1[N+](=O)[O-]. Acetone dinitrophenylhydrazone is an artefact that can be mistaken for the product of histamine reaction with 4-imidazolylacetaldehyde.
4-amino-1-butanol,"4-amino-1-butanol can be converted to an alcohol product in tissues, likely via oxidation.","Entity: 4-amino-1-butanol. SMILES: NCCCCO. 4-amino-1-butanol can be converted to an alcohol product in tissues, likely via oxidation."
putrescine,"Putrescine serves as a substrate for purified pig kidney diamine oxidase and liver or yeast alcohol dehydrogenases, leading to the formation of Camino-1-butanol.","Entity: putrescine. SMILES: NCCCCN. Putrescine serves as a substrate for purified pig kidney diamine oxidase and liver or yeast alcohol dehydrogenases, leading to the formation of Camino-1-butanol."
Prajmaliumbitartrat,"Prajmaliumbitartrat can cause transient elevations in liver enzymes (GOT, GPT, y-GT, GLDH) and abdominal pain, with normalization occurring after discontinuation and resolution of symptoms.","Entity: Prajmaliumbitartrat. SMILES: CCC[N@+]12[C@H](O)[C@@H](CC)[C@@H]3C[C@H]1[C@@H]1N(C)c4ccccc4[C@]14C[C@H]2[C@H]3[C@H]4O.O=C([O-])[C@H](O)[C@@H](O)C(=O)O. Prajmaliumbitartrat can cause transient elevations in liver enzymes (GOT, GPT, y-GT, GLDH) and abdominal pain, with normalization occurring after discontinuation and resolution of symptoms."
Prajmaliumbitartrat,"Prajmaliumbitartrat has better bioavailability compared to Ajmalin, resulting in higher serum levels within one hour of administration.","Entity: Prajmaliumbitartrat. SMILES: CCC[N@+]12[C@H](O)[C@@H](CC)[C@@H]3C[C@H]1[C@@H]1N(C)c4ccccc4[C@]14C[C@H]2[C@H]3[C@H]4O.O=C([O-])[C@H](O)[C@@H](O)C(=O)O. Prajmaliumbitartrat has better bioavailability compared to Ajmalin, resulting in higher serum levels within one hour of administration."
Prajmaliumbitartrat,"Prajmaliumbitartrat is associated with liver injury, with clinical, clinical-chemical, and morphological findings of amalin- and prajmaliumbitartrat-induced liver diseases being identical.","Entity: Prajmaliumbitartrat. SMILES: CCC[N@+]12[C@H](O)[C@@H](CC)[C@@H]3C[C@H]1[C@@H]1N(C)c4ccccc4[C@]14C[C@H]2[C@H]3[C@H]4O.O=C([O-])[C@H](O)[C@@H](O)C(=O)O. Prajmaliumbitartrat is associated with liver injury, with clinical, clinical-chemical, and morphological findings of amalin- and prajmaliumbitartrat-induced liver diseases being identical."
Ajmalin,"Ajmalin is less bioavailable than Prajmaliumbitartrat, resulting in lower serum levels after administration.","Entity: Ajmalin. SMILES: CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)c5ccccc5[C@]45C[C@@H]([C@H]2[C@H]5O)N3[C@@H]1O. Ajmalin is less bioavailable than Prajmaliumbitartrat, resulting in lower serum levels after administration."
aspirin,Aspirin dosage is adjusted in patients receiving gold sodium thiomalate to maintain serum salicylate levels at 20 mg%.,Entity: aspirin. SMILES: CC(=O)Oc1ccccc1C(=O)O. Aspirin dosage is adjusted in patients receiving gold sodium thiomalate to maintain serum salicylate levels at 20 mg%.
gold sodium thiomalate,"Gold sodium thiomalate is administered by weekly injections to patients, with serum gold levels maintained above a minimum of 300 pg% (approximately 700–300 pg%) to exert immunosuppressive effects.","Entity: gold sodium thiomalate. SMILES: O=C([O-])CC(S)C(=O)[O-].O=C([O-])CC(S)C(=O)[O-].[Au+3].[Na+]. Gold sodium thiomalate is administered by weekly injections to patients, with serum gold levels maintained above a minimum of 300 pg% (approximately 700–300 pg%) to exert immunosuppressive effects."
Prednisone,Prednisone is a corticosteroid that can be administered at a maximum dosage of 20 mg per day in patients with rheumatoid arthritis.,Entity: Prednisone. SMILES: C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO. Prednisone is a corticosteroid that can be administered at a maximum dosage of 20 mg per day in patients with rheumatoid arthritis.
Indomethacin,Indomethacin is a nonsteroidal anti-inflammatory drug that can be administered at doses of 100–200 mg daily as part of comprehensive anti-inflammatory therapy for rheumatoid arthritis.,Entity: Indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin is a nonsteroidal anti-inflammatory drug that can be administered at doses of 100–200 mg daily as part of comprehensive anti-inflammatory therapy for rheumatoid arthritis.
Phenylbutazone,Phenylbutazone is a nonsteroidal anti-inflammatory drug that can be administered at doses of 300–600 mg daily as part of comprehensive anti-inflammatory therapy for rheumatoid arthritis.,Entity: Phenylbutazone. SMILES: CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O. Phenylbutazone is a nonsteroidal anti-inflammatory drug that can be administered at doses of 300–600 mg daily as part of comprehensive anti-inflammatory therapy for rheumatoid arthritis.
Aspirin,Aspirin is a nonsteroidal anti-inflammatory drug that can be administered to maintain serum levels of 20 mg/dl as part of comprehensive anti-inflammatory therapy for rheumatoid arthritis.,Entity: Aspirin. SMILES: CC(=O)Oc1ccccc1C(=O)O. Aspirin is a nonsteroidal anti-inflammatory drug that can be administered to maintain serum levels of 20 mg/dl as part of comprehensive anti-inflammatory therapy for rheumatoid arthritis.
gold,"Gold is used in chrysotherapy, and monitoring serum gold levels is important to avoid excessive exposure.","Entity: gold. SMILES: [Au]. Gold is used in chrysotherapy, and monitoring serum gold levels is important to avoid excessive exposure."
gold,"Dermatitis is a common side effect of gold therapy, and may be a manifestation of hypersensitivity rather than toxicity.","Entity: gold. SMILES: [Au]. Dermatitis is a common side effect of gold therapy, and may be a manifestation of hypersensitivity rather than toxicity."
gold sodium thiomalate,"Gold sodium thiomalate, when administered as a weekly, sustained therapy for rheumatoid arthritis, produces maximal suppression of IgG and IgM by the third and fourth years of treatment, with cumulative dosages of 2106 mg (1065–2,885 mg over one year) and 8747 mg (5,385–15,160 mg over at least four years), respectively.","Entity: gold sodium thiomalate. SMILES: O=C([O-])CC(S)C(=O)[O-].O=C([O-])CC(S)C(=O)[O-].[Au+3].[Na+]. Gold sodium thiomalate, when administered as a weekly, sustained therapy for rheumatoid arthritis, produces maximal suppression of IgG and IgM by the third and fourth years of treatment, with cumulative dosages of 2106 mg (1065–2,885 mg over one year) and 8747 mg (5,385–15,160 mg over at least four years), respectively."
Gold,"Gold compounds can act as enzyme inhibitors, stabilize collagen, alter trace metal concentrations, exert activity against infectious agents, and produce immunosuppression.","Entity: Gold. SMILES: [Au]. Gold compounds can act as enzyme inhibitors, stabilize collagen, alter trace metal concentrations, exert activity against infectious agents, and produce immunosuppression."
Gold,"At pulse levels of 700–300 pg%, gold binds disproportionately to immunoglobulins, complement components, and lymphocytes, as well as albumin.","Entity: Gold. SMILES: [Au]. At pulse levels of 700–300 pg%, gold binds disproportionately to immunoglobulins, complement components, and lymphocytes, as well as albumin."
Gold,"In long-term therapy, gold accumulates in lymph nodes, spleen, and other tissues with abundant reticuloendothelial cells.","Entity: Gold. SMILES: [Au]. In long-term therapy, gold accumulates in lymph nodes, spleen, and other tissues with abundant reticuloendothelial cells."
Gold,"Gold compounds decrease the phagocytic activity of leukocytes, particularly macrophages.","Entity: Gold. SMILES: [Au]. Gold compounds decrease the phagocytic activity of leukocytes, particularly macrophages."
Gold,Gold inhibits DNA synthesis in PHA-stimulated sheep lymphocytes.,Entity: Gold. SMILES: [Au]. Gold inhibits DNA synthesis in PHA-stimulated sheep lymphocytes.
gold,"Long-term weekly gold administration leads to a sustained and significant decline in immunoglobulin levels, particularly for IgM, in rheumatoid arthritis patients.","Entity: gold. SMILES: [Au]. Long-term weekly gold administration leads to a sustained and significant decline in immunoglobulin levels, particularly for IgM, in rheumatoid arthritis patients."
gold,Gold complexes are unstable and readily undergo decomposition and valence change in the absence of excess ligand.,Entity: gold. SMILES: [Au]. Gold complexes are unstable and readily undergo decomposition and valence change in the absence of excess ligand.
aspirin,Aspirin does not suppress immunoglobulin levels in rheumatoid arthritis patients.,Entity: aspirin. SMILES: CC(=O)Oc1ccccc1C(=O)O. Aspirin does not suppress immunoglobulin levels in rheumatoid arthritis patients.
Gold,"Gold is administered in chrysotherapy, with patients receiving at least one year of weekly treatment amounting to more than 2 grams per year (yearly mean = 2106 mg; range 1065–2,885 mg; 2–4 year cumulative dosage = 8747 mg; range 5385–15,160 mg).","Entity: Gold. SMILES: [Au]. Gold is administered in chrysotherapy, with patients receiving at least one year of weekly treatment amounting to more than 2 grams per year (yearly mean = 2106 mg; range 1065–2,885 mg; 2–4 year cumulative dosage = 8747 mg; range 5385–15,160 mg)."
α-Aminolävulinsäure,Serum-Harnstoff-N (BUN) is used as a marker of kidney function and has a normal reference range of 28.0 mg/dl in the described patient population.,Entity: α-Aminolävulinsäure. SMILES: CC(=O)CC(N)C(=O)O. Serum-Harnstoff-N (BUN) is used as a marker of kidney function and has a normal reference range of 28.0 mg/dl in the described patient population.
β-Aminolävulinsäure,Serum-Harnstoff-N (BUN) is used as a marker of kidney function and has a normal reference range of 28.0 mg/dl in the described patient population.,Entity: β-Aminolävulinsäure. SMILES: CC(=O)C(N)CC(=O)O. Serum-Harnstoff-N (BUN) is used as a marker of kidney function and has a normal reference range of 28.0 mg/dl in the described patient population.
Progestern,"Progestogens have been used in attempts to positively influence the course of acute intermittent porphyria in women, but with mixed results.","Entity: Progestern. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progestogens have been used in attempts to positively influence the course of acute intermittent porphyria in women, but with mixed results."
Porphobilinogen,Porphobilinogen is a urinary biomarker with a normal reference range of 1700 ± 200 mg/24 h in women.,Entity: Porphobilinogen. SMILES: NCc1[nH]cc(CCC(=O)O)c1CC(=O)O. Porphobilinogen is a urinary biomarker with a normal reference range of 1700 ± 200 mg/24 h in women.
Harnstoff,Serum-Harnstoff-N (BUN) is used as a marker of kidney function and has a normal reference range of 28.0 mg/dl in the described patient population.,Entity: Harnstoff. SMILES: NC(N)=O. Serum-Harnstoff-N (BUN) is used as a marker of kidney function and has a normal reference range of 28.0 mg/dl in the described patient population.
Tri-potassium di-citrato bismuthate,Tri-potassium di-citrato bismuthate may produce a mucin-like layer or combine with mucoprotein to cover the entire gastric mucosa.,Entity: Tri-potassium di-citrato bismuthate. SMILES: O=[Bi]. Tri-potassium di-citrato bismuthate may produce a mucin-like layer or combine with mucoprotein to cover the entire gastric mucosa.
Tri-potassium di-citrato bismuthate,Tri-potassium di-citrato bismuthate may inhibit the action of pepsin by chelation.,Entity: Tri-potassium di-citrato bismuthate. SMILES: O=[Bi]. Tri-potassium di-citrato bismuthate may inhibit the action of pepsin by chelation.
aspirin,Aspirin at a dose of 50 mg/kg administered intragastrically reduces the incidence of glandular ulceration by 55% in rats.,Entity: aspirin. SMILES: CC(=O)Oc1ccccc1C(=O)O. Aspirin at a dose of 50 mg/kg administered intragastrically reduces the incidence of glandular ulceration by 55% in rats.
bismuth tri-potassium citrate,Daily administration of bismuth tri-potassium citrate reduces the incidence of glandular ulceration in rats by 55% when combined with cortisone-induced ulcers.,Entity: bismuth tri-potassium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3].[K+].[K+].[K+]. Daily administration of bismuth tri-potassium citrate reduces the incidence of glandular ulceration in rats by 55% when combined with cortisone-induced ulcers.
cortisone,"Cortisone induces ulcers in rats, and its-induced ulcers can be reduced by 55% when combined with bismuth tri-potassium citrate treatment.","Entity: cortisone. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO. Cortisone induces ulcers in rats, and its-induced ulcers can be reduced by 55% when combined with bismuth tri-potassium citrate treatment."
sodium hydroxide,"Sodium hydroxide is used to neutralize free acid in gastric juice, raising the pH above 4.55 in vitro.","Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to neutralize free acid in gastric juice, raising the pH above 4.55 in vitro."
hydrochloric acid,"Hydrochloric acid is used to lower the pH of gastric juice below 4, resulting in the formation of a heavy precipitate.","Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to lower the pH of gastric juice below 4, resulting in the formation of a heavy precipitate."
bismuth,Bismuth accumulates in canine kidneys at a concentration of 34.5 parts per million (ppm) following administration of 'Ulcerine' at doses approximately 20 times those used in humans.,Entity: bismuth. SMILES: [Bi]. Bismuth accumulates in canine kidneys at a concentration of 34.5 parts per million (ppm) following administration of 'Ulcerine' at doses approximately 20 times those used in humans.
tripotassium di-citrato bismuthate,Tripotassium di-citrato bismuthate treatment results in a 91% reduction in gastric ulcer size at 4 weeks compared to pretreatment area.,Entity: tripotassium di-citrato bismuthate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3].[K+].[K+].[K+]. Tripotassium di-citrato bismuthate treatment results in a 91% reduction in gastric ulcer size at 4 weeks compared to pretreatment area.
bismuth,Longer therapy with tri-potassium dicitrato bismuthate may require monitoring of blood and urine levels of bismuth to assess potential side effects.,Entity: bismuth. SMILES: [Bi]. Longer therapy with tri-potassium dicitrato bismuthate may require monitoring of blood and urine levels of bismuth to assess potential side effects.
bismuth tri-potassium citrate,Bismuth tri-potassium citrate accelerates the rate of healing of gastric and duodenal ulcers in ambulant patients when administered for 4 weeks.,Entity: bismuth tri-potassium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3].[K+].[K+].[K+]. Bismuth tri-potassium citrate accelerates the rate of healing of gastric and duodenal ulcers in ambulant patients when administered for 4 weeks.
bismuth,"Bismuth compounds can form a protective layer at ulcer sites, likely through chelation with proteins and amino acids from necrotic ulcer tissue.","Entity: bismuth. SMILES: [Bi]. Bismuth compounds can form a protective layer at ulcer sites, likely through chelation with proteins and amino acids from necrotic ulcer tissue."
bismuth,Bismuth compounds may inhibit the action of pepsin and/or produce a mucin-like layer to cover the gastric mucosa.,Entity: bismuth. SMILES: [Bi]. Bismuth compounds may inhibit the action of pepsin and/or produce a mucin-like layer to cover the gastric mucosa.
NADPH,"NADPH is consumed by the microsomal electron transport chain of liver cells as part of mixed-function oxidase activity, which oxidizes both endogenous and foreign substances.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is consumed by the microsomal electron transport chain of liver cells as part of mixed-function oxidase activity, which oxidizes both endogenous and foreign substances."
pethidine,Pethidine (meperidine) is a drug whose biotransformation can be retarded by sex steroids due to substrate competition for drug-metabolising enzyme systems.,Entity: pethidine. SMILES: CCOC(=O)C1(c2ccccc2)CCN(C)CC1. Pethidine (meperidine) is a drug whose biotransformation can be retarded by sex steroids due to substrate competition for drug-metabolising enzyme systems.
antipyrine,Antipyrine (phenazone) is a drug whose biotransformation can be retarded by sex steroids due to substrate competition for drug-metabolising enzyme systems.,Entity: antipyrine. SMILES: O=C1CC=Cc2nc3ccccc3nc21. Antipyrine (phenazone) is a drug whose biotransformation can be retarded by sex steroids due to substrate competition for drug-metabolising enzyme systems.
oxygen,"Molecular oxygen is consumed by the microsomal electron transport chain of liver cells as part of mixed-function oxidase activity, which oxidizes both endogenous and foreign substances.","Entity: oxygen. SMILES: O=O. Molecular oxygen is consumed by the microsomal electron transport chain of liver cells as part of mixed-function oxidase activity, which oxidizes both endogenous and foreign substances."
caffeine,"Caffeine, present in some commercial analgesics, has been linked to increased bleeding disorders in women using oral contraceptives.","Entity: caffeine. SMILES: Cn1c(=O)c2c(ncn2C)n(C)c1=O. Caffeine, present in some commercial analgesics, has been linked to increased bleeding disorders in women using oral contraceptives."
antipyrine,"Antipyrine (phenazone), a component of certain commercial analgesics, is associated with a higher risk of bleeding disorders in women on oral contraceptives.","Entity: antipyrine. SMILES: O=C1CC=Cc2nc3ccccc3nc21. Antipyrine (phenazone), a component of certain commercial analgesics, is associated with a higher risk of bleeding disorders in women on oral contraceptives."
phenytoin,Phenytoin is a drug that has been reported to increase bleeding disorders in women using oral contraceptives.,Entity: phenytoin. SMILES: O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1. Phenytoin is a drug that has been reported to increase bleeding disorders in women using oral contraceptives.
chloramphenicol,Chloramphenicol is a drug that has been associated with increased bleeding disorders in women using oral contraceptives.,Entity: chloramphenicol. SMILES: O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl. Chloramphenicol is a drug that has been associated with increased bleeding disorders in women using oral contraceptives.
phenacetin,"Phenacetin, a component of some commercial analgesics, has been linked to increased bleeding disorders in women taking oral contraceptives.","Entity: phenacetin. SMILES: CCOc1ccc(NC(C)=O)cc1. Phenacetin, a component of some commercial analgesics, has been linked to increased bleeding disorders in women taking oral contraceptives."
amidopyrine,"Amidopyrine (aminophenazone), found in certain commercial analgesics, is associated with a higher risk of bleeding disorders in women using oral contraceptives.","Entity: amidopyrine. SMILES: NC1C=Cc2nc3ccccc3nc2C1=O. Amidopyrine (aminophenazone), found in certain commercial analgesics, is associated with a higher risk of bleeding disorders in women using oral contraceptives."
acetylsalicylic acid,"Acetylsalicylic acid, used in some commercial analgesics, has been reported to increase bleeding disorders in women on oral contraceptives.","Entity: acetylsalicylic acid. SMILES: CC(=O)Oc1ccccc1C(=O)O. Acetylsalicylic acid, used in some commercial analgesics, has been reported to increase bleeding disorders in women on oral contraceptives."
nitrofurantoin,"Nitrofurantoin, an antibacterial agent, is associated with a greater incidence of bleeding disorders in women taking oral contraceptives.","Entity: nitrofurantoin. SMILES: O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1. Nitrofurantoin, an antibacterial agent, is associated with a greater incidence of bleeding disorders in women taking oral contraceptives."
gold sodium thiomalate,"Gold sodium thiomalate is associated with postinjection site pain syndrome, which is a mild, transient reaction that can be abolished by substituting gold thiosulfate.","Entity: gold sodium thiomalate. SMILES: O=C([O-])CC(S)C(=O)[O-].O=C([O-])CC(S)C(=O)[O-].[Au+3].[Na+]. Gold sodium thiomalate is associated with postinjection site pain syndrome, which is a mild, transient reaction that can be abolished by substituting gold thiosulfate."
gold thiosulfate,Gold thiosulfate is used as a substitute for gold sodium thiomalate to prevent postinjection site pain syndrome and other nitritoid and nonnitritoid reactions in patients receiving gold therapy.,Entity: gold thiosulfate. SMILES: O=S([O-])([O-])=S.O=S([O-])([O-])=S.O=S([O-])([O-])=S.[Au+3].[Au+3]. Gold thiosulfate is used as a substitute for gold sodium thiomalate to prevent postinjection site pain syndrome and other nitritoid and nonnitritoid reactions in patients receiving gold therapy.
Gold sodium thiomalate,"Gold sodium thiomalate is a form of gold therapy used to treat rheumatoid arthritis, but can cause hypersensitivity reactions including local pain, facial flushing, tachycardia, and hypotension following injection.","Entity: Gold sodium thiomalate. SMILES: O=C([O-])CC(S)C(=O)[O-].O=C([O-])CC(S)C(=O)[O-].[Au+3].[Na+]. Gold sodium thiomalate is a form of gold therapy used to treat rheumatoid arthritis, but can cause hypersensitivity reactions including local pain, facial flushing, tachycardia, and hypotension following injection."
Gold thioglucose,Gold thioglucose is a form of gold therapy used to treat rheumatoid arthritis and can be substituted for gold sodium thiomalate in patients who experience hypersensitivity reactions to the latter.,Entity: Gold thioglucose. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S.[Au]. Gold thioglucose is a form of gold therapy used to treat rheumatoid arthritis and can be substituted for gold sodium thiomalate in patients who experience hypersensitivity reactions to the latter.
leucine,"Growth hormone in vitro significantly stimulates leucine incorporation into protein in diaphragms from untreated dwarf mice aged 5–15 weeks, with the average stimulation magnitude varying from 10% to 40%.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Growth hormone in vitro significantly stimulates leucine incorporation into protein in diaphragms from untreated dwarf mice aged 5–15 weeks, with the average stimulation magnitude varying from 10% to 40%."
3-O-methyl-glucose,Growth hormone does not significantly stimulate 3-O-methyl-glucose uptake in diaphragms from untreated mice aged 11–40 weeks.,Entity: 3-O-methyl-glucose. SMILES: CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](O)C=O. Growth hormone does not significantly stimulate 3-O-methyl-glucose uptake in diaphragms from untreated mice aged 11–40 weeks.
L-leucine,"L-leucine can be labeled with 3H at the 4,5 positions to produce [4,5-3 H(N)]L-leucine for use as a radiolabeled compound.","Entity: L-leucine. SMILES: CC(C)C[C@H](N)C(=O)O. L-leucine can be labeled with 3H at the 4,5 positions to produce [4,5-3 H(N)]L-leucine for use as a radiolabeled compound."
2-aminoisobutyric acid,2-aminoisobutyric acid can be labeled with 14C to produce [1-14 C]2aminoisobutyric acid (AIB) for use as a radiolabeled compound.,Entity: 2-aminoisobutyric acid. SMILES: CC(C)(N)C(=O)O. 2-aminoisobutyric acid can be labeled with 14C to produce [1-14 C]2aminoisobutyric acid (AIB) for use as a radiolabeled compound.
L-thyroxine,"L-thyroxine (T4) is a thyroid hormone that can be dissolved in deionized water made slightly basic with 0.1 N NaOH, diluted to 50 µg/ml in bovine serum albumin, and stored frozen for subcutaneous administration.","Entity: L-thyroxine. SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O. L-thyroxine (T4) is a thyroid hormone that can be dissolved in deionized water made slightly basic with 0.1 N NaOH, diluted to 50 µg/ml in bovine serum albumin, and stored frozen for subcutaneous administration."
L-triiodothyronine,"L-triiodothyronine (T3) is a thyroid hormone that can be dissolved in deionized water made slightly basic with 0.1 N NaOH, diluted to 50 µg/ml in bovine serum albumin, and stored frozen for subcutaneous administration.","Entity: L-triiodothyronine. SMILES: N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O. L-triiodothyronine (T3) is a thyroid hormone that can be dissolved in deionized water made slightly basic with 0.1 N NaOH, diluted to 50 µg/ml in bovine serum albumin, and stored frozen for subcutaneous administration."
sodium hydroxide,Sodium hydroxide is used to adjust the pH of deionized water to slightly basic (0.1 N) for dissolving L-thyroxine and L-triiodothyronine.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to adjust the pH of deionized water to slightly basic (0.1 N) for dissolving L-thyroxine and L-triiodothyronine.
sodium chloride,Sodium chloride is used at 0.9 g/dl concentration in the preparation and dilution of L-thyroxine and L-triiodothyronine solutions for subcutaneous administration.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at 0.9 g/dl concentration in the preparation and dilution of L-thyroxine and L-triiodothyronine solutions for subcutaneous administration.
iodine,"Iodine is required for the response of hypophysectomizedthyroparathyroidectomized rats to GH in vitro, indicating its role in mediating GH action.","Entity: iodine. SMILES: [I]. Iodine is required for the response of hypophysectomizedthyroparathyroidectomized rats to GH in vitro, indicating its role in mediating GH action."
AIB,"AIB is transported across mouse hemidiaphragm in an active transport system, as evidenced by accumulation against a concentration gradient and a distribution ratio greater than 1.0.","Entity: AIB. SMILES: CC(C)(N)C(=O)O. AIB is transported across mouse hemidiaphragm in an active transport system, as evidenced by accumulation against a concentration gradient and a distribution ratio greater than 1.0."
AIB,"The apparent Km for AIB transport by mouse hemidiaphragm is approximately 3 × 10⁻⁶ M, similar to that observed in normal rat diaphragms.","Entity: AIB. SMILES: CC(C)(N)C(=O)O. The apparent Km for AIB transport by mouse hemidiaphragm is approximately 3 × 10⁻⁶ M, similar to that observed in normal rat diaphragms."
AIB,"The rate of AIB transport by mouse hemidiaphragm is diminished by a tenfold excess of unlabelled glycine, indicating competition with glycine for the AIB carrier.","Entity: AIB. SMILES: CC(C)(N)C(=O)O. The rate of AIB transport by mouse hemidiaphragm is diminished by a tenfold excess of unlabelled glycine, indicating competition with glycine for the AIB carrier."
3-OMG,"3-OMG uptake rates can be considerably enhanced by treatment, although the paragraph does not specify the nature of the treatment.","Entity: 3-OMG. SMILES: CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](O)C=O. 3-OMG uptake rates can be considerably enhanced by treatment, although the paragraph does not specify the nature of the treatment."
leucine,Leucine incorporation into protein in mice aged 5 weeks to 2 years is stimulated by growth hormone.,Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine incorporation into protein in mice aged 5 weeks to 2 years is stimulated by growth hormone.
tetracycline,Tetracycline was administered to Sprague-Dawley rats at a concentration of 9.26 g/1 in drinking water.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline was administered to Sprague-Dawley rats at a concentration of 9.26 g/1 in drinking water.
sucrose,Sucrose was administered to Sprague-Dawley rats at a concentration of 5 g/dl in drinking water.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose was administered to Sprague-Dawley rats at a concentration of 5 g/dl in drinking water.
3-OMG,"In hypophysectomized rat muscle, 3-OMG transport is stimulated by growth hormone (GH), but this stimulation is acute and disappears within 2–3 hours, indicating refractoriness after repeated stimulation.","Entity: 3-OMG. SMILES: CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](O)C=O. In hypophysectomized rat muscle, 3-OMG transport is stimulated by growth hormone (GH), but this stimulation is acute and disappears within 2–3 hours, indicating refractoriness after repeated stimulation."
T3,"T3 (triiodothyronine) increases the turnover rates of hepatic and plasma proteins in dwarf mice, but not growth hormone secretion.","Entity: T3. SMILES: N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O. T3 (triiodothyronine) increases the turnover rates of hepatic and plasma proteins in dwarf mice, but not growth hormone secretion."
leucine,"In hypophysectomized rat diaphragm, leucine incorporation into protein is stimulated by GH at a higher threshold concentration than AIB transport.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. In hypophysectomized rat diaphragm, leucine incorporation into protein is stimulated by GH at a higher threshold concentration than AIB transport."
thyroxine,Thyroxine (T4) treatment at 0.3–5 µg/day for 4 days increases the responsiveness of transport systems to growth hormone (GH) in diaphragm muscle from dwarf mice.,Entity: thyroxine. SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O. Thyroxine (T4) treatment at 0.3–5 µg/day for 4 days increases the responsiveness of transport systems to growth hormone (GH) in diaphragm muscle from dwarf mice.
2-aminoisobutyric acid,"2-aminoisobutyric acid (AIB) uptake in diaphragm muscle from untreated dwarf mice is generally low, but can be slightly increased by insulin (50 µU/ml) or by pretreatment with thyroxine (T4) or 3,5,3'-triiodo thyronine (T3).","Entity: 2-aminoisobutyric acid. SMILES: CC(C)(N)C(=O)O. 2-aminoisobutyric acid (AIB) uptake in diaphragm muscle from untreated dwarf mice is generally low, but can be slightly increased by insulin (50 µU/ml) or by pretreatment with thyroxine (T4) or 3,5,3'-triiodo thyronine (T3)."
2-aminoisobutyric acid,"After 4 days of thyroxine (T4) treatment at 0.3–5 µg/day, 0.75 µg/ml growth hormone (GH) stimulates AIB transport in 15-week-old dwarf mice.","Entity: 2-aminoisobutyric acid. SMILES: CC(C)(N)C(=O)O. After 4 days of thyroxine (T4) treatment at 0.3–5 µg/day, 0.75 µg/ml growth hormone (GH) stimulates AIB transport in 15-week-old dwarf mice."
2-aminoisobutyric acid,"At concentrations of 25 µg/ml GH, AIB transport in dwarf mice aged 5 weeks–1 year is stimulated.","Entity: 2-aminoisobutyric acid. SMILES: CC(C)(N)C(=O)O. At concentrations of 25 µg/ml GH, AIB transport in dwarf mice aged 5 weeks–1 year is stimulated."
leucine,Leucine incorporation into protein in diaphragm muscle from dwarf mice aged 5 weeks–2 years is stimulated by 25 µg/ml growth hormone (GH).,Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine incorporation into protein in diaphragm muscle from dwarf mice aged 5 weeks–2 years is stimulated by 25 µg/ml growth hormone (GH).
"3,5,3'-triiodo thyronine","Pretreatment with 3,5,3'-triiodo thyronine (T3) at 0.1 µg/day for 4 days enhances the responsiveness of transport systems to growth hormone (GH) in diaphragm muscle from dwarf mice.","Entity: 3,5,3'-triiodo thyronine. SMILES: N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O. Pretreatment with 3,5,3'-triiodo thyronine (T3) at 0.1 µg/day for 4 days enhances the responsiveness of transport systems to growth hormone (GH) in diaphragm muscle from dwarf mice."
AIB,"AIB is used as a tracer to measure amino acid transport in mouse hemidiaphragms in vitro, with incorporation measured as dpm 3H/mg protein.","Entity: AIB. SMILES: CC(C)(N)C(=O)O. AIB is used as a tracer to measure amino acid transport in mouse hemidiaphragms in vitro, with incorporation measured as dpm 3H/mg protein."
oxygen,Oxygen is provided at 95% concentration in the gassed buffer for incubating mouse hemidiaphragms in vitro.,Entity: oxygen. SMILES: [O]. Oxygen is provided at 95% concentration in the gassed buffer for incubating mouse hemidiaphragms in vitro.
glucose,Glucose is included at 10 µM concentration in the Krebs-Ringer bicarbonate buffer for washing and incubating mouse hemidiaphragms in vitro.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is included at 10 µM concentration in the Krebs-Ringer bicarbonate buffer for washing and incubating mouse hemidiaphragms in vitro.
carbon dioxide,Carbon dioxide is provided at 5% concentration in the gassed buffer for incubating mouse hemidiaphragms in vitro.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is provided at 5% concentration in the gassed buffer for incubating mouse hemidiaphragms in vitro.
leucine,"Leucine is used as a tracer to measure amino acid transport in mouse hemidiaphragms in vitro, with incorporation measured as dpm 3H/mg protein.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine is used as a tracer to measure amino acid transport in mouse hemidiaphragms in vitro, with incorporation measured as dpm 3H/mg protein."
trichloroacetic acid,Trichloroacetic acid is used to homogenize mouse hemidiaphragms for protein analysis in vitro.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to homogenize mouse hemidiaphragms for protein analysis in vitro.
GH,"GH stimulates protein synthesis in diaphragm muscle from untreated dwarf mice, as measured by the rate of leucine incorporation into protein.","Entity: GH. GH stimulates protein synthesis in diaphragm muscle from untreated dwarf mice, as measured by the rate of leucine incorporation into protein."
GH,Thyroxine (T4) treatment at 0.3–5 µg/day for 4 days enhances the responsiveness of transport systems to GH in diaphragm muscle from dwarf mice.,Entity: GH. Thyroxine (T4) treatment at 0.3–5 µg/day for 4 days enhances the responsiveness of transport systems to GH in diaphragm muscle from dwarf mice.
GH,"GH occasionally increases the uptake of 2-aminoisobutyric acid (AIB) in diaphragm muscle from untreated dwarf mice, but this effect is not consistent.","Entity: GH. GH occasionally increases the uptake of 2-aminoisobutyric acid (AIB) in diaphragm muscle from untreated dwarf mice, but this effect is not consistent."
GH,"The maximum response to GH in diaphragm muscle from dwarf mice occurs 1 week after the last injection of T4, indicating that the effect of T4 on GH responsiveness is not permanent.","Entity: GH. The maximum response to GH in diaphragm muscle from dwarf mice occurs 1 week after the last injection of T4, indicating that the effect of T4 on GH responsiveness is not permanent."
GH,"In diaphragm muscle from untreated dwarf mice, GH at 0.75 µg/ml stimulates AIB transport, while 25 µg/ml GH stimulates AIB transport in dwarfs aged 5 weeks to 1 year and leucine incorporation into protein in dwarfs aged 5 weeks to 2 years.","Entity: GH. In diaphragm muscle from untreated dwarf mice, GH at 0.75 µg/ml stimulates AIB transport, while 25 µg/ml GH stimulates AIB transport in dwarfs aged 5 weeks to 1 year and leucine incorporation into protein in dwarfs aged 5 weeks to 2 years."
triiodothyronine,Serum triiodothyronine (T3) is undetectable in athyreotic rats as assessed by radioimmunoassay.,Entity: triiodothyronine. SMILES: N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O. Serum triiodothyronine (T3) is undetectable in athyreotic rats as assessed by radioimmunoassay.
thyroxine,Serum thyroxine (T4) is undetectable in athyreotic rats as assessed by radioimmunoassay.,Entity: thyroxine. SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O. Serum thyroxine (T4) is undetectable in athyreotic rats as assessed by radioimmunoassay.
iodine,Iodine intake in rats is limited to <0.05 µg/g in the test diet and is supplemented with 100 µg NaI per injection to achieve complete thyroidectomy.,Entity: iodine. SMILES: [I]. Iodine intake in rats is limited to <0.05 µg/g in the test diet and is supplemented with 100 µg NaI per injection to achieve complete thyroidectomy.
sodium glycinate,Sodium glycinate buffer at 5 nM concentration and pH 9.5 is used to dissolve lyophilized TSH for gel filtration analysis.,Entity: sodium glycinate. SMILES: NCC(=O)[O-].[Na+]. Sodium glycinate buffer at 5 nM concentration and pH 9.5 is used to dissolve lyophilized TSH for gel filtration analysis.
T 3,T 3 is administered intraperitoneally at a dose of 50 µg per 100 g body weight in hypothyroid rats to study the nature of plasma TSH after T 3 treatment.,Entity: T 3. SMILES: N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O. T 3 is administered intraperitoneally at a dose of 50 µg per 100 g body weight in hypothyroid rats to study the nature of plasma TSH after T 3 treatment.
phosphate,"Phosphate is used as a component of the equilibration buffer (0.01 M phosphate, 0.15 M NaCl, 0.1% azide, pH 7.6) in the purification of rTSH by Sephadex G-100 column chromatography.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate is used as a component of the equilibration buffer (0.01 M phosphate, 0.15 M NaCl, 0.1% azide, pH 7.6) in the purification of rTSH by Sephadex G-100 column chromatography."
sodium chloride,Sodium chloride is included in the equilibration buffer (0.15 M NaCl) for the purification of rTSH using a Sephadex G-100 column.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is included in the equilibration buffer (0.15 M NaCl) for the purification of rTSH using a Sephadex G-100 column.
azide,Azide is used at 0.1% concentration in the equilibration buffer for the purification of rTSH by Sephadex G-100 column chromatography.,Entity: azide. SMILES: [N-]=[N+]=[N-]. Azide is used at 0.1% concentration in the equilibration buffer for the purification of rTSH by Sephadex G-100 column chromatography.
"5a-pregnane-3,20-dione","5a-pregnane-3,20-dione is an effective inhibitor of C17,2o-lyase, the aromatizing enzyme.","Entity: 5a-pregnane-3,20-dione. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. 5a-pregnane-3,20-dione is an effective inhibitor of C17,2o-lyase, the aromatizing enzyme."
"5a-pregnane-3,20-dione","Production of 5a-pregnane-3,20-dione is increased by luteinizing hormone (LH).","Entity: 5a-pregnane-3,20-dione. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Production of 5a-pregnane-3,20-dione is increased by luteinizing hormone (LH)."
Progesterone,"Progesterone is an effective inhibitor of C17,2o-lyase, the aromatizing enzyme.","Entity: Progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone is an effective inhibitor of C17,2o-lyase, the aromatizing enzyme."
Progesterone,Production of progesterone is increased by luteinizing hormone (LH).,Entity: Progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Production of progesterone is increased by luteinizing hormone (LH).
propylene glycol,Propylene glycol is used as a solvent for estrogen precursors in biochemical incubation mixtures.,Entity: propylene glycol. SMILES: CC(O)CO. Propylene glycol is used as a solvent for estrogen precursors in biochemical incubation mixtures.
sucrose,Sucrose is used to resuspend microsomal pellets in buffered solution for biochemical assays.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used to resuspend microsomal pellets in buffered solution for biochemical assays.
MgCl2,MgCl2 is included at 0.01 M concentration in phosphate buffer as a component of incubation mixtures for biochemical assays.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is included at 0.01 M concentration in phosphate buffer as a component of incubation mixtures for biochemical assays.
glucose-6-phosphate,Glucose-6-phosphate is used at 30 nmol as a substrate in enzymatic incubation assays involving glucose-6-phosphate dehydrogenase.,Entity: glucose-6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose-6-phosphate is used at 30 nmol as a substrate in enzymatic incubation assays involving glucose-6-phosphate dehydrogenase.
NADPH,NADPH is used at 10 nmol as a cofactor in enzymatic incubation assays.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is used at 10 nmol as a cofactor in enzymatic incubation assays.
aromatase,"LH treatment in immature rats inhibits ovarian aromatase activity in a non-competitive manner, leading to decreased concentrations of estrogens in the ovaries and blood.","Entity: aromatase. LH treatment in immature rats inhibits ovarian aromatase activity in a non-competitive manner, leading to decreased concentrations of estrogens in the ovaries and blood."
dermatan sulfate,"In coronary arteries of hypophysectomized beagles, dermatan sulfate concentrations are significantly reduced following hypophysectomy and are not affected by subsequent treatment with bovine somatotropin (0.2 mg/kg subcutaneously for 3 weeks).","Entity: dermatan sulfate. SMILES: CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O)[C@H](O)[C@H]2O)[C@@H](OS(=O)(=O)[O-])[C@@H](CO)O[C@H]1O. In coronary arteries of hypophysectomized beagles, dermatan sulfate concentrations are significantly reduced following hypophysectomy and are not affected by subsequent treatment with bovine somatotropin (0.2 mg/kg subcutaneously for 3 weeks)."
chondroitin sulfates,"In coronary arteries of hypophysectomized beagles, chondroitin sulfate concentrations are significantly reduced following hypophysectomy and are not affected by subsequent treatment with bovine somatotropin (0.2 mg/kg subcutaneously for 3 weeks).","Entity: chondroitin sulfates. SMILES: CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@@H](O)[C@H]2O)[C@@H](O)[C@@H](OS(=O)(=O)O)O[C@H]1O. In coronary arteries of hypophysectomized beagles, chondroitin sulfate concentrations are significantly reduced following hypophysectomy and are not affected by subsequent treatment with bovine somatotropin (0.2 mg/kg subcutaneously for 3 weeks)."
dermatan sulfate,"Dermatan sulfate is one of the four distinct glycosaminoglycan fractions (along with hyaluronic acid, heparan sulfate, and isomeric chondroitin sulfates) isolated from tissue digests using electrophoresis.","Entity: dermatan sulfate. SMILES: CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O)[C@H](O)[C@H]2O)[C@@H](OS(=O)(=O)[O-])[C@@H](CO)O[C@H]1O. Dermatan sulfate is one of the four distinct glycosaminoglycan fractions (along with hyaluronic acid, heparan sulfate, and isomeric chondroitin sulfates) isolated from tissue digests using electrophoresis."
Alcian blue,Alcian blue is used as a staining agent to visualize glycosaminoglycan components separated by electrophoresis on cellulose acetate strips.,Entity: Alcian blue. SMILES: CN(C)C(SCc1ccc2c(c1)C1=NC2=NC2=NC(=NC3[N-]C(N=c4[n-]c(c5ccc(CSC(N(C)C)=[N+](C)C)cc45)=N1)c1ccc(CSC(N(C)C)=[N+](C)C)cc13)c1cc(CSC(N(C)C)=[N+](C)C)ccc12)=[N+](C)C.[Cl-].[Cl-].[Cl-].[Cl-].[Cu+2]. Alcian blue is used as a staining agent to visualize glycosaminoglycan components separated by electrophoresis on cellulose acetate strips.
cetylpyridinium chloride,Cetylpyridinium chloride is used as a precipitating agent for the isolation of glycosaminoglycans (GAGs) from tissue digests.,Entity: cetylpyridinium chloride. SMILES: CCCCCCCCCCCCCCCC[n+]1ccccc1.[Cl-]. Cetylpyridinium chloride is used as a precipitating agent for the isolation of glycosaminoglycans (GAGs) from tissue digests.
ZnSO4,ZnSO4 buffer at 0.2 M and pH 5.5 is used as the electrophoresis medium for resolving glycosaminoglycan components on cellulose acetate strips.,Entity: ZnSO4. SMILES: O=S(=O)([O-])[O-].[Zn+2]. ZnSO4 buffer at 0.2 M and pH 5.5 is used as the electrophoresis medium for resolving glycosaminoglycan components on cellulose acetate strips.
dermatan sulfate,"In canine coronary arteries, replacement therapy with somatotropin (GH) treatment raises dermatan sulfate levels to normal values in one or two aortic segments, but effects are usually limited to this range.","Entity: dermatan sulfate. SMILES: CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O)[C@H](O)[C@H]2O)[C@@H](OS(=O)(=O)[O-])[C@@H](CO)O[C@H]1O. In canine coronary arteries, replacement therapy with somatotropin (GH) treatment raises dermatan sulfate levels to normal values in one or two aortic segments, but effects are usually limited to this range."
GH,"GH (somatotropin) increases sulfated glycosaminoglycan content in the aorta but has no appreciable effect on hyaluronic acid, heparan sulfate, dermatan sulfate, or chondroitin sulfate in coronary arteries in hypophysectomized beagles.","Entity: GH. GH (somatotropin) increases sulfated glycosaminoglycan content in the aorta but has no appreciable effect on hyaluronic acid, heparan sulfate, dermatan sulfate, or chondroitin sulfate in coronary arteries in hypophysectomized beagles."
somatotropin,"Somatotropin (GH) increases sulfated glycosaminoglycan content in the aorta but has no appreciable effect on hyaluronic acid, heparan sulfate, dermatan sulfate, or chondroitin sulfate in coronary arteries in hypophysectomized beagles.","Entity: somatotropin. Somatotropin (GH) increases sulfated glycosaminoglycan content in the aorta but has no appreciable effect on hyaluronic acid, heparan sulfate, dermatan sulfate, or chondroitin sulfate in coronary arteries in hypophysectomized beagles."
[14C)glucose,[14C)glucose oxidation to 14CO2 is used as a measure of glucose metabolism in rat uterus following estrogen administration.,Entity: [14C)glucose. SMILES: O=[14CH][C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. [14C)glucose oxidation to 14CO2 is used as a measure of glucose metabolism in rat uterus following estrogen administration.
estradiol,"Estradiol, when injected at 0.1 or 1 µg daily, induces maximal uterine DNA and protein synthesis and glucose oxidation at 24 hours post-injection, with effects depressed to control levels by 24 hours after the last injection.","Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Estradiol, when injected at 0.1 or 1 µg daily, induces maximal uterine DNA and protein synthesis and glucose oxidation at 24 hours post-injection, with effects depressed to control levels by 24 hours after the last injection."
estradiol,"Daily injections of 0.01 µg estradiol result in a lower but sustained pattern of uterine DNA synthesis compared to higher doses, while higher dose estradiol (1 µg) administered after daily 0.01 µg estradiol increases uterine DNA synthesis.","Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Daily injections of 0.01 µg estradiol result in a lower but sustained pattern of uterine DNA synthesis compared to higher doses, while higher dose estradiol (1 µg) administered after daily 0.01 µg estradiol increases uterine DNA synthesis."
estriol,"Estriol, when injected at 1 µg daily or sequentially, does not induce a state of uterine metabolic refractoriness to further estrogen stimulation.","Entity: estriol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O. Estriol, when injected at 1 µg daily or sequentially, does not induce a state of uterine metabolic refractoriness to further estrogen stimulation."
[3H]thymidine,[3H]thymidine incorporation into DNA is used as a marker to assess DNA synthesis in rat uterus following estrogen treatment.,Entity: [3H]thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. [3H]thymidine incorporation into DNA is used as a marker to assess DNA synthesis in rat uterus following estrogen treatment.
[14C]leucine,[14C]leucine incorporation into protein is used to measure protein synthesis in rat uterus after estrogen treatment.,Entity: [14C]leucine. SMILES: CC(C)C[14C@H](N)C(=O)O. [14C]leucine incorporation into protein is used to measure protein synthesis in rat uterus after estrogen treatment.
nafoxidine hydrochloride,Nafoxidine hydrochloride is a non-steroidal antiestrogen that can stimulate uterine growth and causes retention of the estrogen receptor in uterine nuclei for up to 19 days.,Entity: nafoxidine hydrochloride. SMILES: COc1ccc2c(c1)CCC(c1ccccc1)=C2c1ccc(OCCN2CCCC2)cc1.Cl. Nafoxidine hydrochloride is a non-steroidal antiestrogen that can stimulate uterine growth and causes retention of the estrogen receptor in uterine nuclei for up to 19 days.
estradiol,"Estradiol can induce uterine refractoriness, a state in which the uterus becomes unresponsive to further estradiol stimulation, requiring sustained estrogen exposure for its induction.","Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Estradiol can induce uterine refractoriness, a state in which the uterus becomes unresponsive to further estradiol stimulation, requiring sustained estrogen exposure for its induction."
estradiol,"After successive daily injections of estradiol, specifically bound estradiol in uterine nuclei remains at low levels 24 hours post-injection, similar to control rats, indicating adequate cytoplasmic receptor availability for translocation to the nucleus.","Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. After successive daily injections of estradiol, specifically bound estradiol in uterine nuclei remains at low levels 24 hours post-injection, similar to control rats, indicating adequate cytoplasmic receptor availability for translocation to the nucleus."
estriol,"Estriol, which binds estrogen with lower affinity and is retained for a shorter duration in cells than estradiol, does not induce uterine refractoriness and has only a limited effect on increasing DNA synthesis at 18 and 24 hours.","Entity: estriol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O. Estriol, which binds estrogen with lower affinity and is retained for a shorter duration in cells than estradiol, does not induce uterine refractoriness and has only a limited effect on increasing DNA synthesis at 18 and 24 hours."
progesterone,"Progesterone administration to animals previously given estradiol causes only a small increase in DNA synthesis, which is below that observed in control rat uteri.","Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone administration to animals previously given estradiol causes only a small increase in DNA synthesis, which is below that observed in control rat uteri."
progesterone,Progesterone administration alone or in combination with estrogen leads to marked increases in protein synthesis in the uterus.,Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone administration alone or in combination with estrogen leads to marked increases in protein synthesis in the uterus.
"2,5-diphenyloxazole","2,5-diphenyloxazole is used as a scintillation cocktail component for liquid scintillation spectrometry to measure radiolabeled compounds.","Entity: 2,5-diphenyloxazole. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. 2,5-diphenyloxazole is used as a scintillation cocktail component for liquid scintillation spectrometry to measure radiolabeled compounds."
toluene,Toluene is used as a solvent in scintillation fluid for liquid scintillation spectrometry.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a solvent in scintillation fluid for liquid scintillation spectrometry.
hydrochloric acid,Hydrochloric acid is used to wash Dowex 1 x 10 ion exchange resin in the purification of free thymidine from thymidine phosphates.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to wash Dowex 1 x 10 ion exchange resin in the purification of free thymidine from thymidine phosphates.
lithium chloride,Lithium chloride is included in the washing buffer for Dowex 1 x 10 resin during the purification of free thymidine.,Entity: lithium chloride. SMILES: [Cl-].[Li+]. Lithium chloride is included in the washing buffer for Dowex 1 x 10 resin during the purification of free thymidine.
ethanol,Ethanol is included at 20% concentration in the washing buffer for Dowex 1 x 10 resin during the purification of free thymidine.,Entity: ethanol. SMILES: CCO. Ethanol is included at 20% concentration in the washing buffer for Dowex 1 x 10 resin during the purification of free thymidine.
sodium chloride,Sodium chloride is used to rinse rat uteri before homogenization in biochemical assays.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used to rinse rat uteri before homogenization in biochemical assays.
glucose,Glucose oxidation in rat uteri can be measured by determining the amount of CO2 produced during in vitro incubation.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose oxidation in rat uteri can be measured by determining the amount of CO2 produced during in vitro incubation.
thymidine,Thymidine incorporation into DNA in rat uteri can be quantified by hydrolyzing tissue homogenates and measuring free thymidine in the supernatant after ion exchange chromatography.,Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine incorporation into DNA in rat uteri can be quantified by hydrolyzing tissue homogenates and measuring free thymidine in the supernatant after ion exchange chromatography.
leucine,Leucine incorporation into proteins in rat uteri can be assessed by counting the radioactivity in tissue homogenates after solubilization and scintillation counting.,Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine incorporation into proteins in rat uteri can be assessed by counting the radioactivity in tissue homogenates after solubilization and scintillation counting.
perchloric acid,Perchloric acid is used to homogenize rat uteri and to precipitate proteins for subsequent biochemical analysis.,Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid is used to homogenize rat uteri and to precipitate proteins for subsequent biochemical analysis.
glucose,"Glucose is used as a component of solution D for maintaining fetal brain tissue in vitro, at a concentration of 5.5 mM.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is used as a component of solution D for maintaining fetal brain tissue in vitro, at a concentration of 5.5 mM."
sodium chloride,Sodium chloride is included in solution D at a concentration of 137 mM for in vitro maintenance of fetal brain tissue.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is included in solution D at a concentration of 137 mM for in vitro maintenance of fetal brain tissue.
disodium phosphate,Disodium phosphate is present in solution D at a concentration of 0.17 mM for preserving fetal brain tissue.,Entity: disodium phosphate. SMILES: O=P([O-])([O-])O.[Na+].[Na+]. Disodium phosphate is present in solution D at a concentration of 0.17 mM for preserving fetal brain tissue.
potassium chloride,Potassium chloride is a component of solution D at a concentration of 5.4 mM for maintaining fetal brain tissue in vitro.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is a component of solution D at a concentration of 5.4 mM for maintaining fetal brain tissue in vitro.
sucrose,Sucrose is used at a concentration of 5.9 mM in solution D to preserve fetal brain tissue in vitro.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used at a concentration of 5.9 mM in solution D to preserve fetal brain tissue in vitro.
monopotassium phosphate,Monopotassium phosphate is included in solution D at a concentration of 0.22 mM for in vitro preservation of fetal brain tissue.,Entity: monopotassium phosphate. SMILES: O=P([O-])(O)O.[K+]. Monopotassium phosphate is included in solution D at a concentration of 0.22 mM for in vitro preservation of fetal brain tissue.
trypan blue,Trypan blue is used at 0.4% concentration to determine cell viability by counting cells in a hemocytometer.,Entity: trypan blue. SMILES: Cc1cc(-c2ccc(N=Nc3c(S(=O)(=O)[O-])cc4cc(S(=O)(=O)[O-])cc(N)c4c3O)c(C)c2)ccc1N=Nc1c(S(=O)(=O)[O-])cc2cc(S(=O)(=O)[O-])cc(N)c2c1O.[Na+].[Na+].[Na+].[Na+]. Trypan blue is used at 0.4% concentration to determine cell viability by counting cells in a hemocytometer.
thymidine,"Tritiated thymidine ([3H]TdR) is incorporated into DNA during cell proliferation assays, with approximately 10% of the radioactive thymidine incorporated into each DNA fraction.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Tritiated thymidine ([3H]TdR) is incorporated into DNA during cell proliferation assays, with approximately 10% of the radioactive thymidine incorporated into each DNA fraction."
hydrochloric acid,"Hydrochloric acid (HClO4) is used at concentrations of 0.6 N, 0.2 N, and 1.2 N, both ice-cold and at 0°4°C, for DNA extraction from fetal brain cells.","Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (HClO4) is used at concentrations of 0.6 N, 0.2 N, and 1.2 N, both ice-cold and at 0°4°C, for DNA extraction from fetal brain cells."
potassium hydroxide,"Potassium hydroxide (KOH) is used at concentrations of 0.3 N and 1 N, both ice-cold, for DNA extraction and release from protein residues in fetal brain cell proliferation assays.","Entity: potassium hydroxide. SMILES: [K+].[OH-]. Potassium hydroxide (KOH) is used at concentrations of 0.3 N and 1 N, both ice-cold, for DNA extraction and release from protein residues in fetal brain cell proliferation assays."
placental lactogen,"Placental lactogen, at physiological concentrations, does not stimulate DNA synthesis in fetal brain cells in vitro.","Entity: placental lactogen. Placental lactogen, at physiological concentrations, does not stimulate DNA synthesis in fetal brain cells in vitro."
growth hormone,"Growth hormone, at physiological concentrations, does not stimulate DNA synthesis in fetal brain cells in vitro.","Entity: growth hormone. Growth hormone, at physiological concentrations, does not stimulate DNA synthesis in fetal brain cells in vitro."
prolactin,"Prolactin, at physiological concentrations, does not stimulate DNA synthesis in fetal brain cells in vitro.","Entity: prolactin. Prolactin, at physiological concentrations, does not stimulate DNA synthesis in fetal brain cells in vitro."
dithiothreitol,Dithiothreitol is used as a reducing agent in cold buffer solution (1 mM) for tissue homogenization in biochemical assays.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used as a reducing agent in cold buffer solution (1 mM) for tissue homogenization in biochemical assays.
progesterone,Progesterone is administered at 500 µg per animal in ovariectomized hamsters to study its effect on estrogen-induced changes in estrogen receptor levels.,Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone is administered at 500 µg per animal in ovariectomized hamsters to study its effect on estrogen-induced changes in estrogen receptor levels.
estradiol benzoate,Estradiol benzoate is used to induce receptivity and deplete estrogen receptors in ovariectomized hamsters.,Entity: estradiol benzoate. SMILES: C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Estradiol benzoate is used to induce receptivity and deplete estrogen receptors in ovariectomized hamsters.
estradiol,Estradiol is used as a radiolabeled substrate ([3H]estradiol) at a final concentration of 1 x 10^-9 M in cytosol binding assays to measure estrogen receptor activity.,Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Estradiol is used as a radiolabeled substrate ([3H]estradiol) at a final concentration of 1 x 10^-9 M in cytosol binding assays to measure estrogen receptor activity.
prolactin,Combined treatment with estradiol and rat prolactin (3 µg every 8 h for 6 days) synergistically increases CVA content in immature and adult nonestrogenized mouse vaginal epithelial cells.,Entity: prolactin. Combined treatment with estradiol and rat prolactin (3 µg every 8 h for 6 days) synergistically increases CVA content in immature and adult nonestrogenized mouse vaginal epithelial cells.
prolactin,Prolactin alone has no effect on the CVA content in mouse vaginal epithelial cells.,Entity: prolactin. Prolactin alone has no effect on the CVA content in mouse vaginal epithelial cells.
prolactin,"Prolactin, when administered at 3 µg every 8 hours for 6 days, increases the CVA content in both immature and adult nonestrogenized mouse vaginal epithelial cells more efficiently than estradiol alone.","Entity: prolactin. Prolactin, when administered at 3 µg every 8 hours for 6 days, increases the CVA content in both immature and adult nonestrogenized mouse vaginal epithelial cells more efficiently than estradiol alone."
magnesium,"Magnesium suppresses parathyroid hormone release from isolated bovine parathyroid cells, with higher concentrations of magnesium required for equal suppression compared to calcium.","Entity: magnesium. SMILES: [Mg]. Magnesium suppresses parathyroid hormone release from isolated bovine parathyroid cells, with higher concentrations of magnesium required for equal suppression compared to calcium."
oxygen,"Isolated parathyroid cells are relatively insensitive to changes in ambient oxygen, as hormone release is not significantly affected by incubations under 100% O2 or room air.","Entity: oxygen. SMILES: [O]. Isolated parathyroid cells are relatively insensitive to changes in ambient oxygen, as hormone release is not significantly affected by incubations under 100% O2 or room air."
calcium,"Parathyroid hormone release from isolated bovine parathyroid cells is maximal between 0.3–0.5 mM calcium and is inversely proportional to ambient calcium between 0.3 and 1.0 mM, being maximally suppressed above 1.5 mM Ca.","Entity: calcium. SMILES: [Ca]. Parathyroid hormone release from isolated bovine parathyroid cells is maximal between 0.3–0.5 mM calcium and is inversely proportional to ambient calcium between 0.3 and 1.0 mM, being maximally suppressed above 1.5 mM Ca."
theophylline,"Theophylline stimulates parathyroid hormone release, likely by increasing cAMP levels in tissue slices.","Entity: theophylline. SMILES: Cn1c(=O)c2[nH]cnc2n(C)c1=O. Theophylline stimulates parathyroid hormone release, likely by increasing cAMP levels in tissue slices."
cytochalasin B,"Cytochalasin B, a microfilament inhibitor, has been shown to affect hormonal release in biological systems.","Entity: cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B, a microfilament inhibitor, has been shown to affect hormonal release in biological systems."
colchicine,"Colchicine, a microtubular inhibitor, has been shown to affect hormonal release in biological systems.","Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine, a microtubular inhibitor, has been shown to affect hormonal release in biological systems."
vinblastine,"Vinblastine, a microtubular inhibitor, has been shown to affect hormonal release in biological systems.","Entity: vinblastine. SMILES: CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1. Vinblastine, a microtubular inhibitor, has been shown to affect hormonal release in biological systems."
magnesium,"Magnesium suppresses parathyroid hormone release, but is about one-third as potent as calcium in this effect from tissue slices.","Entity: magnesium. SMILES: [Mg]. Magnesium suppresses parathyroid hormone release, but is about one-third as potent as calcium in this effect from tissue slices."
calcium,"Calcium suppresses parathyroid hormone release in a physiologically proportional manner, with little or no further increase in hormone release below 0.3 inM.","Entity: calcium. SMILES: [Ca]. Calcium suppresses parathyroid hormone release in a physiologically proportional manner, with little or no further increase in hormone release below 0.3 inM."
epidermal growth factor,"Testosterone administration to female mice increases submaxillary gland EGF concentrations to levels characteristic of normal males, and this effect is not abolished by superior cervical ganglionectomy.","Entity: epidermal growth factor. Testosterone administration to female mice increases submaxillary gland EGF concentrations to levels characteristic of normal males, and this effect is not abolished by superior cervical ganglionectomy."
epidermal growth factor,Nocturnal reversal of the dark period with one hour light exposure restores the circadian variation of epidermal growth factor (EGF) in mouse submaxillary gland.,Entity: epidermal growth factor. Nocturnal reversal of the dark period with one hour light exposure restores the circadian variation of epidermal growth factor (EGF) in mouse submaxillary gland.
epidermal growth factor,"Epidermal growth factor (EGF) in mouse submaxillary gland displays a circadian variation, with peak concentrations during light hours and trough concentrations during dark, and this variation is abolished by superior cervical ganglionectomy but persists in fasted animals.","Entity: epidermal growth factor. Epidermal growth factor (EGF) in mouse submaxillary gland displays a circadian variation, with peak concentrations during light hours and trough concentrations during dark, and this variation is abolished by superior cervical ganglionectomy but persists in fasted animals."
epidermal growth factor,Plasma epidermal growth factor (EGF) concentrations in mice do not exhibit a circadian variation.,Entity: epidermal growth factor. Plasma epidermal growth factor (EGF) concentrations in mice do not exhibit a circadian variation.
epidermal growth factor,"In female mice, the circadian variation of epidermal growth factor (EGF) in submaxillary gland is shifted by 8 hours relative to males, with peaks occurring earlier in females.","Entity: epidermal growth factor. In female mice, the circadian variation of epidermal growth factor (EGF) in submaxillary gland is shifted by 8 hours relative to males, with peaks occurring earlier in females."
propylene glycol,"Propylene glycol is included in the anesthetic solution for intraperitoneal injection in mice, combined with sodium pentobarbital and ethanol in a 2:2:5 ratio.","Entity: propylene glycol. SMILES: CC(O)CO. Propylene glycol is included in the anesthetic solution for intraperitoneal injection in mice, combined with sodium pentobarbital and ethanol in a 2:2:5 ratio."
sodium pentobarbital,"Sodium pentobarbital is used as an anesthetic in mice, administered intraperitoneally at a concentration of 60 mg/ml in a mixture with ethanol, propylene glycol, and water.","Entity: sodium pentobarbital. SMILES: CCCC(C)C1(CC)C(=O)NC(=O)NC1=O.[Na+]. Sodium pentobarbital is used as an anesthetic in mice, administered intraperitoneally at a concentration of 60 mg/ml in a mixture with ethanol, propylene glycol, and water."
ethanol,"Ethanol is used as a component of the anesthetic solution for intraperitoneal injection in mice, mixed with sodium pentobarbital and propylene glycol in a 2:2:5 ratio.","Entity: ethanol. SMILES: CCO. Ethanol is used as a component of the anesthetic solution for intraperitoneal injection in mice, mixed with sodium pentobarbital and propylene glycol in a 2:2:5 ratio."
docosapentaenoate,"Docosapentaenoate (C22:5), a close analogue of cholesteryl adrenate, is selectively regulated in its levels by gonadal factors.","Entity: docosapentaenoate. SMILES: CCCCCCCCCCCC=CC=CC=CC=CC=CC(=O)[O-]. Docosapentaenoate (C22:5), a close analogue of cholesteryl adrenate, is selectively regulated in its levels by gonadal factors."
adrenic acid,"Adrenic acid is involved in the interconversion with arachidonic and adrenic acids, with its regulation influenced by gonadal factors.","Entity: adrenic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O. Adrenic acid is involved in the interconversion with arachidonic and adrenic acids, with its regulation influenced by gonadal factors."
arachidonic acid,"Arachidonic acid participates in the interconversion with adrenic acids, and its regulation is influenced by gonadal factors.","Entity: arachidonic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. Arachidonic acid participates in the interconversion with adrenic acids, and its regulation is influenced by gonadal factors."
cholesteryl adrenate,"Cholesteryl adrenate (C22:4) is a cholesterol ester whose levels are selectively regulated by gonadal factors, influencing its interconversion with arachidonic and adrenic acids.","Entity: cholesteryl adrenate. SMILES: CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. Cholesteryl adrenate (C22:4) is a cholesterol ester whose levels are selectively regulated by gonadal factors, influencing its interconversion with arachidonic and adrenic acids."
cholesteryl adrenate,"In C57 female mice, cholesteryl adrenate constitutes 39% of the total adrenal cortex steroid profile, while in males it accounts for 24%.","Entity: cholesteryl adrenate. SMILES: CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. In C57 female mice, cholesteryl adrenate constitutes 39% of the total adrenal cortex steroid profile, while in males it accounts for 24%."
cholesteryl adrenate,Ovariectomy in female mice significantly lowers the percentage contribution of cholesteryl adrenate in the adrenal cortex.,Entity: cholesteryl adrenate. SMILES: CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. Ovariectomy in female mice significantly lowers the percentage contribution of cholesteryl adrenate in the adrenal cortex.
estradiol benzoate,Estradiol benzoate does not significantly increase the percentage contribution of cholesteryl adrenate in castrate males or in ovariectomized females.,Entity: estradiol benzoate. SMILES: C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Estradiol benzoate does not significantly increase the percentage contribution of cholesteryl adrenate in castrate males or in ovariectomized females.
progesterone,"Progesterone may be involved in the maintenance of cholesteryl adrenate levels in intact female mice, as its role was not fully mimicked by estrogen administration in the experiment.","Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone may be involved in the maintenance of cholesteryl adrenate levels in intact female mice, as its role was not fully mimicked by estrogen administration in the experiment."
cholesteryl adrenate,"In the DBA mouse strain, androgen treatment sharply suppresses adrenal concentrations of cholesteryl adrenate (C22:4), whereas in the C57 strain, ovarian factors enhance total adrenal cholesterol ester concentration and the per cent contribution of adrenate, with both responses being insensitive to androgen.","Entity: cholesteryl adrenate. SMILES: CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. In the DBA mouse strain, androgen treatment sharply suppresses adrenal concentrations of cholesteryl adrenate (C22:4), whereas in the C57 strain, ovarian factors enhance total adrenal cholesterol ester concentration and the per cent contribution of adrenate, with both responses being insensitive to androgen."
estradiol benzoate,There is no evidence for sexual differentiation of the response to estradiol benzoate in the C57 mouse strain.,Entity: estradiol benzoate. SMILES: C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. There is no evidence for sexual differentiation of the response to estradiol benzoate in the C57 mouse strain.
cholesteryl adrenate,"In rat adrenal tissue, cholesteryl adrenate constitutes 27.7 ± 0.86% of total cholesterol esters in females and 15.6 ± 0.66% in males.","Entity: cholesteryl adrenate. SMILES: CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. In rat adrenal tissue, cholesteryl adrenate constitutes 27.7 ± 0.86% of total cholesterol esters in females and 15.6 ± 0.66% in males."
cholesteryl arachidonate,Cholesteryl arachidonate undergoes significant and preferential depletion in the rat adrenal under stimulation by ACTH or physiological stress.,Entity: cholesteryl arachidonate. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)[O-]. Cholesteryl arachidonate undergoes significant and preferential depletion in the rat adrenal under stimulation by ACTH or physiological stress.
cholesteryl adrenate,"In both DBA and C57 mice, cholesteryl adrenate constitutes a significantly greater percentage of total adrenal cholesterol esters in females than in males.","Entity: cholesteryl adrenate. SMILES: CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. In both DBA and C57 mice, cholesteryl adrenate constitutes a significantly greater percentage of total adrenal cholesterol esters in females than in males."
cholesteryl adrenate,"In the DBA mouse adrenal, cholesteryl adrenate comprises about 12% of total cholesterol esters in intact males but about 41% in females.","Entity: cholesteryl adrenate. SMILES: CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. In the DBA mouse adrenal, cholesteryl adrenate comprises about 12% of total cholesterol esters in intact males but about 41% in females."
cholesteryl adrenate,"The selective suppression of adrenate in the adrenal, including cholesteryl adrenate, is androgen-controlled.","Entity: cholesteryl adrenate. SMILES: CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. The selective suppression of adrenate in the adrenal, including cholesteryl adrenate, is androgen-controlled."
testosterone propionate,"In C57BL/10J mice, castration lowers the concentration of all adrenal cholesterol esters, while in DBA/2J mice, castration lowers the concentration of all adrenal cholesterol esters to a greater extent than ovariectomy.","Entity: testosterone propionate. SMILES: CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. In C57BL/10J mice, castration lowers the concentration of all adrenal cholesterol esters, while in DBA/2J mice, castration lowers the concentration of all adrenal cholesterol esters to a greater extent than ovariectomy."
estradiol benzoate,"In C57BL/10J mice, administration of estradiol benzoate to ovariectomized females increases the concentrations of all adrenal cholesterol esters.","Entity: estradiol benzoate. SMILES: C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. In C57BL/10J mice, administration of estradiol benzoate to ovariectomized females increases the concentrations of all adrenal cholesterol esters."
adrenic acid,Adrenic acid (C22:4) is an adrenal cholesterol ester that shows greater gonadal effects on adrenal cholesterol ester concentrations than other esters in both C57BL/10J and DBA/2J mice.,Entity: adrenic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O. Adrenic acid (C22:4) is an adrenal cholesterol ester that shows greater gonadal effects on adrenal cholesterol ester concentrations than other esters in both C57BL/10J and DBA/2J mice.
methyl palmitate,"Methyl palmitate is used as a calibration standard in gas chromatography for fatty acid analysis, providing a response of 2.4 x 10^3 cm^2 per ng at a sensitivity of 5.0 x 10^10 amps per full-scale recorder response.","Entity: methyl palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)OC. Methyl palmitate is used as a calibration standard in gas chromatography for fatty acid analysis, providing a response of 2.4 x 10^3 cm^2 per ng at a sensitivity of 5.0 x 10^10 amps per full-scale recorder response."
arachidonate,"Arachidonate is represented as cholesteryl eicosa-5,8,11,14-tetraenoate in cholesterol ester fatty acid mixtures from mouse adrenal glands.","Entity: arachidonate. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)[O-]. Arachidonate is represented as cholesteryl eicosa-5,8,11,14-tetraenoate in cholesterol ester fatty acid mixtures from mouse adrenal glands."
"cholesteryl eicosa-5,8,11,14-tetraenoate","Cholesteryl eicosa-5,8,11,14-tetraenoate is the fatty acid component of cholesteryl arachidonate, a major constituent of mouse adrenal cholesterol ester mixtures.","Entity: cholesteryl eicosa-5,8,11,14-tetraenoate. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. Cholesteryl eicosa-5,8,11,14-tetraenoate is the fatty acid component of cholesteryl arachidonate, a major constituent of mouse adrenal cholesterol ester mixtures."
"cholesteryl docosa-7,10,13,16-tetraenoate","Cholesteryl docosa-7,10,13,16-tetraenoate is the fatty acid component of cholesteryl adrenate, a major constituent of mouse adrenal cholesterol ester mixtures.","Entity: cholesteryl docosa-7,10,13,16-tetraenoate. SMILES: CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. Cholesteryl docosa-7,10,13,16-tetraenoate is the fatty acid component of cholesteryl adrenate, a major constituent of mouse adrenal cholesterol ester mixtures."
parathyroid hormone,"Iodinated fragments of parathyroid hormone, representing proteolytically cleaved products, are detected in rat plasma within 12 min after hormone injection and persist in circulation for no more than 48 min.","Entity: parathyroid hormone. Iodinated fragments of parathyroid hormone, representing proteolytically cleaved products, are detected in rat plasma within 12 min after hormone injection and persist in circulation for no more than 48 min."
parathyroid hormone,"Parathyroid hormone undergoes peripheral tissue proteolysis in mammals, with the process being specific to at least mammalian species and potentially critical for controlling the availability of biologically active hormone.","Entity: parathyroid hormone. Parathyroid hormone undergoes peripheral tissue proteolysis in mammals, with the process being specific to at least mammalian species and potentially critical for controlling the availability of biologically active hormone."
parathyroid hormone,"Gel filtration of rat plasma after parathyroid hormone administration shows that the major proteolytically cleaved fragments are heterogeneous polypeptides, with the most abundant fragment having an amino-terminal residue at position 34 and the next most common at position 37, with no fragments closer to the amino-terminus than residue 34 observed before 48 min post-injection.","Entity: parathyroid hormone. Gel filtration of rat plasma after parathyroid hormone administration shows that the major proteolytically cleaved fragments are heterogeneous polypeptides, with the most abundant fragment having an amino-terminal residue at position 34 and the next most common at position 37, with no fragments closer to the amino-terminus than residue 34 observed before 48 min post-injection."
parathyroid hormone,"In rats, intravenous injection of 125I-labeled parathyroid hormone results in a multiexponential disappearance curve, with a rapid initial phase (3 min) and a slower phase (48 min), indicating rapid proteolysis and clearance.","Entity: parathyroid hormone. In rats, intravenous injection of 125I-labeled parathyroid hormone results in a multiexponential disappearance curve, with a rapid initial phase (3 min) and a slower phase (48 min), indicating rapid proteolysis and clearance."
glucagon,Canine pancreatic glucagon has an isoelectric point (pl) of 6.25.,Entity: glucagon. Canine pancreatic glucagon has an isoelectric point (pl) of 6.25.
insulin,"Insulin is present in porcine gastric mucosa at high concentrations, as detected by immunoreactivity, and can be eluted from gastric mucosa by gel filtration in a major peak corresponding to insulin elution volume.","Entity: insulin. Insulin is present in porcine gastric mucosa at high concentrations, as detected by immunoreactivity, and can be eluted from gastric mucosa by gel filtration in a major peak corresponding to insulin elution volume."
Spironolactone,Spironolactone blocks the action of endogenous testosterone in intact mice and reduces seminal vesicle and kidney weight in castrated mice.,Entity: Spironolactone. SMILES: CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@H]12. Spironolactone blocks the action of endogenous testosterone in intact mice and reduces seminal vesicle and kidney weight in castrated mice.
toluidine blue,"Toluidine blue is used to stain Epon thick sections, which are valuable for characterizing liver responses to injury and for implementing the utility of serial biopsies in studies of potential hepatic injury.","Entity: toluidine blue. SMILES: Cc1ccc(Nc2ccc(O)c3c2C(=O)c2c(O)ccc(Nc4ccc(C)cc4S(=O)(=O)[O-])c2C3=O)c(S(=O)(=O)[O-])c1.[Na+].[Na+]. Toluidine blue is used to stain Epon thick sections, which are valuable for characterizing liver responses to injury and for implementing the utility of serial biopsies in studies of potential hepatic injury."
nitrite,Nitrite acts as a potent inhibitor of horse spleen cathepsin D enzymatic activity.,Entity: nitrite. SMILES: O=N[O-]. Nitrite acts as a potent inhibitor of horse spleen cathepsin D enzymatic activity.
sulfhydryl,Catalytic activity of horse spleen cathepsin D does not depend on sulfhydryl residues.,Entity: sulfhydryl. SMILES: [SH]. Catalytic activity of horse spleen cathepsin D does not depend on sulfhydryl residues.
Sodium aurothiomalate,"Sodium aurothiomalate can cause diffuse reversible pulmonary injury, which resolves upon discontinuation of the drug.","Entity: Sodium aurothiomalate. SMILES: O=C([O-])CC([S-])C(=O)[O-].[Au+].[Na+].[Na+]. Sodium aurothiomalate can cause diffuse reversible pulmonary injury, which resolves upon discontinuation of the drug."
Gold,"Gold can cause pulmonary changes, pleurisy, and pericarditis as a manifestation of rheumatoid arthritis.","Entity: Gold. SMILES: [Au]. Gold can cause pulmonary changes, pleurisy, and pericarditis as a manifestation of rheumatoid arthritis."
Sodium aurothiomalate,"Sodium aurothiomalate is implicated as the cause of lung disease in a patient, with symptoms resolving after withdrawal of sodium aurothiomalate and prednisolone therapy.","Entity: Sodium aurothiomalate. SMILES: O=C([O-])CC([S-])C(=O)[O-].[Au+].[Na+].[Na+]. Sodium aurothiomalate is implicated as the cause of lung disease in a patient, with symptoms resolving after withdrawal of sodium aurothiomalate and prednisolone therapy."
Prednisolone,Prednisolone administration led to the resolution of abnormal pulmonary changes following withdrawal of sodium aurothiomalate therapy.,Entity: Prednisolone. SMILES: C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO. Prednisolone administration led to the resolution of abnormal pulmonary changes following withdrawal of sodium aurothiomalate therapy.
Ibuprofen,"Ibuprofen, which had been taken for over a year prior to illness, was resumed after hospital discharge without causing relapse or recurrence of pulmonary symptoms.","Entity: Ibuprofen. SMILES: CC(C)Cc1ccc(C(C)C(=O)O)cc1. Ibuprofen, which had been taken for over a year prior to illness, was resumed after hospital discharge without causing relapse or recurrence of pulmonary symptoms."
Indomethacin,"Indomethacin, used for more than a year before illness, was resumed after hospital discharge without causing relapse or recurrence of pulmonary symptoms.","Entity: Indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin, used for more than a year before illness, was resumed after hospital discharge without causing relapse or recurrence of pulmonary symptoms."
acrolein,Acrolein can be trapped and accumulated using a cold trap containing water and maintained with crushed ice during chemical reactions.,Entity: acrolein. SMILES: C=CC=O. Acrolein can be trapped and accumulated using a cold trap containing water and maintained with crushed ice during chemical reactions.
nitrogen,"Nitrogen can be used as a carrier gas in chemical reactions, with air or nitrogen bubbling through the reaction mixture to trap and collect volatile products such as acrolein.","Entity: nitrogen. SMILES: [N]. Nitrogen can be used as a carrier gas in chemical reactions, with air or nitrogen bubbling through the reaction mixture to trap and collect volatile products such as acrolein."
water,Water serves as the trapping medium in cold traps for collecting volatile compounds like acrolein during chemical reactions.,Entity: water. SMILES: O. Water serves as the trapping medium in cold traps for collecting volatile compounds like acrolein during chemical reactions.
acrolein,"Acrolein is formed as an unstable intermediate during the oxidative degradation of certain amino acids and polyamines, leading to its generation from reactions involving 3-substituted propanals.","Entity: acrolein. SMILES: C=CC=O. Acrolein is formed as an unstable intermediate during the oxidative degradation of certain amino acids and polyamines, leading to its generation from reactions involving 3-substituted propanals."
acrolein,Acrolein can be quantified by its conversion to 7-hydroxyquinoline in acid medium using m-amino-phenol.,Entity: acrolein. SMILES: C=CC=O. Acrolein can be quantified by its conversion to 7-hydroxyquinoline in acid medium using m-amino-phenol.
7-hydroxyquinoline,7-hydroxyquinoline is a fluorescent compound used as a derivatization product for the detection and quantification of acrolein.,Entity: 7-hydroxyquinoline. SMILES: Oc1ccc2cccnc2c1. 7-hydroxyquinoline is a fluorescent compound used as a derivatization product for the detection and quantification of acrolein.
spermidine,Spermidine can be enzymatically oxidized to generate acrolein.,Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine can be enzymatically oxidized to generate acrolein.
spermine,Spermine can be enzymatically oxidized to generate acrolein.,Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine can be enzymatically oxidized to generate acrolein.
acrolein,Acrolein can be spontaneously formed when a 3-substituted propanal is an intermediate in enzymatic oxidation reactions involving spermine or spermidine.,Entity: acrolein. SMILES: C=CC=O. Acrolein can be spontaneously formed when a 3-substituted propanal is an intermediate in enzymatic oxidation reactions involving spermine or spermidine.
acrolein,"Acrolein is a product formed during the degradation of glucose at 100°C in the presence of methionine, glutamic acid, glycine, or lysine.","Entity: acrolein. SMILES: C=CC=O. Acrolein is a product formed during the degradation of glucose at 100°C in the presence of methionine, glutamic acid, glycine, or lysine."
oxygen,"Oxygen acts as an oxidizing compound that can deaminate aliphatic amines, resulting in the formation of aldehydes or ketones.","Entity: oxygen. SMILES: [O]. Oxygen acts as an oxidizing compound that can deaminate aliphatic amines, resulting in the formation of aldehydes or ketones."
ozone,"Ozone is an oxidizing agent known to deaminate aliphatic amines, potentially producing aldehydes or ketones.","Entity: ozone. SMILES: O=[O+][O-]. Ozone is an oxidizing agent known to deaminate aliphatic amines, potentially producing aldehydes or ketones."
acrolein,"Acrolein is generated as a product from the chemical deamination of polyamines such as spermine, spermidine, and 1,3-propanediamine using oxidizing agents like hydrogen peroxide, chlorine dioxide, chromic acid, oxygen, or ozone.","Entity: acrolein. SMILES: C=CC=O. Acrolein is generated as a product from the chemical deamination of polyamines such as spermine, spermidine, and 1,3-propanediamine using oxidizing agents like hydrogen peroxide, chlorine dioxide, chromic acid, oxygen, or ozone."
"1,3-propanediamine","1,3-propanediamine can be chemically deaminated by hydrogen peroxide to produce acrolein.","Entity: 1,3-propanediamine. SMILES: NCCCN. 1,3-propanediamine can be chemically deaminated by hydrogen peroxide to produce acrolein."
spermine,"Spermine can be chemically deaminated by hydrogen peroxide to generate acrolein, with yields in the ratio of 2:1 compared to spermidine under the same conditions.","Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine can be chemically deaminated by hydrogen peroxide to generate acrolein, with yields in the ratio of 2:1 compared to spermidine under the same conditions."
ferrous sulfate,"Ferrous sulfate, when combined with hydrogen peroxide, increases the yield of acrolein from polyamines compared to hydrogen peroxide alone, though over longer periods.","Entity: ferrous sulfate. SMILES: O=S(=O)([O-])[O-].[Fe+2]. Ferrous sulfate, when combined with hydrogen peroxide, increases the yield of acrolein from polyamines compared to hydrogen peroxide alone, though over longer periods."
hydrogen peroxide,"Hydrogen peroxide is a highly effective oxidizing agent for generating acrolein from polyamines such as spermine, spermidine, and 1,3-propanediamine.","Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide is a highly effective oxidizing agent for generating acrolein from polyamines such as spermine, spermidine, and 1,3-propanediamine."
spermidine,"Spermidine can be chemically deaminated by hydrogen peroxide to generate acrolein, with yields in the ratio of 1:2 compared to spermine under the same conditions.","Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine can be chemically deaminated by hydrogen peroxide to generate acrolein, with yields in the ratio of 1:2 compared to spermine under the same conditions."
hydrogen peroxide,"When hydrogen peroxide is used in combination with ferrous sulfate, higher yields of acrolein are obtained from polyamines compared to hydrogen peroxide alone, though over longer periods.","Entity: hydrogen peroxide. SMILES: OO. When hydrogen peroxide is used in combination with ferrous sulfate, higher yields of acrolein are obtained from polyamines compared to hydrogen peroxide alone, though over longer periods."
silver persulfate,"Silver persulfate is an oxidizing compound known to deaminate aliphatic amines, potentially forming aldehydes or ketones.","Entity: silver persulfate. SMILES: O=S(=O)([O-])OOS(=O)(=O)[O-].[Ag+].[Ag+]. Silver persulfate is an oxidizing compound known to deaminate aliphatic amines, potentially forming aldehydes or ketones."
chlorine dioxide,"Chlorine dioxide is an oxidizing compound known to deaminate aliphatic amines, potentially leading to the formation of aldehydes or ketones.","Entity: chlorine dioxide. SMILES: None. Chlorine dioxide is an oxidizing compound known to deaminate aliphatic amines, potentially leading to the formation of aldehydes or ketones."
methionine,"Methionine can be enzymatically oxidized to produce acrolein, with rates and yields higher than those obtained with hydrogen peroxide alone.","Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine can be enzymatically oxidized to produce acrolein, with rates and yields higher than those obtained with hydrogen peroxide alone."
chromic acid,"Chromic acid is an oxidizing compound capable of deaminating aliphatic amines, potentially forming aldehydes or ketones.","Entity: chromic acid. SMILES: O=[Cr](=O)(O)O. Chromic acid is an oxidizing compound capable of deaminating aliphatic amines, potentially forming aldehydes or ketones."
acrolein,Acrolein can be quantified in reaction mixtures using cold traps and is a product formed during the degradation of certain compounds by degrading agents in aqueous solution.,Entity: acrolein. SMILES: C=CC=O. Acrolein can be quantified in reaction mixtures using cold traps and is a product formed during the degradation of certain compounds by degrading agents in aqueous solution.
potassium phosphate,Potassium phosphate is used as a component of phosphate buffer at 0.2 M concentration and pH 7 in enzymatic degradation reactions.,Entity: potassium phosphate. SMILES: O=P([O-])(O)O.[K+]. Potassium phosphate is used as a component of phosphate buffer at 0.2 M concentration and pH 7 in enzymatic degradation reactions.
sodium phosphate,Sodium phosphate is used as a component of phosphate buffer at 0.2 M concentration and pH 7 in enzymatic degradation reactions.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])O.[Na+].[Na+]. Sodium phosphate is used as a component of phosphate buffer at 0.2 M concentration and pH 7 in enzymatic degradation reactions.
water,Water serves as the solvent for both the compound to be degraded and the degrading agent in enzymatic degradation assays.,Entity: water. SMILES: O. Water serves as the solvent for both the compound to be degraded and the degrading agent in enzymatic degradation assays.
ferrous sulfate,Ferrous sulfate is used as a degrading agent for amino acids under aerobic conditions.,Entity: ferrous sulfate. SMILES: O=S(=O)([O-])[O-].[Fe+2]. Ferrous sulfate is used as a degrading agent for amino acids under aerobic conditions.
acrolein,No acrolein accumulates in the described reactions within 1 hour under aerobic conditions.,Entity: acrolein. SMILES: C=CC=O. No acrolein accumulates in the described reactions within 1 hour under aerobic conditions.
hydrogen peroxide,Hydrogen peroxide alone or in combination with ferrous sulfate is excluded from the reaction system to prevent oxygen introduction.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide alone or in combination with ferrous sulfate is excluded from the reaction system to prevent oxygen introduction.
nitrogen,Nitrogen is used to deaerate solutions by bubbling through reaction mixtures and boiling water to remove dissolved oxygen prior to anaerobic experiments.,Entity: nitrogen. SMILES: [N]. Nitrogen is used to deaerate solutions by bubbling through reaction mixtures and boiling water to remove dissolved oxygen prior to anaerobic experiments.
ethanol,Ethanol is used as a solvent to inject methional into deaerated water-buffer mixtures in experimental procedures.,Entity: ethanol. SMILES: CCO. Ethanol is used as a solvent to inject methional into deaerated water-buffer mixtures in experimental procedures.
hydrogen peroxide,"Addition of hydrogen peroxide accelerates the formation of acrolein from methional, especially in the first 10 minutes under anaerobic conditions.","Entity: hydrogen peroxide. SMILES: OO. Addition of hydrogen peroxide accelerates the formation of acrolein from methional, especially in the first 10 minutes under anaerobic conditions."
acrolein,"Acrolein can be generated from methional under anaerobic conditions, with higher amounts formed in 30 minutes compared to methionine mixtures under similar conditions.","Entity: acrolein. SMILES: C=CC=O. Acrolein can be generated from methional under anaerobic conditions, with higher amounts formed in 30 minutes compared to methionine mixtures under similar conditions."
acrolein,Acrolein is suggested as the most likely precursor of acrolein in the Strecker degradation of methionine.,Entity: acrolein. SMILES: C=CC=O. Acrolein is suggested as the most likely precursor of acrolein in the Strecker degradation of methionine.
methionine,"Methionine undergoes the Strecker degradation, in which acrolein is a key intermediate.","Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine undergoes the Strecker degradation, in which acrolein is a key intermediate."
ascorbic acid,"Addition of ascorbic acid accelerates the formation of acrolein from methional, especially in the first 10 minutes under anaerobic conditions.","Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Addition of ascorbic acid accelerates the formation of acrolein from methional, especially in the first 10 minutes under anaerobic conditions."
acrolein,"Acrolein can be generated during the interaction of amino acids and polyamines with compounds capable of producing Strecker or oxidative deaminations under neutral pH and 100°C conditions, which are common in food processing.","Entity: acrolein. SMILES: C=CC=O. Acrolein can be generated during the interaction of amino acids and polyamines with compounds capable of producing Strecker or oxidative deaminations under neutral pH and 100°C conditions, which are common in food processing."
ascorbic acid,"Ascorbic acid acts as a degrading agent that promotes the generation of acrolein from spermine, spermidine, and methionine.","Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid acts as a degrading agent that promotes the generation of acrolein from spermine, spermidine, and methionine."
hydrogen peroxide,"Hydrogen peroxide, in combination with ferrous sulfate, is used as a degrading agent to facilitate acrolein generation from spermidine and methionine.","Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide, in combination with ferrous sulfate, is used as a degrading agent to facilitate acrolein generation from spermidine and methionine."
ferrous sulfate,"Ferrous sulfate, in combination with hydrogen peroxide, serves as a degrading agent for spermidine and methionine to generate acrolein.","Entity: ferrous sulfate. SMILES: O=S(=O)([O-])[O-].[Fe+2]. Ferrous sulfate, in combination with hydrogen peroxide, serves as a degrading agent for spermidine and methionine to generate acrolein."
NAD,NAD is used as a degrading agent in assays measuring the acrolein-generating activity of spermidine.,Entity: NAD. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NAD is used as a degrading agent in assays measuring the acrolein-generating activity of spermidine.
spermine,Spermine contains two acrolein-generating molecular groups and can generate acrolein in its interactions with ascorbic acid and other degrading agents.,Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine contains two acrolein-generating molecular groups and can generate acrolein in its interactions with ascorbic acid and other degrading agents.
glyceraldehyde,Glyceraldehyde is used as a degrading agent in assays to compare the acrolein-generating activity of spermidine and methionine.,Entity: glyceraldehyde. SMILES: O=CC(O)CO. Glyceraldehyde is used as a degrading agent in assays to compare the acrolein-generating activity of spermidine and methionine.
spermidine,Spermidine contains one acrolein-generating molecular group and can generate acrolein in its interactions with ascorbic acid and other degrading agents.,Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine contains one acrolein-generating molecular group and can generate acrolein in its interactions with ascorbic acid and other degrading agents.
spermidine,The acrolein-generating capability of spermidine is similar to that of methionine when hydrogen peroxide-ferrous sulfate or glyceraldehyde are used as degrading agents.,Entity: spermidine. SMILES: NCCCCNCCCN. The acrolein-generating capability of spermidine is similar to that of methionine when hydrogen peroxide-ferrous sulfate or glyceraldehyde are used as degrading agents.
spermidine,"When glucose, inositol, ascorbic acid, or NAD are used as degrading agents, spermidine generates 48 to 73% of the acrolein produced by methionine.","Entity: spermidine. SMILES: NCCCCNCCCN. When glucose, inositol, ascorbic acid, or NAD are used as degrading agents, spermidine generates 48 to 73% of the acrolein produced by methionine."
methionine,Methionine is an acrolein-generating agent whose activity is comparable to spermidine when hydrogen peroxide-ferrous sulfate or glyceraldehyde are used as degrading agents.,Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine is an acrolein-generating agent whose activity is comparable to spermidine when hydrogen peroxide-ferrous sulfate or glyceraldehyde are used as degrading agents.
acrolein,"Acrolein is generated by the interaction of spermine, spermidine, and methionine with ascorbic acid and other degrading agents.","Entity: acrolein. SMILES: C=CC=O. Acrolein is generated by the interaction of spermine, spermidine, and methionine with ascorbic acid and other degrading agents."
spermine,"Spermine can undergo light-catalyzed degradation in the presence of riboflavin and phosphate buffer, producing acrolein as a product.","Entity: spermine. SMILES: NCCCNCCCCNCCCN. Spermine can undergo light-catalyzed degradation in the presence of riboflavin and phosphate buffer, producing acrolein as a product."
spermine,"Under light-catalyzed conditions with riboflavin and phosphate buffer, spermine produces 10 µmole of acrolein in 1 hour and 1.25 µmole in 2 hours (22% and 25% yield, respectively).","Entity: spermine. SMILES: NCCCNCCCCNCCCN. Under light-catalyzed conditions with riboflavin and phosphate buffer, spermine produces 10 µmole of acrolein in 1 hour and 1.25 µmole in 2 hours (22% and 25% yield, respectively)."
spermidine,"Spermidine can undergo light-catalyzed degradation in the presence of riboflavin and phosphate buffer, producing acrolein as a product.","Entity: spermidine. SMILES: NCCCCNCCCN. Spermidine can undergo light-catalyzed degradation in the presence of riboflavin and phosphate buffer, producing acrolein as a product."
spermidine,"Under light-catalyzed conditions with riboflavin and phosphate buffer, spermidine produces 0.84 µmole of acrolein in 1 hour and 0.66 µmole in 2 hours (16% and 13% yield, respectively).","Entity: spermidine. SMILES: NCCCCNCCCN. Under light-catalyzed conditions with riboflavin and phosphate buffer, spermidine produces 0.84 µmole of acrolein in 1 hour and 0.66 µmole in 2 hours (16% and 13% yield, respectively)."
acrolein,Acrolein is formed as a product from the light-catalyzed degradation of spermine and spermidine in the presence of riboflavin and phosphate buffer.,Entity: acrolein. SMILES: C=CC=O. Acrolein is formed as a product from the light-catalyzed degradation of spermine and spermidine in the presence of riboflavin and phosphate buffer.
acrolein,Acrolein has a main absorption peak at 209 nm in the ultraviolet region (200–250 nm).,Entity: acrolein. SMILES: C=CC=O. Acrolein has a main absorption peak at 209 nm in the ultraviolet region (200–250 nm).
acrolein,"Acrolein is a highly toxic aldehyde that can be formed during the degradation of amino acids and polyamines, as well as from sources such as fat pyrolysis, tobacco combustion, and interactions of ubiquitous biochemicals under neutral pH and 100°C conditions commonly used in food processing.","Entity: acrolein. SMILES: C=CC=O. Acrolein is a highly toxic aldehyde that can be formed during the degradation of amino acids and polyamines, as well as from sources such as fat pyrolysis, tobacco combustion, and interactions of ubiquitous biochemicals under neutral pH and 100°C conditions commonly used in food processing."
acrolein,Cold traps can achieve an 80–90% trapping efficiency for 15 pmole of acrolein.,Entity: acrolein. SMILES: C=CC=O. Cold traps can achieve an 80–90% trapping efficiency for 15 pmole of acrolein.
acrolein,"Acrolein can be generated in vitro from methionine-ascorbic acid and methionine-ribose mixtures, yielding 1.25 pmoles (25% yield) and 1.8 pmoles (37% yield) respectively after 2 hours.","Entity: acrolein. SMILES: C=CC=O. Acrolein can be generated in vitro from methionine-ascorbic acid and methionine-ribose mixtures, yielding 1.25 pmoles (25% yield) and 1.8 pmoles (37% yield) respectively after 2 hours."
acrolein,"Acrolein can be generated in vitro from spermine-ascorbic acid mixtures, yielding 1.24 pmoles (24% yield) in 1 hour.","Entity: acrolein. SMILES: C=CC=O. Acrolein can be generated in vitro from spermine-ascorbic acid mixtures, yielding 1.24 pmoles (24% yield) in 1 hour."
ferrous sulfate,"Ferrous sulfate, when combined with hydrogen peroxide, enhances the rate of carbonyl-mediated degradation of α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C.","Entity: ferrous sulfate. SMILES: O=S(=O)([O-])[O-].[Fe+2]. Ferrous sulfate, when combined with hydrogen peroxide, enhances the rate of carbonyl-mediated degradation of α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C."
ribose,Ribose can degrade α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C.,Entity: ribose. SMILES: O=C[C@H](O)[C@H](O)[C@H](O)CO. Ribose can degrade α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C.
glucose,Glucose acts as a carbonyl compound that degrades α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose acts as a carbonyl compound that degrades α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C.
ascorbic acid,Ascorbic acid can degrade α-amino acids to aldehydes and ketones containing one carbon atom less under aerobic conditions at 100°C.,Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid can degrade α-amino acids to aldehydes and ketones containing one carbon atom less under aerobic conditions at 100°C.
glyceraldehyde,Glyceraldehyde acts as a carbonyl compound that degrades α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C.,Entity: glyceraldehyde. SMILES: O=CC(O)CO. Glyceraldehyde acts as a carbonyl compound that degrades α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C.
hydrogen peroxide,"Hydrogen peroxide, alone or with ferrous sulfate, is an effective carbonyl compound for degrading α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C.","Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide, alone or with ferrous sulfate, is an effective carbonyl compound for degrading α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C."
methionine,Methionine serves as a substrate for carbonyl compound-mediated degradation of α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C.,Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine serves as a substrate for carbonyl compound-mediated degradation of α-amino acids to aldehydes and ketones with one carbon atom less under aerobic conditions at 100°C.
methionine,"Methionine can be converted to acrolein in the presence of certain agents under aerobic conditions and 100°C, with 20% conversion to acrolein in 2 hours and higher conversion over longer periods.","Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine can be converted to acrolein in the presence of certain agents under aerobic conditions and 100°C, with 20% conversion to acrolein in 2 hours and higher conversion over longer periods."
homoserine,"Homoserine, which has a terminal α-amino butyric moiety like methionine, reacts with certain agents under aerobic conditions and 100°C to generate acrolein.","Entity: homoserine. SMILES: N[C@@H](CCO)C(=O)O. Homoserine, which has a terminal α-amino butyric moiety like methionine, reacts with certain agents under aerobic conditions and 100°C to generate acrolein."
cystathionine,"Cystathionine, with a terminal α-amino butyric moiety, reacts with certain agents under aerobic conditions and 100°C to produce acrolein, though generally at lower rates than methionine or homoserine.","Entity: cystathionine. SMILES: N[C@@H](CCSC[C@H](N)C(=O)O)C(=O)O. Cystathionine, with a terminal α-amino butyric moiety, reacts with certain agents under aerobic conditions and 100°C to produce acrolein, though generally at lower rates than methionine or homoserine."
homocysteine,"Homocysteine, which has a terminal α-amino butyric moiety, reacts with certain agents under aerobic conditions and 100°C to generate acrolein, but typically at lower rates than methionine or homoserine.","Entity: homocysteine. SMILES: N[C@@H](CCS)C(=O)O. Homocysteine, which has a terminal α-amino butyric moiety, reacts with certain agents under aerobic conditions and 100°C to generate acrolein, but typically at lower rates than methionine or homoserine."
acrolein,"Acrolein is generated as a product from the reaction of methionine, homoserine, homocysteine, and cystathionine with certain agents under aerobic conditions and 100°C.","Entity: acrolein. SMILES: C=CC=O. Acrolein is generated as a product from the reaction of methionine, homoserine, homocysteine, and cystathionine with certain agents under aerobic conditions and 100°C."
oxygen,"Oxygen serves as the carrier gas in the experiments described, and is present in the reaction mixtures under aerobic conditions.","Entity: oxygen. SMILES: [O]. Oxygen serves as the carrier gas in the experiments described, and is present in the reaction mixtures under aerobic conditions."
methionine,"Methionine can undergo oxidative deamination and decarboxylation (Strecker-like degradation) in the presence of hydrogen peroxide and ferrous sulfate, producing a 3-substituted propanal intermediate.","Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine can undergo oxidative deamination and decarboxylation (Strecker-like degradation) in the presence of hydrogen peroxide and ferrous sulfate, producing a 3-substituted propanal intermediate."
ferrous sulfate,Ferrous sulfate acts as a catalyst in the oxidative deamination and decarboxylation of methionine in the presence of hydrogen peroxide.,Entity: ferrous sulfate. SMILES: O=S(=O)([O-])[O-].[Fe+2]. Ferrous sulfate acts as a catalyst in the oxidative deamination and decarboxylation of methionine in the presence of hydrogen peroxide.
hydrogen peroxide,"Hydrogen peroxide serves as an oxidant in the methionine oxidation reaction catalyzed by ferrous sulfate, facilitating Strecker-like degradation.","Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide serves as an oxidant in the methionine oxidation reaction catalyzed by ferrous sulfate, facilitating Strecker-like degradation."
acrolein,"Acrolein can be produced from the oxidative degradation of methionine in the presence of hydrogen peroxide and ferrous sulfate, with an aerobic reaction at 100°C yielding approximately 50% acrolein on a molar basis and near-complete conversion in 30 minutes.","Entity: acrolein. SMILES: C=CC=O. Acrolein can be produced from the oxidative degradation of methionine in the presence of hydrogen peroxide and ferrous sulfate, with an aerobic reaction at 100°C yielding approximately 50% acrolein on a molar basis and near-complete conversion in 30 minutes."
methionine,"Methionine degradation produces methional, a 3-substituted propanal, and acrolein.","Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine degradation produces methional, a 3-substituted propanal, and acrolein."
acrolein,Acrolein is formed during methionine degradation and can also be generated by oxidative deamination of certain sympaticomimetic amines.,Entity: acrolein. SMILES: C=CC=O. Acrolein is formed during methionine degradation and can also be generated by oxidative deamination of certain sympaticomimetic amines.
dehydroascorbic acid,"Dehydroascorbic acid, in combination with ascorbic acid, can be used in vitro to oxidatively deaminate some sympaticomimetic amines.","Entity: dehydroascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(=O)C1=O. Dehydroascorbic acid, in combination with ascorbic acid, can be used in vitro to oxidatively deaminate some sympaticomimetic amines."
ascorbic acid,"Ascorbic acid, together with dehydroascorbic acid, enables oxidative deamination of certain sympaticomimetic amines in vitro.","Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid, together with dehydroascorbic acid, enables oxidative deamination of certain sympaticomimetic amines in vitro."
acrolein,"Acrolein is a volatile and highly toxic unsaturated aldehyde produced by pyrolysis or destructive distillation of fats, tobacco combustion, and automobile exhaust.","Entity: acrolein. SMILES: C=CC=O. Acrolein is a volatile and highly toxic unsaturated aldehyde produced by pyrolysis or destructive distillation of fats, tobacco combustion, and automobile exhaust."
allyl alcohol,Acrolein formed in vivo is considered the metabolite responsible for hepatonecrosis produced by allyl alcohol in experimental animals.,Entity: allyl alcohol. SMILES: C=CCO. Acrolein formed in vivo is considered the metabolite responsible for hepatonecrosis produced by allyl alcohol in experimental animals.
acrolein,"Acrolein is recommended for occupational exposure at a vapor concentration of 0.5 ppm for up to 8 hours per day, which is half the limit for phosgene and chlorine.","Entity: acrolein. SMILES: C=CC=O. Acrolein is recommended for occupational exposure at a vapor concentration of 0.5 ppm for up to 8 hours per day, which is half the limit for phosgene and chlorine."
allyl formate,Acrolein formed in vivo is considered the metabolite responsible for hepatonecrosis produced by allyl formate in experimental animals.,Entity: allyl formate. SMILES: C=CCOC=O. Acrolein formed in vivo is considered the metabolite responsible for hepatonecrosis produced by allyl formate in experimental animals.
acrolein,"Acrolein was formerly used as a war gas, also known as 'papite'.","Entity: acrolein. SMILES: C=CC=O. Acrolein was formerly used as a war gas, also known as 'papite'."
acetaldehyde,Acrolein exhibits ciliostatic activity on bronchial epithelium 30 times greater than acetaldehyde.,Entity: acetaldehyde. SMILES: CC=O. Acrolein exhibits ciliostatic activity on bronchial epithelium 30 times greater than acetaldehyde.
acrolein,Acrolein exhibits ciliostatic activity on bronchial epithelium 30 times greater than acetaldehyde.,Entity: acrolein. SMILES: C=CC=O. Acrolein exhibits ciliostatic activity on bronchial epithelium 30 times greater than acetaldehyde.
acrolein,Acrolein inhibits leukocyte function and the metabolism of human oral fluid-cell harvests by an order of magnitude more than cyanide.,Entity: acrolein. SMILES: C=CC=O. Acrolein inhibits leukocyte function and the metabolism of human oral fluid-cell harvests by an order of magnitude more than cyanide.
acrolein,"Acrolein is a strong in vitro cell-growth inhibitor of mammalian cells and E. coli, and is among the most potent compounds tested against cultured ascites cells.","Entity: acrolein. SMILES: C=CC=O. Acrolein is a strong in vitro cell-growth inhibitor of mammalian cells and E. coli, and is among the most potent compounds tested against cultured ascites cells."
acrolein,Acrolein formed in vivo is considered the metabolite responsible for hepatonecrosis produced by allyl formate or allyl alcohol in experimental animals.,Entity: acrolein. SMILES: C=CC=O. Acrolein formed in vivo is considered the metabolite responsible for hepatonecrosis produced by allyl formate or allyl alcohol in experimental animals.
chlorine,"Chlorine is a toxic gas with an allowable occupational exposure limit of 0.5 ppm for up to 8 hours per day, which is half the limit for acrolein.","Entity: chlorine. SMILES: [Cl]. Chlorine is a toxic gas with an allowable occupational exposure limit of 0.5 ppm for up to 8 hours per day, which is half the limit for acrolein."
phosgene,"Phosgene is a toxic gas with an allowable occupational exposure limit of 0.5 ppm for up to 8 hours per day, which is half the limit for acrolein.","Entity: phosgene. SMILES: O=C(Cl)Cl. Phosgene is a toxic gas with an allowable occupational exposure limit of 0.5 ppm for up to 8 hours per day, which is half the limit for acrolein."
cyanide,Cyanide inhibits the metabolism of human oral fluid-cell harvests by an order of magnitude less than acrolein.,Entity: cyanide. SMILES: [C-]#N. Cyanide inhibits the metabolism of human oral fluid-cell harvests by an order of magnitude less than acrolein.
Malathion,Malathion is a cholinesterase inhibitor that is routinely used in agriculture as an ecto-parasiticide in various species of livestock and poultry.,Entity: Malathion. SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC. Malathion is a cholinesterase inhibitor that is routinely used in agriculture as an ecto-parasiticide in various species of livestock and poultry.
Malathion,"Malathion is eliminated from hens within 24 hours, as shown by studies of its distribution and elimination in poultry.","Entity: Malathion. SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC. Malathion is eliminated from hens within 24 hours, as shown by studies of its distribution and elimination in poultry."
malathion,"Malathion is rapidly absorbed after oral administration in hens, with significant amounts detectable in plasma and whole blood within 30 minutes.","Entity: malathion. SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC. Malathion is rapidly absorbed after oral administration in hens, with significant amounts detectable in plasma and whole blood within 30 minutes."
desmethyl malathion,Desmethyl malathion is a water-soluble metabolite extracted from biological samples for metabolic studies of malathion.,Entity: desmethyl malathion. SMILES: CCOC(=O)CC(SP(O)(=S)OC)C(=O)OCC. Desmethyl malathion is a water-soluble metabolite extracted from biological samples for metabolic studies of malathion.
malathion,"Malathion is metabolized to both chloroform-soluble (malathion and malaoxon) and water-soluble (desmethyl malathion, diacid malathion, malathion monoacid) products, which can be analyzed in biological matrices.","Entity: malathion. SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC. Malathion is metabolized to both chloroform-soluble (malathion and malaoxon) and water-soluble (desmethyl malathion, diacid malathion, malathion monoacid) products, which can be analyzed in biological matrices."
malathion,"Biliary excretion of malathion metabolites is possible, and degradation by gastrointestinal microorganisms is also a potential elimination pathway.","Entity: malathion. SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC. Biliary excretion of malathion metabolites is possible, and degradation by gastrointestinal microorganisms is also a potential elimination pathway."
malathion,"Malathion is rapidly absorbed, quickly metabolized, and excreted, with most of the compound in the liver and kidney present in water-soluble products.","Entity: malathion. SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC. Malathion is rapidly absorbed, quickly metabolized, and excreted, with most of the compound in the liver and kidney present in water-soluble products."
malathion,"Malathion shows uniform distribution in plasma and whole blood, with similar concentrations in both compartments.","Entity: malathion. SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC. Malathion shows uniform distribution in plasma and whole blood, with similar concentrations in both compartments."
malathion,"Malathion is eliminated primarily via urine, likely through filtration rather than tubular reabsorption, although secretion cannot be ruled out.","Entity: malathion. SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC. Malathion is eliminated primarily via urine, likely through filtration rather than tubular reabsorption, although secretion cannot be ruled out."
mercury,Correlations between mercury ingestion and mercury levels in hair have been established.,Entity: mercury. SMILES: [Hg]. Correlations between mercury ingestion and mercury levels in hair have been established.
lead,Lead levels in hair have been related to chronic lead poisoning.,Entity: lead. SMILES: [Pb]. Lead levels in hair have been related to chronic lead poisoning.
nickel,Nickel is uniformly distributed along the hair strand.,Entity: nickel. SMILES: [Ni]. Nickel is uniformly distributed along the hair strand.
nickel,"Nickel does not accumulate in the hair of guinea pigs, making hair nickel measurements an unreliable indicator of nickel exposure.","Entity: nickel. SMILES: [Ni]. Nickel does not accumulate in the hair of guinea pigs, making hair nickel measurements an unreliable indicator of nickel exposure."
nickel,Nickel can be administered to guinea pigs via drinking water at a concentration of 2.5 pg/ml for 4 months to assess its effects on nickel levels in hair.,Entity: nickel. SMILES: [Ni]. Nickel can be administered to guinea pigs via drinking water at a concentration of 2.5 pg/ml for 4 months to assess its effects on nickel levels in hair.
nickel,"Nickel concentrations in samples can be measured by atomic absorption spectrometry using a Perkin-Elmer model 360 instrument in the concentration mode, with linearity established over the 0.4 to 4.0 pg Ni/ml range using nickel standards in nitric acid.","Entity: nickel. SMILES: [Ni]. Nickel concentrations in samples can be measured by atomic absorption spectrometry using a Perkin-Elmer model 360 instrument in the concentration mode, with linearity established over the 0.4 to 4.0 pg Ni/ml range using nickel standards in nitric acid."
nitrous oxide,"In cells exposed to nitrous oxide, spindle reorganization and resumption of normal division occur when the gas is removed, indicating that the spindle is a target of its action.","Entity: nitrous oxide. SMILES: N#[N+][O-]. In cells exposed to nitrous oxide, spindle reorganization and resumption of normal division occur when the gas is removed, indicating that the spindle is a target of its action."
chloroform,"Chloroform, as an anesthetic, can cause mitotic anomalies by targeting cellular organelles such as the spindle and possibly centrioles.","Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform, as an anesthetic, can cause mitotic anomalies by targeting cellular organelles such as the spindle and possibly centrioles."
halothane,Halothane exposure increases the frequency of binucleation and multinucleation in Chinese hamster cells in vitro.,Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane exposure increases the frequency of binucleation and multinucleation in Chinese hamster cells in vitro.
olivetol,"Olivetol treatment of human lymphocytes causes segregational errors during cell division, leading to abnormal cell division and potential aneuploidy.","Entity: olivetol. SMILES: CCCCCc1cc(O)cc(O)c1. Olivetol treatment of human lymphocytes causes segregational errors during cell division, leading to abnormal cell division and potential aneuploidy."
nitrous oxide,Nitrous oxide exposure disarranges microtubules and arrests mitotic cells at metaphase.,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide exposure disarranges microtubules and arrests mitotic cells at metaphase.
epinephrine,"Competitive epinephrine urinary levels are significantly higher than training levels in women athletes, indicating increased catecholamine excretion under mental stress such as athletic competition.","Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. Competitive epinephrine urinary levels are significantly higher than training levels in women athletes, indicating increased catecholamine excretion under mental stress such as athletic competition."
norepinephrine,"Norepinephrine levels rise in both intercollegiate basketball and track and field athletes following training sessions and after athletic competition, correlating with increased physical effort.","Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Norepinephrine levels rise in both intercollegiate basketball and track and field athletes following training sessions and after athletic competition, correlating with increased physical effort."
catecholamine,"Catecholamines, including epinephrine and norepinephrine, exhibit altered urinary patterns in response to mental stress and increased physical effort in athletes.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Catecholamines, including epinephrine and norepinephrine, exhibit altered urinary patterns in response to mental stress and increased physical effort in athletes."
epinephrine,Urine epinephrine levels reflect blood catecholamine levels and are measured using a spectrophotofluorometric method with recovery correction of 73.1%.,Entity: epinephrine. SMILES: CNCC(O)c1ccc(O)c(O)c1. Urine epinephrine levels reflect blood catecholamine levels and are measured using a spectrophotofluorometric method with recovery correction of 73.1%.
norepinephrine,Urine norepinephrine levels reflect blood catecholamine levels and are measured using a spectrophotofluorometric method with recovery correction of 65.6%.,Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Urine norepinephrine levels reflect blood catecholamine levels and are measured using a spectrophotofluorometric method with recovery correction of 65.6%.
hydrochloric acid,Hydrochloric acid is used to adjust urine samples to pH 3.5 ± 0.2 for analysis of catecholamines.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to adjust urine samples to pH 3.5 ± 0.2 for analysis of catecholamines.
hemoglobin,Hemoglobin can be measured from a finger prick sample as part of a routine medical examination.,Entity: hemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. Hemoglobin can be measured from a finger prick sample as part of a routine medical examination.
oxygen,"Oxygen consumption (VO2) is linearly related to the increase in ventilation rate (FOE) in the respiratory system, with a regression equation of Qc = 5.59 VO2 + 3.77, where Qc is the oxygen uptake constant.","Entity: oxygen. SMILES: [O]. Oxygen consumption (VO2) is linearly related to the increase in ventilation rate (FOE) in the respiratory system, with a regression equation of Qc = 5.59 VO2 + 3.77, where Qc is the oxygen uptake constant."
oxygen,"During breath-holding periods when inspiration is not possible, the amount of oxygen that can be transferred across the alveolar membrane critically depends on the individual's diffusing capacity (DL), as alveolar oxygen tension must fall to low levels.","Entity: oxygen. SMILES: [O]. During breath-holding periods when inspiration is not possible, the amount of oxygen that can be transferred across the alveolar membrane critically depends on the individual's diffusing capacity (DL), as alveolar oxygen tension must fall to low levels."
nitrous oxide,Nitrous oxide is used as a test gas in the indirect Fick foreign gas technique to determine alveolar ventilation (Qe).,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used as a test gas in the indirect Fick foreign gas technique to determine alveolar ventilation (Qe).
carbon dioxide,Carbon dioxide concentrations in mixed expired gas samples can be measured using electronic analyzers such as the Beckman F3 and LB-1.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide concentrations in mixed expired gas samples can be measured using electronic analyzers such as the Beckman F3 and LB-1.
oxygen,"Oxygen consumption (ffO2) can be measured by an open-circuit spirometric technique, and mixed expired oxygen concentrations can be analyzed by electronic analyzers.","Entity: oxygen. SMILES: [O]. Oxygen consumption (ffO2) can be measured by an open-circuit spirometric technique, and mixed expired oxygen concentrations can be analyzed by electronic analyzers."
oxygen,Pulmonary capillary blood flow (Qc) and pulmonary diffusing capacity (DLco) are related to oxygen consumption in pre- and post-pubescent boys in a manner similar to adults.,Entity: oxygen. SMILES: [O]. Pulmonary capillary blood flow (Qc) and pulmonary diffusing capacity (DLco) are related to oxygen consumption in pre- and post-pubescent boys in a manner similar to adults.
carbon monoxide,Carbon monoxide is used as a test gas at a concentration of 0.125% in room air for measuring lung function via the steady-state carbon monoxide technique.,Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide is used as a test gas at a concentration of 0.125% in room air for measuring lung function via the steady-state carbon monoxide technique.
oxygen,Oxygen concentration is continuously monitored during lung function tests using the steady-state carbon monoxide technique.,Entity: oxygen. SMILES: [O]. Oxygen concentration is continuously monitored during lung function tests using the steady-state carbon monoxide technique.
carbon dioxide,Carbon dioxide concentration is continuously monitored during lung function tests using the steady-state carbon monoxide technique.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide concentration is continuously monitored during lung function tests using the steady-state carbon monoxide technique.
urea,"Serum urea increases significantly after about 60-70 minutes of prolonged physical exercise, with the magnitude of the increase correlating with exercise duration.","Entity: urea. SMILES: NC(N)=O. Serum urea increases significantly after about 60-70 minutes of prolonged physical exercise, with the magnitude of the increase correlating with exercise duration."
amino nitrogen,"Serum amino nitrogen decreases significantly after about 60-70 minutes of prolonged physical exercise, with the decrease correlating with exercise duration.","Entity: amino nitrogen. SMILES: [N]N. Serum amino nitrogen decreases significantly after about 60-70 minutes of prolonged physical exercise, with the decrease correlating with exercise duration."
tyrosine,"Serum free tyrosine rises significantly after about 60-70 minutes of prolonged physical exercise, with the magnitude of the increase correlating with exercise duration.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Serum free tyrosine rises significantly after about 60-70 minutes of prolonged physical exercise, with the magnitude of the increase correlating with exercise duration."
catecholamine,Plasma catecholamine concentration increases rapidly during dynamic exercise above 70% of maximal aerobic power output (f~O 2 max).,Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Plasma catecholamine concentration increases rapidly during dynamic exercise above 70% of maximal aerobic power output (f~O 2 max).
catecholamine,"The rise in plasma catecholamine during exercise is associated with increased cardiac output and relative work load, as expressed by % VO 2 max.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. The rise in plasma catecholamine during exercise is associated with increased cardiac output and relative work load, as expressed by % VO 2 max."
Catecholamine,"Catecholamine plasma concentration increases during exercise, and this rise is influenced by both beta-blockade and atropinisation, with beta-blockade having less effect on catecholamine response for a given workload and %VO2 max.","Entity: Catecholamine. SMILES: Nc1cccc(O)c1O. Catecholamine plasma concentration increases during exercise, and this rise is influenced by both beta-blockade and atropinisation, with beta-blockade having less effect on catecholamine response for a given workload and %VO2 max."
atropine,Atropine increases plasma catecholamine levels (fn) and raises the area under the catecholamine curve (AC) for a given VO2 and %VO2 max in subjects.,Entity: atropine. SMILES: CN1[C@@H]2CC[C@H]1CC(OC(=O)C(CO)c1ccccc1)C2. Atropine increases plasma catecholamine levels (fn) and raises the area under the catecholamine curve (AC) for a given VO2 and %VO2 max in subjects.
practolol,"Practolol, a γ-blocker, reduces plasma catecholamine levels (fn) without altering the relationship between area under the catecholamine curve (AC) and VO2 max (except in athletes).","Entity: practolol. SMILES: CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1. Practolol, a γ-blocker, reduces plasma catecholamine levels (fn) without altering the relationship between area under the catecholamine curve (AC) and VO2 max (except in athletes)."
catecholamine,"Plasma catecholamine levels (fn) and the area under the catecholamine curve (AC) are associated with relative aerobic energy expenditure, but this association is not causal.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Plasma catecholamine levels (fn) and the area under the catecholamine curve (AC) are associated with relative aerobic energy expenditure, but this association is not causal."
catecholamine,"Catecholamines released from sympathetic nerve endings mediate peripheral vasoconstriction in the skin during exercise, and their levels in blood reflect local blood flow regulation.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Catecholamines released from sympathetic nerve endings mediate peripheral vasoconstriction in the skin during exercise, and their levels in blood reflect local blood flow regulation."
catecholamine,"During exercise, closure of the splanchnic circulation is likely mediated by noradrenaline release from sympathetic nerve endings in visceral blood vessels.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. During exercise, closure of the splanchnic circulation is likely mediated by noradrenaline release from sympathetic nerve endings in visceral blood vessels."
catecholamine,"The adrenal glands contribute little to the pattern of adaptation to exercise, as shown by adrenolectomy in animals and renal catheterisation in man.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. The adrenal glands contribute little to the pattern of adaptation to exercise, as shown by adrenolectomy in animals and renal catheterisation in man."
phentolamine,"Phentolamine, a π-adrenergic blocker, does not affect the vasoconstriction that occurs in the skin during short-term exercise, indicating that this vasoconstriction is not mediated by π-adrenergic pathways.","Entity: phentolamine. SMILES: Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1. Phentolamine, a π-adrenergic blocker, does not affect the vasoconstriction that occurs in the skin during short-term exercise, indicating that this vasoconstriction is not mediated by π-adrenergic pathways."
Carbon dioxide,"Carbon dioxide concentration in exhaled air can be measured using infrared analysis, and end-tidal CO2 can be continuously monitored to identify a stable 6–10 s plateau in respired CO2 tension during rebreathing techniques.","Entity: Carbon dioxide. SMILES: O=C=O. Carbon dioxide concentration in exhaled air can be measured using infrared analysis, and end-tidal CO2 can be continuously monitored to identify a stable 6–10 s plateau in respired CO2 tension during rebreathing techniques."
Oxygen,Oxygen concentration in exhaled air can be measured using paramagnetic analysis.,Entity: Oxygen. SMILES: [O]. Oxygen concentration in exhaled air can be measured using paramagnetic analysis.
catecholamine,Catecholamine is a class of neurotransmitters and hormones whose total concentration in venous blood can be measured following exercise in humans.,Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Catecholamine is a class of neurotransmitters and hormones whose total concentration in venous blood can be measured following exercise in humans.
atropine,Atropine is used as a pharmacological agent that can be administered intravenously to study its effects on physiological measurements during exercise.,Entity: atropine. SMILES: CN1[C@@H]2CC[C@H]1CC(OC(=O)C(CO)c1ccccc1)C2. Atropine is used as a pharmacological agent that can be administered intravenously to study its effects on physiological measurements during exercise.
practolol,Practolol is a drug that can be administered intravenously to investigate its effects on physiological responses during exercise.,Entity: practolol. SMILES: CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1. Practolol is a drug that can be administered intravenously to investigate its effects on physiological responses during exercise.
2-(4'-Hydroxyphenylazo)-benzoic acid,The 2-(4'-Hydroxyphenylazo)-benzoic acid method is used to measure serum albumin concentration.,Entity: 2-(4'-Hydroxyphenylazo)-benzoic acid. SMILES: O=C(O)c1ccccc1N=Nc1ccc(O)cc1. The 2-(4'-Hydroxyphenylazo)-benzoic acid method is used to measure serum albumin concentration.
oxygen,"Oxygen uptake can be measured in humans using the Scholander technique, and oxygen saturation can be determined spectrophotometrically in arterial, mixed venous, and femoral venous blood.","Entity: oxygen. SMILES: [O]. Oxygen uptake can be measured in humans using the Scholander technique, and oxygen saturation can be determined spectrophotometrically in arterial, mixed venous, and femoral venous blood."
oxygen,Oxygen uptake increases by approximately 30% during sustained isometric contraction compared to the resting state.,Entity: oxygen. SMILES: [O]. Oxygen uptake increases by approximately 30% during sustained isometric contraction compared to the resting state.
DNP,DNP inhibits oxygen respiration in Paracoccus denitrificans by 50% at concentrations of about 1000 pM in anaerobically (nitrate) grown cells and about 1000 pM in aerobically grown cells.,Entity: DNP. SMILES: O=[N+]([O-])c1ccc(O)c([N+](=O)[O-])c1. DNP inhibits oxygen respiration in Paracoccus denitrificans by 50% at concentrations of about 1000 pM in anaerobically (nitrate) grown cells and about 1000 pM in aerobically grown cells.
DNP,DNP inhibits nitrite respiration in anaerobically grown Paracoccus denitrificans by 50% at concentrations of about 500 pM.,Entity: DNP. SMILES: O=[N+]([O-])c1ccc(O)c([N+](=O)[O-])c1. DNP inhibits nitrite respiration in anaerobically grown Paracoccus denitrificans by 50% at concentrations of about 500 pM.
CCP,CCP inhibits oxygen respiration in Paracoccus denitrificans by 50% at concentrations of about 3 pM in both anaerobically (nitrate) and aerobically grown cells.,Entity: CCP. SMILES: N#CC(=O)C#N.Oc1cccc(Cl)c1. CCP inhibits oxygen respiration in Paracoccus denitrificans by 50% at concentrations of about 3 pM in both anaerobically (nitrate) and aerobically grown cells.
CCP,CCP inhibits nitrite respiration in anaerobically grown Paracoccus denitrificans by 50% at concentrations of about 35 pM.,Entity: CCP. SMILES: N#CC(=O)C#N.Oc1cccc(Cl)c1. CCP inhibits nitrite respiration in anaerobically grown Paracoccus denitrificans by 50% at concentrations of about 35 pM.
nitrous oxide,Nitrous oxide reduction in denitrifier systems can be inhibited by DNP and azide.,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide reduction in denitrifier systems can be inhibited by DNP and azide.
nitrite,"Nitrite reduction in Pseudomonas denitrificans and Pseudomonas aeruginosa is inhibited by DNP, a weakly acidic uncoupler.","Entity: nitrite. SMILES: O=N[O-]. Nitrite reduction in Pseudomonas denitrificans and Pseudomonas aeruginosa is inhibited by DNP, a weakly acidic uncoupler."
valinomycin,"Valinomycin, an ionophore, fails to inhibit denitrification under the tested conditions.","Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin, an ionophore, fails to inhibit denitrification under the tested conditions."
nigericin,"Nigericin, an ionophore, fails to inhibit denitrification under the tested conditions.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin, an ionophore, fails to inhibit denitrification under the tested conditions."
DNP,"DNP acts as a weakly acidic uncoupler that inhibits the reduction of nitrate, nitrite, and nitrous oxide in Pseudomonas denitrificans and Pseudomonas aeruginosa.","Entity: DNP. SMILES: O=[N+]([O-])c1ccc(O)c([N+](=O)[O-])c1. DNP acts as a weakly acidic uncoupler that inhibits the reduction of nitrate, nitrite, and nitrous oxide in Pseudomonas denitrificans and Pseudomonas aeruginosa."
DNP,DNP at 0.1 mM inhibits the oxidizing side of cytochromes b and c and is specific against nitrous oxide reduction in denitrifier strains of Alcaligenes/Alachlorobacter group.,Entity: DNP. SMILES: O=[N+]([O-])c1ccc(O)c([N+](=O)[O-])c1. DNP at 0.1 mM inhibits the oxidizing side of cytochromes b and c and is specific against nitrous oxide reduction in denitrifier strains of Alcaligenes/Alachlorobacter group.
azide,Azide inhibits denitrification by acting on the oxidizing side of cytochromes b and c.,Entity: azide. SMILES: [N-]=[N+]=[N-]. Azide inhibits denitrification by acting on the oxidizing side of cytochromes b and c.
thiocyanate,"Thiocyanate is a membrane-permeant anion that facilitates counterion transport, thereby enhancing proton permeability across membranes.","Entity: thiocyanate. SMILES: N#C[S-]. Thiocyanate is a membrane-permeant anion that facilitates counterion transport, thereby enhancing proton permeability across membranes."
carbonyl cyanide m-chlorophenyl hydrazone,Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) enhances proton permeability and accelerates proton migration from the medium into cells in the presence of a small amount of hydrochloric acid.,Entity: carbonyl cyanide m-chlorophenyl hydrazone. SMILES: N#CC(C#N)=NNc1cccc(Cl)c1. Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) enhances proton permeability and accelerates proton migration from the medium into cells in the presence of a small amount of hydrochloric acid.
butanol,Butanol at 4% (0.54 M) concentration destroys the permeability barrier to protons across membranes.,Entity: butanol. SMILES: CCCCO. Butanol at 4% (0.54 M) concentration destroys the permeability barrier to protons across membranes.
valinomycin,Valinomycin is a potassium-specific ionophore that strongly facilitates counterion transport and enhances proton permeability across membranes.,Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin is a potassium-specific ionophore that strongly facilitates counterion transport and enhances proton permeability across membranes.
nigericin,"Nigericin is an ionophore that can exchange H+ for K+ across membranes, producing effects similar to valinomycin plus CCCP in terms of membrane permeability.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin is an ionophore that can exchange H+ for K+ across membranes, producing effects similar to valinomycin plus CCCP in terms of membrane permeability."
hydrochloric acid,Hydrochloric acid (HCl) is used to create an acid pulse that enhances proton permeability and facilitates proton migration into cells.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (HCl) is used to create an acid pulse that enhances proton permeability and facilitates proton migration into cells.
nitrous oxide,Nitrous oxide serves as the oxidant in assays measuring cytochrome activity and uncoupler effects in Pseudomonas denitrificans.,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide serves as the oxidant in assays measuring cytochrome activity and uncoupler effects in Pseudomonas denitrificans.
3-nitrophenol,3-nitrophenol causes 50% inhibition of nitrous oxide reduction in Pseudomonas denitrificans at a concentration of 2 mM.,Entity: 3-nitrophenol. SMILES: O=[N+]([O-])c1cccc(O)c1. 3-nitrophenol causes 50% inhibition of nitrous oxide reduction in Pseudomonas denitrificans at a concentration of 2 mM.
nitrite,Nitrite can be used as an oxidant in assays to assess cytochrome activity and uncoupler effects in Pseudomonas denitrificans.,Entity: nitrite. SMILES: O=N[O-]. Nitrite can be used as an oxidant in assays to assess cytochrome activity and uncoupler effects in Pseudomonas denitrificans.
"3,5-dinitrobenzoate","3,5-dinitrobenzoate causes 50% inhibition of nitrous oxide reduction in Pseudomonas denitrificans at a concentration of 2.5 mM.","Entity: 3,5-dinitrobenzoate. SMILES: O=C([O-])c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1. 3,5-dinitrobenzoate causes 50% inhibition of nitrous oxide reduction in Pseudomonas denitrificans at a concentration of 2.5 mM."
phenol,Phenol causes 50% inhibition of nitrous oxide reduction in Pseudomonas denitrificans at a concentration of 20 mM.,Entity: phenol. SMILES: Oc1ccccc1. Phenol causes 50% inhibition of nitrous oxide reduction in Pseudomonas denitrificans at a concentration of 20 mM.
sodium dodecyl sulfate,Sodium dodecyl sulfate causes 50% inhibition of nitrous oxide reduction in Pseudomonas denitrificans at a concentration of 15 mM.,Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate causes 50% inhibition of nitrous oxide reduction in Pseudomonas denitrificans at a concentration of 15 mM.
"3,5-dinitroanisole","3,5-dinitroanisole, a nondissociable analogue, causes 60 to 80% inhibition of nitrous oxide reduction in Pseudomonas denitrificans when the aqueous phase is saturated.","Entity: 3,5-dinitroanisole. SMILES: COc1cc([N+](=O)[O-])cc([N+](=O)[O-])c1. 3,5-dinitroanisole, a nondissociable analogue, causes 60 to 80% inhibition of nitrous oxide reduction in Pseudomonas denitrificans when the aqueous phase is saturated."
butanol,Butanol does not inhibit nitrous oxide reduction in Pseudomonas denitrificans at concentrations up to 20 mM.,Entity: butanol. SMILES: CCCCO. Butanol does not inhibit nitrous oxide reduction in Pseudomonas denitrificans at concentrations up to 20 mM.
ethanol,Ethanol does not inhibit nitrous oxide reduction in Pseudomonas denitrificans at concentrations up to 700 mM.,Entity: ethanol. SMILES: CCO. Ethanol does not inhibit nitrous oxide reduction in Pseudomonas denitrificans at concentrations up to 700 mM.
azide,Azide produces a largely reduced steady state in the presence of uncouplers during nitrous oxide reduction assays.,Entity: azide. SMILES: [N-]=[N+]=[N-]. Azide produces a largely reduced steady state in the presence of uncouplers during nitrous oxide reduction assays.
nitrate,Nitrate is used as an oxidant for anaerobic growth of Pseudomonas denitrificans and Pseudomonas aeruginosa cells at a concentration of 20 mM.,Entity: nitrate. SMILES: O=[N+]([O-])[O-]. Nitrate is used as an oxidant for anaerobic growth of Pseudomonas denitrificans and Pseudomonas aeruginosa cells at a concentration of 20 mM.
phenol,Phenol has a pKa value of about 10 and is less effective than 3-nitrophenol as a membrane inhibitor.,Entity: phenol. SMILES: Oc1ccccc1. Phenol has a pKa value of about 10 and is less effective than 3-nitrophenol as a membrane inhibitor.
"3,5-dinitroanisole","3,5-dinitroanisole is an effective membrane inhibitor, demonstrating that an acidic function is not necessary for membrane inhibition.","Entity: 3,5-dinitroanisole. SMILES: COc1cc([N+](=O)[O-])cc([N+](=O)[O-])c1. 3,5-dinitroanisole is an effective membrane inhibitor, demonstrating that an acidic function is not necessary for membrane inhibition."
"3,5-dinitrobenzoate","3,5-dinitrobenzoate contains a carboxylate group that allows its hydrophobic portion to insert into but not easily traverse the membrane, similar to ionic detergents.","Entity: 3,5-dinitrobenzoate. SMILES: O=C([O-])c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1. 3,5-dinitrobenzoate contains a carboxylate group that allows its hydrophobic portion to insert into but not easily traverse the membrane, similar to ionic detergents."
"3,5-dinitrobenzoate","3,5-dinitrobenzoate is an effective membrane inhibitor, comparable in effectiveness to DNP and CCCP.","Entity: 3,5-dinitrobenzoate. SMILES: O=C([O-])c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1. 3,5-dinitrobenzoate is an effective membrane inhibitor, comparable in effectiveness to DNP and CCCP."
CCCP,"CCCP is a membrane-active compound that inhibits membrane function, with effectiveness similar to DNP and 3,5-dinitrobenzoate.","Entity: CCCP. SMILES: N#CC(C#N)=NNc1cccc(Cl)c1. CCCP is a membrane-active compound that inhibits membrane function, with effectiveness similar to DNP and 3,5-dinitrobenzoate."
DNP,"DNP is a membrane-active compound that inhibits membrane function, with effectiveness similar to CCCP and 3,5-dinitrobenzoate.","Entity: DNP. SMILES: O=[N+]([O-])c1cccc(O)c1[N+](=O)[O-]. DNP is a membrane-active compound that inhibits membrane function, with effectiveness similar to CCCP and 3,5-dinitrobenzoate."
3-nitrophenol,"3-nitrophenol has a pKa value of about 10 and is more effective than phenol as a membrane inhibitor, suggesting that ring substituents can influence membrane inhibition.","Entity: 3-nitrophenol. SMILES: O=[N+]([O-])c1cccc(O)c1. 3-nitrophenol has a pKa value of about 10 and is more effective than phenol as a membrane inhibitor, suggesting that ring substituents can influence membrane inhibition."
valinomycin,"Valinomycin is used as a component in respiratory control experiments to modulate cellular transport processes, such as the active transport of L-glutamate.","Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin is used as a component in respiratory control experiments to modulate cellular transport processes, such as the active transport of L-glutamate."
nigericin,Nigericin is used in cell-based assays to study its effects on cellular transport and respiratory control.,Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin is used in cell-based assays to study its effects on cellular transport and respiratory control.
butanol,Butanol is used as a test compound to assess changes in cellular buffering capacity in respiratory control experiments.,Entity: butanol. SMILES: CCCCO. Butanol is used as a test compound to assess changes in cellular buffering capacity in respiratory control experiments.
CCCP,CCCP (carbonyl cyanide m-chlorophenyl hydrazone) is an inhibitor of mitochondrial respiration used to measure the respiratory control ratio in cell-based assays.,Entity: CCCP. SMILES: N#CC(C#N)=NNc1cccc(Cl)c1. CCCP (carbonyl cyanide m-chlorophenyl hydrazone) is an inhibitor of mitochondrial respiration used to measure the respiratory control ratio in cell-based assays.
L-glutamate,L-glutamate is an endogenous substrate for respiration-dependent active transport in cell-based assays.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate is an endogenous substrate for respiration-dependent active transport in cell-based assays.
KSCN,KSCN (potassium cyanide) is used as a test compound to evaluate changes in cellular buffering capacity in respiratory control experiments.,Entity: KSCN. SMILES: N#C[Fe-3](C#N)(C#N)(C#N)(C#N)C#N.[K+].[K+].[K+]. KSCN (potassium cyanide) is used as a test compound to evaluate changes in cellular buffering capacity in respiratory control experiments.
Nitric oxide,Nitric oxide can be used as an oxidant in spectrophotometric assays to study the reduction of cytochromes in cell lysates.,Entity: Nitric oxide. SMILES: [N]=O. Nitric oxide can be used as an oxidant in spectrophotometric assays to study the reduction of cytochromes in cell lysates.
Nitrous oxide,"Nitrous oxide is used as an oxidant in spectrophotometric assays, and its use does not induce the biphasic reduction response observed with nitrite as the oxidant in cytochromes c.","Entity: Nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used as an oxidant in spectrophotometric assays, and its use does not induce the biphasic reduction response observed with nitrite as the oxidant in cytochromes c."
Dinitrophenol,"Dinitrophenol is an effective uncoupler that produces intense absorption in spectrophotometric assays, but its high concentration requirements make it difficult to obtain useful data.","Entity: Dinitrophenol. SMILES: O=[N+]([O-])c1cccc(O)c1[N+](=O)[O-]. Dinitrophenol is an effective uncoupler that produces intense absorption in spectrophotometric assays, but its high concentration requirements make it difficult to obtain useful data."
Carbonyl cyanide m-chlorophenyl hydrazone,Carbonyl cyanide m-chlorophenyl hydrazone acts as an uncoupler that markedly slows the transition from the glutamate-reduced state to the steady state in spectrophotometric assays of cytochromes.,Entity: Carbonyl cyanide m-chlorophenyl hydrazone. SMILES: N#CC(C#N)=NNc1cccc(Cl)c1. Carbonyl cyanide m-chlorophenyl hydrazone acts as an uncoupler that markedly slows the transition from the glutamate-reduced state to the steady state in spectrophotometric assays of cytochromes.
NaOH,NaOH is used as an anaerobic base to adjust the pH of the system to 6.88–6.90 in membrane equilibration experiments with bacteria.,Entity: NaOH. SMILES: [Na+].[OH-]. NaOH is used as an anaerobic base to adjust the pH of the system to 6.88–6.90 in membrane equilibration experiments with bacteria.
HCl,HCl is used as an acidic solution at 5 mM concentration in 150 mM KCl for pH adjustment and as an injection solution in membrane equilibration assays with bacteria.,Entity: HCl. SMILES: Cl. HCl is used as an acidic solution at 5 mM concentration in 150 mM KCl for pH adjustment and as an injection solution in membrane equilibration assays with bacteria.
KCI,KCl is used as a 150 mM buffer solution in membrane equilibration experiments with bacteria to maintain ionic strength.,Entity: KCI. SMILES: [Cl-].[K+]. KCl is used as a 150 mM buffer solution in membrane equilibration experiments with bacteria to maintain ionic strength.
valinomycin,"Valinomycin is used to permeabilize bacterial membranes, typically by incubation for 3 hours at 5°C prior to membrane equilibration assays.","Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin is used to permeabilize bacterial membranes, typically by incubation for 3 hours at 5°C prior to membrane equilibration assays."
nigericin,"Nigericin is used to permeabilize bacterial membranes, typically by incubation for 3 hours at 5°C prior to membrane equilibration assays.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin is used to permeabilize bacterial membranes, typically by incubation for 3 hours at 5°C prior to membrane equilibration assays."
valinomycin,Valinomycin is used at a concentration of 30 µg/mL for 3 hours at 5°C to study its effect on respiratory control in denitrification assays.,Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin is used at a concentration of 30 µg/mL for 3 hours at 5°C to study its effect on respiratory control in denitrification assays.
nigericin,Nigericin is used at a concentration of 30 µg/mL for 3 hours at 5°C to study its effect on respiratory control in denitrification assays.,Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin is used at a concentration of 30 µg/mL for 3 hours at 5°C to study its effect on respiratory control in denitrification assays.
potassium acetate,Potassium acetate is added immediately before the assay in denitrification experiments.,Entity: potassium acetate. SMILES: CC(=O)[O-].[K+]. Potassium acetate is added immediately before the assay in denitrification experiments.
acetic acid,"Acetic acid, in equilibrium with acetate and used to collapse the appansion potential (ApH) with valinomycin, does not inhibit denitrification.","Entity: acetic acid. SMILES: CC(=O)O. Acetic acid, in equilibrium with acetate and used to collapse the appansion potential (ApH) with valinomycin, does not inhibit denitrification."
carbonyl cyanide m-chlorophenyl hydrazone,Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) behaves similarly to nigericin and valinomycin in terms of its effects on bacterial membrane potential and appansion potential (ApH).,Entity: carbonyl cyanide m-chlorophenyl hydrazone. SMILES: N#CC(C#N)=NNc1cccc(Cl)c1. Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) behaves similarly to nigericin and valinomycin in terms of its effects on bacterial membrane potential and appansion potential (ApH).
nigericin,Nigericin is an ionophore that can penetrate bacterial membranes and collapse the appansion potential (ApH) but not the membrane potential.,Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin is an ionophore that can penetrate bacterial membranes and collapse the appansion potential (ApH) but not the membrane potential.
valinomycin,Valinomycin is an ionophore that can penetrate bacterial membranes and collapse the membrane potential but not the appansion potential (ApH).,Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin is an ionophore that can penetrate bacterial membranes and collapse the membrane potential but not the appansion potential (ApH).
acetate,"Acetate, when used with acetic acid to collapse the appansion potential (ApH) in the presence of valinomycin, does not inhibit denitrification.","Entity: acetate. SMILES: CC(=O)[O-]. Acetate, when used with acetic acid to collapse the appansion potential (ApH) in the presence of valinomycin, does not inhibit denitrification."
L-proline,"L-proline can be accumulated intracellularly by a factor of 200–300 under certain conditions, indicating active transport.","Entity: L-proline. SMILES: N#[N+][O-]. L-proline can be accumulated intracellularly by a factor of 200–300 under certain conditions, indicating active transport."
CCCP,CCCP inhibits denitrification by reducing internal steady-state amino acid levels to half maximum at concentrations of about 1 pM.,Entity: CCCP. SMILES: N#CC(C#N)=NNc1cccc(Cl)c1. CCCP inhibits denitrification by reducing internal steady-state amino acid levels to half maximum at concentrations of about 1 pM.
CCCP,"CCCP inhibits active transport in Pseudomonas denitrifcans, but this inhibition has little effect on the rates of nitrogen oxide reduction even at high external substrate concentrations.","Entity: CCCP. SMILES: N#CC(C#N)=NNc1cccc(Cl)c1. CCCP inhibits active transport in Pseudomonas denitrifcans, but this inhibition has little effect on the rates of nitrogen oxide reduction even at high external substrate concentrations."
L-glutamate,L-glutamate at 10 mM can serve as an oxidizable substrate supporting nitrogen oxide reduction in Pseudomonas denitrifcans despite uncoupler-induced inhibition.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate at 10 mM can serve as an oxidizable substrate supporting nitrogen oxide reduction in Pseudomonas denitrifcans despite uncoupler-induced inhibition.
carbonyl cyanide phenylhydrazone,Carbonyl cyanide phenylhydrazone uncouplers inhibit respiration in nitrogen oxide respirations by acting as nonuncoupling analogues and disrupting the proton motive force.,Entity: carbonyl cyanide phenylhydrazone. SMILES: N#CC(C#N)=NNc1ccccc1. Carbonyl cyanide phenylhydrazone uncouplers inhibit respiration in nitrogen oxide respirations by acting as nonuncoupling analogues and disrupting the proton motive force.
nitrophenol,Nitrophenol uncouplers inhibit respiration in nitrogen oxide respirations by acting as nonuncoupling analogues and interfering with the proton motive force.,Entity: nitrophenol. SMILES: O=[N+]([O-])c1ccccc1O. Nitrophenol uncouplers inhibit respiration in nitrogen oxide respirations by acting as nonuncoupling analogues and interfering with the proton motive force.
nigericin,"Nigericin, which collapses the membrane potential (ApH), does not inhibit nitrogen oxide respirations under the conditions described.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin, which collapses the membrane potential (ApH), does not inhibit nitrogen oxide respirations under the conditions described."
valinomycin,"Valinomycin, which collapses membrane potential, does not inhibit nitrogen oxide respirations under the described conditions.","Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin, which collapses membrane potential, does not inhibit nitrogen oxide respirations under the described conditions."
oxygen,"Oxygen uptake in Pseudomonas denitrificans is not significantly affected by the presence of nitrate, nitrite, or nitrous oxide at 10–20 mM.","Entity: oxygen. SMILES: [O]. Oxygen uptake in Pseudomonas denitrificans is not significantly affected by the presence of nitrate, nitrite, or nitrous oxide at 10–20 mM."
oxygen,Oxygen respiration in Pseudomonas denitrificans is constitutive and occurs at a rate similar to that of nitrite and nitrous oxide respirations.,Entity: oxygen. SMILES: [O]. Oxygen respiration in Pseudomonas denitrificans is constitutive and occurs at a rate similar to that of nitrite and nitrous oxide respirations.
nitrate,"In Pseudomonas denitrificans, nitrate serves as a substrate for denitrification, with nitrite reduction being the rate-determining step.","Entity: nitrate. SMILES: O=[N+]([O-])[O-]. In Pseudomonas denitrificans, nitrate serves as a substrate for denitrification, with nitrite reduction being the rate-determining step."
nitrate,The presence of nitrate at 10–20 mM has little effect on oxygen uptake in Pseudomonas denitrificans.,Entity: nitrate. SMILES: O=[N+]([O-])[O-]. The presence of nitrate at 10–20 mM has little effect on oxygen uptake in Pseudomonas denitrificans.
nitrous oxide,"During denitrification of nitrite in Pseudomonas denitrificans, little or no nitrous oxide is evolved.","Entity: nitrous oxide. SMILES: N#[N+][O-]. During denitrification of nitrite in Pseudomonas denitrificans, little or no nitrous oxide is evolved."
nitrous oxide,The reduction of nitrous oxide in Pseudomonas denitrificans is faster than that of nitrite.,Entity: nitrous oxide. SMILES: N#[N+][O-]. The reduction of nitrous oxide in Pseudomonas denitrificans is faster than that of nitrite.
nitrite,"In Pseudomonas denitrificans, nitrite reduction is the rate-determining step in the denitrification of nitrate.","Entity: nitrite. SMILES: O=N[O-]. In Pseudomonas denitrificans, nitrite reduction is the rate-determining step in the denitrification of nitrate."
nitrite,The presence of nitrite at 10–20 mM has little effect on oxygen uptake in Pseudomonas denitrificans.,Entity: nitrite. SMILES: O=N[O-]. The presence of nitrite at 10–20 mM has little effect on oxygen uptake in Pseudomonas denitrificans.
chloramphenicol,"Chloramphenicol at 100 µg/mL inhibits protein synthesis in Pseudomonas denitrificans, confirming the requirement of protein synthesis for oxygen respiration.","Entity: chloramphenicol. SMILES: O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl. Chloramphenicol at 100 µg/mL inhibits protein synthesis in Pseudomonas denitrificans, confirming the requirement of protein synthesis for oxygen respiration."
oxygen,Oxygen is utilized in Pseudomonas denitrificans in preference to nitrate for respiration.,Entity: oxygen. SMILES: [O]. Oxygen is utilized in Pseudomonas denitrificans in preference to nitrate for respiration.
helium,Helium is used as the carrier gas in gas chromatography assays to monitor the production or uptake of nitrogen and gaseous nitrogen oxides during denitrification experiments.,Entity: helium. SMILES: [He]. Helium is used as the carrier gas in gas chromatography assays to monitor the production or uptake of nitrogen and gaseous nitrogen oxides during denitrification experiments.
nitrous oxide,"Nitrous oxide can be used as an initial substrate for denitrification reactions in cell-based assays, with concentrations ranging from 1×3×20 pmol introduced into vials with 1×10^9 to 3×10^10 cells under helium atmosphere.","Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide can be used as an initial substrate for denitrification reactions in cell-based assays, with concentrations ranging from 1×3×20 pmol introduced into vials with 1×10^9 to 3×10^10 cells under helium atmosphere."
nitrate,"Nitrate can serve as an initial substrate for denitrification reactions in cell-based assays, with concentrations ranging from 1×5 to 2×25 pmol introduced into vials with 1×10^9 to 3×10^10 cells under helium atmosphere.","Entity: nitrate. SMILES: O=[N+]([O-])[O-]. Nitrate can serve as an initial substrate for denitrification reactions in cell-based assays, with concentrations ranging from 1×5 to 2×25 pmol introduced into vials with 1×10^9 to 3×10^10 cells under helium atmosphere."
nitrite,"Nitrite can serve as an initial substrate for denitrification reactions in cell-based assays, with concentrations ranging from 10 to 20 pmol introduced into vials with 1×10^9 to 3×10^10 cells under helium atmosphere.","Entity: nitrite. SMILES: O=N[O-]. Nitrite can serve as an initial substrate for denitrification reactions in cell-based assays, with concentrations ranging from 10 to 20 pmol introduced into vials with 1×10^9 to 3×10^10 cells under helium atmosphere."
oxygen,Oxygen is used to humidify inspired air during periods of spontaneous respiration to facilitate weaning from mechanical ventilation.,Entity: oxygen. SMILES: [O]. Oxygen is used to humidify inspired air during periods of spontaneous respiration to facilitate weaning from mechanical ventilation.
hydrocortisone sodium succinate,Hydrocortisone sodium succinate is administered at a dose of 200 mg every 6 hours as part of drug treatment for severe pulmonary oedema.,Entity: hydrocortisone sodium succinate. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+]. Hydrocortisone sodium succinate is administered at a dose of 200 mg every 6 hours as part of drug treatment for severe pulmonary oedema.
ampicillin,Ampicillin is administered at a dose of 500 mg every 6 hours as part of drug treatment for severe pulmonary oedema.,Entity: ampicillin. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O. Ampicillin is administered at a dose of 500 mg every 6 hours as part of drug treatment for severe pulmonary oedema.
oxygen,Oxygen is administered as part of general anesthesia and for respiratory support in clinical settings.,Entity: oxygen. SMILES: [O]. Oxygen is administered as part of general anesthesia and for respiratory support in clinical settings.
nitrous oxide,Nitrous oxide is used as an anesthetic agent in general anesthesia procedures.,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used as an anesthetic agent in general anesthesia procedures.
phenoperidine,"Phenoperidine is used as an anesthetic agent in general anesthesia procedures, such as tracheostomy.","Entity: phenoperidine. SMILES: CCOC(=O)C1(c2ccccc2)CCN(CCC(O)c2ccccc2)CC1. Phenoperidine is used as an anesthetic agent in general anesthesia procedures, such as tracheostomy."
steroids,Steroids are used as treatment for pulmonary infection following inhalation of ethylene imine vapour.,Entity: steroids. SMILES: CC(=O)N(C)[C@H](C)[C@@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](N(C)C)CC[C@@]4(C)[C@@H]3CC[C@]21C. Steroids are used as treatment for pulmonary infection following inhalation of ethylene imine vapour.
oxygen,Artificial respiration is required to maintain adequate arterial oxygen levels in cases of ethylene imine poisoning.,Entity: oxygen. SMILES: [O]. Artificial respiration is required to maintain adequate arterial oxygen levels in cases of ethylene imine poisoning.
halothane,"Halothane is used as part of a general anaesthesia mixture, in combination with 50% nitrous oxide and oxygen, for intubation in cases of severe airway swelling.","Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane is used as part of a general anaesthesia mixture, in combination with 50% nitrous oxide and oxygen, for intubation in cases of severe airway swelling."
phenoperidine,Phenoperidine is used to achieve sedation in mechanically ventilated patients with respiratory distress.,Entity: phenoperidine. SMILES: CCOC(=O)C1(c2ccccc2)CCN(CCC(O)c2ccccc2)CC1. Phenoperidine is used to achieve sedation in mechanically ventilated patients with respiratory distress.
nitrous oxide,"Nitrous oxide is used as part of a general anaesthesia mixture, in combination with halothane and oxygen, for intubation in cases of severe airway swelling.","Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used as part of a general anaesthesia mixture, in combination with halothane and oxygen, for intubation in cases of severe airway swelling."
hydrocortisone,Hydrocortisone is administered intravenously at 200 mg to reduce airway oedema and support lung function in patients with severe respiratory obstruction.,Entity: hydrocortisone. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO. Hydrocortisone is administered intravenously at 200 mg to reduce airway oedema and support lung function in patients with severe respiratory obstruction.
colistin,Colistin is an antibiotic used to treat infections caused by bacteria such as Staphylococcus pyogenes and Pseudomonas pyocyaneus.,Entity: colistin. SMILES: CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O. Colistin is an antibiotic used to treat infections caused by bacteria such as Staphylococcus pyogenes and Pseudomonas pyocyaneus.
cloxacillin,Cloxacillin is an antibiotic used to treat infections caused by bacteria such as Staphylococcus pyogenes and Pseudomonas pyocyaneus.,Entity: cloxacillin. SMILES: Cc1onc(-c2ccccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O. Cloxacillin is an antibiotic used to treat infections caused by bacteria such as Staphylococcus pyogenes and Pseudomonas pyocyaneus.
hemoglobin,"Hemoglobin levels can decrease rapidly in newborns with hepatic hemangiomas, such as a drop from 16.1 to 11.6 g/dl within a few hours at 3 days of age, indicating significant red-cell destruction.","Entity: hemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. Hemoglobin levels can decrease rapidly in newborns with hepatic hemangiomas, such as a drop from 16.1 to 11.6 g/dl within a few hours at 3 days of age, indicating significant red-cell destruction."
"2,4-dinitrophenylhydrazin","2,4-dinitrophenylhydrazin is used as a qualitative reagent to detect large quantities of ketoacids in urine.","Entity: 2,4-dinitrophenylhydrazin. SMILES: NNc1ccc([N+](=O)[O-])cc1[N+](=O)[O-]. 2,4-dinitrophenylhydrazin is used as a qualitative reagent to detect large quantities of ketoacids in urine."
isoleucine,Isoleucine is a branched-chain amino acid whose levels are markedly increased in the serum and cerebrospinal fluid of infants with certain metabolic disorders.,Entity: isoleucine. SMILES: CC[C@H](C)[C@H](N)C(=O)O. Isoleucine is a branched-chain amino acid whose levels are markedly increased in the serum and cerebrospinal fluid of infants with certain metabolic disorders.
valine,Valine is a branched-chain amino acid whose levels are markedly increased in the serum and cerebrospinal fluid of infants with certain metabolic disorders.,Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. Valine is a branched-chain amino acid whose levels are markedly increased in the serum and cerebrospinal fluid of infants with certain metabolic disorders.
leucine,Leucine is a branched-chain amino acid whose levels are markedly increased in the serum and cerebrospinal fluid of infants with certain metabolic disorders.,Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine is a branched-chain amino acid whose levels are markedly increased in the serum and cerebrospinal fluid of infants with certain metabolic disorders.
"2,4-dinitrophenylhydrazin","The 2,4-dinitrophenylhydrazin test is a qualitative method used to detect the presence of keto acids in urine.","Entity: 2,4-dinitrophenylhydrazin. SMILES: NNc1ccc([N+](=O)[O-])cc1[N+](=O)[O-]. The 2,4-dinitrophenylhydrazin test is a qualitative method used to detect the presence of keto acids in urine."
thiamine hydrochloride,Thiamine hydrochloride does not improve hyperbranchedchain aminoacidemia in the mild variant form of maple syrup-urine disease (MSUD).,Entity: thiamine hydrochloride. SMILES: Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.Cl.[Cl-]. Thiamine hydrochloride does not improve hyperbranchedchain aminoacidemia in the mild variant form of maple syrup-urine disease (MSUD).
valine,Valine is a branched-chain amino acid whose plasma and urine levels are greatly elevated in maple syrup-urine disease (MSUD) patients.,Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. Valine is a branched-chain amino acid whose plasma and urine levels are greatly elevated in maple syrup-urine disease (MSUD) patients.
leucine,Leucine is a branched-chain amino acid whose plasma and urine levels are greatly elevated in maple syrup-urine disease (MSUD) patients.,Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine is a branched-chain amino acid whose plasma and urine levels are greatly elevated in maple syrup-urine disease (MSUD) patients.
isoleucine,Isoleucine is a branched-chain amino acid whose plasma and urine levels are greatly elevated in maple syrup-urine disease (MSUD) patients.,Entity: isoleucine. SMILES: CC[C@H](C)[C@H](N)C(=O)O. Isoleucine is a branched-chain amino acid whose plasma and urine levels are greatly elevated in maple syrup-urine disease (MSUD) patients.
thiamine hydrochloride,"Thiamine hydrochloride is administered at a dose of 100 mg/day and, on the 7th day after administration, results in serum concentrations of leucine (20.25–25.83 mg/dl), isoleucine (9.02–11.15 mg/dl), and valine (9.62–11.21 mg/dl) in a patient.","Entity: thiamine hydrochloride. SMILES: Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.Cl.[Cl-]. Thiamine hydrochloride is administered at a dose of 100 mg/day and, on the 7th day after administration, results in serum concentrations of leucine (20.25–25.83 mg/dl), isoleucine (9.02–11.15 mg/dl), and valine (9.62–11.21 mg/dl) in a patient."
leucine,Serum leucine concentration is in the range of 20.25–25.83 mg/dl on the 7th day after thiamine hydrochloride administration (100 mg/day) and 15.34–23.24 mg/dl on the 5th day after feeding with branched-chain amino acid-free milk.,Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Serum leucine concentration is in the range of 20.25–25.83 mg/dl on the 7th day after thiamine hydrochloride administration (100 mg/day) and 15.34–23.24 mg/dl on the 5th day after feeding with branched-chain amino acid-free milk.
isoleucine,Serum isoleucine concentration is in the range of 9.02–11.15 mg/dl on the 7th day after thiamine hydrochloride administration (100 mg/day) and 7.96–8.57 mg/dl on the 5th day after feeding with branched-chain amino acid-free milk.,Entity: isoleucine. SMILES: CC[C@H](C)[C@H](N)C(=O)O. Serum isoleucine concentration is in the range of 9.02–11.15 mg/dl on the 7th day after thiamine hydrochloride administration (100 mg/day) and 7.96–8.57 mg/dl on the 5th day after feeding with branched-chain amino acid-free milk.
valine,Serum valine concentration is in the range of 9.62–11.21 mg/dl on the 7th day after thiamine hydrochloride administration (100 mg/day) and 11.81–12.76 mg/dl on the 5th day after feeding with branched-chain amino acid-free milk.,Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. Serum valine concentration is in the range of 9.62–11.21 mg/dl on the 7th day after thiamine hydrochloride administration (100 mg/day) and 11.81–12.76 mg/dl on the 5th day after feeding with branched-chain amino acid-free milk.
alanine,Serum alanine concentration is 2.04 mg/dl after an overnight fast of 13 hours.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Serum alanine concentration is 2.04 mg/dl after an overnight fast of 13 hours.
glucose,"Serum glucose level after an overnight fast of 13 hours is 88 mg/dl, indicating normoglycemia.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Serum glucose level after an overnight fast of 13 hours is 88 mg/dl, indicating normoglycemia."
thiamine hydrochloride,"Thiamine hydrochloride is effective in improving urinary ketoacid levels, liver function, electroencephalogram, and general condition in patients with the mild variant of maple syrup urine disease (MSUD), though it does not correct hyperbranched-chain amino acidemia.","Entity: thiamine hydrochloride. SMILES: Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.Cl.[Cl-]. Thiamine hydrochloride is effective in improving urinary ketoacid levels, liver function, electroencephalogram, and general condition in patients with the mild variant of maple syrup urine disease (MSUD), though it does not correct hyperbranched-chain amino acidemia."
thiamine hydrochloride,"Thiamine hydrochloride administration improves hyperuricemia in patients with the mild variant of maple syrup urine disease (MSUD), suggesting a role in inhibiting renal clearance of urates due to branched-chain ketoacid accumulation.","Entity: thiamine hydrochloride. SMILES: Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.Cl.[Cl-]. Thiamine hydrochloride administration improves hyperuricemia in patients with the mild variant of maple syrup urine disease (MSUD), suggesting a role in inhibiting renal clearance of urates due to branched-chain ketoacid accumulation."
thiamine hydrochloride,"Thiamine hydrochloride is administered orally at a dose of 100 mg per day to treat certain clinical conditions, as described in a case report.","Entity: thiamine hydrochloride. SMILES: Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.Cl.[Cl-]. Thiamine hydrochloride is administered orally at a dose of 100 mg per day to treat certain clinical conditions, as described in a case report."
alanine,Serum concentrations of alanine are within the normal range in patients with classic maple syrup urine disease (MSUD) even after overnight fasting.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Serum concentrations of alanine are within the normal range in patients with classic maple syrup urine disease (MSUD) even after overnight fasting.
glutamate,Serum concentrations of glutamate are within the normal range in patients with classic maple syrup urine disease (MSUD) even after overnight fasting.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Serum concentrations of glutamate are within the normal range in patients with classic maple syrup urine disease (MSUD) even after overnight fasting.
glucagon,"Intravenous administration of glucagon at a dose of 30–60 g/kg produces a significant glycemic response, lowering blood glucose from 139 mg/dl to a value not specified 15 minutes after injection.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Intravenous administration of glucagon at a dose of 30–60 g/kg produces a significant glycemic response, lowering blood glucose from 139 mg/dl to a value not specified 15 minutes after injection."
Congo red,"Congo red is a dye that stains amyloid deposits in tissue, appearing positive for amyloidosis and producing a green color when examined in polarized light.","Entity: Congo red. SMILES: Nc1c(N=Nc2ccc(-c3ccc(N=Nc4cc(S(=O)(=O)[O-])c5ccccc5c4N)cc3)cc2)cc(S(=O)(=O)[O-])c2ccccc12.[Na+].[Na+]. Congo red is a dye that stains amyloid deposits in tissue, appearing positive for amyloidosis and producing a green color when examined in polarized light."
xylose,"The xylose test is used to assess intestinal absorption, and significantly increased values after surgery in children with ASD or VSD suggest improved intestinal absorption.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. The xylose test is used to assess intestinal absorption, and significantly increased values after surgery in children with ASD or VSD suggest improved intestinal absorption."
xylose,The xylose test is used as an index of intestinal absorption.,Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. The xylose test is used as an index of intestinal absorption.
xylose,"In healthy subjects aged 3–20 years, at least 30% of an administered xylose dose should be excreted in urine within 5 hours, according to accepted norms.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. In healthy subjects aged 3–20 years, at least 30% of an administered xylose dose should be excreted in urine within 5 hours, according to accepted norms."
urea,"Blood urea nitrogen levels were elevated in seven patients, with one case reaching 145 mg%.","Entity: urea. SMILES: NC(N)=O. Blood urea nitrogen levels were elevated in seven patients, with one case reaching 145 mg%."
potassium,Potassium levels were at the upper limit of normal in patients evaluated.,Entity: potassium. SMILES: [K]. Potassium levels were at the upper limit of normal in patients evaluated.
creatinine,Creatinine levels were at the upper limit of normal in patients evaluated.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Creatinine levels were at the upper limit of normal in patients evaluated.
calcium,"Serum calcium concentrations in healthy, full-term newborn infants are constant and their circulating quantities depend on plasma volume expansion.","Entity: calcium. SMILES: [Ca]. Serum calcium concentrations in healthy, full-term newborn infants are constant and their circulating quantities depend on plasma volume expansion."
magnesium,"Serum magnesium concentrations in healthy, full-term newborn infants are inversely related to plasma volume, so circulating total magnesium remains constant despite plasma volume changes.","Entity: magnesium. SMILES: [Mg]. Serum magnesium concentrations in healthy, full-term newborn infants are inversely related to plasma volume, so circulating total magnesium remains constant despite plasma volume changes."
sodium,"Serum sodium concentrations in healthy, full-term newborn infants are constant and their circulating quantities depend on plasma volume expansion.","Entity: sodium. SMILES: [Na]. Serum sodium concentrations in healthy, full-term newborn infants are constant and their circulating quantities depend on plasma volume expansion."
verapamil,Verapamil does not affect sinus node automaticity.,Entity: verapamil. SMILES: COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC. Verapamil does not affect sinus node automaticity.
calcium gluconate,A rapid injection of calcium gluconate 40 mg/kg reverses the effects of verapamil on conduction and refractory periods in the dog heart.,Entity: calcium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2]. A rapid injection of calcium gluconate 40 mg/kg reverses the effects of verapamil on conduction and refractory periods in the dog heart.
verapamil,Verapamil at 0.30 mg/kg intravenously in dogs causes a small but statistically significant decrease in the ratio between 50 and 90% repolarization in the right atrium and ventricle.,Entity: verapamil. SMILES: COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC. Verapamil at 0.30 mg/kg intravenously in dogs causes a small but statistically significant decrease in the ratio between 50 and 90% repolarization in the right atrium and ventricle.
verapamil,Verapamil increases the effective refractory period (ERP) of the right atrium relative to the monophasic action potential (MAP) duration.,Entity: verapamil. SMILES: COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC. Verapamil increases the effective refractory period (ERP) of the right atrium relative to the monophasic action potential (MAP) duration.
verapamil,Verapamil markedly reduces conduction velocity within the heart and increases the functional and effective refractory period at the AV node.,Entity: verapamil. SMILES: COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC. Verapamil markedly reduces conduction velocity within the heart and increases the functional and effective refractory period at the AV node.
verapamil,"Verapamil does not impair intraatrial, His-Purkinje, or intraventricular conduction, nor does it alter the monophasic action potential (MAP) or functional refractory period (FRP) of the atria.","Entity: verapamil. SMILES: COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC. Verapamil does not impair intraatrial, His-Purkinje, or intraventricular conduction, nor does it alter the monophasic action potential (MAP) or functional refractory period (FRP) of the atria."
renin,"In patients with unilateral renal artery stenosis, the mean renin concentration in the stenosed kidney's juxtaglomerular apparatus is 5.5 ± 1.2 µg·l⁻¹·h⁻¹, which is about ten times higher than the suppressed renin concentration in the contralateral kidney (0.6 ± 0.05 µg·l⁻¹·h⁻¹).","Entity: renin. In patients with unilateral renal artery stenosis, the mean renin concentration in the stenosed kidney's juxtaglomerular apparatus is 5.5 ± 1.2 µg·l⁻¹·h⁻¹, which is about ten times higher than the suppressed renin concentration in the contralateral kidney (0.6 ± 0.05 µg·l⁻¹·h⁻¹)."
renin,"Renin concentrations in the stenosed kidney's intrarenal and renal venous plasma are positively correlated with renin secretion rates, as measured by plasma renin analysis from vena cava and renal veins.","Entity: renin. Renin concentrations in the stenosed kidney's intrarenal and renal venous plasma are positively correlated with renin secretion rates, as measured by plasma renin analysis from vena cava and renal veins."
renin,"Renin from the stenosed kidney's juxtaglomerular apparatus and renal venous plasma has lower apparent Km-values (270 ± 36 µg/l and 198 ± 13 µg/l, respectively) compared to the contralateral side (292 ± 37 µg/l and 301 ± 20 µg/l, respectively), using sheep substrate.","Entity: renin. Renin from the stenosed kidney's juxtaglomerular apparatus and renal venous plasma has lower apparent Km-values (270 ± 36 µg/l and 198 ± 13 µg/l, respectively) compared to the contralateral side (292 ± 37 µg/l and 301 ± 20 µg/l, respectively), using sheep substrate."
renin,No significant differences were found between mean apparent Km-values for renin in peripheral plasma of renovascular hypertensive patients and control subjects using either homologous human or heterologous sheep renin substrate.,Entity: renin. No significant differences were found between mean apparent Km-values for renin in peripheral plasma of renovascular hypertensive patients and control subjects using either homologous human or heterologous sheep renin substrate.
bile acid,"Bile acids such as taurocholate and taurochenodeoxycholate exhibit mean relative storage capacity in the liver of 0.16 ± 0.07 mumol·mumol⁻¹·l⁻¹·kg body weight⁻¹⁻¹ and mean secretory transport maximum of 4.81 ± 1.24 mumol·min⁻¹·kg body weight⁻¹⁻¹, as determined by a multiple infusion method in anaesthetized dogs.","Entity: bile acid. SMILES: CC(CCC(=O)O)C1CCC2C3C(C[C@H](O)C12C)C1(C)CC[C@@H](O)C[C@H]1C[C@H]3O. Bile acids such as taurocholate and taurochenodeoxycholate exhibit mean relative storage capacity in the liver of 0.16 ± 0.07 mumol·mumol⁻¹·l⁻¹·kg body weight⁻¹⁻¹ and mean secretory transport maximum of 4.81 ± 1.24 mumol·min⁻¹·kg body weight⁻¹⁻¹, as determined by a multiple infusion method in anaesthetized dogs."
sodium,"In denervated kidneys, the fraction of filtered sodium excreted (ENa) is doubled compared to intact kidneys during control periods.","Entity: sodium. SMILES: [Na]. In denervated kidneys, the fraction of filtered sodium excreted (ENa) is doubled compared to intact kidneys during control periods."
sodium,Sodium reabsorption in the proximal tubule is decreased and the load to the macula densa is increased following acute denervation in rats.,Entity: sodium. SMILES: [Na]. Sodium reabsorption in the proximal tubule is decreased and the load to the macula densa is increased following acute denervation in rats.
sodium,Renal denervation leads to decreased sodium excretion and reduced sodium excretion in both normal and volume-expanded dogs.,Entity: sodium. SMILES: [Na]. Renal denervation leads to decreased sodium excretion and reduced sodium excretion in both normal and volume-expanded dogs.
water,Renal denervation results in decreased water excretion in both normal and volume-expanded dogs.,Entity: water. SMILES: O. Renal denervation results in decreased water excretion in both normal and volume-expanded dogs.
furosemide,Furosemide eliminates differences in water and sodium excretion between intact and denervated kidneys.,Entity: furosemide. SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl. Furosemide eliminates differences in water and sodium excretion between intact and denervated kidneys.
angiotensin II,The pressor activity of incubated plasma is expressed as micrograms angiotensin II per litre plasma per 1.3 h incubation.,Entity: angiotensin II. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O. The pressor activity of incubated plasma is expressed as micrograms angiotensin II per litre plasma per 1.3 h incubation.
sodium,Sodium concentrations in plasma are determined by flame photometry.,Entity: sodium. SMILES: [Na]. Sodium concentrations in plasma are determined by flame photometry.
furosemide,"Furosemide at a dose of 5 mg/kg abolishes denervation natriuresis in anesthetized dogs with unilateral renal splanchnicotomy, but does not significantly affect glomerular filtration rate or renal plasma flow in either intact or denervated kidneys.","Entity: furosemide. SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl. Furosemide at a dose of 5 mg/kg abolishes denervation natriuresis in anesthetized dogs with unilateral renal splanchnicotomy, but does not significantly affect glomerular filtration rate or renal plasma flow in either intact or denervated kidneys."
sodium,Changes in the sodium load to the macula densa do not play a decisive role in decreasing renin release following renal denervation.,Entity: sodium. SMILES: [Na]. Changes in the sodium load to the macula densa do not play a decisive role in decreasing renin release following renal denervation.
furosemide,Furosemide administration abolishes differences in sodium excretion between intact and denervated kidneys in anaesthetized dogs.,Entity: furosemide. SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl. Furosemide administration abolishes differences in sodium excretion between intact and denervated kidneys in anaesthetized dogs.
furosemide,Furosemide administration does not significantly affect glomerular filtration rate (GFR) and/or fractional excretion of bicarbonate (F?BF) in chronically denervated kidneys.,Entity: furosemide. SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl. Furosemide administration does not significantly affect glomerular filtration rate (GFR) and/or fractional excretion of bicarbonate (F?BF) in chronically denervated kidneys.
furosemide,Furosemide suppresses renin release from chronically denervated kidneys.,Entity: furosemide. SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl. Furosemide suppresses renin release from chronically denervated kidneys.
sodium,Changes in sodium excretion and renin release in the kidney occur in opposite directions under conditions of renal nerve stimulation or denervation.,Entity: sodium. SMILES: [Na]. Changes in sodium excretion and renin release in the kidney occur in opposite directions under conditions of renal nerve stimulation or denervation.
furosemide,"Furosemide administration increases urine flow and sodium excretion, resulting in the excretion of approximately one third of filtered sodium from both kidneys.","Entity: furosemide. SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl. Furosemide administration increases urine flow and sodium excretion, resulting in the excretion of approximately one third of filtered sodium from both kidneys."
furosemide,Furosemide administration depresses renal venous plasma renin activity (RVRA) and renin secretion rate (RSR) on the splanchnicotomized side of the kidney.,Entity: furosemide. SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl. Furosemide administration depresses renal venous plasma renin activity (RVRA) and renin secretion rate (RSR) on the splanchnicotomized side of the kidney.
renin,"Renin secretion rate is depressed by renal splanchnicotomy (renal denervation) in dogs, independent of changes in sodium load to the macula densa.","Entity: renin. Renin secretion rate is depressed by renal splanchnicotomy (renal denervation) in dogs, independent of changes in sodium load to the macula densa."
bicarbonate,Bicarbonate excretion increases in parallel with sodium and water excretion following acute contralateral renal pedicle ligation or acute saline infusion.,Entity: bicarbonate. SMILES: O=C([O-])O. Bicarbonate excretion increases in parallel with sodium and water excretion following acute contralateral renal pedicle ligation or acute saline infusion.
bicarbonate,The degree of prior bicarbonate loading influences the overall responsiveness to bicarbonate excretion changes after acute contralateral renal pedicle ligation.,Entity: bicarbonate. SMILES: O=C([O-])O. The degree of prior bicarbonate loading influences the overall responsiveness to bicarbonate excretion changes after acute contralateral renal pedicle ligation.
sodium,"Sodium excretion increases following acute contralateral renal pedicle ligation, and its transport is reduced by this procedure.","Entity: sodium. SMILES: [Na]. Sodium excretion increases following acute contralateral renal pedicle ligation, and its transport is reduced by this procedure."
sodium,Sodium transport is linked to bicarbonate reabsorption and excretion in the proximal tubule.,Entity: sodium. SMILES: [Na]. Sodium transport is linked to bicarbonate reabsorption and excretion in the proximal tubule.
water,"Water excretion increases following acute contralateral renal pedicle ligation, in parallel with sodium and bicarbonate excretion.","Entity: water. SMILES: O. Water excretion increases following acute contralateral renal pedicle ligation, in parallel with sodium and bicarbonate excretion."
water,Adaptive changes in the remaining nephrons maintain overall salt and water balance following acute reduction of renal mass.,Entity: water. SMILES: O. Adaptive changes in the remaining nephrons maintain overall salt and water balance following acute reduction of renal mass.
potassium,Acute reduction of renal mass leads to compensatory changes in potassium excretion in the functional kidney.,Entity: potassium. SMILES: [K]. Acute reduction of renal mass leads to compensatory changes in potassium excretion in the functional kidney.
sodium,Acute reduction of renal mass results in compensatory changes in sodium excretion in the functional kidney.,Entity: sodium. SMILES: [Na]. Acute reduction of renal mass results in compensatory changes in sodium excretion in the functional kidney.
sodium bicarbonate,"Sodium bicarbonate is excreted in increased amounts when one kidney is eliminated, mainly due to rapid extracellular volume expansion acting on the proximal nephron.","Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Sodium bicarbonate is excreted in increased amounts when one kidney is eliminated, mainly due to rapid extracellular volume expansion acting on the proximal nephron."
sodium bicarbonate,"Infusion of 0.4 mol/l sodium bicarbonate leads to progressive accumulation of both sodium and bicarbonate in animals, with similar degrees of expansion in control and experimental groups.","Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Infusion of 0.4 mol/l sodium bicarbonate leads to progressive accumulation of both sodium and bicarbonate in animals, with similar degrees of expansion in control and experimental groups."
sodium,"Sodium excretion increases rapidly following extracellular volume expansion, primarily through the action of the proximal nephron.","Entity: sodium. SMILES: [Na]. Sodium excretion increases rapidly following extracellular volume expansion, primarily through the action of the proximal nephron."
sodium,Infusion of 0.4 mol/l sodium bicarbonate results in progressive accumulation of sodium in both control and experimental animals.,Entity: sodium. SMILES: [Na]. Infusion of 0.4 mol/l sodium bicarbonate results in progressive accumulation of sodium in both control and experimental animals.
sodium,Sodium excretion increases progressively in the remaining kidney after unilateral kidney exclusion in experimental animals.,Entity: sodium. SMILES: [Na]. Sodium excretion increases progressively in the remaining kidney after unilateral kidney exclusion in experimental animals.
potassium,"Potassium excretion increases slightly but significantly after kidney exclusion in experimental animals, while serum potassium concentration remains constant.","Entity: potassium. SMILES: [K]. Potassium excretion increases slightly but significantly after kidney exclusion in experimental animals, while serum potassium concentration remains constant."
bicarbonate,"Bicarbonate excretion increases in both kidneys after unilateral kidney exclusion, regardless of the degree of hypertonic bicarbonate infusion.","Entity: bicarbonate. SMILES: O=C([O-])O. Bicarbonate excretion increases in both kidneys after unilateral kidney exclusion, regardless of the degree of hypertonic bicarbonate infusion."
potassium,Increased potassium excretion after contralateral pedicle ligation is largely due to increased delivery to the sodium-potassium exchange site.,Entity: potassium. SMILES: [K]. Increased potassium excretion after contralateral pedicle ligation is largely due to increased delivery to the sodium-potassium exchange site.
potassium,Reduced proximal potassium reabsorption and metabolic alkalosis with bicarbonate as a non-reabsorbable anion can augment potassium excretion.,Entity: potassium. SMILES: [K]. Reduced proximal potassium reabsorption and metabolic alkalosis with bicarbonate as a non-reabsorbable anion can augment potassium excretion.
bicarbonate,"Bicarbonate acts as a non-reabsorbable anion in metabolic alkalosis, contributing to increased potassium excretion.","Entity: bicarbonate. SMILES: O=C([O-])O. Bicarbonate acts as a non-reabsorbable anion in metabolic alkalosis, contributing to increased potassium excretion."
sodium bicarbonate,"Sodium bicarbonate is continuously infused into dogs at concentrations of 0.14 mol/l and 0.4 mol/l, which maintains steady levels of GFR, bicarbonate, sodium, potassium, and water excretion during the experiment.","Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Sodium bicarbonate is continuously infused into dogs at concentrations of 0.14 mol/l and 0.4 mol/l, which maintains steady levels of GFR, bicarbonate, sodium, potassium, and water excretion during the experiment."
potassium,Potassium excretion remains at steady levels in dogs during continuous infusion of sodium bicarbonate at concentrations of 0.14 mol/l and 0.4 mol/l.,Entity: potassium. SMILES: [K]. Potassium excretion remains at steady levels in dogs during continuous infusion of sodium bicarbonate at concentrations of 0.14 mol/l and 0.4 mol/l.
sodium,Sodium excretion is maintained at steady levels in dogs during continuous infusion of sodium bicarbonate at concentrations of 0.14 mol/l and 0.4 mol/l.,Entity: sodium. SMILES: [Na]. Sodium excretion is maintained at steady levels in dogs during continuous infusion of sodium bicarbonate at concentrations of 0.14 mol/l and 0.4 mol/l.
water,Water excretion is maintained at steady levels in dogs during continuous infusion of sodium bicarbonate at concentrations of 0.14 mol/l and 0.4 mol/l.,Entity: water. SMILES: O. Water excretion is maintained at steady levels in dogs during continuous infusion of sodium bicarbonate at concentrations of 0.14 mol/l and 0.4 mol/l.
potassium,Potassium excretion in animals increases from 32.8 to 34.7 pmol/min at 5 minutes and to 45.8 pmol/min at 60 minutes after contralateral pedicle ligation.,Entity: potassium. SMILES: [K]. Potassium excretion in animals increases from 32.8 to 34.7 pmol/min at 5 minutes and to 45.8 pmol/min at 60 minutes after contralateral pedicle ligation.
sodium,"Increased sodium and water excretion can occur despite administration of supramaximal doses of DOCA and vasopressin, indicating that altered aldosterone and vasopressin concentration does not explain this response.","Entity: sodium. SMILES: [Na]. Increased sodium and water excretion can occur despite administration of supramaximal doses of DOCA and vasopressin, indicating that altered aldosterone and vasopressin concentration does not explain this response."
bicarbonate,"Reduced proximal sodium reabsorption, which may be associated with diminished colloid oncotic pressure and increased peritubular capillary pressure, is also associated with reduced bicarbonate reabsorption.","Entity: bicarbonate. SMILES: O=C([O-])O. Reduced proximal sodium reabsorption, which may be associated with diminished colloid oncotic pressure and increased peritubular capillary pressure, is also associated with reduced bicarbonate reabsorption."
water,"Increased sodium and water excretion can occur despite administration of supramaximal doses of DOCA and vasopressin, indicating that altered aldosterone and vasopressin concentration does not explain this response.","Entity: water. SMILES: O. Increased sodium and water excretion can occur despite administration of supramaximal doses of DOCA and vasopressin, indicating that altered aldosterone and vasopressin concentration does not explain this response."
aldosterone,"The response to contralateral kidney exclusion does not depend on altered aldosterone concentration, as supramaximal doses of DOCA do not affect the sodium and water excretion.","Entity: aldosterone. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12. The response to contralateral kidney exclusion does not depend on altered aldosterone concentration, as supramaximal doses of DOCA do not affect the sodium and water excretion."
sodium,Reduced colloid oncotic pressure and possibly increased hydrostatic peritubular capillary pressure in the rat are associated with decreased proximal sodium reabsorption.,Entity: sodium. SMILES: [Na]. Reduced colloid oncotic pressure and possibly increased hydrostatic peritubular capillary pressure in the rat are associated with decreased proximal sodium reabsorption.
sodium,"Urinary sodium excretion is related to renal arterial pressure, particularly in isolated kidney studies.","Entity: sodium. SMILES: [Na]. Urinary sodium excretion is related to renal arterial pressure, particularly in isolated kidney studies."
sodium bicarbonate,"Infusion with hypertonic sodium bicarbonate increases the excretory response to sodium bicarbonate in the remaining kidney after contralateral kidney pedicle ligation, as measured by increased excretion rates.","Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Infusion with hypertonic sodium bicarbonate increases the excretory response to sodium bicarbonate in the remaining kidney after contralateral kidney pedicle ligation, as measured by increased excretion rates."
sodium bicarbonate,A significant increase in bicarbonate excretion occurs during infusion of isotonic sodium bicarbonate in the remaining kidney after contralateral kidney pedicle ligation.,Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. A significant increase in bicarbonate excretion occurs during infusion of isotonic sodium bicarbonate in the remaining kidney after contralateral kidney pedicle ligation.
sodium,A marked and nearly immediate reduction in proximal sodium reabsorption with enhanced excretion occurs after complete contralateral kidney pedicle ligation.,Entity: sodium. SMILES: [Na]. A marked and nearly immediate reduction in proximal sodium reabsorption with enhanced excretion occurs after complete contralateral kidney pedicle ligation.
potassium,"Excretion of potassium increases in a corresponding manner to the increased excretion of sodium, water, and bicarbonate following contralateral kidney pedicle ligation.","Entity: potassium. SMILES: [K]. Excretion of potassium increases in a corresponding manner to the increased excretion of sodium, water, and bicarbonate following contralateral kidney pedicle ligation."
water,"Excretion of water increases in a corresponding manner to the increased excretion of sodium, water, and bicarbonate following contralateral kidney pedicle ligation.","Entity: water. SMILES: O. Excretion of water increases in a corresponding manner to the increased excretion of sodium, water, and bicarbonate following contralateral kidney pedicle ligation."
bicarbonate,"Acute contralateral renal pedicle ligation in dogs leads to an immediate and sustained increase in urinary bicarbonate excretion, with the greatest response at the highest bicarbonate infusion rate.","Entity: bicarbonate. SMILES: O=C([O-])O. Acute contralateral renal pedicle ligation in dogs leads to an immediate and sustained increase in urinary bicarbonate excretion, with the greatest response at the highest bicarbonate infusion rate."
sodium,"Acute contralateral renal pedicle ligation in dogs results in an immediate and sustained increase in urinary sodium excretion, parallel with bicarbonate loss.","Entity: sodium. SMILES: [Na]. Acute contralateral renal pedicle ligation in dogs results in an immediate and sustained increase in urinary sodium excretion, parallel with bicarbonate loss."
water,"Acute contralateral renal pedicle ligation in dogs causes an immediate and sustained increase in urinary water excretion, coinciding with elevated urinary bicarbonate.","Entity: water. SMILES: O. Acute contralateral renal pedicle ligation in dogs causes an immediate and sustained increase in urinary water excretion, coinciding with elevated urinary bicarbonate."
sodium bicarbonate,"Continuous infusion of sodium bicarbonate in sham-operated dogs does not induce an abrupt increase in sodium and bicarbonate excretion, indicating that kidney exclusion triggers adaptive changes independent of sodium bicarbonate loading.","Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Continuous infusion of sodium bicarbonate in sham-operated dogs does not induce an abrupt increase in sodium and bicarbonate excretion, indicating that kidney exclusion triggers adaptive changes independent of sodium bicarbonate loading."
hydrogen,"Little is known about the effects of acute reduction of renal mass on hydrogen ion handling, but an adaptive mechanism for acid-base regulation is likely to operate in the remaining kidney after unilateral nephrectomy.","Entity: hydrogen. SMILES: [HH]. Little is known about the effects of acute reduction of renal mass on hydrogen ion handling, but an adaptive mechanism for acid-base regulation is likely to operate in the remaining kidney after unilateral nephrectomy."
sodium,Sodium reabsorption in the proximal tubule is markedly reduced following contralateral renal pedicle ligation in dogs.,Entity: sodium. SMILES: [Na]. Sodium reabsorption in the proximal tubule is markedly reduced following contralateral renal pedicle ligation in dogs.
water,Water reabsorption in the proximal tubule is markedly reduced following contralateral renal pedicle ligation in dogs.,Entity: water. SMILES: O. Water reabsorption in the proximal tubule is markedly reduced following contralateral renal pedicle ligation in dogs.
bicarbonate,"The fate of bicarbonate ions is not well studied in the context of acute reduction of renal mass, but an adaptive mechanism for acid-base regulation is likely to operate in the remaining kidney after unilateral nephrectomy.","Entity: bicarbonate. SMILES: O=C([O-])O. The fate of bicarbonate ions is not well studied in the context of acute reduction of renal mass, but an adaptive mechanism for acid-base regulation is likely to operate in the remaining kidney after unilateral nephrectomy."
angiotensin I,"Angiotensin I is a pressor agent whose arterial concentrations in rats increase slowly at low intravenous infusion rates (0.5 and 5.0 µg/kg/h) but rise sharply when infusion rates exceed 50 µg/kg/h, indicating a possible saturation process involving angiotensinases.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I is a pressor agent whose arterial concentrations in rats increase slowly at low intravenous infusion rates (0.5 and 5.0 µg/kg/h) but rise sharply when infusion rates exceed 50 µg/kg/h, indicating a possible saturation process involving angiotensinases."
angiotensin I,"Intrarenal concentrations of angiotensin I are likely to exceed arterial plasma concentrations, suggesting a role for angiotensin I in regulating intrarenal haemodynamics.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Intrarenal concentrations of angiotensin I are likely to exceed arterial plasma concentrations, suggesting a role for angiotensin I in regulating intrarenal haemodynamics."
angiotensin I,"Angiotensin I infusion rates of 5.0 µg/kg/h, resulting in plasma concentrations comparable to those found under sodium restriction, induce haemodynamic changes in rats of the same order of magnitude as sodium restriction.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I infusion rates of 5.0 µg/kg/h, resulting in plasma concentrations comparable to those found under sodium restriction, induce haemodynamic changes in rats of the same order of magnitude as sodium restriction."
angiotensin I,"Angiotensin I, perhaps even its arterial concentration, plays an important role in the regulation of renal haemodynamics in rats, dogs, and humans.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I, perhaps even its arterial concentration, plays an important role in the regulation of renal haemodynamics in rats, dogs, and humans."
angiotensin I,Angiotensin I plays a role in the regulation of renal blood flow and intrarenal haemodynamics.,Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I plays a role in the regulation of renal blood flow and intrarenal haemodynamics.
angiotensin I,Angiotensin I is involved in the response of the renal vasculature to physiological stimuli.,Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I is involved in the response of the renal vasculature to physiological stimuli.
angiotensin I,"Angiotensin I infusion at 50 and 500 µg·kg⁻¹·h–1 reduces mean renal blood flow and causes a drop in CP I flow fraction, with unpredictable changes in CP I blood flow rates.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I infusion at 50 and 500 µg·kg⁻¹·h–1 reduces mean renal blood flow and causes a drop in CP I flow fraction, with unpredictable changes in CP I blood flow rates."
angiotensin I,"Angiotensin I infusion increases total renal vascular resistance from 25.0 mm Hg·min·ml⁻¹ (baseline) to 41.6 mm Hg·min·ml⁻¹ at 50 µg·kg⁻¹·h–1, and to 44.3 mm Hg·min·ml⁻¹ at 500 µg·kg⁻¹·h–1.","Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I infusion increases total renal vascular resistance from 25.0 mm Hg·min·ml⁻¹ (baseline) to 41.6 mm Hg·min·ml⁻¹ at 50 µg·kg⁻¹·h–1, and to 44.3 mm Hg·min·ml⁻¹ at 500 µg·kg⁻¹·h–1."
angiotensin I,Angiotensin I infusion at doses up to 5.0 pg/kg·h–1 reduces mean renal blood flow from 2.91 ml·min⁻¹·g⁻¹ (control) to 1.67 ml·min⁻¹·g⁻¹ (500 µg A I1·kg⁻¹·h–1) in the kidney.,Entity: angiotensin I. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)O. Angiotensin I infusion at doses up to 5.0 pg/kg·h–1 reduces mean renal blood flow from 2.91 ml·min⁻¹·g⁻¹ (control) to 1.67 ml·min⁻¹·g⁻¹ (500 µg A I1·kg⁻¹·h–1) in the kidney.
angiotensin II,"Angiotensin II induces significant changes in intrarenal haemodynamics in rats, including a decrease in mean renal blood flow (from 2.91 to 1.76 ml·min⁻¹·g⁻¹) and a reduction in the fraction of total renal blood flow supplied to component I (from 84% to 62%) before any changes in systemic blood pressure are detected.","Entity: angiotensin II. Angiotensin II induces significant changes in intrarenal haemodynamics in rats, including a decrease in mean renal blood flow (from 2.91 to 1.76 ml·min⁻¹·g⁻¹) and a reduction in the fraction of total renal blood flow supplied to component I (from 84% to 62%) before any changes in systemic blood pressure are detected."
amino nitrogen,"In dogs, peripheral venous immunoreactive insulin activity increases after feeding 1000 g mashed meat, preceding any enhancement of amino nitrogen concentration.","Entity: amino nitrogen. SMILES: [N]N. In dogs, peripheral venous immunoreactive insulin activity increases after feeding 1000 g mashed meat, preceding any enhancement of amino nitrogen concentration."
amino nitrogen,"In dogs with oesophageal fistula, sham-feeding meat does not alter amino nitrogen concentration, despite causing an early increase in immunoreactive insulin activity.","Entity: amino nitrogen. SMILES: [N]N. In dogs with oesophageal fistula, sham-feeding meat does not alter amino nitrogen concentration, despite causing an early increase in immunoreactive insulin activity."
glucose,A decrease in blood glucose concentration is observed in association with an early increase in immunoreactive insulin activity following sham-feeding meat in dogs with oesophageal fistula.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. A decrease in blood glucose concentration is observed in association with an early increase in immunoreactive insulin activity following sham-feeding meat in dogs with oesophageal fistula.
glucagon,Glucagon exerts a direct influence on pancreatic secretion and can affect blood glucose levels.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon exerts a direct influence on pancreatic secretion and can affect blood glucose levels.
insulin,"Peripheral venous immunoreactive insulin activity (IRI) increases in dogs after feeding 1000 g mashed meat, preceding any enhancement of amino nitrogen concentration.","Entity: insulin. Peripheral venous immunoreactive insulin activity (IRI) increases in dogs after feeding 1000 g mashed meat, preceding any enhancement of amino nitrogen concentration."
triglyceride,Blood triglyceride concentrations are increased in uraemic patients undergoing dialysis compared to those on conservative dietary treatment.,Entity: triglyceride. SMILES: O=COCC(COC=O)OC=O. Blood triglyceride concentrations are increased in uraemic patients undergoing dialysis compared to those on conservative dietary treatment.
glucose,"Blood glucose levels are unchanged in uraemic patients undergoing dialysis, regardless of bath glucose concentration (no glucose, 1 g/l, 2 g/l).","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Blood glucose levels are unchanged in uraemic patients undergoing dialysis, regardless of bath glucose concentration (no glucose, 1 g/l, 2 g/l)."
glucose,"Glucose is often decreased in the dialysis bath of patients with chronic renal failure, and differences in glucose content in dialysis baths have been emphasized.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is often decreased in the dialysis bath of patients with chronic renal failure, and differences in glucose content in dialysis baths have been emphasized."
triglyceride,"Serum triglyceride concentrations are increased in chronic renal failure, a condition known as hypertriglyceridaemia.","Entity: triglyceride. SMILES: O=COCC(COC=O)OC=O. Serum triglyceride concentrations are increased in chronic renal failure, a condition known as hypertriglyceridaemia."
cholesterol,"Blood cholesterol is almost consistently normal in chronic renal failure, in contrast to increased triglyceride levels.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Blood cholesterol is almost consistently normal in chronic renal failure, in contrast to increased triglyceride levels."
cholestyramine,Cholestyramine is a bile-acid-sequestering agent whose effect on esterification of plasma cholesterol in vitro may have clinical implications for subjects with hyperlipidaemia.,Entity: cholestyramine. SMILES: CCC(C)C.CCC(CC(C)c1ccccc1)c1ccc(C[N+](C)(C)C)cc1.N.[Cl-]. Cholestyramine is a bile-acid-sequestering agent whose effect on esterification of plasma cholesterol in vitro may have clinical implications for subjects with hyperlipidaemia.
cholesterol,Cholesterol esterification in plasma can be modulated by bile-acid-sequestering agents such as cholestyramine.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol esterification in plasma can be modulated by bile-acid-sequestering agents such as cholestyramine.
cholestyramine resin,"Cholestyramine resin is used as a therapeutic agent for lowering plasma cholesterol levels, administered at a dose of 1.2 g per day.","Entity: cholestyramine resin. SMILES: CCC(C)C.CCC(CC(C)c1ccccc1)c1ccc(C[N+](C)(C)C)cc1.N.[Cl-]. Cholestyramine resin is used as a therapeutic agent for lowering plasma cholesterol levels, administered at a dose of 1.2 g per day."
ethylenediaminetetraacetate,Ethylenediaminetetraacetate (EDTAA) is used as an anticoagulant for blood collection at a concentration of 2 mg/ml.,Entity: ethylenediaminetetraacetate. SMILES: O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-]. Ethylenediaminetetraacetate (EDTAA) is used as an anticoagulant for blood collection at a concentration of 2 mg/ml.
clofibrate,Clofibrate is a lipid-lowering drug that can be administered at a dose of 2 g per day for several months.,Entity: clofibrate. SMILES: CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1. Clofibrate is a lipid-lowering drug that can be administered at a dose of 2 g per day for several months.
cholestyramine,Cholestyramine treatment significantly decreases plasma cholesterol concentration from 6.69 µ 0.53 mmol/L to 5.46 ± 0.45 mmol/L in both normal and type IIa subjects.,Entity: cholestyramine. SMILES: CC1=C2C(CC1)[C@@H](C)CC[C@H]1[C@@H]2C1(C)C. Cholestyramine treatment significantly decreases plasma cholesterol concentration from 6.69 µ 0.53 mmol/L to 5.46 ± 0.45 mmol/L in both normal and type IIa subjects.
cholestyramine,Cholestyramine resin therapy does not significantly alter plasma LCAT activity in normal subjects and patients with type IIa hyperlipidaemia.,Entity: cholestyramine. SMILES: CCC(C)C.CCC(CC(C)c1ccccc1)c1ccc(C[N+](C)(C)C)cc1.N.[Cl-]. Cholestyramine resin therapy does not significantly alter plasma LCAT activity in normal subjects and patients with type IIa hyperlipidaemia.
cholesterol,Plasma cholesterol concentration is not a unique determinant of plasma LCAT activity in normal subjects and type IIa hyperlipidaemia patients.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Plasma cholesterol concentration is not a unique determinant of plasma LCAT activity in normal subjects and type IIa hyperlipidaemia patients.
cholesterol,The proportion of plasma cholesterol that is esterified can be determined in plasma extracts using the Liebermann-Burchard reaction.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. The proportion of plasma cholesterol that is esterified can be determined in plasma extracts using the Liebermann-Burchard reaction.
triglyceride,Plasma triglyceride concentrations can be measured using established analytical methods such as the Laurel1 method.,Entity: triglyceride. SMILES: O=COCC(COC=O)OC=O. Plasma triglyceride concentrations can be measured using established analytical methods such as the Laurel1 method.
cholesterol,Plasma cholesterol concentrations can be measured using established analytical methods such as the Abell et al. method.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Plasma cholesterol concentrations can be measured using established analytical methods such as the Abell et al. method.
triglyceride,Plasma triglyceride concentration increases significantly in hyperlipidaemic patients treated with the bile-acid-sequestering agent colestipol.,Entity: triglyceride. SMILES: O=COCC(COC=O)OC=O. Plasma triglyceride concentration increases significantly in hyperlipidaemic patients treated with the bile-acid-sequestering agent colestipol.
cholesterol,"Colestipol treatment in patients can markedly increase cholesterol turnover, as measured in vivo, without affecting very low density lipoprotein concentration or cholesterol ester turnover.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Colestipol treatment in patients can markedly increase cholesterol turnover, as measured in vivo, without affecting very low density lipoprotein concentration or cholesterol ester turnover."
methanol,Methanol is used in combination with chloroform as an extraction solvent for separating unesterified and esterified cholesterol in LCAT assays.,Entity: methanol. SMILES: CO. Methanol is used in combination with chloroform as an extraction solvent for separating unesterified and esterified cholesterol in LCAT assays.
cholesterol,"Cholesterol serves as both the substrate and the analyte in LCAT enzymatic assays, with its esterification status determined by thin-layer chromatography.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol serves as both the substrate and the analyte in LCAT enzymatic assays, with its esterification status determined by thin-layer chromatography."
chloroform,Chloroform is used as an extraction solvent to separate unesterified and esterified cholesterol in LCAT assays.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as an extraction solvent to separate unesterified and esterified cholesterol in LCAT assays.
triglyceride,Increased plasma triglyceride concentration is associated with an increase in plasma LCAT (lipoprotein cholesterol acyltransferase) activity.,Entity: triglyceride. SMILES: O=COCC(COC=O)OC=O. Increased plasma triglyceride concentration is associated with an increase in plasma LCAT (lipoprotein cholesterol acyltransferase) activity.
glucagon,"Administration of large doses of glucagon in monkeys increases total liver blood flow by more than doubling it, while cardiac output rises by only 30%.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Administration of large doses of glucagon in monkeys increases total liver blood flow by more than doubling it, while cardiac output rises by only 30%."
epinephrine,"Epinephrine injection elevates free fatty acids (FFA) in plasma, which in turn decreases plasma protein binding of DPH in proportion to the increase in FFA concentration.","Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. Epinephrine injection elevates free fatty acids (FFA) in plasma, which in turn decreases plasma protein binding of DPH in proportion to the increase in FFA concentration."
triglyceride,Triglyceride concentrations in serum can be analyzed using established laboratory procedures.,Entity: triglyceride. SMILES: O=COCC(COC=O)OC=O. Triglyceride concentrations in serum can be analyzed using established laboratory procedures.
cholesterol,Cholesterol concentrations in serum can be analyzed using established laboratory procedures.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol concentrations in serum can be analyzed using established laboratory procedures.
carbon dioxide,Carbon dioxide at 5% in air is used to maintain pH at 7.4 during plasma protein binding assays.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide at 5% in air is used to maintain pH at 7.4 during plasma protein binding assays.
beta-acetyldigoxin,Beta-acetyldigoxin has a bioavailability of 68.3 ± 8.7% after a single oral dose and 68.6 ± 5.9% after multiple oral doses in healthy volunteers.,Entity: beta-acetyldigoxin. SMILES: CC(=O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@@H]1C. Beta-acetyldigoxin has a bioavailability of 68.3 ± 8.7% after a single oral dose and 68.6 ± 5.9% after multiple oral doses in healthy volunteers.
beta-acetyldigoxin,Beta-acetyldigoxin tablets have a bioavailability of 72.8 ± 7.5% after a single oral dose and 66.1 ± 6.0% after multiple oral doses in healthy volunteers.,Entity: beta-acetyldigoxin. SMILES: CC(=O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@@H]1C. Beta-acetyldigoxin tablets have a bioavailability of 72.8 ± 7.5% after a single oral dose and 66.1 ± 6.0% after multiple oral doses in healthy volunteers.
digoxin,"Digoxin concentration in plasma and urine can be measured with a radiimmunoassay, with a sensitivity limit of 0.1 ng/ml plasma and recovery rates greater than 95% from plasma or urine.","Entity: digoxin. SMILES: C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O. Digoxin concentration in plasma and urine can be measured with a radiimmunoassay, with a sensitivity limit of 0.1 ng/ml plasma and recovery rates greater than 95% from plasma or urine."
PPO,PPO (quench-correction reagent) is used in scintillation counting assays for quantifying digoxin concentrations in plasma and urine.,Entity: PPO. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. PPO (quench-correction reagent) is used in scintillation counting assays for quantifying digoxin concentrations in plasma and urine.
dextran,Dextran is used as a component of charcoal-coated columns for the separation of bound and free 3H-digoxin in pharmacokinetic studies.,Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran is used as a component of charcoal-coated columns for the separation of bound and free 3H-digoxin in pharmacokinetic studies.
triton X-100,Triton X-100 is used as a component of scintillation fluid for counting radiolabeled digoxin samples.,Entity: triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used as a component of scintillation fluid for counting radiolabeled digoxin samples.
xylene,Xylene is used as a solvent in the scintillation fluid mixture for counting radiolabeled digoxin samples.,Entity: xylene. SMILES: Cc1ccccc1C. Xylene is used as a solvent in the scintillation fluid mixture for counting radiolabeled digoxin samples.
sodium phosphate,"Sodium phosphate is used as a buffer to provide an unperturbed medium for studying the chemical shift of the [13C]-carboxyl group in enzymes, minimizing interference from ion effects.","Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used as a buffer to provide an unperturbed medium for studying the chemical shift of the [13C]-carboxyl group in enzymes, minimizing interference from ion effects."
chloride,"Chloride can cause upfield shifts in the carboxyl resonance of enzymes at pH values between 5 and 8, due to its interaction with the enzyme's active site.","Entity: chloride. SMILES: [Cl-]. Chloride can cause upfield shifts in the carboxyl resonance of enzymes at pH values between 5 and 8, due to its interaction with the enzyme's active site."
iodide,"Iodide is known to induce upfield shifts in the carboxyl resonance of enzymes, with the magnitude of the shift depending on the enzyme and the pH range.","Entity: iodide. SMILES: [I-]. Iodide is known to induce upfield shifts in the carboxyl resonance of enzymes, with the magnitude of the shift depending on the enzyme and the pH range."
sodium sulfate,"Sodium sulfate is used as a buffer component to provide an unperturbed medium for enzymatic studies, helping to avoid ion effects that can alter chemical shift measurements.","Entity: sodium sulfate. SMILES: O=S(=O)([O-])[O-].[Na+].[Na+]. Sodium sulfate is used as a buffer component to provide an unperturbed medium for enzymatic studies, helping to avoid ion effects that can alter chemical shift measurements."
carboxymethylhistidine,"The carboxyl carbon of carboxymethylhistidine exhibits a chemical shift of -1 ppm (175 ppm) in the enzyme, consistent with the deprotonated species, and remains at this shift down to pH 6.","Entity: carboxymethylhistidine. SMILES: O=C(O)CN[C@@H](Cc1c[nH]cn1)C(=O)O. The carboxyl carbon of carboxymethylhistidine exhibits a chemical shift of -1 ppm (175 ppm) in the enzyme, consistent with the deprotonated species, and remains at this shift down to pH 6."
carboxymethylhistidine,"The Nδ ionization of carboxymethylhistidine is associated with a pKa that shifts to at least pH 5.5 upon removal of Zn(II), indicating a change in the Nδ environment.","Entity: carboxymethylhistidine. SMILES: O=C(O)CN[C@@H](Cc1c[nH]cn1)C(=O)O. The Nδ ionization of carboxymethylhistidine is associated with a pKa that shifts to at least pH 5.5 upon removal of Zn(II), indicating a change in the Nδ environment."
zinc,"Addition of 1 equivalent of zinc to apo-CmHCAB restores the original chemical shift and titration behavior of carboxymethylhistidine, including the Nδ pKa, suggesting zinc is essential for maintaining the native state of the enzyme.","Entity: zinc. SMILES: [Zn]. Addition of 1 equivalent of zinc to apo-CmHCAB restores the original chemical shift and titration behavior of carboxymethylhistidine, including the Nδ pKa, suggesting zinc is essential for maintaining the native state of the enzyme."
ZnCl2,"Addition of ZnCl2 to apocarboxymethyl human carbonic anhydrase B at pH 7.0 causes a 1.3 ppm upfield shift in the resonance of the carboxyl carbon, restoring it to the same chemical shift and line width as the native carboxymethyl human carbonic anhydrase B.","Entity: ZnCl2. SMILES: [Cl-].[Cl-].[Zn+2]. Addition of ZnCl2 to apocarboxymethyl human carbonic anhydrase B at pH 7.0 causes a 1.3 ppm upfield shift in the resonance of the carboxyl carbon, restoring it to the same chemical shift and line width as the native carboxymethyl human carbonic anhydrase B."
iodoacetate,"Iodoacetate binds reversibly to the active center of the enzyme, enabling carboxymethylation of His-200, a reaction dependent on the presence of a metal ion.","Entity: iodoacetate. SMILES: O=C([O-])CI. Iodoacetate binds reversibly to the active center of the enzyme, enabling carboxymethylation of His-200, a reaction dependent on the presence of a metal ion."
bromoacetate,"Bromoacetate binds reversibly to the active center of the enzyme, enabling carboxymethylation of His-200, a reaction dependent on the presence of a metal ion.","Entity: bromoacetate. SMILES: O=C([O-])CBr. Bromoacetate binds reversibly to the active center of the enzyme, enabling carboxymethylation of His-200, a reaction dependent on the presence of a metal ion."
CN-,CN- acts as a powerful anionic inhibitor and competes with the carboxyl group for coordination at the metal ion site at neutral pH.,Entity: CN-. SMILES: [C-]#N. CN- acts as a powerful anionic inhibitor and competes with the carboxyl group for coordination at the metal ion site at neutral pH.
"pyridine-2,6-dicarboxylic acid","Pyridine-2,6-dicarboxylic acid is used to remove zinc from carboxymethylated human carbonic anhydrase B, with complete zinc removal (<3% remaining) achieved in 1 day using 50 mM pyridine-2,6-dicarboxylic acid in 10 mM sodium phosphate buffer at pH 7.","Entity: pyridine-2,6-dicarboxylic acid. SMILES: O=C(O)c1cccc(C(=O)O)n1. Pyridine-2,6-dicarboxylic acid is used to remove zinc from carboxymethylated human carbonic anhydrase B, with complete zinc removal (<3% remaining) achieved in 1 day using 50 mM pyridine-2,6-dicarboxylic acid in 10 mM sodium phosphate buffer at pH 7."
sodium phosphate,Sodium phosphate buffer at 0.1 M concentration causes protein denaturation and is therefore substituted with 10 mM sodium phosphate buffer for protein handling.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate buffer at 0.1 M concentration causes protein denaturation and is therefore substituted with 10 mM sodium phosphate buffer for protein handling.
H-2k,"In H-2k nonresponder mouse strains, the immune response against the (T-T-G-G)-A--L antigen can be reconstituted to high antibody levels by complexing it with methylated bovine serum albumin.","Entity: H-2k. In H-2k nonresponder mouse strains, the immune response against the (T-T-G-G)-A--L antigen can be reconstituted to high antibody levels by complexing it with methylated bovine serum albumin."
cytochalasin B,"Cytochalasin B inhibits macro-pinocytosis and also blocks cell multiplication in human, serum-deprived glia cells.","Entity: cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B inhibits macro-pinocytosis and also blocks cell multiplication in human, serum-deprived glia cells."
acetone,Acetone is used to treat coverslips at -20°C for 1 minute during the preparation for immunofluorescence microscopy.,Entity: acetone. SMILES: CC(C)=O. Acetone is used to treat coverslips at -20°C for 1 minute during the preparation for immunofluorescence microscopy.
formaldehyde,Formaldehyde is used as a fixative for cells at a concentration of 3.7% in phosphate-buffered saline for 8–10 minutes during indirect immunofluorescence microscopy.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a fixative for cells at a concentration of 3.7% in phosphate-buffered saline for 8–10 minutes during indirect immunofluorescence microscopy.
methanol,Methanol is used to treat coverslips at -20°C for 5 minutes during the preparation for immunofluorescence microscopy.,Entity: methanol. SMILES: CO. Methanol is used to treat coverslips at -20°C for 5 minutes during the preparation for immunofluorescence microscopy.
cytochalasin B,"Cytochalasin B is used to enucleate 3T3 cells, disrupting their microtubule network and causing cells to lose their microtubule organization.","Entity: cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B is used to enucleate 3T3 cells, disrupting their microtubule network and causing cells to lose their microtubule organization."
cyanogen bromide,"Cyanogen bromide (CNBr) is used to cleave intact H chains, enabling the determination of amino acid compositions of protein fragments.","Entity: cyanogen bromide. SMILES: N#CBr. Cyanogen bromide (CNBr) is used to cleave intact H chains, enabling the determination of amino acid compositions of protein fragments."
sodium chloride,Sodium chloride is used at a concentration of 0.1 M in the buffer system for recombination studies of VH fragments.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at a concentration of 0.1 M in the buffer system for recombination studies of VH fragments.
sodium acetate,Sodium acetate is used at a concentration of 20 mM as a buffer component in molecular sieving experiments of VH fragments under nondenaturing conditions.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate is used at a concentration of 20 mM as a buffer component in molecular sieving experiments of VH fragments under nondenaturing conditions.
fluorescamine,Fluorescamine is a reagent used to detect proteins and peptides by forming a fluorescent product upon reaction with amine groups.,Entity: fluorescamine. SMILES: O=C1OC2(OC=C(c3ccccc3)C2=O)c2ccccc21. Fluorescamine is a reagent used to detect proteins and peptides by forming a fluorescent product upon reaction with amine groups.
sodium borate,Sodium borate buffer at 50 mM and pH 8.2 is used as a reaction medium for assays involving fluorescamine.,Entity: sodium borate. SMILES: [Na+].[Na+].[Na+].[O-]B([O-])[O-]. Sodium borate buffer at 50 mM and pH 8.2 is used as a reaction medium for assays involving fluorescamine.
acetone,Acetone is used as a solvent for preparing a 30 mg/100 mL fluorescamine solution in protein and peptide assays.,Entity: acetone. SMILES: CC(C)=O. Acetone is used as a solvent for preparing a 30 mg/100 mL fluorescamine solution in protein and peptide assays.
iodoacetamide,"Iodoacetamide is used to alkylate protein chains, introducing sites susceptible to trypsin cleavage.","Entity: iodoacetamide. SMILES: NC(=O)CI. Iodoacetamide is used to alkylate protein chains, introducing sites susceptible to trypsin cleavage."
Gdn-HCI,Gdn-HCI is a buffer solution (5 M) used in the preparation and purification of VH fragments by chromatography.,Entity: Gdn-HCI. SMILES: Cl.N=C(N)N. Gdn-HCI is a buffer solution (5 M) used in the preparation and purification of VH fragments by chromatography.
acetic acid,Acetic acid (0.1 M) is used as a component in the dialysis buffer for heavy-light chain recombinants during antibody VH preparation.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid (0.1 M) is used as a component in the dialysis buffer for heavy-light chain recombinants during antibody VH preparation.
guanidine hydrochloride,Guanidine hydrochloride is used to achieve a 5 M concentration in the preparation of H-chain tryptic peptides for gel filtration.,Entity: guanidine hydrochloride. SMILES: Cl.N=C(N)N. Guanidine hydrochloride is used to achieve a 5 M concentration in the preparation of H-chain tryptic peptides for gel filtration.
acetic acid,Acetic acid is used as a buffer at 0.1 M concentration in the gel filtration and dialysis steps during the preparation of H-chain tryptic peptides.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a buffer at 0.1 M concentration in the gel filtration and dialysis steps during the preparation of H-chain tryptic peptides.
iodoacetamide,Iodoacetamide was used to carboxymethylate heavy protein chains as part of sample preparation for comparative experiments.,Entity: iodoacetamide. SMILES: NC(=O)CI. Iodoacetamide was used to carboxymethylate heavy protein chains as part of sample preparation for comparative experiments.
sodium acetate,Sodium acetate was used at 0.1 M concentration and pH 5.5 in the equilibration and dialysis buffers for protein chain separation and purification.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate was used at 0.1 M concentration and pH 5.5 in the equilibration and dialysis buffers for protein chain separation and purification.
guanidine hydrochloride,Guanidine hydrochloride at 5 M concentration was used as an equilibrating and solubilizing agent for protein chains during gel filtration and dialysis.,Entity: guanidine hydrochloride. SMILES: Cl.N=C(N)N. Guanidine hydrochloride at 5 M concentration was used as an equilibrating and solubilizing agent for protein chains during gel filtration and dialysis.
acetic acid,Acetic acid was used to adjust the pH of distilled water to 5.5 for dialysis of protein chains.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid was used to adjust the pH of distilled water to 5.5 for dialysis of protein chains.
guanidine,Guanidine is used as a buffer component (acid-guanidine) in gel filtration chromatography for peptide separation.,Entity: guanidine. SMILES: N=C(N)N. Guanidine is used as a buffer component (acid-guanidine) in gel filtration chromatography for peptide separation.
acetic acid,Acetic acid at 0.1 M concentration is used as a dialysis buffer for protein fraction purification.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid at 0.1 M concentration is used as a dialysis buffer for protein fraction purification.
guanidine hydrochloride,Guanidine hydrochloride is used as a denaturing agent in chromatography for rechromatography of peptides.,Entity: guanidine hydrochloride. SMILES: Cl.N=C(N)N. Guanidine hydrochloride is used as a denaturing agent in chromatography for rechromatography of peptides.
hydrochloric acid,Hydrochloric acid is used to dissolve TPCK-trypsin for proteolytic digestion of aminoethylated or carboxymethylated H chains.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to dissolve TPCK-trypsin for proteolytic digestion of aminoethylated or carboxymethylated H chains.
acetic acid,Acetic acid is used to lower the pH of the reaction mixture to 3.5 in the TPCK-trypsin digestion of aminoethylated or carboxymethylated H chains.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used to lower the pH of the reaction mixture to 3.5 in the TPCK-trypsin digestion of aminoethylated or carboxymethylated H chains.
sodium hydroxide,Sodium hydroxide is used to adjust the pH of the reaction mixture to 8.5 during the preparation of aminoethylated or carboxymethylated H chains for trypsin digestion.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to adjust the pH of the reaction mixture to 8.5 during the preparation of aminoethylated or carboxymethylated H chains for trypsin digestion.
guanidine hydrochloride,Guanidine hydrochloride is used at 5 M concentration in the presence of 0.1 M sodium acetate and pH 5.5 for protein dialysis.,Entity: guanidine hydrochloride. SMILES: Cl.N=C(N)N. Guanidine hydrochloride is used at 5 M concentration in the presence of 0.1 M sodium acetate and pH 5.5 for protein dialysis.
sodium acetate,Sodium acetate is used at 0.1 M concentration and pH 5.5 in the dialysis buffer for proteins.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate is used at 0.1 M concentration and pH 5.5 in the dialysis buffer for proteins.
water,Distilled water is used as a dialysis buffer for proteins.,Entity: water. SMILES: O. Distilled water is used as a dialysis buffer for proteins.
ethylenimine,"Ethylenimine is used to aminoethylate reduced disulfide bonds in antibodies, applied at a final concentration of 20% in molar excess to free sulfhydryl groups.","Entity: ethylenimine. SMILES: C1CN1. Ethylenimine is used to aminoethylate reduced disulfide bonds in antibodies, applied at a final concentration of 20% in molar excess to free sulfhydryl groups."
EDTA,EDTA is used at 5 mM concentration in dialysis buffer for antibody fractions.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used at 5 mM concentration in dialysis buffer for antibody fractions.
potassium phosphate,Potassium phosphate buffer at 1 mM concentration and pH 7.45 is used for dialysis and as the equilibration buffer in DEAE-cellulose column chromatography for antibody fractionation.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate buffer at 1 mM concentration and pH 7.45 is used for dialysis and as the equilibration buffer in DEAE-cellulose column chromatography for antibody fractionation.
Tris-HCl,Tris-HCl is used as a buffer at 0.5 M concentration and pH 8.4 for dialysis and mild reduction and aminoethylation of antibody fractions.,Entity: Tris-HCl. SMILES: NC(CO)(CO)CO. Tris-HCl is used as a buffer at 0.5 M concentration and pH 8.4 for dialysis and mild reduction and aminoethylation of antibody fractions.
Hydrogen iodide,Hydrogen iodide is used for back-hydrolysis to identify arginine residues in automated Edman degradation protocols.,Entity: Hydrogen iodide. SMILES: I. Hydrogen iodide is used for back-hydrolysis to identify arginine residues in automated Edman degradation protocols.
Arginine,Arginine can be identified in proteins after back-hydrolysis with hydrogen iodide using a Beckman 121 analyzer.,Entity: Arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine can be identified in proteins after back-hydrolysis with hydrogen iodide using a Beckman 121 analyzer.
uridine,Uridine incorporation into RNA in cells is maximal and non-toxic at a concentration of 5 × 10^6 M in culture medium.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine incorporation into RNA in cells is maximal and non-toxic at a concentration of 5 × 10^6 M in culture medium.
uridine,Uridine incorporation into RNA in Chinese hamster lung fibroblasts is characterized by an energy of activation of 19200 calories/mole and a Q10 of 2.71.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine incorporation into RNA in Chinese hamster lung fibroblasts is characterized by an energy of activation of 19200 calories/mole and a Q10 of 2.71.
uridine,"In hamster fibroblasts at 37°C with 5x 10^6 M uridine in the medium, the incorporation rate of uridine is 4.07 × 10^-11 dps/min/10^6 cells, equivalent to 8.81 × 10^-10 mmole/min/10^6 cells or 8.81 × 10^-16 mmole/min/cell.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. In hamster fibroblasts at 37°C with 5x 10^6 M uridine in the medium, the incorporation rate of uridine is 4.07 × 10^-11 dps/min/10^6 cells, equivalent to 8.81 × 10^-10 mmole/min/10^6 cells or 8.81 × 10^-16 mmole/min/cell."
CO2,CO2 is used to maintain a 5% atmosphere in cell culture flasks to support the growth of Chinese hamster fibroblasts (V-79).,Entity: CO2. SMILES: O=C=O. CO2 is used to maintain a 5% atmosphere in cell culture flasks to support the growth of Chinese hamster fibroblasts (V-79).
streptomycin,Streptomycin is included as a supplement in minimal essential medium for culturing Chinese hamster fibroblasts (V-79) in cell flasks.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is included as a supplement in minimal essential medium for culturing Chinese hamster fibroblasts (V-79) in cell flasks.
glutamate,Glutamate is used as a supplement in minimal essential medium for the culture of Chinese hamster fibroblasts (V-79).,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate is used as a supplement in minimal essential medium for the culture of Chinese hamster fibroblasts (V-79).
uridine,Uridine was used at a final concentration of 5 × 10⁻⁶ M in cell culture media to label RNA synthesis rates in experimental assays.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine was used at a final concentration of 5 × 10⁻⁶ M in cell culture media to label RNA synthesis rates in experimental assays.
uridine,"Uridine is incorporated into RNA in Chinese hamster fibroblast cultures, and its cellular uptake rate increases by 2.22-fold over an 8°C temperature range (33–41°C) in the presence of 5 × 10⁻⁶ M uridine.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine is incorporated into RNA in Chinese hamster fibroblast cultures, and its cellular uptake rate increases by 2.22-fold over an 8°C temperature range (33–41°C) in the presence of 5 × 10⁻⁶ M uridine."
uridine,The rate of RNA synthesis in a cell population is proportional to the average rate of uridine incorporation per cell.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. The rate of RNA synthesis in a cell population is proportional to the average rate of uridine incorporation per cell.
toluidine blue,Toluidine blue is used as a staining solution for light microscopy to assess nuclear purity by detecting the presence of cellular components.,Entity: toluidine blue. SMILES: Cc1ccc(Nc2ccc(O)c3c2C(=O)c2c(O)ccc(Nc4ccc(C)cc4S(=O)(=O)[O-])c2C3=O)c(S(=O)(=O)[O-])c1.[Na+].[Na+]. Toluidine blue is used as a staining solution for light microscopy to assess nuclear purity by detecting the presence of cellular components.
2-mercaptoethanol,2-mercaptoethanol is included at 2% concentration in the resuspension buffer for DNA samples prior to electrophoresis.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is included at 2% concentration in the resuspension buffer for DNA samples prior to electrophoresis.
acrylamide,Acrylamide is used at 10% concentration in the separating gel and 6% in the stacking gel for SDS-PAGE electrophoresis.,Entity: acrylamide. SMILES: C=CC(N)=O. Acrylamide is used at 10% concentration in the separating gel and 6% in the stacking gel for SDS-PAGE electrophoresis.
urea,Urea is used at 6.25 M concentration in the pH 3.2 buffer for histone electrophoresis in SDS-PAGE.,Entity: urea. SMILES: NC(N)=O. Urea is used at 6.25 M concentration in the pH 3.2 buffer for histone electrophoresis in SDS-PAGE.
glycerol,Glycerol is included at 2% concentration in the resuspension buffer for DNA samples prior to electrophoresis.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is included at 2% concentration in the resuspension buffer for DNA samples prior to electrophoresis.
sodium chloride,Sodium chloride is used at 0.05 M concentration in extraction buffers for nuclear soluble proteins and ribonuclear particles.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at 0.05 M concentration in extraction buffers for nuclear soluble proteins and ribonuclear particles.
sodium fluoride,Sodium fluoride is included at 0.05 M concentration in extraction buffers for nuclear soluble proteins and ribonuclear particles.,Entity: sodium fluoride. SMILES: [F-].[Na+]. Sodium fluoride is included at 0.05 M concentration in extraction buffers for nuclear soluble proteins and ribonuclear particles.
H2SO4,H2SO4 (sulfuric acid) is used at 0.4 N concentration for histone extraction from chromatin components.,Entity: H2SO4. SMILES: O=S(=O)(O)O. H2SO4 (sulfuric acid) is used at 0.4 N concentration for histone extraction from chromatin components.
formaldehyde,"Formaldehyde inhibits agglutination of both untagged and DNP-tagged cells, but does not block the binding of [3H]ConA to these cells.","Entity: formaldehyde. SMILES: C=O. Formaldehyde inhibits agglutination of both untagged and DNP-tagged cells, but does not block the binding of [3H]ConA to these cells."
glutaraldehyde,"Glutaraldehyde inhibits agglutination of both untagged and DNP-tagged cells, but does not block the binding of [3H]ConA to these cells.","Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde inhibits agglutination of both untagged and DNP-tagged cells, but does not block the binding of [3H]ConA to these cells."
GlNAc,"GlNAc does not specifically block the binding of [3H]ConA to tagged cells, indicating it does not interfere with the ConA-receptor interaction.","Entity: GlNAc. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. GlNAc does not specifically block the binding of [3H]ConA to tagged cells, indicating it does not interfere with the ConA-receptor interaction."
glutaraldehyde,Glutaraldehyde is an aldehyde fixative that inhibits membrane fluidity and prevents cell agglutination by ConA in fixed cells.,Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is an aldehyde fixative that inhibits membrane fluidity and prevents cell agglutination by ConA in fixed cells.
formaldehyde,"Formaldehyde is an aldehyde fixative that can either inhibit membrane fluidity or increase membrane rigidity, thereby affecting cell agglutination by ConA.","Entity: formaldehyde. SMILES: C=O. Formaldehyde is an aldehyde fixative that can either inhibit membrane fluidity or increase membrane rigidity, thereby affecting cell agglutination by ConA."
Triton X-100,Triton X-100 is used to solubilize cell pellets for subsequent radioactivity measurement in binding assays.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used to solubilize cell pellets for subsequent radioactivity measurement in binding assays.
"1-fluoro-2,4-dinitrobenzene","1-fluoro-2,4-dinitrobenzene (DNFB) is used to tag cells for studies of binding interactions, with tagging per se not altering cell size as indicated by surface area measurements.","Entity: 1-fluoro-2,4-dinitrobenzene. SMILES: O=[N+]([O-])c1ccc(F)c([N+](=O)[O-])c1. 1-fluoro-2,4-dinitrobenzene (DNFB) is used to tag cells for studies of binding interactions, with tagging per se not altering cell size as indicated by surface area measurements."
glutaraldehyde,Glutaraldehyde (1%) is used to fix cells for 30 minutes at ambient temperature prior to binding assays.,Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde (1%) is used to fix cells for 30 minutes at ambient temperature prior to binding assays.
formaldehyde,Formaldehyde (10%) is used to fix cells for 30 minutes at ambient temperature prior to binding assays.,Entity: formaldehyde. SMILES: C=O. Formaldehyde (10%) is used to fix cells for 30 minutes at ambient temperature prior to binding assays.
formaldehyde,Formaldehyde is used as a 10% solution to fix granulocytes for 30 minutes at ambient temperature prior to lectin binding assays.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a 10% solution to fix granulocytes for 30 minutes at ambient temperature prior to lectin binding assays.
glutaraldehyde,Glutaraldehyde is used as a 1% solution to fix granulocytes for 30 minutes at ambient temperature prior to lectin binding assays.,Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a 1% solution to fix granulocytes for 30 minutes at ambient temperature prior to lectin binding assays.
dithiothreitol,Dithiothreitol is used at a concentration of 20 mM as a reducing agent in Tris-HCl buffer for homogenizing human lens tissue.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used at a concentration of 20 mM as a reducing agent in Tris-HCl buffer for homogenizing human lens tissue.
EDTA,EDTA is used as a buffer component at a concentration of 5 mM in Tris-HCl buffer (pH 8.5) for homogenizing human lens tissue.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used as a buffer component at a concentration of 5 mM in Tris-HCl buffer (pH 8.5) for homogenizing human lens tissue.
sodium chloride,Sodium chloride is included at 0.1 M concentration in the 50 mM Tris-HCl buffer used for equilibrating and eluting proteins from Sephadex columns.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is included at 0.1 M concentration in the 50 mM Tris-HCl buffer used for equilibrating and eluting proteins from Sephadex columns.
dithiothreitol,"Dithiothreitol is used as a reducing agent in protein purification buffers, as indicated by its addition at 1 mM concentration to the Sephadex and Agarose columns.","Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used as a reducing agent in protein purification buffers, as indicated by its addition at 1 mM concentration to the Sephadex and Agarose columns."
thiothreitol,"Thiothreitol is not required for the formation of high molecular weight protein aggregates in human lens proteins, as shown by similar yields and elution patterns in the presence or absence of thiothreitol during fractionation.","Entity: thiothreitol. SMILES: OC[C@@H](O)[C@H](S)CO. Thiothreitol is not required for the formation of high molecular weight protein aggregates in human lens proteins, as shown by similar yields and elution patterns in the presence or absence of thiothreitol during fractionation."
tryptophan,Tryptophan residues in human E-crystallin contribute to negative vibronic transitions at 292 nm and a peak at 284 nm in the near ultraviolet CD spectrum.,Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan residues in human E-crystallin contribute to negative vibronic transitions at 292 nm and a peak at 284 nm in the near ultraviolet CD spectrum.
tyrosine,Tyrosine residues in human E-crystallin contribute to the 284 nm peak in the near ultraviolet CD spectrum.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine residues in human E-crystallin contribute to the 284 nm peak in the near ultraviolet CD spectrum.
phenylalanine,"Phenylalanine residues in α-crystallin are responsible for vibronic fine structure at 258 nm, 262 nm, and 268 nm in the near ultraviolet CD spectrum.","Entity: phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. Phenylalanine residues in α-crystallin are responsible for vibronic fine structure at 258 nm, 262 nm, and 268 nm in the near ultraviolet CD spectrum."
dithiothreitol,"Dithiothreitol does not affect the elution patterns or yields of cellular proteins, indicating that disulfide bonds are not involved in the formation of protein molecular aggregates.","Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol does not affect the elution patterns or yields of cellular proteins, indicating that disulfide bonds are not involved in the formation of protein molecular aggregates."
cysteine,Cysteine is used as a substrate in the enzymatic assay for GSH synthesis in lens tissue extracts.,Entity: cysteine. SMILES: Cl.N[C@@H](CS)C(=O)O. Cysteine is used as a substrate in the enzymatic assay for GSH synthesis in lens tissue extracts.
glutamic acid,Glutamic acid is included as a substrate at 16 mM concentration in the enzymatic assay for GSH synthesis in lens tissue extracts.,Entity: glutamic acid. SMILES: N[C@@H](CCC(=O)O)C(=O)O. Glutamic acid is included as a substrate at 16 mM concentration in the enzymatic assay for GSH synthesis in lens tissue extracts.
GSH,"GSH (glutathione) is a free amino acid whose synthesis in lens tissue extracts can be studied using an enzymatic assay with cysteine, glutamate, and dithioerythritol as substrates.","Entity: GSH. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. GSH (glutathione) is a free amino acid whose synthesis in lens tissue extracts can be studied using an enzymatic assay with cysteine, glutamate, and dithioerythritol as substrates."
ATP,ATP (adenosine triphosphate) is included at 10 µM concentration in the enzymatic assay for GSH synthesis in lens tissue extracts.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP (adenosine triphosphate) is included at 10 µM concentration in the enzymatic assay for GSH synthesis in lens tissue extracts.
potassium chloride,Potassium chloride is included at 20 µM concentration in the enzymatic assay for GSH synthesis in lens tissue extracts.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is included at 20 µM concentration in the enzymatic assay for GSH synthesis in lens tissue extracts.
dithioerythritol,Dithioerythritol is used as a substrate at 10 µM concentration in the enzymatic assay for GSH synthesis in lens tissue extracts.,Entity: dithioerythritol. SMILES: O[C@H](CS)[C@@H](O)CS. Dithioerythritol is used as a substrate at 10 µM concentration in the enzymatic assay for GSH synthesis in lens tissue extracts.
sodium,Sodium is quantified in lyophilized lens tissue using an appropriate assay method.,Entity: sodium. SMILES: [Na]. Sodium is quantified in lyophilized lens tissue using an appropriate assay method.
taurine,Taurine is a free amino acid that can be quantified in biological extracts using an automatic amino acid analyzer.,Entity: taurine. SMILES: NCCS(=O)(=O)O. Taurine is a free amino acid that can be quantified in biological extracts using an automatic amino acid analyzer.
trichloroacetic acid,Trichloroacetic acid is used in the homogenization of lens tissue and for protein precipitation in biochemical assays.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used in the homogenization of lens tissue and for protein precipitation in biochemical assays.
glucose,"Glucose is used as the carbohydrate component in the control diet for lens tissue studies, replacing galactose.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is used as the carbohydrate component in the control diet for lens tissue studies, replacing galactose."
galactose,Galactose is the primary carbohydrate component in the experimental diet for lens tissue studies.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose is the primary carbohydrate component in the experimental diet for lens tissue studies.
EDTA,EDTA is used as a buffer in the homogenization of lens tissue and as a component in the dialysis buffer for GSH synthesis assays.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used as a buffer in the homogenization of lens tissue and as a component in the dialysis buffer for GSH synthesis assays.
glycine,Glycine is included at 50 µM concentration in the enzymatic assay for GSH synthesis in lens tissue extracts.,Entity: glycine. SMILES: NCC(=O)O. Glycine is included at 50 µM concentration in the enzymatic assay for GSH synthesis in lens tissue extracts.
glutathione,Glutathione (GSH) levels in the lens decrease markedly during the formation of many types of cataract.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione (GSH) levels in the lens decrease markedly during the formation of many types of cataract.
glutathione,Loss of glutathione in lens tissue during cataractogenesis has been correlated with decreased synthesis of glutathione due to inactivation of enzymes involved in its synthesis.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Loss of glutathione in lens tissue during cataractogenesis has been correlated with decreased synthesis of glutathione due to inactivation of enzymes involved in its synthesis.
galactose,"Feeding rats a galactose diet induces the development of cataracts characterized by vacuole formation in the equatorial region of the lens, followed by nuclear opacity, with the process typically beginning between 14 and 20 days post-dietary shift.","Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Feeding rats a galactose diet induces the development of cataracts characterized by vacuole formation in the equatorial region of the lens, followed by nuclear opacity, with the process typically beginning between 14 and 20 days post-dietary shift."
glutathione,"In galactose-fed animal lenses, the concentration of glutathione (GSH) falls rapidly from 6 mmol/g in normal lenses to 1 pmol/g within the first 48 hours of galactose feeding.","Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. In galactose-fed animal lenses, the concentration of glutathione (GSH) falls rapidly from 6 mmol/g in normal lenses to 1 pmol/g within the first 48 hours of galactose feeding."
glutathione,"In lenses from galactose-fed animals, glutathione (GSH) levels decrease to 15% of control levels within 48 hours of galactose feeding and reach only 10% of control levels on the 20th day of galactose feeding.","Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. In lenses from galactose-fed animals, glutathione (GSH) levels decrease to 15% of control levels within 48 hours of galactose feeding and reach only 10% of control levels on the 20th day of galactose feeding."
galactose,"Feeding lenses galactose for 7 days increases polyol concentration to 400 pmol/g dry weight, and this concentration gradually decreases to undetectable levels during the subsequent 7 days on a normal diet.","Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Feeding lenses galactose for 7 days increases polyol concentration to 400 pmol/g dry weight, and this concentration gradually decreases to undetectable levels during the subsequent 7 days on a normal diet."
galactose,Feeding lenses galactose for 12 days results in a maximum polyol concentration of 300 ± 10 µmol/g dry weight.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Feeding lenses galactose for 12 days results in a maximum polyol concentration of 300 ± 10 µmol/g dry weight.
galactose,Galactose is used as a dietary supplement in animal feeding studies to support glutathione (GSH) synthesis in lenses.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose is used as a dietary supplement in animal feeding studies to support glutathione (GSH) synthesis in lenses.
glutathione,Glutathione (GSH) is synthesized in animal lenses at a rate of approximately 7 µmol/g lens dry weight per hour during 20 days of galactose feeding.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione (GSH) is synthesized in animal lenses at a rate of approximately 7 µmol/g lens dry weight per hour during 20 days of galactose feeding.
potassium ion,"Potassium ion is uniformly distributed throughout the lens and shows a recovery during cataract reversal that is similar to that of taurine and other free amino acids, though not as complete as sodium ion recovery.","Entity: potassium ion. SMILES: [K]. Potassium ion is uniformly distributed throughout the lens and shows a recovery during cataract reversal that is similar to that of taurine and other free amino acids, though not as complete as sodium ion recovery."
sodium ion,"Sodium ion accumulates to four times the normal level in the regenerated lens during cataract reversal, in contrast to potassium ion recovery.","Entity: sodium ion. SMILES: [Na]. Sodium ion accumulates to four times the normal level in the regenerated lens during cataract reversal, in contrast to potassium ion recovery."
taurine,Taurine shows a recovery during cataract reversal that is similar to that of potassium ion and other free amino acids in the lens.,Entity: taurine. SMILES: NCCS(=O)(=O)O. Taurine shows a recovery during cataract reversal that is similar to that of potassium ion and other free amino acids in the lens.
Sodium ion,"In lens tissue, sodium ion concentration increases from 20 to 50 mmol/kg lens water after 7 days on a galactose diet, and further to approximately 60 mmol/kg lens water at the end of one week on a normal diet.","Entity: Sodium ion. SMILES: [Na]. In lens tissue, sodium ion concentration increases from 20 to 50 mmol/kg lens water after 7 days on a galactose diet, and further to approximately 60 mmol/kg lens water at the end of one week on a normal diet."
Potassium ion,"In lens tissue, potassium ion concentration decreases from 120 to approximately 10 nmol/kg lens water after 7 days on a galactose diet.","Entity: Potassium ion. SMILES: [K]. In lens tissue, potassium ion concentration decreases from 120 to approximately 10 nmol/kg lens water after 7 days on a galactose diet."
Evans blue,"Evans blue binds extensively to plasma proteins, which complicates its use in tissue and plasma concentration measurements by fluorimetry.","Entity: Evans blue. SMILES: Cc1cc(-c2ccc(N=Nc3ccc4c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c4c3O)c(C)c2)ccc1N=Nc1ccc2c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c2c1O.[Na+].[Na+].[Na+].[Na+]. Evans blue binds extensively to plasma proteins, which complicates its use in tissue and plasma concentration measurements by fluorimetry."
xenon,Xenon is used as an illumination source in a quartz flash lamp system for high-speed photographic recording in microscopy.,Entity: xenon. SMILES: [Xe]. Xenon is used as an illumination source in a quartz flash lamp system for high-speed photographic recording in microscopy.
iodine,Iodine is used as an illumination source in a quartz iodine lamp system for continuous observation in microscopy.,Entity: iodine. SMILES: [I]. Iodine is used as an illumination source in a quartz iodine lamp system for continuous observation in microscopy.
fluorescein,Fluorescein-labelled dextrans of defined molecular sizes have been used to study aqueous humour outflow dynamics and post mortem tissue distribution.,Entity: fluorescein. SMILES: O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21. Fluorescein-labelled dextrans of defined molecular sizes have been used to study aqueous humour outflow dynamics and post mortem tissue distribution.
Evans blue,Evans blue has been used as a dye to demonstrate aqueous humour outflow vessels in vivo in rabbits.,Entity: Evans blue. SMILES: Cc1cc(-c2ccc(N=Nc3ccc4c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c4c3O)c(C)c2)ccc1N=Nc1ccc2c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c(N)c2c1O.[Na+].[Na+].[Na+].[Na+]. Evans blue has been used as a dye to demonstrate aqueous humour outflow vessels in vivo in rabbits.
red dextran,"Red dextran with a molecular weight of 40,000 was used as a tracer to assess uveoscleral flow in cats and rabbits, but failed to show appreciable penetration into suprachoroidal tissues in these species.","Entity: red dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Red dextran with a molecular weight of 40,000 was used as a tracer to assess uveoscleral flow in cats and rabbits, but failed to show appreciable penetration into suprachoroidal tissues in these species."
salicylate,Metys salicylate is used as a clearing agent for whole-mount tissue preparations in histological studies.,Entity: salicylate. SMILES: COC(=O)c1ccccc1O. Metys salicylate is used as a clearing agent for whole-mount tissue preparations in histological studies.
dextran,Dextran can be labelled with fluorescein and used to visualize aqueous humour outflow channels and tissue distribution in the rabbit anterior chamber.,Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran can be labelled with fluorescein and used to visualize aqueous humour outflow channels and tissue distribution in the rabbit anterior chamber.
fluorescein,Fluorescein can be used to label dextrans of various molecular weights for perfusion and histological studies of the anterior chamber and outflow channels in animal tissues.,Entity: fluorescein. SMILES: O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21. Fluorescein can be used to label dextrans of various molecular weights for perfusion and histological studies of the anterior chamber and outflow channels in animal tissues.
formaldehyde,Formaldehyde is used as a component of fixative mixtures to preserve tissue morphology for histological analysis.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a component of fixative mixtures to preserve tissue morphology for histological analysis.
ethanol,"Ethanol, in combination with neutral formaldehyde, is used as a fixative for preparing tissue samples for dehydration and embedding.","Entity: ethanol. SMILES: CCO. Ethanol, in combination with neutral formaldehyde, is used as a fixative for preparing tissue samples for dehydration and embedding."
formaldehyde,Formaldehyde is used as a fixative in histological procedures to preserve tissue structure.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a fixative in histological procedures to preserve tissue structure.
isopropanol,Isopropanol at 70% concentration is used as a warm bath to float out tissue sections during histological processing.,Entity: isopropanol. SMILES: CC(C)O. Isopropanol at 70% concentration is used as a warm bath to float out tissue sections during histological processing.
ethanol,"Ethanol is used in histological processing for dehydration and as a solvent for dextrans, with concentrations above 50% causing precipitation of dextrans.","Entity: ethanol. SMILES: CCO. Ethanol is used in histological processing for dehydration and as a solvent for dextrans, with concentrations above 50% causing precipitation of dextrans."
xylene,Xylene is used as a clearing agent for tissue samples during histological processing.,Entity: xylene. SMILES: Cc1ccccc1C. Xylene is used as a clearing agent for tissue samples during histological processing.
xylose,"Xylose, a carbohydrate with a smaller molecular size than starch, is more likely to be impeded when the anterior chamber is perfused with a mixture of carbohydrates of differing molecular sizes.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose, a carbohydrate with a smaller molecular size than starch, is more likely to be impeded when the anterior chamber is perfused with a mixture of carbohydrates of differing molecular sizes."
Ascorbic acid,"Ascorbic acid at 20 mg/o inhibits rubidium (Rb) uptake by rat lens in the absence of glucose, with greater inhibition at lower concentrations (e.g., 10 mg/o).","Entity: Ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid at 20 mg/o inhibits rubidium (Rb) uptake by rat lens in the absence of glucose, with greater inhibition at lower concentrations (e.g., 10 mg/o)."
Ascorbic acid,The effect of ascorbic acid on rubidium uptake by rat lens is observed in a medium free of glucose.,Entity: Ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. The effect of ascorbic acid on rubidium uptake by rat lens is observed in a medium free of glucose.
Glucose,Glucose restores the ability of rat lens to concentrate rubidium (Rb) uptake to near normal values.,Entity: Glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose restores the ability of rat lens to concentrate rubidium (Rb) uptake to near normal values.
hydrogen peroxide,Hydrogen peroxide lowers the glutathione level in the lens.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide lowers the glutathione level in the lens.
ascorbate,Ascorbate lowers the glutathione level in the lens.,Entity: ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O. Ascorbate lowers the glutathione level in the lens.
ascorbate,The effect of ascorbate on glutathione levels in the lens is similar to that of hydrogen peroxide.,Entity: ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O. The effect of ascorbate on glutathione levels in the lens is similar to that of hydrogen peroxide.
glucose,The addition of glucose to the lens incubation medium abolishes both the hydrogen peroxide and ascorbate effects on glutathione levels.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. The addition of glucose to the lens incubation medium abolishes both the hydrogen peroxide and ascorbate effects on glutathione levels.
hydrogen peroxide,Hydrogen peroxide exposure leads to a decrease in glutathione (GSH) level in lenses.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide exposure leads to a decrease in glutathione (GSH) level in lenses.
glucose,Glucose in the medium protects against the adverse effects of hydrogen peroxide on glutathione (GSH) level in lenses.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose in the medium protects against the adverse effects of hydrogen peroxide on glutathione (GSH) level in lenses.
glutathione,Glutathione (GSH) level decreases in lenses incubated with hydrogen peroxide but is not affected by ascorbate treatment.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione (GSH) level decreases in lenses incubated with hydrogen peroxide but is not affected by ascorbate treatment.
ascorbate,Ascorbate does not affect glutathione (GSH) levels in lenses.,Entity: ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O. Ascorbate does not affect glutathione (GSH) levels in lenses.
rubidium,"The uptake of rubidium in lenses is inhibited by ascorbate, and this inhibition is abolished by catalase.","Entity: rubidium. SMILES: [Rb]. The uptake of rubidium in lenses is inhibited by ascorbate, and this inhibition is abolished by catalase."
Ascorbic acid,Ascorbic acid is present in significant amounts in the lens and may play an important role in lens tissue metabolism.,Entity: Ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid is present in significant amounts in the lens and may play an important role in lens tissue metabolism.
Ascorbic acid,"Ascorbic acid can influence cation transport, such as rubidium, in the lens, potentially by generating hydrogen peroxide during its oxidation.","Entity: Ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid can influence cation transport, such as rubidium, in the lens, potentially by generating hydrogen peroxide during its oxidation."
Hydrogen peroxide,Hydrogen peroxide is formed during the oxidation of ascorbate and can affect lens rubidium transport and glutathione levels.,Entity: Hydrogen peroxide. SMILES: OO. Hydrogen peroxide is formed during the oxidation of ascorbate and can affect lens rubidium transport and glutathione levels.
Rubidium,"The ability of the lens to concentrate rubidium is severely compromised when ascorbate and trace cupric ion are present, and this effect is abolished by glucose or catalase.","Entity: Rubidium. SMILES: [Rb]. The ability of the lens to concentrate rubidium is severely compromised when ascorbate and trace cupric ion are present, and this effect is abolished by glucose or catalase."
Glutathione,Glutathione levels in the lens are affected by hydrogen peroxide generated during ascorbate oxidation.,Entity: Glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione levels in the lens are affected by hydrogen peroxide generated during ascorbate oxidation.
hydrogen peroxide,"Hydrogen peroxide, produced by ascorbate oxidation, inhibits sodium (Rb) uptake in rat lens cells in glucose-free medium, with 0.1 mM hydrogen peroxide causing a 23% inhibition and 0.2 mM causing a 50% inhibition.","Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide, produced by ascorbate oxidation, inhibits sodium (Rb) uptake in rat lens cells in glucose-free medium, with 0.1 mM hydrogen peroxide causing a 23% inhibition and 0.2 mM causing a 50% inhibition."
glucose,"Glucose in the medium depresses the inhibitory effect of hydrogen peroxide on sodium (Rb) uptake in rat lens cells, though less effectively than ascorbate.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose in the medium depresses the inhibitory effect of hydrogen peroxide on sodium (Rb) uptake in rat lens cells, though less effectively than ascorbate."
ascorbate,"Ascorbate induces a marked effect on sodium (Rb) uptake in rat lens cells, and its oxidation produces hydrogen peroxide as a product.","Entity: ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O. Ascorbate induces a marked effect on sodium (Rb) uptake in rat lens cells, and its oxidation produces hydrogen peroxide as a product."
Rheomacrodex,Intravenous injection of a mixture of isotonic saline and Rheomacrodex increases mean arterial blood pressure to 6814 mmHg at the time of flow determination.,Entity: Rheomacrodex. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Intravenous injection of a mixture of isotonic saline and Rheomacrodex increases mean arterial blood pressure to 6814 mmHg at the time of flow determination.
hexamethonium bromide,"Hexamethonium bromide is used as an autonomic ganglion blocker, with intravenous administration of 40–80 mg/kg body weight in rabbits to achieve adequate blockade as evidenced by failure of oculomotor nerve stimulation to induce miosis.","Entity: hexamethonium bromide. SMILES: C[N+](C)(C)CCCCCC[N+](C)(C)C.[Br-].[Br-]. Hexamethonium bromide is used as an autonomic ganglion blocker, with intravenous administration of 40–80 mg/kg body weight in rabbits to achieve adequate blockade as evidenced by failure of oculomotor nerve stimulation to induce miosis."
pentobarbital sodium,Pentobarbital sodium is used as an intravenous anesthetic agent in rabbits at a dose of 40–60 mg/kg body weight for induction and maintenance of anesthesia.,Entity: pentobarbital sodium. SMILES: CCCC(C)C1(CC)C(=O)N=C([O-])NC1=O.[Na+]. Pentobarbital sodium is used as an intravenous anesthetic agent in rabbits at a dose of 40–60 mg/kg body weight for induction and maintenance of anesthesia.
hexamethonium bromide,Hexamethonium bromide at a dose of 40–80 mg/kg body weight completely abolishes the vasoconstrictive response in the iris and ciliary processes following unilateral oculomotor nerve stimulation.,Entity: hexamethonium bromide. SMILES: C[N+](C)(C)CCCCCC[N+](C)(C)C.[Br-].[Br-]. Hexamethonium bromide at a dose of 40–80 mg/kg body weight completely abolishes the vasoconstrictive response in the iris and ciliary processes following unilateral oculomotor nerve stimulation.
phentolamine chloride,Phentolamine chloride at a dose of 10–15 mg/kg body weight reverses the vasoconstrictive effect in the ciliary processes but has no significant effect on the iris response after unilateral oculomotor nerve stimulation.,Entity: phentolamine chloride. SMILES: Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1. Phentolamine chloride at a dose of 10–15 mg/kg body weight reverses the vasoconstrictive effect in the ciliary processes but has no significant effect on the iris response after unilateral oculomotor nerve stimulation.
biperiden lactate,Biperiden lactate at a dose of 2.5–5 mg/kg body weight reduces the vasoconstrictive response in the iris but does not significantly affect the ciliary processes after unilateral oculomotor nerve stimulation.,Entity: biperiden lactate. SMILES: CC(O)C(=O)O.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2. Biperiden lactate at a dose of 2.5–5 mg/kg body weight reduces the vasoconstrictive response in the iris but does not significantly affect the ciliary processes after unilateral oculomotor nerve stimulation.
phentolamine,"Phentolamine causes a marked fall in arterial blood pressure, typically reducing it to around 40 mmHg.","Entity: phentolamine. SMILES: Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1. Phentolamine causes a marked fall in arterial blood pressure, typically reducing it to around 40 mmHg."
DA,"DA, a metabolite of dopamine, inhibits tyrosine hydroxylase in vitro.","Entity: DA. SMILES: NCCc1ccc(O)c(O)c1. DA, a metabolite of dopamine, inhibits tyrosine hydroxylase in vitro."
tryptophan,"Tryptophan hydroxylase has a high Km, suggesting it is not saturated with tryptophan in vivo.","Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan hydroxylase has a high Km, suggesting it is not saturated with tryptophan in vivo."
tryptophan,The Km of tryptophan hydroxylase for tryptophan may be within the range of tryptophan concentrations in the brain.,Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. The Km of tryptophan hydroxylase for tryptophan may be within the range of tryptophan concentrations in the brain.
serotonin,Daily fluctuations of serotonin in the brain are of the order of only 20%.,Entity: serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Daily fluctuations of serotonin in the brain are of the order of only 20%.
tyrosine,Tyrosine hydroxylase has a low Km (3.7 × 10^-9 M) for tyrosine.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine hydroxylase has a low Km (3.7 × 10^-9 M) for tyrosine.
tyrosine,"In the brain, tyrosine concentration is saturated in rats.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. In the brain, tyrosine concentration is saturated in rats."
tyrosine,Tyrosine hydroxylation in vivo is regulated primarily by feedback inhibition rather than substrate availability.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine hydroxylation in vivo is regulated primarily by feedback inhibition rather than substrate availability.
DOPA,"DOPA, the end product of tyrosine hydroxylation, inhibits tyrosine hydroxylase in vitro.","Entity: DOPA. SMILES: N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O. DOPA, the end product of tyrosine hydroxylation, inhibits tyrosine hydroxylase in vitro."
NE,"NE, a metabolite of dopamine, inhibits tyrosine hydroxylase in vitro.","Entity: NE. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. NE, a metabolite of dopamine, inhibits tyrosine hydroxylase in vitro."
Pyridoxine,Pyridoxine is used to facilitate the determination of brain serotonin and 5-hydroxyindoleacetic acid levels by administration and subsequent assay.,Entity: Pyridoxine. SMILES: Cc1ncc(CO)c(CO)c1O. Pyridoxine is used to facilitate the determination of brain serotonin and 5-hydroxyindoleacetic acid levels by administration and subsequent assay.
Tetrahydrobiopterin,Tetrahydrobiopterin serves as a cofactor in the assay for brainstem tryptophan-5-hydroxylase activity.,Entity: Tetrahydrobiopterin. SMILES: CC(O)C(O)C1CNc2nc(N)[nH]c(=O)c2N1. Tetrahydrobiopterin serves as a cofactor in the assay for brainstem tryptophan-5-hydroxylase activity.
Pargyline,Pargyline is used to determine brain serotonin and 5-hydroxyindoleacetic acid levels by administration and subsequent assay.,Entity: Pargyline. SMILES: C#CCN(C)Cc1ccccc1. Pargyline is used to determine brain serotonin and 5-hydroxyindoleacetic acid levels by administration and subsequent assay.
Serotonin,"Serotonin (5-HT) in the brain can be measured after administration of pargyline, probenecid, or pyridoxine using the Curzon and Green (1970) method.","Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin (5-HT) in the brain can be measured after administration of pargyline, probenecid, or pyridoxine using the Curzon and Green (1970) method."
5-Hydroxyindoleacetic acid,"5-Hydroxyindoleacetic acid (5-HIAA) in the brain is determined after administration of pargyline, probenecid, or pyridoxine using the Curzon and Green (1970) method.","Entity: 5-Hydroxyindoleacetic acid. SMILES: O=C(O)Cc1cc2cc(O)ccc2[nH]1. 5-Hydroxyindoleacetic acid (5-HIAA) in the brain is determined after administration of pargyline, probenecid, or pyridoxine using the Curzon and Green (1970) method."
Tryptophan,Plasma total and free tryptophan can be measured using the methods of Denckla and Dewey (1967) and Knott and Curzon (1972) respectively.,Entity: Tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Plasma total and free tryptophan can be measured using the methods of Denckla and Dewey (1967) and Knott and Curzon (1972) respectively.
5-hydroxytryptophan,"5-hydroxytryptophan is decarboxylated by aromatic amino acid decarboxylase to form serotonin, a reaction that requires pyridoxal phosphate as a coenzyme.","Entity: 5-hydroxytryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O. 5-hydroxytryptophan is decarboxylated by aromatic amino acid decarboxylase to form serotonin, a reaction that requires pyridoxal phosphate as a coenzyme."
dopamine,Brain dopamine levels are not affected by pyridoxine deficiency in rats.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Brain dopamine levels are not affected by pyridoxine deficiency in rats.
5-hydroxytryptamine,"5-hydroxytryptamine (serotonin) is synthesized from 5-hydroxytryptophan by the action of aromatic amino acid decarboxylase, which requires pyridoxal phosphate as a coenzyme.","Entity: 5-hydroxytryptamine. SMILES: NCCc1c[nH]c2ccc(O)cc12. 5-hydroxytryptamine (serotonin) is synthesized from 5-hydroxytryptophan by the action of aromatic amino acid decarboxylase, which requires pyridoxal phosphate as a coenzyme."
pyridoxine,Pyridoxine deficiency leads to decreased serotonin and catecholamine synthesis in the brain due to impaired aromatic amino acid decarboxylation.,Entity: pyridoxine. SMILES: Cc1ncc(CO)c(CO)c1O. Pyridoxine deficiency leads to decreased serotonin and catecholamine synthesis in the brain due to impaired aromatic amino acid decarboxylation.
norepinephrine,"Brain norepinephrine levels are not altered in pyridoxine-deficient growing rats, despite decreased serotonin.","Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Brain norepinephrine levels are not altered in pyridoxine-deficient growing rats, despite decreased serotonin."
5-hydroxyindoleacetic acid,"Increased levels of 5-hydroxyindoleacetic acid, a metabolite of serotonin, indicate increased serotonin degradation rather than decreased serotonin synthesis.","Entity: 5-hydroxyindoleacetic acid. SMILES: O=C(O)Cc1cc2cc(O)ccc2[nH]1. Increased levels of 5-hydroxyindoleacetic acid, a metabolite of serotonin, indicate increased serotonin degradation rather than decreased serotonin synthesis."
dihydroxyphenylalanine,Aromatic amino acid decarboxylase decatoxylates dihydroxyphenylalanine as part of its enzymatic activity.,Entity: dihydroxyphenylalanine. SMILES: O=C(O)[C@H](Cc1ccccc1)N(O)O. Aromatic amino acid decarboxylase decatoxylates dihydroxyphenylalanine as part of its enzymatic activity.
Pargyline,"Pargyline is a monoamine oxidase inhibitor that, when administered in vivo, reduces brain serotonin and 5-hydroxyindoleacetic acid (5-HIAA) levels by inhibiting monoamine oxidase activity.","Entity: Pargyline. SMILES: C#CCN(C)Cc1ccccc1. Pargyline is a monoamine oxidase inhibitor that, when administered in vivo, reduces brain serotonin and 5-hydroxyindoleacetic acid (5-HIAA) levels by inhibiting monoamine oxidase activity."
Serotonin,"In pyridoxine-deficient rats, brain serotonin levels increase 2.1-fold within 3 hours after pargyline treatment, indicating depressed serotonin synthesis.","Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. In pyridoxine-deficient rats, brain serotonin levels increase 2.1-fold within 3 hours after pargyline treatment, indicating depressed serotonin synthesis."
5-Hydroxyindoleacetic acid,Brain 5-hydroxyindoleacetic acid (5-HIAA) levels are increased by probenecid treatment and decreased by monoamine oxidase inhibition with pargyline in vivo.,Entity: 5-Hydroxyindoleacetic acid. SMILES: O=C(O)Cc1cc2cc(O)ccc2[nH]1. Brain 5-hydroxyindoleacetic acid (5-HIAA) levels are increased by probenecid treatment and decreased by monoamine oxidase inhibition with pargyline in vivo.
Pyridoxine,Pyridoxine deficiency leads to decreased serotonin synthesis and reduced brain serotonin levels in vivo.,Entity: Pyridoxine. SMILES: Cc1ncc(CO)c(CO)c1O. Pyridoxine deficiency leads to decreased serotonin synthesis and reduced brain serotonin levels in vivo.
serotonin,"Serotonin synthesis in the brain is inhibited by p-chlorophenylalanine, which can antagonize hyperthermia and behavioral stimulation induced by nialamide in mice.","Entity: serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin synthesis in the brain is inhibited by p-chlorophenylalanine, which can antagonize hyperthermia and behavioral stimulation induced by nialamide in mice."
serotonin,A serotoninergic mechanism in the hypothalamus is involved in thermoregulation in rats.,Entity: serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. A serotoninergic mechanism in the hypothalamus is involved in thermoregulation in rats.
nialamide,"Nialamide induces hyperthermia and behavioral stimulation in mice, effects that can be antagonized by p-chlorophenylalanine.","Entity: nialamide. SMILES: O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1. Nialamide induces hyperthermia and behavioral stimulation in mice, effects that can be antagonized by p-chlorophenylalanine."
p-chlorophenylalanine,p-chlorophenylalanine inhibits the synthesis of serotonin and antagonizes the effects of nialamide-induced hyperthermia and behavioral stimulation in mice.,Entity: p-chlorophenylalanine. SMILES: N[C@@H](Cc1ccc(Cl)cc1)C(=O)O. p-chlorophenylalanine inhibits the synthesis of serotonin and antagonizes the effects of nialamide-induced hyperthermia and behavioral stimulation in mice.
pyridoxine,Pyridoxine deficiency in rats is associated with decreased brain serotonin levels.,Entity: pyridoxine. SMILES: Cc1ncc(CO)c(CO)c1O. Pyridoxine deficiency in rats is associated with decreased brain serotonin levels.
norepinephrine,Norepinephrine is a catecholamine synthesized from tyrosine via hydroxylation as a rate-limiting step in monoamine biosynthesis.,Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Norepinephrine is a catecholamine synthesized from tyrosine via hydroxylation as a rate-limiting step in monoamine biosynthesis.
dihydroxyphenylalanine,Dihydroxyphenylalanine (DOPA) is a precursor in the biosynthesis of catecholamines and serotonin.,Entity: dihydroxyphenylalanine. SMILES: O=C(O)[C@H](Cc1ccccc1)N(O)O. Dihydroxyphenylalanine (DOPA) is a precursor in the biosynthesis of catecholamines and serotonin.
tryptophan,Tryptophan serves as the precursor for serotonin biosynthesis through hydroxylation.,Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan serves as the precursor for serotonin biosynthesis through hydroxylation.
5-hydroxytryptophan,5-hydroxytryptophan is a precursor in the biosynthesis of serotonin and is decarboxylated by the same enzyme that decarboxylates dihydroxyphenylalanine (DOPA).,Entity: 5-hydroxytryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O. 5-hydroxytryptophan is a precursor in the biosynthesis of serotonin and is decarboxylated by the same enzyme that decarboxylates dihydroxyphenylalanine (DOPA).
pyridoxal phosphate,Pyridoxal phosphate is the coenzyme required for the activity of aromatic amino acid decarboxylase.,Entity: pyridoxal phosphate. SMILES: Cc1ncc(COP(=O)(O)O)c(C=O)c1O. Pyridoxal phosphate is the coenzyme required for the activity of aromatic amino acid decarboxylase.
tyrosine,Tyrosine is the precursor for catecholamines such as norepinephrine and dopamine via hydroxylation as a rate-limiting step in monoamine biosynthesis.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine is the precursor for catecholamines such as norepinephrine and dopamine via hydroxylation as a rate-limiting step in monoamine biosynthesis.
dopamine,Dopamine is a catecholamine synthesized from tyrosine via hydroxylation as a rate-limiting step in monoamine biosynthesis.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine is a catecholamine synthesized from tyrosine via hydroxylation as a rate-limiting step in monoamine biosynthesis.
pyridoxine,Pyridoxine deficiency affects brain concentrations of catecholamines and serotonin by impairing the function of aromatic amino acid decarboxylase.,Entity: pyridoxine. SMILES: Cc1ncc(CO)c(CO)c1O. Pyridoxine deficiency affects brain concentrations of catecholamines and serotonin by impairing the function of aromatic amino acid decarboxylase.
serotonin,Serotonin is synthesized from tryptophan via hydroxylation as a rate-limiting step in monoamine biosynthesis.,Entity: serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin is synthesized from tryptophan via hydroxylation as a rate-limiting step in monoamine biosynthesis.
pargyline,Pargyline is a monoamine oxidase inhibitor.,Entity: pargyline. SMILES: C#CCN(C)Cc1ccccc1. Pargyline is a monoamine oxidase inhibitor.
probenecid,Probenecid is used to block the transport of 5-hydroxyindoleacetic acid (5-HIAA) from brain tissue.,Entity: probenecid. SMILES: CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1. Probenecid is used to block the transport of 5-hydroxyindoleacetic acid (5-HIAA) from brain tissue.
5-hydroxyindoleacetic acid,5-hydroxyindoleacetic acid (5-HIAA) is a monoamine metabolite whose transport from brain tissue can be blocked by probenecid.,Entity: 5-hydroxyindoleacetic acid. SMILES: O=C(O)Cc1cc2cc(O)ccc2[nH]1. 5-hydroxyindoleacetic acid (5-HIAA) is a monoamine metabolite whose transport from brain tissue can be blocked by probenecid.
procion yellow,"Procion yellow can be used as a pressure-fill solution for microelectrodes, providing a DC resistance of 20–30 M· with a tip diameter of about 0.5 µm.","Entity: procion yellow. SMILES: Cc1cc(Nc2nc(Cl)nc(Cl)n2)ccc1N=Nc1cc(S(=O)(=O)[O-])c2cccc(S(=O)(=O)[O-])c2c1.[Na+].[Na+]. Procion yellow can be used as a pressure-fill solution for microelectrodes, providing a DC resistance of 20–30 M· with a tip diameter of about 0.5 µm."
potassium chloride,"Potassium chloride (3M KCl) is used as a pressure-fill solution for microelectrodes, providing a DC resistance of 5–10 M·.","Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride (3M KCl) is used as a pressure-fill solution for microelectrodes, providing a DC resistance of 5–10 M·."
gallamine triethiodide,"Gallamine triethiodide is used as an intravenous anesthetic agent in cats, administered at a concentration of 0.4% for immobilization during experimental procedures.","Entity: gallamine triethiodide. SMILES: CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC.[I-].[I-].[I-]. Gallamine triethiodide is used as an intravenous anesthetic agent in cats, administered at a concentration of 0.4% for immobilization during experimental procedures."
Halothane,Halothane is used as an anesthetic agent in combination with oxygen and nitrous oxide during surgical procedures in rats.,Entity: Halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane is used as an anesthetic agent in combination with oxygen and nitrous oxide during surgical procedures in rats.
nitrous oxide,Nitrous oxide is used as an anesthetic agent in combination with oxygen and Halothane during surgical procedures in rats.,Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is used as an anesthetic agent in combination with oxygen and Halothane during surgical procedures in rats.
oxygen,Oxygen is used as an anesthetic agent in combination with nitrous oxide and Halothane during surgical procedures in rats.,Entity: oxygen. SMILES: [O]. Oxygen is used as an anesthetic agent in combination with nitrous oxide and Halothane during surgical procedures in rats.
6-hydroxydopamine,6-hydroxydopamine is used to lesion dopamine cell bodies in the substantia nigra of rats by stereotactic injection.,Entity: 6-hydroxydopamine. SMILES: Cl.NCCc1cc(O)c(O)cc1O. 6-hydroxydopamine is used to lesion dopamine cell bodies in the substantia nigra of rats by stereotactic injection.
ascorbic acid,Ascorbic acid is used as a component of the saline solution to dissolve 6-hydroxydopamine for stereotactic injection in rats.,Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid is used as a component of the saline solution to dissolve 6-hydroxydopamine for stereotactic injection in rats.
sodium bicarbonate,Sodium bicarbonate is used at 50 mM concentration in the washing buffer for erythrocytes prior to radiolabeling.,Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Sodium bicarbonate is used at 50 mM concentration in the washing buffer for erythrocytes prior to radiolabeling.
sodium phosphate,"Sodium phosphate is used at 5 mM concentration in both the labeling reaction stop buffer and in the phosphate-buffered saline for washing labeled cells, with pH adjusted to 7.4.","Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used at 5 mM concentration in both the labeling reaction stop buffer and in the phosphate-buffered saline for washing labeled cells, with pH adjusted to 7.4."
azophenyl-EDTA,"Azo-phenyl-EDTA • [111In3+] is used as a radiolabeling agent for erythrocytes and ghosts, enabling the incorporation of 111In3+ into cellular components.","Entity: azophenyl-EDTA. SMILES: N#[N+]c1ccc(C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O)cc1. Azo-phenyl-EDTA • [111In3+] is used as a radiolabeling agent for erythrocytes and ghosts, enabling the incorporation of 111In3+ into cellular components."
sodium chloride,Sodium chloride is used at 50 mM concentration in carbonate buffer for washing erythrocytes prior to radiolabeling.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at 50 mM concentration in carbonate buffer for washing erythrocytes prior to radiolabeling.
sodium carbonate,Sodium carbonate is included at 50 mM concentration in the washing buffer for erythrocytes during the preparation for radiolabeling.,Entity: sodium carbonate. SMILES: O=C([O-])[O-].[Na+].[Na+]. Sodium carbonate is included at 50 mM concentration in the washing buffer for erythrocytes during the preparation for radiolabeling.
NaB3H4,NaB3H4 is used to tritiate erythrocytes by incubation with 0.5 mCi NaB3H4 in phosphate-buffered saline (pH 9.0) at 0°C for 30 minutes.,Entity: NaB3H4. SMILES: [3H][B-]([3H])([3H])[3H].[Na+]. NaB3H4 is used to tritiate erythrocytes by incubation with 0.5 mCi NaB3H4 in phosphate-buffered saline (pH 9.0) at 0°C for 30 minutes.
pyridoxal phosphate,Pyridoxal phosphate is used to label erythrocytes by incubation with 0.5 mM pyridoxal phosphate in phosphate-buffered saline (pH 9.0) at 37°C for 30 minutes.,Entity: pyridoxal phosphate. SMILES: Cc1ncc(COP(=O)(O)O)c(C=O)c1O. Pyridoxal phosphate is used to label erythrocytes by incubation with 0.5 mM pyridoxal phosphate in phosphate-buffered saline (pH 9.0) at 37°C for 30 minutes.
NaBH4,NaBH4 is used to neutralize excess tritiated material in erythrocytes by adding 40 volumes of phosphate-buffered saline (pH 7.4) containing 1 mg NaBH4 after tritiation.,Entity: NaBH4. SMILES: [BH4-].[Na+]. NaBH4 is used to neutralize excess tritiated material in erythrocytes by adding 40 volumes of phosphate-buffered saline (pH 7.4) containing 1 mg NaBH4 after tritiation.
diazodiiodo-sulfanilic acid,"Diazodiiodo-sulfanilic acid is an impermeant probe containing a diazonium ion and is capable of labeling PAS-1 of intact human erythrocyte membrane, but with only slight labeling.","Entity: diazodiiodo-sulfanilic acid. SMILES: [N-]=[N+]=C1C=C(N(I)I)C=CC1S(=O)(=O)O. Diazodiiodo-sulfanilic acid is an impermeant probe containing a diazonium ion and is capable of labeling PAS-1 of intact human erythrocyte membrane, but with only slight labeling."
diazosulfanilic acid,Diazosulfanilic acid is an impermeant probe containing a diazonium ion and does not label PAS-1 of intact human erythrocyte membrane.,Entity: diazosulfanilic acid. SMILES: [N-]=[N+]=Nc1ccc(S(=O)(=O)O)cc1. Diazosulfanilic acid is an impermeant probe containing a diazonium ion and does not label PAS-1 of intact human erythrocyte membrane.
EDTA,"EDTA can chelate [111In3+] ions, but a stable complex of azo-phenyl-EDTA with [111In3+] is formed in the presence of chelex-100, which retains only free [111In3+].","Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA can chelate [111In3+] ions, but a stable complex of azo-phenyl-EDTA with [111In3+] is formed in the presence of chelex-100, which retains only free [111In3+]."
sodium bicarbonate,Sodium bicarbonate buffer at pH 6.0 can be used to complex [111In3+] ions with azo-phenyl-EDTA.,Entity: sodium bicarbonate. SMILES: O=C([O-])O.[Na+]. Sodium bicarbonate buffer at pH 6.0 can be used to complex [111In3+] ions with azo-phenyl-EDTA.
sodium citrate,A 3.8% sodium citrate/HCl buffer at pH 5.3 can be used to complex [111In3+] ions with azo-phenyl-EDTA.,Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. A 3.8% sodium citrate/HCl buffer at pH 5.3 can be used to complex [111In3+] ions with azo-phenyl-EDTA.
calcium chloride,Calcium chloride at 15 mM concentration is used to prepare platelet-rich plasma for aggregation and oxygen consumption assays.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride at 15 mM concentration is used to prepare platelet-rich plasma for aggregation and oxygen consumption assays.
sodium chloride,Sodium chloride at 0.9% concentration is used as a buffer in platelet-based assays and for washing organs in in vivo studies.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride at 0.9% concentration is used as a buffer in platelet-based assays and for washing organs in in vivo studies.
adenosine diphosphate,Adenosine diphosphate at 1 mM concentration is used to induce platelet aggregation in vitro.,Entity: adenosine diphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine diphosphate at 1 mM concentration is used to induce platelet aggregation in vitro.
glutaraldehyde,Glutaraldehyde at 3% concentration is used to fix platelets for electron microscopy.,Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde at 3% concentration is used to fix platelets for electron microscopy.
osmium tetroxide,Osmium tetroxide at 1% concentration is used as a post-fixative for fixed platelets during electron microscopy preparation.,Entity: osmium tetroxide. SMILES: O=[Os](=O)(=O)=O. Osmium tetroxide at 1% concentration is used as a post-fixative for fixed platelets during electron microscopy preparation.
ethanol,Ethanol is used for dehydration of fixed platelets during electron microscopy preparation.,Entity: ethanol. SMILES: CCO. Ethanol is used for dehydration of fixed platelets during electron microscopy preparation.
uranyl acetate,Uranyl acetate is used as a staining agent for electron microscopy of platelets.,Entity: uranyl acetate. SMILES: CC(=O)[O-].CC(=O)[O-].O=[U+2]=O. Uranyl acetate is used as a staining agent for electron microscopy of platelets.
lead citrate,Lead citrate is used as a staining agent for electron microscopy of platelets.,Entity: lead citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Pb+2].[Pb+2].[Pb+2]. Lead citrate is used as a staining agent for electron microscopy of platelets.
hemoglobin,"Hemoglobin binds to the azo-phenyl-EDTA label, with heavy labeling observed when hemoglobin is isolated from intact erythrocytes and when pH is 7.4 for 12 hours.","Entity: hemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. Hemoglobin binds to the azo-phenyl-EDTA label, with heavy labeling observed when hemoglobin is isolated from intact erythrocytes and when pH is 7.4 for 12 hours."
sodium dodecyl sulfate,Sodium dodecyl sulfate gels are commonly used to analyze the molecular weights of many common proteins.,Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate gels are commonly used to analyze the molecular weights of many common proteins.
azophenyl-EDTA,Azo-phenyl-EDTA is used at an isotonic solution concentration of 20–25 µM for platelet incubation.,Entity: azophenyl-EDTA. SMILES: N#[N+]c1ccc(C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O)cc1. Azo-phenyl-EDTA is used at an isotonic solution concentration of 20–25 µM for platelet incubation.
sodium citrate,"Sodium citrate is used as an anticoagulant in blood collection, typically at a 9:1 ratio of blood to citrate.","Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used as an anticoagulant in blood collection, typically at a 9:1 ratio of blood to citrate."
sodium chloride,Sodium chloride is used at a concentration of 0.107 M in modified Ringer solution for platelet washing.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at a concentration of 0.107 M in modified Ringer solution for platelet washing.
potassium chloride,Potassium chloride is included at a concentration of 0.004 M in modified Ringer solution for platelet washing.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is included at a concentration of 0.004 M in modified Ringer solution for platelet washing.
sodium sulfate,Sodium sulfate is present at a concentration of 0.002 M in modified Ringer solution for platelet washing.,Entity: sodium sulfate. SMILES: O=S(=O)([O-])[O-].[Na+].[Na+]. Sodium sulfate is present at a concentration of 0.002 M in modified Ringer solution for platelet washing.
glucose,Glucose is included at a concentration of 1 mg/ml in modified Ringer solution for platelet washing.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is included at a concentration of 1 mg/ml in modified Ringer solution for platelet washing.
indium,Indium-111 (α~In) is a short-half-life radioactive metal with a half-life of approximately 2.8 days.,Entity: indium. SMILES: [In]. Indium-111 (α~In) is a short-half-life radioactive metal with a half-life of approximately 2.8 days.
indium,Less than 3% of total α~In in human serum is transferred to transferrin over 168 hours at 37°C.,Entity: indium. SMILES: [In]. Less than 3% of total α~In in human serum is transferred to transferrin over 168 hours at 37°C.
EDTA,"The EDTA group has strong binding constants for many metals, such as α~In (Kd ~10⁻⁲ M) and Fe 3÷ (Kd ~10⁻⁲ M), enabling multiple labeling techniques.","Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. The EDTA group has strong binding constants for many metals, such as α~In (Kd ~10⁻⁲ M) and Fe 3÷ (Kd ~10⁻⁲ M), enabling multiple labeling techniques."
methylenebisacrylamide,"Methylenebisacrylamide is used at 0.13% or 0.20% concentration in 0.1% and 1% SDS gels, respectively, as a cross-linker in SDS-polyacrylamide gel electrophoresis.","Entity: methylenebisacrylamide. SMILES: NC(=O)C=CCC=CC(N)=O. Methylenebisacrylamide is used at 0.13% or 0.20% concentration in 0.1% and 1% SDS gels, respectively, as a cross-linker in SDS-polyacrylamide gel electrophoresis."
glutaraldehyde,"Glutaraldehyde is used to cross-link human serum albumin and creatine kinase, serving as a calibration standard in SDS-polyacrylamide gel electrophoresis.","Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used to cross-link human serum albumin and creatine kinase, serving as a calibration standard in SDS-polyacrylamide gel electrophoresis."
2-mercaptoethanol,2-mercaptoethanol is included at 100 mM concentration in the solubilizing solution for SDS-polyacrylamide gel electrophoresis to maintain reducing conditions.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is included at 100 mM concentration in the solubilizing solution for SDS-polyacrylamide gel electrophoresis to maintain reducing conditions.
acrylamide,"Acrylamide is used as a gel matrix in SDS-polyacrylamide gel electrophoresis, with concentrations ranging from 4.2% to 8.2% for SDS gels and 5.5% for 1% SDS gels.","Entity: acrylamide. SMILES: C=CC(N)=O. Acrylamide is used as a gel matrix in SDS-polyacrylamide gel electrophoresis, with concentrations ranging from 4.2% to 8.2% for SDS gels and 5.5% for 1% SDS gels."
sodium phosphate,Sodium phosphate is used as a buffer at 10 mM concentration and pH 7.0 in the solubilizing solution for SDS-polyacrylamide gel electrophoresis.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used as a buffer at 10 mM concentration and pH 7.0 in the solubilizing solution for SDS-polyacrylamide gel electrophoresis.
urea,Urea is included at 3.3 M concentration in the solubilizing solution for SDS-polyacrylamide gel electrophoresis to denature membranes or proteins.,Entity: urea. SMILES: NC(N)=O. Urea is included at 3.3 M concentration in the solubilizing solution for SDS-polyacrylamide gel electrophoresis to denature membranes or proteins.
sucrose,Sucrose is used at 10% concentration in the solubilizing solution for SDS-polyacrylamide gel electrophoresis.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used at 10% concentration in the solubilizing solution for SDS-polyacrylamide gel electrophoresis.
ammonium persulfate,Ammonium persulfate is used as a catalyst at a final concentration of 0.15% to initiate polymerization of disc gels or slab gels in SDS-polyacrylamide gel electrophoresis.,Entity: ammonium persulfate. SMILES: O=S(=O)([O-])OOS(=O)(=O)[O-].[NH4+].[NH4+]. Ammonium persulfate is used as a catalyst at a final concentration of 0.15% to initiate polymerization of disc gels or slab gels in SDS-polyacrylamide gel electrophoresis.
NaB3H4,"NaB3H4, in combination with galactose oxidase, enables high-specific incorporation of 3H into membrane proteins and lipids on the outer surface of human erythrocytes, about 150 times higher than pyridoxal phosphate-NaB3H4.","Entity: NaB3H4. SMILES: [BH4-].[Na+]. NaB3H4, in combination with galactose oxidase, enables high-specific incorporation of 3H into membrane proteins and lipids on the outer surface of human erythrocytes, about 150 times higher than pyridoxal phosphate-NaB3H4."
azophenyl-EDTA,Azo-phenyl-EDTA can chelate metals with useful physical properties and can be used as a reporter group for studies of molecular motion by perturbed angular correlations of gamma radiation and for measurement of distance by fluorescence spectroscopy.,Entity: azophenyl-EDTA. SMILES: N#[N+]c1ccc(C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O)cc1. Azo-phenyl-EDTA can chelate metals with useful physical properties and can be used as a reporter group for studies of molecular motion by perturbed angular correlations of gamma radiation and for measurement of distance by fluorescence spectroscopy.
pyridoxal phosphate,Pyridoxal phosphate is a highly specific probe that reacts only with amino groups of proteins.,Entity: pyridoxal phosphate. SMILES: Cc1ncc(COP(=O)(O)O)c(C=O)c1O. Pyridoxal phosphate is a highly specific probe that reacts only with amino groups of proteins.
tyrosine,Tyrosine contains an amino group that can react with azo-phenyl-EDTA • [~l~Ina+] under certain conditions.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine contains an amino group that can react with azo-phenyl-EDTA • [~l~Ina+] under certain conditions.
histidine,Histidine contains an amino group that can react with azo-phenyl-EDTA • [~l~Ina+] under certain conditions.,Entity: histidine. SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O. Histidine contains an amino group that can react with azo-phenyl-EDTA • [~l~Ina+] under certain conditions.
ADP,"ADP induces aggregation of platelets in platelet-poor plasma, and labeled platelets exhibit the same rate and extent of aggregation as unlabeled platelets.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP induces aggregation of platelets in platelet-poor plasma, and labeled platelets exhibit the same rate and extent of aggregation as unlabeled platelets."
oxygen,"Labeled platelets show reduced oxygen uptake activity, with a rate of oxygen consumption that is 62% of that of unlabeled platelets.","Entity: oxygen. SMILES: [O]. Labeled platelets show reduced oxygen uptake activity, with a rate of oxygen consumption that is 62% of that of unlabeled platelets."
dimethylsulfoxide,"Dimethylsulfoxide is used in combination with 2,5-diphenyloxazole for treatment of dried slab gels prior to vacuum drying and subsequent film densitometry.","Entity: dimethylsulfoxide. SMILES: CS(C)=O. Dimethylsulfoxide is used in combination with 2,5-diphenyloxazole for treatment of dried slab gels prior to vacuum drying and subsequent film densitometry."
"2,5-diphenyloxazole","2,5-diphenyloxazole is used in combination with dimethylsulfoxide for treatment of dried slab gels prior to vacuum drying and subsequent film densitometry.","Entity: 2,5-diphenyloxazole. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. 2,5-diphenyloxazole is used in combination with dimethylsulfoxide for treatment of dried slab gels prior to vacuum drying and subsequent film densitometry."
pyridoxal phosphate,"Pyridoxal phosphate, when used as a radioactive label in combination with NaB3H4, labels human erythrocyte proteins including band III (96 000 daltons), PAS-1 (26 000 daltons), PAS-2 (52 000 daltons), and PAS-3 (30 000 daltons), as detected by fluorography.","Entity: pyridoxal phosphate. SMILES: Cc1ncc(COP(=O)(O)O)c(C=O)c1O. Pyridoxal phosphate, when used as a radioactive label in combination with NaB3H4, labels human erythrocyte proteins including band III (96 000 daltons), PAS-1 (26 000 daltons), PAS-2 (52 000 daltons), and PAS-3 (30 000 daltons), as detected by fluorography."
galactose,"Galactose, when used as a radioactive label in combination with NaB3H4, labels human erythrocyte membranes, with a band of about 26 000 daltons detectable after 15 days of fluorogram exposure.","Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose, when used as a radioactive label in combination with NaB3H4, labels human erythrocyte membranes, with a band of about 26 000 daltons detectable after 15 days of fluorogram exposure."
NaB3H4,"NaB3H4 is used as a reducing agent for labeling erythrocytes with galactose oxidase, with 0.5 mCi NaB3H4 applied to 1.5 ml of 30% cell suspension for 30 minutes at room temperature.","Entity: NaB3H4. SMILES: [BH4-].[Na+]. NaB3H4 is used as a reducing agent for labeling erythrocytes with galactose oxidase, with 0.5 mCi NaB3H4 applied to 1.5 ml of 30% cell suspension for 30 minutes at room temperature."
EDTA,EDTA is used in the form of azo-phenyl-EDTA • [111In3+] for labeling erythrocytes.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used in the form of azo-phenyl-EDTA • [111In3+] for labeling erythrocytes.
hemoglobin,"Hemoglobin can be labeled with azo-phenyl-EDTA•[111In3+] by reacting at pH 9.8 for 15 min or at pH 7.4 for 12 h, with labeling stopped by column chromatography and removal of excess reagent by dialysis.","Entity: hemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. Hemoglobin can be labeled with azo-phenyl-EDTA•[111In3+] by reacting at pH 9.8 for 15 min or at pH 7.4 for 12 h, with labeling stopped by column chromatography and removal of excess reagent by dialysis."
sodium citrate,Sodium citrate is used as an anticoagulant in blood collection from normal donors or rabbits.,Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used as an anticoagulant in blood collection from normal donors or rabbits.
naloxone hydrochloride,Naloxone hydrochloride is administered at a dose of 1 mg/kg intraperitoneally to reverse opioid-induced effects in animal studies.,Entity: naloxone hydrochloride. SMILES: C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl. Naloxone hydrochloride is administered at a dose of 1 mg/kg intraperitoneally to reverse opioid-induced effects in animal studies.
morphine sulfate,Morphine sulfate is administered intraperitoneally at a dose of 10 mg/kg in a 1 ml/kg volume to induce opioid effects in animal studies.,Entity: morphine sulfate. SMILES: CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O=S(=O)(O)O. Morphine sulfate is administered intraperitoneally at a dose of 10 mg/kg in a 1 ml/kg volume to induce opioid effects in animal studies.
Morphine,"Morphine exerts its effects in the brain by acting on central neuroanatomical sites, with the caudate nucleus showing a greater affinity for opiates than other sites.","Entity: Morphine. SMILES: CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5. Morphine exerts its effects in the brain by acting on central neuroanatomical sites, with the caudate nucleus showing a greater affinity for opiates than other sites."
Morphine,"Injection of morphine into the caudate nucleus causes hyperalgesia and induces stereotyped, circular leaps (violet activity).","Entity: Morphine. SMILES: CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5. Injection of morphine into the caudate nucleus causes hyperalgesia and induces stereotyped, circular leaps (violet activity)."
Morphine,"Morphine is suggested to have a primary action on nigrastriatal neurons, which contain catecholamines.","Entity: Morphine. SMILES: CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5. Morphine is suggested to have a primary action on nigrastriatal neurons, which contain catecholamines."
Morphine,"Morphine modifies the effects of electrical stimulation or lesions in the ventromedial hypothalamus on adrenocorticotropin (ACTH), growth hormone, thyroid-stimulating hormone, and gonadotrophins.","Entity: Morphine. SMILES: CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5. Morphine modifies the effects of electrical stimulation or lesions in the ventromedial hypothalamus on adrenocorticotropin (ACTH), growth hormone, thyroid-stimulating hormone, and gonadotrophins."
Dopamine,Dopamine is synthesized in the substantia nigra and is present in catecholamine-containing neuronal pathways such as the nigrastriatal system.,Entity: Dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine is synthesized in the substantia nigra and is present in catecholamine-containing neuronal pathways such as the nigrastriatal system.
Naloxone,Naloxone treatment in opioid-dependent animals is associated with a sudden elevation of dopamine levels in the caudate nucleus.,Entity: Naloxone. SMILES: C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5. Naloxone treatment in opioid-dependent animals is associated with a sudden elevation of dopamine levels in the caudate nucleus.
Growth hormone,"The ventromedial hypothalamus regulates the secretion of growth hormone, and its stimulation or lesion can alter growth hormone levels.","Entity: Growth hormone. SMILES: CC(C)C[C@@H]1NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(=O)N2)NC(=O)[C@H](CSS[C@@H](C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)O)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC3=O)NC1=O. The ventromedial hypothalamus regulates the secretion of growth hormone, and its stimulation or lesion can alter growth hormone levels."
noradrenaline,Noradrenaline is a monoamine whose nerve terminals in the cerebral cortex can undergo permanent denervation following treatment with 6-hydroxydopamine.,Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline is a monoamine whose nerve terminals in the cerebral cortex can undergo permanent denervation following treatment with 6-hydroxydopamine.
5-hydroxytryptamine,"5-hydroxytryptamine is a monoamine whose nerve terminals in the cerebral cortex can undergo permanent denervation following treatment with 5,7-dihydroxytryptamine.","Entity: 5-hydroxytryptamine. SMILES: NCCc1c[nH]c2ccc(O)cc12. 5-hydroxytryptamine is a monoamine whose nerve terminals in the cerebral cortex can undergo permanent denervation following treatment with 5,7-dihydroxytryptamine."
6-hydroxydopamine,"6-hydroxydopamine, when administered systemically or intracranially, induces a marked reduction in [SH] noradrenaline uptake in the cerebral cortex, with reductions ranging from 70 to 90% depending on the time interval.","Entity: 6-hydroxydopamine. SMILES: NCCc1cc(O)c(O)cc1O. 6-hydroxydopamine, when administered systemically or intracranially, induces a marked reduction in [SH] noradrenaline uptake in the cerebral cortex, with reductions ranging from 70 to 90% depending on the time interval."
"5,7-dihydroxytryptamine","5,7-dihydroxytryptamine treatment selectively affects 5-hydroxytryptamine neurons, resulting in reduced 5-[3H] hydroxytryptamine uptake in the cerebral cortex.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. 5,7-dihydroxytryptamine treatment selectively affects 5-hydroxytryptamine neurons, resulting in reduced 5-[3H] hydroxytryptamine uptake in the cerebral cortex."
6-hydroxydopamine,6-hydroxydopamine is a monoamine neurotoxin that can be used to induce selective degeneration of monoamine neurons in newborn rats.,Entity: 6-hydroxydopamine. SMILES: NCCc1cc(O)c(O)cc1O. 6-hydroxydopamine is a monoamine neurotoxin that can be used to induce selective degeneration of monoamine neurons in newborn rats.
"5,7-dihydroxytryptamine","5,7-dihydroxytryptamine is a monoamine neurotoxin that can be used to induce selective degeneration of monoamine neurons in newborn rats.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. 5,7-dihydroxytryptamine is a monoamine neurotoxin that can be used to induce selective degeneration of monoamine neurons in newborn rats."
chloroform,Chloroform is used as an anesthetic agent for cervical dislocation in rats during brain dissection.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as an anesthetic agent for cervical dislocation in rats during brain dissection.
6-hydroxydopamine,6-hydroxydopamine is a monoamine neurotoxin that can be administered subcutaneously at 100 µg/kg or intracisternally at 2 X 100 mg/kg in rats to induce neurotoxicity.,Entity: 6-hydroxydopamine. SMILES: NCCc1cc(O)c(O)cc1O. 6-hydroxydopamine is a monoamine neurotoxin that can be administered subcutaneously at 100 µg/kg or intracisternally at 2 X 100 mg/kg in rats to induce neurotoxicity.
"5,7-dihydroxytryptamine","5,7-dihydroxytryptamine is administered subcutaneously at 100 mg/kg in rats as a potential neuroprotective agent.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. 5,7-dihydroxytryptamine is administered subcutaneously at 100 mg/kg in rats as a potential neuroprotective agent."
desipramine,"Desipramine is used as an uptake blocker in rats, administered subcutaneously at 20 mg/kg 30 minutes before administration of monoamine neurotoxins.","Entity: desipramine. SMILES: CNCCCN1c2ccccc2CCc2ccccc21. Desipramine is used as an uptake blocker in rats, administered subcutaneously at 20 mg/kg 30 minutes before administration of monoamine neurotoxins."
sodium chloride,Sodium chloride (0.9% NaCl) is used as a vehicle for subcutaneous and intracisternial administration of drugs and neurotoxins in rats.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride (0.9% NaCl) is used as a vehicle for subcutaneous and intracisternial administration of drugs and neurotoxins in rats.
adrenaline,"The activity of phenylethanolamine N-methyltransferase, a marker of adrenaline neurons, develops normally in the brain independent of changes in noradrenaline neurons induced by 6-hydroxydopamine.","Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. The activity of phenylethanolamine N-methyltransferase, a marker of adrenaline neurons, develops normally in the brain independent of changes in noradrenaline neurons induced by 6-hydroxydopamine."
6-hydroxydopamine,6-hydroxydopamine is a monoamine neurotoxin that selectively induces degeneration of catecholamine neurons and causes permanent denervation of monoamine nerve terminals in the cerebral cortex and neostriatum of rats.,Entity: 6-hydroxydopamine. SMILES: NCCc1cc(O)c(O)cc1O. 6-hydroxydopamine is a monoamine neurotoxin that selectively induces degeneration of catecholamine neurons and causes permanent denervation of monoamine nerve terminals in the cerebral cortex and neostriatum of rats.
6-hydroxydopamine,Systemic administration of 6-hydroxydopamine at birth in rats results in a marked and permanent reduction in noradrenaline uptake in the cerebral cortex and a considerable increase in noradrenaline uptake in the pons-medulla.,Entity: 6-hydroxydopamine. SMILES: NCCc1cc(O)c(O)cc1O. Systemic administration of 6-hydroxydopamine at birth in rats results in a marked and permanent reduction in noradrenaline uptake in the cerebral cortex and a considerable increase in noradrenaline uptake in the pons-medulla.
6-hydroxydopamine,6-hydroxydopamine treatment does not affect the uptake of 5-hydroxytryptamine or dopamine in brain tissue.,Entity: 6-hydroxydopamine. SMILES: NCCc1cc(O)c(O)cc1O. 6-hydroxydopamine treatment does not affect the uptake of 5-hydroxytryptamine or dopamine in brain tissue.
"5,7-dihydroxytryptamine","5,7-dihydroxytryptamine is a monoamine neurotoxin that preferentially targets 5-hydroxytryptamine neurons and induces a 'pruning effect' leading to reduced 5-hydroxytryptamine nerve density in the brain.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. 5,7-dihydroxytryptamine is a monoamine neurotoxin that preferentially targets 5-hydroxytryptamine neurons and induces a 'pruning effect' leading to reduced 5-hydroxytryptamine nerve density in the brain."
noradrenaline,Noradrenaline is a catecholamine whose nerve terminals in the cerebral cortex show a marked and permanent reduction in uptake following neonatal 6-hydroxydopamine treatment in rats.,Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline is a catecholamine whose nerve terminals in the cerebral cortex show a marked and permanent reduction in uptake following neonatal 6-hydroxydopamine treatment in rats.
5-hydroxytryptamine,"5-hydroxytryptamine is a monoamine whose nerve terminals in the brain undergo reduced density after neonatal 5,7-dihydroxytryptamine treatment, due to a 'pruning effect.'","Entity: 5-hydroxytryptamine. SMILES: NCCc1c[nH]c2ccc(O)cc12. 5-hydroxytryptamine is a monoamine whose nerve terminals in the brain undergo reduced density after neonatal 5,7-dihydroxytryptamine treatment, due to a 'pruning effect.'."
dopamine,"Dopamine nerve terminals in the brain are not affected by either 6-hydroxydopamine or 5,7-dihydroxytryptamine treatment in terms of their uptake.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine nerve terminals in the brain are not affected by either 6-hydroxydopamine or 5,7-dihydroxytryptamine treatment in terms of their uptake."
5-hydroxytryptamine,5-hydroxytryptamine uptake can be almost completely blocked in nerve terminals by including 50 pM chlorimipramine in the incubation medium.,Entity: 5-hydroxytryptamine. SMILES: NCCc1c[nH]c2ccc(O)cc12. 5-hydroxytryptamine uptake can be almost completely blocked in nerve terminals by including 50 pM chlorimipramine in the incubation medium.
6-hydroxytryptamine,Uptake-accumulation of 6-hydroxytryptamine can be almost completely blocked by 50 pM chlorimipramine in the incubation medium.,Entity: 6-hydroxytryptamine. SMILES: NCCc1c[nH]c2cc(O)ccc12. Uptake-accumulation of 6-hydroxytryptamine can be almost completely blocked by 50 pM chlorimipramine in the incubation medium.
5-hydroxytryptamine,5-hydroxytryptamine (serotonin) nerve terminal networks develop normally even when the noradrenaline network is markedly altered.,Entity: 5-hydroxytryptamine. SMILES: NCCc1c[nH]c2ccc(O)cc12. 5-hydroxytryptamine (serotonin) nerve terminal networks develop normally even when the noradrenaline network is markedly altered.
"5,7-dihydroxytryptamine","5,7-dihydroxytryptamine studies indicate little or no interaction between growing monoamine nerves during postnatal development.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. 5,7-dihydroxytryptamine studies indicate little or no interaction between growing monoamine nerves during postnatal development."
desipramine,"Desipramine is used to assess desipramine-resistant [3H]noradrenaline uptake, which reflects uptake in dopamine nerve terminals.","Entity: desipramine. SMILES: CNCCCN1c2ccccc2CCc2ccccc21. Desipramine is used to assess desipramine-resistant [3H]noradrenaline uptake, which reflects uptake in dopamine nerve terminals."
dopamine,Dopamine nerve terminals are identified by desipramine-resistant [3H]noradrenaline uptake.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine nerve terminals are identified by desipramine-resistant [3H]noradrenaline uptake.
noradrenaline,Noradrenaline nerve terminals are distinguished from dopamine nerve terminals by [3H]noradrenaline uptake patterns.,Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline nerve terminals are distinguished from dopamine nerve terminals by [3H]noradrenaline uptake patterns.
6-hydroxydopamine,"6-hydroxydopamine induces changes in [3H] noradrenaline uptake in noradrenaline nerve terminals of the cerebral cortex and pons-medulla, without affecting [3H] 5-hydroxytryptamine uptake or desipramine-resistant [3H]noradrenaline uptake, which is indicative of dopamine nerve terminals.","Entity: 6-hydroxydopamine. SMILES: NCCc1cc(O)c(O)cc1O. 6-hydroxydopamine induces changes in [3H] noradrenaline uptake in noradrenaline nerve terminals of the cerebral cortex and pons-medulla, without affecting [3H] 5-hydroxytryptamine uptake or desipramine-resistant [3H]noradrenaline uptake, which is indicative of dopamine nerve terminals."
6-hydroxydopamine,"6-hydroxydopamine is used to induce changes in the density of monoamine nerve terminals, which can be quantitatively measured by assessing alterations in [3H] monoamine uptake.","Entity: 6-hydroxydopamine. SMILES: NCCc1cc(O)c(O)cc1O. 6-hydroxydopamine is used to induce changes in the density of monoamine nerve terminals, which can be quantitatively measured by assessing alterations in [3H] monoamine uptake."
"5,7-dihydroxytryptamine","5,7-dihydroxytryptamine is used to induce changes in the density of monoamine nerve terminals, which can be quantitatively measured by assessing alterations in [3H] monoamine uptake.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. 5,7-dihydroxytryptamine is used to induce changes in the density of monoamine nerve terminals, which can be quantitatively measured by assessing alterations in [3H] monoamine uptake."
6-hydroxydopamine,The neurotoxic actions of 6-hydroxydopamine are completed within 2 to 6 hours after administration to newborn rats.,Entity: 6-hydroxydopamine. SMILES: NCCc1cc(O)c(O)cc1O. The neurotoxic actions of 6-hydroxydopamine are completed within 2 to 6 hours after administration to newborn rats.
"5,7-dihydroxytryptamine","The neurotoxic actions of 5,7-dihydroxytryptamine are completed within 2 to 6 hours after administration to newborn rats.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. The neurotoxic actions of 5,7-dihydroxytryptamine are completed within 2 to 6 hours after administration to newborn rats."
dopamine,Dopamine content in brain tissue can be quantified using a radioenzymatic assay and expressed as nanograms per gram wet weight of tissue.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine content in brain tissue can be quantified using a radioenzymatic assay and expressed as nanograms per gram wet weight of tissue.
noradrenaline,Noradrenaline content in brain tissue can be quantified using a radioenzymatic assay and expressed as nanograms per gram wet weight of tissue.,Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline content in brain tissue can be quantified using a radioenzymatic assay and expressed as nanograms per gram wet weight of tissue.
perchloric acid,Perchloric acid at 0.1 M concentration is used as a cold homogenizing medium for brain tissue in catecholamine assays.,Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid at 0.1 M concentration is used as a cold homogenizing medium for brain tissue in catecholamine assays.
desipramine,"Desipramine has preferential action on the uptake mechanism in noradrenaline neurons and can counteract the effect of 5,7-dihydroxytryptamine on [3H]noradrenaline uptake in the cerebral cortex.","Entity: desipramine. SMILES: CNCCCN1c2ccccc2CCc2ccccc21. Desipramine has preferential action on the uptake mechanism in noradrenaline neurons and can counteract the effect of 5,7-dihydroxytryptamine on [3H]noradrenaline uptake in the cerebral cortex."
noradrenaline,Desipramine has preferential action on the uptake mechanism in noradrenaline neurons.,Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Desipramine has preferential action on the uptake mechanism in noradrenaline neurons.
"5,7-dihydroxytryptamine","5,7-dihydroxytryptamine, when administered systemically at 100 mg/kg subcutaneously to newborn rats, selectively reduces 5-[3H]hydroxytryptamine uptake in the cerebral cortex by approximately 50%.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. 5,7-dihydroxytryptamine, when administered systemically at 100 mg/kg subcutaneously to newborn rats, selectively reduces 5-[3H]hydroxytryptamine uptake in the cerebral cortex by approximately 50%."
"5,7-dihydroxytryptamine","5,7-dihydroxytryptamine increases 5-[3H]hydroxytryptamine uptake by about 50% in the pons-medulla of rats.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. 5,7-dihydroxytryptamine increases 5-[3H]hydroxytryptamine uptake by about 50% in the pons-medulla of rats."
"5,7-dihydroxytryptamine","The effects of 5,7-dihydroxytryptamine on 5-hydroxytryptamine neurons are analogous to those of 6-hydroxydopamine on [SH]noradrenaline uptake.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. The effects of 5,7-dihydroxytryptamine on 5-hydroxytryptamine neurons are analogous to those of 6-hydroxydopamine on [SH]noradrenaline uptake."
"5,7-dihydroxytryptamine","5,7-dihydroxytryptamine treatment produces a small reduction in [3H]noradrenaline uptake in the cerebral cortex of rats, which can be counteracted by desipramine pretreatment.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. 5,7-dihydroxytryptamine treatment produces a small reduction in [3H]noradrenaline uptake in the cerebral cortex of rats, which can be counteracted by desipramine pretreatment."
"5,7-dihydroxytryptamine","The action of 5,7-dihydroxytryptamine is selective for 5-hydroxytryptamine neurons in the presence of desipramine, which has preferential action on the uptake mechanism in noradrenaline neurons.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. The action of 5,7-dihydroxytryptamine is selective for 5-hydroxytryptamine neurons in the presence of desipramine, which has preferential action on the uptake mechanism in noradrenaline neurons."
"5,7-dihydroxytryptamine","Neonatal 5,7-dihydroxytryptamine treatment causes no or only minor changes in [SH]amine uptake in the neostriatum of rats.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. Neonatal 5,7-dihydroxytryptamine treatment causes no or only minor changes in [SH]amine uptake in the neostriatum of rats."
6-hydroxydopamine,"6-hydroxydopamine increases [SH]noradrenaline uptake, with effects analogous to those of 5,7-dihydroxytryptamine on 5-hydroxytryptamine neurons.","Entity: 6-hydroxydopamine. SMILES: NCCc1cc(O)c(O)cc1O. 6-hydroxydopamine increases [SH]noradrenaline uptake, with effects analogous to those of 5,7-dihydroxytryptamine on 5-hydroxytryptamine neurons."
sucrose,Sucrose is used as a homogenizing agent at 0.3 M concentration and 10 w/v in brain tissue homogenization protocols.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used as a homogenizing agent at 0.3 M concentration and 10 w/v in brain tissue homogenization protocols.
pargyline,Pargyline is included at 0.01 rnM in Krebs-Ringer bicarbonate buffer as an inhibitor in in vitro monoamine uptake studies.,Entity: pargyline. SMILES: C#CCN(C)Cc1ccccc1. Pargyline is included at 0.01 rnM in Krebs-Ringer bicarbonate buffer as an inhibitor in in vitro monoamine uptake studies.
ascorbic acid,Ascorbic acid is included at 1 mM in Krebs-Ringer bicarbonate buffer as an antioxidant in in vitro monoamine uptake studies.,Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid is included at 1 mM in Krebs-Ringer bicarbonate buffer as an antioxidant in in vitro monoamine uptake studies.
ethanol,Absolute ethanol is used to extract radioactivity from synaptosome pellets in in vitro uptake assays.,Entity: ethanol. SMILES: CCO. Absolute ethanol is used to extract radioactivity from synaptosome pellets in in vitro uptake assays.
toluene,Toluene is used as an internal standard for quenching radioactivity in liquid scintillation spectrometry assays.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as an internal standard for quenching radioactivity in liquid scintillation spectrometry assays.
ammonia,"Ammonia is supplied to experimental systems as NH4Cl or (NH4)2SO4, with concentrations ranging from 1 to 75 or 100 µg/ml NH3 in 50 ml of seawater.","Entity: ammonia. SMILES: N. Ammonia is supplied to experimental systems as NH4Cl or (NH4)2SO4, with concentrations ranging from 1 to 75 or 100 µg/ml NH3 in 50 ml of seawater."
ammonium chloride,Ammonium chloride (NH4Cl) is used as a source of ammonia in experimental media at concentrations ranging from 1 to 75 or 100 µg/ml NH3 in 50 ml of seawater.,Entity: ammonium chloride. SMILES: [Cl-].[NH4+]. Ammonium chloride (NH4Cl) is used as a source of ammonia in experimental media at concentrations ranging from 1 to 75 or 100 µg/ml NH3 in 50 ml of seawater.
ammonium sulfate,Ammonium sulfate ((NH4)2SO4) is used as a source of ammonia in some experimental studies to assess its effects compared to ammonium chloride.,Entity: ammonium sulfate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Ammonium sulfate ((NH4)2SO4) is used as a source of ammonia in some experimental studies to assess its effects compared to ammonium chloride.
ammonia,"There is a direct linear correlation between the concentration of ambient ammonia and the concentration of blood ammonia in aquatic animals, including snails, when exposed to varying ammonia concentrations.","Entity: ammonia. SMILES: N. There is a direct linear correlation between the concentration of ambient ammonia and the concentration of blood ammonia in aquatic animals, including snails, when exposed to varying ammonia concentrations."
ammonia,Snails such as B. ylabrota can take up ammonia from aqueous media in both its dissociated (NH3) and undissociated (NH4+) forms.,Entity: ammonia. SMILES: N. Snails such as B. ylabrota can take up ammonia from aqueous media in both its dissociated (NH3) and undissociated (NH4+) forms.
ammonia,"Ammonia can be taken up by B. ylabrota from borate-buffered media (pH 9.0) and SSW(l) media (pH 8.3–8.5) by passive diffusion, as these pH values are higher than the pH of molluscan pallial fluid (7.7–8.4) and blood (7.4–7.6).","Entity: ammonia. SMILES: N. Ammonia can be taken up by B. ylabrota from borate-buffered media (pH 9.0) and SSW(l) media (pH 8.3–8.5) by passive diffusion, as these pH values are higher than the pH of molluscan pallial fluid (7.7–8.4) and blood (7.4–7.6)."
ammonia,"Ammonia can be taken up by B. ylabrota from tris-buffered media (pH 7.0) and SS·Y(2) media (<7.0) by passive diffusion, as these pH values are lower than the pH of molluscan pallial fluid and blood.","Entity: ammonia. SMILES: N. Ammonia can be taken up by B. ylabrota from tris-buffered media (pH 7.0) and SS·Y(2) media (<7.0) by passive diffusion, as these pH values are lower than the pH of molluscan pallial fluid and blood."
ammonia,"B. ylabrota may be able to take up ammonia from tris-buffered and SS·Y(2) media by active transport, even though the pH is unfavorable for passive diffusion.","Entity: ammonia. SMILES: N. B. ylabrota may be able to take up ammonia from tris-buffered and SS·Y(2) media by active transport, even though the pH is unfavorable for passive diffusion."
ammonia,"Ammonia at concentrations of 1 µg/ml, 10 µg/ml, 25 µg/ml, 50 µg/ml, 75 µg/ml, and 100 µg/ml can significantly enhance or inhibit the growth of snails in specific experimental conditions.","Entity: ammonia. SMILES: N. Ammonia at concentrations of 1 µg/ml, 10 µg/ml, 25 µg/ml, 50 µg/ml, 75 µg/ml, and 100 µg/ml can significantly enhance or inhibit the growth of snails in specific experimental conditions."
ammonia,"In buffered media (tris or borate), the addition of ammonia at concentrations of 1, 10, 25, 50, 75, and 100 µg/ml leads to statistically significant growth reduction in snails, with 6.2%, 56.2%, 68.7%, 68.7%, 93.7%, and 18.7% of treatments showing significant growth reduction, respectively, when buffered with tris or borate.","Entity: ammonia. SMILES: N. In buffered media (tris or borate), the addition of ammonia at concentrations of 1, 10, 25, 50, 75, and 100 µg/ml leads to statistically significant growth reduction in snails, with 6.2%, 56.2%, 68.7%, 68.7%, 93.7%, and 18.7% of treatments showing significant growth reduction, respectively, when buffered with tris or borate."
ammonium chloride,Addition of ammonia as ammonium chloride at 10 µg/ml in chloride medium causes statistically significant growth enhancement in snails.,Entity: ammonium chloride. SMILES: [Cl-].[NH4+]. Addition of ammonia as ammonium chloride at 10 µg/ml in chloride medium causes statistically significant growth enhancement in snails.
ammonium sulfate,"Addition of ammonia as ammonium sulfate at 1 µg/ml, 2 µg/ml, and 50 µg/ml in SSW leads to statistically significant growth enhancement in snails.","Entity: ammonium sulfate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Addition of ammonia as ammonium sulfate at 1 µg/ml, 2 µg/ml, and 50 µg/ml in SSW leads to statistically significant growth enhancement in snails."
bicarbonate,"In SS·Y(1) media, which are buffered with bicarbonate, the percentage of treatments showing statistically significant growth reduction when exposed to ammonia is higher than in SS·Y(2) media with chloride as the dominant anion.","Entity: bicarbonate. SMILES: O=C([O-])O. In SS·Y(1) media, which are buffered with bicarbonate, the percentage of treatments showing statistically significant growth reduction when exposed to ammonia is higher than in SS·Y(2) media with chloride as the dominant anion."
borate,"When buffered with borate, the addition of ammonia at 1, 10, 25, 50, 75, and 100 µg/ml in snail experiments results in 6.2%, 56.2%, 68.7%, 68.7%, 93.7%, and 18.7% statistically significant growth reduction, respectively.","Entity: borate. SMILES: [O-]B([O-])[O-]. When buffered with borate, the addition of ammonia at 1, 10, 25, 50, 75, and 100 µg/ml in snail experiments results in 6.2%, 56.2%, 68.7%, 68.7%, 93.7%, and 18.7% statistically significant growth reduction, respectively."
chloride,"In SS·Y(2) media, which are buffered with chloride, the percentage of treatments showing statistically significant growth reduction when exposed to ammonia is lower than in SS·Y(1) media with bicarbonate as the dominant anion.","Entity: chloride. SMILES: [Cl-]. In SS·Y(2) media, which are buffered with chloride, the percentage of treatments showing statistically significant growth reduction when exposed to ammonia is lower than in SS·Y(1) media with bicarbonate as the dominant anion."
ammonia,Ammonia concentration in SSW(l) is associated with a progressive decrease in pH over the sixth and ninth days.,Entity: ammonia. SMILES: N. Ammonia concentration in SSW(l) is associated with a progressive decrease in pH over the sixth and ninth days.
urea,"Urea synthesis in snails is suggested to help control the release of ammonia, with urease catalyzing the breakdown of urea.","Entity: urea. SMILES: NC(N)=O. Urea synthesis in snails is suggested to help control the release of ammonia, with urease catalyzing the breakdown of urea."
ammonium chloride,0.3 µg/ml NH4Cl inhibits the growth of carp.,Entity: ammonium chloride. SMILES: [Cl-].[NH4+]. 0.3 µg/ml NH4Cl inhibits the growth of carp.
ammonium hydroxide,Concentrations of NH4OH ranging from 0.3–0.7 mg/ml (0.006–0.018 µg/ml NH3) cause hyperplasia in the gill filaments of salmon parr.,Entity: ammonium hydroxide. SMILES: [NH4+].[OH-]. Concentrations of NH4OH ranging from 0.3–0.7 mg/ml (0.006–0.018 µg/ml NH3) cause hyperplasia in the gill filaments of salmon parr.
glutamine,"Glutamine is involved in the initial steps of urea synthesis from ammonia, either as NH4+ or as a component of glutamine and HCO3³.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine is involved in the initial steps of urea synthesis from ammonia, either as NH4+ or as a component of glutamine and HCO3³."
ammonia,"Ammonia is physiologically important to snails, and they may be able to control its release by synthesizing urea and breaking it down by urease.","Entity: ammonia. SMILES: N. Ammonia is physiologically important to snails, and they may be able to control its release by synthesizing urea and breaking it down by urease."
ammonia,Biomphalaria glabrata can withstand higher levels of ambient ammonia than many other aquatic organisms.,Entity: ammonia. SMILES: N. Biomphalaria glabrata can withstand higher levels of ambient ammonia than many other aquatic organisms.
ammonia,"Molluscs generally have higher concentrations of ammonia in their blood compared with other organisms, with species of Helix, Otala, Anodonta, and Sepia having 7.20, 3.6, 0.51–0.71, and 28–48 µg/ml, respectively, compared to <1.0 µg/ml in amphibia and 0.1–0.3 µg/ml in mammals.","Entity: ammonia. SMILES: N. Molluscs generally have higher concentrations of ammonia in their blood compared with other organisms, with species of Helix, Otala, Anodonta, and Sepia having 7.20, 3.6, 0.51–0.71, and 28–48 µg/ml, respectively, compared to <1.0 µg/ml in amphibia and 0.1–0.3 µg/ml in mammals."
borate,"Borate buffer is used as a buffering agent in experimental media for aquatic organisms, but in this study, borate buffer treatment led to high mortality and severely impaired growth rates in snails, with nearly 100% mortality in 25 and 50 µg/ml borate buffer treatments within three days.","Entity: borate. SMILES: [O-]B([O-])[O-]. Borate buffer is used as a buffering agent in experimental media for aquatic organisms, but in this study, borate buffer treatment led to high mortality and severely impaired growth rates in snails, with nearly 100% mortality in 25 and 50 µg/ml borate buffer treatments within three days."
ammonia,The relative amounts of ionized and free ammonia in solution depend on pH.,Entity: ammonia. SMILES: N. The relative amounts of ionized and free ammonia in solution depend on pH.
borate,Borate buffer is used to achieve a pH of 9.0 in experimental media.,Entity: borate. SMILES: [O-]B([O-])[O-]. Borate buffer is used to achieve a pH of 9.0 in experimental media.
borate,Borate buffer has been successfully used as a buffer in perfusion fluids for invertebrates.,Entity: borate. SMILES: [O-]B([O-])[O-]. Borate buffer has been successfully used as a buffer in perfusion fluids for invertebrates.
citrate,Citrate buffer was tried but rejected for use in the described experiments due to the formation of precipitates on standing in SSW.,Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Citrate buffer was tried but rejected for use in the described experiments due to the formation of precipitates on standing in SSW.
glycine,Glycine buffer was tried but rejected for use in the described experiments due to issues such as precipitate formation in SSW.,Entity: glycine. SMILES: NCC(=O)O. Glycine buffer was tried but rejected for use in the described experiments due to issues such as precipitate formation in SSW.
iron,Iron is an ion that can be depleted in the environment and may contribute to negative feedback effects in snail populations under sub-optimal density or volume conditions.,Entity: iron. SMILES: [Fe]. Iron is an ion that can be depleted in the environment and may contribute to negative feedback effects in snail populations under sub-optimal density or volume conditions.
calcium,Calcium is an ion that can be depleted in the environment and may contribute to negative feedback effects in snail populations under sub-optimal density or volume conditions.,Entity: calcium. SMILES: [Ca]. Calcium is an ion that can be depleted in the environment and may contribute to negative feedback effects in snail populations under sub-optimal density or volume conditions.
oxygen,Oxygen is a resource that can be depleted in the environment and may contribute to negative feedback effects in snail populations under sub-optimal density or volume conditions.,Entity: oxygen. SMILES: [O]. Oxygen is a resource that can be depleted in the environment and may contribute to negative feedback effects in snail populations under sub-optimal density or volume conditions.
calcium,Calcium is included in standard snail water (SSW) at a concentration of 2.0 millimoles per liter.,Entity: calcium. SMILES: [Ca]. Calcium is included in standard snail water (SSW) at a concentration of 2.0 millimoles per liter.
sulfate,Sulfate is included in standard snail water (SSW) at a concentration of 0.13 millimoles per liter.,Entity: sulfate. SMILES: O=S(=O)([O-])[O-]. Sulfate is included in standard snail water (SSW) at a concentration of 0.13 millimoles per liter.
bicarbonate,Bicarbonate is included in standard snail water (SSW) at a concentration of 4.037 millimoles per liter.,Entity: bicarbonate. SMILES: O=C([O-])O. Bicarbonate is included in standard snail water (SSW) at a concentration of 4.037 millimoles per liter.
nitrate,Nitrate is included in standard snail water (SSW) at a concentration of 0.049 millimoles per liter.,Entity: nitrate. SMILES: O=[N+]([O-])[O-]. Nitrate is included in standard snail water (SSW) at a concentration of 0.049 millimoles per liter.
magnesium,Magnesium is included in standard snail water (SSW) at a concentration of 0.13 millimoles per liter.,Entity: magnesium. SMILES: [Mg]. Magnesium is included in standard snail water (SSW) at a concentration of 0.13 millimoles per liter.
chloride,Chloride is included in standard snail water (SSW) at a concentration of 0.63 millimoles per liter (SSW(1)) and 4.0 millimoles per liter (SSW(2)) per liter.,Entity: chloride. SMILES: [Cl-]. Chloride is included in standard snail water (SSW) at a concentration of 0.63 millimoles per liter (SSW(1)) and 4.0 millimoles per liter (SSW(2)) per liter.
sodium,Sodium is included in standard snail water (SSW) at a concentration of 0.63 millimoles per liter.,Entity: sodium. SMILES: [Na]. Sodium is included in standard snail water (SSW) at a concentration of 0.63 millimoles per liter.
potassium,Potassium is included in standard snail water (SSW) at a concentration of 0.086 millimoles per liter.,Entity: potassium. SMILES: [K]. Potassium is included in standard snail water (SSW) at a concentration of 0.086 millimoles per liter.
ammonia,Ammonia toxicity in Biomphalaria glabrata increases with higher pH in the water medium.,Entity: ammonia. SMILES: N. Ammonia toxicity in Biomphalaria glabrata increases with higher pH in the water medium.
ammonia,"Biomphalaria glabrata can utilize ammonia as a nitrogen source when required, and its growth rate is enhanced by increasing ammonia concentration up to critical thresholds, beyond which growth is inhibited.","Entity: ammonia. SMILES: N. Biomphalaria glabrata can utilize ammonia as a nitrogen source when required, and its growth rate is enhanced by increasing ammonia concentration up to critical thresholds, beyond which growth is inhibited."
borate,Borate-buffered media cause a decrease in the growth rate of Biomphalaria glabrata compared to standard seawater (SSW) media.,Entity: borate. SMILES: [O-]B([O-])[O-]. Borate-buffered media cause a decrease in the growth rate of Biomphalaria glabrata compared to standard seawater (SSW) media.
ammonia,"Ammonia produced by snails in closed systems at mean concentrations of 9.3, 8.5, 13.5, and 6.8 µg/ml (after three days of conditioning by B. glabrata in 100, 300, 500, and 700 mg weight categories, respectively, with 8 snails per 200 ml SSW(l)) exerts only a weak inhibitory effect on growth under experimental conditions.","Entity: ammonia. SMILES: N. Ammonia produced by snails in closed systems at mean concentrations of 9.3, 8.5, 13.5, and 6.8 µg/ml (after three days of conditioning by B. glabrata in 100, 300, 500, and 700 mg weight categories, respectively, with 8 snails per 200 ml SSW(l)) exerts only a weak inhibitory effect on growth under experimental conditions."
ammonia,"The percentage of free ammonia in solution depends on pH, with the equation cone of free ammonia = total ammonia conc/1 + antilog (pKa - pH).","Entity: ammonia. SMILES: N. The percentage of free ammonia in solution depends on pH, with the equation cone of free ammonia = total ammonia conc/1 + antilog (pKa - pH)."
ammonia,Ammonia is a major excretory product of aquatic organisms such as snails and is also produced by bacterial decomposition.,Entity: ammonia. SMILES: N. Ammonia is a major excretory product of aquatic organisms such as snails and is also produced by bacterial decomposition.
ammonia,"Ammonia concentration in natural freshwater bodies is typically low due to rapid oxidation by bacteria, assimilation by plants, or loss by diffusion into the air.","Entity: ammonia. SMILES: N. Ammonia concentration in natural freshwater bodies is typically low due to rapid oxidation by bacteria, assimilation by plants, or loss by diffusion into the air."
ammonia,"In African lake surface waters, the distribution of ammonia nitrogen is probably less than 0.040 µg/ml, while higher concentrations (0.168–0.544 µg/ml NH3N) can occur in deoxygenated, lower layers of stratified lakes.","Entity: ammonia. SMILES: N. In African lake surface waters, the distribution of ammonia nitrogen is probably less than 0.040 µg/ml, while higher concentrations (0.168–0.544 µg/ml NH3N) can occur in deoxygenated, lower layers of stratified lakes."
ammonia,Ammonia may facilitate the deposition of calcium carbonate by participating in the reaction NH3 + HC(V+Ca2+) → CaCO3 + NH4+.,Entity: ammonia. SMILES: N. Ammonia may facilitate the deposition of calcium carbonate by participating in the reaction NH3 + HC(V+Ca2+) → CaCO3 + NH4+.
calcium carbonate,"Calcium carbonate can be deposited in areas of shell growth, potentially facilitated by the reaction involving ammonia.","Entity: calcium carbonate. SMILES: O=C([O-])[O-].[Ca+2]. Calcium carbonate can be deposited in areas of shell growth, potentially facilitated by the reaction involving ammonia."
ammonia,Ammonia acts as a proton acceptor (NH3 + H+ = NH4+) and can help maintain blood pH in snails.,Entity: ammonia. SMILES: N. Ammonia acts as a proton acceptor (NH3 + H+ = NH4+) and can help maintain blood pH in snails.
ammonia,Ammonia is involved in physiological processes in snails that are beneficial and result in growth enhancement.,Entity: ammonia. SMILES: N. Ammonia is involved in physiological processes in snails that are beneficial and result in growth enhancement.
carbonic acid,Carbonic acid (HCO3-) is produced in the mantle tissue of snails via the catalytic reaction of carbonic anhydrase: CO2 + H2O = HCO3- + H+.,Entity: carbonic acid. SMILES: O=C(O)O. Carbonic acid (HCO3-) is produced in the mantle tissue of snails via the catalytic reaction of carbonic anhydrase: CO2 + H2O = HCO3- + H+.
water,Water serves as a substrate in the carbonic anhydrase-catalyzed reaction that produces bicarbonate (HCO3-) and hydrogen ions (H+) in snail mantle tissue.,Entity: water. SMILES: O. Water serves as a substrate in the carbonic anhydrase-catalyzed reaction that produces bicarbonate (HCO3-) and hydrogen ions (H+) in snail mantle tissue.
ammonia,Ammonia (NH3) plays a role in controlling the pH of fish blood by acting as a diffusion trip for blood carbon dioxide and helping to regulate blood CO2 concentration and pH.,Entity: ammonia. SMILES: N. Ammonia (NH3) plays a role in controlling the pH of fish blood by acting as a diffusion trip for blood carbon dioxide and helping to regulate blood CO2 concentration and pH.
ammonia,"In borate-buffered media, the ambient pH can be 9.0, which is likely higher than the pH of the internal environment in molluscs.","Entity: ammonia. SMILES: N. In borate-buffered media, the ambient pH can be 9.0, which is likely higher than the pH of the internal environment in molluscs."
ammonia,Ammonia diffuses readily across membranes due to its high lipid solubility.,Entity: ammonia. SMILES: N. Ammonia diffuses readily across membranes due to its high lipid solubility.
ammonia,"The pH of mollusc pallial fluid ranges from 7.7 to 8.4, and mollusc blood from 7.4 to 7.6.","Entity: ammonia. SMILES: N. The pH of mollusc pallial fluid ranges from 7.7 to 8.4, and mollusc blood from 7.4 to 7.6."
chloride ion,"Chloride ion is an endogenous ion released by aquatic animals, including snails, and is coupled with the uptake of exogenous ions such as Na+.","Entity: chloride ion. SMILES: [Cl-]. Chloride ion is an endogenous ion released by aquatic animals, including snails, and is coupled with the uptake of exogenous ions such as Na+."
borate ion,Borate ion is taken up by snails and may have adverse effects on their physiology.,Entity: borate ion. SMILES: [O-]B1OB2OB([O-])OB(O1)O2. Borate ion is taken up by snails and may have adverse effects on their physiology.
bicarbonate ion,"Bicarbonate ion is an endogenous ion released by aquatic animals, including snails, and may be coupled with the uptake of exogenous ions such as Na+.","Entity: bicarbonate ion. SMILES: O=C([O-])O. Bicarbonate ion is an endogenous ion released by aquatic animals, including snails, and may be coupled with the uptake of exogenous ions such as Na+."
carbon dioxide,Tris-buffered solutions can absorb carbon dioxide from the air.,Entity: carbon dioxide. SMILES: O=C=O. Tris-buffered solutions can absorb carbon dioxide from the air.
uridine,Uridine can be incorporated into bacterial DNA as a nucleotide analogue for the labeling of SPO1 phage lysates.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine can be incorporated into bacterial DNA as a nucleotide analogue for the labeling of SPO1 phage lysates.
thymine,"Thymine can be incorporated into bacterial DNA as a nucleotide analogue, with 0.5 εCi of 2-14C thymine per milliliter of MIII minimal medium supporting phage growth.","Entity: thymine. SMILES: Cc1c[nH]c(=O)[nH]c1=O. Thymine can be incorporated into bacterial DNA as a nucleotide analogue, with 0.5 εCi of 2-14C thymine per milliliter of MIII minimal medium supporting phage growth."
trichloroacetic acid,Trichloroacetic acid is used to terminate enzymatic activity in DNA synthesis assays by being added at 5% (w/v) ice-cold concentration.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to terminate enzymatic activity in DNA synthesis assays by being added at 5% (w/v) ice-cold concentration.
6-(p-hydroxyphenylazo)-uracil,"6-(p-hydroxyphenylazo)-uracil (HPUra) is used as an inhibitor in DNA synthesis assays, typically causing approximately 20% inhibition (range 0–40%) in enzymatic systems.","Entity: 6-(p-hydroxyphenylazo)-uracil. SMILES: O=c1cc(N=Nc2ccc(O)cc2)[nH]c(=O)[nH]1. 6-(p-hydroxyphenylazo)-uracil (HPUra) is used as an inhibitor in DNA synthesis assays, typically causing approximately 20% inhibition (range 0–40%) in enzymatic systems."
2-mercaptoethanol,2-mercaptoethanol is included at 1.0 mM in the dialysis buffer for DNA products to maintain reducing conditions during enzymatic digestion.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is included at 1.0 mM in the dialysis buffer for DNA products to maintain reducing conditions during enzymatic digestion.
toluene,"Toluene treatment of minicells prevents the incorporation of [3H]dTTP, indicating its role in inhibiting nucleotide incorporation in this system.","Entity: toluene. SMILES: Cc1ccccc1. Toluene treatment of minicells prevents the incorporation of [3H]dTTP, indicating its role in inhibiting nucleotide incorporation in this system."
chloramphenicol,"Addition of chloramphenicol prior to infection does not decrease DNA synthesis in minicells, indicating that the synthesis is dependent on intracellular enzymes present at the time of infection.","Entity: chloramphenicol. SMILES: O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl. Addition of chloramphenicol prior to infection does not decrease DNA synthesis in minicells, indicating that the synthesis is dependent on intracellular enzymes present at the time of infection."
toluene,"Toluene treatment of Bacillus subtilis minicells infected with bacteriophage phi29, SPP1, or SPO1 enables limited non-replicative DNA synthesis, as measured by [3H]dTTP incorporation.","Entity: toluene. SMILES: Cc1ccccc1. Toluene treatment of Bacillus subtilis minicells infected with bacteriophage phi29, SPP1, or SPO1 enables limited non-replicative DNA synthesis, as measured by [3H]dTTP incorporation."
6-(p-hydroxyphenylazo)-uracil,"6-(p-hydroxyphenylazo)-uracil inhibits host-cell-dependent non-replicative DNA synthesis in bacteriophage-infected, toluene-treated Bacillus subtilis minicells by approximately 20%.","Entity: 6-(p-hydroxyphenylazo)-uracil. SMILES: O=c1cc(N=Nc2ccc(O)cc2)[nH]c(=O)[nH]1. 6-(p-hydroxyphenylazo)-uracil inhibits host-cell-dependent non-replicative DNA synthesis in bacteriophage-infected, toluene-treated Bacillus subtilis minicells by approximately 20%."
sucrose,Sucrose is used to prepare gradients (5–20% w/v in TES buffer) for centrifugation and protein purification applications.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used to prepare gradients (5–20% w/v in TES buffer) for centrifugation and protein purification applications.
SDS,SDS (sodium dodecyl sulfate) is used at 10% (w/v) concentration in TES buffer as a lysis agent in protein extraction protocols.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS (sodium dodecyl sulfate) is used at 10% (w/v) concentration in TES buffer as a lysis agent in protein extraction protocols.
2-mercaptoethanol,2-mercaptoethanol is included at 1.0 mM concentration in the dialysis buffer for exonuclease III digestion of DNA.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is included at 1.0 mM concentration in the dialysis buffer for exonuclease III digestion of DNA.
Tris,Tris-HCl is used at 0.06 M concentration in the dialysis buffer for exonuclease III digestion of DNA.,Entity: Tris. SMILES: NC(CO)(CO)CO. Tris-HCl is used at 0.06 M concentration in the dialysis buffer for exonuclease III digestion of DNA.
trichloroacetic acid,"Trichloroacetic acid is used to precipitate DNA synthesized from [3H]dTTP in minicells, allowing for the detection of incorporated DNA.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to precipitate DNA synthesized from [3H]dTTP in minicells, allowing for the detection of incorporated DNA."
toluene,"Toluene treatment of minicells prevents the incorporation of [3H]dTTP, indicating its role in inhibiting DNA synthesis.","Entity: toluene. SMILES: Cc1ccccc1. Toluene treatment of minicells prevents the incorporation of [3H]dTTP, indicating its role in inhibiting DNA synthesis."
dTTP,"dTTP is incorporated into DNA in minicells during infection, with the synthesis dependent on the presence of all deoxyribonucleoside triphosphates.","Entity: dTTP. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O2)c(=O)[nH]c1=O. dTTP is incorporated into DNA in minicells during infection, with the synthesis dependent on the presence of all deoxyribonucleoside triphosphates."
chloramphenicol,"Addition of chloramphenicol prior to infection does not decrease DNA synthesis in minicells, indicating that the synthesis is dependent on intracellular enzymatic activity.","Entity: chloramphenicol. SMILES: O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl. Addition of chloramphenicol prior to infection does not decrease DNA synthesis in minicells, indicating that the synthesis is dependent on intracellular enzymatic activity."
MgCl2,MgCl2 is used at 0.66 M concentration in the dialysis buffer for exonuclease III digestion of DNA.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used at 0.66 M concentration in the dialysis buffer for exonuclease III digestion of DNA.
K2HPO4,K2HPO4 is used as a component of phosphate buffer at 70 mM concentration and pH 7.4 for suspending and washing minicells during the toluene permeabilization procedure.,Entity: K2HPO4. SMILES: O=P([O-])([O-])O.[K+].[K+]. K2HPO4 is used as a component of phosphate buffer at 70 mM concentration and pH 7.4 for suspending and washing minicells during the toluene permeabilization procedure.
KH2PO4,KH2PO4 is used as a component of phosphate buffer at 70 mM concentration and pH 7.4 for suspending and washing minicells during the toluene permeabilization procedure.,Entity: KH2PO4. SMILES: O=P([O-])(O)O.[K+]. KH2PO4 is used as a component of phosphate buffer at 70 mM concentration and pH 7.4 for suspending and washing minicells during the toluene permeabilization procedure.
toluene,Toluene is used to permeabilize minicells at a concentration of 1% (v/v) for 10 minutes at 25°C to facilitate DNA synthesis in phage-infected minicells.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used to permeabilize minicells at a concentration of 1% (v/v) for 10 minutes at 25°C to facilitate DNA synthesis in phage-infected minicells.
squalene,The pattern of isotopic incorporation into squalene differs between the intima and media of intact arterial segments.,Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. The pattern of isotopic incorporation into squalene differs between the intima and media of intact arterial segments.
sterols,The pattern of isotopic incorporation into sterols differs between the intima and media of intact arterial segments.,Entity: sterols. SMILES: OC1CCC2C(CCC3C4CCCC4CCC23)C1. The pattern of isotopic incorporation into sterols differs between the intima and media of intact arterial segments.
oxygen,"Oxygen diffusion into arterial tissues is greatest from the intimal surface, but due to rapid decline in oxygen tension over distance and tissue thickness, oxygen tension in the arterial media is considerably lower than in the intima.","Entity: oxygen. SMILES: [O]. Oxygen diffusion into arterial tissues is greatest from the intimal surface, but due to rapid decline in oxygen tension over distance and tissue thickness, oxygen tension in the arterial media is considerably lower than in the intima."
lanosterol,"In the intima, 60% of cholesterol sulfate (CsO) sterol activity cochromatographed with lanosterol, indicating significant overlap in sterol species.","Entity: lanosterol. SMILES: CC(C)=CCC[C@@H](C)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@@H]1CC3. In the intima, 60% of cholesterol sulfate (CsO) sterol activity cochromatographed with lanosterol, indicating significant overlap in sterol species."
squalene,"Squalene undergoes cyclization to sterol via the enzyme squalene 2,3-oxidoreductase, which requires molecular oxygen as a substrate.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene undergoes cyclization to sterol via the enzyme squalene 2,3-oxidoreductase, which requires molecular oxygen as a substrate."
lathosterol,Lathosterol is identified as a sterol synthesized by rat aortas from mevalonate.,Entity: lathosterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Lathosterol is identified as a sterol synthesized by rat aortas from mevalonate.
desmosterol,Desmosterol is identified as a sterol synthesized by rat aortas from mevalonate.,Entity: desmosterol. SMILES: CC(C)=CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Desmosterol is identified as a sterol synthesized by rat aortas from mevalonate.
7-dehydrocholesterol,7-dehydrocholesterol is identified as a sterol synthesized by rat aortas from mevalonate.,Entity: 7-dehydrocholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. 7-dehydrocholesterol is identified as a sterol synthesized by rat aortas from mevalonate.
mevalonate,"Mevalonate serves as a precursor for sterol synthesis in arterial tissue in vitro, with the specific sterols produced varying by species.","Entity: mevalonate. SMILES: C[C@@](O)(CCO)CC(=O)[O-]. Mevalonate serves as a precursor for sterol synthesis in arterial tissue in vitro, with the specific sterols produced varying by species."
cholestanol,Cholestanol is a major product of sterol synthesis in human arterial intima from labeled acetate or mevalonate in vitro.,Entity: cholestanol. SMILES: CC(CO)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4CCCC[C@]4(C)[C@H]3CC[C@]12C. Cholestanol is a major product of sterol synthesis in human arterial intima from labeled acetate or mevalonate in vitro.
lanosterol,"Lanosterol is the principal sterol synthesized by rat aortas from mevalonate, accounting for a significant portion of the sterol pool.","Entity: lanosterol. SMILES: CC(C)=CCC[C@@H](C)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@@H]1CC3. Lanosterol is the principal sterol synthesized by rat aortas from mevalonate, accounting for a significant portion of the sterol pool."
cholesterol,Cholesterol is a major product of sterol synthesis in human arterial intima from labeled acetate or mevalonate in vitro.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is a major product of sterol synthesis in human arterial intima from labeled acetate or mevalonate in vitro.
cholesterol,"In pigeon and monkey arteries perfused with [14C]mevalonate, dibromide-pure cholesterol represents 1.6% and 3.1% of the labeled digitonin-precipitable sterol synthesized, respectively.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. In pigeon and monkey arteries perfused with [14C]mevalonate, dibromide-pure cholesterol represents 1.6% and 3.1% of the labeled digitonin-precipitable sterol synthesized, respectively."
cholesterol,"In in vitro studies of arterial sterol synthesis, the proportion of newly synthesized sterol that is cholesterol is generally low, except possibly in human arteries.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. In in vitro studies of arterial sterol synthesis, the proportion of newly synthesized sterol that is cholesterol is generally low, except possibly in human arteries."
mevalonate,Mevalonate is used as a labeled substrate in perfusion studies of pigeon and monkey arteries to trace the synthesis of cholesterol and other sterols.,Entity: mevalonate. SMILES: C[C@@](O)(CCO)CC(=O)[O-]. Mevalonate is used as a labeled substrate in perfusion studies of pigeon and monkey arteries to trace the synthesis of cholesterol and other sterols.
squalene,"Labeled squalene can be used as a substrate in in vitro studies of arterial tissue to assess cholesterol synthesis, but dilution by endogenous squalene pools and potential enzyme denaturation can limit the amount of labeled sterol produced.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Labeled squalene can be used as a substrate in in vitro studies of arterial tissue to assess cholesterol synthesis, but dilution by endogenous squalene pools and potential enzyme denaturation can limit the amount of labeled sterol produced."
squalene,Squalene is synthesized in swine arterial tissue as part of the sterol biosynthesis pathway.,Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene is synthesized in swine arterial tissue as part of the sterol biosynthesis pathway.
cholesterol,Cholesterol is synthesized in swine arterial tissue as part of the sterol biosynthesis pathway.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is synthesized in swine arterial tissue as part of the sterol biosynthesis pathway.
squalene,Squalene is a component of the combined squalene/sterol ester fraction from which cholesterol esters are separated by thin-layer chromatography.,Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene is a component of the combined squalene/sterol ester fraction from which cholesterol esters are separated by thin-layer chromatography.
cholesterol linoleate,"Cholesterol linoleate is a saturated cholesterol ester with a double bond in its fatty-acid moiety, used as a standard in thin-layer chromatography for classing cholesterol esters.","Entity: cholesterol linoleate. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. Cholesterol linoleate is a saturated cholesterol ester with a double bond in its fatty-acid moiety, used as a standard in thin-layer chromatography for classing cholesterol esters."
cholesterol oleate,"Cholesterol oleate is a saturated cholesterol ester with a double bond in its fatty-acid moiety, used as a standard in thin-layer chromatography for classing cholesterol esters.","Entity: cholesterol oleate. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. Cholesterol oleate is a saturated cholesterol ester with a double bond in its fatty-acid moiety, used as a standard in thin-layer chromatography for classing cholesterol esters."
cholesterol stearate,"Cholesterol stearate is a saturated cholesterol ester with a double bond in its fatty-acid moiety, used as a standard in thin-layer chromatography for classing cholesterol esters.","Entity: cholesterol stearate. SMILES: CCCCCCCCCCCCCCCCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. Cholesterol stearate is a saturated cholesterol ester with a double bond in its fatty-acid moiety, used as a standard in thin-layer chromatography for classing cholesterol esters."
cholesterol arachidonate,"Cholesterol arachidonate is a saturated cholesterol ester with a double bond in its fatty-acid moiety, used as a standard in thin-layer chromatography for classing cholesterol esters.","Entity: cholesterol arachidonate. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. Cholesterol arachidonate is a saturated cholesterol ester with a double bond in its fatty-acid moiety, used as a standard in thin-layer chromatography for classing cholesterol esters."
silver nitrate,Silver nitrate is used as an impregnant for silica gel G in thin-layer chromatography to aid in the separation of cholesterol esters.,Entity: silver nitrate. SMILES: O=[N+]([O-])[O-].[Ag+]. Silver nitrate is used as an impregnant for silica gel G in thin-layer chromatography to aid in the separation of cholesterol esters.
benzene,Benzene is used as the solvent in thin-layer chromatography to fractionate cholesterol esters based on the number of double bonds in their fatty-acid moieties.,Entity: benzene. SMILES: c1ccccc1. Benzene is used as the solvent in thin-layer chromatography to fractionate cholesterol esters based on the number of double bonds in their fatty-acid moieties.
glucose,Glucose at a concentration of 5 mM is included in the incubation mixture with Medium 199 and pig serum to maintain arterial endothelium in in vitro studies.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose at a concentration of 5 mM is included in the incubation mixture with Medium 199 and pig serum to maintain arterial endothelium in in vitro studies.
cholesterol,"Cholesterol can be quantified as a standard in argentation chromatography, with recovery rates from thin-layer plates ranging from 92% to 101%.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol can be quantified as a standard in argentation chromatography, with recovery rates from thin-layer plates ranging from 92% to 101%."
rhodamine 6G,Rhodamine 6G is used as a fluorescent spray reagent at 0.05% solution in ethanol to visualize lipid zones on thin-layer chromatography plates under ultraviolet light.,Entity: rhodamine 6G. SMILES: CCNc1cc2oc3cc(=[NH+]CC)c(C)cc-3c(-c3ccccc3C(=O)OCC)c2cc1C.[Cl-]. Rhodamine 6G is used as a fluorescent spray reagent at 0.05% solution in ethanol to visualize lipid zones on thin-layer chromatography plates under ultraviolet light.
ethanol,"Ethanol is used as a solvent for 2',7'-dichlorofluorescein and rhodamine 6G in argentation chromatography.","Entity: ethanol. SMILES: CCO. Ethanol is used as a solvent for 2',7'-dichlorofluorescein and rhodamine 6G in argentation chromatography."
silver nitrate,Silver nitrate is used as a reagent to impregnate thin-layer chromatography plates at 7.5% concentration for argentation chromatography.,Entity: silver nitrate. SMILES: O=[N+]([O-])[O-].[Ag+]. Silver nitrate is used as a reagent to impregnate thin-layer chromatography plates at 7.5% concentration for argentation chromatography.
"2',7'-dichlorofluorescein","2',7'-dichlorofluorescein is used as a fluorescent spray reagent at 0.5% solution in ethanol to visualize lipid zones on thin-layer chromatography plates under ultraviolet light.","Entity: 2',7'-dichlorofluorescein. SMILES: O=C1OC2(c3cc(Cl)c(O)cc3Oc3cc(O)c(Cl)cc32)c2ccccc21. 2',7'-dichlorofluorescein is used as a fluorescent spray reagent at 0.5% solution in ethanol to visualize lipid zones on thin-layer chromatography plates under ultraviolet light."
oxygen,"Oxygen tension within tissues can influence lipid metabolism, and differences in oxygen tension are a factor contributing to metabolic differences observed in arterial intima and media.","Entity: oxygen. SMILES: [O]. Oxygen tension within tissues can influence lipid metabolism, and differences in oxygen tension are a factor contributing to metabolic differences observed in arterial intima and media."
squalene,"Squalene is a precursor in the biosynthesis of sterols in both liver and arterial tissue, with a labeling sequence in rat aortas showing squalene → lanosterol → lathosterol → cholesterol.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene is a precursor in the biosynthesis of sterols in both liver and arterial tissue, with a labeling sequence in rat aortas showing squalene → lanosterol → lathosterol → cholesterol."
lanosterol,"Lanosterol is an intermediate in the biosynthetic pathway from squalene to sterols, and its oxidation in the liver and aorta leads to the formation of dihydrolanosterol.","Entity: lanosterol. SMILES: CC(C)=CCC[C@@H](C)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@@H]1CC3. Lanosterol is an intermediate in the biosynthetic pathway from squalene to sterols, and its oxidation in the liver and aorta leads to the formation of dihydrolanosterol."
lathosterol,Lathosterol is a downstream product in the labeling sequence from squalene to cholesterol in rat aortas incubated with mevalonate.,Entity: lathosterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Lathosterol is a downstream product in the labeling sequence from squalene to cholesterol in rat aortas incubated with mevalonate.
cholesterol,Cholesterol is a final product in the labeling sequence from squalene to cholesterol in rat aortas incubated with mevalonate.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is a final product in the labeling sequence from squalene to cholesterol in rat aortas incubated with mevalonate.
digitonin,"Digitonin is used to precipitate sterols from arterial tissue, and the percentage of C,, sterols precipitated by digitonin can be used to assess sterol composition.","Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin is used to precipitate sterols from arterial tissue, and the percentage of C,, sterols precipitated by digitonin can be used to assess sterol composition."
mevalonate,"Mevalonate labeling experiments in rat aortas reveal a sequential incorporation of [14C]mevalonate into squalene, lanosterol, lathosterol, and cholesterol, with incorporation into C,, sterols (52.6 dpm/mgm dry weight) and labeled C,, sterols accumulating in the media (74.7 dpm/mgm dry weight) after 5-hour incubation.","Entity: mevalonate. SMILES: C[C@@](O)(CCO)CC(=O)[O-]. Mevalonate labeling experiments in rat aortas reveal a sequential incorporation of [14C]mevalonate into squalene, lanosterol, lathosterol, and cholesterol, with incorporation into C,, sterols (52.6 dpm/mgm dry weight) and labeled C,, sterols accumulating in the media (74.7 dpm/mgm dry weight) after 5-hour incubation."
cholestanol,A minor fraction (about 20%) of label cochromatographed with a mixed fraction of cholestanol and lathosterol in Cz7 sterol fractions from arterial intima and media.,Entity: cholestanol. SMILES: CC(CO)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4CCCC[C@]4(C)[C@H]3CC[C@]12C. A minor fraction (about 20%) of label cochromatographed with a mixed fraction of cholestanol and lathosterol in Cz7 sterol fractions from arterial intima and media.
lathosterol,A minor fraction (about 20%) of label cochromatographed with a mixed fraction of cholestanol and lathosterol in Cz7 sterol fractions from arterial intima and media.,Entity: lathosterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. A minor fraction (about 20%) of label cochromatographed with a mixed fraction of cholestanol and lathosterol in Cz7 sterol fractions from arterial intima and media.
7-dehydrocholesterol,Approximately 6% of label cochromatographed with 7-dehydrocholesterol in Cz7 sterol fractions from arterial intima and media.,Entity: 7-dehydrocholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Approximately 6% of label cochromatographed with 7-dehydrocholesterol in Cz7 sterol fractions from arterial intima and media.
digitonin,"In arterial tissue, 51% of the Cz7 sterol fraction is digitonin precipitable, indicating its association with cholesterol-containing domains.","Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. In arterial tissue, 51% of the Cz7 sterol fraction is digitonin precipitable, indicating its association with cholesterol-containing domains."
cholesterol,Approximately 50% of label cochromatographed with cholesterol in Cz7 sterol fractions from arterial intima and media.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Approximately 50% of label cochromatographed with cholesterol in Cz7 sterol fractions from arterial intima and media.
desmosterol,Approximately 20% of label cochromatographed with desmosterol in Cz7 sterol fractions from arterial intima and media.,Entity: desmosterol. SMILES: CC(C)=CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Approximately 20% of label cochromatographed with desmosterol in Cz7 sterol fractions from arterial intima and media.
mevalonate,"Mevalonate is incorporated into sterols, C30 sterols, and squalene in swine aortic intima and media in vitro.","Entity: mevalonate. SMILES: C[C@@](O)(CCO)CC(=O)[O-]. Mevalonate is incorporated into sterols, C30 sterols, and squalene in swine aortic intima and media in vitro."
squalene,"Squalene is synthesized in swine aortic media from [14C]mevalonate, with significantly higher incorporation in media than in intima.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene is synthesized in swine aortic media from [14C]mevalonate, with significantly higher incorporation in media than in intima."
desmosterol,Desmosterol is a sterol compound that can be separated and identified by thin-layer chromatography using chloroform as the eluent.,Entity: desmosterol. SMILES: CC(C)=CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Desmosterol is a sterol compound that can be separated and identified by thin-layer chromatography using chloroform as the eluent.
cholestanol,Cholestanol is a sterol compound that can be separated and identified by thin-layer chromatography using chloroform as the eluent.,Entity: cholestanol. SMILES: CC(CO)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4CCCC[C@]4(C)[C@H]3CC[C@]12C. Cholestanol is a sterol compound that can be separated and identified by thin-layer chromatography using chloroform as the eluent.
cholesterol,Cholesterol is a sterol compound that can be separated and identified by thin-layer chromatography using chloroform as the eluent.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is a sterol compound that can be separated and identified by thin-layer chromatography using chloroform as the eluent.
lathosterol,Lathosterol is a sterol compound that can be separated and identified by thin-layer chromatography using chloroform as the eluent.,Entity: lathosterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Lathosterol is a sterol compound that can be separated and identified by thin-layer chromatography using chloroform as the eluent.
squalene,"In the intima and media of tissue, 93.1 ± 3.2% and 96.5 ± 2.2% of squalene activity, respectively, is recoverable as squalene hexahydrochloride.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C.Cl.Cl.Cl.Cl.Cl.Cl. In the intima and media of tissue, 93.1 ± 3.2% and 96.5 ± 2.2% of squalene activity, respectively, is recoverable as squalene hexahydrochloride."
squalene,The arterial wall is capable of de novo synthesis of squalene from acetate and mevalonate.,Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. The arterial wall is capable of de novo synthesis of squalene from acetate and mevalonate.
mevalonate,Mevalonate serves as a precursor for the de novo synthesis of squalene and sterols in the arterial wall.,Entity: mevalonate. SMILES: C[C@@](O)(CCO)CC(=O)[O-]. Mevalonate serves as a precursor for the de novo synthesis of squalene and sterols in the arterial wall.
acetate,Acetate is a precursor for the de novo synthesis of squalene and sterols in the arterial wall.,Entity: acetate. SMILES: CC(=O)[O-]. Acetate is a precursor for the de novo synthesis of squalene and sterols in the arterial wall.
cholesterol,Cholesterol is typically a minor component of sterols synthesized from radioactive acetate and mevalonate in the arterial wall.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is typically a minor component of sterols synthesized from radioactive acetate and mevalonate in the arterial wall.
squalene,Squalene is a component of the nonsaponifiable fraction of tissues and can be quantified by gas-liquid chromatography with a flame ionization detector.,Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene is a component of the nonsaponifiable fraction of tissues and can be quantified by gas-liquid chromatography with a flame ionization detector.
5-alpha-cholestane,5-alpha-cholestane is used as an internal standard in gas-liquid chromatography for the analysis of squalene in tissue extracts.,Entity: 5-alpha-cholestane. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CCCC[C@]4(C)[C@H]3CC[C@]12C. 5-alpha-cholestane is used as an internal standard in gas-liquid chromatography for the analysis of squalene in tissue extracts.
lanosterol,Lanosterol serves as a carrier sterol to visualize C30 sterol zones on TLC plates when low levels of arterial CsO sterol are present.,Entity: lanosterol. SMILES: CC(C)=CCC[C@@H](C)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@@H]1CC3. Lanosterol serves as a carrier sterol to visualize C30 sterol zones on TLC plates when low levels of arterial CsO sterol are present.
cholesterol,Cholesterol is used as a carrier in the treatment of digitonylated sterols to aid in the isolation of free sterols by TLC.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is used as a carrier in the treatment of digitonylated sterols to aid in the isolation of free sterols by TLC.
squalene,Squalene is separated from sterol esters and other lipids in CHC&-MeOH extracts using thin-layer chromatography.,Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene is separated from sterol esters and other lipids in CHC&-MeOH extracts using thin-layer chromatography.
n-hexane,n-Hexane is used as a component of the solvent system (with diethyl ether and glacial acetic acid) for developing TLC plates to separate C27 and C30 sterols.,Entity: n-hexane. SMILES: CCCCCC. n-Hexane is used as a component of the solvent system (with diethyl ether and glacial acetic acid) for developing TLC plates to separate C27 and C30 sterols.
diethyl ether,Diethyl ether is used as a component of the solvent system (with n-hexane and glacial acetic acid) for developing TLC plates to separate C27 and C30 sterols.,Entity: diethyl ether. SMILES: CCOCC. Diethyl ether is used as a component of the solvent system (with n-hexane and glacial acetic acid) for developing TLC plates to separate C27 and C30 sterols.
digitonin,"Digitonin is used to cleave sterol esters from C27 sterols, facilitating the isolation and analysis of free sterols in lipid extracts.","Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin is used to cleave sterol esters from C27 sterols, facilitating the isolation and analysis of free sterols in lipid extracts."
pyridine,"Pyridine is used to cleave digitonides from digitonylated sterols, enabling the recovery of free sterols for radioactivity analysis.","Entity: pyridine. SMILES: c1ccncc1. Pyridine is used to cleave digitonides from digitonylated sterols, enabling the recovery of free sterols for radioactivity analysis."
squalene,Squalene is synthesized by the intima and media of intact arterial segments in addition to sterols and squalene.,Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene is synthesized by the intima and media of intact arterial segments in addition to sterols and squalene.
arachidonic acid,"De novo synthesized sterols in arterial intima and media are predominantly esterified to arachidonic acid, accounting for 4272% of the fatty acids in labeled sterol esters.","Entity: arachidonic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. De novo synthesized sterols in arterial intima and media are predominantly esterified to arachidonic acid, accounting for 4272% of the fatty acids in labeled sterol esters."
cholesterol dibromide,"Cholesterol dibromide can be synthesized by bromination of digitonin-purified sterol, with an efficiency of 81.8% and 82.6% conversion from sterol to dibromide derivative.","Entity: cholesterol dibromide. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C.[Br-].[Br-]. Cholesterol dibromide can be synthesized by bromination of digitonin-purified sterol, with an efficiency of 81.8% and 82.6% conversion from sterol to dibromide derivative."
cholesterol dibromide,"Purified cholesterol dibromide contains 1.67 × 1.15% of the radioactivity originally present in the digitonin-precipitable material, indicating its formation from cholesterol.","Entity: cholesterol dibromide. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C.[Br-].[Br-]. Purified cholesterol dibromide contains 1.67 × 1.15% of the radioactivity originally present in the digitonin-precipitable material, indicating its formation from cholesterol."
cholesterol,"Swine aorta is capable of synthesizing small amounts of cholesterol de novo, as confirmed by the conversion of sterol to cholesterol dibromide.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Swine aorta is capable of synthesizing small amounts of cholesterol de novo, as confirmed by the conversion of sterol to cholesterol dibromide."
cholesteryl arachidonate,Cholesteryl arachidonate is a sterol ester with a combined total of 5 double bonds (db) and can cochromatograph with up to 71% of total C12 sterols in tissue extracts.,Entity: cholesteryl arachidonate. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]32)C1. Cholesteryl arachidonate is a sterol ester with a combined total of 5 double bonds (db) and can cochromatograph with up to 71% of total C12 sterols in tissue extracts.
desmosterol,Desmosterol is an unsaturated sterol that represents less than 20% of total C12 sterols in tissues.,Entity: desmosterol. SMILES: CC(C)=CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Desmosterol is an unsaturated sterol that represents less than 20% of total C12 sterols in tissues.
squalene,"Squalene can incorporate [14C]mevalonate in arterial tissue, with radioactivity incorporated into squalene measured as dpm/mg dry weight.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene can incorporate [14C]mevalonate in arterial tissue, with radioactivity incorporated into squalene measured as dpm/mg dry weight."
mevalonate,"Mevalonate is incorporated into arterial sterols, sterol esters, and squalene in tissue, with radioactivity incorporated into these lipid fractions measured as dpm/mg dry weight.","Entity: mevalonate. SMILES: C[C@@](O)(CCO)CC(=O)[O-]. Mevalonate is incorporated into arterial sterols, sterol esters, and squalene in tissue, with radioactivity incorporated into these lipid fractions measured as dpm/mg dry weight."
cholesterol,Cholesterol can be purified from arterial lipid extracts by repetitive dibromide derivation.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol can be purified from arterial lipid extracts by repetitive dibromide derivation.
squalene,Squalene can be enriched from arterial lipid extracts by the addition of squalene and purified by hexahydrochloride derivation.,Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene can be enriched from arterial lipid extracts by the addition of squalene and purified by hexahydrochloride derivation.
n-hexane,n-hexane is used to extract nonsaponifiable fractions from arterial lipid extracts.,Entity: n-hexane. SMILES: CCCCCC. n-hexane is used to extract nonsaponifiable fractions from arterial lipid extracts.
pyridine,Pyridine is used to break digitonide complexes during the extraction of digitonin-precipitable sterols from cholesterol-containing fractions.,Entity: pyridine. SMILES: c1ccncc1. Pyridine is used to break digitonide complexes during the extraction of digitonin-precipitable sterols from cholesterol-containing fractions.
diethyl ether,Diethyl ether is used to extract digitonin-precipitable sterols after the addition of cholesterol carrier and treatment with digitonin.,Entity: diethyl ether. SMILES: CCOCC. Diethyl ether is used to extract digitonin-precipitable sterols after the addition of cholesterol carrier and treatment with digitonin.
digitonin,Digitonin is used to precipitate sterols from cholesterol-containing fractions in the purification of cholesterol.,Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin is used to precipitate sterols from cholesterol-containing fractions in the purification of cholesterol.
mevalonate,"Mevalonate is incorporated into squalene in tissue homogenates, serving as a precursor in the biosynthesis of squalene.","Entity: mevalonate. SMILES: C[C@@](O)(CCO)CC(=O)[O-]. Mevalonate is incorporated into squalene in tissue homogenates, serving as a precursor in the biosynthesis of squalene."
hydroxymethylglutaryl CoA,Hydroxymethylglutaryl CoA (HMG CoA) is reduced at a rate that contributes to the calculation of squalene production in pig aorta homogenates.,Entity: hydroxymethylglutaryl CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(CO)CCC(=O)O. Hydroxymethylglutaryl CoA (HMG CoA) is reduced at a rate that contributes to the calculation of squalene production in pig aorta homogenates.
squalene,"Squalene is synthesized in mammalian tissues, with minimal daily production of 0.102 pg/gm of fresh intima tissue and 0.204 pg/gm of fresh media tissue.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene is synthesized in mammalian tissues, with minimal daily production of 0.102 pg/gm of fresh intima tissue and 0.204 pg/gm of fresh media tissue."
lanosteryl acetate,"Lanosteryl acetate is a sterol compound whose presence in Cso sterol activity assays is associated with a specific zone in the assay, and the material in this zone is not identified but may represent oxidation products of lanosterol.","Entity: lanosteryl acetate. SMILES: CC(=O)O[C@H]1CC[C@]2(C)C3=C(CC[C@H]2C1(C)C)[C@]1(C)CC[C@H]([C@H](C)CCC=C(C)C)[C@@]1(C)CC3. Lanosteryl acetate is a sterol compound whose presence in Cso sterol activity assays is associated with a specific zone in the assay, and the material in this zone is not identified but may represent oxidation products of lanosterol."
squalene,"Squalene, isolated from lipid extracts by saponification and TLC, can be converted to its hexahydrochloride derivative and recrystallized without significant change in specific activity.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene, isolated from lipid extracts by saponification and TLC, can be converted to its hexahydrochloride derivative and recrystallized without significant change in specific activity."
lanosterol,Lanosterol can undergo oxidation to form products that are not identified in the context of Cso sterol activity assays.,Entity: lanosterol. SMILES: CC(C)=CCC[C@@H](C)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@@H]1CC3. Lanosterol can undergo oxidation to form products that are not identified in the context of Cso sterol activity assays.
squalene,"In intact arterial tissue, the incorporation of [l'C]nlevalonate into squalene is similar in both intima and media when the intima and media are separated into three or four lamellar strips and incubated under identical conditions.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. In intact arterial tissue, the incorporation of [l'C]nlevalonate into squalene is similar in both intima and media when the intima and media are separated into three or four lamellar strips and incubated under identical conditions."
Wlmevalonate,"Wlmevalonate is incorporated into sterols and squalene by intimal and medial arterial strips in a ratio of approximately 1:1, indicating similar metabolic labeling in both tissue layers.","Entity: Wlmevalonate. SMILES: C[C@@](O)(CCO)CC(=O)[O-]. Wlmevalonate is incorporated into sterols and squalene by intimal and medial arterial strips in a ratio of approximately 1:1, indicating similar metabolic labeling in both tissue layers."
CZ7 sterol,"In arterial tissue strips, the incorporation of Wlmevalonate into CZ7 sterol is similar in both intima and media, with a ratio of incorporation that is essentially unity.","Entity: CZ7 sterol. SMILES: CC(C)=CCC[C@@H](C)[C@H]1CC[C@H]2C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C[C@@H]1CC3. In arterial tissue strips, the incorporation of Wlmevalonate into CZ7 sterol is similar in both intima and media, with a ratio of incorporation that is essentially unity."
C3 sterol,"In arterial tissue strips, the incorporation of Wlmevalonate into C3 sterol is similar in both intima and media, with a ratio of incorporation that is essentially unity.","Entity: C3 sterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. In arterial tissue strips, the incorporation of Wlmevalonate into C3 sterol is similar in both intima and media, with a ratio of incorporation that is essentially unity."
Squalene,"In arterial tissue strips, the incorporation of Wlmevalonate into squalene is similar in both intima and media, with a ratio of incorporation that is essentially unity.","Entity: Squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. In arterial tissue strips, the incorporation of Wlmevalonate into squalene is similar in both intima and media, with a ratio of incorporation that is essentially unity."
sterol,"In the arterial intima, the greatest incorporation of label occurs in the C s1 sterol fraction, which is twofold higher than the C z7 sterol fraction of the underlying media.","Entity: sterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. In the arterial intima, the greatest incorporation of label occurs in the C s1 sterol fraction, which is twofold higher than the C z7 sterol fraction of the underlying media."
sterol,"Sterol esters constitute the lowest arterial lipid fraction in terms of label incorporation, accounting for 0.4–0.7% of total incorporation by intima and media, respectively.","Entity: sterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Sterol esters constitute the lowest arterial lipid fraction in terms of label incorporation, accounting for 0.4–0.7% of total incorporation by intima and media, respectively."
squalene,"Squalene in the arterial media incorporates significantly more label than squalene in the intima, with a twofold higher incorporation rate.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene in the arterial media incorporates significantly more label than squalene in the intima, with a twofold higher incorporation rate."
choline,Incorporation of choline into phosphatidylcholine and disaturated phosphatidylcholine increases tenfold during the fetal lung development between day 19 of gestation and the first postnatal day.,Entity: choline. SMILES: C[N+](C)(C)CCO. Incorporation of choline into phosphatidylcholine and disaturated phosphatidylcholine increases tenfold during the fetal lung development between day 19 of gestation and the first postnatal day.
Glucose,Glucose derived from fetal lung glycogen may contribute to phospholipid synthesis in the fetal lung.,Entity: Glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose derived from fetal lung glycogen may contribute to phospholipid synthesis in the fetal lung.
choline phosphate,Choline phosphate cytidylyltransferase activity increases after birth in the fetal lung.,Entity: choline phosphate. SMILES: C[N+](C)(C)CCOP(=O)(O)O. Choline phosphate cytidylyltransferase activity increases after birth in the fetal lung.
phosphorylcholine,"The lung phosphorylcholine pool declines significantly during development in rats, which may affect the apparent rate of choline incorporation into phosphatidylcholine.","Entity: phosphorylcholine. SMILES: C[N+](C)(C#P=O)CCO. The lung phosphorylcholine pool declines significantly during development in rats, which may affect the apparent rate of choline incorporation into phosphatidylcholine."
choline,Choline incorporation into phosphatidylcholine in lung slices accelerates rapidly during the late fetal and early postnatal period in rats.,Entity: choline. SMILES: C[N+](C)(C)CCO. Choline incorporation into phosphatidylcholine in lung slices accelerates rapidly during the late fetal and early postnatal period in rats.
adenosine-5'-phosphate,Adenosine-5'-phosphate is used as a substrate at 1.5 mM concentration in assays to determine glycogen phosphorylase a and total glycogen phosphorylase activities.,Entity: adenosine-5'-phosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine-5'-phosphate is used as a substrate at 1.5 mM concentration in assays to determine glycogen phosphorylase a and total glycogen phosphorylase activities.
NADPH,NADPH generation rates can be measured fluorimetrically at 20°C to assess enzymatic activity in tissue preparations.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH generation rates can be measured fluorimetrically at 20°C to assess enzymatic activity in tissue preparations.
caffeine,Caffeine is used in assays to determine glycogen phosphorylase a and total glycogen phosphorylase activities in muscle phosphorylase assays.,Entity: caffeine. SMILES: Cn1c(=O)c2c(ncn2C)n(C)c1=O. Caffeine is used in assays to determine glycogen phosphorylase a and total glycogen phosphorylase activities in muscle phosphorylase assays.
NaF,NaF is used as a component of the sonication buffer (20 mM) in the preparation of lung homogenates for glycogen synthase enzyme assays.,Entity: NaF. SMILES: [F-].[Na+]. NaF is used as a component of the sonication buffer (20 mM) in the preparation of lung homogenates for glycogen synthase enzyme assays.
glucose 6-phosphate,Glucose 6-phosphate is included at 10 mM concentration in the assay medium for total glycogen synthase (I + D) activity measurement.,Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose 6-phosphate is included at 10 mM concentration in the assay medium for total glycogen synthase (I + D) activity measurement.
glycylglycine,Glycylglycine is used at 20 mM concentration as a component of the sonication buffer for lung tissue homogenization.,Entity: glycylglycine. SMILES: NCC(=O)NCC(=O)O. Glycylglycine is used at 20 mM concentration as a component of the sonication buffer for lung tissue homogenization.
dithiothreitol,Dithiothreitol is included at 3.0 mM concentration in the sonication buffer for lung tissue homogenization.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is included at 3.0 mM concentration in the sonication buffer for lung tissue homogenization.
ethanol,Ethanol (66%) is used for washing filter paper discs during the isolation of glycogen precipitate in enzyme assays.,Entity: ethanol. SMILES: CCO. Ethanol (66%) is used for washing filter paper discs during the isolation of glycogen precipitate in enzyme assays.
acetone,Acetone is used to rinse filter paper discs after ethanol washing during the isolation of glycogen precipitate in enzyme assays.,Entity: acetone. SMILES: CC(C)=O. Acetone is used to rinse filter paper discs after ethanol washing during the isolation of glycogen precipitate in enzyme assays.
choline,Choline is used as a substrate in tissue homogenate-based assays to measure choline kinase activity by its incorporation into phosphocholine.,Entity: choline. SMILES: C[N+](C)(C)CCO. Choline is used as a substrate in tissue homogenate-based assays to measure choline kinase activity by its incorporation into phosphocholine.
phosphocholine,Phosphocholine is the product formed from choline by the action of choline kinase and is quantified in tissue homogenate assays to assess enzyme activity.,Entity: phosphocholine. SMILES: C[N+](C)(C)CCOP(=O)([O-])O. Phosphocholine is the product formed from choline by the action of choline kinase and is quantified in tissue homogenate assays to assess enzyme activity.
trichloroacetic acid,Trichloroacetic acid is used at 5% concentration to precipitate proteins during the preparation of tissue homogenates for choline kinase assays.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used at 5% concentration to precipitate proteins during the preparation of tissue homogenates for choline kinase assays.
ethanol,Ethanol is used as a component of the mobile phase (with cone and NH4OH/isopropanol) in ascending chromatography for separating choline and phosphocholine.,Entity: ethanol. SMILES: CCO. Ethanol is used as a component of the mobile phase (with cone and NH4OH/isopropanol) in ascending chromatography for separating choline and phosphocholine.
isopropanol,Isopropanol is used as a component of the mobile phase (with ethanol and NH4OH) in ascending chromatography for the separation of choline and phosphocholine.,Entity: isopropanol. SMILES: CC(C)O. Isopropanol is used as a component of the mobile phase (with ethanol and NH4OH) in ascending chromatography for the separation of choline and phosphocholine.
ammonium hydroxide,"Ammonium hydroxide is used as a component of the mobile phase (with ethanol, isopropanol, and cone) in ascending chromatography for the separation of choline and phosphocholine.","Entity: ammonium hydroxide. SMILES: [NH4+].[OH-]. Ammonium hydroxide is used as a component of the mobile phase (with ethanol, isopropanol, and cone) in ascending chromatography for the separation of choline and phosphocholine."
NADPH,NADPH generation is measured at 20°C in a fluorimeter during the glycogen quantification assay.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH generation is measured at 20°C in a fluorimeter during the glycogen quantification assay.
adenosine 5'-phosphate,Adenosine 5'-phosphate is included at 0.5 mM concentration in the assay buffer for glycogen quantification.,Entity: adenosine 5'-phosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine 5'-phosphate is included at 0.5 mM concentration in the assay buffer for glycogen quantification.
MgCl2,MgCl2 is used at 0.9 mM concentration in the assay buffer for glycogen quantification.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used at 0.9 mM concentration in the assay buffer for glycogen quantification.
NaF,NaF is included at 30 mM concentration in the assay buffer for glycogen quantification.,Entity: NaF. SMILES: [F-].[Na+]. NaF is included at 30 mM concentration in the assay buffer for glycogen quantification.
dithiothreitol,Dithiothreitol is used as a reducing agent at 0.5 mM concentration in glycogen assay buffers.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used as a reducing agent at 0.5 mM concentration in glycogen assay buffers.
KH2PO4,KH2PO4 is included at 3.0 mM concentration in the assay buffer for glycogen quantification.,Entity: KH2PO4. SMILES: O=P([O-])(O)O.[K+]. KH2PO4 is included at 3.0 mM concentration in the assay buffer for glycogen quantification.
EDTA,EDTA is used at 0.2 mM concentration as a chelating agent in the glycogen assay buffer.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used at 0.2 mM concentration as a chelating agent in the glycogen assay buffer.
NADP,NADP is included at 60 µM concentration in the assay buffer for glycogen quantification.,Entity: NADP. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP is included at 60 µM concentration in the assay buffer for glycogen quantification.
imidazole,Imidazole is used as a buffer at 50 mM concentration and pH 6.9 in the glycogen assay.,Entity: imidazole. SMILES: c1c[nH]cn1. Imidazole is used as a buffer at 50 mM concentration and pH 6.9 in the glycogen assay.
choline,"Choline is incorporated into pulmonary phosphatidylcholine and disaturated phosphatidylcholine in the fetal lung, with increased amounts and rates observed during fetal lung glycogen depletion.","Entity: choline. SMILES: C[N+](C)(C)CCO. Choline is incorporated into pulmonary phosphatidylcholine and disaturated phosphatidylcholine in the fetal lung, with increased amounts and rates observed during fetal lung glycogen depletion."
glucose 6-phosphate,Glucose 6-phosphate oxidation via the hexose monophosphate pathway serves as an important source of NADPH reducing equivalents necessary for de novo fatty acid synthesis.,Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose 6-phosphate oxidation via the hexose monophosphate pathway serves as an important source of NADPH reducing equivalents necessary for de novo fatty acid synthesis.
glucose 6-phosphate,"In the fetus, oxidation of glucose 6-phosphate derived from lung glycogen provides energy for cell differentiation and lung phospholipid synthesis.","Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. In the fetus, oxidation of glucose 6-phosphate derived from lung glycogen provides energy for cell differentiation and lung phospholipid synthesis."
glucose,Glucose can be metabolized through several pathways that contribute to lung phospholipid synthesis in the fetus.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose can be metabolized through several pathways that contribute to lung phospholipid synthesis in the fetus.
NADPH,NADPH reducing equivalents required for de novo fatty acid synthesis can be supplied by the oxidation of glucose 6-phosphate through the hexose monophosphate pathway.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH reducing equivalents required for de novo fatty acid synthesis can be supplied by the oxidation of glucose 6-phosphate through the hexose monophosphate pathway.
glucose,"Glucose is oxidized through the pentose phosphate pathway to generate NADPH, which is utilized for fatty acid synthesis and protection against oxidant injury in the lung.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is oxidized through the pentose phosphate pathway to generate NADPH, which is utilized for fatty acid synthesis and protection against oxidant injury in the lung."
NADPH,NADPH produced via the pentose phosphate pathway serves as a cofactor for fatty acid synthesis and protects adult lung from oxidant injury.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH produced via the pentose phosphate pathway serves as a cofactor for fatty acid synthesis and protects adult lung from oxidant injury.
NADPH,"In fetal rat lung, the pentose phosphate pathway provides NADPH for lipogenesis.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. In fetal rat lung, the pentose phosphate pathway provides NADPH for lipogenesis."
ribose phosphate,"In fetal rat lung, the pentose phosphate pathway provides ribose phosphate for DNA and RNA synthesis.","Entity: ribose phosphate. SMILES: O=C[C@H](O)[C@H](O)[C@H](O)CO.O=P(O)(O)O. In fetal rat lung, the pentose phosphate pathway provides ribose phosphate for DNA and RNA synthesis."
phosphocholine,"Phosphocholine is a substrate for cholinephosphate cytidylyltransferase (EC 2.7.7.15), which catalyzes the incorporation of phosphocholine into CDPcholine.","Entity: phosphocholine. SMILES: C[N+](C)(C)CCOP(=O)([O-])O. Phosphocholine is a substrate for cholinephosphate cytidylyltransferase (EC 2.7.7.15), which catalyzes the incorporation of phosphocholine into CDPcholine."
trichloroacetic acid,Trichloroacetic acid is used to stop enzymatic reactions in assays involving cholinephosphate cytidylyltransferase.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to stop enzymatic reactions in assays involving cholinephosphate cytidylyltransferase.
KH2PO4,KH2PO4 is used as a buffer component at 3.0 mM concentration in the assay medium for glycogen phosphorylase activity measurement in lung homogenates.,Entity: KH2PO4. SMILES: O=P([O-])(O)O.[K+]. KH2PO4 is used as a buffer component at 3.0 mM concentration in the assay medium for glycogen phosphorylase activity measurement in lung homogenates.
Caffeine,Caffeine is included at 0.4 mM concentration in the assay medium for glycogen phosphorylase activity in lung homogenates.,Entity: Caffeine. SMILES: Cn1c(=O)c2c(ncn2C)n(C)c1=O. Caffeine is included at 0.4 mM concentration in the assay medium for glycogen phosphorylase activity in lung homogenates.
EDTA,EDTA is used at 0.2 mM concentration in the assay medium for glycogen phosphorylase activity in lung homogenates.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used at 0.2 mM concentration in the assay medium for glycogen phosphorylase activity in lung homogenates.
MgCl2,MgCl2 is included at 0.9 mM concentration in the assay medium for glycogen phosphorylase activity in lung homogenates.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is included at 0.9 mM concentration in the assay medium for glycogen phosphorylase activity in lung homogenates.
NADPH,NADPH is generated as a product in the assay measuring glycogen phosphorylase activity in lung homogenates.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is generated as a product in the assay measuring glycogen phosphorylase activity in lung homogenates.
NADP,NADP is used at 30 mM concentration in the assay medium for glycogen phosphorylase activity in lung homogenates.,Entity: NADP. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP is used at 30 mM concentration in the assay medium for glycogen phosphorylase activity in lung homogenates.
NaF,NaF is used at 30 mM concentration in the assay medium for glycogen phosphorylase activity in lung homogenates.,Entity: NaF. SMILES: [F-].[Na+]. NaF is used at 30 mM concentration in the assay medium for glycogen phosphorylase activity in lung homogenates.
Adenosine 5'-phosphate,Adenosine 5'-phosphate is included at optimal saturating concentration in the assay for glycogen phosphorylase activity in lung homogenates.,Entity: Adenosine 5'-phosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine 5'-phosphate is included at optimal saturating concentration in the assay for glycogen phosphorylase activity in lung homogenates.
trimethylsilyl,Linoleate hydroperoxides can be converted into their corresponding trimethylsilyl derivatives for subsequent analysis by gas-liquid chromatography-mass spectrometry.,Entity: trimethylsilyl. SMILES: C[Si](C)C. Linoleate hydroperoxides can be converted into their corresponding trimethylsilyl derivatives for subsequent analysis by gas-liquid chromatography-mass spectrometry.
pyridine,Pyridine is used as a reagent in the derivatization of linoleate hydroperoxides to their trimethylsilyl derivatives prior to gas-liquid chromatography-mass spectrometry analysis.,Entity: pyridine. SMILES: c1ccncc1. Pyridine is used as a reagent in the derivatization of linoleate hydroperoxides to their trimethylsilyl derivatives prior to gas-liquid chromatography-mass spectrometry analysis.
trimethylchlorosilane,Trimethylchlorosilane is used in combination with hexamethyldisilazane and pyridine to derivatize linoleate hydroperoxides for analysis by gas-liquid chromatography-mass spectrometry.,Entity: trimethylchlorosilane. SMILES: C[Si](C)(C)Cl. Trimethylchlorosilane is used in combination with hexamethyldisilazane and pyridine to derivatize linoleate hydroperoxides for analysis by gas-liquid chromatography-mass spectrometry.
oxygen,"In the enzymatic peroxidation of linoleate by Fusarium lipoxygenase, the oxygen atoms incorporated into hydroperoxides originate from the gaseous phase rather than the aqueous phase.","Entity: oxygen. SMILES: [O]. In the enzymatic peroxidation of linoleate by Fusarium lipoxygenase, the oxygen atoms incorporated into hydroperoxides originate from the gaseous phase rather than the aqueous phase."
hexamethyldisilazane,Hexamethyldisilazane is used as a reagent for the derivatization of linoleate hydroperoxides to their trimethylsilyl derivatives prior to gas-liquid chromatography-mass spectrometry analysis.,Entity: hexamethyldisilazane. SMILES: C[Si](C)(C)N[Si](C)(C)C. Hexamethyldisilazane is used as a reagent for the derivatization of linoleate hydroperoxides to their trimethylsilyl derivatives prior to gas-liquid chromatography-mass spectrometry analysis.
e-N-acetyllysine,The PTH-derivative of e-N-acetyllysine can be clearly separated by thin layer chromatography on silica gel in a chloroform/methanol/ethanol (90:7:1) solvent system.,Entity: e-N-acetyllysine. SMILES: CC(=O)N[C@@H](CCCCN)C(=O)O. The PTH-derivative of e-N-acetyllysine can be clearly separated by thin layer chromatography on silica gel in a chloroform/methanol/ethanol (90:7:1) solvent system.
trichloroacetic acid,Trichloroacetic acid is used at 18% (w/v) concentration for protein precipitation and washing steps in protein purification.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used at 18% (w/v) concentration for protein precipitation and washing steps in protein purification.
hydrochloric acid,Hydrochloric acid (0.25 N) is used to redissolve protein precipitates in biochemical procedures.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (0.25 N) is used to redissolve protein precipitates in biochemical procedures.
acetyl-CoA,Acetyl-CoA serves as a substrate for histone transacetylase in enzymatic assays measuring histone acetylation.,Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Acetyl-CoA serves as a substrate for histone transacetylase in enzymatic assays measuring histone acetylation.
iodobenzoate,"Iodobenzoate is used to dimerize proteins, such as histone H3, to facilitate removal of contaminating histones and non-histone proteins during chromatographic purification.","Entity: iodobenzoate. SMILES: O=C([O-])c1ccccc1I. Iodobenzoate is used to dimerize proteins, such as histone H3, to facilitate removal of contaminating histones and non-histone proteins during chromatographic purification."
methanol,Methanol is used as a component of the methanol/ethanol/ether (2:2:1) solvent mixture for washing protein precipitates in purification protocols.,Entity: methanol. SMILES: CO. Methanol is used as a component of the methanol/ethanol/ether (2:2:1) solvent mixture for washing protein precipitates in purification protocols.
ethanol,Ethanol is used as a component of the methanol/ethanol/ether (2:2:1) solvent mixture for washing protein precipitates in purification protocols.,Entity: ethanol. SMILES: CCO. Ethanol is used as a component of the methanol/ethanol/ether (2:2:1) solvent mixture for washing protein precipitates in purification protocols.
acetone,Acetone is used as a precipitating agent for proteins in biochemical purification protocols.,Entity: acetone. SMILES: CC(C)=O. Acetone is used as a precipitating agent for proteins in biochemical purification protocols.
acetyl-coenzyme A,"Acetyl-coenzyme A is used as a substrate in enzymatic reactions, with one unit of enzyme activity catalyzing the incorporation of 1 pmol acetate in 30 minutes at 37°C.","Entity: acetyl-coenzyme A. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Acetyl-coenzyme A is used as a substrate in enzymatic reactions, with one unit of enzyme activity catalyzing the incorporation of 1 pmol acetate in 30 minutes at 37°C."
acetate,"Acetate is produced as a product when acetyl-coenzyme A is enzymatically processed, with 1 pmol acetate incorporated per unit enzyme activity in 30 minutes at 37°C.","Entity: acetate. SMILES: CC(=O)[O-]. Acetate is produced as a product when acetyl-coenzyme A is enzymatically processed, with 1 pmol acetate incorporated per unit enzyme activity in 30 minutes at 37°C."
HCl,"HCl is used to terminate enzymatic reactions, with a final concentration of 0.25 N after addition to the reaction mixture.","Entity: HCl. SMILES: Cl. HCl is used to terminate enzymatic reactions, with a final concentration of 0.25 N after addition to the reaction mixture."
mercaptoethanol,"Mercaptoethanol is used as a reducing agent to convert histone H3 dimer back to its monomer form, as shown by the appearance of radioactivity co-electrophoresing and co-chromatographing with the dimer after reduction.","Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol is used as a reducing agent to convert histone H3 dimer back to its monomer form, as shown by the appearance of radioactivity co-electrophoresing and co-chromatographing with the dimer after reduction."
e-N-acetyl-lysine,"e-N-acetyl-lysine is a radioactive compound that co-migrates with PTH-derivatives of lysine residues in histone H3 after Edman degradation, indicating the presence of acetylated lysine sites in histone H3.","Entity: e-N-acetyl-lysine. SMILES: CC(=O)N[C@@H](CCCCN)C(=O)O. e-N-acetyl-lysine is a radioactive compound that co-migrates with PTH-derivatives of lysine residues in histone H3 after Edman degradation, indicating the presence of acetylated lysine sites in histone H3."
triglyceride,"A triglyceride interface, in combination with bile salt, is unique for the binding of colipase and is essential for the function of pancreatic lipase.","Entity: triglyceride. SMILES: O=COCC(COC=O)OC=O. A triglyceride interface, in combination with bile salt, is unique for the binding of colipase and is essential for the function of pancreatic lipase."
dodecyl sulfate,"Dodecyl sulfate has been shown to displace albumin from an aqueous/n-decane interface, indicating a general detergent effect.","Entity: dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-]. Dodecyl sulfate has been shown to displace albumin from an aqueous/n-decane interface, indicating a general detergent effect."
tributyrin,"Tributyrin, when combined with bile salts, enables the binding of colipase to the interface, suggesting special properties in this system.","Entity: tributyrin. SMILES: CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC. Tributyrin, when combined with bile salts, enables the binding of colipase to the interface, suggesting special properties in this system."
n-decane,n-decane is used as a component in the aqueous/n-decane interface system to study the displacement of albumin by detergents such as dodecyl sulfate.,Entity: n-decane. SMILES: CCCCCCCCCC. n-decane is used as a component in the aqueous/n-decane interface system to study the displacement of albumin by detergents such as dodecyl sulfate.
hexadecane,Hexadecane is used in the colipase/hexadecane/bile salt system to investigate the displacement of albumin from the interface by colipase.,Entity: hexadecane. SMILES: CCCCCCCCCCCCCCCC. Hexadecane is used in the colipase/hexadecane/bile salt system to investigate the displacement of albumin from the interface by colipase.
Taurodeoxycholate,Taurodeoxycholate at concentrations above the critical micellar concentration range (>1 mM) causes a gradual decrease in colipase binding to the tributyrin interface.,Entity: Taurodeoxycholate. SMILES: C[C@H](CCC(=O)NCCS(=O)(=O)[O-])[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Taurodeoxycholate at concentrations above the critical micellar concentration range (>1 mM) causes a gradual decrease in colipase binding to the tributyrin interface.
Taurodeoxycholate,"At low concentrations, taurodeoxycholate has little effect on colipase binding to the tributyrin interface.","Entity: Taurodeoxycholate. SMILES: C[C@H](CCC(=O)NCCS(=O)(=O)[O-])[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. At low concentrations, taurodeoxycholate has little effect on colipase binding to the tributyrin interface."
Hexadecane,Colipase binds to the hexadecane/aqueous interface with similar affinity as to the tributyrin interface.,Entity: Hexadecane. SMILES: CCCCCCCCCCCCCCCC. Colipase binds to the hexadecane/aqueous interface with similar affinity as to the tributyrin interface.
Tributyrin,Colipase binds to the tributyrin interface under conditions of 0.15 M NaCl and pH 7.0.,Entity: Tributyrin. SMILES: CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC. Colipase binds to the tributyrin interface under conditions of 0.15 M NaCl and pH 7.0.
Sodium chloride,Sodium chloride at 0.15 M is used as a salt concentration in experiments measuring colipase binding to the tributyrin interface.,Entity: Sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride at 0.15 M is used as a salt concentration in experiments measuring colipase binding to the tributyrin interface.
Triton X-100,"Triton X-100, a nonionic detergent, reduces colipase binding to the tributyrin interface when its concentration exceeds the critical micellar concentration range (>1 mM).","Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100, a nonionic detergent, reduces colipase binding to the tributyrin interface when its concentration exceeds the critical micellar concentration range (>1 mM)."
Tributyrin,"Tributyrin is an ester of tributric acid and glycerol, commonly used as an emulsifier in enzyme assays.","Entity: Tributyrin. SMILES: CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC. Tributyrin is an ester of tributric acid and glycerol, commonly used as an emulsifier in enzyme assays."
Calcium chloride,Calcium chloride is used as a component of buffer at 1 mM concentration in colipase binding and activity assays.,Entity: Calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride is used as a component of buffer at 1 mM concentration in colipase binding and activity assays.
Sodium taurocholate,Sodium taurocholate is a bile salt that can be synthesized to >97% purity by thin-layer chromatography.,Entity: Sodium taurocholate. SMILES: C[C@H](CCC(=O)NCCS(=O)(=O)[O-])[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C.[Na+]. Sodium taurocholate is a bile salt that can be synthesized to >97% purity by thin-layer chromatography.
Sodium chloride,Sodium chloride is used at 0.15 M concentration in buffer for colipase binding and activity assays.,Entity: Sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at 0.15 M concentration in buffer for colipase binding and activity assays.
n-Hexadecane,n-Hexadecane is a saturated hydrocarbon used as a substrate in colipase binding assays.,Entity: n-Hexadecane. SMILES: CCCCCCCCCCCCCCCC. n-Hexadecane is a saturated hydrocarbon used as a substrate in colipase binding assays.
Iodine,"Iodine is used to determine the critical micellar concentrations of detergents such as N-cholylglucosamine, Nonipol TD 12, and Triton X-100 in 0.15 M NaCl.","Entity: Iodine. SMILES: [I]. Iodine is used to determine the critical micellar concentrations of detergents such as N-cholylglucosamine, Nonipol TD 12, and Triton X-100 in 0.15 M NaCl."
Triton X-100,Triton X-100 is a nonionic detergent with a critical micellar concentration of 0.17 mM in 0.15 M NaCl.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a nonionic detergent with a critical micellar concentration of 0.17 mM in 0.15 M NaCl.
D-galactosamine,D-galactosamine induces acute hepatic injury in a variety of species when administered in large doses.,Entity: D-galactosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. D-galactosamine induces acute hepatic injury in a variety of species when administered in large doses.
D-galactosamine,D-galactosamine inhibits hepatic protein synthesis as an early effect.,Entity: D-galactosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. D-galactosamine inhibits hepatic protein synthesis as an early effect.
D-galactosamine,"D-galactosamine metabolism in the liver produces non-N-acetylated UDP-glucosamine, which acts as a false substrate for the glycogen synthetase enzyme.","Entity: D-galactosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. D-galactosamine metabolism in the liver produces non-N-acetylated UDP-glucosamine, which acts as a false substrate for the glycogen synthetase enzyme."
uridine,Uridine does not reverse the decrease in amino acid incorporation caused by galactosamine.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine does not reverse the decrease in amino acid incorporation caused by galactosamine.
UDP-glucosamine,"Non-N-acetylated UDP-glucosamine, a major product of hepatic galactosamine metabolism, is a false substrate for the glycogen synthetase enzyme.","Entity: UDP-glucosamine. SMILES: N[C@H]1[C@@H](OP(=O)(O)OP(=O)(O)OC[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O. Non-N-acetylated UDP-glucosamine, a major product of hepatic galactosamine metabolism, is a false substrate for the glycogen synthetase enzyme."
galactosamine,"Galactosamine serves as an internal standard in aminoglycogen hydrolysis, decomposing at a rate similar to that of glucosamine under hot HCl conditions.","Entity: galactosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. Galactosamine serves as an internal standard in aminoglycogen hydrolysis, decomposing at a rate similar to that of glucosamine under hot HCl conditions."
glucose,Glucose in aminoglycogen can be estimated using the primary cysteine-sulphuric acid reaction.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose in aminoglycogen can be estimated using the primary cysteine-sulphuric acid reaction.
glucosamine,"Glucosamine is present in aminoglycogen and can be liberated from aminoglycogen by acid hydrolysis, with maximum yield obtained by treating 1 mg/rnI polysaccharide with 4 M HCl at 105°C for 12 hours.","Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine is present in aminoglycogen and can be liberated from aminoglycogen by acid hydrolysis, with maximum yield obtained by treating 1 mg/rnI polysaccharide with 4 M HCl at 105°C for 12 hours."
glucosamine,"The presence of glucosamine in aminoglycogen can be demonstrated by acid hydrolysis, as it is released into the hydrolysate.","Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. The presence of glucosamine in aminoglycogen can be demonstrated by acid hydrolysis, as it is released into the hydrolysate."
glycerol,Glycerol is used as a 2% (v/v) component in TKMglycerol buffer for liver ribosome preparation.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is used as a 2% (v/v) component in TKMglycerol buffer for liver ribosome preparation.
deoxycholate,Deoxycholate is used at 0.2% concentration to lyse liver ribosomal pellets for ribosome preparation.,Entity: deoxycholate. SMILES: C[C@H](CCC(=O)[O-])[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Deoxycholate is used at 0.2% concentration to lyse liver ribosomal pellets for ribosome preparation.
mercaptoethanol,Mercaptoethanol is included at 6 mM in TKMglycerol buffer for liver ribosome extraction.,Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol is included at 6 mM in TKMglycerol buffer for liver ribosome extraction.
ammonium sulphate,"Ammonium sulphate is used as a precipitating agent to treat liver postmitochondrial fractions, enabling the isolation of soluble factors for ribosomal system studies.","Entity: ammonium sulphate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Ammonium sulphate is used as a precipitating agent to treat liver postmitochondrial fractions, enabling the isolation of soluble factors for ribosomal system studies."
L-phenylalanine,"L-phenylalanine is incorporated into aminoacyl-tRNA in the presence of tRNAPhe fractions and is used as a radiolabel (14C, 270 Ci/mol) in ribosomal system experiments.","Entity: L-phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. L-phenylalanine is incorporated into aminoacyl-tRNA in the presence of tRNAPhe fractions and is used as a radiolabel (14C, 270 Ci/mol) in ribosomal system experiments."
KCl,Increasing the ionic strength of the suspending medium by adjusting KCl concentration to 1 M prevents precipitation of liver ribosomes by aminoglycogen.,Entity: KCl. SMILES: [Cl-].[K+]. Increasing the ionic strength of the suspending medium by adjusting KCl concentration to 1 M prevents precipitation of liver ribosomes by aminoglycogen.
D-galactosamine,"D-galactosamine is used as an intraperitoneal injection in mice to deplete liver glycogen, in combination with D-glucose.","Entity: D-galactosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. D-galactosamine is used as an intraperitoneal injection in mice to deplete liver glycogen, in combination with D-glucose."
D-glucose,D-glucose is administered intraperitoneally at 2.5 g/kg body weight to deplete liver glycogen in mice.,Entity: D-glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. D-glucose is administered intraperitoneally at 2.5 g/kg body weight to deplete liver glycogen in mice.
perchloric acid,"Perchloric acid (0.3 M, ice-cold) is used to homogenize liver tissue for glycogen extraction in mice.","Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid (0.3 M, ice-cold) is used to homogenize liver tissue for glycogen extraction in mice."
sodium carbonate,Sodium carbonate is used to neutralize the pH of liver homogenate to 7.0 during glycogen extraction.,Entity: sodium carbonate. SMILES: O=C([O-])[O-].[Na+].[Na+]. Sodium carbonate is used to neutralize the pH of liver homogenate to 7.0 during glycogen extraction.
water,Distilled water is used to dissolve the polysaccharide gel containing aminoglycogen-I and normal glycogen after ultracentrifugation.,Entity: water. SMILES: O. Distilled water is used to dissolve the polysaccharide gel containing aminoglycogen-I and normal glycogen after ultracentrifugation.
ethanol,Ethanol is used as a precipitating agent to precipitate glycogen from the aqueous solution during glycogen purification.,Entity: ethanol. SMILES: CCO. Ethanol is used as a precipitating agent to precipitate glycogen from the aqueous solution during glycogen purification.
dithizone,"Dithizone is used to extract metal ions from solutions of buffer, substrate, or sodium chloride in CCl4.","Entity: dithizone. SMILES: S=C(N=Nc1ccccc1)NNc1ccccc1. Dithizone is used to extract metal ions from solutions of buffer, substrate, or sodium chloride in CCl4."
NTA,NTA is recrystallized from water to ensure purity in experimental procedures.,Entity: NTA. SMILES: O=C(O)CN(CC(=O)O)CC(=O)O. NTA is recrystallized from water to ensure purity in experimental procedures.
Ccl4,Ccl4 is used as a solvent for extracting metal ions from solutions containing dithizone.,Entity: Ccl4. SMILES: ClC(Cl)(Cl)Cl. Ccl4 is used as a solvent for extracting metal ions from solutions containing dithizone.
water,Water is used as a recrystallization medium for NTA to achieve high purity.,Entity: water. SMILES: O. Water is used as a recrystallization medium for NTA to achieve high purity.
EDTA,EDTA is used to standardize stock solutions of metal ions by titration and to clean glassware prior to use.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used to standardize stock solutions of metal ions by titration and to clean glassware prior to use.
MnO2,Manganese(II) can be standardized by spectrophotometry after oxidation to MnO2.,Entity: MnO2. SMILES: [Mn+4].[O-2].[O-2]. Manganese(II) can be standardized by spectrophotometry after oxidation to MnO2.
sodium chloride,Sodium chloride solutions can be treated with dithizone in CCl4 to remove traces of metal ions.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride solutions can be treated with dithizone in CCl4 to remove traces of metal ions.
sodium chloride,Sodium chloride is used as a 1 mM solution as a buffer component in kinetic assays involving protein and metal ion interactions.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used as a 1 mM solution as a buffer component in kinetic assays involving protein and metal ion interactions.
chlorophenol red,"Chlorophenol red, with a pKa of 5.9, is used as a pH indicator in assays monitoring pH changes (0.05–0.10 pH units) in the pH range 6–8.","Entity: chlorophenol red. SMILES: O=S1(=O)OC(c2ccc(O)c(Cl)c2)(c2ccc(O)c(Cl)c2)c2ccccc21. Chlorophenol red, with a pKa of 5.9, is used as a pH indicator in assays monitoring pH changes (0.05–0.10 pH units) in the pH range 6–8."
Pipes,Pipes is used as a buffer at 0.2 mM concentration in kinetic assays monitoring the formation of cobalt–protein complexes with apoenzyme.,Entity: Pipes. SMILES: O=S(=O)(O)CCN1CCN(CCS(=O)(=O)O)CC1. Pipes is used as a buffer at 0.2 mM concentration in kinetic assays monitoring the formation of cobalt–protein complexes with apoenzyme.
Mg,Mg is required as a cofactor for the activity of terminal transferase enzymes.,Entity: Mg. SMILES: [Mg]. Mg is required as a cofactor for the activity of terminal transferase enzymes.
Zn,"Zn has been identified as a cofactor for other transferase enzymes such as E. coli and sea urchin DNA polymerase, DNA dependent T7 RNA polymerase, and reverse transcriptase from mammalian RNA type C viruses.","Entity: Zn. SMILES: [Zn]. Zn has been identified as a cofactor for other transferase enzymes such as E. coli and sea urchin DNA polymerase, DNA dependent T7 RNA polymerase, and reverse transcriptase from mammalian RNA type C viruses."
Zinc,"Zinc is a component of terminal transferase enzymes, present at 0.78 g atoms/mol and 0.91 g atoms/mol in preparations with activities of 13,400 and 16,100 units, respectively.","Entity: Zinc. SMILES: [Zn]. Zinc is a component of terminal transferase enzymes, present at 0.78 g atoms/mol and 0.91 g atoms/mol in preparations with activities of 13,400 and 16,100 units, respectively."
Zinc,Removal of zinc from terminal transferase enzyme results in a Zn-free apoenzyme that retains less than 8% of the original enzyme activity.,Entity: Zinc. SMILES: [Zn]. Removal of zinc from terminal transferase enzyme results in a Zn-free apoenzyme that retains less than 8% of the original enzyme activity.
acridine orange,"Acridine orange is an aromatic dye that binds to DNA at a phosphate/dye ratio greater than 100 and its triplet excitons are quenched by metal ions bound to DNA, resulting in a uniform decrease in triplet lifetime across all bound dye molecules.","Entity: acridine orange. SMILES: CN(C)c1ccc2cc3ccc(N(C)C)cc3nc2c1. Acridine orange is an aromatic dye that binds to DNA at a phosphate/dye ratio greater than 100 and its triplet excitons are quenched by metal ions bound to DNA, resulting in a uniform decrease in triplet lifetime across all bound dye molecules."
oxygen,"The triplet lifetimes of polycyclic aromatic molecules or dyes intercalated between DNA base pairs are typically 20–30 ms in the absence of dissolved oxygen, but can be as long as 150 ms.","Entity: oxygen. SMILES: [O]. The triplet lifetimes of polycyclic aromatic molecules or dyes intercalated between DNA base pairs are typically 20–30 ms in the absence of dissolved oxygen, but can be as long as 150 ms."
manganese(II) sulfate,Manganese(II) sulfate is used as a source of manganese ions in aqueous solution to treat AO-DNA samples.,Entity: manganese(II) sulfate. SMILES: O=S(=O)([O-])[O-].[Mn+2]. Manganese(II) sulfate is used as a source of manganese ions in aqueous solution to treat AO-DNA samples.
silver nitrate,Silver nitrate is used as a source of silver ions in aqueous solution to treat AO-DNA samples.,Entity: silver nitrate. SMILES: O=[N+]([O-])[O-].[Ag+]. Silver nitrate is used as a source of silver ions in aqueous solution to treat AO-DNA samples.
Periodic acid,Periodic acid is used to dissolve 2 mm thick gel slices for detection of radiolabeled proteins after electrophoresis.,Entity: Periodic acid. SMILES: [O-][I+3]([O-])([O-])O. Periodic acid is used to dissolve 2 mm thick gel slices for detection of radiolabeled proteins after electrophoresis.
"N,N'-diallyltartardiamide","N,N'-diallyltartardiamide is used as a marker in gel electrophoresis to estimate molecular weight, replacing N,N'-methylene bisacrylamide.","Entity: N,N'-diallyltartardiamide. SMILES: C=CCNC(=O)[C@H](O)[C@@H](O)C(=O)NCC=C. N,N'-diallyltartardiamide is used as a marker in gel electrophoresis to estimate molecular weight, replacing N,N'-methylene bisacrylamide."
Iodoacetamide,Iodoacetamide is used to alkylate free thiol (-SH) groups of proteins at a concentration of 20 mM for 30 minutes at 2°C.,Entity: Iodoacetamide. SMILES: NC(=O)CI. Iodoacetamide is used to alkylate free thiol (-SH) groups of proteins at a concentration of 20 mM for 30 minutes at 2°C.
DFP,DFP ([3H]DFP) is a radiolabeling reagent used to phosphorylate acetylcholinesterase for proteomic studies.,Entity: DFP. SMILES: CC(C)OP(=O)(F)OC(C)C. DFP ([3H]DFP) is a radiolabeling reagent used to phosphorylate acetylcholinesterase for proteomic studies.
ammonium sulfate,Ammonium sulfate is used for precipitation of acetylcholinesterase homogenates during enzyme purification.,Entity: ammonium sulfate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Ammonium sulfate is used for precipitation of acetylcholinesterase homogenates during enzyme purification.
DTT,DTT is used as a reducing agent to dissociate acetylcholinesterase for proteomic analysis.,Entity: DTT. SMILES: O[C@H](CS)[C@H](O)CS. DTT is used as a reducing agent to dissociate acetylcholinesterase for proteomic analysis.
SDS,SDS is used for denaturation of acetylcholinesterase to facilitate the release of polypeptide chains for proteomic analysis.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used for denaturation of acetylcholinesterase to facilitate the release of polypeptide chains for proteomic analysis.
iodoacetamide,"Iodoacetamide is used as a crosslinking agent to covalently modify cysteine residues in proteins, typically by reacting with free thiols after reduction and denaturation.","Entity: iodoacetamide. SMILES: NC(=O)CI. Iodoacetamide is used as a crosslinking agent to covalently modify cysteine residues in proteins, typically by reacting with free thiols after reduction and denaturation."
Tris,Tris is a buffer commonly used in biochemical and molecular biology applications to maintain pH stability during protein denaturation and reduction procedures.,Entity: Tris. SMILES: NC(CO)(CO)CO. Tris is a buffer commonly used in biochemical and molecular biology applications to maintain pH stability during protein denaturation and reduction procedures.
SDS,SDS (sodium dodecyl sulfate) is an anionic detergent widely used to denature proteins prior to electrophoresis.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS (sodium dodecyl sulfate) is an anionic detergent widely used to denature proteins prior to electrophoresis.
DTT,DTT (dithiothreitol) is a reducing agent used to reduce disulfide bonds in proteins during denaturation protocols.,Entity: DTT. SMILES: O[C@H](CS)[C@H](O)CS. DTT (dithiothreitol) is a reducing agent used to reduce disulfide bonds in proteins during denaturation protocols.
DFP,"DFP (diisopropylfluorophosphate) can block the proteolytic transformation of acetylcholinesterase preparations, indicating its role as a protease inhibitor.","Entity: DFP. SMILES: CC(C)OP(=O)(F)OC(C)C. DFP (diisopropylfluorophosphate) can block the proteolytic transformation of acetylcholinesterase preparations, indicating its role as a protease inhibitor."
acetylcholine,Acetylcholine contains an amide bond that can be hydrolyzed by acetylcholinesterase.,Entity: acetylcholine. SMILES: CC(=O)OCC[N+](C)(C)C. Acetylcholine contains an amide bond that can be hydrolyzed by acetylcholinesterase.
Gallium,"Gallium can occupy the same binding sites as Zinc in transferrin, as indicated by difference addition spectra after exceeding saturation.","Entity: Gallium. SMILES: [Ga]. Gallium can occupy the same binding sites as Zinc in transferrin, as indicated by difference addition spectra after exceeding saturation."
Zinc,"Zinc can displace the original metal in the transferrin-metal complex when added in amounts exceeding saturation, as indicated by difference addition spectra.","Entity: Zinc. SMILES: [Zn]. Zinc can displace the original metal in the transferrin-metal complex when added in amounts exceeding saturation, as indicated by difference addition spectra."
Aluminum,"Aluminum can occupy the same binding sites as Zinc in transferrin, as shown by difference addition spectra after exceeding saturation.","Entity: Aluminum. SMILES: [Al]. Aluminum can occupy the same binding sites as Zinc in transferrin, as shown by difference addition spectra after exceeding saturation."
tryptophan,"Tryptophan residues in proteins can be perturbed by solvent effects, such as burial, as indicated by a negative trough in difference spectra near 300 nm.","Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan residues in proteins can be perturbed by solvent effects, such as burial, as indicated by a negative trough in difference spectra near 300 nm."
tryptophan,The absorbance enhancement factor (AE1) for burying a tryptophan residue in protein is about 1600.,Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. The absorbance enhancement factor (AE1) for burying a tryptophan residue in protein is about 1600.
zinc,"Zinc binding to transferrins produces difference spectra consistent with tyrosine ionization, indicating zinc can substitute for tyrosine in these complexes.","Entity: zinc. SMILES: [Zn]. Zinc binding to transferrins produces difference spectra consistent with tyrosine ionization, indicating zinc can substitute for tyrosine in these complexes."
zinc,"Zinc competes with aluminum and gallium for the same binding sites on transferrins, but may not compete for the same ligands.","Entity: zinc. SMILES: [Zn]. Zinc competes with aluminum and gallium for the same binding sites on transferrins, but may not compete for the same ligands."
aluminum,"Aluminum binding to transferrins produces difference spectra characteristic of perturbation of tryptophan and tyrosine, rather than tyrosine ionization.","Entity: aluminum. SMILES: [Al]. Aluminum binding to transferrins produces difference spectra characteristic of perturbation of tryptophan and tyrosine, rather than tyrosine ionization."
gallium,"Gallium binding to transferrins produces difference spectra characteristic of perturbation of tryptophan and tyrosine, rather than tyrosine ionization.","Entity: gallium. SMILES: [Ga]. Gallium binding to transferrins produces difference spectra characteristic of perturbation of tryptophan and tyrosine, rather than tyrosine ionization."
tyrosine,"Tyrosine is not a ligand in aluminum and gallium binding to transferrins, as these metal ions do not produce spectra indicative of tyrosine ionization.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine is not a ligand in aluminum and gallium binding to transferrins, as these metal ions do not produce spectra indicative of tyrosine ionization."
tryptophan,"Tryptophan is located in or near the metal binding sites on transferrins, as indicated by the spectra produced upon binding of aluminum and gallium.","Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan is located in or near the metal binding sites on transferrins, as indicated by the spectra produced upon binding of aluminum and gallium."
Alz(S04)3,Alz(S04)3 is used as a stock metal solution to determine metal ion concentrations in transferrin assays by atomic absorption analysis.,Entity: Alz(S04)3. SMILES: O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].[Al+3].[Al+3]. Alz(S04)3 is used as a stock metal solution to determine metal ion concentrations in transferrin assays by atomic absorption analysis.
tyrosine,"Tyrosine ionization in transferrins is associated with positive difference bands similar to those observed for tyrosine ionization, with an absorptivity ratio of 4.9.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine ionization in transferrins is associated with positive difference bands similar to those observed for tyrosine ionization, with an absorptivity ratio of 4.9."
Ga2(S04)3,Ga2(S04)3 is used as a stock metal solution to determine metal ion concentrations in transferrin assays by atomic absorption analysis.,Entity: Ga2(S04)3. SMILES: O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].[Ga+3].[Ga+3]. Ga2(S04)3 is used as a stock metal solution to determine metal ion concentrations in transferrin assays by atomic absorption analysis.
ZnS04,ZnS04 is used as a stock metal solution to determine metal ion concentrations in transferrin assays by atomic absorption analysis.,Entity: ZnS04. SMILES: O=S(=O)([O-])[O-].[Zn+2]. ZnS04 is used as a stock metal solution to determine metal ion concentrations in transferrin assays by atomic absorption analysis.
HCl,HCl is used as a 10³ N solution in the preparation of metal ion solutions for spectrophotometric difference spectroscopy of transferrins.,Entity: HCl. SMILES: Cl. HCl is used as a 10³ N solution in the preparation of metal ion solutions for spectrophotometric difference spectroscopy of transferrins.
tryptophan,"Tryptophan perturbation in transferrins is associated with positive difference bands near 292–295 nm, which are readily recognizable in the spectra.","Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan perturbation in transferrins is associated with positive difference bands near 292–295 nm, which are readily recognizable in the spectra."
tyrosine,Tyrosine residues in transferrins may not be fully ionized at pH 11.0.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine residues in transferrins may not be fully ionized at pH 11.0.
tryptophan,Tryptophan is involved in the binding of Fe(II) and Cu(I) to transferrins.,Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan is involved in the binding of Fe(II) and Cu(I) to transferrins.
tyrosine,Tyrosine is involved in the binding of Fe(II) and Cu(I) to transferrins.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine is involved in the binding of Fe(II) and Cu(I) to transferrins.
sodium deoxycholate,"Sodium deoxycholate inhibits the demethylation reaction, indicating that native cytochrome P-450 is required for this process.","Entity: sodium deoxycholate. SMILES: C[C@H](CCC(=O)[O-])[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C.[Na+]. Sodium deoxycholate inhibits the demethylation reaction, indicating that native cytochrome P-450 is required for this process."
oxygen,"Oxygen can exist in active oxygen species that participate in the reaction cycle of cytochrome P-450, potentially serving as the active oxygen in hydroxylation reactions.","Entity: oxygen. SMILES: [O]. Oxygen can exist in active oxygen species that participate in the reaction cycle of cytochrome P-450, potentially serving as the active oxygen in hydroxylation reactions."
oxygen,"Molecular oxygen is reduced at mercury to superoxide ion (O2-) in the potential region between -0.2 and -0.8 V, generating HzO2.","Entity: oxygen. SMILES: [O]. Molecular oxygen is reduced at mercury to superoxide ion (O2-) in the potential region between -0.2 and -0.8 V, generating HzO2."
quinoline,"Quinoline forms hydrophobic films during electrochemical experiments, which can inhibit electron transfer.","Entity: quinoline. SMILES: c1ccc2ncccc2c1. Quinoline forms hydrophobic films during electrochemical experiments, which can inhibit electron transfer."
triphenylphosphine oxide,"Triphenylphosphine oxide forms hydrophobic films during electrochemical experiments, which can inhibit electron transfer.","Entity: triphenylphosphine oxide. SMILES: O=P(c1ccccc1)(c1ccccc1)c1ccccc1. Triphenylphosphine oxide forms hydrophobic films during electrochemical experiments, which can inhibit electron transfer."
benzphetamine,"In the demethylation of benzphetamine, HzO2 is accumulated in solution, with a current yield of 40–60% at pH 6.5.","Entity: benzphetamine. SMILES: C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1. In the demethylation of benzphetamine, HzO2 is accumulated in solution, with a current yield of 40–60% at pH 6.5."
p-nitroanisole,"p-nitroanisole is demethylated by liver microsomes from phenobarbital-induced rabbits in the absence of NADPH, with a linear reaction rate up to at least 3 mg/ml protein and total conversion ranging from 1–90%.","Entity: p-nitroanisole. SMILES: COc1ccc([N+](=O)[O-])cc1. p-nitroanisole is demethylated by liver microsomes from phenobarbital-induced rabbits in the absence of NADPH, with a linear reaction rate up to at least 3 mg/ml protein and total conversion ranging from 1–90%."
benzphetamine,"Benzphetamine is demethylated by liver microsomes from phenobarbital-induced rabbits in the absence of NADPH, with a constant rate of demethylation observed within 1 hour and total conversion ranging from 1–90%.","Entity: benzphetamine. SMILES: C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1. Benzphetamine is demethylated by liver microsomes from phenobarbital-induced rabbits in the absence of NADPH, with a constant rate of demethylation observed within 1 hour and total conversion ranging from 1–90%."
aminopyrine,Aminopyrine is demethylated by liver microsomes from phenobarbital-induced rabbits in the absence of NADPH.,Entity: aminopyrine. SMILES: Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C. Aminopyrine is demethylated by liver microsomes from phenobarbital-induced rabbits in the absence of NADPH.
formaldehyde,"Formaldehyde is produced as a reaction product when benzphetamine, aminopyrine, or p-nitroanisole are demethylated by liver microsomes from phenobarbital-induced rabbits in the absence of NADPH.","Entity: formaldehyde. SMILES: C=O. Formaldehyde is produced as a reaction product when benzphetamine, aminopyrine, or p-nitroanisole are demethylated by liver microsomes from phenobarbital-induced rabbits in the absence of NADPH."
p-nitrophenol,p-nitrophenol is produced as a reaction product when p-nitroanisole is demethylated by liver microsomes from phenobarbital-induced rabbits in the absence of NADPH.,Entity: p-nitrophenol. SMILES: O=[N+]([O-])c1ccc(O)cc1. p-nitrophenol is produced as a reaction product when p-nitroanisole is demethylated by liver microsomes from phenobarbital-induced rabbits in the absence of NADPH.
cyanide,"Cyanide, a typical peroxidase inhibitor, is ineffective in inhibiting cytochrome P-450-mediated demethylation of benzphetamine in microsomes.","Entity: cyanide. SMILES: [C-]#N. Cyanide, a typical peroxidase inhibitor, is ineffective in inhibiting cytochrome P-450-mediated demethylation of benzphetamine in microsomes."
benzphetamine,"Benzphetamine demethylation in microsomes requires cytochrome P-450 and electrochemically reduced oxygen, but is not catalyzed by horse radish peroxidase or typical peroxidase inhibitors such as azide (1 mM) and cyanide.","Entity: benzphetamine. SMILES: C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1. Benzphetamine demethylation in microsomes requires cytochrome P-450 and electrochemically reduced oxygen, but is not catalyzed by horse radish peroxidase or typical peroxidase inhibitors such as azide (1 mM) and cyanide."
oxygen,Electrochemically reduced oxygen is required for the cytochrome P-450-mediated demethylation of benzphetamine in microsomes.,Entity: oxygen. SMILES: [O]. Electrochemically reduced oxygen is required for the cytochrome P-450-mediated demethylation of benzphetamine in microsomes.
carbon monoxide,Carbon monoxide does not influence the HzOz-supported cytochrome P-450-mediated demethylation of benzphetamine.,Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide does not influence the HzOz-supported cytochrome P-450-mediated demethylation of benzphetamine.
azide,"Azide at 1 mM, a typical peroxidase inhibitor, is ineffective in inhibiting cytochrome P-450-mediated demethylation of benzphetamine in microsomes.","Entity: azide. SMILES: [N-]=[N+]=[N-]. Azide at 1 mM, a typical peroxidase inhibitor, is ineffective in inhibiting cytochrome P-450-mediated demethylation of benzphetamine in microsomes."
NADPH,"NADPH is not required for the cytochrome P-450-mediated demethylation of benzphetamine, distinguishing it from NADPH-dependent demethylation reactions.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is not required for the cytochrome P-450-mediated demethylation of benzphetamine, distinguishing it from NADPH-dependent demethylation reactions."
phenobarbital,Phenobarbital pretreatment of rabbits is used to obtain liver microsomes for cytochrome P-450 enzyme assays.,Entity: phenobarbital. SMILES: CCC1(c2ccccc2)C(=O)NC(=O)NC1=O. Phenobarbital pretreatment of rabbits is used to obtain liver microsomes for cytochrome P-450 enzyme assays.
formaldehyde,"Formaldehyde is produced as a measure of demethylation activity in assays of benzphetamine, aminopyrine, and p-nitroanisole.","Entity: formaldehyde. SMILES: C=O. Formaldehyde is produced as a measure of demethylation activity in assays of benzphetamine, aminopyrine, and p-nitroanisole."
water,Hydrogen (H2O) generated during cytochrome P-450-catalyzed demethylation assays is quantified by measuring current in the range of 5–20 nmol per second.,Entity: water. SMILES: O. Hydrogen (H2O) generated during cytochrome P-450-catalyzed demethylation assays is quantified by measuring current in the range of 5–20 nmol per second.
p-nitroanisole,p-nitroanisole demethylation activity is measured by quantifying the amount of formaldehyde produced in microsomal assays.,Entity: p-nitroanisole. SMILES: COc1ccc([N+](=O)[O-])cc1. p-nitroanisole demethylation activity is measured by quantifying the amount of formaldehyde produced in microsomal assays.
benzphetamine,Benzphetamine demethylation activity is assessed by measuring the formaldehyde released in microsomal assays.,Entity: benzphetamine. SMILES: C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1. Benzphetamine demethylation activity is assessed by measuring the formaldehyde released in microsomal assays.
aminopyrine,Aminopyrine demethylation activity is quantified by measuring the amount of formaldehyde generated in microsomal assays.,Entity: aminopyrine. SMILES: Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C. Aminopyrine demethylation activity is quantified by measuring the amount of formaldehyde generated in microsomal assays.
semicarbazide,Semicarbazide is used as a reagent at 2 mM concentration in cytochrome P-450 microsomal demethylation assays.,Entity: semicarbazide. SMILES: NNC(N)=O. Semicarbazide is used as a reagent at 2 mM concentration in cytochrome P-450 microsomal demethylation assays.
glucose,Glucose reacts with glucose oxidase to generate hydrogen peroxide.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose reacts with glucose oxidase to generate hydrogen peroxide.
oxygen,"Oxygen can undergo continuous reduction to produce a more active form of peroxide, such as hydroxyl radical.","Entity: oxygen. SMILES: [O]. Oxygen can undergo continuous reduction to produce a more active form of peroxide, such as hydroxyl radical."
benzphetamine,The demethylation of benzphetamine is slower when hydrogen peroxide is generated by glucose oxidase and glucose compared to cathodic reduction of oxygen.,Entity: benzphetamine. SMILES: C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1. The demethylation of benzphetamine is slower when hydrogen peroxide is generated by glucose oxidase and glucose compared to cathodic reduction of oxygen.
hydroxyl radical,Hydroxyl radical is suggested to be a more active form of peroxide generated by continuous reduction of oxygen.,Entity: hydroxyl radical. SMILES: [OH]. Hydroxyl radical is suggested to be a more active form of peroxide generated by continuous reduction of oxygen.
hydrogen peroxide,Hydrogen peroxide can be generated by the electrolysis of water and by the reaction of glucose oxidase with glucose.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide can be generated by the electrolysis of water and by the reaction of glucose oxidase with glucose.
glucose,The accumulation of hydrogen peroxide (HzO2) in the system is less effective than in systems containing glucose oxidase and glucose.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. The accumulation of hydrogen peroxide (HzO2) in the system is less effective than in systems containing glucose oxidase and glucose.
hydrogen peroxide,"Hydrogen peroxide (H2O2) is formed by the combination of two electrons and a proton during the reduction of molecular oxygen at the electrode, with a pK of 11.6.","Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide (H2O2) is formed by the combination of two electrons and a proton during the reduction of molecular oxygen at the electrode, with a pK of 11.6."
hydroxyl radical,"Hydroxyl radical (HO•) can react with the Fe3+ of cytochrome P-450, which is more energetically favored than interaction with heme iron.","Entity: hydroxyl radical. SMILES: [OH]. Hydroxyl radical (HO•) can react with the Fe3+ of cytochrome P-450, which is more energetically favored than interaction with heme iron."
oxygen,"Molecular oxygen (O2) is reduced at the electrode in the potential region of 0 to 2– electrons, forming hydrogen peroxide (H2O2) via electron transfer.","Entity: oxygen. SMILES: O=O. Molecular oxygen (O2) is reduced at the electrode in the potential region of 0 to 2– electrons, forming hydrogen peroxide (H2O2) via electron transfer."
HzOz,HzOz can support the demethylation of several substrates in the absence of NADPH when cytochrome P-450 is present.,Entity: HzOz. SMILES: OO. HzOz can support the demethylation of several substrates in the absence of NADPH when cytochrome P-450 is present.
NADPH,The demethylation reaction catalyzed by cytochrome P-450 in the presence of HzOz absolutely requires NADPH.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. The demethylation reaction catalyzed by cytochrome P-450 in the presence of HzOz absolutely requires NADPH.
hydrogen peroxide,Hydrogen peroxide was detected in microsomal hydroxylation systems but was excluded as an active species because it could not substitute for NADPH in drug hydroxylation.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide was detected in microsomal hydroxylation systems but was excluded as an active species because it could not substitute for NADPH in drug hydroxylation.
NADPH,"NADPH is required for drug hydroxylation in microsomal systems, and hydrogen peroxide cannot substitute for NADPH in supporting this reaction.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is required for drug hydroxylation in microsomal systems, and hydrogen peroxide cannot substitute for NADPH in supporting this reaction."
oxygen,"In the mixed function oxidase reaction, molecular oxygen is activated by an as yet unknown mechanism, with activated oxygen existing at the redox level of peroxide or atomic oxygen (oxene).","Entity: oxygen. SMILES: [O]. In the mixed function oxidase reaction, molecular oxygen is activated by an as yet unknown mechanism, with activated oxygen existing at the redox level of peroxide or atomic oxygen (oxene)."
aminopyrine,Aminopyrine can be demethylated by catalase in a cumene hydroperoxide-dependent reaction more effectively than microsomes.,Entity: aminopyrine. SMILES: Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C. Aminopyrine can be demethylated by catalase in a cumene hydroperoxide-dependent reaction more effectively than microsomes.
benzphetamine,Benzphetamine can be demethylated by catalase in a cumene hydroperoxide-dependent reaction more effectively than microsomes.,Entity: benzphetamine. SMILES: C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1. Benzphetamine can be demethylated by catalase in a cumene hydroperoxide-dependent reaction more effectively than microsomes.
cumene hydroperoxide,Cumene hydroperoxide serves as a substrate for catalase-catalyzed demethylation of aminopyrine and benzphetamine.,Entity: cumene hydroperoxide. SMILES: CC(C)c1ccccc1.[O-]O. Cumene hydroperoxide serves as a substrate for catalase-catalyzed demethylation of aminopyrine and benzphetamine.
hemin,Cathodically reduced hemin complexes are unable to substitute for microsomes in demethylating substrates using molecular oxygen.,Entity: hemin. SMILES: C=CC1=C(C)c2cc3[n-]c(cc4[n-]c(cc5nc(cc1n2)C(C)=C5C=C)c(C)c4CCC(=O)O)c(CCC(=O)O)c3C.[Cl-].[Fe+3]. Cathodically reduced hemin complexes are unable to substitute for microsomes in demethylating substrates using molecular oxygen.
benzphetamine,Benzphetamine is demethylated in the presence of microsomes upon addition of hydrogen peroxide.,Entity: benzphetamine. SMILES: C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1. Benzphetamine is demethylated in the presence of microsomes upon addition of hydrogen peroxide.
hydrogen peroxide,Hydrogen peroxide acts as an oxidant that increases the demethylation rate of benzphetamine in microsomes.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide acts as an oxidant that increases the demethylation rate of benzphetamine in microsomes.
benzphetamine,The demethylation rate of benzphetamine does not reach saturation even at substrate concentrations ten-fold higher than the Km value in the NADPH-dependent reaction.,Entity: benzphetamine. SMILES: C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1. The demethylation rate of benzphetamine does not reach saturation even at substrate concentrations ten-fold higher than the Km value in the NADPH-dependent reaction.
benzphetamine,The Km of benzphetamine is considerably higher in the NADPH-dependent reaction compared to the cumene hydroperoxide-dependent system.,Entity: benzphetamine. SMILES: C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1. The Km of benzphetamine is considerably higher in the NADPH-dependent reaction compared to the cumene hydroperoxide-dependent system.
p-nitroanisole,The demethylation rate of p-nitroanisole does not reach saturation even at substrate concentrations ten-fold higher than the Km value in the NADPH-dependent reaction.,Entity: p-nitroanisole. SMILES: COc1ccc([N+](=O)[O-])cc1. The demethylation rate of p-nitroanisole does not reach saturation even at substrate concentrations ten-fold higher than the Km value in the NADPH-dependent reaction.
p-nitroanisole,The Km of p-nitroanisole is considerably higher in the NADPH-dependent reaction compared to the cumene hydroperoxide-dependent system.,Entity: p-nitroanisole. SMILES: COc1ccc([N+](=O)[O-])cc1. The Km of p-nitroanisole is considerably higher in the NADPH-dependent reaction compared to the cumene hydroperoxide-dependent system.
NADPH,NADPH is required as a cofactor for the demethylation reaction of benzphetamine and p-nitroanisole.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is required as a cofactor for the demethylation reaction of benzphetamine and p-nitroanisole.
cumene hydroperoxide,Cumene hydroperoxide serves as a cofactor in a system with Km values that are lower for benzphetamine and p-nitroanisole demethylation compared to the NADPH-dependent system.,Entity: cumene hydroperoxide. SMILES: CC(C)c1ccccc1.[O-]O. Cumene hydroperoxide serves as a cofactor in a system with Km values that are lower for benzphetamine and p-nitroanisole demethylation compared to the NADPH-dependent system.
oxalate,"Oxalate ion exhibits much greater affinity for cobalt (II) bovine carbonic anhydrase than acetate ion, with apparent affinity constants increasing dramatically with decreasing pH.","Entity: oxalate. SMILES: O=C([O-])C(=O)[O-]. Oxalate ion exhibits much greater affinity for cobalt (II) bovine carbonic anhydrase than acetate ion, with apparent affinity constants increasing dramatically with decreasing pH."
oxalate,"Oxalate ion can chelate the metal ion and/or interact with the wall of the active cavity in cobalt (II) bovine carbonic anhydrase, as indicated by carbon-13 NMR data.","Entity: oxalate. SMILES: O=C([O-])C(=O)[O-]. Oxalate ion can chelate the metal ion and/or interact with the wall of the active cavity in cobalt (II) bovine carbonic anhydrase, as indicated by carbon-13 NMR data."
propionate,Propionate has very little tendency to bind cobalt (II) bovine carbonic anhydrase compared to oxalate and acetate.,Entity: propionate. SMILES: CCC(=O)[O-]. Propionate has very little tendency to bind cobalt (II) bovine carbonic anhydrase compared to oxalate and acetate.
glutarate,Glutarate has very little tendency to bind cobalt (II) bovine carbonic anhydrase compared to oxalate and acetate.,Entity: glutarate. SMILES: O=C([O-])CCCC(=O)[O-]. Glutarate has very little tendency to bind cobalt (II) bovine carbonic anhydrase compared to oxalate and acetate.
retinal,"In halobacteria, the content of retinal in the purple membrane is reduced by 3-4 fold when bacteria-opsin is supplemented with a retinal analogue, indicating that retinal synthesis is regulated by the availability of bacteria-opsin.","Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1. In halobacteria, the content of retinal in the purple membrane is reduced by 3-4 fold when bacteria-opsin is supplemented with a retinal analogue, indicating that retinal synthesis is regulated by the availability of bacteria-opsin."
retinal,"A 4-keto-retinal analogue forms a complex with bacteria-opsin (Amax = 520 nm), allowing trapping of newly synthesized bacteria-opsin in halobacteria cultures.","Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1. A 4-keto-retinal analogue forms a complex with bacteria-opsin (Amax = 520 nm), allowing trapping of newly synthesized bacteria-opsin in halobacteria cultures."
puromycin,Puromycin is a protein synthesis inhibitor that completely inhibits bacteria-opsin synthesis in halobacteria during the stationary growth phase without affecting cell viability.,Entity: puromycin. SMILES: COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@H](n3cnc4c(N(C)C)ncnc43)O[C@@H]2CO)cc1. Puromycin is a protein synthesis inhibitor that completely inhibits bacteria-opsin synthesis in halobacteria during the stationary growth phase without affecting cell viability.
n-hexane,n-hexane is used as an organic solvent in the extraction and purification of pigments from retinal cells.,Entity: n-hexane. SMILES: CCCCCC. n-hexane is used as an organic solvent in the extraction and purification of pigments from retinal cells.
acetone,Acetone is used as a solvent in the extraction and purification of pigments from retinal cells.,Entity: acetone. SMILES: CC(C)=O. Acetone is used as a solvent in the extraction and purification of pigments from retinal cells.
toluene,Toluene is used as a solvent for extracting pigments from the upper phase during the pigment extraction process from retinal cells.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a solvent for extracting pigments from the upper phase during the pigment extraction process from retinal cells.
ethanol,Ethanol is used as a solvent for dissolving reagents and for washing pigment bands during the extraction and derivatization of retinal.,Entity: ethanol. SMILES: CCO. Ethanol is used as a solvent for dissolving reagents and for washing pigment bands during the extraction and derivatization of retinal.
acetic acid,Acetic acid is used as a solvent for preparing reagent 1 (4% thiourea in acetic acid) in the spectrophotometric quantification of retinal.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a solvent for preparing reagent 1 (4% thiourea in acetic acid) in the spectrophotometric quantification of retinal.
retinal,Retinal is a pigment that can be extracted from retinal cells and quantified by thin-layer chromatography and spectrophotometric measurement of absorbance at 530 nm after derivatization with thiourea and thiobarbituric acid.,Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1. Retinal is a pigment that can be extracted from retinal cells and quantified by thin-layer chromatography and spectrophotometric measurement of absorbance at 530 nm after derivatization with thiourea and thiobarbituric acid.
thiobarbituric acid,Thiobarbituric acid is used as a reagent (0.6% in ethanol) for derivatization in the spectrophotometric quantification of retinal.,Entity: thiobarbituric acid. SMILES: O=C1CC(=O)NC(=S)N1. Thiobarbituric acid is used as a reagent (0.6% in ethanol) for derivatization in the spectrophotometric quantification of retinal.
retinal,"In halobacteria, newly synthesized bacterioopsin is initially incorporated into a specialized membrane domain called the brown membrane, and complex formation with retinal in this domain is required for assembly of the purple membrane.","Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1. In halobacteria, newly synthesized bacterioopsin is initially incorporated into a specialized membrane domain called the brown membrane, and complex formation with retinal in this domain is required for assembly of the purple membrane."
thiourea,Thiourea is used as a reagent (4% in acetic acid) for derivatization in the spectrophotometric quantification of retinal.,Entity: thiourea. SMILES: NC(N)=S. Thiourea is used as a reagent (4% in acetic acid) for derivatization in the spectrophotometric quantification of retinal.
lycopene,Lycopene cyclization is catalyzed by a membrane-bound enzyme system whose activity is strongly inhibited by bacteria-opsin.,Entity: lycopene. SMILES: CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C. Lycopene cyclization is catalyzed by a membrane-bound enzyme system whose activity is strongly inhibited by bacteria-opsin.
retinal,"Retinal synthesis is inhibited when bacteria-opsin is depleted, as the enzyme system catalyzing retinal cyclization is feedback inhibited by bacteria-opsin.","Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1. Retinal synthesis is inhibited when bacteria-opsin is depleted, as the enzyme system catalyzing retinal cyclization is feedback inhibited by bacteria-opsin."
retinal,A slight excess of retinal can inhibit the cyclization of lycopene by the enzyme system responsible for retinal cyclization.,Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1. A slight excess of retinal can inhibit the cyclization of lycopene by the enzyme system responsible for retinal cyclization.
lycopene,"Lycopene is cyclized to P-carotene as part of the pathway for retinal synthesis, a process that can be blocked by nicotine.","Entity: lycopene. SMILES: CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C. Lycopene is cyclized to P-carotene as part of the pathway for retinal synthesis, a process that can be blocked by nicotine."
retinal,"Retinal synthesis in bacteria-opsin-containing cells is dependent on the bacterial-opsin content, with synthesis ceasing once all bacteria-opsin is converted to bacteriorhodopsin.","Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1. Retinal synthesis in bacteria-opsin-containing cells is dependent on the bacterial-opsin content, with synthesis ceasing once all bacteria-opsin is converted to bacteriorhodopsin."
nicotine,Nicotine inhibits the pathway of retinal synthesis by blocking the cyclization of lycopene to P-carotene.,Entity: nicotine. SMILES: CN1CCCC1c1cccnc1. Nicotine inhibits the pathway of retinal synthesis by blocking the cyclization of lycopene to P-carotene.
nicotine,"Nicotine induces the synthesis of bacteria-opsin in cells grown under conditions of limited oxygen supply, resulting in cells with 5-fold higher bacteria-opsin levels compared to cells with sufficient aeration.","Entity: nicotine. SMILES: CN1CCCC1c1cccnc1. Nicotine induces the synthesis of bacteria-opsin in cells grown under conditions of limited oxygen supply, resulting in cells with 5-fold higher bacteria-opsin levels compared to cells with sufficient aeration."
puromycin,Puromycin inhibits the further production of bacteria-opsin in cell suspensions.,Entity: puromycin. SMILES: COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@H](n3cnc4c(N(C)C)ncnc43)O[C@@H]2CO)cc1. Puromycin inhibits the further production of bacteria-opsin in cell suspensions.
lycopene,"In nicotine cells, conversion of lycopene to p-carotene is controlled by the activity of bacteria-opsin.","Entity: lycopene. SMILES: CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C. In nicotine cells, conversion of lycopene to p-carotene is controlled by the activity of bacteria-opsin."
p-carotene,"In nicotine cells, most of the lycopene is converted to p-carotene under nitrogen atmosphere.","Entity: p-carotene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/C=C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. In nicotine cells, most of the lycopene is converted to p-carotene under nitrogen atmosphere."
retinal,"Synthesis of retinal in nicotine cells requires oxygen, as the P-carotene to retinal reaction is oxygen-dependent.","Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1. Synthesis of retinal in nicotine cells requires oxygen, as the P-carotene to retinal reaction is oxygen-dependent."
lycopene,Lycopene is the predominant carotenoid in nicotine cells.,Entity: lycopene. SMILES: CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C. Lycopene is the predominant carotenoid in nicotine cells.
ammonia,"Ammonia inhibits methane and carbon monoxide oxidation by methanotrophic bacteria, with stronger inhibition at lower ammonia concentrations and the effect largely disappearing at high ammonia concentrations, suggesting competitive inhibition.","Entity: ammonia. SMILES: N. Ammonia inhibits methane and carbon monoxide oxidation by methanotrophic bacteria, with stronger inhibition at lower ammonia concentrations and the effect largely disappearing at high ammonia concentrations, suggesting competitive inhibition."
methane,Methane oxidation by methanotrophic bacteria is competitively inhibited by ammonia.,Entity: methane. SMILES: C. Methane oxidation by methanotrophic bacteria is competitively inhibited by ammonia.
carbon monoxide,Carbon monoxide oxidation by methanotrophic bacteria is competitively inhibited by ammonia.,Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide oxidation by methanotrophic bacteria is competitively inhibited by ammonia.
methanol,Methanol inhibits ammonia oxidation by N. europaea cells.,Entity: methanol. SMILES: CO. Methanol inhibits ammonia oxidation by N. europaea cells.
carbon monoxide,No NADH-dependent reaction is known for carbon monoxide oxidation in ammonia oxidation.,Entity: carbon monoxide. SMILES: [C]=O. No NADH-dependent reaction is known for carbon monoxide oxidation in ammonia oxidation.
methane,"In methane oxidation, NADH acts as a stoichiometric electron donor, whereas in ammonia oxidation, its role is more catalytic.","Entity: methane. SMILES: C. In methane oxidation, NADH acts as a stoichiometric electron donor, whereas in ammonia oxidation, its role is more catalytic."
ammonia,"Ammonia is oxidized to produce NADH during the process, with the NADH generation rate being only one tenth that observed in methane oxidation.","Entity: ammonia. SMILES: N. Ammonia is oxidized to produce NADH during the process, with the NADH generation rate being only one tenth that observed in methane oxidation."
ammonia,"NADH is probably not a natural electron donor for ammonia activation, as no NADH-dependent ammonia oxidation reaction is known.","Entity: ammonia. SMILES: N. NADH is probably not a natural electron donor for ammonia activation, as no NADH-dependent ammonia oxidation reaction is known."
ammonia,"The role of NADH in ammonia oxidation appears to be catalytic rather than stoichiometric, becoming significant after ammonia oxidation to nitrite is initiated.","Entity: ammonia. SMILES: N. The role of NADH in ammonia oxidation appears to be catalytic rather than stoichiometric, becoming significant after ammonia oxidation to nitrite is initiated."
nitrite,"Nitrite is produced as an intermediate during ammonia oxidation, and NADH's catalytic role in the process becomes apparent once nitrite is formed.","Entity: nitrite. SMILES: O=N[O-]. Nitrite is produced as an intermediate during ammonia oxidation, and NADH's catalytic role in the process becomes apparent once nitrite is formed."
methane,Methane can stimulate NADH oxidation activity in cell-free extracts of methane-utilizing bacteria.,Entity: methane. SMILES: C. Methane can stimulate NADH oxidation activity in cell-free extracts of methane-utilizing bacteria.
methane,"Methane is oxidized by a monooxygenase (hydroxylase) in the presence of NADH and oxygen, following the stoichiometry CH4 + O2 + NADH + I-l+ → CH4OH + NAD+ + H2O.","Entity: methane. SMILES: C. Methane is oxidized by a monooxygenase (hydroxylase) in the presence of NADH and oxygen, following the stoichiometry CH4 + O2 + NADH + I-l+ → CH4OH + NAD+ + H2O."
carbon monoxide,Carbon monoxide stimulates NADH oxidation activity in cell-free extracts of methane-utilizing bacteria.,Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide stimulates NADH oxidation activity in cell-free extracts of methane-utilizing bacteria.
carbon monoxide,"Carbon monoxide is oxidized by a monooxygenase (hydroxylase) in the presence of NADH and oxygen, following the stoichiometry CO + O2 + NADH + I-l+ → CO2 + NAD+ + H2O.","Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide is oxidized by a monooxygenase (hydroxylase) in the presence of NADH and oxygen, following the stoichiometry CO + O2 + NADH + I-l+ → CO2 + NAD+ + H2O."
hydroxylamine,Hydroxylamine can serve as an electron donor for ammonia oxidation in cell-free extracts of Nitrosomonas.,Entity: hydroxylamine. SMILES: NO. Hydroxylamine can serve as an electron donor for ammonia oxidation in cell-free extracts of Nitrosomonas.
ammonia,Ammonia oxidation in cell-free extracts of Nitrosomonas requires NADH or hydroxylamine as electron donors.,Entity: ammonia. SMILES: N. Ammonia oxidation in cell-free extracts of Nitrosomonas requires NADH or hydroxylamine as electron donors.
ammonia,Ammonia oxidation in the presence of a monooxygenase (hydroxylase) proceeds with the stoichiometry CH4OH + O2 + NADH + I-l+ → CH4OH + NAD+ + H2O.,Entity: ammonia. SMILES: N. Ammonia oxidation in the presence of a monooxygenase (hydroxylase) proceeds with the stoichiometry CH4OH + O2 + NADH + I-l+ → CH4OH + NAD+ + H2O.
nitrite,"Complete oxidation of ammonia in Nitrosomonas extracts leads to the generation of nitrite, which is necessary for NADH oxidation.","Entity: nitrite. SMILES: O=N[O-]. Complete oxidation of ammonia in Nitrosomonas extracts leads to the generation of nitrite, which is necessary for NADH oxidation."
ammonia,"The undissociated form of ammonia, NH3, is the substrate for oxidation by Nitrosomonas, rather than ammonium ion (NH4+).","Entity: ammonia. SMILES: N. The undissociated form of ammonia, NH3, is the substrate for oxidation by Nitrosomonas, rather than ammonium ion (NH4+)."
ammonia,"Ammonia can be replaced by methane, carbon monoxide, or methanol in ammonia oxidation reactions catalyzed by Nitrosomonas, supporting its role as a competitive substrate.","Entity: ammonia. SMILES: N. Ammonia can be replaced by methane, carbon monoxide, or methanol in ammonia oxidation reactions catalyzed by Nitrosomonas, supporting its role as a competitive substrate."
carbon monoxide,Carbon monoxide can substitute for ammonia in ammonia oxidation catalyzed by Nitrosomonas.,Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide can substitute for ammonia in ammonia oxidation catalyzed by Nitrosomonas.
methane,Methane serves as the oxidizable substrate in methane-oxidizing systems and competes with ammonia for the ammonia-binding site of Nitrosomonas.,Entity: methane. SMILES: C. Methane serves as the oxidizable substrate in methane-oxidizing systems and competes with ammonia for the ammonia-binding site of Nitrosomonas.
hydroxylamine,"Hydroxylamine can support NADH oxidation in ammonia oxidation, indicating its role as an intermediate or electron donor in this process.","Entity: hydroxylamine. SMILES: NO. Hydroxylamine can support NADH oxidation in ammonia oxidation, indicating its role as an intermediate or electron donor in this process."
methanol,"Methanol, the first intermediate in methane oxidation, competes with ammonia for the ammonia-binding site of Nitrosomonas.","Entity: methanol. SMILES: CO. Methanol, the first intermediate in methane oxidation, competes with ammonia for the ammonia-binding site of Nitrosomonas."
nitrite,Nitrite can be quantified in biochemical assays using methods described in the referenced literature.,Entity: nitrite. SMILES: O=N[O-]. Nitrite can be quantified in biochemical assays using methods described in the referenced literature.
oxygen,Oxygen disappearance can be measured polarographically in ammonia oxidation assays using an Oxygraph at 25°C.,Entity: oxygen. SMILES: [O]. Oxygen disappearance can be measured polarographically in ammonia oxidation assays using an Oxygraph at 25°C.
potassium phosphate,Potassium phosphate at 0.1 M concentration and pH 7.5 is used as a buffer in ammonia oxidation and protein fractionation assays.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate at 0.1 M concentration and pH 7.5 is used as a buffer in ammonia oxidation and protein fractionation assays.
ammonia,Ammonia oxidation can be monitored by polarographic measurement of oxygen disappearance in enzymatic assays.,Entity: ammonia. SMILES: N. Ammonia oxidation can be monitored by polarographic measurement of oxygen disappearance in enzymatic assays.
ascorbate,Ascorbate acts as an effective electron donor in methane oxidation but does not replace NADH in ammonia oxidation.,Entity: ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O. Ascorbate acts as an effective electron donor in methane oxidation but does not replace NADH in ammonia oxidation.
methane,"Methane competitively inhibits ammonia oxidation by cell-free extracts of N. europaea, with a Ki value comparable to the Km for methane oxidation.","Entity: methane. SMILES: C. Methane competitively inhibits ammonia oxidation by cell-free extracts of N. europaea, with a Ki value comparable to the Km for methane oxidation."
ammonia,"Ammonia oxidation by cell-free extracts of N. europaea is competitively inhibited by methane, carbon monoxide, and methanol.","Entity: ammonia. SMILES: N. Ammonia oxidation by cell-free extracts of N. europaea is competitively inhibited by methane, carbon monoxide, and methanol."
methanol,Methanol competitively inhibits ammonia oxidation by cell-free extracts of N. europaea.,Entity: methanol. SMILES: CO. Methanol competitively inhibits ammonia oxidation by cell-free extracts of N. europaea.
carbon monoxide,"Carbon monoxide competitively inhibits ammonia oxidation by cell-free extracts of N. europaea, with a Ki value comparable to the Km for carbon monoxide oxidation.","Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide competitively inhibits ammonia oxidation by cell-free extracts of N. europaea, with a Ki value comparable to the Km for carbon monoxide oxidation."
adrenalin,Adrenalin is used as a stimulator in adenylyl cyclase assays at a final concentration of 2.25 × 10^4 M.,Entity: adrenalin. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenalin is used as a stimulator in adenylyl cyclase assays at a final concentration of 2.25 × 10^4 M.
glucagon,Glucagon is used as a stimulator in adenylyl cyclase assays at a final concentration of 5 × 10^8 M.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon is used as a stimulator in adenylyl cyclase assays at a final concentration of 5 × 10^8 M.
glycylglycine,Glycylglycine is used as a buffer component at 30 mM concentration and pH 7.4 in adenylyl cyclase assays.,Entity: glycylglycine. SMILES: NCC(=O)NCC(=O)O. Glycylglycine is used as a buffer component at 30 mM concentration and pH 7.4 in adenylyl cyclase assays.
theophylline,Theophylline is included at 5 mM concentration in the adenylyl cyclase assay buffer.,Entity: theophylline. SMILES: Cn1c(=O)c2[nH]cnc2n(C)c1=O. Theophylline is included at 5 mM concentration in the adenylyl cyclase assay buffer.
NaHCO3,NaHCO3 is used as a component of medium I at 2 mM concentration in liver homogenate preparation.,Entity: NaHCO3. SMILES: O=C([O-])O.[Na+]. NaHCO3 is used as a component of medium I at 2 mM concentration in liver homogenate preparation.
perchloric acid,Perchloric acid at 0.6 M concentration is used to stop adenylyl cyclase reactions in the assay.,Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid at 0.6 M concentration is used to stop adenylyl cyclase reactions in the assay.
sucrose,Sucrose is used in gradients at 20–60% (w/w) concentration in liver plasma membrane fractionation.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used in gradients at 20–60% (w/w) concentration in liver plasma membrane fractionation.
indomethacin,"Indomethacin treatment in adrenalectomized rats increases the responsiveness of adenylyl cyclase to adrenalin, resulting in an 8-fold stimulation of adenylyl cyclase activity in liver plasma membranes.","Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin treatment in adrenalectomized rats increases the responsiveness of adenylyl cyclase to adrenalin, resulting in an 8-fold stimulation of adenylyl cyclase activity in liver plasma membranes."
indomethacin,Indomethacin treatment elevates basal cyclic AMP (cAMP) synthesis in plasma membranes from rat livers.,Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin treatment elevates basal cyclic AMP (cAMP) synthesis in plasma membranes from rat livers.
adrenalin,Adrenalin sensitivity is much more labile against dilution with buffer during preparation compared to glucagon.,Entity: adrenalin. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenalin sensitivity is much more labile against dilution with buffer during preparation compared to glucagon.
glucagon,"Glucagon is the primary regulator of liver adenylyl cyclase activity, with a much stronger effect than adrenalin.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon is the primary regulator of liver adenylyl cyclase activity, with a much stronger effect than adrenalin."
adrenalin,Adrenalin weakly stimulates liver plasma membrane adenylyl cyclase activity.,Entity: adrenalin. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenalin weakly stimulates liver plasma membrane adenylyl cyclase activity.
indomethacin,Indomethacin is an inhibitor of prostaglandin synthetase.,Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin is an inhibitor of prostaglandin synthetase.
Indomethacin,Indomethacin inhibits the synthesis of a cyclic AMP antagonist that phosphorylates and inhibits adenylyl cyclase.,Entity: Indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin inhibits the synthesis of a cyclic AMP antagonist that phosphorylates and inhibits adenylyl cyclase.
Indomethacin,Pretreatment of rats with indomethacin increases the responsiveness of liver plasma membrane preparations to both glucagon and adrenalin.,Entity: Indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Pretreatment of rats with indomethacin increases the responsiveness of liver plasma membrane preparations to both glucagon and adrenalin.
Adrenalin,"Adrenalin is poorly responsive in liver plasma membrane preparations, likely due to inhibition of adenylyl cyclase by a cyclic AMP antagonist.","Entity: Adrenalin. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenalin is poorly responsive in liver plasma membrane preparations, likely due to inhibition of adenylyl cyclase by a cyclic AMP antagonist."
Glucagon,"Glucagon is highly responsive in liver plasma membrane preparations, and this response is enhanced by indomethacin pretreatment.","Entity: Glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon is highly responsive in liver plasma membrane preparations, and this response is enhanced by indomethacin pretreatment."
cholesterol,"Cholesterol, when oxidized, forms black lipid membranes (BLMs) that do not bind detectable amounts of the protein-pigment complex under the described experimental conditions.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol, when oxidized, forms black lipid membranes (BLMs) that do not bind detectable amounts of the protein-pigment complex under the described experimental conditions."
lecithin,Lecithin is used as a component of the membrane-forming solution at 1% w/w in decane to facilitate the formation of black lipid membranes (BLMs) for protein-pigment complex incorporation experiments.,Entity: lecithin. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C. Lecithin is used as a component of the membrane-forming solution at 1% w/w in decane to facilitate the formation of black lipid membranes (BLMs) for protein-pigment complex incorporation experiments.
octadecylamine,Octadecylamine is included at 0.025% w/w in the membrane-forming solution with lecithin to create positively charged black lipid membranes (BLMs) for protein-pigment complex studies.,Entity: octadecylamine. SMILES: CCCCCCCCCCCCCCCCCCN. Octadecylamine is included at 0.025% w/w in the membrane-forming solution with lecithin to create positively charged black lipid membranes (BLMs) for protein-pigment complex studies.
decane,Decane serves as the solvent for the membrane-forming solution containing 1% w/w lecithin and 0.025% w/w octadecylamine in black lipid membrane (BLM) preparation.,Entity: decane. SMILES: CCCCCCCCCC. Decane serves as the solvent for the membrane-forming solution containing 1% w/w lecithin and 0.025% w/w octadecylamine in black lipid membrane (BLM) preparation.
sodium chloride,"Sodium chloride concentration in the bathing solution influences the electric break-down potential of the black lipid membranes (BLMs), typically ranging from 100 to 180 mV.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride concentration in the bathing solution influences the electric break-down potential of the black lipid membranes (BLMs), typically ranging from 100 to 180 mV."
guanine,"Guanine nucleotides are interconverted with adenosine monophosphate by AMP deaminase, contributing to the regulation of cellular energy charge.","Entity: guanine. SMILES: Nc1nc2nc[nH]c2c(=O)[nH]1. Guanine nucleotides are interconverted with adenosine monophosphate by AMP deaminase, contributing to the regulation of cellular energy charge."
adenosine monophosphate,"Adenosine monophosphate (AMP) is interconverted with guanine nucleotides by AMP deaminase, which is physiologically important for maintaining cellular energy balance.","Entity: adenosine monophosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine monophosphate (AMP) is interconverted with guanine nucleotides by AMP deaminase, which is physiologically important for maintaining cellular energy balance."
adenosine triphosphate,"Adenosine triphosphate (ATP) is a key player in the purine nucleotide cycle, and its interconversion with other nucleotides is mediated by AMP deaminase.","Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine triphosphate (ATP) is a key player in the purine nucleotide cycle, and its interconversion with other nucleotides is mediated by AMP deaminase."
oleic acid,"Oleic acid decreases the adenylate energy charge in perfused liver systems, indicating its role in reducing cellular energy charge.","Entity: oleic acid. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. Oleic acid decreases the adenylate energy charge in perfused liver systems, indicating its role in reducing cellular energy charge."
palmitoyl-CoA,Palmitoyl-CoA inhibits brain AMP deaminase through a non-competitive mechanism without altering the enzyme's affinity for its substrate.,Entity: palmitoyl-CoA. SMILES: CCCCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Palmitoyl-CoA inhibits brain AMP deaminase through a non-competitive mechanism without altering the enzyme's affinity for its substrate.
CoA,CoA does not inhibit the enzyme activity tested.,Entity: CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. CoA does not inhibit the enzyme activity tested.
palmitate,Palmitate at 200 PM shows a slight activation of the enzyme.,Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Palmitate at 200 PM shows a slight activation of the enzyme.
stearate,Stearate at 200 PM shows a slight activation of the enzyme.,Entity: stearate. SMILES: CCCCCCCCCCCCCCCCCC(=O)[O-]. Stearate at 200 PM shows a slight activation of the enzyme.
acetyl-CoA,Acetyl-CoA does not inhibit the enzyme activity tested.,Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Acetyl-CoA does not inhibit the enzyme activity tested.
potassium phosphate,Potassium phosphate is used as a buffer at 20 mM concentration and pH 7.1 in the preparation and purification of AMP deaminase from bovine brain and liver.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate is used as a buffer at 20 mM concentration and pH 7.1 in the preparation and purification of AMP deaminase from bovine brain and liver.
2-mercaptoethanol,"2-mercaptoethanol is included at 0.1% concentration in the buffer system for the extraction, purification, and elution of AMP deaminase from bovine brain and liver.","Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is included at 0.1% concentration in the buffer system for the extraction, purification, and elution of AMP deaminase from bovine brain and liver."
sodium chloride,Sodium chloride is used at 0.1 M concentration in the buffer system for the extraction and purification of AMP deaminase from bovine brain and liver.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at 0.1 M concentration in the buffer system for the extraction and purification of AMP deaminase from bovine brain and liver.
potassium phosphate,Potassium phosphate is used as a 50 mM buffer at pH 7.1 in assays measuring bovine brain AMP deaminase activity.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate is used as a 50 mM buffer at pH 7.1 in assays measuring bovine brain AMP deaminase activity.
adenosine monophosphate,"Adenosine monophosphate serves as a substrate for AMP deaminase, catalyzing its hydrolysis to produce ammonia.","Entity: adenosine monophosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine monophosphate serves as a substrate for AMP deaminase, catalyzing its hydrolysis to produce ammonia."
ammonia,Ammonia is the product of AMP deaminase-catalyzed hydrolysis of adenosine monophosphate.,Entity: ammonia. SMILES: N. Ammonia is the product of AMP deaminase-catalyzed hydrolysis of adenosine monophosphate.
potassium phosphate,Potassium phosphate buffer at 60 mM and pH 7.1 is used as a component in enzymatic assays measuring AMP deaminase activity.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate buffer at 60 mM and pH 7.1 is used as a component in enzymatic assays measuring AMP deaminase activity.
sodium chloride,Sodium chloride at 0.1 M concentration is included in the reaction mixture for AMP deaminase activity assays.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride at 0.1 M concentration is included in the reaction mixture for AMP deaminase activity assays.
CoA,CoA does not inhibit AMP deaminase activity under the tested conditions.,Entity: CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. CoA does not inhibit AMP deaminase activity under the tested conditions.
acetyl-CoA,Acetyl-CoA does not inhibit AMP deaminase activity under the tested conditions.,Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Acetyl-CoA does not inhibit AMP deaminase activity under the tested conditions.
adenine,The adenine moiety of CoA is a structural component of FA-CoA that is responsible for reversible inhibition of AMP deaminase at low concentrations.,Entity: adenine. SMILES: Nc1ncnc2nc[nH]c12. The adenine moiety of CoA is a structural component of FA-CoA that is responsible for reversible inhibition of AMP deaminase at low concentrations.
palmitoyl-CoA,Palmitoyl-CoA inhibits brain enzyme activity with an IC50 of 5 µM and liver enzyme activity with an IC50 of 12 µM.,Entity: palmitoyl-CoA. SMILES: CCCCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Palmitoyl-CoA inhibits brain enzyme activity with an IC50 of 5 µM and liver enzyme activity with an IC50 of 12 µM.
oleoyl-CoA,Oleoyl-CoA inhibits brain enzyme activity with an IC50 of 11 µM.,Entity: oleoyl-CoA. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Oleoyl-CoA inhibits brain enzyme activity with an IC50 of 11 µM.
stearoyl-CoA,Stearoyl-CoA inhibits brain enzyme activity with an IC50 of 2 µM and liver enzyme activity with an IC50 of 25 µM.,Entity: stearoyl-CoA. SMILES: CCCCCCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Stearoyl-CoA inhibits brain enzyme activity with an IC50 of 2 µM and liver enzyme activity with an IC50 of 25 µM.
oleoyl-CoA,Oleoyl-CoA is a long-chain acyl-CoA derivative that acts as a strong surfactant and detergent.,Entity: oleoyl-CoA. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Oleoyl-CoA is a long-chain acyl-CoA derivative that acts as a strong surfactant and detergent.
oleoyl-CoA,"Oleoyl-CoA is much less inhibitory to citrate synthase (EC 4.1.3.4) and is not appreciably bound to this enzyme, demonstrating that its inhibition is specific and independent of its detergent properties.","Entity: oleoyl-CoA. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Oleoyl-CoA is much less inhibitory to citrate synthase (EC 4.1.3.4) and is not appreciably bound to this enzyme, demonstrating that its inhibition is specific and independent of its detergent properties."
water,"Water is used as a solvent component (in mixtures with ethylene-glycol) for studying protein stability and ligand binding, allowing spectrophotometric analysis of protein-ligand interactions.","Entity: water. SMILES: O. Water is used as a solvent component (in mixtures with ethylene-glycol) for studying protein stability and ligand binding, allowing spectrophotometric analysis of protein-ligand interactions."
KCl,KCl at 0.4 M concentration is included in the solvent mixture to support reversible oxygen binding to Hb Trout IV in experimental studies.,Entity: KCl. SMILES: [Cl-].[K+]. KCl at 0.4 M concentration is included in the solvent mixture to support reversible oxygen binding to Hb Trout IV in experimental studies.
oxygen,Oxygen binding to Hb Trout IV is reversible and can be monitored spectrophotometrically in the visible absorption region (700–360 nm) in ethylene-glycol/water mixtures.,Entity: oxygen. SMILES: [O]. Oxygen binding to Hb Trout IV is reversible and can be monitored spectrophotometrically in the visible absorption region (700–360 nm) in ethylene-glycol/water mixtures.
O2,"The oxygen affinity and apparent cooperativity of Hb Trout IV, a hemoglobin from trout blood, decrease as the pH drops from 8.0 to 6.0.","Entity: O2. SMILES: [O]. The oxygen affinity and apparent cooperativity of Hb Trout IV, a hemoglobin from trout blood, decrease as the pH drops from 8.0 to 6.0."
hemoglobin,"At acid pH (<6), hemoglobin switches to a low affinity conformational state, and the Hill coefficient (n) can be below 1, indicating functional differences between the OL and p subunits.","Entity: hemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. At acid pH (<6), hemoglobin switches to a low affinity conformational state, and the Hill coefficient (n) can be below 1, indicating functional differences between the OL and p subunits."
hemoglobin,"Protons stabilize a low affinity conformational state of hemoglobin tetramer, which becomes the dominant state at acid pH regardless of ligand binding.","Entity: hemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. Protons stabilize a low affinity conformational state of hemoglobin tetramer, which becomes the dominant state at acid pH regardless of ligand binding."
oxygen,Oxygen binding to hemoglobin at acid pH occurs in the presence of equivalent and non-interacting low affinity sites.,Entity: oxygen. SMILES: [O]. Oxygen binding to hemoglobin at acid pH occurs in the presence of equivalent and non-interacting low affinity sites.
S-adenosylmethionine,S-adenosylmethionine (SAM) is used as a reference inhibitor at a concentration of 0.9 mM to assess the inhibition of ethanolaminephosphate cytidylyltransferase in enzymatic assays.,Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine (SAM) is used as a reference inhibitor at a concentration of 0.9 mM to assess the inhibition of ethanolaminephosphate cytidylyltransferase in enzymatic assays.
S-adenosylethionine,S-adenosylethionine (SAE) is a structural analogue of S-adenosylmethionine and is tested for its ability to inhibit the synthesis of CDP-ethanolamine by ethanolaminephosphate cytidylyltransferase.,Entity: S-adenosylethionine. SMILES: CC[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylethionine (SAE) is a structural analogue of S-adenosylmethionine and is tested for its ability to inhibit the synthesis of CDP-ethanolamine by ethanolaminephosphate cytidylyltransferase.
CDP-ethanolamine,"CDP-ethanolamine is the product synthesized by ethanolaminephosphate cytidylyltransferase, and its formation is inhibited by S-adenosylmethionine and S-adenosylethionine in enzymatic assays.","Entity: CDP-ethanolamine. SMILES: NCCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O. CDP-ethanolamine is the product synthesized by ethanolaminephosphate cytidylyltransferase, and its formation is inhibited by S-adenosylmethionine and S-adenosylethionine in enzymatic assays."
S-adenosylhomocysteine,S-adenosylhomocysteine (SAH) is the active form of S-adenosylmethionine and is used as a reference inhibitor in studies of ethanolaminephosphate cytidylyltransferase.,Entity: S-adenosylhomocysteine. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CSCC[C@H](N)C(=O)O)[C@@H](O)[C@H]1O. S-adenosylhomocysteine (SAH) is the active form of S-adenosylmethionine and is used as a reference inhibitor in studies of ethanolaminephosphate cytidylyltransferase.
S-adenosylmethionine,"S-adenosylmethionine inhibits ethanolaminephosphate cytidylyltransferase activity, with inhibition rate increasing progressively and complete inhibition occurring after 20 minutes.","Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine inhibits ethanolaminephosphate cytidylyltransferase activity, with inhibition rate increasing progressively and complete inhibition occurring after 20 minutes."
trichloroacetic acid,Trichloroacetic acid is used to stop protein methylation reactions and to precipitate proteins for subsequent analysis.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to stop protein methylation reactions and to precipitate proteins for subsequent analysis.
sodium hydroxide,Sodium hydroxide is used to dissolve protein pellets in protein quantification assays.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to dissolve protein pellets in protein quantification assays.
MgCl2,MgCl2 is used as a cofactor at 10 mM concentration in the standard incubation mixture for ethanolaminephosphate cytidylyltransferase assays.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used as a cofactor at 10 mM concentration in the standard incubation mixture for ethanolaminephosphate cytidylyltransferase assays.
CTP,CTP is included at 3 mM concentration in the standard incubation mixture for ethanolaminephosphate cytidylyltransferase assays.,Entity: CTP. SMILES: Nc1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)n1. CTP is included at 3 mM concentration in the standard incubation mixture for ethanolaminephosphate cytidylyltransferase assays.
SAM,"SAM is used as an effector in ethanolaminephosphate cytidylyltransferase assays, with its concentration varied during the experiment.","Entity: SAM. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. SAM is used as an effector in ethanolaminephosphate cytidylyltransferase assays, with its concentration varied during the experiment."
phosphatidylethanolamine,N-methylation of phosphatidylethanolamine is a well-known pathway for the biosynthesis of phosphatidylcholine.,Entity: phosphatidylethanolamine. SMILES: CC(=O)OC[C@H](COP(=O)(O)OCCN)OC(C)=O. N-methylation of phosphatidylethanolamine is a well-known pathway for the biosynthesis of phosphatidylcholine.
CDP-ethanolamine,In vivo methylation of CDP-ethanolamine has been reported as part of the biosynthetic pathway for phosphatidylcholine.,Entity: CDP-ethanolamine. SMILES: NCCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O. In vivo methylation of CDP-ethanolamine has been reported as part of the biosynthetic pathway for phosphatidylcholine.
S-adenosylmethionine,S-adenosylmethionine inhibits the in vitro incorporation of ethanolaminephosphate into rat liver phospholipids.,Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine inhibits the in vitro incorporation of ethanolaminephosphate into rat liver phospholipids.
S-adenosylmethionine,"Preincubation of proteins with S-adenosylmethionine (SAM) between 0 and 60 minutes increases enzyme inhibition to 43–74%, compared to a constant enzyme activity in non-treated controls.","Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. Preincubation of proteins with S-adenosylmethionine (SAM) between 0 and 60 minutes increases enzyme inhibition to 43–74%, compared to a constant enzyme activity in non-treated controls."
S-adenosylhomocysteine,S-adenosylhomocysteine does not significantly affect the activity of ethanolaminephosphate cytidylyltransferase.,Entity: S-adenosylhomocysteine. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CSCC[C@H](N)C(=O)O)[C@@H](O)[C@H]1O. S-adenosylhomocysteine does not significantly affect the activity of ethanolaminephosphate cytidylyltransferase.
S-adenosylethionine,S-adenosylethionine does not significantly affect the activity of ethanolaminephosphate cytidylyltransferase.,Entity: S-adenosylethionine. SMILES: CC[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylethionine does not significantly affect the activity of ethanolaminephosphate cytidylyltransferase.
S-adenosylmethionine,S-adenosylmethionine does not significantly affect the activity of ethanolaminephosphate cytidylyltransferase.,Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine does not significantly affect the activity of ethanolaminephosphate cytidylyltransferase.
S-adenosylmethionine,"S-adenosylmethionine inhibits ethanolaminephosphate cytidylyltransferase activity, with inhibition increasing in a concentration-dependent manner and reaching about 50% at 1 mM S-adenosylmethionine.","Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine inhibits ethanolaminephosphate cytidylyltransferase activity, with inhibition increasing in a concentration-dependent manner and reaching about 50% at 1 mM S-adenosylmethionine."
S-adenosyl-L-methionine,S-adenosyl-L-methionine is a methyltransferase cofactor used to methylate proteins in biochemical assays at a concentration of 0.036 mM.,Entity: S-adenosyl-L-methionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosyl-L-methionine is a methyltransferase cofactor used to methylate proteins in biochemical assays at a concentration of 0.036 mM.
S-adenosylmethionine,"S-adenosylmethionine (SAM) can methylate ethanolaminephosphate cytidylyltransferase, potentially inactivating the enzyme through a time-dependent, non-enzymatic reaction.","Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine (SAM) can methylate ethanolaminephosphate cytidylyltransferase, potentially inactivating the enzyme through a time-dependent, non-enzymatic reaction."
S-adenosylhomocysteine,S-adenosylhomocysteine is a classical inhibitor of methyltransferases but does not block the SAM-induced inactivation of ethanolaminephosphate cytidylyltransferase.,Entity: S-adenosylhomocysteine. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CSCC[C@H](N)C(=O)O)[C@@H](O)[C@H]1O. S-adenosylhomocysteine is a classical inhibitor of methyltransferases but does not block the SAM-induced inactivation of ethanolaminephosphate cytidylyltransferase.
ethylene glycol,Ethylene glycol is used as a cryoprotectant at a final concentration of 55% (v/v) to maintain sample clarity during cooling in photochemical experiments.,Entity: ethylene glycol. SMILES: OCCO. Ethylene glycol is used as a cryoprotectant at a final concentration of 55% (v/v) to maintain sample clarity during cooling in photochemical experiments.
dithionite,Dithionite is added to photochemical reaction mixtures at a concentration of 10 n-&I shortly before freezing to act as a reducing agent.,Entity: dithionite. SMILES: O=S([O-])S(=O)[O-]. Dithionite is added to photochemical reaction mixtures at a concentration of 10 n-&I shortly before freezing to act as a reducing agent.
TMPD,TMPD is used at a low concentration of 5 µM as an efficient electron donor for oxidized C-552 in photochemical experiments.,Entity: TMPD. SMILES: CC1=C(C)C(=O)C(C)=C(C)C1=O. TMPD is used at a low concentration of 5 µM as an efficient electron donor for oxidized C-552 in photochemical experiments.
TMPD,"TMPD can efficiently reduce cytochrome in the presence of high-intensity illumination and dithionite, while its oxidized form is reduced by dithionite.","Entity: TMPD. SMILES: CN(C)c1ccccc1N(C)C. TMPD can efficiently reduce cytochrome in the presence of high-intensity illumination and dithionite, while its oxidized form is reduced by dithionite."
bacteriochlorophyll,"Bacteriochlorophyll exhibits an absorption band at 800 nm, which shifts to a broader band at 785 nm upon reduction in the reduced reaction center of C vinosum under high-intensity illumination.","Entity: bacteriochlorophyll. SMILES: CC[C@H]1c2cc3[n-]c4c(c3C)C(=O)[C@H](C(=O)OC)c4c3[nH+]c(cc4[n-]c(cc([nH+]2)[C@@H]1C)c(C(C)=O)c4C)[C@@H](C)[C@@H]3CCC(=O)OC/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C.[Mg+2]. Bacteriochlorophyll exhibits an absorption band at 800 nm, which shifts to a broader band at 785 nm upon reduction in the reduced reaction center of C vinosum under high-intensity illumination."
dithionite,Dithionite reduces oxidized TMPD and causes absorption changes in the ultraviolet part of the spectrum.,Entity: dithionite. SMILES: O=S([O-])S(=O)[O-]. Dithionite reduces oxidized TMPD and causes absorption changes in the ultraviolet part of the spectrum.
bacteriochlorophyll,"Bacteriochlorophylls are chlorophyll-like pigments that can absorb light near 880 nm and 800 nm, with P-870 referring to bacteriochlorophylls absorbing near 880 nm and P-800 to those absorbing near 800 nm.","Entity: bacteriochlorophyll. SMILES: CC[C@H]1c2cc3[n-]c4c(c3C)C(=O)[C@H](C(=O)OC)c4c3[nH+]c(cc4[n-]c(cc([nH+]2)[C@@H]1C)c(C(C)=O)c4C)[C@@H](C)[C@@H]3CCC(=O)OC/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C.[Mg+2]. Bacteriochlorophylls are chlorophyll-like pigments that can absorb light near 880 nm and 800 nm, with P-870 referring to bacteriochlorophylls absorbing near 880 nm and P-800 to those absorbing near 800 nm."
bacteriochlorophyll,"The electronic configuration of P-800 bacteriochlorophyll can change after reduction of bacteriopheophytin, which may result in a blue shift of the 800 nm band.","Entity: bacteriochlorophyll. SMILES: CC[C@H]1c2cc3[n-]c4c(c3C)C(=O)[C@H](C(=O)OC)c4c3[nH+]c(cc4[n-]c(cc([nH+]2)[C@@H]1C)c(C(C)=O)c4C)[C@@H](C)[C@@H]3CCC(=O)OC/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C.[Mg+2]. The electronic configuration of P-800 bacteriochlorophyll can change after reduction of bacteriopheophytin, which may result in a blue shift of the 800 nm band."
mannose,"In glycopeptides derived from isoperoxidase C, the carbohydrate composition near asparagine residues typically consists of 3 residues of mannose.","Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In glycopeptides derived from isoperoxidase C, the carbohydrate composition near asparagine residues typically consists of 3 residues of mannose."
cyanogen bromide,"Cyanogen bromide is used as a reagent for protein cleavage, enabling the generation of peptides for proteomic analysis.","Entity: cyanogen bromide. SMILES: N#CBr. Cyanogen bromide is used as a reagent for protein cleavage, enabling the generation of peptides for proteomic analysis."
cyanogen bromide,"Cyanogen bromide is used to cleave proteins at specific residues, generating peptide fragments such as CN4, CN5, CNl, CN2, and CN3, which can be analyzed for amino acid composition and post-translational modifications.","Entity: cyanogen bromide. SMILES: N#CBr. Cyanogen bromide is used to cleave proteins at specific residues, generating peptide fragments such as CN4, CN5, CNl, CN2, and CN3, which can be analyzed for amino acid composition and post-translational modifications."
acetic acid,Acetic acid at 0.05 M concentration is used as a buffer for gel filtration purification of cyanogen bromide protein fragments.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid at 0.05 M concentration is used as a buffer for gel filtration purification of cyanogen bromide protein fragments.
urea,"Urea at 8 M concentration is used as a buffer for gel filtration purification of large cyanogen bromide protein fragments, and for column isoelectric focusing of these fragments.","Entity: urea. SMILES: NC(N)=O. Urea at 8 M concentration is used as a buffer for gel filtration purification of large cyanogen bromide protein fragments, and for column isoelectric focusing of these fragments."
hemin,"Hemin is a prosthetic group present in the plant peroxidase protein, coordinated by the enzyme's polypeptide chain.","Entity: hemin. SMILES: C=CC1=C(C)c2cc3[n-]c(cc4[n-]c(cc5nc(cc1n2)C(C)=C5C=C)c(C)c4CCC(=O)O)c(CCC(=O)O)c3C.[Cl-].[Fe+3]. Hemin is a prosthetic group present in the plant peroxidase protein, coordinated by the enzyme's polypeptide chain."
phenylisothiocyanate,Phenylisothiocyanate couples well with asparagine linked to neutral carbohydrate side chains in Discussion Sequence work.,Entity: phenylisothiocyanate. SMILES: S=C=Nc1ccccc1. Phenylisothiocyanate couples well with asparagine linked to neutral carbohydrate side chains in Discussion Sequence work.
n-butyl acetate,Less than 10% of the thiazolinone derivative is removed upon extraction with n-butyl acetate in the Discussion Sequence method.,Entity: n-butyl acetate. SMILES: CCCCOC(C)=O. Less than 10% of the thiazolinone derivative is removed upon extraction with n-butyl acetate in the Discussion Sequence method.
dansyl-aspartic acid,Dansyl-aspartic acid is produced correctly by dansyl-Edman sequencing but can be carried through subsequent steps as background.,Entity: dansyl-aspartic acid. SMILES: CN(C)c1cccc2c(S(=O)(=O)N[C@@H](CC(=O)O)C(=O)O)cccc12. Dansyl-aspartic acid is produced correctly by dansyl-Edman sequencing but can be carried through subsequent steps as background.
N-ethylmorpholine acetate,N-ethylmorpholine acetate is used as a buffer at 0.2 M concentration and pH 8.0 for enzymatic digestions at 37°C.,Entity: N-ethylmorpholine acetate. SMILES: CC(=O)O.CCN1CCOCC1. N-ethylmorpholine acetate is used as a buffer at 0.2 M concentration and pH 8.0 for enzymatic digestions at 37°C.
Trasylol,Trasylol is used as a trypsin inhibitor in biochemical assays.,Entity: Trasylol. SMILES: CC[C@@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)CNC(=O)CNC(=O)[C@@H](Cc4ccc(O)cc4)NC(=O)[C@@H](C(C)C)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@@H]([C@@H](C)O)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC3=O)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]([C@@H](C)O)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H](C)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@H]([C@H](C)O)C(=O)NCC(=O)N3CCC[C@@H]3C(=O)N2)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)CC)NC1=O. Trasylol is used as a trypsin inhibitor in biochemical assays.
urea,Urea is deionized before use in biochemical experiments.,Entity: urea. SMILES: NC(N)=O. Urea is deionized before use in biochemical experiments.
pyrrolidonecarboxylic acid,"Pyrrolidonecarboxylic acid is released from incompletely solubilized S-carboxymethylated peroxidase by incubation with pyrrolidonecarboxylyl peptidase, with up to 14% released.","Entity: pyrrolidonecarboxylic acid. SMILES: O=C(O)N1CCCC1=O. Pyrrolidonecarboxylic acid is released from incompletely solubilized S-carboxymethylated peroxidase by incubation with pyrrolidonecarboxylyl peptidase, with up to 14% released."
SDS,"Native peroxidase does not react with phenylisothiocyanate in 50% pyridine or with dansyl chloride when dissolved in 1% SDS, indicating that its N-terminus is buried and not accessible for these reactions.","Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Native peroxidase does not react with phenylisothiocyanate in 50% pyridine or with dansyl chloride when dissolved in 1% SDS, indicating that its N-terminus is buried and not accessible for these reactions."
acetone,Acetone is used in acid-acetone precipitation at -20°C to prepare globin from hemoglobin.,Entity: acetone. SMILES: CC(C)=O. Acetone is used in acid-acetone precipitation at -20°C to prepare globin from hemoglobin.
urea,Urea at 8 M concentration is used as a buffer in carboxymethyl-cellulose (CM 52) chromatography to separate alpha- and beta-globin chains.,Entity: urea. SMILES: NC(N)=O. Urea at 8 M concentration is used as a buffer in carboxymethyl-cellulose (CM 52) chromatography to separate alpha- and beta-globin chains.
EDTA,EDTA is used as a component of Tris-EDTA-borate buffer at pH 8.6 for hemoglobin electrophoresis on cellulose-acetate strips.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used as a component of Tris-EDTA-borate buffer at pH 8.6 for hemoglobin electrophoresis on cellulose-acetate strips.
citrate,Citrate buffer at pH 6.0 is used for hemoglobin electrophoresis on agar-gel.,Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Citrate buffer at pH 6.0 is used for hemoglobin electrophoresis on agar-gel.
isopropanol,Isopropanol is used in the solubility test for determining the solubility of hemoglobin.,Entity: isopropanol. SMILES: CC(C)O. Isopropanol is used in the solubility test for determining the solubility of hemoglobin.
borate,Borate is included in the Tris-EDTA-borate buffer at pH 8.6 for hemoglobin electrophoresis on cellulose-acetate strips.,Entity: borate. SMILES: [O-]B([O-])[O-]. Borate is included in the Tris-EDTA-borate buffer at pH 8.6 for hemoglobin electrophoresis on cellulose-acetate strips.
glutamic acid,The abnormal peptide differs from normal /3T3 peptide in having only one residue of glutamic acid instead of two.,Entity: glutamic acid. SMILES: N[C@@H](CCC(=O)O)C(=O)O. The abnormal peptide differs from normal /3T3 peptide in having only one residue of glutamic acid instead of two.
valine,The abnormal peptide contains an additional valine residue compared to normal /3T3 peptide.,Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. The abnormal peptide contains an additional valine residue compared to normal /3T3 peptide.
HCl,HCl is used to elute the abnormal peptide from preparative fingerprints.,Entity: HCl. SMILES: Cl. HCl is used to elute the abnormal peptide from preparative fingerprints.
SSA,"SSA serves as a precursor in GABA synthesis, both with and without branched chain fatty acids.","Entity: SSA. SMILES: O=CCCC(=O)O. SSA serves as a precursor in GABA synthesis, both with and without branched chain fatty acids."
2-propyl-2-pentenoate,"2-propyl-2-pentenoate is a stronger inhibitor of GABA-T activity compared to other tested compounds, as shown by Ki measurements with purified rat brain GABA-T.","Entity: 2-propyl-2-pentenoate. SMILES: CCC=C(CCC)C(=O)[O-]. 2-propyl-2-pentenoate is a stronger inhibitor of GABA-T activity compared to other tested compounds, as shown by Ki measurements with purified rat brain GABA-T."
2-propyl-2-pentenoate,2-propyl-2-pentenoate leads to a diminution of GABA synthesis from SSA.,Entity: 2-propyl-2-pentenoate. SMILES: CCC=C(CCC)C(=O)[O-]. 2-propyl-2-pentenoate leads to a diminution of GABA synthesis from SSA.
"5,5-dipropyl-pentanoate","The presence of 5,5-dipropyl-pentanoate does not modify the quantity of labelled GABA formed during SSA-based synthesis.","Entity: 5,5-dipropyl-pentanoate. SMILES: CCCC(CCC)CCCC(=O)[O-]. The presence of 5,5-dipropyl-pentanoate does not modify the quantity of labelled GABA formed during SSA-based synthesis."
GABA,GABA synthesis from SSA is specific and can be measured relative to the specific activity of SSA as the precursor.,Entity: GABA. SMILES: NCCCC(=O)O. GABA synthesis from SSA is specific and can be measured relative to the specific activity of SSA as the precursor.
glutamate,"Radioactivity incorporated into glutamate is not significantly different from background counts, indicating that glutamate is not a major site for SSA-derived radioactivity.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Radioactivity incorporated into glutamate is not significantly different from background counts, indicating that glutamate is not a major site for SSA-derived radioactivity."
dipropylacetate,The presence of dipropylacetate does not modify the quantity of labelled GABA formed during SSA-based synthesis.,Entity: dipropylacetate. SMILES: CCCC(CCC)C(=O)[O-]. The presence of dipropylacetate does not modify the quantity of labelled GABA formed during SSA-based synthesis.
2-oxoglutarate,"2-oxoglutarate serves as a substrate for enzymes that transform it into glutamate, with aspartate aminotransferase activity being much higher than GABA-transaminase (GABA-T) activity in rat brain tissue.","Entity: 2-oxoglutarate. SMILES: O=C([O-])CCC(=O)C(=O)[O-]. 2-oxoglutarate serves as a substrate for enzymes that transform it into glutamate, with aspartate aminotransferase activity being much higher than GABA-transaminase (GABA-T) activity in rat brain tissue."
DPA,"DPA does not inhibit GABA-transaminase (GABA-T) activity in rat brain homogenate at concentrations of 5–15 mM, as measured by its effect on glutamate formation from 2-oxoglutarate.","Entity: DPA. SMILES: O=C(O)[C@H](Cc1ccccc1)N(O)O. DPA does not inhibit GABA-transaminase (GABA-T) activity in rat brain homogenate at concentrations of 5–15 mM, as measured by its effect on glutamate formation from 2-oxoglutarate."
GABA,"GABA is present at low concentrations (2 and 5 mM) in rat brain homogenate, and its endogenous aspartate is used as a substrate in enzymatic assays measuring glutamate formation from 2-oxoglutarate.","Entity: GABA. SMILES: NCCCC(=O)O. GABA is present at low concentrations (2 and 5 mM) in rat brain homogenate, and its endogenous aspartate is used as a substrate in enzymatic assays measuring glutamate formation from 2-oxoglutarate."
aspartate,Endogenous aspartate from rat brain tissue is used as a substrate in assays measuring glutamate formation from 2-oxoglutarate.,Entity: aspartate. SMILES: N[C@@H](CC(=O)[O-])C(=O)[O-]. Endogenous aspartate from rat brain tissue is used as a substrate in assays measuring glutamate formation from 2-oxoglutarate.
p-hydroxylbenzaldehyde,"p-hydroxylbenzaldehyde is a potent inhibitor of SSADH, causing practically complete inhibition at a concentration of 10^-4 M.","Entity: p-hydroxylbenzaldehyde. SMILES: O=Cc1ccc(O)cc1. p-hydroxylbenzaldehyde is a potent inhibitor of SSADH, causing practically complete inhibition at a concentration of 10^-4 M."
DPA,DPA (D-Pinitol) is a branched chain fatty acid whose concentration in the rat brain after intraperitoneal injection of 200 mg/kg is close to 10 mM.,Entity: DPA. SMILES: CCCCCCCCCCCC=CC=CC=CC=CC=CC(=O)O. DPA (D-Pinitol) is a branched chain fatty acid whose concentration in the rat brain after intraperitoneal injection of 200 mg/kg is close to 10 mM.
GABA,"GABA (gamma-aminobutyric acid) concentration in the rat brain averages 2 mM, which is close to the concentration used in in vitro studies of GABA degradation.","Entity: GABA. SMILES: NCCCC(=O)O. GABA (gamma-aminobutyric acid) concentration in the rat brain averages 2 mM, which is close to the concentration used in in vitro studies of GABA degradation."
2-propyl-2-pentenoate,"Inhibition of SSADH with 2-propyl-2-pentenoate does not significantly increase cerebral GABA levels, as the limiting activity for GABA accumulation remains GABA-T.","Entity: 2-propyl-2-pentenoate. SMILES: CCC=C(CCC)C(=O)[O-]. Inhibition of SSADH with 2-propyl-2-pentenoate does not significantly increase cerebral GABA levels, as the limiting activity for GABA accumulation remains GABA-T."
dipropylacetate,"Intraperitoneal administration of 400 mg/kg dipropylacetate in Swiss albino mice or Wistar rats does not significantly increase cerebral GABA levels, despite a 30–45% increase in SSA, indicating that SSADH inhibition alone is insufficient to elevate GABA.","Entity: dipropylacetate. SMILES: CCCC(CCC)C(=O)[O-]. Intraperitoneal administration of 400 mg/kg dipropylacetate in Swiss albino mice or Wistar rats does not significantly increase cerebral GABA levels, despite a 30–45% increase in SSA, indicating that SSADH inhibition alone is insufficient to elevate GABA."
GABA,"In the brain, GABA degradation to succinic acid is primarily limited by GABA-transaminase (GABA-T) activity under normal conditions.","Entity: GABA. SMILES: NCCCC(=O)O. In the brain, GABA degradation to succinic acid is primarily limited by GABA-transaminase (GABA-T) activity under normal conditions."
succinic acid,"Succinic acid is the end product of GABA degradation in the brain, with the process being limited by GABA-T activity.","Entity: succinic acid. SMILES: O=C(O)CCC(=O)O. Succinic acid is the end product of GABA degradation in the brain, with the process being limited by GABA-T activity."
"5,5-dipropylpentanoate","In the brain, the residual succinic semialdehyde dehydrogenase (SSADH) activity after administration of 5,5-dipropylpentanoate is inferior to that of GABA-T, indicating a lower capacity for SSADH to limit GABA degradation.","Entity: 5,5-dipropylpentanoate. SMILES: CCCC(CCC)CCCC(=O)[O-]. In the brain, the residual succinic semialdehyde dehydrogenase (SSADH) activity after administration of 5,5-dipropylpentanoate is inferior to that of GABA-T, indicating a lower capacity for SSADH to limit GABA degradation."
"5,5-dipropyl-pentanoate","5,5-dipropyl-pentanoate is a potent inhibitor of GABA-T and SSADH, and its presence in rat brain reduces the rate of GABA degradation by 34% compared to control at 45 minutes after intraperitoneal injection of 200 mg/kg DPA.","Entity: 5,5-dipropyl-pentanoate. SMILES: CCCC(CCC)CCCC(=O)[O-]. 5,5-dipropyl-pentanoate is a potent inhibitor of GABA-T and SSADH, and its presence in rat brain reduces the rate of GABA degradation by 34% compared to control at 45 minutes after intraperitoneal injection of 200 mg/kg DPA."
2-propyl-2-pentenoate,"2-propyl-2-pentenoate is a potent inhibitor of GABA-T and SSADH, and its presence in rat brain reduces the rate of GABA degradation by 34% compared to control at 45 minutes after intraperitoneal injection of 200 mg/kg DPA.","Entity: 2-propyl-2-pentenoate. SMILES: CCC=C(CCC)C(=O)[O-]. 2-propyl-2-pentenoate is a potent inhibitor of GABA-T and SSADH, and its presence in rat brain reduces the rate of GABA degradation by 34% compared to control at 45 minutes after intraperitoneal injection of 200 mg/kg DPA."
GABA,"In rat brain, the rate of GABA degradation is reduced by 34% at 45 minutes after intraperitoneal injection of 200 mg/kg DPA, when GABA and DPA concentrations are present.","Entity: GABA. SMILES: NCCCC(=O)O. In rat brain, the rate of GABA degradation is reduced by 34% at 45 minutes after intraperitoneal injection of 200 mg/kg DPA, when GABA and DPA concentrations are present."
p-hydroxybenzaldehyde,p-hydroxybenzaldehyde is a very potent inhibitor of succinate dehydrogenase (SSADH) with a competitive vis-&is SSA Ki of 2.5 × 10^6 M.,Entity: p-hydroxybenzaldehyde. SMILES: O=Cc1ccc(O)cc1. p-hydroxybenzaldehyde is a very potent inhibitor of succinate dehydrogenase (SSADH) with a competitive vis-&is SSA Ki of 2.5 × 10^6 M.
SSA,SSA (succinic semialdehyde) can be enzymatically synthesized from GABA and 2-oxoglutarate using purified GABA-transaminase from rat brain.,Entity: SSA. SMILES: O=CCCC(=O)O. SSA (succinic semialdehyde) can be enzymatically synthesized from GABA and 2-oxoglutarate using purified GABA-transaminase from rat brain.
SSA,SSA can be assayed as the 2-4 dinitrophenylhydrazone derivative for quantification in enzymatic assays.,Entity: SSA. SMILES: O=CCCC(=O)O. SSA can be assayed as the 2-4 dinitrophenylhydrazone derivative for quantification in enzymatic assays.
GABA,GABA (gamma-aminobutyric acid) serves as a substrate for GABA-transaminase in the enzymatic synthesis of SSA from 2-oxoglutarate.,Entity: GABA. SMILES: NCCCC(=O)O. GABA (gamma-aminobutyric acid) serves as a substrate for GABA-transaminase in the enzymatic synthesis of SSA from 2-oxoglutarate.
2-oxoglutarate,2-oxoglutarate is a substrate in the enzymatic reaction with GABA catalyzed by GABA-transaminase to produce SSA.,Entity: 2-oxoglutarate. SMILES: O=C([O-])CCC(=O)C(=O)[O-]. 2-oxoglutarate is a substrate in the enzymatic reaction with GABA catalyzed by GABA-transaminase to produce SSA.
y-ethoxybutyrolactone,y-ethoxybutyrolactone can be hydrolyzed in boiling water to obtain non-radioactive SSA for use as a standard in enzymatic assays.,Entity: y-ethoxybutyrolactone. SMILES: CCOC1CCC(=O)O1. y-ethoxybutyrolactone can be hydrolyzed in boiling water to obtain non-radioactive SSA for use as a standard in enzymatic assays.
HCl,HCl is used to acidify the reaction mixture to pH 2.0 in enzymatic assays involving SSA synthesis.,Entity: HCl. SMILES: Cl. HCl is used to acidify the reaction mixture to pH 2.0 in enzymatic assays involving SSA synthesis.
pyridoxal phosphate,"Pyridoxal phosphate is a coenzyme that can be inhibited by some GABA transaminase inhibitors, leading to toxicity and lack of specificity.","Entity: pyridoxal phosphate. SMILES: Cc1ncc(COP(=O)(O)O)c(C=O)c1O. Pyridoxal phosphate is a coenzyme that can be inhibited by some GABA transaminase inhibitors, leading to toxicity and lack of specificity."
succinic semialdehyde,"Succinic semialdehyde is a substrate for succinic semialdehyde dehydrogenase, which is inhibited by certain branched chain fatty acids.","Entity: succinic semialdehyde. SMILES: O=CCCC(=O)O. Succinic semialdehyde is a substrate for succinic semialdehyde dehydrogenase, which is inhibited by certain branched chain fatty acids."
sodium dipropylacetate,Sodium dipropylacetate is used as an SSADH inhibitor at a final concentration of 10 mM in incubation assays with 200 µl of 900 X g supernatant fraction at pH 7.4 and 37°C.,Entity: sodium dipropylacetate. SMILES: CCCC(CCC)C(=O)[O-].[Na+]. Sodium dipropylacetate is used as an SSADH inhibitor at a final concentration of 10 mM in incubation assays with 200 µl of 900 X g supernatant fraction at pH 7.4 and 37°C.
"sodium 5,5-dipropylpentanoate","Sodium 5,5-dipropylpentanoate is used as an SSADH inhibitor at a final concentration of 10 mM in incubation assays with 200 µl of 900 X g supernatant fraction at pH 7.4 and 37°C.","Entity: sodium 5,5-dipropylpentanoate. SMILES: CCCC(CCC)CCCC(=O)[O-].[Na+]. Sodium 5,5-dipropylpentanoate is used as an SSADH inhibitor at a final concentration of 10 mM in incubation assays with 200 µl of 900 X g supernatant fraction at pH 7.4 and 37°C."
gamma-amino butyric acid,gamma-amino butyric acid can be specifically labeled with dansyl groups for chromatographic and quantitative analysis.,Entity: gamma-amino butyric acid. SMILES: NCCCC(=O)O. gamma-amino butyric acid can be specifically labeled with dansyl groups for chromatographic and quantitative analysis.
glutamate,Glutamate can be specifically labeled with dansyl groups for chromatographic and quantitative analysis.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate can be specifically labeled with dansyl groups for chromatographic and quantitative analysis.
ammonia,"Ammonia at 2 M concentration is used to elute amino compounds from Dowex 50 WX8, H' form columns in biochemical assays.","Entity: ammonia. SMILES: N. Ammonia at 2 M concentration is used to elute amino compounds from Dowex 50 WX8, H' form columns in biochemical assays."
phosphate,Phosphate buffer at 0.2 M and pH 8.8 is used to redissolve dansylated amino compounds prior to chromatographic analysis.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate buffer at 0.2 M and pH 8.8 is used to redissolve dansylated amino compounds prior to chromatographic analysis.
"3,5-diaminobenzoate","3,5-diaminobenzoate reacts with SSA under acid conditions to produce a fluorescent quinaldehyde.","Entity: 3,5-diaminobenzoate. SMILES: Nc1cc(N)cc(C(=O)[O-])c1. 3,5-diaminobenzoate reacts with SSA under acid conditions to produce a fluorescent quinaldehyde."
quinaldehyde,"Quinaldehyde is a fluorescent product formed by the reaction of SSA with 3,5-diaminobenzoate under acid conditions.","Entity: quinaldehyde. SMILES: O=CC1(O)C[C@@H](O)C(O)[C@H](O)C1. Quinaldehyde is a fluorescent product formed by the reaction of SSA with 3,5-diaminobenzoate under acid conditions."
bis-PEP,"bis-PEP is used as a substrate in the diaphragm incubation technique for fatty acid synthesis assays, applied at a final concentration of 15 or 2 nmol/ml in rat adipose tissue preparations.","Entity: bis-PEP. SMILES: O=C([O-])C(COP(=O)(O)O)OP(=O)(O)O. bis-PEP is used as a substrate in the diaphragm incubation technique for fatty acid synthesis assays, applied at a final concentration of 15 or 2 nmol/ml in rat adipose tissue preparations."
glucose,"Glucose is used as a substrate in the diaphragm incubation technique for fatty acid synthesis assays, applied at a final concentration of 0.5 µmol/ml in rat adipose tissue preparations.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is used as a substrate in the diaphragm incubation technique for fatty acid synthesis assays, applied at a final concentration of 0.5 µmol/ml in rat adipose tissue preparations."
CaCl2,CaCl2 is used as a control substrate in the diaphragm incubation technique for fatty acid synthesis assays in rat adipose tissue preparations.,Entity: CaCl2. SMILES: [Ca+2].[Cl-].[Cl-]. CaCl2 is used as a control substrate in the diaphragm incubation technique for fatty acid synthesis assays in rat adipose tissue preparations.
glucose-1-phosphate,Glucose-1-phosphate is known to play no role in stimulating fatty acid synthesis in mouse adipose tissue.,Entity: glucose-1-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=P(O)(O)OP(=O)(O)O. Glucose-1-phosphate is known to play no role in stimulating fatty acid synthesis in mouse adipose tissue.
potassium tetraborate,Potassium tetraborate is used as a component in the preparation of bis-PEP.,Entity: potassium tetraborate. SMILES: [K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-]. Potassium tetraborate is used as a component in the preparation of bis-PEP.
HCl,HCl is used to neutralize and remove salts from the eluate of a Dowex column during the preparation of bis-PEP.,Entity: HCl. SMILES: Cl. HCl is used to neutralize and remove salts from the eluate of a Dowex column during the preparation of bis-PEP.
glucose-6-phosphate,Glucose-6-phosphate can be present in small amounts in the eluate of a Dowex column and is detectable on a high pressure column during bis-PEP preparation.,Entity: glucose-6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose-6-phosphate can be present in small amounts in the eluate of a Dowex column and is detectable on a high pressure column during bis-PEP preparation.
calcium chloride,Calcium chloride is added to stabilize the compound during the preparation of bis-PEP.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride is added to stabilize the compound during the preparation of bis-PEP.
ammonium chloride,Ammonium chloride is used as a component in the preparation of bis-PEP.,Entity: ammonium chloride. SMILES: [Cl-].[NH4+]. Ammonium chloride is used as a component in the preparation of bis-PEP.
15(S)-15-methyl prostaglandin F2alpha,"15(S)-15-methyl prostaglandin F2alpha, when impregnated in Silastic intravaginal devices at concentrations of 0.25%, 0.5%, and 1.0%, acts as an abortifacient, inducing abortion in patients with gestations ranging from 8 to 19 weeks.","Entity: 15(S)-15-methyl prostaglandin F2alpha. SMILES: CCCCC[C@](C)(O)/C=C/[C@@H]1[C@@H](CC=CCCCC(=O)O)[C@@H](O)C[C@H]1O. 15(S)-15-methyl prostaglandin F2alpha, when impregnated in Silastic intravaginal devices at concentrations of 0.25%, 0.5%, and 1.0%, acts as an abortifacient, inducing abortion in patients with gestations ranging from 8 to 19 weeks."
zinc,Zinc is used as a spermicidal substance in contraceptive formulations.,Entity: zinc. SMILES: [Zn]. Zinc is used as a spermicidal substance in contraceptive formulations.
Triton X-100,Triton X-100 is a surfactant that has been used in spermicidal gels and foams and can increase the rate of flux of ejaculate into a sponge.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a surfactant that has been used in spermicidal gels and foams and can increase the rate of flux of ejaculate into a sponge.
zinc,Zinc in prostatic fluid or seminal plasma immobilizes spermatozoa and inhibits their respiration and lipid metabolism.,Entity: zinc. SMILES: [Zn]. Zinc in prostatic fluid or seminal plasma immobilizes spermatozoa and inhibits their respiration and lipid metabolism.
zinc,"Zinc released from human spermatozoa by chelating agents such as cysteine, ethylenediaminetetraacetate, and histidine stimulates sperm metabolism and increases sperm motility.","Entity: zinc. SMILES: [Zn]. Zinc released from human spermatozoa by chelating agents such as cysteine, ethylenediaminetetraacetate, and histidine stimulates sperm metabolism and increases sperm motility."
zinc,"Zinc has a primary inhibitory effect on the cell functions of spermatozoa, granulocytes, macrophages, platelets, and mast cells.","Entity: zinc. SMILES: [Zn]. Zinc has a primary inhibitory effect on the cell functions of spermatozoa, granulocytes, macrophages, platelets, and mast cells."
cysteine,"Cysteine acts as a chelating agent that releases zinc from human spermatozoa, leading to stimulation of sperm metabolism and increased motility.","Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. Cysteine acts as a chelating agent that releases zinc from human spermatozoa, leading to stimulation of sperm metabolism and increased motility."
ethylenediaminetetraacetate,"Ethylenediaminetetraacetate is a chelating agent that releases zinc from human spermatozoa, resulting in stimulation of sperm metabolism and increased motility.","Entity: ethylenediaminetetraacetate. SMILES: O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-]. Ethylenediaminetetraacetate is a chelating agent that releases zinc from human spermatozoa, resulting in stimulation of sperm metabolism and increased motility."
histidine,"Histidine functions as a chelating agent that releases zinc from human spermatozoa, which stimulates sperm metabolism and enhances motility.","Entity: histidine. SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O. Histidine functions as a chelating agent that releases zinc from human spermatozoa, which stimulates sperm metabolism and enhances motility."
zinc,"Zinc, as a dicarboxylic or diamino acid residue in collagen, can form stable covalent bonds or weaker ionic bonds with the protein, contributing to the exchange capacity of collagen.","Entity: zinc. SMILES: [Zn]. Zinc, as a dicarboxylic or diamino acid residue in collagen, can form stable covalent bonds or weaker ionic bonds with the protein, contributing to the exchange capacity of collagen."
zinc,"Zinc can be physically retained in the fibrillar meshwork of collagen, making it readily available for pharmacologic effects on spermatozoa.","Entity: zinc. SMILES: [Zn]. Zinc can be physically retained in the fibrillar meshwork of collagen, making it readily available for pharmacologic effects on spermatozoa."
copper,"Copper, as a dicarboxylic or diamino acid residue in collagen, can form stable covalent bonds or weaker ionic bonds with the protein, contributing to the exchange capacity of collagen.","Entity: copper. SMILES: [Cu]. Copper, as a dicarboxylic or diamino acid residue in collagen, can form stable covalent bonds or weaker ionic bonds with the protein, contributing to the exchange capacity of collagen."
NaCI,NaCI is used in the preparation of slides for bacteriologic evaluation in gynecological clinical practice.,Entity: NaCI. SMILES: [Cl-].[Na+]. NaCI is used in the preparation of slides for bacteriologic evaluation in gynecological clinical practice.
KOH,KOH is used in the preparation of slides for bacteriologic evaluation in gynecological clinical practice.,Entity: KOH. SMILES: [K+].[OH-]. KOH is used in the preparation of slides for bacteriologic evaluation in gynecological clinical practice.
formaldehyde,Formaldehyde is used as a 10% buffered solution for fixation of tissue sections in laboratory tests.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a 10% buffered solution for fixation of tissue sections in laboratory tests.
hematoxylin,Hematoxylin is used as a staining agent for tissue sections in laboratory tests.,Entity: hematoxylin. SMILES: Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2. Hematoxylin is used as a staining agent for tissue sections in laboratory tests.
eosin,Eosin is used as a staining agent for tissue sections in laboratory tests.,Entity: eosin. SMILES: O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+]. Eosin is used as a staining agent for tissue sections in laboratory tests.
progesterone,Serum progesterone levels can be used as a clinical or laboratory method to establish the presence or absence of ovulation.,Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Serum progesterone levels can be used as a clinical or laboratory method to establish the presence or absence of ovulation.
pregnanediol,Urinary pregnanediol can be assayed as a clinical or laboratory method to help determine whether ovulation has occurred.,Entity: pregnanediol. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4CCCC[C@@]43C)[C@@H]1CC[C@@H]2CC(O)O. Urinary pregnanediol can be assayed as a clinical or laboratory method to help determine whether ovulation has occurred.
prolactin,Serum prolactin levels are elevated in all types of infertile men compared to fertile men.,Entity: prolactin. Serum prolactin levels are elevated in all types of infertile men compared to fertile men.
prolactin,"Hyperprolactinemia is present in a subset of infertile men, including those with oligospermia, azoospermia, and hypogonadotropic hypogonadism.","Entity: prolactin. Hyperprolactinemia is present in a subset of infertile men, including those with oligospermia, azoospermia, and hypogonadotropic hypogonadism."
deoxyribose,Deoxyribose can react with p-nitrophenylhydrazine in the Webb and Levy method for colorimetric detection of DNA.,Entity: deoxyribose. SMILES: O=CC[C@H](O)[C@H](O)CO. Deoxyribose can react with p-nitrophenylhydrazine in the Webb and Levy method for colorimetric detection of DNA.
sulfuric acid,Sulfuric acid is used in the Stumpf method and the Cohen method as a reagent for colorimetric detection of DNA.,Entity: sulfuric acid. SMILES: O=S(=O)(O)O. Sulfuric acid is used in the Stumpf method and the Cohen method as a reagent for colorimetric detection of DNA.
tryptophan,Tryptophan is used as a reagent in the Cohen method for colorimetric determination of DNA.,Entity: tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan is used as a reagent in the Cohen method for colorimetric determination of DNA.
cysteine,Cysteine is used as a reagent in the Stumpf method for colorimetric detection of DNA.,Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. Cysteine is used as a reagent in the Stumpf method for colorimetric detection of DNA.
perchloric acid,Perchloric acid is used as a reagent in the Cohen method for colorimetric determination of DNA.,Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid is used as a reagent in the Cohen method for colorimetric determination of DNA.
p-nitrophenylhydrazine,p-nitrophenylhydrazine reacts with deoxyribose in the Webb and Levy method for colorimetric detection of DNA.,Entity: p-nitrophenylhydrazine. SMILES: NNc1ccc([N+](=O)[O-])cc1. p-nitrophenylhydrazine reacts with deoxyribose in the Webb and Levy method for colorimetric detection of DNA.
diphenylamine,"Diphenylamine reacts with the deoxyribosidic portion of DNA at 100°C in an acid environment to produce blue staining, as used in the Dische method for DNA colorimetric determination.","Entity: diphenylamine. SMILES: c1ccc(Nc2ccccc2)cc1. Diphenylamine reacts with the deoxyribosidic portion of DNA at 100°C in an acid environment to produce blue staining, as used in the Dische method for DNA colorimetric determination."
sulfuric acid,The composition and time of action of sulfuric acid washings are critical parameters affecting the intensity of Feulgen nuclear staining in microspectrophotometric DNA analysis.,Entity: sulfuric acid. SMILES: O=S(=O)(O)O. The composition and time of action of sulfuric acid washings are critical parameters affecting the intensity of Feulgen nuclear staining in microspectrophotometric DNA analysis.
indole,Indole can react with deoxyribose under certain conditions to form the basis of the C'eriotti method for DNA quantification.,Entity: indole. SMILES: c1ccc2[nH]ccc2c1. Indole can react with deoxyribose under certain conditions to form the basis of the C'eriotti method for DNA quantification.
deoxyribose,"Deoxyribose can react with indole under specific conditions in the C'eriotti method, which is approximately 10 times more sensitive than the Dische method for DNA detection.","Entity: deoxyribose. SMILES: O=CC[C@H](O)[C@H](O)CO. Deoxyribose can react with indole under specific conditions in the C'eriotti method, which is approximately 10 times more sensitive than the Dische method for DNA detection."
ethanol,Ethanol is included at 20% concentration in the staining solution for proteins in polyacrylamide gel electrophoresis.,Entity: ethanol. SMILES: CCO. Ethanol is included at 20% concentration in the staining solution for proteins in polyacrylamide gel electrophoresis.
acrylamide,"Acrylamide is used to form the gel matrix for protein electrophoresis, with 15% gel concentration in polyacrylamide gel electrophoresis.","Entity: acrylamide. SMILES: C=CC(N)=O. Acrylamide is used to form the gel matrix for protein electrophoresis, with 15% gel concentration in polyacrylamide gel electrophoresis."
urea,Urea is used at 2.5 M concentration as a buffer additive in polyacrylamide gel electrophoresis for protein separation.,Entity: urea. SMILES: NC(N)=O. Urea is used at 2.5 M concentration as a buffer additive in polyacrylamide gel electrophoresis for protein separation.
Amido black,"Amido black is used as a staining agent for proteins in polyacrylamide gel electrophoresis, applied at 0.1% concentration in 7% acetic acid and 20% ethanol for 45 minutes.","Entity: Amido black. SMILES: Nc1c(N=Nc2ccc([N+](=O)[O-])cc2)c(S(=O)(=O)O)cc2cc(S(=O)(=O)O)c(N=Nc3ccccc3)c(O)c12.[Na+]. Amido black is used as a staining agent for proteins in polyacrylamide gel electrophoresis, applied at 0.1% concentration in 7% acetic acid and 20% ethanol for 45 minutes."
acetic acid,Acetic acid is used as a buffer at 0.9 M concentration for pre-electrophoresis and as a component of the staining and destaining solutions (7% acetic acid) in polyacrylamide gel electrophoresis.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a buffer at 0.9 M concentration for pre-electrophoresis and as a component of the staining and destaining solutions (7% acetic acid) in polyacrylamide gel electrophoresis.
carboxyphenylmaleimide,Carboxyphenylmaleimide is a fluorescent probe that reacts specifically with -SH groups and is used to quantify the number of exposed -SH groups on biological membranes.,Entity: carboxyphenylmaleimide. SMILES: O=C(O)C1=C(c2ccccc2)C(=O)NC1=O. Carboxyphenylmaleimide is a fluorescent probe that reacts specifically with -SH groups and is used to quantify the number of exposed -SH groups on biological membranes.
carboxyphenylmaleimide,"In human ejaculated spermatozoa, the number of exposed -SH groups is 55 ± 8 nmoles per 10^8 cells, as measured by carboxyphenylmaleimide binding.","Entity: carboxyphenylmaleimide. SMILES: O=C(O)C1=C(c2ccccc2)C(=O)NC1=O. In human ejaculated spermatozoa, the number of exposed -SH groups is 55 ± 8 nmoles per 10^8 cells, as measured by carboxyphenylmaleimide binding."
carboxyphenylmaleimide,"In rabbit ejaculated spermatozoa, the number of exposed -SH groups is 35 ± 4.2 nmoles per 10^8 cells, as measured by carboxyphenylmaleimide binding.","Entity: carboxyphenylmaleimide. SMILES: O=C(O)C1=C(c2ccccc2)C(=O)NC1=O. In rabbit ejaculated spermatozoa, the number of exposed -SH groups is 35 ± 4.2 nmoles per 10^8 cells, as measured by carboxyphenylmaleimide binding."
carboxyphenylmaleimide,"Caput epididymal cells bind significantly more carboxyphenylmaleimide (155 ± 22 nmoles/10^8 cells in rabbit, 184 nmoles/10^8 cells in human) than cauda epididymal cells (78 ± 11 nmoles/10^8 cells in rabbit, 110 ± 18 nmoles/10^8 cells in human) or ejaculated spermatozoa.","Entity: carboxyphenylmaleimide. SMILES: O=C(O)C1=C(c2ccccc2)C(=O)NC1=O. Caput epididymal cells bind significantly more carboxyphenylmaleimide (155 ± 22 nmoles/10^8 cells in rabbit, 184 nmoles/10^8 cells in human) than cauda epididymal cells (78 ± 11 nmoles/10^8 cells in rabbit, 110 ± 18 nmoles/10^8 cells in human) or ejaculated spermatozoa."
ethylenediaminetetraacetate,The behavior of membrane-reactive -SH groups in sperm cells when ethylenediaminetetraacetate is added to the incubation media indicates that their participation in sperm physiology is species-specific.,Entity: ethylenediaminetetraacetate. SMILES: O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-]. The behavior of membrane-reactive -SH groups in sperm cells when ethylenediaminetetraacetate is added to the incubation media indicates that their participation in sperm physiology is species-specific.
oxygen,"Binding of carboxyphenylmaleimide to sperm membranes does not affect oxygen uptake, motility, or viability of the sperm cells.","Entity: oxygen. SMILES: [O]. Binding of carboxyphenylmaleimide to sperm membranes does not affect oxygen uptake, motility, or viability of the sperm cells."
selenite,"Selenite, when added to Japanese quail diets containing methylmercury chloride, lowers both egg production and eggshell thickness.","Entity: selenite. SMILES: O=[Se]([O-])[O-]. Selenite, when added to Japanese quail diets containing methylmercury chloride, lowers both egg production and eggshell thickness."
calcium carbonate,"Calcium carbonate forms the major component (about 80%) of the thickness of avian eggshell, with its carbonate radical generated by carbonic anhydrase.","Entity: calcium carbonate. SMILES: O=C([O-])[O-].[Ca+2]. Calcium carbonate forms the major component (about 80%) of the thickness of avian eggshell, with its carbonate radical generated by carbonic anhydrase."
BSTFA,"BSTFA (N,O-bis(trimethylsilyl)trifluoroacetamide) is used as a derivatization reagent to convert hydroxylated polychlorinated biphenyls (PCBs) and chlorophenols into TMS derivatives for gas chromatography analysis.","Entity: BSTFA. SMILES: C[Si](C)(C)N(C(=O)C(F)(F)F)[Si](C)(C)C. BSTFA (N,O-bis(trimethylsilyl)trifluoroacetamide) is used as a derivatization reagent to convert hydroxylated polychlorinated biphenyls (PCBs) and chlorophenols into TMS derivatives for gas chromatography analysis."
"3-hydroxy-2,5,2',5'-tetrachlorobiphenyl","3-hydroxy-2,5,2',5'-tetrachlorobiphenyl requires derivatization with BSTFA containing 1% TMCS to enable its conversion to a TMS derivative suitable for gas chromatography.","Entity: 3-hydroxy-2,5,2',5'-tetrachlorobiphenyl. SMILES: Oc1cc(Cl)cc(-c2cc(Cl)ccc2Cl)c1Cl. 3-hydroxy-2,5,2',5'-tetrachlorobiphenyl requires derivatization with BSTFA containing 1% TMCS to enable its conversion to a TMS derivative suitable for gas chromatography."
TMCS,"TMCS (N,O,O',O''-tetramethylsilyltrifluoroacetamide) is used as a derivatization reagent, typically in 1% concentration in BSTFA, to convert hydroxylated polychlorinated biphenyls and chlorophenols for gas chromatography analysis.","Entity: TMCS. SMILES: FC(F)(F)C(Cl)(Cl)Cl. TMCS (N,O,O',O''-tetramethylsilyltrifluoroacetamide) is used as a derivatization reagent, typically in 1% concentration in BSTFA, to convert hydroxylated polychlorinated biphenyls and chlorophenols for gas chromatography analysis."
"3-hydroxy-2,5,2',5'tetrachlorobiphenyl","The TMS derivative of 3-hydroxy-2,5,2',5'tetrachlorobiphenyl can be prepared using BSTFA with 1% trimethylchlorosilane and heating at 100°C for 1 hour.","Entity: 3-hydroxy-2,5,2',5'tetrachlorobiphenyl. SMILES: Oc1cc(Cl)cc(-c2cc(Cl)ccc2Cl)c1Cl. The TMS derivative of 3-hydroxy-2,5,2',5'tetrachlorobiphenyl can be prepared using BSTFA with 1% trimethylchlorosilane and heating at 100°C for 1 hour."
trimethylchlorosilane,"Trimethylchlorosilane is used as a reagent (1%) in the derivatization of 3-hydroxy-2,5,2',5'tetrachlorobiphenyl with BSTFA to facilitate TMS derivative formation.","Entity: trimethylchlorosilane. SMILES: C[Si](C)(C)Cl. Trimethylchlorosilane is used as a reagent (1%) in the derivatization of 3-hydroxy-2,5,2',5'tetrachlorobiphenyl with BSTFA to facilitate TMS derivative formation."
N-O-bistrimethylsilytrifluoroacetamide,N-O-bistrimethylsilytrifluoroacetamide (BSTFA) is a silylating agent used to form TMS derivatives of hydroxylated PCBs and chlorophenols in acetonitrile at 60°C for 15 minutes.,Entity: N-O-bistrimethylsilytrifluoroacetamide. SMILES: C[Si](C)(C)Cl.C[Si](C)(C)N=C(O[Si](C)(C)C)C(F)(F)F. N-O-bistrimethylsilytrifluoroacetamide (BSTFA) is a silylating agent used to form TMS derivatives of hydroxylated PCBs and chlorophenols in acetonitrile at 60°C for 15 minutes.
acetonitrile,Acetonitrile is used as a solvent for the derivatization of hydroxylated PCBs and chlorophenols with N-O-bistrimethylsilytrifluoroacetamide (BSTFA) at 60°C for 15 minutes.,Entity: acetonitrile. SMILES: CC#N. Acetonitrile is used as a solvent for the derivatization of hydroxylated PCBs and chlorophenols with N-O-bistrimethylsilytrifluoroacetamide (BSTFA) at 60°C for 15 minutes.
"3-hydroxy-2,5,2',5'tetrachlorobiphenyl","3-hydroxy-2,5,2',5'tetrachlorobiphenyl is a hydroxylated polychlorinated biphenyl (PCB) that is difficult to derivatize with N-O-bistrimethylsilytrifluoroacetamide (BSTFA).","Entity: 3-hydroxy-2,5,2',5'tetrachlorobiphenyl. SMILES: Oc1cc(Cl)cc(-c2cc(Cl)ccc2Cl)c1Cl. 3-hydroxy-2,5,2',5'tetrachlorobiphenyl is a hydroxylated polychlorinated biphenyl (PCB) that is difficult to derivatize with N-O-bistrimethylsilytrifluoroacetamide (BSTFA)."
ortho-chloro phenol,"Ortho-chloro phenols exhibit ion ratios in mass spectrometry ranging from 0.71 to 6.3, while non-ortho-chloro phenols have ion ratios between 0.17 and 0.29.","Entity: ortho-chloro phenol. SMILES: Oc1ccccc1Cl. Ortho-chloro phenols exhibit ion ratios in mass spectrometry ranging from 0.71 to 6.3, while non-ortho-chloro phenols have ion ratios between 0.17 and 0.29."
TMS,TMS (trimethylsilyl) groups can undergo migration of an ortho chlorine atom and subsequent rearrangement of methyl groups during fragmentation in mass spectrometry.,Entity: TMS. SMILES: C[Si](C)C. TMS (trimethylsilyl) groups can undergo migration of an ortho chlorine atom and subsequent rearrangement of methyl groups during fragmentation in mass spectrometry.
D-Glucaric acid,Plasma D-glucaric acid excretion is a sensitive and reliable measure of hepatic enzyme activity in humans.,Entity: D-Glucaric acid. SMILES: O=C(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O. Plasma D-glucaric acid excretion is a sensitive and reliable measure of hepatic enzyme activity in humans.
Antipyrine,The plasma half-life of antipyrine is a sensitive indicator of liver enzyme induction in humans.,Entity: Antipyrine. SMILES: Cc1cc(=O)n(-c2ccccc2)n1C. The plasma half-life of antipyrine is a sensitive indicator of liver enzyme induction in humans.
Antipyrine,Occupational exposure to chlorinated hydrocarbon insecticides such as lindane and DDT is associated with a significantly shorter plasma half-life of antipyrine in workers compared to controls.,Entity: Antipyrine. SMILES: Cc1cc(=O)n(-c2ccccc2)n1C. Occupational exposure to chlorinated hydrocarbon insecticides such as lindane and DDT is associated with a significantly shorter plasma half-life of antipyrine in workers compared to controls.
Antipyrine,Plasma half-life of antipyrine is significantly shorter in workers exposed to polychlorinated biphenyls (PCBs) compared to control subjects from the same factory and student volunteers.,Entity: Antipyrine. SMILES: Cc1cc(=O)n(-c2ccccc2)n1C. Plasma half-life of antipyrine is significantly shorter in workers exposed to polychlorinated biphenyls (PCBs) compared to control subjects from the same factory and student volunteers.
Antipyrine,"In a control group of factory workers, the mean plasma half-life of antipyrine is 9.4 to 29.1 hours, while in student volunteers it is 4.8 to 41.7 hours.","Entity: Antipyrine. SMILES: Cc1cc(=O)n(-c2ccccc2)n1C. In a control group of factory workers, the mean plasma half-life of antipyrine is 9.4 to 29.1 hours, while in student volunteers it is 4.8 to 41.7 hours."
"2,5,2',5'-tetrachlorobiphenyl","2,5,2',5'-tetrachlorobiphenyl is metabolized in mice to sulfur-containing products including 3-methylthio-2,5,2',5'-tetrachlorobiphenyl, 4-methylthio-2,5,2',5'-tetrachlorobiphenyl, 3-methylsulfonyl-2,5,2',5'-tetrachlorobiphenyl, and 4-methylsulfonyl-2,5,2',5'-tetrachlorobiphenyl, with the metabolites excreted in feces along with unchanged compound.","Entity: 2,5,2',5'-tetrachlorobiphenyl. SMILES: Clc1ccc(Cl)c(-c2cc(Cl)ccc2Cl)c1. 2,5,2',5'-tetrachlorobiphenyl is metabolized in mice to sulfur-containing products including 3-methylthio-2,5,2',5'-tetrachlorobiphenyl, 4-methylthio-2,5,2',5'-tetrachlorobiphenyl, 3-methylsulfonyl-2,5,2',5'-tetrachlorobiphenyl, and 4-methylsulfonyl-2,5,2',5'-tetrachlorobiphenyl, with the metabolites excreted in feces along with unchanged compound."
"2,4,2',4'-tetrachlorobiphenyl","2,4,2',4'-tetrachlorobiphenyl is metabolized in mice to sulfur-containing metabolites.","Entity: 2,4,2',4'-tetrachlorobiphenyl. SMILES: Clc1ccc(-c2ccc(Cl)cc2Cl)c(Cl)c1. 2,4,2',4'-tetrachlorobiphenyl is metabolized in mice to sulfur-containing metabolites."
nitrogen,"Nitrogen is used as a carrier gas in gas chromatography, applied at a flow rate of 2 kg/cm² in the described system.","Entity: nitrogen. SMILES: [N]. Nitrogen is used as a carrier gas in gas chromatography, applied at a flow rate of 2 kg/cm² in the described system."
diethylene glycol succinate-phosphoric acid,Diethylene glycol succinate-phosphoric acid (DEGS-PA) is used as a stationary phase component at 2%-0.5% in gas chromatography columns packed on Chromosorb W.,Entity: diethylene glycol succinate-phosphoric acid. SMILES: O=C(O)CCC(=O)O.O=P(O)(O)O.OCCOCCO. Diethylene glycol succinate-phosphoric acid (DEGS-PA) is used as a stationary phase component at 2%-0.5% in gas chromatography columns packed on Chromosorb W.
aluminum hydroxide,Aluminum hydroxide is used as an adjuvant in influenza virus vaccines and produces lower antibody titers compared to polymethylmethacrylate-based adjuvants.,Entity: aluminum hydroxide. SMILES: [Al+3].[OH-].[OH-].[OH-]. Aluminum hydroxide is used as an adjuvant in influenza virus vaccines and produces lower antibody titers compared to polymethylmethacrylate-based adjuvants.
methacrylate,"Polymethylmethacrylate particles, when used as adjuvants in influenza virus vaccines, can produce higher antibody titers than aluminum hydroxide or fluid vaccines.","Entity: methacrylate. SMILES: C=C(C)C(=O)[O-]. Polymethylmethacrylate particles, when used as adjuvants in influenza virus vaccines, can produce higher antibody titers than aluminum hydroxide or fluid vaccines."
Magnesium chloride,Magnesium chloride is used as a component (15 mM) in the staining buffer for mithramycin in cytotofluorimetric cell staining protocols.,Entity: Magnesium chloride. SMILES: [Cl-].[Cl-].[Mg+2]. Magnesium chloride is used as a component (15 mM) in the staining buffer for mithramycin in cytotofluorimetric cell staining protocols.
Methanol,Methanol (50%) is used as a fixative for cells at 4°C for 12 hours in cytotofluorimetric analysis.,Entity: Methanol. SMILES: CO. Methanol (50%) is used as a fixative for cells at 4°C for 12 hours in cytotofluorimetric analysis.
Ethanol,Ethanol (70%) is used as a storage solvent for fixed cells in cytotofluorimetric protocols.,Entity: Ethanol. SMILES: CCO. Ethanol (70%) is used as a storage solvent for fixed cells in cytotofluorimetric protocols.
uridine,"Uridine incorporation is decreased following inhibition of thymidine incorporation in target cells, reflecting the suppressive effects of macrophage-mediated interactions.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine incorporation is decreased following inhibition of thymidine incorporation in target cells, reflecting the suppressive effects of macrophage-mediated interactions."
thymidine,"Thymidine incorporation is used as a marker for cell proliferation, and its inhibition by AM indicates a profound impact of macrophage-target cell interactions.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine incorporation is used as a marker for cell proliferation, and its inhibition by AM indicates a profound impact of macrophage-target cell interactions."
N-nitrososarcosine,The ethyl ester of N-nitrososarcosine is a nitroso compound that is suitable for inducing neoplastic lesions of the esophagus.,Entity: N-nitrososarcosine. SMILES: CN(CC(=O)O)N=O. The ethyl ester of N-nitrososarcosine is a nitroso compound that is suitable for inducing neoplastic lesions of the esophagus.
N-2-fluorenyldiacetamide,Young AxC male rats ingesting N-2-fluorenyldiacetamide are more susceptible to liver hyperplasia and carcinoma.,Entity: N-2-fluorenyldiacetamide. SMILES: CC(=O)N(C(C)=O)c1ccc2c(c1)Cc1ccccc1-2. Young AxC male rats ingesting N-2-fluorenyldiacetamide are more susceptible to liver hyperplasia and carcinoma.
carbon tetrachloride,Older BUF female rats receiving subcutaneous injections of carbon tetrachloride develop more hepatic lesions than younger females or male rats.,Entity: carbon tetrachloride. SMILES: ClC(Cl)(Cl)Cl. Older BUF female rats receiving subcutaneous injections of carbon tetrachloride develop more hepatic lesions than younger females or male rats.
3'-methyl-4-dimethylaminoazobenzene,Young BUF strain male rats are more susceptible to liver hyperplasia and carcinoma when administered 3'-methyl-4-dimethylaminoazobenzene.,Entity: 3'-methyl-4-dimethylaminoazobenzene. SMILES: Cc1cccc(N=Nc2ccc(N(C)C)cc2)c1. Young BUF strain male rats are more susceptible to liver hyperplasia and carcinoma when administered 3'-methyl-4-dimethylaminoazobenzene.
n-nitrosopiperidine,n-nitrosopiperidine induces carcinomas of the esophagus in rats.,Entity: n-nitrosopiperidine. SMILES: O=NN1CCCCC1. n-nitrosopiperidine induces carcinomas of the esophagus in rats.
n-butyl-nitrosourethane,n-butyl-nitrosourethane rarely induces carcinoma of the esophagus but almost always induces squamous cell carcinoma of the forestomach in rats.,Entity: n-butyl-nitrosourethane. SMILES: CCCCN(N=O)C(=O)OCC. n-butyl-nitrosourethane rarely induces carcinoma of the esophagus but almost always induces squamous cell carcinoma of the forestomach in rats.
calcium,Calcium-dependent release of compounds from neural tissue in vivo during excitation of specific pathways is considered essential evidence for the transmitter or neurodynamic function of a substance.,Entity: calcium. SMILES: [Ca]. Calcium-dependent release of compounds from neural tissue in vivo during excitation of specific pathways is considered essential evidence for the transmitter or neurodynamic function of a substance.
potassium,Potassium salts at concentrations of 20–60 mM are used to induce transmitter release in neural tissue slice preparations in vitro.,Entity: potassium. SMILES: [K]. Potassium salts at concentrations of 20–60 mM are used to induce transmitter release in neural tissue slice preparations in vitro.
p-hydroxymercuribenzoate,p-hydroxymercuribenzoate acts as a glycine uptake inhibitor and increases the spontaneous efflux of glycine from the spinal cord when added to the perfusion system.,Entity: p-hydroxymercuribenzoate. SMILES: O.O=C([O-])c1ccc([Hg])cc1. p-hydroxymercuribenzoate acts as a glycine uptake inhibitor and increases the spontaneous efflux of glycine from the spinal cord when added to the perfusion system.
glycine,Glycine is an amino acid neurotransmitter that can be released from the spinal cord into perfusate during stimulation of spinal roots.,Entity: glycine. SMILES: NCC(=O)O. Glycine is an amino acid neurotransmitter that can be released from the spinal cord into perfusate during stimulation of spinal roots.
dansyl chloride,"Dansyl chloride is used in a sensitive detection method for amino acids, amines, and other putative transmitters by condensing with free amino or phenolic hydroxyl groups, enabling quantitative measurement of pmol quantities.","Entity: dansyl chloride. SMILES: CN(C)c1cccc2c(S(=O)(=O)Cl)cccc12. Dansyl chloride is used in a sensitive detection method for amino acids, amines, and other putative transmitters by condensing with free amino or phenolic hydroxyl groups, enabling quantitative measurement of pmol quantities."
cytochalasin B,"Cytochalasin B inhibits glucose influx in brain tissue, and this inhibition is completely reversible within 4 minutes of perfusing the brain with cytochalasin-free blood.","Entity: cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B inhibits glucose influx in brain tissue, and this inhibition is completely reversible within 4 minutes of perfusing the brain with cytochalasin-free blood."
Cytochalasin B,"Cytochalasin B is a fungal metabolite that inhibits hexose transport in various cellular types, including erythrocytes, leucocytes, adipose-cell ghosts, fibroblasts, liver cells, and HeLa cells.","Entity: Cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B is a fungal metabolite that inhibits hexose transport in various cellular types, including erythrocytes, leucocytes, adipose-cell ghosts, fibroblasts, liver cells, and HeLa cells."
Cytochalasin B,Cytochalasin B inhibits the uptake of 2-deoxy-[3H] glucose by frog dorsal-ganglia cell bodies.,Entity: Cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B inhibits the uptake of 2-deoxy-[3H] glucose by frog dorsal-ganglia cell bodies.
Cytochalasin B,"Cytochalasin B inhibits the uptake of amines by peripheral adrenergic neurons under anaerobic conditions, a process dependent on glucose provision and transport.","Entity: Cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B inhibits the uptake of amines by peripheral adrenergic neurons under anaerobic conditions, a process dependent on glucose provision and transport."
cytochalasin B,Cytochalasin B is used to adjust the blood glucose concentration in the experimental oxygenator for studies of unidirectional glucose influx into the isolated perfused dog brain.,Entity: cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B is used to adjust the blood glucose concentration in the experimental oxygenator for studies of unidirectional glucose influx into the isolated perfused dog brain.
ethanol,Ethanol is used as a solvent to dissolve cytochalasin B for administration in the experimental oxygenator in dog brain perfusion studies.,Entity: ethanol. SMILES: CCO. Ethanol is used as a solvent to dissolve cytochalasin B for administration in the experimental oxygenator in dog brain perfusion studies.
glucose,Glucose influx into the isolated perfused dog brain can be measured using an indicator-dilution technique with [6-3H]glucose and 22Na as tracers.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose influx into the isolated perfused dog brain can be measured using an indicator-dilution technique with [6-3H]glucose and 22Na as tracers.
cytochalasin B,Cytochalasin B binds to a finite number of binding sites (3 x 10^5 sites per cell) on erythrocytes.,Entity: cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B binds to a finite number of binding sites (3 x 10^5 sites per cell) on erythrocytes.
glucose,"Increasing glucose concentration inhibits the high-affinity binding of cytochalasin to erythrocytes, with half-maximal inhibition at approximately 5 mM.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Increasing glucose concentration inhibits the high-affinity binding of cytochalasin to erythrocytes, with half-maximal inhibition at approximately 5 mM."
t-butyldimethylchlorosilane,"t-butyldimethylchlorosilane reacts with 20fi-hydroxy-4-pregnen-3-one to form t-butyldimethylsilyl derivatives, including the enol-t-butyldimethylsilyl ether.","Entity: t-butyldimethylchlorosilane. SMILES: CC(C)(C)[Si](C)(C)Cl. t-butyldimethylchlorosilane reacts with 20fi-hydroxy-4-pregnen-3-one to form t-butyldimethylsilyl derivatives, including the enol-t-butyldimethylsilyl ether."
pyridine,Pyridine is used as a solvent for t-Butyldimethylchlorosilane and as a base in the preparation of t-butyldimethylsilyl derivatives of steroids.,Entity: pyridine. SMILES: c1ccncc1. Pyridine is used as a solvent for t-Butyldimethylchlorosilane and as a base in the preparation of t-butyldimethylsilyl derivatives of steroids.
methanol,Methanol is used as a component of the eluting solvent (in a 10:10:1 ratio with chloroform and n-heptane) for removing excess t-Butyldimethylchlorosilane by elution through Sephadex LH20.,Entity: methanol. SMILES: CO. Methanol is used as a component of the eluting solvent (in a 10:10:1 ratio with chloroform and n-heptane) for removing excess t-Butyldimethylchlorosilane by elution through Sephadex LH20.
chloroform,Chloroform is used as a component of the eluting solvent (in a 10:10:1 ratio with n-heptane and methanol) for removing excess t-Butyldimethylchlorosilane by elution through Sephadex LH20.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a component of the eluting solvent (in a 10:10:1 ratio with n-heptane and methanol) for removing excess t-Butyldimethylchlorosilane by elution through Sephadex LH20.
n-heptane,n-Heptane is used as a component of the eluting solvent (in a 10:10:1 ratio with chloroform and methanol) for removing excess t-Butyldimethylchlorosilane by elution through Sephadex LH20.,Entity: n-heptane. SMILES: CCCCCCC. n-Heptane is used as a component of the eluting solvent (in a 10:10:1 ratio with chloroform and methanol) for removing excess t-Butyldimethylchlorosilane by elution through Sephadex LH20.
imidazole,Imidazole is not required as a catalyst for the quantitative conversion of non-sterically hindered hydroxyl groups to t-butyldimethylsilyl derivatives in the presence of t-Butyldimethylchlorosilane.,Entity: imidazole. SMILES: c1c[nH]cn1. Imidazole is not required as a catalyst for the quantitative conversion of non-sterically hindered hydroxyl groups to t-butyldimethylsilyl derivatives in the presence of t-Butyldimethylchlorosilane.
NaOH,NaOH is used to freshly distill pyridine to ensure its purity during the preparation of t-butyldimethylsilyl derivatives.,Entity: NaOH. SMILES: [Na+].[OH-]. NaOH is used to freshly distill pyridine to ensure its purity during the preparation of t-butyldimethylsilyl derivatives.
t-Butyldimethylchlorosilane,t-Butyldimethylchlorosilane is used to prepare t-butyldimethylsilyl derivatives of steroids by reaction with approximately 1 molar equivalent in pyridine solution at room temperature.,Entity: t-Butyldimethylchlorosilane. SMILES: CC(C)(C)[Si](C)(C)Cl. t-Butyldimethylchlorosilane is used to prepare t-butyldimethylsilyl derivatives of steroids by reaction with approximately 1 molar equivalent in pyridine solution at room temperature.
t-Butyldimethylchlorosilane,t-Butyldimethylchlorosilane quantitatively converts non-sterically hindered hydroxyl groups of steroids into t-butyldimethylsilyl derivatives in 3–15 hours in the absence of imidazole as catalyst.,Entity: t-Butyldimethylchlorosilane. SMILES: CC(C)(C)[Si](C)(C)Cl. t-Butyldimethylchlorosilane quantitatively converts non-sterically hindered hydroxyl groups of steroids into t-butyldimethylsilyl derivatives in 3–15 hours in the absence of imidazole as catalyst.
dimethylsilanol,Loss of dimethylsilanol from the M-57 fragment produces minor peaks at M-133 in the mass spectra of steroid t-butyldimethylsilyl ethers.,Entity: dimethylsilanol. SMILES: C[SiH](C)O. Loss of dimethylsilanol from the M-57 fragment produces minor peaks at M-133 in the mass spectra of steroid t-butyldimethylsilyl ethers.
t-butyldimethylsilanol,No loss of t-butyldimethylsilanol from the molecular ion is observed in the mass spectra of steroid t-butyldimethylsilyl ethers.,Entity: t-butyldimethylsilanol. SMILES: CC(C)(C)[Si](C)(C)O. No loss of t-butyldimethylsilanol from the molecular ion is observed in the mass spectra of steroid t-butyldimethylsilyl ethers.
trimethylsilyl ether,Trimethylsilyl ethers of A5-3-hydroxy steroids typically produce ions analogous to m/e 129 and M-129 in mass spectra.,Entity: trimethylsilyl ether. SMILES: C[Si](C)(C)O[Si](C)(C)C. Trimethylsilyl ethers of A5-3-hydroxy steroids typically produce ions analogous to m/e 129 and M-129 in mass spectra.
t-butyldimethylsilyl ether,"In the mass spectra of steroid t-butyldimethylsilyl ethers, no loss of t-butyldimethylsilanol from the molecular ion is observed, but minor peaks at M-133 correspond to loss of dimethylsilanol from the M-57 fragments.","Entity: t-butyldimethylsilyl ether. SMILES: CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C. In the mass spectra of steroid t-butyldimethylsilyl ethers, no loss of t-butyldimethylsilanol from the molecular ion is observed, but minor peaks at M-133 correspond to loss of dimethylsilanol from the M-57 fragments."
t-butyldimethylsilyl ether,"For the t-butyldimethylsilyl ether of 20fi-hydroxy-4-pregnen-3-one, the mass spectrum shows a weak ion at M-15, a prominent ion at M-57, and a minor ion at M-133, with an additional ion at M-101 due to loss of a 44a.m.u. fragment from the M-57 ion.","Entity: t-butyldimethylsilyl ether. SMILES: CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C. For the t-butyldimethylsilyl ether of 20fi-hydroxy-4-pregnen-3-one, the mass spectrum shows a weak ion at M-15, a prominent ion at M-57, and a minor ion at M-133, with an additional ion at M-101 due to loss of a 44a.m.u. fragment from the M-57 ion."
t-butyldimethylsilyl ether,A plausible fragmentation pathway for t-butyldimethylsilyl ethers of steroids involves dimethylsilyl migration to the steroid nucleus followed by loss of the sidechain residue.,Entity: t-butyldimethylsilyl ether. SMILES: CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C. A plausible fragmentation pathway for t-butyldimethylsilyl ethers of steroids involves dimethylsilyl migration to the steroid nucleus followed by loss of the sidechain residue.
bis(dimethylamino)dithiazolium chloride,"Bis(dimethylamino)dithiazolium chloride causes extensive damage to the fibrous portion of nerve tissue in cockroaches, leading to separation of nerve fibres and formation of spaces between fibre tracts and corpora pedunculata, likely due to vacuolisation or liquefaction necrosis of nerve fibres.","Entity: bis(dimethylamino)dithiazolium chloride. SMILES: CN(C)c1ns[s+]c1N(C)C.[Cl-]. Bis(dimethylamino)dithiazolium chloride causes extensive damage to the fibrous portion of nerve tissue in cockroaches, leading to separation of nerve fibres and formation of spaces between fibre tracts and corpora pedunculata, likely due to vacuolisation or liquefaction necrosis of nerve fibres."
thiotepa,"Thiotepa induces extensive damage to the fibrous portion of nerve tissue in cockroaches, resulting in separation of nerve fibres and the formation of spaces between fibre tracts and corpora pedunculata, probably as a result of vacuolisation or liquefaction necrosis of nerve fibres.","Entity: thiotepa. SMILES: S=P(N1CC1)(N1CC1)N1CC1. Thiotepa induces extensive damage to the fibrous portion of nerve tissue in cockroaches, resulting in separation of nerve fibres and the formation of spaces between fibre tracts and corpora pedunculata, probably as a result of vacuolisation or liquefaction necrosis of nerve fibres."
bis(dimethylamino)dithiazolium chloride,bis(dimethylamino)dithiazolium chloride is a chemosterilant used to sterilize adult cockroaches by intraperitoneal injection at a dose of 6 µg per insect.,Entity: bis(dimethylamino)dithiazolium chloride. SMILES: CN(C)c1ns[s+]c1N(C)C.[Cl-]. bis(dimethylamino)dithiazolium chloride is a chemosterilant used to sterilize adult cockroaches by intraperitoneal injection at a dose of 6 µg per insect.
thiotepa,thiotepa is a chemosterilant administered to adult cockroaches by intraperitoneal injection at a dose of 5 µg per insect for sterilization purposes.,Entity: thiotepa. SMILES: S=P(N1CC1)(N1CC1)N1CC1. thiotepa is a chemosterilant administered to adult cockroaches by intraperitoneal injection at a dose of 5 µg per insect for sterilization purposes.
eosin,eosin is a histological stain used for staining tissue sections following fixation in Bouin's fluid.,Entity: eosin. SMILES: O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+]. eosin is a histological stain used for staining tissue sections following fixation in Bouin's fluid.
"4-androstene-3,17-dione","4-androstene-3,17-dione is used as a substrate to determine the activities of steroid-metabolizing enzymes in cell extracts.","Entity: 4-androstene-3,17-dione. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. 4-androstene-3,17-dione is used as a substrate to determine the activities of steroid-metabolizing enzymes in cell extracts."
streptomycin,Streptomycin is used as an antibiotic supplement in cell culture media at a concentration of 125 µg/ml to prevent bacterial contamination.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used as an antibiotic supplement in cell culture media at a concentration of 125 µg/ml to prevent bacterial contamination.
flufenamate,Flufenamate at 25 pg/ml completely abolishes the luliberin-induced increase in intracellular prostaglandin E accumulation in dispersed pituitary cells.,Entity: flufenamate. SMILES: O=C([O-])c1ccccc1Nc1cccc(C(F)(F)F)c1. Flufenamate at 25 pg/ml completely abolishes the luliberin-induced increase in intracellular prostaglandin E accumulation in dispersed pituitary cells.
theophylline,Incubation of dispersed pituitary cells with 2 mM S-bromo cyclic AMP or 2 mM theophylline increases intracellular prostaglandin E accumulation.,Entity: theophylline. SMILES: Cn1c(=O)c2[nH]cnc2n(C)c1=O. Incubation of dispersed pituitary cells with 2 mM S-bromo cyclic AMP or 2 mM theophylline increases intracellular prostaglandin E accumulation.
indomethacin,Indomethacin at 50 µg/ml completely abolishes the luliberin-induced increase in intracellular prostaglandin E accumulation in dispersed pituitary cells.,Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin at 50 µg/ml completely abolishes the luliberin-induced increase in intracellular prostaglandin E accumulation in dispersed pituitary cells.
ethyl acetate,"Ethyl acetate is used as a component of solvent systems for chromatographic separation of metabolites on silicagel plates, in combination with dichloromethane and ethanol.","Entity: ethyl acetate. SMILES: CCOC(C)=O. Ethyl acetate is used as a component of solvent systems for chromatographic separation of metabolites on silicagel plates, in combination with dichloromethane and ethanol."
dichloromethane,"Dichloromethane is used as a solvent in chromatographic systems for separating metabolites on silicagel plates, either alone or in mixtures with ethyl acetate, chloroform, and methanol.","Entity: dichloromethane. SMILES: ClCCl. Dichloromethane is used as a solvent in chromatographic systems for separating metabolites on silicagel plates, either alone or in mixtures with ethyl acetate, chloroform, and methanol."
chloroform,"Chloroform is used as a component of solvent systems for chromatographic separation of metabolites on silicagel plates, in combination with dichloromethane and ethanol.","Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a component of solvent systems for chromatographic separation of metabolites on silicagel plates, in combination with dichloromethane and ethanol."
methanol,Methanol is used to elute retained radioactive material from XAD-2 resin and as a solvent for chromatography on Sephadex LH-20 and silicagel plates.,Entity: methanol. SMILES: CO. Methanol is used to elute retained radioactive material from XAD-2 resin and as a solvent for chromatography on Sephadex LH-20 and silicagel plates.
ethanol,"Ethanol is used as a component of solvent systems for chromatographic separation of metabolites on silicagel plates, in combination with ethyl acetate and chloroform.","Entity: ethanol. SMILES: CCO. Ethanol is used as a component of solvent systems for chromatographic separation of metabolites on silicagel plates, in combination with ethyl acetate and chloroform."
p-hydroxy-D-amphetamine,p-hydroxy-D-amphetamine is a major metabolite of D-amphetamine that acts as a weak stimulator of noradrenaline release from noradrenergic synaptosomes.,Entity: p-hydroxy-D-amphetamine. SMILES: [2H]Oc1ccc(CC(C)N)cc1. p-hydroxy-D-amphetamine is a major metabolite of D-amphetamine that acts as a weak stimulator of noradrenaline release from noradrenergic synaptosomes.
p-hydroxy-D-amphetamine,p-hydroxy-D-amphetamine is a strong inhibitor of noradrenaline uptake.,Entity: p-hydroxy-D-amphetamine. SMILES: [2H]Oc1ccc(CC(C)N)cc1. p-hydroxy-D-amphetamine is a strong inhibitor of noradrenaline uptake.
noradrenaline,Noradrenaline is a biogenic amine whose uptake can be strongly inhibited by D-amphetamine and p-hydroxy-D-amphetamine.,Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline is a biogenic amine whose uptake can be strongly inhibited by D-amphetamine and p-hydroxy-D-amphetamine.
5-hydroxytryptamine,"5-hydroxytryptamine uptake is inhibited by p-hydroxy-D-amphetamine, with lower potency for D-amphetamine, p-tyramine, and 8-phenethylamine in striatal synaptosomes.","Entity: 5-hydroxytryptamine. SMILES: NCCc1c[nH]c2ccc(O)cc12. 5-hydroxytryptamine uptake is inhibited by p-hydroxy-D-amphetamine, with lower potency for D-amphetamine, p-tyramine, and 8-phenethylamine in striatal synaptosomes."
dopamine,"Dopamine uptake is inhibited by D-amphetamine, with lower potency for p-hydroxya-amphetamine, p-tyramine, and 8-phenethylamine in striatal synaptosomes.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine uptake is inhibited by D-amphetamine, with lower potency for p-hydroxya-amphetamine, p-tyramine, and 8-phenethylamine in striatal synaptosomes."
p-hydroxy-D-amphetamine,"p-hydroxy-D-amphetamine is a potent inhibitor of noradrenaline uptake in hypothalamic synaptosomes, dopamine uptake in striatal synaptosomes, and 5-hydroxytryptamine uptake in striatal synaptosomes.","Entity: p-hydroxy-D-amphetamine. SMILES: [2H]Oc1ccc(CC(C)N)cc1. p-hydroxy-D-amphetamine is a potent inhibitor of noradrenaline uptake in hypothalamic synaptosomes, dopamine uptake in striatal synaptosomes, and 5-hydroxytryptamine uptake in striatal synaptosomes."
5-hydroxytryptamine,5-hydroxytryptamine ([3H]5-hydroxy-[3H]tryptamine) is used as a radioligand to study uptake and release in rat brain synaptosomes.,Entity: 5-hydroxytryptamine. SMILES: NCCc1c[nH]c2ccc(O)cc12. 5-hydroxytryptamine ([3H]5-hydroxy-[3H]tryptamine) is used as a radioligand to study uptake and release in rat brain synaptosomes.
noradrenaline,Noradrenaline ([3H]noradrenaline) is used as a radioligand to assess uptake and release in rat brain synaptosomes.,Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline ([3H]noradrenaline) is used as a radioligand to assess uptake and release in rat brain synaptosomes.
dopamine,Dopamine ([3H]dopamine) is used as a radioligand to study uptake and release in rat brain synaptosomes.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine ([3H]dopamine) is used as a radioligand to study uptake and release in rat brain synaptosomes.
p-hydroxy-D-amphetamine,"p-hydroxy-D-amphetamine, a derivative of amphetamine with a para-hydroxyl group, shows only modest noradrenaline release activity from rat brain synaptosomes at a concentration of 10 µM.","Entity: p-hydroxy-D-amphetamine. SMILES: [2H]Oc1ccc(CC(C)N)cc1. p-hydroxy-D-amphetamine, a derivative of amphetamine with a para-hydroxyl group, shows only modest noradrenaline release activity from rat brain synaptosomes at a concentration of 10 µM."
benzylamine,"Benzylamine, a derivative of phenethylamine without a side chain, is inactive in promoting noradrenaline release from rat brain synaptosomes at 10 µM.","Entity: benzylamine. SMILES: NCc1ccccc1. Benzylamine, a derivative of phenethylamine without a side chain, is inactive in promoting noradrenaline release from rat brain synaptosomes at 10 µM."
ascorbic acid,Ascorbic acid is used at 1 mM concentration in synaptosomal release assays to maintain reducing conditions.,Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid is used at 1 mM concentration in synaptosomal release assays to maintain reducing conditions.
nialamide,Nialamide is used at 1 mM concentration in synaptosomal release assays to maintain low calcium concentrations.,Entity: nialamide. SMILES: O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1. Nialamide is used at 1 mM concentration in synaptosomal release assays to maintain low calcium concentrations.
di-isopropyl phosphorofluoridate,"Di-isopropyl phosphorofluoridate inhibits the haemolytic activities of subcomponents C G and Clf by binding 1 mol of inhibitor per mol of protein, with the binding site located in the smaller polypeptide chain of both subcomponent C Z and subcomponent CG.","Entity: di-isopropyl phosphorofluoridate. SMILES: CC(C)OP(=O)(F)OC(C)C. Di-isopropyl phosphorofluoridate inhibits the haemolytic activities of subcomponents C G and Clf by binding 1 mol of inhibitor per mol of protein, with the binding site located in the smaller polypeptide chain of both subcomponent C Z and subcomponent CG."
di-isopropyl fluorophosphate,"Di-isopropyl fluorophosphate is an inhibitor of di-isopropyl fluorophosphate-sensitive proteinases, such as subcomponents CG* and CG of the complement C1 complex.","Entity: di-isopropyl fluorophosphate. SMILES: CC(C)OP(=O)(F)OC(C)C. Di-isopropyl fluorophosphate is an inhibitor of di-isopropyl fluorophosphate-sensitive proteinases, such as subcomponents CG* and CG of the complement C1 complex."
Sodium dodecyl sulphate,Sodium dodecyl sulphate is used in sodium dodecyl sulphate/polyacrylamide-gel electrophoresis to analyze the homogeneity of protein subcomponents.,Entity: Sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used in sodium dodecyl sulphate/polyacrylamide-gel electrophoresis to analyze the homogeneity of protein subcomponents.
cysteic acid,Cysteic acid is produced by performic acid oxidation of half-cystine.,Entity: cysteic acid. SMILES: N[C@@H](CS(=O)(=O)O)C(=O)O. Cysteic acid is produced by performic acid oxidation of half-cystine.
performic acid,Performic acid is used to oxidize half-cystine to cysteic acid.,Entity: performic acid. SMILES: O=COO. Performic acid is used to oxidize half-cystine to cysteic acid.
hydrochloric acid,"Hydrochloric acid (5.7 M) is used to hydrolyze protein subcomponents at 110°C for 24, 48, and 72 hours.","Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (5.7 M) is used to hydrolyze protein subcomponents at 110°C for 24, 48, and 72 hours."
Calcium chloride,Calcium chloride is used to adjust the ionic strength of buffer solutions to 5 mM for protein fractionation procedures.,Entity: Calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride is used to adjust the ionic strength of buffer solutions to 5 mM for protein fractionation procedures.
sodium chloride,Sodium chloride is included at 1% concentration in the buffer for suspending liposome-entrapped asparaginase in in vivo studies.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is included at 1% concentration in the buffer for suspending liposome-entrapped asparaginase in in vivo studies.
water,Water is used to dissolve Erwinia asparaginase (12000 units) prior to liposome entrapment in enzyme delivery systems.,Entity: water. SMILES: O. Water is used to dissolve Erwinia asparaginase (12000 units) prior to liposome entrapment in enzyme delivery systems.
stearylamine,Stearylamine is used to form positively charged liposomes for drug entrapment in therapeutic applications.,Entity: stearylamine. SMILES: CCCCCCCCCCCCCCCCCCN. Stearylamine is used to form positively charged liposomes for drug entrapment in therapeutic applications.
cholesterol,Cholesterol is a component of negatively charged liposomes used as carriers for drug delivery and enzyme entrapment.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is a component of negatively charged liposomes used as carriers for drug delivery and enzyme entrapment.
L-asparagine,"L-asparagine is required as an exogenous supply for the survival of certain malignant cells, and its administration in animal models leads to low blood concentrations, rapid tumour regression, and complete cure.","Entity: L-asparagine. SMILES: NC(=O)C[C@H](N)C(=O)O. L-asparagine is required as an exogenous supply for the survival of certain malignant cells, and its administration in animal models leads to low blood concentrations, rapid tumour regression, and complete cure."
sodium phosphate,Sodium phosphate is used as a buffer at 10 mM concentration for suspending liposome-entrapped asparaginase in in vivo experiments.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used as a buffer at 10 mM concentration for suspending liposome-entrapped asparaginase in in vivo experiments.
dicetyl phosphate,Dicetyl phosphate is used in combination with sphingomyelin at a 9:1 ratio to form liposomes with a high transition temperature of about 41°C.,Entity: dicetyl phosphate. SMILES: CCCCCCCCCCCCCCCCOP(=O)([O-])OCCCCCCCCCCCCCCCC. Dicetyl phosphate is used in combination with sphingomyelin at a 9:1 ratio to form liposomes with a high transition temperature of about 41°C.
phosphatidylserine,"Phosphatidylserine, when used as a lipid component in liposomes, is associated with a diminished immune response compared to other lipids.","Entity: phosphatidylserine. SMILES: CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCCCCCCCCCCCCCCCC. Phosphatidylserine, when used as a lipid component in liposomes, is associated with a diminished immune response compared to other lipids."
stearylamine,"Stearylamine, when used in phosphatidylcholine/stearylamine (9:1) liposomes, elicits an immune response to bovine serum albumin in CBAllac mice that is comparable to that induced by phosphatidylcholine/dicetyl phosphate (9:1) liposomes.","Entity: stearylamine. SMILES: CCCCCCCCCCCCCCCCCCN. Stearylamine, when used in phosphatidylcholine/stearylamine (9:1) liposomes, elicits an immune response to bovine serum albumin in CBAllac mice that is comparable to that induced by phosphatidylcholine/dicetyl phosphate (9:1) liposomes."
dicetyl phosphate,"Dicetyl phosphate, when combined with phosphatidylcholine in a 9:1 ratio to form liposomes, supports an immune response to bovine serum albumin in CBAllac mice that is comparable to that induced by stearylamine-containing liposomes.","Entity: dicetyl phosphate. SMILES: CCCCCCCCCCCCCCCCOP(=O)([O-])OCCCCCCCCCCCCCCCC. Dicetyl phosphate, when combined with phosphatidylcholine in a 9:1 ratio to form liposomes, supports an immune response to bovine serum albumin in CBAllac mice that is comparable to that induced by stearylamine-containing liposomes."
cholesterol,Liposomes containing approximately 40 mol % cholesterol are digested more slowly by macrophages compared to those with about 20 mol % cholesterol.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Liposomes containing approximately 40 mol % cholesterol are digested more slowly by macrophages compared to those with about 20 mol % cholesterol.
phosphatidylserine,"Liposomes containing phosphatidylserine as a major lipid component elicit a stronger immune response in CBAllac mice compared to those with other lipid compositions, as measured at days 22 and 37 post-injection.","Entity: phosphatidylserine. SMILES: CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCCCCCCCCCCCCCCCC. Liposomes containing phosphatidylserine as a major lipid component elicit a stronger immune response in CBAllac mice compared to those with other lipid compositions, as measured at days 22 and 37 post-injection."
dicetyl phosphate,Dicetyl phosphate is used as part of a phosphatidylcholine/dicetyl phosphate (9:1) liposome formulation for immunizing mice with bovine serum albumin.,Entity: dicetyl phosphate. SMILES: CCCCCCCCCCCCCCCCOP(=O)([O-])OCCCCCCCCCCCCCCCC. Dicetyl phosphate is used as part of a phosphatidylcholine/dicetyl phosphate (9:1) liposome formulation for immunizing mice with bovine serum albumin.
alanine,"Alanine is an amino acid released from both the epileptic focus and the cerebral cortex of rats in vivo, with its release measured as pmol/min per cm² of cortex superfused or as a proportion of total amino acids released.","Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine is an amino acid released from both the epileptic focus and the cerebral cortex of rats in vivo, with its release measured as pmol/min per cm² of cortex superfused or as a proportion of total amino acids released."
glutamate,"Glutamate is an amino acid released from both the epileptic focus and the cerebral cortex of rats in vivo, with its release measured as pmol/min per cm² of cortex superfused or as a proportion of total amino acids released.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate is an amino acid released from both the epileptic focus and the cerebral cortex of rats in vivo, with its release measured as pmol/min per cm² of cortex superfused or as a proportion of total amino acids released."
glutamine,"Glutamine is released from maturing epileptic focus tissue at a significantly lower amount compared to control tissue, when expressed as a percentage of total amino acids in the superfusates.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine is released from maturing epileptic focus tissue at a significantly lower amount compared to control tissue, when expressed as a percentage of total amino acids in the superfusates."
glutamate,"Glutamate, a transmitter candidate amino acid, shows no evidence of a day-night cycle in its release from normal cerebral cortex superfusates, with little variation in the extent of its release over time.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate, a transmitter candidate amino acid, shows no evidence of a day-night cycle in its release from normal cerebral cortex superfusates, with little variation in the extent of its release over time."
aspartate,"Aspartate is present in normal cerebral cortex superfusates only in small amounts and is detected infrequently, with little variation in its release over time.","Entity: aspartate. SMILES: N[C@@H](CC(=O)[O-])C(=O)[O-]. Aspartate is present in normal cerebral cortex superfusates only in small amounts and is detected infrequently, with little variation in its release over time."
alanine,"Alanine, one of the major amino acids released from normal cerebral cortex, exhibits a clear diurnal rhythm of release to the superfusion fluid, peaking around midnight and being lower in the morning and midday.","Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine, one of the major amino acids released from normal cerebral cortex, exhibits a clear diurnal rhythm of release to the superfusion fluid, peaking around midnight and being lower in the morning and midday."
serine,"Serine, a major amino acid released from normal cerebral cortex, displays a clear diurnal rhythm of release to the superfusion fluid, with highest levels around midnight and lower levels in the morning and midday.","Entity: serine. SMILES: N[C@@H](CO)C(=O)O. Serine, a major amino acid released from normal cerebral cortex, displays a clear diurnal rhythm of release to the superfusion fluid, with highest levels around midnight and lower levels in the morning and midday."
leucine,"Leucine, a nonphysiologically active amino acid, shows no evidence of a day-night cycle in its release from normal cerebral cortex superfusates, with little variation in the extent of its release over time.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine, a nonphysiologically active amino acid, shows no evidence of a day-night cycle in its release from normal cerebral cortex superfusates, with little variation in the extent of its release over time."
cysteine,"Cysteine is present in normal cerebral cortex superfusates only in small amounts and is detected infrequently, with little variation in its release over time.","Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. Cysteine is present in normal cerebral cortex superfusates only in small amounts and is detected infrequently, with little variation in its release over time."
glycine,"Glycine, a major amino acid released from normal cerebral cortex, exhibits a clear diurnal rhythm of release to the superfusion fluid, peaking around midnight and being lower in the morning and midday.","Entity: glycine. SMILES: NCC(=O)O. Glycine, a major amino acid released from normal cerebral cortex, exhibits a clear diurnal rhythm of release to the superfusion fluid, peaking around midnight and being lower in the morning and midday."
glutamine,"Glutamine, one of the major amino acids released from normal cerebral cortex, shows a clear diurnal rhythm of release to the superfusion fluid, with highest levels around midnight and lower levels in the morning and midday.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine, one of the major amino acids released from normal cerebral cortex, shows a clear diurnal rhythm of release to the superfusion fluid, with highest levels around midnight and lower levels in the morning and midday."
valine,"Valine, a nonphysiologically active amino acid, shows no evidence of a day-night cycle in its release from normal cerebral cortex superfusates, with little variation in the extent of its release over time.","Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. Valine, a nonphysiologically active amino acid, shows no evidence of a day-night cycle in its release from normal cerebral cortex superfusates, with little variation in the extent of its release over time."
glutamate,"Glutamate is released in amounts up to fourfold greater from epileptic focus tissue compared to untreated controls during days 3 and 4 after operation, whether measured as absolute amount or as a proportion of total amino acids.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate is released in amounts up to fourfold greater from epileptic focus tissue compared to untreated controls during days 3 and 4 after operation, whether measured as absolute amount or as a proportion of total amino acids."
alanine,Alanine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.
serine,Serine is among the amino acids released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.,Entity: serine. SMILES: N[C@@H](CO)C(=O)O. Serine is among the amino acids released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.
tyrosine,Tyrosine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.
threonine,Threonine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.,Entity: threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. Threonine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.
4-Aminobutyrate,4-Aminobutyrate is present in superfusates at only one-fifth the concentration of glutamate.,Entity: 4-Aminobutyrate. SMILES: NCCCC(=O)[O-]. 4-Aminobutyrate is present in superfusates at only one-fifth the concentration of glutamate.
glycine,Glycine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.,Entity: glycine. SMILES: NCC(=O)O. Glycine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.
methionine,Methionine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.,Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.
phenylalanine,Phenylalanine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.,Entity: phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. Phenylalanine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.
valine,Valine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.,Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. Valine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.
cysteine,Cysteine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.,Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. Cysteine is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.
citrulline,Citrulline is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.,Entity: citrulline. SMILES: NC(=O)NCCC[C@H](N)C(=O)O. Citrulline is released in greater amounts from epileptogenic cortex than control cortex during the first 2 days after operation.
glutamate,"Systematic or intracerebroventricular administration of glutamate can precipitate convulsions, presumably by interacting with excitatory glutamate receptors at glutamate-operated synapses.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)O)C(=O)O. Systematic or intracerebroventricular administration of glutamate can precipitate convulsions, presumably by interacting with excitatory glutamate receptors at glutamate-operated synapses."
glutamate,Glutamate released from focal tissue can cause hyperexcitation both within the focus and in surrounding normal tissue.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)O)C(=O)O. Glutamate released from focal tissue can cause hyperexcitation both within the focus and in surrounding normal tissue.
glutamate,Glutamate release from cobalt-induced epileptic foci has been demonstrated in both short-term (cup placement in cats) and long-term (superfusion cannula in rats) experiments.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)O)C(=O)O. Glutamate release from cobalt-induced epileptic foci has been demonstrated in both short-term (cup placement in cats) and long-term (superfusion cannula in rats) experiments.
4-aminobutyrate,4-aminobutyrate is a tissue amino acid whose concentration changes are implicated in the basic mechanisms generating epilepsy.,Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. 4-aminobutyrate is a tissue amino acid whose concentration changes are implicated in the basic mechanisms generating epilepsy.
4-aminobutyrate,4-aminobutyrate is commonly depleted in human and experimental epilepsy.,Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. 4-aminobutyrate is commonly depleted in human and experimental epilepsy.
taurine,Taurine is a tissue amino acid whose concentration changes are implicated in the basic mechanisms generating epilepsy.,Entity: taurine. SMILES: NCCS(=O)(=O)O. Taurine is a tissue amino acid whose concentration changes are implicated in the basic mechanisms generating epilepsy.
taurine,Taurine is commonly depleted in human and experimental epilepsy.,Entity: taurine. SMILES: NCCS(=O)(=O)O. Taurine is commonly depleted in human and experimental epilepsy.
glutamate,Glutamate is a transmitter amino acid whose tissue concentrations may be involved in the generation of epilepsy.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)O)C(=O)O. Glutamate is a transmitter amino acid whose tissue concentrations may be involved in the generation of epilepsy.
glutamate,Glutamate is commonly depleted in human and experimental epilepsy.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)O)C(=O)O. Glutamate is commonly depleted in human and experimental epilepsy.
oxygen,"Oxygen is used to fully oxygenate the artificial cerebrospinal fluid in a carburettor during superfusion experiments, with a 95:5 ratio of oxygen to carbon dioxide.","Entity: oxygen. SMILES: [O]. Oxygen is used to fully oxygenate the artificial cerebrospinal fluid in a carburettor during superfusion experiments, with a 95:5 ratio of oxygen to carbon dioxide."
carbon dioxide,Carbon dioxide is used in combination with oxygen (95:5 ratio) to fully oxygenate artificial cerebrospinal fluid during superfusion experiments.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is used in combination with oxygen (95:5 ratio) to fully oxygenate artificial cerebrospinal fluid during superfusion experiments.
nitrogen,Nitrogen is used as an inert gas (N2) in the storage reservoir for artificial cerebrospinal fluid during superfusion experiments.,Entity: nitrogen. SMILES: [N]. Nitrogen is used as an inert gas (N2) in the storage reservoir for artificial cerebrospinal fluid during superfusion experiments.
sulfuric acid,Sulfuric acid is used to prepare a final concentration of 0.01 M in the storage tubes for artificial cerebrospinal fluid collected from the cannula outlet.,Entity: sulfuric acid. SMILES: O=S(=O)(O)O. Sulfuric acid is used to prepare a final concentration of 0.01 M in the storage tubes for artificial cerebrospinal fluid collected from the cannula outlet.
glutamate,Glutamate release is specifically enhanced during the period of greatest epileptic activity and is implicated in the epileptic process.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate release is specifically enhanced during the period of greatest epileptic activity and is implicated in the epileptic process.
glutamate,Increased extracellular glutamate concentrations are likely to cause neuronal hyperexcitation.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Increased extracellular glutamate concentrations are likely to cause neuronal hyperexcitation.
asparagine,"Intravenous administration of asparaginase (both entrapped and nonentrapped) in mice leads to a profound decrease in blood serum and tumour concentrations of asparagine within 3.5 and 24 hours, respectively.","Entity: asparagine. SMILES: NC(=O)C[C@H](N)C(=O)O. Intravenous administration of asparaginase (both entrapped and nonentrapped) in mice leads to a profound decrease in blood serum and tumour concentrations of asparagine within 3.5 and 24 hours, respectively."
aspartic acid,Administration of asparaginase (both entrapped and nonentrapped) in mice is accompanied by an increase in blood serum and tumour concentrations of aspartic acid.,Entity: aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. Administration of asparaginase (both entrapped and nonentrapped) in mice is accompanied by an increase in blood serum and tumour concentrations of aspartic acid.
L-asparagine,"L-asparagine is required for the survival of certain malignant cells, and its exogenous supply can induce tumour regression and cure in animal models.","Entity: L-asparagine. SMILES: NC(=O)C[C@H](N)C(=O)O. L-asparagine is required for the survival of certain malignant cells, and its exogenous supply can induce tumour regression and cure in animal models."
sodium phosphate,"Sodium phosphate is used as a buffering agent in biological experiments, such as at a concentration of 10 mM in cell culture.","Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used as a buffering agent in biological experiments, such as at a concentration of 10 mM in cell culture."
sodium chloride,Sodium chloride is used at 1% concentration in buffer solutions for maintaining osmotic balance in biological studies.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at 1% concentration in buffer solutions for maintaining osmotic balance in biological studies.
water,Water is used to dissolve asparaginase enzyme prior to liposome entrapment in biochemical experiments.,Entity: water. SMILES: O. Water is used to dissolve asparaginase enzyme prior to liposome entrapment in biochemical experiments.
stearylamine,Stearylamine is used as a positively charged component in liposomes for drug delivery applications.,Entity: stearylamine. SMILES: CCCCCCCCCCCCCCCCCCN. Stearylamine is used as a positively charged component in liposomes for drug delivery applications.
cholesterol,Cholesterol is used as a component in liposome formulations for drug delivery.,Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is used as a component in liposome formulations for drug delivery.
phenylacetic acid,Phenylacetic acid is excreted conjugated mainly with ornithine in domestic hens and with taurine and glycine in pigeons.,Entity: phenylacetic acid. SMILES: O=C(O)Cc1ccccc1. Phenylacetic acid is excreted conjugated mainly with ornithine in domestic hens and with taurine and glycine in pigeons.
taurine,"Taurine forms conjugates with arylacetic acids except for diphenylacetic acid, with taurine conjugates being major metabolites for four of these acids: 4-nitrophenylacetic acid, 1-naphthylacetic acid, 2-naphthylacetic acid, and indolylacetic acid.","Entity: taurine. SMILES: NCCS(=O)(=O)O. Taurine forms conjugates with arylacetic acids except for diphenylacetic acid, with taurine conjugates being major metabolites for four of these acids: 4-nitrophenylacetic acid, 1-naphthylacetic acid, 2-naphthylacetic acid, and indolylacetic acid."
taurine,"Taurine does not conjugate with benzoic acid or 4-nitrobenzoic acid, and these compounds are excreted conjugated with glycine and glucuronic acid, respectively.","Entity: taurine. SMILES: NCCS(=O)(=O)O. Taurine does not conjugate with benzoic acid or 4-nitrobenzoic acid, and these compounds are excreted conjugated with glycine and glucuronic acid, respectively."
glucuronic acid,"Glucuronic acid conjugates with benzoic acid and 4-nitrobenzoic acid, which are excreted as glucuronides.","Entity: glucuronic acid. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)O. Glucuronic acid conjugates with benzoic acid and 4-nitrobenzoic acid, which are excreted as glucuronides."
glycine,"Glycine conjugates with benzoic acid and 4-nitrobenzoic acid, which are excreted as glycine conjugates.","Entity: glycine. SMILES: NCC(=O)O. Glycine conjugates with benzoic acid and 4-nitrobenzoic acid, which are excreted as glycine conjugates."
4-nitrophenylacetic acid,"4-nitrophenylacetic acid forms a taurine conjugate, which is its major metabolite.","Entity: 4-nitrophenylacetic acid. SMILES: O=C(O)Cc1ccc([N+](=O)[O-])cc1. 4-nitrophenylacetic acid forms a taurine conjugate, which is its major metabolite."
1-naphthylacetic acid,"1-naphthylacetic acid forms a taurine conjugate, which is its major metabolite.","Entity: 1-naphthylacetic acid. SMILES: O=C(O)Cc1cccc2ccccc12. 1-naphthylacetic acid forms a taurine conjugate, which is its major metabolite."
2-naphthylacetic acid,"2-naphthylacetic acid forms a taurine conjugate, which is its major metabolite.","Entity: 2-naphthylacetic acid. SMILES: O=C(O)Cc1ccc2ccccc2c1. 2-naphthylacetic acid forms a taurine conjugate, which is its major metabolite."
indolylacetic acid,"Indolylacetic acid forms a taurine conjugate, which is its major metabolite.","Entity: indolylacetic acid. SMILES: O=C(O)Cc1cc2ccccc2[nH]1. Indolylacetic acid forms a taurine conjugate, which is its major metabolite."
diphenylacetic acid,"Diphenylacetic acid does not conjugate with taurine, does not conjugate with any other amino acid, and is excreted mainly as a glucuronide.","Entity: diphenylacetic acid. SMILES: O=C(O)C(c1ccccc1)c1ccccc1. Diphenylacetic acid does not conjugate with taurine, does not conjugate with any other amino acid, and is excreted mainly as a glucuronide."
indolylacetic acid,Glycine conjugation does not occur in pigeons for indolylacetic acid.,Entity: indolylacetic acid. SMILES: O=C(O)Cc1cc2ccccc2[nH]1. Glycine conjugation does not occur in pigeons for indolylacetic acid.
taurine,"Taurine conjugation is a major metabolic process in pigeons, accounting for up to 70% of excreted 14C in the case of l-napthylacetic acid.","Entity: taurine. SMILES: NCCS(=O)(=O)O. Taurine conjugation is a major metabolic process in pigeons, accounting for up to 70% of excreted 14C in the case of l-napthylacetic acid."
taurine,"In hens, taurine conjugation occurs but is less extensive than in pigeons, with the taurine conjugate of 1-naphthylacetic acid comprising 23% of excreted 14C.","Entity: taurine. SMILES: NCCS(=O)(=O)O. In hens, taurine conjugation occurs but is less extensive than in pigeons, with the taurine conjugate of 1-naphthylacetic acid comprising 23% of excreted 14C."
diphenylacetic acid,Glycine conjugation does not occur for diphenylacetic acid in pigeons.,Entity: diphenylacetic acid. SMILES: O=C(O)C(c1ccccc1)c1ccccc1. Glycine conjugation does not occur for diphenylacetic acid in pigeons.
chlorophenylacetic acid,Ornithine conjugation is a major metabolic process for chlorophenylacetic acid in hens.,Entity: chlorophenylacetic acid. SMILES: O=C(O)C(Cl)c1ccccc1. Ornithine conjugation is a major metabolic process for chlorophenylacetic acid in hens.
ornithine,"Ornithine conjugation does not occur in pigeons with any of the six listed arylacetic acids, but is a major metabolic process in hens for phenyl-, chlorophenyl-, and 4-nitrophenylacetic acid.","Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. Ornithine conjugation does not occur in pigeons with any of the six listed arylacetic acids, but is a major metabolic process in hens for phenyl-, chlorophenyl-, and 4-nitrophenylacetic acid."
phenylacetic acid,Ornithine conjugation is a major metabolic process for phenylacetic acid in hens.,Entity: phenylacetic acid. SMILES: O=C(O)Cc1ccccc1. Ornithine conjugation is a major metabolic process for phenylacetic acid in hens.
4-nitrophenylacetic acid,Ornithine conjugation is a major metabolic process for 4-nitrophenylacetic acid in hens.,Entity: 4-nitrophenylacetic acid. SMILES: O=C(O)Cc1ccc([N+](=O)[O-])cc1. Ornithine conjugation is a major metabolic process for 4-nitrophenylacetic acid in hens.
glycine,"Glycine conjugation is a significant metabolic process in pigeons except for indolylacetic acid and diphenylacetic acid, and is virtually absent in hens for the first four compounds listed.","Entity: glycine. SMILES: NCC(=O)O. Glycine conjugation is a significant metabolic process in pigeons except for indolylacetic acid and diphenylacetic acid, and is virtually absent in hens for the first four compounds listed."
4-Acetamidobenzoic acid,"4-Acetamidobenzoic acid is a urinary metabolite in ferrets, accounting for 3% of the administered 14C dose excreted in urine.","Entity: 4-Acetamidobenzoic acid. SMILES: CC(=O)Nc1ccc(C(=O)O)cc1. 4-Acetamidobenzoic acid is a urinary metabolite in ferrets, accounting for 3% of the administered 14C dose excreted in urine."
4-acetamidohippuric acid,"4-acetamidohippuric acid is a urinary metabolite in ferrets, accounting for 3% of the administered 14C dose excreted in urine.","Entity: 4-acetamidohippuric acid. SMILES: CC(=O)Nc1ccc(C(=O)NCC(=O)O)cc1. 4-acetamidohippuric acid is a urinary metabolite in ferrets, accounting for 3% of the administered 14C dose excreted in urine."
indol-3-ylacetic acid,The rat forms little or no taurine conjugate with indol-3-ylacetic acid.,Entity: indol-3-ylacetic acid. SMILES: O=C(O)Cc1c[nH]c2ccccc12. The rat forms little or no taurine conjugate with indol-3-ylacetic acid.
diphenylacetic acid,"Diphenylacetic acid, with the structure Ar2CHC02H, is not conjugated with taurine in the ferret or rat.","Entity: diphenylacetic acid. SMILES: O=C(O)C(c1ccccc1)c1ccccc1. Diphenylacetic acid, with the structure Ar2CHC02H, is not conjugated with taurine in the ferret or rat."
taurine,"Taurine conjugation is characteristic of ferret metabolism of arylacetic acids with the structure ArCH2C02H, but not of benzoic acids or diphenylacetic acid.","Entity: taurine. SMILES: NCCS(=O)(=O)O. Taurine conjugation is characteristic of ferret metabolism of arylacetic acids with the structure ArCH2C02H, but not of benzoic acids or diphenylacetic acid."
phenylacetic acid,The rat forms little or no taurine conjugate with phenylacetic acid.,Entity: phenylacetic acid. SMILES: O=C(O)Cc1ccccc1. The rat forms little or no taurine conjugate with phenylacetic acid.
4-nitro-phenylacetic acid,The rat forms little or no taurine conjugate with 4-nitro-phenylacetic acid.,Entity: 4-nitro-phenylacetic acid. SMILES: O=C(O)Cc1ccc([N+](=O)[O-])cc1. The rat forms little or no taurine conjugate with 4-nitro-phenylacetic acid.
4-chloro-phenylacetic acid,The rat forms little or no taurine conjugate with 4-chloro-phenylacetic acid.,Entity: 4-chloro-phenylacetic acid. SMILES: O=C(O)Cc1ccc(Cl)cc1. The rat forms little or no taurine conjugate with 4-chloro-phenylacetic acid.
1-naphthylacetic acid,The rat forms little or no taurine conjugate with 1-naphthylacetic acid.,Entity: 1-naphthylacetic acid. SMILES: O=C(O)Cc1cccc2ccccc12. The rat forms little or no taurine conjugate with 1-naphthylacetic acid.
glycine,"In pigeons, glycine forms conjugates with benzoic acids and arylacetic acids, while in hens, glycine forms conjugates with benzoic acid and arylacetic acids of the formula ArCH2C02H.","Entity: glycine. SMILES: NCC(=O)O. In pigeons, glycine forms conjugates with benzoic acids and arylacetic acids, while in hens, glycine forms conjugates with benzoic acid and arylacetic acids of the formula ArCH2C02H."
benzoic acid,"Benzoic acid is metabolized in pigeons to hippuric acid (65% of dose) and benzoylglucuronide (18% of dose), and in hens to ornithine conjugates.","Entity: benzoic acid. SMILES: O=C(O)c1ccccc1. Benzoic acid is metabolized in pigeons to hippuric acid (65% of dose) and benzoylglucuronide (18% of dose), and in hens to ornithine conjugates."
benzoyltaurine,Benzoyltaurine is not detected in the excreta of pigeons when 100 mg/kg [carbo~y-'~C]benzoic acid is administered intraperitoneally.,Entity: benzoyltaurine. SMILES: O=C(NCCS(=O)(=O)O)c1ccccc1. Benzoyltaurine is not detected in the excreta of pigeons when 100 mg/kg [carbo~y-'~C]benzoic acid is administered intraperitoneally.
taurine,"In pigeons, taurine forms conjugates with arylacetic acids such as benzoic acids.","Entity: taurine. SMILES: NCCS(=O)(=O)O. In pigeons, taurine forms conjugates with arylacetic acids such as benzoic acids."
ornithine,"In hens, ornithine forms conjugates with benzoic acid and arylacetic acids of the formula ArCH2C02H.","Entity: ornithine. SMILES: NCCC[C@H](N)C(=O)O. In hens, ornithine forms conjugates with benzoic acid and arylacetic acids of the formula ArCH2C02H."
hippuric acid,Hippuric acid is the major metabolite (65% of dose) formed from [carbo~y-'~C]benzoic acid after intraperitoneal administration in pigeons.,Entity: hippuric acid. SMILES: O=C(O)CNC(=O)c1ccccc1. Hippuric acid is the major metabolite (65% of dose) formed from [carbo~y-'~C]benzoic acid after intraperitoneal administration in pigeons.
phenylacetic acid,Phenylacetic acid binds to rat liver mitochondrial fractions with a binding affinity of 40.,Entity: phenylacetic acid. SMILES: O=C(O)Cc1ccccc1. Phenylacetic acid binds to rat liver mitochondrial fractions with a binding affinity of 40.
hydratropic acid,Hydratropic acid does not form a glycine conjugate in rat liver mitochondria under the tested conditions.,Entity: hydratropic acid. SMILES: CC(C(=O)O)c1ccccc1. Hydratropic acid does not form a glycine conjugate in rat liver mitochondria under the tested conditions.
hydratropic acid,Hydratropic acid undergoes liver microsomal glucuronic acid conjugation with an average rate of 0.3 nmol/min per mg protein.,Entity: hydratropic acid. SMILES: CC(C(=O)O)c1ccccc1. Hydratropic acid undergoes liver microsomal glucuronic acid conjugation with an average rate of 0.3 nmol/min per mg protein.
hydratropic acid,Hydratropic acid binds to rat liver mitochondrial fractions with a binding affinity of 1.,Entity: hydratropic acid. SMILES: CC(C(=O)O)c1ccccc1. Hydratropic acid binds to rat liver mitochondrial fractions with a binding affinity of 1.
KCl,KCl is used as a buffer at 1.15% concentration in rat liver mitochondrial and microsomal binding assays.,Entity: KCl. SMILES: [Cl-].[K+]. KCl is used as a buffer at 1.15% concentration in rat liver mitochondrial and microsomal binding assays.
diphenylacetic acid,Diphenylacetic acid forms a glycine conjugate in rat liver mitochondria with an optimal glycine conjugation rate of 0.0 nmol/40 mg liver per 30 min at 37°C.,Entity: diphenylacetic acid. SMILES: O=C(O)C(c1ccccc1)c1ccccc1. Diphenylacetic acid forms a glycine conjugate in rat liver mitochondria with an optimal glycine conjugation rate of 0.0 nmol/40 mg liver per 30 min at 37°C.
glutathione,Glutathione is included as a cofactor at 20 µmol in rat liver mitochondrial glycine conjugation assays.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione is included as a cofactor at 20 µmol in rat liver mitochondrial glycine conjugation assays.
diphenylacetic acid,Diphenylacetic acid undergoes liver microsomal glucuronic acid conjugation with an average rate of 2.2 nmol/min per mg protein.,Entity: diphenylacetic acid. SMILES: O=C(O)C(c1ccccc1)c1ccccc1. Diphenylacetic acid undergoes liver microsomal glucuronic acid conjugation with an average rate of 2.2 nmol/min per mg protein.
MgCl2,MgCl2 is used as a cofactor at 3 µmol in rat liver mitochondrial glycine conjugation assays.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used as a cofactor at 3 µmol in rat liver mitochondrial glycine conjugation assays.
diphenylacetic acid,"Diphenylacetic acid binds to rat liver mitochondrial fractions with a binding affinity of 2, and to microsomal fractions with a binding affinity of 27.","Entity: diphenylacetic acid. SMILES: O=C(O)C(c1ccccc1)c1ccccc1. Diphenylacetic acid binds to rat liver mitochondrial fractions with a binding affinity of 2, and to microsomal fractions with a binding affinity of 27."
glycine,Glycine is used as a conjugating agent in rat liver mitochondrial glycine conjugation assays.,Entity: glycine. SMILES: NCC(=O)O. Glycine is used as a conjugating agent in rat liver mitochondrial glycine conjugation assays.
phenylacetic acid,Phenylacetic acid forms a glycine conjugate in rat liver mitochondria with an optimal glycine conjugation rate of 8.9 nmol/40 mg liver per 30 min at 37°C.,Entity: phenylacetic acid. SMILES: O=C(O)Cc1ccccc1. Phenylacetic acid forms a glycine conjugate in rat liver mitochondria with an optimal glycine conjugation rate of 8.9 nmol/40 mg liver per 30 min at 37°C.
acetone,Acetone is used to stop the reaction in rat liver mitochondrial glycine conjugation assays.,Entity: acetone. SMILES: CC(C)=O. Acetone is used to stop the reaction in rat liver mitochondrial glycine conjugation assays.
phenylacetic acid,Phenylacetic acid undergoes liver microsomal glucuronic acid conjugation with an average rate of 0 nmol/min per mg protein.,Entity: phenylacetic acid. SMILES: O=C(O)Cc1ccccc1. Phenylacetic acid undergoes liver microsomal glucuronic acid conjugation with an average rate of 0 nmol/min per mg protein.
phenylacetic acid,Phenylacetic acid is metabolized almost entirely by conjugation with glycine in rats.,Entity: phenylacetic acid. SMILES: O=C(O)Cc1ccccc1. Phenylacetic acid is metabolized almost entirely by conjugation with glycine in rats.
hydratropic acid,Hydratropic acid is metabolized almost completely by conjugation with glucuronic acid in rats.,Entity: hydratropic acid. SMILES: CC(C(=O)O)c1ccccc1. Hydratropic acid is metabolized almost completely by conjugation with glucuronic acid in rats.
diphenylacetic acid,Diphenylacetic acid is metabolized almost completely by conjugation with glucuronic acid in rats.,Entity: diphenylacetic acid. SMILES: O=C(O)C(c1ccccc1)c1ccccc1. Diphenylacetic acid is metabolized almost completely by conjugation with glucuronic acid in rats.
α-naphthylacetic acid,a-Naphthylacetic acid is conjugated partly with glycine and partly with glucuronic acid in rats.,Entity: α-naphthylacetic acid. SMILES: O=C(O)Cc1cccc2ccccc12. a-Naphthylacetic acid is conjugated partly with glycine and partly with glucuronic acid in rats.
glycine,"Glycine acts as a conjugating amino acid for certain arylacetic acids, such as phenylacetic acid and a-Naphthylacetic acid, in rats.","Entity: glycine. SMILES: NCC(=O)O. Glycine acts as a conjugating amino acid for certain arylacetic acids, such as phenylacetic acid and a-Naphthylacetic acid, in rats."
glucuronic acid,"Glucuronic acid serves as a conjugating acid for certain arylacetic acids, such as hydratropic acid and diphenylacetic acid, in rats.","Entity: glucuronic acid. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)O. Glucuronic acid serves as a conjugating acid for certain arylacetic acids, such as hydratropic acid and diphenylacetic acid, in rats."
adrenaline,Adrenaline is metabolized by the hepatic microsomal fraction in an oxygen- and NADPH-dependent process.,Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenaline is metabolized by the hepatic microsomal fraction in an oxygen- and NADPH-dependent process.
pargyline,"Pargyline is an inhibitor of monoamine oxidase and produces only a small decrease in hepatic microsomal metabolism of adrenaline and noradrenaline, likely due to inhibition of monoamine oxidase present in the microsomal fraction.","Entity: pargyline. SMILES: C#CCN(C)Cc1ccccc1. Pargyline is an inhibitor of monoamine oxidase and produces only a small decrease in hepatic microsomal metabolism of adrenaline and noradrenaline, likely due to inhibition of monoamine oxidase present in the microsomal fraction."
oxygen,Oxygen is required as a substrate for the hepatic microsomal metabolism of adrenaline and noradrenaline.,Entity: oxygen. SMILES: [O]. Oxygen is required as a substrate for the hepatic microsomal metabolism of adrenaline and noradrenaline.
NADPH,NADPH is required as a cofactor for the hepatic microsomal metabolism of adrenaline and noradrenaline.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is required as a cofactor for the hepatic microsomal metabolism of adrenaline and noradrenaline.
glucose 6-phosphate,Glucose 6-phosphate is used as a substrate at 25 pmol concentration in hepatic microsomal assays measuring catecholamine metabolism.,Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose 6-phosphate is used as a substrate at 25 pmol concentration in hepatic microsomal assays measuring catecholamine metabolism.
(-)-adrenaline,(-)-adrenaline is used as a substrate at 12 nmol concentration in hepatic microsomal assays measuring catecholamine metabolism.,Entity: (-)-adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. (-)-adrenaline is used as a substrate at 12 nmol concentration in hepatic microsomal assays measuring catecholamine metabolism.
nicotinamide,Nicotinamide is included at 50 pmol concentration in hepatic microsomal assays measuring catecholamine metabolism.,Entity: nicotinamide. SMILES: NC(=O)c1cccnc1. Nicotinamide is included at 50 pmol concentration in hepatic microsomal assays measuring catecholamine metabolism.
2-m-adrenaline,2-m-adrenaline inhibits the initial rate of reduction of cytochrome P-450 by NADPH by 6%.,Entity: 2-m-adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. 2-m-adrenaline inhibits the initial rate of reduction of cytochrome P-450 by NADPH by 6%.
NADPH,"NADPH reduces the rate of reduction of cytochrome P-450, and this reduction is inhibited by catecholamines such as 2-m-adrenaline and 2-m-noradrenaline.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH reduces the rate of reduction of cytochrome P-450, and this reduction is inhibited by catecholamines such as 2-m-adrenaline and 2-m-noradrenaline."
adrenaline,"The type I1 spectral change produced by adrenaline in microsomal fractions is not modified by 0.1 mM ascorbate, indicating it is not due to autoxidation.","Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. The type I1 spectral change produced by adrenaline in microsomal fractions is not modified by 0.1 mM ascorbate, indicating it is not due to autoxidation."
noradrenaline,"Noradrenaline interacts directly with cytochrome P-450 in microsomal fractions, as shown by the lack of spectral change when mixed with haemin or flavin in the form of FAD or FMN.","Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline interacts directly with cytochrome P-450 in microsomal fractions, as shown by the lack of spectral change when mixed with haemin or flavin in the form of FAD or FMN."
adrenaline,"Adrenaline interacts directly with cytochrome P-450 in microsomal fractions, as shown by the lack of spectral change when mixed with haemin or flavin in the form of FAD or FMN.","Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenaline interacts directly with cytochrome P-450 in microsomal fractions, as shown by the lack of spectral change when mixed with haemin or flavin in the form of FAD or FMN."
haemin,"Haemin, in the form of FAD or FMN, does not modify the type I1 spectral change produced by noradrenaline or adrenaline in microsomal fractions, indicating it does not interact with cytochrome P-450 in this system.","Entity: haemin. SMILES: C=CC1=C(C)c2cc3[n-]c(cc4nc(cc5[n-]c(cc1n2)c(C)c5C=C)C(C)=C4CCC(=O)O)c(CCC(=O)O)c3C.[Cl-].[Fe+3]. Haemin, in the form of FAD or FMN, does not modify the type I1 spectral change produced by noradrenaline or adrenaline in microsomal fractions, indicating it does not interact with cytochrome P-450 in this system."
FMN,"FMN, in the form of flavin, does not modify the type I1 spectral change produced by noradrenaline or adrenaline in microsomal fractions, indicating it does not interact with cytochrome P-450 in this system.","Entity: FMN. SMILES: Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C. FMN, in the form of flavin, does not modify the type I1 spectral change produced by noradrenaline or adrenaline in microsomal fractions, indicating it does not interact with cytochrome P-450 in this system."
ascorbate,"0.1 mM ascorbate does not modify the type I1 spectral changes produced by noradrenaline or adrenaline in microsomal fractions, indicating the spectral changes are not due to autoxidation products.","Entity: ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O. 0.1 mM ascorbate does not modify the type I1 spectral changes produced by noradrenaline or adrenaline in microsomal fractions, indicating the spectral changes are not due to autoxidation products."
noradrenaline,"Noradrenaline binds to microsomal fractions and produces a type I1 spectral change with a maximum at 433 nm and a minimum at 390 nm, with a spectral dissociation constant (K,) of 0.9 µM.","Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline binds to microsomal fractions and produces a type I1 spectral change with a maximum at 433 nm and a minimum at 390 nm, with a spectral dissociation constant (K,) of 0.9 µM."
adrenaline,"Adrenaline binds to microsomal fractions and produces a type I1 spectral change with a maximum at 422 nm and a minimum at 382 nm, with a spectral dissociation constant (K,) of 1.0 µM.","Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenaline binds to microsomal fractions and produces a type I1 spectral change with a maximum at 422 nm and a minimum at 382 nm, with a spectral dissociation constant (K,) of 1.0 µM."
adrenaline,The type I1 spectral change produced by adrenaline in microsomal fractions is smaller than that of noradrenaline.,Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. The type I1 spectral change produced by adrenaline in microsomal fractions is smaller than that of noradrenaline.
noradrenaline,"The type I1 spectral change produced by noradrenaline in microsomal fractions is not modified by 0.1 mM ascorbate, indicating it is not due to autoxidation.","Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. The type I1 spectral change produced by noradrenaline in microsomal fractions is not modified by 0.1 mM ascorbate, indicating it is not due to autoxidation."
carbon monoxide,"Carbon monoxide inhibits metabolism, indicating involvement of microsomal cytochrome P-450 enzymes.","Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide inhibits metabolism, indicating involvement of microsomal cytochrome P-450 enzymes."
nicotinamide adenine dinucleotide phosphate,Nicotinamide adenine dinucleotide phosphate (NADPH) is required for the metabolism mediated by NADPH-dependent mixed-function oxidases.,Entity: nicotinamide adenine dinucleotide phosphate. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. Nicotinamide adenine dinucleotide phosphate (NADPH) is required for the metabolism mediated by NADPH-dependent mixed-function oxidases.
oxygen,Oxygen is required for the metabolism mediated by NADPH-dependent mixed-function oxidases.,Entity: oxygen. SMILES: [O]. Oxygen is required for the metabolism mediated by NADPH-dependent mixed-function oxidases.
adrenaline,Adrenaline is a type I1 substrate whose metabolism is enhanced by acetone in microsomal incubations.,Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenaline is a type I1 substrate whose metabolism is enhanced by acetone in microsomal incubations.
acetone,Acetone enhances the metabolism of type I1 substrates but inhibits the metabolism of type I substrates in microsomal incubations.,Entity: acetone. SMILES: CC(C)=O. Acetone enhances the metabolism of type I1 substrates but inhibits the metabolism of type I substrates in microsomal incubations.
ATP,"ATP is used as a cofactor in hepatic microsomal enzyme assays at a concentration of 2.5 µM, and increasing its concentration with MgCl2 stimulates the initial rate of acylation.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP is used as a cofactor in hepatic microsomal enzyme assays at a concentration of 2.5 µM, and increasing its concentration with MgCl2 stimulates the initial rate of acylation."
MgCl2,"MgCl2 is used as a cofactor in hepatic microsomal enzyme assays at a concentration of 5.0 µM, and increasing its concentration with ATP stimulates the initial rate of acylation.","Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used as a cofactor in hepatic microsomal enzyme assays at a concentration of 5.0 µM, and increasing its concentration with ATP stimulates the initial rate of acylation."
theophylline,Theophylline is omitted from hepatic microsomal enzyme assays to study acylation reactions.,Entity: theophylline. SMILES: Cn1c(=O)c2[nH]cnc2n(C)c1=O. Theophylline is omitted from hepatic microsomal enzyme assays to study acylation reactions.
oleate,Oleate is incorporated into choline glycerophospholipid in membrane preparations at rates ranging from 0 to 0.27 nmol/min per mg of protein in the presence of ATP and MgCl2.,Entity: oleate. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)[O-]. Oleate is incorporated into choline glycerophospholipid in membrane preparations at rates ranging from 0 to 0.27 nmol/min per mg of protein in the presence of ATP and MgCl2.
choline,Choline is used as a substrate for the incorporation of oleate into choline glycerophospholipid in membrane preparations.,Entity: choline. SMILES: C[N+](C)(C)CCO. Choline is used as a substrate for the incorporation of oleate into choline glycerophospholipid in membrane preparations.
FMN,"FMN, as a form of flavin, does not induce a spectral change when mixed with catecholamines, indicating that catecholamines interact directly with cytochrome P-450 enzymes.","Entity: FMN. SMILES: Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C. FMN, as a form of flavin, does not induce a spectral change when mixed with catecholamines, indicating that catecholamines interact directly with cytochrome P-450 enzymes."
ascorbate,"The presence of 0.1 mM ascorbate does not modify the spectral changes produced by catecholamines, indicating that these changes are not due to autoxidation products of the catecholamines.","Entity: ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O. The presence of 0.1 mM ascorbate does not modify the spectral changes produced by catecholamines, indicating that these changes are not due to autoxidation products of the catecholamines."
adrenaline,"Adrenaline produces a spectral change in the presence of cytochrome P-450 enzymes, with a spectral dissociation constant (K) of 1.0 mM.","Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenaline produces a spectral change in the presence of cytochrome P-450 enzymes, with a spectral dissociation constant (K) of 1.0 mM."
adrenaline,"The spectral change produced by adrenaline is smaller than that of noradrenaline, likely due to substituents near the nitrogen atom decreasing the size of a type I1 spectral change.","Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. The spectral change produced by adrenaline is smaller than that of noradrenaline, likely due to substituents near the nitrogen atom decreasing the size of a type I1 spectral change."
haemin,"Haemin, in the form of FAD or FMN, does not induce a spectral change when mixed with catecholamines, indicating that catecholamines interact directly with cytochrome P-450 enzymes.","Entity: haemin. SMILES: C=CC1=C(C)c2cc3[n-]c(cc4nc(cc5[n-]c(cc1n2)c(C)c5C=C)C(C)=C4CCC(=O)O)c(CCC(=O)O)c3C.[Cl-].[Fe+3]. Haemin, in the form of FAD or FMN, does not induce a spectral change when mixed with catecholamines, indicating that catecholamines interact directly with cytochrome P-450 enzymes."
noradrenaline,Noradrenaline at concentrations of 0.1–0.1 mM stimulates the incorporation of oleate into cholineglycerophospholipid in membranes with low unstimulated acylation rate.,Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline at concentrations of 0.1–0.1 mM stimulates the incorporation of oleate into cholineglycerophospholipid in membranes with low unstimulated acylation rate.
noradrenaline,Noradrenaline depresses acylation in membranes with comparatively high unstimulated acylation rate.,Entity: noradrenaline. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Noradrenaline depresses acylation in membranes with comparatively high unstimulated acylation rate.
adrenaline,Adrenaline at concentrations of 0.1–0.1 mM stimulates the incorporation of oleate into cholineglycerophospholipid in membranes with low unstimulated acylation rate.,Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenaline at concentrations of 0.1–0.1 mM stimulates the incorporation of oleate into cholineglycerophospholipid in membranes with low unstimulated acylation rate.
adrenaline,Adrenaline depresses acylation in membranes with comparatively high unstimulated acylation rate.,Entity: adrenaline. SMILES: CNCC(O)c1ccc(O)c(O)c1. Adrenaline depresses acylation in membranes with comparatively high unstimulated acylation rate.
NADPH,"NADPH acts as a reducing agent that catalyzes the reduction of cytochrome P-450, and this process can be inhibited by catecholamines such as 2m-noradrenaline (by 32%) and 2m-adrenaline (by 6%) by binding to the sixth ligand of the iron in the active site.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH acts as a reducing agent that catalyzes the reduction of cytochrome P-450, and this process can be inhibited by catecholamines such as 2m-noradrenaline (by 32%) and 2m-adrenaline (by 6%) by binding to the sixth ligand of the iron in the active site."
oxygen,"Oxygen is used as a gas to provide a controlled environment for incubating tissue preparations, with 100% oxygen applied to human intestinal biopsy samples.","Entity: oxygen. SMILES: [O]. Oxygen is used as a gas to provide a controlled environment for incubating tissue preparations, with 100% oxygen applied to human intestinal biopsy samples."
bicarbonate,Bicarbonate is used as a component of Krebs-Henseleit buffer for incubating tissue preparations in physiological pH studies.,Entity: bicarbonate. SMILES: O=C([O-])O. Bicarbonate is used as a component of Krebs-Henseleit buffer for incubating tissue preparations in physiological pH studies.
phosphate,Phosphate is used as a component of Krebs-phosphate buffer for incubating human intestinal biopsy samples in physiological pH experiments.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate is used as a component of Krebs-phosphate buffer for incubating human intestinal biopsy samples in physiological pH experiments.
carbon dioxide,Carbon dioxide is used as a gas (in a 95:5 ratio with oxygen) to provide a controlled environment for incubating tissue preparations.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is used as a gas (in a 95:5 ratio with oxygen) to provide a controlled environment for incubating tissue preparations.
methanol,Methanol is used as an analytical-grade fixative for preserving tissue samples in histological and mucosal studies.,Entity: methanol. SMILES: CO. Methanol is used as an analytical-grade fixative for preserving tissue samples in histological and mucosal studies.
galactose,Galactose is sequentially added to a mannosylated peptide core during the maturation of mucin in goblet cells of the intestinal mucosa.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose is sequentially added to a mannosylated peptide core during the maturation of mucin in goblet cells of the intestinal mucosa.
polyphloretin phosphate,"Polyphloretin phosphate, a prostaglandin antagonist, slightly decreases the binding of thyrotropin to membranes from the bovine thyroid.","Entity: polyphloretin phosphate. SMILES: O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O.O=P(O)(O)O. Polyphloretin phosphate, a prostaglandin antagonist, slightly decreases the binding of thyrotropin to membranes from the bovine thyroid."
quinidine,Quinidine increases the binding of thyrotropin to membranes from the bovine thyroid.,Entity: quinidine. SMILES: C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12. Quinidine increases the binding of thyrotropin to membranes from the bovine thyroid.
practolol,Practolol does not affect the binding of thyrotropin to membranes from the bovine thyroid.,Entity: practolol. SMILES: CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1. Practolol does not affect the binding of thyrotropin to membranes from the bovine thyroid.
metoprolol,Metoprolol does not affect the binding of thyrotropin to membranes from the bovine thyroid.,Entity: metoprolol. SMILES: COCCc1ccc(OCC(O)CNC(C)C)cc1. Metoprolol does not affect the binding of thyrotropin to membranes from the bovine thyroid.
calomel,Calomel is used as a reference electrode in salt bridge configurations for pH measurements in biological preparations.,Entity: calomel. SMILES: Cl[Hg].Cl[Hg]. Calomel is used as a reference electrode in salt bridge configurations for pH measurements in biological preparations.
hydrochloric acid,Hydrochloric acid (0.1 M) is used to fill pH-sensitive microelectrodes for recording transmembrane potential differences in biological tissues.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (0.1 M) is used to fill pH-sensitive microelectrodes for recording transmembrane potential differences in biological tissues.
potassium chloride,Potassium chloride (3~KCl) is used in a salt bridge to complete the electrical circuit in microelectrode experiments measuring pH.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride (3~KCl) is used in a salt bridge to complete the electrical circuit in microelectrode experiments measuring pH.
silver,Chloride-treated silver wire is used to connect microelectrodes to an electrometer in electrochemical measurements.,Entity: silver. SMILES: [Ag]. Chloride-treated silver wire is used to connect microelectrodes to an electrometer in electrochemical measurements.
glucose,"Glucose transport across the everted rat jejunum is active, as indicated by a final serosal/mucosal glucose concentration ratio of 1.66 ± 0.23.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose transport across the everted rat jejunum is active, as indicated by a final serosal/mucosal glucose concentration ratio of 1.66 ± 0.23."
benzo[a]pyrene,Benzo[a]pyrene is hydroxylated preferentially by rat cytochrome P-448 in 3-methylcholanthrene-treated animals.,Entity: benzo[a]pyrene. SMILES: c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34. Benzo[a]pyrene is hydroxylated preferentially by rat cytochrome P-448 in 3-methylcholanthrene-treated animals.
benzphetamine,Benzphetamine is metabolized preferentially by rat cytochrome P-450 in phenobarbital-treated animals.,Entity: benzphetamine. SMILES: C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1. Benzphetamine is metabolized preferentially by rat cytochrome P-450 in phenobarbital-treated animals.
3-methylcholanthrene,"3-methylcholanthrene induces a spectrally distinct cytochrome P-448 form in rat liver microsomes, indicating it induces a different protein from cytochrome P-450 in microsomes from untreated or phenobarbital-treated rats.","Entity: 3-methylcholanthrene. SMILES: Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3. 3-methylcholanthrene induces a spectrally distinct cytochrome P-448 form in rat liver microsomes, indicating it induces a different protein from cytochrome P-450 in microsomes from untreated or phenobarbital-treated rats."
carbon monoxide,Carbon monoxide differentially affects cytochrome P-450 activity in liver microsomal fractions.,Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide differentially affects cytochrome P-450 activity in liver microsomal fractions.
phenobarbital,"Phenobarbital treatment of rats does not induce a spectrally distinct cytochrome P-448 form in liver microsomes, distinguishing it from the cytochrome P-448 induced by 3-methylcholanthrene.","Entity: phenobarbital. SMILES: CCC1(c2ccccc2)C(=O)NC(=O)NC1=O. Phenobarbital treatment of rats does not induce a spectrally distinct cytochrome P-448 form in liver microsomes, distinguishing it from the cytochrome P-448 induced by 3-methylcholanthrene."
benztropine,Benztropine is an anti-Parkinson agent that enhances the release of unlabelled dopamine in vivo.,Entity: benztropine. SMILES: CN1[C@@H]2CC[C@H]1CC(OC(c1ccccc1)c1ccccc1)C2. Benztropine is an anti-Parkinson agent that enhances the release of unlabelled dopamine in vivo.
harmaline,"Harmaline, a tremorigenic substance, at 20 mg/kg intravenously decreases the release of dopamine and 3H-labelled dopamine by about 50%.","Entity: harmaline. SMILES: COc1ccc2c3c([nH]c2c1)C(C)=NCC3. Harmaline, a tremorigenic substance, at 20 mg/kg intravenously decreases the release of dopamine and 3H-labelled dopamine by about 50%."
harmine,"Harmine, a tremorigenic substance, at 20 mg/kg intravenously decreases the release of dopamine and 3H-labelled dopamine by about 50%.","Entity: harmine. SMILES: COc1ccc2c(c1)[nH]c1c(C)nccc12. Harmine, a tremorigenic substance, at 20 mg/kg intravenously decreases the release of dopamine and 3H-labelled dopamine by about 50%."
dopamine,"Dopamine release in vivo can be enhanced by benztropine and decreased by intravenous administration of harmaline or harmine (20 mg/kg), with both harmaline and harmine reducing dopamine and 3H-labelled dopamine release by about 50%.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine release in vivo can be enhanced by benztropine and decreased by intravenous administration of harmaline or harmine (20 mg/kg), with both harmaline and harmine reducing dopamine and 3H-labelled dopamine release by about 50%."
dopamine,Direct depolarization of dopaminergic terminals with K+ (30 mM) increases dopamine release by ten times the amount of spontaneous release.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Direct depolarization of dopaminergic terminals with K+ (30 mM) increases dopamine release by ten times the amount of spontaneous release.
dopamine,"The average quantity of dopamine released in the brain is 80 pg/10 min, which is about six times greater than the quantity of labelled dopamine released in experiments with isotopically labelled compounds.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. The average quantity of dopamine released in the brain is 80 pg/10 min, which is about six times greater than the quantity of labelled dopamine released in experiments with isotopically labelled compounds."
tetrodotoxin,"Tetrodotoxin at 10 pg/ml inhibits 3H-labelled amine release by 60% in brain slices, indicating its effect on nerve-impulse-dependent neurotransmitter release.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at 10 pg/ml inhibits 3H-labelled amine release by 60% in brain slices, indicating its effect on nerve-impulse-dependent neurotransmitter release."
dopamine,"Spontaneous release of dopamine in the brain is dependent on nerve-impulse flow, as shown by the inhibition of 3H-labelled amine release by 60% with 10 pg/ml tetrodotoxin and by immediate blockage of transmitter release upon transection of the nigrostriatal pathway.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Spontaneous release of dopamine in the brain is dependent on nerve-impulse flow, as shown by the inhibition of 3H-labelled amine release by 60% with 10 pg/ml tetrodotoxin and by immediate blockage of transmitter release upon transection of the nigrostriatal pathway."
dopamine,"After administration of approximately 400 pCi/lOmin of 3H-labelled tyrosine into the brain superfusate, the quantity of 3H-labelled dopamine in 10-minute fractions reaches about 2 nCi (12 pg) after approximately 90 minutes, representing a steady state.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. After administration of approximately 400 pCi/lOmin of 3H-labelled tyrosine into the brain superfusate, the quantity of 3H-labelled dopamine in 10-minute fractions reaches about 2 nCi (12 pg) after approximately 90 minutes, representing a steady state."
tyrosine,"3H-labelled tyrosine can be introduced into the brain superfusate at a rate of 400 pCi/lOmin, and its metabolism to 3H-labelled dopamine in the brain is measurable within minutes, reaching steady state after about 90 minutes.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. 3H-labelled tyrosine can be introduced into the brain superfusate at a rate of 400 pCi/lOmin, and its metabolism to 3H-labelled dopamine in the brain is measurable within minutes, reaching steady state after about 90 minutes."
dopamine,Dopamine can be spontaneously released from brain tissue for up to 6–8 hours when measured in the 'enckphale isolc' preparation in cats or anesthetized animals.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine can be spontaneously released from brain tissue for up to 6–8 hours when measured in the 'enckphale isolc' preparation in cats or anesthetized animals.
thioproperazine,"The neuroleptic effect of thioproperazine on dopamine release and 3H2O formation depends on the presence of the nigrostriatal pathway, as these effects are lost after transection of the pathway.","Entity: thioproperazine. SMILES: CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1. The neuroleptic effect of thioproperazine on dopamine release and 3H2O formation depends on the presence of the nigrostriatal pathway, as these effects are lost after transection of the pathway."
amphetamine,"Both L- and D-amphetamine (111 mg/kg or 2 mg/kg, intravenous) stimulate the release of dopamine, an effect that can be prevented by prior injection of a-methylparatyrosine (100 mg/kg, intravenous).","Entity: amphetamine. SMILES: CC(N)Cc1ccccc1. Both L- and D-amphetamine (111 mg/kg or 2 mg/kg, intravenous) stimulate the release of dopamine, an effect that can be prevented by prior injection of a-methylparatyrosine (100 mg/kg, intravenous)."
tranylcypromine,"Tranylcypromine increases the release of dopamine and accelerates its synthesis, potentially by acting on the dopamine release process similarly to amphetamine.","Entity: tranylcypromine. SMILES: N[C@@H]1C[C@H]1c1ccccc1. Tranylcypromine increases the release of dopamine and accelerates its synthesis, potentially by acting on the dopamine release process similarly to amphetamine."
pheniprazine,"Pheniprazine increases the release of dopamine and accelerates its synthesis, likely by acting on the dopamine release process in a manner similar to amphetamine.","Entity: pheniprazine. SMILES: CC(Cc1ccccc1)NN. Pheniprazine increases the release of dopamine and accelerates its synthesis, likely by acting on the dopamine release process in a manner similar to amphetamine."
benztropine,"Benztropine, by blocking the re-uptake process, induces a progressive and marked increase in the quantity of 3H-labelled dopamine in superfusates.","Entity: benztropine. SMILES: CN1[C@@H]2CC[C@H]1CC(OC(c1ccccc1)c1ccccc1)C2. Benztropine, by blocking the re-uptake process, induces a progressive and marked increase in the quantity of 3H-labelled dopamine in superfusates."
dopamine,"Dopamine release can be stimulated by amphetamine and inhibited by a-methylparatyrosine, and its synthesis can be increased by tranylcypromine and pheniprazine.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine release can be stimulated by amphetamine and inhibited by a-methylparatyrosine, and its synthesis can be increased by tranylcypromine and pheniprazine."
dopamine,The amount of 3H-labelled dopamine in superfusates increases following blockade of dopamine re-uptake by benztropine.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. The amount of 3H-labelled dopamine in superfusates increases following blockade of dopamine re-uptake by benztropine.
thioproperazine,"Thioproperazine, a potent neuroleptic of the phenothiazine type, induces marked activation of 3H2O formation and 3H-labelled dopamine release when injected at 10 mg/kg intravenously.","Entity: thioproperazine. SMILES: CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1. Thioproperazine, a potent neuroleptic of the phenothiazine type, induces marked activation of 3H2O formation and 3H-labelled dopamine release when injected at 10 mg/kg intravenously."
"3,4-dihydroxyphenethylamine","3,4-dihydroxyphenethylamine (dopamine) is synthesized in dopaminergic nerve endings of the nigrostriatal pathway and can be continuously released and measured in the cat caudate nucleus using a superfusion technique.","Entity: 3,4-dihydroxyphenethylamine. SMILES: NCCc1ccc(O)c(O)c1. 3,4-dihydroxyphenethylamine (dopamine) is synthesized in dopaminergic nerve endings of the nigrostriatal pathway and can be continuously released and measured in the cat caudate nucleus using a superfusion technique."
"3,4-dihydroxyphenethylamine","The rate of release of 3,4-dihydroxyphenethylamine from dopaminergic terminals in the cat caudate nucleus can be continuously monitored by measuring its concentration in superfusates.","Entity: 3,4-dihydroxyphenethylamine. SMILES: NCCc1ccc(O)c(O)c1. The rate of release of 3,4-dihydroxyphenethylamine from dopaminergic terminals in the cat caudate nucleus can be continuously monitored by measuring its concentration in superfusates."
"3,4-dihydroxyphenethylamine","In the cat caudate nucleus, 3,4-dihydroxyphenethylamine is synthesized from tyrosine via hydroxylation, with one molecule of water produced for each molecule of 3,4-dihydroxyphenethylamine synthesized.","Entity: 3,4-dihydroxyphenethylamine. SMILES: NCCc1ccc(O)c(O)c1. In the cat caudate nucleus, 3,4-dihydroxyphenethylamine is synthesized from tyrosine via hydroxylation, with one molecule of water produced for each molecule of 3,4-dihydroxyphenethylamine synthesized."
"3,4-dihydroxyphenethylamine","Inhibition of 3,4-dihydroxyphenethylamine synthesis with a-methylparatyrosine or degeneration of the nigrostriatal pathway by 6-hydroxydopamine abolishes the formation of 3H2O in the cat caudate nucleus.","Entity: 3,4-dihydroxyphenethylamine. SMILES: NCCc1ccc(O)c(O)c1. Inhibition of 3,4-dihydroxyphenethylamine synthesis with a-methylparatyrosine or degeneration of the nigrostriatal pathway by 6-hydroxydopamine abolishes the formation of 3H2O in the cat caudate nucleus."
"3,4-dihydroxyphenethylamine","The formation of 3H2O in the cat caudate nucleus serves as a specific index of the rate of tyrosine hydroxylation to 3,4-dihydroxyphenethylamine.","Entity: 3,4-dihydroxyphenethylamine. SMILES: NCCc1ccc(O)c(O)c1. The formation of 3H2O in the cat caudate nucleus serves as a specific index of the rate of tyrosine hydroxylation to 3,4-dihydroxyphenethylamine."
"3,4-dihydroxyphenylalanine","3,4-dihydroxyphenethylamine is synthesized from tyrosine via hydroxylation to form 3,4-dihydroxyphenethylamine, with one molecule of water produced for each molecule of 3,4-dihydroxyphenethylamine synthesized.","Entity: 3,4-dihydroxyphenylalanine. SMILES: N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O. 3,4-dihydroxyphenethylamine is synthesized from tyrosine via hydroxylation to form 3,4-dihydroxyphenethylamine, with one molecule of water produced for each molecule of 3,4-dihydroxyphenethylamine synthesized."
tyrosine,"Tyrosine is continuously introduced into the cat caudate nucleus via a cup, serving as a substrate for dopaminergic synthesis, and its conversion to 3,4-dihydroxyphenethylamine is monitored by measuring 3H2O in superfusates.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine is continuously introduced into the cat caudate nucleus via a cup, serving as a substrate for dopaminergic synthesis, and its conversion to 3,4-dihydroxyphenethylamine is monitored by measuring 3H2O in superfusates."
water,"Large amounts of labeled water diffuse into superfusates during the synthesis of 3,4-dihydroxyphenethylamine from tyrosine in the cat caudate nucleus, with one molecule of water produced for each molecule of 3,4-dihydroxyphenethylamine synthesized.","Entity: water. SMILES: O. Large amounts of labeled water diffuse into superfusates during the synthesis of 3,4-dihydroxyphenethylamine from tyrosine in the cat caudate nucleus, with one molecule of water produced for each molecule of 3,4-dihydroxyphenethylamine synthesized."
glycine,"In culture, Trypanosoma brucei S42 excretes glycine in equimolar concentrations relative to L-threonine metabolism.","Entity: glycine. SMILES: NCC(=O)O. In culture, Trypanosoma brucei S42 excretes glycine in equimolar concentrations relative to L-threonine metabolism."
acetate,"In culture, Trypanosoma brucei S42 excretes acetate, which is characterized as the p-bromophenacyl derivative.","Entity: acetate. SMILES: CC(=O)[O-]. In culture, Trypanosoma brucei S42 excretes acetate, which is characterized as the p-bromophenacyl derivative."
L-threonine,"L-threonine is metabolized in culture by Trypanosoma brucei S42, with equimolar concentrations of glycine and acetate being excreted.","Entity: L-threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. L-threonine is metabolized in culture by Trypanosoma brucei S42, with equimolar concentrations of glycine and acetate being excreted."
tetraethylthiuram disulphide,"Tetraethylthiuram disulphide inhibits L-threonine dehydrogenase (EC 1.1.1.103), leading to decreased production of acetate and glycine from L-threonine and trypanocidal activity.","Entity: tetraethylthiuram disulphide. SMILES: CCN(CC)C(=S)SSC(=S)N(CC)CC. Tetraethylthiuram disulphide inhibits L-threonine dehydrogenase (EC 1.1.1.103), leading to decreased production of acetate and glycine from L-threonine and trypanocidal activity."
L-threonine,"L-threonine is incorporated into lipid by Trypanosoma brucei, and this process is inhibited by inhibition of L-threonine dehydrogenase.","Entity: L-threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. L-threonine is incorporated into lipid by Trypanosoma brucei, and this process is inhibited by inhibition of L-threonine dehydrogenase."
L-threonine,Inhibition of L-threonine dehydrogenase with tetraethylthiuram disulphide markedly inhibits the incorporation of radioactive carbon from L-threonine into lipid.,Entity: L-threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. Inhibition of L-threonine dehydrogenase with tetraethylthiuram disulphide markedly inhibits the incorporation of radioactive carbon from L-threonine into lipid.
acetate,Acetate production from L-threonine in Trypanosoma brucei is decreased by inhibition of L-threonine dehydrogenase with tetraethylthiuram disulphide.,Entity: acetate. SMILES: CC(=O)[O-]. Acetate production from L-threonine in Trypanosoma brucei is decreased by inhibition of L-threonine dehydrogenase with tetraethylthiuram disulphide.
glycine,Glycine production from L-threonine in Trypanosoma brucei is decreased by inhibition of L-threonine dehydrogenase with tetraethylthiuram disulphide.,Entity: glycine. SMILES: NCC(=O)O. Glycine production from L-threonine in Trypanosoma brucei is decreased by inhibition of L-threonine dehydrogenase with tetraethylthiuram disulphide.
L-threonine,"L-threonine is incorporated into lipids by Trypanosoma brucei, with the pattern of incorporation remaining consistent throughout the growth cycle regardless of whether acetate is added or not.","Entity: L-threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. L-threonine is incorporated into lipids by Trypanosoma brucei, with the pattern of incorporation remaining consistent throughout the growth cycle regardless of whether acetate is added or not."
acetate,"Acetate can be incorporated into lipids by Trypanosoma brucei, and the pattern of acetate incorporation into lipids is indistinguishable from that of L-threonine incorporation throughout the growth cycle.","Entity: acetate. SMILES: CC(=O)[O-]. Acetate can be incorporated into lipids by Trypanosoma brucei, and the pattern of acetate incorporation into lipids is indistinguishable from that of L-threonine incorporation throughout the growth cycle."
L-threonine,"L-threonine serves as a carbon source for lipid synthesis in Trypanosoma brucei, contributing 3–7 carbon atoms to the palmitate (C16:) chain and 6–11 carbon atoms to the stearate (C18:) chain.","Entity: L-threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. L-threonine serves as a carbon source for lipid synthesis in Trypanosoma brucei, contributing 3–7 carbon atoms to the palmitate (C16:) chain and 6–11 carbon atoms to the stearate (C18:) chain."
acetate,"Acetate provides carbon atoms for lipid synthesis in Trypanosoma brucei, contributing between 1 and 1.5 carbon atoms to the palmitate (C16:) chain and 2.5 and 7 carbon atoms to the stearate (C18:) chain.","Entity: acetate. SMILES: CC(=O)[O-]. Acetate provides carbon atoms for lipid synthesis in Trypanosoma brucei, contributing between 1 and 1.5 carbon atoms to the palmitate (C16:) chain and 2.5 and 7 carbon atoms to the stearate (C18:) chain."
palmitate,Palmitate (C16:) is a saturated fatty acid whose chain can be elongated by L-threonine (3–7 carbons) or acetate (1–1.5 carbons) during lipid synthesis in Trypanosoma brucei.,Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Palmitate (C16:) is a saturated fatty acid whose chain can be elongated by L-threonine (3–7 carbons) or acetate (1–1.5 carbons) during lipid synthesis in Trypanosoma brucei.
stearate,Stearate (C18:) is a saturated fatty acid whose chain can be elongated by L-threonine (6–11 carbons) or acetate (2.5–7 carbons) during lipid synthesis in Trypanosoma brucei.,Entity: stearate. SMILES: CCCCCCCCCCCCCCCCCC(=O)[O-]. Stearate (C18:) is a saturated fatty acid whose chain can be elongated by L-threonine (6–11 carbons) or acetate (2.5–7 carbons) during lipid synthesis in Trypanosoma brucei.
L-threonine,L-threonine is metabolized by T. brucei via a pathway involving the NAD+-dependent enzyme L-threonine dehydrogenase (EC 1.1.1.103) to produce acetate and aminoacetone.,Entity: L-threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. L-threonine is metabolized by T. brucei via a pathway involving the NAD+-dependent enzyme L-threonine dehydrogenase (EC 1.1.1.103) to produce acetate and aminoacetone.
aminoacetone,"Aminoacetone is produced enzymically from L-threonine in T. brucei homogenates, representing an intermediate in the L-threonine degradation pathway.","Entity: aminoacetone. SMILES: NNC(N)=O. Aminoacetone is produced enzymically from L-threonine in T. brucei homogenates, representing an intermediate in the L-threonine degradation pathway."
acetate,Acetate produced from radioactively labelled L-threonine serves as a preferred source of lipid carbon even in the presence of exogenous acetate and a tenfold molar excess of glucose.,Entity: acetate. SMILES: CC(=O)[O-]. Acetate produced from radioactively labelled L-threonine serves as a preferred source of lipid carbon even in the presence of exogenous acetate and a tenfold molar excess of glucose.
phosphate,"In muscle tissue, the n.m.r. signal for phosphate is multicomponent and its shape depends on the pH of the buffer, with a linewidth of approximately 60 Hz in dialysed muscle.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. In muscle tissue, the n.m.r. signal for phosphate is multicomponent and its shape depends on the pH of the buffer, with a linewidth of approximately 60 Hz in dialysed muscle."
phosphate,"The phosphate resonance frequency in muscle shifts to lower frequency as the red muscle ages, primarily due to lactic acid accumulation.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. The phosphate resonance frequency in muscle shifts to lower frequency as the red muscle ages, primarily due to lactic acid accumulation."
lactic acid,Lactic acid accumulation in red muscle causes a slight shift of the phosphate resonance frequency to lower frequencies.,Entity: lactic acid. SMILES: CC(O)C(=O)O. Lactic acid accumulation in red muscle causes a slight shift of the phosphate resonance frequency to lower frequencies.
creatine phosphate,"Creatine phosphate accumulates in white muscles to provide energy during short bursts of activity, such as during escape from a predator.","Entity: creatine phosphate. SMILES: CN(CC(=O)O)C(=N)N.O=P(O)(O)O. Creatine phosphate accumulates in white muscles to provide energy during short bursts of activity, such as during escape from a predator."
creatine phosphate,The initial creatine phosphate concentration is lower in red muscle compared to white muscle.,Entity: creatine phosphate. SMILES: CN(CC(=O)O)C(=N)N.O=P(O)(O)O. The initial creatine phosphate concentration is lower in red muscle compared to white muscle.
phosphate,"Phosphate in muscle exhibits a broad resonance due to its distribution among many environments with slightly different frequencies, as indicated by a transverse relaxation time (T2) of approximately 10–100 ms and a linewidth of 3–200 Hz depending on post-excision time.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate in muscle exhibits a broad resonance due to its distribution among many environments with slightly different frequencies, as indicated by a transverse relaxation time (T2) of approximately 10–100 ms and a linewidth of 3–200 Hz depending on post-excision time."
phosphate,"The resonance position of phosphate is highly sensitive to pH, and a distribution of pH values within muscle can account for the observed multicomponent phosphate line shape.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. The resonance position of phosphate is highly sensitive to pH, and a distribution of pH values within muscle can account for the observed multicomponent phosphate line shape."
creatine phosphate,"Creatine phosphate has a pK of 4.6, making its resonance position in NMR largely unaffected by small variations in pH around neutrality.","Entity: creatine phosphate. SMILES: CN(CC(=O)O)C(=N)N.O=P(O)(O)O. Creatine phosphate has a pK of 4.6, making its resonance position in NMR largely unaffected by small variations in pH around neutrality."
creatine phosphate,"The linewidth of the creatine phosphate signal in phosphorus NMR spectra of rabbit intact white muscle remains time-independent, unlike the broadening observed in the phosphate signal.","Entity: creatine phosphate. SMILES: CN(CC(=O)O)C(=N)N.O=P(O)(O)O. The linewidth of the creatine phosphate signal in phosphorus NMR spectra of rabbit intact white muscle remains time-independent, unlike the broadening observed in the phosphate signal."
lactic acid,"Lactic acid accumulation after muscle excision causes acidification of the sarcoplasm, leading to a shift of phosphorus NMR signals to lower frequency.","Entity: lactic acid. SMILES: CC(O)C(=O)O. Lactic acid accumulation after muscle excision causes acidification of the sarcoplasm, leading to a shift of phosphorus NMR signals to lower frequency."
phosphorus,"Phosphorus NMR spectroscopy is used to study changes in phosphate and creatine phosphate pools in rabbit intact white muscle following excision, with the phosphate signal broadening and shifting to lower frequency over time due to acidification.","Entity: phosphorus. SMILES: [P]. Phosphorus NMR spectroscopy is used to study changes in phosphate and creatine phosphate pools in rabbit intact white muscle following excision, with the phosphate signal broadening and shifting to lower frequency over time due to acidification."
succinate,Succinate is used as a substrate in mitochondrial respiration assays to assess respiratory control ratios (state 3/state 4) in rabbit hind-leg red semitendinosus muscle mitochondria.,Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate is used as a substrate in mitochondrial respiration assays to assess respiratory control ratios (state 3/state 4) in rabbit hind-leg red semitendinosus muscle mitochondria.
sucrose,Sucrose at a concentration of 25 mOsm/l is used as a maintenance medium for rabbit hind-leg red semitendinosus muscle mitochondria in respiration assays.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose at a concentration of 25 mOsm/l is used as a maintenance medium for rabbit hind-leg red semitendinosus muscle mitochondria in respiration assays.
succinate,"In rabbit hind-leg red semitendinosus muscle mitochondria, the P/O ratio declines with storage (48–72 h) at 4°C when succinate is used as substrate, indicating an age-related decrease in mitochondrial respiratory efficiency.","Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. In rabbit hind-leg red semitendinosus muscle mitochondria, the P/O ratio declines with storage (48–72 h) at 4°C when succinate is used as substrate, indicating an age-related decrease in mitochondrial respiratory efficiency."
malate,"In rabbit heart and skeletal muscle mitochondria, the P/O ratio remains unchanged with age when malate is used as substrate.","Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. In rabbit heart and skeletal muscle mitochondria, the P/O ratio remains unchanged with age when malate is used as substrate."
succinate,Succinate is added at a concentration of 2 mM to the assay medium to serve as a substrate for mitochondrial respiration in the respiratory control ratio assay.,Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate is added at a concentration of 2 mM to the assay medium to serve as a substrate for mitochondrial respiration in the respiratory control ratio assay.
sucrose,Sucrose is used to achieve a final concentration of 250 mM in the assay medium to induce hypo-osmotic conditions for mitochondrial respiration assays.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used to achieve a final concentration of 250 mM in the assay medium to induce hypo-osmotic conditions for mitochondrial respiration assays.
MgCl2,MgCl2 is used as a component (0.5 mmol) in the assay medium for mitochondrial respiration assays at pH 7.6.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used as a component (0.5 mmol) in the assay medium for mitochondrial respiration assays at pH 7.6.
rotenone,Rotenone is included at a specific volume (10µL) in the assay medium to inhibit mitochondrial respiration in the measurement of the respiratory control ratio.,Entity: rotenone. SMILES: C=C(C)[C@H]1Cc2c(ccc3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1. Rotenone is included at a specific volume (10µL) in the assay medium to inhibit mitochondrial respiration in the measurement of the respiratory control ratio.
KH2PO4,KH2PO4 is used at a volume of 10µL in the assay medium at pH 7.6 for mitochondrial respiration assays.,Entity: KH2PO4. SMILES: O=P(O)(O)O. KH2PO4 is used at a volume of 10µL in the assay medium at pH 7.6 for mitochondrial respiration assays.
ADP,ADP is added at a concentration of 6 µM to the assay medium to initiate mitochondrial respiration in the respiratory control ratio assay.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP is added at a concentration of 6 µM to the assay medium to initiate mitochondrial respiration in the respiratory control ratio assay.
Hepes,Hepes is used as a buffer at 5 mM concentration and pH 7.6 in the isolation of liver mitochondria.,Entity: Hepes. SMILES: O=S(=O)(O)CCN1CCN(CCO)CC1. Hepes is used as a buffer at 5 mM concentration and pH 7.6 in the isolation of liver mitochondria.
sucrose,Sucrose at 250 mM concentration is used as a component of the isolation medium for liver mitochondria.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose at 250 mM concentration is used as a component of the isolation medium for liver mitochondria.
Triton X-100,Triton X-100 is used to clarify mitochondrial suspensions prior to protein concentration measurement by the biuret method.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used to clarify mitochondrial suspensions prior to protein concentration measurement by the biuret method.
folic acid,"Folic acid is a high-molecular-weight folate that is distributed in rat liver and can be detected as a large radioactive peak eluting from Sephadex G-15 and DEAE-cellulose chromatography columns after gel filtration and ion exchange, respectively.","Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid is a high-molecular-weight folate that is distributed in rat liver and can be detected as a large radioactive peak eluting from Sephadex G-15 and DEAE-cellulose chromatography columns after gel filtration and ion exchange, respectively."
5-methyltetrahydrofolate,5-methyltetrahydrofolate is the first folate monoglutamate to elute from a Sephadex G-15 gel-filtration chromatography column.,Entity: 5-methyltetrahydrofolate. SMILES: CN1C(CNc2ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc2)CNC2=NC(N)=NC(=O)C21O. 5-methyltetrahydrofolate is the first folate monoglutamate to elute from a Sephadex G-15 gel-filtration chromatography column.
sodium chloride,Sodium chloride is used as a 0–1.0 M gradient in phosphate buffer (pH 7.0) to elute radioactive material from DEAE-cellulose chromatography columns.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used as a 0–1.0 M gradient in phosphate buffer (pH 7.0) to elute radioactive material from DEAE-cellulose chromatography columns.
folate,"Folate exists in liver extracts as polyglutamated forms, which are rapidly hydrolyzed by the lysozyme conjugate enzyme to produce monoglutamates.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate exists in liver extracts as polyglutamated forms, which are rapidly hydrolyzed by the lysozyme conjugate enzyme to produce monoglutamates."
folic acid,"Folic acid can be administered orally to rats, and high-molecular-weight folates are detected in rat liver extracts after such administration.","Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid can be administered orally to rats, and high-molecular-weight folates are detected in rat liver extracts after such administration."
methyltetrahydrofolate,"[5-1*C]methyltetrahydrofolate does not form polyglutamates in lymphocytes, as shown by the absence of peaks at high ionic strength on DEAE-cellulose chromatography.","Entity: methyltetrahydrofolate. SMILES: COC(=O)CC[C@H](NC(=O)c1ccc(NCC2CNc3nc(N)[nH]c(=O)c3N2)cc1)C(=O)O. [5-1*C]methyltetrahydrofolate does not form polyglutamates in lymphocytes, as shown by the absence of peaks at high ionic strength on DEAE-cellulose chromatography."
5-methyltetrahydrofolate,"5-methyltetrahydrofolate is a folate derivative that carries a net charge similar to the high-molecular-weight folate detected in rats, which does not correspond to polyglutamate form.","Entity: 5-methyltetrahydrofolate. SMILES: CN1c2c(nc(N)[nH]c2=O)NCC1CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1. 5-methyltetrahydrofolate is a folate derivative that carries a net charge similar to the high-molecular-weight folate detected in rats, which does not correspond to polyglutamate form."
folic acid,"Folic acid can form high-molecular-weight species in biological systems, and the 'peaks at high tube number' observed in its metabolism may be artifacts due to the use of highly specific radio-labeled folic acid.","Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid can form high-molecular-weight species in biological systems, and the 'peaks at high tube number' observed in its metabolism may be artifacts due to the use of highly specific radio-labeled folic acid."
folate monoglutamate,"Folate monoglutamate is used as a marker compound for distinguishing folate polyglutamates by its elution behavior on anion-exchange columns, where it elutes at lower ionic strength compared to folate polyglutamates.","Entity: folate monoglutamate. SMILES: N[C@@H](CCC(=O)O)C(=O)O.Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folate monoglutamate is used as a marker compound for distinguishing folate polyglutamates by its elution behavior on anion-exchange columns, where it elutes at lower ionic strength compared to folate polyglutamates."
4a-hydroxy-5-methyltetrahydrofolic acid,4a-hydroxy-5-methyltetrahydrofolic acid is a high-molecular-weight folate that can be resolved from other folate forms by chromatography on Sephadex G-15 columns.,Entity: 4a-hydroxy-5-methyltetrahydrofolic acid. SMILES: CN1C(CNc2ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc2)CNC2=NC(N)=NC(=O)C21O. 4a-hydroxy-5-methyltetrahydrofolic acid is a high-molecular-weight folate that can be resolved from other folate forms by chromatography on Sephadex G-15 columns.
sodium chloride,"Elution of DEAEcellulose columns with NaCl gradients up to 3M does not produce peaks for high-molecular-weight folates, indicating that high ionic strength does not resolve these compounds.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. Elution of DEAEcellulose columns with NaCl gradients up to 3M does not produce peaks for high-molecular-weight folates, indicating that high ionic strength does not resolve these compounds."
folic acid,Folic acid is a major high-molecular-weight folate that can be co-chromatographed with 5-methyltetrahydrofolic acid and an unidentified high-molecular-weight folate peak in rat liver preparations.,Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid is a major high-molecular-weight folate that can be co-chromatographed with 5-methyltetrahydrofolic acid and an unidentified high-molecular-weight folate peak in rat liver preparations.
5-methyltetrahydrofolic acid,5-methyltetrahydrofolic acid is a major high-molecular-weight folate that can be co-chromatographed with folic acid and an unidentified high-molecular-weight folate peak in rat liver preparations.,Entity: 5-methyltetrahydrofolic acid. SMILES: CN1c2c(nc(N)[nH]c2=O)NCC1CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. 5-methyltetrahydrofolic acid is a major high-molecular-weight folate that can be co-chromatographed with folic acid and an unidentified high-molecular-weight folate peak in rat liver preparations.
folate,"Polyglutamate forms of folate are claimed to be present in animal tissues, including rat liver, based on chromatographic and microbiological assays.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Polyglutamate forms of folate are claimed to be present in animal tissues, including rat liver, based on chromatographic and microbiological assays."
p-chlorophenylalanine,"Sustained treatment with p-chlorophenylalanine and phenylalanine for several days decreases the ability of weanling rats to cope with a phenylalanine load, leading to hyperphenylalaninaemia lasting for several hours after a phenylalanine challenge.","Entity: p-chlorophenylalanine. SMILES: N[C@@H](Cc1ccc(Cl)cc1)C(=O)O. Sustained treatment with p-chlorophenylalanine and phenylalanine for several days decreases the ability of weanling rats to cope with a phenylalanine load, leading to hyperphenylalaninaemia lasting for several hours after a phenylalanine challenge."
phenylalanine,A phenylalanine load in weanling rats pretreated with p-chlorophenylalanine and phenylalanine for several days induces hyperphenylalaninaemia lasting for several hours.,Entity: phenylalanine. SMILES: N[C@@H](Cc1ccccc1)C(=O)O. A phenylalanine load in weanling rats pretreated with p-chlorophenylalanine and phenylalanine for several days induces hyperphenylalaninaemia lasting for several hours.
tyrosine,"Plasma tyrosine concentration remains low during hyperphenylalaninaemia in weanling rats pretreated with p-chlorophenylalanine and phenylalanine, resulting in a plasma phenylalaninelyrosine ratio similar to that found in phenylketonuria.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Plasma tyrosine concentration remains low during hyperphenylalaninaemia in weanling rats pretreated with p-chlorophenylalanine and phenylalanine, resulting in a plasma phenylalaninelyrosine ratio similar to that found in phenylketonuria."
bilirubin,Bilirubin can be isolated from rat bile using the method described by Ostrow et al. (1961).,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin can be isolated from rat bile using the method described by Ostrow et al. (1961).
oxygen,"Oxygen enrichment in the atmosphere of living rats can be increased to a constant value and maintained for 2–3 hours, allowing for in vivo metabolic labeling experiments.","Entity: oxygen. SMILES: [O]. Oxygen enrichment in the atmosphere of living rats can be increased to a constant value and maintained for 2–3 hours, allowing for in vivo metabolic labeling experiments."
carbon monoxide,The loss of the α-methene carbon atom as carbon monoxide is a common factor in haem degradation both in vivo and in vitro.,Entity: carbon monoxide. SMILES: [C]=O. The loss of the α-methene carbon atom as carbon monoxide is a common factor in haem degradation both in vivo and in vitro.
bilirubin,"Bilirubin is produced from myoglobin degradation with complete alpha-specificity, yielding a maximum yield of bilirubin.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin is produced from myoglobin degradation with complete alpha-specificity, yielding a maximum yield of bilirubin."
biliverdin,Biliverdin can influence endogenous haem catabolism in vivo.,Entity: biliverdin. SMILES: C=CC1=C(C)C(/C=c2\[nH]/c(=C\c3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)=NC1=O. Biliverdin can influence endogenous haem catabolism in vivo.
carbon monoxide,"In the described system, carbon monoxide produced contains a label from l8O, as indicated by a significant mass spectrometry peak at m/e 30, which is about 10 times higher than predicted stoichiometrically.","Entity: carbon monoxide. SMILES: [C]=O. In the described system, carbon monoxide produced contains a label from l8O, as indicated by a significant mass spectrometry peak at m/e 30, which is about 10 times higher than predicted stoichiometrically."
oxygen,Both terminal oxygen atoms in the described system are derived from molecular oxygen (O2).,Entity: oxygen. SMILES: [O]. Both terminal oxygen atoms in the described system are derived from molecular oxygen (O2).
bilirubin,"The mass spectrum of bilirubin shows a strong molecular ion at m/e 584, with residual peaks at m/e 586 and m/e 588 corresponding to incorporation of one or two oxygen atoms, respectively, after accounting for natural abundances of 13C, 2H, and nitrogen.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. The mass spectrum of bilirubin shows a strong molecular ion at m/e 584, with residual peaks at m/e 586 and m/e 588 corresponding to incorporation of one or two oxygen atoms, respectively, after accounting for natural abundances of 13C, 2H, and nitrogen."
oxygen,"Molecular oxygen (O2) can participate in four different reaction types (A, B, C, and D) with haem oxygenase, leading to the incorporation of one or two oxygen atoms into bilirubin, as distinguished by 180-labeling and mass spectrometry.","Entity: oxygen. SMILES: [O]. Molecular oxygen (O2) can participate in four different reaction types (A, B, C, and D) with haem oxygenase, leading to the incorporation of one or two oxygen atoms into bilirubin, as distinguished by 180-labeling and mass spectrometry."
water,"In the formation of verdohaem as an intermediate, oxygen atoms can be incorporated from both molecular oxygen and water, consistent with Type B reaction schemes in haem oxygenase.","Entity: water. SMILES: O. In the formation of verdohaem as an intermediate, oxygen atoms can be incorporated from both molecular oxygen and water, consistent with Type B reaction schemes in haem oxygenase."
Biliverdin,"Biliverdin is produced as a product from coupled oxidations involving ascorbate, myoglobin, haemoglobin, or pyridine haemochrome as the haem source.","Entity: Biliverdin. SMILES: C=CC1=C(C)C(C=c2[nH]c(=Cc3[nH]c(C=C4NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)OC)c(CCC(=O)OC)c2C)=NC1=O. Biliverdin is produced as a product from coupled oxidations involving ascorbate, myoglobin, haemoglobin, or pyridine haemochrome as the haem source."
Biliverdin,Biliverdin is not converted to bilirubin in these systems because they lack biliverdin reductase.,Entity: Biliverdin. SMILES: C=CC1=C(C)C(C=c2[nH]c(=Cc3[nH]c(C=C4NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)OC)c(CCC(=O)OC)c2C)=NC1=O. Biliverdin is not converted to bilirubin in these systems because they lack biliverdin reductase.
Bilirubin,"Bilirubin is not produced from coupled oxidations with ascorbate, myoglobin, haemoglobin, or pyridine haemochrome due to the absence of biliverdin reductase.","Entity: Bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin is not produced from coupled oxidations with ascorbate, myoglobin, haemoglobin, or pyridine haemochrome due to the absence of biliverdin reductase."
Ascorbate,"Ascorbate serves as a substrate in coupled oxidation reactions with myoglobin, haemoglobin, or pyridine haemochrome to generate biliverdin as a product.","Entity: Ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O. Ascorbate serves as a substrate in coupled oxidation reactions with myoglobin, haemoglobin, or pyridine haemochrome to generate biliverdin as a product."
bilirubin,"Bilirubin is the final product of haem degradation in biological systems, with biliverdin as an intermediate formed during the process.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin is the final product of haem degradation in biological systems, with biliverdin as an intermediate formed during the process."
biliverdin,"Biliverdin is an intermediate formed during haem degradation, and in biological systems, biliverdin reductase ensures its further conversion to bilirubin.","Entity: biliverdin. SMILES: C=CC1=C(C)C(/C=c2\[nH]/c(=C\c3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)=NC1=O. Biliverdin is an intermediate formed during haem degradation, and in biological systems, biliverdin reductase ensures its further conversion to bilirubin."
oxygen,"In the spleen microsomal system, both terminal oxygen atoms in bilirubin are derived from molecular oxygen (O2).","Entity: oxygen. SMILES: [O]. In the spleen microsomal system, both terminal oxygen atoms in bilirubin are derived from molecular oxygen (O2)."
carbon monoxide,"During the degradation of oxyhaem to biliverdin, the α-methene carbon atom bridge is eliminated as carbon monoxide.","Entity: carbon monoxide. SMILES: [C]=O. During the degradation of oxyhaem to biliverdin, the α-methene carbon atom bridge is eliminated as carbon monoxide."
bilirubin,"In the spleen microsomal system, both terminal oxygen atoms in bilirubin are derived from molecular oxygen (O2).","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. In the spleen microsomal system, both terminal oxygen atoms in bilirubin are derived from molecular oxygen (O2)."
biliverdin,"The formation of biliverdin from oxyhaem involves the loss of iron, elimination of the α-methene carbon atom bridge as carbon monoxide, and incorporation of two oxygen atoms into the terminal carbonyl groups of the bile pigment.","Entity: biliverdin. SMILES: C=CC1=C(C)C(/C=c2\[nH]/c(=C\c3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)=NC1=O. The formation of biliverdin from oxyhaem involves the loss of iron, elimination of the α-methene carbon atom bridge as carbon monoxide, and incorporation of two oxygen atoms into the terminal carbonyl groups of the bile pigment."
2-allyl-2-isopropylacetamide,"2-allyl-2-isopropylacetamide promotes the degradation of haem, the formation of 'green pigments', and increases the excretion of high levels of porphyrins.","Entity: 2-allyl-2-isopropylacetamide. SMILES: C=CCC(C(N)=O)C(C)C. 2-allyl-2-isopropylacetamide promotes the degradation of haem, the formation of 'green pigments', and increases the excretion of high levels of porphyrins."
bilirubin,Bilirubin binds to protein A.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin binds to protein A.
carbon monoxide,"Carbon monoxide is produced as a product of haem catabolism, which is stimulated by haem oxygenase.","Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide is produced as a product of haem catabolism, which is stimulated by haem oxygenase."
biliverdin,"Biliverdin exists as four isomers, and their distribution in a reaction mixture is essentially random when free haem or simple haemochromes are oxidized under coupled conditions.","Entity: biliverdin. SMILES: C=CC1=C(C)C(/C=c2\[nH]/c(=C\c3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)=NC1=O. Biliverdin exists as four isomers, and their distribution in a reaction mixture is essentially random when free haem or simple haemochromes are oxidized under coupled conditions."
NADPH,"NADPH serves as the electron donor for cytochrome P-450, supplying reducing equivalents to support its function in microsomal haemoprotein systems.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH serves as the electron donor for cytochrome P-450, supplying reducing equivalents to support its function in microsomal haemoprotein systems."
biliverdin,Biliverdin is formed by oxidative ring-opening of haem at the α-position during normal metabolism.,Entity: biliverdin. SMILES: C=CC1=C(C)C(/C=c2\[nH]/c(=C\c3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)=NC1=O. Biliverdin is formed by oxidative ring-opening of haem at the α-position during normal metabolism.
bilirubin,"Bilirubin is produced immediately after biliverdin in the metabolic pathway, following reduction of biliverdin.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin is produced immediately after biliverdin in the metabolic pathway, following reduction of biliverdin."
stercobilinogen,Stercobilinogen is the end product of bilirubin's further hydrogenation by bacterial organisms during excretion.,Entity: stercobilinogen. SMILES: CC[C@H]1[C@H](Cc2[nH]c(Cc3[nH]c(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC(=O)[C@@H]1C. Stercobilinogen is the end product of bilirubin's further hydrogenation by bacterial organisms during excretion.
NADPH,NADPH serves as the reducing equivalent for the micro-soma1 haemoprotein in the haem cleavage process.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH serves as the reducing equivalent for the micro-soma1 haemoprotein in the haem cleavage process.
ascorbate,Ascorbate acts as the coupled oxidant in the haem cleavage reaction involving soluble haemoproteins.,Entity: ascorbate. SMILES: O=C1O[C@H]([C@@H](O)CO)C([O-])=C1O. Ascorbate acts as the coupled oxidant in the haem cleavage reaction involving soluble haemoproteins.
superoxide,"The superoxide radical is a possible activated form of oxygen generated during the haem cleavage process, which hydroxylates the methine bridge of haem.","Entity: superoxide. SMILES: [O][O-]. The superoxide radical is a possible activated form of oxygen generated during the haem cleavage process, which hydroxylates the methine bridge of haem."
oxygen,"Oxygen binds to the haem group of haemoproteins and is reduced prior to haem cleavage, with the added electrons from the reductant likely converting it into an activated form such as the superoxide radical.","Entity: oxygen. SMILES: [O]. Oxygen binds to the haem group of haemoproteins and is reduced prior to haem cleavage, with the added electrons from the reductant likely converting it into an activated form such as the superoxide radical."
stercobilinogen,"Stercobilinogen is the precursor of stercobilin, which is further dehydrogenated to form kappas Stercobilin (III).","Entity: stercobilinogen. SMILES: CC[C@H]1[C@H](Cc2[nH]c(Cc3[nH]c(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC(=O)[C@@H]1C. Stercobilinogen is the precursor of stercobilin, which is further dehydrogenated to form kappas Stercobilin (III)."
chromic acid,"Chromic acid degradation leads to the formation of imides (V) and (VI) from stercobilin, providing evidence for the structure of stercobilin.","Entity: chromic acid. SMILES: O=[Cr](=O)(O)O. Chromic acid degradation leads to the formation of imides (V) and (VI) from stercobilin, providing evidence for the structure of stercobilin."
stercobilin,Stercobilin is a dehydrogenation product of stercobilinogen and is readily isolated from normal faeces.,Entity: stercobilin. SMILES: CC[C@H]1[C@H](CC2=N/C(=C\c3[nH]c(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC(=O)[C@@H]1C. Stercobilin is a dehydrogenation product of stercobilinogen and is readily isolated from normal faeces.
biliverdin,"Biliverdin is an isomeric product derived from haem cleavage, with the proportions of its isomers varying somewhat depending on species differences in albumin and apohaemoglobin structure.","Entity: biliverdin. SMILES: C=CC1=C(C)C(/C=c2\[nH]/c(=C\c3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)=NC1=O. Biliverdin is an isomeric product derived from haem cleavage, with the proportions of its isomers varying somewhat depending on species differences in albumin and apohaemoglobin structure."
NADPH,NADPH is required as a cofactor for haem cleavage activity promoted by microsomal membrane preparations.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is required as a cofactor for haem cleavage activity promoted by microsomal membrane preparations.
biliverdin,Biliverdin is the product formed by cleavage of the haem group from haemoproteins such as haemoglobin.,Entity: biliverdin. SMILES: C=CC1=C(C)C(/C=c2\[nH]/c(=C\c3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)=NC1=O. Biliverdin is the product formed by cleavage of the haem group from haemoproteins such as haemoglobin.
haem,"Haem can be released from haemoglobin and may enter a hepatic cell haem pool, where it can replace haem bound to cytochrome P-450 in haembinding sites.","Entity: haem. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. Haem can be released from haemoglobin and may enter a hepatic cell haem pool, where it can replace haem bound to cytochrome P-450 in haembinding sites."
haem,The cleavage of haem molecules in haembinding sites can be accelerated and made bridge-selective by the presence of catalytic quantities of haemoproteins such as myoglobin and microsomal haemoprotein.,Entity: haem. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. The cleavage of haem molecules in haembinding sites can be accelerated and made bridge-selective by the presence of catalytic quantities of haemoproteins such as myoglobin and microsomal haemoprotein.
stercobilin,"Stercobilin produces a quasi-molecular ion at m/e 596 (M+2) in field-desorption spectroscopy, indicating the presence of a dimeric species.","Entity: stercobilin. SMILES: CC[C@H]1[C@H](CC2=N/C(=C\c3[nH]c(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC(=O)[C@@H]1C. Stercobilin produces a quasi-molecular ion at m/e 596 (M+2) in field-desorption spectroscopy, indicating the presence of a dimeric species."
stercobilin,Stercobilin undergoes chromic oxide oxidation to yield methyl ethyl succinimide and the methyl ester of haematinic acid under controlled micro-scale conditions.,Entity: stercobilin. SMILES: CC[C@H]1[C@H](CC2=N/C(=C\c3[nH]c(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC(=O)[C@@H]1C. Stercobilin undergoes chromic oxide oxidation to yield methyl ethyl succinimide and the methyl ester of haematinic acid under controlled micro-scale conditions.
methyl ethyl maleimide,Methyl ethyl maleimide is produced exclusively from the chromic oxide oxidation of i-urobilin dimethyl ester under controlled conditions.,Entity: methyl ethyl maleimide. SMILES: CCC1=C(C)C(=O)NC1=O. Methyl ethyl maleimide is produced exclusively from the chromic oxide oxidation of i-urobilin dimethyl ester under controlled conditions.
methyl ethyl succinimide,Methyl ethyl succinimide is formed exclusively from the chromic oxide oxidation of stercobilin under controlled conditions.,Entity: methyl ethyl succinimide. SMILES: CCC1(C)CC(=O)NC1=O. Methyl ethyl succinimide is formed exclusively from the chromic oxide oxidation of stercobilin under controlled conditions.
i-urobilin,"i-urobilin can form a similar pigment to d-urobilin upon treatment with alkali, suggesting the possibility of double-bond migration.","Entity: i-urobilin. SMILES: CCC1=C(C)C(CC2=N/C(=C\c3[nH]c(CC4NC(=O)C(C)=C4CC)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC1=O. i-urobilin can form a similar pigment to d-urobilin upon treatment with alkali, suggesting the possibility of double-bond migration."
chromic acid,Chromic acid oxidation is used in analytical chemistry to study pigment formation and double-bond migration in compounds such as i-urobilin and d-urobilin.,Entity: chromic acid. SMILES: O=[Cr](=O)(O)O. Chromic acid oxidation is used in analytical chemistry to study pigment formation and double-bond migration in compounds such as i-urobilin and d-urobilin.
d-urobilin,"d-urobilin contains one more double bond than i-urobilin, as indicated by its chemical properties and the formation of a red product upon treatment with alkali.","Entity: d-urobilin. SMILES: C=CC1=C(C)C(CC2=N/C(=C\c3[nH]c(CC4NC(=O)C(C)=C4CC)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC1=O. d-urobilin contains one more double bond than i-urobilin, as indicated by its chemical properties and the formation of a red product upon treatment with alkali."
d-urobilin,Most optically active d-urobilin isolated from natural sources contain ethyl groups in both terminal rings.,Entity: d-urobilin. SMILES: C=CC1=C(C)C(CC2=N/C(=C\c3[nH]c(CC4NC(=O)C(C)=C4CC)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC1=O. Most optically active d-urobilin isolated from natural sources contain ethyl groups in both terminal rings.
stercobilinogen,"Stercobilinogen is the precursor of stercobilin, which is formed by dehydrogenation.","Entity: stercobilinogen. SMILES: CC[C@H]1[C@H](Cc2[nH]c(Cc3[nH]c(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC(=O)[C@@H]1C. Stercobilinogen is the precursor of stercobilin, which is formed by dehydrogenation."
stercobilin,Stercobilin is the dehydrogenation product of stercobilinogen and is readily isolated from normal faeces.,Entity: stercobilin. SMILES: CC[C@H]1[C@H](CC2=N/C(=C\c3[nH]c(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC(=O)[C@@H]1C. Stercobilin is the dehydrogenation product of stercobilinogen and is readily isolated from normal faeces.
stercobilin,Stercobilin is strongly laevorotatory and can be crystallized as its hydrochloride salt.,Entity: stercobilin. SMILES: CC[C@H]1[C@H](CC2=N/C(=C\c3[nH]c(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC(=O)[C@@H]1C. Stercobilin is strongly laevorotatory and can be crystallized as its hydrochloride salt.
chromic acid,Chromic acid degradation leads to the formation of imides (V) and (VI) as intermediates in the metabolic pathway of urobilins.,Entity: chromic acid. SMILES: O=[Cr](=O)(O)O. Chromic acid degradation leads to the formation of imides (V) and (VI) as intermediates in the metabolic pathway of urobilins.
d-urobilin,"d-urobilin produces a molecular ion at m/e 590 in electron-impact mass spectra, with the intensity increasing from 160°C to 185°C and predominating at temperatures above 220°C.","Entity: d-urobilin. SMILES: C=CC1=C(C)C(CC2=N/C(=C\c3[nH]c(CC4NC(=O)C(C)=C4CC)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC1=O. d-urobilin produces a molecular ion at m/e 590 in electron-impact mass spectra, with the intensity increasing from 160°C to 185°C and predominating at temperatures above 220°C."
d-urobilin,"d-urobilin exhibits field-desorption mass spectra with M+ 1 ions at m/e 591 (100%) and m/e 589 (4%), showing no fragmentation.","Entity: d-urobilin. SMILES: C=CC1=C(C)C(CC2=N/C(=C\c3[nH]c(CC4NC(=O)C(C)=C4CC)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC1=O. d-urobilin exhibits field-desorption mass spectra with M+ 1 ions at m/e 591 (100%) and m/e 589 (4%), showing no fragmentation."
stercobilin,"stercobilin undergoes disproportionation, resulting in a different mass spectral fragmentation pattern compared to d-urobilin.","Entity: stercobilin. SMILES: CC[C@H]1[C@H](CC2=N/C(=C\c3[nH]c(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC(=O)[C@@H]1C. stercobilin undergoes disproportionation, resulting in a different mass spectral fragmentation pattern compared to d-urobilin."
bilirubin,"Bilirubin can be chemically reduced and then reoxidized to yield urobilins such as d-urobilin, i-urobilin, and urobilin-IXa.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin can be chemically reduced and then reoxidized to yield urobilins such as d-urobilin, i-urobilin, and urobilin-IXa."
stercobilin,Stercobilin is a urobilin pigment isolated from faeces.,Entity: stercobilin. SMILES: CC[C@H]1[C@H](CC2=N/C(=C\c3[nH]c(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC(=O)[C@@H]1C. Stercobilin is a urobilin pigment isolated from faeces.
i-urobilin,"i-urobilin (optically inactive) is obtained by dehydrogenation of mesobilirubinogen, an octahydro derivative formed by sodium amalgam reduction of bilirubin, and can also be found in faeces.","Entity: i-urobilin. SMILES: CCC1=C(C)C(CC2=N/C(=C\c3[nH]c(CC4NC(=O)C(C)=C4CC)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC1=O. i-urobilin (optically inactive) is obtained by dehydrogenation of mesobilirubinogen, an octahydro derivative formed by sodium amalgam reduction of bilirubin, and can also be found in faeces."
d-urobilin,d-urobilin is a urobilin pigment that was originally named for a dextrorotatory pigment isolated from patients treated with broad-spectrum antibiotics and can also be found in the faeces of thalassaemia patients and in faecal bacterial cultures.,Entity: d-urobilin. SMILES: C=CC1=C(C)C(CC2=N/C(=C\c3[nH]c(CC4NC(=O)C(C)=C4CC)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC1=O. d-urobilin is a urobilin pigment that was originally named for a dextrorotatory pigment isolated from patients treated with broad-spectrum antibiotics and can also be found in the faeces of thalassaemia patients and in faecal bacterial cultures.
chromic oxide,Chromic oxide is used as an oxidant in micro-scale oxidations for the degradation of bilirubin and d-urobilin.,Entity: chromic oxide. SMILES: [Cr+3].[Cr+3].[O-2].[O-2].[O-2]. Chromic oxide is used as an oxidant in micro-scale oxidations for the degradation of bilirubin and d-urobilin.
bilirubin,"Bilirubin can be oxidized on a micro-scale using chromic oxide in 1 M H2SO4, producing methyl vinyl maleimide and ethyl maleimide as products.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin can be oxidized on a micro-scale using chromic oxide in 1 M H2SO4, producing methyl vinyl maleimide and ethyl maleimide as products."
ethyl maleimide,Ethyl maleimide can be detected and separated from methyl vinyl maleimide by gas chromatography based on their different mass spectra and retention times.,Entity: ethyl maleimide. SMILES: CCC1=CC(=O)NC1=O. Ethyl maleimide can be detected and separated from methyl vinyl maleimide by gas chromatography based on their different mass spectra and retention times.
methyl vinyl maleimide,"Methyl vinyl maleimide can be detected and separated from ethyl maleimide by gas chromatography using mass spectrometry at m/e 137 (M+ for VII), with zero intensity at the expected retention time for VII.","Entity: methyl vinyl maleimide. SMILES: C=CC1=C(C)C(=O)NC1=O. Methyl vinyl maleimide can be detected and separated from ethyl maleimide by gas chromatography using mass spectrometry at m/e 137 (M+ for VII), with zero intensity at the expected retention time for VII."
d-urobilin,d-urobilin can be degraded by micro-scale oxidations with chromic oxide in 1 M H2SO4.,Entity: d-urobilin. SMILES: C=CC1=C(C)C(CC2=N/C(=C\c3[nH]c(CC4NC(=O)C(C)=C4CC)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC1=O. d-urobilin can be degraded by micro-scale oxidations with chromic oxide in 1 M H2SO4.
stercobilin,"Stercobilin produces a quasi-molecular ion at m/e 596 (M+2) in field-desorption spectroscopy, indicating the presence of a stable M+2 ion species.","Entity: stercobilin. SMILES: CC[C@H]1[C@H](CC2=N/C(=C\c3[nH]c(C[C@@H]4NC(=O)[C@H](CC)[C@H]4C)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC(=O)[C@@H]1C. Stercobilin produces a quasi-molecular ion at m/e 596 (M+2) in field-desorption spectroscopy, indicating the presence of a stable M+2 ion species."
aminolaevulinic acid,"Aminolaevulinic acid serves as a precursor for phycobilins and carbon monoxide in blue-green and red algae, but is not a highly specific precursor for these pigments or porphyrins in prokaryotic blue-green algae due to its extensive metabolism to amino acids and protein incorporation.","Entity: aminolaevulinic acid. SMILES: NCC(=O)CCC(=O)O. Aminolaevulinic acid serves as a precursor for phycobilins and carbon monoxide in blue-green and red algae, but is not a highly specific precursor for these pigments or porphyrins in prokaryotic blue-green algae due to its extensive metabolism to amino acids and protein incorporation."
biliverdin,"Biliverdin is a bile pigment whose biosynthesis in Pieris brussicae involves incorporation of [14C]glycine at specific positions, as demonstrated by the labeling pattern.","Entity: biliverdin. SMILES: C=CC1=C(C)C(/C=c2\[nH]/c(=C\c3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)=NC1=O. Biliverdin is a bile pigment whose biosynthesis in Pieris brussicae involves incorporation of [14C]glycine at specific positions, as demonstrated by the labeling pattern."
phycobilin,"Phycobilins are pigments biosynthesized in blue-green and red algae via a porphyrin pathway, with a specific radioactivity ratio of 7:1 when feeding 5-[4C]aminolaevulinic acid.","Entity: phycobilin. SMILES: C/C=C1C(=C/c2[nH]c(/C=c3\[nH]/c(=C/C4=NC(=O)C(CC)=C4C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)/NC(=O)[C@@H]/1C. Phycobilins are pigments biosynthesized in blue-green and red algae via a porphyrin pathway, with a specific radioactivity ratio of 7:1 when feeding 5-[4C]aminolaevulinic acid."
carbon monoxide,"Carbon monoxide is produced as a byproduct during the biosynthesis of phycobilins in blue-green and red algae, with a specific radioactivity ratio of 1:7 relative to phycobilin when using 5-[4C]aminolaevulinic acid as a precursor.","Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide is produced as a byproduct during the biosynthesis of phycobilins in blue-green and red algae, with a specific radioactivity ratio of 1:7 relative to phycobilin when using 5-[4C]aminolaevulinic acid as a precursor."
phycocyanobilin,"In the blue-green alga Anacystis nidulans, the production of phycocyanobilin is more than 4 times greater than the corresponding haem degradation by microsomal haem oxygenase in rat spleen.","Entity: phycocyanobilin. SMILES: C/C=C1C(=C\c2[nH]c(/C=c3/[nH]/c(=C/C4=NC(=O)C(CC)=C4C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)/NC(=O)C/1C. In the blue-green alga Anacystis nidulans, the production of phycocyanobilin is more than 4 times greater than the corresponding haem degradation by microsomal haem oxygenase in rat spleen."
pterobilin,"In Lepidoptera, pterobilin is a bile pigment whose structural similarity to protoporphyrin is most striking, as the η-methine bridge of haem must have been oxidized in its biosynthesis.","Entity: pterobilin. SMILES: C=Cc1c(/C=C2\NC(=O)C(CCC(=O)O)=C2C)[nH]c(/C=c2\[nH]/c(=C\C3=NC(=O)C(CCC(=O)O)=C3C)c(C)c2C=C)c1C. In Lepidoptera, pterobilin is a bile pigment whose structural similarity to protoporphyrin is most striking, as the η-methine bridge of haem must have been oxidized in its biosynthesis."
orotic acid,"Orotic acid has been administered to both premature and full-term infants to lower serum bilirubin concentrations, with conflicting results.","Entity: orotic acid. SMILES: O=C(O)c1cc(=O)[nH]c(=O)[nH]1. Orotic acid has been administered to both premature and full-term infants to lower serum bilirubin concentrations, with conflicting results."
uridine diphosphate glucuronic acid,Uridine diphosphate glucuronic acid (UDPGA) is the glucuronide donor involved in the conjugation of bilirubin.,Entity: uridine diphosphate glucuronic acid. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)O.O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine diphosphate glucuronic acid (UDPGA) is the glucuronide donor involved in the conjugation of bilirubin.
bilirubin,"Bilirubin serum concentrations can be lowered by administration of orotic acid in infants, although results have been mixed.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin serum concentrations can be lowered by administration of orotic acid in infants, although results have been mixed."
orotic acid,"Orotic acid is a metabolic precursor of uridine diphosphate glucuronic acid (UDPGA), which serves as the glucuronide donor in bilirubin conjugation.","Entity: orotic acid. SMILES: O=C(O)c1cc(=O)[nH]c(=O)[nH]1. Orotic acid is a metabolic precursor of uridine diphosphate glucuronic acid (UDPGA), which serves as the glucuronide donor in bilirubin conjugation."
bilirubin,Bilirubin can act as both a sensitizer and a substrate in the type I1 or singlet O2 mechanism for the formation of methyl vinyl maleimide and dialdehyde.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin can act as both a sensitizer and a substrate in the type I1 or singlet O2 mechanism for the formation of methyl vinyl maleimide and dialdehyde.
methyl vinyl maleimide,Methyl vinyl maleimide formation in the presence of bilirubin and singlet O2 can be explained by a type I1 or singlet O2 mechanism.,Entity: methyl vinyl maleimide. SMILES: C=CC1=C(C)C(=O)NC1=O. Methyl vinyl maleimide formation in the presence of bilirubin and singlet O2 can be explained by a type I1 or singlet O2 mechanism.
dialdehyde,The formation of a dialdehyde in the presence of bilirubin and singlet O2 can be rationalized by a type I1 or singlet O2 mechanism.,Entity: dialdehyde. SMILES: C=C[C@@H](C=O)[C@H](C[C@@H]1NCCc2c1[nH]c1ccccc21)/C(=C/O)C(=O)OC. The formation of a dialdehyde in the presence of bilirubin and singlet O2 can be rationalized by a type I1 or singlet O2 mechanism.
bilirubin,Bilirubin is formed via a type I photo-oxidation mechanism involving photochemical activation to an organic radical intermediate.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin is formed via a type I photo-oxidation mechanism involving photochemical activation to an organic radical intermediate.
oxygen,Oxygen can be activated by photosensitized conversion into singlet oxygen (O2) in type I photo-oxidation reactions.,Entity: oxygen. SMILES: [O]. Oxygen can be activated by photosensitized conversion into singlet oxygen (O2) in type I photo-oxidation reactions.
biliverdin,Biliverdin is a minor product formed in methanol metabolism and is not a key intermediate in the formation of bilirubin fragments.,Entity: biliverdin. SMILES: C=CC1=C(C)C(/C=c2\[nH]/c(=C\c3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)=NC1=O. Biliverdin is a minor product formed in methanol metabolism and is not a key intermediate in the formation of bilirubin fragments.
bilirubin,Photodegradation of bilirubin is likely to proceed via a photo-oxidation mechanism.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Photodegradation of bilirubin is likely to proceed via a photo-oxidation mechanism.
oxygen,"In the first few millimeters from the epidermis, tissues have a steady supply of oxygen via oxyhaemoglobin and/or oxymyoglobin.","Entity: oxygen. SMILES: [O]. In the first few millimeters from the epidermis, tissues have a steady supply of oxygen via oxyhaemoglobin and/or oxymyoglobin."
bilirubin,Bilirubin is very sparingly soluble in water.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin is very sparingly soluble in water.
bilirubin,The effectiveness of phototherapy for bilirubin depends on the photodegradation of bilirubin to water-soluble products.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. The effectiveness of phototherapy for bilirubin depends on the photodegradation of bilirubin to water-soluble products.
bilirubin,Bilirubin is thought to be transported in the bloodstream as a complex with serum albumin.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin is thought to be transported in the bloodstream as a complex with serum albumin.
ammonia,Anhydrous ammonia is used as a solubilizing agent for bilirubin in freshly distilled anhydrous methanol.,Entity: ammonia. SMILES: N. Anhydrous ammonia is used as a solubilizing agent for bilirubin in freshly distilled anhydrous methanol.
methanol,Freshly distilled anhydrous methanol serves as a suitable solvent for reactions involving bilirubin and ammonia.,Entity: methanol. SMILES: CO. Freshly distilled anhydrous methanol serves as a suitable solvent for reactions involving bilirubin and ammonia.
bilirubin,"Bilirubin can be solubilized in freshly distilled anhydrous methanol, especially when anhydrous ammonia is added to the solvent.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin can be solubilized in freshly distilled anhydrous methanol, especially when anhydrous ammonia is added to the solvent."
bilirubin,Bilirubin is one of the most reactive singlet oxygen (O2) acceptors known.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin is one of the most reactive singlet oxygen (O2) acceptors known.
bilirubin,Bilirubin physically quenches singlet oxygen faster than it reacts with it.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin physically quenches singlet oxygen faster than it reacts with it.
bilirubin,Bilirubin can act as both a sensitizer and substrate in the type I1 or singlet O2 mechanism for the formation of methyl vinyl maleimide and dialdehyde.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin can act as both a sensitizer and substrate in the type I1 or singlet O2 mechanism for the formation of methyl vinyl maleimide and dialdehyde.
methyl vinyl maleimide,Methyl vinyl maleimide formation can be explained by a singlet O2 mechanism involving bilirubin as both sensitizer and substrate.,Entity: methyl vinyl maleimide. SMILES: C=CC1=C(C)C(=O)NC1=O. Methyl vinyl maleimide formation can be explained by a singlet O2 mechanism involving bilirubin as both sensitizer and substrate.
dialdehyde,The formation of dialdehyde can be rationalized by a singlet O2 mechanism involving bilirubin as a sensitizer.,Entity: dialdehyde. SMILES: C=C[C@@H](C=O)[C@H](C[C@@H]1NCCc2c1[nH]c1ccccc21)/C(=C/O)C(=O)OC. The formation of dialdehyde can be rationalized by a singlet O2 mechanism involving bilirubin as a sensitizer.
oxygen,"In brown adipose tissue, the rate of oxygen consumption in vitro is many times lower than the values found in vivo, which may limit the tissue's capacity to produce extra heat in the foetus or asphyxiated newborn.","Entity: oxygen. SMILES: [O]. In brown adipose tissue, the rate of oxygen consumption in vitro is many times lower than the values found in vivo, which may limit the tissue's capacity to produce extra heat in the foetus or asphyxiated newborn."
palmitate,Palmitate oxidation and conversion into ketone bodies by liver mitochondria show developmental changes with a minimum at about 9 days of age in mammals.,Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Palmitate oxidation and conversion into ketone bodies by liver mitochondria show developmental changes with a minimum at about 9 days of age in mammals.
dihydroxyacetone phosphate,Dihydroxyacetone phosphate serves as a precursor for triglyceride synthesis in rat epididymal adipose tissue.,Entity: dihydroxyacetone phosphate. SMILES: CC(=O)C(O)O.O=P(O)(O)O. Dihydroxyacetone phosphate serves as a precursor for triglyceride synthesis in rat epididymal adipose tissue.
glycerol 3-phosphate,Glycerol 3-phosphate is utilized as a precursor for triglyceride synthesis in rat epididymal adipose tissue.,Entity: glycerol 3-phosphate. SMILES: O=P(O)(O)OCC(O)CO. Glycerol 3-phosphate is utilized as a precursor for triglyceride synthesis in rat epididymal adipose tissue.
glycerol,Glycerol acts as a precursor in the synthesis of triglycerides in rat epididymal adipose tissue.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol acts as a precursor in the synthesis of triglycerides in rat epididymal adipose tissue.
thyroxine,"Thyroxine, when injected into foetuses in utero, increases the capacity for hepatic fatty acid oxidation, which is measurable by mitochondrial palmityolcarnitine oxidation rate.","Entity: thyroxine. SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O. Thyroxine, when injected into foetuses in utero, increases the capacity for hepatic fatty acid oxidation, which is measurable by mitochondrial palmityolcarnitine oxidation rate."
thyroxine,"Thyroxine, when injected into neonatal rats on day 6, increases hepatic fatty acid oxidation capacity 1 day later and increases 3-hydroxyacyl-CoA dehydrogenase activity on days 13 and 14.","Entity: thyroxine. SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O. Thyroxine, when injected into neonatal rats on day 6, increases hepatic fatty acid oxidation capacity 1 day later and increases 3-hydroxyacyl-CoA dehydrogenase activity on days 13 and 14."
thyroxine,Thyroxine injections in neonatal rats do not increase blood ketone-body concentration compared to control.,Entity: thyroxine. SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O. Thyroxine injections in neonatal rats do not increase blood ketone-body concentration compared to control.
corticosterone,"Corticosterone, when injected into foetuses in utero, increases the capacity for hepatic fatty acid oxidation as measured by mitochondrial palmityolcarnitine oxidation rate.","Entity: corticosterone. SMILES: C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO. Corticosterone, when injected into foetuses in utero, increases the capacity for hepatic fatty acid oxidation as measured by mitochondrial palmityolcarnitine oxidation rate."
corticosterone,"Corticosterone, when injected into neonatal rats on day 6, increases hepatic fatty acid oxidation capacity 1 day later and increases 3-hydroxyacyl-CoA dehydrogenase activity on days 13 and 14.","Entity: corticosterone. SMILES: C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO. Corticosterone, when injected into neonatal rats on day 6, increases hepatic fatty acid oxidation capacity 1 day later and increases 3-hydroxyacyl-CoA dehydrogenase activity on days 13 and 14."
corticosterone,Corticosterone injection on day 6 results in increased blood ketone-body concentration on day 7 in neonatal rats.,Entity: corticosterone. SMILES: C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO. Corticosterone injection on day 6 results in increased blood ketone-body concentration on day 7 in neonatal rats.
glucose 6-phosphate,"In mammary explants from rabbits, the specific activity of glucose 6-phosphate dehydrogenase increases in response to insulin, cortisol, and prolactin during pregnancy, with maximal stimulation observed in mid-pregnant tissue.","Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. In mammary explants from rabbits, the specific activity of glucose 6-phosphate dehydrogenase increases in response to insulin, cortisol, and prolactin during pregnancy, with maximal stimulation observed in mid-pregnant tissue."
stearic acid,Stearic acid is desaturated to oleic acid by enzymes present in freshly secreted goat milk.,Entity: stearic acid. SMILES: CCCCCCCCCCCCCCCCCC(=O)O. Stearic acid is desaturated to oleic acid by enzymes present in freshly secreted goat milk.
oleic acid,Virtually all the oleic acid formed from stearic acid desaturation in goat milk is found in the esterified form.,Entity: oleic acid. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. Virtually all the oleic acid formed from stearic acid desaturation in goat milk is found in the esterified form.
glycerol 3-phosphate,Enzymes of the glycerol 3-phosphate pathway are present in goat milk and are involved in triglyceride biosynthesis.,Entity: glycerol 3-phosphate. SMILES: O=P(O)(O)OCC(O)CO. Enzymes of the glycerol 3-phosphate pathway are present in goat milk and are involved in triglyceride biosynthesis.
CoA,"CoA is required as a cofactor for the glycerol 3-phosphate pathway of triglyceride biosynthesis, but does not stimulate the desaturation of stearic acid to oleic acid in goat milk.","Entity: CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. CoA is required as a cofactor for the glycerol 3-phosphate pathway of triglyceride biosynthesis, but does not stimulate the desaturation of stearic acid to oleic acid in goat milk."
acetate,[l-14C]acetate is incorporated into fatty acids such as butyric acid to palmitic acid in cytoplasmic droplets from goat mammary tissue.,Entity: acetate. SMILES: CC(=O)[O-]. [l-14C]acetate is incorporated into fatty acids such as butyric acid to palmitic acid in cytoplasmic droplets from goat mammary tissue.
glucose,[U-14C]glucose is incorporated into lactose and oxidized to carbon dioxide in cytoplasmic droplets from goat mammary tissue.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. [U-14C]glucose is incorporated into lactose and oxidized to carbon dioxide in cytoplasmic droplets from goat mammary tissue.
leucine,[3H]leucine is incorporated into protein in cytoplasmic droplets from goat mammary tissue.,Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. [3H]leucine is incorporated into protein in cytoplasmic droplets from goat mammary tissue.
thymidine,No incorporation of [3H]thymidine into DNA occurs in cytoplasmic droplets from goat mammary tissue.,Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. No incorporation of [3H]thymidine into DNA occurs in cytoplasmic droplets from goat mammary tissue.
palmitic acid,Palmitic acid is a normal fatty acid synthesized in goat mammary tissue and can be incorporated from [l-14C]acetate into cytoplasmic droplets.,Entity: palmitic acid. SMILES: CCCCCCCCCCCCCCCC(=O)O. Palmitic acid is a normal fatty acid synthesized in goat mammary tissue and can be incorporated from [l-14C]acetate into cytoplasmic droplets.
butyric acid,Butyric acid is a normal fatty acid synthesized in goat mammary tissue and can be incorporated from [l-14C]acetate into cytoplasmic droplets.,Entity: butyric acid. SMILES: CCCC(=O)O. Butyric acid is a normal fatty acid synthesized in goat mammary tissue and can be incorporated from [l-14C]acetate into cytoplasmic droplets.
glycerol 3-phosphate,Cofactors required for triglyceride biosynthesis via the glycerol 3-phosphate pathway are necessary to restore fatty acid-esterifying activity in cytoplasmic droplets from goat mammary tissue.,Entity: glycerol 3-phosphate. SMILES: O=P(O)(O)OCC(O)CO. Cofactors required for triglyceride biosynthesis via the glycerol 3-phosphate pathway are necessary to restore fatty acid-esterifying activity in cytoplasmic droplets from goat mammary tissue.
ethanolamine,Phosphatidyl ethanolamine is diminished in composition in the pre-lytic region of a released membrane compared to the original membrane.,Entity: ethanolamine. SMILES: NCCO. Phosphatidyl ethanolamine is diminished in composition in the pre-lytic region of a released membrane compared to the original membrane.
serine,Phosphatidyl serine is diminished in composition in the pre-lytic region of a released membrane compared to the original membrane.,Entity: serine. SMILES: N[C@@H](CO)C(=O)O. Phosphatidyl serine is diminished in composition in the pre-lytic region of a released membrane compared to the original membrane.
inositol,Phosphatidyl inositol is diminished in composition in the pre-lytic region of a released membrane compared to the original membrane.,Entity: inositol. SMILES: OC1C(O)C(O)C(O)C(O)C1O. Phosphatidyl inositol is diminished in composition in the pre-lytic region of a released membrane compared to the original membrane.
digitonin,"Digitonin treatment of rat microsomal fractions alters the density distribution of certain enzymes, indicating its effect on subcomponent localization within the endoplasmic reticulum.","Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin treatment of rat microsomal fractions alters the density distribution of certain enzymes, indicating its effect on subcomponent localization within the endoplasmic reticulum."
pyrophosphate,"Pyrophosphate treatment causes a decrease in the density of 3-glucuronidase, α-glucosidase, bilirubin UDP-glucuronyltransferase, and arylsulphatase C in microsomal fractions, indicating these enzymes are associated with ribosome-granulated endoplasmic reticulum.","Entity: pyrophosphate. SMILES: O=P([O-])([O-])OP(=O)([O-])[O-]. Pyrophosphate treatment causes a decrease in the density of 3-glucuronidase, α-glucosidase, bilirubin UDP-glucuronyltransferase, and arylsulphatase C in microsomal fractions, indicating these enzymes are associated with ribosome-granulated endoplasmic reticulum."
digitonin,Digitonin is used to treat microsomal fractions to facilitate their subfractionation by isopycnic centrifugation.,Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin is used to treat microsomal fractions to facilitate their subfractionation by isopycnic centrifugation.
pyrophosphate,Pyrophosphate is used to treat microsomal fractions to aid in their subfractionation by isopycnic centrifugation.,Entity: pyrophosphate. SMILES: O=P([O-])([O-])OP(=O)([O-])[O-]. Pyrophosphate is used to treat microsomal fractions to aid in their subfractionation by isopycnic centrifugation.
leucine 2-naphthylamide,Leucine 2-naphthylamide is used as a marker enzyme to assay for its activity in microsomal fractions derived from rat liver.,Entity: leucine 2-naphthylamide. SMILES: CC(C)C[C@H](N)C(=O)Nc1ccc2ccccc2c1. Leucine 2-naphthylamide is used as a marker enzyme to assay for its activity in microsomal fractions derived from rat liver.
NADPH,"NADPH is a substrate for NADPH-cytochrome c reductase, which serves as a marker for the smooth endoplasmic reticulum in microsomal fraction analysis.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is a substrate for NADPH-cytochrome c reductase, which serves as a marker for the smooth endoplasmic reticulum in microsomal fraction analysis."
bilirubin,Bilirubin UDP-glucuronyltransferase activity is measured as a principal submicrosomal marker in rat liver microsomal fractions.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin UDP-glucuronyltransferase activity is measured as a principal submicrosomal marker in rat liver microsomal fractions.
Digitonin,"Digitonin treatment of microsomal fractions from Gunn rats produces responses similar to those from control rats, indicating that Gunn rat microsomes retain functional properties despite lacking bilirubin UDP-glucuronyltransferase activity.","Entity: Digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin treatment of microsomal fractions from Gunn rats produces responses similar to those from control rats, indicating that Gunn rat microsomes retain functional properties despite lacking bilirubin UDP-glucuronyltransferase activity."
Bilirubin,"Within 5 minutes of intravenous injection of tritiated bilirubin, 30–50-fold higher radioactivity appears in the liver compared to control rats, with most bilirubin accumulating in the cytosol and approximately 10% in the microsomal fraction.","Entity: Bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Within 5 minutes of intravenous injection of tritiated bilirubin, 30–50-fold higher radioactivity appears in the liver compared to control rats, with most bilirubin accumulating in the cytosol and approximately 10% in the microsomal fraction."
digitonin,"Digitonin is a microsomal perturbing agent used to selectively modify the density distributions of certain submicrosomal components, aiding in the delineation of their subcellular locations.","Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin is a microsomal perturbing agent used to selectively modify the density distributions of certain submicrosomal components, aiding in the delineation of their subcellular locations."
pyrophosphate,"Pyrophosphate is a microsomal perturbing agent used to selectively modify the density distributions of certain submicrosomal components, facilitating the identification of their subcellular locations.","Entity: pyrophosphate. SMILES: O=P([O-])([O-])OP(=O)([O-])[O-]. Pyrophosphate is a microsomal perturbing agent used to selectively modify the density distributions of certain submicrosomal components, facilitating the identification of their subcellular locations."
concanavalin A,"Concanavalin A binds to both the original membrane and the unretarded membrane fraction in the same amount, as measured by 125I-labelled concanavalin A binding assays.","Entity: concanavalin A. SMILES: CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1.Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O. Concanavalin A binds to both the original membrane and the unretarded membrane fraction in the same amount, as measured by 125I-labelled concanavalin A binding assays."
sodium dodecyl sulphate,Sodium dodecyl sulphate is used in polyacrylamide-gel electrophoresis to assess polypeptide composition of membrane fractions.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used in polyacrylamide-gel electrophoresis to assess polypeptide composition of membrane fractions.
concanavalin A,Concanavalin A can be covalently attached to Sepharose 4B and used to separate fractions of pig lymphocyte plasma membrane that behave as inside-out vesicles.,Entity: concanavalin A. SMILES: CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1.Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O. Concanavalin A can be covalently attached to Sepharose 4B and used to separate fractions of pig lymphocyte plasma membrane that behave as inside-out vesicles.
Triton X-100,Triton X-100 is a detergent used to solubilize membrane-bound enzymes such as glucocerebroside 8-glucosidase.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a detergent used to solubilize membrane-bound enzymes such as glucocerebroside 8-glucosidase.
CaCl2,CaCl2 is used at a concentration of 0.1 mM in the regeneration buffer for concanavalin A-Sepharose chromatography columns.,Entity: CaCl2. SMILES: [Ca+2].[Cl-].[Cl-]. CaCl2 is used at a concentration of 0.1 mM in the regeneration buffer for concanavalin A-Sepharose chromatography columns.
MnCl2,MnCl2 is included at a concentration of 0.1 mM in the regeneration buffer for concanavalin A-Sepharose chromatography columns.,Entity: MnCl2. SMILES: [Cl-].[Cl-].[Mn+2]. MnCl2 is included at a concentration of 0.1 mM in the regeneration buffer for concanavalin A-Sepharose chromatography columns.
chloroform,Chloroform is used in a 9:1 (v/v) mixture with ethanol for protein precipitation from solution during enzyme purification.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used in a 9:1 (v/v) mixture with ethanol for protein precipitation from solution during enzyme purification.
ethanol,Ethanol is used in a 9:1 (v/v) mixture with chloroform for protein precipitation during enzyme purification.,Entity: ethanol. SMILES: CCO. Ethanol is used in a 9:1 (v/v) mixture with chloroform for protein precipitation during enzyme purification.
sodium phosphate,Sodium phosphate buffer at 10 mM concentration and pH 7.0 is used to suspend glucocerebroside B-glucosidase purified from human placenta.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate buffer at 10 mM concentration and pH 7.0 is used to suspend glucocerebroside B-glucosidase purified from human placenta.
sodium taurocholate,"Sodium taurocholate is used as a substrate in enzymatic assays measuring glucocerebroside B-glucosidase activity, at a concentration of 0.1% (w/v).","Entity: sodium taurocholate. SMILES: C[C@H](CCC(=O)NCCS(=O)(=O)[O-])[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C.[Na+]. Sodium taurocholate is used as a substrate in enzymatic assays measuring glucocerebroside B-glucosidase activity, at a concentration of 0.1% (w/v)."
sodium acetate,Sodium acetate buffer at 0.1 M concentration and pH 4.5 is used as the reaction buffer for glucocerebroside B-glucosidase activity assays.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate buffer at 0.1 M concentration and pH 4.5 is used as the reaction buffer for glucocerebroside B-glucosidase activity assays.
Triton X-100,Triton X-100 is included at 0.1% (v/v) in the reaction buffer for glucocerebroside B-glucosidase activity assays.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is included at 0.1% (v/v) in the reaction buffer for glucocerebroside B-glucosidase activity assays.
theophylline,Theophylline decreases both serosal entry and exit permeability of galactose at the mucosal pole of rabbit ileum mucosa to 30% of control values.,Entity: theophylline. SMILES: Cn1c(=O)c2[nH]cnc2n(C)c1=O. Theophylline decreases both serosal entry and exit permeability of galactose at the mucosal pole of rabbit ileum mucosa to 30% of control values.
theophylline,Theophylline increases the steady-state concentration of galactose in the tissue water of rabbit ileum mucosa.,Entity: theophylline. SMILES: Cn1c(=O)c2[nH]cnc2n(C)c1=O. Theophylline increases the steady-state concentration of galactose in the tissue water of rabbit ileum mucosa.
glucose,"In rabbit ileum mucosa incubations, glucose concentration in the serosal exudate continues to rise throughout the incubation period in the presence of theophylline, unlike control preparations where it reaches a steady state.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In rabbit ileum mucosa incubations, glucose concentration in the serosal exudate continues to rise throughout the incubation period in the presence of theophylline, unlike control preparations where it reaches a steady state."
ADP,ADP does not affect glucose uptake in jejunal intestinal tissue rings from either normal or Schistosome-infected mice.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP does not affect glucose uptake in jejunal intestinal tissue rings from either normal or Schistosome-infected mice.
glucose,"Glucose is accumulated by normal mouse jejunal intestinal tissue to a concentration of about 25 pmol/ml after 4 minutes in Krebs/Ringer bicarbonate medium containing 1.1 mM glucose, with a tissue/medium concentration ratio of 2.3.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is accumulated by normal mouse jejunal intestinal tissue to a concentration of about 25 pmol/ml after 4 minutes in Krebs/Ringer bicarbonate medium containing 1.1 mM glucose, with a tissue/medium concentration ratio of 2.3."
glucose,"In Schistosome-infected mouse jejunal tissue, glucose accumulates to a concentration of only 15 µmol/ml after 4 minutes in Krebs/Ringer bicarbonate medium containing 1.1 mM glucose, with a tissue/medium concentration ratio of 1.4.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In Schistosome-infected mouse jejunal tissue, glucose accumulates to a concentration of only 15 µmol/ml after 4 minutes in Krebs/Ringer bicarbonate medium containing 1.1 mM glucose, with a tissue/medium concentration ratio of 1.4."
ADP,ADP at 1 mM concentration prevents the decline in mitochondrial respiration quotient (QO2) of normal mouse jejunal intestinal tissue rings but has no effect on the decline in QO2 of Schistosome-infected tissue rings.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP at 1 mM concentration prevents the decline in mitochondrial respiration quotient (QO2) of normal mouse jejunal intestinal tissue rings but has no effect on the decline in QO2 of Schistosome-infected tissue rings.
ATP,"ATP inhibits the deacylation of acetyl-CoA in T. b. brucei 427, resulting in a 49% decrease in activity when 0.5 mM added nucleoside phosphate is present.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP inhibits the deacylation of acetyl-CoA in T. b. brucei 427, resulting in a 49% decrease in activity when 0.5 mM added nucleoside phosphate is present."
L(-)-carnitine,The effect of L(-)-carnitine on the deacylation of acetyl-CoA is equivocal and depends on the specific assay conditions.,Entity: L(-)-carnitine. SMILES: C[N+](C)(C)CC(O)CC(=O)[O-]. The effect of L(-)-carnitine on the deacylation of acetyl-CoA is equivocal and depends on the specific assay conditions.
acetyl-CoA,"The deacylation of acetyl-CoA is sensitive to the presence of added nucleoside di- and tri-phosphates, with GDP and ATP being inhibitory and ADP being stimulatory.","Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. The deacylation of acetyl-CoA is sensitive to the presence of added nucleoside di- and tri-phosphates, with GDP and ATP being inhibitory and ADP being stimulatory."
GDP,"GDP stimulates the deacylation of acetyl-CoA in T. 6. brucei MIAG 103, resulting in a 100% increase in activity when 0.5 mM added nucleoside phosphate is present.","Entity: GDP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. GDP stimulates the deacylation of acetyl-CoA in T. 6. brucei MIAG 103, resulting in a 100% increase in activity when 0.5 mM added nucleoside phosphate is present."
GDP,"GDP stimulates the deacylation of acetyl-CoA in T. b. brucei 427, resulting in a 75% increase in activity when 0.5 mM added nucleoside phosphate is present.","Entity: GDP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. GDP stimulates the deacylation of acetyl-CoA in T. b. brucei 427, resulting in a 75% increase in activity when 0.5 mM added nucleoside phosphate is present."
ADP,"ADP inhibits the deacylation of acetyl-CoA in T. 6. brucei MIAG 103, resulting in a 32% decrease in activity when 0.5 mM added nucleoside phosphate is present.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP inhibits the deacylation of acetyl-CoA in T. 6. brucei MIAG 103, resulting in a 32% decrease in activity when 0.5 mM added nucleoside phosphate is present."
ADP,"ADP inhibits the deacylation of acetyl-CoA in T. b. brucei 427, resulting in a 31% decrease in activity when 0.5 mM added nucleoside phosphate is present.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP inhibits the deacylation of acetyl-CoA in T. b. brucei 427, resulting in a 31% decrease in activity when 0.5 mM added nucleoside phosphate is present."
alanine,Alanine is synthesized de novo in muscle through transamination of pyruvate with other amino acids.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine is synthesized de novo in muscle through transamination of pyruvate with other amino acids.
pyruvate,"Pyruvate serves as a substrate for transamination with glutamate in muscle, leading to the synthesis of alanine.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate serves as a substrate for transamination with glutamate in muscle, leading to the synthesis of alanine."
glutamate,Glutamate is the primary amino acid that can directly transfer amino groups to pyruvate in muscle via alanine aminotransferase.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate is the primary amino acid that can directly transfer amino groups to pyruvate in muscle via alanine aminotransferase.
2-oxoglutarate,"2-oxoglutarate can serve as an intermediate in muscle transamination reactions, where amino acids are transferred to it and subsequently react with pyruvate to form alanine.","Entity: 2-oxoglutarate. SMILES: O=C([O-])CCC(=O)C(=O)[O-]. 2-oxoglutarate can serve as an intermediate in muscle transamination reactions, where amino acids are transferred to it and subsequently react with pyruvate to form alanine."
alanine,Alanine is a major substrate for hepatic gluconeogenesis.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine is a major substrate for hepatic gluconeogenesis.
alanine,Nearly 50% of total amino nitrogen released from skeletal muscle is in the form of alanine.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Nearly 50% of total amino nitrogen released from skeletal muscle is in the form of alanine.
leucine,"Leucine at 3 mM stimulates the rate of alanine release by hemidiaphragm in vitro, and this stimulation is abolished by L-Cycloserine.","Entity: leucine. SMILES: CC(C)C[C@H](N)C(=O)O. Leucine at 3 mM stimulates the rate of alanine release by hemidiaphragm in vitro, and this stimulation is abolished by L-Cycloserine."
glutamate,Glutamate at 3 mM stimulates the rate of alanine release by hemidiaphragm in vitro.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate at 3 mM stimulates the rate of alanine release by hemidiaphragm in vitro.
L-Cycloserine,L-Cycloserine is an inhibitor of alanine aminotransferase that largely abolishes the stimulation of alanine release by hemidiaphragm in vitro.,Entity: L-Cycloserine. SMILES: N[C@H]1CONC1=O. L-Cycloserine is an inhibitor of alanine aminotransferase that largely abolishes the stimulation of alanine release by hemidiaphragm in vitro.
glucose,"Glucose at 10 mM increases the rate of alanine release by hemidiaphragm in vitro, and this stimulation is blocked by L-Cycloserine, indicating that glucose increases alanine release by providing more pyruvate for transamination.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose at 10 mM increases the rate of alanine release by hemidiaphragm in vitro, and this stimulation is blocked by L-Cycloserine, indicating that glucose increases alanine release by providing more pyruvate for transamination."
alanine,"Alanine is formed by transamination of pyruvate in the hemidiaphragm, as shown by the inhibition of alanine release by L-Cycloserine.","Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine is formed by transamination of pyruvate in the hemidiaphragm, as shown by the inhibition of alanine release by L-Cycloserine."
valine,"Valine at 3 mM stimulates the rate of alanine release by hemidiaphragm in vitro, and this stimulation is abolished by L-Cycloserine.","Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. Valine at 3 mM stimulates the rate of alanine release by hemidiaphragm in vitro, and this stimulation is abolished by L-Cycloserine."
pyruvate,"Pyruvate serves as the substrate for alanine synthesis via transamination in the hemidiaphragm, and its supply is essential for stimulating alanine release.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate serves as the substrate for alanine synthesis via transamination in the hemidiaphragm, and its supply is essential for stimulating alanine release."
sodium dichloroacetate,"Sodium dichloroacetate at 10 mM almost completely abolishes the increased alanine release stimulated by 10 mM glucose or 3 mM valine in hemidiaphragm in vitro, indicating its role in inhibiting pyruvate oxidation.","Entity: sodium dichloroacetate. SMILES: O=C([O-])C(Cl)Cl.[Na+]. Sodium dichloroacetate at 10 mM almost completely abolishes the increased alanine release stimulated by 10 mM glucose or 3 mM valine in hemidiaphragm in vitro, indicating its role in inhibiting pyruvate oxidation."
3-mercaptopicolinate,Inhibition of phosphoenolpyruvate carboxykinase with 3-mercaptopicolinate decreases alanine release by 65% when valine is used as the substrate.,Entity: 3-mercaptopicolinate. SMILES: O=C([O-])c1ncccc1S. Inhibition of phosphoenolpyruvate carboxykinase with 3-mercaptopicolinate decreases alanine release by 65% when valine is used as the substrate.
3-methylvaline,"3-methylvaline, which cannot provide citric acid-cycle intermediates, does not affect alanine release when used as a substrate.","Entity: 3-methylvaline. SMILES: CC(C)(C)[C@H](N)C(=O)O. 3-methylvaline, which cannot provide citric acid-cycle intermediates, does not affect alanine release when used as a substrate."
3-methylleucine,"3-methylleucine, which cannot provide citric acid-cycle intermediates, does not affect alanine release when used as a substrate.","Entity: 3-methylleucine. SMILES: CC(C)C(C)[C@H](N)C(=O)O. 3-methylleucine, which cannot provide citric acid-cycle intermediates, does not affect alanine release when used as a substrate."
oxaloacetate,Oxaloacetate can be withdrawn from the citric acid cycle and used for pyruvate formation in muscle.,Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. Oxaloacetate can be withdrawn from the citric acid cycle and used for pyruvate formation in muscle.
alanine,Most of the pyruvate required for alanine formation in muscle is derived from glycolysis.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Most of the pyruvate required for alanine formation in muscle is derived from glycolysis.
malate,Malate can be withdrawn from the citric acid cycle and used for pyruvate formation in muscle via NADP+-dependent malate dehydrogenase.,Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate can be withdrawn from the citric acid cycle and used for pyruvate formation in muscle via NADP+-dependent malate dehydrogenase.
alanine,"Alanine synthesis in muscle can utilize pyruvate derived from valine, which provides succinyl-CoA as a citric acid-cycle intermediate.","Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine synthesis in muscle can utilize pyruvate derived from valine, which provides succinyl-CoA as a citric acid-cycle intermediate."
NADP,"NADP is required as a cofactor for the enzyme NADP+-dependent malate dehydrogenase, which converts malate to pyruvate in muscle.","Entity: NADP. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)(O)OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP is required as a cofactor for the enzyme NADP+-dependent malate dehydrogenase, which converts malate to pyruvate in muscle."
pyruvate,Pyruvate can be formed in muscle from oxaloacetate via phosphoenolpyruvate carboxykinase or from malate via NADP+-dependent malate dehydrogenase.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate can be formed in muscle from oxaloacetate via phosphoenolpyruvate carboxykinase or from malate via NADP+-dependent malate dehydrogenase.
pyruvate,The branched-chain amino acid valine can provide pyruvate for alanine synthesis in muscle.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. The branched-chain amino acid valine can provide pyruvate for alanine synthesis in muscle.
valine,"Valine, a branched-chain amino acid, can provide pyruvate for alanine synthesis in muscle by serving as a source of succinyl-CoA.","Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. Valine, a branched-chain amino acid, can provide pyruvate for alanine synthesis in muscle by serving as a source of succinyl-CoA."
3-mercaptopicolinate,3-mercaptopicolinate is an inhibitor of phosphoenolpyruvate carboxykinase.,Entity: 3-mercaptopicolinate. SMILES: O=C([O-])c1ncccc1S. 3-mercaptopicolinate is an inhibitor of phosphoenolpyruvate carboxykinase.
alanine,Alanine is a branched-chain amino acid that is preferentially catabolized in muscle.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine is a branched-chain amino acid that is preferentially catabolized in muscle.
alanine,Alanine can be formed in muscle via transamination with 2-oxoglutarate using branched-chain amino acids as substrates.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine can be formed in muscle via transamination with 2-oxoglutarate using branched-chain amino acids as substrates.
2-oxoglutarate,2-oxoglutarate serves as a substrate for transamination with branched-chain amino acids in muscle to form alanine.,Entity: 2-oxoglutarate. SMILES: O=C([O-])CCC(=O)C(=O)[O-]. 2-oxoglutarate serves as a substrate for transamination with branched-chain amino acids in muscle to form alanine.
alanine,"Alanine is formed in muscle and can serve as a source of amino nitrogen and carbon for its own synthesis, as well as for the transfer of amino acid carbon to the liver for glucose synthesis.","Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine is formed in muscle and can serve as a source of amino nitrogen and carbon for its own synthesis, as well as for the transfer of amino acid carbon to the liver for glucose synthesis."
glucose,Glucose synthesis in the liver can utilize amino acid carbon transferred from muscle via alanine release.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose synthesis in the liver can utilize amino acid carbon transferred from muscle via alanine release.
valine,"Valine can be converted into pyruvate, which is further metabolized to acetyl-CoA and can be completely oxidized to provide energy for muscle, sparing carbohydrate oxidation.","Entity: valine. SMILES: CC(C)[C@H](N)C(=O)O. Valine can be converted into pyruvate, which is further metabolized to acetyl-CoA and can be completely oxidized to provide energy for muscle, sparing carbohydrate oxidation."
isoleucine,"Isoleucine can be converted into pyruvate, which is further metabolized to acetyl-CoA and can be completely oxidized to provide energy for muscle, sparing carbohydrate oxidation.","Entity: isoleucine. SMILES: CC[C@H](C)[C@H](N)C(=O)O. Isoleucine can be converted into pyruvate, which is further metabolized to acetyl-CoA and can be completely oxidized to provide energy for muscle, sparing carbohydrate oxidation."
pyruvate,"Pyruvate, derived from valine or isoleucine, can be completely oxidized to acetyl-CoA, providing energy for muscle and sparing carbohydrate oxidation.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate, derived from valine or isoleucine, can be completely oxidized to acetyl-CoA, providing energy for muscle and sparing carbohydrate oxidation."
acetyl-CoA,"Acetyl-CoA is produced from pyruvate and can be further oxidized to provide energy for muscle, sparing carbohydrate oxidation.","Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Acetyl-CoA is produced from pyruvate and can be further oxidized to provide energy for muscle, sparing carbohydrate oxidation."
propylgallate,Propylgallate acts as an antioxidant and has been studied for its protective effects against paracetamol-induced hepatotoxicity.,Entity: propylgallate. SMILES: CCCc1c(C(=O)[O-])cc(O)c(O)c1O. Propylgallate acts as an antioxidant and has been studied for its protective effects against paracetamol-induced hepatotoxicity.
carbon tetrachloride,"Carbon tetrachloride is hepatotoxic, and its toxicity can be modified by antioxidants through mechanisms involving free-radical scavenging and prevention of lipid peroxidation.","Entity: carbon tetrachloride. SMILES: ClC(Cl)(Cl)Cl. Carbon tetrachloride is hepatotoxic, and its toxicity can be modified by antioxidants through mechanisms involving free-radical scavenging and prevention of lipid peroxidation."
paracetamol,"Paracetamol is hepatotoxic, and its toxicity can be reduced by antioxidants such as vitamin E, NN-diphenyl-p-phenylenediamine, and propylgallate, likely through mechanisms involving free-radical scavenging and prevention of lipid peroxidation.","Entity: paracetamol. SMILES: CC(=O)Nc1ccc(O)cc1. Paracetamol is hepatotoxic, and its toxicity can be reduced by antioxidants such as vitamin E, NN-diphenyl-p-phenylenediamine, and propylgallate, likely through mechanisms involving free-radical scavenging and prevention of lipid peroxidation."
citrate,"Citrate content in myocardial tissue declines during the transition from rest to increased work, indicating its role as a substrate whose availability is regulated in the citric acid cycle.","Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Citrate content in myocardial tissue declines during the transition from rest to increased work, indicating its role as a substrate whose availability is regulated in the citric acid cycle."
oxaloacetate,"Oxaloacetate accumulates during the first 30 seconds after an increase in work, suggesting that citrate synthase activity is limited by acetyl-CoA availability in this transition.","Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. Oxaloacetate accumulates during the first 30 seconds after an increase in work, suggesting that citrate synthase activity is limited by acetyl-CoA availability in this transition."
acetyl-CoA,Citrate synthase activity in the citric acid cycle is limited by acetyl-CoA availability during the transition from rest to increased work.,Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Citrate synthase activity in the citric acid cycle is limited by acetyl-CoA availability during the transition from rest to increased work.
pyruvate,Pyruvate dehydrogenase can effectively control citric acid cycle flux by regulating the availability of acetyl-CoA during the transition from rest to increased work.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate dehydrogenase can effectively control citric acid cycle flux by regulating the availability of acetyl-CoA during the transition from rest to increased work.
calcium,An elevated mitochondrial calcium content is expected under conditions of increased cardiac output and transition from rest to increased work.,Entity: calcium. SMILES: [Ca]. An elevated mitochondrial calcium content is expected under conditions of increased cardiac output and transition from rest to increased work.
Paracetamol,Paracetamol-induced liver damage is not mediated via a mechanism involving lipid peroxidation.,Entity: Paracetamol. SMILES: CC(=O)Nc1ccc(O)cc1. Paracetamol-induced liver damage is not mediated via a mechanism involving lipid peroxidation.
propylgallate,Propylgallate exhibits an inhibitory effect on the cytochrome P-450 component of mixed-function oxidase systems.,Entity: propylgallate. SMILES: CCCc1c(C(=O)[O-])cc(O)c(O)c1O. Propylgallate exhibits an inhibitory effect on the cytochrome P-450 component of mixed-function oxidase systems.
propylgallate,"Propylgallate may provide protection in biological systems due to an antioxidant effect, although this is complicated by its inhibitory action on cytochrome P-450 enzymes.","Entity: propylgallate. SMILES: CCCc1c(C(=O)[O-])cc(O)c(O)c1O. Propylgallate may provide protection in biological systems due to an antioxidant effect, although this is complicated by its inhibitory action on cytochrome P-450 enzymes."
paracetamol,The probable mechanism of inactivation of the toxic metabolite of paracetamol involves conjugation with glutathione.,Entity: paracetamol. SMILES: CC(=O)Nc1ccc(O)cc1. The probable mechanism of inactivation of the toxic metabolite of paracetamol involves conjugation with glutathione.
propylgallate,"Propylgallate pretreatment reduces plasma aspartate aminotransferase activity and mortality in rats exposed to paracetamol, indicating protection against paracetamol-induced hepatotoxicity.","Entity: propylgallate. SMILES: CCCc1c(C(=O)[O-])cc(O)c(O)c1O. Propylgallate pretreatment reduces plasma aspartate aminotransferase activity and mortality in rats exposed to paracetamol, indicating protection against paracetamol-induced hepatotoxicity."
Sodium selenite,Sodium selenite is used as a selenium supplement in animal diets at concentrations of 0.4 and 4 p.p.m. to investigate its effects on tissue and blood components in female Wistar rats.,Entity: Sodium selenite. SMILES: O=[Se]([O-])[O-].[Na+].[Na+]. Sodium selenite is used as a selenium supplement in animal diets at concentrations of 0.4 and 4 p.p.m. to investigate its effects on tissue and blood components in female Wistar rats.
Sodium chloride,Sodium chloride (0.9%) is used as a buffer in homogenization and washing procedures for tissue and blood fraction preparation in biochemical assays.,Entity: Sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride (0.9%) is used as a buffer in homogenization and washing procedures for tissue and blood fraction preparation in biochemical assays.
2-allyl-2-isopropylacetamide,"2-allyl-2-isopropylacetamide accumulates green pigments in the liver, which are composed of two novel porphyrins and four oxophlorins.","Entity: 2-allyl-2-isopropylacetamide. SMILES: C=CCC(C(N)=O)C(C)C. 2-allyl-2-isopropylacetamide accumulates green pigments in the liver, which are composed of two novel porphyrins and four oxophlorins."
trifluoroacetic acid,"Trifluoroacetic acid is used to acidify oxophlorin solutions, causing them to turn green and develop strong absorption at 71 ± 8 nm.","Entity: trifluoroacetic acid. SMILES: O=C(O)C(F)(F)F. Trifluoroacetic acid is used to acidify oxophlorin solutions, causing them to turn green and develop strong absorption at 71 ± 8 nm."
chloroform,"Chloroform is used as a solvent for porphyrin and oxophlorin pigments, where the latter appear blue with distinct absorption bands at 591 ± 4 and 638 ± 4 nm.","Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a solvent for porphyrin and oxophlorin pigments, where the latter appear blue with distinct absorption bands at 591 ± 4 and 638 ± 4 nm."
triethylamine,"Triethylamine is used to neutralize acid in oxophlorin solutions, regenerating the original spectra after acidification.","Entity: triethylamine. SMILES: CCN(CC)CC. Triethylamine is used to neutralize acid in oxophlorin solutions, regenerating the original spectra after acidification."
protoporphyrin IX dimethyl ester,Protoporphyrin IX dimethyl ester is a pigment that exhibits strongly fluorescent green bands and can be isolated from rat tissues under specific biochemical procedures.,Entity: protoporphyrin IX dimethyl ester. SMILES: C=Cc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)OC)C(CCC(=O)OC)=C4C)c(C)c3C=C. Protoporphyrin IX dimethyl ester is a pigment that exhibits strongly fluorescent green bands and can be isolated from rat tissues under specific biochemical procedures.
2-Allyl-2-isopropylacetamide,2-Allyl-2-isopropylacetamide was administered subcutaneously at 400 mg/kg in rats 24 hours after the last sodium phenobarbital injection.,Entity: 2-Allyl-2-isopropylacetamide. SMILES: C=CCC(C(N)=O)C(C)C. 2-Allyl-2-isopropylacetamide was administered subcutaneously at 400 mg/kg in rats 24 hours after the last sodium phenobarbital injection.
2-allyl-2-isopropylacetamide,Acute treatment with 2-allyl-2-isopropylacetamide in rats does not cause opening of the porphyrin ring during hepatic haem degradation.,Entity: 2-allyl-2-isopropylacetamide. SMILES: C=CCC(C(N)=O)C(C)C. Acute treatment with 2-allyl-2-isopropylacetamide in rats does not cause opening of the porphyrin ring during hepatic haem degradation.
bilirubin,"Bilirubin is a product of haem catabolism, with the iron complex of a-oxoprotophlorin IX thought to be an intermediate in its biosynthesis.","Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin is a product of haem catabolism, with the iron complex of a-oxoprotophlorin IX thought to be an intermediate in its biosynthesis."
pyridine,"Pyridine, when present in pyridine/water mixtures above 10% (v/v), increases the rate of haem degradation by activating the macrocyclic ring of haem through coordination to the iron atom.","Entity: pyridine. SMILES: c1ccncc1. Pyridine, when present in pyridine/water mixtures above 10% (v/v), increases the rate of haem degradation by activating the macrocyclic ring of haem through coordination to the iron atom."
pyridine,"Pyridine acts as a 'dimer breaker' in haem degradation, promoting the cleavage of haem dimers.","Entity: pyridine. SMILES: c1ccncc1. Pyridine acts as a 'dimer breaker' in haem degradation, promoting the cleavage of haem dimers."
benzene,"In the absence of pyridine, benzene alone is insufficient to promote haem degradation, indicating that pyridine enhances this process.","Entity: benzene. SMILES: c1ccccc1. In the absence of pyridine, benzene alone is insufficient to promote haem degradation, indicating that pyridine enhances this process."
water,"The rate of haem degradation in pyridine/water mixtures is increased compared to water alone, especially when pyridine concentration is above 10% (v/v).","Entity: water. SMILES: O. The rate of haem degradation in pyridine/water mixtures is increased compared to water alone, especially when pyridine concentration is above 10% (v/v)."
4-oxopentanoic acid,4-oxopentanoic acid protects against inactivation by iodoacetic acid.,Entity: 4-oxopentanoic acid. SMILES: CC(=O)CCC(=O)O. 4-oxopentanoic acid protects against inactivation by iodoacetic acid.
diphenyl phosphorylazide,Diphenyl phosphorylazide acts as an effective condensing agent for the synthesis of bilirubin bis-amides from bilirubin and various amines.,Entity: diphenyl phosphorylazide. SMILES: [N-]=[N+]=NP(=O)(c1ccccc1)c1ccccc1. Diphenyl phosphorylazide acts as an effective condensing agent for the synthesis of bilirubin bis-amides from bilirubin and various amines.
triethylamine,Triethylamine is used as a base in the coupling reaction for synthesizing bilirubin bis-amides with diphenyl phosphorylazide.,Entity: triethylamine. SMILES: CCN(CC)CC. Triethylamine is used as a base in the coupling reaction for synthesizing bilirubin bis-amides with diphenyl phosphorylazide.
azide,An excess of azide is required as a reagent in the coupling reaction to facilitate the synthesis of bilirubin bis-amides with diphenyl phosphorylazide.,Entity: azide. SMILES: [N-]=[N+]=[N-]. An excess of azide is required as a reagent in the coupling reaction to facilitate the synthesis of bilirubin bis-amides with diphenyl phosphorylazide.
bilirubin,Bilirubin can be converted into bis-amides by reaction with diphenyl phosphorylazide and various amines in the presence of triethylamine and excess azide.,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin can be converted into bis-amides by reaction with diphenyl phosphorylazide and various amines in the presence of triethylamine and excess azide.
Ampholine,Ampholine is used as a buffer component in sucrose density gradients to determine the isoelectric point of proteins such as hemoglobin.,Entity: Ampholine. SMILES: [Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb]. Ampholine is used as a buffer component in sucrose density gradients to determine the isoelectric point of proteins such as hemoglobin.
sucrose,"Sucrose is used as a density gradient medium in protein purification techniques, such as isoelectric focusing, to separate proteins based on their molecular weight or isoelectric point.","Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used as a density gradient medium in protein purification techniques, such as isoelectric focusing, to separate proteins based on their molecular weight or isoelectric point."
bilirubin dimethyl ester,Bilirubin dimethyl ester can be synthesized in solution in NN-dimethylformamide and incorporates 3H from tritiated water in the presence of sodium methoxide.,Entity: bilirubin dimethyl ester. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)OC)c(CCC(=O)OC)c2C)NC1=O. Bilirubin dimethyl ester can be synthesized in solution in NN-dimethylformamide and incorporates 3H from tritiated water in the presence of sodium methoxide.
O2,"O2 is bound cooperatively by Eunice haemoglobin, as indicated by sigmoidal binding curves and a Hill coefficient (h) as high as 2.6.","Entity: O2. SMILES: [O]. O2 is bound cooperatively by Eunice haemoglobin, as indicated by sigmoidal binding curves and a Hill coefficient (h) as high as 2.6."
O2,Eunice haemoglobin exhibits considerably lower O2 affinity compared to other invertebrate haemoglobins such as Arenicola cristata.,Entity: O2. SMILES: [O]. Eunice haemoglobin exhibits considerably lower O2 affinity compared to other invertebrate haemoglobins such as Arenicola cristata.
Tris/HCl,Tris/HCl buffer at 0.1 M and pH 8.0 is used to dissolve purified Eunice haemoglobin for sedimentation-equilibrium experiments.,Entity: Tris/HCl. SMILES: NC(CO)(CO)CO. Tris/HCl buffer at 0.1 M and pH 8.0 is used to dissolve purified Eunice haemoglobin for sedimentation-equilibrium experiments.
MgCl2,MgCl2 at 10 mM in 6.8 phosphate buffer is used to stabilize Eunice haemoglobin during sedimentation-velocity experiments.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 at 10 mM in 6.8 phosphate buffer is used to stabilize Eunice haemoglobin during sedimentation-velocity experiments.
fucose,"Fucose is a sugar residue present in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis.","Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose is a sugar residue present in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis."
mannose,"Mannose is a sugar residue found in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis.","Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose is a sugar residue found in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis."
galactose,"Galactose is a sugar residue present in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis.","Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose is a sugar residue present in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis."
glucose,"Glucose is a sugar residue found in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is a sugar residue found in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis."
N-acetylglucosamine,"N-acetylglucosamine is a sugar residue present in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis.","Entity: N-acetylglucosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. N-acetylglucosamine is a sugar residue present in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis."
N-acetylgalactosamine,"N-acetylgalactosamine is a sugar residue found in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis.","Entity: N-acetylgalactosamine. SMILES: CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. N-acetylgalactosamine is a sugar residue found in the marine prosobranch haemocyanins B. undatum, N. antiqua, and C. gracilis."
xylose,"Xylose is a sugar residue present in pulmonate-snail haemocyanins, in addition to the sugars found in marine prosobranch haemocyanins.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose is a sugar residue present in pulmonate-snail haemocyanins, in addition to the sugars found in marine prosobranch haemocyanins."
glucose,Both L. stagnalis and H. pomatia haemocyanins have somewhat lower glucose contents than the whelk haemocyanins.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Both L. stagnalis and H. pomatia haemocyanins have somewhat lower glucose contents than the whelk haemocyanins.
mannose,L. stagnalis haemocyanin is especially low in mannose content compared with other haemocyanins.,Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. L. stagnalis haemocyanin is especially low in mannose content compared with other haemocyanins.
sodium acetate,Sodium acetate is used as a buffer at 0.1 M concentration and pH 5.7 for storing haemocyanins in solution.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate is used as a buffer at 0.1 M concentration and pH 5.7 for storing haemocyanins in solution.
carbon monoxide,Carbon monoxide is used as a storage medium at 4°C for preserving haemocyanins in solution.,Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide is used as a storage medium at 4°C for preserving haemocyanins in solution.
sodium azide,Sodium azide is included at 0.01% (w/v) in the buffer solution for storing haemocyanins to prevent microbial growth.,Entity: sodium azide. SMILES: [N-]=[N+]=[N-].[Na+]. Sodium azide is included at 0.01% (w/v) in the buffer solution for storing haemocyanins to prevent microbial growth.
Cysteic acid,Cysteine is measured as cysteic acid in performic acid-oxidized samples using the Leggett Bailey (1962) method.,Entity: Cysteic acid. SMILES: N[C@@H](CS(=O)(=O)O)C(=O)O. Cysteine is measured as cysteic acid in performic acid-oxidized samples using the Leggett Bailey (1962) method.
Performic acid,Performic acid is used to oxidize cysteine in samples prior to its measurement as cysteic acid in amino acid analysis.,Entity: Performic acid. SMILES: O=COO. Performic acid is used to oxidize cysteine in samples prior to its measurement as cysteic acid in amino acid analysis.
Mannitol,Mannitol is used as an internal standard in the preparation of methylglycosides from gastropod haemocyanins.,Entity: Mannitol. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannitol is used as an internal standard in the preparation of methylglycosides from gastropod haemocyanins.
Trimethylchlorosilane,Trimethylchlorosilane is a component of the trimethylsilyl reagent (in a 5:1:1 ratio with pyridine and hexamethyldisilazane) used for derivatization of methylglycosides prior to gas chromatography.,Entity: Trimethylchlorosilane. SMILES: C[Si](C)(C)Cl. Trimethylchlorosilane is a component of the trimethylsilyl reagent (in a 5:1:1 ratio with pyridine and hexamethyldisilazane) used for derivatization of methylglycosides prior to gas chromatography.
Hexamethyldisilazane,Hexamethyldisilazane is a component of the trimethylsilyl reagent (in a 5:1:1 ratio with pyridine and trimethylchlorosilane) used for derivatization of methylglycosides prior to gas chromatography.,Entity: Hexamethyldisilazane. SMILES: C[Si](C)(C)N[Si](C)(C)C. Hexamethyldisilazane is a component of the trimethylsilyl reagent (in a 5:1:1 ratio with pyridine and trimethylchlorosilane) used for derivatization of methylglycosides prior to gas chromatography.
He,He is used as the carrier gas at a flow rate of 5 ml/min in gas chromatography analysis of methylglycosides.,Entity: He. SMILES: [He]. He is used as the carrier gas at a flow rate of 5 ml/min in gas chromatography analysis of methylglycosides.
Tryptophan,Tryptophan is determined by the method of Spies & Chambers (1949) in amino acid analysis.,Entity: Tryptophan. SMILES: N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O. Tryptophan is determined by the method of Spies & Chambers (1949) in amino acid analysis.
concanavalin A,"Concanavalin A binds to all haemocyanins except L. stagnulis, indicating differences in sugar content or arrangement on the protein surface.","Entity: concanavalin A. SMILES: CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1.Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O. Concanavalin A binds to all haemocyanins except L. stagnulis, indicating differences in sugar content or arrangement on the protein surface."
L-aspartate,L-aspartate stimulates brain respiration by oxidation and is a neuroexcitant that is actively taken up into tissue.,Entity: L-aspartate. SMILES: N[C@@H](CC(=O)[O-])C(=O)[O-]. L-aspartate stimulates brain respiration by oxidation and is a neuroexcitant that is actively taken up into tissue.
D-glutamate,D-glutamate stimulates glycolysis by increasing glycolytic enzyme activities through changes in ATP concentrations.,Entity: D-glutamate. SMILES: N[C@H](CCC(=O)[O-])C(=O)[O-]. D-glutamate stimulates glycolysis by increasing glycolytic enzyme activities through changes in ATP concentrations.
L-glutamate,"L-glutamate stimulates brain respiration and glycolysis, with its effects attributed to oxidation of the amino acid.","Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate stimulates brain respiration and glycolysis, with its effects attributed to oxidation of the amino acid."
L-glutamate,L-glutamate is a neuroexcitant and is actively taken up into tissue.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate is a neuroexcitant and is actively taken up into tissue.
D-homocysteate,D-homocysteate does not affect lactate production despite being a stronger excitant than L-glutamate.,Entity: D-homocysteate. SMILES: N[C@H](CCS(=O)(=O)O)C(=O)[O-]. D-homocysteate does not affect lactate production despite being a stronger excitant than L-glutamate.
L-glutamate,L-glutamate stimulates glycolysis but does not affect lactate production.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate stimulates glycolysis but does not affect lactate production.
D-glutamate,D-glutamate stimulates glycolysis but does not affect lactate production.,Entity: D-glutamate. SMILES: N[C@H](CCC(=O)[O-])C(=O)[O-]. D-glutamate stimulates glycolysis but does not affect lactate production.
L-homocysteate,L-homocysteate stimulates glycolysis but does not affect lactate production.,Entity: L-homocysteate. SMILES: N[C@@H](CCS(=O)(=O)O)C(=O)[O-]. L-homocysteate stimulates glycolysis but does not affect lactate production.
L-glutamate,"L-glutamate is actively transported and is neuroexcitatory, and is likely to be metabolized.","Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate is actively transported and is neuroexcitatory, and is likely to be metabolized."
D-homocysteate,D-homocysteate is neuroexcitatory but is probably not actively transported.,Entity: D-homocysteate. SMILES: N[C@H](CCS(=O)(=O)O)C(=O)[O-]. D-homocysteate is neuroexcitatory but is probably not actively transported.
L-homocysteate,L-homocysteate is actively transported and is neuroexcitatory.,Entity: L-homocysteate. SMILES: N[C@@H](CCS(=O)(=O)O)C(=O)[O-]. L-homocysteate is actively transported and is neuroexcitatory.
lactate,Lactate production in rat brain slices can be measured in the incubation medium by a specific assay method.,Entity: lactate. SMILES: CC(O)C(=O)[O-]. Lactate production in rat brain slices can be measured in the incubation medium by a specific assay method.
L-glutamate,"L-glutamate stimulates lactate production and O2 uptake in brain slices, with the effect likely due to energy requirements of active uptake and ionic pump activation by neuronal depolarization rather than amino acid metabolism.","Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate stimulates lactate production and O2 uptake in brain slices, with the effect likely due to energy requirements of active uptake and ionic pump activation by neuronal depolarization rather than amino acid metabolism."
L-glutamate,L-glutamate stimulates lactate production and oxygen uptake in tissue slices when administered as a sodium salt at pH 7.4.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate stimulates lactate production and oxygen uptake in tissue slices when administered as a sodium salt at pH 7.4.
calcium,Calcium concentrations in the metabolic media used for tissue slice experiments were 0.75 mM and 2.8 mM.,Entity: calcium. SMILES: [Ca]. Calcium concentrations in the metabolic media used for tissue slice experiments were 0.75 mM and 2.8 mM.
lactate,Lactate production in tissue slices can be measured during a 10-minute incubation following a 40-minute preincubation.,Entity: lactate. SMILES: CC(O)C(=O)[O-]. Lactate production in tissue slices can be measured during a 10-minute incubation following a 40-minute preincubation.
oxygen,Oxygen uptake in tissue slices can be measured manometrically during an incubation period.,Entity: oxygen. SMILES: [O]. Oxygen uptake in tissue slices can be measured manometrically during an incubation period.
4-aminobutyrate,"4-aminobutyrate is produced by neurons in the dorsal cochlear nucleus, and the recurrent bundle of Lorente de NO does not contribute to this production.","Entity: 4-aminobutyrate. SMILES: NCCCC(=O)O. 4-aminobutyrate is produced by neurons in the dorsal cochlear nucleus, and the recurrent bundle of Lorente de NO does not contribute to this production."
glutamate,"Glutamate decarboxylase activity in the dorsal cochlear nucleus is minimally affected by lesions in the trapezoid body, indicating that most fibers ascending the eighth nerve do not contribute to its content.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate decarboxylase activity in the dorsal cochlear nucleus is minimally affected by lesions in the trapezoid body, indicating that most fibers ascending the eighth nerve do not contribute to its content."
Nembutal,Nembutal is used as an anesthetic agent during surgical procedures such as decochleation in animal studies.,Entity: Nembutal. SMILES: CCCC(C)C1(CC)C(=O)NC(=O)NC1=O. Nembutal is used as an anesthetic agent during surgical procedures such as decochleation in animal studies.
4-aminobutyrate,"4-aminobutyrate concentration is approximately 30% of the levels found in the inferior colliculus and cerebral cortex, and 4-aminobutyrate aminotransferase activity is enriched in the dorsal cochlear nucleus in guinea-pig, rat, and cat.","Entity: 4-aminobutyrate. SMILES: NCCCC(=O)O. 4-aminobutyrate concentration is approximately 30% of the levels found in the inferior colliculus and cerebral cortex, and 4-aminobutyrate aminotransferase activity is enriched in the dorsal cochlear nucleus in guinea-pig, rat, and cat."
4-aminobutyrate,A significant amount of 4-aminobutyrate is produced in the cell bodies of neurons within the dorsal and ventral cochlear nuclei.,Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. A significant amount of 4-aminobutyrate is produced in the cell bodies of neurons within the dorsal and ventral cochlear nuclei.
glutamate,"Glutamate decarboxylase activity is present in both dorsal and ventral cochlear nuclei, with similar proportions recovered in soluble fractions from both divisions.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate decarboxylase activity is present in both dorsal and ventral cochlear nuclei, with similar proportions recovered in soluble fractions from both divisions."
4-aminobutyrate,"4-aminobutyrate is produced by neurons in discrete areas of the mammalian central nervous system, including the lateral vestibular nucleus, hippocampus, and substantia nigra.","Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. 4-aminobutyrate is produced by neurons in discrete areas of the mammalian central nervous system, including the lateral vestibular nucleus, hippocampus, and substantia nigra."
4-aminobutyrate,4-aminobutyrate can decrease the spontaneous discharge of neurons in the mammalian cochlear nucleus when applied iontophoretically.,Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. 4-aminobutyrate can decrease the spontaneous discharge of neurons in the mammalian cochlear nucleus when applied iontophoretically.
4-aminobutyrate,4-aminobutyrate is implicated in an intranuclear pathway involving 4-aminobutyrate-producing neurons in the dorsal cochlear nucleus.,Entity: 4-aminobutyrate. SMILES: NCCCC(=O)O. 4-aminobutyrate is implicated in an intranuclear pathway involving 4-aminobutyrate-producing neurons in the dorsal cochlear nucleus.
sodium phosphate,Sodium phosphate buffer at 10 mM concentration and pH 6.8 is used for homogenizing brain tissue samples prior to enzyme determinations.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate buffer at 10 mM concentration and pH 6.8 is used for homogenizing brain tissue samples prior to enzyme determinations.
ethanol,75% (v/v) ethanol is used for homogenizing brain tissue samples to extract 4-aminobutyrate.,Entity: ethanol. SMILES: CCO. 75% (v/v) ethanol is used for homogenizing brain tissue samples to extract 4-aminobutyrate.
4-aminobutyrate,4-aminobutyrate concentrations in brain tissue can be measured using a modification of the method described by Graham & Aprison (1966).,Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. 4-aminobutyrate concentrations in brain tissue can be measured using a modification of the method described by Graham & Aprison (1966).
palmitoyl-CoA,"Palmitoyl-CoA is a substrate for long-chain fatty acyl-CoA hydrolase, with the enzyme exhibiting a Km of 1.4 × 10⁻⁶ M for palmitoyl-CoA hydrolysis in rat cerebral cortex.","Entity: palmitoyl-CoA. SMILES: CCCCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Palmitoyl-CoA is a substrate for long-chain fatty acyl-CoA hydrolase, with the enzyme exhibiting a Km of 1.4 × 10⁻⁶ M for palmitoyl-CoA hydrolysis in rat cerebral cortex."
oleoyl-CoA,Long-chain fatty acyl-CoA hydrolase in rat cerebral cortex has a Km of 1.4 × 10⁻⁶ M for oleoyl-CoA hydrolysis.,Entity: oleoyl-CoA. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Long-chain fatty acyl-CoA hydrolase in rat cerebral cortex has a Km of 1.4 × 10⁻⁶ M for oleoyl-CoA hydrolysis.
palmitic acid,Palmitic acid at concentrations up to 100 µM does not affect the hydrolysis of palmitoyl-CoA by long-chain fatty acyl-CoA hydrolase in rat cerebral cortex.,Entity: palmitic acid. SMILES: CCCCCCCCCCCCCCCC(=O)O. Palmitic acid at concentrations up to 100 µM does not affect the hydrolysis of palmitoyl-CoA by long-chain fatty acyl-CoA hydrolase in rat cerebral cortex.
diethyl ether,Diethyl ether is used at -20°C to precipitate total proteolipids from total lipid extracts.,Entity: diethyl ether. SMILES: CCOCC. Diethyl ether is used at -20°C to precipitate total proteolipids from total lipid extracts.
diazomethane,"Diazomethane is used to methylate unesterified fatty acids in proteolipid preparations, facilitating their analysis by gas chromatography.","Entity: diazomethane. SMILES: C=[N+]=[N-]. Diazomethane is used to methylate unesterified fatty acids in proteolipid preparations, facilitating their analysis by gas chromatography."
chloroform,Chloroform is used as an equilibrating solvent for Sephadex LH20 columns in the fractionation of proteolipids.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as an equilibrating solvent for Sephadex LH20 columns in the fractionation of proteolipids.
methanol,Methanol is used in a 2:1 (v/v) mixture with chloroform to prepare total lipid extracts from excised cerebral cortex.,Entity: methanol. SMILES: CO. Methanol is used in a 2:1 (v/v) mixture with chloroform to prepare total lipid extracts from excised cerebral cortex.
acetone,Acetone is used to extract proteolipid preparations prior to methylation with diazomethane for fatty acid analysis.,Entity: acetone. SMILES: CC(C)=O. Acetone is used to extract proteolipid preparations prior to methylation with diazomethane for fatty acid analysis.
diazomethane,Diazomethane is used for direct methylation of lipid extracts to facilitate the analysis of fatty acid incorporation in proteolipid fractions.,Entity: diazomethane. SMILES: C=[N+]=[N-]. Diazomethane is used for direct methylation of lipid extracts to facilitate the analysis of fatty acid incorporation in proteolipid fractions.
acetone,Acetone is used to extract unesterified fatty acids from proteolipid fractions prior to methylation in lipid labeling studies.,Entity: acetone. SMILES: CC(C)=O. Acetone is used to extract unesterified fatty acids from proteolipid fractions prior to methylation in lipid labeling studies.
acetate,"Acetate, when administered intraventricularly to rats, is incorporated into unesterified fatty acids of the cerebral cortex, as measured by radioactivity (d.p.m./mg fatty acid) in proteolipid fractions.","Entity: acetate. SMILES: CC(=O)[O-]. Acetate, when administered intraventricularly to rats, is incorporated into unesterified fatty acids of the cerebral cortex, as measured by radioactivity (d.p.m./mg fatty acid) in proteolipid fractions."
diethyl ether,"Diethyl ether is used to precipitate total lipids from rat cerebral cortex, enabling the preparation of proteolipid fractions for further analysis.","Entity: diethyl ether. SMILES: CCOCC. Diethyl ether is used to precipitate total lipids from rat cerebral cortex, enabling the preparation of proteolipid fractions for further analysis."
palmitate,Radioactively labelled palmitate injected intraventricularly does not exchange with proteolipid-bound unesterified fatty acid during a 20-minute period in vivo.,Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Radioactively labelled palmitate injected intraventricularly does not exchange with proteolipid-bound unesterified fatty acid during a 20-minute period in vivo.
acetate,Little measurable incorporation of acetate into the proteolipid-bound unesterified fatty acid pool occurs during the first 12 hours after injection in vivo.,Entity: acetate. SMILES: CC(=O)[O-]. Little measurable incorporation of acetate into the proteolipid-bound unesterified fatty acid pool occurs during the first 12 hours after injection in vivo.
oleic acid,"The turnover time for intracerebroally injected oleic acid is about 5 minutes, consistent with previously reported values.","Entity: oleic acid. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)O. The turnover time for intracerebroally injected oleic acid is about 5 minutes, consistent with previously reported values."
arachidonic acid,"The turnover time for intracerebroally injected arachidonic acid is about 5 minutes, consistent with previously reported values.","Entity: arachidonic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. The turnover time for intracerebroally injected arachidonic acid is about 5 minutes, consistent with previously reported values."
acetone,Acetone is used to extract proteolipid preparations prior to methylation with diazomethane for fatty acid analysis.,Entity: acetone. SMILES: CC(C)=O. Acetone is used to extract proteolipid preparations prior to methylation with diazomethane for fatty acid analysis.
methanol,Methanol is used as a component (in a 1:2 v/v ratio with chloroform) of the solvent mixture for preparing total lipid extracts from excised cerebral cortex.,Entity: methanol. SMILES: CO. Methanol is used as a component (in a 1:2 v/v ratio with chloroform) of the solvent mixture for preparing total lipid extracts from excised cerebral cortex.
diethyl ether,Diethyl ether is used to precipitate total proteolipids from total lipid extracts by mixing with the lipid extract at -20°C.,Entity: diethyl ether. SMILES: CCOCC. Diethyl ether is used to precipitate total proteolipids from total lipid extracts by mixing with the lipid extract at -20°C.
diazomethane,"Diazomethane is used to methylate fatty acids in proteolipid preparations, enabling their analysis as methyl esters for quantification.","Entity: diazomethane. SMILES: C=[N+]=[N-]. Diazomethane is used to methylate fatty acids in proteolipid preparations, enabling their analysis as methyl esters for quantification."
chloroform,Chloroform is used as a solvent for preparing total lipid extracts and for equilibrating Sephadex LH20 chromatography columns in proteolipid fractionation.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a solvent for preparing total lipid extracts and for equilibrating Sephadex LH20 chromatography columns in proteolipid fractionation.
sucrose,Sucrose is used to stabilize pH gradients in chromatography columns for protein separation.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used to stabilize pH gradients in chromatography columns for protein separation.
Congo Red,Congo Red is used as a dye in modified substrate assays to detect elastase activity in protein purification protocols.,Entity: Congo Red. SMILES: Nc1c(N=Nc2ccc(-c3ccc(N=Nc4cc(S(=O)(=O)[O-])c5ccccc5c4N)cc3)cc2)cc(S(=O)(=O)[O-])c2ccccc12.[Na+].[Na+]. Congo Red is used as a dye in modified substrate assays to detect elastase activity in protein purification protocols.
Triton X-100,Triton X-100 is a detergent that can be removed from purified enzyme samples by dialysis against sodium phosphate buffer.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a detergent that can be removed from purified enzyme samples by dialysis against sodium phosphate buffer.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used as a denaturing agent in SDS/polyacrylamide-gel electrophoresis (SDS-PAGE) to resolve peptides.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used as a denaturing agent in SDS/polyacrylamide-gel electrophoresis (SDS-PAGE) to resolve peptides.
2-mercaptoethanol,2-mercaptoethanol is used as a reducing agent in protein purification buffers to maintain protein integrity.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is used as a reducing agent in protein purification buffers to maintain protein integrity.
tyramine,Tyramine is the common substrate for monoamine oxidases A and B.,Entity: tyramine. SMILES: NCCc1ccc(O)cc1. Tyramine is the common substrate for monoamine oxidases A and B.
KCl,KCl is used at approximately M concentration in elution buffers to elute bound proteins from affinity matrices.,Entity: KCl. SMILES: [Cl-].[K+]. KCl is used at approximately M concentration in elution buffers to elute bound proteins from affinity matrices.
potassium phosphate,Potassium phosphate buffer at 100 mM and pH 7.4 is used as the primary buffer in affinity matrix equilibration and elution procedures.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate buffer at 100 mM and pH 7.4 is used as the primary buffer in affinity matrix equilibration and elution procedures.
Triton X-100,Triton X-100 is used as a detergent at 1.5% (v/v) concentration in buffer to solubilize mitochondrial membranes for affinity matrix studies.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used as a detergent at 1.5% (v/v) concentration in buffer to solubilize mitochondrial membranes for affinity matrix studies.
tyramine,"Tyramine is used as a counter-ion in elution buffers to elute bound proteins from affinity matrices, such as in the elution of monoamine oxidase from aminohexyl-Sepharose.","Entity: tyramine. SMILES: NCCc1ccc(O)cc1. Tyramine is used as a counter-ion in elution buffers to elute bound proteins from affinity matrices, such as in the elution of monoamine oxidase from aminohexyl-Sepharose."
butyltyramine,"Butyltyramine-Sepharose can bind monoamine oxidase, and using a linear gradient of 10–100 mM potassium phosphate, it enables purification of monoamine oxidase 20-fold with 50% yield, though 34% of the enzyme remains in the void volume.","Entity: butyltyramine. SMILES: CCCCNCCc1ccc(O)cc1. Butyltyramine-Sepharose can bind monoamine oxidase, and using a linear gradient of 10–100 mM potassium phosphate, it enables purification of monoamine oxidase 20-fold with 50% yield, though 34% of the enzyme remains in the void volume."
hexyltyramine,Increasing amounts of monoamine oxidase bind to hexyltyramine-Sepharose columns as potassium phosphate concentration decreases.,Entity: hexyltyramine. SMILES: CCCCCCNCCc1ccc(O)cc1. Increasing amounts of monoamine oxidase bind to hexyltyramine-Sepharose columns as potassium phosphate concentration decreases.
ethyltyramine,Ethyltyramine-Sepharose does not bind monoamine oxidase under conditions where alkyltyramine-Sepharose does.,Entity: ethyltyramine. SMILES: CCNCCc1ccc(O)cc1. Ethyltyramine-Sepharose does not bind monoamine oxidase under conditions where alkyltyramine-Sepharose does.
KCl,"A KCl gradient (0–100 mM) can be used to elute monoamine oxidase from butyltyramine-Sepharose columns, and washing columns with KCl between uses helps remove tightly bound protein.","Entity: KCl. SMILES: [Cl-].[K+]. A KCl gradient (0–100 mM) can be used to elute monoamine oxidase from butyltyramine-Sepharose columns, and washing columns with KCl between uses helps remove tightly bound protein."
glycerol,Glycerol is used as a component of the equilibration buffer (20% v/v) in chromatography to modify non-covalent interactions between proteins and columns.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is used as a component of the equilibration buffer (20% v/v) in chromatography to modify non-covalent interactions between proteins and columns.
Triton X-100,"Triton X-100 at 1.5% (v/v) in 100 mM potassium phosphate buffer, pH 7.4, is used to equilibrate alkyltyramine-Sepharose columns and abolish binding of monoamine oxidase.","Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 at 1.5% (v/v) in 100 mM potassium phosphate buffer, pH 7.4, is used to equilibrate alkyltyramine-Sepharose columns and abolish binding of monoamine oxidase."
potassium phosphate,"Potassium phosphate buffer is used to control ionic strength and pH in chromatography, with binding of monoamine oxidase to Sepharose matrices depending on its concentration (10 mM vs. 100 mM).","Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate buffer is used to control ionic strength and pH in chromatography, with binding of monoamine oxidase to Sepharose matrices depending on its concentration (10 mM vs. 100 mM)."
propyltyramine,Increasing amounts of monoamine oxidase bind to propyltyramine-Sepharose columns as potassium phosphate concentration decreases.,Entity: propyltyramine. SMILES: CCCNCCc1ccc(O)cc1. Increasing amounts of monoamine oxidase bind to propyltyramine-Sepharose columns as potassium phosphate concentration decreases.
propyltyramine,"Propyltyramine, when bound to Sepharose, forms a strong affinity matrix for monoamine oxidase in 100 mM potassium phosphate buffer at pH 7.4 with 1.5% (v/v) Triton X-100.","Entity: propyltyramine. SMILES: CCCNCCc1ccc(O)cc1. Propyltyramine, when bound to Sepharose, forms a strong affinity matrix for monoamine oxidase in 100 mM potassium phosphate buffer at pH 7.4 with 1.5% (v/v) Triton X-100."
butyltyramine,"Butyltyramine, when bound to Sepharose, forms a strong affinity matrix for monoamine oxidase in 100 mM potassium phosphate buffer at pH 7.4 with 1.5% (v/v) Triton X-100.","Entity: butyltyramine. SMILES: CCCCNCCc1ccc(O)cc1. Butyltyramine, when bound to Sepharose, forms a strong affinity matrix for monoamine oxidase in 100 mM potassium phosphate buffer at pH 7.4 with 1.5% (v/v) Triton X-100."
ethyltyramine,"Ethyltyramine, when bound to Sepharose, does not bind monoamine oxidase in the described buffer system.","Entity: ethyltyramine. SMILES: CCNCCc1ccc(O)cc1. Ethyltyramine, when bound to Sepharose, does not bind monoamine oxidase in the described buffer system."
Triton X-100,Triton X-100 at 1.5% (v/v) is used as a detergent in the binding buffer for affinity chromatography with monoamine oxidase and its analogs.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 at 1.5% (v/v) is used as a detergent in the binding buffer for affinity chromatography with monoamine oxidase and its analogs.
potassium phosphate,Potassium phosphate buffer at 100 mM and pH 7.4 is used as the buffer system for affinity chromatography of monoamine oxidase.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate buffer at 100 mM and pH 7.4 is used as the buffer system for affinity chromatography of monoamine oxidase.
Glycerol,Glycerol has been studied for its effect on the binding of monoamine oxidase in Triton X-100 extracts of rat liver mitochondria.,Entity: Glycerol. SMILES: OCC(O)CO. Glycerol has been studied for its effect on the binding of monoamine oxidase in Triton X-100 extracts of rat liver mitochondria.
Tyramine,"Tyramine, when used as a ligand in diazonium-coupled affinity columns, has been studied for its ability to bind proteins such as monoamine oxidase in mitochondrial extracts.","Entity: Tyramine. SMILES: NCCc1ccc(O)cc1. Tyramine, when used as a ligand in diazonium-coupled affinity columns, has been studied for its ability to bind proteins such as monoamine oxidase in mitochondrial extracts."
Triton X-100,Triton X-100 is used as a detergent to solubilize mitochondrial extracts for the study of monoamine oxidase binding in affinity columns.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used as a detergent to solubilize mitochondrial extracts for the study of monoamine oxidase binding in affinity columns.
potassium phosphate,Potassium phosphate is used as a buffer at 10 mM concentration and pH 6.8 in chromatographic purification protocols for cytochrome oxidase.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate is used as a buffer at 10 mM concentration and pH 6.8 in chromatographic purification protocols for cytochrome oxidase.
Triton X-100,Triton X-100 is used at 1% (w/v) concentration as a detergent in buffer systems for the elution of cytochrome oxidase from affinity columns.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used at 1% (w/v) concentration as a detergent in buffer systems for the elution of cytochrome oxidase from affinity columns.
ninhydrin,Ninhydrin is used to detect the presence of free amino groups in peptides by forming a colorimetric product upon reaction with amino acids.,Entity: ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is used to detect the presence of free amino groups in peptides by forming a colorimetric product upon reaction with amino acids.
hydrochloric acid,"Hydrochloric acid (6 M) is used to hydrolyze peptides, enabling the identification of their amino acid composition after enzymatic cleavage.","Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (6 M) is used to hydrolyze peptides, enabling the identification of their amino acid composition after enzymatic cleavage."
diisopropyl phosphorofluoridate,"Diisopropyl phosphorofluoridate at 0.1 mM inhibits the activity of dipeptidyl peptidase IV in the hydrolysis of Z-Gly-Pro-Leu-Gly-Pro and Z-Gly-Pro-Gly-Gly-Pro-Ala substrates, indicating its role as an inhibitor.","Entity: diisopropyl phosphorofluoridate. SMILES: CC(C)OP(=O)(F)OC(C)C. Diisopropyl phosphorofluoridate at 0.1 mM inhibits the activity of dipeptidyl peptidase IV in the hydrolysis of Z-Gly-Pro-Leu-Gly-Pro and Z-Gly-Pro-Gly-Gly-Pro-Ala substrates, indicating its role as an inhibitor."
oxaloacetate,Oxaloacetate is formed from phosphoenolpyruvate by phosphoenolpyruvate carboxykinase during anaerobic glucose catabolism in M. edulis.,Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. Oxaloacetate is formed from phosphoenolpyruvate by phosphoenolpyruvate carboxykinase during anaerobic glucose catabolism in M. edulis.
malate,"Malate is produced in the cytoplasm of M. edulis by reversal of malate dehydrogenase, involving reoxidation of NADH to NAD+ during anaerobic metabolism.","Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate is produced in the cytoplasm of M. edulis by reversal of malate dehydrogenase, involving reoxidation of NADH to NAD+ during anaerobic metabolism."
malate,Malate can be converted partly into succinate by reversal of part of the tricarboxylic acid cycle and partly into α-ketoglutarate via α-oxoglutarate through the normal tricarboxylic acid cycle in M. edulis.,Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate can be converted partly into succinate by reversal of part of the tricarboxylic acid cycle and partly into α-ketoglutarate via α-oxoglutarate through the normal tricarboxylic acid cycle in M. edulis.
alanine,Alanine is a major end product of anaerobic glucose catabolism in marine bivalves.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Alanine is a major end product of anaerobic glucose catabolism in marine bivalves.
succinate,Succinate is a major end product of anaerobic glucose catabolism in marine bivalves.,Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate is a major end product of anaerobic glucose catabolism in marine bivalves.
glutamate,Glutamate is produced from malate via α-oxoglutarate through the normal tricarboxylic acid cycle during anaerobic metabolism in M. edulis.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate is produced from malate via α-oxoglutarate through the normal tricarboxylic acid cycle during anaerobic metabolism in M. edulis.
α-ketoglutarate,Glutamate is formed from malate via α-oxoglutarate through the normal tricarboxylic acid cycle during anaerobic metabolism in M. edulis.,Entity: α-ketoglutarate. SMILES: O=C([O-])CCC(=O)C(=O)[O-]. Glutamate is formed from malate via α-oxoglutarate through the normal tricarboxylic acid cycle during anaerobic metabolism in M. edulis.
glucose,"Glucose is converted into phosphoenolpyruvate via the Embden-Meyerhof glycolytic pathway, serving as the branchpoint for anaerobic metabolism in marine bivalves.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is converted into phosphoenolpyruvate via the Embden-Meyerhof glycolytic pathway, serving as the branchpoint for anaerobic metabolism in marine bivalves."
phosphoenolpyruvate,"Phosphoenolpyruvate, produced from glucose, is carboxylated to oxaloacetate by phosphoenolpyruvate carboxykinase under anaerobic conditions in M. edulis.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate, produced from glucose, is carboxylated to oxaloacetate by phosphoenolpyruvate carboxykinase under anaerobic conditions in M. edulis."
succinate,"Succinate accumulates in substantial amounts in muscle, mantle, and hepatopancreas tissues under both anaerobiosis and exposure conditions.","Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate accumulates in substantial amounts in muscle, mantle, and hepatopancreas tissues under both anaerobiosis and exposure conditions."
alanine,"High incorporation of radioactive isotope into alanine from glucose, but low incorporation from carbonate and glutamate, is observed in muscle, mantle, and hepatopancreas under anaerobic conditions.","Entity: alanine. SMILES: C[C@H](N)C(=O)O. High incorporation of radioactive isotope into alanine from glucose, but low incorporation from carbonate and glutamate, is observed in muscle, mantle, and hepatopancreas under anaerobic conditions."
pyruvate,"Pyruvate is formed mainly by the action of pyruvate kinase in muscle, mantle, and hepatopancreas under anaerobic conditions.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is formed mainly by the action of pyruvate kinase in muscle, mantle, and hepatopancreas under anaerobic conditions."
glucose,"Glucose serves as a primary substrate for high incorporation of radioactive isotope into alanine in muscle, mantle, and hepatopancreas under anaerobic conditions.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose serves as a primary substrate for high incorporation of radioactive isotope into alanine in muscle, mantle, and hepatopancreas under anaerobic conditions."
carbonate,"Carbonate as a substrate results in low incorporation of radioactive isotope into alanine in muscle, mantle, and hepatopancreas under anaerobic conditions.","Entity: carbonate. SMILES: O=C([O-])[O-]. Carbonate as a substrate results in low incorporation of radioactive isotope into alanine in muscle, mantle, and hepatopancreas under anaerobic conditions."
glutamate,"Glutamate as a substrate leads to low incorporation of radioactive isotope into alanine in muscle, mantle, and hepatopancreas under anaerobic conditions.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)O)C(=O)O. Glutamate as a substrate leads to low incorporation of radioactive isotope into alanine in muscle, mantle, and hepatopancreas under anaerobic conditions."
oxygen,Decreasing oxygen tension is one environmental factor that can affect the distribution of utilized radioactive isotopes in animal tissues.,Entity: oxygen. SMILES: [O]. Decreasing oxygen tension is one environmental factor that can affect the distribution of utilized radioactive isotopes in animal tissues.
succinate,"Succinate does not accumulate in substantial amounts in the gills under submersed anaerobic conditions, but more of the radioactive isotope from glucose or glutamic acid appears in the succinate fraction upon exposure to air.","Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate does not accumulate in substantial amounts in the gills under submersed anaerobic conditions, but more of the radioactive isotope from glucose or glutamic acid appears in the succinate fraction upon exposure to air."
glutamic acid,The incorporation of the radioactive isotope from glutamic acid into other soluble intermediates decreases on exposure compared with submersed anaerobic conditions in animals.,Entity: glutamic acid. SMILES: N[C@@H](CCC(=O)O)C(=O)O. The incorporation of the radioactive isotope from glutamic acid into other soluble intermediates decreases on exposure compared with submersed anaerobic conditions in animals.
glucose,The incorporation of the radioactive isotope from glucose into other soluble intermediates increases on exposure compared with submersed anaerobic conditions in animals.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. The incorporation of the radioactive isotope from glucose into other soluble intermediates increases on exposure compared with submersed anaerobic conditions in animals.
glutamate,"Glutamate incorporation of radioactive isotope decreases with glucose as substrate under anaerobic conditions, consistent with reduced tricarboxylic acid cycle activity.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate incorporation of radioactive isotope decreases with glucose as substrate under anaerobic conditions, consistent with reduced tricarboxylic acid cycle activity."
aspartate,"Aspartate incorporation of radioactive isotope decreases with glucose as substrate under anaerobic conditions, consistent with reduced tricarboxylic acid cycle activity.","Entity: aspartate. SMILES: N[C@@H](CC(=O)[O-])C(=O)[O-]. Aspartate incorporation of radioactive isotope decreases with glucose as substrate under anaerobic conditions, consistent with reduced tricarboxylic acid cycle activity."
pyruvate,Pyruvate pools become enriched in radioactive isotope due to increased incorporation from oxaloacetate under anaerobic conditions.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate pools become enriched in radioactive isotope due to increased incorporation from oxaloacetate under anaerobic conditions.
carbonate,"Under anaerobic conditions, the incorporation of radioactive isotope from carbonate into tissues increases markedly, consistent with decreased tricarboxylic acid cycle operation.","Entity: carbonate. SMILES: O=C([O-])[O-]. Under anaerobic conditions, the incorporation of radioactive isotope from carbonate into tissues increases markedly, consistent with decreased tricarboxylic acid cycle operation."
succinate,Succinate does not accumulate substantial amounts of radioactive isotope from labelled substrates under anaerobic conditions.,Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate does not accumulate substantial amounts of radioactive isotope from labelled substrates under anaerobic conditions.
oxaloacetate,"Increased incorporation of radioactive isotope into oxaloacetate pools leads to higher specific radioactivity in pools such as pyruvate, alanine, and phosphoenolpyruvate under anaerobic conditions.","Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. Increased incorporation of radioactive isotope into oxaloacetate pools leads to higher specific radioactivity in pools such as pyruvate, alanine, and phosphoenolpyruvate under anaerobic conditions."
malate,"Malate accumulates radioactive label when glutamic acid is used as substrate, reflecting tricarboxylic acid cycle activity at a decreased rate.","Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate accumulates radioactive label when glutamic acid is used as substrate, reflecting tricarboxylic acid cycle activity at a decreased rate."
glucose,"With glucose as substrate, the incorporation of radioactive isotope into glutamate and aspartate decreases under anaerobic conditions, reflecting reduced tricarboxylic acid cycle activity.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. With glucose as substrate, the incorporation of radioactive isotope into glutamate and aspartate decreases under anaerobic conditions, reflecting reduced tricarboxylic acid cycle activity."
glutamic acid,"When glutamic acid is used as substrate, radioactive label is incorporated into fumarate, malate, succinate, aspartate, and alanine, indicating tricarboxylic acid cycle operation at a decreased rate.","Entity: glutamic acid. SMILES: N[C@@H](CCC(=O)O)C(=O)O. When glutamic acid is used as substrate, radioactive label is incorporated into fumarate, malate, succinate, aspartate, and alanine, indicating tricarboxylic acid cycle operation at a decreased rate."
phosphoenolpyruvate,Phosphoenolpyruvate pools become enriched in radioactive isotope due to increased incorporation from oxaloacetate under anaerobic conditions.,Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate pools become enriched in radioactive isotope due to increased incorporation from oxaloacetate under anaerobic conditions.
fumarate,"Fumarate accumulates radioactive label when glutamic acid is used as substrate, reflecting tricarboxylic acid cycle activity at a decreased rate.","Entity: fumarate. SMILES: O=C([O-])/C=C/C(=O)[O-]. Fumarate accumulates radioactive label when glutamic acid is used as substrate, reflecting tricarboxylic acid cycle activity at a decreased rate."
alanine,"Increased incorporation of radioactive isotope into alanine under anaerobic conditions, particularly following increased CO2 incorporation, leads to higher specific radioactivity in alanine pools.","Entity: alanine. SMILES: C[C@H](N)C(=O)O. Increased incorporation of radioactive isotope into alanine under anaerobic conditions, particularly following increased CO2 incorporation, leads to higher specific radioactivity in alanine pools."
oxygen,"Oxygen is required for the survival of molluscs, as they are unable to survive in the complete absence of oxygen.","Entity: oxygen. SMILES: [O]. Oxygen is required for the survival of molluscs, as they are unable to survive in the complete absence of oxygen."
nitrogen,"M. edulis can survive for up to 4 days in an atmosphere of pure nitrogen, indicating its ability to tolerate anoxic conditions.","Entity: nitrogen. SMILES: [N]. M. edulis can survive for up to 4 days in an atmosphere of pure nitrogen, indicating its ability to tolerate anoxic conditions."
AMP,AMP is a component of the adenylate pool and acts as a modulator for many regulatory enzymes in both catabolic and anabolic pathways.,Entity: AMP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. AMP is a component of the adenylate pool and acts as a modulator for many regulatory enzymes in both catabolic and anabolic pathways.
ADP,ADP is a component of the adenylate pool and acts as a modulator for many regulatory enzymes in both catabolic and anabolic pathways.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP is a component of the adenylate pool and acts as a modulator for many regulatory enzymes in both catabolic and anabolic pathways.
ATP,"ATP stores most of the available energy in cells, primarily in its high-energy phosphate bond.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP stores most of the available energy in cells, primarily in its high-energy phosphate bond."
ATP,"ATP, together with ADP and AMP, forms the adenylate pool, which serves as a reservoir for energy transport in cells.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP, together with ADP and AMP, forms the adenylate pool, which serves as a reservoir for energy transport in cells."
adenosine 5'-monophosphate,"Adenosine 5'-monophosphate is deaminated to inosine monophosphate by adenosine phosphate aminohydrolase, an enzyme absent in Pecten yessoensis and potentially in M. edulis.","Entity: adenosine 5'-monophosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine 5'-monophosphate is deaminated to inosine monophosphate by adenosine phosphate aminohydrolase, an enzyme absent in Pecten yessoensis and potentially in M. edulis."
inosine monophosphate,Inosine monophosphate is produced from adenosine 5'-monophosphate by the action of adenosine phosphate aminohydrolase.,Entity: inosine monophosphate. SMILES: O=P(O)(O)OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O. Inosine monophosphate is produced from adenosine 5'-monophosphate by the action of adenosine phosphate aminohydrolase.
phosphoenolpyruvate,"Phosphoenolpyruvate exhibits competitive substrate inhibition, as evidenced by linear double-reciprocal plots and non-linear slope-intercept relationships in enzyme assays.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate exhibits competitive substrate inhibition, as evidenced by linear double-reciprocal plots and non-linear slope-intercept relationships in enzyme assays."
ADP,"ADP exhibits competitive substrate inhibition, as shown by linear double-reciprocal plots and non-linear slope-intercept relationships in enzyme assays.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP exhibits competitive substrate inhibition, as shown by linear double-reciprocal plots and non-linear slope-intercept relationships in enzyme assays."
phosphoenolpyruvate,"At high concentrations, phosphoenolpyruvate can inhibit the enzyme in question, and a saturating concentration of phosphoenolpyruvate can overcome this inhibition when ADP is the substrate.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. At high concentrations, phosphoenolpyruvate can inhibit the enzyme in question, and a saturating concentration of phosphoenolpyruvate can overcome this inhibition when ADP is the substrate."
phosphoenolpyruvate,"At high concentrations, phosphoenolpyruvate may induce the formation of additional enzyme complexes or nucleotide dead-end complexes, leading to a higher apparent KFp than initially observed.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. At high concentrations, phosphoenolpyruvate may induce the formation of additional enzyme complexes or nucleotide dead-end complexes, leading to a higher apparent KFp than initially observed."
pyruvate,"Pyruvate can inhibit the enzyme in question, and its inhibition can be overcome by a saturating concentration of phosphoenolpyruvate when ADP is the substrate.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate can inhibit the enzyme in question, and its inhibition can be overcome by a saturating concentration of phosphoenolpyruvate when ADP is the substrate."
ADP,ADP serves as a substrate in enzyme assays where the effect of substrate inhibition can be studied.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP serves as a substrate in enzyme assays where the effect of substrate inhibition can be studied.
ATP,"ATP can form mixed-nucleotide dead-end complexes with the enzyme, similar to the rabbit muscle enzyme.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP can form mixed-nucleotide dead-end complexes with the enzyme, similar to the rabbit muscle enzyme."
ATP,"ATP can inhibit the enzyme-catalyzed reaction in a competitive manner, forming an enzyme-ATP-ADP complex as evidenced by a linear increase in intercepts in double-reciprocal plots with ATP concentration.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP can inhibit the enzyme-catalyzed reaction in a competitive manner, forming an enzyme-ATP-ADP complex as evidenced by a linear increase in intercepts in double-reciprocal plots with ATP concentration."
ATP,"The formation of enzyme-ATP-ATP complexes was demonstrated by the enzyme's response to ATP as an inhibitor, with the inhibition pattern indicating a competitive interaction between the first ADP binding and second ATP inhibition.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. The formation of enzyme-ATP-ATP complexes was demonstrated by the enzyme's response to ATP as an inhibitor, with the inhibition pattern indicating a competitive interaction between the first ADP binding and second ATP inhibition."
ADP,"ADP serves as a substrate in the enzyme-catalyzed reaction, and its concentration was varied to obtain linear double-reciprocal plots for analysis of substrate inhibition.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP serves as a substrate in the enzyme-catalyzed reaction, and its concentration was varied to obtain linear double-reciprocal plots for analysis of substrate inhibition."
phosphoenolpyruvate,"Phosphoenolpyruvate is a substrate in the enzyme-catalyzed reaction, and its concentration was kept low to observe substrate inhibition and the formation of enzyme-ATP-ATP complexes.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate is a substrate in the enzyme-catalyzed reaction, and its concentration was kept low to observe substrate inhibition and the formation of enzyme-ATP-ATP complexes."
ADP,"ADP acts as an inhibitor in enzyme assays, and its concentration influences the reaction rate according to substrate inhibition kinetics.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP acts as an inhibitor in enzyme assays, and its concentration influences the reaction rate according to substrate inhibition kinetics."
ADP,"The inhibitory dissociation constant for ADP binding to the enzyme is 80-fold larger than its dissociation constant for forming a binary complex, indicating less favorable binding in the free enzyme form.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. The inhibitory dissociation constant for ADP binding to the enzyme is 80-fold larger than its dissociation constant for forming a binary complex, indicating less favorable binding in the free enzyme form."
"fructose 1,6-diphosphate","Fructose 1,6-diphosphate is used as a cofactor at a concentration of 500 µM in standard enzyme assay conditions.","Entity: fructose 1,6-diphosphate. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose 1,6-diphosphate is used as a cofactor at a concentration of 500 µM in standard enzyme assay conditions."
pyruvate,Pyruvate is the product formed in an enzyme-catalyzed reaction measured at a rate of pmol per minute per enzyme unit under standard assay conditions.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is the product formed in an enzyme-catalyzed reaction measured at a rate of pmol per minute per enzyme unit under standard assay conditions.
phosphoenolpyruvate,"Phosphoenolpyruvate is a substrate in enzyme assays, and its concentration affects the reaction rate according to substrate inhibition kinetics.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate is a substrate in enzyme assays, and its concentration affects the reaction rate according to substrate inhibition kinetics."
phosphoenolpyruvate,"The inhibitory dissociation constant for phosphoenolpyruvate binding to the enzyme is 45-fold larger than its dissociation constant for forming a binary complex, indicating less favorable binding in the free enzyme form.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. The inhibitory dissociation constant for phosphoenolpyruvate binding to the enzyme is 45-fold larger than its dissociation constant for forming a binary complex, indicating less favorable binding in the free enzyme form."
phosphoenolpyruvate,"Phosphoenolpyruvate acts as a substrate whose reaction rate is subject to substrate inhibition, as shown by a double-reciprocal plot.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate acts as a substrate whose reaction rate is subject to substrate inhibition, as shown by a double-reciprocal plot."
ATP,"ATP can inhibit the enzyme reaction by reversing the activation provided by fructose 1,6-diphosphate, but this inhibition is eliminated by adding fructose 1,6-diphosphate up to approximately 2 mM.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP can inhibit the enzyme reaction by reversing the activation provided by fructose 1,6-diphosphate, but this inhibition is eliminated by adding fructose 1,6-diphosphate up to approximately 2 mM."
dipotassium glycerol 1-phosphate,Dipotassium glycerol 1-phosphate is used as a Mg2+ buffer in enzymatic assays.,Entity: dipotassium glycerol 1-phosphate. SMILES: O=P([O-])([O-])OCC(O)CO.[K+].[K+]. Dipotassium glycerol 1-phosphate is used as a Mg2+ buffer in enzymatic assays.
"fructose 1,6-bisphosphate","Fructose 1,6-bisphosphate is used to activate the enzyme by saturating concentration (5 mM) in enzymatic assays.","Entity: fructose 1,6-bisphosphate. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose 1,6-bisphosphate is used to activate the enzyme by saturating concentration (5 mM) in enzymatic assays."
phosphoenolpyruvate,Phosphoenolpyruvate acts as a substrate that causes substrate inhibition when its concentration is increased relative to a constant low concentration of another substrate in enzymatic reactions.,Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate acts as a substrate that causes substrate inhibition when its concentration is increased relative to a constant low concentration of another substrate in enzymatic reactions.
ADP,ADP functions as a substrate that induces substrate inhibition when its concentration is elevated above a certain low level in enzymatic reactions.,Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP functions as a substrate that induces substrate inhibition when its concentration is elevated above a certain low level in enzymatic reactions.
α-tocopherol,Endogenous α-tocopherol content in both vegetative and induced plants remains similar over a 5-day period.,Entity: α-tocopherol. SMILES: Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2. Endogenous α-tocopherol content in both vegetative and induced plants remains similar over a 5-day period.
β-tocopherol,"Endogenous β-tocopherol content is markedly higher in induced plants compared to vegetative plants, as observed over a 5-day period.","Entity: β-tocopherol. SMILES: Cc1cc(O)c(C)c2c1O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2. Endogenous β-tocopherol content is markedly higher in induced plants compared to vegetative plants, as observed over a 5-day period."
acetone,Acetone is used as a solvent for extracting tocopherols and other isoprenoids from mature leaves.,Entity: acetone. SMILES: CC(C)=O. Acetone is used as a solvent for extracting tocopherols and other isoprenoids from mature leaves.
water,Water is used to wash acetone and other water-soluble materials from the lipid fraction during tocopherol extraction.,Entity: water. SMILES: O. Water is used to wash acetone and other water-soluble materials from the lipid fraction during tocopherol extraction.
α-tocopherol,"A-tocopherol (5,7,8-trimethyltocol) can elicit flowering in strawberries grown under vegetative conditions.","Entity: α-tocopherol. SMILES: Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2. A-tocopherol (5,7,8-trimethyltocol) can elicit flowering in strawberries grown under vegetative conditions."
γ-tocopherol,"y-Tocopherol (7,8-dimethyltocol) accumulates in the leaves immediately before flower formation.","Entity: γ-tocopherol. SMILES: Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2. y-Tocopherol (7,8-dimethyltocol) accumulates in the leaves immediately before flower formation."
ethanol,The effect of ethanol in the assay medium is likely due to stabilization of the tocopherol/phospholipid emulsion.,Entity: ethanol. SMILES: CCO. The effect of ethanol in the assay medium is likely due to stabilization of the tocopherol/phospholipid emulsion.
NaHPO4,NaHPO4 is used as a buffer component at 50 mM concentration in the assay medium for the enzyme in question.,Entity: NaHPO4. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. NaHPO4 is used as a buffer component at 50 mM concentration in the assay medium for the enzyme in question.
citrate,"Citrate is used as a buffer component in the assay medium for the enzyme, together with NaHPO4 at 50 mM concentration and pH 5.5.","Entity: citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-]. Citrate is used as a buffer component in the assay medium for the enzyme, together with NaHPO4 at 50 mM concentration and pH 5.5."
ethanol,"Ethanol is included at 5% (v/v) in the assay medium for the enzyme, and its optimal concentration for activity is about 5% (v/v), although 20% (v/v) has been reported to be more effective in some cases.","Entity: ethanol. SMILES: CCO. Ethanol is included at 5% (v/v) in the assay medium for the enzyme, and its optimal concentration for activity is about 5% (v/v), although 20% (v/v) has been reported to be more effective in some cases."
benzoate,"Benzoate can be converted into benzoyl-CoA in cell-free extracts in the presence of CoA, ATP, and Mg2+ ions in phosphate buffer.","Entity: benzoate. SMILES: O=C([O-])c1ccccc1. Benzoate can be converted into benzoyl-CoA in cell-free extracts in the presence of CoA, ATP, and Mg2+ ions in phosphate buffer."
benzoate,Benzoate can be regenerated from benzoyl-CoA by treatment with 0.1 M NaOH.,Entity: benzoate. SMILES: O=C([O-])c1ccccc1. Benzoate can be regenerated from benzoyl-CoA by treatment with 0.1 M NaOH.
benzoyl-CoA,"Benzoyl-CoA can be synthesized from benzoate in cell-free extracts using CoA, ATP, and Mg2+ ions in phosphate buffer.","Entity: benzoyl-CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)c1ccccc1. Benzoyl-CoA can be synthesized from benzoate in cell-free extracts using CoA, ATP, and Mg2+ ions in phosphate buffer."
ATP,ATP is required as a cofactor for the conversion of benzoate to benzoyl-CoA in cell-free extracts.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP is required as a cofactor for the conversion of benzoate to benzoyl-CoA in cell-free extracts.
CoA,CoA is required as a cofactor for the conversion of benzoate to benzoyl-CoA in cell-free extracts.,Entity: CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. CoA is required as a cofactor for the conversion of benzoate to benzoyl-CoA in cell-free extracts.
NaOH,NaOH (0.1 M) is used to convert benzoyl-CoA back to benzoate in the described reaction system.,Entity: NaOH. SMILES: [Na+].[OH-]. NaOH (0.1 M) is used to convert benzoyl-CoA back to benzoate in the described reaction system.
diazomethane,Diazomethane is used to methylate ether extracts for the preparation of dimethyl ester derivatives in biochemical assays.,Entity: diazomethane. SMILES: C=[N+]=[N-]. Diazomethane is used to methylate ether extracts for the preparation of dimethyl ester derivatives in biochemical assays.
pimelate,"Pimelate can be quantified by preparing its dimethyl ester from the reaction mixture, followed by extraction and methylation with diazomethane.","Entity: pimelate. SMILES: O=C([O-])CCCCCC(=O)[O-]. Pimelate can be quantified by preparing its dimethyl ester from the reaction mixture, followed by extraction and methylation with diazomethane."
ATP,ATP is used as a substrate at 8 pmol concentration in a cell-free enzymatic assay.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP is used as a substrate at 8 pmol concentration in a cell-free enzymatic assay.
MgSO4,MgSO4 is included at 10 pmol concentration in a cell-free enzymatic assay buffer.,Entity: MgSO4. SMILES: O=S(=O)([O-])[O-].[Mg+2]. MgSO4 is included at 10 pmol concentration in a cell-free enzymatic assay buffer.
cyclohex-1-enecarboxylate,Cyclohex-1-enecarboxylate is used as a substrate at 2 pmol concentration in a cell-free enzymatic assay.,Entity: cyclohex-1-enecarboxylate. SMILES: O=C([O-])C1=CCCCC1. Cyclohex-1-enecarboxylate is used as a substrate at 2 pmol concentration in a cell-free enzymatic assay.
NAD+,NAD+ is included at 6 pmol concentration in a cell-free enzymatic assay.,Entity: NAD+. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NAD+ is included at 6 pmol concentration in a cell-free enzymatic assay.
CoA,CoA is used as a substrate at 1 pmol concentration in a cell-free enzymatic assay.,Entity: CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. CoA is used as a substrate at 1 pmol concentration in a cell-free enzymatic assay.
tyrosine,"Tyrosine serves as a substrate for tyrosinase, leading to the formation of melanin and other phenolic intermediates in bacterial cultures.","Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. Tyrosine serves as a substrate for tyrosinase, leading to the formation of melanin and other phenolic intermediates in bacterial cultures."
"3,4-dihydroxyphenylalanine","3,4-dihydroxyphenylalanine (dopa) is produced by bacterial cells containing tyrosinase activity and can be isolated from such cultures.","Entity: 3,4-dihydroxyphenylalanine. SMILES: N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O. 3,4-dihydroxyphenylalanine (dopa) is produced by bacterial cells containing tyrosinase activity and can be isolated from such cultures."
"2,4,5-trimethoxyphenylalanine","2,4,5-trimethoxyphenylalanine is a methylated derivative of 6-hydroxydopa and can be isolated as a crystalline compound.","Entity: 2,4,5-trimethoxyphenylalanine. SMILES: COc1cc(OC)c(OC)cc1C[C@H](N)C(=O)O. 2,4,5-trimethoxyphenylalanine is a methylated derivative of 6-hydroxydopa and can be isolated as a crystalline compound."
6-hydroxydopa,"6-hydroxydopa is a methylated derivative of 2,4,5-trimethoxyphenylalanine and is formed as an intermediate during the enzymatic reaction of dopa with tyrosinase or the ascorbate-Fe2+-O2 system.","Entity: 6-hydroxydopa. SMILES: NC(Cc1cc(O)c(O)cc1O)C(=O)O. 6-hydroxydopa is a methylated derivative of 2,4,5-trimethoxyphenylalanine and is formed as an intermediate during the enzymatic reaction of dopa with tyrosinase or the ascorbate-Fe2+-O2 system."
NADPH,NADPH serves as a hydrogen donor in the reductive conversion of phloroglucinol to dihydrophloroglucinol in a cell-free system from Rhodopseudomonas gelatinosa.,Entity: NADPH. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADPH serves as a hydrogen donor in the reductive conversion of phloroglucinol to dihydrophloroglucinol in a cell-free system from Rhodopseudomonas gelatinosa.
dihydrophloroglucinol,Dihydrophloroglucinol is the first product formed from phloroglucinol in the photosynthetic growth of Rhodopseudomonas gelatinosa.,Entity: dihydrophloroglucinol. SMILES: O=C1C=C(O)CC(O)C1. Dihydrophloroglucinol is the first product formed from phloroglucinol in the photosynthetic growth of Rhodopseudomonas gelatinosa.
phloroglucinol,Phloroglucinol undergoes reductive conversion to dihydrophloroglucinol in a cell-free system using NADPH as the hydrogen donor from Rhodopseudomonas gelatinosa.,Entity: phloroglucinol. SMILES: Oc1cc(O)cc(O)c1. Phloroglucinol undergoes reductive conversion to dihydrophloroglucinol in a cell-free system using NADPH as the hydrogen donor from Rhodopseudomonas gelatinosa.
benzoate,Benzoate photoassimilation in intact cells is severely inhibited by the addition of long-chain fatty acids produced during cell disruption.,Entity: benzoate. SMILES: O=C([O-])c1ccccc1. Benzoate photoassimilation in intact cells is severely inhibited by the addition of long-chain fatty acids produced during cell disruption.
cyclohexenecarboxylate,Cyclohexenecarboxylate is converted into pimelate by a cell-free extract of Rhodopseudomonaspalustris in the presence of specific reactants under both anaerobic and aerobic conditions.,Entity: cyclohexenecarboxylate. SMILES: O=C([O-])C1=CCCCC1. Cyclohexenecarboxylate is converted into pimelate by a cell-free extract of Rhodopseudomonaspalustris in the presence of specific reactants under both anaerobic and aerobic conditions.
pimelate,Pimelate is produced from cyclohexenecarboxylate by a cell-free extract of Rhodopseudomonaspalustris in the presence of required reactants under either anaerobic or aerobic conditions.,Entity: pimelate. SMILES: O=C([O-])CCCCCC(=O)[O-]. Pimelate is produced from cyclohexenecarboxylate by a cell-free extract of Rhodopseudomonaspalustris in the presence of required reactants under either anaerobic or aerobic conditions.
methotrexate,"Methotrexate at a concentration of 1 µM inhibits oxygen uptake by 55% in cells or extracts of Pseudomonas PZ3 metabolizing hydroxypyrazine, presumably by inhibiting a formyl-transfer reaction.","Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Methotrexate at a concentration of 1 µM inhibits oxygen uptake by 55% in cells or extracts of Pseudomonas PZ3 metabolizing hydroxypyrazine, presumably by inhibiting a formyl-transfer reaction."
hydroxypyrazine,"Hydroxypyrazine is metabolized by Pseudomonas PZ3, as evidenced by decreased oxygen uptake in the presence of methotrexate or ad-bipyridyl.","Entity: hydroxypyrazine. SMILES: Oc1cnccn1. Hydroxypyrazine is metabolized by Pseudomonas PZ3, as evidenced by decreased oxygen uptake in the presence of methotrexate or ad-bipyridyl."
oxygen,Oxygen uptake by cells or extracts of Pseudomonas PZ3 metabolizing hydroxypyrazine is inhibited by ad-bipyridyl (90% inhibition at 10 nM) and methotrexate (55% inhibition at 1 µM).,Entity: oxygen. SMILES: [O]. Oxygen uptake by cells or extracts of Pseudomonas PZ3 metabolizing hydroxypyrazine is inhibited by ad-bipyridyl (90% inhibition at 10 nM) and methotrexate (55% inhibition at 1 µM).
pyrazine,The ability to grow on pyrazine substrates implies the ability to utilize pyrazine compounds as carbon sources.,Entity: pyrazine. SMILES: c1cnccn1. The ability to grow on pyrazine substrates implies the ability to utilize pyrazine compounds as carbon sources.
N-formylglycine amide,"N-formylglycine amide contains a primary amide group, an imine, and an aldehyde as indicated by its infrared spectrum.","Entity: N-formylglycine amide. SMILES: NCC(=O)NC=O. N-formylglycine amide contains a primary amide group, an imine, and an aldehyde as indicated by its infrared spectrum."
N-formylglycine amide,N-formylglycine amide can be separated by ion-exchange chromatography on Dowex-1 resin (formate form) using a gradient of 0–0.5 M formic acid.,Entity: N-formylglycine amide. SMILES: NCC(=O)NC=O. N-formylglycine amide can be separated by ion-exchange chromatography on Dowex-1 resin (formate form) using a gradient of 0–0.5 M formic acid.
N-formylglycine amide,N-formylglycine amide yields glycine upon alkaline hydrolysis and glycine amide upon acid hydrolysis.,Entity: N-formylglycine amide. SMILES: NCC(=O)NC=O. N-formylglycine amide yields glycine upon alkaline hydrolysis and glycine amide upon acid hydrolysis.
glycine,"Glycine is a component commonly included in growth media and is metabolized by Pseudomoms PZ3, which convert it into glyoxylate.","Entity: glycine. SMILES: NCC(=O)O. Glycine is a component commonly included in growth media and is metabolized by Pseudomoms PZ3, which convert it into glyoxylate."
glyoxylate,"Glyoxylate is produced from glycine by the enzyme glyoxylate carbo-ligase, which is highly active in Pseudomoms PZ3.","Entity: glyoxylate. SMILES: O=CC(=O)[O-]. Glyoxylate is produced from glycine by the enzyme glyoxylate carbo-ligase, which is highly active in Pseudomoms PZ3."
"2,6-dihydroxypyrazine","2,6-dihydroxypyrazine is an intermediate formed by dihydroxylation of hydroxypyrazine during its metabolic oxidation in Pseudomonas species.","Entity: 2,6-dihydroxypyrazine. SMILES: Oc1cncc(O)n1. 2,6-dihydroxypyrazine is an intermediate formed by dihydroxylation of hydroxypyrazine during its metabolic oxidation in Pseudomonas species."
hydroxypyrazine,"Hydroxypyrazine undergoes metabolism in certain Pseudomonas species via oxidation of its aromatic ring, likely proceeding through dihydroxylation to form 2,6-dihydroxypyrazine, followed by ring cleavage by an oxygenase.","Entity: hydroxypyrazine. SMILES: Oc1cnccn1. Hydroxypyrazine undergoes metabolism in certain Pseudomonas species via oxidation of its aromatic ring, likely proceeding through dihydroxylation to form 2,6-dihydroxypyrazine, followed by ring cleavage by an oxygenase."
dihydroxypyrazine,"Dihydroxypyrazine is a compound that can be separated from hydroxypyrazine by ion-exchange chromatography and is characterized by UV and IR spectra consistent with a dihydroxylated compound, a melting point of 198°C, and a deep-blue color reaction with the Folin–Ciocalteau reagent.","Entity: dihydroxypyrazine. SMILES: Oc1cncc(O)n1. Dihydroxypyrazine is a compound that can be separated from hydroxypyrazine by ion-exchange chromatography and is characterized by UV and IR spectra consistent with a dihydroxylated compound, a melting point of 198°C, and a deep-blue color reaction with the Folin–Ciocalteau reagent."
dihydroxypyrazine,Dihydroxypyrazine forms a stable sepia-colored precipitate with acidic FeCl3.,Entity: dihydroxypyrazine. SMILES: Oc1cncc(O)n1. Dihydroxypyrazine forms a stable sepia-colored precipitate with acidic FeCl3.
dihydroxypyrazine,Dihydroxypyrazine is metabolized by Pseudomonas PZ3 in the absence of ad-bipyridyl at a rate identical to that for hydroxypyrazine.,Entity: dihydroxypyrazine. SMILES: Oc1cncc(O)n1. Dihydroxypyrazine is metabolized by Pseudomonas PZ3 in the absence of ad-bipyridyl at a rate identical to that for hydroxypyrazine.
hydroxypyrazine,Hydroxypyrazine has a melting point of 118°C and is less affected by ad-bipyridyl in the described reaction mixture.,Entity: hydroxypyrazine. SMILES: Oc1cnccn1. Hydroxypyrazine has a melting point of 118°C and is less affected by ad-bipyridyl in the described reaction mixture.
hydroxypyrazine,"Hydroxypyrazine can serve as the sole carbon and nitrogen source for Pseudomonas sp. PZ3, supporting its growth, although cell density is limited by factors other than substrate concentration.","Entity: hydroxypyrazine. SMILES: Oc1cnccn1. Hydroxypyrazine can serve as the sole carbon and nitrogen source for Pseudomonas sp. PZ3, supporting its growth, although cell density is limited by factors other than substrate concentration."
reserpine,Reserpine pretreatment increases brain glutamate and aspartic acid content and alters the distribution of amino acid radioactivity in the brain.,Entity: reserpine. SMILES: COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC. Reserpine pretreatment increases brain glutamate and aspartic acid content and alters the distribution of amino acid radioactivity in the brain.
glutamine,Reserpine pretreatment increases the brain content of glutamine and decreases the specific radioactivity of glutamine in amino acid distributions.,Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Reserpine pretreatment increases the brain content of glutamine and decreases the specific radioactivity of glutamine in amino acid distributions.
alanine,"Reserpine pretreatment does not significantly change the brain content of alanine, but decreases the specific radioactivity of alanine in amino acid distributions.","Entity: alanine. SMILES: C[C@H](N)C(=O)O. Reserpine pretreatment does not significantly change the brain content of alanine, but decreases the specific radioactivity of alanine in amino acid distributions."
aspartic acid,Reserpine pretreatment increases the brain content of aspartic acid and increases the specific radioactivity of aspartate in amino acid distributions.,Entity: aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. Reserpine pretreatment increases the brain content of aspartic acid and increases the specific radioactivity of aspartate in amino acid distributions.
aspartic acid,Electroshock increases the brain content of aspartic acid and increases the specific radioactivity of aspartate in amino acid distributions.,Entity: aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. Electroshock increases the brain content of aspartic acid and increases the specific radioactivity of aspartate in amino acid distributions.
glutamate,Reserpine pretreatment increases the brain content of glutamate and increases the specific radioactivity of glutamate in amino acid distributions.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Reserpine pretreatment increases the brain content of glutamate and increases the specific radioactivity of glutamate in amino acid distributions.
glutamate,Electroshock increases the brain content of glutamate and increases the specific radioactivity of glutamate in amino acid distributions.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Electroshock increases the brain content of glutamate and increases the specific radioactivity of glutamate in amino acid distributions.
glucose,Glucose can be administered intravenously to rats and its metabolic labeling in brain tissue can be assessed by counting radioactivity after electroshock and acid extraction.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose can be administered intravenously to rats and its metabolic labeling in brain tissue can be assessed by counting radioactivity after electroshock and acid extraction.
UTP,UTP can be separated from the acid-soluble fraction of rat brain by thin-layer chromatography for subsequent extraction and analysis.,Entity: UTP. SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. UTP can be separated from the acid-soluble fraction of rat brain by thin-layer chromatography for subsequent extraction and analysis.
phenol,Phenol is used as an extraction reagent for RNA from the acid-soluble fraction of rat brain.,Entity: phenol. SMILES: Oc1ccccc1. Phenol is used as an extraction reagent for RNA from the acid-soluble fraction of rat brain.
HClO,HClO is used as an extraction reagent for RNA from the acid-soluble fraction of rat brain.,Entity: HClO. SMILES: Cl. HClO is used as an extraction reagent for RNA from the acid-soluble fraction of rat brain.
reserpine,"Reserpine at a dose of 5 mg/kg administered 3 hours before decapitation in rats produces a more pronounced electroshock-like effect, including all phases of convulsions, compared to saline-treated rats.","Entity: reserpine. SMILES: COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC. Reserpine at a dose of 5 mg/kg administered 3 hours before decapitation in rats produces a more pronounced electroshock-like effect, including all phases of convulsions, compared to saline-treated rats."
CTP,"An increased concentration of uracil nucleotides, including those derived from UMP, can produce a feedback effect on the breakdown of high-energy phosphates such as CTP.","Entity: CTP. SMILES: Nc1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)n1. An increased concentration of uracil nucleotides, including those derived from UMP, can produce a feedback effect on the breakdown of high-energy phosphates such as CTP."
GTP,"An increased concentration of uracil nucleotides, including those derived from UMP, can produce a feedback effect on the breakdown of high-energy phosphates such as GTP.","Entity: GTP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. An increased concentration of uracil nucleotides, including those derived from UMP, can produce a feedback effect on the breakdown of high-energy phosphates such as GTP."
orotic acid,Orotic acid treatment increases the synthesis of orotidine monophosphate from orotic acid and phosphoribosyl pyrophosphate.,Entity: orotic acid. SMILES: O=C(O)c1cc(=O)[nH]c(=O)[nH]1. Orotic acid treatment increases the synthesis of orotidine monophosphate from orotic acid and phosphoribosyl pyrophosphate.
phosphoribosyl pyrophosphate,Increased demand for phosphoribosyl pyrophosphate can decrease energy resources available for activation of amino acids or assembly of ribosomal protein-synthesizing aggregates.,Entity: phosphoribosyl pyrophosphate. SMILES: O=P([O-])([O-])OP(=O)([O-])OC1O[C@H](CO)[C@@H](O)[C@H]1OP(=O)(O)O. Increased demand for phosphoribosyl pyrophosphate can decrease energy resources available for activation of amino acids or assembly of ribosomal protein-synthesizing aggregates.
orotidine monophosphate,Orotidine monophosphate is synthesized from orotic acid and phosphoribosyl pyrophosphate.,Entity: orotidine monophosphate. SMILES: O=C(O)c1cc(=O)[nH]c(=O)n1[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. Orotidine monophosphate is synthesized from orotic acid and phosphoribosyl pyrophosphate.
UMP,UMP has a direct inhibitory effect on the function of the ribosomal protein-synthesizing system.,Entity: UMP. SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. UMP has a direct inhibitory effect on the function of the ribosomal protein-synthesizing system.
UMP,"UMP can be converted to UDP, UTP, or other nucleotides or nucleosides, which may stimulate protein-synthesizing capacity in microsomal fractions and ribonucleoprotein particles.","Entity: UMP. SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. UMP can be converted to UDP, UTP, or other nucleotides or nucleosides, which may stimulate protein-synthesizing capacity in microsomal fractions and ribonucleoprotein particles."
UTP,UTP can be formed from UMP and may contribute to stimulating protein-synthesizing capacity in microsomal fractions and ribonucleoprotein particles.,Entity: UTP. SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. UTP can be formed from UMP and may contribute to stimulating protein-synthesizing capacity in microsomal fractions and ribonucleoprotein particles.
UDP,UDP can be produced from UMP and may play a role in stimulating protein-synthesizing capacity in microsomal fractions and ribonucleoprotein particles.,Entity: UDP. SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. UDP can be produced from UMP and may play a role in stimulating protein-synthesizing capacity in microsomal fractions and ribonucleoprotein particles.
ATP,"An increased concentration of uracil nucleotides, including those derived from UMP, can produce a feedback effect on the breakdown of high-energy phosphates such as ATP.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. An increased concentration of uracil nucleotides, including those derived from UMP, can produce a feedback effect on the breakdown of high-energy phosphates such as ATP."
uridine,Uridine stimulates both endogenous and poly(U)-directed protein synthesis by microsomal fractions or ribonucleoprotein particles when added to nucleotide hydrolysate fractions.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine stimulates both endogenous and poly(U)-directed protein synthesis by microsomal fractions or ribonucleoprotein particles when added to nucleotide hydrolysate fractions.
orotic acid,Orotic acid decreases the capacity of microsomal fractions to incorporate labelled amino acids.,Entity: orotic acid. SMILES: O=C(O)c1cc(=O)[nH]c(=O)[nH]1. Orotic acid decreases the capacity of microsomal fractions to incorporate labelled amino acids.
cytidine,Cytidine stimulates both endogenous and poly(U)-directed protein synthesis by microsomal fractions or ribonucleoprotein particles when added to nucleotide hydrolysate fractions.,Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Cytidine stimulates both endogenous and poly(U)-directed protein synthesis by microsomal fractions or ribonucleoprotein particles when added to nucleotide hydrolysate fractions.
"2,5-diphenyloxazole","2,5-diphenyloxazole is used as a scintillant in the liquid-scintillation counting method for determining radioactivity in bile samples.","Entity: 2,5-diphenyloxazole. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. 2,5-diphenyloxazole is used as a scintillant in the liquid-scintillation counting method for determining radioactivity in bile samples."
mestranol,"Mestranol can be administered to rats via intraduodenal administration, and its biliary conjugates can be excreted in bile for analysis.","Entity: mestranol. SMILES: C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C. Mestranol can be administered to rats via intraduodenal administration, and its biliary conjugates can be excreted in bile for analysis."
sodium chloride,Sodium chloride (0.9% NaCl) is used as a vehicle for intraduodenal administration of mestranol or its metabolic conjugates in rat studies.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride (0.9% NaCl) is used as a vehicle for intraduodenal administration of mestranol or its metabolic conjugates in rat studies.
toluene,Toluene is used as a component of the solvent mixture for dissolving bile samples prior to radioactivity analysis in liquid-scintillation counting.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a component of the solvent mixture for dissolving bile samples prior to radioactivity analysis in liquid-scintillation counting.
shikimic acid,"Shikimic acid is metabolized by gastrointestinal micro-organisms, as evidenced by the extraction of radioactivity from rat caecal content incubations.","Entity: shikimic acid. SMILES: O=C(O)C1=C[C@@H](O)[C@@H](O)[C@H](O)C1. Shikimic acid is metabolized by gastrointestinal micro-organisms, as evidenced by the extraction of radioactivity from rat caecal content incubations."
shikimic acid,"Shikimic acid is not extracted from aqueous solution under the described extraction conditions, indicating minimal extraction from water.","Entity: shikimic acid. SMILES: O=C(O)C1=C[C@@H](O)[C@@H](O)[C@H](O)C1. Shikimic acid is not extracted from aqueous solution under the described extraction conditions, indicating minimal extraction from water."
ethanolamine,Ethanolamine is used as a 20% (v/v) solution in 2-ethoxyethanol to trap expired CO2 during rat metabolism studies.,Entity: ethanolamine. SMILES: NCCO. Ethanolamine is used as a 20% (v/v) solution in 2-ethoxyethanol to trap expired CO2 during rat metabolism studies.
glucose,Glucose is included at 50 mg/ml in rat caecal content incubations to support microbial metabolism of shikimic acid.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is included at 50 mg/ml in rat caecal content incubations to support microbial metabolism of shikimic acid.
2-ethoxyethanol,2-ethoxyethanol is used as a solvent for trapping expired CO2 in rat metabolism studies.,Entity: 2-ethoxyethanol. SMILES: CCOCCO. 2-ethoxyethanol is used as a solvent for trapping expired CO2 in rat metabolism studies.
shikimic acid,Shikimic acid is a compound of widespread occurrence in plants and certain fruits.,Entity: shikimic acid. SMILES: O=C(O)C1=C[C@@H](O)[C@@H](O)[C@H](O)C1. Shikimic acid is a compound of widespread occurrence in plants and certain fruits.
shikimic acid,Shikimic acid has been reported as carcinogenic in mice.,Entity: shikimic acid. SMILES: O=C(O)C1=C[C@@H](O)[C@@H](O)[C@H](O)C1. Shikimic acid has been reported as carcinogenic in mice.
shikimic acid,"In rats, an oral dose of 100 mg/kg shikimic acid is excreted at 95–98% within 24 hours, with 35–49% in urine, 45–55% in faeces, and 4–6% as expired 14CO2.","Entity: shikimic acid. SMILES: O=C(O)C1=C[C@@H](O)[C@@H](O)[C@H](O)C1. In rats, an oral dose of 100 mg/kg shikimic acid is excreted at 95–98% within 24 hours, with 35–49% in urine, 45–55% in faeces, and 4–6% as expired 14CO2."
hippuric acid,"In rats, 15–21% of an oral shikimic acid dose is excreted as urinary hippuric acid after 24 hours.","Entity: hippuric acid. SMILES: O=C(O)CNC(=O)c1ccccc1. In rats, 15–21% of an oral shikimic acid dose is excreted as urinary hippuric acid after 24 hours."
catechol,"In rats, 0.6–1.8% of an oral shikimic acid dose is excreted as conjugated catechol after 24 hours.","Entity: catechol. SMILES: Oc1ccccc1O. In rats, 0.6–1.8% of an oral shikimic acid dose is excreted as conjugated catechol after 24 hours."
shikimic acid,"Shikimic acid undergoes complete (95–100%) microbial ether-extractable metabolism in rat caecal content after 5 days anaerobic incubation, with the major metabolite identified as cyclohexanecarboxylic acid.","Entity: shikimic acid. SMILES: O=C(O)C1=C[C@@H](O)[C@@H](O)[C@H](O)C1. Shikimic acid undergoes complete (95–100%) microbial ether-extractable metabolism in rat caecal content after 5 days anaerobic incubation, with the major metabolite identified as cyclohexanecarboxylic acid."
cyclohexanecarboxylic acid,"Cyclohexanecarboxylic acid is the major microbial metabolite of shikimic acid in rat caecal content, as confirmed by i.r., nuclear-magnetic-resonance, and mass spectra, and by comparison to authentic samples and reverse isotope dilution analysis via its S-benzylisothiuronium salt.","Entity: cyclohexanecarboxylic acid. SMILES: O=C(O)C1CCCCC1. Cyclohexanecarboxylic acid is the major microbial metabolite of shikimic acid in rat caecal content, as confirmed by i.r., nuclear-magnetic-resonance, and mass spectra, and by comparison to authentic samples and reverse isotope dilution analysis via its S-benzylisothiuronium salt."
benzoic acid,Benzoic acid is suggested to form as a metabolic intermediate during the breakdown of shikimic acid in vivo.,Entity: benzoic acid. SMILES: O=C(O)c1ccccc1. Benzoic acid is suggested to form as a metabolic intermediate during the breakdown of shikimic acid in vivo.
hippuric acid,Hippuric acid is a urinary metabolite formed from the aromatization of shikimic acid in the rat.,Entity: hippuric acid. SMILES: O=C(O)CNC(=O)c1ccccc1. Hippuric acid is a urinary metabolite formed from the aromatization of shikimic acid in the rat.
shikimic acid,"Shikimic acid undergoes aromatization in the rat, resulting in the formation of hippuric acid and a conjugated catechol.","Entity: shikimic acid. SMILES: O=C(O)C1=C[C@@H](O)[C@@H](O)[C@H](O)C1. Shikimic acid undergoes aromatization in the rat, resulting in the formation of hippuric acid and a conjugated catechol."
shikimic acid,Gastrointestinal microflora are responsible for the initial reduction and dehydroxylation of shikimic acid to cyclohexanecarboxylic acid in the rat.,Entity: shikimic acid. SMILES: O=C(O)C1=C[C@@H](O)[C@@H](O)[C@H](O)C1. Gastrointestinal microflora are responsible for the initial reduction and dehydroxylation of shikimic acid to cyclohexanecarboxylic acid in the rat.
cyclohexanecarboxylic acid,Cyclohexanecarboxylic acid is produced from shikimic acid by reduction and dehydroxylation mediated by gut microflora in the rat.,Entity: cyclohexanecarboxylic acid. SMILES: O=C(O)C1CCCCC1. Cyclohexanecarboxylic acid is produced from shikimic acid by reduction and dehydroxylation mediated by gut microflora in the rat.
glucuronic acid,UDP-glucuronyltransferase (EC 2.4.1.17) catalyzes the conjugation of endogenous compounds such as bilirubin and steroids with glucuronic acid.,Entity: glucuronic acid. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)O. UDP-glucuronyltransferase (EC 2.4.1.17) catalyzes the conjugation of endogenous compounds such as bilirubin and steroids with glucuronic acid.
bilirubin,Bilirubin is an endogenous compound that is conjugated with glucuronic acid by the enzyme UDP-glucuronyltransferase (EC 2.4.1.17).,Entity: bilirubin. SMILES: C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O. Bilirubin is an endogenous compound that is conjugated with glucuronic acid by the enzyme UDP-glucuronyltransferase (EC 2.4.1.17).
o-aminophenol,"O-aminophenol serves as a substrate for UDP-glucuronyltransferase activity in Wistar rat liver microsomes, with more than 90% of the enzyme activity retained in the supernatant after centrifugation at 105000g for 60 minutes.","Entity: o-aminophenol. SMILES: Nc1ccccc1O. O-aminophenol serves as a substrate for UDP-glucuronyltransferase activity in Wistar rat liver microsomes, with more than 90% of the enzyme activity retained in the supernatant after centrifugation at 105000g for 60 minutes."
p-nitrophenol,"P-nitrophenol is a substrate for UDP-glucuronyltransferase activity in Wistar rat liver microsomes, with more than 90% of the enzyme activity retained in the supernatant after centrifugation at 105000g for 60 minutes.","Entity: p-nitrophenol. SMILES: O=[N+]([O-])c1ccc(O)cc1. P-nitrophenol is a substrate for UDP-glucuronyltransferase activity in Wistar rat liver microsomes, with more than 90% of the enzyme activity retained in the supernatant after centrifugation at 105000g for 60 minutes."
digitonin,"Digitonin is used to remove the outer membrane and intermembrane space contents from mitochondria, allowing the suspension of mitochondrial matrix in lWmM-Tris/HCl at pH 8.2 at 20°C for enzymatic assays.","Entity: digitonin. SMILES: C[C@@H]1CC[C@@]2(OC1)O[C@H]1[C@@H](O)[C@H]3[C@@H]4CC[C@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C. Digitonin is used to remove the outer membrane and intermembrane space contents from mitochondria, allowing the suspension of mitochondrial matrix in lWmM-Tris/HCl at pH 8.2 at 20°C for enzymatic assays."
benzoyl-CoA,"Benzoyl-CoA synthetase activity is latent in intact mitochondria but is released by sonication, indicating that benzoyl-CoA is generated in the mitochondrial matrix.","Entity: benzoyl-CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)c1ccccc1. Benzoyl-CoA synthetase activity is latent in intact mitochondria but is released by sonication, indicating that benzoyl-CoA is generated in the mitochondrial matrix."
hippurate,Hippurate synthesis in mitochondria occurs at rates of 10 nmol/mg protein during a 1 h incubation with sonication and 3.7 nmol/mg protein during a 1 h incubation in digitonin-treated mitochondrial matrix at pH 8.2 and 20°C.,Entity: hippurate. SMILES: O=C([O-])CNC(=O)c1ccccc1. Hippurate synthesis in mitochondria occurs at rates of 10 nmol/mg protein during a 1 h incubation with sonication and 3.7 nmol/mg protein during a 1 h incubation in digitonin-treated mitochondrial matrix at pH 8.2 and 20°C.
CoA,"CoA is required for high rates of hippurate synthesis by sonicated mitochondria, indicating its role as a cofactor in the enzymatic reaction.","Entity: CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. CoA is required for high rates of hippurate synthesis by sonicated mitochondria, indicating its role as a cofactor in the enzymatic reaction."
benzoyl-CoA,"In intact rat liver mitochondria, the maximum extent of acylation of CoA with deca-2,4,6,8-tetraenoate in the steady state is about 0.5 nmol/mg protein.","Entity: benzoyl-CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)c1ccccc1. In intact rat liver mitochondria, the maximum extent of acylation of CoA with deca-2,4,6,8-tetraenoate in the steady state is about 0.5 nmol/mg protein."
CoA,Rat liver mitochondria contain about 2–3 nmol of CoA per mg of protein.,Entity: CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. Rat liver mitochondria contain about 2–3 nmol of CoA per mg of protein.
CoA,"In rat liver mitochondria, about 50% of CoA is acylated by deca-2,4,6,8-tetraenoate in the steady state.","Entity: CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. In rat liver mitochondria, about 50% of CoA is acylated by deca-2,4,6,8-tetraenoate in the steady state."
hippurate,Hippurate is synthesized in amounts greater than equivalent to glycine added in mitochondrial systems.,Entity: hippurate. SMILES: O=C([O-])CNC(=O)c1ccccc1. Hippurate is synthesized in amounts greater than equivalent to glycine added in mitochondrial systems.
benzoate,Benzoate concentration decreases during glycine-stimulated hippurate synthesis in mitochondrial systems.,Entity: benzoate. SMILES: O=C([O-])c1ccccc1. Benzoate concentration decreases during glycine-stimulated hippurate synthesis in mitochondrial systems.
glycine,Glycine is required for the conversion of benzoate to hippurate in mitochondrial systems.,Entity: glycine. SMILES: NCC(=O)O. Glycine is required for the conversion of benzoate to hippurate in mitochondrial systems.
benzoyl-CoA,"Benzoyl-CoA can be hydrolyzed in the supernatant fraction of sonicated mitochondrial preparations, with an apparent Km of low value.","Entity: benzoyl-CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)c1ccccc1. Benzoyl-CoA can be hydrolyzed in the supernatant fraction of sonicated mitochondrial preparations, with an apparent Km of low value."
ammonium hippurate,"Ammonium hippurate can cross the inner mitochondrial membrane freely, as indicated by rapid swelling of rat liver mitochondria in 1:50 M solutions.","Entity: ammonium hippurate. SMILES: O=C([O-])CNC(=O)c1ccccc1.[NH4+]. Ammonium hippurate can cross the inner mitochondrial membrane freely, as indicated by rapid swelling of rat liver mitochondria in 1:50 M solutions."
glycine,"Glycine can cross the inner mitochondrial membrane freely, as shown by rapid swelling of rat liver mitochondria in 1:50 M solutions.","Entity: glycine. SMILES: NCC(=O)O. Glycine can cross the inner mitochondrial membrane freely, as shown by rapid swelling of rat liver mitochondria in 1:50 M solutions."
ammonium benzoate,"Ammonium benzoate can cross the inner mitochondrial membrane freely, as evidenced by rapid swelling of rat liver mitochondria in 1:50 M solutions.","Entity: ammonium benzoate. SMILES: O=C([O-])c1ccccc1.[NH4+]. Ammonium benzoate can cross the inner mitochondrial membrane freely, as evidenced by rapid swelling of rat liver mitochondria in 1:50 M solutions."
benzoate,"Benzoate is conjugated in the liver with glycine to form hippurate, involving prior conversion to benzoyl-CoA catalyzed by butyryl-CoA synthetase.","Entity: benzoate. SMILES: O=C([O-])c1ccccc1. Benzoate is conjugated in the liver with glycine to form hippurate, involving prior conversion to benzoyl-CoA catalyzed by butyryl-CoA synthetase."
benzoyl-CoA,"Benzoyl-CoA is formed from benzoate by the action of butyryl-CoA synthetase, an enzyme found in the mitochondrial matrix.","Entity: benzoyl-CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)c1ccccc1. Benzoyl-CoA is formed from benzoate by the action of butyryl-CoA synthetase, an enzyme found in the mitochondrial matrix."
hippurate,"Hippurate is formed in the liver by the conjugation of benzoate with glycine, catalyzed by glycine N-acylase.","Entity: hippurate. SMILES: O=C([O-])CNC(=O)c1ccccc1. Hippurate is formed in the liver by the conjugation of benzoate with glycine, catalyzed by glycine N-acylase."
glycine,Glycine reacts with benzoyl-CoA in a transacylation reaction catalyzed by glycine N-acylase to form hippurate.,Entity: glycine. SMILES: NCC(=O)O. Glycine reacts with benzoyl-CoA in a transacylation reaction catalyzed by glycine N-acylase to form hippurate.
benzoylcarnitine,"Activated benzoyl groups, such as those derived from benzoate, can be exported as benzoylcarnitine if glycine N-acylase is located outside the inner mitochondrial membrane.","Entity: benzoylcarnitine. SMILES: C[N+](C)(C)CC(O)(CC(=O)[O-])C(=O)c1ccccc1. Activated benzoyl groups, such as those derived from benzoate, can be exported as benzoylcarnitine if glycine N-acylase is located outside the inner mitochondrial membrane."
MgSO4,MgSO4 is included at 2 mM concentration in the mitochondrial incubation buffer.,Entity: MgSO4. SMILES: O=S(=O)([O-])[O-].[Mg+2]. MgSO4 is included at 2 mM concentration in the mitochondrial incubation buffer.
KC1,KC1 is included at 120 mM concentration in the mitochondrial incubation buffer.,Entity: KC1. SMILES: [Cl-].[K+]. KC1 is included at 120 mM concentration in the mitochondrial incubation buffer.
benzoic acid,Benzoic acid is detected by UV light on chromatographic paper with an Rp value of 0.80.,Entity: benzoic acid. SMILES: O=C(O)c1ccccc1. Benzoic acid is detected by UV light on chromatographic paper with an Rp value of 0.80.
COA,CoA is supplemented at 0.5 mM concentration in the mitochondrial incubation buffer.,Entity: COA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. CoA is supplemented at 0.5 mM concentration in the mitochondrial incubation buffer.
benzoyl-CoA,Benzoyl-CoA is synthesized by standard methods and detected by UV light on chromatographic paper with an Rp value of 0.95.,Entity: benzoyl-CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)c1ccccc1. Benzoyl-CoA is synthesized by standard methods and detected by UV light on chromatographic paper with an Rp value of 0.95.
KOH,KOH is used to adjust the pH of the mitochondrial incubation buffer to 7.2.,Entity: KOH. SMILES: [K+].[OH-]. KOH is used to adjust the pH of the mitochondrial incubation buffer to 7.2.
ammonium hippurate,"Ammonium hippurate can cross the inner mitochondrial membrane freely, as indicated by rapid swelling of rat liver mitochondria in 1:5:0 M solutions of ammonium hippurate.","Entity: ammonium hippurate. SMILES: O=C([O-])CNC(=O)c1ccccc1.[NH4+]. Ammonium hippurate can cross the inner mitochondrial membrane freely, as indicated by rapid swelling of rat liver mitochondria in 1:5:0 M solutions of ammonium hippurate."
ammonium benzoate,"Ammonium benzoate can cross the inner mitochondrial membrane freely, as shown by rapid swelling of rat liver mitochondria in 1:5:0 M solutions of ammonium benzoate.","Entity: ammonium benzoate. SMILES: O=C([O-])c1ccccc1.[NH4+]. Ammonium benzoate can cross the inner mitochondrial membrane freely, as shown by rapid swelling of rat liver mitochondria in 1:5:0 M solutions of ammonium benzoate."
benzoate,"Benzoate can cross the inner mitochondrial membrane freely, as demonstrated by the uptake of [14C]benzoate by rat liver mitochondria.","Entity: benzoate. SMILES: O=C([O-])c1ccccc1. Benzoate can cross the inner mitochondrial membrane freely, as demonstrated by the uptake of [14C]benzoate by rat liver mitochondria."
glycine,"Glycine can cross the inner mitochondrial membrane freely, as evidenced by rapid swelling of rat liver mitochondria in 1:5:0 M solutions of glycine.","Entity: glycine. SMILES: NCC(=O)O. Glycine can cross the inner mitochondrial membrane freely, as evidenced by rapid swelling of rat liver mitochondria in 1:5:0 M solutions of glycine."
benzoyl-CoA,"Benzoyl-CoA is involved in a futile cycle with benzoyl-CoA synthetase and benzoyl-CoA hydrolase, which helps prevent excessive accumulation of benzoyl-CoA by constantly interconverting it.","Entity: benzoyl-CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)c1ccccc1. Benzoyl-CoA is involved in a futile cycle with benzoyl-CoA synthetase and benzoyl-CoA hydrolase, which helps prevent excessive accumulation of benzoyl-CoA by constantly interconverting it."
CoA,"CoA (coenzyme A) is a key cofactor required for various cellular reactions, and its availability can be limited by factors such as glycine supply or conjugation rate, affecting the balance of CoA-requiring processes.","Entity: CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS. CoA (coenzyme A) is a key cofactor required for various cellular reactions, and its availability can be limited by factors such as glycine supply or conjugation rate, affecting the balance of CoA-requiring processes."
hippurate,"Hippurate synthesis is dependent on the supply of glycine and its conjugation rate, and impaired glycine supply can limit hippurate synthesis and affect other CoA-requiring reactions.","Entity: hippurate. SMILES: O=C([O-])CNC(=O)c1ccccc1. Hippurate synthesis is dependent on the supply of glycine and its conjugation rate, and impaired glycine supply can limit hippurate synthesis and affect other CoA-requiring reactions."
CCl,"CCl is a highly toxic compound that, when administered to animals, induces liver enlargement and enhances protective features in the liver, partly due to stimulation of its metabolism by drug-metabolizing enzymes.","Entity: CCl. SMILES: ClC(Cl)(Cl)Cl. CCl is a highly toxic compound that, when administered to animals, induces liver enlargement and enhances protective features in the liver, partly due to stimulation of its metabolism by drug-metabolizing enzymes."
glycerol,"Glycerol, as a nonelectrolyte, induces neurofilament proteins in Myxicola axoplasm to adopt more complex configurations compared to their native state.","Entity: glycerol. SMILES: OCC(O)CO. Glycerol, as a nonelectrolyte, induces neurofilament proteins in Myxicola axoplasm to adopt more complex configurations compared to their native state."
sucrose,"Sucrose, as a nonelectrolyte, causes neurofilament proteins in Myxicola axoplasm to adopt more complex configurations than their native form.","Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose, as a nonelectrolyte, causes neurofilament proteins in Myxicola axoplasm to adopt more complex configurations than their native form."
sodium dodecyl sulphate,"Sodium dodecyl sulphate is used in gel electrophoresis to assess the mobility of tubulin, a protein component of microtubules, but little to none of the protein in Myxicola axoplasm shows tubulin-like mobility under these conditions.","Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used in gel electrophoresis to assess the mobility of tubulin, a protein component of microtubules, but little to none of the protein in Myxicola axoplasm shows tubulin-like mobility under these conditions."
NaCI,"NaCI at 0.75 M, with 20 mM cacodylate and pH 7.0, causes neurofilaments to sediment with a single, highly asymmetric peak in analytical ultracentrifugation, indicating dissociation into subunits at high ionic strength.","Entity: NaCI. SMILES: [Cl-].[Na+]. NaCI at 0.75 M, with 20 mM cacodylate and pH 7.0, causes neurofilaments to sediment with a single, highly asymmetric peak in analytical ultracentrifugation, indicating dissociation into subunits at high ionic strength."
cacodylate,Cacodylate is used at 20 mM as a buffer component at pH 7.0 in neurofilament studies.,Entity: cacodylate. SMILES: C[As](C)(=O)[O-]. Cacodylate is used at 20 mM as a buffer component at pH 7.0 in neurofilament studies.
histidine,Histidine is used at a concentration of 20 mM as a buffer component at pH 7.0 in neurofilament studies.,Entity: histidine. SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O. Histidine is used at a concentration of 20 mM as a buffer component at pH 7.0 in neurofilament studies.
KCI,"KCI is used to raise the ionic strength above 0.3 in neurofilament studies, resulting in reduced neurofilament sedimentation.","Entity: KCI. SMILES: [Cl-].[K+]. KCI is used to raise the ionic strength above 0.3 in neurofilament studies, resulting in reduced neurofilament sedimentation."
sodium dodecyl sulphate,"Sodium dodecyl sulphate is used as a molecular-weight standard in gel electrophoresis, and its availability and specific standard can influence molecular-weight estimates of proteins such as neurofilaments.","Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used as a molecular-weight standard in gel electrophoresis, and its availability and specific standard can influence molecular-weight estimates of proteins such as neurofilaments."
cholate,"Cholate is used as a detergent to disperse lipids and proteins for membrane incorporation, and can be effectively removed by dialysis or dilution.","Entity: cholate. SMILES: C[C@H](CCC(=O)[O-])[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Cholate is used as a detergent to disperse lipids and proteins for membrane incorporation, and can be effectively removed by dialysis or dilution."
lysophosphatidylcholine,Lysophosphatidylcholine at 10% concentration in pre-formed phospholipid vesicles facilitates the incorporation of proteins into the membrane.,Entity: lysophosphatidylcholine. SMILES: CC(=O)OC[C@@H](O)COP(=O)([O-])OCC[N+](C)(C)C. Lysophosphatidylcholine at 10% concentration in pre-formed phospholipid vesicles facilitates the incorporation of proteins into the membrane.
adenosine triphosphate,Adenosine triphosphate (ATP) is required for the activity of the ATP synthetase complex and Complex I in the reconstitution of mitochondrial energy conservation reactions in liposomes.,Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine triphosphate (ATP) is required for the activity of the ATP synthetase complex and Complex I in the reconstitution of mitochondrial energy conservation reactions in liposomes.
NADP,NADP can be reduced by NADH at a rate comparable to that observed in submitochondrial particles when reconstituted in liposomes containing the ATP synthetase complex and Complex I.,Entity: NADP. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)(O)OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP can be reduced by NADH at a rate comparable to that observed in submitochondrial particles when reconstituted in liposomes containing the ATP synthetase complex and Complex I.
rotenone,Rotenone inhibits oxidoreduction in mitochondrial electron transport by more than 90% and completely abolishes ATP synthesis in this system.,Entity: rotenone. SMILES: C=C(C)[C@H]1Cc2c(ccc3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1. Rotenone inhibits oxidoreduction in mitochondrial electron transport by more than 90% and completely abolishes ATP synthesis in this system.
NADP,"The ATP-dependent reduction of NADP+ by NADH, catalyzed by nicotinamide nucleotide transhydrogenase, can be used as an assay for energy coupling at site 0 (the mitochondrial coupling site).","Entity: NADP. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)(O)OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. The ATP-dependent reduction of NADP+ by NADH, catalyzed by nicotinamide nucleotide transhydrogenase, can be used as an assay for energy coupling at site 0 (the mitochondrial coupling site)."
nigericin,"Nigericin, in combination with K+, stimulates NADH-ubiquinone-1 reductase activity catalyzed by Complex I in liposomes by two- to seven-fold.","Entity: nigericin. SMILES: CO[C@@H]1C[C@@H](C[C@H]2CC[C@H](C)[C@H]([C@@H](C)C(=O)O)O2)O[C@]2(O[C@](C)([C@H]3CC[C@@](C)([C@@H]4O[C@@H]([C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C)C[C@@H]4C)O3)C[C@H]2C)[C@@H]1C. Nigericin, in combination with K+, stimulates NADH-ubiquinone-1 reductase activity catalyzed by Complex I in liposomes by two- to seven-fold."
valinomycin,"Valinomycin, in combination with K+, stimulates NADH-ubiquinone-1 reductase activity catalyzed by Complex I in liposomes by two- to seven-fold.","Entity: valinomycin. SMILES: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O. Valinomycin, in combination with K+, stimulates NADH-ubiquinone-1 reductase activity catalyzed by Complex I in liposomes by two- to seven-fold."
phosphatidylethanolamine,"Phosphatidylethanolamine, when combined with phosphatidylcholine in a 3:2 molar ratio, provides optimal stimulation of NADH-ubiquinone-1 reductase activity in Complex I vesicles.","Entity: phosphatidylethanolamine. SMILES: CC(=O)OC[C@H](COP(=O)(O)OCCN)OC(C)=O. Phosphatidylethanolamine, when combined with phosphatidylcholine in a 3:2 molar ratio, provides optimal stimulation of NADH-ubiquinone-1 reductase activity in Complex I vesicles."
phosphatidylethanolamine,Transhydrogenase activity of Complex I is maximal in phosphatidylethanolamine vesicles.,Entity: phosphatidylethanolamine. SMILES: CC(=O)OC[C@H](COP(=O)(O)OCCN)OC(C)=O. Transhydrogenase activity of Complex I is maximal in phosphatidylethanolamine vesicles.
Tricine,Tricine is used as a buffering agent at pH 8.0 in the preparation of Complex I vesicles.,Entity: Tricine. SMILES: O=C(O)CNC(CO)(CO)CO. Tricine is used as a buffering agent at pH 8.0 in the preparation of Complex I vesicles.
potassium cholate,Potassium cholate is included at 20 mg/ml in the preparation of Complex I vesicles to aid in phospholipid dispersion.,Entity: potassium cholate. SMILES: CC(CCC(=O)[O-])C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C.[K+]. Potassium cholate is included at 20 mg/ml in the preparation of Complex I vesicles to aid in phospholipid dispersion.
rotenone,Rotenone is used to correct for the rotenone-insensitive rate of NADH oxidation in the respiratory control assay in Complex I vesicles.,Entity: rotenone. SMILES: C=C(C)[C@H]1Cc2c(ccc3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1. Rotenone is used to correct for the rotenone-insensitive rate of NADH oxidation in the respiratory control assay in Complex I vesicles.
bis(hexafluoroacetonyl)acetone,bis(hexafluoroacetonyl)acetone is used to measure respiratory control ratio in Complex I vesicles by inhibiting the NADH-ubiquinone-1 reductase activity.,Entity: bis(hexafluoroacetonyl)acetone. SMILES: O=C(C=C(C(F)(F)F)C(F)(F)F)C=C(C(F)(F)F)C(F)(F)F. bis(hexafluoroacetonyl)acetone is used to measure respiratory control ratio in Complex I vesicles by inhibiting the NADH-ubiquinone-1 reductase activity.
potassium phosphate,Potassium phosphate is used as a buffer at pH 8.0 in the NADH-ubiquinone-1 reductase activity assay in Complex I vesicles.,Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate is used as a buffer at pH 8.0 in the NADH-ubiquinone-1 reductase activity assay in Complex I vesicles.
"5,6-epoxyretinal","5,6-epoxyretinal does not reconstitute the bioenergetic function of bacteriorhodopsin in intact halobacterial cells.","Entity: 5,6-epoxyretinal. SMILES: CC(=C/C=C/C(C)=C/C=O)/C=C/C12OC1(C)CCCC2(C)C. 5,6-epoxyretinal does not reconstitute the bioenergetic function of bacteriorhodopsin in intact halobacterial cells."
"5,6-epoxyretinal","Addition of 5,6-epoxyretinal to liposomes containing bacteriorhodopsin does not produce measurable pH changes, indicating it does not support proton pumping.","Entity: 5,6-epoxyretinal. SMILES: CC(=C/C=C/C(C)=C/C=O)/C=C/C12OC1(C)CCCC2(C)C. Addition of 5,6-epoxyretinal to liposomes containing bacteriorhodopsin does not produce measurable pH changes, indicating it does not support proton pumping."
retinal,Retinal reconstitutes the bioenergetic function of bacteriorhodopsin equally well as 3-dehydroretinal in intact halobacterial cells.,Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CC=C1. Retinal reconstitutes the bioenergetic function of bacteriorhodopsin equally well as 3-dehydroretinal in intact halobacterial cells.
retinal,"Addition of retinal to liposomes containing bacteriorhodopsin causes large pH changes in cell suspensions, indicating reconstitution of proton pumping.","Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CC=C1. Addition of retinal to liposomes containing bacteriorhodopsin causes large pH changes in cell suspensions, indicating reconstitution of proton pumping."
4-hydroxyretinal,Addition of 4-hydroxyretinal to liposomes containing bacteriorhodopsin produces pH changes in the medium that are smaller than those observed with retinal or dehydroretinal.,Entity: 4-hydroxyretinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1O. Addition of 4-hydroxyretinal to liposomes containing bacteriorhodopsin produces pH changes in the medium that are smaller than those observed with retinal or dehydroretinal.
retinal,"Retinal forms a Schiff base with the e-amino group of a lysine residue in the photoreceptor protein and is then protonated, contributing to the formation of the photoreceptor chromophore.","Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1. Retinal forms a Schiff base with the e-amino group of a lysine residue in the photoreceptor protein and is then protonated, contributing to the formation of the photoreceptor chromophore."
retinal,Retinal participates in retinal-retro-retinal transitions during the photochemical cycle of bacteriorhodopsin.,Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1. Retinal participates in retinal-retro-retinal transitions during the photochemical cycle of bacteriorhodopsin.
lysine,"The e-amino group of a lysine residue in the photoreceptor protein forms a Schiff base with retinal, which is then protonated to contribute to the chromophore structure.","Entity: lysine. SMILES: NCCCC[C@H](N)C(=O)O. The e-amino group of a lysine residue in the photoreceptor protein forms a Schiff base with retinal, which is then protonated to contribute to the chromophore structure."
nicotine,Nicotine is used to induce stationary phase in Halobacterium halobium RIM1 cells.,Entity: nicotine. SMILES: CN1CCCC1c1cccnc1. Nicotine is used to induce stationary phase in Halobacterium halobium RIM1 cells.
3-dehydroretinal,3-dehydroretinal is used as a substrate to reconstitute photophosphorylation in Halobacterium halobium RIM1 cells.,Entity: 3-dehydroretinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CC=C1. 3-dehydroretinal is used as a substrate to reconstitute photophosphorylation in Halobacterium halobium RIM1 cells.
retinal,Retinal is used as a substrate to reconstitute photophosphorylation in Halobacterium halobium RIM1 cells.,Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1. Retinal is used as a substrate to reconstitute photophosphorylation in Halobacterium halobium RIM1 cells.
"5,6-epoxyretinal","5,6-epoxyretinal is used as a substrate to reconstitute photophosphorylation in Halobacterium halobium RIM1 cells.","Entity: 5,6-epoxyretinal. SMILES: CC(=C/C=C/C(C)=C/C=O)/C=C/C12OC1(C)CCCC2(C)C. 5,6-epoxyretinal is used as a substrate to reconstitute photophosphorylation in Halobacterium halobium RIM1 cells."
nicotine,"Halobacteria can grow in the presence of 1 mM nicotine without a change in generation time, but no retinal is biosynthesized and bacteriorhodopsin formation is inhibited under these conditions.","Entity: nicotine. SMILES: CN1CCCC1c1cccnc1. Halobacteria can grow in the presence of 1 mM nicotine without a change in generation time, but no retinal is biosynthesized and bacteriorhodopsin formation is inhibited under these conditions."
retinal,"Retinal is biosynthesized by halobacteria under normal conditions, but its biosynthesis is inhibited when the cells are grown in the presence of 1 mM nicotine.","Entity: retinal. SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=N/O)C(C)(C)CCC1. Retinal is biosynthesized by halobacteria under normal conditions, but its biosynthesis is inhibited when the cells are grown in the presence of 1 mM nicotine."
hydroxylamine,"Hydroxylamine reacts with the chromophore intermediate of the bacteriorhodopsin photochemical cycle, leading to the formation of retinaloxime and a chromophore-free membrane (apomembrane).","Entity: hydroxylamine. SMILES: NO. Hydroxylamine reacts with the chromophore intermediate of the bacteriorhodopsin photochemical cycle, leading to the formation of retinaloxime and a chromophore-free membrane (apomembrane)."
pyruvate,Pyruvate acts as a competitive inhibitor with respect to the substrate phosphoenolpyruvate in the enzyme's active site.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate acts as a competitive inhibitor with respect to the substrate phosphoenolpyruvate in the enzyme's active site.
"fructose 1,6-bisphosphate","Fructose 1,6-bisphosphate is a ligand that inhibits the activity of certain pyruvate kinase isoenzymes, but pyruvate kinase from the leg muscle of C. maenas is insensitive to this ligand.","Entity: fructose 1,6-bisphosphate. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose 1,6-bisphosphate is a ligand that inhibits the activity of certain pyruvate kinase isoenzymes, but pyruvate kinase from the leg muscle of C. maenas is insensitive to this ligand."
glucose,"High concentrations of glucose can be dehydrogenated by glucose 6-phosphate dehydrogenase, limiting its use in enzymatic assays.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. High concentrations of glucose can be dehydrogenated by glucose 6-phosphate dehydrogenase, limiting its use in enzymatic assays."
NADP+,NADP+ solutions must be prepared daily and kept frozen for only a few days to prevent inhibition of the assay system due to its instability.,Entity: NADP+. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP+ solutions must be prepared daily and kept frozen for only a few days to prevent inhibition of the assay system due to its instability.
guanidinium chloride,Guanidinium chloride is used as an elution agent to remove bound proteins from affinity matrices such as Sepharose.,Entity: guanidinium chloride. SMILES: NC(N)=[NH2+].[Cl-]. Guanidinium chloride is used as an elution agent to remove bound proteins from affinity matrices such as Sepharose.
CNBr,"CNBr is used to activate Sepharose gel for immobilization of enzymes, with lower activation levels (0.5–2 mg CNBr per ml gel) resulting in denatured enzyme activities of approximately 20% compared to native values.","Entity: CNBr. SMILES: N#CBr. CNBr is used to activate Sepharose gel for immobilization of enzymes, with lower activation levels (0.5–2 mg CNBr per ml gel) resulting in denatured enzyme activities of approximately 20% compared to native values."
phosphoenolpyruvate,"Phosphoenolpyruvate is a substrate in the pyruvate kinase-catalyzed reaction in Carcinus maenas leg muscle, forming dead-end complexes with enzyme and Mg-enzyme.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate is a substrate in the pyruvate kinase-catalyzed reaction in Carcinus maenas leg muscle, forming dead-end complexes with enzyme and Mg-enzyme."
Mg,"Mg acts as a cofactor in the pyruvate kinase-catalyzed reaction in Carcinus maenas leg muscle, participating in the formation of dead-end complexes with ADP and phosphoenolpyruvate.","Entity: Mg. SMILES: [Mg]. Mg acts as a cofactor in the pyruvate kinase-catalyzed reaction in Carcinus maenas leg muscle, participating in the formation of dead-end complexes with ADP and phosphoenolpyruvate."
"fructose 1,6-bisphosphate","Fructose 1,6-bisphosphate is a substrate for pyruvate kinase, which catalyzes its phosphorylation to form pyruvate and ADP.","Entity: fructose 1,6-bisphosphate. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose 1,6-bisphosphate is a substrate for pyruvate kinase, which catalyzes its phosphorylation to form pyruvate and ADP."
ADP,"ADP can form a complex with the enzyme and pyruvate in the presence of fructose 1,6-bisphosphate, known as the ADP-enzyme-pyruvate complex.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP can form a complex with the enzyme and pyruvate in the presence of fructose 1,6-bisphosphate, known as the ADP-enzyme-pyruvate complex."
ATP,"ATP can form a complex with the enzyme and pyruvate in the presence of fructose 1,6-bisphosphate, known as the ADP-enzyme-ATP complex.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP can form a complex with the enzyme and pyruvate in the presence of fructose 1,6-bisphosphate, known as the ADP-enzyme-ATP complex."
ATP,ATP can act as an inhibitor in enzyme activity assays and can contaminate assay solutions with up to 0.8% (mol/mol) ADP.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP can act as an inhibitor in enzyme activity assays and can contaminate assay solutions with up to 0.8% (mol/mol) ADP.
ADP,"ADP can contaminate ATP solutions in assay mixtures, with a maximum allowable level of 0.8% (mol/mol) in the assay.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP can contaminate ATP solutions in assay mixtures, with a maximum allowable level of 0.8% (mol/mol) in the assay."
ATP,"ATP serves as a label in kinetic studies of the reverse reaction of pyruvate kinase, where its transfer to phosphoenolpyruvate is used to measure reaction rates.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP serves as a label in kinetic studies of the reverse reaction of pyruvate kinase, where its transfer to phosphoenolpyruvate is used to measure reaction rates."
pyruvate,"Pyruvate is used as a substrate in kinetic studies of pyruvate kinase, and when plotted against inhibitor concentration, the reaction rate yields non-linear slopes in replots of double-reciprocal plots.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is used as a substrate in kinetic studies of pyruvate kinase, and when plotted against inhibitor concentration, the reaction rate yields non-linear slopes in replots of double-reciprocal plots."
phosphoenolpyruvate,"Phosphoenolpyruvate acts as a product in the reverse reaction of pyruvate kinase, receiving label from ATP during kinetic assays.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate acts as a product in the reverse reaction of pyruvate kinase, receiving label from ATP during kinetic assays."
ADP,"ADP serves as a substrate in the rabbit muscle pyruvate kinase reaction, being converted into ATP.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP serves as a substrate in the rabbit muscle pyruvate kinase reaction, being converted into ATP."
phosphoenolpyruvate,"Phosphoenolpyruvate is a substrate in the rabbit muscle pyruvate kinase reaction, being converted into pyruvate.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate is a substrate in the rabbit muscle pyruvate kinase reaction, being converted into pyruvate."
pyruvate,"Pyruvate is a substrate in the rabbit muscle pyruvate kinase reaction, being converted into phosphoenolpyruvate.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is a substrate in the rabbit muscle pyruvate kinase reaction, being converted into phosphoenolpyruvate."
ATP,"ATP is the product of the rabbit muscle pyruvate kinase reaction, formed from ADP.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP is the product of the rabbit muscle pyruvate kinase reaction, formed from ADP."
pyruvate,"Pyruvate can directly transfer a phosphate group to phosphoenolpyruvate in a reaction catalyzed by pyruvate kinase, with the exchange rate being linear over the studied time course and indicating equilibrium under physiological conditions.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate can directly transfer a phosphate group to phosphoenolpyruvate in a reaction catalyzed by pyruvate kinase, with the exchange rate being linear over the studied time course and indicating equilibrium under physiological conditions."
phosphoenolpyruvate,"Phosphoenolpyruvate can directly transfer a phosphate group to pyruvate in a reaction catalyzed by pyruvate kinase, with the exchange rate being linear over the studied time course and indicating equilibrium under physiological conditions.","Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate can directly transfer a phosphate group to pyruvate in a reaction catalyzed by pyruvate kinase, with the exchange rate being linear over the studied time course and indicating equilibrium under physiological conditions."
phosphoenolpyruvate,Phosphoenolpyruvate participates in both the pyruvate-to-pyruvate exchange and the ATP-intophosphoenolpyruvate exchange reactions in rabbit muscle pyruvate kinase assays.,Entity: phosphoenolpyruvate. SMILES: C=C(OP(=O)(O)O)C(=O)O. Phosphoenolpyruvate participates in both the pyruvate-to-pyruvate exchange and the ATP-intophosphoenolpyruvate exchange reactions in rabbit muscle pyruvate kinase assays.
pyruvate,Pyruvate is produced from phosphoenolpyruvate in the pyruvate kinase reaction catalyzed by rabbit muscle pyruvate kinase.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is produced from phosphoenolpyruvate in the pyruvate kinase reaction catalyzed by rabbit muscle pyruvate kinase.
ATP,ATP serves as a substrate in the ATP-intophosphoenolpyruvate exchange reaction with phosphoenolpyruvate in rabbit muscle pyruvate kinase assays.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP serves as a substrate in the ATP-intophosphoenolpyruvate exchange reaction with phosphoenolpyruvate in rabbit muscle pyruvate kinase assays.
ADP,"ADP is present as an impurity in ATP used in rabbit muscle pyruvate kinase assays, complicating the analysis of reaction equilibrium.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP is present as an impurity in ATP used in rabbit muscle pyruvate kinase assays, complicating the analysis of reaction equilibrium."
EDTA,EDTA is used as a component (1 mM) in the assay buffer for rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase activity measurements.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used as a component (1 mM) in the assay buffer for rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase activity measurements.
cysteine,Cysteine is included (1 mM) in the assay buffer for rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase activity assays.,Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. Cysteine is included (1 mM) in the assay buffer for rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase activity assays.
potassium phosphate,"Potassium phosphate is used as the buffer (10 mM, pH 7.6) in the preparation and assay of rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase.","Entity: potassium phosphate. SMILES: O=P([O-])([O-])[O-].[K+].[K+].[K+]. Potassium phosphate is used as the buffer (10 mM, pH 7.6) in the preparation and assay of rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase."
potassium chloride,Potassium chloride is included (1 mM) in the assay buffer for rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase activity assays.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is included (1 mM) in the assay buffer for rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase activity assays.
NAD+,NAD+ is used at a concentration of 300 µM in the assay buffer for rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase activity measurements.,Entity: NAD+. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NAD+ is used at a concentration of 300 µM in the assay buffer for rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase activity measurements.
glyceraldehyde 3-phosphate,Glyceraldehyde 3-phosphate serves as a substrate for rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase in enzymatic assays.,Entity: glyceraldehyde 3-phosphate. SMILES: O=CC(O)COP(=O)(O)O. Glyceraldehyde 3-phosphate serves as a substrate for rabbit skeletal-muscle glyceraldehyde 3-phosphate dehydrogenase in enzymatic assays.
glyceraldehyde 3-phosphate,"Glyceraldehyde 3-phosphate serves as the substrate for glyceraldehyde 3-phosphate dehydrogenase, with the enzyme showing an apparent Km of approximately 250 µM for membrane-associated enzyme and 120 µM for solubilized enzyme.","Entity: glyceraldehyde 3-phosphate. SMILES: O=CC(O)COP(=O)(O)O. Glyceraldehyde 3-phosphate serves as the substrate for glyceraldehyde 3-phosphate dehydrogenase, with the enzyme showing an apparent Km of approximately 250 µM for membrane-associated enzyme and 120 µM for solubilized enzyme."
2-mercaptoethanol,2-mercaptoethanol is used as a reducing agent in the preparation of erythrocyte membrane fractions to retain glyceraldehyde 3-phosphate dehydrogenase activity.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is used as a reducing agent in the preparation of erythrocyte membrane fractions to retain glyceraldehyde 3-phosphate dehydrogenase activity.
sodium chloride,"Sodium chloride at concentrations greater than 100 mM elutes glyceraldehyde 3-phosphate dehydrogenase from erythrocyte membranes, allowing separation of the enzyme from membranes by centrifugation.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride at concentrations greater than 100 mM elutes glyceraldehyde 3-phosphate dehydrogenase from erythrocyte membranes, allowing separation of the enzyme from membranes by centrifugation."
glyceraldehyde 3-phosphate,Glyceraldehyde 3-phosphate serves as a substrate in the assay for measuring glyceraldehyde 3-phosphate dehydrogenase activity.,Entity: glyceraldehyde 3-phosphate. SMILES: O=CC(O)COP(=O)(O)O. Glyceraldehyde 3-phosphate serves as a substrate in the assay for measuring glyceraldehyde 3-phosphate dehydrogenase activity.
NaCl,NaCl is used at 500 mM concentration to solubilize membranes for the preparation of glyceraldehyde 3-phosphate dehydrogenase in free solution.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used at 500 mM concentration to solubilize membranes for the preparation of glyceraldehyde 3-phosphate dehydrogenase in free solution.
sodium phosphate,Sodium phosphate is used at 5 mM concentration and pH 8.0 in the preparation of human erythrocyte ghosts.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used at 5 mM concentration and pH 8.0 in the preparation of human erythrocyte ghosts.
NAD+,NAD+ is included at 10 mM concentration in the assay buffer for monitoring NADH production during glyceraldehyde 3-phosphate dehydrogenase activity.,Entity: NAD+. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NAD+ is included at 10 mM concentration in the assay buffer for monitoring NADH production during glyceraldehyde 3-phosphate dehydrogenase activity.
sodium arsenate,Sodium arsenate is included at 10 mM concentration in the assay buffer for glyceraldehyde 3-phosphate dehydrogenase activity.,Entity: sodium arsenate. SMILES: O=[As]([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium arsenate is included at 10 mM concentration in the assay buffer for glyceraldehyde 3-phosphate dehydrogenase activity.
2-mercaptoethanol,2-mercaptoethanol is used as a reducing agent in the preparation of human erythrocyte ghosts and in the assay buffer for glyceraldehyde 3-phosphate dehydrogenase activity.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is used as a reducing agent in the preparation of human erythrocyte ghosts and in the assay buffer for glyceraldehyde 3-phosphate dehydrogenase activity.
glyceraldehyde 3-phosphate,"Glyceraldehyde 3-phosphate is a negatively charged substrate that binds to negatively charged binding sites on erythrocyte membranes, which decreases the affinity of glyceraldehyde 3-phosphate for the enzyme glyceraldehyde 3-phosphate dehydrogenase.","Entity: glyceraldehyde 3-phosphate. SMILES: O=CC(O)COP(=O)(O)O. Glyceraldehyde 3-phosphate is a negatively charged substrate that binds to negatively charged binding sites on erythrocyte membranes, which decreases the affinity of glyceraldehyde 3-phosphate for the enzyme glyceraldehyde 3-phosphate dehydrogenase."
heliotrine,"Heliotrine, when administered alone, does not increase the incidence of pancreatic islet-cell tumours in rats.","Entity: heliotrine. SMILES: CO[C@H](C)[C@](O)(C(=O)OCC1=CCN2CC[C@H](O)[C@@H]12)C(C)C. Heliotrine, when administered alone, does not increase the incidence of pancreatic islet-cell tumours in rats."
orcinol,"Orcinol is used in the orcinol-H2SO4 method to determine the neutral sugar content of proteins, yielding a value of approximately 20% (w/w) for rat intestinal alkaline phosphatase.","Entity: orcinol. SMILES: Cc1cc(O)cc(O)c1. Orcinol is used in the orcinol-H2SO4 method to determine the neutral sugar content of proteins, yielding a value of approximately 20% (w/w) for rat intestinal alkaline phosphatase."
galactose,Galactose is identified as a neutral sugar component attached to rat intestinal alkaline phosphatase.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose is identified as a neutral sugar component attached to rat intestinal alkaline phosphatase.
mannose,Mannose is identified as a neutral sugar component attached to rat intestinal alkaline phosphatase.,Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose is identified as a neutral sugar component attached to rat intestinal alkaline phosphatase.
glucose,Glucose is identified as a neutral sugar component attached to rat intestinal alkaline phosphatase.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is identified as a neutral sugar component attached to rat intestinal alkaline phosphatase.
nicotinamide,Pretreatment with large doses of nicotinamide increases the incidence of pancreatic islet-cell tumours in rats given heliotrine.,Entity: nicotinamide. SMILES: NC(=O)c1cccnc1. Pretreatment with large doses of nicotinamide increases the incidence of pancreatic islet-cell tumours in rats given heliotrine.
glucose,Glucose can be released from glycoproteins by hydrolysis and is analyzed as an alditol acetate derivative in gas chromatography.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose can be released from glycoproteins by hydrolysis and is analyzed as an alditol acetate derivative in gas chromatography.
arabinose,Arabinose is used as an internal standard in gas chromatographic analysis of monosaccharide alditol acetate derivatives.,Entity: arabinose. SMILES: O=C[C@@H](O)[C@H](O)[C@H](O)CO. Arabinose is used as an internal standard in gas chromatographic analysis of monosaccharide alditol acetate derivatives.
galactose,Galactose can be released from glycoproteins by hydrolysis and is analyzed as an alditol acetate derivative in gas chromatography.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose can be released from glycoproteins by hydrolysis and is analyzed as an alditol acetate derivative in gas chromatography.
mannose,Mannose can be released from glycoproteins by hydrolysis and is analyzed as an alditol acetate derivative in gas chromatography.,Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose can be released from glycoproteins by hydrolysis and is analyzed as an alditol acetate derivative in gas chromatography.
fucose,Fucose can be released from glycoproteins by hydrolysis and is analyzed as an alditol acetate derivative in gas chromatography.,Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose can be released from glycoproteins by hydrolysis and is analyzed as an alditol acetate derivative in gas chromatography.
6-guanidine,"6-guanidine, when used to denature rat intestinal alkaline phosphatase by dialysis, results in a protein sediment with a molecular weight of 78000 as determined by ultracentrifugation.","Entity: 6-guanidine. SMILES: N=C(N)N. 6-guanidine, when used to denature rat intestinal alkaline phosphatase by dialysis, results in a protein sediment with a molecular weight of 78000 as determined by ultracentrifugation."
sodium dodecyl sulphate,"Sodium dodecyl sulphate electrophoresis of rat intestinal alkaline phosphatase separates the enzyme into three protein subunits with molecular weights of 64000, 79000, and 92000.","Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate electrophoresis of rat intestinal alkaline phosphatase separates the enzyme into three protein subunits with molecular weights of 64000, 79000, and 92000."
sodium dodecyl sulphate,Treatment of rat intestinal alkaline phosphatase with sodium dodecyl sulphate yields subunits with an average molecular weight of 78000.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Treatment of rat intestinal alkaline phosphatase with sodium dodecyl sulphate yields subunits with an average molecular weight of 78000.
acetic acid,"Acetic acid, when used as a buffer at pH 3.0, is used to denature rat intestinal alkaline phosphatase by dialysis.","Entity: acetic acid. SMILES: CC(=O)O. Acetic acid, when used as a buffer at pH 3.0, is used to denature rat intestinal alkaline phosphatase by dialysis."
sodium acetate,Sodium acetate buffer at pH 3.0 is used for dialysis-induced denaturation of rat intestinal alkaline phosphatase.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate buffer at pH 3.0 is used for dialysis-induced denaturation of rat intestinal alkaline phosphatase.
p-nitrophenyl phosphate,p-nitrophenyl phosphate is a substrate hydrolyzed by rat intestinal alkaline phosphatase (EC 3.1.3.1) with a specific activity of 4.2 pmol/min per mg protein at pH 10 and 30°C in 0.05 M-Tris/HCl buffer.,Entity: p-nitrophenyl phosphate. SMILES: O=[N+]([O-])c1ccc(OP(=O)([O-])[O-])cc1. p-nitrophenyl phosphate is a substrate hydrolyzed by rat intestinal alkaline phosphatase (EC 3.1.3.1) with a specific activity of 4.2 pmol/min per mg protein at pH 10 and 30°C in 0.05 M-Tris/HCl buffer.
sodium dodecyl sulphate,"Sodium dodecyl sulphate is used in sodium dodecyl sulphate/polyacrylamide-gel electrophoresis to determine the subunit weight of proteins, such as rat intestinal alkaline phosphatase.","Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used in sodium dodecyl sulphate/polyacrylamide-gel electrophoresis to determine the subunit weight of proteins, such as rat intestinal alkaline phosphatase."
heliotrine,"Heliotrine, when administered at approximately 200 mg/kg body weight by stomach tube in rats, elevates plasma insulin concentrations in about 50% of treated rats after 14 months.","Entity: heliotrine. SMILES: CO[C@H](C)[C@](O)(C(=O)OCC1=CCN2CC[C@H](O)[C@@H]12)C(C)C. Heliotrine, when administered at approximately 200 mg/kg body weight by stomach tube in rats, elevates plasma insulin concentrations in about 50% of treated rats after 14 months."
nicotinamide,"Nicotinamide, administered at 350 mg/kg body weight by intraperitoneal injection in rats, alone or in combination with heliotrine, can elevate plasma insulin concentrations in a significant proportion of treated rats after 14 months.","Entity: nicotinamide. SMILES: NC(=O)c1cccnc1. Nicotinamide, administered at 350 mg/kg body weight by intraperitoneal injection in rats, alone or in combination with heliotrine, can elevate plasma insulin concentrations in a significant proportion of treated rats after 14 months."
glucose,"Low blood glucose concentration can be associated with a very marked elevation of plasma insulin in rats treated with heliotrine and nicotinamide, suggesting the development of a functional islet-cell tumour.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Low blood glucose concentration can be associated with a very marked elevation of plasma insulin in rats treated with heliotrine and nicotinamide, suggesting the development of a functional islet-cell tumour."
65Zn,"65Zn excretion in rats is used as a marker to assess the effects of dibutyl phthalate treatment, with values expressed as a percentage of control (corn oil) excretion.","Entity: 65Zn. SMILES: [65Zn]. 65Zn excretion in rats is used as a marker to assess the effects of dibutyl phthalate treatment, with values expressed as a percentage of control (corn oil) excretion."
dibutyl phthalate,"Dibutyl phthalate is administered to rats at a dose of 2 g/kg body weight daily for 9 days, with 65Zn excretion measured to evaluate its effects.","Entity: dibutyl phthalate. SMILES: CCCCOC(=O)c1ccccc1C(=O)OCCCC. Dibutyl phthalate is administered to rats at a dose of 2 g/kg body weight daily for 9 days, with 65Zn excretion measured to evaluate its effects."
zinc,Zinc is essential for the maintenance of normal testicular function.,Entity: zinc. SMILES: [Zn]. Zinc is essential for the maintenance of normal testicular function.
zinc,Zinc plays a protective role against testicular atrophy caused by cadmium.,Entity: zinc. SMILES: [Zn]. Zinc plays a protective role against testicular atrophy caused by cadmium.
EDTA,"EDTA, an efficient antioxidant in many lipid peroxidation-involved situations, is ineffective in preventing isocitrate dehydrogenase leakage and potassium loss in paracetamol-treated rat brain slices.","Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA, an efficient antioxidant in many lipid peroxidation-involved situations, is ineffective in preventing isocitrate dehydrogenase leakage and potassium loss in paracetamol-treated rat brain slices."
promethazine,Promethazine (phenergan) at approximately 1 µM concentration acts as a water-soluble antioxidant and significantly decreases leakage of isocitrate dehydrogenase and loss of potassium content in rat brain slices.,Entity: promethazine. SMILES: CC(CN1c2ccccc2Sc2ccccc21)N(C)C. Promethazine (phenergan) at approximately 1 µM concentration acts as a water-soluble antioxidant and significantly decreases leakage of isocitrate dehydrogenase and loss of potassium content in rat brain slices.
Methylene Blue,Methylene Blue at approximately 1 µM concentration functions as a water-soluble antioxidant and considerably reduces leakage of isocitrate dehydrogenase and loss of potassium content in rat brain slices.,Entity: Methylene Blue. SMILES: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.[Cl-]. Methylene Blue at approximately 1 µM concentration functions as a water-soluble antioxidant and considerably reduces leakage of isocitrate dehydrogenase and loss of potassium content in rat brain slices.
paracetamol,"Paracetamol, after activation to a toxic reactive molecule by the cytochrome P-450 system, triggers a sequence of events leading to cell injury in rat brain slices approximately 3–4 hours after administration.","Entity: paracetamol. SMILES: CC(=O)Nc1ccc(O)cc1. Paracetamol, after activation to a toxic reactive molecule by the cytochrome P-450 system, triggers a sequence of events leading to cell injury in rat brain slices approximately 3–4 hours after administration."
triheptadecanoyl glycerol,Triheptadecanoyl glycerol is used as an internal standard at a concentration of 1.2 mg/g of wet liver in liver tissue lipid analysis.,Entity: triheptadecanoyl glycerol. SMILES: CCCCCCCCCCCCCCCCC(=O)C(O)(CO)C(O)(C(=O)CCCCCCCCCCCCCCCC)C(=O)CCCCCCCCCCCCCCCC. Triheptadecanoyl glycerol is used as an internal standard at a concentration of 1.2 mg/g of wet liver in liver tissue lipid analysis.
heptadecanoic acid,Heptadecanoic acid is used as an internal standard at a concentration of 25 pg/g of wet liver in liver tissue lipid analysis.,Entity: heptadecanoic acid. SMILES: CCCCCCCCCCCCCCCCC(=O)O. Heptadecanoic acid is used as an internal standard at a concentration of 25 pg/g of wet liver in liver tissue lipid analysis.
argon,Argon is used as the carrier gas at a flow rate of 60 ml/min in gas chromatography analysis of fatty acyl methyl esters.,Entity: argon. SMILES: [Ar]. Argon is used as the carrier gas at a flow rate of 60 ml/min in gas chromatography analysis of fatty acyl methyl esters.
linoleate,"Linoleate, an essential fatty acid, declines by greater amounts than palmitate during hepatic perfusion.","Entity: linoleate. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)[O-]. Linoleate, an essential fatty acid, declines by greater amounts than palmitate during hepatic perfusion."
arachidonate,"Arachidonate, an essential fatty acid, declines by greater amounts than palmitate during hepatic perfusion.","Entity: arachidonate. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)[O-]. Arachidonate, an essential fatty acid, declines by greater amounts than palmitate during hepatic perfusion."
palmitate,"Palmitate very nearly retains its initial content in triacylglycerols during perfusion, likely due to replacement by fatty acid synthesis which is rapid under the present perfusion conditions.","Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Palmitate very nearly retains its initial content in triacylglycerols during perfusion, likely due to replacement by fatty acid synthesis which is rapid under the present perfusion conditions."
palmitate,Palmitate is the major component of the liver free fatty acid fraction and is also the major product (in free acid form) synthesized by mammalian fatty acid synthetase.,Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Palmitate is the major component of the liver free fatty acid fraction and is also the major product (in free acid form) synthesized by mammalian fatty acid synthetase.
ammonium molybdate,Ammonium molybdate is used as a negative stain in electron microscopy and causes minimal disruption of erythrocyte ghosts.,Entity: ammonium molybdate. SMILES: O=[Mo](=O)([O-])[O-].[NH4+].[NH4+]. Ammonium molybdate is used as a negative stain in electron microscopy and causes minimal disruption of erythrocyte ghosts.
deoxycholate,Deoxycholate inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.,Entity: deoxycholate. SMILES: C[C@H](CCC(=O)[O-])[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Deoxycholate inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.
sarcosyl,Sarcosyl (sodium N-dodecylsarcosinate) inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.,Entity: sarcosyl. SMILES: CCCCCCCCCCCCN(C)CC(=O)[O-].[Na+]. Sarcosyl (sodium N-dodecylsarcosinate) inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.
sphingosine,Sphingosine inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.,Entity: sphingosine. SMILES: CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CO. Sphingosine inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.
lysophosphatidylcholine,Lysophosphatidylcholine inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.,Entity: lysophosphatidylcholine. SMILES: CC(=O)OC[C@@H](O)COP(=O)([O-])OCC[N+](C)(C)C. Lysophosphatidylcholine inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.
acetyltrimethylammonium bromide,Acetyltrimethylammonium bromide inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.,Entity: acetyltrimethylammonium bromide. SMILES: CC(=O)[N+](C)(C)C.[Br-]. Acetyltrimethylammonium bromide inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.
Triton X-100,Triton X-100 is a detergent that inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a detergent that inhibits the enzyme at low concentrations and does not produce an activation peak at higher concentrations.
lysophosphatidylcholine,Lysophosphatidylcholine exhibits inhibitory activity in the assay system described.,Entity: lysophosphatidylcholine. SMILES: CC(=O)OC[C@@H](O)COP(=O)([O-])OCC[N+](C)(C)C. Lysophosphatidylcholine exhibits inhibitory activity in the assay system described.
Triton X-100,"Triton X-100 at 3 mg/ml solubilizes phospholipids but does not solubilize the enzyme in the assay, as 95% of enzyme activity remains sedimentable after centrifugation at 100,000 g for 1 hour.","Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 at 3 mg/ml solubilizes phospholipids but does not solubilize the enzyme in the assay, as 95% of enzyme activity remains sedimentable after centrifugation at 100,000 g for 1 hour."
UDP-galactose,"Under the assay conditions, UDP-galactose undergoes increased hydrolysis to galactose 1-phosphate, indicating stimulation of nucleotide pyrophosphatase activity by phospholipids.","Entity: UDP-galactose. SMILES: O=c1ccn(C2O[C@H](COP(=O)(O)OP(=O)(O)O[C@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1. Under the assay conditions, UDP-galactose undergoes increased hydrolysis to galactose 1-phosphate, indicating stimulation of nucleotide pyrophosphatase activity by phospholipids."
haemoglobin,"Haemoglobin can be present on the surface of erythrocyte ghosts, accessible to both the inner and outer membrane surfaces, and its presence may alter the surface charge of the membrane.","Entity: haemoglobin. SMILES: Cc1ccc2c(=O)cc(-c3ccco3)[nH]c2n1. Haemoglobin can be present on the surface of erythrocyte ghosts, accessible to both the inner and outer membrane surfaces, and its presence may alter the surface charge of the membrane."
ammonium molybdate,Ammonium molybdate is used as a 2% solution for negative staining in electron microscopy to visualize erythrocyte ghosts.,Entity: ammonium molybdate. SMILES: O=[Mo](=O)([O-])[O-].[NH4+].[NH4+]. Ammonium molybdate is used as a 2% solution for negative staining in electron microscopy to visualize erythrocyte ghosts.
Morphine sulfate,"Morphine sulfate was administered intramuscularly at doses of 1, 2, 5, or 10 mg/kg, or saline, to animals prior to behavioral testing sessions involving temperature change paradigms.","Entity: Morphine sulfate. SMILES: CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O=S(=O)(O)O. Morphine sulfate was administered intramuscularly at doses of 1, 2, 5, or 10 mg/kg, or saline, to animals prior to behavioral testing sessions involving temperature change paradigms."
oxygen,"Oxygen is a component of the polyenzymic free-radical generator 'PIGO', which shows cidal activity against exoplasmic parasites in vitro.","Entity: oxygen. SMILES: [O]. Oxygen is a component of the polyenzymic free-radical generator 'PIGO', which shows cidal activity against exoplasmic parasites in vitro."
iodide,"Iodide is a component of the polyenzymic free-radical generator 'PIGO', which exhibits cidal activity against various exoplasmic parasites in vitro.","Entity: iodide. SMILES: [I-]. Iodide is a component of the polyenzymic free-radical generator 'PIGO', which exhibits cidal activity against various exoplasmic parasites in vitro."
glucose,"Glucose is a component of the polyenzymic free-radical generator 'PIGO', which demonstrates cidal activity against exoplasmic parasites in vitro.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is a component of the polyenzymic free-radical generator 'PIGO', which demonstrates cidal activity against exoplasmic parasites in vitro."
p-aminophenol,"p-aminophenol is a nephrotoxin whose effects on renal injury can be assessed by comparing enzyme determinations in urine, enzyme histochemistry, and histology following administration of doses ranging from 0 to 100 mg/kg body weight.","Entity: p-aminophenol. SMILES: Nc1ccc(O)cc1. p-aminophenol is a nephrotoxin whose effects on renal injury can be assessed by comparing enzyme determinations in urine, enzyme histochemistry, and histology following administration of doses ranging from 0 to 100 mg/kg body weight."
mercuric chloride,"Mercuric chloride is a nephrotoxin whose renal injury response can be evaluated using enzyme assays in urine, enzyme histochemistry, and histology after single subcutaneous doses from 0 to 1.4 mg/kg body weight.","Entity: mercuric chloride. SMILES: Cl[Hg]Cl. Mercuric chloride is a nephrotoxin whose renal injury response can be evaluated using enzyme assays in urine, enzyme histochemistry, and histology after single subcutaneous doses from 0 to 1.4 mg/kg body weight."
L-leucine p-nitroanilide,L-leucine p-nitroanilide is used as a substrate in enzymatic assays to measure alkaline phosphatase activity.,Entity: L-leucine p-nitroanilide. SMILES: CC(C)C[C@H](N)C(=O)Nc1ccc([N+](=O)[O-])cc1. L-leucine p-nitroanilide is used as a substrate in enzymatic assays to measure alkaline phosphatase activity.
p-aminophenol,p-aminophenol is administered at a dose of 100 mg/kg daily for three days to rats in histopathology studies.,Entity: p-aminophenol. SMILES: Nc1ccc(O)cc1. p-aminophenol is administered at a dose of 100 mg/kg daily for three days to rats in histopathology studies.
methanol,Methanol is used as a solvent (50 mM) for preparing L-leucine p-nitroanilide in enzymatic assays.,Entity: methanol. SMILES: CO. Methanol is used as a solvent (50 mM) for preparing L-leucine p-nitroanilide in enzymatic assays.
pargyline,Pargyline (N-methyl-Npropargylbenzylamine) is an amine oxidase inhibitor that inhibits hepatic dimethylnitrosamine degradation.,Entity: pargyline. SMILES: C#CCN(C)Cc1ccccc1. Pargyline (N-methyl-Npropargylbenzylamine) is an amine oxidase inhibitor that inhibits hepatic dimethylnitrosamine degradation.
nialamide,Nialamide [N-benzyl-8-(isonicotiny1hydrazine)propionarnide] is an amine oxidase inhibitor that inhibits hepatic dimethylnitrosamine degradation.,Entity: nialamide. SMILES: O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1. Nialamide [N-benzyl-8-(isonicotiny1hydrazine)propionarnide] is an amine oxidase inhibitor that inhibits hepatic dimethylnitrosamine degradation.
aminoacetonitrile,Aminoacetonitrile inhibits dimethylnitrosamine metabolism in vitro without significantly inhibiting the two measured mixed-function oxidases.,Entity: aminoacetonitrile. SMILES: N#CCN. Aminoacetonitrile inhibits dimethylnitrosamine metabolism in vitro without significantly inhibiting the two measured mixed-function oxidases.
aminoacetonitrile,Aminoacetonitrile is a potent inhibitor of dimethylnitrosamine metabolism in both in vivo and in vitro systems.,Entity: aminoacetonitrile. SMILES: N#CCN. Aminoacetonitrile is a potent inhibitor of dimethylnitrosamine metabolism in both in vivo and in vitro systems.
aminoacetonitrile,Aminoacetonitrile is a potent inhibitor of amine oxidase enzymes.,Entity: aminoacetonitrile. SMILES: N#CCN. Aminoacetonitrile is a potent inhibitor of amine oxidase enzymes.
formaldehyde,Formaldehyde is a metabolite produced from the hepatic metabolism of dimethylnitrosamine in rats.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is a metabolite produced from the hepatic metabolism of dimethylnitrosamine in rats.
methanol,Methanol is a metabolite generated during the hepatic degradation of dimethylnitrosamine in rats.,Entity: methanol. SMILES: CO. Methanol is a metabolite generated during the hepatic degradation of dimethylnitrosamine in rats.
pargyline,Pargyline is considered an inhibitor of monoamine oxidase enzymes.,Entity: pargyline. SMILES: C#CCN(C)Cc1ccccc1. Pargyline is considered an inhibitor of monoamine oxidase enzymes.
cadaverine,"Cadaverine, a substrate of diamine oxidase, is ineffective in inhibiting hepatic dimethylnitrosamine demethylase.","Entity: cadaverine. SMILES: NCCCCCN. Cadaverine, a substrate of diamine oxidase, is ineffective in inhibiting hepatic dimethylnitrosamine demethylase."
aminoacetonitrile,Aminoacetonitrile is considered an inhibitor of monoamine oxidase enzymes.,Entity: aminoacetonitrile. SMILES: N#CCN. Aminoacetonitrile is considered an inhibitor of monoamine oxidase enzymes.
nialamide,Nialamide is considered an inhibitor of monoamine oxidase enzymes.,Entity: nialamide. SMILES: O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1. Nialamide is considered an inhibitor of monoamine oxidase enzymes.
dextran,"Dextran increases fibrinogen solubility by steric exclusion, reducing the available volume for fibrinogen in solution.","Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran increases fibrinogen solubility by steric exclusion, reducing the available volume for fibrinogen in solution."
dextran,"Dextran accelerates fibrin gel formation by increasing the rate of fibrin polymerization, with a greater effect observed at higher molecular weights.","Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran accelerates fibrin gel formation by increasing the rate of fibrin polymerization, with a greater effect observed at higher molecular weights."
dextran,Dextran does not significantly affect the rate of proteolysis of fibrinogen by thrombin.,Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran does not significantly affect the rate of proteolysis of fibrinogen by thrombin.
dextran,"Dextran affects the clotting time of fibrinogen solutions by influencing the fibrinogen concentration, with the relationship between clotting time and dextran concentration following the form described by steric exclusion models.","Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran affects the clotting time of fibrinogen solutions by influencing the fibrinogen concentration, with the relationship between clotting time and dextran concentration following the form described by steric exclusion models."
dextran,"Dextran increases the rate of the fibrinogen-to-fibrin transition by steric exclusion, effectively increasing the concentration of fibrinogen and fibrin in solution without significantly altering their concentrations.","Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran increases the rate of the fibrinogen-to-fibrin transition by steric exclusion, effectively increasing the concentration of fibrinogen and fibrin in solution without significantly altering their concentrations."
dextran,"Dextran precipitates fibrinogen from solution solely due to steric exclusion, which increases the effective concentration of fibrinogen.","Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran precipitates fibrinogen from solution solely due to steric exclusion, which increases the effective concentration of fibrinogen."
trichloroacetic acid,"Trichloroacetic acid is used as a reagent to precipitate and wash platelet microtubule proteins, facilitating the isolation of associated proteins or nucleic acids.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used as a reagent to precipitate and wash platelet microtubule proteins, facilitating the isolation of associated proteins or nucleic acids."
trichloroacetic acid,"Hot trichloroacetic acid (35% w/v, 90°C for 25 min) can be used to extract nucleotide or nucleic acid material from protein pellets, with 6% of total radioactivity recovered in the hot trichloroacetic acid extract.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Hot trichloroacetic acid (35% w/v, 90°C for 25 min) can be used to extract nucleotide or nucleic acid material from protein pellets, with 6% of total radioactivity recovered in the hot trichloroacetic acid extract."
H2O2,H2O2 at 30% (w/v) is used to dissolve gel slices containing 32P-labelled proteins prior to liquid scintillation counting.,Entity: H2O2. SMILES: OO. H2O2 at 30% (w/v) is used to dissolve gel slices containing 32P-labelled proteins prior to liquid scintillation counting.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used as a denaturing agent in SDS/polyacrylamide-gel electrophoresis to solubilize proteins for analysis.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used as a denaturing agent in SDS/polyacrylamide-gel electrophoresis to solubilize proteins for analysis.
urea,Urea is used at 8 M concentration as a denaturing agent in SDS/polyacrylamide-gel electrophoresis to disrupt protein secondary and tertiary structure.,Entity: urea. SMILES: NC(N)=O. Urea is used at 8 M concentration as a denaturing agent in SDS/polyacrylamide-gel electrophoresis to disrupt protein secondary and tertiary structure.
MgCl2,MgCl2 is used at 8.5 mM concentration as a component of the buffer in SDS/polyacrylamide-gel electrophoresis to facilitate protein denaturation and maintain protein stability.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used at 8.5 mM concentration as a component of the buffer in SDS/polyacrylamide-gel electrophoresis to facilitate protein denaturation and maintain protein stability.
ATP,ATP is used at 5 µM cyclic AMP and 62.5 µM β-ATP concentration in the preparation of 32P-labelled platelet tubulin for electrophoresis.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP is used at 5 µM cyclic AMP and 62.5 µM β-ATP concentration in the preparation of 32P-labelled platelet tubulin for electrophoresis.
Tris,Tris buffer at pH 7.0 is used as the running buffer in SDS/polyacrylamide-gel electrophoresis for protein separation.,Entity: Tris. SMILES: NC(CO)(CO)CO. Tris buffer at pH 7.0 is used as the running buffer in SDS/polyacrylamide-gel electrophoresis for protein separation.
Bromophenol Blue,Bromophenol Blue is used as a tracking dye in SDS/polyacrylamide-gel electrophoresis to monitor the progress of protein separation.,Entity: Bromophenol Blue. SMILES: O=S1(=O)OC(c2cc(Br)c(O)c(Br)c2)(c2cc(Br)c(O)c(Br)c2)c2ccccc21. Bromophenol Blue is used as a tracking dye in SDS/polyacrylamide-gel electrophoresis to monitor the progress of protein separation.
ATP,"In a pig platelet microtubule protein preparation, ATP serves as the principal acceptor for phosphate in a protein kinase activity associated with tubulin.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. In a pig platelet microtubule protein preparation, ATP serves as the principal acceptor for phosphate in a protein kinase activity associated with tubulin."
acetylacetone,Acetylacetone is used for elution and derivatization of compounds on XAD-2 columns in paper chromatography.,Entity: acetylacetone. SMILES: CC(=O)CC(C)=O. Acetylacetone is used for elution and derivatization of compounds on XAD-2 columns in paper chromatography.
methanol,Methanol is used as the eluent for extracting radioactive peaks from XAD-2 columns in paper chromatography.,Entity: methanol. SMILES: CO. Methanol is used as the eluent for extracting radioactive peaks from XAD-2 columns in paper chromatography.
debrisoquine,Debrisoquine is metabolized in rats to metabolites that are identical in identity to those found in humans.,Entity: debrisoquine. SMILES: N=C(N)N1CCc2ccccc2C1. Debrisoquine is metabolized in rats to metabolites that are identical in identity to those found in humans.
debrisoquine,The extent of debrisoquine metabolism varies more among human subjects than among rats.,Entity: debrisoquine. SMILES: N=C(N)N1CCc2ccccc2C1. The extent of debrisoquine metabolism varies more among human subjects than among rats.
4-hydroxydebrisoquine,"4-hydroxydebrisoquine is a metabolite of debrisoquine, as confirmed by retention time and mass spectrum matching with authentic standards after derivatization.","Entity: 4-hydroxydebrisoquine. SMILES: N=C(N)N1Cc2ccccc2C(O)C1. 4-hydroxydebrisoquine is a metabolite of debrisoquine, as confirmed by retention time and mass spectrum matching with authentic standards after derivatization."
acetylacetone,Acetylacetone is used as a derivatization reagent for extracting and identifying compounds from rat urine samples prior to mass spectrometry analysis.,Entity: acetylacetone. SMILES: CC(=O)CC(C)=O. Acetylacetone is used as a derivatization reagent for extracting and identifying compounds from rat urine samples prior to mass spectrometry analysis.
4-hydroxydebrisoquine,4-hydroxydebrisoquine is a metabolite of debrisoquine that can be detected in trace amounts in rat urine after hydrolysis and derivatization.,Entity: 4-hydroxydebrisoquine. SMILES: N=C(N)N1Cc2ccccc2C(O)C1. 4-hydroxydebrisoquine is a metabolite of debrisoquine that can be detected in trace amounts in rat urine after hydrolysis and derivatization.
4-Hydroxydebrisoquine,4-Hydroxydebrisoquine has a radiolabeling RF value of 0.28 when synthesized from Kx4CN-labelled debrisoquine hydrochloride.,Entity: 4-Hydroxydebrisoquine. SMILES: N=C(N)N1Cc2ccccc2C(O)C1. 4-Hydroxydebrisoquine has a radiolabeling RF value of 0.28 when synthesized from Kx4CN-labelled debrisoquine hydrochloride.
Sodium nitroprusside,Sodium nitroprusside is used as a reagent in H2O2 spray to make compounds visible for detection in analytical assays.,Entity: Sodium nitroprusside. SMILES: N#[O+].O.O.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[Fe+2].[Na+].[Na+]. Sodium nitroprusside is used as a reagent in H2O2 spray to make compounds visible for detection in analytical assays.
Hydrogen peroxide,Hydrogen peroxide is used as part of a spray reagent with sodium nitroprusside to visualize compounds in analytical assays.,Entity: Hydrogen peroxide. SMILES: OO. Hydrogen peroxide is used as part of a spray reagent with sodium nitroprusside to visualize compounds in analytical assays.
sodium 2-(4-chlorophenoxy)-2-methylpropionate,Sodium 2-(4-chlorophenoxy)-2-methylpropionate is used at a concentration of 0.75 mM in perfusate to mimic serum levels in rats fed a standard diet containing 0.25% (w/w) of the drug.,Entity: sodium 2-(4-chlorophenoxy)-2-methylpropionate. SMILES: CC(C)(Oc1ccc(Cl)cc1)C(=O)[O-].[Na+]. Sodium 2-(4-chlorophenoxy)-2-methylpropionate is used at a concentration of 0.75 mM in perfusate to mimic serum levels in rats fed a standard diet containing 0.25% (w/w) of the drug.
oleate,Oleate-labelled chylomicrons are oxidized to δCO2 to the extent of 0.3% of the total dose administered in the liver.,Entity: oleate. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)[O-]. Oleate-labelled chylomicrons are oxidized to δCO2 to the extent of 0.3% of the total dose administered in the liver.
palmitate,Palmitate-labelled chylomicrons are oxidized to δCO2 to the extent of 0.3% of the total dose administered in the liver.,Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Palmitate-labelled chylomicrons are oxidized to δCO2 to the extent of 0.3% of the total dose administered in the liver.
carbon dioxide,Carbon dioxide is produced from the oxidation of oleate- and palmitate-labelled chylomicrons in the liver at a rate of 0.3% of the total dose administered.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is produced from the oxidation of oleate- and palmitate-labelled chylomicrons in the liver at a rate of 0.3% of the total dose administered.
cholesterol,"Cholesterol is present in chylomicron remnants and chylomicrons, and in the liver, but is not directly involved in the observed 60% conversion of chylomicron remnants to higher-density particles.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol is present in chylomicron remnants and chylomicrons, and in the liver, but is not directly involved in the observed 60% conversion of chylomicron remnants to higher-density particles."
palmitate,"Palmitate-labelled chylomicron remnants are oxidized to the extent of 0.62 ± 0.06, indicating the species of long-chain fatty acid influences their metabolic processing.","Entity: palmitate. SMILES: CCCCCCCCCCCCCCCC(=O)[O-]. Palmitate-labelled chylomicron remnants are oxidized to the extent of 0.62 ± 0.06, indicating the species of long-chain fatty acid influences their metabolic processing."
oleate,"Oleate-labelled chylomicron remnants are oxidized to the extent of 1.62 ± 0.60, indicating the species of long-chain fatty acid influences their metabolic processing.","Entity: oleate. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)[O-]. Oleate-labelled chylomicron remnants are oxidized to the extent of 1.62 ± 0.60, indicating the species of long-chain fatty acid influences their metabolic processing."
acetoacetate,"Total ketone bodies increase in liver perfusions, principally due to a doubling in acetoacetate production.","Entity: acetoacetate. SMILES: CC(=O)CC(=O)[O-]. Total ketone bodies increase in liver perfusions, principally due to a doubling in acetoacetate production."
lactate,"The blood [lactate]/[pyruvate] ratio is 8.0 in control liver perfusions and 4.5 in treated liver perfusions, indicating a shift toward a more reduced redox state in treated livers.","Entity: lactate. SMILES: CC(O)C(=O)[O-]. The blood [lactate]/[pyruvate] ratio is 8.0 in control liver perfusions and 4.5 in treated liver perfusions, indicating a shift toward a more reduced redox state in treated livers."
pyruvate,"The blood [lactate]/[pyruvate] ratio is 8.0 in control liver perfusions and 4.5 in treated liver perfusions, indicating a shift toward a more reduced redox state in treated livers.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. The blood [lactate]/[pyruvate] ratio is 8.0 in control liver perfusions and 4.5 in treated liver perfusions, indicating a shift toward a more reduced redox state in treated livers."
3-hydroxybutyrate,"The perfusate [3-hydroxybutyrate]/[acetoacetate] ratio decreases from 1.7 in control liver perfusions to 1.3 in treated liver perfusions, reflecting a shift in redox state.","Entity: 3-hydroxybutyrate. SMILES: CC(O)CC(=O)[O-]. The perfusate [3-hydroxybutyrate]/[acetoacetate] ratio decreases from 1.7 in control liver perfusions to 1.3 in treated liver perfusions, reflecting a shift in redox state."
NAD+,"NAD+ is reducible at the dropping mercury electrode within the potential range of -1.1 V to -1.3 V, and its cathodic wave can be measured in polarographic assays.","Entity: NAD+. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NAD+ is reducible at the dropping mercury electrode within the potential range of -1.1 V to -1.3 V, and its cathodic wave can be measured in polarographic assays."
NADP+,"NADP+ is reducible at the dropping mercury electrode within the potential range of -1.1 V to -1.3 V, and its cathodic wave can be measured in polarographic assays.","Entity: NADP+. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP+ is reducible at the dropping mercury electrode within the potential range of -1.1 V to -1.3 V, and its cathodic wave can be measured in polarographic assays."
NADPH,"NADPH is not electroactive at potentials between -1.1 V and -1.3 V, so it does not interfere with polarographic measurements of dehydrogenases under these conditions.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is not electroactive at potentials between -1.1 V and -1.3 V, so it does not interfere with polarographic measurements of dehydrogenases under these conditions."
labetalol,Labetalol is an a- and 8-receptor antagonist.,Entity: labetalol. SMILES: CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1. Labetalol is an a- and 8-receptor antagonist.
labetalol,"In humans, the major metabolite of labetalol after oral administration is a conjugate of labetalol formed via glucuronidation.","Entity: labetalol. SMILES: CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1. In humans, the major metabolite of labetalol after oral administration is a conjugate of labetalol formed via glucuronidation."
labetalol,Labetalol undergoes hydrolysis of its amide group to form 2-hydroxy-5-methyl-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid.,Entity: labetalol. SMILES: CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1. Labetalol undergoes hydrolysis of its amide group to form 2-hydroxy-5-methyl-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid.
labetalol,Labetalol is partially hydrolyzed by p-glucuronidase to form a 0-phenyl glucuronide metabolite and a secondary metabolite resistant to hydrolysis by glucuronidase and sulphatase.,Entity: labetalol. SMILES: CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1. Labetalol is partially hydrolyzed by p-glucuronidase to form a 0-phenyl glucuronide metabolite and a secondary metabolite resistant to hydrolysis by glucuronidase and sulphatase.
hydrochloric acid,"Hydrochloric acid can hydrolyze the secondary metabolite of labetalol, resulting in the formation of labetalol and 2-hydroxy-5-methyl-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid.","Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid can hydrolyze the secondary metabolite of labetalol, resulting in the formation of labetalol and 2-hydroxy-5-methyl-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid."
labetalol,Labetalol is a major human radioactive metabolite that is partially hydrolyzed by glucuronidase to form a conjugate with a conjugating group.,Entity: labetalol. SMILES: CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1. Labetalol is a major human radioactive metabolite that is partially hydrolyzed by glucuronidase to form a conjugate with a conjugating group.
labetalol,Labetalol undergoes hydrolysis of its amide group to form 2-hydroxy-5-(2-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid.,Entity: labetalol. SMILES: CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1. Labetalol undergoes hydrolysis of its amide group to form 2-hydroxy-5-(2-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid.
2-hydroxy-5-(2-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid,2-hydroxy-5-(2-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid is a metabolite formed by hydrolysis of the amide group of labetalol.,Entity: 2-hydroxy-5-(2-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid. SMILES: CC(CCc1ccccc1)NC(O)Cc1ccc(O)c(C(=O)O)c1. 2-hydroxy-5-(2-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid is a metabolite formed by hydrolysis of the amide group of labetalol.
hydrochloric acid,Hydrochloric acid can hydrolyze a metabolite resistant to glucuronidase and sulphatase to yield labetalol and 2-hydroxy-5-(2-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid can hydrolyze a metabolite resistant to glucuronidase and sulphatase to yield labetalol and 2-hydroxy-5-(2-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzoic acid.
Labetalol,Labetalol is an a- and 8-receptor antagonist with higher activity compared to hydroxylabetalol in this role.,Entity: Labetalol. SMILES: CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1. Labetalol is an a- and 8-receptor antagonist with higher activity compared to hydroxylabetalol in this role.
vinblastine,"Vinblastine is used as a binding agent in assays to measure colchicine-binding activity, with a final concentration of 100 µM in the assay mixture containing 200–400 pg protein in 0.5 ml.","Entity: vinblastine. SMILES: CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O. Vinblastine is used as a binding agent in assays to measure colchicine-binding activity, with a final concentration of 100 µM in the assay mixture containing 200–400 pg protein in 0.5 ml."
pyridine,"Pyridine acts as a ligand in copper(II) and nickel(II) complexes, and its addition to these metal complexes in benzene solution at 30°C is exothermic, with enthalpies of formation ranging from approximately -30 kJ/mol (-7 kcal/mol) for both systems.","Entity: pyridine. SMILES: c1ccncc1. Pyridine acts as a ligand in copper(II) and nickel(II) complexes, and its addition to these metal complexes in benzene solution at 30°C is exothermic, with enthalpies of formation ranging from approximately -30 kJ/mol (-7 kcal/mol) for both systems."
porphyrin,"In some biological systems, the function of metal atoms in porphyrin-type systems involves their ability to act as Lewis acids, increasing their coordination number upon addition of a base.","Entity: porphyrin. SMILES: C1=Cc2cc3ccc(cc4nc(cc5ccc(cc1n2)[nH]5)C=C4)[nH]3. In some biological systems, the function of metal atoms in porphyrin-type systems involves their ability to act as Lewis acids, increasing their coordination number upon addition of a base."
benzene,Benzene is described as an 'inert' solvent in which solvent ordering effects can significantly influence the stability of transition complex adducts.,Entity: benzene. SMILES: c1ccccc1. Benzene is described as an 'inert' solvent in which solvent ordering effects can significantly influence the stability of transition complex adducts.
propionylthiocholine,"In crude homogenates, smooth-muscle cholinesterase preferentially hydrolyzes propionylthiocholine.","Entity: propionylthiocholine. SMILES: CCC(=O)SCC[N+](C)(C)C. In crude homogenates, smooth-muscle cholinesterase preferentially hydrolyzes propionylthiocholine."
propionylthiocholine,"Particulate cholinesterases have an equally preferred affinity for propionylthiocholine as for acetylthiocholine, as judged by K,,, values.","Entity: propionylthiocholine. SMILES: CCC(=O)SCC[N+](C)(C)C. Particulate cholinesterases have an equally preferred affinity for propionylthiocholine as for acetylthiocholine, as judged by K,,, values."
tetraisopropylpyrophosphate,Tetraisopropylpyrophosphate inhibits almost totally all activities of the S fraction of subcellular extracts.,Entity: tetraisopropylpyrophosphate. SMILES: CC(C)OP(=O)(OC(C)C)OP(=O)(OC(C)C)OC(C)C. Tetraisopropylpyrophosphate inhibits almost totally all activities of the S fraction of subcellular extracts.
tetraisopropylpyrophosphate,Tetraisopropylpyrophosphate inhibits 60–70% of the activities of particulate cholinesterase fractions.,Entity: tetraisopropylpyrophosphate. SMILES: CC(C)OP(=O)(OC(C)C)OP(=O)(OC(C)C)OC(C)C. Tetraisopropylpyrophosphate inhibits 60–70% of the activities of particulate cholinesterase fractions.
acetylthiocholine,"Particulate cholinesterases have an equally preferred affinity for acetylthiocholine as for propionylthiocholine, as judged by K,,, values.","Entity: acetylthiocholine. SMILES: CC(=O)SCC[N+](C)(C)C. Particulate cholinesterases have an equally preferred affinity for acetylthiocholine as for propionylthiocholine, as judged by K,,, values."
butyrylthiocholine,"The S fraction of subcellular extracts shows a preferred affinity for butyrylthiocholine as a substrate for cholinesterase activity, as indicated by K,,, values.","Entity: butyrylthiocholine. SMILES: CCCC(=O)SCC[N+](C)(C)C. The S fraction of subcellular extracts shows a preferred affinity for butyrylthiocholine as a substrate for cholinesterase activity, as indicated by K,,, values."
butyrylthiocholine,"In crude homogenates, smooth-muscle cholinesterase preferentially hydrolyzes butyrylthiocholine.","Entity: butyrylthiocholine. SMILES: CCCC(=O)SCC[N+](C)(C)C. In crude homogenates, smooth-muscle cholinesterase preferentially hydrolyzes butyrylthiocholine."
"5,5'-dithiobis-(2-nitrobenzoic acid)","5,5'-dithiobis-(2-nitrobenzoic acid) is used as a chromogenic reagent in coupled enzymatic assays to measure cholinesterase activities.","Entity: 5,5'-dithiobis-(2-nitrobenzoic acid). SMILES: O=C(O)c1cc(SSc2ccc([N+](=O)[O-])c(C(=O)O)c2)ccc1[N+](=O)[O-]. 5,5'-dithiobis-(2-nitrobenzoic acid) is used as a chromogenic reagent in coupled enzymatic assays to measure cholinesterase activities."
acetylthiocholine,Acetylthiocholine iodide serves as a substrate in coupled cholinesterase activity assays to assess enzyme function.,Entity: acetylthiocholine. SMILES: CC(=O)SCC[N+](C)(C)C. Acetylthiocholine iodide serves as a substrate in coupled cholinesterase activity assays to assess enzyme function.
propionylthiocholine,Propionylthiocholine iodide is utilized as a substrate in cholinesterase activity assays to evaluate enzyme inhibition.,Entity: propionylthiocholine. SMILES: CCC(=O)SCC[N+](C)(C)C. Propionylthiocholine iodide is utilized as a substrate in cholinesterase activity assays to evaluate enzyme inhibition.
butyrylthiocholine iodide,Butyrylthiocholine iodide is used as a substrate in cholinesterase activity assays to measure enzyme activity.,Entity: butyrylthiocholine iodide. SMILES: CCCC(=O)SCC[N+](C)(C)C.[I-]. Butyrylthiocholine iodide is used as a substrate in cholinesterase activity assays to measure enzyme activity.
ATP,"ATP forms a complex with magnesium ions, with an association constant (K) of 1.13 x 10^4 M^-1, which is similar to previously reported values.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP forms a complex with magnesium ions, with an association constant (K) of 1.13 x 10^4 M^-1, which is similar to previously reported values."
Mg,"At pH values below 7.0, Mg forms a weak interaction with the ATP complex, with an estimated association constant of about 10^8 M^-1, as demonstrated by proton and 31P NMR spectroscopy.","Entity: Mg. SMILES: [Mg]. At pH values below 7.0, Mg forms a weak interaction with the ATP complex, with an estimated association constant of about 10^8 M^-1, as demonstrated by proton and 31P NMR spectroscopy."
magnesium,"Magnesium is involved in the formation of ATP-noradrenaline complexes at the synapse, which are linked to noradrenaline storage and transport.","Entity: magnesium. SMILES: [Mg]. Magnesium is involved in the formation of ATP-noradrenaline complexes at the synapse, which are linked to noradrenaline storage and transport."
lithium,Lithium inhibits magnesium-dependent enzymes at concentrations in the pharmacological range of 0.5–1.5 mM.,Entity: lithium. SMILES: [Li]. Lithium inhibits magnesium-dependent enzymes at concentrations in the pharmacological range of 0.5–1.5 mM.
lithium,Lithium may exert its action in periodic psychoses by interfering with the metabolism of catecholamine neurotransmitters.,Entity: lithium. SMILES: [Li]. Lithium may exert its action in periodic psychoses by interfering with the metabolism of catecholamine neurotransmitters.
adenosine diphosphate,"Adenosine diphosphate (ADP) can compete with magnesium for binding to pyruvate kinase, as shown by competitive inhibition.","Entity: adenosine diphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine diphosphate (ADP) can compete with magnesium for binding to pyruvate kinase, as shown by competitive inhibition."
porphobilinogen,"During the enzymatic formation of porphobilinogen from 5-aminolaevulinic acid, the pro-S-hydrogen atom from the 5 position of 5-aminolaevulinic acid is retained in the product porphobilinogen, indicating stereospecific formation at the 2 position of the pyrrole ring.","Entity: porphobilinogen. SMILES: NCc1[nH]cc(CCC(=O)O)c1CC(=O)O. During the enzymatic formation of porphobilinogen from 5-aminolaevulinic acid, the pro-S-hydrogen atom from the 5 position of 5-aminolaevulinic acid is retained in the product porphobilinogen, indicating stereospecific formation at the 2 position of the pyrrole ring."
iodoacetic acid,"Iodoacetic acid reacts with groups on the enzyme at or near neutral pH, incorporating carboxymethyl groups into the enzyme octamer and causing a loss of catalytic activity.","Entity: iodoacetic acid. SMILES: O=C(O)CI. Iodoacetic acid reacts with groups on the enzyme at or near neutral pH, incorporating carboxymethyl groups into the enzyme octamer and causing a loss of catalytic activity."
4-oxopentanoic acid,"4-oxopentanoic acid, a substrate analogue of iodoacetic acid, can partially prevent the loss of catalytic activity in the enzyme upon reaction with iodoacetic acid.","Entity: 4-oxopentanoic acid. SMILES: CC(=O)CCC(=O)O. 4-oxopentanoic acid, a substrate analogue of iodoacetic acid, can partially prevent the loss of catalytic activity in the enzyme upon reaction with iodoacetic acid."
2-mercaptoethanol,"2-mercaptoethanol is required for the inactivation of the enzyme by β-iodoacetic acid, as the loss of titrating groups per octamer is dependent on its presence.","Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is required for the inactivation of the enzyme by β-iodoacetic acid, as the loss of titrating groups per octamer is dependent on its presence."
porphobilinogen,"Porphobilinogen is the direct precursor of the macrocyclic rings of haem, chlorophylls, and corrin.","Entity: porphobilinogen. SMILES: NCc1[nH]cc(CCC(=O)O)c1CC(=O)O. Porphobilinogen is the direct precursor of the macrocyclic rings of haem, chlorophylls, and corrin."
dithiothreitol,"Dithiothreitol is a thiol that supports the optimal activity of 5-aminolaevulinate dehydratase, indicating the importance of cysteine residues in its function.","Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is a thiol that supports the optimal activity of 5-aminolaevulinate dehydratase, indicating the importance of cysteine residues in its function."
"5,5'-dithiobis-(2-nitrobenzoic acid)","5,5'-dithiobis-(2-nitrobenzoic acid) reacts with 16 cysteine residues on the enzyme, with eight groups being highly reactive and the others less reactive, as shown by stopped-flow kinetic analysis.","Entity: 5,5'-dithiobis-(2-nitrobenzoic acid). SMILES: O=C(O)c1cc(SSc2ccc([N+](=O)[O-])c(C(=O)O)c2)ccc1[N+](=O)[O-]. 5,5'-dithiobis-(2-nitrobenzoic acid) reacts with 16 cysteine residues on the enzyme, with eight groups being highly reactive and the others less reactive, as shown by stopped-flow kinetic analysis."
iodoacetic acid,"Iodoacetic acid reacts with groups on an enzyme at or near neutral pH, incorporating carboxymethyl groups into the enzyme and causing loss of catalytic activity.","Entity: iodoacetic acid. SMILES: O=C(O)CI. Iodoacetic acid reacts with groups on an enzyme at or near neutral pH, incorporating carboxymethyl groups into the enzyme and causing loss of catalytic activity."
S-carboxymethylcysteine,"S-carboxymethylcysteine is detected as the only carboxymethylated amino acid in a hydrolysate after treatment with iodoacetic acid, as confirmed by paper electrophoresis.","Entity: S-carboxymethylcysteine. SMILES: N[C@@H](CSCC(=O)O)C(=O)O. S-carboxymethylcysteine is detected as the only carboxymethylated amino acid in a hydrolysate after treatment with iodoacetic acid, as confirmed by paper electrophoresis."
4-oxopentanoic acid,"4-oxopentanoic acid, a substrate analogue, can partially prevent the loss of catalytic activity in an enzyme after carboxymethylation with iodoacetic acid.","Entity: 4-oxopentanoic acid. SMILES: CC(=O)CCC(=O)O. 4-oxopentanoic acid, a substrate analogue, can partially prevent the loss of catalytic activity in an enzyme after carboxymethylation with iodoacetic acid."
2-mercaptoethanol,"2-mercaptoethanol is used as a reducing agent to maintain the activity of 5-aminolaevulinate dehydratase, indicating that cysteine residues are important for its enzymatic function.","Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is used as a reducing agent to maintain the activity of 5-aminolaevulinate dehydratase, indicating that cysteine residues are important for its enzymatic function."
dithiothreitol,"Dithiothreitol acts as a reducing agent and maintains the optimal activity of 5-aminolaevulinate dehydratase, suggesting that cysteine residues are important for its function.","Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol acts as a reducing agent and maintains the optimal activity of 5-aminolaevulinate dehydratase, suggesting that cysteine residues are important for its function."
"5,5'-dithiobis-(2-nitrobenzoic acid)","5,5'-dithiobis-(2-nitrobenzoic acid) reacts with 16 cysteine residues on 5-aminolaevulinate dehydratase, with eight groups being highly reactive and the others less reactive, as shown by stopped-flow kinetic analysis.","Entity: 5,5'-dithiobis-(2-nitrobenzoic acid). SMILES: O=C(O)c1cc(SSc2ccc([N+](=O)[O-])c(C(=O)O)c2)ccc1[N+](=O)[O-]. 5,5'-dithiobis-(2-nitrobenzoic acid) reacts with 16 cysteine residues on 5-aminolaevulinate dehydratase, with eight groups being highly reactive and the others less reactive, as shown by stopped-flow kinetic analysis."
porphobilinogen,"Porphobilinogen is the direct precursor of the macrocyclic rings of haem, chlorophylls, and corrin.","Entity: porphobilinogen. SMILES: NCc1[nH]cc(CCC(=O)O)c1CC(=O)O. Porphobilinogen is the direct precursor of the macrocyclic rings of haem, chlorophylls, and corrin."
dithiothreitol,Dithiothreitol is used as a reducing agent in TED buffer at a concentration of 1 mM to maintain a stable pH 7.6 during protein purification and receptor binding assays.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used as a reducing agent in TED buffer at a concentration of 1 mM to maintain a stable pH 7.6 during protein purification and receptor binding assays.
KCI,"KCl is used to elute bound [3H]oestradiol-receptor complexes from affinity columns, with 85% release at 0.5 M KCl and 15% at 1 mM KCl.","Entity: KCI. SMILES: [Cl-].[K+]. KCl is used to elute bound [3H]oestradiol-receptor complexes from affinity columns, with 85% release at 0.5 M KCl and 15% at 1 mM KCl."
NADPH,"Human placenta contains smaller amounts of NADPH compared to NAD+, NADH, and NADP+.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. Human placenta contains smaller amounts of NADPH compared to NAD+, NADH, and NADP+."
oestradiol,"Oestradiol can be used to label estrogen receptor bound to DNA-cellulose or oligo(dT)-cellulose, with the receptor being eluted using 0.4 M KCl.","Entity: oestradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Oestradiol can be used to label estrogen receptor bound to DNA-cellulose or oligo(dT)-cellulose, with the receptor being eluted using 0.4 M KCl."
KCl,KCl at 0.4 M concentration is used to elute estrogen receptor that has been bound to DNA-cellulose or oligo(dT)-cellulose.,Entity: KCl. SMILES: [Cl-].[K+]. KCl at 0.4 M concentration is used to elute estrogen receptor that has been bound to DNA-cellulose or oligo(dT)-cellulose.
oestradiol,"Oestradiol can bind to DNA-cellulose or oligo(dT)-cellulose, but its binding is not required for the interaction of the estrogen receptor with these columns.","Entity: oestradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Oestradiol can bind to DNA-cellulose or oligo(dT)-cellulose, but its binding is not required for the interaction of the estrogen receptor with these columns."
NAD+,"In the oxidation of oestradiol-178, inhibition by ATP is competitive with respect to NAD+, with 83% inhibition observed at ~0.1 mM ATP at pH 8 in potassium phosphate buffer when NAD+ is 200 pM.","Entity: NAD+. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. In the oxidation of oestradiol-178, inhibition by ATP is competitive with respect to NAD+, with 83% inhibition observed at ~0.1 mM ATP at pH 8 in potassium phosphate buffer when NAD+ is 200 pM."
ATP,"ATP acts as a competitive inhibitor of coenzyme-dependent reactions, with inhibition being greater at lower coenzyme concentrations and reversible by increasing ATP concentration.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP acts as a competitive inhibitor of coenzyme-dependent reactions, with inhibition being greater at lower coenzyme concentrations and reversible by increasing ATP concentration."
ATP,The intracellular concentration of ATP in many tissues is of the order of 1 mM.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. The intracellular concentration of ATP in many tissues is of the order of 1 mM.
oestradiol,"Oestradiol can bind to cellular receptors, and its binding can be used to elute receptors from affinity columns in the presence of low-salt KCl.","Entity: oestradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Oestradiol can bind to cellular receptors, and its binding can be used to elute receptors from affinity columns in the presence of low-salt KCl."
trichloroacetic acid,"Trichloroacetic acid is used as a precipitating agent for purifying nucleic acids from cell lysates, applied at 5% (w/v) concentration.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used as a precipitating agent for purifying nucleic acids from cell lysates, applied at 5% (w/v) concentration."
ethanol,"Ethanol, at 95% (v/v) concentration, is used to wash filters containing precipitated nucleic acids during the purification process.","Entity: ethanol. SMILES: CCO. Ethanol, at 95% (v/v) concentration, is used to wash filters containing precipitated nucleic acids during the purification process."
metrizamide,"Metrizamide is used to form a step gradient for density-based centrifugation of cell lysates, with concentrations ranging from 30% to 50% (w/v) in 20 mM Hepes buffer at pH 7.6.","Entity: metrizamide. SMILES: CC(=O)Nc1c(I)c(C(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO)c(I)c(N(C)C(C)=O)c1I. Metrizamide is used to form a step gradient for density-based centrifugation of cell lysates, with concentrations ranging from 30% to 50% (w/v) in 20 mM Hepes buffer at pH 7.6."
metrizamide,"Metrizamide is a non-ionic compound that can be used as a density gradient material for separating chromatin into components based on buoyant density, without inactivating enzymes.","Entity: metrizamide. SMILES: CC(=O)Nc1c(I)c(C(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO)c(I)c(N(C)C(C)=O)c1I. Metrizamide is a non-ionic compound that can be used as a density gradient material for separating chromatin into components based on buoyant density, without inactivating enzymes."
thymidine,"Thymidine is used to label chromatin DNA during a 5-minute pulse at 37°C, with all labeled DNA present in the lighter chromatin component (density 1.23 g/cm³) after shearing.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine is used to label chromatin DNA during a 5-minute pulse at 37°C, with all labeled DNA present in the lighter chromatin component (density 1.23 g/cm³) after shearing."
Triton X-100,Triton X-100 is used at 0.5% (w/v) concentration to lyse BHK-21/C13 cells during chromatin extraction protocols.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used at 0.5% (w/v) concentration to lyse BHK-21/C13 cells during chromatin extraction protocols.
thymidine,Thymidine is used as a nucleotide label in cell culture experiments to identify and quantify newly synthesized DNA in BHK-21/C13 cells.,Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine is used as a nucleotide label in cell culture experiments to identify and quantify newly synthesized DNA in BHK-21/C13 cells.
"5a-androstane-3p,17B-diol","5a-androstane-3p,17B-diol increases the weight of seminal vesicle and prostate, but produces a much smaller effect than 5u-dihydrotestosterone.","Entity: 5a-androstane-3p,17B-diol. SMILES: C[C@]12CC[C@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. 5a-androstane-3p,17B-diol increases the weight of seminal vesicle and prostate, but produces a much smaller effect than 5u-dihydrotestosterone."
squalene,"In the presence of a-melanocyte-stimulating hormone, the percentage labelling of squalene during lipogenesis is increased.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. In the presence of a-melanocyte-stimulating hormone, the percentage labelling of squalene during lipogenesis is increased."
"5a-androstane-3p,17p-diol","5a-androstane-3p,17p-diol, when combined with a-melanocyte-stimulating hormone, produces significant increases in preputial gland weight and lipogenesis.","Entity: 5a-androstane-3p,17p-diol. SMILES: C[C@]12CC[C@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12. 5a-androstane-3p,17p-diol, when combined with a-melanocyte-stimulating hormone, produces significant increases in preputial gland weight and lipogenesis."
Squalene,"Squalene shows increased labeling during lipogenesis in the preputial gland when 5a-androstane-3p,17p-diol and a-melanocyte-stimulating hormone are administered together.","Entity: Squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Squalene shows increased labeling during lipogenesis in the preputial gland when 5a-androstane-3p,17p-diol and a-melanocyte-stimulating hormone are administered together."
testosterone,"Testosterone increases preputial gland size and total lipogenic activity in male rats, but its lipogenic effect is likely part of a general response accompanying accelerated cell proliferation and turnover rather than a specific action on lipid biosynthesis.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone increases preputial gland size and total lipogenic activity in male rats, but its lipogenic effect is likely part of a general response accompanying accelerated cell proliferation and turnover rather than a specific action on lipid biosynthesis."
squalene,"a-Melanocyte-stimulating hormone increases squalene biosynthesis in preputial glands, indicating a specific action on lipid metabolism.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. a-Melanocyte-stimulating hormone increases squalene biosynthesis in preputial glands, indicating a specific action on lipid metabolism."
squalene,"After hypophysectomy, squalene represents a smaller proportion of the total labelled lipid in the preputial gland compared to before pituitary removal.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. After hypophysectomy, squalene represents a smaller proportion of the total labelled lipid in the preputial gland compared to before pituitary removal."
squalene,"In completely hypophysectomized rats, a-melanocyte-stimulating hormone treatment (100 pg/100 g body weight per day for 2 weeks) produces a small effect on the percentage labeling of squalene in tissue lipids.","Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. In completely hypophysectomized rats, a-melanocyte-stimulating hormone treatment (100 pg/100 g body weight per day for 2 weeks) produces a small effect on the percentage labeling of squalene in tissue lipids."
testosterone propionate,"Testosterone propionate at a dose of 0.2 mg/100g body weight per day for 2 weeks increases preputial gland weight and lipogenesis in hypophysectomized rats, though less effectively than in castrated animals.","Entity: testosterone propionate. SMILES: CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Testosterone propionate at a dose of 0.2 mg/100g body weight per day for 2 weeks increases preputial gland weight and lipogenesis in hypophysectomized rats, though less effectively than in castrated animals."
testosterone propionate,"Combined administration of testosterone propionate with another hormone leads to a large increase in preputial gland weight and lipogenic activity, and restores the percentage labeling of wax monoesters/sterol esters and squalene to almost normal levels in rats.","Entity: testosterone propionate. SMILES: CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Combined administration of testosterone propionate with another hormone leads to a large increase in preputial gland weight and lipogenic activity, and restores the percentage labeling of wax monoesters/sterol esters and squalene to almost normal levels in rats."
squalene,The percentage labeling of squalene in the preputial gland is increased by testosterone propionate treatment and is almost restored to normal levels when combined with another hormone in rats.,Entity: squalene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. The percentage labeling of squalene in the preputial gland is increased by testosterone propionate treatment and is almost restored to normal levels when combined with another hormone in rats.
2-mercaptoethanol,2-mercaptoethanol is used as a reducing agent in nuclear homogenisation buffer (5 mM) and in DNA synthesis reaction mixtures (4 mM) to maintain a reduced environment for enzymatic activity.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is used as a reducing agent in nuclear homogenisation buffer (5 mM) and in DNA synthesis reaction mixtures (4 mM) to maintain a reduced environment for enzymatic activity.
Triton X-100,Triton X-100 is used as a detergent in hyperosmotic sucrose solution to remove chloroplast contamination from plant nuclear preparations.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used as a detergent in hyperosmotic sucrose solution to remove chloroplast contamination from plant nuclear preparations.
chlorophyll,"Chlorophyll is present in plant nuclei until the preparation is treated to remove chloroplast contamination, resulting in a chlorophyll-free nuclear extract.","Entity: chlorophyll. SMILES: C=CC1=C(C)C2=NC1=CC1=NC(=Cc3[n-]c4c(c3C)=C([O-])C(C(=O)OC)C=4C3=NC(=C2)C(C)C3CCC(=O)OCC=C(C)CCCC(C)CCCC(C)CCCC(C)C)C(CC)=C1C.[Mg+2]. Chlorophyll is present in plant nuclei until the preparation is treated to remove chloroplast contamination, resulting in a chlorophyll-free nuclear extract."
KCI,KCI at a concentration of 100 mM substantially inhibits the RNA polymerase activity of Triton-treated chloroplasts.,Entity: KCI. SMILES: [Cl-].[K+]. KCI at a concentration of 100 mM substantially inhibits the RNA polymerase activity of Triton-treated chloroplasts.
Amanitin,"Amanitin inhibits the synthesis of heterogeneous RNA and selectively inhibits the synthesis of a class of nuclear proteins, including histones, in hepatocytes.","Entity: Amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin inhibits the synthesis of heterogeneous RNA and selectively inhibits the synthesis of a class of nuclear proteins, including histones, in hepatocytes."
Amanitin,Amanitin does not affect the synthesis of total proteins for at least 20 hours in resting liver hepatocytes and for 2 hours in regenerating rat liver.,Entity: Amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin does not affect the synthesis of total proteins for at least 20 hours in resting liver hepatocytes and for 2 hours in regenerating rat liver.
Amanitin,Amanitin inhibits the synthesis of both arginine- and lysine-rich histones in hepatocytes.,Entity: Amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin inhibits the synthesis of both arginine- and lysine-rich histones in hepatocytes.
Amanitin,Amanitin administration decreases the incorporation of [3H]leucine into acid-soluble proteins to 50% and 30% of control values at 2 and 4 hours after amanitin in regenerating liver.,Entity: Amanitin. SMILES: CCC(C)C1NC(=O)CNC(=O)C2Cc3c([nH]c4cc(O)ccc34)S(=O)CC(NC(=O)CNC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2. Amanitin administration decreases the incorporation of [3H]leucine into acid-soluble proteins to 50% and 30% of control values at 2 and 4 hours after amanitin in regenerating liver.
glucagon,"Glucagon-like-immunoreactivity material binds to metal ions, specifically Zn2+ ions, through a region of the molecule that is not homologous with glucagon.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon-like-immunoreactivity material binds to metal ions, specifically Zn2+ ions, through a region of the molecule that is not homologous with glucagon."
tyrosine,The hydroxyl group of tyrosine can function as an oxygen donor in protein interactions with metal ions.,Entity: tyrosine. SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O. The hydroxyl group of tyrosine can function as an oxygen donor in protein interactions with metal ions.
aspartate,The carboxyl group of aspartate can function as an oxygen donor in protein interactions with metal ions.,Entity: aspartate. SMILES: N[C@@H](CC(=O)[O-])C(=O)[O-]. The carboxyl group of aspartate can function as an oxygen donor in protein interactions with metal ions.
cysteine,The thiol group of cysteine can act as a sulfur donor in protein interactions with metal ions.,Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. The thiol group of cysteine can act as a sulfur donor in protein interactions with metal ions.
histidine,"The imidazole group of histidine, a nitrogen donor, can participate in coordination with metal ions in proteins.","Entity: histidine. SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O. The imidazole group of histidine, a nitrogen donor, can participate in coordination with metal ions in proteins."
lysine,"The &-amino group of lysine, a nitrogen donor, can coordinate to metal ions in proteins.","Entity: lysine. SMILES: NCCCC[C@H](N)C(=O)O. The &-amino group of lysine, a nitrogen donor, can coordinate to metal ions in proteins."
arginine,"The guanidinium group of arginine, a nitrogen donor, can coordinate to metal ions in proteins.","Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. The guanidinium group of arginine, a nitrogen donor, can coordinate to metal ions in proteins."
glutamate,The carboxyl group of glutamate can function as an oxygen donor in protein interactions with metal ions.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. The carboxyl group of glutamate can function as an oxygen donor in protein interactions with metal ions.
aspartate,Aspartate residues can participate in chelate formation with metal ions by providing a terminal amino group that coordinates with the metal center.,Entity: aspartate. SMILES: N[C@@H](CC(=O)O)C(=O)O. Aspartate residues can participate in chelate formation with metal ions by providing a terminal amino group that coordinates with the metal center.
glutamate,"Glutamate residues can contribute to metal chelate formation, but their availability for chelation may be restricted by electrostatic repulsion between vicinal negative charges.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate residues can contribute to metal chelate formation, but their availability for chelation may be restricted by electrostatic repulsion between vicinal negative charges."
threonine,Threonine residues can be involved in metal chelate formation by donating electrons from their amide nitrogen atoms to coordinate with metal ions.,Entity: threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. Threonine residues can be involved in metal chelate formation by donating electrons from their amide nitrogen atoms to coordinate with metal ions.
histidine,"The N-1 atom of the imidazole group in histidine, as well as its amide nitrogen and terminal amino group, can participate in chelate formation with metal ions.","Entity: histidine. SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O. The N-1 atom of the imidazole group in histidine, as well as its amide nitrogen and terminal amino group, can participate in chelate formation with metal ions."
16a-hydroxyandrostenedione,"16a-hydroxyandrostenedione is a metabolite formed in liver microsomal incubations, with its formation increased by phospholipase C-mediated disruption of microsomal phospholipids.","Entity: 16a-hydroxyandrostenedione. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)[C@H](O)C[C@@H]12. 16a-hydroxyandrostenedione is a metabolite formed in liver microsomal incubations, with its formation increased by phospholipase C-mediated disruption of microsomal phospholipids."
testosterone,"Testosterone can be hydroxylated at positions 68 and 7a by cytochrome P-450, and at position 16a by cytochrome P-450, with the 16a-hydroxylase enzyme being less dependent on its phospholipid environment compared to some other cytochrome P-450 enzymes.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone can be hydroxylated at positions 68 and 7a by cytochrome P-450, and at position 16a by cytochrome P-450, with the 16a-hydroxylase enzyme being less dependent on its phospholipid environment compared to some other cytochrome P-450 enzymes."
choline,Choline deficiency leads to decreased formation of polar metabolites in liver microsomal fractions.,Entity: choline. SMILES: C[N+](C)(C)CCO. Choline deficiency leads to decreased formation of polar metabolites in liver microsomal fractions.
acetone,"Acetone is used as a component of the dichloromethane/acetone (40:3, v/v) solvent mixture for t.1.c. separation of metabolites.","Entity: acetone. SMILES: CC(C)=O. Acetone is used as a component of the dichloromethane/acetone (40:3, v/v) solvent mixture for t.1.c. separation of metabolites."
ethyl acetate,Ethyl acetate is used to stop enzymatic reactions and to facilitate extraction of metabolites in microsomal enzyme assays.,Entity: ethyl acetate. SMILES: CCOC(C)=O. Ethyl acetate is used to stop enzymatic reactions and to facilitate extraction of metabolites in microsomal enzyme assays.
androstenedione,Androstenedione is a steroid compound that can be incubated with liver microsomal pellets to study its metabolism in in vitro systems.,Entity: androstenedione. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. Androstenedione is a steroid compound that can be incubated with liver microsomal pellets to study its metabolism in in vitro systems.
NADPH,NADPH is used as an NADPH-regenerating system in microsomal enzyme assays to maintain reducing conditions during in vitro metabolism studies.,Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is used as an NADPH-regenerating system in microsomal enzyme assays to maintain reducing conditions during in vitro metabolism studies.
sodium phosphate,Sodium phosphate buffer at 0.1 M and pH 7.4 is commonly used to maintain physiological pH in microsomal enzyme assays.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate buffer at 0.1 M and pH 7.4 is commonly used to maintain physiological pH in microsomal enzyme assays.
dichloromethane,Dichloromethane is used as a solvent for t.1.c. separation of metabolites in microsomal enzyme assays.,Entity: dichloromethane. SMILES: ClCCl. Dichloromethane is used as a solvent for t.1.c. separation of metabolites in microsomal enzyme assays.
NADPH,"NADPH can be used as an eluting counter-ligand in chromatography for enzymes that specifically bind NADP+, enabling an overall purification factor of 250-fold.","Entity: NADPH. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADPH can be used as an eluting counter-ligand in chromatography for enzymes that specifically bind NADP+, enabling an overall purification factor of 250-fold."
NADPH,"Elution with NADPH can lead to non-specific interaction of the enzyme with the gel matrix, potentially causing inactivation and low enzyme recovery.","Entity: NADPH. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. Elution with NADPH can lead to non-specific interaction of the enzyme with the gel matrix, potentially causing inactivation and low enzyme recovery."
KCl,Including a high concentration of neutral salt such as KCl in the irrigating buffer can minimize non-specific protein-matrix interactions during chromatography.,Entity: KCl. SMILES: [Cl-].[K+]. Including a high concentration of neutral salt such as KCl in the irrigating buffer can minimize non-specific protein-matrix interactions during chromatography.
phosphorus pentoxide,Phosphorus pentoxide is used for hydrolysis of phospholipids to quantify inorganic phosphate (Pi) in lipid assays.,Entity: phosphorus pentoxide. SMILES: O=P(=O)OP(=O)=O. Phosphorus pentoxide is used for hydrolysis of phospholipids to quantify inorganic phosphate (Pi) in lipid assays.
iodine,Iodine vapor is used to localize phospholipids by exposing them to iodine vapor.,Entity: iodine. SMILES: [I]. Iodine vapor is used to localize phospholipids by exposing them to iodine vapor.
chloroform,Chloroform is used as a solvent in the extraction and purification of microsomal phospholipids.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a solvent in the extraction and purification of microsomal phospholipids.
water,Water is used as a component of the solvent system for two-dimensional thin-layer chromatography (t.1.c.) in the separation of phospholipids.,Entity: water. SMILES: O. Water is used as a component of the solvent system for two-dimensional thin-layer chromatography (t.1.c.) in the separation of phospholipids.
methanol,"Methanol is used as a solvent in the extraction and purification of microsomal phospholipids, as well as in the two-dimensional t.1.c. system for phospholipid separation.","Entity: methanol. SMILES: CO. Methanol is used as a solvent in the extraction and purification of microsomal phospholipids, as well as in the two-dimensional t.1.c. system for phospholipid separation."
acetic acid,Acetic acid is used as a component of the solvent system in the two-dimensional t.1.c. for phospholipid separation.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used as a component of the solvent system in the two-dimensional t.1.c. for phospholipid separation.
sodium acetate,Sodium acetate is used to impregnate silica-gel plates for two-dimensional thin-layer chromatography (t.1.c.) of phospholipids.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate is used to impregnate silica-gel plates for two-dimensional thin-layer chromatography (t.1.c.) of phospholipids.
NADPH,"NADPH serves as a cofactor for biliverdin reductase, enabling its NADPH-dependent activity.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH serves as a cofactor for biliverdin reductase, enabling its NADPH-dependent activity."
NADP+,"NADP+ is a cofactor for biliverdin reductase, and biliverdin reductase can be eluted from its immobilized form using soluble NADH, indicating competition between NADP+ and NADH for the same binding site.","Entity: NADP+. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP+ is a cofactor for biliverdin reductase, and biliverdin reductase can be eluted from its immobilized form using soluble NADH, indicating competition between NADP+ and NADH for the same binding site."
NADP+,"NADP+ can be immobilized on a gel matrix and used to retain an enzyme, with its affinity for the enzyme being higher than that of NADH.","Entity: NADP+. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)([O-])[O-])[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP+ can be immobilized on a gel matrix and used to retain an enzyme, with its affinity for the enzyme being higher than that of NADH."
NADPH,"NADPH can be used to elute an enzyme from an NADP+ gel matrix by competing with immobilized NADP+, indicating a higher affinity for the enzyme than NADH.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH can be used to elute an enzyme from an NADP+ gel matrix by competing with immobilized NADP+, indicating a higher affinity for the enzyme than NADH."
p-nitrophenol,The Michaelis constant (K_m) for p-nitrophenol as a substrate in phenol sulphotransferase assays is approximately 4 µM at pH 8.0.,Entity: p-nitrophenol. SMILES: O=[N+]([O-])c1ccc(O)cc1. The Michaelis constant (K_m) for p-nitrophenol as a substrate in phenol sulphotransferase assays is approximately 4 µM at pH 8.0.
p-nitrophenol,"At pH 5.5, p-nitrophenol exhibits complex kinetic behavior in phenol sulphotransferase assays, indicating the presence of multiple enzyme forms or multiple enzyme types with sulphotransferase activity in liver preparations.","Entity: p-nitrophenol. SMILES: O=[N+]([O-])c1ccc(O)cc1. At pH 5.5, p-nitrophenol exhibits complex kinetic behavior in phenol sulphotransferase assays, indicating the presence of multiple enzyme forms or multiple enzyme types with sulphotransferase activity in liver preparations."
p-nitrophenol,p-nitrophenol is used as an acceptor substrate to assay phenol sulphotransferase activity in mouse liver tissue homogenates.,Entity: p-nitrophenol. SMILES: O=[N+]([O-])c1ccc(O)cc1. p-nitrophenol is used as an acceptor substrate to assay phenol sulphotransferase activity in mouse liver tissue homogenates.
sulphur,"Dietary sulphur compounds, mainly sulphur-containing amino acids, are reduced to S2 by rumen microorganisms in ruminants.","Entity: sulphur. SMILES: [S]. Dietary sulphur compounds, mainly sulphur-containing amino acids, are reduced to S2 by rumen microorganisms in ruminants."
copper,Sulphur compounds in the diet can exacerbate secondary copper deficiency in ruminants.,Entity: copper. SMILES: [Cu]. Sulphur compounds in the diet can exacerbate secondary copper deficiency in ruminants.
tungsten,"Feeding guinea pigs tungstate up to 2000 p.p.m. causes weight loss but does not affect plasma copper distribution, which remains normal.","Entity: tungsten. SMILES: [W]. Feeding guinea pigs tungstate up to 2000 p.p.m. causes weight loss but does not affect plasma copper distribution, which remains normal."
molybdenum,Molybdenum supplementation in sheep diets leads to the formation of a new sulfur fraction in the excreted material.,Entity: molybdenum. SMILES: [Mo]. Molybdenum supplementation in sheep diets leads to the formation of a new sulfur fraction in the excreted material.
molybdenum,"In guinea pigs, dietary molybdenum concentrations up to 500 p.p.m. influence the rise in plasma copper concentration, but above 500 p.p.m., further increases in plasma total copper or trichloroacetic acid-soluble copper are not observed.","Entity: molybdenum. SMILES: [Mo]. In guinea pigs, dietary molybdenum concentrations up to 500 p.p.m. influence the rise in plasma copper concentration, but above 500 p.p.m., further increases in plasma total copper or trichloroacetic acid-soluble copper are not observed."
molybdenum,"At low concentrations, dietary molybdenum causes an initial decrease in the trichloroacetic acid-soluble copper fraction in plasma, with total copper rising gradually over several weeks.","Entity: molybdenum. SMILES: [Mo]. At low concentrations, dietary molybdenum causes an initial decrease in the trichloroacetic acid-soluble copper fraction in plasma, with total copper rising gradually over several weeks."
copper,"Plasma copper concentration in guinea pigs increases in response to dietary molybdenum up to 500 p.p.m., with no further increase observed above this level.","Entity: copper. SMILES: [Cu]. Plasma copper concentration in guinea pigs increases in response to dietary molybdenum up to 500 p.p.m., with no further increase observed above this level."
sulphate,"In sheep, sulphate exerts its effect on plasma copper distribution by being converted into S2- in the rumen.","Entity: sulphate. SMILES: O=S(=O)([O-])[O-]. In sheep, sulphate exerts its effect on plasma copper distribution by being converted into S2- in the rumen."
molybdenum,The effect of molybdenum on plasma copper distribution is enhanced by S2- in sheep.,Entity: molybdenum. SMILES: [Mo]. The effect of molybdenum on plasma copper distribution is enhanced by S2- in sheep.
copper,"Plasma copper distribution in sheep is specifically affected by the presence of P i, which is required to produce the observed effect.","Entity: copper. SMILES: [Cu]. Plasma copper distribution in sheep is specifically affected by the presence of P i, which is required to produce the observed effect."
tungsten,Tungsten is chemically similar to molybdenum in its interactions with S2- and copper.,Entity: tungsten. SMILES: [W]. Tungsten is chemically similar to molybdenum in its interactions with S2- and copper.
sodium molybdate,"Sodium molybdate is used as a molybdenum source in semi-synthetic diets for laboratory rats, at a concentration of 1000 p.p.m. (parts per million) as Na2Mo04.","Entity: sodium molybdate. SMILES: O=[Mo](=O)([O-])[O-].[Na+].[Na+]. Sodium molybdate is used as a molybdenum source in semi-synthetic diets for laboratory rats, at a concentration of 1000 p.p.m. (parts per million) as Na2Mo04."
oxygen,Oxygen consumption is measured in liver homogenate assays to monitor sulphide oxidation (sulphide oxidase activity) using an oxygen electrode.,Entity: oxygen. SMILES: [O]. Oxygen consumption is measured in liver homogenate assays to monitor sulphide oxidation (sulphide oxidase activity) using an oxygen electrode.
molybdenum,"Molybdenum is an essential trace element whose dietary concentration affects caeruloplasmin activity in guinea pigs, with normal activity at 100 ppm and decreased activity at higher concentrations.","Entity: molybdenum. SMILES: [Mo]. Molybdenum is an essential trace element whose dietary concentration affects caeruloplasmin activity in guinea pigs, with normal activity at 100 ppm and decreased activity at higher concentrations."
copper,"Copper in plasma can be quantified by atomic-absorption spectrometry, and its concentration is influenced by dietary molybdenum levels in guinea pigs.","Entity: copper. SMILES: [Cu]. Copper in plasma can be quantified by atomic-absorption spectrometry, and its concentration is influenced by dietary molybdenum levels in guinea pigs."
copper,Dietary supplementation with S042 does not alter plasma copper distribution compared to molybdenum alone.,Entity: copper. SMILES: [Cu]. Dietary supplementation with S042 does not alter plasma copper distribution compared to molybdenum alone.
copper,"Dietary supplementation with Sz- increases total plasma copper and decreases trichloroacetic acid-soluble copper, while maintaining normal caeruloplasmin activity.","Entity: copper. SMILES: [Cu]. Dietary supplementation with Sz- increases total plasma copper and decreases trichloroacetic acid-soluble copper, while maintaining normal caeruloplasmin activity."
trichloroacetic acid,"Trichloroacetic acid-soluble copper in plasma decreases when Sz- is added to the diet, even when caeruloplasmin activity remains normal.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid-soluble copper in plasma decreases when Sz- is added to the diet, even when caeruloplasmin activity remains normal."
water,"Water is used as a component of the chloroform/methanol/water (3:1:1, v/v) solvent system for sphingolipid extraction from Aspergillus niger.","Entity: water. SMILES: O. Water is used as a component of the chloroform/methanol/water (3:1:1, v/v) solvent system for sphingolipid extraction from Aspergillus niger."
ammonia,"Ammonia is used as an 8% (v/v) component of the chloroform/methanol/ammonia (9:7:2, v/v/v) solvent system for sphingolipid extraction from Aspergillus niger.","Entity: ammonia. SMILES: N. Ammonia is used as an 8% (v/v) component of the chloroform/methanol/ammonia (9:7:2, v/v/v) solvent system for sphingolipid extraction from Aspergillus niger."
pyridine,"Pyridine is used as a 30% (v/v) component of the chloroform/methanol/pyridine (9:7:1, v/v/v) solvent system for sphingolipid extraction from Aspergillus niger.","Entity: pyridine. SMILES: c1ccncc1. Pyridine is used as a 30% (v/v) component of the chloroform/methanol/pyridine (9:7:1, v/v/v) solvent system for sphingolipid extraction from Aspergillus niger."
chloroform,"Chloroform is used as a solvent in the extraction of sphingolipids from Aspergillus niger, either alone or in combination with methanol, water, or pyridine.","Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used as a solvent in the extraction of sphingolipids from Aspergillus niger, either alone or in combination with methanol, water, or pyridine."
inositol,"Inositol constitutes 14% of the weight in Aspergillus niger sphingolipid preparations, as determined by compositional analysis.","Entity: inositol. SMILES: OC1C(O)C(O)C(O)C(O)C1O. Inositol constitutes 14% of the weight in Aspergillus niger sphingolipid preparations, as determined by compositional analysis."
galactose,"Galactose is a constituent sugar of Aspergillus niger sphingolipid preparations, as shown by paper chromatography.","Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose is a constituent sugar of Aspergillus niger sphingolipid preparations, as shown by paper chromatography."
mannose,"Mannose is a constituent sugar of Aspergillus niger sphingolipid preparations, as shown by paper chromatography.","Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose is a constituent sugar of Aspergillus niger sphingolipid preparations, as shown by paper chromatography."
methanol,"Methanol is used as a component of the chloroform/methanol solvent system (9:7, v/v) for extracting sphingolipids from Aspergillus niger.","Entity: methanol. SMILES: CO. Methanol is used as a component of the chloroform/methanol solvent system (9:7, v/v) for extracting sphingolipids from Aspergillus niger."
silicic acid,Silicic acid chromatography is ineffective for resolving fungal glycolipids when anhydrous solvents are used.,Entity: silicic acid. SMILES: O[Si](O)(O)O. Silicic acid chromatography is ineffective for resolving fungal glycolipids when anhydrous solvents are used.
HCl,Extraction of fungal mycelium with solvents containing HCl removes little precipitable material.,Entity: HCl. SMILES: Cl. Extraction of fungal mycelium with solvents containing HCl removes little precipitable material.
pyridine,Extraction of fungal mycelium with solvents containing pyridine removes little precipitable material.,Entity: pyridine. SMILES: c1ccncc1. Extraction of fungal mycelium with solvents containing pyridine removes little precipitable material.
arsenite,"Arsenite inhibits the NADH-dichlorophenol-indophenol activity of NADH-reduced enzyme, likely by exposing a second site for arsenite interaction.","Entity: arsenite. SMILES: [O-][As]([O-])[O-]. Arsenite inhibits the NADH-dichlorophenol-indophenol activity of NADH-reduced enzyme, likely by exposing a second site for arsenite interaction."
arsenite,"Arsenite treatment of reduced-cyanide-inactivated enzyme does not significantly alter NADH-dichlorophenol-indophenol activity, indicating that pre-reduction alters the binding mode of arsenite to the enzyme's active center.","Entity: arsenite. SMILES: [O-][As]([O-])[O-]. Arsenite treatment of reduced-cyanide-inactivated enzyme does not significantly alter NADH-dichlorophenol-indophenol activity, indicating that pre-reduction alters the binding mode of arsenite to the enzyme's active center."
arsenite,"Arsenite affects NADH diaphorase activity in oxidized or reduced enzyme forms, with the effect depending on the integrity of molybdenum-centre persulphide groups.","Entity: arsenite. SMILES: [O-][As]([O-])[O-]. Arsenite affects NADH diaphorase activity in oxidized or reduced enzyme forms, with the effect depending on the integrity of molybdenum-centre persulphide groups."
arsenite,Arsenite-induced changes in NADH diaphorase activity are observed only when dichlorophenol-indophenol or trinitrobenzene sulphonate are used as electron acceptors.,Entity: arsenite. SMILES: [O-][As]([O-])[O-]. Arsenite-induced changes in NADH diaphorase activity are observed only when dichlorophenol-indophenol or trinitrobenzene sulphonate are used as electron acceptors.
trinitrobenzene sulphonate,"Trinitrobenzene sulphonate acts as an electron acceptor in NADH diaphorase assays, with its interaction dependent on the integrity of molybdenum-centre persulphide groups.","Entity: trinitrobenzene sulphonate. SMILES: O=[N+]([O-])c1ccc(S(=O)(=O)[O-])c([N+](=O)[O-])c1[N+](=O)[O-]. Trinitrobenzene sulphonate acts as an electron acceptor in NADH diaphorase assays, with its interaction dependent on the integrity of molybdenum-centre persulphide groups."
folate,"Serum conjugase, a η-carboxypeptidase, converts polyglutamate forms of folate to their corresponding monoglutamates by cleaving the N-10 bond.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Serum conjugase, a η-carboxypeptidase, converts polyglutamate forms of folate to their corresponding monoglutamates by cleaving the N-10 bond."
folic acid,"Folic acid can be labeled with [2-14C] and, when administered intramuscularly, allows for the detection of its polyglutamate conjugates in vivo.","Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid can be labeled with [2-14C] and, when administered intramuscularly, allows for the detection of its polyglutamate conjugates in vivo."
folate,"Polyglutamate forms of folate can be demonstrated in vivo by using [2-14C]folic acid administered intramuscularly, as these forms have an elution position shifted to the left by serum conjugase.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Polyglutamate forms of folate can be demonstrated in vivo by using [2-14C]folic acid administered intramuscularly, as these forms have an elution position shifted to the left by serum conjugase."
10-formyltetrahydrofolate,"10-formyltetrahydrofolate can be quantitatively converted from 5-CHO-H.pteGlu and 5,1@CH=H.,ReGlu.","Entity: 10-formyltetrahydrofolate. SMILES: Nc1nc2c(c(=O)[nH]1)NC(CN(C=O)c1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1)CN2. 10-formyltetrahydrofolate can be quantitatively converted from 5-CHO-H.pteGlu and 5,1@CH=H.,ReGlu."
5-formyltetrahydrofolate,"5-formyltetrahydrofolate can be quantitatively converted from 5-CHO-H.pteGlu and 5,1@CH=H.,ReGlu.","Entity: 5-formyltetrahydrofolate. SMILES: Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1)CN2. 5-formyltetrahydrofolate can be quantitatively converted from 5-CHO-H.pteGlu and 5,1@CH=H.,ReGlu."
[14C]methyltetrahydropteroylglutamate,[14C]methyltetrahydropteroylglutamate (5-[14C]CH3-H4PteGlu) is used as a substrate to measure cellular uptake in HeLa cells after folate deprivation.,Entity: [14C]methyltetrahydropteroylglutamate. SMILES: [14CH3]N(C(=O)C1C=CC(NCc2cnc3nc(N)[nH]c(=O)c3n2)CC1)[C@@H](CCC(=O)[O-])C(=O)[O-]. [14C]methyltetrahydropteroylglutamate (5-[14C]CH3-H4PteGlu) is used as a substrate to measure cellular uptake in HeLa cells after folate deprivation.
PteGlu,PteGlu ([3H]PteGlu) is used as a radiolabelled substrate to assess cellular uptake in folate-deficient HeLa cells over a 3-hour period.,Entity: PteGlu. SMILES: Nc1nc2ncc(CNC3C=CC(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])CC3)nc2c(=O)[nH]1. PteGlu ([3H]PteGlu) is used as a radiolabelled substrate to assess cellular uptake in folate-deficient HeLa cells over a 3-hour period.
ethanol,"Oral administration of ethanol causes a transient 17% decrease in serum folate concentration, with a maximum blood ethanol concentration of 60 mg/100 ml.","Entity: ethanol. SMILES: CCO. Oral administration of ethanol causes a transient 17% decrease in serum folate concentration, with a maximum blood ethanol concentration of 60 mg/100 ml."
ethanol,Ethanol does not significantly affect serum binding of folate.,Entity: ethanol. SMILES: CCO. Ethanol does not significantly affect serum binding of folate.
ethanol,"Ethanol does not impair the activity of serum conjugase, suggesting hepatic conjugase activity is not affected.","Entity: ethanol. SMILES: CCO. Ethanol does not impair the activity of serum conjugase, suggesting hepatic conjugase activity is not affected."
folate,"Serum folate concentration can be reduced by ethanol, likely due to release from a serum binder rather than inhibition of cellular uptake.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Serum folate concentration can be reduced by ethanol, likely due to release from a serum binder rather than inhibition of cellular uptake."
folate,Folate in serum primarily arises by displacement of hepatic monoglutamates by dietary folate.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate in serum primarily arises by displacement of hepatic monoglutamates by dietary folate.
ethanol,Ethanol does not inhibit cellular uptake of folate in vitro or in vivo.,Entity: ethanol. SMILES: CCO. Ethanol does not inhibit cellular uptake of folate in vitro or in vivo.
ethanol,Ethanol acutely decreases serum folate concentration in humans.,Entity: ethanol. SMILES: CCO. Ethanol acutely decreases serum folate concentration in humans.
ethanol,Ethanol does not enhance urinary folate loss in humans.,Entity: ethanol. SMILES: CCO. Ethanol does not enhance urinary folate loss in humans.
folate,Serum folate concentration is decreased by ethanol administration in humans.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Serum folate concentration is decreased by ethanol administration in humans.
ethanol,Pharmacological amounts of ethanol in vitro do not alter serum binding of [3H]PteGlu as assayed by Sephadex gel filtration.,Entity: ethanol. SMILES: CCO. Pharmacological amounts of ethanol in vitro do not alter serum binding of [3H]PteGlu as assayed by Sephadex gel filtration.
PteGlu,"PteGlu and its monoglutamate form are taken up by HeLa cells via different pathways, with uptake of PteGlu inhibiting uptake of its monoglutamate form, and vice versa.","Entity: PteGlu. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. PteGlu and its monoglutamate form are taken up by HeLa cells via different pathways, with uptake of PteGlu inhibiting uptake of its monoglutamate form, and vice versa."
ethanol,Pharmacological amounts of ethanol in vitro do not inhibit serum conjugase activity or alter HeLa cell uptake of either rH]PteGlu or [14C]CH3-H4PteGlu.,Entity: ethanol. SMILES: CCO. Pharmacological amounts of ethanol in vitro do not inhibit serum conjugase activity or alter HeLa cell uptake of either rH]PteGlu or [14C]CH3-H4PteGlu.
ethanol,Ethanol may decrease serum folate concentration by inhibiting the release of stored folate from the liver.,Entity: ethanol. SMILES: CCO. Ethanol may decrease serum folate concentration by inhibiting the release of stored folate from the liver.
folate,"Folate exists in stored polyglutamate forms in the liver, which are converted to monoglutamate forms for release and transport by plasma folate conjugase.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate exists in stored polyglutamate forms in the liver, which are converted to monoglutamate forms for release and transport by plasma folate conjugase."
pteroylglutamic acid,Serum binding of [3H]PteGlu ([3H]pteroylglutamic acid) can be affected by ethanol and its degradation products.,Entity: pteroylglutamic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Serum binding of [3H]PteGlu ([3H]pteroylglutamic acid) can be affected by ethanol and its degradation products.
PteGlu,"Serum conjugase activity, measured as ng of folate released by 0.1 ml serum, is affected by ethanol concentration in vitro, with optimal activity observed at 40 mg/100 dL ethanol and reduced activity at higher concentrations.","Entity: PteGlu. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Serum conjugase activity, measured as ng of folate released by 0.1 ml serum, is affected by ethanol concentration in vitro, with optimal activity observed at 40 mg/100 dL ethanol and reduced activity at higher concentrations."
PteGlu,"HeLa cell uptake of [3H]PteGlu by Sephadex G-50 gel filtration is reduced by ethanol treatment, with uptake decreasing from 14.3% at 0 mg/100 dL ethanol to 2.9% at 320 mg/100 dL ethanol.","Entity: PteGlu. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. HeLa cell uptake of [3H]PteGlu by Sephadex G-50 gel filtration is reduced by ethanol treatment, with uptake decreasing from 14.3% at 0 mg/100 dL ethanol to 2.9% at 320 mg/100 dL ethanol."
ethanol,Serum conjugase activity is optimal at 40 mg/100 dL ethanol and decreases with increasing ethanol concentration in vitro.,Entity: ethanol. SMILES: CCO. Serum conjugase activity is optimal at 40 mg/100 dL ethanol and decreases with increasing ethanol concentration in vitro.
ethanol,Serum folate concentration is not significantly affected by moderate ethanol exposure (up to 320 mg/100 dL) in normal fasting subjects.,Entity: ethanol. SMILES: CCO. Serum folate concentration is not significantly affected by moderate ethanol exposure (up to 320 mg/100 dL) in normal fasting subjects.
methotrexate,"Methotrexate administered orally to rats results in a higher urinary recovery of radioactivity (34% of the dose) compared to control animals (19% of the dose), indicating increased folate metabolism.","Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Methotrexate administered orally to rats results in a higher urinary recovery of radioactivity (34% of the dose) compared to control animals (19% of the dose), indicating increased folate metabolism."
folate monoglutamate,"Folate monoglutamate is a metabolite of folate that can be separated from polyglutamate forms by Sephadex G-15 chromatography, as shown by its behavior as a distinct peak in rat liver extracts.","Entity: folate monoglutamate. SMILES: N[C@@H](CCC(=O)O)C(=O)O.Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folate monoglutamate is a metabolite of folate that can be separated from polyglutamate forms by Sephadex G-15 chromatography, as shown by its behavior as a distinct peak in rat liver extracts."
5-methyltetrahydrofolate,"5-methyltetrahydrofolate, when administered orally, is metabolized in rat liver to both polyglutamate and monoglutamate forms, as evidenced by chromatographic separation in rat liver extracts.","Entity: 5-methyltetrahydrofolate. SMILES: [14CH3]N1c2c(nc(N)[nH]c2=O)NCC1CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1. 5-methyltetrahydrofolate, when administered orally, is metabolized in rat liver to both polyglutamate and monoglutamate forms, as evidenced by chromatographic separation in rat liver extracts."
5-methyltetrahydrofolate,"5-methyltetrahydrofolate is the major urinary metabolite of folic acid in rats, accounting for approximately 4% of total radioactivity in urine samples from both control and methotrexate-treated animals.","Entity: 5-methyltetrahydrofolate. SMILES: CN1c2c(nc(N)[nH]c2=O)NCC1CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1. 5-methyltetrahydrofolate is the major urinary metabolite of folic acid in rats, accounting for approximately 4% of total radioactivity in urine samples from both control and methotrexate-treated animals."
10-formyltetrahydrofolate,"10-formyltetrahydrofolate is a urinary metabolite of folic acid in rats, present at approximately 4% of total radioactivity in urine samples from control animals and as a major component (90% of radioactivity in 0–6 h) in methotrexate-treated animals.","Entity: 10-formyltetrahydrofolate. SMILES: Nc1nc2c(c(=O)[nH]1)NC(CN(C=O)c1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1)CN2. 10-formyltetrahydrofolate is a urinary metabolite of folic acid in rats, present at approximately 4% of total radioactivity in urine samples from control animals and as a major component (90% of radioactivity in 0–6 h) in methotrexate-treated animals."
10-formylfolate,"10-formylfolate is detected as a minor urinary metabolite of folic acid in both control and methotrexate-treated rats, with a peak corresponding to 4% of total radioactivity in control urine and 10% of total radioactivity in methotrexate-treated urine.","Entity: 10-formylfolate. SMILES: Nc1nc2ncc(CN(C=O)c3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. 10-formylfolate is detected as a minor urinary metabolite of folic acid in both control and methotrexate-treated rats, with a peak corresponding to 4% of total radioactivity in control urine and 10% of total radioactivity in methotrexate-treated urine."
4a-hydroxy-5-methyltetrahydrofolate,"4a-hydroxy-5-methyltetrahydrofolate is a minor urinary metabolite of folic acid in rats, detected at approximately 4% of total radioactivity in urine samples from both control and methotrexate-treated animals.","Entity: 4a-hydroxy-5-methyltetrahydrofolate. SMILES: CN1C(CNc2ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc2)CNC2=NC(N)=NC(=O)C21O. 4a-hydroxy-5-methyltetrahydrofolate is a minor urinary metabolite of folic acid in rats, detected at approximately 4% of total radioactivity in urine samples from both control and methotrexate-treated animals."
methotrexate,"Methotrexate administration in rats leads to a marked change in urinary folate metabolism, with 90% of urinary radioactivity in 0–6 h being unmetabolized folic acid and the major metabolite in 6–24 h being 10-formyltetrahydrofolate.","Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Methotrexate administration in rats leads to a marked change in urinary folate metabolism, with 90% of urinary radioactivity in 0–6 h being unmetabolized folic acid and the major metabolite in 6–24 h being 10-formyltetrahydrofolate."
folic acid,"In rats, folic acid is rapidly metabolized in the urine, with 90% of urinary radioactivity in 0–6 h post-methotrexate administration being unmetabolized [14C]folic acid.","Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. In rats, folic acid is rapidly metabolized in the urine, with 90% of urinary radioactivity in 0–6 h post-methotrexate administration being unmetabolized [14C]folic acid."
methotrexate,Methotrexate is a potent inhibitor of dihydrofolate reductase in vitro.,Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Methotrexate is a potent inhibitor of dihydrofolate reductase in vitro.
methotrexate,Methotrexate has been used to treat a variety of malignant conditions.,Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Methotrexate has been used to treat a variety of malignant conditions.
5-methyltetrahydrofolate,"5-methyltetrahydrofolate is a folate derivative that can be administered orally and is metabolized in vivo, as shown by its detection in rat liver extract 24 hours after administration.","Entity: 5-methyltetrahydrofolate. SMILES: CN1c2c(nc(N)[nH]c2=O)NCC1CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1. 5-methyltetrahydrofolate is a folate derivative that can be administered orally and is metabolized in vivo, as shown by its detection in rat liver extract 24 hours after administration."
methotrexate,"Methotrexate decreases the rate of [14C]folic acid reduction in rats, indicating an effect on folate metabolism.","Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Methotrexate decreases the rate of [14C]folic acid reduction in rats, indicating an effect on folate metabolism."
dihydrofolate,No evidence was found for a build-up of dihydrofolate in rats after methotrexate administration.,Entity: dihydrofolate. SMILES: Nc1nc2c(c(=O)[nH]1)N=C(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1)CN2. No evidence was found for a build-up of dihydrofolate in rats after methotrexate administration.
xanthopterin,"Xanthopterin, a breakdown product of dihydrofolate, was not detected in urine samples of rats after methotrexate administration.","Entity: xanthopterin. SMILES: Nc1nc2ncc(=O)[nH]c2c(=O)[nH]1. Xanthopterin, a breakdown product of dihydrofolate, was not detected in urine samples of rats after methotrexate administration."
folic acid,"Folic acid is metabolized in rats, and its reduction rate can be decreased by methotrexate.","Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid is metabolized in rats, and its reduction rate can be decreased by methotrexate."
tetrahydrofolate,"Methotrexate may affect tetrahydrofolate metabolism in rats by acting on reduced folates rather than inhibiting dihydrofolate reductase, and cycling of tetrahydrofolates through dihydrofolate may not be a major pathway.","Entity: tetrahydrofolate. SMILES: Nc1nc2c(c(=O)[nH]1)NC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1)CN2. Methotrexate may affect tetrahydrofolate metabolism in rats by acting on reduced folates rather than inhibiting dihydrofolate reductase, and cycling of tetrahydrofolates through dihydrofolate may not be a major pathway."
folate,Folate is a vitamin that serves as a precursor for folate coenzymes involved in a variety of biochemical reactions.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate is a vitamin that serves as a precursor for folate coenzymes involved in a variety of biochemical reactions.
10-formyltetrahydrofolate,10-formyltetrahydrofolate is a reduced folate coenzyme required for purine synthesis in the liver.,Entity: 10-formyltetrahydrofolate. SMILES: Nc1nc2c(c(=O)[nH]1)NC(CN(C=O)c1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1)CN2. 10-formyltetrahydrofolate is a reduced folate coenzyme required for purine synthesis in the liver.
"5,10-methenyltetrahydrofolate","5,10-methenyltetrahydrofolate is a reduced folate coenzyme necessary for purine synthesis in the liver.","Entity: 5,10-methenyltetrahydrofolate. SMILES: Nc1nc2c(c(=O)[nH]1)[N+]1=CN(c3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)CC1CN2. 5,10-methenyltetrahydrofolate is a reduced folate coenzyme necessary for purine synthesis in the liver."
folate,"Folate is a vitamin whose coenzymes are involved in folate-metabolizing enzyme activity, and decreased concentrations of folate coenzymes can lead to reduced responses to oestrogen in biological systems.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate is a vitamin whose coenzymes are involved in folate-metabolizing enzyme activity, and decreased concentrations of folate coenzymes can lead to reduced responses to oestrogen in biological systems."
serine,Serine hydroxymethyltransferase activity is decreased in the livers of folate-deficient rats compared to folate-supplemented livers.,Entity: serine. SMILES: N[C@@H](CO)C(=O)O. Serine hydroxymethyltransferase activity is decreased in the livers of folate-deficient rats compared to folate-supplemented livers.
10-formyltetrahydrofolate,10-formyltetrahydrofolate synthetase activity is decreased in the livers of folate-deficient rats compared to folate-supplemented livers.,Entity: 10-formyltetrahydrofolate. SMILES: Nc1nc2c(c(=O)[nH]1)NC(CN(C=O)c1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1)CN2. 10-formyltetrahydrofolate synthetase activity is decreased in the livers of folate-deficient rats compared to folate-supplemented livers.
"5,10-methylenetetrahydrofolate","5,10-methylenetetrahydrofolate dehydrogenase activity is decreased in the livers of folate-deficient rats compared to folate-supplemented livers.","Entity: 5,10-methylenetetrahydrofolate. SMILES: Nc1nc2c(c(=O)[nH]1)N1CN(c3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)CC1CN2. 5,10-methylenetetrahydrofolate dehydrogenase activity is decreased in the livers of folate-deficient rats compared to folate-supplemented livers."
folate,"Folate is a vitamin that, when deficient in rats, decreases hepatic activities of dihydrofolate reductase, serine hydroxymethyltransferase, 5,10-methylenetetrahydrofolate dehydrogenase, and 10-formyltetrahydrofolate synthetase.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate is a vitamin that, when deficient in rats, decreases hepatic activities of dihydrofolate reductase, serine hydroxymethyltransferase, 5,10-methylenetetrahydrofolate dehydrogenase, and 10-formyltetrahydrofolate synthetase."
folate,Increasing folate concentrations in vivo increases the hepatic concentration of dihydrofolate reductase in birds.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Increasing folate concentrations in vivo increases the hepatic concentration of dihydrofolate reductase in birds.
phosphate,Phosphate buffer at 0.1 M and pH 7.4 is used for homogenizing liver samples to prepare enzyme extracts.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Phosphate buffer at 0.1 M and pH 7.4 is used for homogenizing liver samples to prepare enzyme extracts.
folate,"Folate deficiency in chicks causes a decrease in dihydrofolate reductase activity in liver extracts and increases the activities of serine hydroxymethyltransferase, 5,10-methylenetetrahydrofolate dehydrogenase, and 10-formyltetrahydrofolate synthetase.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate deficiency in chicks causes a decrease in dihydrofolate reductase activity in liver extracts and increases the activities of serine hydroxymethyltransferase, 5,10-methylenetetrahydrofolate dehydrogenase, and 10-formyltetrahydrofolate synthetase."
folate,Folate deficiency does not affect glutamate formiminotransferase activity in liver extracts.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate deficiency does not affect glutamate formiminotransferase activity in liver extracts.
histidine,Histidine catabolism in the chicken oviduct is not significantly affected by folate deficiency.,Entity: histidine. SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O. Histidine catabolism in the chicken oviduct is not significantly affected by folate deficiency.
glycine,Glycine-serine interconversion in the chicken oviduct is not significantly affected by folate deficiency.,Entity: glycine. SMILES: NCC(=O)O. Glycine-serine interconversion in the chicken oviduct is not significantly affected by folate deficiency.
serine,"Serine is involved in glycine-serine interconversion in the chicken oviduct, but this process is not significantly affected by folate deficiency.","Entity: serine. SMILES: N[C@@H](CO)C(=O)O. Serine is involved in glycine-serine interconversion in the chicken oviduct, but this process is not significantly affected by folate deficiency."
folate,"Folate is involved in the chicken oviduct, but its roles in glycine-serine interconversion, methionine synthesis, and histidine catabolism are not significant in inhibiting oviduct growth.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate is involved in the chicken oviduct, but its roles in glycine-serine interconversion, methionine synthesis, and histidine catabolism are not significant in inhibiting oviduct growth."
methionine,Methionine synthesis in the chicken oviduct is not significantly affected by folate deficiency.,Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine synthesis in the chicken oviduct is not significantly affected by folate deficiency.
vitamin B-12,"Supplementation of culture medium with vitamin B-12 increases methionine synthetase activity in L-cells, likely due to enhanced de novo synthesis of the enzyme.","Entity: vitamin B-12. SMILES: C/C1=C2/[N-][C@H]([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]2[C@@H](O)[C@@H](n3cnc4cc(C)c(C)cc43)O[C@@H]2CO)[C@]2(C)N=C(/C(C)=C3\N=C(/C=C4\N=C1[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]3(C)CC(N)=O)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[C-]#N.[Co+3]. Supplementation of culture medium with vitamin B-12 increases methionine synthetase activity in L-cells, likely due to enhanced de novo synthesis of the enzyme."
methionine,Supplementation of culture medium with methionine decreases methionine synthetase activity in L-cells compared to regular medium.,Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Supplementation of culture medium with methionine decreases methionine synthetase activity in L-cells compared to regular medium.
folate,Supplementation of culture medium with folate increases methionine synthetase activity in L-cells.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Supplementation of culture medium with folate increases methionine synthetase activity in L-cells.
cycloheximide,Cycloheximide is used to inhibit protein synthesis and can be used to test whether increased methionine synthetase activity in vitamin B-12-supplemented cells is due to enhanced de novo synthesis.,Entity: cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Cycloheximide is used to inhibit protein synthesis and can be used to test whether increased methionine synthetase activity in vitamin B-12-supplemented cells is due to enhanced de novo synthesis.
Vitamin B-12,Vitamin B-12 stimulates the activity of methionine synthetase in L-cells when added to the incubation mixture.,Entity: Vitamin B-12. SMILES: C/C1=C2/[N-][C@H]([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]2[C@@H](O)[C@@H](n3cnc4cc(C)c(C)cc43)O[C@@H]2CO)[C@]2(C)N=C(/C(C)=C3\N=C(/C=C4\N=C1[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]3(C)CC(N)=O)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[C-]#N.[Co+3]. Vitamin B-12 stimulates the activity of methionine synthetase in L-cells when added to the incubation mixture.
Folate,"Folate inhibits the activity of methionine synthetase in L-cells, with its effect potentially depending on its presence in the culture medium or incubation mixture.","Entity: Folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate inhibits the activity of methionine synthetase in L-cells, with its effect potentially depending on its presence in the culture medium or incubation mixture."
Methionine,Methionine inhibits the activity of methionine synthetase in L-cells.,Entity: Methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine inhibits the activity of methionine synthetase in L-cells.
homocysteine,Homocysteine is a substrate or cofactor in enzymatic assays to support specific metabolic pathways.,Entity: homocysteine. SMILES: N[C@@H](CCS)C(=O)O. Homocysteine is a substrate or cofactor in enzymatic assays to support specific metabolic pathways.
5-methyltetrahydrofolate,5-methyltetrahydrofolate is a folate derivative used as a cofactor in enzymatic assays.,Entity: 5-methyltetrahydrofolate. SMILES: CN1c2c(nc(N)[nH]c2=O)NCC1CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1. 5-methyltetrahydrofolate is a folate derivative used as a cofactor in enzymatic assays.
Triton X-100,Triton X-100 is a non-ionic detergent used to solubilize proteins and facilitate extraction of products in biochemical assays.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent used to solubilize proteins and facilitate extraction of products in biochemical assays.
"2,5-diphenyloxazole","2,5-diphenyloxazole is used as a scintillant in liquid-scintillation counting to detect radioactivity.","Entity: 2,5-diphenyloxazole. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. 2,5-diphenyloxazole is used as a scintillant in liquid-scintillation counting to detect radioactivity."
2-mercaptoethanol,2-mercaptoethanol is used as a reducing agent in biochemical reaction mixtures to maintain a reduced environment.,Entity: 2-mercaptoethanol. SMILES: OCCS. 2-mercaptoethanol is used as a reducing agent in biochemical reaction mixtures to maintain a reduced environment.
"1,4-bis-(5-phenyloxazol-2-yl)benzene","1,4-bis-(5-phenyloxazol-2-yl)benzene is used as a scintillant in liquid-scintillation counting for detecting radioactivity.","Entity: 1,4-bis-(5-phenyloxazol-2-yl)benzene. SMILES: c1ccc(-c2cnc(-c3ccc(-c4ncc(-c5ccccc5)o4)cc3)o2)cc1. 1,4-bis-(5-phenyloxazol-2-yl)benzene is used as a scintillant in liquid-scintillation counting for detecting radioactivity."
S-adenosylmethionine,S-adenosylmethionine is a cofactor used in enzymatic assays to provide methyltransferase activity.,Entity: S-adenosylmethionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosylmethionine is a cofactor used in enzymatic assays to provide methyltransferase activity.
streptomycin sulphate,Streptomycin sulphate is an antibiotic commonly used to prevent bacterial contamination in cell culture media.,Entity: streptomycin sulphate. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.O=S(=O)(O)O. Streptomycin sulphate is an antibiotic commonly used to prevent bacterial contamination in cell culture media.
L-glutamine,L-glutamine is a supplement in cell culture media to support cell growth and function.,Entity: L-glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. L-glutamine is a supplement in cell culture media to support cell growth and function.
cyanocobalamin,Cyanocobalamin (vitamin B12) is used as a cofactor in enzymatic assays to support certain metabolic reactions.,Entity: cyanocobalamin. SMILES: C/C1=C2/N=C(/C=C3\N/C(=C(/C)C4=N[C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)(O)O[C@H]1[C@@H](O)[C@@H]([n+]6c[nH]c7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(=N)[O-])[C@@](C)(CC(N)=O)[C@@H]3CCC(=N)[O-])C(C)(C)[C@@H]2CCC(=N)[O-].[C]#N.[Co+2]. Cyanocobalamin (vitamin B12) is used as a cofactor in enzymatic assays to support certain metabolic reactions.
toluene,Toluene is used as a solvent for extracting and measuring radioactively labeled methionine in biochemical assays.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a solvent for extracting and measuring radioactively labeled methionine in biochemical assays.
methionine,"Methionine supplementation at 2 pmol/ml supports methionine synthetase activity in L-cells, though at a lower level compared to supplemented media.","Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine supplementation at 2 pmol/ml supports methionine synthetase activity in L-cells, though at a lower level compared to supplemented media."
folate,Folate supplementation at 2.5 nmol/ml supports methionine synthetase activity in L-cells.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate supplementation at 2.5 nmol/ml supports methionine synthetase activity in L-cells.
vitamin B-12,Vitamin B-12 supplementation at 7 nmol/ml supports methionine synthetase activity in L-cells and may stabilize the enzyme by interacting with its apoenzyme form.,Entity: vitamin B-12. SMILES: C/C1=C2/[N-][C@H]([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]2[C@@H](O)[C@@H](n3cnc4cc(C)c(C)cc43)O[C@@H]2CO)[C@]2(C)N=C(/C(C)=C3\N=C(/C=C4\N=C1[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]3(C)CC(N)=O)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[C-]#N.[Co+3]. Vitamin B-12 supplementation at 7 nmol/ml supports methionine synthetase activity in L-cells and may stabilize the enzyme by interacting with its apoenzyme form.
cycloheximide,"Cycloheximide inhibits the activity of methionine synthetase in L-cells, with activity becoming practically undetectable after 36 hours in regular medium.","Entity: cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Cycloheximide inhibits the activity of methionine synthetase in L-cells, with activity becoming practically undetectable after 36 hours in regular medium."
methyltetrahydrofolate,"Methyltetrahydrofolate acts as the methyl donor in the terminal reaction of methionine biosynthesis, transferring a methyl group to homocysteine and being converted to free tetrahydrofolate in the process.","Entity: methyltetrahydrofolate. SMILES: COC(=O)CC[C@H](NC(=O)c1ccc(NCC2CNc3nc(N)[nH]c(=O)c3N2)cc1)C(=O)O. Methyltetrahydrofolate acts as the methyl donor in the terminal reaction of methionine biosynthesis, transferring a methyl group to homocysteine and being converted to free tetrahydrofolate in the process."
Vitamin B-12,"Vitamin B-12 is required for the activity of methyltetrahydrofolate-homocysteine methyltransferase, the enzyme responsible for the terminal reaction in methionine biosynthesis.","Entity: Vitamin B-12. SMILES: C/C1=C2/[N-][C@H]([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]2[C@@H](O)[C@@H](n3cnc4cc(C)c(C)cc43)O[C@@H]2CO)[C@]2(C)N=C(/C(C)=C3\N=C(/C=C4\N=C1[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]3(C)CC(N)=O)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[C-]#N.[Co+3]. Vitamin B-12 is required for the activity of methyltetrahydrofolate-homocysteine methyltransferase, the enzyme responsible for the terminal reaction in methionine biosynthesis."
tetrahydrofolate,"Tetrahydrofolate is regenerated in the methionine biosynthesis pathway by demethylation of methyltetrahydrofolate, returning it to the intracellular pool.","Entity: tetrahydrofolate. SMILES: Nc1nc2c(c(=O)[nH]1)NC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1)CN2. Tetrahydrofolate is regenerated in the methionine biosynthesis pathway by demethylation of methyltetrahydrofolate, returning it to the intracellular pool."
tetrahydrofolate,Depletion of tetrahydrofolate prevents the biosynthesis of thymidylate and purines.,Entity: tetrahydrofolate. SMILES: Nc1nc2c(c(=O)[nH]1)NC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc1)CN2. Depletion of tetrahydrofolate prevents the biosynthesis of thymidylate and purines.
homocysteine,"Homocysteine serves as the substrate for methyltetrahydrofolate-homocysteine methyltransferase, which catalyzes the transfer of a methyl group from methyltetrahydrofolate to homocysteine in the terminal reaction of methionine biosynthesis.","Entity: homocysteine. SMILES: N[C@@H](CCS)C(=O)O. Homocysteine serves as the substrate for methyltetrahydrofolate-homocysteine methyltransferase, which catalyzes the transfer of a methyl group from methyltetrahydrofolate to homocysteine in the terminal reaction of methionine biosynthesis."
methionine,"Methionine biosynthesis in mammals involves the terminal reaction catalyzed by methyltetrahydrofolate-homocysteine methyltransferase, which transfers a methyl group from methyltetrahydrofolate to homocysteine.","Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine biosynthesis in mammals involves the terminal reaction catalyzed by methyltetrahydrofolate-homocysteine methyltransferase, which transfers a methyl group from methyltetrahydrofolate to homocysteine."
TTP,TTP is a nucleotide analog used to measure DNA synthesis by incorporation into newly synthesized DNA in nuclear extracts of lymphocytes.,Entity: TTP. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O2)c(=O)[nH]c1=O. TTP is a nucleotide analog used to measure DNA synthesis by incorporation into newly synthesized DNA in nuclear extracts of lymphocytes.
5-fluorouracil,Preincubation of normal phytohaemagglutinin-stimulated lymphocytes with 5-fluorouracil for 70–72 hours causes a mean 1.7-fold increase in [3H]TTP incorporation into DNA.,Entity: 5-fluorouracil. SMILES: O=c1[nH]cc(F)c(=O)[nH]1. Preincubation of normal phytohaemagglutinin-stimulated lymphocytes with 5-fluorouracil for 70–72 hours causes a mean 1.7-fold increase in [3H]TTP incorporation into DNA.
folate,Correction of folate deficiency in phytohaemagglutinin-stimulated lymphocytes by supplementation between 0 and 72 hours results in a 2.0-fold increase in [3H]TTP incorporation into DNA.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Correction of folate deficiency in phytohaemagglutinin-stimulated lymphocytes by supplementation between 0 and 72 hours results in a 2.0-fold increase in [3H]TTP incorporation into DNA.
methotrexate,Preincubation of normal phytohaemagglutinin-stimulated lymphocytes with methotrexate for 48–72 hours causes a mean 1.7-fold increase in [3H]TTP incorporation into DNA.,Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Preincubation of normal phytohaemagglutinin-stimulated lymphocytes with methotrexate for 48–72 hours causes a mean 1.7-fold increase in [3H]TTP incorporation into DNA.
hydroxyurea,Preincubation of normal phytohaemagglutinin-stimulated lymphocytes with hydroxyurea for 48–72 hours results in a mean 1.6-fold increase in [3H]TTP incorporation into DNA.,Entity: hydroxyurea. SMILES: NC(=O)NO. Preincubation of normal phytohaemagglutinin-stimulated lymphocytes with hydroxyurea for 48–72 hours results in a mean 1.6-fold increase in [3H]TTP incorporation into DNA.
1-β-D-arabinofuranosylcytosine,Preincubation of normal phytohaemagglutinin-stimulated lymphocytes with 1-β-D-arabinofuranosylcytosine for 71–72 hours causes a mean 2.4-fold increase in [3H]TTP incorporation into DNA.,Entity: 1-β-D-arabinofuranosylcytosine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1. Preincubation of normal phytohaemagglutinin-stimulated lymphocytes with 1-β-D-arabinofuranosylcytosine for 71–72 hours causes a mean 2.4-fold increase in [3H]TTP incorporation into DNA.
vitamin B-12,Correction of vitamin B-12 deficiency in phytohaemagglutinin-stimulated lymphocytes by supplementation between 0 and 72 hours results in a 2.0-fold increase in [3H]TTP incorporation into DNA.,Entity: vitamin B-12. SMILES: C/C1=C2/[N-][C@H]([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]2[C@@H](O)[C@@H](n3cnc4cc(C)c(C)cc43)O[C@@H]2CO)[C@]2(C)N=C(/C(C)=C3\N=C(/C=C4\N=C1[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]3(C)CC(N)=O)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[C-]#N.[Co+3]. Correction of vitamin B-12 deficiency in phytohaemagglutinin-stimulated lymphocytes by supplementation between 0 and 72 hours results in a 2.0-fold increase in [3H]TTP incorporation into DNA.
sulpholene,Sulpholene is used in gradients containing 0.1 M NaCl and 20% (w/v) ethylurea to separate rapidly labelled RNA species associated with rRNA in rat tissues.,Entity: sulpholene. SMILES: O=S1(=O)CC=CC1. Sulpholene is used in gradients containing 0.1 M NaCl and 20% (w/v) ethylurea to separate rapidly labelled RNA species associated with rRNA in rat tissues.
butylated hydroxytoluene,Butylated hydroxytoluene is used as a model inducer to assess its effects on the cytoplasm of hepatocytes in rats.,Entity: butylated hydroxytoluene. SMILES: Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1. Butylated hydroxytoluene is used as a model inducer to assess its effects on the cytoplasm of hepatocytes in rats.
coumarin,Coumarin is used as a model inducer to evaluate its effects on the cytoplasm of hepatocytes in rats.,Entity: coumarin. SMILES: O=c1ccc2ccccc2o1. Coumarin is used as a model inducer to evaluate its effects on the cytoplasm of hepatocytes in rats.
glucose 6-phosphate,Glucose 6-phosphate dehydrogenase activity is assessed histochemically in rat cytoplasmic enzymes.,Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose 6-phosphate dehydrogenase activity is assessed histochemically in rat cytoplasmic enzymes.
ninhydrin,Ninhydrin is used as a protein stain in histochemical analysis of rat cytoplasmic enzymes.,Entity: ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is used as a protein stain in histochemical analysis of rat cytoplasmic enzymes.
sodium chloride,Sodium chloride at 3M concentration is used to extract highly purified ribosomal RNA from rat tissues.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride at 3M concentration is used to extract highly purified ribosomal RNA from rat tissues.
menadione,Menadione is used as a cofactor in histochemical assays for a-glycerophosphate dehydrogenase and succinate dehydrogenase activities in rat cytoplasmic enzymes.,Entity: menadione. SMILES: CC1=CC(=O)c2ccccc2C1=O. Menadione is used as a cofactor in histochemical assays for a-glycerophosphate dehydrogenase and succinate dehydrogenase activities in rat cytoplasmic enzymes.
orotic acid,Orotic acid can be labeled with 14C or 3H and injected intraperitoneally or sub-arachnoidally to assess its effect on RNA synthesis in rat tissues.,Entity: orotic acid. SMILES: O=C(O)c1cc(=O)[nH]c(=O)[nH]1. Orotic acid can be labeled with 14C or 3H and injected intraperitoneally or sub-arachnoidally to assess its effect on RNA synthesis in rat tissues.
uridine,Uridine can be labeled with 14C or 3H and administered intraperitoneally or sub-arachnoidally to study its impact on RNA synthesis in rat tissues.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine can be labeled with 14C or 3H and administered intraperitoneally or sub-arachnoidally to study its impact on RNA synthesis in rat tissues.
ethylurea,Ethylurea at 20% (w/v) is used in sulpholene gradients during ultracentrifugation to separate rapidly labelled RNA fractions associated with rRNA.,Entity: ethylurea. SMILES: CCNC(N)=O. Ethylurea at 20% (w/v) is used in sulpholene gradients during ultracentrifugation to separate rapidly labelled RNA fractions associated with rRNA.
adenosine triphosphate,"Adenosine triphosphate is a substrate for enzymes such as Caz+activated and Mg2+-activated adenosine triphosphatase, which are assayed for activity in rat brain and liver ribosomal fractions.","Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine triphosphate is a substrate for enzymes such as Caz+activated and Mg2+-activated adenosine triphosphatase, which are assayed for activity in rat brain and liver ribosomal fractions."
coumarin,"Chronic administration of coumarin increases the rate of synthesis of various cytoplasmic proteins in the liver, including lactate dehydrogenase, adenosine 5'-phosphatase, and inosine 5'-phosphatase, leading to decreased concentrations of these enzymes in the liver.","Entity: coumarin. SMILES: O=c1ccc2ccccc2o1. Chronic administration of coumarin increases the rate of synthesis of various cytoplasmic proteins in the liver, including lactate dehydrogenase, adenosine 5'-phosphatase, and inosine 5'-phosphatase, leading to decreased concentrations of these enzymes in the liver."
butylated hydroxytoluene,"Butylated hydroxytoluene increases the activity of glucose 6-phosphate dehydrogenase and isocitrate dehydrogenase in hepatocytes, leading to a rapid rise in cytoplasmic protein synthesis and accumulation of smooth endoplasmic reticulum.","Entity: butylated hydroxytoluene. SMILES: Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1. Butylated hydroxytoluene increases the activity of glucose 6-phosphate dehydrogenase and isocitrate dehydrogenase in hepatocytes, leading to a rapid rise in cytoplasmic protein synthesis and accumulation of smooth endoplasmic reticulum."
butylated hydroxytoluene,"Chronic administration of butylated hydroxytoluene increases liver size but does not alter the concentration of transaminases, lactate dehydrogenase, adenosine monophosphatase, inosine monophosphate dehydrogenase, or glucose 6-phosphate dehydrogenase in the liver.","Entity: butylated hydroxytoluene. SMILES: Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1. Chronic administration of butylated hydroxytoluene increases liver size but does not alter the concentration of transaminases, lactate dehydrogenase, adenosine monophosphatase, inosine monophosphate dehydrogenase, or glucose 6-phosphate dehydrogenase in the liver."
adenosine,Adenosine monophosphatase concentration in the liver is not affected by chronic administration of butylated hydroxytoluene or phenobarbitone.,Entity: adenosine. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O. Adenosine monophosphatase concentration in the liver is not affected by chronic administration of butylated hydroxytoluene or phenobarbitone.
inosine monophosphate,Inosine monophosphate dehydrogenase concentration in the liver is not affected by chronic administration of butylated hydroxytoluene or phenobarbitone.,Entity: inosine monophosphate. SMILES: O=P(O)(O)OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O. Inosine monophosphate dehydrogenase concentration in the liver is not affected by chronic administration of butylated hydroxytoluene or phenobarbitone.
MgSO4,MgSO4 is used as a component of bicarbonate buffer at a concentration of 1.2 mM in liver perfusion systems.,Entity: MgSO4. SMILES: O=S(=O)([O-])[O-].[Mg+2]. MgSO4 is used as a component of bicarbonate buffer at a concentration of 1.2 mM in liver perfusion systems.
CaCl2,CaCl2 is included in the bicarbonate buffer at a concentration of 1.3 mM for liver perfusion experiments.,Entity: CaCl2. SMILES: [Ca+2].[Cl-].[Cl-]. CaCl2 is included in the bicarbonate buffer at a concentration of 1.3 mM for liver perfusion experiments.
KH2PO4,KH2PO4 is present in the bicarbonate buffer at a concentration of 1.2 mM in liver perfusion protocols.,Entity: KH2PO4. SMILES: O=P([O-])(O)O.[K+]. KH2PO4 is present in the bicarbonate buffer at a concentration of 1.2 mM in liver perfusion protocols.
NaHCO3,NaHCO3 is used at a concentration of 25 mM in bicarbonate buffer for liver perfusion studies.,Entity: NaHCO3. SMILES: O=C([O-])O.[Na+]. NaHCO3 is used at a concentration of 25 mM in bicarbonate buffer for liver perfusion studies.
glucagon,Glucagon is administered at a continuously controlled concentration into the liver perfusate for metabolic analysis.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon is administered at a continuously controlled concentration into the liver perfusate for metabolic analysis.
oxygen,Oxygen concentration in liver perfusate is measured using an oxygen microelectrode to calculate O2 uptake.,Entity: oxygen. SMILES: [O]. Oxygen concentration in liver perfusate is measured using an oxygen microelectrode to calculate O2 uptake.
adenosine triphosphate,"The ATP/AMP ratio in liver tissue decreases rapidly and remains low shortly after the start of fructose infusion, indicating reduced ATP availability.","Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. The ATP/AMP ratio in liver tissue decreases rapidly and remains low shortly after the start of fructose infusion, indicating reduced ATP availability."
adenosine monophosphate,Adenosine monophosphate levels in liver tissue decrease early after fructose infusion and do not return to baseline within 20 minutes.,Entity: adenosine monophosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine monophosphate levels in liver tissue decrease early after fructose infusion and do not return to baseline within 20 minutes.
fructose,"Fructose infusion in liver tissue causes transient decreases in ATP/AMP and Pi, with minimal Pi reached after 5 minutes and ATP/AMP remaining low during the initial period.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose infusion in liver tissue causes transient decreases in ATP/AMP and Pi, with minimal Pi reached after 5 minutes and ATP/AMP remaining low during the initial period."
glucagon,"Glucagon affects the levels of adenine nucleotides and Pi in liver tissue, but its effect is not explicitly described in the provided paragraph.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon affects the levels of adenine nucleotides and Pi in liver tissue, but its effect is not explicitly described in the provided paragraph."
adenosine triphosphate,Cellular adenosine triphosphate (ATP) content in rat liver decreases as a consequence of fructose metabolism.,Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Cellular adenosine triphosphate (ATP) content in rat liver decreases as a consequence of fructose metabolism.
fructose,Fructose metabolism lowers cellular ATP content in rat liver and increases the content of phosphorylated intermediates.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose metabolism lowers cellular ATP content in rat liver and increases the content of phosphorylated intermediates.
glucagon,Glucagon affects hepatic glycogenolysis in the presence of fructose in intact rat livers.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon affects hepatic glycogenolysis in the presence of fructose in intact rat livers.
glucagon,Glucagon-mediated conversion of phosphorylase b to a is not altered by fructose in rat liver tissue.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon-mediated conversion of phosphorylase b to a is not altered by fructose in rat liver tissue.
fructose,Fructose at 4 mM inhibits glycogenolysis by 40% in the absence of glucagon and 70% in the presence of glucagon in isolated perfused rat livers after 20 min perfusion.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose at 4 mM inhibits glycogenolysis by 40% in the absence of glucagon and 70% in the presence of glucagon in isolated perfused rat livers after 20 min perfusion.
fructose,"Fructose at 4 mM increases glucose formation from glycogen in isolated perfused rat livers, with the effect dependent on glycogenolysis.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose at 4 mM increases glucose formation from glycogen in isolated perfused rat livers, with the effect dependent on glycogenolysis."
fructose,Fructose at 4 mM causes a transient increase in phosphorylase a activity and a decrease in ATP/AMP ratios and tissue Pi levels in isolated perfused rat livers during the first minutes after perfusion.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose at 4 mM causes a transient increase in phosphorylase a activity and a decrease in ATP/AMP ratios and tissue Pi levels in isolated perfused rat livers during the first minutes after perfusion.
Glycerol,"Glycerol at 4 mM has a qualitatively similar, but smaller effect on glucagon-stimulated glycogenolysis compared to fructose in isolated perfused rat livers.","Entity: Glycerol. SMILES: OCC(O)CO. Glycerol at 4 mM has a qualitatively similar, but smaller effect on glucagon-stimulated glycogenolysis compared to fructose in isolated perfused rat livers."
xylitol,"Xylitol at 3 mM has a qualitatively similar, but smaller effect on glucagon-stimulated glycogenolysis compared to fructose in isolated perfused rat livers.","Entity: xylitol. SMILES: OC[C@@H](O)[C@H](O)[C@@H](O)CO. Xylitol at 3 mM has a qualitatively similar, but smaller effect on glucagon-stimulated glycogenolysis compared to fructose in isolated perfused rat livers."
glucose,"Glucose release from isolated perfused rat livers is increased by fructose and enhanced by glucagon, reflecting the net effect of glycogenolysis and gluconeogenesis.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose release from isolated perfused rat livers is increased by fructose and enhanced by glucagon, reflecting the net effect of glycogenolysis and gluconeogenesis."
glucagon,Glucagon inhibits glycogenolysis by 40% (in the absence of fructose) and 70% (in the presence of 4 mM fructose) in isolated perfused rat livers after 20 min perfusion.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon inhibits glycogenolysis by 40% (in the absence of fructose) and 70% (in the presence of 4 mM fructose) in isolated perfused rat livers after 20 min perfusion.
glucagon,Glucagon decreases the release of lactate plus pyruvate and enhances glucose formation from fructose in isolated perfused rat livers without affecting fructose uptake.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon decreases the release of lactate plus pyruvate and enhances glucose formation from fructose in isolated perfused rat livers without affecting fructose uptake.
pyruvate,Glucagon decreases pyruvate production by the same percentage regardless of whether fructose is present.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Glucagon decreases pyruvate production by the same percentage regardless of whether fructose is present.
lactate,Glucagon decreases lactate production by the same percentage regardless of whether fructose is present.,Entity: lactate. SMILES: CC(O)C(=O)[O-]. Glucagon decreases lactate production by the same percentage regardless of whether fructose is present.
glucose,"In the presence of glucagon, the rate of glucose production from fructose increases due to decreased lactate and pyruvate production.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In the presence of glucagon, the rate of glucose production from fructose increases due to decreased lactate and pyruvate production."
fructose,Fructose uptake is not significantly affected by glucagon.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose uptake is not significantly affected by glucagon.
fructose,"During the initial 10 minutes of perfusion with fructose, glycogenolysis is inhibited in the liver, likely due to increased intracellular concentrations of fructose l-phosphate and other phosphate esters.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. During the initial 10 minutes of perfusion with fructose, glycogenolysis is inhibited in the liver, likely due to increased intracellular concentrations of fructose l-phosphate and other phosphate esters."
fructose,"Glucose formation from fructose in the liver does not begin until after 10 minutes of perfusion, indicating a delay in its metabolic conversion.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose formation from fructose in the liver does not begin until after 10 minutes of perfusion, indicating a delay in its metabolic conversion."
oxygen,Oxygen uptake is stimulated during the initial 10 minutes of perfusion with fructose in the liver.,Entity: oxygen. SMILES: [O]. Oxygen uptake is stimulated during the initial 10 minutes of perfusion with fructose in the liver.
glucose,"Total glucose production in the liver is decreased by the presence of fructose and glucagon, mimicking the effects of hereditary fructose intolerance.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Total glucose production in the liver is decreased by the presence of fructose and glucagon, mimicking the effects of hereditary fructose intolerance."
lactate,Lactate production is stimulated during the initial 10 minutes of perfusion with fructose in the liver.,Entity: lactate. SMILES: CC(O)C(=O)[O-]. Lactate production is stimulated during the initial 10 minutes of perfusion with fructose in the liver.
pyruvate,Pyruvate production is stimulated during the initial 10 minutes of perfusion with fructose in the liver.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate production is stimulated during the initial 10 minutes of perfusion with fructose in the liver.
glucagon,"Glucagon impairs the glycogenolytic response to itself in the liver after fructose administration, indicating a complex interaction between glucose regulation and glycogenolysis.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon impairs the glycogenolytic response to itself in the liver after fructose administration, indicating a complex interaction between glucose regulation and glycogenolysis."
fructose,"Fructose inhibits hepatic glucose release in hereditary fructose intolerance, as evidenced by decreased total glucose production in the presence of glucagon.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose inhibits hepatic glucose release in hereditary fructose intolerance, as evidenced by decreased total glucose production in the presence of glucagon."
fructose,"Fructose is rapidly metabolized in the liver, mainly to glucose and lactate.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose is rapidly metabolized in the liver, mainly to glucose and lactate."
fructose,Ingestion of fructose in humans with hereditary fructose intolerance triggers vomiting and hypoglycemia.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Ingestion of fructose in humans with hereditary fructose intolerance triggers vomiting and hypoglycemia.
fructose 1-phosphate,Fructose 1-phosphate competitively inhibits purified phosphorylase a in vitro.,Entity: fructose 1-phosphate. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose 1-phosphate competitively inhibits purified phosphorylase a in vitro.
glucagon,"Glucagon is frequently ineffective in raising blood glucose in hereditary fructose intolerance, even when the liver contains normal amounts of glycogen.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon is frequently ineffective in raising blood glucose in hereditary fructose intolerance, even when the liver contains normal amounts of glycogen."
fructose,"Fructose inhibits glycogenolysis in the intact liver cell, as measured by phosphorylase a activity.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose inhibits glycogenolysis in the intact liver cell, as measured by phosphorylase a activity."
fructose,"In liver tissue perfused with fructose for 20 minutes, total adenine nucleotides and inorganic phosphate (Pi) are decreased.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. In liver tissue perfused with fructose for 20 minutes, total adenine nucleotides and inorganic phosphate (Pi) are decreased."
fructose,"Fructose treatment in liver tissue leads to decreased ATP and ADP content, but does not significantly alter AMP levels after 20 minutes.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose treatment in liver tissue leads to decreased ATP and ADP content, but does not significantly alter AMP levels after 20 minutes."
fructose,"Fructose initially inhibits gluconeogenesis in rat liver, resulting in a 10-minute time lag between fructose infusion and increased glucose production.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose initially inhibits gluconeogenesis in rat liver, resulting in a 10-minute time lag between fructose infusion and increased glucose production."
fructose,Fructose causes oscillations in O2 uptake during the first 10 minutes in rat liver.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose causes oscillations in O2 uptake during the first 10 minutes in rat liver.
fructose,"Fructose serves as a substrate for gluconeogenesis in the liver, and its contribution to glucose formation is quantified by comparing the specific radioactivity of fructose entering and leaving the liver.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose serves as a substrate for gluconeogenesis in the liver, and its contribution to glucose formation is quantified by comparing the specific radioactivity of fructose entering and leaving the liver."
glucose,Glucose formation from fructose in the liver is calculated by multiplying total glucose formation with the relative specific activity of glucose.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose formation from fructose in the liver is calculated by multiplying total glucose formation with the relative specific activity of glucose.
glucose,Glucose formation from glycogen in the liver is determined by subtracting glucose formation from fructose from total glucose production.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose formation from glycogen in the liver is determined by subtracting glucose formation from fructose from total glucose production.
glycerol,"Glucose formation from glycerol in the liver is calculated by dividing the relative specific activity of glucose by 2, accounting for the stoichiometry of glucose formation from glycerol.","Entity: glycerol. SMILES: OCC(O)CO. Glucose formation from glycerol in the liver is calculated by dividing the relative specific activity of glucose by 2, accounting for the stoichiometry of glucose formation from glycerol."
xylitol,"Glucose formation from xylitol in the liver is calculated by dividing the relative specific activity of glucose by 1.2, accounting for the stoichiometry of glucose formation from xylitol.","Entity: xylitol. SMILES: OC[C@@H](O)[C@H](O)[C@@H](O)CO. Glucose formation from xylitol in the liver is calculated by dividing the relative specific activity of glucose by 1.2, accounting for the stoichiometry of glucose formation from xylitol."
glucagon,"Glucagon inhibits hepatic glycogenolysis in isolated rat livers, and this inhibition is not prevented by fructose at 4 mM.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon inhibits hepatic glycogenolysis in isolated rat livers, and this inhibition is not prevented by fructose at 4 mM."
"fructose 1,6-diphosphate","Fructose 1,6-diphosphate inhibits purified phosphorylase a in vitro.","Entity: fructose 1,6-diphosphate. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose 1,6-diphosphate inhibits purified phosphorylase a in vitro."
glycerol 3-phosphate,Glycerol 3-phosphate inhibits purified phosphorylase a in vitro.,Entity: glycerol 3-phosphate. SMILES: O=P(O)(O)OCC(O)CO. Glycerol 3-phosphate inhibits purified phosphorylase a in vitro.
fructose,Fructose at 4 mM inhibits hepatic glycogenolysis in isolated rat livers after 20 minutes of perfusion.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose at 4 mM inhibits hepatic glycogenolysis in isolated rat livers after 20 minutes of perfusion.
glucagon,Glucagon can be administered to rat livers in a non-recirculating perfusion system at a final concentration of 3 nM in the medium.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon can be administered to rat livers in a non-recirculating perfusion system at a final concentration of 3 nM in the medium.
fructose,Fructose can be continuously infused into rat liver perfusate at concentrations of 4 mM and 25 nCi/ml during non-recirculating perfusion.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose can be continuously infused into rat liver perfusate at concentrations of 4 mM and 25 nCi/ml during non-recirculating perfusion.
glucose,Glucose formation from lactate plus pyruvate is increased by glucagon treatment in a perfused liver preparation.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose formation from lactate plus pyruvate is increased by glucagon treatment in a perfused liver preparation.
lactate,Lactate production in perfused livers is inhibited by glucagon when glycolysis is previously stimulated by an alpha adrenergic agonist.,Entity: lactate. SMILES: CC(O)C(=O)[O-]. Lactate production in perfused livers is inhibited by glucagon when glycolysis is previously stimulated by an alpha adrenergic agonist.
fructose,Fructose uptake is not significantly altered by glucagon treatment in a perfused liver preparation.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose uptake is not significantly altered by glucagon treatment in a perfused liver preparation.
pyruvate,"Pyruvate is released together with lactate in glucose metabolism, and its release is inhibited by glucagon in perfused liver preparations.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate is released together with lactate in glucose metabolism, and its release is inhibited by glucagon in perfused liver preparations."
glycerol,"Glycerol uptake in perfused liver preparations increases in response to glucagon, although measurement difficulties exist.","Entity: glycerol. SMILES: OCC(O)CO. Glycerol uptake in perfused liver preparations increases in response to glucagon, although measurement difficulties exist."
xylitol,"Xylitol uptake in perfused liver preparations increases in response to glucagon, although measurement difficulties exist.","Entity: xylitol. SMILES: OC[C@@H](O)[C@H](O)[C@@H](O)CO. Xylitol uptake in perfused liver preparations increases in response to glucagon, although measurement difficulties exist."
glycerol,"Glycerol, when infused at 4 mM, increases glucose formation in the absence of glucagon and decreases it in the presence of glucagon.","Entity: glycerol. SMILES: OCC(O)CO. Glycerol, when infused at 4 mM, increases glucose formation in the absence of glucagon and decreases it in the presence of glucagon."
glucose,Glucose production is increased by 40% in the absence of glucagon and decreased by 30% in the presence of glucagon when fructose is administered.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose production is increased by 40% in the absence of glucagon and decreased by 30% in the presence of glucagon when fructose is administered.
lactate,"Lactate production is stimulated 4.5-fold in response to fructose, and this stimulation is unaffected by glucagon.","Entity: lactate. SMILES: CC(O)C(=O)[O-]. Lactate production is stimulated 4.5-fold in response to fructose, and this stimulation is unaffected by glucagon."
pyruvate,"Pyruvate production is stimulated 4.5-fold in response to fructose, and this stimulation is unaffected by glucagon.","Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate production is stimulated 4.5-fold in response to fructose, and this stimulation is unaffected by glucagon."
fructose,Fructose increases total glucose production by 40% and inhibits glycogenolysis by 40% in the absence of glucagon.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose increases total glucose production by 40% and inhibits glycogenolysis by 40% in the absence of glucagon.
fructose,"In the presence of glucagon, fructose inhibits glycogenolysis by nearly 70% and decreases total glucose production by 30%.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. In the presence of glucagon, fructose inhibits glycogenolysis by nearly 70% and decreases total glucose production by 30%."
fructose,"Fructose causes a 4.5-fold stimulation of lactate plus pyruvate production, which is unaffected by glucagon.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose causes a 4.5-fold stimulation of lactate plus pyruvate production, which is unaffected by glucagon."
xylitol,"Xylitol, when infused at 3 mM, increases glucose formation in the absence of glucagon and decreases it in the presence of glucagon.","Entity: xylitol. SMILES: OC[C@@H](O)[C@H](O)[C@@H](O)CO. Xylitol, when infused at 3 mM, increases glucose formation in the absence of glucagon and decreases it in the presence of glucagon."
AMP,"AMP levels remain depressed after 20 minutes of fructose infusion, indicating reduced cellular ATP.","Entity: AMP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. AMP levels remain depressed after 20 minutes of fructose infusion, indicating reduced cellular ATP."
ATP,"ATP levels are depressed after 20 minutes of fructose infusion, suggesting a decrease in cellular ATP.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP levels are depressed after 20 minutes of fructose infusion, suggesting a decrease in cellular ATP."
fructose,Fructose can be enzymatically converted to fructose 6-phosphate in liver perfusate using hexokinase or glycerokinase and ATP.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose can be enzymatically converted to fructose 6-phosphate in liver perfusate using hexokinase or glycerokinase and ATP.
glucose,Glucose can be separated from other substrates in liver perfusate using ion-exchange chromatography with Dowex 1 X 8 borate resin.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose can be separated from other substrates in liver perfusate using ion-exchange chromatography with Dowex 1 X 8 borate resin.
pyruvate,Pyruvate in perfusate samples can be measured using standard enzymatic assays.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Pyruvate in perfusate samples can be measured using standard enzymatic assays.
xylitol,Xylitol can be quantified in tissue extracts and perfusate samples using standard enzymatic assays.,Entity: xylitol. SMILES: OC[C@@H](O)[C@H](O)[C@@H](O)CO. Xylitol can be quantified in tissue extracts and perfusate samples using standard enzymatic assays.
glucose 6-phosphate,Glucose 6-phosphate can be eluted from Dowex 1 X 8 formate columns using 6 M formic acid after enzymatic conversion in liver perfusate.,Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose 6-phosphate can be eluted from Dowex 1 X 8 formate columns using 6 M formic acid after enzymatic conversion in liver perfusate.
lactate,Lactate in perfusate samples can be measured using standard enzymatic assays.,Entity: lactate. SMILES: CC(O)C(=O)[O-]. Lactate in perfusate samples can be measured using standard enzymatic assays.
glycerol,Glycerol can be enzymatically converted to glycerol 3-phosphate in liver perfusate using hexokinase or glycerokinase and ATP.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol can be enzymatically converted to glycerol 3-phosphate in liver perfusate using hexokinase or glycerokinase and ATP.
hydrochloric acid,Hydrochloric acid (2 M) is used to neutralize perfusate extracts prior to ion-exchange chromatography.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (2 M) is used to neutralize perfusate extracts prior to ion-exchange chromatography.
formic acid,Formic acid (2 M and 6 M) is used for neutralization and elution steps in ion-exchange chromatography of liver perfusate extracts.,Entity: formic acid. SMILES: O=CO. Formic acid (2 M and 6 M) is used for neutralization and elution steps in ion-exchange chromatography of liver perfusate extracts.
water,"Water is used to re-disperse and recover purified glucose 6-phosphate, fructose 6-phosphate, and glycerol 3-phosphate after chromatographic elution.","Entity: water. SMILES: O. Water is used to re-disperse and recover purified glucose 6-phosphate, fructose 6-phosphate, and glycerol 3-phosphate after chromatographic elution."
potassium bicarbonate,Potassium bicarbonate (15 mM K2B40) is used to equilibrate Dowex 1 X 8 borate resin for chromatographic separation.,Entity: potassium bicarbonate. SMILES: O=C([O-])O.[K+]. Potassium bicarbonate (15 mM K2B40) is used to equilibrate Dowex 1 X 8 borate resin for chromatographic separation.
fructose 6-phosphate,Fructose 6-phosphate can be eluted from Dowex 1 X 8 formate columns using 6 M formic acid after enzymatic conversion in liver perfusate.,Entity: fructose 6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose 6-phosphate can be eluted from Dowex 1 X 8 formate columns using 6 M formic acid after enzymatic conversion in liver perfusate.
adenosine triphosphate,Adenosine triphosphate (ATP) is required for the enzymatic conversion of fructose and glycerol to their 6-phosphate forms in liver perfusate.,Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine triphosphate (ATP) is required for the enzymatic conversion of fructose and glycerol to their 6-phosphate forms in liver perfusate.
glycerol 3-phosphate,Glycerol 3-phosphate can be eluted from Dowex 1 X 8 formate columns using 6 M formic acid after enzymatic conversion in liver perfusate.,Entity: glycerol 3-phosphate. SMILES: O=P(O)(O)OCC(O)CO. Glycerol 3-phosphate can be eluted from Dowex 1 X 8 formate columns using 6 M formic acid after enzymatic conversion in liver perfusate.
glucagon,Glucagon-mediated conversion of phosphorylase b to a is not altered by fructose in rat liver tissue.,Entity: glucagon. Glucagon-mediated conversion of phosphorylase b to a is not altered by fructose in rat liver tissue.
glucagon,Glucagon decreases the release of lactate plus pyruvate and enhances glucose formation from fructose in isolated perfused rat livers without affecting fructose uptake.,Entity: glucagon. Glucagon decreases the release of lactate plus pyruvate and enhances glucose formation from fructose in isolated perfused rat livers without affecting fructose uptake.
glucagon,"Glucagon at 3 nM inhibits glycogenolysis by 40% and 70% in the absence and presence of 4 mM fructose, respectively, in isolated perfused rat livers.","Entity: glucagon. Glucagon at 3 nM inhibits glycogenolysis by 40% and 70% in the absence and presence of 4 mM fructose, respectively, in isolated perfused rat livers."
iodide,"Inorganic iodide injected into rats penetrates rapidly into the seminiferous tubules, but does not reach equilibrium with testicular fluids and blood plasma 16 hours after injection.","Entity: iodide. SMILES: [I-]. Inorganic iodide injected into rats penetrates rapidly into the seminiferous tubules, but does not reach equilibrium with testicular fluids and blood plasma 16 hours after injection."
trichloroacetic acid,"Trichloroacetic acid is used to precipitate proteins and measure radioactivity in biological fluids, such as blood plasma and testicular tissues.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to precipitate proteins and measure radioactivity in biological fluids, such as blood plasma and testicular tissues."
rubidium,The initial volume of distribution of rubidium is slightly less in the EDL (ligated) testis compared to the unligated testis of the same animal.,Entity: rubidium. SMILES: [Rb]. The initial volume of distribution of rubidium is slightly less in the EDL (ligated) testis compared to the unligated testis of the same animal.
sodium,The initial volume of distribution of sodium is slightly less in the EDL (ligated) testis compared to the unligated testis of the same animal.,Entity: sodium. SMILES: [Na]. The initial volume of distribution of sodium is slightly less in the EDL (ligated) testis compared to the unligated testis of the same animal.
sucrose,The initial volume of distribution of sucrose is slightly less in the EDL (ligated) testis compared to the unligated testis of the same animal.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. The initial volume of distribution of sucrose is slightly less in the EDL (ligated) testis compared to the unligated testis of the same animal.
potassium,The initial volume of distribution of potassium is slightly less in the EDL (ligated) testis compared to the unligated testis of the same animal.,Entity: potassium. SMILES: [K]. The initial volume of distribution of potassium is slightly less in the EDL (ligated) testis compared to the unligated testis of the same animal.
water,"Tritiated water enters the rat seminiferous tubules more readily than gonadotropins such as FSH and LH, indicating a higher permeability for tritiated water compared to these hormones.","Entity: water. SMILES: O. Tritiated water enters the rat seminiferous tubules more readily than gonadotropins such as FSH and LH, indicating a higher permeability for tritiated water compared to these hormones."
iodide,"Ions, including free iodide, are able to pass into the rat seminiferous tubules, but their entry is appreciably restricted compared to tritiated water.","Entity: iodide. SMILES: [I-]. Ions, including free iodide, are able to pass into the rat seminiferous tubules, but their entry is appreciably restricted compared to tritiated water."
succinimidyl-hydroxyiodophenylpropionate,"When used to label FSH, succinimidyl-hydroxyiodophenylpropionate results in a lower amount of label in the kidney compared to plasma, with kidney counts reaching about twice the plasma values for both total and TCA-precipitable radioactivity.","Entity: succinimidyl-hydroxyiodophenylpropionate. SMILES: O=C1CCC(=O)N1C(O)C(I)(C(=O)[O-])c1ccccc1. When used to label FSH, succinimidyl-hydroxyiodophenylpropionate results in a lower amount of label in the kidney compared to plasma, with kidney counts reaching about twice the plasma values for both total and TCA-precipitable radioactivity."
potassium iodide,Potassium iodide is administered at a dose of 0.5 mg to reduce the uptake of iodide by the thyroid in experimental settings.,Entity: potassium iodide. SMILES: [I-].[K+]. Potassium iodide is administered at a dose of 0.5 mg to reduce the uptake of iodide by the thyroid in experimental settings.
Streptomycin,Streptomycin is used as an antibiotic supplement in cell culture media at a concentration of 50 µg/ml in this experimental setup.,Entity: Streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used as an antibiotic supplement in cell culture media at a concentration of 50 µg/ml in this experimental setup.
testosterone,"Testosterone serves as an effective substrate for estradiol-17beta synthesis by Sertoli cells in primary culture, with stimulation of estradiol-17beta synthesis by follicle-stimulating hormone (FSH) when present at 5 × 10⁻⁷ M in the presence of 5 µg/ml FSH for 24 hours.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone serves as an effective substrate for estradiol-17beta synthesis by Sertoli cells in primary culture, with stimulation of estradiol-17beta synthesis by follicle-stimulating hormone (FSH) when present at 5 × 10⁻⁷ M in the presence of 5 µg/ml FSH for 24 hours."
androstenedione,"Androstenedione can be converted to estradiol-17beta by Sertoli cells in primary culture, with the conversion stimulated by both FSH and dibutyryl cyclic AMP (bu2cAMP), and the effect is similar to that observed with testosterone.","Entity: androstenedione. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. Androstenedione can be converted to estradiol-17beta by Sertoli cells in primary culture, with the conversion stimulated by both FSH and dibutyryl cyclic AMP (bu2cAMP), and the effect is similar to that observed with testosterone."
19-hydroxytestosterone,"19-hydroxytestosterone is a substrate for estradiol-17beta synthesis by Sertoli cells in primary culture, with conversion stimulated by both FSH and dibutyryl cyclic AMP (bu2cAMP), and the effect is similar to that observed with testosterone.","Entity: 19-hydroxytestosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43CO)[C@@H]1CC[C@@H]2O. 19-hydroxytestosterone is a substrate for estradiol-17beta synthesis by Sertoli cells in primary culture, with conversion stimulated by both FSH and dibutyryl cyclic AMP (bu2cAMP), and the effect is similar to that observed with testosterone."
androstenedione,Androstenedione is used as an exogenous substrate in cell culture assays at a final concentration of 5 × 10^-7 M.,Entity: androstenedione. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12. Androstenedione is used as an exogenous substrate in cell culture assays at a final concentration of 5 × 10^-7 M.
testosterone,Testosterone is used as an exogenous substrate in cell culture assays at a final concentration of 5 × 10^-7 M.,Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone is used as an exogenous substrate in cell culture assays at a final concentration of 5 × 10^-7 M.
progesterone,Progesterone is used as an exogenous substrate in cell culture assays at a final concentration of 5 × 10^-7 M.,Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone is used as an exogenous substrate in cell culture assays at a final concentration of 5 × 10^-7 M.
ethylenediamine tetraacetic acid,Ethylenediamine tetraacetic acid is used at 1 mM concentration in 1% sodium dodecyl sulphate to remove cells from culture flasks.,Entity: ethylenediamine tetraacetic acid. SMILES: CC(=O)O.CC(=O)O.CC(=O)O.CC(=O)O.NCCN. Ethylenediamine tetraacetic acid is used at 1 mM concentration in 1% sodium dodecyl sulphate to remove cells from culture flasks.
19-hydroxyandrostenedione,19-hydroxyandrostenedione is used as an exogenous substrate in cell culture assays at a final concentration of 5 × 10^-7 M.,Entity: 19-hydroxyandrostenedione. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43CO)[C@@H]1CCC2=O. 19-hydroxyandrostenedione is used as an exogenous substrate in cell culture assays at a final concentration of 5 × 10^-7 M.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used at 1% concentration in 1 mM ethylenediamine tetraacetic acid to remove cells from culture flasks.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used at 1% concentration in 1 mM ethylenediamine tetraacetic acid to remove cells from culture flasks.
19-hydroxytestosterone,FSH regulates the conversion of 19-hydroxytestosterone to estradiol-17beta.,Entity: 19-hydroxytestosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43CO)[C@@H]1CC[C@@H]2O. FSH regulates the conversion of 19-hydroxytestosterone to estradiol-17beta.
19-hydroxyandrostenedione,FSH regulates the conversion of 19-hydroxyandrostenedione to estradiol-17beta.,Entity: 19-hydroxyandrostenedione. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43CO)[C@@H]1CCC2=O. FSH regulates the conversion of 19-hydroxyandrostenedione to estradiol-17beta.
methyl methionine,Methyl methionine uptake and intracellular pool size do not vary after estrogen administration.,Entity: methyl methionine. SMILES: CN[C@@H](CCSC)C(=O)O. Methyl methionine uptake and intracellular pool size do not vary after estrogen administration.
cytidine,Variations in cytidine uptake are less pronounced than those for uridine and methyl methionine after estrogen administration.,Entity: cytidine. SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1. Variations in cytidine uptake are less pronounced than those for uridine and methyl methionine after estrogen administration.
estradiol,Estradiol administration does not alter the uptake or intracellular pool of methyl methionine.,Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Estradiol administration does not alter the uptake or intracellular pool of methyl methionine.
uridine,Variations in uridine uptake are more pronounced than those for methyl methionine and cytidine after estrogen administration.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Variations in uridine uptake are more pronounced than those for methyl methionine and cytidine after estrogen administration.
estradiol,"Estradiol increases the incorporation of uridine into uterine RNA in immature rats, indicating an effect on RNA transcription and transport rates.","Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Estradiol increases the incorporation of uridine into uterine RNA in immature rats, indicating an effect on RNA transcription and transport rates."
estradiol,"Estradiol increases the incorporation of [3H]uridine into uterine RNA in immature rats over a 6-hour period, with a similar effect observed in different RNA species as early as one hour after hormone treatment.","Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Estradiol increases the incorporation of [3H]uridine into uterine RNA in immature rats over a 6-hour period, with a similar effect observed in different RNA species as early as one hour after hormone treatment."
[3H]uridine,[3H]uridine is preferentially incorporated into rRNA rather than HnRNA or heterogeneous cytoplasmic RNA in uterine RNA of immature rats after estradiol treatment.,Entity: [3H]uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. [3H]uridine is preferentially incorporated into rRNA rather than HnRNA or heterogeneous cytoplasmic RNA in uterine RNA of immature rats after estradiol treatment.
estradiol,Estradiol treatment for 3 hours increases uridine incorporation into uterine RNA by approximately 85% in the absence of actinomycin D and by approximately 50% in the presence of low doses of actinomycin D.,Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Estradiol treatment for 3 hours increases uridine incorporation into uterine RNA by approximately 85% in the absence of actinomycin D and by approximately 50% in the presence of low doses of actinomycin D.
uridine,"Uridine incorporation into uterine RNA is suppressed by high doses of actinomycin D, and by low doses of actinomycin D by about 50% in both control and estradiol-treated animals.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine incorporation into uterine RNA is suppressed by high doses of actinomycin D, and by low doses of actinomycin D by about 50% in both control and estradiol-treated animals."
UDP,The uterine intercellular pool of UDP remains constant in vivo during the 1- and 3-hour labeling period following estradiol injection in animals.,Entity: UDP. SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. The uterine intercellular pool of UDP remains constant in vivo during the 1- and 3-hour labeling period following estradiol injection in animals.
UTP,The uterine intercellular pool of UTP remains constant in vivo during the 1- and 3-hour labeling period following estradiol injection in animals.,Entity: UTP. SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. The uterine intercellular pool of UTP remains constant in vivo during the 1- and 3-hour labeling period following estradiol injection in animals.
estradiol,Estradiol is administered as a single injection in vivo to study its effects on RNA metabolism in animal tissues.,Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. Estradiol is administered as a single injection in vivo to study its effects on RNA metabolism in animal tissues.
uridine,Incorporation of [3H]uridine into total RNA is a linear function of time for at least 1 hour under the described labeling conditions.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Incorporation of [3H]uridine into total RNA is a linear function of time for at least 1 hour under the described labeling conditions.
cytochalasin B,Cytochalasin B is an agent that disrupts the function of microfilaments and is thought to disrupt cellular movements and morphological changes involving actin.,Entity: cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B is an agent that disrupts the function of microfilaments and is thought to disrupt cellular movements and morphological changes involving actin.
SDS,SDS is used as a detergent for protein elution from SDS-PAGE gels.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used as a detergent for protein elution from SDS-PAGE gels.
phenylmethylsulfonylfluoride,Phenylmethylsulfonylfluoride is used as a protease inhibitor during the elution of actin from SDS-PAGE gels.,Entity: phenylmethylsulfonylfluoride. SMILES: O=S(=O)(F)Cc1ccccc1. Phenylmethylsulfonylfluoride is used as a protease inhibitor during the elution of actin from SDS-PAGE gels.
methanol,Methanol is used as a component of the destaining solution for SDS-PAGE gels.,Entity: methanol. SMILES: CO. Methanol is used as a component of the destaining solution for SDS-PAGE gels.
acetic acid,Acetic acid is used in combination with methanol for destaining SDS-PAGE gel slices.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used in combination with methanol for destaining SDS-PAGE gel slices.
sodium phosphate,Sodium phosphate buffer at 0.05 M and pH 7.5 is used as a buffer during the elution of actin from SDS-PAGE gels.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate buffer at 0.05 M and pH 7.5 is used as a buffer during the elution of actin from SDS-PAGE gels.
ninhydrin,"Ninhydrin is used to visualize protein spots on chromatography plates by reacting with free amino groups, allowing identification of carrier chick muscle actin.","Entity: ninhydrin. SMILES: O=C1c2ccccc2C(=O)C1(O)O. Ninhydrin is used to visualize protein spots on chromatography plates by reacting with free amino groups, allowing identification of carrier chick muscle actin."
trichloroacetic acid,Trichloroacetic acid is used as a precipitating agent to precipitate proteins from solution during peptide mapping procedures.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used as a precipitating agent to precipitate proteins from solution during peptide mapping procedures.
SDS,SDS (sodium dodecyl sulfate) is used in SDS-PAGE to elute proteins from gels for subsequent peptide mapping.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS (sodium dodecyl sulfate) is used in SDS-PAGE to elute proteins from gels for subsequent peptide mapping.
urea,"Urea is used as a denaturing agent in SDS-PAGE gel electrophoresis buffers, typically at concentrations of 8 M.","Entity: urea. SMILES: NC(N)=O. Urea is used as a denaturing agent in SDS-PAGE gel electrophoresis buffers, typically at concentrations of 8 M."
Triton X-100,Triton X-100 is a non-ionic detergent commonly included at 1% concentration in SDS-PAGE gel electrophoresis to solubilize proteins and reduce protein aggregation.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent commonly included at 1% concentration in SDS-PAGE gel electrophoresis to solubilize proteins and reduce protein aggregation.
dithiothreitol,Dithiothreitol is a reducing agent frequently included at 0.2 M in sample buffers for protein electrophoresis to maintain protein integrity.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is a reducing agent frequently included at 0.2 M in sample buffers for protein electrophoresis to maintain protein integrity.
uranyl acetate,Uranyl acetate is used as a negative stain for visualizing actin and myosin filaments in electron microscopy at a concentration of 1%.,Entity: uranyl acetate. SMILES: CC(=O)[O-].CC(=O)[O-].O=[U+2]=O. Uranyl acetate is used as a negative stain for visualizing actin and myosin filaments in electron microscopy at a concentration of 1%.
acrylamide,"Acrylamide is used as a gel matrix for electrophoresing proteins, such as actin, in SDS-PAGE.","Entity: acrylamide. SMILES: C=CC(N)=O. Acrylamide is used as a gel matrix for electrophoresing proteins, such as actin, in SDS-PAGE."
glycine,Glycine is included in the Tris-glycine-SDS buffer system for protein electrophoresis.,Entity: glycine. SMILES: NCC(=O)O. Glycine is included in the Tris-glycine-SDS buffer system for protein electrophoresis.
Coomassie blue,Coomassie blue is a dye used to stain proteins separated by SDS-PAGE for visualization.,Entity: Coomassie blue. SMILES: O=S(=O)(O)c1cc(O)c2c(N=Nc3ccc(Nc4ccccc4)c4c(S(=O)(=O)O)cccc34)cc(S(=O)(=O)O)cc2c1.[Na+]. Coomassie blue is a dye used to stain proteins separated by SDS-PAGE for visualization.
Tris,Tris is a component of the Tris-glycine-SDS buffer system used in protein electrophoresis.,Entity: Tris. SMILES: NC(CO)(CO)CO. Tris is a component of the Tris-glycine-SDS buffer system used in protein electrophoresis.
SDS,SDS (sodium dodecyl sulfate) is a detergent used in protein electrophoresis to solubilize proteins for analysis.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS (sodium dodecyl sulfate) is a detergent used in protein electrophoresis to solubilize proteins for analysis.
SDS,"SDS is a detergent used to solubilize proteins from SDS gels, as demonstrated by elution of actin from SDS gel slices after homogenization in 1% SDS.","Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is a detergent used to solubilize proteins from SDS gels, as demonstrated by elution of actin from SDS gel slices after homogenization in 1% SDS."
urea,"Urea is used as a dialysis buffer to elute proteins from SDS gels, with steps involving 8 M urea, 0.8 M urea, and final dialysis in distilled water.","Entity: urea. SMILES: NC(N)=O. Urea is used as a dialysis buffer to elute proteins from SDS gels, with steps involving 8 M urea, 0.8 M urea, and final dialysis in distilled water."
water,Distilled water is used as a final dialysis buffer (200 vol) to elute proteins from SDS gels after urea dialysis.,Entity: water. SMILES: O. Distilled water is used as a final dialysis buffer (200 vol) to elute proteins from SDS gels after urea dialysis.
acrylamide,"Acrylamide is a component of SDS gels used to separate proteins, such as actin, based on their Rf values.","Entity: acrylamide. SMILES: C=CC(N)=O. Acrylamide is a component of SDS gels used to separate proteins, such as actin, based on their Rf values."
sodium dodecyl sulfate,"Sodium dodecyl sulfate (SDS) is used as a detergent to solubilize proteins from tissue homogenates, with 1% SDS in Tris-HCl buffer at pH 6.8 commonly used for SDS-gel electrophoresis sample preparation.","Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate (SDS) is used as a detergent to solubilize proteins from tissue homogenates, with 1% SDS in Tris-HCl buffer at pH 6.8 commonly used for SDS-gel electrophoresis sample preparation."
dithiothreitol,Dithiothreitol is used at 0.2 M concentration in SDS-gel electrophoresis sample buffer to reduce protein disulfide bonds prior to protein analysis.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used at 0.2 M concentration in SDS-gel electrophoresis sample buffer to reduce protein disulfide bonds prior to protein analysis.
methanol,Methanol is used at 15% concentration in methanol-10% acetic acid to destain SDS-acrylamide gel electrophoresis protein samples after staining with Coomassie blue.,Entity: methanol. SMILES: CO. Methanol is used at 15% concentration in methanol-10% acetic acid to destain SDS-acrylamide gel electrophoresis protein samples after staining with Coomassie blue.
glycerol,Glycerol is included at 30% concentration in SDS-gel electrophoresis sample buffer to help maintain protein solubility during electrophoresis.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is included at 30% concentration in SDS-gel electrophoresis sample buffer to help maintain protein solubility during electrophoresis.
acetic acid,Acetic acid is used at 10% concentration in methanol-10% acetic acid to destain SDS-acrylamide gel electrophoresis protein samples after staining with Coomassie blue.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used at 10% concentration in methanol-10% acetic acid to destain SDS-acrylamide gel electrophoresis protein samples after staining with Coomassie blue.
acrylamide,"Acrylamide is used as a component of gels for electrophoretic separation of proteins, such as in Tris-glycine (pH 8.3)-urea gels.","Entity: acrylamide. SMILES: C=CC(N)=O. Acrylamide is used as a component of gels for electrophoretic separation of proteins, such as in Tris-glycine (pH 8.3)-urea gels."
SDS,SDS (sodium dodecyl sulfate) is a detergent used at 0.1% concentration for SDS-acrylamide gel electrophoresis and at 1% concentration for eluting proteins from SDS-containing gels.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS (sodium dodecyl sulfate) is a detergent used at 0.1% concentration for SDS-acrylamide gel electrophoresis and at 1% concentration for eluting proteins from SDS-containing gels.
urea,Urea is used at 8 M concentration in electrophoresis sample buffer and as a component of urea gels for protein analysis.,Entity: urea. SMILES: NC(N)=O. Urea is used at 8 M concentration in electrophoresis sample buffer and as a component of urea gels for protein analysis.
toluidine blue,"Toluidine blue is used as a staining agent for autoradiographic slides at a concentration of 0.05% in 0.05 M sodium borate, pH 8.5.","Entity: toluidine blue. SMILES: Cc1ccc(Nc2ccc(O)c3c2C(=O)c2c(O)ccc(Nc4ccc(C)cc4S(=O)(=O)[O-])c2C3=O)c(S(=O)(=O)[O-])c1.[Na+].[Na+]. Toluidine blue is used as a staining agent for autoradiographic slides at a concentration of 0.05% in 0.05 M sodium borate, pH 8.5."
ethanol,"Ethanol is used in various concentrations (70%, 80%, 90%, 95%) as a washing and permeabilization agent in autoradiographic slide processing.","Entity: ethanol. SMILES: CCO. Ethanol is used in various concentrations (70%, 80%, 90%, 95%) as a washing and permeabilization agent in autoradiographic slide processing."
chloroform,Chloroform is used in Carnoys solution (1:6:3 with glacial acetic acid and ethanol) for 10-minute fixation of cells in autoradiography protocols.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used in Carnoys solution (1:6:3 with glacial acetic acid and ethanol) for 10-minute fixation of cells in autoradiography protocols.
sodium borate,Sodium borate is used as a buffer at 0.05 M and pH 8.5 for staining autoradiographic slides with 0.05% toluidine blue.,Entity: sodium borate. SMILES: [Na+].[Na+].[Na+].[O-]B([O-])[O-]. Sodium borate is used as a buffer at 0.05 M and pH 8.5 for staining autoradiographic slides with 0.05% toluidine blue.
trichloroacetic acid,Trichloroacetic acid (TCA) is used at 5% concentration for 10-minute fixation of cells in autoradiography protocols.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid (TCA) is used at 5% concentration for 10-minute fixation of cells in autoradiography protocols.
p-nitrophenol,p-nitrophenol is used as a chromogenic product to measure the activity of acid phosphatase and N-acetyl hexosaminidase enzymes in palatal tissue homogenates.,Entity: p-nitrophenol. SMILES: O=[N+]([O-])c1ccc(O)cc1. p-nitrophenol is used as a chromogenic product to measure the activity of acid phosphatase and N-acetyl hexosaminidase enzymes in palatal tissue homogenates.
Triton X-100,Triton X-100 is a detergent used at a final concentration of 0.1% to lyse palatal tissue for biochemical enzyme assays.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a detergent used at a final concentration of 0.1% to lyse palatal tissue for biochemical enzyme assays.
cycloheximide,"Cycloheximide decreases the activity of lysosomal enzymes in palatal epithelial cells, indicating its effect on protein synthesis.","Entity: cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Cycloheximide decreases the activity of lysosomal enzymes in palatal epithelial cells, indicating its effect on protein synthesis."
DON,DON does not affect the activity of lysosomal enzymes in palatal epithelial cells.,Entity: DON. SMILES: CC1=C[C@H]2O[C@@H]3[C@H](O)C[C@](C)([C@@]2(CO)[C@H](O)C1=O)[C@]31CO1. DON does not affect the activity of lysosomal enzymes in palatal epithelial cells.
glucosamine 6-phosphate,"Glucosamine 6-phosphate is synthesized from fructose 6-phosphate via a glutamine-dependent conversion that is inhibited by DON, blocking the formation of UDP-activated sugars derived from glucosamine.","Entity: glucosamine 6-phosphate. SMILES: N[C@H]1C(O)O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O. Glucosamine 6-phosphate is synthesized from fructose 6-phosphate via a glutamine-dependent conversion that is inhibited by DON, blocking the formation of UDP-activated sugars derived from glucosamine."
glucosamine,"Glucosamine serves as a precursor for UDP-activated sugars, whose synthesis is blocked by DON through inhibition of the glutamine-dependent conversion of fructose 6-phosphate to glucosamine 6-phosphate.","Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine serves as a precursor for UDP-activated sugars, whose synthesis is blocked by DON through inhibition of the glutamine-dependent conversion of fructose 6-phosphate to glucosamine 6-phosphate."
fructose 6-phosphate,"Fructose 6-phosphate is converted to glucosamine 6-phosphate via a glutamine-dependent pathway, which is inhibited by DON, thereby blocking UDP-activated sugar formation.","Entity: fructose 6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose 6-phosphate is converted to glucosamine 6-phosphate via a glutamine-dependent pathway, which is inhibited by DON, thereby blocking UDP-activated sugar formation."
UDP-glucosamine,UDP-glucosamine is an activated sugar derivative synthesized from glucosamine and its formation is blocked by DON through inhibition of the glutamine-dependent conversion of fructose 6-phosphate to glucosamine 6-phosphate.,Entity: UDP-glucosamine. SMILES: N[C@H]1[C@@H](OP(=O)(O)OP(=O)(O)OC[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O. UDP-glucosamine is an activated sugar derivative synthesized from glucosamine and its formation is blocked by DON through inhibition of the glutamine-dependent conversion of fructose 6-phosphate to glucosamine 6-phosphate.
2-Deoxyglucose,"2-Deoxyglucose, when present in culture medium for 48 hours at concentrations of 5–20 n-&f, prevents medial-edge cell death in epithelial cells in a manner morphologically indistinguishable from that of DON under light microscopy.","Entity: 2-Deoxyglucose. SMILES: O=CC[C@@H](O)[C@H](O)[C@H](O)CO. 2-Deoxyglucose, when present in culture medium for 48 hours at concentrations of 5–20 n-&f, prevents medial-edge cell death in epithelial cells in a manner morphologically indistinguishable from that of DON under light microscopy."
Cycloheximide,"Cycloheximide at 0.1 pg/ml prevents epithelial cell death after 48 hours in culture, but does not inhibit medial-edge cell death or prevent cell death.","Entity: Cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Cycloheximide at 0.1 pg/ml prevents epithelial cell death after 48 hours in culture, but does not inhibit medial-edge cell death or prevent cell death."
streptomycin,Streptomycin is used as an antibiotic supplement in culture media at a concentration of 100 µg/ml to prevent bacterial contamination in organotypic tissue cultures.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used as an antibiotic supplement in culture media at a concentration of 100 µg/ml to prevent bacterial contamination in organotypic tissue cultures.
CO2,CO2 is used to humidify the culture atmosphere at a concentration of 5% during organotypic tissue culture to maintain a stable environment for cell survival.,Entity: CO2. SMILES: O=C=O. CO2 is used to humidify the culture atmosphere at a concentration of 5% during organotypic tissue culture to maintain a stable environment for cell survival.
chloroform,Chloroform is used to overdose pregnant rats on Day 15 of gestation to facilitate the collection of embryos with placenta and fetal membranes for experimental analysis.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used to overdose pregnant rats on Day 15 of gestation to facilitate the collection of embryos with placenta and fetal membranes for experimental analysis.
hadacidin,Hadacidin has been shown to inhibit palatal epithelial cell death in in vitro studies using homologous shelf models.,Entity: hadacidin. SMILES: O=CN(O)CC(=O)O. Hadacidin has been shown to inhibit palatal epithelial cell death in in vitro studies using homologous shelf models.
glucosamine,Glucosamine at 10 mM concentration does not prevent epithelial cell death in the presence of DON (20 pg/ml).,Entity: glucosamine. SMILES: Cl.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine at 10 mM concentration does not prevent epithelial cell death in the presence of DON (20 pg/ml).
glucosamine,Glucosamine at 10 mM concentration partially blocks the cytotoxic effect of DON (20 pg/ml) on epithelial cells in culture.,Entity: glucosamine. SMILES: Cl.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine at 10 mM concentration partially blocks the cytotoxic effect of DON (20 pg/ml) on epithelial cells in culture.
aminoimidazole carboxamide,"Aminoimidazole carboxamide at 10 n&Q or nicotinamide (concentration not specified) was present in the experimental setup, but its effect on cell survival in the presence of DON (20 pg/ml) and glucosamine (10 mM) is not described in the paragraph.","Entity: aminoimidazole carboxamide. SMILES: NC(=O)c1nc(N)c[nH]1. Aminoimidazole carboxamide at 10 n&Q or nicotinamide (concentration not specified) was present in the experimental setup, but its effect on cell survival in the presence of DON (20 pg/ml) and glucosamine (10 mM) is not described in the paragraph."
nicotinamide,"Nicotinamide was present in the experimental setup, but its effect on cell survival in the presence of DON (20 pg/ml) and glucosamine (10 mM) is not described in the paragraph.","Entity: nicotinamide. SMILES: NC(=O)c1cccnc1. Nicotinamide was present in the experimental setup, but its effect on cell survival in the presence of DON (20 pg/ml) and glucosamine (10 mM) is not described in the paragraph."
Cycloheximide,"Cycloheximide inhibits cell death in palatal epithelial cells, but its effect differs from that of deoxynivalenol (DON) and 2-Deoxyglucose in that it does not cause medialedge hypertrophy.","Entity: Cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Cycloheximide inhibits cell death in palatal epithelial cells, but its effect differs from that of deoxynivalenol (DON) and 2-Deoxyglucose in that it does not cause medialedge hypertrophy."
Purine,Deoxynivalenol (DON) does not inhibit cell death by blocking the formation of purines.,Entity: Purine. SMILES: c1ncc2[nH]cnc2n1. Deoxynivalenol (DON) does not inhibit cell death by blocking the formation of purines.
Nicotinamide,"Nicotinamide, when administered with deoxynivalenol (DON), does not prevent DON's effect on cell death.","Entity: Nicotinamide. SMILES: NC(=O)c1cccnc1. Nicotinamide, when administered with deoxynivalenol (DON), does not prevent DON's effect on cell death."
Glucosamine,Glucosamine bypasses the effect of deoxynivalenol (DON) on glycoprotein synthesis and provides substantial protection against DON-induced cell death in vitro.,Entity: Glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine bypasses the effect of deoxynivalenol (DON) on glycoprotein synthesis and provides substantial protection against DON-induced cell death in vitro.
Glucosamine,"Glucosamine is primarily incorporated into glycosaminoglycans and glycoproteins under the conditions tested, indicating it does not override DON's effect by acting on other metabolic pathways.","Entity: Glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine is primarily incorporated into glycosaminoglycans and glycoproteins under the conditions tested, indicating it does not override DON's effect by acting on other metabolic pathways."
Glucosamine,The inhibitory effect of deoxynivalenol (DON) on glycosaminoglycan synthesis in chick embryo fibroblasts can only be partially restored by glucosamine.,Entity: Glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. The inhibitory effect of deoxynivalenol (DON) on glycosaminoglycan synthesis in chick embryo fibroblasts can only be partially restored by glucosamine.
Glucosamine,Glucosamine has been reported to inhibit protein and glycosaminoglycan synthesis in cartilage.,Entity: Glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine has been reported to inhibit protein and glycosaminoglycan synthesis in cartilage.
2-Deoxyglucose,2-Deoxyglucose at 5 to 10 mM inhibits palatal cell death in vitro in a manner morphologically similar to deoxynivalenol (DON).,Entity: 2-Deoxyglucose. SMILES: O=CC[C@@H](O)[C@H](O)[C@H](O)CO. 2-Deoxyglucose at 5 to 10 mM inhibits palatal cell death in vitro in a manner morphologically similar to deoxynivalenol (DON).
2-Deoxyglucose,2-Deoxyglucose has been reported to inhibit glycosylation of proteins.,Entity: 2-Deoxyglucose. SMILES: O=CC[C@@H](O)[C@H](O)[C@H](O)CO. 2-Deoxyglucose has been reported to inhibit glycosylation of proteins.
2-deoxyglucose,"2-deoxyglucose is used as a cell-permeant glucose analog in cell culture experiments, typically applied at concentrations of 5–20 mM to the culture medium at time zero or after 24 hours.","Entity: 2-deoxyglucose. SMILES: O=CC[C@@H](O)[C@H](O)[C@H](O)CO. 2-deoxyglucose is used as a cell-permeant glucose analog in cell culture experiments, typically applied at concentrations of 5–20 mM to the culture medium at time zero or after 24 hours."
Nicotinamide,"Nicotinamide is used as a vitamin B3 supplement in cell culture media, with typical concentrations ranging from 5–20 mM.","Entity: Nicotinamide. SMILES: NC(=O)c1cccnc1. Nicotinamide is used as a vitamin B3 supplement in cell culture media, with typical concentrations ranging from 5–20 mM."
Cycloheximide,"Cycloheximide is an antibiotic commonly used to inhibit protein synthesis in cell culture, typically applied at a concentration of 10 pg/ml at the initiation of the culture.","Entity: Cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Cycloheximide is an antibiotic commonly used to inhibit protein synthesis in cell culture, typically applied at a concentration of 10 pg/ml at the initiation of the culture."
6-Diazo-5-oxo-L-norleucine,"6-Diazo-5-oxo-L-norleucine (DON) is a cell-permeant amino acid analog used to label lysine residues in proteins, applied at concentrations of 10–20 pg/ml in cell culture.","Entity: 6-Diazo-5-oxo-L-norleucine. SMILES: [N-]=[N+]=CC(=O)CC[C@H](N)C(=O)O. 6-Diazo-5-oxo-L-norleucine (DON) is a cell-permeant amino acid analog used to label lysine residues in proteins, applied at concentrations of 10–20 pg/ml in cell culture."
Aminoimidazole carboxamide,"Aminoimidazole carboxamide is used as a supplement in cell culture media, typically at a concentration of 10 mM.","Entity: Aminoimidazole carboxamide. SMILES: NC(=O)c1nc(N)c[nH]1. Aminoimidazole carboxamide is used as a supplement in cell culture media, typically at a concentration of 10 mM."
fructose-6-phosphate,"Fructose-6-phosphate can be produced from glucose-6-phosphate by the action of phosphoglucose isomerase, especially when glucose-6-phosphate concentrations are high and fructose-6-phosphate concentrations are low.","Entity: fructose-6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose-6-phosphate can be produced from glucose-6-phosphate by the action of phosphoglucose isomerase, especially when glucose-6-phosphate concentrations are high and fructose-6-phosphate concentrations are low."
glucose-6-phosphate,"Glucose-6-phosphate can be converted to fructose-6-phosphate by phosphoglucose isomerase activity, particularly under conditions of high glucose-6-phosphate and low fructose-6-phosphate concentrations.","Entity: glucose-6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose-6-phosphate can be converted to fructose-6-phosphate by phosphoglucose isomerase activity, particularly under conditions of high glucose-6-phosphate and low fructose-6-phosphate concentrations."
glutamine,Glutamine forms a complex with the enzyme that competes with UDPGlcNAc for binding in the hexosamine pathway.,Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine forms a complex with the enzyme that competes with UDPGlcNAc for binding in the hexosamine pathway.
fructose-6-phosphate,Fructose-6-phosphate is the substrate for the enzyme in the hexosamine pathway and is directly competed by UDPGlcNAc for binding at the enzyme's active site.,Entity: fructose-6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose-6-phosphate is the substrate for the enzyme in the hexosamine pathway and is directly competed by UDPGlcNAc for binding at the enzyme's active site.
cycloheximide,"Cycloheximide, a protein synthesis inhibitor, allows initial chitin synthesis and cell wall formation to proceed on schedule during Blastocladiella emersonii zoospore germination.","Entity: cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Cycloheximide, a protein synthesis inhibitor, allows initial chitin synthesis and cell wall formation to proceed on schedule during Blastocladiella emersonii zoospore germination."
fructose-6-phosphate,"Fructose-6-phosphate serves as a precursor for chitin synthesis in Blastocladiella emersonii, with the necessary enzymes for this conversion present at high specific activities in zoospore extracts.","Entity: fructose-6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose-6-phosphate serves as a precursor for chitin synthesis in Blastocladiella emersonii, with the necessary enzymes for this conversion present at high specific activities in zoospore extracts."
glutamine,"Glutamine is a required substrate for chitin synthesis in Blastocladiella emersonii, and the enzymes catalyzing this reaction are highly active in zoospore extracts.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine is a required substrate for chitin synthesis in Blastocladiella emersonii, and the enzymes catalyzing this reaction are highly active in zoospore extracts."
GlcN-6-P,GlcN-6-P formation can be assayed in enzymatic reactions using a method modified from Ghosh and Roseman (1962).,Entity: GlcN-6-P. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. GlcN-6-P formation can be assayed in enzymatic reactions using a method modified from Ghosh and Roseman (1962).
Fru-6-P,Fru-6-P is used as a substrate at a concentration of 1.2 pmoles in enzymatic assays to initiate the formation of GlcN-6-P from zoospore extracts.,Entity: Fru-6-P. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fru-6-P is used as a substrate at a concentration of 1.2 pmoles in enzymatic assays to initiate the formation of GlcN-6-P from zoospore extracts.
UDPGlcNAc,"UDPGlcNAc is used as an exogenous substrate in enzymatic assays, but less than 1% of added UDPGlcNAc elutes with the fractions containing enzyme activity from zoospore extracts.","Entity: UDPGlcNAc. SMILES: CC(=O)N[C@H]1C(OP(=O)(O)OP(=O)(O)O)O[C@H](CO)[C@@H](O)[C@@H]1O.O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. UDPGlcNAc is used as an exogenous substrate in enzymatic assays, but less than 1% of added UDPGlcNAc elutes with the fractions containing enzyme activity from zoospore extracts."
fructose-6-phosphate,The functional site of inhibition for UDP-N-acetyl-glucosaminyltransferase is the substrate fructose-6-phosphate.,Entity: fructose-6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. The functional site of inhibition for UDP-N-acetyl-glucosaminyltransferase is the substrate fructose-6-phosphate.
2-deoxy-D-glucose-6-phosphate,2-deoxy-D-glucose-6-phosphate is not metabolized in zoospore extracts.,Entity: 2-deoxy-D-glucose-6-phosphate. SMILES: O=CC[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 2-deoxy-D-glucose-6-phosphate is not metabolized in zoospore extracts.
2-deoxy-D-glucose-6-phosphate,2-deoxy-D-glucose-6-phosphate exhibits linearly competitive inhibition with respect to fructose-6-phosphate and linearly uncompetitive inhibition with respect to glutamine in the enzyme assay.,Entity: 2-deoxy-D-glucose-6-phosphate. SMILES: O=CC[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. 2-deoxy-D-glucose-6-phosphate exhibits linearly competitive inhibition with respect to fructose-6-phosphate and linearly uncompetitive inhibition with respect to glutamine in the enzyme assay.
guanosine triphosphate,"Guanosine triphosphate (GTP) was used as a guanine nucleoside phosphate inhibitor in amidotransferase enzyme assays, with its inhibitory effect modulated by its concentration relative to the substrate and UDPGlcNAc.","Entity: guanosine triphosphate. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. Guanosine triphosphate (GTP) was used as a guanine nucleoside phosphate inhibitor in amidotransferase enzyme assays, with its inhibitory effect modulated by its concentration relative to the substrate and UDPGlcNAc."
adenosine monophosphate,"Adenosine monophosphate (AMP) was tested as a nucleoside phosphate inhibitor in amidotransferase enzyme assays, with its effect on enzyme activity depending on its concentration relative to the substrate and UDPGlcNAc.","Entity: adenosine monophosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine monophosphate (AMP) was tested as a nucleoside phosphate inhibitor in amidotransferase enzyme assays, with its effect on enzyme activity depending on its concentration relative to the substrate and UDPGlcNAc."
adenosine triphosphate,"Adenosine triphosphate (ATP) was used as a nucleoside phosphate inhibitor in amidotransferase enzyme assays, with its inhibitory effect on enzyme activity influenced by its concentration relative to the substrate and UDPGlcNAc.","Entity: adenosine triphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine triphosphate (ATP) was used as a nucleoside phosphate inhibitor in amidotransferase enzyme assays, with its inhibitory effect on enzyme activity influenced by its concentration relative to the substrate and UDPGlcNAc."
guanosine diphosphate,"Guanosine diphosphate (GDP) was tested as a guanine nucleoside phosphate inhibitor in amidotransferase enzyme assays, with its inhibitory effect on enzyme activity depending on its concentration relative to the substrate and UDPGlcNAc.","Entity: guanosine diphosphate. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. Guanosine diphosphate (GDP) was tested as a guanine nucleoside phosphate inhibitor in amidotransferase enzyme assays, with its inhibitory effect on enzyme activity depending on its concentration relative to the substrate and UDPGlcNAc."
glutamine,"Glutamine acts as an inhibitor of amidotransferase activity, with its inhibitory effect influenced by the presence and concentration of UDPGlcNAc and other nucleoside phosphates in the reaction mixture.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine acts as an inhibitor of amidotransferase activity, with its inhibitory effect influenced by the presence and concentration of UDPGlcNAc and other nucleoside phosphates in the reaction mixture."
adenosine diphosphate,"Adenosine diphosphate (ADP) was tested as a nucleoside phosphate inhibitor in amidotransferase enzyme assays, with its effect on enzyme activity depending on its concentration relative to the substrate and UDPGlcNAc.","Entity: adenosine diphosphate. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. Adenosine diphosphate (ADP) was tested as a nucleoside phosphate inhibitor in amidotransferase enzyme assays, with its effect on enzyme activity depending on its concentration relative to the substrate and UDPGlcNAc."
glucose-6-phosphate,"Glucose-6-phosphate (GlcN-6-P) is the product formed in amidotransferase enzyme assays under saturating substrate conditions, and its amount can be quantified to assess enzyme activity.","Entity: glucose-6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose-6-phosphate (GlcN-6-P) is the product formed in amidotransferase enzyme assays under saturating substrate conditions, and its amount can be quantified to assess enzyme activity."
glucose-6-phosphate,"Glucose-6-phosphate can inhibit the L-glutamine:D-fructose-6-phosphate amidotransferase enzyme activity, and the inhibition is enhanced in the presence of UDP-GlcNAc.","Entity: glucose-6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose-6-phosphate can inhibit the L-glutamine:D-fructose-6-phosphate amidotransferase enzyme activity, and the inhibition is enhanced in the presence of UDP-GlcNAc."
fructose-6-phosphate,"Fructose-6-phosphate is a saturating substrate for the UDP-GlcNAc amidotransferase enzyme in the hexosamine biosynthetic pathway, with inhibition of this enzyme by UDP-GlcNAc measured as a percentage of control.","Entity: fructose-6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose-6-phosphate is a saturating substrate for the UDP-GlcNAc amidotransferase enzyme in the hexosamine biosynthetic pathway, with inhibition of this enzyme by UDP-GlcNAc measured as a percentage of control."
acetyl-CoA,"Acetyl-CoA is a substrate for the UDP-GlcNAc acetyltransferase enzyme in the hexosamine biosynthetic pathway, with inhibition of this enzyme by UDP-GlcNAc measured as a percentage of control.","Entity: acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Acetyl-CoA is a substrate for the UDP-GlcNAc acetyltransferase enzyme in the hexosamine biosynthetic pathway, with inhibition of this enzyme by UDP-GlcNAc measured as a percentage of control."
glutamine,"Glutamine serves as a saturating substrate for the UDP-GlcNAc amidotransferase enzyme in the hexosamine biosynthetic pathway, with inhibition of this enzyme by UDP-GlcNAc measured as a percentage of control.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine serves as a saturating substrate for the UDP-GlcNAc amidotransferase enzyme in the hexosamine biosynthetic pathway, with inhibition of this enzyme by UDP-GlcNAc measured as a percentage of control."
N-acetylglucosamine-6-phosphate,N-acetylglucosamine-6-phosphate is used as a substrate to assay enzyme activity in biochemical assays.,Entity: N-acetylglucosamine-6-phosphate. SMILES: CC(=O)N[C@H]1C(O)O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O. N-acetylglucosamine-6-phosphate is used as a substrate to assay enzyme activity in biochemical assays.
histidine,Histidine is used at a concentration of 20 mM in the buffer solution for preparing enzyme extracts.,Entity: histidine. SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O. Histidine is used at a concentration of 20 mM in the buffer solution for preparing enzyme extracts.
MgSO4,MgSO4 is included at a concentration of 20 mM in the buffer solution for enzyme extract preparation.,Entity: MgSO4. SMILES: O=S(=O)([O-])[O-].[Mg+2]. MgSO4 is included at a concentration of 20 mM in the buffer solution for enzyme extract preparation.
orthophosphate,"Orthophosphate is monitored as the product of enzyme activity assays, with correction for phosphate released from the substrate.","Entity: orthophosphate. SMILES: O=P([O-])([O-])[O-]. Orthophosphate is monitored as the product of enzyme activity assays, with correction for phosphate released from the substrate."
fructose-6-phosphate,"Fructose-6-phosphate competes with UDPGlcNAc for the Fru-6-P substrate site on the enzyme, influencing the enzyme's kinetic behavior.","Entity: fructose-6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose-6-phosphate competes with UDPGlcNAc for the Fru-6-P substrate site on the enzyme, influencing the enzyme's kinetic behavior."
GlcNAc-6-P,"GlcNAc-6-P is the product formed in enzymatic reactions using GlcN-6-P and AcCoA as substrates, and its concentration can be measured by absorbance at 600 nm in the range of 10–100 nmoles per reaction mixture.","Entity: GlcNAc-6-P. SMILES: O=C(CO)N[C@H]1C(O)O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O. GlcNAc-6-P is the product formed in enzymatic reactions using GlcN-6-P and AcCoA as substrates, and its concentration can be measured by absorbance at 600 nm in the range of 10–100 nmoles per reaction mixture."
Glc-6-P,Glc-6-P cannot substitute for GlcN-6-P as a substrate in the enzymatic formation of GlcNAc-6-P.,Entity: Glc-6-P. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glc-6-P cannot substitute for GlcN-6-P as a substrate in the enzymatic formation of GlcNAc-6-P.
Galactosamine,Galactosamine cannot substitute for GlcN-6-P as a substrate in the enzymatic formation of GlcNAc-6-P.,Entity: Galactosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O. Galactosamine cannot substitute for GlcN-6-P as a substrate in the enzymatic formation of GlcNAc-6-P.
GlcN-6-P,"GlcN-6-P is a substrate in enzymatic assays for the formation of GlcNAc-6-P, with a substrate constant (K) of 4 x 10^-4 M, and cannot be replaced by Glc-6-P or glucosamine.","Entity: GlcN-6-P. SMILES: N[C@H]1C(O)O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O. GlcN-6-P is a substrate in enzymatic assays for the formation of GlcNAc-6-P, with a substrate constant (K) of 4 x 10^-4 M, and cannot be replaced by Glc-6-P or glucosamine."
Sodium tetraborate,"Sodium tetraborate (0.27 M) is used as a buffer component in enzymatic assays for the formation of GlcNAc-6-P, replacing sodium borate and sodium bicarbonate.","Entity: Sodium tetraborate. SMILES: [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-]. Sodium tetraborate (0.27 M) is used as a buffer component in enzymatic assays for the formation of GlcNAc-6-P, replacing sodium borate and sodium bicarbonate."
Acetyl-CoA,"Acetyl-CoA serves as a substrate in enzymatic assays for the formation of GlcNAc-6-P, with a substrate constant (K) of 1.9 x 10^4 M.","Entity: Acetyl-CoA. SMILES: CC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Acetyl-CoA serves as a substrate in enzymatic assays for the formation of GlcNAc-6-P, with a substrate constant (K) of 1.9 x 10^4 M."
UDPGlcNAc,"UDPGlcNAc inhibits enzyme activity, and uridine nucleoside phosphates that counteract this inhibition do so by interacting at enzyme sites distinct from substrate sites.","Entity: UDPGlcNAc. SMILES: CC(=O)N[C@H]1C(OP(=O)(O)OP(=O)(O)O)O[C@H](CO)[C@@H](O)[C@@H]1O.O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. UDPGlcNAc inhibits enzyme activity, and uridine nucleoside phosphates that counteract this inhibition do so by interacting at enzyme sites distinct from substrate sites."
uridine diphosphate,Uridine diphosphate can competitively exclude the inhibitory effects of UDPGlcNAc on the enzyme without significantly influencing substrate interactions at the substrate sites.,Entity: uridine diphosphate. SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine diphosphate can competitively exclude the inhibitory effects of UDPGlcNAc on the enzyme without significantly influencing substrate interactions at the substrate sites.
uridine triphosphate,Uridine triphosphate can competitively exclude the inhibitory effects of UDPGlcNAc on the enzyme without significantly influencing substrate interactions at the substrate sites.,Entity: uridine triphosphate. SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine triphosphate can competitively exclude the inhibitory effects of UDPGlcNAc on the enzyme without significantly influencing substrate interactions at the substrate sites.
fructose-6-phosphate,Fructose-6-phosphate is a substrate of the UDP-GlcNAcase enzyme and interacts with a kinetically separable site on the enzyme that competes with the inhibitory effects of UDPGlcNAc.,Entity: fructose-6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose-6-phosphate is a substrate of the UDP-GlcNAcase enzyme and interacts with a kinetically separable site on the enzyme that competes with the inhibitory effects of UDPGlcNAc.
glutamine,Glutamine is a substrate of the UDP-GlcNAcase enzyme and interacts with a kinetically separable site on the enzyme that competes with the inhibitory effects of UDPGlcNAc.,Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine is a substrate of the UDP-GlcNAcase enzyme and interacts with a kinetically separable site on the enzyme that competes with the inhibitory effects of UDPGlcNAc.
asparagine,Asparagine does not substitute for glutamine in the amidotransferase reaction.,Entity: asparagine. SMILES: NC(=O)C[C@H](N)C(=O)O. Asparagine does not substitute for glutamine in the amidotransferase reaction.
glucosamine,Glucosamine-HCl can be used as a standard in assays measuring concentrations from 10 to 100 nmole per 200 µl reaction mixture.,Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine-HCl can be used as a standard in assays measuring concentrations from 10 to 100 nmole per 200 µl reaction mixture.
glucose-6-phosphate,Glucose-6-phosphate does not substitute for fructose-6-phosphate as a substrate in the amidotransferase reaction.,Entity: glucose-6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose-6-phosphate does not substitute for fructose-6-phosphate as a substrate in the amidotransferase reaction.
fructose-6-phosphate,"Under amidotransferase activity assay conditions, less than 10% of fructose-6-phosphate is converted to glucose-6-phosphate by phosphoglucose isomerase (EC 5.3.3.1.9).","Entity: fructose-6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Under amidotransferase activity assay conditions, less than 10% of fructose-6-phosphate is converted to glucose-6-phosphate by phosphoglucose isomerase (EC 5.3.3.1.9)."
glutamine,Glutamine does not substitute for asparagine in the amidotransferase reaction.,Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine does not substitute for asparagine in the amidotransferase reaction.
IMP,IMP at concentrations up to 5 mM has no significant effect on the enzyme's activity in the presence or absence of UDPGlcNAc.,Entity: IMP. SMILES: O=P(O)(O)OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O. IMP at concentrations up to 5 mM has no significant effect on the enzyme's activity in the presence or absence of UDPGlcNAc.
GDP,GDP counteracts the inhibitory effects of UDPGlcNAc on the enzyme's activity at concentrations up to 5 mM.,Entity: GDP. SMILES: Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. GDP counteracts the inhibitory effects of UDPGlcNAc on the enzyme's activity at concentrations up to 5 mM.
UDPGlcNAc,"UDPGlcNAc is an inhibitor of the enzyme in the presence or absence of UDP, with its inhibitory effect counteracted by GDP at concentrations up to 5 mM.","Entity: UDPGlcNAc. SMILES: CC(=O)N[C@H]1C(OP(=O)(O)OP(=O)(O)O)O[C@H](CO)[C@@H](O)[C@@H]1O.O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. UDPGlcNAc is an inhibitor of the enzyme in the presence or absence of UDP, with its inhibitory effect counteracted by GDP at concentrations up to 5 mM."
Glc-6-P,"Glc-6-P, the immediate precursor to one of the enzyme's substrates (Fru-6-P), shows a similar inhibition pattern to UDPGlcNAc with rat liver enzyme.","Entity: Glc-6-P. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glc-6-P, the immediate precursor to one of the enzyme's substrates (Fru-6-P), shows a similar inhibition pattern to UDPGlcNAc with rat liver enzyme."
CTP,CTP at concentrations up to 5 mM has no significant effect on the enzyme's activity in the presence or absence of UDPGlcNAc.,Entity: CTP. SMILES: Nc1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)n1. CTP at concentrations up to 5 mM has no significant effect on the enzyme's activity in the presence or absence of UDPGlcNAc.
ATP,ATP at concentrations up to 5 mM has no significant effect on the enzyme's activity in the presence or absence of UDPGlcNAc.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP at concentrations up to 5 mM has no significant effect on the enzyme's activity in the presence or absence of UDPGlcNAc.
UTP,UTP does not significantly affect the enzyme's activity in the presence or absence of UDPGlcNAc.,Entity: UTP. SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1. UTP does not significantly affect the enzyme's activity in the presence or absence of UDPGlcNAc.
Polyoxin D,"Polyoxin D, a structural analog of UDPGlcNAc, does not significantly affect the enzyme's activity at concentrations up to 1 mM in the presence or absence of UDPGlcNAc.","Entity: Polyoxin D. SMILES: NC(=O)OC[C@H](O)[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)O)[C@H]1O[C@@H](n2cc(C(=O)O)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O. Polyoxin D, a structural analog of UDPGlcNAc, does not significantly affect the enzyme's activity at concentrations up to 1 mM in the presence or absence of UDPGlcNAc."
glutamine,"Glutamine forms a complex with the enzyme that is sequentially combined with UDPGlcNAc, with glutamine binding prior to fructose-6-phosphate in the reaction mechanism.","Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine forms a complex with the enzyme that is sequentially combined with UDPGlcNAc, with glutamine binding prior to fructose-6-phosphate in the reaction mechanism."
fructose-6-phosphate,"Fructose-6-phosphate competes with UDPGlcNAc for combination with the enzyme, which is sequentially inhibited by glutamine and then fructose-6-phosphate.","Entity: fructose-6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose-6-phosphate competes with UDPGlcNAc for combination with the enzyme, which is sequentially inhibited by glutamine and then fructose-6-phosphate."
fructose-6-phosphate,Fructose-6-phosphate serves as a substrate in the biosynthetic pathway leading to the formation of UDPGlcNAc from glutamine.,Entity: fructose-6-phosphate. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose-6-phosphate serves as a substrate in the biosynthetic pathway leading to the formation of UDPGlcNAc from glutamine.
glutamine,Glutamine acts as a substrate in the pathway that converts fructose-6-phosphate to UDPGlcNAc.,Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine acts as a substrate in the pathway that converts fructose-6-phosphate to UDPGlcNAc.
glucosamine-6-phosphate,Glucosamine-6-phosphate is a precursor in the biosynthetic pathway for chitin formation.,Entity: glucosamine-6-phosphate. SMILES: N[C@H]1C(O)O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O. Glucosamine-6-phosphate is a precursor in the biosynthetic pathway for chitin formation.
sodium dodecyl sulphate,Sodium dodecyl sulphate is used as a detergent at 1% concentration in buffer B for resuspension of DNA nuclei.,Entity: sodium dodecyl sulphate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulphate is used as a detergent at 1% concentration in buffer B for resuspension of DNA nuclei.
sodium chloride,Sodium chloride is included at 0.1 M concentration in buffer B for the resuspension of DNA nuclei.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is included at 0.1 M concentration in buffer B for the resuspension of DNA nuclei.
SDS,SDS is used at a final concentration of 0.25% to lyse RNA/DNA hybrids and nonspecific duplexes during sample preparation for DNA duplex analysis.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used at a final concentration of 0.25% to lyse RNA/DNA hybrids and nonspecific duplexes during sample preparation for DNA duplex analysis.
ethanol,Ethanol is used to precipitate RNA from solution by adding 2.5 volumes at -20°C during RNA purification.,Entity: ethanol. SMILES: CCO. Ethanol is used to precipitate RNA from solution by adding 2.5 volumes at -20°C during RNA purification.
chloroform,Chloroform is used in a final extraction step to remove phenol from RNA samples during purification.,Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform is used in a final extraction step to remove phenol from RNA samples during purification.
octanol,Octanol is used in combination with chloroform for a final extraction to remove phenol from RNA samples during purification.,Entity: octanol. SMILES: CCCCCCCCO. Octanol is used in combination with chloroform for a final extraction to remove phenol from RNA samples during purification.
sodium acetate,"Sodium acetate buffer (0.1 M, pH 5.2) is used to dissolve RNA pellets and as a component in the RNA extraction and purification process.","Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate buffer (0.1 M, pH 5.2) is used to dissolve RNA pellets and as a component in the RNA extraction and purification process."
SDS,SDS (sodium dodecyl sulfate) is used at 1% concentration in phenol-chloroform extraction to aid in RNA purification.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS (sodium dodecyl sulfate) is used at 1% concentration in phenol-chloroform extraction to aid in RNA purification.
phenol,Phenol is removed from RNA samples by a final chloroform:octanol extraction during RNA purification.,Entity: phenol. SMILES: Oc1ccccc1. Phenol is removed from RNA samples by a final chloroform:octanol extraction during RNA purification.
PB,PB (phosphate buffer) at 0.12 M is used to stop nuclease S activity after incubation at 75°C.,Entity: PB. SMILES: O=P([O-])([O-])OP(=O)([O-])[O-]. PB (phosphate buffer) at 0.12 M is used to stop nuclease S activity after incubation at 75°C.
SDS,SDS is used at 0.25% concentration to lyse nucleic acids prior to HAP chromatography for duplex (RNA/DNA or DNA/DNA) analysis.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used at 0.25% concentration to lyse nucleic acids prior to HAP chromatography for duplex (RNA/DNA or DNA/DNA) analysis.
ZnSO4,ZnSO4 is used at 3 x 10^-6 M concentration in reaction buffers for nuclease S-mediated treatment of hybridization reaction aliquots.,Entity: ZnSO4. SMILES: O=S(=O)([O-])[O-].[Zn+2]. ZnSO4 is used at 3 x 10^-6 M concentration in reaction buffers for nuclease S-mediated treatment of hybridization reaction aliquots.
sodium acetate,Sodium acetate buffer at 0.03 M and pH 4.5 is used in combination with 0.1 M NaCl for nuclease S-mediated strand removal from nucleic acid hybrids.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate buffer at 0.03 M and pH 4.5 is used in combination with 0.1 M NaCl for nuclease S-mediated strand removal from nucleic acid hybrids.
SDS,SDS is used at 0.25% concentration to prevent RNase-mediated binding of H-labeled DNA to the HAP column during chromatography.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS is used at 0.25% concentration to prevent RNase-mediated binding of H-labeled DNA to the HAP column during chromatography.
CP,"CP administered at 45 mg/kg in mice is associated with a higher mean number of revolutions (40) on the rotorod test 4 days after training compared to 0 mg/kg (25) and 30 mg/kg (10) doses, with the 40-mg/kg group performing significantly better than control.","Entity: CP. SMILES: Nc1ncnc2c1ncn2[C@]1(C2CCCC2)O[C@H](CO)[C@@H](O)[C@H]1O. CP administered at 45 mg/kg in mice is associated with a higher mean number of revolutions (40) on the rotorod test 4 days after training compared to 0 mg/kg (25) and 30 mg/kg (10) doses, with the 40-mg/kg group performing significantly better than control."
CP,"CP treatment at 45 mg/kg does not produce malformations in mice but causes subtle defects in locomotor development, as indicated by reduced swimming ability and impaired performance in rod crossing and shock avoidance tasks.","Entity: CP. SMILES: O=P1(N(CCCl)CCCl)NCCCO1. CP treatment at 45 mg/kg does not produce malformations in mice but causes subtle defects in locomotor development, as indicated by reduced swimming ability and impaired performance in rod crossing and shock avoidance tasks."
CP,"Mice treated with CP at 45 mg/kg show normal righting behavior by 10 days of age, with recovery in rod crossing and shock avoidance performance by 21 days of age, and rotorod performance comparable to controls.","Entity: CP. SMILES: O=P1(N(CCCl)CCCl)NCCCO1. Mice treated with CP at 45 mg/kg show normal righting behavior by 10 days of age, with recovery in rod crossing and shock avoidance performance by 21 days of age, and rotorod performance comparable to controls."
methylazoxymethanol,"Methylazoxymethanol treatment induces cerebellar hypoplasia in mice, resulting in gross ataxia by 25 days of age.","Entity: methylazoxymethanol. SMILES: C[N+]([O-])=NCO. Methylazoxymethanol treatment induces cerebellar hypoplasia in mice, resulting in gross ataxia by 25 days of age."
methylazoxymethanol,"Neonatal administration of methylazoxymethanol interferes with neural development, particularly the development of the cerebellum.","Entity: methylazoxymethanol. SMILES: C[N+]([O-])=NCO. Neonatal administration of methylazoxymethanol interferes with neural development, particularly the development of the cerebellum."
CP,CP is an alkylating agent whose primary action is disruption of macromolecular metabolism.,Entity: CP. SMILES: CNNC. CP is an alkylating agent whose primary action is disruption of macromolecular metabolism.
CP,CP treatment can disrupt macromolecular metabolism in the nervous system during development.,Entity: CP. SMILES: CNNC. CP treatment can disrupt macromolecular metabolism in the nervous system during development.
CP,The effects of CP are not specific to neural tissue and can manifest as reduced body weight gain and increased fatality rates in mice even in the absence of gross morphological malformations.,Entity: CP. SMILES: CNNC. The effects of CP are not specific to neural tissue and can manifest as reduced body weight gain and increased fatality rates in mice even in the absence of gross morphological malformations.
CP,CP treatment at 80 mg/kg in 1-day old mice reduces whole brain DNA synthesis for at least 5 days and decreases RNA synthesis on the 1st and 4th days after treatment.,Entity: CP. SMILES: O=P1(N(CCCl)CCCl)NCCCO1. CP treatment at 80 mg/kg in 1-day old mice reduces whole brain DNA synthesis for at least 5 days and decreases RNA synthesis on the 1st and 4th days after treatment.
CP,"CP treatment in neonatal mice reduces the half-life of brain proteins, making neonatal proteins more susceptible to degradation.","Entity: CP. SMILES: O=P1(N(CCCl)CCCl)NCCCO1. CP treatment in neonatal mice reduces the half-life of brain proteins, making neonatal proteins more susceptible to degradation."
CP,"CP-treated mice exhibit behavioral abnormalities and morphological characteristics similar to hypothyroid animals, including delayed maturation of reflexes and impaired behavioral performance.","Entity: CP. SMILES: O=P1(N(CCCl)CCCl)NCCCO1. CP-treated mice exhibit behavioral abnormalities and morphological characteristics similar to hypothyroid animals, including delayed maturation of reflexes and impaired behavioral performance."
hydroxyurea,"Hydroxyurea, a compound that interferes with macromolecular synthesis, has been shown to cause behavioral defects when administered perinatally to rodents.","Entity: hydroxyurea. SMILES: NC(=O)NO. Hydroxyurea, a compound that interferes with macromolecular synthesis, has been shown to cause behavioral defects when administered perinatally to rodents."
methylazoxymethanol,"Methylazoxymethanol, an alkylating agent that interferes with macromolecular synthesis, has been shown to cause behavioral defects when administered perinatally to rodents.","Entity: methylazoxymethanol. SMILES: C[N+]([O-])=NCO. Methylazoxymethanol, an alkylating agent that interferes with macromolecular synthesis, has been shown to cause behavioral defects when administered perinatally to rodents."
scopolamine hydrobromide,Scopolamine hydrobromide is administered intraperitoneally at doses of 0.5 or 1.0 mg/kg in mice to study its effects on locomotor activity.,Entity: scopolamine hydrobromide. SMILES: Br.CN1[C@@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12. Scopolamine hydrobromide is administered intraperitoneally at doses of 0.5 or 1.0 mg/kg in mice to study its effects on locomotor activity.
d-amphetamine,"d-amphetamine at 5.0 mg/kg increases activity in A/J, DBA/2J, and C57BL/6 mice at both 14 and 28 days of age, and at 21 days in all strains except C57BL/6.","Entity: d-amphetamine. SMILES: CC(N)Cc1ccccc1. d-amphetamine at 5.0 mg/kg increases activity in A/J, DBA/2J, and C57BL/6 mice at both 14 and 28 days of age, and at 21 days in all strains except C57BL/6."
scopolamine,"scopolamine treatment increases activity in DBA/2J mice at 21 days of age, but not in A/J or C57BL/6 mice until 28 days postnatally.","Entity: scopolamine. SMILES: CN1[C@@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@H]12. scopolamine treatment increases activity in DBA/2J mice at 21 days of age, but not in A/J or C57BL/6 mice until 28 days postnatally."
catecholamine,"The excitatory catecholamine system in the mouse brain develops more rapidly than the inhibitory cholinergic system, as indicated by strain-specific differences in activity levels and age-dependent changes in response to d-amphetamine and scopolamine.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. The excitatory catecholamine system in the mouse brain develops more rapidly than the inhibitory cholinergic system, as indicated by strain-specific differences in activity levels and age-dependent changes in response to d-amphetamine and scopolamine."
scopolamine,"Scopolamine produces different behavioral effects in mice depending on age, with pronounced increases in activity observed in DBA/2 mice at 3–1 days postnatal and at 28 days of age, and smaller increases in A and C57BL/6 mice that do not reach statistical significance at younger ages.","Entity: scopolamine. SMILES: CN1[C@@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@H]12. Scopolamine produces different behavioral effects in mice depending on age, with pronounced increases in activity observed in DBA/2 mice at 3–1 days postnatal and at 28 days of age, and smaller increases in A and C57BL/6 mice that do not reach statistical significance at younger ages."
scopolamine,"Scopolamine increases activity in C57BL/6 mice at 28 days of age, but produces no effect or a decline in activity in adult animals.","Entity: scopolamine. SMILES: CN1[C@@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@H]12. Scopolamine increases activity in C57BL/6 mice at 28 days of age, but produces no effect or a decline in activity in adult animals."
scopolamine,"Scopolamine does not increase activity in A and C57BL/6 mice until 28 days of age, indicating delayed cholinergic system maturation in these strains.","Entity: scopolamine. SMILES: CN1[C@@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@H]12. Scopolamine does not increase activity in A and C57BL/6 mice until 28 days of age, indicating delayed cholinergic system maturation in these strains."
amphetamine,"Amphetamine increases activity earlier than scopolamine in mice, with effects observed as early as 21 days in DBA/2 and 28 days in A and C57BL/6 mice.","Entity: amphetamine. SMILES: CC(N)Cc1ccccc1. Amphetamine increases activity earlier than scopolamine in mice, with effects observed as early as 21 days in DBA/2 and 28 days in A and C57BL/6 mice."
glucose,"Hepatic gluconeogenesis from lactate is accelerated, leading to increased hepatic glucose output.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Hepatic gluconeogenesis from lactate is accelerated, leading to increased hepatic glucose output."
oleate,In vitro studies with radiolabeled oleate show significant hepatic release of labeled carbon dioxide during lactate-induced stimulation of hepatic gluconeogenesis.,Entity: oleate. SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)[O-]. In vitro studies with radiolabeled oleate show significant hepatic release of labeled carbon dioxide during lactate-induced stimulation of hepatic gluconeogenesis.
carbon dioxide,"Increased hepatic carbon dioxide production occurs during lactate infusion, presumed to result from increased fatty acid uptake rather than enhanced citric acid cycle activity.","Entity: carbon dioxide. SMILES: O=C=O. Increased hepatic carbon dioxide production occurs during lactate infusion, presumed to result from increased fatty acid uptake rather than enhanced citric acid cycle activity."
lactate,"Lactate has an antiketogenic effect, largely due to increased esterification and to a lesser degree due to accelerated citric acid cycle activity.","Entity: lactate. SMILES: CC(O)C(=O)[O-]. Lactate has an antiketogenic effect, largely due to increased esterification and to a lesser degree due to accelerated citric acid cycle activity."
glycerol,"Hepatic glycerol uptake is increased during acceleration of gluconeogenesis, consistent with enhanced fatty acid oxidation to cover hepatic energy requirements.","Entity: glycerol. SMILES: OCC(O)CO. Hepatic glycerol uptake is increased during acceleration of gluconeogenesis, consistent with enhanced fatty acid oxidation to cover hepatic energy requirements."
oxaloacetate,"Oxaloacetate content in the liver is reduced during acceleration of gluconeogenesis, which is associated with reduced citric acid cycle activity.","Entity: oxaloacetate. SMILES: O=C([O-])CC(=O)C(=O)O. Oxaloacetate content in the liver is reduced during acceleration of gluconeogenesis, which is associated with reduced citric acid cycle activity."
alanine,Blood alanine levels can be determined enzymatically in blood samples collected during hepatic blood flow measurement.,Entity: alanine. SMILES: C[C@H](N)C(=O)O. Blood alanine levels can be determined enzymatically in blood samples collected during hepatic blood flow measurement.
glycerol,Blood glycerol levels can be measured enzymatically in blood samples collected during hepatic blood flow measurement.,Entity: glycerol. SMILES: OCC(O)CO. Blood glycerol levels can be measured enzymatically in blood samples collected during hepatic blood flow measurement.
pyruvate,Blood pyruvate levels can be assayed enzymatically within 6 hours of blood collection.,Entity: pyruvate. SMILES: CC(=O)C(=O)[O-]. Blood pyruvate levels can be assayed enzymatically within 6 hours of blood collection.
β-hydroxybutyrate,Blood β-hydroxybutyrate levels can be measured enzymatically in blood samples collected during hepatic blood flow measurement.,Entity: β-hydroxybutyrate. SMILES: CC(O)CC(=O)[O-]. Blood β-hydroxybutyrate levels can be measured enzymatically in blood samples collected during hepatic blood flow measurement.
acetoacetate,Acetoacetate in blood can be measured enzymatically and its concentration is typically determined within 6 hours of blood collection.,Entity: acetoacetate. SMILES: CC(=O)CC(=O)[O-]. Acetoacetate in blood can be measured enzymatically and its concentration is typically determined within 6 hours of blood collection.
perchloric acid,"Perchloric acid is used immediately after blood collection to preserve blood samples for subsequent enzymatic assays of blood glucose, lactate, pyruvate, alanine, glycerol, β-hydroxybutyrate, and acetoacetate.","Entity: perchloric acid. SMILES: [O-][Cl+3]([O-])([O-])O. Perchloric acid is used immediately after blood collection to preserve blood samples for subsequent enzymatic assays of blood glucose, lactate, pyruvate, alanine, glycerol, β-hydroxybutyrate, and acetoacetate."
glucose,Blood glucose levels can be determined enzymatically in blood samples collected during hepatic blood flow measurement.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Blood glucose levels can be determined enzymatically in blood samples collected during hepatic blood flow measurement.
lactate,Blood lactate levels can be measured enzymatically in blood samples collected during hepatic blood flow measurement.,Entity: lactate. SMILES: CC(O)C(=O)[O-]. Blood lactate levels can be measured enzymatically in blood samples collected during hepatic blood flow measurement.
lactate,Lactate can be administered intravenously at a rate of 0.03 mmol/kg/min to induce changes in hepatic substrate balances in humans.,Entity: lactate. SMILES: CC(O)C(=O)[O-].[Na+]. Lactate can be administered intravenously at a rate of 0.03 mmol/kg/min to induce changes in hepatic substrate balances in humans.
sodium chloride,Sodium chloride (0.9% solution) is used as a carrier for heparin in hepatic vein catheterization procedures.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride (0.9% solution) is used as a carrier for heparin in hepatic vein catheterization procedures.
Cardio-green,Cardio-green is used as a bolus tracer to measure blood transit time across the forearm by detecting its peak concentration in the deep vein after injection into the arterial catheter.,Entity: Cardio-green. SMILES: CC1(C)C(=CC=CC=CC=CC2=[N+](CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)N(CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+]. Cardio-green is used as a bolus tracer to measure blood transit time across the forearm by detecting its peak concentration in the deep vein after injection into the arterial catheter.
glucose,"After intravenous glucose administration, arterial glucose peaks at the end of the bolus injection, while venous glucose reaches its peak 1–1.5 minutes later.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. After intravenous glucose administration, arterial glucose peaks at the end of the bolus injection, while venous glucose reaches its peak 1–1.5 minutes later."
Cardio-green,Cardio-green is used to determine the transit time between arterial and deep forearm vein blood for correction in blood glucose and insulin measurements.,Entity: Cardio-green. SMILES: CC1(C)C(=CC=CC=CC=CC2=[N+](CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)N(CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+]. Cardio-green is used to determine the transit time between arterial and deep forearm vein blood for correction in blood glucose and insulin measurements.
iodine,Iodine (specifically 125I) is used to iodinate human monocomponent insulin for radiolabeling in biochemical assays.,Entity: iodine. SMILES: [I]. Iodine (specifically 125I) is used to iodinate human monocomponent insulin for radiolabeling in biochemical assays.
Arginine hydrochloride,Arginine hydrochloride is administered intravenously at a dose of 468 mg/kg over ten minutes in this patient.,Entity: Arginine hydrochloride. SMILES: Cl.N=C(N)NCCC[C@H](N)C(=O)O. Arginine hydrochloride is administered intravenously at a dose of 468 mg/kg over ten minutes in this patient.
Glucose,Glucose is administered orally at a dose of 1.75 g/kg (25% solution) in five minutes during an oral glucose tolerance test.,Entity: Glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is administered orally at a dose of 1.75 g/kg (25% solution) in five minutes during an oral glucose tolerance test.
Ammonium sulphate,Ammonium sulphate is used to precipitate globulins from plasma for subsequent gel chromatography.,Entity: Ammonium sulphate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Ammonium sulphate is used to precipitate globulins from plasma for subsequent gel chromatography.
Dextran,Dextran is used as a component of a mixture with charcoal for the extraction of glycated insulin residues (GIR) from plasma.,Entity: Dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran is used as a component of a mixture with charcoal for the extraction of glycated insulin residues (GIR) from plasma.
ketones,Urine ketones can be quantified in mice using Ketostix reagent strips.,Entity: ketones. SMILES: N#CC(C#N)[C@@]1(CC(=O)c2ccccc2)C(=O)Nc2ccc(Br)cc21. Urine ketones can be quantified in mice using Ketostix reagent strips.
acetic acid,"Acetic acid (1N, pH 2.4) is used for sonication extraction of pancreases to determine insulin content in mice.","Entity: acetic acid. SMILES: CC(=O)O. Acetic acid (1N, pH 2.4) is used for sonication extraction of pancreases to determine insulin content in mice."
glucose,Plasma glucose in mice can be measured using a glucose oxidase method in blood samples.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Plasma glucose in mice can be measured using a glucose oxidase method in blood samples.
glucose,Urine glucose in mice can be estimated using Clinistix reagent strips.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Urine glucose in mice can be estimated using Clinistix reagent strips.
toluidine blue,Toluidine blue is used as a histological stain for coronal sections of the hypothalamus in mouse brain tissue.,Entity: toluidine blue. SMILES: Cc1ccc(Nc2ccc(O)c3c2C(=O)c2c(O)ccc(Nc4ccc(C)cc4S(=O)(=O)[O-])c2C3=O)c(S(=O)(=O)[O-])c1.[Na+].[Na+]. Toluidine blue is used as a histological stain for coronal sections of the hypothalamus in mouse brain tissue.
gold thioglucose,"Gold thioglucose is used to induce obesity and hyperphagia in mice, leading to unmasking of diabetic tendency and increased insulin resistance.","Entity: gold thioglucose. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S.[Au]. Gold thioglucose is used to induce obesity and hyperphagia in mice, leading to unmasking of diabetic tendency and increased insulin resistance."
glucose,"Glucose administration in KK mice treated with MSG results in a marked fall in plasma glucose compared to controls, indicating that hyperglycaemia in these mice is dependent on food intake.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose administration in KK mice treated with MSG results in a marked fall in plasma glucose compared to controls, indicating that hyperglycaemia in these mice is dependent on food intake."
gold thioglucose,"Gold thioglucose is used to induce lesions in the ventromedial nucleus of rodents, which can unmask diabetic tendencies in KK mice.","Entity: gold thioglucose. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S.[Au]. Gold thioglucose is used to induce lesions in the ventromedial nucleus of rodents, which can unmask diabetic tendencies in KK mice."
glucose,"Glucose is involved in carbohydrate metabolism regulated by the hypothalamus, which influences insulin and glucagon secretion.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is involved in carbohydrate metabolism regulated by the hypothalamus, which influences insulin and glucagon secretion."
MSG,"Administration of monosodium glutamate (MSG) to KK mice during the neonatal period induces a syndrome of obesity, stunting, and hypogonadism.","Entity: MSG. SMILES: N[C@@H](CCC(=O)O)C(=O)[O-].[Na+]. Administration of monosodium glutamate (MSG) to KK mice during the neonatal period induces a syndrome of obesity, stunting, and hypogonadism."
MSG,"In some KK mice, administration of MSG during the neonatal period unmasks a genetic predisposition to diabetes, leading to marked hyperglycaemia and/or hyperinsulinaemia.","Entity: MSG. SMILES: N[C@@H](CCC(=O)O)C(=O)[O-].[Na+]. In some KK mice, administration of MSG during the neonatal period unmasks a genetic predisposition to diabetes, leading to marked hyperglycaemia and/or hyperinsulinaemia."
MSG,"In fed MSG-treated KK mice, elevated plasma glucose and insulin levels decrease rapidly after food deprivation.","Entity: MSG. SMILES: N[C@@H](CCC(=O)O)C(=O)[O-].[Na+]. In fed MSG-treated KK mice, elevated plasma glucose and insulin levels decrease rapidly after food deprivation."
MSG,MSG administration in KK mice impairs oral glucose tolerance but does not affect glucose disposal after intraperitoneal glucose challenge.,Entity: MSG. SMILES: N[C@@H](CCC(=O)O)C(=O)[O-].[Na+]. MSG administration in KK mice impairs oral glucose tolerance but does not affect glucose disposal after intraperitoneal glucose challenge.
MSG,Insulin secretion in MSG-treated KK mice is defective after intraperitoneal glucose administration but not after oral glucose administration.,Entity: MSG. SMILES: N[C@@H](CCC(=O)O)C(=O)[O-].[Na+]. Insulin secretion in MSG-treated KK mice is defective after intraperitoneal glucose administration but not after oral glucose administration.
C-peptide,"C-peptide is used as a biomarker to assess insulin therapy in juvenile diabetic patients, with values measured in pmol/ml to monitor treatment effectiveness and adjust insulin regimens.","Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. C-peptide is used as a biomarker to assess insulin therapy in juvenile diabetic patients, with values measured in pmol/ml to monitor treatment effectiveness and adjust insulin regimens."
glucose,Fasting blood glucose can be measured using the hexokinase method in the same blood samples used for C-peptide and insulin assays.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Fasting blood glucose can be measured using the hexokinase method in the same blood samples used for C-peptide and insulin assays.
C-peptide,C-peptide is human C-peptide and can be quantified in serum using a specific radioimmunoassay in which proinsulin is removed by binding to insulin antibodies covalently coupled to Sepharose.,Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. C-peptide is human C-peptide and can be quantified in serum using a specific radioimmunoassay in which proinsulin is removed by binding to insulin antibodies covalently coupled to Sepharose.
C-peptide,"Patients in remission from diabetes, defined as a period of nearly constant normoglycaemia with minimal glycosuria, have higher C-peptide levels compared to those without remission.","Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. Patients in remission from diabetes, defined as a period of nearly constant normoglycaemia with minimal glycosuria, have higher C-peptide levels compared to those without remission."
C-peptide,C-peptide is secreted from pancreatic B-cells in equimolar amounts with insulin.,Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. C-peptide is secreted from pancreatic B-cells in equimolar amounts with insulin.
C-peptide,C-peptide has been used as a measure of endogenous insulin secretion in insulin-treated diabetics.,Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. C-peptide has been used as a measure of endogenous insulin secretion in insulin-treated diabetics.
C-peptide,"In children, detectable serum C-peptide is associated with a higher prevalence of fasting hyperglycaemia (>5.8 mmol/l) at the time of blood sampling.","Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. In children, detectable serum C-peptide is associated with a higher prevalence of fasting hyperglycaemia (>5.8 mmol/l) at the time of blood sampling."
C-peptide,Children with measurable C-peptide levels have a later onset and shorter duration of diabetes compared to those without C-peptide.,Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. Children with measurable C-peptide levels have a later onset and shorter duration of diabetes compared to those without C-peptide.
C-peptide,Patients with measurable C-peptide levels have more frequent and longer early remission periods in diabetes.,Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. Patients with measurable C-peptide levels have more frequent and longer early remission periods in diabetes.
C-peptide,"C-peptide is a biomarker used to detect early diabetes in children, with normal fasting ranges in non-diabetic children and adolescents comparable to those in adults (0.22–0.73 pmol/ml).","Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. C-peptide is a biomarker used to detect early diabetes in children, with normal fasting ranges in non-diabetic children and adolescents comparable to those in adults (0.22–0.73 pmol/ml)."
C-peptide,"C-peptide is a biomarker of residual pancreatic beta-cell function, with measurable levels indicating some degree of endogenous insulin production in patients with juvenile diabetes.","Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. C-peptide is a biomarker of residual pancreatic beta-cell function, with measurable levels indicating some degree of endogenous insulin production in patients with juvenile diabetes."
C-peptide,"C-peptide levels in some juvenile diabetes patients, even after more than two years of treatment, can be within or above the normal range for non-diabetic adults, suggesting variable residual beta-cell function.","Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. C-peptide levels in some juvenile diabetes patients, even after more than two years of treatment, can be within or above the normal range for non-diabetic adults, suggesting variable residual beta-cell function."
C-peptide,"The absence of measurable C-peptide is correlated with high levels of insulin antibodies, suggesting a negative effect of insulin antibodies on B-cell function.","Entity: C-peptide. SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O. The absence of measurable C-peptide is correlated with high levels of insulin antibodies, suggesting a negative effect of insulin antibodies on B-cell function."
tartrate,Tartrate inhibits over 90 percent of prostatic acid phosphatase activity in serum and is considered clinically useful for prostatic cancer diagnosis.,Entity: tartrate. SMILES: O=C([O-])C(O)C(O)C(=O)[O-]. Tartrate inhibits over 90 percent of prostatic acid phosphatase activity in serum and is considered clinically useful for prostatic cancer diagnosis.
tartrate,"Tartrate inhibits prostatic acid phosphatase as well as hepatic, splenic, and renal sources of this enzyme, which can lead to misleading results when elevated serum acid phosphatase is due to altered output from these organs.","Entity: tartrate. SMILES: O=C([O-])C(O)C(O)C(=O)[O-]. Tartrate inhibits prostatic acid phosphatase as well as hepatic, splenic, and renal sources of this enzyme, which can lead to misleading results when elevated serum acid phosphatase is due to altered output from these organs."
phenylphosphate,Phenylphosphate is rapidly hydrolyzed by all acid phosphatases and is prone to false positive enzyme activity assays in sera from hemolyzed blood samples.,Entity: phenylphosphate. SMILES: O=P([O-])([O-])Oc1ccccc1. Phenylphosphate is rapidly hydrolyzed by all acid phosphatases and is prone to false positive enzyme activity assays in sera from hemolyzed blood samples.
N-methyl-N'-nitro-N-nitrosoguanidine,Subcutaneous injection of N-methyl-N'-nitro-N-nitrosoguanidine at 50 mg/kg for 10 days depresses hemolysin production against sheep red blood cells in Wistar rats.,Entity: N-methyl-N'-nitro-N-nitrosoguanidine. SMILES: CN(N=O)C(=N)N[N+](=O)[O-]. Subcutaneous injection of N-methyl-N'-nitro-N-nitrosoguanidine at 50 mg/kg for 10 days depresses hemolysin production against sheep red blood cells in Wistar rats.
N-methyl-N'-nitro-N-nitrosoguanidine,Oral administration of N-methyl-N'-nitro-N-nitrosoguanidine at approximately 35 mg/kg for 30 weeks scarcely suppresses antibody production to heterologous red blood cells and cell-mediated immune response to Walker-256 carcinosarcoma in Wistar rats over a 55-week period.,Entity: N-methyl-N'-nitro-N-nitrosoguanidine. SMILES: CN(N=O)C(=N)N[N+](=O)[O-]. Oral administration of N-methyl-N'-nitro-N-nitrosoguanidine at approximately 35 mg/kg for 30 weeks scarcely suppresses antibody production to heterologous red blood cells and cell-mediated immune response to Walker-256 carcinosarcoma in Wistar rats over a 55-week period.
N-methyl-N'-nitro-N-nitrosoguanidine,Daily oral administration of N-methyl-N'-nitro-N-nitrosoguanidine induces stomach cancer in Wistar rats.,Entity: N-methyl-N'-nitro-N-nitrosoguanidine. SMILES: CN(N=O)C(=N)N[N+](=O)[O-]. Daily oral administration of N-methyl-N'-nitro-N-nitrosoguanidine induces stomach cancer in Wistar rats.
gastrin,"Gastrin secretion is markedly increased in mice with severe parietal cell injury due to immunization and local X-irradiation, and this trophic effect promotes the induction of gastric carcinoma by X-ray over a long period.","Entity: gastrin. Gastrin secretion is markedly increased in mice with severe parietal cell injury due to immunization and local X-irradiation, and this trophic effect promotes the induction of gastric carcinoma by X-ray over a long period."
fucose,"Serum fucose content increases with disease progression in malignant tumors, though the correlation is less significant in early or locally restricted breast and thyroid cancers.","Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Serum fucose content increases with disease progression in malignant tumors, though the correlation is less significant in early or locally restricted breast and thyroid cancers."
fucose,Serum fucose content serves as a useful parameter for assessing therapy effectiveness and patient prognosis in postoperative follow-up studies.,Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Serum fucose content serves as a useful parameter for assessing therapy effectiveness and patient prognosis in postoperative follow-up studies.
fucose,Fucose content in malignant tumor tissue and metastasized lymph nodes is significantly elevated compared to normal tissue.,Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Fucose content in malignant tumor tissue and metastasized lymph nodes is significantly elevated compared to normal tissue.
fucose,Serum fucose content in normal individuals averages 6.84 ± 0.13 mg/100 ml and rarely exceeds 9 mg/100 ml.,Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Serum fucose content in normal individuals averages 6.84 ± 0.13 mg/100 ml and rarely exceeds 9 mg/100 ml.
fucose,"Serum fucose content is significantly elevated in cancer-bearing patients compared to normal values, with over 90% of cancer-bearing patients showing levels above 9 mg/100 ml.","Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Serum fucose content is significantly elevated in cancer-bearing patients compared to normal values, with over 90% of cancer-bearing patients showing levels above 9 mg/100 ml."
haptoglobin,"Haptoglobin exists in different phenotypes, with the Hp1 gene frequency in the normal population being 0.0647.","Entity: haptoglobin. Haptoglobin exists in different phenotypes, with the Hp1 gene frequency in the normal population being 0.0647."
acid phosphatase,The chromosomal locus of the autosomal acid phosphatase (ACPH) gene in Drosophila euronotus is unknown and may involve inversion polymorphism.,Entity: acid phosphatase. The chromosomal locus of the autosomal acid phosphatase (ACPH) gene in Drosophila euronotus is unknown and may involve inversion polymorphism.
chlorpromazine,Chlorpromazine treatment demonstrates the presence of a normal calcium-activated structure in the pawns of Paramecium aurelia.,Entity: chlorpromazine. SMILES: CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21. Chlorpromazine treatment demonstrates the presence of a normal calcium-activated structure in the pawns of Paramecium aurelia.
nitrosoguanidine,Nitrosoguanidine is used as a mutagen in Paramecium aurelia to generate mutants with altered reversal behavior in response to high barium concentrations.,Entity: nitrosoguanidine. SMILES: N=C(N)NN=O. Nitrosoguanidine is used as a mutagen in Paramecium aurelia to generate mutants with altered reversal behavior in response to high barium concentrations.
barium,"High concentrations of barium rapidly paralyze and kill wild-type Paramecium aurelia, with survival in mutants correlated to loss of reversal behavior.","Entity: barium. SMILES: [Ba]. High concentrations of barium rapidly paralyze and kill wild-type Paramecium aurelia, with survival in mutants correlated to loss of reversal behavior."
calcium,Calcium mediates the inward current during excitation and is responsible for the reversal response in Paramecium aurelia.,Entity: calcium. SMILES: [Ca]. Calcium mediates the inward current during excitation and is responsible for the reversal response in Paramecium aurelia.
sulfhydryl,"Both yellow and black melanocytes, regardless of genotype, possess equivalent amounts of histochemically detectable sulfhydryl compounds.","Entity: sulfhydryl. SMILES: [SH]. Both yellow and black melanocytes, regardless of genotype, possess equivalent amounts of histochemically detectable sulfhydryl compounds."
xanthine dehydrogenase,"Xanthine dehydrogenase is an enzyme whose genetic variation, specifically the number of alleles present, can be analyzed by acrylamide gel electrophoresis.","Entity: xanthine dehydrogenase. Xanthine dehydrogenase is an enzyme whose genetic variation, specifically the number of alleles present, can be analyzed by acrylamide gel electrophoresis."
nitrosoguanidine,"Nitrosoguanidine is an alkylating agent to which the rec-1 mutant is extremely sensitive, indicating a high sensitivity to DNA-damaging agents that modify DNA bases.","Entity: nitrosoguanidine. SMILES: N=C(N)NN=O. Nitrosoguanidine is an alkylating agent to which the rec-1 mutant is extremely sensitive, indicating a high sensitivity to DNA-damaging agents that modify DNA bases."
nitrosoguanidine,"Nitrosoguanidine is used as a chemical mutagen in cell-based experiments, where it is dissolved in alcohol and diluted into aqueous cell suspensions at concentrations of 10 or 100 µg/ml for treatment.","Entity: nitrosoguanidine. SMILES: N=C(N)NN=O. Nitrosoguanidine is used as a chemical mutagen in cell-based experiments, where it is dissolved in alcohol and diluted into aqueous cell suspensions at concentrations of 10 or 100 µg/ml for treatment."
NADPH,"NADPH is tested at concentrations two, three, and five times higher than baseline levels to determine optimal substrate saturation in enzyme assays.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is tested at concentrations two, three, and five times higher than baseline levels to determine optimal substrate saturation in enzyme assays."
homoserine,Homoserine is used at twice the baseline level in the reverse reaction to assess enzyme activity under conditions defined at pH 8.9.,Entity: homoserine. SMILES: N[C@@H](CCO)C(=O)O. Homoserine is used at twice the baseline level in the reverse reaction to assess enzyme activity under conditions defined at pH 8.9.
dithiothreitol,"Dithiothreitol is included at 0.5 mM concentration in phosphate buffer (10 mM, pH 7.6) for storing enzyme preparations.","Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is included at 0.5 mM concentration in phosphate buffer (10 mM, pH 7.6) for storing enzyme preparations."
threonine,"Threonine is used as a stabilizing agent at 0.5 mM concentration in phosphate buffer (10 mM, pH 7.6) for storing enzyme preparations.","Entity: threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. Threonine is used as a stabilizing agent at 0.5 mM concentration in phosphate buffer (10 mM, pH 7.6) for storing enzyme preparations."
NADPH,"NADPH is used as a cofactor in the reverse reaction assay of homoserine dehydrogenase at pH 8.9, with concentrations of 184 ×l/ml (sample 1) and 378 ×l/ml (sample 5) in the presence of threonine.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is used as a cofactor in the reverse reaction assay of homoserine dehydrogenase at pH 8.9, with concentrations of 184 ×l/ml (sample 1) and 378 ×l/ml (sample 5) in the presence of threonine."
threonine,"Threonine is used as a substrate in the reverse reaction assay of homoserine dehydrogenase at pH 8.9, applied at a concentration of 5 mM in the enzyme dilution.","Entity: threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. Threonine is used as a substrate in the reverse reaction assay of homoserine dehydrogenase at pH 8.9, applied at a concentration of 5 mM in the enzyme dilution."
alcohol dehydrogenase,"The activity of alcohol dehydrogenase, an enzyme encoded by the structural gene locus Adh, can be regulated in Drosophila melanogaster by genes located on the third chromosome that control the number of ADH molecules produced.","Entity: alcohol dehydrogenase. The activity of alcohol dehydrogenase, an enzyme encoded by the structural gene locus Adh, can be regulated in Drosophila melanogaster by genes located on the third chromosome that control the number of ADH molecules produced."
cholic acid,Cholic acid is a bile acid whose trimethylsilyl derivatives exhibit characteristic peaks at m/e 343 and 253 in mass spectrometry.,Entity: cholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Cholic acid is a bile acid whose trimethylsilyl derivatives exhibit characteristic peaks at m/e 343 and 253 in mass spectrometry.
3α-hydroxy-5-cholen-24-oic acid,3α-hydroxy-5-cholen-24-oic acid is an unsaturated monohydroxy bile acid that can be present at trace amounts in human serum.,Entity: 3α-hydroxy-5-cholen-24-oic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. 3α-hydroxy-5-cholen-24-oic acid is an unsaturated monohydroxy bile acid that can be present at trace amounts in human serum.
lithocholic acid,Lithocholic acid can be identified and quantified in urine samples using combined gas/liquid chromatography-mass spectrometry after preparation as methyl ester acetates or trimethylsilyl ether derivatives.,Entity: lithocholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Lithocholic acid can be identified and quantified in urine samples using combined gas/liquid chromatography-mass spectrometry after preparation as methyl ester acetates or trimethylsilyl ether derivatives.
3α-hydroxy-5-cholen-24-oic acid,3α-hydroxy-5-cholen-24-oic acid can be identified and quantified in urine samples using combined gas/liquid chromatography-mass spectrometry after preparation as methyl ester acetates or trimethylsilyl ether derivatives.,Entity: 3α-hydroxy-5-cholen-24-oic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. 3α-hydroxy-5-cholen-24-oic acid can be identified and quantified in urine samples using combined gas/liquid chromatography-mass spectrometry after preparation as methyl ester acetates or trimethylsilyl ether derivatives.
hyocholic acid,Hyocholic acid can be identified and quantified in urine samples using combined gas/liquid chromatography-mass spectrometry after preparation as methyl ester acetates or trimethylsilyl ether derivatives.,Entity: hyocholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Hyocholic acid can be identified and quantified in urine samples using combined gas/liquid chromatography-mass spectrometry after preparation as methyl ester acetates or trimethylsilyl ether derivatives.
helium,Helium is used as the carrier gas in combined gas/liquid chromatography-mass spectrometry for the analysis of bile acids.,Entity: helium. SMILES: [He]. Helium is used as the carrier gas in combined gas/liquid chromatography-mass spectrometry for the analysis of bile acids.
hyocholic acid,Hyocholic acid is a bile acid that can be detected in human urine and can be identified by comparison of its methyl ester mass spectra to those of authentic hyocholic acid.,Entity: hyocholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Hyocholic acid is a bile acid that can be detected in human urine and can be identified by comparison of its methyl ester mass spectra to those of authentic hyocholic acid.
deoxycholic acid,Deoxycholic acid can be separated from other bile acids and the internal standard 7-ketodeoxycholic acid by gas/liquid chromatography (GLC) in bile acid analysis.,Entity: deoxycholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Deoxycholic acid can be separated from other bile acids and the internal standard 7-ketodeoxycholic acid by gas/liquid chromatography (GLC) in bile acid analysis.
cholic acid,"Serum cholic acid concentrations in the range of 7.0 to 456.0 mM/l can be accurately quantified by radioimmunoassay, with a correlation coefficient of 0.99 and a slope of 0.84.","Entity: cholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Serum cholic acid concentrations in the range of 7.0 to 456.0 mM/l can be accurately quantified by radioimmunoassay, with a correlation coefficient of 0.99 and a slope of 0.84."
lithocholic acid,Lithocholic acid can be separated from other bile acids and the internal standard 7-ketodeoxycholic acid by gas/liquid chromatography (GLC) in bile acid analysis.,Entity: lithocholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Lithocholic acid can be separated from other bile acids and the internal standard 7-ketodeoxycholic acid by gas/liquid chromatography (GLC) in bile acid analysis.
7-ketodeoxycholic acid,7-ketodeoxycholic acid is used as an internal standard in gas/liquid chromatography (GLC) for the separation of individual bile acids.,Entity: 7-ketodeoxycholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C(=O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. 7-ketodeoxycholic acid is used as an internal standard in gas/liquid chromatography (GLC) for the separation of individual bile acids.
cholecystokinin,"Cholecystokinin is used to stimulate bile secretion in patients with suspected biliary disorders, as evidenced by the collection of bile-rich duodenal fluid five to fifteen minutes after stimulation.","Entity: cholecystokinin. SMILES: CCC(C)C(NC(=O)C(CCCNC(=N)N)NC(=O)C(Cc1c[nH]cn1)NC(=O)C(CO)NC(=O)C1CCCN1C(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(CO)NC(=O)C1CCCN1C(=O)C(C)NC(=O)C(N)CCCCN)C(C)CC)C(C)C)C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)NC(CCSC)C(=O)NCC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(Cc1ccccc1)C(N)=O)c1ccc(OS(=O)(=O)O)cc1. Cholecystokinin is used to stimulate bile secretion in patients with suspected biliary disorders, as evidenced by the collection of bile-rich duodenal fluid five to fifteen minutes after stimulation."
creatinine,Serum creatinine is used to assess renal function in patients with cholestasis.,Entity: creatinine. SMILES: CN1CC(=O)N=C1N. Serum creatinine is used to assess renal function in patients with cholestasis.
bile acid,"In cirrhotic patients, serum bile acids are less elevated, and chenodeoxycholic acid is the predominant bile acid.","Entity: bile acid. SMILES: CC(CCC(=O)O)C1CCC2C3C(C[C@H](O)C12C)C1(C)CC[C@@H](O)C[C@H]1C[C@H]3O. In cirrhotic patients, serum bile acids are less elevated, and chenodeoxycholic acid is the predominant bile acid."
bile acid,"In healthy controls, serum bile acids are richer in chenodeoxycholic acid than biliary bile acids, and no bile acids are present in urine.","Entity: bile acid. SMILES: CC(CCC(=O)O)C1CCC2C3C(C[C@H](O)C12C)C1(C)CC[C@@H](O)C[C@H]1C[C@H]3O. In healthy controls, serum bile acids are richer in chenodeoxycholic acid than biliary bile acids, and no bile acids are present in urine."
bile acid,"In cholestasis, conjugation of chenodeoxycholic acid with sulphate becomes a major biochemical pathway, and urine becomes a major route of bile acid excretion.","Entity: bile acid. SMILES: CC(CCC(=O)O)C1CCC2C3C(C[C@H](O)C12C)C1(C)CC[C@@H](O)C[C@H]1C[C@H]3O. In cholestasis, conjugation of chenodeoxycholic acid with sulphate becomes a major biochemical pathway, and urine becomes a major route of bile acid excretion."
hyocholic acid,Hyocholic acid is present in considerable amounts in the urinary bile acids of patients with primary biliary cirrhosis.,Entity: hyocholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Hyocholic acid is present in considerable amounts in the urinary bile acids of patients with primary biliary cirrhosis.
bile acid,"In cholestasis, more than 93% of bile acids in serum are unsulphated, while more than 60% in urine are sulphated.","Entity: bile acid. SMILES: CC(CCC(=O)O)C1CCC2C3C(C[C@H](O)C12C)C1(C)CC[C@@H](O)C[C@H]1C[C@H]3O. In cholestasis, more than 93% of bile acids in serum are unsulphated, while more than 60% in urine are sulphated."
bile acid,"Secondary bile acids are virtually absent in bile, serum, and urine.","Entity: bile acid. SMILES: CC(CCC(=O)O)C1CCC2C3C(C[C@H](O)C12C)C1(C)CC[C@@H](O)C[C@H]1C[C@H]3O. Secondary bile acids are virtually absent in bile, serum, and urine."
bile acid,Urinary excretion of bile acids for 24 hours averages 71–6 mg in patients with complete obstruction.,Entity: bile acid. SMILES: CC(CCC(=O)O)C1CCC2C3C(C[C@H](O)C12C)C1(C)CC[C@@H](O)C[C@H]1C[C@H]3O. Urinary excretion of bile acids for 24 hours averages 71–6 mg in patients with complete obstruction.
muricholic acid,"Muricholic acid forms 7fl epimers that produce a base peak at m/e 285 in mass spectrometry, resulting from fission between carbon atoms 6 and 7.","Entity: muricholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C(O)C(O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Muricholic acid forms 7fl epimers that produce a base peak at m/e 285 in mass spectrometry, resulting from fission between carbon atoms 6 and 7."
"3,6,7-trihydroxy-5β-cholanoic acid","The trimethylsilyl ether derivative of 3,6,7-trihydroxy-5β-cholanoic acid displays a mass spectrometry pattern consistent with the 7a epimer, with a base peak at m/e 458.","Entity: 3,6,7-trihydroxy-5β-cholanoic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C(O)C(O)[C@@H]4CC(O)CC[C@]4(C)[C@H]3CC[C@]12C. The trimethylsilyl ether derivative of 3,6,7-trihydroxy-5β-cholanoic acid displays a mass spectrometry pattern consistent with the 7a epimer, with a base peak at m/e 458."
xylose,"Xylose malabsorption is a common finding in subjects with tropical enteropathy, particularly those with mild jejunal abnormalities.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose malabsorption is a common finding in subjects with tropical enteropathy, particularly those with mild jejunal abnormalities."
xylose,Xylose malabsorption is a common minor jejunal abnormality observed in individuals with tropical enteropathy in Rhodesia.,Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose malabsorption is a common minor jejunal abnormality observed in individuals with tropical enteropathy in Rhodesia.
vitamin B12,"Malabsorption of vitamin B12 is not observed in individuals with tropical enteropathy in Rhodesia, despite the presence of other gastrointestinal abnormalities.","Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Malabsorption of vitamin B12 is not observed in individuals with tropical enteropathy in Rhodesia, despite the presence of other gastrointestinal abnormalities."
xylose,"Xylose absorption in the jejunum improves with tetracycline treatment, as observed in patients with megaloblastic and normochromic normocytic anemias.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose absorption in the jejunum improves with tetracycline treatment, as observed in patients with megaloblastic and normochromic normocytic anemias."
folic acid,"Folic acid supplementation alone does not significantly improve jejunal biopsies, fat, xylose, or B12 absorption compared to tetracycline alone.","Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid supplementation alone does not significantly improve jejunal biopsies, fat, xylose, or B12 absorption compared to tetracycline alone."
vitamin B12,"Vitamin B12 supplementation alone does not significantly improve jejunal biopsies, fat, xylose, or B12 absorption compared to tetracycline alone.","Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 supplementation alone does not significantly improve jejunal biopsies, fat, xylose, or B12 absorption compared to tetracycline alone."
vitamin B12,Patients with subnormal vitamin B12 levels achieve normal values after tetracycline treatment.,Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Patients with subnormal vitamin B12 levels achieve normal values after tetracycline treatment.
tetracycline,"Tetracycline treatment alone improves jejunal biopsies, fat, xylose, and B12 absorption, and increases mean weight gain in patients with megaloblastic and normochromic normocytic anemias.","Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline treatment alone improves jejunal biopsies, fat, xylose, and B12 absorption, and increases mean weight gain in patients with megaloblastic and normochromic normocytic anemias."
tetracycline,"The addition of tetracycline for six months results in greatly improved jejunal biopsies, normal intestinal absorption, and increased weight gain in patients with anemias.","Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. The addition of tetracycline for six months results in greatly improved jejunal biopsies, normal intestinal absorption, and increased weight gain in patients with anemias."
tetracycline,"Tetracycline is used as a treatment regimen, either alone or in combination with folic acid and vitamin B12, for certain medical conditions.","Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline is used as a treatment regimen, either alone or in combination with folic acid and vitamin B12, for certain medical conditions."
folic acid,Folic acid is administered in combination with tetracycline as part of a treatment regimen for specific medical conditions.,Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid is administered in combination with tetracycline as part of a treatment regimen for specific medical conditions.
vitamin B12,Vitamin B12 is used in combination with tetracycline as part of a treatment regimen for certain medical conditions.,Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 is used in combination with tetracycline as part of a treatment regimen for certain medical conditions.
tetracycline,Tetracycline alone can restore normal calcium and phosphate levels in patients with biochemical evidence of osteomalacia.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline alone can restore normal calcium and phosphate levels in patients with biochemical evidence of osteomalacia.
calcium,Normal calcium levels can be achieved in patients with osteomalacia by treatment with tetracycline alone.,Entity: calcium. SMILES: [Ca]. Normal calcium levels can be achieved in patients with osteomalacia by treatment with tetracycline alone.
phosphate,Normal phosphate levels can be restored in patients with osteomalacia by treatment with tetracycline alone.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Normal phosphate levels can be restored in patients with osteomalacia by treatment with tetracycline alone.
folate,Folate is a dietary nutrient whose seasonal scarcity is suggested to favor a primary nutritional cause for megaloblastic anaemias and tropical sprue.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate is a dietary nutrient whose seasonal scarcity is suggested to favor a primary nutritional cause for megaloblastic anaemias and tropical sprue.
folate,Folate supplementation can help restore absorption and jejunal morphology in individuals with tropical sprue.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate supplementation can help restore absorption and jejunal morphology in individuals with tropical sprue.
tetracycline,Tetracycline treatment can aid in recovery of absorption and jejunal morphology in patients with tropical sprue.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline treatment can aid in recovery of absorption and jejunal morphology in patients with tropical sprue.
xylose,Xylose malabsorption is defined as urinary xylose excretion of less than 5–0 mg in patients with suspected malabsorption.,Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose malabsorption is defined as urinary xylose excretion of less than 5–0 mg in patients with suspected malabsorption.
vitamin B12,Vitamin B12 malabsorption is defined as urinary vitamin B12 absorption of less than 0–75 % in patients with suspected malabsorption.,Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 malabsorption is defined as urinary vitamin B12 absorption of less than 0–75 % in patients with suspected malabsorption.
vitamin B12,"Vitamin B12 absorption was measured in six patients from a series of megaloblastic anaemias in Kenya, but the results are not specified in the paragraph.","Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 absorption was measured in six patients from a series of megaloblastic anaemias in Kenya, but the results are not specified in the paragraph."
folate,"Folate absorption was assessed in six patients from a series of megaloblastic anaemias in Kenya, but the results are not specified in the paragraph.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate absorption was assessed in six patients from a series of megaloblastic anaemias in Kenya, but the results are not specified in the paragraph."
xylose,"Xylose excretion was estimated in all 29 patients in a Kenyan study of megaloblastic anaemias, with a mean value of 19%.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose excretion was estimated in all 29 patients in a Kenyan study of megaloblastic anaemias, with a mean value of 19%."
vitamin B12,Vitamin B12 deficiency is associated with megaloblastic bone marrow and low haemoglobin levels (2–7 g/100 g) in patients.,Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 deficiency is associated with megaloblastic bone marrow and low haemoglobin levels (2–7 g/100 g) in patients.
vitamin B12,Patients with megaloblastic bone marrow may have low serum vitamin B12 levels (<400 pg) as a diagnostic indicator.,Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Patients with megaloblastic bone marrow may have low serum vitamin B12 levels (<400 pg) as a diagnostic indicator.
vitamin B12,Patients with normoblastic bone marrow can have normal serum vitamin B12 levels despite subnormal serum or red cell folates.,Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Patients with normoblastic bone marrow can have normal serum vitamin B12 levels despite subnormal serum or red cell folates.
folate,Folate deficiency is associated with megaloblastic bone marrow and low haemoglobin levels (2–7 g/100 g) in patients.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folate deficiency is associated with megaloblastic bone marrow and low haemoglobin levels (2–7 g/100 g) in patients.
folate,Patients with megaloblastic bone marrow may have reduced serum folate (<3 foot_1 ng) or reduced red cell folate (<160 ng) as diagnostic indicators.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Patients with megaloblastic bone marrow may have reduced serum folate (<3 foot_1 ng) or reduced red cell folate (<160 ng) as diagnostic indicators.
vitamin B12,"Abnormal vitamin B12 absorption in the small intestine can improve significantly after treatment, with all 30 patients showing improved results and 25 achieving more than 0.75%, the 95th percentile of healthy African controls.","Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Abnormal vitamin B12 absorption in the small intestine can improve significantly after treatment, with all 30 patients showing improved results and 25 achieving more than 0.75%, the 95th percentile of healthy African controls."
xylose,"Abnormal xylose absorption tests in the small intestine can improve significantly after treatment, with 27 out of 30 patients showing improved results and 20 achieving more than 5 g xylose absorption.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Abnormal xylose absorption tests in the small intestine can improve significantly after treatment, with 27 out of 30 patients showing improved results and 20 achieving more than 5 g xylose absorption."
Vitamin B12,"Vitamin B12 absorption is measured by the plasma uptake method, where normal absorption is defined as more than 0.75% of the administered dose per litre of plasma, corresponding to the 95th percentile in healthy Rhodesian African controls.","Entity: Vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 absorption is measured by the plasma uptake method, where normal absorption is defined as more than 0.75% of the administered dose per litre of plasma, corresponding to the 95th percentile in healthy Rhodesian African controls."
xylose,"In tropical sprue, normal xylose excretion is rarely observed, with reported rates as low as 6% in the West Indies and 9% in a clinical series.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. In tropical sprue, normal xylose excretion is rarely observed, with reported rates as low as 6% in the West Indies and 9% in a clinical series."
vitamin B12,Vitamin B12 malabsorption is associated with steatorrhoea in patients with tropical sprue.,Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 malabsorption is associated with steatorrhoea in patients with tropical sprue.
folic acid,"Folic acid levels in patients with tropical sprue increase with treatment, including regimens of tetracycline, folic acid, and vitamin B12, or tetracycline alone.","Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid levels in patients with tropical sprue increase with treatment, including regimens of tetracycline, folic acid, and vitamin B12, or tetracycline alone."
vitamin B12,"Vitamin B12 levels in patients with tropical sprue improve following treatment with regimens of tetracycline, folic acid, and vitamin B12, or tetracycline alone.","Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 levels in patients with tropical sprue improve following treatment with regimens of tetracycline, folic acid, and vitamin B12, or tetracycline alone."
tetracycline,"Tetracycline alone or in combination with folic acid and vitamin B12 is used as treatment for tropical sprue, and patients typically show clinical and haematological recovery after six months of therapy.","Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline alone or in combination with folic acid and vitamin B12 is used as treatment for tropical sprue, and patients typically show clinical and haematological recovery after six months of therapy."
vitamin B12,Vitamin B12 is administered at a dose of 1000 µg monthly as part of a treatment regimen for patients under observation for weight and reticulocyte count changes.,Entity: vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 is administered at a dose of 1000 µg monthly as part of a treatment regimen for patients under observation for weight and reticulocyte count changes.
tetracycline,Tetracycline is used at a dose of 250 mg four times a day as part of a treatment regimen for patients monitored for weight and reticulocyte count changes.,Entity: tetracycline. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12. Tetracycline is used at a dose of 250 mg four times a day as part of a treatment regimen for patients monitored for weight and reticulocyte count changes.
folic acid,Folic acid is administered at a dose of 5 mg three times daily as part of a treatment regimen for patients monitored for weight and reticulocyte count changes.,Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid is administered at a dose of 5 mg three times daily as part of a treatment regimen for patients monitored for weight and reticulocyte count changes.
xylose,"Xylose absorption in humans varies by socio-economic group, with lower socio-economic groups showing a mean of 5.4 g (39% less than 5 g) and upper socio-economic groups showing a mean of 7.3 g (7% less than 5 g) in a study of Africans.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose absorption in humans varies by socio-economic group, with lower socio-economic groups showing a mean of 5.4 g (39% less than 5 g) and upper socio-economic groups showing a mean of 7.3 g (7% less than 5 g) in a study of Africans."
Vitamin B12,"Vitamin B12 absorption is normal in individuals with tropical enteropathy, indicating predominant involvement of the proximal small intestine.","Entity: Vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 absorption is normal in individuals with tropical enteropathy, indicating predominant involvement of the proximal small intestine."
Xylose,"Xylose excretion in the jejunum is related to socioeconomic status rather than race, with upper socioeconomic Africans and Europeans excreting significantly more xylose than those of lower socioeconomic status.","Entity: Xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose excretion in the jejunum is related to socioeconomic status rather than race, with upper socioeconomic Africans and Europeans excreting significantly more xylose than those of lower socioeconomic status."
xylose,"Xylose malabsorption is common but variable in the tropics outside Africa, with prevalence differing by socioeconomic status and geographical region.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose malabsorption is common but variable in the tropics outside Africa, with prevalence differing by socioeconomic status and geographical region."
xylose,"In Zambia, xylose malabsorption is associated with jejunal abnormalities similar to those observed in Uganda.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. In Zambia, xylose malabsorption is associated with jejunal abnormalities similar to those observed in Uganda."
xylose,"In Liberia, xylose malabsorption is present in 28–6% of schoolchildren and 32% of rural adults.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. In Liberia, xylose malabsorption is present in 28–6% of schoolchildren and 32% of rural adults."
Vitamin B12,"Vitamin B12 malabsorption is more prevalent in the Caribbean than in the Indian subcontinent and South East Asia, except for Bangladesh, indicating more distal involvement in the small intestine.","Entity: Vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 malabsorption is more prevalent in the Caribbean than in the Indian subcontinent and South East Asia, except for Bangladesh, indicating more distal involvement in the small intestine."
Vitamin B12,"Vitamin B12 malabsorption is unusual in India and Thailand, contrasting with its higher prevalence in the Caribbean.","Entity: Vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 malabsorption is unusual in India and Thailand, contrasting with its higher prevalence in the Caribbean."
folic acid,Folic acid malabsorption has been reported in 35% of subjects with jejunal abnormalities in a comprehensive survey from Nigeria.,Entity: folic acid. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1. Folic acid malabsorption has been reported in 35% of subjects with jejunal abnormalities in a comprehensive survey from Nigeria.
Xylose,Xylose excretion is used as a marker for intestinal absorption in metabolic studies.,Entity: Xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose excretion is used as a marker for intestinal absorption in metabolic studies.
Vitamin B12,"Vitamin B12 absorption can be measured using the plasma uptake method, with normal values in C057-labeled vitamin B12 studies ranging from 0% to 22% of the administered dose per litre of plasma.","Entity: Vitamin B12. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Vitamin B12 absorption can be measured using the plasma uptake method, with normal values in C057-labeled vitamin B12 studies ranging from 0% to 22% of the administered dose per litre of plasma."
xylose,"Xylose excretion in Africans of upper socioeconomic status ranged from 3.6 g/l to 16.5 g/l, with a mean of 7.3 g/l, while in Africans of lower socioeconomic status it ranged from 12.2 g/l to 13.2 g/l, with a mean of 5.4 g/l.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose excretion in Africans of upper socioeconomic status ranged from 3.6 g/l to 16.5 g/l, with a mean of 7.3 g/l, while in Africans of lower socioeconomic status it ranged from 12.2 g/l to 13.2 g/l, with a mean of 5.4 g/l."
xylose,Xylose absorption in the intestine is decreased following introduction of bacteria into the intestines of germ-free animals.,Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose absorption in the intestine is decreased following introduction of bacteria into the intestines of germ-free animals.
paracetamol,"Paracetamol can be used as a test bolus in gastric emptying studies, with most of the instilled solution emptying through the pylorus within 30 minutes in healthy subjects.","Entity: paracetamol. SMILES: CC(=O)Nc1ccc(O)cc1. Paracetamol can be used as a test bolus in gastric emptying studies, with most of the instilled solution emptying through the pylorus within 30 minutes in healthy subjects."
aspirin,"Aspirin can be used as a test bolus in gastric emptying studies, with most of the instilled solution emptying through the pylorus within 30 minutes in healthy subjects.","Entity: aspirin. SMILES: CC(=O)Oc1ccccc1C(=O)O. Aspirin can be used as a test bolus in gastric emptying studies, with most of the instilled solution emptying through the pylorus within 30 minutes in healthy subjects."
KCl,KCl is used to prepare saturated KCl solution in agar for creating reference electrodes in gastric emptying measurement techniques.,Entity: KCl. SMILES: [Cl-].[K+]. KCl is used to prepare saturated KCl solution in agar for creating reference electrodes in gastric emptying measurement techniques.
chromium chloride,"Chromium chloride (51Cr) is used as a non-absorbable indicator in flux studies, applied at a concentration of 25 µCi/l in an acidic control solution.","Entity: chromium chloride. SMILES: [Cl-].[Cl-].[Cl-].[Cr+3]. Chromium chloride (51Cr) is used as a non-absorbable indicator in flux studies, applied at a concentration of 25 µCi/l in an acidic control solution."
paracetamol,"Paracetamol is formulated as 0.5 g tablets and used as a test compound in flux studies, where four tablets are ground into a suspension in 200 ml of acid control solution.","Entity: paracetamol. SMILES: CC(=O)Nc1ccc(O)cc1. Paracetamol is formulated as 0.5 g tablets and used as a test compound in flux studies, where four tablets are ground into a suspension in 200 ml of acid control solution."
hydrochloric acid,Hydrochloric acid (HCl) is used at a concentration of 160 mEq/l in both control and wash solutions for ionic flux measurements.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid (HCl) is used at a concentration of 160 mEq/l in both control and wash solutions for ionic flux measurements.
progesterone,"Progesterone causes significant inhibition of DNA synthesis in endometrial carcinoma cells, with a mean reduction of 46% over controls at 80 pg/ml in vitro.","Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone causes significant inhibition of DNA synthesis in endometrial carcinoma cells, with a mean reduction of 46% over controls at 80 pg/ml in vitro."
progesterone,"Progesterone inhibits RNA synthesis in endometrial carcinoma cells, with a mean reduction of 3% over controls at 80 pg/ml in vitro.","Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone inhibits RNA synthesis in endometrial carcinoma cells, with a mean reduction of 3% over controls at 80 pg/ml in vitro."
estradiol,The addition of estradiol does not alter the inhibitory effect of progesterone on DNA synthesis in endometrial carcinoma cells.,Entity: estradiol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O. The addition of estradiol does not alter the inhibitory effect of progesterone on DNA synthesis in endometrial carcinoma cells.
thymidine,Radioactive thymidine is used in clinical studies to assess DNA synthesis in patients treated with polyestradiol phosphate and various progestogens.,Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Radioactive thymidine is used in clinical studies to assess DNA synthesis in patients treated with polyestradiol phosphate and various progestogens.
uridine,Radioactive uridine is used in clinical studies to assess RNA synthesis in patients treated with polyestradiol phosphate and various progestogens.,Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Radioactive uridine is used in clinical studies to assess RNA synthesis in patients treated with polyestradiol phosphate and various progestogens.
progesterone,"Progesterone is used in progestational therapy for endometrial carcinoma, potentially in combination with estrogen priming agents such as diethylstilbestrol or estradiol valerate.","Entity: progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone is used in progestational therapy for endometrial carcinoma, potentially in combination with estrogen priming agents such as diethylstilbestrol or estradiol valerate."
medroxyprogesterone,Medroxyprogesterone is administered at 400 mg intramuscularly three times weekly in combination with estrogen priming agents for progestational therapy in endometrial carcinoma.,Entity: medroxyprogesterone. SMILES: CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C. Medroxyprogesterone is administered at 400 mg intramuscularly three times weekly in combination with estrogen priming agents for progestational therapy in endometrial carcinoma.
estradiol valerate,Estradiol valerate is used as an estrogen priming agent in combination with premarin and hydroxyprogesterone caproate for adjuvant therapy in endometrial carcinoma.,Entity: estradiol valerate. SMILES: CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C. Estradiol valerate is used as an estrogen priming agent in combination with premarin and hydroxyprogesterone caproate for adjuvant therapy in endometrial carcinoma.
premarin,"Premarin, a formulation of estradiol, is used as part of an estrogen priming regimen with hydroxyprogesterone caproate and other agents in adjuvant therapy for endometrial carcinoma.","Entity: premarin. SMILES: C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O.[Na+]. Premarin, a formulation of estradiol, is used as part of an estrogen priming regimen with hydroxyprogesterone caproate and other agents in adjuvant therapy for endometrial carcinoma."
hydroxyprogesterone caproate,"Hydroxyprogesterone caproate has been used in combination with estradiol valerate and premarin in adjuvant therapy for endometrial carcinoma, where its use was associated with a 20% increased response rate.","Entity: hydroxyprogesterone caproate. SMILES: CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C. Hydroxyprogesterone caproate has been used in combination with estradiol valerate and premarin in adjuvant therapy for endometrial carcinoma, where its use was associated with a 20% increased response rate."
diethylstilbestrol,"Diethylstilbestrol has been used as an estrogen priming agent in clinical trials with medroxyprogesterone for progestational therapy in endometrial carcinoma, but showed no clinically detectable benefit in the reported study.","Entity: diethylstilbestrol. SMILES: CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1. Diethylstilbestrol has been used as an estrogen priming agent in clinical trials with medroxyprogesterone for progestational therapy in endometrial carcinoma, but showed no clinically detectable benefit in the reported study."
medrogestone,"Medrogestone is used as a progestational agent in the treatment of tumors, with an objective response rate of 30% observed in 56 patients.","Entity: medrogestone. SMILES: CC(=O)[C@@]1(C)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C. Medrogestone is used as a progestational agent in the treatment of tumors, with an objective response rate of 30% observed in 56 patients."
medroxyprogesterone,Oral medroxyprogesterone is typically administered in a high initial loading dose during the first few weeks to ensure sufficient blood and tissue levels for therapeutic effect.,Entity: medroxyprogesterone. SMILES: CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C. Oral medroxyprogesterone is typically administered in a high initial loading dose during the first few weeks to ensure sufficient blood and tissue levels for therapeutic effect.
ethynodiol diacetate,"Ethynodiol diacetate at a daily dose of 100 mg for 3 weeks induced histologic changes in 4 of 5 patients, indicating a dose-dependent effect.","Entity: ethynodiol diacetate. SMILES: C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C[C@@H](OC(C)=O)CC[C@@H]4[C@H]3CC[C@@]21C. Ethynodiol diacetate at a daily dose of 100 mg for 3 weeks induced histologic changes in 4 of 5 patients, indicating a dose-dependent effect."
megestrol,"Megestrol response rates vary with dose, with 40 mg daily resulting in 14.3% response (1 of 7), 80 mg daily in 42.8% (3 of 7), and 160 mg daily in 48.3% (14 of 29) in a clinical setting.","Entity: megestrol. SMILES: CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C. Megestrol response rates vary with dose, with 40 mg daily resulting in 14.3% response (1 of 7), 80 mg daily in 42.8% (3 of 7), and 160 mg daily in 48.3% (14 of 29) in a clinical setting."
Progesterone,Progesterone induces histologic changes in normal proliferative endometrium in vitro that are characteristic of the postovulatory secretory phase in vivo.,Entity: Progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone induces histologic changes in normal proliferative endometrium in vitro that are characteristic of the postovulatory secretory phase in vivo.
Progesterone,"Progesterone added to proliferative endometrium in organ culture produces giant mitochondria and nucleolar canalicular systems, organelles characteristic of the postovulatory secretory phase endometrium.","Entity: Progesterone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Progesterone added to proliferative endometrium in organ culture produces giant mitochondria and nucleolar canalicular systems, organelles characteristic of the postovulatory secretory phase endometrium."
Hydroxyprogesterone caproate,Hydroxyprogesterone caproate is a true progestogen that contains an acyl group (CH3-CO) in the 17β position.,Entity: Hydroxyprogesterone caproate. SMILES: CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C. Hydroxyprogesterone caproate is a true progestogen that contains an acyl group (CH3-CO) in the 17β position.
Medroxyprogesterone,Medroxyprogesterone is a true progestogen that contains an acyl group (CH3-CO) in the 17β position.,Entity: Medroxyprogesterone. SMILES: CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C. Medroxyprogesterone is a true progestogen that contains an acyl group (CH3-CO) in the 17β position.
Medrogestone,Medrogestone is a true progestogen that contains an acyl group (CH3-CO) in the 17β position.,Entity: Medrogestone. SMILES: CC(=O)[C@@]1(C)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C. Medrogestone is a true progestogen that contains an acyl group (CH3-CO) in the 17β position.
Nitric oxide,Nitric oxide is administered as a 50% solution in oxygen for a few minutes as a preanesthetic analgesic in rabbit preparation procedures.,Entity: Nitric oxide. SMILES: [N]=O. Nitric oxide is administered as a 50% solution in oxygen for a few minutes as a preanesthetic analgesic in rabbit preparation procedures.
Fluothane,Fluothane is used as an anesthetic agent at a concentration of 5% in oxygen for induction of anesthesia in rabbits.,Entity: Fluothane. SMILES: FC(F)(F)C(Cl)Br. Fluothane is used as an anesthetic agent at a concentration of 5% in oxygen for induction of anesthesia in rabbits.
Methylene blue,Methylene blue is used as a 2% solution in Hanks' balanced salt solution to stain cumulus egg masses by supravital staining for approximately 15 minutes.,Entity: Methylene blue. SMILES: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.[Cl-]. Methylene blue is used as a 2% solution in Hanks' balanced salt solution to stain cumulus egg masses by supravital staining for approximately 15 minutes.
cyanoacrylate,Cyanoacrylate tissue glue is used to affix polystyrene microspheres to the mesothelial covering of the oviduct to mark anatomical sites such as the ampulloisthmic junction (AIJ) and specific segments of the mid-ampulla.,Entity: cyanoacrylate. SMILES: C=CC(=O)OC#N. Cyanoacrylate tissue glue is used to affix polystyrene microspheres to the mesothelial covering of the oviduct to mark anatomical sites such as the ampulloisthmic junction (AIJ) and specific segments of the mid-ampulla.
methylene blue,Methylene blue is used as a staining agent to visualize cumulus egg masses during in vitro ciliary transport studies.,Entity: methylene blue. SMILES: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.[Cl-]. Methylene blue is used as a staining agent to visualize cumulus egg masses during in vitro ciliary transport studies.
choline,"Choline is required for the biosynthesis of the choline-dependent component (pi-factor) of the labile factor activity complex, with plasma levels regulated by a pre-translational step.","Entity: choline. SMILES: C[N+](C)(C)CCO. Choline is required for the biosynthesis of the choline-dependent component (pi-factor) of the labile factor activity complex, with plasma levels regulated by a pre-translational step."
choline chloride,Choline chloride at a minimum oral dose of 21.5 mg/kg induces a maximum plasma level of the choline-dependent component (pi-factor) of the labile factor activity complex in chickens on a choline-deficient diet.,Entity: choline chloride. SMILES: C[N+](C)(C)CCO.[Cl-]. Choline chloride at a minimum oral dose of 21.5 mg/kg induces a maximum plasma level of the choline-dependent component (pi-factor) of the labile factor activity complex in chickens on a choline-deficient diet.
choline chloride,"In a t-Factor stimulating activity assay, the minimum dose of choline chloride per kilogram body weight required for maximum response is used to define one activity unit.","Entity: choline chloride. SMILES: C[N+](C)(C)CCO.[Cl-]. In a t-Factor stimulating activity assay, the minimum dose of choline chloride per kilogram body weight required for maximum response is used to define one activity unit."
choline chloride,"Choline chloride induces a specific 7β-factor activity of 46.5 units/g in chickens, with a linear dose-response relationship between the minimum dose for maximum response (21.5 mg/kg) and a lower detection threshold dose (about 7.5 mg/kg).","Entity: choline chloride. SMILES: C[N+](C)(C)CCO.[Cl-]. Choline chloride induces a specific 7β-factor activity of 46.5 units/g in chickens, with a linear dose-response relationship between the minimum dose for maximum response (21.5 mg/kg) and a lower detection threshold dose (about 7.5 mg/kg)."
choline,Choline is a dietary factor required for the maintenance of normal levels of the 7r-factor in homogeneous chicken systems.,Entity: choline. SMILES: C[N+](C)(C)CCO. Choline is a dietary factor required for the maintenance of normal levels of the 7r-factor in homogeneous chicken systems.
phytomenadione,Phytomenadione is a dietary factor necessary for the optimal level of the 7r-factor in homogeneous chicken systems.,Entity: phytomenadione. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/C=C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Phytomenadione is a dietary factor necessary for the optimal level of the 7r-factor in homogeneous chicken systems.
choline chloride,"Intravenous administration of choline chloride in doses of 1–2 units/kg results in an initial lag of about 8 minutes, followed by a rapid increase in rr-factor concentration reaching maximum levels approximately 31 minutes after injection.","Entity: choline chloride. SMILES: C[N+](C)(C)CCO.[Cl-]. Intravenous administration of choline chloride in doses of 1–2 units/kg results in an initial lag of about 8 minutes, followed by a rapid increase in rr-factor concentration reaching maximum levels approximately 31 minutes after injection."
phytoene,"The response of phytoene-substituted factors to choline chloride is similar in rate to the response of yr-factor, with a lag of 8 minutes compared to 10 minutes.","Entity: phytoene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/C=C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. The response of phytoene-substituted factors to choline chloride is similar in rate to the response of yr-factor, with a lag of 8 minutes compared to 10 minutes."
cycloheximide,"Sub-lethal doses of cycloheximide block the response to choline chloride in the yr-factor system, arresting the response within 2–3 minutes when injected after choline.","Entity: cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Sub-lethal doses of cycloheximide block the response to choline chloride in the yr-factor system, arresting the response within 2–3 minutes when injected after choline."
choline chloride,"Choline chloride induces a response in the yr-factor system that is identical in rate to that of phytoene and phytoene-substituted factors, with a lag of 8 minutes.","Entity: choline chloride. SMILES: C[N+](C)(C)CCO.[Cl-]. Choline chloride induces a response in the yr-factor system that is identical in rate to that of phytoene and phytoene-substituted factors, with a lag of 8 minutes."
puromycin,"Sub-lethal doses of puromycin block the response to choline chloride in the yr-factor system, arresting the response within 2–3 minutes when injected after choline.","Entity: puromycin. SMILES: COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@H](n3cnc4c(N(C)C)ncnc43)O[C@@H]2CO)cc1. Sub-lethal doses of puromycin block the response to choline chloride in the yr-factor system, arresting the response within 2–3 minutes when injected after choline."
cycloheximide,"Cycloheximide inhibits the response to dietary factors in chickens, with an inhibition time of 2–3 minutes, indicating involvement of protein synthesis in the regulation of jr-factor biosynthesis.","Entity: cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Cycloheximide inhibits the response to dietary factors in chickens, with an inhibition time of 2–3 minutes, indicating involvement of protein synthesis in the regulation of jr-factor biosynthesis."
puromycin,"Puromycin inhibits the response to dietary factors in chickens, with an inhibition time of 2–3 minutes, suggesting a role for protein synthesis in the regulation of jr-factor biosynthesis.","Entity: puromycin. SMILES: COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@H](n3cnc4c(N(C)C)ncnc43)O[C@@H]2CO)cc1. Puromycin inhibits the response to dietary factors in chickens, with an inhibition time of 2–3 minutes, suggesting a role for protein synthesis in the regulation of jr-factor biosynthesis."
choline,"Choline is required for the function of the labile factor activity complex (jr-factor) in the blood coagulation mechanism of chickens, with its supply limiting the activity of the phytoene-dependent component of jr-factor.","Entity: choline. SMILES: C[N+](C)(C)CCO. Choline is required for the function of the labile factor activity complex (jr-factor) in the blood coagulation mechanism of chickens, with its supply limiting the activity of the phytoene-dependent component of jr-factor."
phytoene,"Phytoene is a component of the labile factor activity complex (jr-factor) in chickens, and its function is dependent on the availability of choline.","Entity: phytoene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/C=C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Phytoene is a component of the labile factor activity complex (jr-factor) in chickens, and its function is dependent on the availability of choline."
cycloheximide,"Cycloheximide, when co-administered or injected after choline chloride at sub-lethal doses, completely blocks or rapidly arrests the induction of β-factor within 2–3 minutes.","Entity: cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Cycloheximide, when co-administered or injected after choline chloride at sub-lethal doses, completely blocks or rapidly arrests the induction of β-factor within 2–3 minutes."
puromycin,"Puromycin, when co-administered or injected after choline chloride at sub-lethal doses, completely blocks or rapidly arrests the induction of β-factor within 2–3 minutes.","Entity: puromycin. SMILES: COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@H](n3cnc4c(N(C)C)ncnc43)O[C@@H]2CO)cc1. Puromycin, when co-administered or injected after choline chloride at sub-lethal doses, completely blocks or rapidly arrests the induction of β-factor within 2–3 minutes."
choline chloride,Choline chloride induces a specific cellular response (β-factor induction) that can be blocked or rapidly arrested by sub-lethal doses of cycloheximide or puromycin.,Entity: choline chloride. SMILES: C[N+](C)(C)CCO.[Cl-]. Choline chloride induces a specific cellular response (β-factor induction) that can be blocked or rapidly arrested by sub-lethal doses of cycloheximide or puromycin.
phytoene,"Phytoene is a component of the labile factor activity complex (jr-factor) in chickens, and its supply limits the activity of the phytoene-dependent component of jr-factor.","Entity: phytoene. SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/C=C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C. Phytoene is a component of the labile factor activity complex (jr-factor) in chickens, and its supply limits the activity of the phytoene-dependent component of jr-factor."
choline chloride,Choline chloride replenishment leads to complete restoration of yr-factor levels in chickens within 32 minutes after injection at optimal doses.,Entity: choline chloride. SMILES: C[N+](C)(C)CCO.[Cl-]. Choline chloride replenishment leads to complete restoration of yr-factor levels in chickens within 32 minutes after injection at optimal doses.
choline chloride,Choline chloride can be administered intravenously at doses of 0.05–0.10 ml/kg body weight for experimental analysis.,Entity: choline chloride. SMILES: C[N+](C)(C)CCO.[Cl-]. Choline chloride can be administered intravenously at doses of 0.05–0.10 ml/kg body weight for experimental analysis.
cycloheximide,Cycloheximide is an antibiotic that can be dissolved in distilled water or saline and administered intravenously at doses of 0.05–0.10 ml/kg body weight for experimental studies.,Entity: cycloheximide. SMILES: C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1. Cycloheximide is an antibiotic that can be dissolved in distilled water or saline and administered intravenously at doses of 0.05–0.10 ml/kg body weight for experimental studies.
puromycin,Puromycin is an antibiotic that can be dissolved in distilled water or saline and administered intravenously at doses of 0.05–0.10 ml/kg body weight for experimental research.,Entity: puromycin. SMILES: COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@H](n3cnc4c(N(C)C)ncnc43)O[C@@H]2CO)cc1. Puromycin is an antibiotic that can be dissolved in distilled water or saline and administered intravenously at doses of 0.05–0.10 ml/kg body weight for experimental research.
carboxymethylcysteine,"Carboxymethylcysteine (CmCys) is a post-translationally modified cysteine residue that can undergo partial oxidation, potentially leading to fragmentation of peptide sequences such as the 132-135 and 254-271 regions in the glutamate dehydrogenase chain.","Entity: carboxymethylcysteine. SMILES: O=C(O)CN[C@@H](CS)C(=O)O. Carboxymethylcysteine (CmCys) is a post-translationally modified cysteine residue that can undergo partial oxidation, potentially leading to fragmentation of peptide sequences such as the 132-135 and 254-271 regions in the glutamate dehydrogenase chain."
methionine,"Methionine recovery is typically very low in amino acid analysis, making it difficult to obtain quantitative data except when 4% (v/v) thioglycollic acid is included in the hydrolysis mixture.","Entity: methionine. SMILES: CSCC[C@H](N)C(=O)O. Methionine recovery is typically very low in amino acid analysis, making it difficult to obtain quantitative data except when 4% (v/v) thioglycollic acid is included in the hydrolysis mixture."
lysine,"Lysine values in amino acid analysis can be falsely elevated due to interference from a peak near NH3, potentially affecting quantitative results.","Entity: lysine. SMILES: NCCCC[C@H](N)C(=O)O. Lysine values in amino acid analysis can be falsely elevated due to interference from a peak near NH3, potentially affecting quantitative results."
EACA,"EACA pretreatment of rats does not alter the ultrastructural appearance of Kupffer cells in the liver at 30 minutes post-colloid injection, as shown by electron microscopy.","Entity: EACA. SMILES: NCCCCCC(=O)O. EACA pretreatment of rats does not alter the ultrastructural appearance of Kupffer cells in the liver at 30 minutes post-colloid injection, as shown by electron microscopy."
silver,"Silver colloid injected into rat liver sinusoids is present in the lumen and on the surface of sinusoidal cells at 10 minutes post-injection, but disappears from the sinusoids by 30 minutes post-injection, except for a few tiny silver particles.","Entity: silver. SMILES: [Ag]. Silver colloid injected into rat liver sinusoids is present in the lumen and on the surface of sinusoidal cells at 10 minutes post-injection, but disappears from the sinusoids by 30 minutes post-injection, except for a few tiny silver particles."
EACA,EACA is an inhibitor of enzymatic fibrinolysis.,Entity: EACA. SMILES: NCCCCCC(=O)O. EACA is an inhibitor of enzymatic fibrinolysis.
Trasylol,Trasylol is an inhibitor of enzymatic fibrinolysis.,Entity: Trasylol. SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC3=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N2)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)CC)NC1=O. Trasylol is an inhibitor of enzymatic fibrinolysis.
silver,"Silver colloid undergoes intense uptake by reticuloendothelial cells of the liver, spleen, and lamina propria of the small intestine following injection.","Entity: silver. SMILES: [Ag]. Silver colloid undergoes intense uptake by reticuloendothelial cells of the liver, spleen, and lamina propria of the small intestine following injection."
silver,"Colloidal silver can be injected into tissues to facilitate morphological studies of fibrin, enabling detection of small fibrin strands due to its strong yellow to brown colour.","Entity: silver. SMILES: [Ag]. Colloidal silver can be injected into tissues to facilitate morphological studies of fibrin, enabling detection of small fibrin strands due to its strong yellow to brown colour."
silver,"Injection of colloidal silver induces intravascu lar coagulation in rats, as evidenced by the formation of fibrin in the liver after administration.","Entity: silver. SMILES: [Ag]. Injection of colloidal silver induces intravascu lar coagulation in rats, as evidenced by the formation of fibrin in the liver after administration."
silver,"Injection of colloidal silver into rat liver during perfusion fixation causes rapid bleaching of the liver tissue and reduces blood components in sinusoids, with fibrillar material accumulating in the periphery of liver lobules after 10 minutes.","Entity: silver. SMILES: [Ag]. Injection of colloidal silver into rat liver during perfusion fixation causes rapid bleaching of the liver tissue and reduces blood components in sinusoids, with fibrillar material accumulating in the periphery of liver lobules after 10 minutes."
haematoxylin,Haematoxylin is a histological stain used to visualize cell nuclei in tissue sections.,Entity: haematoxylin. SMILES: Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2. Haematoxylin is a histological stain used to visualize cell nuclei in tissue sections.
periodic acid,"Periodic acid is used as a histological reagent for staining tissue sections, often in combination with other dyes such as haematoxylin and Schiff reagents.","Entity: periodic acid. SMILES: [O-][I+3]([O-])([O-])O. Periodic acid is used as a histological reagent for staining tissue sections, often in combination with other dyes such as haematoxylin and Schiff reagents."
formaldehyde,Formaldehyde is used as a 4% solution in 0.1 M phosphate buffer (pH 7.4) for tissue fixation in histological procedures.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a 4% solution in 0.1 M phosphate buffer (pH 7.4) for tissue fixation in histological procedures.
Nembutal,Nembutal is an anesthetic agent administered at 6 mg/100 g body weight intraperitoneally to rats.,Entity: Nembutal. SMILES: CCCC(C)C1(CC)C(=O)NC(=O)NC1=O. Nembutal is an anesthetic agent administered at 6 mg/100 g body weight intraperitoneally to rats.
Trasylol,Trasylol administration in rats supports the conclusion that fibrin elimination from the lung depends on enzymatic lysis rather than phagocytosis.,Entity: Trasylol. SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC3=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N2)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)CC)NC1=O. Trasylol administration in rats supports the conclusion that fibrin elimination from the lung depends on enzymatic lysis rather than phagocytosis.
EACA,EACA administration in rats supports the conclusion that fibrin elimination from the lung depends on enzymatic lysis rather than phagocytosis.,Entity: EACA. SMILES: NCCCCCC(=O)O. EACA administration in rats supports the conclusion that fibrin elimination from the lung depends on enzymatic lysis rather than phagocytosis.
glutaraldehyde,"Glutaraldehyde is used as a fixative in electron microscopy to preserve tissue structure, including Kupffer cells and fibrin in the liver.","Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a fixative in electron microscopy to preserve tissue structure, including Kupffer cells and fibrin in the liver."
tannic acid,"Tannic acid is used as a tracer to label extracellular spaces in electron microscopy, allowing visualization of the location of fibrin-entangled Kupffer cell pseudopods.","Entity: tannic acid. SMILES: O=C(OC[C@H]1OC(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1. Tannic acid is used as a tracer to label extracellular spaces in electron microscopy, allowing visualization of the location of fibrin-entangled Kupffer cell pseudopods."
EACA,"EACA (ethylenediaminetetraacetic acid) can slow the clearance of carbon from the blood, an effect attributed to diminished disaggregation of platelet-carbon aggregates.","Entity: EACA. SMILES: NCCCCCC(=O)O. EACA (ethylenediaminetetraacetic acid) can slow the clearance of carbon from the blood, an effect attributed to diminished disaggregation of platelet-carbon aggregates."
EACA,"EACA does not block the endocytic mechanism of Kupffer cells, as the rate of clearance of fibrin monomers by liver macrophages in rabbits is not influenced by EACA pretreatment.","Entity: EACA. SMILES: NCCCCCC(=O)O. EACA does not block the endocytic mechanism of Kupffer cells, as the rate of clearance of fibrin monomers by liver macrophages in rabbits is not influenced by EACA pretreatment."
Trasylol,"Trasylol, an antifibrinolytic agent, can result in the continued presence of colloid in sinusoids up to 30 and 60 minutes after administration.","Entity: Trasylol. SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC3=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N2)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)CC)NC1=O. Trasylol, an antifibrinolytic agent, can result in the continued presence of colloid in sinusoids up to 30 and 60 minutes after administration."
Trasylol,"Trasylol is a thrombin inhibitor used at a concentration of 15,000 IKE/ml in laboratory preparations.","Entity: Trasylol. SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC3=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N2)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)CC)NC1=O. Trasylol is a thrombin inhibitor used at a concentration of 15,000 IKE/ml in laboratory preparations."
thrombin,"Thrombin can induce disseminated intravascular coagulation in rats, leading to the deposition of fibrin in major organs.","Entity: thrombin. Thrombin can induce disseminated intravascular coagulation in rats, leading to the deposition of fibrin in major organs."
ADP,"ADP binds specifically to platelet plasma membranes, as evidenced by the reversible binding and aggregation of platelet plasma membranes upon ADP addition.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP binds specifically to platelet plasma membranes, as evidenced by the reversible binding and aggregation of platelet plasma membranes upon ADP addition."
ADP,"ADP binds to membrane vesicles in a stable, non-metabolically labile form, allowing for precise measurement of its binding without interference from metabolites.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP binds to membrane vesicles in a stable, non-metabolically labile form, allowing for precise measurement of its binding without interference from metabolites."
ADP,"ADP can bind to membranes, with binding kinetics and reversibility tested using various concentrations and incubation times in membrane binding assays.","Entity: ADP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ADP can bind to membranes, with binding kinetics and reversibility tested using various concentrations and incubation times in membrane binding assays."
dextran,"Dextran has an antiaggregating effect and, when used in perioperative infusions, contributes to the beneficial effect of combined prophylaxis with low dose heparin and acetylsalicylic acid.","Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran has an antiaggregating effect and, when used in perioperative infusions, contributes to the beneficial effect of combined prophylaxis with low dose heparin and acetylsalicylic acid."
acetylsalicylic acid,"Acetylsalicylic acid, when administered at 900 mg intravenously or 1.5 g orally, suppresses collagen-induced platelet aggregation.","Entity: acetylsalicylic acid. SMILES: CC(=O)Oc1ccccc1C(=O)O. Acetylsalicylic acid, when administered at 900 mg intravenously or 1.5 g orally, suppresses collagen-induced platelet aggregation."
acetylsalicylic acid,Combined prophylaxis with acetylsalicylic acid and low dose heparin produces a significant reduction in deep vein thrombosis (DVT) due to an additive effect.,Entity: acetylsalicylic acid. SMILES: CC(=O)Oc1ccccc1C(=O)O. Combined prophylaxis with acetylsalicylic acid and low dose heparin produces a significant reduction in deep vein thrombosis (DVT) due to an additive effect.
acetylsalicylic lysine,Acetylsalicylic lysine is administered intravenously at a dose of 900 mg every 48 hours from the evening of the first postoperative day until the 15th postoperative day in patients after surgery.,Entity: acetylsalicylic lysine. SMILES: CC(=O)Oc1ccccc1C(=O)O.NCCCC[C@H](N)C(=O)O. Acetylsalicylic lysine is administered intravenously at a dose of 900 mg every 48 hours from the evening of the first postoperative day until the 15th postoperative day in patients after surgery.
iodine-125,Iodine-125 is used to label fibrinogen for diagnostic imaging procedures such as the detection of deep vein thrombosis (DVT) by nuclear scanning.,Entity: iodine-125. SMILES: [125IH]. Iodine-125 is used to label fibrinogen for diagnostic imaging procedures such as the detection of deep vein thrombosis (DVT) by nuclear scanning.
potassium iodide,Potassium iodide is administered orally to block the thyroid gland during diagnostic procedures involving iodine-125.,Entity: potassium iodide. SMILES: [I-].[K+]. Potassium iodide is administered orally to block the thyroid gland during diagnostic procedures involving iodine-125.
Oncovin,"Oncovin is a chemotherapeutic agent used as part of the COPP regimen (cyclophosphamide, Oncovin, prednisone, and procarbazine) in the treatment of Hodgkin's disease.","Entity: Oncovin. SMILES: CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O. Oncovin is a chemotherapeutic agent used as part of the COPP regimen (cyclophosphamide, Oncovin, prednisone, and procarbazine) in the treatment of Hodgkin's disease."
radium,Radium was administered at a dose of 4000 mg/hour using a Fletcher-Suit applicator for external irradiation in the treatment of pathologic Stage II carcinoma of the endometrium.,Entity: radium. SMILES: [Ra]. Radium was administered at a dose of 4000 mg/hour using a Fletcher-Suit applicator for external irradiation in the treatment of pathologic Stage II carcinoma of the endometrium.
ferrous sulfate,"Ferrous sulfate is used as a dosimeter material for absolute dose determination in radiation therapy, with comparisons made at 10 and 20 MeV photon energies.","Entity: ferrous sulfate. SMILES: O=S(=O)([O-])[O-].[Fe+2]. Ferrous sulfate is used as a dosimeter material for absolute dose determination in radiation therapy, with comparisons made at 10 and 20 MeV photon energies."
magnesium,The concentration of magnesium in glass can be determined analytically and may have potential value for classification and discrimination of glass types.,Entity: magnesium. SMILES: [Mg]. The concentration of magnesium in glass can be determined analytically and may have potential value for classification and discrimination of glass types.
chloride,Chloride content in left heart blood has been reported to be lower than in control material in some cases of fresh water drowning.,Entity: chloride. SMILES: [Cl-]. Chloride content in left heart blood has been reported to be lower than in control material in some cases of fresh water drowning.
sodium,Serum sodium levels in left heart blood have been found to be lowered in fresh water drowning cases compared to femoral blood or cerebrospinal fluid.,Entity: sodium. SMILES: [Na]. Serum sodium levels in left heart blood have been found to be lowered in fresh water drowning cases compared to femoral blood or cerebrospinal fluid.
chloride,"Chloride content in blood can be lowered after drowning in fresh water and elevated after drowning in sea water, indicating a role for osmotic changes in blood as a factor of pathogenetic importance in drowning cases.","Entity: chloride. SMILES: [Cl-]. Chloride content in blood can be lowered after drowning in fresh water and elevated after drowning in sea water, indicating a role for osmotic changes in blood as a factor of pathogenetic importance in drowning cases."
sodium,"A Na+ concentration lower than 25 mequiv/l in blood from the left heart, compared to cerebrospinal fluid, strongly indicates death by fresh water drowning.","Entity: sodium. SMILES: [Na]. A Na+ concentration lower than 25 mequiv/l in blood from the left heart, compared to cerebrospinal fluid, strongly indicates death by fresh water drowning."
potassium,"A Na+K concentration lower than 25 mequiv/l in blood from the left heart, compared to cerebrospinal fluid, strongly indicates death by fresh water drowning.","Entity: potassium. SMILES: [K]. A Na+K concentration lower than 25 mequiv/l in blood from the left heart, compared to cerebrospinal fluid, strongly indicates death by fresh water drowning."
potassium,"In drowned cases, potassium concentration in blood is higher than in living individuals.","Entity: potassium. SMILES: [K]. In drowned cases, potassium concentration in blood is higher than in living individuals."
sodium,"In drowned cases, sodium concentration in blood is lower than in living individuals.","Entity: sodium. SMILES: [Na]. In drowned cases, sodium concentration in blood is lower than in living individuals."
sodium,"In drowning cases, the sodium concentration in left heart blood is typically more than 25 mequiv/l lower than in cerebrospinal fluid, and in vitreous humor compared to control cases.","Entity: sodium. SMILES: [Na]. In drowning cases, the sodium concentration in left heart blood is typically more than 25 mequiv/l lower than in cerebrospinal fluid, and in vitreous humor compared to control cases."
potassium,"In drowning cases, the potassium concentration in left heart blood is typically more than 25 mequiv/l lower than in cerebrospinal fluid, and in vitreous humor compared to control cases.","Entity: potassium. SMILES: [K]. In drowning cases, the potassium concentration in left heart blood is typically more than 25 mequiv/l lower than in cerebrospinal fluid, and in vitreous humor compared to control cases."
β-endosulfan,The ultraviolet absorption spectrum of β-endosulfan in a 0.01% w/v 0.1 N NaOH solution shows a maximum at 278 nm with an extinction of 0.25.,Entity: β-endosulfan. SMILES: O=S1OC[C@@H]2[C@H](CO1)[C@]1(Cl)C(Cl)=C(Cl)[C@@]2(Cl)C1(Cl)Cl. The ultraviolet absorption spectrum of β-endosulfan in a 0.01% w/v 0.1 N NaOH solution shows a maximum at 278 nm with an extinction of 0.25.
Et2O,Et2O (diethyl ether) is used as an extraction solvent for blood and tissue samples to isolate analytes prior to chromatographic or spectrophotometric analysis.,Entity: Et2O. SMILES: CCOCC. Et2O (diethyl ether) is used as an extraction solvent for blood and tissue samples to isolate analytes prior to chromatographic or spectrophotometric analysis.
sodium sulphate,"Anhydrous sodium sulphate is used to dry organic extracts by removing water, facilitating subsequent chromatographic or analytical procedures.","Entity: sodium sulphate. SMILES: O=S(=O)([O-])[O-].[Na+].[Na+]. Anhydrous sodium sulphate is used to dry organic extracts by removing water, facilitating subsequent chromatographic or analytical procedures."
HCl,HCl (hydrochloric acid) is used to acidify blood samples to facilitate extraction of analytes.,Entity: HCl. SMILES: Cl. HCl (hydrochloric acid) is used to acidify blood samples to facilitate extraction of analytes.
n-hexane,"n-hexane is used as an extraction solvent for tissues, such as liver, kidney, and brain, to minimize emulsion formation during extraction.","Entity: n-hexane. SMILES: CCCCCC. n-hexane is used as an extraction solvent for tissues, such as liver, kidney, and brain, to minimize emulsion formation during extraction."
succinate,Succinate is used as a substrate in mitochondrial oxygen uptake assays to measure cellular respiration.,Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate is used as a substrate in mitochondrial oxygen uptake assays to measure cellular respiration.
carbonyl cyanide p-trifluoromethoxyphenyl hydrazone,Carbonyl cyanide p-trifluoromethoxyphenyl hydrazone (FCCP) is used as a mitochondrial uncoupler to disrupt mitochondrial phosphorylation.,Entity: carbonyl cyanide p-trifluoromethoxyphenyl hydrazone. SMILES: N#CC(C#N)=NNc1ccc(OC(F)(F)F)cc1. Carbonyl cyanide p-trifluoromethoxyphenyl hydrazone (FCCP) is used as a mitochondrial uncoupler to disrupt mitochondrial phosphorylation.
succinate,"Succinate stimulates oxygen uptake in hepatocytes, and this stimulation is lost after an anoxic period, indicating its role in maintaining plasma membrane integrity during anoxia.","Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate stimulates oxygen uptake in hepatocytes, and this stimulation is lost after an anoxic period, indicating its role in maintaining plasma membrane integrity during anoxia."
oxygen,"Oxygen uptake in hepatocytes is stimulated by succinate, serving as an early indicator of plasma membrane permeability during anoxia.","Entity: oxygen. SMILES: [O]. Oxygen uptake in hepatocytes is stimulated by succinate, serving as an early indicator of plasma membrane permeability during anoxia."
trypan blue,"Trypan blue permeability increases in hepatocytes following anoxic injury, reflecting increased plasma membrane permeability.","Entity: trypan blue. SMILES: Cc1cc(-c2ccc(N=Nc3c(S(=O)(=O)[O-])cc4cc(S(=O)(=O)[O-])cc(N)c4c3O)c(C)c2)ccc1N=Nc1c(S(=O)(=O)[O-])cc2cc(S(=O)(=O)[O-])cc(N)c2c1O.[Na+].[Na+].[Na+].[Na+]. Trypan blue permeability increases in hepatocytes following anoxic injury, reflecting increased plasma membrane permeability."
succinate,"Succinate is able to permeate the plasma membrane of freshly isolated cells, as indicated by its use in stimulating oxygen uptake.","Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate is able to permeate the plasma membrane of freshly isolated cells, as indicated by its use in stimulating oxygen uptake."
lactate,"Extracellular lactate dehydrogenase activity increases by approximately 10^-20% in freshly isolated cells, indicating a change in plasma membrane permeability.","Entity: lactate. SMILES: CC(O)C(=O)[O-]. Extracellular lactate dehydrogenase activity increases by approximately 10^-20% in freshly isolated cells, indicating a change in plasma membrane permeability."
oxygen,Oxygen uptake in freshly isolated cells remains relatively stable at around -15 nmol per minute per 10^6 cells during incubation.,Entity: oxygen. SMILES: [O]. Oxygen uptake in freshly isolated cells remains relatively stable at around -15 nmol per minute per 10^6 cells during incubation.
adriamycin,"Adriamycin is generally well tolerated by patients, with only occasional moderate myelosuppression and rare cases of congestive cardiac failure associated with its use.","Entity: adriamycin. SMILES: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1. Adriamycin is generally well tolerated by patients, with only occasional moderate myelosuppression and rare cases of congestive cardiac failure associated with its use."
DTIC,"DTIC is generally well tolerated by patients, with the course sometimes shortened to 2 to 3 days to manage myelosuppression and maintain satisfactory hematological response.","Entity: DTIC. SMILES: CN(C)/N=N/c1nc[nH]c1C(N)=O. DTIC is generally well tolerated by patients, with the course sometimes shortened to 2 to 3 days to manage myelosuppression and maintain satisfactory hematological response."
lecithin,Lecithin is administered intraamnially to prevent respiratory distress syndrome in preterm infants.,Entity: lecithin. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C. Lecithin is administered intraamnially to prevent respiratory distress syndrome in preterm infants.
lecithin,"A high phospholipid level in amniotic fluid, such as that provided by lecithin, is associated with increased fetal resorption.","Entity: lecithin. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C. A high phospholipid level in amniotic fluid, such as that provided by lecithin, is associated with increased fetal resorption."
dithionite,Dithionite reduces horse heart cytochrome c at pH 7.0 with rate constants of 2.8 × 10^8 M^(-1) sec^(-1) for SO2 and 6 × 10^5 M^(-1) sec^(-1) for S2O4 at infinite dilution.,Entity: dithionite. SMILES: O=S([O-])S(=O)[O-]. Dithionite reduces horse heart cytochrome c at pH 7.0 with rate constants of 2.8 × 10^8 M^(-1) sec^(-1) for SO2 and 6 × 10^5 M^(-1) sec^(-1) for S2O4 at infinite dilution.
dithionite,Dithionite reduction of cytochrome c involves electron transfer at an exposed heme edge where positively charged amino acid side chains participate.,Entity: dithionite. SMILES: O=S([O-])S(=O)[O-]. Dithionite reduction of cytochrome c involves electron transfer at an exposed heme edge where positively charged amino acid side chains participate.
potassium ferrocyanide,Potassium ferrocyanide reduces ferri-horse heart cytochrome c through a kinetically complex mechanism involving transient complexes with ferrocyanide and ferricyanide and ferrocytochrome c.,Entity: potassium ferrocyanide. SMILES: N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N.[K+].[K+].[K+].[K+]. Potassium ferrocyanide reduces ferri-horse heart cytochrome c through a kinetically complex mechanism involving transient complexes with ferrocyanide and ferricyanide and ferrocytochrome c.
potassium ferrocyanide,Potassium ferrocyanide reduction of cytochrome c involves electron transfer at an exposed heme edge where positively charged amino acid side chains participate.,Entity: potassium ferrocyanide. SMILES: N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N.[K+].[K+].[K+].[K+]. Potassium ferrocyanide reduction of cytochrome c involves electron transfer at an exposed heme edge where positively charged amino acid side chains participate.
potassium ferrocyanide,"The kinetic distinction between ferrocyanide and dithionite reduction of cytochrome c lies in the lifetime of the transient complex formed, with ferrocyanide resulting in a longer-lived complex than dithionite.","Entity: potassium ferrocyanide. SMILES: N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N.[K+].[K+].[K+].[K+]. The kinetic distinction between ferrocyanide and dithionite reduction of cytochrome c lies in the lifetime of the transient complex formed, with ferrocyanide resulting in a longer-lived complex than dithionite."
cytochrome c,"The reduction of cytochrome c by ferrocyanide proceeds through transient complexes with ferricytochrome c and ferrocytochrome c, with a mechanism that is kinetically more complex than that of dithionite reduction.","Entity: cytochrome c. The reduction of cytochrome c by ferrocyanide proceeds through transient complexes with ferricytochrome c and ferrocytochrome c, with a mechanism that is kinetically more complex than that of dithionite reduction."
cytochrome c,"The reduction of ferricytochrome c requires at least two pK values for description, with pK1 = 7.0 ± 0.4 and pK2 = 9.3 ± 0.3.","Entity: cytochrome c. The reduction of ferricytochrome c requires at least two pK values for description, with pK1 = 7.0 ± 0.4 and pK2 = 9.3 ± 0.3."
cytochrome c,"Cytochrome c undergoes reduction at its exposed heme edge, with electron transfer involving positively charged amino acid side chains, including residues with low pK values such as lysine.","Entity: cytochrome c. Cytochrome c undergoes reduction at its exposed heme edge, with electron transfer involving positively charged amino acid side chains, including residues with low pK values such as lysine."
cytochrome c,"For horse heart cytochrome c, sodium dithionite reduction at pH 7.0 yields rate constants of 2.8 × 10^8 M^(-1) sec^(-1) for SO2 and 6 × 10^5 M^(-1) sec^(-1) for S2O4 at infinite dilution.","Entity: cytochrome c. For horse heart cytochrome c, sodium dithionite reduction at pH 7.0 yields rate constants of 2.8 × 10^8 M^(-1) sec^(-1) for SO2 and 6 × 10^5 M^(-1) sec^(-1) for S2O4 at infinite dilution."
triethanolamine,Triethanolamine is not mutagenic to Bacillus subtilis on its own but becomes mutagenic when reacted with sodium nitrite under acidic conditions or when heated.,Entity: triethanolamine. SMILES: OCCN(CCO)CCO. Triethanolamine is not mutagenic to Bacillus subtilis on its own but becomes mutagenic when reacted with sodium nitrite under acidic conditions or when heated.
triethanolamine,"Dietary intake of triethanolamine at 0.3% or 0.03% in mice is associated with the development of malignant tumors, particularly in lymphoid tissues of females.","Entity: triethanolamine. SMILES: OCCN(CCO)CCO. Dietary intake of triethanolamine at 0.3% or 0.03% in mice is associated with the development of malignant tumors, particularly in lymphoid tissues of females."
glucagon,Excess glucagon can be corrected during experimental diabetes by administration of large or physiological amounts of insulin.,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Excess glucagon can be corrected during experimental diabetes by administration of large or physiological amounts of insulin.
sulphate,"Serum levels of inorganic sulphate are monitored to account for gross changes in sulphate, which can alter the specific activity of labeled sulphate used for quantifying serum methaemoglobin (SM) levels.","Entity: sulphate. SMILES: O=S(=O)([O-])[O-]. Serum levels of inorganic sulphate are monitored to account for gross changes in sulphate, which can alter the specific activity of labeled sulphate used for quantifying serum methaemoglobin (SM) levels."
sulphate,Serum sulphate concentrations in rats increase approximately 3-fold from gestational day 21 to postnatal day 4.,Entity: sulphate. SMILES: O=S(=O)([O-])[O-]. Serum sulphate concentrations in rats increase approximately 3-fold from gestational day 21 to postnatal day 4.
insulin,"Serum insulin levels in rats are highest at 1 and 4 days post birth, decline sharply between 4 and 8 days, and are lowest at 19 days (42.5 ± 4.3 uU/ml) and 40 days (42.5 ± 4.3 uU/ml), with no significant change in between.","Entity: insulin. SMILES: CC[C@@H](C)[C@H](NC(=O)CN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@H]2NC(=O)[C@H]([C@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)O)[C@H](C)O)[C@H](C)O)CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)NC1=O)C(C)C. Serum insulin levels in rats are highest at 1 and 4 days post birth, decline sharply between 4 and 8 days, and are lowest at 19 days (42.5 ± 4.3 uU/ml) and 40 days (42.5 ± 4.3 uU/ml), with no significant change in between."
inorganic sulphate,"Serum inorganic sulphate concentrations in neonatal rats increase significantly from 0.33 ± 0.03 nMol/l at 21 days in utero to 1.02 ± 0.06 mMol/l at 4 days post birth, with no significant changes up to 40 days of age.","Entity: inorganic sulphate. SMILES: O=S(=O)([O-])[O-]. Serum inorganic sulphate concentrations in neonatal rats increase significantly from 0.33 ± 0.03 nMol/l at 21 days in utero to 1.02 ± 0.06 mMol/l at 4 days post birth, with no significant changes up to 40 days of age."
somatomedin,"Somatomedin activity is not detectable in the serum of fetal rats, but becomes measurable at low levels only from 11 days after birth until 40 days post natal in rats.","Entity: somatomedin. Somatomedin activity is not detectable in the serum of fetal rats, but becomes measurable at low levels only from 11 days after birth until 40 days post natal in rats."
gastrin,"In dogs with antral exclusion, gastrin levels increase to 349 ± 64 pg/ml, compared to normal levels of 76 ± 19 pg/ml.","Entity: gastrin. In dogs with antral exclusion, gastrin levels increase to 349 ± 64 pg/ml, compared to normal levels of 76 ± 19 pg/ml."
iodine,"Iodine is used to label peptides, such as secretins, with 125I for radiolabeling and quantification in biochemical assays.","Entity: iodine. SMILES: [I]. Iodine is used to label peptides, such as secretins, with 125I for radiolabeling and quantification in biochemical assays."
secretin,"125I-(DATA)-secretin, a secretin analogue with a (Des-Tyr-betaAla)-residue, serves as a superior tracer for sensitive secretin radioimmunoassay due to its higher conformational integrity and superior immunoreactivity with rabbit anti-secretin sera compared to other iodinated secretin forms.","Entity: secretin. 125I-(DATA)-secretin, a secretin analogue with a (Des-Tyr-betaAla)-residue, serves as a superior tracer for sensitive secretin radioimmunoassay due to its higher conformational integrity and superior immunoreactivity with rabbit anti-secretin sera compared to other iodinated secretin forms."
glucagon,The increase in blood sugar response to exogenous alanine in both nonpregnant and pregnant mice is mediated by glucagon.,Entity: glucagon. The increase in blood sugar response to exogenous alanine in both nonpregnant and pregnant mice is mediated by glucagon.
nicotinic acid,"Nicotinic acid increases insulin-like growth factor 1 (IRG) secretion, an effect attributed to drug-induced stress rather than direct IRG stimulation.","Entity: nicotinic acid. SMILES: O=C(O)c1cccnc1. Nicotinic acid increases insulin-like growth factor 1 (IRG) secretion, an effect attributed to drug-induced stress rather than direct IRG stimulation."
glucagon,The secretion of glucagon is less influenced by changes in blood lipid concentrations compared to the secretion of human growth hormone (HGH).,Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. The secretion of glucagon is less influenced by changes in blood lipid concentrations compared to the secretion of human growth hormone (HGH).
glucagon,"Glucagon administration in obese subjects results in a higher peak of insulin and total insulin area compared to nonobese subjects, with the difference becoming noticeable between 2 and 30 minutes post-glucagon.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon administration in obese subjects results in a higher peak of insulin and total insulin area compared to nonobese subjects, with the difference becoming noticeable between 2 and 30 minutes post-glucagon."
glucose,"Glucose administration in obese subjects results in a higher peak of insulin and total insulin area compared to nonobese subjects, with the difference becoming noticeable between 30 and 120 minutes post-glucose.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose administration in obese subjects results in a higher peak of insulin and total insulin area compared to nonobese subjects, with the difference becoming noticeable between 30 and 120 minutes post-glucose."
glucagon,"Glucagon administration induces a peak of insulin secretion in humans, reaching this peak between 2 and 15 minutes post-glucagon.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon administration induces a peak of insulin secretion in humans, reaching this peak between 2 and 15 minutes post-glucagon."
indomethacin,"Indomethacin-induced decrease in plasma calcium becomes apparent as early as 4 hours after injection, with effects persisting up to 24 hours.","Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin-induced decrease in plasma calcium becomes apparent as early as 4 hours after injection, with effects persisting up to 24 hours."
indomethacin,Indomethacin-induced increase in plasma phosphorus becomes evident by 12 hours after injection and persists up to 24 hours.,Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin-induced increase in plasma phosphorus becomes evident by 12 hours after injection and persists up to 24 hours.
calcium,Plasma calcium concentration is lowered by indomethacin treatment in vivo.,Entity: calcium. SMILES: [Ca]. Plasma calcium concentration is lowered by indomethacin treatment in vivo.
phosphorus,Plasma phosphorus concentration is increased by indomethacin treatment in vivo.,Entity: phosphorus. SMILES: [P]. Plasma phosphorus concentration is increased by indomethacin treatment in vivo.
indomethacin,Indomethacin at doses of 1.5 mg/100 g body weight or 6 mg/100 g body weight administered by injection lowers plasma calcium and raises plasma phosphorus levels in vivo.,Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin at doses of 1.5 mg/100 g body weight or 6 mg/100 g body weight administered by injection lowers plasma calcium and raises plasma phosphorus levels in vivo.
Calcium,Calcium release from bone is stimulated by PGE2 in vitro.,Entity: Calcium. SMILES: [Ca]. Calcium release from bone is stimulated by PGE2 in vitro.
Calcium,PGE2 increases blood calcium concentration in rats.,Entity: Calcium. SMILES: [Ca]. PGE2 increases blood calcium concentration in rats.
Phosphorus,Indomethacin increases circulating phosphorus levels in both intact and thyroparathyroidectomized rats.,Entity: Phosphorus. SMILES: [P]. Indomethacin increases circulating phosphorus levels in both intact and thyroparathyroidectomized rats.
Indomethacin,Indomethacin is an inhibitor of prostaglandin synthesis.,Entity: Indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin is an inhibitor of prostaglandin synthesis.
Indomethacin,Indomethacin lowers circulating levels of calcium and increases circulating levels of phosphorus in both intact and thyroparathyroidectomized rats.,Entity: Indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin lowers circulating levels of calcium and increases circulating levels of phosphorus in both intact and thyroparathyroidectomized rats.
Indomethacin,Indomethacin inhibits the hypercalcemic and hypophosphatemic actions of parathyroid hormone in rats.,Entity: Indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin inhibits the hypercalcemic and hypophosphatemic actions of parathyroid hormone in rats.
indomethacin,Indomethacin impairs the response to parathyroid hormone by inhibiting the increase in plasma calcium and decrease in plasma phosphorus induced by parathyroid hormone in the TPTX rat.,Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin impairs the response to parathyroid hormone by inhibiting the increase in plasma calcium and decrease in plasma phosphorus induced by parathyroid hormone in the TPTX rat.
indomethacin,"Indomethacin causes further lowering of plasma calcium and raising of plasma phosphorus in the TPTX rat, indicating a fundamental disturbance in ion metabolism at the cellular level.","Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin causes further lowering of plasma calcium and raising of plasma phosphorus in the TPTX rat, indicating a fundamental disturbance in ion metabolism at the cellular level."
calcium,Plasma calcium levels are increased by parathyroid hormone and decreased by indomethacin in the TPTX rat.,Entity: calcium. SMILES: [Ca]. Plasma calcium levels are increased by parathyroid hormone and decreased by indomethacin in the TPTX rat.
phosphorus,Plasma phosphorus levels are decreased by parathyroid hormone and increased by indomethacin in the TPTX rat.,Entity: phosphorus. SMILES: [P]. Plasma phosphorus levels are decreased by parathyroid hormone and increased by indomethacin in the TPTX rat.
calcium,"Calcium is involved in maintaining cellular and intracellular calcium homeostasis, with mitochondria playing a role in controlling intracellular calcium levels.","Entity: calcium. SMILES: [Ca]. Calcium is involved in maintaining cellular and intracellular calcium homeostasis, with mitochondria playing a role in controlling intracellular calcium levels."
phosphorus,Blood phosphorus levels are not affected by intraperitoneal administration of aspirin at doses up to 6 mg/100 gm in propylene glycol.,Entity: phosphorus. SMILES: [P]. Blood phosphorus levels are not affected by intraperitoneal administration of aspirin at doses up to 6 mg/100 gm in propylene glycol.
indomethacin,"Indomethacin inhibits the movement of calcium into mitochondria, which are organelles believed to control intracellular calcium levels.","Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin inhibits the movement of calcium into mitochondria, which are organelles believed to control intracellular calcium levels."
aspirin,"Aspirin, when injected intraperitoneally in propylene glycol up to a dose of 6 mg/100 gm, does not affect blood calcium and phosphorus levels.","Entity: aspirin. SMILES: CC(=O)Oc1ccccc1C(=O)O. Aspirin, when injected intraperitoneally in propylene glycol up to a dose of 6 mg/100 gm, does not affect blood calcium and phosphorus levels."
somatostatin,"Prolonged somatostatin infusion can induce fasting hyperglycemia in patients, independent of intact basal glucagon secretion.","Entity: somatostatin. SMILES: C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O. Prolonged somatostatin infusion can induce fasting hyperglycemia in patients, independent of intact basal glucagon secretion."
glucose,Fasting hyperglycemia during prolonged somatostatin infusion is likely due to changes in liver glucose production rather than altered peripheral glucose uptake in humans.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Fasting hyperglycemia during prolonged somatostatin infusion is likely due to changes in liver glucose production rather than altered peripheral glucose uptake in humans.
glucagon,"Glucagon levels can be suppressed during prolonged somatostatin infusion, even when fasting hyperglycemia develops.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Glucagon levels can be suppressed during prolonged somatostatin infusion, even when fasting hyperglycemia develops."
steroids,The luminal contents of the middle segment of the mouse epididymis show histochemical utilization of a number of steroids.,Entity: steroids. SMILES: CC(=O)N(C)[C@H](C)[C@@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](N(C)C)CC[C@@]4(C)[C@@H]3CC[C@]21C. The luminal contents of the middle segment of the mouse epididymis show histochemical utilization of a number of steroids.
melatonin,Endogenous melatonin exerts feedback inhibitory regulation on the activities of N-acetyl transferase (NAT) and hydroxyindole-O-methyl transferase (HIOMT) in pineals of Coturnix quail.,Entity: melatonin. SMILES: COc1ccc2[nH]cc(CCNC(C)=O)c2c1. Endogenous melatonin exerts feedback inhibitory regulation on the activities of N-acetyl transferase (NAT) and hydroxyindole-O-methyl transferase (HIOMT) in pineals of Coturnix quail.
hydroxyindole-O-methyl transferase,Hydroxyindole-O-methyl transferase activity in Coturnix quail pineals is modulated by the feedback inhibitory influence of endogenous melatonin.,Entity: hydroxyindole-O-methyl transferase. Hydroxyindole-O-methyl transferase activity in Coturnix quail pineals is modulated by the feedback inhibitory influence of endogenous melatonin.
hydroxyindole-O-methyl transferase,Hydroxyindole-O-methyl transferase activity in Coturnix quail pineals is decreased by castration and restored by selective gonadal steroids.,Entity: hydroxyindole-O-methyl transferase. Hydroxyindole-O-methyl transferase activity in Coturnix quail pineals is decreased by castration and restored by selective gonadal steroids.
hydroxyindole-O-methyl transferase,Hydroxyindole-O-methyl transferase activity in Coturnix quail pineals is increased twofold during darkness exposure (16L:8D) in both male and female birds.,Entity: hydroxyindole-O-methyl transferase. Hydroxyindole-O-methyl transferase activity in Coturnix quail pineals is increased twofold during darkness exposure (16L:8D) in both male and female birds.
triglyceride,Plasma triglyceride levels increase by 36% during the third trimester of pregnancy in healthy women.,Entity: triglyceride. SMILES: O=COCC(COC=O)OC=O. Plasma triglyceride levels increase by 36% during the third trimester of pregnancy in healthy women.
phosphatidylethanolamine,Phosphatidylethanolamine is a testicular phospholipid whose content is markedly depleted in the testes of adult rats following treatment with prolactin or prolactin plus progesterone.,Entity: phosphatidylethanolamine. SMILES: CC(=O)OC[C@H](COP(=O)(O)OCCN)OC(C)=O. Phosphatidylethanolamine is a testicular phospholipid whose content is markedly depleted in the testes of adult rats following treatment with prolactin or prolactin plus progesterone.
prolactin,"Prolactin administration reduces total testicular lipids, with a more pronounced effect in the presence of progesterone (28% and 50% reduction, respectively).","Entity: prolactin. Prolactin administration reduces total testicular lipids, with a more pronounced effect in the presence of progesterone (28% and 50% reduction, respectively)."
prolactin,Prolactin treatment increases the weight of seminal vesicles but does not affect testicular weight in adult rats.,Entity: prolactin. Prolactin treatment increases the weight of seminal vesicles but does not affect testicular weight in adult rats.
prolactin,Prolactin increases esterified cholesterol and decreases free cholesterol in the testes of adult rats.,Entity: prolactin. Prolactin increases esterified cholesterol and decreases free cholesterol in the testes of adult rats.
prolactin,Prolactin appears to play a role in steroidogenesis and in the secretory processes of the testes.,Entity: prolactin. Prolactin appears to play a role in steroidogenesis and in the secretory processes of the testes.
prolactin,"Prolactin treatment depletes testicular phospholipids, particularly phosphatidylcholine and phosphatidylethanolamine, mainly by enhancing tubular fluid flow rather than altering biosynthetic pathways.","Entity: prolactin. Prolactin treatment depletes testicular phospholipids, particularly phosphatidylcholine and phosphatidylethanolamine, mainly by enhancing tubular fluid flow rather than altering biosynthetic pathways."
agarose,Agarose is used as a matrix for affinity chromatography to purify enzymes that exhibit affinity towards specific ligands.,Entity: agarose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H]3OC[C@@H]2O[C@@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]4[C@H]5OC[C@@H]4O[C@@H](O)[C@H]5O)[C@@H]2O)[C@H]3O)[C@H](O)[C@@H](O)[C@H]1O. Agarose is used as a matrix for affinity chromatography to purify enzymes that exhibit affinity towards specific ligands.
S-adenosyl-L-methionine,S-adenosyl-L-methionine serves as a methyl donor for methyltransferases that convert myo-inositol to D-bornesitol and L-bornesitol.,Entity: S-adenosyl-L-methionine. SMILES: C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O. S-adenosyl-L-methionine serves as a methyl donor for methyltransferases that convert myo-inositol to D-bornesitol and L-bornesitol.
L-glutamate,L-glutamate acts both as a precursor of 4-aminobutyrate and as an independent substance in synaptosomes.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate acts both as a precursor of 4-aminobutyrate and as an independent substance in synaptosomes.
sucrose,"Sucrose is used to prepare density gradients for centrifugation, with fractions at 0.8 M, 0.9 M, and 1.0 M sucrose density being analyzed for synaptosome purification.","Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used to prepare density gradients for centrifugation, with fractions at 0.8 M, 0.9 M, and 1.0 M sucrose density being analyzed for synaptosome purification."
4-aminobutyrate,4-aminobutyrate is used as a radiolabeled substrate to assay for enzymatic activity in synaptosome fractions during gradient centrifugation.,Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. 4-aminobutyrate is used as a radiolabeled substrate to assay for enzymatic activity in synaptosome fractions during gradient centrifugation.
L-glutamate,L-glutamate is used as a radiolabeled substrate to assay for enzymatic activity in synaptosome fractions during gradient centrifugation.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate is used as a radiolabeled substrate to assay for enzymatic activity in synaptosome fractions during gradient centrifugation.
H2SO4,Sulfuric acid (4N) is used to stop enzymatic reactions in assays measuring glutamate decarboxylase activity.,Entity: H2SO4. SMILES: O=S(=O)(O)O. Sulfuric acid (4N) is used to stop enzymatic reactions in assays measuring glutamate decarboxylase activity.
pyridoxal phosphate,Pyridoxal phosphate is used as a cofactor at a final concentration of 1 mM in enzyme assays measuring glutamate decarboxylase activity.,Entity: pyridoxal phosphate. SMILES: Cc1ncc(COP(=O)(O)O)c(C=O)c1O. Pyridoxal phosphate is used as a cofactor at a final concentration of 1 mM in enzyme assays measuring glutamate decarboxylase activity.
L-glutamate,L-glutamate is used as a substrate at a final concentration of 1 mM in enzyme assays measuring glutamate decarboxylase activity.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate is used as a substrate at a final concentration of 1 mM in enzyme assays measuring glutamate decarboxylase activity.
Triton X-100,Triton X-100 is used at a final concentration of 0.25% in enzyme assays to solubilize proteins and enzymes.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used at a final concentration of 0.25% in enzyme assays to solubilize proteins and enzymes.
mercaptoethanol,Mercaptoethanol is included at a final concentration of 1 mM in enzyme assays to maintain reducing conditions.,Entity: mercaptoethanol. SMILES: CC(O)S. Mercaptoethanol is included at a final concentration of 1 mM in enzyme assays to maintain reducing conditions.
4-Aminobutyrat,4-Aminobutyrat is synthesized from L-glutamate with the aid of the highly specific enzyme glutamate decarboxylase.,Entity: 4-Aminobutyrat. SMILES: NCCCC(=O)[O-]. 4-Aminobutyrat is synthesized from L-glutamate with the aid of the highly specific enzyme glutamate decarboxylase.
4-Aminobutyrat,4-Aminobutyrat is a closely related potential neurotransmitter in the central nervous system to L-glutamate.,Entity: 4-Aminobutyrat. SMILES: NCCCC(=O)[O-]. 4-Aminobutyrat is a closely related potential neurotransmitter in the central nervous system to L-glutamate.
L-Glutamat,L-Glutamat is a closely related potential neurotransmitter in the central nervous system to 4-Aminobutyrat.,Entity: L-Glutamat. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-Glutamat is a closely related potential neurotransmitter in the central nervous system to 4-Aminobutyrat.
L-Glutamat,Glial cells may be involved in the uptake of labelled L-glutamate.,Entity: L-Glutamat. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glial cells may be involved in the uptake of labelled L-glutamate.
4-aminobutyrate,"In cortex slices, approximately 58% of [3H]4-aminobutyrate is found in the cytoplasmic and membrane fragment zone (Peak 1), which also has the highest relative specific concentration of 4-aminobutyrate.","Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. In cortex slices, approximately 58% of [3H]4-aminobutyrate is found in the cytoplasmic and membrane fragment zone (Peak 1), which also has the highest relative specific concentration of 4-aminobutyrate."
4-aminobutyrate,"In nuclear-free cortex homogenate fractions, 4-aminobutyrate shows higher relative specific concentration in synaptosome-containing peaks compared to other fractions.","Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. In nuclear-free cortex homogenate fractions, 4-aminobutyrate shows higher relative specific concentration in synaptosome-containing peaks compared to other fractions."
L-glutamate,"In cortex slices, approximately 73% of [3H]L-glutamate is found in the cytoplasmic and membrane fragment zone (Peak 1), which also has the highest relative specific concentration of L-glutamate.","Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. In cortex slices, approximately 73% of [3H]L-glutamate is found in the cytoplasmic and membrane fragment zone (Peak 1), which also has the highest relative specific concentration of L-glutamate."
L-glutamate,"In nuclear-free cortex homogenate fractions, L-glutamate shows higher relative specific concentration in synaptosome-containing peaks compared to other fractions.","Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. In nuclear-free cortex homogenate fractions, L-glutamate shows higher relative specific concentration in synaptosome-containing peaks compared to other fractions."
L-glutamate,"L-glutamate is a metabolically related potential neurotransmitter that can be accumulated by slightly different sub-populations of synaptosomes, though with significant overlap in size.","Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate is a metabolically related potential neurotransmitter that can be accumulated by slightly different sub-populations of synaptosomes, though with significant overlap in size."
4-aminobutyrate,"4-aminobutyrate is a metabolically related potential neurotransmitter that can be accumulated by slightly different sub-populations of synaptosomes, though with significant overlap in size.","Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. 4-aminobutyrate is a metabolically related potential neurotransmitter that can be accumulated by slightly different sub-populations of synaptosomes, though with significant overlap in size."
L-glutamate,"In cortex slices, the major part of L-glutamate taken up (73%) is found in the cytoplasmic fraction, which also contains glial cytoplasm.","Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. In cortex slices, the major part of L-glutamate taken up (73%) is found in the cytoplasmic fraction, which also contains glial cytoplasm."
L-glutamate,Glial cells possess high-affinity transport mechanisms for L-glutamate.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glial cells possess high-affinity transport mechanisms for L-glutamate.
4-aminobutyrate,"In cortex slices, the major part of 4-aminobutyrate taken up (58%) is found in the cytoplasmic fraction, which also contains glial cytoplasm.","Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. In cortex slices, the major part of 4-aminobutyrate taken up (58%) is found in the cytoplasmic fraction, which also contains glial cytoplasm."
4-aminobutyrate,4-aminobutyrate is a potential neurotransmitter that is metabolically linked to glutamate via the enzyme glutamate decarboxylase.,Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. 4-aminobutyrate is a potential neurotransmitter that is metabolically linked to glutamate via the enzyme glutamate decarboxylase.
glutamate,Glutamate is a potential neurotransmitter that is metabolically linked to 4-aminobutyrate through the enzyme glutamate decarboxylase.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate is a potential neurotransmitter that is metabolically linked to 4-aminobutyrate through the enzyme glutamate decarboxylase.
Triton X-100,Triton X-100 is used to solubilize occluded lactate dehydrogenase from membrane-bound or particulate forms in enzyme activity assays.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used to solubilize occluded lactate dehydrogenase from membrane-bound or particulate forms in enzyme activity assays.
L-glutamate,L-glutamate accumulates in specific types of nerve endings that differ in membrane properties.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate accumulates in specific types of nerve endings that differ in membrane properties.
4-aminobutyrate,4-aminobutyrate accumulates in specific types of nerve endings that differ in membrane properties.,Entity: 4-aminobutyrate. SMILES: NCCCC(=O)O. 4-aminobutyrate accumulates in specific types of nerve endings that differ in membrane properties.
L-glutamate,"Recentrifugation of synaptosomal fractions does not result in further purification of synaptosomes specific for L-glutamate, as L-glutamate content remains unchanged after recentrifugation.","Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Recentrifugation of synaptosomal fractions does not result in further purification of synaptosomes specific for L-glutamate, as L-glutamate content remains unchanged after recentrifugation."
4-aminobutyrate,"Recentrifugation of synaptosomal fractions does not result in further purification of synaptosomes specific for 4-aminobutyrate, as 4-aminobutyrate concentration remains unchanged after recentrifugation.","Entity: 4-aminobutyrate. SMILES: NCCCC(=O)[O-]. Recentrifugation of synaptosomal fractions does not result in further purification of synaptosomes specific for 4-aminobutyrate, as 4-aminobutyrate concentration remains unchanged after recentrifugation."
Saccharose,Saccharose is used to create discontinuous density gradients for zonal centrifugation to separate synaptosomes based on their buoyant density.,Entity: Saccharose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Saccharose is used to create discontinuous density gradients for zonal centrifugation to separate synaptosomes based on their buoyant density.
L-glutamate,L-glutamate can be used to label glutamate-containing synaptosomes for subsequent separation from 4-aminobutyrate-containing synaptosomes by zonal centrifugation on a sucrose density gradient.,Entity: L-glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. L-glutamate can be used to label glutamate-containing synaptosomes for subsequent separation from 4-aminobutyrate-containing synaptosomes by zonal centrifugation on a sucrose density gradient.
4-Aminobutyrate,4-Aminobutyrate can be used to label 4-aminobutyrate-containing synaptosomes for separation from glutamate-containing synaptosomes by zonal centrifugation on a sucrose density gradient.,Entity: 4-Aminobutyrate. SMILES: NCCCC(=O)[O-]. 4-Aminobutyrate can be used to label 4-aminobutyrate-containing synaptosomes for separation from glutamate-containing synaptosomes by zonal centrifugation on a sucrose density gradient.
methylcellosolve,Methylcellosolve is used as a component (400 ml) in the preparation of scintillator cocktails for liquid scintillation counting assays.,Entity: methylcellosolve. SMILES: C1COCCO1. Methylcellosolve is used as a component (400 ml) in the preparation of scintillator cocktails for liquid scintillation counting assays.
POPOP,POPOP (100 mg) is included as a component in the scintillator mixture for liquid scintillation counting.,Entity: POPOP. SMILES: c1ccc(-c2cnc(-c3ccc(-c4ncc(-c5ccccc5)o4)cc3)o2)cc1. POPOP (100 mg) is included as a component in the scintillator mixture for liquid scintillation counting.
toluene,Toluene (1000 ml) serves as the solvent in the formulation of scintillator cocktails for liquid scintillation counting.,Entity: toluene. SMILES: Cc1ccccc1. Toluene (1000 ml) serves as the solvent in the formulation of scintillator cocktails for liquid scintillation counting.
PPO,PPO (4.0 g) is a component of the scintillator mixture used in liquid scintillation counting assays.,Entity: PPO. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. PPO (4.0 g) is a component of the scintillator mixture used in liquid scintillation counting assays.
glutamate decarboxylase,"Glutamate decarboxylase is an enzyme that metabolically links 4-aminobutyrate and L-glutamate, which are both potential neurotransmitters.","Entity: glutamate decarboxylase. Glutamate decarboxylase is an enzyme that metabolically links 4-aminobutyrate and L-glutamate, which are both potential neurotransmitters."
KCN,"KCN inhibits the saturable uptake of cholic acid by rat hepatocytes, indicating its effect on an energy-dependent carrier-mediated transport process.","Entity: KCN. SMILES: [C-]#N.[K+]. KCN inhibits the saturable uptake of cholic acid by rat hepatocytes, indicating its effect on an energy-dependent carrier-mediated transport process."
Cholsäure,"Cholsäure is taken up by rat liver hepatocytes via both cellular uptake and adsorption, with a cell-associated adsorption capacity of 24 nmol per mg cell protein and an association constant of 0.59 x 10^3 M^-1.","Entity: Cholsäure. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Cholsäure is taken up by rat liver hepatocytes via both cellular uptake and adsorption, with a cell-associated adsorption capacity of 24 nmol per mg cell protein and an association constant of 0.59 x 10^3 M^-1."
Cholsäure,"Cholsäure is taken up by rat liver hepatocytes in a concentration-dependent, diffusion-controlled manner, with a diffusion coefficient of 1.76 x 10^5 min^-1 x (mg protein)^-1.","Entity: Cholsäure. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Cholsäure is taken up by rat liver hepatocytes in a concentration-dependent, diffusion-controlled manner, with a diffusion coefficient of 1.76 x 10^5 min^-1 x (mg protein)^-1."
Cholsäure,"At 37°C, the apparent Michaelis-Menten (A°m) value for cholsäure uptake in rat liver hepatocytes is 61 nmol/min/mg protein and the inhibition constant (I) is 0.8 nmol/min/mg protein.","Entity: Cholsäure. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. At 37°C, the apparent Michaelis-Menten (A°m) value for cholsäure uptake in rat liver hepatocytes is 61 nmol/min/mg protein and the inhibition constant (I) is 0.8 nmol/min/mg protein."
Cholsäure,"The sätturable cholsäure uptake process in rat liver hepatocytes is temperature-dependent, with an activation energy of 13 kcal/mol (5.44 l×O4 J).","Entity: Cholsäure. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. The sätturable cholsäure uptake process in rat liver hepatocytes is temperature-dependent, with an activation energy of 13 kcal/mol (5.44 l×O4 J)."
Cholsäure,Cholsäure uptake in rat liver hepatocytes is inhibited by oligomycin and KCN.,Entity: Cholsäure. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Cholsäure uptake in rat liver hepatocytes is inhibited by oligomycin and KCN.
Taurocholsäure,Taurocholsäure can be cotransported with cholsäure across rat liver hepatocytes.,Entity: Taurocholsäure. SMILES: C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Taurocholsäure can be cotransported with cholsäure across rat liver hepatocytes.
KCN,KCN inhibits the uptake of cholsäure by rat liver hepatocytes.,Entity: KCN. SMILES: [C-]#N.[K+]. KCN inhibits the uptake of cholsäure by rat liver hepatocytes.
ouabain,Ouabain has been reported to inhibit taurocholic acid uptake in isolated rat hepatocytes.,Entity: ouabain. SMILES: C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O. Ouabain has been reported to inhibit taurocholic acid uptake in isolated rat hepatocytes.
cholic acid,Cholic acid uptake in isolated rat hepatocytes is energy-dependent.,Entity: cholic acid. SMILES: C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Cholic acid uptake in isolated rat hepatocytes is energy-dependent.
taurocholic acid,Taurocholic acid uptake in isolated rat hepatocytes is inhibited by ouabain.,Entity: taurocholic acid. SMILES: C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C. Taurocholic acid uptake in isolated rat hepatocytes is inhibited by ouabain.
KCN,"KCN significantly inhibits the uptake rate of bile acids at 37 °C, indicating that bile acid uptake is energy-dependent.","Entity: KCN. SMILES: [C-]#N.[K+]. KCN significantly inhibits the uptake rate of bile acids at 37 °C, indicating that bile acid uptake is energy-dependent."
ouabain,Ouabain does not inhibit cholic acid uptake under the described experimental conditions.,Entity: ouabain. SMILES: C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O. Ouabain does not inhibit cholic acid uptake under the described experimental conditions.
trypan blue,"Trypan blue is used to determine cell viability by exclusion assay, with typical viability ranges for hepatocytes being 85–95%.","Entity: trypan blue. SMILES: Cc1cc(-c2ccc(N=Nc3c(S(=O)(=O)[O-])cc4cc(S(=O)(=O)[O-])cc(N)c4c3O)c(C)c2)ccc1N=Nc1c(S(=O)(=O)[O-])cc2cc(S(=O)(=O)[O-])cc(N)c2c1O.[Na+].[Na+].[Na+].[Na+]. Trypan blue is used to determine cell viability by exclusion assay, with typical viability ranges for hepatocytes being 85–95%."
hydrogen carbonate,"Hydrogen carbonate is commonly used as a buffering agent in cell suspension buffers, but in this protocol, it was replaced by 10 mM sodium phosphate in modified Hanks buffer (pH 7.4).","Entity: hydrogen carbonate. SMILES: O=C([O-])O. Hydrogen carbonate is commonly used as a buffering agent in cell suspension buffers, but in this protocol, it was replaced by 10 mM sodium phosphate in modified Hanks buffer (pH 7.4)."
sodium phosphate,Sodium phosphate is used as a buffering agent in modified Hanks buffer (pH 7.4) to replace hydrogen carbonate in hepatocyte suspension.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used as a buffering agent in modified Hanks buffer (pH 7.4) to replace hydrogen carbonate in hepatocyte suspension.
mannose,Mannose is a sugar component covalently linked to human fibrin and fibrinogen.,Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose is a sugar component covalently linked to human fibrin and fibrinogen.
galactose,Galactose is a sugar component covalently linked to human fibrin and fibrinogen.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose is a sugar component covalently linked to human fibrin and fibrinogen.
glucosamine,Glucosamine is a sugar component covalently linked to human fibrin and fibrinogen.,Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine is a sugar component covalently linked to human fibrin and fibrinogen.
glucosamine,Glucosamine can be quantified in peptide samples using hydrolysis with 4M methanesulfonic acid and 0.5% indolepropionic acid at 110°C for 24 hours.,Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine can be quantified in peptide samples using hydrolysis with 4M methanesulfonic acid and 0.5% indolepropionic acid at 110°C for 24 hours.
methanesulfonic acid,Methanesulfonic acid is used as a hydrolyzing agent for peptide samples in amino acid analysis.,Entity: methanesulfonic acid. SMILES: CS(=O)(=O)O. Methanesulfonic acid is used as a hydrolyzing agent for peptide samples in amino acid analysis.
indolepropionic acid,Indolepropionic acid is used as a scavenger in peptide hydrolysis to facilitate amino acid analysis.,Entity: indolepropionic acid. SMILES: O=C(O)CCc1cc2ccccc2[nH]1. Indolepropionic acid is used as a scavenger in peptide hydrolysis to facilitate amino acid analysis.
cyanogen bromide,"Cyanogen bromide is used to cleave peptides at methionine residues, enabling the release of C-terminal fragments for sequence analysis.","Entity: cyanogen bromide. SMILES: N#CBr. Cyanogen bromide is used to cleave peptides at methionine residues, enabling the release of C-terminal fragments for sequence analysis."
glucosamine,Glucosamine is a residue found in the C-terminal part of tryptic glycopeptides and can be detected by amino acid analysis after hydrolysis.,Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine is a residue found in the C-terminal part of tryptic glycopeptides and can be detected by amino acid analysis after hydrolysis.
glutamic acid,Glutamic acid is present in the C-terminal part of tryptic glycopeptides and can be identified by manual V-terminal sequence analysis using phenylthiohydantoins.,Entity: glutamic acid. SMILES: N[C@@H](CCC(=O)O)C(=O)O. Glutamic acid is present in the C-terminal part of tryptic glycopeptides and can be identified by manual V-terminal sequence analysis using phenylthiohydantoins.
arginine,Arginine is a residue in the C-terminal part of tryptic glycopeptides and can be identified by manual V-terminal sequence analysis.,Entity: arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. Arginine is a residue in the C-terminal part of tryptic glycopeptides and can be identified by manual V-terminal sequence analysis.
aspartic acid,Aspartic acid is present in the C-terminal part of tryptic glycopeptides and can be identified by amino acid analysis after hydrolysis with hydrochloric acid at 80°C.,Entity: aspartic acid. SMILES: N[C@@H](CC(=O)O)C(=O)O. Aspartic acid is present in the C-terminal part of tryptic glycopeptides and can be identified by amino acid analysis after hydrolysis with hydrochloric acid at 80°C.
threonine,"Threonine is an additional residue in the C-terminal part of the cyanogen bromide-cleaved β-chain glycopeptide compared to the tryptic fragment, and its presence is confirmed by sequence analysis.","Entity: threonine. SMILES: C[C@@H](O)[C@H](N)C(=O)O. Threonine is an additional residue in the C-terminal part of the cyanogen bromide-cleaved β-chain glycopeptide compared to the tryptic fragment, and its presence is confirmed by sequence analysis."
glycine,Glycine is present in the C-terminal part of tryptic glycopeptides and can be identified by manual V-terminal sequence analysis using phenylthiohydantoins.,Entity: glycine. SMILES: NCC(=O)O. Glycine is present in the C-terminal part of tryptic glycopeptides and can be identified by manual V-terminal sequence analysis using phenylthiohydantoins.
ethyl acetate,Ethyl acetate is used to extract the C-terminal dipeptide from dry peptide mixtures after derivatization with phenylthiocarbamoylated amino acids.,Entity: ethyl acetate. SMILES: CCOC(C)=O. Ethyl acetate is used to extract the C-terminal dipeptide from dry peptide mixtures after derivatization with phenylthiocarbamoylated amino acids.
formic acid,"Formic acid is used as a solvent in both the cyanogen bromide cleavage and glycopeptide sample preparation procedures, with concentrations ranging from 70% to 0.04% in the described protocols.","Entity: formic acid. SMILES: O=CO. Formic acid is used as a solvent in both the cyanogen bromide cleavage and glycopeptide sample preparation procedures, with concentrations ranging from 70% to 0.04% in the described protocols."
trifluoroacetic acid,"Trifluoroacetic acid is used as the mobile phase in the Sephadex G-50 superfine column chromatography for glycopeptide purification, at a concentration of 0.04%.","Entity: trifluoroacetic acid. SMILES: O=C(O)C(F)(F)F. Trifluoroacetic acid is used as the mobile phase in the Sephadex G-50 superfine column chromatography for glycopeptide purification, at a concentration of 0.04%."
water,Water is used to dilute and reduce the volume of peptide mixtures after cyanogen bromide cleavage or glycopeptide treatment prior to column chromatography.,Entity: water. SMILES: O. Water is used to dilute and reduce the volume of peptide mixtures after cyanogen bromide cleavage or glycopeptide treatment prior to column chromatography.
cyanogen bromide,"Cyanogen bromide is used as a reagent for cleaving 0-chains from peptides, with protocols involving 1.6 g in 5 ml of 70% formic acid for 15 hours or 24 mg in 0.3 ml 70% formic acid for 8 hours.","Entity: cyanogen bromide. SMILES: N#CBr. Cyanogen bromide is used as a reagent for cleaving 0-chains from peptides, with protocols involving 1.6 g in 5 ml of 70% formic acid for 15 hours or 24 mg in 0.3 ml 70% formic acid for 8 hours."
galactose,"Galactose is a neutral sugar present in human fibrin-chain, as determined by gas chromatographic analysis.","Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose is a neutral sugar present in human fibrin-chain, as determined by gas chromatographic analysis."
mannose,"Mannose is a neutral sugar present in human fibrin-chain, as determined by gas chromatographic analysis.","Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose is a neutral sugar present in human fibrin-chain, as determined by gas chromatographic analysis."
glucosamine,"Glucosamine is an amino sugar present in human fibrin-chain, with 5.8 residues per 10 mg of protein as determined by amino acid analysis.","Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. Glucosamine is an amino sugar present in human fibrin-chain, with 5.8 residues per 10 mg of protein as determined by amino acid analysis."
neuraminic acid,Neuraminic acid can be detected and quantified in human fibrin-chain by colorimetric analysis.,Entity: neuraminic acid. SMILES: N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(O)(C(=O)O)C[C@@H]1O. Neuraminic acid can be detected and quantified in human fibrin-chain by colorimetric analysis.
glucosamine,"In the glycopeptide derived from the ß-chain, 3.2 residues of glucosamine correspond to the carbohydrate moiety.","Entity: glucosamine. SMILES: N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O. In the glycopeptide derived from the ß-chain, 3.2 residues of glucosamine correspond to the carbohydrate moiety."
galactose,"In the glycopeptide derived from the ß-chain, 1.8 residues of galactose correspond to the carbohydrate moiety.","Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. In the glycopeptide derived from the ß-chain, 1.8 residues of galactose correspond to the carbohydrate moiety."
neuraminic acid,"In the glycopeptide derived from the ß-chain, 1.2 residues of neuraminic acid correspond to the carbohydrate moiety.","Entity: neuraminic acid. SMILES: N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(O)(C(=O)O)C[C@@H]1O. In the glycopeptide derived from the ß-chain, 1.2 residues of neuraminic acid correspond to the carbohydrate moiety."
mannose,"In the glycopeptide derived from the ß-chain, 2.0 residues of mannose correspond to the carbohydrate moiety.","Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In the glycopeptide derived from the ß-chain, 2.0 residues of mannose correspond to the carbohydrate moiety."
Cyanogen bromide,"Cyanogen bromide is used to split IgG and Fc fragments, as well as partially reduced and alkylated F(ab)-fragments, to generate products that can be characterized by amino acid analysis and end group determination.","Entity: Cyanogen bromide. SMILES: N#CBr. Cyanogen bromide is used to split IgG and Fc fragments, as well as partially reduced and alkylated F(ab)-fragments, to generate products that can be characterized by amino acid analysis and end group determination."
vinorelbine tartrate,"Vinorelbine tartrate is administered as a weekly outpatient intravenous infusion at 30 mg/m2 and is used as a palliative agent in women with advanced epithelial ovarian cancer, including those with platinum-resistant or platinum-sensitive disease.","Entity: vinorelbine tartrate. SMILES: CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)[C@H](O)[C@@H](O)C(=O)O.O=C(O)[C@H](O)[C@@H](O)C(=O)O. Vinorelbine tartrate is administered as a weekly outpatient intravenous infusion at 30 mg/m2 and is used as a palliative agent in women with advanced epithelial ovarian cancer, including those with platinum-resistant or platinum-sensitive disease."
vinorelbine tartrate,"In a phase II trial, vinorelbine tartrate produced an objective response rate of 29% (11 of 38 patients) with a median duration of response of 19 weeks in women with persistent or recurrent advanced epithelial ovarian cancer who had received one prior platinum-based chemotherapy regimen.","Entity: vinorelbine tartrate. SMILES: CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)[C@H](O)[C@@H](O)C(=O)O.O=C(O)[C@H](O)[C@@H](O)C(=O)O. In a phase II trial, vinorelbine tartrate produced an objective response rate of 29% (11 of 38 patients) with a median duration of response of 19 weeks in women with persistent or recurrent advanced epithelial ovarian cancer who had received one prior platinum-based chemotherapy regimen."
vinorelbine tartrate,"The most common nonhematologic toxicities associated with vinorelbine tartrate in this patient population were nausea (34% of grade 3 or less), constipation (29% of grade 3 or less), and asthenia (24% of grade 2 or less).","Entity: vinorelbine tartrate. SMILES: CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)[C@H](O)[C@@H](O)C(=O)O.O=C(O)[C@H](O)[C@@H](O)C(=O)O. The most common nonhematologic toxicities associated with vinorelbine tartrate in this patient population were nausea (34% of grade 3 or less), constipation (29% of grade 3 or less), and asthenia (24% of grade 2 or less)."
vinorelbine tartrate,"Dose-limiting granulocytopenia occurred in 62% (23 of 37) of patients treated with vinorelbine tartrate, but this toxicity was manageable.","Entity: vinorelbine tartrate. SMILES: CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)[C@H](O)[C@@H](O)C(=O)O.O=C(O)[C@H](O)[C@@H](O)C(=O)O. Dose-limiting granulocytopenia occurred in 62% (23 of 37) of patients treated with vinorelbine tartrate, but this toxicity was manageable."
"3-[4,5-dimethyl-2-thiazolyl]-2, 5-diphenyl-2H-tetrazolium bromide","3-[4,5-dimethyl-2-thiazolyl]-2, 5-diphenyl-2H-tetrazolium bromide (MTT) is used as an assay to determine cell viability and assess drug resistance in vitro.","Entity: 3-[4,5-dimethyl-2-thiazolyl]-2, 5-diphenyl-2H-tetrazolium bromide. SMILES: Cc1nc(N2N=C(c3ccccc3)[NH2+]N2c2ccccc2)sc1C.[Br-]. 3-[4,5-dimethyl-2-thiazolyl]-2, 5-diphenyl-2H-tetrazolium bromide (MTT) is used as an assay to determine cell viability and assess drug resistance in vitro."
prolactin,"Prolactin treatment of mature virgin mammary epithelial cells induces a developmental block similar to that observed in primiparous mice, affecting the ability to synthesize casein and alpha-lactalbumin.","Entity: prolactin. Prolactin treatment of mature virgin mammary epithelial cells induces a developmental block similar to that observed in primiparous mice, affecting the ability to synthesize casein and alpha-lactalbumin."
alpha-lactalbumin,"In mammary epithelial cells from mature virgin mice, alpha-lactalbumin synthesis is dependent on the cell cycle, whereas in primiparous mice, cells can synthesize alpha-lactalbumin without traversing the cell cycle.","Entity: alpha-lactalbumin. In mammary epithelial cells from mature virgin mice, alpha-lactalbumin synthesis is dependent on the cell cycle, whereas in primiparous mice, cells can synthesize alpha-lactalbumin without traversing the cell cycle."
dodecyl sulfate,"Dodecyl sulfate can be used as a component of media to dissolve cholera toxin/sialoglycolipid precipitates, but heating to 100°C is required to disrupt ligand-toxin complexes formed in dodecyl sulfate solutions.","Entity: dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-]. Dodecyl sulfate can be used as a component of media to dissolve cholera toxin/sialoglycolipid precipitates, but heating to 100°C is required to disrupt ligand-toxin complexes formed in dodecyl sulfate solutions."
sodium dodecylsulfate,"Sodium dodecylsulfate is a detergent that can disrupt complexes between cholera toxin and gangliosides, allowing the toxin to enter polyacrylamide gels during electrophoresis.","Entity: sodium dodecylsulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecylsulfate is a detergent that can disrupt complexes between cholera toxin and gangliosides, allowing the toxin to enter polyacrylamide gels during electrophoresis."
monosialo-gangliotetraosyl-ceramide,"Monosialo-gangliotetraosyl-ceramide is a ganglioside that serves as the membrane receptor for the B-protein of cholera toxin, mediating specific binding to the cell surface.","Entity: monosialo-gangliotetraosyl-ceramide. SMILES: CCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O[C@@H]4O[C@H](CO)[C@H](O)[C@H](O)[C@H]4O)[C@H]3NC(C)=O)[C@H](O[C@]3(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O3)[C@H]2O)[C@H](O)[C@H]1O)NC(=O)CCCCCCCCCCCCCCCCC. Monosialo-gangliotetraosyl-ceramide is a ganglioside that serves as the membrane receptor for the B-protein of cholera toxin, mediating specific binding to the cell surface."
Natrium dodecylsulfat,Natrium dodecylsulfat can inhibit the effects of choleratoxin on the B-protein by preventing reassembly of protein subunits.,Entity: Natrium dodecylsulfat. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Natrium dodecylsulfat can inhibit the effects of choleratoxin on the B-protein by preventing reassembly of protein subunits.
Natrium dodecylsulfat,Sodium dodecylsulfate facilitates the degradation of the B-protein of cholera toxin into protein subunits.,Entity: Natrium dodecylsulfat. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecylsulfate facilitates the degradation of the B-protein of cholera toxin into protein subunits.
sodium dodecylsulfate,Sodium dodecylsulfate facilitates the degradation of the B-protein of cholera toxin into protein subunits.,Entity: sodium dodecylsulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecylsulfate facilitates the degradation of the B-protein of cholera toxin into protein subunits.
dodecylsulfate,"Dodecylsulfate is used in dodecylsulfate polyacrylamide gel electrophoresis to denature proteins, causing them to unfold and become more accessible to electrophoretic mobility changes.","Entity: dodecylsulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-]. Dodecylsulfate is used in dodecylsulfate polyacrylamide gel electrophoresis to denature proteins, causing them to unfold and become more accessible to electrophoretic mobility changes."
2-aminoerythritol,"2-aminoerythritol is a product formed from the sphingosine moiety of glycosphingolipids after ozonolysis, reduction, and hydrolysis, with a molar ratio of approximately 1:0.3 relative to 2-aminopropanediol.","Entity: 2-aminoerythritol. SMILES: N[C@](O)(CO)[C@H](O)CO. 2-aminoerythritol is a product formed from the sphingosine moiety of glycosphingolipids after ozonolysis, reduction, and hydrolysis, with a molar ratio of approximately 1:0.3 relative to 2-aminopropanediol."
2-aminopropanediol,"2-aminopropanediol is a product derived from the sphingosine moiety of glycosphingolipids following ozonolysis, reduction, and hydrolysis, present in a molar ratio of approximately 0.3 relative to 2-aminoerythritol.","Entity: 2-aminopropanediol. SMILES: CC(N)C(O)O. 2-aminopropanediol is a product derived from the sphingosine moiety of glycosphingolipids following ozonolysis, reduction, and hydrolysis, present in a molar ratio of approximately 0.3 relative to 2-aminoerythritol."
lignoceric acid,Gangliosidoides carrying fatty acyl moieties of 16 carbon atoms (lignoceroyl-) can form visible white precipitates with cholera toxin when added at molar excess of two or more.,Entity: lignoceric acid. SMILES: CCCCCCCCCCCCCCCCCCCCCCCC(=O)O. Gangliosidoides carrying fatty acyl moieties of 16 carbon atoms (lignoceroyl-) can form visible white precipitates with cholera toxin when added at molar excess of two or more.
ammonia,Ammonia can be used for reductamination of gangliosidoides to form derivatives that do not induce precipitation with cholera toxin.,Entity: ammonia. SMILES: N. Ammonia can be used for reductamination of gangliosidoides to form derivatives that do not induce precipitation with cholera toxin.
hydrochloric acid,The precipitates formed from ganglioside and cholera toxin can be dissolved in cold O.N hydrochloric acid.,Entity: hydrochloric acid. SMILES: Cl. The precipitates formed from ganglioside and cholera toxin can be dissolved in cold O.N hydrochloric acid.
sphingosine,"Ozonolysis of sphingosine can yield a 4-carbon unit as indicated by molecular ions at m/e 384 and 398, and by the presence of m/e 1632 and 1662.","Entity: sphingosine. SMILES: CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CO. Ozonolysis of sphingosine can yield a 4-carbon unit as indicated by molecular ions at m/e 384 and 398, and by the presence of m/e 1632 and 1662."
stearic acid,"Retained stearic acid in modified gangliosides is indicated by abundant ions at m/e 1574, containing the complete saccharide and the stearyl residue, as well as by specific fatty acid ions at m/e 296 and 310.","Entity: stearic acid. SMILES: CCCCCCCCCCCCCCCCCC(=O)O. Retained stearic acid in modified gangliosides is indicated by abundant ions at m/e 1574, containing the complete saccharide and the stearyl residue, as well as by specific fatty acid ions at m/e 296 and 310."
histidine,The imidazol function of histidine can be selectively acylated using 1-adamantyl fluoroformate.,Entity: histidine. SMILES: N[C@@H](Cc1c[nH]cn1)C(=O)O. The imidazol function of histidine can be selectively acylated using 1-adamantyl fluoroformate.
1-Adamantyl fluoroformate,1-Adamantyl fluoroformate is a crystalline and stable reagent that reacts with amino acids to produce 1-adamantyloxycarbonyl derivatives in high yields.,Entity: 1-Adamantyl fluoroformate. SMILES: O=C(F)OC12CC3CC(CC(C3)C1)C2. 1-Adamantyl fluoroformate is a crystalline and stable reagent that reacts with amino acids to produce 1-adamantyloxycarbonyl derivatives in high yields.
1-Adamantyl fluoroformate,1-Adamantyl fluoroformate is ideally reactive for the acylation of the imidazol function of histidine and histidine-containing peptides.,Entity: 1-Adamantyl fluoroformate. SMILES: O=C(F)OC12CC3CC(CC(C3)C1)C2. 1-Adamantyl fluoroformate is ideally reactive for the acylation of the imidazol function of histidine and histidine-containing peptides.
fluorophosgene,Fluorophosgene is used as a reagent in the synthesis of 1-adamantyl fluoroformate from 1-adamantol.,Entity: fluorophosgene. SMILES: F[ClH]C(=O)Cl. Fluorophosgene is used as a reagent in the synthesis of 1-adamantyl fluoroformate from 1-adamantol.
nitric oxide,Nitric oxide is a universal intercellular messenger that potently dilates blood vessels (vasodilatory effect) and modulates gene expression in target cells.,Entity: nitric oxide. SMILES: [N]=O. Nitric oxide is a universal intercellular messenger that potently dilates blood vessels (vasodilatory effect) and modulates gene expression in target cells.
nitric oxide,Nitric oxide is involved in the killing of microorganisms and tumor cells by activated macrophages.,Entity: nitric oxide. SMILES: [N]=O. Nitric oxide is involved in the killing of microorganisms and tumor cells by activated macrophages.
nitric oxide,"Nitric oxide functions as a novel, unconventional type of neurotransmitter.","Entity: nitric oxide. SMILES: [N]=O. Nitric oxide functions as a novel, unconventional type of neurotransmitter."
Nitric oxide,Nitric oxide acts as a diffusible universal messenger that plays a crucial role in the pathogenesis of inflammatory and autoimmune diseases.,Entity: Nitric oxide. SMILES: [N]=O. Nitric oxide acts as a diffusible universal messenger that plays a crucial role in the pathogenesis of inflammatory and autoimmune diseases.
Nitric oxide,"Nitric oxide can activate both stress-activated (p38-MAPK) and mitogen-activated (ERK p44-MAPK) protein kinase cascades in glomerular mesangial cells, as shown by phosphorylation of ATF2 and cytosolic phospholipase A2, respectively.","Entity: Nitric oxide. SMILES: [N]=O. Nitric oxide can activate both stress-activated (p38-MAPK) and mitogen-activated (ERK p44-MAPK) protein kinase cascades in glomerular mesangial cells, as shown by phosphorylation of ATF2 and cytosolic phospholipase A2, respectively."
p44-MAPK,"Both MAHMA-NO and spermine-NO activate the classical extracellular signal-regulated kinase (ERK) p44-MAPK cascade in mesangial cells, as shown by phosphorylation of the specific substrate cytosolic phospholipase A2.","Entity: p44-MAPK. Both MAHMA-NO and spermine-NO activate the classical extracellular signal-regulated kinase (ERK) p44-MAPK cascade in mesangial cells, as shown by phosphorylation of the specific substrate cytosolic phospholipase A2."
interleukin-1beta,Interleukin-1beta is a well-known activator of the p8-MAPK pathway in mesangial cells.,Entity: interleukin-1beta. Interleukin-1beta is a well-known activator of the p8-MAPK pathway in mesangial cells.
activator of transcription factor-2,Phosphorylation of the activator of transcription factor-2 (ATF2) serves as a marker for activation of the p8-MAPK cascade in mesangial cells upon exposure to nitric oxide-releasing compounds.,Entity: activator of transcription factor-2. Phosphorylation of the activator of transcription factor-2 (ATF2) serves as a marker for activation of the p8-MAPK cascade in mesangial cells upon exposure to nitric oxide-releasing compounds.
stress-activated protein kinase,Nitric oxide activates the stress-activated protein kinase (SAPK) cascade in mesangial cells.,Entity: stress-activated protein kinase. Nitric oxide activates the stress-activated protein kinase (SAPK) cascade in mesangial cells.
cytosolic phospholipase A2,Phosphorylation of cytosolic phospholipase A2 is used as a measure of p44-MAPK activation in mesangial cells.,Entity: cytosolic phospholipase A2. Phosphorylation of cytosolic phospholipase A2 is used as a measure of p44-MAPK activation in mesangial cells.
extracellular signal-regulated kinase,The classical extracellular signal-regulated kinase (ERK) p44-MAPK cascade is activated in mesangial cells by exposure to nitric oxide-releasing compounds.,Entity: extracellular signal-regulated kinase. The classical extracellular signal-regulated kinase (ERK) p44-MAPK cascade is activated in mesangial cells by exposure to nitric oxide-releasing compounds.
p44-MAPK,Mesangial cells exposed to NO donors exhibit a second delayed peak of p44-MAPK activation after 4–24 hours of stimulation.,Entity: p44-MAPK. Mesangial cells exposed to NO donors exhibit a second delayed peak of p44-MAPK activation after 4–24 hours of stimulation.
p44-MAPK,A 10-minute stimulation with MAHMA-NO or spermine-NO causes rapid activation of p44-MAPK in mesangial cells.,Entity: p44-MAPK. A 10-minute stimulation with MAHMA-NO or spermine-NO causes rapid activation of p44-MAPK in mesangial cells.
butyl-dicarbonate,"Di-tert.-butyl-dicarbonate is an effective reagent for tert.-butyloxycarbonylating amino acids and their derivatives, offering a good balance of reaction rate and procedural simplicity.","Entity: butyl-dicarbonate. SMILES: CCCCOC(=O)OC(=O)[O-]. Di-tert.-butyl-dicarbonate is an effective reagent for tert.-butyloxycarbonylating amino acids and their derivatives, offering a good balance of reaction rate and procedural simplicity."
ammonia,"Ammonia is excreted in freshwater rainbow trout primarily via diffusion across the gill membrane, with ammonium loading directly stimulating unidirectional Na+ influx (JNain) without significantly affecting net acidic equivalent excretion.","Entity: ammonia. SMILES: N. Ammonia is excreted in freshwater rainbow trout primarily via diffusion across the gill membrane, with ammonium loading directly stimulating unidirectional Na+ influx (JNain) without significantly affecting net acidic equivalent excretion."
ammonia,Branchial ammonia excretion (JAmm) in freshwater rainbow trout is elevated approximately threefold by intravascular infusion with either 70 mmol l-1 (NH4)2SO4 or 140 mmol l-1 NH4HCO3 at a rate of approximately 400 micromol kg-1 h-1 for 24 hours.,Entity: ammonia. SMILES: N. Branchial ammonia excretion (JAmm) in freshwater rainbow trout is elevated approximately threefold by intravascular infusion with either 70 mmol l-1 (NH4)2SO4 or 140 mmol l-1 NH4HCO3 at a rate of approximately 400 micromol kg-1 h-1 for 24 hours.
ammonia,"In freshwater rainbow trout, both (NH4)2SO4 and NH4HCO3 infusions increase arterial plasma total [ammonia] and PNH3 by about threefold, while JAmm increases approximately threefold.","Entity: ammonia. SMILES: N. In freshwater rainbow trout, both (NH4)2SO4 and NH4HCO3 infusions increase arterial plasma total [ammonia] and PNH3 by about threefold, while JAmm increases approximately threefold."
fura-2,Fura-2 is a Ca2+-sensitive dye used in digital Ca2+-imaging experiments to monitor changes in intracellular Ca2+]i in biological cells.,Entity: fura-2. SMILES: Cc1ccc(N(CC(=O)O)CC(=O)O)c(OCCOc2cc3cc(-c4ncc(C(=O)O)o4)oc3cc2N(CC(=O)O)CC(=O)O)c1. Fura-2 is a Ca2+-sensitive dye used in digital Ca2+-imaging experiments to monitor changes in intracellular Ca2+]i in biological cells.
dopamine,"Dopamine stimulates salivary duct cells of Periplaneta americana by inducing a slow, dose-dependent, reversible elevation in intracellular Ca2+]i, rising from 48 ± 4 nmol/l to 311 ± 43 nmol/l within 200–300 s at 10⁻⁶ mol/l, in the presence of 10⁻⁴ mol/l La3+.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine stimulates salivary duct cells of Periplaneta americana by inducing a slow, dose-dependent, reversible elevation in intracellular Ca2+]i, rising from 48 ± 4 nmol/l to 311 ± 43 nmol/l within 200–300 s at 10⁻⁶ mol/l, in the presence of 10⁻⁴ mol/l La3+."
dopamine,"Dopamine at 10⁻⁶ mol/l depolarizes the basolateral membrane of salivary duct cells from -67 ± 1 mV to -41 ± 2 mV, an effect blocked by La3+ and abolished by reducing bath Na+ to 10 mmol/l.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine at 10⁻⁶ mol/l depolarizes the basolateral membrane of salivary duct cells from -67 ± 1 mV to -41 ± 2 mV, an effect blocked by La3+ and abolished by reducing bath Na+ to 10 mmol/l."
dopamine,Dopamine stimulates fluid secretion from the salivary glands of Periplaneta americana.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine stimulates fluid secretion from the salivary glands of Periplaneta americana.
serotonin,Serotonin does not affect intracellular Ca2+]i or basolateral membrane potential in salivary duct cells of Periplaneta americana.,Entity: serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin does not affect intracellular Ca2+]i or basolateral membrane potential in salivary duct cells of Periplaneta americana.
sterols,"Dietary sterols can be classified as suitable or unsuitable based on their effect on grasshopper feeding behavior, with unsuitable sterols detected post-ingestively and leading to reduced meal duration.","Entity: sterols. SMILES: OC1CCC2C(CCC3C4CCCC4CCC23)C1. Dietary sterols can be classified as suitable or unsuitable based on their effect on grasshopper feeding behavior, with unsuitable sterols detected post-ingestively and leading to reduced meal duration."
CAULIFLOWER,CAULIFLOWER is a meristem identity gene that prevents TERMINAL FLOWER 1 transcription in floral meristems on the periphery of the shoot apex.,Entity: CAULIFLOWER. CAULIFLOWER is a meristem identity gene that prevents TERMINAL FLOWER 1 transcription in floral meristems on the periphery of the shoot apex.
LEAFY,LEAFY is a meristem identity gene that prevents TERMINAL FLOWER 1 transcription in floral meristems on the periphery of the shoot apex.,Entity: LEAFY. LEAFY is a meristem identity gene that prevents TERMINAL FLOWER 1 transcription in floral meristems on the periphery of the shoot apex.
TERMINAL FLOWER 1,The expression pattern of TERMINAL FLOWER 1 in wild-type Arabidopsis depends on the relative timing of its upregulation compared to meristem identity genes.,Entity: TERMINAL FLOWER 1. The expression pattern of TERMINAL FLOWER 1 in wild-type Arabidopsis depends on the relative timing of its upregulation compared to meristem identity genes.
TERMINAL FLOWER 1,TERMINAL FLOWER 1 is an antagonistic gene to meristem identity genes and can inhibit the activity of meristem identity genes at the center of the shoot apex by delaying their upregulation and by preventing the meristem from responding to LEAFY or APETALA 1.,Entity: TERMINAL FLOWER 1. TERMINAL FLOWER 1 is an antagonistic gene to meristem identity genes and can inhibit the activity of meristem identity genes at the center of the shoot apex by delaying their upregulation and by preventing the meristem from responding to LEAFY or APETALA 1.
APETALA 1,"APETALA 1 is a meristem identity gene that can be inhibited by TERMINAL FLOWER 1, preventing the shoot apex meristem from responding to APETALA 1.","Entity: APETALA 1. APETALA 1 is a meristem identity gene that can be inhibited by TERMINAL FLOWER 1, preventing the shoot apex meristem from responding to APETALA 1."
LEAFY,LEAFY can inhibit the activity of meristem identity genes at the center of the shoot apex by delaying their upregulation.,Entity: LEAFY. LEAFY can inhibit the activity of meristem identity genes at the center of the shoot apex by delaying their upregulation.
Sex combs reduced,"In Porcellio scaber, Sex combs reduced (Scr) mRNA is present in the second maxillary segment and the first pair of thoracic legs in early embryos, while Scr protein accumulates only in the second maxillae. Later, high levels of SCR protein appear in the T1 legs, coinciding with the transformation of these appendages into maxillipeds.","Entity: Sex combs reduced. In Porcellio scaber, Sex combs reduced (Scr) mRNA is present in the second maxillary segment and the first pair of thoracic legs in early embryos, while Scr protein accumulates only in the second maxillae. Later, high levels of SCR protein appear in the T1 legs, coinciding with the transformation of these appendages into maxillipeds."
abdominal-A,Changes in the expression patterns of the homeotic gene abdominal-A have been implicated in the evolution of maxillipeds from anterior thoracic appendages in several crustacean lineages.,Entity: abdominal-A. Changes in the expression patterns of the homeotic gene abdominal-A have been implicated in the evolution of maxillipeds from anterior thoracic appendages in several crustacean lineages.
Bruno,Bruno is an RNA-binding protein that binds to discrete sites in the 3' untranslated region of the oskar mRNA and mediates translational repression of oskar mRNA prior to its localization at the posterior pole in Drosophila oocytes.,Entity: Bruno. Bruno is an RNA-binding protein that binds to discrete sites in the 3' untranslated region of the oskar mRNA and mediates translational repression of oskar mRNA prior to its localization at the posterior pole in Drosophila oocytes.
apontic,Apontic is an RNA-binding protein that specifically binds certain regions of the oskar mRNA 3' untranslated region and interacts physically with Bruno in Drosophila.,Entity: apontic. Apontic is an RNA-binding protein that specifically binds certain regions of the oskar mRNA 3' untranslated region and interacts physically with Bruno in Drosophila.
oskar,"Oskar mRNA is subject to translational repression prior to localization at the posterior pole in Drosophila oocytes, a process mediated in part by the Bruno protein and involving the RNA-binding protein Apontic.","Entity: oskar. Oskar mRNA is subject to translational repression prior to localization at the posterior pole in Drosophila oocytes, a process mediated in part by the Bruno protein and involving the RNA-binding protein Apontic."
endothelin-3,Endothelin-3 inhibits neuronal development in mouse enteric neural crest-derived cultures but promotes smooth muscle development in non-crest-derived cultures.,Entity: endothelin-3. Endothelin-3 inhibits neuronal development in mouse enteric neural crest-derived cultures but promotes smooth muscle development in non-crest-derived cultures.
endothelin-3,"Endothelin-3 is present in both crest- and non-crest-derived cells of the E11-13 mouse gut, but mRNA encoding preproendothelin-3 is detected only in non-crest-derived cells.","Entity: endothelin-3. Endothelin-3 is present in both crest- and non-crest-derived cells of the E11-13 mouse gut, but mRNA encoding preproendothelin-3 is detected only in non-crest-derived cells."
laminin alpha1,Laminin alpha1 is a smooth muscle-derived promoter of neuronal development whose transcription is inhibited by endothelin-3 in mouse enteric neural crest-derived cultures.,Entity: laminin alpha1. Laminin alpha1 is a smooth muscle-derived promoter of neuronal development whose transcription is inhibited by endothelin-3 in mouse enteric neural crest-derived cultures.
endothelin-3,Endothelin-3 fails to stimulate the incorporation of [3H]thymidine or bromodeoxyuridine in mouse enteric neural crest-derived cultures.,Entity: endothelin-3. Endothelin-3 fails to stimulate the incorporation of [3H]thymidine or bromodeoxyuridine in mouse enteric neural crest-derived cultures.
endothelin-3,"Endothelin-3/endothelin B normally prevents the premature differentiation of crest-derived precursors migrating to and within the fetal bowel, enabling the precursor population to persist long enough to colonize the bowel.","Entity: endothelin-3. Endothelin-3/endothelin B normally prevents the premature differentiation of crest-derived precursors migrating to and within the fetal bowel, enabling the precursor population to persist long enough to colonize the bowel."
endothelin-3,"Endothelin-3 inhibits the transcription of laminin alpha1, a smooth muscle-derived promoter of neuronal development, in mouse enteric neural crest-derived cultures.","Entity: endothelin-3. Endothelin-3 inhibits the transcription of laminin alpha1, a smooth muscle-derived promoter of neuronal development, in mouse enteric neural crest-derived cultures."
kismet,Kismet is a gene required for proper larval body segmentation in Drosophila.,Entity: kismet. Kismet is a gene required for proper larval body segmentation in Drosophila.
kismet,"Kismet is required for proper larval body segmentation, and loss of kismet function leads to homeotic transformations similar to those associated with loss-of-function mutations in the homeotic genes Sex combs reduced and Abdominal-B.","Entity: kismet. Kismet is required for proper larval body segmentation, and loss of kismet function leads to homeotic transformations similar to those associated with loss-of-function mutations in the homeotic genes Sex combs reduced and Abdominal-B."
Brahma,"Brahma is a member of the trithorax group of proteins, which are involved in chromatin remodeling and regulation of gene expression.","Entity: Brahma. Brahma is a member of the trithorax group of proteins, which are involved in chromatin remodeling and regulation of gene expression."
Polycomb,Polycomb is a repressor of homeotic genes.,Entity: Polycomb. Polycomb is a repressor of homeotic genes.
kismet,Kismet encodes several large nuclear proteins that are ubiquitously expressed along the anterior-posterior axis.,Entity: kismet. Kismet encodes several large nuclear proteins that are ubiquitously expressed along the anterior-posterior axis.
kismet,Loss of maternal kismet function causes segmentation defects similar to those caused by mutations in the pair-rule gene even-skipped.,Entity: kismet. Loss of maternal kismet function causes segmentation defects similar to those caused by mutations in the pair-rule gene even-skipped.
kismet,Kismet mutations suppress the Polycomb mutant phenotype by blocking ectopic transcription of homeotic genes.,Entity: kismet. Kismet mutations suppress the Polycomb mutant phenotype by blocking ectopic transcription of homeotic genes.
kismet,"The kismet gene encodes proteins that contain a domain conserved in the trithorax group protein Brahma and related chromatin-remodeling factors, indicating a role in altering chromatin structure to maintain spatially restricted patterns of homeotic gene transcription.","Entity: kismet. The kismet gene encodes proteins that contain a domain conserved in the trithorax group protein Brahma and related chromatin-remodeling factors, indicating a role in altering chromatin structure to maintain spatially restricted patterns of homeotic gene transcription."
Otx2,"Otx2 gene expression is repressed by FGF8 in chick embryos, playing a key role in the negative feedback loop regulating midbrain and anterior hindbrain patterning.","Entity: Otx2. Otx2 gene expression is repressed by FGF8 in chick embryos, playing a key role in the negative feedback loop regulating midbrain and anterior hindbrain patterning."
En1,"En1 expression is ectopically induced in the vicinity of FGF8-beads in chick embryos, contributing to the formation of the ectopic midbrain.","Entity: En1. En1 expression is ectopically induced in the vicinity of FGF8-beads in chick embryos, contributing to the formation of the ectopic midbrain."
Wnt1,"Wnt1 expression is ectopically induced in a ring-like domain around FGF8-beads in chick embryos, with the Wnt1 ring forming the outermost layer of the ectopic signaling center.","Entity: Wnt1. Wnt1 expression is ectopically induced in a ring-like domain around FGF8-beads in chick embryos, with the Wnt1 ring forming the outermost layer of the ectopic signaling center."
FGF8,"FGF8 induces the formation of a ring-like ectopic signaling center (organizer) in the lateral wall of the brain, similar to the isthmic organizer at the midbrain-hindbrain boundary.","Entity: FGF8. FGF8 induces the formation of a ring-like ectopic signaling center (organizer) in the lateral wall of the brain, similar to the isthmic organizer at the midbrain-hindbrain boundary."
FGF8,"FGF8 mediates its morphogenetic effects by repressing Otx2 gene expression and inducing En1, Fgf8, and Wnt1 expression in chick embryos.","Entity: FGF8. FGF8 mediates its morphogenetic effects by repressing Otx2 gene expression and inducing En1, Fgf8, and Wnt1 expression in chick embryos."
FGF8,"FGF8, when delivered as beads in chick embryos, induces the formation of ectopic midbrains by promoting neuroepithelial changes and ectopic expression of genes such as En1, Fgf8, and Wnt1 in the vicinity of the bead.","Entity: FGF8. FGF8, when delivered as beads in chick embryos, induces the formation of ectopic midbrains by promoting neuroepithelial changes and ectopic expression of genes such as En1, Fgf8, and Wnt1 in the vicinity of the bead."
Kruppel,Kruppel is a gap gene product that acts as a maternal and early embryonic transcription factor involved in developmental patterning of the Drosophila embryo.,Entity: Kruppel. Kruppel is a gap gene product that acts as a maternal and early embryonic transcription factor involved in developmental patterning of the Drosophila embryo.
snail,Snail is a gap gene product that functions as a maternal and early embryonic transcription factor important for mesoderm-specific developmental patterning in Drosophila.,Entity: snail. Snail is a gap gene product that functions as a maternal and early embryonic transcription factor important for mesoderm-specific developmental patterning in Drosophila.
knirps,Knirps is a gap gene product that acts as a maternal and early embryonic transcription factor contributing to developmental patterning in Drosophila.,Entity: knirps. Knirps is a gap gene product that acts as a maternal and early embryonic transcription factor contributing to developmental patterning in Drosophila.
Xnr1,Ectopic expression of Xnr1 in the right lateral plate induces Pitx2 transcription in Xenopus embryos.,Entity: Xnr1. Ectopic expression of Xnr1 in the right lateral plate induces Pitx2 transcription in Xenopus embryos.
Pitx2,Pitx2 expression continues to be localized in the left lateral plate mesoderm and is associated with asymmetric looping morphogenesis of the heart and gut.,Entity: Pitx2. Pitx2 expression continues to be localized in the left lateral plate mesoderm and is associated with asymmetric looping morphogenesis of the heart and gut.
Pitx2,"Misexpression of Pitx2 affects situs and morphology of organs, indicating a role in promoting looping of the linear heart and gut.","Entity: Pitx2. Misexpression of Pitx2 affects situs and morphology of organs, indicating a role in promoting looping of the linear heart and gut."
Pitx2,"Pitx2 is a homeobox gene asymmetrically expressed in the left lateral plate mesoderm, tubular heart, and early gut tube during embryonic development in mouse, frog, and zebrafish.","Entity: Pitx2. Pitx2 is a homeobox gene asymmetrically expressed in the left lateral plate mesoderm, tubular heart, and early gut tube during embryonic development in mouse, frog, and zebrafish."
ome,"The ome gene is involved in the regulation of neuronal patterning in the zebrafish retina, with mutations causing a loss of retinal lamination and defects in the differentiation of at least seven retinal cell types.","Entity: ome. The ome gene is involved in the regulation of neuronal patterning in the zebrafish retina, with mutations causing a loss of retinal lamination and defects in the differentiation of at least seven retinal cell types."
DnaJ,DnaJ is a co-chaperone protein involved in protein folding and is structurally related to the Mrj protein.,Entity: DnaJ. DnaJ is a co-chaperone protein involved in protein folding and is structurally related to the Mrj protein.
Err2,Err2 is a chorionic trophoblast-specific transcription factor gene whose expression is significantly reduced in Mrj mutants of the mouse placenta.,Entity: Err2. Err2 is a chorionic trophoblast-specific transcription factor gene whose expression is significantly reduced in Mrj mutants of the mouse placenta.
terra,Terra is a highly conserved protein that plays specific roles in early somitogenesis of vertebrates.,Entity: terra. Terra is a highly conserved protein that plays specific roles in early somitogenesis of vertebrates.
terra,Terra has both human and mouse homologs and is specifically expressed in mouse somites.,Entity: terra. Terra has both human and mouse homologs and is specifically expressed in mouse somites.
terra,"Overexpression of terra induces rapid apoptosis both in vitro and in vivo, indicating the need for tight regulation of terra expression during embryogenesis.","Entity: terra. Overexpression of terra induces rapid apoptosis both in vitro and in vivo, indicating the need for tight regulation of terra expression during embryogenesis."
terra,Terra expression is reduced by hedgehog signaling and enhanced by BMP signaling during embryogenesis.,Entity: terra. Terra expression is reduced by hedgehog signaling and enhanced by BMP signaling during embryogenesis.
terra,Terra is a zebrafish zinc-finger gene encoding a transcription factor with a DNA binding domain similar to Drosophila doublesex.,Entity: terra. Terra is a zebrafish zinc-finger gene encoding a transcription factor with a DNA binding domain similar to Drosophila doublesex.
terra,Terra is transiently expressed in the presomitic mesoderm and newly formed somites during embryogenesis.,Entity: terra. Terra is transiently expressed in the presomitic mesoderm and newly formed somites during embryogenesis.
terra,Terra expression in presomitic mesoderm is restricted to cells that lack MyoD expression.,Entity: terra. Terra expression in presomitic mesoderm is restricted to cells that lack MyoD expression.
PCNA,Neither enhanced apoptosis nor reduced cell proliferation is observed in the myocardium of Csx/Nkx2.5 null mice.,Entity: PCNA. Neither enhanced apoptosis nor reduced cell proliferation is observed in the myocardium of Csx/Nkx2.5 null mice.
HAND1,Expression of HAND1 is disturbed in the mutant heart of Csx/Nkx2.5 null mice.,Entity: HAND1. Expression of HAND1 is disturbed in the mutant heart of Csx/Nkx2.5 null mice.
MLC2V,Expression of MLC2V is disturbed in the mutant heart of Csx/Nkx2.5 null mice.,Entity: MLC2V. Expression of MLC2V is disturbed in the mutant heart of Csx/Nkx2.5 null mice.
BNP,Expression of BNP is disturbed in the mutant heart of Csx/Nkx2.5 null mice.,Entity: BNP. Expression of BNP is disturbed in the mutant heart of Csx/Nkx2.5 null mice.
Nkx2.5,"In chimeric mice generated from Nkx2.5 null ES cells, more than 20% of cells in the heart are deficient in Nkx2.5, and these cells exert dominant interfering effects on cardiac development.","Entity: Nkx2.5. In chimeric mice generated from Nkx2.5 null ES cells, more than 20% of cells in the heart are deficient in Nkx2.5, and these cells exert dominant interfering effects on cardiac development."
Nkx2.5,Nkx2.5 is required for later differentiation of cardiac myocytes and for the regulation of several essential transcription factors in the developing heart.,Entity: Nkx2.5. Nkx2.5 is required for later differentiation of cardiac myocytes and for the regulation of several essential transcription factors in the developing heart.
Nkx2.5,"Complete null mutations of Nkx2.5 in mice cause arrest of cardiac development after looping, severe defects in vascular formation and hematopoiesis in the yolk sac, and disturbances in the expression of genes such as ANF, BNP, MLC2V, N-myc, MEF2C, HAND1, and Msx2 in the developing heart.","Entity: Nkx2.5. Complete null mutations of Nkx2.5 in mice cause arrest of cardiac development after looping, severe defects in vascular formation and hematopoiesis in the yolk sac, and disturbances in the expression of genes such as ANF, BNP, MLC2V, N-myc, MEF2C, HAND1, and Msx2 in the developing heart."
Nkx2.5,"Nkx2.5 is a vertebrate homeobox gene with sequence homology to the Drosophila tinman, which is required for dorsal mesoderm specification.","Entity: Nkx2.5. Nkx2.5 is a vertebrate homeobox gene with sequence homology to the Drosophila tinman, which is required for dorsal mesoderm specification."
N-cadherin,N-cadherin is colocalized with the mXin protein in the intercalated discs of adult mouse hearts.,Entity: N-cadherin. N-cadherin is colocalized with the mXin protein in the intercalated discs of adult mouse hearts.
Nkx2.5,Nkx2.5 is a cardiac-restricted transcription factor that can induce Xin expression and can transactivate a luciferase reporter driven by the mXin promoter in mouse fibroblasts.,Entity: Nkx2.5. Nkx2.5 is a cardiac-restricted transcription factor that can induce Xin expression and can transactivate a luciferase reporter driven by the mXin promoter in mouse fibroblasts.
Xin,"Xin encodes proteins with 2,562 amino acids in chick (cXin) and 1,677 amino acids in mouse (mXin), and its derived amino acid sequences share 46% similarity.","Entity: Xin. Xin encodes proteins with 2,562 amino acids in chick (cXin) and 1,677 amino acids in mouse (mXin), and its derived amino acid sequences share 46% similarity."
Xin,"Inhibition of Xin expression in chick embryos by antisense oligonucleotides results in abnormal cardiac morphogenesis, including thickened myocardium and multiple invaginations into the heart cavity.","Entity: Xin. Inhibition of Xin expression in chick embryos by antisense oligonucleotides results in abnormal cardiac morphogenesis, including thickened myocardium and multiple invaginations into the heart cavity."
Xin,"Xin is a gene required for cardiac morphogenesis and looping, with homologous genes cXin in chick and mXin in mouse.","Entity: Xin. Xin is a gene required for cardiac morphogenesis and looping, with homologous genes cXin in chick and mXin in mouse."
Xin,"Xin expression is specifically restricted to cardiac progenitor cells in chick embryos as early as stage 8, continuing in the myocardium of developing hearts and also present in myotomes of developing somites by stage 15.","Entity: Xin. Xin expression is specifically restricted to cardiac progenitor cells in chick embryos as early as stage 8, continuing in the myocardium of developing hearts and also present in myotomes of developing somites by stage 15."
Xin,"Xin expression is regulated by a BMP-Nkx2.5-MEF2C pathway, as both MEF2C and Nkx2.5 can transactivate a luciferase reporter driven by the mXin promoter in mouse fibroblasts.","Entity: Xin. Xin expression is regulated by a BMP-Nkx2.5-MEF2C pathway, as both MEF2C and Nkx2.5 can transactivate a luciferase reporter driven by the mXin promoter in mouse fibroblasts."
Xin,"Xin proteins contain conserved domain structures including proline-rich regions, 16 amino acid repeats, DNA-binding domains, SH3-binding motifs, and nuclear localization signals.","Entity: Xin. Xin proteins contain conserved domain structures including proline-rich regions, 16 amino acid repeats, DNA-binding domains, SH3-binding motifs, and nuclear localization signals."
Xin,"Xin expression can be induced by bone morphogenetic protein (BMP) in explants of anterior medial mesoendoderm from stage 6 chick embryos, a tissue normally non-cardiogenic.","Entity: Xin. Xin expression can be induced by bone morphogenetic protein (BMP) in explants of anterior medial mesoendoderm from stage 6 chick embryos, a tissue normally non-cardiogenic."
GDF-5,"GDF-5 is a member of the TGF-beta superfamily and plays a critical role in controlling skeletogenesis, including the size and proliferation of chondrocytes during limb development.","Entity: GDF-5. GDF-5 is a member of the TGF-beta superfamily and plays a critical role in controlling skeletogenesis, including the size and proliferation of chondrocytes during limb development."
GDF-5,GDF-5 increases the number of chondrocytes and promotes both early cartilage condensation and later skeletal element development during chick limb development.,Entity: GDF-5. GDF-5 increases the number of chondrocytes and promotes both early cartilage condensation and later skeletal element development during chick limb development.
GDF-5,"Mutations in GDF-5 are associated with autosomal recessive syndromes such as brachypod in mice and Hunter-Thompson and Grebe-type chondrodysplasias in humans, all characterized by shortened appendicular skeleton and joint abnormalities.","Entity: GDF-5. Mutations in GDF-5 are associated with autosomal recessive syndromes such as brachypod in mice and Hunter-Thompson and Grebe-type chondrodysplasias in humans, all characterized by shortened appendicular skeleton and joint abnormalities."
GDF-5,"In in vitro micromass cultures, GDF-5 increases chondrogenesis in a dose-dependent manner, but does not affect cell proliferation.","Entity: GDF-5. In in vitro micromass cultures, GDF-5 increases chondrogenesis in a dose-dependent manner, but does not affect cell proliferation."
GDF-5,"The level of GDF-5 expression or activity is important for controlling the size of skeletal elements, contributing to variation in the severity of skeletal defects from GDF-5 mutations.","Entity: GDF-5. The level of GDF-5 expression or activity is important for controlling the size of skeletal elements, contributing to variation in the severity of skeletal defects from GDF-5 mutations."
GDF-5,"At later stages of skeletal development, GDF-5 can increase proliferation of chondrocytes in chick limbs.","Entity: GDF-5. At later stages of skeletal development, GDF-5 can increase proliferation of chondrocytes in chick limbs."
GDF-5,"In chick limb development, GDF-5 can increase cell adhesion, which is a critical determinant of early chondrogenesis.","Entity: GDF-5. In chick limb development, GDF-5 can increase cell adhesion, which is a critical determinant of early chondrogenesis."
plakoglobin,"Plakoglobin is a paralog of beta-catenin and can activate Wnt signaling when tethered to the membrane, suggesting it can signal independently or indirectly by elevating endogenous beta-catenin levels.","Entity: plakoglobin. Plakoglobin is a paralog of beta-catenin and can activate Wnt signaling when tethered to the membrane, suggesting it can signal independently or indirectly by elevating endogenous beta-catenin levels."
Wnt,"Wnt signaling stabilizes Armadillo/beta-catenin, leading to their accumulation in nuclei and activation of Wingless/Wnt responsive genes through binding to TCF/LEF family proteins.","Entity: Wnt. Wnt signaling stabilizes Armadillo/beta-catenin, leading to their accumulation in nuclei and activation of Wingless/Wnt responsive genes through binding to TCF/LEF family proteins."
mab-21,mab-21 is negatively regulated downstream in the male tail development pathway by the cet-1/sma pathway in Caenorhabditis elegans.,Entity: mab-21. mab-21 is negatively regulated downstream in the male tail development pathway by the cet-1/sma pathway in Caenorhabditis elegans.
sma-2,"sma-2 is involved in a developmental pathway with cet-1, sma-3, and sma-4 that affects body length and male tail development in Caenorhabditis elegans.","Entity: sma-2. sma-2 is involved in a developmental pathway with cet-1, sma-3, and sma-4 that affects body length and male tail development in Caenorhabditis elegans."
sma-4,"sma-4 is part of a common pathway with cet-1, sma-2, and sma-3 that regulates developmental processes in Caenorhabditis elegans.","Entity: sma-4. sma-4 is part of a common pathway with cet-1, sma-2, and sma-3 that regulates developmental processes in Caenorhabditis elegans."
sma-3,"sma-3 is part of a developmental pathway with cet-1, sma-2, and sma-4 that influences body length and male tail development in Caenorhabditis elegans.","Entity: sma-3. sma-3 is part of a developmental pathway with cet-1, sma-2, and sma-4 that influences body length and male tail development in Caenorhabditis elegans."
SLP-76,SLP-76 is a major adaptor protein associated with Gads in vivo and forms a constitutive interaction with Gads via its carboxy-terminal SH3 domain and a 20 amino-acid proline-rich region.,Entity: SLP-76. SLP-76 is a major adaptor protein associated with Gads in vivo and forms a constitutive interaction with Gads via its carboxy-terminal SH3 domain and a 20 amino-acid proline-rich region.
SLP-76,"Overexpression of SLP-76 synergistically augments T-cell signaling with Gads, requiring a functional Gads SH2 domain.","Entity: SLP-76. Overexpression of SLP-76 synergistically augments T-cell signaling with Gads, requiring a functional Gads SH2 domain."
Nia2,"Systemic acquired silencing (SAS) of Nia2 is activated by both sense, antisense, and promoterless Nia2 DNA constructs, indicating that transcription is not required for silencing activation but is stimulated by it.","Entity: Nia2. Systemic acquired silencing (SAS) of Nia2 is activated by both sense, antisense, and promoterless Nia2 DNA constructs, indicating that transcription is not required for silencing activation but is stimulated by it."
Nia2,"Nia2 DNA, when introduced into plants by biolistics, can activate both localized acquired silencing (LAS) in bombarded leaves and systemic acquired silencing (SAS) in class II tobacco transformants, even when the targeted leaf is removed 2 days after bombardment.","Entity: Nia2. Nia2 DNA, when introduced into plants by biolistics, can activate both localized acquired silencing (LAS) in bombarded leaves and systemic acquired silencing (SAS) in class II tobacco transformants, even when the targeted leaf is removed 2 days after bombardment."
Misshapen,Expression of a dominant-negative Msn mutant protein blocks the activation of JNK by DTRAF1 in Drosophila.,Entity: Misshapen. Expression of a dominant-negative Msn mutant protein blocks the activation of JNK by DTRAF1 in Drosophila.
SPS1,SPS1 family members are protein kinases closely related to Ste20 in their kinase domain but do not bind or are not activated by GTP-bound p21Rac and Cdc42.,Entity: SPS1. SPS1 family members are protein kinases closely related to Ste20 in their kinase domain but do not bind or are not activated by GTP-bound p21Rac and Cdc42.
DTRAF2,DTRAF2 is a Drosophila TNF-receptor-associated factor that contains an amino-terminal Ring-finger domain but is not specifically bound by Misshapen (Msn).,Entity: DTRAF2. DTRAF2 is a Drosophila TNF-receptor-associated factor that contains an amino-terminal Ring-finger domain but is not specifically bound by Misshapen (Msn).
p21-activated protein kinase,p21-activated protein kinase (Pak) is a family of protein kinases closely related to Ste20 in their kinase domain.,Entity: p21-activated protein kinase. p21-activated protein kinase (Pak) is a family of protein kinases closely related to Ste20 in their kinase domain.
Ste20,Ste20 is a protein kinase to which the p21-activated protein kinase (Pak) and SPS1 families are closely related in their kinase domain.,Entity: Ste20. Ste20 is a protein kinase to which the p21-activated protein kinase (Pak) and SPS1 families are closely related in their kinase domain.
JNK,JNK is a mitogen-activated protein kinase whose activation in Drosophila is dependent on the Msn-DTRAF1 pathway.,Entity: JNK. JNK is a mitogen-activated protein kinase whose activation in Drosophila is dependent on the Msn-DTRAF1 pathway.
TNF-receptor-associated factor,"In Drosophila, DTRAF1 is a TNF-receptor-associated factor that interacts with and activates Misshapen (Msn) to regulate the JNK pathway.","Entity: TNF-receptor-associated factor. In Drosophila, DTRAF1 is a TNF-receptor-associated factor that interacts with and activates Misshapen (Msn) to regulate the JNK pathway."
Misshapen,Coexpression of Msn with DTRAF1 leads to synergistic activation of JNK in Drosophila.,Entity: Misshapen. Coexpression of Msn with DTRAF1 leads to synergistic activation of JNK in Drosophila.
Misshapen,Misshapen (Msn) is a MAP kinase kinase kinase kinase in Drosophila that activates the JNK pathway by activating upstream MAP kinase kinase kinases.,Entity: Misshapen. Misshapen (Msn) is a MAP kinase kinase kinase kinase in Drosophila that activates the JNK pathway by activating upstream MAP kinase kinase kinases.
JNK,Failure to activate JNK in Drosophila leads to embryonic lethality due to the failure of dorsal closure.,Entity: JNK. Failure to activate JNK in Drosophila leads to embryonic lethality due to the failure of dorsal closure.
Misshapen,Misshapen (Msn) specifically binds the TRAF domain of DTRAF1 but not that of DTRAF2 in Drosophila.,Entity: Misshapen. Misshapen (Msn) specifically binds the TRAF domain of DTRAF1 but not that of DTRAF2 in Drosophila.
streptofactin,Streptofactin is a class I hydrophobin produced by Streptomyces tendae that can substitute for SC3 in the medium and contribute to reducing water surface tension at the water-air interface in filamentous fungi.,Entity: streptofactin. SMILES: CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)N[C@@H](C(=O)O)[C@H](C)O)C(C)C. Streptofactin is a class I hydrophobin produced by Streptomyces tendae that can substitute for SC3 in the medium and contribute to reducing water surface tension at the water-air interface in filamentous fungi.
phosphotyrosine,"A host phosphotyrosine protein is required for the nucleation of actin filaments by vaccinia virus, suggesting a role in membrane-associated nucleation of actin.","Entity: phosphotyrosine. SMILES: N[C@@H](Cc1ccc(OP(=O)(O)O)cc1)C(=O)O. A host phosphotyrosine protein is required for the nucleation of actin filaments by vaccinia virus, suggesting a role in membrane-associated nucleation of actin."
Arp2,"Arp2 is a component of the actin-related protein complex of Arp2 and Arp3, which is involved in actin-based motility of pathogens.","Entity: Arp2. Arp2 is a component of the actin-related protein complex of Arp2 and Arp3, which is involved in actin-based motility of pathogens."
zyxin,Zyxin is an actin-cytoskeleton-associated protein that has been implicated in the motility of pathogens such as Listeria and Shigella.,Entity: zyxin. Zyxin is an actin-cytoskeleton-associated protein that has been implicated in the motility of pathogens such as Listeria and Shigella.
Arp3,Arp3 is an actin-related protein complex component involved in actin-based motility of pathogens such as Listeria and Shigella.,Entity: Arp3. Arp3 is an actin-related protein complex component involved in actin-based motility of pathogens such as Listeria and Shigella.
vinculin,Vinculin is an actin-cytoskeleton-associated protein implicated in the motility of pathogens like Listeria and Shigella.,Entity: vinculin. Vinculin is an actin-cytoskeleton-associated protein implicated in the motility of pathogens like Listeria and Shigella.
Hoxd13,Hoxd13 is ectopically expressed in the anterior region of affected limb buds in mouse hemimelia-luxate group mutants.,Entity: Hoxd13. Hoxd13 is ectopically expressed in the anterior region of affected limb buds in mouse hemimelia-luxate group mutants.
Hx,"Hx is a mouse mutant of the hemimelia-luxate group, characterized by preaxial polydactyly and longbone abnormalities.","Entity: Hx. Hx is a mouse mutant of the hemimelia-luxate group, characterized by preaxial polydactyly and longbone abnormalities."
Fgf8,Fgf8 is ectopically expressed in the anterior region of affected limb buds in mouse hemimelia-luxate group mutants.,Entity: Fgf8. Fgf8 is ectopically expressed in the anterior region of affected limb buds in mouse hemimelia-luxate group mutants.
Rim4,"Rim4 is a mouse mutant of the hemimelia-luxate group, exhibiting preaxial polydactyly and longbone abnormalities.","Entity: Rim4. Rim4 is a mouse mutant of the hemimelia-luxate group, exhibiting preaxial polydactyly and longbone abnormalities."
fibroblast growth factor-4,Fibroblast growth factor-4 (Fgf4) is ectopically expressed in the anterior region of affected limb buds in mouse hemimelia-luxate group mutants.,Entity: fibroblast growth factor-4. Fibroblast growth factor-4 (Fgf4) is ectopically expressed in the anterior region of affected limb buds in mouse hemimelia-luxate group mutants.
Distal-less,Distal-less (Dll) expression is regulated by Ubx in a unique manner in butterfly hindwings compared to Drosophila haltere.,Entity: Distal-less. Distal-less (Dll) expression is regulated by Ubx in a unique manner in butterfly hindwings compared to Drosophila haltere.
Hox,Morphological diversity of homologous structures between animals is likely to arise from changes in the regulation of Hox target genes.,Entity: Hox. Morphological diversity of homologous structures between animals is likely to arise from changes in the regulation of Hox target genes.
Hox,Hox genes are transcription factors that control the development of homologous appendages in different organisms.,Entity: Hox. Hox genes are transcription factors that control the development of homologous appendages in different organisms.
CD3,"Anti-CD3 antibody induces apoptosis in immature thymocytes, and this apoptosis is dependent on JNK2 for its induction in vivo.","Entity: CD3. Anti-CD3 antibody induces apoptosis in immature thymocytes, and this apoptosis is dependent on JNK2 for its induction in vivo."
IL-4,IL-4 production in peripheral T cells is reduced in mice lacking JNK2 after stimulation with anti-CD3 antibody.,Entity: IL-4. IL-4 production in peripheral T cells is reduced in mice lacking JNK2 after stimulation with anti-CD3 antibody.
alpha-amanitin,"Alpha-amanitin, a global inhibitor of RNA polymerase II transcription, abolishes the association of U2 snRNA genes with coiled bodies in human cells.","Entity: alpha-amanitin. SMILES: CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2. Alpha-amanitin, a global inhibitor of RNA polymerase II transcription, abolishes the association of U2 snRNA genes with coiled bodies in human cells."
Dbl,Dbl is a guanine-nucleotide exchange factor of RhoA that promotes focus formation and cell transformation.,Entity: Dbl. Dbl is a guanine-nucleotide exchange factor of RhoA that promotes focus formation and cell transformation.
mNET1,mNET1 is a guanine-nucleotide exchange factor of RhoA that promotes focus formation and cell transformation.,Entity: mNET1. mNET1 is a guanine-nucleotide exchange factor of RhoA that promotes focus formation and cell transformation.
Raf,"Raf is a kinase involved in Ras-mediated transformation, and its ability to cooperate with activated Raf in focus formation assays is weak in the presence of a truncated ROCK derivative.","Entity: Raf. Raf is a kinase involved in Ras-mediated transformation, and its ability to cooperate with activated Raf in focus formation assays is weak in the presence of a truncated ROCK derivative."
Pep12p,Pep12p/Vps6p is an endosomal target (t) SNARE that binds directly to Vps45p and is involved in the VPS pathway for vacuolar protein sorting.,Entity: Pep12p. Pep12p/Vps6p is an endosomal target (t) SNARE that binds directly to Vps45p and is involved in the VPS pathway for vacuolar protein sorting.
Vps45p,Vps45p is a Sec1p homologue that binds directly to Pep12p/Vps6p and is involved in the VPS pathway for vacuolar protein sorting.,Entity: Vps45p. Vps45p is a Sec1p homologue that binds directly to Pep12p/Vps6p and is involved in the VPS pathway for vacuolar protein sorting.
Vac1p,"Vac1p genetically and physically interacts with the activated, GTP-bound form of Vps21p, a Rab GTPase involved in Golgi-to-endosome transport.","Entity: Vac1p. Vac1p genetically and physically interacts with the activated, GTP-bound form of Vps21p, a Rab GTPase involved in Golgi-to-endosome transport."
Vps21p,"Vps21p is a Rab GTPase that functions in Golgi-to-endosome transport and interacts with the activated, GTP-bound form with Vac1p.","Entity: Vps21p. Vps21p is a Rab GTPase that functions in Golgi-to-endosome transport and interacts with the activated, GTP-bound form with Vac1p."
Vps34,"Vps34 is a phosphatidylinositol 3-kinase that produces phosphatidylinositol 3-phosphate (PI(3)P), which is bound by Vac1p/Pep7p/Vps19p.","Entity: Vps34. Vps34 is a phosphatidylinositol 3-kinase that produces phosphatidylinositol 3-phosphate (PI(3)P), which is bound by Vac1p/Pep7p/Vps19p."
Vac1p,"Vac1p is a multivalent adaptor protein that interacts with both phosphoinositide (Vps34p) and GTPase (Vps21p) signals, ensuring high fidelity of vesicle docking and fusion in the vacuolar protein sorting pathway.","Entity: Vac1p. Vac1p is a multivalent adaptor protein that interacts with both phosphoinositide (Vps34p) and GTPase (Vps21p) signals, ensuring high fidelity of vesicle docking and fusion in the vacuolar protein sorting pathway."
Vac1p,Vac1p is a novel Sec1p-family-binding protein.,Entity: Vac1p. Vac1p is a novel Sec1p-family-binding protein.
Inscuteable,"In neuroblasts, Inscuteable localizes into an apical cortical crescent during late interphase and most of mitosis.","Entity: Inscuteable. In neuroblasts, Inscuteable localizes into an apical cortical crescent during late interphase and most of mitosis."
Inscuteable,"In Inscuteable, the central 364 amino acid domain is necessary and sufficient for its localization and function.","Entity: Inscuteable. In Inscuteable, the central 364 amino acid domain is necessary and sufficient for its localization and function."
Numb,"Numb is asymmetrically segregated into the basal daughter cell during mitosis in neuroblasts, with Inscuteable required for this segregation.","Entity: Numb. Numb is asymmetrically segregated into the basal daughter cell during mitosis in neuroblasts, with Inscuteable required for this segregation."
Inscuteable,"A 158 amino acid fragment of Inscuteable can localize asymmetrically when coexpressed with the full-length protein and can bind Inscuteable in vitro, suggesting involvement in self-association in vivo.","Entity: Inscuteable. A 158 amino acid fragment of Inscuteable can localize asymmetrically when coexpressed with the full-length protein and can bind Inscuteable in vitro, suggesting involvement in self-association in vivo."
Inscuteable,Ectopic expression of Inscuteable in epidermal cells causes them to reorient their mitotic spindle and divide perpendicularly to the embryo surface.,Entity: Inscuteable. Ectopic expression of Inscuteable in epidermal cells causes them to reorient their mitotic spindle and divide perpendicularly to the embryo surface.
Miranda,"Miranda is asymmetrically segregated into the basal daughter cell during mitosis in neuroblasts, with Inscuteable required for this segregation.","Entity: Miranda. Miranda is asymmetrically segregated into the basal daughter cell during mitosis in neuroblasts, with Inscuteable required for this segregation."
Inscuteable,"Within the Inscuteable asymmetry domain, a 100 amino acid region is required for asymmetric localization along the cortex, and a 158 amino acid region directs localization to the cell cortex.","Entity: Inscuteable. Within the Inscuteable asymmetry domain, a 100 amino acid region is required for asymmetric localization along the cortex, and a 158 amino acid region directs localization to the cell cortex."
Inscuteable,Inscuteable is a key regulator of asymmetric cell division during the development of the Drosophila nervous system.,Entity: Inscuteable. Inscuteable is a key regulator of asymmetric cell division during the development of the Drosophila nervous system.
Inscuteable,"During mitosis, Inscuteable is required for the correct apical-basal orientation of the mitotic spindle and for the asymmetric segregation of Numb, Prospero, and Miranda into the basal daughter cell.","Entity: Inscuteable. During mitosis, Inscuteable is required for the correct apical-basal orientation of the mitotic spindle and for the asymmetric segregation of Numb, Prospero, and Miranda into the basal daughter cell."
Prospero,"Prospero is asymmetrically segregated into the basal daughter cell during mitosis in neuroblasts, with Inscuteable required for this segregation.","Entity: Prospero. Prospero is asymmetrically segregated into the basal daughter cell during mitosis in neuroblasts, with Inscuteable required for this segregation."
vanadium,"Vanadium is a component of vanadium-containing haloperoxidase enzymes, which catalyze halogenation, sulfoxidation, epoxidation, and oxidation of indoles among other biotransformations.","Entity: vanadium. SMILES: [V]. Vanadium is a component of vanadium-containing haloperoxidase enzymes, which catalyze halogenation, sulfoxidation, epoxidation, and oxidation of indoles among other biotransformations."
Na-citrat,Na-citrat is used at a concentration of 1% in a solution with hyaluronidase to permeabilize testicular tissue for 20 minutes at 37°C to facilitate single-cell suspension preparation.,Entity: Na-citrat. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Na-citrat is used at a concentration of 1% in a solution with hyaluronidase to permeabilize testicular tissue for 20 minutes at 37°C to facilitate single-cell suspension preparation.
orcein,Orcein is used at a 1% solution to stain air-dried slides of testicular tissue.,Entity: orcein. SMILES: CC1=c2c(oc3cc(O)c(Nc4c(C)cc(O)cc4O)c(C)c23)=CC(=O)C1=Nc1c(C)cc(O)cc1O. Orcein is used at a 1% solution to stain air-dried slides of testicular tissue.
acetic acid,Acetic acid is used at a 1% solution to stain air-dried slides of testicular tissue.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used at a 1% solution to stain air-dried slides of testicular tissue.
lividomycin A,"The phosphorylation site of lividomycin A by AAC(6')-APH(2"") is the 5""-OH of the pentose ring C.","Entity: lividomycin A. SMILES: NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)C[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O. The phosphorylation site of lividomycin A by AAC(6')-APH(2"") is the 5""-OH of the pentose ring C."
lividomycin A,"Lividomycin A is an aminoglycoside that lacks a 6'-amino group and can be acetylated by the bifunctional enzyme AAC(6')-APH(2"").","Entity: lividomycin A. SMILES: NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)C[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O. Lividomycin A is an aminoglycoside that lacks a 6'-amino group and can be acetylated by the bifunctional enzyme AAC(6')-APH(2"")."
sodium chloride,Sodium chloride is used at a concentration of 0.15 M in 0.1 SSC buffer for staining procedures involving spindle apparatus and repetitive DNA in histological protocols.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at a concentration of 0.15 M in 0.1 SSC buffer for staining procedures involving spindle apparatus and repetitive DNA in histological protocols.
sodium citrate,Sodium citrate is used at a concentration of 0.015 M in 0.1 SSC buffer for staining procedures involving spindle apparatus and repetitive DNA in histological protocols.,Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used at a concentration of 0.015 M in 0.1 SSC buffer for staining procedures involving spindle apparatus and repetitive DNA in histological protocols.
acridine orange,Acridine orange is used as a fluorescent dye to identify allocyclic X in cells during microscopy and staining procedures.,Entity: acridine orange. SMILES: CN(C)c1ccc2cc3ccc(N(C)C)cc3nc2c1. Acridine orange is used as a fluorescent dye to identify allocyclic X in cells during microscopy and staining procedures.
carbol fuchsin,Carbol fuchsin is used as a histological stain for processing slides in autoradiography to assess cellular structures such as allocyclic X.,Entity: carbol fuchsin. SMILES: CC1=CC(=C(c2ccc(N)cc2)c2ccc(N)c(C)c2)C=CC1=N.Cl. Carbol fuchsin is used as a histological stain for processing slides in autoradiography to assess cellular structures such as allocyclic X.
ethanol,"Ethanol (70%) is used to remove fluorescent dyes, such as acridine orange, from stained microscope slides.","Entity: ethanol. SMILES: CCO. Ethanol (70%) is used to remove fluorescent dyes, such as acridine orange, from stained microscope slides."
intercellular adhesion molecule (ICAM)-1,Intercellular adhesion molecule (ICAM)-1 expressed in the donor vessel wall promotes transplant-associated arteriosclerosis by reducing neointima formation in recipient arteries.,Entity: intercellular adhesion molecule (ICAM)-1. Intercellular adhesion molecule (ICAM)-1 expressed in the donor vessel wall promotes transplant-associated arteriosclerosis by reducing neointima formation in recipient arteries.
tissue factor pathway inhibitor,"Tissue factor pathway inhibitor (TFPI) is a protein that inhibits the tissue factor/factor VIIa coagulation pathway, and its Kunitz-type domain-1 is essential for this inhibitory function.","Entity: tissue factor pathway inhibitor. Tissue factor pathway inhibitor (TFPI) is a protein that inhibits the tissue factor/factor VIIa coagulation pathway, and its Kunitz-type domain-1 is essential for this inhibitory function."
aquaporin-1,"Aquaporin-1 is the principal water channel in the thin descending limb of the Henle's loop, as shown by its high density of tetramers in wild-type mice and its absence in AQP1-null mice.","Entity: aquaporin-1. Aquaporin-1 is the principal water channel in the thin descending limb of the Henle's loop, as shown by its high density of tetramers in wild-type mice and its absence in AQP1-null mice."
aquaporin-1,"Osmotic equilibration along the thin descending limb of the Henle's loop by water transport, mediated by aquaporin-1, is a key mechanism in the renal countercurrent concentrating system.","Entity: aquaporin-1. Osmotic equilibration along the thin descending limb of the Henle's loop by water transport, mediated by aquaporin-1, is a key mechanism in the renal countercurrent concentrating system."
Parathyroid hormone,Calcemic responses to intraperitoneal injection of PTH are blunted in mice homozygous for a Col1a1 mutation (r/r) compared to wild-type mice.,Entity: Parathyroid hormone. Calcemic responses to intraperitoneal injection of PTH are blunted in mice homozygous for a Col1a1 mutation (r/r) compared to wild-type mice.
Parathyroid hormone,"In wild-type mice, subcutaneous administration of human PTH(1-34) four times daily for three days increases osteoclast numbers, bone marrow space size, and periosteal proliferation in the calvaria.","Entity: Parathyroid hormone. In wild-type mice, subcutaneous administration of human PTH(1-34) four times daily for three days increases osteoclast numbers, bone marrow space size, and periosteal proliferation in the calvaria."
Parathyroid hormone,"In mice homozygous for a Col1a1 mutation (r/r) that confer resistance to collagenase cleavage of type I collagen, PTH-induced bone resorption responses are minimal.","Entity: Parathyroid hormone. In mice homozygous for a Col1a1 mutation (r/r) that confer resistance to collagenase cleavage of type I collagen, PTH-induced bone resorption responses are minimal."
Parathyroid hormone,"Parathyroid hormone stimulates bone resorption by acting directly on osteoblasts/stromal cells to increase collagenase gene transcription and synthesis, and indirectly by promoting osteoclast differentiation and function.","Entity: Parathyroid hormone. Parathyroid hormone stimulates bone resorption by acting directly on osteoblasts/stromal cells to increase collagenase gene transcription and synthesis, and indirectly by promoting osteoclast differentiation and function."
Nomega-nitro-L-arginine methyl ester,Nomega-nitro-L-arginine methyl ester is a nitric oxide synthase inhibitor that completely abrogates the increase in effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) elicited by chronic administration of purified porcine relaxin in rats.,Entity: Nomega-nitro-L-arginine methyl ester. SMILES: COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]. Nomega-nitro-L-arginine methyl ester is a nitric oxide synthase inhibitor that completely abrogates the increase in effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) elicited by chronic administration of purified porcine relaxin in rats.
nitric oxide,Nitric oxide mediates the increase in effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) induced by chronic administration of purified porcine relaxin in rats.,Entity: nitric oxide. SMILES: [N]=O. Nitric oxide mediates the increase in effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) induced by chronic administration of purified porcine relaxin in rats.
angiotensin II,Angiotensin II induces a renal vasoconstrictory response that is attenuated by chronic administration of relaxin (RLX) in rats.,Entity: angiotensin II. Angiotensin II induces a renal vasoconstrictory response that is attenuated by chronic administration of relaxin (RLX) in rats.
Ara h 3,Single amino acid changes within the IgE-binding epitopes of Ara h 3 can reduce or abolish IgE binding.,Entity: Ara h 3. Single amino acid changes within the IgE-binding epitopes of Ara h 3 can reduce or abolish IgE binding.
Ara h 1,Ara h 1 is a peanut allergen that has been previously characterized.,Entity: Ara h 1. Ara h 1 is a peanut allergen that has been previously characterized.
Ara h 3,"Ara h 3 contains four IgE-binding epitopes, each between 10 and 15 amino acids in length, within its primary sequence.","Entity: Ara h 3. Ara h 3 contains four IgE-binding epitopes, each between 10 and 15 amino acids in length, within its primary sequence."
Ara h 3,Ara h 3 is a peanut allergen that is recognized by serum IgE from approximately 45% of peanut-allergic patients.,Entity: Ara h 3. Ara h 3 is a peanut allergen that is recognized by serum IgE from approximately 45% of peanut-allergic patients.
Ara h 3,The deduced amino acid sequence of Ara h 3 shows homology to 11S seed-storage proteins.,Entity: Ara h 3. The deduced amino acid sequence of Ara h 3 shows homology to 11S seed-storage proteins.
AQP1,AQP1 facilitates hydrostatically driven lung edema but is not required for active near-isosmolar absorption of alveolar fluid.,Entity: AQP1. AQP1 facilitates hydrostatically driven lung edema but is not required for active near-isosmolar absorption of alveolar fluid.
AQP1,AQP1 is expressed in microvascular endothelia of the mammalian lung and facilitates osmotically driven water transport across microvessels via a transcellular route.,Entity: AQP1. AQP1 is expressed in microvascular endothelia of the mammalian lung and facilitates osmotically driven water transport across microvessels via a transcellular route.
superoxide,"Superoxide production by macrophages is markedly deficient in GM-CSF-deficient (GM-/-) mice, contributing to impaired clearance of group B streptococcus (GBS) in the lungs.","Entity: superoxide. SMILES: [O][O-]. Superoxide production by macrophages is markedly deficient in GM-CSF-deficient (GM-/-) mice, contributing to impaired clearance of group B streptococcus (GBS) in the lungs."
Granulocyte-macrophage colony-stimulating factor,"Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances clearance of group B streptococcus (GBS) in vivo, in part by increasing superoxide and hydrogen peroxide production and bacterial killing by alveolar macrophages.","Entity: Granulocyte-macrophage colony-stimulating factor. Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances clearance of group B streptococcus (GBS) in vivo, in part by increasing superoxide and hydrogen peroxide production and bacterial killing by alveolar macrophages."
Coxsackie virus and adenovirus receptor,"The Coxsackie virus and adenovirus receptor (CAR) is a high-affinity receptor that mediates adenovirus entry into cells, and its deficiency on adenovirus targets can be circumvented by supplying CAR or by modifying the adenovirus fiber to bind to alternative cell-surface receptors.","Entity: Coxsackie virus and adenovirus receptor. The Coxsackie virus and adenovirus receptor (CAR) is a high-affinity receptor that mediates adenovirus entry into cells, and its deficiency on adenovirus targets can be circumvented by supplying CAR or by modifying the adenovirus fiber to bind to alternative cell-surface receptors."
DMPK,"DMPK (myotonic dystrophy protein kinase) is a gene whose haploinsufficiency is linked to cardiac conduction defects, including first-, second-, and third-degree atrioventricular block, in myotonic dystrophy.","Entity: DMPK. DMPK (myotonic dystrophy protein kinase) is a gene whose haploinsufficiency is linked to cardiac conduction defects, including first-, second-, and third-degree atrioventricular block, in myotonic dystrophy."
DMPK,DMPK loss specifically compromises the atrioventricular node and His-Purkinje regions of the cardiac conduction system.,Entity: DMPK. DMPK loss specifically compromises the atrioventricular node and His-Purkinje regions of the cardiac conduction system.
vancomycin,"Vancomycin is used as a primary treatment for infections due to Staphylococcus aureus with intermediate resistance to glycopeptides, as defined by a minimal inhibitory concentration of 8 to 16 µg/mL.","Entity: vancomycin. SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O. Vancomycin is used as a primary treatment for infections due to Staphylococcus aureus with intermediate resistance to glycopeptides, as defined by a minimal inhibitory concentration of 8 to 16 µg/mL."
methicillin,Methicillin is a beta-lactam antibiotic whose resistance in Staphylococcus aureus led to the emergence of methicillin-resistant strains.,Entity: methicillin. SMILES: COc1cccc(OC)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O. Methicillin is a beta-lactam antibiotic whose resistance in Staphylococcus aureus led to the emergence of methicillin-resistant strains.
vancomycin,"Vancomycin is a glycopeptide antibiotic that remains the only uniformly effective treatment for staphylococcal infections, including those caused by methicillin-resistant Staphylococcus aureus.","Entity: vancomycin. SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O. Vancomycin is a glycopeptide antibiotic that remains the only uniformly effective treatment for staphylococcal infections, including those caused by methicillin-resistant Staphylococcus aureus."
growth hormone,"Long-term growth hormone therapy in children with idiopathic short stature increases the mean standard-deviation score for height from -2.7 to -1.4, indicating greater height variability above the mean for chronologic age.","Entity: growth hormone. Long-term growth hormone therapy in children with idiopathic short stature increases the mean standard-deviation score for height from -2.7 to -1.4, indicating greater height variability above the mean for chronologic age."
growth hormone,"Long-term administration of growth hormone to children with idiopathic short stature increases adult height, with treated boys achieving a mean increase in adult height of +5.0 ± 5.1 cm and treated girls a mean increase of +5.9 ± 5.2 cm compared to predicted adult height.","Entity: growth hormone. Long-term administration of growth hormone to children with idiopathic short stature increases adult height, with treated boys achieving a mean increase in adult height of +5.0 ± 5.1 cm and treated girls a mean increase of +5.9 ± 5.2 cm compared to predicted adult height."
CP,"CP induces hydroxylating enzyme systems in the human liver, which can lead to autoinduction.","Entity: CP. SMILES: O=P1(N(CCCl)CCCl)NCCCO1. CP induces hydroxylating enzyme systems in the human liver, which can lead to autoinduction."
DPH,DPH induces hydroxylating enzyme systems in the human liver.,Entity: DPH. SMILES: Oc1cccc(Cl)c1Cl. DPH induces hydroxylating enzyme systems in the human liver.
Dextran,Dextran with 145000 molecular weight achieves rapid and complete release in a burst fashion from calcium-alginate gel beads.,Entity: Dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran with 145000 molecular weight achieves rapid and complete release in a burst fashion from calcium-alginate gel beads.
Dextran,"Minimal dextran release occurs in simulated gastric fluid at pH 1.2, while rapid release in simulated intestinal fluid at pH 6.8 is observed.","Entity: Dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Minimal dextran release occurs in simulated gastric fluid at pH 1.2, while rapid release in simulated intestinal fluid at pH 6.8 is observed."
Dextran,"Dextran release from calcium-alginate gel beads is molecular weight-dependent, with lower molecular weight dextran (9400) releasing primarily by diffusion through the gel matrix, while higher molecular weight dextran (145000) release is strongly influenced by alginate matrix dissolution and Ca2+ ion exchange.","Entity: Dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran release from calcium-alginate gel beads is molecular weight-dependent, with lower molecular weight dextran (9400) releasing primarily by diffusion through the gel matrix, while higher molecular weight dextran (145000) release is strongly influenced by alginate matrix dissolution and Ca2+ ion exchange."
calcein AM,Calcein AM is used as a 'live' cell probe in confocal laser scanning microscopy to assess the viability of buccal mucosa biopsies in vitro.,Entity: calcein AM. SMILES: CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)Cc1cc2c(cc1OC(C)=O)Oc1cc(OC(C)=O)c(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)cc1C21OC(=O)c2ccccc21. Calcein AM is used as a 'live' cell probe in confocal laser scanning microscopy to assess the viability of buccal mucosa biopsies in vitro.
quinacrine dihydrochloride,Quinacrine dihydrochloride is used as a stain in cytogenetic analysis to assess Y chromosome chromatin frequency in sperm smears.,Entity: quinacrine dihydrochloride. SMILES: CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12.Cl.Cl. Quinacrine dihydrochloride is used as a stain in cytogenetic analysis to assess Y chromosome chromatin frequency in sperm smears.
phenacetin,The release rate of phenacetin from a PEO-carboxyvinylpolymer (CP) solid dispersion can be controlled by varying the molecular weight of poly(ethylene oxide) (PEO).,Entity: phenacetin. SMILES: CCOc1ccc(NC(C)=O)cc1. The release rate of phenacetin from a PEO-carboxyvinylpolymer (CP) solid dispersion can be controlled by varying the molecular weight of poly(ethylene oxide) (PEO).
"2-[4-(((3, 5-dichloroanilino)-carbonyl) methyl) phenoxy]-2-methylpropionic acid","2-[4-(((3, 5-dichloroanilino)-carbonyl) methyl) phenoxy]-2-methylpropionic acid (RSR-4) is an allosteric effector that decreases hemoglobin oxygen affinity, as evidenced by an increase in P50 and a decrease in arterial oxygen saturation (Tc-SO2) following administration in rabbits.","Entity: 2-[4-(((3, 5-dichloroanilino)-carbonyl) methyl) phenoxy]-2-methylpropionic acid. SMILES: CC(C)(Oc1ccc(CC(=O)Nc2cc(Cl)cc(Cl)c2)cc1)C(=O)O. 2-[4-(((3, 5-dichloroanilino)-carbonyl) methyl) phenoxy]-2-methylpropionic acid (RSR-4) is an allosteric effector that decreases hemoglobin oxygen affinity, as evidenced by an increase in P50 and a decrease in arterial oxygen saturation (Tc-SO2) following administration in rabbits."
Nomega-nitro-L-arginine,"Nomega-nitro-L-arginine (L-NNA, 10^-5 M) converts the inhibitory junction potential in guinea pig lower esophageal sphincter muscles to a muscarinic excitatory junction potential in the presence of apamin (10^-7 M).","Entity: Nomega-nitro-L-arginine. SMILES: N=C(NCCC[C@H](N)C(=O)O)N[N+](=O)[O-]. Nomega-nitro-L-arginine (L-NNA, 10^-5 M) converts the inhibitory junction potential in guinea pig lower esophageal sphincter muscles to a muscarinic excitatory junction potential in the presence of apamin (10^-7 M)."
Nomega-nitro-L-arginine,Nomega-nitro-L-arginine (10^-5 M) reduces the amplitude of the inhibitory junction potential by 41% in atropinized guinea pig lower esophageal sphincter muscle tissue.,Entity: Nomega-nitro-L-arginine. SMILES: N=C(NCCC[C@H](N)C(=O)O)N[N+](=O)[O-]. Nomega-nitro-L-arginine (10^-5 M) reduces the amplitude of the inhibitory junction potential by 41% in atropinized guinea pig lower esophageal sphincter muscle tissue.
nitric oxide,Nitric oxide released from nitrergic nerves contributes to the generation of the inhibitory junction potential in guinea pig lower esophageal sphincter muscles.,Entity: nitric oxide. SMILES: [N]=O. Nitric oxide released from nitrergic nerves contributes to the generation of the inhibitory junction potential in guinea pig lower esophageal sphincter muscles.
nitric oxide,Hyperpolarizations produced by nitric oxide in guinea pig lower esophageal sphincter muscles are inhibited by apamin.,Entity: nitric oxide. SMILES: [N]=O. Hyperpolarizations produced by nitric oxide in guinea pig lower esophageal sphincter muscles are inhibited by apamin.
calcium,"Calcium influx from extracellular source, mediated by protein kinase C, is implicated in the vasoconstrictor and positive inotropic effects of acetylcholine in isolated rat hearts.","Entity: calcium. SMILES: [Ca]. Calcium influx from extracellular source, mediated by protein kinase C, is implicated in the vasoconstrictor and positive inotropic effects of acetylcholine in isolated rat hearts."
staurosporine,"Staurosporine, a protein kinase C inhibitor, abolishes acetylcholine-induced negative chronotropic and positive inotropic effects in isolated rat hearts.","Entity: staurosporine. SMILES: CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4. Staurosporine, a protein kinase C inhibitor, abolishes acetylcholine-induced negative chronotropic and positive inotropic effects in isolated rat hearts."
acetylcholine,"Acetylcholine produces positive inotropic, negative chronotropic, and coronary vasoconstrictor effects in isolated rat hearts, mediated by muscarinic receptor activation, prostaglandin modulation, and calcium influx.","Entity: acetylcholine. SMILES: CC(=O)OCC[N+](C)(C)C. Acetylcholine produces positive inotropic, negative chronotropic, and coronary vasoconstrictor effects in isolated rat hearts, mediated by muscarinic receptor activation, prostaglandin modulation, and calcium influx."
L-NAME,"L-NAME, an inhibitor of nitric oxide synthesis, abolishes acetylcholine-induced negative chronotropic and positive inotropic effects in isolated rat hearts.","Entity: L-NAME. SMILES: COC(=O)[C@@H](N)CCCN=C(N)N[N+](=O)[O-]. L-NAME, an inhibitor of nitric oxide synthesis, abolishes acetylcholine-induced negative chronotropic and positive inotropic effects in isolated rat hearts."
saponin,"Saponin disrupts the endothelium in isolated rat hearts, abolishing the vasoconstrictor effect of acetylcholine without altering its negative chronotropic and positive inotropic effects.","Entity: saponin. SMILES: CC1(C)C2CC[C@]3(C)[C@H](CCC45OCC6(CC[C@@](C)(C=O)C[C@@H]64)[C@H](O)C[C@]53C)[C@@]2(C)CC[C@@H]1O[C@@H]1OC[C@H](O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. Saponin disrupts the endothelium in isolated rat hearts, abolishing the vasoconstrictor effect of acetylcholine without altering its negative chronotropic and positive inotropic effects."
Nomega-nitro-L-arginine methyl ester,Nomega-nitro-L-arginine methyl ester is an inhibitor of nitric oxide synthesis that abolishes acetylcholine-induced negative chronotropic and positive inotropic effects in isolated rat hearts.,Entity: Nomega-nitro-L-arginine methyl ester. SMILES: COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]. Nomega-nitro-L-arginine methyl ester is an inhibitor of nitric oxide synthesis that abolishes acetylcholine-induced negative chronotropic and positive inotropic effects in isolated rat hearts.
prostaglandins,Prostaglandins modulate acetylcholine-induced vasoconstriction and positive inotropy in isolated rat hearts.,Entity: prostaglandins. SMILES: CCCCCC(/C=C/C1C=CC(=O)C1C/C=C/CCCC(=O)OC)OC(C)=O. Prostaglandins modulate acetylcholine-induced vasoconstriction and positive inotropy in isolated rat hearts.
indomethacin,"Indomethacin, a cyclooxygenase inhibitor, prevents acetylcholine from significantly decreasing heart rate and coronary flow in isolated rat hearts.","Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin, a cyclooxygenase inhibitor, prevents acetylcholine from significantly decreasing heart rate and coronary flow in isolated rat hearts."
nitric oxide,"Nitric oxide synthesis is inhibited by Nomega-nitro-L-arginine methyl ester (L-NAME), which abolishes acetylcholine-induced negative chronotropic and positive inotropic effects in isolated rat hearts.","Entity: nitric oxide. SMILES: [N]=O. Nitric oxide synthesis is inhibited by Nomega-nitro-L-arginine methyl ester (L-NAME), which abolishes acetylcholine-induced negative chronotropic and positive inotropic effects in isolated rat hearts."
dantrolene sodium,"Dantrolene sodium, an inhibitor of calcium release from intracellular stores, abolishes acetylcholine-induced positive inotropic effect and increases coronary perfusion pressure in isolated rat hearts.","Entity: dantrolene sodium. SMILES: O=C1N=C([O-])CN1/N=C/c1ccc(-c2ccc([N+](=O)[O-])cc2)o1.[Na+]. Dantrolene sodium, an inhibitor of calcium release from intracellular stores, abolishes acetylcholine-induced positive inotropic effect and increases coronary perfusion pressure in isolated rat hearts."
verapamil,"Verapamil, a calcium channel antagonist, abolishes acetylcholine-induced negative chronotropic and positive inotropic effects in isolated rat hearts.","Entity: verapamil. SMILES: COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC. Verapamil, a calcium channel antagonist, abolishes acetylcholine-induced negative chronotropic and positive inotropic effects in isolated rat hearts."
propionate,Incorporation of radiolabeled propionate into TCA-precipitable material via the Krebs cycle intermediates serves as a measure of total propionate pathway activity in fibroblasts.,Entity: propionate. SMILES: CCC(=O)O. Incorporation of radiolabeled propionate into TCA-precipitable material via the Krebs cycle intermediates serves as a measure of total propionate pathway activity in fibroblasts.
propionyl CoA,"Propionyl CoA carboxylase deficiency in fibroblasts is associated with impaired propionate pathway activity, as indicated by reduced incorporation of 14C into TCA-precipitable material.","Entity: propionyl CoA. SMILES: CCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Propionyl CoA carboxylase deficiency in fibroblasts is associated with impaired propionate pathway activity, as indicated by reduced incorporation of 14C into TCA-precipitable material."
methylmalonic acid,"Methylmalonic acidemias are associated with defects in the methylmalonyl CoA mutase apoenzyme, leading to impaired propionate pathway activity in fibroblasts.","Entity: methylmalonic acid. SMILES: CC(C(=O)O)C(=O)O. Methylmalonic acidemias are associated with defects in the methylmalonyl CoA mutase apoenzyme, leading to impaired propionate pathway activity in fibroblasts."
AdoCbl,"AdoCbl is a cofactor involved in the propionate pathway, and disorders in its synthesis in fibroblasts result in reduced pathway activity.","Entity: AdoCbl. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@H]([C@H](CC(N)=O)[C@]4(C)CCC(=O)NC[C@H](C)OP(=O)([O-])O[C@H]4[C@@H](O)[C@@H](n5cnc6cc(C)c(C)cc65)O[C@@H]4CO)[C@]4(C)N=C1[C@@H](CCC(N)=O)[C@]4(C)CC(N)=O)[C@@H](CCC(N)=O)C3(C)C)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[CH2-][C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O.[Co]. AdoCbl is a cofactor involved in the propionate pathway, and disorders in its synthesis in fibroblasts result in reduced pathway activity."
methylmalonyl CoA,"Methylmalonyl CoA mutase deficiency in fibroblasts is linked to decreased incorporation of 14C into TCA-precipitable material, indicating reduced propionate pathway activity.","Entity: methylmalonyl CoA. SMILES: CC(C(=O)O)C(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Methylmalonyl CoA mutase deficiency in fibroblasts is linked to decreased incorporation of 14C into TCA-precipitable material, indicating reduced propionate pathway activity."
trichloroacetic acid,"Trichloroacetic acid (TCA) is used to precipitate proteins from solution, allowing for their collection and subsequent solubilization for biochemical analysis.","Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid (TCA) is used to precipitate proteins from solution, allowing for their collection and subsequent solubilization for biochemical analysis."
sodium hydroxide,Sodium hydroxide (NaOH) is used to solubilize TCA-precipitated protein material prior to biochemical assays.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide (NaOH) is used to solubilize TCA-precipitated protein material prior to biochemical assays.
EDTA,EDTA is used as a component of trypsin solutions (0.250/0 trypsin-EDTA or 0.125·o trypsin) for cell dissociation in cell culture assays.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used as a component of trypsin solutions (0.250/0 trypsin-EDTA or 0.125·o trypsin) for cell dissociation in cell culture assays.
glucose,Glucose is included at a concentration of 5 × 10⁻¹ M in Puck's saline F to support cell growth in culture assays.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is included at a concentration of 5 × 10⁻¹ M in Puck's saline F to support cell growth in culture assays.
NaCl,NaCl is a major cation in phosphate buffered saline (PBS) used for rinsing cells prior to incubation in cell culture assays.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is a major cation in phosphate buffered saline (PBS) used for rinsing cells prior to incubation in cell culture assays.
KCl,KCl is present at 0.003 M in phosphate buffered saline (PBS) for cell rinsing in cell culture assays.,Entity: KCl. SMILES: [Cl-].[K+]. KCl is present at 0.003 M in phosphate buffered saline (PBS) for cell rinsing in cell culture assays.
Na propionate,Na propionate is used at a final concentration of 10⁻¹ M and is radiolabeled with 14C (1 × 10⁻¹ Ci/mmol; 1 × 10⁻¹ Ci/ml) in cell culture assays to study its uptake by cells.,Entity: Na propionate. SMILES: CCC(=O)[O-].[Na+]. Na propionate is used at a final concentration of 10⁻¹ M and is radiolabeled with 14C (1 × 10⁻¹ Ci/mmol; 1 × 10⁻¹ Ci/ml) in cell culture assays to study its uptake by cells.
AdoCbl,"AdoCbl (adenosylcobalamin) is required as a cofactor for methylmalonyl CoA mutase activity, and its presence is used to assess residual enzyme activity in amniotic cell lysates.","Entity: AdoCbl. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@H]([C@H](CC(N)=O)[C@]4(C)CCC(=O)NC[C@H](C)OP(=O)([O-])O[C@H]4[C@@H](O)[C@@H](n5cnc6cc(C)c(C)cc65)O[C@@H]4CO)[C@]4(C)N=C1[C@@H](CCC(N)=O)[C@]4(C)CC(N)=O)[C@@H](CCC(N)=O)C3(C)C)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[CH2-][C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O.[Co]. AdoCbl (adenosylcobalamin) is required as a cofactor for methylmalonyl CoA mutase activity, and its presence is used to assess residual enzyme activity in amniotic cell lysates."
methylmalonic acid,"Methylmalonic acidemia is a disorder caused by defects in the methylmalonyl CoA mutase enzyme, leading to impaired metabolism and potentially severe clinical manifestations.","Entity: methylmalonic acid. SMILES: CC(C(=O)O)C(=O)O. Methylmalonic acidemia is a disorder caused by defects in the methylmalonyl CoA mutase enzyme, leading to impaired metabolism and potentially severe clinical manifestations."
succinate,"Succinate is used as a product to measure methylmalonyl CoA mutase activity in amniotic cell lysates, with low levels indicating reduced enzyme activity.","Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate is used as a product to measure methylmalonyl CoA mutase activity in amniotic cell lysates, with low levels indicating reduced enzyme activity."
cob(I)alamin,"Cob(I)alamin, also referred to as hydroxocobalamin (cob(III)alamin), is a form of cobalamin (vitamin B12) involved in inborn errors of metabolism.","Entity: cob(I)alamin. SMILES: C/C1=C2/[N-][C@H]([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)(O)O[C@H]2[C@@H](O)[C@@H](n3cnc4cc(C)c(C)cc43)O[C@@H]2CO)[C@]2(C)N=C(/C(C)=C3\N=C(/C=C4\N=C1[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]3(C)CC(N)=O)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[Co]. Cob(I)alamin, also referred to as hydroxocobalamin (cob(III)alamin), is a form of cobalamin (vitamin B12) involved in inborn errors of metabolism."
cobalamin,Cobalamin (vitamin B12) is required as a cofactor for methylmalonyl CoA mutase activity in inborn errors of metabolism.,Entity: cobalamin. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@@H](n6cnc7cc(C)c(C)cc76)O[C@@H]1CO)[C@H]5CC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O.[C-]#N.[Co+3]. Cobalamin (vitamin B12) is required as a cofactor for methylmalonyl CoA mutase activity in inborn errors of metabolism.
cob(II)alamin,"Cob(II)alamin, also referred to as adenosylcobalamin, is a cobalamin coenzyme required for methylmalonyl CoA mutase activity.","Entity: cob(II)alamin. SMILES: C/C1=C2/[N-][C@H]([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]2[C@@H](O)[C@@H](n3cnc4cc(C)c(C)cc43)O[C@@H]2CO)[C@]2(C)N=C(/C(C)=C3\N=C(/C=C4\N=C1[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]3(C)CC(N)=O)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[Co]. Cob(II)alamin, also referred to as adenosylcobalamin, is a cobalamin coenzyme required for methylmalonyl CoA mutase activity."
propionate,Propionate is a substrate in the propionate pathway that is converted to succinyl CoA via D-methylmalonyl CoA and L-methylmalonyl CoA.,Entity: propionate. SMILES: CCC(=O)[O-]. Propionate is a substrate in the propionate pathway that is converted to succinyl CoA via D-methylmalonyl CoA and L-methylmalonyl CoA.
trichloroacetic acid,Trichloroacetic acid is used in autoradiographic procedures to precipitate TCA-precipitable cell material for measuring incorporation of [1-14C]propionate in inborn error of metabolism studies.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used in autoradiographic procedures to precipitate TCA-precipitable cell material for measuring incorporation of [1-14C]propionate in inborn error of metabolism studies.
methylcobalamin,Methylcobalamin is a coenzyme form of cobalamin (vitamin B12) whose synthesis is impaired in certain inborn errors of metabolism.,Entity: methylcobalamin. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-]C(C(CC(N)=O)C4(C)CCC(=O)NCC(C)OP(=O)([O-])OC4C(CO)OC(n5cnc6cc(C)c(C)cc65)C4O)C4(C)N=C1C(CCC(N)=O)C4(C)CC(N)=O)C(CCC(N)=O)C3(C)C)C(CCC(N)=O)C2(C)CC(N)=O.[CH3-].[Co+3]. Methylcobalamin is a coenzyme form of cobalamin (vitamin B12) whose synthesis is impaired in certain inborn errors of metabolism.
adenosylcobalamin,"Adenosylcobalamin, also known as cob(II)alamin, is a cobalamin coenzyme required for methylmalonyl CoA mutase activity and its synthesis is defective in specific inborn errors of metabolism.","Entity: adenosylcobalamin. SMILES: C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4\[N-][C@H]([C@H](CC(N)=O)[C@]4(C)CCC(=O)NC[C@H](C)OP(=O)([O-])O[C@H]4[C@@H](O)[C@@H](n5cnc6cc(C)c(C)cc65)O[C@@H]4CO)[C@]4(C)N=C1[C@@H](CCC(N)=O)[C@]4(C)CC(N)=O)[C@@H](CCC(N)=O)C3(C)C)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[CH2-][C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O.[Co]. Adenosylcobalamin, also known as cob(II)alamin, is a cobalamin coenzyme required for methylmalonyl CoA mutase activity and its synthesis is defective in specific inborn errors of metabolism."
methylmalonate,"Inborn errors of methylmalonate metabolism in humans result in recessively inherited blocks in intermediary metabolism, leading to acute ketoacidosis, protein intolerance, and failure to thrive during infancy.","Entity: methylmalonate. SMILES: CC(C(=O)[O-])C(=O)[O-]. Inborn errors of methylmalonate metabolism in humans result in recessively inherited blocks in intermediary metabolism, leading to acute ketoacidosis, protein intolerance, and failure to thrive during infancy."
succinyl CoA,"Succinyl CoA is the end product of the propionate pathway, formed from propionyl CoA via D-methylmalonyl CoA and L-methylmalonyl CoA.","Entity: succinyl CoA. SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(=O)O. Succinyl CoA is the end product of the propionate pathway, formed from propionyl CoA via D-methylmalonyl CoA and L-methylmalonyl CoA."
hydroxocobalamin,"Hydroxocobalamin, also known as cob(III)alamin, is a form of cobalamin (vitamin B12) involved in inborn errors of metabolism.","Entity: hydroxocobalamin. SMILES: C/C1=C2/[N-][C@H]([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]2[C@@H](O)[C@@H](n3cnc4cc(C)c(C)cc43)O[C@@H]2CO)[C@]2(C)N=C(/C(C)=C3\N=C(/C=C4\N=C1[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]3(C)CC(N)=O)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O.[Co+3].[OH-]. Hydroxocobalamin, also known as cob(III)alamin, is a form of cobalamin (vitamin B12) involved in inborn errors of metabolism."
propionyl CoA,Propionyl CoA is an intermediate in the propionate pathway that is converted to succinyl CoA via D-methylmalonyl CoA and L-methylmalonyl CoA.,Entity: propionyl CoA. SMILES: CCC(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Propionyl CoA is an intermediate in the propionate pathway that is converted to succinyl CoA via D-methylmalonyl CoA and L-methylmalonyl CoA.
methylmalonic acid,"Methylmalonic acidemias can be screened for using a cell-based assay that quantifies total pathway activity, making it suitable for rapid prenatal diagnosis.","Entity: methylmalonic acid. SMILES: CC(C(=O)O)C(=O)O. Methylmalonic acidemias can be screened for using a cell-based assay that quantifies total pathway activity, making it suitable for rapid prenatal diagnosis."
propionic acid,"Propionic acidemia can be diagnosed rapidly and reliably using a cell-based assay that monitors total pathway activity, especially in prenatal settings.","Entity: propionic acid. SMILES: CCC(=O)O. Propionic acidemia can be diagnosed rapidly and reliably using a cell-based assay that monitors total pathway activity, especially in prenatal settings."
galactose,Disorders of galactose metabolism can be detected using a cell-based assay that assesses total pathway activity.,Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Disorders of galactose metabolism can be detected using a cell-based assay that assesses total pathway activity.
urea,Urea cycle disorders can be studied using a sensitive and reliable cell-based assay that monitors total pathway activity.,Entity: urea. SMILES: NC(N)=O. Urea cycle disorders can be studied using a sensitive and reliable cell-based assay that monitors total pathway activity.
propionate,"Propionate serves as a substrate in the propionate pathway, and reduced incorporation of 14C-labeled propionate into TCA-precipitable material indicates defects in the pathway.","Entity: propionate. SMILES: CCC(=O)[O-]. Propionate serves as a substrate in the propionate pathway, and reduced incorporation of 14C-labeled propionate into TCA-precipitable material indicates defects in the pathway."
methylmalonyl CoA,"Methylmalonyl CoA is a key intermediate in the propionate pathway, and its metabolism is assessed by measuring 14C incorporation into TCA-precipitable material in mutant fibroblast lines.","Entity: methylmalonyl CoA. SMILES: CC(C(=O)O)C(=O)SCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O. Methylmalonyl CoA is a key intermediate in the propionate pathway, and its metabolism is assessed by measuring 14C incorporation into TCA-precipitable material in mutant fibroblast lines."
propionate,Propionate is used as a substrate in assays to detect inborn errors of propionate metabolism by measuring its incorporation into TCA-precipitable cell material in cultured amniotic cells and skin fibroblasts.,Entity: propionate. SMILES: CCC(=O)[O-]. Propionate is used as a substrate in assays to detect inborn errors of propionate metabolism by measuring its incorporation into TCA-precipitable cell material in cultured amniotic cells and skin fibroblasts.
[1-14C]propionate,"[1-14C]propionate is a labeled form of propionate used to measure its incorporation into TCA-precipitable cell material in cultured amniotic cells and skin fibroblasts, with controls showing 6.89 nanoatoms 14C/mg protein in 10 hours.","Entity: [1-14C]propionate. SMILES: CC[14C](=O)[O-]. [1-14C]propionate is a labeled form of propionate used to measure its incorporation into TCA-precipitable cell material in cultured amniotic cells and skin fibroblasts, with controls showing 6.89 nanoatoms 14C/mg protein in 10 hours."
trichloroacetic acid,Trichloroacetic acid is used to precipitate proteins from cell material in assays for detecting inborn errors of propionate metabolism.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to precipitate proteins from cell material in assays for detecting inborn errors of propionate metabolism.
propionate,"Propionate is a substrate involved in the propionate pathway, which can be directly quantified in human skin fibroblast and amniotic cell cultures using a modified autoradiography technique.","Entity: propionate. SMILES: CCC(=O)[O-]. Propionate is a substrate involved in the propionate pathway, which can be directly quantified in human skin fibroblast and amniotic cell cultures using a modified autoradiography technique."
methylmalonate,"Methylmalonate is a metabolite in the propionate pathway and can be detected in human skin fibroblast and amniotic cell cultures using a sensitive, quantitative autoradiography method.","Entity: methylmalonate. SMILES: CC(C(=O)[O-])C(=O)[O-]. Methylmalonate is a metabolite in the propionate pathway and can be detected in human skin fibroblast and amniotic cell cultures using a sensitive, quantitative autoradiography method."
3-phosphoglycerate,"3-phosphoglycerate is produced from 1,3-diphosphoglycerate by the reversible reaction catalyzed by phosphoglycerate kinase (EC 2.7.2.3.), which transfers a high-energy phosphate group from 1,3-diphosphoglycerate to ADP.","Entity: 3-phosphoglycerate. SMILES: O=C([O-])C(O)COP(=O)(O)O. 3-phosphoglycerate is produced from 1,3-diphosphoglycerate by the reversible reaction catalyzed by phosphoglycerate kinase (EC 2.7.2.3.), which transfers a high-energy phosphate group from 1,3-diphosphoglycerate to ADP."
phenazine methosulfate,Phenazine methosulfate is used as a reagent for counterdevelopment in electrophoresis to visualize enzyme activity sites as colorless zones against a blue background.,Entity: phenazine methosulfate. SMILES: COS(=O)(=O)[O-].C[n+]1c2ccccc2nc2ccccc21. Phenazine methosulfate is used as a reagent for counterdevelopment in electrophoresis to visualize enzyme activity sites as colorless zones against a blue background.
linoleic acid,Linoleic acid is a fatty acid present at a 19-fold higher concentration in rat serum than in fetal calf serum.,Entity: linoleic acid. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. Linoleic acid is a fatty acid present at a 19-fold higher concentration in rat serum than in fetal calf serum.
linoleic acid,Linoleic acid is capable of maintaining the growth of a carcinogen-induced rat mammary tumor cell line in delipidized serum or in whole fetal calf serum-supplemented medium.,Entity: linoleic acid. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. Linoleic acid is capable of maintaining the growth of a carcinogen-induced rat mammary tumor cell line in delipidized serum or in whole fetal calf serum-supplemented medium.
methylcellulose,Methylcellulose is used as a component (20%) in bone marrow cell suspension medium to support colony-forming cell cultures in vitro.,Entity: methylcellulose. SMILES: COCC1OC(OC2C(COC)OC(OC)C(OC)C2OC)C(OC)C(OC)C1OC. Methylcellulose is used as a component (20%) in bone marrow cell suspension medium to support colony-forming cell cultures in vitro.
uridine,"Uridine can be labeled with tritium (3H) to produce tritiated uridine, which is used as a radioactive tracer in molecular hybridization experiments.","Entity: uridine. SMILES: O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Uridine can be labeled with tritium (3H) to produce tritiated uridine, which is used as a radioactive tracer in molecular hybridization experiments."
mitomycin,Mitomycin induces chromatid exchanges that preferentially occur between chromosome 1 and 9 heterochromatin and the short arms of acrocentric chromosomes.,Entity: mitomycin. SMILES: CO[C@@]12[C@@H]3N[C@@H]3CN1C1=C(C(=O)C(N)=C(C)C1=O)[C@@H]2COC(N)=O. Mitomycin induces chromatid exchanges that preferentially occur between chromosome 1 and 9 heterochromatin and the short arms of acrocentric chromosomes.
bromodeoxyuridine,"Bromodeoxyuridine is used as a labeling agent in cell culture experiments to study cell cycle progression and mitotic activity, with pulse-labeling experiments in the Ham's F-10/PHA-system showing a predominance of second mitoses at 72 hours after culture initiation in non-irradiated cultures.","Entity: bromodeoxyuridine. SMILES: O=c1ccn([C@@]2(Br)C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. Bromodeoxyuridine is used as a labeling agent in cell culture experiments to study cell cycle progression and mitotic activity, with pulse-labeling experiments in the Ham's F-10/PHA-system showing a predominance of second mitoses at 72 hours after culture initiation in non-irradiated cultures."
thymidine,"Thymidine, in the form of (3H)TdR, is used as a pulse-labeling agent in cell culture experiments to study cell cycle progression and mitotic activity, with labeling experiments in the Ham's F-10/PHA-system indicating a cell cycle delay of at least 9 hours after culture initiation.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine, in the form of (3H)TdR, is used as a pulse-labeling agent in cell culture experiments to study cell cycle progression and mitotic activity, with labeling experiments in the Ham's F-10/PHA-system indicating a cell cycle delay of at least 9 hours after culture initiation."
dihydrostreptomycin,Dihydrostreptomycin is used as an antibiotic supplement in leukocyte culture media at a concentration of 1.0 mg/ml in combination with 100 IU penicillin.,Entity: dihydrostreptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O. Dihydrostreptomycin is used as an antibiotic supplement in leukocyte culture media at a concentration of 1.0 mg/ml in combination with 100 IU penicillin.
acetic acid,Acetic acid is used in a 1:3 mixture with methanol as a fixative solution for chromosome preparation in cells.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid is used in a 1:3 mixture with methanol as a fixative solution for chromosome preparation in cells.
methanol,Methanol is used in a 1:3 mixture with acetic acid as a fixative solution for chromosome preparation in cells.,Entity: methanol. SMILES: CO. Methanol is used in a 1:3 mixture with acetic acid as a fixative solution for chromosome preparation in cells.
caffeine,Caffeine is used at a concentration of 10% in cell suspension medium to facilitate in situ chromosome preparation in irradiated cells.,Entity: caffeine. SMILES: Cn1c(=O)c2c(ncn2C)n(C)c1=O. Caffeine is used at a concentration of 10% in cell suspension medium to facilitate in situ chromosome preparation in irradiated cells.
colchicine,Colchicine is applied at a concentration of approximately 1 µg/ml 3 hours before in situ chromosome preparation to aid in chromosome condensation.,Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine is applied at a concentration of approximately 1 µg/ml 3 hours before in situ chromosome preparation to aid in chromosome condensation.
glutamicpyruvic transaminase,Glutamicpyruvic transaminase (GPT) is a biomarker commonly measured in blood samples for diagnostic purposes.,Entity: glutamicpyruvic transaminase. Glutamicpyruvic transaminase (GPT) is a biomarker commonly measured in blood samples for diagnostic purposes.
polypropylene,Polypropylene is used as a mesh material in inguinal and femoral hernia repair procedures.,Entity: polypropylene. SMILES: CC(C[*:1])[*:2]. Polypropylene is used as a mesh material in inguinal and femoral hernia repair procedures.
vasopressin,Vasopressin is implicated as a low-molecular-weight component of prolactin that can stimulate lipid incorporation in rat mammary tumor cells.,Entity: vasopressin. Vasopressin is implicated as a low-molecular-weight component of prolactin that can stimulate lipid incorporation in rat mammary tumor cells.
prolactin,"Prolactin stimulates the incorporation of [14C]acetate into lipids in a rat mammary tumor cell line, with maximal activity observed 36 hours after hormone addition and insulin required for full response.","Entity: prolactin. Prolactin stimulates the incorporation of [14C]acetate into lipids in a rat mammary tumor cell line, with maximal activity observed 36 hours after hormone addition and insulin required for full response."
prolactin,"The biological activity of prolactin in rat mammary tumor cells is associated with a low-molecular-weight fraction, likely containing vasopressin or oxytocin.","Entity: prolactin. The biological activity of prolactin in rat mammary tumor cells is associated with a low-molecular-weight fraction, likely containing vasopressin or oxytocin."
beta-casein,Beta-casein is a protein antigen that can cross-react with polyclonal antibodies in ELISA assays for bovine beta-LG in human milk.,Entity: beta-casein. Beta-casein is a protein antigen that can cross-react with polyclonal antibodies in ELISA assays for bovine beta-LG in human milk.
alpha-lactalbumin,Alpha-lactalbumin is a protein antigen that can cross-react with polyclonal antibodies used in ELISA assays for detecting bovine beta-LG in human milk.,Entity: alpha-lactalbumin. Alpha-lactalbumin is a protein antigen that can cross-react with polyclonal antibodies used in ELISA assays for detecting bovine beta-LG in human milk.
steroids,"Antenatal steroid treatment reduces the incidence of respiratory distress syndrome, intraventricular hemorrhage, bronchopulmonary dysplasia, and mortality in preterm infants when administered to the mother at risk for preterm delivery.","Entity: steroids. SMILES: CC(=O)N(C)[C@H](C)[C@@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](N(C)C)CC[C@@]4(C)[C@@H]3CC[C@]21C. Antenatal steroid treatment reduces the incidence of respiratory distress syndrome, intraventricular hemorrhage, bronchopulmonary dysplasia, and mortality in preterm infants when administered to the mother at risk for preterm delivery."
bis (chloromethyl) ether,bis (chloromethyl) ether has been reported carcinogenic in animal tests prior to the availability of epidemiological data.,Entity: bis (chloromethyl) ether. SMILES: ClCOCCl. bis (chloromethyl) ether has been reported carcinogenic in animal tests prior to the availability of epidemiological data.
styrene,Styrene has been tested for carcinogenic potential using experimental models to assess risk.,Entity: styrene. SMILES: C=Cc1ccccc1. Styrene has been tested for carcinogenic potential using experimental models to assess risk.
acrylonitrile,Acrylonitrile has been evaluated for carcinogenic risk using experimental models and screening tests.,Entity: acrylonitrile. SMILES: C=CC#N. Acrylonitrile has been evaluated for carcinogenic risk using experimental models and screening tests.
vinylidene chloride,"Vinylidene chloride has undergone testing for carcinogenic potential, including experimental models and screening assays.","Entity: vinylidene chloride. SMILES: C=C(Cl)Cl. Vinylidene chloride has undergone testing for carcinogenic potential, including experimental models and screening assays."
carotenoid,Neonatal carotenoid concentrations are strictly related to maternal carotenoid levels and are lower than maternal levels in healthy full-term infants.,Entity: carotenoid. SMILES: CC(C=C[C@H]1C(C)=C[C@H](O)CC1(C)C)=CC=CC(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C. Neonatal carotenoid concentrations are strictly related to maternal carotenoid levels and are lower than maternal levels in healthy full-term infants.
sodium,"Excessive sodium intake is correlated with the onset of preeclampsia symptomatology, and reducing sodium intake during the early stage of preeclampsia symptoms favors the disappearance of its clinical signs.","Entity: sodium. SMILES: [Na]. Excessive sodium intake is correlated with the onset of preeclampsia symptomatology, and reducing sodium intake during the early stage of preeclampsia symptoms favors the disappearance of its clinical signs."
superoxide,"Superoxide (O2), generated by a system comprised of phenazine methosulfate and NADH, contributes to the metabolism of 14C-vinyl chloride in rat liver microsomes, leading to metabolites that irreversibly bind to albumin.","Entity: superoxide. SMILES: [O][O-]. Superoxide (O2), generated by a system comprised of phenazine methosulfate and NADH, contributes to the metabolism of 14C-vinyl chloride in rat liver microsomes, leading to metabolites that irreversibly bind to albumin."
phenazine methosulfate,"Phenazine methosulfate, in combination with NADH, acts as a superoxide (O2) generating system that metabolizes 14C-vinyl chloride in rat liver microsomes, producing metabolites that irreversibly bind to albumin.","Entity: phenazine methosulfate. SMILES: COS(=O)(=O)[O-].C[n+]1c2ccccc2nc2ccccc21. Phenazine methosulfate, in combination with NADH, acts as a superoxide (O2) generating system that metabolizes 14C-vinyl chloride in rat liver microsomes, producing metabolites that irreversibly bind to albumin."
albumin,Metabolites of 14 C-vinyl chloride generated by a phenazine methosulfate and NADH superoxide system irreversibly bind to albumin in rat liver.,Entity: albumin. Metabolites of 14 C-vinyl chloride generated by a phenazine methosulfate and NADH superoxide system irreversibly bind to albumin in rat liver.
agar,"Agar is used as a medium for colony formation assays to assess cell transformation, serving as a criterion for control in long-term cell transformation tests.","Entity: agar. SMILES: CO[C@H]1[C@@H](O)[C@@H](CO)OC(OC2C3CO[C@H]2[C@H](O)C(C)O3)[C@@H]1O. Agar is used as a medium for colony formation assays to assess cell transformation, serving as a criterion for control in long-term cell transformation tests."
Cytochrome P450,"Cytochrome P450 monooxygenases are involved in insecticide resistance in insects, with increased monooxygenase activities and cytochrome P450 content often associated with resistance.","Entity: Cytochrome P450. Cytochrome P450 monooxygenases are involved in insecticide resistance in insects, with increased monooxygenase activities and cytochrome P450 content often associated with resistance."
cyromazine,"Cyromazine is an insecticide to which Lucilia cuprina populations have remained susceptible after almost 20 years of exposure, indicating a lack of significant resistance development.","Entity: cyromazine. SMILES: Nc1nc(N)nc(NC2CC2)n1. Cyromazine is an insecticide to which Lucilia cuprina populations have remained susceptible after almost 20 years of exposure, indicating a lack of significant resistance development."
malathion,Malathion is an insecticide to which single-gene variants of Lucilia cuprina have developed resistance through genetic mutations.,Entity: malathion. SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC. Malathion is an insecticide to which single-gene variants of Lucilia cuprina have developed resistance through genetic mutations.
dieldrin,Dieldrin is an insecticide to which single-gene variants of Lucilia cuprina have developed resistance through genetic mutations.,Entity: dieldrin. SMILES: ClC1=C(Cl)[C@]2(Cl)[C@@H]3[C@@H]4C[C@@H]([C@H]5O[C@@H]45)[C@@H]3[C@@]1(Cl)C2(Cl)Cl. Dieldrin is an insecticide to which single-gene variants of Lucilia cuprina have developed resistance through genetic mutations.
phenyl pyrazole,Phenyl pyrazole insecticides have been tested as alternative treatments for bed nets or curtains in malaria vector control.,Entity: phenyl pyrazole. SMILES: c1ccc(-c2cc[nH]n2)cc1. Phenyl pyrazole insecticides have been tested as alternative treatments for bed nets or curtains in malaria vector control.
carbamate,Carbamate insecticides have been tested as alternative treatments for bed nets or curtains in malaria vector control.,Entity: carbamate. SMILES: NC(=O)[O-]. Carbamate insecticides have been tested as alternative treatments for bed nets or curtains in malaria vector control.
IL4,Th2 cells producing IL4 are essential for parasite clearance in late infection in some rodent malaria models.,Entity: IL4. Th2 cells producing IL4 are essential for parasite clearance in late infection in some rodent malaria models.
CD8,CD8+ T cells carrying alpha/beta T cell receptors play a limited role in blood stage Plasmodium falciparum infections compared to CD4+ T cells.,Entity: CD8. CD8+ T cells carrying alpha/beta T cell receptors play a limited role in blood stage Plasmodium falciparum infections compared to CD4+ T cells.
CD8,"The CD4/CD8 ratio increased from 0.7 to 1.4 in a patient with disseminated M. tuberculosis infection after six months of anti-tuberculous therapy, indicating a shift in immune balance toward cytotoxic T cells.","Entity: CD8. The CD4/CD8 ratio increased from 0.7 to 1.4 in a patient with disseminated M. tuberculosis infection after six months of anti-tuberculous therapy, indicating a shift in immune balance toward cytotoxic T cells."
benzo[a]pyrene,"Benzo[a]pyrene is classified as a pollutant of primary interest due to its carcinogenic, mutagenic, or cofactor activity.","Entity: benzo[a]pyrene. SMILES: c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34. Benzo[a]pyrene is classified as a pollutant of primary interest due to its carcinogenic, mutagenic, or cofactor activity."
benzo[a]pyrene,"Concentrations of benzo[a]pyrene have been reported in urban atmospheres, highly polluted atmospheres, and in various environmental mixtures.","Entity: benzo[a]pyrene. SMILES: c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34. Concentrations of benzo[a]pyrene have been reported in urban atmospheres, highly polluted atmospheres, and in various environmental mixtures."
nitrosamines,"Nitrosamines are considered air pollutants of primary interest because of their carcinogenic, mutagenic, or cofactor activity.","Entity: nitrosamines. SMILES: NN=O. Nitrosamines are considered air pollutants of primary interest because of their carcinogenic, mutagenic, or cofactor activity."
sulfite,"Sulfate is identified as a key air pollutant of primary interest due to its carcinogenic, mutagenic, or cofactor activity.","Entity: sulfite. SMILES: O=S([O-])[O-]. Sulfate is identified as a key air pollutant of primary interest due to its carcinogenic, mutagenic, or cofactor activity."
nitroso,The nitroso group is associated with the induction of many different types of cancer in animals.,Entity: nitroso. SMILES: [N]=O. The nitroso group is associated with the induction of many different types of cancer in animals.
nitrosamines,Nitrosamines are compounds whose carcinogenic potential is linked to the presence of the nitroso group.,Entity: nitrosamines. SMILES: NN=O. Nitrosamines are compounds whose carcinogenic potential is linked to the presence of the nitroso group.
nitrosamines,Nitrosamines can induce the development of various types of cancer in animals.,Entity: nitrosamines. SMILES: NN=O. Nitrosamines can induce the development of various types of cancer in animals.
nitrosamines,Adequate analytical methods are available for the determination of volatile nitrosamines at concentrations down to the mug/dg level.,Entity: nitrosamines. SMILES: NN=O. Adequate analytical methods are available for the determination of volatile nitrosamines at concentrations down to the mug/dg level.
prolactin,Prolactin is a hormone whose constant or periodic increase in serum concentrations indicates functional or organic damage to the hypothalamic-pituitary axis.,Entity: prolactin. Prolactin is a hormone whose constant or periodic increase in serum concentrations indicates functional or organic damage to the hypothalamic-pituitary axis.
CD8,"CD8+ T cells, which are cytotoxic and suppressor cells, decrease in number with age, leading to an increase in the CD4/CD8 ratio.","Entity: CD8. CD8+ T cells, which are cytotoxic and suppressor cells, decrease in number with age, leading to an increase in the CD4/CD8 ratio."
cyclosporin A,Cyclosporin A is a drug used to circumvent classical multidrug resistance (MDR) in acute myelogenous leukemia (AML) and is successfully applied in refractory and relapsed AML cases.,Entity: cyclosporin A. SMILES: C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C. Cyclosporin A is a drug used to circumvent classical multidrug resistance (MDR) in acute myelogenous leukemia (AML) and is successfully applied in refractory and relapsed AML cases.
cyclosporin D,Cyclosporin D (SDZ PCS 833) is a drug used to overcome classical multidrug resistance (MDR) in acute myelogenous leukemia (AML) and is effective in refractory and relapsed AML.,Entity: cyclosporin D. SMILES: C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C. Cyclosporin D (SDZ PCS 833) is a drug used to overcome classical multidrug resistance (MDR) in acute myelogenous leukemia (AML) and is effective in refractory and relapsed AML.
colchicine,Colchicine is a cytotoxic compound of natural origin whose resistance in AML can be mediated by the P-glycoprotein (Pgp) drug-efflux pump.,Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine is a cytotoxic compound of natural origin whose resistance in AML can be mediated by the P-glycoprotein (Pgp) drug-efflux pump.
amsacrine,Amsacrine is a cytotoxic compound of natural origin to which resistance in AML can be conferred by the P-glycoprotein (Pgp) drug-efflux pump.,Entity: amsacrine. SMILES: COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12. Amsacrine is a cytotoxic compound of natural origin to which resistance in AML can be conferred by the P-glycoprotein (Pgp) drug-efflux pump.
nitroglycerin,"Nitroglycerin ointment produces significant hemodynamic improvement in patients with congestive heart failure refractory to diuretics, digitalis, and salt restriction by lowering pulmonary wedge pressure, increasing pulse pressure, and reducing myocardial oxygen consumption.","Entity: nitroglycerin. SMILES: O=[N+]([O-])C(O)C(O)CO. Nitroglycerin ointment produces significant hemodynamic improvement in patients with congestive heart failure refractory to diuretics, digitalis, and salt restriction by lowering pulmonary wedge pressure, increasing pulse pressure, and reducing myocardial oxygen consumption."
sodium nitroprusside,Sodium nitroprusside is a vasodilator that reduces afterload on the left ventricle and produces beneficial effects in patients with heart failure.,Entity: sodium nitroprusside. SMILES: N#[O+].O.O.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[Fe+2].[Na+].[Na+]. Sodium nitroprusside is a vasodilator that reduces afterload on the left ventricle and produces beneficial effects in patients with heart failure.
sodium nitroprusside,Sodium nitroprusside requires intravenous administration and cannot be used for long-term therapy in heart failure.,Entity: sodium nitroprusside. SMILES: N#[O+].O.O.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[Fe+2].[Na+].[Na+]. Sodium nitroprusside requires intravenous administration and cannot be used for long-term therapy in heart failure.
phentolamine,Phentolamine is a vasodilator that reduces afterload on the left ventricle and produces beneficial effects in patients with heart failure.,Entity: phentolamine. SMILES: Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1. Phentolamine is a vasodilator that reduces afterload on the left ventricle and produces beneficial effects in patients with heart failure.
phentolamine,Phentolamine requires intravenous administration and cannot be used for long-term therapy in heart failure.,Entity: phentolamine. SMILES: Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1. Phentolamine requires intravenous administration and cannot be used for long-term therapy in heart failure.
nitroglycerin,"Nitroglycerin ointment is used as a chronic therapy to improve symptoms in patients with dyspnea at rest, with maintenance doses of digitalis and diuretics continued alongside nitroglycerin ointment.","Entity: nitroglycerin. SMILES: O=[N+]([O-])C(O)C(O)CO. Nitroglycerin ointment is used as a chronic therapy to improve symptoms in patients with dyspnea at rest, with maintenance doses of digitalis and diuretics continued alongside nitroglycerin ointment."
"5-Methoxy-7-methyl-7H-pyrido[4,3-c]carbazole","5-Methoxy-7-methyl-7H-pyrido[4,3-c]carbazole inhibits HIV replication in H9 lymphocytes with an EC50 value of 0.0054 µg/mL and a therapeutic index (TI) of 503.","Entity: 5-Methoxy-7-methyl-7H-pyrido[4,3-c]carbazole. SMILES: COc1cc2c(c3cnccc13)c1ccccc1n2C. 5-Methoxy-7-methyl-7H-pyrido[4,3-c]carbazole inhibits HIV replication in H9 lymphocytes with an EC50 value of 0.0054 µg/mL and a therapeutic index (TI) of 503."
phosphoramidate,"Phosphoramidate groups can be present alpha- to the carboxylate moiety in isoxazolinylacetamides, contributing to high affinity binding to GPIIb/IIIa and potent antagonism of ADP-mediated platelet aggregation.","Entity: phosphoramidate. SMILES: NP(=O)([O-])[O-]. Phosphoramidate groups can be present alpha- to the carboxylate moiety in isoxazolinylacetamides, contributing to high affinity binding to GPIIb/IIIa and potent antagonism of ADP-mediated platelet aggregation."
phosphinate,Phosphinate-based compounds can act as inhibitors of MMP-1 and MMP-13 by binding into the S2 pocket of these enzymes.,Entity: phosphinate. SMILES: O=[PH2][O-]. Phosphinate-based compounds can act as inhibitors of MMP-1 and MMP-13 by binding into the S2 pocket of these enzymes.
calpain,"Calpain is a protein whose peptide binding region interacts critically with the P1-P2 amide bond of dipeptide aldehydes, which is absent in ketomethylene isosteres, resulting in significantly reduced potency.","Entity: calpain. Calpain is a protein whose peptide binding region interacts critically with the P1-P2 amide bond of dipeptide aldehydes, which is absent in ketomethylene isosteres, resulting in significantly reduced potency."
indolocarbazole,Indolocarbazole derivatives can possess potent activity against human topoisomerase I (Topo I).,Entity: indolocarbazole. SMILES: c1ccc2c(c1)N=c1ccc3c(c1-2)N=c1ccccc1=3. Indolocarbazole derivatives can possess potent activity against human topoisomerase I (Topo I).
1-(beta-D-xylofuranosyl) adenine,1-(beta-D-xylofuranosyl) adenine can substitute for conserved ribopurine residues at positions A15.1 and A6 in a stabilized hammerhead ribozyme and retain close to wild-type catalytic activity.,Entity: 1-(beta-D-xylofuranosyl) adenine. SMILES: Nc1c2ncnc-2ncn1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O. 1-(beta-D-xylofuranosyl) adenine can substitute for conserved ribopurine residues at positions A15.1 and A6 in a stabilized hammerhead ribozyme and retain close to wild-type catalytic activity.
1-(beta-D-xylofuranosyl) guanine,"1-(beta-D-xylofuranosyl) guanine substitutions at positions G5, G8, and G12 in a stabilized hammerhead ribozyme substantially lower catalytic rates compared to the parent enzyme.","Entity: 1-(beta-D-xylofuranosyl) guanine. SMILES: Nc1nc2nc[nH]c2c(=O)n1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O. 1-(beta-D-xylofuranosyl) guanine substitutions at positions G5, G8, and G12 in a stabilized hammerhead ribozyme substantially lower catalytic rates compared to the parent enzyme."
glycopeptide,"Glycopeptides of hMOG(30-50) containing a glucosyl moiety on the side-chains of Asn, Ser, or Hyp at position 31 can be used to detect anti-hMOG(30-50) antibodies in patient sera by ELISA.","Entity: glycopeptide. SMILES: CCN[C@H]1C(O)O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2NC(C)=O)[C@@H]1OC(C)C(=O)N[C@H](C)C(=O)N[C@H](CCC(=O)N[C@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(N)=O. Glycopeptides of hMOG(30-50) containing a glucosyl moiety on the side-chains of Asn, Ser, or Hyp at position 31 can be used to detect anti-hMOG(30-50) antibodies in patient sera by ELISA."
Anisylazoformyllysine,Anisylazoformyllysine is rapidly hydrolyzed at the acyl-lysine linkage by the zinc-enzyme porcine carboxypeptidase B.,Entity: Anisylazoformyllysine. SMILES: COc1ccc(CN=NC(=O)N[C@@H](CCCCN)C(=O)O)cc1. Anisylazoformyllysine is rapidly hydrolyzed at the acyl-lysine linkage by the zinc-enzyme porcine carboxypeptidase B.
Anisylazoformyllysine,The hydrolysis of Anisylazoformyllysine by porcine carboxypeptidase B is readily monitored spectrophotometrically by the disappearance of its intense azo chromophore absorption at 348.5 nm (epsilon 18400) after substrate cleavage.,Entity: Anisylazoformyllysine. SMILES: COc1ccc(CN=NC(=O)N[C@@H](CCCCN)C(=O)O)cc1. The hydrolysis of Anisylazoformyllysine by porcine carboxypeptidase B is readily monitored spectrophotometrically by the disappearance of its intense azo chromophore absorption at 348.5 nm (epsilon 18400) after substrate cleavage.
2-trifluoroacetonylbenzoxazole,"2-trifluoroacetonylbenzoxazole exhibits strong inhibitory activity against Helicobacter pylori, with an MIC50 that is 20-fold more potent than metronidazole and twice as potent as clarithromycin.","Entity: 2-trifluoroacetonylbenzoxazole. SMILES: O=C(Cc1nc2ccccc2o1)C(F)(F)F. 2-trifluoroacetonylbenzoxazole exhibits strong inhibitory activity against Helicobacter pylori, with an MIC50 that is 20-fold more potent than metronidazole and twice as potent as clarithromycin."
fluorescein,Fluorescein can be used to prepare active esters for the synthesis of haptens conjugates via resin-supported active ester chemistry.,Entity: fluorescein. SMILES: O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21. Fluorescein can be used to prepare active esters for the synthesis of haptens conjugates via resin-supported active ester chemistry.
estriol,Estriol can be conjugated to haptens using active esters prepared from N-hydroxysuccinimidyl resin in high yield.,Entity: estriol. SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O. Estriol can be conjugated to haptens using active esters prepared from N-hydroxysuccinimidyl resin in high yield.
thyroxine,Thyroxine can be conjugated to haptens using active esters prepared from N-hydroxysuccinimidyl resin in high yield.,Entity: thyroxine. SMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O. Thyroxine can be conjugated to haptens using active esters prepared from N-hydroxysuccinimidyl resin in high yield.
coumarin,Coumarin can be used to prepare active esters for the synthesis of haptens conjugates via resin-supported active ester chemistry.,Entity: coumarin. SMILES: O=c1ccc2ccccc2o1. Coumarin can be used to prepare active esters for the synthesis of haptens conjugates via resin-supported active ester chemistry.
acridinium,Acridinium can be used to prepare active esters for the synthesis of haptens conjugates using resin-supported active ester technology.,Entity: acridinium. SMILES: c1ccc2[nH+]c3ccccc3cc2c1. Acridinium can be used to prepare active esters for the synthesis of haptens conjugates using resin-supported active ester technology.
"imidazo[1,2-e]purine","imidazo[1,2-e]purine can be synthesized by cyclization of 8-bromo-9-alkylaminoethyl-adenine.","Entity: imidazo[1,2-e]purine. SMILES: c1cn2c(n1)[nH]c1cncnc12. imidazo[1,2-e]purine can be synthesized by cyclization of 8-bromo-9-alkylaminoethyl-adenine."
"imidazo[1,2-e]purine-acridine","imidazo[1,2-e]purine-acridine is a heterodimer formed by the interaction of imidazo[1,2-e]purine with abasic site-containing oligonucleotides.","Entity: imidazo[1,2-e]purine-acridine. SMILES: c1ccc2nc3ccccc3cc2c1.c1cn2c(n1)[nH]c1cncnc12. imidazo[1,2-e]purine-acridine is a heterodimer formed by the interaction of imidazo[1,2-e]purine with abasic site-containing oligonucleotides."
Phosphonic acid,Phosphonic acid derivatives are highly water-soluble and act as potent anticonvulsant agents in the electroshock-induced convulsion assay in mice.,Entity: Phosphonic acid. SMILES: O=[PH](O)O. Phosphonic acid derivatives are highly water-soluble and act as potent anticonvulsant agents in the electroshock-induced convulsion assay in mice.
"4-oxospiro[benzopyran-2,4'-piperidine]","The 4-oxospiro[benzopyran-2,4'-piperidine] ring system is a structural component of potent class III antiarrhythmic agents.","Entity: 4-oxospiro[benzopyran-2,4'-piperidine]. SMILES: O=C1CC2(CCNCC2)Oc2ccccc21. The 4-oxospiro[benzopyran-2,4'-piperidine] ring system is a structural component of potent class III antiarrhythmic agents."
nitrous oxide,"Nitrous oxide produces analgesia in rats, with the maximum possible effect reaching 78% at 30 minutes and declining to 38% at 120 minutes in the tail-flick test.","Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide produces analgesia in rats, with the maximum possible effect reaching 78% at 30 minutes and declining to 38% at 120 minutes in the tail-flick test."
nitrous oxide,"Nitrous oxide-induced analgesia in rats is mediated primarily by activation of the descending inhibitory noradrenergic (NAergic) system and/or increased NA release at the spinal cord, leading to presynaptic inhibition of primary afferent neurotransmitter release and hyperpolarization of dorsal horn neurons via alpha 2 receptors.","Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide-induced analgesia in rats is mediated primarily by activation of the descending inhibitory noradrenergic (NAergic) system and/or increased NA release at the spinal cord, leading to presynaptic inhibition of primary afferent neurotransmitter release and hyperpolarization of dorsal horn neurons via alpha 2 receptors."
nitrous oxide,"Nitrous oxide exposure in rats decreases noradrenergic neuronal activity, reducing NA content by 52% in the locus coeruleus and by 20% in the spinal cord.","Entity: nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide exposure in rats decreases noradrenergic neuronal activity, reducing NA content by 52% in the locus coeruleus and by 20% in the spinal cord."
naloxone,"Naloxone, at a dose sufficient to block morphine-induced analgesia, does not attenuate the analgesic effect of nitrous oxide in rats.","Entity: naloxone. SMILES: C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5. Naloxone, at a dose sufficient to block morphine-induced analgesia, does not attenuate the analgesic effect of nitrous oxide in rats."
clonidine,"Clonidine, an alpha 2 adrenoceptor agonist, potentiates the analgesic effect of nitrous oxide at 120 minutes, increasing the maximum possible effect from 38% to 80% in the tail-flick test in rats.","Entity: clonidine. SMILES: Clc1cccc(Cl)c1NC1=NCCN1. Clonidine, an alpha 2 adrenoceptor agonist, potentiates the analgesic effect of nitrous oxide at 120 minutes, increasing the maximum possible effect from 38% to 80% in the tail-flick test in rats."
nitrosamines,"Nitrosamines are formed in the stomachs of Wistar rats when sodium nitrite is present in drinking water and dietary amines such as DMA or pyrrolidine are added at concentrations exceeding 1,000 mg/kg.","Entity: nitrosamines. SMILES: NN=O. Nitrosamines are formed in the stomachs of Wistar rats when sodium nitrite is present in drinking water and dietary amines such as DMA or pyrrolidine are added at concentrations exceeding 1,000 mg/kg."
nitrite,"The concentration of dietary nitrite in drinking water has less influence on nitrosamine formation in the stomachs of rats than the concentration of dietary amine, especially at concentrations up to 1,000 mg/l.","Entity: nitrite. SMILES: O=N[O-]. The concentration of dietary nitrite in drinking water has less influence on nitrosamine formation in the stomachs of rats than the concentration of dietary amine, especially at concentrations up to 1,000 mg/l."
prostaglandins,Prostaglandins have been implicated as regulators of cervical maturation during pregnancy.,Entity: prostaglandins. SMILES: CCCCCC(/C=C/C1C=CC(=O)C1C/C=C/CCCC(=O)OC)OC(C)=O. Prostaglandins have been implicated as regulators of cervical maturation during pregnancy.
nitrosobenzylmethylamine,"In mass spectrometry, nitrosobenzylmethylamine forms M+-OH fragments that can be explained by intramolecular hydrogen transfer followed by OH-radical cleavage.","Entity: nitrosobenzylmethylamine. SMILES: CN(Cc1ccccc1)N=O. In mass spectrometry, nitrosobenzylmethylamine forms M+-OH fragments that can be explained by intramolecular hydrogen transfer followed by OH-radical cleavage."
nitrosobenzylmethylamine,"Deuterated derivatives of nitrosobenzylmethylamine show that hydrogen transfer within the molecular ion occurs selectively onto the oxygen of the nitroso group from the benzylethylene group, likely via a five-membered cyclic transition state.","Entity: nitrosobenzylmethylamine. SMILES: CN(Cc1ccccc1)N=O. Deuterated derivatives of nitrosobenzylmethylamine show that hydrogen transfer within the molecular ion occurs selectively onto the oxygen of the nitroso group from the benzylethylene group, likely via a five-membered cyclic transition state."
Nitrosamines,Nitrosamines (R1R2NO) with certain R groups produce mass spectra with M+-OH fragments that can be attributed to intramolecular hydrogen shift and subsequent OH-radical cleavage.,Entity: Nitrosamines. SMILES: NN=O. Nitrosamines (R1R2NO) with certain R groups produce mass spectra with M+-OH fragments that can be attributed to intramolecular hydrogen shift and subsequent OH-radical cleavage.
bromocresol green,Bromocresol green is a pH-indicator dye with a visual transition interval of 3.6 to 5.4 and absorption peaks at 430 nm (acid) and 618 nm (alkaline).,Entity: bromocresol green. SMILES: Cc1c(C2(c3cc(Br)c(O)c(Br)c3C)OS(=O)(=O)c3ccccc32)cc(Br)c(O)c1Br. Bromocresol green is a pH-indicator dye with a visual transition interval of 3.6 to 5.4 and absorption peaks at 430 nm (acid) and 618 nm (alkaline).
citric acid,Citric acid is used as a buffer component at 1% concentration in a buffer solution to maintain pH 5.0 in photochemical cycle experiments with bacteriorhodopsin.,Entity: citric acid. SMILES: O=C(O)CC(O)(CC(=O)O)C(=O)O. Citric acid is used as a buffer component at 1% concentration in a buffer solution to maintain pH 5.0 in photochemical cycle experiments with bacteriorhodopsin.
hydrochloric acid,Hydrochloric acid is used to adjust the pH of aqueous samples to 5.0 in photochemical cycle experiments with bacteriorhodopsin.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid is used to adjust the pH of aqueous samples to 5.0 in photochemical cycle experiments with bacteriorhodopsin.
nitric oxide,"Peritoneal macrophages from mice treated with Dimycolate of Trehalose (TDM) accumulate high amounts of nitric oxide (NO2-), which decreases to the level of untreated resident peritoneal macrophages in the presence of NMMA, an inhibitor of NO-synthases.","Entity: nitric oxide. SMILES: [N]=O. Peritoneal macrophages from mice treated with Dimycolate of Trehalose (TDM) accumulate high amounts of nitric oxide (NO2-), which decreases to the level of untreated resident peritoneal macrophages in the presence of NMMA, an inhibitor of NO-synthases."
lactose,Lactose utilization is a phenotypic trait that can vary among acid- and bile-tolerant isolates of Lactobacillus acidophilus compared to their parental strains.,Entity: lactose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O. Lactose utilization is a phenotypic trait that can vary among acid- and bile-tolerant isolates of Lactobacillus acidophilus compared to their parental strains.
hydrochloric acid,Hydrochloric acid at pH 3.5 is used as a selective agent to induce acid-tolerance in Lactobacillus acidophilus strains.,Entity: hydrochloric acid. SMILES: Cl. Hydrochloric acid at pH 3.5 is used as a selective agent to induce acid-tolerance in Lactobacillus acidophilus strains.
somatotropin,Somatotropin (bST) at 100 ng/ml does not alter basal or isoproterenol-stimulated lipolysis in chronic cultures of lactating cow adipose tissue after 48 hours.,Entity: somatotropin. Somatotropin (bST) at 100 ng/ml does not alter basal or isoproterenol-stimulated lipolysis in chronic cultures of lactating cow adipose tissue after 48 hours.
somatotropin,"Somatotropin (bST) reduces the ability of adenosine to inhibit lipolysis in chronic cultures of lactating cow adipose tissue, indicating an alteration of the antilipolytic response to adenosine.","Entity: somatotropin. Somatotropin (bST) reduces the ability of adenosine to inhibit lipolysis in chronic cultures of lactating cow adipose tissue, indicating an alteration of the antilipolytic response to adenosine."
insulin,"Insulin, when combined with dexamethasone, enhances lipolysis in chronic cultures of lactating cow adipose tissue, as measured by isoproterenol stimulation and increased sensitivity to adenosine inhibition.","Entity: insulin. Insulin, when combined with dexamethasone, enhances lipolysis in chronic cultures of lactating cow adipose tissue, as measured by isoproterenol stimulation and increased sensitivity to adenosine inhibition."
ferric chloride,Supplementation with 50 µM ferric chloride reverses the inhibitory effects of bovine IgG and apolactoferrin on the growth of coliform bacteria in iron-restricted media.,Entity: ferric chloride. SMILES: Cl[Fe](Cl)Cl. Supplementation with 50 µM ferric chloride reverses the inhibitory effects of bovine IgG and apolactoferrin on the growth of coliform bacteria in iron-restricted media.
lactoferrin,Lactoferrin at 0.5 mg/ml in chemically defined medium alone does not significantly inhibit the growth of coliform bacteria (E. coli and Klebsiella pneumoniae) derived from bovine intramammary infection.,Entity: lactoferrin. Lactoferrin at 0.5 mg/ml in chemically defined medium alone does not significantly inhibit the growth of coliform bacteria (E. coli and Klebsiella pneumoniae) derived from bovine intramammary infection.
lactose,Milk lactose content is increased in Holstein cows when they are fed diets containing brown midrib corn silage compared to normal corn silage.,Entity: lactose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O. Milk lactose content is increased in Holstein cows when they are fed diets containing brown midrib corn silage compared to normal corn silage.
lignin,"Lignin content is reduced in corn silage when the brown midrib is retained, resulting in lower lignin levels in the silage.","Entity: lignin. SMILES: CC(=O)Nc1ccc(S(=O)(=O)[O-])c2cc(S(=O)(=O)[O-])c(N=Nc3ccccc3)c(O)c12.[Na+].[Na+]. Lignin content is reduced in corn silage when the brown midrib is retained, resulting in lower lignin levels in the silage."
Nitrogen,Supplementation with soybean hulls or corn increases bacterial N flow (as a percentage of N intake) and enhances fiber digestion in the rumen.,Entity: Nitrogen. SMILES: [N]. Supplementation with soybean hulls or corn increases bacterial N flow (as a percentage of N intake) and enhances fiber digestion in the rumen.
Nitrogen,"Energy supplementation in the rumen reduces NH3 N flow and NH3 N concentration, which are indicators of nitrogen utilization.","Entity: Nitrogen. SMILES: [N]. Energy supplementation in the rumen reduces NH3 N flow and NH3 N concentration, which are indicators of nitrogen utilization."
Nitrogen,Nitrogen utilization by ruminal microorganisms is maximized when supplemented with soybean hulls or corn twice a day in continuous culture fermenters.,Entity: Nitrogen. SMILES: [N]. Nitrogen utilization by ruminal microorganisms is maximized when supplemented with soybean hulls or corn twice a day in continuous culture fermenters.
kappa-casein,Kappa-casein is a milk protein whose concentration in cow milk is affected by both dietary treatments and the protein phenotype of the cow.,Entity: kappa-casein. Kappa-casein is a milk protein whose concentration in cow milk is affected by both dietary treatments and the protein phenotype of the cow.
PSA,"PSA (prostate-specific antigen) is a marker used to assess tumor growth and treatment response in LNCaP tumor-bearing models, with alterations in tissue and serum PSA levels observed following paclitaxel, thalidomide, and orchiectomy treatment.","Entity: PSA. PSA (prostate-specific antigen) is a marker used to assess tumor growth and treatment response in LNCaP tumor-bearing models, with alterations in tissue and serum PSA levels observed following paclitaxel, thalidomide, and orchiectomy treatment."
diaminobenzidine,Diaminobenzidine (DAB) is oxidized by reactive oxygen species to form a brown reaction product that can be visualized under light microscopy.,Entity: diaminobenzidine. SMILES: NNc1ccc(-c2ccc(NN)cc2)cc1. Diaminobenzidine (DAB) is oxidized by reactive oxygen species to form a brown reaction product that can be visualized under light microscopy.
diethylenetriaminepentaacetate,Diethylenetriaminepentaacetate is used in perfusion buffers to detect hydrogen peroxide (H2O2) in brain tissue by reacting with oxidized iron.,Entity: diethylenetriaminepentaacetate. SMILES: O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CCN(CC(=O)[O-])CC(=O)[O-]. Diethylenetriaminepentaacetate is used in perfusion buffers to detect hydrogen peroxide (H2O2) in brain tissue by reacting with oxidized iron.
iron,"Iron is used in perfusion buffers to detect hydrogen peroxide (H2O2) in brain tissue, as the free radical oxidizes iron to produce a detectable product.","Entity: iron. SMILES: [Fe]. Iron is used in perfusion buffers to detect hydrogen peroxide (H2O2) in brain tissue, as the free radical oxidizes iron to produce a detectable product."
catecholamine,"Plasma catecholamine levels are increased in Dahl salt-sensitive hypertensive rats, reflecting heightened sympathetic nervous system activity associated with sodium loading and hypertension.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Plasma catecholamine levels are increased in Dahl salt-sensitive hypertensive rats, reflecting heightened sympathetic nervous system activity associated with sodium loading and hypertension."
sodium,High sodium diet (8% NaCl) in Dahl salt-sensitive rats leads to increased sodium and water retention and the development of diastolic hypertension.,Entity: sodium. SMILES: [Na]. High sodium diet (8% NaCl) in Dahl salt-sensitive rats leads to increased sodium and water retention and the development of diastolic hypertension.
epinephrine,"No strain differences in renal alpha 2-adrenoceptor and epinephrine levels were found between Dahl salt-sensitive and Dahl salt-resistant rats in weanling, prehypertensive, or low sodium diet adult animals.","Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. No strain differences in renal alpha 2-adrenoceptor and epinephrine levels were found between Dahl salt-sensitive and Dahl salt-resistant rats in weanling, prehypertensive, or low sodium diet adult animals."
norepinephrine,"Renal alpha 2-adrenoceptor density is increased by 29% and norepinephrine levels are elevated by 53% in Dahl salt-sensitive hypertensive rats following high sodium diet, compared to Dahl salt-resistant rats.","Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Renal alpha 2-adrenoceptor density is increased by 29% and norepinephrine levels are elevated by 53% in Dahl salt-sensitive hypertensive rats following high sodium diet, compared to Dahl salt-resistant rats."
fluoride,"Inorganic fluoride administration in rats leads to a reduction in fluid excretion and an increase in sodium excretion, resulting in a higher sodium/fluid excretion ratio compared to controls.","Entity: fluoride. SMILES: [F-]. Inorganic fluoride administration in rats leads to a reduction in fluid excretion and an increase in sodium excretion, resulting in a higher sodium/fluid excretion ratio compared to controls."
sodium,"In rats, administration of inorganic fluoride increases sodium excretion and elevates the sodium/fluid excretion ratio, with a greater effect observed in diabetic compared to nondiabetic animals.","Entity: sodium. SMILES: [Na]. In rats, administration of inorganic fluoride increases sodium excretion and elevates the sodium/fluid excretion ratio, with a greater effect observed in diabetic compared to nondiabetic animals."
[2-13C]propionate,[2-13C]propionate is formed by scrambling of [3-13C]propionate during propionate degradation in mesophilic anaerobic and microaerobic sludge types.,Entity: [2-13C]propionate. SMILES: C[13CH2]C(=O)[O-]. [2-13C]propionate is formed by scrambling of [3-13C]propionate during propionate degradation in mesophilic anaerobic and microaerobic sludge types.
[3-13C]propionate,"[3-13C]propionate undergoes randomising degradation in mesophilic anaerobic and microaerobic sludge types, resulting in the formation of [2-13C]propionate and acetate with C1 and C2 positions labeled.","Entity: [3-13C]propionate. SMILES: [13CH3]CC(=O)[O-]. [3-13C]propionate undergoes randomising degradation in mesophilic anaerobic and microaerobic sludge types, resulting in the formation of [2-13C]propionate and acetate with C1 and C2 positions labeled."
[3-13C]propionate,"In the absence of sulfate, [3-13C]propionate is not further degraded but undergoes limited scrambling in mesophilic anaerobic and microaerobic sludge types.","Entity: [3-13C]propionate. SMILES: [13CH3]CC(=O)[O-]. In the absence of sulfate, [3-13C]propionate is not further degraded but undergoes limited scrambling in mesophilic anaerobic and microaerobic sludge types."
"[2,3-13C]propionate","Anaerobic sludges convert [2,3-13C]propionate partly into the higher fatty acid 2-methyl[2,3-13C]butyrate during simultaneous degradation with butyrate.","Entity: [2,3-13C]propionate. SMILES: [13CH3][13CH2]C(=O)[O-]. Anaerobic sludges convert [2,3-13C]propionate partly into the higher fatty acid 2-methyl[2,3-13C]butyrate during simultaneous degradation with butyrate."
"2-methyl[2,3-13C]butyrate","2-methyl[2,3-13C]butyrate is produced from [2,3-13C]propionate by anaerobic granular sludge during simultaneous degradation with butyrate.","Entity: 2-methyl[2,3-13C]butyrate. SMILES: C[13CH2][13CH](C)C(=O)[O-]. 2-methyl[2,3-13C]butyrate is produced from [2,3-13C]propionate by anaerobic granular sludge during simultaneous degradation with butyrate."
butyrate,"Butyrate is co-degraded with propionate in anaerobic sludges, leading to the formation of 2-methyl[2,3-13C]butyrate and [4,5-13C]valerate.","Entity: butyrate. SMILES: CCCC(=O)[O-]. Butyrate is co-degraded with propionate in anaerobic sludges, leading to the formation of 2-methyl[2,3-13C]butyrate and [4,5-13C]valerate."
propionate,"Propionate is degraded via the randomising pathway in mesophilic anaerobic and microaerobic sludge types, with up to 10% of the original propionate converted to alternative products.","Entity: propionate. SMILES: CCC(=O)[O-]. Propionate is degraded via the randomising pathway in mesophilic anaerobic and microaerobic sludge types, with up to 10% of the original propionate converted to alternative products."
methane,"In thermophilic anaerobic treatment of sulphur-rich paper mill wastewater, about 70 to 80% of the removed chemical oxygen demand (COD) is converted to methane.","Entity: methane. SMILES: C. In thermophilic anaerobic treatment of sulphur-rich paper mill wastewater, about 70 to 80% of the removed chemical oxygen demand (COD) is converted to methane."
hydrogen,"In thermophilic anaerobic treatment of sulphur-rich paper mill wastewater, sulphide is produced from hydrogen or its precursors.","Entity: hydrogen. SMILES: [H]. In thermophilic anaerobic treatment of sulphur-rich paper mill wastewater, sulphide is produced from hydrogen or its precursors."
propionate,Propionate-utilising sulphur-reducing bacteria (SRB) outcompete hydrogenophilic methanogens and propionate syntrophs in the digester after 5 years of operation during citric acid wastewater treatment.,Entity: propionate. SMILES: CCC(=O)[O-]. Propionate-utilising sulphur-reducing bacteria (SRB) outcompete hydrogenophilic methanogens and propionate syntrophs in the digester after 5 years of operation during citric acid wastewater treatment.
citric acid,Citric acid production wastewater can be treated using a full-scale fixed-bed digester with a COD:sulphate ratio of 3–4:1.,Entity: citric acid. SMILES: O=C(O)CC(O)(CC(=O)O)C(=O)O. Citric acid production wastewater can be treated using a full-scale fixed-bed digester with a COD:sulphate ratio of 3–4:1.
Butyrate,Butyrate-degrading syntrophs remain active in the digester after 5 years of operation during citric acid wastewater treatment.,Entity: Butyrate. SMILES: CCCC(=O)[O-]. Butyrate-degrading syntrophs remain active in the digester after 5 years of operation during citric acid wastewater treatment.
hydrogen sulfide,"Hydrogen sulfide is a component of sour waste streams, such as sour water and sour gases, commonly found in petroleum production and refining.","Entity: hydrogen sulfide. SMILES: S. Hydrogen sulfide is a component of sour waste streams, such as sour water and sour gases, commonly found in petroleum production and refining."
bisulfide,"Bisulfide is a salt of sulfide and hydrogen sulfide, and can be present in sour waste streams from the petroleum industry.","Entity: bisulfide. SMILES: [SH-]. Bisulfide is a salt of sulfide and hydrogen sulfide, and can be present in sour waste streams from the petroleum industry."
dimethyl sulfide,"Dimethyl sulfide is a volatile organic sulfur compound present as a predominant odorant in emissions from a wide range of bio-industrial activities including aerobic wastewater treatment plants, composting plants, and rendering plants.","Entity: dimethyl sulfide. SMILES: CSC. Dimethyl sulfide is a volatile organic sulfur compound present as a predominant odorant in emissions from a wide range of bio-industrial activities including aerobic wastewater treatment plants, composting plants, and rendering plants."
carbon disulfide,"Carbon disulfide is a volatile organic sulfur compound that is a predominant odorant in the emission of various bio-industrial activities such as aerobic wastewater treatment plants, composting plants, and rendering plants.","Entity: carbon disulfide. SMILES: S=C=S. Carbon disulfide is a volatile organic sulfur compound that is a predominant odorant in the emission of various bio-industrial activities such as aerobic wastewater treatment plants, composting plants, and rendering plants."
hypochlorite,Hypochlorite can be used for chemical oxidation of volatile organic sulfur compounds in scrubber systems to control odor emissions from bio-industrial processes.,Entity: hypochlorite. SMILES: [O-]Cl. Hypochlorite can be used for chemical oxidation of volatile organic sulfur compounds in scrubber systems to control odor emissions from bio-industrial processes.
methanethiol,"Methanethiol is a volatile organic sulfur compound identified as a predominant odorant in the emission from various bio-industrial activities such as aerobic wastewater treatment plants, composting plants, and rendering plants.","Entity: methanethiol. SMILES: CS. Methanethiol is a volatile organic sulfur compound identified as a predominant odorant in the emission from various bio-industrial activities such as aerobic wastewater treatment plants, composting plants, and rendering plants."
hydrogen,Hydrogen serves as an energy source for sulfate-reducing bacteria to produce sulfide from gypsum.,Entity: hydrogen. SMILES: [H]. Hydrogen serves as an energy source for sulfate-reducing bacteria to produce sulfide from gypsum.
hydrogen sulfide,"Hydrogen sulfide is produced by sulfate-reducing bacteria using hydrogen as an energy source and can inhibit microbial activity, with a reported inhibition level of 25.1 mM in certain strains.","Entity: hydrogen sulfide. SMILES: S. Hydrogen sulfide is produced by sulfate-reducing bacteria using hydrogen as an energy source and can inhibit microbial activity, with a reported inhibition level of 25.1 mM in certain strains."
pyrite,"Pyrite can be removed from coal by microbial action under mild conditions, requiring simple equipment, minimal chemicals, but longer reaction times.","Entity: pyrite. SMILES: S=[Fe]=S. Pyrite can be removed from coal by microbial action under mild conditions, requiring simple equipment, minimal chemicals, but longer reaction times."
iron sulfate,Iron sulfate is present in process water generated during coal desulfurization and requires treatment.,Entity: iron sulfate. SMILES: O=S(=O)([O-])[O-].[Fe+2]. Iron sulfate is present in process water generated during coal desulfurization and requires treatment.
pyrite,Pyrite (FeS2) is a mineral that contains sulfur and is present in coal either as part of the molecular structure or as a contaminant.,Entity: pyrite. SMILES: S=[Fe]=S. Pyrite (FeS2) is a mineral that contains sulfur and is present in coal either as part of the molecular structure or as a contaminant.
protoporphyrin IX,"Magnesium chelatase catalyzes the insertion of Mg2+ into protoporphyrin IX, representing the first enzyme unique to the (bacterio)chlorophyll specific branch of the porphyrin biosynthetic pathway.","Entity: protoporphyrin IX. SMILES: C=Cc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)C(CCC(=O)O)=C4C)c(C)c3C=C. Magnesium chelatase catalyzes the insertion of Mg2+ into protoporphyrin IX, representing the first enzyme unique to the (bacterio)chlorophyll specific branch of the porphyrin biosynthetic pathway."
porphyrin,"The porphyrin biosynthetic pathway is divided into two branches: one for chlorophyll and the other for bacteriochlorophyll, with magnesium chelatase being a key enzyme unique to the bacteriochlorophyll branch.","Entity: porphyrin. SMILES: C1=Cc2cc3ccc(cc4nc(cc5ccc(cc1n2)[nH]5)C=C4)[nH]3. The porphyrin biosynthetic pathway is divided into two branches: one for chlorophyll and the other for bacteriochlorophyll, with magnesium chelatase being a key enzyme unique to the bacteriochlorophyll branch."
purine,"Genes with function in purine synthesis have been identified in the Chlorobium vibrioforme genome, indicating involvement of this bacterium in purine biosynthesis.","Entity: purine. SMILES: c1ncc2[nH]cnc2n1. Genes with function in purine synthesis have been identified in the Chlorobium vibrioforme genome, indicating involvement of this bacterium in purine biosynthesis."
ceftazidime sodium,Ceftazidime sodium is an antibiotic used to treat infections caused by ceftazidime-resistant gram-negative bacteria that harbor extended-spectrum beta-lactamases (ESBLs).,Entity: ceftazidime sodium. SMILES: CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)[O-].[Na+]. Ceftazidime sodium is an antibiotic used to treat infections caused by ceftazidime-resistant gram-negative bacteria that harbor extended-spectrum beta-lactamases (ESBLs).
ciprofloxacin hydrochloride,"Ciprofloxacin hydrochloride is an antibiotic to which ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae from nursing home patients were found to be resistant in a high percentage (96% and 41%, respectively).","Entity: ciprofloxacin hydrochloride. SMILES: Cl.O.O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O. Ciprofloxacin hydrochloride is an antibiotic to which ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae from nursing home patients were found to be resistant in a high percentage (96% and 41%, respectively)."
ciprofloxacin hydrochloride,Prior receipt of ciprofloxacin hydrochloride is an independent risk factor for colonization with ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae in nursing home patients.,Entity: ciprofloxacin hydrochloride. SMILES: Cl.O.O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O. Prior receipt of ciprofloxacin hydrochloride is an independent risk factor for colonization with ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae in nursing home patients.
tobramycin,Tobramycin is an antibiotic to which ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae from nursing home patients were found to be resistant.,Entity: tobramycin. SMILES: NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O. Tobramycin is an antibiotic to which ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae from nursing home patients were found to be resistant.
XPA,"XPA is a gene involved in nucleotide excision repair (NER), and mutations in XPA cause cancer-prone human disorders such as xeroderma pigmentosum, characterized by accelerated ageing and increased risk of tumors.","Entity: XPA. XPA is a gene involved in nucleotide excision repair (NER), and mutations in XPA cause cancer-prone human disorders such as xeroderma pigmentosum, characterized by accelerated ageing and increased risk of tumors."
XPA,Deficiency in the XPA gene leads to accelerated accumulation of somatic mutations in liver tissue but not in brain tissue in vivo.,Entity: XPA. Deficiency in the XPA gene leads to accelerated accumulation of somatic mutations in liver tissue but not in brain tissue in vivo.
[1-13C] leucine,[1-13C] leucine is used as a tracer to measure whole-body protein turnover in neonates with necrotizing enterocolitis by quantifying its incorporation into plasma proteins.,Entity: [1-13C] leucine. SMILES: CC(C)C[C@H](N)[13C](=O)O. [1-13C] leucine is used as a tracer to measure whole-body protein turnover in neonates with necrotizing enterocolitis by quantifying its incorporation into plasma proteins.
epidermal growth factor,"Following massive small bowel resection in mice, salivary EGF levels increase from 1183 ± 119 nmol (sham) to 2209 ± 266 nmol, while urinary EGF levels decrease from 940 ± 143 nmol (sham) to 417 ± 58 nmol.","Entity: epidermal growth factor. Following massive small bowel resection in mice, salivary EGF levels increase from 1183 ± 119 nmol (sham) to 2209 ± 266 nmol, while urinary EGF levels decrease from 940 ± 143 nmol (sham) to 417 ± 58 nmol."
epidermal growth factor,"Endogenous epidermal growth factor (EGF) plays a crucial role in the pathogenesis of intestinal adaptation after massive small bowel resection, as evidenced by increased salivary EGF levels and enhanced EGF receptor activation in the ileum.","Entity: epidermal growth factor. Endogenous epidermal growth factor (EGF) plays a crucial role in the pathogenesis of intestinal adaptation after massive small bowel resection, as evidenced by increased salivary EGF levels and enhanced EGF receptor activation in the ileum."
octanoic acid,"Octanoic acid, a medium-chain fatty acid, shows lymphatic absorption of 5.6 ± 2.1%, portal venous absorption of 27.3 ± 6.5%, and total absorption of 32.9 ± 4.8% in a rat model with mesenteric lymph duct cannulation.","Entity: octanoic acid. SMILES: CCCCCCCC(=O)O. Octanoic acid, a medium-chain fatty acid, shows lymphatic absorption of 5.6 ± 2.1%, portal venous absorption of 27.3 ± 6.5%, and total absorption of 32.9 ± 4.8% in a rat model with mesenteric lymph duct cannulation."
Lauric acid,"Lauric acid, a medium-chain fatty acid, exhibits lymphatic absorption of 32.9 ± 6.7%, portal venous absorption of 7.5 ± 2.9%, and total absorption of 40.4 ± 6.3% in a rat model with mesenteric lymph duct cannulation.","Entity: Lauric acid. SMILES: CCCCCCCCCCCC(=O)O. Lauric acid, a medium-chain fatty acid, exhibits lymphatic absorption of 32.9 ± 6.7%, portal venous absorption of 7.5 ± 2.9%, and total absorption of 40.4 ± 6.3% in a rat model with mesenteric lymph duct cannulation."
palmitic acid,"Palmitic acid, a long-chain fatty acid, demonstrates lymphatic absorption of 49.2 ± 7.4%, portal venous absorption of 19.8 ± 15%, and total absorption of 69 ± 12.4% in a rat model with mesenteric lymph duct cannulation.","Entity: palmitic acid. SMILES: CCCCCCCCCCCCCCCC(=O)O. Palmitic acid, a long-chain fatty acid, demonstrates lymphatic absorption of 49.2 ± 7.4%, portal venous absorption of 19.8 ± 15%, and total absorption of 69 ± 12.4% in a rat model with mesenteric lymph duct cannulation."
steroids,Steroids are used as part of medical management strategies for infantile hepatic hemangioendothelioma.,Entity: steroids. SMILES: CC(=O)N(C)[C@H](C)[C@@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](N(C)C)CC[C@@]4(C)[C@@H]3CC[C@]21C. Steroids are used as part of medical management strategies for infantile hepatic hemangioendothelioma.
Von Willebrand Factor,Von Willebrand Factor (vWF) staining is used to assess endothelialization by confirming the presence of endothelial cells on the luminal surface of small intestinal submucosa (SIS) grafts.,Entity: Von Willebrand Factor. Von Willebrand Factor (vWF) staining is used to assess endothelialization by confirming the presence of endothelial cells on the luminal surface of small intestinal submucosa (SIS) grafts.
Polytetrafluoroethylene,Polytetrafluoroethylene (PTFE) is the synthetic material most widely used for reconstruction in instances of partial and complete diaphragmatic agenesis.,Entity: Polytetrafluoroethylene. SMILES: FC(F)(C(F)(F)[*:2])[*:1]. Polytetrafluoroethylene (PTFE) is the synthetic material most widely used for reconstruction in instances of partial and complete diaphragmatic agenesis.
Triton X-100,Triton X-100 is used as a component of scintillation solvent for liquid scintillation counting of radioactivity.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used as a component of scintillation solvent for liquid scintillation counting of radioactivity.
ammonium sulfate,Ammonium sulfate is used to precipitate proteins and is applied at 75% saturation in the hapten-binding assay described by Stupp et al. (1969).,Entity: ammonium sulfate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Ammonium sulfate is used to precipitate proteins and is applied at 75% saturation in the hapten-binding assay described by Stupp et al. (1969).
toluene,Toluene is used as a solvent in the scintillation mixture for liquid scintillation counting of radioactivity.,Entity: toluene. SMILES: Cc1ccccc1. Toluene is used as a solvent in the scintillation mixture for liquid scintillation counting of radioactivity.
"2,5-diphenyloxazole","2,5-diphenyloxazole is used as a scintillant in scintillation solvents for detecting radioactivity in liquid scintillation counting.","Entity: 2,5-diphenyloxazole. SMILES: c1ccc(-c2cnc(-c3ccccc3)o2)cc1. 2,5-diphenyloxazole is used as a scintillant in scintillation solvents for detecting radioactivity in liquid scintillation counting."
"2,4-dinitrobenzene sulfonic acid","2,4-dinitrobenzene sulfonic acid is used to derivatize proteins, such as BSA and ovalbumin, by reacting with their amino groups to introduce dinitrophenyl (DNP) residues.","Entity: 2,4-dinitrobenzene sulfonic acid. SMILES: O=[N+]([O-])c1ccc(S(=O)(=O)O)c([N+](=O)[O-])c1. 2,4-dinitrobenzene sulfonic acid is used to derivatize proteins, such as BSA and ovalbumin, by reacting with their amino groups to introduce dinitrophenyl (DNP) residues."
ampholine,Ampholine is used as a component (2%) in the gel matrix for isoelectric separation of proteins on polyacrylamide gel columns.,Entity: ampholine. SMILES: [Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb].[Tb]. Ampholine is used as a component (2%) in the gel matrix for isoelectric separation of proteins on polyacrylamide gel columns.
urea,Urea is used at a concentration of 3 M in the gel matrix for isoelectric separation of proteins on polyacrylamide gel columns.,Entity: urea. SMILES: NC(N)=O. Urea is used at a concentration of 3 M in the gel matrix for isoelectric separation of proteins on polyacrylamide gel columns.
epidermal growth factor,Epidermal growth factor (EGF) treatment in mice with 50% proximal small bowel resection does not significantly alter enterocyte-specific enzyme activity (alkaline phosphatase and sucrase) when normalized for protein.,Entity: epidermal growth factor. Epidermal growth factor (EGF) treatment in mice with 50% proximal small bowel resection does not significantly alter enterocyte-specific enzyme activity (alkaline phosphatase and sucrase) when normalized for protein.
epidermal growth factor,"Epidermal growth factor (EGF) at 50 µg/kg/day enhances adaptation after massive small bowel resection in mice, as evidenced by increased ileal wet weight, enterocyte protein, and DNA content.","Entity: epidermal growth factor. Epidermal growth factor (EGF) at 50 µg/kg/day enhances adaptation after massive small bowel resection in mice, as evidenced by increased ileal wet weight, enterocyte protein, and DNA content."
titanium,Titanium orthodontic wires exhibit the least corrosive potential among the tested materials.,Entity: titanium. SMILES: [Ti]. Titanium orthodontic wires exhibit the least corrosive potential among the tested materials.
nickel,"Nickel is released from corroding orthodontic wires containing nickel, and is implicated in allergic reactions in susceptible patients.","Entity: nickel. SMILES: [Ni]. Nickel is released from corroding orthodontic wires containing nickel, and is implicated in allergic reactions in susceptible patients."
nickel titanium,"Nickel titanium orthodontic wires exhibit a breakdown potential of 300 mV in 0.9% NaCl solution at neutral pH and room temperature, indicating moderate corrosion potential.","Entity: nickel titanium. SMILES: [Ni].[Ti]. Nickel titanium orthodontic wires exhibit a breakdown potential of 300 mV in 0.9% NaCl solution at neutral pH and room temperature, indicating moderate corrosion potential."
nickel titanium,"Nickel titanium orthodontic wires are susceptible to pitting and localized corrosion, as shown by SEM photographs.","Entity: nickel titanium. SMILES: [Ni].[Ti]. Nickel titanium orthodontic wires are susceptible to pitting and localized corrosion, as shown by SEM photographs."
titanium,"Titanium orthodontic wires exhibit a breakdown potential greater than 2000 mV in 0.9% NaCl solution at neutral pH and room temperature, indicating very low corrosion potential.","Entity: titanium. SMILES: [Ti]. Titanium orthodontic wires exhibit a breakdown potential greater than 2000 mV in 0.9% NaCl solution at neutral pH and room temperature, indicating very low corrosion potential."
Nitric oxide,Nitric oxide is a nonconventional neurotransmitter produced on demand by the enzyme nitric oxide synthase (NOS).,Entity: Nitric oxide. SMILES: [N]=O. Nitric oxide is a nonconventional neurotransmitter produced on demand by the enzyme nitric oxide synthase (NOS).
Nitric oxide,"Nitric oxide is produced by various cells in the chick eye, including retinal amacrine and ganglion cells, Muller cells, retinal pigmented epithelium, and cells in the choroid, and likely serves broad visual and regulatory functions.","Entity: Nitric oxide. SMILES: [N]=O. Nitric oxide is produced by various cells in the chick eye, including retinal amacrine and ganglion cells, Muller cells, retinal pigmented epithelium, and cells in the choroid, and likely serves broad visual and regulatory functions."
Talpha1 alpha-tubulin,"Transcription of the Talpha1 alpha-tubulin promoter commences at the time of terminal mitosis in cortical progenitors, as indicated by the timing of Talpha1:nlacZ and betaIII-tubulin expression.","Entity: Talpha1 alpha-tubulin. Transcription of the Talpha1 alpha-tubulin promoter commences at the time of terminal mitosis in cortical progenitors, as indicated by the timing of Talpha1:nlacZ and betaIII-tubulin expression."
betaIII-tubulin,BetaIII-tubulin is a neuron-specific tubulin isotype that is turned on shortly after terminal mitosis in neurons.,Entity: betaIII-tubulin. BetaIII-tubulin is a neuron-specific tubulin isotype that is turned on shortly after terminal mitosis in neurons.
nestin,"Nestin is a marker of dividing, nestin-positive progenitors in cortical cultures.","Entity: nestin. Nestin is a marker of dividing, nestin-positive progenitors in cortical cultures."
Talpha1 alpha-tubulin,Talpha1 alpha-tubulin is an early panneuronal gene whose promoter drives expression coincident with neuronal birth dates in both the peripheral and central nervous systems.,Entity: Talpha1 alpha-tubulin. Talpha1 alpha-tubulin is an early panneuronal gene whose promoter drives expression coincident with neuronal birth dates in both the peripheral and central nervous systems.
Neuropeptide Y,"Neuropeptide Y is present in the region of the ventromedial nucleus of the hypothalamus (VMH) in embryonic mice, as identified by immunocytochemical analysis.","Entity: Neuropeptide Y. Neuropeptide Y is present in the region of the ventromedial nucleus of the hypothalamus (VMH) in embryonic mice, as identified by immunocytochemical analysis."
hydroquinone,"Hydroquinone is present in the mainstream smoke and sidestream smoke of smoked methamphetamine mixed with tobacco, as detected by gas chromatography-tandem mass spectrometry.","Entity: hydroquinone. SMILES: Oc1ccc(O)cc1. Hydroquinone is present in the mainstream smoke and sidestream smoke of smoked methamphetamine mixed with tobacco, as detected by gas chromatography-tandem mass spectrometry."
"2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one","2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one is present in the mainstream smoke of smoked methamphetamine mixed with tobacco.","Entity: 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one. SMILES: CC1=C(O)C(=O)C(O)CO1. 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one is present in the mainstream smoke of smoked methamphetamine mixed with tobacco."
"3,4-dihydro-2-naphthalenone","3,4-dihydro-2-naphthalenone is detected in the sidestream smoke of smoked methamphetamine mixed with tobacco.","Entity: 3,4-dihydro-2-naphthalenone. SMILES: O=C1CCc2ccccc2C1. 3,4-dihydro-2-naphthalenone is detected in the sidestream smoke of smoked methamphetamine mixed with tobacco."
N-methyl-N-(2-phenylethyl)-acetamide,N-methyl-N-(2-phenylethyl)-acetamide is detected in the mainstream smoke of smoked methamphetamine mixed with tobacco.,Entity: N-methyl-N-(2-phenylethyl)-acetamide. SMILES: CC(=O)N(C)CCc1ccccc1. N-methyl-N-(2-phenylethyl)-acetamide is detected in the mainstream smoke of smoked methamphetamine mixed with tobacco.
propanoic acid,"Propanoic acid is present in the mainstream smoke of smoked methamphetamine mixed with tobacco, as identified by gas chromatography-tandem mass spectrometry.","Entity: propanoic acid. SMILES: CCC(=O)O. Propanoic acid is present in the mainstream smoke of smoked methamphetamine mixed with tobacco, as identified by gas chromatography-tandem mass spectrometry."
phenylacetone,Phenylacetone is detected in the sidestream smoke of smoked methamphetamine mixed with tobacco.,Entity: phenylacetone. SMILES: CC(=O)Cc1ccccc1. Phenylacetone is detected in the sidestream smoke of smoked methamphetamine mixed with tobacco.
2-methylpropyl-benzene,"2-methylpropyl-benzene is present in the mainstream smoke of smoked methamphetamine mixed with tobacco, as determined by gas chromatography-tandem mass spectrometry.","Entity: 2-methylpropyl-benzene. SMILES: CC(C)Cc1ccccc1. 2-methylpropyl-benzene is present in the mainstream smoke of smoked methamphetamine mixed with tobacco, as determined by gas chromatography-tandem mass spectrometry."
"4-(3-hydroxy-1-butenyl)-3,5,5-trimethyl-2-cyclohexene-1-one","4-(3-hydroxy-1-butenyl)-3,5,5-trimethyl-2-cyclohexene-1-one is detected in the mainstream smoke of smoked methamphetamine mixed with tobacco.","Entity: 4-(3-hydroxy-1-butenyl)-3,5,5-trimethyl-2-cyclohexene-1-one. SMILES: CC1=CC(=O)CC(C)(C)C1C=CC(C)O. 4-(3-hydroxy-1-butenyl)-3,5,5-trimethyl-2-cyclohexene-1-one is detected in the mainstream smoke of smoked methamphetamine mixed with tobacco."
dimethylamphetamine,"Dimethylamphetamine is present in both the mainstream smoke and sidestream smoke of smoked methamphetamine mixed with tobacco, as identified by gas chromatography-tandem mass spectrometry.","Entity: dimethylamphetamine. SMILES: CC(Cc1ccccc1)N(C)C. Dimethylamphetamine is present in both the mainstream smoke and sidestream smoke of smoked methamphetamine mixed with tobacco, as identified by gas chromatography-tandem mass spectrometry."
bibenzyl,Bibenzyl is detected in the sidestream smoke of smoked methamphetamine mixed with tobacco.,Entity: bibenzyl. SMILES: c1ccc(CCc2ccccc2)cc1. Bibenzyl is detected in the sidestream smoke of smoked methamphetamine mixed with tobacco.
2-propenyl benzene,2-propenyl benzene is present in the sidestream smoke of smoked methamphetamine mixed with tobacco.,Entity: 2-propenyl benzene. SMILES: CC=Cc1ccccc1. 2-propenyl benzene is present in the sidestream smoke of smoked methamphetamine mixed with tobacco.
furfurylmethylamphetamine,Furfurylmethylamphetamine is detected in both the mainstream smoke and sidestream smoke of smoked methamphetamine mixed with tobacco.,Entity: furfurylmethylamphetamine. SMILES: CC(Cc1ccccc1)NCCc1ccco1. Furfurylmethylamphetamine is detected in both the mainstream smoke and sidestream smoke of smoked methamphetamine mixed with tobacco.
benzophenone,Benzophenones are hydrophobic metabolites formed by hydrolysis of benzodiazepines and are easier to separate from matrices than the parent benzodiazepines.,Entity: benzophenone. SMILES: O=C(c1ccccc1)c1ccccc1. Benzophenones are hydrophobic metabolites formed by hydrolysis of benzodiazepines and are easier to separate from matrices than the parent benzodiazepines.
oxazolam,"Oxazolam is a benzodiazepine that can be quantitatively measured in human urine after acid hydrolysis using GC-ECD with DI-SPME, achieving recoveries of 1–25% and a calibration range of 10–500 ng/mL.","Entity: oxazolam. SMILES: CC1CN2CC(=O)Nc3ccc(Cl)cc3C2(c2ccccc2)O1. Oxazolam is a benzodiazepine that can be quantitatively measured in human urine after acid hydrolysis using GC-ECD with DI-SPME, achieving recoveries of 1–25% and a calibration range of 10–500 ng/mL."
oxazolam,"Oxazolam can be detected in human urine for up to 32 hours after a therapeutic dose of 1.2 mg, as shown by GC-ECD analysis.","Entity: oxazolam. SMILES: CC1CN2CC(=O)Nc3ccc(Cl)cc3C2(c2ccccc2)O1. Oxazolam can be detected in human urine for up to 32 hours after a therapeutic dose of 1.2 mg, as shown by GC-ECD analysis."
bromazepam,Bromazepam is a benzodiazepine that yields the lowest recovery (1–25%) among tested drugs when extracted from human urine by DI-SPME and GC-ECD.,Entity: bromazepam. SMILES: O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1. Bromazepam is a benzodiazepine that yields the lowest recovery (1–25%) among tested drugs when extracted from human urine by DI-SPME and GC-ECD.
clonazepam,"Clonazepam can be quantitatively measured in human urine after acid hydrolysis using GC-ECD with DI-SPME, with calibration linear from 10 to 500 ng/mL.","Entity: clonazepam. SMILES: O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1. Clonazepam can be quantitatively measured in human urine after acid hydrolysis using GC-ECD with DI-SPME, with calibration linear from 10 to 500 ng/mL."
nimetazepam,"Nimetazepam can be quantitatively measured in human urine after acid hydrolysis using GC-ECD with DI-SPME, with calibration linear from 10 to 500 ng/mL.","Entity: nimetazepam. SMILES: CN1C(=O)CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc21. Nimetazepam can be quantitatively measured in human urine after acid hydrolysis using GC-ECD with DI-SPME, with calibration linear from 10 to 500 ng/mL."
haloxazolam,"Haloxazolam can be quantitatively measured in human urine after acid hydrolysis using GC-ECD with DI-SPME, with calibration linear from 10 to 500 ng/mL.","Entity: haloxazolam. SMILES: O=C1CN2CCOC2(c2ccccc2F)c2cc(Br)ccc2N1. Haloxazolam can be quantitatively measured in human urine after acid hydrolysis using GC-ECD with DI-SPME, with calibration linear from 10 to 500 ng/mL."
recoverin,"Recoverin is a 23-kDa protein whose antibodies can be found in patients with cancer-associated retinopathy, indicating an autoimmune component in this syndrome.","Entity: recoverin. Recoverin is a 23-kDa protein whose antibodies can be found in patients with cancer-associated retinopathy, indicating an autoimmune component in this syndrome."
uracil,"Uracil is incorporated into DNA in excess during folate deficiency, resulting in single- and double-strand breaks and chromosomal instability.","Entity: uracil. SMILES: O=c1cc[nH]c(=O)[nH]1. Uracil is incorporated into DNA in excess during folate deficiency, resulting in single- and double-strand breaks and chromosomal instability."
acetyl carnitine,"Acetyl carnitine, when administered to old rats, restores mitochondrial function, lowers oxidants to the level of a young rat, and increases ambulatory activity.","Entity: acetyl carnitine. SMILES: CC(=O)C(O)(CC(=O)[O-])C[N+](C)(C)C. Acetyl carnitine, when administered to old rats, restores mitochondrial function, lowers oxidants to the level of a young rat, and increases ambulatory activity."
iron,"Iron deficiency can mimic the effects of radiation by causing single- and double-strand DNA breaks, oxidative lesions, or both.","Entity: iron. SMILES: [Fe]. Iron deficiency can mimic the effects of radiation by causing single- and double-strand DNA breaks, oxidative lesions, or both."
folate,Folate deficiency occurs in approximately 10% of the US population and is more prevalent in the poor.,Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate deficiency occurs in approximately 10% of the US population and is more prevalent in the poor.
folate,"Folate deficiency causes extensive incorporation of uracil into human DNA (4 million/cell), leading to chromosomal breaks.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate deficiency causes extensive incorporation of uracil into human DNA (4 million/cell), leading to chromosomal breaks."
cannabinoids,Cannabinoids exert immune modulation and other biological effects by binding to G protein-coupled receptors CB1 and CB2.,Entity: cannabinoids. SMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O.CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21. Cannabinoids exert immune modulation and other biological effects by binding to G protein-coupled receptors CB1 and CB2.
cannabinoids,Cannabinoids negatively regulate adenylate cyclase activity through a pertussis toxin sensitive GTP-binding protein at both CB1 and CB2 receptors.,Entity: cannabinoids. SMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O.CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21. Cannabinoids negatively regulate adenylate cyclase activity through a pertussis toxin sensitive GTP-binding protein at both CB1 and CB2 receptors.
cannabinoids,Cannabinoids inhibit the cAMP signaling cascade by decreasing adenylate cyclase and protein kinase A activity and reducing DNA binding by cAMP response element binding proteins.,Entity: cannabinoids. SMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O.CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21. Cannabinoids inhibit the cAMP signaling cascade by decreasing adenylate cyclase and protein kinase A activity and reducing DNA binding by cAMP response element binding proteins.
cannabinoids,Cannabinoids disrupt leukocyte function by inhibiting the cAMP signaling cascade and related signaling pathways that regulate cytokine gene expression.,Entity: cannabinoids. SMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O.CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21. Cannabinoids disrupt leukocyte function by inhibiting the cAMP signaling cascade and related signaling pathways that regulate cytokine gene expression.
GTP-binding protein,GTP-binding protein acts as a negative regulator of CB1 and CB2 receptors by coupling to adenylate cyclase and inhibiting its activity.,Entity: GTP-binding protein. GTP-binding protein acts as a negative regulator of CB1 and CB2 receptors by coupling to adenylate cyclase and inhibiting its activity.
Z-Asp-CH2-DCB,"Z-Asp-CH2-DCB is a caspase inhibitor that inhibits NOC18-induced apoptosis in SH-SY5Y cells, indicating its role in blocking caspase-mediated neuronal apoptosis.","Entity: Z-Asp-CH2-DCB. SMILES: O=C(O)C[C@H](NC(=O)OCc1ccccc1)C(=O)COC(=O)c1c(Cl)cccc1Cl. Z-Asp-CH2-DCB is a caspase inhibitor that inhibits NOC18-induced apoptosis in SH-SY5Y cells, indicating its role in blocking caspase-mediated neuronal apoptosis."
glyceraldehyde-3 phosphate dehydrogenase,Koningic acid (KO) is a chemical modifier and enzyme inhibitor of glyceraldehyde-3 phosphate dehydrogenase (GAPDH).,Entity: glyceraldehyde-3 phosphate dehydrogenase. Koningic acid (KO) is a chemical modifier and enzyme inhibitor of glyceraldehyde-3 phosphate dehydrogenase (GAPDH).
Stat1,Stat1 is phosphorylated and translocates into the nucleus in response to IFNgamma stimulation in cultured C6 rat glioma cells.,Entity: Stat1. Stat1 is phosphorylated and translocates into the nucleus in response to IFNgamma stimulation in cultured C6 rat glioma cells.
Jak2,Jak2 is phosphorylated in response to IFNgamma stimulation in cultured C6 rat glioma cells.,Entity: Jak2. Jak2 is phosphorylated in response to IFNgamma stimulation in cultured C6 rat glioma cells.
IFNgamma,"IFNgamma induces phosphorylation of Jak2 and Stat1, followed by nuclear translocation of Stat1 in cultured C6 rat glioma cells.","Entity: IFNgamma. IFNgamma induces phosphorylation of Jak2 and Stat1, followed by nuclear translocation of Stat1 in cultured C6 rat glioma cells."
"2-amino-3-methylimidazo[4,5-f]quinoline","2-amino-3-methylimidazo[4,5-f]quinoline (IQ) is a food-born mutagenic and carcinogenic heterocyclic amine.","Entity: 2-amino-3-methylimidazo[4,5-f]quinoline. SMILES: Cn1c(N)nc2c3cccnc3ccc21. 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) is a food-born mutagenic and carcinogenic heterocyclic amine."
"2-amino-3-methylimidazo[4,5-f]quinoline","2-amino-3-methylimidazo[4,5-f]quinoline suppresses IL-2 secretion and its mRNA expression in murine spleen cells.","Entity: 2-amino-3-methylimidazo[4,5-f]quinoline. SMILES: Cn1c(N)nc2c3cccnc3ccc21. 2-amino-3-methylimidazo[4,5-f]quinoline suppresses IL-2 secretion and its mRNA expression in murine spleen cells."
"2-amino-3-methylimidazo[4,5-f]quinoline","2-amino-3-methylimidazo[4,5-f]quinoline decreases PKC activity in both the membrane and cytosol fractions of murine spleen cells.","Entity: 2-amino-3-methylimidazo[4,5-f]quinoline. SMILES: Cn1c(N)nc2c3cccnc3ccc21. 2-amino-3-methylimidazo[4,5-f]quinoline decreases PKC activity in both the membrane and cytosol fractions of murine spleen cells."
"2-amino-3-methylimidazo[4,5-f]quinoline","2-amino-3-methylimidazo[4,5-f]quinoline inhibits activation of NF-kappaB and AP-1 transcription factors in PMA/PHA-stimulated murine spleen cells.","Entity: 2-amino-3-methylimidazo[4,5-f]quinoline. SMILES: Cn1c(N)nc2c3cccnc3ccc21. 2-amino-3-methylimidazo[4,5-f]quinoline inhibits activation of NF-kappaB and AP-1 transcription factors in PMA/PHA-stimulated murine spleen cells."
NF-kappaB,"NF-kappaB activation is markedly inhibited by 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in PMA/PHA-stimulated murine spleen cells.","Entity: NF-kappaB. NF-kappaB activation is markedly inhibited by 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in PMA/PHA-stimulated murine spleen cells."
TNF alpha,TNF alpha is a member of the tumour necrosis factor alpha (TNF alpha) family of cell surface receptors.,Entity: TNF alpha. TNF alpha is a member of the tumour necrosis factor alpha (TNF alpha) family of cell surface receptors.
transforming growth factor-beta1,Transforming growth factor-beta1 (TGF beta1) is an exogenous stimulus that can induce apoptosis in rat hepatocytes.,Entity: transforming growth factor-beta1. Transforming growth factor-beta1 (TGF beta1) is an exogenous stimulus that can induce apoptosis in rat hepatocytes.
TNF alpha,"TNF alpha, possibly released by liver Kupffer cells in response to peroxisome proliferators, may play a key role in mediating the effects of peroxisome proliferators on hepatocyte growth regulation.","Entity: TNF alpha. TNF alpha, possibly released by liver Kupffer cells in response to peroxisome proliferators, may play a key role in mediating the effects of peroxisome proliferators on hepatocyte growth regulation."
phosphatidylserine,Externalisation of phosphatidylserine is a marker of the late apoptosis phase in human monocytic THP.1 cells induced by etoposide and N-tosyl-L-phenylalanyl chloromethyl ketone.,Entity: phosphatidylserine. SMILES: CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCCCCCCCCCCCCCCCC. Externalisation of phosphatidylserine is a marker of the late apoptosis phase in human monocytic THP.1 cells induced by etoposide and N-tosyl-L-phenylalanyl chloromethyl ketone.
N-tosyl-L-phenylalanyl chloromethyl ketone,"N-tosyl-L-phenylalanyl chloromethyl ketone induces apoptosis in human monocytic THP.1 cells, accompanied by caspase activation, externalisation of phosphatidylserine, and reduction in mitochondrial membrane potential.","Entity: N-tosyl-L-phenylalanyl chloromethyl ketone. SMILES: Cc1ccc(S(=O)(=O)N[C@@H](Cc2ccccc2)C(=O)C(=O)CCl)cc1. N-tosyl-L-phenylalanyl chloromethyl ketone induces apoptosis in human monocytic THP.1 cells, accompanied by caspase activation, externalisation of phosphatidylserine, and reduction in mitochondrial membrane potential."
etoposide,"Etoposide induces apoptosis in human monocytic THP.1 cells, associated with caspase activation, externalisation of phosphatidylserine, and reduction in mitochondrial membrane potential.","Entity: etoposide. SMILES: COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O. Etoposide induces apoptosis in human monocytic THP.1 cells, associated with caspase activation, externalisation of phosphatidylserine, and reduction in mitochondrial membrane potential."
carbamate,Xenopus laevis acetylcholinesterase exhibits exceptionally high resistance to carbamate anticholinesterases.,Entity: carbamate. SMILES: NC(=O)[O-]. Xenopus laevis acetylcholinesterase exhibits exceptionally high resistance to carbamate anticholinesterases.
parathion,"Parathion is a pro-insecticide whose poisonous metabolite, paraoxon, shows effective in vivo penetrance to Xenopus laevis tadpole tissues.","Entity: parathion. SMILES: CCOP(=S)(OCC)Oc1ccc([N+](=O)[O-])cc1. Parathion is a pro-insecticide whose poisonous metabolite, paraoxon, shows effective in vivo penetrance to Xenopus laevis tadpole tissues."
paraoxon,"Xenopus laevis acetylcholinesterase displays impressive resistance to paraoxon, a metabolite of parathion, compared to recombinant human acetylcholinesterase.","Entity: paraoxon. SMILES: CCOP(=O)(OCC)Oc1ccc([N+](=O)[O-])cc1. Xenopus laevis acetylcholinesterase displays impressive resistance to paraoxon, a metabolite of parathion, compared to recombinant human acetylcholinesterase."
acetylcholinesterase,The susceptibility of acetylcholinesterase to enzymatic inhibition is strongly correlated with the systemic toxicity of anticholinesterases.,Entity: acetylcholinesterase. The susceptibility of acetylcholinesterase to enzymatic inhibition is strongly correlated with the systemic toxicity of anticholinesterases.
aflatoxin B1,"Characteristic p53 mutation spectra in human cancer have been associated with dietary aflatoxin B1 exposure, indicating a role for aflatoxin B1 in carcinogenesis.","Entity: aflatoxin B1. SMILES: COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2. Characteristic p53 mutation spectra in human cancer have been associated with dietary aflatoxin B1 exposure, indicating a role for aflatoxin B1 in carcinogenesis."
cadmium(II),"Cadmium(II) is a toxic metal ion that targets DNA repair systems, causing diminished removal of endogenous DNA lesions and environmental DNA damage, which may increase the risk of tumor formation.","Entity: cadmium(II). SMILES: [Cd+2]. Cadmium(II) is a toxic metal ion that targets DNA repair systems, causing diminished removal of endogenous DNA lesions and environmental DNA damage, which may increase the risk of tumor formation."
nickel,"Nickel(II) is a toxic metal ion that targets DNA repair systems, leading to reduced removal of endogenous DNA lesions and environmental DNA damage, which may contribute to increased tumor risk.","Entity: nickel. SMILES: [Ni]. Nickel(II) is a toxic metal ion that targets DNA repair systems, leading to reduced removal of endogenous DNA lesions and environmental DNA damage, which may contribute to increased tumor risk."
chromium(VI),Chromium(VI) is a well-known carcinogen whose mode of action involves direct genotoxic effects that are relatively strong and/or occur at comparatively high concentrations.,Entity: chromium(VI). SMILES: [Cr+6]. Chromium(VI) is a well-known carcinogen whose mode of action involves direct genotoxic effects that are relatively strong and/or occur at comparatively high concentrations.
arsenic(III),"Arsenic(III) is a toxic metal ion that targets DNA repair systems, leading to diminished removal of endogenous DNA lesions and DNA damage from environmental agents, which may increase tumor risk.","Entity: arsenic(III). SMILES: [As+3]. Arsenic(III) is a toxic metal ion that targets DNA repair systems, leading to diminished removal of endogenous DNA lesions and DNA damage from environmental agents, which may increase tumor risk."
cobalt(II),"Cobalt(II) is a toxic metal ion that targets DNA repair systems, resulting in reduced removal of endogenous DNA lesions and environmental DNA damage, potentially raising tumor risk.","Entity: cobalt(II). SMILES: [Co+2]. Cobalt(II) is a toxic metal ion that targets DNA repair systems, resulting in reduced removal of endogenous DNA lesions and environmental DNA damage, potentially raising tumor risk."
nitric oxide,"Alveolar macrophages produce increased amounts of nitric oxide following ozone inhalation, contributing to cytotoxic and inflammatory responses in the lung.","Entity: nitric oxide. SMILES: [N]=O. Alveolar macrophages produce increased amounts of nitric oxide following ozone inhalation, contributing to cytotoxic and inflammatory responses in the lung."
gadolinium chloride,"Gadolinium chloride inhibits macrophage activation, thereby abrogating ozone-induced inflammation, mediator production, and tissue injury in the lung.","Entity: gadolinium chloride. SMILES: [Cl-].[Cl-].[Cl-].[Gd+3]. Gadolinium chloride inhibits macrophage activation, thereby abrogating ozone-induced inflammation, mediator production, and tissue injury in the lung."
tumor necrosis factor-alpha,"Tumor necrosis factor-alpha is a proinflammatory cytokine released by activated alveolar macrophages following ozone inhalation, contributing to tissue injury and inflammation in the lung.","Entity: tumor necrosis factor-alpha. Tumor necrosis factor-alpha is a proinflammatory cytokine released by activated alveolar macrophages following ozone inhalation, contributing to tissue injury and inflammation in the lung."
Ah receptor,"Prenatal administration of an Ah receptor agonist, such as 2,3,7,8-TCDD or PCB 169, in male rats produces effects including reduced ejaculated sperm numbers.","Entity: Ah receptor. Prenatal administration of an Ah receptor agonist, such as 2,3,7,8-TCDD or PCB 169, in male rats produces effects including reduced ejaculated sperm numbers."
tributyltin,Tributyltin is an anti-fouling agent that can masculinize female molluscs when they are exposed to it.,Entity: tributyltin. SMILES: CCCC[Sn](CCCC)CCCC. Tributyltin is an anti-fouling agent that can masculinize female molluscs when they are exposed to it.
glutamate,"Increased glutamate release is associated with serious neurological disorders such as epilepsy, stroke, Alzheimer's disease, and other brain injuries.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Increased glutamate release is associated with serious neurological disorders such as epilepsy, stroke, Alzheimer's disease, and other brain injuries."
glutamate,"Excessive glutamate release and subsequent glutamatergic neuronal stimulation increase the production of reactive oxygen species (ROS), leading to oxidative stress, excitotoxicity, and neuronal damage.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Excessive glutamate release and subsequent glutamatergic neuronal stimulation increase the production of reactive oxygen species (ROS), leading to oxidative stress, excitotoxicity, and neuronal damage."
glutamate,Exposure to glutamate in combination with environmental toxins such as lead amplifies glutamate excitotoxicity and cell death through apoptosis or necrosis.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Exposure to glutamate in combination with environmental toxins such as lead amplifies glutamate excitotoxicity and cell death through apoptosis or necrosis.
glutamate,"Glutamate exposure induces the expression of immediate early genes, including c-fos, which are important in regulating the expression of other neuronal genes.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate exposure induces the expression of immediate early genes, including c-fos, which are important in regulating the expression of other neuronal genes."
glutamate,Elevated expression of genes encoding Hsp70 and cyclo-oxygenase-2 is associated with apoptosis or necrosis induced by glutamate.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Elevated expression of genes encoding Hsp70 and cyclo-oxygenase-2 is associated with apoptosis or necrosis induced by glutamate.
quinolone,Quinolone phototoxicity in vivo induces auricular skin inflammation characterized by edema and neutrophil infiltration in BALB/c mice when administered orally and exposed to ultraviolet-A (UVA) irradiation for 4 hours.,Entity: quinolone. SMILES: O=c1ccc2ccccc2[nH]1. Quinolone phototoxicity in vivo induces auricular skin inflammation characterized by edema and neutrophil infiltration in BALB/c mice when administered orally and exposed to ultraviolet-A (UVA) irradiation for 4 hours.
quinolone,"Quinolone-induced phototoxicity in BALB/c 3T3 mouse fibroblast cells stimulates the release of prostaglandin E2 (PGE2) and 6-keto-PGF1alpha, but not leukotriene B4, under UVA irradiation.","Entity: quinolone. SMILES: O=c1ccc2ccccc2[nH]1. Quinolone-induced phototoxicity in BALB/c 3T3 mouse fibroblast cells stimulates the release of prostaglandin E2 (PGE2) and 6-keto-PGF1alpha, but not leukotriene B4, under UVA irradiation."
quinolone,"The release of PGE2 from BALB/c 3T3 mouse fibroblast cells after quinolone and UVA exposure is inhibited by cyclooxygenase inhibitors, antioxidants, protein kinase C (PKC) inhibitors, and a tyrosine kinase (TK) inhibitor, but not by antibodies against TNF alpha or IL-1.","Entity: quinolone. SMILES: O=c1ccc2ccccc2[nH]1. The release of PGE2 from BALB/c 3T3 mouse fibroblast cells after quinolone and UVA exposure is inhibited by cyclooxygenase inhibitors, antioxidants, protein kinase C (PKC) inhibitors, and a tyrosine kinase (TK) inhibitor, but not by antibodies against TNF alpha or IL-1."
Erythrosine,"Erythrosine (FDC Red No. 3) is a food color that has been shown to affect the thyroid gland in rats, as studied through endocrinologic and histopathologic data.","Entity: Erythrosine. SMILES: O=C1OC2(c3ccccc31)c1cc(I)c([O-])c(I)c1Oc1c2cc(I)c([O-])c1I.[Na+].[Na+]. Erythrosine (FDC Red No. 3) is a food color that has been shown to affect the thyroid gland in rats, as studied through endocrinologic and histopathologic data."
sulfamethazine,"Sulfamethazine acts as a thyroperoxidase (TPO) inhibitor, disrupting thyroid function in rodents by inhibiting the synthesis of thyroid hormones.","Entity: sulfamethazine. SMILES: Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1. Sulfamethazine acts as a thyroperoxidase (TPO) inhibitor, disrupting thyroid function in rodents by inhibiting the synthesis of thyroid hormones."
thyroperoxidase,Thyroperoxidase is an important enzyme whose inhibition by certain chemicals can disrupt thyroid function in rodents.,Entity: thyroperoxidase. Thyroperoxidase is an important enzyme whose inhibition by certain chemicals can disrupt thyroid function in rodents.
parathyroid hormone-related protein,Parathyroid hormone-related protein is a major causative factor in cancer-associated hypercalcemia.,Entity: parathyroid hormone-related protein. Parathyroid hormone-related protein is a major causative factor in cancer-associated hypercalcemia.
domoate,Domoate is a tricarboxylic amino acid structurally related to kainic acid and glutamic acid.,Entity: domoate. SMILES: C/C(=C\C=C/C(C)C(=O)O)C1CNC(C(=O)O)C1CC(=O)O. Domoate is a tricarboxylic amino acid structurally related to kainic acid and glutamic acid.
domoate,Domoate is produced by certain phytoplankton and can contaminate seafood.,Entity: domoate. SMILES: C/C(=C\C=C/C(C)C(=O)O)C1CNC(C(=O)O)C1CC(=O)O. Domoate is produced by certain phytoplankton and can contaminate seafood.
domoate,Domoate at doses of 0.5–1.0 mg/kg intravenously in cynomolgus monkeys causes degeneration of axons and cell bodies in the hippocampal CA2 stratum lucidum.,Entity: domoate. SMILES: C/C(=C\C=C/C(C)C(=O)O)C1CNC(C(=O)O)C1CC(=O)O. Domoate at doses of 0.5–1.0 mg/kg intravenously in cynomolgus monkeys causes degeneration of axons and cell bodies in the hippocampal CA2 stratum lucidum.
domoate,"For a 5% oral absorption rate, domoic acid exposure via seafood is considered safe if subjects consume 200 g of seafood containing 12 ppm (S-F approach), 6 ppm (BM approach), or 10 ppm (Q approach) domoic acid.","Entity: domoate. SMILES: C/C(=C\C=C/C(C)C(=O)O)C1CNC(C(=O)O)C1CC(=O)O. For a 5% oral absorption rate, domoic acid exposure via seafood is considered safe if subjects consume 200 g of seafood containing 12 ppm (S-F approach), 6 ppm (BM approach), or 10 ppm (Q approach) domoic acid."
kainic acid,Kainic acid is structurally related to domoic acid.,Entity: kainic acid. SMILES: C=C(C)[C@H]1CN[C@H](C(=O)O)[C@H]1CC(=O)O. Kainic acid is structurally related to domoic acid.
glutamic acid,Glutamic acid is structurally related to domoic acid.,Entity: glutamic acid. SMILES: N[C@@H](CCC(=O)O)C(=O)O. Glutamic acid is structurally related to domoic acid.
N-desmethyltamoxifen,"N-desmethyltamoxifen forms DNA adducts in rat liver, specifically as an adduct of N2-deoxyguanosine with a linkage through the alpha-carbon of the tamoxifen structure.","Entity: N-desmethyltamoxifen. SMILES: CC/C(=C(\c1ccccc1)c1ccc(OCCNC)cc1)c1ccccc1. N-desmethyltamoxifen forms DNA adducts in rat liver, specifically as an adduct of N2-deoxyguanosine with a linkage through the alpha-carbon of the tamoxifen structure."
zetaglobin,"Zetaglobin is used to promote the development of the Tg.AC (zetaglobin promoted v-Ha-ras) transgenic mouse model, which is evaluated as a short-term carcinogenicity bioassay.","Entity: zetaglobin. Zetaglobin is used to promote the development of the Tg.AC (zetaglobin promoted v-Ha-ras) transgenic mouse model, which is evaluated as a short-term carcinogenicity bioassay."
hematoxylin,Hematoxylin is a histological stain used to visualize cell structures in tissue sections.,Entity: hematoxylin. SMILES: Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2. Hematoxylin is a histological stain used to visualize cell structures in tissue sections.
eosin,Eosin is a histological stain used in combination with hematoxylin to provide contrast in tissue sections.,Entity: eosin. SMILES: O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+]. Eosin is a histological stain used in combination with hematoxylin to provide contrast in tissue sections.
mono-(2-ethylhexyl)phthalate,Mono-(2-ethylhexyl)phthalate is a Sertoli cell toxicant that increases the expression of Fas system components (RIP and FAP-1) in the testis and induces massive germ cell death.,Entity: mono-(2-ethylhexyl)phthalate. SMILES: CCCCC(CC)COC(=O)c1ccccc1C(=O)[O-]. Mono-(2-ethylhexyl)phthalate is a Sertoli cell toxicant that increases the expression of Fas system components (RIP and FAP-1) in the testis and induces massive germ cell death.
Fas ligand,"Fas ligand is expressed postnatally in rat testis, with peak expression associated with high levels of germ cell apoptosis during the first wave of spermatogenesis.","Entity: Fas ligand. Fas ligand is expressed postnatally in rat testis, with peak expression associated with high levels of germ cell apoptosis during the first wave of spermatogenesis."
Fas receptor,"Fas receptor is expressed postnatally in rat testis, with peak expression associated with high levels of germ cell apoptosis during the first wave of spermatogenesis.","Entity: Fas receptor. Fas receptor is expressed postnatally in rat testis, with peak expression associated with high levels of germ cell apoptosis during the first wave of spermatogenesis."
pyridostigmine bromide,"Pyridostigmine bromide is associated with delayed-onset neurotoxic syndromes in Gulf War veterans exposed to specific chemical agents, including pesticide-containing flea and tick collars, nerve agent alarms, and insect repellent (DEET).","Entity: pyridostigmine bromide. SMILES: CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-]. Pyridostigmine bromide is associated with delayed-onset neurotoxic syndromes in Gulf War veterans exposed to specific chemical agents, including pesticide-containing flea and tick collars, nerve agent alarms, and insect repellent (DEET)."
sarin,"A single dose of sarin can produce only transient adverse effects at doses that cause substantial acetylcholinesterase inhibition, as demonstrated in controlled clinical trials.","Entity: sarin. SMILES: CC(C)OP(C)(=O)F. A single dose of sarin can produce only transient adverse effects at doses that cause substantial acetylcholinesterase inhibition, as demonstrated in controlled clinical trials."
ethoxycoumarin,"Ethoxycoumarin O-deethylation activity in rat hepatocytes is increased by linuron, nitrofen, and chlomethoxifen at concentrations similar to those required for benzo[a]pyrene-induced activity.","Entity: ethoxycoumarin. SMILES: CCOc1cc2ccccc2oc1=O. Ethoxycoumarin O-deethylation activity in rat hepatocytes is increased by linuron, nitrofen, and chlomethoxifen at concentrations similar to those required for benzo[a]pyrene-induced activity."
benzo[a]pyrene,Benzo[a]pyrene induces ethoxycoumarin O-deethylation activity in rat hepatocytes.,Entity: benzo[a]pyrene. SMILES: c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34. Benzo[a]pyrene induces ethoxycoumarin O-deethylation activity in rat hepatocytes.
metyrapone,Metyrapone inhibits the cytotoxicity of prometryn and ametryn on freshly isolated rat hepatocytes (FIH).,Entity: metyrapone. SMILES: CC(C)(C(=O)c1cccnc1)c1cccnc1. Metyrapone inhibits the cytotoxicity of prometryn and ametryn on freshly isolated rat hepatocytes (FIH).
Linuron,Linuron increases ethoxycoumarin O-deethylation activity in rat hepatocytes and induces this activity in vivo.,Entity: Linuron. SMILES: CON(C)C(=O)Nc1ccc(Cl)c(Cl)c1. Linuron increases ethoxycoumarin O-deethylation activity in rat hepatocytes and induces this activity in vivo.
prometryn,Prometryn shows cytotoxicity on primary cultured rat hepatocytes (PCH) at lower concentrations than on SIRC cells.,Entity: prometryn. SMILES: CSc1nc(NC(C)C)nc(NC(C)C)n1. Prometryn shows cytotoxicity on primary cultured rat hepatocytes (PCH) at lower concentrations than on SIRC cells.
Epoxybutanediol,Epoxybutanediol is an epoxide metabolite of butadiene.,Entity: Epoxybutanediol. SMILES: CCC1OC1(O)O. Epoxybutanediol is an epoxide metabolite of butadiene.
Epoxybutanediol,"Epoxybutanediol forms N-1-adenine adducts with deoxyadenosine 5'-monophosphate, which can be detected in DNA from exposed organisms.","Entity: Epoxybutanediol. SMILES: CCC1OC1(O)O. Epoxybutanediol forms N-1-adenine adducts with deoxyadenosine 5'-monophosphate, which can be detected in DNA from exposed organisms."
diepoxybutane,Diepoxybutane-treated DNA in vitro contains adenine adducts formed by epoxybutanediol.,Entity: diepoxybutane. SMILES: C1OC1C1CO1. Diepoxybutane-treated DNA in vitro contains adenine adducts formed by epoxybutanediol.
N6-trihydroxybutyl-adenine,N6-trihydroxybutyl-adenine is a rearranged product formed from N-1-adenine adducts of epoxybutanediol in a base-catalysed reaction.,Entity: N6-trihydroxybutyl-adenine. SMILES: OC(O)(O)CCCNc1ncnc2nc[nH]c12. N6-trihydroxybutyl-adenine is a rearranged product formed from N-1-adenine adducts of epoxybutanediol in a base-catalysed reaction.
butadiene,"Butadiene is metabolized to epoxybutanediol, which can react with DNA to form mutagenic adenine adducts.","Entity: butadiene. SMILES: C=CC=C. Butadiene is metabolized to epoxybutanediol, which can react with DNA to form mutagenic adenine adducts."
"CYP1A, 2A5","CYP1A and CYP2A5 are cytochrome P450 enzymes whose expression and related enzymatic activities (7-ethoxyresorufin O-deethylation, 7-methoxyresorufin O-deethylation, coumarin 7-hydroxylation) are not altered in livers from ATX mice compared to controls.","Entity: CYP1A, 2A5. CYP1A and CYP2A5 are cytochrome P450 enzymes whose expression and related enzymatic activities (7-ethoxyresorufin O-deethylation, 7-methoxyresorufin O-deethylation, coumarin 7-hydroxylation) are not altered in livers from ATX mice compared to controls."
NADPH-d,"NADPH-d reactivity is distributed unevenly in lumbosacral dorsal root ganglion neurons, with more intensely stained cells in the rostral (L1-L3) segments compared to the caudal (L6-S4) segments.","Entity: NADPH-d. SMILES: [2H]C1C=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=C1C(N)=O. NADPH-d reactivity is distributed unevenly in lumbosacral dorsal root ganglion neurons, with more intensely stained cells in the rostral (L1-L3) segments compared to the caudal (L6-S4) segments."
NADPH-d,"In lumbosacral dorsal root ganglion, NADPH-d positive neurons are not uniformly associated with nitric oxide synthase (NOS) immunoreactivity, as some NADPH-d positive neurons are NOS negative.","Entity: NADPH-d. SMILES: [2H]C1C=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=C1C(N)=O. In lumbosacral dorsal root ganglion, NADPH-d positive neurons are not uniformly associated with nitric oxide synthase (NOS) immunoreactivity, as some NADPH-d positive neurons are NOS negative."
NADPH-d,"Ultrastructurally, NADPH-d reaction product is associated with the membranes of various subcellular organelles, including rough endoplasmic reticulum, Golgi saccules, mitochondria, and some segments of the nuclear envelope in dorsal root ganglion neurons.","Entity: NADPH-d. SMILES: [2H]C1C=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=C1C(N)=O. Ultrastructurally, NADPH-d reaction product is associated with the membranes of various subcellular organelles, including rough endoplasmic reticulum, Golgi saccules, mitochondria, and some segments of the nuclear envelope in dorsal root ganglion neurons."
nitric oxide,Nitric oxide may function as a neurotransmitter in afferent pathways at lumbosacral spinal cord segments.,Entity: nitric oxide. SMILES: [N]=O. Nitric oxide may function as a neurotransmitter in afferent pathways at lumbosacral spinal cord segments.
nitric oxide synthase,Nitric oxide synthase (NOS) immune-precipitate is patchily distributed throughout the cytoplasm of neurons in the lumbosacral dorsal root ganglia.,Entity: nitric oxide synthase. Nitric oxide synthase (NOS) immune-precipitate is patchily distributed throughout the cytoplasm of neurons in the lumbosacral dorsal root ganglia.
nitric oxide synthase,"Nitric oxide synthase (NOS) immunoreactivity is present in a subset of neurons in the lumbosacral dorsal root ganglia, with a smaller number of NOS-positive neurons compared to NADPH-d-positive neurons.","Entity: nitric oxide synthase. Nitric oxide synthase (NOS) immunoreactivity is present in a subset of neurons in the lumbosacral dorsal root ganglia, with a smaller number of NOS-positive neurons compared to NADPH-d-positive neurons."
SPR,"SPR (Substance P receptor) is a receptor-like structure present in the medullary visceral zone of the rat, with its distribution generally matching that of Substance P receptor-like immunoreactivity (SPR-LI) in normal control animals.","Entity: SPR. SPR (Substance P receptor) is a receptor-like structure present in the medullary visceral zone of the rat, with its distribution generally matching that of Substance P receptor-like immunoreactivity (SPR-LI) in normal control animals."
sodium,"Sodium currents are present in neuroepithelial cells of chick embryo eye primordia, with both inward and outward currents evoked by depolarization.","Entity: sodium. SMILES: [Na]. Sodium currents are present in neuroepithelial cells of chick embryo eye primordia, with both inward and outward currents evoked by depolarization."
PHF-tau,PHF-tau is a hyperphosphorylated form of tau protein that is a major component of neurofibrillary tangles found in Alzheimer's disease.,Entity: PHF-tau. PHF-tau is a hyperphosphorylated form of tau protein that is a major component of neurofibrillary tangles found in Alzheimer's disease.
glial fibrillary acidic protein,Glial fibrillary acidic protein is used as an immunohistological marker to identify glial cells in the retina.,Entity: glial fibrillary acidic protein. Glial fibrillary acidic protein is used as an immunohistological marker to identify glial cells in the retina.
iberiotoxin,"Iberiotoxin blocks large-conductance, Ca2+-activated K+ (BK(Ca)) channels in Muller glial cells.","Entity: iberiotoxin. SMILES: CSCCC(NC(=O)C1CSSCC(NC(=O)C(NC(=O)C(CO)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C2CSSCC(NC(=O)C(CC(=O)O)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(NC(=O)C(Cc3ccccc3)NC(=O)C3CCC(=O)N3)C(C)O)C(C)C)C(=O)NC(CO)C(=O)NC(C(C)C)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)N2)C(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(Cc2ccccc2)C(=O)NCC(=O)NC(C(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCCN)C(=O)N1)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC1CSSCC(C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(CCC(N)=O)C(=O)O)NC(=O)C(CCCNC(=N)N)NC1=O. Iberiotoxin blocks large-conductance, Ca2+-activated K+ (BK(Ca)) channels in Muller glial cells."
ammonia,Exposure of retinal explant cultures to 7 mM ammonia for one day induces Muller cell reactivity as indicated by increased immunopositivity for glial fibrillary acidic protein.,Entity: ammonia. SMILES: N. Exposure of retinal explant cultures to 7 mM ammonia for one day induces Muller cell reactivity as indicated by increased immunopositivity for glial fibrillary acidic protein.
ammonia,"Four days of exposure to elevated ammonia (7 mM) in retinal explant cultures causes severe deformation of Muller cells, disorganization of the retinal layered structure, and significant neuronal cell death.","Entity: ammonia. SMILES: N. Four days of exposure to elevated ammonia (7 mM) in retinal explant cultures causes severe deformation of Muller cells, disorganization of the retinal layered structure, and significant neuronal cell death."
ammonia,Ammonia exposure in retinal explant cultures leads to the loss of inwardly rectifying K+ (K(IR)) channels in Muller cell membranes after four days.,Entity: ammonia. SMILES: N. Ammonia exposure in retinal explant cultures leads to the loss of inwardly rectifying K+ (K(IR)) channels in Muller cell membranes after four days.
glial fibrillary acidic protein,"Immunopositivity for glial fibrillary acidic protein increases in Muller cells of the mammalian retina one day after exposure to elevated ammonia (7 mM), indicating Muller cell reactivity.","Entity: glial fibrillary acidic protein. Immunopositivity for glial fibrillary acidic protein increases in Muller cells of the mammalian retina one day after exposure to elevated ammonia (7 mM), indicating Muller cell reactivity."
preproenkephalin,"Preproenkephalin (PPE) mRNA expression in neurons of the caudal spinal trigeminal nucleus and first cervical cord increases 2 hours and 4 hours after formalin injection, and remains elevated 48 hours post-injection.","Entity: preproenkephalin. Preproenkephalin (PPE) mRNA expression in neurons of the caudal spinal trigeminal nucleus and first cervical cord increases 2 hours and 4 hours after formalin injection, and remains elevated 48 hours post-injection."
preproenkephalin,Preproenkephalin (PPE) mRNA expression increases in neurons of the superficial (laminae I-II) and deep (lamina V) layers of the caudal spinal trigeminal nucleus and the first cervical cord following peripheral noxious stimulation such as subcutaneous formalin injection in the orofacial region.,Entity: preproenkephalin. Preproenkephalin (PPE) mRNA expression increases in neurons of the superficial (laminae I-II) and deep (lamina V) layers of the caudal spinal trigeminal nucleus and the first cervical cord following peripheral noxious stimulation such as subcutaneous formalin injection in the orofacial region.
2-amino-4-phosphonobutyric acid,"2-amino-4-phosphonobutyric acid is a glutamate agonist that, when injected intravitreally in neonatal rats, does not alter the pattern of SNAP-25 immunoreactivity in photoreceptors, inner and outer plexiform layers, or optic nerve fibres.","Entity: 2-amino-4-phosphonobutyric acid. SMILES: NC(CCP(=O)(O)O)C(=O)O. 2-amino-4-phosphonobutyric acid is a glutamate agonist that, when injected intravitreally in neonatal rats, does not alter the pattern of SNAP-25 immunoreactivity in photoreceptors, inner and outer plexiform layers, or optic nerve fibres."
synaptosomal-associated protein-25,"Synaptosomal-associated protein-25 (SNAP-25) immunoreactivity is primarily expressed in postnatal rat photoreceptors, inner and outer plexiform layers, and optic nerve fibres in a highly age-related manner.","Entity: synaptosomal-associated protein-25. Synaptosomal-associated protein-25 (SNAP-25) immunoreactivity is primarily expressed in postnatal rat photoreceptors, inner and outer plexiform layers, and optic nerve fibres in a highly age-related manner."
FOS,FOS is a protein whose expression is induced by c-fos proto-oncogene in response to orofacial noxious stimulation.,Entity: FOS. FOS is a protein whose expression is induced by c-fos proto-oncogene in response to orofacial noxious stimulation.
catalase,Catalase HPII from Escherichia coli is a homotetramer of 753-residue subunits and is the largest known catalase.,Entity: catalase. Catalase HPII from Escherichia coli is a homotetramer of 753-residue subunits and is the largest known catalase.
diamidinobenzofuranyl ethene,Diamidinobenzofuranyl ethene is a synthetic inhibitor of Factor Xa (FXa) whose binding mode and interactions with the specificity pocket residue Asp-189 and the active site water molecule WAT522 can be analyzed using computational docking.,Entity: diamidinobenzofuranyl ethene. SMILES: N=C(N)C(=Cc1cc2ccccc2o1)C(=N)N. Diamidinobenzofuranyl ethene is a synthetic inhibitor of Factor Xa (FXa) whose binding mode and interactions with the specificity pocket residue Asp-189 and the active site water molecule WAT522 can be analyzed using computational docking.
amidinophenyl pyruvic acid,Amidinophenyl pyruvic acid is a synthetic inhibitor of Factor Xa (FXa) whose binding mode and interactions with the specificity pocket residue Asp-189 and the active site water molecule WAT522 can be studied using computational docking.,Entity: amidinophenyl pyruvic acid. SMILES: N=C(N)C(C(=O)C(=O)O)c1ccccc1. Amidinophenyl pyruvic acid is a synthetic inhibitor of Factor Xa (FXa) whose binding mode and interactions with the specificity pocket residue Asp-189 and the active site water molecule WAT522 can be studied using computational docking.
glycylglycine,Glycylglycine is a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.,Entity: glycylglycine. SMILES: NCC(=O)NCC(=O)O. Glycylglycine is a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.
N-valproylglycinamide,N-valproylglycinamide is a glycine derivative and a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.,Entity: N-valproylglycinamide. SMILES: CCCC(CCC)C(=O)NC(=O)CN. N-valproylglycinamide is a glycine derivative and a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.
N-acetylglycine,N-acetylglycine is a glycine derivative and a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.,Entity: N-acetylglycine. SMILES: CC(=O)NCC(=O)O. N-acetylglycine is a glycine derivative and a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.
phthaloylglycinamide,Phthaloylglycinamide is a glycine derivative and a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.,Entity: phthaloylglycinamide. SMILES: NC(=O)CNC(=O)c1ccccc1C(=O)O. Phthaloylglycinamide is a glycine derivative and a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.
N-benzyloxycarbonylglycine,N-benzyloxycarbonylglycine is a glycine derivative and a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.,Entity: N-benzyloxycarbonylglycine. SMILES: O=C(O)CNC(=O)OCc1ccccc1. N-benzyloxycarbonylglycine is a glycine derivative and a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.
glycinamide,Glycinamide is a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.,Entity: glycinamide. SMILES: NCC(N)=O. Glycinamide is a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.
N-acetylglycylglycinamide,N-acetylglycylglycinamide is a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.,Entity: N-acetylglycylglycinamide. SMILES: CC(=O)NCC(=O)NCC(N)=O. N-acetylglycylglycinamide is a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.
glycylglycinamide,Glycylglycinamide is a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.,Entity: glycylglycinamide. SMILES: NCC(=O)NCC(N)=O. Glycylglycinamide is a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.
N-acetylglycinamide,N-acetylglycinamide is a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.,Entity: N-acetylglycinamide. SMILES: CC(=O)NC(=O)CN. N-acetylglycinamide is a dipeptide of glycinamide that was found to be inactive in anticonvulsant and neurotoxicity screening in animal models.
allopregnanolone,Allopregnanolone is a positive modulator of the GABA(A) receptor.,Entity: allopregnanolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Allopregnanolone is a positive modulator of the GABA(A) receptor.
allopregnanolone,"Intraperitoneal administration of allopregnanolone at doses from 5 to 20 mg/kg increases the number and total duration of spike-wave discharges in WAG/Rij rats, a genetic model for generalized absence epilepsy, in a dose-dependent manner.","Entity: allopregnanolone. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Intraperitoneal administration of allopregnanolone at doses from 5 to 20 mg/kg increases the number and total duration of spike-wave discharges in WAG/Rij rats, a genetic model for generalized absence epilepsy, in a dose-dependent manner."
pregnenolone sulfate,Pregnenolone sulfate is a positive modulator of NMDA receptors.,Entity: pregnenolone sulfate. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OS(=O)(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C. Pregnenolone sulfate is a positive modulator of NMDA receptors.
pregnenolone sulfate,"Intraperitoneal administration of pregnenolone sulfate at 100 mg/kg increases the number and total duration of spike-wave discharges in WAG/Rij rats, a genetic model for generalized absence epilepsy.","Entity: pregnenolone sulfate. SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OS(=O)(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C. Intraperitoneal administration of pregnenolone sulfate at 100 mg/kg increases the number and total duration of spike-wave discharges in WAG/Rij rats, a genetic model for generalized absence epilepsy."
phenobarbital,"Postmortem decrease in phenobarbital serum concentrations is observed, which should be considered when interpreting 'subtherapeutic' serum levels and assessing noncompliance in cases of sudden unexplained death or fatal intoxication.","Entity: phenobarbital. SMILES: CCC1(c2ccccc2)C(=O)NC(=O)NC1=O. Postmortem decrease in phenobarbital serum concentrations is observed, which should be considered when interpreting 'subtherapeutic' serum levels and assessing noncompliance in cases of sudden unexplained death or fatal intoxication."
carbamazepine,"Premortem serum concentrations of carbamazepine are highly correlated (r = 0.985) with postmortem serum concentrations, but 16% of premortem values are higher than postmortem values in patients who died from epilepsy.","Entity: carbamazepine. SMILES: NC(=O)N1c2ccccc2C=Cc2ccccc21. Premortem serum concentrations of carbamazepine are highly correlated (r = 0.985) with postmortem serum concentrations, but 16% of premortem values are higher than postmortem values in patients who died from epilepsy."
carbamazepine,The ratio of premortem to postmortem carbamazepine serum concentrations (CE/CBZ) does not show significant differences between sudden unexplained death and known cause of death in epilepsy patients.,Entity: carbamazepine. SMILES: NC(=O)N1c2ccccc2C=Cc2ccccc21. The ratio of premortem to postmortem carbamazepine serum concentrations (CE/CBZ) does not show significant differences between sudden unexplained death and known cause of death in epilepsy patients.
CBZ,"Premortem serum concentrations of CBZ are highly correlated (r = 0.985) with postmortem serum concentrations, but 16% of premortem values are higher than postmortem values in patients who died from epilepsy.","Entity: CBZ. SMILES: O=[C]OCc1ccccc1. Premortem serum concentrations of CBZ are highly correlated (r = 0.985) with postmortem serum concentrations, but 16% of premortem values are higher than postmortem values in patients who died from epilepsy."
phenobarbital,"Premortem serum concentrations of phenobarbital are highly correlated (r = 0.991) with postmortem serum concentrations, but 65% of premortem values are higher than postmortem values in patients who died from epilepsy.","Entity: phenobarbital. SMILES: CCC1(c2ccccc2)C(=O)NC(=O)NC1=O. Premortem serum concentrations of phenobarbital are highly correlated (r = 0.991) with postmortem serum concentrations, but 65% of premortem values are higher than postmortem values in patients who died from epilepsy."
vigabatrin,"Vigabatrin (gamma-vinyl GABA) is an anticonvulsant that, when administered chronically at 75 mg/kg per day via subcutaneous osmotic minipump for 2 months, does not prevent loss of hilar neurons or mossy fiber sprouting in the epileptic rat hippocampus after kainic acid-induced status epilepticus.","Entity: vigabatrin. SMILES: C=CC(N)CCC(=O)O. Vigabatrin (gamma-vinyl GABA) is an anticonvulsant that, when administered chronically at 75 mg/kg per day via subcutaneous osmotic minipump for 2 months, does not prevent loss of hilar neurons or mossy fiber sprouting in the epileptic rat hippocampus after kainic acid-induced status epilepticus."
vigabatrin,"Vigabatrin administered 2 days after kainic acid-induced status epilepticus provides a mild neuroprotective effect on somatostatin-immunoreactive (SOM-ir) neurons in the septal end of the rat hippocampus, with 92% of SOM-ir neurons remaining compared to vehicle-treated controls.","Entity: vigabatrin. SMILES: C=CC(N)CCC(=O)O. Vigabatrin administered 2 days after kainic acid-induced status epilepticus provides a mild neuroprotective effect on somatostatin-immunoreactive (SOM-ir) neurons in the septal end of the rat hippocampus, with 92% of SOM-ir neurons remaining compared to vehicle-treated controls."
vigabatrin,"Vigabatrin does not prevent mossy fiber sprouting in the rat hippocampus, and treatment initiated 1 hour after status epilepticus actually increases mossy fiber sprouting in the septal end compared to vehicle-treated controls.","Entity: vigabatrin. SMILES: C=CC(N)CCC(=O)O. Vigabatrin does not prevent mossy fiber sprouting in the rat hippocampus, and treatment initiated 1 hour after status epilepticus actually increases mossy fiber sprouting in the septal end compared to vehicle-treated controls."
vigabatrin,Chronic elevation of brain GABA levels after status epilepticus in rats does not substantially affect neuronal loss or mossy fiber sprouting in the hippocampus.,Entity: vigabatrin. SMILES: C=CC(N)CCC(=O)O. Chronic elevation of brain GABA levels after status epilepticus in rats does not substantially affect neuronal loss or mossy fiber sprouting in the hippocampus.
somatostatin,"Somatostatin is used as an immunohistochemical marker to identify somatostatin-immunoreactive (SOM-ir) neurons in the hippocampus, which are selectively lost after kainic acid-induced status epilepticus.","Entity: somatostatin. Somatostatin is used as an immunohistochemical marker to identify somatostatin-immunoreactive (SOM-ir) neurons in the hippocampus, which are selectively lost after kainic acid-induced status epilepticus."
STa receptor,"The STa receptor on enterocytes exhibits higher density and affinity in 2-day-old Swiss Webster mice compared to older mice, as measured by 125I-STa binding assays.","Entity: STa receptor. The STa receptor on enterocytes exhibits higher density and affinity in 2-day-old Swiss Webster mice compared to older mice, as measured by 125I-STa binding assays."
beta-actin,Beta-actin is used as a normalization factor in quantitative PCR assays to account for variations in RNA extraction and reverse transcription steps.,Entity: beta-actin. Beta-actin is used as a normalization factor in quantitative PCR assays to account for variations in RNA extraction and reverse transcription steps.
beta-actin,Beta-actin cDNA can be amplified in triplicate PCR reactions from oligo-dT primed RT reactions and used to generate standard curves for normalizing cytokine mRNA quantification.,Entity: beta-actin. Beta-actin cDNA can be amplified in triplicate PCR reactions from oligo-dT primed RT reactions and used to generate standard curves for normalizing cytokine mRNA quantification.
interleukin-10,"Interleukin-10 (IL-10) mRNA levels can be quantified using a noncompetitive PCR assay with plasmid-derived standard curves, allowing for sensitive detection of at least 2-fold differences in IL-10 mRNA content.","Entity: interleukin-10. Interleukin-10 (IL-10) mRNA levels can be quantified using a noncompetitive PCR assay with plasmid-derived standard curves, allowing for sensitive detection of at least 2-fold differences in IL-10 mRNA content."
IFN,"Type I interferons are expressed in eukaryotic cells as the first line of defense against viral infection, preventing viral replication and protecting cells from virus-induced cell destruction.","Entity: IFN. Type I interferons are expressed in eukaryotic cells as the first line of defense against viral infection, preventing viral replication and protecting cells from virus-induced cell destruction."
CD8,CD8 antibodies are used in combination with CD3 and CD4 antibodies in flow cytometry panels to measure CD4 and CD8 counts in whole blood samples.,Entity: CD8. CD8 antibodies are used in combination with CD3 and CD4 antibodies in flow cytometry panels to measure CD4 and CD8 counts in whole blood samples.
sodium,"Sodium ions can penetrate the macula densa in response to increased sodium levels in the convoluted portion of the distal tubule, leading to augmented renin secretion from epithelioid cells of the juxtaglomerular apparatus.","Entity: sodium. SMILES: [Na]. Sodium ions can penetrate the macula densa in response to increased sodium levels in the convoluted portion of the distal tubule, leading to augmented renin secretion from epithelioid cells of the juxtaglomerular apparatus."
chloride,"Chloride ions accompany sodium ions in their penetration of the macula densa when sodium levels increase in the distal tubule, contributing to augmented renin secretion from juxtaglomerular apparatus cells.","Entity: chloride. SMILES: [Cl-]. Chloride ions accompany sodium ions in their penetration of the macula densa when sodium levels increase in the distal tubule, contributing to augmented renin secretion from juxtaglomerular apparatus cells."
pentobarbital,Pentobarbital is used as an anesthetic agent for inducing narcosis in animals during surgical procedures such as laparotomy.,Entity: pentobarbital. SMILES: CCCC(C)C1(CC)C(=O)NC(=O)NC1=O. Pentobarbital is used as an anesthetic agent for inducing narcosis in animals during surgical procedures such as laparotomy.
cacodylate,Cacodylate is used as a buffering agent in histological and electron microscopy sample preparation to maintain pH stability.,Entity: cacodylate. SMILES: C[As](C)(=O)[O-]. Cacodylate is used as a buffering agent in histological and electron microscopy sample preparation to maintain pH stability.
acetone,Acetone is used as a dehydrant in the preparation of biological tissue samples for embedding in resin prior to sectioning.,Entity: acetone. SMILES: CC(C)=O. Acetone is used as a dehydrant in the preparation of biological tissue samples for embedding in resin prior to sectioning.
osmium tetroxide,Osmium tetroxide is used as a postfixation agent in electron microscopy to preserve and contrast biological tissue samples.,Entity: osmium tetroxide. SMILES: O=[Os](=O)(=O)=O. Osmium tetroxide is used as a postfixation agent in electron microscopy to preserve and contrast biological tissue samples.
glutaraldehyde,Glutaraldehyde is used as a fixative in histological and electron microscopy sample preparation to preserve cellular structure.,Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a fixative in histological and electron microscopy sample preparation to preserve cellular structure.
TRH,"The TRH test is used as a diagnostic tool for TSH-secreting tumors, with sensitivities of 64% and 90% and specificities of 100% and 82% in untreated and treated patients, respectively, in a series of 25 patients.","Entity: TRH. The TRH test is used as a diagnostic tool for TSH-secreting tumors, with sensitivities of 64% and 90% and specificities of 100% and 82% in untreated and treated patients, respectively, in a series of 25 patients."
folate,"Folate intake influences plasma homocysteine concentrations, and marginal folate deficiency induced by gastroplasty can promote hyperhomocysteinemia in severely obese patients.","Entity: folate. SMILES: Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)O)cc3)nc2c(=O)[nH]1. Folate intake influences plasma homocysteine concentrations, and marginal folate deficiency induced by gastroplasty can promote hyperhomocysteinemia in severely obese patients."
GHRH,"Biologically and immunologically active GHRH and messenger ribonucleic acid for GHRH are found in human breast, endometrial, and ovarian cancers, supporting a role for locally produced GHRH in tumor cell proliferation.","Entity: GHRH. Biologically and immunologically active GHRH and messenger ribonucleic acid for GHRH are found in human breast, endometrial, and ovarian cancers, supporting a role for locally produced GHRH in tumor cell proliferation."
GHRH,"GHRH gene expression and biologically active GHRH peptide are present in 17 of 22 endometrial cancer specimens, 17 of 22 ovarian cancer specimens, and all human endometrial, ovarian, and breast cancer xenografts.","Entity: GHRH. GHRH gene expression and biologically active GHRH peptide are present in 17 of 22 endometrial cancer specimens, 17 of 22 ovarian cancer specimens, and all human endometrial, ovarian, and breast cancer xenografts."
GHRH,"GHRH is produced in various extrahypothalamic tissues, including some human neoplasms.","Entity: GHRH. GHRH is produced in various extrahypothalamic tissues, including some human neoplasms."
GHRH,Immunoreactive GHRH peptide is detected in endometrial and breast cancer specimens and xenografts at levels equivalent to 2.7–6.4 ng GHRH-(1–29)/g tissue.,Entity: GHRH. Immunoreactive GHRH peptide is detected in endometrial and breast cancer specimens and xenografts at levels equivalent to 2.7–6.4 ng GHRH-(1–29)/g tissue.
GHRH,Purified extract from human endometrial or breast cancer xenografts induces powerful stimulation of GH release from rat pituitary cells.,Entity: GHRH. Purified extract from human endometrial or breast cancer xenografts induces powerful stimulation of GH release from rat pituitary cells.
estradiol valerate,"Estradiol valerate supplementation for 8 weeks at 2 mg daily attenuates blood pressure, cortisol, ACTH, epinephrine, norepinephrine, and norepinephrine spillover responses to psychological stress in perimenopausal women.","Entity: estradiol valerate. SMILES: CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C. Estradiol valerate supplementation for 8 weeks at 2 mg daily attenuates blood pressure, cortisol, ACTH, epinephrine, norepinephrine, and norepinephrine spillover responses to psychological stress in perimenopausal women."
norepinephrine,Total body norepinephrine spillover is significantly reduced by estradiol valerate supplementation in perimenopausal women after a 10-minute mental arithmetic stress test.,Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Total body norepinephrine spillover is significantly reduced by estradiol valerate supplementation in perimenopausal women after a 10-minute mental arithmetic stress test.
epinephrine,Plasma epinephrine response to psychological stress is significantly attenuated by estradiol valerate supplementation in perimenopausal women.,Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. Plasma epinephrine response to psychological stress is significantly attenuated by estradiol valerate supplementation in perimenopausal women.
catecholamine,"Catecholamine responses, including epinephrine and norepinephrine, to psychological stress are significantly attenuated by estradiol valerate supplementation in perimenopausal women.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Catecholamine responses, including epinephrine and norepinephrine, to psychological stress are significantly attenuated by estradiol valerate supplementation in perimenopausal women."
epinephrine,"Epinephrine release from human adrenal medullary chromaffin cells is increased in a concentration-dependent manner by cerebellin, with minimal and maximal effective concentrations of 10⁻⁹ mol/L and 10⁻⁷ mol/L, respectively.","Entity: epinephrine. SMILES: CNC[C@H](O)c1ccc(O)c(O)c1. Epinephrine release from human adrenal medullary chromaffin cells is increased in a concentration-dependent manner by cerebellin, with minimal and maximal effective concentrations of 10⁻⁹ mol/L and 10⁻⁷ mol/L, respectively."
catecholamine,"Cerebellin increases basal catecholamine (norepinephrine and epinephrine) release from human adrenal slices containing medullary chromaffin tissue in a concentration-dependent manner, with minimal and maximal effective concentrations of 10⁻⁹ mol/L and 10⁻⁷ mol/L, respectively.","Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Cerebellin increases basal catecholamine (norepinephrine and epinephrine) release from human adrenal slices containing medullary chromaffin tissue in a concentration-dependent manner, with minimal and maximal effective concentrations of 10⁻⁹ mol/L and 10⁻⁷ mol/L, respectively."
catecholamine,Cerebellin stimulates catecholamine release via the adenylate cyclase/protein kinase A-dependent signaling pathway in human adrenal tissue.,Entity: catecholamine. SMILES: Nc1cccc(O)c1O. Cerebellin stimulates catecholamine release via the adenylate cyclase/protein kinase A-dependent signaling pathway in human adrenal tissue.
norepinephrine,"Norepinephrine release from human adrenal medullary chromaffin cells is increased in a concentration-dependent manner by cerebellin, with minimal and maximal effective concentrations of 10⁻⁹ mol/L and 10⁻⁷ mol/L, respectively.","Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Norepinephrine release from human adrenal medullary chromaffin cells is increased in a concentration-dependent manner by cerebellin, with minimal and maximal effective concentrations of 10⁻⁹ mol/L and 10⁻⁷ mol/L, respectively."
PRL,"PRL (prolactin) is synthesized and released by several extrapituitary tissues, including decidualized endometrial stromal cells.","Entity: PRL. PRL (prolactin) is synthesized and released by several extrapituitary tissues, including decidualized endometrial stromal cells."
PRL,The inhibition of PRL release by IL-2 is secondary to inhibition of PRL synthesis in decidual human endometrial stromal cells.,Entity: PRL. The inhibition of PRL release by IL-2 is secondary to inhibition of PRL synthesis in decidual human endometrial stromal cells.
PRL,"IL-2 (interleukin-2) at 50 ng/mL inhibits PRL release from primary cultures of human decidual cells by 71.0 ± 0.9% after 5 days of exposure, with maximal inhibition observed at 48 h.","Entity: PRL. IL-2 (interleukin-2) at 50 ng/mL inhibits PRL release from primary cultures of human decidual cells by 71.0 ± 0.9% after 5 days of exposure, with maximal inhibition observed at 48 h."
leptin,"Sustained increases in circulating leptin concentrations, such as those seen with obesity, prolonged energy restriction, or diabetes, may be more important for regulating food intake in primates than acute changes.","Entity: leptin. Sustained increases in circulating leptin concentrations, such as those seen with obesity, prolonged energy restriction, or diabetes, may be more important for regulating food intake in primates than acute changes."
leptin,Peripheral administration of leptin at 1 and 3 µg/kg (s.c.) does not inhibit food intake over the subsequent 3 days in rhesus monkeys.,Entity: leptin. Peripheral administration of leptin at 1 and 3 µg/kg (s.c.) does not inhibit food intake over the subsequent 3 days in rhesus monkeys.
leptin,Intracerebroventricular administration of leptin in rhesus monkeys acutely increases circulating norepinephrine levels by 55 ± 16% 1 hour post-administration.,Entity: leptin. Intracerebroventricular administration of leptin in rhesus monkeys acutely increases circulating norepinephrine levels by 55 ± 16% 1 hour post-administration.
leptin,"Central administration of leptin (1 µg/kg, intracerebroventricularly) causes a significant and sustained suppression (40–50%) of food intake during the entire following day in rhesus monkeys.","Entity: leptin. Central administration of leptin (1 µg/kg, intracerebroventricularly) causes a significant and sustained suppression (40–50%) of food intake during the entire following day in rhesus monkeys."
norepinephrine,"Plasma norepinephrine is unaffected by BNP infusion, NEP inhibition, or combined treatment.","Entity: norepinephrine. SMILES: NC[C@H](O)c1ccc(O)c(O)c1. Plasma norepinephrine is unaffected by BNP infusion, NEP inhibition, or combined treatment."
SCH 42495,"SCH 42495 is a neutral endopeptidase (NEP) inhibitor that, when administered as a single oral dose (300 mg), increases plasma BNP, cGMP, and cortisol, and reduces the metabolic clearance rate of exogenous BNP by 25%.","Entity: SCH 42495. SMILES: CCOC(=O)[C@H](CCSC)NC(=O)[C@@H](CSC(C)=O)Cc1ccccc1C. SCH 42495 is a neutral endopeptidase (NEP) inhibitor that, when administered as a single oral dose (300 mg), increases plasma BNP, cGMP, and cortisol, and reduces the metabolic clearance rate of exogenous BNP by 25%."
SCH 42495,"SCH 42495 inhibits NEP, leading to increased urine sodium excretion and augmented endogenous plasma atrial natriuretic peptide (ANP) compared to BNP.","Entity: SCH 42495. SMILES: CCOC(=O)[C@H](CCSC)NC(=O)[C@@H](CSC(C)=O)Cc1ccccc1C. SCH 42495 inhibits NEP, leading to increased urine sodium excretion and augmented endogenous plasma atrial natriuretic peptide (ANP) compared to BNP."
sodium,Inhibition of neutral endopeptidase (NEP) increases urine sodium excretion.,Entity: sodium. SMILES: [Na]. Inhibition of neutral endopeptidase (NEP) increases urine sodium excretion.
oncostatin M,"Oncostatin M shows intense immunoreaction in Leydig cells of fetuses, newborns, and adults, but is weak in elderly men and absent in children and pubertal boys, suggesting its expression is associated with functionally active and differentiated Leydig cells.","Entity: oncostatin M. Oncostatin M shows intense immunoreaction in Leydig cells of fetuses, newborns, and adults, but is weak in elderly men and absent in children and pubertal boys, suggesting its expression is associated with functionally active and differentiated Leydig cells."
oncostatin M,"Oncostatin M immunostains Sertoli cells only in fetuses, indicating its expression is downregulated early in human spermatogenesis.","Entity: oncostatin M. Oncostatin M immunostains Sertoli cells only in fetuses, indicating its expression is downregulated early in human spermatogenesis."
erbB-2,"erbB-2 is a target antigen recognized by a chimeric receptor consisting of an anti-erbB-2 monoclonal antibody scFv domain linked to the Fc receptor gamma chain, enabling non-MHC-restricted lysis of erbB-2-expressing breast carcinoma target cells.","Entity: erbB-2. erbB-2 is a target antigen recognized by a chimeric receptor consisting of an anti-erbB-2 monoclonal antibody scFv domain linked to the Fc receptor gamma chain, enabling non-MHC-restricted lysis of erbB-2-expressing breast carcinoma target cells."
MUC1,"MUC1 is a tumor-specific antigen expressed by pancreatic adenocarcinoma cell lines such as Panc02-MUC1, and its expression in orthotopically injected tumors in mice is associated with progressive tumor growth and induction of tumor-specific immune responses.","Entity: MUC1. MUC1 is a tumor-specific antigen expressed by pancreatic adenocarcinoma cell lines such as Panc02-MUC1, and its expression in orthotopically injected tumors in mice is associated with progressive tumor growth and induction of tumor-specific immune responses."
ChAT,"ChAT immunoreactivity in the rabbit retina changes in nature after 75 minutes of ischemia, and in the rat retina after 60 minutes of ischemia followed by 3 days of reperfusion.","Entity: ChAT. ChAT immunoreactivity in the rabbit retina changes in nature after 75 minutes of ischemia, and in the rat retina after 60 minutes of ischemia followed by 3 days of reperfusion."
Thy-1,Thy-1 immunoreactivity in the rat retina is only clearly altered after a reperfusion period of 7 days following ischemia/reperfusion injury.,Entity: Thy-1. Thy-1 immunoreactivity in the rat retina is only clearly altered after a reperfusion period of 7 days following ischemia/reperfusion injury.
aspartate,"Intravitreal injection of aspartate eliminates the fast-positive component of the rat ERG off-response, indicating that aspartate selectively suppresses the fast-positive component associated with rod activity.","Entity: aspartate. SMILES: N[C@@H](CC(=O)[O-])C(=O)[O-]. Intravitreal injection of aspartate eliminates the fast-positive component of the rat ERG off-response, indicating that aspartate selectively suppresses the fast-positive component associated with rod activity."
"5,7-dihydroxytryptamine","Elevation of 5,7-dihydroxytryptamine levels in the developing superior colliculus reduces the postnatal refinement of crossed retinotectal axons.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. Elevation of 5,7-dihydroxytryptamine levels in the developing superior colliculus reduces the postnatal refinement of crossed retinotectal axons."
"5,7-dihydroxytryptamine","Administration of a single subcutaneous dose of 5,7-dihydroxytryptamine to newborn hamsters increases serotonergic (5-HT) fiber density in the superficial layers of the superior colliculus and alters the uncrossed retinotectal projection when the animals reach adulthood.","Entity: 5,7-dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. Administration of a single subcutaneous dose of 5,7-dihydroxytryptamine to newborn hamsters increases serotonergic (5-HT) fiber density in the superficial layers of the superior colliculus and alters the uncrossed retinotectal projection when the animals reach adulthood."
glutamate,Glutamate acts as a non-NMDA receptor agonist and can induce pathomorphology and cell death in chick embryo retina neurons when combined with the NMDA receptor antagonist MK-801.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate acts as a non-NMDA receptor agonist and can induce pathomorphology and cell death in chick embryo retina neurons when combined with the NMDA receptor antagonist MK-801.
glutamate,"Glutamate can prevent KA-induced toxicity in chick embryo retina neurons, as measured by a biochemical assay of cell death.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate can prevent KA-induced toxicity in chick embryo retina neurons, as measured by a biochemical assay of cell death."
glutamate,Glutamate selectively blocks KA-induced pathomorphological changes in bipolar cells in chick embryo retina.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate selectively blocks KA-induced pathomorphological changes in bipolar cells in chick embryo retina.
cyclothiazide,Cyclothiazide increases the toxicity of AMPA and glutamate by blocking AMPA receptor desensitization.,Entity: cyclothiazide. SMILES: NS(=O)(=O)c1cc2c(cc1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O. Cyclothiazide increases the toxicity of AMPA and glutamate by blocking AMPA receptor desensitization.
dopamine,Dopamine acts as a neurotransmitter that modulates synaptic actions in the vertebrate central nervous system.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine acts as a neurotransmitter that modulates synaptic actions in the vertebrate central nervous system.
glutamate,Glutamate is a neurotransmitter whose synaptic actions are modulated by ascorbate in the vertebrate central nervous system.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate is a neurotransmitter whose synaptic actions are modulated by ascorbate in the vertebrate central nervous system.
glutamate,"Glutamate is taken up by glial cells and neurons of the central nervous system, including retinal Muller cells, at high affinity to inactivate synaptically released glutamate and maintain low extracellular concentrations.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate is taken up by glial cells and neurons of the central nervous system, including retinal Muller cells, at high affinity to inactivate synaptically released glutamate and maintain low extracellular concentrations."
glutamate,"Glutamate uptake by retinal Muller cells continues under conditions simulating ischemia and high extracellular K+, but the uptake system saturates at a lower concentration of exogenous glutamate under high K+ conditions compared to normal K+ conditions.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate uptake by retinal Muller cells continues under conditions simulating ischemia and high extracellular K+, but the uptake system saturates at a lower concentration of exogenous glutamate under high K+ conditions compared to normal K+ conditions."
glutamate,"Disruption of glutamate uptake by retinal Muller cells can lead to excess extracellular glutamate accumulation, which may contribute to neurotoxicity following ischemic insult.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Disruption of glutamate uptake by retinal Muller cells can lead to excess extracellular glutamate accumulation, which may contribute to neurotoxicity following ischemic insult."
cobalt,"Low cobalt reduces a late depolarizing wave in the horizontal cell light-evoked waveform, indicating suppression of horizontal cell to cone feedback.","Entity: cobalt. SMILES: [Co]. Low cobalt reduces a late depolarizing wave in the horizontal cell light-evoked waveform, indicating suppression of horizontal cell to cone feedback."
cobalt,"Low cobalt selectively suppresses the depolarizing component of chromatic horizontal cells, consistent with inhibition of horizontal cell to cone feedback.","Entity: cobalt. SMILES: [Co]. Low cobalt selectively suppresses the depolarizing component of chromatic horizontal cells, consistent with inhibition of horizontal cell to cone feedback."
cobalt,Low cobalt reduces or completely blocks the receptive-field surrounds of a subset of bipolar and amacrine cells in the retina.,Entity: cobalt. SMILES: [Co]. Low cobalt reduces or completely blocks the receptive-field surrounds of a subset of bipolar and amacrine cells in the retina.
dopamine,"Dopamine, at concentrations that similarly constrict the receptive area of horizontal cells, does not block ganglion cell receptive-field surrounds in the retina.","Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine, at concentrations that similarly constrict the receptive area of horizontal cells, does not block ganglion cell receptive-field surrounds in the retina."
cobalt,Cobalt at sub-millimolar concentrations blocks horizontal cell to cone feedback in the retina without attenuating direct cone to second-order cell synaptic transmission.,Entity: cobalt. SMILES: [Co]. Cobalt at sub-millimolar concentrations blocks horizontal cell to cone feedback in the retina without attenuating direct cone to second-order cell synaptic transmission.
cobalt,Low concentrations of cobalt (0.25–0.5 mM) block ganglion cell receptive-field surrounds by inhibiting horizontal cell to cone feedback.,Entity: cobalt. SMILES: [Co]. Low concentrations of cobalt (0.25–0.5 mM) block ganglion cell receptive-field surrounds by inhibiting horizontal cell to cone feedback.
cobalt,Low cobalt reduces the integrating area of the horizontal cell network in the retina.,Entity: cobalt. SMILES: [Co]. Low cobalt reduces the integrating area of the horizontal cell network in the retina.
picrotoxin,Picrotoxin does not antagonize both bicuculline-sensitive (GABA(A)-like) and bicuculline-insensitive (GABAc-like) GABA responses in dissociated rat retinal neurons.,Entity: picrotoxin. SMILES: C=C(C)[C@@H]1C2OC(=O)C1[C@]1(O)CC3O[C@]34C(=O)O[C@H]2[C@]14C.CC(C)(O)[C@@H]1C2OC(=O)C1[C@]1(O)C[C@H]3O[C@]34C(=O)O[C@H]2[C@]14C. Picrotoxin does not antagonize both bicuculline-sensitive (GABA(A)-like) and bicuculline-insensitive (GABAc-like) GABA responses in dissociated rat retinal neurons.
cis-4-Aminocrotonic acid,"Few bipolar cells or retinal ganglion cells in rat retina respond to cis-4-Aminocrotonic acid (CACA), indicating low sensitivity for this ligand.","Entity: cis-4-Aminocrotonic acid. SMILES: NC/C=C\C(=O)O. Few bipolar cells or retinal ganglion cells in rat retina respond to cis-4-Aminocrotonic acid (CACA), indicating low sensitivity for this ligand."
2-hydroxysaclofen,"2-hydroxysaclofen does not antagonize bicuculline-insensitive, Cl(-)-dependent, GABAc-like GABA responses in dissociated rat retinal neurons.","Entity: 2-hydroxysaclofen. SMILES: NCC(O)(CS(=O)(=O)O)c1ccc(Cl)cc1. 2-hydroxysaclofen does not antagonize bicuculline-insensitive, Cl(-)-dependent, GABAc-like GABA responses in dissociated rat retinal neurons."
trans-4-Aminocrotonic acid,"Trans-4-Aminocrotonic acid (TACA) is a ligand that evokes GABA-sensitive responses in dissociated rat retinal neurons, with interchangeable sensitivity to GABA.","Entity: trans-4-Aminocrotonic acid. SMILES: NC/C=C/C(=O)O. Trans-4-Aminocrotonic acid (TACA) is a ligand that evokes GABA-sensitive responses in dissociated rat retinal neurons, with interchangeable sensitivity to GABA."
testosterone propionate,Perinatal treatment with testosterone propionate in female rats leads to a shift in neuronal size distribution in the medial geniculate nucleus toward a greater proportion of small neurons.,Entity: testosterone propionate. SMILES: CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C. Perinatal treatment with testosterone propionate in female rats leads to a shift in neuronal size distribution in the medial geniculate nucleus toward a greater proportion of small neurons.
twist,Twist is a member of the basic helix-loop-helix (bHLH) transcription factor family and is implicated in transcriptional regulation during cell type determination and differentiation.,Entity: twist. Twist is a member of the basic helix-loop-helix (bHLH) transcription factor family and is implicated in transcriptional regulation during cell type determination and differentiation.
Dermo-1,Dermo-1 mRNA levels are decreased about fourfold in C3H10T1/2 cells treated with recombinant human bone morphogenetic protein (rhBMP-2) by Northern blot analysis.,Entity: Dermo-1. Dermo-1 mRNA levels are decreased about fourfold in C3H10T1/2 cells treated with recombinant human bone morphogenetic protein (rhBMP-2) by Northern blot analysis.
Dermo-1,Dermo-1 is a member of the basic helix-loop-helix (bHLH) transcription factor family and is expressed in osteoblastic osteosarcoma ROS17/2.8 cells and MC3T3-E1 cells.,Entity: Dermo-1. Dermo-1 is a member of the basic helix-loop-helix (bHLH) transcription factor family and is expressed in osteoblastic osteosarcoma ROS17/2.8 cells and MC3T3-E1 cells.
twist,Twist mRNA levels are decreased by treatment with recombinant human bone morphogenetic protein (rhBMP-2) in C3H10T1/2 cells.,Entity: twist. Twist mRNA levels are decreased by treatment with recombinant human bone morphogenetic protein (rhBMP-2) in C3H10T1/2 cells.
Dermo-1,Dermo-1 is suggested to be involved in osteoblastic differentiation in a negative manner.,Entity: Dermo-1. Dermo-1 is suggested to be involved in osteoblastic differentiation in a negative manner.
Dermo-1,Dermo-1 mRNA is detected at lower levels in 21-day-old differentiated MC3T3-E1 cells compared with 3-day-old undifferentiated MC3T3-E1 cells.,Entity: Dermo-1. Dermo-1 mRNA is detected at lower levels in 21-day-old differentiated MC3T3-E1 cells compared with 3-day-old undifferentiated MC3T3-E1 cells.
GDF7,"GDF7, also known as BMP12, is a member of the bone morphogenetic protein (BMP) superfamily that induces formation of tendon-like tissue in ectopic implantation experiments.","Entity: GDF7. GDF7, also known as BMP12, is a member of the bone morphogenetic protein (BMP) superfamily that induces formation of tendon-like tissue in ectopic implantation experiments."
lysyl oxidase-like,The substrate specificity of lysyl oxidase-like (LOXL) protein may be different from that of lysyl oxidase and may vary depending on collagen type.,Entity: lysyl oxidase-like. The substrate specificity of lysyl oxidase-like (LOXL) protein may be different from that of lysyl oxidase and may vary depending on collagen type.
lysyl oxidase,"Lysyl oxidase mRNA shows increased steady-state levels throughout the onset of hepatic fibrosis in mice, parallel with increased pro-alphaI collagen mRNA.","Entity: lysyl oxidase. Lysyl oxidase mRNA shows increased steady-state levels throughout the onset of hepatic fibrosis in mice, parallel with increased pro-alphaI collagen mRNA."
lysyl oxidase-like,Lysyl oxidase-like (LOXL) protein is involved in the development of lysine-derived cross-links in collagenous substrates.,Entity: lysyl oxidase-like. Lysyl oxidase-like (LOXL) protein is involved in the development of lysine-derived cross-links in collagenous substrates.
versican,Versican's proliferative effects are mediated by both the G3 domain (via EGF-like motifs) and the G1 domain (by reducing cell adhesion).,Entity: versican. Versican's proliferative effects are mediated by both the G3 domain (via EGF-like motifs) and the G1 domain (by reducing cell adhesion).
aggrecan,"The G1 domain of aggrecan is structurally similar to the G1 domain of versican, both of which are involved in cell adhesion.","Entity: aggrecan. The G1 domain of aggrecan is structurally similar to the G1 domain of versican, both of which are involved in cell adhesion."
versican,"Versican stimulates cell proliferation through its G3 domain, which contains two EGF-like motifs that promote cell growth.","Entity: versican. Versican stimulates cell proliferation through its G3 domain, which contains two EGF-like motifs that promote cell growth."
versican,Versican can reduce cell adhesion and enhance cell proliferation by destabilizing cell-substratum interactions via its G1 domain.,Entity: versican. Versican can reduce cell adhesion and enhance cell proliferation by destabilizing cell-substratum interactions via its G1 domain.
Osteoprotegerin,"Osteoprotegerin (OPG) is a soluble decoy receptor that binds to its ligand OPGL, inhibiting osteoclastogenesis and bone resorption.","Entity: Osteoprotegerin. Osteoprotegerin (OPG) is a soluble decoy receptor that binds to its ligand OPGL, inhibiting osteoclastogenesis and bone resorption."
didemnin B,"Didemnin B induces apoptosis in HL-60 and Daudi cells, as evidenced by caspase activation and cleavage of the caspase substrate poly(ADP-ribose)polymerase.","Entity: didemnin B. SMILES: CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C)O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O. Didemnin B induces apoptosis in HL-60 and Daudi cells, as evidenced by caspase activation and cleavage of the caspase substrate poly(ADP-ribose)polymerase."
hCLIM1,hCLIM1 is the human homolog of rat CLP36 and is located at human chromosome 10q26.,Entity: hCLIM1. hCLIM1 is the human homolog of rat CLP36 and is located at human chromosome 10q26.
hCLIM1,"hCLIM1 is a 36-kDa human protein containing a carboxyl terminal LIM domain and a PDZ domain at the amino terminus, with a predicted open reading frame of 329 amino-acid residues.","Entity: hCLIM1. hCLIM1 is a 36-kDa human protein containing a carboxyl terminal LIM domain and a PDZ domain at the amino terminus, with a predicted open reading frame of 329 amino-acid residues."
hCLIM1,"hCLIM1 mRNA is expressed at high levels in heart and skeletal muscle, moderate levels in spleen, small intestine, colon, placenta, and lung, and lower levels in liver, thymus, kidney, prostate, and pancreas, with no detectable expression in brain, testis, ovary, or peripheral blood leukocytes.","Entity: hCLIM1. hCLIM1 mRNA is expressed at high levels in heart and skeletal muscle, moderate levels in spleen, small intestine, colon, placenta, and lung, and lower levels in liver, thymus, kidney, prostate, and pancreas, with no detectable expression in brain, testis, ovary, or peripheral blood leukocytes."
CLP36,CLP36 is a rat protein that is homologous to the human 36-kDa carboxyl terminal LIM domain protein (hCLIM1).,Entity: CLP36. CLP36 is a rat protein that is homologous to the human 36-kDa carboxyl terminal LIM domain protein (hCLIM1).
aldosterone synthase,"Aldosterone synthase is activated by prolactin in rat zona glomerulosa cells, contributing to the increase in aldosterone secretion.","Entity: aldosterone synthase. Aldosterone synthase is activated by prolactin in rat zona glomerulosa cells, contributing to the increase in aldosterone secretion."
prolactin,"Prolactin stimulates aldosterone secretion by increasing cAMP accumulation, activating both L- and T-type Ca2+ channels, and activating 21-hydroxylase and aldosterone synthase in rat zona glomerulosa cells.","Entity: prolactin. Prolactin stimulates aldosterone secretion by increasing cAMP accumulation, activating both L- and T-type Ca2+ channels, and activating 21-hydroxylase and aldosterone synthase in rat zona glomerulosa cells."
angiotensin II,Angiotensin II attenuates the stimulatory effect of prolactin on aldosterone secretion in rat zona glomerulosa cells.,Entity: angiotensin II. Angiotensin II attenuates the stimulatory effect of prolactin on aldosterone secretion in rat zona glomerulosa cells.
prolactin,Prolactin increases aldosterone secretion in rat zona glomerulosa cells in a dose-dependent manner.,Entity: prolactin. Prolactin increases aldosterone secretion in rat zona glomerulosa cells in a dose-dependent manner.
colchicine,Colchicine at 10 µM disrupts microtubules in Swiss 3T3 mouse fibroblasts.,Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine at 10 µM disrupts microtubules in Swiss 3T3 mouse fibroblasts.
phospholipase C-beta1,Activation of nuclear phospholipase C-beta1 is linked to its phosphorylation and translocation to the nucleus in Swiss 3T3 mouse fibroblasts.,Entity: phospholipase C-beta1. Activation of nuclear phospholipase C-beta1 is linked to its phosphorylation and translocation to the nucleus in Swiss 3T3 mouse fibroblasts.
"1,25-dihydroxyvitamin D3","1,25-dihydroxyvitamin D3 (1,25(OH)2D3) promotes the formation of osteoclast-like cells from primitive myeloid colony-forming cells in a dose-dependent manner.","Entity: 1,25-dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) promotes the formation of osteoclast-like cells from primitive myeloid colony-forming cells in a dose-dependent manner."
"1,25-dihydroxyvitamin D3","1,25-dihydroxyvitamin D3 inhibits colony-forming unit (CFU) formation of myeloid progenitors by up to 90% at 100 nM in suspension cultures stimulated with GM-CSF or 5637 conditioned medium.","Entity: 1,25-dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. 1,25-dihydroxyvitamin D3 inhibits colony-forming unit (CFU) formation of myeloid progenitors by up to 90% at 100 nM in suspension cultures stimulated with GM-CSF or 5637 conditioned medium."
"1,25-dihydroxyvitamin D3","The inhibition of myeloid colony formation by 1,25-dihydroxyvitamin D3 is almost abolished (89%) when anti-tumor necrosis factor-alpha monoclonal antibody is added to the culture medium, suggesting TNF-alpha mediates this effect.","Entity: 1,25-dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. The inhibition of myeloid colony formation by 1,25-dihydroxyvitamin D3 is almost abolished (89%) when anti-tumor necrosis factor-alpha monoclonal antibody is added to the culture medium, suggesting TNF-alpha mediates this effect."
osteocalcin,"Osteocalcin is a matrix molecule whose expression is increased in rat bone marrow stromal cells in the presence of dexamethasone, reflecting its involvement in osteoprogenitor cell differentiation.","Entity: osteocalcin. Osteocalcin is a matrix molecule whose expression is increased in rat bone marrow stromal cells in the presence of dexamethasone, reflecting its involvement in osteoprogenitor cell differentiation."
osteopontin,"Osteopontin is a matrix molecule whose expression is increased in rat bone marrow stromal cells in the presence of dexamethasone, indicating its role in osteoprogenitor cell differentiation.","Entity: osteopontin. Osteopontin is a matrix molecule whose expression is increased in rat bone marrow stromal cells in the presence of dexamethasone, indicating its role in osteoprogenitor cell differentiation."
RNA-binding protein,RNA-binding protein (RBP) in FTO-2B rat hepatoma cells is a complex protein of about 400 kDa composed of RNA-binding subunits and regulatory subunits.,Entity: RNA-binding protein. RNA-binding protein (RBP) in FTO-2B rat hepatoma cells is a complex protein of about 400 kDa composed of RNA-binding subunits and regulatory subunits.
CAP1,CAP1 is a rat sperm protein that shares significant sequence identity with the rat RNA-binding protein RS.,Entity: CAP1. CAP1 is a rat sperm protein that shares significant sequence identity with the rat RNA-binding protein RS.
DJ-1,DJ-1 is a recently discovered protein with oncogenic potential that shares almost identical sequence identity with the rat RNA-binding protein RS.,Entity: DJ-1. DJ-1 is a recently discovered protein with oncogenic potential that shares almost identical sequence identity with the rat RNA-binding protein RS.
granulocyte colony-stimulating factor,"Granulocyte colony-stimulating factor (G-CSF) is a cytokine produced by KU-19-19 bladder cancer cells, contributing to their autocrine growth.","Entity: granulocyte colony-stimulating factor. Granulocyte colony-stimulating factor (G-CSF) is a cytokine produced by KU-19-19 bladder cancer cells, contributing to their autocrine growth."
growth hormone,"Growth hormone (hGH) can be delivered to the brain of rodents by implanting microencapsulated mouse C2C12 myoblasts expressing hGH, with detectable levels in surrounding brain regions at 7, 28, 56, and 112 days postimplantation.","Entity: growth hormone. Growth hormone (hGH) can be delivered to the brain of rodents by implanting microencapsulated mouse C2C12 myoblasts expressing hGH, with detectable levels in surrounding brain regions at 7, 28, 56, and 112 days postimplantation."
interferon alpha2b,"Interferon alpha2b, when delivered intratumorally via recombinant adenovirus, results in complete regression of tumor growth in vivo.","Entity: interferon alpha2b. Interferon alpha2b, when delivered intratumorally via recombinant adenovirus, results in complete regression of tumor growth in vivo."
GUSB,"GUSB secretion from intramuscular sources is inefficient, limiting the therapeutic efficacy of AAV-mediated gene transfer for MPS VII.","Entity: GUSB. GUSB secretion from intramuscular sources is inefficient, limiting the therapeutic efficacy of AAV-mediated gene transfer for MPS VII."
GUSB,"GUSB activity in mouse liver is significantly reduced at 16 weeks after AAV-mediated gene transfer, indicating a reduction in lysosomal storage.","Entity: GUSB. GUSB activity in mouse liver is significantly reduced at 16 weeks after AAV-mediated gene transfer, indicating a reduction in lysosomal storage."
GUSB,"GUSB expression in mouse quadriceps, liver, and spleen persists for at least 16 weeks after AAV-mediated gene transfer in neonatal MPS VII mice.","Entity: GUSB. GUSB expression in mouse quadriceps, liver, and spleen persists for at least 16 weeks after AAV-mediated gene transfer in neonatal MPS VII mice."
CIITA,"CIITA is a transactivator gene whose expression in C6 gliomas, induced by EBV-based transduction, leads to induction of MHC I and MHC II, mimicking therapeutic immune responses.","Entity: CIITA. CIITA is a transactivator gene whose expression in C6 gliomas, induced by EBV-based transduction, leads to induction of MHC I and MHC II, mimicking therapeutic immune responses."
Rev,"Rev protein induces expression of genes placed under its control, as demonstrated by >300-fold increased interferon production in HeLa cells expressing an interferon alpha2 gene under Tat and Rev control.","Entity: Rev. Rev protein induces expression of genes placed under its control, as demonstrated by >300-fold increased interferon production in HeLa cells expressing an interferon alpha2 gene under Tat and Rev control."
interferon alpha2,"Interferon alpha2 production can be induced by both Tat and Rev proteins in HeLa cells, serving as a reporter for Tat and Rev activity.","Entity: interferon alpha2. Interferon alpha2 production can be induced by both Tat and Rev proteins in HeLa cells, serving as a reporter for Tat and Rev activity."
CD8,"CD8+ T cells can express the CC49-zeta chimeric immune receptor, enabling them to bind TAG-72, produce cytokines, and kill tumor cells expressing this antigen.","Entity: CD8. CD8+ T cells can express the CC49-zeta chimeric immune receptor, enabling them to bind TAG-72, produce cytokines, and kill tumor cells expressing this antigen."
Mac-1alpha,Administration of antibodies against Mac-1alpha reduces neutrophil influx and diminishes proinflammatory cytokine levels in bronchoalveolar lavage fluid (BALF) after cationic lipid-mediated gene transfer with unmethylated plasmid DNA.,Entity: Mac-1alpha. Administration of antibodies against Mac-1alpha reduces neutrophil influx and diminishes proinflammatory cytokine levels in bronchoalveolar lavage fluid (BALF) after cationic lipid-mediated gene transfer with unmethylated plasmid DNA.
methotrexate,"Methotrexate can be delivered specifically to tumor cells via a gene-dependent enzyme/prodrug therapy (GDEPT) strategy involving mutant carboxypeptidase A1 (CPA) that cleaves its propeptide, enabling receptor-mediated internalization and inhibition of dihydrofolate reductase.","Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. Methotrexate can be delivered specifically to tumor cells via a gene-dependent enzyme/prodrug therapy (GDEPT) strategy involving mutant carboxypeptidase A1 (CPA) that cleaves its propeptide, enabling receptor-mediated internalization and inhibition of dihydrofolate reductase."
methotrexate,"The endogenously activated mutant carboxypeptidase A1 (CPA95) can effectively sensitize squamous cell carcinoma cells to methotrexate-Phe, reducing the IC50 of methotrexate-Phe by 25-fold compared to parental lines.","Entity: methotrexate. SMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1. The endogenously activated mutant carboxypeptidase A1 (CPA95) can effectively sensitize squamous cell carcinoma cells to methotrexate-Phe, reducing the IC50 of methotrexate-Phe by 25-fold compared to parental lines."
beta-galactosidase,"Beta-galactosidase gene expression in hepatocytes of regenerating rat liver can be achieved in vivo by retroviral vector delivery via bile duct perfusion, with transduction rates ranging from 31.4% to 58.7% of hepatocytes 7 days after partial hepatectomy, depending on hepatic artery blood flow during perfusion.","Entity: beta-galactosidase. Beta-galactosidase gene expression in hepatocytes of regenerating rat liver can be achieved in vivo by retroviral vector delivery via bile duct perfusion, with transduction rates ranging from 31.4% to 58.7% of hepatocytes 7 days after partial hepatectomy, depending on hepatic artery blood flow during perfusion."
Rag1,"Rag1-deficient mice infused with adenovirus-transduced hepatocytes are susceptible to elimination of transgene expression by intrahepatic lymphocytes, highlighting the importance of Rag1 for this immune response.","Entity: Rag1. Rag1-deficient mice infused with adenovirus-transduced hepatocytes are susceptible to elimination of transgene expression by intrahepatic lymphocytes, highlighting the importance of Rag1 for this immune response."
FasL,"Fas ligand is essential for the cytolytic activity of intrahepatic lymphocytes against adenovirus-transduced hepatocytes, as shown by the failure of FasL-deficient mice to eliminate transgene expression in Rag1-deficient recipients.","Entity: FasL. Fas ligand is essential for the cytolytic activity of intrahepatic lymphocytes against adenovirus-transduced hepatocytes, as shown by the failure of FasL-deficient mice to eliminate transgene expression in Rag1-deficient recipients."
doxycycline,Doxycycline is a potent analog of tetracycline that efficiently regulates transgene expression in human adult astrocytes under a tetracycline-based regulatory system (tet-off).,Entity: doxycycline. SMILES: C[C@H]1c2cccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21. Doxycycline is a potent analog of tetracycline that efficiently regulates transgene expression in human adult astrocytes under a tetracycline-based regulatory system (tet-off).
L-dopa,Human adult astrocytes transduced with an adenoviral vector encoding human tyrosine hydroxylase (hTH) under a tet-off system efficiently synthesize and release L-dopa.,Entity: L-dopa. SMILES: N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O. Human adult astrocytes transduced with an adenoviral vector encoding human tyrosine hydroxylase (hTH) under a tet-off system efficiently synthesize and release L-dopa.
Atrial natriuretic factor,"Atrial natriuretic factor is a potent natriuretic, diuretic, and vasoactive hormone produced and released by atrial cardiomyocytes.","Entity: Atrial natriuretic factor. Atrial natriuretic factor is a potent natriuretic, diuretic, and vasoactive hormone produced and released by atrial cardiomyocytes."
mitozolomide,"Mitozolomide is a chloroethylating agent that induces cytotoxicity in human cervical carcinoma (HeLa) and erythroleukemic (K562) cells, and resistance to its toxic effects can be conferred by rAAV-mediated expression of human O6-alkylguanine-DNA-alkyltransferase (hAT) at levels 800- to 1500-fold higher than background.","Entity: mitozolomide. SMILES: NC(=O)c1ncn2c(=O)n(CCCl)nnc12. Mitozolomide is a chloroethylating agent that induces cytotoxicity in human cervical carcinoma (HeLa) and erythroleukemic (K562) cells, and resistance to its toxic effects can be conferred by rAAV-mediated expression of human O6-alkylguanine-DNA-alkyltransferase (hAT) at levels 800- to 1500-fold higher than background."
beta-galactosidase,Beta-galactosidase is a marker gene product used to assess transgene expression in intracerebrovascularly injected adenovirus and lipoDNA vectors in brain tumors.,Entity: beta-galactosidase. Beta-galactosidase is a marker gene product used to assess transgene expression in intracerebrovascularly injected adenovirus and lipoDNA vectors in brain tumors.
nifedipine,Nifedipine does not affect the maintenance of repetitive discharge in postnatal retinal ganglion neurons.,Entity: nifedipine. SMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]. Nifedipine does not affect the maintenance of repetitive discharge in postnatal retinal ganglion neurons.
tetrodotoxin,"Tetrodotoxin-sensitive Na+ currents in retinal ganglion neurons show changes in density and activation kinetics that parallel changes in firing thresholds and action potential size, but are not directly related to the maintenance of repetitive firing.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin-sensitive Na+ currents in retinal ganglion neurons show changes in density and activation kinetics that parallel changes in firing thresholds and action potential size, but are not directly related to the maintenance of repetitive firing."
alpha2A,"Increased alpha2A mRNA and protein expression in the neocortex occurs in the cortical plate and intermediate and subventricular zones, corresponding to tiers of migrating and differentiating neurons.","Entity: alpha2A. Increased alpha2A mRNA and protein expression in the neocortex occurs in the cortical plate and intermediate and subventricular zones, corresponding to tiers of migrating and differentiating neurons."
alpha2A,"The expression of alpha2A mRNA and protein in the neocortex changes markedly during the first week of postnatal development, resulting in a more mature pattern of anatomical distribution.","Entity: alpha2A. The expression of alpha2A mRNA and protein in the neocortex changes markedly during the first week of postnatal development, resulting in a more mature pattern of anatomical distribution."
alpha2A,"Alpha2A mRNA expression in the neocortex is strongly increased by embryonic day 19 and 20, and protein expression by embryonic day 20.","Entity: alpha2A. Alpha2A mRNA expression in the neocortex is strongly increased by embryonic day 19 and 20, and protein expression by embryonic day 20."
aromatase,Aromatization of androgens to estrogens is necessary for the development of masculine SNB dendritic morphology in the rat lumbar spinal cord.,Entity: aromatase. Aromatization of androgens to estrogens is necessary for the development of masculine SNB dendritic morphology in the rat lumbar spinal cord.
transforming growth factor-alpha,"Transforming growth factor-alpha can induce replacement of neonatal mammalian auditory hair cells in culture after aminoglycoside treatment, acting through EGFR signaling.","Entity: transforming growth factor-alpha. Transforming growth factor-alpha can induce replacement of neonatal mammalian auditory hair cells in culture after aminoglycoside treatment, acting through EGFR signaling."
EGF,"EGF can induce replacement of neonatal mammalian auditory hair cells in culture after aminoglycoside treatment, acting through EGFR signaling.","Entity: EGF. EGF can induce replacement of neonatal mammalian auditory hair cells in culture after aminoglycoside treatment, acting through EGFR signaling."
Epidermal growth factor receptor,"Epidermal growth factor receptor (EGFR) is predominantly localized in the stereociliary bundles of hair cells, supporting cells, and the apical junctions between Kolliker organ cells in the organ of Corti.","Entity: Epidermal growth factor receptor. Epidermal growth factor receptor (EGFR) is predominantly localized in the stereociliary bundles of hair cells, supporting cells, and the apical junctions between Kolliker organ cells in the organ of Corti."
Epidermal growth factor receptor,"In the organ of Corti, epidermal growth factor receptor (EGFR) levels are doubled after neomycin-induced damage, indicating up-regulation following neomycin treatment.","Entity: Epidermal growth factor receptor. In the organ of Corti, epidermal growth factor receptor (EGFR) levels are doubled after neomycin-induced damage, indicating up-regulation following neomycin treatment."
N-methyl-D-aspartate (NMDA) receptor,Blocking N-methyl-D-aspartate (NMDA) receptor activity in postsynaptic neurons leads to decreased rates of branch tip additions and retractions in optic tectal neurons and increased rates of branch additions in retinal axons over 2 hours in vivo.,Entity: N-methyl-D-aspartate (NMDA) receptor. Blocking N-methyl-D-aspartate (NMDA) receptor activity in postsynaptic neurons leads to decreased rates of branch tip additions and retractions in optic tectal neurons and increased rates of branch additions in retinal axons over 2 hours in vivo.
N-methyl-D-aspartate (NMDA) receptor,N-methyl-D-aspartate (NMDA) receptor activity stabilizes the morphology of both presynaptic retinal axons and postsynaptic optic tectal neuronal dendrites in vivo.,Entity: N-methyl-D-aspartate (NMDA) receptor. N-methyl-D-aspartate (NMDA) receptor activity stabilizes the morphology of both presynaptic retinal axons and postsynaptic optic tectal neuronal dendrites in vivo.
thrombin receptor-activating peptide,"A thrombin receptor-activating peptide (TRAP, SFLLRNPNDKYEPF) produces a decrement of neuromuscular synapse strength in mouse spinal cord and muscle cells.","Entity: thrombin receptor-activating peptide. A thrombin receptor-activating peptide (TRAP, SFLLRNPNDKYEPF) produces a decrement of neuromuscular synapse strength in mouse spinal cord and muscle cells."
brain-derived neurotrophic factor,Brain-derived neurotrophic factor (BDNF) acts as a neurotrophic factor that protects adult rat retinal ganglion cells (RGCs) from degeneration.,Entity: brain-derived neurotrophic factor. Brain-derived neurotrophic factor (BDNF) acts as a neurotrophic factor that protects adult rat retinal ganglion cells (RGCs) from degeneration.
glial cell line-derived neurotrophic factor,Glial cell line-derived neurotrophic factor (GDNF) is a neurotrophic factor known for supporting dopaminergic and motor neurons and can provide neurotrophic support to adult rat retinal ganglion cells (RGCs).,Entity: glial cell line-derived neurotrophic factor. Glial cell line-derived neurotrophic factor (GDNF) is a neurotrophic factor known for supporting dopaminergic and motor neurons and can provide neurotrophic support to adult rat retinal ganglion cells (RGCs).
Epidermal growth factor,"Epidermal growth factor is used to generate secondary neurospheres from postnatal mouse hippocampal stem cells, which can be grafted into the CNS to support neurite outgrowth.","Entity: Epidermal growth factor. Epidermal growth factor is used to generate secondary neurospheres from postnatal mouse hippocampal stem cells, which can be grafted into the CNS to support neurite outgrowth."
BDNF,"BDNF stimulates extensive outgrowth of vestibular ganglion neurons at embryonic day 8-12 in chick embryos, but its neurotrophic effect declines and becomes undetectable by E16.","Entity: BDNF. BDNF stimulates extensive outgrowth of vestibular ganglion neurons at embryonic day 8-12 in chick embryos, but its neurotrophic effect declines and becomes undetectable by E16."
glial cell line-derived neurotrophic factor,"Glial cell line-derived neurotrophic factor (GDNF) promotes neurite outgrowth from vestibular ganglia in chick embryos at E12-16, with its timing correlating with the completion of synaptogenesis on target neurons.","Entity: glial cell line-derived neurotrophic factor. Glial cell line-derived neurotrophic factor (GDNF) promotes neurite outgrowth from vestibular ganglia in chick embryos at E12-16, with its timing correlating with the completion of synaptogenesis on target neurons."
NT-3,"Neurotrophin-3 (NT-3) has strong neurotrophic effects on embryonic day 12 cochlear ganglion neurons in chick embryos, but its effect is weaker than BDNF on vestibular ganglion neurons at the same stage.","Entity: NT-3. Neurotrophin-3 (NT-3) has strong neurotrophic effects on embryonic day 12 cochlear ganglion neurons in chick embryos, but its effect is weaker than BDNF on vestibular ganglion neurons at the same stage."
neurotrophin-3,"Neurotrophin-3 (NT-3) is a neurotrophin that supports the development of vestibular and cochlear ganglion neurons in the inner ear, with stronger neurotrophic effects on cochlear ganglion neurons than BDNF in chick embryos.","Entity: neurotrophin-3. Neurotrophin-3 (NT-3) is a neurotrophin that supports the development of vestibular and cochlear ganglion neurons in the inner ear, with stronger neurotrophic effects on cochlear ganglion neurons than BDNF in chick embryos."
beta-glucuronidase,"Recombinant beta-glucuronidase administration from birth significantly reduces glycosaminoglycan storage in most tissues, increases life span, and improves cognitive ability and mobility in mice with mucopolysaccharidosis type VII (MPS VII).","Entity: beta-glucuronidase. Recombinant beta-glucuronidase administration from birth significantly reduces glycosaminoglycan storage in most tissues, increases life span, and improves cognitive ability and mobility in mice with mucopolysaccharidosis type VII (MPS VII)."
"1,25-dihydroxyvitamin D3","Maternal administration of 1,25-dihydroxyvitamin D3 (15 ng/100 g) during week 3 of pregnancy restores duodenal calbindin-D9K concentrations to normal in spontaneously diabetic rats.","Entity: 1,25-dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. Maternal administration of 1,25-dihydroxyvitamin D3 (15 ng/100 g) during week 3 of pregnancy restores duodenal calbindin-D9K concentrations to normal in spontaneously diabetic rats."
calbindin-D9K,"Calbindin-D9K is present at lower concentrations in the placenta of diabetic rats compared to nondiabetic rats, and its restoration to normal levels in diabetic rat fetuses by maternal 1,25-dihydroxyvitamin D3 treatment does not restore mineralization.","Entity: calbindin-D9K. Calbindin-D9K is present at lower concentrations in the placenta of diabetic rats compared to nondiabetic rats, and its restoration to normal levels in diabetic rat fetuses by maternal 1,25-dihydroxyvitamin D3 treatment does not restore mineralization."
calbindin-D9K,"In diabetic rat placentas, calbindin-D9K shows weak but homogeneous staining in the labyrinth, while placentas of rats fed high Sr diets exhibit degenerative zones.","Entity: calbindin-D9K. In diabetic rat placentas, calbindin-D9K shows weak but homogeneous staining in the labyrinth, while placentas of rats fed high Sr diets exhibit degenerative zones."
osteocalcin,"Fetuses of diabetic rats have lower plasma osteocalcin levels compared to nondiabetic rats, indicating retarded bone maturation.","Entity: osteocalcin. Fetuses of diabetic rats have lower plasma osteocalcin levels compared to nondiabetic rats, indicating retarded bone maturation."
G-CSF,Dexamethasone (DEX) does not significantly augment G-CSF production induced by Candida albicans in neonatal mononuclear cells.,Entity: G-CSF. Dexamethasone (DEX) does not significantly augment G-CSF production induced by Candida albicans in neonatal mononuclear cells.
G-CSF,Neonatal mononuclear cells from infants with acute physiology scores of ≥10 produce significantly less G-CSF in response to PMA/PHA stimulation compared to those with lower scores.,Entity: G-CSF. Neonatal mononuclear cells from infants with acute physiology scores of ≥10 produce significantly less G-CSF in response to PMA/PHA stimulation compared to those with lower scores.
G-CSF,G-CSF production by neonatal mononuclear cells is significantly increased by PMA/PHA stimulation and is markedly augmented by dexamethasone (DEX) treatment.,Entity: G-CSF. G-CSF production by neonatal mononuclear cells is significantly increased by PMA/PHA stimulation and is markedly augmented by dexamethasone (DEX) treatment.
nitric oxide,Nitric oxide is a specific pulmonary vasodilator.,Entity: nitric oxide. SMILES: [N]=O. Nitric oxide is a specific pulmonary vasodilator.
nitric oxide,"Nitric oxide can act as a pro-oxidant or antioxidant, influencing other pulmonary functions in addition to vasodilation.","Entity: nitric oxide. SMILES: [N]=O. Nitric oxide can act as a pro-oxidant or antioxidant, influencing other pulmonary functions in addition to vasodilation."
nitric oxide,"In premature rabbits, exposure to low-dose inhaled nitric oxide (14 ppm for 20 h) prevented or partially reversed the decrease in surfactant surface activity and content of surfactant protein B caused by acute hyperoxia in bronchoalveolar lavage fluid.","Entity: nitric oxide. SMILES: [N]=O. In premature rabbits, exposure to low-dose inhaled nitric oxide (14 ppm for 20 h) prevented or partially reversed the decrease in surfactant surface activity and content of surfactant protein B caused by acute hyperoxia in bronchoalveolar lavage fluid."
nitric oxide,Inhaled nitric oxide decreased malondialdehyde levels and tended to increase glutathione in the epithelial lining fluid of premature rabbits exposed to hyperoxia.,Entity: nitric oxide. SMILES: [N]=O. Inhaled nitric oxide decreased malondialdehyde levels and tended to increase glutathione in the epithelial lining fluid of premature rabbits exposed to hyperoxia.
Nitrotyrosine,Nitrotyrosine was not detectable in bronchoalveolar lavage fluid after exposure to nitric oxide in premature rabbits.,Entity: Nitrotyrosine. SMILES: O=C(O)[C@H](Cc1ccc(O)cc1)N[N+](=O)[O-]. Nitrotyrosine was not detectable in bronchoalveolar lavage fluid after exposure to nitric oxide in premature rabbits.
malondialdehyde,"Malondialdehyde content in epithelial lining fluid increases after hyperoxia in premature rabbits, but is decreased by low-dose inhaled nitric oxide.","Entity: malondialdehyde. SMILES: O=CCC=O. Malondialdehyde content in epithelial lining fluid increases after hyperoxia in premature rabbits, but is decreased by low-dose inhaled nitric oxide."
surfactant protein B,Exposure to hyperoxia decreases the content of surfactant protein B in bronchoalveolar lavage fluid in premature rabbits.,Entity: surfactant protein B. Exposure to hyperoxia decreases the content of surfactant protein B in bronchoalveolar lavage fluid in premature rabbits.
ristocetin,Washed platelets from neonatal or adult sources show a higher response in conventional aggregometry assays when ristocetin is added to plasma from neonates compared to adults.,Entity: ristocetin. SMILES: COC(=O)[C@H]1NC(=O)[C@H]2NC(=O)[C@H](NC(=O)[C@@H]3NC(=O)[C@H]4NC(=O)[C@H](NC(=O)[C@H](N)c5ccc(O)c(c5)Oc5cc4cc(O)c5C)[C@H](O)c4ccc(cc4)Oc4cc3cc(c4O[C@@H]3O[C@H](COC4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](CO)[C@H](O)[C@@H](O)[C@H]3O[C@@H]3OC[C@@H](O)[C@@H](O)[C@@H]3O)Oc3ccc(cc3)[C@H]2O[C@@H]2C[C@@H](N)[C@@H](O)[C@H](C)O2)c2ccc(O)c(c2)-c2c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)cc(O)cc21. Washed platelets from neonatal or adult sources show a higher response in conventional aggregometry assays when ristocetin is added to plasma from neonates compared to adults.
von Willebrand factor,"Neonatal plasma contains more multimerized and active von Willebrand factor, which mediates extensive platelet deposition on ECM and contributes to primary hemostasis in neonates.","Entity: von Willebrand factor. Neonatal plasma contains more multimerized and active von Willebrand factor, which mediates extensive platelet deposition on ECM and contributes to primary hemostasis in neonates."
indomethacin,Indomethacin is a cyclooxygenase inhibitor that only slightly attenuates adrenomedullin-induced increases in fetal pulmonary blood flow in sheep.,Entity: indomethacin. SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1. Indomethacin is a cyclooxygenase inhibitor that only slightly attenuates adrenomedullin-induced increases in fetal pulmonary blood flow in sheep.
nitric oxide,Nitric oxide release is a key mediator of adrenomedullin-induced increases in fetal pulmonary blood flow in sheep.,Entity: nitric oxide. SMILES: [N]=O. Nitric oxide release is a key mediator of adrenomedullin-induced increases in fetal pulmonary blood flow in sheep.
N(omega)-nitro-L-arginine,N(omega)-nitro-L-arginine is a nitric oxide synthase inhibitor that completely inhibits adrenomedullin-induced increases in fetal pulmonary blood flow in sheep.,Entity: N(omega)-nitro-L-arginine. SMILES: N=C(NCCC[C@H](N)C(=O)O)N[N+](=O)[O-]. N(omega)-nitro-L-arginine is a nitric oxide synthase inhibitor that completely inhibits adrenomedullin-induced increases in fetal pulmonary blood flow in sheep.
adrenomedullin,"Adrenomedullin induces an increase in fetal pulmonary blood flow, with the response dependent largely on nitric oxide release and partly on ATP-dependent potassium (K(ATP)) channel activation, and does not involve calcitonin gene-related peptide (CGRP) receptor or cyclooxygenase-mediated mechanisms in the fetal pulmonary circulation.","Entity: adrenomedullin. Adrenomedullin induces an increase in fetal pulmonary blood flow, with the response dependent largely on nitric oxide release and partly on ATP-dependent potassium (K(ATP)) channel activation, and does not involve calcitonin gene-related peptide (CGRP) receptor or cyclooxygenase-mediated mechanisms in the fetal pulmonary circulation."
Adrenomedullin,"Immunohistochemical analysis shows that adrenomedullin is present and distributed in fetal lung tissues throughout gestation, with predominant localization in epithelial cells of bronchi and also staining endothelial cells.","Entity: Adrenomedullin. Immunohistochemical analysis shows that adrenomedullin is present and distributed in fetal lung tissues throughout gestation, with predominant localization in epithelial cells of bronchi and also staining endothelial cells."
Adrenomedullin,Immunohistochemical expression of adrenomedullin in the late organogenetic period and its increasing staining during fetal lung development suggest a role in fetal lung differentiation and/or maturation.,Entity: Adrenomedullin. Immunohistochemical expression of adrenomedullin in the late organogenetic period and its increasing staining during fetal lung development suggest a role in fetal lung differentiation and/or maturation.
Adrenomedullin,Adrenomedullin is a potent hypotensive peptide that increases pulmonary blood flow in fetal sheep.,Entity: Adrenomedullin. Adrenomedullin is a potent hypotensive peptide that increases pulmonary blood flow in fetal sheep.
Adrenomedullin,"The intensity and percentage of positive bronchial epithelial cells for adrenomedullin increase as gestation progresses, but staining is absent in tissues collected after breathing and in adult lung controls.","Entity: Adrenomedullin. The intensity and percentage of positive bronchial epithelial cells for adrenomedullin increase as gestation progresses, but staining is absent in tissues collected after breathing and in adult lung controls."
raf,Activation of the raf/MEK/MAPK pathway can induce growth inhibitory pathways and suppress growth in human prostate cancer cells.,Entity: raf. Activation of the raf/MEK/MAPK pathway can induce growth inhibitory pathways and suppress growth in human prostate cancer cells.
FGF-2,"Human antisense FGF-2 mRNA is synthesized in Jurkat T cells, with two cDNAs corresponding to 1069- and 1173-nucleotide antisense FGF-2 mRNAs cloned from these cells.","Entity: FGF-2. Human antisense FGF-2 mRNA is synthesized in Jurkat T cells, with two cDNAs corresponding to 1069- and 1173-nucleotide antisense FGF-2 mRNAs cloned from these cells."
FGF-2,"The human antisense FGF-2 gene is regulated by a 2.5-kilobase promoter region, and Ets-like transcription factors are significant in its regulation in Jurkat cells.","Entity: FGF-2. The human antisense FGF-2 gene is regulated by a 2.5-kilobase promoter region, and Ets-like transcription factors are significant in its regulation in Jurkat cells."
secretin,"Secretin is a ligand that stimulates the human secretin receptor, leading to increases in intracellular cAMP accumulation and extracellular acidification in CHO cells.","Entity: secretin. Secretin is a ligand that stimulates the human secretin receptor, leading to increases in intracellular cAMP accumulation and extracellular acidification in CHO cells."
secretin,"The human secretin receptor exhibits low EC50 values for both intracellular cAMP accumulation (0.2–0.5 nM) and extracellular acidification (0.1 nM) upon stimulation with secretin, indicating high sensitivity.","Entity: secretin. The human secretin receptor exhibits low EC50 values for both intracellular cAMP accumulation (0.2–0.5 nM) and extracellular acidification (0.1 nM) upon stimulation with secretin, indicating high sensitivity."
Raf,Raf is a component of the cellular signal transduction machinery that regulates bone growth by controlling the activity of downstream kinases such as MEK1/2 and ERK1/2.,Entity: Raf. Raf is a component of the cellular signal transduction machinery that regulates bone growth by controlling the activity of downstream kinases such as MEK1/2 and ERK1/2.
CD45,"CD45 is an epitope expressed on pre-B-cell progenitors, granulocytic and monocytic precursors, and macrophages, which are components of the bone marrow hematopoietic cell population.","Entity: CD45. CD45 is an epitope expressed on pre-B-cell progenitors, granulocytic and monocytic precursors, and macrophages, which are components of the bone marrow hematopoietic cell population."
CD11b,"CD11b is an epitope expressed on pre-B-cell progenitors, granulocytic and monocytic precursors, and macrophages, which are components of the bone marrow hematopoietic cell population.","Entity: CD11b. CD11b is an epitope expressed on pre-B-cell progenitors, granulocytic and monocytic precursors, and macrophages, which are components of the bone marrow hematopoietic cell population."
DNase I,DNase I hypersensitive sites are normally present in bone-derived cells expressing the osteocalcin gene and are associated with basal tissue-specific expression and steroid hormone regulation.,Entity: DNase I. DNase I hypersensitive sites are normally present in bone-derived cells expressing the osteocalcin gene and are associated with basal tissue-specific expression and steroid hormone regulation.
osteocalcin,Osteocalcin is a gene whose transcriptional activity and chromatin structure remodeling in bone-derived cells require phosphorylation-dephosphorylation events distinct from protein kinase C-dependent reactions.,Entity: osteocalcin. Osteocalcin is a gene whose transcriptional activity and chromatin structure remodeling in bone-derived cells require phosphorylation-dephosphorylation events distinct from protein kinase C-dependent reactions.
penicillamine,Penicillamine treatment in Wilson's disease patients increases metallothionein concentrations in the duodenal mucosa by 150% compared to untreated patients and controls.,Entity: penicillamine. SMILES: CC(C)(S)[C@H](N)C(=O)O. Penicillamine treatment in Wilson's disease patients increases metallothionein concentrations in the duodenal mucosa by 150% compared to untreated patients and controls.
iron,Mucosal iron concentration increases in the duodenal mucosa of Wilson's disease patients regardless of treatment with zinc or penicillamine.,Entity: iron. SMILES: [Fe]. Mucosal iron concentration increases in the duodenal mucosa of Wilson's disease patients regardless of treatment with zinc or penicillamine.
zinc sulphate,Zinc sulphate administration in Wilson's disease patients increases metallothionein concentrations in the duodenal mucosa by 1500% compared to untreated patients and controls.,Entity: zinc sulphate. SMILES: O=S(=O)([O-])[O-].[Zn+2]. Zinc sulphate administration in Wilson's disease patients increases metallothionein concentrations in the duodenal mucosa by 1500% compared to untreated patients and controls.
erythromycin,"Erythromycin, administered intravenously, induces phase 3 in the stomach and doubles the gastrointestinal sound index in healthy humans.","Entity: erythromycin. SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O. Erythromycin, administered intravenously, induces phase 3 in the stomach and doubles the gastrointestinal sound index in healthy humans."
Scopolamine,Scopolamine delays small intestinal transit time and decreases the gastrointestinal sound index in healthy humans.,Entity: Scopolamine. SMILES: CN1[C@@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@H]12. Scopolamine delays small intestinal transit time and decreases the gastrointestinal sound index in healthy humans.
Somatostatin,"Somatostatin analogue induces phase-3-like clustered contractions in the duodenum and inhibits antral contractions, leading to decreased gastrointestinal sound index in healthy humans.","Entity: Somatostatin. Somatostatin analogue induces phase-3-like clustered contractions in the duodenum and inhibits antral contractions, leading to decreased gastrointestinal sound index in healthy humans."
Prostaglandins,Prostaglandins regulate gastric motor function.,Entity: Prostaglandins. SMILES: CCCCCC(/C=C/C1C=CC(=O)C1C/C=C/CCCC(=O)OC)OC(C)=O. Prostaglandins regulate gastric motor function.
clupanodonic acid,Patients with Crohn's disease have significantly higher levels of clupanodonic acid (22:5n-3) in plasma phospholipids and adipose tissue compared to healthy controls.,Entity: clupanodonic acid. SMILES: CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O. Patients with Crohn's disease have significantly higher levels of clupanodonic acid (22:5n-3) in plasma phospholipids and adipose tissue compared to healthy controls.
arachidonic acid,Patients with Crohn's disease have significantly lower levels of arachidonic acid (20:4n-6) in plasma phospholipids and adipose tissue compared to healthy controls.,Entity: arachidonic acid. SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O. Patients with Crohn's disease have significantly lower levels of arachidonic acid (20:4n-6) in plasma phospholipids and adipose tissue compared to healthy controls.
docosahexaenoic,Patients with Crohn's disease have significantly lower levels of docosahexaenoic (22:6n-3) in plasma phospholipids and adipose tissue compared to healthy controls.,Entity: docosahexaenoic. SMILES: CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)O. Patients with Crohn's disease have significantly lower levels of docosahexaenoic (22:6n-3) in plasma phospholipids and adipose tissue compared to healthy controls.
linoleic acid,The percentage of linoleic acid in plasma phospholipids and adipose tissue is not significantly different between patients with Crohn's disease and healthy controls.,Entity: linoleic acid. SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)O. The percentage of linoleic acid in plasma phospholipids and adipose tissue is not significantly different between patients with Crohn's disease and healthy controls.
alpha-linolenic acid,The percentage of alpha-linolenic acid in plasma phospholipids and adipose tissue is not significantly different between patients with Crohn's disease and healthy controls.,Entity: alpha-linolenic acid. SMILES: CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O. The percentage of alpha-linolenic acid in plasma phospholipids and adipose tissue is not significantly different between patients with Crohn's disease and healthy controls.
6-mercaptopurine,6-mercaptopurine is used as a treatment for inflammatory bowel disease (IBD) and increases the frequency of shingles (herpes zoster) in treated patients compared to those not treated with 6-mercaptopurine.,Entity: 6-mercaptopurine. SMILES: Sc1ncnc2nc[nH]c12. 6-mercaptopurine is used as a treatment for inflammatory bowel disease (IBD) and increases the frequency of shingles (herpes zoster) in treated patients compared to those not treated with 6-mercaptopurine.
6-mercaptopurine,"The course of shingles in patients with IBD treated with 6-mercaptopurine is usually benign, with no reported mortality, but severe cases such as herpes zoster ophthalmicus and encephalitis can occur.","Entity: 6-mercaptopurine. SMILES: Sc1ncnc2nc[nH]c12. The course of shingles in patients with IBD treated with 6-mercaptopurine is usually benign, with no reported mortality, but severe cases such as herpes zoster ophthalmicus and encephalitis can occur."
6-mercaptopurine,"6-mercaptopurine should be temporarily stopped during the acute phase of shingles in IBD patients until the severity is established, but can be restarted if the underlying IBD disease warrants continued treatment.","Entity: 6-mercaptopurine. SMILES: Sc1ncnc2nc[nH]c12. 6-mercaptopurine should be temporarily stopped during the acute phase of shingles in IBD patients until the severity is established, but can be restarted if the underlying IBD disease warrants continued treatment."
Acyclovir,"Acyclovir is the treatment of choice for shingles (herpes zoster), although it was only used in three of the twelve cases reported in the study.","Entity: Acyclovir. SMILES: Nc1nc2c(ncn2COCCO)c(=O)[nH]1. Acyclovir is the treatment of choice for shingles (herpes zoster), although it was only used in three of the twelve cases reported in the study."
steroids,"Steroids can immunocompromise young people, making varicella (chickenpox) and herpes zoster (shingles) more severe.","Entity: steroids. SMILES: CC(=O)N(C)[C@H](C)[C@@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](N(C)C)CC[C@@]4(C)[C@@H]3CC[C@]21C. Steroids can immunocompromise young people, making varicella (chickenpox) and herpes zoster (shingles) more severe."
azathioprine,The influence of azathioprine on the severity of shingles in patients with inflammatory bowel disease is not discussed in the paragraph.,Entity: azathioprine. SMILES: Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12. The influence of azathioprine on the severity of shingles in patients with inflammatory bowel disease is not discussed in the paragraph.
doxycycline,"Doxycycline can induce gastric injury, as evidenced by a case report of doxycycline-induced gastric ulcer.","Entity: doxycycline. SMILES: C[C@H]1c2cccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21. Doxycycline can induce gastric injury, as evidenced by a case report of doxycycline-induced gastric ulcer."
potassium chloride,"Ingestion of potassium chloride pills can cause gastric ulceration, as shown by a case where multiple pills were found in the crater of a large gastric ulcer.","Entity: potassium chloride. SMILES: [Cl-].[K+]. Ingestion of potassium chloride pills can cause gastric ulceration, as shown by a case where multiple pills were found in the crater of a large gastric ulcer."
Polypropylene,Polypropylene is used as a mesh prosthesis for inguinal hernioplasty during simultaneous repair with radical retropubic prostatectomy.,Entity: Polypropylene. SMILES: CC(C[*:1])[*:2]. Polypropylene is used as a mesh prosthesis for inguinal hernioplasty during simultaneous repair with radical retropubic prostatectomy.
soluble malate dehydrogenase,The increase in soluble malate dehydrogenase activity following trinactin-induced heat sensitive puff induction in Drosophila melanogaster larval salivary gland homogenates is associated with de novo synthesis.,Entity: soluble malate dehydrogenase. The increase in soluble malate dehydrogenase activity following trinactin-induced heat sensitive puff induction in Drosophila melanogaster larval salivary gland homogenates is associated with de novo synthesis.
lactate dehydrogenase,The increase in lactate dehydrogenase activity following trinactin-induced heat sensitive puff induction in Drosophila melanogaster larval salivary gland homogenates is associated with de novo synthesis.,Entity: lactate dehydrogenase. The increase in lactate dehydrogenase activity following trinactin-induced heat sensitive puff induction in Drosophila melanogaster larval salivary gland homogenates is associated with de novo synthesis.
pyruvate kinase,Pyruvate kinase activity in larval Drosophila melanogaster salivary gland homogenates does not change after induction of heat sensitive puffs with trinactin.,Entity: pyruvate kinase. Pyruvate kinase activity in larval Drosophila melanogaster salivary gland homogenates does not change after induction of heat sensitive puffs with trinactin.
lactate dehydrogenase,"The activity of lactate dehydrogenase in larval Drosophila melanogaster salivary gland homogenates is enhanced after induction of heat sensitive puffs with trinactin, and this effect is abolished by cycloheximide.","Entity: lactate dehydrogenase. The activity of lactate dehydrogenase in larval Drosophila melanogaster salivary gland homogenates is enhanced after induction of heat sensitive puffs with trinactin, and this effect is abolished by cycloheximide."
soluble malate dehydrogenase,"The activity of soluble malate dehydrogenase in larval Drosophila melanogaster salivary gland homogenates is increased after induction of heat sensitive puffs with trinactin, and this effect is abolished by cycloheximide.","Entity: soluble malate dehydrogenase. The activity of soluble malate dehydrogenase in larval Drosophila melanogaster salivary gland homogenates is increased after induction of heat sensitive puffs with trinactin, and this effect is abolished by cycloheximide."
ADPbetaS,"ADPbetaS is a potent P2y purinoceptor agonist that induces dose-dependent relaxation in human precontracted corporal cavernosal strips, with maximal relaxation of 45.5 ± 5.0% and an EC50 of 11.7 µM in the presence of a functional endothelium.","Entity: ADPbetaS. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(O)(O)=S)[C@@H](O)[C@H]1O. ADPbetaS is a potent P2y purinoceptor agonist that induces dose-dependent relaxation in human precontracted corporal cavernosal strips, with maximal relaxation of 45.5 ± 5.0% and an EC50 of 11.7 µM in the presence of a functional endothelium."
ADPbetaS,"The relaxant effect of ADPbetaS in human corporal cavernosal strips is reduced by 77.1 ± 7.0% with the P2y antagonist reactive blue 2 (20 µM), indicating its action via P2y purinoceptors.","Entity: ADPbetaS. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(O)(O)=S)[C@@H](O)[C@H]1O. The relaxant effect of ADPbetaS in human corporal cavernosal strips is reduced by 77.1 ± 7.0% with the P2y antagonist reactive blue 2 (20 µM), indicating its action via P2y purinoceptors."
ADPbetaS,"ADPbetaS-induced relaxation in human corporal cavernosal strips is abolished by L-NAME (100 µM), an NO synthase inhibitor, reducing it by 86.83 ± 0.5%.","Entity: ADPbetaS. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(O)(O)=S)[C@@H](O)[C@H]1O. ADPbetaS-induced relaxation in human corporal cavernosal strips is abolished by L-NAME (100 µM), an NO synthase inhibitor, reducing it by 86.83 ± 0.5%."
ADPbetaS,"ADPbetaS-induced relaxation in human corporal cavernosal strips is endothelium-dependent, as it is reduced to 87.1 ± 5% when the endothelial lining is disrupted.","Entity: ADPbetaS. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(O)(O)=S)[C@@H](O)[C@H]1O. ADPbetaS-induced relaxation in human corporal cavernosal strips is endothelium-dependent, as it is reduced to 87.1 ± 5% when the endothelial lining is disrupted."
Acetylcholine,"Acetylcholine induces relaxation in human precontracted corporal cavernosal strips, serving as a control for endothelial function.","Entity: Acetylcholine. SMILES: CC(=O)OCC[N+](C)(C)C. Acetylcholine induces relaxation in human precontracted corporal cavernosal strips, serving as a control for endothelial function."
L-NAME,L-NAME (L-Nitro Arginin Methyl Ester) is a selective NO synthase inhibitor that reduces acetylcholine- and ADPbetaS-induced relaxations by 86.59 ± 3.24% and 86.83 ± 0.5% respectively in human corporal cavernosal strips.,Entity: L-NAME. SMILES: COC(=O)[C@@H](N)CCCN=C(N)N[N+](=O)[O-]. L-NAME (L-Nitro Arginin Methyl Ester) is a selective NO synthase inhibitor that reduces acetylcholine- and ADPbetaS-induced relaxations by 86.59 ± 3.24% and 86.83 ± 0.5% respectively in human corporal cavernosal strips.
reactive blue 2,Reactive blue 2 is a P2y antagonist that reduces the relaxant effect of ADPbetaS by 77.1 ± 7.0% in human corporal cavernosal strips.,Entity: reactive blue 2. SMILES: Nc1c(S(=O)(=O)O)cc(Nc2ccc(Nc3nc(Cl)nc(Nc4cccc(S(=O)(=O)O)c4)n3)c(S(=O)(=O)O)c2)c2c1C(=O)c1ccccc1C2=O. Reactive blue 2 is a P2y antagonist that reduces the relaxant effect of ADPbetaS by 77.1 ± 7.0% in human corporal cavernosal strips.
nitric oxide synthase,"Bacterial endotoxin (lipopolysaccharide) exposure can lead to non-endothelial overproduction of nitric oxide and inhibition of endothelium-derived nitric oxide production in rabbit cavernous smooth muscles, contributing to impaired contraction and relaxation.","Entity: nitric oxide synthase. Bacterial endotoxin (lipopolysaccharide) exposure can lead to non-endothelial overproduction of nitric oxide and inhibition of endothelium-derived nitric oxide production in rabbit cavernous smooth muscles, contributing to impaired contraction and relaxation."
interferon alpha-2b,Interferon alpha-2b is more effective than autoclaved BCG in stimulating IL-6 and TNF-alpha production in J82 human bladder cancer cells.,Entity: interferon alpha-2b. Interferon alpha-2b is more effective than autoclaved BCG in stimulating IL-6 and TNF-alpha production in J82 human bladder cancer cells.
interferon alpha-2b,"Interferon alpha-2b increases IL-1beta, IL-6, IL-8, GM-CSF, and TNF-alpha production in human bladder cancer cell lines.","Entity: interferon alpha-2b. Interferon alpha-2b increases IL-1beta, IL-6, IL-8, GM-CSF, and TNF-alpha production in human bladder cancer cell lines."
interferon alpha-2b,The combination of interferon alpha-2b and BCG has additive effects on cytokine production from human bladder cancer cells.,Entity: interferon alpha-2b. The combination of interferon alpha-2b and BCG has additive effects on cytokine production from human bladder cancer cells.
Erythromycin,"Erythromycin does not affect contractions evoked by bradykinin, phenylephrine, or substance P in rat urinary bladder strips.","Entity: Erythromycin. SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O. Erythromycin does not affect contractions evoked by bradykinin, phenylephrine, or substance P in rat urinary bladder strips."
tetrodotoxin,"Tetrodotoxin, a nerve blocker, does not alter the inhibitory effect of erythromycin on rat urinary bladder smooth muscle contractions.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin, a nerve blocker, does not alter the inhibitory effect of erythromycin on rat urinary bladder smooth muscle contractions."
carbachol,"Carbachol is a muscarinic agonist that induces contractions in rat urinary bladder smooth muscle, which can be reduced by erythromycin in a concentration-dependent manner.","Entity: carbachol. SMILES: C[N+](C)(C)CCOC(N)=O.[Cl-]. Carbachol is a muscarinic agonist that induces contractions in rat urinary bladder smooth muscle, which can be reduced by erythromycin in a concentration-dependent manner."
Erythromycin,"Erythromycin exerts a dual effect on smooth muscle: an excitatory effect via motilin receptors mainly in the stomach and duodenum, and a direct inhibitory effect in the gallbladder, guinea-pig small intestine, and bronchial smooth muscle.","Entity: Erythromycin. SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O. Erythromycin exerts a dual effect on smooth muscle: an excitatory effect via motilin receptors mainly in the stomach and duodenum, and a direct inhibitory effect in the gallbladder, guinea-pig small intestine, and bronchial smooth muscle."
Erythromycin,"In isolated rat urinary bladder strips, erythromycin reduces carbachol-induced contractions in a concentration-dependent manner, by 46% at 5 x 10^4 M and 57% at 10^-3 M.","Entity: Erythromycin. SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O. In isolated rat urinary bladder strips, erythromycin reduces carbachol-induced contractions in a concentration-dependent manner, by 46% at 5 x 10^4 M and 57% at 10^-3 M."
Erythromycin,Erythromycin at 5 x 10^-4 M reduces electric field-stimulated contractions at 0.5 Hz by 15% and at 10^-3 Hz by 23% in rat urinary bladder strips.,Entity: Erythromycin. SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O. Erythromycin at 5 x 10^-4 M reduces electric field-stimulated contractions at 0.5 Hz by 15% and at 10^-3 Hz by 23% in rat urinary bladder strips.
l-arginine,L-arginine is used as a pharmacological agent to induce relaxation in bladder strip stimulation studies.,Entity: l-arginine. SMILES: N=C(N)NCCC[C@H](N)C(=O)O. L-arginine is used as a pharmacological agent to induce relaxation in bladder strip stimulation studies.
carbachol,Carbachol is used as a cholinergic agonist to stimulate bladder contraction in strip stimulation studies.,Entity: carbachol. SMILES: C[N+](C)(C)CCOC(N)=O.[Cl-]. Carbachol is used as a cholinergic agonist to stimulate bladder contraction in strip stimulation studies.
sodium nitroprusside,Sodium nitroprusside is used as a pharmacological agent to induce relaxation in bladder strip stimulation studies.,Entity: sodium nitroprusside. SMILES: N#[O+].O.O.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[Fe+2].[Na+].[Na+]. Sodium nitroprusside is used as a pharmacological agent to induce relaxation in bladder strip stimulation studies.
GSTT1,"GSTT1 is a glutathione S-transferase whose null genotype is a putatively risk genotype for upper aerodigestive tract cancers, but no association was found between GSTT1 genotypes and cancer susceptibility in this study.","Entity: GSTT1. GSTT1 is a glutathione S-transferase whose null genotype is a putatively risk genotype for upper aerodigestive tract cancers, but no association was found between GSTT1 genotypes and cancer susceptibility in this study."
terfenadine,Terfenadine at 20 µM inhibits midazolam 1'-hydroxylation formation by expressed CYP3A4 in vitro.,Entity: terfenadine. SMILES: CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1. Terfenadine at 20 µM inhibits midazolam 1'-hydroxylation formation by expressed CYP3A4 in vitro.
terfenadine,Terfenadine at 20 µM has little effect on midazolam 1'-hydroxylation formation by fetal liver microsomes in vitro.,Entity: terfenadine. SMILES: CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1. Terfenadine at 20 µM has little effect on midazolam 1'-hydroxylation formation by fetal liver microsomes in vitro.
testosterone,Testosterone at 10 and 100 µM regioselectively stimulates midazolam 4-hydroxylation formation by adult liver microsomes and expressed CYP3A4 by up to 269% in vitro.,Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone at 10 and 100 µM regioselectively stimulates midazolam 4-hydroxylation formation by adult liver microsomes and expressed CYP3A4 by up to 269% in vitro.
testosterone,Testosterone at 100 µM inhibits midazolam 1'-hydroxylation and 4-hydroxylation formation by fetal liver microsomes (>40% inhibition) in vitro.,Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. Testosterone at 100 µM inhibits midazolam 1'-hydroxylation and 4-hydroxylation formation by fetal liver microsomes (>40% inhibition) in vitro.
testosterone,"In adult liver microsomes, 100 µM testosterone decreases the Km for midazolam 4-hydroxylation formation by up to 94%.","Entity: testosterone. SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O. In adult liver microsomes, 100 µM testosterone decreases the Km for midazolam 4-hydroxylation formation by up to 94%."
sodium phosphate,The concentration of sodium phosphate buffer differentially affects the rates of midazolam 1'-hydroxylation and 4-hydroxylation in human CYP3A-mediated in vitro metabolism assays.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. The concentration of sodium phosphate buffer differentially affects the rates of midazolam 1'-hydroxylation and 4-hydroxylation in human CYP3A-mediated in vitro metabolism assays.
alpha-naphthoflavone,Alpha-naphthoflavone at 10 µM regioselectively stimulates midazolam 1'-hydroxylation formation by human CYP3A4-containing microsomes from adult and fetal liver in vitro.,Entity: alpha-naphthoflavone. SMILES: O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12. Alpha-naphthoflavone at 10 µM regioselectively stimulates midazolam 1'-hydroxylation formation by human CYP3A4-containing microsomes from adult and fetal liver in vitro.
alpha-naphthoflavone,"In human hepatocytes, alpha-naphthoflavone up to 100% stimulates midazolam 1'-hydroxylation formation.","Entity: alpha-naphthoflavone. SMILES: O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12. In human hepatocytes, alpha-naphthoflavone up to 100% stimulates midazolam 1'-hydroxylation formation."
terfenadine,Terfenadine at 20 µM regioselectively stimulates midazolam 1'-hydroxylation formation in Tris (1–200 mM) and phosphate (1–10 mM) buffers by up to 159% in human CYP3A-mediated in vitro assays.,Entity: terfenadine. SMILES: CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1. Terfenadine at 20 µM regioselectively stimulates midazolam 1'-hydroxylation formation in Tris (1–200 mM) and phosphate (1–10 mM) buffers by up to 159% in human CYP3A-mediated in vitro assays.
hCGbeta,"hCGbeta is a heterodimeric glycoprotein hormone composed of an alpha-subunit and a beta-subunit, each with two N-glycosylation sites.","Entity: hCGbeta. hCGbeta is a heterodimeric glycoprotein hormone composed of an alpha-subunit and a beta-subunit, each with two N-glycosylation sites."
hCGbeta,All carbohydrate deficient hCGbeta heterodimers exhibit a 6–8% decrease in ordered structure compared to wild type hCG.,Entity: hCGbeta. All carbohydrate deficient hCGbeta heterodimers exhibit a 6–8% decrease in ordered structure compared to wild type hCG.
hCGbeta,Loss of the N-glycosyl chain at beta13Asn in the hCGbeta monomer results in a 4–6% decrease in ordered structure compared to wild type hCGbeta.,Entity: hCGbeta. Loss of the N-glycosyl chain at beta13Asn in the hCGbeta monomer results in a 4–6% decrease in ordered structure compared to wild type hCGbeta.
hCGbeta,Loss of the N-glycosyl chain at beta30Asn in the hCGbeta monomer does not alter the conformation of the hormone compared to wild type hCGbeta.,Entity: hCGbeta. Loss of the N-glycosyl chain at beta30Asn in the hCGbeta monomer does not alter the conformation of the hormone compared to wild type hCGbeta.
Peroxisome proliferator-activated receptor gamma,Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists induce UCP1 expression in brown postnatal preadipocytes but do not induce UCP1 in white preadipocytes.,Entity: Peroxisome proliferator-activated receptor gamma. Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists induce UCP1 expression in brown postnatal preadipocytes but do not induce UCP1 in white preadipocytes.
uncoupled protein-1,"Uncoupled protein-1 (UCP1) is a marker of brown preadipocytes and its expression is induced in postnatal brown preadipocytes by PPARgamma agonists, especially when combined with beta3-adrenergic agonists.","Entity: uncoupled protein-1. Uncoupled protein-1 (UCP1) is a marker of brown preadipocytes and its expression is induced in postnatal brown preadipocytes by PPARgamma agonists, especially when combined with beta3-adrenergic agonists."
ERbeta,ERbeta mRNA distribution in the brain appears to be more widespread in females than in males in rhesus macaques.,Entity: ERbeta. ERbeta mRNA distribution in the brain appears to be more widespread in females than in males in rhesus macaques.
estrogen receptor,"Estrogen exerts profound effects on different tissues, likely mediated by at least two estrogen receptor subtypes: ERalpha and ERbeta.","Entity: estrogen receptor. Estrogen exerts profound effects on different tissues, likely mediated by at least two estrogen receptor subtypes: ERalpha and ERbeta."
ERbeta,"ERbeta is an estrogen receptor subtype whose mRNA is expressed in both male and female reproductive organs, several endocrine and non-endocrine tissues, and various regions of the brain in rhesus macaques.","Entity: ERbeta. ERbeta is an estrogen receptor subtype whose mRNA is expressed in both male and female reproductive organs, several endocrine and non-endocrine tissues, and various regions of the brain in rhesus macaques."
ERbeta,"In some brain regions such as the putamen, internal capsule, hippocampus, and paraventricular hypothalamus, ERbeta mRNA is expressed only in female rhesus macaques but not in males.","Entity: ERbeta. In some brain regions such as the putamen, internal capsule, hippocampus, and paraventricular hypothalamus, ERbeta mRNA is expressed only in female rhesus macaques but not in males."
iodide,"Iodide uptake activity in thyroid epithelial cells is driven by the Na+ K+ ATPase located at the basolateral pole, which generates the necessary driving force for iodide uptake.","Entity: iodide. SMILES: [I-]. Iodide uptake activity in thyroid epithelial cells is driven by the Na+ K+ ATPase located at the basolateral pole, which generates the necessary driving force for iodide uptake."
sodium,"Na+ K+ ATPase is a key enzyme in thyroid epithelial cells responsible for maintaining sodium gradients and is involved in the uptake of iodide, contributing to thyroid hormone synthesis.","Entity: sodium. SMILES: [Na]. Na+ K+ ATPase is a key enzyme in thyroid epithelial cells responsible for maintaining sodium gradients and is involved in the uptake of iodide, contributing to thyroid hormone synthesis."
CYP2D16,CYP2D16 is highly expressed in the zona reticularis but not in the zona fasciculata of the guinea pig adrenal cortex in control animals.,Entity: CYP2D16. CYP2D16 is highly expressed in the zona reticularis but not in the zona fasciculata of the guinea pig adrenal cortex in control animals.
CYP17,"After ACTH treatment in guinea pigs, the intensity of CYP17 staining and enzymatic activity is similar in both the zona fasciculata and zona reticularis, largely due to increased CYP17 expression in the zona reticularis.","Entity: CYP17. After ACTH treatment in guinea pigs, the intensity of CYP17 staining and enzymatic activity is similar in both the zona fasciculata and zona reticularis, largely due to increased CYP17 expression in the zona reticularis."
CYP2D16,ACTH treatment dramatically reduces the intensity of CYP2D16 mRNA and protein staining in the zona reticularis of guinea pigs.,Entity: CYP2D16. ACTH treatment dramatically reduces the intensity of CYP2D16 mRNA and protein staining in the zona reticularis of guinea pigs.
CYP17,"CYP17 protein is present in both the zona fasciculata and zona reticularis of the guinea pig adrenal cortex, with greater immunostaining intensity in the zona fasciculata.","Entity: CYP17. CYP17 protein is present in both the zona fasciculata and zona reticularis of the guinea pig adrenal cortex, with greater immunostaining intensity in the zona fasciculata."
menadione,Menadione acts as a thiol-reactive oxidant that causes a dose-dependent loss of DNA-binding capacity in recombinant estrogen receptor (ER) and ER-enriched extracts from CHO(ER) and MCF-7 cells.,Entity: menadione. SMILES: CC1=CC(=O)c2ccccc2C1=O. Menadione acts as a thiol-reactive oxidant that causes a dose-dependent loss of DNA-binding capacity in recombinant estrogen receptor (ER) and ER-enriched extracts from CHO(ER) and MCF-7 cells.
diamide,"Diamide, a thiol-reacting oxidant, produces a dose-dependent loss of DNA-binding capacity in recombinant estrogen receptor (ER) and ER-enriched extracts from CHO(ER) and MCF-7 cells.","Entity: diamide. SMILES: CN(C)C(=O)/N=N/C(=O)N(C)C. Diamide, a thiol-reacting oxidant, produces a dose-dependent loss of DNA-binding capacity in recombinant estrogen receptor (ER) and ER-enriched extracts from CHO(ER) and MCF-7 cells."
staurosporine,Preincubation with staurosporine significantly increases rhFSH-stimulated cAMP accumulation in murine granulosa cells expressing the human FSH receptor.,Entity: staurosporine. SMILES: CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4. Preincubation with staurosporine significantly increases rhFSH-stimulated cAMP accumulation in murine granulosa cells expressing the human FSH receptor.
sodium fluoride,"Prestimulation with sodium fluoride, a G-protein inhibitor, followed by rhFSH challenge, decreases cAMP-mediated responsiveness to rhFSH in murine granulosa cells expressing the human FSH receptor, down to 69.4 ± 2.8% of control.","Entity: sodium fluoride. SMILES: [F-].[Na+]. Prestimulation with sodium fluoride, a G-protein inhibitor, followed by rhFSH challenge, decreases cAMP-mediated responsiveness to rhFSH in murine granulosa cells expressing the human FSH receptor, down to 69.4 ± 2.8% of control."
forskolin,"Forskolin, a non-specific activator of adenylate cyclase, induces progesterone production in murine granulosa cells expressing the human FSH receptor, and its stimulation is inhibited by TPA preincubation (65–74% of control).","Entity: forskolin. SMILES: C=C[C@@]1(C)CC(=O)[C@]2(O)[C@@]3(C)[C@@H](O)CCC(C)(C)[C@@H]3[C@H](O)[C@H](OC(C)=O)[C@@]2(C)O1. Forskolin, a non-specific activator of adenylate cyclase, induces progesterone production in murine granulosa cells expressing the human FSH receptor, and its stimulation is inhibited by TPA preincubation (65–74% of control)."
staurosporine,"Staurosporine, a protein kinase C (PKC) inhibitor, completely abolishes the suppression of rhFSH-induced cAMP synthesis caused by TPA preincubation in murine granulosa cells expressing the human FSH receptor.","Entity: staurosporine. SMILES: CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4. Staurosporine, a protein kinase C (PKC) inhibitor, completely abolishes the suppression of rhFSH-induced cAMP synthesis caused by TPA preincubation in murine granulosa cells expressing the human FSH receptor."
follicle-stimulating hormone,"Follicle-stimulating hormone (FSH) induces cAMP synthesis in humanized murine granulosa cells, but subsequent stimulation shows reduced cAMP formation due to receptor desensitization mediated by PKC-beta.","Entity: follicle-stimulating hormone. Follicle-stimulating hormone (FSH) induces cAMP synthesis in humanized murine granulosa cells, but subsequent stimulation shows reduced cAMP formation due to receptor desensitization mediated by PKC-beta."
PKC alpha,"The increased expression of PKC alpha protein in diabetic rats is reversed by insulin but not by phlorizin, indicating it is not due to hyperglycemia.","Entity: PKC alpha. The increased expression of PKC alpha protein in diabetic rats is reversed by insulin but not by phlorizin, indicating it is not due to hyperglycemia."
PKC alpha,"STZ-induced diabetes induces the expression of a biologically inactive form of PKC alpha in rat liver, likely due to a post-translational modification such as increased phosphorylation.","Entity: PKC alpha. STZ-induced diabetes induces the expression of a biologically inactive form of PKC alpha in rat liver, likely due to a post-translational modification such as increased phosphorylation."
PKC alpha,"In STZ-induced diabetic rats, the abundance of the 90 kDa PKC alpha protein increases in cytosolic and microsomal fractions by 180% compared to controls, while the 81 kDa PKC alpha protein remains unchanged.","Entity: PKC alpha. In STZ-induced diabetic rats, the abundance of the 90 kDa PKC alpha protein increases in cytosolic and microsomal fractions by 180% compared to controls, while the 81 kDa PKC alpha protein remains unchanged."
angiotensin II,Angiotensin II mediates control of adrenal aldosterone secretion through activation of specific adrenal receptors.,Entity: angiotensin II. Angiotensin II mediates control of adrenal aldosterone secretion through activation of specific adrenal receptors.
growth hormone-binding protein,"Growth hormone-binding protein (hGH-BP) release from human IM-9 cells is dose-dependently enhanced by phorbol 12,13-dibutyrate (PDBu), reaching a plateau at 100 nM after 60 min incubation.","Entity: growth hormone-binding protein. Growth hormone-binding protein (hGH-BP) release from human IM-9 cells is dose-dependently enhanced by phorbol 12,13-dibutyrate (PDBu), reaching a plateau at 100 nM after 60 min incubation."
deoxycortisol,"Deoxycortisol serves as a substrate for Japanese eel cytochrome P450(11 beta) (11beta-hydroxylase), which converts it into cortisol and cortisone.","Entity: deoxycortisol. SMILES: C[C@]12CCCC=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO. Deoxycortisol serves as a substrate for Japanese eel cytochrome P450(11 beta) (11beta-hydroxylase), which converts it into cortisol and cortisone."
cortisone,Cortisone is produced from deoxycortisol by the enzymatic activity of Japanese eel cytochrome P450(11 beta) (11beta-hydroxylase).,Entity: cortisone. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO. Cortisone is produced from deoxycortisol by the enzymatic activity of Japanese eel cytochrome P450(11 beta) (11beta-hydroxylase).
11-dehydrocorticosterone,11-dehydrocorticosterone is generated from 11-deoxycorticosterone by the action of Japanese eel cytochrome P450(11 beta) (11beta-hydroxylase).,Entity: 11-dehydrocorticosterone. SMILES: C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO. 11-dehydrocorticosterone is generated from 11-deoxycorticosterone by the action of Japanese eel cytochrome P450(11 beta) (11beta-hydroxylase).
oxytetracycline hydrochloride,"Nerve injury has been reported following injections of oxytetracycline hydrochloride, although such reports are rare in the English literature.","Entity: oxytetracycline hydrochloride. SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12.Cl. Nerve injury has been reported following injections of oxytetracycline hydrochloride, although such reports are rare in the English literature."
titanium,"Titanium implants with a hydroxyapatite coating and a groove depth of 1 mm promote optimal bony ingrowth in cancellous bone of the distal femur, as shown by histological and mechanical evaluation.","Entity: titanium. SMILES: [Ti]. Titanium implants with a hydroxyapatite coating and a groove depth of 1 mm promote optimal bony ingrowth in cancellous bone of the distal femur, as shown by histological and mechanical evaluation."
titanium,"Titanium implants with a hydroxyapatite coating and a groove depth of 1 mm provide better fixation at 4 weeks post-implantation compared to traditional beads-coated porous titanium implants, but show significantly inferior fixation at 12 weeks.","Entity: titanium. SMILES: [Ti]. Titanium implants with a hydroxyapatite coating and a groove depth of 1 mm provide better fixation at 4 weeks post-implantation compared to traditional beads-coated porous titanium implants, but show significantly inferior fixation at 12 weeks."
fluoride,Fluoride release from glass-ionomer cements may complement their in vivo ability to inhibit caries development by neutralizing surrounding aqueous solutions.,Entity: fluoride. SMILES: [F-]. Fluoride release from glass-ionomer cements may complement their in vivo ability to inhibit caries development by neutralizing surrounding aqueous solutions.
titanium,"Cast or machined ASTM Grade II CP titanium exhibits a distinctive passive region in polarization diagrams ranging from approximately 0 to +1300 mV vs Ag/AgCl in both acidic saline (0.1 M lactic acid/0.1 M NaCl, pH 2) and artificial saliva corrosion media.","Entity: titanium. SMILES: [Ti]. Cast or machined ASTM Grade II CP titanium exhibits a distinctive passive region in polarization diagrams ranging from approximately 0 to +1300 mV vs Ag/AgCl in both acidic saline (0.1 M lactic acid/0.1 M NaCl, pH 2) and artificial saliva corrosion media."
titanium,"The corrosion behavior of cast CP titanium is similar to that of machined titanium, with surface roughness being a more prominent factor than surface reaction layers in polarization behavior under the described experimental conditions.","Entity: titanium. SMILES: [Ti]. The corrosion behavior of cast CP titanium is similar to that of machined titanium, with surface roughness being a more prominent factor than surface reaction layers in polarization behavior under the described experimental conditions."
titanium,"Sandblasted CP titanium specimens with surface reaction layers show a significantly higher increase in titanium dissolution compared to polished specimens after six months of immersion in acidic saline solution (0.1 M lactic acid/0.1 M NaCl, pH 2).","Entity: titanium. SMILES: [Ti]. Sandblasted CP titanium specimens with surface reaction layers show a significantly higher increase in titanium dissolution compared to polished specimens after six months of immersion in acidic saline solution (0.1 M lactic acid/0.1 M NaCl, pH 2)."
titanium,Surface roughness and the presence of surface reaction layers both affect the dissolution of titanium in CP titanium under the tested conditions.,Entity: titanium. SMILES: [Ti]. Surface roughness and the presence of surface reaction layers both affect the dissolution of titanium in CP titanium under the tested conditions.
lactic acid,"Lactic acid is used as a component (0.1 M) in acidic saline solution (with 0.1 M NaCl, pH 2) as a corrosion medium for studying titanium.","Entity: lactic acid. SMILES: CC(O)C(=O)O. Lactic acid is used as a component (0.1 M) in acidic saline solution (with 0.1 M NaCl, pH 2) as a corrosion medium for studying titanium."
sodium butyrate,"Sodium butyrate treatment increases the replication of cytomegalovirus (CMV) in endothelial cells in vitro, but the resulting extracellular virus remains infectious for fibroblasts but not for endothelial cells.","Entity: sodium butyrate. SMILES: CCCC(=O)[O-].[Na+]. Sodium butyrate treatment increases the replication of cytomegalovirus (CMV) in endothelial cells in vitro, but the resulting extracellular virus remains infectious for fibroblasts but not for endothelial cells."
K252a,K252a is a tyrosine kinase inhibitor that blocks the inhibitory effect of cotransfection with full-length trkB.TK+ on the morphological response of trkB.T1-transfected N2a neuroblastoma cells.,Entity: K252a. SMILES: COC(=O)[C@]1(O)CC2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4. K252a is a tyrosine kinase inhibitor that blocks the inhibitory effect of cotransfection with full-length trkB.TK+ on the morphological response of trkB.T1-transfected N2a neuroblastoma cells.
p16,P16/Ink4A protein expression is significantly upregulated in papillomas and carcinomas of UVB-exposed mouse skin.,Entity: p16. P16/Ink4A protein expression is significantly upregulated in papillomas and carcinomas of UVB-exposed mouse skin.
cdk2,"Cdk2 protein expression is upregulated during UVB-induced tumorigenesis in mouse skin, particularly in papillomas and carcinomas.","Entity: cdk2. Cdk2 protein expression is upregulated during UVB-induced tumorigenesis in mouse skin, particularly in papillomas and carcinomas."
Ral GDP dissociation stimulator,Ral GDP dissociation stimulator (RalGDS) is a small GTP-binding protein that interacts with Ral and is recruited to the plasma membrane by the addition of a Ras farnesylation site (RalGDS-CAAX).,Entity: Ral GDP dissociation stimulator. Ral GDP dissociation stimulator (RalGDS) is a small GTP-binding protein that interacts with Ral and is recruited to the plasma membrane by the addition of a Ras farnesylation site (RalGDS-CAAX).
Ral GDP dissociation stimulator,Ral GDP dissociation stimulator (RalGDS) can activate Ral in the absence of RasG12V when targeted to the plasma membrane by RalGDS-CAAX.,Entity: Ral GDP dissociation stimulator. Ral GDP dissociation stimulator (RalGDS) can activate Ral in the absence of RasG12V when targeted to the plasma membrane by RalGDS-CAAX.
Ral,Ral is activated by Ral GDP dissociation stimulator (RalGDS) when RalGDS is recruited to the plasma membrane by the addition of a Ras farnesylation site (RalGDS-CAAX).,Entity: Ral. Ral is activated by Ral GDP dissociation stimulator (RalGDS) when RalGDS is recruited to the plasma membrane by the addition of a Ras farnesylation site (RalGDS-CAAX).
Raf,"Raf is a protein kinase that is part of the Ras/Raf/MEK/MAP kinase signaling pathway, mediating the transmission of oncogenic signals downstream of receptor tyrosine kinases.","Entity: Raf. Raf is a protein kinase that is part of the Ras/Raf/MEK/MAP kinase signaling pathway, mediating the transmission of oncogenic signals downstream of receptor tyrosine kinases."
ER71,ER71 is a member of the ETS subfamily of the ETS gene family in vertebrates.,Entity: ER71. ER71 is a member of the ETS subfamily of the ETS gene family in vertebrates.
AML1,AML1 (also known as CBFA2) is a DNA-binding factor encoded by a gene on chromosome 21.,Entity: AML1. AML1 (also known as CBFA2) is a DNA-binding factor encoded by a gene on chromosome 21.
ETO-2,"ETO-2 is a murine cDNA encoding a new member of the ETO protein family, sharing 75% identity with murine ETO and high sequence identity over domains I-III and the zinc-finger region.","Entity: ETO-2. ETO-2 is a murine cDNA encoding a new member of the ETO protein family, sharing 75% identity with murine ETO and high sequence identity over domains I-III and the zinc-finger region."
ETO-2,"The nuclear localization of ETO-2 is confirmed, and its domain III and zinc-finger region are not required for this function.","Entity: ETO-2. The nuclear localization of ETO-2 is confirmed, and its domain III and zinc-finger region are not required for this function."
ETO-2,"ETO-2 is expressed in many murine tissues, developing mouse embryo, and in myeloid and erythroid cell lines.","Entity: ETO-2. ETO-2 is expressed in many murine tissues, developing mouse embryo, and in myeloid and erythroid cell lines."
sulfonylurea,"Sulfonylurea is a ligand that binds to K-ATP channels, and the affinity of K-ATP channels for sulfonylurea varies between different isoforms, resulting in species with distinct metabolic sensitivities.","Entity: sulfonylurea. SMILES: NC(=O)N=S(=O)=O. Sulfonylurea is a ligand that binds to K-ATP channels, and the affinity of K-ATP channels for sulfonylurea varies between different isoforms, resulting in species with distinct metabolic sensitivities."
sulfonylurea receptor,The sulfonylurea receptor (SUR) is a subunit of K-ATP channels that can co-express with Kir6.X to form functional K-ATP channels with differential metabolic sensitivity.,Entity: sulfonylurea receptor. The sulfonylurea receptor (SUR) is a subunit of K-ATP channels that can co-express with Kir6.X to form functional K-ATP channels with differential metabolic sensitivity.
fibulin-1,Fragments alpha2LG1-3 and alpha2LG4-5 of the laminin alpha2 chain bind to fibulin-1 with Kd values of 13–150 nM.,Entity: fibulin-1. Fragments alpha2LG1-3 and alpha2LG4-5 of the laminin alpha2 chain bind to fibulin-1 with Kd values of 13–150 nM.
laminin alpha2,"Fragments alpha2LG1-3 and alpha2LG4-5 of the laminin alpha2 chain bind to fibulin-1, fibulin-2, and nidogen-2 with Kd values of 13–150 nM.","Entity: laminin alpha2. Fragments alpha2LG1-3 and alpha2LG4-5 of the laminin alpha2 chain bind to fibulin-1, fibulin-2, and nidogen-2 with Kd values of 13–150 nM."
laminin alpha2,"Tandem fragments alpha2LG1-3 and alpha2LG4-5 of the laminin alpha2 chain bind strongly to alpha-dystroglycan, and this interaction is abolished by EDTA but not by high concentrations of heparin and NaCl.","Entity: laminin alpha2. Tandem fragments alpha2LG1-3 and alpha2LG4-5 of the laminin alpha2 chain bind strongly to alpha-dystroglycan, and this interaction is abolished by EDTA but not by high concentrations of heparin and NaCl."
laminin alpha1,"In the laminin alpha1 chain, strong heparin binding is found on alpha1LG4 but not on alpha1LG5.","Entity: laminin alpha1. In the laminin alpha1 chain, strong heparin binding is found on alpha1LG4 but not on alpha1LG5."
laminin alpha2,The C-terminal G domain of the mouse laminin alpha2 chain consists of five lamin-type G domain (LG) modules (alpha2LG1 to alpha2LG5).,Entity: laminin alpha2. The C-terminal G domain of the mouse laminin alpha2 chain consists of five lamin-type G domain (LG) modules (alpha2LG1 to alpha2LG5).
molybdenum,"Increasing molybdenum content in stainless steels beyond 2 percent improves pitting corrosion resistance but also impairs ductility and formability, especially after cold deformation.","Entity: molybdenum. SMILES: [Mo]. Increasing molybdenum content in stainless steels beyond 2 percent improves pitting corrosion resistance but also impairs ductility and formability, especially after cold deformation."
molybdenum,Molybdenum is added to stainless steels to improve their resistance to pitting attack in chloride-containing environments.,Entity: molybdenum. SMILES: [Mo]. Molybdenum is added to stainless steels to improve their resistance to pitting attack in chloride-containing environments.
molybdenum,The minimum molybdenum content required for adequate resistance to pitting corrosion in stainless steels is about 2 percent.,Entity: molybdenum. SMILES: [Mo]. The minimum molybdenum content required for adequate resistance to pitting corrosion in stainless steels is about 2 percent.
manganese sulphide,Manganese sulphide is identified as a predominant inclusion type in the screws and plates of the examined implant materials.,Entity: manganese sulphide. SMILES: [Mn+2].[S-2]. Manganese sulphide is identified as a predominant inclusion type in the screws and plates of the examined implant materials.
Nickel,"Nickel is an alloying addition in stainless steels that contributes to their excellent general corrosion resistance, which is the basis for their 'stainless' characteristics.","Entity: Nickel. SMILES: [Ni]. Nickel is an alloying addition in stainless steels that contributes to their excellent general corrosion resistance, which is the basis for their 'stainless' characteristics."
Chromium,"Chromium is an alloying addition in stainless steels that confers upon them excellent general corrosion resistance, defining their 'stainless' properties.","Entity: Chromium. SMILES: [Cr]. Chromium is an alloying addition in stainless steels that confers upon them excellent general corrosion resistance, defining their 'stainless' properties."
Molybdenum,Molybdenum is used as an alloying element in stainless steels to enhance their corrosion resistance.,Entity: Molybdenum. SMILES: [Mo]. Molybdenum is used as an alloying element in stainless steels to enhance their corrosion resistance.
Carbon,Carbon is present as an alloying element in stainless steels.,Entity: Carbon. SMILES: [C]. Carbon is present as an alloying element in stainless steels.
Chromium,"Chromium is present as an impurity in stainless steels and, except in the case of sensitization, has little effect on corrosion behavior.","Entity: Chromium. SMILES: [Cr]. Chromium is present as an impurity in stainless steels and, except in the case of sensitization, has little effect on corrosion behavior."
Chromium,"In austenitic stainless steels, slow cooling or heating through the GO-55°C temperature range can cause chromium carbide precipitation at grain boundaries, leading to sensitization and increased susceptibility to intergranular corrosion.","Entity: Chromium. SMILES: [Cr]. In austenitic stainless steels, slow cooling or heating through the GO-55°C temperature range can cause chromium carbide precipitation at grain boundaries, leading to sensitization and increased susceptibility to intergranular corrosion."
Carbon,"Low carbon content in stainless steels, such as in 316L, helps prevent sensitization and intergranular corrosion by reducing the availability of carbon for chromium carbide precipitation.","Entity: Carbon. SMILES: [C]. Low carbon content in stainless steels, such as in 316L, helps prevent sensitization and intergranular corrosion by reducing the availability of carbon for chromium carbide precipitation."
Titanium,Stabilization of stainless steels with small amounts of titanium prevents sensitization and intergranular corrosion by reducing the carbon content available for chromium carbide formation.,Entity: Titanium. SMILES: [Ti]. Stabilization of stainless steels with small amounts of titanium prevents sensitization and intergranular corrosion by reducing the carbon content available for chromium carbide formation.
Niobium,Stabilization of stainless steels with small amounts of niobium prevents sensitization and intergranular corrosion by reducing the carbon content available for chromium carbide formation.,Entity: Niobium. SMILES: [Nb]. Stabilization of stainless steels with small amounts of niobium prevents sensitization and intergranular corrosion by reducing the carbon content available for chromium carbide formation.
fizzy,"Fizzy-related is involved in the introduction of G1 during Drosophila embryogenesis, with a function complementary to rbf.","Entity: fizzy. Fizzy-related is involved in the introduction of G1 during Drosophila embryogenesis, with a function complementary to rbf."
RNR2,RNR2 is an E2F-regulated gene whose expression is repressed by RBF during Drosophila embryogenesis.,Entity: RNR2. RNR2 is an E2F-regulated gene whose expression is repressed by RBF during Drosophila embryogenesis.
PCNA,PCNA is an E2F-regulated gene whose expression is repressed by RBF during Drosophila embryogenesis.,Entity: PCNA. PCNA is an E2F-regulated gene whose expression is repressed by RBF during Drosophila embryogenesis.
rbf,"RBF is necessary for the maintenance of the G1 phase in Drosophila epidermal cells, but not for the initiation of G1.","Entity: rbf. RBF is necessary for the maintenance of the G1 phase in Drosophila epidermal cells, but not for the initiation of G1."
rbf,RBF has a function complementary to that of dacapo and fizzy-related in the introduction of G1 during Drosophila embryogenesis.,Entity: rbf. RBF has a function complementary to that of dacapo and fizzy-related in the introduction of G1 during Drosophila embryogenesis.
E2F,E2F is a transcription factor whose target genes are repressed by RBF during Drosophila embryogenesis.,Entity: E2F. E2F is a transcription factor whose target genes are repressed by RBF during Drosophila embryogenesis.
rbf,RBF is required for the transcriptional repression of E2F-regulated genes such as PCNA and RNR2 during Drosophila embryogenesis.,Entity: rbf. RBF is required for the transcriptional repression of E2F-regulated genes such as PCNA and RNR2 during Drosophila embryogenesis.
dacapo,"Dacapo is involved in the introduction of G1 during Drosophila embryogenesis, with a function complementary to rbf.","Entity: dacapo. Dacapo is involved in the introduction of G1 during Drosophila embryogenesis, with a function complementary to rbf."
gamma-globin,Developmental silencing of gamma-globin genes is unaffected by deletion of a DNA element in the beta-globin locus.,Entity: gamma-globin. Developmental silencing of gamma-globin genes is unaffected by deletion of a DNA element in the beta-globin locus.
pervanadate,"Pervanadate, in combination with H2O2, induces nuclear translocation of Ag-STAT protein in midgut epithelial cells of Anopheles gambiae.","Entity: pervanadate. SMILES: O=[V]([O-])([O-])[O-].OO.OO.OO.[Na+].[Na+].[Na+]. Pervanadate, in combination with H2O2, induces nuclear translocation of Ag-STAT protein in midgut epithelial cells of Anopheles gambiae."
D-STAT,"D-STAT is a Drosophila STAT family member that is most similar to Ag-STAT and vertebrate STATs 5 and 6, forming a proposed ancient class A of the STAT family.","Entity: D-STAT. D-STAT is a Drosophila STAT family member that is most similar to Ag-STAT and vertebrate STATs 5 and 6, forming a proposed ancient class A of the STAT family."
Pip,"Pip is recruited to its DNA binding site by phosphorylated PU.1, which binds to the ets and IRF DNA-binding domains and the phosphorylated PEST region of PU.1 and a lysine-requiring putative alpha-helix in Pip.","Entity: Pip. Pip is recruited to its DNA binding site by phosphorylated PU.1, which binds to the ets and IRF DNA-binding domains and the phosphorylated PEST region of PU.1 and a lysine-requiring putative alpha-helix in Pip."
Pip,Pip (IRF-4) is an IRF protein that interacts with PU.1 to regulate B cell-specific gene expression.,Entity: Pip. Pip (IRF-4) is an IRF protein that interacts with PU.1 to regulate B cell-specific gene expression.
Sec3p,Sec3p is a subunit of the exocyst that marks the sites of exocytosis on the plasma membrane.,Entity: Sec3p. Sec3p is a subunit of the exocyst that marks the sites of exocytosis on the plasma membrane.
CD8,CD8(+) T cells recognize antigenic peptides presented by MHC class I molecules.,Entity: CD8. CD8(+) T cells recognize antigenic peptides presented by MHC class I molecules.
cdc37,"cdc37 is an Hsp90 chaperone protein that forms a heterodimer with p50(cdc37), which is required for Raf-1 activity and MAPK pathway signaling.","Entity: cdc37. cdc37 is an Hsp90 chaperone protein that forms a heterodimer with p50(cdc37), which is required for Raf-1 activity and MAPK pathway signaling."
cyclobutane pyrimidine,"Cyclobutane pyrimidine dimers on UV-irradiated mononucleosomes are substantially less accessible to T4 endonuclease V than on naked DNA, indicating that Gadd45 reduces DNA accessibility to this enzyme in response to UV-induced chromatin alterations.","Entity: cyclobutane pyrimidine. SMILES: C1CCC1.c1cncnc1. Cyclobutane pyrimidine dimers on UV-irradiated mononucleosomes are substantially less accessible to T4 endonuclease V than on naked DNA, indicating that Gadd45 reduces DNA accessibility to this enzyme in response to UV-induced chromatin alterations."
C/EBPbeta,C/EBPbeta is an intronless gene that produces several N-terminally truncated isoforms through alternative translation initiation at downstream AUG codons.,Entity: C/EBPbeta. C/EBPbeta is an intronless gene that produces several N-terminally truncated isoforms through alternative translation initiation at downstream AUG codons.
C/EBPbeta,"In C/EBPalpha-/- mice, the proteolytic cleavage activity that generates the 21-kDa LIP isoform of C/EBPbeta is completely abolished, correlating with decreased liver levels of LIP.","Entity: C/EBPbeta. In C/EBPalpha-/- mice, the proteolytic cleavage activity that generates the 21-kDa LIP isoform of C/EBPbeta is completely abolished, correlating with decreased liver levels of LIP."
C/EBPbeta,"C/EBPbeta can generate four isoforms: a full-length 38-kDa protein, a 35-kDa LAP (liver-enriched transcriptional activator protein), a 21-kDa LIP (liver-enriched transcriptional inhibitory protein), and a 14-kDa isoform.","Entity: C/EBPbeta. C/EBPbeta can generate four isoforms: a full-length 38-kDa protein, a 35-kDa LAP (liver-enriched transcriptional activator protein), a 21-kDa LIP (liver-enriched transcriptional inhibitory protein), and a 14-kDa isoform."
C/EBPbeta,"The 21-kDa LIP isoform of C/EBPbeta can be produced by alternative translation and by a C/EBPalpha-dependent, specific proteolytic cleavage of full-length C/EBPbeta.","Entity: C/EBPbeta. The 21-kDa LIP isoform of C/EBPbeta can be produced by alternative translation and by a C/EBPalpha-dependent, specific proteolytic cleavage of full-length C/EBPbeta."
SC35,SC35 is a serine/arginine (SR)-rich splicing factor that can activate specific classes of selected splicing enhancer elements in S100 complementation assays.,Entity: SC35. SC35 is a serine/arginine (SR)-rich splicing factor that can activate specific classes of selected splicing enhancer elements in S100 complementation assays.
9G8,9G8 is a serine/arginine (SR)-rich splicing factor that can activate specific classes of selected splicing enhancer elements in S100 complementation assays.,Entity: 9G8. 9G8 is a serine/arginine (SR)-rich splicing factor that can activate specific classes of selected splicing enhancer elements in S100 complementation assays.
doublesex,Doublesex is a transcription factor that acts as a pre-mRNA enhancer-dependent splicing substrate in Drosophila.,Entity: doublesex. Doublesex is a transcription factor that acts as a pre-mRNA enhancer-dependent splicing substrate in Drosophila.
SF2,SF2 is a serine/arginine (SR)-rich splicing factor capable of activating specific classes of selected splicing enhancer elements in S100 complementation assays.,Entity: SF2. SF2 is a serine/arginine (SR)-rich splicing factor capable of activating specific classes of selected splicing enhancer elements in S100 complementation assays.
CDC42,"Ral-GEF activity may function, at least in part, through inhibition of the Rho family GTPase CDC42.","Entity: CDC42. Ral-GEF activity may function, at least in part, through inhibition of the Rho family GTPase CDC42."
Ral-GEF,"Ral-GEF activity acts in opposition to other Ras effectors, such as Raf and PI3 kinases, in PC12 cells.","Entity: Ral-GEF. Ral-GEF activity acts in opposition to other Ras effectors, such as Raf and PI3 kinases, in PC12 cells."
Ral-GEF,"Ral-GEF activity, when inhibited by expression of a dominant negative Ral mutant, accelerates cell cycle arrest and enhances neurite outgrowth in response to nerve growth factor (NGF) treatment in PC12 cells.","Entity: Ral-GEF. Ral-GEF activity, when inhibited by expression of a dominant negative Ral mutant, accelerates cell cycle arrest and enhances neurite outgrowth in response to nerve growth factor (NGF) treatment in PC12 cells."
Rgr,"Rgr is a Ral-specific guanine nucleotide exchange factor (Ral-GEF) whose catalytic domain, when expressed in PC12 cells, suppresses cell cycle arrest and neurite outgrowth induced by nerve growth factor (NGF) treatment.","Entity: Rgr. Rgr is a Ral-specific guanine nucleotide exchange factor (Ral-GEF) whose catalytic domain, when expressed in PC12 cells, suppresses cell cycle arrest and neurite outgrowth induced by nerve growth factor (NGF) treatment."
Ral-GEF,Ral-GEF activity can be elevated by transfection of a mutant Ras protein that preferentially activates Ral-GEFs or by transfection of the catalytic domain of the Ral-GEF Rgr.,Entity: Ral-GEF. Ral-GEF activity can be elevated by transfection of a mutant Ras protein that preferentially activates Ral-GEFs or by transfection of the catalytic domain of the Ral-GEF Rgr.
Ral-GEF,Ral-GEF signaling induced by nerve growth factor (NGF) delays the onset of cell cycle arrest and neurite outgrowth induced by other Ras effectors.,Entity: Ral-GEF. Ral-GEF signaling induced by nerve growth factor (NGF) delays the onset of cell cycle arrest and neurite outgrowth induced by other Ras effectors.
wortmannin,"Wortmannin, a phosphatidylinositol 3-kinase inhibitor, specifically blocks UV-stimulated activation of JNK1 but does not affect UV-driven activation of ERK2 in NIH 3T3 cells.","Entity: wortmannin. SMILES: COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O. Wortmannin, a phosphatidylinositol 3-kinase inhibitor, specifically blocks UV-stimulated activation of JNK1 but does not affect UV-driven activation of ERK2 in NIH 3T3 cells."
mafosfamide,"Mafosfamide, an antineoplastic drug, does not elicit activation of JNK1 or increased c-Jun protein and AP-1 binding activity in NIH 3T3 cells upon UV-C or methyl methanesulfonate treatment.","Entity: mafosfamide. SMILES: O=[P@@]1(N(CCCl)CCCl)N[C@@H](SCCS(=O)(=O)O)CCO1. Mafosfamide, an antineoplastic drug, does not elicit activation of JNK1 or increased c-Jun protein and AP-1 binding activity in NIH 3T3 cells upon UV-C or methyl methanesulfonate treatment."
methyl methanesulfonate,Methyl methanesulfonate (MMS) treatment activates JNK1 and increases c-Jun protein and AP-1 binding activity in NIH 3T3 cells.,Entity: methyl methanesulfonate. SMILES: COS(C)(=O)=O. Methyl methanesulfonate (MMS) treatment activates JNK1 and increases c-Jun protein and AP-1 binding activity in NIH 3T3 cells.
eth1,Elimination of ETH1 in apn1 yeast strains increases spontaneous mutation rates as measured by reversion to adenine prototrophy by 9-fold and to lysine prototrophy by 31-fold compared to wild type.,Entity: eth1. Elimination of ETH1 in apn1 yeast strains increases spontaneous mutation rates as measured by reversion to adenine prototrophy by 9-fold and to lysine prototrophy by 31-fold compared to wild type.
eth1,"In Saccharomyces cerevisiae, eth1 encodes a putative protein homologous to the exonuclease III family of AP endonucleases, with a 347-residue segment showing 34% identity to the Schizosaccharomyces pombe eth1(+) gene product.","Entity: eth1. In Saccharomyces cerevisiae, eth1 encodes a putative protein homologous to the exonuclease III family of AP endonucleases, with a 347-residue segment showing 34% identity to the Schizosaccharomyces pombe eth1(+) gene product."
eth1,"Expression of ETH1 mRNA in apn1 yeast strains increases sensitivity to methyl methanesulfonate (MMS) by approximately 15-fold and to hydrogen peroxide by 2- to 3-fold, and also increases sensitivity to phleomycin D1.","Entity: eth1. Expression of ETH1 mRNA in apn1 yeast strains increases sensitivity to methyl methanesulfonate (MMS) by approximately 15-fold and to hydrogen peroxide by 2- to 3-fold, and also increases sensitivity to phleomycin D1."
APN1,"APN1 is the major AP endonuclease gene in Saccharomyces cerevisiae, encoding a protein required for base excision repair of DNA.","Entity: APN1. APN1 is the major AP endonuclease gene in Saccharomyces cerevisiae, encoding a protein required for base excision repair of DNA."
Pak1,Pak1 is a serine threonine kinase that is activated downstream of Ras via the Rac/Cdc42 pathway.,Entity: Pak1. Pak1 is a serine threonine kinase that is activated downstream of Ras via the Rac/Cdc42 pathway.
Cdc42,Cdc42 is a small G protein that is activated downstream of PI 3-kinase and acts as an effector of Rac.,Entity: Cdc42. Cdc42 is a small G protein that is activated downstream of PI 3-kinase and acts as an effector of Rac.
Pak1,"Pak1 activation is necessary, but not sufficient, for cooperative transformation of Rat-1 fibroblasts by Ras, Rac, and Rho.","Entity: Pak1. Pak1 activation is necessary, but not sufficient, for cooperative transformation of Rat-1 fibroblasts by Ras, Rac, and Rho."
extracellular signal-activated kinase,Extracellular signal-activated kinase (ERK) is activated downstream of Ras via the Ras > Raf > Mek > ERK cascade.,Entity: extracellular signal-activated kinase. Extracellular signal-activated kinase (ERK) is activated downstream of Ras via the Ras > Raf > Mek > ERK cascade.
Pak1,"Pak1 activation is dependent on cooperation between Ras, PI 3-kinase, and Rac/Cdc42, as shown by synergistic activation in transformation assays.","Entity: Pak1. Pak1 activation is dependent on cooperation between Ras, PI 3-kinase, and Rac/Cdc42, as shown by synergistic activation in transformation assays."
phosphotyrosine,"Phosphotyrosine residues can be recognized by the SH2 domains of RasGAP, mediating its binding to tyrosine-phosphorylated proteins and influencing its intracellular localization and activity.","Entity: phosphotyrosine. SMILES: N[C@@H](Cc1ccc(OP(=O)(O)O)cc1)C(=O)O. Phosphotyrosine residues can be recognized by the SH2 domains of RasGAP, mediating its binding to tyrosine-phosphorylated proteins and influencing its intracellular localization and activity."
p120 Ras-GAP,"The in vivo effects of p120 Ras-GAP overexpression require intact SH2 domains, indicating that SH2-phosphotyrosine interactions are important for its activity.","Entity: p120 Ras-GAP. The in vivo effects of p120 Ras-GAP overexpression require intact SH2 domains, indicating that SH2-phosphotyrosine interactions are important for its activity."
p120 Ras-GAP,p120 Ras-GAP is tyrosine phosphorylated in embryos and its Src homology 2 (SH2) domains can bind in vitro to a small number of tyrosine-phosphorylated proteins expressed at various developmental stages.,Entity: p120 Ras-GAP. p120 Ras-GAP is tyrosine phosphorylated in embryos and its Src homology 2 (SH2) domains can bind in vitro to a small number of tyrosine-phosphorylated proteins expressed at various developmental stages.
Breathless,Breathless is a Drosophila receptor tyrosine kinase of the fibroblast growth factor receptor family.,Entity: Breathless. Breathless is a Drosophila receptor tyrosine kinase of the fibroblast growth factor receptor family.
p120 Ras-GAP,p120 Ras-GAP can function as an inhibitor of signaling pathways mediated by Ras and receptor tyrosine kinases in vivo.,Entity: p120 Ras-GAP. p120 Ras-GAP can function as an inhibitor of signaling pathways mediated by Ras and receptor tyrosine kinases in vivo.
p120 Ras-GAP,Genetic interactions suggest that p120 Ras-GAP has a Ras-independent role in the regulation of growth.,Entity: p120 Ras-GAP. Genetic interactions suggest that p120 Ras-GAP has a Ras-independent role in the regulation of growth.
p120 Ras-GAP,Ectopic expression of p120 Ras-GAP in the Drosophila wing imaginal disc reduces the size of the adult wing by up to 45% and suppresses ectopic wing vein formation caused by activated forms of Breathless and Heartless.,Entity: p120 Ras-GAP. Ectopic expression of p120 Ras-GAP in the Drosophila wing imaginal disc reduces the size of the adult wing by up to 45% and suppresses ectopic wing vein formation caused by activated forms of Breathless and Heartless.
p120 Ras-GAP,p120 Ras-GAP is a mammalian Ras GTPase-activating protein (GAP) that acts as both a downregulator and effector of Ras proteins.,Entity: p120 Ras-GAP. p120 Ras-GAP is a mammalian Ras GTPase-activating protein (GAP) that acts as both a downregulator and effector of Ras proteins.
p120 Ras-GAP,p120 Ras-GAP stimulates the intrinsic GTPase activity of normal mammalian H-Ras but not that of the oncogenic Val12 mutant H-Ras.,Entity: p120 Ras-GAP. p120 Ras-GAP stimulates the intrinsic GTPase activity of normal mammalian H-Ras but not that of the oncogenic Val12 mutant H-Ras.
Heartless,Heartless is a Drosophila receptor tyrosine kinase of the fibroblast growth factor receptor family.,Entity: Heartless. Heartless is a Drosophila receptor tyrosine kinase of the fibroblast growth factor receptor family.
maturation-promoting factor,"The maturation-promoting factor (MPF) pathway, when activated by cyclin B1 RNA or purified cyclin B1 protein, induces Mos protein accumulation and Mos mRNA polyadenylation in Xenopus oocytes, but this action of MPF requires MAPK activity.","Entity: maturation-promoting factor. The maturation-promoting factor (MPF) pathway, when activated by cyclin B1 RNA or purified cyclin B1 protein, induces Mos protein accumulation and Mos mRNA polyadenylation in Xenopus oocytes, but this action of MPF requires MAPK activity."
cyclin B1,"Cyclin B1 is involved in the activation of the maturation-promoting factor (MPF) pathway, which induces Mos protein accumulation and Mos mRNA polyadenylation in Xenopus oocytes.","Entity: cyclin B1. Cyclin B1 is involved in the activation of the maturation-promoting factor (MPF) pathway, which induces Mos protein accumulation and Mos mRNA polyadenylation in Xenopus oocytes."
Mos,Progesterone-induced Mos mRNA polyadenylation in Xenopus oocytes is attenuated by the MAPK phosphatase rVH6.,Entity: Mos. Progesterone-induced Mos mRNA polyadenylation in Xenopus oocytes is attenuated by the MAPK phosphatase rVH6.
Mos,MAPK-stimulated Mos mRNA cytoplasmic polyadenylation is a key component of the positive-feedback loop that contributes to the all-or-none process of oocyte maturation.,Entity: Mos. MAPK-stimulated Mos mRNA cytoplasmic polyadenylation is a key component of the positive-feedback loop that contributes to the all-or-none process of oocyte maturation.
MAPK,"The MAPK signaling pathway mediates progesterone-stimulated oocyte maturation in Xenopus by activating the MAPK pathway, which is required for MPF-mediated Mos protein accumulation and mRNA polyadenylation.","Entity: MAPK. The MAPK signaling pathway mediates progesterone-stimulated oocyte maturation in Xenopus by activating the MAPK pathway, which is required for MPF-mediated Mos protein accumulation and mRNA polyadenylation."
Mos,Mos protein kinase is a key regulator of vertebrate oocyte maturation.,Entity: Mos. Mos protein kinase is a key regulator of vertebrate oocyte maturation.
Mos,Both the MAPK and maturation-promoting factor (MPF) signaling pathways mediate progesterone-stimulated oocyte maturation in Xenopus.,Entity: Mos. Both the MAPK and maturation-promoting factor (MPF) signaling pathways mediate progesterone-stimulated oocyte maturation in Xenopus.
Mos,"Activation of the maturation-promoting factor (MPF) pathway by cyclin B1 RNA or purified cyclin B1 protein induces Mos protein accumulation and Mos mRNA polyadenylation in oocytes, but this action of MPF requires MAPK activity.","Entity: Mos. Activation of the maturation-promoting factor (MPF) pathway by cyclin B1 RNA or purified cyclin B1 protein induces Mos protein accumulation and Mos mRNA polyadenylation in oocytes, but this action of MPF requires MAPK activity."
Mos,"In Xenopus oocytes, the translation of Mos protein requires progesterone-induced polyadenylation of maternal Mos mRNA.","Entity: Mos. In Xenopus oocytes, the translation of Mos protein requires progesterone-induced polyadenylation of maternal Mos mRNA."
Mos,Activation of the MAPK pathway by Mos RNA injection induces both polyadenylation of synthetic Mos mRNA substrates and accumulation of endogenous Mos protein in oocytes.,Entity: Mos. Activation of the MAPK pathway by Mos RNA injection induces both polyadenylation of synthetic Mos mRNA substrates and accumulation of endogenous Mos protein in oocytes.
msh2,"msh2 is a gene involved in mismatch repair in Saccharomyces cerevisiae, and its disruption leads to increased mutation rates when combined with pol3-01 mutations.","Entity: msh2. msh2 is a gene involved in mismatch repair in Saccharomyces cerevisiae, and its disruption leads to increased mutation rates when combined with pol3-01 mutations."
Exo1,Exo1 is a 5'-->3' DNA polymerase exonuclease that plays an important role in mismatch repair and replication fidelity in Saccharomyces cerevisiae.,Entity: Exo1. Exo1 is a 5'-->3' DNA polymerase exonuclease that plays an important role in mismatch repair and replication fidelity in Saccharomyces cerevisiae.
msh6,msh6 is a gene involved in mismatch repair in Saccharomyces cerevisiae.,Entity: msh6. msh6 is a gene involved in mismatch repair in Saccharomyces cerevisiae.
msh3,msh3 is a gene involved in mismatch repair in Saccharomyces cerevisiae.,Entity: msh3. msh3 is a gene involved in mismatch repair in Saccharomyces cerevisiae.
Prp24p,Prp24p is a component of the yeast spliceosomal snRNP and its mutation leads to disassembly of the U4/U6 snRNP particle and degradation of the U6 snRNA.,Entity: Prp24p. Prp24p is a component of the yeast spliceosomal snRNP and its mutation leads to disassembly of the U4/U6 snRNP particle and degradation of the U6 snRNA.
sad1-1,"sad1-1 extracts fail to splice pre-mRNA substrates in vitro, indicating a block in splicing at the nuclear level.","Entity: sad1-1. sad1-1 extracts fail to splice pre-mRNA substrates in vitro, indicating a block in splicing at the nuclear level."
sad1-1,sad1-1 is a yeast mutant with a splicing defect that preferentially affects assembly of newly synthesized U4 snRNA into the U4/U6 snRNP particle.,Entity: sad1-1. sad1-1 is a yeast mutant with a splicing defect that preferentially affects assembly of newly synthesized U4 snRNA into the U4/U6 snRNP particle.
Prp3p,Prp3p is a component of the yeast spliceosomal snRNP and its mutation leads to disassembly of the U4/U6 snRNP particle and degradation of the U6 snRNA.,Entity: Prp3p. Prp3p is a component of the yeast spliceosomal snRNP and its mutation leads to disassembly of the U4/U6 snRNP particle and degradation of the U6 snRNA.
Prp4p,Prp4p is a component of the yeast spliceosomal snRNP and its mutation leads to disassembly of the U4/U6 snRNP particle and degradation of the U6 snRNA.,Entity: Prp4p. Prp4p is a component of the yeast spliceosomal snRNP and its mutation leads to disassembly of the U4/U6 snRNP particle and degradation of the U6 snRNA.
sad1-1,"sad1-1 is severely impaired in splicing at the restrictive temperature, with RP29 pre-mRNA strongly accumulating and splicing-dependent production of beta-galactosidase from reporter constructs being abolished.","Entity: sad1-1. sad1-1 is severely impaired in splicing at the restrictive temperature, with RP29 pre-mRNA strongly accumulating and splicing-dependent production of beta-galactosidase from reporter constructs being abolished."
Nrg1,Nrg1 is a 25-kDa C2H2 zinc finger protein that acts as a transcriptional repressor by specifically binding to two regions in the upstream activation sequence of the STA1 gene in Saccharomyces cerevisiae.,Entity: Nrg1. Nrg1 is a 25-kDa C2H2 zinc finger protein that acts as a transcriptional repressor by specifically binding to two regions in the upstream activation sequence of the STA1 gene in Saccharomyces cerevisiae.
tup1,Tup1 is a component of the Ssn6-Tup1 complex that interacts with Nrg1 and mediates glucose-dependent repression of gene transcription.,Entity: tup1. Tup1 is a component of the Ssn6-Tup1 complex that interacts with Nrg1 and mediates glucose-dependent repression of gene transcription.
Nrg1,Disruption of the NRG1 gene in Saccharomyces cerevisiae causes a fivefold increase in the level of the STA1 transcript in the presence of glucose.,Entity: Nrg1. Disruption of the NRG1 gene in Saccharomyces cerevisiae causes a fivefold increase in the level of the STA1 transcript in the presence of glucose.
Nrg1,The expression of NRG1 itself is inhibited in the absence of glucose in Saccharomyces cerevisiae.,Entity: Nrg1. The expression of NRG1 itself is inhibited in the absence of glucose in Saccharomyces cerevisiae.
Nrg1,DNA-bound LexA-Nrg1 represses transcription of a target gene 10.7-fold in a glucose-dependent manner in Saccharomyces cerevisiae.,Entity: Nrg1. DNA-bound LexA-Nrg1 represses transcription of a target gene 10.7-fold in a glucose-dependent manner in Saccharomyces cerevisiae.
Nrg1,"Nrg1 interacts with Ssn6 both in vivo and in vitro, as shown by two-hybrid and glutathione S-transferase pull-down experiments.","Entity: Nrg1. Nrg1 interacts with Ssn6 both in vivo and in vitro, as shown by two-hybrid and glutathione S-transferase pull-down experiments."
Nrg1,Nrg1 mediates glucose repression of STA1 gene expression by recruiting the Ssn6-Tup1 complex to DNA.,Entity: Nrg1. Nrg1 mediates glucose repression of STA1 gene expression by recruiting the Ssn6-Tup1 complex to DNA.
ssn6,Ssn6 is a component of the Ssn6-Tup1 complex that interacts with Nrg1 and mediates glucose-dependent repression of gene transcription.,Entity: ssn6. Ssn6 is a component of the Ssn6-Tup1 complex that interacts with Nrg1 and mediates glucose-dependent repression of gene transcription.
forskolin,"Forskolin was used at a concentration of 10 µM to stimulate transfected cells for 72 hours in a culture medium supplemented with 5% calf serum, 3.6 ng/ml cortisol, 5 µg/ml transferrin, 10 ng/ml glycyl-L-histidyl-L-lysine acetate, 10 ng/ml somatostatin, and 1 mU bovine TSH for 72 hours in a luciferase and CAT reporter assay.","Entity: forskolin. SMILES: C=C[C@@]1(C)CC(=O)[C@]2(O)[C@@]3(C)[C@@H](O)CCC(C)(C)[C@@H]3[C@H](O)[C@H](OC(C)=O)[C@@]2(C)O1. Forskolin was used at a concentration of 10 µM to stimulate transfected cells for 72 hours in a culture medium supplemented with 5% calf serum, 3.6 ng/ml cortisol, 5 µg/ml transferrin, 10 ng/ml glycyl-L-histidyl-L-lysine acetate, 10 ng/ml somatostatin, and 1 mU bovine TSH for 72 hours in a luciferase and CAT reporter assay."
somatostatin,Somatostatin was included at a concentration of 10 ng/ml in the culture medium for 72 hours to study its effect on transfected cells in a luciferase and CAT reporter assay.,Entity: somatostatin. SMILES: C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O. Somatostatin was included at a concentration of 10 ng/ml in the culture medium for 72 hours to study its effect on transfected cells in a luciferase and CAT reporter assay.
glycyl-L-histidyl-L-lysine acetate,Glycyl-L-histidyl-L-lysine acetate was used at a concentration of 10 ng/ml in the culture medium for 72 hours to assess its effect on transfected cells in a luciferase and CAT reporter assay.,Entity: glycyl-L-histidyl-L-lysine acetate. SMILES: CC(=O)O.NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CN)C(=O)O. Glycyl-L-histidyl-L-lysine acetate was used at a concentration of 10 ng/ml in the culture medium for 72 hours to assess its effect on transfected cells in a luciferase and CAT reporter assay.
Pax8,"Expression of Pax8 in nonthyroid cells results in transcriptional activation of the Na/I symporter (NIS) upstream enhancer (NUE), indicating a role for Pax8 in enhancer activity.","Entity: Pax8. Expression of Pax8 in nonthyroid cells results in transcriptional activation of the Na/I symporter (NIS) upstream enhancer (NUE), indicating a role for Pax8 in enhancer activity."
protein kinase A,The Na/I symporter (NIS) upstream enhancer (NUE) responds to cAMP through both protein kinase A-dependent and -independent mechanisms.,Entity: protein kinase A. The Na/I symporter (NIS) upstream enhancer (NUE) responds to cAMP through both protein kinase A-dependent and -independent mechanisms.
Pax8,"Pax8 is a thyroid-specific transcription factor that binds to two of the four relevant sites in the Na/I symporter (NIS) upstream enhancer (NUE), and its binding is required for enhancer activity.","Entity: Pax8. Pax8 is a thyroid-specific transcription factor that binds to two of the four relevant sites in the Na/I symporter (NIS) upstream enhancer (NUE), and its binding is required for enhancer activity."
Groucho,Groucho does not form stable associations with other proteins in the nucleus but may assemble into homomultimeric complexes.,Entity: Groucho. Groucho does not form stable associations with other proteins in the nucleus but may assemble into homomultimeric complexes.
Engrailed,"Engrailed contains an En homology region 1 (eh1)/GEH motif, which is likely involved in tethering the Groucho corepressor to the promoter.","Entity: Engrailed. Engrailed contains an En homology region 1 (eh1)/GEH motif, which is likely involved in tethering the Groucho corepressor to the promoter."
Groucho,"Groucho is a corepressor that is recruited to target promoters by short peptide motifs such as WRPW and eh1/GEH, and is required for the function of repressors like Engrailed and Goosecoid.","Entity: Groucho. Groucho is a corepressor that is recruited to target promoters by short peptide motifs such as WRPW and eh1/GEH, and is required for the function of repressors like Engrailed and Goosecoid."
Goosecoid,"Goosecoid is a developmental regulator whose repressor domain (GscR) includes an eh1/GEH-like motif, mediating efficient repression in Drosophila blastoderm embryos that requires Groucho corepressor function.","Entity: Goosecoid. Goosecoid is a developmental regulator whose repressor domain (GscR) includes an eh1/GEH-like motif, mediating efficient repression in Drosophila blastoderm embryos that requires Groucho corepressor function."
Engrailed,Engrailed is a developmental repressor that requires association with the Groucho corepressor for its function.,Entity: Engrailed. Engrailed is a developmental repressor that requires association with the Groucho corepressor for its function.
ionomycin,"Ionomycin is a pharmacological mimic of T-cell receptor activation that induces upregulation of Fas (CD95) expression in Jurkat T-cells, leading to approximately 10-fold increase in fas mRNA within 2 hours.","Entity: ionomycin. SMILES: C[C@H](CCC(=O)O)C[C@H](C)C[C@H](C)C(=O)/C=C(\O)[C@H](C)C[C@H](C)C/C=C/[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](O)C[C@@H]1CC[C@@](C)([C@H]2CC[C@@](C)([C@@H](C)O)O2)O1. Ionomycin is a pharmacological mimic of T-cell receptor activation that induces upregulation of Fas (CD95) expression in Jurkat T-cells, leading to approximately 10-fold increase in fas mRNA within 2 hours."
SWM1,Homozygous swm1Delta diploids can undergo both meiotic divisions but fail to produce mature asci due to defects in spore wall formation.,Entity: SWM1. Homozygous swm1Delta diploids can undergo both meiotic divisions but fail to produce mature asci due to defects in spore wall formation.
SWM1,Deletion of SWM1 specifically affects the expression of mid-late and late sporulation-specific genes in Saccharomyces cerevisiae.,Entity: SWM1. Deletion of SWM1 specifically affects the expression of mid-late and late sporulation-specific genes in Saccharomyces cerevisiae.
SWM1,"SWM1 is expressed at low levels during vegetative growth but is strongly induced under sporulating conditions, with kinetics similar to middle sporulation-specific genes.","Entity: SWM1. SWM1 is expressed at low levels during vegetative growth but is strongly induced under sporulating conditions, with kinetics similar to middle sporulation-specific genes."
SWM1,"Swm1p, the product of the SWM1 gene, is a nuclear protein that participates in a signal transduction pathway distinct from the Sps1p-Smk1p-MAP kinase pathway and is required for coordination of biochemical and morphological events during the last phase of sporulation.","Entity: SWM1. Swm1p, the product of the SWM1 gene, is a nuclear protein that participates in a signal transduction pathway distinct from the Sps1p-Smk1p-MAP kinase pathway and is required for coordination of biochemical and morphological events during the last phase of sporulation."
SMK1,"SMK1 is a putative component of a sporulation-specific MAP kinase cascade in Saccharomyces cerevisiae, and its deletion produces phenotypes similar to swm1Delta mutants.","Entity: SMK1. SMK1 is a putative component of a sporulation-specific MAP kinase cascade in Saccharomyces cerevisiae, and its deletion produces phenotypes similar to swm1Delta mutants."
SPS1,"SPS1 is a putative component of a sporulation-specific MAP kinase cascade in Saccharomyces cerevisiae, and its deletion produces phenotypes similar to swm1Delta mutants.","Entity: SPS1. SPS1 is a putative component of a sporulation-specific MAP kinase cascade in Saccharomyces cerevisiae, and its deletion produces phenotypes similar to swm1Delta mutants."
SWM1,SWM1 is a gene required for the completion of late events in the sporulation program and for the formation of spore-specific walls in Saccharomyces cerevisiae.,Entity: SWM1. SWM1 is a gene required for the completion of late events in the sporulation program and for the formation of spore-specific walls in Saccharomyces cerevisiae.
"2,3,7,8-tetrachlorodibenzo-p-dioxin","2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) treatment increases UDP-glucuronyltransferase activity in intestinal crypt cells by 50% at 10 hours and by 200% at 1 day, while increasing tip cell activity by 20% at 10 hours and by 50% at 1 day after administration.","Entity: 2,3,7,8-tetrachlorodibenzo-p-dioxin. SMILES: Clc1cc2c(cc1Cl)Oc1cc(Cl)c(Cl)cc1O2. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) treatment increases UDP-glucuronyltransferase activity in intestinal crypt cells by 50% at 10 hours and by 200% at 1 day, while increasing tip cell activity by 20% at 10 hours and by 50% at 1 day after administration."
"2,3,7,8-tetrachlorodibenzo-p-dioxin","The ratio of UDP-glucuronyltransferase activity between tip and crypt cells in the intestine decreases from 2.1 at control to 0.9 at 1 day and increases to approximately 1.3 at 3 and 5 days after 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) treatment.","Entity: 2,3,7,8-tetrachlorodibenzo-p-dioxin. SMILES: Clc1cc2c(cc1Cl)Oc1cc(Cl)c(Cl)cc1O2. The ratio of UDP-glucuronyltransferase activity between tip and crypt cells in the intestine decreases from 2.1 at control to 0.9 at 1 day and increases to approximately 1.3 at 3 and 5 days after 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) treatment."
"2,3,7,8-tetrachlorodibenzo-p-dioxin","2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has an oral LD50 value of approximately 100 µg/kg in adult female rats.","Entity: 2,3,7,8-tetrachlorodibenzo-p-dioxin. SMILES: Clc1cc2c(cc1Cl)Oc1cc(Cl)c(Cl)cc1O2. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has an oral LD50 value of approximately 100 µg/kg in adult female rats."
p-nitrophenol,"UDP-glucuronyltransferase catalyzes the glucuronidation of p-nitrophenol in the small intestine, with activity varying by 10-fold between proximal and distal segments in female rats.","Entity: p-nitrophenol. SMILES: O=[N+]([O-])c1ccc(O)cc1. UDP-glucuronyltransferase catalyzes the glucuronidation of p-nitrophenol in the small intestine, with activity varying by 10-fold between proximal and distal segments in female rats."
sodium citrate,"Sodium citrate is used as a component of the assay mixture for acid phosphatase activity measurement, at a concentration of 50 mM and pH 4.8.","Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used as a component of the assay mixture for acid phosphatase activity measurement, at a concentration of 50 mM and pH 4.8."
p-nitrophenylphosphate,p-nitrophenylphosphate is used at 15 mM concentration in the assay mixture for alkaline phosphatase activity measurement.,Entity: p-nitrophenylphosphate. SMILES: O=[N+]([O-])c1ccc(OP(=O)([O-])[O-])cc1. p-nitrophenylphosphate is used at 15 mM concentration in the assay mixture for alkaline phosphatase activity measurement.
NaOH,NaOH is used to adjust the pH to 9.8 in the assay mixture for alkaline phosphatase activity measurement.,Entity: NaOH. SMILES: [Na+].[OH-]. NaOH is used to adjust the pH to 9.8 in the assay mixture for alkaline phosphatase activity measurement.
glycine,Glycine buffer at pH 10.4 is used to stop the reaction in the enzyme assays.,Entity: glycine. SMILES: NCC(=O)O. Glycine buffer at pH 10.4 is used to stop the reaction in the enzyme assays.
MgCl2,MgCl2 is included at 10 mM concentration in the UDP-glucuronyltransferase enzyme assay.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is included at 10 mM concentration in the UDP-glucuronyltransferase enzyme assay.
glucose,Glucose is included at 12.5 µmol/ml in the Krebs-Ringer-bicarbonate buffer for the [3H]thymidine incorporation assay in intact cells.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is included at 12.5 µmol/ml in the Krebs-Ringer-bicarbonate buffer for the [3H]thymidine incorporation assay in intact cells.
trichloroacetic acid,Trichloroacetic acid is used to terminate the reaction in the [3H]thymidine incorporation assay for DNA synthesis in intact cells.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to terminate the reaction in the [3H]thymidine incorporation assay for DNA synthesis in intact cells.
Triton X-100,Triton X-100 is used to treat cells in the UDP-glucuronyltransferase enzyme assay.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used to treat cells in the UDP-glucuronyltransferase enzyme assay.
thymidine,"Thymidine, labeled with 3H (125 µCi/gmol), is incorporated into DNA in intact cells to measure DNA synthesis.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine, labeled with 3H (125 µCi/gmol), is incorporated into DNA in intact cells to measure DNA synthesis."
diethanolamine,Diethanolamine is used at 0.1 M concentration and pH 9.8 in the assay mixture for alkaline phosphatase activity measurement.,Entity: diethanolamine. SMILES: OCCNCCO. Diethanolamine is used at 0.1 M concentration and pH 9.8 in the assay mixture for alkaline phosphatase activity measurement.
HCl,HCl is used to adjust the pH to 9.8 in the assay mixture for alkaline phosphatase activity measurement.,Entity: HCl. SMILES: Cl. HCl is used to adjust the pH to 9.8 in the assay mixture for alkaline phosphatase activity measurement.
phenol,Phenol reagent is used to measure protein content in cell lysates.,Entity: phenol. SMILES: Oc1ccccc1. Phenol reagent is used to measure protein content in cell lysates.
p-nitrophenol,p-nitrophenol is used at 0.9 mM concentration in the UDP-glucuronyltransferase enzyme assay and is measured at 405 nm to quantify product formation.,Entity: p-nitrophenol. SMILES: O=[N+]([O-])c1ccc(O)cc1. p-nitrophenol is used at 0.9 mM concentration in the UDP-glucuronyltransferase enzyme assay and is measured at 405 nm to quantify product formation.
glutaraldehyde,Glutaraldehyde is used as a fixative for preparing cells for electron microscopic analysis.,Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a fixative for preparing cells for electron microscopic analysis.
TCDD,TCDD is a chemical compound used to treat animals for the preparation of cell samples for biochemical analysis.,Entity: TCDD. SMILES: Clc1cc2c(cc1Cl)Oc1cc(Cl)c(Cl)cc1O2. TCDD is a chemical compound used to treat animals for the preparation of cell samples for biochemical analysis.
trypan blue,Trypan blue is used as a dye to assess cell viability by exclusion during cell preparation.,Entity: trypan blue. SMILES: Cc1cc(-c2ccc(N=Nc3c(S(=O)(=O)[O-])cc4cc(S(=O)(=O)[O-])cc(N)c4c3O)c(C)c2)ccc1N=Nc1c(S(=O)(=O)[O-])cc2cc(S(=O)(=O)[O-])cc(N)c2c1O.[Na+].[Na+].[Na+].[Na+]. Trypan blue is used as a dye to assess cell viability by exclusion during cell preparation.
dithiothreitol,Dithiothreitol is used at a concentration of 0.4 mM in isotonic saline at pH 7.4 for washing the intestinal lumen during cell isolation.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used at a concentration of 0.4 mM in isotonic saline at pH 7.4 for washing the intestinal lumen during cell isolation.
formaldehyde,Formaldehyde is used in combination with glutaraldehyde to fix cells for electron microscopic analysis.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used in combination with glutaraldehyde to fix cells for electron microscopic analysis.
Pseudouridine,"Pseudouridine residues are localized in Saccharomyces cerevisiae spliceosomal U small nuclear RNAs (UsnRNAs) at positions involved in intermolecular RNA-RNA or RNA-protein interactions, and their formation is catalyzed by the UsnRNA pseudouridine synthase Pus1p.","Entity: Pseudouridine. SMILES: O=c1[nH]cc([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1. Pseudouridine residues are localized in Saccharomyces cerevisiae spliceosomal U small nuclear RNAs (UsnRNAs) at positions involved in intermolecular RNA-RNA or RNA-protein interactions, and their formation is catalyzed by the UsnRNA pseudouridine synthase Pus1p."
PUS1,"PUS1 is the first UsnRNA pseudouridine synthase characterized, exhibiting dual substrate specificity by catalyzing Psi44 formation in both tRNAs and U2 snRNA.","Entity: PUS1. PUS1 is the first UsnRNA pseudouridine synthase characterized, exhibiting dual substrate specificity by catalyzing Psi44 formation in both tRNAs and U2 snRNA."
PUS1,Loss of Pus1p activity abolishes Psi44 formation in the Saccharomyces cerevisiae U2 snRNA.,Entity: PUS1. Loss of Pus1p activity abolishes Psi44 formation in the Saccharomyces cerevisiae U2 snRNA.
PUS4,PUS4 is a pseudouridine synthase gene in Saccharomyces cerevisiae involved in the modification of UsnRNAs.,Entity: PUS4. PUS4 is a pseudouridine synthase gene in Saccharomyces cerevisiae involved in the modification of UsnRNAs.
PUS3,PUS3 is a pseudouridine synthase gene in Saccharomyces cerevisiae involved in the modification of UsnRNAs.,Entity: PUS3. PUS3 is a pseudouridine synthase gene in Saccharomyces cerevisiae involved in the modification of UsnRNAs.
Cbf5p,"Cbf5p is an rRNA-pseudouridine synthase in Saccharomyces cerevisiae, but its depletion does not affect UsnRNA Psi content, indicating that UsnRNA Psi modification is not dependent on the Cbf5p-snoRNA guided mechanism.","Entity: Cbf5p. Cbf5p is an rRNA-pseudouridine synthase in Saccharomyces cerevisiae, but its depletion does not affect UsnRNA Psi content, indicating that UsnRNA Psi modification is not dependent on the Cbf5p-snoRNA guided mechanism."
PUS2,PUS2 is a pseudouridine synthase gene in Saccharomyces cerevisiae involved in the modification of UsnRNAs.,Entity: PUS2. PUS2 is a pseudouridine synthase gene in Saccharomyces cerevisiae involved in the modification of UsnRNAs.
mog-1,mog-1 mRNA is expressed in both germ line and somatic tissues of Caenorhabditis elegans.,Entity: mog-1. mog-1 mRNA is expressed in both germ line and somatic tissues of Caenorhabditis elegans.
mog-1,mog-1 is required for robust germ line proliferation and for normal growth during development in Caenorhabditis elegans.,Entity: mog-1. mog-1 is required for robust germ line proliferation and for normal growth during development in Caenorhabditis elegans.
mog-1,mog-1 encodes a member of the DEAH-box family of RNA-binding proteins.,Entity: mog-1. mog-1 encodes a member of the DEAH-box family of RNA-binding proteins.
fem-3,"In Caenorhabditis elegans hermaphrodite germ line, fem-3 is repressed posttranscriptionally to arrest spermatogenesis and permit oogenesis.","Entity: fem-3. In Caenorhabditis elegans hermaphrodite germ line, fem-3 is repressed posttranscriptionally to arrest spermatogenesis and permit oogenesis."
mog-1,mog-1 plays a broader role in RNA regulation than previously considered.,Entity: mog-1. mog-1 plays a broader role in RNA regulation than previously considered.
Staufen,Staufen is a protein from Drosophila melanogaster known for its ability to bind double-stranded RNA.,Entity: Staufen. Staufen is a protein from Drosophila melanogaster known for its ability to bind double-stranded RNA.
Stau,"In humans, Stau is encoded by four differentially spliced transcripts that produce two proteins with different N-terminal extremities.","Entity: Stau. In humans, Stau is encoded by four differentially spliced transcripts that produce two proteins with different N-terminal extremities."
Stau,Stau is a double-stranded RNA (dsRNA)-binding protein involved in mRNA transport and localization in Drosophila.,Entity: Stau. Stau is a double-stranded RNA (dsRNA)-binding protein involved in mRNA transport and localization in Drosophila.
Stau,"Immunofluorescent double labeling shows that Stau is localized to the rough endoplasmic reticulum (RER) in mammalian cells, implicating it in mRNA targeting to the RER.","Entity: Stau. Immunofluorescent double labeling shows that Stau is localized to the rough endoplasmic reticulum (RER) in mammalian cells, implicating it in mRNA targeting to the RER."
Stau,"In vitro, human Stau (hStau) and mouse Stau (mStau) bind dsRNA via two full-length dsRNA-binding domains and tubulin via a region similar to the microtubule-binding domain of MAP-1B.","Entity: Stau. In vitro, human Stau (hStau) and mouse Stau (mStau) bind dsRNA via two full-length dsRNA-binding domains and tubulin via a region similar to the microtubule-binding domain of MAP-1B."
Pax,"Pax family transcription factors bind DNA through their paired domain, which contains two helix-turn-helix motifs and a beta-hairpin structure.","Entity: Pax. Pax family transcription factors bind DNA through their paired domain, which contains two helix-turn-helix motifs and a beta-hairpin structure."
Pax,"Pax proteins can recruit Ets proteins to bind DNA, a property conserved across the Pax family.","Entity: Pax. Pax proteins can recruit Ets proteins to bind DNA, a property conserved across the Pax family."
cdk2,"Cyclin E- and cyclin A-cdk2 kinases are activated and hyperphosphorylate pRb and p107 in the uterine epithelium after 17beta-estradiol treatment, and this activation is inhibited by progesterone pretreatment.","Entity: cdk2. Cyclin E- and cyclin A-cdk2 kinases are activated and hyperphosphorylate pRb and p107 in the uterine epithelium after 17beta-estradiol treatment, and this activation is inhibited by progesterone pretreatment."
p107,"In the uterine epithelium, p107 is hyperphosphorylated by cyclin E- and cyclin A-cdk2 kinases following 17beta-estradiol treatment, and this phosphorylation is inhibited by progesterone pretreatment.","Entity: p107. In the uterine epithelium, p107 is hyperphosphorylated by cyclin E- and cyclin A-cdk2 kinases following 17beta-estradiol treatment, and this phosphorylation is inhibited by progesterone pretreatment."
pRb,"pRb is hyperphosphorylated by cyclin E- and cyclin A-cdk2 kinases in the uterine epithelium following 17beta-estradiol treatment, and this hyperphosphorylation is inhibited by progesterone pretreatment.","Entity: pRb. pRb is hyperphosphorylated by cyclin E- and cyclin A-cdk2 kinases in the uterine epithelium following 17beta-estradiol treatment, and this hyperphosphorylation is inhibited by progesterone pretreatment."
Pex14p,Overexpression of Pex14p in humans leads to the decoration of tubular structures and mislocalization of peroxisomal catalase to the cytosol.,Entity: Pex14p. Overexpression of Pex14p in humans leads to the decoration of tubular structures and mislocalization of peroxisomal catalase to the cytosol.
Pex14p,"Homo-oligomerization or interaction of Pex14p with the PTS2-receptor or HsPex13p was not observed, distinguishing it from its yeast counterpart.","Entity: Pex14p. Homo-oligomerization or interaction of Pex14p with the PTS2-receptor or HsPex13p was not observed, distinguishing it from its yeast counterpart."
Pex14p,"Pex14p is a carbonate-resistant peroxisomal membrane protein in humans, with its C terminus exposed to the cytosol and the N terminus inaccessible to exogenously added antibodies or protease, suggesting it may protrude into the peroxisomal lumen.","Entity: Pex14p. Pex14p is a carbonate-resistant peroxisomal membrane protein in humans, with its C terminus exposed to the cytosol and the N terminus inaccessible to exogenously added antibodies or protease, suggesting it may protrude into the peroxisomal lumen."
Pex14p,"Pex14p binds the cytosolic receptor for the peroxisomal targeting signal 1 (PTS1), indicating a role as a membrane receptor in peroxisomal protein import.","Entity: Pex14p. Pex14p binds the cytosolic receptor for the peroxisomal targeting signal 1 (PTS1), indicating a role as a membrane receptor in peroxisomal protein import."
Pex14p,"Pex14p is a central component of the peroxisomal protein import machinery in yeast, serving as a convergence point for PTS1- and PTS2-dependent protein import.","Entity: Pex14p. Pex14p is a central component of the peroxisomal protein import machinery in yeast, serving as a convergence point for PTS1- and PTS2-dependent protein import."
retinal degeneration B protein,The Drosophila retinal degeneration B protein (rdgB) is a protein implicated in the visual transduction pathway in flies and is homologous to the Nir proteins.,Entity: retinal degeneration B protein. The Drosophila retinal degeneration B protein (rdgB) is a protein implicated in the visual transduction pathway in flies and is homologous to the Nir proteins.
Sry,Sry is a gene product essential for gonadal differentiation.,Entity: Sry. Sry is a gene product essential for gonadal differentiation.
WT1,WT1 can activate the Dax-1 promoter and does so via GC-rich binding sites located upstream of the Dax-1 TATA box.,Entity: WT1. WT1 can activate the Dax-1 promoter and does so via GC-rich binding sites located upstream of the Dax-1 TATA box.
WT1,WT1-mediated activation of Dax-1 is inhibited by two WT1-interacting proteins: the product of a Denys-Drash syndrome allele of wt1 and prostate apoptosis response-4 protein.,Entity: WT1. WT1-mediated activation of Dax-1 is inhibited by two WT1-interacting proteins: the product of a Denys-Drash syndrome allele of wt1 and prostate apoptosis response-4 protein.
Dax-1,Dax-1 is a nuclear receptor gene whose expression is regulated by WT1 through GC-rich binding sites upstream of its TATA box.,Entity: Dax-1. Dax-1 is a nuclear receptor gene whose expression is regulated by WT1 through GC-rich binding sites upstream of its TATA box.
WT1,"WT1 is a gene product essential for gonadal differentiation, acting as a transcription factor that regulates the expression of downstream targets such as Dax-1.","Entity: WT1. WT1 is a gene product essential for gonadal differentiation, acting as a transcription factor that regulates the expression of downstream targets such as Dax-1."
Dax-1,The WT1-DAX-1 pathway is an early event in the process of mammalian sex determination.,Entity: Dax-1. The WT1-DAX-1 pathway is an early event in the process of mammalian sex determination.
NFAT2,"NFAT2 is a member of the nuclear factor of activated T cells (NFAT) family of transcription factors involved in the regulation of gene expression, including interleukin-2.","Entity: NFAT2. NFAT2 is a member of the nuclear factor of activated T cells (NFAT) family of transcription factors involved in the regulation of gene expression, including interleukin-2."
ribosomal protein S21,"Ribosomal protein S21 (RpS21) is bound to native 40S ribosomal subunits in a salt-labile association and is absent from polysomes, indicating its role as a translation initiation factor rather than a core ribosomal protein.","Entity: ribosomal protein S21. Ribosomal protein S21 (RpS21) is bound to native 40S ribosomal subunits in a salt-labile association and is absent from polysomes, indicating its role as a translation initiation factor rather than a core ribosomal protein."
P40,"P40 is a ribosomal peripheral protein that interacts strongly with RpS21, and its underexpression enhances imaginal disc overgrowth in rpS21-deficient Drosophila larvae.","Entity: P40. P40 is a ribosomal peripheral protein that interacts strongly with RpS21, and its underexpression enhances imaginal disc overgrowth in rpS21-deficient Drosophila larvae."
D-p38a,D-p38a is one of the two p38 genes present in Drosophila melanogaster.,Entity: D-p38a. D-p38a is one of the two p38 genes present in Drosophila melanogaster.
p38 mitogen-activated protein kinase,p38 mitogen-activated protein kinase is a stress-responsive kinase that can also modulate Dpp signaling in Drosophila melanogaster.,Entity: p38 mitogen-activated protein kinase. p38 mitogen-activated protein kinase is a stress-responsive kinase that can also modulate Dpp signaling in Drosophila melanogaster.
dpp,dpp is a secretory ligand belonging to the transforming growth factor beta superfamily that triggers morphogenetic processes through interaction with the Thick veins (Tkv) receptor.,Entity: dpp. dpp is a secretory ligand belonging to the transforming growth factor beta superfamily that triggers morphogenetic processes through interaction with the Thick veins (Tkv) receptor.
DEF-1,Ectopic expression of DEF-1 in fibroblasts induces differentiation of a significant fraction of cells into adipocytes.,Entity: DEF-1. Ectopic expression of DEF-1 in fibroblasts induces differentiation of a significant fraction of cells into adipocytes.
DEF-1,"DEF-1 mRNA is highly expressed in adipose tissue from obese and diabetes mice compared to wild-type mice, indicating a role in adipogenesis.","Entity: DEF-1. DEF-1 mRNA is highly expressed in adipose tissue from obese and diabetes mice compared to wild-type mice, indicating a role in adipogenesis."
DEF-1,DEF-1 enhances the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA in NIH 3T3 cells.,Entity: DEF-1. DEF-1 enhances the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA in NIH 3T3 cells.
peroxisome proliferator-activated receptor gamma,Peroxisome proliferator-activated receptor gamma (PPARgamma) is a transcription factor whose expression and activity are induced by DEF-1 in fibroblasts.,Entity: peroxisome proliferator-activated receptor gamma. Peroxisome proliferator-activated receptor gamma (PPARgamma) is a transcription factor whose expression and activity are induced by DEF-1 in fibroblasts.
Src,The Src homology 3 (SH3) motif is a structural domain found in numerous signal transduction proteins involved in cellular growth and differentiation.,Entity: Src. The Src homology 3 (SH3) motif is a structural domain found in numerous signal transduction proteins involved in cellular growth and differentiation.
DEF-1,DEF-1 is a protein purified from bovine brain that contains a Src homology 3 (SH3) motif and is involved in signal transduction related to cellular growth and differentiation.,Entity: DEF-1. DEF-1 is a protein purified from bovine brain that contains a Src homology 3 (SH3) motif and is involved in signal transduction related to cellular growth and differentiation.
DEF-1,"DEF-1 mRNA is detected in multiple tissues, suggesting its involvement in signal transduction pathways beyond adipogenesis.","Entity: DEF-1. DEF-1 mRNA is detected in multiple tissues, suggesting its involvement in signal transduction pathways beyond adipogenesis."
Sin3,Sin3 proteins are a family of proteins known for their interaction with histone deacetylases and their role in the histone acetylation process.,Entity: Sin3. Sin3 proteins are a family of proteins known for their interaction with histone deacetylases and their role in the histone acetylation process.
pst1,Pst1 is a host gene in Schizosaccharomyces pombe that is essential for the transposition of the Tf1 retrotransposon and shows high sequence homology to the Sin3 family of proteins.,Entity: pst1. Pst1 is a host gene in Schizosaccharomyces pombe that is essential for the transposition of the Tf1 retrotransposon and shows high sequence homology to the Sin3 family of proteins.
XPA,"XPA is a protein required for nucleotide excision repair (NER), and XPA-deficient mice do not show the growth failure and premature death observed in xpg-deficient mice.","Entity: XPA. XPA is a protein required for nucleotide excision repair (NER), and XPA-deficient mice do not show the growth failure and premature death observed in xpg-deficient mice."
xpg,"In xpg-deficient mice, the XPG protein performs an additional function beyond NER, as these mice exhibit postnatal growth failure and premature death.","Entity: xpg. In xpg-deficient mice, the XPG protein performs an additional function beyond NER, as these mice exhibit postnatal growth failure and premature death."
xpg,"xpg is the mouse gene encoding the XPG protein, which is a structure-specific DNA endonuclease involved in nucleotide excision repair (NER).","Entity: xpg. xpg is the mouse gene encoding the XPG protein, which is a structure-specific DNA endonuclease involved in nucleotide excision repair (NER)."
NMD3,NMD3 is an essential gene required for stable 60S ribosomal subunits.,Entity: NMD3. NMD3 is an essential gene required for stable 60S ribosomal subunits.
Nmd3p,"Nmd3p contains an amino-terminal domain with four repeats of Cx2C, which are reminiscent of zinc-binding proteins involved in nucleic acid binding or protein oligomerization.","Entity: Nmd3p. Nmd3p contains an amino-terminal domain with four repeats of Cx2C, which are reminiscent of zinc-binding proteins involved in nucleic acid binding or protein oligomerization."
NMD3,"A mutation in NMD3 is lethal in the absence of XRN1, indicating its requirement for efficient mRNA turnover.","Entity: NMD3. A mutation in NMD3 is lethal in the absence of XRN1, indicating its requirement for efficient mRNA turnover."
XRN1,XRN1 encodes the major cytoplasmic exoribonuclease responsible for mRNA turnover.,Entity: XRN1. XRN1 encodes the major cytoplasmic exoribonuclease responsible for mRNA turnover.
Nmd3p,Nmd3p is a cytoplasmic protein required for a late cytoplasmic assembly step of the 60S ribosomal subunit but is not a ribosomal protein.,Entity: Nmd3p. Nmd3p is a cytoplasmic protein required for a late cytoplasmic assembly step of the 60S ribosomal subunit but is not a ribosomal protein.
sit4,"sit4 mutants in yeast have improved cell growth and increased expression of G1 cyclins when high-copy-number HAL3/SIS2 is expressed, due to the negative regulation of Ppz1.","Entity: sit4. sit4 mutants in yeast have improved cell growth and increased expression of G1 cyclins when high-copy-number HAL3/SIS2 is expressed, due to the negative regulation of Ppz1."
Cln2,"Cln2 is a G1 cyclin whose expression is delayed in yeast cells overexpressing Ppz1, indicating a role for Ppz1 in regulating the G1 to S phase transition.","Entity: Cln2. Cln2 is a G1 cyclin whose expression is delayed in yeast cells overexpressing Ppz1, indicating a role for Ppz1 in regulating the G1 to S phase transition."
cln3,"cln3 mutants in yeast exhibit a synthetic lethal phenotype with sit4 mutants, which is rescued by mutation of PPZ1.","Entity: cln3. cln3 mutants in yeast exhibit a synthetic lethal phenotype with sit4 mutants, which is rescued by mutation of PPZ1."
SIS2,"SIS2 encodes a negative regulator of the Ser/Thr protein phosphatase Ppz1, and its overexpression rescues the growth defect caused by Ppz1 overexpression in yeast.","Entity: SIS2. SIS2 encodes a negative regulator of the Ser/Thr protein phosphatase Ppz1, and its overexpression rescues the growth defect caused by Ppz1 overexpression in yeast."
Clb5,"Clb5 is a G1 cyclin whose expression is delayed in yeast cells overexpressing Ppz1, reflecting the effect of Ppz1 on the G1 to S phase transition.","Entity: Clb5. Clb5 is a G1 cyclin whose expression is delayed in yeast cells overexpressing Ppz1, reflecting the effect of Ppz1 on the G1 to S phase transition."
Ppz1,"Ppz1 is a Ser/Thr protein phosphatase that acts as a negative regulator of the G1/S transition in yeast, with its activity modulated by HAL3/SIS2 and its function opposed to that of Sit4.","Entity: Ppz1. Ppz1 is a Ser/Thr protein phosphatase that acts as a negative regulator of the G1/S transition in yeast, with its activity modulated by HAL3/SIS2 and its function opposed to that of Sit4."
Stat1,Tyrosine phosphorylation of Stat1 is markedly elevated in Shp-2(-/-) mouse fibroblast cells upon IFN-gamma treatment and to a lesser extent upon IFN-alpha stimulation.,Entity: Stat1. Tyrosine phosphorylation of Stat1 is markedly elevated in Shp-2(-/-) mouse fibroblast cells upon IFN-gamma treatment and to a lesser extent upon IFN-alpha stimulation.
Ste6,"Ste6 is a transporter responsible for a-factor (the yeast a-factor mating peptide) transport, and is normally expressed only in MATa haploid cells.","Entity: Ste6. Ste6 is a transporter responsible for a-factor (the yeast a-factor mating peptide) transport, and is normally expressed only in MATa haploid cells."
Ste6,"Ste6 can transport a-factor from both MATalpha haploid and MATa/alpha diploid yeast cells, indicating that no MATa-specific function is required for its transport activity.","Entity: Ste6. Ste6 can transport a-factor from both MATalpha haploid and MATa/alpha diploid yeast cells, indicating that no MATa-specific function is required for its transport activity."
cytochrome b,"Cytochrome b is a gene located in the mitochondrial genome of Trichophyton rubrum, as identified in a 9761 nt-long mitochondrial genome sequence.","Entity: cytochrome b. Cytochrome b is a gene located in the mitochondrial genome of Trichophyton rubrum, as identified in a 9761 nt-long mitochondrial genome sequence."
pectate lyase,Pectate lyase (PL1) is an enzyme produced by Fusarium oxysporum f.sp. lycopersici and is involved in the degradation of pectate.,Entity: pectate lyase. Pectate lyase (PL1) is an enzyme produced by Fusarium oxysporum f.sp. lycopersici and is involved in the degradation of pectate.
HIS5,"The HIS5 gene from Saccharomyces cerevisiae complements histidine auxotrophy in Candida oleophila, indicating functional conservation of histidine biosynthesis pathways between the two species.","Entity: HIS5. The HIS5 gene from Saccharomyces cerevisiae complements histidine auxotrophy in Candida oleophila, indicating functional conservation of histidine biosynthesis pathways between the two species."
BMP-2,BMP-2 induces ventral mesoderm concomitantly with the differentiation of erythrocytes and leukocytes in Xenopus blastula explants.,Entity: BMP-2. BMP-2 induces ventral mesoderm concomitantly with the differentiation of erythrocytes and leukocytes in Xenopus blastula explants.
BMP-4,BMP-4 antagonizes the leukopoietic effect of basic fibroblast growth factor (bFGF) in Xenopus blastula explants.,Entity: BMP-4. BMP-4 antagonizes the leukopoietic effect of basic fibroblast growth factor (bFGF) in Xenopus blastula explants.
basic fibroblast growth factor,A combination of basic fibroblast growth factor (bFGF) and activin A induces differentiation of muscle with few blood cells in Xenopus blastula explants.,Entity: basic fibroblast growth factor. A combination of basic fibroblast growth factor (bFGF) and activin A induces differentiation of muscle with few blood cells in Xenopus blastula explants.
basic fibroblast growth factor,The leukopoietic effect of basic fibroblast growth factor (bFGF) is antagonized by BMP-4 in Xenopus blastula explants.,Entity: basic fibroblast growth factor. The leukopoietic effect of basic fibroblast growth factor (bFGF) is antagonized by BMP-4 in Xenopus blastula explants.
basic fibroblast growth factor,Basic fibroblast growth factor (bFGF) induces the formation of ventral mesoderm and blood-like cells with infrequent leukocytes and rare erythrocytes in Xenopus blastula explants.,Entity: basic fibroblast growth factor. Basic fibroblast growth factor (bFGF) induces the formation of ventral mesoderm and blood-like cells with infrequent leukocytes and rare erythrocytes in Xenopus blastula explants.
BMP-4,"BMP-4 induces primitive erythrocytes and leukocytes in Xenopus blastula explants, but requires high concentrations for these cells to differentiate in only a small proportion of explants.","Entity: BMP-4. BMP-4 induces primitive erythrocytes and leukocytes in Xenopus blastula explants, but requires high concentrations for these cells to differentiate in only a small proportion of explants."
BMP-2,"BMP-2, when combined with activin A, synergistically increases the numbers of both leukocytes and erythrocytes in Xenopus blastula explants.","Entity: BMP-2. BMP-2, when combined with activin A, synergistically increases the numbers of both leukocytes and erythrocytes in Xenopus blastula explants."
basic fibroblast growth factor,Basic fibroblast growth factor (bFGF) synergizes with BMP-2 to induce numerous leukocytes and fewer erythrocytes in Xenopus blastula explants.,Entity: basic fibroblast growth factor. Basic fibroblast growth factor (bFGF) synergizes with BMP-2 to induce numerous leukocytes and fewer erythrocytes in Xenopus blastula explants.
BMP-4,"BMP-4, when combined with activin A, synergistically increases the numbers of both leukocytes and erythrocytes in Xenopus blastula explants.","Entity: BMP-4. BMP-4, when combined with activin A, synergistically increases the numbers of both leukocytes and erythrocytes in Xenopus blastula explants."
BMP-2,"BMP-2 induces primitive erythrocytes, leukocytes, and ventral mesoderm in Xenopus blastula explants, but requires high concentrations for these cells to differentiate in only a small proportion of explants.","Entity: BMP-2. BMP-2 induces primitive erythrocytes, leukocytes, and ventral mesoderm in Xenopus blastula explants, but requires high concentrations for these cells to differentiate in only a small proportion of explants."
teashirt,"In Drosophila melanogaster, teashirt is a homeotic gene whose expression is restricted to the anterior compartment of the embryo, whereas in Thermobia domestica, teashirt homologue shows greater variability, as it is not expressed strongly in the Thermobia abdomen.","Entity: teashirt. In Drosophila melanogaster, teashirt is a homeotic gene whose expression is restricted to the anterior compartment of the embryo, whereas in Thermobia domestica, teashirt homologue shows greater variability, as it is not expressed strongly in the Thermobia abdomen."
formamide,"Formamide is used as a component of the washing buffer (50% formamide, 2× SSC, 100 mM DTT) for in situ hybridisation sections at 45°C to enhance stringency in ASISH protocols.","Entity: formamide. SMILES: NC=O. Formamide is used as a component of the washing buffer (50% formamide, 2× SSC, 100 mM DTT) for in situ hybridisation sections at 45°C to enhance stringency in ASISH protocols."
sodium citrate,"Sodium citrate is used in the washing buffer (50% formamide, 2× SSC, 100 mM DTT) for in situ hybridisation sections at 45°C to improve stringency in ASISH analysis.","Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used in the washing buffer (50% formamide, 2× SSC, 100 mM DTT) for in situ hybridisation sections at 45°C to improve stringency in ASISH analysis."
dithiothreitol,"Dithiothreitol (DTT) is included at 100 mM in the washing buffer (50% formamide, 2× SSC, 100 mM DTT) for in situ hybridisation sections at 45°C to enhance stringency in ASISH protocols.","Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol (DTT) is included at 100 mM in the washing buffer (50% formamide, 2× SSC, 100 mM DTT) for in situ hybridisation sections at 45°C to enhance stringency in ASISH protocols."
SDS,"SDS (sodium dodecyl sulfate) is used as a detergent in hybridization and washing buffers for Northern blot hybridization, such as in 0.1% and 0.5% concentrations during the hybridization and washing steps.","Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS (sodium dodecyl sulfate) is used as a detergent in hybridization and washing buffers for Northern blot hybridization, such as in 0.1% and 0.5% concentrations during the hybridization and washing steps."
formaldehyde,Formaldehyde is used to prepare agarose gels for electrophoretic separation of RNA samples in Northern blot hybridization protocols.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used to prepare agarose gels for electrophoretic separation of RNA samples in Northern blot hybridization protocols.
formamide,"Formamide is used as a denaturing agent in hybridization buffers for Northern blot hybridization, as in the example where 50% formamide was used in the hybridization solution.","Entity: formamide. SMILES: NC=O. Formamide is used as a denaturing agent in hybridization buffers for Northern blot hybridization, as in the example where 50% formamide was used in the hybridization solution."
Cnil,"Cnil is a mouse cornichon gene homolog that maps to mouse chromosome 14 and encodes an open reading frame of 144 amino acids, which is 93% homologous (68% identical) to the Drosophila cornichon protein.","Entity: Cnil. Cnil is a mouse cornichon gene homolog that maps to mouse chromosome 14 and encodes an open reading frame of 144 amino acids, which is 93% homologous (68% identical) to the Drosophila cornichon protein."
Cnil,"Cnil mRNA is only detectable after activation of the embryonic genome at the eight-cell stage in mice, indicating its role in embryonic development.","Entity: Cnil. Cnil mRNA is only detectable after activation of the embryonic genome at the eight-cell stage in mice, indicating its role in embryonic development."
cornichon,"Cornichon is a multigene family in the mouse, with at least three homologous genes: Cnih, Cnil, and additional loci possibly representing pseudogenes.","Entity: cornichon. Cornichon is a multigene family in the mouse, with at least three homologous genes: Cnih, Cnil, and additional loci possibly representing pseudogenes."
cornichon,"In Drosophila, cornichon genes are involved in the establishment of both anterior-posterior and dorso-ventral polarity via the epidermal growth factor (EGF)-receptor signaling pathway.","Entity: cornichon. In Drosophila, cornichon genes are involved in the establishment of both anterior-posterior and dorso-ventral polarity via the epidermal growth factor (EGF)-receptor signaling pathway."
epidermal growth factor (EGF)-receptor,"The EGF-receptor signaling pathway is involved in the establishment of anterior-posterior and dorso-ventral polarity in Drosophila, mediated by cornichon genes.","Entity: epidermal growth factor (EGF)-receptor. The EGF-receptor signaling pathway is involved in the establishment of anterior-posterior and dorso-ventral polarity in Drosophila, mediated by cornichon genes."
Triton X-100,Triton X-100 is used as a detergent in phosphate buffered saline (PBT) at 0.1% concentration for permeabilizing biological tissues during in situ hybridization procedures.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used as a detergent in phosphate buffered saline (PBT) at 0.1% concentration for permeabilizing biological tissues during in situ hybridization procedures.
hydrogen peroxide,Hydrogen peroxide at 1% (v/v) is used to bleach embryos for overnight treatment during in situ hybridization to facilitate probe hybridization.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide at 1% (v/v) is used to bleach embryos for overnight treatment during in situ hybridization to facilitate probe hybridization.
sodium phosphate,Sodium phosphate is used as a buffer component at 0.1 M concentration and pH 7.4 in both phosphate buffered saline (PBT) and osmium fixation solutions for in situ hybridization and tissue embedding.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used as a buffer component at 0.1 M concentration and pH 7.4 in both phosphate buffered saline (PBT) and osmium fixation solutions for in situ hybridization and tissue embedding.
osmium tetroxide,Osmium tetroxide at 1% (w/v) in phosphate buffer on ice in the dark is used for post-fixation of embryos to preserve tissue structure during in situ hybridization.,Entity: osmium tetroxide. SMILES: O=[Os](=O)(=O)=O. Osmium tetroxide at 1% (w/v) in phosphate buffer on ice in the dark is used for post-fixation of embryos to preserve tissue structure during in situ hybridization.
Xbagpipe,Xbagpipe (Xbap) is a bagpipe-related gene described in Xenopus.,Entity: Xbagpipe. Xbagpipe (Xbap) is a bagpipe-related gene described in Xenopus.
zampogna,"In Xenopus, zampogna (zax) is a bagpipe-related gene homologue that is transcribed in the muscular layer of the forming midgut and in the embryonic head, where it marks the pharyngeal endoderm and future infrarostral cartilage.","Entity: zampogna. In Xenopus, zampogna (zax) is a bagpipe-related gene homologue that is transcribed in the muscular layer of the forming midgut and in the embryonic head, where it marks the pharyngeal endoderm and future infrarostral cartilage."
bagpipe,"In Drosophila, the bagpipe homeobox gene is expressed in a subset of dorsal mesodermal cells, and its absence disrupts the development of the visceral musculature.","Entity: bagpipe. In Drosophila, the bagpipe homeobox gene is expressed in a subset of dorsal mesodermal cells, and its absence disrupts the development of the visceral musculature."
methyl salicylate,Methyl salicylate is used as an immersion medium in histological preparation to achieve good transparency for optical confocal sectioning of tissue samples.,Entity: methyl salicylate. SMILES: COC(=O)c1ccccc1O. Methyl salicylate is used as an immersion medium in histological preparation to achieve good transparency for optical confocal sectioning of tissue samples.
potassium chloride,Potassium chloride is a component of phosphate-buffered saline (PBS) used for rinsing brain tissue during histological preparation.,Entity: potassium chloride. SMILES: [Cl-].[K+]. Potassium chloride is a component of phosphate-buffered saline (PBS) used for rinsing brain tissue during histological preparation.
sodium chloride,Sodium chloride is a component of phosphate-buffered saline (PBS) used for rinsing brain tissue during histological preparation.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is a component of phosphate-buffered saline (PBS) used for rinsing brain tissue during histological preparation.
methyl salicylate,Methyl salicylate is used as a mounting medium for whole-mount brain preparations in microscopy.,Entity: methyl salicylate. SMILES: COC(=O)c1ccccc1O. Methyl salicylate is used as a mounting medium for whole-mount brain preparations in microscopy.
Triton X-100,Triton X-100 is a non-ionic detergent used at 0.1% concentration in PBS for rinsing and incubating brain tissue during histological staining procedures.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent used at 0.1% concentration in PBS for rinsing and incubating brain tissue during histological staining procedures.
xylol,Xylol is used as a 5-minute fixative in the dehydration process of brain tissue preparation for microscopy.,Entity: xylol. SMILES: Cc1ccccc1C. Xylol is used as a 5-minute fixative in the dehydration process of brain tissue preparation for microscopy.
ethanol,"Ethanol is used in a series of concentrations (50%, 70%, 90%, 99%, 100%) for 10-minute washes during the dehydration of brain tissue for microscopy.","Entity: ethanol. SMILES: CCO. Ethanol is used in a series of concentrations (50%, 70%, 90%, 99%, 100%) for 10-minute washes during the dehydration of brain tissue for microscopy."
disodium phosphate,Disodium phosphate is a component of phosphate-buffered saline (PBS) used for rinsing brain tissue during histological preparation.,Entity: disodium phosphate. SMILES: O=P([O-])([O-])O.[Na+].[Na+]. Disodium phosphate is a component of phosphate-buffered saline (PBS) used for rinsing brain tissue during histological preparation.
calcium,"Intestinal absorption of calcium decreases with age, and deficiency in calcium absorption has been suggested as a factor in some patients with osteoporosis.","Entity: calcium. SMILES: [Ca]. Intestinal absorption of calcium decreases with age, and deficiency in calcium absorption has been suggested as a factor in some patients with osteoporosis."
potassium,"Diuretics can affect potassium metabolism, which may contribute to their physiological effects.","Entity: potassium. SMILES: [K]. Diuretics can affect potassium metabolism, which may contribute to their physiological effects."
phosphate,"Diuretics can affect phosphate metabolism, which may contribute to their physiological effects.","Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Diuretics can affect phosphate metabolism, which may contribute to their physiological effects."
frusemide,"Frusemide at a dose of 80 mg by mouth increases urinary calcium excretion, likely due to decreased tubular absorption.","Entity: frusemide. SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl. Frusemide at a dose of 80 mg by mouth increases urinary calcium excretion, likely due to decreased tubular absorption."
potassium,"Long-term administration of bendrofluazide can cause hypophosphataemia and low potassium levels, leading to renal tubular defects and impaired phosphate absorption.","Entity: potassium. SMILES: [K]. Long-term administration of bendrofluazide can cause hypophosphataemia and low potassium levels, leading to renal tubular defects and impaired phosphate absorption."
phosphate,Long-term administration of bendrofluazide can impair phosphate absorption by causing hypophosphataemia and renal tubular defects.,Entity: phosphate. SMILES: O=P([O-])([O-])[O-]. Long-term administration of bendrofluazide can impair phosphate absorption by causing hypophosphataemia and renal tubular defects.
calcium,Urinary calcium excretion increases following administration of 80 mg frusemide by mouth.,Entity: calcium. SMILES: [Ca]. Urinary calcium excretion increases following administration of 80 mg frusemide by mouth.
Triton X-100,Triton X-100 is a non-ionic detergent used at 0.01% concentration in blocking and working buffers to permeabilize tissue sections for immunohistochemistry.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent used at 0.01% concentration in blocking and working buffers to permeabilize tissue sections for immunohistochemistry.
diaminobenzidine,"Diaminobenzidine (DAB) is a chromogenic substrate used at 0.05% in TBS with 0.01% hydrogen peroxide for immunohistochemical detection, producing a brown precipitate upon reaction with peroxidase.","Entity: diaminobenzidine. SMILES: NNc1ccc(-c2ccc(NN)cc2)cc1. Diaminobenzidine (DAB) is a chromogenic substrate used at 0.05% in TBS with 0.01% hydrogen peroxide for immunohistochemical detection, producing a brown precipitate upon reaction with peroxidase."
hydrogen peroxide,Hydrogen peroxide is used at 0.01% in the DAB staining solution to react with peroxidase and produce a colorimetric product in immunohistochemistry.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide is used at 0.01% in the DAB staining solution to react with peroxidase and produce a colorimetric product in immunohistochemistry.
xylene,Xylene is used to clear dehydrated tissue sections prior to coverslipping in the mounting procedure for microscopy.,Entity: xylene. SMILES: Cc1ccccc1C. Xylene is used to clear dehydrated tissue sections prior to coverslipping in the mounting procedure for microscopy.
ethanol,Ethanol is used in a graded series to dehydrate tissue sections during the preparation for microscopy.,Entity: ethanol. SMILES: CCO. Ethanol is used in a graded series to dehydrate tissue sections during the preparation for microscopy.
sodium orthovanadate,Sodium orthovanadate is used at a concentration of 0.1 mM in all buffers during synaptosome preparation from brain tissue.,Entity: sodium orthovanadate. SMILES: O=[V]([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium orthovanadate is used at a concentration of 0.1 mM in all buffers during synaptosome preparation from brain tissue.
sucrose,"Sucrose is used in 0.85M, 1.0M, and 1.2M concentrations for density gradient centrifugation to isolate synaptosomes from brain tissue homogenates.","Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used in 0.85M, 1.0M, and 1.2M concentrations for density gradient centrifugation to isolate synaptosomes from brain tissue homogenates."
NBD-ceramide,NBD-ceramide is used as a marker for the trans-Golgi network in living cells.,Entity: NBD-ceramide. SMILES: CCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](CO)NC(=O)CCCCCNc1ccc([N+](=O)[O-])c2nonc12. NBD-ceramide is used as a marker for the trans-Golgi network in living cells.
α-bungarotoxin,α-bungarotoxin is a fluorescently labeled toxin that can be conjugated to rhodamine for use in fluorescence microscopy or flow cytometry.,Entity: α-bungarotoxin. SMILES: C=C(C=O)C[C@H]1C[C@H](O)[C@]2(C)O[C@@H]3C[C@@H]4O[C@@H]5C[C@]6(C)O[C@]7(C)CC[C@@H]8O[C@@H]9C[C@]%10(C)O[C@@H]%11C(C)=CC(=O)O[C@H]%11C[C@H]%10O[C@H]9C[C@@H](C)[C@H]8O[C@H]7C[C@H]6O[C@@]5(C)C/C=C\[C@H]4O[C@H]3C[C@H]2O1. α-bungarotoxin is a fluorescently labeled toxin that can be conjugated to rhodamine for use in fluorescence microscopy or flow cytometry.
α-bungarotoxin,α-bungarotoxin can be conjugated to tetramethylrhodamine for use as a fluorescent label in double-labeling experiments at the neuromuscular junction.,Entity: α-bungarotoxin. SMILES: C=C(C=O)C[C@H]1C[C@H](O)[C@]2(C)O[C@@H]3C[C@@H]4O[C@@H]5C[C@]6(C)O[C@]7(C)CC[C@@H]8O[C@@H]9C[C@]%10(C)O[C@@H]%11C(C)=CC(=O)O[C@H]%11C[C@H]%10O[C@H]9C[C@@H](C)[C@H]8O[C@H]7C[C@H]6O[C@@]5(C)C/C=C\[C@H]4O[C@H]3C[C@H]2O1. α-bungarotoxin can be conjugated to tetramethylrhodamine for use as a fluorescent label in double-labeling experiments at the neuromuscular junction.
fluorescein,Fluorescein can be conjugated to antibodies to create fluorescent secondary antibodies for double-labeling experiments in immunofluorescence.,Entity: fluorescein. SMILES: O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21. Fluorescein can be conjugated to antibodies to create fluorescent secondary antibodies for double-labeling experiments in immunofluorescence.
tetramethylrhodamine,Tetramethylrhodamine is used as a fluorescent label for α-bungarotoxin in double-labeling protocols at the neuromuscular junction.,Entity: tetramethylrhodamine. SMILES: CN(C)c1ccc2c(-c3ccccc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1. Tetramethylrhodamine is used as a fluorescent label for α-bungarotoxin in double-labeling protocols at the neuromuscular junction.
Triton,Triton is a non-ionic detergent that can be included at 0.01–0.1% concentration in PBS to permeabilize tissue sections for immunohistochemistry.,Entity: Triton. SMILES: [3H+]. Triton is a non-ionic detergent that can be included at 0.01–0.1% concentration in PBS to permeabilize tissue sections for immunohistochemistry.
NCS-1,"The widespread distribution of NCS-1 suggests activity in various calcium-dependent neuronal functions, while its localization to the Golgi apparatus and neurofilament-rich structures indicates specialized roles in calcium-regulated protein trafficking and cytoskeletal interactions.","Entity: NCS-1. The widespread distribution of NCS-1 suggests activity in various calcium-dependent neuronal functions, while its localization to the Golgi apparatus and neurofilament-rich structures indicates specialized roles in calcium-regulated protein trafficking and cytoskeletal interactions."
NCS-1,"NCS-1 is localized to neuronal cell bodies and axons throughout the rat brain and spinal cord, but not to glial cells.","Entity: NCS-1. NCS-1 is localized to neuronal cell bodies and axons throughout the rat brain and spinal cord, but not to glial cells."
NCS-1,"NCS-1 is most abundantly present in the perikarya, associated with the membranes of the trans saccules of the Golgi apparatus.","Entity: NCS-1. NCS-1 is most abundantly present in the perikarya, associated with the membranes of the trans saccules of the Golgi apparatus."
NCS-1,NCS-1 is a member of a highly conserved neuron-specific family of calcium-binding proteins that also includes frequenin and recoverin.,Entity: NCS-1. NCS-1 is a member of a highly conserved neuron-specific family of calcium-binding proteins that also includes frequenin and recoverin.
NCS-1,"NCS-1 shows the most intense labeling in myelinated axons, axonal ramifications of the basket cell in the cerebellar cortex, and large neurons in the brainstem and pons.","Entity: NCS-1. NCS-1 shows the most intense labeling in myelinated axons, axonal ramifications of the basket cell in the cerebellar cortex, and large neurons in the brainstem and pons."
picric acid,Picric acid is used at 0.2% concentration in 0.1 M phosphate buffer (pH 7.4) as a component of the perfusion fixative solution for tissue perfusion during immunohistochemical procedures.,Entity: picric acid. SMILES: O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1. Picric acid is used at 0.2% concentration in 0.1 M phosphate buffer (pH 7.4) as a component of the perfusion fixative solution for tissue perfusion during immunohistochemical procedures.
phenoxyethanol,Phenoxyethanol is used at 0.04% (v/v) concentration to anesthetize fish prior to tissue perfusion in immunohistochemical procedures.,Entity: phenoxyethanol. SMILES: CC(O)Oc1ccccc1. Phenoxyethanol is used at 0.04% (v/v) concentration to anesthetize fish prior to tissue perfusion in immunohistochemical procedures.
glycerol,Glycerol is used in a 1:1 mixture with phosphate buffer (PB) to mount tissue sections for examination under a microscope in immunohistochemistry.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is used in a 1:1 mixture with phosphate buffer (PB) to mount tissue sections for examination under a microscope in immunohistochemistry.
water,Distilled water is used to stop the peroxidase reaction after immunohistochemical staining by being added to the tissue sections.,Entity: water. SMILES: O. Distilled water is used to stop the peroxidase reaction after immunohistochemical staining by being added to the tissue sections.
4-chloro-1-naphthol,4-chloro-1-naphthol is used at 48 mg/100 ml in 0.05 M TRIS buffer containing 0.02% perhydrol as a substrate for peroxidase-conjugated secondary antibodies in immunohistochemical visualization.,Entity: 4-chloro-1-naphthol. SMILES: Oc1ccc(Cl)c2ccccc12. 4-chloro-1-naphthol is used at 48 mg/100 ml in 0.05 M TRIS buffer containing 0.02% perhydrol as a substrate for peroxidase-conjugated secondary antibodies in immunohistochemical visualization.
Triton X-100,Triton X-100 is used at 0.2% concentration in 0.1 M veronal buffer (pH 7.6) as a detergent to permeabilize tissue sections during immunohistochemical procedures.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used at 0.2% concentration in 0.1 M veronal buffer (pH 7.6) as a detergent to permeabilize tissue sections during immunohistochemical procedures.
sucrose,Sucrose is used at 15% concentration in phosphate buffer (PB; pH 7.4) as a component of the tissue perfusion and incubation solution for immunohistochemical procedures.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used at 15% concentration in phosphate buffer (PB; pH 7.4) as a component of the tissue perfusion and incubation solution for immunohistochemical procedures.
sodium chloride,Sodium chloride is used at 0.65% concentration in perfusion buffer for tissue perfusion during immunohistochemical procedures.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at 0.65% concentration in perfusion buffer for tissue perfusion during immunohistochemical procedures.
hydrogen peroxide,Hydrogen peroxide is used at 30% concentration in 0.05 M TRIS buffer as a substrate for peroxidase-conjugated secondary antibodies in immunohistochemical visualization.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide is used at 30% concentration in 0.05 M TRIS buffer as a substrate for peroxidase-conjugated secondary antibodies in immunohistochemical visualization.
water,Water is used as a component of the mobile phase (in a 12:87.9:0.1 v/v/v mixture with acetonitrile and trifluoroacetic acid) for reversed-phase HPLC analysis of tissue extracts.,Entity: water. SMILES: O. Water is used as a component of the mobile phase (in a 12:87.9:0.1 v/v/v mixture with acetonitrile and trifluoroacetic acid) for reversed-phase HPLC analysis of tissue extracts.
trifluoroacetic acid,Trifluoroacetic acid is included at 0.1% (v/v) in the mobile phase for reversed-phase HPLC separation of peptides from tissue extracts.,Entity: trifluoroacetic acid. SMILES: O=C(O)C(F)(F)F. Trifluoroacetic acid is included at 0.1% (v/v) in the mobile phase for reversed-phase HPLC separation of peptides from tissue extracts.
acetonitrile,"Acetonitrile is used at 12%, 28%, and 80% concentrations over time as the mobile phase in a gradient for reversed-phase HPLC analysis of tissue extracts.","Entity: acetonitrile. SMILES: CC#N. Acetonitrile is used at 12%, 28%, and 80% concentrations over time as the mobile phase in a gradient for reversed-phase HPLC analysis of tissue extracts."
acetonitrile,Acetonitrile is used as an elution solvent (in a 60:39.96:0.04 vol/vol mixture with water and trifluoroacetic acid) to recover bound peptide material from Sep-Pak C 18 cartridges.,Entity: acetonitrile. SMILES: CC#N. Acetonitrile is used as an elution solvent (in a 60:39.96:0.04 vol/vol mixture with water and trifluoroacetic acid) to recover bound peptide material from Sep-Pak C 18 cartridges.
trifluoroacetic acid,Trifluoroacetic acid is used as a component of the elution solvent (in a 60:39.96:0.04 vol/vol mixture with acetonitrile and water) for recovering bound peptide material from Sep-Pak C 18 cartridges.,Entity: trifluoroacetic acid. SMILES: O=C(O)C(F)(F)F. Trifluoroacetic acid is used as a component of the elution solvent (in a 60:39.96:0.04 vol/vol mixture with acetonitrile and water) for recovering bound peptide material from Sep-Pak C 18 cartridges.
acetic acid,Acetic acid (2 N) is used to boil tissue samples for 10 minutes to inactivate proteolytic enzymes during tissue extraction.,Entity: acetic acid. SMILES: CC(=O)O. Acetic acid (2 N) is used to boil tissue samples for 10 minutes to inactivate proteolytic enzymes during tissue extraction.
picric acid,Picric acid is used as a 15% saturated solution for fixation of hypophyses in histological studies.,Entity: picric acid. SMILES: O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1. Picric acid is used as a 15% saturated solution for fixation of hypophyses in histological studies.
xylol,Xylol is used as a clearing agent for dehydrated tissue samples during histological processing.,Entity: xylol. SMILES: Cc1ccccc1C. Xylol is used as a clearing agent for dehydrated tissue samples during histological processing.
ethanol,Ethanol is used for dehydration of tissue samples prior to embedding in paraffin in histological procedures.,Entity: ethanol. SMILES: CCO. Ethanol is used for dehydration of tissue samples prior to embedding in paraffin in histological procedures.
Forene,Forene is an inhalant anesthetic agent used for animal sacrifice in experimental protocols.,Entity: Forene. SMILES: FC(F)OC(Cl)C(F)(F)F. Forene is an inhalant anesthetic agent used for animal sacrifice in experimental protocols.
hydrogen peroxide,Hydrogen peroxide is used to block endogenous peroxidase in immunohistochemistry protocols.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide is used to block endogenous peroxidase in immunohistochemistry protocols.
"3,3'-diaminobenzidine","3,3'-diaminobenzidine is used as a chromogenic substrate to visualize immunohistochemical reactions.","Entity: 3,3'-diaminobenzidine. SMILES: Nc1ccc(-c2ccc(N)c(N)c2)cc1N. 3,3'-diaminobenzidine is used as a chromogenic substrate to visualize immunohistochemical reactions."
methanol,Methanol is used as a solvent for hydrogen peroxide in the blocking of endogenous peroxidase in immunohistochemistry.,Entity: methanol. SMILES: CO. Methanol is used as a solvent for hydrogen peroxide in the blocking of endogenous peroxidase in immunohistochemistry.
aromatase,"Aromatase is immunohistochemically expressed in the hypophysis of adult rats, with sex-dependent differences in expression, as 34.40% of hypophyseal cells in males are immunoreactive compared to only 0.84% in females.","Entity: aromatase. Aromatase is immunohistochemically expressed in the hypophysis of adult rats, with sex-dependent differences in expression, as 34.40% of hypophyseal cells in males are immunoreactive compared to only 0.84% in females."
aromatase,Aromatase expression in the rat hypophysis is sex-dependent and may be involved in the regulation of adenohypophyseal cytology by androgens.,Entity: aromatase. Aromatase expression in the rat hypophysis is sex-dependent and may be involved in the regulation of adenohypophyseal cytology by androgens.
sucrose,Sucrose is used as a component of homogenization buffer at 0.25 M concentration in protein extraction protocols.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used as a component of homogenization buffer at 0.25 M concentration in protein extraction protocols.
Tween 20,Tween 20 is used at 0.1% concentration in PBS to reduce nonspecific binding during immunoblotting.,Entity: Tween 20. SMILES: CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO. Tween 20 is used at 0.1% concentration in PBS to reduce nonspecific binding during immunoblotting.
phenylmethylsulfonyl fluoride,Phenylmethylsulfonyl fluoride is used as a protease inhibitor at 1 mM concentration in homogenization buffer to prevent protein degradation.,Entity: phenylmethylsulfonyl fluoride. SMILES: O=S(=O)(F)Cc1ccccc1. Phenylmethylsulfonyl fluoride is used as a protease inhibitor at 1 mM concentration in homogenization buffer to prevent protein degradation.
sodium dodecyl sulfate,Sodium dodecyl sulfate is used in SDS-PAGE sample buffer to denature proteins for electrophoresis.,Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate is used in SDS-PAGE sample buffer to denature proteins for electrophoresis.
Coomassie blue,Coomassie blue is used to stain SDS-PAGE gels for visualization of proteins.,Entity: Coomassie blue. SMILES: O=S(=O)(O)c1cc(O)c2c(N=Nc3ccc(Nc4ccccc4)c4c(S(=O)(=O)O)cccc34)cc(S(=O)(=O)O)cc2c1.[Na+]. Coomassie blue is used to stain SDS-PAGE gels for visualization of proteins.
Texas red,"Texas red is a fluorescent dye used for immunolabeling, with excitation laser light at 568 nm in confocal laser scanning microscopy to avoid cross-talk with FITC.","Entity: Texas red. SMILES: O=S(=O)([O-])c1cc(S(=O)(=O)Cl)ccc1C1=c2cc3c4c(c2Oc2c1cc1c5c2CCCN5CCC1)CCC[N+]=4CCC3. Texas red is a fluorescent dye used for immunolabeling, with excitation laser light at 568 nm in confocal laser scanning microscopy to avoid cross-talk with FITC."
Triton X-100,Triton X-100 is a non-ionic detergent used at 0.3% concentration in PBS for permeabilizing tissue specimens in immunohistochemistry.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent used at 0.3% concentration in PBS for permeabilizing tissue specimens in immunohistochemistry.
acetone,Acetone is used to inflate the ileum or colon for tissue preparation in immunohistochemistry and is also used to immerse specimens for 10 minutes at -20°C to facilitate antigen retrieval.,Entity: acetone. SMILES: CC(C)=O. Acetone is used to inflate the ileum or colon for tissue preparation in immunohistochemistry and is also used to immerse specimens for 10 minutes at -20°C to facilitate antigen retrieval.
Texas red,Texas red is a fluorescent dye used to label secondary antibodies in immunohistochemistry for detection of specific antigens.,Entity: Texas red. SMILES: O=S(=O)([O-])c1cc(S(=O)(=O)Cl)ccc1C1=c2cc3c4c(c2Oc2c1cc1c5c2CCCN5CCC1)CCC[N+]=4CCC3. Texas red is a fluorescent dye used to label secondary antibodies in immunohistochemistry for detection of specific antigens.
biotinamide,Biotinamide is used at 2% concentration in culture medium as a tracer for electroporation experiments.,Entity: biotinamide. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biotinamide is used at 2% concentration in culture medium as a tracer for electroporation experiments.
saponin,Saponin from Quillaja Bark is included at 0.02% concentration in artificial intracellular solutions for electroporation of cells.,Entity: saponin. SMILES: CC1(C)C2CC[C@]3(C)[C@H](CCC45OCC6(CC[C@@](C)(C=O)C[C@@H]64)[C@H](O)C[C@]53C)[C@@]2(C)CC[C@@H]1O[C@@H]1OC[C@H](O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. Saponin from Quillaja Bark is included at 0.02% concentration in artificial intracellular solutions for electroporation of cells.
sodium gluconate,Sodium gluconate can be used as a substitute for potassium gluconate (150 mM) in artificial intracellular solutions for electroporation of cells.,Entity: sodium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Na+]. Sodium gluconate can be used as a substitute for potassium gluconate (150 mM) in artificial intracellular solutions for electroporation of cells.
monopotassium L-glutamic acid,Monopotassium L-glutamic acid is used at 150 mM concentration as the primary cation in artificial intracellular solutions for electroporation of cells.,Entity: monopotassium L-glutamic acid. SMILES: N[C@@H](CCC(=O)O)C(=O)O.[K]. Monopotassium L-glutamic acid is used at 150 mM concentration as the primary cation in artificial intracellular solutions for electroporation of cells.
magnesium chloride,Magnesium chloride is included at 7 mM concentration in artificial intracellular solutions for electroporation of cells.,Entity: magnesium chloride. SMILES: [Cl-].[Cl-].[Mg+2]. Magnesium chloride is included at 7 mM concentration in artificial intracellular solutions for electroporation of cells.
potassium gluconate,Potassium gluconate can be substituted for monopotassium L-glutamic acid (150 mM) in artificial intracellular solutions for electroporation of cells.,Entity: potassium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[K+]. Potassium gluconate can be substituted for monopotassium L-glutamic acid (150 mM) in artificial intracellular solutions for electroporation of cells.
glucose,Glucose is present at 5 mM concentration in artificial intracellular solutions for electroporation of cells.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is present at 5 mM concentration in artificial intracellular solutions for electroporation of cells.
colchicine,Colchicine at 80 µM is included in culture medium to establish the role of microtubule-dependent axonal transport in experiments using biocytin or biotinamide tracers.,Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine at 80 µM is included in culture medium to establish the role of microtubule-dependent axonal transport in experiments using biocytin or biotinamide tracers.
biocytin,"Biocytin can be used as a tracer in electroporation experiments, with 2% biocytin in culture medium tested for its effectiveness.","Entity: biocytin. SMILES: N[C@@H](CCCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)C(=O)O. Biocytin can be used as a tracer in electroporation experiments, with 2% biocytin in culture medium tested for its effectiveness."
calcium chloride,Calcium chloride can be added to artificial intracellular solutions at 3 mM concentration for electroporation of cells.,Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Calcium chloride can be added to artificial intracellular solutions at 3 mM concentration for electroporation of cells.
hydroxyeicosapentaenoic acid,Hydroxyeicosapentaenoic acid (HEPES) buffer is included at 20 mM concentration in artificial intracellular solutions for electroporation of cells.,Entity: hydroxyeicosapentaenoic acid. SMILES: CCCCCCCCCC=CC=CC=CC=CC=C(O)C(=O)O. Hydroxyeicosapentaenoic acid (HEPES) buffer is included at 20 mM concentration in artificial intracellular solutions for electroporation of cells.
dimethyl sulphoxide,Dimethyl sulphoxide (DMSO) is used at 1% concentration as a membrane-permeabilising agent in artificial intracellular solutions for electroporation of cells.,Entity: dimethyl sulphoxide. SMILES: CS(C)=O. Dimethyl sulphoxide (DMSO) is used at 1% concentration as a membrane-permeabilising agent in artificial intracellular solutions for electroporation of cells.
biotinamide,"Biotinamide can be translocated across synapses in enteric neurons, but transneuronal transport of biotinamide is not detectable in pericellular baskets of sympathetic nerve fibres under the conditions described.","Entity: biotinamide. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biotinamide can be translocated across synapses in enteric neurons, but transneuronal transport of biotinamide is not detectable in pericellular baskets of sympathetic nerve fibres under the conditions described."
biotinamide,"Biotinamide is used as a tracer in vivo to label nerve fibres anterogradely, with successful filling of varicosities indicating postganglionic sympathetic origin in most cases.","Entity: biotinamide. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biotinamide is used as a tracer in vivo to label nerve fibres anterogradely, with successful filling of varicosities indicating postganglionic sympathetic origin in most cases."
biotinamide,"Biotinamide-filled varicosities in nerve ganglia are immunoreactive for tyrosine hydroxylase (TH), indicating sympathetic origin, while CGRP-immunoreactive fibres are not filled with biotinamide.","Entity: biotinamide. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biotinamide-filled varicosities in nerve ganglia are immunoreactive for tyrosine hydroxylase (TH), indicating sympathetic origin, while CGRP-immunoreactive fibres are not filled with biotinamide."
calcium chloride,"Addition of 3 mM calcium chloride to tracer solutions reduces the distance of nerve fibre filling compared to control solutions, suggesting calcium's role in biotinamide uptake.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Addition of 3 mM calcium chloride to tracer solutions reduces the distance of nerve fibre filling compared to control solutions, suggesting calcium's role in biotinamide uptake."
fluorogold,Fluorogold is used as a tracer in vivo but was not successful in anterograde labelling of nerve fibres when applied in the same manner as biotinamide.,Entity: fluorogold. SMILES: F[Au]. Fluorogold is used as a tracer in vivo but was not successful in anterograde labelling of nerve fibres when applied in the same manner as biotinamide.
fast blue,Fast blue is used as a tracer in vivo but was not successful in anterograde labelling of nerve fibres when applied in the same manner as biotinamide.,Entity: fast blue. SMILES: COc1cc(-c2ccc([N+]#N)c(OC)c2)ccc1[N+]#N.[Cl-].[Cl-]. Fast blue is used as a tracer in vivo but was not successful in anterograde labelling of nerve fibres when applied in the same manner as biotinamide.
biotinamide,"Biotinamide labels nerve fibres and varicosities in the myenteric plexus and associated ganglia, allowing their visualization in mesenteric nerves.","Entity: biotinamide. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biotinamide labels nerve fibres and varicosities in the myenteric plexus and associated ganglia, allowing their visualization in mesenteric nerves."
biocytin,"Biocytin is a tracer that labels varicose and non-varicose fibres in the myenteric plexus after 20 hours in artificial intracellular solution, but provides less intense and shorter labeling compared to biotinamide.","Entity: biocytin. SMILES: N[C@@H](CCCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)C(=O)O. Biocytin is a tracer that labels varicose and non-varicose fibres in the myenteric plexus after 20 hours in artificial intracellular solution, but provides less intense and shorter labeling compared to biotinamide."
biotinamide,"Biotinamide is a tracer that labels varicose and non-varicose fibres in the myenteric plexus after 20 hours in artificial intracellular solution, with the best labeling among tested tracers.","Entity: biotinamide. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biotinamide is a tracer that labels varicose and non-varicose fibres in the myenteric plexus after 20 hours in artificial intracellular solution, with the best labeling among tested tracers."
fluorogold,Fluorogold does not label any fibres in the myenteric plexus after 20 hours in artificial intracellular solution under the tested conditions.,Entity: fluorogold. SMILES: F[Au]. Fluorogold does not label any fibres in the myenteric plexus after 20 hours in artificial intracellular solution under the tested conditions.
fast blue,Fast blue does not label any fibres in the myenteric plexus after 20 hours in artificial intracellular solution under the tested conditions.,Entity: fast blue. SMILES: COc1cc(-c2ccc([N+]#N)c(OC)c2)ccc1[N+]#N.[Cl-].[Cl-]. Fast blue does not label any fibres in the myenteric plexus after 20 hours in artificial intracellular solution under the tested conditions.
saponin,"Saponins have been used to permeabilize hepatocytes and other cell lines, but less commonly in the nervous system.","Entity: saponin. SMILES: CC1(C)C2CC[C@]3(C)[C@H](CCC45OCC6(CC[C@@](C)(C=O)C[C@@H]64)[C@H](O)C[C@]53C)[C@@]2(C)CC[C@@H]1O[C@@H]1OC[C@H](O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. Saponins have been used to permeabilize hepatocytes and other cell lines, but less commonly in the nervous system."
cholesterol,"Cholesterol in animal cell membranes forms pores when complexed with saponins, thereby increasing membrane permeability.","Entity: cholesterol. SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C. Cholesterol in animal cell membranes forms pores when complexed with saponins, thereby increasing membrane permeability."
biotinamide hydrobromide,Biotinamide hydrobromide is one of the two forms of biotinamide used as anterograde tracers in the central nervous system following either intracellular injection or extracellular application around intact nerve cell bodies.,Entity: biotinamide hydrobromide. SMILES: Br.NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biotinamide hydrobromide is one of the two forms of biotinamide used as anterograde tracers in the central nervous system following either intracellular injection or extracellular application around intact nerve cell bodies.
colchicine,"Colchicine disrupts microtubules and abolishes fast axonal transport, but does not abolish biotinamide or biocytin labeling in axons.","Entity: colchicine. SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2. Colchicine disrupts microtubules and abolishes fast axonal transport, but does not abolish biotinamide or biocytin labeling in axons."
biocytin,"Biocytin is used as an anterograde tracer in the central nervous system, following either intracellular injection or extracellular application around intact nerve cell bodies.","Entity: biocytin. SMILES: N[C@@H](CCCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)C(=O)O. Biocytin is used as an anterograde tracer in the central nervous system, following either intracellular injection or extracellular application around intact nerve cell bodies."
saponin,"Saponins are glycosides that complex with cholesterol in animal cell membranes, forming pores and increasing membrane permeability.","Entity: saponin. SMILES: CC1(C)C2CC[C@]3(C)[C@H](CCC45OCC6(CC[C@@](C)(C=O)C[C@@H]64)[C@H](O)C[C@]53C)[C@@]2(C)CC[C@@H]1O[C@@H]1OC[C@H](O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. Saponins are glycosides that complex with cholesterol in animal cell membranes, forming pores and increasing membrane permeability."
Catecholamine,"Catecholamine is a marker used to identify noradrenergic postganglionic sympathetic nerve fibres in the intestine, as demonstrated by catecholamine fluorescence or immunohistochemistry for tyrosine hydroxylase (TH).","Entity: Catecholamine. SMILES: Nc1cccc(O)c1O. Catecholamine is a marker used to identify noradrenergic postganglionic sympathetic nerve fibres in the intestine, as demonstrated by catecholamine fluorescence or immunohistochemistry for tyrosine hydroxylase (TH)."
biocytin,"Biocytin is a tracer used to label axons in mesenteric nerve preparations, but standard solutions of biocytin in Krebs solution or standard culture medium rarely label axons unless the axonal membranes are permeabilized.","Entity: biocytin. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biocytin is a tracer used to label axons in mesenteric nerve preparations, but standard solutions of biocytin in Krebs solution or standard culture medium rarely label axons unless the axonal membranes are permeabilized."
biocytin,Addition of 1 mM disodium ATP to a 2% biocytin solution in 50 mM KCl does not significantly improve biocytin labeling of axons in mesenteric nerve preparations.,Entity: biocytin. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Addition of 1 mM disodium ATP to a 2% biocytin solution in 50 mM KCl does not significantly improve biocytin labeling of axons in mesenteric nerve preparations.
glycerol,"Addition of 10% glycerol to biocytin tracer solutions helps permeabilize axonal membranes, resulting in faintly labelled axons in mesentery nerve preparations.","Entity: glycerol. SMILES: OCC(O)CO. Addition of 10% glycerol to biocytin tracer solutions helps permeabilize axonal membranes, resulting in faintly labelled axons in mesentery nerve preparations."
ethanol,"Addition of 1-10% ethanol to biocytin tracer solutions helps permeabilize axonal membranes, resulting in faintly labelled axons in mesentery nerve preparations.","Entity: ethanol. SMILES: CCO. Addition of 1-10% ethanol to biocytin tracer solutions helps permeabilize axonal membranes, resulting in faintly labelled axons in mesentery nerve preparations."
picric acid,"Picric acid is used as a component of Zamboni's fixative for tissue preservation, typically at a concentration of 15% saturated solution.","Entity: picric acid. SMILES: O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1. Picric acid is used as a component of Zamboni's fixative for tissue preservation, typically at a concentration of 15% saturated solution."
formaldehyde,Formaldehyde is included in Zamboni's fixative at a concentration of 2% for tissue preservation.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is included in Zamboni's fixative at a concentration of 2% for tissue preservation.
sodium phosphate,"Sodium phosphate is used as a buffer in both Zamboni's fixative (0.1 M, pH 7.0) and phosphate-buffered saline (PBS; 100 mM, pH 7.2) for tissue preparation.","Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used as a buffer in both Zamboni's fixative (0.1 M, pH 7.0) and phosphate-buffered saline (PBS; 100 mM, pH 7.2) for tissue preparation."
sodium chloride,Sodium chloride is a component of phosphate-buffered saline (PBS; 150 mM) used for rinsing tissues during preparation.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is a component of phosphate-buffered saline (PBS; 150 mM) used for rinsing tissues during preparation.
streptomycin,Streptomycin is used as an antibiotic supplement in the culture medium at a concentration of 100 µg/ml to inhibit bacterial growth in cell culture.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used as an antibiotic supplement in the culture medium at a concentration of 100 µg/ml to inhibit bacterial growth in cell culture.
CaCl2,CaCl2 is used as a supplement in culture medium at a concentration of 1.8 mM for maintaining optimal conditions in cell culture experiments.,Entity: CaCl2. SMILES: [Ca+2].[Cl-].[Cl-]. CaCl2 is used as a supplement in culture medium at a concentration of 1.8 mM for maintaining optimal conditions in cell culture experiments.
fungizone,Fungizone is included in the culture medium at a concentration of 2.5 µg/ml to prevent fungal contamination during cell culture.,Entity: fungizone. SMILES: C[C@@H]1[C@H](O)[C@@H](C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@H]1C)C[C@H](O)[C@H]2C(=O)O. Fungizone is included in the culture medium at a concentration of 2.5 µg/ml to prevent fungal contamination during cell culture.
Biotinamide,"Biotinamide, when dissolved in artificial intracellular solution and applied to cut nerve ends, enables rapid anterograde labeling of nerve fibres in vitro, allowing visualization of peripheral nerve branches up to 15 mm from the application site.","Entity: Biotinamide. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biotinamide, when dissolved in artificial intracellular solution and applied to cut nerve ends, enables rapid anterograde labeling of nerve fibres in vitro, allowing visualization of peripheral nerve branches up to 15 mm from the application site."
5-hydroxytryptamine,Pericellular baskets formed by anterogradely labeled nerve fibres preferentially surround 5-hydroxytryptamine-handling myenteric neurons in the myenteric plexus.,Entity: 5-hydroxytryptamine. SMILES: NCCc1c[nH]c2ccc(O)cc12. Pericellular baskets formed by anterogradely labeled nerve fibres preferentially surround 5-hydroxytryptamine-handling myenteric neurons in the myenteric plexus.
calcium chloride,"Addition of 3 mM calcium chloride to the artificial intracellular solution makes fiber filling less consistent, resulting in fewer labeled fibers and less intense staining.","Entity: calcium chloride. SMILES: [Ca+2].[Cl-].[Cl-]. Addition of 3 mM calcium chloride to the artificial intracellular solution makes fiber filling less consistent, resulting in fewer labeled fibers and less intense staining."
biotinamide,Replacing the artificial intracellular tracer solution with standard supplemented DME/F12 containing 2% biotinamide results in faint labeling of a small number of fibers for a short distance into the myenteric plexus.,Entity: biotinamide. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Replacing the artificial intracellular tracer solution with standard supplemented DME/F12 containing 2% biotinamide results in faint labeling of a small number of fibers for a short distance into the myenteric plexus.
DMSO,"DMSO, as a permeabilising agent, increases the intensity of staining of labeled fibers in the myenteric plexus, though it is not essential for adequate filling.","Entity: DMSO. SMILES: CS(C)=O. DMSO, as a permeabilising agent, increases the intensity of staining of labeled fibers in the myenteric plexus, though it is not essential for adequate filling."
saponin,"Saponin, as a permeabilising agent, increases the intensity of staining of labeled fibers in the myenteric plexus, though it is not essential for adequate filling.","Entity: saponin. SMILES: CC1(C)C2CC[C@]3(C)[C@H](CCC45OCC6(CC[C@@](C)(C=O)C[C@@H]64)[C@H](O)C[C@]53C)[C@@]2(C)CC[C@@H]1O[C@@H]1OC[C@H](O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O. Saponin, as a permeabilising agent, increases the intensity of staining of labeled fibers in the myenteric plexus, though it is not essential for adequate filling."
potassium glutamate,Using potassium glutamate at 118 mM concentration and making the solution isotonic produces labeling intensity and distance comparable to standard tracer solutions.,Entity: potassium glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-].[K+].[K+]. Using potassium glutamate at 118 mM concentration and making the solution isotonic produces labeling intensity and distance comparable to standard tracer solutions.
sodium gluconate,Substituting sodium gluconate for potassium glutamate as the major anion in the artificial intracellular solution decreases the number and distance of fibers filled and reduces staining intensity.,Entity: sodium gluconate. SMILES: O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Na+]. Substituting sodium gluconate for potassium glutamate as the major anion in the artificial intracellular solution decreases the number and distance of fibers filled and reduces staining intensity.
biotinamide,Biotinamide is used to fill nerve cell bodies in myenteric ganglia for retrograde tracing of neurons in vitro.,Entity: biotinamide. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biotinamide is used to fill nerve cell bodies in myenteric ganglia for retrograde tracing of neurons in vitro.
acetylcholine,"Acetylcholine is a major neurotransmitter utilized by intestinofugal neurons, which are postganglionic sympathetic neurons in the enteric nervous system.","Entity: acetylcholine. SMILES: CC(=O)OCC[N+](C)(C)C. Acetylcholine is a major neurotransmitter utilized by intestinofugal neurons, which are postganglionic sympathetic neurons in the enteric nervous system."
5-HT,5-HT-handling neurons are a class of descending interneurons in the enteric nervous system.,Entity: 5-HT. SMILES: NCCc1c[nH]c2ccc(O)cc12. 5-HT-handling neurons are a class of descending interneurons in the enteric nervous system.
VIP,VIP (vasoactive intestinal peptide) is a marker found in secreto-/vasomotor neurons that project to the submucosa of the enteric nervous system.,Entity: VIP. SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O. VIP (vasoactive intestinal peptide) is a marker found in secreto-/vasomotor neurons that project to the submucosa of the enteric nervous system.
Biotinamide,"Biotinamide can be used for anterograde filling of nerve fibres in organ culture, allowing for rapid visualization of nerve terminals.","Entity: Biotinamide. SMILES: NC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21. Biotinamide can be used for anterograde filling of nerve fibres in organ culture, allowing for rapid visualization of nerve terminals."
tyrosine hydroxylase,"Most anterogradely labelled nerve fibres and many pericellular baskets in the myenteric plexus of the guinea-pig small intestine are immunoreactive for tyrosine hydroxylase, indicating their postganglionic sympathetic origin.","Entity: tyrosine hydroxylase. Most anterogradely labelled nerve fibres and many pericellular baskets in the myenteric plexus of the guinea-pig small intestine are immunoreactive for tyrosine hydroxylase, indicating their postganglionic sympathetic origin."
choline acetyltransferase,"Many pericellular baskets in the myenteric plexus of the guinea-pig small intestine are immunoreactive for choline acetyltransferase, indicating their origin from spinal sensory neurons.","Entity: choline acetyltransferase. Many pericellular baskets in the myenteric plexus of the guinea-pig small intestine are immunoreactive for choline acetyltransferase, indicating their origin from spinal sensory neurons."
sodium borate,Sodium borate is used as a 1% solution as a component of toluidine blue staining in histological studies of lung tissue.,Entity: sodium borate. SMILES: [Na+].[Na+].[Na+].[O-]B([O-])[O-]. Sodium borate is used as a 1% solution as a component of toluidine blue staining in histological studies of lung tissue.
toluidine blue,Toluidine blue is a histological stain used at 0.1% concentration in 1% sodium borate solution to visualize alveolar wall vessels in lung tissue sections.,Entity: toluidine blue. SMILES: Cc1ccc(Nc2ccc(O)c3c2C(=O)c2c(O)ccc(Nc4ccc(C)cc4S(=O)(=O)[O-])c2C3=O)c(S(=O)(=O)[O-])c1.[Na+].[Na+]. Toluidine blue is a histological stain used at 0.1% concentration in 1% sodium borate solution to visualize alveolar wall vessels in lung tissue sections.
aminoethylcarbazole,Aminoethylcarbazole (AEC) is used as a substrate-chromogen to produce a red reaction product at immunopositive sites in immunocytochemistry.,Entity: aminoethylcarbazole. SMILES: NCCc1cccc2c1[nH]c1ccccc12. Aminoethylcarbazole (AEC) is used as a substrate-chromogen to produce a red reaction product at immunopositive sites in immunocytochemistry.
methanol,Methanol is used as a solvent for quenching endogenous peroxide in tissue sections during immunocytochemistry.,Entity: methanol. SMILES: CO. Methanol is used as a solvent for quenching endogenous peroxide in tissue sections during immunocytochemistry.
hematoxylin,Hematoxylin is used to stain cell nuclei blue in immunocytochemistry protocols.,Entity: hematoxylin. SMILES: Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2. Hematoxylin is used to stain cell nuclei blue in immunocytochemistry protocols.
hydrogen peroxide,Hydrogen peroxide is used to quench endogenous peroxide in tissue sections during immunocytochemistry procedures.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide is used to quench endogenous peroxide in tissue sections during immunocytochemistry procedures.
sodium chloride,Sodium chloride is included at 0.3 M in the hybridization cocktail and at 0.5 M in the RNase digestion buffer for in situ hybridization procedures.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is included at 0.3 M in the hybridization cocktail and at 0.5 M in the RNase digestion buffer for in situ hybridization procedures.
ethylenediaminetetraacetic acid,Ethylenediaminetetraacetic acid (EDTA) is used at 1 mM concentration in the hybridization cocktail and at 2 mM in the RNase digestion buffer for in situ hybridization.,Entity: ethylenediaminetetraacetic acid. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. Ethylenediaminetetraacetic acid (EDTA) is used at 1 mM concentration in the hybridization cocktail and at 2 mM in the RNase digestion buffer for in situ hybridization.
3-aminopropyl-ethoxysilane,3-aminopropyl-ethoxysilane is used to coat slides to facilitate tissue section adhesion during in situ hybridization.,Entity: 3-aminopropyl-ethoxysilane. SMILES: CCO[SiH2]CCCN. 3-aminopropyl-ethoxysilane is used to coat slides to facilitate tissue section adhesion during in situ hybridization.
dithiothreitol,Dithiothreitol is included at 0.1 M in the hybridization cocktail for in situ hybridization.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is included at 0.1 M in the hybridization cocktail for in situ hybridization.
ethanolamine,Ethanolamine is used at 0.1 M concentration as a buffer component during acetylation of tissue sections for in situ hybridization.,Entity: ethanolamine. SMILES: NCCO. Ethanolamine is used at 0.1 M concentration as a buffer component during acetylation of tissue sections for in situ hybridization.
formamide,"Formamide is used as a component of the hybridization cocktail (50% formamide, 20 mM TRIS-HCl, 1 mM EDTA, 0.3 M NaCl, 0.1 M dithiothreitol, 0.5 µg/ml yeast tRNA, 0.1 µg/ml polyA-RNA, 1×Denhardt's solution, 10% dextran sulfate) for in situ hybridization of tissue sections.","Entity: formamide. SMILES: NC=O. Formamide is used as a component of the hybridization cocktail (50% formamide, 20 mM TRIS-HCl, 1 mM EDTA, 0.3 M NaCl, 0.1 M dithiothreitol, 0.5 µg/ml yeast tRNA, 0.1 µg/ml polyA-RNA, 1×Denhardt's solution, 10% dextran sulfate) for in situ hybridization of tissue sections."
acetic anhydride,"Acetic anhydride is used to acetylate tissue sections during the preparation for in situ hybridization, applied at 0.25% in 0.1 M ethanolamine for 20 minutes.","Entity: acetic anhydride. SMILES: CC(=O)OC(C)=O. Acetic anhydride is used to acetylate tissue sections during the preparation for in situ hybridization, applied at 0.25% in 0.1 M ethanolamine for 20 minutes."
"3,3-diaminobenzidine-4 HCl","3,3-diaminobenzidine-4 HCl is used as a chromogenic substrate in immunohistochemistry to develop peroxidase reactions, with a typical concentration of 0.05% in the reaction mixture.","Entity: 3,3-diaminobenzidine-4 HCl. SMILES: Cl.Cl.Cl.Cl.NC1=CC=C(c2ccc(N)cc2)CC1(N)N. 3,3-diaminobenzidine-4 HCl is used as a chromogenic substrate in immunohistochemistry to develop peroxidase reactions, with a typical concentration of 0.05% in the reaction mixture."
Triton X-100,"Triton X-100 is a non-ionic detergent commonly used in immunohistochemistry protocols to permeabilize tissue sections, typically at a concentration of 0.3% in blocking buffer.","Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent commonly used in immunohistochemistry protocols to permeabilize tissue sections, typically at a concentration of 0.3% in blocking buffer."
hydrogen peroxide,"Hydrogen peroxide is used as a substrate in peroxidase-based immunohistochemistry to facilitate the chromogenic reaction, often at a concentration of 0.003% in the reaction mixture.","Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide is used as a substrate in peroxidase-based immunohistochemistry to facilitate the chromogenic reaction, often at a concentration of 0.003% in the reaction mixture."
trkC,"No catalytic trkC mRNA is found in rat thyroid tissue, indicating the absence of functional trkC receptors.","Entity: trkC. No catalytic trkC mRNA is found in rat thyroid tissue, indicating the absence of functional trkC receptors."
trkB,"Very low levels of mRNA for truncated trkB receptor are found in rat thyroid tissue, indicating the absence of functional trkB receptors.","Entity: trkB. Very low levels of mRNA for truncated trkB receptor are found in rat thyroid tissue, indicating the absence of functional trkB receptors."
neurotrophin 3,Neurotrophin 3 (NT-3) mRNA is expressed in rat thyroid tissue at a level threefold lower than in adult rat hippocampus.,Entity: neurotrophin 3. Neurotrophin 3 (NT-3) mRNA is expressed in rat thyroid tissue at a level threefold lower than in adult rat hippocampus.
brain-derived neurotrophic factor,Brain-derived neurotrophic factor (BDNF) mRNA is undetectable in rat thyroid tissue.,Entity: brain-derived neurotrophic factor. Brain-derived neurotrophic factor (BDNF) mRNA is undetectable in rat thyroid tissue.
neurotrophin 4,Neurotrophin 4 (NT-4) mRNA is expressed in rat thyroid tissue at a level sixfold higher than in adult rat hippocampus.,Entity: neurotrophin 4. Neurotrophin 4 (NT-4) mRNA is expressed in rat thyroid tissue at a level sixfold higher than in adult rat hippocampus.
calcitonin,Calcitonin is used as a specific marker in in situ hybridization/immunocytochemistry experiments to identify parafollicular cells in thyroid tissue.,Entity: calcitonin. Calcitonin is used as a specific marker in in situ hybridization/immunocytochemistry experiments to identify parafollicular cells in thyroid tissue.
glial cell line-derived neurotrophic factor,"Thyroid tissue shows a high level of transcripts for the GDNF receptor subunits GDNFR-alpha and Ret, while GDNF mRNA is undetectable.","Entity: glial cell line-derived neurotrophic factor. Thyroid tissue shows a high level of transcripts for the GDNF receptor subunits GDNFR-alpha and Ret, while GDNF mRNA is undetectable."
trkA,"No catalytic trkA mRNA is found in rat thyroid tissue, indicating the absence of functional trkA receptors.","Entity: trkA. No catalytic trkA mRNA is found in rat thyroid tissue, indicating the absence of functional trkA receptors."
ret,ret mRNA is selectively expressed in a subpopulation of cells scattered in the follicular epithelium and interfollicular spaces of rat thyroid tissue.,Entity: ret. ret mRNA is selectively expressed in a subpopulation of cells scattered in the follicular epithelium and interfollicular spaces of rat thyroid tissue.
GDNFR-alpha,"GDNFR-alpha expression is more homogeneous and widespread in rat thyroid tissue, including the more abundant follicular cell type.","Entity: GDNFR-alpha. GDNFR-alpha expression is more homogeneous and widespread in rat thyroid tissue, including the more abundant follicular cell type."
sodium dodecyl sulfate,Sodium dodecyl sulfate is used as a denaturing agent in SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) to separate proteins based on molecular weight.,Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate is used as a denaturing agent in SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) to separate proteins based on molecular weight.
picrate,Picrate is used as a component of fixative solution in histological staining protocols.,Entity: picrate. SMILES: O=[N+]([O-])c1cc([N+](=O)[O-])c([O-])c([N+](=O)[O-])c1. Picrate is used as a component of fixative solution in histological staining protocols.
methylene blue,"Methylene blue is used as a histological stain in intestinal tissue, applied at a concentration of 50 µM during incubation in Tyrode's solution for 45 minutes.","Entity: methylene blue. SMILES: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.[Cl-]. Methylene blue is used as a histological stain in intestinal tissue, applied at a concentration of 50 µM during incubation in Tyrode's solution for 45 minutes."
dextran,"Dextran can be taken up by macrophages and mesothelial cells in the gastrointestinal tract, resulting in the formation of dextran-filled vesicles or granules as observed by electron microscopy after intravenous or intraperitoneal injection.","Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran can be taken up by macrophages and mesothelial cells in the gastrointestinal tract, resulting in the formation of dextran-filled vesicles or granules as observed by electron microscopy after intravenous or intraperitoneal injection."
fluorescein,Fluorescein is commonly used as a fluorescent label for biomolecules such as dextran in microscopy and imaging applications.,Entity: fluorescein. SMILES: O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21. Fluorescein is commonly used as a fluorescent label for biomolecules such as dextran in microscopy and imaging applications.
sodium chloride,Sodium chloride is used as a 0.9% solution as a physiological saline buffer in injection protocols for biological studies.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used as a 0.9% solution as a physiological saline buffer in injection protocols for biological studies.
dextran,Dextran can be labeled with fluorescein (FITC) and used as a tracer in immunological and histological studies.,Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran can be labeled with fluorescein (FITC) and used as a tracer in immunological and histological studies.
isopentane,Isopentane is used as a cooling medium for rapid freezing of biological tissue specimens prior to storage at -80°C.,Entity: isopentane. SMILES: CCC(C)C. Isopentane is used as a cooling medium for rapid freezing of biological tissue specimens prior to storage at -80°C.
acetone,"Acetone, in ice-cold form, is used for brief fixation of unfixed cryostat sections in immunohistochemistry.","Entity: acetone. SMILES: CC(C)=O. Acetone, in ice-cold form, is used for brief fixation of unfixed cryostat sections in immunohistochemistry."
hydrogen peroxide,Hydrogen peroxide is used at 0.035% concentration in PBS as a substrate in the chromogenic immunohistochemical detection system with diaminobenzidine.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide is used at 0.035% concentration in PBS as a substrate in the chromogenic immunohistochemical detection system with diaminobenzidine.
diaminobenzidine,"Diaminobenzidine is used as a chromogene at 0.5% concentration in PBS for immunohistochemical staining, producing a brown precipitate upon reaction with hydrogen peroxide.","Entity: diaminobenzidine. SMILES: NNc1ccc(-c2ccc(NN)cc2)cc1. Diaminobenzidine is used as a chromogene at 0.5% concentration in PBS for immunohistochemical staining, producing a brown precipitate upon reaction with hydrogen peroxide."
CD3,"CD3 is a cell surface antigen used to identify T lymphocytes, and both control and op/op mice lack cells expressing CD3 in the muscularis externa.","Entity: CD3. CD3 is a cell surface antigen used to identify T lymphocytes, and both control and op/op mice lack cells expressing CD3 in the muscularis externa."
F4/80,"F4/80 is an immunohistochemical marker used to identify macrophages, and both control and op/op mice lack F4/80-positive macrophages in the muscularis externa.","Entity: F4/80. F4/80 is an immunohistochemical marker used to identify macrophages, and both control and op/op mice lack F4/80-positive macrophages in the muscularis externa."
CD45R,"CD45R, also known as B220, is a cell surface antigen used to identify B lymphocytes, and both control and op/op mice lack cells expressing CD45R in the muscularis externa.","Entity: CD45R. CD45R, also known as B220, is a cell surface antigen used to identify B lymphocytes, and both control and op/op mice lack cells expressing CD45R in the muscularis externa."
sodium ethanolate,Sodium ethanolate solution is used to remove epoxy resin from tissue sections after embedding.,Entity: sodium ethanolate. SMILES: CC[O-].[Na+]. Sodium ethanolate solution is used to remove epoxy resin from tissue sections after embedding.
glycerol,Glycerol containing propylgallate is used as a mounting medium for cover-slipping tissue sections in microscopy.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol containing propylgallate is used as a mounting medium for cover-slipping tissue sections in microscopy.
glutaraldehyde,Glutaraldehyde is used as a component of high-strength fixative solutions for preserving biological tissue samples.,Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a component of high-strength fixative solutions for preserving biological tissue samples.
picric acid,Picric acid is used in combination with glutaraldehyde as a fixative in high-strength solutions for tissue preservation.,Entity: picric acid. SMILES: O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1. Picric acid is used in combination with glutaraldehyde as a fixative in high-strength solutions for tissue preservation.
epoxy resin,Epoxy resin is used as an embedding medium for preparing tissue sections for microscopy.,Entity: epoxy resin. SMILES: C=CC(=O)O.CC(C)(c1ccc(O)cc1)c1ccc(O)cc1.ClCC1CO1. Epoxy resin is used as an embedding medium for preparing tissue sections for microscopy.
3-aminopropyl-diethoxy-methylsilane,3-aminopropyl-diethoxy-methylsilane is used to silanize glass slides to prevent nonspecific protein binding during immunohistochemistry.,Entity: 3-aminopropyl-diethoxy-methylsilane. SMILES: CCO[Si](C)(CCCN)OCC. 3-aminopropyl-diethoxy-methylsilane is used to silanize glass slides to prevent nonspecific protein binding during immunohistochemistry.
ethanol,Ethanol is used in rising concentrations for dehydration of tissue samples during the preparation of semithin sections.,Entity: ethanol. SMILES: CCO. Ethanol is used in rising concentrations for dehydration of tissue samples during the preparation of semithin sections.
propylene oxide,Propylene oxide is used in rising concentrations for dehydration of tissue samples during the preparation of semithin sections.,Entity: propylene oxide. SMILES: CC1CO1. Propylene oxide is used in rising concentrations for dehydration of tissue samples during the preparation of semithin sections.
sodium cacodylate hydrochloride,"Sodium cacodylate hydrochloride buffer (0.1 M, pH 7.3) is used as the buffer component in glutaraldehyde solutions for immunofluorescence and immunoelectron-microscopic fixation, and in glutaraldehyde solutions for scanning electron microscopy.","Entity: sodium cacodylate hydrochloride. SMILES: C[As](C)(=O)[O-].Cl.[Na+]. Sodium cacodylate hydrochloride buffer (0.1 M, pH 7.3) is used as the buffer component in glutaraldehyde solutions for immunofluorescence and immunoelectron-microscopic fixation, and in glutaraldehyde solutions for scanning electron microscopy."
glutaraldehyde,"Glutaraldehyde is used as a fixative at 2.5% concentration in sodium cacodylate hydrochloride buffer for immunofluorescence and immunoelectron-microscopic studies, and at 1.25% concentration for scanning electron microscopy.","Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a fixative at 2.5% concentration in sodium cacodylate hydrochloride buffer for immunofluorescence and immunoelectron-microscopic studies, and at 1.25% concentration for scanning electron microscopy."
ketamine,Ketamine is administered intraperitoneally as an anesthetic agent for young adult male Wistar rats during tissue preparation.,Entity: ketamine. SMILES: CNC1(c2ccccc2Cl)CCCCC1=O. Ketamine is administered intraperitoneally as an anesthetic agent for young adult male Wistar rats during tissue preparation.
procaine hydrochloride,Procaine hydrochloride is used as an anticoagulant in cold PBS for intracardiac perfusion of rat thoracic vascular system during tissue fixation.,Entity: procaine hydrochloride. SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1.Cl. Procaine hydrochloride is used as an anticoagulant in cold PBS for intracardiac perfusion of rat thoracic vascular system during tissue fixation.
picric acid,Picric acid is included at 0.05% concentration in glutaraldehyde solutions for immunofluorescence and immunoelectron-microscopic studies of tissue fixation.,Entity: picric acid. SMILES: O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1. Picric acid is included at 0.05% concentration in glutaraldehyde solutions for immunofluorescence and immunoelectron-microscopic studies of tissue fixation.
tetrodotoxin,"Tetrodotoxin at 6 µM concentration for 24 hours blocks Na+ channels in MAT-LyLu rat prostate cancer cells, resulting in more compact cells with shorter, thicker processes and increased process thickness.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at 6 µM concentration for 24 hours blocks Na+ channels in MAT-LyLu rat prostate cancer cells, resulting in more compact cells with shorter, thicker processes and increased process thickness."
tetrodotoxin,"Tetrodotoxin (TTX) exhibits striking efficacy in inhibiting functional voltage-gated Na+ channels in the MAT-LyLu cell line, but has little effect on the cell body diameter of AT-2 cells at equimolar concentrations.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin (TTX) exhibits striking efficacy in inhibiting functional voltage-gated Na+ channels in the MAT-LyLu cell line, but has little effect on the cell body diameter of AT-2 cells at equimolar concentrations."
trypan blue,"Trypan blue is used as a dye to determine cell viability by exclusion assay, with 4% trypan blue solution added to cells and incubated for 10 minutes to distinguish live from dead cells under a microscope.","Entity: trypan blue. SMILES: Cc1cc(-c2ccc(N=Nc3c(S(=O)(=O)[O-])cc4cc(S(=O)(=O)[O-])cc(N)c4c3O)c(C)c2)ccc1N=Nc1c(S(=O)(=O)[O-])cc2cc(S(=O)(=O)[O-])cc(N)c2c1O.[Na+].[Na+].[Na+].[Na+]. Trypan blue is used as a dye to determine cell viability by exclusion assay, with 4% trypan blue solution added to cells and incubated for 10 minutes to distinguish live from dead cells under a microscope."
tetrodotoxin,Tetrodotoxin is a toxin tested at a concentration of 6 µM for its potential cytotoxic effects on cells in a proliferation assay.,Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin is a toxin tested at a concentration of 6 µM for its potential cytotoxic effects on cells in a proliferation assay.
tetrodotoxin,"Tetrodotoxin at a concentration of 6 µM is not cytotoxic to MAT-LyLu or AT-2 cells after 24 hours of incubation, with cell death rates remaining below 10% in both cell lines.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at a concentration of 6 µM is not cytotoxic to MAT-LyLu or AT-2 cells after 24 hours of incubation, with cell death rates remaining below 10% in both cell lines."
tetrodotoxin,Tetrodotoxin at a concentration of 6 µM for 24 hours does not affect cell density in MAT-LyLu or AT-2 cells compared to untreated controls incubated in supplemented medium.,Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at a concentration of 6 µM for 24 hours does not affect cell density in MAT-LyLu or AT-2 cells compared to untreated controls incubated in supplemented medium.
tetrodotoxin,"Tetrodotoxin at 6 µM reduces the field diameter of process-bearing MAT-LyLu cells, with monopolar cells showing a 28% reduction (range 21%–43%; from 104±2 µm to 75±1 µm), bipolar cells a 37% reduction (range 23%–48%; from 164±3 µm to 104±3 µm), and multipolar cells a 26% reduction (range 19%–34%; from 119±4 µm to 88±3 µm) over 24 hours of incubation.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at 6 µM reduces the field diameter of process-bearing MAT-LyLu cells, with monopolar cells showing a 28% reduction (range 21%–43%; from 104±2 µm to 75±1 µm), bipolar cells a 37% reduction (range 23%–48%; from 164±3 µm to 104±3 µm), and multipolar cells a 26% reduction (range 19%–34%; from 119±4 µm to 88±3 µm) over 24 hours of incubation."
tetrodotoxin,"Tetrodotoxin at a concentration of 6 µM increases process thickness in MAT-LyLu cells, with monopolar cells showing a 75% increase (from 2.0±0.5 µm to 3.5±0.5 µm), bipolar cells a 67% increase (from 3.0±0.5 µm to 5.0±0.5 µm), and multipolar cells a 50% increase (from 3.0±0.5 µm to 4.5±0.5 µm), while causing no significant change in process thickness of monopolar AT-2 cells (3.5±0.5 µm) or bipolar cells (4.0±0.5 µm).","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at a concentration of 6 µM increases process thickness in MAT-LyLu cells, with monopolar cells showing a 75% increase (from 2.0±0.5 µm to 3.5±0.5 µm), bipolar cells a 67% increase (from 3.0±0.5 µm to 5.0±0.5 µm), and multipolar cells a 50% increase (from 3.0±0.5 µm to 4.5±0.5 µm), while causing no significant change in process thickness of monopolar AT-2 cells (3.5±0.5 µm) or bipolar cells (4.0±0.5 µm)."
tetrodotoxin,"Tetrodotoxin is a Na+ channel blocker that, at 6 µM, alters the morphology of MAT-LyLu cells by decreasing cell process length and field diameter, increasing cell body diameter and process thickness after 24 h incubation.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin is a Na+ channel blocker that, at 6 µM, alters the morphology of MAT-LyLu cells by decreasing cell process length and field diameter, increasing cell body diameter and process thickness after 24 h incubation."
tetrodotoxin,Tetrodotoxin is a voltage-activated Na+ channel blocker that significantly reduces the invasiveness of MAT-LyLu rat prostatic cancer cells in vitro.,Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin is a voltage-activated Na+ channel blocker that significantly reduces the invasiveness of MAT-LyLu rat prostatic cancer cells in vitro.
dimethylsulphoxide,"Dimethylsulphoxide (DMSO) is used to solubilize formazan crystals in the MTT cell proliferation assay, enabling spectrophotometric quantification of cell viability.","Entity: dimethylsulphoxide. SMILES: CS(C)=O. Dimethylsulphoxide (DMSO) is used to solubilize formazan crystals in the MTT cell proliferation assay, enabling spectrophotometric quantification of cell viability."
glycine,Glycine buffer is used in the MTT cell proliferation assay to facilitate the release of formazan from cells and to stabilize the reaction for spectrophotometric measurement.,Entity: glycine. SMILES: NCC(=O)O. Glycine buffer is used in the MTT cell proliferation assay to facilitate the release of formazan from cells and to stabilize the reaction for spectrophotometric measurement.
tetrodotoxin,Tetrodotoxin (TTX) is a neurotoxin that can be used at 6 µM concentration to treat cells for 24 hours in proliferation and toxicity assays.,Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin (TTX) is a neurotoxin that can be used at 6 µM concentration to treat cells for 24 hours in proliferation and toxicity assays.
"3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide","3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) is a colorimetric reagent used to assess cell proliferation by measuring metabolic activity in cultured cells.","Entity: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide. SMILES: Cc1nc(N2N=C(c3ccccc3)[NH2+]N2c2ccccc2)sc1C.[Br-]. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) is a colorimetric reagent used to assess cell proliferation by measuring metabolic activity in cultured cells."
tetrodotoxin,"Tetrodotoxin is a Na+ channel blocker that, at a concentration of 6 µM, completely suppresses the activity of Na+ channels in cells after 24 hours of treatment.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin is a Na+ channel blocker that, at a concentration of 6 µM, completely suppresses the activity of Na+ channels in cells after 24 hours of treatment."
tetrodotoxin,"Tetrodotoxin at 6 µM induces clear alterations in cell morphology of the MAT-LyLu cell line after 24 hours of incubation, whereas the AT-2 cell line shows no apparent change under the same conditions.","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at 6 µM induces clear alterations in cell morphology of the MAT-LyLu cell line after 24 hours of incubation, whereas the AT-2 cell line shows no apparent change under the same conditions."
tetrodotoxin,Tetrodotoxin at 6 µM concentration does not significantly affect the cell body size of AT-2 cells.,Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at 6 µM concentration does not significantly affect the cell body size of AT-2 cells.
tetrodotoxin,"Tetrodotoxin at a concentration of 6 µM reduces process length in MAT-LyLu cells, with monopolar cells showing a 31% reduction (from 82±2 µm to 57±1 µm), bipolar cells a 37% reduction (from 73±2 µm to 46±1 µm), and multipolar cells a 30% reduction (from 43±1 µm to 30±1 µm).","Entity: tetrodotoxin. SMILES: NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO. Tetrodotoxin at a concentration of 6 µM reduces process length in MAT-LyLu cells, with monopolar cells showing a 31% reduction (from 82±2 µm to 57±1 µm), bipolar cells a 37% reduction (from 73±2 µm to 46±1 µm), and multipolar cells a 30% reduction (from 43±1 µm to 30±1 µm)."
streptomycin,Streptomycin is used as a supplement at 1% concentration in RPMI 1640 medium for culturing prostatic carcinoma cells.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used as a supplement at 1% concentration in RPMI 1640 medium for culturing prostatic carcinoma cells.
L-glutamine,L-glutamine is used as a supplement at 2 mM concentration in RPMI 1640 medium for culturing prostatic carcinoma cells.,Entity: L-glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. L-glutamine is used as a supplement at 2 mM concentration in RPMI 1640 medium for culturing prostatic carcinoma cells.
dexamethasone,Dexamethasone is used as a supplement at 250 nM concentration in RPMI 1640 medium for culturing prostatic carcinoma cells.,Entity: dexamethasone. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO. Dexamethasone is used as a supplement at 250 nM concentration in RPMI 1640 medium for culturing prostatic carcinoma cells.
"4',6-diamidino-2-phenylindole","4',6-diamidino-2-phenylindole (DAPI) is used as a nuclear counterstain in immunofluorescence microscopy, applied at 2 µg/ml for conventional microscopy and 2 µM for TO-PRO-3 iodide in laser confocal microscopy.","Entity: 4',6-diamidino-2-phenylindole. SMILES: N=C(N)c1ccc(-c2cc3ccc(C(=N)N)cc3[nH]2)cc1. 4',6-diamidino-2-phenylindole (DAPI) is used as a nuclear counterstain in immunofluorescence microscopy, applied at 2 µg/ml for conventional microscopy and 2 µM for TO-PRO-3 iodide in laser confocal microscopy."
formaldehyde,"Formaldehyde is used as a fixative for tissue sections, but AQP5 protein can be poorly detected in formaldehyde-fixed samples when using anti-AQP5 antibody.","Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a fixative for tissue sections, but AQP5 protein can be poorly detected in formaldehyde-fixed samples when using anti-AQP5 antibody."
ethanol,"Ethanol is used as a fixative for tissue sections, and ethanol fixation at -20°C for 30 min effectively preserves AQP5 protein for immunofluorescence detection.","Entity: ethanol. SMILES: CCO. Ethanol is used as a fixative for tissue sections, and ethanol fixation at -20°C for 30 min effectively preserves AQP5 protein for immunofluorescence detection."
sucrose,Sucrose is used as a 2.3 M solution in sodium phosphate buffer (pH 7.4) for tissue fixation during immunohistochemical studies with semithin frozen sections.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used as a 2.3 M solution in sodium phosphate buffer (pH 7.4) for tissue fixation during immunohistochemical studies with semithin frozen sections.
sodium phosphate,"Sodium phosphate buffer (0.1 M, pH 7.4) is used for tissue fixation in immunohistochemical studies, both in fresh tissue and in 1% formaldehyde solution.","Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate buffer (0.1 M, pH 7.4) is used for tissue fixation in immunohistochemical studies, both in fresh tissue and in 1% formaldehyde solution."
formaldehyde,Formaldehyde is used at a concentration of 1% in sodium phosphate buffer (pH 7.4) for 1-hour fixation of tissue specimens in immunohistochemical studies.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used at a concentration of 1% in sodium phosphate buffer (pH 7.4) for 1-hour fixation of tissue specimens in immunohistochemical studies.
phenylmethylsulfonyl fluoride,Phenylmethylsulfonyl fluoride is included at 2 mM concentration in homogenization buffer to inhibit protein degradation during tissue homogenization.,Entity: phenylmethylsulfonyl fluoride. SMILES: O=S(=O)(F)Cc1ccccc1. Phenylmethylsulfonyl fluoride is included at 2 mM concentration in homogenization buffer to inhibit protein degradation during tissue homogenization.
dithiothreitol,Dithiothreitol is used at 23 mg/ml in denaturation buffer for protein samples prior to SDS-polyacrylamide gel electrophoresis.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used at 23 mg/ml in denaturation buffer for protein samples prior to SDS-polyacrylamide gel electrophoresis.
bromophenol blue,Bromophenol blue is included at 0.005% concentration in denaturation buffer for protein samples prior to SDS-polyacrylamide gel electrophoresis.,Entity: bromophenol blue. SMILES: O=S1(=O)OC(c2cc(Br)c(O)c(Br)c2)(c2cc(Br)c(O)c(Br)c2)c2ccccc21. Bromophenol blue is included at 0.005% concentration in denaturation buffer for protein samples prior to SDS-polyacrylamide gel electrophoresis.
leupeptin,Leupeptin is included at 2 µg/ml in homogenization buffer to inhibit protein degradation during tissue homogenization.,Entity: leupeptin. SMILES: CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N. Leupeptin is included at 2 µg/ml in homogenization buffer to inhibit protein degradation during tissue homogenization.
glycerol,Glycerol is included at 25% concentration in denaturation buffer for protein samples prior to SDS-polyacrylamide gel electrophoresis.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is included at 25% concentration in denaturation buffer for protein samples prior to SDS-polyacrylamide gel electrophoresis.
sodium dodecyl sulfate,Sodium dodecyl sulfate is used as a denaturing agent at 2% concentration in denaturation buffer for protein samples prior to SDS-polyacrylamide gel electrophoresis.,Entity: sodium dodecyl sulfate. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. Sodium dodecyl sulfate is used as a denaturing agent at 2% concentration in denaturation buffer for protein samples prior to SDS-polyacrylamide gel electrophoresis.
potassium,"In the duct system of salivary glands, potassium ions (K+) are secreted into saliva.","Entity: potassium. SMILES: [K]. In the duct system of salivary glands, potassium ions (K+) are secreted into saliva."
chloride,"In the duct system of salivary glands, chloride ions (Cl-) are reabsorbed from saliva.","Entity: chloride. SMILES: [Cl-]. In the duct system of salivary glands, chloride ions (Cl-) are reabsorbed from saliva."
bicarbonate,"In the duct system of salivary glands, bicarbonate ions (HCO3-) are secreted into saliva.","Entity: bicarbonate. SMILES: O=C([O-])O. In the duct system of salivary glands, bicarbonate ions (HCO3-) are secreted into saliva."
sodium,"In the duct system of salivary glands, sodium ions (Na+) are reabsorbed from saliva.","Entity: sodium. SMILES: [Na]. In the duct system of salivary glands, sodium ions (Na+) are reabsorbed from saliva."
water,"The duct system of salivary glands is impermeable to water, resulting in saliva that is hypotonic compared to primary saliva.","Entity: water. SMILES: O. The duct system of salivary glands is impermeable to water, resulting in saliva that is hypotonic compared to primary saliva."
Aquaporin-5,"Aquaporin-5 is localized to the apical membranes of secretory acinar cells in submandibular, parotid, and sublingual salivary glands, including intercellular secretory canaliculi.","Entity: Aquaporin-5. Aquaporin-5 is localized to the apical membranes of secretory acinar cells in submandibular, parotid, and sublingual salivary glands, including intercellular secretory canaliculi."
Aquaporin-5,"In the submandibular gland, Aquaporin-5 is also present at the apical membrane of intercalated duct cells.","Entity: Aquaporin-5. In the submandibular gland, Aquaporin-5 is also present at the apical membrane of intercalated duct cells."
Aquaporin-5,Aquaporin-5 is a candidate molecule responsible for water movement in salivary glands.,Entity: Aquaporin-5. Aquaporin-5 is a candidate molecule responsible for water movement in salivary glands.
Aquaporin-5,Aquaporin-5 is a water channel protein that plays an important role in water movement across the plasma membrane.,Entity: Aquaporin-5. Aquaporin-5 is a water channel protein that plays an important role in water movement across the plasma membrane.
trichloroacetic acid,Trichloroacetic acid (TCA) is used to precipitate DNA and collagen from cell lysates in biochemical assays.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid (TCA) is used to precipitate DNA and collagen from cell lysates in biochemical assays.
thymidine,Thymidine is used as a radiolabel ([3H]thymidine) to measure DNA synthesis in cells by incorporation into newly synthesized DNA.,Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine is used as a radiolabel ([3H]thymidine) to measure DNA synthesis in cells by incorporation into newly synthesized DNA.
sodium hydroxide,Sodium hydroxide (NaOH) is used to dissolve TCA-insoluble fractions in DNA and collagen assays to facilitate detection of incorporated radiolabeled nucleotides or amino acids.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide (NaOH) is used to dissolve TCA-insoluble fractions in DNA and collagen assays to facilitate detection of incorporated radiolabeled nucleotides or amino acids.
proline,Proline is used as a radiolabel ([3H]proline) to measure collagen synthesis in cells by incorporation into newly synthesized collagen.,Entity: proline. SMILES: O=C(O)[C@@H]1CCCN1. Proline is used as a radiolabel ([3H]proline) to measure collagen synthesis in cells by incorporation into newly synthesized collagen.
sodium chlorate,Sodium chlorate at 15 mM does not induce toxic effects on osteoblastic cells in culture when used for 1–8 days.,Entity: sodium chlorate. SMILES: [Na+].[O-][Cl+2]([O-])[O-]. Sodium chlorate at 15 mM does not induce toxic effects on osteoblastic cells in culture when used for 1–8 days.
ascorbic acid,Ascorbic acid is used as a supplement at 300 µg/ml in Fitton-Jackson modified BGJb medium for culturing mandibular condyles and calvarias.,Entity: ascorbic acid. SMILES: O=C1O[C@H]([C@@H](O)CO)C(O)=C1O. Ascorbic acid is used as a supplement at 300 µg/ml in Fitton-Jackson modified BGJb medium for culturing mandibular condyles and calvarias.
streptomycin,Streptomycin is included as an antibiotic at 100 µg/ml in the culture medium for mandibular condyle and calvaria tissue samples.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is included as an antibiotic at 100 µg/ml in the culture medium for mandibular condyle and calvaria tissue samples.
chlorate,Chlorate inhibits sulfation of membrane-associated chondroitin sulfate and heparan sulfate chains.,Entity: chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Chlorate inhibits sulfation of membrane-associated chondroitin sulfate and heparan sulfate chains.
chlorate,Chlorate reduces the synthesis and incorporation of chondroitin sulfate proteoglycans.,Entity: chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Chlorate reduces the synthesis and incorporation of chondroitin sulfate proteoglycans.
chlorate,Undersulfation of glycosaminoglycans (GAGs) by chlorate reduces tritiated proline uptake in calvaria.,Entity: chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Undersulfation of glycosaminoglycans (GAGs) by chlorate reduces tritiated proline uptake in calvaria.
chlorate,"Cholate does not abolish the effect of recombinant human FGF-2 on protein synthesis, as measured by [35S]sulfate incorporation, in condyle or calvaria cells.","Entity: chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Cholate does not abolish the effect of recombinant human FGF-2 on protein synthesis, as measured by [35S]sulfate incorporation, in condyle or calvaria cells."
chlorate,"Cholate does not inhibit the effect of recombinant human FGF-2 on collagen synthesis, as measured by [3H]proline incorporation, in condyle or calvaria cells.","Entity: chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Cholate does not inhibit the effect of recombinant human FGF-2 on collagen synthesis, as measured by [3H]proline incorporation, in condyle or calvaria cells."
chlorate,Cholate does not inhibit the stimulatory effect of recombinant human FGF-2 on DNA synthesis in calvaria or condyle cells.,Entity: chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Cholate does not inhibit the stimulatory effect of recombinant human FGF-2 on DNA synthesis in calvaria or condyle cells.
chlorate,Chlorate is an inhibitor of adenylyltransferase that blocks all types of protein sulfation and inhibits [35S]sulfate incorporation into glycosaminoglycans (GAGs).,Entity: chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Chlorate is an inhibitor of adenylyltransferase that blocks all types of protein sulfation and inhibits [35S]sulfate incorporation into glycosaminoglycans (GAGs).
dermatan sulfate,"Dermatan sulfate is a type of glycosaminoglycan (GAG) chain that can be secreted by cells, with β-xylosides increasing its secretion.","Entity: dermatan sulfate. SMILES: CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O)[C@H](O)[C@H]2O)[C@@H](OS(=O)(=O)[O-])[C@@H](CO)O[C@H]1O. Dermatan sulfate is a type of glycosaminoglycan (GAG) chain that can be secreted by cells, with β-xylosides increasing its secretion."
dermatan sulfate,Dermatan sulfate is a type of glycosaminoglycan that can be attached to a core protein in proteoglycans.,Entity: dermatan sulfate. SMILES: CC(=O)N[C@@H]1[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O)[C@H](O)[C@H]2O)[C@@H](OS(=O)(=O)[O-])[C@@H](CO)O[C@H]1O. Dermatan sulfate is a type of glycosaminoglycan that can be attached to a core protein in proteoglycans.
chondroitin sulfate,Chondroitin sulfate is a type of glycosaminoglycan that can be attached to a core protein in proteoglycans and is associated with large and small proteoglycans in bone and cartilage matrices.,Entity: chondroitin sulfate. SMILES: CC(=O)N[C@H]1[C@@H](OC2OC(C(=O)O)=C[C@@H](O)[C@H]2O)[C@@H](O)[C@@H](CO)O[C@H]1O. Chondroitin sulfate is a type of glycosaminoglycan that can be attached to a core protein in proteoglycans and is associated with large and small proteoglycans in bone and cartilage matrices.
chlorate,"Cholate inhibits proteoglycan synthesis and deposition in the matrix of neonatal mandibular condyle and calvaria, as shown by reduced alcian blue staining at both 1 and 4 days of culture in condyle and at 4 and 8 days in calvaria.","Entity: chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Cholate inhibits proteoglycan synthesis and deposition in the matrix of neonatal mandibular condyle and calvaria, as shown by reduced alcian blue staining at both 1 and 4 days of culture in condyle and at 4 and 8 days in calvaria."
methyl methacrylate,Methyl methacrylate is used as an embedding medium for undecalcified tissue sections in morphological and histological analysis.,Entity: methyl methacrylate. SMILES: C=C(C)C(=O)OC. Methyl methacrylate is used as an embedding medium for undecalcified tissue sections in morphological and histological analysis.
proline,Proline can be used as a radiolabeling agent ([3H]proline) to label newly synthesized collagenous matrix in tissue explants.,Entity: proline. SMILES: O=C(O)[C@@H]1CCCN1. Proline can be used as a radiolabeling agent ([3H]proline) to label newly synthesized collagenous matrix in tissue explants.
formaldehyde,Formaldehyde is used as a fixative for tissue samples prior to dehydration and embedding in histological analysis.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a fixative for tissue samples prior to dehydration and embedding in histological analysis.
toluidine blue,"Toluidine blue is used as a counterstain in histological processing, specifically at pH 2.7, to visualize tissue sections after autoradiography.","Entity: toluidine blue. SMILES: Cc1ccc(Nc2ccc(O)c3c2C(=O)c2c(O)ccc(Nc4ccc(C)cc4S(=O)(=O)[O-])c2C3=O)c(S(=O)(=O)[O-])c1.[Na+].[Na+]. Toluidine blue is used as a counterstain in histological processing, specifically at pH 2.7, to visualize tissue sections after autoradiography."
trichloroacetic acid,Trichloroacetic acid is used as a precipitating agent for collecting glycosaminoglycan-containing samples in proteoglycan synthesis studies.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used as a precipitating agent for collecting glycosaminoglycan-containing samples in proteoglycan synthesis studies.
magnesium sulfate,Magnesium sulfate is used in combination with trichloroacetic acid to precipitate samples during proteoglycan synthesis analysis.,Entity: magnesium sulfate. SMILES: O=S(=O)([O-])[O-].[Mg+2]. Magnesium sulfate is used in combination with trichloroacetic acid to precipitate samples during proteoglycan synthesis analysis.
sodium hydroxide,Sodium hydroxide is used to dissolve precipitated samples at 65°C for 1 hour in proteoglycan synthesis assays.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used to dissolve precipitated samples at 65°C for 1 hour in proteoglycan synthesis assays.
proline,Tritiated proline uptake is used as an assay to evaluate collagenous matrix synthesis in skeletal cells.,Entity: proline. SMILES: O=C(O)[C@@H]1CCCN1. Tritiated proline uptake is used as an assay to evaluate collagenous matrix synthesis in skeletal cells.
thymidine,Thymidine incorporation into DNA is used as a measure of cell proliferation in skeletal cells.,Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine incorporation into DNA is used as a measure of cell proliferation in skeletal cells.
chlorate,"Chorate reduces tritiated proline uptake in calvaria, indicating an effect on collagenous matrix synthesis in this tissue.","Entity: chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Chorate reduces tritiated proline uptake in calvaria, indicating an effect on collagenous matrix synthesis in this tissue."
Triton,Triton is a non-ionic detergent used at 0.01% concentration in phosphate-buffered saline to reduce unspecific binding in immunocytochemistry.,Entity: Triton. SMILES: [3H+]. Triton is a non-ionic detergent used at 0.01% concentration in phosphate-buffered saline to reduce unspecific binding in immunocytochemistry.
alcian blue,Alcian blue is a histological stain used at pH 1 to evaluate sulfated proteoglycans in tissue sections.,Entity: alcian blue. SMILES: CN(C)C(SCc1ccc2c(c1)C1=NC2=NC2=NC(=NC3[N-]C(N=c4[n-]c(c5ccc(CSC(N(C)C)=[N+](C)C)cc45)=N1)c1ccc(CSC(N(C)C)=[N+](C)C)cc13)c1cc(CSC(N(C)C)=[N+](C)C)ccc12)=[N+](C)C.[Cl-].[Cl-].[Cl-].[Cl-].[Cu+2]. Alcian blue is a histological stain used at pH 1 to evaluate sulfated proteoglycans in tissue sections.
ethylenediamine tetraacetic acid,Ethylenediamine tetraacetic acid (EDTA) is used as a decalcifying agent for calvarias in histological sample preparation.,Entity: ethylenediamine tetraacetic acid. SMILES: CC(=O)O.CC(=O)O.CC(=O)O.CC(=O)O.NCCN. Ethylenediamine tetraacetic acid (EDTA) is used as a decalcifying agent for calvarias in histological sample preparation.
xylene,Xylene is used for deparaffinization of tissue sections in immunocytochemistry protocols.,Entity: xylene. SMILES: Cc1ccccc1C. Xylene is used for deparaffinization of tissue sections in immunocytochemistry protocols.
diaminobenzidine,Diaminobenzidine is used as a chromogenic substrate at 1 mg/ml in 10 mM TRIS buffer (pH 7.6) with 0.05% hydrogen peroxide to visualize specific antigen-antibody binding in immunohistochemistry.,Entity: diaminobenzidine. SMILES: NNc1ccc(-c2ccc(NN)cc2)cc1. Diaminobenzidine is used as a chromogenic substrate at 1 mg/ml in 10 mM TRIS buffer (pH 7.6) with 0.05% hydrogen peroxide to visualize specific antigen-antibody binding in immunohistochemistry.
hydrogen peroxide,Hydrogen peroxide is used at 3% concentration for 30 minutes to eliminate endogenous peroxidase activity in tissue sections and at 0.05% in the immunohistochemical staining solution to enhance colorimetric detection.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide is used at 3% concentration for 30 minutes to eliminate endogenous peroxidase activity in tissue sections and at 0.05% in the immunohistochemical staining solution to enhance colorimetric detection.
sodium chlorate,"Sodium chlorate is a competitive inhibitor of glycoconjugate sulfation that, when applied at 15 mM for 1–8 days, inhibits cellular proteoglycan synthesis by 60–80% in neonatal rat condyle and calvaria as measured by [35S]sulfate incorporation.","Entity: sodium chlorate. SMILES: [Na+].[O-][Cl+2]([O-])[O-]. Sodium chlorate is a competitive inhibitor of glycoconjugate sulfation that, when applied at 15 mM for 1–8 days, inhibits cellular proteoglycan synthesis by 60–80% in neonatal rat condyle and calvaria as measured by [35S]sulfate incorporation."
[35S]sulfate,[35S]sulfate incorporation is used as a biochemical assay to evaluate cellular proteoglycan synthesis in neonatal rat condyle and calvaria in vitro.,Entity: [35S]sulfate. SMILES: O=[35S](=O)([O-])[O-]. [35S]sulfate incorporation is used as a biochemical assay to evaluate cellular proteoglycan synthesis in neonatal rat condyle and calvaria in vitro.
chlorate,"Cholate inhibits the mitogenic effects of rhFGF-2 in calvaria, and also inhibits the mitogenic effects of GM-CSF in cultured osteoblastic cells.","Entity: chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Cholate inhibits the mitogenic effects of rhFGF-2 in calvaria, and also inhibits the mitogenic effects of GM-CSF in cultured osteoblastic cells."
Chlorate,"In cultured calvaria, chlorate inhibits chondroitin sulfate matrix deposition by 54% at 8 days of culture.","Entity: Chlorate. SMILES: [O-][Cl+2]([O-])[O-]. In cultured calvaria, chlorate inhibits chondroitin sulfate matrix deposition by 54% at 8 days of culture."
Chlorate,"The inhibitory effect of chlorate on proteoglycan synthesis in skeletal cells is reversible, as restoration of chondroitin sulfate deposition occurs after removal of chlorate.","Entity: Chlorate. SMILES: [O-][Cl+2]([O-])[O-]. The inhibitory effect of chlorate on proteoglycan synthesis in skeletal cells is reversible, as restoration of chondroitin sulfate deposition occurs after removal of chlorate."
Chlorate,"Chlorate reversibly inhibits proteoglycan synthesis by skeletal cells, reducing chondroitin sulfate deposition in cartilage and bone matrices.","Entity: Chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Chlorate reversibly inhibits proteoglycan synthesis by skeletal cells, reducing chondroitin sulfate deposition in cartilage and bone matrices."
Chlorate,"In cultured condyle, chlorate inhibits chondroitin sulfate matrix deposition by 55% at 8 days of culture.","Entity: Chlorate. SMILES: [O-][Cl+2]([O-])[O-]. In cultured condyle, chlorate inhibits chondroitin sulfate matrix deposition by 55% at 8 days of culture."
chlorate,Cholate inhibits osteogenesis by preventing the formation of bone matrix in condyles during culture.,Entity: chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Cholate inhibits osteogenesis by preventing the formation of bone matrix in condyles during culture.
Proline,"Proline uptake in osteoid is reduced in cultured calvaria after treatment with β-D-xyloside for 4 days, indicating decreased collagen deposition in the bone matrix.","Entity: Proline. SMILES: O=C(O)[C@@H]1CCCN1. Proline uptake in osteoid is reduced in cultured calvaria after treatment with β-D-xyloside for 4 days, indicating decreased collagen deposition in the bone matrix."
Chlorate,"Chlorate inhibits osteogenesis in cultured calvaria, as evidenced by reduced osteoid formation and proline uptake in bone matrix after 4 days of treatment.","Entity: Chlorate. SMILES: [O-][Cl+2]([O-])[O-]. Chlorate inhibits osteogenesis in cultured calvaria, as evidenced by reduced osteoid formation and proline uptake in bone matrix after 4 days of treatment."
FGF-2,"FGF-2 exerts its mitogenic response in calvaria, which is blocked by inhibition of proteoglycan synthesis, indicating that functional proteoglycans are essential for FGF-2-mediated osteogenic differentiation in vitro.","Entity: FGF-2. FGF-2 exerts its mitogenic response in calvaria, which is blocked by inhibition of proteoglycan synthesis, indicating that functional proteoglycans are essential for FGF-2-mediated osteogenic differentiation in vitro."
Dopamine,Dopamine is synthesized from tyrosine via a pathway involving the enzyme tyrosine hydroxylase.,Entity: Dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine is synthesized from tyrosine via a pathway involving the enzyme tyrosine hydroxylase.
Serotonin,"Serotonin is a product of the biosynthetic pathway from tyrosine, catalyzed by tyrosine hydroxylase.","Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin is a product of the biosynthetic pathway from tyrosine, catalyzed by tyrosine hydroxylase."
Texas red,"Texas red is a fluorescent dye used as a label for secondary antibodies in immunocytochemistry, enabling detection with a specific filter set.","Entity: Texas red. SMILES: O=S(=O)([O-])c1cc(S(=O)(=O)Cl)ccc1C1=c2cc3c4c(c2Oc2c1cc1c5c2CCCN5CCC1)CCC[N+]=4CCC3. Texas red is a fluorescent dye used as a label for secondary antibodies in immunocytochemistry, enabling detection with a specific filter set."
Serotonin,Serotonin is distributed in serotonin-containing neurons that modulate stomatogastric complex (CPGs) in various crustacean species.,Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin is distributed in serotonin-containing neurons that modulate stomatogastric complex (CPGs) in various crustacean species.
Serotonin,"In Cancer crab, the serotonergic innervation of the stomatogastric ganglion (STG) is supplied solely by GPR neurons, with their somata located in lateral ventral nerves or small nerves branching from them, and their dendrites embedded in adjacent gastric muscles.","Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. In Cancer crab, the serotonergic innervation of the stomatogastric ganglion (STG) is supplied solely by GPR neurons, with their somata located in lateral ventral nerves or small nerves branching from them, and their dendrites embedded in adjacent gastric muscles."
Serotonin,"Homologous serotonin-containing proprioceptor neurons to GPR cells have been found in species such as Homarus americanus, Callinectes sapidus, Pagurus pollicaris, and Procambarus clarkii.","Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Homologous serotonin-containing proprioceptor neurons to GPR cells have been found in species such as Homarus americanus, Callinectes sapidus, Pagurus pollicaris, and Procambarus clarkii."
Dopamine,The antiserum used to detect serotonin in crustacean tissues is non-cross-reactive with dopamine.,Entity: Dopamine. SMILES: NCCc1ccc(O)c(O)c1. The antiserum used to detect serotonin in crustacean tissues is non-cross-reactive with dopamine.
Octopamine,The antiserum used to detect serotonin in crustacean tissues is non-cross-reactive with octopamine.,Entity: Octopamine. SMILES: NCC(O)c1ccc(O)cc1. The antiserum used to detect serotonin in crustacean tissues is non-cross-reactive with octopamine.
Triton X-100,"Triton X-100 is a non-ionic detergent commonly used in immunocytochemistry protocols to permeabilize tissue membranes, typically at a concentration of 4% in PBS.","Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent commonly used in immunocytochemistry protocols to permeabilize tissue membranes, typically at a concentration of 4% in PBS."
D-glucose,"D-glucose is a component of Millonig's buffer, a fixative solution used in immunocytochemistry for preserving tissue morphology.","Entity: D-glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. D-glucose is a component of Millonig's buffer, a fixative solution used in immunocytochemistry for preserving tissue morphology."
glycerol,"Glycerol is used as a mounting medium for immunocytochemically stained tissues, often combined with 5% n-propyl gallate.","Entity: glycerol. SMILES: OCC(O)CO. Glycerol is used as a mounting medium for immunocytochemically stained tissues, often combined with 5% n-propyl gallate."
fluorescein,"Fluorescein is used as a fluorescent label for secondary antibodies in immunocytochemistry, with excitation at 460-500 nm and emission in the 510-550 nm range.","Entity: fluorescein. SMILES: O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21. Fluorescein is used as a fluorescent label for secondary antibodies in immunocytochemistry, with excitation at 460-500 nm and emission in the 510-550 nm range."
n-propyl gallate,"n-propyl gallate is used as a mounting medium for immunocytochemically stained tissues, typically at a concentration of 5% in glycerol.","Entity: n-propyl gallate. SMILES: CCCOC(=O)c1cc(O)c(O)c(O)c1. n-propyl gallate is used as a mounting medium for immunocytochemically stained tissues, typically at a concentration of 5% in glycerol."
Texas red,"Texas red is used as a fluorescent label for secondary antibodies in immunocytochemistry, with excitation at 530-550 nm and emission in the 590-650 nm range.","Entity: Texas red. SMILES: O=S(=O)([O-])c1cc(S(=O)(=O)Cl)ccc1C1=c2cc3c4c(c2Oc2c1cc1c5c2CCCN5CCC1)CCC[N+]=4CCC3. Texas red is used as a fluorescent label for secondary antibodies in immunocytochemistry, with excitation at 530-550 nm and emission in the 590-650 nm range."
Proctolin,"Proctolin is a peptide neurotransmitter whose distribution and immunostaining variability in the ion-iln nerves of decapod crustaceans are species-specific, with differences observed even among congeneric species.","Entity: Proctolin. SMILES: CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)[C@@H](C)O. Proctolin is a peptide neurotransmitter whose distribution and immunostaining variability in the ion-iln nerves of decapod crustaceans are species-specific, with differences observed even among congeneric species."
Serotonin,"Serotonin (5-HT) is a neurotransmitter whose immunolabeling and distribution in the ion-iln nerves of decapod crustaceans vary among species, with some species showing prominent staining, while others display only faint or no staining, and differences may reflect quantitative or qualitative differences in its presence or distribution.","Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin (5-HT) is a neurotransmitter whose immunolabeling and distribution in the ion-iln nerves of decapod crustaceans vary among species, with some species showing prominent staining, while others display only faint or no staining, and differences may reflect quantitative or qualitative differences in its presence or distribution."
Dopamine,"Dopamine (DA) distribution and immunostaining in the ion-iln nerves of decapod crustaceans are species-specific, with variability observed in the number of dopamine-containing somata and axons among closely related species.","Entity: Dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine (DA) distribution and immunostaining in the ion-iln nerves of decapod crustaceans are species-specific, with variability observed in the number of dopamine-containing somata and axons among closely related species."
Serotonin,"Serotonin is present in the L cell of American lobster (H. americanus) and in the L cells of H. gammarus, where it co-occurs with dopamine.","Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin is present in the L cell of American lobster (H. americanus) and in the L cells of H. gammarus, where it co-occurs with dopamine."
Proctolin,"Proctolin is present in the L cells of American lobster (H. americanus), Cancer irroratus, and Cancer borealis, but absent in crayfish L cells.","Entity: Proctolin. SMILES: CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)[C@@H](C)O. Proctolin is present in the L cells of American lobster (H. americanus), Cancer irroratus, and Cancer borealis, but absent in crayfish L cells."
Dopamine,"Dopamine is present in the L cell of all species examined, including American lobster (H. americanus), Cancer irroratus, Cancer borealis, and crayfish, and can co-occur with serotonin or proctolin depending on the species.","Entity: Dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine is present in the L cell of all species examined, including American lobster (H. americanus), Cancer irroratus, Cancer borealis, and crayfish, and can co-occur with serotonin or proctolin depending on the species."
Lucifer yellow,"Lucifer yellow is used as a fluorescent tracer to backfill nerve fibers in immunocytochemistry techniques, allowing visualization of axonal projections.","Entity: Lucifer yellow. SMILES: NNC(=O)N1C(=O)c2cc(S(=O)(=O)[O-])cc3c(N)c(S(=O)(=O)[O-])cc(c23)C1=O.[Li+].[Li+]. Lucifer yellow is used as a fluorescent tracer to backfill nerve fibers in immunocytochemistry techniques, allowing visualization of axonal projections."
Texas red,"Texas red is used as a fluorescent dye in immunocytochemistry, conjugated to secondary antibodies to enable detection of specific targets with a separate filter set.","Entity: Texas red. SMILES: O=S(=O)([O-])c1cc(S(=O)(=O)Cl)ccc1C1=c2cc3c4c(c2Oc2c1cc1c5c2CCCN5CCC1)CCC[N+]=4CCC3. Texas red is used as a fluorescent dye in immunocytochemistry, conjugated to secondary antibodies to enable detection of specific targets with a separate filter set."
Serotonin,Serotonin can be specifically labeled in neuronal tissues using immunocytochemical methods with a Texas red-conjugated secondary antibody.,Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin can be specifically labeled in neuronal tissues using immunocytochemical methods with a Texas red-conjugated secondary antibody.
Texas red,"Texas red is used as a fluorescent dye to visualize structures in crayfish nervous tissue, such as somata and axonal processes, in combination with anti-serotonin antibodies.","Entity: Texas red. SMILES: O=S(=O)([O-])c1cc(S(=O)(=O)Cl)ccc1C1=c2cc3c4c(c2Oc2c1cc1c5c2CCCN5CCC1)CCC[N+]=4CCC3. Texas red is used as a fluorescent dye to visualize structures in crayfish nervous tissue, such as somata and axonal processes, in combination with anti-serotonin antibodies."
Lucifer yellow,"Lucifer yellow is used as a fluorescent backfill to trace axonal pathways in crayfish nervous tissue, but in this context, it did not label the same structures as anti-serotonin antibodies, indicating potential staining differences.","Entity: Lucifer yellow. SMILES: NNC(=O)N1C(=O)c2cc(S(=O)(=O)[O-])cc3c(N)c(S(=O)(=O)[O-])cc(c23)C1=O.[Li+].[Li+]. Lucifer yellow is used as a fluorescent backfill to trace axonal pathways in crayfish nervous tissue, but in this context, it did not label the same structures as anti-serotonin antibodies, indicating potential staining differences."
Serotonin,"Preincubation with serotonin (10^-5 M) intensifies the staining of somata in crayfish commissural ganglia and increases the brightness of axonal processes, especially in somata adjacent to the L cell.","Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Preincubation with serotonin (10^-5 M) intensifies the staining of somata in crayfish commissural ganglia and increases the brightness of axonal processes, especially in somata adjacent to the L cell."
Fluorescein,"Fluorescein is used as a fluorescent dye to visualize structures in crayfish nervous tissue, such as somata and axonal processes, in combination with anti-serotonin antibodies.","Entity: Fluorescein. SMILES: O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21. Fluorescein is used as a fluorescent dye to visualize structures in crayfish nervous tissue, such as somata and axonal processes, in combination with anti-serotonin antibodies."
Serotonin,"Serotonin is a target amine for which specific antibodies are available, and these antibodies are designed to avoid cross-reactivity with other amines such as octopamine and dopamine.","Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin is a target amine for which specific antibodies are available, and these antibodies are designed to avoid cross-reactivity with other amines such as octopamine and dopamine."
ATP,"ATP is used as a radioactive label for end-labeling DNA primers in PCR reactions, with [␥-32 P]ATP providing 6000 Ci/mmole label strength.","Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP is used as a radioactive label for end-labeling DNA primers in PCR reactions, with [␥-32 P]ATP providing 6000 Ci/mmole label strength."
KCl,KCl is used at a concentration of 50 mM in PCR reaction mixtures to maintain ionic strength during DNA amplification.,Entity: KCl. SMILES: [Cl-].[K+]. KCl is used at a concentration of 50 mM in PCR reaction mixtures to maintain ionic strength during DNA amplification.
MgCl2,MgCl2 is included at a concentration of 2 mM in PCR reaction mixtures to facilitate DNA polymerase activity.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is included at a concentration of 2 mM in PCR reaction mixtures to facilitate DNA polymerase activity.
Tris-Cl,Tris-Cl is used at a concentration of 10 mM and pH 8.3 as a buffering agent in PCR reaction mixtures.,Entity: Tris-Cl. SMILES: NC(CO)(CO)CO. Tris-Cl is used at a concentration of 10 mM and pH 8.3 as a buffering agent in PCR reaction mixtures.
SDS,SDS (sodium dodecyl sulfate) is used as a detergent at 0.5% concentration in hybridization buffers for nucleic acid hybridization procedures.,Entity: SDS. SMILES: CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]. SDS (sodium dodecyl sulfate) is used as a detergent at 0.5% concentration in hybridization buffers for nucleic acid hybridization procedures.
GDF6,"GDF6 is a member of the TGF-beta superfamily and is encoded by the zebrafish genes dynamo and radar, as well as the mammalian gene GDF6.","Entity: GDF6. GDF6 is a member of the TGF-beta superfamily and is encoded by the zebrafish genes dynamo and radar, as well as the mammalian gene GDF6."
GDF7,"GDF7 is a member of the TGF-beta superfamily and is encoded by the zebrafish gene gdf7, which is orthologous to mammalian GDF7/Gdf7.","Entity: GDF7. GDF7 is a member of the TGF-beta superfamily and is encoded by the zebrafish gene gdf7, which is orthologous to mammalian GDF7/Gdf7."
radar,Radar is a zebrafish gene encoding a protein most similar to mouse GDF6 and is orthologous to mammalian GDF6/Gdf6.,Entity: radar. Radar is a zebrafish gene encoding a protein most similar to mouse GDF6 and is orthologous to mammalian GDF6/Gdf6.
gdf7,"gdf7 is a zebrafish gene belonging to the Gdf5, 6, 7 subgroup and is orthologous to mammalian GDF7/Gdf7.","Entity: gdf7. gdf7 is a zebrafish gene belonging to the Gdf5, 6, 7 subgroup and is orthologous to mammalian GDF7/Gdf7."
plexin,Plexin is a member of a protein family that includes the novel protein identified in cosmid clones from Drosophila melanogaster chromosome 4.,Entity: plexin. Plexin is a member of a protein family that includes the novel protein identified in cosmid clones from Drosophila melanogaster chromosome 4.
ribosomal protein S3a,A gene with a predicted amino acid sequence similar to ribosomal protein S3a was identified in a cosmid clone from Drosophila melanogaster chromosome 4.,Entity: ribosomal protein S3a. A gene with a predicted amino acid sequence similar to ribosomal protein S3a was identified in a cosmid clone from Drosophila melanogaster chromosome 4.
zinc-finger-homolog-2,Zinc-finger-homolog-2 (zfh-2) is a gene whose two shortest 5'-most exons were identified in a cosmid clone from Drosophila melanogaster chromosome 4.,Entity: zinc-finger-homolog-2. Zinc-finger-homolog-2 (zfh-2) is a gene whose two shortest 5'-most exons were identified in a cosmid clone from Drosophila melanogaster chromosome 4.
cubitus interruptus,Cubitus interruptus (ci) is a gene previously described and included in one of the cosmid clones from Drosophila melanogaster chromosome 4.,Entity: cubitus interruptus. Cubitus interruptus (ci) is a gene previously described and included in one of the cosmid clones from Drosophila melanogaster chromosome 4.
AIRE,"AIRE is a putative transcription-associated factor encoded by the human AIRE gene, which is associated with the autoimmune disease APECED (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy; OMIM 240300).","Entity: AIRE. AIRE is a putative transcription-associated factor encoded by the human AIRE gene, which is associated with the autoimmune disease APECED (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy; OMIM 240300)."
Aire,"Three splice variant isoforms of Aire are detected by RT-PCR in various mouse tissues, with one isoform conserved between human and mouse, suggesting biological significance.","Entity: Aire. Three splice variant isoforms of Aire are detected by RT-PCR in various mouse tissues, with one isoform conserved between human and mouse, suggesting biological significance."
AIRE,"AIRE expression in both mouse and human tissues is mainly restricted to a few cells in the thymus, indicating a tissue-specific function for the AIRE gene product.","Entity: AIRE. AIRE expression in both mouse and human tissues is mainly restricted to a few cells in the thymus, indicating a tissue-specific function for the AIRE gene product."
Aire,"Aire is the murine ortholog of the human AIRE gene, sharing 73% conceptual protein homology and the same typical functional domains.","Entity: Aire. Aire is the murine ortholog of the human AIRE gene, sharing 73% conceptual protein homology and the same typical functional domains."
sucrose,"Sucrose, when used to supplement brain heart infusion broth, enables Streptococcus mutans and Streptococcus sanguis to trigger polymorphonuclear leukocyte enzyme release.","Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose, when used to supplement brain heart infusion broth, enables Streptococcus mutans and Streptococcus sanguis to trigger polymorphonuclear leukocyte enzyme release."
sucrose,Bacterial synthesis of glucans from sucrose may contribute to the modulation of polymorphonuclear neutrophil-bacterial interactions.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Bacterial synthesis of glucans from sucrose may contribute to the modulation of polymorphonuclear neutrophil-bacterial interactions.
dextran,Dextran promotes polymorphonuclear leukocyte enzyme release when used to preincubate viable Streptococcus mutans.,Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran promotes polymorphonuclear leukocyte enzyme release when used to preincubate viable Streptococcus mutans.
dextran,Dextran may modulate polymorphonuclear neutrophil-bacterial interactions by promoting microbial adhesiveness or aggregation.,Entity: dextran. SMILES: O=CC(O)C(O)C(O)C(O)COC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O. Dextran may modulate polymorphonuclear neutrophil-bacterial interactions by promoting microbial adhesiveness or aggregation.
glucose,"Supplementation of brain heart infusion broth with glucose, but not sucrose, does not induce polymorphonuclear leukocyte enzyme release from Streptococcus mutans or Streptococcus sanguis.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Supplementation of brain heart infusion broth with glucose, but not sucrose, does not induce polymorphonuclear leukocyte enzyme release from Streptococcus mutans or Streptococcus sanguis."
DMBA,"DMBA binds to hamster embryo cell DNA, RNA, and protein maximally after 22 hours of treatment.","Entity: DMBA. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. DMBA binds to hamster embryo cell DNA, RNA, and protein maximally after 22 hours of treatment."
DMBA,The binding of DMBA to hamster embryo cell DNA decreases approximately 100-fold between population doubling numbers 8 and 20.,Entity: DMBA. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. The binding of DMBA to hamster embryo cell DNA decreases approximately 100-fold between population doubling numbers 8 and 20.
DMBA,"In transformable hamster embryo cell cultures, DMBA binds to DNA to a greater extent than to RNA or protein.","Entity: DMBA. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. In transformable hamster embryo cell cultures, DMBA binds to DNA to a greater extent than to RNA or protein."
DMBA,DMBA exhibits the best correlation between binding to nucleic acids and carcinogenicity and transforming activity among the tested polycyclic aromatic hydrocarbons.,Entity: DMBA. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. DMBA exhibits the best correlation between binding to nucleic acids and carcinogenicity and transforming activity among the tested polycyclic aromatic hydrocarbons.
"dibenz[a,h]anthracene","Dibenz[a,h]anthracene shows low binding to hamster embryo cell DNA, RNA, and protein at all tested population doubling numbers.","Entity: dibenz[a,h]anthracene. SMILES: c1ccc2c(c1)ccc1cc3c(ccc4ccccc43)cc12. Dibenz[a,h]anthracene shows low binding to hamster embryo cell DNA, RNA, and protein at all tested population doubling numbers."
"dibenz-[a,c]anthracene","Dibenz-[a,c]anthracene exhibits low binding to hamster embryo cell DNA, RNA, and protein at all tested population doubling numbers.","Entity: dibenz-[a,c]anthracene. SMILES: c1ccc2cc3c4ccccc4c4ccccc4c3cc2c1. Dibenz-[a,c]anthracene exhibits low binding to hamster embryo cell DNA, RNA, and protein at all tested population doubling numbers."
"7,12-Dimethylbenzanthrone","7,12-Dimethylbenzanthrone binds to human embryo cell protein to a much higher degree than to DNA or RNA, with binding increasing until population doubling number 70.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. 7,12-Dimethylbenzanthrone binds to human embryo cell protein to a much higher degree than to DNA or RNA, with binding increasing until population doubling number 70."
"7,12-Dimethylbenzanthrone","7,12-Dimethylbenzanthrone binds to hamster embryo cell DNA and RNA at much higher levels than to human embryo cells.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. 7,12-Dimethylbenzanthrone binds to hamster embryo cell DNA and RNA at much higher levels than to human embryo cells."
"7,12-Dimethylbenzanthrone","7,12-Dimethylbenzanthrone binds to the DNA, RNA, and protein of hamster embryo cells, with DNA binding being 4–5-fold greater than RNA binding and protein binding being similar or lower, depending on the population doubling number.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. 7,12-Dimethylbenzanthrone binds to the DNA, RNA, and protein of hamster embryo cells, with DNA binding being 4–5-fold greater than RNA binding and protein binding being similar or lower, depending on the population doubling number."
"7,12-Dimethylbenzanthrone","The binding of 7,12-Dimethylbenzanthrone to hamster embryo cells is highest at population doubling numbers 0, 1, and 8, and decreases between population doubling numbers 8 and 14, remaining at basal levels by population doubling number 20.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. The binding of 7,12-Dimethylbenzanthrone to hamster embryo cells is highest at population doubling numbers 0, 1, and 8, and decreases between population doubling numbers 8 and 14, remaining at basal levels by population doubling number 20."
"7,12-Dimethylbenzanthrone","The binding of 7,12-Dimethylbenzanthrone to hamster embryo cells is about 100 times greater than that of DB[a,h]A for DNA, and is lower than for RNA.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. The binding of 7,12-Dimethylbenzanthrone to hamster embryo cells is about 100 times greater than that of DB[a,h]A for DNA, and is lower than for RNA."
"7,12-Dimethylbenzanthrone","7,12-Dimethylbenzanthrone binds to hamster embryo cell protein at each population doubling number, but the values are lower than or equal to those for DB[a,h]A.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. 7,12-Dimethylbenzanthrone binds to hamster embryo cell protein at each population doubling number, but the values are lower than or equal to those for DB[a,h]A."
"7,12-dimethylbenzanthrone","7,12-dimethylbenzanthrone binds to human diploid WI-38 DNA and protein in culture.","Entity: 7,12-dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. 7,12-dimethylbenzanthrone binds to human diploid WI-38 DNA and protein in culture."
benzo(a)pyrene,Benzo(a)pyrene binds to primary human embryonic lung cells.,Entity: benzo(a)pyrene. SMILES: c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34. Benzo(a)pyrene binds to primary human embryonic lung cells.
"7,12-dimethylbenzanthrone","7,12-dimethylbenzanthrone is a radiolabeled carcinogen used in cell culture experiments, with a radiochemical purity greater than 96% as determined by thin layer chromatography.","Entity: 7,12-dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. 7,12-dimethylbenzanthrone is a radiolabeled carcinogen used in cell culture experiments, with a radiochemical purity greater than 96% as determined by thin layer chromatography."
dimethylsulfoxide,Dimethylsulfoxide is used as a solvent to dissolve radiolabeled carcinogens such as [aH]DMBA in cell culture experiments.,Entity: dimethylsulfoxide. SMILES: CS(C)=O. Dimethylsulfoxide is used as a solvent to dissolve radiolabeled carcinogens such as [aH]DMBA in cell culture experiments.
L-glutamine,L-glutamine is used as a supplement at 2 mM concentration in Dulbecco's Modified Eagle's Medium (DMEM) for cell culture.,Entity: L-glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. L-glutamine is used as a supplement at 2 mM concentration in Dulbecco's Modified Eagle's Medium (DMEM) for cell culture.
hexane,"Hexane is used as a component of the solvent system (with benzene, 15:1) for thin layer chromatography to determine the radiochemical purity of carcinogens.","Entity: hexane. SMILES: CCCCCC. Hexane is used as a component of the solvent system (with benzene, 15:1) for thin layer chromatography to determine the radiochemical purity of carcinogens."
benzene,"Benzene is used as a component of the solvent system (with hexane, 15:1) for thin layer chromatography to assess the radiochemical purity of carcinogens.","Entity: benzene. SMILES: c1ccccc1. Benzene is used as a component of the solvent system (with hexane, 15:1) for thin layer chromatography to assess the radiochemical purity of carcinogens."
"7,12-dimethylbenzanthrone","7,12-dimethylbenzanthrone is used as a test carcinogen in hamster embryo cell cultures to evaluate transformation potential at different population doubling levels.","Entity: 7,12-dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. 7,12-dimethylbenzanthrone is used as a test carcinogen in hamster embryo cell cultures to evaluate transformation potential at different population doubling levels."
dimethylsulfoxide,"Dimethylsulfoxide is used as a final concentration of 0.1% in cell treatment experiments involving DMBA and DB[a,c]A and DB[a,h]A.","Entity: dimethylsulfoxide. SMILES: CS(C)=O. Dimethylsulfoxide is used as a final concentration of 0.1% in cell treatment experiments involving DMBA and DB[a,c]A and DB[a,h]A."
methylcholanthrene,Methylcholanthrene is used as a standard carcinogen to assess transformation potential in hamster embryo cell cultures at the first population doubling level.,Entity: methylcholanthrene. SMILES: CC1Cc2cccc3cc4c(ccc5ccccc54)c1c23. Methylcholanthrene is used as a standard carcinogen to assess transformation potential in hamster embryo cell cultures at the first population doubling level.
ethanol,Ethanol is used as a washing and precipitation agent for RNA and DNA during nucleic acid purification protocols.,Entity: ethanol. SMILES: CCO. Ethanol is used as a washing and precipitation agent for RNA and DNA during nucleic acid purification protocols.
chloroform,"Chloroform, in combination with isoamyl alcohol, is used for deproteinization of DNA solutions during nucleic acid purification.","Entity: chloroform. SMILES: ClC(Cl)Cl. Chloroform, in combination with isoamyl alcohol, is used for deproteinization of DNA solutions during nucleic acid purification."
sodium acetate,Sodium acetate is used as a component (2%) in cold 70% ethanol for DNA precipitation during nucleic acid purification.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate is used as a component (2%) in cold 70% ethanol for DNA precipitation during nucleic acid purification.
trisodium citrate,Trisodium citrate is used at 1.5 mM in SSC buffer for dissolving RNA after precipitation in nucleic acid purification.,Entity: trisodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Trisodium citrate is used at 1.5 mM in SSC buffer for dissolving RNA after precipitation in nucleic acid purification.
isoamyl alcohol,Isoamyl alcohol is used in a 24:1 mixture with chloroform for deproteinization of DNA solutions during nucleic acid purification.,Entity: isoamyl alcohol. SMILES: CC(C)CCO. Isoamyl alcohol is used in a 24:1 mixture with chloroform for deproteinization of DNA solutions during nucleic acid purification.
sodium chloride,Sodium chloride is used at 15 mM in SSC buffer for dissolving RNA after precipitation in nucleic acid purification.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at 15 mM in SSC buffer for dissolving RNA after precipitation in nucleic acid purification.
"7,12-Dimethylbenzanthrone","The binding of 7,12-Dimethylbenzanthrone to DNA, RNA, and protein in hamster embryo cells decreases as the population doubling number increases, which is associated with a decrease in transformation frequency.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. The binding of 7,12-Dimethylbenzanthrone to DNA, RNA, and protein in hamster embryo cells decreases as the population doubling number increases, which is associated with a decrease in transformation frequency."
"7,12-Dimethylbenzanthrone","7,12-Dimethylbenzanthrone generally binds to hamster cell protein to a greater extent than 7,12-Dimethylbenzanthracene and DB(a,c)A, but less than DB[a,h]A.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. 7,12-Dimethylbenzanthrone generally binds to hamster cell protein to a greater extent than 7,12-Dimethylbenzanthracene and DB(a,c)A, but less than DB[a,h]A."
"7,12-Dimethylbenzanthrone","7,12-Dimethylbenzanthrone binds to hamster embryo DNA and RNA to a greater extent than 7,12-Dimethylbenzanthracene, and shows the best correlation of carcinogenicity, transforming activity, and binding with hamster embryo cell DNA and RNA.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. 7,12-Dimethylbenzanthrone binds to hamster embryo DNA and RNA to a greater extent than 7,12-Dimethylbenzanthracene, and shows the best correlation of carcinogenicity, transforming activity, and binding with hamster embryo cell DNA and RNA."
"7,12-Dimethylbenzanthrone","The binding of 7,12-Dimethylbenzanthrone to cellular macromolecules in human embryo cells increases with higher cell confluence and decreases when serum concentration is increased from 5% to 10%.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. The binding of 7,12-Dimethylbenzanthrone to cellular macromolecules in human embryo cells increases with higher cell confluence and decreases when serum concentration is increased from 5% to 10%."
"7,12-Dimethylbenzanthrone","The binding affinity of 7,12-Dimethylbenzanthrone to hamster embryo cell DNA, RNA, and protein decreases by at least 50% between population doubling numbers 0 and 8, and becomes barely detectable by population doubling number 20.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. The binding affinity of 7,12-Dimethylbenzanthrone to hamster embryo cell DNA, RNA, and protein decreases by at least 50% between population doubling numbers 0 and 8, and becomes barely detectable by population doubling number 20."
"7,12-Dimethylbenzanthrone","The binding of 7,12-Dimethylbenzanthrone to DNA in hamster embryo cells shows a 150-fold decrease between population doubling numbers 8 and 14.","Entity: 7,12-Dimethylbenzanthrone. SMILES: Cc1c2c(c(C)c3c1ccc1ccccc13)=CCC(=O)C=2. The binding of 7,12-Dimethylbenzanthrone to DNA in hamster embryo cells shows a 150-fold decrease between population doubling numbers 8 and 14."
5'-DFUR,5'-DFUR was administered at a dose of 50 mg/kg in mice to evaluate its effect on MDA-MB-231 tumor growth in combination with OCT.,Entity: 5'-DFUR. SMILES: O=c1ccn([C@@H]2O[C@H](CF)[C@@H](O)[C@H]2O)c(=O)[nH]1. 5'-DFUR was administered at a dose of 50 mg/kg in mice to evaluate its effect on MDA-MB-231 tumor growth in combination with OCT.
"1,25-Dihydroxyvitamin D3","1,25-Dihydroxyvitamin D3 induces angiogenesis by up-regulating VEGF expression in osteoblast-like cells.","Entity: 1,25-Dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. 1,25-Dihydroxyvitamin D3 induces angiogenesis by up-regulating VEGF expression in osteoblast-like cells."
"1,25-Dihydroxyvitamin D3","1,25-Dihydroxyvitamin D3 exerts an anabolic effect on osteoblasts by enhancing their production of VEGF, which stimulates endothelial cell receptors and promotes osteotropic growth factor production.","Entity: 1,25-Dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. 1,25-Dihydroxyvitamin D3 exerts an anabolic effect on osteoblasts by enhancing their production of VEGF, which stimulates endothelial cell receptors and promotes osteotropic growth factor production."
"1,25-Dihydroxyvitamin D3","1,25-Dihydroxyvitamin D3 and its analogues have demonstrated antiangiogenic effects in several in vivo systems, including inhibiting embryonic angiogenesis in chick embryo chorioallantoic membranes and suppressing angiogenesis in renal cell carcinoma.","Entity: 1,25-Dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. 1,25-Dihydroxyvitamin D3 and its analogues have demonstrated antiangiogenic effects in several in vivo systems, including inhibiting embryonic angiogenesis in chick embryo chorioallantoic membranes and suppressing angiogenesis in renal cell carcinoma."
Octreotide,Octreotide significantly suppresses VEGF protein levels in MDA-MB-231 tumors.,Entity: Octreotide. SMILES: C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O. Octreotide significantly suppresses VEGF protein levels in MDA-MB-231 tumors.
Octreotide,Octreotide has a strong inhibitory effect on embryonic angiogenesis in chick embryo chorioallantoic membranes.,Entity: Octreotide. SMILES: C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O. Octreotide has a strong inhibitory effect on embryonic angiogenesis in chick embryo chorioallantoic membranes.
Octreotide,Octreotide suppresses angiogenesis in renal cell carcinoma.,Entity: Octreotide. SMILES: C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O. Octreotide suppresses angiogenesis in renal cell carcinoma.
"1,25-Dihydroxyvitamin D3","In breast cancer, the presence of VDR is associated with a longer disease-free interval compared to VDR-negative tumors.","Entity: 1,25-Dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. In breast cancer, the presence of VDR is associated with a longer disease-free interval compared to VDR-negative tumors."
"1,25-Dihydroxyvitamin D3","The level of VDR does not predict survival in breast cancer, but correlates with the late development of lymph node metastasis.","Entity: 1,25-Dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. The level of VDR does not predict survival in breast cancer, but correlates with the late development of lymph node metastasis."
"1,25-Dihydroxyvitamin D3","1,25-Dihydroxyvitamin D3 inhibits the proliferation of both ER-positive (T-47D and ZR-75-1) and ER-negative (MDA-MB-231 and BT-20) breast cancer cell lines.","Entity: 1,25-Dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. 1,25-Dihydroxyvitamin D3 inhibits the proliferation of both ER-positive (T-47D and ZR-75-1) and ER-negative (MDA-MB-231 and BT-20) breast cancer cell lines."
"1,25-Dihydroxyvitamin D3","Continuous treatment with high concentrations of 1,25-Dihydroxyvitamin D3 decreases the cell number in MDA-MB-231 breast cancer cells.","Entity: 1,25-Dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. Continuous treatment with high concentrations of 1,25-Dihydroxyvitamin D3 decreases the cell number in MDA-MB-231 breast cancer cells."
"1,25-Dihydroxyvitamin D3","MDA-MB-231 breast cancer cells, which have relatively low VDR levels, still contain high-affinity receptors for 1,25-Dihydroxyvitamin D3.","Entity: 1,25-Dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. MDA-MB-231 breast cancer cells, which have relatively low VDR levels, still contain high-affinity receptors for 1,25-Dihydroxyvitamin D3."
Octreotide,Octreotide displays antitumor effects on MDA-MB-231 tumors in athymic mice at sufficient doses.,Entity: Octreotide. SMILES: C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O. Octreotide displays antitumor effects on MDA-MB-231 tumors in athymic mice at sufficient doses.
"1,25-Dihydroxyvitamin D3","1,25-Dihydroxyvitamin D3 displays antitumor effects in various in vitro and in vivo assay systems.","Entity: 1,25-Dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. 1,25-Dihydroxyvitamin D3 displays antitumor effects in various in vitro and in vivo assay systems."
"1,25-Dihydroxyvitamin D3","1,25-Dihydroxyvitamin D3 binds to the vitamin D receptor (VDR) and induces differentiation of tumor cells, contributing to its antitumor effects.","Entity: 1,25-Dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. 1,25-Dihydroxyvitamin D3 binds to the vitamin D receptor (VDR) and induces differentiation of tumor cells, contributing to its antitumor effects."
OCT,"Oral administration of OCT at doses of 0.1 µg/kg/day or more significantly suppresses the growth of MDA-MB-231 tumors in mice, with tumor size changes at the fourth week ranging from 184% to 192% compared to untreated controls.","Entity: OCT. SMILES: N[C@@H]1CCCC[C@H]1N.O=C([O-])C(=O)[O-].[Pt+2]. Oral administration of OCT at doses of 0.1 µg/kg/day or more significantly suppresses the growth of MDA-MB-231 tumors in mice, with tumor size changes at the fourth week ranging from 184% to 192% compared to untreated controls."
OCT,Combined treatment with OCT and 5'-DFUR produces equivalent antitumor effects to single-agent OCT therapy in MDA-MB-231 tumors in mice.,Entity: OCT. SMILES: N[C@@H]1CCCC[C@H]1N.O=C([O-])C(=O)[O-].[Pt+2]. Combined treatment with OCT and 5'-DFUR produces equivalent antitumor effects to single-agent OCT therapy in MDA-MB-231 tumors in mice.
5'-DFUR,Combined treatment with 5'-DFUR and OCT produces equivalent antitumor effects to single-agent OCT therapy in MDA-MB-231 tumors in mice.,Entity: 5'-DFUR. SMILES: O=c1ccn([C@@H]2O[C@H](CF)[C@@H](O)[C@H]2O)c(=O)[nH]1. Combined treatment with 5'-DFUR and OCT produces equivalent antitumor effects to single-agent OCT therapy in MDA-MB-231 tumors in mice.
"1,25-dihydroxyvitamin D3","1,25-dihydroxyvitamin D3 has been reported to inhibit angiogenesis in a transgenic retinoblastoma murine model.","Entity: 1,25-dihydroxyvitamin D3. SMILES: C=C1/C(=C/C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O. 1,25-dihydroxyvitamin D3 has been reported to inhibit angiogenesis in a transgenic retinoblastoma murine model."
vesnarinone,Vesnarinone is a quinolinone derivative and a novel inotropic agent used in the treatment of heart failure.,Entity: vesnarinone. SMILES: COc1ccc(C(=O)N2CCN(c3ccc4c(c3)CCC(=O)N4)CC2)cc1OC. Vesnarinone is a quinolinone derivative and a novel inotropic agent used in the treatment of heart failure.
vesnarinone,"Vesnarinone exhibits anti-cancer activity by directly inhibiting tumor cell growth and sensitizing cells to irradiation, leading to increased apoptosis and reduced required irradiation dose.","Entity: vesnarinone. SMILES: COc1ccc(C(=O)N2CCN(c3ccc4c(c3)CCC(=O)N4)CC2)cc1OC. Vesnarinone exhibits anti-cancer activity by directly inhibiting tumor cell growth and sensitizing cells to irradiation, leading to increased apoptosis and reduced required irradiation dose."
granulocyte-CSF,"The human bladder cell line T-24 elaborates by far the highest amounts of granulocyte-CSF among the tested tumor cell lines, and pretreatment with TPA can more than double these levels.","Entity: granulocyte-CSF. The human bladder cell line T-24 elaborates by far the highest amounts of granulocyte-CSF among the tested tumor cell lines, and pretreatment with TPA can more than double these levels."
pentapeptide,"The growth-inhibiting epidermal pentapeptide pyroGlu-Glu-Asp-Ser-GlyOH (EPP) reduces proliferation and induces G1/S phase transition in both non-transformed and transformed fibroblast cell lines at concentrations of 1,000 ng/ml (1 nanomol/ml).","Entity: pentapeptide. SMILES: C[C@H]([NH3+])C(=O)N[C@H](CCC(=O)N[C@@H](CCC[C@@H]([NH3+])C(=O)[O-])C(=O)N[C@H](C)C(=O)N[C@H](C)C(=O)[O-])C(=O)[O-]. The growth-inhibiting epidermal pentapeptide pyroGlu-Glu-Asp-Ser-GlyOH (EPP) reduces proliferation and induces G1/S phase transition in both non-transformed and transformed fibroblast cell lines at concentrations of 1,000 ng/ml (1 nanomol/ml)."
pentapeptide,"Treatment with the growth-inhibiting pentapeptide EPP decreases RNA expression of c-fos, ki-ras, and neu genes in transformed TC3H10 cells.","Entity: pentapeptide. SMILES: C[C@H]([NH3+])C(=O)N[C@H](CCC(=O)N[C@@H](CCC[C@@H]([NH3+])C(=O)[O-])C(=O)N[C@H](C)C(=O)N[C@H](C)C(=O)[O-])C(=O)[O-]. Treatment with the growth-inhibiting pentapeptide EPP decreases RNA expression of c-fos, ki-ras, and neu genes in transformed TC3H10 cells."
neu,RNA expression of the neu gene decreases in TC3H10 transformed fibroblast cells after treatment with the growth-inhibiting peptide EPP.,Entity: neu. RNA expression of the neu gene decreases in TC3H10 transformed fibroblast cells after treatment with the growth-inhibiting peptide EPP.
mercury,Both inorganic and organic mercury concentrations in workers' hair are similar to those in controls except for elevated inorganic mercury in chloralkali workers and female Hg-battery workers.,Entity: mercury. SMILES: [Hg]. Both inorganic and organic mercury concentrations in workers' hair are similar to those in controls except for elevated inorganic mercury in chloralkali workers and female Hg-battery workers.
mercury,"Washing hair with a 2 M cysteine HCl solution reduces both inorganic and organic mercury concentrations in the hair of chloralkali workers, but not in controls.","Entity: mercury. SMILES: [Hg]. Washing hair with a 2 M cysteine HCl solution reduces both inorganic and organic mercury concentrations in the hair of chloralkali workers, but not in controls."
cysteine,"A 2 M cysteine HCl solution is capable of diminishing both inorganic and organic mercury concentrations in hair, particularly in chloralkali workers.","Entity: cysteine. SMILES: N[C@@H](CS)C(=O)O. A 2 M cysteine HCl solution is capable of diminishing both inorganic and organic mercury concentrations in hair, particularly in chloralkali workers."
inorganic mercury,"Inorganic mercury concentrations in red blood cells are minimal (O 1 ng/ml in men, undetectable in women) in control groups, while plasma concentrations are 0.8 ng/ml in both sexes.","Entity: inorganic mercury. SMILES: [Hg]. Inorganic mercury concentrations in red blood cells are minimal (O 1 ng/ml in men, undetectable in women) in control groups, while plasma concentrations are 0.8 ng/ml in both sexes."
inorganic mercury,Inorganic mercury exists predominantly in plasma rather than in red blood cells in both control and exposed groups.,Entity: inorganic mercury. SMILES: [Hg]. Inorganic mercury exists predominantly in plasma rather than in red blood cells in both control and exposed groups.
inorganic mercury,"Inorganic mercury concentrations in red blood cells and plasma are elevated in all worker groups, with the blood cells-to-plasma ratio being greater in the copper wire and mercury battery groups compared to the chloralkali group.","Entity: inorganic mercury. SMILES: [Hg]. Inorganic mercury concentrations in red blood cells and plasma are elevated in all worker groups, with the blood cells-to-plasma ratio being greater in the copper wire and mercury battery groups compared to the chloralkali group."
mercury,"Exposure to elemental and/or inorganic mercury can elevate organic mercury levels in red blood cells, plasma, and urine, but not in hair, in workers.","Entity: mercury. SMILES: [Hg]. Exposure to elemental and/or inorganic mercury can elevate organic mercury levels in red blood cells, plasma, and urine, but not in hair, in workers."
mercury,"The relationship between total mercury in hair (T-H) and total mercury in whole blood (T-B) varies by regression coefficient from 140 to 280, and between total or organic mercury in hair (T-H or O-H) and total mercury in red blood cells (T-RC) from 48 to 230.","Entity: mercury. SMILES: [Hg]. The relationship between total mercury in hair (T-H) and total mercury in whole blood (T-B) varies by regression coefficient from 140 to 280, and between total or organic mercury in hair (T-H or O-H) and total mercury in red blood cells (T-RC) from 48 to 230."
mercury,"In hair regression analyses, regression coefficients for O-H on T-RC ranged from 47.80 in mercury workers to 117 in female controls and 150 in male controls.","Entity: mercury. SMILES: [Hg]. In hair regression analyses, regression coefficients for O-H on T-RC ranged from 47.80 in mercury workers to 117 in female controls and 150 in male controls."
mercury,"In chloralkali workers, inorganic mercury is predominantly ionic, while in other mercury workers, it is more elemental.","Entity: mercury. SMILES: [Hg]. In chloralkali workers, inorganic mercury is predominantly ionic, while in other mercury workers, it is more elemental."
mercury,"Organic mercury concentrations in red blood cells and hair are significantly correlated in most cases, except for specific occupational groups such as control women's basal parts and mercury workers' tips.","Entity: mercury. SMILES: [Hg]. Organic mercury concentrations in red blood cells and hair are significantly correlated in most cases, except for specific occupational groups such as control women's basal parts and mercury workers' tips."
mercury,"Elevated levels of inorganic mercury in red blood cells, plasma, and urine of workers are indicative of occupational exposure rather than dietary intake.","Entity: mercury. SMILES: [Hg]. Elevated levels of inorganic mercury in red blood cells, plasma, and urine of workers are indicative of occupational exposure rather than dietary intake."
mercury,"Inorganic mercury binds more strongly to tissue binding sites than organic mercury, leading to the release and redistribution of organic mercury in the body.","Entity: mercury. SMILES: [Hg]. Inorganic mercury binds more strongly to tissue binding sites than organic mercury, leading to the release and redistribution of organic mercury in the body."
mercury,Organic mercury has a weaker binding affinity to tissue binding sites compared to inorganic mercury.,Entity: mercury. SMILES: [Hg]. Organic mercury has a weaker binding affinity to tissue binding sites compared to inorganic mercury.
D-Penicillamine,"D-Penicillamine administration enhances urinary excretion of organic mercury more readily than inorganic mercury, indicating weaker tissue binding of organic mercury.","Entity: D-Penicillamine. SMILES: CC(C)(S)[C@@H](N)C(=O)O. D-Penicillamine administration enhances urinary excretion of organic mercury more readily than inorganic mercury, indicating weaker tissue binding of organic mercury."
mercury,"The average daily intake of mercury in general populations is estimated to be 1–4 g Hg of elemental and/or inorganic mercury, and a few to several pg Hg of methylmercury.","Entity: mercury. SMILES: [Hg]. The average daily intake of mercury in general populations is estimated to be 1–4 g Hg of elemental and/or inorganic mercury, and a few to several pg Hg of methylmercury."
mercury,"Inorganic mercury exists in two forms: elemental (HgO) and inorganic mercury (Hg2+), which are not distinguishable in the body by the method used in the study.","Entity: mercury. SMILES: [Hg]. Inorganic mercury exists in two forms: elemental (HgO) and inorganic mercury (Hg2+), which are not distinguishable in the body by the method used in the study."
methylmercury,The average daily intake of methylmercury in general populations is estimated to be a few to several pg Hg.,Entity: methylmercury. SMILES: C[Hg]. The average daily intake of methylmercury in general populations is estimated to be a few to several pg Hg.
methylmercury,"Methylmercury accumulates in hair at levels approximately 300 times higher than in whole blood, according to a Swedish expert group (Berglund et al, 1971) and a task group on metal accumulation (1973).","Entity: methylmercury. SMILES: C[Hg]. Methylmercury accumulates in hair at levels approximately 300 times higher than in whole blood, according to a Swedish expert group (Berglund et al, 1971) and a task group on metal accumulation (1973)."
Hepatic leukemia factor,"In the developing pituitary gland, hepatic leukemia factor (HLF) is highly expressed in the rostral tip of the anterior lobe in mice.","Entity: Hepatic leukemia factor. In the developing pituitary gland, hepatic leukemia factor (HLF) is highly expressed in the rostral tip of the anterior lobe in mice."
Hepatic leukemia factor,Hepatic leukemia factor (HLF) expression increases in the central nervous system and is found throughout the brain by adulthood in mice.,Entity: Hepatic leukemia factor. Hepatic leukemia factor (HLF) expression increases in the central nervous system and is found throughout the brain by adulthood in mice.
Hepatic leukemia factor,"Hepatic leukemia factor (HLF) is not normally expressed in lymphoid cells but is detected in the liver, kidney, lung, and adult nervous system by Northern blotting.","Entity: Hepatic leukemia factor. Hepatic leukemia factor (HLF) is not normally expressed in lymphoid cells but is detected in the liver, kidney, lung, and adult nervous system by Northern blotting."
Hepatic leukemia factor,Hepatic leukemia factor (HLF) expression is not associated with cells undergoing programmed cell death in the nervous system.,Entity: Hepatic leukemia factor. Hepatic leukemia factor (HLF) expression is not associated with cells undergoing programmed cell death in the nervous system.
Hepatic leukemia factor,"In mouse embryonic brain development, hepatic leukemia factor (HLF) expression is restricted to the anterior pituitary and meninges, and by early postnatal life, it is highly expressed in somatosensory cortex, thalamic nuclei, and structures arising from ectodermal placodes.","Entity: Hepatic leukemia factor. In mouse embryonic brain development, hepatic leukemia factor (HLF) expression is restricted to the anterior pituitary and meninges, and by early postnatal life, it is highly expressed in somatosensory cortex, thalamic nuclei, and structures arising from ectodermal placodes."
Hepatic leukemia factor,Hepatic leukemia factor (HLF) plays a role in the function of differentiated neurons in the adult nervous system rather than in programmed cell death.,Entity: Hepatic leukemia factor. Hepatic leukemia factor (HLF) plays a role in the function of differentiated neurons in the adult nervous system rather than in programmed cell death.
Hepatic leukemia factor,Hepatic leukemia factor (HLF) is a bZIP transcription factor related to the CES-2 protein and is involved in the regulation of apoptosis in NSM serotoninergic neurons of Caenorhabditis elegans.,Entity: Hepatic leukemia factor. Hepatic leukemia factor (HLF) is a bZIP transcription factor related to the CES-2 protein and is involved in the regulation of apoptosis in NSM serotoninergic neurons of Caenorhabditis elegans.
CES-2,CES-2 is a protein related to hepatic leukemia factor (HLF) and is involved in the regulation of apoptosis in NSM serotoninergic neurons of Caenorhabditis elegans.,Entity: CES-2. CES-2 is a protein related to hepatic leukemia factor (HLF) and is involved in the regulation of apoptosis in NSM serotoninergic neurons of Caenorhabditis elegans.
Hepatic leukemia factor,Hepatic leukemia factor (HLF) expression increases markedly with synaptogenesis and is coincident with barrel formation as revealed by cytochrome oxidase staining.,Entity: Hepatic leukemia factor. Hepatic leukemia factor (HLF) expression increases markedly with synaptogenesis and is coincident with barrel formation as revealed by cytochrome oxidase staining.
Tef,Tef is an HLF-related bZIP protein expressed in the anterior pituitary of the adult mouse.,Entity: Tef. Tef is an HLF-related bZIP protein expressed in the anterior pituitary of the adult mouse.
Sodium cyanate,"Sodium cyanate induces carbamoylation of proteins, reduces nerve conduction velocity, and blocks axonal transport.","Entity: Sodium cyanate. SMILES: N#C[O-].[Na+]. Sodium cyanate induces carbamoylation of proteins, reduces nerve conduction velocity, and blocks axonal transport."
Sodium cyanate,"In vitro, sodium cyanate inhibits cytochrome c oxidase activity and uncouples oxidative phosphorylation.","Entity: Sodium cyanate. SMILES: N#C[O-].[Na+]. In vitro, sodium cyanate inhibits cytochrome c oxidase activity and uncouples oxidative phosphorylation."
Sodium cyanate,Sodium cyanate shows reactivity towards sulfhydryl groups.,Entity: Sodium cyanate. SMILES: N#C[O-].[Na+]. Sodium cyanate shows reactivity towards sulfhydryl groups.
Sodium cyanate,"Sodium cyanate is an effective drug for the treatment of sickle-cell anemia but its use was discontinued due to neurotoxicity, causing neuronal damage in the brain, spinal cord, and peripheral nerves in rhesus monkeys, and cataracts in humans.","Entity: Sodium cyanate. SMILES: N#C[O-].[Na+]. Sodium cyanate is an effective drug for the treatment of sickle-cell anemia but its use was discontinued due to neurotoxicity, causing neuronal damage in the brain, spinal cord, and peripheral nerves in rhesus monkeys, and cataracts in humans."
Sodium cyanate,Prolonged administration of high doses of sodium cyanate causes hindlimb paralysis in rats and spastic quadriplegia in monkeys.,Entity: Sodium cyanate. SMILES: N#C[O-].[Na+]. Prolonged administration of high doses of sodium cyanate causes hindlimb paralysis in rats and spastic quadriplegia in monkeys.
glutathione,Glutathione is included as a component in the assay mixture for the glutathione peroxidase (GSH-Px) activity assay.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione is included as a component in the assay mixture for the glutathione peroxidase (GSH-Px) activity assay.
tert-butyl hydroperoxide,tert-butyl hydroperoxide is used as a substrate in the glutathione peroxidase (GSH-Px) assay to initiate the oxidation of NADPH by the enzyme.,Entity: tert-butyl hydroperoxide. SMILES: CC(C)(C)OO. tert-butyl hydroperoxide is used as a substrate in the glutathione peroxidase (GSH-Px) assay to initiate the oxidation of NADPH by the enzyme.
NADPH,"NADPH serves as a reducing substrate in the glutathione peroxidase (GSH-Px) assay, with its oxidation rate used to quantify GSH-Px activity.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH serves as a reducing substrate in the glutathione peroxidase (GSH-Px) assay, with its oxidation rate used to quantify GSH-Px activity."
cyanide,"In regions of Africa with low protein intake and high cyanogenic cassava consumption, cyanide is preferentially converted to cyanate.","Entity: cyanide. SMILES: [C-]#N. In regions of Africa with low protein intake and high cyanogenic cassava consumption, cyanide is preferentially converted to cyanate."
cyanate,"Cyanate is a product of cyanide metabolism that has been implicated as a possible cause of neurodegeneration in konzo w x and TAN 16, 40, 41, 44 in African populations.","Entity: cyanate. SMILES: N#C[O-]. Cyanate is a product of cyanide metabolism that has been implicated as a possible cause of neurodegeneration in konzo w x and TAN 16, 40, 41, 44 in African populations."
glutathione disulfide,"Glutathione disulfide (GSSG) levels in rat brain are higher than anticipated after saline perfusion, possibly due to assay timing.","Entity: glutathione disulfide. SMILES: N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O. Glutathione disulfide (GSSG) levels in rat brain are higher than anticipated after saline perfusion, possibly due to assay timing."
glutathione,"Glutathione (GSH) and glutathione disulfide (GSSG) ratios in rat brain regions are used as indicators of oxidative stress, with GSHrGSSG ratios in saline-treated controls set at 100%.","Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione (GSH) and glutathione disulfide (GSSG) ratios in rat brain regions are used as indicators of oxidative stress, with GSHrGSSG ratios in saline-treated controls set at 100%."
sodium orthovanadate,"Sodium orthovanadate at 100 mg/kg has no significant effect on the GSHrGSSG ratio in the cerebellum, hippocampus, and striatum of rat brain, but causes an approximately 45% decrease in the cerebral cortex.","Entity: sodium orthovanadate. SMILES: O=[V]([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium orthovanadate at 100 mg/kg has no significant effect on the GSHrGSSG ratio in the cerebellum, hippocampus, and striatum of rat brain, but causes an approximately 45% decrease in the cerebral cortex."
sodium orthovanadate,"Sodium orthovanadate at 300 mg/kg decreases the GSHrGSSG ratio by 45% in the cerebellum, 25% in the hippocampus, and 55% in the cerebral cortex of rat brain.","Entity: sodium orthovanadate. SMILES: O=[V]([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium orthovanadate at 300 mg/kg decreases the GSHrGSSG ratio by 45% in the cerebellum, 25% in the hippocampus, and 55% in the cerebral cortex of rat brain."
sodium orthovanadate,Sodium orthovanadate at 300 mg/kg causes a maximum decrease of 70% in the GSHrGSSG ratio in the striatum of rat brain.,Entity: sodium orthovanadate. SMILES: O=[V]([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium orthovanadate at 300 mg/kg causes a maximum decrease of 70% in the GSHrGSSG ratio in the striatum of rat brain.
sodium hydroxide,"Sodium hydroxide is used as a component of the buffer system (0.1 M sodium phosphate buffer, pH 7.0) in biochemical assays.","Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used as a component of the buffer system (0.1 M sodium phosphate buffer, pH 7.0) in biochemical assays."
trichloroacetic acid,Trichloroacetic acid is used to precipitate proteins from supernatants in biochemical assays.,Entity: trichloroacetic acid. SMILES: O=C(O)C(Cl)(Cl)Cl. Trichloroacetic acid is used to precipitate proteins from supernatants in biochemical assays.
"5,5'-dithiobis(2-nitrobenzoic acid)","5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) is a reagent used to determine glutathione content by measuring absorbance of a yellow product formed in the presence of glutathione.","Entity: 5,5'-dithiobis(2-nitrobenzoic acid). SMILES: O=C(O)c1cc(SSc2ccc([N+](=O)[O-])c(C(=O)O)c2)ccc1[N+](=O)[O-]. 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) is a reagent used to determine glutathione content by measuring absorbance of a yellow product formed in the presence of glutathione."
sodium phosphate,"Sodium phosphate is used as a buffer component (0.1 M, pH 7.0) in biochemical assays.","Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used as a buffer component (0.1 M, pH 7.0) in biochemical assays."
glutathione,"Glutathione (GSH) content can be quantified in biological supernatants using the DTNB assay, which measures the yellow product formed upon reaction with glutathione.","Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione (GSH) content can be quantified in biological supernatants using the DTNB assay, which measures the yellow product formed upon reaction with glutathione."
sodium cyanide,"Sodium cyanide (NaOCN) is used at concentrations of 1, 5, and 10 mM to treat mitochondrial fractions in biochemical assays.","Entity: sodium cyanide. SMILES: [C-]#N.[Na+]. Sodium cyanide (NaOCN) is used at concentrations of 1, 5, and 10 mM to treat mitochondrial fractions in biochemical assays."
sucrose,Sucrose is used at 0.25 M concentration as a suspension medium for mitochondrial fractions in biochemical assays.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used at 0.25 M concentration as a suspension medium for mitochondrial fractions in biochemical assays.
NADPH,"NADPH is used as a substrate at 2 mM concentration in the assay for glucose reductase (GR) activity, where it is oxidized to produce a measurable absorbance at 340 nm.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is used as a substrate at 2 mM concentration in the assay for glucose reductase (GR) activity, where it is oxidized to produce a measurable absorbance at 340 nm."
GSSG,"GSSG is used as a substrate at 20 mM concentration in the assay for glucose reductase (GR) activity, where it is oxidized in the presence of NADPH and phosphate buffer.","Entity: GSSG. SMILES: N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O. GSSG is used as a substrate at 20 mM concentration in the assay for glucose reductase (GR) activity, where it is oxidized in the presence of NADPH and phosphate buffer."
NaOCN,"NaOCN causes a concentration-dependent loss of glutathione (GSH) in mouse brain P-2 fraction, with 5 mM NaOCN reducing GSH concentration from 8.5 ± 1.1 nmol/mg protein to 5.3 ± 0.1 nmol/mg protein (a 38% decrease after 30 min treatment at 10 mM).","Entity: NaOCN. SMILES: [C-]#N.[Na+]. NaOCN causes a concentration-dependent loss of glutathione (GSH) in mouse brain P-2 fraction, with 5 mM NaOCN reducing GSH concentration from 8.5 ± 1.1 nmol/mg protein to 5.3 ± 0.1 nmol/mg protein (a 38% decrease after 30 min treatment at 10 mM)."
GSH,"GSH content in mouse brain P-2 fraction is depleted in a concentration-dependent manner by NaOCN treatment, with 5 mM NaOCN reducing GSH levels from 8.5 ± 1.1 nmol/mg protein to 5.3 ± 0.1 nmol/mg protein after 30 min incubation.","Entity: GSH. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. GSH content in mouse brain P-2 fraction is depleted in a concentration-dependent manner by NaOCN treatment, with 5 mM NaOCN reducing GSH levels from 8.5 ± 1.1 nmol/mg protein to 5.3 ± 0.1 nmol/mg protein after 30 min incubation."
NaOCN,NaOCN differentially impacts glutathione (GSH) status in selected brain regions.,Entity: NaOCN. SMILES: N#C[O-].[Na+]. NaOCN differentially impacts glutathione (GSH) status in selected brain regions.
NaOCN,"NaOCN inhibits glutathione reductase (GR) activity in all brain regions, with maximum inhibition in the striatum.","Entity: NaOCN. SMILES: N#C[O-].[Na+]. NaOCN inhibits glutathione reductase (GR) activity in all brain regions, with maximum inhibition in the striatum."
carbamoyl,Carbamoyl derivatives can be formed when cyanate reacts with the N-amino group of proteins such as cytochrome P-450 36.,Entity: carbamoyl. SMILES: N[C]=O. Carbamoyl derivatives can be formed when cyanate reacts with the N-amino group of proteins such as cytochrome P-450 36.
Diethyl maleate,Diethyl maleate reduces brain and liver glutathione (GSH) levels in a dose- and time-dependent manner.,Entity: Diethyl maleate. SMILES: CCOC(=O)/C=C\C(=O)OCC. Diethyl maleate reduces brain and liver glutathione (GSH) levels in a dose- and time-dependent manner.
Diethyl maleate,"Hepatic glutathione levels return to normal within 6 hours after diethyl maleate administration, while brain glutathione remains significantly lower up to 12 hours and recovers after 48 hours.","Entity: Diethyl maleate. SMILES: CCOC(=O)/C=C\C(=O)OCC. Hepatic glutathione levels return to normal within 6 hours after diethyl maleate administration, while brain glutathione remains significantly lower up to 12 hours and recovers after 48 hours."
Glutathione,"Glutathione turnover in the brain is much slower than in the liver, as indicated by the delayed recovery of brain glutathione after diethyl maleate administration.","Entity: Glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione turnover in the brain is much slower than in the liver, as indicated by the delayed recovery of brain glutathione after diethyl maleate administration."
sodium cyanate,"Sodium cyanate, when administered intraperitoneally at doses of 100 or 300 mg/kg in rats, affects glutathione reductase (GR) activity in selected brain regions after 30 minutes.","Entity: sodium cyanate. SMILES: N#C[O-].[Na+]. Sodium cyanate, when administered intraperitoneally at doses of 100 or 300 mg/kg in rats, affects glutathione reductase (GR) activity in selected brain regions after 30 minutes."
sodium nitroprusside,"Sodium nitroprusside, when administered intraperitoneally at 200 mg/kg in mice, causes a time-dependent depletion of brain glutathione, with significant depletion observed after 15–30 minutes and reduced levels at 60 and 120 minutes.","Entity: sodium nitroprusside. SMILES: N#[O+].O.O.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[Fe+2].[Na+].[Na+]. Sodium nitroprusside, when administered intraperitoneally at 200 mg/kg in mice, causes a time-dependent depletion of brain glutathione, with significant depletion observed after 15–30 minutes and reduced levels at 60 and 120 minutes."
glutathione,"In mouse brain, glutathione levels decrease over time following intraperitoneal administration of sodium nitroprusside, with baseline levels of 18.7 ± 1.7 nmol/mg protein in control mice.","Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. In mouse brain, glutathione levels decrease over time following intraperitoneal administration of sodium nitroprusside, with baseline levels of 18.7 ± 1.7 nmol/mg protein in control mice."
glutathione,Glutathione (GSH) levels are decreased in all selected mouse brain regions following a single intraperitoneal injection of 300 mg/kg NaOCN.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione (GSH) levels are decreased in all selected mouse brain regions following a single intraperitoneal injection of 300 mg/kg NaOCN.
glutathione,Glutathione levels in the mouse cerebellum and hypothalamus are reduced by 65% relative to saline-treated controls after NaOCN administration.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione levels in the mouse cerebellum and hypothalamus are reduced by 65% relative to saline-treated controls after NaOCN administration.
glutathione,Glutathione levels in the mouse striatum and midbrain are reduced by 55% relative to saline-treated controls after NaOCN administration.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione levels in the mouse striatum and midbrain are reduced by 55% relative to saline-treated controls after NaOCN administration.
glutathione,Glutathione levels in the mouse cerebral cortex are reduced by 40% and in the hippocampus by 45% relative to saline-treated controls after NaOCN administration.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione levels in the mouse cerebral cortex are reduced by 40% and in the hippocampus by 45% relative to saline-treated controls after NaOCN administration.
NADPH,"Glutathione reductase (GR) activity in the mouse cerebral cortex is inhibited by about 20% and in the cerebellum by about 25% after administration of 100 and 300 mg/kg NaOCN, respectively, compared to saline-treated controls.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. Glutathione reductase (GR) activity in the mouse cerebral cortex is inhibited by about 20% and in the cerebellum by about 25% after administration of 100 and 300 mg/kg NaOCN, respectively, compared to saline-treated controls."
glutathione,"Glutathione (GSH) content and its ratio to glutathione disulfide (GSSG) in rat liver decrease in a dose-dependent manner after a single injection of NaOCN, with GSHrGSSG ratios of 55% and 45% in 100 and 300 mgrkg NaOCN-treated animals compared to saline controls.","Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione (GSH) content and its ratio to glutathione disulfide (GSSG) in rat liver decrease in a dose-dependent manner after a single injection of NaOCN, with GSHrGSSG ratios of 55% and 45% in 100 and 300 mgrkg NaOCN-treated animals compared to saline controls."
glutathione disulfide,"Glutathione disulfide (GSSG) content in rat liver is increased following a single injection of NaOCN, as indicated by a decrease in the GSHrGSSG ratio.","Entity: glutathione disulfide. SMILES: N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O. Glutathione disulfide (GSSG) content in rat liver is increased following a single injection of NaOCN, as indicated by a decrease in the GSHrGSSG ratio."
glutathione,"In the human brain, glutathione (GSH) concentration ranges from 0.5 to 3.3 mmol/g wet weight.","Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. In the human brain, glutathione (GSH) concentration ranges from 0.5 to 3.3 mmol/g wet weight."
glutathione,"Maintaining adequate glutathione (GSH) levels is important for DNA repair efficiency in all tissues, as subnormal nuclear GSH sensitizes cells to DNA alkylating and other genotoxic agents.","Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Maintaining adequate glutathione (GSH) levels is important for DNA repair efficiency in all tissues, as subnormal nuclear GSH sensitizes cells to DNA alkylating and other genotoxic agents."
glutathione,"Loss of mitochondrial glutathione (GSH) is implicated in several human neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and Huntington's disease.","Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Loss of mitochondrial glutathione (GSH) is implicated in several human neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and Huntington's disease."
glutathione,A subnormal GSH/GSSG ratio in the brain has been reported in Parkinson's disease.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. A subnormal GSH/GSSG ratio in the brain has been reported in Parkinson's disease.
methylazoxymethanol,Methylazoxymethanol is a genotoxic agent that increases neuronal DNA damage and reduces DNA repair capacity in vitro.,Entity: methylazoxymethanol. SMILES: C[N+]([O-])=NCO. Methylazoxymethanol is a genotoxic agent that increases neuronal DNA damage and reduces DNA repair capacity in vitro.
cyanate,Cyanate is known to induce neuronal and/or axonal damage in humans and other mammals.,Entity: cyanate. SMILES: N#C[O-]. Cyanate is known to induce neuronal and/or axonal damage in humans and other mammals.
ammonia,Ammonia is a metabolic product of the conversion of cyanate to its final products.,Entity: ammonia. SMILES: N. Ammonia is a metabolic product of the conversion of cyanate to its final products.
carbon dioxide,Carbon dioxide is a metabolic product of the conversion of cyanate to its final products.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is a metabolic product of the conversion of cyanate to its final products.
glutathione,The neurotoxic potential of cyanate may be mediated in part by disruption of glutathione homeostasis in neural tissue.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. The neurotoxic potential of cyanate may be mediated in part by disruption of glutathione homeostasis in neural tissue.
hydrogen cyanide,Hydrogen cyanide is liberated from cyanogenic glucosides in cassava and is normally converted to thiocyanate by the enzyme rhodanese.,Entity: hydrogen cyanide. SMILES: C#N. Hydrogen cyanide is liberated from cyanogenic glucosides in cassava and is normally converted to thiocyanate by the enzyme rhodanese.
thiocyanate,Thiocyanate is produced from cyanohydrin and hydrogen cyanide via the action of the enzyme rhodanese.,Entity: thiocyanate. SMILES: N#C[S-]. Thiocyanate is produced from cyanohydrin and hydrogen cyanide via the action of the enzyme rhodanese.
cyanate,Cyanate is a neurotoxic species that can be formed from cyanide and is metabolized to ammonia and carbon dioxide.,Entity: cyanate. SMILES: N#C[O-]. Cyanate is a neurotoxic species that can be formed from cyanide and is metabolized to ammonia and carbon dioxide.
glutathione reductase,"Sodium cyanate dose-dependently inhibits glutathione reductase activity in the brain, leading to disruption of glutathione homeostasis.","Entity: glutathione reductase. Sodium cyanate dose-dependently inhibits glutathione reductase activity in the brain, leading to disruption of glutathione homeostasis."
glutamate,Glutamatergic axon terminals in the rat visceral nucleus tractus solitarius generally make asymmetric synaptic contacts.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamatergic axon terminals in the rat visceral nucleus tractus solitarius generally make asymmetric synaptic contacts.
glutamate,Glutamate is a principal fast neurotransmitter in the central nervous system.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate is a principal fast neurotransmitter in the central nervous system.
glutamate,"In the rat visceral nucleus tractus solitarius, nearly 61% of axon terminals are glutamatergic.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. In the rat visceral nucleus tractus solitarius, nearly 61% of axon terminals are glutamatergic."
IL-1alpha,"IL-1alpha mRNA expression in the mouse CNS after stroke shows a model-dependent shift in temporal expression, with delayed induction compared to other cytokines.","Entity: IL-1alpha. IL-1alpha mRNA expression in the mouse CNS after stroke shows a model-dependent shift in temporal expression, with delayed induction compared to other cytokines."
TGFbeta1,TGFbeta1 mRNA expression in the mouse CNS after stroke increases comparatively late (96 hours) following permanent or transient middle cerebral artery occlusion.,Entity: TGFbeta1. TGFbeta1 mRNA expression in the mouse CNS after stroke increases comparatively late (96 hours) following permanent or transient middle cerebral artery occlusion.
IL-1beta,"IL-1beta mRNA expression in the mouse CNS after stroke exhibits a model-dependent temporal shift, with delayed induction following reperfusion.","Entity: IL-1beta. IL-1beta mRNA expression in the mouse CNS after stroke exhibits a model-dependent temporal shift, with delayed induction following reperfusion."
NaCl,NaCl was present at a concentration of 147 mM in Ringer's solution used for microdialysis probe perfusion.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl was present at a concentration of 147 mM in Ringer's solution used for microdialysis probe perfusion.
CaCl,CaCl was present at a concentration of 1.2 mM in Ringer's solution used for microdialysis probe perfusion.,Entity: CaCl. SMILES: [Ca+2].[Cl-].[Cl-]. CaCl was present at a concentration of 1.2 mM in Ringer's solution used for microdialysis probe perfusion.
KCl,KCl was present at a concentration of 4 mM in Ringer's solution used for microdialysis probe perfusion.,Entity: KCl. SMILES: [Cl-].[K+]. KCl was present at a concentration of 4 mM in Ringer's solution used for microdialysis probe perfusion.
8-OH-DPAT,8-OH-DPAT was used at a concentration of 500 mM in Ringer's solution for perfusion through microdialysis probes during a 60-minute behavioral test.,Entity: 8-OH-DPAT. SMILES: CCCN(CCC)C1CCc2cccc(O)c2C1. 8-OH-DPAT was used at a concentration of 500 mM in Ringer's solution for perfusion through microdialysis probes during a 60-minute behavioral test.
8-Hydroxy-2-(di-n-propylamino)tetralin,8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) administration into the medial preoptic area (MPOA) increases extracellular levels of both 5-Hydroxytryptamine (5-HT) and Dopamine (DA).,Entity: 8-Hydroxy-2-(di-n-propylamino)tetralin. SMILES: CCCN(CCC)C1CCc2cccc(O)c2C1. 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) administration into the medial preoptic area (MPOA) increases extracellular levels of both 5-Hydroxytryptamine (5-HT) and Dopamine (DA).
8-Hydroxy-2-(di-n-propylamino)tetralin,8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) may act at the 5-HT transporter to elevate extracellular 5-HT levels in the MPOA.,Entity: 8-Hydroxy-2-(di-n-propylamino)tetralin. SMILES: CCCN(CCC)C1CCc2cccc(O)c2C1. 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) may act at the 5-HT transporter to elevate extracellular 5-HT levels in the MPOA.
5-Hydroxytryptamine,5-Hydroxytryptamine (5-HT) extracellular levels in the medial preoptic area (MPOA) are increased by administration of 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).,Entity: 5-Hydroxytryptamine. SMILES: NCCc1c[nH]c2ccc(O)cc12. 5-Hydroxytryptamine (5-HT) extracellular levels in the medial preoptic area (MPOA) are increased by administration of 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).
Dopamine,Dopamine extracellular levels in the medial preoptic area (MPOA) are increased by administration of 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).,Entity: Dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine extracellular levels in the medial preoptic area (MPOA) are increased by administration of 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).
"5,7-Dihydroxytryptamine","5,7-Dihydroxytryptamine (5,7-DHT) is a 5-HT neurotoxin that depletes neurotransmitter from axonal terminals by requiring transport into these terminals.","Entity: 5,7-Dihydroxytryptamine. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. 5,7-Dihydroxytryptamine (5,7-DHT) is a 5-HT neurotoxin that depletes neurotransmitter from axonal terminals by requiring transport into these terminals."
8-Hydroxy-di-propylaminotetralin,8-Hydroxy-di-propylaminotetralin is a serotonin (5-HT) agonist that facilitates ejaculation in male rats.,Entity: 8-Hydroxy-di-propylaminotetralin. SMILES: CCCN(CCC)C1CCCc2cccc(O)c21. 8-Hydroxy-di-propylaminotetralin is a serotonin (5-HT) agonist that facilitates ejaculation in male rats.
8-Hydroxy-di-propylaminotetralin,"Systemic administration of 8-Hydroxy-di-propylaminotetralin decreases the number of intromissions before ejaculation, ejaculation latency, and the post-ejaculatory interval in male rats.","Entity: 8-Hydroxy-di-propylaminotetralin. SMILES: CCCN(CCC)C1CCCc2cccc(O)c21. Systemic administration of 8-Hydroxy-di-propylaminotetralin decreases the number of intromissions before ejaculation, ejaculation latency, and the post-ejaculatory interval in male rats."
8-Hydroxy-di-propylaminotetralin,"Central infusion of 8-Hydroxy-di-propylaminotetralin into the cerebral ventricles, intrathecal space, medial preoptic area, nucleus accumbens, and median raphe nucleus produces behavioral effects similar to systemic administration in male rats.","Entity: 8-Hydroxy-di-propylaminotetralin. SMILES: CCCN(CCC)C1CCCc2cccc(O)c21. Central infusion of 8-Hydroxy-di-propylaminotetralin into the cerebral ventricles, intrathecal space, medial preoptic area, nucleus accumbens, and median raphe nucleus produces behavioral effects similar to systemic administration in male rats."
Serotonin,Serotonin (5-HT) neurotransmission in the brain inhibits the expression of masculine sexual behavior in male rats.,Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin (5-HT) neurotransmission in the brain inhibits the expression of masculine sexual behavior in male rats.
Dopamine,Dopamine enhances the expression of masculine sexual behavior in male rats.,Entity: Dopamine. SMILES: NCCc1ccc(O)c(O)c1. Dopamine enhances the expression of masculine sexual behavior in male rats.
5-HT,5-HT (serotonin) generally inhibits sexual behavior.,Entity: 5-HT. SMILES: NCCc1c[nH]c2ccc(O)cc12. 5-HT (serotonin) generally inhibits sexual behavior.
8-OH-DPAT,8-OH-DPAT may enhance sexual behavior by decreasing 5-HT activity in terminal regions.,Entity: 8-OH-DPAT. SMILES: CCCN(CCC)C1CCc2cccc(O)c2C1. 8-OH-DPAT may enhance sexual behavior by decreasing 5-HT activity in terminal regions.
8-OH-DPAT,8-OH-DPAT may exert behavioral effects by stimulating forebrain 5-HT postsynaptic receptors.,Entity: 8-OH-DPAT. SMILES: CCCN(CCC)C1CCc2cccc(O)c2C1. 8-OH-DPAT may exert behavioral effects by stimulating forebrain 5-HT postsynaptic receptors.
8-OH-DPAT,8-OH-DPAT decreases the ejaculation threshold when infused into specific forebrain sites such as the medial preoptic area (MPOA).,Entity: 8-OH-DPAT. SMILES: CCCN(CCC)C1CCc2cccc(O)c2C1. 8-OH-DPAT decreases the ejaculation threshold when infused into specific forebrain sites such as the medial preoptic area (MPOA).
"5,7-DHT","5,7-DHT is a 5-HT neurotoxin that abolishes presynaptic 5-HT input but does not prevent 8-OH-DPAT's effects on sexual behavior.","Entity: 5,7-DHT. SMILES: NCCc1c[nH]c2c(O)cc(O)cc12. 5,7-DHT is a 5-HT neurotoxin that abolishes presynaptic 5-HT input but does not prevent 8-OH-DPAT's effects on sexual behavior."
8-hydroxy-di-propylaminotetralin,The effects of 8-hydroxy-di-propylaminotetralin in the MPOA on male rat copulatory behavior may be mediated at least in part by its activity at D2 dopamine receptors or by increasing extracellular dopamine.,Entity: 8-hydroxy-di-propylaminotetralin. SMILES: CCCN(CCC)C1CCCc2cccc(O)c21. The effects of 8-hydroxy-di-propylaminotetralin in the MPOA on male rat copulatory behavior may be mediated at least in part by its activity at D2 dopamine receptors or by increasing extracellular dopamine.
4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-ben zamide hydrochloride,4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-ben zamide hydrochloride is a 5-HT1A receptor antagonist.,Entity: 4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-ben zamide hydrochloride. SMILES: COc1ccccc1N1CCN(CCN(C(=O)c2ccc(I)cc2)c2ccccn2)CC1.Cl. 4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-ben zamide hydrochloride is a 5-HT1A receptor antagonist.
dopamine,Retrodialysis of 8-hydroxy-di-propylaminotetralin into the MPOA increases extracellular dopamine levels in rats.,Entity: dopamine. SMILES: NCCc1ccc(O)c(O)c1. Retrodialysis of 8-hydroxy-di-propylaminotetralin into the MPOA increases extracellular dopamine levels in rats.
8-hydroxy-di-propylaminotetralin,8-hydroxy-di-propylaminotetralin is a serotonin agonist that acts at the 5-HT1A receptor and also at dopamine D2 receptors.,Entity: 8-hydroxy-di-propylaminotetralin. SMILES: CCCN(CCC)C1CCCc2cccc(O)c21. 8-hydroxy-di-propylaminotetralin is a serotonin agonist that acts at the 5-HT1A receptor and also at dopamine D2 receptors.
8-hydroxy-di-propylaminotetralin,Systemic or medial preoptic area (MPOA) injection of 8-hydroxy-di-propylaminotetralin reduces the ejaculatory threshold in male rats.,Entity: 8-hydroxy-di-propylaminotetralin. SMILES: CCCN(CCC)C1CCCc2cccc(O)c21. Systemic or medial preoptic area (MPOA) injection of 8-hydroxy-di-propylaminotetralin reduces the ejaculatory threshold in male rats.
8-hydroxy-di-propylaminotetralin,"Retrodialysis of 8-hydroxy-di-propylaminotetralin (500 µM) into the MPOA increases male copulatory behavior, including ejaculation frequency and decreasing ejaculation latency, postejaculatory interval, and mount frequency in rats.","Entity: 8-hydroxy-di-propylaminotetralin. SMILES: CCCN(CCC)C1CCCc2cccc(O)c21. Retrodialysis of 8-hydroxy-di-propylaminotetralin (500 µM) into the MPOA increases male copulatory behavior, including ejaculation frequency and decreasing ejaculation latency, postejaculatory interval, and mount frequency in rats."
Raclopride,"Raclopride, a D-serotonin receptor antagonist, blocks 8-OH-DPAT's effects on ejaculation frequency and latency but does not prevent 8-OH-DPAT from decreasing PEI or the number of intromissions preceding ejaculation in the 1A medial preoptic area.","Entity: Raclopride. SMILES: CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC. Raclopride, a D-serotonin receptor antagonist, blocks 8-OH-DPAT's effects on ejaculation frequency and latency but does not prevent 8-OH-DPAT from decreasing PEI or the number of intromissions preceding ejaculation in the 1A medial preoptic area."
8-Hydroxy-2-(di-n-propylamino)tetralin,"8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a 5-HT agonist that, when delivered to the 1A medial preoptic area by microinjection or reverse dialysis, decreases ejaculation latency, PEI, and the number of mounts and intromissions preceding ejaculation, while increasing the number of ejaculations.","Entity: 8-Hydroxy-2-(di-n-propylamino)tetralin. SMILES: CCCN(CCC)C1CCc2cccc(O)c2C1. 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a 5-HT agonist that, when delivered to the 1A medial preoptic area by microinjection or reverse dialysis, decreases ejaculation latency, PEI, and the number of mounts and intromissions preceding ejaculation, while increasing the number of ejaculations."
Cresyl violet,Cresyl violet is a histological stain used to visualize tissue sections under a microscope.,Entity: Cresyl violet. SMILES: Cc1cc2nc3c(cc(N)c4ccccc43)oc-2cc1=[N+](C)C.[Cl-]. Cresyl violet is a histological stain used to visualize tissue sections under a microscope.
5-HT1A,5-HT1A is a receptor site at which the serotonin agonist 8-hydroxy-di-propylaminotetralin (8-OH-DPAT) acts.,Entity: 5-HT1A. 5-HT1A is a receptor site at which the serotonin agonist 8-hydroxy-di-propylaminotetralin (8-OH-DPAT) acts.
NMDA,"In cutaneous nerves ipsilateral to inflammation, 61% of unmyelinated axons and 43% of myelinated axons are labeled for the NMDA receptor.","Entity: NMDA. SMILES: CN[C@H](CC(=O)[O-])C(=O)[O-]. In cutaneous nerves ipsilateral to inflammation, 61% of unmyelinated axons and 43% of myelinated axons are labeled for the NMDA receptor."
AMPA,"In cutaneous nerves ipsilateral to inflammation, 43% of unmyelinated axons and 42% of myelinated axons are labeled for the AMPA receptor.","Entity: AMPA. SMILES: Cc1onc(O)c1CC(N)C(=O)O. In cutaneous nerves ipsilateral to inflammation, 43% of unmyelinated axons and 42% of myelinated axons are labeled for the AMPA receptor."
glutamate,"Glutamate receptors are present on peripheral sensory axons, and their populations can increase as a result of inflammation, potentially contributing to peripheral sensitization and hyperalgesia.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate receptors are present on peripheral sensory axons, and their populations can increase as a result of inflammation, potentially contributing to peripheral sensitization and hyperalgesia."
bradykinin,"Bradykinin receptors, specifically the B2 subtype, predominate in most tissues and mediate most physiological functions under normal circumstances.","Entity: bradykinin. SMILES: NC(N)=NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N)C(=O)O. Bradykinin receptors, specifically the B2 subtype, predominate in most tissues and mediate most physiological functions under normal circumstances."
bradykinin,The B1 receptor subtype of bradykinin is not present in normal tissue but can be synthesized and expressed in response to inflammatory processes.,Entity: bradykinin. SMILES: NC(N)=NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N)C(=O)O. The B1 receptor subtype of bradykinin is not present in normal tissue but can be synthesized and expressed in response to inflammatory processes.
glutamate,"Glutamate receptors are present on Ab fibers in normal animals, but may be insufficient in number to initiate a response in these fibers.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate receptors are present on Ab fibers in normal animals, but may be insufficient in number to initiate a response in these fibers."
capsaicin,"Capsaicin-induced stimulation of the sciatic nerve increases glutamate levels in the hindpaw, as measured by microdialysis.","Entity: capsaicin. SMILES: COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O. Capsaicin-induced stimulation of the sciatic nerve increases glutamate levels in the hindpaw, as measured by microdialysis."
glutamate,"Glutamate levels in the hindpaw increase following electrical or capsaicin-induced stimulation of the sciatic nerve or after intraplantar injection of formalin, as shown by microdialysis.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate levels in the hindpaw increase following electrical or capsaicin-induced stimulation of the sciatic nerve or after intraplantar injection of formalin, as shown by microdialysis."
sodium borohydride,Sodium borohydride is used at a concentration of 1% in phosphate buffer to remove excess aldehydes from tissue prior to immunostaining.,Entity: sodium borohydride. SMILES: [BH4-].[Na+]. Sodium borohydride is used at a concentration of 1% in phosphate buffer to remove excess aldehydes from tissue prior to immunostaining.
araldite,Araldite is used as a component of the embedding medium for tissue sections during histological and ultrastructural analysis.,Entity: araldite. SMILES: CC(C)(c1ccccc1)c1ccc(OCC(O)COc2ccc(C(C)(C)c3ccc(OCC(O)COc4ccc(C(C)(C)c5ccc(OCC(O)CO)cc5)cc4)cc3)cc2)cc1. Araldite is used as a component of the embedding medium for tissue sections during histological and ultrastructural analysis.
N-methyl-D-aspartate,N-methyl-D-aspartate receptors are involved in the transmission of pain signals and play a role in inflammatory pain.,Entity: N-methyl-D-aspartate. SMILES: CN[C@H](CC(=O)[O-])C(=O)[O-]. N-methyl-D-aspartate receptors are involved in the transmission of pain signals and play a role in inflammatory pain.
glutamate,"Glutamate acts as an agonist at both NMDA and non-NMDA ionotropic glutamate receptors, which are implicated in pain signaling.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate acts as an agonist at both NMDA and non-NMDA ionotropic glutamate receptors, which are implicated in pain signaling."
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid,"α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid is a ligand for AMPA receptors, which are ionotropic glutamate receptors involved in pain transmission.","Entity: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. SMILES: Cc1onc(O)c1CC(N)C(=O)O. α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid is a ligand for AMPA receptors, which are ionotropic glutamate receptors involved in pain transmission."
glutamate,"Glutamate acts on AMPA and KA receptors expressed on unmyelinated cutaneous axons, and increased expression of these receptors in inflamed cutaneous nerves is associated with increased sensitivity of cutaneous axons to local glutamate.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate acts on AMPA and KA receptors expressed on unmyelinated cutaneous axons, and increased expression of these receptors in inflamed cutaneous nerves is associated with increased sensitivity of cutaneous axons to local glutamate."
N-methyl-D-aspartate,"N-methyl-D-aspartate receptors are present in unmyelinated and myelinated sensory axons in cutaneous nerves, and their numbers increase following CFA-induced inflammation in the inflamed paw.","Entity: N-methyl-D-aspartate. SMILES: CN[C@H](CC(=O)[O-])C(=O)[O-]. N-methyl-D-aspartate receptors are present in unmyelinated and myelinated sensory axons in cutaneous nerves, and their numbers increase following CFA-induced inflammation in the inflamed paw."
glutamate,Intraplantar injections of glutamate evoke nociceptive behaviors that can be blocked by local injection of glutamate receptor antagonists.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Intraplantar injections of glutamate evoke nociceptive behaviors that can be blocked by local injection of glutamate receptor antagonists.
glutamate,Local peripheral injection of glutamate receptor antagonists significantly reduces nociceptive behaviors following carrageenan-induced inflammation of the hindpaw or kaolin-carrageenan-induced inflammation of the knee joint in animal models of inflammatory pain.,Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Local peripheral injection of glutamate receptor antagonists significantly reduces nociceptive behaviors following carrageenan-induced inflammation of the hindpaw or kaolin-carrageenan-induced inflammation of the knee joint in animal models of inflammatory pain.
glutamate,"Nociceptive behaviors induced by intraplantar injection of formalin or capsaicin, which produce inflammation, are attenuated by local peripheral injection of glutamate receptor antagonists.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Nociceptive behaviors induced by intraplantar injection of formalin or capsaicin, which produce inflammation, are attenuated by local peripheral injection of glutamate receptor antagonists."
capsaicin,"Nociceptive behaviors induced by intraplantar injection of capsaicin, which produces inflammation, are attenuated by local peripheral injection of glutamate receptor antagonists.","Entity: capsaicin. SMILES: COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O. Nociceptive behaviors induced by intraplantar injection of capsaicin, which produces inflammation, are attenuated by local peripheral injection of glutamate receptor antagonists."
N-methyl-D-aspartate,"N-methyl-D-aspartate receptors are expressed on a relatively high percentage of axons in the sural and plantar nerves in normal, non-inflamed animals.","Entity: N-methyl-D-aspartate. SMILES: CN[C@H](CC(=O)[O-])C(=O)[O-]. N-methyl-D-aspartate receptors are expressed on a relatively high percentage of axons in the sural and plantar nerves in normal, non-inflamed animals."
N-methyl-D-aspartate,Local peripheral injection of N-methyl-D-aspartate receptor antagonists significantly reduces nociceptive behaviors following carrageenan-induced inflammation of the hindpaw or kaolin-carrageenan-induced inflammation of the knee joint in animal models of inflammatory pain.,Entity: N-methyl-D-aspartate. SMILES: CN[C@H](CC(=O)[O-])C(=O)[O-]. Local peripheral injection of N-methyl-D-aspartate receptor antagonists significantly reduces nociceptive behaviors following carrageenan-induced inflammation of the hindpaw or kaolin-carrageenan-induced inflammation of the knee joint in animal models of inflammatory pain.
N-methyl-D-aspartate,"Nociceptive behaviors induced by intraplantar injection of formalin or capsaicin, which produce inflammation, are attenuated by local peripheral injection of N-methyl-D-aspartate receptor antagonists.","Entity: N-methyl-D-aspartate. SMILES: CN[C@H](CC(=O)[O-])C(=O)[O-]. Nociceptive behaviors induced by intraplantar injection of formalin or capsaicin, which produce inflammation, are attenuated by local peripheral injection of N-methyl-D-aspartate receptor antagonists."
glutamate,"Glutamate receptors, including NMDA, AMPA, and w x KA receptors, are expressed on a relatively high percentage of axons in the sural and plantar nerves in normal, non-inflamed animals.","Entity: glutamate. SMILES: N[C@@H](CCC(=O)[O-])C(=O)[O-]. Glutamate receptors, including NMDA, AMPA, and w x KA receptors, are expressed on a relatively high percentage of axons in the sural and plantar nerves in normal, non-inflamed animals."
formaldehyde,"Formaldehyde is used as a component (1%) in perfusion fixative solutions for tissue processing, such as in histological analysis.","Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a component (1%) in perfusion fixative solutions for tissue processing, such as in histological analysis."
glutaraldehyde,"Glutaraldehyde is used as a component (2.5%) in perfusion fixative solutions for tissue processing, preserving nerve tissue for histological examination.","Entity: glutaraldehyde. SMILES: O=CCCCC=O. Glutaraldehyde is used as a component (2.5%) in perfusion fixative solutions for tissue processing, preserving nerve tissue for histological examination."
picric acid,Picric acid (0.1%) is included in perfusion fixative solutions to help stabilize and preserve tissue during perfusion and subsequent processing.,Entity: picric acid. SMILES: O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1. Picric acid (0.1%) is included in perfusion fixative solutions to help stabilize and preserve tissue during perfusion and subsequent processing.
pentobarbital,Pentobarbital is used as an anesthetic agent at a dose of 50 mg/kg intraperitoneally in animal studies.,Entity: pentobarbital. SMILES: CCCC(C)C1(CC)C(=O)NC(=O)NC1=O. Pentobarbital is used as an anesthetic agent at a dose of 50 mg/kg intraperitoneally in animal studies.
glucose,"Glucose can rapidly restore the activity of a suppressed GnRH pulse generator, indicating a critical role in maintaining GnRH neuron activity and acting directly on the central nervous system.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose can rapidly restore the activity of a suppressed GnRH pulse generator, indicating a critical role in maintaining GnRH neuron activity and acting directly on the central nervous system."
fructose,"Fructose does not cross the blood-brain barrier and has a slower effect on GnRH pulse generator activity compared to glucose, likely due to its conversion to glucose in the body.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose does not cross the blood-brain barrier and has a slower effect on GnRH pulse generator activity compared to glucose, likely due to its conversion to glucose in the body."
mannose,Mannose abolishes compensatory changes in glucose release during insulin-induced hypoglycemia.,Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose abolishes compensatory changes in glucose release during insulin-induced hypoglycemia.
glucose,Glucose release during insulin-induced hypoglycemia is subject to compensatory changes.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose release during insulin-induced hypoglycemia is subject to compensatory changes.
mannose,Mannose is able to penetrate the blood-brain barrier.,Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose is able to penetrate the blood-brain barrier.
mannose,Mannose is transported into cerebellar granule neurons.,Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannose is transported into cerebellar granule neurons.
D-glucose,"D-glucose is required to support synaptic activity in guinea pig hippocampal slices, whereas fructose, galactose, xylose, and lactate do not have this effect.","Entity: D-glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. D-glucose is required to support synaptic activity in guinea pig hippocampal slices, whereas fructose, galactose, xylose, and lactate do not have this effect."
glucose,"Glucose restores pulsatile luteinizing hormone (LH) secretion and the electrical activity of the GnRH pulse generator in insulin-suppressed estrogen-primed ovariectomized rats, more rapidly and effectively than fructose or lactate.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose restores pulsatile luteinizing hormone (LH) secretion and the electrical activity of the GnRH pulse generator in insulin-suppressed estrogen-primed ovariectomized rats, more rapidly and effectively than fructose or lactate."
glucose,"Glucose availability is an essential factor for maintaining the electrical activity of the GnRH pulse generator, which is responsible for pulsatile LH secretion.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose availability is an essential factor for maintaining the electrical activity of the GnRH pulse generator, which is responsible for pulsatile LH secretion."
Fructose,"Fructose can recover pulsatile luteinizing hormone (LH) secretion and the electrical activity of the GnRH pulse generator suppressed by insulin, but does so more slowly than glucose.","Entity: Fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose can recover pulsatile luteinizing hormone (LH) secretion and the electrical activity of the GnRH pulse generator suppressed by insulin, but does so more slowly than glucose."
2-deoxy-D-glucose,"2-deoxy-D-glucose, which induces cellular glycopenia, decreases the activity of the GnRH pulse generator in rats.","Entity: 2-deoxy-D-glucose. SMILES: O=CC[C@@H](O)[C@H](O)[C@H](O)CO. 2-deoxy-D-glucose, which induces cellular glycopenia, decreases the activity of the GnRH pulse generator in rats."
glucose,Glucose administration restores the activity of the GnRH pulse generator that has been suppressed by insulin in rats.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose administration restores the activity of the GnRH pulse generator that has been suppressed by insulin in rats.
mannose,"Intravenous injection of mannose results in an LH pulse that appears almost instantly with latency significantly smaller than that after galactose, xylose, lactate, and saline.","Entity: mannose. SMILES: O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Intravenous injection of mannose results in an LH pulse that appears almost instantly with latency significantly smaller than that after galactose, xylose, lactate, and saline."
fructose,"Fructose administration produces a shorter pulse latency compared to saline and xylose, but not galactose.","Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Fructose administration produces a shorter pulse latency compared to saline and xylose, but not galactose."
galactose,"Galactose administration results in a longer pulse latency compared to glucose and mannose, but shortens the latency after saline.","Entity: galactose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO. Galactose administration results in a longer pulse latency compared to glucose and mannose, but shortens the latency after saline."
xylose,"Xylose administration produces a longer pulse latency compared to glucose and mannose, and shortens the latency after saline.","Entity: xylose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO. Xylose administration produces a longer pulse latency compared to glucose and mannose, and shortens the latency after saline."
glucose,"Intravenous injection of glucose results in an LH pulse that appears almost instantly with latency significantly smaller than that after galactose, xylose, lactate, and saline.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Intravenous injection of glucose results in an LH pulse that appears almost instantly with latency significantly smaller than that after galactose, xylose, lactate, and saline."
lactate,Lactate administration has no significant effect on pulse latency.,Entity: lactate. SMILES: CC(O)C(=O)[O-]. Lactate administration has no significant effect on pulse latency.
2-deoxyglucose,"2-deoxyglucose induces cellular glycopenia and suppresses pulsatile luteinizing hormone (LH) secretion in monkeys, sheep, and rats.","Entity: 2-deoxyglucose. SMILES: O=CC[C@@H](O)[C@H](O)[C@H](O)CO. 2-deoxyglucose induces cellular glycopenia and suppresses pulsatile luteinizing hormone (LH) secretion in monkeys, sheep, and rats."
glucose,Cellular glucose deprivation suppresses pulsatile luteinizing hormone (LH) secretion in various animal species.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Cellular glucose deprivation suppresses pulsatile luteinizing hormone (LH) secretion in various animal species.
glucose,Injection of glucose in rats induces an immediate MUA (median uterine artery) volley and a subsequent pulse of luteinizing hormone (LH).,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Injection of glucose in rats induces an immediate MUA (median uterine artery) volley and a subsequent pulse of luteinizing hormone (LH).
fructose,Injection of fructose in rats induces an MUA (median uterine artery) volley that occurs significantly earlier than saline injection but significantly later than glucose injection.,Entity: fructose. SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO. Injection of fructose in rats induces an MUA (median uterine artery) volley that occurs significantly earlier than saline injection but significantly later than glucose injection.
Dexfenfluramine,Dexfenfluramine is a serotonergic agonist that induces anorexia and conditioned flavor aversion in rats.,Entity: Dexfenfluramine. SMILES: CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1. Dexfenfluramine is a serotonergic agonist that induces anorexia and conditioned flavor aversion in rats.
Dexfenfluramine,"The anorectic effect of dexfenfluramine in rats is not dependent on the area postrema (AP) or nucleus of the solitary tract (NTS), as shown by the absence of Fos-like immunoreactivity in these regions after dexfenfluramine administration.","Entity: Dexfenfluramine. SMILES: CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1. The anorectic effect of dexfenfluramine in rats is not dependent on the area postrema (AP) or nucleus of the solitary tract (NTS), as shown by the absence of Fos-like immunoreactivity in these regions after dexfenfluramine administration."
Dexfenfluramine,"Injection of Dexfenfluramine in rats produces a flavor aversion, which may be mediated by the area postrema and the dorsal vagal complex.","Entity: Dexfenfluramine. SMILES: CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1. Injection of Dexfenfluramine in rats produces a flavor aversion, which may be mediated by the area postrema and the dorsal vagal complex."
Serotonin,Serotonin is implicated as a neurotransmitter whose release is increased by Dexfenfluramine in the brain.,Entity: Serotonin. SMILES: NCCc1c[nH]c2ccc(O)cc12. Serotonin is implicated as a neurotransmitter whose release is increased by Dexfenfluramine in the brain.
Dexfenfluramine,Dexfenfluramine is an anorectic agent that most likely acts by increasing serotonin 5HT release in the brain.,Entity: Dexfenfluramine. SMILES: CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1. Dexfenfluramine is an anorectic agent that most likely acts by increasing serotonin 5HT release in the brain.
Dexfenfluramine,"Dexfenfluramine induces regional increases in Fos-like immunoreactivity, a marker of cellular activation, in rat brain regions such as the external lateral parabrachial nucleus and the caudal nucleus of the tractus solitarius.","Entity: Dexfenfluramine. SMILES: CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1. Dexfenfluramine induces regional increases in Fos-like immunoreactivity, a marker of cellular activation, in rat brain regions such as the external lateral parabrachial nucleus and the caudal nucleus of the tractus solitarius."
Dexfenfluramine,The anorectic action of Dexfenfluramine is partially abolished by lesions of the external lateral parabrachial nucleus and completely abolished by lesions of the lateral central nucleus of the amygdala and the laterodorsal bed nucleus of the stria terminalis in rats.,Entity: Dexfenfluramine. SMILES: CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1. The anorectic action of Dexfenfluramine is partially abolished by lesions of the external lateral parabrachial nucleus and completely abolished by lesions of the lateral central nucleus of the amygdala and the laterodorsal bed nucleus of the stria terminalis in rats.
Dexfenfluramine,Chronic supracollicular brainstem transection in rats sensitizes them to the anorectic action of Dexfenfluramine.,Entity: Dexfenfluramine. SMILES: CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1. Chronic supracollicular brainstem transection in rats sensitizes them to the anorectic action of Dexfenfluramine.
Triton X-100,Triton X-100 is a non-ionic detergent commonly used at 0.2% concentration in antibody incubation buffers to permeabilize cell membranes.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent commonly used at 0.2% concentration in antibody incubation buffers to permeabilize cell membranes.
diaminobenzidine,"Diaminobenzidine is a chromogenic substrate used to visualize peroxidase activity in immunohistochemistry, producing a brown precipitate upon reaction with peroxidase.","Entity: diaminobenzidine. SMILES: NNc1ccc(-c2ccc(NN)cc2)cc1. Diaminobenzidine is a chromogenic substrate used to visualize peroxidase activity in immunohistochemistry, producing a brown precipitate upon reaction with peroxidase."
formamide,Formamide is included at 50% concentration in the hybridization buffer for in situ hybridization.,Entity: formamide. SMILES: NC=O. Formamide is included at 50% concentration in the hybridization buffer for in situ hybridization.
sodium citrate,Sodium citrate is included at 15 mM concentration in the saline sodium citrate (SSC) buffer used for in situ hybridization.,Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is included at 15 mM concentration in the saline sodium citrate (SSC) buffer used for in situ hybridization.
sodium pyrophosphate,Sodium pyrophosphate is included at 1 mM concentration and pH 7.0 in the hybridization buffer for in situ hybridization.,Entity: sodium pyrophosphate. SMILES: O=P([O-])([O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+]. Sodium pyrophosphate is included at 1 mM concentration and pH 7.0 in the hybridization buffer for in situ hybridization.
sodium phosphate,Sodium phosphate is used at 50 mM concentration and pH 7.0 in hybridization buffer for in situ hybridization experiments.,Entity: sodium phosphate. SMILES: O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]. Sodium phosphate is used at 50 mM concentration and pH 7.0 in hybridization buffer for in situ hybridization experiments.
ethanol,Ethanol is used for dehydration of slides during the preparation for autoradiography in in situ hybridization protocols.,Entity: ethanol. SMILES: CCO. Ethanol is used for dehydration of slides during the preparation for autoradiography in in situ hybridization protocols.
sodium chloride,Sodium chloride is included at 150 mM concentration in the saline sodium citrate (SSC) buffer used for in situ hybridization.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is included at 150 mM concentration in the saline sodium citrate (SSC) buffer used for in situ hybridization.
dithiothreitol,Dithiothreitol (DTT) is used at 40 mM concentration in the hybridization buffer for in situ hybridization.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol (DTT) is used at 40 mM concentration in the hybridization buffer for in situ hybridization.
corticotrophin-releasing hormone,"Corticotrophin-releasing hormone (CRH) stimulates increases in adrenocorticotropin (ACTH) output from fetal corticotrophs, and this response is not significantly affected by gestational day 129 or 138.","Entity: corticotrophin-releasing hormone. Corticotrophin-releasing hormone (CRH) stimulates increases in adrenocorticotropin (ACTH) output from fetal corticotrophs, and this response is not significantly affected by gestational day 129 or 138."
AVP,Oxytocin does not produce a synergistic interaction with vasopressin (AVP) in stimulating adrenocorticotropin (ACTH) output from fetal corticotrophs in vitro.,Entity: AVP. Oxytocin does not produce a synergistic interaction with vasopressin (AVP) in stimulating adrenocorticotropin (ACTH) output from fetal corticotrophs in vitro.
pro-opiomelanocortin,Oxytocin does not affect cellular pro-opiomelanocortin (POMC) mRNA levels in fetal pituitary cells in vitro.,Entity: pro-opiomelanocortin. Oxytocin does not affect cellular pro-opiomelanocortin (POMC) mRNA levels in fetal pituitary cells in vitro.
DAB,DAB is used as a chromogenic substrate for visualization of immunoreactions in tissue sections.,Entity: DAB. SMILES: Nc1ccc(-c2ccc(N)c(N)c2)cc1N. DAB is used as a chromogenic substrate for visualization of immunoreactions in tissue sections.
Triton X-100,Triton X-100 is a non-ionic detergent commonly used to permeabilize biological tissues for immunohistochemistry.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent commonly used to permeabilize biological tissues for immunohistochemistry.
substance P,Substance P is a neuropeptide with antidiuretic properties.,Entity: substance P. Substance P is a neuropeptide with antidiuretic properties.
Fos,Fos protein expression in dorsolateral funiculus neurons is increased by innocuous mechanical brush stimulation of an inflamed hindpaw and is reduced in dorsolateral funiculus neurons after dorsolateral funiculus lesion in rats.,Entity: Fos. Fos protein expression in dorsolateral funiculus neurons is increased by innocuous mechanical brush stimulation of an inflamed hindpaw and is reduced in dorsolateral funiculus neurons after dorsolateral funiculus lesion in rats.
helium,"Helium is used in the measurement of forced vital capacity (VC), forced expiratory volume in 1 second (FEV1), and functional residual capacity (FRC) by the helium dilution technique.","Entity: helium. SMILES: [He]. Helium is used in the measurement of forced vital capacity (VC), forced expiratory volume in 1 second (FEV1), and functional residual capacity (FRC) by the helium dilution technique."
helium,Helium is used as a tracer gas in the single breath diffusing capacity test to assess lung function.,Entity: helium. SMILES: [He]. Helium is used as a tracer gas in the single breath diffusing capacity test to assess lung function.
carbon monoxide,Carbon monoxide is used as a tracer gas in the single breath diffusing capacity test (a modification of the Krogh technique) to evaluate lung function.,Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide is used as a tracer gas in the single breath diffusing capacity test (a modification of the Krogh technique) to evaluate lung function.
carbon dioxide,Carbon dioxide is produced in small quantities during the combustion of polyvinylchloride.,Entity: carbon dioxide. SMILES: O=C=O. Carbon dioxide is produced in small quantities during the combustion of polyvinylchloride.
phosgene,Phosgene is produced in very small quantities during the combustion of polyvinylchloride.,Entity: phosgene. SMILES: O=C(Cl)Cl. Phosgene is produced in very small quantities during the combustion of polyvinylchloride.
carbon monoxide,"Carbon monoxide is produced in considerable amounts during polyvinylchloride combustion, especially when oxygen is abundant.","Entity: carbon monoxide. SMILES: [C]=O. Carbon monoxide is produced in considerable amounts during polyvinylchloride combustion, especially when oxygen is abundant."
phthalic acid,Phthalic acid is used as a softener in the manufacturing of polyvinylchloride insulation material for electrical wiring.,Entity: phthalic acid. SMILES: O=C(O)c1ccccc1C(=O)O. Phthalic acid is used as a softener in the manufacturing of polyvinylchloride insulation material for electrical wiring.
hydrogen chloride,Hydrogen chloride is the main product formed during the combustion of polyvinylchloride.,Entity: hydrogen chloride. SMILES: Cl. Hydrogen chloride is the main product formed during the combustion of polyvinylchloride.
Ferrochelatase,A region containing a CACCC box and a neighboring GC box in the mouse ferrochelatase promoter contributes to the inducible activity of the gene in MEL cells upon induction with dimethylsulfoxide.,Entity: Ferrochelatase. A region containing a CACCC box and a neighboring GC box in the mouse ferrochelatase promoter contributes to the inducible activity of the gene in MEL cells upon induction with dimethylsulfoxide.
Ferrochelatase,A Sp1 binding site located at -37/-32 in the mouse ferrochelatase promoter is essential for basic expression of the gene in both mouse erythroleukemia (MEL) and non-erythroid EL4 cells.,Entity: Ferrochelatase. A Sp1 binding site located at -37/-32 in the mouse ferrochelatase promoter is essential for basic expression of the gene in both mouse erythroleukemia (MEL) and non-erythroid EL4 cells.
Ferrochelatase,"The promoter region of the mouse ferrochelatase gene contains multiple Sp1 sites, a CACCC box, and GATA-1 binding sites.","Entity: Ferrochelatase. The promoter region of the mouse ferrochelatase gene contains multiple Sp1 sites, a CACCC box, and GATA-1 binding sites."
Ferrochelatase,"Ferrochelatase (EC.4.99.1.1) is the final enzyme in the biosynthesis of heme and is widely expressed in various tissues, with higher expression in erythroid cells.","Entity: Ferrochelatase. Ferrochelatase (EC.4.99.1.1) is the final enzyme in the biosynthesis of heme and is widely expressed in various tissues, with higher expression in erythroid cells."
Ferrochelatase,"The mouse ferrochelatase gene spans about 25 kb and consists of 11 exons, with exon/intron boundary sequences conforming to consensus acceptor (GTn)/donor (nAG) sequences.","Entity: Ferrochelatase. The mouse ferrochelatase gene spans about 25 kb and consists of 11 exons, with exon/intron boundary sequences conforming to consensus acceptor (GTn)/donor (nAG) sequences."
alachlor,Alachlor is a herbicide that induces chromosomal aberrations in human peripheral lymphocytes.,Entity: alachlor. SMILES: CCc1cccc(CC)c1N(COC)C(=O)CCl. Alachlor is a herbicide that induces chromosomal aberrations in human peripheral lymphocytes.
trifluralin,Trifluralin is a herbicide that does not induce chromosomal aberrations in human peripheral lymphocytes.,Entity: trifluralin. SMILES: CCCN(CCC)c1c([N+](=O)[O-])cc(C(F)(F)F)cc1[N+](=O)[O-]. Trifluralin is a herbicide that does not induce chromosomal aberrations in human peripheral lymphocytes.
maleic hydrazide,Maleic hydrazide is a herbicide that induces chromosomal aberrations in human peripheral lymphocytes.,Entity: maleic hydrazide. SMILES: NNC(=O)/C=C\C(=O)O. Maleic hydrazide is a herbicide that induces chromosomal aberrations in human peripheral lymphocytes.
"1,2-dibromo-4-chlorophenyl sulfone","1,2-dibromo-4-chlorophenyl sulfone exposure increases reversion frequency in the SPD8 assay and Sp5 cell assay, with statistically significant and dose-dependent effects observed in both systems.","Entity: 1,2-dibromo-4-chlorophenyl sulfone. SMILES: O=S(=O)(C1(Br)C=CC(Cl)=CC1Br)C1(Br)C=CC(Cl)=CC1Br. 1,2-dibromo-4-chlorophenyl sulfone exposure increases reversion frequency in the SPD8 assay and Sp5 cell assay, with statistically significant and dose-dependent effects observed in both systems."
Tetrabromobisphenol A,Tetrabromobisphenol A is an environmental contaminant that is covalently bound to polymers in modern plastics as a flame retardant.,Entity: Tetrabromobisphenol A. SMILES: CC(C)(c1ccc(O)cc1)c1c(Br)c(Br)c(O)c(Br)c1Br. Tetrabromobisphenol A is an environmental contaminant that is covalently bound to polymers in modern plastics as a flame retardant.
Tetrabromobisphenol A,"Small amounts of Tetrabromobisphenol A do not react with polymers and remain unbound, and these free molecules can leach out.","Entity: Tetrabromobisphenol A. SMILES: CC(C)(c1ccc(O)cc1)c1c(Br)c(Br)c(O)c(Br)c1Br. Small amounts of Tetrabromobisphenol A do not react with polymers and remain unbound, and these free molecules can leach out."
Tetrabromobisphenol A,"Tetrabromobisphenol A has been reported to be negative in the Ames test, both with and without metabolic activation.","Entity: Tetrabromobisphenol A. SMILES: CC(C)(c1ccc(O)cc1)c1c(Br)c(Br)c(O)c(Br)c1Br. Tetrabromobisphenol A has been reported to be negative in the Ames test, both with and without metabolic activation."
Tetrabromobisphenol A,Tetrabromobisphenol A caused no effect in either the SPD8 or Sp5 recombination assay.,Entity: Tetrabromobisphenol A. SMILES: CC(C)(c1ccc(O)cc1)c1c(Br)c(Br)c(O)c(Br)c1Br. Tetrabromobisphenol A caused no effect in either the SPD8 or Sp5 recombination assay.
L-azaserine,L-azaserine is used at a concentration of 5 mM in HMEM medium to support the selection of revertants with a functional hprt gene phenotype in cell-based reversion assays.,Entity: L-azaserine. SMILES: [N-]=[N+]=CC(=O)OC[C@H](N)C(=O)O. L-azaserine is used at a concentration of 5 mM in HMEM medium to support the selection of revertants with a functional hprt gene phenotype in cell-based reversion assays.
hypoxanthine,Hypoxanthine is included at a concentration of 50 mM in HMEM medium as part of the selection process for revertants with a functional hprt gene phenotype in cell-based assays.,Entity: hypoxanthine. SMILES: O=c1[nH]cnc2nc[nH]c12. Hypoxanthine is included at a concentration of 50 mM in HMEM medium as part of the selection process for revertants with a functional hprt gene phenotype in cell-based assays.
thymidine,Thymidine is provided at a concentration of 10 mM in HMEM medium to facilitate the selection of revertants with a functional hprt gene phenotype in cell-based reversion assays.,Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine is provided at a concentration of 10 mM in HMEM medium to facilitate the selection of revertants with a functional hprt gene phenotype in cell-based reversion assays.
methanol,Methanol is used as a component of the staining solution (methy-Ž-lene bluermethanol) for visualizing fixed colonies in cell-based reversion assays.,Entity: methanol. SMILES: CO. Methanol is used as a component of the staining solution (methy-Ž-lene bluermethanol) for visualizing fixed colonies in cell-based reversion assays.
HBCD,"HBCD is a flame retardant compound that can leach out of materials such as polystyrene, latex, and textiles.","Entity: HBCD. SMILES: BrC1(Br)CCCCCCCCCC(Br)(Br)C1(Br)Br. HBCD is a flame retardant compound that can leach out of materials such as polystyrene, latex, and textiles."
HBCD,"HBCD treatment elevates recombination frequency by 2.2-fold in the Sp5 assay and 1.9-fold in SPD8 cells, with a statistically significant dose-dependent effect.","Entity: HBCD. SMILES: BrC1(Br)CCCCCCCCCC(Br)(Br)C1(Br)Br. HBCD treatment elevates recombination frequency by 2.2-fold in the Sp5 assay and 1.9-fold in SPD8 cells, with a statistically significant dose-dependent effect."
hexabromocyclododecane,Hexabromocyclododecane (HBCD) is a brominated flame retardant that induces statistically significant increases in intragenic recombination frequency in mammalian cells in both SPD8 and Sp5 assay systems.,Entity: hexabromocyclododecane. SMILES: BrC1(Br)CCCCCCCCCC(Br)(Br)C1(Br)Br. Hexabromocyclododecane (HBCD) is a brominated flame retardant that induces statistically significant increases in intragenic recombination frequency in mammalian cells in both SPD8 and Sp5 assay systems.
hexabromocyclododecane,"Hexabromocyclododecane (HBCD) is considered a modern additive to plastics and is associated with genetic recombination induction, a process linked to diseases such as cancer.","Entity: hexabromocyclododecane. SMILES: BrC1(Br)CCCCCCCCCC(Br)(Br)C1(Br)Br. Hexabromocyclododecane (HBCD) is considered a modern additive to plastics and is associated with genetic recombination induction, a process linked to diseases such as cancer."
HBCD,"HBCD is a brominated flame retardant that is not covalently bound to the material to which it is added, allowing it to be released into the environment and potentially accumulate.","Entity: HBCD. SMILES: BrC1(Br)CCCCCCCCCC(Br)(Br)C1(Br)Br. HBCD is a brominated flame retardant that is not covalently bound to the material to which it is added, allowing it to be released into the environment and potentially accumulate."
"2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether is recombinogenic in the SPD8 cell assay, contributing to a 3.2-fold increase in recombination frequency.","Entity: 2,2',4,4'-tetrabromodiphenyl ether. SMILES: Brc1ccc(Oc2ccc(Br)cc2Br)c(Br)c1. 2,2',4,4'-tetrabromodiphenyl ether is recombinogenic in the SPD8 cell assay, contributing to a 3.2-fold increase in recombination frequency."
"2,2',4,4'-tetrabromodiphenyl ether","2,2',4,4'-tetrabromodiphenyl ether exhibits cytotoxic effects in the SPD8 assay, with the dose required to inhibit growth by 50% (IC50-G) and reduce cloning ability to 50% (IC50-C), corresponding to a 1.8-fold induction.","Entity: 2,2',4,4'-tetrabromodiphenyl ether. SMILES: Brc1ccc(Oc2ccc(Br)cc2Br)c(Br)c1. 2,2',4,4'-tetrabromodiphenyl ether exhibits cytotoxic effects in the SPD8 assay, with the dose required to inhibit growth by 50% (IC50-G) and reduce cloning ability to 50% (IC50-C), corresponding to a 1.8-fold induction."
"2,2',4-tribromodiphenyl ether","2,2',4-tribromodiphenyl ether is recombinogenic in the SPD8 cell assay, contributing to a 2.7-fold increase in recombination frequency.","Entity: 2,2',4-tribromodiphenyl ether. SMILES: Brc1ccc(Oc2ccccc2Br)c(Br)c1. 2,2',4-tribromodiphenyl ether is recombinogenic in the SPD8 cell assay, contributing to a 2.7-fold increase in recombination frequency."
"2,2',4-tribromodiphenyl ether","2,2',4-tribromodiphenyl ether exhibits cytotoxic effects in the SPD8 assay, with the dose required to inhibit growth by 50% (IC50-G) and reduce cloning ability to 50% (IC50-C), corresponding to a 1.8-fold induction.","Entity: 2,2',4-tribromodiphenyl ether. SMILES: Brc1ccc(Oc2ccccc2Br)c(Br)c1. 2,2',4-tribromodiphenyl ether exhibits cytotoxic effects in the SPD8 assay, with the dose required to inhibit growth by 50% (IC50-G) and reduce cloning ability to 50% (IC50-C), corresponding to a 1.8-fold induction."
DmMCM5,"DmMCM5 is a member of the MCM gene family in Drosophila melanogaster and is homologous to the human MCM5 protein, suggesting a conserved function in DNA replication.","Entity: DmMCM5. DmMCM5 is a member of the MCM gene family in Drosophila melanogaster and is homologous to the human MCM5 protein, suggesting a conserved function in DNA replication."
DmMCM4,"DmMCM4 is a member of the MCM gene family in Drosophila melanogaster and is homologous to the human MCM4 protein, suggesting a conserved function in DNA replication.","Entity: DmMCM4. DmMCM4 is a member of the MCM gene family in Drosophila melanogaster and is homologous to the human MCM4 protein, suggesting a conserved function in DNA replication."
DmMCM2,"DmMCM2 is a member of the MCM gene family in Drosophila melanogaster and is homologous to the human MCM2 protein, indicating a conserved function in DNA replication.","Entity: DmMCM2. DmMCM2 is a member of the MCM gene family in Drosophila melanogaster and is homologous to the human MCM2 protein, indicating a conserved function in DNA replication."
benzo[h]quinoline,Benzo[h]quinoline is a benzene-fused quinoline derivative whose genotoxicity is proposed to occur via an enamine epoxide activation mechanism.,Entity: benzo[h]quinoline. SMILES: c1ccc2c(c1)ccc1cccnc12. Benzo[h]quinoline is a benzene-fused quinoline derivative whose genotoxicity is proposed to occur via an enamine epoxide activation mechanism.
"1,7-phenanthroline","1,7-phenanthroline is a heteroaromatic compound structurally related to quinoline and its genotoxicity is proposed to involve an enamine epoxide activation mechanism.","Entity: 1,7-phenanthroline. SMILES: c1cnc2c(c1)ccc1ncccc12. 1,7-phenanthroline is a heteroaromatic compound structurally related to quinoline and its genotoxicity is proposed to involve an enamine epoxide activation mechanism."
benzo[f]quinoline,Benzo[f]quinoline is a benzene-fused quinoline derivative whose genotoxicity is proposed to occur via an enamine epoxide activation mechanism.,Entity: benzo[f]quinoline. SMILES: c1ccc2c(c1)ccc1ncccc12. Benzo[f]quinoline is a benzene-fused quinoline derivative whose genotoxicity is proposed to occur via an enamine epoxide activation mechanism.
3-fluoroquinoline,3-fluoroquinoline is non-mutagenic and non-cytotoxic in the whole dose range from 0 to 8 mmol/plate.,Entity: 3-fluoroquinoline. SMILES: Fc1cnc2ccccc2c1. 3-fluoroquinoline is non-mutagenic and non-cytotoxic in the whole dose range from 0 to 8 mmol/plate.
6-fluoroquinoline,6-fluoroquinoline is weakly mutagenic and appears to be more cytotoxic than 3-fluoroquinoline.,Entity: 6-fluoroquinoline. SMILES: Fc1ccc2ncccc2c1. 6-fluoroquinoline is weakly mutagenic and appears to be more cytotoxic than 3-fluoroquinoline.
Quinoline,Quinoline is a potent mutagen in Salmonella typhimurium TA100 in the presence of rat liver microsomal enzymes.,Entity: Quinoline. SMILES: c1ccc2ncccc2c1. Quinoline is a potent mutagen in Salmonella typhimurium TA100 in the presence of rat liver microsomal enzymes.
Quinoline,"Metabolic oxidation of the pyridine moiety in quinoline produces a 1,4-hydrated 2,3-epoxide, which is responsible for its mutagenic modification of DNA.","Entity: Quinoline. SMILES: c1ccc2ncccc2c1. Metabolic oxidation of the pyridine moiety in quinoline produces a 1,4-hydrated 2,3-epoxide, which is responsible for its mutagenic modification of DNA."
3-Fluoroquinoline,3-Fluoroquinoline lacks the potency to induce liver GST-P-positive foci in rats and in vivo mutation in the liver.,Entity: 3-Fluoroquinoline. SMILES: Fc1cnc2ccccc2c1. 3-Fluoroquinoline lacks the potency to induce liver GST-P-positive foci in rats and in vivo mutation in the liver.
quinoline,The mutagenic potency of quinoline decreases in the higher dose range compared to 5-fluorinated quinoline derivatives.,Entity: quinoline. SMILES: c1ccc2ncccc2c1. The mutagenic potency of quinoline decreases in the higher dose range compared to 5-fluorinated quinoline derivatives.
"6,7-diFQ","In the higher dose range, the mutagenic potency of 6,7-diFQ declines below that of quinoline.","Entity: 6,7-diFQ. SMILES: Fc1cc2cccnc2cc1F. In the higher dose range, the mutagenic potency of 6,7-diFQ declines below that of quinoline."
"6,7,8-triFQ","In the higher dose range, the mutagenic potency of 6,7,8-triFQ declines below that of quinoline.","Entity: 6,7,8-triFQ. SMILES: Fc1cc2cccnc2c(F)c1F. In the higher dose range, the mutagenic potency of 6,7,8-triFQ declines below that of quinoline."
"5,6,7,8-tetrafluoroquinoline","5,6,7,8-tetrafluoroquinoline is only marginally mutagenic despite having fluorine atoms at positions 5 and 7.","Entity: 5,6,7,8-tetrafluoroquinoline. SMILES: Fc1c(F)c(F)c2ncccc2c1F. 5,6,7,8-tetrafluoroquinoline is only marginally mutagenic despite having fluorine atoms at positions 5 and 7."
perfluorodecaline,"Perfluorodecaline, a perfluorinated compound used in artificial blood, is generally inert in chemical and biochemical reactions.","Entity: perfluorodecaline. SMILES: FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F. Perfluorodecaline, a perfluorinated compound used in artificial blood, is generally inert in chemical and biochemical reactions."
quinoline,"Quinoline exhibits mutagenic potency toward Salmonella typhimurium TA100 in the presence of S9-mix, with 1.0 revertants induced per plate per nmol revertants per plate.","Entity: quinoline. SMILES: c1ccc2ncccc2c1. Quinoline exhibits mutagenic potency toward Salmonella typhimurium TA100 in the presence of S9-mix, with 1.0 revertants induced per plate per nmol revertants per plate."
"5,6-difluorouracil","5,6-difluorouracil shows mutagenic potency toward Salmonella typhimurium TA100 in the presence of S9-mix, with 3.0 revertants induced per plate per nmol revertants per plate at higher doses.","Entity: 5,6-difluorouracil. SMILES: O=c1[nH]c(F)c(F)c(=O)[nH]1. 5,6-difluorouracil shows mutagenic potency toward Salmonella typhimurium TA100 in the presence of S9-mix, with 3.0 revertants induced per plate per nmol revertants per plate at higher doses."
"3,5-difluorouracil","3,5-difluorouracil does not induce mutagenic revertants in Salmonella typhimurium TA100 in the presence of S9-mix.","Entity: 3,5-difluorouracil. SMILES: O=c1[nH]cc(F)c(=O)n1F. 3,5-difluorouracil does not induce mutagenic revertants in Salmonella typhimurium TA100 in the presence of S9-mix."
3-fluorouracil,3-fluorouracil does not induce mutagenic revertants in Salmonella typhimurium TA100 in the presence of S9-mix.,Entity: 3-fluorouracil. SMILES: O=c1cc[nH]c(=O)n1F. 3-fluorouracil does not induce mutagenic revertants in Salmonella typhimurium TA100 in the presence of S9-mix.
6-fluorouracil,"6-fluorouracil shows mutagenic potency toward Salmonella typhimurium TA100 in the presence of S9-mix, with 0.2 revertants induced per plate per nmol revertants per plate.","Entity: 6-fluorouracil. SMILES: O=c1cc(F)[nH]c(=O)[nH]1. 6-fluorouracil shows mutagenic potency toward Salmonella typhimurium TA100 in the presence of S9-mix, with 0.2 revertants induced per plate per nmol revertants per plate."
CHCl,CHCl (chloroform) is used as an extraction solvent in the purification of 3-amino-7-fluoroquinoline from the reaction mixture.,Entity: CHCl. SMILES: ClC(Cl)Cl. CHCl (chloroform) is used as an extraction solvent in the purification of 3-amino-7-fluoroquinoline from the reaction mixture.
tetramethylsilane,Tetramethylsilane is used as an internal standard in analytical procedures.,Entity: tetramethylsilane. SMILES: C[Si](C)(C)C. Tetramethylsilane is used as an internal standard in analytical procedures.
3-aminoquinoline,3-aminoquinoline can be synthesized from quinoline using a method involving 7-fluoroquinoline as a precursor.,Entity: 3-aminoquinoline. SMILES: Nc1cnc2ccccc2c1. 3-aminoquinoline can be synthesized from quinoline using a method involving 7-fluoroquinoline as a precursor.
3-amino-7-fluoroquinoline,3-amino-7-fluoroquinoline is synthesized from 7-fluoroquinoline using BrCN as a reagent.,Entity: 3-amino-7-fluoroquinoline. SMILES: Nc1cnc2cc(F)ccc2c1. 3-amino-7-fluoroquinoline is synthesized from 7-fluoroquinoline using BrCN as a reagent.
"3,3,7-trifluoroquinoline","3,3,7-trifluoroquinoline is a fluorinated quinoline derivative.","Entity: 3,3,7-trifluoroquinoline. SMILES: Fc1ccc2c(c1)=NCC(F)(F)C=2. 3,3,7-trifluoroquinoline is a fluorinated quinoline derivative."
7-fluoroquinoline,"7-fluoroquinoline is a fluorinated quinoline derivative used as a precursor in the synthesis of 3-amino-7-fluoroquinoline and 3,3,7-trifluoroquinoline.","Entity: 7-fluoroquinoline. SMILES: Fc1ccc2cccnc2c1. 7-fluoroquinoline is a fluorinated quinoline derivative used as a precursor in the synthesis of 3-amino-7-fluoroquinoline and 3,3,7-trifluoroquinoline."
MeOH,Methanol (MeOH) is used as a solvent in the synthesis of 3-amino-7-fluoroquinoline from 7-fluoroquinoline.,Entity: MeOH. SMILES: CO. Methanol (MeOH) is used as a solvent in the synthesis of 3-amino-7-fluoroquinoline from 7-fluoroquinoline.
"5,7-difluoroquinoline","5,7-difluoroquinoline is a fluorinated quinoline derivative.","Entity: 5,7-difluoroquinoline. SMILES: Fc1cc(F)c2cccnc2c1. 5,7-difluoroquinoline is a fluorinated quinoline derivative."
BrCN,"BrCN (bromo cyanide) is used as a reagent in the synthesis of 3-amino-7-fluoroquinoline and 3,3,7-trifluoroquinoline from 7-fluoroquinoline.","Entity: BrCN. SMILES: N#CBr. BrCN (bromo cyanide) is used as a reagent in the synthesis of 3-amino-7-fluoroquinoline and 3,3,7-trifluoroquinoline from 7-fluoroquinoline."
water,Water is used to quench and precipitate the product during the synthesis of 3-amino-7-fluoroquinoline from 7-fluoroquinoline.,Entity: water. SMILES: O. Water is used to quench and precipitate the product during the synthesis of 3-amino-7-fluoroquinoline from 7-fluoroquinoline.
quinoline,Quinoline is a heterocyclic aromatic organic compound that serves as a starting material for the synthesis of 3-aminoquinoline and its fluorinated derivatives.,Entity: quinoline. SMILES: c1ccc2ncccc2c1. Quinoline is a heterocyclic aromatic organic compound that serves as a starting material for the synthesis of 3-aminoquinoline and its fluorinated derivatives.
"5,8-difluoroquinoline","5,8-difluoroquinoline is a fluorinated quinoline derivative.","Entity: 5,8-difluoroquinoline. SMILES: Fc1ccc(F)c2ncccc12. 5,8-difluoroquinoline is a fluorinated quinoline derivative."
quinoline,"Tetrafluorination of quinoline derivatives leads to a decrease in mutagenicity, approaching the deactivating effect of perfluorination.","Entity: quinoline. SMILES: c1ccc2ncccc2c1. Tetrafluorination of quinoline derivatives leads to a decrease in mutagenicity, approaching the deactivating effect of perfluorination."
quinoline,3-fluorine substitution in the pyridine moiety of quinoline derivatives is a useful means of antimutagenic structural modification.,Entity: quinoline. SMILES: c1ccc2ncccc2c1. 3-fluorine substitution in the pyridine moiety of quinoline derivatives is a useful means of antimutagenic structural modification.
5-fluoroquinoline,Fluorine substitution at position 5 in quinoline derivatives enhances mutagenicity in Salmonella typhimurium TA100 with S9 mix assays.,Entity: 5-fluoroquinoline. SMILES: Fc1cccc2ncccc12. Fluorine substitution at position 5 in quinoline derivatives enhances mutagenicity in Salmonella typhimurium TA100 with S9 mix assays.
quinoline,"Quinoline derivatives with di- or trifluoro substitution at positions 3, 5, or 7 show mutagenic activity in Salmonella typhimurium TA100 with S9 mix, with mutagenicity generally increasing with the number of fluorine substituents at these positions.","Entity: quinoline. SMILES: c1ccc2ncccc2c1. Quinoline derivatives with di- or trifluoro substitution at positions 3, 5, or 7 show mutagenic activity in Salmonella typhimurium TA100 with S9 mix, with mutagenicity generally increasing with the number of fluorine substituents at these positions."
quinoline,Quinoline is a genotoxic N-containing heteroaromatic compound that is carcinogenic and mutagenic in vivo.,Entity: quinoline. SMILES: c1ccc2ncccc2c1. Quinoline is a genotoxic N-containing heteroaromatic compound that is carcinogenic and mutagenic in vivo.
5-fluoroquinoline,"5-fluoroquinoline is carcinogenic and mutagenic in vivo, exhibiting mutagenic potency comparable to quinoline.","Entity: 5-fluoroquinoline. SMILES: Fc1cccc2ncccc12. 5-fluoroquinoline is carcinogenic and mutagenic in vivo, exhibiting mutagenic potency comparable to quinoline."
8-fluoroquinoline,"8-fluoroquinoline is readily metabolized to its 5,6-diol form in rat microsomal enzymes.","Entity: 8-fluoroquinoline. SMILES: Fc1cccc2cccnc12. 8-fluoroquinoline is readily metabolized to its 5,6-diol form in rat microsomal enzymes."
"5,7-difluoroquinoline","5,7-difluoroquinoline substitution at position 5 and 7 in the benzene moiety of quinoline deprives the compound of its mutagenicity.","Entity: 5,7-difluoroquinoline. SMILES: Fc1cc(F)c2cccnc2c1. 5,7-difluoroquinoline substitution at position 5 and 7 in the benzene moiety of quinoline deprives the compound of its mutagenicity."
5-fluoroquinoline,5-fluoroquinoline substitution at position 5 in the benzene moiety of quinoline enhances mutagenicity.,Entity: 5-fluoroquinoline. SMILES: Fc1cccc2ncccc12. 5-fluoroquinoline substitution at position 5 in the benzene moiety of quinoline enhances mutagenicity.
5-fluoroquinoline,"5-fluoroquinoline substitution at position 5 in the benzene moiety of quinoline inhibits the major detoxification metabolism of quinoline, specifically 5,6-epoxidation, in rat microsomal enzymes.","Entity: 5-fluoroquinoline. SMILES: Fc1cccc2ncccc12. 5-fluoroquinoline substitution at position 5 in the benzene moiety of quinoline inhibits the major detoxification metabolism of quinoline, specifically 5,6-epoxidation, in rat microsomal enzymes."
7-fluoroquinoline,7-fluoroquinoline substitution at position 7 in the benzene moiety of quinoline enhances mutagenicity.,Entity: 7-fluoroquinoline. SMILES: Fc1ccc2cccnc2c1. 7-fluoroquinoline substitution at position 7 in the benzene moiety of quinoline enhances mutagenicity.
7-fluoroquinoline,"7-fluoroquinoline substitution at position 7 in the benzene moiety of quinoline inhibits the major detoxification metabolism of quinoline, specifically 5,6-epoxidation, in rat microsomal enzymes.","Entity: 7-fluoroquinoline. SMILES: Fc1ccc2cccnc2c1. 7-fluoroquinoline substitution at position 7 in the benzene moiety of quinoline inhibits the major detoxification metabolism of quinoline, specifically 5,6-epoxidation, in rat microsomal enzymes."
quinoline,"Quinoline undergoes 5,6-epoxidation as its major detoxification metabolism, which can be completely inhibited by 5-fluoro, 6-fluoro, or 7-fluoro substitution at the benzene moiety.","Entity: quinoline. SMILES: c1ccc2ncccc2c1. Quinoline undergoes 5,6-epoxidation as its major detoxification metabolism, which can be completely inhibited by 5-fluoro, 6-fluoro, or 7-fluoro substitution at the benzene moiety."
"fructose-1,6-bisphosphate","Fructose-1,6-bisphosphate is a key intermediate in glycolysis and gluconeogenesis, and its synthesis and degradation are catalyzed by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (EC 2.7.1.105/EC 3.1.3.46).","Entity: fructose-1,6-bisphosphate. SMILES: O=C(COP(=O)(O)O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Fructose-1,6-bisphosphate is a key intermediate in glycolysis and gluconeogenesis, and its synthesis and degradation are catalyzed by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (EC 2.7.1.105/EC 3.1.3.46)."
Ficoll 400,Ficoll 400 is used as a component of Denhardt's solution at 0.02% (m/v) concentration in hybridization buffers for Northern blotting.,Entity: Ficoll 400. SMILES: ClCC1CO1.OC[C@H]1C[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O. Ficoll 400 is used as a component of Denhardt's solution at 0.02% (m/v) concentration in hybridization buffers for Northern blotting.
phenylmethylsulfonyl fluoride,Phenylmethylsulfonyl fluoride is included at 1 mM concentration in cold homogenization buffer for liver extract preparation.,Entity: phenylmethylsulfonyl fluoride. SMILES: O=S(=O)(F)Cc1ccccc1. Phenylmethylsulfonyl fluoride is included at 1 mM concentration in cold homogenization buffer for liver extract preparation.
cesium chloride,Cesium chloride is used to isolate RNA from tissue samples by gradient centrifugation.,Entity: cesium chloride. SMILES: [Cl-].[Cs+]. Cesium chloride is used to isolate RNA from tissue samples by gradient centrifugation.
formaldehyde,Formaldehyde is used at 0.67 M concentration in agarose gels for RNA separation in Northern blotting.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used at 0.67 M concentration in agarose gels for RNA separation in Northern blotting.
sodium chloride,Sodium chloride is used at 150 mM (in 1 USSC buffer) and 1 M (in hybridization buffer) concentrations in Northern blotting and enzyme assays.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used at 150 mM (in 1 USSC buffer) and 1 M (in hybridization buffer) concentrations in Northern blotting and enzyme assays.
sodium citrate,Sodium citrate is used at 150 mM concentration in 1 USSC buffer for RNA transfer in Northern blotting.,Entity: sodium citrate. SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+]. Sodium citrate is used at 150 mM concentration in 1 USSC buffer for RNA transfer in Northern blotting.
guanidinium thiocyanate,Guanidinium thiocyanate is used as a lysis buffer for homogenizing tissue samples in RNA extraction.,Entity: guanidinium thiocyanate. SMILES: N#C[S-].NC(N)=[NH2+]. Guanidinium thiocyanate is used as a lysis buffer for homogenizing tissue samples in RNA extraction.
benzamidine,Benzamidine is included at 1 mM concentration in cold homogenization buffer for liver extract preparation.,Entity: benzamidine. SMILES: N=C(N)c1ccccc1. Benzamidine is included at 1 mM concentration in cold homogenization buffer for liver extract preparation.
dCTP,"dCTP is used as a radiolabeling agent for probes in cDNA library screening, as demonstrated by its incorporation into the SP1 cDNA fragment for detection in a Rediprime random primer labeling kit.","Entity: dCTP. SMILES: Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O2)c(=O)n1. dCTP is used as a radiolabeling agent for probes in cDNA library screening, as demonstrated by its incorporation into the SP1 cDNA fragment for detection in a Rediprime random primer labeling kit."
glucagon,"Increased glucagon levels induce specific phosphorylation and allosteric modulation of 6PF-2-K/Fru-2,6-P 2 ase, simultaneously inhibiting its kinase activity and activating its bisphosphatase activity.","Entity: glucagon. SMILES: CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O. Increased glucagon levels induce specific phosphorylation and allosteric modulation of 6PF-2-K/Fru-2,6-P 2 ase, simultaneously inhibiting its kinase activity and activating its bisphosphatase activity."
"1,8-dinitropyrene","1,8-dinitropyrene is a mutagen used to assess the sensitivity of S. typhimurium strains with disrupted oat genes, with both oat-deficient and conventional strains showing resistance to its mutagenicity.","Entity: 1,8-dinitropyrene. SMILES: O=[N+]([O-])c1ccc2ccc3ccc([N+](=O)[O-])c4ccc1c2c34. 1,8-dinitropyrene is a mutagen used to assess the sensitivity of S. typhimurium strains with disrupted oat genes, with both oat-deficient and conventional strains showing resistance to its mutagenicity."
"2-amino-3-methyl-3H-imidazo[4, 5-f]quinoline","2-amino-3-methyl-3H-imidazo[4, 5-f]quinoline (IQ) is a mutagen to which S. typhimurium strains with disrupted oat genes exhibit resistance.","Entity: 2-amino-3-methyl-3H-imidazo[4, 5-f]quinoline. SMILES: Cn1c(N)nc2c3cccnc3ccc21. 2-amino-3-methyl-3H-imidazo[4, 5-f]quinoline (IQ) is a mutagen to which S. typhimurium strains with disrupted oat genes exhibit resistance."
"3-amino-1-methyl-5H-pyrido[4, 3-b]indole","3-amino-1-methyl-5H-pyrido[4, 3-b]indole (Trp-P-2) is a mutagen for which S. typhimurium strains with disrupted oat genes are not resistant.","Entity: 3-amino-1-methyl-5H-pyrido[4, 3-b]indole. SMILES: Cc1nc(N)cc2[nH]c3ccccc3c12. 3-amino-1-methyl-5H-pyrido[4, 3-b]indole (Trp-P-2) is a mutagen for which S. typhimurium strains with disrupted oat genes are not resistant."
lead,"In humans, daily ingestion of 20 g/kg lead for 21 days in females results in a twofold increase in protoporphyrin in erythrocytes, while in males, 30 g/kg lead causes only a small increase in protoporphyrin and leads to higher blood lead concentrations.","Entity: lead. SMILES: [Pb]. In humans, daily ingestion of 20 g/kg lead for 21 days in females results in a twofold increase in protoporphyrin in erythrocytes, while in males, 30 g/kg lead causes only a small increase in protoporphyrin and leads to higher blood lead concentrations."
lead,"Lead exposure is monitored using blood biomarkers such as FEP (ferric porphyrin excretion) and ALAD (aminolevulinic acid deaminase) activity, with FEP increase indicating a lead-induced effect on heme synthesis.","Entity: lead. SMILES: [Pb]. Lead exposure is monitored using blood biomarkers such as FEP (ferric porphyrin excretion) and ALAD (aminolevulinic acid deaminase) activity, with FEP increase indicating a lead-induced effect on heme synthesis."
Lead,"Lead in bone marrow increases lead content in newly formed erythrocytes, leading to elevated free erythrocyte porphyrin (FEP) in peripheral blood until all erythrocytes are replaced, which takes several months.","Entity: Lead. SMILES: [Pb]. Lead in bone marrow increases lead content in newly formed erythrocytes, leading to elevated free erythrocyte porphyrin (FEP) in peripheral blood until all erythrocytes are replaced, which takes several months."
Lead,"FEP in peripheral blood serves as an indicator of lead in bone marrow, as well as lead in soft tissues, blood, or recent lead intake after several months of exposure.","Entity: Lead. SMILES: [Pb]. FEP in peripheral blood serves as an indicator of lead in bone marrow, as well as lead in soft tissues, blood, or recent lead intake after several months of exposure."
iron,Serum iron (Fe-S) measurements are used as an indicator of iron supply and can help explain elevated free erythrocyte porphyrin (FEP) levels in lead-exposed individuals.,Entity: iron. SMILES: [Fe]. Serum iron (Fe-S) measurements are used as an indicator of iron supply and can help explain elevated free erythrocyte porphyrin (FEP) levels in lead-exposed individuals.
glutathione,Reduced glutathione (GSH) in erythrocytes is measured as an indicator of oxidative stress and has been observed to be depressed in lead-exposed subjects.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Reduced glutathione (GSH) in erythrocytes is measured as an indicator of oxidative stress and has been observed to be depressed in lead-exposed subjects.
lead,Lead exposure can cause delayed increases in free erythrocyte porphyrin (FEP) and is associated with reduced erythrocyte glutathione (GSH) levels.,Entity: lead. SMILES: [Pb]. Lead exposure can cause delayed increases in free erythrocyte porphyrin (FEP) and is associated with reduced erythrocyte glutathione (GSH) levels.
lead,"The effect of inorganic lead on free erythrocyte porphyrin (FEP) in blood is influenced by factors such as the amount of lead ingested, gastrointestinal absorption, distribution of lead to body compartments, and chemical factors like iron and hormones.","Entity: lead. SMILES: [Pb]. The effect of inorganic lead on free erythrocyte porphyrin (FEP) in blood is influenced by factors such as the amount of lead ingested, gastrointestinal absorption, distribution of lead to body compartments, and chemical factors like iron and hormones."
uranyl acetate,"Uranyl acetate is used as a positive stain for polyplex particles, and at higher charge ratios (greater than 1.0 +/3), polyplexes prepared with PLLs become positively stained with uranyl acetate, which can reduce the contrast and make the particles appear smaller under electron microscopy.","Entity: uranyl acetate. SMILES: CC(=O)[O-].CC(=O)[O-].O=[U+2]=O. Uranyl acetate is used as a positive stain for polyplex particles, and at higher charge ratios (greater than 1.0 +/3), polyplexes prepared with PLLs become positively stained with uranyl acetate, which can reduce the contrast and make the particles appear smaller under electron microscopy."
mannitol,"Polyplexes prepared in mannitol maintain similar structures to those prepared in water, but appear positively stained with uranyl acetate in electron micrographs.","Entity: mannitol. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Polyplexes prepared in mannitol maintain similar structures to those prepared in water, but appear positively stained with uranyl acetate in electron micrographs."
glycine,"Polyplexes prepared in glycine have structures similar to those prepared in water, but are positively stained with uranyl acetate in electron micrographs.","Entity: glycine. SMILES: NCC(=O)O. Polyplexes prepared in glycine have structures similar to those prepared in water, but are positively stained with uranyl acetate in electron micrographs."
uranyl acetate,Uranyl acetate is used as a staining agent that produces a positive stain on polyplexes prepared in mannitol or glycine in electron micrographs.,Entity: uranyl acetate. SMILES: CC(=O)[O-].CC(=O)[O-].O=[U+2]=O. Uranyl acetate is used as a staining agent that produces a positive stain on polyplexes prepared in mannitol or glycine in electron micrographs.
sodium chloride,PLL polyplexes prepared in NaCl at concentrations ranging from 10 to 150 mM do not adhere well to grids and provide unreliable electron microscopy results.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. PLL polyplexes prepared in NaCl at concentrations ranging from 10 to 150 mM do not adhere well to grids and provide unreliable electron microscopy results.
sucrose,Sucrose is used at a 20% concentration in PBS to infuse liver pieces during fixation for 2 hours prior to freezing in cryomolds.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used at a 20% concentration in PBS to infuse liver pieces during fixation for 2 hours prior to freezing in cryomolds.
hematoxylin,Hematoxylin is used as a counterstain for liver tissue sections following immunohistochemical staining.,Entity: hematoxylin. SMILES: Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2. Hematoxylin is used as a counterstain for liver tissue sections following immunohistochemical staining.
eosin,Eosin is used as a counterstain for liver tissue sections following immunohistochemical staining.,Entity: eosin. SMILES: O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+]. Eosin is used as a counterstain for liver tissue sections following immunohistochemical staining.
mannitol,"Mannitol is used as an isotonic solution at 287 mM concentration to formulate polyplexes for in vivo studies, providing stability comparable to water and water-based polyplexes.","Entity: mannitol. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannitol is used as an isotonic solution at 287 mM concentration to formulate polyplexes for in vivo studies, providing stability comparable to water and water-based polyplexes."
glycine,"Glycine is used as an isotonic solution at 220 mM concentration to formulate polyplexes for in vivo studies, providing stability comparable to water and water-based polyplexes.","Entity: glycine. SMILES: NCC(=O)O. Glycine is used as an isotonic solution at 220 mM concentration to formulate polyplexes for in vivo studies, providing stability comparable to water and water-based polyplexes."
isopentane,Isopentane chilled with liquid nitrogen is used to rapidly freeze liver pieces in cryomolds for preservation prior to sectioning.,Entity: isopentane. SMILES: CCC(C)C. Isopentane chilled with liquid nitrogen is used to rapidly freeze liver pieces in cryomolds for preservation prior to sectioning.
agarose,"Agarose is a polysaccharide used as a solidifying agent in microscopy and electrophoresis, with normal melting agarose being commonly used for preparing cell suspension slides.","Entity: agarose. SMILES: OC[C@H]1O[C@@H](O[C@H]2[C@H]3OC[C@@H]2O[C@@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]4[C@H]5OC[C@@H]4O[C@@H](O)[C@H]5O)[C@@H]2O)[C@H]3O)[C@H](O)[C@@H](O)[C@H]1O. Agarose is a polysaccharide used as a solidifying agent in microscopy and electrophoresis, with normal melting agarose being commonly used for preparing cell suspension slides."
EDTA,"EDTA is a chelating agent used in lysis and electrophoresis buffers to sequester divalent cations such as Mg2+ and Ca2+, facilitating protein denaturation and DNA strand separation.","Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is a chelating agent used in lysis and electrophoresis buffers to sequester divalent cations such as Mg2+ and Ca2+, facilitating protein denaturation and DNA strand separation."
sodium chloride,Sodium chloride is used as a component of lysis and electrophoresis buffers to maintain osmotic pressure and aid in protein extraction and DNA electrophoresis.,Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is used as a component of lysis and electrophoresis buffers to maintain osmotic pressure and aid in protein extraction and DNA electrophoresis.
Triton X-100,Triton X-100 is a non-ionic detergent used in lysis buffers to solubilize membrane proteins and disrupt cellular membranes.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent used in lysis buffers to solubilize membrane proteins and disrupt cellular membranes.
sodium hydroxide,Sodium hydroxide is used in alkaline electrophoresis buffers at pH 13 to denature DNA for electrophoretic analysis.,Entity: sodium hydroxide. SMILES: [Na+].[OH-]. Sodium hydroxide is used in alkaline electrophoresis buffers at pH 13 to denature DNA for electrophoretic analysis.
DMSO,DMSO (dimethyl sulfoxide) is a polar aprotic solvent used in lysis buffers to enhance protein denaturation and membrane permeabilization.,Entity: DMSO. SMILES: CS(C)=O. DMSO (dimethyl sulfoxide) is a polar aprotic solvent used in lysis buffers to enhance protein denaturation and membrane permeabilization.
ethidium bromide,Ethidium bromide is a fluorescent dye used to stain DNA for visualization under microscopy.,Entity: ethidium bromide. SMILES: CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc21.[Br-]. Ethidium bromide is a fluorescent dye used to stain DNA for visualization under microscopy.
griseofulvin,Griseofulvin is a known aneugen that induces micronuclei formation in V79 cells as detected by the in vitro micronucleus test using three different protocols.,Entity: griseofulvin. SMILES: COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O. Griseofulvin is a known aneugen that induces micronuclei formation in V79 cells as detected by the in vitro micronucleus test using three different protocols.
cytochalasin B,"Cytochalasin B is an inhibitor of cell division but not of nucleus division and, in V79 cells with a near-constant cell cycle, its use in the micronucleus assay provides no advantage over other protocols.","Entity: cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B is an inhibitor of cell division but not of nucleus division and, in V79 cells with a near-constant cell cycle, its use in the micronucleus assay provides no advantage over other protocols."
cyclophosphamide,Cyclophosphamide is a known clastogen that induces micronuclei formation in V79 cells as detected by the in vitro micronucleus test using three different protocols.,Entity: cyclophosphamide. SMILES: O=P1(N(CCCl)CCCl)NCCCO1. Cyclophosphamide is a known clastogen that induces micronuclei formation in V79 cells as detected by the in vitro micronucleus test using three different protocols.
cytochalasin B,Cytochalasin B is used in the cytokinesis block (CB) assay to arrest cells in an asynchronously growing population for genotoxicity testing.,Entity: cytochalasin B. SMILES: C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O. Cytochalasin B is used in the cytokinesis block (CB) assay to arrest cells in an asynchronously growing population for genotoxicity testing.
cyclophosphamide,Cyclophosphamide is a clastogen used to induce chromosomal damage in V79 cells in genotoxicity assays.,Entity: cyclophosphamide. SMILES: O=P1(N(CCCl)CCCl)NCCCO1. Cyclophosphamide is a clastogen used to induce chromosomal damage in V79 cells in genotoxicity assays.
griseofulvin,Griseofulvin is an aneusgen tested for its ability to induce chromosomal aberrations in V79 cells.,Entity: griseofulvin. SMILES: COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O. Griseofulvin is an aneusgen tested for its ability to induce chromosomal aberrations in V79 cells.
NADP,NADP was included at a final concentration of 1.0 mmol/L in the S9-fraction-containing rat liver cell culture medium.,Entity: NADP. SMILES: NC(=O)c1ccc[n+]([C@@H]2O[C@H](COP(=O)(O)OP(=O)([O-])OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)c1. NADP was included at a final concentration of 1.0 mmol/L in the S9-fraction-containing rat liver cell culture medium.
glucose 6-phosphate,Glucose 6-phosphate was included at a final concentration of 1.0 mmol/L in the S9-fraction-containing rat liver cell culture medium.,Entity: glucose 6-phosphate. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O. Glucose 6-phosphate was included at a final concentration of 1.0 mmol/L in the S9-fraction-containing rat liver cell culture medium.
5-methylthioribose,"5-methylthioribose induces a time-dependent increase in micronucleated cells in V79 cells at concentrations relevant to standard micronucleus assays, without observed toxicity in the tested range.","Entity: 5-methylthioribose. SMILES: CC(O)[C@@H](O)[C@@H](O)[C@@H](O)C=S. 5-methylthioribose induces a time-dependent increase in micronucleated cells in V79 cells at concentrations relevant to standard micronucleus assays, without observed toxicity in the tested range."
Triton X-100,Triton X-100 is used at a concentration of 1% in the lysis buffer for cell lysis in a luciferase reporter assay.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used at a concentration of 1% in the lysis buffer for cell lysis in a luciferase reporter assay.
glycerol,Glycerol is included at a concentration of 10% in the lysis buffer for cell lysis in a luciferase reporter assay.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is included at a concentration of 10% in the lysis buffer for cell lysis in a luciferase reporter assay.
NaCl,NaCl is present at a concentration of 137 mM in the STBS buffer for cell lysis in a luciferase reporter assay.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is present at a concentration of 137 mM in the STBS buffer for cell lysis in a luciferase reporter assay.
DTT,DTT is included at a concentration of 2 mM in the lysis buffer for cell lysis in a luciferase reporter assay.,Entity: DTT. SMILES: O[C@H](CS)[C@H](O)CS. DTT is included at a concentration of 2 mM in the lysis buffer for cell lysis in a luciferase reporter assay.
MgCl2,MgCl2 is used at a concentration of 0.6 mM in the STBS buffer for cell lysis in a luciferase reporter assay.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is used at a concentration of 0.6 mM in the STBS buffer for cell lysis in a luciferase reporter assay.
CaCl2,CaCl2 is included at a concentration of 0.7 mM in the STBS buffer for cell lysis in a luciferase reporter assay.,Entity: CaCl2. SMILES: [Ca+2].[Cl-].[Cl-]. CaCl2 is included at a concentration of 0.7 mM in the STBS buffer for cell lysis in a luciferase reporter assay.
trasylol,Trasylol is used as a protease inhibitor at a concentration of 10 U/ml during nuclear protein extraction to prevent proteolytic degradation.,Entity: trasylol. SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC3=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N2)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)CC)NC1=O. Trasylol is used as a protease inhibitor at a concentration of 10 U/ml during nuclear protein extraction to prevent proteolytic degradation.
Hepes,Hepes is used as a buffering agent at 10 mM concentration (pH 7.9) in both the cell suspension and homogenization buffers for nuclear protein extraction.,Entity: Hepes. SMILES: O=S(=O)(O)CCN1CCN(CCO)CC1. Hepes is used as a buffering agent at 10 mM concentration (pH 7.9) in both the cell suspension and homogenization buffers for nuclear protein extraction.
glycerol,Glycerol is included at 25% (v/v) concentration in the homogenization and dialysis buffers for nuclear protein extraction to help maintain protein stability.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is included at 25% (v/v) concentration in the homogenization and dialysis buffers for nuclear protein extraction to help maintain protein stability.
MgCl2,MgCl2 is included at 4 mM concentration in the buffer for electrophoretic mobility shift assays to act as a cofactor for protein-DNA interactions.,Entity: MgCl2. SMILES: [Cl-].[Cl-].[Mg+2]. MgCl2 is included at 4 mM concentration in the buffer for electrophoretic mobility shift assays to act as a cofactor for protein-DNA interactions.
glycerol,Glycerol is used at 12% concentration in the buffer for electrophoretic mobility shift assays to help stabilize protein complexes.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is used at 12% concentration in the buffer for electrophoretic mobility shift assays to help stabilize protein complexes.
EDTA,EDTA is used as a buffer component at 1 mM concentration in electrophoretic mobility shift assays to chelate divalent cations and stabilize protein complexes.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used as a buffer component at 1 mM concentration in electrophoretic mobility shift assays to chelate divalent cations and stabilize protein complexes.
KCl,KCl is included at 60 mM concentration in the buffer for electrophoretic mobility shift assays to maintain ionic strength and facilitate protein-DNA interactions.,Entity: KCl. SMILES: [Cl-].[K+]. KCl is included at 60 mM concentration in the buffer for electrophoretic mobility shift assays to maintain ionic strength and facilitate protein-DNA interactions.
Hepes,Hepes is used as a buffering agent at 12.5 mM concentration in electrophoretic mobility shift assays to maintain pH stability.,Entity: Hepes. SMILES: O=S(=O)(O)CCN1CCN(CCO)CC1. Hepes is used as a buffering agent at 12.5 mM concentration in electrophoretic mobility shift assays to maintain pH stability.
ATP,ATP is used as a phosphorylation reagent by T4 polynucleotide kinase to label DNA fragments for electrophoretic mobility shift assays.,Entity: ATP. SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O. ATP is used as a phosphorylation reagent by T4 polynucleotide kinase to label DNA fragments for electrophoretic mobility shift assays.
CH3ONa,CH3ONa (acetate) is used as a component of the electrophoresis buffer at 3.3 mM concentration in electrophoretic mobility shift assays.,Entity: CH3ONa. SMILES: CC(=O)[O-].[Na+]. CH3ONa (acetate) is used as a component of the electrophoresis buffer at 3.3 mM concentration in electrophoretic mobility shift assays.
ATF-2,"ATF-2 is a transcription factor known to bind to the cyclic AMP responsive element (CRE), with a consensus sequence of TGA(C/G)TCA.","Entity: ATF-2. ATF-2 is a transcription factor known to bind to the cyclic AMP responsive element (CRE), with a consensus sequence of TGA(C/G)TCA."
ATF-2,"The EL13-binding protein is almost identical with rat ATF-2, suggesting ATF-2 plays a role in Ly49A expression via binding to EL13.","Entity: ATF-2. The EL13-binding protein is almost identical with rat ATF-2, suggesting ATF-2 plays a role in Ly49A expression via binding to EL13."
Ly49A,Ly49A is a gene whose expression is regulated by a 13-bp element (EL13) that is highly homologous to several virus DNAs and is not homologous to known regulatory elements.,Entity: Ly49A. Ly49A is a gene whose expression is regulated by a 13-bp element (EL13) that is highly homologous to several virus DNAs and is not homologous to known regulatory elements.
1-Hydroxymethylpyrene,1-Hydroxymethylpyrene is metabolically activated by most sulfotransferases and induces DNA repair synthesis in V79-derived rat hepatic cell lines.,Entity: 1-Hydroxymethylpyrene. SMILES: OCc1ccc2ccc3cccc4ccc1c2c34. 1-Hydroxymethylpyrene is metabolically activated by most sulfotransferases and induces DNA repair synthesis in V79-derived rat hepatic cell lines.
Acetone oxime,"Acetone oxime, the tautomeric form of the first reduction product of 2-nitropropane, is inactive in inducing DNA repair synthesis in V79-derived rat hepatic cell lines expressing sulfotransferases.","Entity: Acetone oxime. SMILES: CC(C)=NO. Acetone oxime, the tautomeric form of the first reduction product of 2-nitropropane, is inactive in inducing DNA repair synthesis in V79-derived rat hepatic cell lines expressing sulfotransferases."
SULT1C1,SULT1C1 is a rat hepatic sulfotransferase capable of metabolically activating propane 2-nitronate (P2N) to genotoxic DNA-reactive species in rat liver.,Entity: SULT1C1. SULT1C1 is a rat hepatic sulfotransferase capable of metabolically activating propane 2-nitronate (P2N) to genotoxic DNA-reactive species in rat liver.
SULT1A1,SULT1A1 is a rat hepatic sulfotransferase capable of metabolically activating propane 2-nitronate (P2N) to genotoxic DNA-reactive species in rat liver.,Entity: SULT1A1. SULT1A1 is a rat hepatic sulfotransferase capable of metabolically activating propane 2-nitronate (P2N) to genotoxic DNA-reactive species in rat liver.
l-arabinose,l-arabinose serves as a carbon source that enables inducible expression control of genes in Gram-negative bacteria and Agrobacterium tumefaciens using BHR PBAD vectors.,Entity: l-arabinose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)CO. l-arabinose serves as a carbon source that enables inducible expression control of genes in Gram-negative bacteria and Agrobacterium tumefaciens using BHR PBAD vectors.
d-fucose,d-fucose acts as an anti-inducer that allows modulation of l-arabinose induction in Agrobacterium tumefaciens when used in combination with BHR PBAD vectors.,Entity: d-fucose. SMILES: C[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O. d-fucose acts as an anti-inducer that allows modulation of l-arabinose induction in Agrobacterium tumefaciens when used in combination with BHR PBAD vectors.
arabinose,Arabinose utilization in E. coli is subject to multiple levels of regulation.,Entity: arabinose. SMILES: O=C[C@@H](O)[C@H](O)[C@H](O)CO. Arabinose utilization in E. coli is subject to multiple levels of regulation.
malate,"Malate, an intermediate of the citric acid cycle, is a preferred carbon source for A. tumefaciens.","Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate, an intermediate of the citric acid cycle, is a preferred carbon source for A. tumefaciens."
mannitol,"Mannitol, a sugar alcohol, is a preferred carbon source for A. tumefaciens.","Entity: mannitol. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannitol, a sugar alcohol, is a preferred carbon source for A. tumefaciens."
succinate,"Succinate, an intermediate of the citric acid cycle, is a preferred carbon source for A. tumefaciens.","Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate, an intermediate of the citric acid cycle, is a preferred carbon source for A. tumefaciens."
succinate,Succinate represses expression of genes involved in the degradation of plant tumor metabolites called opines in A. tumefaciens.,Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate represses expression of genes involved in the degradation of plant tumor metabolites called opines in A. tumefaciens.
-arabinose,"-arabinose, the non-inducing isomer of arabinose, has the most modest effect on reducing P BAD ::lacZ expression in A. tumefaciens A136 cultures induced with -arabinose.","Entity: -arabinose. SMILES: O=C[C@@H](O)[C@H](O)[C@H](O)CO. -arabinose, the non-inducing isomer of arabinose, has the most modest effect on reducing P BAD ::lacZ expression in A. tumefaciens A136 cultures induced with -arabinose."
-arabinose,"-arabinose is an inducing sugar for P BAD ::lacZ expression in A. tumefaciens A136, but all tested carbon sources at 0.5% concentration modestly reduce induction compared to arabinose alone.","Entity: -arabinose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)CO. -arabinose is an inducing sugar for P BAD ::lacZ expression in A. tumefaciens A136, but all tested carbon sources at 0.5% concentration modestly reduce induction compared to arabinose alone."
mannitol,"Mannitol has a mild, reproducible effect on reducing P BAD ::lacZ expression in A. tumefaciens A136 cultures induced with -arabinose.","Entity: mannitol. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Mannitol has a mild, reproducible effect on reducing P BAD ::lacZ expression in A. tumefaciens A136 cultures induced with -arabinose."
malate,"Malate reduces P BAD ::lacZ expression in A. tumefaciens A136, with the effect varying depending on the bacterial strain.","Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate reduces P BAD ::lacZ expression in A. tumefaciens A136, with the effect varying depending on the bacterial strain."
glucose,"Glucose reduces P BAD ::lacZ expression by 70% in A. tumefaciens A136 cultures induced with -arabinose, despite the reported lack of glucose repression in this bacterium.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose reduces P BAD ::lacZ expression by 70% in A. tumefaciens A136 cultures induced with -arabinose, despite the reported lack of glucose repression in this bacterium."
sucrose,"Sucrose has a mild, reproducible effect on reducing P BAD ::lacZ expression in A. tumefaciens A136 cultures induced with -arabinose.","Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose has a mild, reproducible effect on reducing P BAD ::lacZ expression in A. tumefaciens A136 cultures induced with -arabinose."
D-fucose,D-fucose can inhibit P BAD activity by providing an alternative strategy for modulating P BAD induction in microbes such as E. coli.,Entity: D-fucose. SMILES: C[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O. D-fucose can inhibit P BAD activity by providing an alternative strategy for modulating P BAD induction in microbes such as E. coli.
L-arabinose,"L-arabinose can induce P BAD activity in certain microbes, with induction being reasonably tight under conditions using 0.5% final concentration.","Entity: L-arabinose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)CO. L-arabinose can induce P BAD activity in certain microbes, with induction being reasonably tight under conditions using 0.5% final concentration."
-arabinose,"The P BAD promoter in Agrobacterium tumefaciens is -arabinose-responsive, with induction increasing in a graded manner over several orders of magnitude of -arabinose concentration.","Entity: -arabinose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)CO. The P BAD promoter in Agrobacterium tumefaciens is -arabinose-responsive, with induction increasing in a graded manner over several orders of magnitude of -arabinose concentration."
L-arabinose,"In E. coli, L-arabinose induces the P BAD promoter, leading to high levels of expression of recombinant gene products.","Entity: L-arabinose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)CO. In E. coli, L-arabinose induces the P BAD promoter, leading to high levels of expression of recombinant gene products."
glucose,"In E. coli, glucose does not induce the P BAD promoter, resulting in lower or no expression of recombinant gene products.","Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. In E. coli, glucose does not induce the P BAD promoter, resulting in lower or no expression of recombinant gene products."
arabinose,"Arabinose can be used as an inducer for gene expression in E. coli cultures, with induction levels up to 60 units higher when low -fucose concentrations are present.","Entity: arabinose. SMILES: O=C[C@@H](O)[C@H](O)[C@H](O)CO. Arabinose can be used as an inducer for gene expression in E. coli cultures, with induction levels up to 60 units higher when low -fucose concentrations are present."
fucose,"Low -fucose concentrations can induce arabinose production in E. coli cultures, supporting higher arabinose-based gene expression induction.","Entity: fucose. SMILES: C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O. Low -fucose concentrations can induce arabinose production in E. coli cultures, supporting higher arabinose-based gene expression induction."
fumarate,"Fumarate uptake and degradation in E. coli are influenced by the presence of additional carbon sources, affecting its intracellular pool.","Entity: fumarate. SMILES: O=C([O-])/C=C/C(=O)[O-]. Fumarate uptake and degradation in E. coli are influenced by the presence of additional carbon sources, affecting its intracellular pool."
L-arabinose,L-arabinose uptake and degradation in E. coli are profoundly influenced by the intracellular pool of the sugar and the presence of additional carbon sources.,Entity: L-arabinose. SMILES: O=C[C@H](O)[C@@H](O)[C@@H](O)CO. L-arabinose uptake and degradation in E. coli are profoundly influenced by the intracellular pool of the sugar and the presence of additional carbon sources.
glycerol,Glycerol supplementation at 0.5% in AT minimal medium is used to support E. coli cultures in studies of -arabinose induction.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol supplementation at 0.5% in AT minimal medium is used to support E. coli cultures in studies of -arabinose induction.
succinate,"Succinate uptake and degradation in E. coli are influenced by the presence of additional carbon sources, affecting its intracellular pool.","Entity: succinate. SMILES: O=C([O-])CCC(=O)[O-]. Succinate uptake and degradation in E. coli are influenced by the presence of additional carbon sources, affecting its intracellular pool."
malate,"Malate uptake and degradation in E. coli are influenced by the presence of additional carbon sources, affecting its intracellular pool.","Entity: malate. SMILES: O=C([O-])CC(O)C(=O)[O-]. Malate uptake and degradation in E. coli are influenced by the presence of additional carbon sources, affecting its intracellular pool."
glucose,Glucose uptake and utilization in E. coli strains influence the intracellular pool of glucose and affect the regulation of P BAD induction.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose uptake and utilization in E. coli strains influence the intracellular pool of glucose and affect the regulation of P BAD induction.
mannitol,"The presence of additional carbon sources, such as mannitol, greatly impacts the rate of uptake and subsequent degradation of many sugars in E. coli.","Entity: mannitol. SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. The presence of additional carbon sources, such as mannitol, greatly impacts the rate of uptake and subsequent degradation of many sugars in E. coli."
sucrose,Sucrose uptake and utilization in E. coli strains affect the intracellular pool of sucrose and influence the rate of its degradation.,Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose uptake and utilization in E. coli strains affect the intracellular pool of sucrose and influence the rate of its degradation.
isoflurane,Isoflurane is capable of inducing significant DNA damage as measured by the alkaline comet assay.,Entity: isoflurane. SMILES: FC(F)OC(Cl)C(F)(F)F. Isoflurane is capable of inducing significant DNA damage as measured by the alkaline comet assay.
halothane,Halothane is capable of inducing significant DNA damage as measured by the alkaline comet assay.,Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane is capable of inducing significant DNA damage as measured by the alkaline comet assay.
bromochlorodifluoroethylene,Bromochlorodifluoroethylene is a toxic or even genotoxic compound that may be formed via a reductive defluorination pathway from halothane.,Entity: bromochlorodifluoroethylene. SMILES: FC(Cl)=C(F)Br. Bromochlorodifluoroethylene is a toxic or even genotoxic compound that may be formed via a reductive defluorination pathway from halothane.
bromochlorodifluoroethylene,Bromochlorodifluoroethylene is described as an alkylating agent.,Entity: bromochlorodifluoroethylene. SMILES: FC(Cl)=C(F)Br. Bromochlorodifluoroethylene is described as an alkylating agent.
halothane,Halothane is an anesthetic agent known to induce fulminant hepatitis in susceptible individuals.,Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane is an anesthetic agent known to induce fulminant hepatitis in susceptible individuals.
halothane,"Halothane exposure can cause cytogenetic changes, mitotic anomalies, and chromosomal abnormalities in mammalian cells.","Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane exposure can cause cytogenetic changes, mitotic anomalies, and chromosomal abnormalities in mammalian cells."
halothane,Halothane has been reported to have mutagenic effects in D. melanogaster after long-term exposure.,Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane has been reported to have mutagenic effects in D. melanogaster after long-term exposure.
halothane,Halothane was not mutagenic in the Ames test with or without metabolic activation in a variety of bacterial strains.,Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane was not mutagenic in the Ames test with or without metabolic activation in a variety of bacterial strains.
trifluoroacetic acid,Trifluoroacetic acid is the major metabolite of halothane and is relatively non-reactive and considered non-toxic.,Entity: trifluoroacetic acid. SMILES: O=C(O)C(F)(F)F. Trifluoroacetic acid is the major metabolite of halothane and is relatively non-reactive and considered non-toxic.
NaCl,NaCl is used at 2.5 M concentration in lysis solution for protein removal in the alkaline comet assay.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is used at 2.5 M concentration in lysis solution for protein removal in the alkaline comet assay.
Tris,Tris is used at 10 mM concentration in lysis solution for protein removal in the alkaline comet assay.,Entity: Tris. SMILES: NC(CO)(CO)CO. Tris is used at 10 mM concentration in lysis solution for protein removal in the alkaline comet assay.
EDTA,EDTA is used at 0.1 M concentration in lysis solution for protein removal in the alkaline comet assay.,Entity: EDTA. SMILES: O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O. EDTA is used at 0.1 M concentration in lysis solution for protein removal in the alkaline comet assay.
Triton X-100,Triton X-100 is used at 1% concentration in lysis solution to solubilize proteins during the alkaline comet assay protocol.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used at 1% concentration in lysis solution to solubilize proteins during the alkaline comet assay protocol.
isoflurane,"Isofurane is a polyfluorinated anesthetic that can induce DNA damage, potentially through alkylation at the N7 position of purines or via reactive metabolites.","Entity: isoflurane. SMILES: FC(F)OC(Cl)C(F)(F)F. Isofurane is a polyfluorinated anesthetic that can induce DNA damage, potentially through alkylation at the N7 position of purines or via reactive metabolites."
isoflurane,"Isofurane has a lower partition coefficient for oil/gas at 37°C (90.8) compared to halothane, indicating lower lipid solubility.","Entity: isoflurane. SMILES: FC(F)OC(Cl)C(F)(F)F. Isofurane has a lower partition coefficient for oil/gas at 37°C (90.8) compared to halothane, indicating lower lipid solubility."
halothane,"Halothane is a polyfluorinated anesthetic that can induce DNA damage, likely by alkylation at the N7 position of purines or through reactive metabolites.","Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane is a polyfluorinated anesthetic that can induce DNA damage, likely by alkylation at the N7 position of purines or through reactive metabolites."
halothane,"Halothane has a higher partition coefficient for oil/gas at 37°C (224) compared to isoflurane, indicating higher lipid solubility.","Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane has a higher partition coefficient for oil/gas at 37°C (224) compared to isoflurane, indicating higher lipid solubility."
halothane,Halothane can penetrate into cells more effectively due to its higher lipid solubility.,Entity: halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane can penetrate into cells more effectively due to its higher lipid solubility.
"1-bromo-1-chloro-2,2-difluoroethylene","1-bromo-1-chloro-2,2-difluoroethylene is a known metabolite of halothane and acts as an alkylating agent.","Entity: 1-bromo-1-chloro-2,2-difluoroethylene. SMILES: FC(F)=C(Cl)Br. 1-bromo-1-chloro-2,2-difluoroethylene is a known metabolite of halothane and acts as an alkylating agent."
Halothane,Some metabolites of halothane are weak mutagens in the Ames Salmonella test.,Entity: Halothane. SMILES: FC(F)(F)C(Cl)Br. Some metabolites of halothane are weak mutagens in the Ames Salmonella test.
Halothane,Halothane and halothanernitrous oxide exposure induce cytogenetic changes in Chinese hamster fibroblasts and rat spermatogonial cells.,Entity: Halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane and halothanernitrous oxide exposure induce cytogenetic changes in Chinese hamster fibroblasts and rat spermatogonial cells.
Trichloroethylene,"Trichloroethylene is mutagenic in E. coli, S. typhimurium, Saccharomyces cerevisiae, and in mice.","Entity: Trichloroethylene. SMILES: ClC=C(Cl)Cl. Trichloroethylene is mutagenic in E. coli, S. typhimurium, Saccharomyces cerevisiae, and in mice."
Enflurane,Enflurane was not mutagenic in the Salmonella S9 test.,Entity: Enflurane. SMILES: FC(F)OC(F)(F)C(F)Cl. Enflurane was not mutagenic in the Salmonella S9 test.
Divinyl ether,Divinyl ether increases the frequency of revertants in Salmonella typhimurium with microsomal activation and increases the rate of sister chromatid exchange (SCE) in CHO cells.,Entity: Divinyl ether. SMILES: C=COC=C. Divinyl ether increases the frequency of revertants in Salmonella typhimurium with microsomal activation and increases the rate of sister chromatid exchange (SCE) in CHO cells.
Nitrous oxide,Nitrous oxide is a weak mutagen for Tradescantia cells in plant systems.,Entity: Nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide is a weak mutagen for Tradescantia cells in plant systems.
Nitrous oxide,Nitrous oxide exposure can induce cytogenetic changes in Chinese hamster fibroblasts and rat spermatogonial cells.,Entity: Nitrous oxide. SMILES: N#[N+][O-]. Nitrous oxide exposure can induce cytogenetic changes in Chinese hamster fibroblasts and rat spermatogonial cells.
Isoflurane,Isoflurane was not mutagenic in the Salmonella S9 test.,Entity: Isoflurane. SMILES: FC(F)OC(Cl)C(F)(F)F. Isoflurane was not mutagenic in the Salmonella S9 test.
Diethyl ether,Diethyl ether was not mutagenic in the Salmonella S9 test.,Entity: Diethyl ether. SMILES: CCOCC. Diethyl ether was not mutagenic in the Salmonella S9 test.
Halothane,Halothane causes a slight increase in mutation frequency in the Drosophila melanogaster sex-linked recessive lethal test.,Entity: Halothane. SMILES: FC(F)(F)C(Cl)Br. Halothane causes a slight increase in mutation frequency in the Drosophila melanogaster sex-linked recessive lethal test.
bizelesin,Bizelesin is used to induce interstrand crosslinks in SV40 DNA and its fragments when treated at approximately 50 Ål volume in 10 mM Tris-EDTA buffer at 37°C for 8 hours.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is used to induce interstrand crosslinks in SV40 DNA and its fragments when treated at approximately 50 Ål volume in 10 mM Tris-EDTA buffer at 37°C for 8 hours.
bizelesin,"Bizelesin is a drug that causes adduct formation in DNA, leading to premature termination of primer extension during polymerase extension assays.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is a drug that causes adduct formation in DNA, leading to premature termination of primer extension during polymerase extension assays."
bizelesin,"At pharmacologically relevant concentrations, bizelesin forms primarily monoadducts rather than crosslinks in genomic DNA, with only a small fraction of adducts corresponding to crosslinks due to the much lower drug levels.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. At pharmacologically relevant concentrations, bizelesin forms primarily monoadducts rather than crosslinks in genomic DNA, with only a small fraction of adducts corresponding to crosslinks due to the much lower drug levels."
bizelesin,"Bizelesin induces interstrand crosslinks in DNA, as evidenced by the slower migration of SV40 DNA strands under alkaline agarose electrophoresis, resulting in a DNA band approximately 10.4 × 10^3 nt in size compared to the 5.0 × 10^3 nt control band.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin induces interstrand crosslinks in DNA, as evidenced by the slower migration of SV40 DNA strands under alkaline agarose electrophoresis, resulting in a DNA band approximately 10.4 × 10^3 nt in size compared to the 5.0 × 10^3 nt control band."
bizelesin,"Bizelesin forms DNA adducts at similar sites in both intracellularly treated and naked SV40 DNA, with the primary DNA sequence being the main determinant of the drug binding pattern regardless of the environment.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin forms DNA adducts at similar sites in both intracellularly treated and naked SV40 DNA, with the primary DNA sequence being the main determinant of the drug binding pattern regardless of the environment."
bizelesin,Bizelesin is a drug whose DNA adduct formation and effects on DNA lesions have been studied in the context of SV40 DNA in virus-infected cells.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is a drug whose DNA adduct formation and effects on DNA lesions have been studied in the context of SV40 DNA in virus-infected cells.
bizelesin,Bizelesin is a drug used to treat BSC-1 cells for 4 hours to facilitate interstrand crosslink determination in genomic DNA.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is a drug used to treat BSC-1 cells for 4 hours to facilitate interstrand crosslink determination in genomic DNA.
thymidine,"Thymidine is a nucleoside used as a radiolabeling agent in cells, with [14C]thymidine incorporated to label cells for interstrand crosslink analysis and [3H]thymidine for controls.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine is a nucleoside used as a radiolabeling agent in cells, with [14C]thymidine incorporated to label cells for interstrand crosslink analysis and [3H]thymidine for controls."
sucrose,"Sucrose is used to form gradients for sedimentation procedures, such as alkaline sucrose gradient centrifugation, to fractionate cellular components based on density.","Entity: sucrose. SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O. Sucrose is used to form gradients for sedimentation procedures, such as alkaline sucrose gradient centrifugation, to fractionate cellular components based on density."
Triton X-100,Triton X-100 is a non-ionic detergent used at 0.2% concentration in hypotonic buffer for cell lysis in interstrand crosslink analysis.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is a non-ionic detergent used at 0.2% concentration in hypotonic buffer for cell lysis in interstrand crosslink analysis.
bizelesin,"Bizelesin induces interstrand crosslinks in cellular DNA, but these crosslinks are only detectable at high drug levels.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin induces interstrand crosslinks in cellular DNA, but these crosslinks are only detectable at high drug levels."
bizelesin,"Bizelesin is a bifunctional AT-specific DNA alkylating drug that induces interstrand crosslinks in genomic DNA of BSC-1 cells at concentrations of 5–100 nM, resulting in approximately 0.3 to 6.03 ± 0.85 interstrand crosslinks per 10^6 base pairs.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is a bifunctional AT-specific DNA alkylating drug that induces interstrand crosslinks in genomic DNA of BSC-1 cells at concentrations of 5–100 nM, resulting in approximately 0.3 to 6.03 ± 0.85 interstrand crosslinks per 10^6 base pairs."
bizelesin,Bizelesin does not induce DNA-protein crosslinks or strand breaks in genomic DNA.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin does not induce DNA-protein crosslinks or strand breaks in genomic DNA.
bizelesin,"Bizelesin preferentially forms adducts at AT-rich tracts, including 5'-T(A/T)4A-3', in both DNA and SV40 DNA, with many sites co-mapping on both strands, indicating interstrand crosslinks.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin preferentially forms adducts at AT-rich tracts, including 5'-T(A/T)4A-3', in both DNA and SV40 DNA, with many sites co-mapping on both strands, indicating interstrand crosslinks."
bizelesin,"Bizelesin-induced interstrand crosslinks are localized in AT-rich tracts of replication-related regions, consistent with its potent anti-replicative properties.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin-induced interstrand crosslinks are localized in AT-rich tracts of replication-related regions, consistent with its potent anti-replicative properties."
bizelesin,Bizelesin forms adducts that can be converted to DNA breaks upon heating at 90°C during repetitive primer extension (RPE) assays.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin forms adducts that can be converted to DNA breaks upon heating at 90°C during repetitive primer extension (RPE) assays.
bizelesin,"Bizelesin forms highly specific lesions in intracellularly drug-treated SV40 DNA, leading to the generation of shorter, prematurely terminated extension products that serve as templates for sequencing analysis.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin forms highly specific lesions in intracellularly drug-treated SV40 DNA, leading to the generation of shorter, prematurely terminated extension products that serve as templates for sequencing analysis."
bizelesin,"Bizelesin adducts are formed at a limited number of sites in SV40 DNA but can eliminate the majority of SV40 molecules as templates for longer DNA extension products when present at appropriate concentrations (e.g., 0.5·10 µM).","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin adducts are formed at a limited number of sites in SV40 DNA but can eliminate the majority of SV40 molecules as templates for longer DNA extension products when present at appropriate concentrations (e.g., 0.5·10 µM)."
dGTP,dGTP is used as a radioactive nucleotide in PCR reactions at a concentration of 0.5 µCi/reaction to facilitate quantification of DNA template by quantitative PCR stop assay.,Entity: dGTP. SMILES: Nc1nc2c(ncn2[C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O2)c(=O)[nH]1. dGTP is used as a radioactive nucleotide in PCR reactions at a concentration of 0.5 µCi/reaction to facilitate quantification of DNA template by quantitative PCR stop assay.
bizelesin,"Bizelesin is a chemical agent that forms DNA crosslinks as its primary lethal event, but generates many more monoadducts than crosslinks.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is a chemical agent that forms DNA crosslinks as its primary lethal event, but generates many more monoadducts than crosslinks."
bizelesin,"Bizelesin induces interstrand crosslinks in genomic DNA of BSC-1 cells, as confirmed by alkaline sucrose gradient sedimentation analysis.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin induces interstrand crosslinks in genomic DNA of BSC-1 cells, as confirmed by alkaline sucrose gradient sedimentation analysis."
bizelesin,Bizelesin does not induce detectable strand breaks or DNA lesions that cause slower sedimentation in BSC-1 cells.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin does not induce detectable strand breaks or DNA lesions that cause slower sedimentation in BSC-1 cells.
bizelesin,"Bizelesin forms DNA adducts at specific nucleotide sites that are virtually identical in both naked and intracellular DNA, with the primary DNA sequence being the major determinant of adduct site.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin forms DNA adducts at specific nucleotide sites that are virtually identical in both naked and intracellular DNA, with the primary DNA sequence being the major determinant of adduct site."
bizelesin,T-antigen binding to naked SV40 origin (ori) DNA does not afford protection against bizelesin-induced alkylation.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. T-antigen binding to naked SV40 origin (ori) DNA does not afford protection against bizelesin-induced alkylation.
bizelesin,"Bizelesin does not induce DNA-protein crosslinks in genomic DNA, in contrast to interstrand crosslinks.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin does not induce DNA-protein crosslinks in genomic DNA, in contrast to interstrand crosslinks."
bizelesin,Bizelesin treatment does not significantly alter the fraction of protein-bound DNA in BSC-1 cells as measured by a K/SDS assay.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin treatment does not significantly alter the fraction of protein-bound DNA in BSC-1 cells as measured by a K/SDS assay.
nitracrine,"Nitracrine induces a significant increase in the fraction of protein-bound DNA in BSC-1 cells, as shown by a K/SDS assay.","Entity: nitracrine. SMILES: CN(C)CCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12. Nitracrine induces a significant increase in the fraction of protein-bound DNA in BSC-1 cells, as shown by a K/SDS assay."
formaldehyde,"Formaldehyde induces a significant increase in the fraction of protein-bound DNA in BSC-1 cells, as shown by a K/SDS assay.","Entity: formaldehyde. SMILES: C=O. Formaldehyde induces a significant increase in the fraction of protein-bound DNA in BSC-1 cells, as shown by a K/SDS assay."
bizelesin,"Bizelesin binds to replication-related origin of replication (ORI) and marker (MAR) regions of SV40 DNA, as well as to the entire SV40 genome and genomic DNA in intact cells.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin binds to replication-related origin of replication (ORI) and marker (MAR) regions of SV40 DNA, as well as to the entire SV40 genome and genomic DNA in intact cells."
bizelesin,"Bizelesin induces DNA strand breaks upon heating, which can be used to detect its adduct formation in DNA.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin induces DNA strand breaks upon heating, which can be used to detect its adduct formation in DNA."
bizelesin,As few as 100 bizelesin-induced DNA lesions per cell are sufficient to potently inhibit DNA replication and cell growth.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. As few as 100 bizelesin-induced DNA lesions per cell are sufficient to potently inhibit DNA replication and cell growth.
bizelesin,"Bizelesin binds to AT-rich regions of DNA involved in replication, which may contribute to its potent effects.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin binds to AT-rich regions of DNA involved in replication, which may contribute to its potent effects."
Bizelesin,Bizelesin is a cyclopropylpyrroloindole (CPI) family member that acts as a DNA minor groove binding and alkylating agent.,Entity: Bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is a cyclopropylpyrroloindole (CPI) family member that acts as a DNA minor groove binding and alkylating agent.
Bizelesin,Bizelesin binds non-covalently to the minor groove of DNA and then alkylates position N3 of an adenine at the 3' end of the binding site.,Entity: Bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin binds non-covalently to the minor groove of DNA and then alkylates position N3 of an adenine at the 3' end of the binding site.
Bizelesin,Bizelesin can form either mono- or bi-functional covalent adducts via its two chloromethyl groups.,Entity: Bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin can form either mono- or bi-functional covalent adducts via its two chloromethyl groups.
Bizelesin,"The majority of bizelesin adducts in naked DNA are found at 5' position T(A/T) 4' A-3' and 5' position A(A/T) 4' A-3' sites, indicating 6-nucleotide crosslink and monoadduct sites, respectively.","Entity: Bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. The majority of bizelesin adducts in naked DNA are found at 5' position T(A/T) 4' A-3' and 5' position A(A/T) 4' A-3' sites, indicating 6-nucleotide crosslink and monoadduct sites, respectively."
Bizelesin,"Bizelesin forms 6-nucleotide DNA crosslinks within 5' position TAATTA-3', 5' position TAAATA-3', and 5' position TAAAAA-3' sequences.","Entity: Bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin forms 6-nucleotide DNA crosslinks within 5' position TAATTA-3', 5' position TAAATA-3', and 5' position TAAAAA-3' sequences."
Bizelesin,Bizelesin forms 7-nucleotide DNA crosslinks less frequently within 5' position TAAAAAA-3' sequences.,Entity: Bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin forms 7-nucleotide DNA crosslinks less frequently within 5' position TAAAAAA-3' sequences.
Bizelesin,Non-adenine bizelesin adducts can occasionally be found in drug-treated DNA fragments.,Entity: Bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Non-adenine bizelesin adducts can occasionally be found in drug-treated DNA fragments.
bizelesin,"Bizelesin forms AT-specific DNA crosslinks, with adducts detected on both DNA strands at a distance of approximately 6^7 bp at sites containing the classical T(A/T)4A sequence.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin forms AT-specific DNA crosslinks, with adducts detected on both DNA strands at a distance of approximately 6^7 bp at sites containing the classical T(A/T)4A sequence."
bizelesin,Bizelesin is capable of forming occasional non-A DNA adducts and 7 bp DNA crosslinks.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is capable of forming occasional non-A DNA adducts and 7 bp DNA crosslinks.
ethidium bromide,"Ethidium bromide is used as a fluorescent dye to stain DNA gels, enabling visualization of DNA size markers and electrophoretic analysis.","Entity: ethidium bromide. SMILES: CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc21.[Br-]. Ethidium bromide is used as a fluorescent dye to stain DNA gels, enabling visualization of DNA size markers and electrophoretic analysis."
thymidine,"Thymidine is used as a radioactive label for DNA, with [14C]thymidine incorporated into SV40 DNA at a concentration of 0.05 µCi/ml for 24–40 hours post infection.","Entity: thymidine. SMILES: Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O. Thymidine is used as a radioactive label for DNA, with [14C]thymidine incorporated into SV40 DNA at a concentration of 0.05 µCi/ml for 24–40 hours post infection."
bizelesin,"Bizelesin is a chemical compound that can be used to treat cells, such as in a 4-hour incubation with SV40 DNA-containing cells.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is a chemical compound that can be used to treat cells, such as in a 4-hour incubation with SV40 DNA-containing cells."
bizelesin,"Bizelesin inhibits amplification of specific DNA regions, including ORI (positions 5010–116) and MAR (positions 3946–4450), in naked SV40 DNA using a quantitative PCR stop assay.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin inhibits amplification of specific DNA regions, including ORI (positions 5010–116) and MAR (positions 3946–4450), in naked SV40 DNA using a quantitative PCR stop assay."
bizelesin,"Bizelesin induces DNA adduct formation in naked SV40 DNA at lesion frequencies of 4.3 ± 0.3 lesions/kbp in MAR, 4.4 ± 0.5 lesions/kbp in ORI, and 4.6 ± 0.5 lesions/kbp in a region referred to as NO (positions 1892–2210) within the assay's resolution.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin induces DNA adduct formation in naked SV40 DNA at lesion frequencies of 4.3 ± 0.3 lesions/kbp in MAR, 4.4 ± 0.5 lesions/kbp in ORI, and 4.6 ± 0.5 lesions/kbp in a region referred to as NO (positions 1892–2210) within the assay's resolution."
bizelesin,"Bizelesin targets AT-rich islands in the human genome, specifically domains containing clusters of potential binding sites (T(A/T)4A) and features characteristic of MAR elements.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin targets AT-rich islands in the human genome, specifically domains containing clusters of potential binding sites (T(A/T)4A) and features characteristic of MAR elements."
bizelesin,"Bizelesin and its related drug CC-1065 preferentially target MAR and ORI regions of SV40 DNA, as confirmed by mapping at approximately 50 bp resolution.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin and its related drug CC-1065 preferentially target MAR and ORI regions of SV40 DNA, as confirmed by mapping at approximately 50 bp resolution."
bizelesin,"Bizelesin forms DNA adducts in SV40 DNA, with prominent adduct sites identified in the origin of replication (ORI), mid-antena repeat (MAR), and negative orientation (NO) regions of SV40 DNA in BSC-1 cells after 4 h treatment at 0.5 × 10 × M.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin forms DNA adducts in SV40 DNA, with prominent adduct sites identified in the origin of replication (ORI), mid-antena repeat (MAR), and negative orientation (NO) regions of SV40 DNA in BSC-1 cells after 4 h treatment at 0.5 × 10 × M."
bizelesin,"Bizelesin is a 6-base pair DNA crosslinking agent that can induce adducts at or near classical crosslinking sites such as 5P-T(A/T)4A-3P, as well as at sites spanning 7 bp or with guanine as the adducted base in SV40 DNA.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is a 6-base pair DNA crosslinking agent that can induce adducts at or near classical crosslinking sites such as 5P-T(A/T)4A-3P, as well as at sites spanning 7 bp or with guanine as the adducted base in SV40 DNA."
bizelesin,"Bizelesin induces interstrand crosslinks in both intracellular and naked SV40 DNA, with crosslink frequencies of 0.07 and 0.15 crosslinks/kb at 1 µM and 5 µM, respectively, in SV40 DNA.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin induces interstrand crosslinks in both intracellular and naked SV40 DNA, with crosslink frequencies of 0.07 and 0.15 crosslinks/kb at 1 µM and 5 µM, respectively, in SV40 DNA."
bizelesin,Bizelesin is an atypical DNA-reactive antitumor drug that forms highly sequence-specific DNA adducts clustered in AT-rich sites of intracellular DNA.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is an atypical DNA-reactive antitumor drug that forms highly sequence-specific DNA adducts clustered in AT-rich sites of intracellular DNA.
bizelesin,"Bizelesin exerts potent anti-replicative properties by targeting AT-rich regions, including origin and mid-array replication regions (ORI and MAR), which are essential for synchronous replicon initiation.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin exerts potent anti-replicative properties by targeting AT-rich regions, including origin and mid-array replication regions (ORI and MAR), which are essential for synchronous replicon initiation."
bizelesin,"Bizelesin crosslinks in AT-rich repetitive sequences can stabilize DNA duplex structure by preventing strand separation, thereby inhibiting replication initiation.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin crosslinks in AT-rich repetitive sequences can stabilize DNA duplex structure by preventing strand separation, thereby inhibiting replication initiation."
bizelesin,"Bizelesin can distort (straighten) bent AT-rich DNA elements, which are important for topological separation of DNA loops and replicon initiation.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin can distort (straighten) bent AT-rich DNA elements, which are important for topological separation of DNA loops and replicon initiation."
carzelesin,"Carzelesin is a clinical CPI analog that forms only monoadducts in DNA, which is less cytotoxic than bizelesin.","Entity: carzelesin. SMILES: CCN(CC)c1ccc2cc(C(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(OC(=O)Nc5ccccc5)c5[nH]cc(C)c65)cc4c3)oc2c1. Carzelesin is a clinical CPI analog that forms only monoadducts in DNA, which is less cytotoxic than bizelesin."
adozelesin,"Adozelesin is a clinical CPI analog that forms only monoadducts in DNA, which is less cytotoxic than bizelesin.","Entity: adozelesin. SMILES: Cc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O. Adozelesin is a clinical CPI analog that forms only monoadducts in DNA, which is less cytotoxic than bizelesin."
bizelesin,"Bizelesin is a clinical CPI analog that forms interstrand crosslinks in DNA, distinguishing it from other CPI analogs such as adozelesin and carzelesin, which form only monoadducts.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is a clinical CPI analog that forms interstrand crosslinks in DNA, distinguishing it from other CPI analogs such as adozelesin and carzelesin, which form only monoadducts."
bizelesin,Bizelesin is typically more cytotoxic than adozelesin and carzelesin due to its ability to form interstrand crosslinks.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is typically more cytotoxic than adozelesin and carzelesin due to its ability to form interstrand crosslinks.
bizelesin,"Bizelesin forms crosslinks in AT-rich tracts, with these AT-specific crosslinks being a major lesion type that contributes to its potent inhibition of replication and cell growth.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin forms crosslinks in AT-rich tracts, with these AT-specific crosslinks being a major lesion type that contributes to its potent inhibition of replication and cell growth."
cisplatin,"Cisplatin is a relatively non-specific drug that induces a much larger number of stop sites in SV40 DNA regions compared to bizelesin, with a preference for G clusters.","Entity: cisplatin. SMILES: Cl[Pt]Cl.N.N. Cisplatin is a relatively non-specific drug that induces a much larger number of stop sites in SV40 DNA regions compared to bizelesin, with a preference for G clusters."
bizelesin,"Bizelesin exhibits a strong preference for binding to AT-rich loci in intracellular SV40 DNA, with over 90% of nucleotide residues most likely to be occupied by A or T.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin exhibits a strong preference for binding to AT-rich loci in intracellular SV40 DNA, with over 90% of nucleotide residues most likely to be occupied by A or T."
bizelesin,"Bizelesin induces distinct patterns of stop sites in SV40 DNA that are markedly different from the more numerous sites induced by cisplatin, which prefers G clusters.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin induces distinct patterns of stop sites in SV40 DNA that are markedly different from the more numerous sites induced by cisplatin, which prefers G clusters."
bizelesin,"Bizelesin forms interstrand crosslinks and monoadducts in SV40 DNA, with preferred binding sites conforming to the motifs 5P-T(A/T)4A-3P and 5P-A(A/T)4A-3P.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin forms interstrand crosslinks and monoadducts in SV40 DNA, with preferred binding sites conforming to the motifs 5P-T(A/T)4A-3P and 5P-A(A/T)4A-3P."
bizelesin,"Long AT runs in SV40 DNA provide multiple overlapping potential sites for bizelesin adduction, making them particularly good targets for the drug.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Long AT runs in SV40 DNA provide multiple overlapping potential sites for bizelesin adduction, making them particularly good targets for the drug."
nitracrine,Nitracrine is used as a positive control for the detection of DNA adduct formation in mapping studies.,Entity: nitracrine. SMILES: CN(C)CCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12. Nitracrine is used as a positive control for the detection of DNA adduct formation in mapping studies.
formaldehyde,Formaldehyde is used as a positive control for the detection of DNA adduct formation in mapping studies.,Entity: formaldehyde. SMILES: C=O. Formaldehyde is used as a positive control for the detection of DNA adduct formation in mapping studies.
dimethylacetamide,Dimethylacetamide is used as a negative control for DNA adduct mapping experiments.,Entity: dimethylacetamide. SMILES: CC(=O)N(C)C. Dimethylacetamide is used as a negative control for DNA adduct mapping experiments.
bizelesin,"Bizelesin induces interstrand crosslinks in genomic DNA in a concentration-dependent manner, with at least 6.0 þ 0.9 interstrand crosslinks per 10^6 bp and 8.2 þ 0.6 total adducts per 10^6 bp observed at 100 nM.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin induces interstrand crosslinks in genomic DNA in a concentration-dependent manner, with at least 6.0 þ 0.9 interstrand crosslinks per 10^6 bp and 8.2 þ 0.6 total adducts per 10^6 bp observed at 100 nM."
bizelesin,Bizelesin induces interstrand crosslinks in both full-length and restriction fragment (2.3 and 2.9 kbp) of SV40 DNA in BSC-1 cells.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin induces interstrand crosslinks in both full-length and restriction fragment (2.3 and 2.9 kbp) of SV40 DNA in BSC-1 cells.
bizelesin,The minimum effective concentration (D10) of bizelesin for inducing interstrand crosslinks in BSC-1 cells is 0.12 nM.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. The minimum effective concentration (D10) of bizelesin for inducing interstrand crosslinks in BSC-1 cells is 0.12 nM.
bizelesin,"Bizelesin forms adducts in DNA, and its adduct localization can be determined by linear amplification of DNA fragments prematurely terminated during primer extension.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin forms adducts in DNA, and its adduct localization can be determined by linear amplification of DNA fragments prematurely terminated during primer extension."
bizelesin,Bizelesin is approximately 100 times more potent than CPI analogs such as adozelesin and CC-1065 in terms of DNA lesion formation required for 90% cell growth inhibition (bizelesin at 0.12 nM in BSC-1 cells).,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin is approximately 100 times more potent than CPI analogs such as adozelesin and CC-1065 in terms of DNA lesion formation required for 90% cell growth inhibition (bizelesin at 0.12 nM in BSC-1 cells).
adozelesin,"Adozelesin, a CPI analog that forms only monoadducts, is typically one order of magnitude less potent than bizelesin and requires forming markedly more DNA lesions for an equitoxic effect.","Entity: adozelesin. SMILES: Cc1c[nH]c2c1[C@@]13C[C@@H]1CN(C(=O)c1cc4cc(NC(=O)c5cc6ccccc6o5)ccc4[nH]1)C3=CC2=O. Adozelesin, a CPI analog that forms only monoadducts, is typically one order of magnitude less potent than bizelesin and requires forming markedly more DNA lesions for an equitoxic effect."
bizelesin,Bizelesin generates interstrand DNA crosslinks but does not form DNA-protein crosslinks or strand breaks.,Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin generates interstrand DNA crosslinks but does not form DNA-protein crosslinks or strand breaks.
bizelesin,"At a concentration of 5·100 nM, bizelesin induces DNA crosslinks at a frequency of approximately 0.3 to 6 lesions per 10·6 base pairs in treated cells.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. At a concentration of 5·100 nM, bizelesin induces DNA crosslinks at a frequency of approximately 0.3 to 6 lesions per 10·6 base pairs in treated cells."
bizelesin,"Bizelesin occupies a 6 bp stretch of DNA, and a monoadduct in one of the overlapping sites in the AT tract in the upper strand could block crosslink formation at an adjacent position.","Entity: bizelesin. SMILES: Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)c1cc2cc(NC(=O)Nc3ccc4[nH]c(C(=O)N5C[C@@H](CCl)c6c5cc(O)c5[nH]cc(C)c65)cc4c3)ccc2[nH]1. Bizelesin occupies a 6 bp stretch of DNA, and a monoadduct in one of the overlapping sites in the AT tract in the upper strand could block crosslink formation at an adjacent position."
"1,2-epoxy-3-butene","1,2-epoxy-3-butene is an epoxide metabolite of 1,3-butadiene that induces sister chromatid exchanges in human whole-blood lymphocyte cultures, with the response depending on the GSTM1 and GSTT1 genotypes of blood donors.","Entity: 1,2-epoxy-3-butene. SMILES: C=CC1CO1. 1,2-epoxy-3-butene is an epoxide metabolite of 1,3-butadiene that induces sister chromatid exchanges in human whole-blood lymphocyte cultures, with the response depending on the GSTM1 and GSTT1 genotypes of blood donors."
monoepoxybutene,"Monoepoxybutene is an epoxide metabolite of 1,3-butadiene that induces sister chromatid exchanges in human whole-blood lymphocyte cultures, with the response influenced by GSTM1 and GSTT1 genotypes.","Entity: monoepoxybutene. SMILES: CCC1=CO1. Monoepoxybutene is an epoxide metabolite of 1,3-butadiene that induces sister chromatid exchanges in human whole-blood lymphocyte cultures, with the response influenced by GSTM1 and GSTT1 genotypes."
"1,3-butadiene","1,3-butadiene is metabolized to the epoxide monoepoxybutene, which can induce sister chromatid exchanges in human whole-blood lymphocyte cultures.","Entity: 1,3-butadiene. SMILES: C=CC=C. 1,3-butadiene is metabolized to the epoxide monoepoxybutene, which can induce sister chromatid exchanges in human whole-blood lymphocyte cultures."
GSTT1,"GSTT1 is a glutathione S-transferase family member whose genotype, along with GSTM1, can influence the response to 1,2-epoxy-3-butene (monoepoxybutene, MEB)-induced sister chromatid exchanges in human whole-blood lymphocyte cultures.","Entity: GSTT1. GSTT1 is a glutathione S-transferase family member whose genotype, along with GSTM1, can influence the response to 1,2-epoxy-3-butene (monoepoxybutene, MEB)-induced sister chromatid exchanges in human whole-blood lymphocyte cultures."
paraquat,Paraquat is an intracellular generator of superoxide that induces chromatid-type chromosome aberrations at high toxic concentrations.,Entity: paraquat. SMILES: C[n+]1ccc(-c2cc[n+](C)cc2)cc1. Paraquat is an intracellular generator of superoxide that induces chromatid-type chromosome aberrations at high toxic concentrations.
superoxide,Superoxide promotes Fenton reactions and accelerates DNA damage by elevating free-iron levels.,Entity: superoxide. SMILES: [O][O-]. Superoxide promotes Fenton reactions and accelerates DNA damage by elevating free-iron levels.
potassium superoxide,Potassium superoxide generates high amounts of superoxide and induces DNA single strand breaks and mutations in mammalian cells.,Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide generates high amounts of superoxide and induces DNA single strand breaks and mutations in mammalian cells.
potassium bromate,Potassium bromate leads to characteristic genotoxic effects in mammalian cells.,Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate leads to characteristic genotoxic effects in mammalian cells.
potassium bromate,"Potassium bromate induces gene mutations at the HPRT locus in yeast cells at high concentrations, reducing survival to up to 13% and causing reduced cloning efficiency of about 85% during mutant selection.","Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate induces gene mutations at the HPRT locus in yeast cells at high concentrations, reducing survival to up to 13% and causing reduced cloning efficiency of about 85% during mutant selection."
potassium bromate,"In TG-resistant yeast cells, potassium bromate treatment leads to mutations such as total deletion of the HPRT coding sequence, partial exon deletions, splice mutations in exons 2, 3, 4, 5, 7, and point mutations (G to T transversions in exons 3, 6, 8, and A to G transition in exon 6) in the HPRT gene.","Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. In TG-resistant yeast cells, potassium bromate treatment leads to mutations such as total deletion of the HPRT coding sequence, partial exon deletions, splice mutations in exons 2, 3, 4, 5, 7, and point mutations (G to T transversions in exons 3, 6, 8, and A to G transition in exon 6) in the HPRT gene."
potassium superoxide,"Potassium superoxide induces cytotoxicity, chromosome aberrations, and increased DNA migration in the alkaline comet assay in V79 Chinese hamster cells.","Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide induces cytotoxicity, chromosome aberrations, and increased DNA migration in the alkaline comet assay in V79 Chinese hamster cells."
potassium superoxide,Potassium superoxide does not significantly increase levels of 8-oxodeoxyguanosine in V79 Chinese hamster cells compared to control.,Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide does not significantly increase levels of 8-oxodeoxyguanosine in V79 Chinese hamster cells compared to control.
potassium superoxide,Potassium superoxide has only a small effect on HPRT mutant frequencies in V79 Chinese hamster cells.,Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide has only a small effect on HPRT mutant frequencies in V79 Chinese hamster cells.
8-oxodeoxyguanosine,8-oxodeoxyguanosine levels are significantly increased in V79 Chinese hamster cells after potassium bromate treatment.,Entity: 8-oxodeoxyguanosine. SMILES: NC1=NC(=O)C2=NC(=O)N([C@H]3C[C@H](O)[C@@H](CO)O3)C2=N1. 8-oxodeoxyguanosine levels are significantly increased in V79 Chinese hamster cells after potassium bromate treatment.
8-oxoguanine,"8-oxoguanine is specifically targeted by FPG protein, which nicks DNA at sites of 8-oxoguanines and formamidopyrimidines.","Entity: 8-oxoguanine. SMILES: Nc1nc2c(c(=O)[nH]1)=NC(=O)N=2. 8-oxoguanine is specifically targeted by FPG protein, which nicks DNA at sites of 8-oxoguanines and formamidopyrimidines."
potassium bromate,"Potassium bromate induces cytotoxicity, chromosome aberrations, and increased DNA migration in the alkaline comet assay in V79 Chinese hamster cells.","Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate induces cytotoxicity, chromosome aberrations, and increased DNA migration in the alkaline comet assay in V79 Chinese hamster cells."
potassium bromate,Potassium bromate treatment leads to significantly increased levels of 8-oxodeoxyguanosine as detected by HPLC in V79 Chinese hamster cells.,Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate treatment leads to significantly increased levels of 8-oxodeoxyguanosine as detected by HPLC in V79 Chinese hamster cells.
potassium bromate,"Potassium bromate induces gene mutations at the HPRT locus in V79 Chinese hamster cells, with a high proportion of deletion mutations and three out of four point mutations being G to T transversions.","Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate induces gene mutations at the HPRT locus in V79 Chinese hamster cells, with a high proportion of deletion mutations and three out of four point mutations being G to T transversions."
DMSO,"DMSO is used as a component of the lysing solution in the comet assay, at a concentration of 10%.","Entity: DMSO. SMILES: CS(C)=O. DMSO is used as a component of the lysing solution in the comet assay, at a concentration of 10%."
Triton X-100,Triton X-100 is included in the lysing solution for the comet assay at a concentration of 1%.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is included in the lysing solution for the comet assay at a concentration of 1%.
Tris,Tris is used as a component of the lysing solution in the comet assay at a concentration of 10 mM.,Entity: Tris. SMILES: NC(CO)(CO)CO. Tris is used as a component of the lysing solution in the comet assay at a concentration of 10 mM.
NaCl,NaCl is included in the lysing solution for the comet assay at a concentration of 2.5 M.,Entity: NaCl. SMILES: [Cl-].[Na+]. NaCl is included in the lysing solution for the comet assay at a concentration of 2.5 M.
potassium bromate,Bromine radicals generated from potassium bromate act as reactive intermediates responsible for DNA damage rather than hydroxyl radicals or singlet oxygen.,Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Bromine radicals generated from potassium bromate act as reactive intermediates responsible for DNA damage rather than hydroxyl radicals or singlet oxygen.
potassium superoxide,"Potassium superoxide generates superoxide anions, which are generally poorly reactive but can generate toxic products such as hydroxyl radicals via the Fenton reaction in the presence of metal ions.","Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide generates superoxide anions, which are generally poorly reactive but can generate toxic products such as hydroxyl radicals via the Fenton reaction in the presence of metal ions."
superoxide,"Superoxide is generally poorly reactive and does not react directly with DNA, but under certain conditions such as the presence of metal ions, it can generate more toxic products like hydroxyl radicals via the Fenton reaction.","Entity: superoxide. SMILES: [O][O-]. Superoxide is generally poorly reactive and does not react directly with DNA, but under certain conditions such as the presence of metal ions, it can generate more toxic products like hydroxyl radicals via the Fenton reaction."
8-oxoguanine,8-oxoguanine is a DNA lesion generated in excess of DNA strand breaks in mammalian cells upon exposure to potassium bromate and glutathione.,Entity: 8-oxoguanine. SMILES: Nc1nc2c(c(=O)[nH]1)=NC(=O)N=2. 8-oxoguanine is a DNA lesion generated in excess of DNA strand breaks in mammalian cells upon exposure to potassium bromate and glutathione.
glutathione,Glutathione is present in mammalian cells and reacts with potassium bromate to generate 8-oxoguanine and DNA strand breaks.,Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione is present in mammalian cells and reacts with potassium bromate to generate 8-oxoguanine and DNA strand breaks.
potassium bromate,Potassium bromate is a complete carcinogen whose reactive bromine radicals generated from bromate induce oxidative DNA damage in mammalian cells.,Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate is a complete carcinogen whose reactive bromine radicals generated from bromate induce oxidative DNA damage in mammalian cells.
potassium bromate,"In mammalian cells, potassium bromate in the presence of glutathione generates 8-oxoguanine and causes DNA strand breaks.","Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. In mammalian cells, potassium bromate in the presence of glutathione generates 8-oxoguanine and causes DNA strand breaks."
potassium superoxide,Potassium superoxide induces cytotoxic and mutagenic effects that are parallel to the formation of superoxide anions.,Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide induces cytotoxic and mutagenic effects that are parallel to the formation of superoxide anions.
potassium superoxide,Potassium superoxide mainly causes DNA single-strand breaks in the alkaline elution assay and multi-locus deletion mutations in the gpt-test with AS52 cells.,Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide mainly causes DNA single-strand breaks in the alkaline elution assay and multi-locus deletion mutations in the gpt-test with AS52 cells.
potassium superoxide,"The genotoxic effects of potassium superoxide are not primarily due to oxidative base damage, as indicated by comet assay and FPG protein markers.","Entity: potassium superoxide. SMILES: O=O.[K+]. The genotoxic effects of potassium superoxide are not primarily due to oxidative base damage, as indicated by comet assay and FPG protein markers."
potassium superoxide,Potassium superoxide exhibits a weak mutagenic effect compared to potassium bromate under the same treatment conditions.,Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide exhibits a weak mutagenic effect compared to potassium bromate under the same treatment conditions.
superoxide,Superoxide anions are reactive oxygen species that can induce DNA strand breaks and cytotoxicity.,Entity: superoxide. SMILES: OO. Superoxide anions are reactive oxygen species that can induce DNA strand breaks and cytotoxicity.
superoxide,Superoxide does not react directly with DNA but is thought to generate hydroxyl radicals via the dismutation reaction of the superoxide anion radical.,Entity: superoxide. SMILES: OO. Superoxide does not react directly with DNA but is thought to generate hydroxyl radicals via the dismutation reaction of the superoxide anion radical.
superoxide,"Superoxide can release iron from storage proteins or enzymatic 4Fe-4S clusters, promoting Fenton reactions that accelerate DNA damage.","Entity: superoxide. SMILES: OO. Superoxide can release iron from storage proteins or enzymatic 4Fe-4S clusters, promoting Fenton reactions that accelerate DNA damage."
hydroxyl radical,The hydroxyl radical is considered to act as a complete carcinogen.,Entity: hydroxyl radical. SMILES: [OH]. The hydroxyl radical is considered to act as a complete carcinogen.
8-oxodeoxyguanosine,8-oxodeoxyguanosine is a biomarker for oxidative DNA base damage.,Entity: 8-oxodeoxyguanosine. SMILES: NC1=NC(=O)C2=NC(=O)N([C@H]3C[C@H](O)[C@@H](CO)O3)C2=N1. 8-oxodeoxyguanosine is a biomarker for oxidative DNA base damage.
potassium superoxide,Potassium superoxide generates superoxide anions in a concentration-related manner.,Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide generates superoxide anions in a concentration-related manner.
potassium bromate,Potassium bromate is a superoxide-producing chemical that induces mutagenic effects under certain treatment conditions.,Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate is a superoxide-producing chemical that induces mutagenic effects under certain treatment conditions.
potassium bromate,"Potassium bromate induces FPG-sensitive base modifications, indicating the formation of 8-oxoguanine residues in V79 cells.","Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate induces FPG-sensitive base modifications, indicating the formation of 8-oxoguanine residues in V79 cells."
potassium bromate,Potassium bromate induces gene mutations at the HPRT locus and is associated with G to T transversions in V79 cells.,Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate induces gene mutations at the HPRT locus and is associated with G to T transversions in V79 cells.
potassium bromate,Potassium bromate is a known carcinogen.,Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate is a known carcinogen.
potassium superoxide,Potassium superoxide induces genotoxic effects in V79 cells.,Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide induces genotoxic effects in V79 cells.
8-oxoguanine,8-oxoguanine is a pre-mutagenic DNA lesion that induces G to T transversions and is directly involved in the process of carcinogenesis.,Entity: 8-oxoguanine. SMILES: Nc1nc2c(c(=O)[nH]1)=NC(=O)N=2. 8-oxoguanine is a pre-mutagenic DNA lesion that induces G to T transversions and is directly involved in the process of carcinogenesis.
potassium bromate,"Potassium bromate induces DNA strand breaks, oxidative DNA base damage, chromosome aberrations, and gene mutations in V79 cells in vitro.","Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate induces DNA strand breaks, oxidative DNA base damage, chromosome aberrations, and gene mutations in V79 cells in vitro."
citric acid,Citric acid is used as a buffer component at 12.5 mM concentration in the mobile phase for HPLC analysis of 8-oxodeoxyguanosine.,Entity: citric acid. SMILES: O=C(O)CC(O)(CC(=O)O)C(=O)O. Citric acid is used as a buffer component at 12.5 mM concentration in the mobile phase for HPLC analysis of 8-oxodeoxyguanosine.
sodium acetate,Sodium acetate is used as a buffer component at 25 mM concentration in the mobile phase for HPLC analysis of 8-oxodeoxyguanosine.,Entity: sodium acetate. SMILES: CC(=O)[O-].[Na+]. Sodium acetate is used as a buffer component at 25 mM concentration in the mobile phase for HPLC analysis of 8-oxodeoxyguanosine.
methanol,Methanol is included at 9.5% volume in the mobile phase for HPLC separation of 8-oxodeoxyguanosine.,Entity: methanol. SMILES: CO. Methanol is included at 9.5% volume in the mobile phase for HPLC separation of 8-oxodeoxyguanosine.
8-oxodeoxyguanosine,8-oxodeoxyguanosine can be quantitatively analyzed by HPLC using electrochemical detection with calibration curves relating its concentration to the integrated detector response.,Entity: 8-oxodeoxyguanosine. SMILES: NC1=NC(=O)C2=NC(=O)N([C@H]3C[C@H](O)[C@@H](CO)O3)C2=N1. 8-oxodeoxyguanosine can be quantitatively analyzed by HPLC using electrochemical detection with calibration curves relating its concentration to the integrated detector response.
deoxyguanosine,Deoxyguanosine concentration can be quantified in HPLC by measuring its integrated UV absorbance for calibration purposes.,Entity: deoxyguanosine. SMILES: Nc1nc2c(ncn2[C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. Deoxyguanosine concentration can be quantified in HPLC by measuring its integrated UV absorbance for calibration purposes.
potassium bromate,"Potassium bromate induces a concentration-related increase in DNA migration in the comet assay, with detectable effects up to 5 mM under standard test conditions.","Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate induces a concentration-related increase in DNA migration in the comet assay, with detectable effects up to 5 mM under standard test conditions."
potassium bromate,"Potassium bromate exposure elevates 8-oxodGuo levels, indicating oxidative DNA damage, at concentrations that also induce HPRT gene mutations.","Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate exposure elevates 8-oxodGuo levels, indicating oxidative DNA damage, at concentrations that also induce HPRT gene mutations."
potassium superoxide,Potassium superoxide at tested concentrations does not show a significantly increased frequency of 8-oxodGuo compared to control in genotoxicity assays using the comet assay.,Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide at tested concentrations does not show a significantly increased frequency of 8-oxodGuo compared to control in genotoxicity assays using the comet assay.
potassium bromate,"Potassium bromate exerts a strong and concentration-dependent cytotoxic effect on V79 cells, causing total inhibition of clonal cell growth at 20 mM concentration after 1 hour treatment.","Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate exerts a strong and concentration-dependent cytotoxic effect on V79 cells, causing total inhibition of clonal cell growth at 20 mM concentration after 1 hour treatment."
potassium bromate,"Potassium bromate induces micronuclei in V79 cells in the concentration range effective for cytotoxicity, with higher frequencies of micronucleated cells observed under less toxic conditions.","Entity: potassium bromate. SMILES: [K+].[O-][Br+2]([O-])[O-]. Potassium bromate induces micronuclei in V79 cells in the concentration range effective for cytotoxicity, with higher frequencies of micronucleated cells observed under less toxic conditions."
potassium superoxide,Potassium superoxide causes total inhibition of clonal cell growth in V79 cells at a concentration of 0.6 mM after 1 hour treatment.,Entity: potassium superoxide. SMILES: O=O.[K+]. Potassium superoxide causes total inhibition of clonal cell growth in V79 cells at a concentration of 0.6 mM after 1 hour treatment.
HPRT,"Potassium bromate induces gene mutations at the HPRT locus in V79 Chinese hamster cells, with a high proportion of deletion mutations and three out of four point mutations being G to T transversions, which typically occur after replication of 8-oxoguanine.","Entity: HPRT. Potassium bromate induces gene mutations at the HPRT locus in V79 Chinese hamster cells, with a high proportion of deletion mutations and three out of four point mutations being G to T transversions, which typically occur after replication of 8-oxoguanine."
concanavalin A,Concanavalin A is used as a stimulant for rat thymocytes at a concentration of 10 µg/ml in cell culture.,Entity: concanavalin A. SMILES: CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1.Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O. Concanavalin A is used as a stimulant for rat thymocytes at a concentration of 10 µg/ml in cell culture.
hydrogen peroxide,Hydrogen peroxide diminishes the binding of Sp1 and AP1 transcription factors to DNA.,Entity: hydrogen peroxide. SMILES: OO. Hydrogen peroxide diminishes the binding of Sp1 and AP1 transcription factors to DNA.
penicillin G,Penicillin G is used as an antibiotic supplement in cell culture media at a concentration of 200 U/ml to prevent bacterial contamination.,Entity: penicillin G. SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O. Penicillin G is used as an antibiotic supplement in cell culture media at a concentration of 200 U/ml to prevent bacterial contamination.
sodium chloride,"Sodium chloride is a component of phosphate-buffered saline (PBS) at a concentration of 137 mM, commonly used for washing cells in cell culture.","Entity: sodium chloride. SMILES: [Cl-].[Na+]. Sodium chloride is a component of phosphate-buffered saline (PBS) at a concentration of 137 mM, commonly used for washing cells in cell culture."
streptomycin,Streptomycin is used as an antibiotic supplement in cell culture media at a concentration of 100 U/ml to prevent bacterial contamination.,Entity: streptomycin. SMILES: CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O. Streptomycin is used as an antibiotic supplement in cell culture media at a concentration of 100 U/ml to prevent bacterial contamination.
glucose,Glucose repression of laccase in Cryptococcus neoformans is mediated by transcriptional regulation involving pathways regulated by the Xho1 site and the G-protein alpha subunit GPA1.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose repression of laccase in Cryptococcus neoformans is mediated by transcriptional regulation involving pathways regulated by the Xho1 site and the G-protein alpha subunit GPA1.
glutamine,Glutamine represses phenoloxidase activity in all tested isolates of Cryptococcus neoformans except for serotype B.,Entity: glutamine. SMILES: NC(=O)CC[C@H](N)C(=O)O. Glutamine represses phenoloxidase activity in all tested isolates of Cryptococcus neoformans except for serotype B.
ammonium sulfate,Ammonium sulfate represses phenoloxidase activity in all tested isolates of Cryptococcus neoformans except those of serotype A.,Entity: ammonium sulfate. SMILES: O=S(=O)([O-])[O-].[NH4+].[NH4+]. Ammonium sulfate represses phenoloxidase activity in all tested isolates of Cryptococcus neoformans except those of serotype A.
glucose,Glucose acts as a strong repressor of laccase enzyme activity in Cryptococcus neoformans at concentrations as low as 0.55 mM for all tested strains.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose acts as a strong repressor of laccase enzyme activity in Cryptococcus neoformans at concentrations as low as 0.55 mM for all tested strains.
glucose,Glucose is used as an inducer of transcriptional activity in a whole-cell assay system for monitoring CNLAC1 transcription in Cryptococcus neoformans.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is used as an inducer of transcriptional activity in a whole-cell assay system for monitoring CNLAC1 transcription in Cryptococcus neoformans.
dithiothreitol,Dithiothreitol is used at a concentration of 20 mM in the lysis buffer to maintain reducing conditions and preserve enzymatic activity during extraction of transcriptional activity from Trichoderma harzianum.,Entity: dithiothreitol. SMILES: O[C@H](CS)[C@H](O)CS. Dithiothreitol is used at a concentration of 20 mM in the lysis buffer to maintain reducing conditions and preserve enzymatic activity during extraction of transcriptional activity from Trichoderma harzianum.
azinobis(3-ethylbenzthiazoline-6-sulfonic acid,Azinobis(3-ethylbenzthiazoline-6-sulfonic acid) is used as a substrate at 1 mM concentration to measure laccase activity in enzymatic assays.,Entity: azinobis(3-ethylbenzthiazoline-6-sulfonic acid. SMILES: CCn1/c(=N\N=c2\sc3cc(S(=O)(=O)[O-])ccc3n2CC)sc2cc(S(=O)(=O)[O-])ccc21.[NH4+].[NH4+]. Azinobis(3-ethylbenzthiazoline-6-sulfonic acid) is used as a substrate at 1 mM concentration to measure laccase activity in enzymatic assays.
ethidium bromide,Ethidium bromide is used to stain genomic DNA for detection of plasmid integration in Southern blot analysis.,Entity: ethidium bromide. SMILES: CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc21.[Br-]. Ethidium bromide is used to stain genomic DNA for detection of plasmid integration in Southern blot analysis.
asparagine,Asparagine is used as the sole carbon source in the growth medium for Strains formans 10S BUFOA cells.,Entity: asparagine. SMILES: NC(=O)C[C@H](N)C(=O)O. Asparagine is used as the sole carbon source in the growth medium for Strains formans 10S BUFOA cells.
glucose,Glucose is used at 2% concentration in the growth medium to test its effect on laccase activity in Strains formans 10S BUFOA cells.,Entity: glucose. SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO. Glucose is used at 2% concentration in the growth medium to test its effect on laccase activity in Strains formans 10S BUFOA cells.
CNLAC1,"CNLAC1 is a virulence gene in Cryptococcus neoformans whose 5'-enhancer region contains multiple interactive DNA binding sites, including consensus Sp1 and E2F sites, over a 1.5 kb upstream region, indicating complex transcriptional regulation.","Entity: CNLAC1. CNLAC1 is a virulence gene in Cryptococcus neoformans whose 5'-enhancer region contains multiple interactive DNA binding sites, including consensus Sp1 and E2F sites, over a 1.5 kb upstream region, indicating complex transcriptional regulation."
methanol,Methanol is used in combination with glacial acetic acid (3:1) to fix cells for cytogenetic analysis.,Entity: methanol. SMILES: CO. Methanol is used in combination with glacial acetic acid (3:1) to fix cells for cytogenetic analysis.
lead acetate,Lead acetate is used to maintain blood lead levels at 400–50 ppb in human subjects during a 7-week exposure phase in cytogenetic studies.,Entity: lead acetate. SMILES: CC(=O)[O-].CC(=O)[O-].[Pb+2]. Lead acetate is used to maintain blood lead levels at 400–50 ppb in human subjects during a 7-week exposure phase in cytogenetic studies.
lead,"Chronic exposure to lead is associated with an increased incidence of chromosomal aberrations, including chromatid and unstable chromosome aberrations, in occupationally exposed individuals.","Entity: lead. SMILES: [Pb]. Chronic exposure to lead is associated with an increased incidence of chromosomal aberrations, including chromatid and unstable chromosome aberrations, in occupationally exposed individuals."
lead,"Occupational exposure to lead can increase the rate of abnormal metaphases, primarily chromatid and one-break chromosome aberrations, in human lymphocytes, with doubling of the rate after 1 month and further increase after 2 months of exposure.","Entity: lead. SMILES: [Pb]. Occupational exposure to lead can increase the rate of abnormal metaphases, primarily chromatid and one-break chromosome aberrations, in human lymphocytes, with doubling of the rate after 1 month and further increase after 2 months of exposure."
lead,"Blood lead levels were elevated in the study population, ranging from 340 ± 126 ppb at the start to up to 1100 ppb during the first 3 months, with an average of 450 → 568 ppb during that period.","Entity: lead. SMILES: [Pb]. Blood lead levels were elevated in the study population, ranging from 340 ± 126 ppb at the start to up to 1100 ppb during the first 3 months, with an average of 450 → 568 ppb during that period."
GSH,"Glutathione (GSH) at 5 mM concentration acts as a biomimetic activator, improving the linearity and mutagenicity of chloropicrin (CCl3NO2) and its dechlorination products in the Salmonella typhimurium TA100 preincubation assay.","Entity: GSH. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione (GSH) at 5 mM concentration acts as a biomimetic activator, improving the linearity and mutagenicity of chloropicrin (CCl3NO2) and its dechlorination products in the Salmonella typhimurium TA100 preincubation assay."
GSH,"GSH can activate chloropicrin (CCl3NO2) to more active metabolites such as CHCl2NO2 and CH2ClNO2 via reductive dechlorination, which are both moderately potent bacterial mutagens.","Entity: GSH. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. GSH can activate chloropicrin (CCl3NO2) to more active metabolites such as CHCl2NO2 and CH2ClNO2 via reductive dechlorination, which are both moderately potent bacterial mutagens."
CHBrCl,CHBrCl (bromo-chloroform) is a dihalomethane that is less potent as a mutagen and toxicant than CHBr (bromoform) in the S. typhimurium TA100 preincubation assay.,Entity: CHBrCl. SMILES: ClCBr. CHBrCl (bromo-chloroform) is a dihalomethane that is less potent as a mutagen and toxicant than CHBr (bromoform) in the S. typhimurium TA100 preincubation assay.
CCl4,"CCl4 (carbon tetrachloride) does not produce a mutagenic effect in the S. typhimurium TA100 preincubation assay when tested alone or in the presence of microsomes, as it does not react with GSH in the absence of S-transferase.","Entity: CCl4. SMILES: ClC(Cl)(Cl)Cl. CCl4 (carbon tetrachloride) does not produce a mutagenic effect in the S. typhimurium TA100 preincubation assay when tested alone or in the presence of microsomes, as it does not react with GSH in the absence of S-transferase."
CHCl,CHCl (chloroform) is a dihalomethane that is less potent as a mutagen and toxicant than CHBr (bromoform) in the S. typhimurium TA100 preincubation assay.,Entity: CHCl. SMILES: CCl. CHCl (chloroform) is a dihalomethane that is less potent as a mutagen and toxicant than CHBr (bromoform) in the S. typhimurium TA100 preincubation assay.
CHI,CHI (iodoform) is a dihalomethane that is less potent as a mutagen and toxicant than CHBr (bromoform) in the S. typhimurium TA100 preincubation assay.,Entity: CHI. SMILES: CI. CHI (iodoform) is a dihalomethane that is less potent as a mutagen and toxicant than CHBr (bromoform) in the S. typhimurium TA100 preincubation assay.
GSH,"GSH (glutathione) can react with chloronitromethanes to form chemically reactive and unstable GSH conjugates, which are considered genotoxicants.","Entity: GSH. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. GSH (glutathione) can react with chloronitromethanes to form chemically reactive and unstable GSH conjugates, which are considered genotoxicants."
GSH,"GSH conjugates of dihalomethanes and 1,2-dihaloethanes can form adducts with nucleobases or DNA, contributing to their genotoxicity.","Entity: GSH. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. GSH conjugates of dihalomethanes and 1,2-dihaloethanes can form adducts with nucleobases or DNA, contributing to their genotoxicity."
CHBr,CHBr (bromoform) is a halonitromethane that is significantly more potent as a mutagen and toxicant than the corresponding dihalomethane (CHBrCl) in the S. typhimurium TA100 preincubation assay.,Entity: CHBr. SMILES: CBr. CHBr (bromoform) is a halonitromethane that is significantly more potent as a mutagen and toxicant than the corresponding dihalomethane (CHBrCl) in the S. typhimurium TA100 preincubation assay.
dimethyl sulfoxide,Dimethyl sulfoxide is used as a solvent for dissolving test compounds in in vitro assays involving bacterial cultures and liver microsomes.,Entity: dimethyl sulfoxide. SMILES: CS(C)=O. Dimethyl sulfoxide is used as a solvent for dissolving test compounds in in vitro assays involving bacterial cultures and liver microsomes.
glutathione,"Glutathione is included at 10 mmol in the preincubation buffer, resulting in 14 mM GSH in the mixture and 5 mM GSH in the final top agar layer in standard in vitro assays.","Entity: glutathione. SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O. Glutathione is included at 10 mmol in the preincubation buffer, resulting in 14 mM GSH in the mixture and 5 mM GSH in the final top agar layer in standard in vitro assays."
NADPH,"NADPH is used at 1.5 mg per 0.1 ml buffer in in vitro assays with liver microsomes, contributing to a final concentration of 1.5 mg/mL in the reaction mixture.","Entity: NADPH. SMILES: NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](OP(=O)(O)O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1. NADPH is used at 1.5 mg per 0.1 ml buffer in in vitro assays with liver microsomes, contributing to a final concentration of 1.5 mg/mL in the reaction mixture."
CClNO,CClNO is a compound whose lytic instability as an impurity in CHClNO does not significantly contribute to the overall mutagenicity of CHClNO.,Entity: CClNO. SMILES: O=[N+]([O-])c1ccccc1[N+](=O)[O-]. CClNO is a compound whose lytic instability as an impurity in CHClNO does not significantly contribute to the overall mutagenicity of CHClNO.
Tween 20,Tween 20 is used at 0.1% concentration in PBS for rinsing slides during antibody staining procedures.,Entity: Tween 20. SMILES: CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO. Tween 20 is used at 0.1% concentration in PBS for rinsing slides during antibody staining procedures.
propidium iodide,Propidium iodide is used at 0.5 mg/ml in PBS containing 90% glycerol and 2.5% DABCO as a counterstain for DNA in microscopy slides.,Entity: propidium iodide. SMILES: CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc21.[I-].[I-]. Propidium iodide is used at 0.5 mg/ml in PBS containing 90% glycerol and 2.5% DABCO as a counterstain for DNA in microscopy slides.
glycerol,Glycerol is used at 90% concentration in PBS with 2.5% DABCO as a component of the antifade solution for microscopy slides.,Entity: glycerol. SMILES: OCC(O)CO. Glycerol is used at 90% concentration in PBS with 2.5% DABCO as a component of the antifade solution for microscopy slides.
Triton X-100,Triton X-100 is used at 0.1% concentration in PBS to permeabilize tissue for 3 minutes during kinetochore staining protocols.,Entity: Triton X-100. SMILES: CC(C)(C)CC(C)(C)c1ccc(OCCO)cc1. Triton X-100 is used at 0.1% concentration in PBS to permeabilize tissue for 3 minutes during kinetochore staining protocols.
propidium iodide,"Propidium iodide is used as a fluorescent stain for nuclear identification in fluorescence microscopy, with optimal observation in the 510–560 nm wavelength range.","Entity: propidium iodide. SMILES: CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc21.[I-].[I-]. Propidium iodide is used as a fluorescent stain for nuclear identification in fluorescence microscopy, with optimal observation in the 510–560 nm wavelength range."
fluorescein,"Fluorescein is used as a fluorescent stain for nuclear identification in fluorescence microscopy, with optimal observation in the 450–490 nm wavelength range.","Entity: fluorescein. SMILES: O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21. Fluorescein is used as a fluorescent stain for nuclear identification in fluorescence microscopy, with optimal observation in the 450–490 nm wavelength range."
Ethanol,"Ethanol consumption has been suggested to increase DNA oxidation, which may be reflected in elevated 8-hydroxy-2'-deoxyguanosine (8-OHdG) frequency in leukocytes.","Entity: Ethanol. SMILES: CCO. Ethanol consumption has been suggested to increase DNA oxidation, which may be reflected in elevated 8-hydroxy-2'-deoxyguanosine (8-OHdG) frequency in leukocytes."
8-Hydroxy-2'-deoxyguanosine,"8-Hydroxy-2'-deoxyguanosine (8-OHdG) levels in leukocyte DNA are associated with coffee drinking, in a direction independent of smoking, and may reflect efficient DNA repair mechanisms.","Entity: 8-Hydroxy-2'-deoxyguanosine. SMILES: Nc1nc2c(nc(O)n2[C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. 8-Hydroxy-2'-deoxyguanosine (8-OHdG) levels in leukocyte DNA are associated with coffee drinking, in a direction independent of smoking, and may reflect efficient DNA repair mechanisms."
8-Hydroxy-2'-deoxyguanosine,"The frequency of 8-Hydroxy-2'-deoxyguanosine (8-OHdG) in rat leukocytes varies between 20 and 55 per 10^6 dGuo, depending on the study.","Entity: 8-Hydroxy-2'-deoxyguanosine. SMILES: Nc1nc2c(nc(O)n2[C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1. The frequency of 8-Hydroxy-2'-deoxyguanosine (8-OHdG) in rat leukocytes varies between 20 and 55 per 10^6 dGuo, depending on the study."
